WO2015157070A2 - Crispr/cas-related methods and compositions for treating cystic fibrosis - Google Patents

Crispr/cas-related methods and compositions for treating cystic fibrosis Download PDF

Info

Publication number
WO2015157070A2
WO2015157070A2 PCT/US2015/023960 US2015023960W WO2015157070A2 WO 2015157070 A2 WO2015157070 A2 WO 2015157070A2 US 2015023960 W US2015023960 W US 2015023960W WO 2015157070 A2 WO2015157070 A2 WO 2015157070A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
molecule
nucleotides
domain
grna
Prior art date
Application number
PCT/US2015/023960
Other languages
French (fr)
Other versions
WO2015157070A3 (en
Inventor
Deepak REYON
Morgan L. MAEDER
Ari E. FRIEDLAND
G. Grant Welstead
David A. Bumcrot
Original Assignee
Editas Medicine, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53059403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2015157070(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Editas Medicine, Inc. filed Critical Editas Medicine, Inc.
Priority to EP19157864.0A priority Critical patent/EP3556858A3/en
Priority to EP15721376.0A priority patent/EP3129485B2/en
Publication of WO2015157070A2 publication Critical patent/WO2015157070A2/en
Publication of WO2015157070A3 publication Critical patent/WO2015157070A3/en
Priority to US15/288,475 priority patent/US11028394B2/en
Priority to US17/246,081 priority patent/US20210380987A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/34Allele or polymorphism specific uses

Definitions

  • the invention relates to CRISPR/CAS-related methods and components for editing of target nucleic acid sequence, and applications thereof in connection with Cystic Fibrosis (CF) CF-like disease.
  • CF Cystic Fibrosis
  • Cystic fibrosis is an autosomal recessive, hereditary disease caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
  • the CFTR gene encodes a cAMP-gated channel that is involved in chloride and bicarbonate transport. It regulates sodium transport through inhibition of the epithelial sodium channel, which is encoded by the SCNN1A gene.
  • CFTR is expressed on the apical surface of epithelial cells in the airway, gastrointestinal tract, reproductive tract, sweat glands and submucosal glands.
  • CF affects one in 3,500 children born in the United States. It is the most common fatal autosomal recessive disease in individuals of European descent (Tobias 2011; Essential Medical Genetics, John Wiley & Sons, ed. p. 312). There are approximately 30,000 subjects in the United States with the disease (From The Cystic Fibrosis Foundation; cff.org, accessed on 3/19/2015).
  • the most common mutation in the CFTR gene is a deletion of the three nucleotides encoding Phenylalanine (F) at position 508 of the CFTR protein (also sometime referred to herein as "F508del”). This mutation is the causative mutation in approximately two-thirds of CF cases. The remaining cases are caused by at least 1000 different mutations, many of which cause a less severe form of the disease.
  • Subjects having CF can present at birth or in early infancy with pancreatic insufficiency. Pancreatic dysfunction leads to malabsorption of fat and fat-soluble vitamins, which causes poor growth as well as gallstones and biliary disease.
  • the lung manifestations of the disease can be more severe but may present slightly after pancreatic manifestations, in infancy or early childhood. Aberrant chloride and sodium transport due to decreased CFTR activity causes lowered apical surface fluid levels in the lungs, which leads to "sticky" mucous and lower airway obstruction.
  • Subjects having CF or CF-like disease suffer from frequent infections due to inability to clear mucous. Local inflammatory mediators try to clear the infection but have difficulty. The triad of inflammation, infection and obstruction leads to progressive destruction of the lung parenchyma. Eventually, many subjects having CF or CF-like disease die in their late 30' s due to respiratory failure.
  • Treatments for the pulmonary manifestations of CF or CF-like disease include: antibiotics (oral, inhaled and intravenous), CFTR modulators (including CFTR potentiators), DNase, chest physiotherapy to loosen secretions and anti-inflammatory therapeutics.
  • Treatment of the gastrointestinal manifestations includes supplemental gut soluble vitamins, high calorie diet and oral pancreatic enzymes.
  • Subjects who develop diabetes are treated with insulin injections or an insulin pump. At the end stage, patients may benefit from lung transplant. Lung transplant may be combined with liver and/or pancreatic transplant.
  • the average life expectancy for subjects having CF or CF-like disease is 37 years of age
  • Methods and compositions discussed herein provide for the treatment and prevention of Cystic Fibrosis (CF) and CF-like disease.
  • the approach described herein aims to restore CFTR channel function, restore chloride, bicarbonate and/or sodium balance, and/or decrease mucous viscosity within the lungs, airways, gastrointestinal tract and reproductive tract.
  • CFTR modulators both approved and in development improve the functioning of mutant CFTR. These therapeutics improve CFTR functioning but do not return functionality to wild type levels. The approach described herein is expected to restore CFTR function through complete correction of the gene.
  • Gene therapy approaches are in development that deliver the CFTR channel gene to the lungs of CF or CF-like disease patients.
  • gene therapy may require constant readministration over the course of the lifetime of a subject due to high cell turnover in target epithelial cells.
  • the approach described herein is expected to restore CFTR function and/or ameliorate SCNN1A disinhibition permanently through one, two or several doses.
  • the CFTR gene encodes a 180-kDA cAMP-gated chloride (C1-) channel.
  • the channel has six transmembrane spanning domains and is expressed by epithelial cells, lymphocytes and cardiac myocytes.
  • the CFTR regulates the viscosity of mucous through its activity in the epithelial cells of the lungs, gastrointestinal tract and reproductive tract. Mutations in the CFTR result in decreased CFTR activity. Decreased CFTR activity can lead to aberrant ion transport, which gives rise to various disease symptoms in the lungs and other tissues, such as
  • CFTR mutations will ameliorate or cure lung, gastrointestinal and/or reproductive symptoms of CF or CF-like disease.
  • the SCNN1A gene encodes the alpha subunit of the epithelial sodium channel (ENaC).
  • ENaC epithelial sodium channel
  • the channel comprised of alpha, beta and gamma subunits, regulates sodium transport into epithelial cells, including the epithelium of the lungs, sweat glands and kidneys.
  • Mutations in the SCNN1A gene (e.g. Vail 14ILE) have been shown to cause CF-like disease, characterized by pulmonary disease, including bronchiectasis. Mutations in SCNN1A also cause
  • pseudohypoaldosteronism a severe disease of the kidney.
  • Pseudohypoaldosteronism is due to defective sodium transport within kidney epithelial cells; it is not caused by defective sodium transport in other tissues.
  • the methods described herein include the targeted knockout of SCNN1A in the lung, gastrointestinal tract and/or reproductive tract. The methods described herein will not target kidney epithelium and will avoid the negative consequences of SCNN1A mutations within the kidney epithelium.
  • One mutation in the SCNN1A gene, a 1477T>G substitution (W493R) has been identified in subjects who also have a mutation in CFTR. This mutation is associated with a severe CF or CF-like disease phenotype, including severe
  • ENaC overactivity can lead to further reduction in viscosity of mucous in CF or CF-like disease subjects, as more sodium is absorbed at the apical surface of epithelial cells, followed by increased fluid absorption from the mucous layer within the lung (Baker et al., 2012; Medicine & Science in Sports and Exercise 44(12): 2315-2321). Increased fluid absorption from the mucous layer reduces mucous viscosity.
  • Inhibition of ENaC through SCNN1A knockout and/or knockdown in subjects with CF or CF-like disease can ameliorate the symptoms of CF or CF-like disease.
  • CFTR gene also known as ABC35, ATP-binding cassette sub-family C, member 7, CFTR/MRP, dJ760C5.1 , MRP 7 and TNR-CFTR
  • CFTR gene leading to CF and/or CF-like disease can be described based on their target position in the CFTR protein.
  • the target position is F508, e.g., F508del (also sometimes referred to herein as "AF508"), in the CFTR protein, which corresponds to a deletion of three nucleotides c.l521_1523delCTT in the CFTR gene (e.g., c.l521_1523delCTT (p.Phe508delPhe)).
  • the target position is G551, e.g., G551D, in the CFTR protein, which corresponds to c. l652G>A in the CFTR gene.
  • the target position is G542, e.g., G542X, in the CFTR protein, which corresponds to c. l624G>T in the CFTR gene.
  • the target position is N1303, e.g., N1303K, in the CFTR protein, which corresponds to c.3909C>G in the CFTR gene.
  • the target position is Rl 17, e.g., Rl 17H, in the CFTR protein, which corresponds to c.350G>A in the CFTR gene.
  • the target position is W1282, e.g., W1282X, in the CFTR protein, which corresponds to c.
  • the target position is R553, e.g., R553X, in the CFTR protein, which corresponds to c.l657C>T in the CFTR gene.
  • the target position is c.3717+12191, also known as c.3849+10kb, which corresponds to 3717+12191C>T in the CFTR gene.
  • the target position is c.2657+5, also known as c.2789+5, which corresponds to 2657+5G>A in the CFTR gene.
  • the target position is c.3140-26, also known as c.3272-26, which corresponds to c.3140-26A>G in the CFTR gene.
  • SCNNIA gene also known as sodium channel, non-voltage-gated 1 alpha subunit; amiloride- sensitive epithelial sodium channel alpha subunit; BESC2; ENaCa; SCNEA; SCNN1;
  • ENaCalpha to treat or prevent CF or CF-like disease, by targeting the SCNNIA gene, e.g., the non-coding or coding regions, e.g., a promoter region, or a transcribed sequence, e.g., intronic or exonic sequence.
  • the target position is VI 14, which corresponds to VI 141 in the SCNNIA gene.
  • SCNNIA encodes an epithelial sodium channel, ENaC, that is negatively regulated by CFTR. In subjects with CFTR mutations, knocking out or knocking down the SCNNIA gene in certain cells will reduce or reverse the effect of defective CFTR. In subjects with no CFTR mutations but CF-like disease caused by SCNNIA mutations or other mechanisms, knocking out or knocking down the SCNNIA gene in certain cells will improve the viscosity of mucous and ameliorate disease.
  • Methods and compositions disclosed herein provide a number of approaches for treating or preventing CF and/or CF-like disease. As is discussed in more detail below, methods described herein provide for treating or preventing CF or CF-like disease by correcting a target position in the CFTR gene to provide corrected, or functional, e.g., wild type, CFTR. Other methods described herein allow for treating or preventing CF or CF-like disease by inducing or introducing a mutation that reduces the level of functional SCNNIA gene product.
  • methods and compositions discussed herein provide for the correction of the underlying cause of CF or CF-like disease, e.g., the correction of a mutation at a target position in the CFTR gene, e.g., correction of a mutation in the CFTR gene that corresponds to amino acid position 508, e.g., an F508 deletion (F508del), in CFTR protein.
  • the correction of the underlying cause of CF or CF-like disease e.g., the correction of a mutation at a target position in the CFTR gene, e.g., correction of a mutation in the CFTR gene that corresponds to amino acid position 508, e.g., an F508 deletion (F508del), in CFTR protein.
  • F508del an F508 deletion
  • CF target mutant position refers to a target position in the CFTR gene, which, if mutated, can result in a mutant protein and give rise to CF or CF-like disease.
  • the target position comprises one, two, or three nucleotides.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at F508, e.g., F508del.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at G551, e.g., G551D.
  • the CF target mutant mutant position refers to a target position in the CFTR gene, which, if mutated, can result in a mutant protein and give rise to CF or CF-like disease.
  • the target position comprises one, two, or three nucleotides.
  • the CF target mutant position is a position in the CFTR gene at
  • the 5535.1 position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at G542, e.g., G542X, in the CFTR protein, which corresponds to c. l624G>T in the CFTR gene.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at N1303, e.g., N1303K, in the CFTR protein, which corresponds to c.3909C>G in the CFTR gene.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at Rl 17, e.g., Rl 17H, in the CFTR protein, which corresponds to c.350G>A in the CFTR gene.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at W1282, e.g., W1282X, in the CFTR protein, which corresponds to c. c.3846G>A in the CFTR gene.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at R553, e.g., R553X, in the CFTR protein, which corresponds to c. l657C>T in the CFTR gene.
  • the CF target mutant position is c.3717+12191, also known as c.3849+10kb, which corresponds to 3717+12191C>T in the CFTR gene.
  • the CF target mutant position is c.2657+5, also known as c.2789+5, which corresponds to 2657+5G>A in the CFTR gene.
  • the CF target mutant position is c.3140-26, also known as c.3272-26, which corresponds to c.3140-26 A>G in the CFTR gene.
  • the CF target mutant position is a position in the SCNN1A gene at which a change can give rise to a mutant protein having a mutation at VI 14, which corresponds to VI 141 in the SCNN1A gene.
  • an F508 mutant protein e.g., a F508del mutant protein
  • a G551 mutant protein e.g., a G551D mutant protein
  • a G542 mutant protein e.g., G542X mutant protein
  • a N1303 mutant protein e.g., a N1303K mutant protein
  • a Rl 17 mutant protein e.g., an Rl 17H mutant protein
  • a W1282 mutant protein e.g., a W1282X mutant protein
  • an R553 mutant protein e.g., an R553X mutant protein
  • a c.2789+5bp intronic mutant e.g., a c.2789+5bp G>A mutant
  • a c.3272-26bp intronic mutant e.g., a c.3272-26bp A>G mutant
  • a mutation at a CF target mutant position is corrected by homology directed repair (HDR), as described herein.
  • HDR homology directed repair
  • SCNNIA gene also known as sodium channel, non-voltage-gated 1 alpha subunit
  • methods and compositions discussed herein may be used to alter the SCNNIA gene (also known as sodium channel, non-voltage-gated 1 alpha subunit) to treat or prevent CF or CF-like disease, by targeting the SCNNIA gene, e.g., the non-coding or coding regions, e.g., a promoter region, or a transcribed sequence, e.g., intronic or exonic sequence.
  • SCNNIA encodes an epithelial sodium channel that is negatively regulated by CFTR. By knocking out the SCNNIA gene in certain cells, the effect of defective CFTR can be reduced or reversed.
  • the methods and compositions discussed herein may be used to alter the SCNNIA gene to treat or prevent CF or CF-like disease by targeting the coding sequence of the SCNNIA gene.
  • the gene e.g., the coding sequence of the SCNNIA gene
  • is targeted to knockout the gene e.g., to eliminate expression of the gene, e.g., to knockout one or both alleles of the SCNNIA gene, e.g., by induction of an alteration comprising a deletion or mutation in the SCNNIA gene.
  • the method provides an alteration that comprises an insertion or deletion.
  • coding region e.g., an early coding region, of the SCNNIA gene
  • coding region is targeted for alteration and knockout.
  • an early coding region of the SCNNIA gene is targeted to knockout the SCNNIA gene.
  • targeting affects both alleles of the SCNNIA gene.
  • targeting affects one allele of the SCNNIA gene.
  • a targeted knockout approach reduces or eliminates expression of functional SCNNIA gene product.
  • the method provides an alteration in the SCNNIA gene that comprises an insertion or deletion.
  • the methods and compositions discussed herein may be used to alter the SCNNIA gene to treat or prevent CF or CF-like disease by targeting non-coding sequence of the SCNNIA gene, e.g., promoter, an enhancer, an intron, 3'UTR, and/or polyadenylation signal.
  • the gene e.g., the non-coding sequence of the SCNNIA gene
  • is targeted to knockout the gene e.g., to eliminate expression of the gene, e.g., to knockout one or both alleles of the SCNNIA gene, e.g., by induction of an alteration comprising a deletion or mutation in the
  • the method provides an alteration that comprises an insertion or deletion.
  • a targeted knockout approach is mediated by non-homologous end joining (NHEJ) using a CRISPR/Cas system comprising an enzymatically active Cas9 (eaCas9).
  • NHEJ non-homologous end joining
  • eaCas9 enzymatically active Cas9
  • CF target knockout position refers to a position in the SCNNIA gene, which if altered by NHEJ-mediated alteration, results in alleviation of a symptom of CF or CF- like disease.
  • the alteration results in reduction or elimination of expression of functional SCNNIA gene product.
  • the position is in the SCNNIA coding region, e.g., an early coding region.
  • the promoter region of the SCNNIA gene is targeted to knock down the expression of the SCNNIA gene. This type of alteration is also sometimes referred to as “knocking down" the SCNNIA gene. While not wishing to be bound by theory, in an
  • a targeted knockdown approach is mediated by a CRISPR/Cas system comprising a Cas9 molecule, e.g., an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain or chromatin modifying protein), as described herein.
  • the SCNNIA gene is targeted to alter (e.g., to block, reduce, or decrease) the transcription of the SCNNIA gene.
  • the SCNNIA gene is targeted to alter the chromatin structure (e.g., one or more histone and/or DNA modifications) of the SCNNIA gene.
  • a CF targe knockdown position is targeted by genome editing using the CRISPR/Cas9 system.
  • one or more gRNA molecules comprising a targeting domain are configured to target an enzymatically inactive Cas9 (eiCas9) or an eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain), sufficiently close to a CF target knockdown position to reduce, decrease or repress expression of the SCNNIA gene.
  • eiCas9 enzymatically inactive Cas9
  • an eiCas9 fusion protein e.g., an eiCas9 fused to a transcription repressor domain
  • CF target knockdown position refers to a position in the SCNNIA gene, which if targeted, e.g., by an eiCas9 molecule or an eiCas9 fusion described herein, results in reduction or elimination of expression of functional SCNNIA gene product.
  • the transcription of the SCNNIA gene is reduced or eliminated.
  • the chromatin structure of the SCNNIA gene is altered.
  • CF target knockin position refers to a sequence, which if modified by the insertion of CFTR sequence, results in an optimization of CFTR activity, e.g., by resulting in a CFTR sequence that encodes a protein having wild type activity.
  • exemplary CF target knockin position include: CFTR sequence within intron 2, into which, e.g., can be introduced CFTR sequence that codes for CFTR exons 3-27; and sequence within CFTR intron 10, into which sequence that codes for CFTR exons 11-27 can be introduced.
  • a CF target knockin position includes CFTR intronic sequence between a second and a third exon (e.g., intron 2), and CFTR sequence encoding the third exon through the final exon (exon 27), is introduced, resulting in a CFTR sequence that is free of one or more cryptic splice sites and that encodes a CFTR protein having wild type activity.
  • a CF target knockin position is a position which is upstream of a mutation, or upsteam of an intron having a mutation, and introduction of wild-type CFTR sequence results in a CFTR sequence that is free of the mutation.
  • the CF target knockin position is in CFTR intronic sequence: between exon2 and exon 3; or between exon 10 and exon 11.
  • the resulting CFTR sequence comprises subject sequence upstream from the CF target knockin position and newly introduced sequence downstream from the CF target knockin position, which taken together, encode a CFTR protein having wild type activity.
  • the point of insertion is 3' to a splice donor site and 5' from a splice acceptor site.
  • CFTR sequence encoding exons 3-27 is inserted under control of the promoter, e.g., at the transcription start site.
  • CFTR sequence introduced can exclude introns, e.g., a sequence encoding exons, but without introns, is inserted, e.g., CFTR CDNA sequence is introduced.
  • CF target position refers to a CF target mutant position, CF target knockout position, CF target knockdown position, and/or CF target knockin position, as described herein.
  • a gRNA molecule e.g., an isolated or non-naturally occurring gRNA molecule, comprising a targeting domain which is complementary with a target domain from the CFTR gene or SCNNIA gene.
  • the targeting domain of the gRNA molecule is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a CF target position in the CFTR gene or SCNNIA gene to allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of a CF target position in the CFTR gene or SCNNIA gene.
  • a cleavage event e.g., a double strand break or a single strand break
  • the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of a CF target position.
  • the break e.g., a double strand or single strand break, can be positioned upstream or downstream of a CF target position in the CFTR gene or SCNN1A gene.
  • a second gRNA molecule comprising a second targeting domain is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to the CF target position in the CFTR gene or SCNN1A gene, to allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of the CF target position in the CFTR gene or SCNN1A gene, either alone or in combination with the break positioned by said first gRNA molecule.
  • a cleavage event e.g., a double strand break or a single strand break
  • the targeting domains of the first and second gRNA molecules are configured such that a cleavage event, e.g., a double strand or single strand break, is positioned, independently for each of the gRNA molecules, within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position.
  • the breaks e.g., double strand or single strand breaks, are positioned on both sides of a nucleotide of a CF target position in the CFTR gene or SCNN1A gene.
  • the breaks e.g., double strand or single strand breaks
  • the breaks are positioned on one side, e.g., upstream or downstream, of a nucleotide of a CF target position in the CFTR gene or SCNN1A gene.
  • a single strand break is accompanied by an additional single strand break, positioned by a second gRNA molecule, as discussed below.
  • the targeting domains are configured such that a cleavage event, e.g., the two single strand breaks, are positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of a CF target position.
  • the first and second gRNA molecules are configured such, that when guiding a Cas9 molecule, e.g., a Cas9 nickase, a single strand break will be accompanied by an additional single strand break, positioned by a second gRNA, sufficiently close to one another to result in alteration of a CF target position in the CFTR gene or SCNN1A gene.
  • the first and second gRNA molecules are configured such that a single strand break positioned by said second gRNA is within 10, 20, 30, 40, or 50 nucleotides of the break positioned by said first gRNA molecule, e.g., when the Cas9 molecule is a nickase.
  • the two gRNA molecules are configured to position
  • 5535.1 cuts at the same position, or within a few nucleotides of one another, on different strands, e.g., essentially mimicking a double strand break.
  • a double strand break can be accompanied by an additional double strand break, positioned by a second gRNA molecule, as is discussed below.
  • the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of a CF target position in the CFTR gene or SCNNIA gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position; and the targeting domain of a second gRNA molecule is configured such that a double strand break is positioned downstream of a CF target position in the CFTR gene or SCNNIA gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position.
  • a double strand break can be accompanied by two additional single strand breaks, positioned by a second gRNA molecule and a third gRNA molecule.
  • the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of a CF target position in the CFTR gene or SCNNIA gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position; and the targeting domains of a second and third gRNA molecule are configured such that two single strand breaks are positioned downstream of a CF target position in the CFTR gene or SCNNIA gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position.
  • a first and second single strand breaks can be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule.
  • the targeting domain of a first and second gRNA molecule are configured such that two single strand breaks are positioned upstream of a CF target position in the CFTR gene or SCNNIA gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position; and the targeting domains of a third and fourth gRNA molecule are configured such that two single strand breaks are positioned downstream of a CF target position in the CFTR gene or SCNNIA gene, e.g.,
  • two double stranded breaks e.g., flanking a CF target position, e.g., a mutation (e.g., to remove a piece of DNA, e.g., to introduce a deletion mutation) or to create more than one indel in the gene, e.g., in a coding region, e.g., an early coding region, (3) one double stranded break and two paired nicks flanking a CF target position, e.g., a mutation (e.g., to remove a piece of DNA, e.g., to introduce a deletion mutation) or (4) four single stranded breaks, two on each side of a position, e.g., a mutation, that they are targeting the same CF target position. It is further contemplated herein that multiple gRNAs may be used to target more than
  • the targeting domain of the first gRNA molecule and the targeting domain of the second gRNA molecules are complementary to opposite strands of the target nucleic acid molecule.
  • the gRNA molecule and the second gRNA molecule are configured such that the PAMs are oriented outward.
  • the targeting domain of a gRNA molecule is configured to avoid unwanted target chromosome elements, such as repeat elements, e.g., Alu repeats, in the target domain.
  • the gRNA molecule may be a first, second, third and/or fourth gRNA molecule, as described herein.
  • the targeting domain of a gRNA molecule is configured to position a cleavage event sufficiently far from a preselected nucleotide, e.g., the nucleotide of a coding region, such that the nucleotide is not altered.
  • the targeting domain of a gRNA molecule is configured to position an intronic cleavage event sufficiently far from an intron/exon border, or naturally occurring splice signal, to avoid alteration of the exonic sequence or unwanted splicing events.
  • the gRNA molecule may be a first, second, third and/or fourth gRNA molecule, as described herein.
  • a CF target mutant position e.g., a deletion in the CFTR gene, e.g., at F508, e.g., F508del
  • the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 1A-1E, lOA-lOC, 11A-11E or 12A-12C.
  • the targeting domain is independently selected
  • the targeting domain is independently selected from:
  • each guide RNA is independently selected from one of Tables 1A-1E, lOA-lOC, 11A-11E or 12A-12C.
  • a CF target mutant position e.g., a mutation in the CFTR gene, e.g., at G551, e.g., G551D
  • the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 2A-2E, 16A-16D, 17A-17E, or 18A-18C.
  • the targeting domain is independently selected from those in Tables 2A-2E, 16A-16D, 17A-17E, or 18A-18C.
  • the targeting domain is independently selected from:
  • more than one gRNA is used to position breaks, e.g., two single stranded breaks or two double stranded breaks, or a combination of single strand and double strand breaks, e.g., to create one or more indels, in the target nucleic acid sequence.
  • the targeting domain of each guide RNA is independently selected from one of Tables 2A-2E, 16A-16D, 17A-17E, or 18A-18C.
  • a mutation in the CFTR gene e.g., at N1303, e.g., N1303K
  • the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 19A-19D, 20A-20E, or 21A-21B.
  • the targeting domain is independently selected from those in Tables 19A- 19D, 20A-20E, or 21A-21B.
  • the targeting domain is selected from:
  • each guide RNA is independently selected from one of Tables 19A-19D, 20A- 20E, or 21A-21B.
  • a mutation in the CFTR gene e.g., at W1282, e.g., W1282X
  • the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 28A-28D, 29A-29E, or 30A-30B.
  • the targeting domain is independently selected from those in Tables 28A- 28D, 29A-29E, or 30A-30B.
  • the targeting domain is selected from:
  • GGAAAAAUCCAGAUCGA SEQ ID NO: 2994
  • each guide RNA is independently selected from one of Tables 28A-28D, 29A- 29E, or 30A-30B.
  • a mutation in the CFTR gene e.g., at R553, e.g., R553X
  • the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 25A-25D, 26A-26E, or 27A-27D.
  • the targeting domain is independently selected from those in Tables 25A-25D, 26A-26E, or 27A-27D.
  • the targeting domain is selected from:
  • GCUUUAUAUUCUGUUUC (SEQ ID NO: 466);
  • GGUGAAUAACUAAUUAU SEQ ID NO: 465
  • each guide RNA is independently selected from one of Tables 25A-25D, 26A- 26E, or 27A-27D.
  • a mutation in the CFTR gene e.g., at 371 7+1 21 91 C>T, also known as 3849+10kbC>T is targeted, e.g., for correction.
  • the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 34A-34D, 35A-35D, or 36A-36D. In some embodiments, the targeting domain is independently selected from those
  • the targeting domain is selected from:
  • each guide RNA is independently selected from one of Tables 34A-34D, 35A- 35D, or 36A-36D.
  • a mutation in the CFTR gene e.g., at 2657+5G>A, also known as 2789+5G>A is targeted, e.g., for correction.
  • the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 4A-4D, 5A-5E, or 6A-6C.
  • the targeting domain is independently selected from those in Tables 4A-4D, 5A-5E, or 6A-6C.
  • the targeting domain is selected from:
  • GGAAUAUUCACUUUCCA (SEQ ID NO: 938);
  • each guide RNA is independently selected from one of Tables 4A-4D, 5A-5E, or 6A- 6C.
  • a mutation in the CFTR gene e.g., at 3140-26A>G, also known as 3272-26A>G
  • the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 7A-7D, 8A-8E, or 9A-9B.
  • the targeting domain is independently selected from those in Tables 7A-7D, 8A-8E, or 9A-9B.
  • the targeting domain is selected from:
  • each guide RNA is independently selected from one of Tables 7A-7D, 8A-8E, or 9A- 9B.
  • a CF target knockout position e.g., a position in the coding region, e.g., the early coding region, of the SCNN1A gene is targeted, e.g., for knockout.
  • the targeting domain comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 3A-3D, 43A-43E, 44A-44G, or 45A-45E.
  • the targeting domain is
  • the targeting domain is independently selected from:
  • GCCCUCCACAGUCCACUCCA (SEQ ID NO: 499);
  • each guide RNA is independently selected from one of Tables 3A-3D, 43A-43E, 44A-44G, or 45A-45E.
  • the targeting domain of the gRNA molecule is configured to target an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain), sufficiently close to a SCNNIA transcription start site (TSS) to reduce (e.g., block) transcription, e.g., transcription initiation or elongation, binding of one or more transcription enhancers or activators, and/or RNA polymerase.
  • eiCas9 enzymatically inactive Cas9
  • an eiCas9 fusion protein e.g., an eiCas9 fused to a transcription repressor domain
  • TSS transcription start site
  • the targeting domain is configured to target between 1000 bp upstream and 1000 bp downstream (e.g., between 500 bp upstream and 1000 bp downstream, between 1000 bp upstream and 500 bp downstream, between 500 bp upstream and 500 bp downstream, within 500 bp upstream, or within 500 bp downstream) of the TSS of the SCNNIA gene.
  • One or more gRNAs may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
  • the targeting domain when the SCNNIA promoter region is targeted, e.g., for knockdown, can comprise a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 46A-46E, 47A- 47G, or 48A-48E. In an embodiment, the targeting domain is independently selected from those in Tables 46A-46E, 47A-47G, or 48A-48E.
  • the targeting domain is independently selected from those in Table 46A. In an embodiment, the targeting domain is independently selected from those in Table
  • the targeting domain is independently selected from those in Table 48A.
  • the targeting domain for each guide RNA is independently selected from one of
  • the gRNA e.g., a gRNA comprising a targeting domain, which is complementary with the CFTR gene or SCNN1A gene, is a modular gRNA.
  • a gRNA comprising a targeting domain which is complementary with the CFTR gene or SCNN1A gene
  • the gRNA is a unimolecular or chimeric gRNA.
  • the targeting domain which is complementary with a target domain from the CF target position in the CFTR gene or SCNN1A gene is 16 nucleotides or more in length. In an embodiment, the targeting domain is 16 nucleotides in length. In an embodiment, the targeting domain is 17 nucleotides in length. In another embodiment, the targeting domain is 18 nucleotides in length. In still another embodiment, the targeting domain is 19 nucleotides in length. In still another embodiment, the targeting domain is 20 nucleotides in length. In still another embodiment, the targeting domain is 21 nucleotides in length. In still another embodiment, the targeting domain is 22 nucleotides in length. In still another embodiment, the targeting domain is 23 nucleotides in length. In still another embodiment, the targeting domain is 24 nucleotides in length. In still another embodiment, the targeting domain is 25 nucleotides in length. In still another embodiment, the targeting domain is 26 nucleotides in length.
  • the targeting domain comprises 16 nucleotides.
  • the targeting domain comprises 17 nucleotides.
  • the targeting domain comprises 18 nucleotides.
  • the targeting domain comprises 19 nucleotides.
  • the targeting domain comprises 20 nucleotides.
  • the targeting domain comprises 21 nucleotides.
  • the targeting domain comprises 22 nucleotides.
  • the targeting domain comprises 23 nucleotides.
  • the targeting domain comprises 24 nucleotides.
  • the targeting domain comprises 25 nucleotides.
  • the targeting domain comprises 26 nucleotides.
  • a gRNA as described herein may comprise from 5' to 3': a targeting domain
  • proximal domain and tail domain are taken together as a single domain.
  • a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
  • a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
  • a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 35 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
  • a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
  • a cleavage event e.g., a double strand or single strand break
  • the Cas9 molecule may be an enzymatically active Cas9 (eaCas9) molecule, e.g., an eaCas9 molecule that forms a double strand break in a target nucleic acid or an eaCas9 molecule forms a single strand break in a target nucleic acid (e.g., a nickase molecule).
  • eaCas9 enzymatically active Cas9
  • the eaCas9 molecule catalyzes a double strand break.
  • the eaCas9 molecule comprises HNH-like domain cleavage activity but has no, or no significant, N-terminal RuvC-like domain cleavage activity.
  • the eaCas9 molecule is an HNH-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at D10, e.g., D10A.
  • the eaCas9 molecule comprises N-
  • the eaCas9 molecule is an N-terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at H840, e.g., H840A.
  • the eaCas9 molecule is an N-terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at N863, e.g., an N863A mutation.
  • a single strand break is formed in the strand of the target nucleic acid to which the targeting domain of said gRNA is complementary. In another embodiment, a single strand break is formed in the strand of the target nucleic acid other than the strand to which the targeting domain of said gRNA is complementary.
  • nucleic acid e.g., an isolated or non-naturally occurring nucleic acid, e.g., DNA, that comprises (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain, e.g., with a CF target position, in the CFTR gene or SCNNIA gene as disclosed herein.
  • the nucleic acid encodes a gRNA molecule, e.g., a first gRNA molecule, comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a CF target position in the CFTR gene or SCNNIA gene to allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of a CF target position in the CFTR gene or SCNNIA gene.
  • a gRNA molecule e.g., a first gRNA molecule
  • a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a CF target position in the CFTR gene or SCNNIA gene to allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of a CF target position in the CFTR gene or SCNNIA gene
  • the nucleic acid encodes a gRNA molecule, e.g., a first gRNA molecule, comprising a targeting domain configured to target an enzymatically inactive Cas9
  • eiCas9 molecule or an eiCas9 fustion protein (e.g., an eiCas9 fused to a transcription repressor domain), sufficiently close to a CF knockdown target position to reduce, decrease or repress expression of the SCNNIA gene.
  • the nucleic acid encodes a gRNA molecule, e.g., the first gRNA molecule, comprising a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence as described herein, e.g., from any one of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D
  • the nucleic acid encodes a gRNA molecule comprising a targeting domain as described herein, e.g., that is selected from those in Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, 10A- 10C, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-
  • the nucleic acid encodes a modular gRNA, e.g., one or more nucleic acids encode a modular gRNA.
  • the nucleic acid encodes a chimeric gRNA.
  • the nucleic acid may encode a gRNA, e.g., the first gRNA molecule, comprising a targeting domain comprising 16 nucleotides or more in length.
  • the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 16 nucleotides in length.
  • the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 17 nucleotides in length. In yet another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 18 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 19 nucleotides in length.
  • the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 20 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 21 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 22 nucleotides in length.
  • the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 23 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 24 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 25 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 26 nucleotides in length.
  • the targeting domain comprises 16 nucleotides.
  • the targeting domain comprises 17 nucleotides.
  • the targeting domain comprises 18 nucleotides.
  • the targeting domain comprises 19 nucleotides.
  • the targeting domain comprises 20 nucleotides.
  • the targeting domain comprises 21 nucleotides.
  • the targeting domain comprises 22 nucleotides.
  • the targeting domain comprises 23 nucleotides.
  • the targeting domain comprises 24 nucleotides.
  • the targeting domain comprises 25 nucleotides.
  • the targeting domain comprises 26 nucleotides.
  • a nucleic acid encodes a gRNA comprising from
  • proximal domain and tail domain are taken together as a single domain.
  • a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 35 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • a nucleic acid encodes a gRNA comprising e.g., the first gRNA molecule, a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • a nucleic acid comprises (a) a sequence that encodes a gRNA molecule, e.g., the first gRNA molecule, comprising a targeting domain that is complementary with a target domain in the CFTR gene or SCNN1A gene as disclosed herein, and further comprising (b) a sequence that encodes a Cas9 molecule.
  • the Cas9 molecule may be a nickase molecule, an enzymatically activating Cas9
  • eaCas9 molecule e.g., an eaCas9 molecule that forms a double strand break in a target nucleic acid and/or an eaCas9 molecule forms a single strand break in a target nucleic acid.
  • a single strand break is formed in the strand of the target nucleic acid to which the targeting domain of said gRNA is complementary.
  • a single strand break is formed in the strand of the target nucleic acid other than the strand to which to which the targeting domain of said gRNA is complementary.
  • the eaCas9 molecule catalyzes a double strand break.
  • the eaCas9 molecule comprises HNH-like domain cleavage activity but has no, or no significant, N-terminal RuvC-like domain cleavage activity.
  • the said eaCas9 molecule is an HNH-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at D10, e.g., D10A.
  • the eaCas9 molecule comprises N-terminal RuvC-like domain cleavage activity but has no, or no significant, HNH-like domain cleavage activity.
  • the eaCas9 molecule is an N- terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at H840, e.g., H840A.
  • the eaCas9 molecule is an N-terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at N863, e.g., an N863A mutation.
  • a nucleic acid disclosed herein may comprise (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the CFTR and/or SCNN1A gene as disclosed herein; (b) a sequence that encodes a Cas9 molecule.
  • the Cas9 molecule is an enzymatically active Cas9 (eaCas9) molecule.
  • the Cas9 molecule is an enzymatically inactive Cas9 (eiCas9) molecule or a modified eiCas9 molecule, e.g., the eiCas9 molecule is fused to Kriippel-associated box (KRAB) to generate an eiCas9-KRAB fusion protein molecule.
  • eiCas9 enzymatically inactive Cas9
  • KRAB Kriippel-associated box
  • a nucleic acid disclosed herein may comprise (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the CFTR gene or SCNN1A gene as disclosed herein; (b) a sequence that encodes a Cas9 molecule; and
  • 5535.1 further may comprise (c)(i) a sequence that encodes a second gRNA molecule described herein having a targeting domain that is complementary to a second target domain of the CFTR gene or SCNNIA gene, and optionally, (c)(ii) a sequence that encodes a third gRNA molecule described herein having a targeting domain that is complementary to a third target domain of the CFTR gene or SCNNIA gene; and optionally, (c)(iii) a sequence that encodes a fourth gRNA molecule described herein having a targeting domain that is complementary to a fourth target domain of the CFTR gene or SCNNIA gene.
  • a nucleic acid encodes a second gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a CF target position in the CFTR gene or SCNNIA gene, to allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of a CF target position in the CFTR gene or SCNNIA gene, either alone or in combination with the break positioned by said first gRNA molecule.
  • a cleavage event e.g., a double strand break or a single strand break
  • a nucleic acid encodes a second gRNA molecule comprising a targeting domain configured to target an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fustion protein (e.g., an eiCas9 fused to a transcription repressor domain), sufficiently close to a CF knockdown target position to reduce, decrease or repress expression of the SCNNIA gene.
  • eiCas9 enzymatically inactive Cas9
  • eiCas9 fustion protein e.g., an eiCas9 fused to a transcription repressor domain
  • a nucleic acid encodes a third gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a CF target position in the CFTR gene or SCNNIA gene to allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of a CF target position in the CFTR gene or SCNNIA gene, either alone or in combination with the break positioned by the first and/or second gRNA molecule.
  • a cleavage event e.g., a double strand break or a single strand break
  • a nucleic acid encodes a third gRNA molecule comprising a targeting domain configured to target an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fustion protein (e.g., an eiCas9 fused to a transcription repressor domain), sufficiently close to a CF knockdown target position to reduce, decrease or repress expression of the SCNNIA gene.
  • eiCas9 enzymatically inactive Cas9
  • eiCas9 fustion protein e.g., an eiCas9 fused to a transcription repressor domain
  • a nucleic acid encodes a fourth gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a CF target position in the CFTR gene or SCNNIA gene to
  • 5535.1 allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of a CF target position in the CFTR gene or SCNN1A gene, either alone or in combination with the break positioned by the first gRNA molecule, the second gRNA molecule and/or the third gRNA molecule.
  • the nucleic acid encodes a second gRNA molecule.
  • the second gRNA is selected to target the same CF target position as the first gRNA molecule.
  • the nucleic acid may encode a third gRNA, and further optionally, the nucleic acid may encode a fourth gRNA molecule.
  • the third gRNA molecule and the fourth gRNA molecule are selected to target the same CF target position as the first and second gRNA molecules.
  • the nucleic acid encodes a second gRNA molecule comprising a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from one of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A- 14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D,
  • the nucleic acid encodes a second gRNA molecule comprising a targeting domain selected from those in Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42
  • the third and fourth gRNA molecules may independently comprise a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from one of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A- 14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34A-34
  • the third and fourth gRNA molecules may independently comprise a targeting domain selected from those in Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A- 20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A- 29E, 30A-30B, 31A-
  • the nucleic acid encodes a second gRNA which is a modular gRNA, e.g., wherein one or more nucleic acid molecules encode a modular gRNA.
  • the nucleic acid encoding a second gRNA is a chimeric gRNA.
  • the third and fourth gRNA may be a modular gRNA or a chimeric gRNA.
  • a nucleic acid may encode a second, a third, and/or a fourth gRNA, each independently, comprising a targeting domain comprising 16 nucleotides or more in length.
  • the nucleic acid encodes a second gRNA comprising a targeting domain that is 16 nucleotides in length.
  • the nucleic acid encodes a second gRNA comprising a targeting domain that is 17 nucleotides in length.
  • the nucleic acid encodes a second gRNA comprising a targeting domain that is 18 nucleotides in length.
  • the nucleic acid encodes a second gRNA comprising a targeting domain that is 19 nucleotides in length.
  • the nucleic acid encodes a second gRNA comprising a targeting domain that is 20 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 21 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 22 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 23 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 24 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 25 nucleotides in length. In still another another
  • the nucleic acid encodes a second gRNA comprising a targeting domain that is 26 nucleotides in length.
  • the targeting domain comprises 16 nucleotides.
  • the targeting domain comprises 17 nucleotides.
  • the targeting domain comprises 18 nucleotides.
  • the targeting domain comprises 19 nucleotides.
  • the targeting domain comprises 20 nucleotides.
  • the targeting domain comprises 21 nucleotides.
  • the targeting domain comprises 22 nucleotides.
  • the targeting domain comprises 23 nucleotides.
  • the targeting domain comprises 24 nucleotides.
  • the targeting domain comprises 25 nucleotides.
  • the targeting domain comprises 26 nucleotides.
  • a nucleic acid encodes a second, a third, and/or
  • a targeting domain comprising a "core domain", and optionally a "secondary domain”
  • a first complementarity domain comprising a linking domain; a second complementarity domain; a proximal domain; and a tail domain.
  • the proximal domain and tail domain are taken together as a single domain.
  • a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
  • a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
  • a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 35 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
  • a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
  • the nucleic acid when the CFTR gene is corrected by HDR, the nucleic acid encodes
  • a sequence that encodes a Cas9 molecule optionally, (c)(i) a sequence that encodes a second gRNA molecule described herein having a targeting domain that is complementary to a second target domain of the CFTR gene, and further optionally, (c)(ii) a sequence that encodes a third gRNA molecule described herein having a targeting domain that is complementary to a third target domain of the CFTR gene; and still further optionally, (c)(iii) a sequence that encodes a fourth gRNA molecule described herein having a targeting domain that is complementary to a fourth target domain of the CFTR gene; and further may comprise (d) a template nucleic acid, e.g., a template nucleic acid described herein.
  • the template nucleic acid is a single stranded nucleic acid. In another embodiment, the template nucleic acid is a double stranded nucleic acid. In an embodiment, the template nucleic acid comprises a nucleotide sequence, e.g., of one or more nucleotides, that will be added to or will template a change in the target nucleic acid. In another embodiment, the template nucleic acid comprises a nucleotide sequence that may be used to modify the target position. In another embodiment, the template nucleic acid comprises a nucleotide sequence, e.g., of one or more nucleotides, that corresponds to wild type sequence of the target nucleic acid, e.g., of the target position.
  • the template nucleic acid may comprise a replacement sequence, e.g., a replacement sequence from the Table 49.
  • the template nucleic acid comprises a 5' homology arm, e.g., a 5' homology arm from Table 49.
  • the template nucleic acid comprises a 3' homology arm, e.g., a 3' homology arm from Table 49.
  • a nucleic acid encodes (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the CFTR gene or SCNNIA gene as disclosed herein, and (b) a sequence that encodes a Cas9 molecule, e.g., a Cas9 molecule described herein. In an embodiment, (a) and (b) are present on the same nucleic acid
  • the nucleic acid molecule is an AAV vector.
  • Exemplary AAV vectors that may be used in any of the described compositions and methods include an AAV2 vector, a modified AAV2 vector, an AAV3 vector, a modified AAV3 vector, an AAV6 vector, a modified AAV6 vector, an AAV8 vector and an AAV9 vector.
  • first nucleic acid molecule e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector
  • second nucleic acid molecule e.g., a second vector, e.g., a second vector, e.g., a second AAV vector.
  • the first and second nucleic acid molecules may be AAV vectors.
  • the nucleic acid may further comprise (c) a sequence that encodes a second, third and/or fourth gRNA molecule as described herein.
  • the nucleic acid comprises (a), (b) and (c)(i). Each of (a) and (c)(i) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., the same adeno-associated virus (AAV) vector.
  • the nucleic acid molecule is an AAV vector.
  • (a) and (c)(i) are on different vectors.
  • a first nucleic acid molecule e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector
  • a second nucleic acid molecule e.g., a second vector, e.g., a second vector, e.g., a second AAV vector.
  • the first and second nucleic acid molecules are AAV vectors.
  • each of (a), (b), and (c)(i) are present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector.
  • the nucleic acid molecule is an AAV vector.
  • one of (a), (b), and (c)(i) is encoded on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and a second and third of (a), (b), and (c)(i) is encoded on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector.
  • the first and second nucleic acid molecule may be AAV vectors.
  • first nucleic acid molecule e.g., a first vector, e.g., a first viral vector, a first AAV vector
  • second nucleic acid molecule e.g., a second vector, e.g., a second vector, e.g., a second AAV vector.
  • the first and second nucleic acid molecule may be AAV vectors.
  • first nucleic acid molecule e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector
  • second nucleic acid molecule e.g., a second vector, e.g., a second vector, e.g., a second AAV vector.
  • the first and second nucleic acid molecule may be AAV vectors.
  • (c)(i) is present on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (b) and (a) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector.
  • the first and second nucleic acid molecule may be AAV vectors.
  • each of (a), (b) and (c)(i) are present on different nucleic acid molecules, e.g., different vectors, e.g., different viral vectors, e.g., different AAV vector.
  • vectors e.g., different viral vectors, e.g., different AAV vector.
  • (a) may be on a first nucleic acid molecule
  • (c)(i) on a third nucleic acid molecule may be AAV vectors.
  • each of (a), (b), (c)(i), (c)(ii) and (c)(iii) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector.
  • the nucleic acid molecule is an AAV vector.
  • each of (a), (b), (c)(i), (c)(ii) and (c)(iii) may be present on more than one nucleic acid molecule, but fewer than five nucleic acid molecules, e.g., AAV vectors.
  • each of (a), (b), and (d) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector.
  • the nucleic acid molecule is an AAV vector.
  • each of (a), (b), and (d) may be present on the different nucleic acid molecules, e.g., different vectors, e.g., the different viral vectors, e.g., different AAV vectors.
  • each of (a), (b), and (d) may be present on more than one nucleic acid molecule, but fewer than three nucleic acid molecules, e.g., AAV vectors.
  • each of (a), (b), (c)(i) and (d) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector.
  • the nucleic acid molecule is an AAV
  • each of (a), (b), (c)(i) and (d) may be present on the different nucleic acid molecules, e.g., different vectors, e.g., the different viral vectors, e.g., different AAV vectors.
  • each of (a), (b), (c)(i) and (d) may be present on more than one nucleic acid molecule, but fewer than four nucleic acid molecules, e.g., AAV vectors.
  • nucleic acid molecule e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector.
  • the nucleic acid molecule is an AAV vector.
  • each of (a), (b), (c)(i), (c)(ii) and (d) may be present on the different nucleic acid molecules, e.g., different vectors, e.g., the different viral vectors, e.g., different AAV vectors.
  • (d) may be present on more than one nucleic acid molecule, but fewer than five nucleic acid molecules, e.g., AAV vectors.
  • each of (a), (b), (c)(i), (c)(ii), (c)(iii) and (d) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector.
  • the nucleic acid molecule is an AAV vector.
  • each of (a), (b), (c)(i), (c)(ii), (c)(iii) and (d) may be present on the different nucleic acid molecules, e.g., different vectors, e.g., the different viral vectors, e.g., different AAV vectors.
  • each of (a), (b), (c)(i), (c)(ii), (c)(iii) and (d) may be present on more than one nucleic acid molecule, but fewer than six nucleic acid molecules, e.g., AAV vectors.
  • the nucleic acids described herein may comprise a promoter operably linked to the sequence that encodes the gRNA molecule of (a), e.g., a promoter described herein.
  • the nucleic acid may further comprise a second promoter operably linked to the sequence that encodes the second, third and/or fourth gRNA molecule of (c), e.g., a promoter described herein.
  • the promoter and second promoter differ from one another. In some embodiments, the promoter and second promoter are the same.
  • nucleic acids described herein may further comprise a promoter operably linked to the sequence that encodes the Cas9 molecule of (b), e.g., a promoter described herein.
  • composition comprising (a) a gRNA molecule comprising a targeting domain that is complementary with a target domain in the CFTR gene or
  • composition of (a) may further comprise (b) a Cas9 molecule, e.g., a Cas9 molecule as described herein.
  • a composition of (a) and (b) may further comprise (c) a second, third and/or fourth gRNA molecule, e.g., a second, third and/or fourth gRNA molecule described herein.
  • a composition of (a), (b) and (c) may further comprise (d) a template nucleic acid, e.g., a template nucleic acid described herein.
  • the composition is a pharmaceutical composition.
  • the compositions described herein, e.g., pharmaceutical compositions described herein can be used in the treatment or prevention of CF or CF-like disease in a subject, e.g., in accordance with a method disclosed herein.
  • a method of altering a cell comprising contacting said cell with: (a) a gRNA that targets the CFTR gene or SCNN1A gene, e.g., a gRNA as described herein; (b) a Cas9 molecule, e.g., a Cas9 molecule as described herein; and optionally, (c) a second, third and/or fourth gRNA that targets CFTR gene or SCNN1A gene, e.g., a second, third and/or fourth gRNA as described herein; and optionally, (d) a template nucleic acid, e.g., a template nucleic acid as described herein.
  • the method comprises contacting said cell with (a) and (b).
  • the method comprises contacting said cell with (a), (b), and (c). In an embodiment, the method comprises contacting said cell with (a), (b), (c) and (d).
  • the gRNA of (a) and optionally (c) may be selected from any of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A- 13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-
  • the method comprises contacting a cell from a subject suffering from or likely to develop CF or CF-like disease.
  • the cell may be from a subject having a mutation at a CF target position in the CFTR gene or a subject which would benefit from having a mutation at a CF target position in the SCNN1A gene.
  • the cell being contacted in the disclosed method is an epithelial cell, e.g., a pulmonary epithelial cell, e.g., a bronchial epithelial cell or an alveolar epithelial cell.
  • the contacting may be performed ex vivo and the contacted cell may be returned to the subject's body after the contacting step. In other embodiments, the contacting step may be performed in vivo.
  • the method of altering a cell as described herein comprises acquiring knowledge of the sequence at a CF target position in said cell, prior to the contacting step.
  • Acquiring knowledge of the sequence at a CF target position in the cell may be by sequencing the CFTR gene or SCNN1A gene, or a portion of the CFTR gene or SCNN1A gene.
  • the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses at least one of (a), (b), and (c).
  • the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses each of (a), (b), and (c).
  • the contacting step of the method comprises delivering to the cell a Cas9 molecule of (b) and a nucleic acid which encodes a gRNA of (a) and optionally, a second gRNA (c)(i) and further optionally, a third gRNA (c)(ii) and/or fourth gRNA (c)(iii)).
  • the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses at least one of (a), (b), (c) and (d).
  • the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses each of (a), (b), and (c).
  • the contacting step of the method comprises delivering to the cell a Cas9 molecule of (b), a nucleic acid which encodes a gRNA of (a) and a template nucleic acid of (d), and optionally, a second gRNA (c)(i) and further optionally, a third gRNA (c)(ii) and/or fourth gRNA (c)(iii).
  • contacting comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, e.g., an AAV2 vector, a modified AAV2 vector, an AAV3 vector, a modified AAV3 vector, an AAV6 vector, a modified AAV6 vector, an AAV8 vector or an AAV9 vector, as described herein.
  • a nucleic acid e.g., a vector, e.g., an AAV vector, e.g., an AAV2 vector, a modified AAV2 vector, an AAV3 vector, a modified AAV3 vector, an AAV6 vector, a modified AAV6 vector, an AAV8 vector or an AAV9 vector, as described herein.
  • contacting comprises delivering to the cell a Cas9 molecule of (b), as a protein or an mRNA, and a nucleic acid which encodes a gRNA of (a) and optionally a second, third and/or fourth gRNA of (c).
  • contacting comprises delivering to the cell a Cas9 molecule of (b), as a protein or an mRNA, said gRNA of (a), as an RNA, and optionally said second, third and/or fourth gRNA of (c), as an RNA.
  • contacting comprises delivering to the cell a gRNA of (a) as an RNA, optionally the second, third and/or fourth gRNA of (c) as an RNA, and a nucleic acid that encodes the Cas9 molecule of (b).
  • a method of treating or preventing a subject suffering from or likely to develop CF or CF-like disease e.g., altering the structure, e.g., sequence, of a target nucleic acid of the subject, comprising contacting the subject (or a cell from the subject) with:
  • a gRNA that targets the CFTR gene or SCNN1A gene e.g., a gRNA disclosed herein;
  • a Cas9 molecule e.g., a Cas9 molecule disclosed herein;
  • a second gRNA that targets the CFTR gene or SCNN1A gene e.g., a second gRNA disclosed herein, and
  • the method of treating a subject may further comprise contacting the subject (or a cell from the subject) with (d) a template nucleic acid, e.g., a template nucleic acid disclosed herein.
  • a template nucleic acid is used when the method of treating a subject uses HDR to alter the sequence of the target nucleic acid of the subject.
  • contacting comprises contacting with (a) and (b).
  • contacting comprises contacting with (a), (b), and (c)(i).
  • contacting comprises contacting with (a), (b), (c)(i) and (c)(ii).
  • contacting comprises contacting with (a), (b), (c)(i), (c)(ii) and (c)(iii).
  • contacting comprises contacting with (a), (b), (c)(i) and (d). In some embodiments, contacting comprises contacting with (a), (b), (c)(i), (c)(ii) and
  • contacting comprises contacting with (a), (b), (c)(i), (c)(ii), (c)(iii) and (d).
  • the gRNA of (a) or (c) (e.g., (c)(i), (c)(ii), or (c)(iii)) may be selected from any of Tables
  • the method comprises acquiring knowledge of the sequence (e.g., a mutation) of a CF target position in said subject.
  • the method comprises acquiring knowledge of the sequence (e.g., a mutation) of a CF target position in said subject by sequencing the CFTR gene or SCNNIA gene or a portion of the CFTR gene or SCNNIA gene.
  • the method comprises correcting a mutation at a CF target position in the CFTR gene.
  • the method comprises correcting a mutation at a CF target position in the CFTR gene by HDR.
  • the method comprises introducing a mutation at a CF target position in the SCNNIA gene.
  • the method comprises introducing a mutation at a CF target position in the SCNNIA gene by NHEJ.
  • a Cas9 of (b) at least one guide RNA, e.g., a guide RNA of (a) and a template nucleic acid of (d) are included in the contacting step.
  • a cell of the subject is contacted ex vivo with (a), (b), (d) and optionally (c). In an embodiment, said cell is returned to the subject's body.
  • a cell of the subject is contacted is in vivo with (a), (b) (d) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
  • the cell of the subject is contacted in vivo by inhalation delivery, e.g., via nebulizer, of (a), (b), (d) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
  • the cell of the subject is contacted in vivo by intravenous delivery of (a), (b), (d) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
  • the cell of the subject is contacted in vivo by intraparenchymal delivery of (a), (b), (d) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii), e.g., to lung tissue or bronchial tree.
  • the contacting step comprises contacting the subject with a nucleic acid, e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), (d) and optionally (c)(i), further optionally (c)(ii), and still further optionally
  • a nucleic acid e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), (d) and optionally (c)(i), further optionally (c)(ii), and still further optionally
  • the contacting step comprises delivering to said subject said Cas9 molecule of (b), as a protein or mRNA, and a nucleic acid which encodes (a), a nucleic acid of
  • the contacting step comprises delivering to the subject the Cas9 molecule of (b), as a protein or mRNA, the gRNA of (a), as an RNA, a nucleic acid of (d) and optionally the second gRNA of (c)(i), further optionally said third gRNA of (c)(ii), and still further optionally said fourth gRNA of (c)(iii), as an RNA.
  • the contacting step comprises delivering to the subject the gRNA of (a), as an RNA, optionally said second gRNA of (c)(i), further optionally said third gRNA of (c)(ii), and still further optionally said fourth gRNA of (c)(iii), as an RNA, a nucleic acid that encodes the Cas9 molecule of (b), and a nucleic acid of (d).
  • the method comprises (1) introducing a mutation at a CF target position by NHEJ or (2) knocking down expression of the SCNN1A gene by targeting the promoter region, a Cas9 of (b) and at least one guide RNA, e.g., a guide RNA of (a) are included in the contacting step.
  • a cell of the subject is contacted ex vivo with (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
  • said cell is returned to the subject's body.
  • a population of cells from a subject is contacted ex vivo with (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d) to correct the F508del or G551D mutation in the CFTR gene and a second population of cells from the subject is contacted ex vivo with (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii), to introduce a mutation in the SCNN1A gene to knockout the SCNN1A gene.
  • a mixture of the two cell populations may be returned to the subject's body to treat or prevent CF or CF-like disease.
  • a cell of the subject is contacted is in vivo with (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d).
  • the cell of the subject is contacted in vivo by inhalation delivery, e.g., via nebulizer, of (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d).
  • the cell of the subject is contacted in vivo by intravenous delivery of (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d).
  • the cell of the subject is contacted in vivo by intraparenchymal delivery of (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d), e.g., to lung tissue or bronchial tree.
  • contacting comprises contacting the subject with a nucleic acid, e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d).
  • a nucleic acid e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d).
  • contacting comprises delivering to said subject said Cas9 molecule of (b), as a protein or mRNA, and a nucleic acid which encodes (a) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d).
  • contacting comprises delivering to the subject the Cas9 molecule of (b), as a protein or mRNA, the gRNA of (a), as an RNA, and optionally the second gRNA of
  • contacting comprises delivering to the subject the gRNA of (a), as an RNA, optionally said second gRNA of (c)(i), further optionally said third gRNA of (c)(ii), and still further optionally said fourth gRNA of (c)(iii), as an RNA, and a nucleic acid that encodes the Cas9 molecule of (b), and optionally a nucleic acid that encodes the template nucleic acid of
  • a reaction mixture comprising a gRNA molecule, a nucleic acid, or a composition described herein, and a cell, e.g., a cell from a subject having, or likely to develop CF or CF-like disease, or a subject having a mutation at a CF target position in the CFTR gene, or a cell from a subject which would benefit from having a mutation at a CF target position in the SCNN1A gene.
  • kits comprising, (a) a gRNA molecule described herein, or nucleic acid that encodes the gRNA, and one or more of the following:
  • a Cas9 molecule e.g., a Cas9 molecule described herein, or a nucleic acid or mRNA that encodes the Cas9;
  • a second gRNA molecule e.g., a second gRNA molecule described herein or a nucleic acid that encodes (c)(i);
  • a third gRNA molecule e.g., a second gRNA molecule described herein or a nucleic acid that encodes (c)(ii);
  • a fourth gRNA molecule e.g., a second gRNA molecule described herein or a nucleic acid that encodes (c)(iii);
  • a template nucleic acid e.g, a template nucleic acid described herein.
  • the kit comprises nucleic acid, e.g., an AAV vector, that encodes one or more of (a), (b), (c)(i), (c)(ii), (c)(iii) and (d).
  • nucleic acid e.g., an AAV vector
  • non-naturally occurring template nucleic acid described herein is non-naturally occurring template nucleic acid described herein.
  • a gRNA molecule e.g., a gRNA molecule described herein, for use in treating or preventing CF or CF-like disease in a subject, e.g., in accordance with a method of treating or preventing CF or CF-like disease as described herein.
  • the gRNA molecule in used in combination with a Cas9 molecule, e.g., a Cas9 molecule described herein. Additionally or alternatively, in an embodiment, the gRNA molecule is used in combination with a second, third and/or fouth gRNA molecule, e.g., a second, third and/or fouth gRNA molecule described herein.
  • a gRNA molecule e.g., a gRNA molecule described herein, in the manufacture of a medicament for treating or preventing CF or CF-like disease in a subject, e.g., in accordance with a method of treating or preventing CF or CF-like disease as described herein.
  • the medicament comprises a Cas9 molecule, e.g., a Cas9 molecule described herein. Additionaly or alternatively, in an embodiment, the medicament comprises a second, third and/or fouth gRNA molecule, e.g., a second, third and/or fouth gRNA molecule described herein.
  • a governing gRNA molecule refers to a gRNA molecule comprising a targeting domain which is complementary to a target domain on a nucleic acid that encodes a component of the CRISPR/Cas system introduced into a cell or subject.
  • the methods described herein can further include contacting a cell or subject with a governing gRNA molecule or a nucleic acid encoding a governing molecule.
  • the governing gRNA molecule targets a nucleic acid that encodes a Cas9 molecule or a nucleic acid that encodes a target gene gRNA molecule.
  • the governing gRNA comprises a targeting domain that is complementary to a target domain in a sequence that encodes a Cas9 component, e.g., a Cas9 molecule or target gene gRNA molecule.
  • the target domain is designed with, or has, minimal homology to other nucleic acid sequences in the cell, e.g., to minimize off-target cleavage.
  • the targeting domain on the governing gRNA can be selected to reduce or minimize off-target effects.
  • a target domain for a governing gRNA can be disposed in the control or coding region of a Cas9 molecule or disposed between a control region and a transcribed region.
  • a target domain for a governing gRNA can be disposed in the control or coding region of a target gene gRNA molecule or disposed between a control region and a transcribed region for a target gene gRNA. While not wishing to be bound by theory, in an embodiment, it is believed that altering, e.g., inactivating, a nucleic acid that encodes a Cas9 molecule or a
  • nucleic acid that encodes a target gene gRNA molecule can be effected by cleavage of the targeted nucleic acid sequence or by binding of a Cas9 molecule/governing gRNA molecule complex to the targeted nucleic acid sequence.
  • compositions, reaction mixtures and kits, as disclosed herein, can also include a governing gRNA molecule, e.g., a governing gRNA molecule disclosed herein.
  • a governing gRNA molecule e.g., a governing gRNA molecule disclosed herein.
  • Headings including numeric and alphabetical headings and subheadings, are for organization and presentation and are not intended to be limiting.
  • FIGs. 1A-1I are representations of several exemplary gRNAs.
  • Fig. 1A depicts a modular gRNA molecule derived in part (or modeled on a sequence in part) from Streptococcus pyogenes (S. pyogenes) as a duplexed structure (SEQ ID NOS: 42 and 43, respectively, in order of appearance);
  • Fig. IB depicts a unimolecular (or chimeric) gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 44);
  • Fig. 1C depicts a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 45);
  • Fig. ID depicts a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 46);
  • Fig. IE depicts a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 47);
  • Fig. IF depicts a modular gRNA molecule derived in part from Streptococcus thermophilus (S. thermophilus) as a duplexed structure (SEQ ID NOS: 48 and 49, respectively, in order of appearance);
  • Fig. 1G depicts an alignment of modular gRNA molecules of S. pyogenes and S.
  • thermophilus SEQ ID NOS: 50-53, respectively, in order of appearance.
  • Figs. 1H-1I depicts additional exemplary structures of unimolecular gRNA molecules.
  • Fig. 1H shows an exemplary structure of a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 45).
  • Fig. II shows an exemplary structure of a unimolecular gRNA molecule derived in part from S. aureus as a duplexed structure (SEQ ID NO: 40).
  • Figs. 2A-2G depict an alignment of Cas9 sequences from Chylinski et al. (RNA Biol. 2013; 10(5): 726-737).
  • the N-terminal RuvC-like domain is boxed and indicated with a "Y”.
  • the other two RuvC-like domains are boxed and indicated with a "B”.
  • the HNH-like domain is boxed and indicated by a "G”.
  • Sm S. mutans (SEQ ID NO: 1); Sp: S. pyogenes (SEQ ID NO: 2); St: S. thermophilus (SEQ ID NO: 3); Li: L. innocua (SEQ ID NO: 4).
  • Motif this is a motif based on the four sequences: residues conserved in all four sequences are indicated by single letter amino acid abbreviation; "*" indicates any amino acid found in the corresponding position of any of the four sequences; and "-” indicates any amino acid, e.g., any of the 20 naturally occurring amino acids, or absent.
  • Figs. 3A-3B show an alignment of the N-terminal RuvC-like domain from the Cas9 molecules disclosed in Chylinski et al (SEQ ID NOS: 54-103, respectively, in order of appearance).
  • the last line of Fig. 3B identifies 4 highly conserved residues.
  • Figs. 4A-4B show an alignment of the N-terminal RuvC-like domain from the Cas9 molecules disclosed in Chylinski et al. with sequence outliers removed (SEQ ID NOS: 104-177, respectively, in order of appearance).
  • SEQ ID NOS: 104-177 sequence outliers removed.
  • the last line of Fig. 4B identifies 3 highly conserved residues.
  • Figs. 5A-5C show an alignment of the HNH-like domain from the Cas9 molecules disclosed in Chylinski et al (SEQ ID NOS: 178-252, respectively, in order of appearance). The last line of Fig. 5C identifies conserved residues.
  • Figs. 6A-6B show an alignment of the HNH-like domain from the Cas9 molecules disclosed in Chylinski et al. with sequence outliers removed (SEQ ID NOS: 253-302,
  • Figs. 7A-7B depict an alignment of Cas9 sequences from S. pyogenes and Neisseria meningitidis (N. meningitidis).
  • the N-terminal RuvC-like domain is boxed and indicated with a "Y”.
  • the other two RuvC-like domains are boxed and indicated with a "B”.
  • the HNH-like domain is boxed and indicated with a "G”.
  • Sp S. pyogenes
  • Nm N. meningitidis.
  • Motif this is a motif based on the two sequences: residues conserved in both sequences are indicated by a single amino acid designation; "*" indicates any amino acid found in the corresponding position of any of the two sequences; "-" indicates any amino acid, e.g., any of the 20 naturally occurring amino acids, and "-” indicates any amino acid, e.g., any of the 20 naturally occurring amino acids, or absent.
  • Fig. 8 shows a nucleic acid sequence encoding Cas9 of N. meningitidis (SEQ ID NO: 303). Sequence indicated by an "R” is an SV40 NLS; sequence indicated as “G” is an HA tag; and sequence indicated by an “O” is a synthetic NLS sequence; the remaining (unmarked) sequence is the open reading frame (ORF).
  • Figs. 9A and 9B are schematic representations of the domain organization of S. pyogenes Cas 9.
  • Fig. 9A shows the organization of the Cas9 domains, including amino acid positions, in reference to the two lobes of Cas9 (recognition (REC) and nuclease (NUC) lobes).
  • Fig. 9B shows the percent homology of each domain across 83 Cas9 orthologs.
  • CF target mutant position refers to a target position in the CFTR gene, which, if mutated, can result in a mutant protein and give rise to CF or CF-like disease.
  • the target position comprises one, two, or three nucleotides.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at F508, e.g., F508del.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at G551, e.g., G551D.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at G542, e.g., G542X, in the CFTR protein, which corresponds to c. l624G>T
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at N1303, e.g., N1303K, in the CFTR protein, which corresponds to c.3909C>G in the CFTR gene.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at Rl 17, e.g., Rl 17H, in the CFTR protein, which corresponds to c.350G>A in the CFTR gene.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at W1282, e.g., W1282X, in the CFTR protein, which corresponds to c. c.3846G>A in the CFTR gene.
  • the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at R553, e.g., R553X, in the CFTR protein, which corresponds to c. l657C>T in the CFTR gene.
  • the CF target mutant position is c.3717+12191, also known as c.3849+10kb, which corresponds to 3717+12191C>T in the CFTR gene.
  • the CF target mutant position is c.2657+5, also known as c.2789+5, which corresponds to 2657+5G>A in the CFTR gene.
  • the CF target mutant position is c.3140-26, also known as c.3272-26, which corresponds to c.3140-26 A>G in the CFTR gene.
  • the CF target mutant position is a position in the SCNNIA gene at which a change can give rise to a mutant protein having a mutation at VI 14, which corresponds to VI 141 in the SCNNIA gene.
  • CF target knockout position refers to a position in the CFTR and/or SCNNIA gene, which if altered by NHEJ-mediated alteration, results in alleviation of a symptom of CF or CF-like disease.
  • the alteration restores expression of functional CFTR gene product.
  • the position is in the CFTR non-coding region, e.g., an intronic region (e.g., the alternation corrects a cryptic splice site).
  • the alteration results in reduction or elimination of expression of functional SCNNIA gene product.
  • the position is in the SCNNIA coding region, e.g., an early coding region.
  • CF target knockdown position refers to a position in the SCNNIA gene, which if targeted, e.g., by an eiCas9 molecule or an eiCas9 fusion described herein, results in reduction or elimination of expression of functional SCNNIA gene product.
  • the transcription of the SCNNIA gene is reduced or eliminated.
  • the chromatin structure of the SCNNIA gene is altered.
  • the position is in the
  • SCNNIA early coding region sequence In an embodiment, a position in early coding region of
  • the SCNN1A gene is targeted by an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9- fusion protein, as described herein.
  • eiCas9 enzymatically inactive Cas9
  • CF target knockin position refers to a sequence, which if modified by the insertion of CFTR sequence, results in an optimization of CFTR activity, e.g., by resulting in a CFTR sequence that encodes a protein having wild type activity.
  • exemplary CF target knockin position include: CFTR sequence within intron 2, into which, e.g., can be introduced CFTR sequence that codes for CFTR exons 3-27; and sequence within CFTR intron 10, into which sequence that codes for CFTR exons 11-27 can be introduced.
  • a CF target knockin position includes CFTR intronic sequence between a second and a third exon (e.g., intron 2), and CFTR sequence encoding the third exon through the final exon (exon 27), is introduced, resulting in a CFTR sequence that is free of one or more cryptic splice sites and that encodes a CFTR protein having wild type activity.
  • a CF target knockin position is a position which is upstream of a mutation, or upsteam of an intron having a mutation, and introduction of wild-type CFTR sequence results in a CFTR sequence that is free of the mutation.
  • the CF target knockin position is in CFTR intronic sequence: between exon2 and exon 3; or between exon 10 and exon 11.
  • the resulting CFTR sequence comprises subject sequence upstream from the CF target knockin position and newly introduced sequence downstream from the CF target knockin position, which taken together, encode a CFTR protein having wild type activity.
  • the point of insertion is 3' to a splice donor site and 5' from a splice acceptor site.
  • CFTR sequence encoding exons 3-27 is inserted under control of the promoter, e.g., at the transcription start site.
  • CFTR sequence introduced can exclude introns, e.g., a sequence encoding exons, but without introns, is inserted, e.g., CFTR CDNA sequence is introduced.
  • CF target position refers to a CF target mutant position, CF target knockout position, CF target knockdown position, and/or CF target knockin position, as described herein.
  • Domain is used to describe segments of a protein or nucleic acid. Unless otherwise indicated, a domain is not required to have any specific functional property.
  • the optimal alignment is determined as the best score using the GAP program in the GCG software package with a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frame shift gap penalty of 5.
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
  • the percent identity between the two sequences is a function of the number of identical positions shared by the sequences.
  • Governing gRNA molecule refers to a gRNA molecule that comprises a targeting domain that is complementary to a target domain on a nucleic acid that comprises a sequence that encodes a component of the CRISPR/Cas system that is introduced into a cell or subject. A governing gRNA does not target an endogenous cell or subject sequence.
  • a governing gRNA molecule comprises a targeting domain that is complementary with a target sequence on: (a) a nucleic acid that encodes a Cas9 molecule; (b) a nucleic acid that encodes a gRNA which comprises a targeting domain that targets the CFTR or SCNN1A gene (a target gene gRNA); or on more than one nucleic acid that encodes a CRISPR/Cas component, e.g., both (a) and (b).
  • a nucleic acid molecule that encodes a CRISPR/Cas component comprises more than one target domain that is complementary with a governing gRNA targeting domain. While not wishing to be bound by theory, in an embodiment, it is believed that a governing gRNA molecule complexes with a Cas9 molecule and results in Cas9 mediated inactivation of the targeted nucleic acid, e.g., by cleavage or by binding to the nucleic acid, and results in cessation or reduction of the production of a CRISPR/Cas system component.
  • the Cas9 molecule forms two complexes: a complex comprising a Cas9 molecule with a target gene gRNA, which complex will alter the CFTR or SCNN1A gene; and a complex comprising a Cas9 molecule with a governing gRNA molecule, which complex will act to prevent further production of a CRISPR/Cas system component, e.g., a Cas9 molecule or a target gene gRNA molecule.
  • a CRISPR/Cas system component e.g., a Cas9 molecule or a target gene gRNA molecule.
  • a governing gRNA molecule/Cas9 molecule complex binds to or promotes cleavage of a control region sequence, e.g., a promoter, operably linked to a sequence that encodes a Cas9 molecule, a sequence that encodes a transcribed region, an exon, or an
  • a governing gRNA molecule/Cas9 molecule complex binds to or promotes cleavage of a control region sequence, e.g., a promoter, operably linked to a gRNA molecule, or a sequence that encodes the gRNA molecule.
  • the governing gRNA e.g., a Cas9-targeting governing gRNA molecule, or a target gene gRNA- targeting governing gRNA molecule, limits the effect of the Cas9 molecule/target gene gRNA molecule complex-mediated gene targeting.
  • a governing gRNA places temporal, level of expression, or other limits, on activity of the Cas9 molecule/target gene gRNA molecule complex. In an embodiment, a governing gRNA reduces off-target or other unwanted activity. In an embodiment, a governing gRNA molecule inhibits, e.g., entirely or substantially entirely inhibits, the production of a component of the Cas9 system and thereby limits, or governs, its activity.
  • Modulator refers to an entity, e.g., a drug, that can alter the activity (e.g., enzymatic activity, transcriptional activity, or translational activity), amount, distribution, or structure of a subject molecule or genetic sequence.
  • modulation comprises cleavage, e.g., breaking of a covalent or non-covalent bond, or the forming of a covalent or non- covalent bond, e.g., the attachment of a moiety, to the subject molecule.
  • a modulator alters the, three dimensional, secondary, tertiary, or quaternary structure, of a subject molecule.
  • a modulator can increase, decrease, initiate, or eliminate a subject activity.
  • Large molecule refers to a molecule having a molecular weight of at least 2, 3, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 kD. Large molecules include proteins, polypeptides, nucleic acids, biologies, and carbohydrates.
  • Polypeptide refers to a polymer of amino acids having less than 100 amino acid residues. In an embodiment, it has less than 50, 20, or 10 amino acid residues.
  • Reference molecule e.g., a reference Cas9 molecule or reference gRNA, as used herein, refers to a molecule to which a subject molecule, e.g., a subject Cas9 molecule of subject gRNA molecule, e.g., a modified or candidate Cas9 molecule is compared.
  • a Cas9 molecule can be characterized as having no more than 10% of the nuclease activity of a reference Cas9 molecule.
  • reference Cas9 molecules include naturally occurring unmodified Cas9 molecules, e.g., a naturally occurring Cas9 molecule such as a Cas9 molecule of S.
  • the reference Cas9 molecule is the naturally occurring Cas9 molecule having the closest sequence identity or homology with the
  • the reference Cas9 molecule is a sequence, e.g., a naturally occurring or known sequence, which is the parental form on which a change, e.g., a mutation has been made.
  • Small molecule refers to a compound having a molecular weight less than about 2 kD, e.g., less than about 2 kD, less than about 1.5 kD, less than about 1 kD, or less than about 0.75 kD.
  • Subject may mean either a human or non-human animal.
  • the term includes, but is not limited to, mammals (e.g., humans, other primates, pigs, rodents (e.g., mice and rats or hamsters), rabbits, guinea pigs, cows, horses, cats, dogs, sheep, and goats).
  • the subject is a human.
  • the subject is poultry.
  • Treatment mean the treatment of a disease in a mammal, e.g., in a human, including (a) inhibiting the disease, i.e., arresting or preventing its development; (b) relieving the disease, i.e., causing regression of the disease state; and (c) curing the disease.
  • X refers to any amino acid (e.g., any of the twenty natural amino acids) unless otherwise specified.
  • Cystic fibrosis is an autosomal recessive hereditary disease caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
  • the CFTR gene encodes a cAMP-gated channel that is involved in chloride and bicarbonate transport. It regulates sodium transport through inhibition of the epithelial sodium channel, which is encoded by the SCNN1A gene.
  • CFTR is expressed on the apical surface of epithelial cells in the airway, gastrointestinal tract, reproductive tract, sweat glands and submucosal glands.
  • Subjects having CF or CF-like disease may present at birth or in early infancy with pancreatic insufficiency.
  • Pancreatic dysfunction leads to malabsorption of fat and fat-soluble vitamins, which causes poor growth as well as gallstones and biliary disease.
  • the lung manifestations of the disease can be more severe but may present slightly after pancreatic manifestations, in infancy or early childhood. Aberrant chloride and sodium transport due to
  • CFTR activity causes lowered apical surface fluid levels in the lungs, which leads to "sticky" mucous and lower airway obstruction.
  • Subjects having CF or CF-like disease suffer from frequent infections due to inability to clear mucous. Local inflammatory mediators try to clear the infection but have difficulty. The triad of inflammation, infection and obstruction leads to progressive destruction of the lung parenchyma. Eventually, many subjects having CF or CF- like disease die in their late 30' s due to respiratory failure.
  • Treatments for the pulmonary manifestations of CF or CF-like disease include:
  • CFTR modulators including CFTR potentiators
  • DNase chest physiotherapy to loosen secretions and anti-inflammatory therapeutics.
  • Treatment of the gastrointestinal manifestations includes supplemental gut soluble vitamins, high calorie diet and oral pancreatic enzymes.
  • Subjects who develop diabetes are treated with insulin injections or an insulin pump. At the end stage, patients may benefit from lung transplant. Lung transplant may be combined with liver and/or pancreatic transplant. The average life expectancy for subjects having CF or CF-like disease is nearing 40 years of age.
  • Methods and compositions discussed herein provide for the treatment and prevention of Cystic Fibrosis (CF) and CF-like disease.
  • the approach described herein aims to restore CFTR channel function, restore chloride, bicarbonate and/or sodium balance, and/or decrease mucous viscosity within the lungs, airways, gastrointestinal tract and reproductive tract.
  • CFTR modulators both approved and in development improve the functioning of mutant CFTR. These therapeutics improve CFTR functioning but do not return functionality to wild type levels. The approach described herein is expected to restore CFTR function through complete correction of the gene.
  • Gene therapy approaches are in development that deliver the CFTR channel gene to the lungs of CF patients.
  • gene therapy may require constant readministration over the course of the lifetime of a subject due to high cell turnover in target epithelial cells.
  • the approach described herein is expected to restore CFTR function and/or ameliorate SCNN1A disinhibition permanently through one, two or several doses.
  • the CFTR gene encodes a 180-kDA cAMP-gated chloride (C1-) channel.
  • the channel has six transmembrane spanning domains and is expressed by epithelial cells, lymphocytes and cardiac myocytes.
  • the CFTR regulates the viscosity of mucous through its activity in the epithelial cells of the lungs, gastrointestinal tract and reproductive tract. Mutations in the CFTR result in decreased CFTR activity. Decreased CFTR activity can lead to aberrant ion transport, which gives rise to various disease symptoms in the lungs and other tissues, such as
  • CFTR mutations will ameliorate or cure lung, gastrointestinal and/or reproductive symptoms of CF.
  • the SCNN1A gene encodes the alpha subunit of the epithelial sodium channel (ENaC).
  • the channel comprised of alpha, beta and gamma subunits, regulates sodium transport into epithelial cells, including the epithelium of the lungs, sweat glands and kidneys.
  • Mutations in the SCNN1A gene (e.g. Vail 14ILE) have been shown to cause CF-like disease, characterized by pulmonary disease, including bronchiectasis. Mutations in SCNN1A also cause
  • pseudohypoaldosteronism a severe disease of the kidney.
  • Pseudohypoaldosteronism is due to defective sodium transport within kidney epithelial cells; it is not caused by defective sodium transport in other tissues.
  • the methods described herein include the targeted knockout of SCNN1A in the lung, gastrointestinal tract and/or reproductive tract. The methods described herein will not target kidney epithelium and will avoid the negative consequences of SCNN1A mutations within the kidney epithelium.
  • One mutation in the SCNN1A gene, a 1477T>G substitution (W493R) has been identified in subjects who also have a mutation in CFTR.
  • This mutation is associated with a severe CF phenotype, including severe bronchiectasis, chronic bronchitis and/or severe gastrointestinal symptoms. This mutation has been found to be associated with 4-fold overactivity of the ENaC channel (Azad et al., 2009; Human Mutation 30: 1093-1103). Overactivity of the SCNNlA-encoded ENaC channel can contribute to CF and CF- like disease. In all subjects, the CFTR is involved in inhibition of ENaC. CFTR mutations in subjects with CF or CF-like disease leads to ENaC disinhibition, leading to overactivity of the ENaC channel.
  • ENaC overactivity can lead to further reduction in viscosity of mucous in CF or CF-like disease subjects, as more sodium is absorbed at the apical surface of epithelial cells, followed by increased fluid absorption from the mucous layer within the lung (Baker et al., 2012; Medicine & Science in Sports and Exercise 44(12): 2315-2321). Increased fluid absorption from
  • the mucous layer reduces mucous viscosity.
  • Inhibition of ENaC through SCNNIA knockout and/or knockdown in subjects with CF or CF-like disease can ameliorate the symptoms of CF or CF-like disease.
  • F508del Phenylalanine
  • SCNNIA gene also known as sodium channel, non-voltage-gated 1 alpha subunit; amiloride- sensitive epithelial sodium channel alpha subunit; BESC2; ENaCa; SCNEA; SCNN1;
  • ENaCalpha to treat or prevent CF or CF-like disease, by targeting the SCNNIA gene, e.g., the non-coding or coding regions, e.g., a promoter region, or a transcribed sequence, e.g., intronic or exonic sequence.
  • the target position is VI 14, which corresponds to VI 141 in the SCNNIA gene.
  • SCNNIA encodes an epithelial sodium channel, ENaC, that is negatively regulated by CFTR. In subjects with CFTR mutations, knocking out or knocking down the SCNNIA gene in certain cells will reduce or reverse the effect of defective CFTR. In subjects with no CFTR mutations but CF-like disease caused by SCNNIA mutations or other mechanisms, knocking out or knocking down the SCNNIA gene in certain cells will improve the viscosity of mucous and ameliorate disease.
  • Correction of the CFTR mutation e.g., F508 deletion, e.g., G551D substitution, e.g.,
  • G542X nonsense mutation e.g., N1303K substitution, e.g., R117H substitution, e.g., W1282X nonsense mutation, e.g., R553X nonsense mutation, e.g., 3849+10kbC>T substitution, e.g., 2789+5G>A substitution, e.g., 3273-26A>G substitution) or inactivationor knockdown of the SCNNIA gene, e.g., using the methods disclosed herein, can ameliorate the disease.
  • the method leads to normalized ion transport, less viscous mucous, and/or reduced mucous plugging and inflammation, e.g., early in the disease course.
  • the method leads to normalized ion transport, less viscous mucous, and/or reduced mucous plugging and inflammation, e.g., early in the disease course.
  • the method results in fewer infections, decreased lung tissue destruction, and/or slowing in progression of disease.
  • the method improves mucous production and/or reduce frequency and/or length of infections, e.g., in later stages of the disease.
  • the method reduces or prevents further damage by ameliorating the triad of inflammation, infection and obstruction.
  • the method delays progression of the disease.
  • the method reduces or prevents further damage by ameliorating the triad of inflammation, infection and obstruction.
  • the method leads to normalized ion transport, and restoration of fertility.
  • the method leads to normalized ion transport, and improved gastrointestinal motility, absorption, and/or function.
  • the CFTR channel is corrected and chloride and bicarbonate balance restored, e.g., within the lung, e.g., within the airway, e.g., within the gastrointestinal tract, e.g., within the
  • CFTR modulators both approved and in development improve the functioning of mutant CFTR. These therapeutics improve CFTR functioning but do not return functionality to wild type levels.
  • the approach described herein restores CFTR function through complete correction of the CFTR gene.
  • the approach described herein inactivates the SCNN1A gene, e.g., in the pulmonary epithelium, e.g., in the airway epithelium, e.g., in the gastrointestinal epithelium, e.g. in the reproductive epithelium, e.g., in the
  • hepatobiliary epithelium e.g. in the pancreatic ducts, in order to inhibit the abnormal sodium ion transport associated with reduced CFTR activity and/or in order to inhibit abnormal sodium ion transport associated with overactive ENaC activity.
  • these two approaches are combined to treat or prevent CF or CF-like disease.
  • the approaches described herein provide advantages over CFTR modulators.
  • compositions disclosed herein may be administered once or more than once (e.g., 2, 3, 4, 5, or more times) to correct a mutation in the CFTR gene or to inactivate or knock-down the SCNN1A gene. It is further contemplated that when the compositions disclosed herein are administered more than one time that the multiple
  • administrations are intended to increase the number of cells (e.g., the number of cells in the subject) containing the corrected form of the CFTR gene and/or the inactivated/knocked-down form of the SCNNIA gene, thereby increasing the effectiveness of the treatment.
  • the methods of treatment described herein can be initiated for subjects at all stages of the disease.
  • the treatment is initiated after disease onset, e.g., as the subject presents with lung infections, wheezing and obstructed airways, and/or pancreatic insufficiency, decreased gastrointestinal function, malabsorption, and/or infertility.
  • repair of the CFTR gene or inactivation/knock-down of the SCNNIA gene after disease onset but early in the disease course reduces or prevents progression of the disease.
  • the method comprises treating a subject with advanced disease.
  • the method reduces or prevents further progression of symptoms, with or without reversing pathology.
  • the treatment is initiated prior to disease onset. In another embodiment, the treatment is initiated at an early stage of the disease, e.g., before the subject has noticed any decline in function or symptoms.
  • treatment is initiated in utero.
  • treatment is initiated after birth.
  • treatment is initiated prior to the age of 1.
  • treatment is initiated prior to the age of 2.
  • treatment is initiated prior to the age of 5.
  • treatment is initiated prior to the age of 10.
  • the subject has tested positive for a mutation in the CFTR gene, e.g., a mutation described herein.
  • the subject has tested positive for a mutation in the SCNNIA gene, e.g., a mutation described herein.
  • the treatment is initiated at appearance of a symptom of CF or CF-like disease, e.g., any of the following symptoms: frequent lung infections, chronic cough, sputum production, or chronic wheeze.
  • the subject has a positive "sweat test” or elevated sweat Chloride indicating dysfunction of the CFTR channel and/or overactivity of the SCNNIA channel.
  • the subject has an elevated sweat Chloride, bronchiectasis and is found to have no mutation in the CFTR gene.
  • the treatment is initiated if the subject is tested positive for a defect, e.g., a genetic defect, in the CFTR gene.
  • the treatment is initiated if the subject is tested positive for a defect, e.g., a genetic defect, in the SCNN1A gene.
  • a defect e.g., a genetic defect
  • the treatment is initiated if a family member of the subject has been diagnosed with CF or CF-like disease.
  • the subject has a symptom or sign of CF or CF-like disease.
  • the subject has a mutation in the CFTR gene, e.g., a mutation described herein.
  • the treatment is initiated at the appearance of any of the following findings consistent with CF or CF-like disease, including but not limited to, obstructive lung disease on lung function tests; persistent colonization with B. cepacia, P. aeruginosa and S. aureus and other CF-related pathogens; chronic radiologic abnormalities on chest x-ray; or chronic sinusitis.
  • the method comprises initiating treatment at the appearance of any of the following gastrointestinal findings consistent with CF or CF-like disease, including but not limited to: failure to thrive, steatorrhea, hypoproteinemia, vitamin deficiency due to fat- soluble vitamin malabsorption, meconium ileus, rectal prolapse, malabsorption, pancreatic insufficiency, pancreatitis, or chronic hepatobiliary disease.
  • Evidence of chronic hepatobiliary disease can include, e.g., elevated transaminases and/or hyperbilirubinemia.
  • a cell is treated ex vivo. In an embodiment, the cell is returned to the subject.
  • a population of cells from a subject may be contacted ex vivo to correct a mutation in the CFTR gene, e.g., F508del, e.g., G542X, e.g., G551D, e.g., N1303K, e.g., R117H, e.g., W1282X, e.g., R553X, e.g., 3849+10kbC>T, e.g., 2789+5G>A, e.g., 3273-26A>G, and a second population of cells from the subject is contacted ex vivo to introduce a mutation in the SCNN1A gene to knockout or knockdown SCNN1A.
  • a mixture of the two cell populations may be returned to the subject's body to prevent or treat CF or CF-like disease.
  • the cell is harvested from epidermis, pulmonary tree, hepatobiliary tree, gastrointestinal tract, reproductive tract, or other organ. In an embodiment, the cell is reprogrammed to an induced pluripotent stem (iPS) cell.
  • iPS induced pluripotent stem
  • the iPS cell is differentiated into airway epithelium, pulmonary epithelium, submucosal glands, submucosal ducts, biliary epithelium, gastrointestinal epithelium, pancreatic duct cells, reproductive epithelium, epidydimal cells, and/or cells of the hepatobiliary tree, e.g., clara cells, e.g., ciliated cells, e.g., goblet cells, e.g., basal cells, e.g., acinus cells, e.g., bronchioalveolar stem cell e.g., lung epithelial cells, e.g., nasal epithelial cells, e.g., tracheal epithelial cells, e.g., bronchial epithelial cells, e.g., enteroendocrine cells, e.g., Brunner's gland cells, e.g., clar
  • the CFTR gene in the cell is corrected with the method described herein.
  • the SCNNIA gene in the cell is corrected with the method described herein.
  • the CFTR gene and the SCNNIA gene in the cell is corrected with the method described herein.
  • the cell is re-introduced into an appropriate location in the subject, e.g., airway, pulmonary tree, bile duct system, gastrointestinal tract, pancreas, hepatobiliary tree, and/or reproductive tract.
  • an autologous stem cell can be treated ex vivo, differentiated into airway epithelium, pulmonary epithelium, submucosal glands, submucosal ducts, biliary epithelium, gastrointestinal epithelium, pancreatic duct cells, reproductive epithelium, epidydimal cells, and/or cells of the hepatobiliary tree, e.g., clara cells, e.g., ciliated cells, e.g., goblet cells, e.g., basal cells, e.g., acinus cells, e.g., bronchioalveolar stem cell e.g., lung epithelial cells, e.g., nasal epithelial cells, e.g., tracheal epithelial cells, e.g., bronchial epithelial cells, e.g., enteroendocrine cells, e.g., Brunner'
  • a heterologous stem cell can be treated ex vivo, differentiated into airway epithelium, pulmonary epithelium, submucosal glands, submucosal ducts, biliary epithelium, gastrointestinal epithelium, pancreatic duct cells, reproductive epithelium, epidydimal cells, and/or cells of the hepatobiliary tree, e.g., clara cells, e.g., ciliated cells, e.g., goblet cells, e.g., basal cells, e.g., acinus cells, e.g., bronchioalveolar stem cell e.g., lung epithelial cells, e.g., nasal epithelial cells, e.g., tracheal epithelial cells, e.g., bronchial epithelial cells, e.g., enteroendocrine cells, e.g., Brunner
  • the method described herein comprises delivery of gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid, by inhalation, e.g., via nebulizer.
  • the method described herein comprises delivery of gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid by intravenous administration.
  • the method described herein comprises delivery of gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid by intraparenchymal injection into lung tissue.
  • the method described herein comprises delivery of gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid, by intraparenchymal, intralveolar, intrabronchial, intratracheal injection into the trachea, bronchial tree and/or alveoli.
  • gRNA or other components described herein e.g., a Cas9 molecule and a template nucleic acid
  • the method described herein comprises delivery of gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid, by intravenous, intraparenchymal or other directed injection or administration to any of the following locations: the portal circulation, liver parenchyma, pancreas, pancreatic duct, bile duct, jejunum, ileum, duodenum, stomach, upper intestine, lower intestine, gastrointestinal tract, epididymis, or reproductive tract.
  • gRNA or other components described herein e.g., a Cas9 molecule and a template nucleic acid
  • a gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid are delivered, e.g., to a subject, by AAV, e.g., via nebulizer, or via nasal spray or inhaled, with or without accelerants to aid in absorption.
  • a gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid are delivered, e.g., to a subject, by Sendai virus, adenovirus, lentivirus or other modified or unmodified viral delivery particle.
  • a gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid are delivered, e.g., to a subject, via nebulizer or jet nebulizer, nasal spray, or inhalation.
  • a gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid is formulated in an aerosolized cationic liposome, lipid nanoparticle, lipoplex, non-lipid polymer complex or dry powder, e.g., for delivery via nebulizer, with or without accelerants to aid in absorption.
  • a gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid are delivered, e.g., to a subject, via liposome GL67A.
  • GL67A is described, e.g., www.cfgenetherapy.org.uk/clinical/product.html; Eastman et al., Hum Gene Ther. 1997 Apr 10; 8(6):765-73.
  • Methods and compositions disclosed herein provide a number of approaches for treating or preventing CF and CF-like disease.
  • methods described herein provide for treating or preventing CF and CF-like disease by correcting a target position in the CFTR gene to provide corrected, or functional, e.g., wild type, CFTR.
  • methods described herein allow for treating or preventing CF and CF-like disease by inducing or introducing a mutation that reduces the level of functional SCNN1A gene product. In subjects with CF or CF- like disease, these methods can be used alone, e.g. CFTR correction, e.g., SCNN1A knockout or knockdown, or in combination, e.g., CFTR correction with SCNN1A knockout or knockdown.
  • approaches 1, 2 and 3 correspond to methods to alter CFTR.
  • approach 4 and 6 correspond to methods to alter SCNN1A.
  • approaches 1, 2, and 3 can be used alone or approach 1 can be combined with approach 4, or approach 2 can be combined with approach 4 or approach 3 (e.g., 3 A or 3B) can be combined with approach 4.
  • methods and compositions discussed herein provide for the correction of the underlying cause of CF or CF-like disease, e.g., the correction of a mutation at a target position in the CFTR gene.
  • the CFTR gene can be altered by gene editing, e.g., using CRISPR- Cas9 mediated methods as described herein. Methods and compositions discussed herein, provide for altering a CF target position in the CFTR gene.
  • a CF target position can be altered by gene editing, e.g., using CRISPR-Cas9 mediated methods to alter the CFTR gene.
  • an F508 mutant protein e.g., F508del mutant protein
  • a G551 mutant protein e.g., G551D mutant protein
  • a G542 mutant protein e.g., G542X mutant protein
  • a mutant protein e.g., mutant protein
  • a N1303 mutant protein e.g., N1303K mutant protein
  • a Rl 17 mutant protein e.g., Rl 17H mutant protein
  • W1282 mutant protein e.g., W1282X mutant protein
  • a R553 mutant protein e.g., R553X mutant protein
  • a c.3717+12191 mutant protein e.g., c.3717+12191C>T mutant protein
  • a c.3717+12191 mutant protein e.g., c.3717+12191C>T mutant protein
  • the methods and compositions herein are broadly applicable to any mutation, e.g., a point mutation or a deletion, in the CFTR gene that gives rise to CF or CF-like disease.
  • the alteration of the CFTR gene can be mediated by any mechanism.
  • exemplary mechanisms that can be associated with the alteration of the CFTR gene include, but are not limited to, non-homologous end joining (e.g., classical or alternative), microhomology-mediated end joining (MMEJ), homology-directed repair (e.g., endogenous donor template mediated), SDSA (synthesis dependent strand annealing) or single strand annealing or single strand invasion, all with or without the addition of an endogenous- promoter driven cDNA encoding the CFTR gene.
  • non-homologous end joining e.g., classical or alternative
  • MMEJ microhomology-mediated end joining
  • homology-directed repair e.g., endogenous donor template mediated
  • SDSA synthesis dependent strand annealing
  • single strand annealing or single strand invasion all with or without the addition of an endogenous- promoter driven cDNA encoding the CFTR gene.
  • one approach to treat or prevent CF or CF-like disease is to repair (i.e., correct) one or more mutations in the CFTR gene, e.g., by HDR. While not wishing to be bound by theory, it is believed that correction of the mutation(s) (e.g., mediated by HDR) restore the mutant CFTR gene to its wild type state.
  • single stranded oligonucleotides ssODNs
  • ssODNs single stranded oligonucleotides
  • double stranded DNA donor is used as a donor template. Donor templates contain DNA sequence which, upon incorporation, result in the expression of a functional version of the CFTR protein.
  • one CFTR allele is repaired in the subject.
  • both CFTR alleles are repaired in the subject.
  • methods and compositions discussed herein provide for the correction of the underlying genetic cause of CF or CF-like disease, e.g., the correction of a mutation at a target position in the CFTR gene, e.g., correction of a mutation (e.g., delF508, G551DG542X, N1303K, R117H, W1282X, or R553X) in the CFTR gene.
  • a mutation e.g., delF508, G551DG542X, N1303K, R117H, W1282X, or R553X
  • Mutations in the CFTR gene amenable to the approach described herein include, but are not limited to any of the following mutations, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X.
  • the homology-directed repair of genomic sequence including the mutation at the CF target position gives rise to alteration of the CFTR gene.
  • This approach leads to the cessation of production of mutant CFTR channel and results in the production of wild-type CFTR channel.
  • the method provides for the correction of a mutation at a target position in the CFTR gene, e.g., correction of a mutation, e.g., an F508del, G551D, G542X, N1303K, Rl 17H, W1282X, or R553X substitution in the CFTR gene.
  • correction of a mutation e.g., an F508del, G551D, G542X, N1303K, Rl 17H, W1282X, or R553X substitution in the CFTR gene.
  • the method comprises the introduction of one or more breaks (e.g., single strand breaks or double strand breaks) sufficiently close to (e.g., either 5' or 3' to) the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X.
  • breaks e.g., single strand breaks or double strand breaks
  • the targeting domain of the gRNA molecule is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to (e.g., either 5' or 3' to) the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X to allow correction, e.g., an alteration in the CFTR gene, e.g., an alternation associated with HDR.
  • a cleavage event e.g., a double strand break or a single strand break
  • the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, Rl 17H, W1282X, or R553X.
  • a cleavage event e.g., a double strand or single strand break
  • the break e.g., a double strand or single strand break
  • the break can be positioned upstream or downstream of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X.
  • a second, third and/or fourth gRNA molecule is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to (e.g., either 5' or 3' to) the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, Rl 17H, W1282X, or R553X to allow correction, e.g., an alteration associated with HDR in the CFTR gene.
  • a cleavage event e.g., a double strand break or a single strand break
  • the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X.
  • a cleavage event e.g., a double strand or single strand break
  • the break e.g., a double strand or single strand break
  • the break can be positioned upstream or downstream of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, Rl 17H, W1282X, or R553X.
  • a single strand break is accompanied by an additional single strand break, positioned by a second, third and/or fourth gRNA molecule, as discussed below.
  • the targeting domains bind configured such that a cleavage event, e.g., the two single strand breaks, are positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X.
  • the first and second gRNA molecules are configured such, that when guiding a Cas9 nickase, a single strand break will be accompanied by an additional single strand break, positioned by a second gRNA, sufficiently close to one another to result in an alteration of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X.
  • the first and second gRNA molecules are configured such that a single strand break positioned by said second gRNA is within 10, 20, 30, 40, or 50 nucleotides of the break positioned by said first gRNA molecule, e.g., when the Cas9 is a nickase.
  • the two gRNA molecules are configured to position cuts at the same position, or within a few nucleotides of one another, on different strands, e.g., essentially mimicking a double strand break.
  • a double strand break can be accompanied by an additional double strand break, positioned by a second, third and/or fourth gRNA molecule, as is discussed below.
  • the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of the target position in the CFTR gene, e.g., F508del,
  • G551D, G542X, N1303K, R117H, W1282X, or R553X e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position; and the targeting domain of a second gRNA molecule is configured such that a double strand break is positioned downstream the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position.
  • a double strand break can be accompanied by two additional single strand breaks, positioned by a second gRNA molecule and a third gRNA molecule.
  • the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of the target position in the CFTR gene, e.g., F508del, G551D,
  • the targeting domains of a second and third gRNA molecule are configured such that two single strand breaks are positioned downstream of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position; and the targeting domains of a second and third gRNA molecule are configured such that two single strand breaks are positioned downstream of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80
  • a first and second single strand breaks can be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule.
  • the targeting domain of a first and second gRNA molecule are configured such that two single strand breaks are positioned upstream of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, Rl 17H, W1282X, or R553X; and the targeting domains of a third and fourth gRNA molecule
  • a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a single gRNA molecule e.g., with a Cas9 nickase
  • the gRNA is configured such that the single strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a single gRNA molecule (e.g., with a Cas9 nuclease other than a Cas9 nickase) is used to create a double strand break at or in close proximity to the CF target position, e.g., the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream of (e.g., within 200 bp downstream) of a CF target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • two gRNA molecules e.g., with one or two Cas9 nickcases
  • the gRNAs molecules are configured such that both of the single strand breaks are positioned upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position.
  • two gRNA molecules are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 200 bp upstream) and a second single strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • two gRNA molecules e.g., with one or two Cas9 nucleases that are not Cas9 nickases
  • the gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within 200 bp upstream) and a second double strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • one double strand break and two single strand breaks are introduced (e.g., positioned by three gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • three gRNA molecules e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases
  • the gRNA molecules are configured such that
  • the double strand break is positioned upstream or downstream of (e.g., within 200 bp upstream or downstream) of the CF target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstream (within 200 bp downstream or upstream), of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • four gRNA molecule e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank an CF target position in the CFTR gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 200 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two or more (e.g., three or four) gRNA molecules are used with one
  • Cas9 molecule when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
  • a CF target knockin position is altered. Altering the CF target knockin position refers to homology-directed knockin of genomic sequence, including the delivery of cDNA template of contiguous exons (X+1) through exon 27 of CFTR gene, wherein exon X is any exon between exon 1 and exon 27. Targeted knockin of CFTR cDNA leads to the cessation of production of mutant or truncated CFTR protein and results in the production of functional CFTR protein.
  • a donor template is provided to mediate HDR-mediated knockin.
  • said donor template comprise homology arms, splice acceptor, contiguous coding sequence of exons (X+1) through exon 27 of CFTR gene and polyadenylation
  • CFTR double stranded DNA donor
  • Donor templates contain DNA sequence which, upon incorporation, would result in the expression of a functional version of the CFTR protein.
  • one CFTR allele is repaired in the subject.
  • both CFTR alleles are repaired in the subject.
  • methods and compositions discussed herein provide for the correction of the underlying genetic cause of CF or CF-like disease, e.g., the correction of a mutation at a CF target position in the CFTR gene, e.g., correction of a mutation.
  • This approach leads to the cessation of production of mutant or truncated CFTR protein and results in the production of functional CFTR protein.
  • This approach prevents the development or progression of lung, gastrointestinal and/or reproductive disease in a subject due to the cessation of production of mutant CFTR protein and restoration of functional CFTR protein production.
  • This approach cures and/or prevents the progression of lung, gastrointestinal and/or reproductive disease in any subject with CF or CF-like disease deficiency who has a mutation in exon (X+l) through exon 27 of the CFTR gene, or in any subject who has a mutation in an intronic or exonic region of the CFTR gene that is after exon X.
  • homology-directed repair of the CFTR gene in any subjects with CF mutations in exons 3 through 27 and introns 2 through 26 by targeting intronic region between exons 2 and 3 and with delivery of a homology-directed repair template including homology arms, splice acceptor, coding sequence of contiguous exons 3-27 of CFTR gene and
  • the CF target position is the intronic region between exons 2 and 3.
  • Altering the CF target position refers to homology-directed repair of genomic sequence including the delivery of cDNA template of exons 3-27 of CFTR gene.
  • This approach cures and/or prevents the progression of lung, gastrointestinal and/or reproductive disease in any subject with CF or CF-like disease deficiency who has a mutation in exons 3-27 of the CFTR gene, or in any subject who has a mutation in an intronic or exonic region of the CFTR gene that is on or after the second intron, including but not limited to the following mutations: e.g., F508del,
  • the CF target position is the intronic region between exons 10 and 11.
  • Altering the CF target position refers to homology-directed repair of genomic sequence including the delivery of cDNA template of exons 11-27 of CFTR gene.
  • This approach cures and/or prevents the progression of lung, gastrointestinal and/or reproductive disease in any subject with CF or CF-like disease deficiency who has a mutation in exons 11-27 of the CFTR gene, or in any subject who has a mutation in an intronic or exonic region of the CFTR gene that is on or after the second intron, including but not limited to the following mutations: e.g., F508del.
  • the method provides for the correction of a mutation at a target position in the CFTR gene, e.g., F508del, G551D,G542X, N1303K, R117H, W1282X, R553X, c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G.
  • the method comprises the introduction of one or more breaks (e.g., single strand breaks or double strand breaks) sufficiently close to (e.g., either 5' or 3' to) the target position in the CFTR gene, e.g., intron 2 or intron 10.
  • the targeting domain of the gRNA molecule is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to (e.g., either 5' or 3' to) the target position e.g., intron 2 or intron 10 allow correction, e.g., an alteration in the CFTR gene, e.g., an alternation associated with HDR.
  • a cleavage event e.g., a double strand break or a single strand break
  • the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position in the CFTR gene, e.g., intron 2 or intron 10.
  • the break e.g., a double strand or single strand break, can be positioned upstream or downstream of the target position in the CFTR gene, e.g., intron 2 or intron 10.
  • a second, third and/or fourth gRNA molecule is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to (e.g., either 5' or 3' to) the target position e.g., intron 2 or intron 10 to allow correction, e.g., an alteration associated with HDR in the CFTR gene.
  • a cleavage event e.g., a double strand break or a single strand break
  • the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position in the CFTR gene, e.g., intron 2 or intron 10.
  • the break e.g., a double strand or single strand break, can be positioned upstream or downstream of the target position in the CFTR gene, e.g., intron 2 or intron 10.
  • a single strand break is accompanied by an additional single strand break, positioned by a second, third and/or fourth gRNA molecule, as discussed below.
  • the targeting domains bind configured such that a cleavage event, e.g., the two single strand breaks, are positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position in the CFTR gene, e.g., intron 2 or intron 10.
  • the first and second gRNA molecules are configured such, that when guiding a Cas9 nickase, a single strand break will be accompanied by an additional single strand break, positioned by a second gRNA, sufficiently close to one another to result in an alteration of the target position in the CFTR gene, e.g., intron 2 or intron 10.
  • the first and second gRNA molecules are configured such that a single strand break positioned by said second gRNA is within 10, 20, 30, 40, or 50 nucleotides of the break positioned by said first gRNA molecule, e.g., when the Cas9 is a nickase.
  • the two gRNA molecules are configured to position cuts at the same position, or within a few nucleotides of one another, on different strands, e.g., essentially mimicking a double strand break.
  • a double strand break can be accompanied by an additional double strand break, positioned by a second, third and/or fourth gRNA molecule, as is discussed below.
  • the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of the target position in the CFTR gene, e.g., intron 2 or intron 10, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position; and the targeting domain of a second gRNA molecule is configured such that a double strand break is positioned downstream the target position in the CFTR gene, e.g., intron 2 or intron 10, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position.
  • a double strand break can be accompanied by two additional single strand breaks, positioned by a second gRNA molecule and a third gRNA molecule.
  • the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of the target position in the CFTR gene, e.g., intron 2 or intron 10 e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position; and the targeting domains of a second and third gRNA molecule are configured such that two single strand breaks are positioned downstream of the target position in the CFTR gene, e.g., intron 2 or intron 10, e.g., within 1, 2, 3, 4, 5, 10, 15, 20,
  • the targeting domain of the first, second and third gRNA molecules are configured such that a cleavage event, e.g., a double strand or single strand break, is positioned,
  • a first and second single strand breaks can be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule.
  • the targeting domain of a first and second gRNA molecule are configured such that two single strand breaks are positioned upstream of the target position in the CFTR gene, e.g., intron 2 or intron 10, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position in the CFTR gene, e.g., intron 2 or intron 10; and the targeting domains of a third and fourth gRNA molecule are configured such that two single strand breaks are positioned downstream of the target position in the CFTR gene, e.g., intron 2 or intron 10, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90,
  • a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a single gRNA molecule e.g., with a Cas9 nickase
  • the gRNA is configured such that the single strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a single gRNA molecule e.g., with a Cas9 nuclease other than a Cas9 nickase
  • the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream of (e.g., within 200 bp downstream) of a CF target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • two gRNA molecules e.g., with one or two Cas9 nickcases
  • the gRNAs molecules are configured such that both of the single strand breaks are positioned upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position.
  • two gRNA molecules are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 200 bp upstream) and a second single strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • two gRNA molecules e.g., with one or two Cas9 nucleases that are not Cas9 nickases
  • the gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within 200 bp upstream) and a second double strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • one double strand break and two single strand breaks are introduced (e.g., positioned by three gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • three gRNA molecules e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases
  • the gRNA molecules are configured such that the double strand break is positioned upstream or downstream of (e.g., within 200 bp upstream or downstream) of the CF target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstream (within 200 bp downstream or upstream), of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • four gRNA molecule e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank an CF target position in the CFTR gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 200 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two or more (e.g., three or four) gRNA molecules are used with one
  • Cas9 molecule when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
  • Approach 3A In an embodiment, Cas9-mediated removal and/or disruption of an intronic segment of DNA, within a CFTR intron, to restore post-transcriptional processing accuracy, e.g., without the use of homology-directed repair.
  • CFTR mutations e.g.,
  • c.3717+12191C>T can cause abbarent post- transcriptional processing, such as missplicing by the creation of novel splice sites which can lead to the early truncation of non-functional CFTR protein resulting in aberrant CFTR channel formation.
  • methods and compositions discussed herein provide for altering the CF target position in the CFTR gene.
  • the CF target position e.g.
  • c.3717+12191 also known as c.3849+10kb, e.g., c.2657+5, also known as c.2789+5, e.g., C.3140-26A, also known as c.3272- 26
  • CF target position is 500bp upstream and/or downstream of c.3717+12191 within intron 22.
  • the CF target position is 200bp upstream within exon 16, and intron 16 and intron 15 and/or downstream of c.2657+5 within intron 16.
  • the CF target position is 200bp upstream within exon 16, and intron 16 and intron 15 and/or downstream of c.2657+5 within intron 16.
  • the CF target position is 200bp upstream and/or downstream of c.3140-26 within intron 19 and exon 20.
  • the removal, disruption and/or repair of a splice site mutation will restore accurate splicing and cease production of aberrant truncation of CFTR protein.
  • This approach will lead to the cessation of production of truncatednon-functional CFTR channel and will lead to the production of wild-type CFTR channel.
  • This approach will prevent the development or progression of lung, gastrointestinal and/or reproductive disease in subjects with CFTR mutations.
  • methods and compositions discussed herein provide for altering the CF target position in the CFTR gene.
  • the alteration can be achieved by (1) break- induced introduction of an indel (also referred to herein as NHEJ-mediated introduction of an indel) in close proximity to or including a CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G), or (2) break-induced deletion (also referred to herein as NHEJ-mediated deletion) of genomic sequence including the mutation at a CF target position (e.g.,
  • the method comprises introducing a break-induced indel in close proximity to or including the CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G).
  • the method comprises the
  • a single gRNAs e.g., unimolecular (or chimeric) or modular gRNA molecules, is configured to position a double strand break sufficiently close to the CF target position in the CFTR gene.
  • the double strand break may be positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) upstream of the CF target poistion, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that NHEJ-mediated repair of the double strand break allows for the NHEJ-mediated introduction of an indel in close proximity to or including the CF target position.
  • the method comprises the introduction of a pair of single strand breaks sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G), such that the break-induced indel could be reasonably expected to span the mutation.
  • Two gRNAs e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two single strand breaks sufficiently close to the CF target position in the CFTR gene.
  • the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that NHEJ mediated repair of the pair of single strand breaks allows for the NHEJ-mediated introduction of an indel in close proximity to or including the CF target position.
  • the pair of single strand breaks may be accompanied by an additional double strand break, positioned by a third gRNA molecule, as is discussed below.
  • the pair of single strand breaks may be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule, as is discussed below.
  • the method comprises the introduction of two sets of breaks (e.g., a pair of double strand breaks targeted by two gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G). such that the break-induced indel could be reasonably expected to span the mutation.
  • Two gRNAs e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., a pair of double strand breaks) sufficiently close to the CF target position in the CFTR gene.
  • the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) downstream of the CF target position.
  • 500 nucleotides e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides
  • NHEJ mediated repair of two sets of breaks allows for the NHEJ-mediated introduction of an indel in close proximity to or including the CF target position.
  • the method comprises the introduction of two sets of breaks (e.g., one double strand break and a pair of single strand breaks targeted by three gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G). such that the break-induced indel could be reasonably expected to span the mutation.
  • two sets of breaks e.g., one double strand break and a pair of single strand breaks targeted by three gRNAs
  • the mutation at the CF target position e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G.
  • Two gRNAs e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., one double strand break and a pair of single strand breaks) sufficiently close to the CF target position in the CFTR gene.
  • the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an
  • NHEJ mediated repair of two sets of breaks allows for the NHEJ-mediated introduction of an indel in close proximity to or including the CF target position.
  • the method comprises the introduction of two sets of breaks (e.g., two pairs of single strand breaks targeted by four gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G). such that the break-induced indel could be reasonably expected to span the mutation.
  • Two gRNAs e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., two pairs of single strand breaks s)
  • the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) downstream of the CF target position.
  • 500 nucleotides e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides
  • NHEJ mediated repair of two sets of breaks allows for the NHEJ-mediated introduction of an indel in close proximity to or including the CF target position.
  • a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a single gRNA molecule (e.g., with a Cas9 nickase) is used to create a single strand break at or in close proximity to the CF target position, e.g., the gRNA is configured such that the single strand break is positioned either upstream (e.g., within 500 bp, e.g., within 200 bp upstream) or downstream (e.g., within 500 bp, e.g., within 200 bp downstream) of the CF target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a single gRNA molecule e.g., with a Cas9 nuclease other than a Cas9 nickase
  • the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 500 bp, e.g., within 200 bp upstream) or downstream of (e.g., within 500 bp, e.g., within 200 bp downstream) of a CF target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • two gRNA molecules e.g., with one or two Cas9 nickcases
  • the gRNAs molecules are configured such that both of the single strand breaks are positioned upstream (e.g., within 500 bp, e.g., within 200 bp upstream) or downstream (e.g., within 500 bp, e.g., within 200 bp downstream) of the CF target position.
  • two gRNA molecules are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 500 bp, e.g., within 200 bp upstream) and a second single strand break is positioned downstream (e.g., within 500 bp, e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • two gRNA molecules e.g., with one or two Cas9 nucleases that are not Cas9 nickases
  • are used to create two double strand breaks to flank a CF target position e.g., the
  • gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within 500 bp, e.g., within 200 bp upstream) and a second double strand break is positioned downstream (e.g., within 500 bp, e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • one double strand break and two single strand breaks are introduced (e.g., positioned by three gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • three gRNA molecules e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases
  • the gRNA molecules are configured such that the double strand break is positioned upstream or downstream of (e.g., within 500 bp, e.g., within 200 bp upstream or downstream) of the CF target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstream (within 200 bp downstream or upstream), of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e
  • four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • four gRNA molecule e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank an CF target position in the CFTR gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 500 bp, e.g., within 200 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 500 bp, e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two or more (e.g., three or four) gRNA molecules are used with one
  • Cas9 molecule when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
  • a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a single gRNA molecule e.g., with a Cas9 nickase
  • the gRNA is configured such that the single strand break is positioned either upstream (e.g., within 500 bp upstream) or downstream (e.g., within 500 bp downstream) of the CF target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a single gRNA molecule e.g., with a Cas9 nuclease other than a Cas9 nickase
  • the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 500 bp upstream) or downstream of (e.g., within 500 bp downstream) of a CF target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • two gRNA molecules e.g., with one or two Cas9 nickcases
  • the gRNAs molecules are configured such that both of the single strand breaks are positioned upstream (e.g., within 500 bp upstream) or downstream (e.g., within 500 bp downstream) of the CF target position.
  • two gRNA molecules are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 500 bp upstream) and a second single strand break is positioned downstream (e.g., within 500 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • two gRNA molecules e.g., with one or two Cas9 nucleases that are not Cas9 nickases
  • are used to create two double strand breaks to flank a CF target position e.g., the
  • gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within 500 bp upstream) and a second double strand break is positioned downstream (e.g., within 500 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • one double strand break and two single strand breaks are introduced
  • three gRNA molecules e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases
  • the gRNA molecules are configured such that the double strand break is positioned upstream or downstream of (e.g., within 500 bp upstream or downstream) of the CF target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstream (within 500 bp downstream or upstream), of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • four gRNA molecule e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank an CF target position in the CFTR gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 500 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 500 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two or more (e.g., three or four) gRNA molecules are used with one Cas9 molecule.
  • at least one Cas9 molecule is from a different species than the other Cas9 molecule(s).
  • one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
  • the CF target position (e.g., c.2657+5, e.g., C.3140-26A) can be altered by non-homologous end-joining mediated removal of a splice site mutation.
  • the CF target position is 200 bp upstream and/or downstream of c.2657+5 within within exon 16, and intron 16 and intron 15.
  • the CF target position is 200 bp upstream and/or downstream of c.3140-26 within exon 20 and intron 19.
  • approach in a subject with a target mutation in close proximity to an exon (including, but not limited to the mutations, e.g., 2789+5G>A, e.g., 3272-26A>G), approach may include Cas-9 mediated removal and/or disruption of an intronic segment at or near the target site with homology-directed repair with delivery of Cas9 nuclease (or nickase, or dead-Cas9), CRISPR-gRNAs, and homology-directed repair donor templates.
  • the donor template will be comprised of a single- strand oligonucleotide donor of 50 NT to 200 NT (or more as the technology becomes available).
  • the donor template will be comprised of a double- strand DNA donor with homology arms of length 700 bps to 1200 bps.
  • the repair of a splice site mutation will restore accurate splicing and cease aberrant truncation of CFTR transcript. This approach will lead to the cessation of production of truncated CFTR channel and will lead to the production of wild-type CFTR channel. This approach will prevent the development or progression of lung,
  • the method comprises the introduction of a double strand break sufficiently close to (e.g., either 5' or 3' to) the CF target position (e.g., c2657+5G>A, or c.3140- 26A>G), such that the break-induced indel could be reasonably expected to span the mutation.
  • a single gRNAs e.g., unimolecular (or chimeric) or modular gRNA molecules, is configured to position a double strand break sufficiently close to the CF target position in the CFTR gene (e.g., 2657+5G>A, or c.3140-26A>G).
  • the double strand break may be positioned within 200
  • nucleotides e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides
  • 500 nucleotides e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that HDR mediated repair of the break(s) restores the functional CFTR protein.
  • the method comprises the introduction of a pair of single strand breaks sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c2657+5G>A, or c.3140-26A>G), such that the break- induced indel could be reasonably expected to span the mutation.
  • Two gRNAs e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two single strand breaks sufficiently close to the CF target position in the CFTR gene.
  • the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides)
  • the pair of single strand breaks may be accompanied by an additional double strand break, positioned by a third gRNA molecule, as is discussed below.
  • the pair of single strand breaks may be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule, as is discussed below.
  • the method comprises the introduction of two sets of breaks (e.g., a pair of double strand breaks targeted by two gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c2657+5G>A, or c.3140-26A>G), such that the break-induced indel could be reasonably expected to span the mutation.
  • Two gRNAs e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., a pair of double strand breaks) sufficiently close to the CF target position in the CFTR gene.
  • the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) downstream of the CF
  • HDR mediated repair of the break(s) restores the functional CFTR protein.
  • the method comprises the introduction of two sets of breaks (e.g., one double strand break and a pair of single strand breaks targeted by three gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c2657+5G>A, or c.3140-26A>G), such that the break- induced indel could be reasonably expected to span the mutation.
  • Two gRNAs e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., one double strand break and a pair of single strand breaks) sufficiently close to the CF target position in the CFTR gene.
  • the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that HDR mediated repair of the break(s) restores the functional CFTR protein.
  • the method comprises the introduction of two sets of breaks (e.g., two pairs of single strand breaks targeted by four gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c2657+5G>A, or c.3140-26A>G), such that the break-induced indel could be reasonably expected to span the mutation.
  • Two gRNAs e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., two pairs of single strand breaks s) sufficiently close to the CF target position in the CFTR gene.
  • the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that HDR mediated repair of the break(s) restores the functional CFTR protein.
  • a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a single gRNA molecule e.g., with a Cas9 nickase
  • the gRNA is configured such that the single strand
  • break is positioned either upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene.
  • a single gRNA molecule e.g., with a Cas9 nuclease other than a Cas9 nickase
  • the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream of (e.g., within 200 bp downstream) of a CF target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • two gRNA molecules e.g., with one or two Cas9 nickcases
  • the gRNAs molecules are configured such that both of the single strand breaks are positioned upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position.
  • two gRNA molecules are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 200 bp upstream) and a second single strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • two gRNA molecules e.g., with one or two Cas9 nucleases that are not Cas9 nickases
  • the gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within 200 bp upstream) and a second double strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • one double strand break and two single strand breaks are introduced (e.g., positioned by three gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • three gRNA molecules e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases
  • the gRNA molecules are configured such that the double strand break is positioned upstream or downstream of (e.g., within 200 bp upstream or downstream) of the CF target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstream (within 200 bp downstream or upstream), of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the CFTR gene.
  • four gRNA molecule e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank an CF target position in the CFTR gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 200 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 200 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two or more (e.g., three or four) gRNA molecules are used with one
  • Cas9 molecule when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
  • cleavage events e.g., double strand or single strand breaks
  • the two or more cleavage events may be made by the same or different Cas9 proteins.
  • a single Cas9 nuclease may be used to create both double strand breaks.
  • a single Cas9 nickase may be used to create the two or more single strand breaks.
  • two Cas9 proteins may be used, e.g., one Cas9 nuclease and one Cas9 nickase. It is contemplated that when two or more Cas9 proteins are used that the two or more Cas9 proteins may be delivered sequentially to control specificity of a double strand versus a single strand break at the desired position in the target nucleic acid.
  • the targeting domain of the first gRNA molecule and the targeting domain of the second gRNA molecule hybridize to the target domain through complementary base pairing to opposite strands of the target nucleic acid molecule.
  • the gRNA molecule and the second gRNA molecule are configured such that the PAMs are oriented outward.
  • the targeting domain of a gRNA molecule is configured to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat, or the endogenous CFTR splice sites, in the target domain.
  • the gRNA molecule may be a first, second, third and/or fourth gRNA molecule.
  • the targeting domain of a gRNA molecule is configured to position a cleavage event sufficiently far from a preselected nucleotide, e.g., the nucleotide of a coding region, such that the nucleotide is not altered.
  • the targeting domain of a gRNA molecule is configured to position an intronic cleavage event sufficiently far from an intron/exon border, or naturally occurring splice signal, to avoid alteration of the exonic sequence or unwanted splicing events.
  • the gRNA molecule may be a first, second, third and/or fourth gRNA molecule, as described herein.
  • the targeting domain of said gRNA molecule is configured to position a cleavage event sufficiently far from a preselected nucleotide, e.g., the nucleotide of a coding region, such that the nucleotide is not be altered.
  • the targeting domain of said gRNA molecule is configured to position an intronic cleavage event sufficiently far from an intron/exon border, or naturally occurring splice signal, to avoid alteration of the exonic sequence or unwanted splicing events.
  • the SCNNIA gene can be altered by gene editing, e.g., using CRISPR-Cas9 mediated methods as described herein.
  • a CF or CF-like target position can be altered by gene editing, e.g., using CRISPR-Cas9 mediated methods to alter the SCNNIA gene.
  • the alteration of the SCNNIA gene can be mediated by any mechanism.
  • CRISPR-Cas9 mediated methods to knockdown or knockout the SCNNIA gene may be applied to any subject with any CF mutation, including but not limited to, e.g., F508del, e.g., G551D, e.g., G542X, e.g., N1303K, e.g., R117H, e.g., W1282X, e.g., R553X, e.g., c.3717+12191, e.g., c.2657+5, e.g., C.3140-26A and/or any subject with any CF-like mutation, including but not limited to a SCNNIA mutation, e.g., VI 141.
  • F508del e.g., G551D, e.g., G542X, e.g., N1303K
  • R117H e.g., W1282X, e.g.,
  • Exemplary mechanisms that can be associated with the alteration of the SCNNA1 gene include, but are not limited to, non-homologous end joining (e.g., classical or alternative), microhomology-mediated end joining (MMEJ), SDSA (synthesis dependent strand annealing) or single strand annealing or single strand invasion, all with or without the alteration of the CFTR gene, including but not limited to the addition of an endogenous- promoter driven cDNA encoding the CFTR gene, or homology-directed repair mediated correction of mutations within the CFTR gene or CRISPR-cas9 mediated repair of splice mutations within the CFTR gene.
  • non-homologous end joining e.g., classical or alternative
  • MMEJ microhomology-mediated end joining
  • SDSA synthesis dependent strand annealing
  • single strand annealing or single strand invasion all with or without the alteration of the CFTR gene, including but not limited to the addition of an endogenous- promoter driven
  • the SCNNIA gene can be targeted (e.g., altered) by gene editing, e.g., using CRISPR-Cas9 mediated methods as described herein.
  • Methods and compositions discussed herein provide for targeting (e.g., altering) a CF target position in the SCNNIA gene.
  • a CF target position can be targeted (e.g., altered) by gene editing, e.g., using CRISPR-Cas9 mediated methods to target (e.g. alter) the SCNNIA gene.
  • Targeting e.g., altering a SCNNIA target position in the SCNNIA gene.
  • Targeting e.g., altering the CF target position is achieved, e.g., by:
  • methods described herein introduce one or more breaks near the early coding region in at least one allele of the SCNNIA gene.
  • methods described herein introduce two or more breaks to flank at least a portion of the SCNNIA gene. The two or more breaks remove (e.g., delete) a genomic sequence including at least a portion of the SCNNIA gene.
  • methods described herein comprise knocking down the SCNNIA gene mediated by enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9- fusion protein by targeting the promoter region of SCNNIA target knockdown position. All methods described herein result in targeting (e.g., alteration) of the SCNNIA gene.
  • the targeting (e.g., alteration) of the SCNNIA gene can be mediated by any mechanism.
  • exemplary mechanisms that can be associated with the alteration of the SCNNIA gene include, but are not limited to, non-homologous end joining (e.g., classical or alternative),
  • MMEJ microhomology-mediated end joining
  • homology-directed repair e.g., endogenous donor template mediated
  • SDSA synthesis dependent strand annealing
  • single strand annealing or single strand invasion.
  • the method comprises introducing an insertion or deletion of one more nucleotides in close proximity to the SCNNIA target knockout position (e.g., the early coding region) of the SCNNIA gene.
  • the method comprises the introduction of one or more breaks (e.g., single strand breaks or double strand breaks) sufficiently close to (e.g., either 5' or 3' to) the early coding region of the CF target knockout position, such that the break-induced indel could be reasonably expected to span the CF target knockout position (e.g., the early coding region in the SCNNIA gene). While not wishing to be bound by theory, it is believed that NHEJ-mediated repair of the break(s) allows for the NHEJ- mediated introduction of an indel in close proximity to within the early coding region of the CF target knockout position.
  • the method comprises introducing a deletion of a genomic sequence comprising at least a portion of the SCNNIA gene.
  • the method comprises the introduction of two double stand breaks - one 5' and the other 3' to (i.e., flanking) the CF target position.
  • two gRNAs e.g., unimolecular (or
  • chimeric or modular gRNA molecules are configured to position the two double strand breaks on opposite sides of the CF target knockout position in the SCNN1A gene.
  • a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the SCNN1A gene.
  • a single gRNA molecule (e.g., with a Cas9 nickase) is used to create a single strand break at or in close proximity to the CF target position, e.g., the gRNA is configured such that the single strand break is positioned either upstream (e.g., within 500 bp upstream, e.g., within 200 bp upstream) or downstream (e.g., within 500 bp downstream, e.g., within 200 bp downstream) of the CF target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the SCNN1A gene.
  • a single gRNA molecule (e.g., with a Cas9 nuclease other than a Cas9 nickase) is used to create a double strand break at or in close proximity to the CF target position, e.g., the gRNA molecule is configured such that the double strand break is positioned either upstream
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the SCNN1A gene.
  • two gRNA molecules e.g., with one or two Cas9 nickcases
  • the gRNAs molecules are configured such that both of the single strand breaks are positioned e.g., within 500 bp upstream, upstream) or downstream (e.g., within 500 bp downstream downstream) of the CF target position.
  • two gRNA molecules are used to create two single strand breaks at or in close proximity to the SCNN1A target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 500 bp upstream) and a second single strand break is positioned downstream (e.g., within 500 bp downstream) of the SCNN1A target position.
  • the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 500 bp upstream) and a second single strand break is positioned downstream (e.g., within 500 bp downstream) of the SCNN1A target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the SCNN1A gene.
  • two gRNA molecules e.g., with one or two Cas9 nucleases that are not Cas9 nickases
  • the gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within500 bp upstream) and a second double strand break is positioned downstream (e.g., within 500 bp downstream) of the SCNN1A target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • one double strand break and two single strand breaks are introduced
  • three gRNA molecules e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases
  • the gRNA molecules are configured such that the double strand break is positioned upstream or downstream of (e.g., within 500 bp upstreamor downstream) of the SCNN1A target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstrea m (e.g., within 500 bp downstream or upstream), of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the SCNN1A gene.
  • four gRNA molecule e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank a CF target position in the SCNN1A gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 500 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within500 bp downstream) of the CF target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two or more (e.g., three or four) gRNA molecules are used with one Cas9 molecule.
  • at least one Cas9 molecule is from a different species than the
  • Cas9 molecule(s) when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
  • a targeted knockdown approach reduces or eliminates expression of functional SCNN1A gene product.
  • a targeted knockdown is mediated by targeting an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fused to a transcription repressor domain or chromatin modifying protein to alter transcription, e.g., to block, reduce, or decrease transcription, of the SCNN1A gene.
  • eiCas9 enzymatically inactive Cas9
  • Methods and compositions discussed herein may be used to alter the expression of the SCNN1A gene to treat or prevent CF or CF-like disease by targeting a promoter region of the SCNN1A gene.
  • the promoter region is targeted to knock down expression of the SCNN1A gene.
  • a targeted knockdown approach reduces or eliminates expression of functional SCNN1A gene product.
  • a targeted gene product As described herein, in an embodiment, a targeted
  • knockdown is mediated by targeting an enzymatically inactive Cas9 (eiCas9) or an eiCas9 fused to a transcription repressor domain or chromatin modifying protein to alter transcription, e.g., to block, reduce, or decrease transcription, of the SCNN1A gene.
  • eiCas9 enzymatically inactive Cas9
  • one or more eiCas9 molecules may be used to block binding of one or more endogenous transcription factors.
  • an eiCas9 molecule can be fused to a chromatin modifying protein. Altering chromatin status can result in decreased expression of the target gene.
  • One or more eiCas9 molecules fused to one or more chromatin modifying proteins may be used to alter chromatin status.
  • This approach is performed in any subject with CF or CF-like disease, with or without a CFTR mutation and a WT or mutant SCNN1A.
  • the CF or CF-like target position is at or near the transcription start site of the
  • altering the CF or CF-like target position refers to delivering a dCas9 that
  • a gRNA molecule refers to a nucleic acid that promotes the specific targeting or homing of a gRNA molecule/Cas9 molecule complex to a target nucleic acid.
  • gRNA molecules can be unimolecular (having a single RNA molecule), sometimes referred to herein as "chimeric" gRNAs, or modular (comprising more than one, and typically two, separate RNA molecules).
  • a gRNA molecule comprises a number of domains. The gRNA molecule domains are described in more detail below.
  • Figs. 1A-1G Several exemplary gRNA structures, with domains indicated thereon, are provided in Figs. 1A-1G. While not wishing to be bound by theory, in an embodiment, with regard to the three dimensional form, or intra- or inter-strand interactions of an active form of a gRNA, regions of high complementarity are sometimes shown as duplexes in Figs. 1A-1G and other depictions provided herein.
  • a unimolecular, or chimeric, gRNA comprises, preferably from 5' to
  • a targeting domain (which is complementary to a target nucleic acid in the CFTR gene or SCNNIA gene, e.g., a targeting domain as described herein, e.g., a targeting domain from any of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A- 5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A- 13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E,
  • a targeting domain which is complementary to a target nucleic acid in the CFTR gene or SCNNIA gene, e.g., a targeting domain as described herein, e.g., a targeting domain from any of Tables
  • a tail domain optionally, a tail domain.
  • a modular gRNA comprises:
  • a first strand comprising, preferably from 5' to 3' ;
  • a targeting domain (which is complementary to a target nucleic acid in the CFTR gene or SCNNIA gene, e.g., a targeting domain as described herein, e.g., a targeting domain from any of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A- 6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A- 29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37
  • a second strand comprising, preferably from 5' to 3':
  • a tail domain optionally, a tail domain.
  • the Targeting Domain Figs. 1A-1G provide examples of the placement of targeting domains.
  • the targeting domain comprises a nucleotide sequence that is complementary, e.g., at least 80, 85, 90, or 95% complementary, e.g., fully complementary, to the target sequence on the target nucleic acid.
  • the targeting domain is part of an RNA molecule and will therefore comprise the base uracil (U), while any DNA encoding the gRNA molecule will comprise the base thymine (T). While not wishing to be bound by theory, in an embodiment, it is believed that the complementarity of the targeting domain with the target sequence contributes to specificity of the interaction of the gRNA molecule/Cas9 molecule complex with a target nucleic acid.
  • the uracil bases in the targeting domain will pair with the adenine bases in the target sequence.
  • the target domain itself comprises in the 5' to 3' direction, an optional secondary domain, and a core domain.
  • the core domain is fully complementary with the target sequence.
  • the targeting domain is 5 to 50 nucleotides in length.
  • the strand of the target nucleic acid with which the targeting domain is complementary is referred to herein as the complementary strand.
  • Some or all of the nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
  • the targeting domain is 16 nucleotides in length.
  • the targeting domain is 17 nucleotides in length.
  • the targeting domain is 18 nucleotides in length.
  • the targeting domain is 19 nucleotides in length.
  • the targeting domain is 20 nucleotides in length.
  • the targeting domain is 21 nucleotides in length.
  • the targeting domain is 22 nucleotides in length.
  • the targeting domain is 23 nucleotides in length.
  • the targeting domain is 24 nucleotides in length.
  • the targeting domain is 25 nucleotides in length.
  • the targeting domain is 26 nucleotides in length.
  • the targeting domain comprises 16 nucleotides.
  • the targeting domain comprises 17 nucleotides.
  • the targeting domain comprises 18 nucleotides.
  • the targeting domain comprises 19 nucleotides.
  • the targeting domain comprises 20 nucleotides.
  • the targeting domain comprises 21 nucleotides.
  • the targeting domain comprises 22 nucleotides.
  • the targeting domain comprises 23 nucleotides.
  • the targeting domain comprises 24 nucleotides.
  • the targeting domain comprises 25 nucleotides.
  • the targeting domain comprises 26 nucleotides.
  • Figs. 1A-1G provide examples of first complementarity domains.
  • the first complementarity domain is complementary with the second complementarity domain, and in an embodiment, has sufficient complementarity to the second complementarity domain to form a duplexed region under at least some physiological conditions.
  • the first complementarity domain is 5 to 30 nucleotides in length.
  • the first complementarity domain is 5 to 25 nucleotides in length. In an
  • the first complementary domain is 7 to 25 nucleotides in length. In an
  • the first complementary domain is 7 to 22 nucleotides in length. In an
  • the first complementary domain is 7 to 18 nucleotides in length.
  • the first complementary domain is 7 to 15 nucleotides in length.
  • the first complementary domain is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length.
  • the first complementarity domain comprises 3 subdomains, which, in the 5' to 3' direction are: a 5' subdomain, a central subdomain, and a 3' subdomain.
  • the 5' subdomain is 4 to 9, e.g., 4, 5, 6, 7, 8 or 9 nucleotides in length.
  • the central subdomain is 1, 2, or 3, e.g., 1, nucleotide in length.
  • the 3' subdomain is 3 to 25, e.g., 4 to 22, 4 to 18, or 4 to 10, or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length.
  • the first complementarity domain can share homology with, or be derived from, a naturally occurring first complementarity domain. In an embodiment, it has at least 50%
  • first complementarity domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, first complementarity domain.
  • nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
  • Figs. 1A-1G provide examples of linking domains.
  • a linking domain serves to link the first complementarity domain with the second complementarity domain of a unimolecular gRNA.
  • the linking domain can link the first and second complementarity domains covalently or non-covalently.
  • the linkage is covalent.
  • the linking domain covalently couples the first and second complementarity domains, see, e.g., Figs. IB-IE.
  • the linking domain is, or comprises, a covalent bond interposed between the first complementarity domain and the second complementarity domain.
  • the linking domain comprises one or more, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.
  • linking domains are suitable for use in unimolecular gRNA molecules.
  • Linking domains can consist of a covalent bond, or be as short as one or a few nucleotides, e.g., 1, 2, 3, 4, or 5 nucleotides in length.
  • a linking domain is 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 or more nucleotides in length.
  • a linking domain is 2 to 50, 2 to 40, 2 to 30, 2 to 20, 2 to 10, or 2 to 5 nucleotides in length.
  • a linking domain shares homology with, or is derived from, a naturally occurring sequence, e.g., the sequence of a tracrRNA that is 5' to the second complementarity domain.
  • the linking domain has at least 50% homology with a linking domain disclosed herein.
  • nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
  • a modular gRNA can comprise additional sequence, 5' to the second complementarity domain, referred to herein as the 5' extension domain, see, e.g., Fig. 1A.
  • the 5' extension domain is, 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4 nucleotides in length.
  • the 5' extension domain is 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides in length.
  • Figs. 1A-1G provide examples of second complementarity domains.
  • the second complementarity domain is complementary with the first complementarity domain, and in an embodiment, has sufficient complementarity to the second complementarity domain to form a duplexed region under at least some physiological conditions.
  • the second complementarity domain can include sequence that lacks complementarity with the first complementarity domain, e.g., sequence that loops out from the duplexed region.
  • the second complementarity domain is 5 to 27 nucleotides in length.
  • the second complementary domain is 7 to 27 nucleotides in length. In an embodiment, the second complementary domain is 7 to 25 nucleotides in length. In an embodiment, the second complementary domain is 7 to 20 nucleotides in length. In an embodiment, the second complementary domain is 7 to 17 nucleotides in length. In an embodiment, the complementary domain is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length.
  • the second complementarity domain comprises 3 subdomains, which, in the 5' to 3' direction are: a 5' subdomain, a central subdomain, and a 3' subdomain.
  • the 5' subdomain is 3 to 25, e.g., 4 to 22, 4 tol8, or 4 to 10, or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length.
  • the central subdomain is 1, 2, 3, 4 or 5, e.g., 3, nucleotides in length.
  • the 3' subdomain is 4 to 9, e.g., 4, 5, 6, 7, 8 or 9 nucleotides in length.
  • the 5' subdomain and the 3' subdomain of the first complementarity domain are respectively, complementary, e.g., fully complementary, with the 3' subdomain and the 5' subdomain of the second complementarity domain.
  • the second complementarity domain can share homology with or be derived from a naturally occurring second complementarity domain. In an embodiment, it has at least 50% homology with a second complementarity domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, first complementarity domain.
  • nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
  • Figs. 1A-1G provide examples of proximal domains.
  • the proximal domain is 5 to 20 nucleotides in length.
  • the proximal domain can share homology with or be derived from a naturally occurring proximal domain. In an embodiment, it has at least 50% homology with a proximal domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, proximal domain.
  • nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
  • Figs. 1A-1G provide examples of tail domains.
  • the tail domain is 0 (absent), 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length.
  • the tail domain nucleotides are from or share homology with sequence from the 5' end of a naturally occurring tail domain, see e.g., Fig. ID or Fig. IE.
  • the tail domain includes sequences that are complementary to each other and which, under at least some physiological conditions, form a duplexed region.
  • the tail domain is absent or is 1 to 50 nucleotides in length.
  • the tail domain can share homology with or be derived from a naturally occurring proximal tail domain. In an embodiment, it has at least 50% homology with a tail domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, tail domain.
  • the tail domain includes nucleotides at the 3' end that are related to the method of in vitro or in vivo transcription.
  • a T7 promoter is used for in vitro
  • these nucleotides may be any nucleotides present before the 3' end of the DNA template.
  • these nucleotides may be the sequence UUUUUU.
  • these nucleotides may be various numbers or uracil bases or may include alternate bases.
  • gRNA molecules The domains of gRNA molecules are described in more detail below.
  • the "targeting domain" of the gRNA is complementary to the "target domain” on the target nucleic acid.
  • the strand of the target nucleic acid comprising the nucleotide sequence complementary to the core domain of the gRNA is referred to herein as the "complementary strand" of the target nucleic acid.
  • Guidance on the selection of targeting domains can be found, e.g., in Fu Y et al, Nat Biotechnol 2014 (doi: 10.1038/nbt.2808) and Sternberg SH et al., Nature 2014 (doi: 10.1038/naturel3011).
  • the targeting domain is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • the targeting domain is 16 nucleotides in length.
  • the targeting domain is 17 nucleotides in length.
  • the targeting domain is 18 nucleotides in length.
  • the targeting domain is 19 nucleotides in length.
  • the targeting domain is 20 nucleotides in length.
  • the targeting domain is 21 nucleotides in length.
  • the targeting domain is 22 nucleotides in length.
  • the targeting domain is 23 nucleotides in length.
  • the targeting domain is 24 nucleotides in length.
  • the targeting domain is 25 nucleotides in length.
  • the targeting domain is 26 nucleotides in length.
  • the targeting domain comprises 16 nucleotides.
  • the targeting domain comprises 17 nucleotides.
  • the targeting domain comprises 18 nucleotides.
  • the targeting domain comprises 19 nucleotides.
  • the targeting domain comprises 20 nucleotides.
  • the targeting domain comprises 21 nucleotides.
  • the targeting domain comprises 22 nucleotides.
  • the targeting domain comprises 23 nucleotides.
  • the targeting domain comprises 24 nucleotides.
  • the targeting domain comprises 25 nucleotides.
  • the targeting domain comprises 26 nucleotides.
  • the targeting domain is 10 +/-5, 20+/-5, 30+/-5, 40+/-5, 50+/-5, 60+/- 5, 70+/-5, 80+/-5, 90+/-5, or 100+/-5 nucleotides, in length.
  • the targeting domain is 20+/-5 nucleotides in length.
  • the targeting domain is 20+/- 10, 30+/- 10, 40+/- 10, 50+/- 10, 60+/- 10,
  • the targeting domain is 30+/- 10 nucleotides in length.
  • the targeting domain is 10 to 100, 10 to 90, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 10 to 20 or 10 to 15 nucleotides in length. In another embodiment, the targeting domain is 20 to 100, 20 to 90, 20 to 80, 20 to 70, 20 to 60, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides in length.
  • the targeting domain has full complementarity with the target sequence.
  • the targeting domain has or includes 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain.
  • the target domain includes 1, 2, 3, 4 or 5 nucleotides that are complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 5' end. In an embodiment, the target domain includes 1, 2, 3, 4 or 5 nucleotides that are complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 3' end.
  • the target domain includes 1, 2, 3, or 4 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 5' end. In an embodiment, the target domain includes 1, 2, 3, or 4 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 3' end.
  • the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
  • the targeting domain comprises two consecutive nucleotides that are not complementary to the target domain ("non-complementary nucleotides”), e.g., two consecutive noncomplementary nucleotides that are within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or more than 5 nucleotides away from one or both ends of the targeting domain.
  • non-complementary nucleotides two consecutive nucleotides that are within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or more than 5 nucleotides away from one or both ends of the targeting domain.
  • no two consecutive nucleotides within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain, are not complementary to the targeting domain.
  • the targeting domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the targeting domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the targeting domain can be modified with a phosphorothioate, or other
  • a nucleotide of the targeting domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
  • the targeting domain includes 1, 2, 3, 4, 5, 6, 7 or 8 or more modifications. In an embodiment, the targeting domain includes 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end. In an embodiment, the targeting domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end.
  • the targeting domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or more than 5 nucleotides away from one or both ends of the targeting domain.
  • no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or
  • nucleotide is modified within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain.
  • Modifications in the targeting domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate targeting domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated in a system in Section IV.
  • the candidate targeting domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • all of the modified nucleotides are complementary to and capable of hybridizing to corresponding nucleotides present in the target domain.
  • modified nucleotides are not complementary to or capable of hybridizing to corresponding nucleotides present in the target domain.
  • the targeting domain comprises, preferably in the 5' ⁇ 3' direction: a secondary domain and a core domain. These domains are discussed in more detail below.
  • the “core domain” of the targeting domain is complementary to the “core domain target” on the target nucleic acid.
  • the core domain comprises about 8 to about 13 nucleotides from the 3' end of the targeting domain (e.g., the most 3' 8 to 13 nucleotides of the targeting domain).
  • the core domain and targeting domain are independently, 6 +1-2, 1+1- 2, 8+/-2, 9+/-2, 10+/-2, 11+/-2, 12+/-2, 13+/-2, 14+/-2, 15+/-2, or 16+-2, nucleotides in length.
  • the core domain and targeting domain are independently, 10+/-2 nucleotides in length.
  • the core domain and targeting domain are independently, 10+/-4 nucleotides in length.
  • the core domain and targeting domain are independently 6, 7, 8, 9, 10,
  • the core domain and targeting domain are independently 3 to 20, 4 to 20, 5 to 20, 6 to 20, 7 to 20, 8 to 20, 9 to 20 10 to 20 or 15 to 20 nucleotides in length.
  • the core domain and targeting domain are independently 3 to 15, e.g., 6 to 15, 7 to 14, 7 to 13, 6 to 12, 7 to 12, 7 to 11, 7 to 10, 8 to 14, 8 to 13, 8 to 12, 8 to 11, 8 to 10 or 8 to 9 nucleotides in length.
  • the core domain is complementary with the core domain target.
  • the core domain has exact complementarity with the core domain target.
  • the core domain can have 1, 2, 3, 4 or 5 nucleotides that are not complementary with the corresponding nucleotide of the core domain.
  • the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
  • the "secondary domain" of the targeting domain of the gRNA is complementary to the "secondary domain target" of the target nucleic acid.
  • the secondary domain is positioned 5' to the core domain.
  • the secondary domain is absent or optional.
  • the targeting domain is 26 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 12 to 17 nucleotides in length.
  • the targeting domain is 25 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 12 to 17 nucleotides in length.
  • the targeting domain is 24 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 11 to 16 nucleotides in length.
  • the targeting domain is 23 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 10 to 15 nucleotides in length.
  • the targeting domain is 22 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 9 to 14 nucleotides in length.
  • the targeting domain is 21 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 8 to 13 nucleotides in length.
  • the targeting domain is 20 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 7 to 12 nucleotides in length.
  • the targeting domain is 19 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 6 to 11 nucleotides in length.
  • the targeting domain is 18 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 5 to 10 nucleotides in length.
  • the targeting domain is 17 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 4 to 9 nucleotides in length.
  • the targeting domain is 16 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 3 to 8 nucleotides in length.
  • the secondary domain is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 nucleotides in length.
  • the secondary domain is complementary with the secondary domain target.
  • the secondary domain has exact complementarity with the secondary domain target.
  • the secondary domain can have 1, 2, 3, 4 or 5 nucleotides that are not
  • the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
  • the core domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the core domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the core domain can be modified with a phosphorothioate, or other modification(s)
  • a nucleotide of the core domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
  • a core domain will contain no more than 1, 2, or 3 modifications.
  • Modifications in the core domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate core domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated in the system described at Section IV.
  • the candidate core domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • the secondary domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the secondary domain comprises one or more modifications, e.g., modifications that render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the secondary domain can be modified with a phosphorothioate, or other modification(s) from Section VIII.
  • a nucleotide of the secondary domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
  • a secondary domain will contain no more than 1, 2, or 3 modifications.
  • Modifications in the secondary domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate secondary domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated in the system described at Section IV.
  • the candidate secondary domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • (1) the degree of complementarity between the core domain and its target, and (2) the degree of complementarity between the secondary domain and its target may differ. In an embodiment, (1) may be greater than (2). In an embodiment, (1) may be less than (2). In an embodiment, (1) and (2) are the same, e.g., each may be completely complementary with its target.
  • (1) the number of modifications (e.g., modifications from Section VIII) of the nucleotides of the core domain and (2) the number of modifications (e.g., modifications from Section VIII) of the nucleotides of the secondary domain may differ. In an embodiment, (1) may be less than (2). In an embodiment, (1) may be greater than (2). In an embodiment, (1) and (2) may be the same, e.g., each may be free of modifications.
  • the first complementarity domain is complementary with the second complementarity domain.
  • the first domain does not have exact complementarity with the second complementarity domain target.
  • the first complementarity domain can have 1, 2, 3, 4 or 5 nucleotides that are not complementary with the corresponding nucleotide of the second complementarity domain.
  • 1, 2, 3, 4, 5 or 6, e.g., 3 nucleotides will not pair in the duplex, and, e.g., form a non-duplexed or looped-out region.
  • an unpaired, or loop-out, region e.g., a loop-out of 3 nucleotides, is present on the second complementarity domain.
  • the unpaired region begins 1, 2, 3, 4, 5, or 6, e.g., 4, nucleotides from the 5' end of the second complementarity domain.
  • the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
  • the first and second complementarity domains are:
  • the second complementarity domain is longer than the first complementarity domain, e.g., 2, 3, 4, 5, or 6, e.g., 6, nucleotides longer.
  • the first and second complementary domains independently, do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the first and second complementary domains independently, comprise one or more modifications, e.g., modifications that the render the domain less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the domain can be modified with a phosphorothioate, or other modification(s) from Section VIII.
  • a nucleotide of the domain can comprise a 2'
  • modification e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
  • first and second complementary domains independently, include 1, 2, 3, 4, 5, 6, 7 or 8 or more modifications.
  • first and second complementary domains independently, include 1, 2, 3, 4, 5, 6, 7 or 8 or more modifications.
  • complementary domains independently, include 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end.
  • first and second complementary domains independently, include as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end.
  • the first and second complementary domains independently, include modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the domain, within 5 nucleotides of the 3' end of the domain, or more than 5 nucleotides away from one or both ends of the domain.
  • the first and second complementary domains independently, include no two consecutive nucleotides that are modified, within 5 nucleotides of the 5' end of the domain, within 5 nucleotides of the 3' end of the domain, or within a region that is more than 5 nucleotides away from one or both ends of the domain.
  • the first and second complementary domains independently, include no nucleotide that is modified within 5 nucleotides of the 5' end of the domain, within 5 nucleotides of the 3' end of the domain, or within a region that is more than 5 nucleotides away from one or both ends of the domain.
  • Modifications in a complementarity domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate complementarity domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated in the system described in Section IV.
  • the candidate complementarity domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • the first complementarity domain has at least 60, 70, 80, 85%, 90% or 95% homology with, or differs by no more than 1, 2, 3, 4, 5, or 6 nucleotides from, a reference first complementarity domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus, first complementarity domain, or a first complementarity domain described herein, e.g., from Figs. 1A-1G.
  • a reference first complementarity domain e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus
  • first complementarity domain e.g., from Figs. 1A-1G.
  • the second complementarity domain has at least 60, 70, 80, 85%, 90%, or 95% homology with, or differs by no more than 1, 2, 3, 4, 5, or 6 nucleotides from, a reference second complementarity domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus, second complementarity domain, or a second complementarity domain described herein, e.g., from Figs. 1A-1G.
  • a reference second complementarity domain e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus
  • second complementarity domain e.g., from Figs. 1A-1G.
  • the duplexed region formed by first and second complementarity domains is typically 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 base pairs in length (excluding any looped out or unpaired nucleotides).
  • the first and second complementarity domains when duplexed, comprise 11 paired nucleotides, for example, in the gRNA sequence (one paired strand underlined, one bolded):
  • the first and second complementarity domains when duplexed, comprise 15 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
  • the first and second complementarity domains when duplexed, comprise 16 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
  • the first and second complementarity domains when duplexed, comprise 21 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
  • nucleotides are exchanged to remove poly-U tracts, for example in the gRNA sequences (exchanged nucleotides underlined):
  • a modular gRNA can comprise additional sequence, 5' to the second complementarity domain.
  • the 5' extension domain is 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, or 2 to 4 nucleotides in length.
  • the 5' extension domain is 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides in length.
  • the 5' extension domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the 5' extension domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the 5' extension domain can be modified with a phosphorothioate, or other modification(s) from Section VIII.
  • a nucleotide of the 5' extension domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other
  • the 5' extension domain can comprise as many as 1, 2, 3, 4, 5, 6, 7 or
  • the 5' extension domain comprises as many as 1, 2, 3, or 4
  • the 5' extension domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end, e.g., in a modular gRNA molecule.
  • the 5' extension domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the 5' extension domain, within 5 nucleotides of the 3' end of the 5' extension domain, or more than 5 nucleotides away from one or both ends of the 5' extension domain. In an embodiment, no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the 5' extension domain, within 5 nucleotides of the 3' end of the 5' extension domain, or within a region that is more than 5 nucleotides away from one or both ends of the 5' extension domain.
  • no nucleotide is modified within 5 nucleotides of the 5' end of the 5' extension domain, within 5 nucleotides of the 3' end of the 5' extension domain, or within a region that is more than 5 nucleotides away from one or both ends of the 5' extension domain.
  • Modifications in the 5' extension domain can be selected so as to not interfere with gRNA molecule efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate 5' extension domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated in the system described at Section IV.
  • the candidate 5' extension domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • the 5' extension domain has at least 60, 70, 80, 85, 90 or 95% homology with, or differs by no more than 1, 2, 3, 4, 5, or 6 nucleotides from, a reference 5' extension domain, e.g., a naturally occurring, e.g., an S. pyogenes, or S. aureus S. thermophilus, 5' extension domain, or a 5' extension domain described herein, e.g., from Figs. 1A-1G.
  • a reference 5' extension domain e.g., a naturally occurring, e.g., an S. pyogenes, or S. aureus S. thermophilus
  • 5' extension domain or a 5' extension domain described herein, e.g., from Figs. 1A-1G.
  • the linking domain is disposed between the first and second complementarity domains.
  • the two molecules are associated with one another by the complementarity domains.
  • the linking domain is 10 +/-5, 20+/-5, 30+/-5, 40+/-5, 50+/-5, 60+/-5,
  • the linking domain is 20+/- 10, 30+/- 10, 40+/- 10, 50+/- 10, 60+/- 10, 70+/- 10, 80+/- 10, 90+/- 10, or 100+/- 10 nucleotides, in length.
  • the linking domain is 10 to 100, 10 to 90, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 10 to 20 or 10 to 15 nucleotides in length. In other embodiments, the linking domain is 20 to 100, 20 to 90, 20 to 80, 20 to 70, 20 to 60, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides in length.
  • the linking domain is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 17, 18, 19, or 20 nucleotides in length.
  • the linking domain is a covalent bond.
  • the linking domain comprises a duplexed region, typically adjacent to or within 1, 2, or 3 nucleotides of the 3' end of the first complementarity domain and/or the 5- end of the second complementarity domain.
  • the duplexed region can be 20+/-10 base pairs in length.
  • the duplexed region can be 10+/-5, 15+/-5, 20+/-5, or 30+/-5 base pairs in length.
  • the duplexed region can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 base pairs in length.
  • sequences forming the duplexed region have exact complementarity with one another, though in some embodiments as many as 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides are not complementary with the corresponding nucleotides.
  • the linking domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the linking domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the linking domain can be modified with a phosphorothioate, or other
  • a nucleotide of the linking domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
  • the linking domain can comprise as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications.
  • Modifications in a linking domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate linking domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated a system described in
  • a candidate linking domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • the linking domain has at least 60, 70, 80, 85, 90 or 95% homology with, or differs by no more than 1, 2, 3, 4, 5 ,or 6 nucleotides from, a reference linking domain, e.g., a linking domain described herein, e.g., from Figs. 1A-1G.
  • the proximal domain is 6 +1-2, 1+1-2, 8+/-2, 9+1-2, 10+/-2, 11+/-2, 12+/-2, 13+/-2, 14+/-2, 14+/-2, 16+/-2, 17+/-2, 18+/-2, 19+/-2, or 20+/-2 nucleotides in length.
  • the proximal domain is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • the proximal domain is 5 to 20, 7, to 18, 9 to 16, or 10 to 14 nucleotides in length.
  • the proximal domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the proximal domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the proximal domain can be modified with a phosphorothioate, or other
  • a nucleotide of the proximal domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
  • the proximal domain can comprise as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications. In an embodiment, the proximal domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end, e.g., in a modular gRNA molecule. In an embodiment, the target domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end, e.g., in a modular gRNA molecule.
  • the proximal domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the proximal domain, within 5 nucleotides of the 3' end of the proximal domain, or more than 5 nucleotides away from one or both ends of the proximal domain. In an embodiment, no two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the proximal domain, within 5 nucleotides of the 3' end of the proximal domain, or more than 5 nucleotides away from one or both ends of the proximal domain. In an embodiment, no two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the proximal domain, within 5 nucleotides of the 3' end of the proximal domain,
  • nucleotides are modified within 5 nucleotides of the 5' end of the proximal domain, within 5 nucleotides of the 3' end of the proximal domain, or within a region that is more than 5 nucleotides away from one or both ends of the proximal domain.
  • no nucleotide is modified within 5 nucleotides of the 5' end of the proximal domain, within 5 nucleotides of the 3' end of the proximal domain, or within a region that is more than 5 nucleotides away from one or both ends of the proximal domain.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

CRISPR/CAS-related compositions and methods for treatment of Cystic Fibrosis (CF).

Description

CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING
CYSTIC FIBROSIS
REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of U.S. Provisional Application No.
61/977,488, filed April 9, 2014, the contents of which are hereby incorporated by reference in their entirety.
FIELD OF THE INVENTION
The invention relates to CRISPR/CAS-related methods and components for editing of target nucleic acid sequence, and applications thereof in connection with Cystic Fibrosis (CF) CF-like disease.
BACKGROUND
Cystic fibrosis (CF) is an autosomal recessive, hereditary disease caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR gene encodes a cAMP-gated channel that is involved in chloride and bicarbonate transport. It regulates sodium transport through inhibition of the epithelial sodium channel, which is encoded by the SCNN1A gene. CFTR is expressed on the apical surface of epithelial cells in the airway, gastrointestinal tract, reproductive tract, sweat glands and submucosal glands.
CF affects one in 3,500 children born in the United States. It is the most common fatal autosomal recessive disease in individuals of European descent (Tobias 2011; Essential Medical Genetics, John Wiley & Sons, ed. p. 312). There are approximately 30,000 subjects in the United States with the disease (From The Cystic Fibrosis Foundation; cff.org, accessed on 3/19/2015).
The most common mutation in the CFTR gene is a deletion of the three nucleotides encoding Phenylalanine (F) at position 508 of the CFTR protein (also sometime referred to herein as "F508del"). This mutation is the causative mutation in approximately two-thirds of CF cases. The remaining cases are caused by at least 1000 different mutations, many of which cause a less severe form of the disease.
1
5535.1 Subjects having CF can present at birth or in early infancy with pancreatic insufficiency. Pancreatic dysfunction leads to malabsorption of fat and fat-soluble vitamins, which causes poor growth as well as gallstones and biliary disease. The lung manifestations of the disease can be more severe but may present slightly after pancreatic manifestations, in infancy or early childhood. Aberrant chloride and sodium transport due to decreased CFTR activity causes lowered apical surface fluid levels in the lungs, which leads to "sticky" mucous and lower airway obstruction. Subjects having CF or CF-like disease suffer from frequent infections due to inability to clear mucous. Local inflammatory mediators try to clear the infection but have difficulty. The triad of inflammation, infection and obstruction leads to progressive destruction of the lung parenchyma. Eventually, many subjects having CF or CF-like disease die in their late 30' s due to respiratory failure.
Current treatments for CF or CF-like disease delay lung destruction and slow disease progression. Treatments for the pulmonary manifestations of CF or CF-like disease include: antibiotics (oral, inhaled and intravenous), CFTR modulators (including CFTR potentiators), DNase, chest physiotherapy to loosen secretions and anti-inflammatory therapeutics. Treatment of the gastrointestinal manifestations includes supplemental gut soluble vitamins, high calorie diet and oral pancreatic enzymes. Subjects who develop diabetes are treated with insulin injections or an insulin pump. At the end stage, patients may benefit from lung transplant. Lung transplant may be combined with liver and/or pancreatic transplant.
Current treatments do not reverse the damage to the lungs or cure CF or CF-like disease.
The average life expectancy for subjects having CF or CF-like disease is 37 years of age
(MacKenzie et al, 2014; Annals of Internal Medicine 161(4):233-41). 80% of patients with CF or CF-like disease die from end-stage lung disease.
In spite of current therapies, there is a need for a therapy that prevents or delays the progression of disease in CF or CF-like disease.
SUMMARY OF THE INVENTION
Methods and compositions discussed herein provide for the treatment and prevention of Cystic Fibrosis (CF) and CF-like disease. The approach described herein aims to restore CFTR channel function, restore chloride, bicarbonate and/or sodium balance, and/or decrease mucous viscosity within the lungs, airways, gastrointestinal tract and reproductive tract.
2
5535.1 CFTR modulators (both approved and in development) improve the functioning of mutant CFTR. These therapeutics improve CFTR functioning but do not return functionality to wild type levels. The approach described herein is expected to restore CFTR function through complete correction of the gene.
Gene therapy approaches are in development that deliver the CFTR channel gene to the lungs of CF or CF-like disease patients. However, gene therapy may require constant readministration over the course of the lifetime of a subject due to high cell turnover in target epithelial cells. The approach described herein is expected to restore CFTR function and/or ameliorate SCNN1A disinhibition permanently through one, two or several doses.
The CFTR gene encodes a 180-kDA cAMP-gated chloride (C1-) channel. The channel has six transmembrane spanning domains and is expressed by epithelial cells, lymphocytes and cardiac myocytes. The CFTR regulates the viscosity of mucous through its activity in the epithelial cells of the lungs, gastrointestinal tract and reproductive tract. Mutations in the CFTR result in decreased CFTR activity. Decreased CFTR activity can lead to aberrant ion transport, which gives rise to various disease symptoms in the lungs and other tissues, such as
accumulation of sticky mucus, airway obstruction, infection and inflammation. Correction of CFTR mutations will ameliorate or cure lung, gastrointestinal and/or reproductive symptoms of CF or CF-like disease.
The SCNN1A gene encodes the alpha subunit of the epithelial sodium channel (ENaC). The channel, comprised of alpha, beta and gamma subunits, regulates sodium transport into epithelial cells, including the epithelium of the lungs, sweat glands and kidneys. Mutations in the SCNN1A gene, (e.g. Vail 14ILE) have been shown to cause CF-like disease, characterized by pulmonary disease, including bronchiectasis. Mutations in SCNN1A also cause
pseudohypoaldosteronism, a severe disease of the kidney. Pseudohypoaldosteronism is due to defective sodium transport within kidney epithelial cells; it is not caused by defective sodium transport in other tissues. The methods described herein include the targeted knockout of SCNN1A in the lung, gastrointestinal tract and/or reproductive tract. The methods described herein will not target kidney epithelium and will avoid the negative consequences of SCNN1A mutations within the kidney epithelium. One mutation in the SCNN1A gene, a 1477T>G substitution (W493R) has been identified in subjects who also have a mutation in CFTR. This mutation is associated with a severe CF or CF-like disease phenotype, including severe
3
5535.1 bronchiectasis, chronic bronchitis and/or severe gastrointestinal symptoms. This mutation has been found to be associated with 4-fold overactivity of the ENaC channel (Azad et al., 2009; Human Mutation 30: 1093-1103). Overactivity of the SCNNlA-encoded ENaC channel can contribute to CF and CF-like disease. In all subjects, the CFTR is involved in inhibition of ENaC. CFTR mutations in subjects with CF or CF-like disease leads to ENaC disinhibition, leading to overactivity of the ENaC channel. ENaC overactivity can lead to further reduction in viscosity of mucous in CF or CF-like disease subjects, as more sodium is absorbed at the apical surface of epithelial cells, followed by increased fluid absorption from the mucous layer within the lung (Baker et al., 2012; Medicine & Science in Sports and Exercise 44(12): 2315-2321). Increased fluid absorption from the mucous layer reduces mucous viscosity. Inhibition of ENaC through SCNN1A knockout and/or knockdown in subjects with CF or CF-like disease can ameliorate the symptoms of CF or CF-like disease. Mutations in the CFTR gene (also known as ABC35, ATP-binding cassette sub-family C, member 7, CFTR/MRP, dJ760C5.1 , MRP 7 and TNR-CFTR) have been shown to cause CF and/or CF-like disease. Mutations in the CFTR gene leading to CF and/or CF-like disease can be described based on their target position in the CFTR protein. In an embodiment, the target position is F508, e.g., F508del (also sometimes referred to herein as "AF508"), in the CFTR protein, which corresponds to a deletion of three nucleotides c.l521_1523delCTT in the CFTR gene (e.g., c.l521_1523delCTT (p.Phe508delPhe)). In an embodiment, the target position is G551, e.g., G551D, in the CFTR protein, which corresponds to c. l652G>A in the CFTR gene. In an embodiment, the target position is G542, e.g., G542X, in the CFTR protein, which corresponds to c. l624G>T in the CFTR gene. In an embodiment, the target position is N1303, e.g., N1303K, in the CFTR protein, which corresponds to c.3909C>G in the CFTR gene. In an embodiment, the target position is Rl 17, e.g., Rl 17H, in the CFTR protein, which corresponds to c.350G>A in the CFTR gene. In an embodiment, the target position is W1282, e.g., W1282X, in the CFTR protein, which corresponds to c. c.3846G>A in the CFTR gene. In an embodiment, the target position is R553, e.g., R553X, in the CFTR protein, which corresponds to c.l657C>T in the CFTR gene. In an embodiment, the target position is c.3717+12191, also known as c.3849+10kb, which corresponds to 3717+12191C>T in the CFTR gene. In an embodiment, the target position is c.2657+5, also known as c.2789+5, which corresponds to 2657+5G>A in the CFTR gene. In an embodiment, the target position is c.3140-26, also known as c.3272-26, which corresponds to c.3140-26A>G in the CFTR gene.
4
5535.1 Overactivity of the SCNNIA gene has been shown to contribute to bronchiectasis, bronchitis, and gastrointestinal symptoms in subjects with CF and in subjects with CF-like disease. In another aspect, methods and compositions discussed herein may be used to alter the SCNNIA gene (also known as sodium channel, non-voltage-gated 1 alpha subunit; amiloride- sensitive epithelial sodium channel alpha subunit; BESC2; ENaCa; SCNEA; SCNN1;
ENaCalpha) to treat or prevent CF or CF-like disease, by targeting the SCNNIA gene, e.g., the non-coding or coding regions, e.g., a promoter region, or a transcribed sequence, e.g., intronic or exonic sequence. In an embodiment, the target position is VI 14, which corresponds to VI 141 in the SCNNIA gene. SCNNIA encodes an epithelial sodium channel, ENaC, that is negatively regulated by CFTR. In subjects with CFTR mutations, knocking out or knocking down the SCNNIA gene in certain cells will reduce or reverse the effect of defective CFTR. In subjects with no CFTR mutations but CF-like disease caused by SCNNIA mutations or other mechanisms, knocking out or knocking down the SCNNIA gene in certain cells will improve the viscosity of mucous and ameliorate disease.
Methods and compositions disclosed herein provide a number of approaches for treating or preventing CF and/or CF-like disease. As is discussed in more detail below, methods described herein provide for treating or preventing CF or CF-like disease by correcting a target position in the CFTR gene to provide corrected, or functional, e.g., wild type, CFTR. Other methods described herein allow for treating or preventing CF or CF-like disease by inducing or introducing a mutation that reduces the level of functional SCNNIA gene product.
In one aspect, methods and compositions discussed herein, provide for the correction of the underlying cause of CF or CF-like disease, e.g., the correction of a mutation at a target position in the CFTR gene, e.g., correction of a mutation in the CFTR gene that corresponds to amino acid position 508, e.g., an F508 deletion (F508del), in CFTR protein.
"CF target mutant position", as used herein, refers to a target position in the CFTR gene, which, if mutated, can result in a mutant protein and give rise to CF or CF-like disease. In an embodiment, the target position comprises one, two, or three nucleotides. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at F508, e.g., F508del. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at G551, e.g., G551D. In an embodiment, the CF target mutant
5
5535.1 position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at G542, e.g., G542X, in the CFTR protein, which corresponds to c. l624G>T in the CFTR gene. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at N1303, e.g., N1303K, in the CFTR protein, which corresponds to c.3909C>G in the CFTR gene. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at Rl 17, e.g., Rl 17H, in the CFTR protein, which corresponds to c.350G>A in the CFTR gene. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at W1282, e.g., W1282X, in the CFTR protein, which corresponds to c. c.3846G>A in the CFTR gene. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at R553, e.g., R553X, in the CFTR protein, which corresponds to c. l657C>T in the CFTR gene. In an embodiment, the CF target mutant position is c.3717+12191, also known as c.3849+10kb, which corresponds to 3717+12191C>T in the CFTR gene. In an embodiment, the CF target mutant position is c.2657+5, also known as c.2789+5, which corresponds to 2657+5G>A in the CFTR gene. In an embodiment, the CF target mutant position is c.3140-26, also known as c.3272-26, which corresponds to c.3140-26 A>G in the CFTR gene. In an embodiment, the CF target mutant position is a position in the SCNN1A gene at which a change can give rise to a mutant protein having a mutation at VI 14, which corresponds to VI 141 in the SCNN1A gene.
While some of the disclosure herein is presented in the context of the mutation in the CFTR gene that gives rise to an F508 mutant protein (e.g., a F508del mutant protein) ,a G551 mutant protein (e.g., a G551D mutant protein), a G542 mutant protein (e.g., G542X mutant protein), a N1303 mutant protein (e.g., a N1303K mutant protein), a Rl 17 mutant protein (e.g., an Rl 17H mutant protein), a W1282 mutant protein (e.g., a W1282X mutant protein), an R553 mutant protein (e.g., an R553X mutant protein), a c.2789+5bp intronic mutant (e.g., a c.2789+5bp G>A mutant), or a c.3272-26bp intronic mutant (e.g., a c.3272-26bp A>G mutant), the methods and compositions herein are broadly applicable to any mutation, e.g., a point mutation or a deletion, in the CFTR gene that gives rise to CF or CF-like disease.
6
5535.1 While not wishing to be bound by theory, it is believed that, in an embodiment, a mutation at a CF target mutant position is corrected by homology directed repair (HDR), as described herein.
In another aspect, methods and compositions discussed herein may be used to alter the SCNNIA gene (also known as sodium channel, non-voltage-gated 1 alpha subunit) to treat or prevent CF or CF-like disease, by targeting the SCNNIA gene, e.g., the non-coding or coding regions, e.g., a promoter region, or a transcribed sequence, e.g., intronic or exonic sequence. SCNNIA encodes an epithelial sodium channel that is negatively regulated by CFTR. By knocking out the SCNNIA gene in certain cells, the effect of defective CFTR can be reduced or reversed.
In another aspect, the methods and compositions discussed herein may be used to alter the SCNNIA gene to treat or prevent CF or CF-like disease by targeting the coding sequence of the SCNNIA gene. In one embodiment, the gene, e.g., the coding sequence of the SCNNIA gene, is targeted to knockout the gene, e.g., to eliminate expression of the gene, e.g., to knockout one or both alleles of the SCNNIA gene, e.g., by induction of an alteration comprising a deletion or mutation in the SCNNIA gene. In an embodiment, the method provides an alteration that comprises an insertion or deletion.
In an embodiment, coding region, e.g., an early coding region, of the SCNNIA gene, is targeted for alteration and knockout. In one embodiment, an early coding region of the SCNNIA gene is targeted to knockout the SCNNIA gene. In an embodiment, targeting affects both alleles of the SCNNIA gene. In an embodiment, targeting affects one allele of the SCNNIA gene. In an embodiment, a targeted knockout approach reduces or eliminates expression of functional SCNNIA gene product. In an embodiment, the method provides an alteration in the SCNNIA gene that comprises an insertion or deletion.
In another aspect, the methods and compositions discussed herein may be used to alter the SCNNIA gene to treat or prevent CF or CF-like disease by targeting non-coding sequence of the SCNNIA gene, e.g., promoter, an enhancer, an intron, 3'UTR, and/or polyadenylation signal. In an embodiment, the gene, e.g., the non-coding sequence of the SCNNIA gene, is targeted to knockout the gene, e.g., to eliminate expression of the gene, e.g., to knockout one or both alleles of the SCNNIA gene, e.g., by induction of an alteration comprising a deletion or mutation in the
7
5535.1 SCNNIA gene. In an embodiment, the method provides an alteration that comprises an insertion or deletion.
As described herein, in an embodiment, a targeted knockout approach is mediated by non-homologous end joining (NHEJ) using a CRISPR/Cas system comprising an enzymatically active Cas9 (eaCas9).
"CF target knockout position", as used herein, refers to a position in the SCNNIA gene, which if altered by NHEJ-mediated alteration, results in alleviation of a symptom of CF or CF- like disease. In an embodiment, the alteration results in reduction or elimination of expression of functional SCNNIA gene product. In an embodiment, the position is in the SCNNIA coding region, e.g., an early coding region.
In an embodiment, the promoter region of the SCNNIA gene is targeted to knock down the expression of the SCNNIA gene. This type of alteration is also sometimes referred to as "knocking down" the SCNNIA gene. While not wishing to be bound by theory, in an
embodiment, a targeted knockdown approach is mediated by a CRISPR/Cas system comprising a Cas9 molecule, e.g., an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain or chromatin modifying protein), as described herein. In an embodiment, the SCNNIA gene is targeted to alter (e.g., to block, reduce, or decrease) the transcription of the SCNNIA gene. In another embodiment, the SCNNIA gene is targeted to alter the chromatin structure (e.g., one or more histone and/or DNA modifications) of the SCNNIA gene. In an embodiment, a CF targe knockdown position is targeted by genome editing using the CRISPR/Cas9 system. In an embodiment, one or more gRNA molecules comprising a targeting domain are configured to target an enzymatically inactive Cas9 (eiCas9) or an eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain), sufficiently close to a CF target knockdown position to reduce, decrease or repress expression of the SCNNIA gene.
"CF target knockdown position", as used herein, refers to a position in the SCNNIA gene, which if targeted, e.g., by an eiCas9 molecule or an eiCas9 fusion described herein, results in reduction or elimination of expression of functional SCNNIA gene product. In an embodiment, the transcription of the SCNNIA gene is reduced or eliminated. In another embodiment, the chromatin structure of the SCNNIA gene is altered.
8
5535.1 "CF target knockin position", as used herein, refers to a sequence, which if modified by the insertion of CFTR sequence, results in an optimization of CFTR activity, e.g., by resulting in a CFTR sequence that encodes a protein having wild type activity. Exemplary CF target knockin position include: CFTR sequence within intron 2, into which, e.g., can be introduced CFTR sequence that codes for CFTR exons 3-27; and sequence within CFTR intron 10, into which sequence that codes for CFTR exons 11-27 can be introduced. In an embodiment, a CF target knockin position includes CFTR intronic sequence between a second and a third exon (e.g., intron 2), and CFTR sequence encoding the third exon through the final exon (exon 27), is introduced, resulting in a CFTR sequence that is free of one or more cryptic splice sites and that encodes a CFTR protein having wild type activity. In an embodiment, a CF target knockin position, is a position which is upstream of a mutation, or upsteam of an intron having a mutation, and introduction of wild-type CFTR sequence results in a CFTR sequence that is free of the mutation. In an embodiment the CF target knockin position is in CFTR intronic sequence: between exon2 and exon 3; or between exon 10 and exon 11. In an embodiment, the resulting CFTR sequence comprises subject sequence upstream from the CF target knockin position and newly introduced sequence downstream from the CF target knockin position, which taken together, encode a CFTR protein having wild type activity. In an embodiment, the point of insertion is 3' to a splice donor site and 5' from a splice acceptor site. In an embodiment, CFTR sequence encoding exons 3-27 is inserted under control of the promoter, e.g., at the transcription start site. In an embodiment, CFTR sequence introduced can exclude introns, e.g., a sequence encoding exons, but without introns, is inserted, e.g., CFTR CDNA sequence is introduced.
"CF target position", as used herein, refers to a CF target mutant position, CF target knockout position, CF target knockdown position, and/or CF target knockin position, as described herein.
In one aspect, disclosed herein is a gRNA molecule, e.g., an isolated or non-naturally occurring gRNA molecule, comprising a targeting domain which is complementary with a target domain from the CFTR gene or SCNNIA gene.
In an embodiment, the targeting domain of the gRNA molecule is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a CF target position in the CFTR gene or SCNNIA gene to allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of a CF target position in the CFTR gene or SCNNIA gene. In
9
5535.1 an embodiment, the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of a CF target position. The break, e.g., a double strand or single strand break, can be positioned upstream or downstream of a CF target position in the CFTR gene or SCNN1A gene.
In an embodiment, a second gRNA molecule comprising a second targeting domain is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to the CF target position in the CFTR gene or SCNN1A gene, to allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of the CF target position in the CFTR gene or SCNN1A gene, either alone or in combination with the break positioned by said first gRNA molecule. In an embodiment, the targeting domains of the first and second gRNA molecules are configured such that a cleavage event, e.g., a double strand or single strand break, is positioned, independently for each of the gRNA molecules, within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position. In an embodiment, the breaks, e.g., double strand or single strand breaks, are positioned on both sides of a nucleotide of a CF target position in the CFTR gene or SCNN1A gene. In an embodiment, the breaks, e.g., double strand or single strand breaks, are positioned on one side, e.g., upstream or downstream, of a nucleotide of a CF target position in the CFTR gene or SCNN1A gene.
In an embodiment, a single strand break is accompanied by an additional single strand break, positioned by a second gRNA molecule, as discussed below. For example, the targeting domains are configured such that a cleavage event, e.g., the two single strand breaks, are positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of a CF target position. In an embodiment, the first and second gRNA molecules are configured such, that when guiding a Cas9 molecule, e.g., a Cas9 nickase, a single strand break will be accompanied by an additional single strand break, positioned by a second gRNA, sufficiently close to one another to result in alteration of a CF target position in the CFTR gene or SCNN1A gene. In an embodiment, the first and second gRNA molecules are configured such that a single strand break positioned by said second gRNA is within 10, 20, 30, 40, or 50 nucleotides of the break positioned by said first gRNA molecule, e.g., when the Cas9 molecule is a nickase. In an embodiment, the two gRNA molecules are configured to position
10
5535.1 cuts at the same position, or within a few nucleotides of one another, on different strands, e.g., essentially mimicking a double strand break.
In an embodiment, a double strand break can be accompanied by an additional double strand break, positioned by a second gRNA molecule, as is discussed below. For example, the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of a CF target position in the CFTR gene or SCNNIA gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position; and the targeting domain of a second gRNA molecule is configured such that a double strand break is positioned downstream of a CF target position in the CFTR gene or SCNNIA gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position.
In an embodiment, a double strand break can be accompanied by two additional single strand breaks, positioned by a second gRNA molecule and a third gRNA molecule. For example, the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of a CF target position in the CFTR gene or SCNNIA gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position; and the targeting domains of a second and third gRNA molecule are configured such that two single strand breaks are positioned downstream of a CF target position in the CFTR gene or SCNNIA gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position. In an embodiment, the targeting domain of the first, second and third gRNA molecules are configured such that a cleavage event, e.g., a double strand or single strand break, is positioned, independently for each of the gRNA molecules.
In an embodiment, a first and second single strand breaks can be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule. For example, the targeting domain of a first and second gRNA molecule are configured such that two single strand breaks are positioned upstream of a CF target position in the CFTR gene or SCNNIA gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position; and the targeting domains of a third and fourth gRNA molecule are configured such that two single strand breaks are positioned downstream of a CF target position in the CFTR gene or SCNNIA gene, e.g.,
11
5535.1 within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 225, 250, or 300 nucleotides of the target position.
It is contemplated herein that, in an embodiment, when multiple gRNAs are used to generate (1) two single stranded breaks in close proximity, (2) two double stranded breaks, e.g., flanking a CF target position, e.g., a mutation (e.g., to remove a piece of DNA, e.g., to introduce a deletion mutation) or to create more than one indel in the gene, e.g., in a coding region, e.g., an early coding region, (3) one double stranded break and two paired nicks flanking a CF target position, e.g., a mutation (e.g., to remove a piece of DNA, e.g., to introduce a deletion mutation) or (4) four single stranded breaks, two on each side of a position, e.g., a mutation, that they are targeting the same CF target position. It is further contemplated herein that multiple gRNAs may be used to target more than one CF target position (e.g., mutation) in the same gene.
In an embodiment, the targeting domain of the first gRNA molecule and the targeting domain of the second gRNA molecules are complementary to opposite strands of the target nucleic acid molecule. In an embodiment, the gRNA molecule and the second gRNA molecule are configured such that the PAMs are oriented outward.
In an embodiment, the targeting domain of a gRNA molecule is configured to avoid unwanted target chromosome elements, such as repeat elements, e.g., Alu repeats, in the target domain. The gRNA molecule may be a first, second, third and/or fourth gRNA molecule, as described herein.
In an embodiment, the targeting domain of a gRNA molecule is configured to position a cleavage event sufficiently far from a preselected nucleotide, e.g., the nucleotide of a coding region, such that the nucleotide is not altered. In an embodiment, the targeting domain of a gRNA molecule is configured to position an intronic cleavage event sufficiently far from an intron/exon border, or naturally occurring splice signal, to avoid alteration of the exonic sequence or unwanted splicing events. The gRNA molecule may be a first, second, third and/or fourth gRNA molecule, as described herein.
In an embodiment, a CF target mutant position, e.g., a deletion in the CFTR gene, e.g., at F508, e.g., F508del, is targeted, e.g., for correction. In an embodiment, the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 1A-1E, lOA-lOC, 11A-11E or 12A-12C. In some embodiments, the targeting domain is independently selected
12
5535.1 from those in Tables 1A-1E, lOA-lOC, 11A-11E or 12A-12C. For example, in certain embodiments, the targeting domain is independently selected from:
GAGGGUAAAAUUAAGCACAG (SEQ ID NO: 387);
AGUUUCUUACCUCUUCUAGU (SEQ ID NO: 388);
AAUGGUGCCAGGCAUAAUCC (SEQ ID NO: 389);
GGUAAAAUUAAGCACAG (SEQ ID NO: 390);
AGCAUGCCAACUAGAAG (SEQ ID NO: 391); or
GUAUCUAUAUUCAUCAU (SEQ ID NO: 392).
In an embodiment, when the CF target mutant position is F508, e.g., F508del, and two gRNAs are used to position two breaks, e.g., two single stranded breaks, in the target nucleic acid sequence, each guide RNA is independently selected from one of Tables 1A-1E, lOA-lOC, 11A-11E or 12A-12C.
In an embodiment, a CF target mutant position, e.g., a mutation in the CFTR gene, e.g., at G551, e.g., G551D, is targeted, e.g., for correction. In an embodiment, the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 2A-2E, 16A-16D, 17A-17E, or 18A-18C. In some embodiments, the targeting domain is independently selected from those in Tables 2A-2E, 16A-16D, 17A-17E, or 18A-18C. For example, in certain embodiments, the targeting domain is independently selected from:
GAGAAAGACAAUAUAGUUCU (SEQ ID NO: 453);
GGUGGAAUCACACUGAGUGG (SEQ ID NO: 454);
CCCACUAGCCAUAAAACCCC (SEQ ID NO: 455);
GGUGGAAUCACACUGAG (SEQ ID NO: 456);
GGAAUCACACUGAGUGG (SEQ ID NO: 457);
GGGGUUUUAUGGCUAGU (SEQ ID NO: 458); or
ACUAGCCAUAAAACCCC (SEQ ID NO: 459).
In an embodiment, more than one gRNA is used to position breaks, e.g., two single stranded breaks or two double stranded breaks, or a combination of single strand and double strand breaks, e.g., to create one or more indels, in the target nucleic acid sequence. In an embodiment, the targeting domain of each guide RNA is independently selected from one of Tables 2A-2E, 16A-16D, 17A-17E, or 18A-18C.
13
5535.1 In an embodiment, a mutation in the CFTR gene, e.g., at N1303, e.g., N1303K, is targeted, e.g., for correction. In an embodiment, the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 19A-19D, 20A-20E, or 21A-21B. In some embodiments, the targeting domain is independently selected from those in Tables 19A- 19D, 20A-20E, or 21A-21B. . For example, in certain embodiments, the targeting domain is selected from:
GGAGUGAUCAAGAAAUA (SEQ ID NO: 2223);
GAGUACCCUAACAUACC (SEQ ID NO: 2224);
GUGUGUGCACAACUUUAAAA (SEQ ID NO: 2225);
GGAAAGUUGCAGAUGAGGUA (SEQ ID NO: 2226);
GAACUUGAUGGUAAGUACAU (SEQ ID NO: 2227); or
GCUAUAUCAGCCAUUUGUGU (SEQ ID NO: 2228).
In an embodiment, when the CF target mutant position is N1303, e.g., N1303K, and two gRNAs are used to position two breaks, e.g., two single stranded breaks, in the target nucleic acid sequence, each guide RNA is independently selected from one of Tables 19A-19D, 20A- 20E, or 21A-21B.
In an embodiment, a mutation in the CFTR gene, e.g., at W1282, e.g., W1282X, is targeted, e.g., for correction. In an embodiment, the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 28A-28D, 29A-29E, or 30A-30B. In some embodiments, the targeting domain is independently selected from those in Tables 28A- 28D, 29A-29E, or 30A-30B. For example, in certain embodiments, the targeting domain is selected from:
GAAUUAUGUUUAUGGCA (SEQ ID NO: 2993);
GGAGAAAUCCAGAUCGA (SEQ ID NO: 2994);
GGCCUCUUGGGAAGAAC (SEQ ID NO: 2995);
GUCCUUUUGCUCACCUG (SEQ ID NO: 2996);
GAUCGAUGGUGUGUCUU (SEQ ID NO: 2997);
GAAGGAGAAAUCCAGAUCGA (SEQ ID NO: 2998);
GUGGGCCUCUUGGGAAGAAC (SEQ ID NO: 2999).
14
5535.1 In an embodiment, when the CF target mutant position is W1282, e.g., W1282X, and two gRNAs are used to position two breaks, e.g., two single stranded breaks, in the target nucleic acid sequence, each guide RNA is independently selected from one of Tables 28A-28D, 29A- 29E, or 30A-30B.
In an embodiment, a mutation in the CFTR gene, e.g., at R553, e.g., R553X, is targeted, e.g., for correction. In an embodiment, the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 25A-25D, 26A-26E, or 27A-27D. In some embodiments, the targeting domain is independently selected from those in Tables 25A-25D, 26A-26E, or 27A-27D. For example, in certain embodiments, the targeting domain is selected from:
GCUUUAUAUUCUGUUUC (SEQ ID NO: 466);
GGUGGAAUCACACUGAG (SEQ ID NO: 456);
GGAAUCACACUGAGUGG (SEQ ID NO: 457);
GUUCAAAAUUUCAACUG (SEQ ID NO: 464);
GGUGAAUAACUAAUUAU (SEQ ID NO: 465);
GGGGUUUUAUGGCUAGU (SEQ ID NO: 458);
GAGCAAGAAUUUCUUUAGCA (SEQ ID NO: 462);
GACAAUAUAGUUCUUGGAGA (SEQ ID NO: 460);
GAAGGUGGAAUCACACUGAG (SEQ ID NO: 461);
GGUGGAAUCACACUGAGUGG (SEQ ID NO: 454); or
GAGAAAGACAAUAUAGUUCU (SEQ ID NO: 453).
In an embodiment, when the CF target mutant position is R553, e.g., R553X, and two gRNAs are used to position two breaks, e.g., two single stranded breaks, in the target nucleic acid sequence, each guide RNA is independently selected from one of Tables 25A-25D, 26A- 26E, or 27A-27D.
In an embodiment, a mutation in the CFTR gene, e.g., at 371 7+1 21 91 C>T, also known as 3849+10kbC>T is targeted, e.g., for correction. In an embodiment, the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 34A-34D, 35A-35D, or 36A-36D. In some embodiments, the targeting domain is independently selected from those
15
5535.1 in Tables 34A-34D, 35A-35D, or 36A-36D. For example, in certain embodiments, the targeting domain is selected from:
GAGUAAGACACCCUGAA (SEQ ID NO: 3344);
GAUUUCUGGAGACCACA (SEQ ID NO: 3345);
GGUUUUAGCUAUUACUC (SEQ ID NO: 3346);
GUAGUUGAAUCAUUCAG (SEQ ID NO: 3347);
GAACUCAGUUUUUAGGU (SEQ ID NO: 3348);
GAAAGGAAAUGUUCUAUUCA (SEQ ID NO: 3349);
GUUUUUAGGUUGGGAAAGAC (SEQ ID NO: 3350);
GCACAUAAUAAUUAGUUUCC (SEQ ID NO: 3351);
GAGAACUCAGUUUUUAGGUU (SEQ ID NO: 3352); or
GAAAACACUGACUUAGAUUU (SEQ ID NO: 3353).
In an embodiment, when the CF target mutant position is 371 7+121 91 C>T and two gRNAs are used to position two breaks, e.g., two single stranded breaks, in the target nucleic acid sequence, each guide RNA is independently selected from one of Tables 34A-34D, 35A- 35D, or 36A-36D.
In an embodiment, a mutation in the CFTR gene, e.g., at 2657+5G>A, also known as 2789+5G>A is targeted, e.g., for correction. In an embodiment, the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 4A-4D, 5A-5E, or 6A-6C. In some embodiments, the targeting domain is independently selected from those in Tables 4A-4D, 5A-5E, or 6A-6C. For example, in certain embodiments, the targeting domain is selected from:
GAAGCAGCCACCUGGAA (SEQ ID NO: 937);
GGAAUAUUCACUUUCCA (SEQ ID NO: 938);
GAAUUUAGAUGUGGGCA (SEQ ID NO: 939);
GUGUCUUGUUCCAUUCC (SEQ ID NO: 940);
GUGGGCAUGGGAGGAAU (SEQ ID NO: 941);
GUUGUGCUGUGGCUCCU (SEQ ID NO: 942);
GAUGUGAAUUUAGAUGU (SEQ ID NO: 943);
GACCCAGGAACACAAAGCAA (SEQ ID NO: 944);
16
5535.1 GUGUCACCUCACCCAACUAA (SEQ ID NO: 945);
GUGUCUUGUUCCAUUCCAGG (SEQ ID NO: 946);
GAUGUGGGCAUGGGAGGAAU (SEQ ID NO: 947);
GUGAAUUUAGAUGUGGGCAU (SEQ ID NO: 948).
In an embodiment, when the CF target mutant position is 2657+5G>A and two gRNAs are used to position two breaks, e.g., two single stranded breaks, in the target nucleic acid sequence, each guide RNA is independently selected from one of Tables 4A-4D, 5A-5E, or 6A- 6C.
In an embodiment, a mutation in the CFTR gene, e.g., at 3140-26A>G, also known as 3272-26A>G, is targeted, e.g., for correction. In an embodiment, the targeting domain of a gRNA molecule comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 7A-7D, 8A-8E, or 9A-9B. In some embodiments, the targeting domain is independently selected from those in Tables 7A-7D, 8A-8E, or 9A-9B. For example, in certain embodiments, the targeting domain is selected from:
GUAAGGCUGCCGUCCGA (SEQ ID NO: 1282);
GGAAAUAUUUCACAGGC (SEQ ID NO: 1283);
GUAAAUUCAGAGCUUUG (SEQ ID NO: 1284);
GGACACUUCGUGCCUUCGGA (SEQ ID NO: 1285);
GGAACCAGCGCAGUGUUGAC (SEQ ID NO: 1286);
GUAACAAGAUGAGUGAAAAU (SEQ ID NO: 1287).
In an embodiment, when the CF target mutant position is 3140-26 A>G and two gRNAs are used to position two breaks, e.g., two single stranded breaks, in the target nucleic acid sequence, each guide RNA is independently selected from one of Tables 7A-7D, 8A-8E, or 9A- 9B.
In another embodiment, a CF target knockout position, e.g., a position in the coding region, e.g., the early coding region, of the SCNN1A gene is targeted, e.g., for knockout. In an embodiment, the targeting domain comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 3A-3D, 43A-43E, 44A-44G, or 45A-45E. In an embodiment, the targeting domain is
17
5535.1 independently selected from those in Tables 3A-3D, 43A-43E, 44A-44G, or 45A-45E. In another embodiment, the targeting domain is independently selected from:
GCCCAUACCAGGUCUCAUGG (SEQ ID NO: 497);
CCAUACCAGGUCUCAUGGAG (SEQ ID NO: 498);
GCCCUCCACAGUCCACUCCA (SEQ ID NO: 499);
CCCCUCCAUGAGACCUGGUA (SEQ ID NO: 500);
AUACCAGGUCUCAUGGA (SEQ ID NO: 501); or
CUCCAUGAGACCUGGUA (SEQ ID NO: 502).
In an embodiment, when the CF target knockout position is the SCNNIA coding region, e.g., early coding region, and more than one gRNA is used to position breaks, e.g., two single stranded breaks or two double stranded breaks, or a combination of single strand and double strand breaks, e.g., to create one or more indels, in the target nucleic acid sequence, each guide RNA is independently selected from one of Tables 3A-3D, 43A-43E, 44A-44G, or 45A-45E.
In an embodiment, the targeting domain of the gRNA molecule is configured to target an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain), sufficiently close to a SCNNIA transcription start site (TSS) to reduce (e.g., block) transcription, e.g., transcription initiation or elongation, binding of one or more transcription enhancers or activators, and/or RNA polymerase. In an embodiment, the targeting domain is configured to target between 1000 bp upstream and 1000 bp downstream (e.g., between 500 bp upstream and 1000 bp downstream, between 1000 bp upstream and 500 bp downstream, between 500 bp upstream and 500 bp downstream, within 500 bp upstream, or within 500 bp downstream) of the TSS of the SCNNIA gene. One or more gRNAs may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
In an embodiment, when the SCNNIA promoter region is targeted, e.g., for knockdown, the targeting domain can comprise a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 46A-46E, 47A- 47G, or 48A-48E. In an embodiment, the targeting domain is independently selected from those in Tables 46A-46E, 47A-47G, or 48A-48E.
In an embodiment, the targeting domain is independently selected from those in Table 46A. In an embodiment, the targeting domain is independently selected from those in Table
18
5535.1 47A. In an embodiment, the targeting domain is independently selected from those in Table 48A.
In an embodiment, when the CF target knockdown position is the SCNN1A promoter region and more than one gRNA is used to position an eiCas9 molecule or an eiCas9-fusion protein (e.g., an eiCas9-transcription repressor domain fusion protein), in the target nucleic acid sequence, the targeting domain for each guide RNA is independently selected from one of
Tables 46A-46E, 47A-47G, or 48A-48E.
In an embodiment, the gRNA, e.g., a gRNA comprising a targeting domain, which is complementary with the CFTR gene or SCNN1A gene, is a modular gRNA. In other
embodiments, the gRNA is a unimolecular or chimeric gRNA.
In an embodiment, the targeting domain which is complementary with a target domain from the CF target position in the CFTR gene or SCNN1A gene is 16 nucleotides or more in length. In an embodiment, the targeting domain is 16 nucleotides in length. In an embodiment, the targeting domain is 17 nucleotides in length. In another embodiment, the targeting domain is 18 nucleotides in length. In still another embodiment, the targeting domain is 19 nucleotides in length. In still another embodiment, the targeting domain is 20 nucleotides in length. In still another embodiment, the targeting domain is 21 nucleotides in length. In still another embodiment, the targeting domain is 22 nucleotides in length. In still another embodiment, the targeting domain is 23 nucleotides in length. In still another embodiment, the targeting domain is 24 nucleotides in length. In still another embodiment, the targeting domain is 25 nucleotides in length. In still another embodiment, the targeting domain is 26 nucleotides in length.
In an embodiment, the targeting domain comprises 16 nucleotides.
In an embodiment, the targeting domain comprises 17 nucleotides.
In an embodiment, the targeting domain comprises 18 nucleotides.
In an embodiment, the targeting domain comprises 19 nucleotides.
In an embodiment, the targeting domain comprises 20 nucleotides.
In an embodiment, the targeting domain comprises 21 nucleotides.
In an embodiment, the targeting domain comprises 22 nucleotides.
In an embodiment, the targeting domain comprises 23 nucleotides.
In an embodiment, the targeting domain comprises 24 nucleotides.
In an embodiment, the targeting domain comprises 25 nucleotides.
19
5535.1 In an embodiment, the targeting domain comprises 26 nucleotides.
A gRNA as described herein may comprise from 5' to 3': a targeting domain
(comprising a "core domain", and optionally a "secondary domain"); a first complementarity domain; a linking domain; a second complementarity domain; a proximal domain; and a tail domain. In some embodiments, the proximal domain and tail domain are taken together as a single domain.
In an embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
In another embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
In another embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 35 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
In another embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
A cleavage event, e.g., a double strand or single strand break, is generated by a Cas9 molecule. The Cas9 molecule may be an enzymatically active Cas9 (eaCas9) molecule, e.g., an eaCas9 molecule that forms a double strand break in a target nucleic acid or an eaCas9 molecule forms a single strand break in a target nucleic acid (e.g., a nickase molecule).
In an embodiment, the eaCas9 molecule catalyzes a double strand break.
In some embodiments, the eaCas9 molecule comprises HNH-like domain cleavage activity but has no, or no significant, N-terminal RuvC-like domain cleavage activity. In this case, the eaCas9 molecule is an HNH-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at D10, e.g., D10A. In other embodiments, the eaCas9 molecule comprises N-
20
5535.1 terminal RuvC-like domain cleavage activity but has no, or no significant, HNH-like domain cleavage activity. In an embodiment, the eaCas9 molecule is an N-terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at H840, e.g., H840A. In an
embodiment, the eaCas9 molecule is an N-terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at N863, e.g., an N863A mutation.
In an embodiment, a single strand break is formed in the strand of the target nucleic acid to which the targeting domain of said gRNA is complementary. In another embodiment, a single strand break is formed in the strand of the target nucleic acid other than the strand to which the targeting domain of said gRNA is complementary.
In another aspect, disclosed herein is a nucleic acid, e.g., an isolated or non-naturally occurring nucleic acid, e.g., DNA, that comprises (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain, e.g., with a CF target position, in the CFTR gene or SCNNIA gene as disclosed herein.
In an embodiment, the nucleic acid encodes a gRNA molecule, e.g., a first gRNA molecule, comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a CF target position in the CFTR gene or SCNNIA gene to allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of a CF target position in the CFTR gene or SCNNIA gene.
In an embodiment, the nucleic acid encodes a gRNA molecule, e.g., a first gRNA molecule, comprising a targeting domain configured to target an enzymatically inactive Cas9
(eiCas9) molecule or an eiCas9 fustion protein (e.g., an eiCas9 fused to a transcription repressor domain), sufficiently close to a CF knockdown target position to reduce, decrease or repress expression of the SCNNIA gene.
In an embodiment, the nucleic acid encodes a gRNA molecule, e.g., the first gRNA molecule, comprising a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence as described herein, e.g., from any one of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G,
21
5535.1 45A-45E, 46A-46E, 47A-47G, or 48A-48E. In an embodiment, the nucleic acid encodes a gRNA molecule comprising a targeting domain as described herein, e.g., that is selected from those in Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, 10A- 10C, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E.
In an embodiment, the nucleic acid encodes a modular gRNA, e.g., one or more nucleic acids encode a modular gRNA. In another embodiment, the nucleic acid encodes a chimeric gRNA. The nucleic acid may encode a gRNA, e.g., the first gRNA molecule, comprising a targeting domain comprising 16 nucleotides or more in length. In an embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 16 nucleotides in length. In another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 17 nucleotides in length. In yet another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 18 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 19 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 20 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 21 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 22 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 23 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 24 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 25 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 26 nucleotides in length.
In an embodiment, the targeting domain comprises 16 nucleotides.
22
5535.1 In an embodiment, the targeting domain comprises 17 nucleotides.
In an embodiment, the targeting domain comprises 18 nucleotides.
In an embodiment, the targeting domain comprises 19 nucleotides.
In an embodiment, the targeting domain comprises 20 nucleotides.
In an embodiment, the targeting domain comprises 21 nucleotides.
In an embodiment, the targeting domain comprises 22 nucleotides.
In an embodiment, the targeting domain comprises 23 nucleotides.
In an embodiment, the targeting domain comprises 24 nucleotides.
In an embodiment, the targeting domain comprises 25 nucleotides.
In an embodiment, the targeting domain comprises 26 nucleotides.
In an embodiment, a nucleic acid encodes a gRNA comprising from
domain (comprising a "core domain", and optionally a "secondary domain"); a first
complementarity domain; a linking domain; a second complementarity domain; a proximal domain; and a tail domain. In some embodiments, the proximal domain and tail domain are taken together as a single domain.
In an embodiment, a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 35 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, a nucleic acid encodes a gRNA comprising e.g., the first gRNA molecule, a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
23
5535.1 In an embodiment, a nucleic acid comprises (a) a sequence that encodes a gRNA molecule, e.g., the first gRNA molecule, comprising a targeting domain that is complementary with a target domain in the CFTR gene or SCNN1A gene as disclosed herein, and further comprising (b) a sequence that encodes a Cas9 molecule.
The Cas9 molecule may be a nickase molecule, an enzymatically activating Cas9
(eaCas9) molecule, e.g., an eaCas9 molecule that forms a double strand break in a target nucleic acid and/or an eaCas9 molecule forms a single strand break in a target nucleic acid. In an embodiment, a single strand break is formed in the strand of the target nucleic acid to which the targeting domain of said gRNA is complementary. In another embodiment, a single strand break is formed in the strand of the target nucleic acid other than the strand to which to which the targeting domain of said gRNA is complementary.
In an embodiment, the eaCas9 molecule catalyzes a double strand break.
In an embodiment, the eaCas9 molecule comprises HNH-like domain cleavage activity but has no, or no significant, N-terminal RuvC-like domain cleavage activity. In another embodiment, the said eaCas9 molecule is an HNH-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at D10, e.g., D10A. In another embodiment, the eaCas9 molecule comprises N-terminal RuvC-like domain cleavage activity but has no, or no significant, HNH-like domain cleavage activity. In another embodiment, the eaCas9 molecule is an N- terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at H840, e.g., H840A. In another embodiment, the eaCas9 molecule is an N-terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at N863, e.g., an N863A mutation.
A nucleic acid disclosed herein may comprise (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the CFTR and/or SCNN1A gene as disclosed herein; (b) a sequence that encodes a Cas9 molecule.
In an embodiment, the Cas9 molecule is an enzymatically active Cas9 (eaCas9) molecule.
In an embodiment, the Cas9 molecule is an enzymatically inactive Cas9 (eiCas9) molecule or a modified eiCas9 molecule, e.g., the eiCas9 molecule is fused to Kriippel-associated box (KRAB) to generate an eiCas9-KRAB fusion protein molecule.
A nucleic acid disclosed herein may comprise (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the CFTR gene or SCNN1A gene as disclosed herein; (b) a sequence that encodes a Cas9 molecule; and
24
5535.1 further may comprise (c)(i) a sequence that encodes a second gRNA molecule described herein having a targeting domain that is complementary to a second target domain of the CFTR gene or SCNNIA gene, and optionally, (c)(ii) a sequence that encodes a third gRNA molecule described herein having a targeting domain that is complementary to a third target domain of the CFTR gene or SCNNIA gene; and optionally, (c)(iii) a sequence that encodes a fourth gRNA molecule described herein having a targeting domain that is complementary to a fourth target domain of the CFTR gene or SCNNIA gene.
In an embodiment, a nucleic acid encodes a second gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a CF target position in the CFTR gene or SCNNIA gene, to allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of a CF target position in the CFTR gene or SCNNIA gene, either alone or in combination with the break positioned by said first gRNA molecule.
In an embodiment, a nucleic acid encodes a second gRNA molecule comprising a targeting domain configured to target an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fustion protein (e.g., an eiCas9 fused to a transcription repressor domain), sufficiently close to a CF knockdown target position to reduce, decrease or repress expression of the SCNNIA gene.
In an embodiment, a nucleic acid encodes a third gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a CF target position in the CFTR gene or SCNNIA gene to allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of a CF target position in the CFTR gene or SCNNIA gene, either alone or in combination with the break positioned by the first and/or second gRNA molecule.
In an embodiment, a nucleic acid encodes a third gRNA molecule comprising a targeting domain configured to target an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fustion protein (e.g., an eiCas9 fused to a transcription repressor domain), sufficiently close to a CF knockdown target position to reduce, decrease or repress expression of the SCNNIA gene.
In an embodiment, a nucleic acid encodes a fourth gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a CF target position in the CFTR gene or SCNNIA gene to
25
5535.1 allow alteration, e.g., alteration associated with, respectively, HDR or NHEJ, of a CF target position in the CFTR gene or SCNN1A gene, either alone or in combination with the break positioned by the first gRNA molecule, the second gRNA molecule and/or the third gRNA molecule.
In an embodiment, the nucleic acid encodes a second gRNA molecule. The second gRNA is selected to target the same CF target position as the first gRNA molecule. Optionally, the nucleic acid may encode a third gRNA, and further optionally, the nucleic acid may encode a fourth gRNA molecule. The third gRNA molecule and the fourth gRNA molecule are selected to target the same CF target position as the first and second gRNA molecules.
In an embodiment, the nucleic acid encodes a second gRNA molecule comprising a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from one of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A- 14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E. In an embodiment, the nucleic acid encodes a second gRNA molecule comprising a targeting domain selected from those in Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E. In an embodiment, when a third or fourth gRNA molecule are present, the third and fourth gRNA molecules may independently comprise a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from one of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A- 14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D,
26
5535.1 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E. In a further embodiment, when a third or fourth gRNA molecule are present, the third and fourth gRNA molecules may independently comprise a targeting domain selected from those in Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A- 20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A- 29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A- 38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A- 47G, or 48A-48E.
In an embodiment, the nucleic acid encodes a second gRNA which is a modular gRNA, e.g., wherein one or more nucleic acid molecules encode a modular gRNA. In another embodiment, the nucleic acid encoding a second gRNA is a chimeric gRNA. In another embodiment, when a nucleic acid encodes a third or fourth gRNA, the third and fourth gRNA may be a modular gRNA or a chimeric gRNA. When multiple gRNAs are used, any
combination of modular or chimeric gRNAs may be used.
A nucleic acid may encode a second, a third, and/or a fourth gRNA, each independently, comprising a targeting domain comprising 16 nucleotides or more in length. In an embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 16 nucleotides in length. In an embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 17 nucleotides in length. In another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 18 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 19 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 20 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 21 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 22 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 23 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 24 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 25 nucleotides in length. In still another
27
5535.1 embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 26 nucleotides in length.
In an embodiment, the targeting domain comprises 16 nucleotides.
In an embodiment, the targeting domain comprises 17 nucleotides.
In an embodiment, the targeting domain comprises 18 nucleotides.
In an embodiment, the targeting domain comprises 19 nucleotides.
In an embodiment, the targeting domain comprises 20 nucleotides.
In an embodiment, the targeting domain comprises 21 nucleotides.
In an embodiment, the targeting domain comprises 22 nucleotides.
In an embodiment, the targeting domain comprises 23 nucleotides.
In an embodiment, the targeting domain comprises 24 nucleotides.
In an embodiment, the targeting domain comprises 25 nucleotides.
In an embodiment, the targeting domain comprises 26 nucleotides.
In an embodiment, a nucleic acid encodes a second, a third, and/or
independently, comprising from 5' to 3': a targeting domain (comprising a "core domain", and optionally a "secondary domain"); a first complementarity domain; a linking domain; a second complementarity domain; a proximal domain; and a tail domain. In some embodiments, the proximal domain and tail domain are taken together as a single domain.
In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 35 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
28
5535.1 In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
In an embodiment, when the CFTR gene is corrected by HDR, the nucleic acid encodes
(a) a sequence that encodes a gRNA molecule comprising a targeting domain that is
complementary with a target domain in the CFTR gene as disclosed herein; (b) a sequence that encodes a Cas9 molecule; optionally, (c)(i) a sequence that encodes a second gRNA molecule described herein having a targeting domain that is complementary to a second target domain of the CFTR gene, and further optionally, (c)(ii) a sequence that encodes a third gRNA molecule described herein having a targeting domain that is complementary to a third target domain of the CFTR gene; and still further optionally, (c)(iii) a sequence that encodes a fourth gRNA molecule described herein having a targeting domain that is complementary to a fourth target domain of the CFTR gene; and further may comprise (d) a template nucleic acid, e.g., a template nucleic acid described herein.
In an embodiment, the template nucleic acid is a single stranded nucleic acid. In another embodiment, the template nucleic acid is a double stranded nucleic acid. In an embodiment, the template nucleic acid comprises a nucleotide sequence, e.g., of one or more nucleotides, that will be added to or will template a change in the target nucleic acid. In another embodiment, the template nucleic acid comprises a nucleotide sequence that may be used to modify the target position. In another embodiment, the template nucleic acid comprises a nucleotide sequence, e.g., of one or more nucleotides, that corresponds to wild type sequence of the target nucleic acid, e.g., of the target position.
The template nucleic acid may comprise a replacement sequence, e.g., a replacement sequence from the Table 49. In some embodiments, the template nucleic acid comprises a 5' homology arm, e.g., a 5' homology arm from Table 49. In other embodiments, the template nucleic acid comprises a 3' homology arm, e.g., a 3' homology arm from Table 49.
In an embodiment, a nucleic acid encodes (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the CFTR gene or SCNNIA gene as disclosed herein, and (b) a sequence that encodes a Cas9 molecule, e.g., a Cas9 molecule described herein. In an embodiment, (a) and (b) are present on the same nucleic acid
29
5535.1 molecule, e.g., the same vector, e.g., the same viral vector, e.g., the same adeno-associated virus (AAV) vector. In an embodiment, the nucleic acid molecule is an AAV vector. Exemplary AAV vectors that may be used in any of the described compositions and methods include an AAV2 vector, a modified AAV2 vector, an AAV3 vector, a modified AAV3 vector, an AAV6 vector, a modified AAV6 vector, an AAV8 vector and an AAV9 vector.
In another embodiment, (a) is present on a first nucleic acid molecule, e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (b) is present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecules may be AAV vectors.
In another embodiment, the nucleic acid may further comprise (c) a sequence that encodes a second, third and/or fourth gRNA molecule as described herein. In another embodiment, the nucleic acid comprises (a), (b) and (c)(i). Each of (a) and (c)(i) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., the same adeno-associated virus (AAV) vector. In an embodiment, the nucleic acid molecule is an AAV vector.
In another embodiment, (a) and (c)(i) are on different vectors. For example, (a) may be present on a first nucleic acid molecule, e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (c)(i) may be present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. In an embodiment, the first and second nucleic acid molecules are AAV vectors.
In another embodiment, each of (a), (b), and (c)(i) are present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, one of (a), (b), and (c)(i) is encoded on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and a second and third of (a), (b), and (c)(i) is encoded on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.
In an embodiment, (a) is present on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, a first AAV vector; and (b) and (c)(i) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.
30
5535.1 In another embodiment, (b) is present on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (a) and (c)(i) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.
In another embodiment, (c)(i) is present on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (b) and (a) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.
In another embodiment, each of (a), (b) and (c)(i) are present on different nucleic acid molecules, e.g., different vectors, e.g., different viral vectors, e.g., different AAV vector. For example, (a) may be on a first nucleic acid molecule, (b) on a second nucleic acid molecule, and (c)(i) on a third nucleic acid molecule. The first, second and third nucleic acid molecule may be AAV vectors.
In another embodiment, when a third and/or fourth gRNA molecule are present, each of (a), (b), (c)(i), (c)(ii) and (c)(iii) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, each of (a), (b), (c)(i), (c)(ii) and
(c) (iii) may be present on the different nucleic acid molecules, e.g., different vectors, e.g., the different viral vectors, e.g., different AAV vectors. In a further embodiment, each of (a), (b), (c)(i), (c)(ii) and (c)(iii) may be present on more than one nucleic acid molecule, but fewer than five nucleic acid molecules, e.g., AAV vectors.
In another embodiment, when (d) a template nucleic acid is present, each of (a), (b), and
(d) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, each of (a), (b), and (d) may be present on the different nucleic acid molecules, e.g., different vectors, e.g., the different viral vectors, e.g., different AAV vectors. In a further embodiment, each of (a), (b), and (d) may be present on more than one nucleic acid molecule, but fewer than three nucleic acid molecules, e.g., AAV vectors.
In another embodiment, when (d) a template nucleic acid is present, each of (a), (b), (c)(i) and (d) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV
31
5535.1 vector. In an alternate embodiment, each of (a), (b), (c)(i) and (d) may be present on the different nucleic acid molecules, e.g., different vectors, e.g., the different viral vectors, e.g., different AAV vectors. In a further embodiment, each of (a), (b), (c)(i) and (d) may be present on more than one nucleic acid molecule, but fewer than four nucleic acid molecules, e.g., AAV vectors.
In another embodiment, when (d) a template nucleic acid is present, each of (a), (b),
(c) (i), (c)(ii) and (d) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, each of (a), (b), (c)(i), (c)(ii) and (d) may be present on the different nucleic acid molecules, e.g., different vectors, e.g., the different viral vectors, e.g., different AAV vectors. In a further embodiment, each of (a), (b), (c)(i), (c)(ii) and
(d) may be present on more than one nucleic acid molecule, but fewer than five nucleic acid molecules, e.g., AAV vectors.
In another embodiment, when (d) a template nucleic acid is present, each of (a), (b), (c)(i), (c)(ii), (c)(iii) and (d) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, each of (a), (b), (c)(i), (c)(ii), (c)(iii) and (d) may be present on the different nucleic acid molecules, e.g., different vectors, e.g., the different viral vectors, e.g., different AAV vectors. In a further embodiment, each of (a), (b), (c)(i), (c)(ii), (c)(iii) and (d) may be present on more than one nucleic acid molecule, but fewer than six nucleic acid molecules, e.g., AAV vectors.
The nucleic acids described herein may comprise a promoter operably linked to the sequence that encodes the gRNA molecule of (a), e.g., a promoter described herein. The nucleic acid may further comprise a second promoter operably linked to the sequence that encodes the second, third and/or fourth gRNA molecule of (c), e.g., a promoter described herein. The promoter and second promoter differ from one another. In some embodiments, the promoter and second promoter are the same.
The nucleic acids described herein may further comprise a promoter operably linked to the sequence that encodes the Cas9 molecule of (b), e.g., a promoter described herein.
In another aspect, disclosed herein is a composition comprising (a) a gRNA molecule comprising a targeting domain that is complementary with a target domain in the CFTR gene or
32
5535.1 SCNN1A gene, as described herein. The composition of (a) may further comprise (b) a Cas9 molecule, e.g., a Cas9 molecule as described herein. A composition of (a) and (b) may further comprise (c) a second, third and/or fourth gRNA molecule, e.g., a second, third and/or fourth gRNA molecule described herein. A composition of (a), (b) and (c) may further comprise (d) a template nucleic acid, e.g., a template nucleic acid described herein. In an embodiment, the composition is a pharmaceutical composition. The compositions described herein, e.g., pharmaceutical compositions described herein, can be used in the treatment or prevention of CF or CF-like disease in a subject, e.g., in accordance with a method disclosed herein.
In another aspect, disclosed herein is a method of altering a cell, e.g., altering the structure, e.g., altering the sequence, of a target nucleic acid of a cell, comprising contacting said cell with: (a) a gRNA that targets the CFTR gene or SCNN1A gene, e.g., a gRNA as described herein; (b) a Cas9 molecule, e.g., a Cas9 molecule as described herein; and optionally, (c) a second, third and/or fourth gRNA that targets CFTR gene or SCNN1A gene, e.g., a second, third and/or fourth gRNA as described herein; and optionally, (d) a template nucleic acid, e.g., a template nucleic acid as described herein.
In an embodiment, the method comprises contacting said cell with (a) and (b).
In an embodiment, the method comprises contacting said cell with (a), (b), and (c). In an embodiment, the method comprises contacting said cell with (a), (b), (c) and (d). The gRNA of (a) and optionally (c) may be selected from any of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A- 13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A- 48E, or a gRNA that differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E.
33
5535.1 In an embodiment, the method comprises contacting a cell from a subject suffering from or likely to develop CF or CF-like disease. The cell may be from a subject having a mutation at a CF target position in the CFTR gene or a subject which would benefit from having a mutation at a CF target position in the SCNN1A gene.
In an embodiment, the cell being contacted in the disclosed method is an epithelial cell, e.g., a pulmonary epithelial cell, e.g., a bronchial epithelial cell or an alveolar epithelial cell. The contacting may be performed ex vivo and the contacted cell may be returned to the subject's body after the contacting step. In other embodiments, the contacting step may be performed in vivo.
In an embodiment, the method of altering a cell as described herein comprises acquiring knowledge of the sequence at a CF target position in said cell, prior to the contacting step.
Acquiring knowledge of the sequence at a CF target position in the cell may be by sequencing the CFTR gene or SCNN1A gene, or a portion of the CFTR gene or SCNN1A gene.
In an embodiment, the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses at least one of (a), (b), and (c). In an embodiment, the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses each of (a), (b), and (c). In another embodiment, the contacting step of the method comprises delivering to the cell a Cas9 molecule of (b) and a nucleic acid which encodes a gRNA of (a) and optionally, a second gRNA (c)(i) and further optionally, a third gRNA (c)(ii) and/or fourth gRNA (c)(iii)).
In an embodiment, the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses at least one of (a), (b), (c) and (d). In an embodiment, the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses each of (a), (b), and (c). In another embodiment, the contacting step of the method comprises delivering to the cell a Cas9 molecule of (b), a nucleic acid which encodes a gRNA of (a) and a template nucleic acid of (d), and optionally, a second gRNA (c)(i) and further optionally, a third gRNA (c)(ii) and/or fourth gRNA (c)(iii).
In an embodiment, contacting comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, e.g., an AAV2 vector, a modified AAV2 vector, an AAV3 vector, a modified AAV3 vector, an AAV6 vector, a modified AAV6 vector, an AAV8 vector or an AAV9 vector, as described herein.
In an embodiment, contacting comprises delivering to the cell a Cas9 molecule of (b), as a protein or an mRNA, and a nucleic acid which encodes a gRNA of (a) and optionally a second, third and/or fourth gRNA of (c).
In an embodiment, contacting comprises delivering to the cell a Cas9 molecule of (b), as a protein or an mRNA, said gRNA of (a), as an RNA, and optionally said second, third and/or fourth gRNA of (c), as an RNA.
In an embodiment, contacting comprises delivering to the cell a gRNA of (a) as an RNA, optionally the second, third and/or fourth gRNA of (c) as an RNA, and a nucleic acid that encodes the Cas9 molecule of (b).
In another aspect, disclosed herein is a method of treating or preventing a subject suffering from or likely to develop CF or CF-like disease, e.g., altering the structure, e.g., sequence, of a target nucleic acid of the subject, comprising contacting the subject (or a cell from the subject) with:
(a) a gRNA that targets the CFTR gene or SCNN1A gene, e.g., a gRNA disclosed herein;
(b) a Cas9 molecule, e.g., a Cas9 molecule disclosed herein; and
optionally, (c)(i) a second gRNA that targets the CFTR gene or SCNN1A gene, e.g., a second gRNA disclosed herein, and
further optionally, (c)(ii) a third gRNA, and still further optionally, (c)(iii) a fourth gRNA that target the CFTR gene or SCNN1A gene, e.g., a third and fourth gRNA disclosed herein.
The method of treating a subject may further comprise contacting the subject (or a cell from the subject) with (d) a template nucleic acid, e.g., a template nucleic acid disclosed herein. A template nucleic acid is used when the method of treating a subject uses HDR to alter the sequence of the target nucleic acid of the subject.
In some embodiments, contacting comprises contacting with (a) and (b).
In some embodiments, contacting comprises contacting with (a), (b), and (c)(i).
In some embodiments, contacting comprises contacting with (a), (b), (c)(i) and (c)(ii).
In some embodiments, contacting comprises contacting with (a), (b), (c)(i), (c)(ii) and (c)(iii).
In some embodiments, contacting comprises contacting with (a), (b), (c)(i) and (d). In some embodiments, contacting comprises contacting with (a), (b), (c)(i), (c)(ii) and
(d).
In some embodiments, contacting comprises contacting with (a), (b), (c)(i), (c)(ii), (c)(iii) and (d).
The gRNA of (a) or (c) (e.g., (c)(i), (c)(ii), or (c)(iii)) may be selected from any of Tables
1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A- 20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A- 29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A- 38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A- 47G, or 48A-48E, or a gRNA that differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A- 16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A- 25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A- 34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A- 43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E.
In an embodiment, the method comprises acquiring knowledge of the sequence (e.g., a mutation) of a CF target position in said subject.
In an embodiment, the method comprises acquiring knowledge of the sequence (e.g., a mutation) of a CF target position in said subject by sequencing the CFTR gene or SCNNIA gene or a portion of the CFTR gene or SCNNIA gene.
In an embodiment, the method comprises correcting a mutation at a CF target position in the CFTR gene.
In an embodiment, the method comprises correcting a mutation at a CF target position in the CFTR gene by HDR.
In an embodiment, the method comprises introducing a mutation at a CF target position in the SCNNIA gene.
In an embodiment, the method comprises introducing a mutation at a CF target position in the SCNNIA gene by NHEJ.
36
5535.1 When the method comprises correcting the mutation at a CF target position by HDR, a Cas9 of (b), at least one guide RNA, e.g., a guide RNA of (a) and a template nucleic acid of (d) are included in the contacting step.
In an embodiment, a cell of the subject is contacted ex vivo with (a), (b), (d) and optionally (c). In an embodiment, said cell is returned to the subject's body.
In an embodiment, a cell of the subject is contacted is in vivo with (a), (b) (d) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
In an embodiment, the cell of the subject is contacted in vivo by inhalation delivery, e.g., via nebulizer, of (a), (b), (d) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
In an embodiment, the cell of the subject is contacted in vivo by intravenous delivery of (a), (b), (d) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
In an embodiment, the cell of the subject is contacted in vivo by intraparenchymal delivery of (a), (b), (d) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii), e.g., to lung tissue or bronchial tree.
In an embodiment, the contacting step comprises contacting the subject with a nucleic acid, e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), (d) and optionally (c)(i), further optionally (c)(ii), and still further optionally
(c) (iii).
In an embodiment, the contacting step comprises delivering to said subject said Cas9 molecule of (b), as a protein or mRNA, and a nucleic acid which encodes (a), a nucleic acid of
(d) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
In an embodiment, the contacting step comprises delivering to the subject the Cas9 molecule of (b), as a protein or mRNA, the gRNA of (a), as an RNA, a nucleic acid of (d) and optionally the second gRNA of (c)(i), further optionally said third gRNA of (c)(ii), and still further optionally said fourth gRNA of (c)(iii), as an RNA.
In an embodiment, the contacting step comprises delivering to the subject the gRNA of (a), as an RNA, optionally said second gRNA of (c)(i), further optionally said third gRNA of (c)(ii), and still further optionally said fourth gRNA of (c)(iii), as an RNA, a nucleic acid that encodes the Cas9 molecule of (b), and a nucleic acid of (d).
37
5535.1 When the method comprises (1) introducing a mutation at a CF target position by NHEJ or (2) knocking down expression of the SCNN1A gene by targeting the promoter region, a Cas9 of (b) and at least one guide RNA, e.g., a guide RNA of (a) are included in the contacting step.
In an embodiment, a cell of the subject is contacted ex vivo with (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii). In an embodiment, said cell is returned to the subject's body.
In an embodiment, a population of cells from a subject is contacted ex vivo with (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d) to correct the F508del or G551D mutation in the CFTR gene and a second population of cells from the subject is contacted ex vivo with (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii), to introduce a mutation in the SCNN1A gene to knockout the SCNN1A gene. A mixture of the two cell populations may be returned to the subject's body to treat or prevent CF or CF-like disease.
In an embodiment, a cell of the subject is contacted is in vivo with (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d). In an embodiment, the cell of the subject is contacted in vivo by inhalation delivery, e.g., via nebulizer, of (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d). In an embodiment, the cell of the subject is contacted in vivo by intravenous delivery of (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d). In an embodiment, the cell of the subject is contacted in vivo by intraparenchymal delivery of (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d), e.g., to lung tissue or bronchial tree.
In an embodiment, contacting comprises contacting the subject with a nucleic acid, e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d).
In an embodiment, contacting comprises delivering to said subject said Cas9 molecule of (b), as a protein or mRNA, and a nucleic acid which encodes (a) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii) and/or (d).
In an embodiment, contacting comprises delivering to the subject the Cas9 molecule of (b), as a protein or mRNA, the gRNA of (a), as an RNA, and optionally the second gRNA of
38
5535.1 (c) (i), further optionally said third gRNA of (c)(ii), and still further optionally said fourth gRNA of (c)(iii), as an RNA, and further optionally the template nucleic acid of (d) as a DNA.
In an embodiment, contacting comprises delivering to the subject the gRNA of (a), as an RNA, optionally said second gRNA of (c)(i), further optionally said third gRNA of (c)(ii), and still further optionally said fourth gRNA of (c)(iii), as an RNA, and a nucleic acid that encodes the Cas9 molecule of (b), and optionally a nucleic acid that encodes the template nucleic acid of
(d) .
In another aspect, disclosed herein is a reaction mixture comprising a gRNA molecule, a nucleic acid, or a composition described herein, and a cell, e.g., a cell from a subject having, or likely to develop CF or CF-like disease, or a subject having a mutation at a CF target position in the CFTR gene, or a cell from a subject which would benefit from having a mutation at a CF target position in the SCNN1A gene.
In another aspect, disclosed herein is a kit comprising, (a) a gRNA molecule described herein, or nucleic acid that encodes the gRNA, and one or more of the following:
(b) a Cas9 molecule, e.g., a Cas9 molecule described herein, or a nucleic acid or mRNA that encodes the Cas9;
(c)(i) a second gRNA molecule, e.g., a second gRNA molecule described herein or a nucleic acid that encodes (c)(i);
(c)(ii) a third gRNA molecule, e.g., a second gRNA molecule described herein or a nucleic acid that encodes (c)(ii);
(c) (iii) a fourth gRNA molecule, e.g., a second gRNA molecule described herein or a nucleic acid that encodes (c)(iii); and
(d) a template nucleic acid, e.g, a template nucleic acid described herein.
In an embodiment, the kit comprises nucleic acid, e.g., an AAV vector, that encodes one or more of (a), (b), (c)(i), (c)(ii), (c)(iii) and (d).
In another aspect, disclosed herein is non-naturally occurring template nucleic acid described herein.
In yet another aspect, disclosed herein is a gRNA molecule, e.g., a gRNA molecule described herein, for use in treating or preventing CF or CF-like disease in a subject, e.g., in accordance with a method of treating or preventing CF or CF-like disease as described herein.
39
5535.1 In an embodiment, the gRNA molecule in used in combination with a Cas9 molecule, e.g., a Cas9 molecule described herein. Additionally or alternatively, in an embodiment, the gRNA molecule is used in combination with a second, third and/or fouth gRNA molecule, e.g., a second, third and/or fouth gRNA molecule described herein.
In still another aspect, disclosed herein is use of a gRNA molecule, e.g., a gRNA molecule described herein, in the manufacture of a medicament for treating or preventing CF or CF-like disease in a subject, e.g., in accordance with a method of treating or preventing CF or CF-like disease as described herein.
In an embodiment, the medicament comprises a Cas9 molecule, e.g., a Cas9 molecule described herein. Additionaly or alternatively, in an embodiment, the medicament comprises a second, third and/or fouth gRNA molecule, e.g., a second, third and/or fouth gRNA molecule described herein.
The gRNA molecules and methods, as disclosed herein, can be used in combination with a governing gRNA molecule. As used herein, a governing gRNA molecule refers to a gRNA molecule comprising a targeting domain which is complementary to a target domain on a nucleic acid that encodes a component of the CRISPR/Cas system introduced into a cell or subject. For example, the methods described herein can further include contacting a cell or subject with a governing gRNA molecule or a nucleic acid encoding a governing molecule. In an embodiment, the governing gRNA molecule targets a nucleic acid that encodes a Cas9 molecule or a nucleic acid that encodes a target gene gRNA molecule. In an embodiment, the governing gRNA comprises a targeting domain that is complementary to a target domain in a sequence that encodes a Cas9 component, e.g., a Cas9 molecule or target gene gRNA molecule. In an embodiment, the target domain is designed with, or has, minimal homology to other nucleic acid sequences in the cell, e.g., to minimize off-target cleavage. For example, the targeting domain on the governing gRNA can be selected to reduce or minimize off-target effects. In an embodiment, a target domain for a governing gRNA can be disposed in the control or coding region of a Cas9 molecule or disposed between a control region and a transcribed region. In an embodiment, a target domain for a governing gRNA can be disposed in the control or coding region of a target gene gRNA molecule or disposed between a control region and a transcribed region for a target gene gRNA. While not wishing to be bound by theory, in an embodiment, it is believed that altering, e.g., inactivating, a nucleic acid that encodes a Cas9 molecule or a
40
5535.1 nucleic acid that encodes a target gene gRNA molecule can be effected by cleavage of the targeted nucleic acid sequence or by binding of a Cas9 molecule/governing gRNA molecule complex to the targeted nucleic acid sequence.
The compositions, reaction mixtures and kits, as disclosed herein, can also include a governing gRNA molecule, e.g., a governing gRNA molecule disclosed herein.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Headings, including numeric and alphabetical headings and subheadings, are for organization and presentation and are not intended to be limiting.
Other features and advantages of the invention will be apparent from the detailed description, drawings, and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS Figs. 1A-1I are representations of several exemplary gRNAs.
Fig. 1A depicts a modular gRNA molecule derived in part (or modeled on a sequence in part) from Streptococcus pyogenes (S. pyogenes) as a duplexed structure (SEQ ID NOS: 42 and 43, respectively, in order of appearance);
Fig. IB depicts a unimolecular (or chimeric) gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 44);
Fig. 1C depicts a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 45);
Fig. ID depicts a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 46);
Fig. IE depicts a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 47);
41
5535.1 Fig. IF depicts a modular gRNA molecule derived in part from Streptococcus thermophilus (S. thermophilus) as a duplexed structure (SEQ ID NOS: 48 and 49, respectively, in order of appearance);
Fig. 1G depicts an alignment of modular gRNA molecules of S. pyogenes and S.
thermophilus (SEQ ID NOS: 50-53, respectively, in order of appearance).
Figs. 1H-1I depicts additional exemplary structures of unimolecular gRNA molecules. Fig. 1H shows an exemplary structure of a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 45). Fig. II shows an exemplary structure of a unimolecular gRNA molecule derived in part from S. aureus as a duplexed structure (SEQ ID NO: 40).
Figs. 2A-2G depict an alignment of Cas9 sequences from Chylinski et al. (RNA Biol. 2013; 10(5): 726-737). The N-terminal RuvC-like domain is boxed and indicated with a "Y". The other two RuvC-like domains are boxed and indicated with a "B". The HNH-like domain is boxed and indicated by a "G". Sm: S. mutans (SEQ ID NO: 1); Sp: S. pyogenes (SEQ ID NO: 2); St: S. thermophilus (SEQ ID NO: 3); Li: L. innocua (SEQ ID NO: 4). Motif: this is a motif based on the four sequences: residues conserved in all four sequences are indicated by single letter amino acid abbreviation; "*" indicates any amino acid found in the corresponding position of any of the four sequences; and "-" indicates any amino acid, e.g., any of the 20 naturally occurring amino acids, or absent.
Figs. 3A-3B show an alignment of the N-terminal RuvC-like domain from the Cas9 molecules disclosed in Chylinski et al (SEQ ID NOS: 54-103, respectively, in order of appearance). The last line of Fig. 3B identifies 4 highly conserved residues.
Figs. 4A-4B show an alignment of the N-terminal RuvC-like domain from the Cas9 molecules disclosed in Chylinski et al. with sequence outliers removed (SEQ ID NOS: 104-177, respectively, in order of appearance). The last line of Fig. 4B identifies 3 highly conserved residues.
Figs. 5A-5C show an alignment of the HNH-like domain from the Cas9 molecules disclosed in Chylinski et al (SEQ ID NOS: 178-252, respectively, in order of appearance). The last line of Fig. 5C identifies conserved residues.
Figs. 6A-6B show an alignment of the HNH-like domain from the Cas9 molecules disclosed in Chylinski et al. with sequence outliers removed (SEQ ID NOS: 253-302,
42
5535.1 respectively, in order of appearance). The last line of Fig. 6B identifies 3 highly conserved residues.
Figs. 7A-7B depict an alignment of Cas9 sequences from S. pyogenes and Neisseria meningitidis (N. meningitidis). The N-terminal RuvC-like domain is boxed and indicated with a "Y". The other two RuvC-like domains are boxed and indicated with a "B". The HNH-like domain is boxed and indicated with a "G". Sp: S. pyogenes; Nm: N. meningitidis. Motif: this is a motif based on the two sequences: residues conserved in both sequences are indicated by a single amino acid designation; "*" indicates any amino acid found in the corresponding position of any of the two sequences; "-" indicates any amino acid, e.g., any of the 20 naturally occurring amino acids, and "-" indicates any amino acid, e.g., any of the 20 naturally occurring amino acids, or absent.
Fig. 8 shows a nucleic acid sequence encoding Cas9 of N. meningitidis (SEQ ID NO: 303). Sequence indicated by an "R" is an SV40 NLS; sequence indicated as "G" is an HA tag; and sequence indicated by an "O" is a synthetic NLS sequence; the remaining (unmarked) sequence is the open reading frame (ORF).
Figs. 9A and 9B are schematic representations of the domain organization of S. pyogenes Cas 9. Fig. 9A shows the organization of the Cas9 domains, including amino acid positions, in reference to the two lobes of Cas9 (recognition (REC) and nuclease (NUC) lobes). Fig. 9B shows the percent homology of each domain across 83 Cas9 orthologs.
DETAILED DESCRIPTION
Definitions
"CF target mutant position", as used herein, refers to a target position in the CFTR gene, which, if mutated, can result in a mutant protein and give rise to CF or CF-like disease. In an embodiment, the target position comprises one, two, or three nucleotides. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at F508, e.g., F508del. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at G551, e.g., G551D. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at G542, e.g., G542X, in the CFTR protein, which corresponds to c. l624G>T
43
5535.1 in the CFTR gene. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at N1303, e.g., N1303K, in the CFTR protein, which corresponds to c.3909C>G in the CFTR gene. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at Rl 17, e.g., Rl 17H, in the CFTR protein, which corresponds to c.350G>A in the CFTR gene. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at W1282, e.g., W1282X, in the CFTR protein, which corresponds to c. c.3846G>A in the CFTR gene. In an embodiment, the CF target mutant position is a position in the CFTR gene at which a change can give rise to a mutant protein having a mutation at R553, e.g., R553X, in the CFTR protein, which corresponds to c. l657C>T in the CFTR gene. In an embodiment, the CF target mutant position is c.3717+12191, also known as c.3849+10kb, which corresponds to 3717+12191C>T in the CFTR gene. In an embodiment, the CF target mutant position is c.2657+5, also known as c.2789+5, which corresponds to 2657+5G>A in the CFTR gene. In an embodiment, the CF target mutant position is c.3140-26, also known as c.3272-26, which corresponds to c.3140-26 A>G in the CFTR gene. In an embodiment, the CF target mutant position is a position in the SCNNIA gene at which a change can give rise to a mutant protein having a mutation at VI 14, which corresponds to VI 141 in the SCNNIA gene.
"CF target knockout position", as used herein, refers to a position in the CFTR and/or SCNNIA gene, which if altered by NHEJ-mediated alteration, results in alleviation of a symptom of CF or CF-like disease. In an embodiment, the alteration restores expression of functional CFTR gene product. In an embodiment, the position is in the CFTR non-coding region, e.g., an intronic region (e.g., the alternation corrects a cryptic splice site). In an embodiment, the alteration results in reduction or elimination of expression of functional SCNNIA gene product. In an embodiment, the position is in the SCNNIA coding region, e.g., an early coding region.
"CF target knockdown position", as used herein, refers to a position in the SCNNIA gene, which if targeted, e.g., by an eiCas9 molecule or an eiCas9 fusion described herein, results in reduction or elimination of expression of functional SCNNIA gene product. In an embodiment, the transcription of the SCNNIA gene is reduced or eliminated. In another embodiment, the chromatin structure of the SCNNIA gene is altered. In an embodiment, the position is in the
SCNNIA early coding region sequence. In an embodiment, a position in early coding region of
44
5535.1 the SCNN1A gene is targeted by an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9- fusion protein, as described herein.
"CF target knockin position", as used herein, refers to a sequence, which if modified by the insertion of CFTR sequence, results in an optimization of CFTR activity, e.g., by resulting in a CFTR sequence that encodes a protein having wild type activity. Exemplary CF target knockin position include: CFTR sequence within intron 2, into which, e.g., can be introduced CFTR sequence that codes for CFTR exons 3-27; and sequence within CFTR intron 10, into which sequence that codes for CFTR exons 11-27 can be introduced. In an embodiment, a CF target knockin position includes CFTR intronic sequence between a second and a third exon (e.g., intron 2), and CFTR sequence encoding the third exon through the final exon (exon 27), is introduced, resulting in a CFTR sequence that is free of one or more cryptic splice sites and that encodes a CFTR protein having wild type activity. In an embodiment, a CF target knockin position, is a position which is upstream of a mutation, or upsteam of an intron having a mutation, and introduction of wild-type CFTR sequence results in a CFTR sequence that is free of the mutation. In an embodiment the CF target knockin position is in CFTR intronic sequence: between exon2 and exon 3; or between exon 10 and exon 11. In an embodiment, the resulting CFTR sequence comprises subject sequence upstream from the CF target knockin position and newly introduced sequence downstream from the CF target knockin position, which taken together, encode a CFTR protein having wild type activity. In an embodiment, the point of insertion is 3' to a splice donor site and 5' from a splice acceptor site. In an embodiment, CFTR sequence encoding exons 3-27 is inserted under control of the promoter, e.g., at the transcription start site. In an embodiment, CFTR sequence introduced can exclude introns, e.g., a sequence encoding exons, but without introns, is inserted, e.g., CFTR CDNA sequence is introduced.
"CF target position", as used herein, refers to a CF target mutant position, CF target knockout position, CF target knockdown position, and/or CF target knockin position, as described herein.
"Domain", as used herein, is used to describe segments of a protein or nucleic acid. Unless otherwise indicated, a domain is not required to have any specific functional property.
Calculations of homology or sequence identity between two sequences (the terms are used interchangeably herein) are performed as follows. The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino
45
5535.1 acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The optimal alignment is determined as the best score using the GAP program in the GCG software package with a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frame shift gap penalty of 5. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences.
"Governing gRNA molecule", as used herein, refers to a gRNA molecule that comprises a targeting domain that is complementary to a target domain on a nucleic acid that comprises a sequence that encodes a component of the CRISPR/Cas system that is introduced into a cell or subject. A governing gRNA does not target an endogenous cell or subject sequence. In an embodiment, a governing gRNA molecule comprises a targeting domain that is complementary with a target sequence on: (a) a nucleic acid that encodes a Cas9 molecule; (b) a nucleic acid that encodes a gRNA which comprises a targeting domain that targets the CFTR or SCNN1A gene (a target gene gRNA); or on more than one nucleic acid that encodes a CRISPR/Cas component, e.g., both (a) and (b). In an embodiment, a nucleic acid molecule that encodes a CRISPR/Cas component, e.g., that encodes a Cas9 molecule or a target gene gRNA, comprises more than one target domain that is complementary with a governing gRNA targeting domain. While not wishing to be bound by theory, in an embodiment, it is believed that a governing gRNA molecule complexes with a Cas9 molecule and results in Cas9 mediated inactivation of the targeted nucleic acid, e.g., by cleavage or by binding to the nucleic acid, and results in cessation or reduction of the production of a CRISPR/Cas system component. In an embodiment, the Cas9 molecule forms two complexes: a complex comprising a Cas9 molecule with a target gene gRNA, which complex will alter the CFTR or SCNN1A gene; and a complex comprising a Cas9 molecule with a governing gRNA molecule, which complex will act to prevent further production of a CRISPR/Cas system component, e.g., a Cas9 molecule or a target gene gRNA molecule. In an embodiment, a governing gRNA molecule/Cas9 molecule complex binds to or promotes cleavage of a control region sequence, e.g., a promoter, operably linked to a sequence that encodes a Cas9 molecule, a sequence that encodes a transcribed region, an exon, or an
46
5535.1 intron, for the Cas9 molecule. In an embodiment, a governing gRNA molecule/Cas9 molecule complex binds to or promotes cleavage of a control region sequence, e.g., a promoter, operably linked to a gRNA molecule, or a sequence that encodes the gRNA molecule. In an embodiment, the governing gRNA, e.g., a Cas9-targeting governing gRNA molecule, or a target gene gRNA- targeting governing gRNA molecule, limits the effect of the Cas9 molecule/target gene gRNA molecule complex-mediated gene targeting. In an embodiment, a governing gRNA places temporal, level of expression, or other limits, on activity of the Cas9 molecule/target gene gRNA molecule complex. In an embodiment, a governing gRNA reduces off-target or other unwanted activity. In an embodiment, a governing gRNA molecule inhibits, e.g., entirely or substantially entirely inhibits, the production of a component of the Cas9 system and thereby limits, or governs, its activity.
"Modulator", as used herein, refers to an entity, e.g., a drug, that can alter the activity (e.g., enzymatic activity, transcriptional activity, or translational activity), amount, distribution, or structure of a subject molecule or genetic sequence. In an embodiment, modulation comprises cleavage, e.g., breaking of a covalent or non-covalent bond, or the forming of a covalent or non- covalent bond, e.g., the attachment of a moiety, to the subject molecule. In an embodiment, a modulator alters the, three dimensional, secondary, tertiary, or quaternary structure, of a subject molecule. A modulator can increase, decrease, initiate, or eliminate a subject activity.
"Large molecule", as used herein, refers to a molecule having a molecular weight of at least 2, 3, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 kD. Large molecules include proteins, polypeptides, nucleic acids, biologies, and carbohydrates.
"Polypeptide", as used herein, refers to a polymer of amino acids having less than 100 amino acid residues. In an embodiment, it has less than 50, 20, or 10 amino acid residues.
"Reference molecule", e.g., a reference Cas9 molecule or reference gRNA, as used herein, refers to a molecule to which a subject molecule, e.g., a subject Cas9 molecule of subject gRNA molecule, e.g., a modified or candidate Cas9 molecule is compared. For example, a Cas9 molecule can be characterized as having no more than 10% of the nuclease activity of a reference Cas9 molecule. Examples of reference Cas9 molecules include naturally occurring unmodified Cas9 molecules, e.g., a naturally occurring Cas9 molecule such as a Cas9 molecule of S.
pyogenes, S. aureus or S. thermophilus. In an embodiment, the reference Cas9 molecule is the naturally occurring Cas9 molecule having the closest sequence identity or homology with the
47
5535.1 Cas9 molecule to which it is being compared. In an embodiment, the reference Cas9 molecule is a sequence, e.g., a naturally occurring or known sequence, which is the parental form on which a change, e.g., a mutation has been made.
"Replacement", or "replaced", as used herein with reference to a modification of a molecule does not require a process limitation but merely indicates that the replacement entity is present.
"Small molecule", as used herein, refers to a compound having a molecular weight less than about 2 kD, e.g., less than about 2 kD, less than about 1.5 kD, less than about 1 kD, or less than about 0.75 kD.
"Subject", as used herein, may mean either a human or non-human animal. The term includes, but is not limited to, mammals (e.g., humans, other primates, pigs, rodents (e.g., mice and rats or hamsters), rabbits, guinea pigs, cows, horses, cats, dogs, sheep, and goats). In an embodiment, the subject is a human. In other embodiments, the subject is poultry.
"Treat", "treating" and "treatment", as used herein, mean the treatment of a disease in a mammal, e.g., in a human, including (a) inhibiting the disease, i.e., arresting or preventing its development; (b) relieving the disease, i.e., causing regression of the disease state; and (c) curing the disease.
"X" as used herein in the context of an amino acid sequence, refers to any amino acid (e.g., any of the twenty natural amino acids) unless otherwise specified. Cystic Fibrosis and CF-like Disease
Cystic fibrosis (CF) is an autosomal recessive hereditary disease caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR gene encodes a cAMP-gated channel that is involved in chloride and bicarbonate transport. It regulates sodium transport through inhibition of the epithelial sodium channel, which is encoded by the SCNN1A gene. CFTR is expressed on the apical surface of epithelial cells in the airway, gastrointestinal tract, reproductive tract, sweat glands and submucosal glands.
Subjects having CF or CF-like disease may present at birth or in early infancy with pancreatic insufficiency. Pancreatic dysfunction leads to malabsorption of fat and fat-soluble vitamins, which causes poor growth as well as gallstones and biliary disease. The lung manifestations of the disease can be more severe but may present slightly after pancreatic manifestations, in infancy or early childhood. Aberrant chloride and sodium transport due to
48
5535.1 decreased CFTR activity causes lowered apical surface fluid levels in the lungs, which leads to "sticky" mucous and lower airway obstruction. Subjects having CF or CF-like disease suffer from frequent infections due to inability to clear mucous. Local inflammatory mediators try to clear the infection but have difficulty. The triad of inflammation, infection and obstruction leads to progressive destruction of the lung parenchyma. Eventually, many subjects having CF or CF- like disease die in their late 30' s due to respiratory failure.
Current treatments for CF or CF-like disease can increase the life expectancy of subjects with CF or CF-like disease. These treatments delay lung destruction and slow disease progression. These treatments do not reverse the damage to the lungs or cure CF or CF-like disease. Subjects having CF or CF-like disease eventually suffer from end-stage lung disease.
Treatments for the pulmonary manifestations of CF or CF-like disease include:
antibiotics (oral, inhaled and intravenous), CFTR modulators (including CFTR potentiators), DNase, chest physiotherapy to loosen secretions and anti-inflammatory therapeutics. Treatment of the gastrointestinal manifestations includes supplemental gut soluble vitamins, high calorie diet and oral pancreatic enzymes. Subjects who develop diabetes are treated with insulin injections or an insulin pump. At the end stage, patients may benefit from lung transplant. Lung transplant may be combined with liver and/or pancreatic transplant. The average life expectancy for subjects having CF or CF-like disease is nearing 40 years of age.
Methods and compositions discussed herein provide for the treatment and prevention of Cystic Fibrosis (CF) and CF-like disease. The approach described herein aims to restore CFTR channel function, restore chloride, bicarbonate and/or sodium balance, and/or decrease mucous viscosity within the lungs, airways, gastrointestinal tract and reproductive tract.
CFTR modulators (both approved and in development) improve the functioning of mutant CFTR. These therapeutics improve CFTR functioning but do not return functionality to wild type levels. The approach described herein is expected to restore CFTR function through complete correction of the gene.
Gene therapy approaches are in development that deliver the CFTR channel gene to the lungs of CF patients. However, gene therapy may require constant readministration over the course of the lifetime of a subject due to high cell turnover in target epithelial cells. The approach described herein is expected to restore CFTR function and/or ameliorate SCNN1A disinhibition permanently through one, two or several doses.
49
5535.1 The CFTR gene encodes a 180-kDA cAMP-gated chloride (C1-) channel. The channel has six transmembrane spanning domains and is expressed by epithelial cells, lymphocytes and cardiac myocytes. The CFTR regulates the viscosity of mucous through its activity in the epithelial cells of the lungs, gastrointestinal tract and reproductive tract. Mutations in the CFTR result in decreased CFTR activity. Decreased CFTR activity can lead to aberrant ion transport, which gives rise to various disease symptoms in the lungs and other tissues, such as
accumulation of sticky mucus, airway obstruction, infection and inflammation. Correction of CFTR mutations will ameliorate or cure lung, gastrointestinal and/or reproductive symptoms of CF.
The SCNN1A gene encodes the alpha subunit of the epithelial sodium channel (ENaC).
The channel, comprised of alpha, beta and gamma subunits, regulates sodium transport into epithelial cells, including the epithelium of the lungs, sweat glands and kidneys. Mutations in the SCNN1A gene, (e.g. Vail 14ILE) have been shown to cause CF-like disease, characterized by pulmonary disease, including bronchiectasis. Mutations in SCNN1A also cause
pseudohypoaldosteronism, a severe disease of the kidney. Pseudohypoaldosteronism is due to defective sodium transport within kidney epithelial cells; it is not caused by defective sodium transport in other tissues. The methods described herein include the targeted knockout of SCNN1A in the lung, gastrointestinal tract and/or reproductive tract. The methods described herein will not target kidney epithelium and will avoid the negative consequences of SCNN1A mutations within the kidney epithelium. One mutation in the SCNN1A gene, a 1477T>G substitution (W493R) has been identified in subjects who also have a mutation in CFTR. This mutation is associated with a severe CF phenotype, including severe bronchiectasis, chronic bronchitis and/or severe gastrointestinal symptoms. This mutation has been found to be associated with 4-fold overactivity of the ENaC channel (Azad et al., 2009; Human Mutation 30: 1093-1103). Overactivity of the SCNNlA-encoded ENaC channel can contribute to CF and CF- like disease. In all subjects, the CFTR is involved in inhibition of ENaC. CFTR mutations in subjects with CF or CF-like disease leads to ENaC disinhibition, leading to overactivity of the ENaC channel. ENaC overactivity can lead to further reduction in viscosity of mucous in CF or CF-like disease subjects, as more sodium is absorbed at the apical surface of epithelial cells, followed by increased fluid absorption from the mucous layer within the lung (Baker et al., 2012; Medicine & Science in Sports and Exercise 44(12): 2315-2321). Increased fluid absorption from
50
5535.1 the mucous layer reduces mucous viscosity. Inhibition of ENaC through SCNNIA knockout and/or knockdown in subjects with CF or CF-like disease can ameliorate the symptoms of CF or CF-like disease.
One common mutation in the CFTR gene is a deletion of the three nucleotides encoding Phenylalanine (F) at position 508 of the CFTR protein F508del (also sometime referred to herein as "F508del" or "delF508"). This mutation is the causative mutation in approximately two-thirds of CF cases. The remaining cases are caused by at least 1000 different mutations, many of which cause a less severe form of the disease.
Overactivity of the SCNNIA gene has been shown to contribute to bronchiectasis, bronchitis, and gastrointestinal symptoms in subjects with CF and in subjects with CF-like disease. In another aspect, methods and compositions discussed herein may be used to alter the SCNNIA gene (also known as sodium channel, non-voltage-gated 1 alpha subunit; amiloride- sensitive epithelial sodium channel alpha subunit; BESC2; ENaCa; SCNEA; SCNN1;
ENaCalpha) to treat or prevent CF or CF-like disease, by targeting the SCNNIA gene, e.g., the non-coding or coding regions, e.g., a promoter region, or a transcribed sequence, e.g., intronic or exonic sequence. In an embodiment, the target position is VI 14, which corresponds to VI 141 in the SCNNIA gene. SCNNIA encodes an epithelial sodium channel, ENaC, that is negatively regulated by CFTR. In subjects with CFTR mutations, knocking out or knocking down the SCNNIA gene in certain cells will reduce or reverse the effect of defective CFTR. In subjects with no CFTR mutations but CF-like disease caused by SCNNIA mutations or other mechanisms, knocking out or knocking down the SCNNIA gene in certain cells will improve the viscosity of mucous and ameliorate disease.
Methods to Treat or Prevent Cystic Fibrosis and Cystic Fibrosis-like Disease
Correction of the CFTR mutation (e.g., F508 deletion, e.g., G551D substitution, e.g.,
G542X nonsense mutation, e.g., N1303K substitution, e.g., R117H substitution, e.g., W1282X nonsense mutation, e.g., R553X nonsense mutation, e.g., 3849+10kbC>T substitution, e.g., 2789+5G>A substitution, e.g., 3273-26A>G substitution) or inactivationor knockdown of the SCNNIA gene, e.g., using the methods disclosed herein, can ameliorate the disease. In an embodiment, the method leads to normalized ion transport, less viscous mucous, and/or reduced mucous plugging and inflammation, e.g., early in the disease course. In an embodiment, the
51
5535.1 method results in fewer infections, decreased lung tissue destruction, and/or slowing in progression of disease. In an embodiment, the method improves mucous production and/or reduce frequency and/or length of infections, e.g., in later stages of the disease. In an embodiment, the method reduces or prevents further damage by ameliorating the triad of inflammation, infection and obstruction. In an embodiment, the method delays progression of the disease. In an embodiment, the method reduces or prevents further damage by ameliorating the triad of inflammation, infection and obstruction. In an embodiment, the method leads to normalized ion transport, and restoration of fertility. In an embodiment, the method leads to normalized ion transport, and improved gastrointestinal motility, absorption, and/or function.
Disclosed herein are the approaches to treat or prevent CF or CF-like disease, using the compositions and methods described herein.
While not wishing to be bound by theory, it is believed that, in an embodiment described herein, the CFTR channel is corrected and chloride and bicarbonate balance restored, e.g., within the lung, e.g., within the airway, e.g., within the gastrointestinal tract, e.g., within the
reproductive tract, e.g., in the hepatobiliary epithelium, e.g. in the pancreas. CFTR modulators (both approved and in development) improve the functioning of mutant CFTR. These therapeutics improve CFTR functioning but do not return functionality to wild type levels.
In an embodiment, the approach described herein restores CFTR function through complete correction of the CFTR gene. In another embodiment, the approach described herein inactivates the SCNN1A gene, e.g., in the pulmonary epithelium, e.g., in the airway epithelium, e.g., in the gastrointestinal epithelium, e.g. in the reproductive epithelium, e.g., in the
hepatobiliary epithelium, e.g. in the pancreatic ducts, in order to inhibit the abnormal sodium ion transport associated with reduced CFTR activity and/or in order to inhibit abnormal sodium ion transport associated with overactive ENaC activity. In an embodiment, these two approaches are combined to treat or prevent CF or CF-like disease. In an embodiment, the approaches described herein provide advantages over CFTR modulators.
It is contemplated that the compositions disclosed herein may be administered once or more than once (e.g., 2, 3, 4, 5, or more times) to correct a mutation in the CFTR gene or to inactivate or knock-down the SCNN1A gene. It is further contemplated that when the compositions disclosed herein are administered more than one time that the multiple
administrations are intended to increase the number of cells (e.g., the number of cells in the subject) containing the corrected form of the CFTR gene and/or the inactivated/knocked-down form of the SCNNIA gene, thereby increasing the effectiveness of the treatment.
The methods of treatment described herein can be initiated for subjects at all stages of the disease. In an embodiment, the treatment is initiated after disease onset, e.g., as the subject presents with lung infections, wheezing and obstructed airways, and/or pancreatic insufficiency, decreased gastrointestinal function, malabsorption, and/or infertility. While not wishing to be bound by theory, in an embodiment, repair of the CFTR gene or inactivation/knock-down of the SCNNIA gene after disease onset but early in the disease course reduces or prevents progression of the disease. In an embodiment, the method comprises treating a subject with advanced disease. In an embodiment, the method reduces or prevents further progression of symptoms, with or without reversing pathology.
In an embodiment, the treatment is initiated prior to disease onset. In another embodiment, the treatment is initiated at an early stage of the disease, e.g., before the subject has noticed any decline in function or symptoms.
In an embodiment, treatment is initiated in utero.
In an embodiment, treatment is initiated after birth.
In an embodiment, treatment is initiated prior to the age of 1.
In an embodiment, treatment is initiated prior to the age of 2.
In an embodiment, treatment is initiated prior to the age of 5.
In an embodiment, treatment is initiated prior to the age of 10.
In an embodiment, the subject has tested positive for a mutation in the CFTR gene, e.g., a mutation described herein.
In an embodiment, the subject has tested positive for a mutation in the SCNNIA gene, e.g., a mutation described herein.
In an embodiment, the treatment is initiated at appearance of a symptom of CF or CF-like disease, e.g., any of the following symptoms: frequent lung infections, chronic cough, sputum production, or chronic wheeze. In an embodiment, the subject has a positive "sweat test" or elevated sweat Chloride indicating dysfunction of the CFTR channel and/or overactivity of the SCNNIA channel. In an embodiment, the subject has an elevated sweat Chloride, bronchiectasis and is found to have no mutation in the CFTR gene. In an embodiment, the treatment is initiated if the subject is tested positive for a defect, e.g., a genetic defect, in the CFTR gene.
In an embodiment, the treatment is initiated if the subject is tested positive for a defect, e.g., a genetic defect, in the SCNN1A gene.
In an embodiment, the treatment is initiated if a family member of the subject has been diagnosed with CF or CF-like disease. In an embodiment, the subject has a symptom or sign of CF or CF-like disease. In an embodiment, the subject has a mutation in the CFTR gene, e.g., a mutation described herein.
In an embodiment, the treatment is initiated at the appearance of any of the following findings consistent with CF or CF-like disease, including but not limited to, obstructive lung disease on lung function tests; persistent colonization with B. cepacia, P. aeruginosa and S. aureus and other CF-related pathogens; chronic radiologic abnormalities on chest x-ray; or chronic sinusitis.
In an embodiment, the method comprises initiating treatment at the appearance of any of the following gastrointestinal findings consistent with CF or CF-like disease, including but not limited to: failure to thrive, steatorrhea, hypoproteinemia, vitamin deficiency due to fat- soluble vitamin malabsorption, meconium ileus, rectal prolapse, malabsorption, pancreatic insufficiency, pancreatitis, or chronic hepatobiliary disease. Evidence of chronic hepatobiliary disease can include, e.g., elevated transaminases and/or hyperbilirubinemia.
In an embodiment, a cell is treated ex vivo. In an embodiment, the cell is returned to the subject.
In an embodiment, it is contemplated herein that a population of cells from a subject may be contacted ex vivo to correct a mutation in the CFTR gene, e.g., F508del, e.g., G542X, e.g., G551D, e.g., N1303K, e.g., R117H, e.g., W1282X, e.g., R553X, e.g., 3849+10kbC>T, e.g., 2789+5G>A, e.g., 3273-26A>G, and a second population of cells from the subject is contacted ex vivo to introduce a mutation in the SCNN1A gene to knockout or knockdown SCNN1A. A mixture of the two cell populations may be returned to the subject's body to prevent or treat CF or CF-like disease.
In an embodiment, the cell is harvested from epidermis, pulmonary tree, hepatobiliary tree, gastrointestinal tract, reproductive tract, or other organ. In an embodiment, the cell is reprogrammed to an induced pluripotent stem (iPS) cell. In an embodiment, the iPS cell is differentiated into airway epithelium, pulmonary epithelium, submucosal glands, submucosal ducts, biliary epithelium, gastrointestinal epithelium, pancreatic duct cells, reproductive epithelium, epidydimal cells, and/or cells of the hepatobiliary tree, e.g., clara cells, e.g., ciliated cells, e.g., goblet cells, e.g., basal cells, e.g., acinus cells, e.g., bronchioalveolar stem cell e.g., lung epithelial cells, e.g., nasal epithelial cells, e.g., tracheal epithelial cells, e.g., bronchial epithelial cells, e.g., enteroendocrine cells, e.g., Brunner's gland cells, e.g., epididymal epithelium. In an embodiment, the CFTR gene in the cell is corrected with the method described herein. In an embodiment, the SCNNIA gene in the cell is corrected with the method described herein. In an embodiment, the CFTR gene and the SCNNIA gene in the cell is corrected with the method described herein. In an embodiment, the cell is re-introduced into an appropriate location in the subject, e.g., airway, pulmonary tree, bile duct system, gastrointestinal tract, pancreas, hepatobiliary tree, and/or reproductive tract.
In an embodiment, an autologous stem cell can be treated ex vivo, differentiated into airway epithelium, pulmonary epithelium, submucosal glands, submucosal ducts, biliary epithelium, gastrointestinal epithelium, pancreatic duct cells, reproductive epithelium, epidydimal cells, and/or cells of the hepatobiliary tree, e.g., clara cells, e.g., ciliated cells, e.g., goblet cells, e.g., basal cells, e.g., acinus cells, e.g., bronchioalveolar stem cell e.g., lung epithelial cells, e.g., nasal epithelial cells, e.g., tracheal epithelial cells, e.g., bronchial epithelial cells, e.g., enteroendocrine cells, e.g., Brunner's gland cells, e.g., epididymal epithelium, and transplanted into the subject.
In an embodiment, a heterologous stem cell can be treated ex vivo, differentiated into airway epithelium, pulmonary epithelium, submucosal glands, submucosal ducts, biliary epithelium, gastrointestinal epithelium, pancreatic duct cells, reproductive epithelium, epidydimal cells, and/or cells of the hepatobiliary tree, e.g., clara cells, e.g., ciliated cells, e.g., goblet cells, e.g., basal cells, e.g., acinus cells, e.g., bronchioalveolar stem cell e.g., lung epithelial cells, e.g., nasal epithelial cells, e.g., tracheal epithelial cells, e.g., bronchial epithelial cells, e.g., enteroendocrine cells, e.g., Brunner's gland cells, e.g., epididymal epithelium, and transplanted into the subject.
In an embodiment, the method described herein comprises delivery of gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid, by inhalation, e.g., via nebulizer. In an embodiment, the method described herein comprises delivery of gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid by intravenous administration. In an embodiment, the method described herein comprises delivery of gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid by intraparenchymal injection into lung tissue. In an embodiment, the method described herein comprises delivery of gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid, by intraparenchymal, intralveolar, intrabronchial, intratracheal injection into the trachea, bronchial tree and/or alveoli. In an embodiment, the method described herein comprises delivery of gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid, by intravenous, intraparenchymal or other directed injection or administration to any of the following locations: the portal circulation, liver parenchyma, pancreas, pancreatic duct, bile duct, jejunum, ileum, duodenum, stomach, upper intestine, lower intestine, gastrointestinal tract, epididymis, or reproductive tract.
In an embodiment, a gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid are delivered, e.g., to a subject, by AAV, e.g., via nebulizer, or via nasal spray or inhaled, with or without accelerants to aid in absorption. In an embodiment, a gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid are delivered, e.g., to a subject, by Sendai virus, adenovirus, lentivirus or other modified or unmodified viral delivery particle.
In an embodiment, a gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid are delivered, e.g., to a subject, via nebulizer or jet nebulizer, nasal spray, or inhalation. In an embodiment, a gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid, is formulated in an aerosolized cationic liposome, lipid nanoparticle, lipoplex, non-lipid polymer complex or dry powder, e.g., for delivery via nebulizer, with or without accelerants to aid in absorption.
In an embodiment, a gRNA or other components described herein, e.g., a Cas9 molecule and a template nucleic acid are delivered, e.g., to a subject, via liposome GL67A. GL67A is described, e.g., www.cfgenetherapy.org.uk/clinical/product.html; Eastman et al., Hum Gene Ther. 1997 Apr 10; 8(6):765-73.
Disclosed herein are methods for altering the CF target position in the CFTR and/or SCNN1A genes.
56
5535.1 Methods and compositions disclosed herein provide a number of approaches for treating or preventing CF and CF-like disease. In an embodiment, methods described herein provide for treating or preventing CF and CF-like disease by correcting a target position in the CFTR gene to provide corrected, or functional, e.g., wild type, CFTR. In an embodiment, methods described herein allow for treating or preventing CF and CF-like disease by inducing or introducing a mutation that reduces the level of functional SCNN1A gene product. In subjects with CF or CF- like disease, these methods can be used alone, e.g. CFTR correction, e.g., SCNN1A knockout or knockdown, or in combination, e.g., CFTR correction with SCNN1A knockout or knockdown.
Several approaches are detailed in the following, including target positions and mutations amenable to approach. In the description below, approaches 1, 2 and 3 (e.g., 3A and 3B) correspond to methods to alter CFTR. In the description below, approach 4 and 6 correspond to methods to alter SCNN1A. One or more of the approaches can be used alone or in combination. For example, approaches 1, 2, and 3 can be used alone or approach 1 can be combined with approach 4, or approach 2 can be combined with approach 4 or approach 3 (e.g., 3 A or 3B) can be combined with approach 4.
Methods to Alter CFTR
In one aspect, methods and compositions discussed herein, provide for the correction of the underlying cause of CF or CF-like disease, e.g., the correction of a mutation at a target position in the CFTR gene.
As disclosed herein, the CFTR gene can be altered by gene editing, e.g., using CRISPR- Cas9 mediated methods as described herein. Methods and compositions discussed herein, provide for altering a CF target position in the CFTR gene. A CF target position can be altered by gene editing, e.g., using CRISPR-Cas9 mediated methods to alter the CFTR gene.
In an embodiment, while some of the disclosure herein is presented in the context of the mutation in the CFTR gene that gives rise to an F508 mutant protein (e.g., F508del mutant protein) or a G551 mutant protein (e.g., G551D mutant protein), or a G542 mutant protein (e.g., G542X mutant protein), or a mutant protein (e.g., mutant protein), or a N1303 mutant protein (e.g., N1303K mutant protein), or a Rl 17 mutant protein (e.g., Rl 17H mutant protein), or a W1282 mutant protein (e.g., W1282X mutant protein), or a R553 mutant protein (e.g., R553X mutant protein), or a c.3717+12191 mutant protein (e.g., c.3717+12191C>T mutant protein), or a
57
5535.1 c.2657+5 mutant protein (e.g., c.2657+5G>A mutant protein), or a c.3140-26 mutant protein (e.g., c.3140-26 A>G mutant protein), the methods and compositions herein are broadly applicable to any mutation, e.g., a point mutation or a deletion, in the CFTR gene that gives rise to CF or CF-like disease.
The alteration of the CFTR gene can be mediated by any mechanism. Exemplary mechanisms that can be associated with the alteration of the CFTR gene include, but are not limited to, non-homologous end joining (e.g., classical or alternative), microhomology-mediated end joining (MMEJ), homology-directed repair (e.g., endogenous donor template mediated), SDSA (synthesis dependent strand annealing) or single strand annealing or single strand invasion, all with or without the addition of an endogenous- promoter driven cDNA encoding the CFTR gene.
Approach 1: In an embodiment, one approach to treat or prevent CF or CF-like disease is to repair (i.e., correct) one or more mutations in the CFTR gene, e.g., by HDR. While not wishing to be bound by theory, it is believed that correction of the mutation(s) (e.g., mediated by HDR) restore the mutant CFTR gene to its wild type state. In an embodiment, single stranded oligonucleotides (ssODNs) are used as a donor template. In another embodiment, double stranded DNA donor is used as a donor template. Donor templates contain DNA sequence which, upon incorporation, result in the expression of a functional version of the CFTR protein. In an embodiment, one CFTR allele is repaired in the subject. In another embodiment, both CFTR alleles are repaired in the subject. In one aspect, methods and compositions discussed herein, provide for the correction of the underlying genetic cause of CF or CF-like disease, e.g., the correction of a mutation at a target position in the CFTR gene, e.g., correction of a mutation (e.g., delF508, G551DG542X, N1303K, R117H, W1282X, or R553X) in the CFTR gene.
Mutations in the CFTR gene amenable to the approach described herein include, but are not limited to any of the following mutations, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X.
In an embodiment, the homology-directed repair of genomic sequence including the mutation at the CF target position (e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X) gives rise to alteration of the CFTR gene. This approach leads to the cessation of production of mutant CFTR channel and results in the production of wild-type CFTR channel.
58
5535.1 This approach will prevent the development or progression of lung, gastrointestinal and/or reproductive disease in subjects with CFTR mutations.
In an embodiment, the method provides for the correction of a mutation at a target position in the CFTR gene, e.g., correction of a mutation, e.g., an F508del, G551D, G542X, N1303K, Rl 17H, W1282X, or R553X substitution in the CFTR gene. As described herein, in an embodiment, the method comprises the introduction of one or more breaks (e.g., single strand breaks or double strand breaks) sufficiently close to (e.g., either 5' or 3' to) the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X.
In an embodiment, the targeting domain of the gRNA molecule is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to (e.g., either 5' or 3' to) the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X to allow correction, e.g., an alteration in the CFTR gene, e.g., an alternation associated with HDR. In an embodiment, the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, Rl 17H, W1282X, or R553X. The break, e.g., a double strand or single strand break, can be positioned upstream or downstream of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X.
In an embodiment, a second, third and/or fourth gRNA molecule is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to (e.g., either 5' or 3' to) the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, Rl 17H, W1282X, or R553X to allow correction, e.g., an alteration associated with HDR in the CFTR gene. In an embodiment, the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X. The break, e.g., a double strand or single strand break, can be positioned upstream or downstream of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, Rl 17H, W1282X, or R553X.
59
5535.1 In an embodiment, a single strand break is accompanied by an additional single strand break, positioned by a second, third and/or fourth gRNA molecule, as discussed below. For example, The targeting domains bind configured such that a cleavage event, e.g., the two single strand breaks, are positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X. In an embodiment, the first and second gRNA molecules are configured such, that when guiding a Cas9 nickase, a single strand break will be accompanied by an additional single strand break, positioned by a second gRNA, sufficiently close to one another to result in an alteration of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X. In an embodiment, the first and second gRNA molecules are configured such that a single strand break positioned by said second gRNA is within 10, 20, 30, 40, or 50 nucleotides of the break positioned by said first gRNA molecule, e.g., when the Cas9 is a nickase. In an embodiment, the two gRNA molecules are configured to position cuts at the same position, or within a few nucleotides of one another, on different strands, e.g., essentially mimicking a double strand break.
In an embodiment, a double strand break can be accompanied by an additional double strand break, positioned by a second, third and/or fourth gRNA molecule, as is discussed below. For example, the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of the target position in the CFTR gene, e.g., F508del,
G551D, G542X, N1303K, R117H, W1282X, or R553X, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position; and the targeting domain of a second gRNA molecule is configured such that a double strand break is positioned downstream the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position.
In an embodiment, a double strand break can be accompanied by two additional single strand breaks, positioned by a second gRNA molecule and a third gRNA molecule. For example, the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of the target position in the CFTR gene, e.g., F508del, G551D,
60
5535.1 G542X, N1303K, R117H, W1282X, or R553X, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position; and the targeting domains of a second and third gRNA molecule are configured such that two single strand breaks are positioned downstream of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position. In an embodiment, the targeting domain of the first, second and third gRNA molecules are configured such that a cleavage event, e.g., a double strand or single strand break, is positioned, independently for each of the gRNA molecules.
In an embodiment, a first and second single strand breaks can be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule. For example, the targeting domain of a first and second gRNA molecule are configured such that two single strand breaks are positioned upstream of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, Rl 17H, W1282X, or R553X; and the targeting domains of a third and fourth gRNA molecule are configured such that two single strand breaks are positioned downstream of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides of the target position in the CFTR gene, e.g., F508del, G551D, G542X, N1303K, R117H, W1282X, or R553X.
In an embodiment, a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, a single gRNA molecule (e.g., with a Cas9 nickase) is used to create a single strand break at or in close proximity to the CF target position, e.g., the gRNA is configured such that the single strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene. In an embodiment,
61
5535.1 a single gRNA molecule (e.g., with a Cas9 nuclease other than a Cas9 nickase) is used to create a double strand break at or in close proximity to the CF target position, e.g., the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream of (e.g., within 200 bp downstream) of a CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that both of the single strand breaks are positioned upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position. In another embodiment, two gRNA molecules (e.g., with two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 200 bp upstream) and a second single strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nucleases that are not Cas9 nickases) are used to create two double strand breaks to flank a CF target position, e.g., the gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within 200 bp upstream) and a second double strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, one double strand break and two single strand breaks are introduced (e.g., positioned by three gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, three gRNA molecules (e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases) to create one double strand break and two single strand breaks to flank an CF target position, e.g., the gRNA molecules are configured such that
62
5535.1 the double strand break is positioned upstream or downstream of (e.g., within 200 bp upstream or downstream) of the CF target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstream (within 200 bp downstream or upstream), of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, four gRNA molecule (e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank an CF target position in the CFTR gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 200 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two or more (e.g., three or four) gRNA molecules are used with one
Cas9 molecule. In another embodiment, when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
Approach 2: HDR-mediated knockin of cDNA to alter the CFTR gene. In an
embodiment, a CF target knockin position is altered. Altering the CF target knockin position refers to homology-directed knockin of genomic sequence, including the delivery of cDNA template of contiguous exons (X+1) through exon 27 of CFTR gene, wherein exon X is any exon between exon 1 and exon 27. Targeted knockin of CFTR cDNA leads to the cessation of production of mutant or truncated CFTR protein and results in the production of functional CFTR protein. In an embodiment, a donor template is provided to mediate HDR-mediated knockin. In an embodiment, said donor template comprise homology arms, splice acceptor, contiguous coding sequence of exons (X+1) through exon 27 of CFTR gene and polyadenylation
63
5535.1 signal. While not wishing to be bound by theory, it is believed that correction of the mutation(s) (e.g., mediated by HDR) retore the mutant CFTR gene to its wild type state. In another embodiment, double stranded DNA donor is used as a donor template. Donor templates contain DNA sequence which, upon incorporation, would result in the expression of a functional version of the CFTR protein. In an embodiment, one CFTR allele is repaired in the subject. In another embodiment, both CFTR alleles are repaired in the subject. In one aspect, methods and compositions discussed herein, provide for the correction of the underlying genetic cause of CF or CF-like disease, e.g., the correction of a mutation at a CF target position in the CFTR gene, e.g., correction of a mutation. This approach leads to the cessation of production of mutant or truncated CFTR protein and results in the production of functional CFTR protein. This approach prevents the development or progression of lung, gastrointestinal and/or reproductive disease in a subject due to the cessation of production of mutant CFTR protein and restoration of functional CFTR protein production. This approach cures and/or prevents the progression of lung, gastrointestinal and/or reproductive disease in any subject with CF or CF-like disease deficiency who has a mutation in exon (X+l) through exon 27 of the CFTR gene, or in any subject who has a mutation in an intronic or exonic region of the CFTR gene that is after exon X.
In an embodiment, homology-directed repair of the CFTR gene in any subjects with CF mutations in exons 3 through 27 and introns 2 through 26 by targeting intronic region between exons 2 and 3 and with delivery of a homology-directed repair template including homology arms, splice acceptor, coding sequence of contiguous exons 3-27 of CFTR gene and
polyadenylation signal.
In an embodiment, the CF target position is the intronic region between exons 2 and 3. Altering the CF target position refers to homology-directed repair of genomic sequence including the delivery of cDNA template of exons 3-27 of CFTR gene. This approach cures and/or prevents the progression of lung, gastrointestinal and/or reproductive disease in any subject with CF or CF-like disease deficiency who has a mutation in exons 3-27 of the CFTR gene, or in any subject who has a mutation in an intronic or exonic region of the CFTR gene that is on or after the second intron, including but not limited to the following mutations: e.g., F508del,
G551D,G542X, N1303K, R117H, W1282X, R553X, c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G.
64
5535.1 In an embodiment, the CF target position is the intronic region between exons 10 and 11. Altering the CF target position refers to homology-directed repair of genomic sequence including the delivery of cDNA template of exons 11-27 of CFTR gene. This approach cures and/or prevents the progression of lung, gastrointestinal and/or reproductive disease in any subject with CF or CF-like disease deficiency who has a mutation in exons 11-27 of the CFTR gene, or in any subject who has a mutation in an intronic or exonic region of the CFTR gene that is on or after the second intron, including but not limited to the following mutations: e.g., F508del.
In an embodiment, the method provides for the correction of a mutation at a target position in the CFTR gene, e.g., F508del, G551D,G542X, N1303K, R117H, W1282X, R553X, c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G. As described herein, in one embodiment, the method comprises the introduction of one or more breaks (e.g., single strand breaks or double strand breaks) sufficiently close to (e.g., either 5' or 3' to) the target position in the CFTR gene, e.g., intron 2 or intron 10.
In an embodiment, the targeting domain of the gRNA molecule is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to (e.g., either 5' or 3' to) the target position e.g., intron 2 or intron 10 allow correction, e.g., an alteration in the CFTR gene, e.g., an alternation associated with HDR. In an embodiment, the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position in the CFTR gene, e.g., intron 2 or intron 10. The break, e.g., a double strand or single strand break, can be positioned upstream or downstream of the target position in the CFTR gene, e.g., intron 2 or intron 10.
In an embodiment, a second, third and/or fourth gRNA molecule is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to (e.g., either 5' or 3' to) the target position e.g., intron 2 or intron 10 to allow correction, e.g., an alteration associated with HDR in the CFTR gene. In an embodiment, the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position in the CFTR gene, e.g., intron 2 or intron 10. The break, e.g., a double strand or single strand break, can be positioned upstream or downstream of the target position in the CFTR gene, e.g., intron 2 or intron 10.
65
5535.1 In an embodiment, a single strand break is accompanied by an additional single strand break, positioned by a second, third and/or fourth gRNA molecule, as discussed below. For example, The targeting domains bind configured such that a cleavage event, e.g., the two single strand breaks, are positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position in the CFTR gene, e.g., intron 2 or intron 10. In an embodiment, the first and second gRNA molecules are configured such, that when guiding a Cas9 nickase, a single strand break will be accompanied by an additional single strand break, positioned by a second gRNA, sufficiently close to one another to result in an alteration of the target position in the CFTR gene, e.g., intron 2 or intron 10. In an embodiment, the first and second gRNA molecules are configured such that a single strand break positioned by said second gRNA is within 10, 20, 30, 40, or 50 nucleotides of the break positioned by said first gRNA molecule, e.g., when the Cas9 is a nickase. In an embodiment, the two gRNA molecules are configured to position cuts at the same position, or within a few nucleotides of one another, on different strands, e.g., essentially mimicking a double strand break.
In an embodiment, a double strand break can be accompanied by an additional double strand break, positioned by a second, third and/or fourth gRNA molecule, as is discussed below. For example, the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of the target position in the CFTR gene, e.g., intron 2 or intron 10, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position; and the targeting domain of a second gRNA molecule is configured such that a double strand break is positioned downstream the target position in the CFTR gene, e.g., intron 2 or intron 10, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position.
In an embodiment, a double strand break can be accompanied by two additional single strand breaks, positioned by a second gRNA molecule and a third gRNA molecule. For example, the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of the target position in the CFTR gene, e.g., intron 2 or intron 10 e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position; and the targeting domains of a second and third gRNA molecule are configured such that two single strand breaks are positioned downstream of the target position in the CFTR gene, e.g., intron 2 or intron 10, e.g., within 1, 2, 3, 4, 5, 10, 15, 20,
66
5535.1 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position. In an embodiment, the targeting domain of the first, second and third gRNA molecules are configured such that a cleavage event, e.g., a double strand or single strand break, is positioned,
independently for each of the gRNA molecules.
In an embodiment, a first and second single strand breaks can be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule. For example, the targeting domain of a first and second gRNA molecule are configured such that two single strand breaks are positioned upstream of the target position in the CFTR gene, e.g., intron 2 or intron 10, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position in the CFTR gene, e.g., intron 2 or intron 10; and the targeting domains of a third and fourth gRNA molecule are configured such that two single strand breaks are positioned downstream of the target position in the CFTR gene, e.g., intron 2 or intron 10, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the target position in the CFTR gene, e.g., intron 2 or intron 10.
In an embodiment, a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, a single gRNA molecule (e.g., with a Cas9 nickase) is used to create a single strand break at or in close proximity to the CF target position, e.g., the gRNA is configured such that the single strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, a single gRNA molecule (e.g., with a Cas9 nuclease other than a Cas9 nickase) is used to create a double strand break at or in close proximity to the CF target position, e.g., the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream of (e.g., within 200 bp downstream) of a CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
67
5535.1 In an embodiment, two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that both of the single strand breaks are positioned upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position. In another embodiment, two gRNA molecules (e.g., with two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 200 bp upstream) and a second single strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nucleases that are not Cas9 nickases) are used to create two double strand breaks to flank a CF target position, e.g., the gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within 200 bp upstream) and a second double strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, one double strand break and two single strand breaks are introduced (e.g., positioned by three gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, three gRNA molecules (e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases) to create one double strand break and two single strand breaks to flank an CF target position, e.g., the gRNA molecules are configured such that the double strand break is positioned upstream or downstream of (e.g., within 200 bp upstream or downstream) of the CF target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstream (within 200 bp downstream or upstream), of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
68
5535.1 In an embodiment, four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, four gRNA molecule (e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank an CF target position in the CFTR gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 200 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two or more (e.g., three or four) gRNA molecules are used with one
Cas9 molecule. In another embodiment, when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
Approach 3A: In an embodiment, Cas9-mediated removal and/or disruption of an intronic segment of DNA, within a CFTR intron, to restore post-transcriptional processing accuracy, e.g., without the use of homology-directed repair. CFTR mutations (e.g.,
c.3717+12191C>T, e.g., 2657+5G>A, e.g., c.3140-26A>G) can cause abbarent post- transcriptional processing, such as missplicing by the creation of novel splice sites which can lead to the early truncation of non-functional CFTR protein resulting in aberrant CFTR channel formation. In one aspect, methods and compositions discussed herein, provide for altering the CF target position in the CFTR gene. The CF target position (e.g. c.3717+12191, also known as c.3849+10kb, e.g., c.2657+5, also known as c.2789+5, e.g., C.3140-26A, also known as c.3272- 26) can be altered, e.g., by non-homologous end-joining mediated removal and/or disruption of a splice site mutation. In the case of a subject with a 3717+12191C>T mutation, the CF target position is 500bp upstream and/or downstream of c.3717+12191 within intron 22. In the case of a subject with a c.2657+5G>A mutation, the CF target position is 200bp upstream within exon 16, and intron 16 and intron 15 and/or downstream of c.2657+5 within intron 16. In the case of a
69
5535.1 subject with a c.3140-26A>G mutation, the CF target position is 200bp upstream and/or downstream of c.3140-26 within intron 19 and exon 20. The removal, disruption and/or repair of a splice site mutation will restore accurate splicing and cease production of aberrant truncation of CFTR protein. This approach will lead to the cessation of production of truncatednon-functional CFTR channel and will lead to the production of wild-type CFTR channel. This approach will prevent the development or progression of lung, gastrointestinal and/or reproductive disease in subjects with CFTR mutations.
In an embodiment, methods and compositions discussed herein, provide for altering the CF target position in the CFTR gene. The alteration can be achieved by (1) break- induced introduction of an indel (also referred to herein as NHEJ-mediated introduction of an indel) in close proximity to or including a CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G), or (2) break-induced deletion (also referred to herein as NHEJ-mediated deletion) of genomic sequence including the mutation at a CF target position (e.g.,
c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G). Both approaches give rise to the loss or destruction of the abbarent post- transcriptional processing.
In an embodiment, the method comprises introducing a break-induced indel in close proximity to or including the CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G). As described herein, in one embodiment, the method comprises the
introduction of a double strand break sufficiently close to (e.g., either 5' or 3' to) the CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G), such that the break-induced indel could be reasonably expected to span the mutation. A single gRNAs, e.g., unimolecular (or chimeric) or modular gRNA molecules, is configured to position a double strand break sufficiently close to the CF target position in the CFTR gene. The double strand break may be positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) upstream of the CF target poistion, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that NHEJ-mediated repair of the double strand break allows for the NHEJ-mediated introduction of an indel in close proximity to or including the CF target position.
70
5535.1 In another embodiment, the method comprises the introduction of a pair of single strand breaks sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G), such that the break-induced indel could be reasonably expected to span the mutation. Two gRNAs, e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two single strand breaks sufficiently close to the CF target position in the CFTR gene. In an embodiment, the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that NHEJ mediated repair of the pair of single strand breaks allows for the NHEJ-mediated introduction of an indel in close proximity to or including the CF target position. In an embodiment, the pair of single strand breaks may be accompanied by an additional double strand break, positioned by a third gRNA molecule, as is discussed below. In another embodiment, the pair of single strand breaks may be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule, as is discussed below.
In another embodiment, the method comprises the introduction of two sets of breaks (e.g., a pair of double strand breaks targeted by two gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G). such that the break-induced indel could be reasonably expected to span the mutation. Two gRNAs, e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., a pair of double strand breaks) sufficiently close to the CF target position in the CFTR gene. In an embodiment, the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that NHEJ mediated repair of two sets of breaks (e.g., a pair of double strand breaks) allows for the NHEJ-mediated introduction of an indel in close proximity to or including the CF target position.
71
5535.1 In another embodiment, the method comprises the introduction of two sets of breaks (e.g., one double strand break and a pair of single strand breaks targeted by three gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G). such that the break-induced indel could be reasonably expected to span the mutation. Two gRNAs, e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., one double strand break and a pair of single strand breaks) sufficiently close to the CF target position in the CFTR gene. In an embodiment, the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an
embodiment, it is believed that NHEJ mediated repair of two sets of breaks (e.g., one double strand break and a pair of single strand breaks) allows for the NHEJ-mediated introduction of an indel in close proximity to or including the CF target position.
In another embodiment, the method comprises the introduction of two sets of breaks (e.g., two pairs of single strand breaks targeted by four gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G). such that the break-induced indel could be reasonably expected to span the mutation. Two gRNAs, e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., two pairs of single strand breaks s)
sufficiently close to the CF target position in the CFTR gene. In an embodiment, the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, 200, 300, 400 or 500 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that NHEJ mediated repair of two sets of breaks (e.g., two pairs of single strand breaks) allows for the NHEJ-mediated introduction of an indel in close proximity to or including the CF target position.
In an embodiment, a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene. In an embodiment,
72
5535.1 a single gRNA molecule (e.g., with a Cas9 nickase) is used to create a single strand break at or in close proximity to the CF target position, e.g., the gRNA is configured such that the single strand break is positioned either upstream (e.g., within 500 bp, e.g., within 200 bp upstream) or downstream (e.g., within 500 bp, e.g., within 200 bp downstream) of the CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, a single gRNA molecule (e.g., with a Cas9 nuclease other than a Cas9 nickase) is used to create a double strand break at or in close proximity to the CF target position, e.g., the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 500 bp, e.g., within 200 bp upstream) or downstream of (e.g., within 500 bp, e.g., within 200 bp downstream) of a CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that both of the single strand breaks are positioned upstream (e.g., within 500 bp, e.g., within 200 bp upstream) or downstream (e.g., within 500 bp, e.g., within 200 bp downstream) of the CF target position. In another embodiment, two gRNA molecules (e.g., with two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 500 bp, e.g., within 200 bp upstream) and a second single strand break is positioned downstream (e.g., within 500 bp, e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nucleases that are not Cas9 nickases) are used to create two double strand breaks to flank a CF target position, e.g., the
73
5535.1 gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within 500 bp, e.g., within 200 bp upstream) and a second double strand break is positioned downstream (e.g., within 500 bp, e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, one double strand break and two single strand breaks are introduced (e.g., positioned by three gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, three gRNA molecules (e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases) to create one double strand break and two single strand breaks to flank an CF target position, e.g., the gRNA molecules are configured such that the double strand break is positioned upstream or downstream of (e.g., within 500 bp, e.g., within 200 bp upstream or downstream) of the CF target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstream (within 200 bp downstream or upstream), of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, four gRNA molecule (e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank an CF target position in the CFTR gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 500 bp, e.g., within 200 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 500 bp, e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two or more (e.g., three or four) gRNA molecules are used with one
Cas9 molecule. In another embodiment, when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
74
5535.1 In an embodiment, a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, a single gRNA molecule (e.g., with a Cas9 nickase) is used to create a single strand break at or in close proximity to the CF target position, e.g., the gRNA is configured such that the single strand break is positioned either upstream (e.g., within 500 bp upstream) or downstream (e.g., within 500 bp downstream) of the CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, a single gRNA molecule (e.g., with a Cas9 nuclease other than a Cas9 nickase) is used to create a double strand break at or in close proximity to the CF target position, e.g., the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 500 bp upstream) or downstream of (e.g., within 500 bp downstream) of a CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that both of the single strand breaks are positioned upstream (e.g., within 500 bp upstream) or downstream (e.g., within 500 bp downstream) of the CF target position. In another embodiment, two gRNA molecules (e.g., with two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 500 bp upstream) and a second single strand break is positioned downstream (e.g., within 500 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nucleases that are not Cas9 nickases) are used to create two double strand breaks to flank a CF target position, e.g., the
75
5535.1 gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within 500 bp upstream) and a second double strand break is positioned downstream (e.g., within 500 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, one double strand break and two single strand breaks are introduced
(e.g., positioned by three gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, three gRNA molecules (e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases) to create one double strand break and two single strand breaks to flank an CF target position, e.g., the gRNA molecules are configured such that the double strand break is positioned upstream or downstream of (e.g., within 500 bp upstream or downstream) of the CF target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstream (within 500 bp downstream or upstream), of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, four gRNA molecule (e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank an CF target position in the CFTR gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 500 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 500 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two or more (e.g., three or four) gRNA molecules are used with one Cas9 molecule. In another embodiment, when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
76
5535.1 Approach 3B: In an embodiment, Cas9-mediated removal and/or disruption of an intronic segment of DNA, within a CFTR intron, to restore post-transcriptional processing accuracy, e.g., with the use of homology-directed repair. CFTR mutations e.g., c.2657+5 (also known as c.2789+5), or C.3140-26A (also known as c.3272-26) can cause abbarent post- transcriptional processing, such as missplicing by the creation of novel splice sites which can lead to production of non-functional CFTR protein resulting in aberrant CFTR channel formation. In one aspect, methods and compositions discussed herein, provide for altering the CF target position in the CFTR gene. The CF target position (e.g., c.2657+5, e.g., C.3140-26A) can be altered by non-homologous end-joining mediated removal of a splice site mutation. In the case of a subject with a c.2657+5G>A mutation, the CF target position is 200 bp upstream and/or downstream of c.2657+5 within within exon 16, and intron 16 and intron 15. In the case of a subject with a c.3140-26A>G mutation, the CF target position is 200 bp upstream and/or downstream of c.3140-26 within exon 20 and intron 19. In an embodiment, in a subject with a target mutation in close proximity to an exon (including, but not limited to the mutations, e.g., 2789+5G>A, e.g., 3272-26A>G), approach may include Cas-9 mediated removal and/or disruption of an intronic segment at or near the target site with homology-directed repair with delivery of Cas9 nuclease (or nickase, or dead-Cas9), CRISPR-gRNAs, and homology-directed repair donor templates. In an embodiment, the donor template will be comprised of a single- strand oligonucleotide donor of 50 NT to 200 NT (or more as the technology becomes available). In an embodiment, the donor template will be comprised of a double- strand DNA donor with homology arms of length 700 bps to 1200 bps. The repair of a splice site mutation will restore accurate splicing and cease aberrant truncation of CFTR transcript. This approach will lead to the cessation of production of truncated CFTR channel and will lead to the production of wild-type CFTR channel. This approach will prevent the development or progression of lung,
gastrointestinal and/or reproductive disease in subjects with CFTR mutations.
In an embodiment, the method comprises the introduction of a double strand break sufficiently close to (e.g., either 5' or 3' to) the CF target position (e.g., c2657+5G>A, or c.3140- 26A>G), such that the break-induced indel could be reasonably expected to span the mutation. A single gRNAs, e.g., unimolecular (or chimeric) or modular gRNA molecules, is configured to position a double strand break sufficiently close to the CF target position in the CFTR gene (e.g., 2657+5G>A, or c.3140-26A>G). The double strand break may be positioned within 200
77
5535.1 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) upstream of the CF target poistion, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that HDR mediated repair of the break(s) restores the functional CFTR protein.
In another embodiment, the method comprises the introduction of a pair of single strand breaks sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c2657+5G>A, or c.3140-26A>G), such that the break- induced indel could be reasonably expected to span the mutation. Two gRNAs, e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two single strand breaks sufficiently close to the CF target position in the CFTR gene. In an embodiment, the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides)
downstream of the CF target position. While not wishing to be bound by theory, in an
embodiment, it is believed that HDR mediated repair of the break(s) restores the functional CFTR protein. In an embodiment, the pair of single strand breaks may be accompanied by an additional double strand break, positioned by a third gRNA molecule, as is discussed below. In another embodiment, the pair of single strand breaks may be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule, as is discussed below.
In another embodiment, the method comprises the introduction of two sets of breaks (e.g., a pair of double strand breaks targeted by two gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c2657+5G>A, or c.3140-26A>G), such that the break-induced indel could be reasonably expected to span the mutation. Two gRNAs, e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., a pair of double strand breaks) sufficiently close to the CF target position in the CFTR gene. In an embodiment, the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) downstream of the CF
78
5535.1 target position. While not wishing to be bound by theory, in an embodiment, it is believed that HDR mediated repair of the break(s) restores the functional CFTR protein.
In another embodiment, the method comprises the introduction of two sets of breaks (e.g., one double strand break and a pair of single strand breaks targeted by three gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c2657+5G>A, or c.3140-26A>G), such that the break- induced indel could be reasonably expected to span the mutation. Two gRNAs, e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., one double strand break and a pair of single strand breaks) sufficiently close to the CF target position in the CFTR gene. In an embodiment, the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that HDR mediated repair of the break(s) restores the functional CFTR protein.
In another embodiment, the method comprises the introduction of two sets of breaks (e.g., two pairs of single strand breaks targeted by four gRNAs) sufficiently close to (either 5' or 3' to, respectively) the mutation at the CF target position (e.g., c2657+5G>A, or c.3140-26A>G), such that the break-induced indel could be reasonably expected to span the mutation. Two gRNAs, e.g., unimolecular (or chimeric) or modular gRNA molecules, are configured to position the two sets of breaks (e.g., two pairs of single strand breaks s) sufficiently close to the CF target position in the CFTR gene. In an embodiment, the pair of single strand breaks is positioned within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) upstream of the CF target position, or within 500 nucleotides (e.g., within 1, 2, 3, 4, 5, 10, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 100, or 200 nucleotides) downstream of the CF target position. While not wishing to be bound by theory, in an embodiment, it is believed that HDR mediated repair of the break(s) restores the functional CFTR protein.
In an embodiment, a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, a single gRNA molecule (e.g., with a Cas9 nickase) is used to create a single strand break at or in close proximity to the CF target position, e.g., the gRNA is configured such that the single strand
79
5535.1 break is positioned either upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, a single gRNA molecule (e.g., with a Cas9 nuclease other than a Cas9 nickase) is used to create a double strand break at or in close proximity to the CF target position, e.g., the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream of (e.g., within 200 bp downstream) of a CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that both of the single strand breaks are positioned upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the CF target position. In another embodiment, two gRNA molecules (e.g., with two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 200 bp upstream) and a second single strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nucleases that are not Cas9 nickases) are used to create two double strand breaks to flank a CF target position, e.g., the gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within 200 bp upstream) and a second double strand break is positioned downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
80
5535.1 In an embodiment, one double strand break and two single strand breaks are introduced (e.g., positioned by three gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, three gRNA molecules (e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases) to create one double strand break and two single strand breaks to flank an CF target position, e.g., the gRNA molecules are configured such that the double strand break is positioned upstream or downstream of (e.g., within 200 bp upstream or downstream) of the CF target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstream (within 200 bp downstream or upstream), of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the CFTR gene. In an embodiment, four gRNA molecule (e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank an CF target position in the CFTR gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 200 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 200 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two or more (e.g., three or four) gRNA molecules are used with one
Cas9 molecule. In another embodiment, when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
When two or more gRNAs are used to position two or more cleavage events, e.g., double strand or single strand breaks, in a target nucleic acid, it is contemplated that the two or more cleavage events may be made by the same or different Cas9 proteins. For example, when two gRNAs are used to position two double strand breaks, a single Cas9 nuclease may be used to create both double strand breaks. When two or more gRNAs are used to position two or more
81
5535.1 single stranded breaks (single strand breaks), a single Cas9 nickase may be used to create the two or more single strand breaks. When two or more gRNAs are used to position at least one double strand break and at least one single strand break, two Cas9 proteins may be used, e.g., one Cas9 nuclease and one Cas9 nickase. It is contemplated that when two or more Cas9 proteins are used that the two or more Cas9 proteins may be delivered sequentially to control specificity of a double strand versus a single strand break at the desired position in the target nucleic acid.
In some embodiments, the targeting domain of the first gRNA molecule and the targeting domain of the second gRNA molecule hybridize to the target domain through complementary base pairing to opposite strands of the target nucleic acid molecule. In some embodiments, the gRNA molecule and the second gRNA molecule are configured such that the PAMs are oriented outward.
In an embodiment, the targeting domain of a gRNA molecule is configured to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat, or the endogenous CFTR splice sites, in the target domain. The gRNA molecule may be a first, second, third and/or fourth gRNA molecule.
In an embodiment, the targeting domain of a gRNA molecule is configured to position a cleavage event sufficiently far from a preselected nucleotide, e.g., the nucleotide of a coding region, such that the nucleotide is not altered. In an embodiment, the targeting domain of a gRNA molecule is configured to position an intronic cleavage event sufficiently far from an intron/exon border, or naturally occurring splice signal, to avoid alteration of the exonic sequence or unwanted splicing events. The gRNA molecule may be a first, second, third and/or fourth gRNA molecule, as described herein.
In an embodiment, the targeting domain of said gRNA molecule is configured to position a cleavage event sufficiently far from a preselected nucleotide, e.g., the nucleotide of a coding region, such that the nucleotide is not be altered. In an embodiment, the targeting domain of said gRNA molecule is configured to position an intronic cleavage event sufficiently far from an intron/exon border, or naturally occurring splice signal, to avoid alteration of the exonic sequence or unwanted splicing events.
Methods to Alter SCNN1A
82
5535.1 As disclosed herein, the SCNNIA gene can be altered by gene editing, e.g., using CRISPR-Cas9 mediated methods as described herein. A CF or CF-like target position can be altered by gene editing, e.g., using CRISPR-Cas9 mediated methods to alter the SCNNIA gene. The alteration of the SCNNIA gene can be mediated by any mechanism. In an embodiment, CRISPR-Cas9 mediated methods to knockdown or knockout the SCNNIA gene may be applied to any subject with any CF mutation, including but not limited to, e.g., F508del, e.g., G551D, e.g., G542X, e.g., N1303K, e.g., R117H, e.g., W1282X, e.g., R553X, e.g., c.3717+12191, e.g., c.2657+5, e.g., C.3140-26A and/or any subject with any CF-like mutation, including but not limited to a SCNNIA mutation, e.g., VI 141. Exemplary mechanisms that can be associated with the alteration of the SCNNA1 gene include, but are not limited to, non-homologous end joining (e.g., classical or alternative), microhomology-mediated end joining (MMEJ), SDSA (synthesis dependent strand annealing) or single strand annealing or single strand invasion, all with or without the alteration of the CFTR gene, including but not limited to the addition of an endogenous- promoter driven cDNA encoding the CFTR gene, or homology-directed repair mediated correction of mutations within the CFTR gene or CRISPR-cas9 mediated repair of splice mutations within the CFTR gene.
As disclosed herein, the SCNNIA gene can be targeted (e.g., altered) by gene editing, e.g., using CRISPR-Cas9 mediated methods as described herein.
Methods and compositions discussed herein, provide for targeting (e.g., altering) a CF target position in the SCNNIA gene. A CF target position can be targeted (e.g., altered) by gene editing, e.g., using CRISPR-Cas9 mediated methods to target (e.g. alter) the SCNNIA gene.
Disclosed herein are methods for targeting (e.g., altering) a SCNNIA target position in the SCNNIA gene. Targeting (e.g., altering) the CF target position is achieved, e.g., by:
(1) knocking out the SCNNIA gene byinsertion or deletion (e.g., NHEJ-mediated insertion or deletion) of one or more nucleotides in close proximity to or within the early coding region of the SCNNIA gene, or
(2) knocking down the SCNNIA gene mediated by enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9-fusion protein by targeting non-coding region, e.g., a promoter region, of the gene.
All approaches give rise to targeting (e.g., alteration) of the SCNNIA gene.
83
5535.1 In an embodiment, methods described herein introduce one or more breaks near the early coding region in at least one allele of the SCNNIA gene. In another embodiment, methods described herein introduce two or more breaks to flank at least a portion of the SCNNIA gene. The two or more breaks remove (e.g., delete) a genomic sequence including at least a portion of the SCNNIA gene. In another embodiment, methods described herein comprise knocking down the SCNNIA gene mediated by enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9- fusion protein by targeting the promoter region of SCNNIA target knockdown position. All methods described herein result in targeting (e.g., alteration) of the SCNNIA gene.
The targeting (e.g., alteration) of the SCNNIA gene can be mediated by any mechanism. Exemplary mechanisms that can be associated with the alteration of the SCNNIA gene include, but are not limited to, non-homologous end joining (e.g., classical or alternative),
microhomology-mediated end joining (MMEJ), homology-directed repair (e.g., endogenous donor template mediated), SDSA (synthesis dependent strand annealing), single strand annealing or single strand invasion.
Approach 4: Knocking out SCNNIA by introducing an indel or a deletion in the SCNNIA gene
In an embodiment, the method comprises introducing an insertion or deletion of one more nucleotides in close proximity to the SCNNIA target knockout position (e.g., the early coding region) of the SCNNIA gene. As described herein, in one embodiment, the method comprises the introduction of one or more breaks (e.g., single strand breaks or double strand breaks) sufficiently close to (e.g., either 5' or 3' to) the early coding region of the CF target knockout position, such that the break-induced indel could be reasonably expected to span the CF target knockout position (e.g., the early coding region in the SCNNIA gene). While not wishing to be bound by theory, it is believed that NHEJ-mediated repair of the break(s) allows for the NHEJ- mediated introduction of an indel in close proximity to within the early coding region of the CF target knockout position.
In an embodiment, the method comprises introducing a deletion of a genomic sequence comprising at least a portion of the SCNNIA gene. As described herein, in an embodiment, the method comprises the introduction of two double stand breaks - one 5' and the other 3' to (i.e., flanking) the CF target position. In an embodiment, two gRNAs, e.g., unimolecular (or
84
5535.1 chimeric) or modular gRNA molecules, are configured to position the two double strand breaks on opposite sides of the CF target knockout position in the SCNN1A gene.
In an embodiment, a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the SCNN1A gene. In an
embodiment, a single gRNA molecule (e.g., with a Cas9 nickase) is used to create a single strand break at or in close proximity to the CF target position, e.g., the gRNA is configured such that the single strand break is positioned either upstream (e.g., within 500 bp upstream, e.g., within 200 bp upstream) or downstream (e.g., within 500 bp downstream, e.g., within 200 bp downstream) of the CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a CF target position in the SCNN1A gene. In an
embodiment, a single gRNA molecule (e.g., with a Cas9 nuclease other than a Cas9 nickase) is used to create a double strand break at or in close proximity to the CF target position, e.g., the gRNA molecule is configured such that the double strand break is positioned either upstream
(e.g., within 500 bp upstream, upstream) or downstream of (e.g., within 500 bp downstream) of a CF target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the SCNN1A gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the CF target position, e.g., the gRNAs molecules are configured such that both of the single strand breaks are positioned e.g., within 500 bp upstream, upstream) or downstream (e.g., within 500 bp downstream downstream) of the CF target position. In another embodiment, two gRNA molecules (e.g., with two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the SCNN1A target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 500 bp upstream) and a second single strand break is positioned downstream (e.g., within 500 bp downstream) of the SCNN1A target position. In an
embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
85
5535.1 In an embodiment, two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a CF target position in the SCNN1A gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nucleases that are not Cas9 nickases) are used to create two double strand breaks to flank a CF target position, e.g., the gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within500 bp upstream) and a second double strand break is positioned downstream (e.g., within 500 bp downstream) of the SCNN1A target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, one double strand break and two single strand breaks are introduced
(e.g., positioned by three gRNA molecules) at or in close proximity to a CF target position in the SCNN1A gene. In an embodiment, three gRNA molecules (e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases) to create one double strand break and two single strand breaks to flank a CF target position, e.g., the gRNA molecules are configured such that the double strand break is positioned upstream or downstream of (e.g., within 500 bp upstreamor downstream) of the SCNN1A target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstrea m (e.g., within 500 bp downstream or upstream), of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a CF target position in the SCNN1A gene. In an embodiment, four gRNA molecule (e.g., with one or more Cas9 nickases are used to create four single strand breaks to flank a CF target position in the SCNN1A gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 500 bp upstream) of the CF target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within500 bp downstream) of the CF target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two or more (e.g., three or four) gRNA molecules are used with one Cas9 molecule. In another embodiment, when two ore more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the
86
5535.1 other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
Approach 5: Knocking down SCNN1A mediated by an enzymatically inactive Cas9 (eiCas9) molecule
A targeted knockdown approach reduces or eliminates expression of functional SCNN1A gene product. As described herein, in an embodiment, a targeted knockdown is mediated by targeting an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fused to a transcription repressor domain or chromatin modifying protein to alter transcription, e.g., to block, reduce, or decrease transcription, of the SCNN1A gene.
Methods and compositions discussed herein may be used to alter the expression of the SCNN1A gene to treat or prevent CF or CF-like disease by targeting a promoter region of the SCNN1A gene. In an embodiment, the promoter region is targeted to knock down expression of the SCNN1A gene. A targeted knockdown approach reduces or eliminates expression of functional SCNN1A gene product. As described herein, in an embodiment, a targeted
knockdown is mediated by targeting an enzymatically inactive Cas9 (eiCas9) or an eiCas9 fused to a transcription repressor domain or chromatin modifying protein to alter transcription, e.g., to block, reduce, or decrease transcription, of the SCNN1A gene. In an embodiment, one or more eiCas9 molecules may be used to block binding of one or more endogenous transcription factors. In another embodiment, an eiCas9 molecule can be fused to a chromatin modifying protein. Altering chromatin status can result in decreased expression of the target gene. One or more eiCas9 molecules fused to one or more chromatin modifying proteins may be used to alter chromatin status.
An eiCas9mediated knock down of one of two SCNN1A allele/s by targeting the transcription start site of SCNN1A gene in exon I of all transcripts (including 500 bp upstream and downstream of transcription start site on all transcripts). This approach is performed in any subject with CF or CF-like disease, with or without a CFTR mutation and a WT or mutant SCNN1A. The CF or CF-like target position is at or near the transcription start site of the
SCNN1A gene. Or, altering the CF or CF-like target position refers to delivering a dCas9 that
87
5535.1 sterically hinders transcription of either or both SCNNIA allele/s. This approach gives rise to the loss or destruction of transcription of the SCNNIA gene. This approach will lead to the reduction or cessation of production of ENaC. This approach will prevent the disinhibition of the ENaC channel in subjects with CF or CF-like disease. The viscosity of lung, gastrointestinal and reproductive tract mucous in subjects with CF or CF-like disease will not be further increased. This will lead to a reduction in viscosity of mucous within the lung, gastrointestinal and reproductive tract mucous in subjects with CF or CF-like disease. This approach will prevent the progression of CF and CF-like disease.
I. gRNA Molecules
A gRNA molecule, as that term is used herein, refers to a nucleic acid that promotes the specific targeting or homing of a gRNA molecule/Cas9 molecule complex to a target nucleic acid. gRNA molecules can be unimolecular (having a single RNA molecule), sometimes referred to herein as "chimeric" gRNAs, or modular (comprising more than one, and typically two, separate RNA molecules). A gRNA molecule comprises a number of domains. The gRNA molecule domains are described in more detail below.
Several exemplary gRNA structures, with domains indicated thereon, are provided in Figs. 1A-1G. While not wishing to be bound by theory, in an embodiment, with regard to the three dimensional form, or intra- or inter-strand interactions of an active form of a gRNA, regions of high complementarity are sometimes shown as duplexes in Figs. 1A-1G and other depictions provided herein.
In an embodiment, a unimolecular, or chimeric, gRNA comprises, preferably from 5' to
3':
a targeting domain (which is complementary to a target nucleic acid in the CFTR gene or SCNNIA gene, e.g., a targeting domain as described herein, e.g., a targeting domain from any of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A- 5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A- 13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E,
27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B,
88
5535.1 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, and 48A-48E;
a first complementarity domain;
a linking domain;
a second complementarity domain (which is complementary to the first
complementarity domain);
a proximal domain; and
optionally, a tail domain.
In an embodiment, a modular gRNA comprises:
a first strand comprising, preferably from 5' to 3' ;
a targeting domain (which is complementary to a target nucleic acid in the CFTR gene or SCNNIA gene, e.g., a targeting domain as described herein, e.g., a targeting domain from any of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A- 6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A- 29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A- 44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E); and
a first complementarity domain; and
a second strand, comprising, preferably from 5' to 3':
optionally, a 5' extension domain;
a second complementarity domain;
a proximal domain; and
optionally, a tail domain.
The domains are discussed briefly below.
The Targeting Domain Figs. 1A-1G provide examples of the placement of targeting domains.
The targeting domain comprises a nucleotide sequence that is complementary, e.g., at least 80, 85, 90, or 95% complementary, e.g., fully complementary, to the target sequence on the target nucleic acid. The targeting domain is part of an RNA molecule and will therefore comprise the base uracil (U), while any DNA encoding the gRNA molecule will comprise the base thymine (T). While not wishing to be bound by theory, in an embodiment, it is believed that the complementarity of the targeting domain with the target sequence contributes to specificity of the interaction of the gRNA molecule/Cas9 molecule complex with a target nucleic acid. It is understood that in a targeting domain and target sequence pair, the uracil bases in the targeting domain will pair with the adenine bases in the target sequence. In an embodiment, the target domain itself comprises in the 5' to 3' direction, an optional secondary domain, and a core domain. In an embodiment, the core domain is fully complementary with the target sequence. In an embodiment, the targeting domain is 5 to 50 nucleotides in length. The strand of the target nucleic acid with which the targeting domain is complementary is referred to herein as the complementary strand. Some or all of the nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
In an embodiment, the targeting domain is 16 nucleotides in length.
In an embodiment, the targeting domain is 17 nucleotides in length.
In an embodiment, the targeting domain is 18 nucleotides in length.
In an embodiment, the targeting domain is 19 nucleotides in length.
In an embodiment, the targeting domain is 20 nucleotides in length.
In an embodiment, the targeting domain is 21 nucleotides in length.
In an embodiment, the targeting domain is 22 nucleotides in length.
In an embodiment, the targeting domain is 23 nucleotides in length.
In an embodiment, the targeting domain is 24 nucleotides in length.
In an embodiment, the targeting domain is 25 nucleotides in length.
In an embodiment, the targeting domain is 26 nucleotides in length.
In an embodiment, the targeting domain comprises 16 nucleotides.
In an embodiment, the targeting domain comprises 17 nucleotides.
In an embodiment, the targeting domain comprises 18 nucleotides.
In an embodiment, the targeting domain comprises 19 nucleotides.
90
5535.1 In an embodiment, the targeting domain comprises 20 nucleotides.
In an embodiment, the targeting domain comprises 21 nucleotides.
In an embodiment, the targeting domain comprises 22 nucleotides.
In an embodiment, the targeting domain comprises 23 nucleotides.
In an embodiment, the targeting domain comprises 24 nucleotides.
In an embodiment, the targeting domain comprises 25 nucleotides.
In an embodiment, the targeting domain comprises 26 nucleotides.
Targeting domains are discussed in more detail below. The First Complementarity Domain
Figs. 1A-1G provide examples of first complementarity domains.
The first complementarity domain is complementary with the second complementarity domain, and in an embodiment, has sufficient complementarity to the second complementarity domain to form a duplexed region under at least some physiological conditions. In an embodiment, the first complementarity domain is 5 to 30 nucleotides in length. In an
embodiment, the first complementarity domain is 5 to 25 nucleotides in length. In an
embodiment, the first complementary domain is 7 to 25 nucleotides in length. In an
embodiment, the first complementary domain is 7 to 22 nucleotides in length. In an
embodiment, the first complementary domain is 7 to 18 nucleotides in length. In an
embodiment, the first complementary domain is 7 to 15 nucleotides in length. In an
embodiment, the first complementary domain is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length.
In an embodiment, the first complementarity domain comprises 3 subdomains, which, in the 5' to 3' direction are: a 5' subdomain, a central subdomain, and a 3' subdomain. In an embodiment, the 5' subdomain is 4 to 9, e.g., 4, 5, 6, 7, 8 or 9 nucleotides in length. In an embodiment, the central subdomain is 1, 2, or 3, e.g., 1, nucleotide in length. In an embodiment, the 3' subdomain is 3 to 25, e.g., 4 to 22, 4 to 18, or 4 to 10, or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length.
The first complementarity domain can share homology with, or be derived from, a naturally occurring first complementarity domain. In an embodiment, it has at least 50%
91
5535.1 homology with a first complementarity domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, first complementarity domain.
Some or all of the nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
First complementarity domains are discussed in more detail below.
The Linking Domain
Figs. 1A-1G provide examples of linking domains.
A linking domain serves to link the first complementarity domain with the second complementarity domain of a unimolecular gRNA. The linking domain can link the first and second complementarity domains covalently or non-covalently. In an embodiment, the linkage is covalent. In an embodiment, the linking domain covalently couples the first and second complementarity domains, see, e.g., Figs. IB-IE. In an embodiment, the linking domain is, or comprises, a covalent bond interposed between the first complementarity domain and the second complementarity domain. Typically the linking domain comprises one or more, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.
In modular gRNA molecules the two molecules are associated by virtue of the
hybridization of the complementarity domains see e.g., Fig. 1A.
A wide variety of linking domains are suitable for use in unimolecular gRNA molecules. Linking domains can consist of a covalent bond, or be as short as one or a few nucleotides, e.g., 1, 2, 3, 4, or 5 nucleotides in length. In an embodiment, a linking domain is 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 or more nucleotides in length. In an embodiment, a linking domain is 2 to 50, 2 to 40, 2 to 30, 2 to 20, 2 to 10, or 2 to 5 nucleotides in length. In an embodiment, a linking domain shares homology with, or is derived from, a naturally occurring sequence, e.g., the sequence of a tracrRNA that is 5' to the second complementarity domain. In an embodiment, the linking domain has at least 50% homology with a linking domain disclosed herein.
Some or all of the nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
Linking domains are discussed in more detail below.
The 5' Extension Domain
92
5535.1 In an embodiment, a modular gRNA can comprise additional sequence, 5' to the second complementarity domain, referred to herein as the 5' extension domain, see, e.g., Fig. 1A. In an embodiment, the 5' extension domain is, 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4 nucleotides in length. In an embodiment, the 5' extension domain is 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides in length.
The Second Complementarity Domain
Figs. 1A-1G provide examples of second complementarity domains.
The second complementarity domain is complementary with the first complementarity domain, and in an embodiment, has sufficient complementarity to the second complementarity domain to form a duplexed region under at least some physiological conditions. In an embodiment, e.g., as shown in Figs. 1A-1B, the second complementarity domain can include sequence that lacks complementarity with the first complementarity domain, e.g., sequence that loops out from the duplexed region.
In an embodiment, the second complementarity domain is 5 to 27 nucleotides in length.
In an embodiment, it is longer than the first complementarity region. In an embodiment the second complementary domain is 7 to 27 nucleotides in length. In an embodiment, the second complementary domain is 7 to 25 nucleotides in length. In an embodiment, the second complementary domain is 7 to 20 nucleotides in length. In an embodiment, the second complementary domain is 7 to 17 nucleotides in length. In an embodiment, the complementary domain is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length.
In an embodiment, the second complementarity domain comprises 3 subdomains, which, in the 5' to 3' direction are: a 5' subdomain, a central subdomain, and a 3' subdomain. In an embodiment, the 5' subdomain is 3 to 25, e.g., 4 to 22, 4 tol8, or 4 to 10, or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. In an embodiment, the central subdomain is 1, 2, 3, 4 or 5, e.g., 3, nucleotides in length. In an embodiment, the 3' subdomain is 4 to 9, e.g., 4, 5, 6, 7, 8 or 9 nucleotides in length.
In an embodiment, the 5' subdomain and the 3' subdomain of the first complementarity domain, are respectively, complementary, e.g., fully complementary, with the 3' subdomain and the 5' subdomain of the second complementarity domain.
93
5535.1 The second complementarity domain can share homology with or be derived from a naturally occurring second complementarity domain. In an embodiment, it has at least 50% homology with a second complementarity domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, first complementarity domain.
Some or all of the nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
A Proximal domain
Figs. 1A-1G provide examples of proximal domains.
In an embodiment, the proximal domain is 5 to 20 nucleotides in length. In an embodiment, the proximal domain can share homology with or be derived from a naturally occurring proximal domain. In an embodiment, it has at least 50% homology with a proximal domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, proximal domain.
Some or all of the nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
A Tail Domain
Figs. 1A-1G provide examples of tail domains.
As can be seen by inspection of the tail domains in Figs. 1A-1E, a broad spectrum of tail domains are suitable for use in gRNA molecules. In an embodiment, the tail domain is 0 (absent), 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In embodiment, the tail domain nucleotides are from or share homology with sequence from the 5' end of a naturally occurring tail domain, see e.g., Fig. ID or Fig. IE. In an embodiment, the tail domain includes sequences that are complementary to each other and which, under at least some physiological conditions, form a duplexed region.
In an embodiment, the tail domain is absent or is 1 to 50 nucleotides in length. In an embodiment, the tail domain can share homology with or be derived from a naturally occurring proximal tail domain. In an embodiment, it has at least 50% homology with a tail domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, tail domain.
In an embodiment, the tail domain includes nucleotides at the 3' end that are related to the method of in vitro or in vivo transcription. When a T7 promoter is used for in vitro
94
5535.1 transcription of the gRNA, these nucleotides may be any nucleotides present before the 3' end of the DNA template. When a U6 promoter is used for in vivo transcription, these nucleotides may be the sequence UUUUUU. When alternate pol-III promoters are used, these nucleotides may be various numbers or uracil bases or may include alternate bases.
The domains of gRNA molecules are described in more detail below.
The Targeting Domain
The "targeting domain" of the gRNA is complementary to the "target domain" on the target nucleic acid. The strand of the target nucleic acid comprising the nucleotide sequence complementary to the core domain of the gRNA is referred to herein as the "complementary strand" of the target nucleic acid. Guidance on the selection of targeting domains can be found, e.g., in Fu Y et al, Nat Biotechnol 2014 (doi: 10.1038/nbt.2808) and Sternberg SH et al., Nature 2014 (doi: 10.1038/naturel3011).
In an embodiment, the targeting domain is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, the targeting domain is 16 nucleotides in length.
In an embodiment, the targeting domain is 17 nucleotides in length.
In an embodiment, the targeting domain is 18 nucleotides in length.
In an embodiment, the targeting domain is 19 nucleotides in length.
In an embodiment, the targeting domain is 20 nucleotides in length.
In an embodiment, the targeting domain is 21 nucleotides in length.
In an embodiment, the targeting domain is 22 nucleotides in length.
In an embodiment, the targeting domain is 23 nucleotides in length.
In an embodiment, the targeting domain is 24 nucleotides in length.
In an embodiment, the targeting domain is 25 nucleotides in length.
In an embodiment, the targeting domain is 26 nucleotides in length.
In an embodiment, the targeting domain comprises 16 nucleotides.
In an embodiment, the targeting domain comprises 17 nucleotides.
In an embodiment, the targeting domain comprises 18 nucleotides.
In an embodiment, the targeting domain comprises 19 nucleotides.
In an embodiment, the targeting domain comprises 20 nucleotides.
95
5535.1 In an embodiment, the targeting domain comprises 21 nucleotides.
In an embodiment, the targeting domain comprises 22 nucleotides.
In an embodiment, the targeting domain comprises 23 nucleotides.
In an embodiment, the targeting domain comprises 24 nucleotides.
In an embodiment, the targeting domain comprises 25 nucleotides.
In an embodiment, the targeting domain comprises 26 nucleotides.
In an embodiment, the targeting domain is 10 +/-5, 20+/-5, 30+/-5, 40+/-5, 50+/-5, 60+/- 5, 70+/-5, 80+/-5, 90+/-5, or 100+/-5 nucleotides, in length.
In an embodiment, the targeting domain is 20+/-5 nucleotides in length.
In an embodiment, the targeting domain is 20+/- 10, 30+/- 10, 40+/- 10, 50+/- 10, 60+/- 10,
70+/- 10, 80+/- 10, 90+/- 10, or 100+/- 10 nucleotides, in length.
In an embodiment, the targeting domain is 30+/- 10 nucleotides in length.
In an embodiment, the targeting domain is 10 to 100, 10 to 90, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 10 to 20 or 10 to 15 nucleotides in length. In another embodiment, the targeting domain is 20 to 100, 20 to 90, 20 to 80, 20 to 70, 20 to 60, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides in length.
Typically the targeting domain has full complementarity with the target sequence. In an embodiment the targeting domain has or includes 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain.
In an embodiment, the target domain includes 1, 2, 3, 4 or 5 nucleotides that are complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 5' end. In an embodiment, the target domain includes 1, 2, 3, 4 or 5 nucleotides that are complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 3' end.
In an embodiment, the target domain includes 1, 2, 3, or 4 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 5' end. In an embodiment, the target domain includes 1, 2, 3, or 4 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 3' end.
In an embodiment, the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
96
5535.1 In an embodiment, the targeting domain comprises two consecutive nucleotides that are not complementary to the target domain ("non-complementary nucleotides"), e.g., two consecutive noncomplementary nucleotides that are within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or more than 5 nucleotides away from one or both ends of the targeting domain.
In an embodiment, no two consecutive nucleotides within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain, are not complementary to the targeting domain.
In an embodiment, there are no noncomplementary nucleotides within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain.
In an embodiment, the targeting domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the targeting domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the targeting domain can be modified with a phosphorothioate, or other
modification(s) from Section VIII. In an embodiment, a nucleotide of the targeting domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
In an embodiment, the targeting domain includes 1, 2, 3, 4, 5, 6, 7 or 8 or more modifications. In an embodiment, the targeting domain includes 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end. In an embodiment, the targeting domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end.
In an embodiment, the targeting domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or more than 5 nucleotides away from one or both ends of the targeting domain.
In an embodiment, no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or
97
5535.1 within a region that is more than 5 nucleotides away from one or both ends of the targeting domain. In an embodiment, no nucleotide is modified within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain.
Modifications in the targeting domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate targeting domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in a system in Section IV. The candidate targeting domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, all of the modified nucleotides are complementary to and capable of hybridizing to corresponding nucleotides present in the target domain. In another embodiment,
I, 2, 3, 4, 5, 6, 7 or 8 or more modified nucleotides are not complementary to or capable of hybridizing to corresponding nucleotides present in the target domain.
In an embodiment, the targeting domain comprises, preferably in the 5'→3' direction: a secondary domain and a core domain. These domains are discussed in more detail below.
The Core Domain and Secondary Domain of the Targeting Domain
The "core domain" of the targeting domain is complementary to the "core domain target" on the target nucleic acid. In an embodiment, the core domain comprises about 8 to about 13 nucleotides from the 3' end of the targeting domain (e.g., the most 3' 8 to 13 nucleotides of the targeting domain).
In an embodiment, the core domain and targeting domain, are independently, 6 +1-2, 1+1- 2, 8+/-2, 9+/-2, 10+/-2, 11+/-2, 12+/-2, 13+/-2, 14+/-2, 15+/-2, or 16+-2, nucleotides in length.
In an embodiment, the core domain and targeting domain, are independently, 10+/-2 nucleotides in length.
In an embodiment, the core domain and targeting domain, are independently, 10+/-4 nucleotides in length.
In an embodiment, the core domain and targeting domain are independently 6, 7, 8, 9, 10,
I I, 12, 13, 14, 15, 16, 17, or 18 nucleotides in length.
98
5535.1 In an embodiment, the core domain and targeting domain are independently 3 to 20, 4 to 20, 5 to 20, 6 to 20, 7 to 20, 8 to 20, 9 to 20 10 to 20 or 15 to 20 nucleotides in length.
In an embodiment, the core domain and targeting domain are independently 3 to 15, e.g., 6 to 15, 7 to 14, 7 to 13, 6 to 12, 7 to 12, 7 to 11, 7 to 10, 8 to 14, 8 to 13, 8 to 12, 8 to 11, 8 to 10 or 8 to 9 nucleotides in length.
The core domain is complementary with the core domain target. Typically the core domain has exact complementarity with the core domain target. In some embodiments, the core domain can have 1, 2, 3, 4 or 5 nucleotides that are not complementary with the corresponding nucleotide of the core domain. In an embodiment, the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
The "secondary domain" of the targeting domain of the gRNA is complementary to the "secondary domain target" of the target nucleic acid.
In an embodiment, the secondary domain is positioned 5' to the core domain.
In an embodiment, the secondary domain is absent or optional.
In an embodiment, if the targeting domain is 26 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 12 to 17 nucleotides in length.
In an embodiment, if the targeting domain is 25 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 12 to 17 nucleotides in length.
In an embodiment, if the targeting domain is 24 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 11 to 16 nucleotides in length.
In an embodiment, if the targeting domain is 23 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 10 to 15 nucleotides in length.
In an embodiment, if the targeting domain is 22 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 9 to 14 nucleotides in length.
99
5535.1 In an embodiment, if the targeting domain is 21 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 8 to 13 nucleotides in length.
In an embodiment, if the targeting domain is 20 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 7 to 12 nucleotides in length.
In an embodiment, if the targeting domain is 19 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 6 to 11 nucleotides in length.
In an embodiment, if the targeting domain is 18 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 5 to 10 nucleotides in length.
In an embodiment, if the targeting domain is 17 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 4 to 9 nucleotides in length.
In an embodiment, if the targeting domain is 16 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 3 to 8 nucleotides in length.
In an embodiment, the secondary domain is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 nucleotides in length.
The secondary domain is complementary with the secondary domain target. Typically the secondary domain has exact complementarity with the secondary domain target. In an embodiment, the secondary domain can have 1, 2, 3, 4 or 5 nucleotides that are not
complementary with the corresponding nucleotide of the secondary domain. In an embodiment, the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
In an embodiment, the core domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the core domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the core domain can be modified with a phosphorothioate, or other modification(s)
100
5535.1 from Section VIII. In an embodiment a nucleotide of the core domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII. Typically, a core domain will contain no more than 1, 2, or 3 modifications.
Modifications in the core domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate core domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described at Section IV. The candidate core domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, the secondary domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the secondary domain comprises one or more modifications, e.g., modifications that render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the secondary domain can be modified with a phosphorothioate, or other modification(s) from Section VIII. In an embodiment a nucleotide of the secondary domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII. Typically, a secondary domain will contain no more than 1, 2, or 3 modifications.
Modifications in the secondary domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate secondary domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described at Section IV. The candidate secondary domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, (1) the degree of complementarity between the core domain and its target, and (2) the degree of complementarity between the secondary domain and its target, may differ. In an embodiment, (1) may be greater than (2). In an embodiment, (1) may be less than (2). In an embodiment, (1) and (2) are the same, e.g., each may be completely complementary with its target.
101
5535.1 In an embodiment, (1) the number of modifications (e.g., modifications from Section VIII) of the nucleotides of the core domain and (2) the number of modifications (e.g., modifications from Section VIII) of the nucleotides of the secondary domain may differ. In an embodiment, (1) may be less than (2). In an embodiment, (1) may be greater than (2). In an embodiment, (1) and (2) may be the same, e.g., each may be free of modifications.
The First and Second Complementarity Domains
The first complementarity domain is complementary with the second complementarity domain.
Typically the first domain does not have exact complementarity with the second complementarity domain target. In some embodiments, the first complementarity domain can have 1, 2, 3, 4 or 5 nucleotides that are not complementary with the corresponding nucleotide of the second complementarity domain. In an embodiment, 1, 2, 3, 4, 5 or 6, e.g., 3 nucleotides, will not pair in the duplex, and, e.g., form a non-duplexed or looped-out region. In an embodiment, an unpaired, or loop-out, region, e.g., a loop-out of 3 nucleotides, is present on the second complementarity domain. In an embodiment, the unpaired region begins 1, 2, 3, 4, 5, or 6, e.g., 4, nucleotides from the 5' end of the second complementarity domain.
In an embodiment, the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
In an embodiment, the first and second complementarity domains are:
independently, 6 +1-2, 1+1-2, 8+/-2, 9+1-2, 10+/-2, 11+/-2, 12+/-2, 13+/-2, 14+/-2, 15+/-2, 16+/-2, 17+/-2, 18+/-2, 19+/-2, or 20+/-2, 21+/-2, 22+/-2, 23+/-2, or 24+/-2 nucleotides in length;
independently, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26, nucleotides in length; or
independently, 5 to 24, 5 to 23, 5 to 22, 5 to 21, 5 to 20, 7 to 18, 9 to 16, or 10 to 14 nucleotides in length.
In an embodiment, the second complementarity domain is longer than the first complementarity domain, e.g., 2, 3, 4, 5, or 6, e.g., 6, nucleotides longer.
In an embodiment, the first and second complementary domains, independently, do not comprise modifications, e.g., modifications of the type provided in Section VIII.
102
5535.1 In an embodiment, the first and second complementary domains, independently, comprise one or more modifications, e.g., modifications that the render the domain less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the domain can be modified with a phosphorothioate, or other modification(s) from Section VIII. In an embodiment a nucleotide of the domain can comprise a 2'
modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
In an embodiment, the first and second complementary domains, independently, include 1, 2, 3, 4, 5, 6, 7 or 8 or more modifications. In an embodiment, the first and second
complementary domains, independently, include 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end. In an embodiment, the first and second complementary domains, independently, include as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end.
In an embodiment, the first and second complementary domains, independently, include modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the domain, within 5 nucleotides of the 3' end of the domain, or more than 5 nucleotides away from one or both ends of the domain. In an embodiment, the first and second complementary domains, independently, include no two consecutive nucleotides that are modified, within 5 nucleotides of the 5' end of the domain, within 5 nucleotides of the 3' end of the domain, or within a region that is more than 5 nucleotides away from one or both ends of the domain. In an embodiment, the first and second complementary domains, independently, include no nucleotide that is modified within 5 nucleotides of the 5' end of the domain, within 5 nucleotides of the 3' end of the domain, or within a region that is more than 5 nucleotides away from one or both ends of the domain.
Modifications in a complementarity domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate complementarity domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described in Section IV. The candidate complementarity domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
103
5535.1 In an embodiment, the first complementarity domain has at least 60, 70, 80, 85%, 90% or 95% homology with, or differs by no more than 1, 2, 3, 4, 5, or 6 nucleotides from, a reference first complementarity domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus, first complementarity domain, or a first complementarity domain described herein, e.g., from Figs. 1A-1G.
In an embodiment, the second complementarity domain has at least 60, 70, 80, 85%, 90%, or 95% homology with, or differs by no more than 1, 2, 3, 4, 5, or 6 nucleotides from, a reference second complementarity domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus, second complementarity domain, or a second complementarity domain described herein, e.g., from Figs. 1A-1G.
The duplexed region formed by first and second complementarity domains is typically 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 base pairs in length (excluding any looped out or unpaired nucleotides).
In some embodiments, the first and second complementarity domains, when duplexed, comprise 11 paired nucleotides, for example, in the gRNA sequence (one paired strand underlined, one bolded):
NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGG CUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 5).
In some embodiments, the first and second complementarity domains, when duplexed, comprise 15 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAUGCUGAAAAGCAUAGCAAGUUA AAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 27).
In some embodiments the first and second complementarity domains, when duplexed, comprise 16 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAUGCUGGAAACAGCAUAGCAAGU UAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC
(SEQ ID NO: 28).
104
5535.1 In some embodiments the first and second complementarity domains, when duplexed, comprise 21 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAUGCUGUUUUGGAAACAAAACAG CAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGC (SEQ ID NO: 29).
In some embodiments, nucleotides are exchanged to remove poly-U tracts, for example in the gRNA sequences (exchanged nucleotides underlined):
NNNNNNNNNNNNNNNNNNNNGUAUUAGAGCUAGAAAUAGCAAGUUAAUAUAAGG CUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 30);
NNNNNNNNNNNNNNNNNNNNGUUUAAGAGCUAGAAAUAGCAAGUUUAAAUAAGG CUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 31); or NNNNNNNNNNNNNNNNNNNNGUAUUAGAGCUAUGCUGUAUUGGAAACAAUACAG CAUAGCAAGUUAAUAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGA GUCGGUGC (SEQ ID NO: 32).
The 5' Extension Domain
In an embodiment, a modular gRNA can comprise additional sequence, 5' to the second complementarity domain. In an embodiment, the 5' extension domain is 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, or 2 to 4 nucleotides in length. In an embodiment, the 5' extension domain is 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides in length.
In an embodiment, the 5' extension domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the 5' extension domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the 5' extension domain can be modified with a phosphorothioate, or other modification(s) from Section VIII. In an embodiment, a nucleotide of the 5' extension domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other
modification(s) from Section VIII.
In an embodiment, the 5' extension domain can comprise as many as 1, 2, 3, 4, 5, 6, 7 or
8 modifications. In an embodiment, the 5' extension domain comprises as many as 1, 2, 3, or 4
105
5535.1 modifications within 5 nucleotides of its 5' end, e.g., in a modular gRNA molecule. In an embodiment, the 5' extension domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end, e.g., in a modular gRNA molecule.
In an embodiment, the 5' extension domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the 5' extension domain, within 5 nucleotides of the 3' end of the 5' extension domain, or more than 5 nucleotides away from one or both ends of the 5' extension domain. In an embodiment, no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the 5' extension domain, within 5 nucleotides of the 3' end of the 5' extension domain, or within a region that is more than 5 nucleotides away from one or both ends of the 5' extension domain. In an embodiment, no nucleotide is modified within 5 nucleotides of the 5' end of the 5' extension domain, within 5 nucleotides of the 3' end of the 5' extension domain, or within a region that is more than 5 nucleotides away from one or both ends of the 5' extension domain.
Modifications in the 5' extension domain can be selected so as to not interfere with gRNA molecule efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate 5' extension domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described at Section IV. The candidate 5' extension domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, the 5' extension domain has at least 60, 70, 80, 85, 90 or 95% homology with, or differs by no more than 1, 2, 3, 4, 5, or 6 nucleotides from, a reference 5' extension domain, e.g., a naturally occurring, e.g., an S. pyogenes, or S. aureus S. thermophilus, 5' extension domain, or a 5' extension domain described herein, e.g., from Figs. 1A-1G.
The Linking Domain
In a unimolecular gRNA molecule the linking domain is disposed between the first and second complementarity domains. In a modular gRNA molecule, the two molecules are associated with one another by the complementarity domains.
In an embodiment, the linking domain is 10 +/-5, 20+/-5, 30+/-5, 40+/-5, 50+/-5, 60+/-5,
70+/-5, 80+/-5, 90+/-5, or 100+/-5 nucleotides, in length.
106
5535.1 In an embodiment, the linking domain is 20+/- 10, 30+/- 10, 40+/- 10, 50+/- 10, 60+/- 10, 70+/- 10, 80+/- 10, 90+/- 10, or 100+/- 10 nucleotides, in length.
In an embodiment, the linking domain is 10 to 100, 10 to 90, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 10 to 20 or 10 to 15 nucleotides in length. In other embodiments, the linking domain is 20 to 100, 20 to 90, 20 to 80, 20 to 70, 20 to 60, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides in length.
In an embodiment, the linking domain is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 17, 18, 19, or 20 nucleotides in length.
In an embodiment, the linking domain is a covalent bond.
In an embodiment, the linking domain comprises a duplexed region, typically adjacent to or within 1, 2, or 3 nucleotides of the 3' end of the first complementarity domain and/or the 5- end of the second complementarity domain. In an embodiment, the duplexed region can be 20+/-10 base pairs in length. In an embodiment, the duplexed region can be 10+/-5, 15+/-5, 20+/-5, or 30+/-5 base pairs in length. In an embodiment, the duplexed region can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 base pairs in length.
Typically the sequences forming the duplexed region have exact complementarity with one another, though in some embodiments as many as 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides are not complementary with the corresponding nucleotides.
In an embodiment, the linking domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the linking domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the linking domain can be modified with a phosphorothioate, or other
modification(s) from Section VIII. In an embodiment a nucleotide of the linking domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII. In some embodiments, the linking domain can comprise as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications.
Modifications in a linking domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate linking domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated a system described in
107
5535.1 Section IV. A candidate linking domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, the linking domain has at least 60, 70, 80, 85, 90 or 95% homology with, or differs by no more than 1, 2, 3, 4, 5 ,or 6 nucleotides from, a reference linking domain, e.g., a linking domain described herein, e.g., from Figs. 1A-1G.
The Proximal Domain
In an embodiment, the proximal domain is 6 +1-2, 1+1-2, 8+/-2, 9+1-2, 10+/-2, 11+/-2, 12+/-2, 13+/-2, 14+/-2, 14+/-2, 16+/-2, 17+/-2, 18+/-2, 19+/-2, or 20+/-2 nucleotides in length.
In an embodiment, the proximal domain is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, the proximal domain is 5 to 20, 7, to 18, 9 to 16, or 10 to 14 nucleotides in length.
In an embodiment, the proximal domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the proximal domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the proximal domain can be modified with a phosphorothioate, or other
modification(s) from Section VIII. In an embodiment a nucleotide of the proximal domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
In an embodiment, the proximal domain can comprise as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications. In an embodiment, the proximal domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end, e.g., in a modular gRNA molecule. In an embodiment, the target domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end, e.g., in a modular gRNA molecule.
In an embodiment, the proximal domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the proximal domain, within 5 nucleotides of the 3' end of the proximal domain, or more than 5 nucleotides away from one or both ends of the proximal domain. In an embodiment, no two
108
5535.1 consecutive nucleotides are modified within 5 nucleotides of the 5' end of the proximal domain, within 5 nucleotides of the 3' end of the proximal domain, or within a region that is more than 5 nucleotides away from one or both ends of the proximal domain. In an embodiment, no nucleotide is modified within 5 nucleotides of the 5' end of the proximal domain, within 5 nucleotides of the 3' end of the proximal domain, or within a region that is more than 5 nucleotides away from one or both ends of the proximal domain.
Modifications in the proximal domain can be selected so as to not interfere with gRNA molecule efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate proximal domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described at Section IV. The candidate proximal domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, the proximal domain has at least 60, 70, 80, 85 90 or 95% homology with, or differs by no more than 1, 2, 3, 4, 5 , or 6 nucleotides from, a reference proximal domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus, proximal domain, or a proximal domain described herein, e.g., from Figs. 1A-1G.
The Tail Domain
In an embodiment, the tail domain is 10 +/-5, 20+/-5, 30+/-5, 40+/-5, 50+/-5, 60+/-5,
70+/-5, 80+/-5, 90+/-5, or 100+/-5 nucleotides, in length.
In an embodiment, the tail domain is 20+/-5 nucleotides in length.
In an embodiment, the tail domain is 20+/- 10, 30+/- 10, 40+/- 10, 50+/- 10, 60+/- 10, 70+/- 10, 80+/- 10, 90+/- 10, or 100+/- 10 nucleotides, in length.
In an embodiment, the tail domain is 25+/- 10 nucleotides in length.
In an embodiment, the tail domain is 10 to 100, 10 to 90, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 10 to 20 or 10 to 15 nucleotides in length.
In other embodiments, the tail domain is 20 to 100, 20 to 90, 20 to 80, 20 to 70, 20 to 60, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides in length.
In an embodiment, the tail domain is 1 to 20, 1 to 15, 1 to 10, or 1 to 5 nucleotides in length.
109
5535.1 In an embodiment, the tail domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the tail domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the tail domain can be modified with a phosphorothioate, or other modification(s) from
Section VIII. In an embodiment a nucleotide of the tail domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
In some embodiments, the tail domain can have as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications. In an embodiment, the target domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end. In an embodiment, the target domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end.
In an embodiment, the tail domain comprises a tail duplex domain, which can form a tail duplexed region. In an embodiment, the tail duplexed region can be 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 base pairs in length. In an embodiment, a further single stranded domain, exists 3' to the tail duplexed domain. In an embodiment, this domain is 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In an embodiment it is 4 to 6 nucleotides in length.
In an embodiment, the tail domain has at least 60, 70, 80, or 90% homology with, or differs by no more than 1, 2, 3, 4, 5 ,or 6 nucleotides from, a reference tail domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus, tail domain, or a tail domain described herein, e.g., from Figs. 1A-1G.
In an embodiment, the proximal and tail domain, taken together, comprise the following sequences:
AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU (SEQ ID NO: 33), or
AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC (SEQ ID NO: 34), or
AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCGGAUC (SEQ ID NO: 35), or
AAGGCUAGUCCGUUAUCAACUUGAAAAAGUG (SEQ ID NO: 36), or
AAGGCUAGUCCGUUAUCA (SEQ ID NO: 37), or
AAGGCUAGUCCG (SEQ ID NO: 38).
110
5535.1 In an embodiment, the tail domain comprises the 3' sequence UUUUUU, e.g., if a U6 promoter is used for transcription.
In an embodiment, the tail domain comprises the 3' sequence UUUU, e.g., if an HI promoter is used for transcription.
In an embodiment, tail domain comprises variable numbers of 3' Us depending, e.g., on the termination signal of the pol-III promoter used.
In an embodiment, the tail domain comprises variable 3' sequence derived from the DNA template if a T7 promoter is used.
In an embodiment, the tail domain comprises variable 3' sequence derived from the DNA template, e.g., if in vitro transcription is used to generate the RNA molecule.
In an embodiment, the tail domain comprises variable 3' sequence derived from the DNA template, e., if a pol-II promoter is used to drive transcription.
Modifications in the tail domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate tail domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described in Section IV. The candidate tail domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, the tail domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the tail domain, within 5 nucleotides of the 3' end of the tail domain, or more than 5 nucleotides away from one or both ends of the tail domain. In an embodiment, no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the tail domain, within 5 nucleotides of the 3' end of the tail domain, or within a region that is more than 5 nucleotides away from one or both ends of the tail domain. In an embodiment, no nucleotide is modified within 5 nucleotides of the 5' end of the tail domain, within 5 nucleotides of the 3' end of the tail domain, or within a region that is more than 5 nucleotides away from one or both ends of the tail domain.
In an embodiment a gRNA has the following structure:
111
5535.1 5' [targeting domain] -[first complementarity domain] -[linking domain] -[second complementarity domain] -[proximal domain] -[tail domain] -3'
wherein, the targeting domain comprises a core domain and optionally a secondary domain, and is 10 to 50 nucleotides in length;
the first complementarity domain is 5 to 25 nucleotides in length and, In an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference first complementarity domain disclosed herein;
the linking domain is 1 to 5 nucleotides in length;
the second complementarity domain is 5 to 27 nucleotides in length and, in an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference second complementarity domain disclosed herein;
the proximal domain is 5 to 20 nucleotides in length and, in an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference proximal domain disclosed herein; and the tail domain is absent or a nucleotide sequence is 1 to 50 nucleotides in length and, in an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference tail domain disclosed herein.
Exemplary Chimeric gRNAs
In an embodiment, a unimolecular, or chimeric, gRNA comprises, preferably from 5' to a targeting domain (which is complementary to a target nucleic acid);
a first complementarity domain, e.g., comprising 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, or 26 nucleotides;
a linking domain;
a second complementarity domain (which is complementary to the first complementarity domain);
a proximal domain; and
a tail domain,
wherein,
(a) the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides;
112
5535.1 (b) there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain; or
(c) there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the sequence from (a), (b), or (c), has at least 60, 75, 80, 85, 90, 95, or 99% homology with the corresponding sequence of a naturally occurring gRNA, or with a gRNA described herein.
In an embodiment, the proximal and tail domain, when taken together, comprise at least
15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is
complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length.
113
5535.1 In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides
(e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides
(e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the
114
5535.1 targeting domain is 16 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40,
45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and the proximal and tail domain, when taken together, comprise at leastl5, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides
(e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
115
5535.1 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides
(e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40,
45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the
116
5535.1 targeting domain is 21 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40,
45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides
(e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides
(e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the
117
5535.1 targeting domain is 23 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40,
45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides
(e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
118
5535.1 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the unimolecular, or chimeric, gRNA molecule (comprising a targeting domain, a first complementary domain, a linking domain, a second complementary domain, a proximal domain and, optionally, a tail domain) comprises the following sequence in which the targeting domain is depicted as 20 Ns but could be any sequence and range in length from 16 to 26 nucleotides and in which the gRNA sequence is followed by 6 Us, which serve as a termination signal for the U6 promoter, but which could be either absent or fewer in number: NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGG CUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUU (SEQ ID NO: 45). In an embodiment, the unimolecular, or chimeric, gRNA molecule is a S. pyogenes gRNA molecule.
In some embodiments, the unimolecular, or chimeric, gRNA molecule (comprising a targeting domain, a first complementary domain, a linking domain, a second complementary domain, a proximal domain and, optionally, a tail domain) comprises the following sequence in which the targeting domain is depicted as 20 Ns but could be any sequence and range in length from 16 to 26 nucleotides and in which the gRNA sequence is followed by 6 Us, which serve as a termination signal for the U6 promoter, but which could be either absent or fewer in number:
119
5535.1 NNNNNNNNNNNNNNNNNNNNGUUUUAGUACUCUGGAAACAGAAUCUACUAAAAC AAGGCAAAAUGCCGUGUUUAUCUCGUCAACUUGUUGGCGAGAUUUUUU (SEQ ID NO: 40). In an embodiment, the unimolecular, or chimeric, gRNA molecule is a S. aureus gRNA molecule.
Exemplary Modular gRNAs
In an embodiment, a modular gRNA comprises:
a first strand comprising, preferably from 5' to 3' ;
a targeting domain, e.g., comprising 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides;
a first complementarity domain; and
a second strand, comprising, preferably from 5' to 3':
optionally a 5' extension domain;
a second complementarity domain;
a proximal domain; and
a tail domain,
wherein:
(a) the proximal and tail domain, when taken together, comprise
at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides; (b) there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain; or
(c) there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the sequence from (a), (b), or (c), has at least 60, 75, 80, 85, 90, 95, or 99% homology with the corresponding sequence of a naturally occurring gRNA, or with a gRNA described herein.
In an embodiment, the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
120
5535.1 In an embodiment, there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is
complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides
(e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides
(e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length.
121
5535.1 In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides
(e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides
(e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the
122
5535.1 targeting domain is 17 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40,
45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides
(e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
123
5535.1 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides
(e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40,
45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the
124
5535.1 targeting domain is 22 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40,
45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides
(e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides
(e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the
125
5535.1 targeting domain is 24 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40,
45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides
(e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41,
126
5535.1 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
II. Methods for Designing gRNAs
Methods for designing gRNAs are described herein, including methods for selecting, designing and validating target domains. Exemplary targeting domains are also provided herein. Targeting Domains discussed herein can be incorporated into the gRNAs described herein.
Methods for selection and validation of target sequences as well as off-target analyses are described, e.g., in Mali et al., 2013 SCIENCE 339(6121): 823-826; Hsu et al. NAT BIOTECHNOL, 31(9): 827-32; Fu et al., 2014 NAT BIOTECHNOL, doi: 10.1038/nbt.2808. PubMed PMID:
24463574; Heigwer et al., 2014 NAT METHODS l l(2): 122-3. doi: 10.1038/nmeth.2812. PubMed PMID: 24481216; Bae et al., 2014 BIOINFO MATICS PubMed PMID: 24463181; Xiao A et al., 2014 BIOINFORMATICS PubMed PMID: 24389662.
For example, a software tool can be used to optimize the choice of gRNA within a user' s target sequence, e.g., to minimize total off-target activity across the genome. Off target activity may be other than cleavage. For each possible gRNA choice using S. pyogenes Cas9, the tool can identify all off-target sequences (preceding either NAG or NGG PAMs) across the genome that contain up to certain number (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of mismatched base-pairs. The cleavage efficiency at each off-target sequence can be predicted, e.g., using an
experimentally-derived weighting scheme. Each possible gRNA is then ranked according to its total predicted off-target cleavage; the top-ranked gRNAs represent those that are likely to have the greatest on-target and the least off-target cleavage. Other functions, e.g., automated reagent design for CRISPR construction, primer design for the on-target Surveyor assay, and primer design for high-throughput detection and quantification of off-target cleavage via next-gen sequencing, can also be included in the tool. Candidate gRNA molecules can be evaluated by art-known methods or as described in Section IV herein.
The Targeting Domains discussed herein can be incorporated into the gRNAs described herein.
127
5535.1 Strategies to identify gRNAs for S. pyogenes, S. Aureus, and N. meningitidis to knock out the SCNN1A gene
As an example, three strategies were utilized to identify gRNAs for use with S. pyogenes, S. aureus and N. meningitidis Cas9 enzymes.
In the first strategy, guide RNAs (gRNAs) for use with the S. pyogenes Cas9 (Tables 3A-
3C) were identified using the publically available web-based ZiFiT server (Fu et al., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014 Jan 26. doi: 10.1038/nbt.2808. PubMed PMID: 24463574, for the original references see Sander et al., 2007, NAR 35:W599-605; Sander et al., 2010, NAR 38: W462-8). In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available Repeat-Masker program. RepeatMmasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence. Following
identification, gRNAs for use with a S. pyogenes Cas9 were ranked into 3 or 4 tiers, as described below.
The gRNAs in tier 1 were selected based on their distance to the target site and their orthogonality in the genome (based on the ZiFiT identification of close matches in the human genome containing an NGG PAM). As an example, for all targets, both 17-mer and 20-mer gRNAs were designed. gRNAs were also selected both for single-gRNA nuclease cutting and for the dual gRNA nickase strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for which strategy is based on several considerations:
1. For the dual nickase strategy, gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the
entire intervening sequence at a reasonable frequency. However, it will also often result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus just causing indel mutations at the site of one gRNA.
128
5535.1 While it can be desirable to have gRNAs start with a 5' G, this requirement was relaxed for some gRNAs in tier 1 in order to identify guides in the correct orientation, within a reasonable distance to the mutation and with a high level of orthogonality. In order to find a pair for the dual-nickase strategy it was necessary to either extend the distance from the mutation or remove the requirement for the 5'G. For selection of tier 2 gRNAs, the distance restriction was relaxed in some cases such that a longer sequence was scanned, but the 5'G was required for all gRNAs. Whether or not the distance requirement was relaxed depended on how many sites were found within the original search window. Tier 3 uses the same distance restriction as tier 2, but removes the requirement for a 5'G. Note that tiers are non-inclusive (each gRNA is listed only once).
As discussed above, gRNAs were identified for single-gRNA nuclease cleavage as well as for a dual-gRNA paired "nickase" strategy, as indicated.
gRNAs for use with the S. aureus (Tables 3D) Cas9s were identified manually by scanning genomic DNA sequence for the presence of PAM sequences. These gRNAs were not separated into tiers, but are provided in single lists for each species.
In a second strategy, Guide RNAs (gRNAs) for use with S. pyogenes, S. aureus and N. meningitidis Cas9s were identified using a DNA sequence searching algorithm. Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas- offinder (reference:Cas-OFFinder: a fast and versatile algorithm that searches for potential off- target sites of Cas9 RNA-guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID:24463181). Said custom guide RNA design software scores guides after calculating their genomewide off-target propensity. Typically matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24. Once the off- target sites are computationally determined , an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface. In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available RepeatMasker program. RepeatMasker searches
129
5535.1 input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
Following identification, gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of S. aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM). Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence. A "high level of orthogonality" or "good orthogonality" may, for example, refer to 20-mer gRNAs that have no identical sequences in the human genome besides the intended target, nor any sequences that contain one or two mismatches in the target sequence. Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
As an example, for S. pyogenes and N. meningitidis targets, 17-mer, or 20-mer gRNAs were designed. As another example, for S. aureus targets, 18-mer, 19-mer, 20-mer, 21-mer, 22- mer, 23-mer and 24-mer gRNAs were designed. Targeting domains, disclosed herein, may comprise the 17-mer described in Tables 43A-43E, 44A-44G or 45A-45E, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 43A- 43E, 44A-44G or 45A-45E. Targeting domains, disclosed herein, may comprises the 18-mer described in Tables 43A-43E, 44A-44G or 45A-45E, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 43A-43E, 44A-44G or 45A- 45E. Targeting domains, disclosed herein, may comprises the 19-mer described in Tables 43A- 43E, 44A-44G or 45A-45E, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 43A-43E, 44A-44G or 45A-45E. Targeting domains, disclosed herein, may comprises the 20-mer gRNAs described in Tables 43A-43E, 44A-44G or 45A-45E, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 43A-43E, 44A-44G or 45A-45E. Targeting domains, disclosed herein, may comprises the 21-mer described in Tables 43A-43E, 44A-44G or 45A-45E, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in
Tables 43A-43E, 44A-44G or 45A-45E. Targeting domains, disclosed herein, may comprises the 22-mer described in Tables 43A-43E, 44A-44G or 45A-45E, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 43A-43E, 44A-
130
5535.1 44G or 45A-45E. Targeting domains, disclosed herein, may comprises the 23-mer described in Tables 43A-43E, 44A-44G or 45A-45E,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 43A-43E, 44A-44G or 45A-45E.
Targeting domains, disclosed herein, may comprises the 24-mer described in Tables 43A-43E, 44A-44G or 45A-45E, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 43A-43E, 44A-44G or 45A-45E. gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for the dual-gRNA paired "nickase" strategy is based on two considerations:
1. gRNA pairs should be oriented on the DNA such that PAMs are facing out and
cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, cleaving with dual nickase pairs can also result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus causing indel mutations at the site of one gRNA.
The targeting domains discussed herein can be incorporated into the gRNAs described herein. gRNAs were identified and ranked into 5 tiers for S. pyogenes (Tables 43A-43E), and N. meningitidis (Tables 45A-45E); and 7 tiers for S. aureus (Tables 44A-44G). For S. pyogenes, and N. meningitidis, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality and (3) the presence of 5'G. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) a high level of orthogonality. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) the presence of 5'G. The targeting domain for tier 4 gRNA molecules were selected based on distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon). The targeting domain for tier 5 gRNA molecules were selected based on distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g.,
131
5535.1 anywhere from +500 (relative to the start codon) to the stop codon). For S. aureus, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, and (3) PAM is NNGRRT. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRT. The targeting domain for tier 4 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRV. The targeting domain for tier 5 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g.,
downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon), (2) the presence of 5'G and (3) PAM is NNGRRT. The targeting domain for tier 6 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRT. The targeting domain for tier 7 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRV. Note that tiers are non-inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier.
Strategies to identify gRNAs for S. pyogenes, S. Aureus, and N. meningitidis to knock down the SCNN1A gene
As an example, three strategies were utilized to identify gRNAs for use with S. pyogenes, S. aureus and N. meningitidis Cas9 enzymes.
Guide RNAs (gRNAs) for use with S. pyogenes, S. aureus and N. meningitidis Cas9s were identified using a DNA sequence searching algorithm. Guide RNA design was carried out
132
5535.1 using a custom guide RNA design software based on the public tool cas-offinder (reference:Cas- OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA- guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID:24463181). Said custom guide RNA design software scores guides after calculating their genomewide off- target propensity. Typically matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24. Once the off-target sites are
computationally determined , an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface. In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available RepeatMasker program. RepeatMasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
Following identification, gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of S. aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM). Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence. A "high level of orthogonality" or "good orthogonality" may, for example, refer to 20-mer gRNAs that have no identical sequences in the human genome besides the intended target, nor any sequences that contain one or two mismatches in the target sequence. Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
As an example, for S. pyogenes and N. meningitidis targets, 17-mer, or 20-mer gRNAs were designed. As another example, for S. aureus targets, 18-mer, 19-mer, 20-mer, 21-mer, 22- mer, 23-mer and 24-mer gRNAs were designed. Targeting domains, disclosed herein, may comprise the 17-mer described in Tables 46A-46E, 47A-47G or 48A-48E, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 46A- 46E, 47A-47G or 48A-48E. Targeting domains, disclosed herein, may comprises the 18-mer described in Tables 46A-46E, 47A-47G or 48A-48E, e.g., the targeting domains of 19 or more
133
5535.1 nucleotides may comprise the 18-mer gRNAs described in Tables 46A-46E, 47A-47G or 48A- 48E. Targeting domains, disclosed herein, may comprises the 19-mer described in Tables 46A- 46E, 47A-47G or 48A-48E, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 46A-46E, 47A-47G or 48A-48E. Targeting domains, disclosed herein, may comprises the 20-mer gRNAs described in Tables 46A-46E, 47A-47G or 48A-48E, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 46A-46E, 47A-47G or 48A-48E. Targeting domains, disclosed herein, may comprises the 21-mer described in Tables 46A-46E, 47A-47G or 48A-48E, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in
Tables 46A-46E, 47A-47G or 48A-48E. Targeting domains, disclosed herein, may comprises the 22-mer described in Tables 46A-46E, 47A-47G or 48A-48E, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 46A-46E, 47A- 47G or 48A-48E. Targeting domains, disclosed herein, may comprises the 23-mer described in Tables 46A-46E, 47A-47G or 48A-48E,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 46A-46E, 47A-47G or 48A-48E.
Targeting domains, disclosed herein, may comprises the 24-mer described in Tables 46A-46E, 47A-47G or 48A-48E, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 46A-46E, 47A-47G or 48A-48E.
The targeting domains discussed herein can be incorporated into the gRNAs described herein. gRNAs were identified and ranked into 5 tiers for S. pyogenes (Tables 46A-46E), and N. meningitidis (Tables 48A-48E); and 7 tiers for S. aureus (Tables 47A-47G). For S. pyogenes, and N. meningitidis, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), (2) a high level of orthogonality and (3) the presence of 5'G. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS) and (2) a high level of orthogonality. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS) and (2) the presence of 5'G. The targeting domain for tier 4 gRNA molecules were selected based on distance to a target site, e.g., within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS). The targeting domain for tier 5 gRNA molecules were selected
134
5535.1 based on distance to the target site, e.g., within the additional 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), e.g., extending to lkb upstream and downstream of a TSS. For S. aureus, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is
NNGRRT. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), (2) a high level of orthogonality, and (3) PAM is NNGRRT. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS) and (2) PAM is NNGRRT. The targeting domain for tier 4 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS) and (2) PAM is NNGRRV. The targeting domain for tier 5 gRNA molecules were selected based on (1) distance to the target site, e.g., within the additional 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), e.g., extending to lkb upstream and downstream of a TSS , (2) the presence of 5'G and (3) PAM is NNGRRT. The targeting domain for tier 6 gRNA molecules were selected based on (1) distance to the target site, e.g., within the additional 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), e.g., extending to lkb upstream and downstream of a TSS and (2) PAM is NNGRRT. The targeting domain for tier 7 gRNA molecules were selected based on (1) distance to the target site, e.g., within the additional 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), e.g., extending to lkb upstream and downstream of a TSS and (2) PAM is NNGRRV. Note that tiers are non-inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier.
Strategies to identify gRNAs for S. pyogenes, S. Aureus, and N. for correcting a mutation (e.g., delF508, G551D, G542X, N1303K, R117H, W1282X, R553X, 2789+5G->A, or 3272-26A->G) in the CFTR gene
As an example, three strategies were utilized to identify gRNAs for use with S. pyogenes, S. aureus and N. meningitidis Cas9 enzymes.
135
5535.1 In the first strategy, guide RNAs (gRNAs) for use with the S. pyogenes Cas9 (Tables 1A- 1C or 2A-2C) were identified using the publically available web-based ZiFiT server (Fu et al., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014 Jan 26. doi: 10.1038/nbt.2808. PubMed PMID: 24463574, for the original references see Sander et al., 2007, NAR 35:W599-605; Sander et al., 2010, NAR 38: W462-8). In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available Repeat-Masker program. RepeatMmasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence. Following identification, gRNAs for use with a S. pyogenes Cas9 were ranked into 3 or 4 tiers, as described below.
The gRNAs in tier 1 were selected based on their distance to the target site and their orthogonality in the genome (based on the ZiFiT identification of close matches in the human genome containing an NGG PAM). As an example, for all targets, both 17-mer and 20-mer gRNAs were designed. gRNAs were also selected both for single-gRNA nuclease cutting and for the dual gRNA nickase strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for which strategy is based on several considerations:
3. For the dual nickase strategy, gRNA pairs should be oriented on the DNA such that
PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
4. An assumption that cleaving with dual nickase pairs will result in deletion of the
entire intervening sequence at a reasonable frequency. However, it will also often result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus just causing indel mutations at the site of one gRNA.
While it can be desirable to have gRNAs start with a 5' G, this requirement was relaxed for some gRNAs in tier 1 in order to identify guides in the correct orientation, within a reasonable distance to the mutation and with a high level of orthogonality. In order to find a pair for the dual-nickase strategy it was necessary to either extend the distance from the mutation or
136
5535.1 remove the requirement for the 5'G. For selection of tier 2 gRNAs, the distance restriction was relaxed in some cases such that a longer sequence was scanned, but the 5'G was required for all gRNAs. Whether or not the distance requirement was relaxed depended on how many sites were found within the original search window. Tier 3 uses the same distance restriction as tier 2, but removes the requirement for a 5'G. Note that tiers are non-inclusive (each gRNA is listed only once).
As discussed above, gRNAs were identified for single-gRNA nuclease cleavage as well as for a dual-gRNA paired "nickase" strategy, as indicated.
gRNAs for use with the N. meningitidis (Tables IE or 2E) and S. aureus (Tables ID or 2D) Cas9s were identified manually by scanning genomic DNA sequence for the presence of PAM sequences. These gRNAs were not separated into tiers, but are provided in single lists for each species.
In a second strategy, Guide RNAs (gRNAs) for use with S. pyogenes, S. aureus and N. meningitidis Cas9s were identified using a DNA sequence searching algorithm. Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas- offinder (reference:Cas-OFFinder: a fast and versatile algorithm that searches for potential off- target sites of Cas9 RNA-guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID:24463181). Said custom guide RNA design software scores guides after calculating their genomewide off-target propensity. Typically matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24. Once the off- target sites are computationally determined , an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface. In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available RepeatMasker program. RepeatMasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
Following identification, gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in
137
5535.1 the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of S. aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM). Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence. A "high level of orthogonality" or "good orthogonality" may, for example, refer to 20-mer gRNAs that have no identical sequences in the human genome besides the intended target, nor any sequences that contain one or two mismatches in the target sequence. Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
As an example, for S. pyogenes and N. meningitidis targets, 17-mer, or 20-mer gRNAs were designed. As another example, for S. aureus targets, 18-mer, 19-mer, 20-mer, 21-mer, 22- mer, 23-mer and 24-mer gRNAs were designed. Targeting domains, disclosed herein, may comprise the 17-mer described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, 10A- 10C, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A- 9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A- 18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A- 27D, 28A-28D, 29A-29E, or 30A-30B. Targeting domains, disclosed herein, may comprises the 18-mer described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A- 11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A- 19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A- 28D, 29A-29E, or 30A-30B. Targeting domains, disclosed herein, may comprises the 19-mer described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A- 12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer
138
5535.1 gRNAs described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A- 11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B. Targeting domains, disclosed herein, may comprises the 20-mer gRNAs described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A- 12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A- HE, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B. Targeting domains, disclosed herein, may comprises the 21-mer described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A- 12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A- 11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B. Targeting domains, disclosed herein, may comprises the 22-mer described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A- 12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A- 11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B. Targeting domains, disclosed herein, may comprises the 23-mer described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A- 12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E,
139
5535.1 or 30A-30B,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A- 11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B. Targeting domains, disclosed herein, may comprises the 24-mer described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A- 12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A- 11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, or 30A-30B. gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for the dual-gRNA paired "nickase" strategy is based on two considerations:
1. gRNA pairs should be oriented on the DNA such that PAMs are facing out and
cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, cleaving with dual nickase pairs can also result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus causing indel mutations at the site of one gRNA.
The targeting domains discussed herein can be incorporated into the gRNAs described herein.
In an embodiment, gRNAs were identified and ranked into 4 tiers for S. pyogenes
(Tables 4A-4D, 7A-7D, lOA-lOC, 13A-13D, 16A-16D, 19A-19D, 12A-12D, 22A-22D, 25A- 25D or 28A-28D), and N. meningitidis (Tables 6A-6C, 9A-9B, 12A-12C, 15A-15C, 18A-18C, 21A-21B, 24A-24D, 27A-27D, or 30A-30B); and 5 tiers for S. aureus (Tables 5A-5E, 8A-8E, 11A-11E, 14A-14E, 17A-17E, 20A-20E, 23A-23E, 26A-26E, or 29A-29E). For S. pyogenes, and N. meningitidis, the targeting domaior tier 1 gRNA molecules were selected based on (1) distance to a target site, e.g., within 200 bp from a mutation (e.g., delF508, G551D, G542X,
140
5535.1 N1303K, R117H, W1282X, R553X, 2789+5G->A, or 3272-26A->G) , (2) a high level of orthogonality and (3) the presence of 5'G. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site, e.g., within 200 bp from a mutation (e.g., delF508, G551D, G542X, N1303K, R117H, W1282X, R553X, 2789+5G->A, or 3272-26A->G) and (2) a high level of orthogonality. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site, e.g., within 200 bp from a mutation (e.g., delF508, G551D, G542X, N1303K, R117H, W1282X, R553X, 2789+5G->A, or 3272-26A->G) and (2) the presence of 5'G. The targeting domain for tier 4 gRNA molecules were selected based on distance to a target site, e.g., within 200 bp from a mutation (e.g., delF508, G551D, G542X, N1303K, Rl 17H, W1282X, R553X, 2789+5G->A, or 3272-26A->G) . For S. aureus, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site, e.g., within 200 bp from a mutation (e.g., delF508, G551D, G542X, N1303K, R117H, W1282X, R553X, 2789+5G->A, or 3272-26A->G) , (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site, e.g., within 200 bp from a mutation (e.g., delF508, G551D, G542X, N1303K, R117H, W1282X, R553X, 2789+5G->A, or 3272-26A->G) , (2) a high level of orthogonality, and (3) PAM is NNGRRT. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site, e.g., within 200 bp from a mutation (e.g., delF508, G551D, G542X, N1303K, R117H, W1282X, R553X, 2789+5G->A, or 3272-26A->G) , (2) the presence of a 5'G and (2) PAM is NNGRRT. The targeting domain for tier 4 gRNA molecules were selected based on (1) distance to a target site, e.g., within 200 bp from a mutation (e.g., delF508, G551D, G542X, N1303K, R117H, W1282X, R553X, 2789+5G->A, or 3272-26A->G) and (2) PAM is NNGRRT. The targeting domain for tier 5 gRNA molecules were selected based on (1) (1) distance to a target site, e.g., within 200 bp from a mutation (e.g., delF508, G551D, G542X, N1303K, R117H, W1282X, R553X, 2789+5G->A, or 3272-26A->G) and (2) PAM is NNGRRV. Note that tiers are non-inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier.
141
5535.1 Strategies to identify gRNAs for S. pyogenes, S. Aureus, and N. meningitidis for targeting an intronic mutation (e.g., 3849+10kbC->T or 3272-26A->G) regions of the CFTR gene (e.g., mediated by NHEJ)
As an example, three strategies were utilized to identify gRNAs for use with S. pyogenes, S. aureus and N. meningitidis Cas9 enzymes.
Guide RNAs (gRNAs) for use with S. pyogenes, S. aureus and N. meningitidis Cas9s were identified using a DNA sequence searching algorithm. Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas-offinder (reference:Cas- OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA- guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID:24463181). Said custom guide RNA design software scores guides after calculating their genomewide off- target propensity. Typically matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24. Once the off-target sites are
computationally determined, an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface. In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available RepeatMasker program. RepeatMasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
Following identification, gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of S. aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a
NNNNGATT or NNNNGCTT PAM). Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence. A "high level of orthogonality" or "good orthogonality" may, for example, refer to 20-mer gRNAs that have no identical sequences in the human genome besides the intended target, nor any sequences that contain one or two mismatches in the target sequence. Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
142
5535.1 As an example, for S. pyogenes and N. meningitidis targets, 17-mer, or 20-mer gRNAs were designed. As another example, for S. aureus targets, 18-mer, 19-mer, 20-mer, 21-mer, 22- mer, 23-mer and 24-mer gRNAs were designed. Targeting domains, disclosed herein, may comprise the 17-mer described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D. Targeting domains, disclosed herein, may comprises the 18-mer described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 31A-31D, 32A-32D, 33A- 33B, 34A-34D, 35A-35D, 36A-36D. Targeting domains, disclosed herein, may comprises the 19-mer described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D. Targeting domains, disclosed herein, may comprises the 20-mer gRNAs described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D. Targeting domains, disclosed herein, may comprises the 21-mer described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in Tables 31 A- 31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D. Targeting domains, disclosed herein, may comprises the 22-mer described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A- 35D, 36A-36D, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D. Targeting domains, disclosed herein, may comprises the 23-mer described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 31A-31D, 32A-32D, 33A- 33B, 34A-34D, 35A-35D, 36A-36D. Targeting domains, disclosed herein, may comprises the 24-mer described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D. gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria
143
5535.1 for selecting gRNAs and the determination for which gRNAs can be used for the dual-gRNA paired "nickase" strategy is based on two considerations:
1. gRNA pairs should be oriented on the DNA such that PAMs are facing out and
cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, cleaving with dual nickase pairs can also result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus causing indel mutations at the site of one gRNA.
The targeting domains discussed herein can be incorporated into the gRNAs described herein.
In an embodiment, gRNAs were identified and ranked into 4 tiers for S. pyogenes
(Tables 31A-31D or 34A-34D), and N. meningitidis (Tables 33A-33B or 36A-36D); and 4 tiers for S. aureus (Tables 32A-32D or 35A-35D). For S. pyogenes, and N. meningitidis, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500bp, e.g., within 200 bp from a mutation (e.g., 3849+10kbC->T or 3272-26A- >G), (2) a high level of orthogonality and (3) the presence of 5'G. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500bp, e.g., within 200 bp from a mutation (e.g., 3849+10kbC->T or 3272-26A->G) and (2) a high level of orthogonality. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500bp, e.g., within 200 bp from a mutation (e.g.,
3849+10kbC->T or 3272-26A->G) and (2) the presence of 5'G. The targeting domain for tier 4 gRNA molecules were selected based on distance to a target site, e.g., within 500bp, e.g., within 200 bp from a mutation (e.g., 3849+10kbC->T or 3272-26A->G). For S. aureus, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500bp, e.g., within 200 bp from a mutation (e.g., 3849+10kbC->T or 3272-26A->G), (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500bp, e.g., within 200 bp from a mutation (e.g., 3849+10kbC->T or 3272-26A->G), (2) a high level of orthogonality, and (3) PAM is NNGRRT. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site, e.g., within 500bp, e.g., within 200 bp from a mutation (e.g., 3849+10kbC->T or 3272-26A->G) and (2) PAM is NNGRRT. The
144
5535.1 targeting domain for tier 4 gRNA molecules were selected based on (1) (1) distance to a target site, e.g., within 500bp, e.g., within 200 bp from a mutation (e.g., 3849+10kbC->T or 3272- 26A->G) and (2) PAM is NNGRRV. Note that tiers are non-inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier.
Strategies to identify gRNAs for S. pyogenes, S. Aureus, and N. for targeting an intronic region (e.g., intron 2 or intron 10) of the CFTR gene (e.g., mediated by cDNA)
Guide RNAs (gRNAs) for use with S. pyogenes, S. aureus and N. meningitidis Cas9s were identified using a DNA sequence searching algorithm. Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas-offinder (reference:Cas- OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA- guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID:24463181). Said custom guide RNA design software scores guides after calculating their genomewide off- target propensity. Typically matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24. Once the off-target sites are
computationally determined , an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface. In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available RepeatMasker program. RepeatMasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
Following identification, gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of S. aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM). Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence. A "high level of orthogonality" or "good orthogonality" may, for example, refer to 20-mer gRNAs that
145
5535.1 have no identical sequences in the human genome besides the intended target, nor any sequences that contain one or two mismatches in the target sequence. Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
As an example, for S. pyogenes and N. meningitidis targets, 17-mer, or 20-mer gRNAs were designed. As another example, for S. aureus targets, 18-mer, 19-mer, 20-mer, 21-mer, 22- mer, 23-mer and 24-mer gRNAs were designed. Targeting domains, disclosed herein, may comprise the 17-mer described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D. Targeting domains, disclosed herein, may comprises the 18-mer described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 37A-37D, 38A-38E, 39A- 39D, 40A-40D, 41A-41E, or 42A-42D. Targeting domains, disclosed herein, may comprises the 19-mer described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D. Targeting domains, disclosed herein, may comprises the 20-mer gRNAs described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 37A-37D, 38A-38E, 39A- 39D, 40A-40D, 41A-41E, or 42A-42D. Targeting domains, disclosed herein, may comprises the 21-mer described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D. Targeting domains, disclosed herein, may comprises the 22-mer described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D. Targeting domains, disclosed herein, may comprises the 23-mer described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in
Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D. Targeting domains, disclosed herein, may comprises the 24-mer described in Tables 37A-37D, 38A-38E, 39A-39D,
146
5535.1 40A-40D, 41A-41E, or 42A-42D, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D,
41A-41E, or 42A-42D. gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for the dual-gRNA paired "nickase" strategy is based on two considerations:
1. gRNA pairs should be oriented on the DNA such that PAMs are facing out and
cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, cleaving with dual nickase pairs can also result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus causing indel mutations at the site of one gRNA.
The targeting domains discussed herein can be incorporated into the gRNAs described herein.
In an embodiment, gRNAs were identified and ranked into 4 tiers for S. pyogenes
(Tables 37A-37D or 40A-40D), and N. meningitidis (Tables 39A-39D or 42A-42D); and 4 tiers for S. aureus (Tables 38A-38E or 41A-41E). For S. pyogenes, and N. meningitidis, the targeting domain for tier 1 gRNA molecules were selected based on (1) target position, e.g., intron 2 or intron 10, (2) a high level of orthogonality and (3) the presence of 5'G. The targeting domain for tier 2 gRNA molecules were selected based on (1) target position, e.g., intron 2 or intron 10 and (2) a high level of orthogonality. The targeting domain for tier 3 gRNA molecules were selected based on (1) target position, e.g., intron 2 or intron 10 and (2) the presence of 5'G. The targeting domain for tier 4 gRNA molecules were selected based on target position, e.g., intron 2 or intron 10. For S. aureus, the targeting domain for tier 1 gRNA molecules were selected based on (1) target position, e.g., intron 2 or intron 10, (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT. The targeting domain for tier 2 gRNA molecules were selected based on (1) target position, e.g., intron 2 or intron 10, (2) a high level of orthogonality, and (3) PAM is NNGRRT. The targeting domain for tier 3 gRNA molecules were selected based on (1) target position, e.g., intron 2 or intron 10, (2) the presence of a 5'G and (2) PAM is NNGRRT. The targeting domain for tier 4 gRNA molecules were selected based on (1) target position, e.g., intron 2 or intron 10 and (2) PAM is NNGRRT. The targeting domain for tier 5 gRNA molecules
147
5535.1 were selected based on (1) (1) target position, e.g., intron 2 or intron 10 and (2) PAM is
NNGRRV. Note that tiers are non-inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier.
In an embodiment, two or more (e.g., three or four) gRNA molecules are used with one Cas9 molecule. In another embodiment, when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
Any of the targeting domains in the tables described herein can be used with a Cas9 nickase molecule to generate a single strand break.
Any of the targeting domains in the tables described herein can be used with a Cas9 nuclease molecule to generate a double strand break.
When two gRNAs designed for use to target two Cas9 molecules, one Cas9 can be one species, the second Cas9 can be from a different species. Both Cas9 species are used to generate a single or double- strand break, as desired.
It is contemplated herein that any upstream gRNA described herein may be paired with any downstream gRNA described herein. When an upstream gRNA designed for use with one species of Cas9 is paired with a downstream gRNA designed for use from a different species of Cas9, both Cas9 species are used to generate a single or double-strand break, as desired.
Exemplary Targeting Domains
Table 1A provides exemplary targeting domains for the F508del target position in the CFTR gene selected according to the first tier parameters. The targeting domains are selected based on close proximity to mutation and orthogonality in the human genome. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with
148
5535.1 two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp. In an embodiment, two 17-mer RNAs are used to target two Cas9 nucleases or two Cas9 nickases, e.g., CFTR-18 and CFTR- 16 are used.
Table 1A
Figure imgf000150_0001
Table IB provides exemplary targeting domains for the F508del target position in the CFTR gene selected according to the second tier parameters. The targeting domains are selected based on the presence of a 5' G and reasonable proximity to mutation. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table IB
Figure imgf000150_0002
149
5535.1 CFT -24 - GAUAAUGACCUAAUAAUGAU 20 395
CFTR-29 - GGGAGAACUGGAGCCUUCAG 20 396
CFTR-30 - GGAGAACUGGAGCCUUCAGA 20 397
CFTR-37 + GUAGACUAACCGAUUGAAUA 20 398
CFTR-44 + GUCAUUAUCAAAUCACGCUC 20 399
CFTR-50 - GGUGAUUAUGGGAGAAC 17 400
CFTR-52 - GAACUGGAGCCUUCAGA 17 401
CFTR-57 - GGGUAAGCUACUGUGAA 17 402
CFTR-59 + G ACU AACCG AU UG AAU A 17 403
CFTR-60 + GAGCCAAAUAUAUAAUU 17 404
Table 1C provides exemplary targeting domains for the F508del target position in the CFTR gene selected according to the third tier parameters. The targeting domains are selected based on reasonable proximity to mutation. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 1C
Figure imgf000151_0001
150
5535.1 CFT -13 - UCUGUUCUCAGUUUUCC 17 413
CFTR-14 - UUUUCCUGGAUUAUGCC 17 414
CFTR-15 - AAAGAAAAUAUCAUCUU 17 415
CFTR-16 - AGCAUGCCAACUAGAAG 17 391
CFTR-17 + UUCUUACCUCUUCUAGU 17 416
CFTR-20 + UUUUCUUUAAUGGUGCC 17 417
CFTR-22 + UUAAUUUUACCCUCUGA 17 418
CFTR-23 - UGAUAAUGACCUAAUAAUGA 20 419
CFTR-25 - UUUCCAGACUUCACUUCUAA 20 420
CFTR-26 - UUCACUUCUAAUGGUGAUUA 20 421
CFTR-27 - UCACUUCUAAUGGUGAUUAU 20 422
CFTR-28 - AAUGGUGAUUAUGGGAGAAC 20 423
CFTR-31 - CACUACCCAAAUUAUAUAUU 20 424
CFTR-32 - UAUUUGGCUCCAUAUUCAAU 20 425
CFTR-33 - AUAUAUUUAUGUUUCCUCUA 20 426
CFTR-34 - UAUAUUUAUGUUUCCUCUAU 20 427
CFTR-35 - UAUGGGUAAGCUACUGUGAA 20 428
CFTR-36 + UCACAGUAGCUUACCCAUAG 20 429
CFTR-38 + AUGG AGCCAAAU AU AU AAU U 20 430
CFTR-39 + UGGAGCCAAAUAUAUAAUUU 20 431
CFTR-40 + AUAUAAUUUGGGUAGUGUGA 20 432
CFTR-41 + UAUAAUUUGGGUAGUGUGAA 20 433
CFTR-42 + UCACCAU U AG AAG UG AAG UC 20 434
CFTR-43 + AAAUAAAACCCAUCAUUAUU 20 435
CFTR-45 - UAAUGACCUAAUAAUGA 17 436
CFTR-46 - AAUGACCUAAUAAUGAU 17 437
CFTR-47 - CCAGACUUCACUUCUAA 17 438
CFTR-48 - ACUUCUAAUGGUGAUUA 17 439
CFTR-49 - CUUCUAAUGGUGAUUAU 17 440
CFTR-51 - AGAACUGGAGCCUUCAG 17 441
CFTR-53 - UACCCAAAUUAUAUAUU 17 442
CFTR-54 - UUGGCUCCAUAUUCAAU 17 443
CFTR-55 - UAUUUAUGUUUCCUCUA 17 444
CFTR-56 - AUUUAUGUUUCCUCUAU 17 445
CFTR-58 + CAGUAGCUUACCCAUAG 17 446
CFTR-61 + AGCCAAAU AUAUAAUUU 17 447
CFTR-62 + UAAUUUGGGUAGUGUGA 17 448
CFTR-63 + AAUUUGGGUAGUGUGAA 17 449
CFTR-64 + CCAUUAGAAGUGAAGUC 17 450
CFTR-65 + UAAAACCCAUCAUUAUU 17 451
CFTR-66 + AUUAUCAAAUCACGCUC 17 452
151
5535.1 Table ID provides exemplary targeting domains for the F508del target position in the CFTR gene selected based on reasonable proximity to mutation. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. aureus Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. aureus Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table ID
Figure imgf000153_0001
152
5535.1 CFT -134 - UCCUCUAUGGGUAAGCUACU 20 674
CFTR-135 - CUAUGGGUAAGCUACUGUGA 20 675
CFTR-136 + GGUCAUUAUCAAAUCACGCU 20 676
CFTR-42 + UCACCAUUAGAAGUGAAGUC 20 434
CFTR-138 + AU CACC AU U AG AAG UG AAG U 20 677
CFTR-139 + UCCCAUAAUCACCAUUAGAA 20 678
CFTR-140 + AGUUCUCCCAUAAUCACCAU 20 679
CFTR-141 + ACUGUGCUUAAUUUUACCCU 20 680
CFTR-142 + CCAGGAAAACUGAGAACAGA 20 681
CFTR-143 + UAAUCCAGGAAAACUGAGAA 20 682
CFTR-144 + AGGCAUAAUCCAGGAAAACU 20 683
CFTR-145 + CCAGGCAUAAUCCAGGAAAA 20 684
CFTR-10 + AAUGGUGCCAGGCAUAAUCC 20 389
CFTR-147 + UAAUGGUGCCAGGCAUAAUC 20 685
CFTR-7 + UCUGUAUCUAUAUUCAUCAU 20 409
CFTR-149 + UUCUGUAUCUAUAUUCAUCA 20 686
CFTR-150 + UAUAUAAUUUGGGUAGUGUG 20 687
CFTR-151 + AAAUAUAUAAUUUGGGUAGU 20 688
CFTR-152 + UAUGGAGCCAAAUAUAUAAU 20 689
CFTR-37 + GUAGACUAACCGAUUGAAUA 20 398
CFTR-154 + UGUAGACUAACCGAUUGAAU 20 690
CFTR-155 + AAUAUAUGUAGACUAACCGA 20 691
CFTR-36 + UCACAGUAGCUUACCCAUAG 20 429
CFTR-157 + U UCACAG U AGCU U ACCCAU A 20 692
CFTR-158 + CAUUCACAGUAGCUUACCCA 20 693
CFTR-159 - UUGGAGGCAAGUGAAUC 17 694
CFTR-160 - AUAAUGACCUAAUAAUG 17 695
CFTR-161 - CACUUCUAAUGGUGAUU 17 696
CFTR-48 - ACUUCUAAUGGUGAUUA 17 439
CFTR-49 - CUUCUAAUGGUGAUUAU 17 440
CFTR-164 - UCUAAUGGUGAUUAUGG 17 697
CFTR-165 - UGGUGAUUAUGGGAGAA 17 698
CFTR-50 - GGUGAUUAUGGGAGAAC 17 400
CFTR-167 - GGGAGAACUGGAGCCUU 17 699
CFTR-168 - GAGAACUGGAGCCUUCA 17 700
CFTR-169 - GGGUAAAAUUAAGCACA 17 701
CFTR-12 - GGUAAAAUUAAGCACAG 17 390
CFTR-171 - AA AA U U AAG C AC AG U G G 17 702
CFTR-172 - UUCUGUUCUCAGUUUUC 17 703
CFTR-173 - UAUGCCUGGCACCAUUA 17 704
CFTR-174 - CUUUGGUGUUUCCUAUG 17 705
CFTR-175 - UAUGAUGAAUAUAGAUA 17 706
CFTR-176 - C A U C AA AG CAUGCCAAC 17 707
153
5535.1 CFT -177 - CAAAGCAUGCCAACUAG 17 708
CFTR-178 - UGCCAACUAGAAGAGGU 17 709
CFTR-179 - AAGAGGUAAGAAACUAU 17 710
CFTR-180 - ACUUUUUGAUUAUGCAU 17 711
CFTR-181 - AUAUUUAUGUUUCCUCU 17 712
CFTR-182 - UCUAUGGGUAAGCUACU 17 713
CFTR-183 - UGGGUAAGCUACUGUGA 17 714
CFTR-184 + CAUUAUCAAAUCACGCU 17 715
CFTR-64 + CCAUUAGAAGUGAAGUC 17 450
CFTR-186 + ACCAUUAGAAGUGAAGU 17 716
CFTR-187 + CAUAAUCACCAUUAGAA 17 717
CFTR-188 + UCUCCCAUAAUCACCAU 17 718
CFTR-189 + GUGCUUAAUUUUACCCU 17 719
CFTR-190 + GGAAAACUGAGAACAGA 17 720
CFTR-191 + UCCAGGAAAACUGAGAA 17 721
CFTR-192 + CAUAAUCCAGGAAAACU 17 722
CFTR-193 + GGCAUAAUCCAGGAAAA 17 723
CFTR-21 + GGUGCCAGGCAUAAUCC 17 394
CFTR-195 + UGGUGCCAGGCAUAAUC 17 724
CFTR-18 + GUAUCUAUAUUCAUCAU 17 392
CFTR-197 + UGUAUCUAUAUUCAUCA 17 725
CFTR-198 + AUAAUUUGGGUAGUGUG 17 726
CFTR-199 + UAUAUAAUUUGGGUAGU 17 727
CFTR-200 + GGAGCCAAAUAUAUAAU 17 728
CFTR-59 + GACUAACCGAUUGAAUA 17 403
CFTR-202 + AG ACU AACCG AU UGAAU 17 729
CFTR-203 + AUAUGUAGACUAACCGA 17 730
CFTR-58 + CAGUAGCUUACCCAUAG 17 446
CFTR-205 + ACAGUAGCUUACCCAUA 17 731
CFTR-206 + UCACAGUAGCUUACCCA 17 732
Table IE provides exemplary targeting domains for the F508del target position in the CFTR gene selected based on reasonable proximity to mutation. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that gives
154
5535.1 double stranded cleavage. Any of the targeting domains in the table can be used with a N.
meningitidis Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using N. meningitidis Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table IE
Figure imgf000156_0001
Table 2A provides exemplary targeting domains for the G551D target position in the
CFTR gene selected according to the first tier parameters. The targeting domains are selected based close proximity to mutation and orthogonality in the human genome. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus
155
5535.1 strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 2A
Figure imgf000157_0001
Table 2B provides exemplary targeting domains for the G551D target position in the CFTR gene selected according to the second tier parameters. The targeting domains are selected based on the presence of a 5' G and reasonable proximity to mutation. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 2B
Figure imgf000157_0002
156
5535.1 CFT -102 - GGAAUUGAAAAAAUCCU 17 467
CFTR-103 - GAAUUGAAAAAAUCCUG 17 468
CFTR-109 + GUCUUUCUCUGCAAACU 17 469
Table 2C provides exemplary targeting domains for the G551D target position in the CFTR gene selected according to the third tier parameters. The targeting domains are selected based on reasonable proximity to mutation. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 2C
Figure imgf000158_0001
157
5535.1 CFT -93 - AAAGACAAUAUAGUUCU 17 488
CFTR-94 - AAUAUAGUUCUUGGAGA 17 489
CFTR-95 - AUAGUUCUUGGAGAAGG 17 490
CFTR-98 - CAAGAAUU UCU U UAGCA 17 491
CFTR-101 - UGGAAUUGAAAAAAUCC 17 492
CFTR-104 - AAAAUCCUGGGGUUUUA 17 493
CFTR-105 - UGGGGUUUUAUGGCUAG 17 494
CFTR-107 - UUAAGAACUAUAAAUAA 17 495
CFTR-110 + CUCAAUCUGAAUUUGAA 17 496
Table 2D provides exemplary targeting domains for the G551D target position in the CFTR gene selected based on reasonable proximity to mutation. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. aureus Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. aureus Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 2D
Figure imgf000159_0001
158
5535.1 CFT -232 - AGAAGGUGGAAUCACACUGA 20 743
CFTR-74 - GAAGGUGGAAUCACACUGAG 20 461
CFTR-234 - AUCACACUGAGUGGAGGUCA 20 744
CFTR-235 - CUGAGUGGAGGUCAACGAGC 20 745
CFTR-236 - GCAAGAAUUUCUUUAGCAAG 20 746
CFTR-237 - UAUUGCUUUAUAUUCUGUUU 20 747
CFTR-78 - AUUGCUUUAUAUUCUGUUUC 20 476
CFTR-239 - UUUAUAUUCUGUUUCUGGAA 20 748
CFTR-240 - UUUCUGGAAUUGAAAAAAUC 20 749
CFTR-79 - U UCUGGAAU UG AAAAAAUCC 20 477
CFTR-242 - AUCCUGGGGUUUUAUGGCUA 20 750
CFTR-243 - GGUUUUAUGGCUAGUGGGUU 20 751
CFTR-244 - GUGGGUUAAGAAUCACAUUU 20 752
CFTR-245 + CUUUAACCACAGUUGAAAUU 20 753
CFTR-246 + CACUAUUGCUUUAACCACAG 20 754
CFTR-247 + UUAGUAUGCUCAAUCUGAAU 20 755
CFTR-248 + UCACUUUUAGUAUGCUCAAU 20 756
CFTR-249 + UUACCAAAAAUAGAAAAUUA 20 757
CFTR-250 + U AU U ACCAAAAAU AG AAAAU 20 758
CFTR-251 + AGAUGUCCUAUUACCAAAAA 20 759
CFTR-87 + AUUGUCUUUCUCUGCAAACU 20 483
CFTR-253 + UAUUGUCUUUCUCUGCAAAC 20 760
CFTR-254 + AGUGUGAUUCCACCUUCUCC 20 761
CFTR-255 + AUUAGUUAUUCACCUUGCUA 20 762
CFTR-256 + AAUGUCUGUAAUUUUUUUAC 20 763
CFTR-257 + AAACAGAAUAUAAAGCAAUA 20 764
CFTR-258 + AGAAACAGAAUAUAAAGCAA 20 765
CFTR-259 + GAUUUUUU CAAU U CC AG AAA 20 766
CFTR-260 + CCCCAGGAUUUUUUCAAUUC 20 767
CFTR-261 - GUGAUAUAUGAUUACAU 17 768
CFTR-262 - AUAUAUGAUUACAUUAG 17 769
CFTR-90 - UAUAUGAUUACAUUAGA 17 485
159
5535.1 CFT -264 - UGCCU U UCAAAU UCAGA 17 770
CFTR-265 - UUUUCUAUUUUUGGUAA 17 771
CFTR-266 - GGACAUCUCCAAGUUUG 17 772
CFTR-267 - ACAUCUCCAAGUUUGCA 17 773
CFTR-268 - GAAAGACAAUAUAGUUC 17 774
CFTR-93 - AAAGACAAUAUAGUUCU 17 488
CFTR-270 - AGACAAUAUAGUUCUUG 17 775
CFTR-271 - UAUAGUUCUUGGAGAAG 17 776
CFTR-95 - AUAGUUCUUGGAGAAGG 17 490
CFTR-273 - GAGAAGGUGGAAUCACA 17 777
CFTR-274 - AGGUGGAAUCACACUGA 17 778
CFTR-96 - GGUGGAAUCACACUGAG 17 456
CFTR-276 - ACACUGAGUGGAGGUCA 17 779
CFTR-277 - AGUGGAGGUCAACGAGC 17 780
CFTR-278 - AGAAUUUCUUUAGCAAG 17 781
CFTR-279 - UGCUUUAUAUUCUGUUU 17 782
CFTR-100 - GCUUUAUAUUCUGUUUC 17 466
CFTR-281 - AUAUUCUGUUUCUGGAA 17 783
CFTR-282 - CUGGAAUUGAAAAAAUC 17 784
CFTR-101 - UGGAAUUGAAAAAAUCC 17 492
CFTR-284 - CUGGGGUUUUAUGGCUA 17 785
CFTR-285 - UUUAUGGCUAGUGGGUU 17 786
CFTR-286 - GGUUAAGAAUCACAUUU 17 787
CFTR-287 + U AACC AC AG U U G A AA U U 17 788
CFTR-288 + U AU UGCU U U AACCACAG 17 789
CFTR-289 + GUAUGCUCAAUCUGAAU 17 790
CFTR-290 + CUUUUAGUAUGCUCAAU 17 791
CFTR-291 + CCAAAAAUAGAAAAUUA 17 792
CFTR-292 + UACCAAAAAUAGAAAAU 17 793
CFTR-293 + UGUCCUAUUACCAAAAA 17 794
CFTR-109 + GUCUUUCUCUGCAAACU 17 469
CFTR-295 + UGUCUUUCUCUGCAAAC 17 795
CFTR-296 + GUGAUUCCACCUUCUCC 17 796
CFTR-297 + AGUUAUUCACCUUGCUA 17 797
CFTR-298 + GUCUGUAAUUUUUUUAC 17 798
CFTR-299 + CAGAAUAUAAAGCAAUA 17 799
CFTR-300 + AACAGAAUAUAAAGCAA 17 800
CFTR-301 + U U U U U CAAU UCC AG AAA 17 801
CFTR-302 + CAGGAUUUUUUCAAUUC 17 802
160
5535.1 Table 2E provides exemplary targeting domains for the G551D target position in the CFTR gene selected based on reasonable proximity to mutation. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a N.
meningitidis Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using N. meningitidis Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 2E
Figure imgf000162_0001
Table 3A provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the first tier parameters. The targeting domains are selected based close proximity to start codon and orthogonality in the human genome. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S.
pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising
161
5535.1 any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp. In an embodiment, two 20-mer RNAs are used to target two Cas9 nucleases or two Cas9 nickases, e.g., SCNNlA-78 and SCNNlA-9 are used.
Table 3A
Figure imgf000163_0001
Table 3B provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the second tier parameters. The targeting domains are selected based on the presence of a 5' G and reasonable proximity to start codon. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S.
pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp. In an embodiment, two 20-mer RNAs are used to target two Cas9 nucleases or two Cas9 nickases, e.g., SCNNlA-78 and SCNNlA-9 are used.
Table 3B
Figure imgf000163_0002
162
5535.1 SCNNlA-7 - GGGGAACAAGCUGGAGGAGC 20 504
SCNNlA-10 - GUCCACUCCAGGGCUCAUGA 20 505
SCNNlA-14 - GGGGAACAAGCGUGAGGAGC 20 506
SCNNlA-15 - GGGAACAAGCGUGAGGAGCA 20 507
SCNNlA-16 - GGAACAAGCGUGAGGAGCAG 20 508
SCNNlA-19 - GGGGCUGGGCCCCGAACCUG 20 509
SCNNlA-21 - GGCGCCCCAGCAGCCCACGG 20 510
SCNNlA-22 - GCCCCAGCAGCCCACGGCGG 20 511
SCNNlA-24 - GCAGCCCACGGCGGAGGAGG 20 512
SCNNlA-31 - GUGCUGUGGCUCUGCACCUU 20 513
SCNNlA-32 - GCACCUUUGGCAUGAUGUAC 20 514
SCNNlA-33 - GGCAUGAUGUACUGGCAAUU 20 515
SCNNlA-36 + GUAGGGAUUGAGGGUGCAGA 20 516
SCNNlA-37 + GAGGGUGCAGAUGGUCACUG 20 517
SCNNlA-39 + GGGUGCAGAUGGUCACUGCG 20 518
SCNNlA-42 + GAGGUUGAUGUUGAGGCUGA 20 519
SCNNlA-44 + GGUUGAUGUUGAGGCUGACG 20 520
SCNNlA-47 + GAGCCACAGCACUGCCCAGA 20 521
SCNNlA-51 + GGUUGUGCUGGGAGCACACC 20 522
SCNNlA-56 + GCGGAUGGCGCCGUGGAUGG 20 523
SCNNlA-58 + GAACUCGAAGAGCUCUCGGU 20 524
SCNNlA-62 + GGAGCGGUGGAACUCGAUCA 20 525
SCNNlA-68 + GUGGGCUGCUGGGGCGCCGC 20 526
SCNNlA-71 + GCUGGGGCGCCGCAGGUUCG 20 527
SCNNlA-76 + GCCCUGGAGUGGACUGUGGA 20 528
SCNNlA-80 - GCCCAUACCAGGUCUCA 17 529
SCNNlA-85 - GGAGGGGAACAAGCUGG 17 530
SCNNlA-86 - GAACAAGCUGGAGGAGC 17 531
SCNNlA-92 - GAAGGGGAACAAGCGUG 17 532
SCNNlA-93 - GAACAAGCGUGAGGAGC 17 533
SCNNlA-96 - GCGUGAGGAGCAGGGGC 17 534
SCNNlA-98 - GCUGGGCCCCGAACCUG 17 535
SCNNlA-99 - GGCGCCCCAGCAGCCCA 17 536
SCNNlA-100 - GCCCCAGCAGCCCACGG 17 537
SCNNlA-102 - GCAGCCCACGGCGGAGG 17 538
SCNNlA-103 - GCCCACGGCGGAGGAGG 17 539
SCNNlA-106 - GCACAACCGCAUGAAGA 17 540
SCNNlA-107 - GCAUGAAGACGGCCUUC 17 541
SCNNlA-115 + GGGAUUGAGGGUGCAGA 17 542
SCNNlA-116 + GGUGCAGAUGGUCACUG 17 543
SCNNlA-117 + GUGCAGAUGGUCACUGC 17 544
SCNNlA-121 + GUUGAUGUUGAGGCUGA 17 545
SCNNlA-131 + GCUGGGAGCACACCAGG 17 546
163
5535.1 SCNNlA-132 + GGAGCACACCAGGCGGA 17 547
SCNNlA-134 + GCGGAUGGCGCCGUGGA 17 548
SCNNlA-135 + GAUGGCGCCGUGGAUGG 17 549
SCNNlA-139 + GCUCUCGGUAGGAGCGG 17 550
SCNNlA-141 + GCGGUGGAACUCGAUCA 17 551
SCNNlA-142 + GGCCUCCUCCUCCGCCG 17 552
SCNNlA-143 + GCCUCCUCCUCCGCCGU 17 553
SCNNlA-147 + GGCUGCUGGGGCGCCGC 17 554
SCNNlA-150 + GGGGCGCCGCAGGUUCG 17 555
Table 3C provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the third tier parameters. The targeting domains are selected based on reasonable proximity to start codon. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp. In an embodiment, two 20-mer RNAs are used to target two Cas9 nucleases or two Cas9 nickases, e.g., SCNNlA-78 and SCNNlA-9 are used. Table 3C
Figure imgf000165_0001
164
5535.1 SCNNlA-23 - CCAGCAGCCCACGGCGGAGG 20 566
SCNNlA-25 - UGCAACAACACCACCAUCCA 20 567
SCNNlA-26 - CAUCCACGGCGCCAUCCGCC 20 568
SCNNlA-27 - CCAGCACAACCGCAUGAAGA 20 569
SCNNlA-28 - ACCGCAUGAAGACGGCCUUC 20 570
SCNNlA-29 - CCGCAUGAAGACGGCCUUCU 20 571
SCNNlA-30 - CGGCCUUCUGGGCAGUGCUG 20 572
SCNNlA-34 - UGGCAAUUCGGCCUGCUUUU 20 573
SCNNlA-35 - CCUCAACAUCAACCUCAACU 20 574
SCNNlA-38 + AGGGUGCAGAUGGUCACUGC 20 575
SCNNlA-40 + AGACGAGCUUGUCCGAGUUG 20 576
SCNNlA-41 + CCGAGUUGAGGUUGAUGUUG 20 577
SCNNlA-43 + AGGUUGAUGUUGAGGCUGAC 20 578
SCNNlA-45 + UGAAGUACUCUCCGAAAAGC 20 579
SCNNlA-46 + UUGCCAGUACAUCAUGCCAA 20 580
SCNNlA-48 + CCCAGAAGGCCGUCUUCAUG 20 581
SCNNlA-49 + CCGUCUUCAUGCGGUUGUGC 20 582
SCNNlA-50 + CGUCUUCAUGCGGUUGUGCU 20 583
SCNNlA-52 + UGUGCUGGGAGCACACCAGG 20 584
SCNNlA-53 + CUGGGAGCACACCAGGCGGA 20 585
SCNNlA-54 + ACACCAGGCGGAUGGCGCCG 20 586
SCNNlA-55 + CAGGCGGAUGGCGCCGUGGA 20 587
SCNNlA-57 + AGAAGAACUCGAAGAGCUCU 20 588
SCNNlA-59 + CGAAGAGCUCUCGGUAGGAG 20 589
SCNNlA-60 + AGAGCUCUCGGUAGGAGCGG 20 590
SCNNlA-61 + AGGAGCGGUGGAACUCGAUC 20 591
SCNNlA-63 + CAGGGCCUCCUCCUCCGCCG 20 592
SCNNlA-64 + AGGGCCUCCUCCUCCGCCGU 20 593
SCNNlA-65 + CCUCCUCCGCCGUGGGCUGC 20 594
SCNNlA-66 + CUCCUCCGCCGUGGGCUGCU 20 595
SCNNlA-67 + UCCUCCGCCGUGGGCUGCUG 20 596
SCNNlA-69 + CUGCUGGGGCGCCGCAGGUU 20 597
SCNNlA-70 + UGCUGGGGCGCCGCAGGUUC 20 598
SCNNlA-72 + UUGUUCCCCUUCAUGAGCCC 20 599
SCNNlA-73 + CCCCUUCAUGAGCCCUGGAG 20 600
SCNNlA-74 + AUGAGCCCUGGAGUGGACUG 20 601
SCNNlA-75 + AGCCCUGGAGUGGACUGUGG 20 602
SCNNlA-77 + UUGUUCCCCUCCAUGAGACC 20 603
SCNNlA-79 + CCCUCCAUGAGACCUGGUAU 20 604
SCNNlA-81 - CAUACCAGGUCUCAUGG 17 605
SCNNlA-83 - UACCAGGUCUCAUGGAG 17 606
SCNNlA-84 - CAUGGAGGGGAACAAGC 17 607
165
5535.1 SCNNlA-87 - CCUCCACAGUCCACUCC 17 608
SCNNlA-88 - CUCCACAGUCCACUCCA 17 609
SCNNlA-89 - CACUCCAGGGCUCAUGA 17 610
SCNNlA-90 - ACUCCAGGGCUCAUGAA 17 611
SCNNlA-91 - CUCCAGGGCUCAUGAAG 17 612
SCNNlA-94 - AACAAGCGUGAGGAGCA 17 613
SCNNlA-95 - ACAAGCGUGAGGAGCAG 17 614
SCNNlA-97 - CGUGAGGAGCAGGGGCU 17 615
SCNNlA-101 - CCAGCAGCCCACGGCGG 17 616
SCNNlA-104 - AACAAC ACCACC AU CC A 17 617
SCNNlA-105 - CCACGGCGCCAUCCGCC 17 618
SCNNlA-108 - CAUGAAGACGGCCUUCU 17 619
SCNNlA-109 - CCUUCUGGGCAGUGCUG 17 620
SCNNlA-110 - CUGUGGCUCUGCACCUU 17 621
SCNNlA-111 - CCUUUGGCAUGAUGUAC 17 622
SCNNlA-112 - AUGAUGUACUGGCAAUU 17 623
SCNNlA-113 - CAAUUCGGCCUGCUUUU 17 624
SCNNlA-114 - CAAC AU CAACCU CAAC U 17 625
SCNNlA-118 + UGCAGAUGGUCACUGCG 17 626
SCNNlA-119 + CGAGCUUGUCCGAGUUG 17 627
SCNNlA-120 + AGUUGAGGUUGAUGUUG 17 628
SCNNlA-122 + UUGAUGUUGAGGCUGAC 17 629
SCNNlA-123 + UGAUGUUGAGGCUGACG 17 630
SCNNlA-124 + AGUACUCUCCGAAAAGC 17 631
SCNNlA-125 + CCAGUACAUCAUGCCAA 17 632
SCNNlA-126 + CCACAGCACUGCCCAGA 17 633
SCNNlA-127 + AGAAGGCCGUCUUCAUG 17 634
SCNNlA-128 + UCUUCAUGCGGUUGUGC 17 635
SCNNlA-129 + CUUCAUGCGGUUGUGCU 17 636
SCNNlA-130 + UGUGCUGGGAGCACACC 17 637
SCNNlA-133 + CCAGGCGGAUGGCGCCG 17 638
SCNNlA-136 + AGAACUCGAAGAGCUCU 17 639
166
5535.1 SCNNlA-137 + CUCGAAGAGCUCUCGGU 17 640
SCNNlA-138 + AGAGCUCUCGGUAGGAG 17 641
SCNNlA-140 + AGCGGUGGAACUCGAUC 17 642
SCNNlA-144 + CCUCCGCCGUGGGCUGC 17 643
SCNNlA-145 + CUCCGCCGUGGGCUGCU 17 644
SCNNlA-146 + UCCGCCGUGGGCUGCUG 17 645
SCNNlA-148 + CUGGGGCGCCGCAGGUU 17 646
SCNNlA-149 + UGGGGCGCCGCAGGUUC 17 647
SCNNlA-151 + UUCCCCUUCAUGAGCCC 17 648
SCNNlA-152 + CUUCAUGAGCCCUGGAG 17 649
SCNNlA-153 + AGCCCUGGAGUGGACUG 17 650
SCNNlA-154 + CCUGGAGUGGACUGUGG 17 651
SCNNlA-155 + CUGGAGUGGACUGUGGA 17 652
SCNNlA-156 + UUCCCCUCCAUGAGACC 17 653
SCNNlA-158 + UCCAUGAGACCUGGUAU 17 654
Table 3D provides exemplary targeting domains for knocking out the SCNN1A gene selected based on reasonable proximity to the start codon. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. aureus Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. aureus Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 3D
Figure imgf000168_0001
167
5535.1 SCNNlA-165 - GUCUCAUGGAGGGGAACAAG 20 805
SCNNlA-5 - UCUCAUGGAGGGGAACAAGC 20 557
SCNNlA-167 - UCAUGGAGGGGAACAAGCUG 20 806
SCNNlA-6 - CAUGGAGGGGAACAAGCUGG 20 558
SCNNlA-169 - AGGGGAACAAGCUGGAGGAG 20 807
SCNNlA-170 - UAGCCCUCCACAGUCCACUC 20 808
SCNNlA-171 - CACAGUCCACUCCAGGGCUC 20 809
SCNNlA-172 - AGUCCACUCCAGGGCUCAUG 20 810
SCNNlA-10 - GUCCACUCCAGGGCUCAUGA 20 505
SCNNlA-11 - UCCACUCCAGGGCUCAUGAA 20 560
SCNNlA-12 - CCACUCCAGGGCUCAUGAAG 20 561
SCNNlA-176 - GCUCAUGAAGGGGAACAAGC 20 811
SCNNlA-177 - UCAUGAAGGGGAACAAGCGU 20 812
SCNNlA-13 - CAUGAAGGGGAACAAGCGUG 20 562
SCNNlA-179 - AGGGGAACAAGCGUGAGGAG 20 813
SCNNlA-14 - GGGGAACAAGCGUGAGGAGC 20 506
SCNNlA-181 - ACAAGCGUGAGGAGCAGGGG 20 814
SCNNlA-182 - UGAGGAGCAGGGGCUGGGCC 20 815
SCNNlA-183 - CGGCGCCCCAGCAGCCCACG 20 816
SCNNlA-21 - GGCGCCCCAGCAGCCCACGG 20 510
SCNNlA-185 - CGCCCCAGCAGCCCACGGCG 20 817
SCNNlA-22 - GCCCCAGCAGCCCACGGCGG 20 511
SCNNlA-187 - CCCAGCAGCCCACGGCGGAG 20 818
SCNNlA-23 - CCAGCAGCCCACGGCGGAGG 20 566
SCNNlA-189 - GGCGGAGGAGGAGGCCCUGA 20 819
SCNNlA-190 - AUCGAGUUCCACCGCUCCUA 20 820
SCNNlA-191 - CGAGUUCCACCGCUCCUACC 20 821
SCNNlA-192 - CCGCUCCUACCGAGAGCUCU 20 822
SCNNlA-193 - UGUGCUCCCAGCACAACCGC 20 823
SCNNlA-194 - AACCGCAUGAAGACGGCCUU 20 824
SCNNlA-195 - CUGGCAAUUCGGCCUGCUUU 20 825
SCNNlA-34 - UGGCAAUUCGGCCUGCUUUU 20 573
SCNNlA-197 - GCAAUUCGGCCUGCUUUUCG 20 826
SCNNlA-198 - GCCUCAACAUCAACCUCAAC 20 827
SCNNlA-199 + UCCCCUCCAUGAGACCUGGU 20 828
SCNNlA-200 + CCUCCAGCUUGUUCCCCUCC 20 829
SCNNlA-201 + UGGAGUGGACUGUGGAGGGC 20 830
SCNNlA-202 + GAGCCCUGGAGUGGACUGUG 20 831
SCNNlA-74 + AUGAGCCCUGGAGUGGACUG 20 601
SCNNlA-204 + CAUGAGCCCUGGAGUGGACU 20 832
SCNNlA-205 + UCCCCUUCAUGAGCCCUGGA 20 833
SCNNlA-72 + UUGUUCCCCUUCAUGAGCCC 20 599
SCNNlA-207 + CUUGUUCCCCUUCAUGAGCC 20 834
168
5535.1 SCNNlA-208 + CCUCACGCUUGUUCCCCUUC 20 835
SCNNlA-69 + CUGCUGGGGCGCCGCAGGUU 20 597
SCNNlA-210 + GCUGCUGGGGCGCCGCAGGU 20 836
SCNNlA-65 + CCUCCUCCGCCGUGGGCUGC 20 594
SCNNlA-212 + UCCUCCUCCGCCGUGGGCUG 20 837
SCNNlA-213 + UCAGGGCCUCCUCCUCCGCC 20 838
SCNNlA-214 + UAGGAGCGGUGGAACUCGAU 20 839
SCNNlA-60 + AGAGCUCUCGGUAGGAGCGG 20 590
SCNNlA-216 + AAGAGCUCUCGGUAGGAGCG 20 840
SCNNlA-58 + GAACUCGAAGAGCUCUCGGU 20 524
SCNNlA-218 + AGAACUCGAAGAGCUCUCGG 20 841
SCNNlA-219 + U G U U G U U GC AG AAG AAC UCG 20 842
SCNNlA-220 + UGGUGUUGUUGCAGAAGAAC 20 843
SCNNlA-221 + GGAUGGUGGUGUUGUUGCAG 20 844
SCNNlA-222 + CGUGGAUGGUGGUGUUGUUG 20 845
SCNNlA-223 + CACACCAGGCGGAUGGCGCC 20 846
SCNNlA-224 + UUGUGCUGGGAGCACACCAG 20 847
SCNNlA-50 + CGUCUUCAUGCGGUUGUGCU 20 583
SCNNlA-49 + CCGUCUUCAUGCGGUUGUGC 20 582
SCNNlA-227 + GCCGUCUUCAUGCGGUUGUG 20 848
SCNNlA-228 + UGCAGAGCCACAGCACUGCC 20 849
SCNNlA-229 + AGUACAUCAUGCCAAAGGUG 20 850
SCNNlA-230 + AGUACUCUCCGAAAAGCAGG 20 851
SCNNlA-231 + CGGGGUAGCUGAAGUACUCU 20 852
SCNNlA-232 + UGUUGAGGCUGACGGGGUAG 20 853
SCNNlA-42 + GAGGUUGAUGUUGAGGCUGA 20 519
SCNNlA-234 + UGAGGUUGAUGUUGAGGCUG 20 854
SCNNlA-235 + UGUCCGAGUUGAGGUUGAUG 20 855
SCNNlA-236 + GGAAGACGAGCUUGUCCGAG 20 856
SCNNlA-237 + UGCGGGGAAGACGAGCUUGU 20 857
SCNNlA-238 + AGAUGGUCACUGCGGGGAAG 20 858
SCNNlA-39 + GGGUGCAGAUGGUCACUGCG 20 518
SCNNlA-38 + AGGGUGCAGAUGGUCACUGC 20 575
169
5535.1 SCNNlA-37 + GAGGGUGCAGAUGGUCACUG 20 517
SCNNlA-242 + UGAGGGUGCAGAUGGUCACU 20 859
SCNNlA-243 - AGCCCAUACCAGGUCUC 17 860
SCNNlA-80 - GCCCAUACCAGGUCUCA 17 529
SCNNlA-245 - CCAUACCAGGUCUCAUG 17 861
SCNNlA-81 - CAUACCAGGUCUCAUGG 17 605
SCNNlA-82 - AUACCAGGUCUCAUGGA 17 501
SCNNlA-83 - UACCAGGUCUCAUGGAG 17 606
SCNNlA-249 - UCAUGGAGGGGAACAAG 17 862
SCNNlA-84 - CAUGGAGGGGAACAAGC 17 607
SCNNlA-251 - UGGAGGGGAACAAGCUG 17 863
SCNNlA-85 - GGAGGGGAACAAGCUGG 17 530
SCNNlA-253 - GGAACAAGCUGGAGGAG 17 864
SCNNlA-254 - CCCUCCACAGUCCACUC 17 865
SCNNlA-255 - AGUCCACUCCAGGGCUC 17 866
SCNNlA-256 - CCACUCCAGGGCUCAUG 17 867
SCNNlA-89 - CACUCCAGGGCUCAUGA 17 610
SCNNlA-90 - ACUCCAGGGCUCAUGAA 17 611
SCNNlA-91 - CUCCAGGGCUCAUGAAG 17 612
SCNNlA-260 - CAUGAAGGGGAACAAGC 17 868
SCNNlA-261 - UGAAGGGGAACAAGCGU 17 869
SCNNlA-92 - GAAGGGGAACAAGCGUG 17 532
SCNNlA-263 - GGAACAAGCGUGAGGAG 17 870
SCNNlA-93 - GAACAAGCGUGAGGAGC 17 533
SCNNlA-265 - AGCGUGAGGAGCAGGGG 17 871
SCNNlA-266 - GGAGCAGGGGCUGGGCC 17 872
SCNNlA-267 - CGCCCCAGCAGCCCACG 17 873
SCNNlA-100 - GCCCCAGCAGCCCACGG 17 537
SCNNlA-269 - CCCAGCAGCCCACGGCG 17 874
SCNNlA-101 - CCAGCAGCCCACGGCGG 17 616
SCNNlA-271 - AGCAGCCCACGGCGGAG 17 875
SCNNlA-102 - GCAGCCCACGGCGGAGG 17 538
170
5535.1 SCNNlA-273 - GGAGGAGGAGGCCCUGA 17 876
SCNNlA-274 - GAGUUCCACCGCUCCUA 17 877
SCNNlA-275 - GUUCCACCGCUCCUACC 17 878
SCNNlA-276 - CUCCUACCGAGAGCUCU 17 879
SCNNlA-277 - GCUCCCAGCACAACCGC 17 880
SCNNlA-278 - CGCAUGAAGACGGCCUU 17 881
SCNNlA-279 - GCAAUUCGGCCUGCUUU 17 882
SCNNlA-113 - CAAUUCGGCCUGCUUUU 17 624
SCNNlA-281 - AUUCGGCCUGCUUUUCG 17 883
SCNNlA-282 - U CAAC AU CAACCU CAAC 17 884
SCNNlA-283 + CCUCCAUGAGACCUGGU 17 885
SCNNlA-284 + CCAGCUUGUUCCCCUCC 17 886
SCNNlA-285 + AGUGGACUGUGGAGGGC 17 887
SCNNlA-286 + CCCUGGAGUGGACUGUG 17 888
SCNNlA-153 + AGCCCUGGAGUGGACUG 17 650
SCNNlA-288 + GAGCCCUGGAGUGGACU 17 889
SCNNlA-289 + CCUUCAUGAGCCCUGGA 17 890
SCNNlA-151 + UUCCCCUUCAUGAGCCC 17 648
SCNNlA-291 + GUUCCCCUUCAUGAGCC 17 891
SCNNlA-292 + CACGCUUGUUCCCCUUC 17 892
SCNNlA-148 + CUGGGGCGCCGCAGGUU 17 646
SCNNlA-294 + GCUGGGGCGCCGCAGGU 17 893
SCNNlA-144 + CCUCCGCCGUGGGCUGC 17 643
SCNNlA-296 + UCCUCCGCCGUGGGCUG 17 894
SCNNlA-297 + GGGCCUCCUCCUCCGCC 17 895
SCNNlA-298 + GAGCGGUGGAACUCGAU 17 896
SCNNlA-139 + GCUCUCGGUAGGAGCGG 17 550
SCNNlA-300 + AGCUCUCGGUAGGAGCG 17 897
SCNNlA-137 + CUCGAAGAGCUCUCGGU 17 640
SCNNlA-302 + ACUCGAAGAGCUCUCGG 17 898
SCNNlA-303 + UGUUGCAGAAGAACUCG 17 899
SCNNlA-304 + U G U U G U U GC AG AAG AAC 17 900
171
5535.1 SCNNlA-305 + UGGUGGUGUUGUUGCAG 17 901
SCNNlA-306 + GGAUGGUGGUGUUGUUG 17 902
SCNNlA-307 + ACCAGGCGGAUGGCGCC 17 903
SCNNlA-308 + U G C U G G G AG C AC ACC AG 17 904
SCNNlA-129 + CUUCAUGCGGUUGUGCU 17 636
SCNNlA-128 + UCUUCAUGCGGUUGUGC 17 635
SCNNlA-311 + GUCUUCAUGCGGUUGUG 17 905
SCNNlA-312 + AGAGCCACAGCACUGCC 17 906
SCNNlA-313 + ACAUCAUGCCAAAGGUG 17 907
SCNNlA-314 + ACUCUCCGAAAAGCAGG 17 908
SCNNlA-315 + GGUAGCUGAAGUACUCU 17 909
SCNNlA-316 + UGAGGCUGACGGGGUAG 17 910
SCNNlA-121 + GUUGAUGUUGAGGCUGA 17 545
SCNNlA-318 + GGUUGAUGUUGAGGCUG 17 911
SCNNlA-319 + CCGAGUUGAGGUUGAUG 17 912
SCNNlA-320 + AGACGAGCUUGUCCGAG 17 913
SCNNlA-321 + GGGGAAGACGAGCUUGU 17 914
SCNNlA-322 + UGGUCACUGCGGGGAAG 17 915
SCNNlA-118 + UGCAGAUGGUCACUGCG 17 626
SCNNlA-117 + GUGCAGAUGGUCACUGC 17 544
SCNNlA-116 + GGUGCAGAUGGUCACUG 17 543
SCNNlA-326 + GGGUGCAGAUGGUCACU 17 916
Table 4A provides exemplary targeting domains for correcting a mutation (e.g., 2789+5G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 4A
Figure imgf000173_0001
172
5535.1 CFTR-2789-3 - GAAUUUAGAUGUGGGCA 17 939
CFTR-2789-4 - GUGUCUUGU UCCAUUCC 17 940
CFTR-2789-5 - GUGGGCAUGGGAGGAAU 17 941
CFTR-2789-6 - GUUGUGCUG UGGCUCCU 17 942
CFTR-2789-7 - GAUGUGAAUUUAGAUGU 17 943
CFTR-2789-8 - GACCCAGGAACACAAAGCAA 20 944
CFTR-2789-9 + GUGUCACCUCACCCAACUAA 20 945
CFTR-2789-10 - GUGUCUUGU UCCAUUCCAGG 20 946
CFTR-2789-11 - GAUGUGGGCAUGGGAGGAAU 20 947
CFTR-2789-12 - GUGAAU UUAGAUGUGGGCAU 20 948
Table 4B provides exemplary targeting domains for correcting a mutation (e.g., 2789+5G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 4B
Figure imgf000174_0001
173
5535.1 CFTR-2789-30 - CCAGGUGGCUGCUUCU U 17 966
CFTR-2789-31 - AU AU UGG U ACACACAU CAAA 20 967
CFTR-2789-32 + A A AG AAGCAGCCACCUGGAA 20 968
CFTR-2789-33 + ACAAUCUACACAAUAGGACA 20 969
CFTR-2789-34 - UGUGAAUUUAGAUGUGGGCA 20 970
CFTR-2789-35 + UGAUGUGUGUACCAAUAUCA 20 971
CFTR-2789-36 - AUUAUGGUAGUGGAAAGAUA 20 972
CFTR-2789-37 - UUCAUUUCUCCCAAGCAUUA 20 973
CFTR-2789-38 + CAACCAAAGAAGCAGCCACC 20 974
CFTR-2789-39 - ACUGUGUCU UGUUCCAUUCC 20 975
CFTR-2789-40 + CUUCCU UUGCU UUGUGUUCC 20 976
CFTR-2789-41 + UACAAUACAUACAAACAUAG 20 977
CFTR-2789-42 - UCUCCCAAGCAUUAUGGUAG 20 978
CFTR-2789-43 - AAUUUAGAUGUGGGCAUGGG 20 979
CFTR-2789-44 - CUGCUUCUUUGGU UGUGCUG 20 980
CFTR-2789-45 - UGAUGACCAUUAGUUGGGUG 20 981
CFTR-2789-46 - AAUUGUGUGUACCUUGAUAU 20 982
CFTR-2789-47 - UUGGUUGUGCUGUGGCUCCU 20 983
CFTR-2789-48 + CUUUCCACUACCAUAAUGCU 20 984
CFTR-2789-49 - UUUAAAUGAUGACCAUUAGU 20 985
CFTR-2789-50 - UGUGAUGUGAAUUUAGAUGU 20 986
CFTR-2789-51 + UUUCCACUACCAUAAUGCUU 20 987
CFTR-2789-52 - AUUCCAGGUGGCUGCU UCUU 20 988
CFTR-2789-53 - UUAAAUGAUGACCAUUAGUU 20 989
Table 4C provides exemplary targeting domains for correcting a mutation (e.g., 2789+5G) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 4C
Figure imgf000175_0001
174
5535.1 Table 4D provides exemplary targeting domains for correcting a mutation (e.g., 2789+5G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase). Table 4D
Figure imgf000176_0001
Table 5A provides exemplary targeting domains for correcting a mutation (e.g.,
2789+5G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 5A
Figure imgf000176_0002
175
5535.1 Length
CFTR-2789-71 + G AU U ACAAU ACAU ACAAACAU A 22 1007
CFTR-2789-72 + GGAUUACAAUACAUACAAACAUA 23 1008
CFTR-2789-73 - GCUGUGGCUCCUUGGAAA 18 1009
CFTR-2789-74 - GUGCUGUGGCUCCUUGGAAA 20 1010
CFTR-2789-75 - GUUGUGCUGUGGCUCCUUGGAAA 23 1011
CFTR-2789-76 - GGUUGUGCUGUGGCUCCUUGGAAA 24
1012
CFTR-2789-77 - GUUUAAAUGAUGACCAUUAG 20 1013
CFTR-2789-78 - GUACACACAUCAAAUGGUGUGAU 23 1014
CFTR-2789-79 - GGUACACACAUCAAAUGGUGUGAU 24 1015
Table 5B provides exemplary targeting domains for correcting a mutation (e.g., 2789+5G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 5B
Figure imgf000177_0001
176
5535.1 CFTR-2789-95 - UUGUGCUGUGGCUCCUUGGAAA 22 1031
CFTR-2789-96 - UUAAAUGAUGACCAUUAG 18 1032
CFTR-2789-97 - UUUAAAUGAUGACCAUUAG 19 1033
CFTR-2789-98 - UGUUUAAAUGAUGACCAUUAG 21 1034
CFTR-2789-99 - UUGUUUAAAUGAUGACCAUUAG 22 1035
CFTR-2789-
- UUUGUUUAAAUGAUGACCAUUAG 23
100 1036
CFTR-2789-
- UUUUGUUUAAAUGAUGACCAUUAG 24
101 1037
CFTR-2789-
- UUUAGAUGUGGGCAUGGG 18
102 1038
CFTR-2789-
- AUUUAGAUGUGGGCAUGGG 19
103 1039
CFTR-2789-43 - AAUUUAGAUGUGGGCAUGGG 20 979
CFTR-2789-
- CACAUCAAAUGGUGUGAU 18
104 1040
CFTR-2789-
- ACACAUCAAAUGGUGUGAU 19
105 1041
CFTR-2789-
- CACACAUCAAAUGGUGUGAU 20
106 1042
CFTR-2789-
- ACA CACAUCAAAUGGUGUGAU 21
107 1043
CFTR-2789-
- UACACACAUCAAAUGGUGUGAU 22
108 1044
Table 5C provides exemplary targeting domains for correcting a mutation (e.g., 2789+5G) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G), starts with a 5'G and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 5C
Figure imgf000178_0001
177
5535.1 110
CFTR-2789-
+ GCACAACCAAAGAAGCAGCCACC 23
111 1047
CFTR-2789-
- GAAUUUAGAUGUGGGCAUGGG 21
112 1048
CFTR-2789-
- GUGAAUUUAGAUGUGGGCAUGGG 23
113 1049
Table 5D provides exemplary targeting domains for correcting a mutation (e.g., 2789+5G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G), and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 5D
Figure imgf000179_0001
178
5535.1 CFTR-2789-
+ UGGAGGAGCUAGGACUAC 18
123 1059
CFTR-2789-
+ UGUGGAGGAGCUAGGACUAC 20
67 1003
CFTR-2789-
+ ACAACCAAAG AAG CAGCCACC 21
124 1060
CFTR-2789-
+ CACAACCAAAG AAG CAGCCACC 22
125 1061
CFTR-2789-
+ AGCACAACCAAAGAAGCAGCCACC 24
126 1062
CFTR-2789-
+ AUCUUCCUUUGCUUUGUGUUC 21
127 1063
CFTR-2789-
+ CAUCUUCCUUUGCUUUGUGUUC 22
128 1064
CFTR-2789-
+ UCAUCUUCCUUUGCUUUGUGUUC 23
129 1065
CFTR-2789-
+ UUCAUCUUCCUUUGCUUUGUGUUC 24
130 1066
CFTR-2789-
- UGAAUUUAGAUGUGGGCAUGGG 22
131 1067
CFTR-2789-
- UGUGAAUUUAGAUGUGGGCAUGGG 24
132 1068
Table 5E provides exemplary targeting domains for correcting a mutation (e.g.,
2789+5G) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G), and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 5E
Figure imgf000180_0001
179
5535.1 135
CFTR-2789-
+ AAUAAAACACAAUCUACACAA 21
136 1072
CFTR-2789-
+ AAAUAAAACACAAUCUACACAA 22
137 1073
CFTR-2789-
+ GAAAUAAAACACAAUCUACACAA 23
138 1074
CFTR-2789-
+ AGAAAUAAAACACAAUCUACACAA 24
139 1075
CFTR-2789-
+ AU U ACAAU AU U U AAU CAA 18
140 1076
CFTR-2789-
+ G AU U ACAAU AU U U AAU CAA 19
141 1077
CFTR-2789-
+ GGAUUACAAUAUUUAAUCAA 20
142 1078
CFTR-2789-
+ UGGAUUACAAUAUUUAAUCAA 21
143 1079
CFTR-2789-
+ GUGGAUUACAAUAUUUAAUCAA 22
144 1080
CFTR-2789-
+ AG UGG AU U ACAAU AU U U AAU CAA 23
145 1081
CFTR-2789-
+ UAGUGGAUUACAAUAUUUAAUCAA 24
146 1082
CFTR-2789-
+ CCAUAAUGCUUGGGAGAA 18
147 1083
CFTR-2789-
+ ACCAUAAUGCUUGGGAGAA 19
148 1084
CFTR-2789-
+ UACCAUAAUGCUUGGGAGAA 20
149 1085
CFTR-2789-
+ CUACCAUAAUGCUUGGGAGAA 21
150 1086
CFTR-2789-
+ ACUACCAUAAUGCUUGGGAGAA 22
151 1087
CFTR-2789-
+ CACU ACCAUAAUGCUUGGGAGAA 23
152 1088
CFTR-2789-
+ CCACUACCAUAAUGCUUGGGAGAA 24
153 1089
CFTR-2789-
+ AGAAGCAGCCACCUGGAA 18
154 1090
CFTR-2789-
+ AAGAAGCAGCCACCUGGAA 19
155 1091
CFTR-2789-
+ A A AG AAGCAGCCACCUGGAA 20
32 968
180
5535.1 CFTR-2789-
+ CAA AG AAG CAG CC ACC U G G AA 21
156 1092
CFTR-2789-
+ CCAAAGAAGCAGCCACCUGGAA 22
157 1093
CFTR-2789-
+ ACCAAAGAAGCAGCCACCUGGAA 23
158 1094
CFTR-2789-
+ AACCAAAGAAGCAGCCACCUGGAA 24
159 1095
CFTR-2789-
+ GGAGCCACAGCACAACCA 18
160 1096
CFTR-2789-
+ AG GAG CC ACAG CAC AACCA 19
161 1097
CFTR-2789-
+ AAG GAG CC ACAG CAC AACCA 20
162 1098
CFTR-2789-
+ CAAGGAGCCACAGCACAACCA 21
163 1099
CFTR-2789-
+ CCAAGGAGCCACAGCACAACCA 22
164 1100
CFTR-2789-
+ U CC A AG G AG C C A C AG C A C A AC C A 23
165 1101
CFTR-2789-
+ UUCCAAGGAGCCACAGCACAACCA 24
166 1102
CFTR-2789-
+ UGGAAUAUUCACUUUCCA 18
167 1103
CFTR-2789-
+ AUGGAAUAUUCACUUUCCA 19
168 1104
CFTR-2789-
+ CAUGGAAUAUUCACUUUCCA 20
65 1001
CFTR-2789-
+ ACAUGGAAUAUUCACUUUCCA 21
169 1105
CFTR-2789-
+ GACAUGGAAUAUUCACUUUCCA 22
170 1106
CFTR-2789-
+ GGACAUGGAAUAUUCACUUUCCA 23
171 1107
CFTR-2789-
+ AGGACAUGGAAUAUUCACUUUCCA 24
172 1108
CFTR-2789-
+ AAGAAGCAGCCACCUGGA 18
173 1109
CFTR-2789-
+ AAAGAAGCAGCCACCUGGA 19
174 1110
CFTR-2789-
+ CAAAGAAGCAGCCACCUGGA 20
175 1111
CFTR-2789- + CCAAAGAAGCAGCCACCUGGA 21 1112
181
5535.1 176
CFTR-2789-
+ ACCAAAGAAGCAGCCACCUGGA 22
177 1113
CFTR-2789-
+ A AC C A A AG AAGCAGCCACCUGGA 23
178 1114
CFTR-2789-
+ CAACCAAAGAAGCAGCCACCUGGA 24
179 1115
CFTR-2789-
+ GUGGAGGAGCUAGGACUA 18
180 1116
CFTR-2789-
+ UGUGGAGGAGCUAGGACUA 19
181 1117
CFTR-2789-
+ CUGUGGAGGAGCUAGGACUA 20
182 1118
CFTR-2789-
+ A ACC AAAG AAG CAG CCAC 18
183 1119
CFTR-2789-
+ CAACCAAAG AAG CAG CCAC 19
184 1120
CFTR-2789-
+ ACAACCAAAGAAGCAGCCAC 20
185 1121
CFTR-2789-
+ CACAACCAAAGAAGCAGCCAC 21
186 1122
CFTR-2789-
+ G CACAACCAAAG AAGCAG CCAC 22
187 1123
CFTR-2789-
+ AG CACAACCAAAG AAG CAG CCAC 23
188 1124
CFTR-2789-
+ CAG CACAACCAAAG AAG CAG CCAC 24
189 1125
CFTR-2789-
+ CAAUCUACACAAUAGGAC 18
190 1126
CFTR-2789-
+ ACAAUCUACACAAUAGGAC 19
191 1127
CFTR-2789-
+ CACAAUCUACACAAUAGGAC 20
192 1128
CFTR-2789-
+ ACACAAUCUACACAAUAGGAC 21
193 1129
CFTR-2789-
+ AACACAAUCUACACAAUAGGAC 22
194 1130
CFTR-2789-
+ AAACACAAUCUACACAAUAGGAC 23
195 1131
CFTR-2789-
+ AAAACACAAUCUACACAAUAGGAC 24
196 1132
CFTR-2789-
+ AUGGAAUAUUCACUUUCC 18
197 1133
182
5535.1 CFTR-2789-
+ CAUGGAAUAUUCACUUUCC 19
198 1134
CFTR-2789-
+ ACAUGGAAUAUUCACUUUCC 20
199 1135
CFTR-2789-
+ GACAUGGAAUAUUCACUUUCC 21
200 1136
CFTR-2789-
+ GGACAUGGAAUAUUCACUUUCC 22
201 1137
CFTR-2789-
+ AGGACAUGGAAUAUUCACUUUCC 23
202 1138
CFTR-2789-
+ UAGGACAUGGAAUAUUCACUUUCC 24
203 1139
CFTR-2789-
+ UUUCCACUACCAUAAUGC 18
204 1140
CFTR-2789-
+ CUUUCCACUACCAUAAUGC 19
205 1141
CFTR-2789-
+ UCUUUCCACUACCAUAAUGC 20
206 1142
CFTR-2789-
+ AUCUUUCCACUACCAUAAUGC 21
207 1143
CFTR-2789-
+ UAUCUUUCCACUACCAUAAUGC 22
208 1144
CFTR-2789-
+ UUAUCUUUCCACUACCAUAAUGC 23
209 1145
CFTR-2789-
+ CUUAUCUUUCCACUACCAUAAUGC 24
210 1146
CFTR-2789-
+ CACUACCAUAAUGCUUGG 18
211 1147
CFTR-2789-
+ CCACUACCAUAAUGCUUGG 19
212 1148
CFTR-2789-
+ UCCACUACCAUAAUGCUUGG 20
213 1149
CFTR-2789-
+ UUCCACUACCAUAAUGCUUGG 21
214 1150
CFTR-2789-
+ UUUCCACUACCAUAAUGCUUGG 22
215 1151
CFTR-2789-
+ CUUUCCACUACCAUAAUGCUUGG 23
216 1152
CFTR-2789-
+ UCUUUCCACUACCAUAAUGCUUGG 24
217 1153
CFTR-2789-
+ UUCCACUACCAUAAUGCU 18
218 1154
CFTR-2789- + UUUCCACUACCAUAAUGCU 19 1155
183
5535.1 219
CFTR-2789-
+ CUU UCCACUACCAUAAUGCU 20
48 984
CFTR-2789-
+ UCU UUCCACUACCAUAAUGCU 21
220 1156
CFTR-2789-
+ AUCUUUCCACUACCAUAAUGCU 22
221 1157
CFTR-2789-
+ UAUCUUUCCACUACCAUAAUGCU 23
222 1158
CFTR-2789-
+ U UAUCUUUCCACUACCAUAAUGCU 24
223 1159
CFTR-2789-
+ UCCACUACCAUAAUGCUU 18
224 1160
CFTR-2789-
+ U UCCACUACCAUAAUGCUU 19
225 1161
CFTR-2789-
+ U UUCCACUACCAUAAUGCUU 20
51 987
CFTR-2789-
+ CUU UCCACUACCAUAAUGCUU 21
226 1162
CFTR-2789-
+ UCU UUCCACUACCAUAAUGCUU 22
227 1163
CFTR-2789-
+ AUCUUUCCACUACCAUAAUGCUU 23
228 1164
CFTR-2789-
+ UAUCUUUCCACUACCAUAAUGCUU 24
229 1165
CFTR-2789-
- CCCAGGAACACAAAGCAA 18
230 1166
CFTR-2789-
- ACCCAG G A ACAC AAAG C AA 19
231 1167
CFTR-2789-8 - GACCCAGGAACACAAAGCAA 20 944
CFTR-2789-
- GGACCCAGGAACACAAAGCAA 21
232 1168
CFTR-2789-
- U G G ACCCAG GAACACAA AG C AA 22
233 1169
CFTR-2789-
- CUGGACCCAGGAACACAAAGCAA 23
234 1170
CFTR-2789-
- GCUGGACCCAGGAACACAAAGCAA 24
235 1171
CFTR-2789-
- ACCCAGGAACACAAAGCA 18
236 1172
CFTR-2789-
- GACCCAGGAACACAAAGCA 19
237 1173
CFTR-2789- - GGACCCAGGAACACAAAGCA 20 1174
184
5535.1 238
CFTR-2789-
- UGGACCCAGGAACACAAAGCA 21
239 1175
CFTR-2789-
- CUGGACCCAGGAACACAAAGCA 22
240 1176
CFTR-2789-
- GCUGGACCCAGGAACACAAAGCA 23
241 1177
CFTR-2789-
- UGCUGGACCCAGGAACACAAAGCA 24
242 1178
CFTR-2789-
- UGAAUUUAGAUGUGGGCA 18
243 1179
CFTR-2789-
- GUGAAUUUAGAUGUGGGCA 19
244 1180
CFTR-2789-
- UGUGAAUUUAGAUGUGGGCA 20
34 970
CFTR-2789-
- AUGUGAAUUUAGAUGUGGGCA 21
245 1181
CFTR-2789-
- GAUGUGAAUUUAGAUGUGGGCA 22
246 1182
CFTR-2789-
- UGAUGUGAAUUUAGAUGUGGGCA 23
247 1183
CFTR-2789-
- GUGAUGUGAAUUUAGAUGUGGGCA 24
248 1184
CFTR-2789-
- CUCCCAAGCAUUAUGGUA 18
249 1185
CFTR-2789-
- UCUCCCAAGCAUUAUGGUA 19
250 1186
CFTR-2789-
- UUCUCCCAAGCAUUAUGGUA 20
251 1187
CFTR-2789-
- UUUCUCCCAAGCAUUAUGGUA 21
252 1188
CFTR-2789-
- AUUUCUCCCAAGCAUUAUGGUA 22
253 1189
CFTR-2789-
- CAUUUCUCCCAAGCAUUAUGGUA 23
254 1190
CFTR-2789-
- UCAUUUCUCCCAAGCAUUAUGGUA 24
255 1191
CFTR-2789-
- UGGUUGUGCUGUGGCUCC 18
256 1192
CFTR-2789-
- UUGGUUGUGCUGUGGCUCC 19
257 1193
CFTR-2789-
- UUUGGUUGUGCUGUGGCUCC 20
258 1194
185
5535.1 CFTR-2789-
- CUUUGGUUGUGCUGUGGCUCC 21
259 1195
CFTR-2789-
- UCUUUGGUUGUGCUGUGGCUCC 22
260 1196
CFTR-2789-
- UUCUUUGGU UGUGCUGUGGCUCC 23
261 1197
CFTR-2789-
- CUUCUUUGGUUGUGCUGUGGCUCC 24
262 1198
CFTR-2789-
- GUGAAUUUAGAUGUGGGC 18
263 1199
CFTR-2789-
- UGUGAAUUUAGAUGUGGGC 19
264 1200
CFTR-2789-
- AUGUGAAUUUAGAUGUGGGC 20
265 1201
CFTR-2789-
- GAUGUGAAUUUAGAUGUGGGC 21
266 1202
CFTR-2789-
- UGAUGUGAAUUUAGAUGUGGGC 22
267 1203
CFTR-2789-
- GUGAUGUGAAUUUAGAUGUGGGC 23
268 1204
CFTR-2789-
- UGUGAUGUGAAUUUAGAUGUGGGC 24
269 1205
CFTR-2789-
- AACACAAAGCAAAGGAAG 18
270 1206
CFTR-2789-
- GAACACAAAGCAAAGGAAG 19
271 1207
CFTR-2789-
- GGAACACAAAGCAAAGGAAG 20
272 1208
CFTR-2789-
- AGGAACACAAAGCAAAGGAAG 21
273 1209
CFTR-2789-
- CAGGAACACAAAGCAAAGGAAG 22
274 1210
CFTR-2789-
- CCAGG AACACAAAGCAAAGGAAG 23
275 1211
CFTR-2789-
- CCCAGG AACACAAAGCAAAGGAAG 24
276 1212
CFTR-2789-
- UGGGCAUGGGAGGAAUAG 18
277 1213
CFTR-2789-
- GUGGGCAUGGGAGGAAUAG 19
278 1214
CFTR-2789-
- UGUGGGCAUGGGAGGAAUAG 20
279 1215
CFTR-2789- - AUGUGGGCAUGGGAGGAAUAG 21 1216
186
5535.1 280
CFTR-2789-
- GAUGUGGGCAUGGGAGGAAUAG 22
281 1217
CFTR-2789-
- AGAUGUGGGCAUGGGAGGAAUAG 23
282 1218
CFTR-2789-
- UAGAUGUGGGCAUGGGAGGAAUAG 24
283 1219
CFTR-2789-
- UCCCAAGCAUUAUGGUAG 18
284 1220
CFTR-2789-
- CUCCCAAGCAUUAUGGUAG 19
285 1221
CFTR-2789-
- UCUCCCAAGCAUUAUGGUAG 20
42 978
CFTR-2789-
- UUCUCCCAAGCAUUAUGGUAG 21
286 1222
CFTR-2789-
- UU UCUCCCAAGCAUUAUGGUAG 22
287 1223
CFTR-2789-
- AUUUCUCCCAAGCAUUAUGGUAG 23
288 1224
CFTR-2789-
- CAU UUCUCCCAAGCAUUAUGGUAG 24
289 1225
CFTR-2789-
- AUUUAGAUGUGGGCAUGG 18
290 1226
CFTR-2789-
- AAUUUAGAUGUGGGCAUGG 19
291 1227
CFTR-2789-
- GAAUUUAGAUGUGGGCAUGG 20
292 1228
CFTR-2789-
- UGAAUUUAGAUGUGGGCAUGG 21
293 1229
CFTR-2789-
- GUGAAUUUAGAUGUGGGCAUGG 22
294 1230
CFTR-2789-
- UGUGAAUUUAGAUGUGGGCAUGG 23
295 1231
CFTR-2789-
- AUGUGAAUUUAGAUGUGGGCAUGG 24
296 1232
CFTR-2789-
- AUGAUGACCAUUAGUUGG 18
297 1233
CFTR-2789-
- AAUGAUGACCAUUAGU UGG 19
298 1234
CFTR-2789-
- AAAUGAUGACCAUUAGUUGG 20
299 1235
CFTR-2789-
- UAAAUGAUGACCAUUAGUUGG 21
300 1236
187
5535.1 CFTR-2789-
- UUAAAUGAUGACCAUUAGUUGG 22
301 1237
CFTR-2789-
- UUUAAAUGAUGACCAUUAGUUGG 23
302 1238
CFTR-2789-
- GUUUAAAUGAUGACCAUUAGUUGG 24
303 1239
CFTR-2789-
- GAAUUUAGAUGUGGGCAU 18
304 1240
CFTR-2789-
- UGAAUUUAGAUGUGGGCAU 19
305 1241
CFTR-2789-
- GUGAAUUUAGAUGUGGGCAU 20
12 948
CFTR-2789-
- UGUGAAUUUAGAUGUGGGCAU 21
306 1242
CFTR-2789-
- AUGUGAAUUUAGAUGUGGGCAU 22
307 1243
CFTR-2789-
- GAUGUGAAUUUAGAUGUGGGCAU 23
308 1244
CFTR-2789-
- UGAUGUGAAUUUAGAUGUGGGCAU 24
309 1245
CFTR-2789-
- UGUGAUGUGAAUUUAGAU 18
310 1246
CFTR-2789-
- GUGUGAUGUGAAUUUAGAU 19
311 1247
CFTR-2789-
- GGUGUGAUGUGAAUUUAGAU 20
312 1248
CFTR-2789-
- UGGUGUGAUGUGAAUUUAGAU 21
313 1249
CFTR-2789-
- AUGGUGUGAUGUGAAUUUAGAU 22
314 1250
CFTR-2789-
- AAUGGUGUGAUGUGAAUUUAGAU 23
315 1251
CFTR-2789-
- AAAUGGUGUGAUGUGAAUUUAGAU 24
316 1252
CFTR-2789-
- GGUUGUGCUGUGGCUCCU 18
317 1253
CFTR-2789-
- UGGUUGUGCUGUGGCUCCU 19
318 1254
CFTR-2789-
- UUGGUUGUGCUGUGGCUCCU 20
47 983
CFTR-2789-
- UUUGGUUGUGCUGUGGCUCCU 21
319 1255
CFTR-2789- - CUUUGGUUGUGCUGUGGCUCCU 22 1256
188
5535.1 320
CFTR-2789-
- UCUUUGGUUGUGCUGUGGCUCCU 23
321 1257
CFTR-2789-
- UUCUUUGGUUGUGCUGUGGCUCCU 24
322 1258
CFTR-2789-
- AGGAAUAGGUGAAGAUGU 18
323 1259
CFTR-2789-
- GAGGAAUAGGUGAAGAUGU 19
324 1260
CFTR-2789-
- GGAGGAAUAGGUGAAGAUGU 20
325 1261
CFTR-2789-
- GGGAGGAAUAGGUGAAGAUGU 21
326 1262
CFTR-2789-
- UGGGAGGAAUAGGUGAAGAUGU 22
327 1263
CFTR-2789-
- AUGGGAGGAAUAGGUGAAGAUGU 23
328 1264
CFTR-2789-
- CAUGGGAGGAAUAGGUGAAGAUGU 24
329 1265
Table 6A provides exemplary targeting domains for correcting a mutation (e.g., 2789+5G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 6A
Figure imgf000190_0001
Table 6B provides exemplary targeting domains for correcting a mutation (e.g., 2789+5G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G) and have a high level of
189
5535.1 orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 6B
Figure imgf000191_0001
Table 6C provides exemplary targeting domains for correcting a mutation (e.g.,
2789+5G) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 6C
Figure imgf000191_0002
Table 6D provides exemplary targeting domains for correcting a mutation (e.g.,
2789+5G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 2789+5G). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base
190
5535.1 pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 6D
Figure imgf000192_0001
Table 7A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26A->G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26A->G), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 7A
Figure imgf000192_0002
Table 7B provides exemplary targeting domains for correcting a mutation (e.g., 3272-
26A->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26A->G) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
191
5535.1 Table 7B
Figure imgf000193_0001
Table 7C provides exemplary targeting domains for correcting a mutation (e.g., 3272- 6A->G) in the CFTR gene selected according to the third tier parameters. The targeting
192
5535.1 domains bind within 200 bp from a mutation (e.g., 3272-26A->G) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 7C
Figure imgf000194_0001
Table 7D provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26A->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26A->G). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 7D
Figure imgf000194_0002
Table 8A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26A->G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26A->G), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of
193
5535.1 the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 8A
Figure imgf000195_0001
Table 8B provides exemplary targeting domains for correcting a mutation (e.g., 3272-
26A->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26A->G), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 8B
Figure imgf000195_0002
194
5535.1 CFTR-3272-69 + UUUUUUCACACUGGUGCCAUUCU 23 1350
CFTR-3272-70 + UUUUUUUCACACUGGUGCCAUUCU 24 1351
CFTR-3272-71 - ACAAAUCAUAUCUAUUCA 18 1352
CFTR-3272-72 - AACAAAUCAUAUCUAUUCA 19 1353
CFTR-3272-73 - UAACAAAUCAUAUCUAU UCA 20 1354
CFTR-3272-74 - AUAACAAAUCAUAUCUAUUCA 21 1355
CFTR-3272-75 - AAUAACAAAUCAUAUCUAUUCA 22 1356
CFTR-3272-76 - AAAUAACAAAUCAUAUCUAUUCA 23 1357
CFTR-3272-77 - AAAAUAACAAAUCAUAUCUAUUCA 24 1358
CFTR-3272-78 - UGGAAAUAUUUCACAGGC 18 1359
CFTR-3272-79 - AUGGAAAUAUUUCACAGGC 19 1360
CFTR-3272-33 - UAUGGAAAUAUUUCACAGGC 20 1314
CFTR-3272-80 - ACUGCGCUGGUUCCAAAU 18 1361
CFTR-3272-81 - CACUGCGCUGGUUCCAAAU 19 1362
CFTR-3272-82 - ACACUGCGCUGGUUCCAAAU 20 1363
CFTR-3272-83 - AACACUGCGCUGGUUCCAAAU 21 1364
CFTR-3272-84 - CAACACUGCGCUGGUUCCAAAU 22 1365
CFTR-3272-85 - UCAACACUGCGCUGGUUCCAAAU 23 1366
CFTR-3272-86 - ACUCUGUUCCACAAAGCU 18 1367
CFTR-3272-87 - AACUCUGUUCCACAAAGCU 19 1368
CFTR-3272-88 - AAACUCUGUUCCACAAAGCU 20 1369
Table 8C provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26A->G) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26A->G), start with a 5'G and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 8C
Figure imgf000196_0001
195
5535.1 Table 8D provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26A->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26A->G), and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 8D
Figure imgf000197_0001
196
5535.1 107
CFTR-3272-
- CUCUGGUAGCCAAGU A A A A A A A 22
108 1389
CFTR-3272-
- UCUCUGGUAGCCAAGU A A A A A A A 23
109 1390
CFTR-3272-
- AUCUCUGGUAGCCAAGUAAAAAAA 24
110 1391
CFTR-3272-
- CUAUGGAAAUAUUUCACAGGC 21
111 1392
CFTR-3272-
- UCUAUGGAAAUAUUUCACAGGC 22
112 1393
CFTR-3272-
- UUCUAUGGAAAUAUUUCACAGGC 23
113 1394
CFTR-3272-
- UUUCUAUGGAAAUAUUUCACAGGC 24
114 1395
CFTR-3272-
- UGAAACUCUGUUCCACAAAGCU 22
115 1396
CFTR-3272-
- U UGAAACUC U G U U CC AC AAAG C U 23
116 1397
CFTR-3272-
- UUUGAAACUCUGUUCCACAAAGCU 24
117 1398
Table 8E provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26A->G) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26A->G), and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 8E
Figure imgf000198_0001
197
5535.1 CFTR-3272-
+ UUGUAACAAGAUGAGUGAAAA 21
121 1402
CFTR-3272-
+ CUUGUAACAAGAUGAGUGAAAA 22
122 1403
CFTR-3272-
+ GCUUGUAACAAGAUGAGUGAAAA 23
123 1404
CFTR-3272-
+ AGCUUGUAACAAGAUGAGUGAAAA 24
124 1405
CFTR-3272-
+ GCCUGUGAAAUAUUUCCA 18
125 1406
CFTR-3272-
+ UGCCUGUGAAAUAUUUCCA 19
126 1407
CFTR-3272-
+ CUGCCUGUGAAAUAUUUCCA 20
127 1408
CFTR-3272-
+ CCUGCCUGUGAAAUAUUUCCA 21
128 1409
CFTR-3272-
+ UCCUGCCUGUGAAAUAUUUCCA 22
129 1410
CFTR-3272-
+ CUCCUGCCUGUGAAAUAUUUCCA 23
130 1411
CFTR-3272-
+ ACUCCUGCCUGUGAAAUAUUUCCA 24
131 1412
CFTR-3272-
+ UUACUUGGCUACCAGAGA 18
132 1413
CFTR-3272-
+ UUUACUUGGCUACCAGAGA 19
133 1414
CFTR-3272-
+ UUUUACUUGGCUACCAGAGA 20
25 1306
CFTR-3272-
+ UUUUUACUUGGCUACCAGAGA 21
134 1415
CFTR-3272-
+ UUUUUUACUUGGCUACCAGAGA 22
135 1416
CFTR-3272-
+ UUUUUUUACUUGGCUACCAGAGA 23
136 1417
CFTR-3272-
+ CUUUUUUUACUUGGCUACCAGAGA 24
137 1418
CFTR-3272-
+ AAGCUUGUAACAAGAUGA 18
138 1419
CFTR-3272-
+ UAAGCUUGUAACAAGAUGA 19
139 1420
CFTR-3272-
+ UUAAGCUUGUAACAAGAUGA 20
140 1421
CFTR-3272- + UUUAAGCUUGUAACAAGAUGA 21 1422
198
5535.1 141
CFTR-3272-
+ UUUUAAGCUUGUAACAAGAUGA 22
142 1423
CFTR-3272-
+ CUUUUAAGCUUGUAACAAGAUGA 23
143 1424
CFTR-3272-
+ CCUUUUAAGCUUGUAACAAGAUGA 24
144 1425
CFTR-3272-
+ CUUUUUUUACUUGGCUAC 18
145 1426
CFTR-3272-
+ UCUUUUUUUACUUGGCUAC 19
146 1427
CFTR-3272-
+ CUCUUUUUUUACUUGGCUAC 20
147 1428
CFTR-3272-
+ CCUCUUUUUUUACUUGGCUAC 21
148 1429
CFTR-3272-
+ CCCUCUUUUUUUACUUGGCUAC 22
149 1430
CFTR-3272-
+ ACCCUCUUUUUUUACUUGGCUAC 23
150 1431
CFTR-3272-
+ UACCCUCUUUUUUUACUUGGCUAC 24
151 1432
CFTR-3272-
+ CGCAGUGUUGACAGGUAC 18
152 1433
CFTR-3272-
+ GCGCAGUGUUGACAGGUAC 19
153 1434
CFTR-3272-
+ AGCGCAGUGUUGACAGGUAC 20
154 1435
CFTR-3272-
+ CAGCGCAGUGUUGACAGGUAC 21
155 1436
CFTR-3272-
+ CCAGCGCAGUGUUGACAGGUAC 22
156 1437
CFTR-3272-
+ ACCAGCGCAGUGUUGACAGGUAC 23
157 1438
CFTR-3272-
+ AACCAGCGCAGUGUUGACAGGUAC 24
158 1439
CFTR-3272-
+ UUUCAUAAUAUCUUGUAC 18
159 1440
CFTR-3272-
+ AUUUCAUAAUAUCUUGUAC 19
160 1441
CFTR-3272-
+ AAUUUCAUAAUAUCUUGUAC 20
161 1442
CFTR-3272-
+ UAAUUUCAUAAUAUCUUGUAC 21
162 1443
199
5535.1 CFTR-3272-
+ GUAAUUUCAUAAUAUCUUGUAC 22
163 1444
CFTR-3272-
+ UGUAAUUUCAUAAUAUCUUGUAC 23
164 1445
CFTR-3272-
+ AUGUAAUUUCAUAAUAUCUUGUAC 24
165 1446
CFTR-3272-
+ AGGCUGCCGUCCGAAGGC 18
166 1447
CFTR-3272-
+ AAGGCUGCCGUCCGAAGGC 19
167 1448
CFTR-3272-
+ UAAGGCUGCCGUCCGAAGGC 20
168 1449
CFTR-3272-
+ GU AAGGCUGCCGUCCGAAGGC 21
169 1450
CFTR-3272-
+ AGUAAGGCUGCCGUCCGAAGGC 22
170 1451
CFTR-3272-
+ AAGUAAGGCUGCCGUCCGAAGGC 23
171 1452
CFTR-3272-
+ AAAGUAAGGCUGCCGUCCGAAGGC 24
172 1453
CFTR-3272-
+ UUUACUUGGCUACCAGAG 18
173 1454
CFTR-3272-
+ UUUUACUUGGCUACCAGAG 19
174 1455
CFTR-3272-
+ UUUUUACUUGGCUACCAGAG 20
175 1456
CFTR-3272-
+ UUUUUUACUUGGCUACCAGAG 21
176 1457
CFTR-3272-
+ UUUUUUUACUUGGCUACCAGAG 22
177 1458
CFTR-3272-
+ CUUUUUUUACUUGGCUACCAGAG 23
178 1459
CFTR-3272-
+ UCUUUUUUUACUUGGCUACCAGAG 24
179 1460
CFTR-3272-
+ UGUAAAUUCAGAGCUUUG 18
180 1461
CFTR-3272-
+ AUGUAAAUUCAGAGCUUUG 19
181 1462
CFTR-3272-
+ UAUGUAAAUUCAGAGCUUUG 20
35 1316
CFTR-3272-
+ GUAUGUAAAUUCAGAGCUUUG 21
182 1463
CFTR-3272- + AGUAUGUAAAUUCAGAGCUUUG 22 1464
200
5535.1 183
CFTR-3272-
+ CAGUAUGUAAAUUCAGAGCUUUG 23
184 1465
CFTR-3272-
+ GCAGUAUGUAAAUUCAGAGCUUUG 24
185 1466
CFTR-3272-
+ UACUUGGCUACCAGAGAU 18
186 1467
CFTR-3272-
+ UUACUUGGCUACCAGAGAU 19
187 1468
CFTR-3272-
+ UUUACUUGGCUACCAGAGAU 20
37 1318
CFTR-3272-
+ UUUUACUUGGCUACCAGAGAU 21
188 1469
CFTR-3272-
+ UUUUUACUUGGCUACCAGAGAU 22
189 1470
CFTR-3272-
+ UUUUUUACUUGGCUACCAGAGAU 23
190 1471
CFTR-3272-
+ UUUUUUUACUUGGCUACCAGAGAU 24
191 1472
CFTR-3272-
+ AAAAUUGGACUCCUGCCU 18
192 1473
CFTR-3272-
+ GAAAAUUGGACUCCUGCCU 19
193 1474
CFTR-3272-
+ UGAAAAUUGGACUCCUGCCU 20
194 1475
CFTR-3272-
+ GUGAAAAUUGGACUCCUGCCU 21
195 1476
CFTR-3272-
+ AGUGAAAAUUGGACUCCUGCCU 22
196 1477
CFTR-3272-
+ GAGUGAAAAUUGGACUCCUGCCU 23
197 1478
CFTR-3272-
+ UGAGUGAAAAUUGGACUCCUGCCU 24
198 1479
CFTR-3272-
+ UCAAAGUAAGGCUGCCGU 18
199 1480
CFTR-3272-
+ UUCAAAGUAAGGCUGCCGU 19
200 1481
CFTR-3272-
+ UUUCAAAGUAAGGCUGCCGU 20
201 1482
CFTR-3272-
+ GUUUCAAAGUAAGGCUGCCGU 21
202 1483
CFTR-3272-
+ AGUUUCAAAGUAAGGCUGCCGU 22
203 1484
201
5535.1 CFTR-3272-
+ GAGUUUCAAAGUAAGGCUGCCGU 23
204 1485
CFTR-3272-
+ AGAGUUUCAAAGUAAGGCUGCCGU 24
205 1486
CFTR-3272-
+ GUUGGCAGUAUGUAAAUU 18
206 1487
CFTR-3272-
+ AGUUGGCAGUAUGUAAAUU 19
207 1488
CFTR-3272-
+ CAGU UGGCAGUAUGUAAAUU 20
208 1489
CFTR-3272-
+ CCAGU UGGCAGUAUGUAAAUU 21
209 1490
CFTR-3272-
+ ACCAGUUGGCAGUAUGUAAAUU 22
210 1491
CFTR-3272-
+ AACCAGUUGGCAGUAUGUAAAUU 23
211 1492
CFTR-3272-
+ G AACCAG U UGG CAG U AUG U AAAU U 24
212 1493
CFTR-3272-
+ AUGUAAAUUCAGAGCUUU 18
213 1494
CFTR-3272-
+ UAUGUAAAUUCAGAGCUUU 19
214 1495
CFTR-3272-
+ GUAUGUAAAUUCAGAGCUUU 20
215 1496
CFTR-3272-
+ AGUAUGUAAAUUCAGAGCUUU 21
216 1497
CFTR-3272-
+ CAGUAUGUAAAUUCAGAGCUUU 22
217 1498
CFTR-3272-
+ GCAGUAUGUAAAUUCAGAGCUUU 23
218 1499
CFTR-3272-
+ GGCAGUAUGUAAAUUCAGAGCUUU 24
219 1500
CFTR-3272-
- CUGGUAGC C A AG U A A A A A 18
220 1501
CFTR-3272-
- UCUGGUAGCCAAGU A A A A A 19
221 1502
CFTR-3272-
- CUCUGGUAGCCAAGU A A A A A 20
222 1503
CFTR-3272-
- UCUCUGGUAGCCAAGUAAAAA 21
223 1504
CFTR-3272-
- AUCUCUGGUAGCCAAGUAAAAA 22
224 1505
CFTR-3272- - CAUCUCUGGUAGCCAAGU A A A A A 23 1506
202
5535.1 225
CFTR-3272-
- CCAUCUCUGGUAGCCAAGUAAAAA 24
226 1507
CFTR-3272-
- ACACUGCGCUGGUUCCAA 18
227 1508
CFTR-3272-
- AACACUGCGCUGGUUCCAA 19
228 1509
CFTR-3272-
- CAACACUGCGCUGGUUCCAA 20
229 1510
CFTR-3272-
- UCAACACUGCGCUGGUUCCAA 21
230 1511
CFTR-3272-
- GUCAACACUGCGCUGGU UCCAA 22
231 1512
CFTR-3272-
- UGUCAACACUGCGCUGGUUCCAA 23
232 1513
CFTR-3272-
- CUGUCAACACUGCGCUGGUUCCAA 24
233 1514
CFTR-3272-
- GCUGGU UCCAAAUGAGAA 18
234 1515
CFTR-3272-
- CGCUGGU UCCAAAUGAGAA 19
235 1516
CFTR-3272-
- GCGCUGGU UCCAAAUGAGAA 20
236 1517
CFTR-3272-
- UGCGCUGGUUCCAAAUGAGAA 21
237 1518
CFTR-3272-
- CUGCGCUGGUUCCAAAUGAGAA 22
238 1519
CFTR-3272-
- ACUGCGCUGGUUCCAAAUGAGAA 23
239 1520
CFTR-3272-
- CACUGCGCUGGUUCCAAAUGAGAA 24
240 1521
CFTR-3272-
- AUCUUGUUACAAGCUUAA 18
241 1522
CFTR-3272-
- CAUCUUGUUACAAGCUUAA 19
242 1523
CFTR-3272-
- UCAUCUUGUUACAAGCUUAA 20
243 1524
CFTR-3272-
- CUCAUCUUGUUACAAGCUUAA 21
244 1525
CFTR-3272-
- ACUCAUCUUGUUACAAGCUUAA 22
245 1526
CFTR-3272-
- CACUCAUCUUGUUACAAGCUUAA 23
246 1527
203
5535.1 CFTR-3272-
- UCACUCAUCUUGUUACAAGCUUAA 24
247 1528
CFTR-3272-
- UAUUUGCAGUGUUUUCUA 18
248 1529
CFTR-3272-
- UUAUUUGCAGUGUUUUCUA 19
249 1530
CFTR-3272-
- GUUAUUUGCAGUGUUUUCUA 20
42 1323
CFTR-3272-
- UGUUAUUUGCAGUGUUUUCUA 21
250 1531
CFTR-3272-
- AUGUUAUUUGCAGUGU UUUCUA 22
251 1532
CFTR-3272-
- UAUGUUAUUUGCAGUGUUUUCUA 23
252 1533
CFTR-3272-
- UUAUGUUAUUUGCAGUGUUUUCUA 24
253 1534
CFTR-3272-
- AUGGAAAUAUUUCACAGG 18
254 1535
CFTR-3272-
- UAUGGAAAUAUUUCACAGG 19
255 1536
CFTR-3272-
- CUAUGGAAAUAUUUCACAGG 20
256 1537
CFTR-3272-
- UCUAUGGAAAUAUUUCACAGG 21
257 1538
CFTR-3272-
- UUCUAUGGAAAUAUUUCACAGG 22
258 1539
CFTR-3272-
- UU UCUAUGGAAAUAUU UCACAGG 23
259 1540
CFTR-3272-
- UU UUCUAUGGAAAUAU UUCACAGG 24
260 1541
CFTR-3272-
- UACAAGCUUAAAAGGACU 18
261 1542
CFTR-3272-
- UUACAAGCUUAAAAGGACU 19
262 1543
CFTR-3272-
- GU UACAAGCUUAAAAGGACU 20
263 1544
CFTR-3272-
- UGUUACAAGCUUAAAAGGACU 21
264 1545
CFTR-3272-
- U UG U UACAAGCU U AAAAGG ACU 22
265 1546
CFTR-3272-
- CUUGUUACAAGCUUAAAAGGACU 23
266 1547
CFTR-3272- - UCUUGUUACAAGCUUAAAAGGACU 24 1548
204
5535.1 267
CFTR-3272-
- UCGGACGGCAGCCU UACU 18
268 1549
CFTR-3272-
- UUCGGACGGCAGCCUUACU 19
269 1550
CFTR-3272-
- CUUCGGACGGCAGCCUUACU 20
270 1551
CFTR-3272-
- CCUUCGGACGGCAGCCU UACU 21
271 1552
CFTR-3272-
- GCCUUCGGACGGCAGCCUUACU 22
272 1553
CFTR-3272-
- UGCCUUCGGACGGCAGCCUUACU 23
273 1554
CFTR-3272-
- GUGCCU UCGGACGGCAGCCUUACU 24
274 1555
CFTR-3272-
- UAUGGACACUUCGUGCCU 18
275 1556
CFTR-3272-
- CUAUGGACACUUCGUGCCU 19
276 1557
CFTR-3272-
- ACUAUGGACACUUCGUGCCU 20
277 1558
CFTR-3272-
- GACUAUGGACACUUCGUGCCU 21
278 1559
CFTR-3272-
- GGACUAUGGACACUUCGUGCCU 22
279 1560
CFTR-3272-
- AGGACUAUGGACACUUCGUGCCU 23
280 1561
CFTR-3272-
- AAGGACUAUGGACACUUCGUGCCU 24
281 1562
CFTR-3272-
- UUAUUUGCAGUGU UUUCU 18
282 1563
CFTR-3272-
- GU UAUUUGCAGUGUUU UCU 19
283 1564
CFTR-3272-
- UGUUAUUUGCAGUGUU UUCU 20
284 1565
CFTR-3272-
- AUGUUAUUUGCAGUGUUUUCU 21
285 1566
CFTR-3272-
- UAUGUUAUUUGCAGUGUUUUCU 22
286 1567
CFTR-3272-
- UUAUGUUAUUUGCAGUGUUUUCU 23
287 1568
CFTR-3272-
- UU UAUGUUAUUUGCAGUGUUUUCU 24
288 1569
205
5535.1 CFTR-3272-
- U C A A AG A A U G G C AC C AG U 18
289 1570
CFTR-3272-
- UUCAAAGAAUGGCACCAGU 19
290 1571
CFTR-3272-
- AUUCAAAGAAUGGCACCAGU 20
291 1572
CFTR-3272-
- UAUUCAAAGAAUGGCACCAGU 21
292 1573
CFTR-3272-
- CUAUUCAAAGAAUGGCACCAGU 22
293 1574
CFTR-3272-
- U C U A U U C A A AG A A UGGCACCAGU 23
294 1575
CFTR-3272-
- AUCUAUUCAAAGAAUGGCACCAGU 24
295 1576
CFTR-3272-
- UUUCAGGUACAAGAUAUU 18
296 1577
CFTR-3272-
- UUUUCAGGUACAAGAUAUU 19
297 1578
CFTR-3272-
- UUUUUCAGGUACAAGAUAUU 20
298 1579
CFTR-3272-
- CUUUUUCAGGUACAAGAUAUU 21
299 1580
CFTR-3272-
- UCUUUUUCAGGUACAAGAUAUU 22
300 1581
CFTR-3272-
- GUCUUUUUCAGGUACAAGAUAUU 23
301 1582
CFTR-3272-
- AGUCUUUUUCAGGUACAAGAUAUU 24
302 1583
Table 9A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26A->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26A->G) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 9A
Figure imgf000207_0001
206
5535.1 Length
CFTR-3272-303 - AUGGCACCAGUGUGAAA 17 1584
CFTR-3272-304 + UGCCAUUCUUUGAAUAG 17 1585
CFTR-3272-305 + UUGGCAGUAUGUAAAUU 17 1586
CFTR-3272-306 + AAGUGUCCAUAGUCCUU 17 1587
CFTR-3272-307 - AGAAUGGCACCAGUGUGAAA 20 1588
CFTR-3272-308 + UGGUGCCAUUCUUUGAAUAG 20 1589
CFTR-3272-309 + ACGAAGUGUCCAUAGUCCUU 20 1590
Table 9B provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26A->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26A->G). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 9B
Figure imgf000208_0001
Table 10A provides exemplary targeting domains for correcting a mutation (e.g., deltaF508) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., deltaF508), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 10A
207
5535.1 1st Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR-
- GGGUAAGCUACUGUGAA 17
DeltaF508-l 402
CFTR-
- GAACUGGAGCCUUCAGA 17
DeltaF508-2 401
CFTR-
+ GACUAACCGAUUGAAUA 17
DeltaF508-3 403
CFTR-
- GGUGAUUAUGGGAGAAC 17
DeltaF508-4 400
CFTR-
+ GGUGCCAGGCAUAAUCC 17
DeltaF508-5 394
CFTR-
- G G U A A A A U U A AG C AC AG 17
DeltaF508-6 390
CFTR-
+ GUAUCUAUAUUCAUCAU 17
DeltaF508-7 392
CFTR-
+ GAGCCAAAUAUAUAAUU 17
DeltaF508-8 404
CFTR-
- GGAGAACUGGAGCCUUCAGA 20
DeltaF508-9 397
CFTR-
+ GUAGACUAACCGAUUGAAUA 20
DeltaF508-10 398
CFTR-
+ GUCAUUAUCAAAUCACGCUC 20
DeltaF508-ll 399
CFTR-
- G AG G G U A A A A U U A AG C AC AG 20
DeltaF508-12 387
CFTR-
- GGGAGAACUGGAGCCUUCAG 20
DeltaF508-13 396
CFTR-
- GAUAAUGACCUAAUAAUGAU 20
DeltaF508-14 395
Table 10B provides exemplary targeting domains for correcting a mutation (e.g., deltaF508) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., deltaF508) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 10B
208
5535.1 2nd Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR-
+ AAUUUGGGUAGUGUGAA 17
DeltaF508-15 449
CFTR-
- CCAGACUUCACUUCUAA 17
DeltaF508-16 438
CFTR-
- UAAUGACCUAAUAAUGA 17
DeltaF508-17 436
CFTR-
+ UUAAUUUUACCCUCUGA 17
DeltaF508-18 418
CFTR-
+ UAAUUUGGGUAGUGUGA 17
DeltaF508-19 448
CFTR-
- UUUUCCUGGAUUAUGCC 17
DeltaF508-20 414
CFTR-
+ UUUUCUUUAAUGGUGCC 17
DeltaF508-21 417
CFTR-
- UCUGUUCUCAGUUUUCC 17
DeltaF508-22 413
CFTR-
+ AUUAUCAAAUCACGCUC 17
DeltaF508-23 452
CFTR-
+ CCAUUAGAAGUGAAGUC 17
DeltaF508-24 450
CFTR-
- AGCAUGCCAACUAGAAG 17
DeltaF508-25 391
CFTR-
- AGAACUGGAGCCUUCAG 17
DeltaF508-26 441
CFTR-
+ CAGUAGCUUACCCAUAG 17
DeltaF508-27 446
CFTR-
- UUGGCUCCAUAUUCAAU 17
DeltaF508-28 443
CFTR-
- CUUCUAAUGGUGAUUAU 17
DeltaF508-29 440
CFTR-
+ UUCUUACCUCUUCUAGU 17
DeltaF508-30 416
CFTR-
- UACCCAAAUUAUAUAUU 17
DeltaF508-31 442
CFTR-
- UAUGGGUAAGCUACUGUGAA 20
DeltaF508-32 428
CFTR-
+ UAUAAUUUGGGUAGUGUGAA 20
DeltaF508-33 433
CFTR-
- UUUCCAGACUUCACUUCUAA 20
DeltaF508-34 420
209
5535.1 CFTR-
+ ACCAAUGAUAUUUUCU UUAA 20
DeltaF508-35 1597
CFTR-
- UGAUAAUGACCUAAUAAUGA 20
DeltaF508-36 419
CFTR-
+ UGCU UAAUUUUACCCUCUGA 20
DeltaF508-37 412
CFTR-
+ AUAUAAUUUGGGUAGUGUGA 20
DeltaF508-38 432
CFTR-
- UUCACUUCUAAUGGUGAUUA 20
DeltaF508-39 421
CFTR-
- AAUGGUGAUUAUGGGAGAAC 20
DeltaF508-40 423
CFTR-
- CAGU UUUCCUGGAUUAUGCC 20
DeltaF508-41 406
CFTR-
+ AUAUUUUCUUUAAUGGUGCC 20
DeltaF508-42 411
CFTR-
+ AAUGGUGCCAGGCAUAAUCC 20
DeltaF508-43 389
CFTR-
- CAU UCUGUUCUCAGUU UUCC 20
DeltaF508-44 405
CFTR-
+ UCACCAUUAGAAGUGAAGUC 20
DeltaF508-45 434
CFTR-
- C A A AG C A U G C C A AC U AG A AG 20
DeltaF508-46 408
CFTR-
+ UCACAGUAGCUUACCCAUAG 20
DeltaF508-47 429
CFTR-
- UAUUUGGCUCCAUAUUCAAU 20
DeltaF508-48 425
CFTR-
+ UCUGUAUCUAUAUUCAUCAU 20
DeltaF508-49 409
CFTR-
- ACCAUUAAAGAAAAUAUCAU 20
DeltaF508-50 1598
CFTR-
- UCACUUCUAAUGGUGAUUAU 20
DeltaF508-51 422
CFTR-
+ AGUUUCUUACCUCUUCUAGU 20
DeltaF508-52 388
CFTR-
+ AUGGAGCCAAAUAUAUAAUU 20
DeltaF508-53 430
CFTR-
- CACUACCCAAAUUAUAUAUU 20
DeltaF508-54 424
210
5535.1 Table IOC provides exemplary targeting domains for correcting a mutation (e.g., deltaF508) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., deltaF508). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table IOC
Figure imgf000212_0001
Table 11A provides exemplary targeting domains for correcting a mutation (e.g. deltaF508) in the CFTR gene selected according to the first tier parameters. The targetin domains bind within 200 bp from a mutation (e.g., deltaF508), have a high level of
211
5535.1 orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 11A
Figure imgf000213_0001
Table 11B provides exemplary targeting domains for correcting a mutation (e.g., deltaF508) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., deltaF508), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting
212
5535.1 domains in the Table can be used with a S. aureus Cas9 molecule that generates stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 11B
Figure imgf000214_0001
213
5535.1 CFTR-
+ AUGGAGCCAAAUAUAUAAU 19
DeltaF508-97 1626
CFTR-
+ UAUGGAGCCAAAUAUAUAAU 20
DeltaF508-98 689
CFTR-
+ AUAUGGAGCCAAAUAUAUAAU 21
DeltaF508-99 1627
CFTR- DeltaF508- + AAUAUGGAGCCAAAUAUAUAAU 22
100 1628
CFTR- DeltaF508- + UGAAUAUGGAGCCAAAUAUAUAAU 24
101 1629
CFTR- DeltaF508- + UCAUUAUCAAAUCACGCU 18
102 1630
CFTR- DeltaF508- + AGGUCAUUAUCAAAUCACGCU 21
103 1631
CFTR- DeltaF508- + UAGGUCAUUAUCAAAUCACGCU 22
104 1632
CFTR- DeltaF508- + UUAGGUCAUUAUCAAAUCACGCU 23
105 1633
CFTR- DeltaF508- + AUUAGGUCAUUAUCAAAUCACGCU 24
106 1634
CFTR- DeltaF508- - UGGGAGAACUGGAGCCUUCA 20
107 661
CFTR- DeltaF508- - AUGGGUAAGCUACUGUGA 18
108 1635
CFTR- DeltaF508- - UAUGGGUAAGCUACUGUGA 19
109 1636
CFTR- DeltaF508- - CUAUGGGUAAGCUACUGUGA 20
110 675
CFTR- DeltaF508- - UCUAUGGGUAAGCUACUGUGA 21
111 1637
214
5535.1 CFTR- DeltaF508- - CUCUAUGGGUAAGCUACUGUGA 22
112 1638
CFTR- DeltaF508- - CCUCUAUGGGUAAGCUACUGUGA 23
113 1639
CFTR- DeltaF508- - UCCUCUAUGGGUAAGCUACUGUGA 24
114 1640
CFTR- DeltaF508- - AUUCUGUUCUCAGUUUUC 18
115 1641
CFTR- DeltaF508- - CAUUCUGUUCUCAGUUUUC 19
116 1642
CFTR- DeltaF508- - UCAUUCUGUUCUCAGUUUUC 20
117 664
CFTR- DeltaF508- - UUCAUUCUGUUCUCAGUUUUC 21
118 1643
CFTR- DeltaF508- - UUUCAUUCUGUUCUCAGUUUUC 22
119 1644
CFTR- DeltaF508- - AUUUCAUUCUGUUCUCAGUUUUC 23
120 1645
CFTR- DeltaF508- - AAUUUCAUUCUGUUCUCAGUUUUC 24
121 1646
CFTR- DeltaF508- - U A A A A UUAAGCACAGUGG 18
122 1647
CFTR- DeltaF508- - AGGGUAAAAUUAAGCACAGUGG 22
123 1648
CFTR- DeltaF508- - AGAGGGUAAAAUUAAGCACAGUGG 24
124 1649
CFTR- DeltaF508- - UGAUAAUGACCUAAUAAUG 19
125 1650
215
5535.1 CFTR- DeltaF508- - UUGAUAAUGACCUAAUAAUG 20
126 656
CFTR- DeltaF508- - UUUGAUAAUGACCUAAUAAUG 21
127 1651
CFTR- DeltaF508- - AUUUGAUAAUGACCUAAUAAUG 22
128 1652
CFTR- DeltaF508- - UGAUUUGAUAAUGACCUAAUAAUG 24
129 1653
CFTR- DeltaF508- - UCAUUGGUGUUUCCUAUG 18
130 1654
CFTR- DeltaF508- - AUCAUUGGUGUUUCCUAUG 19
131 1655
CFTR- DeltaF508- - UAUCAUUGGUGUUUCCUAUG 20
132 1656
CFTR- DeltaF508- - AUAUCAUUGGUGUUUCCUAUG 21
133 1657
CFTR- DeltaF508- - AAUAUCAUUGGUGUUUCCUAUG 22
134 1658
CFTR- DeltaF508- - AAAUAUCAUUGGUGUUUCCUAUG 23
135 1659
CFTR- DeltaF508- - AAAAUAUCAUUGGUGUUUCCUAUG 24
136 1660
CFTR- DeltaF508- - CUCUAUGGGUAAGCUACU 18
137 1661
CFTR- DeltaF508- - CCUCUAUGGGUAAGCUACU 19
138 1662
CFTR- DeltaF508- - UCCUCUAUGGGUAAGCUACU 20
139 674
216
5535.1 CFTR- DeltaF508- - UUCCUCUAUGGGUAAGCUACU 21
140 1663
CFTR- DeltaF508- - UUUCCUCUAUGGGUAAGCUACU 22
141 1664
CFTR- DeltaF508- - UGUUUCCUCUAUGGGUAAGCUACU 24
142 1665
CFTR- DeltaF508- - UAUAUUUAUGUUUCCUCU 18
143 1666
CFTR- DeltaF508- - AUAUAUUUAUGUUUCCUCU 19
144 1667
CFTR- DeltaF508- - CAUAUAUUUAUGUUUCCUCU 20
145 673
CFTR- DeltaF508- - ACAUAUAUUUAUGUUUCCUCU 21
146 1668
CFTR- DeltaF508- - UACAUAUAUUUAUGUUUCCUCU 22
147 1669
CFTR- DeltaF508- - CUACAUAUAUUUAUGUUUCCUCU 23
148 1670
CFTR- DeltaF508- - UCUACAUAUAUUUAUGUUUCCUCU 24
149 1671
Table 11C provides exemplary targeting domains for correcting a mutation (e.g., deltaF508) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., deltaF508), start with a 5'G and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 11C
3rd Tier
217
5535.1 Target Site gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR-
+ GCAUAAUCCAGGAAAACUGAGAA 23
DeltaF508-150 1672
CFTR-
+ GGCAUAAUCCAGGAAAACUGAGAA 24
DeltaF508-151 1673
Table 11D provides exemplary targeting domains for correcting a mutation (e.g., deltaF508) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., deltaF508), and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 11D
Figure imgf000219_0001
Table HE provides exemplary targeting domains for correcting a mutation (e.g., deltaF508) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., deltaF508), and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with
218
5535.1 a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table HE
Figure imgf000220_0001
219
5535.1 CFTR- DeltaF508- + UUCUCCCAUAAUCACCAUUAGAA 23
170 1690
CFTR- DeltaF508- + GUUCUCCCAUAAUCACCAUUAGAA 24
171 1691
CFTR- DeltaF508- + UUCACAGUAGCUUACCCA 18
172 1692
CFTR- DeltaF508- + AUUCACAGUAGCUUACCCA 19
173 1693
CFTR- DeltaF508- + CAUUCACAGUAGCUUACCCA 20
174 693
CFTR- DeltaF508- + CCAUUCACAGUAGCUUACCCA 21
175 1694
CFTR- DeltaF508- + UCCAUUCACAGUAGCUUACCCA 22
176 1695
CFTR- DeltaF508- + AUCCAUUCACAGUAGCUUACCCA 23
177 1696
CFTR- DeltaF508- + GAUCCAUUCACAGUAGCUUACCCA 24
178 1697
CFTR- DeltaF508- + CUGUAUCUAUAUUCAUCA 18
179 1698
CFTR- DeltaF508- + UCUGUAUCUAUAUUCAUCA 19
180 1699
CFTR- DeltaF508- + UUCUGUAUCUAUAUUCAUCA 20
181 686
CFTR- DeltaF508- + CUUCUGUAUCUAUAUUCAUCA 21
182 1700
CFTR- DeltaF508- + GCUUCUGUAUCUAUAUUCAUCA 22
183 1701
220
5535.1 CFTR- DeltaF508- + CGCUUCUGUAUCUAUAUUCAUCA 23
184 1702
CFTR- DeltaF508- + ACGCUUCUGUAUCUAUAUUCAUCA 24
185 1703
CFTR- DeltaF508- + AGGAAAACUGAGAACAGA 18
186 1704
CFTR- DeltaF508- + CAGGAAAACUGAGAACAGA 19
187 1705
CFTR- DeltaF508- + CCAGGAAAACUGAGAACAGA 20
188 681
CFTR- DeltaF508- + UCCAGGAAAACUGAGAACAGA 21
189 1706
CFTR- DeltaF508- + AUCCAGGAAAACUGAGAACAGA 22
190 1707
CFTR- DeltaF508- + AAUCCAGGAAAACUGAGAACAGA 23
191 1708
CFTR- DeltaF508- + UAAUCCAGGAAAACUGAGAACAGA 24
192 1709
CFTR- DeltaF508- + AGACUAACCGAUUGAAUA 18
193 1710
CFTR- DeltaF508- + UAGACUAACCGAUUGAAUA 19
194 1711
CFTR-
+ GU AGACUAACCGAUUGAAUA 20
DeltaF508-10 398
CFTR- DeltaF508- + UGUAGACUAACCGAUUGAAUA 21
195 1712
CFTR- DeltaF508- + AUGUAGACUAACCGAUUGAAUA 22
196 1713
CFTR-
+ UAUGUAGACUAACCGAUUGAAUA 23
DeltaF508- 1714
221
5535.1 197
CFTR- DeltaF508- + AUAUGUAGACUAACCGAUUGAAUA 24
198 1715
CFTR- DeltaF508- + CACAGUAGCUUACCCAUA 18
199 1716
CFTR- DeltaF508- + UCACAGUAGCUUACCCAUA 19
200 1717
CFTR- DeltaF508- + U UCACAGUAGCU UACCCAUA 20
201 692
CFTR- DeltaF508- + AUUCACAGUAGCUUACCCAUA 21
202 1718
CFTR- DeltaF508- + CAUUCACAGUAGCUUACCCAUA 22
203 1719
CFTR- DeltaF508- + CCAUUCACAGUAGCUUACCCAUA 23
204 1720
CFTR- DeltaF508- + UCCAUUCACAGUAGCUUACCCAUA 24
205 1721
CFTR- DeltaF508- + UGGUGCCAGGCAUAAUCC 18
206 1722
CFTR- DeltaF508- + AUGGUGCCAGGCAUAAUCC 19
207 1723
CFTR-
+ AAUGGUGCCAGGCAUAAUCC 20
DeltaF508-43 389
CFTR- DeltaF508- + UAAUGGUGCCAGGCAUAAUCC 21
208 1724
CFTR- DeltaF508- + UUAAUGGUGCCAGGCAUAAUCC 22
209 1725
CFTR- DeltaF508- + UUUAAUGGUGCCAGGCAUAAUCC 23
210 1726
222
5535.1 CFTR- DeltaF508- + CUU UAAUGGUGCCAGGCAUAAUCC 24
211 1727
CFTR- DeltaF508- + AUGGUGCCAGGCAUAAUC 18
212 1728
CFTR- DeltaF508- + AAUGGUGCCAGGCAUAAUC 19
213 1729
CFTR- DeltaF508- + UAAUGGUGCCAGGCAUAAUC 20
214 685
CFTR- DeltaF508- + U UAAUGGUGCCAGGCAUAAUC 21
215 1730
CFTR- DeltaF508- + U UUAAUGGUGCCAGGCAUAAUC 22
216 1731
CFTR- DeltaF508- + CUUUAAUGGUGCCAGGCAUAAUC 23
217 1732
CFTR- DeltaF508- + UCU UUAAUGGUGCCAGGCAUAAUC 24
218 1733
CFTR- DeltaF508- + ACCAUUAGAAGUGAAGUC 18
219 1734
CFTR- DeltaF508- + CACCAU U AG AAG UG AAG U C 19
220 1735
CFTR-
+ UCACCAUUAGAAGUGAAGUC 20
DeltaF508-45 434
CFTR- DeltaF508- + AUCACCAUUAGAAGUGAAGUC 21
221 1736
CFTR- DeltaF508- + AAUCACCAUUAGAAGUGAAGUC 22
222 1737
CFTR- DeltaF508- + UAAUCACCAUUAGAAGUGAAGUC 23
223 1738
CFTR-
+ AU AAU CACCAU U AG AAG UG AAG U C 24
DeltaF508- 1739
223
5535.1 CFTR- DeltaF508- + ACAGUAGCUUACCCAUAG 18
225 1740
CFTR- DeltaF508- + CACAGUAGCUUACCCAUAG 19
226 1741
CFTR-
+ UCACAGUAGCUUACCCAUAG 20
DeltaF508-47 429
CFTR- DeltaF508- + U UCACAGUAGCU UACCCAUAG 21
227 1742
CFTR- DeltaF508- + AUUCACAGUAGCUUACCCAUAG 22
228 1743
CFTR- DeltaF508- + CAUUCACAGUAGCUUACCCAUAG 23
229 1744
CFTR- DeltaF508- + CCAU UCACAGUAGCUUACCCAUAG 24
230 1745
CFTR- DeltaF508- + UAGACUAACCGAUUGAAU 18
231 1746
CFTR- DeltaF508- + GUAGACUAACCGAUUGAAU 19
232 1747
CFTR- DeltaF508- + UGUAGACUAACCGAUUGAAU 20
233 690
CFTR- DeltaF508- + AUGUAGACUAACCGAUUGAAU 21
234 1748
CFTR- DeltaF508- + UAUGUAGACUAACCGAU UGAAU 22
235 1749
CFTR- DeltaF508- + AUAUGUAGACUAACCGAUUGAAU 23
236 1750
CFTR- DeltaF508- + UAUAUGUAGACUAACCGAUUGAAU 24
237 1751
224
5535.1 CFTR- DeltaF508- + UUCUCCCAUAAUCACCAU 18
238 1752
CFTR- DeltaF508- + GU UCUCCCAUAAUCACCAU 19
239 1753
CFTR- DeltaF508- + AGUUCUCCCAUAAUCACCAU 20
240 679
CFTR- DeltaF508- + CAGU UCUCCCAUAAUCACCAU 21
241 1754
CFTR- DeltaF508- + CCAGU UCUCCCAUAAUCACCAU 22
242 1755
CFTR- DeltaF508- + UCCAGUUCUCCCAUAAUCACCAU 23
243 1756
CFTR- DeltaF508- + CUCCAGU UCUCCCAUAAUCACCAU 24
244 1757
CFTR- DeltaF508- + UGUAUCUAUAUUCAUCAU 18
245 1758
CFTR- DeltaF508- + CUGUAUCUAUAUUCAUCAU 19
246 1759
CFTR-
+ UCUGUAUCUAUAUUCAUCAU 20
DeltaF508-49 409
CFTR- DeltaF508- + UUCUGUAUCUAUAUUCAUCAU 21
247 1760
CFTR- DeltaF508- + CUUCUGUAUCUAUAUUCAUCAU 22
248 1761
CFTR- DeltaF508- + GCUUCUGUAUCUAUAU UCAUCAU 23
249 1762
CFTR- DeltaF508- + CGCUUCUGUAUCUAUAUUCAUCAU 24
250 1763
CFTR-
+ GCAUAAUCCAGGAAAACU 18
DeltaF508- 1764
225
5535.1 251
CFTR- DeltaF508- + GGCAUAAUCCAGGAAAACU 19
252 1765
CFTR- DeltaF508- + AGGCAUAAUCCAGGAAAACU 20
253 683
CFTR- DeltaF508- + CAGGCAUAAUCCAGGAAAACU 21
254 1766
CFTR- DeltaF508- + CCAGGCAUAAUCCAGGAAAACU 22
255 1767
CFTR- DeltaF508- + GCCAGGCAUAAUCCAGGAAAACU 23
256 1768
CFTR- DeltaF508- + UGCCAGGCAUAAUCCAGGAAAACU 24
257 1769
CFTR- DeltaF508- + UGUGCUUAAUUU UACCCU 18
258 1770
CFTR- DeltaF508- + CUGUGCUUAAU UUUACCCU 19
259 1771
CFTR- DeltaF508- + ACUGUGCUUAAUUUUACCCU 20
260 680
CFTR- DeltaF508- + CACUGUGCUUAAUUUUACCCU 21
261 1772
CFTR- DeltaF508- + CCACUGUGCUUAAUUUUACCCU 22
262 1773
CFTR- DeltaF508- + UCCACUGUGCUUAAUUUUACCCU 23
263 1774
CFTR- DeltaF508- + UUCCACUGUGCUUAAUUUUACCCU 24
264 1775
CFTR-
+ CACCAU U AG AAG UG AAG U 18
DeltaF508- 1776
226
5535.1 265
CFTR- DeltaF508- + U CACCAU U AG AAG UG AAG U 19
266 1777
CFTR- DeltaF508- + AUCACCAUUAGAAGUGAAGU 20
267 677
CFTR- DeltaF508- + AAUCACCAUUAGAAGUGAAGU 21
268 1778
CFTR- DeltaF508- + UAAUCACCAUUAGAAGUGAAGU 22
269 1779
CFTR- DeltaF508- + AUAAUCACCAUUAGAAGUGAAGU 23
270 1780
CFTR- DeltaF508- + CAUAAUCACCAUUAGAAGUGAAGU 24
271 1781
CFTR- DeltaF508- + AUAUAUAAUUUGGGUAGU 18
272 1782
CFTR- DeltaF508- + AAUAUAUAAUUUGGGUAGU 19
273 1783
CFTR- DeltaF508- + AAAUAUAUAAUUUGGGUAGU 20
274 688
CFTR- DeltaF508- + CAAAUAUAUAAUUUGGGUAGU 21
275 1784
CFTR- DeltaF508- + CCAAAUAUAUAAUUUGGGUAGU 22
276 1785
CFTR- DeltaF508- + GCCAAAUAUAUAAUUUGGGUAGU 23
277 1786
CFTR- DeltaF508- + AGCCAAAUAUAUAAUUUGGGUAGU 24
278 1787
CFTR-
- AUGGUGAUUAUGGGAGAA 18
DeltaF508- 1788
227
5535.1 279
CFTR- DeltaF508- - AAUGGUGAUUAUGGGAGAA 19
280 1789
CFTR- DeltaF508- - UAAUGGUGAUUAUGGGAGAA 20
281 659
CFTR- DeltaF508- - CUAAUGGUGAUUAUGGGAGAA 21
282 1790
CFTR- DeltaF508- - UCUAAUGGUGAUUAUGGGAGAA 22
283 1791
CFTR- DeltaF508- - UUCUAAUGGUGAUUAUGGGAGAA 23
284 1792
CFTR- DeltaF508- - CUUCUAAUGGUGAUUAUGGGAGAA 24
285 1793
CFTR- DeltaF508- - AGGG U AAAAU UAAGCACA 18
286 1794
CFTR- DeltaF508- - GAGGGUAAAAUUAAGCACA 19
287 1795
CFTR- DeltaF508- - AGAGGGU AAAAU UAAGCACA 20
288 662
CFTR- DeltaF508- - CAGAGGGUAAAAUUAAGCACA 21
289 1796
CFTR- DeltaF508- - UCAGAGGGU A A A A U U A AG CACA 22
290 1797
CFTR- DeltaF508- - U U CAG AGGG U AAAAU U AAG CACA 23
291 1798
CFTR- DeltaF508- - CUUCAGAGGGUAAAAU UAAGCACA 24
292 1799
CFTR-
- CUAUGAUGAAUAUAGAUA 18
DeltaF508- 1800
228
5535.1 293
CFTR- DeltaF508- - CCUAUGAUGAAUAUAGAUA 19
294 1801
CFTR- DeltaF508- - UCCUAUGAUGAAUAUAGAUA 20
295 667
CFTR- DeltaF508- - UUCCUAUGAUGAAUAUAGAUA 21
296 1802
CFTR- DeltaF508- - UUUCCUAUGAUGAAUAUAGAUA 22
297 1803
CFTR- DeltaF508- - GU UUCCUAUGAUGAAUAUAGAUA 23
298 1804
CFTR- DeltaF508- - UGUUUCCUAUGAUGAAUAUAGAUA 24
299 1805
CFTR- DeltaF508- - UUAUGCCUGGCACCAUUA 18
300 1806
CFTR- DeltaF508- - AUUAUGCCUGGCACCAU UA 19
301 1807
CFTR- DeltaF508- - GAUUAUGCCUGGCACCAUUA 20
302 665
CFTR- DeltaF508- - GGAUUAUGCCUGGCACCAUUA 21
303 1808
CFTR- DeltaF508- - UGGAUUAUGCCUGGCACCAUUA 22
304 1809
CFTR- DeltaF508- - CUGGAUUAUGCCUGGCACCAUUA 23
305 1810
CFTR- DeltaF508- - CCUGGAUUAUGCCUGGCACCAUUA 24
306 1811
CFTR-
- CACUUCUAAUGGUGAUUA 18
DeltaF508- 1812
229
5535.1 307
CFTR- DeltaF508- - UCACUUCUAAUGGUGAUUA 19
308 1813
CFTR-
- UUCACUUCUAAUGGUGAUUA 20
DeltaF508-39 421
CFTR- DeltaF508- - CUUCACUUCUAAUGGUGAUUA 21
309 1814
CFTR- DeltaF508- - ACUUCACUUCUAAUGGUGAUUA 22
310 1815
CFTR- DeltaF508- - GACUUCACUUCUAAUGGUGAUUA 23
311 1816
CFTR- DeltaF508- - AGACUUCACUUCUAAUGGUGAUUA 24
312 1817
CFTR- DeltaF508- - UCAUCAAAGCAUGCCAAC 18
313 1818
CFTR- DeltaF508- - G U C A U C A A AG CAUGCCAAC 19
314 1819
CFTR- DeltaF508- - CGUCAUCAAAGCAUGCCAAC 20
315 668
CFTR- DeltaF508- - GCGUCAUCAAAGCAUGCCAAC 21
316 1820
CFTR- DeltaF508- - AGCGUCAUCAAAGCAUGCCAAC 22
317 1821
CFTR- DeltaF508- - AAG CG U CAU C AAAG C AU G CCAAC 23
318 1822
CFTR- DeltaF508- - G AAG CG U CAU CAAAGCAUG CCAAC 24
319 1823
CFTR- DeltaF508- - UGGUGAUUAUGGGAGAAC 18
320 1824
230
5535.1 CFTR- DeltaF508- - AUGGUGAUUAUGGGAGAAC 19
321 1825
CFTR-
- AAUGGUGAUUAUGGGAGAAC 20
DeltaF508-40 423
CFTR- DeltaF508- - UAAUGGUGAUUAUGGGAGAAC 21
322 1826
CFTR- DeltaF508- - CUAAUGGUGAUUAUGGGAGAAC 22
323 1827
CFTR- DeltaF508- - UCUAAUGGUGAUUAUGGGAGAAC 23
324 1828
CFTR- DeltaF508- - UUCUAAUGGUGAUUAUGGGAGAAC 24
325 1829
CFTR- DeltaF508- - AUUGGAGGCAAGUGAAUC 18
326 1830
CFTR- DeltaF508- - AAUUGGAGGCAAGUGAAUC 19
327 1831
CFTR- DeltaF508- - UAAUUGGAGGCAAGUGAAUC 20
328 655
CFTR- DeltaF508- - GGG UAAAAU UAAG CACAG 18
329 1832
CFTR- DeltaF508- - AG G G U A A A A U U A AG C AC AG 19
330 1833
CFTR-
- GAGGG UAAAAU UAAGCACAG 20
DeltaF508-12 387
CFTR- DeltaF508- - AG AG G G U A A A A U U A AG CACAG 21
331 1834
CFTR- DeltaF508- - CAGAGGGUAAAAUUAAGCACAG 22
332 1835
CFTR- DeltaF508- - UCAGAGGGUAAAAUUAAGCACAG 23
333 1836
231
5535.1 CFTR- DeltaF508- - U UCAGAGGGUAAAAUUAAGCACAG 24
334 1837
CFTR- DeltaF508- - UCAAAGCAUGCCAACUAG 18
335 1838
CFTR- DeltaF508- - A U C A A AG C A U G C C A AC U AG 19
336 1839
CFTR- DeltaF508- - CAUCAAAGCAUGCCAACUAG 20
337 669
CFTR- DeltaF508- - U C A U C A A AG C A U G C C A AC U AG 21
338 1840
CFTR- DeltaF508- - GUCAUCAAAGCAUGCCAACUAG 22
339 1841
CFTR- DeltaF508- - CGUCAUCAAAGCAUGCCAACUAG 23
340 1842
CFTR- DeltaF508- - GCGUCAUCAAAGCAUGCCAACUAG 24
341 1843
CFTR- DeltaF508- - UUCUAAUGGUGAUUAUGG 18
342 1844
CFTR- DeltaF508- - CUUCUAAUGGUGAUUAUGG 19
343 1845
CFTR- DeltaF508- - ACUUCUAAUGGUGAU UAUGG 20
344 658
CFTR- DeltaF508- - CACUUCUAAUGGUGAU UAUGG 21
345 1846
CFTR- DeltaF508- - UCACUUCUAAUGGUGAUUAUGG 22
346 1847
CFTR- DeltaF508- - UUCACUUCUAAUGGUGAUUAUGG 23
347 1848
232
5535.1 CFTR- DeltaF508- - CUUCACUUCUAAUGGUGAUUAUGG 24
348 1849
CFTR- DeltaF508- - AACUUUUUGAUUAUGCAU 18
349 1850
CFTR- DeltaF508- - AAACUUUUUGAUUAUGCAU 19
350 1851
CFTR- DeltaF508- - AAAACUUUUUGAUUAUGCAU 20
351 672
CFTR- DeltaF508- - GAAAACUUUUUGAUUAUGCAU 21
352 1852
CFTR- DeltaF508- - UGAAAACUUUUUGAUUAUGCAU 22
353 1853
CFTR- DeltaF508- - GUGAAAACUUUUUGAUUAUGCAU 23
354 1854
CFTR- DeltaF508- - UGUGAAAACUUUUUGAUUAUGCAU 24
355 1855
CFTR- DeltaF508- - GAAGAGGUAAGAAACUAU 18
356 1856
CFTR- DeltaF508- - AGAAGAGGUAAGAAACUAU 19
357 1857
CFTR- DeltaF508- - UAGAAGAGGUAAGAAACUAU 20
358 671
CFTR- DeltaF508- - CUAGAAGAGGUAAGAAACUAU 21
359 1858
CFTR- DeltaF508- - ACU AGAAGAGGUAAGAAACUAU 22
360 1859
CFTR- DeltaF508- - AACUAGAAGAGGUAAGAAACUAU 23
361 1860
233
5535.1 CFTR- DeltaF508- - CAACUAGAAGAGGUAAGAAACUAU 24
362 1861
CFTR- DeltaF508- - ACU UCUAAUGGUGAUUAU 18
363 1862
CFTR- DeltaF508- - CACUUCUAAUGGUGAUUAU 19
364 1863
CFTR-
- UCACUUCUAAUGGUGAUUAU 20
DeltaF508-51 422
CFTR- DeltaF508- - UUCACUUCUAAUGGUGAUUAU 21
365 1864
CFTR- DeltaF508- - CUUCACUUCUAAUGGUGAUUAU 22
366 1865
CFTR- DeltaF508- - ACU UCACUUCUAAUGGUGAUUAU 23
367 1866
CFTR- DeltaF508- - GACU UCACUUCUAAUGGUGAUUAU 24
368 1867
CFTR- DeltaF508- - AUGCCAACUAGAAGAGGU 18
369 1868
CFTR- DeltaF508- - CAUGCCAACUAGAAGAGGU 19
370 1869
CFTR- DeltaF508- - GCAUGCCAACUAGAAGAGGU 20
371 670
CFTR- DeltaF508- - AGCAUGCCAACUAGAAGAGGU 21
372 1870
CFTR- DeltaF508- - AAGCAUGCCAACUAGAAGAGGU 22
373 1871
CFTR- DeltaF508- - A A AG CAUGCCAACUAGAAGAGGU 23
374 1872
CFTR-
- CAAAGCAUGCCAACUAGAAGAGGU 24
DeltaF508- 1873
234
5535.1 375
CFTR- DeltaF508- - UCACU UCUAAUGGUGAUU 18
376 1874
CFTR- DeltaF508- - UUCACUUCUAAUGGUGAUU 19
377 1875
CFTR- DeltaF508- - CUUCACUUCUAAUGGUGAUU 20
378 657
CFTR- DeltaF508- - ACUUCACUUCUAAUGGUGAUU 21
379 1876
CFTR- DeltaF508- - GACUUCACUUCUAAUGGUGAUU 22
380 1877
CFTR- DeltaF508- - AGACUUCACUUCUAAUGGUGAUU 23
381 1878
CFTR- DeltaF508- - CAGACU UCACUUCUAAUGGUGAUU 24
382 1879
CFTR- DeltaF508- - UGGGAGAACUGGAGCCUU 18
383 1880
CFTR- DeltaF508- - AUGGGAGAACUGGAGCCUU 19
384 1881
CFTR- DeltaF508- - UAUGGGAGAACUGGAGCCUU 20
385 660
CFTR- DeltaF508- - UUAUGGGAGAACUGGAGCCUU 21
386 1882
CFTR- DeltaF508- - AUUAUGGGAGAACUGGAGCCUU 22
387 1883
CFTR- DeltaF508- - GAUUAUGGGAGAACUGGAGCCUU 23
388 1884
CFTR-
- UGAUUAUGGGAGAACUGGAGCCUU 24
DeltaF508- 1885
235
5535.1
Figure imgf000237_0001
Table 12A provides exemplary targeting domains for correcting a mutation (e.g., deltaF508) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., deltaF508), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 12A
Figure imgf000237_0002
Table 12B provides exemplary targeting domains for correcting a mutation (e.g., deltaF508) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., deltaF508) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 12B
Figure imgf000237_0003
236
5535.1 CFTR-
+ CUUACCUCUUCUAGUUG 17
DeltaF508-394 1887
CFTR-
- UU UCCAGACUUCACUUCUAA 20
DeltaF508-34 420
CFTR-
- UGGAGGCAAGUGAAUCCUGA 20
DeltaF508-395 917
CFTR-
+ U UCUAGUUGGCAUGCUUUGA 20
DeltaF508-396 1888
CFTR-
+ AGGUCAUUAUCAAAUCACGC 20
DeltaF508-397 920
CFTR-
- UAAGAAACUAUGUGAAAACU 20
DeltaF508-398 919
Table 12C provides exemplary targeting domains for correcting a mutation (e.g., deltaF508) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., deltaF508). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 12C
Figure imgf000238_0001
237
5535.1 Table 13A provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break
(Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 13A
Figure imgf000239_0001
Table 13B provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 13B
Figure imgf000239_0002
238
5535.1 CFTR-G542X-
- UAUAUGAUUACAUUAGA 17
12 485
CFTR-G542X-
- AAAAUCCUGGGGUUUUA 17
13 493
CFTR-G542X-
+ ACUAGCCAUAAAACCCC 17
14 459
CFTR-G542X-
- UGGGGUUUUAUGGCUAG 17
15 494
CFTR-G542X-
- AUAGUUCUUUGAGAAGG 17
16 1892
CFTR-G542X-
+ AUGCUCAAUCUGAAUUUGAA 20
17 484
CFTR-G542X-
- UGAUAUAUGAUUACAUUAGA 20
18 471
CFTR-G542X-
+ CCCACUAGCCAUAAAACCCC 20
19 455
CFTR-G542X-
- UUCUGGAAUUGAAAAAAUCC 20
20 477
CFTR-G542X-
- CUGGAAUUGAAAAAAUCCUG 20
21 479
CFTR-G542X-
- CAAGGUGAAUAACUAAU UAU 20
22 475
CFTR-G542X-
- CCUGGGGU UUUAUGGCUAGU 20
23 481
Table 13C provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 13C
Figure imgf000240_0001
239
5535.1 25
CFTR-G542X-
- GGAAUUGAAAAAAUCCU 17
26 467
CFTR-G542X-
- GACAAUAUAGUUCUUUGAGA 20
27 1893
CFTR-G542X-
- GAAAAAAUCCUGGGGUUUUA 20
28 463
Table 13D provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 13D
Figure imgf000241_0001
240
5535.1 CFTR-G542X-
+ AUUGUCUUUCUCUGCAAACU 20
40 483
CFTR-G542X-
- UCUGGAAUUGAAAAAAUCCU 20
41 478
CFTR-G542X-
- ACUCUCUAAUU UUCUAU UUU 20
42 472
Table 14A provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 14A
Figure imgf000242_0001
241
5535.1 53
Table 14B provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 14B
Figure imgf000243_0001
242
5535.1 CFTR-G542X-
+ U UAACCCACUAGCCAUAAAACCC 23
67 1918
CFTR-G542X-
+ CUUAACCCACUAGCCAUAAAACCC 24
68 1919
CFTR-G542X-
+ ACUUUUAGUAUGCUCAAU 18
69 1920
CFTR-G542X-
+ CACUUUUAGUAUGCUCAAU 19
70 1921
CFTR-G542X-
+ UCACUUUUAGUAUGCUCAAU 20
71 756
CFTR-G542X-
+ AGUCACUUUUAGUAUGCUCAAU 22
72 1922
CFTR-G542X-
+ AGAGUCACUUUUAGUAUGCUCAAU 24
73 1923
CFTR-G542X-
- CCUGGGGU UUUAUGGCUA 18
74 1924
CFTR-G542X-
- UCCUGGGGUUUUAUGGCUA 19
75 1925
CFTR-G542X-
- AUCCUGGGGUUUUAUGGCUA 20
76 750
CFTR-G542X-
- AAUCCUGGGGUUUUAUGGCUA 21
77 1926
CFTR-G542X-
- AAAUCCUGGGGUUUUAUGGCUA 22
78 1927
CFTR-G542X-
- AAAAUCCUGGGGUUUUAUGGCUA 23
79 1928
CFTR-G542X-
- AAAAAUCCUGGGGUUUUAUGGCUA 24
80 1929
CFTR-G542X-
- UGAGUGGAGGUCAACGAGC 19
81 1930
CFTR-G542X-
- CUGAGUGGAGGUCAACGAGC 20
82 745
CFTR-G542X-
- UGCUUUAUAUUCUGUUUC 18
83 1931
CFTR-G542X-
- UUGCUUUAUAUUCUGU UUC 19
84 1932
CFTR-G542X-
- AUUGCUUUAUAUUCUGUUUC 20
35 476
CFTR-G542X-
- UAUUGCUUUAUAUUCUGUUUC 21
85 1933
CFTR-G542X-
- CUAUUGCUUUAUAUUCUGUUUC 22
86 1934
CFTR-G542X- - UCUAUUGCU UUAUAUUCUGUUUC 23 1935
243
5535.1 87
CFTR-G542X-
- CUCUAUUGCUUUAUAU UCUGUUUC 24
88 1936
CFTR-G542X-
- AAGAAUUUCUUUAGCAAG 18
89 1937
CFTR-G542X-
- CAAGAAUUUCUUUAGCAAG 19
90 1938
CFTR-G542X-
- AGCAAGAAUUUCUUUAGCAAG 21
91 1939
CFTR-G542X-
- CG AG CAAGAAU U U CU U U AG CAAG 23
92 1940
CFTR-G542X-
- ACG AG CAAGAAU U U CU U UAGCAAG 24
93 1941
CFTR-G542X-
- UU UUAUGGCUAGUGGGUU 18
94 1942
CFTR-G542X-
- UGGGGUUUUAUGGCUAGUGGGUU 23
95 1943
CFTR-G542X-
- CUGGGGUUUUAUGGCUAGUGGGUU 24
96 1944
Table 14C provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X), start with a 5'G and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 14C
Figure imgf000245_0001
244
5535.1 CFTR-G542X-
- GACAAUAUAGUUCUUUGAGAAGG 23
101 1949
Table 14D provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X), and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 14D
Figure imgf000246_0001
245
5535.1 114
CFTR-G542X-
- UCUUUGAGAAGGUGGAAUCACA 22
115 1962
CFTR-G542X-
- UUCUUUGAGAAGGUGGAAUCACA 23
116 1963
CFTR-G542X-
- CUGGAAUUGAAAAAAUCC 18
117 1964
CFTR-G542X-
- UCUGGAAUUGAAAAAAUCC 19
118 1965
CFTR-G542X-
- UUCUGGAAUUGAAAAAAUCC 20
20 477
CFTR-G542X-
- UUUCUGGAAUUGAAAAAAUCC 21
119 1966
CFTR-G542X-
- UGUUUCUGGAAUUGAAAAAAUCC 23
120 1967
CFTR-G542X-
- CUGUUUCUGGAAUUGAAAAAAUCC 24
121 1968
CFTR-G542X-
- ACUGAGUGGAGGUCAACGAGC 21
122 1969
CFTR-G542X-
- CACUGAGUGGAGGUCAACGAGC 22
123 1970
CFTR-G542X-
- ACACUGAGUGGAGGUCAACGAGC 23
124 1971
CFTR-G542X-
- CACACUGAGUGGAGGUCAACGAGC 24
125 1972
CFTR-G542X-
- UAUAGUUCUUUGAGAAGG 18
126 1973
CFTR-G542X-
- AUAUAGUUCUUUGAGAAGG 19
127 1974
CFTR-G542X-
- AAUAUAGUUCUUUGAGAAGG 20
37 1897
CFTR-G542X-
- CAAUAUAGUUCUUUGAGAAGG 21
128 1975
CFTR-G542X-
- ACAAUAUAGUUCUUUGAGAAGG 22
129 1976
CFTR-G542X-
- AG ACAAU AU AG U U CU U UG AG AAGG 24
130 1977
Table 14E provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X), and PAM is NNGRRV. It is contemplated herein
246
5535.1 that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with ; aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 14E
Figure imgf000248_0001
247
5535.1 147
CFTR-G542X-
+ CAGUGUGAUUCCACCUUCUCA 21
148 1993
CFTR-G542X-
+ UCAGUGUGAUUCCACCUUCUCA 22
149 1994
CFTR-G542X-
+ CUCAGUGUGAUUCCACCUUCUCA 23
150 1995
CFTR-G542X-
+ ACUCAGUGUGAUUCCACCUUCUCA 24
151 1996
CFTR-G542X-
+ ACAGAAUAUAAAGCAAUA 18
152 1997
CFTR-G542X-
+ AACAGAAUAUAAAGCAAUA 19
153 1998
CFTR-G542X-
+ A A AC AG A A U A U A A AG C A A U A 20
154 764
CFTR-G542X-
+ G A A AC AG A A U A U A A AG C A A U A 21
155 1999
CFTR-G542X-
+ AGAAACAGAAUAUAAAGCAAUA 22
156 2000
CFTR-G542X-
+ C AG A A AC AG A A U A U A A AG C A A U A 23
157 2001
CFTR-G542X-
+ CCAGAAACAGAAUAUAAAGCAAUA 24
158 2002
CFTR-G542X-
+ UAGUUAUUCACCUUGCUA 18
159 2003
CFTR-G542X-
+ UUAGUUAUUCACCUUGCUA 19
160 2004
CFTR-G542X-
+ AUUAGUUAUUCACCUUGCUA 20
161 762
CFTR-G542X-
+ AAUUAGUUAUUCACCU UGCUA 21
162 2005
CFTR-G542X-
+ UAAUUAGUUAUUCACCUUGCUA 22
163 2006
CFTR-G542X-
+ AUAAUUAGUUAUUCACCUUGCUA 23
164 2007
CFTR-G542X-
+ AAUAAUUAGUUAUUCACCUUGCUA 24
165 2008
CFTR-G542X-
+ UUGUCUUUCUCUGCAAAC 18
166 2009
CFTR-G542X-
+ AUUGUCUUUCUCUGCAAAC 19
167 2010
CFTR-G542X-
+ UAUUGUCUUUCUCUGCAAAC 20
168 760
248
5535.1 CFTR-G542X-
+ AUAUUGUCUUUCUCUGCAAAC 21
169 2011
CFTR-G542X-
+ UAUAUUGUCUUUCUCUGCAAAC 22
170 2012
CFTR-G542X-
+ CUAUAUUGUCU UUCUCUGCAAAC 23
171 2013
CFTR-G542X-
+ ACUAUAUUGUCUUUCUCUGCAAAC 24
172 2014
CFTR-G542X-
+ CCAGGAUUUUU UCAAU UC 18
173 2015
CFTR-G542X-
+ CCCAGGAUUU UUUCAAU UC 19
174 2016
CFTR-G542X-
+ CCCCAGGAU UUUUUCAAUUC 20
175 767
CFTR-G542X-
+ ACCCCAGGAUUUUUUCAAUUC 21
176 2017
CFTR-G542X-
+ AACCCCAGGAUUUUUUCAAUUC 22
177 2018
CFTR-G542X-
+ AAACCCCAGG AU UUUUUCAAUUC 23
178 2019
CFTR-G542X-
+ AAAACCCCAGG AU U U U U U CAAU U C 24
179 2020
CFTR-G542X-
+ CUAUUGCUUUAACCACAG 18
180 2021
CFTR-G542X-
+ ACUAUUGCUUUAACCACAG 19
181 2022
CFTR-G542X-
+ CACUAUUGCUUUAACCACAG 20
182 754
CFTR-G542X-
+ ACACUAUUGCUU UAACCACAG 21
183 2023
CFTR-G542X-
+ CACACUAUUGCUUUAACCACAG 22
184 2024
CFTR-G542X-
+ U CACACU AU UG CU U U AACCACAG 23
185 2025
CFTR-G542X-
+ AUCACACUAUUGCUUUAACCACAG 24
186 2026
CFTR-G542X-
+ U U ACCAAAAAU AG AAAAU 18
187 2027
CFTR-G542X-
+ AUUACCAAAAAUAGAAAAU 19
188 2028
CFTR-G542X-
+ UAU U ACCAAAAAU AGAAAAU 20
189 758
CFTR-G542X- + CU AU U ACCAAAAAU AG AAAAU 21 2029
249
5535.1 190
CFTR-G542X-
+ CCU AUU ACCAAAAAU AGAAAAU 22
191 2030
CFTR-G542X-
+ UCCUAUUACCAAAAAUAGAAAAU 23
192 2031
CFTR-G542X-
+ G U CCU AU U ACCAAAAAU AG AAAAU 24
193 2032
CFTR-G542X-
+ AGUAUGCUCAAUCUGAAU 18
194 2033
CFTR-G542X-
+ UAGUAUGCUCAAUCUGAAU 19
195 2034
CFTR-G542X-
+ U UAGUAUGCUCAAUCUGAAU 20
196 755
CFTR-G542X-
+ U UUAGUAUGCUCAAUCUGAAU 21
197 2035
CFTR-G542X-
+ U UUUAGUAUGCUCAAUCUGAAU 22
198 2036
CFTR-G542X-
+ CUU UUAGUAUGCUCAAUCUGAAU 23
199 2037
CFTR-G542X-
+ ACUUUUAGUAUGCUCAAUCUGAAU 24
200 2038
CFTR-G542X-
+ UGUCUUUCUCUGCAAACU 18
201 2039
CFTR-G542X-
+ UUGUCUUUCUCUGCAAACU 19
202 2040
CFTR-G542X-
+ AUUGUCUUUCUCUGCAAACU 20
40 483
CFTR-G542X-
+ UAUUGUCUUUCUCUGCAAACU 21
203 2041
CFTR-G542X-
+ AUAUUGUCUUUCUCUGCAAACU 22
204 2042
CFTR-G542X-
+ UAUAUUGUCUUUCUCUGCAAACU 23
205 2043
CFTR-G542X-
+ CUAUAUUGUCU UUCUCUGCAAACU 24
206 2044
CFTR-G542X-
+ U U AACCACAG UUGAAAU U 18
207 2045
CFTR-G542X-
+ U U U AACCACAG UUGAAAU U 19
208 2046
CFTR-G542X-
+ CUUU AACCACAG UUGAAAU U 20
209 753
CFTR-G542X-
+ G CU U U AACCACAG UUGAAAU U 21
210 2047
250
5535.1 CFTR-G542X-
+ UGCUUUAACCACAGUUGAAAUU 22
211 2048
CFTR-G542X-
+ U UGCUUUAACCACAGUUGAAAUU 23
212 2049
CFTR-G542X-
+ AU UG CU U U AACCACAG U UG AAAU U 24
213 2050
CFTR-G542X-
- UAUAUUCUGUUUCUGGAA 18
214 2051
CFTR-G542X-
- UUAUAUUCUGUUUCUGGAA 19
215 2052
CFTR-G542X-
- UU UAUAUUCUGUUUCUGGAA 20
216 748
CFTR-G542X-
- CUUUAUAUUCUGUUUCUGGAA 21
217 2053
CFTR-G542X-
- GCUU UAUAUUCUGUUUCUGGAA 22
218 2054
CFTR-G542X-
- UGCU UUAUAUUCUGUU UCUGGAA 23
219 2055
CFTR-G542X-
- UUGCUUUAUAUUCUGU UUCUGGAA 24
220 2056
CFTR-G542X-
- AAAUUGCAUUUGAAAUAA 18
221 2057
CFTR-G542X-
- UAAAUUGCAUUUGAAAUAA 19
222 2058
CFTR-G542X-
- AUAAAUUGCAUUUGAAAUAA 20
34 1896
CFTR-G542X-
- AUUUUCUAUUU UUGGUAA 18
223 2059
CFTR-G542X-
- AAUUUUCUAUUUUUGGUAA 19
224 2060
CFTR-G542X-
- UAAUUUUCUAUUUUUGGUAA 20
225 736
CFTR-G542X-
- CUAAUUUUCUAU UUUUGGUAA 21
226 2061
CFTR-G542X-
- UCUAAUUUUCUAUUUUUGGUAA 22
227 2062
CFTR-G542X-
- CUCUAAUUUUCUAUUUUUGGUAA 23
228 2063
CFTR-G542X-
- UCUCUAAUUUUCUAUUUUUGGUAA 24
229 2064
CFTR-G542X-
- GACAUCUCCAAGUUUGCA 18
230 2065
CFTR-G542X- - GGACAUCUCCAAGU UUGCA 19 2066
251
5535.1 231
CFTR-G542X-
- AGGACAUCUCCAAGUUUGCA 20
232 738
CFTR-G542X-
- UAGGACAUCUCCAAGUU UGCA 21
233 2067
CFTR-G542X-
- AUAGGACAUCUCCAAGU UUGCA 22
234 2068
CFTR-G542X-
- AAUAGGACAUCUCCAAGUUUGCA 23
235 2069
CFTR-G542X-
- UAAUAGGACAUCUCCAAGUUUGCA 24
236 2070
CFTR-G542X-
- CACACUGAGUGGAGGUCA 18
237 2071
CFTR-G542X-
- UCACACUGAGUGGAGGUCA 19
238 2072
CFTR-G542X-
- AUCACACUGAGUGGAGGUCA 20
239 744
CFTR-G542X-
- AAUCACACUGAGUGGAGGUCA 21
240 2073
CFTR-G542X-
- GAAUCACACUGAGUGGAGGUCA 22
241 2074
CFTR-G542X-
- GGAAUCACACUGAGUGGAGGUCA 23
242 2075
CFTR-G542X-
- UGGAAUCACACUGAGUGGAGGUCA 24
243 2076
CFTR-G542X-
- GUGCCU UUCAAAUUCAGA 18
244 2077
CFTR-G542X-
- UGUGCCUUUCAAAUUCAGA 19
245 2078
CFTR-G542X-
- AUGUGCCUU UCAAAUUCAGA 20
246 735
CFTR-G542X-
- GAUGUGCCUU UCAAAU UCAGA 21
247 2079
CFTR-G542X-
- AGAUGUGCCUUUCAAAUUCAGA 22
248 2080
CFTR-G542X-
- AAGAUGUGCCUUUCAAAUUCAGA 23
249 2081
CFTR-G542X-
- GAAGAUGUGCCUUUCAAAUUCAGA 24
250 2082
CFTR-G542X-
- AUAUAUGAUUACAUUAGA 18
251 2083
CFTR-G542X-
- GAUAUAUGAUUACAUUAGA 19
252 2084
252
5535.1 CFTR-G542X-
- UGAUAUAUGAUUACAUUAGA 20
18 471
CFTR-G542X-
- GUGAUAUAUGAUUACAUUAGA 21
253 2085
CFTR-G542X-
- UGUGAUAUAUGAUUACAUUAGA 22
254 2086
CFTR-G542X-
- GUGUGAUAUAUGAUUACAUUAGA 23
255 2087
CFTR-G542X-
- AGUGUGAUAUAUGAUUACAUUAGA 24
256 2088
CFTR-G542X-
- AAGGUGGAAUCACACUGA 18
257 2089
CFTR-G542X-
- GAAGGUGGAAUCACACUGA 19
258 2090
CFTR-G542X-
- AGAAGGUGGAAUCACACUGA 20
259 743
CFTR-G542X-
- GAGAAGGUGGAAUCACACUGA 21
260 2091
CFTR-G542X-
- UGAGAAGGUGGAAUCACACUGA 22
261 2092
CFTR-G542X-
- UUGAGAAGGUGGAAUCACACUGA 23
262 2093
CFTR-G542X-
- UU UGAGAAGGUGGAAUCACACUGA 24
263 2094
CFTR-G542X-
- UAAAUUGCAUUUGAAAUA 18
264 2095
CFTR-G542X-
- AUAAAUUGCAUUUGAAAUA 19
265 2096
CFTR-G542X-
- AAUAAAUUGCAUUUGAAAUA 20
266 2097
CFTR-G542X-
- UCUGGAAUUGAAAAAAUC 18
267 2098
CFTR-G542X-
- UUCUGGAAUUGAAAAAAUC 19
268 2099
CFTR-G542X-
- UUUCUGGAAUUGAAAAAAUC 20
269 749
CFTR-G542X-
- GU UUCUGGAAUUGAAAAAAUC 21
270 2100
CFTR-G542X-
- UGUUUCUGGAAUUGAAAAAAUC 22
271 2101
CFTR-G542X-
- CUGU UUCUGGAAUUGAAAAAAUC 23
272 2102
CFTR-G542X- - UCUGUUUCUGGAAUUGAAAAAAUC 24 2103
253
5535.1 273
CFTR-G542X-
- AUAUAGUUCUUUGAGAAG 18
274 2104
CFTR-G542X-
- AAUAUAGUUCUUUGAGAAG 19
275 2105
CFTR-G542X-
- CAAUAUAGUUCUUUGAGAAG 20
276 2106
CFTR-G542X-
- ACAAUAUAGUUCUUUGAGAAG 21
277 2107
CFTR-G542X-
- GACAAUAUAGUUCUUUGAGAAG 22
278 2108
CFTR-G542X-
- AG ACAAU AU AG U U CU U UG AG AAG 23
279 2109
CFTR-G542X-
- AAG ACAAU AU AG U U CU U UG AG AAG 24
280 2110
CFTR-G542X-
- AGGUGGAAUCACACUGAG 18
281 2111
CFTR-G542X-
- AAGGUGGAAUCACACUGAG 19
282 2112
CFTR-G542X-
- GAAGGUGGAAUCACACUGAG 20
8 461
CFTR-G542X-
- AGAAGGUGGAAUCACACUGAG 21
283 2113
CFTR-G542X-
- GAGAAGGUGGAAUCACACUGAG 22
284 2114
CFTR-G542X-
- UGAGAAGGUGGAAUCACACUGAG 23
285 2115
CFTR-G542X-
- UUGAGAAGGUGGAAUCACACUGAG 24
286 2116
CFTR-G542X-
- GAUAUAUGAUUACAUUAG 18
287 2117
CFTR-G542X-
- UGAUAUAUGAUUACAU UAG 19
288 2118
CFTR-G542X-
- GUGAUAUAUGAUUACAUUAG 20
289 734
CFTR-G542X-
- UGUGAUAUAUGAUUACAUUAG 21
290 2119
CFTR-G542X-
- GUGUGAUAUAUGAUUACAUUAG 22
291 2120
CFTR-G542X-
- AGUGUGAUAUAUGAUUACAUUAG 23
292 2121
CFTR-G542X-
- UAGUGUGAUAUAUGAUUACAUUAG 24
293 2122
254
5535.1 CFTR-G542X-
- AGGACAUCUCCAAGUUUG 18
294 2123
CFTR-G542X-
- UAGGACAUCUCCAAGUU UG 19
295 2124
CFTR-G542X-
- AUAGGACAUCUCCAAGU UUG 20
296 737
CFTR-G542X-
- AAUAGGACAUCUCCAAGUUUG 21
297 2125
CFTR-G542X-
- UAAUAGGACAUCUCCAAGUUUG 22
298 2126
CFTR-G542X-
- GU AAUAGGACAUCUCCAAGUUUG 23
299 2127
CFTR-G542X-
- GGUAAUAGGACAUCUCCAAGUUUG 24
300 2128
CFTR-G542X-
- UGUGAUAUAUGAUUACAU 18
301 2129
CFTR-G542X-
- GUGUGAUAUAUGAUUACAU 19
302 2130
CFTR-G542X-
- AGUGUGAUAUAUGAUUACAU 20
303 733
CFTR-G542X-
- UAGUGUGAUAUAUGAU UACAU 21
304 2131
CFTR-G542X-
- AUAGUGUGAUAUAUGAUUACAU 22
305 2132
CFTR-G542X-
- AAUAGUGUGAUAUAUGAUUACAU 23
306 2133
CFTR-G542X-
- CAAUAGUGUGAUAUAUGAUUACAU 24
307 2134
CFTR-G542X-
- GAAAGACAAUAUAGUUCU 18
308 2135
CFTR-G542X-
- AG AAAG ACAAU AU AG U U CU 19
309 2136
CFTR-G542X-
- GAGAAAGACAAUAUAGUUCU 20
310 453
CFTR-G542X-
- AG AG AAAG ACAAU AU AG U U CU 21
311 2137
CFTR-G542X-
- CAGAGAAAGACAAUAUAGUUCU 22
312 2138
CFTR-G542X-
- GCAG AG AAAG ACAAU AU AG U U CU 23
313 2139
CFTR-G542X-
- UGCAGAGAAAGACAAUAUAGUUCU 24
314 2140
CFTR-G542X- - AAG ACAAU AU AG U U CU U U 18 2141
255
5535.1 315
CFTR-G542X-
- AAAGACAAUAUAGUUCUUU 19
316 2142
CFTR-G542X-
- GAAAGACAAUAUAGUUCUUU 20
317 2143
CFTR-G542X-
- AG AAAG ACAAU AU AG U U CU U U 21
318 2144
CFTR-G542X-
- GAGAAAGACAAUAUAGUUCUUU 22
319 2145
CFTR-G542X-
- AG AG AAAG ACAAU AU AG U U CU U U 23
320 2146
CFTR-G542X-
- CAG AG AAAG ACAAU AU AG U U CU U U 24
321 2147
CFTR-G542X-
- UUGCUUUAUAUUCUGUUU 18
322 2148
CFTR-G542X-
- AUUGCUUUAUAUUCUGUUU 19
323 2149
CFTR-G542X-
- UAUUGCUUUAUAUUCUGUUU 20
324 747
CFTR-G542X-
- CUAUUGCUUUAUAUUCUGUUU 21
325 2150
CFTR-G542X-
- UCUAUUGCUUUAUAUUCUGUUU 22
326 2151
CFTR-G542X-
- CUCUAUUGCUUUAUAUUCUGUUU 23
327 2152
CFTR-G542X-
- UCUCUAUUGCUUUAUAUUCUGUUU 24
328 2153
Table 15A provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 15A
Figure imgf000257_0001
256
5535.1 CFTR-G542X-
+ GUAAUCAUAUAUCACAC 17
329 2154
CFTR-G542X-
- GGU UAAAGCAAUAGUGUGAU 20
330 927
Table 15B provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 15B
Figure imgf000258_0001
Table 15C provides exemplary targeting domains for correcting a mutation (e.g., G542X) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G542X). It is contemplated herein that in an
257
5535.1 embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break
(Cas9 nickase).
Table 15C
Figure imgf000259_0001
Table 16A provides exemplary targeting domains for correcting a mutation (e.g., G551D) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G551D), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break
(Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 16A
Figure imgf000259_0002
258
5535.1 Table 16B provides exemplary targeting domains for correcting a mutation (e.g., G551D) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G551D) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 16B
Figure imgf000260_0001
259
5535.1 24
CFTR-G551D-
- CAAGGUGAAUAACUAAUUAU 20
25 475
CFTR-G551D-
- CCUGGGGUUUUAUGGCUAGU 20
26 481
Table 16C provides exemplary targeting domains for correcting a mutation (e.g., G551D) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G551D) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 16C
Figure imgf000261_0001
Table 16D provides exemplary targeting domains for correcting a mutation (e.g., G551D) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G551D). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 16D
Figure imgf000261_0002
260
5535.1 CFTR-G551D-
- U UAAGAACUAUAAAUAA 17
31 495
CFTR-G551D-
- UGGAAUUGAAAAAAUCC 17
32 492
CFTR-G551D-
- UUUCUAUUUUUGGUAAU 17
33 487
CFTR-G551D-
- CUCUAAUUUUCUAUUUU 17
34 486
CFTR-G551D-
- CAUU UAAGAACUAUAAAUAA 20
35 482
CFTR-G551D-
- AUUGCUUUAUAUUCUGUUUC 20
36 476
CFTR-G551D-
- UCCUGGGGUUUUAUGGCUAG 20
37 480
CFTR-G551D-
- AAUGUUCAAAAUUUCAACUG 20
38 470
CFTR-G551D-
- AAUUUUCUAUUUUUGGUAAU 20
39 473
CFTR-G551D-
+ AUUGUCUUUCUCUGCAAACU 20
40 483
CFTR-G551D-
- UCUGGAAUUGAAAAAAUCCU 20
41 478
CFTR-G551D-
- ACUCUCUAAUUUUCUAUUUU 20
42 472
Table 17A provides exemplary targeting domains for correcting a mutation (e.g., G551D) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G551D), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 17A
Figure imgf000262_0001
261
5535.1 44
CFTR-G551D-
+ GUCACUUUUAGUAUGCUCAAU 21
45 1899
CFTR-G551D-
+ GAGUCACUUUUAGUAUGCUCAAU 23
46 1900
CFTR-G551D-
- GGAGAAGGUGGAAUCACA 18
47 2160
CFTR-G551D-
- GUUCUUGGAGAAGGUGGAAUCACA 24
48 2161
CFTR-G551D-
- GCAAGAAUUUCUUUAGCAAG 20
49 746
CFTR-G551D-
- GAG CAAGAAU U U CU UUAGCAAG 22
50 1902
CFTR-G551D-
- GACAAUAUAGUUCUUGGAGAAGG 23
51 2162
CFTR-G551D-
- GUUUUAUGGCUAGUGGGUU 19
52 1903
CFTR-G551D-
- GGUUUUAUGGCUAGUGGGUU 20
53 751
CFTR-G551D-
- GGGUUUUAUGGCUAGUGGGUU 21
54 1904
CFTR-G551D-
- GGGGUUUUAUGGCUAGUGGGUU 22
55 1905
Table 17B provides exemplary targeting domains for correcting a mutation (e.g., G551D) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G551D), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 17B
Figure imgf000263_0001
262
5535.1 CFTR-G551D-
+ AGGAUUUUUUCAAUU CCAG AAA 22
58 1908
CFTR-G551D-
+ CAGG AU U U U U U CAAU U CCAG AAA 23
59 1909
CFTR-G551D-
+ CCAGG AU U U U U U CAAU U CCAG AAA 24
60 1910
CFTR-G551D-
+ UGUCUGUAAUUUUUUUAC 18
61 1911
CFTR-G551D-
+ AUGUCUGUAAUUUUUUUAC 19
62 1912
CFTR-G551D-
+ AAUGUCUGUAAUUUUUUUAC 20
63 763
CFTR-G551D-
+ CCACUAGCCAUAAAACCC 18
64 1913
CFTR-G551D-
+ CCCACUAGCCAUAAAACCC 19
65 1914
CFTR-G551D-
+ ACCCACUAGCCAUAAAACCC 20
66 1915
CFTR-G551D-
+ AACCCACUAGCCAUAAAACCC 21
67 1916
CFTR-G551D-
+ UAACCCACUAGCCAUAAAACCC 22
68 1917
CFTR-G551D-
+ UUAACCCACUAGCCAUAAAACCC 23
69 1918
CFTR-G551D-
+ CUUAACCCACUAGCCAUAAAACCC 24
70 1919
CFTR-G551D-
+ ACUUUUAGUAUGCUCAAU 18
71 1920
CFTR-G551D-
+ CACUUUUAGUAUGCUCAAU 19
72 1921
CFTR-G551D-
+ UCACUUUUAGUAUGCUCAAU 20
73 756
CFTR-G551D-
+ AGUCACUUUUAGUAUGCUCAAU 22
74 1922
CFTR-G551D-
+ AGAGUCACUUUUAGUAUGCUCAAU 24
75 1923
CFTR-G551D-
- UGGAGAAGGUGGAAUCACA 19
76 2163
CFTR-G551D-
- UUGGAGAAGGUGGAAUCACA 20
77 742
CFTR-G551D-
- CUUGGAGAAGGUGGAAUCACA 21
78 2164
CFTR-G551D- - UCUUGGAGAAGGUGGAAUCACA 22 2165
263
5535.1 79
CFTR-G551D-
- UUCUUGGAGAAGGUGGAAUCACA 23
80 2166
CFTR-G551D-
- CCUGGGGUUUUAUGGCUA 18
81 1924
CFTR-G551D-
- UCCUGGGGUUUUAUGGCUA 19
82 1925
CFTR-G551D-
- AUCCUGGGGUUUUAUGGCUA 20
83 750
CFTR-G551D-
- AAUCCUGGGGUUUUAUGGCUA 21
84 1926
CFTR-G551D-
- AAAUCCUGGGGUUUUAUGGCUA 22
85 1927
CFTR-G551D-
- AAAAUCCUGGGGUUUUAUGGCUA 23
86 1928
CFTR-G551D-
- AAAAAUCCUGGGGUUUUAUGGCUA 24
87 1929
CFTR-G551D-
- UGCUUUAUAUUCUGUUUC 18
88 1931
CFTR-G551D-
- UUGCUUUAUAUUCUGUUUC 19
89 1932
CFTR-G551D-
- AUUGCUUUAUAUUCUGUUUC 20
36 476
CFTR-G551D-
- UAUUGCUUUAUAUUCUGUUUC 21
90 1933
CFTR-G551D-
- CUAUUGCUUUAUAUUCUGUUUC 22
91 1934
CFTR-G551D-
- UCUAUUGCUUUAUAUUCUGUUUC 23
92 1935
CFTR-G551D-
- CUCUAUUGCUUUAUAUUCUGUUUC 24
93 1936
CFTR-G551D-
- AAGAAUUUCUUUAGCAAG 18
94 1937
CFTR-G551D-
- CAAGAAUUUCUUUAGCAAG 19
95 1938
CFTR-G551D-
- AGCAAGAAUUUCUUUAGCAAG 21
96 1939
CFTR-G551D-
- CG AGCAAG AAU U U CU U U AGCAAG 23
97 1940
CFTR-G551D-
- ACG AGCAAG AAU U U CU U U AG CAAG 24
98 1941
CFTR-G551D-
- UAUAGUUCUUGGAGAAGG 18
99 2167
264
5535.1 CFTR-G551D-
- AUAUAGUUCUUGGAGAAGG 19
100 2168
CFTR-G551D-
- AAUAUAGUUCUUGGAGAAGG 20
23 474
CFTR-G551D-
- CAAUAUAGUUCUUGGAGAAGG 21
101 2169
CFTR-G551D-
- ACAAUAUAGUUCUUGGAGAAGG 22
102 2170
CFTR-G551D-
- AGACAAUAUAGUUCUUGGAGAAGG 24
103 2171
CFTR-G551D-
- UUUUAUGGCUAGUGGGUU 18
104 1942
CFTR-G551D-
- UGGGGUUUUAUGGCUAGUGGGUU 23
105 1943
CFTR-G551D-
- CUGGGGUUUUAUGGCUAGUGGGUU 24
106 1944
Table 17C provides exemplary targeting domains for correcting a mutation (e.g., G551D) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G551D), start with a 5'G and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 17C
Figure imgf000266_0001
Table 17D provides exemplary targeting domains for correcting a mutation (e.g
G551D) in the CFTR gene selected according to the fourth tier parameters. The targetin
265
5535.1 domains bind within 200 bp from a mutation (e.g., G551D), and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 17D
Figure imgf000267_0001
266
5535.1 CFTR-G551D-
- CUGAGUGGAGAUCAACGAGC 20
126 2174
CFTR-G551D-
- ACUGAGUGGAGAUCAACGAGC 21
127 2175
CFTR-G551D-
- CACUGAGUGGAGAUCAACGAGC 22
128 2176
CFTR-G551D-
- ACACUGAGUGGAGAUCAACGAGC 23
129 2177
CFTR-G551D-
- CACACUGAGUGGAGAUCAACGAGC 24
130 2178
Table 17E provides exemplary targeting domains for correcting a mutation (e.g., G551D) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G551D), and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 17E
Figure imgf000268_0001
267
5535.1 139
CFTR-G551D-
+ AGAAACAGAAUAUAAAGCAA 20
140 765
CFTR-G551D-
+ C AG A A AC AG A A U A U A A AG C A A 21
141 1986
CFTR-G551D-
+ C C AG A A AC AG A A U A U A A AG C A A 22
142 1987
CFTR-G551D-
+ UCCAGAAACAGAAUAUAAAGCAA 23
143 1988
CFTR-G551D-
+ UUCCAGAAACAGAAUAUAAAGCAA 24
144 1989
CFTR-G551D-
+ ACAGAAUAUAAAGCAAUA 18
145 1997
CFTR-G551D-
+ A AC AG A A U A U A A AG C A A U A 19
146 1998
CFTR-G551D-
+ AAACAGAAUAUAAAGCAAUA 20
147 764
CFTR-G551D-
+ G A A AC AG A A U A U A A AG C A A U A 21
148 1999
CFTR-G551D-
+ AG A A AC AG A A U A U A A AG C A A U A 22
149 2000
CFTR-G551D-
+ C AG A A AC AG A A U A U A A AG C A A U A 23
150 2001
CFTR-G551D-
+ CCAGAAACAGAAUAUAAAGCAAUA 24
151 2002
CFTR-G551D-
+ UAGUUAUUCACCUUGCUA 18
152 2003
CFTR-G551D-
+ UUAGUUAUUCACCUUGCUA 19
153 2004
CFTR-G551D-
+ AUUAGUUAUUCACCUUGCUA 20
154 762
CFTR-G551D-
+ AAUUAGUUAUUCACCUUGCUA 21
155 2005
CFTR-G551D-
+ UAAUUAGUUAUUCACCUUGCUA 22
156 2006
CFTR-G551D-
+ AUAAUUAGUUAUUCACCUUGCUA 23
157 2007
CFTR-G551D-
+ AAUAAUUAGUUAUUCACCUUGCUA 24
158 2008
CFTR-G551D-
+ UUGUCUUUCUCUGCAAAC 18
159 2009
CFTR-G551D-
+ AUUGUCUUUCUCUGCAAAC 19
160 2010
268
5535.1 CFTR-G551D-
+ UAUUGUCUUUCUCUGCAAAC 20
161 760
CFTR-G551D-
+ AUAUUGUCUUUCUCUGCAAAC 21
162 2011
CFTR-G551D-
+ UAUAUUGUCUUUCUCUGCAAAC 22
163 2012
CFTR-G551D-
+ CUAUAUUGUCUUUCUCUGCAAAC 23
164 2013
CFTR-G551D-
+ ACUAUAUUGUCUUUCUCUGCAAAC 24
165 2014
CFTR-G551D-
+ UGUGAUUCCACCUUCUCC 18
166 2179
CFTR-G551D-
+ GUGUGAUUCCACCUUCUCC 19
167 2180
CFTR-G551D-
+ AGUGUGAUUCCACCUUCUCC 20
168 761
CFTR-G551D-
+ CAGUGUGAUUCCACCUUCUCC 21
169 2181
CFTR-G551D-
+ UCAGUGUGAUUCCACCUUCUCC 22
170 2182
CFTR-G551D-
+ CUCAGUGUGAUUCCACCUUCUCC 23
171 2183
CFTR-G551D-
+ ACUCAGUGUGAUUCCACCUUCUCC 24
172 2184
CFTR-G551D-
+ CCAGGAUUUUUUCAAUUC 18
173 2015
CFTR-G551D-
+ CCCAGGAUUUUUUCAAUUC 19
174 2016
CFTR-G551D-
+ CCCCAGG AU U U U U U CAAU U C 20
175 767
CFTR-G551D-
+ ACCCCAGGAUUUUUUCAAUUC 21
176 2017
CFTR-G551D-
+ AACCCCAGGAUUUUUUCAAUUC 22
177 2018
CFTR-G551D-
+ AAACCCCAGGAUUUUUUCAAUUC 23
178 2019
CFTR-G551D-
+ AAAACCCCAGG AU UUUUUCAAUUC 24
179 2020
CFTR-G551D-
+ CUAUUGCUUUAACCACAG 18
180 2021
CFTR-G551D-
+ ACUAUUGCUUUAACCACAG 19
181 2022
CFTR-G551D- + CACUAUUGCUUUAACCACAG 20 754
269
5535.1 182
CFTR-G551D-
+ ACACUAUUGCUUUAACCACAG 21
183 2023
CFTR-G551D-
+ CACACUAUUGCUUUAACCACAG 22
184 2024
CFTR-G551D-
+ U CACACU AU UG CU U U AACCACAG 23
185 2025
CFTR-G551D-
+ AUCACACUAUUGCUUUAACCACAG 24
186 2026
CFTR-G551D-
+ U U ACCAAAAAU AGAAAAU 18
187 2027
CFTR-G551D-
+ AU U ACCAAAAAU AG AAAAU 19
188 2028
CFTR-G551D-
+ U AU U ACCAAAAAU AG AAAAU 20
189 758
CFTR-G551D-
+ CUAUU ACCAAAAAU AG AAAAU 21
190 2029
CFTR-G551D-
+ CCU AUU ACCAAAAAU AG AAAAU 22
191 2030
CFTR-G551D-
+ U CCU AU U ACCAAAAAU AG AAAAU 23
192 2031
CFTR-G551D-
+ G U CCU AU U ACCAAAAAU AG AAAAU 24
193 2032
CFTR-G551D-
+ AGUAUGCUCAAUCUGAAU 18
194 2033
CFTR-G551D-
+ UAGUAUGCUCAAUCUGAAU 19
195 2034
CFTR-G551D-
+ UUAGUAUGCUCAAUCUGAAU 20
196 755
CFTR-G551D-
+ UUUAGUAUGCUCAAUCUGAAU 21
197 2035
CFTR-G551D-
+ UUUUAGUAUGCUCAAUCUGAAU 22
198 2036
CFTR-G551D-
+ CUUUUAGUAUGCUCAAUCUGAAU 23
199 2037
CFTR-G551D-
+ ACUUUUAGUAUGCUCAAUCUGAAU 24
200 2038
CFTR-G551D-
+ UGUCUUUCUCUGCAAACU 18
201 2039
CFTR-G551D-
+ UUGUCUUUCUCUGCAAACU 19
202 2040
CFTR-G551D-
+ AUUGUCUUUCUCUGCAAACU 20
40 483
270
5535.1 CFTR-G551D-
+ UAUUGUCUUUCUCUGCAAACU 21
203 2041
CFTR-G551D-
+ AUAUUGUCUUUCUCUGCAAACU 22
204 2042
CFTR-G551D-
+ UAUAUUGUCUUUCUCUGCAAACU 23
205 2043
CFTR-G551D-
+ CUAUAUUGUCUUUCUCUGCAAACU 24
206 2044
CFTR-G551D-
+ U U AACCACAG UUGAAAU U 18
207 2045
CFTR-G551D-
+ UUUAACCACAGU U G AAA U U 19
208 2046
CFTR-G551D-
+ CU U U AACCACAG UUGAAAU U 20
209 753
CFTR-G551D-
+ GCUUU AACCACAG UUGAAAU U 21
210 2047
CFTR-G551D-
+ UGCUUUAACCACAGUUGAAAUU 22
211 2048
CFTR-G551D-
+ U UG CU U U AACCACAG UUGAAAU U 23
212 2049
CFTR-G551D-
+ AUUGCUUUAACCACAGUUGAAAUU 24
213 2050
CFTR-G551D-
- UAUAUUCUGUUUCUGGAA 18
214 2051
CFTR-G551D-
- UUAUAUUCUGUUUCUGGAA 19
215 2052
CFTR-G551D-
- UUUAUAUUCUGUUUCUGGAA 20
216 748
CFTR-G551D-
- CUUUAUAUUCUGUUUCUGGAA 21
217 2053
CFTR-G551D-
- GCUUUAUAUUCUGUUUCUGGAA 22
218 2054
CFTR-G551D-
- UGCUUUAUAUUCUGUUUCUGGAA 23
219 2055
CFTR-G551D-
- UUGCUUUAUAUUCUGUUUCUGGAA 24
220 2056
CFTR-G551D-
- AUUUUCUAUUUUUGGUAA 18
221 2059
CFTR-G551D-
- AAUUUUCUAUUUUUGGUAA 19
222 2060
CFTR-G551D-
- UAAUUUUCUAUUUUUGGUAA 20
223 736
CFTR-G551D- - CUAAUUUUCUAUUUUUGGUAA 21 2061
271
5535.1 224
CFTR-G551D-
- UCUAAUUUUCUAUUUU UGGUAA 22
225 2062
CFTR-G551D-
- CUCUAAUUUUCUAUUU UUGGUAA 23
226 2063
CFTR-G551D-
- UCUCUAAUUU UCUAUU UUUGGUAA 24
227 2064
CFTR-G551D-
- GACAUCUCCAAGU UUGCA 18
228 2065
CFTR-G551D-
- GGACAUCUCCAAGUUUGCA 19
229 2066
CFTR-G551D-
- AGGACAUCUCCAAGU UUGCA 20
230 738
CFTR-G551D-
- UAGGACAUCUCCAAGUUUGCA 21
231 2067
CFTR-G551D-
- AUAGGACAUCUCCAAGUUUGCA 22
232 2068
CFTR-G551D-
- AAUAGGACAUCUCCAAGUUUGCA 23
233 2069
CFTR-G551D-
- UAAUAGGACAUCUCCAAGUUUGCA 24
234 2070
CFTR-G551D-
- CACACU G AG UGG AG AU CA 18
235 2185
CFTR-G551D-
- UCACACUGAGUGGAGAUCA 19
236 2186
CFTR-G551D-
- AUCACACUGAGUGGAGAUCA 20
237 2187
CFTR-G551D-
- AAUCACACUGAGUGGAGAUCA 21
238 2188
CFTR-G551D-
- GAAUCACACUGAGUGGAGAUCA 22
239 2189
CFTR-G551D-
- GGAAUCACACUGAGUGGAGAUCA 23
240 2190
CFTR-G551D-
- UGGAAUCACACUGAGUGGAGAUCA 24
241 2191
CFTR-G551D-
- GUGCCUUUCAAAUUCAGA 18
242 2077
CFTR-G551D-
- UGUGCCUU UCAAAUUCAGA 19
243 2078
CFTR-G551D-
- AUGUGCCUUUCAAAUUCAGA 20
244 735
CFTR-G551D-
- GAUGUGCCUUUCAAAUUCAGA 21
245 2079
272
5535.1 CFTR-G551D-
- AGAUGUGCCUUUCAAAUUCAGA 22
246 2080
CFTR-G551D-
- AAGAUGUGCCUUUCAAAUUCAGA 23
247 2081
CFTR-G551D-
- GAAGAUGUGCCUUUCAAAUUCAGA 24
248 2082
CFTR-G551D-
- AUAUAUGAUUACAUUAGA 18
249 2083
CFTR-G551D-
- GAUAUAUGAUUACAUUAGA 19
250 2084
CFTR-G551D-
- UGAUAUAUGAUUACAU UAGA 20
20 471
CFTR-G551D-
- GUGAUAUAUGAUUACAUUAGA 21
251 2085
CFTR-G551D-
- UGUGAUAUAUGAUUACAUUAGA 22
252 2086
CFTR-G551D-
- GUGUGAUAUAUGAUUACAUUAGA 23
253 2087
CFTR-G551D-
- AGUGUGAUAUAUGAUUACAUUAGA 24
254 2088
CFTR-G551D-
- AAGGUGGAAUCACACUGA 18
255 2089
CFTR-G551D-
- GAAGGUGGAAUCACACUGA 19
256 2090
CFTR-G551D-
- AGAAGGUGGAAUCACACUGA 20
257 743
CFTR-G551D-
- GAGAAGGUGGAAUCACACUGA 21
258 2091
CFTR-G551D-
- GGAGAAGGUGGAAUCACACUGA 22
259 2192
CFTR-G551D-
- UGGAGAAGGUGGAAUCACACUGA 23
260 2193
CFTR-G551D-
- UUGGAGAAGGUGGAAUCACACUGA 24
261 2194
CFTR-G551D-
- UCUGGAAUUGAAAAAAUC 18
262 2098
CFTR-G551D-
- UUCUGGAAUUGAAAAAAUC 19
263 2099
CFTR-G551D-
- UU UCUGGAAUUGAAAAAAUC 20
264 749
CFTR-G551D-
- GUUUCUGGAAUUGAAAAAAUC 21
265 2100
CFTR-G551D- - UGUUUCUGGAAUUGAAAAAAUC 22 2101
273
5535.1 266
CFTR-G551D-
- CUGUUUCUGGAAUUGAAAAAAUC 23
267 2102
CFTR-G551D-
- UCUGUUUCUGGAAUUGAAAAAAUC 24
268 2103
CFTR-G551D-
- AGAAAGACAAUAUAGUUC 18
269 2195
CFTR-G551D-
- GAGAAAGACAAUAUAGUUC 19
270 2196
CFTR-G551D-
- AGAGAAAGACAAUAUAGUUC 20
271 739
CFTR-G551D-
- CAG AG AAAG ACAAU AU AG U U C 21
272 2197
CFTR-G551D-
- GCAGAGAAAGACAAUAUAGUUC 22
273 2198
CFTR-G551D-
- UGCAGAGAAAGACAAUAUAGUUC 23
274 2199
CFTR-G551D-
- UUGCAGAGAAAGACAAUAUAGUUC 24
275 2200
CFTR-G551D-
- AUAUAGUUCUUGGAGAAG 18
276 2201
CFTR-G551D-
- AAUAUAGUUCUUGGAGAAG 19
277 2202
CFTR-G551D-
- CAAUAUAGUUCUUGGAGAAG 20
278 741
CFTR-G551D-
- ACAAUAUAGUUCUUGGAGAAG 21
279 2203
CFTR-G551D-
- GACAAUAUAGUUCUUGGAGAAG 22
280 2204
CFTR-G551D-
- AGACAAUAUAGUUCUUGGAGAAG 23
281 2205
CFTR-G551D-
- AAG ACAAU AU AG U U CU U GG AG AAG 24
282 2206
CFTR-G551D-
- AGGUGGAAUCACACUGAG 18
283 2111
CFTR-G551D-
- AAGGUGGAAUCACACUGAG 19
284 2112
CFTR-G551D-
- GAAGGUGGAAUCACACUGAG 20
8 461
CFTR-G551D-
- AGAAGGUGGAAUCACACUGAG 21
285 2113
CFTR-G551D-
- GAGAAGGUGGAAUCACACUGAG 22
286 2114
274
5535.1 CFTR-G551D-
- GGAGAAGGUGGAAUCACACUGAG 23
287 2207
CFTR-G551D-
- UGGAGAAGGUGGAAUCACACUGAG 24
288 2208
CFTR-G551D-
- GAUAUAUGAUUACAUUAG 18
289 2117
CFTR-G551D-
- UGAUAUAUGAUUACAUUAG 19
290 2118
CFTR-G551D-
- GUGAUAUAUGAUUACAUUAG 20
291 734
CFTR-G551D-
- UGUGAUAUAUGAUUACAUUAG 21
292 2119
CFTR-G551D-
- GUGUGAUAUAUGAUUACAUUAG 22
293 2120
CFTR-G551D-
- AGUGUGAUAUAUGAUUACAUUAG 23
294 2121
CFTR-G551D-
- UAGUGUGAUAUAUGAUUACAUUAG 24
295 2122
CFTR-G551D-
- AAGACAAUAUAGUUCUUG 18
296 2209
CFTR-G551D-
- AAAGACAAUAUAGUUCUUG 19
297 2210
CFTR-G551D-
- GAAAGACAAUAUAGUUCUUG 20
298 740
CFTR-G551D-
- AGAAAGACAAUAUAGUUCUUG 21
299 2211
CFTR-G551D-
- GAGAAAGACAAUAUAGUUCUUG 22
300 2212
CFTR-G551D-
- AG AG AAAG ACAAU AU AG U U CU UG 23
301 2213
CFTR-G551D-
- CAG AG AAAG ACAAU AU AG U U CU UG 24
302 2214
CFTR-G551D-
- AGGACAUCUCCAAGUUUG 18
303 2123
CFTR-G551D-
- UAGGACAUCUCCAAGUUUG 19
304 2124
CFTR-G551D-
- AUAGGACAUCUCCAAGUUUG 20
305 737
CFTR-G551D-
- AAUAGGACAUCUCCAAGUUUG 21
306 2125
CFTR-G551D-
- UAAUAGGACAUCUCCAAGUUUG 22
307 2126
CFTR-G551D- - GUAAUAGGACAUCUCCAAGUUUG 23 2127
275
5535.1 308
CFTR-G551D-
- GGUAAUAGGACAUCUCCAAGUUUG 24
309 2128
CFTR-G551D-
- UGUGAUAUAUGAUUACAU 18
310 2129
CFTR-G551D-
- GUGUGAUAUAUGAUUACAU 19
311 2130
CFTR-G551D-
- AGUGUGAUAUAUGAUUACAU 20
312 733
CFTR-G551D-
- UAGUGUGAUAUAUGAUUACAU 21
313 2131
CFTR-G551D-
- AUAGUGUGAUAUAUGAUUACAU 22
314 2132
CFTR-G551D-
- AAUAGUGUGAUAUAUGAUUACAU 23
315 2133
CFTR-G551D-
- CAAUAGUGUGAUAUAUGAUUACAU 24
316 2134
CFTR-G551D-
- G AAAG ACAAU AU AG U U CU 18
317 2135
CFTR-G551D-
- AGAAAGACAAUAUAGUUCU 19
318 2136
CFTR-G551D-
- GAG AAAG ACAAU AU AG U U CU 20
9 453
CFTR-G551D-
- AGAGAAAGACAAUAUAGUUCU 21
319 2137
CFTR-G551D-
- CAG AG AAAG ACAAU AU AG U U CU 22
320 2138
CFTR-G551D-
- GCAGAGAAAGACAAUAUAGUUCU 23
321 2139
CFTR-G551D-
- UGCAGAGAAAGACAAUAUAGUUCU 24
322 2140
CFTR-G551D-
- GGGU U AAG AAU CACAU U U 18
323 2215
CFTR-G551D-
- UGGGUUAAGAAUCACAUUU 19
324 2216
CFTR-G551D-
- GUGGGUUAAGAAUCACAUUU 20
325 752
CFTR-G551D-
- AGUGGGUUAAGAAUCACAUUU 21
326 2217
CFTR-G551D-
- UAGUGGGUUAAGAAUCACAUUU 22
327 2218
CFTR-G551D-
- CUAGUGGGUUAAGAAUCACAUUU 23
328 2219
276
5535.1 CFTR-G551D-
- GCUAGUGGGUUAAGAAUCACAUUU 24
329 2220
CFTR-G551D-
- UUGCUUUAUAUUCUGUUU 18
330 2148
CFTR-G551D-
- AUUGCUUUAUAUUCUGUUU 19
331 2149
CFTR-G551D-
- UAUUGCUUUAUAUUCUGUUU 20
332 747
CFTR-G551D-
- CUAUUGCUUUAUAUUCUGUUU 21
333 2150
CFTR-G551D-
- UCUAUUGCUUUAUAUUCUGUUU 22
334 2151
CFTR-G551D-
- CUCUAUUGCUUUAUAUUCUGUUU 23
335 2152
CFTR-G551D-
- UCUCUAUUGCUUUAUAUUCUGUUU 24
336 2153
Table 18A provides exemplary targeting domains for correcting a mutation (e.g., G551D) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G551D), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 18A
Figure imgf000278_0001
Table 18B provides exemplary targeting domains for correcting a mutation (e.g., G551D) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G551D) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with
277
5535.1 a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 18B
Figure imgf000279_0001
Table 18C provides exemplary targeting domains for correcting a mutation (e.g.,
G551D) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., G551D). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 18C
Figure imgf000279_0002
278
5535.1 CFTR-G551D-
- AAUUACAGACAUUUCUC 17
349 2158
CFTR-G551D-
+ CCAUUAUUUAUAGUUCUUAA 20
350 931
CFTR-G551D-
+ UGCUCGUUGAUCUCCACUCA 20
351 2222
CFTR-G551D-
- AAAAAUUACAGACAUUUCUC 20
352 2159
Table 19A provides exemplary targeting domains for correcting a mutation (e.g., N1303K) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., N1303K), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 19A
Figure imgf000280_0001
Table 19B provides exemplary targeting domains for correcting a mutation (e.g., N1303K) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., N1303K) and have a high level of
orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the
279
5535.1 Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 19B
Figure imgf000281_0001
Table 19C provides exemplary targeting domains for correcting a mutation (e.g N1303K) in the CFTR gene selected according to the third tier parameters. The targetin domains bind within 200 bp from a mutation (e.g., N1303K) and start with a 5'G. It is
280
5535.1 contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 19C
Figure imgf000282_0001
Table 19D provides exemplary targeting domains for correcting a mutation (e.g., N1303K) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., N1303K). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 19D
Figure imgf000282_0002
281
5535.1 31
CFTR-N 1303K-
- UAACUGAAAUGAUUUUGAAA 20
32 2254
CFTR-N 1303K-
- CUAACUGAAAUGAUUU UGAA 20
33 2255
CFTR-N 1303K-
- AAU AU U U U ACAAU ACAAU AA 20
34 2256
CFTR-N 1303K-
- UAAAAUUUGAGAGAACUUGA 20
35 2257
CFTR-N 1303K-
- AAAU AU U U U ACAAU ACAAU A 20
36 2258
CFTR-N 1303K-
- AUGGAGUACCCUAACAUACC 20
37 2259
CFTR-N 1303K-
- UAGAAAGUAUUUAUUUUUUC 20
38 2260
CFTR-N 1303K-
- AACUGAAAUGAUUUUGAAAG 20
39 2261
CFTR-N 1303K-
- AGUUGGAUCCCUAUGAACAG 20
40 2262
CFTR-N 1303K-
- UGGAACAUUUAG A A A A A AG U 20
41 2263
Table 20A provides exemplary targeting domains for correcting a mutation (e.g., N1303K) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., N1303K), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 20A
Figure imgf000283_0001
282
5535.1 CFTR-N1303K-
- GCUAACUGAAAUGAUU UUGAA 21
44 2266
CFTR-N1303K-
- GCUGCUAACUGAAAUGAUUUUGAA 24
45 2267
CFTR-N1303K-
- GAACUUGAUGGUAAGUAC 18
46 2268
CFTR-N1303K-
- GAGAACUUGAUGGUAAGUAC 20
47 2269
CFTR-N1303K-
- GAGAGAACUUGAUGGUAAGUAC 22
48 2270
Table 20B provides exemplary targeting domains for correcting a mutation (e.g., N1303K) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., N1303K), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 20B
Figure imgf000284_0001
283
5535.1 56
CFTR-N 1303K-
- AGAACUUGAUGGUAAGUAC 19
57 2279
CFTR-N 1303K-
- AGAGAACUUGAUGGUAAGUAC 21
58 2280
CFTR-N 1303K-
- UGAGAGAACUUGAUGGUAAGUAC 23
59 2281
CFTR-N 1303K-
- UUGAGAGAACUUGAUGGUAAGUAC 24
60 2282
Table 20C provides exemplary targeting domains for correcting a mutation (e.g., N1303K) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., N1303K), start with a 5'G and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 20C
Figure imgf000285_0001
Table 20D provides exemplary targeting domains for correcting a mutation (e.g., N1303K) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., N1303K), and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 20D
4th Tier
284
5535.1 Target Site gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR-N1303K-
+ ACAUGCACACAAAGUGUG 18
65 2287
CFTR-N1303K-
+ U ACAU G CAC ACAAAG U G U G 19
66 2288
CFTR-N1303K-
+ AUACAUGCACACAAAGUGUG 20
67 2289
CFTR-N1303K-
+ CAUACAUGCACACAAAGUGUG 21
68 2290
CFTR-N1303K-
+ ACAUACAUGCACACAAAGUGUG 22
69 2291
CFTR-N1303K-
+ CACAUACAUGCACACAAAGUGUG 23
70 2292
CFTR-N1303K-
+ ACACAUACAUGCACACAAAGUGUG 24
71 2293
CFTR-N1303K-
+ AG AAAAG AAG AAG AAAG U 18
72 2294
CFTR-N1303K-
+ AAG AAAAG AAG AAG AAAG U 19
73 2295
CFTR-N1303K-
+ AAAG AAAAG AAG AAG AAAG U 20
74 2296
CFTR-N1303K-
+ AAAAG AAAAG AAG AAG AAAG U 21
75 2297
CFTR-N1303K-
+ AAAAAG AAAAG AAG AAG AAAG U 22
76 2298
CFTR-N1303K-
+ AAAAAAG AAAAG AAG AAG AAAG U 23
77 2299
CFTR-N1303K-
+ CAAAAAAG AAAAG AAG AAG AAAG U 24
78 2300
CFTR-N1303K-
+ UCAGCCAUUUGUGUUGGU 18
79 2301
CFTR-N1303K-
+ AUCAGCCAUUUGUGUUGGU 19
80 2302
CFTR-N1303K-
+ UAUCAGCCAUUUGUGU UGGU 20
81 2303
CFTR-N1303K-
+ AUAUCAGCCAUUUGUGUUGGU 21
82 2304
CFTR-N1303K-
+ UAUAUCAGCCAUU UGUGUUGGU 22
83 2305
CFTR-N1303K-
+ CUAUAUCAGCCAUUUGUGUUGGU 23
84 2306
CFTR-N1303K- - UGUGUGUGCACAACUUUAAAA 21 2307
285
5535.1 85
CFTR-N1303K-
- AUGUGUGUGCACAACU UUAAAA 22
86 2308
CFTR-N1303K-
- UAUGUGUGUGCACAACUUUAAAA 23
87 2309
CFTR-N1303K-
- AACUGAAAUGAUUUUGAA 18
88 2310
CFTR-N1303K-
- UAACUGAAAUGAUUUUGAA 19
89 2311
CFTR-N1303K-
- CUAACUGAAAUGAUUU UGAA 20
33 2255
CFTR-N1303K-
- UGGAACAUUUAGAAAAAAG 19
90 2312
CFTR-N1303K-
- CUGGAACAUUUAGAAAAAAG 20
91 2313
CFTR-N1303K-
- UCUGGAACAUUUAGAAAAAAG 21
92 2314
CFTR-N1303K-
- U U CUGG AACAU U U AG AAAAAAG 22
93 2315
CFTR-N1303K-
- UU UCUGGAACAUUUAGAAAAAAG 23
94 2316
CFTR-N1303K-
- U U U U CUGG AACAU U U AG AAAAAAG 24
95 2317
CFTR-N1303K-
- UUGGAUCCCUAUGAACAG 18
96 2318
CFTR-N1303K-
- AGUUGGAUCCCUAUGAACAG 20
40 2262
CFTR-N1303K-
- AAGUUGGAUCCCUAUGAACAG 21
97 2319
CFTR-N1303K-
- AAAGUUGGAUCCCUAUGAACAG 22
98 2320
CFTR-N1303K-
- AAAAGUUGGAUCCCUAUGAACAG 23
99 2321
CFTR-N1303K-
- AAAAAGUUGGAUCCCUAUGAACAG 24
100 2322
Table 20E provides exemplary targeting domains for correcting a mutation (e.g., N1303K) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., N1303K), and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with
286
5535.1 a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 20E
Figure imgf000288_0001
287
5535.1 CFTR-
+ UUCUUGAUCACUCCACUGUUCA 22
N1303K-119 2341
CFTR-
+ UUUCUUGAUCACUCCACUGUUCA 23
N1303K-120 2342
CFTR-
+ AUUUCUUGAUCACUCCACUGUUCA 24
N1303K-121 2343
CFTR-
+ ACUUUUUUCUAAAUGUUC 18
N1303K-122 2344
CFTR-
+ AACUUUUUUCUAAAUGUUC 19
N1303K-123 2345
CFTR-
+ CAACUUUUUUCUAAAUGUUC 20
N1303K-124 2346
CFTR-
+ CCAACUUUUUUCUAAAUGUUC 21
N1303K-125 2347
CFTR-
+ UCCAACUUUUUUCUAAAUGUUC 22
N1303K-126 2348
CFTR-
+ AUCCAACUUUUUUCUAAAUGUUC 23
N1303K-127 2349
CFTR-
+ GAUCCAACUUUUUUCUAAAUGUUC 24
N1303K-128 2350
CFTR-
+ U A U AG C A A A A A AG A A A AG 18
N1303K-129 2351
CFTR-
+ C U A U AG C A A A A A AG A A A AG 19
N1303K-130 2352
CFTR-
+ U C U A U AG C A A A A A AG A A A AG 20
N1303K-131 2353
CFTR-
+ UUCUAUAG C A A A A A AG A A A AG 21
N1303K-132 2354
CFTR-
+ UUUCUAUAG C A A A A A AG A A A AG 22
N1303K-133 2355
CFTR-
+ CUUUCUAUAG C A A A A A AG A A A AG 23
N1303K-134 2356
CFTR-
+ ACUUUCUAUAGCAAAAAAGAAAAG 24
N1303K-135 2357
CFTR-
+ AU UG U AAAAU AU U U CAAG 18
N1303K-136 2358
CFTR-
+ U AU UG U AAAAU AU U U CAAG 19
N1303K-137 2359
CFTR-
+ GUAUUGUAAAAUAUUUCAAG 20
N1303K-138 2360
CFTR-
+ UGUAUUGUAAAAUAUUUCAAG 21
N1303K-139 2361
CFTR- + UUGUAUUGUAAAAUAUUUCAAG 22 2362
288
5535.1 N1303K-140
CFTR-
+ AUUGUAUUGUAAAAUAUUUCAAG 23
N1303K-141 2363
CFTR-
+ UAUUGUAUUGUAAAAUAUUUCAAG 24
N1303K-142 2364
CFTR-
+ AGCAAAAAAGAAAAGAAG 18
N1303K-143 2365
CFTR-
+ U AG C A A A A A AG A A A AG AAG 19
N1303K-144 2366
CFTR-
+ AU AGCAAAAAAGAAAAGAAG 20
N1303K-145 2367
CFTR-
+ UAU AGCAAAAAAGAAAAGAAG 21
N1303K-146 2368
CFTR-
+ C U A U AG C A A A A A AG A A A AG A AG 22
N1303K-147 2369
CFTR-
+ UCUAU AGCAAAAAAGAAAAGAAG 23
N1303K-148 2370
CFTR-
+ UUCUAUAGCAAAAAAGAAAAGAAG 24
N1303K-149 2371
CFTR-
+ G AAAAAU U AU U U U AAAAU 18
N1303K-150 2372
CFTR-
+ AG AAAAAU U AU U U U AAAAU 19
N1303K-151 2373
CFTR-
+ U AG AAAAAU U AU U U U AAAAU 20
N1303K-152 2374
CFTR-
+ G U AG AAAAAU U AU U U U AAAAU 21
N1303K-153 2375
CFTR-
+ AG U AG AAAAAU U AU U U U AAAAU 22
N1303K-154 2376
CFTR-
+ AAG U AG AAAAAU U AU U U U AAAAU 23
N1303K-155 2377
CFTR-
+ CAAG U AG AAAAAU U AU U U U AAAAU 24
N1303K-156 2378
CFTR-
- UGUGUGCACAACUUUAAA 18
N1303K-157 2379
CFTR-
- GUGUGUGCACAACUUUAAA 19
N1303K-158 2380
CFTR-
- UGUGUGUGCACAACUUUAAA 20
N1303K-159 2381
CFTR-
- AUGUGUGUGCACAACUUUAAA 21
N1303K-160 2382
CFTR-
- UAUGUGUGUGCACAACUUUAAA 22
N1303K-161 2383
289
5535.1 CFTR-
- GUAUGUGUGUGCACAACUUUAAA 23
N1303K-162 2384
CFTR-
- UGUAUGUGUGUGCACAACUUUAAA 24
N 1303K-163 2385
CFTR-
- U AU U U U ACAAU ACAAU AA 18
N 1303K-164 2386
CFTR-
- AU AU U U U ACAAU ACAAU AA 19
N 1303K-165 2387
CFTR-
- AAU AU U U U ACAAU ACAAU AA 20
N 1303K-34 2256
CFTR-
- AAAU AU U U U ACAAU ACAAU AA 21
N 1303K-166 2388
CFTR-
- G AAAU AU U U U ACAAU ACAAU AA 22
N 1303K-167 2389
CFTR-
- UG AAAU AU U U U ACAAU ACAAU AA 23
N 1303K-168 2390
CFTR-
- U U G AAAU AU U U U ACAAU ACAAU AA 24
N 1303K-169 2391
CFTR-
- AUGAGGUAAGGCUGCUAA 18
N 1303K-170 2392
CFTR-
- GAUGAGGUAAGGCUGCUAA 19
N 1303K-171 2393
CFTR-
- AGAUGAGGUAAGGCUGCUAA 20
N 1303K-172 2394
CFTR-
- CAGAUGAGGUAAGGCUGCUAA 21
N 1303K-173 2395
CFTR-
- GCAGAUGAGGUAAGGCUGCUAA 22
N 1303K-174 2396
CFTR-
- UGCAGAUGAGGUAAGGCUGCUAA 23
N 1303K-175 2397
CFTR-
- UUGCAGAUGAGGUAAGGCUGCUAA 24
N 1303K-176 2398
CFTR-
- GU UGGAUCCCUAUGAACA 18
N 1303K-177 2399
CFTR-
- AGUUGGAUCCCUAUGAACA 19
N 1303K-178 2400
CFTR-
- AAGUUGGAUCCCUAUGAACA 20
N 1303K-179 2401
CFTR-
- AAAGUUGGAUCCCUAUGAACA 21
N 1303K-180 2402
CFTR-
- AAAAGUUGGAUCCCUAUGAACA 22
N 1303K-181 2403
CFTR- - AAAAAGUUGGAUCCCUAUGAACA 23 2404
290
5535.1 N1303K-182
CFTR-
- AAAAAAGUUGGAUCCCUAUGAACA 24
N1303K-183 2405
CFTR-
- U AAAAU AU U AAAAU U UG A 18
N1303K-184 2406
CFTR-
- AU AAAAU AUU AAAAU UUGA 19
N1303K-185 2407
CFTR-
- GAU AAAAU AUU AAAAU UUGA 20
N1303K-186 2408
CFTR-
- UG AU AAAAU AU U AAAAU UUGA 21
N1303K-187 2409
CFTR-
- AUGAUAAAAUAUUAAAAUUUGA 22
N1303K-188 2410
CFTR-
- CAU GAU AAAAU AU U AAAAU UUGA 23
N1303K-189 2411
CFTR-
- ACAUG AU AAAAU AU U AAAAU UUGA 24
N1303K-190 2412
CFTR-
- UAACUGAAAUGAUUUUGA 18
N1303K-191 2413
CFTR-
- CUAACUGAAAUGAUUUUGA 19
N1303K-192 2414
CFTR-
- GCUAACUGAAAUGAUUUUGA 20
N1303K-193 2415
CFTR-
- UGCUAACUGAAAUGAUUUUGA 21
N1303K-194 2416
CFTR-
- CUGCUAACUGAAAUGAUUUUGA 22
N1303K-195 2417
CFTR-
- GCUGCUAACUGAAAUGAUUUUGA 23
N1303K-196 2418
CFTR-
- GGCUGCUAACUGAAAUGAUUUUGA 24
N1303K-197 2419
CFTR-
- UGGAGUGAUCAAGAAAUA 18
N1303K-198 2420
CFTR-
- GUGGAGUGAUCAAGAAAUA 19
N1303K-199 2421
CFTR-
- AGUGGAGUGAUCAAGAAAUA 20
N1303K-18 2240
CFTR-
- CAGUGGAGUGAUCAAGAAAUA 21
N1303K-200 2422
CFTR-
- ACAGUGGAGUGAUCAAGAAAUA 22
N1303K-201 2423
CFTR-
- AACAGUGGAGUGAUCAAGAAAUA 23
N1303K-202 2424
291
5535.1 CFTR-
- GAACAGUGGAGUGAUCAAGAAAUA 24
N1303K-203 2425
CFTR-
- AUAUUUUACAAUACAAUA 18
N1303K-204 2426
CFTR-
- AAU AU U U U ACAAU ACAAU A 19
N1303K-205 2427
CFTR-
- AAAUAU U U U ACAAU ACAAU A 20
N1303K-36 2258
CFTR-
- G AAAU AU U U U ACAAU ACAAU A 21
N1303K-206 2428
CFTR-
- UG AAAUAU U U U ACAAU ACAAU A 22
N1303K-207 2429
CFTR-
- U UG AAAU AU U U U ACAAU ACAAU A 23
N1303K-208 2430
CFTR-
- CUUGAAAUAUUUUACAAUACAAUA 24
N1303K-209 2431
CFTR-
- UUCUUUUCUUUUUUGCUA 18
N1303K-210 2432
CFTR-
- CUUCUUUUCUUUUUUGCUA 19
N1303K-211 2433
CFTR-
- UCUUCUUUUCUUUUUUGCUA 20
N1303K-212 2434
CFTR-
- UUCUUCUUUUCUUUUUUGCUA 21
N1303K-213 2435
CFTR-
- CUUCUUCUUUUCUUUUUUGCUA 22
N1303K-214 2436
CFTR-
- UCUUCUUCUUUUCUUUUUUGCUA 23
N1303K-215 2437
CFTR-
- UUCUUCUUCUUUUCUUUUUUGCUA 24
N1303K-216 2438
CFTR-
- UGGAGUACCCUAACAUAC 18
N1303K-217 2439
CFTR-
- AUGGAGUACCCUAACAUAC 19
N1303K-218 2440
CFTR-
- AAUGGAGUACCCUAACAUAC 20
N1303K-219 2441
CFTR-
- AAAUGGAGUACCCUAACAUAC 21
N1303K-220 2442
CFTR-
- AAAAUGGAGUACCCUAACAUAC 22
N1303K-221 2443
CFTR-
- UAAAAUGGAGUACCCUAACAUAC 23
N1303K-222 2444
CFTR- - UUAAAAUGGAGUACCCUAACAUAC 24 2445
292
5535.1 N1303K-223
CFTR-
- UUAAAAUAAUUUUUCUAC 18
N1303K-224 2446
CFTR-
- U U UAAAAUAAU U U U U CU AC 19
N1303K-225 2447
CFTR-
- U U U UAAAAUAAU U U U U CU AC 20
N1303K-226 2448
CFTR-
- AU U U UAAAAUAAU U U U U CU AC 21
N1303K-227 2449
CFTR-
- UAUUUUAAAAUAAUUUUUCUAC 22
N1303K-228 2450
CFTR-
- UUAUUUUAAAAUAAUUUUUCUAC 23
N1303K-229 2451
CFTR-
- CUUAUUUUAAAAUAAUUUUUCUAC 24
N1303K-230 2452
CFTR-
- GGAGUACCCUAACAUACC 18
N1303K-231 2453
CFTR-
- UGGAGUACCCUAACAUACC 19
N1303K-232 2454
CFTR-
- AUGGAGUACCCUAACAUACC 20
N1303K-37 2259
CFTR-
- AAUGGAGUACCCUAACAUACC 21
N1303K-233 2455
CFTR-
- AAAUGGAGUACCCUAACAUACC 22
N1303K-234 2456
CFTR-
- AAAAUGGAGUACCCUAACAUACC 23
N1303K-235 2457
CFTR-
- UAAAAUGGAGUACCCUAACAUACC 24
N1303K-236 2458
CFTR-
- AUGAACAGUGGAGUGAUC 18
N1303K-237 2459
CFTR-
- UAUGAACAGUGGAGUGAUC 19
N1303K-238 2460
CFTR-
- CUAUGAACAGUGGAGUGAUC 20
N1303K-239 2461
CFTR-
- CCUAUGAACAGUGGAGUGAUC 21
N1303K-240 2462
CFTR-
- CCCUAUGAACAGUGGAGUGAUC 22
N1303K-241 2463
CFTR-
- UCCCUAUGAACAGUGGAGUGAUC 23
N1303K-242 2464
CFTR-
- AUCCCUAUGAACAGUGGAGUGAUC 24
N1303K-243 2465
293
5535.1 CFTR-
- GAAAGUAUUUAUUUUUUC 18
N1303K-244 2466
CFTR-
- AGAAAGUAUUUAUUUUUUC 19
N 1303K-245 2467
CFTR-
- UAGAAAGUAUUUAUUUUUUC 20
N 1303K-38 2260
CFTR-
- AUAGAAAGUAUUUAUUUUUUC 21
N 1303K-246 2468
CFTR-
- UAUAGAAAGUAUUUAUUUUUUC 22
N 1303K-247 2469
CFTR-
- CUAUAGAAAGUAUUUAUUUUUUC 23
N 1303K-248 2470
CFTR-
- GCUAUAGAAAGUAUUUAUUUUUUC 24
N 1303K-249 2471
CFTR-
- AAAUAUGGAAAGUUGCAG 18
N 1303K-250 2472
CFTR-
- GAAAUAUGGAAAGUUGCAG 19
N 1303K-251 2473
CFTR-
- AGAAAUAUGGAAAGUUGCAG 20
N 1303K-252 2474
CFTR-
- A AG AAA U A U G G A A AG U U G C AG 21
N 1303K-253 2475
CFTR-
- C A AG AAA U A U G G A A AG U U G C AG 22
N 1303K-254 2476
CFTR-
- UCAAGAAAUAUGGAAAGUUGCAG 23
N 1303K-255 2477
CFTR-
- AUCAAGAAAUAUGGAAAGUUGCAG 24
N 1303K-256 2478
CFTR-
- AUGAUAAAAUAUUAAAAU 18
N 1303K-257 2479
CFTR-
- CAUGAUAAAAUAUUAAAAU 19
N 1303K-258 2480
CFTR-
- ACAUGAUAAAAUAUUAAAAU 20
N 1303K-259 2481
CFTR-
- GUGGAGUGAUCAAGAAAU 18
N 1303K-260 2482
CFTR-
- AGUGGAGUGAUCAAGAAAU 19
N 1303K-261 2483
CFTR-
- CAGUGGAGUGAUCAAGAAAU 20
N 1303K-262 2484
CFTR-
- ACAGUGGAGUGAUCAAGAAAU 21
N 1303K-263 2485
CFTR- - AACAGUGGAGUGAUCAAGAAAU 22 2486
294
5535.1 N1303K-264
CFTR-
- GAACAGUGGAGUGAUCAAGAAAU 23
N 1303K-265 2487
CFTR-
- UGAACAGUGGAGUGAUCAAGAAAU 24
N 1303K-266 2488
CFTR-
- AAU AU U U U ACAAU ACAAU 18
N 1303K-267 2489
CFTR-
- AAAU AU U U U ACAAU ACAAU 19
N 1303K-268 2490
CFTR-
- G AAAU AU U U U ACAAU ACAAU 20
N 1303K-269 2491
CFTR-
- UG AAAU AU U U U ACAAU ACAAU 21
N 1303K-270 2492
CFTR-
- U U G AAAU AU U U U ACAAU ACAAU 22
N 1303K-271 2493
CFTR-
- CU U G AAAU AU U U U ACAAU ACAAU 23
N 1303K-272 2494
CFTR-
- ACUUGAAAUAUUUUACAAUACAAU 24
N 1303K-273 2495
CFTR-
- GAAAAAAGUUGGAUCCCU 18
N 1303K-274 2496
CFTR-
- AGAAAAAAGUUGGAUCCCU 19
N 1303K-275 2497
CFTR-
- UAGAAAAAAGUUGGAUCCCU 20
N 1303K-276 2498
CFTR-
- UUAGAAAAAAGUUGGAUCCCU 21
N 1303K-277 2499
CFTR-
- UUUAGAAAAAAGUUGGAUCCCU 22
N 1303K-278 2500
CFTR-
- AU U U AG AAAAAAG UUGGAUCCCU 23
N 1303K-279 2501
CFTR-
- CAU U U AG AAAAAAG UUGGAUCCCU 24
N 1303K-280 2502
CFTR-
- UAUUUUUUCUGGAACAUU 18
N 1303K-281 2503
CFTR-
- UUAUUUUUUCUGGAACAUU 19
N 1303K-282 2504
CFTR-
- UUUAUUUUUUCUGGAACAUU 20
N 1303K-283 2505
CFTR-
- AUUUAUUUUUUCUGGAACAUU 21
N 1303K-284 2506
CFTR-
- UAUUUAUUUUUUCUGGAACAUU 22
N 1303K-285 2507
295
5535.1 CFTR-
- GUAUUUAUUUUUUCUGGAACAUU 23
N1303K-286 2508
CFTR-
- AGUAUUUAUUUUUUCUGGAACAUU 24
N1303K-287 2509
CFTR-
- CUGCUAACUGAAAUGAUU 18
N1303K-288 2510
CFTR-
- GCUGCUAACUGAAAUGAUU 19
N1303K-289 2511
CFTR-
- GGCUGCUAACUGAAAUGAUU 20
N1303K-290 2512
CFTR-
- AGGCUGCUAACUGAAAUGAUU 21
N1303K-291 2513
CFTR-
- AAGGCUGCUAACUGAAAUGAUU 22
N1303K-292 2514
CFTR-
- UAAGGCUGCUAACUGAAAUGAUU 23
N1303K-293 2515
CFTR-
- GUAAGGCUGCUAACUGAAAUGAUU 24
N1303K-294 2516
CFTR-
- G AU AAAAU AU UAAAAU U U 18
N1303K-295 2517
CFTR-
- UG AU AAAAU AU UAAAAU U U 19
N1303K-296 2518
CFTR-
- AUG AU AAAAU AU UAAAAU U U 20
N1303K-297 2519
CFTR-
- AGAAAGUAUUUAUUUUUU 18
N1303K-298 2520
CFTR-
- UAGAAAGUAUUUAUUUUUU 19
N1303K-299 2521
CFTR-
- AUAGAAAGUAUUUAUUUUUU 20
N1303K-300 2522
CFTR-
- UAUAGAAAGUAUUUAUUUUUU 21
N1303K-301 2523
CFTR-
- CUAUAGAAAGUAUUUAUUUUUU 22
N1303K-302 2524
CFTR-
- GCUAUAGAAAGUAUUUAUUUUUU 23
N1303K-303 2525
CFTR-
- UGCUAUAGAAAGUAUUUAUUUUUU 24
N1303K-304 2526
Table 21A provides exemplary targeting domains for correcting a mutation (e.g., N1303K) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., N1303K), have a high level of orthogonality and start
296
5535.1 with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 21A
Figure imgf000298_0001
Table 21B provides exemplary targeting domains for correcting a mutation (e.g., N1303K) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., N1303K) and have a high level of
orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 21B
Figure imgf000298_0002
Table 22A provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 22A
I 1st Tier I
297
5535.1 Target Site gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR-R117H-1 + GUGAUGAAGGCCAAAAA 17 2529
CFTR-R117H-2 + GGUGACUUCCUACAAAA 17 2530
CFTR-R117H-3 + GCCAUGGGGCCUGUGCA 17 2531
CFTR-R117H-4 + GCAUUCCAAUGUGAUGA 17 2532
CFTR-R117H-5 - GUAAUACUUCCUUGCAC 17 2533
CFTR-R117H-6 + GUGACUUCCUACAAAAG 17 2534
CFTR-R117H-7 - GCCUUCUCUUUAUUGUG 17 2535
CFTR-R117H-8 - GCGAUUUAUCUAGGCAU 17 2536
CFTR-R117H-9 - GUACAGCCUCUCUUACU 17 2537
CFTR-R117H-10 + GAAGGCCAAAAAUGGCU 17 2538
CFTR-R117H-11 + GAGAGGCUGUACUGCUU 17 2539
CFTR-R117H-12 + GAUACAGAAUAUAUGUGCCA 20 2540
CFTR-R117H-13 - GUCUUGUGUUGAAAUUCUCA 20 2541
CFTR-R117H-14 + GUGUCCUCACAAUAAAGAGA 20 2542
CFTR-R117H-15 - GCAGUACAGCCUCUCUUACU 20 2543
CFTR-R117H-16 + GAUGAAGGCCAAAAAUGGCU 20 2544
CFTR-R117H-17 + GGCCAAAAAUGGCUGGGUGU 20 2545
Table 22B provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 22B
Figure imgf000299_0001
298
5535.1 CFTR-R117H-
+ UCCUCACAAUAAAGAGA 17
22 2550
CFTR-R117H-
- AGUACAGCCUCUCUUAC 17
23 2551
CFTR-R117H-
- CAUAGCUUCCUAUGACC 17
24 2552
CFTR-R117H-
+ UGAAGGCCAAAAAUGGC 17
25 2553
CFTR-R117H-
+ UGUUCCUCCUUGUUAUC 17
26 2554
CFTR-R117H-
- CUUGUGUUGAAAUUCUC 17
27 2555
CFTR-R117H-
+ AUUCUUCCCAGUAAGAG 17
28 2556
CFTR-R117H-
+ AGACUUUUCAUCUUUAG 17
29 2557
CFTR-R117H-
- UGACCCGGAUAACAAGG 17
30 2558
CFTR-R117H-
- UUUGGCCUUCAUCACAU 17
31 2559
CFTR-R117H-
+ CAGAAUAUAUGUGCCAU 17
32 2560
CFTR-R117H-
+ CUUGUUAUCCGGGUCAU 17
33 2561
CFTR-R117H-
- UCUAUCGCGAUUUAUCU 17
34 2562
CFTR-R117H-
+ CAAAAAUGGCUGGGUGU 17
35 2563
CFTR-R117H-
- CUACACCCAGCCAUUUU 17
36 2564
CFTR-R117H-
+ AAUGUGAUGAAGGCCAAAAA 20
37 2565
CFTR-R117H-
+ UUUGGUGACUUCCUACAAAA 20
38 2566
CFTR-R117H-
+ CUUUGGUGACUUCCUACAAA 20
39 2567
CFTR-R117H-
- UUCCUAUGACCCGGAUAACA 20
40 2568
CFTR-R117H-
- ACUUCCUUGCACAGGCCCCA 20
41 2569
CFTR-R117H-
+ UGUGCCAUGGGGCCUGUGCA 20
42 2570
CFTR-R117H- + UCUGCAUUCCAAUGUGAUGA 20 2571
299
5535.1 43
CFTR-R117H-
- AAGGUAAUACUUCCUUGCAC 20
44 2572
CFTR-R117H-
- AGCAGUACAGCCUCUCU UAC 20
45 2573
CFTR-R117H-
- AAUCAUAGCUUCCUAUGACC 20
46 2574
CFTR-R117H-
+ UGAUGAAGGCCAAAAAUGGC 20
47 2575
CFTR-R117H-
- AGUCUUGUGUUGAAAUUCUC 20
48 2576
CFTR-R117H-
+ U UGGUGACUUCCUACAAAAG 20
49 2577
CFTR-R117H-
+ AUGAUUCUUCCCAGUAAGAG 20
50 2578
CFTR-R117H-
+ CUUAAAAUGAGUUUAUAUAG 20
51 2579
CFTR-R117H-
+ ACAAGACUU UUCAUCUU UAG 20
52 2580
CFTR-R117H-
- CUAUGACCCGGAUAACAAGG 20
53 2581
CFTR-R117H-
+ UACAGAAUAUAUGUGCCAUG 20
54 2582
CFTR-R117H-
- UAUGCCUUCUCUUUAU UGUG 20
55 2583
CFTR-R117H-
- AUUUUUGGCCUUCAUCACAU 20
56 2584
CFTR-R117H-
+ AUACAGAAUAUAUGUGCCAU 20
57 2585
CFTR-R117H-
- AUCGCGAUUUAUCUAGGCAU 20
58 2586
CFTR-R117H-
+ CUCCUUGUUAUCCGGGUCAU 20
59 2587
CFTR-R117H-
+ UAAGAGAGGCUGUACUGCUU 20
60 2588
CFTR-R117H-
- CUCCUACACCCAGCCAU UUU 20
61 2589
Table 22C provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H) and start with a 5'G. It is contemplated herein that
300
5535.1 in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 22C
Figure imgf000302_0001
Table 22D provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 22D
Figure imgf000302_0002
301
5535.1 71
CFTR-R117H-
+ AGUGUUCCUCCUUGUUAUCC 20
72 2600
CFTR-R117H-
- CACUCUAUCGCGAUUUAUCU 20
73 2601
CFTR-R117H-
- CUCUGUUUUUCCCCUUUUGU 20
74 2602
Table 23A provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 23A
Figure imgf000303_0001
302
5535.1 CFTR-R117H-
- GAAAAGUCUUGUGUUGAAAUUCU 23
85 2613
Table 23B provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 23B
Figure imgf000304_0001
303
5535.1 98
CFTR-R117H-
+ AUUAAAACAUGUACGAUA 18
99 2627
CFTR-R117H-
+ CAUUAAAACAUGUACGAUA 19
100 2628
CFTR-R117H-
+ ACAUUAAAACAUGUACGAUA 20
101 2629
CFTR-R117H-
+ UUAAAAUGAGUUUAUAUA 18
102 2630
CFTR-R117H-
+ CUUAAAAUGAGUUUAUAUA 19
103 2631
CFTR-R117H-
+ ACUUAAAAUGAGUUUAUAUA 20
104 2632
CFTR-R117H-
+ UGAUGAAGGCCAAAAAUGG 19
105 2633
CFTR-R117H-
+ UGUGAUGAAGGCCAAAAAUGG 21
106 2634
CFTR-R117H-
+ AUGUGAUGAAGGCCAAAAAUGG 22
107 2635
CFTR-R117H-
+ AAUGUGAUGAAGGCCAAAAAUGG 23
108 2636
CFTR-R117H-
+ CAAUGUGAUGAAGGCCAAAAAUGG 24
109 2637
CFTR-R117H-
+ UUUCUCAUAAAAUACCCU 18
110 2638
CFTR-R117H-
+ AUUUCUCAUAAAAUACCCU 19
111 2639
CFTR-R117H-
+ UAUUUCUCAUAAAAUACCCU 20
112 2640
CFTR-R117H-
- AUCAUAGCUUCCUAUGAC 18
113 2641
CFTR-R117H-
- AAUCAUAGCUUCCUAUGAC 19
114 2642
CFTR-R117H-
- AGAAUCAUAGCUUCCUAUGAC 21
115 2643
CFTR-R117H-
- AAGAAUCAUAGCUUCCUAUGAC 22
116 2644
CFTR-R117H-
- ACAGCCUCUCUUACUGGG 18
117 2645
CFTR-R117H-
- UACAGCCUCUCUUACUGGG 19
118 2646
CFTR-R117H-
- AGUACAGCCUCUCUUACUGGG 21
119 2647
304
5535.1 CFTR-R117H-
- CAGUACAGCCUCUCUUACUGGG 22
120 2648
CFTR-R117H-
- AGCAGUACAGCCUCUCUUACUGGG 24
121 2649
CFTR-R117H-
- UUUUGGCCUUCAUCACAU 18
122 2650
CFTR-R117H-
- UUUUUGGCCUUCAUCACAU 19
123 2651
CFTR-R117H-
- AUUUUUGGCCUUCAUCACAU 20
56 2584
CFTR-R117H-
- CAUUUUUGGCCUUCAUCACAU 21
124 2652
CFTR-R117H-
- CCAUUUUUGGCCUUCAUCACAU 22
125 2653
CFTR-R117H-
- AGCCAUUUUUGGCCUUCAUCACAU 24
126 2654
CFTR-R117H-
- AGUCUUGUGUUGAAAUUCU 19
127 2655
CFTR-R117H-
- AAGUCUUGUGUUGAAAUUCU 20
128 2656
CFTR-R117H-
- AAAGUCUUGUGUUGAAAUUCU 21
129 2657
CFTR-R117H-
- AAAAGUCUUGUGUUGAAAUUCU 22
130 2658
CFTR-R117H-
- UGAAAAGUCUUGUGUUGAAAUUCU 24
131 2659
Table 23C provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H), start with a 5'G and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 23C
Figure imgf000306_0001
305
5535.1 132
CFTR-R117H-
+ GAGACUUAAAAUGAGUUUAUAUA 23
133 2661
CFTR-R117H-
+ GGAGACUUAAAAUGAGUUUAUAUA 24
134 2662
CFTR-R117H-
+ GAGUGUUCCUCCUUGUUAU 19
135 2663
CFTR-R117H-
+ GAUAGAGUGUUCCUCCUUGUUAU 23
136 2664
Table 23D provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H), and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 23D
Figure imgf000307_0001
306
5535.1 CFTR-R117H-
+ CAUUUAUUUCUCAUAAAAUACCCU 24
146 2674
CFTR-R117H-
- UCACAUUGGAAUGCAGAU 18
147 2675
CFTR-R117H-
- AUCACAUUGGAAUGCAGAU 19
148 2676
CFTR-R117H-
- CAUCACAUUGGAAUGCAGAU 20
149 2677
CFTR-R117H-
- UCAUCACAUUGGAAUGCAGAU 21
150 2678
CFTR-R117H-
- UUCAUCACAUUGGAAUGCAGAU 22
151 2679
CFTR-R117H-
- CUUCAUCACAUUGGAAUGCAGAU 23
152 2680
CFTR-R117H-
- CCUUCAUCACAUUGGAAUGCAGAU 24
153 2681
Table 23E provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H), and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 23E
Figure imgf000308_0001
307
5535.1 159
CFTR-R117H-
+ UGACUUCCUACAAAAGGGGAAAAA 24
160 2688
CFTR-R117H-
+ UGGUGACUUCCUACAAAA 18
161 2689
CFTR-R117H-
+ UUGGUGACUUCCUACAAAA 19
162 2690
CFTR-R117H-
+ UUUGGUGACUUCCUACAAAA 20
38 2566
CFTR-R117H-
+ CUUUGGUGACUUCCUACAAAA 21
163 2691
CFTR-R117H-
+ GCUUUGGUGACUUCCUACAAAA 22
164 2692
CFTR-R117H-
+ UGCUUUGGUGACUUCCUACAAAA 23
165 2693
CFTR-R117H-
+ CUGCUUUGGUGACUUCCUACAAAA 24
166 2694
CFTR-R117H-
+ UUGGUGACUUCCUACAAA 18
167 2695
CFTR-R117H-
+ UUUGGUGACUUCCUACAAA 19
168 2696
CFTR-R117H-
+ CUUUGGUGACUUCCUACAAA 20
39 2567
CFTR-R117H-
+ GCUUUGGUGACUUCCUACAAA 21
169 2697
CFTR-R117H-
+ UGCUUUGGUGACUUCCUACAAA 22
170 2698
CFTR-R117H-
+ CUGCUUUGGUGACUUCCUACAAA 23
171 2699
CFTR-R117H-
+ ACUGCUUUGGUGACUUCCUACAAA 24
172 2700
CFTR-R117H-
+ CAGUGUCCUCACAAUAAA 18
173 2701
CFTR-R117H-
+ GCAGUGUCCUCACAAUAAA 19
174 2702
CFTR-R117H-
+ AGCAGUGUCCU C ACAAU AAA 20
175 2703
CFTR-R117H-
+ G AG C AG U G U CC U C ACAA U AAA 21
176 2704
CFTR-R117H-
+ GGAGCAGUGUCCUCACAAUAAA 22
177 2705
CFTR-R117H-
+ AGGAGCAGUGUCCUCACAAU AAA 23
178 2706
308
5535.1 CFTR-R117H-
+ UAGGAGCAGUGUCCUCACAAUAAA 24
179 2707
CFTR-R117H-
+ UUUGGUGACUUCCUACAA 18
180 2708
CFTR-R117H-
+ CUUUGGUGACUUCCUACAA 19
181 2709
CFTR-R117H-
+ GCUUUGGUGACUUCCUACAA 20
182 2710
CFTR-R117H-
+ UGCUUUGGUGACUUCCUACAA 21
183 2711
CFTR-R117H-
+ CUGCUUUGGUGACUUCCUACAA 22
184 2712
CFTR-R117H-
+ ACUGCUUUGGUGACUUCCUACAA 23
185 2713
CFTR-R117H-
+ UACUGCUUUGGUGACUUCCUACAA 24
186 2714
CFTR-R117H-
+ UAUGAUUCUUCCCAGUAA 18
187 2715
CFTR-R117H-
+ CUAUGAUUCUUCCCAGUAA 19
188 2716
CFTR-R117H-
+ GCUAUGAUUCUUCCCAGUAA 20
189 2717
CFTR-R117H-
+ AGCUAUGAUUCUUCCCAGUAA 21
190 2718
CFTR-R117H-
+ AAGCUAUGAUUCUUCCCAGUAA 22
191 2719
CFTR-R117H-
+ GAAGCUAUGAUUCUUCCCAGUAA 23
192 2720
CFTR-R117H-
+ GGAAGCUAUGAUUCUUCCCAGUAA 24
193 2721
CFTR-R117H-
+ U ACAAAAG GG G AAAAAC A 18
194 2722
CFTR-R117H-
+ CUACAAAAGGGGAAAAACA 19
195 2723
CFTR-R117H-
+ CCUACAAAAGGGGAAAAACA 20
196 2724
CFTR-R117H-
+ UCCUACAAAAGGGGAAAAACA 21
197 2725
CFTR-R117H-
+ UUCCUACAAAAGGGGAAAAACA 22
198 2726
CFTR-R117H-
+ CUUCCUACAAAAGGGGAAAAACA 23
199 2727
CFTR-R117H- + ACUUCCUACAAAAGGGGAAAAACA 24 2728
309
5535.1 200
CFTR-R117H-
+ UACAGAAUAUAUGUGCCA 18
201 2729
CFTR-R117H-
+ AUACAGAAUAUAUGUGCCA 19
202 2730
CFTR-R117H-
+ GAUACAGAAUAUAUGUGCCA 20
12 2540
CFTR-R117H-
+ CGAUACAGAAUAUAUGUGCCA 21
203 2731
CFTR-R117H-
+ ACGAUACAGAAUAUAUGUGCCA 22
204 2732
CFTR-R117H-
+ UACGAUACAGAAUAUAUGUGCCA 23
205 2733
CFTR-R117H-
+ GUACGAUACAGAAUAUAUGUGCCA 24
206 2734
CFTR-R117H-
+ UGCCAUGGGGCCUGUGCA 18
207 2735
CFTR-R117H-
+ GUGCCAUGGGGCCUGUGCA 19
208 2736
CFTR-R117H-
+ UGUGCCAUGGGGCCUGUGCA 20
42 2570
CFTR-R117H-
+ AUGUGCCAUGGGGCCUGUGCA 21
209 2737
CFTR-R117H-
+ UAUGUGCCAUGGGGCCUGUGCA 22
210 2738
CFTR-R117H-
+ AUAUGUGCCAUGGGGCCUGUGCA 23
211 2739
CFTR-R117H-
+ UAUAUGUGCCAUGGGGCCUGUGCA 24
212 2740
CFTR-R117H-
+ UCCUUGUUAUCCGGGUCA 18
213 2741
CFTR-R117H-
+ CUCCUUGUUAUCCGGGUCA 19
214 2742
CFTR-R117H-
+ CCUCCUUGUUAUCCGGGUCA 20
215 2743
CFTR-R117H-
+ UCCUCCUUGUUAUCCGGGUCA 21
216 2744
CFTR-R117H-
+ UUCCUCCUUGUUAUCCGGGUCA 22
217 2745
CFTR-R117H-
+ GUUCCUCCUUGUUAUCCGGGUCA 23
218 2746
CFTR-R117H-
+ UGUUCCUCCUUGUUAUCCGGGUCA 24
219 2747
310
5535.1 CFTR-R117H-
+ AGCAGUGUCCUCACAAUA 18
220 2748
CFTR-R117H-
+ GAGCAGUGUCCUCACAAUA 19
221 2749
CFTR-R117H-
+ GGAGCAGUGUCCUCACAAUA 20
222 2750
CFTR-R117H-
+ AGGAGCAGUGUCCUCACAAUA 21
223 2751
CFTR-R117H-
+ UAGGAGCAGUGUCCUCACAAUA 22
224 2752
CFTR-R117H-
+ GU AGGAGCAGUGUCCUCACAAUA 23
225 2753
CFTR-R117H-
+ UGUAGGAGCAGUGUCCUCACAAUA 24
226 2754
CFTR-R117H-
+ ACUUAAAAUGAGUUUAUA 18
227 2755
CFTR-R117H-
+ GACUUAAAAUGAGUUUAUA 19
228 2756
CFTR-R117H-
+ AGACUUAAAAUGAGUUUAUA 20
229 2757
CFTR-R117H-
+ GAGACUUAAAAUGAGUUUAUA 21
230 2758
CFTR-R117H-
+ GGAGACUUAAAAUGAGUUUAUA 22
231 2759
CFTR-R117H-
+ AGGAGACUUAAAAUGAGUUUAUA 23
232 2760
CFTR-R117H-
+ GAGGAGACUUAAAAUGAGUUUAUA 24
233 2761
CFTR-R117H-
+ CAAGACUUUUCAUCUUUA 18
234 2762
CFTR-R117H-
+ ACAAGACUUUUCAUCUUUA 19
235 2763
CFTR-R117H-
+ CACAAG ACU UUUCAUCUUUA 20
236 2764
CFTR-R117H-
+ ACACAAGACUUUUCAUCUUUA 21
237 2765
CFTR-R117H-
+ AACACAAGACUUUUCAUCUUUA 22
238 2766
CFTR-R117H-
+ CAACACAAG ACU U UUCAUCUUUA 23
239 2767
CFTR-R117H-
+ U CAACACAAG ACU UUUCAUCUUUA 24
240 2768
CFTR-R117H- + UAUUUCUCAUAAAAUACC 18 2769
311
5535.1 241
CFTR-R117H-
+ UUAUUUCUCAUAAAAUACC 19
242 2770
CFTR-R117H-
+ UUUAUUUCUCAUAAAAUACC 20
243 2771
CFTR-R117H-
+ AUUUAUUUCUCAUAAAAUACC 21
244 2772
CFTR-R117H-
+ CAUUUAUUUCUCAUAAAAUACC 22
245 2773
CFTR-R117H-
+ UCAUUUAUUUCUCAUAAAAUACC 23
246 2774
CFTR-R117H-
+ UUCAUUUAUUUCUCAUAAAAUACC 24
247 2775
CFTR-R117H-
+ AUACAGAAUAUAUGUGCC 18
248 2776
CFTR-R117H-
+ GAUACAGAAUAUAUGUGCC 19
249 2777
CFTR-R117H-
+ CGAUACAGAAUAUAUGUGCC 20
250 2778
CFTR-R117H-
+ ACGAUACAGAAUAUAUGUGCC 21
251 2779
CFTR-R117H-
+ UACGAUACAGAAUAUAUGUGCC 22
252 2780
CFTR-R117H-
+ GUACGAUACAGAAUAUAUGUGCC 23
253 2781
CFTR-R117H-
+ UGUACGAUACAGAAUAUAUGUGCC 24
254 2782
CFTR-R117H-
+ GUGCCAUGGGGCCUGUGC 18
255 2783
CFTR-R117H-
+ UGUGCCAUGGGGCCUGUGC 19
256 2784
CFTR-R117H-
+ AUGUGCCAUGGGGCCUGUGC 20
257 2785
CFTR-R117H-
+ UAUGUGCCAUGGGGCCUGUGC 21
258 2786
CFTR-R117H-
+ AUAUGUGCCAUGGGGCCUGUGC 22
259 2787
CFTR-R117H-
+ UAUAUGUGCCAUGGGGCCUGUGC 23
260 2788
CFTR-R117H-
+ AUAUAUGUGCCAUGGGGCCUGUGC 24
261 2789
CFTR-R117H-
+ GGUGACUUCCUACAAAAG 18
262 2790
312
5535.1 CFTR-R117H-
+ UGGUGACUUCCUACAAAAG 19
263 2791
CFTR-R117H-
+ UUGGUGACUUCCUACAAAAG 20
49 2577
CFTR-R117H-
+ UUUGGUGACUUCCUACAAAAG 21
264 2792
CFTR-R117H-
+ CUUUGGUGACUUCCUACAAAAG 22
265 2793
CFTR-R117H-
+ GCUUUGGUGACUUCCUACAAAAG 23
266 2794
CFTR-R117H-
+ UGCUUUGGUGACUUCCUACAAAAG 24
267 2795
CFTR-R117H-
+ AAGACUUUUCAUCUUUAG 18
268 2796
CFTR-R117H-
+ CAAGACUUUUCAUCUUUAG 19
269 2797
CFTR-R117H-
+ ACAAGACUUUUCAUCUUUAG 20
52 2580
CFTR-R117H-
+ CACAAGACUUUUCAUCUUUAG 21
270 2798
CFTR-R117H-
+ ACA CAAGACUUUUCAUCUUUAG 22
271 2799
CFTR-R117H-
+ AACACAAG ACU U UUCAUCUUUAG 23
272 2800
CFTR-R117H-
+ CAACACAAG ACU U UUCAUCUUUAG 24
273 2801
CFTR-R117H-
+ GCCAAAAAUGGCUGGGUG 18
274 2802
CFTR-R117H-
+ GGCCAAAAAUGGCUGGGUG 19
275 2803
CFTR-R117H-
+ AGGCCAAAAAUGGCUGGGUG 20
276 2804
CFTR-R117H-
+ AAGGCCAAAAAUGGCUGGGUG 21
277 2805
CFTR-R117H-
+ GAAGGCCAAAAAUGGCUGGGUG 22
278 2806
CFTR-R117H-
+ UGAAGGCCAAAAAUGGCUGGGUG 23
279 2807
CFTR-R117H-
+ AUGAAGGCCAAAAAUGGCUGGGUG 24
280 2808
CFTR-R117H-
+ CAUCUGCAUUCCAAUGUG 18
281 2809
CFTR-R117H- + UCAUCUGCAUUCCAAUGUG 19 2810
313
5535.1 282
CFTR-R117H-
+ CUCAUCUGCAUUCCAAUGUG 20
283 2811
CFTR-R117H-
+ UCUCAUCUGCAUUCCAAUGUG 21
284 2812
CFTR-R117H-
+ UUCUCAUCUGCAUUCCAAUGUG 22
285 2813
CFTR-R117H-
+ AUUCUCAUCUGCAUUCCAAUGUG 23
286 2814
CFTR-R117H-
+ UAUUCUCAUCUGCAUUCCAAUGUG 24
287 2815
CFTR-R117H-
+ CCUUGUUAUCCGGGUCAU 18
288 2816
CFTR-R117H-
+ UCCUUGUUAUCCGGGUCAU 19
289 2817
CFTR-R117H-
+ CUCCUUGUUAUCCGGGUCAU 20
59 2587
CFTR-R117H-
+ CCUCCUUGUUAUCCGGGUCAU 21
290 2818
CFTR-R117H-
+ UCCUCCUUGUUAUCCGGGUCAU 22
291 2819
CFTR-R117H-
+ UUCCUCCUUGUUAUCCGGGUCAU 23
292 2820
CFTR-R117H-
+ GUUCCUCCUUGUUAUCCGGGUCAU 24
293 2821
CFTR-R117H-
+ GCUAUGAUUCUUCCCAGU 18
294 2822
CFTR-R117H-
+ AGCUAUGAUUCUUCCCAGU 19
295 2823
CFTR-R117H-
+ AAGCUAUGAUUCUUCCCAGU 20
296 2824
CFTR-R117H-
+ GAAGCUAUGAUUCUUCCCAGU 21
297 2825
CFTR-R117H-
+ GGAAGCUAUGAUUCUUCCCAGU 22
298 2826
CFTR-R117H-
+ AGGAAGCUAUGAUUCUUCCCAGU 23
299 2827
CFTR-R117H-
+ UAGGAAGCUAUGAUUCUUCCCAGU 24
300 2828
CFTR-R117H-
+ CCAAAAAUGGCUGGGUGU 18
301 2829
CFTR-R117H-
+ GCCAAAAAUGGCUGGGUGU 19
302 2830
314
5535.1 CFTR-R117H-
+ GGCCAAAAAUGGCUGGGUGU 20
17 2545
CFTR-R117H-
+ AGGCCAAAAAUGGCUGGGUGU 21
303 2831
CFTR-R117H-
+ AAGGCCAAAAAUGGCUGGGUGU 22
304 2832
CFTR-R117H-
+ GAAGGCCAAAAAUGGCUGGGUGU 23
305 2833
CFTR-R117H-
+ UGAAGGCCAAAAAUGGCUGGGUGU 24
306 2834
CFTR-R117H-
+ CACAAGACUUUUCAUCUU 18
307 2835
CFTR-R117H-
+ ACACAAGACUUUUCAUCUU 19
308 2836
CFTR-R117H-
+ AACACAAG ACU U U U CAU CU U 20
309 2837
CFTR-R117H-
+ CAACACAAG ACU UUUCAUCUU 21
310 2838
CFTR-R117H-
+ UCAACACAAGACUUUUCAUCUU 22
311 2839
CFTR-R117H-
+ U U CAACACAAG AC U UUUCAUCUU 23
312 2840
CFTR-R117H-
+ U U U CAACACAAG AC U UUUCAUCUU 24
313 2841
CFTR-R117H-
- GUAUUUUAUGAGAAAUAA 18
314 2842
CFTR-R117H-
- GGUAUUUUAUGAGAAAUAA 19
315 2843
CFTR-R117H-
- GGGUAUUUUAUGAGAAAUAA 20
316 2844
CFTR-R117H-
- AGGGUAUUUUAUGAGAAAUAA 21
317 2845
CFTR-R117H-
- CAGGGUAUUUUAUGAGAAAUAA 22
318 2846
CFTR-R117H-
- UCAGGGUAUUUUAUGAGAAAUAA 23
319 2847
CFTR-R117H-
- CUCAGGGUAUUUUAUGAGAAAUAA 24
320 2848
CFTR-R117H-
- CCUAUGACCCGGAUAACA 18
321 2849
CFTR-R117H-
- UCCUAUGACCCGGAUAACA 19
322 2850
CFTR-R117H- - UUCCUAUGACCCGGAUAACA 20 2568
315
5535.1 40
CFTR-R117H-
- CUUCCUAUGACCCGGAUAACA 21
323 2851
CFTR-R117H-
- GCUUCCUAUGACCCGGAUAACA 22
324 2852
CFTR-R117H-
- AGCU UCCUAUGACCCGGAUAACA 23
325 2853
CFTR-R117H-
- UAGCUUCCUAUGACCCGGAUAACA 24
326 2854
CFTR-R117H-
- UU UUUGGCCUUCAUCACA 18
327 2855
CFTR-R117H-
- AUUUUUGGCCUUCAUCACA 19
328 2856
CFTR-R117H-
- CAU UUUUGGCCUUCAUCACA 20
329 2857
CFTR-R117H-
- CCAUU UUUGGCCU UCAUCACA 21
330 2858
CFTR-R117H-
- GCCAUUUUUGGCCUUCAUCACA 22
331 2859
CFTR-R117H-
- AGCCAUUUUUGGCCUUCAUCACA 23
332 2860
CFTR-R117H-
- CAGCCAUUUU UGGCCUUCAUCACA 24
333 2861
CFTR-R117H-
- GCAGUACAGCCUCUCU UA 18
334 2862
CFTR-R117H-
- AGCAGUACAGCCUCUCU UA 19
335 2863
CFTR-R117H-
- AAGCAGUACAGCCUCUCUUA 20
336 2864
CFTR-R117H-
- AAAGCAGUACAGCCUCUCUUA 21
337 2865
CFTR-R117H-
- CAAAGCAGUACAGCCUCUCUUA 22
338 2866
CFTR-R117H-
- CCAAAGCAGUACAGCCUCUCUUA 23
339 2867
CFTR-R117H-
- ACCAAAGCAGUACAGCCUCUCUUA 24
340 2868
CFTR-R117H-
- UCCUAUGACCCGGAUAAC 18
341 2869
CFTR-R117H-
- UUCCUAUGACCCGGAUAAC 19
342 2870
CFTR-R117H-
- CUUCCUAUGACCCGGAUAAC 20
343 2871
316
5535.1 CFTR-R117H-
- GCUUCCUAUGACCCGGAUAAC 21
344 2872
CFTR-R117H-
- AGCUUCCUAUGACCCGGAUAAC 22
345 2873
CFTR-R117H-
- UAGCUUCCUAUGACCCGGAUAAC 23
346 2874
CFTR-R117H-
- AUAGCUUCCUAUGACCCGGAUAAC 24
347 2875
CFTR-R117H-
- CAGUACAGCCUCUCUUAC 18
348 2876
CFTR-R117H-
- GCAGUACAGCCUCUCU UAC 19
349 2877
CFTR-R117H-
- AGCAGUACAGCCUCUCUUAC 20
45 2573
CFTR-R117H-
- AAGCAGUACAGCCUCUCUUAC 21
350 2878
CFTR-R117H-
- AAAGCAGUACAGCCUCUCUUAC 22
351 2879
CFTR-R117H-
- CAAAGCAGUACAGCCUCUCUUAC 23
352 2880
CFTR-R117H-
- CCAAAGCAGUACAGCCUCUCUUAC 24
353 2881
CFTR-R117H-
- UUUAAGUCUCCUCUAAAG 18
354 2882
CFTR-R117H-
- UUUUAAGUCUCCUCUAAAG 19
355 2883
CFTR-R117H-
- AUUUUAAGUCUCCUCUAAAG 20
356 2884
CFTR-R117H-
- CAU UUUAAGUCUCCUCUAAAG 21
357 2885
CFTR-R117H-
- UCAUUUUAAGUCUCCUCUAAAG 22
358 2886
CFTR-R117H-
- CUCAUUUUAAGUCUCCUCUAAAG 23
359 2887
CFTR-R117H-
- ACUCAUUUUAAGUCUCCUCUAAAG 24
360 2888
CFTR-R117H-
- UAUGACCCGGAUAACAAG 18
361 2889
CFTR-R117H-
- CUAUGACCCGGAUAACAAG 19
362 2890
CFTR-R117H-
- CCUAUGACCCGGAUAACAAG 20
363 2891
CFTR-R117H- - UCCUAUGACCCGGAUAACAAG 21 2892
317
5535.1 364
CFTR-R117H-
- UUCCUAUGACCCGGAUAACAAG 22
365 2893
CFTR-R117H-
- CUUCCUAUGACCCGGAUAACAAG 23
366 2894
CFTR-R117H-
- GCUUCCUAUGACCCGGAUAACAAG 24
367 2895
CFTR-R117H-
- CAUCACAUUGGAAUGCAG 18
368 2896
CFTR-R117H-
- UCAUCACAUUGGAAUGCAG 19
369 2897
CFTR-R117H-
- UUCAUCACAUUGGAAUGCAG 20
370 2898
CFTR-R117H-
- CUUCAUCACAUUGGAAUGCAG 21
371 2899
CFTR-R117H-
- CCUUCAUCACAUUGGAAUGCAG 22
372 2900
CFTR-R117H-
- GCCUUCAUCACAUUGGAAUGCAG 23
373 2901
CFTR-R117H-
- GGCCUUCAUCACAUUGGAAUGCAG 24
374 2902
CFTR-R117H-
- AUGACCCGGAUAACAAGG 18
375 2903
CFTR-R117H-
- UAUGACCCGGAUAACAAGG 19
376 2904
CFTR-R117H-
- CUAUGACCCGGAUAACAAGG 20
53 2581
CFTR-R117H-
- CCUAUGACCCGGAUAACAAGG 21
377 2905
CFTR-R117H-
- UCCUAUGACCCGGAUAACAAGG 22
378 2906
CFTR-R117H-
- UUCCU AUGACCCGGAUAACAAGG 23
379 2907
CFTR-R117H-
- CUUCCUAUGACCCGGAUAACAAGG 24
380 2908
CFTR-R117H-
- AAGAUGAAAAGUCUUGUG 18
381 2909
CFTR-R117H-
- AAAGAUGAAAAGUCUUGUG 19
382 2910
CFTR-R117H-
- UAAAGAUGAAAAGUCUUGUG 20
383 2911
CFTR-R117H-
- CUAAAGAUGAAAAGUCUUGUG 21
384 2912
318
5535.1 CFTR-R117H-
- UCUAAAGAUGAAAAGUCUUGUG 22
385 2913
CFTR-R117H-
- CUCUAAAGAUGAAAAGUCUUGUG 23
386 2914
CFTR-R117H-
- CCUCUAAAGAUGAAAAGUCUUGUG 24
387 2915
CFTR-R117H-
- UCUGUUUUUCCCCUUUUG 18
388 2916
CFTR-R117H-
- CUCUGUUUUUCCCCUUUUG 19
389 2917
CFTR-R117H-
- UCUCUGUUUUUCCCCUUUUG 20
390 2918
CFTR-R117H-
- UUCUCUGUUUUUCCCCUUUUG 21
391 2919
CFTR-R117H-
- UUUCUCUGUUUUUCCCCUUUUG 22
392 2920
CFTR-R117H-
- AUUUCUCUGUUUUUCCCCUUUUG 23
393 2921
CFTR-R117H-
- AAUUUCUCUGUUUUUCCCCUUUUG 24
394 2922
CFTR-R117H-
- AUGUUUAGUUUGAUUUAU 18
395 2923
CFTR-R117H-
- UAUGUUUAGUUUGAUUUAU 19
396 2924
CFTR-R117H-
- CUAUGUUUAGUUUGAUUUAU 20
397 2925
CFTR-R117H-
- GCUAUGUUUAGUUUGAUUUAU 21
398 2926
CFTR-R117H-
- AGCUAUGUUUAGUUUGAUUUAU 22
399 2927
CFTR-R117H-
- UAGCUAUGUUUAGUUUGAUUUAU 23
400 2928
CFTR-R117H-
- AUAGCUAUGUUUAGUUUGAUUUAU 24
401 2929
CFTR-R117H-
- AUUCUCAGGGUAUUUUAU 18
402 2930
CFTR-R117H-
- AAUUCUCAGGGUAUUUUAU 19
403 2931
CFTR-R117H-
- AAAUUCUCAGGGUAUUUUAU 20
404 2932
CFTR-R117H-
- GAAAUUCUCAGGGUAUUUUAU 21
405 2933
CFTR-R117H- - UGAAAUUCUCAGGGUAUUUUAU 22 2934
319
5535.1 406
CFTR-R117H-
- UUGAAAUUCUCAGGGUAUUUUAU 23
407 2935
CFTR-R117H-
- GUUGAAAUUCUCAGGGUAUUUUAU 24
408 2936
CFTR-R117H-
- AGUACAGCCUCUCUUACU 18
409 2937
CFTR-R117H-
- CAGUACAGCCUCUCUUACU 19
410 2938
CFTR-R117H-
- GCAGUACAGCCUCUCUUACU 20
15 2543
CFTR-R117H-
- AGCAGUACAGCCUCUCUUACU 21
411 2939
CFTR-R117H-
- AAGCAGUACAGCCUCUCUUACU 22
412 2940
CFTR-R117H-
- AAAGCAGUACAGCCUCUCUUACU 23
413 2941
CFTR-R117H-
- CAAAGCAGUACAGCCUCUCUUACU 24
414 2942
CFTR-R117H-
- AUGCCUUCUCUUUAUUGU 18
415 2943
CFTR-R117H-
- UAUGCCUUCUCUUUAUUGU 19
416 2944
CFTR-R117H-
- UUAUGCCUUCUCUUUAUUGU 20
417 2945
CFTR-R117H-
- CUUAUGCCUUCUCUUUAUUGU 21
418 2946
CFTR-R117H-
- GCUUAUGCCUUCUCUUUAUUGU 22
419 2947
CFTR-R117H-
- GGCUUAUGCCUUCUCUUUAUUGU 23
420 2948
CFTR-R117H-
- AGGCUUAUGCCUUCUCUUUAUUGU 24
421 2949
CFTR-R117H-
- CUGUUUUUCCCCUUUUGU 18
422 2950
CFTR-R117H-
- UCUGUUUUUCCCCUUUUGU 19
423 2951
CFTR-R117H-
- CUCUGUUUUUCCCCUUUUGU 20
74 2602
CFTR-R117H-
- UCUCUGUUUUUCCCCUUUUGU 21
424 2952
CFTR-R117H-
- UUCUCUGUUUUUCCCCUUUUGU 22
425 2953
320
5535.1 CFTR-R117H-
- UUUCUCUGUUUUUCCCCUUUUGU 23
426 2954
CFTR-R117H-
- AUUUCUCUGUUUUUCCCCUUUUGU 24
427 2955
CFTR-R117H-
- UUAUGCCUUCUCUUUAUU 18
428 2956
CFTR-R117H-
- CUUAUGCCUUCUCUUUAUU 19
429 2957
CFTR-R117H-
- GCUUAUGCCUUCUCUUUAUU 20
430 2958
CFTR-R117H-
- GGCUUAUGCCUUCUCUUUAUU 21
431 2959
CFTR-R117H-
- AGGCUUAUGCCUUCUCUUUAUU 22
432 2960
CFTR-R117H-
- UAGGCUUAUGCCUUCUCUUUAUU 23
433 2961
CFTR-R117H-
- AUAGGCUUAUGCCUUCUCUUUAUU 24
434 2962
CFTR-R117H-
- AAAUUCUCAGGGUAUUUU 18
435 2963
CFTR-R117H-
- GAAAUUCUCAGGGUAUUUU 19
436 2964
CFTR-R117H-
- UGAAAUUCUCAGGGUAUUUU 20
437 2965
CFTR-R117H-
- UUGAAAUUCUCAGGGUAUUUU 21
438 2966
CFTR-R117H-
- GUUGAAAUUCUCAGGGUAUUUU 22
439 2967
CFTR-R117H-
- UGUUGAAAUUCUCAGGGUAUUUU 23
440 2968
CFTR-R117H-
- GUGUUGAAAUUCUCAGGGUAUUUU 24
441 2969
Table 24A provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
321
5535.1 Table 24A
Figure imgf000323_0001
Table 24B provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 24B
Figure imgf000323_0002
Table 24C provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9
322
5535.1 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 24C
Figure imgf000324_0001
Table 24D provides exemplary targeting domains for correcting a mutation (e.g., Rl 17H) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., Rl 17H). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 24D
Figure imgf000324_0002
Table 25A provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 25A
323
5535.1 1st Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR-R553X-1 - GCUUUAUAUUCUGUUUC 17 466
CFTR-R553X-2 - GGUGGAAUCACACUGAG 17 456
CFTR-R553X-3 - GGAAUCACACUGAGUGG 17 457
CFTR-R553X-4 - GUUCAAAAUUUCAACUG 17 464
CFTR-R553X-5 - GGUGAAUAACUAAUUAU 17 465
CFTR-R553X-6 - GGGGUUUUAUGGCUAGU 17 458
CFTR-R553X-7 - GAGCAAGAAUUUCUUUAGCA 20 462
CFTR-R553X-8 - GACAAUAUAGUUCUUGGAGA 20 460
CFTR-R553X-9 - GAAGGUGGAAUCACACUGAG 20 461
CFTR-R553X-10 - GGUGGAAUCACACUGAGUGG 20 454
CFTR-R553X-11 - GAGAAAGACAAUAUAGUUCU 20 453
Table 25B provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 25B
Figure imgf000325_0001
324
5535.1 CFTR-R553X-25 - AAUAUAGUUCUUGGAGAAGG 20 474
CFTR-R553X-26 - CUGGAAUUGAAAAAAUCCUG 20 479
CFTR-R553X-27 - CAAGGUGAAUAACUAAU UAU 20 475
CFTR-R553X-28 - CCUGGGGU UUUAUGGCUAGU 20 481
Table 25C provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 25C
Figure imgf000326_0001
Table 25D provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 25D
Figure imgf000326_0002
325
5535.1 CFTR-R553X-38 - AUUGCUUUAUAUUCUGUUUC 20 476
CFTR-R553X-39 - UCCUGGGGUUUUAUGGCUAG 20 480
CFTR-R553X-40 - AAUUUUCUAUUUUUGGUAAU 20 473
CFTR-R553X-41 + AUUGUCUUUCUCUGCAAACU 20 483
CFTR-R553X-42 - UCUGGAAUUGAAAAAAUCCU 20 478
CFTR-R553X-43 - ACUCUCUAAUU UUCUAU UUU 20 472
Table 26A provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 26A
Figure imgf000327_0001
326
5535.1 54
CFTR-R553X-
- GGGGUUUUAUGGCUAGUGGGUU 22
55 1905
Table 26B provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 26B
Figure imgf000328_0001
327
5535.1 CFTR-R553X-
+ UAACCCACUAGCCAUAAAACCC 22
68 1917
CFTR-R553X-
+ U UAACCCACUAGCCAUAAAACCC 23
69 1918
CFTR-R553X-
+ CUUAACCCACUAGCCAUAAAACCC 24
70 1919
CFTR-R553X-
+ ACUUUUAGUAUGCUCAAU 18
71 1920
CFTR-R553X-
+ CACUUUUAGUAUGCUCAAU 19
72 1921
CFTR-R553X-
+ UCACUUUUAGUAUGCUCAAU 20
73 756
CFTR-R553X-
+ AGUCACUUUUAGUAUGCUCAAU 22
74 1922
CFTR-R553X-
+ AGAGUCACUUUUAGUAUGCUCAAU 24
75 1923
CFTR-R553X-
- UGGAGAAGGUGGAAUCACA 19
76 2163
CFTR-R553X-
- UUGGAGAAGGUGGAAUCACA 20
77 742
CFTR-R553X-
- CUUGGAGAAGGUGGAAUCACA 21
78 2164
CFTR-R553X-
- UCU UGGAGAAGGUGGAAUCACA 22
79 2165
CFTR-R553X-
- UUCUUGGAGAAGGUGGAAUCACA 23
80 2166
CFTR-R553X-
- CCUGGGGU UUUAUGGCUA 18
81 1924
CFTR-R553X-
- UCCUGGGGUUUUAUGGCUA 19
82 1925
CFTR-R553X-
- AUCCUGGGGUUUUAUGGCUA 20
83 750
CFTR-R553X-
- AAUCCUGGGGUUUUAUGGCUA 21
84 1926
CFTR-R553X-
- AAAUCCUGGGGUUUUAUGGCUA 22
85 1927
CFTR-R553X-
- AAAAUCCUGGGGUUUUAUGGCUA 23
86 1928
CFTR-R553X-
- AAAAAUCCUGGGGUUUUAUGGCUA 24
87 1929
CFTR-R553X-
- UGCUUUAUAUUCUGUUUC 18
88 1931
CFTR-R553X- - UUGCUUUAUAUUCUGU UUC 19 1932
328
5535.1 89
CFTR-R553X-
- AUUGCUUUAUAUUCUGUUUC 20
38 476
CFTR-R553X-
- UAUUGCUUUAUAUUCUGUUUC 21
90 1933
CFTR-R553X-
- CUAUUGCUUUAUAUUCUGUUUC 22
91 1934
CFTR-R553X-
- UCUAUUGCUUUAUAUUCUGUUUC 23
92 1935
CFTR-R553X-
- CUCUAUUGCUUUAUAU UCUGUUUC 24
93 1936
CFTR-R553X-
- AAGAAUUUCUUUAGCAAG 18
94 1937
CFTR-R553X-
- CAAGAAUUUCUUUAGCAAG 19
95 1938
CFTR-R553X-
- UAUAGUUCUUGGAGAAGG 18
96 2167
CFTR-R553X-
- AUAUAGUUCUUGGAGAAGG 19
97 2168
CFTR-R553X-
- AAUAUAGUUCUUGGAGAAGG 20
25 474
CFTR-R553X-
- CAAUAUAGUUCUUGGAGAAGG 21
98 2169
CFTR-R553X-
- ACAAUAUAGUUCUUGGAGAAGG 22
99 2170
CFTR-R553X-
- AGACAAUAUAGUUCUUGGAGAAGG 24
100 2171
CFTR-R553X-
- UU UUAUGGCUAGUGGGUU 18
101 1942
CFTR-R553X-
- UGGGGUUUUAUGGCUAGUGGGUU 23
102 1943
CFTR-R553X-
- CUGGGGUUUUAUGGCUAGUGGGUU 24
103 1944
Table 26C provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X), start with a 5'G and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with
329
5535.1 a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 26C
Figure imgf000331_0001
Table 26D provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X), and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 26D
Figure imgf000331_0002
330
5535.1 CFTR-R553X-
+ CU AU U ACCAAAAAU AG AAAAU U A 23
114 1954
CFTR-R553X-
+ CCU AU U ACCAAAAAU AG AAAAU U A 24
115 1955
CFTR-R553X-
+ AAAUGUCUGUAAUUUUUUUAC 21
116 1956
CFTR-R553X-
+ AGAAAUGUCUGUAAUU UUUUUAC 23
117 1957
CFTR-R553X-
- CUGGAAUUGAAAAAAUCC 18
118 1964
CFTR-R553X-
- UCUGGAAUUGAAAAAAUCC 19
119 1965
CFTR-R553X-
- UUCUGGAAUUGAAAAAAUCC 20
24 477
CFTR-R553X-
- UUUCUGGAAUUGAAAAAAUCC 21
120 1966
CFTR-R553X-
- UGUUUCUGGAAUUGAAAAAAUCC 23
121 1967
CFTR-R553X-
- CUGUUUCUGGAAUUGAAAAAAUCC 24
122 1968
CFTR-R553X-
- UGAGUGGAGGUCAAUGAGC 19
123 2983
CFTR-R553X-
- CUGAGUGGAGGUCAAUGAGC 20
124 2984
CFTR-R553X-
- ACUGAGUGGAGGUCAAUGAGC 21
125 2985
CFTR-R553X-
- CACUGAGUGGAGGUCAAUGAGC 22
126 2986
CFTR-R553X-
- ACACUGAGUGGAGGUCAAUGAGC 23
127 2987
CFTR-R553X-
- CACACUGAGUGGAGGUCAAUGAGC 24
128 2988
CFTR-R553X-
- AGCAAGAAUUUCUUUAGCAAG 21
129 1939
CFTR-R553X-
- UGAGCAAGAAUUUCUUUAGCAAG 23
130 2989
CFTR-R553X-
- AUGAGCAAGAAUUUCU UUAGCAAG 24
131 2990
Table 26E provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X), and PAM is NNGRRV. It is contemplated herein
331
5535.1 that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with ; aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 26E
Figure imgf000333_0001
332
5535.1 148
CFTR-R553X-
+ G A A AC AG A A U A U A A AG C A A U A 21
149 1999
CFTR-R553X-
+ AGAAACAGAAUAUAAAGCAAUA 22
150 2000
CFTR-R553X-
+ C AG A A AC AG A A U A U A A AG C A A U A 23
151 2001
CFTR-R553X-
+ CCAGAAACAGAAUAUAAAGCAAUA 24
152 2002
CFTR-R553X-
+ UAGUUAUUCACCUUGCUA 18
153 2003
CFTR-R553X-
+ UUAGUUAUUCACCUUGCUA 19
154 2004
CFTR-R553X-
+ AUUAGUUAUUCACCUUGCUA 20
155 762
CFTR-R553X-
+ AAUUAGUUAUUCACCU UGCUA 21
156 2005
CFTR-R553X-
+ UAAUUAGUUAUUCACCUUGCUA 22
157 2006
CFTR-R553X-
+ AUAAUUAGUUAUUCACCUUGCUA 23
158 2007
CFTR-R553X-
+ AAUAAUUAGUUAUUCACCUUGCUA 24
159 2008
CFTR-R553X-
+ UUGUCUUUCUCUGCAAAC 18
160 2009
CFTR-R553X-
+ AUUGUCUUUCUCUGCAAAC 19
161 2010
CFTR-R553X-
+ UAUUGUCUUUCUCUGCAAAC 20
162 760
CFTR-R553X-
+ AUAUUGUCUUUCUCUGCAAAC 21
163 2011
CFTR-R553X-
+ UAUAUUGUCUUUCUCUGCAAAC 22
164 2012
CFTR-R553X-
+ CUAUAUUGUCU UUCUCUGCAAAC 23
165 2013
CFTR-R553X-
+ ACUAUAUUGUCUUUCUCUGCAAAC 24
166 2014
CFTR-R553X-
+ UGUGAUUCCACCUUCUCC 18
167 2179
CFTR-R553X-
+ GUGUGAUUCCACCUUCUCC 19
168 2180
CFTR-R553X-
+ AGUGUGAUUCCACCUUCUCC 20
169 761
333
5535.1 CFTR-R553X-
+ CAGUGUGAUUCCACCUUCUCC 21
170 2181
CFTR-R553X-
+ UCAGUGUGAUUCCACCU UCUCC 22
171 2182
CFTR-R553X-
+ CUCAGUGUGAUUCCACCUUCUCC 23
172 2183
CFTR-R553X-
+ ACUCAGUGUGAUUCCACCUUCUCC 24
173 2184
CFTR-R553X-
+ CCAGGAUUUUU UCAAU UC 18
174 2015
CFTR-R553X-
+ CCCAGGAUUU UUUCAAU UC 19
175 2016
CFTR-R553X-
+ CCCCAGGAU UUUUUCAAUUC 20
176 767
CFTR-R553X-
+ ACCCCAGGAUUUUUUCAAUUC 21
177 2017
CFTR-R553X-
+ AACCCCAGGAUUUUUUCAAUUC 22
178 2018
CFTR-R553X-
+ AAACCCCAGG AU UUUUUCAAUUC 23
179 2019
CFTR-R553X-
+ AAAACCCCAGG AU U U U U U CAAU U C 24
180 2020
CFTR-R553X-
+ CUAUUGCUUUAACCACAG 18
181 2021
CFTR-R553X-
+ ACUAUUGCUUUAACCACAG 19
182 2022
CFTR-R553X-
+ CACUAUUGCUUUAACCACAG 20
183 754
CFTR-R553X-
+ ACACUAUUGCUU UAACCACAG 21
184 2023
CFTR-R553X-
+ CACACUAUUGCUUUAACCACAG 22
185 2024
CFTR-R553X-
+ U CACACU AU UG CU U U AACCACAG 23
186 2025
CFTR-R553X-
+ AUCACACUAUUGCUUUAACCACAG 24
187 2026
CFTR-R553X-
+ U U ACCAAAAAU AG AAAAU 18
188 2027
CFTR-R553X-
+ AUUACCAAAAAUAGAAAAU 19
189 2028
CFTR-R553X-
+ UAU U ACCAAAAAU AGAAAAU 20
190 758
CFTR-R553X- + CU AU U ACCAAAAAU AG AAAAU 21 2029
334
5535.1 191
CFTR-R553X-
+ CCU AUU ACCAAAAAU AGAAAAU 22
192 2030
CFTR-R553X-
+ UCCUAUUACCAAAAAUAGAAAAU 23
193 2031
CFTR-R553X-
+ G U CCU AU U ACCAAAAAU AG AAAAU 24
194 2032
CFTR-R553X-
+ AGUAUGCUCAAUCUGAAU 18
195 2033
CFTR-R553X-
+ UAGUAUGCUCAAUCUGAAU 19
196 2034
CFTR-R553X-
+ U UAGUAUGCUCAAUCUGAAU 20
197 755
CFTR-R553X-
+ U UUAGUAUGCUCAAUCUGAAU 21
198 2035
CFTR-R553X-
+ U UUUAGUAUGCUCAAUCUGAAU 22
199 2036
CFTR-R553X-
+ CUU UUAGUAUGCUCAAUCUGAAU 23
200 2037
CFTR-R553X-
+ ACUUUUAGUAUGCUCAAUCUGAAU 24
201 2038
CFTR-R553X-
+ UGUCUUUCUCUGCAAACU 18
202 2039
CFTR-R553X-
+ UUGUCUUUCUCUGCAAACU 19
203 2040
CFTR-R553X-
+ AUUGUCUUUCUCUGCAAACU 20
41 483
CFTR-R553X-
+ UAUUGUCUUUCUCUGCAAACU 21
204 2041
CFTR-R553X-
+ AUAUUGUCUUUCUCUGCAAACU 22
205 2042
CFTR-R553X-
+ UAUAUUGUCUUUCUCUGCAAACU 23
206 2043
CFTR-R553X-
+ CUAUAUUGUCU UUCUCUGCAAACU 24
207 2044
CFTR-R553X-
+ U U AACCACAG UUGAAAU U 18
208 2045
CFTR-R553X-
+ U U U AACCACAG UUGAAAU U 19
209 2046
CFTR-R553X-
+ CUUU AACCACAG UUGAAAU U 20
210 753
CFTR-R553X-
+ G CU U U AACCACAG UUGAAAU U 21
211 2047
335
5535.1 CFTR-R553X-
+ UGCUUUAACCACAGUUGAAAUU 22
212 2048
CFTR-R553X-
+ U UGCUUUAACCACAGUUGAAAUU 23
213 2049
CFTR-R553X-
+ AU UG CU U U AACCACAG U UG AAAU U 24
214 2050
CFTR-R553X-
- UAUAUUCUGUUUCUGGAA 18
215 2051
CFTR-R553X-
- UUAUAUUCUGUUUCUGGAA 19
216 2052
CFTR-R553X-
- UU UAUAUUCUGUUUCUGGAA 20
217 748
CFTR-R553X-
- CUUUAUAUUCUGUUUCUGGAA 21
218 2053
CFTR-R553X-
- GCUU UAUAUUCUGUUUCUGGAA 22
219 2054
CFTR-R553X-
- UGCU UUAUAUUCUGUU UCUGGAA 23
220 2055
CFTR-R553X-
- UUGCUUUAUAUUCUGU UUCUGGAA 24
221 2056
CFTR-R553X-
- AUUUUCUAUUU UUGGUAA 18
222 2059
CFTR-R553X-
- AAUUUUCUAUUUUUGGUAA 19
223 2060
CFTR-R553X-
- UAAUUUUCUAUUUUUGGUAA 20
224 736
CFTR-R553X-
- CUAAUUUUCUAU UUUUGGUAA 21
225 2061
CFTR-R553X-
- UCUAAUUUUCUAUUUUUGGUAA 22
226 2062
CFTR-R553X-
- CUCUAAUUUUCUAUUUUUGGUAA 23
227 2063
CFTR-R553X-
- UCUCUAAUUUUCUAUUUUUGGUAA 24
228 2064
CFTR-R553X-
- GACAUCUCCAAGUUUGCA 18
229 2065
CFTR-R553X-
- GGACAUCUCCAAGUUUGCA 19
230 2066
CFTR-R553X-
- AGGACAUCUCCAAGUUUGCA 20
231 738
CFTR-R553X-
- UAGGACAUCUCCAAGUU UGCA 21
232 2067
CFTR-R553X- - AUAGGACAUCUCCAAGU UUGCA 22 2068
336
5535.1 233
CFTR-R553X-
- AAUAGGACAUCUCCAAGUUUGCA 23
234 2069
CFTR-R553X-
- UAAUAGGACAUCUCCAAGUUUGCA 24
235 2070
CFTR-R553X-
- CACACUGAGUGGAGGUCA 18
236 2071
CFTR-R553X-
- UCACACUGAGUGGAGGUCA 19
237 2072
CFTR-R553X-
- AUCACACUGAGUGGAGGUCA 20
238 744
CFTR-R553X-
- AAUCACACUGAGUGGAGGUCA 21
239 2073
CFTR-R553X-
- GAAUCACACUGAGUGGAGGUCA 22
240 2074
CFTR-R553X-
- GGAAUCACACUGAGUGGAGGUCA 23
241 2075
CFTR-R553X-
- UGGAAUCACACUGAGUGGAGGUCA 24
242 2076
CFTR-R553X-
- GUGCCU UUCAAAUUCAGA 18
243 2077
CFTR-R553X-
- UGUGCCUUUCAAAUUCAGA 19
244 2078
CFTR-R553X-
- AUGUGCCUU UCAAAUUCAGA 20
245 735
CFTR-R553X-
- GAUGUGCCUU UCAAAU UCAGA 21
246 2079
CFTR-R553X-
- AGAUGUGCCUUUCAAAUUCAGA 22
247 2080
CFTR-R553X-
- AAGAUGUGCCUUUCAAAUUCAGA 23
248 2081
CFTR-R553X-
- GAAGAUGUGCCUUUCAAAUUCAGA 24
249 2082
CFTR-R553X-
- AUAUAUGAUUACAUUAGA 18
250 2083
CFTR-R553X-
- GAUAUAUGAUUACAUUAGA 19
251 2084
CFTR-R553X-
- UGAUAUAUGAUUACAUUAGA 20
22 471
CFTR-R553X-
- GUGAUAUAUGAUUACAUUAGA 21
252 2085
CFTR-R553X-
- UGUGAUAUAUGAUUACAUUAGA 22
253 2086
337
5535.1 CFTR-R553X-
- GUGUGAUAUAUGAUUACAUUAGA 23
254 2087
CFTR-R553X-
- AGUGUGAUAUAUGAUUACAUUAGA 24
255 2088
CFTR-R553X-
- AAGGUGGAAUCACACUGA 18
256 2089
CFTR-R553X-
- GAAGGUGGAAUCACACUGA 19
257 2090
CFTR-R553X-
- AGAAGGUGGAAUCACACUGA 20
258 743
CFTR-R553X-
- GAGAAGGUGGAAUCACACUGA 21
259 2091
CFTR-R553X-
- GGAGAAGGUGGAAUCACACUGA 22
260 2192
CFTR-R553X-
- UGGAGAAGGUGGAAUCACACUGA 23
261 2193
CFTR-R553X-
- UUGGAGAAGGUGGAAUCACACUGA 24
262 2194
CFTR-R553X-
- UCUGGAAUUGAAAAAAUC 18
263 2098
CFTR-R553X-
- UUCUGGAAUUGAAAAAAUC 19
264 2099
CFTR-R553X-
- UUUCUGGAAUUGAAAAAAUC 20
265 749
CFTR-R553X-
- GU UUCUGGAAUUGAAAAAAUC 21
266 2100
CFTR-R553X-
- UGUUUCUGGAAUUGAAAAAAUC 22
267 2101
CFTR-R553X-
- CUGU UUCUGGAAUUGAAAAAAUC 23
268 2102
CFTR-R553X-
- UCUGUUUCUGGAAUUGAAAAAAUC 24
269 2103
CFTR-R553X-
- AG AAAG ACAAU AU AG U U C 18
270 2195
CFTR-R553X-
- G AG AAAG ACAAU AU AG U U C 19
271 2196
CFTR-R553X-
- AG AG AAAG ACAAU AU AG U U C 20
272 739
CFTR-R553X-
- CAGAGAAAGACAAUAUAGUUC 21
273 2197
CFTR-R553X-
- GCAG AG AAAG ACAAU AU AG U U C 22
274 2198
CFTR-R553X- - UGCAGAGAAAGACAAUAUAGUUC 23 2199
338
5535.1 275
CFTR-R553X-
- U UG CAG AG AAAG ACAAU AU AG U U C 24
276 2200
CFTR-R553X-
- AUAUAGUUCUUGGAGAAG 18
277 2201
CFTR-R553X-
- AAUAUAGUUCUUGGAGAAG 19
278 2202
CFTR-R553X-
- CAAUAUAGUUCUUGGAGAAG 20
279 741
CFTR-R553X-
- ACAAUAUAGUUCUUGGAGAAG 21
280 2203
CFTR-R553X-
- GACAAUAUAGUUCUUGGAGAAG 22
281 2204
CFTR-R553X-
- AGACAAUAUAGUUCUUGGAGAAG 23
282 2205
CFTR-R553X-
- AAGACAAUAUAGUUCUUGGAGAAG 24
283 2206
CFTR-R553X-
- AGGUGGAAUCACACUGAG 18
284 2111
CFTR-R553X-
- AAGGUGGAAUCACACUGAG 19
285 2112
CFTR-R553X-9 - GAAGGUGGAAUCACACUGAG 20 461
CFTR-R553X-
- AGAAGGUGGAAUCACACUGAG 21
286 2113
CFTR-R553X-
- GAGAAGGUGGAAUCACACUGAG 22
287 2114
CFTR-R553X-
- GGAGAAGGUGGAAUCACACUGAG 23
288 2207
CFTR-R553X-
- UGGAGAAGGUGGAAUCACACUGAG 24
289 2208
CFTR-R553X-
- GAUAUAUGAUUACAUUAG 18
290 2117
CFTR-R553X-
- UGAUAUAUGAUUACAU UAG 19
291 2118
CFTR-R553X-
- GUGAUAUAUGAUUACAUUAG 20
292 734
CFTR-R553X-
- UGUGAUAUAUGAUUACAUUAG 21
293 2119
CFTR-R553X-
- GUGUGAUAUAUGAUUACAUUAG 22
294 2120
CFTR-R553X-
- AGUGUGAUAUAUGAUUACAUUAG 23
295 2121
339
5535.1 CFTR-R553X-
- UAGUGUGAUAUAUGAUUACAUUAG 24
296 2122
CFTR-R553X-
- AAGACAAUAUAGUUCUUG 18
297 2209
CFTR-R553X-
- AAAG ACAAU AU AG U U CU UG 19
298 2210
CFTR-R553X-
- GAAAGACAAUAUAGUUCUUG 20
299 740
CFTR-R553X-
- AG AAAG ACAAU AU AG U U CU UG 21
300 2211
CFTR-R553X-
- GAG AAAG ACAAU AU AG U U CU UG 22
301 2212
CFTR-R553X-
- AGAGAAAGACAAUAUAGUUCUUG 23
302 2213
CFTR-R553X-
- CAGAGAAAGACAAUAUAGUUCUUG 24
303 2214
CFTR-R553X-
- AGGACAUCUCCAAGUUUG 18
304 2123
CFTR-R553X-
- UAGGACAUCUCCAAGUU UG 19
305 2124
CFTR-R553X-
- AUAGGACAUCUCCAAGU UUG 20
306 737
CFTR-R553X-
- AAUAGGACAUCUCCAAGUUUG 21
307 2125
CFTR-R553X-
- UAAUAGGACAUCUCCAAGUUUG 22
308 2126
CFTR-R553X-
- GU AAUAGGACAUCUCCAAGUUUG 23
309 2127
CFTR-R553X-
- GGUAAUAGGACAUCUCCAAGUUUG 24
310 2128
CFTR-R553X-
- UGUGAUAUAUGAUUACAU 18
311 2129
CFTR-R553X-
- GUGUGAUAUAUGAUUACAU 19
312 2130
CFTR-R553X-
- AGUGUGAUAUAUGAUUACAU 20
313 733
CFTR-R553X-
- UAGUGUGAUAUAUGAU UACAU 21
314 2131
CFTR-R553X-
- AUAGUGUGAUAUAUGAUUACAU 22
315 2132
CFTR-R553X-
- AAUAGUGUGAUAUAUGAUUACAU 23
316 2133
CFTR-R553X- - CAAUAGUGUGAUAUAUGAUUACAU 24 2134
340
5535.1 317
CFTR-R553X-
- GAAAGACAAUAUAGUUCU 18
318 2135
CFTR-R553X-
- AG AAAG ACAAU AU AG U U CU 19
319 2136
CFTR-R553X-
- GAGAAAGACAAUAUAGUUCU 20
11 453
CFTR-R553X-
- AG AG AAAG ACAAU AU AG U U CU 21
320 2137
CFTR-R553X-
- CAGAGAAAGACAAUAUAGUUCU 22
321 2138
CFTR-R553X-
- GCAG AG AAAG ACAAU AU AG U U CU 23
322 2139
CFTR-R553X-
- UGCAGAGAAAGACAAUAUAGUUCU 24
323 2140
CFTR-R553X-
- GGGU UAAGAAUCACAU UU 18
324 2215
CFTR-R553X-
- UGGGUUAAGAAUCACAUUU 19
325 2216
CFTR-R553X-
- GUGGGUUAAGAAUCACAUUU 20
326 752
CFTR-R553X-
- AGUGGGUUAAGAAUCACAUUU 21
327 2217
CFTR-R553X-
- UAGUGGGUUAAGAAUCACAUUU 22
328 2218
CFTR-R553X-
- CUAGUGGGUUAAGAAUCACAUUU 23
329 2219
CFTR-R553X-
- GCUAGUGGGUUAAGAAUCACAUUU 24
330 2220
CFTR-R553X-
- UUGCUUUAUAUUCUGU UU 18
331 2148
CFTR-R553X-
- AUUGCUUUAUAUUCUGUUU 19
332 2149
CFTR-R553X-
- UAUUGCUUUAUAUUCUGUUU 20
333 747
CFTR-R553X-
- CUAUUGCUU UAUAUUCUGUUU 21
334 2150
CFTR-R553X-
- UCUAUUGCU UUAUAUUCUGUUU 22
335 2151
CFTR-R553X-
- CUCUAUUGCUUUAUAUUCUGUUU 23
336 2152
CFTR-R553X-
- UCUCUAUUGCUUUAUAUUCUGUUU 24
337 2153
341
5535.1 Table 27 A provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 27
Figure imgf000343_0001
Table 27B provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 27B
Figure imgf000343_0002
342
5535.1 CFTR-R553X-
+ AAUGUAAUCAUAUAUCACAC 20
344 2156
CFTR-R553X-
+ AACCCACUAGCCAUAAAACC 20
345 930
CFTR-R553X-
+ ACAUGAAUGACAUUUACAGC 20
346 2157
Table 27C provides exemplary targeting domains for correcting a mutation (e.g., R553X) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., R553X). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 27C
Figure imgf000344_0001
Table 28A provides exemplary targeting domains for correcting a mutation (e.g., W1282X) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., W1282X), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting
343
5535.1 domains in the Table lean be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 28A
Figure imgf000345_0001
Table 28B provides exemplary targeting domains for correcting a mutation (e.g.,
W1282X) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., W1282X) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table lean be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 28B
Figure imgf000345_0002
344
5535.1 CFTR-W1282X-
+ CUAUAAGGUAAAAGUGA 17
11 3003
CFTR-W1282X-
- UAACUUUGCAACAGUGA 17
12 3004
CFTR-W1282X-
+ CAAGAGGCCCACCUAUA 17
13 3005
CFTR-W1282X-
- CUUUGGAGUGAUACCAC 17
14 3006
CFTR-W1282X-
+ CUAUGAGAAAACUGCAC 17
15 3007
CFTR-W1282X-
+ AAGACACACCAUCGAUC 17
16 3008
CFTR-W1282X-
- UUGGGAAGAACUGGAUC 17
17 3009
CFTR-W1282X-
+ AUCCAGUUCUUCCCAAG 17
18 3010
CFTR-W1282X-
- CACUUUUACCUUAUAGG 17
19 3011
CFTR-W1282X-
- CAGUGCAGUUUUCUCAU 17
20 3012
CFTR-W1282X-
+ UAUAAGGUAAAAGUGAU 17
21 3013
CFTR-W1282X-
+ UCACUUCUGUGACAUAU 17
22 3014
CFTR-W1282X-
- CAUCACUUUUACCUUAU 17
23 3015
CFTR-W1282X-
- CUUAUAGGUGGGCCUCU 17
24 3016
CFTR-W1282X-
- AGAUCGAUGGUGUGUCU 17
25 3017
CFTR-W1282X-
- ACUUUUACCUUAUAGGU 17
26 3018
CFTR-W1282X-
- UUAUAGGUGGGCCUCUU 17
27 3019
CFTR-W1282X-
- AAAGGACUUAGCCAGAAAAA 20
28 3020
CFTR-W1282X-
+ CACCUGUGGUAUCACUCCAA 20
29 3021
CFTR-W1282X-
- ACUGAAUUAUGUUUAUGGCA 20
30 3022
CFTR-W1282X-
- UCUUGGGAAGAACUGGAUCA 20
31 3023
CFTR-W1282X- - UUGAGACUACUGAACACUGA 20 3024
345
5535.1 32
CFTR-W1282X-
+ CACCUAUAAGGUAAAAGUGA 20
33 3025
CFTR-W1282X-
+ UCCCAAGAGGCCCACCUAUA 20
34 3026
CFTR-W1282X-
- ACAAUACUGAAUUAUGUUUA 20
35 3027
CFTR-W1282X-
- AGCCUU UGGAGUGAUACCAC 20
36 3028
CFTR-W1282X-
+ UGCCUAUGAGAAAACUGCAC 20
37 3029
CFTR-W1282X-
+ CCCAAGACACACCAUCGAUC 20
38 3030
CFTR-W1282X-
- CUCUUGGGAAGAACUGGAUC 20
39 3031
CFTR-W1282X-
+ UAAUUUAGUUGCCUUU UUUC 20
40 3032
CFTR-W1282X-
+ CUGAUCCAGUUCUUCCCAAG 20
41 3033
CFTR-W1282X-
- CAUCACUUUUACCUUAUAGG 20
42 3034
CFTR-W1282X-
+ UAAGUCCUUUUGCUCACCUG 20
43 3035
CFTR-W1282X-
- CUCCAGUGCAGUUUUCUCAU 20
44 3036
CFTR-W1282X-
+ ACCUAUAAGGUAAAAGUGAU 20
45 3037
CFTR-W1282X-
- UCCCAUCACU UUUACCU UAU 20
46 3038
CFTR-W1282X-
- UACCU UAUAGGUGGGCCUCU 20
47 3039
CFTR-W1282X-
- UCCAGAUCGAUGGUGUGUCU 20
48 3040
CFTR-W1282X-
- AUCACUUUUACCUUAUAGGU 20
49 3041
CFTR-W1282X-
- CCAGAUCGAUGGUGUGUCUU 20
50 3042
Table 28C provides exemplary targeting domains for correcting a mutation (e.g., W1282X) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., W1282X) and start with a 5'G. It is
346
5535.1 contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table lean be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 28C
Figure imgf000348_0001
Table 28D provides exemplary targeting domains for correcting a mutation (e.g., W1282X) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., W1282X). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table lean be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 28D
Figure imgf000348_0002
347
5535.1 59
CFTR-W1282X-
- ACCUUAUAGGUGGGCCUCUU 20
60 3052
Table 29A provides exemplary targeting domains for correcting a mutation (e.g., W1282X) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., W1282X), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table lean be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 29A
Figure imgf000349_0001
Table 29B provides exemplary targeting domains for correcting a mutation (e.g., W1282X) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., W1282X), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain
348
5535.1 hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table lean be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 29B
Figure imgf000350_0001
349
5535.1 CFTR-
+ AUCCCAAGACACACCAUCGAU 21
W1282X-86 3078
CFTR-
+ AAUCCCAAGACACACCAUCGAU 22
W1282X-87 3079
CFTR-
+ UGAAUCCCAAGACACACCAUCGAU 24
W1282X-88 3080
CFTR-
- UGGGCCUCU UGGGAAGAA 18
W1282X-89 3081
CFTR-
- AGGUGGGCCUCUUGGGAAGAA 21
W1282X-90 3082
CFTR-
- UAGGUGGGCCUCUUGGGAAGAA 22
W1282X-91 3083
CFTR-
- AUAGGUGGGCCUCUUGGGAAGAA 23
W1282X-92 3084
CFTR-
- UAUAGGUGGGCCUCUUGGGAAGAA 24
W1282X-93 3085
CFTR-
- UGGGAAGAACUGGAUCAGGG 20
W1282X-94 3086
CFTR-
- UUGGGAAGAACUGGAUCAGGG 21
W1282X-95 3087
CFTR-
- CUUGGGAAGAACUGGAUCAGGG 22
W1282X-96 3088
CFTR-
- UCUUGGGAAGAACUGGAUCAGGG 23
W1282X-97 3089
CFTR-
- CUCUUGGGAAGAACUGGAUCAGGG 24
W1282X-98 3090
CFTR-
- CAGAUCGAUGGUGUGUCU 18
W1282X-99 3091
CFTR-
- CCAGAUCGAUGGUGUGUCU 19
W1282X-100 3092
CFTR-
- UCCAGAUCGAUGGUGUGUCU 20
W1282X-48 3040
CFTR-
- AUCCAGAUCGAUGGUGUGUCU 21
W1282X-101 3093
CFTR-
- AAUCCAGAUCGAUGGUGUGUCU 22
W1282X-102 3094
CFTR-
- AAAUCCAGAUCGAUGGUGUGUCU 23
W1282X-103 3095
Table 29C provides exemplary targeting domains for correcting a mutation (e.g., W1282X) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., W1282X), start with a 5'G and PAM is
350
5535.1 NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table lean be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 29C
Figure imgf000352_0001
Table 29D provides exemplary targeting domains for correcting a mutation (e.g., W1282X) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., W1282X), and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table lean be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 29D
Figure imgf000352_0002
351
5535.1 CFTR-
+ UUUCCUUCACUGUUGCAAAGUUA 23
W1282X-112 3104
CFTR-
+ CUUUCCUUCACUGUUGCAAAGUUA 24
W1282X-113 3105
CFTR-
+ CAG AG U AAU AUG AAU U U C 18
W1282X-114 3106
CFTR-
+ UGCAGAGUAAUAUGAAUUUC 20
W1282X-115 3107
CFTR-
+ AUGCAUAACAAAUAUAUUUUG 21
W1282X-116 3108
CFTR-
+ AAUGCAUAACAAAUAUAUUUUG 22
W1282X-117 3109
CFTR-
+ CAAUG CAU AACAAAU AU AU U U UG 23
W1282X-118 3110
CFTR-
+ AAAU AU AU U U UG CAG AG U AAU 21
W1282X-119 3111
CFTR-
+ CAAAUAUAUUUUGCAGAGUAAU 22
W1282X-120 3112
CFTR-
+ ACAAAU AU AU U U UG CAG AG U AAU 23
W1282X-121 3113
CFTR-
+ AACAAAU AU AU U U UGCAG AG U AAU 24
W1282X-122 3114
CFTR-
- ACAGUGAAGGAAAGCCUU 18
W1282X-123 3115
CFTR-
- AACAG UGAAGGAAAG CC U U 19
W1282X-124 3116
CFTR-
- CAACAGUGAAGGAAAGCCUU 20
W1282X-59 3051
CFTR-
- U G CAACAG UGAAGGAAAG CC U U 22
W1282X-125 3117
CFTR-
- U U G CAACAG U G AAG G AA AG CCU U 23
W1282X-126 3118
CFTR-
- UUUGCAACAGUGAAGG A A AG C C U U 24
W1282X-127 3119
Table 29E provides exemplary targeting domains for correcting a mutation (e.g., W1282X) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., W1282X), and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table lean be used
352
5535.1 with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 29E
Figure imgf000354_0001
353
5535.1 CFTR-
+ CUUCCCUGAUCCAGUUCUUCCC 22
W1282X-145 3137
CFTR-
+ UCUUCCCUGAUCCAGUUCUUCCC 23
W1282X-146 3138
CFTR-
+ CUCUUCCCUGAUCCAGUUCUUCCC 24
W1282X-147 3139
CFTR-
+ UAUGAGAAAACUGCACUG 18
W1282X-148 3140
CFTR-
+ CUAUGAGAAAACUGCACUG 19
W1282X-149 3141
CFTR-
+ CCUAUGAGAAAACUGCACUG 20
W1282X-150 3142
CFTR-
+ GCCUAUGAGAAAACUGCACUG 21
W1282X-151 3143
CFTR-
+ UGCCUAUGAGAAAACUGCACUG 22
W1282X-152 3144
CFTR-
+ CUGCCUAUGAGAAAACUGCACUG 23
W1282X-153 3145
CFTR-
+ UCUGCCUAUGAGAAAACUGCACUG 24
W1282X-154 3146
CFTR-
+ ACCUAUAAGGUAAAAGUG 18
W1282X-155 3147
CFTR-
+ CACCUAUAAGGUAAAAGUG 19
W1282X-156 3148
CFTR-
+ CCACCUAUAAGGUAAAAGUG 20
W1282X-157 3149
CFTR-
+ CCCACCUAUAAGGUAAAAGUG 21
W1282X-158 3150
CFTR-
+ GCCCACCUAUAAGGUAAAAGUG 22
W1282X-159 3151
CFTR-
+ GGCCCACCUAUAAGGUAAAAGUG 23
W1282X-160 3152
CFTR-
+ AGGCCCACCUAUAAGGUAAAAGUG 24
W1282X-161 3153
CFTR-
+ GACAUCUUUUCUGCCUAU 18
W1282X-162 3154
CFTR-
+ AGACAUCUUUUCUGCCUAU 19
W1282X-163 3155
CFTR-
+ GAGACAUCUUUUCUGCCUAU 20
W1282X-164 3156
CFTR-
+ AGAGACAUCUUUUCUGCCUAU 21
W1282X-165 3157
354
5535.1 CFTR-
+ UAGAGACAUCUUUUCUGCCUAU 22
W1282X-166 3158
CFTR-
+ UUAGAGACAUCUUUUCUGCCUAU 23
W1282X-167 3159
CFTR-
+ UUUAGAGACAUCUUUUCUGCCUAU 24
W1282X-168 3160
CFTR-
+ GAGACAUCUUUUCUGCCU 18
W1282X-169 3161
CFTR-
+ AGAGACAUCUUUUCUGCCU 19
W1282X-170 3162
CFTR-
+ UAGAGACAUCUUUUCUGCCU 20
W1282X-171 3163
CFTR-
+ UUAGAGACAUCUUUUCUGCCU 21
W1282X-172 3164
CFTR-
+ UUUAGAGACAUCUUUUCUGCCU 22
W1282X-173 3165
CFTR-
+ UUUUAGAGACAUCUUUUCUGCCU 23
W1282X-174 3166
CFTR-
+ CUUUUAGAGACAUCUUUUCUGCCU 24
W1282X-175 3167
CFTR-
- GAUACCACAGGUGAGCAA 18
W1282X-176 3168
CFTR-
- UGAUACCACAGGUGAGCAA 19
W1282X-177 3169
CFTR-
- GUGAUACCACAGGUGAGCAA 20
W1282X-178 3170
CFTR-
- AGUGAUACCACAGGUGAGCAA 21
W1282X-179 3171
CFTR-
- GAGUGAUACCACAGGUGAGCAA 22
W1282X-180 3172
CFTR-
- GGAGUGAUACCACAGGUGAGCAA 23
W1282X-181 3173
CFTR-
- UGGAGUGAUACCACAGGUGAGCAA 24
W1282X-182 3174
CFTR-
- UUCAAUAACUUUGCAACA 18
W1282X-183 3175
CFTR-
- AUUCAAUAACUUUGCAACA 19
W1282X-184 3176
CFTR-
- GAUUCAAUAACUUUGCAACA 20
W1282X-185 3177
CFTR-
- GGAUUCAAUAACUUUGCAACA 21
W1282X-186 3178
355
5535.1 CFTR-
- GGGAUUCAAUAACUUUGCAACA 22
W1282X-187 3179
CFTR-
- UGGGAUUCAAUAACUUUGCAACA 23
W1282X-188 3180
CFTR-
- UUGGGAUUCAAUAACUUUGCAACA 24
W1282X-189 3181
CFTR-
- UUUUGAGACUACUGAACA 18
W1282X-190 3182
CFTR-
- UUUUUGAGACUACUGAACA 19
W1282X-191 3183
CFTR-
- UUUUUUGAGACUACUGAACA 20
W1282X-192 3184
CFTR-
- CUUUUUUGAGACUACUGAACA 21
W1282X-193 3185
CFTR-
- GCUUUUUUGAGACUACUGAACA 22
W1282X-194 3186
CFTR-
- AGCUUUUUUGAGACUACUGAACA 23
W1282X-195 3187
CFTR-
- CAGCUUUUUUGAGACUACUGAACA 24
W1282X-196 3188
CFTR-
- UUGGGAAGAACUGGAUCA 18
W1282X-197 3189
CFTR-
- CUUGGGAAGAACUGGAUCA 19
W1282X-198 3190
CFTR-
- UCUUGGGAAGAACUGGAUCA 20
W1282X-31 3023
CFTR-
- CUCUUGGGAAGAACUGGAUCA 21
W1282X-199 3191
CFTR-
- CCUCUUGGGAAGAACUGGAUCA 22
W1282X-200 3192
CFTR-
- GCCUCUUGGGAAGAACUGGAUCA 23
W1282X-201 3193
CFTR-
- GGCCUCUUGGGAAGAACUGGAUCA 24
W1282X-202 3194
CFTR-
- CAUGGUACCUAUAUGUCA 18
W1282X-203 3195
CFTR-
- GCAUGGUACCUAUAUGUCA 19
W1282X-204 3196
CFTR-
- GGCAUGGUACCUAUAUGUCA 20
W1282X-205 3197
CFTR-
- UGGCAUGGUACCUAUAUGUCA 21
W1282X-206 3198
356
5535.1 CFTR-
- AUGGCAUGGUACCUAUAUGUCA 22
W1282X-207 3199
CFTR-
- UAUGGCAUGGUACCUAUAUGUCA 23
W1282X-208 3200
CFTR-
- UUAUGGCAUGGUACCUAUAUGUCA 24
W1282X-209 3201
CFTR-
- GAGACUACUGAACACUGA 18
W1282X-210 3202
CFTR-
- UGAGACUACUGAACACUGA 19
W1282X-211 3203
CFTR-
- UUGAGACUACUGAACACUGA 20
W1282X-32 3024
CFTR-
- UUUGAGACUACUGAACACUGA 21
W1282X-212 3204
CFTR-
- UUUUGAGACUACUGAACACUGA 22
W1282X-213 3205
CFTR-
- UUUUUGAGACUACUGAACACUGA 23
W1282X-214 3206
CFTR-
- UUUUUUGAGACUACUGAACACUGA 24
W1282X-215 3207
CFTR-
- AUAACUUUGCAACAGUGA 18
W1282X-216 3208
CFTR-
- AAUAACUUUGCAACAGUGA 19
W1282X-217 3209
CFTR-
- CAAUAACUUUGCAACAGUGA 20
W1282X-58 3050
CFTR-
- UCAAUAACUUUGCAACAGUGA 21
W1282X-218 3210
CFTR-
- UUCAAUAACUUUGCAACAGUGA 22
W1282X-219 3211
CFTR-
- AU U CAAU AACU U UG CAACAG UG A 23
W1282X-220 3212
CFTR-
- GAUUCAAUAACUUUGCAACAGUGA 24
W1282X-221 3213
CFTR-
- UCAGCUUUUUUGAGACUA 18
W1282X-222 3214
CFTR-
- AUCAGCUUUUUUGAGACUA 19
W1282X-223 3215
CFTR-
- UAUCAGCUUUUUUGAGACUA 20
W1282X-224 3216
CFTR-
- UUAUCAGCUUUUUUGAGACUA 21
W1282X-225 3217
357
5535.1 CFTR-
- GU UAUCAGCUU UUUUGAGACUA 22
W1282X-226 3218
CFTR-
- UGUUAUCAGCU UUUUUGAGACUA 23
W1282X-227 3219
CFTR-
- UUGUUAUCAGCUUUUUUGAGACUA 24
W1282X-228 3220
CFTR-
- UGAGCAAAAGGACUUAGC 18
W1282X-229 3221
CFTR-
- G U G AG CAAAAG G AC U U AG C 19
W1282X-230 3222
CFTR-
- GGUGAGCAAAAGGACU UAGC 20
W1282X-231 3223
CFTR-
- AGGUGAGCAAAAGGACUUAGC 21
W1282X-232 3224
CFTR-
- CAG G U G AG CAAAAG G AC U U AG C 22
W1282X-233 3225
CFTR-
- ACAGG U G AG CAAAAG G AC U U AG C 23
W1282X-234 3226
CFTR-
- CACAGGUGAGCAAAAGGACUUAGC 24
W1282X-235 3227
CFTR-
- CUUGGGAAGAACUGGAUC 18
W1282X-236 3228
CFTR-
- UCU UGGGAAGAACUGGAUC 19
W1282X-237 3229
CFTR-
- CUCUUGGGAAGAACUGGAUC 20
W1282X-39 3031
CFTR-
- CCUCUUGGGAAGAACUGGAUC 21
W1282X-238 3230
CFTR-
- GCCUCUUGGGAAGAACUGGAUC 22
W1282X-239 3231
CFTR-
- GGCCUCUUGGGAAGAACUGGAUC 23
W1282X-240 3232
CFTR-
- GGGCCUCUUGGGAAGAACUGGAUC 24
W1282X-241 3233
CFTR-
- UAUUUGAUACUUGUACUC 18
W1282X-242 3234
CFTR-
- CUAUUUGAUACUUGUACUC 19
W1282X-243 3235
CFTR-
- GCUAUUUGAUACU UGUACUC 20
W1282X-244 3236
CFTR-
- UGCUAUUUGAUACUUGUACUC 21
W1282X-245 3237
358
5535.1 CFTR-
- CUGCUAUUUGAUACUUGUACUC 22
W1282X-246 3238
CFTR-
- ACUGCUAUUUGAUACU UGUACUC 23
W1282X-247 3239
CFTR-
- UACUGCUAUUUGAUACUUGUACUC 24
W1282X-248 3240
CFTR-
- ACCUUAUAGGUGGGCCUC 18
W1282X-249 3241
CFTR-
- UACCUUAUAGGUGGGCCUC 19
W1282X-250 3242
CFTR-
- UUACCUUAUAGGUGGGCCUC 20
W1282X-251 3243
CFTR-
- UU UACCUUAUAGGUGGGCCUC 21
W1282X-252 3244
CFTR-
- UU UUACCUUAUAGGUGGGCCUC 22
W1282X-253 3245
CFTR-
- CUUUUACCUUAUAGGUGGGCCUC 23
W1282X-254 3246
CFTR-
- ACUUUUACCUUAUAGGUGGGCCUC 24
W1282X-255 3247
CFTR-
- CCAGAUCGAUGGUGUGUC 18
W1282X-256 3248
CFTR-
- UCCAGAUCGAUGGUGUGUC 19
W1282X-257 3249
CFTR-
- AUCCAGAUCGAUGGUGUGUC 20
W1282X-258 3250
CFTR-
- AAUCCAGAUCGAUGGUGUGUC 21
W1282X-259 3251
CFTR-
- AAAUCCAGAUCGAUGGUGUGUC 22
W1282X-260 3252
CFTR-
- GAAAUCCAGAUCGAUGGUGUGUC 23
W1282X-261 3253
CFTR-
- AGAAAUCCAGAUCGAUGGUGUGUC 24
W1282X-262 3254
CFTR-
- GACUACUGAACACUGAAG 18
W1282X-263 3255
CFTR-
- AGACUACUGAACACUGAAG 19
W1282X-264 3256
CFTR-
- GAGACUACUGAACACUGAAG 20
W1282X-265 3257
CFTR-
- UGAGACUACUGAACACUGAAG 21
W1282X-266 3258
359
5535.1 CFTR-
- UUGAGACUACUGAACACUGAAG 22
W1282X-267 3259
CFTR-
- UUUGAGACUACUGAACACUGAAG 23
W1282X-268 3260
CFTR-
- UU UUGAGACUACUGAACACUGAAG 24
W1282X-269 3261
CFTR-
- UU UGGAGUGAUACCACAG 18
W1282X-270 3262
CFTR-
- CUU UGGAGUGAUACCACAG 19
W1282X-271 3263
CFTR-
- CCUUUGGAGUGAUACCACAG 20
W1282X-272 3264
CFTR-
- GCCUUUGGAGUGAUACCACAG 21
W1282X-273 3265
CFTR-
- AGCCUUUGGAGUGAUACCACAG 22
W1282X-274 3266
CFTR-
- AAGCCU UUGGAGUGAUACCACAG 23
W1282X-275 3267
CFTR-
- AAAGCCUUUGGAGUGAUACCACAG 24
W1282X-276 3268
CFTR-
- AUCACUUUUACCUUAUAG 18
W1282X-277 3269
CFTR-
- CAUCACUUUUACCUUAUAG 19
W1282X-278 3270
CFTR-
- CCAUCACU UUUACCUUAUAG 20
W1282X-279 3271
CFTR-
- CCCAUCACUUUUACCUUAUAG 21
W1282X-280 3272
CFTR-
- UCCCAUCACUUUUACCUUAUAG 22
W1282X-281 3273
CFTR-
- AUCCCAUCACUUUUACCUUAUAG 23
W1282X-282 3274
CFTR-
- GAUCCCAUCACUUUUACCUUAUAG 24
W1282X-283 3275
CFTR-
- GUGCAGUUUUCUCAUAGG 18
W1282X-284 3276
CFTR-
- AGUGCAGUUUUCUCAUAGG 19
W1282X-285 3277
CFTR-
- CAGUGCAGUUUUCUCAUAGG 20
W1282X-286 3278
CFTR-
- CCAGUGCAGUUUUCUCAUAGG 21
W1282X-287 3279
360
5535.1 CFTR-
- UCCAGUGCAGU UUUCUCAUAGG 22
W1282X-288 3280
CFTR-
- CUCCAGUGCAGUUUUCUCAUAGG 23
W1282X-289 3281
CFTR-
- UCUCCAGUGCAGUUUUCUCAUAGG 24
W1282X-290 3282
CFTR-
- AUAGGUGGGCCUCUUGGG 18
W1282X-291 3283
CFTR-
- UAUAGGUGGGCCUCUUGGG 19
W1282X-292 3284
CFTR-
- UUAUAGGUGGGCCUCU UGGG 20
W1282X-293 3285
CFTR-
- CUUAUAGGUGGGCCUCUUGGG 21
W1282X-294 3286
CFTR-
- CCUUAUAGGUGGGCCUCUUGGG 22
W1282X-295 3287
CFTR-
- ACCUUAUAGGUGGGCCUCUUGGG 23
W1282X-296 3288
CFTR-
- UACCU UAUAGGUGGGCCUCUUGGG 24
W1282X-297 3289
CFTR-
- UGAGACUACUGAACACUG 18
W1282X-298 3290
CFTR-
- UUGAGACUACUGAACACUG 19
W1282X-299 3291
CFTR-
- UU UGAGACUACUGAACACUG 20
W1282X-300 3292
CFTR-
- UU UUGAGACUACUGAACACUG 21
W1282X-301 3293
CFTR-
- UUUUUGAGACUACUGAACACUG 22
W1282X-302 3294
CFTR-
- UUUUUUGAGACUACUGAACACUG 23
W1282X-303 3295
CFTR-
- CUU UUUUGAGACUACUGAACACUG 24
W1282X-304 3296
CFTR-
- AAUAACUUUGCAACAGUG 18
W1282X-305 3297
CFTR-
- CAAUAACUUUGCAACAGUG 19
W1282X-306 3298
CFTR-
- UCAAUAACUUUGCAACAGUG 20
W1282X-307 3299
CFTR-
- UUCAAUAACUUUGCAACAGUG 21
W1282X-308 3300
361
5535.1 CFTR-
- AUUCAAUAACUUUGCAACAGUG 22
W1282X-309 3301
CFTR-
- G AU U CAAU AACU UUGCAACAGUG 23
W1282X-310 3302
CFTR-
- GGAUUCAAUAACUUUGCAACAGUG 24
W1282X-311 3303
CFTR-
- UCU UGGGAAGAACUGGAU 18
W1282X-312 3304
CFTR-
- CUCUUGGGAAGAACUGGAU 19
W1282X-313 3305
CFTR-
- CCUCUUGGGAAGAACUGGAU 20
W1282X-314 3306
CFTR-
- GCCUCU UGGGAAGAACUGGAU 21
W1282X-315 3307
CFTR-
- GGCCUCU UGGGAAGAACUGGAU 22
W1282X-316 3308
CFTR-
- GGGCCUCUUGGGAAGAACUGGAU 23
W1282X-317 3309
CFTR-
- UGGGCCUCU UGGGAAGAACUGGAU 24
W1282X-318 3310
CFTR-
- AACAGUGAAGG AAAG C C U 18
W1282X-319 3311
CFTR-
- CAACAGUGAAGGAAAGCCU 19
W1282X-320 3312
CFTR-
- GCAACAGUGAAGGAAAGCCU 20
W1282X-321 3313
CFTR-
- U G CAAC AG U G A AG G AAAG C C U 21
W1282X-322 3314
CFTR-
- UUGCAACAGUGAAGGAAAGCCU 22
W1282X-323 3315
CFTR-
- U U U G CAAC AG U G A AG G AAAG CC U 23
W1282X-324 3316
CFTR-
- C U U U G CAAC AG U G AAG G AAAG CC U 24
W1282X-325 3317
CFTR-
- CCUUAUAGGUGGGCCUCU 18
W1282X-326 3318
CFTR-
- ACCUUAUAGGUGGGCCUCU 19
W1282X-327 3319
CFTR-
- UACCU UAUAGGUGGGCCUCU 20
W1282X-47 3039
CFTR-
- UUACCUUAUAGGUGGGCCUCU 21
W1282X-328 3320
362
5535.1 CFTR-
- U UUACCUUAUAGGUGGGCCUCU 22
W1282X-329 3321
CFTR-
- UU UUACCUUAUAGGUGGGCCUCU 23
W1282X-330 3322
CFTR-
- CUU UUACCUUAUAGGUGGGCCUCU 24
W1282X-331 3323
CFTR-
- CUUAUAGGUGGGCCUCUU 18
W1282X-332 3324
CFTR-
- CCUUAUAGGUGGGCCUCUU 19
W1282X-333 3325
CFTR-
- ACCUUAUAGGUGGGCCUCUU 20
W1282X-60 3052
CFTR-
- UACCU UAUAGGUGGGCCUCUU 21
W1282X-334 3326
CFTR-
- UUACCUUAUAGGUGGGCCUCUU 22
W1282X-335 3327
CFTR-
- UU UACCUUAUAGGUGGGCCUCUU 23
W1282X-336 3328
CFTR-
- UU UUACCUUAUAGGUGGGCCUCUU 24
W1282X-337 3329
CFTR-
- ACUUUGUUAUCAGCUUUU 18
W1282X-338 3330
CFTR-
- UACUUUGUUAUCAGCUUUU 19
W1282X-339 3331
CFTR-
- GUACUUUGUUAUCAGCUUUU 20
W1282X-340 3332
CFTR-
- AGUACUUUGUUAUCAGCUUUU 21
W1282X-341 3333
CFTR-
- GAGUACUUUGUUAUCAGCUUUU 22
W1282X-342 3334
CFTR-
- AGAGUACUUUGUUAUCAGCUUUU 23
W1282X-343 3335
CFTR-
- AAGAGUACUUUGUUAUCAGCUUUU 24
W1282X-344 3336
Table 30A provides exemplary targeting domains for correcting a mutation (e.g., W1282X) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., W1282X), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting
363
5535.1 domains in the Table lean be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 30A
Figure imgf000365_0001
Table 30B provides exemplary targeting domains for correcting a mutation (e.g.,
W1282X) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., W1282X) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table lean be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 30B
Figure imgf000365_0002
Table 31A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the first tier parameters. The targeting domains
364
5535.1 bind within 200 bp from a mutation (e.g., 3272-26->G), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 31A
Figure imgf000366_0001
Table 31B provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26->G) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 31B
Figure imgf000366_0002
365
5535.1 CFTR-3272-17 - CUAAUUUAGUCUU UUUC 17 1298
CFTR-3272-18 + CAUAUCACAAAUGUCAU 17 1299
CFTR-3272-19 + ACUUGGCUACCAGAGAU 17 1300
CFTR-3272-20 + UACCCUCUUU UUUUACU 17 1301
CFTR-3272-21 + CAGG U ACAAG AACCAG U 17 1302
CFTR-3272-22 - UGGACACUUCG UGCCU U 17 1303
CFTR-3272-23 - CAUCUUGUUACAAGCUUAAA 20 1304
CFTR-3272-24 - AAUCAUAUCUAUUCAAAGAA 20 1305
CFTR-3272-25 + UUUUACUUGGCUACCAGAGA 20 1306
CFTR-3272-26 + AAAGUAAGGCUGCCGUCCGA 20 1307
CFTR-3272-27 - UUACAAGCUUAAAAGGACUA 20 1308
CFTR-3272-28 + UGGAACAGAGUUU C A A AG U A 20 1309
CFTR-3272-29 - UGAAU UUACAUACUGCCAAC 20 1310
CFTR-3272-30 + U AAA AAG CUUUUUUUCACAC 20 1311
CFTR-3272-31 - UUUCUAUGGAAAUAUUUCAC 20 1312
CFTR-3272-32 - UGUACCUGUCAACACUGCGC 20 1313
CFTR-3272-33 - UAUGGAAAUAUUUCACAGGC 20 1314
CFTR-3272-34 - UGGUAGCCAAGU A A A A A A AG 20 1315
CFTR-3272-35 + UAUGUAAAUUCAGAGCUUUG 20 1316
CFTR-3272-36 + AAUCAUAUCACAAAUGUCAU 20 1317
CFTR-3272-37 + UUUACUUGGCUACCAGAGAU 20 1318
CFTR-3272-38 + AGUUACCCUCU UUUUU UACU 20 1319
CFTR-3272-39 + UGACAGGUACAAGAACCAGU 20 1320
CFTR-3272-40 - CUAUGGACACU UCGUGCCUU 20 1321
Table 31C provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26->G) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 31C
Figure imgf000367_0001
366
5535.1 Table 31D provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26->G). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 31D
Figure imgf000368_0001
Table 32A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26->G), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 32A
Figure imgf000368_0002
Table 32B provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26->G), have a high level of
367
5535.1 orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 32B
Figure imgf000369_0001
368
5535.1 CFTR-3272-83 - AACACUGCGCUGGUUCCAAAU 21 1364
CFTR-3272-84 - CAACACUGCGCUGGUUCCAAAU 22 1365
CFTR-3272-85 - UCAACACUGCGCUGGUUCCAAAU 23 1366
CFTR-3272-86 - ACUCUGUUCCACAAAGCU 18 1367
CFTR-3272-87 - AACUCUGUUCCACAAAGCU 19 1368
CFTR-3272-88 - AAACUCUGUUCCACAAAGCU 20 1369
Table 32C provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26->G), and PAM is NNGRRT. It is
contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 32C
Figure imgf000370_0001
369
5535.1 CFTR-3272-108 - UCUCUGGUAGCCAAGU A A A A A A A 23 1390
CFTR-3272-109 - AUCUCUGGUAGCCAAGUAAAAAAA 24 1391
CFTR-3272-110 - CUAUGGAAAUAUUUCACAGGC 21 1392
CFTR-3272-111 - UCUAUGGAAAUAUUUCACAGGC 22 1393
CFTR-3272-112 - UUCUAUGGAAAUAUUUCACAGGC 23 1394
CFTR-3272-113 - UUUCUAUGGAAAUAUUUCACAGGC 24 1395
CFTR-3272-114 - GAAACUCUGUUCCACAAAGCU 21 1373
CFTR-3272-115 - UGAAACUCUGUUCCACAAAGCU 22 1396
CFTR-3272-116 - U UGAAACUC U G U U CC AC AAAG C U 23 1397
CFTR-3272-117 - UUUGAAACUCUGUUCCACAAAGCU 24 1398
Table 32D provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26->G), and PAM is NNGRRV. It is
contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 32D
Figure imgf000371_0001
370
5535.1 CFTR-3272-
+ UGCCUGUGAAAUAUUUCCA 19
126 1407
CFTR-3272-
+ CUGCCUGUGAAAUAUUUCCA 20
127 1408
CFTR-3272-
+ CCUGCCUGUGAAAUAUUUCCA 21
128 1409
CFTR-3272-
+ UCCUGCCUGUGAAAUAUUUCCA 22
129 1410
CFTR-3272-
+ CUCCUGCCUGUGAAAUAUUUCCA 23
130 1411
CFTR-3272-
+ ACUCCUGCCUGUGAAAUAUUUCCA 24
131 1412
CFTR-3272-
+ UUACUUGGCUACCAGAGA 18
132 1413
CFTR-3272-
+ UUUACUUGGCUACCAGAGA 19
133 1414
CFTR-3272-
+ UUUUACUUGGCUACCAGAGA 20
25 1306
CFTR-3272-
+ UUUUUACUUGGCUACCAGAGA 21
134 1415
CFTR-3272-
+ UUUUUUACUUGGCUACCAGAGA 22
135 1416
CFTR-3272-
+ UUUUUUUACUUGGCUACCAGAGA 23
136 1417
CFTR-3272-
+ CUUUUUUUACUUGGCUACCAGAGA 24
137 1418
CFTR-3272-
+ AAGCUUGUAACAAGAUGA 18
138 1419
CFTR-3272-
+ UAAGCUUGUAACAAGAUGA 19
139 1420
CFTR-3272-
+ UUAAGCUUGUAACAAGAUGA 20
140 1421
CFTR-3272-
+ UUUAAGCUUGUAACAAGAUGA 21
141 1422
CFTR-3272-
+ UUUUAAGCUUGUAACAAGAUGA 22
142 1423
CFTR-3272-
+ CUU UUAAGCUUGUAACAAGAUGA 23
143 1424
CFTR-3272-
+ CCUUUUAAGCUUGUAACAAGAUGA 24
144 1425
CFTR-3272-
+ CUUUUUUUACUUGGCUAC 18
145 1426
CFTR-3272- + UCUUUUUUUACUUGGCUAC 19 1427
371
5535.1 146
CFTR-3272-
+ CUCUUUUUUUACUUGGCUAC 20
147 1428
CFTR-3272-
+ CCUCUUUUUUUACUUGGCUAC 21
148 1429
CFTR-3272-
+ CCCUCUUUUUUUACUUGGCUAC 22
149 1430
CFTR-3272-
+ ACCCUCUUUUUUUACUUGGCUAC 23
150 1431
CFTR-3272-
+ UACCCUCUUUUUUUACUUGGCUAC 24
151 1432
CFTR-3272-
+ CGCAGUGUUGACAGGUAC 18
152 1433
CFTR-3272-
+ GCGCAGUGUUGACAGGUAC 19
153 1434
CFTR-3272-
+ AGCGCAGUGUUGACAGGUAC 20
154 1435
CFTR-3272-
+ CAGCGCAGUGUUGACAGGUAC 21
155 1436
CFTR-3272-
+ CCAGCGCAGUGUUGACAGGUAC 22
156 1437
CFTR-3272-
+ ACCAGCGCAGUGUUGACAGGUAC 23
157 1438
CFTR-3272-
+ AACCAGCGCAGUGUUGACAGGUAC 24
158 1439
CFTR-3272-
+ UUUCAUAAUAUCUUGUAC 18
159 1440
CFTR-3272-
+ AUUUCAUAAUAUCUUGUAC 19
160 1441
CFTR-3272-
+ AAUUUCAUAAUAUCUUGUAC 20
161 1442
CFTR-3272-
+ UAAUUUCAUAAUAUCUUGUAC 21
162 1443
CFTR-3272-
+ GUAAUUUCAUAAUAUCUUGUAC 22
163 1444
CFTR-3272-
+ UGUAAUUUCAUAAUAUCUUGUAC 23
164 1445
CFTR-3272-
+ AUGUAAUUUCAUAAUAUCUUGUAC 24
165 1446
CFTR-3272-
+ AGGCUGCCGUCCGAAGGC 18
166 1447
CFTR-3272-
+ AAGGCUGCCGUCCGAAGGC 19
167 1448
372
5535.1 CFTR-3272-
+ UAAGGCUGCCGUCCGAAGGC 20
168 1449
CFTR-3272-
+ GUAAGGCUGCCGUCCGAAGGC 21
169 1450
CFTR-3272-
+ AGUAAGGCUGCCGUCCGAAGGC 22
170 1451
CFTR-3272-
+ AAGUAAGGCUGCCGUCCGAAGGC 23
171 1452
CFTR-3272-
+ AAAGUAAGGCUGCCGUCCGAAGGC 24
172 1453
CFTR-3272-
+ UUUACUUGGCUACCAGAG 18
173 1454
CFTR-3272-
+ UUUUACUUGGCUACCAGAG 19
174 1455
CFTR-3272-
+ UUUUUACUUGGCUACCAGAG 20
175 1456
CFTR-3272-
+ UUUUUUACUUGGCUACCAGAG 21
176 1457
CFTR-3272-
+ UUUUUUUACUUGGCUACCAGAG 22
177 1458
CFTR-3272-
+ CUUUUUUUACUUGGCUACCAGAG 23
178 1459
CFTR-3272-
+ UCUUUUUUUACUUGGCUACCAGAG 24
179 1460
CFTR-3272-
+ UGUAAAUUCAGAGCUUUG 18
180 1461
CFTR-3272-
+ AUGUAAAUUCAGAGCUUUG 19
181 1462
CFTR-3272-
+ UAUGUAAAUUCAGAGCUUUG 20
35 1316
CFTR-3272-
+ GUAUGUAAAUUCAGAGCUUUG 21
182 1463
CFTR-3272-
+ AGUAUGUAAAUUCAGAGCUUUG 22
183 1464
CFTR-3272-
+ CAGUAUGUAAAUUCAGAGCUUUG 23
184 1465
CFTR-3272-
+ GCAGUAUGUAAAUUCAGAGCUUUG 24
185 1466
CFTR-3272-
+ UACUUGGCUACCAGAGAU 18
186 1467
CFTR-3272-
+ UUACUUGGCUACCAGAGAU 19
187 1468
CFTR-3272- + UUUACUUGGCUACCAGAGAU 20 1318
373
5535.1 37
CFTR-3272-
+ UUUUACUUGGCUACCAGAGAU 21
188 1469
CFTR-3272-
+ UUUUUACUUGGCUACCAGAGAU 22
189 1470
CFTR-3272-
+ UUUUUUACUUGGCUACCAGAGAU 23
190 1471
CFTR-3272-
+ UUUUUUUACUUGGCUACCAGAGAU 24
191 1472
CFTR-3272-
+ AAAAUUGGACUCCUGCCU 18
192 1473
CFTR-3272-
+ GAAAAUUGGACUCCUGCCU 19
193 1474
CFTR-3272-
+ UGAAAAUUGGACUCCUGCCU 20
194 1475
CFTR-3272-
+ GUGAAAAUUGGACUCCUGCCU 21
195 1476
CFTR-3272-
+ AGUGAAAAUUGGACUCCUGCCU 22
196 1477
CFTR-3272-
+ GAGUGAAAAUUGGACUCCUGCCU 23
197 1478
CFTR-3272-
+ UGAGUGAAAAUUGGACUCCUGCCU 24
198 1479
CFTR-3272-
+ UCAAAGUAAGGCUGCCGU 18
199 1480
CFTR-3272-
+ UUCAAAGUAAGGCUGCCGU 19
200 1481
CFTR-3272-
+ UUUCAAAGUAAGGCUGCCGU 20
201 1482
CFTR-3272-
+ GUUUCAAAGUAAGGCUGCCGU 21
202 1483
CFTR-3272-
+ AGUUUCAAAGUAAGGCUGCCGU 22
203 1484
CFTR-3272-
+ GAGUUUCAAAGUAAGGCUGCCGU 23
204 1485
CFTR-3272-
+ AGAGUUUCAAAGUAAGGCUGCCGU 24
205 1486
CFTR-3272-
+ GUUGGCAGUAUGUAAAUU 18
206 1487
CFTR-3272-
+ AGUUGGCAGUAUGUAAAUU 19
207 1488
CFTR-3272-
+ CAGUUGGCAGUAUGUAAAUU 20
208 1489
374
5535.1 CFTR-3272-
+ CCAGU UGGCAGUAUGUAAAUU 21
209 1490
CFTR-3272-
+ ACCAGUUGGCAGUAUGUAAAUU 22
210 1491
CFTR-3272-
+ AACCAGUUGGCAGUAUGUAAAUU 23
211 1492
CFTR-3272-
+ G AACCAG U UGG CAG U AUG U AAAU U 24
212 1493
CFTR-3272-
+ AUGUAAAUUCAGAGCUUU 18
213 1494
CFTR-3272-
+ UAUGUAAAUUCAGAGCUUU 19
214 1495
CFTR-3272-
+ GUAUGUAAAUUCAGAGCUUU 20
215 1496
CFTR-3272-
+ AGUAUGUAAAUUCAGAGCUUU 21
216 1497
CFTR-3272-
+ CAGUAUGUAAAUUCAGAGCUUU 22
217 1498
CFTR-3272-
+ GCAGUAUGUAAAUUCAGAGCUUU 23
218 1499
CFTR-3272-
+ GGCAGUAUGUAAAUUCAGAGCUUU 24
219 1500
CFTR-3272-
- CUGGUAGC C A AG U A A A A A 18
220 1501
CFTR-3272-
- UCUGGUAGCCAAGU A A A A A 19
221 1502
CFTR-3272-
- CUCUGGUAGCCAAGU A A A A A 20
222 1503
CFTR-3272-
- UCUCUGGUAGCCAAGUAAAAA 21
223 1504
CFTR-3272-
- AUCUCUGGUAGCCAAGUAAAAA 22
224 1505
CFTR-3272-
- CAUCUCUGGUAGCCAAGU A A A A A 23
225 1506
CFTR-3272-
- CCAUCUCUGGUAGCCAAGUAAAAA 24
226 1507
CFTR-3272-
- ACACUGCGCUGGUUCCAA 18
227 1508
CFTR-3272-
- AACACUGCGCUGGUUCCAA 19
228 1509
CFTR-3272-
- CAACACUGCGCUGGUUCCAA 20
229 1510
CFTR-3272- - UCAACACUGCGCUGGU UCCAA 21 1511
375
5535.1 230
CFTR-3272-
- GUCAACACUGCGCUGGU UCCAA 22
231 1512
CFTR-3272-
- UGUCAACACUGCGCUGGUUCCAA 23
232 1513
CFTR-3272-
- CUGUCAACACUGCGCUGGUUCCAA 24
233 1514
CFTR-3272-
- GCUGGU UCCAAAUGAGAA 18
234 1515
CFTR-3272-
- CGCUGGU UCCAAAUGAGAA 19
235 1516
CFTR-3272-
- GCGCUGGU UCCAAAUGAGAA 20
236 1517
CFTR-3272-
- UGCGCUGGUUCCAAAUGAGAA 21
237 1518
CFTR-3272-
- CUGCGCUGGUUCCAAAUGAGAA 22
238 1519
CFTR-3272-
- ACUGCGCUGGUUCCAAAUGAGAA 23
239 1520
CFTR-3272-
- CACUGCGCUGGUUCCAAAUGAGAA 24
240 1521
CFTR-3272-
- AUCUUGUUACAAGCUUAA 18
241 1522
CFTR-3272-
- CAUCUUGUUACAAGCUUAA 19
242 1523
CFTR-3272-
- UCAUCUUGUUACAAGCUUAA 20
243 1524
CFTR-3272-
- CUCAUCUUGUUACAAGCUUAA 21
244 1525
CFTR-3272-
- ACUCAUCUUGUUACAAGCUUAA 22
245 1526
CFTR-3272-
- CACUCAUCUUGUUACAAGCUUAA 23
246 1527
CFTR-3272-
- UCACUCAUCUUGUUACAAGCUUAA 24
247 1528
CFTR-3272-
- UAUUUGCAGUGUUUUCUA 18
248 1529
CFTR-3272-
- UUAUUUGCAGUGUUUUCUA 19
249 1530
CFTR-3272-
- GUUAUUUGCAGUGUUUUCUA 20
42 1323
CFTR-3272-
- UGUUAUUUGCAGUGUUUUCUA 21
250 1531
376
5535.1 CFTR-3272-
- AUGUUAUUUGCAGUGU UUUCUA 22
251 1532
CFTR-3272-
- UAUGUUAUUUGCAGUGUUUUCUA 23
252 1533
CFTR-3272-
- UUAUGUUAUUUGCAGUGUUUUCUA 24
253 1534
CFTR-3272-
- AUGGAAAUAUUUCACAGG 18
254 1535
CFTR-3272-
- UAUGGAAAUAUUUCACAGG 19
255 1536
CFTR-3272-
- CUAUGGAAAUAUUUCACAGG 20
256 1537
CFTR-3272-
- UCUAUGGAAAUAUUUCACAGG 21
257 1538
CFTR-3272-
- UUCUAUGGAAAUAUUUCACAGG 22
258 1539
CFTR-3272-
- UU UCUAUGGAAAUAUU UCACAGG 23
259 1540
CFTR-3272-
- UU UUCUAUGGAAAUAU UUCACAGG 24
260 1541
CFTR-3272-
- UACAAGCUUAAAAGGACU 18
261 1542
CFTR-3272-
- UUACAAGCUUAAAAGGACU 19
262 1543
CFTR-3272-
- GU UACAAGCUUAAAAGGACU 20
263 1544
CFTR-3272-
- UGUUACAAGCUUAAAAGGACU 21
264 1545
CFTR-3272-
- U UG U UACAAGCU U AAAAGG ACU 22
265 1546
CFTR-3272-
- CUUGUUACAAGCUUAAAAGGACU 23
266 1547
CFTR-3272-
- UCUUGUUACAAGCUUAAAAGGACU 24
267 1548
CFTR-3272-
- UCGGACGGCAGCCU UACU 18
268 1549
CFTR-3272-
- UUCGGACGGCAGCCUUACU 19
269 1550
CFTR-3272-
- CUUCGGACGGCAGCCUUACU 20
270 1551
CFTR-3272-
- CCUUCGGACGGCAGCCU UACU 21
271 1552
CFTR-3272- - GCCUUCGGACGGCAGCCUUACU 22 1553
377
5535.1 272
CFTR-3272-
- UGCCUUCGGACGGCAGCCUUACU 23
273 1554
CFTR-3272-
- GUGCCU UCGGACGGCAGCCUUACU 24
274 1555
CFTR-3272-
- UAUGGACACUUCGUGCCU 18
275 1556
CFTR-3272-
- CUAUGGACACUUCGUGCCU 19
276 1557
CFTR-3272-
- ACUAUGGACACUUCGUGCCU 20
277 1558
CFTR-3272-
- GACUAUGGACACUUCGUGCCU 21
278 1559
CFTR-3272-
- GGACUAUGGACACUUCGUGCCU 22
279 1560
CFTR-3272-
- AGGACUAUGGACACUUCGUGCCU 23
280 1561
CFTR-3272-
- AAGGACUAUGGACACUUCGUGCCU 24
281 1562
CFTR-3272-
- UUAUUUGCAGUGU UUUCU 18
282 1563
CFTR-3272-
- GU UAUUUGCAGUGUUU UCU 19
283 1564
CFTR-3272-
- UGUUAUUUGCAGUGUU UUCU 20
284 1565
CFTR-3272-
- AUGUUAUUUGCAGUGUUUUCU 21
285 1566
CFTR-3272-
- UAUGUUAUUUGCAGUGUUUUCU 22
286 1567
CFTR-3272-
- UUAUGUUAUUUGCAGUGUUUUCU 23
287 1568
CFTR-3272-
- UU UAUGUUAUUUGCAGUGUUUUCU 24
288 1569
CFTR-3272-
- U C A A AG A A U G G C AC C AG U 18
289 1570
CFTR-3272-
- UUCAAAGAAUGGCACCAGU 19
290 1571
CFTR-3272-
- AUUCAAAGAAUGGCACCAGU 20
291 1572
CFTR-3272-
- UAUUCAAAGAAUGGCACCAGU 21
292 1573
CFTR-3272-
- CUAUUCAAAGAAUGGCACCAGU 22
293 1574
378
5535.1 CFTR-3272-
- UCUAUUCAAAGAAUGGCACCAGU 23
294 1575
CFTR-3272-
- AUCUAUUCAAAGAAUGGCACCAGU 24
295 1576
CFTR-3272-
- UUUCAGGUACAAGAUAUU 18
296 1577
CFTR-3272-
- UUUUCAGGUACAAGAUAUU 19
297 1578
CFTR-3272-
- UUUUUCAGGUACAAGAUAUU 20
298 1579
CFTR-3272-
- CUUUUUCAGGUACAAGAUAUU 21
299 1580
CFTR-3272-
- UCUUUUUCAGGUACAAGAUAUU 22
300 1581
CFTR-3272-
- GUCUUUUUCAGGUACAAGAUAUU 23
301 1582
CFTR-3272-
- AGUCUUUUUCAGGUACAAGAUAUU 24
302 1583
Table 33A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26->G) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break
(Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 33A
Figure imgf000380_0001
379
5535.1 Table 33B provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 200 bp from a mutation (e.g., 3272-26->G). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 33B
Figure imgf000381_0001
Table 34A provides exemplary targeting domains for correcting a mutation (e.g.,
3849+10kbC->T) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 34A
Figure imgf000381_0002
380
5535.1 CFTR-3849-7 + GUUUUUAGGUUGGGAAAGAC 20 3350
CFTR-3849-8 + GCACAUAAUAAUUAGUUUCC 20 3351
CFTR-3849-9 + GAGAACUCAGUUUUUAGGUU 20 3352
CFTR-3849-10 - GAAAACACUGACUUAGAUUU 20 3353
Table 34B provides exemplary targeting domains for correcting a mutation (e.g., 3849+10kbC->T) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 34B
Figure imgf000382_0001
381
5535.1 CFTR-3849-34 - CAACAUUCUCAGGGAGG 17 3377
CFTR-3849-35 - AUCCAACAUUCUCAGGG 17 3378
CFTR-3849-36 + AUACAAUAUACCAUAUG 17 3379
CFTR-3849-37 - CAAUUAUAAUCACCUUG 17 3380
CFTR-3849-38 - UCUAUCUUGAUAAACAU 17 3381
CFTR-3849-39 - UAGUUGAAUCAUUCAGU 17 3382
CFTR-3849-40 + CUCCUCCCUGAGAAUGU 17 3383
CFTR-3849-41 - AAACAAG AAG ACU U UG U 17 3384
CFTR-3849-42 + AACUCAGUUUUUAGGUU 17 3385
CFTR-3849-43 - AAC AAG AAG AC U U U G U U 17 3386
CFTR-3849-44 - AACACUGACU UAGAUUU 17 3387
CFTR-3849-45 - UUUAAGGUCUAUACUU U 17 3388
CFTR-3849-46 - CAUCUGUUGCAGUAUUAAAA 20 3389
CFTR-3849-47 + U AU U U U CAAG AG ACU ACAAA 20 3390
CFTR-3849-48 + AUAUCUGACACAUUU UUCAA 20 3391
CFTR-3849-49 + AAUCU UUGGUUUAGCU UUAA 20 3392
CFTR-3849-50 - CUUGAUU UCUGGAGACCACA 20 3393
CFTR-3849-51 + UGACACAU UUUUCAAAGGCA 20 3394
CFTR-3849-52 - AUCUUGAUCCAACAUUCUCA 20 3395
CFTR-3849-53 + CAU U U U AAU ACUG CAACAG A 20 3396
CFTR-3849-54 + UCUCAGUGAUCUGUUGAAUA 20 3397
CFTR-3849-55 - CU U AAU CAAAAU U CCU CAU A 20 3398
CFTR-3849-56 - ACCAGCAGUUCAAUGAUAUA 20 3399
CFTR-3849-57 - AAAACACUGACUUAGAUUUA 20 3400
CFTR-3849-58 - AGAUAUUUGAUAGUACUUUA 20 3401
CFTR-3849-59 + UUUCAAAGGCAAGGAAUCAC 20 3402
CFTR-3849-60 - UAUUGUAUAUAUCACAGUAC 20 3403
CFTR-3849-61 - CAACAGAUCACUGAGAAGCC 20 3404
CFTR-3849-62 - AAGCCUGGAAAAACAAAUCC 20 3405
CFTR-3849-63 + UUUCCGGGAU UUGUUU UUCC 20 3406
CFTR-3849-64 + UCCUUAUAUCAUUGAACUGC 20 3407
CFTR-3849-65 - UGUCUUAAAAGCUUAU UUGC 20 3408
CFTR-3849-66 + AAAGGUUUUAGCUAUUACUC 20 3409
CFTR-3849-67 - UAUCUUGAUCCAACAUUCUC 20 3410
CFTR-3849-68 - UGACUUGUCAUCUUGAUUUC 20 3411
CFTR-3849-69 + UGAAUAGAACAUUUCCUUUC 20 3412
CFTR-3849-70 + UUGGGAAAGACUGGAUGAAG 20 3413
CFTR-3849-71 + UCAAAUAUCUAUUUAAUCAG 20 3414
CFTR-3849-72 - A A AG UAGUUGAAUCAUUCAG 20 3415
CFTR-3849-73 - AUCCAACAUUCUCAGGGAGG 20 3416
CFTR-3849-74 - UUGAUCCAACAUUCUCAGGG 20 3417
CFTR-3849-75 - AUUCAAUUAUAAUCACCUUG 20 3418
382
5535.1 CFTR-3849-76 - AUGUCU UAAAAGCUUAUUUG 20 3419
CFTR-3849-77 - UUUUCUAUCUUGAUAAACAU 20 3420
CFTR-3849-78 + AGAGAACUCAGUUUUUAGGU 20 3421
CFTR-3849-79 + CACCUCCUCCCUGAGAAUGU 20 3422
CFTR-3849-80 - UAUAAACAAGAAGACUUUGU 20 3423
CFTR-3849-81 + AAGUUAAACAGUGUUGAAUU 20 3424
CFTR-3849-82 - AUAAACAAGAAGACUUUGUU 20 3425
CFTR-3849-83 + AACAA AG C AAACAAG U AU U U 20 3426
CFTR-3849-84 - UACUUUAAGGUCUAUACUUU 20 3427
Table 34C provides exemplary targeting domains for correcting a mutation (e.g., 3849+10kbC->T) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 34C
Figure imgf000384_0001
Table 34D provides exemplary targeting domains for correcting a mutation (e.g., 3849+10kbC->T) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 34D
383
5535.1 4th Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR-3849-91 - UUUUUUUCUGAAGAAAA 17 3434
CFTR-3849-92 + U U U AU CAAG AU AG AAAA 17 3435
CFTR-3849-93 - CUGUUGCAGUAUUAAAA 17 3436
CFTR-3849-94 + U U U CAAG AG ACU ACAAA 17 3437
CFTR-3849-95 - AUUUUUUUCUGAAGAAA 17 3438
CFTR-3849-96 + CACAUUUUU C A A AG G C A 17 3439
CFTR-3849-97 - AAUUUAUAAGAAUAUCA 17 3440
CFTR-3849-98 + UAGAACAUUUCCUUUCA 17 3441
CFTR-3849-99 - AAUCAAAAUUCCUCAUA 17 3442
CFTR-3849-100 - UAUUUGAUAGUACUUUA 17 3443
CFTR-3849-101 - CCUGGAAAAACAAAUCC 17 3444
CFTR-3849-102 - CUUGUCAUCUUGAUUUC 17 3445
CFTR-3849-103 - UUUUUUCUGAAGAAAAG 17 3446
CFTR-3849-104 + UAUUUUUCAUUACCUUG 17 3447
CFTR-3849-105 - UCUUAAAAGCUUAUUUG 17 3448
CFTR-3849-106 + U U A U CAAG A U AG A A A A U 17 3449
CFTR-3849-107 + UUAAACAGUGUUGAAUU 17 3450
CFTR-3849-108 + A AAG C AAA CAAG U AU U U 17 3451
CFTR-3849-109 + UAGAGAACUCAGUUUUU 17 3452
CFTR-3849-110 + AUGUUUAUCAAGAUAGAAAA 20 3453
CFTR-3849-111 - AGUAUUUUUUUCUGAAGAAA 20 3454
CFTR-3849-112 + AACUG AAAU U U AG AU CCACA 20 3455
CFTR-3849-113 - AAUAAUUUAUAAGAAUAUCA 20 3456
CFTR-3849-114 + AGUCUUCUUGUUUAUAUAAC 20 3457
CFTR-3849-115 - UAUUUUUUUCUGAAGAAAAG 20 3458
CFTR-3849-116 + UAUAUACAAUAUACCAUAUG 20 3459
CFTR-3849-117 + AAUUAUUUUUCAUUACCUUG 20 3460
CFTR-3849-118 + UGUUUAUCAAGAUAGAAAAU 20 3461
CFTR-3849-119 - AAGUAGUUGAAUCAUUCAGU 20 3462
CFTR-3849-120 + AGAGGCAAUUUGUAAAUCUU 20 3463
CFTR-3849-121 + UUUUAGAGAACUCAGUUUUU 20 3464
Table 35A provides exemplary targeting domains for correcting a mutation (e.g., 3849+10kbC->T) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base
384
5535.1 pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 35A
Figure imgf000386_0001
385
5535.1 139
CFTR-3849-
- GCAGUUCAAUGAUAUAAGGAAAC 23
140 3483
CFTR-3849-
- GUAAUGAAAAAUAAUUAC 18
141 3484
CFTR-3849-
- GG U AAUG AAAAAU AAU U AC 19
142 3485
CFTR-3849-
- GAAAUAAUUUAUAAGAAUAUC 21
143 3486
CFTR-3849-
- GAUAAACAUUGGUGUAAAGUAG 22
144 3487
CFTR-3849-
- GUUAUAUAAACAAGAAGACUUUG 23
145 3488
CFTR-3849-
- GAAAACACUGACUUAGAUU 19
146 3489
CFTR-3849-
- GUACUUUAAGGUCUAUACUU 20
147 3490
CFTR-3849-
- GAUAGUACUUUAAGGUCUAUACUU 24
148 3491
CFTR-3849-
- GAUUCAAUUAUAAUCACCUU 20
149 3492
Table 35B provides exemplary targeting domains for correcting a mutation (e.g., 3849+10kbC->T) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 35B
Figure imgf000387_0001
386
5535.1 CFTR-3849-
+ AUCCACAAGGUGAUUAUAA 19
152 3495
CFTR-3849-
+ AUAUGCUGCUUAUACCCA 18
153 3496
CFTR-3849-
+ AAUAUGCUGCUUAUACCCA 19
154 3497
CFTR-3849-
+ ACACAUUUUUCAAAGGCA 18
155 3498
CFTR-3849-
+ UGACACAUUUUUCAAAGGCA 20
51 3394
CFTR-3849-
+ CUGACACAUUUUUCAAAGGCA 21
156 3499
CFTR-3849-
+ UCUGACACAUUUUUCAAAGGCA 22
157 3500
CFTR-3849-
+ AUCUGACACAUUU UUCAAAGGCA 23
158 3501
CFTR-3849-
+ UAUCUGACACAUU UUUCAAAGGCA 24
159 3502
CFTR-3849-
+ UUUUUAGGUUGGGAAAGA 18
160 3503
CFTR-3849-
+ AGUUUUUAGGUUGGGAAAGA 20
161 3504
CFTR-3849-
+ CAGUUUUUAGGUUGGGAAAGA 21
162 3505
CFTR-3849-
+ UCAGUUUUUAGGU UGGGAAAGA 22
163 3506
CFTR-3849-
+ CUCAGUUUUUAGGUUGGGAAAGA 23
164 3507
CFTR-3849-
+ ACUCAGUUUUUAGGUUGGGAAAGA 24
165 3508
CFTR-3849-
+ CUGUAAUUGCAUUGUACC 18
166 3509
CFTR-3849-
+ AGCUGUAAUUGCAUUGUACC 20
167 3510
CFTR-3849-
+ UAGCUGUAAUUGCAUUGUACC 21
168 3511
CFTR-3849-
+ CUAGCUGUAAUUGCAU UGUACC 22
169 3512
CFTR-3849-
+ UGCUAGCUGUAAUUGCAUUGUACC 24
170 3513
CFTR-3849-
+ UGAUCUGUUGAAUAAGGC 18
171 3514
CFTR-3849- + AGUGAUCUGUUGAAUAAGGC 20 3515
387
5535.1 172
CFTR-3849-
+ CAGUGAUCUGUUGAAUAAGGC 21
173 3516
CFTR-3849-
+ UCAGUGAUCUGU UGAAUAAGGC 22
174 3517
CFTR-3849-
+ CUCAGUGAUCUGUUGAAUAAGGC 23
175 3518
CFTR-3849-
+ UCUCAGUGAUCUGUUGAAUAAGGC 24
176 3519
CFTR-3849-
+ CACAU AAU AAU U AG U U U C 18
177 3520
CFTR-3849-
+ UGGCACAUAAUAAUUAGUUUC 21
178 3521
CFTR-3849-
+ CUGGCACAUAAUAAUUAGUUUC 22
179 3522
CFTR-3849-
+ ACUGGCACAUAAUAAUUAGUUUC 23
180 3523
CFTR-3849-
+ AACUGGCACAUAAUAAUUAGUUUC 24
181 3524
CFTR-3849-
+ ACCUCCUCCCUGAGAAUG 18
182 3525
CFTR-3849-
+ CACCUCCUCCCUGAGAAUG 19
183 3526
CFTR-3849-
+ UGCACCUCCUCCCUGAGAAUG 21
184 3527
CFTR-3849-
+ AUGCACCUCCUCCCUGAGAAUG 22
185 3528
CFTR-3849-
+ AAUGCACCUCCUCCCUGAGAAUG 23
186 3529
CFTR-3849-
+ CAAUGCACCUCCUCCCUGAGAAUG 24
187 3530
CFTR-3849-
+ AAGUCCAGAUUUAUCAUG 18
188 3531
CFTR-3849-
+ UAAGUCCAGAUUUAUCAUG 19
189 3532
CFTR-3849-
+ U UAAG U CCAG AU U U AU CAUG 20
190 3533
CFTR-3849-
+ AUUAAGUCCAGAUUUAUCAUG 21
191 3534
CFTR-3849-
+ UGAUUAAGUCCAGAUU UAUCAUG 23
192 3535
CFTR-3849-
+ U UGAUUAAGUCCAGAU UUAUCAUG 24
193 3536
388
5535.1 CFTR-3849-
+ UAUACAAUAUACCAUAUG 18
194 3537
CFTR-3849-
+ AUAUACAAUAUACCAUAUG 19
195 3538
CFTR-3849-
+ UAUAUACAAUAUACCAUAUG 20
116 3459
CFTR-3849-
+ AUAUAUACAAUAUACCAUAUG 21
196 3539
CFTR-3849-
+ UGAUAUAUACAAUAUACCAUAUG 23
197 3540
CFTR-3849-
+ AGGCUUCUCAGUGAUCUG 18
198 3541
CFTR-3849-
+ CAGGCUUCUCAGUGAUCUG 19
199 3542
CFTR-3849-
+ CCAGGCUUCUCAGUGAUCUG 20
200 3543
CFTR-3849-
+ UCCAGGCU UCUCAGUGAUCUG 21
201 3544
CFTR-3849-
+ U UCCAGGCUUCUCAGUGAUCUG 22
202 3545
CFTR-3849-
+ U UUCCAGGCUUCUCAGUGAUCUG 23
203 3546
CFTR-3849-
+ U UUUCCAGGCUUCUCAGUGAUCUG 24
204 3547
CFTR-3849-
+ UGUUGAAAGUUAAACAGUG 19
205 3548
CFTR-3849-
+ AUGUUGAAAGUUAAACAGUG 20
206 3549
CFTR-3849-
+ UAUGUUGAAAGUUAAACAGUG 21
207 3550
CFTR-3849-
+ AUAUGUUGAAAGUUAAACAGUG 22
208 3551
CFTR-3849-
+ AAUAUGUUGAAAGUUAAACAGUG 23
209 3552
CFTR-3849-
+ UAAUAUGUUGAAAGUUAAACAGUG 24
210 3553
CFTR-3849-
+ UGUUUGUGCUGAUAUGAU 18
211 3554
CFTR-3849-
+ AGGUGUUUGUGCUGAUAUGAU 21
212 3555
CFTR-3849-
+ UAGGUGUUUGUGCUGAUAUGAU 22
213 3556
CFTR-3849- + UUAGGUGUUUGUGCUGAUAUGAU 23 3557
389
5535.1 214
CFTR-3849-
+ UUUAGGUGUUUGUGCUGAUAUGAU 24
215 3558
CFTR-3849-
+ UCAAUGCACCUCCUCCCU 18
216 3559
CFTR-3849-
+ UUCAAUGCACCUCCUCCCU 19
217 3560
CFTR-3849-
+ CUUCAAUGCACCUCCUCCCU 20
218 3561
CFTR-3849-
+ ACU UCAAUGCACCUCCUCCCU 21
219 3562
CFTR-3849-
+ AACUUCAAUGCACCUCCUCCCU 22
220 3563
CFTR-3849-
+ UAACUUCAAUGCACCUCCUCCCU 23
221 3564
CFTR-3849-
+ AUAACUUCAAUGCACCUCCUCCCU 24
222 3565
CFTR-3849-
+ U UAAUGAAACAUAGUAUU 18
223 3566
CFTR-3849-
+ AUUAAUGAAACAUAGUAUU 19
224 3567
CFTR-3849-
+ UAUUAAUGAAACAUAGUAUU 20
225 3568
CFTR-3849-
+ UUAUUAAUGAAACAUAGUAUU 21
226 3569
CFTR-3849-
+ AUUAUUAAUGAAACAUAGUAUU 22
227 3570
CFTR-3849-
+ AAUUAUUAAUGAAACAUAGUAUU 23
228 3571
CFTR-3849-
+ UAAUUAUUAAUGAAACAUAGUAUU 24
229 3572
CFTR-3849-
+ CAUGAAUAGAACAUUUCCUUU 21
230 3573
CFTR-3849-
+ CCAU G AAU AG AACAU U U CCU U U 22
231 3574
CFTR-3849-
+ ACCAUGAAUAGAACAUUUCCUUU 23
232 3575
CFTR-3849-
+ UACCAUGAAUAGAACAUUUCCUUU 24
233 3576
CFTR-3849-
- UCUUUCCCAACCUAAAAA 18
234 3577
CFTR-3849-
- AGUCUUUCCCAACCUAAAAA 20
235 3578
390
5535.1 CFTR-3849-
- CAGUCUUUCCCAACCUAAAAA 21
236 3579
CFTR-3849-
- CCAGUCUU UCCCAACCUAAAAA 22
237 3580
CFTR-3849-
- UCCAGUCU UUCCCAACCUAAAAA 23
238 3581
CFTR-3849-
- AUCCAGUCUU UCCCAACCUAAAAA 24
239 3582
CFTR-3849-
- AAGUAGUUGAAUCAUUCA 18
240 3583
CFTR-3849-
- AAAGUAGUUGAAUCAUUCA 19
241 3584
CFTR-3849-
- UAAAGUAGUUGAAUCAUUCA 20
242 3585
CFTR-3849-
- AUUGUAUAUAUCACAGUA 18
243 3586
CFTR-3849-
- UAUUGUAUAUAUCACAGUA 19
244 3587
CFTR-3849-
- AUAUUGUAUAUAUCACAGUA 20
245 3588
CFTR-3849-
- UCAAUGAUAUAAGGAAAC 18
246 3589
CFTR-3849-
- UUCAAUGAUAUAAGGAAAC 19
247 3590
CFTR-3849-
- AGUUCAAUGAUAUAAGGAAAC 21
248 3591
CFTR-3849-
- CAGUUCAAUGAUAUAAGGAAAC 22
249 3592
CFTR-3849-
- AGCAGUUCAAUGAUAUAAGGAAAC 24
250 3593
CFTR-3849-
- AGGUAAUGAAAAAUAAUUAC 20
251 3594
CFTR-3849-
- AGAAAUAAUUUAUAAGAAUAUC 22
252 3595
CFTR-3849-
- CAG AAAU AAU U U AU AAG AAU AU C 23
253 3596
CFTR-3849-
- UCAGAAAUAAUUUAUAAGAAUAUC 24
254 3597
CFTR-3849-
- AACAUUGGUGUAAAGUAG 18
255 3598
CFTR-3849-
- AAACAUUGGUGUAAAGUAG 19
256 3599
CFTR-3849- - UAAACAUUGGUGUAAAGUAG 20 3600
391
5535.1 257
CFTR-3849-
- AUAAACAUUGGUGUAAAGUAG 21
258 3601
CFTR-3849-
- UGAUAAACAUUGGUGUAAAGUAG 23
259 3602
CFTR-3849-
- U U GAU AAACAU UGG UG U AAAG U AG 24
260 3603
CFTR-3849-
- UGUUGCAGUAUUAAAAUG 18
261 3604
CFTR-3849-
- CUGU UGCAGUAU UAAAAUG 19
262 3605
CFTR-3849-
- UCUGUUGCAGUAUUAAAAUG 20
263 3606
CFTR-3849-
- AUCUGUUGCAGUAUUAAAAUG 21
264 3607
CFTR-3849-
- CAUCUGUUGCAGUAUUAAAAUG 22
265 3608
CFTR-3849-
- CCAUCUGU UGCAGUAU UAAAAUG 23
266 3609
CFTR-3849-
- UCCAUCUGUUGCAGUAUUAAAAUG 24
267 3610
CFTR-3849-
- AU AAACAAG AAG ACU U UG 18
268 3611
CFTR-3849-
- UAU AAACAAG AAG ACU U UG 19
269 3612
CFTR-3849-
- AUAUAAACAAGAAGACUUUG 20
270 3613
CFTR-3849-
- U AU AU AAACAAG AAG ACU U UG 21
271 3614
CFTR-3849-
- U U AU AU AAACAAG AAG ACU U UG 22
272 3615
CFTR-3849-
- AG U U AU AU AAACAAG AAG ACU U UG 24
273 3616
CFTR-3849-
- AAAACACUGACUUAGAU U 18
274 3617
CFTR-3849-
- AG AAAACACUG ACU U AG AU U 20
275 3618
CFTR-3849-
- UAGAAAACACUGACUUAGAUU 21
276 3619
CFTR-3849-
- UUAGAAAACACUGACUUAGAUU 22
277 3620
CFTR-3849-
- AUUAGAAAACACUGACUUAGAUU 23
278 3621
392
5535.1 CFTR-3849-
- UAUUAGAAAACACUGACUUAGAUU 24
279 3622
CFTR-3849-
- ACU UUAAGGUCUAUACUU 18
280 3623
CFTR-3849-
- UACUUUAAGGUCUAUACUU 19
281 3624
CFTR-3849-
- AGUACUUUAAGGUCUAUACUU 21
282 3625
CFTR-3849-
- UAGUACUUUAAGGUCUAUACUU 22
283 3626
CFTR-3849-
- AUAGUACUUUAAGGUCUAUACUU 23
284 3627
CFTR-3849-
- U U CAAU UAUAAUCACCU U 18
285 3628
CFTR-3849-
- AUUCAAUUAUAAUCACCUU 19
286 3629
CFTR-3849-
- AGAUUCAAUUAUAAUCACCUU 21
287 3630
CFTR-3849-
- AAGAUUCAAUUAUAAUCACCUU 22
288 3631
CFTR-3849-
- A A AG A U U CAAU UAUAAUCACCUU 23
289 3632
CFTR-3849-
- AAAAGAU U CAAU UAUAAUCACCUU 24
290 3633
Table 35C provides exemplary targeting domains for correcting a mutation (e.g., 3849+10kbC->T) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T), and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 35C
Figure imgf000394_0001
393
5535.1 292
CFTR-3849-
+ CCAAUG U U UAU CAAG AU AG AAAA 23
293 3636
CFTR-3849-
+ ACCAAUG U U UAU CAAG AU AG AAAA 24
294 3637
CFTR-3849-
+ AGAUCCACAAGGUGAUUAUAA 21
295 3638
CFTR-3849-
+ UAGAUCCACAAGGUGAUUAUAA 22
296 3639
CFTR-3849-
+ UUAGAUCCACAAGGUGAUUAUAA 23
297 3640
CFTR-3849-
+ UUUAGAUCCACAAGGUGAUUAUAA 24
298 3641
CFTR-3849-
+ AGAAUAUGCUGCUUAUACCCA 21
299 3642
CFTR-3849-
+ GAGAAUAUGCUGCUUAUACCCA 22
300 3643
CFTR-3849-
+ UGAGAAUAUGCUGCUUAUACCCA 23
301 3644
CFTR-3849-
+ UUGAGAAUAUGCUGCU UAUACCCA 24
302 3645
CFTR-3849-
+ G AAU AG AACAU U U CCU U U 18
303 3646
CFTR-3849-
+ UGAAUAGAACAUUUCCUUU 19
304 3647
CFTR-3849-
+ AUGAAUAGAACAUUUCCUUU 20
305 3648
CFTR-3849-
- GUAAAGUAGUUGAAUCAUUCA 21
306 3649
CFTR-3849-
- UGUAAAGUAGUUGAAUCAUUCA 22
307 3650
CFTR-3849-
- GUGUAAAGUAGUUGAAUCAUUCA 23
308 3651
CFTR-3849-
- GGUGUAAAGUAGUUGAAUCAUUCA 24
309 3652
CFTR-3849-
- UAUAUUGUAUAUAUCACAGUA 21
310 3653
CFTR-3849-
- GUAUAUUGUAUAUAUCACAGUA 22
311 3654
CFTR-3849-
- GGUAUAUUGUAUAUAUCACAGUA 23
312 3655
CFTR-3849-
- UGGUAUAUUGUAUAUAUCACAGUA 24
313 3656
394
5535.1 CFTR-3849-
- AAGGUAAUGAAAAAUAAUUAC 21
314 3657
CFTR-3849-
- C A AG G U A A U G A A A A A U A A U U AC 22
315 3658
CFTR-3849-
- ACAAGG U AAUG AAAAAU AAU U AC 23
316 3659
CFTR-3849-
- CACAAGGUAAUGAAAAAUAAUUAC 24
317 3660
CFTR-3849-
- AUAAUUUAUAAGAAUAUC 18
318 3661
CFTR-3849-
- AAUAAUUUAUAAGAAUAUC 19
319 3662
CFTR-3849-
- AAAUAAUUUAUAAGAAUAUC 20
320 3663
CFTR-3849-
- AU U U CAG AAAU AAU U U AU 18
321 3664
CFTR-3849-
- AAU U U CAG AAAU AAU U U AU 19
322 3665
CFTR-3849-
- AAAU U U CAG AAAU AAU U U AU 20
323 3666
CFTR-3849-
- G AAAU U U CAG AAAU AAU U U AU 21
324 3667
CFTR-3849-
- AG AAAU U U CAG AAAU AAU U U AU 22
325 3668
CFTR-3849-
- CAG AAAU U U CAG AAAU AAU U U AU 23
326 3669
CFTR-3849-
- A CAG AAAU U U CAG AAAU AAU U U AU 24
327 3670
Table 35D provides exemplary targeting domains for correcting a mutation (e.g., 3849+10kbC->T) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T), and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 35D
Figure imgf000396_0001
395
5535.1 Length
CFTR-3849-
+ U U U U CAAG AG ACU ACAAA 18
328 3671
CFTR-3849-
+ AU U U U CAAG AG ACU ACAAA 19
329 3672
CFTR-3849-47 + U AU U U U CAAG AG ACU ACAAA 20 3390
CFTR-3849-
+ G U AU U U U CAAG AG ACU ACAAA 21
330 3673
CFTR-3849-
+ UGUAUUUUCAAGAGACUACAAA 22
331 3674
CFTR-3849-
+ CUGUAUUUU CAAG AG ACU ACAAA 23
332 3675
CFTR-3849-
+ UCUGUAUUUUCAAGAGACUACAAA 24
333 3676
CFTR-3849-
+ UGUUUAUCAAGAUAGAAA 18
334 3677
CFTR-3849-
+ AUG U U U AU CAAG AU AG AAA 19
335 3678
CFTR-3849-
+ AAUGUUUAUCAAGAUAGAAA 20
336 3679
CFTR-3849-
+ CAAUGUUUAUCAAGAUAGAAA 21
337 3680
CFTR-3849-
+ CCAAUG U U U AU CAAG AU AG AAA 22
338 3681
CFTR-3849-
+ ACCAAUGUUUAUCAAGAUAGAAA 23
339 3682
CFTR-3849-
+ CACCAAUG U U U AU CAAG AU AG AAA 24
340 3683
CFTR-3849-
+ AUUUUCAAGAGACUACAA 18
341 3684
CFTR-3849-
+ UAUUUUCAAGAGACUACAA 19
342 3685
CFTR-3849-
+ GU AUUUUCAAGAGACUACAA 20
343 3686
CFTR-3849-
+ UGUAUUUUCAAGAGACUACAA 21
344 3687
CFTR-3849-
+ CUGUAUUUUCAAGAGACUACAA 22
345 3688
CFTR-3849-
+ UCUGUAUUUU CAAG AG ACU ACAA 23
346 3689
CFTR-3849-
+ U UCUGUAUUUU CAAG AG ACU ACAA 24
347 3690
CFTR-3849- + AUCAAGAUGACAAGUCAA 18 3691
396
5535.1 348
CFTR-3849-
+ AAUCAAGAUGACAAGUCAA 19
349 3692
CFTR-3849-
+ AAAUCAAGAUGACAAGUCAA 20
350 3693
CFTR-3849-
+ GAAAUCAAGAUGACAAGUCAA 21
351 3694
CFTR-3849-
+ AGAAAUCAAGAUGACAAGUCAA 22
352 3695
CFTR-3849-
+ C AG AAA U C A AG A U G AC A AG U C A A 23
353 3696
CFTR-3849-
+ CCAGAAAUCAAGAUGACAAGUCAA 24
354 3697
CFTR-3849-
+ AUUGCAUUGUACCAUGAA 18
355 3698
CFTR-3849-
+ AAUUGCAUUGUACCAUGAA 19
356 3699
CFTR-3849-
+ UAAUUGCAUUGUACCAUGAA 20
357 3700
CFTR-3849-
+ GUAAUUGCAUUGUACCAUGAA 21
358 3701
CFTR-3849-
+ UGUAAUUGCAUUGUACCAUGAA 22
359 3702
CFTR-3849-
+ CUGUAAUUGCAUUGUACCAUGAA 23
360 3703
CFTR-3849-
+ GCUGUAAUUGCAU UGUACCAUGAA 24
361 3704
CFTR-3849-
+ CAAAUAUCUAUUUAAUCA 18
362 3705
CFTR-3849-
+ UCAAAUAUCUAUUUAAUCA 19
363 3706
CFTR-3849-
+ AUCAAAUAUCUAUUUAAUCA 20
364 3707
CFTR-3849-
+ UAUCAAAUAUCUAUUUAAUCA 21
365 3708
CFTR-3849-
+ CUAUCAAAUAUCUAUUUAAUCA 22
366 3709
CFTR-3849-
+ ACUAUCAAAUAUCUAUUUAAUCA 23
367 3710
CFTR-3849-
+ UACUAUCAAAUAUCUAUUUAAUCA 24
368 3711
CFTR-3849-
+ UCUGGUUUCCUUAUAUCA 18
369 3712
397
5535.1 CFTR-3849-
+ CUCUGGUU UCCUUAUAUCA 19
370 3713
CFTR-3849-
+ ACUCUGGUUUCCU UAUAUCA 20
371 3714
CFTR-3849-
+ UACUCUGGUUUCCUUAUAUCA 21
372 3715
CFTR-3849-
+ U UACUCUGGUUUCCUUAUAUCA 22
373 3716
CFTR-3849-
+ AUUACUCUGGU UUCCU UAUAUCA 23
374 3717
CFTR-3849-
+ UAUUACUCUGGUUUCCUUAUAUCA 24
375 3718
CFTR-3849-
+ CACCAAUG U U U AU CAAG A 18
376 3719
CFTR-3849-
+ ACACCAAUG U U U AU CAAG A 19
377 3720
CFTR-3849-
+ U ACACCAAUG U U U AU CAAG A 20
378 3721
CFTR-3849-
+ UUACACCAAUGUU UAUCAAGA 21
379 3722
CFTR-3849-
+ UUUACACCAAUGU UUAUCAAGA 22
380 3723
CFTR-3849-
+ CUU UACACCAAUGUUUAUCAAGA 23
381 3724
CFTR-3849-
+ ACU U U ACACCAAUG U U U AU CAAG A 24
382 3725
CFTR-3849-
+ UUUUAAUACUGCAACAGA 18
383 3726
CFTR-3849-
+ AUUUUAAUACUGCAACAGA 19
384 3727
CFTR-3849-53 + CAU U U U AAU ACUG CAACAG A 20 3396
CFTR-3849-
+ CCAUUUUAAUACUGCAACAGA 21
385 3728
CFTR-3849-
+ ACCAUUUUAAUACUGCAACAGA 22
386 3729
CFTR-3849-
+ CACCAU UUUAAUACUGCAACAGA 23
387 3730
CFTR-3849-
+ UCACCAUUUUAAUACUGCAACAGA 24
388 3731
CFTR-3849-
+ UAUUAAUGAAACAUAGUA 18
389 3732
CFTR-3849-
+ UUAUUAAUGAAACAUAGUA 19
390 3733
398
5535.1 CFTR-3849-
+ AUUAUUAAUGAAACAUAGUA 20
391 3734
CFTR-3849-
+ AAU U AU U AAUG AAACAU AG U A 21
392 3735
CFTR-3849-
+ UAAUUAUUAAUGAAACAUAGUA 22
393 3736
CFTR-3849-
+ UUAAUUAUUAAUGAAACAUAGUA 23
394 3737
CFTR-3849-
+ AUUAAUUAUUAAUGAAACAUAGUA 24
395 3738
CFTR-3849-
+ UAUCUCUAUUAAUUAUUA 18
396 3739
CFTR-3849-
+ AUAUCUCUAUUAAUUAUUA 19
397 3740
CFTR-3849-
+ UAUAUCUCUAUUAAUUAUUA 20
398 3741
CFTR-3849-
+ AUAUAUCUCUAUUAAUUAUUA 21
399 3742
CFTR-3849-
+ CAUAUAUCUCUAUUAAUUAUUA 22
400 3743
CFTR-3849-
+ UCAUAUAUCUCUAUUAAUUAUUA 23
401 3744
CFTR-3849-
+ UUCAUAUAUCUCUAUUAAUUAUUA 24
402 3745
CFTR-3849-
+ AAAAU ACU AAAAU U U U U A 18
403 3746
CFTR-3849-
+ AAAAAU ACU AAAAU U U U U A 19
404 3747
CFTR-3849-
+ AAAAAAU ACU AAAAU U U U U A 20
405 3748
CFTR-3849-
+ AAAAAAAU ACU AAAAU U U U U A 21
406 3749
CFTR-3849-
+ G AAAAAAAU ACU AAAAU U U U U A 22
407 3750
CFTR-3849-
+ AG AAAAAAAU ACU AAAAU U U U U A 23
408 3751
CFTR-3849-
+ CAG AAAAAAAU ACU AAAAU U U U U A 24
409 3752
CFTR-3849-
+ CUUCAAUGCACCUCCUCC 18
410 3753
CFTR-3849-
+ ACU UCAAUGCACCUCCUCC 19
411 3754
CFTR-3849- + AACUUCAAUGCACCUCCUCC 20 3755
399
5535.1 412
CFTR-3849-
+ UAACUUCAAUGCACCUCCUCC 21
413 3756
CFTR-3849-
+ AUAACUUCAAUGCACCUCCUCC 22
414 3757
CFTR-3849-
+ AAUAACUUCAAUGCACCUCCUCC 23
415 3758
CFTR-3849-
+ UAAUAACUUCAAUGCACCUCCUCC 24
416 3759
CFTR-3849-
+ GACACAUUUUUCAAAGGC 18
417 3760
CFTR-3849-
+ UGACACAUUUUU CAAAG G C 19
418 3761
CFTR-3849-
+ CUGACACAUUUU UCAAAGGC 20
419 3762
CFTR-3849-
+ UCUGACACAUUU UUCAAAGGC 21
420 3763
CFTR-3849-
+ AUCUGACACAUUUUUCAAAGGC 22
421 3764
CFTR-3849-
+ UAUCUGACACAUUUUUCAAAGGC 23
422 3765
CFTR-3849-
+ AUAUCUGACACAUUU UUCAAAGGC 24
423 3766
CFTR-3849-
+ AUUAAGUCCAGAUUUAUC 18
424 3767
CFTR-3849-
+ GAUUAAGUCCAGAUUUAUC 19
425 3768
CFTR-3849-
+ UGAUUAAGUCCAGAUU UAUC 20
426 3769
CFTR-3849-
+ U UGAUUAAGUCCAGAU UUAUC 21
427 3770
CFTR-3849-
+ U UUGAUUAAGUCCAGAUUUAUC 22
428 3771
CFTR-3849-
+ U UUUGAUUAAGUCCAGAUUUAUC 23
429 3772
CFTR-3849-
+ AUUUUGAUUAAGUCCAGAUUUAUC 24
430 3773
CFTR-3849-
+ UCAUUACCUUGUGGUCUC 18
431 3774
CFTR-3849-
+ UUCAUUACCUUGUGGUCUC 19
432 3775
CFTR-3849-
+ UUUCAUUACCUUGUGGUCUC 20
433 3776
400
5535.1 CFTR-3849-
+ UUUUCAUUACCUUGUGGUCUC 21
434 3777
CFTR-3849-
+ UUUUUCAUUACCUUGUGGUCUC 22
435 3778
CFTR-3849-
+ AUUUUUCAUUACCUUGUGGUCUC 23
436 3779
CFTR-3849-
+ UAUUUUUCAUUACCUUGUGGUCUC 24
437 3780
CFTR-3849-
+ UGAAAUUUCUGUAUUUUC 18
438 3781
CFTR-3849-
+ CUGAAAUUUCUGUAU UUUC 19
439 3782
CFTR-3849-
+ UCUGAAAUUUCUGUAUUUUC 20
440 3783
CFTR-3849-
+ UUCUGAAAUUUCUGUAUUUUC 21
441 3784
CFTR-3849-
+ UUUCUGAAAUUUCUGUAUUUUC 22
442 3785
CFTR-3849-
+ AUUUCUGAAAUUUCUGUAUUUUC 23
443 3786
CFTR-3849-
+ UAUUUCUGAAAUUUCUGUAUUUUC 24
444 3787
CFTR-3849-
+ AUUUUAAUACUGCAACAG 18
445 3788
CFTR-3849-
+ CAUUUUAAUACUGCAACAG 19
446 3789
CFTR-3849-
+ CCAU U U U AAU ACU GCAACAG 20
447 3790
CFTR-3849-
+ ACCAUUUUAAUACUGCAACAG 21
448 3791
CFTR-3849-
+ CACCAUUUUAAUACUGCAACAG 22
449 3792
CFTR-3849-
+ U CACCAU U U U AAU ACUG CAACAG 23
450 3793
CFTR-3849-
+ CUCACCAU UUUAAUACUGCAACAG 24
451 3794
CFTR-3849-
+ GAGAACUCAGUUUUUAGG 18
452 3795
CFTR-3849-
+ AGAGAACUCAGUUUUUAGG 19
453 3796
CFTR-3849-
+ UAGAGAACUCAGUUUU UAGG 20
454 3797
CFTR-3849- + UUAGAGAACUCAGUUU UUAGG 21 3798
401
5535.1 455
CFTR-3849-
+ U UUAGAGAACUCAGUU UUUAGG 22
456 3799
CFTR-3849-
+ U U U U AG AG AACU CAG U U U U U AGG 23
457 3800
CFTR-3849-
+ U U U U U AG AG AACU CAG U U U U U AGG 24
458 3801
CFTR-3849-
+ UAGGUUGGGAAAGACUGG 18
459 3802
CFTR-3849-
+ UUAGGUUGGGAAAGACUGG 19
460 3803
CFTR-3849-
+ UUUAGGUUGGGAAAGACUGG 20
461 3804
CFTR-3849-
+ UUUUAGGUUGGGAAAGACUGG 21
462 3805
CFTR-3849-
+ UUUUUAGGUUGGGAAAGACUGG 22
463 3806
CFTR-3849-
+ GUUUUUAGGUUGGGAAAGACUGG 23
464 3807
CFTR-3849-
+ AGUUUUUAGGUUGGGAAAGACUGG 24
465 3808
CFTR-3849-
+ UUCAAGAGACUACAAAUG 18
466 3809
CFTR-3849-
+ U U U CAAG AG ACU ACAAAUG 19
467 3810
CFTR-3849-
+ U U U U CAAG AG ACU ACAAAUG 20
468 3811
CFTR-3849-
+ AUUUUCAAGAGACUACAAAUG 21
469 3812
CFTR-3849-
+ UAUUUUCAAGAGACUACAAAUG 22
470 3813
CFTR-3849-
+ G U AU U U U CAAG AG ACU ACAAAUG 23
471 3814
CFTR-3849-
+ UGUAUUUUCAAGAGACUACAAAUG 24
472 3815
CFTR-3849-
+ GU UGGGAAAGACUGGAUG 18
473 3816
CFTR-3849-
+ GGU UGGGAAAGACUGGAUG 19
474 3817
CFTR-3849-
+ AGGUUGGGAAAGACUGGAUG 20
475 3818
CFTR-3849-
+ UAGGUUGGGAAAGACUGGAUG 21
476 3819
402
5535.1 CFTR-3849-
+ UUAGGUUGGGAAAGACUGGAUG 22
477 3820
CFTR-3849-
+ U UUAGGUUGGGAAAGACUGGAUG 23
478 3821
CFTR-3849-
+ U UUUAGGUUGGGAAAGACUGGAUG 24
479 3822
CFTR-3849-
+ AUAAAUCAAAAUAAUAUG 18
480 3823
CFTR-3849-
+ GAUAAAUCAAAAUAAUAUG 19
481 3824
CFTR-3849-
+ AGAUAAAUCAAAAUAAUAUG 20
482 3825
CFTR-3849-
+ AAGAUAAAUCAAAAUAAUAUG 21
483 3826
CFTR-3849-
+ CAAGAUAAAUCAAAAUAAUAUG 22
484 3827
CFTR-3849-
+ UCAAGAUAAAUCAAAAUAAUAUG 23
485 3828
CFTR-3849-
+ AUCAAGAUAAAUCAAAAUAAUAUG 24
486 3829
CFTR-3849-
+ AUCAAAUAUCUAUUUAAU 18
487 3830
CFTR-3849-
+ UAUCAAAUAUCUAUUUAAU 19
488 3831
CFTR-3849-
+ CUAUCAAAUAUCUAUUUAAU 20
489 3832
CFTR-3849-
+ ACUAUCAAAUAUCUAUU UAAU 21
490 3833
CFTR-3849-
+ UACUAUCAAAUAUCUAU UUAAU 22
491 3834
CFTR-3849-
+ GUACUAUCAAAUAUCUAUUUAAU 23
492 3835
CFTR-3849-
+ AGUACUAUCAAAUAUCUAUUUAAU 24
493 3836
CFTR-3849-
+ AUAUAUACAAUAUACCAU 18
494 3837
CFTR-3849-
+ GAUAUAUACAAUAUACCAU 19
495 3838
CFTR-3849-
+ UGAUAUAUACAAUAUACCAU 20
496 3839
CFTR-3849-
+ GUGAUAUAUACAAUAUACCAU 21
497 3840
CFTR-3849- + UGUGAUAUAUACAAUAUACCAU 22 3841
403
5535.1 498
CFTR-3849-
+ CUGUGAUAUAUACAAUAUACCAU 23
499 3842
CFTR-3849-
+ ACUGUGAUAUAUACAAUAUACCAU 24
500 3843
CFTR-3849-
+ AUAUACAAUAUACCAUAU 18
501 3844
CFTR-3849-
+ UAUAUACAAUAUACCAUAU 19
502 3845
CFTR-3849-
+ AUAUAUACAAUAUACCAUAU 20
503 3846
CFTR-3849-
+ GAUAUAUACAAUAUACCAUAU 21
504 3847
CFTR-3849-
+ UGAUAUAUACAAUAUACCAUAU 22
505 3848
CFTR-3849-
+ GUGAUAUAUACAAUAUACCAUAU 23
506 3849
CFTR-3849-
+ UGUGAUAUAUACAAUAUACCAUAU 24
507 3850
CFTR-3849-
+ AGAACUCAGUUUUUAGGU 18
508 3851
CFTR-3849-
+ GAGAACUCAGUUUUUAGGU 19
509 3852
CFTR-3849-78 + AGAGAACUCAGUUUUUAGGU 20 3421
CFTR-3849-
+ UAGAGAACUCAGUUUU UAGGU 21
510 3853
CFTR-3849-
+ U UAGAGAACUCAGUUU UUAGGU 22
511 3854
CFTR-3849-
+ U U U AG AG AACU CAG UU UUUAGGU 23
512 3855
CFTR-3849-
+ U U U U AG AG AACU CAG U UUUUAGGU 24
513 3856
CFTR-3849-
+ GAACUCAGUUUUUAGGUU 18
514 3857
CFTR-3849-
+ AGAACUCAGUUUUUAGGUU 19
515 3858
CFTR-3849-9 + GAG AACU CAG U U U U U AGG U U 20 3352
CFTR-3849-
+ AGAGAACUCAGUUUUUAGGUU 21
516 3859
CFTR-3849-
+ UAGAGAACUCAGUUUU UAGGUU 22
517 3860
CFTR-3849-
+ U U AG AG AACU CAG UUU UUAGGUU 23
518 3861
404
5535.1 CFTR-3849-
+ U U U AG AG AACU CAG UU UUUAGGUU 24
519 3862
CFTR-3849-
+ UAUUCUUAUAAAUUAU UU 18
520 3863
CFTR-3849-
+ AUAUUCUUAUAAAUUAUUU 19
521 3864
CFTR-3849-
+ GAUAUUCUUAUAAAUUAUUU 20
522 3865
CFTR-3849-
+ UGAUAUUCUUAUAAAU UAUUU 21
523 3866
CFTR-3849-
+ UUGAUAUUCUUAUAAAUUAUUU 22
524 3867
CFTR-3849-
+ CUUGAUAUUCUUAUAAAUUAUUU 23
525 3868
CFTR-3849-
+ CCUUGAUAUUCUUAUAAAUUAUUU 24
526 3869
CFTR-3849-
+ G CACAU AAU AAU U AG U U U 18
527 3870
CFTR-3849-
+ GGCACAUAAUAAUUAGU UU 19
528 3871
CFTR-3849-
+ UGGCACAUAAUAAUUAGUUU 20
529 3872
CFTR-3849-
+ CUGGCACAUAAUAAUUAGUUU 21
530 3873
CFTR-3849-
+ ACUGGCACAUAAUAAUUAGUUU 22
531 3874
CFTR-3849-
+ AACUGGCACAUAAUAAUUAGUUU 23
532 3875
CFTR-3849-
+ UAACUGGCACAUAAUAAUUAGUUU 24
533 3876
CFTR-3849-
+ AAAAAAU ACU AAAAU U U U 18
534 3877
CFTR-3849-
+ AAAAAAAU ACU AAAAU U U U 19
535 3878
CFTR-3849-
+ G AAAAAAAU ACU AAAAU U U U 20
536 3879
CFTR-3849-
+ AG AAAAAAAU ACU AAAAU U U U 21
537 3880
CFTR-3849-
+ CAG AAAAAAAU ACU AAAAU U U U 22
538 3881
CFTR-3849-
+ U CAG AAAAAAAU ACU AAAAU U U U 23
539 3882
CFTR-3849- + U U CAG AAAAAAAU ACU AAAAU U U U 24 3883
405
5535.1 540
CFTR-3849-
- AUUUUUUUCUGAAGAAAA 18
541 3884
CFTR-3849-
- UAUUUUUUUCUGAAGAAAA 19
542 3885
CFTR-3849-87 - GUAUUUUUUUCUGAAGAAAA 20 3430
CFTR-3849-
- AGUAUUUUUUUCUGAAGAAAA 21
543 3886
CFTR-3849-
- UAGUAUUUUUUU CUGAAGAAAA 22
544 3887
CFTR-3849-
- UUAGUAUUUUUUUCUGAAGAAAA 23
545 3888
CFTR-3849-
- UU UAGUAUUUUUU UCUGAAGAAAA 24
546 3889
CFTR-3849-
- UAUUUUUUUCUGAAGAAA 18
547 3890
CFTR-3849-
- GUAUUUUUUUCUGAAGAAA 19
548 3891
CFTR-3849-
- AGUAUUUUUUUCUGAAGAAA 20
111 3454
CFTR-3849-
- UAGUAUUUUUUUCUGAAGAAA 21
549 3892
CFTR-3849-
- UUAGUAUUUUUUUCUGAAGAAA 22
550 3893
CFTR-3849-
- UU UAGUAUUUUUU UCUGAAGAAA 23
551 3849
CFTR-3849-
- UU UUAGUAUUUUU UUCUGAAGAAA 24
552 3895
CFTR-3849-
- GUAUUUUUUUCUGAAGAA 18
553 3896
CFTR-3849-
- AGUAUUUUUUUCUGAAGAA 19
554 3897
CFTR-3849-
- UAGUAUUUUUUUCUGAAGAA 20
555 3898
CFTR-3849-
- UUAGUAUUUUUUUCUGAAGAA 21
556 3899
CFTR-3849-
- UUUAGUAUUUUUUUCUGAAGAA 22
557 3900
CFTR-3849-
- UUUUAGUAUUUUUUUCUGAAGAA 23
558 3901
CFTR-3849-
- AUUUUAGUAUUUUU UUCUGAAGAA 24
559 3902
CFTR-3849- - UGAGUAAGACACCCUGAA 18 3903
406
5535.1 560
CFTR-3849-
- GUGAGUAAGACACCCUGAA 19
561 3904
CFTR-3849-88 - GGUGAGUAAGACACCCUGAA 20 3431
CFTR-3849-
- UGGUGAGUAAGACACCCUGAA 21
562 3905
CFTR-3849-
- AUGGUGAGUAAGACACCCUGAA 22
563 3906
CFTR-3849-
- AAUGGUGAGUAAGACACCCUGAA 23
564 3907
CFTR-3849-
- AAAUGGUGAGUAAGACACCCUGAA 24
565 3908
CFTR-3849-
- UGUUUCAUUAAUAAUUAA 18
566 3909
CFTR-3849-
- AUGUUUCAUUAAUAAU UAA 19
567 3910
CFTR-3849-
- UAUGUUUCAUUAAUAAUUAA 20
568 3911
CFTR-3849-
- CUAUGUUUCAU UAAUAAUUAA 21
569 3912
CFTR-3849-
- ACUAUGUUUCAUUAAUAAUUAA 22
570 3913
CFTR-3849-
- UACUAUGUUUCAUUAAUAAUUAA 23
571 3914
CFTR-3849-
- AUACUAUGUUUCAU UAAUAAUUAA 24
572 3915
CFTR-3849-
- UCUCAGGGAGGAGGUGCA 18
573 3916
CFTR-3849-
- UUCUCAGGGAGGAGGUGCA 19
574 3917
CFTR-3849-
- AUUCUCAGGGAGGAGGUGCA 20
575 3918
CFTR-3849-
- CAU UCUCAGGGAGGAGGUGCA 21
576 3919
CFTR-3849-
- ACAUUCUCAGGGAGGAGGUGCA 22
577 3920
CFTR-3849-
- AACAUUCUCAGGGAGGAGGUGCA 23
578 3921
CFTR-3849-
- CAACAUUCUCAGGGAGGAGGUGCA 24
579 3922
CFTR-3849-
- GCCUUAUUCAACAGAUCA 18
580 3923
CFTR-3849- - AGCCUUAUUCAACAGAUCA 19 3924
407
5535.1 581
CFTR-3849-
- UAGCCUUAUUCAACAGAUCA 20
582 3925
CFTR-3849-
- CUAGCCUUAU UCAACAGAUCA 21
583 3926
CFTR-3849-
- UCUAGCCU UAUUCAACAGAUCA 22
584 3927
CFTR-3849-
- CUCUAGCCUUAUUCAACAGAUCA 23
585 3928
CFTR-3849-
- ACUCUAGCCUUAUUCAACAGAUCA 24
586 3929
CFTR-3849-
- CUUGAUCCAACAUUCUCA 18
587 3930
CFTR-3849-
- UCU UGAUCCAACAUUCUCA 19
588 3931
CFTR-3849-52 - AUCUUGAUCCAACAUUCUCA 20 3395
CFTR-3849-
- UAUCUUGAUCCAACAUUCUCA 21
589 3932
CFTR-3849-
- UUAUCUUGAUCCAACAU UCUCA 22
590 3933
CFTR-3849-
- UUUAUCUUGAUCCAACAUUCUCA 23
591 3934
CFTR-3849-
- AUUUAUCUUGAUCCAACAUUCUCA 24
592 3935
CFTR-3849-
- GUGAGUAAGACACCCUGA 18
593 3936
CFTR-3849-
- GGUGAGUAAGACACCCUGA 19
594 3937
CFTR-3849-
- UGGUGAGUAAGACACCCUGA 20
595 3938
CFTR-3849-
- AUGGUGAGUAAGACACCCUGA 21
596 3939
CFTR-3849-
- AAUGGUGAGUAAGACACCCUGA 22
597 3940
CFTR-3849-
- AAAUGGUGAGUAAGACACCCUGA 23
598 3941
CFTR-3849-
- AAAAUGGUGAGUAAGACACCCUGA 24
599 3942
CFTR-3849-
- UGUAGUCUCUUGAAAAUA 18
600 3943
CFTR-3849-
- UUGUAGUCUCUUGAAAAUA 19
601 3944
CFTR-3849- - UUUGUAGUCUCUUGAAAAUA 20 3945
408
5535.1 602
CFTR-3849-
- AUUUGUAGUCUCUUGAAAAUA 21
603 3946
CFTR-3849-
- CAUUUGUAGUCUCUUGAAAAUA 22
604 3947
CFTR-3849-
- CCAUU UGUAGUCUCU UGAAAAUA 23
605 3948
CFTR-3849-
- UCCAU UUGUAGUCUCUUGAAAAUA 24
606 3949
CFTR-3849-
- CAGCAGUUCAAUGAUAUA 18
607 3950
CFTR-3849-
- CCAGCAGU UCAAUGAUAUA 19
608 3951
CFTR-3849-56 - ACCAGCAGUUCAAUGAUAUA 20 3399
CFTR-3849-
- UACCAGCAGUUCAAUGAUAUA 21
609 3952
CFTR-3849-
- UUACCAGCAGUUCAAUGAUAUA 22
610 3953
CFTR-3849-
- AUUACCAGCAGUUCAAUGAUAUA 23
611 3954
CFTR-3849-
- CAUUACCAGCAGUUCAAUGAUAUA 24
612 3955
CFTR-3849-
- UCUGGAGACCACAAGGUA 18
613 3956
CFTR-3849-
- UUCUGGAGACCACAAGGUA 19
614 3957
CFTR-3849-
- UUUCUGGAGACCACAAGGUA 20
615 3958
CFTR-3849-
- AUUUCUGGAGACCACAAGGUA 21
616 3959
CFTR-3849-
- GAUUUCUGGAGACCACAAGGUA 22
617 3960
CFTR-3849-
- UGAUUUCUGGAGACCACAAGGUA 23
618 3961
CFTR-3849-
- UUGAUUUCUGGAGACCACAAGGUA 24
619 3962
CFTR-3849-
- UGUGCCAGUUAUAUAAAC 18
620 3963
CFTR-3849-
- AUGUGCCAGUUAUAUAAAC 19
621 3964
CFTR-3849-
- UAUGUGCCAGUUAUAUAAAC 20
622 3965
CFTR-3849- - UUAUGUGCCAGUUAUAUAAAC 21 3966
409
5535.1 623
CFTR-3849-
- AUUAUGUGCCAGU UAUAUAAAC 22
624 3967
CFTR-3849-
- UAUUAUGUGCCAGUUAUAUAAAC 23
625 3968
CFTR-3849-
- UUAUUAUGUGCCAGUUAUAUAAAC 24
626 3969
CFTR-3849-
- AAUGGUGAGUAAGACACC 18
627 3970
CFTR-3849-
- AAAUGGUGAGUAAGACACC 19
628 3971
CFTR-3849-
- AAAAUGGUGAGUAAGACACC 20
629 3972
CFTR-3849-
- UAAAAUGGUGAGUAAGACACC 21
630 3973
CFTR-3849-
- UUAAAAUGGUGAGUAAGACACC 22
631 3974
CFTR-3849-
- AU UAAAAUGGUGAGUAAGACACC 23
632 3975
CFTR-3849-
- UAUUAAAAUGGUGAGUAAGACACC 24
633 3976
CFTR-3849-
- ACAGAUCACUGAGAAGCC 18
634 3977
CFTR-3849-
- AACAGAUCACUGAGAAGCC 19
635 3978
CFTR-3849-61 - CAACAGAUCACUGAGAAGCC 20 3404
CFTR-3849-
- UCAACAGAUCACUGAGAAGCC 21
636 3979
CFTR-3849-
- UUCAACAGAUCACUGAGAAGCC 22
637 3980
CFTR-3849-
- AUUCAACAGAUCACUGAGAAGCC 23
638 3981
CFTR-3849-
- UAUUCAACAGAUCACUGAGAAGCC 24
639 3982
CFTR-3849-
- GCCUGGAAAAACAAAUCC 18
640 3983
CFTR-3849-
- AGCCUGGAAAAACAAAUCC 19
641 3984
CFTR-3849-62 - AAGCCUGGAAAAACAAAUCC 20 3405
CFTR-3849-
- GAAGCCUGGAAAAACAAAUCC 21
642 3985
CFTR-3849-
- AGAAGCCUGGAAAAACAAAUCC 22
643 3986
410
5535.1 CFTR-3849-
- GAGAAGCCU G G A A A A AC A A A U C C 23
644 3987
CFTR-3849-
- UGAGAAGCCUGGAAAAACAAAUCC 24
645 3988
CFTR-3849-
- AACAGAUCACUGAGAAGC 18
646 3989
CFTR-3849-
- CAACAGAUCACUGAGAAGC 19
647 3990
CFTR-3849-
- UCAACAGAUCACUGAGAAGC 20
648 3991
CFTR-3849-
- UUCAACAGAUCACUGAGAAGC 21
649 3992
CFTR-3849-
- AUUCAACAGAUCACUGAGAAGC 22
650 3993
CFTR-3849-
- UAUUCAACAGAUCACUGAGAAGC 23
651 3994
CFTR-3849-
- UUAUUCAACAGAUCACUGAGAAGC 24
652 3995
CFTR-3849-
- UCU UAAAAGCUUAUUUGC 18
653 3996
CFTR-3849-
- GUCUUAAAAGCUUAUU UGC 19
654 3997
CFTR-3849-65 - UGUCUUAAAAGCUUAU UUGC 20 3408
CFTR-3849-
- AUGUCUUAAAAGCUUAUUUGC 21
655 3998
CFTR-3849-
- UAUGUCUUAAAAGCUUAUUUGC 22
656 3999
CFTR-3849-
- GUAUGUCUUAAAAGCUUAUUUGC 23
657 4000
CFTR-3849-
- GGUAUGUCUUAAAAGCUUAUUUGC 24
658 4001
CFTR-3849-
- AG CC U G G AAAAAC AAAU C 18
659 4002
CFTR-3849-
- AAGCCUGGAAAAACAAAUC 19
660 4003
CFTR-3849-
- GAAGCCUGGAAAAACAAAUC 20
661 4004
CFTR-3849-
- AGAAGCCUGGAAAAACAAAUC 21
662 4005
CFTR-3849-
- GAGAAGCCU G G A A A A AC A A A U C 22
663 4006
CFTR-3849-
- UGAGAAGCCUGGAAAAACAAAUC 23
664 4007
411
5535.1 CFTR-3849-
- CUGAGAAGCCUGGAAAAACAAAUC 24
665 4008
CFTR-3849-
- UUCUCCAU UUGUAGUCUC 18
666 4009
CFTR-3849-
- UU UCUCCAUUUGUAGUCUC 19
667 4010
CFTR-3849-
- CUU UCUCCAUUUGUAGUCUC 20
668 4011
CFTR-3849-
- GCUU UCUCCAUUUGUAGUCUC 21
669 4012
CFTR-3849-
- UGCU UUCUCCAUUUGUAGUCUC 22
670 4013
CFTR-3849-
- CUGCUU UCUCCAUUUGUAGUCUC 23
671 4014
CFTR-3849-
- ACUGCUUUCUCCAU UUGUAGUCUC 24
672 4015
CFTR-3849-
- UCUUGAUCCAACAUUCUC 18
673 4016
CFTR-3849-
- AUCUUGAUCCAACAUUCUC 19
674 4017
CFTR-3849-67 - UAUCUUGAUCCAACAUUCUC 20 3410
CFTR-3849-
- UUAUCUUGAUCCAACAUUCUC 21
675 4018
CFTR-3849-
- UU UAUCUUGAUCCAACAUUCUC 22
676 4019
CFTR-3849-
- AUUUAUCUUGAUCCAACAUUCUC 23
677 4020
CFTR-3849-
- GAUUUAUCUUGAUCCAACAUUCUC 24
678 4021
CFTR-3849-
- ACUUGUCAUCUUGAUUUC 18
679 4022
CFTR-3849-
- GACU UGUCAUCUUGAU UUC 19
680 4023
CFTR-3849-68 - UGACUUGUCAUCUUGAUUUC 20 3411
CFTR-3849-
- UUGACUUGUCAUCUUGAUUUC 21
681 4024
CFTR-3849-
- GU UGACUUGUCAUCUUGAUUUC 22
682 4025
CFTR-3849-
- AGUUGACUUGUCAUCU UGAUUUC 23
683 4026
CFTR-3849-
- CAGUUGACUUGUCAUCUUGAUUUC 24
684 4027
CFTR-3849- - UUUU UUUCUGAAGAAAAG 18 4028
412
5535.1 685
CFTR-3849-
- AUUUUUUUCUGAAGAAAAG 19
686 4029
CFTR-3849-
- UAUUUUUUU CUG AAG AAAAG 20
115 3458
CFTR-3849-
- GU AUUUUUUUCUGAAGAAAAG 21
687 4030
CFTR-3849-
- AGUAUUUUUUUCUGAAGAAAAG 22
688 4031
CFTR-3849-
- UAGUAUUUUUUU CUG AAG AAAAG 23
689 4032
CFTR-3849-
- UU AG UAUUUUUUU CUG AAG AAAAG 24
690 4033
CFTR-3849-
- UGAUCCAACAUUCUCAGG 18
691 4034
CFTR-3849-
- UUGAUCCAACAUUCUCAGG 19
692 4035
CFTR-3849-
- CUUGAUCCAACAUUCUCAGG 20
693 4036
CFTR-3849-
- UCUUGAUCCAACAUUCUCAGG 21
694 4037
CFTR-3849-
- AUCUUGAUCCAACAUUCUCAGG 22
695 4038
CFTR-3849-
- UAUCUUGAUCCAACAUUCUCAGG 23
696 4039
CFTR-3849-
- UUAUCUUGAUCCAACAUUCUCAGG 24
697 4040
CFTR-3849-
- GAUCCAACAUUCUCAGGG 18
698 4041
CFTR-3849-
- UGAUCCAACAUUCUCAGGG 19
699 4042
CFTR-3849-74 - UUGAUCCAACAUUCUCAGGG 20 3417
CFTR-3849-
- CUUGAUCCAACAUUCUCAGGG 21
700 4043
CFTR-3849-
- UCUUGAUCCAACAUUCUCAGGG 22
701 4044
CFTR-3849-
- AUCUUGAUCCAACAUUCUCAGGG 23
702 4045
CFTR-3849-
- UAUCUUGAUCCAACAUUCUCAGGG 24
703 4046
CFTR-3849-
- UAAGGUCUAUACUUU UGG 18
704 4047
CFTR-3849- - UUAAGGUCUAUACUU UUGG 19 4048
413
5535.1 705
CFTR-3849-
- UUUAAGGUCUAUACUUUUGG 20
706 4049
CFTR-3849-
- CUUUAAGGUCUAUACUUUUGG 21
707 4050
CFTR-3849-
- ACUUUAAGGUCUAUACUUUUGG 22
708 4051
CFTR-3849-
- UACUUUAAGGUCUAUACUUUUGG 23
709 4052
CFTR-3849-
- GUACUUUAAGGUCUAUACUUUUGG 24
710 4053
CFTR-3849-
- UUUUAGUAUUUUUUUCUG 18
711 4054
CFTR-3849-
- AUUUUAGUAUUUUUUUCUG 19
712 4055
CFTR-3849-
- AAUUUUAGUAUUUUUUUCUG 20
713 4056
CFTR-3849-
- AAAUUUUAGUAUUUUUUUCUG 21
714 4057
CFTR-3849-
- AAAAUUUUAGUAUUUUUUUCUG 22
715 4058
CFTR-3849-
- AAAAAUUUUAGUAUUUUUUUCUG 23
716 4059
CFTR-3849-
- UAAAAAUUUUAGUAUUUUUUUCUG 24
717 4060
CFTR-3849-
- GUCUUAAAAGCUUAUUUG 18
718 4061
CFTR-3849-
- UGUCUUAAAAGCUUAUUUG 19
719 4062
CFTR-3849-76 - AUGUCUUAAAAGCUUAUUUG 20 3419
CFTR-3849-
- UAUGUCUUAAAAGCUUAUUUG 21
720 4063
CFTR-3849-
- GUAUGUCUUAAAAGCUUAUUUG 22
721 4064
CFTR-3849-
- GGUAUGUCUUAAAAGCUUAUUUG 23
722 4065
CFTR-3849-
- GGGUAUGUCUUAAAAGCUUAUUUG 24
723 4066
CFTR-3849-
- AAUAAUUAAUAGAGAUAU 18
724 4067
CFTR-3849-
- UAAUAAUUAAUAGAGAUAU 19
725 4068
CFTR-3849- - UUAAUAAUUAAUAGAGAUAU 20 4069
414
5535.1 726
CFTR-3849-
- AUUAAUAAUUAAUAGAGAUAU 21
727 4070
CFTR-3849-
- CAU UAAUAAUUAAUAGAGAUAU 22
728 4071
CFTR-3849-
- UCAUUAAUAAUUAAUAGAGAUAU 23
729 4072
CFTR-3849-
- UUCAUUAAUAAUUAAUAGAGAUAU 24
730 4073
CFTR-3849-
- CCAG CAG U U CAAUG AU AU 18
731 4074
CFTR-3849-
- ACCAGCAGUUCAAUGAUAU 19
732 4075
CFTR-3849-
- UACCAGCAGUUCAAUGAUAU 20
733 4076
CFTR-3849-
- UUACCAGCAGUUCAAUGAUAU 21
734 4077
CFTR-3849-
- AUUACCAGCAGUUCAAUGAUAU 22
735 4078
CFTR-3849-
- CAU UACCAGCAGU UCAAUGAUAU 23
736 4079
CFTR-3849-
- GCAU UACCAGCAGUUCAAUGAUAU 24
737 4080
CFTR-3849-
- GAGGUGCAUUGAAGUUAU 18
738 4081
CFTR-3849-
- GGAGGUGCAUUGAAGU UAU 19
739 4082
CFTR-3849-
- AGGAGGUGCAUUGAAGUUAU 20
740 4083
CFTR-3849-
- GAGGAGGUGCAUUGAAGUUAU 21
741 4084
CFTR-3849-
- GGAGGAGGUGCAUUGAAGUUAU 22
742 4085
CFTR-3849-
- GGGAGGAGGUGCAUUGAAGUUAU 23
743 4086
CFTR-3849-
- AGGGAGGAGGUGCAUUGAAGUUAU 24
744 4087
CFTR-3849-
- CUUAUUCAACAGAUCACU 18
745 4088
CFTR-3849-
- CCUUAUUCAACAGAUCACU 19
746 4089
CFTR-3849-
- GCCUUAUUCAACAGAUCACU 20
747 4090
415
5535.1 CFTR-3849-
- AGCCU UAUUCAACAGAUCACU 21
748 4091
CFTR-3849-
- UAGCCU UAUUCAACAGAUCACU 22
749 4092
CFTR-3849-
- CUAGCCU UAUUCAACAGAUCACU 23
750 4093
CFTR-3849-
- UCUAGCCUUAUUCAACAGAUCACU 24
751 4094
CFTR-3849-
- ACCAGUGAUUCCUUGCCU 18
752 4095
CFTR-3849-
- AACCAGUGAUUCCUUGCCU 19
753 4096
CFTR-3849-
- AAACCAGUGAUUCCU UGCCU 20
754 4097
CFTR-3849-
- CAAACCAGUGAUUCCUUGCCU 21
755 4098
CFTR-3849-
- ACAAACCAGUGAUUCCUUGCCU 22
756 4099
CFTR-3849-
- UACAAACCAGUGAUUCCUUGCCU 23
757 4100
CFTR-3849-
- GUACAAACCAGUGAUUCCUUGCCU 24
758 4101
CFTR-3849-
- AUCUUGAUCCAACAUUCU 18
759 4102
CFTR-3849-
- UAUCUUGAUCCAACAUUCU 19
760 4103
CFTR-3849-
- UUAUCUUGAUCCAACAU UCU 20
761 4104
CFTR-3849-
- UUUAUCUUGAUCCAACAUUCU 21
762 4105
CFTR-3849-
- AUUUAUCUUGAUCCAACAUUCU 22
763 4106
CFTR-3849-
- GAUUUAUCUUGAUCCAACAUUCU 23
764 4107
CFTR-3849-
- UGAUUUAUCUUGAUCCAACAUUCU 24
765 4108
CFTR-3849-
- U UG AAAAU ACAG AAAU U U 18
766 4109
CFTR-3849-
- CUUGAAAAUACAGAAAUUU 19
767 4110
CFTR-3849-
- UCUUGAAAAUACAGAAAUUU 20
768 4111
CFTR-3849- - CUCUUGAAAAUACAGAAAUUU 21 4112
416
5535.1 769
CFTR-3849-
- U CU CU UG AAAAU ACAG AAAU U U 22
770 4113
CFTR-3849-
- G U CU CU UG AAAAU ACAG AAAU U U 23
771 4114
CFTR-3849-
- AG U CU CU UG AAAAU ACAG AAAU U U 24
772 4115
CFTR-3849-
- GACUUGUCAUCUUGAUUU 18
773 4116
CFTR-3849-
- UGACUUGUCAUCUUGAUUU 19
774 4117
CFTR-3849-
- UUGACUUGUCAUCUUGAUUU 20
775 4118
CFTR-3849-
- GUUGACUUGUCAUCUUGAUUU 21
776 4119
CFTR-3849-
- AGUUGACUUGUCAUCUUGAUUU 22
777 4120
CFTR-3849-
- CAGUUGACUUGUCAUCUUGAUUU 23
778 4121
CFTR-3849-
- UCAGUUGACUUGUCAUCUUGAUUU 24
779 4122
CFTR-3849-
- UGUCUUAAAAGCUUAUUU 18
780 4123
CFTR-3849-
- AUGUCUUAAAAGCUUAUUU 19
781 4124
CFTR-3849-
- UAUGUCUUAAAAGCUUAUUU 20
782 4125
CFTR-3849-
- GUAUGUCUUAAAAGCUUAUUU 21
783 4126
CFTR-3849-
- GGUAUGUCUUAAAAGCUUAUUU 22
784 4127
CFTR-3849-
- GGGUAUGUCUUAAAAGCUUAUUU 23
785 4128
CFTR-3849-
- AGGGUAUGUCUUAAAAGCUUAUUU 24
786 4129
CFTR-3849-
- AAAUUUUAGUAUUUUUUU 18
787 4130
CFTR-3849-
- AAAAUUUUAGUAUUUUUUU 19
788 4131
CFTR-3849-
- AAAAAUUUUAGUAUUUUUUU 20
789 4132
CFTR-3849-
- UAAAAAUUUUAGUAUUUUUUU 21
790 4133
417
5535.1 CFTR-3849-
- CUAAAAAU UUUAGUAUUUUUUU 22
791 4134
CFTR-3849-
- UCUAAAAAUUUUAGUAUUUUUUU 23
792 4135
CFTR-3849-
- CUCUAAAAAUUUUAGUAUUUUUUU 24
793 4136
Table 36A provides exemplary targeting domains for correcting a mutation (e.g., 3849+10kbC->T) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 36A
Figure imgf000419_0001
Table 36B provides exemplary targeting domains for correcting a mutation (e.g., 3849+10kbC->T) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 36B
418
5535.1 2nd Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR-3849-803 + UAGAGUACUUCCCGCAA 17 4146
CFTR-3849-804 + AUAUACCAUAUGAGGAA 17 4147
CFTR-3849-13 + UGAAAU U U AG AU CCACA 17 3356
CFTR-3849-805 - UUUCAGUUGACUUGUCA 17 4148
CFTR-3849-806 + ACAUAGUAUUGAGAAUA 17 4149
CFTR-3849-807 - U AACU U U CAACAU AU U A 17 4150
CFTR-3849-808 - CUUUGUUGGGUACAAAC 17 4151
CFTR-3849-809 - AACCU U UAAAGCUAAAC 17 4152
CFTR-3849-810 - CACAGUACUGGAUAGUC 17 4153
CFTR-3849-811 + AAUUUGUAAAUCUUUGG 17 4154
CFTR-3849-812 + UUUAGGUGUUUGUGCUG 17 4155
CFTR-3849-813 - UACUUUUGGAUGAACUU 17 4156
CFTR-3849-814 + CACAU AAU AAU U AG U U U 17 4157
CFTR-3849-815 + ACAAUAUACCAUAUGAGGAA 20 4158
CFTR-3849-112 + AACUG AAAU U U AG AU CCACA 20 3455
CFTR-3849-816 - AAAUUUCAGUUGACUUGUCA 20 4159
CFTR-3849-817 - AGACUUUGUUGGGUACAAAC 20 4160
CFTR-3849-818 - U AAAACCU U UAAAGCUAAAC 20 4161
CFTR-3849-819 - UAUCACAGUACUGGAUAGUC 20 4162
CFTR-3849-820 + UAUGAGGAAUUUUGAUUAAG 20 4163
CFTR-3849-821 - AUAGAGAUAUAUGAA CACAU 20 4164
CFTR-3849-822 + AUAUGCUGCUUAUACCCACU 20 4165
CFTR-3849-823 - CUAUACUUUUGGAUGAACUU 20 4166
CFTR-3849-824 - UUAGAUUUAGGGUAUGUCUU 20 4167
CFTR-3849-529 + UGGCACAUAAUAAUUAGUUU 20 3872
Table 36C provides exemplary targeting domains for correcting a mutation (e.g., 3849+10kbC->T) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 36C
Figure imgf000420_0001
419
5535.1 Length
CFTR-3849-825 - GAAAUAAU U UAUAAGAAUAU 20 4168
Table 36D provides exemplary targeting domains for correcting a mutation (e.g., 3849+10kbC->T) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within 500 bp from a mutation (e.g., 3849+10kbC->T). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 36D
Figure imgf000421_0001
Table 37A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within intron 2, have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 37A
Figure imgf000421_0002
420
5535.1 CFTR-lntron2-4 + GACUAUGAGUGGCCCAA 17 15104
CFTR-lntron2-5 - GCCUUGCUCUCUAGGAA 17 15105
CFTR-lntron2-6 + GCUCUAAAUCACUCUAA 17 15106
CFTR-lntron2-7 - GGGAAGUCUUAAGGUAA 17 15107
CFTR-lntron2-8 + G U U ACCAU AAG UAAACA 17 15108
CFTR-lntron2-9 + GCAAAGAGUUCUAACCA 17 15109
CFTR-lntron2-
- GGAACUCAAUGGGACCA 17
10 15110
CFTR-lntron2-
- GCUCAAUUUUGUGACCA 17
11 15111
CFTR-lntron2-
+ GCCAGGGUCACUUCCCA 17
12 15112
CFTR-lntron2-
+ GUAGAGGAUUCAAUCCA 17
13 15113
CFTR-lntron2-
+ GACCUCAGCUGGAAUCA 17
14 15114
CFTR-lntron2-
+ GUAGUUACCUGAGGAGA 17
15 15115
CFTR-lntron2-
- GGAGAAGCAUGUGGGGA 17
16 15116
CFTR-lntron2-
+ GUCCCAUUGAGUUCCUA 17
17 15117
CFTR-lntron2-
- GCAAAUGCCAUGAGGUA 17
18 15118
CFTR-lntron2-
+ GAGGUCUCUAGUGACCC 17
19 15119
CFTR-lntron2-
+ GCAAUACAGACCUCAGC 17
20 15120
CFTR-lntron2-
- GAAACCUGUAGCAUUGC 17
21 15121
CFTR-lntron2-
+ GAUUCAUGUUCUCUAUC 17
22 15122
CFTR-lntron2-
- GAAUUUGCAGAAUUAUC 17
23 15123
CFTR-lntron2-
- GACCUUGCCUUCUCCUC 17
24 15124
CFTR-lntron2-
- GUUCCAAGAUUGUAGUC 17
25 15125
CFTR-lntron2-
+ G G U U C A A U G U G A A A A AG 17
26 15126
CFTR-lntron2-
+ GUAAUAGGCCGGGGCAG 17
27 15127
CFTR-lntron2- + GCUUUACGUUUCAUCAG 17 15128
421
5535.1 28
CFTR-lntron2-
+ GAGAGAUUCUUUAUGGG 17
29 15129
CFTR-lntron2-
- GAUCUGGGCCUGGUAUG 17
30 15130
CFTR-lntron2-
- GGCCUUAGGAACUCAAU 17
31 15131
CFTR-lntron2-
- GGUAACUUGACAGUAAU 17
32 15132
CFTR-lntron2-
+ GAUCCUAACCUUUUGAU 17
33 15133
CFTR-lntron2-
+ GUGAAACUUGAACAACU 17
34 15134
CFTR-lntron2-
- GAACUAUGUGAAGACCU 17
35 15135
CFTR-lntron2-
+ GGUGGCAUUUGAGUCCU 17
36 15136
CFTR-lntron2-
- GUAUUGCCUUGCUCUCU 17
37 15137
CFTR-lntron2-
- GAAUGAU U AAU CAG AG U 17
38 15138
CFTR-lntron2-
+ GGUGAUGUGGUUCUAGU 17
39 15139
CFTR-lntron2-
- GGUGGAGAACUGGCCUU 17
40 15140
CFTR-lntron2-
- GAGUGACAUACCAUUUU 17
41 15141
CFTR-lntron2-
+ GCCUUCAAAAUGCCAAAAAA 20
42 15142
CFTR-lntron2-
+ GAGGUACAAAGUACCAAAAA 20
43 15143
CFTR-lntron2-
+ G UG U ACAU AAACCAACAAAA 20
44 15144
CFTR-lntron2-
- GGUAAUUAGGCUUUAUAGAA 20
45 15145
CFTR-lntron2-
+ GCAAUGUAGUUUUAGGAACA 20
46 15146
CFTR-lntron2-
+ GGAGCAAAGAGUUCUAACCA 20
47 15147
CFTR-lntron2-
+ GAAGCCAGGGUCACUUCCCA 20
48 15148
CFTR-lntron2-
+ GGAUUUUUCACAUUUAGCCA 20
49 15149
422
5535.1 CFTR-lntron2-
- GAUUCACACUUCUAAGAUCA 20
50 15150
CFTR-lntron2-
- GCCCUCAAGUGGUUGCCAGA 20
51 15151
CFTR-lntron2-
+ GGGGUAGUUACCUGAGGAGA 20
52 15152
CFTR-lntron2-
- GGUGGAGAAGCAUGUGGGGA 20
53 15153
CFTR-lntron2-
- GAGUAACCAAAUGUUAUGGA 20
54 15154
CFTR-lntron2-
- GGGAAUGAUUAAUCAGAGUA 20
55 15155
CFTR-lntron2-
- GUACUCCCUGGGAAGUCUUA 20
56 15156
CFTR-lntron2-
+ GGAAACUGAGAGAUUCUUUA 20
57 15157
CFTR-lntron2-
- GAGUCUCGUGCCAACAGCAC 20
58 15158
CFTR-lntron2-
+ GUAAAUUGGGUUUCUGUCAC 20
59 15159
CFTR-lntron2-
+ GAAAGUGAAG U AG AG AG ACC 20
60 15160
CFTR-lntron2-
- GCACCCUUGGGAAGUGACCC 20
61 15161
CFTR-lntron2-
- GCUAACAUUCUCUGCUCUCC 20
62 15162
CFTR-lntron2-
+ GUUAAUGUUCUUCAACCAUC 20
63 15163
CFTR-lntron2-
- GACCAGCU U U CU ACAU AAAG 20
64 15164
CFTR-lntron2-
+ GUGUUGUUAUAUUUCAUAAG 20
65 15165
CFTR-lntron2-
+ GGAGUAAUAGGCCGGGGCAG 20
66 15166
CFTR-lntron2-
+ GUCACUUCCCAAGGGUGCAG 20
67 15167
CFTR-lntron2-
- GAUAAAAGGGUGAGUGAAGG 20
68 15168
CFTR-lntron2-
- GAACUAUGUGAAGACCUAGG 20
69 15169
CFTR-lntron2-
- GUUUACCUAGUUCUUCCUUG 20
70 15170
CFTR-lntron2- + GGUCGGGGAAUUUCUUUAAU 20 15171
423
5535.1 71
CFTR-lntron2-
+ GUCACAAAAUUGAGCCAGAU 20
72 15172
CFTR-lntron2-
+ GAAACUGAGAGAUUCUUUAU 20
73 15173
CFTR-lntron2-
- GAGUCAUAGUGCUUACCCCU 20
74 15174
CFTR-lntron2-
- GCUCUCAUUAGCAAGCUUCU 20
75 15175
CFTR-lntron2-
+ GUAGGUGAUGUGGUUCUAGU 20
76 15176
CFTR-lntron2-
- GAAGAGUGACAUACCAUUUU 20
77 15177
Table 37B provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within intron 2 and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 37B
Figure imgf000425_0001
424
5535.1 CFTR-lntron2-
- UGGCCUUAGGAACUCAA 17
85 15185
CFTR-lntron2-
+ CCAGGCCCAGAUCAGAA 17
86 15186
CFTR-lntron2-
- AAUUAGGCUUUAUAGAA 17
87 15187
CFTR-lntron2-
+ ACGGAAGUAAUGUAGAA 17
88 15188
CFTR-lntron2-
+ UAACCUUUUGAUUGGAA 17
89 15189
CFTR-lntron2-
+ UGACUACAAUCUUGGAA 17
90 15190
CFTR-lntron2-
+ CACGAUUUACUUCAUAA 17
91 15191
CFTR-lntron2-
- UGGUAACUUGACAGUAA 17
92 15192
CFTR-lntron2-
+ UCGGGGAAUUUCUUUAA 17
93 15193
CFTR-lntron2-
+ AUGUAGUUUUAGGAACA 17
94 15194
CFTR-lntron2-
+ AAAU U U CAUG AACCACA 17
95 15195
CFTR-lntron2-
+ U GAAAAAG U GG U CC ACA 17
96 15196
CFTR-lntron2-
+ UGAGGGCCAUGGUCACA 17
97 15197
CFTR-lntron2-
- UAACUGCCUUGUGACCA 17
98 15198
CFTR-lntron2-
+ AGACUAUGAGUGGCCCA 17
99 15199
CFTR-lntron2-
- UAAAACUACAUUGCCCA 17
100 15200
CFTR-lntron2-
+ UACCUUAAGACUUCCCA 17
101 15201
CFTR-lntron2-
+ UUUUUCACAUUUAGCCA 17
102 15202
CFTR-lntron2-
+ CAACCACUUGAGGGCCA 17
103 15203
CFTR-lntron2-
+ CUGGCAAUCUCUAAGCA 17
104 15204
CFTR-lntron2-
+ ACCAUUCCUAGAGAGCA 17
105 15205
CFTR-lntron2- + UACCUGAGGAGAAGGCA 17 15206
425
5535.1 106
CFTR-lntron2-
- UCACACUUCUAAGAUCA 17
107 15207
CFTR-lntron2-
+ AAAGUAUCCCUACCUCA 17
108 15208
CFTR-lntron2-
+ UCACAAAAUCCAUCUCA 17
109 15209
CFTR-lntron2-
- UUAAGGACCACGAAAGA 17
110 15210
CFTR-lntron2-
- CUCAAGUGGUUGCCAGA 17
111 15211
CFTR-lntron2-
+ ACCAGGCCCAGAUCAGA 17
112 15212
CFTR-lntron2-
- UAAUUAGGCUUUAUAGA 17
113 15213
CFTR-lntron2-
- UAACCAAAUGUUAUGGA 17
114 15214
CFTR-lntron2-
- UGCCAGUUAAUGAAUGA 17
115 15215
CFTR-lntron2-
+ AUCUGGCAACCACUUGA 17
116 15216
CFTR-lntron2-
- UCAUUAGCAAGCUUCUA 17
117 15217
CFTR-lntron2-
- UCUCAGCUCCUGAAGUA 17
118 15218
CFTR-lntron2-
- AAUGAUUAAUCAGAGUA 17
119 15219
CFTR-lntron2-
- AGAGCCAUGUUUACUUA 17
120 15220
CFTR-lntron2-
- CUCCCUGGGAAGUCUUA 17
121 15221
CFTR-lntron2-
- UGAGUAACCAAAUGUUA 17
122 15222
CFTR-lntron2-
- CUUUGCUCCUAUCUUUA 17
123 15223
CFTR-lntron2-
+ AACUGAGAGAUUCUUUA 17
124 15224
CFTR-lntron2-
+ UUAAAUAGUCUGAAAAC 17
125 15225
CFTR-lntron2-
- AGACCUAGGUGGAGAAC 17
126 15226
CFTR-lntron2-
+ UCUACCUGGCAUGUAAC 17
127 15227
426
5535.1 CFTR-lntron2-
+ CUCCAUCAUUCAUUAAC 17
128 15228
CFTR-lntron2-
- UCUCGUGCCAACAGCAC 17
129 15229
CFTR-lntron2-
- CUUAAGGUAAUGGCUAC 17
130 15230
CFTR-lntron2-
+ CUCUCCAGCAAUGCUAC 17
131 15231
CFTR-lntron2-
+ AACGUAUGGGUUUGUAC 17
132 15232
CFTR-lntron2-
+ AGCAAAGAGUUCUAACC 17
133 15233
CFTR-lntron2-
+ AUAAGGCAAAUGCCACC 17
134 15234
CFTR-lntron2-
- AGGACUCAAAUGCCACC 17
135 15235
CFTR-lntron2-
+ AG UG AAG U AG AG AG ACC 17
136 15236
CFTR-lntron2-
+ UAGUAGGACCACAUACC 17
137 15237
CFTR-lntron2-
+ AGAGGAGAUAUUCUACC 17
138 15238
CFTR-lntron2-
- CCCUUGGGAAGUGACCC 17
139 15239
CFTR-lntron2-
- CUAAAACUACAUUGCCC 17
140 15240
CFTR-lntron2-
- AAUACAAAUGUACUCCC 17
141 15241
CFTR-lntron2-
- UACAUAAAGUGGGUCCC 17
142 15242
CFTR-lntron2-
+ UUACCUUAAGACUUCCC 17
143 15243
CFTR-lntron2-
+ UUAUGAAAUGUGAAGCC 17
144 15244
CFTR-lntron2-
+ UAAAGGAGUAAUAGGCC 17
145 15245
CFTR-lntron2-
- CAUGCUUAGAGAUUGCC 17
146 15246
CFTR-lntron2-
+ ACUUAGAUAUUCAAAGC 17
147 15247
CFTR-lntron2-
+ CACUUUAUGUAGAAAGC 17
148 15248
CFTR-lntron2- + UGUUCAAUAAUAGAAGC 17 15249
427
5535.1 149
CFTR-lntron2-
- U A A U AAA U AC A A U C AG C 17
150 15250
CFTR-lntron2-
+ CUAAAGGAGUAAUAGGC 17
151 15251
CFTR-lntron2-
- AUUAAUCAGAGUAGGGC 17
152 15252
CFTR-lntron2-
- UGGCAUUUGCCUUAUGC 17
153 15253
CFTR-lntron2-
- UAAACAUAAUCCAUUGC 17
154 15254
CFTR-lntron2-
+ AAUGUUCUUCAACCAUC 17
155 15255
CFTR-lntron2-
+ CCCUUUUAUCUGGCAUC 17
156 15256
CFTR-lntron2-
- AAGAACAUUAACCUAUC 17
157 15257
CFTR-lntron2-
+ UCACUCACCCUUUUAUC 17
158 15258
CFTR-lntron2-
+ UAUGACUCAAGAGUCUC 17
159 15259
CFTR-lntron2-
+ UAUGUAGAAAGCUGGUC 17
160 15260
CFTR-lntron2-
+ AGGUCUUCACAUAGUUC 17
161 15261
CFTR-lntron2-
- CAGCUUUCUACAUAAAG 17
162 15262
CFTR-lntron2-
+ ACUAUGAGUGGCCCAAG 17
163 15263
CFTR-lntron2-
- UGACCAUGGCCCUCAAG 17
164 15264
CFTR-lntron2-
+ UUGUUAUAUUUCAUAAG 17
165 15265
CFTR-lntron2-
+ ACUUCCCAAGGGUGCAG 17
166 15266
CFTR-lntron2-
+ AUGCUUUCCACUCAGAG 17
167 15267
CFTR-lntron2-
+ UCAUUCUAGACUAUGAG 17
168 15268
CFTR-lntron2-
- U C A A AG A A U U A AG C U AG 17
169 15269
CFTR-lntron2-
- CAUUAGCAAGCUUCUAG 17
170 15270
428
5535.1 CFTR-lntron2-
+ ACACUGCAGUUAUGUAG 17
171 15271
CFTR-lntron2-
+ AAAGGAGUAAUAGGCCG 17
172 15272
CFTR-lntron2-
+ AGGAGAAGGCAAGGUCG 17
173 15273
CFTR-lntron2-
+ AAGGGCUCCUUCUUUCG 17
174 15274
CFTR-lntron2-
- CUAUGUGAAGACCUAGG 17
175 15275
CFTR-lntron2-
+ AGAGAUUCUUUAUGGGG 17
176 15276
CFTR-lntron2-
- UGGAGAAGCAUGUGGGG 17
177 15277
CFTR-lntron2-
- CAAAUGUUAUGGAUGGG 17
178 15278
CFTR-lntron2-
+ UAGUUUUAGGAACAUGG 17
179 15279
CFTR-lntron2-
+ UGAGAGAUUCUUUAUGG 17
180 15280
CFTR-lntron2-
- ACUCAAAUGCCACCUGG 17
181 15281
CFTR-lntron2-
+ UAAAUUGAAUCAACAUG 17
182 15282
CFTR-lntron2-
- UGUGUGCAAAUGCCAUG 17
183 15283
CFTR-lntron2-
- AAAGGUGGAGAAGCAUG 17
184 15284
CFTR-lntron2-
+ AAUGGGGUAGUUACCUG 17
185 15285
CFTR-lntron2-
- AGCCAUGAUUCCAGCUG 17
186 15286
CFTR-lntron2-
- UCUACAUUACUUCCGUG 17
187 15287
CFTR-lntron2-
+ AUCUUGGAACGGAUGUG 17
188 15288
CFTR-lntron2-
+ CAUCUGGCAACCACUUG 17
189 15289
CFTR-lntron2-
+ CCUAUUCUAGGCACUUG 17
190 15290
CFTR-lntron2-
- UACCUAGUUCUUCCUUG 17
191 15291
CFTR-lntron2- - UUGGUGCUAACAAUUUG 17 15292
429
5535.1 192
CFTR-lntron2-
+ UACUUAAGCUAGUAAAU 17
193 15293
CFTR-lntron2-
- CCCCAAGUGCCUAGAAU 17
194 15294
CFTR-lntron2-
+ CACUCUAAAGGAGUAAU 17
195 15295
CFTR-lntron2-
+ CGGGGAAUUUCUUUAAU 17
196 15296
CFTR-lntron2-
+ UCGUGGUCCUUAAAGAU 17
197 15297
CFTR-lntron2-
+ ACAAAAUUGAGCCAGAU 17
198 15298
CFTR-lntron2-
- UGGGGAGGGAAAUAGAU 17
199 15299
CFTR-lntron2-
- AACCAAAUGUUAUGGAU 17
200 15300
CFTR-lntron2-
+ AAAAU AAU AG AACG U AU 17
201 15301
CFTR-lntron2-
- AAAAGG AACG AAU U U AU 17
202 15302
CFTR-lntron2-
+ ACUGAGAGAUUCUUUAU 17
203 15303
CFTR-lntron2-
+ AACCACAAGGAAGAACU 17
204 15304
CFTR-lntron2-
- AUAGUCUAGAAUGAACU 17
205 15305
CFTR-lntron2-
+ AGGCCAGUUCUCCACCU 17
206 15306
CFTR-lntron2-
- UUGUACCUCUGCACCCU 17
207 15307
CFTR-lntron2-
+ AGGUCUCUAGUGACCCU 17
208 15308
CFTR-lntron2-
- UCAUAGUGCUUACCCCU 17
209 15309
CFTR-lntron2-
- AUACAAAUGUACUCCCU 17
210 15310
CFTR-lntron2-
- UGUACACACCCCUUCCU 17
211 15311
CFTR-lntron2-
+ CUUAGAUAUUCAAAGCU 17
212 15312
CFTR-lntron2-
- UUAAUCAGAGUAGGGCU 17
213 15313
430
5535.1 CFTR-lntron2-
+ UAUCCUGACUACAAUCU 17
214 15314
CFTR-lntron2-
+ UCUCUAAGCAUGGAUCU 17
215 15315
CFTR-lntron2-
- ACCACAUCACCUACUCU 17
216 15316
CFTR-lntron2-
+ AUGACUCAAGAGUCUCU 17
217 15317
CFTR-lntron2-
- CUCAUUAGCAAGCUUCU 17
218 15318
CFTR-lntron2-
+ U UG U U AG CACCAAG AG U 17
219 15319
CFTR-lntron2-
- CAAAGAAU U AAG CU AG U 17
220 15320
CFTR-lntron2-
- AAGGUGGAGAAGCAUGU 17
221 15321
CFTR-lntron2-
+ CAUCAGGCCUGUGCUGU 17
222 15322
CFTR-lntron2-
- CAUUGAACCCAUUUUGU 17
223 15323
CFTR-lntron2-
+ ACUUAAGCUAGUAAAUU 17
224 15324
CFTR-lntron2-
+ CUCCCAUCCAUAACAUU 17
225 15325
CFTR-lntron2-
- UGUACCUCUGCACCCUU 17
226 15326
CFTR-lntron2-
- CAUAGUGCUUACCCCUU 17
227 15327
CFTR-lntron2-
- U U U CC AAU CAAAAG G U U 17
228 15328
CFTR-lntron2-
- AGGCCUGAUGCCAGAUAAAA 20
229 15329
CFTR-lntron2-
+ CUUCUCCAU C A A AG GAG AAA 20
230 15330
CFTR-lntron2-
- AUCCAUGAUGGAAUGUGAAA 20
231 15331
CFTR-lntron2-
- CAGGCCUGAUGCCAGAUAAA 20
232 15332
CFTR-lntron2-
+ AGCCUUUUUUCUCUUCACAA 20
233 15333
CFTR-lntron2-
+ CUAGGUAAACAAUUAGACAA 20
234 15334
CFTR-lntron2- + U CACAU U U AGCCAAGG ACAA 20 15335
431
5535.1 235
CFTR-l ntron2-
+ CUAGACUAUGAGUGGCCCAA 20
236 15336
CFTR-l ntron2-
+ AAGCCAGGGUCACUUCCCAA 20
237 15337
CFTR-l ntron2-
+ ACU UGUCAAUAUACCUGCAA 20
238 15338
CFTR-l ntron2-
+ AGACUCACCUUCUCCAUCAA 20
239 15339
CFTR-l ntron2-
- AUUCACACUUCUAAGAUCAA 20
240 15340
CFTR-l ntron2-
- AACUGGCCUUAGGAACUCAA 20
241 15341
CFTR-l ntron2-
+ AUACCAGGCCCAGAUCAGAA 20
242 15342
CFTR-l ntron2-
- UAGCUCUGUGUGUGAGAGAA 20
243 15343
CFTR-l ntron2-
+ CACACGGAAGUAAUGUAGAA 20
244 15344
CFTR-l ntron2-
- AUUGCCUUGCUCUCUAGGAA 20
245 15345
CFTR-l ntron2-
+ UCCUAACCUUUUGAUUGGAA 20
246 15346
CFTR-l ntron2-
+ UCCUGACUACAAUCUUGGAA 20
247 15347
CFTR-l ntron2-
- CAGAUAAAAGGGUGAGUGAA 20
248 15348
CFTR-l ntron2-
+ AUACACGAUUUACUUCAUAA 20
249 15349
CFTR-l ntron2-
+ AUGGCUCUAAAUCACUCUAA 20
250 15350
CFTR-l ntron2-
- UUAUGGUAACUUGACAGUAA 20
251 15351
CFTR-l ntron2-
- CCUGGGAAGUCUUAAGGUAA 20
252 15352
CFTR-l ntron2-
+ CUACUAAAAUCAUGUAUUAA 20
253 15353
CFTR-l ntron2-
+ AGGUCGGGGAAUUUCUUUAA 20
254 15354
CFTR-l ntron2-
+ CAAG U U ACCAU AAG UAAACA 20
255 15355
CFTR-l ntron2-
+ AUGUGAAAAAGUGGUCCACA 20
256 15356
432
5535.1 CFTR-l ntron2-
+ ACU UGAGGGCCAUGGUCACA 20
257 15357
CFTR-l ntron2-
- UUAGGAACUCAAUGGGACCA 20
258 15358
CFTR-l ntron2-
- UCAUAACUGCCUUGUGACCA 20
259 15359
CFTR-l ntron2-
- CUGGCUCAAUUUUGUGACCA 20
260 15360
CFTR-l ntron2-
+ UCUAGACUAUGAGUGGCCCA 20
261 15361
CFTR-l ntron2-
- UCCUAAAACUACAUUGCCCA 20
262 15362
CFTR-l ntron2-
+ CAUUACCUUAAGACUUCCCA 20
263 15363
CFTR-l ntron2-
+ AGUUAUGAAAUGUGAAGCCA 20
264 15364
CFTR-l ntron2-
+ UGGCAACCACUUGAGGGCCA 20
265 15365
CFTR-l ntron2-
+ UAUGUAGAGGAUUCAAUCCA 20
266 15366
CFTR-l ntron2-
+ AGCCUGGCAAUCUCUAAGCA 20
267 15367
CFTR-l ntron2-
+ ACUACCAUUCCUAGAGAGCA 20
268 15368
CFTR-l ntron2-
+ AGUUACCUGAGGAGAAGGCA 20
269 15369
CFTR-l ntron2-
+ ACAGACCUCAGCUGGAAUCA 20
270 15370
CFTR-l ntron2-
+ AGCCAUUUCACAUUCCAUCA 20
271 15371
CFTR-l ntron2-
+ AACAAAGUAUCCCUACCUCA 20
272 15372
CFTR-l ntron2-
+ U UUUCACAAAAUCCAUCUCA 20
273 15373
CFTR-l ntron2-
- UCUUUAAGGACCACGAAAGA 20
274 15374
CFTR-l ntron2-
+ CAUACCAGGCCCAGAUCAGA 20
275 15375
CFTR-l ntron2-
+ CAAAGGAGAAAUGGAUCAGA 20
276 15376
CFTR-l ntron2-
- UCUUAUUAGAGACCAUGAGA 20
277 15377
CFTR-l ntron2- - CAUGUGGGGAGGGAAAUAGA 20 15378
433
5535.1 278
CFTR-lntron2-
- AGGUAAUUAGGCUUUAUAGA 20
279 15379
CFTR-lntron2-
+ UCAGAUGGGAAAGCCAAGGA 20
280 15380
CFTR-lntron2-
- CUUUGCCAGUUAAUGAAUGA 20
281 15381
CFTR-lntron2-
- AAGUUUUAAUUGGAUGCUGA 20
282 15382
CFTR-lntron2-
- CCAGAUAAAAGGGUGAGUGA 20
283 15383
CFTR-lntron2-
+ ACCAUCUGGCAACCACUUGA 20
284 15384
CFTR-lntron2-
- CUGAUCCAUUUCUCCUUUGA 20
285 15385
CFTR-lntron2-
- UCCUUUUUUUGGCAUUUUGA 20
286 15386
CFTR-lntron2-
+ UCAGAGUAAGAAGCU AAA U A 20
287 15387
CFTR-lntron2-
- AUCCCCAAGUGCCUAGAAUA 20
288 15388
CFTR-lntron2-
+ UUGGUCCCAUUGAGUUCCUA 20
289 15389
CFTR-lntron2-
- CUCUCAUUAGCAAGCUUCUA 20
290 15390
CFTR-lntron2-
- ACAUCUCAGCUCCUGAAGUA 20
291 15391
CFTR-lntron2-
- UGUGCAAAUGCCAUGAGGUA 20
292 15392
CFTR-lntron2-
- UUUAGAGCCAUGUUUACUUA 20
293 15393
CFTR-lntron2-
- CUCUGAGUAACCAAAUGUUA 20
294 15394
CFTR-lntron2-
- ACUCUUUGCUCCUAUCUUUA 20
295 15395
CFTR-lntron2-
+ ACAU U AAAU AG UCUGAAAAC 20
296 15396
CFTR-lntron2-
+ AUGGGGGAUACAGUGAAAAC 20
297 15397
CFTR-lntron2-
- UGAAGACCUAGGUGGAGAAC 20
298 15398
CFTR-lntron2-
+ UAUUCUACCUGGCAUGUAAC 20
299 15399
434
5535.1 CFTR-lntron2-
+ UGGCUCCAUCAUUCAUUAAC 20
300 15400
CFTR-lntron2-
- CUGGUUUUAUUUUCUCAGAC 20
301 15401
CFTR-lntron2-
- AGUCUUAAGGUAAUGGCUAC 20
302 15402
CFTR-lntron2-
+ UAUCUCUCCAGCAAUGCUAC 20
303 15403
CFTR-lntron2-
+ UAGAACGUAUGGGUUUGUAC 20
304 15404
CFTR-lntron2-
+ AGG AGCAAAG AG U U CU AACC 20
305 15405
CFTR-lntron2-
+ AGCAUAAGGCAAAUGCCACC 20
306 15406
CFTR-lntron2-
- CCAAGGACUCAAAUGCCACC 20
307 15407
CFTR-lntron2-
+ UUCUAGUAGGACCACAUACC 20
308 15408
CFTR-lntron2-
+ CUGAGAGGAGAUAUUCUACC 20
309 15409
CFTR-lntron2-
+ UAAGAGGUCUCUAGUGACCC 20
310 15410
CFTR-lntron2-
- UUCCUAAAACUACAUUGCCC 20
311 15411
CFTR-lntron2-
- UUGAAUACAAAUGUACUCCC 20
312 15412
CFTR-lntron2-
- UUCUACAUAAAGUGGGUCCC 20
313 15413
CFTR-lntron2-
+ CCAUUACCUUAAGACUUCCC 20
314 15414
CFTR-lntron2-
+ CAGUUAUGAAAUGUGAAGCC 20
315 15415
CFTR-lntron2-
- CUUCCCUUCUGAUCUGGGCC 20
316 15416
CFTR-lntron2-
- AUCCAUGCUUAGAGAUUGCC 20
317 15417
CFTR-lntron2-
+ AAAACUUAGAUAUUCAAAGC 20
318 15418
CFTR-lntron2-
+ ACCCACUUUAUGUAGAAAGC 20
319 15419
CFTR-lntron2-
+ AAGUGUUCAAUAAUAGAAGC 20
320 15420
CFTR-lntron2- - ACUUAAUAAAUACAAUCAGC 20 15421
435
5535.1 321
CFTR-l ntron2-
+ AAGGCAAUACAGACCUCAGC 20
322 15422
CFTR-l ntron2-
- AUGAUUAAUCAGAGUAGGGC 20
323 15423
CFTR-l ntron2-
- AUAUAAACAUAAUCCAUUGC 20
324 15424
CFTR-l ntron2-
- AUAGAAACCUGUAGCAU UGC 20
325 15425
CFTR-l ntron2-
- AAACUUCUUCCCUUCUGAUC 20
326 15426
CFTR-l ntron2-
- UUGAAGAACAUUAACCUAUC 20
327 15427
CFTR-l ntron2-
+ UCAGAUUCAUGUUCUCUAUC 20
328 15428
CFTR-l ntron2-
- UCUGAAUUUGCAGAAU UAUC 20
329 15429
CFTR-l ntron2-
- CCCGACCUUGCCUUCUCCUC 20
330 15430
CFTR-l ntron2-
+ CACUAUGACUCAAGAGUCUC 20
331 15431
CFTR-l ntron2-
- UCCGUUCCAAGAUUGUAGUC 20
332 15432
CFTR-l ntron2-
+ CCUGAGGAGAAGGCAAGGUC 20
333 15433
CFTR-l ntron2-
+ CUUUAUGUAGAAAGCUGGUC 20
334 15434
CFTR-l ntron2-
+ CCUAGGUCUUCACAUAGUUC 20
335 15435
CFTR-l ntron2-
+ AUGGGUUCAAUGUGAAAAAG 20
336 15436
CFTR-l ntron2-
+ UAGACUAUGAGUGGCCCAAG 20
337 15437
CFTR-l ntron2-
- UUGUGACCAUGGCCCUCAAG 20
338 15438
CFTR-l ntron2-
- CU U U CAU U AACAG AAAU CAG 20
339 15439
CFTR-l ntron2-
+ AAGGCUUUACGUUUCAUCAG 20
340 15440
CFTR-l ntron2-
+ AUGAUGCUUUCCACUCAGAG 20
341 15441
CFTR-l ntron2-
+ AGUUCAUUCUAGACUAUGAG 20
342 15442
436
5535.1 CFTR-lntron2-
+ UUCCACUCAGAGUGGCUGAG 20
343 15443
CFTR-lntron2-
- CUCCUCUCAGCCACUCUGAG 20
344 15444
CFTR-lntron2-
- UAUUCAAAGAAUUAAGCUAG 20
345 15445
CFTR-lntron2-
- UCUCAUUAGCAAGCUUCUAG 20
346 15446
CFTR-lntron2-
+ UGCACACUGCAGUUAUGUAG 20
347 15447
CFTR-lntron2-
+ UCUAAAGGAGUAAUAGGCCG 20
348 15448
CFTR-lntron2-
+ CUGAGGAGAAGGCAAGGUCG 20
349 15449
CFTR-lntron2-
+ AUAAGGCAAAUGCCACCAGG 20
350 15450
CFTR-lntron2-
+ CUGAGAGAUUCUUUAUGGGG 20
351 15451
CFTR-lntron2-
- AACCAAAUGUUAUGGAUGGG 20
352 15452
CFTR-lntron2-
+ ACUGAGAGAUUCUUUAUGGG 20
353 15453
CFTR-lntron2-
+ UUUAAAUUGAAUCAACAUGG 20
354 15454
CFTR-lntron2-
+ AUGUAGUUUUAGGAACAUGG 20
355 15455
CFTR-lntron2-
+ AACUGAGAGAUUCUUUAUGG 20
356 15456
CFTR-lntron2-
- AGGACUCAAAUGCCACCUGG 20
357 15457
CFTR-lntron2-
+ UUUUAAAUUGAAUCAACAUG 20
358 15458
CFTR-lntron2-
+ AGCACCAAGAGUAGGUGAUG 20
359 15459
CFTR-lntron2-
- UCUGAUCUGGGCCUGGUAUG 20
360 15460
CFTR-lntron2-
+ AAACUGAGAGAUUCUUUAUG 20
361 15461
CFTR-lntron2-
+ UAGAAUGGGGUAGUUACCUG 20
362 15462
CFTR-lntron2-
- UGGAGCCAUGAUUCCAGCUG 20
363 15463
CFTR-lntron2- - UAAGUUUUAAUUGGAUGCUG 20 15464
437
5535.1 364
CFTR-lntron2-
- CUUUCUACAUUACUUCCGUG 20
365 15465
CFTR-lntron2-
+ ACAAUCUUGGAACGGAUGUG 20
366 15466
CFTR-lntron2-
+ AACCAUCUGGCAACCACUUG 20
367 15467
CFTR-lntron2-
- CUCUUGGUGCUAACAAUUUG 20
368 15468
CFTR-lntron2-
+ UGUACAUAAACCAACAAAAU 20
369 15469
CFTR-lntron2-
+ AUUUACUUAAGCUAGUAAAU 20
370 15470
CFTR-lntron2-
- ACUGGCCUUAGGAACUCAAU 20
371 15471
CFTR-lntron2-
- CAAGUUCAAAAUAAUAUAAU 20
372 15472
CFTR-lntron2-
- UAUGGUAACUUGACAGUAAU 20
373 15473
CFTR-lntron2-
+ AAUCACUCUAAAGGAGUAAU 20
374 15474
CFTR-lntron2-
+ CUUUCGUGGUCCUUAAAGAU 20
375 15475
CFTR-lntron2-
+ AAAGGAGAAAUGGAUCAGAU 20
376 15476
CFTR-lntron2-
- AUGUGGGGAGGGAAAUAGAU 20
377 15477
CFTR-lntron2-
- AGUAACCAAAUGUUAUGGAU 20
378 15478
CFTR-lntron2-
+ AAGGAUCCUAACCUUUUGAU 20
379 15479
CFTR-lntron2-
+ ACAAAAAUAAUAGAACGUAU 20
380 15480
CFTR-lntron2-
- AAU AAAAGG AACG AAU U U AU 20
381 15481
CFTR-lntron2-
+ UGGGUGAAACUUGAACAACU 20
382 15482
CFTR-lntron2-
+ AUGAACCACAAGGAAGAACU 20
383 15483
CFTR-lntron2-
- CUCAUAGUCUAGAAUGAACU 20
384 15484
CFTR-lntron2-
- AGCUUCUAUUAUUGAACACU 20
385 15485
438
5535.1 CFTR-lntron2-
+ CUAAGGCCAGUUCUCCACCU 20
386 15486
CFTR-lntron2-
- CCUGAACUAUGUGAAGACCU 20
387 15487
CFTR-lntron2-
+ AAGAGGUCUCUAGUGACCCU 20
388 15488
CFTR-lntron2-
- UGAAUACAAAUGUACUCCCU 20
389 15489
CFTR-lntron2-
+ CCAGGUGGCAUUUGAGUCCU 20
390 15490
CFTR-lntron2-
- AAGAAGGAGCCCUUUGUCCU 20
391 15491
CFTR-lntron2-
- UUAUGUACACACCCCUUCCU 20
392 15492
CFTR-lntron2-
+ AAACUUAGAUAUUCAAAGCU 20
393 15493
CFTR-lntron2-
- UGAUUAAUCAGAGUAGGGCU 20
394 15494
CFTR-lntron2-
+ UCAUAUCCUGACUACAAUCU 20
395 15495
CFTR-lntron2-
+ CAAUCUCUAAGCAUGGAUCU 20
396 15496
CFTR-lntron2-
- AACUUCUUCCCUUCUGAUCU 20
397 15497
CFTR-lntron2-
- AGAACCACAUCACCUACUCU 20
398 15498
CFTR-lntron2-
- UCUGUAUUGCCUUGCUCUCU 20
399 15499
CFTR-lntron2-
+ ACUAUGACUCAAGAGUCUCU 20
400 15500
CFTR-lntron2-
- ACCAGCUUUCUACAUAAAGU 20
401 15501
CFTR-lntron2-
+ AAAUUGUUAGCACCAAGAGU 20
402 15502
CFTR-lntron2-
- AGGGAAUGAUUAAUCAGAGU 20
403 15503
CFTR-lntron2-
- AUUCAAAGAAUUAAGCUAGU 20
404 15504
CFTR-lntron2-
+ ACCUGAGGAGAAGGCAAGGU 20
405 15505
CFTR-lntron2-
- AGAAAGGUGGAGAAGCAUGU 20
406 15506
CFTR-lntron2- + UGGCAUCAGGCCUGUGCUGU 20 15507
439
5535.1 407
CFTR-lntron2-
- UCACAUUGAACCCAUUUUGU 20
408 15508
CFTR-lntron2-
- AUAGAUGGGAAAAGGUAAUU 20
409 15509
CFTR-lntron2-
+ AACCUCCCAUCCAUAACAUU 20
410 15510
CFTR-lntron2-
+ UCAACUCAAUGUUUUUACUU 20
411 15511
CFTR-lntron2-
- CUUUGUACCUCUGCACCCUU 20
412 15512
CFTR-lntron2-
- AGUCAUAGUGCUUACCCCUU 20
413 15513
CFTR-lntron2-
- CUAGGUGGAGAACUGGCCUU 20
414 15514
CFTR-lntron2-
- UCCUUUCCAAUCAAAAGGUU 20
415 15515
CFTR-lntron2-
+ ACCCUGGGCAAUGUAGUUUU 20
416 15516
Table 37C provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within intron 2 and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 37C
Figure imgf000441_0001
440
5535.1 CFTR-lntron2-
- GUUGAAUGAAUCCAUGA 17
422 15522
CFTR-lntron2-
- GAUAAAAGGGUGAGUGA 17
423 15523
CFTR-lntron2-
+ GAGUAAGAAGCUAAAUA 17
424 15524
CFTR-lntron2-
- GAAUAGGGCCUGGCAUA 17
425 15525
CFTR-lntron2-
+ GGGGAUACAGUGAAAAC 17
426 15526
CFTR-lntron2-
- GUUUUAUUUUCUCAGAC 17
427 15527
CFTR-lntron2-
+ GAGAAUCACUUGAACCC 17
428 15528
CFTR-lntron2-
+ GAGAUUCGCUUGAACCC 17
429 15529
CFTR-lntron2-
- GUCUCGCUGUGUCACCC 17
430 15530
CFTR-lntron2-
- GGCGUGAGCCACUGCCC 17
431 15531
CFTR-lntron2-
- GUCUUGCUCUGUUGCCC 17
432 15532
CFTR-lntron2-
+ GG AG U U CAAG ACCAGCC 17
433 15533
CFTR-lntron2-
- GCAUGCACCACCAGGCC 17
434 15534
CFTR-lntron2-
- GUGCCUAGAAUAGGGCC 17
435 15535
CFTR-lntron2-
- GUUUUGCUAUGCUGGCC 17
436 15536
CFTR-lntron2-
- GUUUCGCCAUGUUGGCC 17
437 15537
CFTR-lntron2-
- GCACUCGCCACAAUGCC 17
438 15538
CFTR-lntron2-
+ GAGGAGAAGGCAAGGUC 17
439 15539
CFTR-lntron2-
+ GCAGAUCACUUGAGGUC 17
440 15540
CFTR-lntron2-
+ GGUGGAAACCAUACUUC 17
441 15541
CFTR-lntron2-
+ G A A A AG AAGUAACAGGG 17
442 15542
CFTR-lntron2- - GUUUUAAUUGGAUGCUG 17 15543
441
5535.1 CFTR-lntron2-
+ GGCGGGCAGAUCACUUG 17
444 15544
CFTR-lntron2-
+ GGUGGGCAGAUCACUUG 17
445 15545
CFTR-lntron2-
+ GAAAGAAAAAAUAGAAU 17
446 15546
CFTR-lntron2-
- G U U CAAAAU AAU AU AAU 17
447 15547
CFTR-lntron2-
+ GGAGAAAUGGAUCAGAU 17
448 15548
CFTR-lntron2-
+ GCCCUAUUCUAGGCACU 17
449 15549
CFTR-lntron2-
- GUGGAGUUUCGCCAUGU 17
450 15550
CFTR-lntron2-
- GAUGGGAAAAGGUAAUU 17
451 15551
CFTR-lntron2-
- GUUUUUUAUUUUUUAUU 17
452 15552
CFTR-lntron2-
- GUGUAAUGGUGCAAUUU 17
453 15553
CFTR-lntron2-
- GGAGGGAAAUAGAUGGGAAA 20
454 15554
CFTR-lntron2-
+ GAAAAAU U U CAUG AACCACA 20
455 15555
CFTR-lntron2-
+ GAGAAAAUAAAACCAGCAUA 20
456 15556
CFTR-lntron2-
- GACUACAGGCAUGCACCACC 20
457 15557
CFTR-lntron2-
- GGGGUUUUGCUAUGCUGGCC 20
458 15558
CFTR-lntron2-
- GGAGUUUCGCCAUGUUGGCC 20
459 15559
CFTR-lntron2-
- GCCUCAGCCUCUCGAGUAGC 20
460 15560
CFTR-lntron2-
+ GCUACUCGAGAGGCUGAGGC 20
461 15561
CFTR-lntron2-
- GAGACGGGGUUUUGCUAUGC 20
462 15562
CFTR-lntron2-
+ GCCUGUAGUCCCAGCUACUC 20
463 15563
CFTR-lntron2-
+ GACUUUGUUUUUAAAAGUAG 20
464 15564
442
5535.1 CFTR-lntron2-
- GGCUAAUUUUUGUAGAGACG 20
465 15565
CFTR-lntron2-
+ GAGAUUCGCUUGAACCCAGG 20
466 15566
CFTR-lntron2-
- GAGAAAGGUGGAGAAGCAUG 20
467 15567
CFTR-lntron2-
- GAAAGGUGGAGAAGCAUGUG 20
468 15568
CFTR-lntron2-
+ GGCCCUAUUCUAGGCACUUG 20
469 15569
CFTR-lntron2-
+ GCACCAUUACACUCCAGCCU 20
470 15570
CFTR-lntron2-
+ GCAUUUUGGGAGGCCAAGGU 20
471 15571
CFTR-lntron2-
- GUGUGCAAAUGCCAUGAGGU 20
472 15572
CFTR-lntron2-
- GAUGUGGAGUUUCGCCAUGU 20
473 15573
CFTR-lntron2-
- GCCUUGGCCUCCCAAAGUGU 20
474 15574
CFTR-lntron2-
- GGAGUGUAAUGGUGCAAUUU 20
475 15575
CFTR-lntron2-
+ GCCACUAAUCCCAACACUUU 20
476 15576
Table 37D provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within intron 2. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 37D
Figure imgf000444_0001
443
5535.1 479
CFTR-lntron2-
- UUUCCUUUCCAAUCAAA 17
480 15580
CFTR-lntron2-
+ UGUCACUGGCAAUCAAA 17
481 15581
CFTR-lntron2-
+ CUCCAUCAAAGGAGAAA 17
482 15582
CFTR-lntron2-
- CAUGAUGGAAUGUGAAA 17
483 15583
CFTR-lntron2-
- UAGCUUAAGUAAAUAAA 17
484 15584
CFTR-lntron2-
+ CUUUUUUCUCUUCACAA 17
485 15585
CFTR-lntron2-
- CUCUGUGUGUGAGAGAA 17
486 15586
CFTR-lntron2-
+ U G A A AG A A A A A A U AG A A 17
487 15587
CFTR-lntron2-
+ AUGGGAAAGCCAAGGAA 17
488 15588
CFTR-lntron2-
- AUAAAAGGGUGAGUGAA 17
489 15589
CFTR-lntron2-
+ ACAAACAAAAAACAUAA 17
490 15590
CFTR-lntron2-
+ UUUGUAUUCAAAUAUAA 17
491 15591
CFTR-lntron2-
- AG U U CAAAAU AAU AU AA 17
492 15592
CFTR-lntron2-
- CCCAGGCUGGAGUGUAA 17
493 15593
CFTR-lntron2-
+ CUAAAAUCAUGUAUUAA 17
494 15594
CFTR-lntron2-
+ U U U AAAU UG AAU CAACA 17
495 15595
CFTR-lntron2-
+ U AAG AAAAG AAG U AACA 17
496 15596
CFTR-lntron2-
+ AUCAGAUGGGAAAGCCA 17
497 15597
CFTR-lntron2-
+ UAUGAAAUGUGAAGCCA 17
498 15598
CFTR-lntron2-
+ AACACUUUGGGAGGCCA 17
499 15599
CFTR-lntron2-
+ AGCAUUUUGGGAGGCCA 17
500 15600
444
5535.1 CFTR-lntron2-
+ CAUUUCACAUUCCAUCA 17
501 15601
CFTR-lntron2-
+ AGGAGAAAUGGAUCAGA 17
502 15602
CFTR-lntron2-
- UUCUCCUUUGAUGGAGA 17
503 15603
CFTR-lntron2-
- UAUUAGAGACCAUGAGA 17
504 15604
CFTR-lntron2-
- UUUUAAUUGGAUGCUGA 17
505 15605
CFTR-lntron2-
- AUCCAUUUCUCCUUUGA 17
506 15606
CFTR-lntron2-
- UUUUUUUGGCAUUUUGA 17
507 15607
CFTR-lntron2-
- CCCAAGUGCCUAGAAUA 17
508 15608
CFTR-lntron2-
+ AAAAUAAAACCAGCAUA 17
509 15609
CFTR-lntron2-
+ AAAAAUAAUAGAACGUA 17
510 15610
CFTR-lntron2-
- UGAUACAUUUGUAUUUA 17
511 15611
CFTR-lntron2-
+ AU AAG AAAAG AAG U AAC 17
512 15612
CFTR-lntron2-
+ AAUUGGGUUUCUGUCAC 17
513 15613
CFTR-lntron2-
- CUAAUUUUUGUAGAGAC 17
514 15614
CFTR-lntron2-
- UGAGUAGCUGGGACUAC 17
515 15615
CFTR-lntron2-
- CGAGUAGCUGGGUUUAC 17
516 15616
CFTR-lntron2-
- UACAGGCAUGCACCACC 17
517 15617
CFTR-lntron2-
+ AGAUUUGAAGACAAGCC 17
518 15618
CFTR-lntron2-
+ ACCACUACACUCCAGCC 17
519 15619
CFTR-lntron2-
+ ACCAUUACACUCCAGCC 17
520 15620
CFTR-lntron2-
+ AAAUACAAAAAUUAGCC 17
521 15621
CFTR-lntron2- + CUCUACAAAAAUUAGCC 17 15622
445
5535.1 522
CFTR-lntron2-
+ CAAAAAUUAGCCAGGCC 17
523 15623
CFTR-lntron2-
- CCCUUCUGAUCUGGGCC 17
524 15624
CFTR-lntron2-
- AGUACCUGUUACAUGCC 17
525 15625
CFTR-lntron2-
+ AGUAUAUACCAUAUGCC 17
526 15626
CFTR-lntron2-
- CUGCAAACUCUGCCUCC 17
527 15627
CFTR-lntron2-
- AACAUUCUCUGCUCUCC 17
528 15628
CFTR-lntron2-
- CUGCAAACUUCGUCUCC 17
529 15629
CFTR-lntron2-
- UCAGCCUCUCGAGUAGC 17
530 15630
CFTR-lntron2-
- UCAGUCUCCUGAGUAGC 17
531 15631
CFTR-lntron2-
+ CUUUGGGAGGCCAAGGC 17
532 15632
CFTR-lntron2-
- CGCUGUGUCACCCAGGC 17
533 15633
CFTR-lntron2-
- UGCUCUGUUGCCCAGGC 17
534 15634
CFTR-lntron2-
- UGCUAUGCUGGCCAGGC 17
535 15635
CFTR-lntron2-
- CGCCAUGUUGGCCAGGC 17
536 15636
CFTR-lntron2-
+ ACUCGAGAGGCUGAGGC 17
537 15637
CFTR-lntron2-
- UUGGCCUCCCAAAAUGC 17
538 15638
CFTR-lntron2-
- ACGGGGUUUUGCUAUGC 17
539 15639
CFTR-lntron2-
- CUUCUUCCCUUCUGAUC 17
540 15640
CFTR-lntron2-
+ UGUAGUCCCAGCUACUC 17
541 15641
CFTR-lntron2-
+ CCAAAUGUGUAUUUUUC 17
542 15642
CFTR-lntron2-
+ UGGGAAAGCCAAGGAAG 17
543 15643
446
5535.1 CFTR-lntron2-
- UAAAAGGGUGAGUGAAG 17
544 15644
CFTR-lntron2-
- UCAUUAACAGAAAUCAG 17
545 15645
CFTR-lntron2-
+ AAACCCAGCUACUCGAG 17
546 15646
CFTR-lntron2-
+ CACUCAGAGUGGCUGAG 17
547 15647
CFTR-lntron2-
- CUCUCAGCCACUCUGAG 17
548 15648
CFTR-lntron2-
+ UUCAAAGCUGGGCAUAG 17
549 15649
CFTR-lntron2-
+ UUUGUUUUUAAAAGUAG 17
550 15650
CFTR-lntron2-
- CCCAGGCUGGAGUGUAG 17
551 15651
CFTR-lntron2-
- CAAAGUGUUGGGAUUAG 17
552 15652
CFTR-lntron2-
- UAAUUUUUGUAGAGACG 17
553 15653
CFTR-lntron2-
- UGUGUGUGAGAGAAAGG 17
554 15654
CFTR-lntron2-
+ ACUUUGGGAGGCCAAGG 17
555 15655
CFTR-lntron2-
+ AUUUUGGGAGGCCAAGG 17
556 15656
CFTR-lntron2-
- AAAAGGGUGAGUGAAGG 17
557 15657
CFTR-lntron2-
+ AGGCAAAUGCCACCAGG 17
558 15658
CFTR-lntron2-
+ AUUCGCUUGAACCCAGG 17
559 15659
CFTR-lntron2-
+ AAUCCCAACACUUUGGG 17
560 15660
CFTR-lntron2-
+ AAUCCCAGCAUUUUGGG 17
561 15661
CFTR-lntron2-
+ AAAUUGAAUCAACAUGG 17
562 15662
CFTR-lntron2-
+ AAAUUAGCCAGGCCUGG 17
563 15663
CFTR-lntron2-
+ A A AG A A A A A A U AG A A U G 17
564 15664
CFTR-lntron2- - UUGUAUUUUAGUAGAUG 17 15665
447
5535.1 565
CFTR-lntron2-
+ ACCAAG AG U AGG UG AU G 17
566 15666
CFTR-lntron2-
+ CUGAGAGAUUCUUUAUG 17
567 15667
CFTR-lntron2-
- U A C AG A A A AG C A A AC U G 17
568 15668
CFTR-lntron2-
+ AGCUACUCGAGAGGCUG 17
569 15669
CFTR-lntron2-
- AGGUGGAGAAGCAUGUG 17
570 15670
CFTR-lntron2-
+ AAAUUAGCCAGGCAUUG 17
571 15671
CFTR-lntron2-
+ ACAUAAACCAACAAAAU 17
572 15672
CFTR-lntron2-
- UUCUUUUCU U AU AAAAU 17
573 15673
CFTR-lntron2-
+ UUGAAUUGAAGUAAAAU 17
574 15674
CFTR-lntron2-
- AAUAUCUAAGUUUUAAU 17
575 15675
CFTR-lntron2-
+ UUAAAUUGAAUCAACAU 17
576 15676
CFTR-lntron2-
+ UUUCUUUUAAAUACUAU 17
577 15677
CFTR-lntron2-
- CAAAAUGCUGGGAUUAU 17
578 15678
CFTR-lntron2-
- UGUUUUUUAUUUUUUAU 17
579 15679
CFTR-lntron2-
- UUCUAUUAUUGAACACU 17
580 15680
CFTR-lntron2-
- AAGUGAUCUGCCCACCU 17
581 15681
CFTR-lntron2-
+ CCACUACACUCCAGCCU 17
582 15682
CFTR-lntron2-
+ CCAUUACACUCCAGCCU 17
583 15683
CFTR-lntron2-
- AAGUGAUCUGCCCGCCU 17
584 15684
CFTR-lntron2-
- UGCAAACUCUGCCUCCU 17
585 15685
CFTR-lntron2-
- UGCAAACUUCGUCUCCU 17
586 15686
448
5535.1 CFTR-lntron2-
- AAGGAGCCCUUUGUCCU 17
587 15687
CFTR-lntron2-
- CAGCCUCUCGAGUAGCU 17
588 15688
CFTR-lntron2-
- CAGUCUCCUGAGUAGCU 17
589 15689
CFTR-lntron2-
- UGGCCUCCCAAAAUGCU 17
590 15690
CFTR-lntron2-
- UUCUUCCCUUCUGAUCU 17
591 15691
CFTR-lntron2-
+ AUGCCAGGCCCUAUUCU 17
592 15692
CFTR-lntron2-
- AGCUUUCUACAUAAAGU 17
593 15693
CFTR-lntron2-
+ UUUUGGGAGGCCAAGGU 17
594 15694
CFTR-lntron2-
+ UGAGGAGAAGGCAAGGU 17
595 15695
CFTR-lntron2-
- UGCAAAUGCCAUGAGGU 17
596 15696
CFTR-lntron2-
- UUGGCCUCCCAAAGUGU 17
597 15697
CFTR-lntron2-
- CCUGAAAAAUACACAUU 17
598 15698
CFTR-lntron2-
+ CACUAAUCCCAACACUU 17
599 15699
CFTR-lntron2-
+ CCCUAUUCUAGGCACUU 17
600 15700
CFTR-lntron2-
+ ACUCAAUGUUUUUACUU 17
601 15701
CFTR-lntron2-
- UGGCCUCCCAAAGUGUU 17
602 15702
CFTR-lntron2-
+ CUAUAAUCCCAGCAUUU 17
603 15703
CFTR-lntron2-
- AAUUUAUUGAAAUAUUU 17
604 15704
CFTR-lntron2-
+ ACUAAUCCCAACACUUU 17
605 15705
CFTR-lntron2-
+ UAUAAUCCCAGCAUUUU 17
606 15706
CFTR-lntron2-
+ CUGGGCAAUGUAGUUUU 17
607 15707
CFTR-lntron2- - AAUUCAUUUCCUUUUUU 17 15708
449
5535.1 608
CFTR-lntron2-
- UUCCUUUGUGAAGAGAAAAA 20
609 15709
CFTR-lntron2-
+ CACAUUUAGCCAAGGACAAA 20
610 15710
CFTR-lntron2-
- CAGUUUCCUUUCCAAUCAAA 20
611 15711
CFTR-lntron2-
+ UUCUGUCACUGGCAAUCAAA 20
612 15712
CFTR-lntron2-
- U ACU AG CU UAAG U AAAU AAA 20
613 15713
CFTR-lntron2-
+ CUAUGAAAGAAAAAAUAGAA 20
614 15714
CFTR-lntron2-
+ CAGAUGGGAAAGCCAAGGAA 20
615 15715
CFTR-lntron2-
+ CAAACAAACAAAAAACAUAA 20
616 15716
CFTR-lntron2-
+ ACAUUUGUAUUCAAAUAUAA 20
617 15717
CFTR-lntron2-
- ACAAG U U CAAAAU AAU AU AA 20
618 15718
CFTR-lntron2-
- UUGCCCAGGCUGGAGUGUAA 20
619 15719
CFTR-lntron2-
+ CAAGACCAGCCUGGCCAACA 20
620 15720
CFTR-lntron2-
+ U U U U U U AAAU UG AAU CAACA 20
621 15721
CFTR-lntron2-
+ UUAUAAGAAAAGAAGUAACA 20
622 15722
CFTR-lntron2-
+ UGGAUCAGAUGGGAAAGCCA 20
623 15723
CFTR-lntron2-
+ CCCAACACUUUGGGAGGCCA 20
624 15724
CFTR-lntron2-
+ CCCAGCAUUUUGGGAGGCCA 20
625 15725
CFTR-lntron2-
- CUGGCUAAUUUUUGUAGAGA 20
626 15726
CFTR-lntron2-
- CAUUUCUCCUUUGAUGGAGA 20
627 15727
CFTR-lntron2-
- UUUGUUGAAUGAAUCCAUGA 20
628 15728
CFTR-lntron2-
- CUAGAAUAGGGCCUGGCAUA 20
629 15729
450
5535.1 CFTR-l ntron2-
+ AACAAAAAUAAUAGAACGUA 20
630 15730
CFTR-l ntron2-
- AUGUGAUACAUUUGUAUUUA 20
631 15731
CFTR-l ntron2-
+ U U U AU AAG AAAAG AAG U AAC 20
632 15732
CFTR-l ntron2-
- UGGCUAAUUUUUGUAGAGAC 20
633 15733
CFTR-l ntron2-
- UCCUGAGUAGCUGGGACUAC 20
634 15734
CFTR-l ntron2-
- UCUCGAGUAGCUGGGU UUAC 20
635 15735
CFTR-l ntron2-
+ CAGGAGAAUCACUUGAACCC 20
636 15736
CFTR-l ntron2-
+ ACUGAGAUUCGCUUGAACCC 20
637 15737
CFTR-l ntron2-
- AGAGUCUCGCUGUGUCACCC 20
638 15738
CFTR-l ntron2-
- AGUGGCGUGAGCCACUGCCC 20
639 15739
CFTR-l ntron2-
- AGAGUCUUGCUCUGUUGCCC 20
640 15740
CFTR-l ntron2-
+ CUGAGAUUUGAAGACAAGCC 20
641 15741
CFTR-l ntron2-
+ UCAGGAGUUCAAGACCAGCC 20
642 15742
CFTR-l ntron2-
+ CACACCACUACACUCCAGCC 20
643 15743
CFTR-l ntron2-
+ UGCACCAUUACACUCCAGCC 20
644 15744
CFTR-l ntron2-
+ C U A A A A U AC A A A A A U U AG C C 20
645 15745
CFTR-l ntron2-
+ CGUCUCUACAAAAAUUAGCC 20
646 15746
CFTR-l ntron2-
- CAGGCAUGCACCACCAGGCC 20
647 15747
CFTR-l ntron2-
+ CUACAAAAAUUAGCCAGGCC 20
648 15748
CFTR-l ntron2-
+ CUCUAAAGGAGUAAUAGGCC 20
649 15749
CFTR-l ntron2-
- CAAGUGCCUAGAAUAGGGCC 20
650 15750
CFTR-l ntron2- - CAGGCACUCGCCACAAUGCC 20 15751
451
5535.1 651
CFTR-lntron2-
- UUGAGUACCUGUUACAUGCC 20
652 15752
CFTR-lntron2-
+ UUGAGUAUAUACCAUAUGCC 20
653 15753
CFTR-lntron2-
- UCACUGCAAACUCUGCCUCC 20
654 15754
CFTR-lntron2-
- UCACUGCAAACUUCGUCUCC 20
655 15755
CFTR-lntron2-
- AUCUCAGUCUCCUGAGUAGC 20
656 15756
CFTR-lntron2-
+ ACACUUUGGGAGGCCAAGGC 20
657 15757
CFTR-lntron2-
- UCUCGCUGUGUCACCCAGGC 20
658 15758
CFTR-lntron2-
- UCUUGCUCUGUUGCCCAGGC 20
659 15759
CFTR-lntron2-
- UUUUGCUAUGCUGGCCAGGC 20
660 15760
CFTR-lntron2-
- UUUCGCCAUGUUGGCCAGGC 20
661 15761
CFTR-lntron2-
+ ACUCUAAAGGAGUAAUAGGC 20
662 15762
CFTR-lntron2-
- ACCUUGGCCUCCCAAAAUGC 20
663 15763
CFTR-lntron2-
- UGGUGGCAUUUGCCUUAUGC 20
664 15764
CFTR-lntron2-
+ UCACCCUUUUAUCUGGCAUC 20
665 15765
CFTR-lntron2-
+ CCUUCACUCACCCUUUUAUC 20
666 15766
CFTR-lntron2-
+ CGGGCAGAUCACUUGAGGUC 20
667 15767
CFTR-lntron2-
+ UGGGCAGAUCACUUGAGGUC 20
668 15768
CFTR-lntron2-
+ CAUGGUGGAAACCAUACUUC 20
669 15769
CFTR-lntron2-
+ AAACCAAAUGUGUAUUUUUC 20
670 15770
CFTR-lntron2-
+ AGAUGGGAAAGCCAAGGAAG 20
671 15771
CFTR-lntron2-
- AGAUAAAAGGGUGAGUGAAG 20
672 15772
452
5535.1 CFTR-lntron2-
+ UGUAAACCCAGCUACUCGAG 20
673 15773
CFTR-lntron2-
+ AUAUUCAAAGCUGGGCAUAG 20
674 15774
CFTR-lntron2-
- UCACCCAGGCUGGAGUGUAG 20
675 15775
CFTR-lntron2-
- UCCCAAAGUGUUGGGAUUAG 20
676 15776
CFTR-lntron2-
+ ACAAAGGGCUCCUUCUUUCG 20
677 15777
CFTR-lntron2-
- CUCUGUGUGUGAGAGAAAGG 20
678 15778
CFTR-lntron2-
+ AACACUUUGGGAGGCCAAGG 20
679 15779
CFTR-lntron2-
+ AGCAUUUUGGGAGGCCAAGG 20
680 15780
CFTR-lntron2-
+ UAAGAAAAGAAGUAACAGGG 20
681 15781
CFTR-lntron2-
- AGGUGGAGAAGCAUGUGGGG 20
682 15782
CFTR-lntron2-
+ ACUAAUCCCAACACUUUGGG 20
683 15783
CFTR-lntron2-
+ UAUAAUCCCAGCAUUUUGGG 20
684 15784
CFTR-lntron2-
+ CAAAAAUUAGCCAGGCCUGG 20
685 15785
CFTR-lntron2-
+ AUGAAAGAAAAAAUAGAAUG 20
686 15786
CFTR-lntron2-
- UGGUGUGUGCAAAUGCCAUG 20
687 15787
CFTR-lntron2-
- UUUUUGUAUUUUAGUAGAUG 20
688 15788
CFTR-lntron2-
- U U U U AC AG AAAAG CAAAC U G 20
689 15789
CFTR-lntron2-
+ CCCAGCUACUCGAGAGGCUG 20
690 15790
CFTR-lntron2-
+ C A A A A A UUAGCCAGGCAUUG 20
691 15791
CFTR-lntron2-
+ CAAGGCGGGCAGAUCACUUG 20
692 15792
CFTR-lntron2-
+ CAAGGUGGGCAGAUCACUUG 20
693 15793
CFTR-lntron2- - UACUUCUUUUCUUAUAAAAU 20 15794
453
5535.1 694
CFTR-lntron2-
+ UUGUUGAAUUGAAGUAAAAU 20
695 15795
CFTR-lntron2-
+ UAUGAAAGAAAAAAUAGAAU 20
696 15796
CFTR-lntron2-
- UAUCCCCAAGUGCCUAGAAU 20
697 15797
CFTR-lntron2-
- UUGAAUAUCUAAGUUUUAAU 20
698 15798
CFTR-lntron2-
+ U U U U U AAAU UG AAU CAACAU 20
699 15799
CFTR-lntron2-
+ UGUUUUCUUUUAAAUACUAU 20
700 15800
CFTR-lntron2-
- UCCCAAAAUGCUGGGAUUAU 20
701 15801
CFTR-lntron2-
- UUUUGUUUUUUAUUUUUUAU 20
702 15802
CFTR-lntron2-
+ CAGGCCCUAUUCUAGGCACU 20
703 15803
CFTR-lntron2-
- CUCAAGUGAUCUGCCCACCU 20
704 15804
CFTR-lntron2-
- ACUUUGUACCUCUGCACCCU 20
705 15805
CFTR-lntron2-
+ ACACCACUACACUCCAGCCU 20
706 15806
CFTR-lntron2-
- CUCAAGUGAUCUGCCCGCCU 20
707 15807
CFTR-lntron2-
- CACUGCAAACUCUGCCUCCU 20
708 15808
CFTR-lntron2-
- CACUGCAAACUUCGUCUCCU 20
709 15809
CFTR-lntron2-
- CCUCAGCCUCUCGAGUAGCU 20
710 15810
CFTR-lntron2-
- UCUCAGUCUCCUGAGUAGCU 20
711 15811
CFTR-lntron2-
- CCUUGGCCUCCCAAAAUGCU 20
712 15812
CFTR-lntron2-
+ CAUAUGCCAGGCCCUAUUCU 20
713 15813
CFTR-lntron2-
+ UUUACUUAAGCUAGUAAAUU 20
714 15814
CFTR-lntron2-
- U U U CCUG AAAAAU ACACAU U 20
715 15815
454
5535.1 CFTR-lntron2-
- UUUGUUUUUUAUUUUUUAUU 20
716 15816
CFTR-lntron2-
+ CGCCACUAAUCCCAACACUU 20
717 15817
CFTR-lntron2-
+ AGGCCCUAUUCUAGGCACUU 20
718 15818
CFTR-lntron2-
- CCUUGGCCUCCCAAAGUGUU 20
719 15819
CFTR-lntron2-
+ CACCUAUAAUCCCAGCAUUU 20
720 15820
CFTR-lntron2-
- UGAAAUUUAUUGAAAUAUUU 20
721 15821
CFTR-lntron2-
+ ACCUAUAAUCCCAGCAUUUU 20
722 15822
CFTR-lntron2-
- UUAAAUUCAUUUCCUUUUUU 20
723 15823
Table 38A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within intron 2, have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 38A
Figure imgf000456_0001
455
5535.1 729
CFTR-lntron2-
+ GCCUUUUUUCUCUUCACAA 19
730 15830
CFTR-lntron2-
+ GAAAGCCUUUUUUCUCUUCACAA 23
731 15831
CFTR-lntron2-
+ GGCUCUAAAUCACUCUAA 18
732 15832
CFTR-lntron2-
+ GCAUUUGAGUCCUUGGUCCCA 21
733 15833
CFTR-lntron2-
+ GGCAUUUGAGUCCUUGGUCCCA 22
734 15834
CFTR-lntron2-
+ GUGGCAUUUGAGUCCUUGGUCCCA 24
735 15835
CFTR-lntron2-
+ GCCAUUACCUUAAGACUUCCCA 22
736 15836
CFTR-lntron2-
+ GUAGAGAGACCAGGAGAGCA 20
737 15837
CFTR-lntron2-
+ GUCCUUAAAGAUAGGAGCA 19
738 15838
CFTR-lntron2-
+ GGUCCUUAAAGAUAGGAGCA 20
739 15839
CFTR-lntron2-
+ GUGGUCCUUAAAGAUAGGAGCA 22
740 15840
CFTR-lntron2-
+ GAACUUGUCAAUAUACCUGCA 21
741 15841
CFTR-lntron2-
+ GCACACUGCAGUUAUGUA 18
742 15842
CFTR-lntron2-
+ GUUUGCACACUGCAGUUAUGUA 22
743 15843
CFTR-lntron2-
+ GGUUUGCACACUGCAGUUAUGUA 23
744 15844
CFTR-lntron2-
+ GGUCGGGGAAUUUCUUUA 18
745 15845
CFTR-lntron2-
+ GCAAGGUCGGGGAAUUUCUUUA 22
746 15846
CFTR-lntron2-
+ GGCAAGGUCGGGGAAUUUCUUUA 23
747 15847
CFTR-lntron2-
+ G CCACAAAU UG U U AG CACC 19
748 15848
CFTR-lntron2-
+ GUGCCACAAAUUGUUAGCACC 21
749 15849
CFTR-lntron2-
+ GGUGCCACAAAUUGUUAGCACC 22
750 15850
456
5535.1 CFTR-lntron2-
+ GAAGCCAGGGUCACUUCCC 19
751 15851
CFTR-lntron2-
+ GUGAAGCCAGGGUCACUUCCC 21
752 15852
CFTR-lntron2-
+ GCAGUUAUGAAAUGUGAAGC 20
753 15853
CFTR-lntron2-
+ GGCAGUUAUGAAAUGUGAAGC 21
754 15854
CFTR-lntron2-
+ GCCUGGCAAUCUCUAAGC 18
755 15855
CFTR-lntron2-
+ GACAAGCCUGGCAAUCUCUAAGC 23
756 15856
CFTR-lntron2-
+ GGCAAUACAGACCUCAGC 18
757 15857
CFTR-lntron2-
+ GCAAGGCAAUACAGACCUCAGC 22
758 15858
CFTR-lntron2-
+ GAGCAAGGCAAUACAGACCUCAGC 24
759 15859
CFTR-lntron2-
+ GCCAUUUCACAUUCCAUC 18
760 15860
CFTR-lntron2-
+ GCUAGCCAUUUCACAUUCCAUC 22
761 15861
CFTR-lntron2-
+ GGGUAAGCACUAUGACUC 18
762 15862
CFTR-lntron2-
+ GGGGUAAGCACUAUGACUC 19
763 15863
CFTR-lntron2-
+ GCACUAUGACUCAAGAGUCUC 21
764 15864
CFTR-lntron2-
+ GAGGAGAAGGCAAGGUCG 18
765 15865
CFTR-lntron2-
+ GUUUGUACUGGCAUAGCAUUG 21
766 15866
CFTR-lntron2-
+ GGUUUGUACUGGCAUAGCAUUG 22
767 15867
CFTR-lntron2-
+ GGGUUUGUACUGGCAUAGCAUUG 23
768 15868
CFTR-lntron2-
+ GCAAAUGCCACCAGGUGGCAU 21
769 15869
CFTR-lntron2-
+ GGCAAAUGCCACCAGGUGGCAU 22
770 15870
CFTR-lntron2-
+ GAUAAUGAUGCUUUCCACU 19
771 15871
CFTR-lntron2- + GCCUAGUUCAUUCUAGACU 19 15872
457
5535.1 772
CFTR-lntron2-
+ GCUACUCCCACUAGCUUAAUUCU 23
773 15873
CFTR-lntron2-
+ GCCCUUGAUCUUAGAAGU 18
774 15874
CFTR-lntron2-
+ GGCCCUUGAUCUUAGAAGU 19
775 15875
CFTR-lntron2-
+ GCUGGCCCUUGAUCUUAGAAGU 22
776 15876
CFTR-lntron2-
- GACCAGCUUUCUACAUAAA 19
777 15877
CFTR-lntron2-
- GGACCAGCUUUCUACAUAAA 20
778 15878
CFTR-lntron2-
- GACCGGACCAGCUUUCUACAUAAA 24
779 15879
CFTR-lntron2-
- GCACAGGCCUGAUGCCAGAUAA 22
780 15880
CFTR-lntron2-
- GCUUUGAAUAUCUAAGUUUUAA 22
781 15881
CFTR-lntron2-
- G AAAAAU ACACAU UUGGUUUCA 22
782 15882
CFTR-lntron2-
- G C U U A AG U AAA U A A A AG G A 19
783 15883
CFTR-lntron2-
- GCUCAAUUUUGUGACCAUGGA 21
784 15884
CFTR-lntron2-
- GGCUCAAUUUUGUGACCAUGGA 22
785 15885
CFTR-lntron2-
- GUUUUAAUUGGAUGCUGA 18
786 15886
CFTR-lntron2-
- GAAUGGUAGUCCCCCCCAUA 20
787 15887
CFTR-lntron2-
- GGAAUGGUAGUCCCCCCCAUA 21
788 15888
CFTR-lntron2-
- GACAAGUUCAAAAUAAUAUA 20
789 15889
CFTR-lntron2-
- GCUCUCAUUAGCAAGCUUCUA 21
790 15890
CFTR-lntron2-
- GGCUCUCAUUAGCAAGCUUCUA 22
791 15891
CFTR-lntron2-
- GGGCUCUCAUUAGCAAGCUUCUA 23
792 15892
CFTR-lntron2-
- GUUCAAAAUAAUAUAAUGGGUA 22
793 15893
458
5535.1 CFTR-lntron2-
- GAUAAUAUACUUUGCCAGUUA 21
794 15894
CFTR-lntron2-
- GAGAUAAUAUACUUUGCCAGUUA 23
795 15895
CFTR-lntron2-
- GUAUUUAUGGCCAGAUAGAGAAC 23
796 15896
CFTR-lntron2-
- GAUGUAUCCCCAAGUGCC 18
797 15897
CFTR-lntron2-
- GUUCCUAAAACUACAUUGCC 20
798 15898
CFTR-lntron2-
- GAAAAAUCCCAGAGACUC 18
799 15899
CFTR-lntron2-
- GUGAAAAAUCCCAGAGACUC 20
800 15900
CFTR-lntron2-
- GCCAGAUAAAAGGGUGAGUGAAG 23
801 15901
CFTR-lntron2-
- GUCUUAUUAGAGACCAUGAG 20
802 15902
CFTR-lntron2-
- GCCUGAUGCCAGAUAAAAGG 20
803 15903
CFTR-lntron2-
- GUACCUGUUACAUGCCAGG 19
804 15904
CFTR-lntron2-
- GAGUACCUGUUACAUGCCAGG 21
805 15905
CFTR-lntron2-
- GAAUGAUUAAUCAGAGUAGGG 21
806 15906
CFTR-lntron2-
- GGAAUGAUUAAUCAGAGUAGGG 22
807 15907
CFTR-lntron2-
- GGGAAUGAUUAAUCAGAGUAGGG 23
808 15908
CFTR-lntron2-
- GAACAUGAAUCUGAAUUUG 19
809 15909
CFTR-lntron2-
- GCCAGAUAGAGAACAUGAAU 20
810 15910
CFTR-lntron2-
- GAUGCUGAGGGAAUGAUUAAU 21
811 15911
CFTR-lntron2-
- GGAUGCUGAGGGAAUGAUUAAU 22
812 15912
CFTR-lntron2-
- GCUUUCAAAACCUUUAUAU 19
813 15913
CFTR-lntron2-
- GAAUAUCUCCUCUCAGCCACU 21
814 15914
CFTR-lntron2- - GUAGAAUAUCUCCUCUCAGCCACU 24 15915
459
5535.1 815
CFTR-lntron2-
- GCUCCAUAUUUAGCUUCUUACU 22
816 15916
CFTR-lntron2-
- GUCUGUAUUGCCUUGCUCUCU 21
817 15917
CFTR-lntron2-
- GGUCUGUAUUGCCUUGCUCUCU 22
818 15918
CFTR-lntron2-
- GAGGUCUGUAUUGCCUUGCUCUCU 24
819 15919
CFTR-lntron2-
- GUUUCCUUUCCAAUCAAAAGGU 22
820 15920
CFTR-lntron2-
- GCCCCGGCCUAUUACUCCUU 20
821 15921
CFTR-lntron2-
- GUCAGGAUAUGAACUUUUU 19
822 15922
CFTR-lntron2-
- GUAGUCAGGAUAUGAACUUUUU 22
823 15923
Table 38B provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within intron 2, have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 38B
Figure imgf000461_0001
460
5535.1 CFTR-lntron2-
+ UUUAUUUACUUAAGCUAGUAAA 22
829 15929
CFTR-lntron2-
+ UUUUAUUUACUUAAGCUAGUAAA 23
830 15930
CFTR-lntron2-
+ CUUUUAUUUACUUAAGCUAGUAAA 24
831 15931
CFTR-lntron2-
+ CCUUUUUUCUCUUCACAA 18
832 15932
CFTR-lntron2-
+ AGCCUUUUUUCUCUUCACAA 20
233 15333
CFTR-lntron2-
+ AAGCCUUUUUUCUCUUCACAA 21
833 15933
CFTR-lntron2-
+ AAAGCCUUUUUUCUCUUCACAA 22
834 15934
CFTR-lntron2-
+ UGAAAGCCUUUUUUCUCUUCACAA 24
835 15935
CFTR-lntron2-
+ ACCUUCUCCAUCAAAGGAGAA 21
836 15936
CFTR-lntron2-
+ CACCUUCUCCAUCAAAGGAGAA 22
837 15937
CFTR-lntron2-
+ U CACCU U CU CCAU CAAAGG AG AA 23
838 15938
CFTR-lntron2-
+ CUCACCUUCUCCAUCAAAGGAGAA 24
839 15939
CFTR-lntron2-
+ UGGCUCUAAAUCACUCUAA 19
840 15940
CFTR-lntron2-
+ AUGGCUCUAAAUCACUCUAA 20
250 15350
CFTR-lntron2-
+ CAUGGCUCUAAAUCACUCUAA 21
841 15941
CFTR-lntron2-
+ ACAUGGCUCUAAAUCACUCUAA 22
842 15942
CFTR-lntron2-
+ AACAUGGCUCUAAAUCACUCUAA 23
843 15943
CFTR-lntron2-
+ AAACAUGGCUCUAAAUCACUCUAA 24
844 15944
CFTR-lntron2-
+ UAGACUAUGAGUGGCCCA 18
845 15945
CFTR-lntron2-
+ CUAGACUAUGAGUGGCCCA 19
846 15946
CFTR-lntron2-
+ UCUAGACUAUGAGUGGCCCA 20
261 15361
CFTR-lntron2- + UUCUAGACUAUGAGUGGCCCA 21 15947
461
5535.1 847
CFTR-lntron2-
+ AUUCUAGACUAUGAGUGGCCCA 22
848 15948
CFTR-lntron2-
+ CAUUCUAGACUAUGAGUGGCCCA 23
849 15949
CFTR-lntron2-
+ UCAUUCUAGACUAUGAGUGGCCCA 24
850 15950
CFTR-lntron2-
+ UUUGAGUCCUUGGUCCCA 18
851 15951
CFTR-lntron2-
+ AUUUGAGUCCUUGGUCCCA 19
852 15952
CFTR-lntron2-
+ CAUUUGAGUCCUUGGUCCCA 20
853 15953
CFTR-lntron2-
+ UGGCAUUUGAGUCCUUGGUCCCA 23
854 15954
CFTR-lntron2-
+ UUACCUUAAGACUUCCCA 18
855 15955
CFTR-lntron2-
+ AUUACCUUAAGACUUCCCA 19
856 15956
CFTR-lntron2-
+ CAUUACCUUAAGACUUCCCA 20
263 15363
CFTR-lntron2-
+ CCAUUACCUUAAGACUUCCCA 21
857 15957
CFTR-lntron2-
+ AGCCAUUACCUUAAGACUUCCCA 23
858 15958
CFTR-lntron2-
+ UAGCCAUUACCUUAAGACUUCCCA 24
859 15959
CFTR-lntron2-
+ AGAGAGACCAGGAGAGCA 18
860 15960
CFTR-lntron2-
+ UAGAGAGACCAGGAGAGCA 19
861 15961
CFTR-lntron2-
+ UCCUUAAAGAUAGGAGCA 18
862 15962
CFTR-lntron2-
+ UGGUCCUUAAAGAUAGGAGCA 21
863 15963
CFTR-lntron2-
+ CGUGGUCCUUAAAGAUAGGAGCA 23
864 15964
CFTR-lntron2-
+ UCGUGGUCCUUAAAGAUAGGAGCA 24
865 15965
CFTR-lntron2-
+ CUUGUCAAUAUACCUGCA 18
866 15966
CFTR-lntron2-
+ ACUUGUCAAUAUACCUGCA 19
867 15967
462
5535.1 CFTR-lntron2-
+ AACUUGUCAAUAUACCUGCA 20
868 15968
CFTR-lntron2-
+ UGAACUUGUCAAUAUACCUGCA 22
869 15969
CFTR-lntron2-
+ UUGAACUUGUCAAUAUACCUGCA 23
870 15970
CFTR-lntron2-
+ UUUGAACUUGUCAAUAUACCUGCA 24
871 15971
CFTR-lntron2-
+ AGAUGGGAAAGCCAAGGA 18
872 15972
CFTR-lntron2-
+ CAGAUGGGAAAGCCAAGGA 19
873 15973
CFTR-lntron2-
+ UCAGAUGGGAAAGCCAAGGA 20
280 15380
CFTR-lntron2-
+ CCUGACUACAAUCUUGGA 18
874 15974
CFTR-lntron2-
+ UCCUGACUACAAUCUUGGA 19
875 15975
CFTR-lntron2-
+ AUCCUGACUACAAUCUUGGA 20
876 15976
CFTR-lntron2-
+ UAUCCUGACUACAAUCUUGGA 21
877 15977
CFTR-lntron2-
+ AUAUCCUGACUACAAUCUUGGA 22
878 15978
CFTR-lntron2-
+ CAUAUCCUGACUACAAUCUUGGA 23
879 15979
CFTR-lntron2-
+ UCAUAUCCUGACUACAAUCUUGGA 24
880 15980
CFTR-lntron2-
+ UGCACACUGCAGUUAUGUA 19
881 15981
CFTR-lntron2-
+ UUGCACACUGCAGUUAUGUA 20
882 15982
CFTR-lntron2-
+ UUUGCACACUGCAGUUAUGUA 21
883 15983
CFTR-lntron2-
+ UGGUUUGCACACUGCAGUUAUGUA 24
884 15984
CFTR-lntron2-
+ AGGUCGGGGAAUUUCUUUA 19
885 15985
CFTR-lntron2-
+ AAGGUCGGGGAAUUUCUUUA 20
886 15986
CFTR-lntron2-
+ CAAGGUCGGGGAAUUUCUUUA 21
887 15987
463
5535.1 CFTR-lntron2-
+ AGGCAAGGUCGGGGAAUUUCUUUA 24
888 15988
CFTR-lntron2-
+ CCACAAAUUGUUAGCACC 18
889 15989
CFTR-lntron2-
+ UGCCACAAAUUGUUAGCACC 20
890 15990
CFTR-lntron2-
+ UGGUGCCACAAAUUGUUAGCACC 23
891 15991
CFTR-lntron2-
+ UUGGUGCCACAAAUUGUUAGCACC 24
892 15992
CFTR-lntron2-
+ AAGCCAGGGUCACUUCCC 18
893 15993
CFTR-lntron2-
+ UGAAGCCAGGGUCACUUCCC 20
894 15994
CFTR-lntron2-
+ UGUGAAGCCAGGGUCACUUCCC 22
895 15995
CFTR-lntron2-
+ AUGUGAAGCCAGGGUCACUUCCC 23
896 15996
CFTR-lntron2-
+ AAUGUGAAGCCAGGGUCACUUCCC 24
897 15997
CFTR-lntron2-
+ AGUUAUGAAAUGUGAAGC 18
898 15998
CFTR-lntron2-
+ CAGUUAUGAAAUGUGAAGC 19
899 15999
CFTR-lntron2-
+ AGGCAGUUAUGAAAUGUGAAGC 22
900 16000
CFTR-lntron2-
+ AAGGCAGUUAUGAAAUGUGAAGC 23
901 16001
CFTR-lntron2-
+ CAAGGCAGUUAUGAAAUGUGAAGC 24
902 16002
CFTR-lntron2-
+ AGCCUGGCAAUCUCUAAGC 19
903 16003
CFTR-lntron2-
+ AAGCCUGGCAAUCUCUAAGC 20
904 16004
CFTR-lntron2-
+ CAAGCCUGGCAAUCUCUAAGC 21
905 16005
CFTR-lntron2-
+ ACAAGCCUGGCAAUCUCUAAGC 22
906 16006
CFTR-lntron2-
+ AGACAAGCCUGGCAAUCUCUAAGC 24
907 16007
CFTR-lntron2-
+ AGGCAAUACAGACCUCAGC 19
908 16008
CFTR-lntron2- + AAGGCAAUACAGACCUCAGC 20 15422
464
5535.1 322
CFTR-lntron2-
+ CAAGGCAAUACAGACCUCAGC 21
909 16009
CFTR-lntron2-
+ AGCAAGGCAAUACAGACCUCAGC 23
910 16010
CFTR-lntron2-
+ AGCCAUUUCACAUUCCAUC 19
911 16011
CFTR-lntron2-
+ UAGCCAUUUCACAUUCCAUC 20
912 16012
CFTR-lntron2-
+ CUAGCCAUUUCACAUUCCAUC 21
913 16013
CFTR-lntron2-
+ UGCUAGCCAUUUCACAUUCCAUC 23
914 16014
CFTR-lntron2-
+ AUGCUAGCCAUUUCACAUUCCAUC 24
915 16015
CFTR-lntron2-
+ AGGGGUAAGCACUAUGACUC 20
916 16016
CFTR-lntron2-
+ AAGGGGUAAGCACUAUGACUC 21
917 16017
CFTR-lntron2-
+ CAAGGGGUAAGCACUAUGACUC 22
918 16018
CFTR-lntron2-
+ CCAAGGGGUAAGCACUAUGACUC 23
919 16019
CFTR-lntron2-
+ CCCAAGGGGUAAGCACUAUGACUC 24
920 16020
CFTR-lntron2-
+ CUAUGACUCAAGAGUCUC 18
921 16021
CFTR-lntron2-
+ ACUAUGACUCAAGAGUCUC 19
922 16022
CFTR-lntron2-
+ CACUAUGACUCAAGAGUCUC 20
331 15431
CFTR-lntron2-
+ AGCACUAUGACUCAAGAGUCUC 22
923 16023
CFTR-lntron2-
+ AAGCACUAUGACUCAAGAGUCUC 23
924 16024
CFTR-lntron2-
+ UAAGCACUAUGACUCAAGAGUCUC 24
925 16025
CFTR-lntron2-
+ UGAGGAGAAGGCAAGGUCG 19
926 16026
CFTR-lntron2-
+ CUGAGGAGAAGGCAAGGUCG 20
349 15449
CFTR-lntron2-
+ UUAAAUUGAAUCAACAUG 18
927 16027
465
5535.1 CFTR-lntron2-
+ UUUAAAUUGAAUCAACAUG 19
928 16028
CFTR-lntron2-
+ UUUUAAAUUGAAUCAACAUG 20
358 15458
CFTR-lntron2-
+ UGUACUGGCAUAGCAUUG 18
929 16029
CFTR-lntron2-
+ UUGUACUGGCAUAGCAUUG 19
930 16030
CFTR-lntron2-
+ UUUGUACUGGCAUAGCAUUG 20
931 16031
CFTR-lntron2-
+ UGGGUUUGUACUGGCAUAGCAUUG 24
932 16032
CFTR-lntron2-
+ AGGCAAAUGCCACCAGGUGGCAU 23
933 16033
CFTR-lntron2-
+ AAGGCAAAUGCCACCAGGUGGCAU 24
934 16034
CFTR-lntron2-
+ AUAAUGAUGCUUUCCACU 18
935 16035
CFTR-lntron2-
+ AGAUAAUGAUGCUUUCCACU 20
936 16036
CFTR-lntron2-
+ CCUAGUUCAUUCUAGACU 18
937 16037
CFTR-lntron2-
+ AGCCUAGUUCAUUCUAGACU 20
938 16038
CFTR-lntron2-
+ CAGCCUAGUUCAUUCUAGACU 21
939 16039
CFTR-lntron2-
+ UCAGCCUAGUUCAUUCUAGACU 22
940 16040
CFTR-lntron2-
+ CUCAGCCUAGUUCAUUCUAGACU 23
941 16041
CFTR-lntron2-
+ ACUCAGCCUAGUUCAUUCUAGACU 24
942 16042
CFTR-lntron2-
+ CCAUAACAUUUGGUUACU 18
943 16043
CFTR-lntron2-
+ UCCAUAACAUUUGGUUACU 19
944 16044
CFTR-lntron2-
+ AUCCAUAACAUUUGGUUACU 20
945 16045
CFTR-lntron2-
+ CAUCCAUAACAUUUGGUUACU 21
946 16046
CFTR-lntron2-
+ CCAUCCAUAACAUUUGGUUACU 22
947 16047
CFTR-lntron2- + CCCAUCCAUAACAUUUGGUUACU 23 16048
466
5535.1 948
CFTR-lntron2-
+ UCCCAUCCAUAACAUUUGGUUACU 24
949 16049
CFTR-lntron2-
+ UCCCACUAGCUUAAUUCU 18
950 16050
CFTR-lntron2-
+ CUCCCACUAGCUUAAUUCU 19
951 16051
CFTR-lntron2-
+ ACUCCCACUAGCUUAAUUCU 20
952 16052
CFTR-lntron2-
+ UACUCCCACUAGCUUAAUUCU 21
953 16053
CFTR-lntron2-
+ CUACUCCCACUAGCUUAAUUCU 22
954 16054
CFTR-lntron2-
+ UGCUACUCCCACUAGCUUAAUUCU 24
955 16055
CFTR-lntron2-
+ UGGCCCUUGAUCUUAGAAGU 20
956 16056
CFTR-lntron2-
+ CUGGCCCUUGAUCUUAGAAGU 21
957 16057
CFTR-lntron2-
+ AGCUGGCCCUUGAUCUUAGAAGU 23
958 16058
CFTR-lntron2-
+ AAGCUGGCCCUUGAUCUUAGAAGU 24
959 16059
CFTR-lntron2-
- ACCAGCUUUCUACAUAAA 18
960 16060
CFTR-lntron2-
- CGGACCAGCUUUCUACAUAAA 21
961 16061
CFTR-lntron2-
- CCGGACCAGCUUUCUACAUAAA 22
962 16062
CFTR-lntron2-
- ACCGGACCAGCUUUCUACAUAAA 23
963 16063
CFTR-lntron2-
- AGGCCUGAUGCCAGAUAA 18
964 16064
CFTR-lntron2-
- CAGGCCUGAUGCCAGAUAA 19
965 16065
CFTR-lntron2-
- ACAGGCCUGAUGCCAGAUAA 20
966 16066
CFTR-lntron2-
- CACAGGCCUGAUGCCAGAUAA 21
967 16067
CFTR-lntron2-
- AGCA CAGGCCUGAUGCCAGAUAA 23
968 16068
CFTR-lntron2-
- CAGCACAGGCCUGAUGCCAGAUAA 24
969 16069
467
5535.1 CFTR-lntron2-
- CUUUGAAUAUCUAAGUUUUAA 21
970 16070
CFTR-lntron2-
- AGCUUUGAAUAUCUAAGUUUUAA 23
971 16071
CFTR-lntron2-
- CAG CU U UG AAU AU CU AAG U U U U AA 24
972 16072
CFTR-lntron2-
- UGCACCAAAGUAAAAACA 18
973 16073
CFTR-lntron2-
- U U G C ACCAAAG U AAAAACA 19
974 16074
CFTR-lntron2-
- AU UG CACCAAAG U AAAAACA 20
975 16075
CFTR-lntron2-
- UAU UG CACCAAAG U AAAAACA 21
976 16076
CFTR-lntron2-
- U UAU UG CACCAAAG U AAAAACA 22
977 16077
CFTR-lntron2-
- AUUAUUGCACCAAAGUAAAAACA 23
978 16078
CFTR-lntron2-
- AAU UAU UG CACCAAAG U AAAAACA 24
979 16079
CFTR-lntron2-
- AAAAAUACACAUUUGGUUUCA 21
980 16080
CFTR-lntron2-
- UGAAAAAUACACAUUUGGUUUCA 23
981 16081
CFTR-lntron2-
- CUG AAAAAU ACACAU UUGGUUUCA 24
982 16082
CFTR-lntron2-
- CU U AAG U AAA U A A A AG G A 18
983 16083
CFTR-lntron2-
- AGCUUAAGUAAAUAAAAGGA 20
984 16084
CFTR-lntron2-
- CAAUUUUGUGACCAUGGA 18
985 16085
CFTR-lntron2-
- UCAAUUUUGUGACCAUGGA 19
986 16086
CFTR-lntron2-
- CUCAAUUUUGUGACCAUGGA 20
987 16087
CFTR-lntron2-
- UGGCUCAAUUUUGUGACCAUGGA 23
988 16088
CFTR-lntron2-
- CUGGCUCAAUUUUGUGACCAUGGA 24
989 16089
CFTR-lntron2-
- AGUUUUAAUUGGAUGCUGA 19
990 16090
CFTR-lntron2- - AAGUUUUAAUUGGAUGCUGA 20 15382
468
5535.1 282
CFTR-lntron2-
- UAAGUUUUAAUUGGAUGCUGA 21
991 16091
CFTR-lntron2-
- CUAAGUUUUAAUUGGAUGCUGA 22
992 16092
CFTR-lntron2-
- UCUAAGUUUUAAUUGGAUGCUGA 23
993 16093
CFTR-lntron2-
- AUCUAAGUUUUAAUUGGAUGCUGA 24
994 16094
CFTR-lntron2-
- AUGGUAGUCCCCCCCAUA 18
995 16095
CFTR-lntron2-
- AAUGGUAGUCCCCCCCAUA 19
996 16096
CFTR-lntron2-
- AGGAAUGGUAGUCCCCCCCAUA 22
997 16097
CFTR-lntron2-
- UAGGAAUGGUAGUCCCCCCCAUA 23
998 16098
CFTR-lntron2-
- CUAGGAAUGGUAGUCCCCCCCAUA 24
999 16099
CFTR-lntron2-
- CAAG UU CAAAAU AAU AU A 18
1000 16100
CFTR-lntron2-
- ACAAG U U CAAAAU AAU AU A 19
1001 16101
CFTR-lntron2-
- UGACAAGUUCAAAAUAAUAUA 21
1002 16102
CFTR-lntron2-
- UUGACAAGUUCAAAAUAAUAUA 22
1003 16103
CFTR-lntron2-
- AU UG ACAAG U U CAAAAU AAU AU A 23
1004 16104
CFTR-lntron2-
- U AU UG ACAAG U U CAAAAU AAU AU A 24
1005 16105
CFTR-lntron2-
- CUCAUUAGCAAGCUUCUA 18
1006 16106
CFTR-lntron2-
- UCUCAUUAGCAAGCUUCUA 19
1007 16107
CFTR-lntron2-
- CUCUCAUUAGCAAGCUUCUA 20
290 15390
CFTR-lntron2-
- AGGGCUCUCAUUAGCAAGCUUCUA 24
1008 16108
CFTR-lntron2-
- AAAAUAAUAUAAUGGGUA 18
1009 16109
CFTR-lntron2-
- CAAAAUAAUAUAAUGGGUA 19
1010 16110
469
5535.1 CFTR-lntron2-
- UCAAAAUAAUAUAAUGGGUA 20
1011 16111
CFTR-lntron2-
- U U CAAAAU AAU AU AAUGGG U A 21
1012 16112
CFTR-lntron2-
- AGUUCAAAAUAAUAUAAUGGGUA 23
1013 16113
CFTR-lntron2-
- AAG U U CAAAAU AAU AU AAUGGG U A 24
1014 16114
CFTR-lntron2-
- AAUAUACUUUGCCAGUUA 18
1015 16115
CFTR-lntron2-
- UAAUAUACUUUGCCAGUUA 19
1016 16116
CFTR-lntron2-
- AUAAUAUACUUUGCCAGUUA 20
1017 16117
CFTR-lntron2-
- AGAUAAUAUACUUUGCCAGUUA 22
1018 16118
CFTR-lntron2-
- AGAGAUAAUAUACUUUGCCAGUUA 24
1019 16119
CFTR-lntron2-
- UAUGGCCAGAUAGAGAAC 18
1020 16120
CFTR-lntron2-
- UUAUGGCCAGAUAGAGAAC 19
1021 16121
CFTR-lntron2-
- UUUAUGGCCAGAUAGAGAAC 20
1022 16122
CFTR-lntron2-
- AUUUAUGGCCAGAUAGAGAAC 21
1023 16123
CFTR-lntron2-
- UAUUUAUGGCCAGAUAGAGAAC 22
1024 16124
CFTR-lntron2-
- UGUAUUUAUGGCCAGAUAGAGAAC 24
1025 16125
CFTR-lntron2-
- UGGCUCAAUUUUGUGACC 18
1026 16126
CFTR-lntron2-
- CUGGCUCAAUUUUGUGACC 19
1027 16127
CFTR-lntron2-
- UCUGGCUCAAUUUUGUGACC 20
1028 16128
CFTR-lntron2-
- AUCUGGCUCAAUUUUGUGACC 21
1029 16129
CFTR-lntron2-
- UAUCUGGCUCAAUUUUGUGACC 22
1030 16130
CFTR-lntron2-
- CUAUCUGGCUCAAUUUUGUGACC 23
1031 16131
470
5535.1 CFTR-lntron2-
- CCUAUCUGGCUCAAUUUUGUGACC 24
1032 16132
CFTR-lntron2-
- UGAUGUAUCCCCAAGUGCC 19
1033 16133
CFTR-lntron2-
- AUGAUGUAUCCCCAAGUGCC 20
1034 16134
CFTR-lntron2-
- UCCUAAAACUACAUUGCC 18
1035 16135
CFTR-lntron2-
- UUCCUAAAACUACAUUGCC 19
1036 16136
CFTR-lntron2-
- UGUUCCUAAAACUACAUUGCC 21
1037 16137
CFTR-lntron2-
- AUGUUCCUAAAACUACAUUGCC 22
1038 16138
CFTR-lntron2-
- CAUGUUCCUAAAACUACAUUGCC 23
1039 16139
CFTR-lntron2-
- CCAUGUUCCUAAAACUACAUUGCC 24
1040 16140
CFTR-lntron2-
- UGAAAAAUCCCAGAGACUC 19
1041 16141
CFTR-lntron2-
- UGUGAAAAAUCCCAGAGACUC 21
1042 16142
CFTR-lntron2-
- AUGUGAAAAAUCCCAGAGACUC 22
1043 16143
CFTR-lntron2-
- AAUGUGAAAAAUCCCAGAGACUC 23
1044 16144
CFTR-lntron2-
- AAAUGUGAAAAAUCCCAGAGACUC 24
1045 16145
CFTR-lntron2-
- CUUGGGCCACUCAUAGUC 18
1046 16146
CFTR-lntron2-
- CCUUGGGCCACUCAUAGUC 19
1047 16147
CFTR-lntron2-
- CCCUUGGGCCACUCAUAGUC 20
1048 16148
CFTR-lntron2-
- CCCCUUGGGCCACUCAUAGUC 21
1049 16149
CFTR-lntron2-
- ACCCCUUGGGCCACUCAUAGUC 22
1050 16150
CFTR-lntron2-
- UACCCCUUGGGCCACUCAUAGUC 23
1051 16151
CFTR-lntron2-
- UUACCCCUUGGGCCACUCAUAGUC 24
1052 16152
471
5535.1 CFTR-lntron2-
- AUUUCUCCUUUGAUGGAGAAG 21
1053 16153
CFTR-lntron2-
- CAUUUCUCCUUUGAUGGAGAAG 22
1054 16154
CFTR-lntron2-
- CCAUUUCUCCUUUGAUGGAGAAG 23
1055 16155
CFTR-lntron2-
- UCCAUUUCUCCUUUGAUGGAGAAG 24
1056 16156
CFTR-lntron2-
- CAGAUAAAAGGGUGAGUGAAG 21
1057 16157
CFTR-lntron2-
- CCAGAUAAAAGGGUGAGUGAAG 22
1058 16158
CFTR-lntron2-
- UGCCAGAUAAAAGGGUGAGUGAAG 24
1059 16159
CFTR-lntron2-
- CUUAUUAGAGACCAUGAG 18
1060 16160
CFTR-lntron2-
- UCUUAUUAGAGACCAUGAG 19
1061 16161
CFTR-lntron2-
- UGUCUUAUUAGAGACCAUGAG 21
1062 16162
CFTR-lntron2-
- UUGUCUUAUUAGAGACCAUGAG 22
1063 16163
CFTR-lntron2-
- UUUGUCUUAUUAGAGACCAUGAG 23
1064 16164
CFTR-lntron2-
- AUUUGUCUUAUUAGAGACCAUGAG 24
1065 16165
CFTR-lntron2-
- CUGAUGCCAGAUAAAAGG 18
1066 16166
CFTR-lntron2-
- CCUGAUGCCAGAUAAAAGG 19
1067 16167
CFTR-lntron2-
- UACCUGUUACAUGCCAGG 18
1068 16168
CFTR-lntron2-
- AGUACCUGUUACAUGCCAGG 20
1069 16169
CFTR-lntron2-
- UGAGUACCUGUUACAUGCCAGG 22
1070 16170
CFTR-lntron2-
- UUGAGUACCUGUUACAUGCCAGG 23
1071 16171
CFTR-lntron2-
- UUUGAGUACCUGUUACAUGCCAGG 24
1072 16172
CFTR-lntron2-
- AGUCUAGAAUGAACUAGG 18
1073 16173
472
5535.1 CFTR-lntron2-
- UAGUCUAGAAUGAACUAGG 19
1074 16174
CFTR-lntron2-
- AUAGUCUAGAAUGAACUAGG 20
1075 16175
CFTR-lntron2-
- CAUAGUCUAGAAUGAACUAGG 21
1076 16176
CFTR-lntron2-
- UCAUAGUCUAGAAUGAACUAGG 22
1077 16177
CFTR-lntron2-
- CUCAUAGUCUAGAAUGAACUAGG 23
1078 16178
CFTR-lntron2-
- ACUCAUAGUCUAGAAUGAACUAGG 24
1079 16179
CFTR-lntron2-
- UGAUUAAUCAGAGUAGGG 18
1080 16180
CFTR-lntron2-
- AUGAUUAAUCAGAGUAGGG 19
1081 16181
CFTR-lntron2-
- AAUGAUUAAUCAGAGUAGGG 20
1082 16182
CFTR-lntron2-
- AGGGAAUGAUUAAUCAGAGUAGGG 24
1083 16183
CFTR-lntron2-
- UUUAUUGAAAUAUUUUGG 18
1084 16184
CFTR-lntron2-
- AUUUAUUGAAAUAUUUUGG 19
1085 16185
CFTR-lntron2-
- AAUUUAUUGAAAUAUUUUGG 20
1086 16186
CFTR-lntron2-
- AACAUGAAUCUGAAUUUG 18
1087 16187
CFTR-lntron2-
- AGAACAUGAAUCUGAAUUUG 20
1088 16188
CFTR-lntron2-
- CAGAUAGAGAACAUGAAU 18
1089 16189
CFTR-lntron2-
- CCAGAUAGAGAACAUGAAU 19
1090 16190
CFTR-lntron2-
- UGGUAACUUGACAGUAAU 18
1091 16191
CFTR-lntron2-
- AUGGUAACUUGACAGUAAU 19
1092 16192
CFTR-lntron2-
- UAUGGUAACUUGACAGUAAU 20
373 15473
CFTR-lntron2-
- UUAUGGUAACUUGACAGUAAU 21
1093 16193
473
5535.1 CFTR-lntron2-
- CUUAUGGUAACUUGACAGUAAU 22
1094 16194
CFTR-lntron2-
- ACUUAUGGUAACUUGACAGUAAU 23
1095 16195
CFTR-lntron2-
- UACUUAUGGUAACUUGACAGUAAU 24
1096 16196
CFTR-lntron2-
- UGGAUGCUGAGGGAAUGAUUAAU 23
1097 16197
CFTR-lntron2-
- UUGGAUGCUGAGGGAAUGAUUAAU 24
1098 16198
CFTR-lntron2-
- CUUUCAAAACCUUUAUAU 18
1099 16199
CFTR-lntron2-
- UGCUUUCAAAACCUUUAUAU 20
1100 16200
CFTR-lntron2-
- UAUCUCCUCUCAGCCACU 18
1101 16201
CFTR-lntron2-
- AUAUCUCCUCUCAGCCACU 19
1102 16202
CFTR-lntron2-
- AAUAUCUCCUCUCAGCCACU 20
1103 16203
CFTR-lntron2-
- AGAAUAUCUCCUCUCAGCCACU 22
1104 16204
CFTR-lntron2-
- UAGAAUAUCUCCUCUCAGCCACU 23
1105 16205
CFTR-lntron2-
- CAUAUUUAGCUUCUUACU 18
1106 16206
CFTR-lntron2-
- CCAUAUUUAGCUUCUUACU 19
1107 16207
CFTR-lntron2-
- UCCAUAUUUAGCUUCUUACU 20
1108 16208
CFTR-lntron2-
- CUCCAUAUUUAGCUUCUUACU 21
1109 16209
CFTR-lntron2-
- UGCUCCAUAUUUAGCUUCUUACU 23
1110 16210
CFTR-lntron2-
- CUGCUCCAUAUUUAGCUUCUUACU 24
1111 16211
CFTR-lntron2-
- UGUAUUGCCUUGCUCUCU 18
1112 16212
CFTR-lntron2-
- CUGUAUUGCCUUGCUCUCU 19
1113 16213
CFTR-lntron2-
- UCUGUAUUGCCUUGCUCUCU 20
399 15499
474
5535.1 CFTR-lntron2-
- AGGUCUGUAUUGCCUUGCUCUCU 23
1114 16214
CFTR-lntron2-
- U CAAAG AAU U AAG CU AG U 18
1115 16215
CFTR-lntron2-
- U U CAAAG AAU U AAG CU AG U 19
1116 16216
CFTR-lntron2-
- AUUCAAAGAAUUAAGCUAGU 20
404 15504
CFTR-lntron2-
- UAUUCAAAGAAUUAAGCUAGU 21
1117 16217
CFTR-lntron2-
- UU AUUCAAAGAAUUAAGCUAGU 22
1118 16218
CFTR-lntron2-
- U U U AU U CAAAG AAU U AAG CU AG U 23
1119 16219
CFTR-lntron2-
- U U U U AU U CAAAG AAU U AAG CU AG U 24
1120 16220
CFTR-lntron2-
- CCG U U CCAAG AU UG U AG U 18
1121 16221
CFTR-lntron2-
- U CCG U U CCAAG AU UG U AG U 19
1122 16222
CFTR-lntron2-
- AUCCGUUCCAAGAUUGUAGU 20
1123 16223
CFTR-lntron2-
- CAU CCG U U CCAAG AU UG U AG U 21
1124 16224
CFTR-lntron2-
- ACAUCCGUUCCAAGAUUGUAGU 22
1125 16225
CFTR-lntron2-
- CACAUCCGUUCCAAGAUUGUAGU 23
1126 16226
CFTR-lntron2-
- ACACAUCCGUUCCAAGAUUGUAGU 24
1127 16227
CFTR-lntron2-
- CCUUUCCAAUCAAAAGGU 18
1128 16228
CFTR-lntron2-
- U CC U U U CC AAU CAAAAG G U 19
1129 16229
CFTR-lntron2-
- UU CCUUUCCAAUCAAAAGGU 20
1130 16230
CFTR-lntron2-
- UUUCCUUUCCAAUCAAAAGGU 21
1131 16231
CFTR-lntron2-
- AGUUUCCUUUCCAAUCAAAAGGU 23
1132 16232
CFTR-lntron2-
- CAGUUUCCUUUCCAAUCAAAAGGU 24
1133 16233
475
5535.1 CFTR-lntron2-
- CCCGGCCUAUUACUCCUU 18
1134 16234
CFTR-lntron2-
- CCCCGGCCUAUUACUCCUU 19
1135 16235
CFTR-lntron2-
- UGCCCCGGCCUAUUACUCCUU 21
1136 16236
CFTR-lntron2-
- CUGCCCCGGCCUAUUACUCCUU 22
1137 16237
CFTR-lntron2-
- ACUGCCCCGGCCUAUUACUCCUU 23
1138 16238
CFTR-lntron2-
- CACUGCCCCGGCCUAUUACUCCUU 24
1139 16239
CFTR-lntron2-
- UCUGAGUAACCAAAUGUU 18
1140 16240
CFTR-lntron2-
- CUCUGAGUAACCAAAUGUU 19
1141 16241
CFTR-lntron2-
- ACUCUGAGUAACCAAAUGUU 20
1142 16242
CFTR-lntron2-
- UACUCUGAGUAACCAAAUGUU 21
1143 16243
CFTR-lntron2-
- UUACUCUGAGUAACCAAAUGUU 22
1144 16244
CFTR-lntron2-
- CUUACUCUGAGUAACCAAAUGUU 23
1145 16245
CFTR-lntron2-
- UCUUACUCUGAGUAACCAAAUGUU 24
1146 16246
CFTR-lntron2-
- UCAGGAUAUGAACUUUUU 18
1147 16247
CFTR-lntron2-
- AGUCAGGAUAUGAACUUUUU 20
1148 16248
CFTR-lntron2-
- UAGUCAGGAUAUGAACUUUUU 21
1149 16249
CFTR-lntron2-
- UGUAGUCAGGAUAUGAACUUUUU 23
1150 16250
CFTR-lntron2-
- UUGUAGUCAGGAUAUGAACUUUUU 24
1151 16251
Table 38C provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within intron 2, start with a 5'G and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
476
5535.1 complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 38C
Figure imgf000478_0001
477
5535.1 CFTR-lntron2-
+ GUGGGCAGAUCACUUGAGGUC 21
1169 16269
CFTR-lntron2-
+ GGUGGGCAGAUCACUUGAGGUC 22
1170 16270
CFTR-lntron2-
+ GCUACUCGAGAGGCUGAGGCAG 22
1171 16271
CFTR-lntron2-
+ GAUUCGCUUGAACCCAGGAGG 21
1172 16272
CFTR-lntron2-
+ GAGAUUCGCUUGAACCCAGGAGG 23
1173 16273
CFTR-lntron2-
+ GAGAUAAUGAUGCUUUCCACU 21
1174 16274
CFTR-lntron2-
+ GCCCUAUUCUAGGCACUU 18
1175 16275
CFTR-lntron2-
+ GGCCCUAUUCUAGGCACUU 19
1176 16276
CFTR-lntron2-
+ GCCAGGCCCUAUUCUAGGCACUU 23
1177 16277
CFTR-lntron2-
- GCAAACUCUGCCUCCUGGGUUCAA 24
1178 16278
CFTR-lntron2-
- GGCUAAUUUUUGUAGAGA 18
1179 16279
CFTR-lntron2-
- GCCUGGCUAAUUUUUGUAGAGA 22
1180 16280
CFTR-lntron2-
- GGCCUGGCUAAUUUUUGUAGAGA 23
1181 16281
CFTR-lntron2-
- GUUGCUGUUGUUUUUGAGA 19
1182 16282
CFTR-lntron2-
- GUUGUUGCUGUUGUUUUUGAGA 22
1183 16283
CFTR-lntron2-
- GUGUUGUUUGUUUUUGAGA 19
1184 16284
CFTR-lntron2-
- GUUUGUGUUGUUUGUUUUUGAGA 23
1185 16285
CFTR-lntron2-
- GUUUUGUUUUUUAUUUUUUA 20
1186 16286
CFTR-lntron2-
- GUUUAUGAUGUAUCCCCAAGUGCC 24
1187 16287
CFTR-lntron2-
- GUCUCGCUGUGUCACCCAGGC 21
1188 16288
CFTR-lntron2-
- GAGUCUCGCUGUGUCACCCAGGC 23
1189 16289
478
5535.1 CFTR-lntron2-
- GUCUUGCUCUGUUGCCCAGGC 21
1190 16290
CFTR-lntron2-
- GAGUCUUGCUCUGUUGCCCAGGC 23
1191 16291
CFTR-lntron2-
- GCCCACCUUGGCCUCCCAAAAUGC 24
1192 16292
CFTR-lntron2-
- GAUUCUCCUGCCUCAGCCUC 20
1193 16293
CFTR-lntron2-
- GUGAUUCUCCUGCCUCAGCCUC 22
1194 16294
CFTR-lntron2-
- GCUCACUGCAAACUCUGCCUC 21
1195 16295
CFTR-lntron2-
- GUUCAAGCGAAUCUCAGUCUC 21
1196 16296
CFTR-lntron2-
- GGUUCAAGCGAAUCUCAGUCUC 22
1197 16297
CFTR-lntron2-
- GGGUUCAAGCGAAUCUCAGUCUC 23
1198 16298
CFTR-lntron2-
- GCUCACUGCAAACUUCGUCUC 21
1199 16299
CFTR-lntron2-
- GGCUCACUGCAAACUUCGUCUC 22
1200 16300
CFTR-lntron2-
- GAUAAAAGGGUGAGUGAAG 19
1201 16301
CFTR-lntron2-
- GCCUCAGCCUCUCGAGUAG 19
1202 16302
CFTR-lntron2-
- GGCCUGAUGCCAGAUAAAAGG 21
1203 16303
CFTR-lntron2-
- GAAAUUUAUUGAAAUAUUUUGG 22
1204 16304
CFTR-lntron2-
- GAGAACAUGAAUCUGAAUUUG 21
1205 16305
CFTR-lntron2-
- GUAUAUACUCAAUAAAUAUUUG 22
1206 16306
CFTR-lntron2-
- GGUAUAUACUCAAUAAAUAUUUG 23
1207 16307
CFTR-lntron2-
- GGCCAGAUAGAGAACAUGAAU 21
1208 16308
CFTR-lntron2-
- GCUGAGGGAAUGAUUAAU 18
1209 16309
CFTR-lntron2-
- GAGCCACUAUGCCCAGCU 18
1210 16310
479
5535.1 CFTR-lntron2-
- GUGAGCCACUAUGCCCAGCU 20
1211 16311
CFTR-lntron2-
- GUGUGAGCCACUAUGCCCAGCU 22
1212 16312
CFTR-lntron2-
- GGUGUGAGCCACUAUGCCCAGCU 23
1213 16313
CFTR-lntron2-
- GUGCAAAUGCCAUGAGGU 18
1214 16314
CFTR-lntron2-
- GUGUGCAAAUGCCAUGAGGU 20
472 15572
CFTR-lntron2-
- GUGUGUGCAAAUGCCAUGAGGU 22
1215 16315
CFTR-lntron2-
- GGUGUGUGCAAAUGCCAUGAGGU 23
1216 16316
CFTR-lntron2-
- GCCUUGGCCUCCCAAAGUGU 20
474 15574
CFTR-lntron2-
- GCCCGCCUUGGCCUCCCAAAGUGU 24
1217 16317
Table 38D provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within intron 2, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 38D
Figure imgf000481_0001
480
5535.1 CFTR-lntron2-
+ UAUUUACUUAAGCUAGUAAA 20
1223 16323
CFTR-lntron2-
+ AUAGGUAUAUUUUUUAAA 18
1224 16324
CFTR-lntron2-
+ AAUAGGUAUAUUUUUUAAA 19
1225 16325
CFTR-lntron2-
+ AAAU AGG UAUAUUUUU U AAA 20
1226 16326
CFTR-lntron2-
+ AAAAU AGG UAUAUUUUU U AAA 21
1227 16327
CFTR-lntron2-
+ U AAAAU AGG UAUAUUUUU U AAA 22
1228 16328
CFTR-lntron2-
+ AG U AAAAU AGG UAUAUUUUU U AAA 24
1229 16329
CFTR-lntron2-
+ UCUGUCACUGGCAAUCAA 18
1230 16330
CFTR-lntron2-
+ UUCUGUCACUGGCAAUCAA 19
1231 16331
CFTR-lntron2-
+ UUUCUGUCACUGGCAAUCAA 20
1232 16332
CFTR-lntron2-
+ UGGGUUUCUGUCACUGGCAAUCAA 24
1233 16333
CFTR-lntron2-
+ UUCUCCAUCAAAGGAGAA 18
1234 16334
CFTR-lntron2-
+ CUUCUCCAUCAAAGGAGAA 19
1235 16335
CFTR-lntron2-
+ CCUUCUCCAUCAAAGGAGAA 20
1236 16336
CFTR-lntron2-
+ AUGAAAGAAAAAAUAGAA 18
1237 16337
CFTR-lntron2-
+ UAUGAAAGAAAAAAUAGAA 19
1238 16338
CFTR-lntron2-
+ CUAUGAAAGAAAAAAUAGAA 20
614 15714
CFTR-lntron2-
+ AG C U A U G A A AG A A A A A A U AG A A 22
1239 16339
CFTR-lntron2-
+ UAGCUAUGAAAGAAAAAAUAGAA 23
1240 16340
CFTR-lntron2-
+ U UAGCUAUGAAAGAAAAAAUAGAA 24
1241 16341
CFTR-lntron2-
+ AAA U G CCA A A A A A AG G A A 18
1242 16342
481
5535.1 CFTR-lntron2-
+ A A A A U G C C A A A A A AAG G A A 19
1243 16343
CFTR-lntron2-
+ C A A A A U G CCA A A A A A AG G A A 20
1244 16344
CFTR-lntron2-
+ U C A A A A U G CCA A A A A A AG G A A 21
1245 16345
CFTR-lntron2-
+ U U C A A A A U G CCA A A A A A AG G A A 22
1246 16346
CFTR-lntron2-
+ CUUCAAAAUGCCAAAAAAAGGAA 23
1247 16347
CFTR-lntron2-
+ CCUUCAAAAUGCCAAAAAAAGGAA 24
1248 16348
CFTR-lntron2-
+ AACAAACAAAAAACAUAA 18
1249 16349
CFTR-lntron2-
+ AAACAAACAAAAAACAUAA 19
1250 16350
CFTR-lntron2-
+ CAAACAAACAAAAAACAUAA 20
616 15716
CFTR-lntron2-
+ ACAAACAAACAAAAAACAUAA 21
1251 16351
CFTR-lntron2-
+ CACAAACAAACAAAAAACAUAA 22
1252 16352
CFTR-lntron2-
+ ACACAAACAAACAAAAAACAUAA 23
1253 16353
CFTR-lntron2-
+ AACACAAACAAACAAAAAACAUAA 24
1254 16354
CFTR-lntron2-
+ U UAU AAG AAAAG AAG UAA 18
1255 16355
CFTR-lntron2-
+ U U UAU AAG AAAAG AAG UAA 19
1256 16356
CFTR-lntron2-
+ U U U UAU AAG AAAAG AAG UAA 20
1257 16357
CFTR-lntron2-
+ AU U U UAU AAG AAAAG AAG UAA 21
1258 16358
CFTR-lntron2-
+ AAUUU UAU AAG AAAAG AAG UAA 22
1259 16359
CFTR-lntron2-
+ CAAU U U UAU AAG AAAAG AAG UAA 23
1260 16360
CFTR-lntron2-
+ CCAAU U U UAU AAG AAAAG AAG UAA 24
1261 16361
CFTR-lntron2-
+ AGUAGAGAGACCAGGAGAGCA 21
1262 16362
482
5535.1 CFTR-lntron2-
+ AAGUAGAGAGACCAGGAGAGCA 22
1263 16363
CFTR-lntron2-
+ UGAAGUAGAGAGACCAGGAGAGCA 24
1264 16364
CFTR-lntron2-
+ AUCAGAUGGGAAAGCCAAGGA 21
1265 16365
CFTR-lntron2-
+ UGGAUCAGAUGGGAAAGCCAAGGA 24
1266 16366
CFTR-lntron2-
+ UCAUUCAACAAAUAUUUA 18
1267 16367
CFTR-lntron2-
+ UUCAUUCAACAAAUAUUUA 19
1268 16368
CFTR-lntron2-
+ AUUCAUUCAACAAAUAUUUA 20
1269 16369
CFTR-lntron2-
+ UGG AU U CAU U CAACAAAU AU U U A 23
1270 16370
CFTR-lntron2-
+ AUGGAUUCAUUCAACAAAUAUUUA 24
1271 16371
CFTR-lntron2-
+ ACACCACUACACUCCAGC 18
1272 16372
CFTR-lntron2-
+ CACACCACUACACUCCAGC 19
1273 16373
CFTR-lntron2-
+ UCACACCACUACACUCCAGC 20
1274 16374
CFTR-lntron2-
+ AUCACACCACUACACUCCAGC 21
1275 16375
CFTR-lntron2-
+ AGAUCACACCACUACACUCCAGC 23
1276 16376
CFTR-lntron2-
+ CGGGCAGAUCACUUGAGGUC 20
667 15767
CFTR-lntron2-
+ AGGCGGGCAGAUCACUUGAGGUC 23
1277 16377
CFTR-lntron2-
+ AAGGCGGGCAGAUCACUUGAGGUC 24
1278 16378
CFTR-lntron2-
+ UGGGCAGAUCACUUGAGGUC 20
668 15768
CFTR-lntron2-
+ AGGUGGGCAGAUCACUUGAGGUC 23
1279 16379
CFTR-lntron2-
+ AAGGUGGGCAGAUCACUUGAGGUC 24
1280 16380
CFTR-lntron2-
+ CUCGAGAGGCUGAGGCAG 18
1281 16381
483
5535.1 CFTR-lntron2-
+ ACUCGAGAGGCUGAGGCAG 19
1282 16382
CFTR-lntron2-
+ UACUCGAGAGGCUGAGGCAG 20
1283 16383
CFTR-lntron2-
+ CUACUCGAGAGGCUGAGGCAG 21
1284 16384
CFTR-lntron2-
+ AGCU ACUCGAGAGGCUGAGGCAG 23
1285 16385
CFTR-lntron2-
+ CAGCUACUCGAGAGGCUGAGGCAG 24
1286 16386
CFTR-lntron2-
+ CCUGAGGAGAAGGCAAGGUCG 21
1287 16387
CFTR-lntron2-
+ ACCUGAGGAGAAGGCAAGGUCG 22
1288 16388
CFTR-lntron2-
+ UACCUGAGGAGAAGGCAAGGUCG 23
1289 16389
CFTR-lntron2-
+ UUACCUGAGGAGAAGGCAAGGUCG 24
1290 16390
CFTR-lntron2-
+ UCGCUUGAACCCAGGAGG 18
1291 16391
CFTR-lntron2-
+ UUCGCUUGAACCCAGGAGG 19
1292 16392
CFTR-lntron2-
+ AUUCGCUUGAACCCAGGAGG 20
1293 16393
CFTR-lntron2-
+ AGAUUCGCUUGAACCCAGGAGG 22
1294 16394
CFTR-lntron2-
+ UGAGAUUCGCUUGAACCCAGGAGG 24
1295 16395
CFTR-lntron2-
+ UUUUUAAAUUGAAUCAACAUG 21
1296 16396
CFTR-lntron2-
+ UUUUUUAAAUUGAAUCAACAUG 22
1297 16397
CFTR-lntron2-
+ AU U U U U U AAAU UG AAU CAACAUG 23
1298 16398
CFTR-lntron2-
+ U AU U U U U U AAAU UG AAU CAACAUG 24
1299 16399
CFTR-lntron2-
+ AAUUAGCCAGGCAUUGUG 18
1300 16400
CFTR-lntron2-
+ AAAUUAGCCAGGCAUUGUG 19
1301 16401
CFTR-lntron2-
+ AAAAUUAGCCAGGCAUUGUG 20
1302 16402
484
5535.1 CFTR-lntron2-
+ A A A A A UUAGCCAGGCAUUGUG 21
1303 16403
CFTR-lntron2-
+ C A A A A A UUAGCCAGGCAUUGUG 22
1304 16404
CFTR-lntron2-
+ ACAAAAAUUAGCCAGGCAUUGUG 23
1305 16405
CFTR-lntron2-
+ UACAAAAAUUAGCCAGGCAUUGUG 24
1306 16406
CFTR-lntron2-
+ AAUGCCACCAGGUGGCAU 18
1307 16407
CFTR-lntron2-
+ AAAUGCCACCAGGUGGCAU 19
1308 16408
CFTR-lntron2-
+ CAAAUGCCACCAGGUGGCAU 20
1309 16409
CFTR-lntron2-
+ AGAGAUAAUGAUGCUUUCCACU 22
1310 16410
CFTR-lntron2-
+ UAGAGAUAAUGAUGCUUUCCACU 23
1311 16411
CFTR-lntron2-
+ AUAGAGAUAAUGAUGCUUUCCACU 24
1312 16412
CFTR-lntron2-
+ UAUAUUUUCUAUUAUAGU 18
1313 16413
CFTR-lntron2-
+ AUAUAUUUUCUAUUAUAGU 19
1314 16414
CFTR-lntron2-
+ UAUAUAUUUUCUAUUAUAGU 20
1315 16415
CFTR-lntron2-
+ UUAUAUAUUUUCUAUUAUAGU 21
1316 16416
CFTR-lntron2-
+ AUUAUAUAUUUUCUAUUAUAGU 22
1317 16417
CFTR-lntron2-
+ AAUUAUAUAUUUUCUAUUAUAGU 23
1318 16418
CFTR-lntron2-
+ AAAUUAUAUAUUUUCUAUUAUAGU 24
1319 16419
CFTR-lntron2-
+ A C A A A A A U A A U AG A ACG U 18
1320 16420
CFTR-lntron2-
+ AACAAAAAU AAU AG AACG U 19
1321 16421
CFTR-lntron2-
+ AAACAAAAAUAAUAGAACGU 20
1322 16422
CFTR-lntron2-
+ AAAACAAAAAU AAU AG AACG U 21
1323 16423
485
5535.1 CFTR-lntron2-
+ CAAAACAAAAAUAAUAGAACGU 22
1324 16424
CFTR-lntron2-
+ ACAAAACAAAAAU AAU AG AACG U 23
1325 16425
CFTR-lntron2-
+ AACAAAACAAAAAUAAUAGAACGU 24
1326 16426
CFTR-lntron2-
+ AGGCCCUAUUCUAGGCACUU 20
718 15818
CFTR-lntron2-
+ CAGGCCCUAUUCUAGGCACUU 21
1327 16427
CFTR-lntron2-
+ CCAGGCCCUAUUCUAGGCACUU 22
1328 16428
CFTR-lntron2-
+ UGCCAGGCCCUAUUCUAGGCACUU 24
1329 16429
CFTR-lntron2-
- UCUGCCUCCUGGGUUCAA 18
1330 16430
CFTR-lntron2-
- CUCUGCCUCCUGGGUUCAA 19
1331 16431
CFTR-lntron2-
- ACUCUGCCUCCUGGGUUCAA 20
1332 16432
CFTR-lntron2-
- AACUCUGCCUCCUGGGUUCAA 21
1333 16433
CFTR-lntron2-
- AAACUCUGCCUCCUGGGUUCAA 22
1334 16434
CFTR-lntron2-
- CAAACUCUGCCUCCUGGGUUCAA 23
1335 16435
CFTR-lntron2-
- UGAAUAUCUAAGUUUUAA 18
1336 16436
CFTR-lntron2-
- UUGAAUAUCUAAGUUUUAA 19
1337 16437
CFTR-lntron2-
- UUUGAAUAUCUAAGUUUUAA 20
1338 16438
CFTR-lntron2-
- UUUUAUUGAUUUUAUUCA 18
1339 16439
CFTR-lntron2-
- UUUUUAUUGAUUUUAUUCA 19
1340 16440
CFTR-lntron2-
- AUUUUUAUUGAUUUUAUUCA 20
1341 16441
CFTR-lntron2-
- UAUUUUUAUUGAUUUUAUUCA 21
1342 16442
CFTR-lntron2-
- UUAUUUUUAUUGAUUUUAUUCA 22
1343 16443
486
5535.1 CFTR-lntron2-
- UUUAUUUUUAUUGAUUUUAUUCA 23
1344 16444
CFTR-lntron2-
- CUUUAUUUUUAUUGAUUUUAUUCA 24
1345 16445
CFTR-lntron2-
- AAUACACAUUUGGUUUCA 18
1346 16446
CFTR-lntron2-
- AAAUACACAUUUGGUUUCA 19
1347 16447
CFTR-lntron2-
- AAAAU ACACAU UUGGUUUCA 20
1348 16448
CFTR-lntron2-
- UGGCUAAUUUUUGUAGAGA 19
1349 16449
CFTR-lntron2-
- CUGGCUAAUUUUUGUAGAGA 20
626 15726
CFTR-lntron2-
- CCUGGCUAAUUUUUGUAGAGA 21
1350 16450
CFTR-lntron2-
- AGGCCUGGCUAAUUUUUGUAGAGA 24
1351 16451
CFTR-lntron2-
- UUGCUGUUGUUUUUGAGA 18
1352 16452
CFTR-lntron2-
- UGUUGCUGUUGUUUUUGAGA 20
1353 16453
CFTR-lntron2-
- UUGUUGCUGUUGUUUUUGAGA 21
1354 16454
CFTR-lntron2-
- UGUUGUUGCUGUUGUUUUUGAGA 23
1355 16455
CFTR-lntron2-
- UUGUUGUUGCUGUUGUUUUUGAGA 24
1356 16456
CFTR-lntron2-
- UGUUGUUUGUUUUUGAGA 18
1357 16457
CFTR-lntron2-
- UGUGUUGUUUGUUUUUGAGA 20
1358 16458
CFTR-lntron2-
- UUGUGUUGUUUGUUUUUGAGA 21
1359 16459
CFTR-lntron2-
- UUUGUGUUGUUUGUUUUUGAGA 22
1360 16460
CFTR-lntron2-
- UGUUUGUGUUGUUUGUUUUUGAGA 24
1361 16461
CFTR-lntron2-
- U AG CU UAAG U AAA U A A A AG G A 21
1362 16462
CFTR-lntron2-
- CUAGCUUAAGU AAA U A A A AG G A 22
1363 16463
487
5535.1 CFTR-lntron2-
- ACUAGCUUAAGUAAAUAAAAGGA 23
1364 16464
CFTR-lntron2-
- UACUAGCUUAAGUAAAUAAAAGGA 24
1365 16465
CFTR-lntron2-
- UGUUGAAUGAAUCCAUGA 18
1366 16466
CFTR-lntron2-
- UUGUUGAAUGAAUCCAUGA 19
1367 16467
CFTR-lntron2-
- UUUGUUGAAUGAAUCCAUGA 20
628 15728
CFTR-lntron2-
- AUUUGUUGAAUGAAUCCAUGA 21
1368 16468
CFTR-lntron2-
- UAUUUGUUGAAUGAAUCCAUGA 22
1369 16469
CFTR-lntron2-
- AUAUUUGUUGAAUGAAUCCAUGA 23
1370 16470
CFTR-lntron2-
- AAUAUUUGUUGAAUGAAUCCAUGA 24
1371 16471
CFTR-lntron2-
- UCAAUAAAUAUUUGUUGA 18
1372 16472
CFTR-lntron2-
- CUCAAUAAAUAUUUGUUGA 19
1373 16473
CFTR-lntron2-
- ACUCAAUAAAUAUUUGUUGA 20
1374 16474
CFTR-lntron2-
- UACUCAAUAAAUAUUUGUUGA 21
1375 16475
CFTR-lntron2-
- AUACUCAAUAAAUAUUUGUUGA 22
1376 16476
CFTR-lntron2-
- UAUACUCAAUAAAUAUUUGUUGA 23
1377 16477
CFTR-lntron2-
- AUAUACUCAAUAAAUAUUUGUUGA 24
1378 16478
CFTR-lntron2-
- UUUGUUUUUUAUUUUUUA 18
1379 16479
CFTR-lntron2-
- UUUUGUUUUUUAUUUUUUA 19
1380 16480
CFTR-lntron2-
- UGUUUUGUUUUUUAUUUUUUA 21
1381 16481
CFTR-lntron2-
- UUGUUUUGUUUUUUAUUUUUUA 22
1382 16482
CFTR-lntron2-
- UUUGUUUUGUUUUUUAUUUUUUA 23
1383 16483
488
5535.1 CFTR-lntron2-
- CUUUGUUUUGUUUUUUAUUUUUUA 24
1384 16484
CFTR-lntron2-
- UAUGAUGUAUCCCCAAGUGCC 21
1385 16485
CFTR-lntron2-
- UUAUGAUGUAUCCCCAAGUGCC 22
1386 16486
CFTR-lntron2-
- UUUAUGAUGUAUCCCCAAGUGCC 23
1387 16487
CFTR-lntron2-
- UCGCUGUGUCACCCAGGC 18
1388 16488
CFTR-lntron2-
- CUCGCUGUGUCACCCAGGC 19
1389 16489
CFTR-lntron2-
- UCUCGCUGUGUCACCCAGGC 20
658 15758
CFTR-lntron2-
- AGUCUCGCUGUGUCACCCAGGC 22
1390 16490
CFTR-lntron2-
- AGAGUCUCGCUGUGUCACCCAGGC 24
1391 16491
CFTR-lntron2-
- UUGCUCUGUUGCCCAGGC 18
1392 16492
CFTR-lntron2-
- CUUGCUCUGUUGCCCAGGC 19
1393 16493
CFTR-lntron2-
- UCUUGCUCUGUUGCCCAGGC 20
659 15759
CFTR-lntron2-
- AGUCUUGCUCUGUUGCCCAGGC 22
1394 16494
CFTR-lntron2-
- AGAGUCUUGCUCUGUUGCCCAGGC 24
1395 16495
CFTR-lntron2-
- CUUGGCCUCCCAAAAUGC 18
1396 16496
CFTR-lntron2-
- CCUUGGCCUCCCAAAAUGC 19
1397 16497
CFTR-lntron2-
- ACCUUGGCCUCCCAAAAUGC 20
663 15763
CFTR-lntron2-
- CACCUUGGCCUCCCAAAAUGC 21
1398 16498
CFTR-lntron2-
- CCACCUUGGCCUCCCAAAAUGC 22
1399 16499
CFTR-lntron2-
- CCCACCUUGGCCUCCCAAAAUGC 23
1400 16500
CFTR-lntron2-
- UUCUCCUGCCUCAGCCUC 18
1401 16501
489
5535.1 CFTR-lntron2-
- AUUCUCCUGCCUCAGCCUC 19
1402 16502
CFTR-lntron2-
- UGAUUCUCCUGCCUCAGCCUC 21
1403 16503
CFTR-lntron2-
- AGUGAUUCUCCUGCCUCAGCCUC 23
1404 16504
CFTR-lntron2-
- AAGUGAUUCUCCUGCCUCAGCCUC 24
1405 16505
CFTR-lntron2-
- CACUGCAAACUCUGCCUC 18
1406 16506
CFTR-lntron2-
- UCACUGCAAACUCUGCCUC 19
1407 16507
CFTR-lntron2-
- CUCACUGCAAACUCUGCCUC 20
1408 16508
CFTR-lntron2-
- AGCUCACUGCAAACUCUGCCUC 22
1409 16509
CFTR-lntron2-
- CAGCUCACUGCAAACUCUGCCUC 23
1410 16510
CFTR-lntron2-
- UCAGCUCACUGCAAACUCUGCCUC 24
1411 16511
CFTR-lntron2-
- CAAGCGAAUCUCAGUCUC 18
1412 16512
CFTR-lntron2-
- UCAAGCGAAUCUCAGUCUC 19
1413 16513
CFTR-lntron2-
- UUCAAGCGAAUCUCAGUCUC 20
1414 16514
CFTR-lntron2-
- UGGGUUCAAGCGAAUCUCAGUCUC 24
1415 16515
CFTR-lntron2-
- CACUGCAAACUUCGUCUC 18
1416 16516
CFTR-lntron2-
- UCACUGCAAACUUCGUCUC 19
1417 16517
CFTR-lntron2-
- CUCACUGCAAACUUCGUCUC 20
1418 16518
CFTR-lntron2-
- UGGCUCACUGCAAACUUCGUCUC 23
1419 16519
CFTR-lntron2-
- UUGGCUCACUGCAAACUUCGUCUC 24
1420 16520
CFTR-lntron2-
- UCUCCUUUGAUGGAGAAG 18
1421 16521
CFTR-lntron2-
- UUCUCCUUUGAUGGAGAAG 19
1422 16522
490
5535.1 CFTR-lntron2-
- UUUCUCCUUUGAUGGAGAAG 20
1423 16523
CFTR-lntron2-
- AUAAAAGGGUGAGUGAAG 18
1424 16524
CFTR-lntron2-
- AGAUAAAAGGGUGAGUGAAG 20
672 15772
CFTR-lntron2-
- CCUCAGCCUCUCGAGUAG 18
1425 16525
CFTR-lntron2-
- UGCCUCAGCCUCUCGAGUAG 20
1426 16526
CFTR-lntron2-
- CUGCCUCAGCCUCUCGAGUAG 21
1427 16527
CFTR-lntron2-
- CCUGCCUCAGCCUCUCGAGUAG 22
1428 16528
CFTR-lntron2-
- UCCUGCCUCAGCCUCUCGAGUAG 23
1429 16529
CFTR-lntron2-
- CUCCUGCCUCAGCCUCUCGAGUAG 24
1430 16530
CFTR-lntron2-
- AGGCCUGAUGCCAGAUAAAAGG 22
1431 16531
CFTR-lntron2-
- CAGGCCUGAUGCCAGAUAAAAGG 23
1432 16532
CFTR-lntron2-
- ACAGGCCUGAUGCCAGAUAAAAGG 24
1433 16533
CFTR-lntron2-
- AAAUUUAUUGAAAUAUUUUGG 21
1434 16534
CFTR-lntron2-
- UGAAAUUUAUUGAAAUAUUUUGG 23
1435 16535
CFTR-lntron2-
- UUGAAAUUUAUUGAAAUAUUUUGG 24
1436 16536
CFTR-lntron2-
- UUUGUAUUUUAGUAGAUG 18
1437 16537
CFTR-lntron2-
- UUUUGUAUUUUAGUAGAUG 19
1438 16538
CFTR-lntron2-
- UUUUUGUAUUUUAGUAGAUG 20
688 15788
CFTR-lntron2-
- AUUUUUGUAUUUUAGUAGAUG 21
1439 16539
CFTR-lntron2-
- AAUUUUUGUAUUUUAGUAGAUG 22
1440 16540
CFTR-lntron2-
- UAAUUUUUGUAUUUUAGUAGAUG 23
1441 16541
491
5535.1 CFTR-lntron2-
- CUAAUUUUUGUAUUUUAGUAGAUG 24
1442 16542
CFTR-lntron2-
- AGAGAACAUGAAUCUGAAUUUG 22
1443 16543
CFTR-lntron2-
- UAGAGAACAUGAAUCUGAAUUUG 23
1444 16544
CFTR-lntron2-
- AUAGAGAACAUGAAUCUGAAUUUG 24
1445 16545
CFTR-lntron2-
- AUACUCAAUAAAUAUUUG 18
1446 16546
CFTR-lntron2-
- UAUACUCAAUAAAUAUUUG 19
1447 16547
CFTR-lntron2-
- AUAUACUCAAUAAAUAUUUG 20
1448 16548
CFTR-lntron2-
- UAUAUACUCAAUAAAUAUUUG 21
1449 16549
CFTR-lntron2-
- UGGUAUAUACUCAAUAAAUAUUUG 24
1450 16550
CFTR-lntron2-
- UGGCCAGAUAGAGAACAUGAAU 22
1451 16551
CFTR-lntron2-
- AUGGCCAGAUAGAGAACAUGAAU 23
1452 16552
CFTR-lntron2-
- UAUGGCCAGAUAGAGAACAUGAAU 24
1453 16553
CFTR-lntron2-
- UGCUGAGGGAAUGAUUAAU 19
1454 16554
CFTR-lntron2-
- AUGCUGAGGGAAUGAUUAAU 20
1455 16555
CFTR-lntron2-
- UUGCUUUCAAAACCUUUAUAU 21
1456 16556
CFTR-lntron2-
- UUUGCUUUCAAAACCUUUAUAU 22
1457 16557
CFTR-lntron2-
- AUUUGCUUUCAAAACCUUUAUAU 23
1458 16558
CFTR-lntron2-
- UAUUUGCUUUCAAAACCUUUAUAU 24
1459 16559
CFTR-lntron2-
- UGAGCCACUAUGCCCAGCU 19
1460 16560
CFTR-lntron2-
- UGUGAGCCACUAUGCCCAGCU 21
1461 16561
CFTR-lntron2-
- AGGUGUGAGCCACUAUGCCCAGCU 24
1462 16562
492
5535.1 CFTR-lntron2-
- UGUGCAAAUGCCAUGAGGU 19
1463 16563
CFTR-lntron2-
- UGUGUGCAAAUGCCAUGAGGU 21
1464 16564
CFTR-lntron2-
- UGGUGUGUGCAAAUGCCAUGAGGU 24
1465 16565
CFTR-lntron2-
- CUUGGCCUCCCAAAGUGU 18
1466 16566
CFTR-lntron2-
- CCUUGGCCUCCCAAAGUGU 19
1467 16567
CFTR-lntron2-
- CGCCUUGGCCUCCCAAAGUGU 21
1468 16568
CFTR-lntron2-
- CCGCCUUGGCCUCCCAAAGUGU 22
1469 16569
CFTR-lntron2-
- CCCGCCUUGGCCUCCCAAAGUGU 23
1470 16570
CFTR-lntron2-
- UGUAAAAAUUGUAUAUUU 18
1471 16571
CFTR-lntron2-
- AUGUAAAAAUUGUAUAUUU 19
1472 16572
CFTR-lntron2-
- AAUGUAAAAAUUGUAUAUUU 20
1473 16573
CFTR-lntron2-
- AAAUG U AAAAAU UG U AU AU U U 21
1474 16574
CFTR-lntron2-
- CAAAUG U AAAAAU UG U AU AU U U 22
1475 16575
CFTR-lntron2-
- ACAAAUG U AAAAAU UG U AU AU U U 23
1476 16576
CFTR-lntron2-
- AACAAAUG U AAAAAU UG U AU AU U U 24
1477 16577
Table 3 8E provides exemplary targeting domains for correcting a mutation (e.g., 3272-
26->G) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within intron 2, and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 38E
Figure imgf000494_0001
493
5535.1 CFTR-
+ C U U C A A A A U G C C A A A A A A 18
lntron2-1478 16578
CFTR-
+ CC U U C A A A A U G C C A A A A A A 19
lntron2-1479 16579
CFTR-
+ G CC U U C A A A A U G C C A A A A A A 20
lntron2-42 15142
CFTR-
+ U G CC U U CAAAAUG CC AAAAAA 21
Intron2-1480 16580
CFTR-
+ UUGCCUUCAAAAUGCCAAAAAA 22
lntron2-1481 16581
CFTR-
+ UUUGCCUUCAAAAUGCCAAAAAA 23
lntron2-1482 16582
CFTR-
+ CUUUGCCUUCAAAAUGCCAAAAAA 24
lntron2-1483 16583
CFTR-
+ CCU U CAAAAUG CCAAAAA 18
lntron2-1484 16584
CFTR-
+ GCCUUCAAAAUGCCAAAAA 19
lntron2-1485 16585
CFTR-
+ U G CC U U CAAAAUG CCAAAAA 20
lntron2-1486 16586
CFTR-
+ U U G CC U U C A A A A U G C C A A A A A 21
lntron2-1487 16587
CFTR-
+ UUUGCCUUCAAAAUGCCAAAAA 22
lntron2-1488 16588
CFTR-
+ CUUUGCCUUCAAAAUGCCAAAAA 23
lntron2-1489 16589
CFTR-
+ ACUUUGCCUUCAAAAUGCCAAAAA 24
Intron2-1490 16590
CFTR-
+ CAAUCCAUGGU C AC A A A A 18
lntron2-1491 16591
CFTR-
+ UCAAUCCAUGGUCACAAAA 19
lntron2-1492 16592
CFTR-
+ UUCAAUCCAUGGUCACAAAA 20
lntron2-1493 16593
CFTR-
+ AUUCAAUCCAUGGUCACAAAA 21
lntron2-1494 16594
CFTR-
+ GAUUCAAUCCAUGGUCACAAAA 22
lntron2-1495 16595
CFTR-
+ GGAUUCAAUCCAUGGUCACAAAA 23
lntron2-1496 16596
CFTR-
+ AGGAUUCAAUCCAUGGUCACAAAA 24
lntron2-1497 16597
494
5535.1 CFTR-
+ UGGGGGAUACAGUGAAAA 18
lntron2-1498 16598
CFTR-
+ AUGGGGGAUACAGUGAAAA 19
lntron2-1499 16599
CFTR-
+ CAUGGGGGAUACAGUGAAAA 20
Intron2-1500 16600
CFTR-
+ ACAUGGGGGAUACAGUGAAAA 21
Intron2-1501 16601
CFTR-
+ AACAUGGGGGAUACAGUGAAAA 22
Intron2-1502 16602
CFTR-
+ CAA CAUGGGGGAUACAGUGAAAA 23
Intron2-1503 16603
CFTR-
+ UCAACAUGGGGGAUACAGUGAAAA 24
Intron2-1504 16604
CFTR-
+ AUUAAAGGUCUUUGAAAA 18
Intron2-1505 16605
CFTR-
+ UAUUAAAGGUCUUUGAAAA 19
Intron2-1506 16606
CFTR-
+ GU AUUAAAGGUCUUUGAAAA 20
Intron2-1507 16607
CFTR-
+ UGUAUUAAAGGUCUUUGAAAA 21
Intron2-1508 16608
CFTR-
+ AUGUAUUAAAGGUCUUUGAAAA 22
Intron2-1509 16609
CFTR-
+ CAUGUAUUAAAGGUCUUUGAAAA 23
Intron2-1510 16610
CFTR-
+ UCAUGUAUUAAAGGUCUUUGAAAA 24
lntron2-1511 16611
CFTR-
+ GUUUGCUUUUCUGUAAAA 18
lntron2-1512 16612
CFTR-
+ AGUUUGCUUUUCUGUAAAA 19
lntron2-1513 16613
CFTR-
+ CAGUUUGCUUUUCUGUAAAA 20
lntron2-1514 16614
CFTR-
+ UCAGUUUGCUUUUCUGUAAAA 21
lntron2-1515 16615
CFTR-
+ CUCAGUUUGCUUUUCUGUAAAA 22
lntron2-1516 16616
CFTR-
+ CCUCAGUUUGCUUUUCUGUAAAA 23
lntron2-1517 16617
CFTR-
+ GCCUCAGUUUGCUUUUCUGUAAAA 24
lntron2-1518 16618
495
5535.1 CFTR-
+ UUUUGAUUGGAAAGGAAA 18
lntron2-1519 16619
CFTR-
+ CUUUUGAUUGGAAAGGAAA 19
Intron2-1520 16620
CFTR-
+ CCUUUUGAUUGGAAAGGAAA 20
lntron2-1521 16621
CFTR-
+ ACCUUUUGAUUGGAAAGGAAA 21
lntron2-1522 16622
CFTR-
+ AACCUUUUGAUUGGAAAGGAAA 22
lntron2-1523 16623
CFTR-
+ UAACCUUUUGAUUGGAAAGGAAA 23
lntron2-1524 16624
CFTR-
+ CUAACCUUUUGAUUGGAAAGGAAA 24
lntron2-1525 16625
CFTR-
+ GCUGAGAUGUAAAUGAAA 18
lntron2-1526 16626
CFTR-
+ AGCUGAGAUGUAAAUGAAA 19
lntron2-1527 16627
CFTR-
+ GAGCUGAGAUGUAAAUGAAA 20
lntron2-1528 16628
CFTR-
+ GGAGCUGAGAUGUAAAUGAAA 21
lntron2-1529 16629
CFTR-
+ AGGAGCUGAGAUGUAAAUGAAA 22
Intron2-1530 16630
CFTR-
+ CAGGAGCUGAGAUGUAAAUGAAA 23
lntron2-1531 16631
CFTR-
+ UCAGGAGCUGAGAUGUAAAUGAAA 24
lntron2-1532 16632
CFTR-
+ GGGAUACAUCAUAAACAA 18
lntron2-1533 16633
CFTR-
+ GGGGAUACAUCAUAAACAA 19
lntron2-1534 16634
CFTR-
+ UGGGGAUACAUCAUAAACAA 20
lntron2-1535 16635
CFTR-
+ UUGGGGAUACAUCAUAAACAA 21
lntron2-1536 16636
CFTR-
+ CUUGGGGAUACAUCAUAAACAA 22
lntron2-1537 16637
CFTR-
+ ACU UGGGGAUACAUCAUAAACAA 23
lntron2-1538 16638
CFTR-
+ CACUUGGGGAUACAUCAUAAACAA 24
lntron2-1539 16639
496
5535.1 CFTR-
+ ACACUCCAGCCUGGGCAA 18
Intron2-1540 16640
CFTR-
+ UACACUCCAGCCUGGGCAA 19
lntron2-1541 16641
CFTR-
+ UUACACUCCAGCCUGGGCAA 20
lntron2-1542 16642
CFTR-
+ AUUACACUCCAGCCUGGGCAA 21
lntron2-1543 16643
CFTR-
+ CAUUACACUCCAGCCUGGGCAA 22
lntron2-1544 16644
CFTR-
+ CCAUUACACUCCAGCCUGGGCAA 23
lntron2-1545 16645
CFTR-
+ ACCAUUACACUCCAGCCUGGGCAA 24
lntron2-1546 16646
CFTR-
+ ACUCACCUUCUCCAUCAA 18
lntron2-1547 16647
CFTR-
+ GACUCACCUUCUCCAUCAA 19
lntron2-1548 16648
CFTR-
+ AGACUCACCUUCUCCAUCAA 20
lntron2-239 15339
CFTR-
+ CAGACUCACCUUCUCCAUCAA 21
lntron2-1549 16649
CFTR-
+ GCAGACUCACCUUCUCCAUCAA 22
Intron2-1550 16650
CFTR-
+ AGCAGACUCACCUUCUCCAUCAA 23
lntron2-1551 16651
CFTR-
+ GAGCAGACUCACCUUCUCCAUCAA 24
lntron2-1552 16652
CFTR-
+ AU ACCAAU U U U AU AAG AA 18
lntron2-1553 16653
CFTR-
+ AAU ACCAAU U U U AU AAG AA 19
lntron2-1554 16654
CFTR-
+ AAAU ACCAAU U U U AU AAG AA 20
lntron2-1555 16655
CFTR-
+ CAAAU ACCAAU U U U AU AAG AA 21
lntron2-1556 16656
CFTR-
+ U CAAAU ACCAAU U U U AU AAG AA 22
lntron2-1557 16657
CFTR-
+ U U CAAAU ACCAAU U U U AU AAG AA 23
lntron2-1558 16658
CFTR-
+ U U U CAAAU ACCAAU U U U AU AAG AA 24
lntron2-1559 16659
497
5535.1 CFTR-
+ ACCAGGCCCAGAUCAGAA 18
Intron2-1560 16660
CFTR-
+ UACCAGGCCCAGAUCAGAA 19
lntron2-1561 16661
CFTR-
+ AUACCAGGCCCAGAUCAGAA 20
lntron2-242 15342
CFTR-
+ CAU ACCAGGCCCAGAUCAGAA 21
lntron2-1562 16662
CFTR-
+ ACAUACCAGGCCCAGAUCAGAA 22
lntron2-1563 16663
CFTR-
+ CACAUACCAGGCCCAGAUCAGAA 23
lntron2-1564 16664
CFTR-
+ CCACAU ACCAGGCCCAGAUCAGAA 24
lntron2-1565 16665
CFTR-
+ CUAACCUUUUGAUUGGAA 18
lntron2-1566 16666
CFTR-
+ CCUAACCUUUUGAUUGGAA 19
lntron2-1567 16667
CFTR-
+ UCCUAACCUUUUGAUUGGAA 20
lntron2-246 15346
CFTR-
+ AUCCUAACCUUUUGAUUGGAA 21
lntron2-1568 16668
CFTR-
+ GAUCCUAACCUUUUGAUUGGAA 22
lntron2-1569 16669
CFTR-
+ GGAUCCUAACCUUUUGAUUGGAA 23
Intron2-1570 16670
CFTR-
+ AGGAUCCUAACCUUUUGAUUGGAA 24
lntron2-1571 16671
CFTR-
+ UGGCAUAGCAUUGUUGAA 18
lntron2-1572 16672
CFTR-
+ CUGGCAUAGCAUUGUUGAA 19
lntron2-1573 16673
CFTR-
+ ACUGGCAUAGCAUUGUUGAA 20
lntron2-1574 16674
CFTR-
+ UACUGGCAUAGCAUUGUUGAA 21
lntron2-1575 16675
CFTR-
+ GUACUGGCAUAGCAUUGUUGAA 22
lntron2-1576 16676
CFTR-
+ UGUACUGGCAUAGCAUUGUUGAA 23
lntron2-1577 16677
CFTR-
+ UUGUACUGGCAUAGCAUUGUUGAA 24
lntron2-1578 16678
498
5535.1 CFTR-
+ AAAACAAAACAAAAAUAA 18
lntron2-1579 16679
CFTR-
+ CAAAACAAAACAAAAAUAA 19
Intron2-1580 16680
CFTR-
+ ACAAAACAAAACAAAAAUAA 20
lntron2-1581 16681
CFTR-
+ AACAAAACAAAACAAAAAUAA 21
lntron2-1582 16682
CFTR-
+ AAACAAAACAAAACAAAAAUAA 22
lntron2-1583 16683
CFTR-
+ AAAA CAAAACAAAACAAAAAUAA 23
lntron2-1584 16684
CFTR-
+ AAAAACAAAACAAAACAAAAAUAA 24
lntron2-1585 16685
CFTR-
+ A C AC C A AG U G U U C A A U A A 18
lntron2-1586 16686
CFTR-
+ CAC ACC AAG U G U U CAAU AA 19
lntron2-1587 16687
CFTR-
+ ACACACCAAG UG U U CAAU AA 20
lntron2-1588 16688
CFTR-
+ CACACACCAAGUGUUCAAUAA 21
lntron2-1589 16689
CFTR-
+ GCACACACCAAGUGUUCAAUAA 22
Intron2-1590 16690
CFTR-
+ UGCACACACCAAGUGUUCAAUAA 23
lntron2-1591 16691
CFTR-
+ UUGCACACACCAAGUGUUCAAUAA 24
lntron2-1592 16692
CFTR-
+ UCAGGAGCUGAGAUGUAA 18
lntron2-1593 16693
CFTR-
+ UUCAGGAGCUGAGAUGUAA 19
lntron2-1594 16694
CFTR-
+ CUUCAGGAGCUGAGAUGUAA 20
lntron2-1595 16695
CFTR-
+ ACUUCAGGAGCUGAGAUGUAA 21
lntron2-1596 16696
CFTR-
+ UACUUCAGGAGCUGAGAUGUAA 22
lntron2-1597 16697
CFTR-
+ AUACUUCAGGAGCUGAGAUGUAA 23
lntron2-1598 16698
CFTR-
+ CAUACUUCAGGAGCUGAGAUGUAA 24
lntron2-1599 16699
499
5535.1 CFTR-
+ GGAAAUGAAUUUAAUUAA 18
Intron2-1600 16700
CFTR-
+ AGGAAAUGAAUUUAAUUAA 19
Intron2-1601 16701
CFTR-
+ AAGG AAAUG AAU U U AAU U AA 20
Intron2-1602 16702
CFTR-
+ AAAGGAAAUGAAUUUAAUUAA 21
Intron2-1603 16703
CFTR-
+ AAAAGG AAAUG AAU U U AAU U AA 22
Intron2-1604 16704
CFTR-
+ AAAAAGG AAAUG AAU U U AAU U AA 23
Intron2-1605 16705
CFTR-
+ AAAAAAGGAAAUGAAUUUAAUUAA 24
Intron2-1606 16706
CFTR-
+ U U U U AAAU UG AAU CAACA 18
Intron2-1607 16707
CFTR-
+ U U U U U AAAU UG AAU CAACA 19
Intron2-1608 16708
CFTR-
+ U U U U U U AAAU UG AAU CAACA 20
lntron2-621 15721
CFTR-
+ AUUUUUUAAAUUGAAUCAACA 21
Intron2-1609 16709
CFTR-
+ UAUUUUUUAAAUUGAAUCAACA 22
Intron2-1610 16710
CFTR-
+ AUAUUUUU U AAAU UG AAU CAACA 23
lntron2-1611 16711
CFTR-
+ UAUAUUUUU U AAAU UG AAU CAACA 24
lntron2-1612 16712
CFTR-
+ CCACCUUUCUCUCACACA 18
lntron2-1613 16713
CFTR-
+ UCCACCUUUCUCUCACACA 19
lntron2-1614 16714
CFTR-
+ CUCCACCUUUCUCUCACACA 20
lntron2-1615 16715
CFTR-
+ UCUCCACCUUUCUCUCACACA 21
lntron2-1616 16716
CFTR-
+ UUCUCCACCUUUCUCUCACACA 22
lntron2-1617 16717
CFTR-
+ CUUCUCCACCUUUCUCUCACACA 23
lntron2-1618 16718
CFTR-
+ GCUUCUCCACCUUUCUCUCACACA 24
lntron2-1619 16719
500
5535.1 CFTR-
+ UCCAGCCUGGGUGACACA 18
Intron2-1620 16720
CFTR-
+ CUCCAGCCUGGGUGACACA 19
lntron2-1621 16721
CFTR-
+ ACUCCAGCCUGGGUGACACA 20
lntron2-1622 16722
CFTR-
+ CACUCCAGCCUGGGUGACACA 21
lntron2-1623 16723
CFTR-
+ ACACUCCAGCCUGGGUGACACA 22
lntron2-1624 16724
CFTR-
+ UACACUCCAGCCUGGGUGACACA 23
lntron2-1625 16725
CFTR-
+ CUACACUCCAGCCUGGGUGACACA 24
lntron2-1626 16726
CFTR-
+ AAAAU U U CAUG AACCACA 18
lntron2-1627 16727
CFTR-
+ AAAAAU U U CAUG AACCACA 19
lntron2-1628 16728
CFTR-
+ GAAAAAU U U CAUG AACCACA 20
lntron2-455 15555
CFTR-
+ UGAAAAAUUUCAUGAACCACA 21
lntron2-1629 16729
CFTR-
+ AUGAAAAAUUUCAUGAACCACA 22
Intron2-1630 16730
CFTR-
+ GAUGAAAAAUUUCAUGAACCACA 23
lntron2-1631 16731
CFTR-
+ AGAUGAAAAAUUUCAUGAACCACA 24
lntron2-1632 16732
CFTR-
+ G U GAAAAAG U GG U CC AC A 18
lntron2-1633 16733
CFTR-
+ U G U GAAAAAG U GG U CC AC A 19
lntron2-1634 16734
CFTR-
+ AUGUGAAAAAGUGGUCCACA 20
lntron2-256 15356
CFTR-
+ AAUGUGAAAAAGUGGUCCACA 21
lntron2-1635 16735
CFTR-
+ C A A U G U G A A A A AG UGGUCCACA 22
lntron2-1636 16736
CFTR-
+ UCAAUGUGAAAAAGUGGUCCACA 23
lntron2-1637 16737
CFTR-
+ UUCAAUGUGAAAAAGUGGUCCACA 24
lntron2-1638 16738
501
5535.1 CFTR-
+ GCCUUUUUUCUCUUCACA 18
lntron2-1639 16739
CFTR-
+ AGCCUUUUUUCUCUUCACA 19
Intron2-1640 16740
CFTR-
+ AAGCCUUUUUUCUCUUCACA 20
lntron2-1641 16741
CFTR-
+ AAAGCCUUUUUUCUCUUCACA 21
lntron2-1642 16742
CFTR-
+ GAAAGCCUUUUUUCUCUUCACA 22
lntron2-1643 16743
CFTR-
+ UGAAAGCCUUUUUUCUCUUCACA 23
lntron2-1644 16744
CFTR-
+ AUGAAAGCCUUUUUUCUCUUCACA 24
lntron2-1645 16745
CFTR-
+ CACAU U U AG CCAAGG ACA 18
lntron2-1646 16746
CFTR-
+ UCACAUUUAGCCAAGGACA 19
lntron2-1647 16747
CFTR-
+ UUCACAUUUAGCCAAGGACA 20
lntron2-1648 16748
CFTR-
+ UUUCACAUUUAGCCAAGGACA 21
lntron2-1649 16749
CFTR-
+ U U U U CACAU U U AGCCAAGG ACA 22
Intron2-1650 16750
CFTR-
+ U U U U U CACAU U U AGCCAAGG ACA 23
lntron2-1651 16751
CFTR-
+ AU U U U U CACAU U U AG CCAAGG ACA 24
lntron2-1652 16752
CFTR-
+ AUCAACAUGGGGGAUACA 18
lntron2-1653 16753
CFTR-
+ AAUCAACAUGGGGGAUACA 19
lntron2-1654 16754
CFTR-
+ GAAUCAACAUGGGGGAUACA 20
lntron2-1655 16755
CFTR-
+ UGAAUCAACAUGGGGGAUACA 21
lntron2-1656 16756
CFTR-
+ UUGAAUCAACAUGGGGGAUACA 22
lntron2-1657 16757
CFTR-
+ AUUGAAUCAACAUGGGGGAUACA 23
lntron2-1658 16758
CFTR-
+ AAUUGAAUCAACAUGGGGGAUACA 24
lntron2-1659 16759
502
5535.1 CFTR-
+ GAUCAGAUGGGAAAGCCA 18
Intron2-1660 16760
CFTR-
+ GGAUCAGAUGGGAAAGCCA 19
lntron2-1661 16761
CFTR-
+ UGGAUCAGAUGGGAAAGCCA 20
lntron2-623 15723
CFTR-
+ AUGGAUCAGAUGGGAAAGCCA 21
lntron2-1662 16762
CFTR-
+ AAUGGAUCAGAUGGGAAAGCCA 22
lntron2-1663 16763
CFTR-
+ AAAUGGAUCAGAUGGGAAAGCCA 23
lntron2-1664 16764
CFTR-
+ GAAAUGGAUCAGAUGGGAAAGCCA 24
lntron2-1665 16765
CFTR-
+ CAGGAGACGAAGUUUGCA 18
lntron2-1666 16766
CFTR-
+ CCAGGAGACGAAGUUUGCA 19
lntron2-1667 16767
CFTR-
+ CCCAGGAGACGAAGUUUGCA 20
lntron2-1668 16768
CFTR-
+ ACCCAGGAGACGAAGUUUGCA 21
lntron2-1669 16769
CFTR-
+ AACCCAGG AG ACG AAG U U UG CA 22
Intron2-1670 16770
CFTR-
+ G AACCCAGG AG ACG AAG U U UG CA 23
lntron2-1671 16771
CFTR-
+ UGAACCCAGGAGACGAAGUUUGCA 24
lntron2-1672 16772
CFTR-
+ CAGGAGGCAGAGUUUGCA 18
lntron2-1673 16773
CFTR-
+ CCAGGAGGCAGAGUUUGCA 19
lntron2-1674 16774
CFTR-
+ CCCAGGAGGCAGAGUUUGCA 20
lntron2-1675 16775
CFTR-
+ ACCCAGGAGGCAGAGUUUGCA 21
lntron2-1676 16776
CFTR-
+ AACCCAGGAGGCAGAGUUUGCA 22
lntron2-1677 16777
CFTR-
+ GAACCCAGGAGGCAGAGUUUGCA 23
lntron2-1678 16778
CFTR-
+ UGAACCCAGGAGGCAGAGUUUGCA 24
lntron2-1679 16779
503
5535.1 CFTR-
+ GACUCACCUUCUCCAUCA 18
Intron2-1680 16780
CFTR-
+ AGACUCACCUUCUCCAUCA 19
lntron2-1681 16781
CFTR-
+ CAGACUCACCUUCUCCAUCA 20
lntron2-1682 16782
CFTR-
+ GCAGACUCACCUUCUCCAUCA 21
lntron2-1683 16783
CFTR-
+ AGCAGACUCACCUUCUCCAUCA 22
lntron2-1684 16784
CFTR-
+ GAGCAGACUCACCUUCUCCAUCA 23
lntron2-1685 16785
CFTR-
+ GGAGCAGACUCACCUUCUCCAUCA 24
lntron2-1686 16786
CFTR-
+ UUUCGUGGUCCUUAAAGA 18
lntron2-1687 16787
CFTR-
+ CUUUCGUGGUCCUUAAAGA 19
lntron2-1688 16788
CFTR-
+ UCUUUCGUGGUCCUUAAAGA 20
lntron2-1689 16789
CFTR-
+ UUCUUUCGUGGUCCUUAAAGA 21
Intron2-1690 16790
CFTR-
+ CUUCUUUCGUGGUCCUUAAAGA 22
lntron2-1691 16791
CFTR-
+ CCUUCUUUCGUGGUCCUUAAAGA 23
lntron2-1692 16792
CFTR-
+ UCCUUCUUUCGUGGUCCUUAAAGA 24
lntron2-1693 16793
CFTR-
+ UACCAGGCCCAGAUCAGA 18
lntron2-1694 16794
CFTR-
+ AUACCAGGCCCAGAUCAGA 19
lntron2-1695 16795
CFTR-
+ CAUACCAGGCCCAGAUCAGA 20
lntron2-275 15375
CFTR-
+ ACAUACCAGGCCCAGAUCAGA 21
lntron2-1696 16796
CFTR-
+ CACAUACCAGGCCCAGAUCAGA 22
lntron2-1697 16797
CFTR-
+ CCACAUACCAGGCCCAGAUCAGA 23
lntron2-1698 16798
CFTR-
+ ACCACAUACCAGGCCCAGAUCAGA 24
lntron2-1699 16799
504
5535.1 CFTR-
+ AAGGAGAAAUGGAUCAGA 18
Intron2-1700 16800
CFTR-
+ AAAGGAGAAAUGGAUCAGA 19
Intron2-1701 16801
CFTR-
+ CAAAGGAGAAAUGGAUCAGA 20
lntron2-276 15376
CFTR-
+ U C A A AG GAG AAA UGGAUCAGA 21
Intron2-1702 16802
CFTR-
+ AUCAAAGGAGAAAUGGAUCAGA 22
Intron2-1703 16803
CFTR-
+ CAUCAAAGGAGAAAUGGAUCAGA 23
Intron2-1704 16804
CFTR-
+ CCAUCAAAGGAGAAAUGGAUCAGA 24
Intron2-1705 16805
CFTR-
+ CAUCAUAAACAAAAGAGA 18
Intron2-1706 16806
CFTR-
+ ACAUCAUAAACAAAAGAGA 19
Intron2-1707 16807
CFTR-
+ UACAUCAUAAACAAAAGAGA 20
Intron2-1708 16808
CFTR-
+ AUACAUCAUAAACAAAAGAGA 21
Intron2-1709 16809
CFTR-
+ GAUACAUCAUAAACAAAAGAGA 22
Intron2-1710 16810
CFTR-
+ GGAUACAUCAUAAACAAAAGAGA 23
lntron2-1711 16811
CFTR-
+ GGGAUACAUCAUAAACAAAAGAGA 24
lntron2-1712 16812
CFTR-
+ UCCCAGCUACUCAGGAGA 18
lntron2-1713 16813
CFTR-
+ GUCCCAGCUACUCAGGAGA 19
lntron2-1714 16814
CFTR-
+ AGUCCCAGCUACUCAGGAGA 20
lntron2-1715 16815
CFTR-
+ UAGUCCCAGCUACUCAGGAGA 21
lntron2-1716 16816
CFTR-
+ GUAGUCCCAGCUACUCAGGAGA 22
lntron2-1717 16817
CFTR-
+ UGUAGUCCCAGCUACUCAGGAGA 23
lntron2-1718 16818
CFTR-
+ CUGUAGUCCCAGCUACUCAGGAGA 24
lntron2-1719 16819
505
5535.1 CFTR-
+ UAUGAAAGAAAAAAUAGA 18
Intron2-1720 16820
CFTR-
+ CUAUGAAAGAAAAAAUAGA 19
lntron2-1721 16821
CFTR-
+ G C U A U G A A AG A A A A A A U AG A 20
lntron2-1722 16822
CFTR-
+ AGCUAUGAAAGAAAAAAUAGA 21
lntron2-1723 16823
CFTR-
+ U AG C U A U G A A AG A A A A A A U AG A 22
lntron2-1724 16824
CFTR-
+ U U AGCUAUGAAAGAAAAAAUAGA 23
lntron2-1725 16825
CFTR-
+ GUUAGCUAUGAAAGAAAAAAUAGA 24
lntron2-1726 16826
CFTR-
+ GAUACAGUGAAAACUGGA 18
lntron2-1727 16827
CFTR-
+ GGAUACAGUGAAAACUGGA 19
lntron2-1728 16828
CFTR-
+ GGGAUACAGUGAAAACUGGA 20
lntron2-1729 16829
CFTR-
+ GGGGAUACAGUGAAAACUGGA 21
Intron2-1730 16830
CFTR-
+ GGGGGAUACAGUGAAAACUGGA 22
lntron2-1731 16831
CFTR-
+ UGGGGGAUACAGUGAAAACUGGA 23
lntron2-1732 16832
CFTR-
+ AUGGGGGAUACAGUGAAAACUGGA 24
lntron2-1733 16833
CFTR-
+ CCUAACCUUUUGAUUGGA 18
lntron2-1734 16834
CFTR-
+ UCCUAACCUUUUGAUUGGA 19
lntron2-1735 16835
CFTR-
+ AUCCUAACCUUUUGAUUGGA 20
lntron2-1736 16836
CFTR-
+ GAUCCUAACCUUUUGAUUGGA 21
lntron2-1737 16837
CFTR-
+ GGAUCCUAACCUUUUGAUUGGA 22
lntron2-1738 16838
CFTR-
+ AGGAUCCUAACCUUUUGAUUGGA 23
lntron2-1739 16839
CFTR-
+ AAGGAUCCUAACCUUUUGAUUGGA 24
Intron2-1740 16840
506
5535.1 CFTR-
+ AGAGAAUGUUAGCUAUGA 18
lntron2-1741 16841
CFTR-
+ CAGAGAAUGUUAGCUAUGA 19
lntron2-1742 16842
CFTR-
+ GCAGAGAAUGUUAGCUAUGA 20
lntron2-1743 16843
CFTR-
+ AGCAGAGAAUGUUAGCUAUGA 21
lntron2-1744 16844
CFTR-
+ GAGCAGAGAAUGUUAGCUAUGA 22
lntron2-1745 16845
CFTR-
+ AGAGCAGAGAAUGUUAGCUAUGA 23
lntron2-1746 16846
CFTR-
+ GAGAGCAGAGAAUGUUAGCUAUGA 24
lntron2-1747 16847
CFTR-
+ UCCACUCAGAGUGGCUGA 18
lntron2-1748 16848
CFTR-
+ UUCCACUCAGAGUGGCUGA 19
lntron2-1749 16849
CFTR-
+ UUUCCACUCAGAGUGGCUGA 20
Intron2-1750 16850
CFTR-
+ CUUUCCACUCAGAGUGGCUGA 21
lntron2-1751 16851
CFTR-
+ GCUUUCCACUCAGAGUGGCUGA 22
lntron2-1752 16852
CFTR-
+ UGCUUUCCACUCAGAGUGGCUGA 23
lntron2-1753 16853
CFTR-
+ AUGCUUUCCACUCAGAGUGGCUGA 24
lntron2-1754 16854
CFTR-
+ AGGAUCCUAACCUUUUGA 18
lntron2-1755 16855
CFTR-
+ AAGGAUCCUAACCUUUUGA 19
lntron2-1756 16856
CFTR-
+ AAAGGAUCCUAACCUUUUGA 20
lntron2-1757 16857
CFTR-
+ AAAAGGAUCCUAACCUUUUGA 21
lntron2-1758 16858
CFTR-
+ CAAAAGGAUCCUAACCUUUUGA 22
lntron2-1759 16859
CFTR-
+ UCAAAAGGAUCCUAACCUUUUGA 23
Intron2-1760 16860
CFTR-
+ AUCAAAAGGAUCCUAACCUUUUGA 24
lntron2-1761 16861
507
5535.1 CFTR-
+ AGAGUAAGAAGCU AAA U A 18
lntron2-1762 16862
CFTR-
+ C AG AG U A AG A AG C U AAA U A 19
lntron2-1763 16863
CFTR-
+ UCAGAGUAAGAAGCUAAAUA 20
lntron2-287 15387
CFTR-
+ CUCAGAGUAAGAAGCUAAAUA 21
lntron2-1764 16864
CFTR-
+ ACUCAGAGUAAGAAGCU AAA U A 22
lntron2-1765 16865
CFTR-
+ UACUCAGAGUAAGAAGCUAAAUA 23
lntron2-1766 16866
CFTR-
+ UUACUCAGAGUAAGAAGCUAAAUA 24
lntron2-1767 16867
CFTR-
+ AAACAAACAAAAAACAUA 18
lntron2-1768 16868
CFTR-
+ CAAACAAACAAAAAACAUA 19
lntron2-1769 16869
CFTR-
+ ACAAACAAACAAAAAACAUA 20
Intron2-1770 16870
CFTR-
+ CACAAACAAACAAAAAACAUA 21
lntron2-1771 16871
CFTR-
+ ACACAAACAAACAAAAAACAUA 22
lntron2-1772 16872
CFTR-
+ AACACAAACAAACAAAAAACAUA 23
lntron2-1773 16873
CFTR-
+ CAACACAAACAAACAAAAAACAUA 24
lntron2-1774 16874
CFTR-
+ GUUUUCUUUUAAAUACUA 18
lntron2-1775 16875
CFTR-
+ UGUUUUCUUUUAAAUACUA 19
lntron2-1776 16876
CFTR-
+ CUGUUUUCUUUUAAAUACUA 20
lntron2-1777 16877
CFTR-
+ UCUGUUUUCUUUUAAAUACUA 21
lntron2-1778 16878
CFTR-
+ UUCUGUUUUCUUUUAAAUACUA 22
lntron2-1779 16879
CFTR-
+ UUUCUGUUUUCUUUUAAAUACUA 23
Intron2-1780 16880
CFTR-
+ CUUUCUGUUUUCUUUUAAAUACUA 24
lntron2-1781 16881
508
5535.1 CFTR-
+ GGGGGACUACCAUUCCUA 18
lntron2-1782 16882
CFTR-
+ GGGGGGACUACCAUUCCUA 19
lntron2-1783 16883
CFTR-
+ GGGGGGGACUACCAUUCCUA 20
lntron2-1784 16884
CFTR-
+ UGGGGGGGACUACCAUUCCUA 21
lntron2-1785 16885
CFTR-
+ AUGGGGGGGACUACCAUUCCUA 22
lntron2-1786 16886
CFTR-
+ UAUGGGGGGGACUACCAUUCCUA 23
lntron2-1787 16887
CFTR-
+ UUAUGGGGGGGACUACCAUUCCUA 24
lntron2-1788 16888
CFTR-
+ UCCCCUAGAAGCUUGCUA 18
lntron2-1789 16889
CFTR-
+ AUCCCCUAGAAGCUUGCUA 19
Intron2-1790 16890
CFTR-
+ CAUCCCCUAGAAGCUUGCUA 20
lntron2-1791 16891
CFTR-
+ GCAUCCCCUAGAAGCUUGCUA 21
lntron2-1792 16892
CFTR-
+ GGCAUCCCCUAGAAGCUUGCUA 22
lntron2-1793 16893
CFTR-
+ UGGCAUCCCCUAGAAGCUUGCUA 23
lntron2-1794 16894
CFTR-
+ UUGGCAUCCCCUAGAAGCUUGCUA 24
lntron2-1795 16895
CFTR-
+ UGGCUCUAAAUCACUCUA 18
lntron2-1796 16896
CFTR-
+ AUGGCUCUAAAUCACUCUA 19
lntron2-1797 16897
CFTR-
+ CAUGGCUCUAAAUCACUCUA 20
lntron2-1798 16898
CFTR-
+ ACAUGGCUCUAAAUCACUCUA 21
lntron2-1799 16899
CFTR-
+ AACAUGGCUCUAAAUCACUCUA 22
Intron2-1800 16900
CFTR-
+ AAACAUGGCUCUAAAUCACUCUA 23
Intron2-1801 16901
CFTR-
+ UAAACAUGGCUCUAAAUCACUCUA 24
Intron2-1802 16902
509
5535.1 CFTR-
+ GUAAAUGAAAGUGAAGUA 18
Intron2-1803 16903
CFTR-
+ UGUAAAUGAAAGUGAAGUA 19
Intron2-1804 16904
CFTR-
+ AUGUAAAUGAAAGUGAAGUA 20
Intron2-1805 16905
CFTR-
+ GAUGUAAAUGAAAGUGAAGUA 21
Intron2-1806 16906
CFTR-
+ AGAUGUAAAUGAAAGUGAAGUA 22
Intron2-1807 16907
CFTR-
+ GAGAUGUAAAUGAAAGUGAAGUA 23
Intron2-1808 16908
CFTR-
+ UGAGAUGUAAAUGAAAGUGAAGUA 24
Intron2-1809 16909
CFTR-
+ CUUAAUUUUCAAACUGUA 18
Intron2-1810 16910
CFTR-
+ UCUUAAUUUUCAAACUGUA 19
lntron2-1811 16911
CFTR-
+ AUCUUAAUUUUCAAACUGUA 20
lntron2-1812 16912
CFTR-
+ CAUCUUAAUUUUCAAACUGUA 21
lntron2-1813 16913
CFTR-
+ UCAUCUUAAUUUUCAAACUGUA 22
lntron2-1814 16914
CFTR-
+ AUCAUCUUAAUUUUCAAACUGUA 23
lntron2-1815 16915
CFTR-
+ UAUCAUCUUAAUUUUCAAACUGUA 24
lntron2-1816 16916
CFTR-
+ UGCCACUGAUUUCUGUUA 18
lntron2-1817 16917
CFTR-
+ UUGCCACUGAUUUCUGUUA 19
lntron2-1818 16918
CFTR-
+ AUUGCCACUGAUUUCUGUUA 20
lntron2-1819 16919
CFTR-
+ UAUUGCCACUGAUUUCUGUUA 21
Intron2-1820 16920
CFTR-
+ UUAUUGCCACUGAUUUCUGUUA 22
lntron2-1821 16921
CFTR-
+ GUUAUUGCCACUGAUUUCUGUUA 23
lntron2-1822 16922
CFTR-
+ AGUUAUUGCCACUGAUUUCUGUUA 24
lntron2-1823 16923
510
5535.1 CFTR-
+ AAACUGAGAGAUUCUUUA 18
lntron2-1824 16924
CFTR-
+ GAAACUGAGAGAUUCUUUA 19
lntron2-1825 16925
CFTR-
+ GGAAACUGAGAGAUUCUUUA 20
lntron2-57 15157
CFTR-
+ AGGAAACUGAGAGAUUCUUUA 21
lntron2-1826 16926
CFTR-
+ AAGGAAACUGAGAGAUUCUUUA 22
lntron2-1827 16927
CFTR-
+ AAAGGAAACUGAGAGAUUCUUUA 23
lntron2-1828 16928
CFTR-
+ G AAAGG AAACUG AG AG AU U CU U U A 24
lntron2-1829 16929
CFTR-
+ GGGGGAUACAGUGAAAAC 18
Intron2-1830 16930
CFTR-
+ UGGGGGAUACAGUGAAAAC 19
lntron2-1831 16931
CFTR-
+ AUGGGGGAUACAGUGAAAAC 20
lntron2-297 15397
CFTR-
+ CAUGGGGGAUACAGUGAAAAC 21
lntron2-1832 16932
CFTR-
+ ACAUGGGGGAUACAGUGAAAAC 22
lntron2-1833 16933
CFTR-
+ AACAUGGGGGAUACAGUGAAAAC 23
lntron2-1834 16934
CFTR-
+ CAACAUGGGGGAUACAGUGAAAAC 24
lntron2-1835 16935
CFTR-
+ UUCUUUAAUGGGUGAAAC 18
lntron2-1836 16936
CFTR-
+ UUUCUUUAAUGGGUGAAAC 19
lntron2-1837 16937
CFTR-
+ AUUUCUUUAAUGGGUGAAAC 20
lntron2-1838 16938
CFTR-
+ AAUUUCUUUAAUGGGUGAAAC 21
lntron2-1839 16939
CFTR-
+ GAAUUUCUUUAAUGGGUGAAAC 22
Intron2-1840 16940
CFTR-
+ GGAAUUUCUUUAAUGGGUGAAAC 23
lntron2-1841 16941
CFTR-
+ GGGAAUUUCUUUAAUGGGUGAAAC 24
lntron2-1842 16942
511
5535.1 CFTR-
+ U U U U U AAAU UG AAU CAAC 18
lntron2-1843 16943
CFTR-
+ U U U U U U AAAU UG AAU CAAC 19
lntron2-1844 16944
CFTR-
+ AU U U U U U AAAU UG AAU CAAC 20
lntron2-1845 16945
CFTR-
+ UAUUUUUUAAAUUGAAUCAAC 21
lntron2-1846 16946
CFTR-
+ AUAUUUUUUAAAUUGAAUCAAC 22
lntron2-1847 16947
CFTR-
+ UAUAUUUUU U AAAU UG AAU CAAC 23
lntron2-1848 16948
CFTR-
+ GUAUAUUUUUUAAAUUGAAUCAAC 24
lntron2-1849 16949
CFTR-
+ G G AG C A A AG AGUUCUAAC 18
Intron2-1850 16950
CFTR-
+ AGG AGCAAAG AG U U CU AAC 19
lntron2-1851 16951
CFTR-
+ UAGGAGCAAAGAGUUCUAAC 20
lntron2-1852 16952
CFTR-
+ AUAGGAGCAAAGAGUUCUAAC 21
lntron2-1853 16953
CFTR-
+ GAUAGGAGCAAAGAGUUCUAAC 22
lntron2-1854 16954
CFTR-
+ AG AU AGG AGCAAAG AG U U CU AAC 23
lntron2-1855 16955
CFTR-
+ AAGAUAGGAGCAAAGAGUUCUAAC 24
lntron2-1856 16956
CFTR-
+ CAACCAUCUGGCAACCAC 18
lntron2-1857 16957
CFTR-
+ UCAACCAUCUGGCAACCAC 19
lntron2-1858 16958
CFTR-
+ UUCAACCAUCUGGCAACCAC 20
lntron2-1859 16959
CFTR-
+ CU UCAACCAUCUGGCAACCAC 21
Intron2-1860 16960
CFTR-
+ UCU UCAACCAUCUGGCAACCAC 22
lntron2-1861 16961
CFTR-
+ UUCUUCAACCAUCUGGCAACCAC 23
lntron2-1862 16962
CFTR-
+ GUUCUUCAACCAUCUGGCAACCAC 24
lntron2-1863 16963
512
5535.1 CFTR-
+ AAAAAU U U CAUG AACCAC 18
lntron2-1864 16964
CFTR-
+ GAAAAAU U U CAUG AACCAC 19
lntron2-1865 16965
CFTR-
+ UGAAAAAUUUCAUGAACCAC 20
lntron2-1866 16966
CFTR-
+ AUGAAAAAUUUCAUGAACCAC 21
lntron2-1867 16967
CFTR-
+ GAUGAAAAAUUUCAUGAACCAC 22
lntron2-1868 16968
CFTR-
+ AGAUGAAAAAUUUCAUGAACCAC 23
lntron2-1869 16969
CFTR-
+ GAGAUGAAAAAUUUCAUGAACCAC 24
Intron2-1870 16970
CFTR-
+ UGUGAAAAAGUGGUCCAC 18
lntron2-1871 16971
CFTR-
+ AUGUGAAAAAGUGGUCCAC 19
lntron2-1872 16972
CFTR-
+ AAUGUGAAAAAGUGGUCCAC 20
lntron2-1873 16973
CFTR-
+ CAAUGUGAAAAAGUGGUCCAC 21
lntron2-1874 16974
CFTR-
+ UCAAUGUGAAAAAGUGGUCCAC 22
lntron2-1875 16975
CFTR-
+ UUCAAUGUGAAAAAGUGGUCCAC 23
lntron2-1876 16976
CFTR-
+ GUUCAAUGUGAAAAAGUGGUCCAC 24
lntron2-1877 16977
CFTR-
+ AGGCCCUAUUCUAGGCAC 18
lntron2-1878 16978
CFTR-
+ CAGGCCCUAUUCUAGGCAC 19
lntron2-1879 16979
CFTR-
+ CCAGGCCCUAUUCUAGGCAC 20
Intron2-1880 16980
CFTR-
+ GCCAGGCCCUAUUCUAGGCAC 21
lntron2-1881 16981
CFTR-
+ UGCCAGGCCCUAUUCUAGGCAC 22
lntron2-1882 16982
CFTR-
+ AUGCCAGGCCCUAUUCUAGGCAC 23
lntron2-1883 16983
CFTR-
+ UAUGCCAGGCCCUAUUCUAGGCAC 24
lntron2-1884 16984
513
5535.1 CFTR-
+ CUGAGGCAGGAGAAUCAC 18
lntron2-1885 16985
CFTR-
+ GCUGAGGCAGGAGAAUCAC 19
lntron2-1886 16986
CFTR-
+ GGCUGAGGCAGGAGAAUCAC 20
lntron2-1887 16987
CFTR-
+ AGGCUGAGGCAGGAGAAUCAC 21
lntron2-1888 16988
CFTR-
+ GAGGCUGAGGCAGGAGAAUCAC 22
lntron2-1889 16989
CFTR-
+ AGAGGCUGAGGCAGGAGAAUCAC 23
Intron2-1890 16990
CFTR-
+ GAGAGGCUGAGGCAGGAGAAUCAC 24
lntron2-1891 16991
CFTR-
+ CCAAGGCGGGCAGAUCAC 18
lntron2-1892 16992
CFTR-
+ GCCAAGGCGGGCAGAUCAC 19
lntron2-1893 16993
CFTR-
+ GGCCAAGGCGGGCAGAUCAC 20
lntron2-1894 16994
CFTR-
+ AGGCCAAGGCGGGCAGAUCAC 21
lntron2-1895 16995
CFTR-
+ GAGGCCAAGGCGGGCAGAUCAC 22
lntron2-1896 16996
CFTR-
+ GGAGGCCAAGGCGGGCAGAUCAC 23
lntron2-1897 16997
CFTR-
+ GGGAGGCCAAGGCGGGCAGAUCAC 24
lntron2-1898 16998
CFTR-
+ CCAAGGUGGGCAGAUCAC 18
lntron2-1899 16999
CFTR-
+ GCCAAGGUGGGCAGAUCAC 19
Intron2-1900 17000
CFTR-
+ GGCCAAGGUGGGCAGAUCAC 20
Intron2-1901 17001
CFTR-
+ AGGCCAAGGUGGGCAGAUCAC 21
Intron2-1902 17002
CFTR-
+ GAGGCCAAGGUGGGCAGAUCAC 22
Intron2-1903 17003
CFTR-
+ GGAGGCCAAGGUGGGCAGAUCAC 23
Intron2-1904 17004
CFTR-
+ GGGAGGCCAAGGUGGGCAGAUCAC 24
Intron2-1905 17005
514
5535.1 CFTR-
+ AAAGUGAAG U AG AG AG AC 18
Intron2-1906 17006
CFTR-
+ GAAAGUGAAG U AG AG AG AC 19
Intron2-1907 17007
CFTR-
+ U GAAAGUGAAG U AG AG AG AC 20
Intron2-1908 17008
CFTR-
+ AUGAAAGUGAAGUAGAGAGAC 21
Intron2-1909 17009
CFTR-
+ AAUGAAAGUGAAGUAGAGAGAC 22
Intron2-1910 17010
CFTR-
+ AAA U G A A AG UGAAGUAGAGAGAC 23
lntron2-1911 17011
CFTR-
+ UAAAUGAAAGUGAAGUAGAGAGAC 24
lntron2-1912 17012
CFTR-
+ GCCUGUAAACCCAGCUAC 18
lntron2-1913 17013
CFTR-
+ UGCCUGUAAACCCAGCUAC 19
lntron2-1914 17014
CFTR-
+ GUGCCUGUAAACCCAGCUAC 20
lntron2-1915 17015
CFTR-
+ AGUGCCUGUAAACCCAGCUAC 21
lntron2-1916 17016
CFTR-
+ GAGUGCCUGUAAACCCAGCUAC 22
lntron2-1917 17017
CFTR-
+ CGAGUGCCUGUAAACCCAGCUAC 23
lntron2-1918 17018
CFTR-
+ GCGAGUGCCUGUAAACCCAGCUAC 24
lntron2-1919 17019
CFTR-
+ AUAGAAUGGGGUAGUUAC 18
Intron2-1920 17020
CFTR-
+ AAUAGAAUGGGGUAGUUAC 19
lntron2-1921 17021
CFTR-
+ AAAUAGAAUGGGGUAGUUAC 20
lntron2-1922 17022
CFTR-
+ AAAAUAGAAUGGGGUAGUUAC 21
lntron2-1923 17023
CFTR-
+ AAAAAUAGAAUGGGGUAGUUAC 22
lntron2-1924 17024
CFTR-
+ AAAAAAUAGAAUGGGGUAGUUAC 23
lntron2-1925 17025
CFTR-
+ GAAAAAAUAGAAUGGGGUAGUUAC 24
lntron2-1926 17026
515
5535.1 CFTR-
+ AGGAGAAUCACUUGAACC 18
lntron2-1927 17027
CFTR-
+ CAGGAGAAUCACUUGAACC 19
lntron2-1928 17028
CFTR-
+ GCAGGAGAAUCACUUGAACC 20
lntron2-1929 17029
CFTR-
+ GGCAGGAGAAUCACUUGAACC 21
Intron2-1930 17030
CFTR-
+ AGGCAGGAGAAUCACUUGAACC 22
lntron2-1931 17031
CFTR-
+ GAGGCAGGAGAAUCACUUGAACC 23
lntron2-1932 17032
CFTR-
+ UGAGGCAGGAGAAUCACUUGAACC 24
lntron2-1933 17033
CFTR-
+ CUGAGAUUCGCUUGAACC 18
lntron2-1934 17034
CFTR-
+ ACUGAGAUUCGCUUGAACC 19
lntron2-1935 17035
CFTR-
+ GACUGAGAUUCGCUUGAACC 20
lntron2-1936 17036
CFTR-
+ AGACUGAGAUUCGCUUGAACC 21
lntron2-1937 17037
CFTR-
+ GAGACUGAGAUUCGCUUGAACC 22
lntron2-1938 17038
CFTR-
+ GGAGACUGAGAUUCGCUUGAACC 23
lntron2-1939 17039
CFTR-
+ AGGAGACUGAGAUUCGCUUGAACC 24
Intron2-1940 17040
CFTR-
+ GAG C A A AG AGUUCUAACC 18
lntron2-1941 17041
CFTR-
+ GGAGCAAAGAGUUCUAACC 19
lntron2-1942 17042
CFTR-
+ AGGAGCAAAGAGUUCUAACC 20
Intron2-305 15405
CFTR-
+ UAGGAGCAAAGAGUUCUAACC 21
lntron2-1943 17043
CFTR-
+ AUAGGAGCAAAGAGUUCUAACC 22
lntron2-1944 17044
CFTR-
+ GAUAGGAGCAAAGAGUUCUAACC 23
lntron2-1945 17045
CFTR-
+ AGAUAGGAGCAAAGAGUUCUAACC 24
lntron2-1946 17046
516
5535.1 CFTR-
+ AAGUGAAGUAGAGAGACC 18
lntron2-1947 17047
CFTR-
+ AAAGUGAAGUAGAGAGACC 19
lntron2-1948 17048
CFTR-
+ GAAAGUGAAGUAGAGAGACC 20
Intron2-60 15160
CFTR-
+ UGAAAGUGAAGUAGAGAGACC 21
lntron2-1949 17049
CFTR-
+ AUGAAAGUGAAGUAGAGAGACC 22
Intron2-1950 17050
CFTR-
+ AAUGAAAGUGAAGUAGAGAGACC 23
lntron2-1951 17051
CFTR-
+ AAAUGAAAGUGAAGUAGAGAGACC 24
lntron2-1952 17052
CFTR-
+ AAGAGGUCUCUAGUGACC 18
lntron2-1953 17053
CFTR-
+ UAAGAGGUCUCUAGUGACC 19
lntron2-1954 17054
CFTR-
+ AUAAGAGGUCUCUAGUGACC 20
lntron2-1955 17055
CFTR-
+ CAU AAGAGGUCUCUAGUGACC 21
lntron2-1956 17056
CFTR-
+ UCAUAAGAGGUCUCUAGUGACC 22
lntron2-1957 17057
CFTR-
+ UUCAUAAGAGGUCUCUAGUGACC 23
lntron2-1958 17058
CFTR-
+ UUUCAUAAGAGGUCUCUAGUGACC 24
lntron2-1959 17059
CFTR-
+ GGAGAAUCACUUGAACCC 18
Intron2-1960 17060
CFTR-
+ AGGAGAAUCACUUGAACCC 19
lntron2-1961 17061
CFTR-
+ CAGGAGAAUCACUUGAACCC 20
lntron2-636 15736
CFTR-
+ GCAGGAGAAUCACUUGAACCC 21
lntron2-1962 17062
CFTR-
+ GGCAGGAGAAUCACUUGAACCC 22
lntron2-1963 17063
CFTR-
+ AGGCAGGAGAAUCACUUGAACCC 23
lntron2-1964 17064
CFTR-
+ GAGGCAGGAGAAUCACUUGAACCC 24
lntron2-1965 17065
517
5535.1 CFTR-
+ UGAGAUUCGCUUGAACCC 18
lntron2-1966 17066
CFTR-
+ CUGAGAUUCGCUUGAACCC 19
lntron2-1967 17067
CFTR-
+ ACUGAGAUUCGCUUGAACCC 20
lntron2-637 15737
CFTR-
+ GACUGAGAUUCGCUUGAACCC 21
lntron2-1968 17068
CFTR-
+ AGACUGAGAUUCGCUUGAACCC 22
lntron2-1969 17069
CFTR-
+ GAGACUGAGAUUCGCUUGAACCC 23
Intron2-1970 17070
CFTR-
+ GGAGACUGAGAUUCGCUUGAACCC 24
lntron2-1971 17071
CFTR-
+ AUGGAUCUUGGCAUCCCC 18
lntron2-1972 17072
CFTR-
+ CAUGGAUCUUGGCAUCCCC 19
lntron2-1973 17073
CFTR-
+ GCAUGGAUCUUGGCAUCCCC 20
lntron2-1974 17074
CFTR-
+ AGCAUGGAUCUUGGCAUCCCC 21
lntron2-1975 17075
CFTR-
+ AAGCAUGGAUCUUGGCAUCCCC 22
lntron2-1976 17076
CFTR-
+ UAAGCAUGGAUCUUGGCAUCCCC 23
lntron2-1977 17077
CFTR-
+ CUAAGCAUGGAUCUUGGCAUCCCC 24
lntron2-1978 17078
CFTR-
+ CUAGACUAUGAGUGGCCC 18
lntron2-1979 17079
CFTR-
+ UCUAGACUAUGAGUGGCCC 19
Intron2-1980 17080
CFTR-
+ UUCUAGACUAUGAGUGGCCC 20
lntron2-1981 17081
CFTR-
+ AUUCUAGACUAUGAGUGGCCC 21
lntron2-1982 17082
CFTR-
+ CAUUCUAGACUAUGAGUGGCCC 22
lntron2-1983 17083
CFTR-
+ UCAUUCUAGACUAUGAGUGGCCC 23
lntron2-1984 17084
CFTR-
+ UUCAUUCUAGACUAUGAGUGGCCC 24
lntron2-1985 17085
518
5535.1 CFTR-
+ AUUACCUUAAGACUUCCC 18
lntron2-1986 17086
CFTR-
+ CAUUACCUUAAGACUUCCC 19
lntron2-1987 17087
CFTR-
+ CCAUUACCUUAAGACUUCCC 20
lntron2-314 15414
CFTR-
+ GCCAUUACCUUAAGACUUCCC 21
lntron2-1988 17088
CFTR-
+ AGCCAUUACCUUAAGACUUCCC 22
lntron2-1989 17089
CFTR-
+ UAGCCAUUACCUUAAGACUUCCC 23
Intron2-1990 17090
CFTR-
+ GUAGCCAUUACCUUAAGACUUCCC 24
lntron2-1991 17091
CFTR-
+ GGAUCAGAUGGGAAAGCC 18
lntron2-1992 17092
CFTR-
+ UGGAUCAGAUGGGAAAGCC 19
lntron2-1993 17093
CFTR-
+ AUGGAUCAGAUGGGAAAGCC 20
lntron2-1994 17094
CFTR-
+ AAUGGAUCAGAUGGGAAAGCC 21
lntron2-1995 17095
CFTR-
+ AAAUGGAUCAGAUGGGAAAGCC 22
lntron2-1996 17096
CFTR-
+ GAAAUGGAUCAGAUGGGAAAGCC 23
lntron2-1997 17097
CFTR-
+ AGAAAUGGAUCAGAUGGGAAAGCC 24
lntron2-1998 17098
CFTR-
+ GAUUUUUCACAUUUAGCC 18
lntron2-1999 17099
CFTR-
+ GGAUUUUUCACAUUUAGCC 19
Intron2-2000 17100
CFTR-
+ GGGAUUUUUCACAUUUAGCC 20
Intron2-2001 17101
CFTR-
+ UGGGAUUUUUCACAUUUAGCC 21
Intron2-2002 17102
CFTR-
+ CUGGGAUUUUUCACAUUUAGCC 22
Intron2-2003 17103
CFTR-
+ UCUGGGAUUUUUCACAUUUAGCC 23
Intron2-2004 17104
CFTR-
+ CUCUGGGAUUUUUCACAUUUAGCC 24
Intron2-2005 17105
519
5535.1 CFTR-
+ GGGGGGGACUACCAUUCC 18
Intron2-2006 17106
CFTR-
+ UGGGGGGGACUACCAUUCC 19
Intron2-2007 17107
CFTR-
+ AUGGGGGGGACUACCAUUCC 20
Intron2-2008 17108
CFTR-
+ UAUGGGGGGGACUACCAUUCC 21
Intron2-2009 17109
CFTR-
+ UUAUGGGGGGGACUACCAUUCC 22
Intron2-2010 17110
CFTR-
+ UUUAUGGGGGGGACUACCAUUCC 23
Intron2-2011 17111
CFTR-
+ CUUUAUGGGGGGGACUACCAUUCC 24
Intron2-2012 17112
CFTR-
+ CAUUACCUUAAGACUUCC 18
Intron2-2013 17113
CFTR-
+ CCAUUACCUUAAGACUUCC 19
Intron2-2014 17114
CFTR-
+ GCCAU UACCUUAAGACUUCC 20
Intron2-2015 17115
CFTR-
+ AGCCAUUACCUUAAGACUUCC 21
Intron2-2016 17116
CFTR-
+ UAGCCAUUACCUUAAGACUUCC 22
Intron2-2017 17117
CFTR-
+ GUAGCCAUUACCUUAAGACUUCC 23
Intron2-2018 17118
CFTR-
+ AGUAGCCAUUACCUUAAGACUUCC 24
Intron2-2019 17119
CFTR-
+ GCACCAUUACACUCCAGC 18
Intron2-2020 17120
CFTR-
+ UGCACCAUUACACUCCAGC 19
Intron2-2021 17121
CFTR-
+ UUGCACCAUUACACUCCAGC 20
Intron2-2022 17122
CFTR-
+ AUUGCACCAUUACACUCCAGC 21
Intron2-2023 17123
CFTR-
+ AAUUGCACCAUUACACUCCAGC 22
Intron2-2024 17124
CFTR-
+ AAAUUGCACCAUUACACUCCAGC 23
Intron2-2025 17125
CFTR-
+ AAAAUUGCACCAUUACACUCCAGC 24
Intron2-2026 17126
520
5535.1 CFTR-
+ CAGGAGACUGAGAUUCGC 18
Intron2-2027 17127
CFTR-
+ UCAGGAGACUGAGAUUCGC 19
Intron2-2028 17128
CFTR-
+ CUCAGGAGACUGAGAUUCGC 20
Intron2-2029 17129
CFTR-
+ ACUCAGGAGACUGAGAUUCGC 21
Intron2-2030 17130
CFTR-
+ UACUCAGGAGACUGAGAUUCGC 22
Intron2-2031 17131
CFTR-
+ CUACUCAGGAGACUGAGAUUCGC 23
Intron2-2032 17132
CFTR-
+ GCUACUCAGGAGACUGAGAUUCGC 24
Intron2-2033 17133
CFTR-
+ UACUCGAGAGGCUGAGGC 18
Intron2-2034 17134
CFTR-
+ CUACUCGAGAGGCUGAGGC 19
Intron2-2035 17135
CFTR-
+ GCUACUCGAGAGGCUGAGGC 20
lntron2-461 15561
CFTR-
+ AGCUACUCGAGAGGCUGAGGC 21
Intron2-2036 17136
CFTR-
+ CAGCUACUCGAGAGGCUGAGGC 22
Intron2-2037 17137
CFTR-
+ CCAGCUACUCGAGAGGCUGAGGC 23
Intron2-2038 17138
CFTR-
+ CCCAGCUACUCGAGAGGCUGAGGC 24
Intron2-2039 17139
CFTR-
+ U CU AAAGG AG U AAU AGG C 18
Intron2-2040 17140
CFTR-
+ CUCUAAAGGAGUAAUAGGC 19
Intron2-2041 17141
CFTR-
+ ACUCUAAAGGAGUAAUAGGC 20
lntron2-662 15762
CFTR-
+ CACUCUAAAGGAGUAAUAGGC 21
Intron2-2042 17142
CFTR-
+ UCACUCUAAAGGAGUAAUAGGC 22
Intron2-2043 17143
CFTR-
+ AUCACUCUAAAGGAGUAAUAGGC 23
Intron2-2044 17144
CFTR-
+ AAUCACUCUAAAGGAGUAAUAGGC 24
Intron2-2045 17145
521
5535.1 CFTR-
+ CAGGCCUGUGCUGUUGGC 18
Intron2-2046 17146
CFTR-
+ UCAGGCCUGUGCUGUUGGC 19
Intron2-2047 17147
CFTR-
+ AUCAGGCCUGUGCUGUUGGC 20
Intron2-2048 17148
CFTR-
+ CAUCAGGCCUGUGCUGUUGGC 21
Intron2-2049 17149
CFTR-
+ GCAUCAGGCCUGUGCUGUUGGC 22
Intron2-2050 17150
CFTR-
+ GGCAUCAGGCCUGUGCUGUUGGC 23
Intron2-2051 17151
CFTR-
+ UGGCAUCAGGCCUGUGCUGUUGGC 24
Intron2-2052 17152
CFTR-
+ CAUAUCCUGACUACAAUC 18
Intron2-2053 17153
CFTR-
+ UCAUAUCCUGACUACAAUC 19
Intron2-2054 17154
CFTR-
+ UUCAUAUCCUGACUACAAUC 20
Intron2-2055 17155
CFTR-
+ GUUCAUAUCCUGACUACAAUC 21
Intron2-2056 17156
CFTR-
+ AGUUCAUAUCCUGACUACAAUC 22
Intron2-2057 17157
CFTR-
+ AAGUUCAUAUCCUGACUACAAUC 23
Intron2-2058 17158
CFTR-
+ AAAGUUCAUAUCCUGACUACAAUC 24
Intron2-2059 17159
CFTR-
+ CUGUAAACCCAGCUACUC 18
Intron2-2060 17160
CFTR-
+ CCUGUAAACCCAGCUACUC 19
Intron2-2061 17161
CFTR-
+ GCCUGUAAACCCAGCUACUC 20
Intron2-2062 17162
CFTR-
+ UGCCUGUAAACCCAGCUACUC 21
Intron2-2063 17163
CFTR-
+ GUGCCUGUAAACCCAGCUACUC 22
Intron2-2064 17164
CFTR-
+ AGUGCCUGUAAACCCAGCUACUC 23
Intron2-2065 17165
CFTR-
+ GAGUGCCUGUAAACCCAGCUACUC 24
Intron2-2066 17166
522
5535.1 CFTR-
+ CUGUAGUCCCAGCUACUC 18
Intron2-2067 17167
CFTR-
+ CCUGUAGUCCCAGCUACUC 19
Intron2-2068 17168
CFTR-
+ GCCUGUAGUCCCAGCUACUC 20
lntron2-463 15563
CFTR-
+ UGCCUGUAGUCCCAGCUACUC 21
Intron2-2069 17169
CFTR-
+ AUGCCUGUAGUCCCAGCUACUC 22
Intron2-2070 17170
CFTR-
+ CAUGCCUGUAGUCCCAGCUACUC 23
Intron2-2071 17171
CFTR-
+ GCAUGCCUGUAGUCCCAGCUACUC 24
Intron2-2072 17172
CFTR-
+ UGAGGAGAAGGCAAGGUC 18
Intron2-2073 17173
CFTR-
+ CUGAGGAGAAGGCAAGGUC 19
Intron2-2074 17174
CFTR-
+ CCUGAGGAGAAGGCAAGGUC 20
lntron2-333 15433
CFTR-
+ ACCUGAGGAGAAGGCAAGGUC 21
Intron2-2075 17175
CFTR-
+ UACCUGAGGAGAAGGCAAGGUC 22
Intron2-2076 17176
CFTR-
+ UUACCUGAGGAGAAGGCAAGGUC 23
Intron2-2077 17177
CFTR-
+ GUUACCUGAGGAGAAGGCAAGGUC 24
Intron2-2078 17178
CFTR-
+ UGGUGGAAACCAUACUUC 18
Intron2-2079 17179
CFTR-
+ AUGGUGGAAACCAUACUUC 19
Intron2-2080 17180
CFTR-
+ CAUGGUGGAAACCAUACUUC 20
lntron2-669 15769
CFTR-
+ ACAUGGUGGAAACCAUACUUC 21
Intron2-2081 17181
CFTR-
+ AACAUGGUGGAAACCAUACUUC 22
Intron2-2082 17182
CFTR-
+ GAACAUGGUGGAAACCAUACUUC 23
Intron2-2083 17183
CFTR-
+ GGAACAUGGUGGAAACCAUACUUC 24
Intron2-2084 17184
523
5535.1 CFTR-
+ UCACAUAGUUCAGGCUUC 18
Intron2-2085 17185
CFTR-
+ UUCACAUAGUUCAGGCUUC 19
Intron2-2086 17186
CFTR-
+ CUUCACAUAGUUCAGGCUUC 20
Intron2-2087 17187
CFTR-
+ UCUUCACAUAGUUCAGGCUUC 21
Intron2-2088 17188
CFTR-
+ GUCUUCACAUAGUUCAGGCUUC 22
Intron2-2089 17189
CFTR-
+ GGUCUUCACAUAGUUCAGGCUUC 23
Intron2-2090 17190
CFTR-
+ AGGUCUUCACAUAGUUCAGGCUUC 24
Intron2-2091 17191
CFTR-
+ ACAG AG AUG AAAAAU U U C 18
Intron2-2092 17192
CFTR-
+ U ACAG AG AUG AAAAAU U U C 19
Intron2-2093 17193
CFTR-
+ GUACAGAGAUGAAAAAUUUC 20
Intron2-2094 17194
CFTR-
+ UGUACAGAGAUGAAAAAUUUC 21
Intron2-2095 17195
CFTR-
+ CUGUACAGAGAUGAAAAAUUUC 22
Intron2-2096 17196
CFTR-
+ ACUG U ACAG AG AUG AAAAAU U U C 23
Intron2-2097 17197
CFTR-
+ AACUGUACAGAGAUGAAAAAUUUC 24
Intron2-2098 17198
CFTR-
+ ACCAAAUGUGUAUUUUUC 18
Intron2-2099 17199
CFTR-
+ AACCAAAUGUGUAUUUUUC 19
Intron2-2100 17200
CFTR-
+ AAACCAAAUGUGUAUUUUUC 20
Intron2-670 15770
CFTR-
+ GAAACCAAAUGUGUAUUUUUC 21
Intron2-2101 17201
CFTR-
+ UGAAACCAAAUGUGUAUUUUUC 22
Intron2-2102 17202
CFTR-
+ CUGAAACCAAAUGUGUAUUUUUC 23
Intron2-2103 17203
CFTR-
+ UCUGAAACCAAAUGUGUAUUUUUC 24
Intron2-2104 17204
524
5535.1 CFTR-
+ UCACCUUCUCCAUCAAAG 18
Intron2-2105 17205
CFTR-
+ CUCACCUUCUCCAUCAAAG 19
Intron2-2106 17206
CFTR-
+ ACUCACCUUCUCCAUCAAAG 20
Intron2-2107 17207
CFTR-
+ GACUCACCUUCUCCAUCAAAG 21
Intron2-2108 17208
CFTR-
+ AGACUCACCUUCUCCAUCAAAG 22
Intron2-2109 17209
CFTR-
+ CAGACUCACCUUCUCCAUCAAAG 23
Intron2-2110 17210
CFTR-
+ GCAGACUCACCUUCUCCAUCAAAG 24
lntron2-2111 17211
CFTR-
+ AAACU U AG AU AU U CAAAG 18
lntron2-2112 17212
CFTR-
+ AAAACU U AG AU AU U CAAAG 19
lntron2-2113 17213
CFTR-
+ U AAAACU U AG AU AU U CAAAG 20
lntron2-2114 17214
CFTR-
+ U U AAAACU U AG AU AU U CAAAG 21
lntron2-2115 17215
CFTR-
+ AU U AAAACU U AG AU AU U CAAAG 22
lntron2-2116 17216
CFTR-
+ AAU U AAAACU U AG AU AU U CAAAG 23
lntron2-2117 17217
CFTR-
+ CAAU U AAAACU U AG AU AU U CAAAG 24
lntron2-2118 17218
CFTR-
+ ACACUUUGGGAGGCCAAG 18
lntron2-2119 17219
CFTR-
+ AACACUUUGGGAGGCCAAG 19
Intron2-2120 17220
CFTR-
+ CAACACUUUGGGAGGCCAAG 20
lntron2-2121 17221
CFTR-
+ CCAACACUUUGGGAGGCCAAG 21
lntron2-2122 17222
CFTR-
+ CCCAACACUUUGGGAGGCCAAG 22
lntron2-2123 17223
CFTR-
+ UCCCAACACUUUGGGAGGCCAAG 23
lntron2-2124 17224
CFTR-
+ AUCCCAACACUUUGGGAGGCCAAG 24
lntron2-2125 17225
525
5535.1 CFTR-
+ GCAUUUUGGGAGGCCAAG 18
lntron2-2126 17226
CFTR-
+ AGCAUUUUGGGAGGCCAAG 19
lntron2-2127 17227
CFTR-
+ CAG CA U U U U GG G AG G CCAAG 20
lntron2-2128 17228
CFTR-
+ CCAGCAUUUUGGGAGGCCAAG 21
lntron2-2129 17229
CFTR-
+ CCCAGCAUUUUGGGAGGCCAAG 22
Intron2-2130 17230
CFTR-
+ UCCCAGCAUUUUGGGAGGCCAAG 23
lntron2-2131 17231
CFTR-
+ AUCCCAGCAUUUUGGGAGGCCAAG 24
lntron2-2132 17232
CFTR-
+ AUGUAAAUGAAAGUGAAG 18
lntron2-2133 17233
CFTR-
+ GAUGUAAAUGAAAGUGAAG 19
lntron2-2134 17234
CFTR-
+ AGAUGUAAAUGAAAGUGAAG 20
lntron2-2135 17235
CFTR-
+ GAGAUGUAAAUGAAAGUGAAG 21
lntron2-2136 17236
CFTR-
+ UGAGAUGUAAAUGAAAGUGAAG 22
lntron2-2137 17237
CFTR-
+ CUGAGAUGUAAAUGAAAGUGAAG 23
lntron2-2138 17238
CFTR-
+ GCUGAGAUGUAAAUGAAAGUGAAG 24
lntron2-2139 17239
CFTR-
+ UAAAGGAGUAAUACACAG 18
Intron2-2140 17240
CFTR-
+ AUAAAGGAGUAAUACACAG 19
lntron2-2141 17241
CFTR-
+ CAUAAAGGAGUAAUACACAG 20
lntron2-2142 17242
CFTR-
+ ACAUAAAGGAGUAAUACACAG 21
lntron2-2143 17243
CFTR-
+ AACAUAAAGGAGUAAUACACAG 22
lntron2-2144 17244
CFTR-
+ AAACAUAAAGGAGUAAUACACAG 23
lntron2-2145 17245
CFTR-
+ AAAACAUAAAGGAGUAAUACACAG 24
lntron2-2146 17246
526
5535.1 CFTR-
+ GUGAAGUAGAGAGACCAG 18
lntron2-2147 17247
CFTR-
+ AGUGAAGUAGAGAGACCAG 19
lntron2-2148 17248
CFTR-
+ AAGUGAAG U AG AG AG ACCAG 20
lntron2-2149 17249
CFTR-
+ AAAGUGAAGUAGAGAGACCAG 21
Intron2-2150 17250
CFTR-
+ GAAAGUGAAG U AG AG AG ACCAG 22
lntron2-2151 17251
CFTR-
+ UGAAAGUGAAGUAGAGAGACCAG 23
lntron2-2152 17252
CFTR-
+ AUGAAAGUGAAGUAGAGAGACCAG 24
lntron2-2153 17253
CFTR-
+ AUACCAGGCCCAGAUCAG 18
lntron2-2154 17254
CFTR-
+ CAUACCAGGCCCAGAUCAG 19
lntron2-2155 17255
CFTR-
+ ACAUACCAGGCCCAGAUCAG 20
lntron2-2156 17256
CFTR-
+ CACAUACCAGGCCCAGAUCAG 21
lntron2-2157 17257
CFTR-
+ CCACAUACCAGGCCCAGAUCAG 22
lntron2-2158 17258
CFTR-
+ ACCA CAUACCAGGCCCAGAUCAG 23
lntron2-2159 17259
CFTR-
+ GACCACAUACCAGGCCCAGAUCAG 24
Intron2-2160 17260
CFTR-
+ A A AG GAG AAA U G G A U C AG 18
lntron2-2161 17261
CFTR-
+ CAAAGGAGAAAUGGAUCAG 19
lntron2-2162 17262
CFTR-
+ UCAAAGGAGAAAUGGAUCAG 20
lntron2-2163 17263
CFTR-
+ A U C A A AG GAG AAA U G G A U C AG 21
lntron2-2164 17264
CFTR-
+ C A U C A A AG GAG AAA U G G A U C AG 22
lntron2-2165 17265
CFTR-
+ C C A U C A A AG GAG AAA UGGAUCAG 23
lntron2-2166 17266
CFTR-
+ UCCAUCAAAGGAGAAAUGGAUCAG 24
lntron2-2167 17267
527
5535.1 CFTR-
+ AGGCAAUACAGACCUCAG 18
lntron2-2168 17268
CFTR-
+ AAGGCAAUACAGACCUCAG 19
lntron2-2169 17269
CFTR-
+ CAAGGCAAUACAGACCUCAG 20
Intron2-2170 17270
CFTR-
+ GCAAGGCAAUACAGACCUCAG 21
lntron2-2171 17271
CFTR-
+ AGCAAGGCAAUACAGACCUCAG 22
lntron2-2172 17272
CFTR-
+ GAGCAAGGCAAUACAGACCUCAG 23
lntron2-2173 17273
CFTR-
+ AGAGCAAGGCAAUACAGACCUCAG 24
lntron2-2174 17274
CFTR-
+ U U U U CAAACUG U ACAG AG 18
lntron2-2175 17275
CFTR-
+ AUUUUCAAACUGUACAGAG 19
lntron2-2176 17276
CFTR-
+ AAU U U U CAAACUG U ACAG AG 20
lntron2-2177 17277
CFTR-
+ U AAU U U U CAAACUG U ACAG AG 21
lntron2-2178 17278
CFTR-
+ U U AAU U U U CAAACUG U ACAG AG 22
lntron2-2179 17279
CFTR-
+ CUUAAUUUU CAAACUG U ACAG AG 23
Intron2-2180 17280
CFTR-
+ UCUUAAUUUU CAAACUG U ACAG AG 24
lntron2-2181 17281
CFTR-
+ GUAGAGAGACCAGGAGAG 18
lntron2-2182 17282
CFTR-
+ AGUAGAGAGACCAGGAGAG 19
lntron2-2183 17283
CFTR-
+ AAGUAGAGAGACCAGGAGAG 20
lntron2-2184 17284
CFTR-
+ GAAGUAGAGAGACCAGGAGAG 21
lntron2-2185 17285
CFTR-
+ UGAAGUAGAGAGACCAGGAGAG 22
lntron2-2186 17286
CFTR-
+ GUGAAGUAGAGAGACCAGGAGAG 23
lntron2-2187 17287
CFTR-
+ AG UG AAG U AG AG AG ACCAGG AG AG 24
lntron2-2188 17288
528
5535.1 CFTR-
+ AUCACUUGAACCCAGGAG 18
lntron2-2189 17289
CFTR-
+ AAUCACUUGAACCCAGGAG 19
Intron2-2190 17290
CFTR-
+ GAAUCACUUGAACCCAGGAG 20
lntron2-2191 17291
CFTR-
+ AGAAUCACUUGAACCCAGGAG 21
lntron2-2192 17292
CFTR-
+ GAGAAUCACUUGAACCCAGGAG 22
lntron2-2193 17293
CFTR-
+ GGAGAAUCACUUGAACCCAGGAG 23
lntron2-2194 17294
CFTR-
+ AGGAGAAUCACUUGAACCCAGGAG 24
lntron2-2195 17295
CFTR-
+ GAAACCAUACUUCAGGAG 18
lntron2-2196 17296
CFTR-
+ GGAAACCAUACUUCAGGAG 19
lntron2-2197 17297
CFTR-
+ UGGAAACCAUACUUCAGGAG 20
lntron2-2198 17298
CFTR-
+ GUGGAAACCAUACUUCAGGAG 21
lntron2-2199 17299
CFTR-
+ GGUGGAAACCAUACUUCAGGAG 22
Intron2-2200 17300
CFTR-
+ UGGUGGAAACCAUACUUCAGGAG 23
Intron2-2201 17301
CFTR-
+ AUGGUGGAAACCAUACUUCAGGAG 24
Intron2-2202 17302
CFTR-
+ AUGGGGUAGUUACCUGAG 18
Intron2-2203 17303
CFTR-
+ AAUGGGGUAGUUACCUGAG 19
Intron2-2204 17304
CFTR-
+ GAAUGGGGUAGUUACCUGAG 20
Intron2-2205 17305
CFTR-
+ AGAAUGGGGUAGUUACCUGAG 21
Intron2-2206 17306
CFTR-
+ UAGAAUGGGGUAGUUACCUGAG 22
Intron2-2207 17307
CFTR-
+ AUAGAAUGGGGUAGUUACCUGAG 23
Intron2-2208 17308
CFTR-
+ AAUAGAAUGGGGUAGUUACCUGAG 24
Intron2-2209 17309
529
5535.1 CFTR-
+ CCACUCAGAGUGGCUGAG 18
Intron2-2210 17310
CFTR-
+ UCCACUCAGAGUGGCUGAG 19
lntron2-2211 17311
CFTR-
+ UUCCACUCAGAGUGGCUGAG 20
lntron2-343 15443
CFTR-
+ UUUCCACUCAGAGUGGCUGAG 21
lntron2-2212 17312
CFTR-
+ CUUUCCACUCAGAGUGGCUGAG 22
lntron2-2213 17313
CFTR-
+ GCUUUCCACUCAGAGUGGCUGAG 23
lntron2-2214 17314
CFTR-
+ UGCUUUCCACUCAGAGUGGCUGAG 24
lntron2-2215 17315
CFTR-
+ GGCAGAGUUUGCAGUGAG 18
lntron2-2216 17316
CFTR-
+ AGGCAGAGUUUGCAGUGAG 19
lntron2-2217 17317
CFTR-
+ GAGGCAGAGUUUGCAGUGAG 20
lntron2-2218 17318
CFTR-
+ GGAGGCAGAGUUUGCAGUGAG 21
lntron2-2219 17319
CFTR-
+ AGGAGGCAGAGUUUGCAGUGAG 22
Intron2-2220 17320
CFTR-
+ CAGGAGGCAGAGUUUGCAGUGAG 23
lntron2-2221 17321
CFTR-
+ CCAGGAGGCAGAGUUUGCAGUGAG 24
lntron2-2222 17322
CFTR-
+ UAGGUGAUGUGGUUCUAG 18
lntron2-2223 17323
CFTR-
+ GUAGGUGAUGUGGUUCUAG 19
lntron2-2224 17324
CFTR-
+ AGUAGGUGAUGUGGUUCUAG 20
lntron2-2225 17325
CFTR-
+ GAGUAGGUGAUGUGGUUCUAG 21
lntron2-2226 17326
CFTR-
+ AGAGUAGGUGAUGUGGUUCUAG 22
lntron2-2227 17327
CFTR-
+ AAGAGUAGGUGAUGUGGUUCUAG 23
lntron2-2228 17328
CFTR-
+ CAAGAGUAGGUGAUGUGGUUCUAG 24
lntron2-2229 17329
530
5535.1 CFTR-
+ AUUUCAUGAACCACAAGG 18
I ntron2-2230 17330
CFTR-
+ AAUUUCAUGAACCACAAGG 19
lntron2-2231 17331
CFTR-
+ AAAU U U CAUG AACCACAAGG 20
lntron2-2232 17332
CFTR-
+ AAAAUUUCAUGAACCACAAGG 21
lntron2-2233 17333
CFTR-
+ AAAAAU U U CAUG AACCACAAGG 22
lntron2-2234 17334
CFTR-
+ GAAAAAUUUCAUGAACCACAAGG 23
lntron2-2235 17335
CFTR-
+ UGAAAAAUUUCAUGAACCACAAGG 24
lntron2-2236 17336
CFTR-
+ C AG A U GG G AAAG CCAAG G 18
lntron2-2237 17337
CFTR-
+ UCAGAUGGGAAAGCCAAGG 19
lntron2-2238 17338
CFTR-
+ AUCAGAUGGGAAAGCCAAGG 20
lntron2-2239 17339
CFTR-
+ GAUCAGAUGGGAAAGCCAAGG 21
Intron2-2240 17340
CFTR-
+ GGAUCAGAUGGGAAAGCCAAGG 22
lntron2-2241 17341
CFTR-
+ UGGAUCAGAUGGGAAAGCCAAGG 23
lntron2-2242 17342
CFTR-
+ AUGGAUCAGAUGGGAAAGCCAAGG 24
lntron2-2243 17343
CFTR-
+ CCUGAGGAGAAGGCAAGG 18
lntron2-2244 17344
CFTR-
+ ACCUGAGGAGAAGGCAAGG 19
lntron2-2245 17345
CFTR-
+ UACCUGAGGAGAAGGCAAGG 20
lntron2-2246 17346
CFTR-
+ UUACCUGAGGAGAAGGCAAGG 21
lntron2-2247 17347
CFTR-
+ GU UACCUGAGGAGAAGGCAAGG 22
lntron2-2248 17348
CFTR-
+ AGUUACCUGAGGAGAAGGCAAGG 23
lntron2-2249 17349
CFTR-
+ UAGUUACCUGAGGAGAAGGCAAGG 24
Intron2-2250 17350
531
5535.1 CFTR-
+ AAG AAAAG AAG U AACAGG 18
l ntron2-2251 17351
CFTR-
+ U AAG AAAAG AAG U AACAGG 19
lntron2-2252 17352
CFTR-
+ AUAAGAAAAGAAGUAACAGG 20
lntron2-2253 17353
CFTR-
+ UAUAAGAAAAGAAGUAACAGG 21
lntron2-2254 17354
CFTR-
+ U U AUAAGAAAAGAAGUAACAGG 22
lntron2-2255 17355
CFTR-
+ U UUAUAAGAAAAGAAGUAACAGG 23
lntron2-2256 17356
CFTR-
+ U U U UAU AAG AAAAG AAG U AACAGG 24
lntron2-2257 17357
CFTR-
+ ACCCAGCUACUCGAGAGG 18
lntron2-2258 17358
CFTR-
+ AACCCAGCUACUCGAGAGG 19
lntron2-2259 17359
CFTR-
+ AAACCCAGCUACUCGAGAGG 20
Intron2-2260 17360
CFTR-
+ UAAACCCAGCUACUCGAGAGG 21
lntron2-2261 17361
CFTR-
+ GUAAACCCAGCUACUCGAGAGG 22
lntron2-2262 17362
CFTR-
+ UGUAAACCCAGCUACUCGAGAGG 23
lntron2-2263 17363
CFTR-
+ CUGUAAACCCAGCUACUCGAGAGG 24
lntron2-2264 17364
CFTR-
+ CUACUCGAGAGGCUGAGG 18
lntron2-2265 17365
CFTR-
+ GCUACUCGAGAGGCUGAGG 19
lntron2-2266 17366
CFTR-
+ AGCUACUCGAGAGGCUGAGG 20
lntron2-2267 17367
CFTR-
+ CAGCUACUCGAGAGGCUGAGG 21
lntron2-2268 17368
CFTR-
+ CCAGCUACUCGAGAGGCUGAGG 22
lntron2-2269 17369
CFTR-
+ CCCAGCUACUCGAGAGGCUGAGG 23
Intron2-2270 17370
CFTR-
+ ACCCAGCUACUCGAGAGGCUGAGG 24
lntron2-2271 17371
532
5535.1 CFTR-
+ CUCUAAAGGAGUAAUAGG 18
lntron2-2272 17372
CFTR-
+ ACUCUAAAGGAGUAAUAGG 19
lntron2-2273 17373
CFTR-
+ CACUCUAAAGGAGUAAUAGG 20
lntron2-2274 17374
CFTR-
+ UCACUCUAAAGGAGUAAUAGG 21
lntron2-2275 17375
CFTR-
+ AUCACUCUAAAGGAGUAAUAGG 22
lntron2-2276 17376
CFTR-
+ AAUCACUCUAAAGGAGUAAUAGG 23
lntron2-2277 17377
CFTR-
+ AAAUCACUCUAAAGGAGUAAUAGG 24
lntron2-2278 17378
CFTR-
+ AGGCCCAGAUCAGAAGGG 18
lntron2-2279 17379
CFTR-
+ CAGGCCCAGAUCAGAAGGG 19
Intron2-2280 17380
CFTR-
+ CCAGGCCCAGAUCAGAAGGG 20
lntron2-2281 17381
CFTR-
+ ACCAGGCCCAGAUCAGAAGGG 21
lntron2-2282 17382
CFTR-
+ UACCAGGCCCAGAUCAGAAGGG 22
lntron2-2283 17383
CFTR-
+ AUACCAGGCCCAGAUCAGAAGGG 23
lntron2-2284 17384
CFTR-
+ CAUACCAGGCCCAGAUCAGAAGGG 24
lntron2-2285 17385
CFTR-
+ AGAAAAGAAGUAACAGGG 18
lntron2-2286 17386
CFTR-
+ AAGAAAAGAAGUAACAGGG 19
lntron2-2287 17387
CFTR-
+ UAAGAAAAGAAGUAACAGGG 20
lntron2-681 15781
CFTR-
+ AU AAGAAAAGAAGUAACAGGG 21
lntron2-2288 17388
CFTR-
+ UAU AAGAAAAGAAGUAACAGGG 22
lntron2-2289 17389
CFTR-
+ UUAUAAGAAAAGAAGUAACAGGG 23
Intron2-2290 17390
CFTR-
+ UUUAUAAGAAAAGAAGUAACAGGG 24
lntron2-2291 17391
533
5535.1 CFTR-
+ UGAGAGAUUCUUUAUGGG 18
lntron2-2292 17392
CFTR-
+ CUGAGAGAUUCUUUAUGGG 19
lntron2-2293 17393
CFTR-
+ ACUGAGAGAUUCUUUAUGGG 20
lntron2-353 15453
CFTR-
+ AACUGAGAGAUUCUUUAUGGG 21
lntron2-2294 17394
CFTR-
+ AAACUGAGAGAUUCUUUAUGGG 22
lntron2-2295 17395
CFTR-
+ GAAACUGAGAGAUUCUUUAUGGG 23
lntron2-2296 17396
CFTR-
+ GGAAACUGAGAGAUUCUUUAUGGG 24
lntron2-2297 17397
CFTR-
+ GGGGAAUUUCUUUAAUGG 18
lntron2-2298 17398
CFTR-
+ CGGGGAAUUUCUUUAAUGG 19
lntron2-2299 17399
CFTR-
+ UCGGGGAAUUUCUUUAAUGG 20
Intron2-2300 17400
CFTR-
+ GUCGGGGAAUUUCUUUAAUGG 21
Intron2-2301 17401
CFTR-
+ GGUCGGGGAAUUUCUUUAAUGG 22
Intron2-2302 17402
CFTR-
+ AGGUCGGGGAAUUUCUUUAAUGG 23
Intron2-2303 17403
CFTR-
+ AAGGUCGGGGAAUUUCUUUAAUGG 24
Intron2-2304 17404
CFTR-
+ GUAGUUUUAGGAACAUGG 18
Intron2-2305 17405
CFTR-
+ UGUAGUUUUAGGAACAUGG 19
Intron2-2306 17406
CFTR-
+ AUGUAGUUUUAGGAACAUGG 20
lntron2-355 15455
CFTR-
+ AAUGUAGUUUUAGGAACAUGG 21
Intron2-2307 17407
CFTR-
+ CAAUGUAGUUUUAGGAACAUGG 22
Intron2-2308 17408
CFTR-
+ GCAAUGUAGUUUUAGGAACAUGG 23
Intron2-2309 17409
CFTR-
+ GGCAAUGUAGUUUUAGGAACAUGG 24
Intron2-2310 17410 CFTR-
+ CUGAGAGAUUCUUUAUGG 18
lntron2-2311 17411
CFTR-
+ ACUGAGAGAUUCUUUAUGG 19
lntron2-2312 17412
CFTR-
+ AACUGAGAGAUUCUUUAUGG 20
lntron2-356 15456
CFTR-
+ AAACUGAGAGAUUCUUUAUGG 21
lntron2-2313 17413
CFTR-
+ GAAACUGAGAGAUUCUUUAUGG 22
lntron2-2314 17414
CFTR-
+ GGAAACUGAGAGAUUCUUUAUGG 23
lntron2-2315 17415
CFTR-
+ AGGAAACUGAGAGAUUCUUUAUGG 24
lntron2-2316 17416
CFTR-
+ AAAUAGUCUGAAAACUGG 18
lntron2-2317 17417
CFTR-
+ UAAAUAGUCUGAAAACUGG 19
lntron2-2318 17418
CFTR-
+ UUAAAUAGUCUGAAAACUGG 20
lntron2-2319 17419
CFTR-
+ AUUAAAUAGUCUGAAAACUGG 21
Intron2-2320 17420
CFTR-
+ CAUUAAAUAGUCUGAAAACUGG 22
lntron2-2321 17421
CFTR-
+ ACAUUAAAUAGUCUGAAAACUGG 23
lntron2-2322 17422
CFTR-
+ GACAUUAAAUAGUCUGAAAACUGG 24
lntron2-2323 17423
CFTR-
+ GCUUUCCACUCAGAGUGG 18
lntron2-2324 17424
CFTR-
+ UGCUUUCCACUCAGAGUGG 19
lntron2-2325 17425
CFTR-
+ AUGCUUUCCACUCAGAGUGG 20
lntron2-2326 17426
CFTR-
+ GAUGCUUUCCACUCAGAGUGG 21
lntron2-2327 17427
CFTR-
+ UGAUGCUUUCCACUCAGAGUGG 22
lntron2-2328 17428
CFTR-
+ AUGAUGCUUUCCACUCAGAGUGG 23
lntron2-2329 17429
CFTR-
+ AAUGAUGCUUUCCACUCAGAGUGG 24
Intron2-2330 17430 CFTR-
+ GUCCACACGGAAGUAAUG 18
lntron2-2331 17431
CFTR-
+ GGUCCACACGGAAGUAAUG 19
lntron2-2332 17432
CFTR-
+ UGGUCCACACGGAAGUAAUG 20
lntron2-2333 17433
CFTR-
+ GUGGUCCACACGGAAGUAAUG 21
lntron2-2334 17434
CFTR-
+ AGUGGUCCACACGGAAGUAAUG 22
lntron2-2335 17435
CFTR-
+ AAGUGGUCCACACGGAAGUAAUG 23
lntron2-2336 17436
CFTR-
+ AAAGUGGUCCACACGGAAGUAAUG 24
lntron2-2337 17437
CFTR-
+ ACCAGCCUGGCCAACAUG 18
lntron2-2338 17438
CFTR-
+ GACCAGCCUGGCCAACAUG 19
lntron2-2339 17439
CFTR-
+ AGACCAGCCUGGCCAACAUG 20
Intron2-2340 17440
CFTR-
+ AAGACCAGCCUGGCCAACAUG 21
lntron2-2341 17441
CFTR-
+ CAAGACCAGCCUGGCCAACAUG 22
lntron2-2342 17442
CFTR-
+ UCAAGACCAGCCUGGCCAACAUG 23
lntron2-2343 17443
CFTR-
+ UUCAAGACCAGCCUGGCCAACAUG 24
lntron2-2344 17444
CFTR-
+ UGUAGUUUUAGGAACAUG 18
lntron2-2345 17445
CFTR-
+ AUGUAGUUUUAGGAACAUG 19
lntron2-2346 17446
CFTR-
+ AAUGUAGUUUUAGGAACAUG 20
lntron2-2347 17447
CFTR-
+ CAAUGUAGUUUUAGGAACAUG 21
lntron2-2348 17448
CFTR-
+ GCAAUGUAGUUUUAGGAACAUG 22
lntron2-2349 17449
CFTR-
+ GGCAAUGUAGUUUUAGGAACAUG 23
Intron2-2350 17450
CFTR-
+ GGGCAAUGUAGUUUUAGGAACAUG 24
lntron2-2351 17451
536
5535.1 CFTR-
+ UUGCACACUGCAGUUAUG 18
lntron2-2352 17452
CFTR-
+ UUUGCACACUGCAGUUAUG 19
lntron2-2353 17453
CFTR-
+ GUUUGCACACUGCAGUUAUG 20
lntron2-2354 17454
CFTR-
+ GGUUUGCACACUGCAGUUAUG 21
lntron2-2355 17455
CFTR-
+ UGGUUUGCACACUGCAGUUAUG 22
lntron2-2356 17456
CFTR-
+ GUGGUUUGCACACUGCAGUUAUG 23
lntron2-2357 17457
CFTR-
+ UGUGGUUUGCACACUGCAGUUAUG 24
lntron2-2358 17458
CFTR-
+ CCAGGGACCCACUUUAUG 18
lntron2-2359 17459
CFTR-
+ ACCAGGGACCCACUUUAUG 19
Intron2-2360 17460
CFTR-
+ AACCAGGGACCCACUUUAUG 20
lntron2-2361 17461
CFTR-
+ UAACCAGGGACCCACUUUAUG 21
lntron2-2362 17462
CFTR-
+ CUAACCAGGGACCCACUUUAUG 22
lntron2-2363 17463
CFTR-
+ UCUAACCAGGGACCCACUUUAUG 23
lntron2-2364 17464
CFTR-
+ UUCUAACCAGGGACCCACUUUAUG 24
lntron2-2365 17465
CFTR-
+ ACUGAGAGAUUCUUUAUG 18
lntron2-2366 17466
CFTR-
+ AACUGAGAGAUUCUUUAUG 19
lntron2-2367 17467
CFTR-
+ AAACUGAGAGAUUCUUUAUG 20
lntron2-361 15461
CFTR-
+ GAAACUGAGAGAUUCUUUAUG 21
lntron2-2368 17468
CFTR-
+ GGAAACUGAGAGAUUCUUUAUG 22
lntron2-2369 17469
CFTR-
+ AGGAAACUGAGAGAUUCUUUAUG 23
Intron2-2370 17470
CFTR-
+ AAGGAAACUGAGAGAUUCUUUAUG 24
lntron2-2371 17471
537
5535.1 CFTR-
+ GAAUGGGGUAGUUACCUG 18
lntron2-2372 17472
CFTR-
+ AGAAUGGGGUAGUUACCUG 19
lntron2-2373 17473
CFTR-
+ UAGAAUGGGGUAGUUACCUG 20
lntron2-362 15462
CFTR-
+ AUAGAAUGGGGUAGUUACCUG 21
lntron2-2374 17474
CFTR-
+ AAUAGAAUGGGGUAGUUACCUG 22
lntron2-2375 17475
CFTR-
+ AAAUAGAAUGGGGUAGUUACCUG 23
lntron2-2376 17476
CFTR-
+ AAAAUAGAAUGGGGUAGUUACCUG 24
lntron2-2377 17477
CFTR-
+ GGUCACUUCCCAAGGGUG 18
lntron2-2378 17478
CFTR-
+ GGGUCACUUCCCAAGGGUG 19
lntron2-2379 17479
CFTR-
+ AGGGUCACUUCCCAAGGGUG 20
Intron2-2380 17480
CFTR-
+ CAGGGUCACUUCCCAAGGGUG 21
lntron2-2381 17481
CFTR-
+ CCAGGGUCACUUCCCAAGGGUG 22
lntron2-2382 17482
CFTR-
+ GCCAGGGUCACUUCCCAAGGGUG 23
lntron2-2383 17483
CFTR-
+ AGCCAGGGUCACUUCCCAAGGGUG 24
lntron2-2384 17484
CFTR-
+ UAAAGGUCUUUGAAAAAU 18
lntron2-2385 17485
CFTR-
+ U U AAAGG U CU U UG AAAAAU 19
lntron2-2386 17486
CFTR-
+ AUUAAAGGUCUUUGAAAAAU 20
lntron2-2387 17487
CFTR-
+ UAUUAAAGGUCUUUGAAAAAU 21
lntron2-2388 17488
CFTR-
+ GUAUUAAAGGUCUUUGAAAAAU 22
lntron2-2389 17489
CFTR-
+ UGUAUUAAAGGUCUUUGAAAAAU 23
Intron2-2390 17490
CFTR-
+ AUG U AU U AAAGG U CU U UG AAAAAU 24
lntron2-2391 17491
538
5535.1 CFTR-
+ ACAAGG CAG U U AUG AAAU 18
lntron2-2392 17492
CFTR-
+ CACAAGG CAG U U AUG AAAU 19
lntron2-2393 17493
CFTR-
+ U CACAAGG CAG U U AUG AAAU 20
lntron2-2394 17494
CFTR-
+ GUCACAAGGCAGUUAUGAAAU 21
lntron2-2395 17495
CFTR-
+ GGUCACAAGGCAGUUAUGAAAU 22
lntron2-2396 17496
CFTR-
+ UGGUCACAAGGCAGUUAUGAAAU 23
lntron2-2397 17497
CFTR-
+ AUGGUCACAAGGCAGUUAUGAAAU 24
lntron2-2398 17498
CFTR-
+ CAGAGUAAGAAGCUAAAU 18
lntron2-2399 17499
CFTR-
+ UCAGAGUAAGAAGCU AAA U 19
Intron2-2400 17500
CFTR-
+ CUCAGAGUAAGAAGCUAAAU 20
Intron2-2401 17501
CFTR-
+ ACUCAGAGUAAGAAGCUAAAU 21
Intron2-2402 17502
CFTR-
+ UACUCAGAGUAAGAAGCUAAAU 22
Intron2-2403 17503
CFTR-
+ UUACUCAGAGUAAGAAGCUAAAU 23
Intron2-2404 17504
CFTR-
+ GUUACUCAGAGUAAGAAGCUAAAU 24
Intron2-2405 17505
CFTR-
+ CAACAAAAUGGGUUCAAU 18
Intron2-2406 17506
CFTR-
+ CCAACAAAAUGGGUUCAAU 19
Intron2-2407 17507
CFTR-
+ ACCAACAAAAUGGGUUCAAU 20
Intron2-2408 17508
CFTR-
+ AACCAACAAAAUGGGUUCAAU 21
Intron2-2409 17509
CFTR-
+ AAACCAACAAAAUGGGUUCAAU 22
Intron2-2410 17510
CFTR-
+ UAAACCAACAAAAUGGGUUCAAU 23
lntron2-2411 17511
CFTR-
+ AUAAACCAACAAAAUGGGUUCAAU 24
lntron2-2412 17512
539
5535.1 CFTR-
+ CCCUAGAAGCUUGCUAAU 18
lntron2-2413 17513
CFTR-
+ CCCCUAGAAGCUUGCUAAU 19
lntron2-2414 17514
CFTR-
+ UCCCCUAGAAGCUUGCUAAU 20
lntron2-2415 17515
CFTR-
+ AUCCCCUAGAAGCUUGCUAAU 21
lntron2-2416 17516
CFTR-
+ CAUCCCCUAGAAGCUUGCUAAU 22
lntron2-2417 17517
CFTR-
+ GCAUCCCCUAGAAGCUUGCUAAU 23
lntron2-2418 17518
CFTR-
+ GGCAUCCCCUAGAAGCUUGCUAAU 24
lntron2-2419 17519
CFTR-
+ U U U AAAU UG AAU CAACAU 18
Intron2-2420 17520
CFTR-
+ U U U U AAAU UG AAU CAACAU 19
lntron2-2421 17521
CFTR-
+ U U U U U AAAU UG AAU CAACAU 20
lntron2-699 15799
CFTR-
+ U U U U U U AAAU UG AAU CAACAU 21
lntron2-2422 17522
CFTR-
+ AU U U U U U AAAU UG AAU CAACAU 22
lntron2-2423 17523
CFTR-
+ U AU U U U U U AAAU UG AAU CAACAU 23
lntron2-2424 17524
CFTR-
+ AUAUUUUU U AAAU UG AAU CAACAU 24
lntron2-2425 17525
CFTR-
+ GGUGUUGUUAUAUUUCAU 18
lntron2-2426 17526
CFTR-
+ AGGUGUUGUUAUAUUUCAU 19
lntron2-2427 17527
CFTR-
+ AAGGUGUUGUUAUAUUUCAU 20
lntron2-2428 17528
CFTR-
+ AAAGGUGUUGUUAUAUUUCAU 21
lntron2-2429 17529
CFTR-
+ GAAAGGUGUUGUUAUAUUUCAU 22
Intron2-2430 17530
CFTR-
+ AGAAAGGUGUUGUUAUAUUUCAU 23
lntron2-2431 17531
CFTR-
+ UAGAAAGGUGUUGUUAUAUUUCAU 24
lntron2-2432 17532
540
5535.1 CFTR-
+ UUCGUGGUCCUUAAAGAU 18
lntron2-2433 17533
CFTR-
+ UUUCGUGGUCCUUAAAGAU 19
lntron2-2434 17534
CFTR-
+ CUUUCGUGGUCCUUAAAGAU 20
lntron2-375 15475
CFTR-
+ UCUUUCGUGGUCCUUAAAGAU 21
lntron2-2435 17535
CFTR-
+ UUCUUUCGUGGUCCUUAAAGAU 22
lntron2-2436 17536
CFTR-
+ CUUCUUUCGUGGUCCUUAAAGAU 23
lntron2-2437 17537
CFTR-
+ CCUUCUUUCGUGGUCCUUAAAGAU 24
lntron2-2438 17538
CFTR-
+ CACAUACCAGGCCCAGAU 18
lntron2-2439 17539
CFTR-
+ CCACAUACCAGGCCCAGAU 19
Intron2-2440 17540
CFTR-
+ ACCACAUACCAGGCCCAGAU 20
lntron2-2441 17541
CFTR-
+ GACCACAUACCAGGCCCAGAU 21
lntron2-2442 17542
CFTR-
+ GGACCACAUACCAGGCCCAGAU 22
lntron2-2443 17543
CFTR-
+ AGGACCACAUACCAGGCCCAGAU 23
lntron2-2444 17544
CFTR-
+ UAGGACCACAUACCAGGCCCAGAU 24
lntron2-2445 17545
CFTR-
+ AGGAGAAAUGGAUCAGAU 18
lntron2-2446 17546
CFTR-
+ AAGGAGAAAUGGAUCAGAU 19
lntron2-2447 17547
CFTR-
+ AAAGGAGAAAUGGAUCAGAU 20
lntron2-376 15476
CFTR-
+ C A A AG GAG AAA UGGAUCAGAU 21
lntron2-2448 17548
CFTR-
+ U C A A AG GAG AAA UGGAUCAGAU 22
lntron2-2449 17549
CFTR-
+ AUCAAAGGAGAAAUGGAUCAGAU 23
Intron2-2450 17550
CFTR-
+ CAUCAAAGGAGAAAUGGAUCAGAU 24
lntron2-2451 17551
541
5535.1 CFTR-
+ GUAAUACACAGCUGAGAU 18
lntron2-2452 17552
CFTR-
+ AGUAAUACACAGCUGAGAU 19
lntron2-2453 17553
CFTR-
+ GAGUAAUACACAGCUGAGAU 20
lntron2-2454 17554
CFTR-
+ GGAGUAAUACACAGCUGAGAU 21
lntron2-2455 17555
CFTR-
+ AGGAGUAAUACACAGCUGAGAU 22
lntron2-2456 17556
CFTR-
+ AAGGAGUAAUACACAGCUGAGAU 23
lntron2-2457 17557
CFTR-
+ AAAGGAGUAAUACACAGCUGAGAU 24
lntron2-2458 17558
CFTR-
+ GGAUCCUAACCUUUUGAU 18
lntron2-2459 17559
CFTR-
+ AGGAUCCUAACCUUUUGAU 19
Intron2-2460 17560
CFTR-
+ AAGGAUCCUAACCUUUUGAU 20
lntron2-379 15479
CFTR-
+ AAAGGAUCCUAACCUUUUGAU 21
lntron2-2461 17561
CFTR-
+ AAAAGGAUCCUAACCUUUUGAU 22
lntron2-2462 17562
CFTR-
+ CAAAAGGAUCCUAACCUUUUGAU 23
lntron2-2463 17563
CFTR-
+ UCAAAAGGAUCCUAACCUUUUGAU 24
lntron2-2464 17564
CFTR-
+ UUUUCUUUUAAAUACUAU 18
lntron2-2465 17565
CFTR-
+ GUUUUCUUUUAAAUACUAU 19
lntron2-2466 17566
CFTR-
+ UGUUUUCUUUUAAAUACUAU 20
Intron2-700 15800
CFTR-
+ CUGUUUUCUUUUAAAUACUAU 21
lntron2-2467 17567
CFTR-
+ UCUGUUUUCUUUUAAAUACUAU 22
lntron2-2468 17568
CFTR-
+ UUCUGUUUUCUUUUAAAUACUAU 23
lntron2-2469 17569
CFTR-
+ UUUCUGUUUUCUUUUAAAUACUAU 24
Intron2-2470 17570
542
5535.1 CFTR-
+ AACUGAGAGAUUCUUUAU 18
lntron2-2471 17571
CFTR-
+ AAACUGAGAGAUUCUUUAU 19
lntron2-2472 17572
CFTR-
+ GAAACUGAGAGAUUCUUUAU 20
lntron2-73 15173
CFTR-
+ GGAAACUGAGAGAUUCUUUAU 21
lntron2-2473 17573
CFTR-
+ AGGAAACUGAGAGAUUCUUUAU 22
lntron2-2474 17574
CFTR-
+ AAGGAAACUGAGAGAUUCUUUAU 23
lntron2-2475 17575
CFTR-
+ AAAGGAAACUGAGAGAUUCUUUAU 24
lntron2-2476 17576
CFTR-
+ U U CAAAU ACCAAU U U U AU 18
lntron2-2477 17577
CFTR-
+ U U U CAAAU ACCAAU U U U AU 19
lntron2-2478 17578
CFTR-
+ AU U U CAAAU ACCAAU U U U AU 20
lntron2-2479 17579
CFTR-
+ AAUUU CAAAU ACCAAU U U U AU 21
Intron2-2480 17580
CFTR-
+ AAAU U U CAAAU ACCAAU U U U AU 22
lntron2-2481 17581
CFTR-
+ U AAAU U U CAAAU ACCAAU U U U AU 23
lntron2-2482 17582
CFTR-
+ AU AAAU U U CAAAU ACCAAU U U U AU 24
lntron2-2483 17583
CFTR-
+ UUGAUUGGAAAGGAAACU 18
lntron2-2484 17584
CFTR-
+ UUUGAUUGGAAAGGAAACU 19
lntron2-2485 17585
CFTR-
+ UUUUGAUUGGAAAGGAAACU 20
lntron2-2486 17586
CFTR-
+ CUUUUGAUUGGAAAGGAAACU 21
lntron2-2487 17587
CFTR-
+ CCUUUUGAUUGGAAAGGAAACU 22
lntron2-2488 17588
CFTR-
+ ACCU UUUGAUUGGAAAGGAAACU 23
lntron2-2489 17589
CFTR-
+ AACCUUUUGAUUGGAAAGGAAACU 24
Intron2-2490 17590
543
5535.1 CFTR-
+ GCCACUAAUCCCAACACU 18
l ntron2-2491 17591
CFTR-
+ CGCCACUAAUCCCAACACU 19
lntron2-2492 17592
CFTR-
+ ACGCCACUAAUCCCAACACU 20
lntron2-2493 17593
CFTR-
+ CACGCCACUAAUCCCAACACU 21
lntron2-2494 17594
CFTR-
+ UCACGCCACUAAUCCCAACACU 22
lntron2-2495 17595
CFTR-
+ CUCACGCCACUAAUCCCAACACU 23
lntron2-2496 17596
CFTR-
+ GCUCACGCCACUAAUCCCAACACU 24
lntron2-2497 17597
CFTR-
+ GGCCCUAU UCUAGGCACU 18
lntron2-2498 17598
CFTR-
+ AGGCCCUAUUCUAGGCACU 19
lntron2-2499 17599
CFTR-
+ CAGGCCCUAUUCUAGGCACU 20
I ntron2-703 15803
CFTR-
+ CCAGGCCCUAU UCUAGGCACU 21
Intron2-2500 17600
CFTR-
+ GCCAGGCCCUAUUCUAGGCACU 22
Intron2-2501 17601
CFTR-
+ UGCCAGGCCCUAUUCUAGGCACU 23
Intron2-2502 17602
CFTR-
+ AUGCCAGGCCCUAUUCUAGGCACU 24
Intron2-2503 17603
CFTR-
+ CCUGUAGUCCCAGCUACU 18
Intron2-2504 17604
CFTR-
+ GCCUGUAGUCCCAGCUACU 19
Intron2-2505 17605
CFTR-
+ UGCCUGUAGUCCCAGCUACU 20
Intron2-2506 17606
CFTR-
+ AUGCCUGUAGUCCCAGCUACU 21
Intron2-2507 17607
CFTR-
+ CAUGCCUGUAGUCCCAGCUACU 22
Intron2-2508 17608
CFTR-
+ GCAUGCCUGUAGUCCCAGCUACU 23
Intron2-2509 17609
CFTR-
+ UGCAUGCCUGUAGUCCCAGCUACU 24
Intron2-2510 17610
544
5535.1 CFTR-
+ AGAAUGGGGUAGUUACCU 18
lntron2-2511 17611
CFTR-
+ UAGAAUGGGGUAGUUACCU 19
lntron2-2512 17612
CFTR-
+ AUAGAAUGGGGUAGUUACCU 20
lntron2-2513 17613
CFTR-
+ AAUAGAAUGGGGUAGUUACCU 21
lntron2-2514 17614
CFTR-
+ AAAUAGAAUGGGGUAGUUACCU 22
lntron2-2515 17615
CFTR-
+ AAAAUAGAAUGGGGUAGUUACCU 23
lntron2-2516 17616
CFTR-
+ AAAAAUAGAAUGGGGUAGUUACCU 24
lntron2-2517 17617
CFTR-
+ GAGCAGAGAAUGUUAGCU 18
lntron2-2518 17618
CFTR-
+ AGAGCAGAGAAUGUUAGCU 19
lntron2-2519 17619
CFTR-
+ GAGAGCAGAGAAUGUUAGCU 20
Intron2-2520 17620
CFTR-
+ GGAGAGCAGAGAAUGUUAGCU 21
lntron2-2521 17621
CFTR-
+ AGGAGAGCAGAGAAUGUUAGCU 22
lntron2-2522 17622
CFTR-
+ CAGGAGAGCAGAGAAUGUUAGCU 23
lntron2-2523 17623
CFTR-
+ CCAGGAGAGCAGAGAAUGUUAGCU 24
lntron2-2524 17624
CFTR-
+ UUUCCACUCAGAGUGGCU 18
lntron2-2525 17625
CFTR-
+ CUUUCCACUCAGAGUGGCU 19
lntron2-2526 17626
CFTR-
+ GCUUUCCACUCAGAGUGGCU 20
lntron2-2527 17627
CFTR-
+ UGCUUUCCACUCAGAGUGGCU 21
lntron2-2528 17628
CFTR-
+ AUGCUUUCCACUCAGAGUGGCU 22
lntron2-2529 17629
CFTR-
+ GAUGCUUUCCACUCAGAGUGGCU 23
Intron2-2530 17630
CFTR-
+ UGAUGCUUUCCACUCAGAGUGGCU 24
lntron2-2531 17631
545
5535.1 CFTR-
+ AUAUCCUGACUACAAUCU 18
lntron2-2532 17632
CFTR-
+ CAUAUCCUGACUACAAUCU 19
lntron2-2533 17633
CFTR-
+ UCAUAUCCUGACUACAAUCU 20
lntron2-395 15495
CFTR-
+ UUCAUAUCCUGACUACAAUCU 21
lntron2-2534 17634
CFTR-
+ GUUCAUAUCCUGACUACAAUCU 22
lntron2-2535 17635
CFTR-
+ AGUUCAUAUCCUGACUACAAUCU 23
lntron2-2536 17636
CFTR-
+ AAGUUCAUAUCCUGACUACAAUCU 24
lntron2-2537 17637
CFTR-
+ GAAGCUGGCCCUUGAUCU 18
lntron2-2538 17638
CFTR-
+ AGAAGCUGGCCCUUGAUCU 19
lntron2-2539 17639
CFTR-
+ UAGAAGCUGGCCCUUGAUCU 20
Intron2-2540 17640
CFTR-
+ AUAGAAGCUGGCCCUUGAUCU 21
lntron2-2541 17641
CFTR-
+ AAUAGAAGCUGGCCCUUGAUCU 22
lntron2-2542 17642
CFTR-
+ UAAUAGAAGCUGGCCCUUGAUCU 23
lntron2-2543 17643
CFTR-
+ AUAAUAGAAGCUGGCCCUUGAUCU 24
lntron2-2544 17644
CFTR-
+ GCAAAGUAUAUUAUCUCU 18
lntron2-2545 17645
CFTR-
+ GGCAAAGUAUAUUAUCUCU 19
lntron2-2546 17646
CFTR-
+ UGGCAAAGUAUAUUAUCUCU 20
lntron2-2547 17647
CFTR-
+ CUGGCAAAGUAUAUUAUCUCU 21
lntron2-2548 17648
CFTR-
+ ACUGGCAAAGUAUAUUAUCUCU 22
lntron2-2549 17649
CFTR-
+ AACUGGCAAAGUAUAUUAUCUCU 23
Intron2-2550 17650
CFTR-
+ UAACUGGCAAAGUAUAUUAUCUCU 24
lntron2-2551 17651
546
5535.1 CFTR-
+ ACUAUGACUCAAGAGUCU 18
lntron2-2552 17652
CFTR-
+ CACUAUGACUCAAGAGUCU 19
lntron2-2553 17653
CFTR-
+ GCACUAUGACUCAAGAGUCU 20
lntron2-2554 17654
CFTR-
+ AGCACUAUGACUCAAGAGUCU 21
lntron2-2555 17655
CFTR-
+ AAGCACUAUGACUCAAGAGUCU 22
lntron2-2556 17656
CFTR-
+ UAAGCACUAUGACUCAAGAGUCU 23
lntron2-2557 17657
CFTR-
+ GUAAGCACUAUGACUCAAGAGUCU 24
lntron2-2558 17658
CFTR-
+ AUCAUGUAUUAAAGGUCU 18
lntron2-2559 17659
CFTR-
+ AAUCAUGUAUUAAAGGUCU 19
Intron2-2560 17660
CFTR-
+ AAAUCAUGUAUUAAAGGUCU 20
lntron2-2561 17661
CFTR-
+ AAAAUCAUGUAUUAAAGGUCU 21
lntron2-2562 17662
CFTR-
+ UAAAAUCAUGUAUUAAAGGUCU 22
lntron2-2563 17663
CFTR-
+ CUAAAAUCAUGUAUUAAAGGUCU 23
lntron2-2564 17664
CFTR-
+ ACUAAAAUCAUGUAUUAAAGGUCU 24
lntron2-2565 17665
CFTR-
+ AGAAAGCUGGUCCGGUCU 18
lntron2-2566 17666
CFTR-
+ UAGAAAGCUGGUCCGGUCU 19
lntron2-2567 17667
CFTR-
+ GUAGAAAGCUGGUCCGGUCU 20
lntron2-2568 17668
CFTR-
+ UGUAGAAAGCUGGUCCGGUCU 21
lntron2-2569 17669
CFTR-
+ AUGUAGAAAGCUGGUCCGGUCU 22
Intron2-2570 17670
CFTR-
+ UAUGUAGAAAGCUGGUCCGGUCU 23
lntron2-2571 17671
CFTR-
+ UUAUGUAGAAAGCUGGUCCGGUCU 24
lntron2-2572 17672
547
5535.1 CFTR-
+ U CU AAU AAG ACAAAU U CU 18
lntron2-2573 17673
CFTR-
+ CUCUAAUAAGACAAAUUCU 19
lntron2-2574 17674
CFTR-
+ UCUCUAAUAAGACAAAUUCU 20
lntron2-2575 17675
CFTR-
+ GUCUCUAAUAAGACAAAUUCU 21
lntron2-2576 17676
CFTR-
+ GGUCUCUAAUAAGACAAAUUCU 22
lntron2-2577 17677
CFTR-
+ UGGUCUCUAAUAAGACAAAUUCU 23
lntron2-2578 17678
CFTR-
+ AUGGUCUCUAAUAAGACAAAUUCU 24
lntron2-2579 17679
CFTR-
+ CAUUUGGUUACUCAGAGU 18
Intron2-2580 17680
CFTR-
+ ACAUUUGGUUACUCAGAGU 19
lntron2-2581 17681
CFTR-
+ AACAUUUGGUUACUCAGAGU 20
lntron2-2582 17682
CFTR-
+ UAACAUUUGGUUACUCAGAGU 21
lntron2-2583 17683
CFTR-
+ AUAACAUUUGGUUACUCAGAGU 22
lntron2-2584 17684
CFTR-
+ CAUAACAUUUGGUUACUCAGAGU 23
lntron2-2585 17685
CFTR-
+ CCAU AACAU U UGG U U ACU CAG AG U 24
lntron2-2586 17686
CFTR-
+ G AAU AG ACAU U AAAU AG U 18
lntron2-2587 17687
CFTR-
+ AGAAUAGACAUUAAAUAGU 19
lntron2-2588 17688
CFTR-
+ AAG AAU AG ACAU U AAAU AG U 20
lntron2-2589 17689
CFTR-
+ U AAG AAU AG ACAU U AAAU AG U 21
Intron2-2590 17690
CFTR-
+ G U AAG AAU AG ACAU U AAAU AG U 22
lntron2-2591 17691
CFTR-
+ AG U AAG AAU AG ACAU U AAAU AG U 23
lntron2-2592 17692
CFTR-
+ U AG U AAG AAU AG ACAU U AAAU AG U 24
lntron2-2593 17693
548
5535.1 CFTR-
+ CUGAGGAGAAGGCAAGGU 18
lntron2-2594 17694
CFTR-
+ CCUGAGGAGAAGGCAAGGU 19
lntron2-2595 17695
CFTR-
+ ACCUGAGGAGAAGGCAAGGU 20
Intron2-405 15505
CFTR-
+ UACCUGAGGAGAAGGCAAGGU 21
lntron2-2596 17696
CFTR-
+ UUACCUGAGGAGAAGGCAAGGU 22
lntron2-2597 17697
CFTR-
+ GU UACCUGAGGAGAAGGCAAGGU 23
lntron2-2598 17698
CFTR-
+ AGUUACCUGAGGAGAAGGCAAGGU 24
lntron2-2599 17699
CFTR-
+ GGGCAGAUCACUUGAGGU 18
Intron2-2600 17700
CFTR-
+ CGGGCAGAUCACUUGAGGU 19
Intron2-2601 17701
CFTR-
+ GCGGGCAGAUCACUUGAGGU 20
Intron2-2602 17702
CFTR-
+ GGCGGGCAGAUCACUUGAGGU 21
Intron2-2603 17703
CFTR-
+ AGGCGGGCAGAUCACUUGAGGU 22
Intron2-2604 17704
CFTR-
+ AAGGCGGGCAGAUCACUUGAGGU 23
Intron2-2605 17705
CFTR-
+ CAAGGCGGGCAGAUCACUUGAGGU 24
Intron2-2606 17706
CFTR-
+ UGGGCAGAUCACUUGAGGU 19
Intron2-2607 17707
CFTR-
+ GUGGGCAGAUCACUUGAGGU 20
Intron2-2608 17708
CFTR-
+ GGUGGGCAGAUCACUUGAGGU 21
Intron2-2609 17709
CFTR-
+ AGGUGGGCAGAUCACUUGAGGU 22
Intron2-2610 17710
CFTR-
+ AAGGUGGGCAGAUCACUUGAGGU 23
lntron2-2611 17711
CFTR-
+ CAAGGUGGGCAGAUCACUUGAGGU 24
lntron2-2612 17712
CFTR-
+ GUAGAAAGCUGGUCCGGU 18
lntron2-2613 17713
549
5535.1 CFTR-
+ UGUAGAAAGCUGGUCCGGU 19
lntron2-2614 17714
CFTR-
+ AUGUAGAAAGCUGGUCCGGU 20
lntron2-2615 17715
CFTR-
+ UAUGUAGAAAGCUGGUCCGGU 21
lntron2-2616 17716
CFTR-
+ UUAUGUAGAAAGCUGGUCCGGU 22
lntron2-2617 17717
CFTR-
+ UUUAUGUAGAAAGCUGGUCCGGU 23
lntron2-2618 17718
CFTR-
+ CUUUAUGUAGAAAGCUGGUCCGGU 24
lntron2-2619 17719
CFTR-
+ ACCUAUAAUCCCAGCAUU 18
Intron2-2620 17720
CFTR-
+ CACCUAUAAUCCCAGCAUU 19
lntron2-2621 17721
CFTR-
+ ACACCUAUAAUCCCAGCAUU 20
lntron2-2622 17722
CFTR-
+ CACACCUAUAAUCCCAGCAUU 21
lntron2-2623 17723
CFTR-
+ UCACACCUAUAAUCCCAGCAUU 22
lntron2-2624 17724
CFTR-
+ CUCACACCUAUAAUCCCAGCAUU 23
lntron2-2625 17725
CFTR-
+ GCUCACACCUAUAAUCCCAGCAUU 24
lntron2-2626 17726
CFTR-
+ AAUACCCAUUAUAUUAUU 18
lntron2-2627 17727
CFTR-
+ CAAUACCCAUUAUAUUAUU 19
lntron2-2628 17728
CFTR-
+ UCAAUACCCAUUAUAUUAUU 20
lntron2-2629 17729
CFTR-
+ UUCAAUACCCAUUAUAUUAUU 21
Intron2-2630 17730
CFTR-
+ AUUCAAUACCCAUUAUAUUAUU 22
lntron2-2631 17731
CFTR-
+ UAUUCAAUACCCAUUAUAUUAUU 23
lntron2-2632 17732
CFTR-
+ AUAUUCAAUACCCAUUAUAUUAUU 24
lntron2-2633 17733
CFTR-
+ CCACUAAUCCCAACACUU 18
lntron2-2634 17734
550
5535.1 CFTR-
+ GCCACUAAUCCCAACACUU 19
l ntron2-2635 17735
CFTR-
+ CGCCACUAAUCCCAACACUU 20
l ntron2-717 15817
CFTR-
+ ACGCCACUAAUCCCAACACUU 21
lntron2-2636 17736
CFTR-
+ CACGCCACUAAUCCCAACACUU 22
lntron2-2637 17737
CFTR-
+ UCACGCCACUAAUCCCAACACUU 23
lntron2-2638 17738
CFTR-
+ CUCACGCCACUAAUCCCAACACUU 24
lntron2-2639 17739
CFTR-
+ ACCAUCUGGCAACCACU U 18
Intron2-2640 17740
CFTR-
+ AACCAUCUGGCAACCACUU 19
lntron2-2641 17741
CFTR-
+ CAACCAUCUGGCAACCACUU 20
lntron2-2642 17742
CFTR-
+ UCAACCAUCUGGCAACCACUU 21
lntron2-2643 17743
CFTR-
+ UUCAACCAUCUGGCAACCACUU 22
lntron2-2644 17744
CFTR-
+ CUUCAACCAUCUGGCAACCACUU 23
lntron2-2645 17745
CFTR-
+ UCU UCAACCAUCUGGCAACCACUU 24
lntron2-2646 17746
CFTR-
+ AUGGUGGAAACCAUACU U 18
lntron2-2647 17747
CFTR-
+ CAUGGUGGAAACCAUACUU 19
lntron2-2648 17748
CFTR-
+ ACAUGGUGGAAACCAUACUU 20
lntron2-2649 17749
CFTR-
+ AACAUGGUGGAAACCAUACUU 21
Intron2-2650 17750
CFTR-
+ GAACAUGGUGGAAACCAUACUU 22
lntron2-2651 17751
CFTR-
+ GGAACAUGGUGGAAACCAUACUU 23
lntron2-2652 17752
CFTR-
+ AGGAACAUGGUGGAAACCAUACUU 24
lntron2-2653 17753
CFTR-
+ C A U G G U C AC A AG G C AG U U 18
lntron2-2654 17754
551
5535.1 CFTR-
+ CCAUGGUCACAAGGCAGUU 19
lntron2-2655 17755
CFTR-
+ GCCAUGGUCACAAGGCAGUU 20
lntron2-2656 17756
CFTR-
+ GGCCAUGGUCACAAGGCAGUU 21
lntron2-2657 17757
CFTR-
+ GGGCCAUGGUCACAAGGCAGUU 22
lntron2-2658 17758
CFTR-
+ AGGGCCAUGGUCACAAGGCAGUU 23
lntron2-2659 17759
CFTR-
+ GAGGGCCAUGGUCACAAGGCAGUU 24
Intron2-2660 17760
CFTR-
+ UAUUCAAAUAUAAAGGUU 18
lntron2-2661 17761
CFTR-
+ GUAUUCAAAUAUAAAGGUU 19
lntron2-2662 17762
CFTR-
+ UGUAUUCAAAUAUAAAGGUU 20
lntron2-2663 17763
CFTR-
+ UUGUAUUCAAAUAUAAAGGUU 21
lntron2-2664 17764
CFTR-
+ UUUGUAUUCAAAUAUAAAGGUU 22
lntron2-2665 17765
CFTR-
+ AUUUGUAUU CAAAU AU AAAGG U U 23
lntron2-2666 17766
CFTR-
+ CAUUUGUAUUCAAAUAUAAAGGUU 24
lntron2-2667 17767
CFTR-
+ CCUAUAAUCCCAGCAUUU 18
lntron2-2668 17768
CFTR-
+ ACCUAUAAUCCCAGCAUUU 19
lntron2-2669 17769
CFTR-
+ CACCUAUAAUCCCAGCAUUU 20
Intron2-720 15820
CFTR-
+ ACACCUAUAAUCCCAGCAUUU 21
Intron2-2670 17770
CFTR-
+ CACACCUAUAAUCCCAGCAUUU 22
lntron2-2671 17771
CFTR-
+ UCACACCUAUAAUCCCAGCAUUU 23
lntron2-2672 17772
CFTR-
+ CUCACACCUAUAAUCCCAGCAUUU 24
lntron2-2673 17773
CFTR-
+ CACUAAUCCCAACACUUU 18
lntron2-2674 17774 CFTR-
+ CCACU AAU CCCAACACU U U 19
lntron2-2675 17775
CFTR-
+ GCCACUAAUCCCAACACUUU 20
lntron2-476 15576
CFTR-
+ CGCCACUAAUCCCAACACUUU 21
lntron2-2676 17776
CFTR-
+ ACGCCACUAAUCCCAACACUUU 22
lntron2-2677 17777
CFTR-
+ CACGCCACUAAUCCCAACACUUU 23
lntron2-2678 17778
CFTR-
+ U CACGCCACU AAU CCCAACACU U U 24
lntron2-2679 17779
CFTR-
+ GAAACUGAGAGAUUCUUU 18
Intron2-2680 17780
CFTR-
+ GGAAACUGAGAGAUUCUUU 19
lntron2-2681 17781
CFTR-
+ AGGAAACUGAGAGAUUCUUU 20
lntron2-2682 17782
CFTR-
+ AAGGAAACUGAGAGAUUCUUU 21
lntron2-2683 17783
CFTR-
+ AAAGG AAACUG AG AG AU U CU U U 22
lntron2-2684 17784
CFTR-
+ GAAAGGAAACUGAGAGAUUCUUU 23
lntron2-2685 17785
CFTR-
+ GGAAAGGAAACUGAGAGAUUCUUU 24
lntron2-2686 17786
CFTR-
+ CCCUGGGCAAUGUAGUUU 18
lntron2-2687 17787
CFTR-
+ ACCCUGGGCAAUGUAGUUU 19
lntron2-2688 17788
CFTR-
+ GACCCUGGGCAAUGUAGUUU 20
lntron2-2689 17789
CFTR-
+ UGACCCUGGGCAAUGUAGUUU 21
Intron2-2690 17790
CFTR-
+ GUGACCCUGGGCAAUGUAGUUU 22
lntron2-2691 17791
CFTR-
+ AGUGACCCUGGGCAAUGUAGUUU 23
lntron2-2692 17792
CFTR-
+ UAGUGACCCUGGGCAAUGUAGUUU 24
lntron2-2693 17793
CFTR-
+ CUAUAAUCCCAGCAUUUU 18
lntron2-2694 17794 CFTR-
+ CCUAUAAUCCCAGCAUUUU 19
lntron2-2695 17795
CFTR-
+ ACCUAUAAUCCCAGCAUUUU 20
lntron2-722 15822
CFTR-
+ CACCUAUAAUCCCAGCAUUUU 21
lntron2-2696 17796
CFTR-
+ ACACCUAUAAUCCCAGCAUUUU 22
lntron2-2697 17797
CFTR-
+ CACACCUAUAAUCCCAGCAUUUU 23
lntron2-2698 17798
CFTR-
+ UCACACCUAUAAUCCCAGCAUUUU 24
lntron2-2699 17799
CFTR-
+ CCUGGGCAAUGUAGUUUU 18
Intron2-2700 17800
CFTR-
+ CCCUGGGCAAUGUAGUUUU 19
Intron2-2701 17801
CFTR-
+ ACCCUGGGCAAUGUAGUUUU 20
lntron2-416 15516
CFTR-
+ GACCCUGGGCAAUGUAGUUUU 21
Intron2-2702 17802
CFTR-
+ UGACCCUGGGCAAUGUAGUUUU 22
Intron2-2703 17803
CFTR-
+ GUGACCCUGGGCAAUGUAGUUUU 23
Intron2-2704 17804
CFTR-
+ AGUGACCCUGGGCAAUGUAGUUUU 24
Intron2-2705 17805
CFTR-
+ AACCAAAUGUGUAUUUUU 18
Intron2-2706 17806
CFTR-
+ AAACCAAAUGUGUAUUUUU 19
Intron2-2707 17807
CFTR-
+ GAAACCAAAUGUGUAUUUUU 20
Intron2-2708 17808
CFTR-
+ UGAAACCAAAUGUGUAUUUUU 21
Intron2-2709 17809
CFTR-
+ CUGAAACCAAAUGUGUAUUUUU 22
Intron2-2710 17810
CFTR-
+ UCUGAAACCAAAUGUGUAUUUUU 23
lntron2-2711 17811
CFTR-
+ CUCUGAAACCAAAUGUGUAUUUUU 24
lntron2-2712 17812
CFTR-
- AU AG U AU U U AAAAG AAAA 18
lntron2-2713 17813
554
5535.1 CFTR-
- UAUAGUAUU U AAAAG AAAA 19
lntron2-2714 17814
CFTR-
- CUAUAGUAUU U AAAAG AAAA 20
lntron2-2715 17815
CFTR-
- CCUAUAGUAUU U AAAAG AAAA 21
lntron2-2716 17816
CFTR-
- UCCUAUAGUAUU U AAAAG AAAA 22
lntron2-2717 17817
CFTR-
- UUCCUAUAGUAUU U AAAAG AAAA 23
lntron2-2718 17818
CFTR-
- GUUCCUAUAGUAUUUAAAAGAAAA 24
lntron2-2719 17819
CFTR-
- AUUUUACAG AAAAG C A A A 18
Intron2-2720 17820
CFTR-
- U AU U U UACAG AAAAG CAAA 19
lntron2-2721 17821
CFTR-
- CUAUUUUACAG AAAAG C A A A 20
lntron2-2722 17822
CFTR-
- UCUAUUUUACAG AAAAG CAAA 21
lntron2-2723 17823
CFTR-
- CUCUAUUUUACAGAAAAGCAAA 22
lntron2-2724 17824
CFTR-
- UCUCUAUUU U AC AG A A A AG CAAA 23
lntron2-2725 17825
CFTR-
- AUCUCUAUUUUACAGAAAAGCAAA 24
lntron2-2726 17826
CFTR-
- UGAUUUUAGUAGUUGAAA 18
lntron2-2727 17827
CFTR-
- AUGAUUUUAGUAGUUGAAA 19
lntron2-2728 17828
CFTR-
- CAUGAUUUUAGUAGUUGAAA 20
lntron2-2729 17829
CFTR-
- ACAUGAUUUUAGUAGUUGAAA 21
Intron2-2730 17830
CFTR-
- UACAUGAUUUUAGUAGUUGAAA 22
lntron2-2731 17831
CFTR-
- AUACAUGAUUUUAGUAGUUGAAA 23
lntron2-2732 17832
CFTR-
- AAUACAUGAUUUUAGUAGUUGAAA 24
lntron2-2733 17833
CFTR-
- CU AG CU UAAG U AAAU AAA 18
lntron2-2734 17834
555
5535.1 CFTR-
- ACUAGCUUAAGUAAAUAAA 19
lntron2-2735 17835
CFTR-
- UACUAGCUUAAGUAAAUAAA 20
lntron2-613 15713
CFTR-
- UUACUAGCUUAAGUAAAUAAA 21
lntron2-2736 17836
CFTR-
- U U U ACU AG CU UAAG U AAAU AAA 22
lntron2-2737 17837
CFTR-
- AUUUACUAGCUUAAGUAAAUAAA 23
lntron2-2738 17838
CFTR-
- AAUUUACUAGCUUAAGUAAAUAAA 24
lntron2-2739 17839
CFTR-
- CUGGCCUUAGGAACUCAA 18
Intron2-2740 17840
CFTR-
- ACUGGCCUUAGGAACUCAA 19
lntron2-2741 17841
CFTR-
- AACUGGCCUUAGGAACUCAA 20
lntron2-241 15341
CFTR-
- GAACUGGCCUUAGGAACUCAA 21
lntron2-2742 17842
CFTR-
- AGAACUGGCCUUAGGAACUCAA 22
lntron2-2743 17843
CFTR-
- GAGAACUGGCCUUAGGAACUCAA 23
lntron2-2744 17844
CFTR-
- GGAGAACUGGCCUUAGGAACUCAA 24
lntron2-2745 17845
CFTR-
- AUCCCCAAGUGCCUAGAA 18
lntron2-2746 17846
CFTR-
- UAUCCCCAAGUGCCUAGAA 19
lntron2-2747 17847
CFTR-
- GUAUCCCCAAGUGCCUAGAA 20
lntron2-2748 17848
CFTR-
- UGUAUCCCCAAGUGCCUAGAA 21
lntron2-2749 17849
CFTR-
- AUGUAUCCCCAAGUGCCUAGAA 22
Intron2-2750 17850
CFTR-
- GAUGUAUCCCCAAGUGCCUAGAA 23
lntron2-2751 17851
CFTR-
- UGAUGUAUCCCCAAGUGCCUAGAA 24
lntron2-2752 17852
CFTR-
- GAUAAAAGGGUGAGUGAA 18
lntron2-2753 17853
556
5535.1 CFTR-
- AGAUAAAAGGGUGAGUGAA 19
lntron2-2754 17854
CFTR-
- CAGAUAAAAGGGUGAGUGAA 20
lntron2-248 15348
CFTR-
- CCAGAUAAAAGGGUGAGUGAA 21
lntron2-2755 17855
CFTR-
- GCCAGAUAAAAGGGUGAGUGAA 22
lntron2-2756 17856
CFTR-
- UGCCAGAUAAAAGGGUGAGUGAA 23
lntron2-2757 17857
CFTR-
- AUGCCAGAUAAAAGGGUGAGUGAA 24
lntron2-2758 17858
CFTR-
- AUUUUAUUCCUUUGUGAA 18
lntron2-2759 17859
CFTR-
- UAUUUUAUUCCUUUGUGAA 19
Intron2-2760 17860
CFTR-
- AUAUUUUAUUCCUUUGUGAA 20
lntron2-2761 17861
CFTR-
- GAUAUUUUAUUCCUUUGUGAA 21
lntron2-2762 17862
CFTR-
- AGAUAUUUUAUUCCUUUGUGAA 22
lntron2-2763 17863
CFTR-
- GAGAUAUUUUAUUCCUUUGUGAA 23
lntron2-2764 17864
CFTR-
- AGAGAUAUUUUAUUCCUUUGUGAA 24
lntron2-2765 17865
CFTR-
- ACU AG CU UAAG UAAAUAA 18
lntron2-2766 17866
CFTR-
- UACUAGCUUAAGUAAAUAA 19
lntron2-2767 17867
CFTR-
- U U ACU AG CU UAAG UAAAUAA 20
lntron2-2768 17868
CFTR-
- U U U ACU AG CU UAAG UAAAUAA 21
lntron2-2769 17869
CFTR-
- AUUUACUAGCU UAAG UAAAUAA 22
Intron2-2770 17870
CFTR-
- AAU U U ACU AG CU UAAG UAAAUAA 23
lntron2-2771 17871
CFTR-
- CAAUUUACUAGCUUAAGUAAAUAA 24
lntron2-2772 17872
CFTR-
- UGUCUAUUCUUACUAUAA 18
lntron2-2773 17873
557
5535.1 CFTR-
- AUGUCUAUUCUUACUAUAA 19
lntron2-2774 17874
CFTR-
- AAUGUCUAUUCUUACUAUAA 20
lntron2-2775 17875
CFTR-
- UAAUGUCUAUUCUUACUAUAA 21
lntron2-2776 17876
CFTR-
- UUAAUGUCUAUUCUUACUAUAA 22
lntron2-2777 17877
CFTR-
- UUUAAUGUCUAUUCUUACUAUAA 23
lntron2-2778 17878
CFTR-
- AUUUAAUGUCUAUUCUUACUAUAA 24
lntron2-2779 17879
CFTR-
- AUGGUAACUUGACAGUAA 18
Intron2-2780 17880
CFTR-
- UAUGGUAACUUGACAGUAA 19
lntron2-2781 17881
CFTR-
- UUAUGGUAACUUGACAGUAA 20
lntron2-251 15351
CFTR-
- CUUAUGGUAACUUGACAGUAA 21
lntron2-2782 17882
CFTR-
- ACUUAUGGUAACUUGACAGUAA 22
lntron2-2783 17883
CFTR-
- UACUUAUGGUAACUUGACAGUAA 23
lntron2-2784 17884
CFTR-
- UUACUUAUGGUAACUUGACAGUAA 24
lntron2-2785 17885
CFTR-
- AAAAAAGG CUUU CAU UAA 18
lntron2-2786 17886
CFTR-
- G A A A A A AG GCUUUCAUUAA 19
lntron2-2787 17887
CFTR-
- AGAAAAAAGGCUUUCAUUAA 20
lntron2-2788 17888
CFTR-
- GAGAAAAAAGGCUUUCAUUAA 21
lntron2-2789 17889
CFTR-
- AG AG AAAAAAGG CU U U CAU UAA 22
Intron2-2790 17890
CFTR-
- AAG AG A A A A A AG GCUUUCAUUAA 23
lntron2-2791 17891
CFTR-
- G AAG AG AAAAAAGG CU U U CAU UAA 24
lntron2-2792 17892
CFTR-
- AGAGUAGGGCUGGGUUAA 18
lntron2-2793 17893
558
5535.1 CFTR-
- CAGAGUAGGGCUGGGUUAA 19
lntron2-2794 17894
CFTR-
- UCAGAGUAGGGCUGGGUUAA 20
lntron2-2795 17895
CFTR-
- AUCAGAGUAGGGCUGGGUUAA 21
lntron2-2796 17896
CFTR-
- AAUCAGAGUAGGGCUGGGUUAA 22
lntron2-2797 17897
CFTR-
- UAAUCAGAGUAGGGCUGGGUUAA 23
lntron2-2798 17898
CFTR-
- UUAAUCAGAGUAGGGCUGGGUUAA 24
lntron2-2799 17899
CFTR-
- UGUUCCUAUAGUAUUUAA 18
Intron2-2800 17900
CFTR-
- GUGUUCCUAUAGUAUUUAA 19
Intron2-2801 17901
CFTR-
- GGUGUUCCUAUAGUAUUUAA 20
Intron2-2802 17902
CFTR-
- UGGUGUUCCUAUAGUAUUUAA 21
Intron2-2803 17903
CFTR-
- CUGGUGUUCCUAUAGUAUUUAA 22
Intron2-2804 17904
CFTR-
- GCUGGUGUUCCUAUAGUAUUUAA 23
Intron2-2805 17905
CFTR-
- AGCUGGUGUUCCUAUAGUAUUUAA 24
Intron2-2806 17906
CFTR-
- GUGGACCACUUUUUCACA 18
Intron2-2807 17907
CFTR-
- UGUGGACCACUUUUUCACA 19
Intron2-2808 17908
CFTR-
- GUGUGGACCACUUUUUCACA 20
Intron2-2809 17909
CFTR-
- CGUGUGGACCACUUUUUCACA 21
Intron2-2810 17910
CFTR-
- CCGUGUGGACCACUUUUUCACA 22
lntron2-2811 17911
CFTR-
- UCCGUGUGGACCACUUUUUCACA 23
lntron2-2812 17912
CFTR-
- UUCCGUGUGGACCACUUUUUCACA 24
lntron2-2813 17913
CFTR-
- GAAAUGGCUAGCAUUACA 18
lntron2-2814 17914
559
5535.1 CFTR-
- UGAAAUGGCUAGCAUUACA 19
lntron2-2815 17915
CFTR-
- GUGAAAUGGCUAGCAUUACA 20
lntron2-2816 17916
CFTR-
- UGUGAAAUGGCUAGCAUUACA 21
lntron2-2817 17917
CFTR-
- AUGUGAAAUGGCUAGCAUUACA 22
lntron2-2818 17918
CFTR-
- AAUGUGAAAUGGCUAGCAUUACA 23
lntron2-2819 17919
CFTR-
- GAAUGUGAAAUGGCUAGCAUUACA 24
Intron2-2820 17920
CFTR-
- ACUGGCCUUAGGAACUCA 18
lntron2-2821 17921
CFTR-
- AACUGGCCUUAGGAACUCA 19
lntron2-2822 17922
CFTR-
- GAACUGGCCUUAGGAACUCA 20
lntron2-2823 17923
CFTR-
- AGAACUGGCCUUAGGAACUCA 21
lntron2-2824 17924
CFTR-
- GAGAACUGGCCUUAGGAACUCA 22
lntron2-2825 17925
CFTR-
- GGAGAACUGGCCUUAGGAACUCA 23
lntron2-2826 17926
CFTR-
- UGGAGAACUGGCCUUAGGAACUCA 24
lntron2-2827 17927
CFTR-
- AAAG CAAAC U G AG G C U C A 18
lntron2-2828 17928
CFTR-
- A A A AG C A A AC U G AG G C U C A 19
lntron2-2829 17929
CFTR-
- GAAAAGCAAACUGAGGCUCA 20
Intron2-2830 17930
CFTR-
- AG AAAAG CAAAC U GAG G C U CA 21
lntron2-2831 17931
CFTR-
- CAGAAAAG CAAAC U GAG G C U CA 22
lntron2-2832 17932
CFTR-
- ACAGAAAAGCAAACUGAGGCUCA 23
lntron2-2833 17933
CFTR-
- UACAGAAAAGCAAACUGAGGCUCA 24
lntron2-2834 17934
CFTR-
- U U U AAGG ACCACG AAAG A 18
lntron2-2835 17935
560
5535.1 CFTR-
- CU U U AAGG ACCACG AAAG A 19
lntron2-2836 17936
CFTR-
- UCUUUAAGGACCACGAAAGA 20
lntron2-274 15374
CFTR-
- AUCUUUAAGGACCACGAAAGA 21
lntron2-2837 17937
CFTR-
- UAUCUUUAAGGACCACGAAAGA 22
lntron2-2838 17938
CFTR-
- CUAUCUUUAAGGACCACGAAAGA 23
lntron2-2839 17939
CFTR-
- CCUAUCUUUAAGGACCACGAAAGA 24
Intron2-2840 17940
CFTR-
- UUUGUAUUUAUGGCCAGA 18
lntron2-2841 17941
CFTR-
- AUUUGUAUUUAUGGCCAGA 19
lntron2-2842 17942
CFTR-
- CAUUUGUAUUUAUGGCCAGA 20
lntron2-2843 17943
CFTR-
- ACAUUUGUAUUUAUGGCCAGA 21
lntron2-2844 17944
CFTR-
- UACAUUUGUAUUUAUGGCCAGA 22
lntron2-2845 17945
CFTR-
- AUACAUUUGUAUUUAUGGCCAGA 23
lntron2-2846 17946
CFTR-
- GAUACAUUUGUAUUUAUGGCCAGA 24
lntron2-2847 17947
CFTR-
- UGGUUUUAUUUUCUCAGA 18
lntron2-2848 17948
CFTR-
- CUGGUUUUAUUUUCUCAGA 19
lntron2-2849 17949
CFTR-
- GCUGGUUUUAUUUUCUCAGA 20
Intron2-2850 17950
CFTR-
- UGCUGGUUUUAUUUUCUCAGA 21
lntron2-2851 17951
CFTR-
- AUGCUGGUUUUAUUUUCUCAGA 22
lntron2-2852 17952
CFTR-
- UAUGCUGGUUUUAUUUUCUCAGA 23
lntron2-2853 17953
CFTR-
- UUAUGCUGGUUUUAUUUUCUCAGA 24
lntron2-2854 17954
CFTR-
- UGUGGGGAGGGAAAUAGA 18
lntron2-2855 17955
561
5535.1 CFTR-
- AUGUGGGGAGGGAAAUAGA 19
lntron2-2856 17956
CFTR-
- CAUGUGGGGAGGGAAAUAGA 20
lntron2-278 15378
CFTR-
- GCAUGUGGGGAGGGAAAUAGA 21
lntron2-2857 17957
CFTR-
- AGCAUGUGGGGAGGGAAAUAGA 22
lntron2-2858 17958
CFTR-
- AAGCAUGUGGGGAGGGAAAUAGA 23
lntron2-2859 17959
CFTR-
- GAAGCAUGUGGGGAGGGAAAUAGA 24
Intron2-2860 17960
CFTR-
- GGCCACUCAUAGUCUAGA 18
lntron2-2861 17961
CFTR-
- GGGCCACUCAUAGUCUAGA 19
lntron2-2862 17962
CFTR-
- UGGGCCACUCAUAGUCUAGA 20
lntron2-2863 17963
CFTR-
- UUGGGCCACUCAUAGUCUAGA 21
lntron2-2864 17964
CFTR-
- CUUGGGCCACUCAUAGUCUAGA 22
lntron2-2865 17965
CFTR-
- CCUUGGGCCACUCAUAGUCUAGA 23
lntron2-2866 17966
CFTR-
- CCCUUGGGCCACUCAUAGUCUAGA 24
lntron2-2867 17967
CFTR-
- UAUCUUUAAGGACCACGA 18
lntron2-2868 17968
CFTR-
- CUAUCUUUAAGGACCACGA 19
lntron2-2869 17969
CFTR-
- CCUAUCUUUAAGGACCACGA 20
Intron2-2870 17970
CFTR-
- UCCUAUCUUUAAGGACCACGA 21
lntron2-2871 17971
CFTR-
- CUCCUAUCUUUAAGGACCACGA 22
lntron2-2872 17972
CFTR-
- GCUCCUAUCUUUAAGGACCACGA 23
lntron2-2873 17973
CFTR-
- UGCUCCUAUCUUUAAGGACCACGA 24
lntron2-2874 17974
CFTR-
- UGGAGAAGCAUGUGGGGA 18
lntron2-2875 17975
562
5535.1 CFTR-
- GUGGAGAAGCAUGUGGGGA 19
lntron2-2876 17976
CFTR-
- GGUGGAGAAGCAUGUGGGGA 20
lntron2-53 15153
CFTR-
- AGGUGGAGAAGCAUGUGGGGA 21
lntron2-2877 17977
CFTR-
- AAGGUGGAGAAGCAUGUGGGGA 22
lntron2-2878 17978
CFTR-
- AAAGGUGGAGAAGCAUGUGGGGA 23
lntron2-2879 17979
CFTR-
- GAAAGGUGGAGAAGCAUGUGGGGA 24
Intron2-2880 17980
CFTR-
- GUAACCAAAUGUUAUGGA 18
lntron2-2881 17981
CFTR-
- AGUAACCAAAUGUUAUGGA 19
lntron2-2882 17982
CFTR-
- GAGUAACCAAAUGUUAUGGA 20
lntron2-54 15154
CFTR-
- UGAGUAACCAAAUGUUAUGGA 21
lntron2-2883 17983
CFTR-
- CUGAGUAACCAAAUGUUAUGGA 22
lntron2-2884 17984
CFTR-
- UCUGAGUAACCAAAUGUUAUGGA 23
lntron2-2885 17985
CFTR-
- CUCUGAGUAACCAAAUGUUAUGGA 24
lntron2-2886 17986
CFTR-
- UUGCCAGUUAAUGAAUGA 18
lntron2-2887 17987
CFTR-
- UUUGCCAGUUAAUGAAUGA 19
lntron2-2888 17988
CFTR-
- CUUUGCCAGUUAAUGAAUGA 20
lntron2-281 15381
CFTR-
- ACUUUGCCAGUUAAUGAAUGA 21
lntron2-2889 17989
CFTR-
- UACUUUGCCAGUUAAUGAAUGA 22
Intron2-2890 17990
CFTR-
- AUACUUUGCCAGUUAAUGAAUGA 23
lntron2-2891 17991
CFTR-
- UAUACUUUGCCAGUUAAUGAAUGA 24
lntron2-2892 17992
CFTR-
- UCCUCUCAGCCACUCUGA 18
lntron2-2893 17993
563
5535.1 CFTR-
- CUCCUCUCAGCCACUCUGA 19
lntron2-2894 17994
CFTR-
- UCUCCUCUCAGCCACUCUGA 20
lntron2-2895 17995
CFTR-
- AUCUCCUCUCAGCCACUCUGA 21
lntron2-2896 17996
CFTR-
- UAUCUCCUCUCAGCCACUCUGA 22
lntron2-2897 17997
CFTR-
- AUAUCUCCUCUCAGCCACUCUGA 23
lntron2-2898 17998
CFTR-
- AAUAUCUCCUCUCAGCCACUCUGA 24
lntron2-2899 17999
CFTR-
- CCUUUUGAUUGCCAGUGA 18
Intron2-2900 18000
CFTR-
- UCCUUUUGAUUGCCAGUGA 19
Intron2-2901 18001
CFTR-
- AUCCUUUUGAUUGCCAGUGA 20
Intron2-2902 18002
CFTR-
- GAUCCUUUUGAUUGCCAGUGA 21
Intron2-2903 18003
CFTR-
- GGAUCCUUUUGAUUGCCAGUGA 22
Intron2-2904 18004
CFTR-
- AGGAUCCUUUUGAUUGCCAGUGA 23
Intron2-2905 18005
CFTR-
- UAGGAUCCUUUUGAUUGCCAGUGA 24
Intron2-2906 18006
CFTR-
- AGAUAAAAGGGUGAGUGA 18
Intron2-2907 18007
CFTR-
- CAGAUAAAAGGGUGAGUGA 19
Intron2-2908 18008
CFTR-
- CCAGAUAAAAGGGUGAGUGA 20
lntron2-283 15383
CFTR-
- GCCAGAUAAAAGGGUGAGUGA 21
Intron2-2909 18009
CFTR-
- UGCCAGAUAAAAGGGUGAGUGA 22
Intron2-2910 18010
CFTR-
- AUGCCAGAUAAAAGGGUGAGUGA 23
lntron2-2911 18011
CFTR-
- GAUGCCAGAUAAAAGGGUGAGUGA 24
lntron2-2912 18012
CFTR-
- UGCCAGAUAAAAGGGUGA 18
lntron2-2913 18013
564
5535.1 CFTR-
- AUGCCAGAUAAAAGGGUGA 19
lntron2-2914 18014
CFTR-
- GAUGCCAGAUAAAAGGGUGA 20
lntron2-2915 18015
CFTR-
- UGAUGCCAGAUAAAAGGGUGA 21
lntron2-2916 18016
CFTR-
- CUGAUGCCAGAUAAAAGGGUGA 22
lntron2-2917 18017
CFTR-
- CCUGAUGCCAGAUAAAAGGGUGA 23
lntron2-2918 18018
CFTR-
- GCCUGAUGCCAGAUAAAAGGGUGA 24
lntron2-2919 18019
CFTR-
- GGUUAGCUCUGUGUGUGA 18
Intron2-2920 18020
CFTR-
- AGGUUAGCUCUGUGUGUGA 19
lntron2-2921 18021
CFTR-
- GAGGUUAGCUCUGUGUGUGA 20
lntron2-2922 18022
CFTR-
- GGAGGUUAGCUCUGUGUGUGA 21
lntron2-2923 18023
CFTR-
- GGGAGGUUAGCUCUGUGUGUGA 22
lntron2-2924 18024
CFTR-
- UGGGAGGUUAGCUCUGUGUGUGA 23
lntron2-2925 18025
CFTR-
- AUGGGAGGUUAGCUCUGUGUGUGA 24
lntron2-2926 18026
CFTR-
- GAUCCAUUUCUCCUUUGA 18
lntron2-2927 18027
CFTR-
- UGAUCCAUUUCUCCUUUGA 19
lntron2-2928 18028
CFTR-
- CUGAUCCAUUUCUCCUUUGA 20
lntron2-285 15385
CFTR-
- UCUGAUCCAUUUCUCCUUUGA 21
lntron2-2929 18029
CFTR-
- AUCUGAUCCAUUUCUCCUUUGA 22
Intron2-2930 18030
CFTR-
- CAUCUGAUCCAUUUCUCCUUUGA 23
lntron2-2931 18031
CFTR-
- CCAUCUGAUCCAUUUCUCCUUUGA 24
lntron2-2932 18032
CFTR-
- UGUAUUUAUGGCCAGAUA 18
lntron2-2933 18033
565
5535.1 CFTR-
- UUGUAUUUAUGGCCAGAUA 19
lntron2-2934 18034
CFTR-
- UUUGUAUUUAUGGCCAGAUA 20
lntron2-2935 18035
CFTR-
- AUUUGUAUUUAUGGCCAGAUA 21
lntron2-2936 18036
CFTR-
- CAUUUGUAUUUAUGGCCAGAUA 22
lntron2-2937 18037
CFTR-
- ACAUUUGUAUUUAUGGCCAGAUA 23
lntron2-2938 18038
CFTR-
- UACAUUUGUAUUUAUGGCCAGAUA 24
lntron2-2939 18039
CFTR-
- AUUCAAAGAAUUAAGCUA 18
Intron2-2940 18040
CFTR-
- UAUUCAAAGAAUUAAGCUA 19
lntron2-2941 18041
CFTR-
- UUAUUCAAAGAAUUAAGCUA 20
lntron2-2942 18042
CFTR-
- UU UAUUCAAAGAAUUAAGCUA 21
lntron2-2943 18043
CFTR-
- U U U U AU U CAAAG AAU U AAG CU A 22
lntron2-2944 18044
CFTR-
- AUUUUAUUCAAAGAAUUAAGCUA 23
lntron2-2945 18045
CFTR-
- GAUUUUAUU CAAAG AAU U AAG CU A 24
lntron2-2946 18046
CFTR-
- UAUGGUAACUUGACAGUA 18
lntron2-2947 18047
CFTR-
- UUAUGGUAACUUGACAGUA 19
lntron2-2948 18048
CFTR-
- CUUAUGGUAACUUGACAGUA 20
lntron2-2949 18049
CFTR-
- ACU UAUGGUAACUUGACAGUA 21
Intron2-2950 18050
CFTR-
- UACUUAUGGUAACUUGACAGUA 22
lntron2-2951 18051
CFTR-
- UUACUUAUGGUAACUUGACAGUA 23
lntron2-2952 18052
CFTR-
- UUUACUUAUGGUAACUUGACAGUA 24
lntron2-2953 18053
CFTR-
- U U CAAG U U U CACCCAU U A 18
lntron2-2954 18054
566
5535.1 CFTR-
- GUUCAAGUUUCACCCAUUA 19
lntron2-2955 18055
CFTR-
- UGUUCAAGUUUCACCCAUUA 20
lntron2-2956 18056
CFTR-
- UUGUUCAAGUUUCACCCAUUA 21
lntron2-2957 18057
CFTR-
- GUUGUUCAAGUUUCACCCAUUA 22
lntron2-2958 18058
CFTR-
- AGUUGUUCAAGUUUCACCCAUUA 23
lntron2-2959 18059
CFTR-
- AAGUUGUUCAAGUUUCACCCAUUA 24
Intron2-2960 18060
CFTR-
- AAGGGCCAGCUUCUAUUA 18
lntron2-2961 18061
CFTR-
- CAAGGGCCAGCUUCUAUUA 19
lntron2-2962 18062
CFTR-
- UCAAGGGCCAGCUUCUAUUA 20
lntron2-2963 18063
CFTR-
- AUCAAGGGCCAGCUUCUAUUA 21
lntron2-2964 18064
CFTR-
- GAUCAAGGGCCAGCUUCUAUUA 22
lntron2-2965 18065
CFTR-
- AGAUCAAGGGCCAGCUUCUAUUA 23
lntron2-2966 18066
CFTR-
- AAGAUCAAGGGCCAGCUUCUAUUA 24
lntron2-2967 18067
CFTR-
- AUUGGUAUUUGAAAUUUA 18
lntron2-2968 18068
CFTR-
- AAUUGGUAUUUGAAAUUUA 19
lntron2-2969 18069
CFTR-
- AAAUUGGUAUUUGAAAUUUA 20
Intron2-2970 18070
CFTR-
- AAAAUUGGUAUUUGAAAUUUA 21
lntron2-2971 18071
CFTR-
- UAAAAUUGGUAUUUGAAAUUUA 22
lntron2-2972 18072
CFTR-
- AUAAAAUUGGUAUUUGAAAUUUA 23
lntron2-2973 18073
CFTR-
- U AU AAAAU UGG U AU U U G AAAU U U A 24
lntron2-2974 18074
CFTR-
- AAAGGUAAUUAGGCUUUA 18
lntron2-2975 18075
567
5535.1 CFTR-
- AAAAGGUAAUUAGGCUUUA 19
lntron2-2976 18076
CFTR-
- GAAAAGGUAAUUAGGCUUUA 20
lntron2-2977 18077
CFTR-
- GGAAAAGG UAAUUAGGCUUUA 21
lntron2-2978 18078
CFTR-
- GGGAAAAGGUAAUUAGGCUUUA 22
lntron2-2979 18079
CFTR-
- UGGGAAAAGGUAAUUAGGCUUUA 23
Intron2-2980 18080
CFTR-
- AUGGGAAAAGGUAAUUAGGCUUUA 24
lntron2-2981 18081
CFTR-
- AUCAUUAUCUCUAUUUUA 18
lntron2-2982 18082
CFTR-
- CAUCAUUAUCUCUAUUUUA 19
lntron2-2983 18083
CFTR-
- GCAUCAUUAUCUCUAUUUUA 20
lntron2-2984 18084
CFTR-
- AGCAUCAUUAUCUCUAUUUUA 21
lntron2-2985 18085
CFTR-
- AAGCAUCAUUAUCUCUAUUUUA 22
lntron2-2986 18086
CFTR-
- AAAGCAUCAUUAUCUCUAUUUUA 23
lntron2-2987 18087
CFTR-
- GAAAGCAUCAUUAUCUCUAUUUUA 24
lntron2-2988 18088
CFTR-
- UACAUUGCCCAGGGUCAC 18
lntron2-2989 18089
CFTR-
- CUACAUUGCCCAGGGUCAC 19
Intron2-2990 18090
CFTR-
- ACUACAUUGCCCAGGGUCAC 20
lntron2-2991 18091
CFTR-
- AACUACAUUGCCCAGGGUCAC 21
lntron2-2992 18092
CFTR-
- AAACUACAUUGCCCAGGGUCAC 22
lntron2-2993 18093
CFTR-
- AAAACUACAUUGCCCAGGGUCAC 23
lntron2-2994 18094
CFTR-
- UAAAACUACAUUGCCCAGGGUCAC 24
lntron2-2995 18095
CFTR-
- CCUGGUAUGUGGUCCUAC 18
lntron2-2996 18096
568
5535.1 CFTR-
- GCCUGGUAUGUGGUCCUAC 19
lntron2-2997 18097
CFTR-
- GGCCUGGUAUGUGGUCCUAC 20
lntron2-2998 18098
CFTR-
- GGGCCUGGUAUGUGGUCCUAC 21
lntron2-2999 18099
CFTR-
- UGGGCCUGGUAUGUGGUCCUAC 22
Intron2-3000 18100
CFTR-
- CUGGGCCUGGUAUGUGGUCCUAC 23
Intron2-3001 18101
CFTR-
- UCUGGGCCUGGUAUGUGGUCCUAC 24
Intron2-3002 18102
CFTR-
- UUUGUCUUAUUAGAGACC 18
Intron2-3003 18103
CFTR-
- AUUUGUCUUAUUAGAGACC 19
Intron2-3004 18104
CFTR-
- AAUUUGUCUUAUUAGAGACC 20
Intron2-3005 18105
CFTR-
- GAAUUUGUCUUAUUAGAGACC 21
Intron2-3006 18106
CFTR-
- AGAAUUUGUCUUAUUAGAGACC 22
Intron2-3007 18107
CFTR-
- GAGAAUUUGUCUUAUUAGAGACC 23
Intron2-3008 18108
CFTR-
- AGAGAAUUUGUCUUAUUAGAGACC 24
Intron2-3009 18109
CFTR-
- CUCCUAUCUUUAAGGACC 18
Intron2-3010 18110
CFTR-
- GCUCCUAUCUUUAAGGACC 19
Intron2-3011 18111
CFTR-
- UGCUCCUAUCUUUAAGGACC 20
Intron2-3012 18112
CFTR-
- UUGCUCCUAUCUUUAAGGACC 21
Intron2-3013 18113
CFTR-
- UUUGCUCCUAUCUUUAAGGACC 22
Intron2-3014 18114
CFTR-
- CUUUGCUCCUAUCUUUAAGGACC 23
Intron2-3015 18115
CFTR-
- UCUUUGCUCCUAUCUUUAAGGACC 24
Intron2-3016 18116
CFTR-
- UAGGAACUCAAUGGGACC 18
Intron2-3017 18117
569
5535.1 CFTR-
- UUAGGAACUCAAUGGGACC 19
Intron2-3018 18118
CFTR-
- CUUAGGAACUCAAUGGGACC 20
Intron2-3019 18119
CFTR-
- CCUUAGGAACUCAAUGGGACC 21
Intron2-3020 18120
CFTR-
- GCCUUAGGAACUCAAUGGGACC 22
Intron2-3021 18121
CFTR-
- GGCCUUAGGAACUCAAUGGGACC 23
Intron2-3022 18122
CFTR-
- UGGCCUUAGGAACUCAAUGGGACC 24
Intron2-3023 18123
CFTR-
- CUUUGUACCUCUGCACCC 18
Intron2-3024 18124
CFTR-
- ACUUUGUACCUCUGCACCC 19
Intron2-3025 18125
CFTR-
- UACUUUGUACCUCUGCACCC 20
Intron2-3026 18126
CFTR-
- GUACUUUGUACCUCUGCACCC 21
Intron2-3027 18127
CFTR-
- GGUACUUUGUACCUCUGCACCC 22
Intron2-3028 18128
CFTR-
- UGGUACUUUGUACCUCUGCACCC 23
Intron2-3029 18129
CFTR-
- UUGGUACUUUGUACCUCUGCACCC 24
Intron2-3030 18130
CFTR-
- AGUCAUAGUGCUUACCCC 18
Intron2-3031 18131
CFTR-
- GAGUCAUAGUGCUUACCCC 19
Intron2-3032 18132
CFTR-
- UGAGUCAUAGUGCUUACCCC 20
Intron2-3033 18133
CFTR-
- UUGAGUCAUAGUGCUUACCCC 21
Intron2-3034 18134
CFTR-
- CUUGAGUCAUAGUGCUUACCCC 22
Intron2-3035 18135
CFTR-
- UCUUGAGUCAUAGUGCUUACCCC 23
Intron2-3036 18136
CFTR-
- CUCUUGAGUCAUAGUGCUUACCCC 24
Intron2-3037 18137
CFTR-
- GAAUACAAAUGUACUCCC 18
Intron2-3038 18138
570
5535.1 CFTR-
- UGAAUACAAAUGUACUCCC 19
Intron2-3039 18139
CFTR-
- UUGAAUACAAAUGUACUCCC 20
lntron2-312 15412
CFTR-
- UUUGAAUACAAAUGUACUCCC 21
Intron2-3040 18140
CFTR-
- AUUUGAAUACAAAUGUACUCCC 22
Intron2-3041 18141
CFTR-
- UAUUUGAAUACAAAUGUACUCCC 23
Intron2-3042 18142
CFTR-
- AUAUUUGAAUACAAAUGUACUCCC 24
Intron2-3043 18143
CFTR-
- UUGGUGUGUGCAAAUGCC 18
Intron2-3044 18144
CFTR-
- CUUGGUGUGUGCAAAUGCC 19
Intron2-3045 18145
CFTR-
- ACUUGGUGUGUGCAAAUGCC 20
Intron2-3046 18146
CFTR-
- CACUUGGUGUGUGCAAAUGCC 21
Intron2-3047 18147
CFTR-
- ACACUUGGUGUGUGCAAAUGCC 22
Intron2-3048 18148
CFTR-
- AACACUUGGUGUGUGCAAAUGCC 23
Intron2-3049 18149
CFTR-
- GAACACUUGGUGUGUGCAAAUGCC 24
Intron2-3050 18150
CFTR-
- GCUAAAUGUGAAAAAUCC 18
Intron2-3051 18151
CFTR-
- GGCUAAAUGUGAAAAAUCC 19
Intron2-3052 18152
CFTR-
- UGGCUAAAUGUGAAAAAUCC 20
Intron2-3053 18153
CFTR-
- UUGGCUAAAUGUGAAAAAUCC 21
Intron2-3054 18154
CFTR-
- CUUGGCUAAAUGUGAAAAAUCC 22
Intron2-3055 18155
CFTR-
- CCUUGGCUAAAUGUGAAAAAUCC 23
Intron2-3056 18156
CFTR-
- UCCUUGGCUAAAUGUGAAAAAUCC 24
Intron2-3057 18157
CFTR-
- UGAAUACAAAUGUACUCC 18
Intron2-3058 18158
571
5535.1 CFTR-
- UUGAAUACAAAUGUACUCC 19
Intron2-3059 18159
CFTR-
- UUUGAAUACAAAUGUACUCC 20
Intron2-3060 18160
CFTR-
- AUUUGAAUACAAAUGUACUCC 21
Intron2-3061 18161
CFTR-
- UAUUUGAAUACAAAUGUACUCC 22
Intron2-3062 18162
CFTR-
- AUAUUUGAAUACAAAUGUACUCC 23
Intron2-3063 18163
CFTR-
- UAUAUUUGAAUACAAAUGUACUCC 24
Intron2-3064 18164
CFTR-
- UUUAUUGGCUCAUGAAGC 18
Intron2-3065 18165
CFTR-
- AUUUAUUGGCUCAUGAAGC 19
Intron2-3066 18166
CFTR-
- AAUUUAUUGGCUCAUGAAGC 20
Intron2-3067 18167
CFTR-
- GAAUUUAUUGGCUCAUGAAGC 21
Intron2-3068 18168
CFTR-
- CGAAUUUAUUGGCUCAUGAAGC 22
Intron2-3069 18169
CFTR-
- ACGAAUUUAUUGGCUCAUGAAGC 23
Intron2-3070 18170
CFTR-
- AACGAAUUUAUUGGCUCAUGAAGC 24
Intron2-3071 18171
CFTR-
- CUCAGUCUCCUGAGUAGC 18
Intron2-3072 18172
CFTR-
- UCUCAGUCUCCUGAGUAGC 19
Intron2-3073 18173
CFTR-
- AUCUCAGUCUCCUGAGUAGC 20
lntron2-656 15756
CFTR-
- AAUCUCAGUCUCCUGAGUAGC 21
Intron2-3074 18174
CFTR-
- GAAUCUCAGUCUCCUGAGUAGC 22
Intron2-3075 18175
CFTR-
- CGAAUCUCAGUCUCCUGAGUAGC 23
Intron2-3076 18176
CFTR-
- GCGAAUCUCAGUCUCCUGAGUAGC 24
Intron2-3077 18177
CFTR-
- AGUGUUGGGAUUAGUGGC 18
Intron2-3078 18178
572
5535.1 CFTR-
- AAGUGUUGGGAUUAGUGGC 19
Intron2-3079 18179
CFTR-
- AAAGUGUUGGGAUUAGUGGC 20
Intron2-3080 18180
CFTR-
- CAAAGUGUUGGGAUUAGUGGC 21
Intron2-3081 18181
CFTR-
- CCAAAGUGUUGGGAUUAGUGGC 22
Intron2-3082 18182
CFTR-
- CCCAAAGUGUUGGGAUUAGUGGC 23
Intron2-3083 18183
CFTR-
- UCCCAAAGUGUUGGGAUUAGUGGC 24
Intron2-3084 18184
CFTR-
- AGAAACCUGUAGCAUUGC 18
Intron2-3085 18185
CFTR-
- UAGAAACCUGUAGCAUUGC 19
Intron2-3086 18186
CFTR-
- AUAGAAACCUGUAGCAUUGC 20
lntron2-325 15425
CFTR-
- CAU AGAAACCUGUAGCAUUGC 21
Intron2-3087 18187
CFTR-
- ACAUAGAAACCUGUAGCAUUGC 22
Intron2-3088 18188
CFTR-
- UACAUAGAAACCUGUAGCAUUGC 23
Intron2-3089 18189
CFTR-
- UUACAUAGAAACCUGUAGCAUUGC 24
Intron2-3090 18190
CFTR-
- AUUCACACUUCUAAGAUC 18
Intron2-3091 18191
CFTR-
- GAUUCACACUUCUAAGAUC 19
Intron2-3092 18192
CFTR-
- AGAUUCACACUUCUAAGAUC 20
Intron2-3093 18193
CFTR-
- CAGAUUCACACUUCUAAGAUC 21
Intron2-3094 18194
CFTR-
- GCAGAUUCACACUUCUAAGAUC 22
Intron2-3095 18195
CFTR-
- AGCAGAUUCACACUUCUAAGAUC 23
Intron2-3096 18196
CFTR-
- UAGCAGAUUCACACUUCUAAGAUC 24
Intron2-3097 18197
CFTR-
- UCAUUUACAUCUCAGCUC 18
Intron2-3098 18198
573
5535.1 CFTR-
- UUCAUUUACAUCUCAGCUC 19
Intron2-3099 18199
CFTR-
- UUUCAUUUACAUCUCAGCUC 20
Intron2-3100 18200
CFTR-
- CUUUCAUUUACAUCUCAGCUC 21
Intron2-3101 18201
CFTR-
- ACUUUCAUUUACAUCUCAGCUC 22
Intron2-3102 18202
CFTR-
- CACUUUCAUUUACAUCUCAGCUC 23
Intron2-3103 18203
CFTR-
- UCACUUUCAUUUACAUCUCAGCUC 24
Intron2-3104 18204
CFTR-
- GAACGAAUUUAUUGGCUC 18
Intron2-3105 18205
CFTR-
- GGAACGAAUUUAUUGGCUC 19
Intron2-3106 18206
CFTR-
- AGGAACGAAUUUAUUGGCUC 20
Intron2-3107 18207
CFTR-
- AAGGAACGAAUUUAUUGGCUC 21
Intron2-3108 18208
CFTR-
- AAAGGAACGAAUUUAUUGGCUC 22
Intron2-3109 18209
CFTR-
- AAAAGGAACGAAUUUAUUGGCUC 23
Intron2-3110 18210
CFTR-
- UAAAAGGAACGAAUUUAUUGGCUC 24
lntron2-3111 18211
CFTR-
- CUGUAUUGCCUUGCUCUC 18
lntron2-3112 18212
CFTR-
- UCUGUAUUGCCUUGCUCUC 19
lntron2-3113 18213
CFTR-
- GUCUGUAUUGCCUUGCUCUC 20
lntron2-3114 18214
CFTR-
- GGUCUGUAUUGCCUUGCUCUC 21
lntron2-3115 18215
CFTR-
- AGGUCUGUAUUGCCUUGCUCUC 22
lntron2-3116 18216
CFTR-
- GAGGUCUGUAUUGCCUUGCUCUC 23
lntron2-3117 18217
CFTR-
- UGAGGUCUGUAUUGCCUUGCUCUC 24
lntron2-3118 18218
CFTR-
- AUGCUGGCCAGGCUGGUC 18
lntron2-3119 18219
574
5535.1 CFTR-
- UAUGCUGGCCAGGCUGGUC 19
Intron2-3120 18220
CFTR-
- CUAUGCUGGCCAGGCUGGUC 20
lntron2-3121 18221
CFTR-
- GCUAUGCUGGCCAGGCUGGUC 21
lntron2-3122 18222
CFTR-
- UGCUAUGCUGGCCAGGCUGGUC 22
lntron2-3123 18223
CFTR-
- UUGCUAUGCUGGCCAGGCUGGUC 23
lntron2-3124 18224
CFTR-
- UUUGCUAUGCUGGCCAGGCUGGUC 24
lntron2-3125 18225
CFTR-
- AUGUUGGCCAGGCUGGUC 18
lntron2-3126 18226
CFTR-
- CAUGUUGGCCAGGCUGGUC 19
lntron2-3127 18227
CFTR-
- CCAUGUUGGCCAGGCUGGUC 20
lntron2-3128 18228
CFTR-
- GCCAUGUUGGCCAGGCUGGUC 21
lntron2-3129 18229
CFTR-
- CGCCAUGUUGGCCAGGCUGGUC 22
Intron2-3130 18230
CFTR-
- UCGCCAUGUUGGCCAGGCUGGUC 23
lntron2-3131 18231
CFTR-
- UUCGCCAUGUUGGCCAGGCUGGUC 24
lntron2-3132 18232
CFTR-
- CUCUCAUUAGCAAGCUUC 18
lntron2-3133 18233
CFTR-
- GCUCUCAUUAGCAAGCUUC 19
lntron2-3134 18234
CFTR-
- GGCUCUCAUUAGCAAGCUUC 20
lntron2-3135 18235
CFTR-
- GGGCUCUCAUUAGCAAGCUUC 21
lntron2-3136 18236
CFTR-
- AGGGCUCUCAUUAGCAAGCUUC 22
lntron2-3137 18237
CFTR-
- AAGGGCUCUCAUUAGCAAGCUUC 23
lntron2-3138 18238
CFTR-
- GAAGGGCUCUCAUUAGCAAGCUUC 24
lntron2-3139 18239
CFTR-
- AGUUCUUCCUUGUGGUUC 18
Intron2-3140 18240
575
5535.1 CFTR-
- UAGUUCUUCCUUGUGGUUC 19
lntron2-3141 18241
CFTR-
- CUAGUUCUUCCUUGUGGUUC 20
lntron2-3142 18242
CFTR-
- CCUAGUUCUUCCUUGUGGUUC 21
lntron2-3143 18243
CFTR-
- ACCUAGUUCUUCCUUGUGGUUC 22
lntron2-3144 18244
CFTR-
- UACCUAGUUCUUCCUUGUGGUUC 23
lntron2-3145 18245
CFTR-
- UUACCUAGUUCUUCCUUGUGGUUC 24
lntron2-3146 18246
CFTR-
- UCUGUGUGUGAGAGAAAG 18
lntron2-3147 18247
CFTR-
- CUCUGUGUGUGAGAGAAAG 19
lntron2-3148 18248
CFTR-
- GCUCUGUGUGUGAGAGAAAG 20
lntron2-3149 18249
CFTR-
- AGCUCUGUGUGUGAGAGAAAG 21
Intron2-3150 18250
CFTR-
- UAGCUCUGUGUGUGAGAGAAAG 22
lntron2-3151 18251
CFTR-
- UUAGCUCUGUGUGUGAGAGAAAG 23
lntron2-3152 18252
CFTR-
- GUUAGCUCUGUGUGUGAGAGAAAG 24
lntron2-3153 18253
CFTR-
- CUUUAAGGACCACGAAAG 18
lntron2-3154 18254
CFTR-
- UCUUUAAGGACCACGAAAG 19
lntron2-3155 18255
CFTR-
- AU CU U U AAGG ACCACG AAAG 20
lntron2-3156 18256
CFTR-
- U AU CU U U AAGG ACCACG AAAG 21
lntron2-3157 18257
CFTR-
- CUAUCUUUAAGGACCACGAAAG 22
lntron2-3158 18258
CFTR-
- CCUAUCUU U AAGG ACCACG AAAG 23
lntron2-3159 18259
CFTR-
- UCCUAUCUUUAAGGACCACGAAAG 24
Intron2-3160 18260
CFTR-
- AUGGAGCCAUGAUUCCAG 18
lntron2-3161 18261
576
5535.1 CFTR-
- GAUGGAGCCAUGAUUCCAG 19
lntron2-3162 18262
CFTR-
- UGAUGGAGCCAUGAUUCCAG 20
lntron2-3163 18263
CFTR-
- AUGAUGGAGCCAUGAUUCCAG 21
lntron2-3164 18264
CFTR-
- AAUGAUGGAGCCAUGAUUCCAG 22
lntron2-3165 18265
CFTR-
- GAAUGAUGGAGCCAUGAUUCCAG 23
lntron2-3166 18266
CFTR-
- UGAAUGAUGGAGCCAUGAUUCCAG 24
lntron2-3167 18267
CFTR-
- GGGAAUGAUUAAUCAGAG 18
lntron2-3168 18268
CFTR-
- AGGGAAUGAUUAAUCAGAG 19
lntron2-3169 18269
CFTR-
- GAGGGAAUGAUUAAUCAGAG 20
Intron2-3170 18270
CFTR-
- UGAGGGAAUGAUUAAUCAGAG 21
lntron2-3171 18271
CFTR-
- CUGAGGGAAUGAUUAAUCAGAG 22
lntron2-3172 18272
CFTR-
- GCUGAGGGAAUGAUUAAUCAGAG 23
lntron2-3173 18273
CFTR-
- UGCUGAGGGAAUGAUUAAUCAGAG 24
lntron2-3174 18274
CFTR-
- UGGCUAAUUUUUGUAGAG 18
lntron2-3175 18275
CFTR-
- CUGGCUAAUUUUUGUAGAG 19
lntron2-3176 18276
CFTR-
- CCUGGCUAAUUUUUGUAGAG 20
lntron2-3177 18277
CFTR-
- GCCUGGCUAAUUUUUGUAGAG 21
lntron2-3178 18278
CFTR-
- GGCCUGGCUAAUUUUUGUAGAG 22
lntron2-3179 18279
CFTR-
- AGGCCUGGCUAAUUUUUGUAGAG 23
Intron2-3180 18280
CFTR-
- CAGGCCUGGCUAAUUUUUGUAGAG 24
lntron2-3181 18281
CFTR-
- CCUCUCAGCCACUCUGAG 18
lntron2-3182 18282
577
5535.1 CFTR-
- UCCUCUCAGCCACUCUGAG 19
lntron2-3183 18283
CFTR-
- CUCCUCUCAGCCACUCUGAG 20
lntron2-344 15444
CFTR-
- UCUCCUCUCAGCCACUCUGAG 21
lntron2-3184 18284
CFTR-
- AUCUCCUCUCAGCCACUCUGAG 22
lntron2-3185 18285
CFTR-
- UAUCUCCUCUCAGCCACUCUGAG 23
lntron2-3186 18286
CFTR-
- AUAUCUCCUCUCAGCCACUCUGAG 24
lntron2-3187 18287
CFTR-
- AUGUGGGGAGGGAAAUAG 18
lntron2-3188 18288
CFTR-
- CAUGUGGGGAGGGAAAUAG 19
lntron2-3189 18289
CFTR-
- GCAUGUGGGGAGGGAAAUAG 20
Intron2-3190 18290
CFTR-
- AGCAUGUGGGGAGGGAAAUAG 21
lntron2-3191 18291
CFTR-
- AAGCAUGUGGGGAGGGAAAUAG 22
lntron2-3192 18292
CFTR-
- GAAGCAUGUGGGGAGGGAAAUAG 23
lntron2-3193 18293
CFTR-
- AGAAGCAUGUGGGGAGGGAAAUAG 24
lntron2-3194 18294
CFTR-
- GGUAAUUAGGCUUUAUAG 18
lntron2-3195 18295
CFTR-
- AGGUAAUUAGGCUUUAUAG 19
lntron2-3196 18296
CFTR-
- AAGGUAAUUAGGCUUUAUAG 20
lntron2-3197 18297
CFTR-
- AAAGGUAAUUAGGCUUUAUAG 21
lntron2-3198 18298
CFTR-
- AAAAGGUAAUUAGGCUUUAUAG 22
lntron2-3199 18299
CFTR-
- GAAAAGGUAAUUAGGCUUUAUAG 23
Intron2-3200 18300
CFTR-
- GGAAAAGGUAAUUAGGCUUUAUAG 24
Intron2-3201 18301
CFTR-
- AACUAUGUGAAGACCUAG 18
Intron2-3202 18302
578
5535.1 CFTR-
- GAACUAUGUGAAGACCUAG 19
Intron2-3203 18303
CFTR-
- UGAACUAUGUGAAGACCUAG 20
Intron2-3204 18304
CFTR-
- CUGAACUAUGUGAAGACCUAG 21
Intron2-3205 18305
CFTR-
- CCUGAACUAUGUGAAGACCUAG 22
Intron2-3206 18306
CFTR-
- GCCUGAACUAUGUGAAGACCUAG 23
Intron2-3207 18307
CFTR-
- AGCCUGAACUAUGUGAAGACCUAG 24
Intron2-3208 18308
CFTR-
- U U CAAAG AAU UAAGCU AG 18
Intron2-3209 18309
CFTR-
- A U U CAAAG A A UUAAGCUAG 19
Intron2-3210 18310
CFTR-
- U A U U CAAAG A A UUAAGCUAG 20
lntron2-345 15445
CFTR-
- UUAUUCAAAGAAUUAAGCUAG 21
lntron2-3211 18311
CFTR-
- UUUAUUCAAAGAAUUAAGCUAG 22
lntron2-3212 18312
CFTR-
- UUUUAUUCAAAGAAUUAAGCUAG 23
lntron2-3213 18313
CFTR-
- AUUUUAUU CAAAG AAU U AAG CU AG 24
lntron2-3214 18314
CFTR-
- UCUCAGUCUCCUGAGUAG 18
lntron2-3215 18315
CFTR-
- AUCUCAGUCUCCUGAGUAG 19
lntron2-3216 18316
CFTR-
- AAUCUCAGUCUCCUGAGUAG 20
lntron2-3217 18317
CFTR-
- GAAUCUCAGUCUCCUGAGUAG 21
lntron2-3218 18318
CFTR-
- CGAAUCUCAGUCUCCUGAGUAG 22
lntron2-3219 18319
CFTR-
- GCGAAUCUCAGUCUCCUGAGUAG 23
Intron2-3220 18320
CFTR-
- AGCGAAUCUCAGUCUCCUGAGUAG 24
lntron2-3221 18321
CFTR-
- AAUACAUGAUUUUAGUAG 18
lntron2-3222 18322
579
5535.1 CFTR-
- UAAUACAUGAUUUUAGUAG 19
lntron2-3223 18323
CFTR-
- UUAAUACAUGAUUUUAGUAG 20
lntron2-3224 18324
CFTR-
- UUUAAUACAUGAUUUUAGUAG 21
lntron2-3225 18325
CFTR-
- CUUUAAUACAUGAUUUUAGUAG 22
lntron2-3226 18326
CFTR-
- CCUUUAAUACAUGAUUUUAGUAG 23
lntron2-3227 18327
CFTR-
- ACCUUUAAUACAUGAUUUUAGUAG 24
lntron2-3228 18328
CFTR-
- CUGUGUGUGAGAGAAAGG 18
lntron2-3229 18329
CFTR-
- UCUGUGUGUGAGAGAAAGG 19
Intron2-3230 18330
CFTR-
- CUCUGUGUGUGAGAGAAAGG 20
lntron2-678 15778
CFTR-
- GCUCUGUGUGUGAGAGAAAGG 21
lntron2-3231 18331
CFTR-
- AGCUCUGUGUGUGAGAGAAAGG 22
lntron2-3232 18332
CFTR-
- UAGCUCUGUGUGUGAGAGAAAGG 23
lntron2-3233 18333
CFTR-
- UUAGCUCUGUGUGUGAGAGAAAGG 24
lntron2-3234 18334
CFTR-
- CUCGCUGUGUCACCCAGG 18
lntron2-3235 18335
CFTR-
- UCUCGCUGUGUCACCCAGG 19
lntron2-3236 18336
CFTR-
- GUCUCGCUGUGUCACCCAGG 20
lntron2-3237 18337
CFTR-
- AGUCUCGCUGUGUCACCCAGG 21
lntron2-3238 18338
CFTR-
- GAGUCUCGCUGUGUCACCCAGG 22
lntron2-3239 18339
CFTR-
- AGAGUCUCGCUGUGUCACCCAGG 23
Intron2-3240 18340
CFTR-
- CAGAGUCUCGCUGUGUCACCCAGG 24
lntron2-3241 18341
CFTR-
- CUUGCUCUGUUGCCCAGG 18
lntron2-3242 18342
580
5535.1 CFTR-
- UCUUGCUCUGUUGCCCAGG 19
lntron2-3243 18343
CFTR-
- GUCUUGCUCUGUUGCCCAGG 20
lntron2-3244 18344
CFTR-
- AGUCUUGCUCUGUUGCCCAGG 21
lntron2-3245 18345
CFTR-
- GAGUCUUGCUCUGUUGCCCAGG 22
lntron2-3246 18346
CFTR-
- AGAGUCUUGCUCUGUUGCCCAGG 23
lntron2-3247 18347
CFTR-
- CAGAGUCUUGCUCUGUUGCCCAGG 24
lntron2-3248 18348
CFTR-
- UGUGCAAAUGCCAUGAGG 18
lntron2-3249 18349
CFTR-
- GUGUGCAAAUGCCAUGAGG 19
Intron2-3250 18350
CFTR-
- UGUGUGCAAAUGCCAUGAGG 20
lntron2-3251 18351
CFTR-
- GUGUGUGCAAAUGCCAUGAGG 21
lntron2-3252 18352
CFTR-
- GGUGUGUGCAAAUGCCAUGAGG 22
lntron2-3253 18353
CFTR-
- UGGUGUGUGCAAAUGCCAUGAGG 23
lntron2-3254 18354
CFTR-
- UUGGUGUGUGCAAAUGCCAUGAGG 24
lntron2-3255 18355
CFTR-
- ACUAUGUGAAGACCUAGG 18
lntron2-3256 18356
CFTR-
- AACUAUGUGAAGACCUAGG 19
lntron2-3257 18357
CFTR-
- GAACUAUGUGAAGACCUAGG 20
lntron2-69 15169
CFTR-
- UGAACUAUGUGAAGACCUAGG 21
lntron2-3258 18358
CFTR-
- CUGAACUAUGUGAAGACCUAGG 22
lntron2-3259 18359
CFTR-
- CCUGAACUAUGUGAAGACCUAGG 23
Intron2-3260 18360
CFTR-
- GCCUGAACUAUGUGAAGACCUAGG 24
lntron2-3261 18361
CFTR-
- GUGGAGAAGCAUGUGGGG 18
lntron2-3262 18362
581
5535.1 CFTR-
- GGUGGAGAAGCAUGUGGGG 19
lntron2-3263 18363
CFTR-
- AGGUGGAGAAGCAUGUGGGG 20
lntron2-682 15782
CFTR-
- AAGGUGGAGAAGCAUGUGGGG 21
lntron2-3264 18364
CFTR-
- AAAGGUGGAGAAGCAUGUGGGG 22
lntron2-3265 18365
CFTR-
- GAAAGGUGGAGAAGCAUGUGGGG 23
lntron2-3266 18366
CFTR-
- AGAAAGGUGGAGAAGCAUGUGGGG 24
lntron2-3267 18367
CFTR-
- GGUGGAGAAGCAUGUGGG 18
lntron2-3268 18368
CFTR-
- AGGUGGAGAAGCAUGUGGG 19
lntron2-3269 18369
CFTR-
- AAGGUGGAGAAGCAUGUGGG 20
Intron2-3270 18370
CFTR-
- AAAGGUGGAGAAGCAUGUGGG 21
lntron2-3271 18371
CFTR-
- GAAAGGUGGAGAAGCAUGUGGG 22
lntron2-3272 18372
CFTR-
- AGAAAGGUGGAGAAGCAUGUGGG 23
lntron2-3273 18373
CFTR-
- GAGAAAGGUGGAGAAGCAUGUGGG 24
lntron2-3274 18374
CFTR-
- CAAGUGGUUGCCAGAUGG 18
lntron2-3275 18375
CFTR-
- UCAAGUGGUUGCCAGAUGG 19
lntron2-3276 18376
CFTR-
- CUCAAGUGGUUGCCAGAUGG 20
lntron2-3277 18377
CFTR-
- CCUCAAGUGGUUGCCAGAUGG 21
lntron2-3278 18378
CFTR-
- CCCUCAAGUGGUUGCCAGAUGG 22
lntron2-3279 18379
CFTR-
- GCCCUCAAGUGGUUGCCAGAUGG 23
Intron2-3280 18380
CFTR-
- GGCCCUCAAGUGGUUGCCAGAUGG 24
lntron2-3281 18381
CFTR-
- AGUAACCAAAUGUUAUGG 18
lntron2-3282 18382
582
5535.1 CFTR-
- GAGUAACCAAAUGUUAUGG 19
lntron2-3283 18383
CFTR-
- UGAGUAACCAAAUGUUAUGG 20
lntron2-3284 18384
CFTR-
- CUGAGUAACCAAAUGUUAUGG 21
lntron2-3285 18385
CFTR-
- UCUGAGUAACCAAAUGUUAUGG 22
lntron2-3286 18386
CFTR-
- CUCUGAGUAACCAAAUGUUAUGG 23
lntron2-3287 18387
CFTR-
- ACUCUGAGUAACCAAAUGUUAUGG 24
lntron2-3288 18388
CFTR-
- CCUUGGCCUCCCAAAAUG 18
lntron2-3289 18389
CFTR-
- ACCUUGGCCUCCCAAAAUG 19
Intron2-3290 18390
CFTR-
- CACCUUGGCCUCCCAAAAUG 20
lntron2-3291 18391
CFTR-
- CCACCUUGGCCUCCCAAAAUG 21
lntron2-3292 18392
CFTR-
- CCCACCUUGGCCUCCCAAAAUG 22
lntron2-3293 18393
CFTR-
- GCCCACCUUGGCCUCCCAAAAUG 23
lntron2-3294 18394
CFTR-
- UGCCCACCUUGGCCUCCCAAAAUG 24
lntron2-3295 18395
CFTR-
- UUUGCCAGUUAAUGAAUG 18
lntron2-3296 18396
CFTR-
- CUUUGCCAGUUAAUGAAUG 19
lntron2-3297 18397
CFTR-
- ACUUUGCCAGUUAAUGAAUG 20
lntron2-3298 18398
CFTR-
- UACUUUGCCAGUUAAUGAAUG 21
lntron2-3299 18399
CFTR-
- AUACUUUGCCAGUUAAUGAAUG 22
Intron2-3300 18400
CFTR-
- UAUACUUUGCCAGUUAAUGAAUG 23
Intron2-3301 18401
CFTR-
- AUAUACUUUGCCAGUUAAUGAAUG 24
Intron2-3302 18402
CFTR-
- UUGUUGAAUGAAUCCAUG 18
Intron2-3303 18403
583
5535.1 CFTR-
- UUUGUUGAAUGAAUCCAUG 19
Intron2-3304 18404
CFTR-
- AUUUGUUGAAUGAAUCCAUG 20
Intron2-3305 18405
CFTR-
- UAUUUGUUGAAUGAAUCCAUG 21
Intron2-3306 18406
CFTR-
- AUAUUUGUUGAAUGAAUCCAUG 22
Intron2-3307 18407
CFTR-
- AAUAUUUGUUGAAUGAAUCCAUG 23
Intron2-3308 18408
CFTR-
- AAAUAUUUGUUGAAUGAAUCCAUG 24
Intron2-3309 18409
CFTR-
- GAAAGGUGGAGAAGCAUG 18
Intron2-3310 18410
CFTR-
- AGAAAGGUGGAGAAGCAUG 19
lntron2-3311 18411
CFTR-
- GAGAAAGGUGGAGAAGCAUG 20
lntron2-467 15567
CFTR-
- AGAGAAAGGUGGAGAAGCAUG 21
lntron2-3312 18412
CFTR-
- GAGAGAAAGGUGGAGAAGCAUG 22
lntron2-3313 18413
CFTR-
- UGAGAGAAAGGUGGAGAAGCAUG 23
lntron2-3314 18414
CFTR-
- GUGAGAGAAAGGUGGAGAAGCAUG 24
lntron2-3315 18415
CFTR-
- CUAAGUUUUAAUUGGAUG 18
lntron2-3316 18416
CFTR-
- UCUAAGUUUUAAUUGGAUG 19
lntron2-3317 18417
CFTR-
- AUCUAAGUUUUAAUUGGAUG 20
lntron2-3318 18418
CFTR-
- UAUCUAAGUUUUAAUUGGAUG 21
lntron2-3319 18419
CFTR-
- AUAUCUAAGUUUUAAUUGGAUG 22
Intron2-3320 18420
CFTR-
- AAUAUCUAAGUUUUAAUUGGAUG 23
lntron2-3321 18421
CFTR-
- GAAUAUCUAAGUUUUAAUUGGAUG 24
lntron2-3322 18422
CFTR-
- UCCAUUUCUCCUUUGAUG 18
lntron2-3323 18423
584
5535.1 CFTR-
- AUCCAUUUCUCCUUUGAUG 19
lntron2-3324 18424
CFTR-
- GAUCCAUUUCUCCUUUGAUG 20
lntron2-3325 18425
CFTR-
- UGAUCCAUUUCUCCUUUGAUG 21
lntron2-3326 18426
CFTR-
- CUGAUCCAUUUCUCCUUUGAUG 22
lntron2-3327 18427
CFTR-
- UCUGAUCCAUUUCUCCUUUGAUG 23
lntron2-3328 18428
CFTR-
- AUCUGAUCCAUUUCUCCUUUGAUG 24
lntron2-3329 18429
CFTR-
- UAAUGGGAAUAACCACUG 18
Intron2-3330 18430
CFTR-
- GUAAUGGGAAUAACCACUG 19
lntron2-3331 18431
CFTR-
- AGUAAUGGGAAUAACCACUG 20
lntron2-3332 18432
CFTR-
- CAGUAAUGGGAAUAACCACUG 21
lntron2-3333 18433
CFTR-
- ACAGUAAUGGGAAUAACCACUG 22
lntron2-3334 18434
CFTR-
- GACAGUAAUGGGAAUAACCACUG 23
lntron2-3335 18435
CFTR-
- UGACAGUAAUGGGAAUAACCACUG 24
lntron2-3336 18436
CFTR-
- AGUUUUAAUUGGAUGCUG 18
lntron2-3337 18437
CFTR-
- AAGUUUUAAUUGGAUGCUG 19
lntron2-3338 18438
CFTR-
- UAAGUUUUAAUUGGAUGCUG 20
lntron2-364 15464
CFTR-
- CUAAGUUUUAAUUGGAUGCUG 21
lntron2-3339 18439
CFTR-
- UCUAAGUUUUAAUUGGAUGCUG 22
Intron2-3340 18440
CFTR-
- AUCUAAGUUUUAAUUGGAUGCUG 23
lntron2-3341 18441
CFTR-
- UAUCUAAGUUUUAAUUGGAUGCUG 24
lntron2-3342 18442
CFTR-
- AAACCUGUAGCAUUGCUG 18
lntron2-3343 18443
585
5535.1 CFTR-
- GAAACCUGUAGCAUUGCUG 19
lntron2-3344 18444
CFTR-
- AGAAACCUGUAGCAUUGCUG 20
lntron2-3345 18445
CFTR-
- UAGAAACCUGUAGCAUUGCUG 21
lntron2-3346 18446
CFTR-
- AUAGAAACCUGUAGCAUUGCUG 22
lntron2-3347 18447
CFTR-
- CAUAGAAACCUGUAGCAUUGCUG 23
lntron2-3348 18448
CFTR-
- ACAUAGAAACCUGUAGCAUUGCUG 24
lntron2-3349 18449
CFTR-
- CCUUGGCCUCCCAAAGUG 18
Intron2-3350 18450
CFTR-
- GCCUUGGCCUCCCAAAGUG 19
lntron2-3351 18451
CFTR-
- CGCCUUGGCCUCCCAAAGUG 20
lntron2-3352 18452
CFTR-
- CCGCCUUGGCCUCCCAAAGUG 21
lntron2-3353 18453
CFTR-
- CCCGCCUUGGCCUCCCAAAGUG 22
lntron2-3354 18454
CFTR-
- GCCCGCCUUGGCCUCCCAAAGUG 23
lntron2-3355 18455
CFTR-
- UGCCCGCCUUGGCCUCCCAAAGUG 24
lntron2-3356 18456
CFTR-
- CAGAUAAAAGGGUGAGUG 18
lntron2-3357 18457
CFTR-
- CCAGAUAAAAGGGUGAGUG 19
lntron2-3358 18458
CFTR-
- GCCAGAUAAAAGGGUGAGUG 20
lntron2-3359 18459
CFTR-
- UGCCAGAUAAAAGGGUGAGUG 21
Intron2-3360 18460
CFTR-
- AUGCCAGAUAAAAGGGUGAGUG 22
lntron2-3361 18461
CFTR-
- GAUGCCAGAUAAAAGGGUGAGUG 23
lntron2-3362 18462
CFTR-
- UGAUGCCAGAUAAAAGGGUGAGUG 24
lntron2-3363 18463
CFTR-
- GUGUGUGAGAGAAAGGUG 18
lntron2-3364 18464
586
5535.1 CFTR-
- UGUGUGUGAGAGAAAGGUG 19
lntron2-3365 18465
CFTR-
- CUGUGUGUGAGAGAAAGGUG 20
lntron2-3366 18466
CFTR-
- UCUGUGUGUGAGAGAAAGGUG 21
lntron2-3367 18467
CFTR-
- CUCUGUGUGUGAGAGAAAGGUG 22
lntron2-3368 18468
CFTR-
- GCUCUGUGUGUGAGAGAAAGGUG 23
lntron2-3369 18469
CFTR-
- AGCUCUGUGUGUGAGAGAAAGGUG 24
Intron2-3370 18470
CFTR-
- UAUGUGAAGACCUAGGUG 18
lntron2-3371 18471
CFTR-
- CUAUGUGAAGACCUAGGUG 19
lntron2-3372 18472
CFTR-
- ACUAUGUGAAGACCUAGGUG 20
lntron2-3373 18473
CFTR-
- AACUAUGUGAAGACCUAGGUG 21
lntron2-3374 18474
CFTR-
- GAACUAUGUGAAGACCUAGGUG 22
lntron2-3375 18475
CFTR-
- UGAACUAUGUGAAGACCUAGGUG 23
lntron2-3376 18476
CFTR-
- CUGAACUAUGUGAAGACCUAGGUG 24
lntron2-3377 18477
CFTR-
- AAGGUGGAGAAGCAUGUG 18
lntron2-3378 18478
CFTR-
- AAAGGUGGAGAAGCAUGUG 19
lntron2-3379 18479
CFTR-
- GAAAGGUGGAGAAGCAUGUG 20
lntron2-468 15568
CFTR-
- AGAAAGGUGGAGAAGCAUGUG 21
Intron2-3380 18480
CFTR-
- GAGAAAGGUGGAGAAGCAUGUG 22
lntron2-3381 18481
CFTR-
- AGAGAAAGGUGGAGAAGCAUGUG 23
lntron2-3382 18482
CFTR-
- GAGAGAAAGGUGGAGAAGCAUGUG 24
lntron2-3383 18483
CFTR-
- AUAUUUUAUUCCUUUGUG 18
lntron2-3384 18484
587
5535.1 CFTR-
- GAUAUUUUAUUCCUUUGUG 19
lntron2-3385 18485
CFTR-
- AGAUAUUUUAUUCCUUUGUG 20
lntron2-3386 18486
CFTR-
- GAGAUAUUUUAUUCCUUUGUG 21
lntron2-3387 18487
CFTR-
- AGAGAUAUUUUAUUCCUUUGUG 22
lntron2-3388 18488
CFTR-
- UAGAGAUAUUUUAUUCCUUUGUG 23
lntron2-3389 18489
CFTR-
- UUAGAGAUAUUUUAUUCCUUUGUG 24
Intron2-3390 18490
CFTR-
- UAGAAACCUGUAGCAUUG 18
lntron2-3391 18491
CFTR-
- AUAGAAACCUGUAGCAUUG 19
lntron2-3392 18492
CFTR-
- CAUAGAAACCUGUAGCAUUG 20
lntron2-3393 18493
CFTR-
- ACAUAGAAACCUGUAGCAUUG 21
lntron2-3394 18494
CFTR-
- UACAUAGAAACCUGUAGCAUUG 22
lntron2-3395 18495
CFTR-
- UUACAUAGAAACCUGUAGCAUUG 23
lntron2-3396 18496
CFTR-
- AUUACAUAGAAACCUGUAGCAUUG 24
lntron2-3397 18497
CFTR-
- GUGGUUGCCAGAUGGUUG 18
lntron2-3398 18498
CFTR-
- AGUGGUUGCCAGAUGGUUG 19
lntron2-3399 18499
CFTR-
- AAGUGGUUGCCAGAUGGUUG 20
Intron2-3400 18500
CFTR-
- CAAGUGGUUGCCAGAUGGUUG 21
Intron2-3401 18501
CFTR-
- UCAAGUGGUUGCCAGAUGGUUG 22
Intron2-3402 18502
CFTR-
- CUCAAGUGGUUGCCAGAUGGUUG 23
Intron2-3403 18503
CFTR-
- CCUCAAGUGGUUGCCAGAUGGUUG 24
Intron2-3404 18504
CFTR-
- UGAUCCAUUUCUCCUUUG 18
Intron2-3405 18505
588
5535.1 CFTR-
- CUGAUCCAUUUCUCCUUUG 19
Intron2-3406 18506
CFTR-
- UCUGAUCCAUUUCUCCUUUG 20
Intron2-3407 18507
CFTR-
- AUCUGAUCCAUUUCUCCUUUG 21
Intron2-3408 18508
CFTR-
- CAUCUGAUCCAUUUCUCCUUUG 22
Intron2-3409 18509
CFTR-
- CCAUCUGAUCCAUUUCUCCUUUG 23
Intron2-3410 18510
CFTR-
- CCCAUCUGAUCCAUUUCUCCUUUG 24
lntron2-3411 18511
CFTR-
- AGGCCUGGCUAAUUUUUG 18
lntron2-3412 18512
CFTR-
- CAGGCCUGGCUAAUUUUUG 19
lntron2-3413 18513
CFTR-
- CCAGGCCUGGCUAAUUUUUG 20
lntron2-3414 18514
CFTR-
- ACCAGGCCUGGCUAAUUUUUG 21
lntron2-3415 18515
CFTR-
- CACCAGGCCUGGCUAAUUUUUG 22
lntron2-3416 18516
CFTR-
- CCACCAGGCCUGGCUAAUUUUUG 23
lntron2-3417 18517
CFTR-
- ACCACCAGGCCUGGCUAAUUUUUG 24
lntron2-3418 18518
CFTR-
- CUUUGUCCUUGGCUAAAU 18
lntron2-3419 18519
CFTR-
- CCUUUGUCCUUGGCUAAAU 19
Intron2-3420 18520
CFTR-
- CCCUUUGUCCUUGGCUAAAU 20
lntron2-3421 18521
CFTR-
- GCCCUUUGUCCUUGGCUAAAU 21
lntron2-3422 18522
CFTR-
- AGCCCUUUGUCCUUGGCUAAAU 22
lntron2-3423 18523
CFTR-
- GAGCCCUUUGUCCUUGGCUAAAU 23
lntron2-3424 18524
CFTR-
- GGAGCCCUUUGUCCUUGGCUAAAU 24
lntron2-3425 18525
CFTR-
- AUGAAUCCAUGAUGGAAU 18
lntron2-3426 18526
589
5535.1 CFTR-
- AAUGAAUCCAUGAUGGAAU 19
lntron2-3427 18527
CFTR-
- GAAUGAAUCCAUGAUGGAAU 20
lntron2-3428 18528
CFTR-
- UGAAUGAAUCCAUGAUGGAAU 21
lntron2-3429 18529
CFTR-
- UUGAAUGAAUCCAUGAUGGAAU 22
Intron2-3430 18530
CFTR-
- GU UGAAUGAAUCCAUGAUGGAAU 23
lntron2-3431 18531
CFTR-
- UGUUGAAUGAAUCCAUGAUGGAAU 24
lntron2-3432 18532
CFTR-
- AGAAAGGUGGAGAAGCAU 18
lntron2-3433 18533
CFTR-
- GAGAAAGGUGGAGAAGCAU 19
lntron2-3434 18534
CFTR-
- AGAGAAAGGUGGAGAAGCAU 20
lntron2-3435 18535
CFTR-
- GAGAGAAAGGUGGAGAAGCAU 21
lntron2-3436 18536
CFTR-
- UGAGAGAAAGGUGGAGAAGCAU 22
lntron2-3437 18537
CFTR-
- GUGAGAGAAAGGUGGAGAAGCAU 23
lntron2-3438 18538
CFTR-
- UGUGAGAGAAAGGUGGAGAAGCAU 24
lntron2-3439 18539
CFTR-
- GUGGGGAGGGAAAUAGAU 18
Intron2-3440 18540
CFTR-
- UGUGGGGAGGGAAAUAGAU 19
lntron2-3441 18541
CFTR-
- AUGUGGGGAGGGAAAUAGAU 20
lntron2-377 15477
CFTR-
- CAUGUGGGGAGGGAAAUAGAU 21
lntron2-3442 18542
CFTR-
- GCAUGUGGGGAGGGAAAUAGAU 22
lntron2-3443 18543
CFTR-
- AGCAUGUGGGGAGGGAAAUAGAU 23
lntron2-3444 18544
CFTR-
- AAGCAUGUGGGGAGGGAAAUAGAU 24
lntron2-3445 18545
CFTR-
- UUUUGUAUUUUAGUAGAU 18
lntron2-3446 18546
590
5535.1 CFTR-
- UUUUUGUAUUUUAGUAGAU 19
lntron2-3447 18547
CFTR-
- AUUUUUGUAUUUUAGUAGAU 20
lntron2-3448 18548
CFTR-
- AAUUUUUGUAUUUUAGUAGAU 21
lntron2-3449 18549
CFTR-
- UAAUUUUUGUAUUUUAGUAGAU 22
Intron2-3450 18550
CFTR-
- CUAAUUUUUGUAUUUUAGUAGAU 23
lntron2-3451 18551
CFTR-
- GCUAAUUUUUGUAUUUUAGUAGAU 24
lntron2-3452 18552
CFTR-
- CAAGAUUGUAGUCAGGAU 18
lntron2-3453 18553
CFTR-
- CCAAGAUUGUAGUCAGGAU 19
lntron2-3454 18554
CFTR-
- UCCAAGAUUGUAGUCAGGAU 20
lntron2-3455 18555
CFTR-
- U U CCAAG AU UG U AG U CAGG AU 21
lntron2-3456 18556
CFTR-
- GU UCCAAGAUUGUAGUCAGGAU 22
lntron2-3457 18557
CFTR-
- CG U U CCAAG AU UG U AG U CAGG AU 23
lntron2-3458 18558
CFTR-
- CCGUUCCAAGAUUGUAGUCAGGAU 24
lntron2-3459 18559
CFTR-
- UAACCAAAUGUUAUGGAU 18
Intron2-3460 18560
CFTR-
- GUAACCAAAUGUUAUGGAU 19
lntron2-3461 18561
CFTR-
- AGUAACCAAAUGUUAUGGAU 20
lntron2-378 15478
CFTR-
- GAGUAACCAAAUGUUAUGGAU 21
lntron2-3462 18562
CFTR-
- UGAGUAACCAAAUGUUAUGGAU 22
lntron2-3463 18563
CFTR-
- CUGAGUAACCAAAUGUUAUGGAU 23
lntron2-3464 18564
CFTR-
- UCUGAGUAACCAAAUGUUAUGGAU 24
lntron2-3465 18565
CFTR-
- AACUUCUUCCCUUCUGAU 18
lntron2-3466 18566
591
5535.1 CFTR-
- AAACUUCUUCCCUUCUGAU 19
lntron2-3467 18567
CFTR-
- AAAACUUCUUCCCUUCUGAU 20
lntron2-3468 18568
CFTR-
- UAAAACUUCUUCCCUUCUGAU 21
lntron2-3469 18569
CFTR-
- AUAAAACUUCUUCCCUUCUGAU 22
Intron2-3470 18570
CFTR-
- AAUAAAACUUCUUCCCUUCUGAU 23
lntron2-3471 18571
CFTR-
- GAAUAAAACUUCUUCCCUUCUGAU 24
lntron2-3472 18572
CFTR-
- UCAUGAAGCCUGAACUAU 18
lntron2-3473 18573
CFTR-
- CUCAUGAAGCCUGAACUAU 19
lntron2-3474 18574
CFTR-
- GCUCAUGAAGCCUGAACUAU 20
lntron2-3475 18575
CFTR-
- GGCUCAUGAAGCCUGAACUAU 21
lntron2-3476 18576
CFTR-
- UGGCUCAUGAAGCCUGAACUAU 22
lntron2-3477 18577
CFTR-
- UUGGCUCAUGAAGCCUGAACUAU 23
lntron2-3478 18578
CFTR-
- AUUGGCUCAUGAAGCCUGAACUAU 24
lntron2-3479 18579
CFTR-
- UUCUUAUAAAAUUGGUAU 18
Intron2-3480 18580
CFTR-
- UUUCUUAUAAAAUUGGUAU 19
lntron2-3481 18581
CFTR-
- UUUUCUUAUAAAAUUGGUAU 20
lntron2-3482 18582
CFTR-
- CUUUUCUUAUAAAAUUGGUAU 21
lntron2-3483 18583
CFTR-
- UCUUUUCUUAUAAAAUUGGUAU 22
lntron2-3484 18584
CFTR-
- UUCUUUUCUUAUAAAAUUGGUAU 23
lntron2-3485 18585
CFTR-
- CUUCUUUUCUUAUAAAAUUGGUAU 24
lntron2-3486 18586
CFTR-
- UCAGAGAAUUUGUCUUAU 18
lntron2-3487 18587
592
5535.1 CFTR-
- UUCAGAGAAUUUGUCUUAU 19
lntron2-3488 18588
CFTR-
- UUUCAGAGAAUUUGUCUUAU 20
lntron2-3489 18589
CFTR-
- GUUUCAGAGAAUUUGUCUUAU 21
Intron2-3490 18590
CFTR-
- GGUUUCAGAGAAUUUGUCUUAU 22
lntron2-3491 18591
CFTR-
- UGGUUUCAGAGAAUUUGUCUUAU 23
lntron2-3492 18592
CFTR-
- UUGGUUUCAGAGAAUUUGUCUUAU 24
lntron2-3493 18593
CFTR-
- UUUGUACCUCUGCACCCU 18
lntron2-3494 18594
CFTR-
- CUUUGUACCUCUGCACCCU 19
lntron2-3495 18595
CFTR-
- ACUUUGUACCUCUGCACCCU 20
Intron2-705 15805
CFTR-
- UACUUUGUACCUCUGCACCCU 21
lntron2-3496 18596
CFTR-
- GUACUUUGUACCUCUGCACCCU 22
lntron2-3497 18597
CFTR-
- GGUACUUUGUACCUCUGCACCCU 23
lntron2-3498 18598
CFTR-
- UGGUACUUUGUACCUCUGCACCCU 24
lntron2-3499 18599
CFTR-
- AAUACAAAUGUACUCCCU 18
Intron2-3500 18600
CFTR-
- GAAUACAAAUGUACUCCCU 19
Intron2-3501 18601
CFTR-
- UGAAUACAAAUGUACUCCCU 20
lntron2-389 15489
CFTR-
- UUGAAUACAAAUGUACUCCCU 21
Intron2-3502 18602
CFTR-
- UUUGAAUACAAAUGUACUCCCU 22
Intron2-3503 18603
CFTR-
- AUUUGAAUACAAAUGUACUCCCU 23
Intron2-3504 18604
CFTR-
- UAUUUGAAUACAAAUGUACUCCCU 24
Intron2-3505 18605
CFTR-
- UAGGUGGAGAACUGGCCU 18
Intron2-3506 18606
593
5535.1 CFTR-
- CUAGGUGGAGAACUGGCCU 19
Intron2-3507 18607
CFTR-
- CCUAGGUGGAGAACUGGCCU 20
Intron2-3508 18608
CFTR-
- ACCUAGGUGGAGAACUGGCCU 21
Intron2-3509 18609
CFTR-
- GACCUAGGUGGAGAACUGGCCU 22
Intron2-3510 18610
CFTR-
- AGACCUAGGUGGAGAACUGGCCU 23
lntron2-3511 18611
CFTR-
- AAGACCUAGGUGGAGAACUGGCCU 24
lntron2-3512 18612
CFTR-
- GAAAAG CAAAC U G AG G C U 18
lntron2-3513 18613
CFTR-
- AG AAAAG CAAAC U GAG G C U 19
lntron2-3514 18614
CFTR-
- CAGAAAAG CAAAC U GAG G C U 20
lntron2-3515 18615
CFTR-
- A C AG AAAAG C A A AC U G AG G C U 21
lntron2-3516 18616
CFTR-
- U A C AG AAAAG C A A AC U G AG G C U 22
lntron2-3517 18617
CFTR-
- U U AC AG AAAAG C A A AC U G AG G C U 23
lntron2-3518 18618
CFTR-
- UUUACAGAAAAGCAAACUGAGGCU 24
lntron2-3519 18619
CFTR-
- GAUGCCAAGAUCCAUGCU 18
Intron2-3520 18620
CFTR-
- GGAUGCCAAGAUCCAUGCU 19
lntron2-3521 18621
CFTR-
- GGGAUGCCAAGAUCCAUGCU 20
lntron2-3522 18622
CFTR-
- GGGGAUGCCAAGAUCCAUGCU 21
lntron2-3523 18623
CFTR-
- AGGGGAUGCCAAGAUCCAUGCU 22
lntron2-3524 18624
CFTR-
- UAGGGGAUGCCAAGAUCCAUGCU 23
lntron2-3525 18625
CFTR-
- CUAGGGGAUGCCAAGAUCCAUGCU 24
lntron2-3526 18626
CFTR-
- AAGUUUUAAUUGGAUGCU 18
lntron2-3527 18627
594
5535.1 CFTR-
- UAAGUUUUAAUUGGAUGCU 19
lntron2-3528 18628
CFTR-
- CUAAGUUUUAAUUGGAUGCU 20
lntron2-3529 18629
CFTR-
- UCUAAGUUUUAAUUGGAUGCU 21
Intron2-3530 18630
CFTR-
- AUCUAAGUUUUAAUUGGAUGCU 22
lntron2-3531 18631
CFTR-
- UAUCUAAGUUUUAAUUGGAUGCU 23
lntron2-3532 18632
CFTR-
- AUAUCUAAGUUUUAAUUGGAUGCU 24
lntron2-3533 18633
CFTR-
- UCUCAUUAGCAAGCUUCU 18
lntron2-3534 18634
CFTR-
- CUCUCAUUAGCAAGCUUCU 19
lntron2-3535 18635
CFTR-
- GCUCUCAUUAGCAAGCUUCU 20
lntron2-75 15175
CFTR-
- GGCUCUCAUUAGCAAGCUUCU 21
lntron2-3536 18636
CFTR-
- GGGCUCUCAUUAGCAAGCUUCU 22
lntron2-3537 18637
CFTR-
- AGGGCUCUCAUUAGCAAGCUUCU 23
lntron2-3538 18638
CFTR-
- AAGGGCUCUCAUUAGCAAGCUUCU 24
lntron2-3539 18639
CFTR-
- UUUUCAUCUCUGUACAGU 18
Intron2-3540 18640
CFTR-
- UUUUUCAUCUCUGUACAGU 19
lntron2-3541 18641
CFTR-
- AUUUUUCAUCUCUGUACAGU 20
lntron2-3542 18642
CFTR-
- AAUUUUUCAUCUCUGUACAGU 21
lntron2-3543 18643
CFTR-
- AAAUUUUUCAUCUCUGUACAGU 22
lntron2-3544 18644
CFTR-
- GAAAUUUUUCAUCUCUGUACAGU 23
lntron2-3545 18645
CFTR-
- UGAAAUUUUUCAUCUCUGUACAGU 24
lntron2-3546 18646
CFTR-
- UUUCUACAUUACUUCCGU 18
lntron2-3547 18647
595
5535.1 CFTR-
- CUUUCUACAUUACUUCCGU 19
lntron2-3548 18648
CFTR-
- CCUUUCUACAUUACUUCCGU 20
lntron2-3549 18649
CFTR-
- ACCUUUCUACAUUACUUCCGU 21
Intron2-3550 18650
CFTR-
- CACCUUUCUACAUUACUUCCGU 22
lntron2-3551 18651
CFTR-
- ACACCUUUCUACAUUACUUCCGU 23
lntron2-3552 18652
CFTR-
- AACACCUUUCUACAUUACUUCCGU 24
lntron2-3553 18653
CFTR-
- AAUGCUGGGAUUAUAGGU 18
lntron2-3554 18654
CFTR-
- AAAUGCUGGGAUUAUAGGU 19
lntron2-3555 18655
CFTR-
- AAAAUGCUGGGAUUAUAGGU 20
lntron2-3556 18656
CFTR-
- CAAAAUGCUGGGAUUAUAGGU 21
lntron2-3557 18657
CFTR-
- CCAAAAUGCUGGGAUUAUAGGU 22
lntron2-3558 18658
CFTR-
- CCCAAAAUGCUGGGAUUAUAGGU 23
lntron2-3559 18659
CFTR-
- UCCCAAAAUGCUGGGAUUAUAGGU 24
Intron2-3560 18660
CFTR-
- AUAAAGUGGGUCCCUGGU 18
lntron2-3561 18661
CFTR-
- CAUAAAGUGGGUCCCUGGU 19
lntron2-3562 18662
CFTR-
- ACAUAAAGUGGGUCCCUGGU 20
lntron2-3563 18663
CFTR-
- UACAUAAAGUGGGUCCCUGGU 21
lntron2-3564 18664
CFTR-
- CUACAUAAAGUGGGUCCCUGGU 22
lntron2-3565 18665
CFTR-
- UCUACAUAAAGUGGGUCCCUGGU 23
lntron2-3566 18666
CFTR-
- UUCUACAUAAAGUGGGUCCCUGGU 24
lntron2-3567 18667
CFTR-
- AAAGGUGGAGAAGCAUGU 18
lntron2-3568 18668
596
5535.1 CFTR-
- GAAAGGUGGAGAAGCAUGU 19
lntron2-3569 18669
CFTR-
- AG A A AG GUGGAGAAGCAUGU 20
Intron2-406 15506
CFTR-
- GAGAAAGGUGGAGAAGCAUGU 21
Intron2-3570 18670
CFTR-
- AGAGAAAGGUGGAGAAGCAUGU 22
lntron2-3571 18671
CFTR-
- GAGAGAAAGGUGGAGAAGCAUGU 23
lntron2-3572 18672
CFTR-
- UGAGAGAAAGGUGGAGAAGCAUGU 24
lntron2-3573 18673
CFTR-
- GGGAGGUUAGCUCUGUGU 18
lntron2-3574 18674
CFTR-
- UGGGAGGUUAGCUCUGUGU 19
lntron2-3575 18675
CFTR-
- AUGGGAGGUUAGCUCUGUGU 20
lntron2-3576 18676
CFTR-
- GAUGGGAGGUUAGCUCUGUGU 21
lntron2-3577 18677
CFTR-
- GGAUGGGAGGUUAGCUCUGUGU 22
lntron2-3578 18678
CFTR-
- UGGAUGGGAGGUUAGCUCUGUGU 23
lntron2-3579 18679
CFTR-
- AUGGAUGGGAGGUUAGCUCUGUGU 24
Intron2-3580 18680
CFTR-
- GAGGUUAGCUCUGUGUGU 18
lntron2-3581 18681
CFTR-
- GGAGGUUAGCUCUGUGUGU 19
lntron2-3582 18682
CFTR-
- GGGAGGUUAGCUCUGUGUGU 20
lntron2-3583 18683
CFTR-
- UGGGAGGUUAGCUCUGUGUGU 21
lntron2-3584 18684
CFTR-
- AUGGGAGGUUAGCUCUGUGUGU 22
lntron2-3585 18685
CFTR-
- GAUGGGAGGUUAGCUCUGUGUGU 23
lntron2-3586 18686
CFTR-
- GGAUGGGAGGUUAGCUCUGUGUGU 24
lntron2-3587 18687
CFTR-
- AACUAAAGUAACACCAUU 18
lntron2-3588 18688
597
5535.1 CFTR-
- AAACU AAAG U AACACCAU U 19
lntron2-3589 18689
CFTR-
- AAAACUAAAGUAACACCAUU 20
Intron2-3590 18690
CFTR-
- G AAAACU AAAG U AACACCAU U 21
lntron2-3591 18691
CFTR-
- UG AAAACU AAAG U AACACCAU U 22
lntron2-3592 18692
CFTR-
- G UG AAAACU AAAG U AACACCAU U 23
lntron2-3593 18693
CFTR-
- UG UG AAAACU AAAG U AACACCAU U 24
lntron2-3594 18694
CFTR-
- UUUCCUUUUUUUGGCAUU 18
lntron2-3595 18695
CFTR-
- AUUUCCUUUUUUUGGCAUU 19
lntron2-3596 18696
CFTR-
- CAUUUCCUUUUUUUGGCAUU 20
lntron2-3597 18697
CFTR-
- UCAUUUCCUUUUUUUGGCAUU 21
lntron2-3598 18698
CFTR-
- UUCAUUUCCUUUUUUUGGCAUU 22
lntron2-3599 18699
CFTR-
- AUUCAUUUCCUUUUUUUGGCAUU 23
Intron2-3600 18700
CFTR-
- AAUUCAUUUCCUUUUUUUGGCAUU 24
Intron2-3601 18701
CFTR-
- UACUCCUUUAGAGUGAUU 18
Intron2-3602 18702
CFTR-
- UUACUCCUUUAGAGUGAUU 19
Intron2-3603 18703
CFTR-
- AUUACUCCUUUAGAGUGAUU 20
Intron2-3604 18704
CFTR-
- UAUUACUCCUUUAGAGUGAUU 21
Intron2-3605 18705
CFTR-
- CUAUUACUCCUUUAGAGUGAUU 22
Intron2-3606 18706
CFTR-
- CCUAUUACUCCUUUAGAGUGAUU 23
Intron2-3607 18707
CFTR-
- GCCUAUUACUCCUUUAGAGUGAUU 24
Intron2-3608 18708
CFTR-
- GAAAUUUAUUGAAAUAUU 18
Intron2-3609 18709
598
5535.1 CFTR-
- UGAAAUUUAUUGAAAUAUU 19
Intron2-3610 18710
CFTR-
- UUGAAAUUUAUUGAAAUAUU 20
lntron2-3611 18711
CFTR-
- UUUGAAAUUUAUUGAAAUAUU 21
lntron2-3612 18712
CFTR-
- AUUUGAAAUUUAUUGAAAUAUU 22
lntron2-3613 18713
CFTR-
- UAUUUGAAAUUUAUUGAAAUAUU 23
lntron2-3614 18714
CFTR-
- GUAUUUGAAAUUUAUUGAAAUAUU 24
lntron2-3615 18715
CFTR-
- AAUUAAGAUGAUAAUAUU 18
lntron2-3616 18716
CFTR-
- AAAUUAAGAUGAUAAUAUU 19
lntron2-3617 18717
CFTR-
- AAAAUUAAGAUGAUAAUAUU 20
lntron2-3618 18718
CFTR-
- GAAAAUUAAGAUGAUAAUAUU 21
lntron2-3619 18719
CFTR-
- UGAAAAUUAAGAUGAUAAUAUU 22
Intron2-3620 18720
CFTR-
- U U GAAAAU U AAG AUG AU AAU AU U 23
lntron2-3621 18721
CFTR-
- UUUGAAAAUUAAGAUGAUAAUAUU 24
lntron2-3622 18722
CFTR-
- UUGUACCUCUGCACCCUU 18
lntron2-3623 18723
CFTR-
- UUUGUACCUCUGCACCCUU 19
lntron2-3624 18724
CFTR-
- CUUUGUACCUCUGCACCCUU 20
lntron2-412 15512
CFTR-
- ACUUUGUACCUCUGCACCCUU 21
lntron2-3625 18725
CFTR-
- UACUUUGUACCUCUGCACCCUU 22
lntron2-3626 18726
CFTR-
- GUACUUUGUACCUCUGCACCCUU 23
lntron2-3627 18727
CFTR-
- GGUACUUUGUACCUCUGCACCCUU 24
lntron2-3628 18728
CFTR-
- AGGUGGAGAACUGGCCUU 18
lntron2-3629 18729
599
5535.1 CFTR-
- UAGGUGGAGAACUGGCCUU 19
Intron2-3630 18730
CFTR-
- CUAGGUGGAGAACUGGCCUU 20
lntron2-414 15514
CFTR-
- CCUAGGUGGAGAACUGGCCUU 21
lntron2-3631 18731
CFTR-
- ACCUAGGUGGAGAACUGGCCUU 22
lntron2-3632 18732
CFTR-
- GACCUAGGUGGAGAACUGGCCUU 23
lntron2-3633 18733
CFTR-
- AGACCUAGGUGGAGAACUGGCCUU 24
lntron2-3634 18734
CFTR-
- GGUCACUAGAGACCUCUU 18
lntron2-3635 18735
CFTR-
- GGGUCACUAGAGACCUCUU 19
lntron2-3636 18736
CFTR-
- AGGGUCACUAGAGACCUCUU 20
lntron2-3637 18737
CFTR-
- CAGGGUCACUAGAGACCUCUU 21
lntron2-3638 18738
CFTR-
- CCAGGGUCACUAGAGACCUCUU 22
lntron2-3639 18739
CFTR-
- CCCAGGGUCACUAGAGACCUCUU 23
Intron2-3640 18740
CFTR-
- GCCCAGGGUCACUAGAGACCUCUU 24
lntron2-3641 18741
CFTR-
- AAAUUUAUUGAAAUAUUU 18
lntron2-3642 18742
CFTR-
- GAAAUUUAUUGAAAUAUUU 19
lntron2-3643 18743
CFTR-
- UGAAAUUUAUUGAAAUAUUU 20
lntron2-721 15821
CFTR-
- U U GAAAU U U AU UG AAAU AU U U 21
lntron2-3644 18744
CFTR-
- UUUGAAAUUUAUUGAAAUAUUU 22
lntron2-3645 18745
CFTR-
- AUUUGAAAUUUAUUGAAAUAUUU 23
lntron2-3646 18746
CFTR-
- UAUUUGAAAUUUAUUGAAAUAUUU 24
lntron2-3647 18747
CFTR-
- GAGAUAUUUUAUUCCUUU 18
lntron2-3648 18748
600
5535.1 CFTR-
- AGAGAUAUUUUAUUCCUUU 19
lntron2-3649 18749
CFTR-
- UAGAGAUAUUUUAUUCCUUU 20
Intron2-3650 18750
CFTR-
- UUAGAGAUAUUUUAUUCCUUU 21
lntron2-3651 18751
CFTR-
- UUUAGAGAUAUUUUAUUCCUUU 22
lntron2-3652 18752
CFTR-
- AUUUAGAGAUAUUUUAUUCCUUU 23
lntron2-3653 18753
CFTR-
- UAUUUAGAGAUAUUUUAUUCCUUU 24
lntron2-3654 18754
CFTR-
- CUCUUUGCUCCUAUCUUU 18
lntron2-3655 18755
CFTR-
- ACUCUUUGCUCCUAUCUUU 19
lntron2-3656 18756
CFTR-
- AACUCUUUGCUCCUAUCUUU 20
lntron2-3657 18757
CFTR-
- GAACUCUUUGCUCCUAUCUUU 21
lntron2-3658 18758
CFTR-
- AGAACUCUUUGCUCCUAUCUUU 22
lntron2-3659 18759
CFTR-
- UAGAACUCUUUGCUCCUAUCUUU 23
Intron2-3660 18760
CFTR-
- UUAGAACUCUUUGCUCCUAUCUUU 24
lntron2-3661 18761
CFTR-
- AAAAU ACACAU U UGG U U U 18
lntron2-3662 18762
CFTR-
- AAAAAUACACAUUUGGUUU 19
lntron2-3663 18763
CFTR-
- GAAAAAUACACAUUUGGUUU 20
lntron2-3664 18764
CFTR-
- UGAAAAAUACACAUUUGGUUU 21
lntron2-3665 18765
CFTR-
- CUG AAAAAU ACACAU U U GG U U U 22
lntron2-3666 18766
CFTR-
- CCUG AAAAAU ACACAU U UGG U U U 23
lntron2-3667 18767
CFTR-
- U CCUG AAAAAU ACACAU U UGG U U U 24
lntron2-3668 18768
CFTR-
- UUGUUGUUGCUGUUGUUU 18
lntron2-3669 18769
601
5535.1 CFTR-
- GUUGUUGUUGCUGUUGUUU 19
Intron2-3670 18770
CFTR-
- UGUUGUUGUUGCUGUUGUUU 20
lntron2-3671 18771
CFTR-
- UUGUUGUUGUUGCUGUUGUUU 21
lntron2-3672 18772
CFTR-
- GUUGUUGUUGUUGCUGUUGUUU 22
lntron2-3673 18773
CFTR-
- UGUUGUUGUUGUUGCUGUUGUUU 23
lntron2-3674 18774
CFTR-
- UUGUUGUUGUUGUUGCUGUUGUUU 24
lntron2-3675 18775
CFTR-
- UGUUUGUGUUGUUUGUUU 18
lntron2-3676 18776
CFTR-
- UUGUUUGUGUUGUUUGUUU 19
lntron2-3677 18777
CFTR-
- UUUGUUUGUGUUGUUUGUUU 20
lntron2-3678 18778
CFTR-
- GUUUGUUUGUGUUGUUUGUUU 21
lntron2-3679 18779
CFTR-
- UGUUUGUUUGUGUUGUUUGUUU 22
Intron2-3680 18780
CFTR-
- UUGUUUGUUUGUGUUGUUUGUUU 23
lntron2-3681 18781
CFTR-
- UUUGUUUGUUUGUGUUGUUUGUUU 24
lntron2-3682 18782
CFTR-
- GACCAUGAGAUGGAUUUU 18
lntron2-3683 18783
CFTR-
- AGACCAUGAGAUGGAUUUU 19
lntron2-3684 18784
CFTR-
- GAGACCAUGAGAUGGAUUUU 20
lntron2-3685 18785
CFTR-
- AGAGACCAUGAGAUGGAUUUU 21
lntron2-3686 18786
CFTR-
- UAGAGACCAUGAGAUGGAUUUU 22
lntron2-3687 18787
CFTR-
- UU AGAGACCAUGAGAUGGAUUUU 23
lntron2-3688 18788
CFTR-
- AUUAGAGACCAUGAGAUGGAUUUU 24
lntron2-3689 18789
602
5535.1 Table 39A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within intron 2, have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 39A
Figure imgf000604_0001
603
5535.1 Table 39B provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within intron 2 and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 39B
Figure imgf000605_0001
604
5535.1 CFTR-lntron2-
+ AAAGGAGUAAUACACAG 17
3716 18816
CFTR-lntron2-
- CACU U CU AAG AU CAAGG 17
3717 18817
CFTR-lntron2-
- UUAAUUGGAUGCUGAGG 17
3718 18818
CFTR-lntron2-
- UUAUUUUCUCAGACCGG 17
3719 18819
CFTR-lntron2-
- UCCAUGCUUAGAGAUUG 17
3720 18820
CFTR-lntron2-
- U U U CAAAG ACCU UUAAU 17
3721 18821
CFTR-lntron2-
- CUAGGGGAUGCCAAGAU 17
3722 18822
CFTR-lntron2-
- UGAAGUAAAUCGUGUAU 17
3723 18823
CFTR-lntron2-
+ UGAUUGGAAAGGAAACU 17
3724 18824
CFTR-lntron2-
- AUGCCAAGAUCCAUGCU 17
3725 18825
CFTR-lntron2-
- AUUAAGCUAGUGGGAGU 17
3726 18826
CFTR-lntron2-
+ CUAGGUCUUCACAUAGU 17
3727 18827
CFTR-lntron2-
- CAAACCACACAUCCGUU 17
3728 18828
CFTR-lntron2-
- AAAUAGAUGGGAAAAGGUAA 20
3729 18829
CFTR-lntron2-
- AGUUUUCACUGUAUCCCCCA 20
3730 18830
CFTR-lntron2-
- UCCCAGAGACUCUUGAGUCA 20
3731 18831
CFTR-lntron2-
- UGUCUUAUUAGAGACCAUGA 20
3732 18832
CFTR-lntron2-
+ UUUCAAUUAACCCAGCCCUA 20
3733 18833
CFTR-lntron2-
- AAUCUGAAUUUGCAGAAUUA 20
3734 18834
CFTR-lntron2-
- CCCGGCCUAUUACUCCUUUA 20
3735 18835
CFTR-lntron2-
+ AACU AGG U AAACAAU U AG AC 20
3736 18836
605
5535.1 CFTR-lntron2-
- CUGCACCCUUGGGAAGUGAC 20
3737 18837
CFTR-lntron2-
- AUCUGGCUCAAUUUUGUGAC 20
3738 18838
CFTR-lntron2-
+ CAAUCAAAAGGAUCCUAACC 20
3739 18839
CFTR-lntron2-
+ U U AAAU ACU AU AGGAACACC 20
3740 18840
CFTR-lntron2-
+ AGUGUGAAUCUGCUACUCCC 20
3741 18841
CFTR-lntron2-
- CAAUCAAAAGGUUAGGAUCC 20
3742 18842
CFTR-lntron2-
+ CAUAAAGGAGUAAUACACAG 20
2142 17242
CFTR-lntron2-
- UCACACUUCUAAGAUCAAGG 20
3743 18843
CFTR-lntron2-
+ CUAGCCAUUUCACAUUCCAU 20
3744 18844
CFTR-lntron2-
- CUUCUAGGGGAUGCCAAGAU 20
3745 18845
CFTR-lntron2-
+ UUUUGAUUGGAAAGGAAACU 20
2486 17586
CFTR-lntron2-
+ CAUGGAUCUUGGCAUCCCCU 20
3746 18846
CFTR-lntron2-
- AGAAUUAAGCUAGUGGGAGU 20
3747 18847
CFTR-lntron2-
+ CACCUAGGUCUUCACAUAGU 20
3748 18848
CFTR-lntron2-
+ UUUGCACACUGCAGUUAUGU 20
3749 18849
CFTR-lntron2-
- CAGUGACAGAAACCCAAUUU 20
3750 18850
Table 39C provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within intron 2 and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 39C
606
5535.1 3rd Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR-lntron2-
- GUUAAUGAAUGAUGGAG 17
3751 18851
CFTR-lntron2-
+ GCCAUUUCACAUUCCAU 17
3752 18852
Table 39D provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within intron 2. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 39D
Figure imgf000608_0001
607
5535.1 CFTR-lntron2-
- AGGUGUGAGCCACUAUG 17
3764 18864
CFTR-lntron2-
- CUUGGCCUCCCAAAGUG 17
3765 18865
CFTR-lntron2-
+ CUAUGACUCAAGAGUCU 17
3766 18866
CFTR-lntron2-
- UG ACAG AAACCCAAU U U 17
3767 18867
CFTR-lntron2-
- AAG AAAACAG AAAG U U U 17
3768 18868
CFTR-lntron2-
- AUAUUAAACUUUAUUUU 17
3769 18869
CFTR-lntron2-
+ AAGCCAGAUAAUUCUGCAAA 20
3770 18870
CFTR-lntron2-
- UAUUCCUUUGUGAAGAGAAA 20
3771 18871
CFTR-lntron2-
+ U U U CUG U AAAAU AG AG AU AA 20
3772 18872
CFTR-lntron2-
+ UAUUAUCUCUCUGAGCCUCA 20
3773 18873
CFTR-lntron2-
+ AGUCCCAGCUACUCAGGAGA 20
1715 16815
CFTR-lntron2-
- UUAUAGAAGGGCUCUCAUUA 20
3774 18874
CFTR-lntron2-
+ UCCCAUCUAUUUCCCUCCCC 20
3775 18875
CFTR-lntron2-
+ UGUAUUUAUUAAGUUAUUGC 20
3776 18876
CFTR-lntron2-
- AAACUUCGUCUCCUGGGUUC 20
3777 18877
CFTR-lntron2-
- CCAGUUAAUGAAUGAUGGAG 20
3778 18878
CFTR-lntron2-
+ CAGCUACUCAGGAGACUGAG 20
3779 18879
CFTR-lntron2-
- CACCUUGGCCUCCCAAAAUG 20
3291 18391
CFTR-lntron2-
- UAUAGGUGUGAGCCACUAUG 20
3780 18880
CFTR-lntron2-
- CGCCUUGGCCUCCCAAAGUG 20
3352 18452
CFTR-lntron2-
- AGAUCCAUGCUUAGAGAUUG 20
3781 18881
608
5535.1 CFTR-lntron2-
- AUUUUUCAAAGACCUUUAAU 20
3782 18882
CFTR-lntron2-
+ AAGGUUUUGAAAGCAAAUAU 20
3783 18883
CFTR-lntron2-
- UUAUGAAGUAAAUCGUGUAU 20
3784 18884
CFTR-lntron2-
- U AAAAG AAAACAG AAAG U U U 20
3785 18885
CFTR-lntron2-
- AAGAUAUUAAACUUUAUUUU 20
3786 18886
Table 40A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within intron 10, have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 40A
Figure imgf000610_0001
609
5535.1 9
CFTR-lntronlO-
- GUGCCACUAGUGAUGCA 17
10 18896
CFTR-lntronlO-
- GUACAAGUCUAGUUUCA 17
11 18897
CFTR-lntronlO-
- GGCUGGUAGUGUGAAGA 17
12 18898
CFTR-lntronlO-
+ GUGAUGCAGACAACAGA 17
13 18899
CFTR-lntronlO-
+ GACUAAAACUGAGUAGA 17
14 18900
CFTR-lntronlO-
+ GGUACAAAUUUCAGGGA 17
15 18901
CFTR-lntronlO-
+ GUCUCUCUAAGGUGUGA 17
16 18902
CFTR-lntronlO-
+ GUUCUUAGGGUGGGAUA 17
17 18903
CFTR-lntronlO-
- GUGUAGGGGUUAGCCUA 17
18 18904
CFTR-lntronlO-
+ GCCUAUCACCUAGGCUA 17
19 18905
CFTR-lntronlO-
+ GUGUGAGGGUCUCUCUA 17
20 18906
CFTR-lntronlO-
- GACUGAAAGCUGGCUUA 17
21 18907
CFTR-lntronlO-
+ G U AUG U AGG AAAACAAC 17
22 18908
CFTR-lntronlO-
+ GUAUUAAGUAUAGCCAC 17
23 18909
CFTR-lntronlO-
- GUGAGAUUAGAGGCCAC 17
24 18910
CFTR-lntronlO-
- GAUGAGCAGAUAAUUAC 17
25 18911
CFTR-lntronlO-
+ GUAUCUCCAAAUAUGCC 17
26 18912
CFTR-lntronlO-
- GAAUGAAUGUGGUAUCC 17
27 18913
CFTR-lntronlO-
+ GACAUCAGUUGGGUUCC 17
28 18914
CFTR-lntronlO-
+ GUUGGAUGAGGGAAUGC 17
29 18915
CFTR-lntronlO-
+ GCUAUUUAAACAGAAUC 17
30 18916
610
5535.1 CFTR-lntronlO-
- GACUGACUAUACCUGUC 17
31 18917
CFTR-lntronlO-
- GUCUAUUGUGCCAGUUC 17
32 18918
CFTR-lntronlO-
+ GAAUUGG UACAAAU U U C 17
33 18919
CFTR-lntronlO-
- GAUGAUUCCAAGCU UUC 17
34 18920
CFTR-lntronlO-
+ GAUAUCUUAGGUCAAAG 17
35 18921
CFTR-lntronlO-
- GUCUAGUUUCAAGGAAG 17
36 18922
CFTR-lntronlO-
+ GCUAAAGUAUUACCCAG 17
37 18923
CFTR-lntronlO-
- GGCAUUCUAAGUAUUAG 17
38 18924
CFTR-lntronlO-
- GUCAGAGAAGUAAUCGG 17
39 18925
CFTR-lntronlO-
- GAAGUAAUCGGCGGUGG 17
40 18926
CFTR-lntronlO-
+ GCUACCUUGGUUGGAUG 17
41 18927
CFTR-lntronlO-
- GAUUGUCAUUUUAGCUG 17
42 18928
CFTR-lntronlO-
+ GAAAUGGGGUAUAAGUG 17
43 18929
CFTR-lntronlO-
- GAUGGUAUUGCAGGGUG 17
44 18930
CFTR-lntronlO-
- GAGCCAAAAAUUGGGUG 17
45 18931
CFTR-lntronlO-
- GGCAUCUCACCAGUGUG 17
46 18932
CFTR-lntronlO-
+ GGUCUCUCUAAGGUGUG 17
47 18933
CFTR-lntronlO-
- GGUAAGCUCAAGCAUUG 17
48 18934
CFTR-lntronlO-
- GUAUUUACCAUAUAUUG 17
49 18935
CFTR-lntronlO-
- GGUUUCCACUCAACAAU 17
50 18936
CFTR-lntronlO-
- GCUGGUAGUGUGAAGAU 17
51 18937
CFTR-lntronlO- - GUGCAAAGCUUUCAGAU 17 18938
611
5535.1 52
CFTR-lntronlO-
- GAAGGGUGUUAUCAACU 17
53 18939
CFTR-lntronlO-
- GAAUUGAAUAUGAGACU 17
54 18940
CFTR-lntronlO-
- GGAAGGCAGUGGUCCCU 17
55 18941
CFTR-lntronlO-
- GUGAAAAUAUCACUUCU 17
56 18942
CFTR-lntronlO-
- GGAGCCAAAAAUUGGGU 17
57 18943
CFTR-lntronlO-
+ GGAUUGGCUACCUUGGU 17
58 18944
CFTR-lntronlO-
- GUCACUGUAUUGUCUGU 17
59 18945
CFTR-lntronlO-
- GCAUCUCACCAGUGUGU 17
60 18946
CFTR-lntronlO-
+ GAAG U AG AAG AACU AU U 17
61 18947
CFTR-lntronlO-
+ GUUUGUCUUAGAUUAU U 17
62 18948
CFTR-lntronlO-
- GAUUAGCUUAUAUACU U 17
63 18949
CFTR-lntronlO-
- GAAGGCAGUGGUCCCUU 17
64 18950
CFTR-lntronlO-
+ GAGUGCAUAAAGGUUGAAAA 20
65 18951
CFTR-lntronlO-
- GCUAUUCUGUAGGGAGACAA 20
66 18952
CFTR-lntronlO-
- GAUACUAAAUAAGUUAGCAA 20
67 18953
CFTR-lntronlO-
- GAGGGUUGAUAAGAAGAGAA 20
68 18954
CFTR-lntronlO-
- GCCGUUUACUAGAAAGAUAA 20
69 18955
CFTR-lntronlO-
- GGGUGUAGGGGUUAGCCUAA 20
70 18956
CFTR-lntronlO-
- GGGGCUGGAUAAGAUUCUAA 20
71 18957
CFTR-lntronlO-
+ GGUAUAAGUGUGGAGUGUAA 20
72 18958
CFTR-lntronlO-
- GGAAGAUCCAAUAGGAUUAA 20
73 18959
612
5535.1 CFTR-lntronlO-
- GGCUGGCAUAGAGUAAGACA 20
74 18960
CFTR-lntronlO-
- GGCUAUUCUGUAGGGAGACA 20
75 18961
CFTR-lntronlO-
+ GAAGUGUUUAAAUAUUCCCA 20
76 18962
CFTR-lntronlO-
+ GUGCUAUUUAAACAGAAUCA 20
77 18963
CFTR-lntronlO-
+ GGAUUGCUUGAUGUUAUUCA 20
78 18964
CFTR-lntronlO-
- GAUGUACAAGUCUAGUUUCA 20
79 18965
CFTR-lntronlO-
- GGGGGCUGGUAGUGUGAAGA 20
80 18966
CFTR-lntronlO-
+ GCUGUGAUGCAGACAACAGA 20
81 18967
CFTR-lntronlO-
- G C A AG U G C A A AG CUUUCAGA 20
82 18968
CFTR-lntronlO-
- GGCAUAGAGUAAGACAGGGA 20
83 18969
CFTR-lntronlO-
+ GUUGUUCUUAGGGUGGGAUA 20
84 18970
CFTR-lntronlO-
- GGGGUGUAGGGGUUAGCCUA 20
85 18971
CFTR-lntronlO-
- GUCUGGUUUGAAGAACAGUA 20
86 18972
CFTR-lntronlO-
+ GCCAGGUUAAGUUGUUCUUA 20
87 18973
CFTR-lntronlO-
- GAG U U U U AAACAG AAG U AAC 20
88 18974
CFTR-lntronlO-
+ GACUGAAACUCCCCACACAC 20
89 18975
CFTR-lntronlO-
+ GCUAAGAGACUCCUGAAUCC 20
90 18976
CFTR-lntronlO-
+ GU UUUAGUAGAAACCUAAUC 20
91 18977
CFTR-lntronlO-
- GGAUUAGGGAAUGCAGACUC 20
92 18978
CFTR-lntronlO-
- GGAGUCUAUUGUGCCAGUUC 20
93 18979
CFTR-lntronlO-
+ GCUUGACAUCAGUUGGGUUC 20
94 18980
CFTR-lntronlO- - GAUAAGAUUCU A A AG G A A AG 20 18981
613
5535.1 95
CFTR-lntronlO-
+ GGGUCAAUUGUAUUAGCAAG 20
96 18982
CFTR-lntronlO-
+ GGCU UAACCCAUCUAUUAAG 20
97 18983
CFTR-lntronlO-
+ GCAUAUUGGACCAGACACAG 20
98 18984
CFTR-lntronlO-
- GCAUAUGAGAAAAGUCACAG 20
99 18985
CFTR-lntronlO-
+ GCCUAGAUGAUUAUUAAUAG 20
100 18986
CFTR-lntronlO-
- GUAAUCGGCGGUGGAGGUAG 20
101 18987
CFTR-lntronlO-
+ GAUCAAUAAUAGAGACAAGG 20
102 18988
CFTR-lntronlO-
- GUCUAGUUUCAAGGAAGAGG 20
103 18989
CFTR-lntronlO-
- GU UUACUAACUCAAUCUAGG 20
104 18990
CFTR-lntronlO-
- GUCAGAGAAGUAAUCGGCGG 20
105 18991
CFTR-lntronlO-
- GGGCUGGUAGUGUGAAGAUG 20
106 18992
CFTR-lntronlO-
+ G U U ACAU AAAAAG AG AGG UG 20
107 18993
CFTR-lntronlO-
+ GAGGGUCUCUCUAAGGUGUG 20
108 18994
CFTR-lntronlO-
- GCUU UGAAGGAAGAUCCAAU 20
109 18995
CFTR-lntronlO-
- GAGCU UUCUAGUAUUAGAAU 20
110 18996
CFTR-lntronlO-
- GGGGCUGGUAGUGUGAAGAU 20
111 18997
CFTR-lntronlO-
- GUCU UUUCCUCUUAAUAGAU 20
112 18998
CFTR-lntronlO-
- GCAGAAGGGUGUUAUCAACU 20
113 18999
CFTR-lntronlO-
- GAAGAAUUGAAUAUGAGACU 20
114 19000
CFTR-lntronlO-
+ GU UACAACAGUCUUUAUACU 20
115 19001
CFTR-lntronlO-
+ GUUACCUGGAUUGGCUACCU 20
116 19002
614
5535.1 CFTR-lntronlO-
+ GU UACUCAGUCCAGAAAGCU 20
117 19003
CFTR-lntronlO-
- GGAGUUUACUAACUCAAUCU 20
118 19004
CFTR-lntronlO-
- GAUUAGGGAAUGCAGACUCU 20
119 19005
CFTR-lntronlO-
+ GGAAAGUUGUCCAAGAUAGU 20
120 19006
CFTR-lntronlO-
- GUAUUAGAGGUUAAGGAGGU 20
121 19007
CFTR-lntronlO-
- GGAAGCAGUGCUGCUGCUGU 20
122 19008
CFTR-lntronlO-
- GAAGUCACUGUAUUGUCUGU 20
123 19009
CFTR-lntronlO-
- GU UACCCAAUAAAAAAAAUU 20
124 19010
CFTR-lntronlO-
- GCUUUCAGGAG CCA A A A A U U 20
125 19011
CFTR-lntronlO-
- GGCUGCCUUUUAGUAGUAUU 20
126 19012
CFTR-lntronlO-
- GAGGAAGGCAGUGGUCCCUU 20
127 19013
CFTR-lntronlO-
- GU UUUGGAUGGAGCUUGGUU 20
128 19014
CFTR-lntronlO-
- GGGU UUGAUUAGAUAAAUUU 20
129 19015
CFTR-lntronlO-
- GUUGUUAUCUCUGAAAUUUU 20
130 19016
CFTR-lntronlO-
+ GGGCUCCCCCACCCAAUU UU 20
131 19017
Table 40B provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within intron 10 and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 40B
615
5535.1 2nd Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR-lntronlO-
+ AGCUAUGCCCUUAAAAA 17
132 19018
CFTR-lntronlO-
- AUCAUCUAGGCUGCAAA 17
133 19019
CFTR-lntronlO-
- ACCUUCAUGUUGAUAAA 17
134 19020
CFTR-lntronlO-
+ UUCCUAAUACUACUAAA 17
135 19021
CFTR-lntronlO-
- UAUUAGAAUGGGCUAAA 17
136 19022
CFTR-lntronlO-
+ UCACGUGGUGUUUUAAA 17
137 19023
CFTR-lntronlO-
+ UACCAUUAUCUACACAA 17
138 19024
CFTR-lntronlO-
- AUUCUGUAGGGAGACAA 17
139 19025
CFTR-lntronlO-
- ACUAAAUAAG U UAGCAA 17
140 19026
CFTR-lntronlO-
+ AG CC AG CU U U CAG U CAA 17
141 19027
CFTR-lntronlO-
- UGUUGAUAAAGGGUCAA 17
142 19028
CFTR-lntronlO-
- ACUGAUGUCAAGCAGAA 17
143 19029
CFTR-lntronlO-
- UUUAGUAGUAUUAGGAA 17
144 19030
CFTR-lntronlO-
- UAAGAAAGACUCCUGAA 17
145 19031
CFTR-lntronlO-
+ A AG CAA AG AG U G C A U A A 17
146 19032
CFTR-lntronlO-
- ACCCAUUGUGUAGAUAA 17
147 19033
CFTR-lntronlO-
- AACCUUCAUGUUGAUAA 17
148 19034
CFTR-lntronlO-
- UUGGUGUAGUUCUAUAA 17
149 19035
CFTR-lntronlO-
- UGUAGGGGUUAGCCUAA 17
150 19036
CFTR-lntronlO-
+ AUAAGUGUGGAGUGUAA 17
151 19037
616
5535.1 CFTR-lntronlO-
- AGAUCCAAUAGGAUUAA 17
152 19038
CFTR-lntronlO-
+ UCAACUUUAUCUGUUAA 17
153 19039
CFTR-lntronlO-
+ UACCUUUCAAUGUUUAA 17
154 19040
CFTR-lntronlO-
- UAGCAAUGGUCUAAACA 17
155 19041
CFTR-lntronlO-
+ ACAAUCAAAUGGGAACA 17
156 19042
CFTR-lntronlO-
+ ACCUAUAAGGAAUAACA 17
157 19043
CFTR-lntronlO-
- UGGCAUAGAGUAAGACA 17
158 19044
CFTR-lntronlO-
- UAUUCUGUAGGGAGACA 17
159 19045
CFTR-lntronlO-
+ UUACAAUUCUUAUUACA 17
160 19046
CFTR-lntronlO-
- AUUCCCUCAUCCAACCA 17
161 19047
CFTR-lntronlO-
+ UAAAGACUUCACCCUCA 17
162 19048
CFTR-lntronlO-
+ AAGCCAGCUUUCAGUCA 17
163 19049
CFTR-lntronlO-
+ AUCUAAAAGCUAAUUCA 17
164 19050
CFTR-lntronlO-
+ UUGCUUGAUGU UAUUCA 17
165 19051
CFTR-lntronlO-
- UCUAGUUUCAAGGAAGA 17
166 19052
CFTR-lntronlO-
- AACUGAUGUCAAGCAGA 17
167 19053
CFTR-lntronlO-
- AG U G C A A AG C U U U C AG A 17
168 19054
CFTR-lntronlO-
+ ACCCUUUAUCAACAUGA 17
169 19055
CFTR-lntronlO-
+ CUACCUUGGUUGGAUGA 17
170 19056
CFTR-lntronlO-
- AUGAAAAGCAGCUAUGA 17
171 19057
CFTR-lntronlO-
- UUAAAGAAUGACUGUGA 17
172 19058
617
5535.1 CFTR-lntronlO-
- CGGUGUCU UCUGAAAUA 17
173 19059
CFTR-lntronlO-
+ CUAGAUGAUUAUUAAUA 17
174 19060
CFTR-lntronlO-
- ACUAAUUGUAGUACAUA 17
175 19061
CFTR-lntronlO-
+ AAAUUACAGAACCUAUA 17
176 19062
CFTR-lntronlO-
- UGAUCAUUGCCUCACUA 17
177 19063
CFTR-lntronlO-
- AGUGCUCGUAAAGACUA 17
178 19064
CFTR-lntronlO-
- UGACCUAAGAUAUCCUA 17
179 19065
CFTR-lntronlO-
- AAUCGGCGGUGGAGGUA 17
180 19066
CFTR-lntronlO-
+ ACUCUAUUUAGAGUGUA 17
181 19067
CFTR-lntronlO-
+ AGGUUAAGUUGUUCUUA 17
182 19068
CFTR-lntronlO-
+ UAUCAACAUGAAGGUUA 17
183 19069
CFTR-lntronlO-
- CUAAGUAUUAGAGGUUA 17
184 19070
CFTR-lntronlO-
+ CUAUUAUUCAACAUUUA 17
185 19071
CFTR-lntronlO-
+ UCU UUACGAGCACUUUA 17
186 19072
CFTR-lntronlO-
+ CAAGCCUGUAUUGUUUA 17
187 19073
CFTR-lntronlO-
+ CU U ACCG U AAU AG CAAC 17
188 19074
CFTR-lntronlO-
+ UCAUCACUUGCCUGAAC 17
189 19075
CFTR-lntronlO-
+ AACCUAUAAGGAAUAAC 17
190 19076
CFTR-lntronlO-
- CUUAUUCUUGUAAUAAC 17
191 19077
CFTR-lntronlO-
- UUUCUGGACUGAGUAAC 17
192 19078
CFTR-lntronlO-
+ UGAAACUCCCCACACAC 17
193 19079
618
5535.1 CFTR-lntronlO-
+ CGUAUUUCAGAAGACAC 17
194 19080
CFTR-lntronlO-
- CAU U U CAACU U AU ACAC 17
195 19081
CFTR-lntronlO-
- UUCUGUUUAAAUAGCAC 17
196 19082
CFTR-lntronlO-
- AUAGAAUUUUGCAUCAC 17
197 19083
CFTR-lntronlO-
- CUGGCAUAGAGUAAGAC 17
198 19084
CFTR-lntronlO-
+ UG U U CU U CAAACCAG AC 17
199 19085
CFTR-lntronlO-
- AGUGCCUAGCACUUGAC 17
200 19086
CFTR-lntronlO-
+ UACAACAGUCUUUAUAC 17
201 19087
CFTR-lntronlO-
- CAAAU U CCAAG ACU U AC 17
202 19088
CFTR-lntronlO-
- CU AAGAA CAACU UAACC 17
203 19089
CFTR-lntronlO-
+ CUACUUCCACUACUACC 17
204 19090
CFTR-lntronlO-
- CUAACACCUACCCUACC 17
205 19091
CFTR-lntronlO-
+ U UACUGUGAAUGGUGCC 17
206 19092
CFTR-lntronlO-
- ACCAAGGUAGCCAAUCC 17
207 19093
CFTR-lntronlO-
+ AAGAGACUCCUGAAUCC 17
208 19094
CFTR-lntronlO-
+ UAUAGCUCUGAUAAUCC 17
209 19095
CFTR-lntronlO-
- AAGACAGCUGGCUAUCC 17
210 19096
CFTR-lntronlO-
+ AUUAGCAAGUGGACUCC 17
211 19097
CFTR-lntronlO-
- UUCUUUUGAUAUACUCC 17
212 19098
CFTR-lntronlO-
- UGCCCUUGACUGAAAGC 17
213 19099
CFTR-lntronlO-
- UAAAUUUGGUGUCAGGC 17
214 19100
619
5535.1 CFTR-lntronlO-
- UAGUGUGAAGAUGGGGC 17
215 19101
CFTR-lntronlO-
+ UCAUGUUAGACAUAUGC 17
216 19102
CFTR-lntronlO-
+ CAAGACUUCACACCUGC 17
217 19103
CFTR-lntronlO-
- AGCAGACCCAAAUCUGC 17
218 19104
CFTR-lntronlO-
+ AUUUAUCUCGAAAUUGC 17
219 19105
CFTR-lntronlO-
+ U U AG U AG AAACCU AAU C 17
220 19106
CFTR-lntronlO-
- UUAGGGAAUGCAGACUC 17
221 19107
CFTR-lntronlO-
- AGCUGUGCAUUU UCCUC 17
222 19108
CFTR-lntronlO-
- ACUAAGGCUUAUUUCUC 17
223 19109
CFTR-lntronlO-
- UAACUUUUCUUAUUGUC 17
224 19110
CFTR-lntronlO-
- ACCAAAACU UUAUUGUC 17
225 19111
CFTR-lntronlO-
- CUGGCUAUCCAGGAUUC 17
226 19112
CFTR-lntronlO-
+ UGACAUCAGUUGGGUUC 17
227 19113
CFTR-lntronlO-
+ UCAAUUGUAUUAGCAAG 17
228 19114
CFTR-lntronlO-
- AGUAGGCUUCCUAUAAG 17
229 19115
CFTR-lntronlO-
+ U UAACCCAUCUAUUAAG 17
230 19116
CFTR-lntronlO-
+ UAUUGGACCAGACACAG 17
231 19117
CFTR-lntronlO-
- CUAGUUUCAAGGAAGAG 17
232 19118
CFTR-lntronlO-
+ UACCAAAUUGUAUUGAG 17
233 19119
CFTR-lntronlO-
+ ACACCAAAU U U AU UG AG 17
234 19120
CFTR-lntronlO-
+ AAAG U UG U CCAAG AU AG 17
235 19121
620
5535.1 CFTR-lntronlO-
+ U UUCCGUGCAUCACUAG 17
236 19122
CFTR-lntronlO-
- CUUGAUCCAGGUAGUAG 17
237 19123
CFTR-lntronlO-
- AUCGGCGGUGGAGGUAG 17
238 19124
CFTR-lntronlO-
- AAGAGAAAGGGGUGUAG 17
239 19125
CFTR-lntronlO-
- UCUCUGGGUGAGAUUAG 17
240 19126
CFTR-lntronlO-
+ AUCAACAUGAAGGUUAG 17
241 19127
CFTR-lntronlO-
- U G U G AG A A A A AG U U U AG 17
242 19128
CFTR-lntronlO-
- AAAUCAGUGCUUUUUCG 17
243 19129
CFTR-lntronlO-
+ CAAUAAUAGAGACAAGG 17
244 19130
CFTR-lntronlO-
- AGUAUUAGAGGUUAAGG 17
245 19131
CFTR-lntronlO-
- U U CAACU U AU ACACAGG 17
246 19132
CFTR-lntronlO-
- AUUAGAGGUUAAGGAGG 17
247 19133
CFTR-lntronlO-
- UACUAACUCAAUCUAGG 17
248 19134
CFTR-lntronlO-
- UCGGCGGUGGAGGUAGG 17
249 19135
CFTR-lntronlO-
- AGAGAAGUAAUCGGCGG 17
250 19136
CFTR-lntronlO-
- CAUAGAGUAAGACAGGG 17
251 19137
CFTR-lntronlO-
+ UUAAGUUGUUCUUAGGG 17
252 19138
CFTR-lntronlO-
- AGGAGCCAAAAAUUGGG 17
253 19139
CFTR-lntronlO-
- AGCCAAAAAUUGGGUGG 17
254 19140
CFTR-lntronlO-
- CUGGUAGUGUGAAGAUG 17
255 19141
CFTR-lntronlO-
- UAUCAAUAUCUAAGAUG 17
256 19142
621
5535.1 CFTR-lntronlO-
+ AUCUGUUAGUAAUGCUG 17
257 19143
CFTR-lntronlO-
- UUAAGGGCAUAGCUCUG 17
258 19144
CFTR-lntronlO-
+ AACUCAGUACCAUAGUG 17
259 19145
CFTR-lntronlO-
+ CUGU UAGUAAUGCUGUG 17
260 19146
CFTR-lntronlO-
- CAUCUCACCAGUGUGUG 17
261 19147
CFTR-lntronlO-
- CUCUCU UUUAACUAUUG 17
262 19148
CFTR-lntronlO-
+ UGAGUGGAAAUUUUUUG 17
263 19149
CFTR-lntronlO-
- U U U C AG G AG C C A A A A A U 17
264 19150
CFTR-lntronlO-
+ ACCAUUAUCUACACAAU 17
265 19151
CFTR-lntronlO-
- AUGGGCUAAAGGGCAAU 17
266 19152
CFTR-lntronlO-
- CUU UCUAGUAUUAGAAU 17
267 19153
CFTR-lntronlO-
+ AUGGCAUGAGUACGAAU 17
268 19154
CFTR-lntronlO-
+ CCUAGAUGAUUAUUAAU 17
269 19155
CFTR-lntronlO-
- UUUUCCUCUUAAUAGAU 17
270 19156
CFTR-lntronlO-
+ AAAAAAGUUACCUGGAU 17
271 19157
CFTR-lntronlO-
+ UUAUCCAUUAAUCCUAU 17
272 19158
CFTR-lntronlO-
+ AAUGCUUGACCACUUAU 17
273 19159
CFTR-lntronlO-
- UCCCUGU UAUUCCUUAU 17
274 19160
CFTR-lntronlO-
+ ACAACAGUCUUUAUACU 17
275 19161
CFTR-lntronlO-
+ UUGCUUCACCUGCUACU 17
276 19162
CFTR-lntronlO-
+ AUCUUAUAGAGAUUACU 17
277 19163
622
5535.1 CFTR-lntronlO-
+ UUUUGAGCCUAUCACCU 17
278 19164
CFTR-lntronlO-
+ ACCUGGAUUGGCUACCU 17
279 19165
CFTR-lntronlO-
+ CACU UGUUGACAGUCCU 17
280 19166
CFTR-lntronlO-
+ ACU CAG U CC AG AAAG C U 17
281 19167
CFTR-lntronlO-
+ ACUCAUAAGGGACCGCU 17
282 19168
CFTR-lntronlO-
- AAAUUUGGUGUCAGGCU 17
283 19169
CFTR-lntronlO-
+ AGCCUAUCACCUAGGCU 17
284 19170
CFTR-lntronlO-
+ UAUACCUGUCAAGUGCU 17
285 19171
CFTR-lntronlO-
- CCUAU UAAUAAUCAUCU 17
286 19172
CFTR-lntronlO-
- UAGGGAAUGCAGACUCU 17
287 19173
CFTR-lntronlO-
+ UAGAGAGAAACAUCUCU 17
288 19174
CFTR-lntronlO-
- CUAAGGCUUAUUUCUCU 17
289 19175
CFTR-lntronlO-
+ UAAUUGCCAGUAAGUCU 17
290 19176
CFTR-lntronlO-
+ AUUUUCUCGGUAUUUCU 17
291 19177
CFTR-lntronlO-
- AUUUUUGACUAUACAGU 17
292 19178
CFTR-lntronlO-
+ U UCUGCU UGACAUCAGU 17
293 19179
CFTR-lntronlO-
+ ACCAAAUUGUAUUGAGU 17
294 19180
CFTR-lntronlO-
+ AAGUUGUCCAAGAUAGU 17
295 19181
CFTR-lntronlO-
- CAAAU AG AG AUG U U AG U 17
296 19182
CFTR-lntronlO-
+ UGUGAAUGGUGCCAGGU 17
297 19183
CFTR-lntronlO-
- UAAUCGGCGGUGGAGGU 17
298 19184
623
5535.1 CFTR-lntronlO-
- UGAUGGUAUUGCAGGGU 17
299 19185
CFTR-lntronlO-
+ AUGGUGCCAGGUAGGGU 17
300 19186
CFTR-lntronlO-
+ UAAGUUGUUCUUAGGGU 17
301 19187
CFTR-lntronlO-
- UUGACUAUACAGUGGGU 17
302 19188
CFTR-lntronlO-
+ AAAGCUGUUUCGUAUGU 17
303 19189
CFTR-lntronlO-
+ UCUGUUAGUAAUGCUGU 17
304 19190
CFTR-lntronlO-
- AGCAGUGCUGCUGCUGU 17
305 19191
CFTR-lntronlO-
- UU UUUAGGCUAU UCUGU 17
306 19192
CFTR-lntronlO-
- U U C AG G AG C C A A A A A U U 17
307 19193
CFTR-lntronlO-
- ACCCACU CAAU ACAAU U 17
308 19194
CFTR-lntronlO-
- AUGCUAAUAAUACAAUU 17
309 19195
CFTR-lntronlO-
- AAUAUCACCAACUCAU U 17
310 19196
CFTR-lntronlO-
+ AUCUCUGCAAACAUAU U 17
311 19197
CFTR-lntronlO-
- ACUUAACCUGGCAUAUU 17
312 19198
CFTR-lntronlO-
+ CAACUAACAUCUCUAUU 17
313 19199
CFTR-lntronlO-
- UGCCUU UUAGUAGUAU U 17
314 19200
CFTR-lntronlO-
+ CAAUGGUUGUCUGUAU U 17
315 19201
CFTR-lntronlO-
+ AUACUUAGAAUGCCCUU 17
316 19202
CFTR-lntronlO-
- UUGCAGGGUGGGGCCU U 17
317 19203
CFTR-lntronlO-
- AUGUGCAAAAAUAGCUU 17
318 19204
CFTR-lntronlO-
+ CAGGUUAAGUUGUUCU U 17
319 19205
624
5535.1 CFTR-lntronlO-
- U U AG U U AGCAU AAAG U U 17
320 19206
CFTR-lntronlO-
+ UCUGCUUGACAUCAGUU 17
321 19207
CFTR-lntronlO-
+ U U AU CAACAUG AAGG U U 17
322 19208
CFTR-lntronlO-
- AGUGCUUUUUCGAGGU U 17
323 19209
CFTR-lntronlO-
- UUGGAUGGAGCUUGGUU 17
324 19210
CFTR-lntronlO-
+ UUCAUGGAAAGCUUGU U 17
325 19211
CFTR-lntronlO-
- UUGUGUACUUGUGAUU U 17
326 19212
CFTR-lntronlO-
- UAUGCACUCUUUGCU UU 17
327 19213
CFTR-lntronlO-
+ UCCUGACAAUAAAGUUU 17
328 19214
CFTR-lntronlO-
- UGGAUGGAGCUUGGUUU 17
329 19215
CFTR-lntronlO-
- AGAGCUAUAUUGUGUU U 17
330 19216
CFTR-lntronlO-
+ CUCCCCCACCCAAUUUU 17
331 19217
CFTR-lntronlO-
+ CAGAGCUAUGCCCUUAAAAA 20
332 19218
CFTR-lntronlO-
- UGCU UCAGAAGUCUAUAAAA 20
333 19219
CFTR-lntronlO-
- AUAAUCAUCUAGGCUGCAAA 20
334 19220
CFTR-lntronlO-
+ C AG C U A A A A U G AC A A U C A A A 20
335 19221
CFTR-lntronlO-
- CGUGUUAUUCAGCCAAUAAA 20
336 19222
CFTR-lntronlO-
- CUAACCUUCAUGUUGAUAAA 20
337 19223
CFTR-lntronlO-
+ CCAUUCCUAAUACUACUAAA 20
338 19224
CFTR-lntronlO-
- UAGUAUUAGAAUGGGCUAAA 20
339 19225
CFTR-lntronlO-
+ CCCAUUAUCUUUCUAGUAAA 20
340 19226
625
5535.1 CFTR-lntronlO-
- UUAAUGGAUAAGUUGAACAA 20
341 19227
CFTR-lntronlO-
+ U UUUACCAUUAUCUACACAA 20
342 19228
CFTR-lntronlO-
- CUAGGUUUAAUUUUGUACAA 20
343 19229
CFTR-lntronlO-
+ AAGUGUUUAAAUAUUCCCAA 20
344 19230
CFTR-lntronlO-
+ U C A A A AG A A U A AG G C A U C A A 20
345 19231
CFTR-lntronlO-
+ AUAAGCCAGCUUUCAGUCAA 20
346 19232
CFTR-lntronlO-
- CCAACUGAUGUCAAGCAGAA 20
347 19233
CFTR-lntronlO-
- AGAGCUUUCUAGUAU UAGAA 20
348 19234
CFTR-lntronlO-
+ CUAAAACUGAGUAGAAGGAA 20
349 19235
CFTR-lntronlO-
- CCUUUUAGUAGUAUUAGGAA 20
350 19236
CFTR-lntronlO-
- AAUUAAGAAAGACUCCUGAA 20
351 19237
CFTR-lntronlO-
- AGUGGCCUUUAAACAUUGAA 20
352 19238
CFTR-lntronlO-
- AAUG U AG U AU U AAACCAU AA 20
353 19239
CFTR-lntronlO-
+ CUAAAGCAAAGAGUGCAUAA 20
354 19240
CFTR-lntronlO-
- AUAACCCAUUGUGUAGAUAA 20
355 19241
CFTR-lntronlO-
- CCUAACCU UCAUGUUGAUAA 20
356 19242
CFTR-lntronlO-
- AUUUUGGUGUAGUUCUAUAA 20
357 19243
CFTR-lntronlO-
- UU UGACCUAAGAUAUCCUAA 20
358 19244
CFTR-lntronlO-
- CUAGUAUUAGAAUGGGCUAA 20
359 19245
CFTR-lntronlO-
+ UUGGGUAACAAUAAUAUUAA 20
360 19246
CFTR-lntronlO-
+ AAUUCAACUUUAUCUGUUAA 20
361 19247
626
5535.1 CFTR-lntronlO-
- AGUUAGCAAUGGUCUAAACA 20
362 19248
CFTR-lntronlO-
+ AUGACAAUCAAAUGGGAACA 20
363 19249
CFTR-lntronlO-
+ AGAACCUAUAAGGAAUAACA 20
364 19250
CFTR-lntronlO-
- AG U U U U AAACAG AAG U AACA 20
365 19251
CFTR-lntronlO-
- UGCAUUCCCUCAUCCAACCA 20
366 19252
CFTR-lntronlO-
+ UACUAAAGACUUCACCCUCA 20
367 19253
CFTR-lntronlO-
+ CAUAAGCCAGCUUUCAGUCA 20
368 19254
CFTR-lntronlO-
+ UAAAUCUAAAAGCUAAUUCA 20
369 19255
CFTR-lntronlO-
+ ACGAAUUGG UACAAAU U U CA 20
370 19256
CFTR-lntronlO-
- AUAAGAUUCU A AAG G A A AG A 20
371 19257
CFTR-lntronlO-
- AAGUCUAGUUUCAAGGAAGA 20
372 19258
CFTR-lntronlO-
- CCCAACUGAUGUCAAGCAGA 20
373 19259
CFTR-lntronlO-
+ ACUGACUAAAACUGAGUAGA 20
374 19260
CFTR-lntronlO-
+ UGGCUACCUUGGUUGGAUGA 20
375 19261
CFTR-lntronlO-
- CC AG U U CAG G CAAG U G A U G A 20
376 19262
CFTR-lntronlO-
- CUUAUGAAAAGCAGCUAUGA 20
377 19263
CFTR-lntronlO-
- UUGUUAAAGAAUGACUGUGA 20
378 19264
CFTR-lntronlO-
+ AGGGUCUCUCUAAGGUGUGA 20
379 19265
CFTR-lntronlO-
- AACCGGUGUCUUCUGAAAUA 20
380 19266
CFTR-lntronlO-
+ AGGAGUAUAU C A A A AG A A U A 20
381 19267
CFTR-lntronlO-
+ AGUCCUCUGUGCUU UGAAUA 20
382 19268
627
5535.1 CFTR-lntronlO-
- CCCAUAAAUGUUGAAUAAUA 20
383 19269
CFTR-lntronlO-
+ AGCCUAGAUGAUUAUUAAUA 20
384 19270
CFTR-lntronlO-
- UAUUGAUCAUUGCCUCACUA 20
385 19271
CFTR-lntronlO-
- UAAAGUGCUCGUAAAGACUA 20
386 19272
CFTR-lntronlO-
- CUUUGACCUAAGAUAUCCUA 20
387 19273
CFTR-lntronlO-
+ UGAGCCUAUCACCUAGGCUA 20
388 19274
CFTR-lntronlO-
- AGUAAUCGGCGGUGGAGGUA 20
389 19275
CFTR-lntronlO-
- UGUUUUUAGGCUAUUCUGUA 20
390 19276
CFTR-lntronlO-
+ AGCACUCUAUUUAGAGUGUA 20
391 19277
CFTR-lntronlO-
- UAAGAAGAGAAAGGGGUGUA 20
392 19278
CFTR-lntronlO-
+ CAAUUAGUUUUAUGCCAUUA 20
393 19279
CFTR-lntronlO-
- UUGCAGGAGGUGAGGGAUUA 20
394 19280
CFTR-lntronlO-
- CUUGACUGAAAGCUGGCUUA 20
395 19281
CFTR-lntronlO-
+ CUU UAUCAACAUGAAGGUUA 20
396 19282
CFTR-lntronlO-
- AUUCUAAGUAUUAGAGGUUA 20
397 19283
CFTR-lntronlO-
+ CCCCUAUUAUUCAACAUUUA 20
398 19284
CFTR-lntronlO-
+ UAGUCUUUACGAGCACUUUA 20
399 19285
CFTR-lntronlO-
- AGAAAGAUAAUGGGAGAAAC 20
400 19286
CFTR-lntronlO-
+ UACGAUAUAAGAAAUGAAAC 20
401 19287
CFTR-lntronlO-
+ UUCGUAUGUAGGAAAACAAC 20
402 19288
CFTR-lntronlO-
+ CAGAACCUAUAAGGAAUAAC 20
403 19289
628
5535.1 CFTR-lntronlO-
- UAGCUUAUUCUUGUAAUAAC 20
404 19290
CFTR-lntronlO-
- AUGAAACUGUUAUAAUUAAC 20
405 19291
CFTR-lntronlO-
+ CUCCGUAUUUCAGAAGACAC 20
406 19292
CFTR-lntronlO-
- UAUCAUUUCAACU UAUACAC 20
407 19293
CFTR-lntronlO-
+ UUAGUAUUAAGUAUAGCCAC 20
408 19294
CFTR-lntronlO-
- UGGGUGAGAUUAGAGGCCAC 20
409 19295
CFTR-lntronlO-
- UGAUUCUGUU UAAAUAGCAC 20
410 19296
CFTR-lntronlO-
- AGUAUAGAAUUUUGCAUCAC 20
411 19297
CFTR-lntronlO-
- AGGCUGGCAUAGAGUAAGAC 20
412 19298
CFTR-lntronlO-
+ UACUGUUCU UCAAACCAGAC 20
413 19299
CFTR-lntronlO-
+ UGUUACAACAGUCUUUAUAC 20
414 19300
CFTR-lntronlO-
- AUUGAUGAGCAGAUAAUUAC 20
415 19301
CFTR-lntronlO-
- UUACAAAU UCCAAGACU U AC 20
416 19302
CFTR-lntronlO-
+ UACAAAUAUUGACUAUUUAC 20
417 19303
CFTR-lntronlO-
- ACCCUAAGAACAACUUAACC 20
418 19304
CFTR-lntronlO-
+ AUACUACUUCCACUACUACC 20
419 19305
CFTR-lntronlO-
- ACACUAACACCUACCCUACC 20
420 19306
CFTR-lntronlO-
+ AG AU ACU AAAAAAAG U U ACC 20
421 19307
CFTR-lntronlO-
+ UCU UUACUGUGAAUGGUGCC 20
422 19308
CFTR-lntronlO-
- CCAACCAAGGUAGCCAAUCC 20
423 19309
CFTR-lntronlO-
+ CAAUAUAGCUCUGAUAAUCC 20
424 19310
629
5535.1 CFTR-lntronlO-
- AGUGAAUGAAUGUGGUAUCC 20
425 19311
CFTR-lntronlO-
+ UGUAUUAGCAAGUGGACUCC 20
426 19312
CFTR-lntronlO-
+ CUUGACAUCAGU UGGGUUCC 20
427 19313
CFTR-lntronlO-
- AGUAAGGAGGUCACUGAGGC 20
428 19314
CFTR-lntronlO-
- AGUUUCAAGGAAGAGGGGGC 20
429 19315
CFTR-lntronlO-
- UGGUAGUGUGAAGAUGGGGC 20
430 19316
CFTR-lntronlO-
+ U UGGUUGGAUGAGGGAAUGC 20
431 19317
CFTR-lntronlO-
+ UUUUCAUGUUAGACAUAUGC 20
432 19318
CFTR-lntronlO-
+ AGUGCUAUUUAAACAGAAUC 20
433 19319
CFTR-lntronlO-
- AAAAGCUGUGCAUUUUCCUC 20
434 19320
CFTR-lntronlO-
- AAGACUAAGGCUUAUUUCUC 20
435 19321
CFTR-lntronlO-
- UGGGACUGACUAUACCUGUC 20
436 19322
CFTR-lntronlO-
+ AAUAGAGACAAGGUGGUGUC 20
437 19323
CFTR-lntronlO-
- CACUCAAUAAAUUUGGUGUC 20
438 19324
CFTR-lntronlO-
- UUCUAACUUU UCUUAU UGUC 20
439 19325
CFTR-lntronlO-
- AGGACCAAAACUUUAUUGUC 20
440 19326
CFTR-lntronlO-
- CAGCUGGCUAUCCAGGAUUC 20
441 19327
CFTR-lntronlO-
+ UAUUAAGAGGAAAAGACUUC 20
442 19328
CFTR-lntronlO-
+ UACGAAUUGGUACAAAUUUC 20
443 19329
CFTR-lntronlO-
- CUUACUGGCAAUUAAAUUUC 20
444 19330
CFTR-lntronlO-
+ UUGAUAAAUAAUUGCCUUUC 20
445 19331
630
5535.1 CFTR-lntronlO-
+ CCUAAAAACAUUAGCCAAAG 20
446 19332
CFTR-lntronlO-
+ UAGGAUAUCUUAGGUCAAAG 20
447 19333
CFTR-lntronlO-
+ UAGGGUGGGAUAUGGAGAAG 20
448 19334
CFTR-lntronlO-
- CAAGUCUAGUUUCAAGGAAG 20
449 19335
CFTR-lntronlO-
- UUUCCAUAUUCAAAGCACAG 20
450 19336
CFTR-lntronlO-
+ ACAGCUAAAGUAUUACCCAG 20
451 19337
CFTR-lntronlO-
- AGUCUAUAUUUGUUUUCCAG 20
452 19338
CFTR-lntronlO-
+ UGCUAUUUAAACAGAAUCAG 20
453 19339
CFTR-lntronlO-
+ AUAUUGUUACAUAAAAAGAG 20
454 19340
CFTR-lntronlO-
- AG U CU AG U U U CAAGG AAG AG 20
455 19341
CFTR-lntronlO-
+ AAUUACCAAAUUGUAUUGAG 20
456 19342
CFTR-lntronlO-
+ CUGACACCAAAUUUAU UGAG 20
457 19343
CFTR-lntronlO-
- CCAUAAAUGUUGAAUAAUAG 20
458 19344
CFTR-lntronlO-
+ UGGAAAGUUGUCCAAGAUAG 20
459 19345
CFTR-lntronlO-
+ ACUUUUCCGUGCAUCACUAG 20
460 19346
CFTR-lntronlO-
- UGGCUUGAUCCAGGUAGUAG 20
461 19347
CFTR-lntronlO-
- AUUUCUCUGGGUGAGAUUAG 20
462 19348
CFTR-lntronlO-
- AAGGGCAUUCUAAGUAUUAG 20
463 19349
CFTR-lntronlO-
- AGCUAUGAAGGCAGAGUUAG 20
464 19350
CFTR-lntronlO-
+ U UUAUCAACAUGAAGGUUAG 20
465 19351
CFTR-lntronlO-
- AUAAAAUCAGUGCUUUUUCG 20
466 19352
631
5535.1 CFTR-lntronlO-
- CUAAGUAUUAGAGGUUAAGG 20
467 19353
CFTR-lntronlO-
- CAU U U CAACU U AU ACACAGG 20
468 19354
CFTR-lntronlO-
+ U UGUUACAUAAAAAGAGAGG 20
469 19355
CFTR-lntronlO-
- AGUAUUAGAGGUUAAGGAGG 20
470 19356
CFTR-lntronlO-
- UAAUCGGCGGUGGAGGUAGG 20
471 19357
CFTR-lntronlO-
- ACUGUCAGAGAAGUAAUCGG 20
472 19358
CFTR-lntronlO-
- AUUCUGUAGGGAGACAAGGG 20
473 19359
CFTR-lntronlO-
- UGGCAUAGAGUAAGACAGGG 20
474 19360
CFTR-lntronlO-
+ AGGUUAAGUUGUUCUUAGGG 20
475 19361
CFTR-lntronlO-
- UUCAGGAGCCAAAAAUUGGG 20
476 19362
CFTR-lntronlO-
- AGAGAAGUAAUCGGCGGUGG 20
477 19363
CFTR-lntronlO-
- AGGAGCCAAAAAUUGGGUGG 20
478 19364
CFTR-lntronlO-
- ACAAAGCUAGUGAAUGAAUG 20
479 19365
CFTR-lntronlO-
- AUUUAUCAAUAUCUAAGAUG 20
480 19366
CFTR-lntronlO-
+ U UGGCUACCUUGGUUGGAUG 20
481 19367
CFTR-lntronlO-
+ CCUAUUAUUCAACAUUUAUG 20
482 19368
CFTR-lntronlO-
+ CACGAAUAUAUUCUU UUAUG 20
483 19369
CFTR-lntronlO-
- UUUGAUUGUCAUUUUAGCUG 20
484 19370
CFTR-lntronlO-
+ AUCAUCUGUUAGUAAUGCUG 20
485 19371
CFTR-lntronlO-
- UUUUUAAGGGCAUAGCUCUG 20
486 19372
CFTR-lntronlO-
+ AAGGAAAUGGGGUAUAAGUG 20
487 19373
632
5535.1 CFTR-lntronlO-
+ UAAAACUCAGUACCAUAGUG 20
488 19374
CFTR-lntronlO-
- CAGGAGCCAAAAAUUGGGUG 20
489 19375
CFTR-lntronlO-
+ CAUCUGUUAGUAAUGCUGUG 20
490 19376
CFTR-lntronlO-
- UAUGGCAUCUCACCAGUGUG 20
491 19377
CFTR-lntronlO-
- UGGCAUCUCACCAGUGUGUG 20
492 19378
CFTR-lntronlO-
- UACGGUAAGCUCAAGCAUUG 20
493 19379
CFTR-lntronlO-
- UUGGUAUUUACCAUAUAUUG 20
494 19380
CFTR-lntronlO-
- UUGCUCUCUUUUAACUAUUG 20
495 19381
CFTR-lntronlO-
+ UAUUGAGUGGAAAUUU UUUG 20
496 19382
CFTR-lntronlO-
- UGCUUUCAGGAG CCA A A A A U 20
497 19383
CFTR-lntronlO-
+ AG C U A A A A U G AC A A U C A A A U 20
498 19384
CFTR-lntronlO-
- AGAAUGGGCUAAAGGGCAAU 20
499 19385
CFTR-lntronlO-
+ UGUAUGGCAUGAGUACGAAU 20
500 19386
CFTR-lntronlO-
- CCG U U U ACU AG AAAG AU AAU 20
501 19387
CFTR-lntronlO-
- AAUACUGU CAG AG AAG U AAU 20
502 19388
CFTR-lntronlO-
+ CAGCCUAGAUGAUUAU UAAU 20
503 19389
CFTR-lntronlO-
- C A AG U G C A A AG CUUUCAGAU 20
504 19390
CFTR-lntronlO-
+ CUAAAAAAAGUUACCUGGAU 20
505 19391
CFTR-lntronlO-
+ UCU UUGUGUUAACAAAAUAU 20
506 19392
CFTR-lntronlO-
+ AACUUAUCCAUUAAUCCUAU 20
507 19393
CFTR-lntronlO-
+ ACAAAUGCUUGACCACU UAU 20
508 19394
633
5535.1 CFTR-lntronlO-
+ CCCUAU UAUUCAACAUU UAU 20
509 19395
CFTR-lntronlO-
+ U U CU U U AACAAACCU U U U AU 20
510 19396
CFTR-lntronlO-
- AGCUUAUUCUUGUAAUAACU 20
511 19397
CFTR-lntronlO-
+ CACUUGCU UCACCUGCUACU 20
512 19398
CFTR-lntronlO-
+ AAAAUCUUAUAGAGAUUACU 20
513 19399
CFTR-lntronlO-
+ UUUUUUUGAGCCUAUCACCU 20
514 19400
CFTR-lntronlO-
- AGAGGAAGGCAGUGGUCCCU 20
515 19401
CFTR-lntronlO-
+ AGGCACUUGUUGACAGUCCU 20
516 19402
CFTR-lntronlO-
- AACAGGUUUUGGAUGGAGCU 20
517 19403
CFTR-lntronlO-
+ AAAACUCAUAAGGGACCGCU 20
518 19404
CFTR-lntronlO-
- AAUAAAUUUGGUGUCAGGCU 20
519 19405
CFTR-lntronlO-
+ U UGAGCCUAUCACCUAGGCU 20
520 19406
CFTR-lntronlO-
- UUCAAAUUAUUUCUACUGCU 20
521 19407
CFTR-lntronlO-
+ UAAUAUACCUGUCAAGUGCU 20
522 19408
CFTR-lntronlO-
- UCCCCUAUUAAUAAUCAUCU 20
523 19409
CFTR-lntronlO-
- UCUUGCU UUUCCCACUAUCU 20
524 19410
CFTR-lntronlO-
- AGACUAAGGCUUAUUUCUCU 20
525 19411
CFTR-lntronlO-
+ AUUUAAUUGCCAGUAAGUCU 20
526 19412
CFTR-lntronlO-
+ AAUAAUUUGAACAACAUUCU 20
527 19413
CFTR-lntronlO-
- UAUGUGAAAAUAUCACUUCU 20
528 19414
CFTR-lntronlO-
+ CCCUUCUGCU UGACAUCAGU 20
529 19415
634
5535.1 CFTR-lntronlO-
+ AGUCAGUUUUAUUU UUCAGU 20
530 19416
CFTR-lntronlO-
+ UGUACAUUUUCCUAAUGAGU 20
531 19417
CFTR-lntronlO-
+ AUUACCAAAUUGUAUUGAGU 20
532 19418
CFTR-lntronlO-
- AGUAGUGGAAGUAGUAUAGU 20
533 19419
CFTR-lntronlO-
+ UACUGUGAAUGGUGCCAGGU 20
534 19420
CFTR-lntronlO-
+ UGUUACAUAAAAAGAGAGGU 20
535 19421
CFTR-lntronlO-
- AAGUAAUCGGCGGUGGAGGU 20
536 19422
CFTR-lntronlO-
- UCAGGAGCCAAAAAUUGGGU 20
537 19423
CFTR-lntronlO-
+ CCUGGAUUGGCUACCUUGGU 20
538 19424
CFTR-lntronlO-
+ U UAAAAGCUGUUUCGUAUGU 20
539 19425
CFTR-lntronlO-
+ UCAUCUGUUAGUAAUGCUGU 20
540 19426
CFTR-lntronlO-
- AUGUUUUUAGGCUAUUCUGU 20
541 19427
CFTR-lntronlO-
- AUGGCAUCUCACCAGUGUGU 20
542 19428
CFTR-lntronlO-
- CUUACCCACUCAAUACAAUU 20
543 19429
CFTR-lntronlO-
- AAAAAUAUCACCAACUCAUU 20
544 19430
CFTR-lntronlO-
+ AAGAUCUCUGCAAACAUAUU 20
545 19431
CFTR-lntronlO-
- ACAACUUAACCUGGCAUAUU 20
546 19432
CFTR-lntronlO-
+ AUCCAACUAACAUCUCUAUU 20
547 19433
CFTR-lntronlO-
+ CAUCAAUGGUUGUCUGUAUU 20
548 19434
CFTR-lntronlO-
- CAGAAGUAACAGGGCCACUU 20
549 19435
CFTR-lntronlO-
- AUAGAUUAGCUUAUAUACUU 20
550 19436
635
5535.1 CFTR-lntronlO-
+ CUAAUACUUAGAAUGCCCUU 20
551 19437
CFTR-lntronlO-
- UAGAUGUGCAAAAAUAGCUU 20
552 19438
CFTR-lntronlO-
+ UGCCAGGUUAAGUUGUUCUU 20
553 19439
CFTR-lntronlO-
+ CCUUCUGCUUGACAUCAGUU 20
554 19440
CFTR-lntronlO-
+ CCUUUAUCAACAUGAAGGUU 20
555 19441
CFTR-lntronlO-
- AUCAGUGCUUUUUCGAGGUU 20
556 19442
CFTR-lntronlO-
+ UAAUUCAUGGAAAGCUUGUU 20
557 19443
CFTR-lntronlO-
- CAUUUGUGUACUUGUGAUUU 20
558 19444
CFTR-lntronlO-
+ AGAUCUCUGCAAACAUAUUU 20
559 19445
CFTR-lntronlO-
- CUUUAUGCACUCUUUGCUUU 20
560 19446
CFTR-lntronlO-
+ UUCUCCUGACAAUAAAGUUU 20
561 19447
CFTR-lntronlO-
- AUAAUGGGAGAAACAGGUUU 20
562 19448
CFTR-lntronlO-
- UUUUGGAUGGAGCUUGGUUU 20
563 19449
CFTR-lntronlO-
- AUCAGAGCUAUAUUGUGUUU 20
564 19450
CFTR-lntronlO-
- CCACUUUGGCUAAUGUUUUU 20
565 19451
Table 40C provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within intron 10 and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 40C
Figure imgf000637_0001
636
5535.1 Length
CFTR-lntronlO-
+ GACCAUCCCGGCUAAAA 17
566 19452
CFTR-lntronlO-
- G U UG AU AAG AAG AG AAA 17
567 19453
CFTR-lntronlO-
- GAUGUUUAUUUAUGAAA 17
568 19454
CFTR-lntronlO-
- GUUAUUCAGCCAAUAAA 17
569 19455
CFTR-lntronlO-
- GGUUUAAUUUUGUACAA 17
570 19456
CFTR-lntronlO-
+ GACUAAUCACCUCCCAA 17
571 19457
CFTR-lntronlO-
+ GUUCUCACAUGGCAGAA 17
572 19458
CFTR-lntronlO-
- GGUUGAUAAGAAGAGAA 17
573 19459
CFTR-lntronlO-
+ GAGGGAAUGCAGGAGAA 17
574 19460
CFTR-lntronlO-
+ GGGAGGCUGAAGCGGAA 17
575 19461
CFTR-lntronlO-
+ GGAUUUCAACAUAUGAA 17
576 19462
CFTR-lntronlO-
+ GGUAACAAUAAUAUUAA 17
577 19463
CFTR-lntronlO-
- GACCAGCGUGGGCAACA 17
578 19464
CFTR-lntronlO-
+ GUACAGUGGUGCAAUCA 17
579 19465
CFTR-lntronlO-
- GAAGGAAGGAAGUAAGA 17
580 19466
CFTR-lntronlO-
- G A A AG C A A UAGUAGAGA 17
581 19467
CFTR-lntronlO-
- GUAGGAGGAAGGAAGGA 17
582 19468
CFTR-lntronlO-
- GGAAGUAGGAGGAAGGA 17
583 19469
CFTR-lntronlO-
- GAAAAAGAAAGAGAGGA 17
584 19470
CFTR-lntronlO-
- GAAAGGAAGUAGGAGGA 17
585 19471
CFTR-lntronlO-
+ GUCCCAGCUACUUGGGA 17
586 19472
637
5535.1 CFTR-lntronlO-
- GUAUUCUAUCAUAUGGA 17
587 19473
CFTR-lntronlO-
- G AG AAACAGG U U U UGG A 17
588 19474
CFTR-lntronlO-
- GU UCAGGCAAGUGAUGA 17
589 19475
CFTR-lntronlO-
+ GGGUGAGGGUCUCUCUA 17
590 19476
CFTR-lntronlO-
+ GUGAAUGGUGCCAGGUA 17
591 19477
CFTR-lntronlO-
- GAAGAGAAAGGGGUGUA 17
592 19478
CFTR-lntronlO-
+ G AAAAAAAAU U CAAAAC 17
593 19479
CFTR-lntronlO-
+ GAUAUAAGAAAUGAAAC 17
594 19480
CFTR-lntronlO-
- GUAUUUUUAGUAGAGAC 17
595 19481
CFTR-lntronlO-
+ GGAGAAUGGCGUGAACC 17
596 19482
CFTR-lntronlO-
+ GAGAAUGGCGUGAACCC 17
597 19483
CFTR-lntronlO-
+ GUCUCACUCUGUCACCC 17
598 19484
CFTR-lntronlO-
- GUCUUACUCUGUCACCC 17
599 19485
CFTR-lntronlO-
+ GAGAAUUGCUUGAGCCC 17
600 19486
CFTR-lntronlO-
- GUCUCGCUCUGUCGCCC 17
601 19487
CFTR-lntronlO-
+ GCCACUGCACUCCAGCC 17
602 19488
CFTR-lntronlO-
+ GGAGAAUUGCUUGAGCC 17
603 19489
CFTR-lntronlO-
- GCCACUGCACUCUAGCC 17
604 19490
CFTR-lntronlO-
+ GUUUCACUGUGUUAGCC 17
605 19491
CFTR-lntronlO-
- GUUUCACCGUUUUAGCC 17
606 19492
CFTR-lntronlO-
- GCGCCCGCCACUACGCC 17
607 19493
638
5535.1 CFTR-lntronlO-
- GCGUGAGCCACCGCGCC 17
608 19494
CFTR-lntronlO-
- GU UUCACCAUGUUGGCC 17
609 19495
CFTR-lntronlO-
- GGAGAUCAAGACCAUCC 17
610 19496
CFTR-lntronlO-
+ GGAGAUCGAGACCAUCC 17
611 19497
CFTR-lntronlO-
- GUGAAUUGCUUGAGUCC 17
612 19498
CFTR-lntronlO-
- GGU UUCACCGUUUUAGC 17
613 19499
CFTR-lntronlO-
- GGCUGGAGUGCAGUGGC 17
614 19500
CFTR-lntronlO-
+ GCACCCGCCAUCACGUC 17
615 19501
CFTR-lntronlO-
+ GGGCGGAUCACGAGGUC 17
616 19502
CFTR-lntronlO-
- GCAUGAGCCACUGUGUC 17
617 19503
CFTR-lntronlO-
+ GGUGGGAUAUGGAGAAG 17
618 19504
CFTR-lntronlO-
+ G U A A U AG C A AC AG G A AG 17
619 19505
CFTR-lntronlO-
- GAUUUUUGACUAUACAG 17
620 19506
CFTR-lntronlO-
- GAGUUAGAGGAAGGCAG 17
621 19507
CFTR-lntronlO-
+ GU UUGUGUUUUUUGUAG 17
622 19508
CFTR-lntronlO-
+ GAGGCGGGCGGAUCACG 17
623 19509
CFTR-lntronlO-
- GAGUCAAAAAUUAUACG 17
624 19510
CFTR-lntronlO-
- GGAGUUUGAGACCAGCG 17
625 19511
CFTR-lntronlO-
- GAACAAAGACUUGCAGG 17
626 19512
CFTR-lntronlO-
+ GGCGUGAACCCGGGAGG 17
627 19513
CFTR-lntronlO-
- G G A AG A A AG G A AG U AG G 17
628 19514
639
5535.1 CFTR-lntronlO-
- GUGAUGGUAUUGCAGGG 17
629 19515
CFTR-lntronlO-
- GAAGAAAGAAGGAAAUG 17
630 19516
CFTR-lntronlO-
- GAGGUGAUUAGUCCAUG 17
631 19517
CFTR-lntronlO-
+ GAGGCAGGCAGAUCAUG 17
632 19518
CFTR-lntronlO-
+ GAAUAUAUUCUUUUAUG 17
633 19519
CFTR-lntronlO-
+ G U AG C A A A U G A U A A A A U 17
634 19520
CFTR-lntronlO-
- GU UUACUAACUCAAUCU 17
635 19521
CFTR-lntronlO-
+ GUGCAGUGGCGCGAUCU 17
636 19522
CFTR-lntronlO-
- GCACAGUGGUGCGAUCU 17
637 19523
CFTR-lntronlO-
- GUGCAGUGGCGGGAUCU 17
638 19524
CFTR-lntronlO-
- GCUGUGCAUUUUCCUCU 17
639 19525
CFTR-lntronlO-
- GAGUUUGAGACCAGCGU 17
640 19526
CFTR-lntronlO-
+ GUGUUUUUUGUAGAGGU 17
641 19527
CFTR-lntronlO-
- GUACUACUGUAAUAAUU 17
642 19528
CFTR-lntronlO-
- GCAGGAGGUGAGGGAUU 17
643 19529
CFTR-lntronlO-
- GUUAUCUCUGAAAUUU U 17
644 19530
CFTR-lntronlO-
+ GAAUGCAGGAGAAUGGAAAA 20
645 19531
CFTR-lntronlO-
+ GUGUUCUCACAUGGCAGAAA 20
646 19532
CFTR-lntronlO-
+ GCAUCACGUGGUGUUU UAAA 20
647 19533
CFTR-lntronlO-
+ GGGAGGCUGAGGCAGGAGAA 20
648 19534
CFTR-lntronlO-
+ GAUGAGGGAAUGCAGGAGAA 20
649 19535
640
5535.1 CFTR-lntronlO-
- GGGAGACAAGGGAGGAAGCA 20
650 19536
CFTR-lntronlO-
+ GGCUGGGAAGUCCAAGAUCA 20
651 19537
CFTR-lntronlO-
- GAAGUAGGAGGAAGGAAGGA 20
652 19538
CFTR-lntronlO-
- GAAGAAAGGAAGUAGGAGGA 20
653 19539
CFTR-lntronlO-
+ GUAGUCCCAGCUACUUGGGA 20
654 19540
CFTR-lntronlO-
- GGGAGGUGAUUAGUCCAUGA 20
655 19541
CFTR-lntronlO-
- GACUGUUUAUGUUAUCUGUA 20
656 19542
CFTR-lntronlO-
- GCCACUUCCUGUUGCUAUUA 20
657 19543
CFTR-lntronlO-
- GUGUGUAUAUGUGUGUAUUA 20
658 19544
CFTR-lntronlO-
+ GUUCAAGCCUGUAUUGUUUA 20
659 19545
CFTR-lntronlO-
+ GAGCUUACCGUAAUAGCAAC 20
660 19546
CFTR-lntronlO-
+ GCAGGAGAAUGGCGUGAACC 20
661 19547
CFTR-lntronlO-
- GCAUAUAUAUAUUUUUAACC 20
662 19548
CFTR-lntronlO-
- GACAGAGUCUUACUGUCACC 20
663 19549
CFTR-lntronlO-
- GGAGUCUCGCUCUGUCGCCC 20
664 19550
CFTR-lntronlO-
+ GCAGGAGAAUUGCUUGAGCC 20
665 19551
CFTR-lntronlO-
+ GGAGUUUCACUGUGUUAGCC 20
666 19552
CFTR-lntronlO-
- GGGGU UUCACCGUUUUAGCC 20
667 19553
CFTR-lntronlO-
- GGGGU UUCACCAUGUUGGCC 20
668 19554
CFTR-lntronlO-
+ GAUGUAUCUCCAAAUAUGCC 20
669 19555
CFTR-lntronlO-
- GGAUGCCCU UGACUGAAAGC 20
670 19556
641
5535.1 CFTR-lntronlO-
- GAACACAGCAGGAAGACAGC 20
671 19557
CFTR-lntronlO-
- GCCUCACCCUCCCAAGUAGC 20
672 19558
CFTR-lntronlO-
- GCCUCAGCCUCCCAAGUAGC 20
673 19559
CFTR-lntronlO-
- GGAAGAGUCUUCCAAGUAGC 20
674 19560
CFTR-lntronlO-
+ GCCUCAGCCUCCCGAGUAGC 20
675 19561
CFTR-lntronlO-
+ GUUUGCCAUGUUGCCCACGC 20
676 19562
CFTR-lntronlO-
- GAGUCUUACUGUCACCAGGC 20
677 19563
CFTR-lntronlO-
- GCACUUUUGGAGGCAGAGGC 20
678 19564
CFTR-lntronlO-
+ GCACUUUGGGAGGCCGAGGC 20
679 19565
CFTR-lntronlO-
- GCUACUCGGGAGGCUGAGGC 20
680 19566
CFTR-lntronlO-
+ GCUACUUGGGAGGCUGAGGC 20
681 19567
CFTR-lntronlO-
+ GCUACUUGGGAGGGUGAGGC 20
682 19568
CFTR-lntronlO-
+ GAUUUCAACAUAUGAAUGGC 20
683 19569
CFTR-lntronlO-
+ GUGCAAGACUUCACACCUGC 20
684 19570
CFTR-lntronlO-
- GCUUCAGCCUCCCAAAGUGC 20
685 19571
CFTR-lntronlO-
- GCCUCGGCCUCCCAAAGUGC 20
686 19572
CFTR-lntronlO-
- GCCCGUAGUCCCAGCUACUC 20
687 19573
CFTR-lntronlO-
+ GGCGGGCGGAUCACGAGGUC 20
688 19574
CFTR-lntronlO-
+ GAAUUUAUUUCUCACAGUUC 20
689 19575
CFTR-lntronlO-
+ GUGUGUGUGUGUCCUUGUUC 20
690 19576
CFTR-lntronlO-
- GGGUUGAUAAGAAGAGAAAG 20
691 19577
642
5535.1 CFTR-lntronlO-
- GAUCACCUGAGCCUGAGAAG 20
692 19578
CFTR-lntronlO-
- G A A AG A AG G A AG G A AG U A AG 20
693 19579
CFTR-lntronlO-
- G U CACC AG G C U G G AG CACAG 20
694 19580
CFTR-lntronlO-
- GUGGAUUUUUGACUAUACAG 20
695 19581
CFTR-lntronlO-
- GCAGAGUUAGAGGAAGGCAG 20
696 19582
CFTR-lntronlO-
+ GCCGAGGCGGGCGGAUCACG 20
697 19583
CFTR-lntronlO-
- GUGGAGUCAAAAAUUAUACG 20
698 19584
CFTR-lntronlO-
+ GAAAUGAAACAGGCCGGGCG 20
699 19585
CFTR-lntronlO-
- GAGAAUGGCGUGAACCCAGG 20
700 19586
CFTR-lntronlO-
+ GU UUGUGUUUUUUGUAGAGG 20
701 19587
CFTR-lntronlO-
+ GAGAAUGGCGUGAACCCGGG 20
702 19588
CFTR-lntronlO-
+ GAGAAUUGCUUGAGCCCGGG 20
703 19589
CFTR-lntronlO-
- GUUCAGGCAAGUGAUGAUGG 20
704 19590
CFTR-lntronlO-
+ GCCGAGGCAGGCAGAUCAUG 20
705 19591
CFTR-lntronlO-
- GAACAG U AAGG AGG U CACUG 20
706 19592
CFTR-lntronlO-
- GGUGAUGGUAUUGCAGGGUG 20
707 19593
CFTR-lntronlO-
- G G C U C A A A A A A A A A A A A A A U 20
708 19594
CFTR-lntronlO-
- GCACCACUGUACCCUAGCCU 20
709 19595
CFTR-lntronlO-
- GCGCCACUGCACUCUAGCCU 20
710 19596
CFTR-lntronlO-
- GGAGCACAGUGGUGCGAUCU 20
711 19597
CFTR-lntronlO-
- GGAGUGCAGUGGCGGGAUCU 20
712 19598
643
5535.1 CFTR-lntronlO-
- GCUACUUGGGAGGCUGAGGU 20
713 19599
CFTR-lntronlO-
+ GGUUAAGUUGUUCUUAGGGU 20
714 19600
CFTR-lntronlO-
- GAGACGGGGUUUCACCAUGU 20
715 19601
CFTR-lntronlO-
- GCCUCGGCCUCCCAAAGUGU 20
716 19602
CFTR-lntronlO-
- GCAAUGCUAAUAAUACAAUU 20
717 19603
CFTR-lntronlO-
+ GAUCAAGGUGCCAGCAGAUU 20
718 19604
CFTR-lntronlO-
+ GUUUCCAAAUUUUUUUUAUU 20
719 19605
CFTR-lntronlO-
+ GCCUGUAGUCCCAGCUACUU 20
720 19606
CFTR-lntronlO-
- GUAUUGCAGGGUGGGGCCUU 20
721 19607
CFTR-lntronlO-
+ GCCUGUAAUCCCAACACUUU 20
722 19608
CFTR-lntronlO-
+ GCCUAUAAACCCAGCACUUU 20
723 19609
CFTR-lntronlO-
+ GCCUGUAAUCCCAGCACUUU 20
724 19610
CFTR-lntronlO-
- GAACACUUUAUAGUUUUUUU 20
725 19611
Table 40D provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within intron 10. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 40D
Figure imgf000645_0001
644
5535.1 CFTR-lntronlO-
+ UAUGAUUUUAUGAAAAA 17
727 19613
CFTR-lntronlO-
+ UGCAGGAGAAUGG A A A A 17
728 19614
CFTR-lntronlO-
+ UGCAUAAAGGUUGAAAA 17
729 19615
CFTR-lntronlO-
- UUCAGAAGUCUAU A A A A 17
730 19616
CFTR-lntronlO-
- A AAG AAAAAAC AG C AAA 17
731 19617
CFTR-lntronlO-
+ AG U AAAAAAAAAU CAAA 17
732 19618
CFTR-lntronlO-
+ CUAAAAUGACAAUCAAA 17
733 19619
CFTR-lntronlO-
+ A A A AG C U G A A AG U CAAA 17
734 19620
CFTR-lntronlO-
+ AUUCAAUGAAAAAGAAA 17
735 19621
CFTR-lntronlO-
+ U UCUCACAUGGCAGAAA 17
736 19622
CFTR-lntronlO-
- UAAACACUUCUGAGAAA 17
737 19623
CFTR-lntronlO-
+ UAAACAAACAAAGGAAA 17
738 19624
CFTR-lntronlO-
+ AUUAUCUUUCUAGUAAA 17
739 19625
CFTR-lntronlO-
+ ACCAAAUAAACAAACAA 17
740 19626
CFTR-lntronlO-
- AUGGAUAAGUUGAACAA 17
741 19627
CFTR-lntronlO-
- AUUAGGAAAAUGUACAA 17
742 19628
CFTR-lntronlO-
+ UG U U UAAAUAU U CCCAA 17
743 19629
CFTR-lntronlO-
+ A A AG A A U A AG G C A U C A A 17
744 19630
CFTR-lntronlO-
+ AAAUAUAUU CAAA AG A A 17
745 19631
CFTR-lntronlO-
+ UGAGAGACAGUAAAGAA 17
746 19632
CFTR-lntronlO-
- AAGGAAAUGAGGAAGAA 17
747 19633
645
5535.1 CFTR-lntronlO-
+ AGGCUGAGGCAGGAGAA 17
748 19634
CFTR-lntronlO-
+ AAACUGAGUAGAAGGAA 17
749 19635
CFTR-lntronlO-
+ U UUCUCUUUACUGUGAA 17
750 19636
CFTR-lntronlO-
+ A AG A A A AG U A U C A A U A A 17
751 19637
CFTR-lntronlO-
+ CAG UG ACU U CAU AAU AA 17
752 19638
CFTR-lntronlO-
+ AUAGAGAAAACUCAUAA 17
753 19639
CFTR-lntronlO-
+ ACAAAAAUUAAAACUAA 17
754 19640
CFTR-lntronlO-
+ U CU AG AAAACAAUG U AA 17
755 19641
CFTR-lntronlO-
- AG AU AAAG U UG AAU U AA 17
756 19642
CFTR-lntronlO-
+ AAGCCUGUAUUGUUUAA 17
757 19643
CFTR-lntronlO-
- AUUUUGACCAUUU UUAA 17
758 19644
CFTR-lntronlO-
+ UACCAUCCUGGCCAACA 17
759 19645
CFTR-lntronlO-
- UUAUAGCAGCCUGAACA 17
760 19646
CFTR-lntronlO-
- UU UAAACAGAAGUAACA 17
761 19647
CFTR-lntronlO-
+ AGAGAGAACUGCUCACA 17
762 19648
CFTR-lntronlO-
+ CCUGCUGUGUUCUCACA 17
763 19649
CFTR-lntronlO-
- UGAAAUCCUAAUUCCCA 17
764 19650
CFTR-lntronlO-
- UUUAUUUUUAUAUUCCA 17
765 19651
CFTR-lntronlO-
- AGACAAGGGAGGAAGCA 17
766 19652
CFTR-lntronlO-
+ UCAACAUAUGAAUGGCA 17
767 19653
CFTR-lntronlO-
- UACAGGCUUGAACUGCA 17
768 19654
646
5535.1 CFTR-lntronlO-
- AAGGUGAUGGUAUUGCA 17
769 19655
CFTR-lntronlO-
+ CU AU U U AAACAG AAU CA 17
770 19656
CFTR-lntronlO-
+ UGGGAAGUCCAAGAUCA 17
771 19657
CFTR-lntronlO-
+ UUCACUAAAAUAAUUCA 17
772 19658
CFTR-lntronlO-
+ UAUAUUUUAUGCAUUCA 17
773 19659
CFTR-lntronlO-
- AUAAGCCACACAGUUCA 17
774 19660
CFTR-lntronlO-
+ U UGAGCCCAGGAGUUCA 17
775 19661
CFTR-lntronlO-
+ AAUUGGUACAAAUUUCA 17
776 19662
CFTR-lntronlO-
- AGAGGAAGGAAGAAAGA 17
777 19663
CFTR-lntronlO-
- AG A U U C U A A AG G A A AG A 17
778 19664
CFTR-lntronlO-
- AAG G AAG G AAG G AAAG A 17
779 19665
CFTR-lntronlO-
+ UGUAUUUUUAGUAGAGA 17
780 19666
CFTR-lntronlO-
- UUUUUUUUU UUUUGAGA 17
781 19667
CFTR-lntronlO-
- CUUUUCCUCUUAAUAGA 17
782 19668
CFTR-lntronlO-
+ A U A U U C A A A AG AAAG G A 17
783 19669
CFTR-lntronlO-
- AAGGAAGGAAAGAAGGA 17
784 19670
CFTR-lntronlO-
+ CACUGUGUUAGCCAGGA 17
785 19671
CFTR-lntronlO-
- CACCAUGUUGGCCAGGA 17
786 19672
CFTR-lntronlO-
- AAGGCAGAGUUAGAGGA 17
787 19673
CFTR-lntronlO-
- AAAAUUAUACUAUAGGA 17
788 19674
CFTR-lntronlO-
- AUAGAGUAAGACAGGGA 17
789 19675
647
5535.1 CFTR-lntronlO-
- CACCGUUU UAGCCGGGA 17
790 19676
CFTR-lntronlO-
- UGGACUGAGUAACUGGA 17
791 19677
CFTR-lntronlO-
- AUAUAUGUGUGUCUGGA 17
792 19678
CFTR-lntronlO-
- AGGUGAUUAGUCCAUGA 17
793 19679
CFTR-lntronlO-
+ UGGCAUAGCUGCACUGA 17
794 19680
CFTR-lntronlO-
- AAAUUAGCCAGACGUGA 17
795 19681
CFTR-lntronlO-
- CCUAAUUCCCAAGGUGA 17
796 19682
CFTR-lntronlO-
- AGACUUGCAGGAGGUGA 17
797 19683
CFTR-lntronlO-
+ AUGGCAGAAAGGGGUGA 17
798 19684
CFTR-lntronlO-
- UUCAGGACAUGCUUUGA 17
799 19685
CFTR-lntronlO-
+ U UCAAUUCUUCAAAAUA 17
800 19686
CFTR-lntronlO-
+ AGUAUAUCAAAAGAAUA 17
801 19687
CFTR-lntronlO-
+ CCUCUGUGCUUUGAAUA 17
802 19688
CFTR-lntronlO-
- AUAAAUGUUGAAUAAUA 17
803 19689
CFTR-lntronlO-
- CAUAGUAUUCUAUCAUA 17
804 19690
CFTR-lntronlO-
+ CAUAGAGAAAACUCAUA 17
805 19691
CFTR-lntronlO-
+ CUGCAGACCUCAAUAUA 17
806 19692
CFTR-lntronlO-
- AAGUUUCUCAUCUUAUA 17
807 19693
CFTR-lntronlO-
+ CCGAGUAGCUGGGACUA 17
808 19694
CFTR-lntronlO-
- UGGUUUGAAGAACAGUA 17
809 19695
CFTR-lntronlO-
- UGUUUAUGUUAUCUGUA 17
810 19696
648
5535.1 CFTR-lntronlO-
- UUUUAGGCUAUUCUGUA 17
811 19697
CFTR-lntronlO-
+ ACUAGUGGCACUUUGUA 17
812 19698
CFTR-lntronlO-
+ U UAGUUUUAUGCCAUUA 17
813 19699
CFTR-lntronlO-
- CAGGAGGUGAGGGAUUA 17
814 19700
CFTR-lntronlO-
- ACU UCCUGUUGCUAUUA 17
815 19701
CFTR-lntronlO-
- UGUAUAUGUGUGUAUUA 17
816 19702
CFTR-lntronlO-
+ AUGUUAUUCAAGGUUUA 17
817 19703
CFTR-lntronlO-
- CAU UUUGACCAU UUUUA 17
818 19704
CFTR-lntronlO-
- AAGAUAAUGGGAGAAAC 17
819 19705
CFTR-lntronlO-
+ UGUGGCUUAUAAACAAC 17
820 19706
CFTR-lntronlO-
- U U U U AAACAG AAG U AAC 17
821 19707
CFTR-lntronlO-
- AAACUGUUAUAAUUAAC 17
822 19708
CFTR-lntronlO-
- UGACCCUUAAACAAUAC 17
823 19709
CFTR-lntronlO-
+ CAAGUAGCUGGGACUAC 17
824 19710
CFTR-lntronlO-
+ CGAGUAGCUGGGACUAC 17
825 19711
CFTR-lntronlO-
- CAAAGUGCUGGGAUUAC 17
826 19712
CFTR-lntronlO-
- CAAAGUGUUGGGAUUAC 17
827 19713
CFTR-lntronlO-
+ UGCAAUAUGCAAUUUAC 17
828 19714
CFTR-lntronlO-
+ AAAUAUUGACUAUUUAC 17
829 19715
CFTR-lntronlO-
- UAUAUAUAUUUUUAACC 17
830 19716
CFTR-lntronlO-
- AGAGUCUUACUGUCACC 17
831 19717
649
5535.1 CFTR-lntronlO-
+ U ACU AAAAAAAG U U ACC 17
832 19718
CFTR-lntronlO-
+ AAAGGUCAAUUGAGCCC 17
833 19719
CFTR-lntronlO-
- UGCAAGCUCCGCCUCCC 17
834 19720
CFTR-lntronlO-
- UGCAACCUCUGCCUCCC 17
835 19721
CFTR-lntronlO-
+ ACCACUGUGCUCCAGCC 17
836 19722
CFTR-lntronlO-
+ ACCACUGAAGUUCAGCC 17
837 19723
CFTR-lntronlO-
+ AAUACAAAAAAUUAGCC 17
838 19724
CFTR-lntronlO-
+ AAGAAAUGAAACAGGCC 17
839 19725
CFTR-lntronlO-
+ AGAGAUCAAUACCAUCC 17
840 19726
CFTR-lntronlO-
- UGAUGGUGGCUUGAUCC 17
841 19727
CFTR-lntronlO-
+ CGCUGGUCUCAAACUCC 17
842 19728
CFTR-lntronlO-
- CUGUAACCUUGAACUCC 17
843 19729
CFTR-lntronlO-
- CUGCAAGCUCCGCCUCC 17
844 19730
CFTR-lntronlO-
- CUGCAACCUCUGCCUCC 17
845 19731
CFTR-lntronlO-
+ CUGCAAGUUCUGCCUCC 17
846 19732
CFTR-lntronlO-
- CCAUG U G AG AACACAG C 17
847 19733
CFTR-lntronlO-
- CAC AG C AG G AAG ACAG C 17
848 19734
CFTR-lntronlO-
- AGUGCAGCUAUGCCAGC 17
849 19735
CFTR-lntronlO-
- U U U U AAAACAAAAU AGC 17
850 19736
CFTR-lntronlO-
- AAACAAAAGAAAAUAGC 17
851 19737
CFTR-lntronlO-
- UCACCCUCCCAAGUAGC 17
852 19738
650
5535.1 CFTR-lntronlO-
+ UCAGCCUCCCAAGUAGC 17
853 19739
CFTR-lntronlO-
- AG AG U CU U CCAAG U AG C 17
854 19740
CFTR-lntronlO-
+ UCAGCCUCCCGAGUAGC 17
855 19741
CFTR-lntronlO-
+ AAA U AC A A A A A A U U AG C 17
856 19742
CFTR-lntronlO-
+ UGCCAUGUUGCCCACGC 17
857 19743
CFTR-lntronlO-
+ UAAGAAAUGAAACAGGC 17
858 19744
CFTR-lntronlO-
- UCU UACUGUCACCAGGC 17
859 19745
CFTR-lntronlO-
- CGCUCUGUCGCCCAGGC 17
860 19746
CFTR-lntronlO-
- CUU UUGGAGGCAGAGGC 17
861 19747
CFTR-lntronlO-
+ CUUUGGGAGGCCGAGGC 17
862 19748
CFTR-lntronlO-
+ CUCACAGUUCUGGAGGC 17
863 19749
CFTR-lntronlO-
- AAGGAGGUCACUGAGGC 17
864 19750
CFTR-lntronlO-
- ACUCGGGAGGCUGAGGC 17
865 19751
CFTR-lntronlO-
+ ACUUGGGAGGCUGAGGC 17
866 19752
CFTR-lntronlO-
+ ACU UGGGAGGGUGAGGC 17
867 19753
CFTR-lntronlO-
- UUCAAGGAAGAGGGGGC 17
868 19754
CFTR-lntronlO-
+ U UCAACAUAUGAAUGGC 17
869 19755
CFTR-lntronlO-
- UAGCCAGACGUGAUGGC 17
870 19756
CFTR-lntronlO-
+ UAGCCGGGCGUAGUGGC 17
871 19757
CFTR-lntronlO-
- UCAGCCUCCCAAAGUGC 17
872 19758
CFTR-lntronlO-
- UCGGCCUCCCAAAGUGC 17
873 19759
651
5535.1 CFTR-lntronlO-
- CAAGGUGAUGGUAUUGC 17
874 19760
CFTR-lntronlO-
- UU UGAACAAAGACUUGC 17
875 19761
CFTR-lntronlO-
- CGUAGUCCCAGCUACUC 17
876 19762
CFTR-lntronlO-
+ CUCCACU UCUCAGGCUC 17
877 19763
CFTR-lntronlO-
+ AUAGAGAGAAACAUCUC 17
878 19764
CFTR-lntronlO-
+ UGCAGCCUCCACU UCUC 17
879 19765
CFTR-lntronlO-
+ AGAGACAAGGUGGUGUC 17
880 19766
CFTR-lntronlO-
- UCAAUAAAUUUGGUGUC 17
881 19767
CFTR-lntronlO-
- AUGUAUAUAUGUGUGUC 17
882 19768
CFTR-lntronlO-
+ UCU UUCUAAU UUCAUUC 17
883 19769
CFTR-lntronlO-
- AGGAAGUGAUCAGAUUC 17
884 19770
CFTR-lntronlO-
+ UAAGAGGAAAAGACUUC 17
885 19771
CFTR-lntronlO-
+ UUUAUUUCUCACAGUUC 17
886 19772
CFTR-lntronlO-
+ UGUGUGUGUCCUUGUUC 17
887 19773
CFTR-lntronlO-
- ACUGGCAAUUAAAUUUC 17
888 19774
CFTR-lntronlO-
- UCU UUUGAAUAUAUU UC 17
889 19775
CFTR-lntronlO-
+ AUAAAUAAUUGCCUUUC 17
890 19776
CFTR-lntronlO-
- AUUAUAACACUGCUU UC 17
891 19777
CFTR-lntronlO-
+ AAAAUUUGUUUUCUU UC 17
892 19778
CFTR-lntronlO-
+ AAAAACAUUAGCCAAAG 17
893 19779
CFTR-lntronlO-
+ UCUCACAUGGCAG A A AG 17
894 19780
652
5535.1 CFTR-lntronlO-
- U UGAU AAG AAGAG AAAG 17
895 19781
CFTR-lntronlO-
- A AG A U U C U A A AG G A A AG 17
896 19782
CFTR-lntronlO-
- UGAAUUUUUUUUCCAAG 17
897 19783
CFTR-lntronlO-
- CACCUGAGCCUGAGAAG 17
898 19784
CFTR-lntronlO-
+ ACU UUGGGAGGCUGAAG 17
899 19785
CFTR-lntronlO-
+ A A A A A U U C AC A A A U A AG 17
900 19786
CFTR-lntronlO-
- AAAU U AG AAAG AAU AAG 17
901 19787
CFTR-lntronlO-
- A A A A A U A A A A A U A U A AG 17
902 19788
CFTR-lntronlO-
- AGAAGGAAGGAAGUAAG 17
903 19789
CFTR-lntronlO-
- C C A U A U U C A A AG C AC AG 17
904 19790
CFTR-lntronlO-
- ACCAGGCUGGAGCACAG 17
905 19791
CFTR-lntronlO-
+ UUAAUGGCUGUGCACAG 17
906 19792
CFTR-lntronlO-
- UAUGAGAAAAGUCACAG 17
907 19793
CFTR-lntronlO-
+ CCUAGGCUAGGGUACAG 17
908 19794
CFTR-lntronlO-
+ UGUUUAAAACUCUCCAG 17
909 19795
CFTR-lntronlO-
- CUAUAUUUGUUUUCCAG 17
910 19796
CFTR-lntronlO-
+ AG G AAAG GAG G U AG CAG 17
911 19797
CFTR-lntronlO-
+ UUGAGCCCGGGAGGCAG 17
912 19798
CFTR-lntronlO-
- AGCACU UUUGGAGGCAG 17
913 19799
CFTR-lntronlO-
+ CAACAUAUGAAUGGCAG 17
914 19800
CFTR-lntronlO-
+ CCCAGGCUAGAGUGCAG 17
915 19801
653
5535.1 CFTR-lntronlO-
- CCCAGGCUGGAGUGCAG 17
916 19802
CFTR-lntronlO-
- UGUCAGGCUGGGUGCAG 17
917 19803
CFTR-lntronlO-
+ U AU U U AAACAG AAU CAG 17
918 19804
CFTR-lntronlO-
- AAUGUUAAUUUAUU CAG 17
919 19805
CFTR-lntronlO-
- CCCAGGCUGAACUUCAG 17
920 19806
CFTR-lntronlO-
+ U UGUUACAUAAAAAGAG 17
921 19807
CFTR-lntronlO-
- AACAGAAAAAGAAAGAG 17
922 19808
CFTR-lntronlO-
- AAAUUAUACUAUAGGAG 17
923 19809
CFTR-lntronlO-
+ AAUAGCCUAUUGUUGAG 17
924 19810
CFTR-lntronlO-
- UAAAUGUUGAAUAAUAG 17
925 19811
CFTR-lntronlO-
+ UAGAUGAUUAUUAAUAG 17
926 19812
CFTR-lntronlO-
- UAAAAAGUGAUCUCUAG 17
927 19813
CFTR-lntronlO-
+ AAAUUAGCCGGGCGUAG 17
928 19814
CFTR-lntronlO-
- UAUGAAGGCAGAGUUAG 17
929 19815
CFTR-lntronlO-
+ AGAUGAUUAGCAUCACG 17
930 19816
CFTR-lntronlO-
- UAUUUUUAGUAGAGACG 17
931 19817
CFTR-lntronlO-
+ AACACUUUGGGAGGCCG 17
932 19818
CFTR-lntronlO-
+ AGCACUUUGGGAGGCCG 17
933 19819
CFTR-lntronlO-
+ AUGAAACAGGCCGGGCG 17
934 19820
CFTR-lntronlO-
+ A A A A A A A A A U C A A A AG G 17
935 19821
CFTR-lntronlO-
+ CUGAGUAGAAGGAAAGG 17
936 19822
654
5535.1 CFTR-lntronlO-
- U UUGAAGAACAG UAAGG 17
937 19823
CFTR-lntronlO-
- AAUGGCGUGAACCCAGG 17
938 19824
CFTR-lntronlO-
- UAGUUUCAAGGAAGAGG 17
939 19825
CFTR-lntronlO-
+ U U ACAU AAAAAG AG AGG 17
940 19826
CFTR-lntronlO-
+ UGUGUUUUU UGUAGAGG 17
941 19827
CFTR-lntronlO-
+ ACU UUGGGAGGCCGAGG 17
942 19828
CFTR-lntronlO-
- UACUUGGGAGGCUGAGG 17
943 19829
CFTR-lntronlO-
- AAAAAUUAUACUAUAGG 17
944 19830
CFTR-lntronlO-
+ AAACAGGCCGGGCGCGG 17
945 19831
CFTR-lntronlO-
- CUGUAGGGAGACAAGGG 17
946 19832
CFTR-lntronlO-
+ AAUGGCGUGAACCCGGG 17
947 19833
CFTR-lntronlO-
+ AAUUGCUUGAGCCCGGG 17
948 19834
CFTR-lntronlO-
+ UGGGAGGCCGAGGCGGG 17
949 19835
CFTR-lntronlO-
- AGUCCCAGCUACUCGGG 17
950 19836
CFTR-lntronlO-
- UGGGAGGCUGAGGUGGG 17
951 19837
CFTR-lntronlO-
+ AGUCCCAGCUACUUGGG 17
952 19838
CFTR-lntronlO-
+ AAUCCCAACACUU UGGG 17
953 15660
CFTR-lntronlO-
+ AAACCCAGCACUUUGGG 17
954 19839
CFTR-lntronlO-
+ AAUCCCAGCACUUUGGG 17
955 19840
CFTR-lntronlO-
- AGGGUGGGGCCUUUGGG 17
956 19841
CFTR-lntronlO-
- CAGGCAAGUGAUGAUGG 17
957 19842
655
5535.1 CFTR-lntronlO-
- UUAGCCAGACGUGAUGG 17
958 19843
CFTR-lntronlO-
+ AUUUCUCACAGUUCUGG 17
959 19844
CFTR-lntronlO-
- CUGAGCCUGAGAAGUGG 17
960 19845
CFTR-lntronlO-
- AGGCUGGAGUGCAGUGG 17
961 19846
CFTR-lntronlO-
+ U UAGCCGGGCGUAGUGG 17
962 19847
CFTR-lntronlO-
- AAAAUAGCUGGGUGUGG 17
963 19848
CFTR-lntronlO-
+ UCAAAAAAUAUUUGUGG 17
964 19849
CFTR-lntronlO-
- AAUCCUAGCACUUUUGG 17
965 19850
CFTR-lntronlO-
- AAUUUUAUAUAGAAAUG 17
966 19851
CFTR-lntronlO-
+ AACAAACAAAGGAAAUG 17
967 19852
CFTR-lntronlO-
- AAGCUAGUGAAUGAAUG 17
968 19853
CFTR-lntronlO-
+ AUUAUUCAACAUUUAUG 17
969 19854
CFTR-lntronlO-
- CAGUAAGGAGGUCACUG 17
970 19855
CFTR-lntronlO-
- AGCUACUCGGGAGGCUG 17
971 19856
CFTR-lntronlO-
+ AGCUACUUGGGAGGCUG 17
972 19857
CFTR-lntronlO-
+ C A A A A A UUAGCUGAGUG 17
973 19858
CFTR-lntronlO-
+ A C A U A A A A AG AG AG G U G 17
974 19859
CFTR-lntronlO-
+ UGUUUUUUGUAGAGGUG 17
975 19860
CFTR-lntronlO-
- AAGACUUGCAGGAGGUG 17
976 19861
CFTR-lntronlO-
+ AGCUACUUGGGAGGGUG 17
977 19862
CFTR-lntronlO-
+ CAUGGCAGAAAGGGGUG 17
978 19863
656
5535.1 CFTR-lntronlO-
- AAGAAAAUAGCUGGGUG 17
979 19864
CFTR-lntronlO-
+ AAAUACCAUGAACUGUG 17
980 19865
CFTR-lntronlO-
- U U U AU AAAAAAU AAU UG 17
981 19866
CFTR-lntronlO-
+ U AU U C AAAAAAU AU U UG 17
982 19867
CFTR-lntronlO-
- ACAUUGGAAAAUUUUUG 17
983 19868
CFTR-lntronlO-
- UAGUAGUUAAGUUUUUG 17
984 19869
CFTR-lntronlO-
- U C A A A A A A A A A A A A A A U 17
985 19870
CFTR-lntronlO-
+ UAAAAUGACAAUCAAAU 17
986 19871
CFTR-lntronlO-
+ CUAUUUGGAUGUCAAAU 17
987 19872
CFTR-lntronlO-
+ AAACAAACAAAGGAAAU 17
988 19873
CFTR-lntronlO-
- UUGAAGGAAGAUCCAAU 17
989 19874
CFTR-lntronlO-
- CAUAAAUGUUGAAUAAU 17
990 19875
CFTR-lntronlO-
- U U U ACU AG AAAG AU AAU 17
991 19876
CFTR-lntronlO-
- ACUG U CAG AG AAG U AAU 17
992 19877
CFTR-lntronlO-
- UUUUUCAGUUAAUACAU 17
993 19878
CFTR-lntronlO-
+ UACAAUUCUUAUUACAU 17
994 19879
CFTR-lntronlO-
- ACAGGCUUGAACUGCAU 17
995 19880
CFTR-lntronlO-
- ACCCUAGCCUAGGUGAU 17
996 19881
CFTR-lntronlO-
+ U UGUGUUAACAAAAUAU 17
997 19882
CFTR-lntronlO-
+ AAUAUAUAUAUGCAUAU 17
998 19883
CFTR-lntronlO-
- U U AAAAAAU U AU ACU AU 17
999 19884
657
5535.1 CFTR-lntronlO-
- AAAGUUUCUCAUCUUAU 17
1000 19885
CFTR-lntronlO-
+ UAUUAUUCAACAUUUAU 17
1001 19886
CFTR-lntronlO-
- CAAAGUGCUGGGUU UAU 17
1002 19887
CFTR-lntronlO-
+ UCAGACUUUUAUUUUAU 17
1003 19888
CFTR-lntronlO-
+ U U U AACAAACCU U U U AU 17
1004 19889
CFTR-lntronlO-
+ UUCCAAAUUUUU UUUAU 17
1005 19890
CFTR-lntronlO-
- UUAUUCUUGUAAUAACU 17
1006 19891
CFTR-lntronlO-
- CCGUAGUCCCAGCUACU 17
1007 19892
CFTR-lntronlO-
+ CUGUAGUCCCAGCUACU 17
1008 19893
CFTR-lntronlO-
+ CUGCAAUACCAUCACCU 17
1009 19894
CFTR-lntronlO-
+ CCACUGCACUCCAGCCU 17
1010 19895
CFTR-lntronlO-
+ CCACUGAAGUUCAGCCU 17
1011 19896
CFTR-lntronlO-
- CCACUGUACCCUAGCCU 17
1012 19897
CFTR-lntronlO-
- CCACUGCACUCUAGCCU 17
1013 19898
CFTR-lntronlO-
- UCGUGAUCCGCCCGCCU 17
1014 19899
CFTR-lntronlO-
- UCAUGAUCUGCCUGCCU 17
1015 19900
CFTR-lntronlO-
- UGUAACCUUGAACUCCU 17
1016 19901
CFTR-lntronlO-
+ UGCAAGUUCUGCCUCCU 17
1017 19902
CFTR-lntronlO-
- AGGUUUUGGAUGGAGCU 17
1018 19903
CFTR-lntronlO-
- A AC A A A AG A A A A U AG C U 17
1019 19904
CFTR-lntronlO-
- CACCCUCCCAAGUAGCU 17
1020 19905
658
5535.1 CFTR-lntronlO-
+ CAGCCUCCCAAGUAGCU 17
1021 19906
CFTR-lntronlO-
+ CAGCCUCCCGAGUAGCU 17
1022 19907
CFTR-lntronlO-
+ UCACAGUUCUGGAGGCU 17
1023 19908
CFTR-lntronlO-
- AAAUUAUUUCUACUGCU 17
1024 19909
CFTR-lntronlO-
+ CUGCCUCCAAAAGUGCU 17
1025 19910
CFTR-lntronlO-
- CAGCCUCCCAAAGUGCU 17
1026 19911
CFTR-lntronlO-
- CGGCCUCCCAAAGUGCU 17
1027 19912
CFTR-lntronlO-
- AAAAAAG UUGAGUUGCU 17
1028 19913
CFTR-lntronlO-
- UGCUGGCACCUUGAUCU 17
1029 19914
CFTR-lntronlO-
- UGCUUUUCCCACUAUCU 17
1030 19915
CFTR-lntronlO-
+ AAUUUGAACAACAUUCU 17
1031 19916
CFTR-lntronlO-
+ U UUUUCAUUAUGAUUCU 17
1032 19917
CFTR-lntronlO-
+ CUUUUUCUUAAUUUUCU 17
1033 19918
CFTR-lntronlO-
- UGAGGAAGAAAGGAAGU 17
1034 19919
CFTR-lntronlO-
- UCUGCAAUUGUAUCAGU 17
1035 19920
CFTR-lntronlO-
+ CAGUUUUAUUUU UCAGU 17
1036 19921
CFTR-lntronlO-
+ ACAUUUUCCUAAUGAGU 17
1037 19922
CFTR-lntronlO-
- AGUGGAAGUAGUAUAGU 17
1038 19923
CFTR-lntronlO-
+ U ACAU AAAAAG AG AGG U 17
1039 19924
CFTR-lntronlO-
- UUAGAGGUUAAGGAGGU 17
1040 19925
CFTR-lntronlO-
- ACUUGGGAGGCUGAGGU 17
1041 19926
659
5535.1 CFTR-lntronlO-
- ACGGGGUUUCACCAUGU 17
1042 19927
CFTR-lntronlO-
- UCGGCCUCCCAAAGUGU 17
1043 19928
CFTR-lntronlO-
- AGAAGAGAAAGGGGUGU 17
1044 19929
CFTR-lntronlO-
- ACCCAAU AAAAAAAAU U 17
1045 19930
CFTR-lntronlO-
- U U U CCACU CAAUAAAU U 17
1046 19931
CFTR-lntronlO-
+ CCAUCACCUUGGGAAUU 17
1047 19932
CFTR-lntronlO-
- CACUAUUGAUUGACAUU 17
1048 19933
CFTR-lntronlO-
+ CAAGGUGCCAGCAGAUU 17
1049 19934
CFTR-lntronlO-
- UAUUCUUUUUAGAGAUU 17
1050 19935
CFTR-lntronlO-
- UACUUUUCUUCCUGAU U 17
1051 19936
CFTR-lntronlO-
- UUUUCAUUGAAUGUAUU 17
1052 19937
CFTR-lntronlO-
- UCCUU UGUUUGUUUAUU 17
1053 19938
CFTR-lntronlO-
+ CAGACUUUUAUUUUAU U 17
1054 19939
CFTR-lntronlO-
+ UCCAAAUUUUUU UUAUU 17
1055 19940
CFTR-lntronlO-
+ CUGUAAUCCCAACACUU 17
1056 19941
CFTR-lntronlO-
- AAGUAACAGGGCCACUU 17
1057 19942
CFTR-lntronlO-
+ CUAUAAACCCAGCACUU 17
1058 19943
CFTR-lntronlO-
+ CUGUAAUCCCAGCACUU 17
1059 19944
CFTR-lntronlO-
- AAUUGAAUAUGAGACUU 17
1060 19945
CFTR-lntronlO-
+ UGUAGUCCCAGCUACUU 17
1061 19946
CFTR-lntronlO-
+ UGCAAUACCAUCACCUU 17
1062 19947
660
5535.1 CFTR-lntronlO-
+ AUGUUAAAUUUUCCCUU 17
1063 19948
CFTR-lntronlO-
+ U UCCCU UAGGAUAUCU U 17
1064 19949
CFTR-lntronlO-
- AAGCAAGGAGAUGAGUU 17
1065 19950
CFTR-lntronlO-
- CGGCCUCCCAAAGUGUU 17
1066 19951
CFTR-lntronlO-
- UGUUAUCUCUGAAAUU U 17
1067 19952
CFTR-lntronlO-
- UUUGAUUAGAUAAAUU U 17
1068 19953
CFTR-lntronlO-
- UCAAUAUUUUGGAAUU U 17
1069 19954
CFTR-lntronlO-
- ACUAUUGAUUGACAUU U 17
1070 19955
CFTR-lntronlO-
+ AAGGUGCCAGCAGAUUU 17
1071 19956
CFTR-lntronlO-
- UAGUUUUAUCAAUAUU U 17
1072 19957
CFTR-lntronlO-
+ UCUCUGCAAACAUAUUU 17
1073 19958
CFTR-lntronlO-
- CAU UAUUCAUGAUAUUU 17
1074 19959
CFTR-lntronlO-
- UUUCAUUGAAUGUAUUU 17
1075 19960
CFTR-lntronlO-
+ UGUAAUCCCAACACUUU 17
1076 19961
CFTR-lntronlO-
+ UAUAAACCCAGCACUUU 17
1077 19962
CFTR-lntronlO-
+ UGUAAUCCCAGCACUUU 17
1078 19963
CFTR-lntronlO-
- UGUAAUCCUAGCACUUU 17
1079 19964
CFTR-lntronlO-
- UGCAGGGUGGGGCCUU U 17
1080 19965
CFTR-lntronlO-
- UUUAACUGAAUAUCUUU 17
1081 19966
CFTR-lntronlO-
- AUGGGAGAAACAGGUUU 17
1082 19967
CFTR-lntronlO-
- AUACAUUGGAAAAUUU U 17
1083 19968
661
5535.1 CFTR-lntronlO-
- CAAUAUUUUGGAAUUU U 17
1084 19969
CFTR-lntronlO-
- U ACAU UGG AAAAU U U U U 17
1085 19970
CFTR-lntronlO-
- CUUUGGCUAAUGUUUUU 17
1086 19971
CFTR-lntronlO-
- CACUU UAUAGUUU UUUU 17
1087 19972
CFTR-lntronlO-
+ ACAAACAAAGAAACAAAAAA 20
1088 19973
CFTR-lntronlO-
+ ACAUAUGAUUUUAUGAAAAA 20
1089 19974
CFTR-lntronlO-
+ CGAGACCAUCCCGGCUAAAA 20
1090 19975
CFTR-lntronlO-
- UAGAAAGAAAAAACAGCAAA 20
1091 19976
CFTR-lntronlO-
+ AU U AG U AAAAAAAAAU CAAA 20
1092 19977
CFTR-lntronlO-
+ AAG AAAAG CUG AAAG U CAAA 20
1093 19978
CFTR-lntronlO-
+ UACAUUCAAUGAAAAAGAAA 20
1094 19979
CFTR-lntronlO-
- AGGGUUGAUAAGAAGAGAAA 20
1095 19980
CFTR-lntronlO-
- AUUUAAACACUUCUGAGAAA 20
1096 19981
CFTR-lntronlO-
+ AAAUAAACAAACAAAGGAAA 20
1097 19982
CFTR-lntronlO-
- AAGGAUGUUUAUUUAUGAAA 20
1098 19983
CFTR-lntronlO-
+ AAAACCAAAUAAACAAACAA 20
1099 19984
CFTR-lntronlO-
- CUCAUUAGGAAAAUGUACAA 20
1100 19985
CFTR-lntronlO-
+ AUGGACUAAUCACCUCCCAA 20
1101 19986
CFTR-lntronlO-
- UCAUGUUGAUAAAGGGUCAA 20
1102 19987
CFTR-lntronlO-
+ CUGAAAUAUAUU CAAA AG A A 20
1103 19988
CFTR-lntronlO-
+ AGAUGAGAGACAGUAAAGAA 20
1104 19989
662
5535.1 CFTR-lntronlO-
- AAGAAGGAAAUGAGGAAGAA 20
1105 19990
CFTR-lntronlO-
+ UGUGUUCUCACAUGGCAGAA 20
1106 19991
CFTR-lntronlO-
+ U UUGGGAGGCUGAAGCGGAA 20
1107 19992
CFTR-lntronlO-
+ UUAGGAUUUCAACAUAUGAA 20
1108 19993
CFTR-lntronlO-
+ ACAUUUCUCUUUACUGUGAA 20
1109 19994
CFTR-lntronlO-
+ AGGAAGAAAAGUAUCAAUAA 20
1110 19995
CFTR-lntronlO-
+ AUACAGUGACUUCAUAAUAA 20
1111 19996
CFTR-lntronlO-
+ AACAUAGAGAAAACUCAUAA 20
1112 19997
CFTR-lntronlO-
+ UGAACAAAAAUUAAAACUAA 20
1113 19998
CFTR-lntronlO-
+ UUUUCUAGAAAACAAUGUAA 20
1114 19999
CFTR-lntronlO-
- AACAG AU AAAG U UG AAU U AA 20
1115 20000
CFTR-lntronlO-
+ UGUUACCUU UCAAUGUUUAA 20
1116 20001
CFTR-lntronlO-
+ UUCAAGCCUGUAUUGUUUAA 20
1117 20002
CFTR-lntronlO-
- AUCAUUUUGACCAUUUUUAA 20
1118 20003
CFTR-lntronlO-
+ CAAUACCAUCCUGGCCAACA 20
1119 20004
CFTR-lntronlO-
- UGAGACCAGCGUGGGCAACA 20
1120 20005
CFTR-lntronlO-
- UUGUUAUAGCAGCCUGAACA 20
1121 20006
CFTR-lntronlO-
+ UGGAGAGAGAACUGCUCACA 20
1122 20007
CFTR-lntronlO-
+ CUUCCUGCUGUGUUCUCACA 20
1123 20008
CFTR-lntronlO-
+ AAUGAUCAAUAAUAGAGACA 20
1124 20009
CFTR-lntronlO-
+ AUUUUACAAUUCUUAUUACA 20
1125 20010
663
5535.1 CFTR-lntronlO-
- UGUUGAAAUCCUAAUUCCCA 20
1126 20011
CFTR-lntronlO-
- UUCUUUAUU UUUAUAUUCCA 20
1127 20012
CFTR-lntronlO-
+ AUUUCAACAUAUGAAUGGCA 20
1128 20013
CFTR-lntronlO-
- AAAGUGCCACUAGUGAUGCA 20
1129 20014
CFTR-lntronlO-
- CAA U ACAG G C U U G AAC U G CA 20
1130 20015
CFTR-lntronlO-
- CCCAAGGUGAUGGUAU UGCA 20
1131 20016
CFTR-lntronlO-
+ AGGGUACAGUGGUGCAAUCA 20
1132 20017
CFTR-lntronlO-
+ UGCUUCACUAAAAUAAUUCA 20
1133 20018
CFTR-lntronlO-
+ ACAUAUAUUUUAUGCAUUCA 20
1134 20019
CFTR-lntronlO-
- UUUAUAAGCCACACAGUUCA 20
1135 20020
CFTR-lntronlO-
+ CAAUUGAGCCCAGGAGUUCA 20
1136 20021
CFTR-lntronlO-
- AAGAGAGGAAGGAAGAAAGA 20
1137 20022
CFTR-lntronlO-
- AGGAAGGAAGGAAGGAAAGA 20
1138 20023
CFTR-lntronlO-
- A A AG A AG G A AG G A AG U A AG A 20
1139 20024
CFTR-lntronlO-
- AAUGAAAGCAAUAGUAGAGA 20
1140 20025
CFTR-lntronlO-
+ UUUUGUAUUUUUAGUAGAGA 20
1141 20026
CFTR-lntronlO-
- UUUUUUUUU UUUUUUUGAGA 20
1142 20027
CFTR-lntronlO-
- AGUCUUUUCCUCUUAAUAGA 20
1143 20028
CFTR-lntronlO-
+ AAUAUAUU CAA A AG A A AG G A 20
1144 20029
CFTR-lntronlO-
- AG G AAG G AAG G AAAG AAG G A 20
1145 20030
CFTR-lntronlO-
- AAAGGAAGUAGGAGGAAGGA 20
1146 20031
664
5535.1 CFTR-lntronlO-
+ U UUCACUGUGUUAGCCAGGA 20
1147 20032
CFTR-lntronlO-
- UU UCACCAUGUUGGCCAGGA 20
1148 20033
CFTR-lntronlO-
- ACAGAAAAAGAAAGAGAGGA 20
1149 20034
CFTR-lntronlO-
- AUGAAGGCAGAGUUAGAGGA 20
1150 20035
CFTR-lntronlO-
- UAAAAAAUUAUACUAUAGGA 20
1151 20036
CFTR-lntronlO-
+ AUUGGUACAAAUUUCAGGGA 20
1152 20037
CFTR-lntronlO-
- UU UCACCGUUUUAGCCGGGA 20
1153 20038
CFTR-lntronlO-
- AUAGUAUUCUAUCAUAUGGA 20
1154 20039
CFTR-lntronlO-
- UUCUGGACUGAGUAACUGGA 20
1155 20040
CFTR-lntronlO-
- UGUAUAUAUGUGUGUCUGGA 20
1156 20041
CFTR-lntronlO-
- UGGGAGAAACAGGUUU UGGA 20
1157 20042
CFTR-lntronlO-
+ U UGACCCUUUAUCAACAUGA 20
1158 20043
CFTR-lntronlO-
+ UGCUGGCAUAGCUGCACUGA 20
1159 20044
CFTR-lntronlO-
- AAAAAAUUAGCCAGACGUGA 20
1160 20045
CFTR-lntronlO-
- AAUCCUAAUUCCCAAGGUGA 20
1161 20046
CFTR-lntronlO-
- CAAAGACUUGCAGGAGGUGA 20
1162 20047
CFTR-lntronlO-
+ CACAUGGCAGAAAGGGGUGA 20
1163 20048
CFTR-lntronlO-
- AGAUUCAGGACAUGCUUUGA 20
1164 20049
CFTR-lntronlO-
+ AUAUUCAAUUCUUCAAAAUA 20
1165 20050
CFTR-lntronlO-
- AAAACU AAU UG U AG U ACAU A 20
1166 20051
CFTR-lntronlO-
- AUGCAUAGUAUUCUAUCAUA 20
1167 20052
665
5535.1 CFTR-lntronlO-
+ AAACAUAGAGAAAACUCAUA 20
1168 20053
CFTR-lntronlO-
+ UAGCUGCAGACCUCAAUAUA 20
1169 20054
CFTR-lntronlO-
+ CAAAAAUUACAGAACCUAUA 20
1170 20055
CFTR-lntronlO-
- AAAAAGUUUCUCAUCUUAUA 20
1171 20056
CFTR-lntronlO-
+ CUCCCGAGUAGCUGGGACUA 20
1172 20057
CFTR-lntronlO-
+ AAGGGGUGAGGGUCUCUCUA 20
1173 20058
CFTR-lntronlO-
+ AAGGUGUGAGGGUCUCUCUA 20
1174 20059
CFTR-lntronlO-
+ ACUGUGAAUGGUGCCAGGUA 20
1175 20060
CFTR-lntronlO-
+ AUCACUAGUGGCACUUUGUA 20
1176 20061
CFTR-lntronlO-
+ UUGAUGUUAUUCAAGGUUUA 20
1177 20062
CFTR-lntronlO-
- UAUCAUUUUGACCAUU UUUA 20
1178 20063
CFTR-lntronlO-
+ U U G G AAAAAAAAU U CAAAAC 20
1179 20064
CFTR-lntronlO-
+ CUGUGUGGCUUAUAAACAAC 20
1180 20065
CFTR-lntronlO-
+ CCAUCAUCACUUGCCUGAAC 20
1181 20066
CFTR-lntronlO-
- AGCUUUCUGGACUGAGUAAC 20
1182 20067
CFTR-lntronlO-
- UU UGUAUUUUUAGUAGAGAC 20
1183 20068
CFTR-lntronlO-
- ACAAGUGCCUAGCACUUGAC 20
1184 20069
CFTR-lntronlO-
- AAUUGACCCU U AAACAAU AC 20
1185 20070
CFTR-lntronlO-
+ UCCCAAGUAGCUGGGACUAC 20
1186 20071
CFTR-lntronlO-
+ UCCCGAGUAGCUGGGACUAC 20
1187 20072
CFTR-lntronlO-
- UCCCAAAGUGCUGGGAU UAC 20
1188 20073
666
5535.1 CFTR-lntronlO-
- UCCCAAAGUGUUGGGAUUAC 20
1189 20074
CFTR-lntronlO-
+ UACUGCAAUAUGCAAUU UAC 20
1190 20075
CFTR-lntronlO-
+ CAGGAGAAUGGCGUGAACCC 20
1191 20076
CFTR-lntronlO-
+ AGAGUCUCACUCUGUCACCC 20
1192 20077
CFTR-lntronlO-
- UAGGUCUUACUCUGUCACCC 20
1193 20078
CFTR-lntronlO-
+ CGGAAAGGUCAAUUGAGCCC 20
1194 20079
CFTR-lntronlO-
+ CAGGAGAAUUGCUUGAGCCC 20
1195 20080
CFTR-lntronlO-
- CACUGCAAGCUCCGCCUCCC 20
1196 20081
CFTR-lntronlO-
- CACUGCAACCUCUGCCUCCC 20
1197 20082
CFTR-lntronlO-
+ CCCGCCACUGCACUCCAGCC 20
1198 20083
CFTR-lntronlO-
+ CGCACCACUGUGCUCCAGCC 20
1199 20084
CFTR-lntronlO-
+ CACACCACU G AAG U U CAG CC 20
1200 20085
CFTR-lntronlO-
- CGCGCCACUGCACUCUAGCC 20
1201 20086
CFTR-lntronlO-
+ AAAAAUACAAAAAAUUAGCC 20
1202 20087
CFTR-lntronlO-
- CAGGCGCCCGCCACUACGCC 20
1203 20088
CFTR-lntronlO-
- CAGGCGUGAGCCACCGCGCC 20
1204 20089
CFTR-lntronlO-
+ UAUAAGAAAUGAAACAGGCC 20
1205 20090
CFTR-lntronlO-
- UUAGGAGAUCAAGACCAUCC 20
1206 20091
CFTR-lntronlO-
+ UCAGGAGAUCGAGACCAUCC 20
1207 20092
CFTR-lntronlO-
+ UCAAGAGAUCAAUACCAUCC 20
1208 20093
CFTR-lntronlO-
- UGAUGAUGGUGGCU UGAUCC 20
1209 20094
667
5535.1 CFTR-lntronlO-
- AGGAAGACAGCUGGCUAUCC 20
1210 20095
CFTR-lntronlO-
+ CCACGCUGGUCUCAAACUCC 20
1211 20096
CFTR-lntronlO-
- UCACUGUAACCUUGAACUCC 20
1212 20097
CFTR-lntronlO-
- UUAUUCUUU UGAUAUACUCC 20
1213 20098
CFTR-lntronlO-
- UCACUGCAAGCUCCGCCUCC 20
1214 20099
CFTR-lntronlO-
- UCACUGCAACCUCUGCCUCC 20
1215 20100
CFTR-lntronlO-
+ UCACUGCAAGUUCUGCCUCC 20
1216 20101
CFTR-lntronlO-
- CAGGUGAAUUGCUUGAGUCC 20
1217 20102
CFTR-lntronlO-
- CUGCCAUGUGAGAACACAGC 20
1218 20103
CFTR-lntronlO-
- AUCAGUGCAGCUAUGCCAGC 20
1219 20104
CFTR-lntronlO-
- AGCU U U U AAAACAAAAU AG C 20
1220 20105
CFTR-lntronlO-
- CACAAACAAAAGAAAAUAGC 20
1221 20106
CFTR-lntronlO-
+ ACCUCAGCCUCCCAAGUAGC 20
1222 20107
CFTR-lntronlO-
+ UAAAAAUACAAAAAAUUAGC 20
1223 20108
CFTR-lntronlO-
- CGGGGUUUCACCGUUU UAGC 20
1224 20109
CFTR-lntronlO-
+ AUAUAAGAAAUGAAACAGGC 20
1225 20110
CFTR-lntronlO-
- UCUCGCUCUGUCGCCCAGGC 20
1226 20111
CFTR-lntronlO-
- CAAUAAAUUUGGUGUCAGGC 20
1227 20112
CFTR-lntronlO-
+ ACACUUUGGGAGGCCGAGGC 20
1228 20113
CFTR-lntronlO-
+ UUUCUCACAGUUCUGGAGGC 20
1229 20114
CFTR-lntronlO-
- AAUUAGCCAGACGUGAUGGC 20
1230 20115
668
5535.1 CFTR-lntronlO-
- CCAGGCUGGAGUGCAGUGGC 20
1231 20116
CFTR-lntronlO-
+ AAUUAGCCGGGCGUAGUGGC 20
1232 20117
CFTR-lntronlO-
- CUUAGCAGACCCAAAUCUGC 20
1233 20118
CFTR-lntronlO-
+ UUCAUUUAUCUCGAAAUUGC 20
1234 20119
CFTR-lntronlO-
- UCCCAAGGUGAUGGUAUUGC 20
1235 20120
CFTR-lntronlO-
- ACAUUUGAACAAAGACUUGC 20
1236 20121
CFTR-lntronlO-
+ AGCCUCCACU UCUCAGGCUC 20
1237 20122
CFTR-lntronlO-
+ UAUAUAGAGAGAAACAUCUC 20
1238 20123
CFTR-lntronlO-
+ CACUGCAGCCUCCACU UCUC 20
1239 20124
CFTR-lntronlO-
+ CGGGCACCCGCCAUCACGUC 20
1240 20125
CFTR-lntronlO-
- UAGGCAUGAGCCACUGUGUC 20
1241 20126
CFTR-lntronlO-
- UGUAUGUAUAUAUGUGUGUC 20
1242 20127
CFTR-lntronlO-
+ UAUUCUUUCUAAUUUCAUUC 20
1243 20128
CFTR-lntronlO-
- AGUAGGAAGUGAUCAGAUUC 20
1244 20129
CFTR-lntronlO-
- CUUUCUUUUGAAUAUAUUUC 20
1245 20130
CFTR-lntronlO-
- AAAGAUGAUUCCAAGCUUUC 20
1246 20131
CFTR-lntronlO-
- UUCAUUAUAACACUGCUUUC 20
1247 20132
CFTR-lntronlO-
+ AAGAAAAUUUGUUUUCUUUC 20
1248 20133
CFTR-lntronlO-
+ UGUUCUCACAUGGCAGAAAG 20
1249 20134
CFTR-lntronlO-
- UU UUGAAUUUUUU UUCCAAG 20
1250 20135
CFTR-lntronlO-
+ ACCGUAAUAGCAACAGGAAG 20
1251 20136
669
5535.1 CFTR-lntronlO-
+ AGCACUUUGGGAGGCUGAAG 20
1252 20137
CFTR-lntronlO-
+ A A A A A A A A U U C AC A A A U A AG 20
1253 20138
CFTR-lntronlO-
- AUGAAAUUAGAAAGAAUAAG 20
1254 20139
CFTR-lntronlO-
- A U C A A A A A U A A A A A U A U A AG 20
1255 20140
CFTR-lntronlO-
- AUCAGUAGGCUUCCUAUAAG 20
1256 20141
CFTR-lntronlO-
+ AUAUUAAUGGCUGUGCACAG 20
1257 20142
CFTR-lntronlO-
+ UCACCUAGGCUAGGGUACAG 20
1258 20143
CFTR-lntronlO-
+ UUCUGUUUAAAACUCUCCAG 20
1259 20144
CFTR-lntronlO-
+ AG AAG G AAAG G AG G U AG CAG 20
1260 20145
CFTR-lntronlO-
+ UGCUUGAGCCCGGGAGGCAG 20
1261 20146
CFTR-lntronlO-
- CCUAGCACU UUUGGAGGCAG 20
1262 20147
CFTR-lntronlO-
+ U UUCAACAUAUGAAUGGCAG 20
1263 20148
CFTR-lntronlO-
+ UCACCCAGGCUAGAGUGCAG 20
1264 20149
CFTR-lntronlO-
- UCGCCCAGGCUGGAGUGCAG 20
1265 20150
CFTR-lntronlO-
- UGGUGUCAGGCUGGGUGCAG 20
1266 20151
CFTR-lntronlO-
- AGGAAUGUUAAUUUAUUCAG 20
1267 20152
CFTR-lntronlO-
- UCACCCAGGCUGAACUUCAG 20
1268 20153
CFTR-lntronlO-
- ACAAACAGAAAAAGAAAGAG 20
1269 20154
CFTR-lntronlO-
- AAAAAAUUAUACUAUAGGAG 20
1270 20155
CFTR-lntronlO-
+ ACUAAUAGCCUAUUGUUGAG 20
1271 20156
CFTR-lntronlO-
- CAGUAAAAAGUGAUCUCUAG 20
1272 20157
670
5535.1 CFTR-lntronlO-
+ AAAAAAUUAGCCGGGCGUAG 20
1273 20158
CFTR-lntronlO-
- AAGAAGAGAAAGGGGUGUAG 20
1274 20159
CFTR-lntronlO-
+ UUUGUUUGUGUUUUUUGUAG 20
1275 20160
CFTR-lntronlO-
- AAA U G U G AG A A A A AG U U U AG 20
1276 20161
CFTR-lntronlO-
+ CGGAGAUGAUUAGCAUCACG 20
1277 20162
CFTR-lntronlO-
- UUGUAUUUUUAGUAGAGACG 20
1278 20163
CFTR-lntronlO-
+ CCCAACACU UUGGGAGGCCG 20
1279 20164
CFTR-lntronlO-
+ CCCAGCACUUUGGGAGGCCG 20
1280 20165
CFTR-lntronlO-
- CCAGGAGUUUGAGACCAGCG 20
1281 20166
CFTR-lntronlO-
+ AG U AAAAAAAAAU CAAAAGG 20
1282 20167
CFTR-lntronlO-
+ AAACUGAGUAGAAGGAAAGG 20
1283 20168
CFTR-lntronlO-
- UGGUUUGAAGAACAGUAAGG 20
1284 20169
CFTR-lntronlO-
- UU UGAACAAAGACUUGCAGG 20
1285 20170
CFTR-lntronlO-
+ AGCACUUUGGGAGGCCGAGG 20
1286 20171
CFTR-lntronlO-
+ AAUGGCGUGAACCCGGGAGG 20
1287 20172
CFTR-lntronlO-
- AGCUACUUGGGAGGCUGAGG 20
1288 20173
CFTR-lntronlO-
- U U AAAAAAU UAUACUAUAGG 20
1289 20174
CFTR-lntronlO-
- UGAGGAAGAAAGGAAGUAGG 20
1290 20175
CFTR-lntronlO-
+ AUGAAACAGGCCGGGCGCGG 20
1291 20176
CFTR-lntronlO-
- AAGGUGAUGGUAUUGCAGGG 20
1292 20177
CFTR-lntronlO-
+ CUU UGGGAGGCCGAGGCGGG 20
1293 20178
671
5535.1 CFTR-lntronlO-
- CGUAGUCCCAGCUACUCGGG 20
1294 20179
CFTR-lntronlO-
- ACUUGGGAGGCUGAGGUGGG 20
1295 20180
CFTR-lntronlO-
+ UGUAGUCCCAGCUACUUGGG 20
1296 20181
CFTR-lntronlO-
+ UGUAAUCCCAACACUUUGGG 20
1297 20182
CFTR-lntronlO-
+ UAUAAACCCAGCACU UUGGG 20
1298 20183
CFTR-lntronlO-
+ UGUAAUCCCAGCACUUUGGG 20
1299 20184
CFTR-lntronlO-
- UGCAGGGUGGGGCCUU UGGG 20
1300 20185
CFTR-lntronlO-
- AAAUUAGCCAGACGUGAUGG 20
1301 20186
CFTR-lntronlO-
+ U UUAUUUCUCACAGUUCUGG 20
1302 20187
CFTR-lntronlO-
- CACCUGAGCCUGAGAAGUGG 20
1303 20188
CFTR-lntronlO-
- CCCAGGCUGGAGUGCAGUGG 20
1304 20189
CFTR-lntronlO-
+ AAAUUAGCCGGGCGUAGUGG 20
1305 20190
CFTR-lntronlO-
- AAGAAAAUAGCUGGGUGUGG 20
1306 20191
CFTR-lntronlO-
+ UAUUCAAAAAAUAUUUGUGG 20
1307 20192
CFTR-lntronlO-
- UGUAAUCCUAGCACUUU UGG 20
1308 20193
CFTR-lntronlO-
- AGGAAUUUUAUAUAGAAAUG 20
1309 20194
CFTR-lntronlO-
+ AUAAACAAACAAAGGAAAUG 20
1310 20195
CFTR-lntronlO-
- AAGGAAGAAAGAAGGAAAUG 20
1311 20196
CFTR-lntronlO-
- UGGGAGGUGAUUAGUCCAUG 20
1312 20197
CFTR-lntronlO-
- CCCAGCUACUCGGGAGGCUG 20
1313 20198
CFTR-lntronlO-
+ CCCAGCUACU UGGGAGGCUG 20
1314 20199
672
5535.1 CFTR-lntronlO-
+ AUACAAAAAUUAGCUGAGUG 20
1315 20200
CFTR-lntronlO-
+ UUGUGUUUU UUGUAGAGGUG 20
1316 20201
CFTR-lntronlO-
- ACAAAGACUUGCAGGAGGUG 20
1317 20202
CFTR-lntronlO-
+ CCCAGCUACUUGGGAGGGUG 20
1318 20203
CFTR-lntronlO-
+ UCACAUGGCAGAAAGGGGUG 20
1319 20204
CFTR-lntronlO-
- C A A A AG A A A A UAGCUGGGUG 20
1320 20205
CFTR-lntronlO-
+ ACAAAAUACCAUGAACUGUG 20
1321 20206
CFTR-lntronlO-
- AU U U U U AU AAAAAAU AAU UG 20
1322 20207
CFTR-lntronlO-
+ AUCUAUUCAAAAAAUAUUUG 20
1323 20208
CFTR-lntronlO-
- AAUACAUUGGAAAAUUUUUG 20
1324 20209
CFTR-lntronlO-
- UAUUAGUAGUUAAGUUUUUG 20
1325 20210
CFTR-lntronlO-
+ AUAGUAGCAAAUGAUAAAAU 20
1326 20211
CFTR-lntronlO-
+ UCUCUAUU UGGAUGUCAAAU 20
1327 20212
CFTR-lntronlO-
+ AAUAAACAAACAAAGGAAAU 20
1328 20213
CFTR-lntronlO-
- UAAGGUUUCCACUCAACAAU 20
1329 20214
CFTR-lntronlO-
+ U UUACCAUUAUCUACACAAU 20
1330 20215
CFTR-lntronlO-
- CCCCAUAAAUGUUGAAUAAU 20
1331 20216
CFTR-lntronlO-
- UU UUUUUUCAGUUAAUACAU 20
1332 20217
CFTR-lntronlO-
+ U UUUACAAUUCUUAUUACAU 20
1333 20218
CFTR-lntronlO-
- AAUACAGGCUUGAACUGCAU 20
1334 20219
CFTR-lntronlO-
- UGUACCCUAGCCUAGGUGAU 20
1335 20220
673
5535.1 CFTR-lntronlO-
+ AAAAAUAUAUAUAUGCAUAU 20
1336 20221
CFTR-lntronlO-
- CUAUUAAAAAAUUAUACUAU 20
1337 20222
CFTR-lntronlO-
- UUCUCCCUGUUAU UCCUUAU 20
1338 20223
CFTR-lntronlO-
- UAAAAAGUUUCUCAUCUUAU 20
1339 20224
CFTR-lntronlO-
- UCCCAAAGUGCUGGGUUUAU 20
1340 20225
CFTR-lntronlO-
+ UUCUCAGACU UUUAUUUUAU 20
1341 20226
CFTR-lntronlO-
+ AGUUUCCAAAUUUU UUUUAU 20
1342 20227
CFTR-lntronlO-
- UGCCCGUAGUCCCAGCUACU 20
1343 20228
CFTR-lntronlO-
+ CGCCUGUAGUCCCAGCUACU 20
1344 20229
CFTR-lntronlO-
+ UGCCUGUAGUCCCAGCUACU 20
1345 17606
CFTR-lntronlO-
+ ACCCUGCAAUACCAUCACCU 20
1346 20230
CFTR-lntronlO-
+ CCGCCACUGCACUCCAGCCU 20
1347 20231
CFTR-lntronlO-
+ ACACCACUGAAGUUCAGCCU 20
1348 20232
CFTR-lntronlO-
- ACCUCGUGAUCCGCCCGCCU 20
1349 20233
CFTR-lntronlO-
- ACCUCAUGAUCUGCCUGCCU 20
1350 20234
CFTR-lntronlO-
- CACUGUAACCU UGAACUCCU 20
1351 20235
CFTR-lntronlO-
+ CACUGCAAGUUCUGCCUCCU 20
1352 20236
CFTR-lntronlO-
- ACAAACAAAAGAAAAUAGCU 20
1353 20237
CFTR-lntronlO-
- CCUCACCCUCCCAAGUAGCU 20
1354 20238
CFTR-lntronlO-
+ CCUCAGCCUCCCAAGUAGCU 20
1355 20239
CFTR-lntronlO-
+ CCUCAGCCUCCCGAGUAGCU 20
1356 20240
674
5535.1 CFTR-lntronlO-
+ U UCUCACAGUUCUGGAGGCU 20
1357 20241
CFTR-lntronlO-
+ CCUCUGCCUCCAAAAGUGCU 20
1358 20242
CFTR-lntronlO-
- CUUCAGCCUCCCAAAGUGCU 20
1359 20243
CFTR-lntronlO-
- CCUCGGCCUCCCAAAGUGCU 20
1360 20244
CFTR-lntronlO-
- A AG A A A A A AG UUGAGUUGCU 20
1361 20245
CFTR-lntronlO-
+ AGAGUGCAGUGGCGCGAUCU 20
1362 20246
CFTR-lntronlO-
- AUCUGCUGGCACCUUGAUCU 20
1363 20247
CFTR-lntronlO-
- AAAGCUGUGCAUUUUCCUCU 20
1364 20248
CFTR-lntronlO-
+ AUAUAGAGAGAAACAUCUCU 20
1365 20249
CFTR-lntronlO-
+ AUAUUUUUCAUUAUGAUUCU 20
1366 20250
CFTR-lntronlO-
+ U UAAUUUUCUCGGUAU UUCU 20
1367 20251
CFTR-lntronlO-
+ UUACUUUUUCUUAAUUUUCU 20
1368 20252
CFTR-lntronlO-
- AAAUGAGGAAGAAAGGAAGU 20
1369 20253
CFTR-lntronlO-
- UGGAUUUUUGACUAUACAGU 20
1370 20254
CFTR-lntronlO-
- ACAUCUGCAAUUGUAUCAGU 20
1371 20255
CFTR-lntronlO-
- AU CCAAAU AG AG AUG U U AG U 20
1372 20256
CFTR-lntronlO-
- CAGG AG U U UG AG ACCAG CG U 20
1373 20257
CFTR-lntronlO-
+ UUUGUGUUU UUUGUAGAGGU 20
1374 20258
CFTR-lntronlO-
- AGGUGAUGGUAUUGCAGGGU 20
1375 20259
CFTR-lntronlO-
+ UGAAUGGUGCCAGGUAGGGU 20
1376 20260
CFTR-lntronlO-
- UUUUUGACUAUACAGUGGGU 20
1377 20261
675
5535.1 CFTR-lntronlO-
- A U A AG A AG AG A A AG G G G U G U 20
1378 20262
CFTR-lntronlO-
- AAAUUUCCACUCAAUAAAUU 20
1379 20263
CFTR-lntronlO-
+ AUACCAUCACCUUGGGAAUU 20
1380 20264
CFTR-lntronlO-
- AUGGUACUACUGUAAUAAUU 20
1381 20265
CFTR-lntronlO-
- AAUCACUAUUGAUUGACAUU 20
1382 20266
CFTR-lntronlO-
- UU UUAUUCU UUUUAGAGAUU 20
1383 20267
CFTR-lntronlO-
- CUUGCAGGAGGUGAGGGAUU 20
1384 20268
CFTR-lntronlO-
- UGAUACUUUUCUUCCUGAUU 20
1385 20269
CFTR-lntronlO-
+ AU AG AAG U AG AAG AACU AU U 20
1386 20270
CFTR-lntronlO-
- UCUUUUUCAUUGAAUGUAUU 20
1387 20271
CFTR-lntronlO-
+ UCUGUUUGUCUUAGAU UAUU 20
1388 20272
CFTR-lntronlO-
- AUUUCCUU UGUUUGUU UAUU 20
1389 20273
CFTR-lntronlO-
+ UCUCAGACUU UUAUUUUAUU 20
1390 20274
CFTR-lntronlO-
+ UGCCUGUAAUCCCAACACUU 20
1391 20275
CFTR-lntronlO-
+ UGCCUAUAAACCCAGCACUU 20
1392 20276
CFTR-lntronlO-
+ CGCCUGUAAUCCCAGCACUU 20
1393 20277
CFTR-lntronlO-
- AAGAAUUGAAUAUGAGACUU 20
1394 20278
CFTR-lntronlO-
+ CCCUGCAAUACCAUCACCUU 20
1395 20279
CFTR-lntronlO-
+ AAAAUGUUAAAUUUUCCCUU 20
1396 20280
CFTR-lntronlO-
+ AUUUUCCCUUAGGAUAUCUU 20
1397 20281
CFTR-lntronlO-
- CUU UUAGUUAGCAUAAAGUU 20
1398 20282
676
5535.1 CFTR-lntronlO-
- AGGAAGCAAGGAGAUGAGUU 20
1399 20283
CFTR-lntronlO-
- CCUCGGCCUCCCAAAGUGUU 20
1400 20284
CFTR-lntronlO-
- AGUUGUUAUCUCUGAAAUUU 20
1401 20285
CFTR-lntronlO-
- UUAUCAAUAUUUUGGAAUUU 20
1402 20286
CFTR-lntronlO-
- AUCACUAUUGAUUGACAUUU 20
1403 20287
CFTR-lntronlO-
+ AUCAAGGUGCCAGCAGAUUU 20
1404 20288
CFTR-lntronlO-
- AAAUAGUUUUAUCAAUAUUU 20
1405 20289
CFTR-lntronlO-
- CAUCAUUAUUCAUGAUAUUU 20
1406 20290
CFTR-lntronlO-
- CUUUUUCAUUGAAUGUAUUU 20
1407 20291
CFTR-lntronlO-
- ACU UGUAAUCCUAGCACUUU 20
1408 20292
CFTR-lntronlO-
- UAUUGCAGGGUGGGGCCUUU 20
1409 20293
CFTR-lntronlO-
- AAAUUUAACUGAAUAUCUUU 20
1410 20294
CFTR-lntronlO-
- U U AAU ACAU UGG AAAAU U U U 20
1411 20295
CFTR-lntronlO-
- UAUCAAUAUUUUGGAAUUUU 20
1412 20296
CFTR-lntronlO-
- U AAU ACAU UGG AAAAU U U U U 20
1413 20297
Table 41A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within intron 10, have a high level of orthogonality, start with a 5'G, and PAM is
NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 41A
677
5535.1 1st Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR- IntronlO- + GAUAAUACUACUGACUAAAA 20
1414 20298
CFTR- IntronlO- + GUAACUCCAGUGCUAUUUAAA 21
1415 20299
CFTR- IntronlO- + GGUAACUCCAGUGCUAUUUAAA 22
1416 20300
CFTR- IntronlO- + GACUCCAGGAGUAUAUCAA 19
1417 20301
CFTR- IntronlO- + GGACUCCAGGAGUAUAUCAA 20
1418 20302
CFTR- IntronlO- + GUGGACUCCAGGAGUAUAUCAA 22
1419 20303
CFTR- IntronlO- + GAUGAGAGACAGUAAAGAA 19
1420 20304
CFTR- IntronlO- + GCUAUUUUUGCACAUCUAUCA 21
1421 20305
CFTR- IntronlO- + GCUACCUUGGUUGGAUGA 18
1422 20306
CFTR- IntronlO- + GGCUACCUUGGUUGGAUGA 19
1423 20307
CFTR- IntronlO- + GAUUGGCUACCUUGGUUGGAUGA 23
1424 20308
CFTR- IntronlO- + GGAUUGGCUACCUUGGUUGGAUGA 24
1425 20309
CFTR- IntronlO- + GAAUAUCCAUCCAUAUGA 18
1426 20310
678
5535.1 CFTR- IntronlO- + GUUACAACAGUCUUUAUA 18
1427 20311
CFTR- IntronlO- + GUUCAACUUAUCCAUUAAUCCUA 23
1428 20312
CFTR- IntronlO- + GAUACAAAUUACCAAAUUGUA 21
1429 20313
CFTR- IntronlO- + GCACCCAGCCUGACACCAAAUUUA 24
1430 20314
CFTR- IntronlO- + GUACAAAUAUUGACUAUUUA 20
1431 20315
CFTR- IntronlO- + GCAAGUACAAAUAUUGACUAUUUA 24
1432 20316
CFTR- IntronlO- + GAGCUCAUAUUAGUGAAC 18
1433 20317
CFTR- IntronlO- + GAUACUAAAAAAAGUUAC 18
1434 20318
CFTR- IntronlO- + GUAUUAGCAAGUGGACUCC 19
1435 20319
CFTR- IntronlO- + GCACUCUAUUUAGAGUGUAUGGC 23
1436 20320
CFTR- IntronlO- + GAAAAGGCUCUUUAUAAUGC 20
1437 20321
CFTR- IntronlO- + GCUAAGAGACUCCUGAAUC 19
1438 20322
CFTR- IntronlO- + GUCUGCUAAGAGACUCCUGAAUC 23
1439 20323
CFTR- IntronlO- + GGUCUGCUAAGAGACUCCUGAAUC 24
1440 20324
679
5535.1 CFTR- IntronlO- + G U AG AAG ACCU AAAU AU C 18
1441 20325
CFTR- IntronlO- + GAUGUAGAAGACCUAAAUAUC 21
1442 20326
CFTR- IntronlO- + GAAGAUGUAGAAGACCUAAAUAUC 24
1443 20327
CFTR- IntronlO- + GGGUCUGCUAAGAGACUC 18
1444 20328
CFTR- IntronlO- + GAUUUGGGUCUGCUAAGAGACUC 23
1445 20329
CFTR- IntronlO- + GAUAUUUUUCAUUAUGAUUC 20
1446 20330
CFTR-
+ GCUUGACAUCAGUUGGGUUC 20
lntronlO-94 18980
CFTR- IntronlO- + GAUAAAUAAUUGCCUUUC 18
1447 20331
CFTR- IntronlO- + GAUAUUGAUAAAUAAUUGCCUUUC 24
1448 20332
CFTR- IntronlO- + GUUGGAUGAGGGAAUGCAG 19
1449 20333
CFTR- IntronlO- + GGUUGGAUGAGGGAAUGCAG 20
1450 20334
CFTR- IntronlO- + GAAUUGAUCUUGAAGACAUACG 22
1451 20335
CFTR- IntronlO- + GCCUAGAUGAUUAUUAAUAGGG 22
1452 20336
CFTR- IntronlO- + GUUAAGUUGUUCUUAGGG 18
1453 20337
CFTR-
+ GGUUAAGUUGUUCUUAGGG 19
IntronlO- 20338
680
5535.1 1454
CFTR- IntronlO- + GCCAGGUUAAGUUGUUCUUAGGG 23
1455 20339
CFTR- IntronlO- + GUUACCUGGAUUGGCUACCUUGG 23
1456 20340
CFTR- IntronlO- + GGAAAUGGGGUAUAAGUG 18
1457 20341
CFTR-
+ G U U ACAU AAAAAG AG AGG UG 20
lntronlO-107 18993
CFTR- IntronlO- + GCUAAUAGCUUAUUCUAUACAU 22
1458 20342
CFTR- IntronlO- + GAGCUAAUAGCUUAUUCUAUACAU 24
1459 20343
CFTR- IntronlO- + GAAUAAUGAUGUACAUUUAAUAU 23
1460 20344
CFTR- IntronlO- + GUAAUGGAAACACUAUAUAU 20
1461 20345
CFTR- IntronlO- + GUACAUCCAACUAACAUCUCUAU 23
1462 20346
CFTR- IntronlO- + GGAAAAUGU UAAAU U U U CCCU 21
1463 20347
CFTR- IntronlO- + GCACUUGUUGACAGUCCU 18
1464 20348
CFTR- IntronlO- + GGCACUUGUUGACAGUCCU 19
1465 20349
CFTR- IntronlO- + GCUAGGCACUUGUUGACAGUCCU 23
1466 20350
CFTR-
+ GUUACUCAGUCCAGAAAGCU 20
lntronlO-117 19003
681
5535.1 CFTR- IntronlO- + GUGCAAGUCCUCUGUGCU 18
1467 20351
CFTR- IntronlO- + GCCAGGUUAAGUUGUUCU 18
1468 20352
CFTR- IntronlO- + GAGGGUCUCUCUAAGGUGU 19
1469 20353
CFTR- IntronlO- + GUGAGGGUCUCUCUAAGGUGU 21
1470 20354
CFTR- IntronlO- + GGUGAGGGUCUCUCUAAGGUGU 22
1471 20355
CFTR- IntronlO- + GGGUGAGGGUCUCUCUAAGGUGU 23
1472 20356
CFTR- IntronlO- + GGGGUGAGGGUCUCUCUAAGGUGU 24
1473 20357
CFTR- IntronlO- + GGAAAUCAGCACUCUAUU 18
1474 20358
CFTR- IntronlO- + GGGAAAUCAGCACUCUAUU 19
1475 20359
CFTR- IntronlO- + GGGGAAAUCAGCACUCUAUU 20
1476 20360
CFTR- IntronlO- + GUGGGGAAAUCAGCACUCUAUU 22
1477 20361
CFTR- IntronlO- + GUAACUCUUUAUUCACUU 18
1478 20362
CFTR- IntronlO- - GCUUUCAGGAG CCA A A A A 18
1479 20363
CFTR- IntronlO- - GAUAAGAUUCUAAAGGAAA 19
1480 20364
682
5535.1 CFTR- IntronlO- - GGAUAAGAUUCUAAAGGAAA 20
1481 20365
CFTR- IntronlO- - GCUGGAUAAGAUUCUAAAGGAAA 23
1482 20366
CFTR- IntronlO- - GGCUGGAUAAGAUUCUAAAGGAAA 24
1483 20367
CFTR- IntronlO- - GUACUCAUGCCAUACACUCUAAA 23
1484 20368
CFTR- IntronlO- - GCUUUGAAGGAAGAUCCAA 19
1485 20369
CFTR- IntronlO- - GGAGAACCAUAUUUUGAAGAA 21
1486 20370
CFTR- IntronlO- - G AGG AG AACCAU AU U U UG AAG AA 23
1487 20371
CFTR- IntronlO- - GGGUUGAUAAGAAGAGAA 18
1488 20372
CFTR-
- GAGGGUUGAUAAGAAGAGAA 20
lntronlO-68 18954
CFTR- IntronlO- - GAAAGAGGGUUGAUAAGAAGAGAA 24
1489 20373
CFTR- IntronlO- - GUACUUGCUCUCUGACCACAUAA 23
1490 20374
CFTR- IntronlO- - GUAUAUGAUAUACUCUUAA 19
1491 20375
CFTR- IntronlO- - GAUGUAUAUGAUAUACUCUUAA 22
1492 20376
CFTR- IntronlO- - GGAUGUAUAUGAUAUACUCUUAA 23
1493 20377
CFTR-
- GUAUAGAAUUUUGCAUCA 18
IntronlO- 20378
683
5535.1 1494
CFTR- IntronlO- - GGUAGUAAUUGUGUUUCA 18
1495 20379
CFTR- IntronlO- - GAAAAGGUAGUAAUUGUGUUUCA 23
1496 20380
CFTR- IntronlO- - GAUCUAGCUAAAAUAUAAGA 20
1497 20381
CFTR- IntronlO- - GAUUCCAAGCUUUCUGGA 18
1498 20382
CFTR- IntronlO- - GAUAUACUCUUAAGUGAAUA 20
1499 20383
CFTR- IntronlO- - GAUGGAUAUUCUAUGAUAUA 20
1500 20384
CFTR- IntronlO- - GGAUGGAUAUUCUAUGAUAUA 21
1501 20385
CFTR- IntronlO- - GUUUUUGCUUGCUUUUUAUA 20
1502 20386
CFTR- IntronlO- - GUCUGAGAAGACAAAGCUA 19
1503 20387
CFTR- IntronlO- - GUAAUCGGCGGUGGAGGUA 19
1504 20388
CFTR- IntronlO- - GAAGUAAUCGGCGGUGGAGGUA 22
1505 20389
CFTR- IntronlO- - GAGAAGUAAUCGGCGGUGGAGGUA 24
1506 20390
CFTR- IntronlO- - GAUCAUUGCCUCACUAUGGUA 21
1507 20391
CFTR-
- GUAAUAACUGGGACUCAUAUGUA 23
IntronlO- 20392
684
5535.1 1508
CFTR- IntronlO- - GAAGAUCCAAUAGGAUUA 18
1509 20393
CFTR- IntronlO- - GGAAGAUCCAAUAGGAUUA 19
1510 20394
CFTR- IntronlO- - GAAGGAAGAUCCAAUAGGAUUA 22
1511 20395
CFTR- IntronlO- - GCAGGAGGUGAGGGAUUA 18
1512 20396
CFTR- IntronlO- - GUUAGCAAUGGUCUAAAC 18
1513 20397
CFTR- IntronlO- - GAUUCUGUUUAAAUAGCAC 19
1514 20398
CFTR- IntronlO- - GAGAAGGUCAAACUUGAC 18
1515 20399
CFTR- IntronlO- - GUAGAGAAGGUCAAACUUGAC 21
1516 20400
CFTR- IntronlO- - GCCUUAUUCUUUUGAUAUACUCC 23
1517 20401
CFTR- IntronlO- - GUCUUGCGCUUAUGAAACUUCC 22
1518 20402
CFTR- IntronlO- - G C U U U U A A A AC A A A A U AG C 19
1519 20403
CFTR- IntronlO- - GGAAGACAGCUGGCUAUC 18
1520 20404
CFTR- IntronlO- - GCAGGAAGACAGCUGGCUAUC 21
1521 20405
CFTR-
- GCUGGCUAUCCAGGAUUC 18
IntronlO- 20406
685
5535.1 1522
CFTR- IntronlO- - GACAGCUGGCUAUCCAGGAUUC 22
1523 20407
CFTR- IntronlO- - GUUCUGUAAUUUUUGCUUC 19
1524 20408
CFTR- IntronlO- - GGUUCUGUAAUUUUUGCUUC 20
1525 20409
CFTR- IntronlO- - GACUUUGUAGUGAUCUUC 18
1526 20410
CFTR- IntronlO- - GAAGACUUUGUAGUGAUCUUC 21
1527 20411
CFTR- IntronlO- - GAGAAGACUUUGUAGUGAUCUUC 23
1528 20412
CFTR- IntronlO- - GGAGAAGACUUUGUAGUGAUCUUC 24
1529 20413
CFTR- IntronlO- - GCUUUUCAAAAUACUUUC 18
1530 20414
CFTR- IntronlO- - GAAGCUUUUCAAAAUACUUUC 21
1531 20415
CFTR- IntronlO- - GUAACAGUACAAGAAAAAAG 20
1532 20416
CFTR-
- GCAUAUGAGAAAAGUCACAG 20
lntronlO-99 18985
CFTR- IntronlO- - GGCAUAUGAGAAAAGUCACAG 21
1533 20417
CFTR- IntronlO- - GAACCCAACUGAUGUCAAGCAG 22
1534 20418
CFTR- IntronlO- - GGAACCCAACUGAUGUCAAGCAG 23
1535 20419
686
5535.1 CFTR- IntronlO- - GUAUUAGAGGUUAAGGAG 18
1536 20420
CFTR- IntronlO- - GUCUUUUCCUCUUAAUAG 18
1537 20421
CFTR- IntronlO- - GAAGUCUUUUCCUCUUAAUAG 21
1538 20422
CFTR- IntronlO- - G A A A AG CAGCUAUGAAGG 18
1539 20423
CFTR- IntronlO- - GCUUAUGAAAAGCAGCUAUGAAGG 24
1540 20424
CFTR- IntronlO- - GGCAUAGAGUAAGACAGG 18
1541 20425
CFTR- IntronlO- - GCUGGCAUAGAGUAAGACAGG 21
1542 20426
CFTR- IntronlO- - GGCUGGCAUAGAGUAAGACAGG 22
1543 20427
CFTR- IntronlO- - GAGGCUGGCAUAGAGUAAGACAGG 24
1544 20428
CFTR- IntronlO- - GGUAGUGUGAAGAUGGGG 18
1545 20429
CFTR- IntronlO- - GCUGGUAGUGUGAAGAUGGGG 21
1546 20430
CFTR- IntronlO- - GGCUGGUAGUGUGAAGAUGGGG 22
1547 20431
CFTR- IntronlO- - GGGCUGGUAGUGUGAAGAUGGGG 23
1548 20432
CFTR- IntronlO- - GGGGCUGGUAGUGUGAAGAUGGGG 24
1549 20433
687
5535.1 CFTR- IntronlO- - GGGAAUGCAGACUCUGGG 18
1550 20434
CFTR- IntronlO- - GAUUAGGGAAUGCAGACUCUGGG 23
1551 20435
CFTR- IntronlO- - GGAUUAGGGAAUGCAGACUCUGGG 24
1552 20436
CFTR- IntronlO- - GGGGGAGCCCCAUAAAUG 18
1553 20437
CFTR- IntronlO- - GUGGGGGAGCCCCAUAAAUG 20
1554 20438
CFTR- IntronlO- - GUGAGAUUAGAGGCCACUG 19
1555 20439
CFTR- IntronlO- - GGUGAGAUUAGAGGCCACUG 20
1556 20440
CFTR- IntronlO- - GCACAUAUGUUCAGACUG 18
1557 20441
CFTR- IntronlO- - GACUUGCACAUAUGUUCAGACUG 23
1558 20442
CFTR- IntronlO- - GGACUUGCACAUAUGUUCAGACUG 24
1559 20443
CFTR- IntronlO- - GCAUCUCACCAGUGUGUG 18
1560 20444
CFTR- IntronlO- - GGCAUCUCACCAGUGUGUG 19
1561 20445
CFTR- IntronlO- - GAGGAGAACCAUAUUUUG 18
1562 20446
CFTR- IntronlO- - GAUGAGGAGAACCAUAUUUUG 21
1563 20447
688
5535.1 CFTR- IntronlO- - GCCCCAUAAAUGUUGAAUAAU 21
1564 20448
CFTR- IntronlO- - GAGCCCCAUAAAUGUUGAAUAAU 23
1565 20449
CFTR- IntronlO- - GGAGCCCCAUAAAUGUUGAAUAAU 24
1566 20450
CFTR- IntronlO- - GAUUUUUUCCCAUGUAAU 18
1567 20451
CFTR- IntronlO- - GAAUCACUAUUGAUUGACAU 20
1568 20452
CFTR- IntronlO- - GUAGUUUCUAUUAAUAGAU 19
1569 20453
CFTR- IntronlO- - GUGUAGUUUCUAUUAAUAGAU 21
1570 20454
CFTR- IntronlO- - GAAAGAGCUUUCUAGUAU 18
1571 20455
CFTR- IntronlO- - GAGAAAGAGCUUUCUAGUAU 20
1572 20456
CFTR- IntronlO- - GUUCAAAUUAUUUCUACUGCU 21
1573 20457
CFTR- IntronlO- - GUUGUUCAAAUUAUUUCUACUGCU 24
1574 20458
CFTR- IntronlO- - GUAAAGACUAAGGCUUAUUUCU 22
1575 20459
CFTR- IntronlO- - GAUAAGAAGAGAAAGGGGUGU 21
1576 20460
CFTR- IntronlO- - GUUGAUAAGAAGAGAAAGGGGUGU 24
1577 20461
689
5535.1 CFTR- IntronlO- - GUUGUUAUCUCUGAAAUU 18
1578 20462
CFTR- IntronlO- - GCUAUUACGGUAAGCUCAAGCAUU 24
1579 20463
CFTR- IntronlO- - GCUGCCUUUUAGUAGUAUU 19
1580 20464
CFTR-
- GGCUGCCUUUUAGUAGUAUU 20
lntronlO-126 19012
CFTR- IntronlO- - GAGGCUGCCUUUUAGUAGUAUU 22
1581 20465
CFTR- IntronlO- - GGAGGCUGCCUUUUAGUAGUAUU 23
1582 20466
CFTR- IntronlO- - GAAUAGAUUAGCUUAUAUACUU 22
1583 20467
CFTR- IntronlO- - GUUAGAGGAAGGCAGUGGUCCCUU 24
1584 20468
CFTR- IntronlO- - GAUGUGCAAAAAUAGCUU 18
1585 20469
CFTR- IntronlO- - GAUAGAUGUGCAAAAAUAGCUU 22
1586 20470
CFTR- IntronlO- - GUUACAUGACCUUCCUUUCUU 21
1587 20471
CFTR- IntronlO- - GAUAAUGGGAGAAACAGGUU 20
1588 20472
CFTR- IntronlO- - GCACUGGAGUUACCUGUU 18
1589 20473
CFTR- IntronlO- - GCAAAU AG UUUUAUCAAUAUUU 22
1590 20474
CFTR-
- GUUUUGGAUGGAGCUUGGUUU 21
IntronlO- 20475
690
5535.1 1591
CFTR- IntronlO- - GGUUUUGGAUGGAGCUUGGUUU 22
1592 20476
CFTR- IntronlO- - GUCCUCCACAAAUAUUUU 18
1593 20477
Table 41B provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within intron 10, have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 41B
Figure imgf000692_0001
691
5535.1 1600
CFTR- IntronlO- + UAACUCCAGUGCUAUUUAAA 20
1601 20485
CFTR- IntronlO- + AGGUAACUCCAGUGCUAUUUAAA 23
1602 20486
CFTR- IntronlO- + CAGGUAACUCCAGUGCUAUUUAAA 24
1603 20487
CFTR- IntronlO- + ACUCCAGGAGUAUAUCAA 18
1604 20488
CFTR- IntronlO- + UGGACUCCAGGAGUAUAUCAA 21
1605 20489
CFTR- IntronlO- + AGUGGACUCCAGGAGUAUAUCAA 23
1606 20490
CFTR- IntronlO- + AAGUGGACUCCAGGAGUAUAUCAA 24
1607 20491
CFTR- IntronlO- + AUGAGAGACAGUAAAGAA 18
1608 20492
CFTR- IntronlO- + AGAUGAGAGACAGUAAAGAA 20
1104 19989
CFTR- IntronlO- + AGGGUGGGAUAUGGAGAA 18
1609 20493
CFTR- IntronlO- + UAGGGUGGGAUAUGGAGAA 19
1610 20494
CFTR- IntronlO- + UUAGGGUGGGAUAUGGAGAA 20
1611 20495
CFTR- IntronlO- + UUUACCAUUAUCUACACA 18
1612 20496
CFTR-
+ UUUUACCAUUAUCUACACA 19
IntronlO- 20497
692
5535.1 1613
CFTR- IntronlO- + UUUUUACCAUUAUCUACACA 20
1614 20498
CFTR- IntronlO- + UAGUGAACUAGAGUCACA 18
1615 20499
CFTR- IntronlO- + UUAGUGAACUAGAGUCACA 19
1616 20500
CFTR- IntronlO- + AUUAGUGAACUAGAGUCACA 20
1617 20501
CFTR- IntronlO- + UAUUAGUGAACUAGAGUCACA 21
1618 20502
CFTR- IntronlO- + AUAUUAGUGAACUAGAGUCACA 22
1619 20503
CFTR- IntronlO- + CAUAUUAGUGAACUAGAGUCACA 23
1620 20504
CFTR- IntronlO- + UCAUAUUAGUGAACUAGAGUCACA 24
1621 20505
CFTR- IntronlO- + UGGAGAAGAGGAUGACCA 18
1622 20506
CFTR- IntronlO- + AUGGAGAAGAGGAUGACCA 19
1623 20507
CFTR- IntronlO- + UAUGGAGAAGAGGAUGACCA 20
1624 20508
CFTR- IntronlO- + AGAGACACACCUAAAGCA 18
1625 20509
CFTR- IntronlO- + AAGAGACACACCUAAAGCA 19
1626 20510
CFTR-
+ AAAGAGACACACCUAAAGCA 20
IntronlO- 20511
693
5535.1 1627
CFTR- IntronlO- + UAGUGAUUCAUUAUAUCA 18
1628 20512
CFTR- IntronlO- + AUAGUGAUUCAUUAUAUCA 19
1629 20513
CFTR- IntronlO- + AAUAGUGAUUCAUUAUAUCA 20
1630 20514
CFTR- IntronlO- + AUUUUUGCACAUCUAUCA 18
1631 20515
CFTR- IntronlO- + UAUUUUUGCACAUCUAUCA 19
1632 20516
CFTR- IntronlO- + CUAUUUUUGCACAUCUAUCA 20
1633 20517
CFTR- IntronlO- + AGCUAUUUUUGCACAUCUAUCA 22
1634 20518
CFTR- IntronlO- + AAGCUAUUUUUGCACAUCUAUCA 23
1635 20519
CFTR- IntronlO- + AAAGCUAUUUUUGCACAUCUAUCA 24
1636 20520
CFTR- IntronlO- + AAAAGGCAGCCUCCUAGA 18
1637 20521
CFTR- IntronlO- + UAAAAGGCAGCCUCCUAGA 19
1638 20522
CFTR- IntronlO- + CUAAAAGGCAGCCUCCUAGA 20
1639 20523
CFTR-
+ UGGCUACCUUGGUUGGAUGA 20
lntronlO-375 19261
CFTR- IntronlO- + UUGGCUACCUUGGUUGGAUGA 21
1640 20524
694
5535.1 CFTR- IntronlO- + AUUGGCUACCUUGGUUGGAUGA 22
1641 20525
CFTR- IntronlO- + AGAAUAUCCAUCCAUAUGA 19
1642 20526
CFTR- IntronlO- + UAGAAUAUCCAUCCAUAUGA 20
1643 20527
CFTR- IntronlO- + AUAGAAUAUCCAUCCAUAUGA 21
1644 20528
CFTR- IntronlO- + CAUAGAAUAUCCAUCCAUAUGA 22
1645 20529
CFTR- IntronlO- + UCAUAGAAUAUCCAUCCAUAUGA 23
1646 20530
CFTR- IntronlO- + AUCAUAGAAUAUCCAUCCAUAUGA 24
1647 20531
CFTR- IntronlO- + AUUACCAAAUUGUAUUGA 18
1648 20532
CFTR- IntronlO- + AAUUACCAAAUUGUAUUGA 19
1649 20533
CFTR- IntronlO- + AAAUUACCAAAUUGUAUUGA 20
1650 20534
CFTR- IntronlO- + AAAAUUACAGAACCUAUA 18
1651 20535
CFTR- IntronlO- + AAAAAU U ACAG AACCU AU A 19
1652 20536
CFTR- IntronlO- + CAAAAAUUACAGAACCUAUA 20
1170 20055
CFTR- IntronlO- + UGUUACAACAGUCUUUAUA 19
1653 20537
695
5535.1 CFTR- IntronlO- + UUGUUACAACAGUCUUUAUA 20
1654 20538
CFTR- IntronlO- + UCCUCCCUUGUCUCCCUA 18
1655 20539
CFTR- IntronlO- + UUCCUCCCUUGUCUCCCUA 19
1656 20540
CFTR- IntronlO- + CUUCCUCCCUUGUCUCCCUA 20
1657 20541
CFTR- IntronlO- + ACUUAUCCAUUAAUCCUA 18
1658 20542
CFTR- IntronlO- + AACUUAUCCAUUAAUCCUA 19
1659 20543
CFTR- IntronlO- + CAACUUAUCCAUUAAUCCUA 20
1660 20544
CFTR- IntronlO- + UCAACUUAUCCAUUAAUCCUA 21
1661 20545
CFTR- IntronlO- + UUCAACUUAUCCAUUAAUCCUA 22
1662 20546
CFTR- IntronlO- + UGUUCAACUUAUCCAUUAAUCCUA 24
1663 20547
CFTR- IntronlO- + ACAAAU U ACCAAAU UG U A 18
1664 20548
CFTR- IntronlO- + U ACAAAU U ACCAAAU UGU A 19
1665 20549
CFTR- IntronlO- + AU ACAAAU U ACCAAAU UG U A 20
1666 20550
CFTR- IntronlO- + U GAU ACAAAU U ACCAAAU UG U A 22
1667 20551
696
5535.1 CFTR- IntronlO- + CUGAUACAAAUUACCAAAUUGUA 23
1668 20552
CFTR- IntronlO- + UCUGAUACAAAUUACCAAAUUGUA 24
1669 20553
CFTR- IntronlO- + AGCCUGACACCAAAUUUA 18
1670 20554
CFTR- IntronlO- + CAGCCUGACACCAAAUUUA 19
1671 20555
CFTR- IntronlO- + CCAGCCUGACACCAAAUUUA 20
1672 20556
CFTR- IntronlO- + CCCAGCCUGACACCAAAUUUA 21
1673 20557
CFTR- IntronlO- + ACCCAGCCUGACACCAAAUUUA 22
1674 20558
CFTR- IntronlO- + CACCCAG CCUG ACACCAAAU U U A 23
1675 20559
CFTR- IntronlO- + ACAAAUAUUGACUAUUUA 18
1676 20560
CFTR- IntronlO- + UACAAAUAUUGACUAUUUA 19
1677 20561
CFTR- IntronlO- + AGUACAAAUAUUGACUAUUUA 21
1678 20562
CFTR- IntronlO- + AAGUACAAAUAUUGACUAUUUA 22
1679 20563
CFTR- IntronlO- + CAAGUACAAAUAUUGACUAUUUA 23
1680 20564
CFTR- IntronlO- + AGAGCUCAUAUUAGUGAAC 19
1681 20565
697
5535.1 CFTR- IntronlO- + CAGAGCUCAUAUUAGUGAAC 20
1682 20566
CFTR- IntronlO- + UCAGAGCUCAUAUUAGUGAAC 21
1683 20567
CFTR- IntronlO- + AUCAGAGCUCAUAUUAGUGAAC 22
1684 20568
CFTR- IntronlO- + UAUCAGAGCUCAUAUUAGUGAAC 23
1685 20569
CFTR- IntronlO- + UUAUCAGAGCUCAUAUUAGUGAAC 24
1686 20570
CFTR- IntronlO- + UCUAUUAAUAGAAACUAC 18
1687 20571
CFTR- IntronlO- + AUCUAUUAAUAGAAACUAC 19
1688 20572
CFTR- IntronlO- + AAUCUAUUAAUAGAAACUAC 20
1689 20573
CFTR- IntronlO- + UAAUCUAUUAAUAGAAACUAC 21
1690 20574
CFTR- IntronlO- + CUAAUCUAUUAAUAGAAACUAC 22
1691 20575
CFTR- IntronlO- + UCUAAUCUAUUAAUAGAAACUAC 23
1692 20576
CFTR- IntronlO- + CUCUAAUCUAUUAAUAGAAACUAC 24
1693 20577
CFTR- IntronlO- + UACUACUUCCACUACUAC 18
1694 20578
CFTR- IntronlO- + AUACUACUUCCACUACUAC 19
1695 20579
698
5535.1 CFTR- IntronlO- + UAUACUACUUCCACUACUAC 20
1696 20580
CFTR- IntronlO- + CUAUACUACUUCCACUACUAC 21
1697 20581
CFTR- IntronlO- + ACUAUACUACUUCCACUACUAC 22
1698 20582
CFTR- IntronlO- + UACUAUACUACUUCCACUACUAC 23
1699 20583
CFTR- IntronlO- + CUACUAUACUACUUCCACUACUAC 24
1700 20584
CFTR- IntronlO- + AUGAGUCCCAGUUAUUAC 18
1701 20585
CFTR- IntronlO- + UAUGAGUCCCAGUUAUUAC 19
1702 20586
CFTR- IntronlO- + AUAUGAGUCCCAGUUAUUAC 20
1703 20587
CFTR- IntronlO- + CAUAUGAGUCCCAGUUAUUAC 21
1704 20588
CFTR- IntronlO- + ACAUAUGAGUCCCAGUUAUUAC 22
1705 20589
CFTR- IntronlO- + UACAUAUGAGUCCCAGUUAUUAC 23
1706 20590
CFTR- IntronlO- + AUACAUAUGAGUCCCAGUUAUUAC 24
1707 20591
CFTR- IntronlO- + AGAUACUAAAAAAAGUUAC 19
1708 20592
CFTR- IntronlO- + A AG A U AC U A A A A A A AG U U AC 20
1709 20593
699
5535.1 CFTR- IntronlO- + UAUUAGCAAGUGGACUCC 18
1710 20594
CFTR-
+ UGUAUUAGCAAGUGGACUCC 20
lntronlO-426 19312
CFTR- IntronlO- + UUGUAUUAGCAAGUGGACUCC 21
1711 20595
CFTR- IntronlO- + AUUGUAUUAGCAAGUGGACUCC 22
1712 20596
CFTR- IntronlO- + AAUUGUAUUAGCAAGUGGACUCC 23
1713 20597
CFTR- IntronlO- + CAAUUGUAUUAGCAAGUGGACUCC 24
1714 20598
CFTR- IntronlO- + UGAGCCUAUCACCUAGGC 18
1715 20599
CFTR- IntronlO- + UUGAGCCUAUCACCUAGGC 19
1716 20600
CFTR- IntronlO- + UUUGAGCCUAUCACCUAGGC 20
1717 20601
CFTR- IntronlO- + CUAUUUAGAGUGUAUGGC 18
1718 20602
CFTR- IntronlO- + UCUAUUUAGAGUGUAUGGC 19
1719 20603
CFTR- IntronlO- + CUCUAUUUAGAGUGUAUGGC 20
1720 20604
CFTR- IntronlO- + ACUCUAUUUAGAGUGUAUGGC 21
1721 20605
CFTR- IntronlO- + CACUCUAUUUAGAGUGUAUGGC 22
1722 20606
CFTR-
+ AGCACUCUAUUUAGAGUGUAUGGC 24
IntronlO- 20607
700
5535.1 1723
CFTR- IntronlO- + AAAGGCUCUUUAUAAUGC 18
1724 20608
CFTR- IntronlO- + AAAAGGCUCUUUAUAAUGC 19
1725 20609
CFTR- IntronlO- + AGAAAAGGCUCUUUAUAAUGC 21
1726 20610
CFTR- IntronlO- + AAGAAAAGGCUCUUUAUAAUGC 22
1727 20611
CFTR- IntronlO- + AAAGAAAAGGCUCUUUAUAAUGC 23
1728 20612
CFTR- IntronlO- + AAAAGAAAAGGCUCUUUAUAAUGC 24
1729 20613
CFTR- IntronlO- + CUAAGAGACUCCUGAAUC 18
1730 20614
CFTR- IntronlO- + UGCUAAGAGACUCCUGAAUC 20
1731 20615
CFTR- IntronlO- + CUGCUAAGAGACUCCUGAAUC 21
1732 20616
CFTR- IntronlO- + UCUGCUAAGAGACUCCUGAAUC 22
1733 20617
CFTR- IntronlO- + UGUAGAAGACCUAAAUAUC 19
1734 20618
CFTR- IntronlO- + AUGUAGAAGACCUAAAUAUC 20
1735 20619
CFTR- IntronlO- + AGAUGUAGAAGACCUAAAUAUC 22
1736 20620
CFTR-
+ AAGAUGUAGAAGACCUAAAUAUC 23
IntronlO- 20621
701
5535.1 1737
CFTR- IntronlO- + UGGGUCUGCUAAGAGACUC 19
1738 20622
CFTR- IntronlO- + UUGGGUCUGCUAAGAGACUC 20
1739 20623
CFTR- IntronlO- + UUUGGGUCUGCUAAGAGACUC 21
1740 20624
CFTR- IntronlO- + AUUUGGGUCUGCUAAGAGACUC 22
1741 20625
CFTR- IntronlO- + AGAUUUGGGUCUGCUAAGAGACUC 24
1742 20626
CFTR- IntronlO- + UACUAUUGCUUUCAUUAAGUC 21
1743 20627
CFTR- IntronlO- + CUACUAUUGCUUUCAUUAAGUC 22
1744 20628
CFTR- IntronlO- + UCUACUAUUGCUUUCAUUAAGUC 23
1745 20629
CFTR- IntronlO- + CUCUACUAUUGCUUUCAUUAAGUC 24
1746 20630
CFTR- IntronlO- + UAGAGACAAGGUGGUGUC 18
1747 20631
CFTR- IntronlO- + AUAGAGACAAGGUGGUGUC 19
1748 20632
CFTR-
+ AAUAGAGACAAGGUGGUGUC 20
lntronlO-437 19323
CFTR- IntronlO- + UAAUAGAGACAAGGUGGUGUC 21
1749 20633
CFTR- IntronlO- + AUAAUAGAGACAAGGUGGUGUC 22
1750 20634
702
5535.1 CFTR- IntronlO- + AAUAAUAGAGACAAGGUGGUGUC 23
1751 20635
CFTR- IntronlO- + CAAUAAUAGAGACAAGGUGGUGUC 24
1752 20636
CFTR- IntronlO- + UAUUUUUCAUUAUGAUUC 18
1753 20637
CFTR- IntronlO- + AUAUUUUUCAUUAUGAUUC 19
1754 20638
CFTR- IntronlO- + UUGACAUCAGUUGGGUUC 18
1755 20639
CFTR- IntronlO- + CUUGACAUCAGUUGGGUUC 19
1756 20640
CFTR- IntronlO- + UGCUUGACAUCAGUUGGGUUC 21
1757 20641
CFTR- IntronlO- + CUGCUUGACAUCAGUUGGGUUC 22
1758 20642
CFTR- IntronlO- + UCUGCUUGACAUCAGUUGGGUUC 23
1759 20643
CFTR- IntronlO- + UUCUGCUUGACAUCAGUUGGGUUC 24
1760 20644
CFTR- IntronlO- + UGAUAAAUAAUUGCCUUUC 19
1761 20645
CFTR-
+ UUGAUAAAUAAUUGCCUUUC 20
Intron 10-445 19331
CFTR- IntronlO- + AUUGAUAAAUAAUUGCCUUUC 21
1762 20646
CFTR- IntronlO- + UAUUGAUAAAUAAUUGCCUUUC 22
1763 20647
CFTR-
+ AUAUUGAUAAAUAAUUGCCUUUC 23
IntronlO- 20648
703
5535.1 1764
CFTR- IntronlO- + UUGGAUGAGGGAAUGCAG 18
1765 20649
CFTR- IntronlO- + UGGUUGGAUGAGGGAAUGCAG 21
1766 20650
CFTR- IntronlO- + UUGGUUGGAUGAGGGAAUGCAG 22
1767 20651
CFTR- IntronlO- + CUUGGUUGGAUGAGGGAAUGCAG 23
1768 20652
CFTR- IntronlO- + CCUUGGUUGGAUGAGGGAAUGCAG 24
1769 20653
CFTR- IntronlO- + CCUUCUGCUUGACAUCAG 18
1770 20654
CFTR- IntronlO- + CCCUUCUGCUUGACAUCAG 19
1771 20655
CFTR- IntronlO- + ACCCUUCUGCUUGACAUCAG 20
1772 20656
CFTR- IntronlO- + CACCCUUCUGCUUGACAUCAG 21
1773 20657
CFTR- IntronlO- + ACACCCUUCUGCUUGACAUCAG 22
1774 20658
CFTR- IntronlO- + AACACCCUUCUGCUUGACAUCAG 23
1775 20659
CFTR- IntronlO- + UAACACCCUUCUGCUUGACAUCAG 24
1776 20660
CFTR- IntronlO- + AAUUGAUCUUGAAGACAUACG 21
1777 20661
CFTR-
+ AGAAUUGAUCUUGAAGACAUACG 23
IntronlO- 20662
704
5535.1 1778
CFTR- IntronlO- + UAGAAUUGAUCUUGAAGACAUACG 24
1779 20663
CFTR- IntronlO- + ACUGUGAAUGGUGCCAGG 18
1780 20664
CFTR- IntronlO- + UACUGUGAAUGGUGCCAGG 19
1781 20665
CFTR- IntronlO- + UUACUGUGAAUGGUGCCAGG 20
1782 20666
CFTR- IntronlO- + UUUACUGUGAAUGGUGCCAGG 21
1783 20667
CFTR- IntronlO- + CUUUACUGUGAAUGGUGCCAGG 22
1784 20668
CFTR- IntronlO- + UCUUUACUGUGAAUGGUGCCAGG 23
1785 20669
CFTR- IntronlO- + CUCUUUACUGUGAAUGGUGCCAGG 24
1786 20670
CFTR- IntronlO- + AGAUGAUUAUUAAUAGGG 18
1787 20671
CFTR- IntronlO- + UAGAUGAUUAUUAAUAGGG 19
1788 20672
CFTR- IntronlO- + CUAGAUGAUUAUUAAUAGGG 20
1789 20673
CFTR- IntronlO- + CCUAGAUGAUUAUUAAUAGGG 21
1790 20674
CFTR- IntronlO- + AGCCUAGAUGAUUAUUAAUAGGG 23
1791 20675
CFTR-
+ CAGCCUAGAUGAUUAUUAAUAGGG 24
IntronlO- 20676
705
5535.1 1792
CFTR-
+ AGGUUAAGUUGUUCUUAGGG 20
lntronlO-475 19361
CFTR- IntronlO- + CAGGUUAAGUUGUUCUUAGGG 21
1793 20677
CFTR- IntronlO- + CCAGGUUAAGUUGUUCUUAGGG 22
1794 20678
CFTR- IntronlO- + UGCCAGGUUAAGUUGUUCUUAGGG 24
1795 20679
CFTR- IntronlO- + UAACAAACCUUUUAUUGG 18
1796 20680
CFTR- IntronlO- + U U AACAAACCU UUUAUUGG 19
1797 20681
CFTR- IntronlO- + U U U AACAAACCU UUUAUUGG 20
1798 20682
CFTR- IntronlO- + CUGGAUUGGCUACCUUGG 18
1799 20683
CFTR- IntronlO- + CCUGGAUUGGCUACCUUGG 19
1800 20684
CFTR- IntronlO- + ACCUGGAUUGGCUACCUUGG 20
1801 20685
CFTR- IntronlO- + UACCUGGAUUGGCUACCUUGG 21
1802 20686
CFTR- IntronlO- + UUACCUGGAUUGGCUACCUUGG 22
1803 20687
CFTR- IntronlO- + AGUUACCUGGAUUGGCUACCUUGG 24
1804 20688
CFTR- IntronlO- + AGGAAAUGGGGUAUAAGUG 19
1805 20689
706
5535.1 CFTR-
+ AAGGAAAUGGGGUAUAAGUG 20
Intron 10-487 19373
CFTR- IntronlO- + UACAUAAAAAGAGAGGUG 18
1806 20690
CFTR- IntronlO- + UUACAUAAAAAGAGAGGUG 19
1807 20691
CFTR- IntronlO- + UGUUACAUAAAAAGAGAGGUG 21
1808 20692
CFTR- IntronlO- + UUGUUACAUAAAAAGAGAGGUG 22
1809 20693
CFTR- IntronlO- + AUUGUUACAUAAAAAGAGAGGUG 23
1810 20694
CFTR- IntronlO- + UAUUGUUACAUAAAAAGAGAGGUG 24
1811 20695
CFTR- IntronlO- + ACAGUUUCAUCUUACUUG 18
1812 20696
CFTR- IntronlO- + AACAGUUUCAUCUUACUUG 19
1813 20697
CFTR- IntronlO- + UAACAGUUUCAUCUUACUUG 20
1814 20698
CFTR- IntronlO- + AUAACAGUUUCAUCUUACUUG 21
1815 20699
CFTR- IntronlO- + UAUAACAGUUUCAUCUUACUUG 22
1816 20700
CFTR- IntronlO- + UUAUAACAGUUUCAUCUUACUUG 23
1817 20701
CFTR- IntronlO- + AUUAUAACAGUUUCAUCUUACUUG 24
1818 20702
CFTR-
+ UAUUACAUGGGAAAAAAU 18
IntronlO- 20703
707
5535.1 1819
CFTR- IntronlO- + UUAUUACAUGGGAAAAAAU 19
1820 20704
CFTR- IntronlO- + CUUAUUACAUGGGAAAAAAU 20
1821 20705
CFTR- IntronlO- + UCUUAUUACAUGGGAAAAAAU 21
1822 20706
CFTR- IntronlO- + UUCUUAUUACAUGGGAAAAAAU 22
1823 20707
CFTR- IntronlO- + AUUCUUAUUACAUGGGAAAAAAU 23
1824 20708
CFTR- IntronlO- + AAUUCUUAUUACAUGGGAAAAAAU 24
1825 20709
CFTR- IntronlO- + AUAGCUUAUUCUAUACAU 18
1826 20710
CFTR- IntronlO- + AAUAGCUUAUUCUAUACAU 19
1827 20711
CFTR- IntronlO- + UAAUAGCUUAUUCUAUACAU 20
1828 20712
CFTR- IntronlO- + CUAAUAGCUUAUUCUAUACAU 21
1829 20713
CFTR- IntronlO- + AGCUAAUAGCUUAUUCUAUACAU 23
1830 20714
CFTR- IntronlO- + AUGAUGUACAUUUAAUAU 18
1831 20715
CFTR- IntronlO- + AAUGAUGUACAUUUAAUAU 19
1832 20716
CFTR-
+ UAAUGAUGUACAUUUAAUAU 20
IntronlO- 20717
708
5535.1 1833
CFTR- IntronlO- + AUAAUGAUGUACAUUUAAUAU 21
1834 20718
CFTR- IntronlO- + AAUAAUGAUGUACAUUUAAUAU 22
1835 20719
CFTR- IntronlO- + UGAAUAAUGAUGUACAUUUAAUAU 24
1836 20720
CFTR- IntronlO- + AGAUCUCUGCAAACAUAU 18
1837 20721
CFTR- IntronlO- + AAGAUCUCUGCAAACAUAU 19
1838 20722
CFTR- IntronlO- + UAAGAUCUCUGCAAACAUAU 20
1839 20723
CFTR- IntronlO- + AUAAGAUCUCUGCAAACAUAU 21
1840 20724
CFTR- IntronlO- + CAUAAGAUCUCUGCAAACAUAU 22
1841 20725
CFTR- IntronlO- + ACAUAAGAUCUCUGCAAACAUAU 23
1842 20726
CFTR- IntronlO- + UACAUAAGAUCUCUGCAAACAUAU 24
1843 20727
CFTR- IntronlO- + AAUGGAAACACUAUAUAU 18
1844 20728
CFTR- IntronlO- + UAAUGGAAACACUAUAUAU 19
1845 20729
CFTR- IntronlO- + UGUAAUGGAAACACUAUAUAU 21
1846 20730
CFTR-
+ AUGUAAUGGAAACACUAUAUAU 22
IntronlO- 20731
709
5535.1 1847
CFTR- IntronlO- + AAUGUAAUGGAAACACUAUAUAU 23
1848 20732
CFTR- IntronlO- + CAAUGUAAUGGAAACACUAUAUAU 24
1849 20733
CFTR- IntronlO- + UCCAACUAACAUCUCUAU 18
1850 20734
CFTR- IntronlO- + AUCCAACUAACAUCUCUAU 19
1851 20735
CFTR- IntronlO- + CAUCCAACUAACAUCUCUAU 20
1852 20736
CFTR- IntronlO- + ACAU CCAACU AACAU CU CU AU 21
1853 20737
CFTR- IntronlO- + UACAUCCAACUAACAUCUCUAU 22
1854 20738
CFTR- IntronlO- + UGUACAUCCAACUAACAUCUCUAU 24
1855 20739
CFTR- IntronlO- + UCCUUAACCUCUAAUACU 18
1856 20740
CFTR- IntronlO- + CUCCUUAACCUCUAAUACU 19
1857 20741
CFTR- IntronlO- + CCUCCUUAACCUCUAAUACU 20
1858 20742
CFTR- IntronlO- + ACCUCCUUAACCUCUAAUACU 21
1859 20743
CFTR- IntronlO- + CACCUCCUUAACCUCUAAUACU 22
1860 20744
CFTR-
+ CCACCUCCUUAACCUCUAAUACU 23
IntronlO- 20745
710
5535.1 1861
CFTR- IntronlO- + CCCACCUCCUUAACCUCUAAUACU 24
1862 20746
CFTR- IntronlO- + UGGAAAAUGUUAAAUUUUCCCU 22
1863 20747
CFTR- IntronlO- + CUGGAAAAUGUUAAAUUUUCCCU 23
1864 20748
CFTR- IntronlO- + UCUGGAAAAUGUUAAAUUUUCCCU 24
1865 20749
CFTR-
+ AGGCACUUGUUGACAGUCCU 20
lntronlO-516 19402
CFTR- IntronlO- + UAGGCACUUGUUGACAGUCCU 21
1866 20750
CFTR- IntronlO- + CUAGGCACUUGUUGACAGUCCU 22
1867 20751
CFTR- IntronlO- + UGCUAGGCACUUGUUGACAGUCCU 24
1868 20752
CFTR- IntronlO- + UACUCAGUCCAGAAAGCU 18
1869 20753
CFTR- IntronlO- + UUACUCAGUCCAGAAAGCU 19
1870 20754
CFTR- IntronlO- + UGUGCAAGUCCUCUGUGCU 19
1871 20755
CFTR- IntronlO- + AUGUGCAAGUCCUCUGUGCU 20
1872 20756
CFTR- IntronlO- + UAUGUGCAAGUCCUCUGUGCU 21
1873 20757
CFTR- IntronlO- + AUAUGUGCAAGUCCUCUGUGCU 22
1874 20758
711
5535.1 CFTR- IntronlO- + CAUAUGUGCAAGUCCUCUGUGCU 23
1875 20759
CFTR- IntronlO- + ACAUAUGUGCAAGUCCUCUGUGCU 24
1876 20760
CFTR- IntronlO- + UUAAUUGCCAGUAAGUCU 18
1877 20761
CFTR- IntronlO- + UUUAAUUGCCAGUAAGUCU 19
1878 20762
CFTR-
+ AUUUAAUUGCCAGUAAGUCU 20
lntronlO-526 19412
CFTR- IntronlO- + UGCCAGGUUAAGUUGUUCU 19
1879 20763
CFTR- IntronlO- + AUGCCAGGUUAAGUUGUUCU 20
1880 20764
CFTR- IntronlO- + AGAGUGUAUGGCAUGAGU 18
1881 20765
CFTR- IntronlO- + UAGAGUGUAUGGCAUGAGU 19
1882 20766
CFTR- IntronlO- + UUAGAGUGUAUGGCAUGAGU 20
1883 20767
CFTR- IntronlO- + UUUAGAGUGUAUGGCAUGAGU 21
1884 20768
CFTR- IntronlO- + AUUUAGAGUGUAUGGCAUGAGU 22
1885 20769
CFTR- IntronlO- + UAUUUAGAGUGUAUGGCAUGAGU 23
1886 20770
CFTR- IntronlO- + CUAUUUAGAGUGUAUGGCAUGAGU 24
1887 20771
CFTR-
+ AGGGUCUCUCUAAGGUGU 18
IntronlO- 20772
712
5535.1 1888
CFTR- IntronlO- + UGAGGGUCUCUCUAAGGUGU 20
1889 20773
CFTR- IntronlO- + UGGGGAAAUCAGCACUCUAUU 21
1890 20774
CFTR- IntronlO- + UGUGGGGAAAUCAGCACUCUAUU 23
1891 20775
CFTR- IntronlO- + CUGUGGGGAAAUCAGCACUCUAUU 24
1892 20776
CFTR- IntronlO- + UGUAACUCUUUAUUCACUU 19
1893 20777
CFTR- IntronlO- + UUGUAACUCUUUAUUCACUU 20
1894 20778
CFTR- IntronlO- + UUUGUAACUCUUUAUUCACUU 21
1895 20779
CFTR- IntronlO- + UUUUGUAACUCUUUAUUCACUU 22
1896 20780
CFTR- IntronlO- + AUUUUGUAACUCUUUAUUCACUU 23
1897 20781
CFTR- IntronlO- + CAUUUUGUAACUCUUUAUUCACUU 24
1898 20782
CFTR- IntronlO- + UAUCAACCCUCUUUCCUU 18
1899 20783
CFTR- IntronlO- + UUAUCAACCCUCUUUCCUU 19
1900 20784
CFTR- IntronlO- + CUUAUCAACCCUCUUUCCUU 20
1901 20785
CFTR-
+ UCUUAUCAACCCUCUUUCCUU 21
IntronlO- 20786
713
5535.1 1902
CFTR- IntronlO- + UUCUUAUCAACCCUCUUUCCUU 22
1903 20787
CFTR- IntronlO- + CUUCUUAUCAACCCUCUUUCCUU 23
1904 20788
CFTR- IntronlO- + UCUUCUUAUCAACCCUCUUUCCUU 24
1905 20789
CFTR- IntronlO- + U U U AU CAACAUG AAGG U U 18
1906 20790
CFTR- IntronlO- + CUUUAUCAACAUGAAGGUU 19
1907 20791
CFTR-
+ CCUUUAUCAACAUGAAGGUU 20
lntronlO-555 19441
CFTR- IntronlO- - UGCUUUCAGGAG CCAAAAA 19
1908 20792
CFTR- IntronlO- - C U G C U U U CAG G AG CCAAAAA 20
1909 20793
CFTR- IntronlO- - ACUGCUUUCAGGAGCCAAAAA 21
1910 20794
CFTR- IntronlO- - CACUGCUUU CAG GAG CCAAAAA 22
1911 20795
CFTR- IntronlO- - ACACUGCUUUCAGGAGCCAAAAA 23
1912 20796
CFTR- IntronlO- - AACACUG CU U U CAGG AG CCAAAAA 24
1913 20797
CFTR- IntronlO- - UUAAACACUUCUGAGAAA 18
1914 20798
CFTR- IntronlO- - UUUAAACACUUCUGAGAAA 19
1915 20799
714
5535.1 CFTR- IntronlO- - AUUUAAACACUUCUGAGAAA 20
1096 19981
CFTR- IntronlO- - AUAAGAUUCU A A AG G AAA 18
1916 20800
CFTR- IntronlO- - UGGAUAAGAUUCUAAAGGAAA 21
1917 20801
CFTR- IntronlO- - CUGGAUAAGAUUCUAAAGGAAA 22
1918 20802
CFTR- IntronlO- - CAUGCCAUACACUCUAAA 18
1919 20803
CFTR- IntronlO- - UCAUGCCAUACACUCUAAA 19
1920 20804
CFTR- IntronlO- - CUCAUGCCAUACACUCUAAA 20
1921 20805
CFTR- IntronlO- - ACUCAUGCCAUACACUCUAAA 21
1922 20806
CFTR- IntronlO- - UACUCAUGCCAUACACUCUAAA 22
1923 20807
CFTR- IntronlO- - CGUACUCAUGCCAUACACUCUAAA 24
1924 20808
CFTR- IntronlO- - AGGUUUAAUUUUGUACAA 18
1925 20809
CFTR- IntronlO- - UAGGUUUAAUUUUGUACAA 19
1926 20810
CFTR-
- CUAGGUUUAAUUUUGUACAA 20
lntronlO-343 19229
CFTR- IntronlO- - UCUAGGUUUAAUUUUGUACAA 21
1927 20811
CFTR-
- UUCUAGGUUUAAUUUUGUACAA 22
IntronlO- 20812
715
5535.1 1928
CFTR- IntronlO- - CUUCUAGGUUUAAUUUUGUACAA 23
1929 20813
CFTR- IntronlO- - ACUUCUAGGUUUAAUUUUGUACAA 24
1930 20814
CFTR- IntronlO- - CUUUGAAGGAAGAUCCAA 18
1931 20815
CFTR- IntronlO- - UGCUUUGAAGGAAGAUCCAA 20
1932 20816
CFTR- IntronlO- - UAAUCAUCUAGGCUGCAA 18
1933 20817
CFTR- IntronlO- - AUAAUCAUCUAGGCUGCAA 19
1934 20818
CFTR- IntronlO- - AAUAAUCAUCUAGGCUGCAA 20
1935 20819
CFTR- IntronlO- - UAAUAAUCAUCUAGGCUGCAA 21
1936 20820
CFTR- IntronlO- - UUAAUAAUCAUCUAGGCUGCAA 22
1937 20821
CFTR- IntronlO- - AUUAAUAAUCAUCUAGGCUGCAA 23
1938 20822
CFTR- IntronlO- - UAUUAAUAAUCAUCUAGGCUGCAA 24
1939 20823
CFTR- IntronlO- - AGG AG AACCAU AU U U U G AAG AA 22
1940 20824
CFTR- IntronlO- - UGAGGAGAACCAUAUUUUGAAGAA 24
1941 20825
CFTR-
- AGGGUUGAUAAGAAGAGAA 19
IntronlO- 20826
716
5535.1 1942
CFTR- IntronlO- - AGAGGGUUGAUAAGAAGAGAA 21
1943 20827
CFTR- IntronlO- - AAGAGGGUUGAUAAGAAGAGAA 22
1944 20828
CFTR- IntronlO- - AAAGAGGGUUGAUAAGAAGAGAA 23
1945 20829
CFTR- IntronlO- - UGCUCUCUGACCACAUAA 18
1946 20830
CFTR- IntronlO- - UUGCUCUCUGACCACAUAA 19
1947 20831
CFTR- IntronlO- - CUUGCUCUCUGACCACAUAA 20
1948 20832
CFTR- IntronlO- - ACUUGCUCUCUGACCACAUAA 21
1949 20833
CFTR- IntronlO- - UACUUGCUCUCUGACCACAUAA 22
1950 20834
CFTR- IntronlO- - UGUACUUGCUCUCUGACCACAUAA 24
1951 20835
CFTR- IntronlO- - UAUAUGAUAUACUCUUAA 18
1952 20836
CFTR- IntronlO- - UGUAUAUGAUAUACUCUUAA 20
1953 20837
CFTR- IntronlO- - AUGUAUAUGAUAUACUCUUAA 21
1954 20838
CFTR- IntronlO- - CGGAUGUAUAUGAUAUACUCUUAA 24
1955 20839
CFTR-
- AACU CAU U AGG AAAAUG U ACA 21
IntronlO- 20840
717
5535.1 1956
CFTR- IntronlO- - CAACUCAUUAGGAAAAUGUACA 22
1957 20841
CFTR- IntronlO- - CCAACUCAUUAGGAAAAUGUACA 23
1958 20842
CFTR- IntronlO- - ACCAACU CAU U AGG AAAAUG U ACA 24
1959 20843
CFTR- IntronlO- - A U G A AG U U A A A A AC A U C A 18
1960 20844
CFTR- IntronlO- - UAUGAAGUU A A A A AC A U C A 19
1961 20845
CFTR- IntronlO- - AUAUGAAGUUAAAAACAUCA 20
1962 20846
CFTR- IntronlO- - AGUAUAGAAUUUUGCAUCA 19
1963 20847
CFTR- IntronlO- - UAGUAUAGAAUUUUGCAUCA 20
1964 20848
CFTR- IntronlO- - AGGUAGUAAUUGUGUUUCA 19
1965 20849
CFTR- IntronlO- - AAGGUAGUAAUUGUGUUUCA 20
1966 20850
CFTR- IntronlO- - AAAGGUAGUAAUUGUGUUUCA 21
1967 20851
CFTR- IntronlO- - AAAAGGUAGUAAUUGUGUUUCA 22
1968 20852
CFTR- IntronlO- - UGAAAAGGUAGUAAUUGUGUUUCA 24
1969 20853
CFTR-
- AGAGCCUUUUCUUUUUCA 18
IntronlO- 20854
718
5535.1 1970
CFTR- IntronlO- - AAGAGCCUUUUCUUUUUCA 19
1971 20855
CFTR- IntronlO- - AAAGAGCCUUUUCUUUUUCA 20
1972 20856
CFTR- IntronlO- - UCUAGCUAAAAUAUAAGA 18
1973 20857
CFTR- IntronlO- - AUCUAGCUAAAAUAUAAGA 19
1974 20858
CFTR- IntronlO- - CUUGACCAGAAUGAAAUUAGA 21
1975 20859
CFTR- IntronlO- - ACUUGACCAGAAUGAAAUUAGA 22
1976 20860
CFTR- IntronlO- - AACUUGACCAGAAUGAAAUUAGA 23
1977 20861
CFTR- IntronlO- - AAACUUGACCAGAAUGAAAUUAGA 24
1978 20862
CFTR- IntronlO- - AGGAAAAUGUACAAAGGA 18
1979 20863
CFTR- IntronlO- - UAGGAAAAUGUACAAAGGA 19
1980 20864
CFTR- IntronlO- - UU AGGAAAAUGUACAAAGGA 20
1981 20865
CFTR- IntronlO- - UGAUUCCAAGCUUUCUGGA 19
1982 20866
CFTR- IntronlO- - AUGAUUCCAAGCUUUCUGGA 20
1983 20867
CFTR-
- UAUACUCUUAAGUGAAUA 18
IntronlO- 20868
719
5535.1 1984
CFTR- IntronlO- - AUAUACUCUUAAGUGAAUA 19
1985 20869
CFTR- IntronlO- - UGAUAUACUCUUAAGUGAAUA 21
1986 20870
CFTR- IntronlO- - AUGAUAUACUCUUAAGUGAAUA 22
1987 20871
CFTR- IntronlO- - UAUGAUAUACUCUUAAGUGAAUA 23
1988 20872
CFTR- IntronlO- - AUAUGAUAUACUCUUAAGUGAAUA 24
1989 20873
CFTR- IntronlO- - CUAACCUUCAUGUUGAUA 18
1990 20874
CFTR- IntronlO- - CCUAACCUUCAUGUUGAUA 19
1991 20875
CFTR- IntronlO- - CCCUAACCUUCAUGUUGAUA 20
1992 20876
CFTR- IntronlO- - UGGAUAUUCUAUGAUAUA 18
1993 20877
CFTR- IntronlO- - AUGGAUAUUCUAUGAUAUA 19
1994 20878
CFTR- IntronlO- - UGGAUGGAUAUUCUAUGAUAUA 22
1995 20879
CFTR- IntronlO- - AUGGAUGGAUAUUCUAUGAUAUA 23
1996 20880
CFTR- IntronlO- - UAUGGAUGGAUAUUCUAUGAUAUA 24
1997 20881
CFTR-
- AUACUUUCUAGAAUUAUA 18
IntronlO- 20882
720
5535.1 1998
CFTR- IntronlO- - AAUACUUUCUAGAAUUAUA 19
1999 20883
CFTR- IntronlO- - AAAUACUUUCUAGAAUUAUA 20
2000 20884
CFTR- IntronlO- - UUUUGCUUGCUUUUUAUA 18
2001 20885
CFTR- IntronlO- - UUUUUGCUUGCUUUUUAUA 19
2002 20886
CFTR- IntronlO- - UCUGAGAAGACAAAGCUA 18
2003 20887
CFTR- IntronlO- - AGUCUGAGAAGACAAAGCUA 20
2004 20888
CFTR- IntronlO- - AAGUCUGAGAAGACAAAGCUA 21
2005 20889
CFTR- IntronlO- - AAAGUCUGAGAAGACAAAGCUA 22
2006 20890
CFTR- IntronlO- - A AAAG U C U GAG AAG AC AAAG C U A 23
2007 20891
CFTR- IntronlO- - UAAAAGUCUGAGAAGACAAAGCUA 24
2008 20892
CFTR- IntronlO- - AGUGAAGCAAUAUUAGUA 18
2009 20893
CFTR- IntronlO- - UAGUGAAGCAAUAUUAGUA 19
2010 20894
CFTR- IntronlO- - UU AGUGAAGCAAUAUUAGUA 20
2011 20895
CFTR-
- UUUAGUGAAGCAAUAUUAGUA 21
IntronlO- 20896
721
5535.1 2012
CFTR- IntronlO- - UUUUAGUGAAGCAAUAUUAGUA 22
2013 20897
CFTR- IntronlO- - AUUUUAGUGAAGCAAUAUUAGUA 23
2014 20898
CFTR- IntronlO- - UAUUUUAGUGAAGCAAUAUUAGUA 24
2015 20899
CFTR- IntronlO- - UAAUCGGCGGUGGAGGUA 18
2016 20900
CFTR-
- AGUAAUCGGCGGUGGAGGUA 20
lntronlO-389 19275
CFTR- IntronlO- - AAGUAAUCGGCGGUGGAGGUA 21
2017 20901
CFTR- IntronlO- - AGAAGUAAUCGGCGGUGGAGGUA 23
2018 20902
CFTR- IntronlO- - CAUUGCCUCACUAUGGUA 18
2019 20903
CFTR- IntronlO- - UCAUUGCCUCACUAUGGUA 19
2020 20904
CFTR- IntronlO- - AUCAUUGCCUCACUAUGGUA 20
2021 20905
CFTR- IntronlO- - UGAUCAUUGCCUCACUAUGGUA 22
2022 20906
CFTR- IntronlO- - UUGAUCAUUGCCUCACUAUGGUA 23
2023 20907
CFTR- IntronlO- - AUUGAUCAUUGCCUCACUAUGGUA 24
2024 20908
CFTR- IntronlO- - AACUGGGACUCAUAUGUA 18
2025 20909
722
5535.1 CFTR- IntronlO- - UAACUGGGACUCAUAUGUA 19
2026 20910
CFTR- IntronlO- - AUAACUGGGACUCAUAUGUA 20
2027 20911
CFTR- IntronlO- - AAUAACUGGGACUCAUAUGUA 21
2028 20912
CFTR- IntronlO- - UAAUAACUGGGACUCAUAUGUA 22
2029 20913
CFTR- IntronlO- - UGUAAUAACUGGGACUCAUAUGUA 24
2030 20914
CFTR- IntronlO- - AGGAAGAUCCAAUAGGAUUA 20
2031 20915
CFTR- IntronlO- - AAGGAAGAUCCAAUAGGAUUA 21
2032 20916
CFTR- IntronlO- - UGAAGGAAGAUCCAAUAGGAUUA 23
2033 20917
CFTR- IntronlO- - UUGAAGGAAGAUCCAAUAGGAUUA 24
2034 20918
CFTR- IntronlO- - UGCAGGAGGUGAGGGAUUA 19
2035 20919
CFTR-
- UUGCAGGAGGUGAGGGAUUA 20
lntronlO-394 19280
CFTR- IntronlO- - CAGCCAAUAAAAGGUUUGUUA 21
2036 20920
CFTR- IntronlO- - UCAGCCAAUAAAAGGUUUGUUA 22
2037 20921
CFTR- IntronlO- - U U CAG CCAAU AAAAGG U U UG U U A 23
2038 20922
CFTR-
- AUUCAGCCAAUAAAAGGUUUGUUA 24
IntronlO- 20923
723
5535.1 2039
CFTR- IntronlO- - AGUUAGCAAUGGUCUAAAC 19
2040 20924
CFTR- IntronlO- - AAGUUAGCAAUGGUCUAAAC 20
2041 20925
CFTR- IntronlO- - AUUCUGUUUAAAUAGCAC 18
2042 20926
CFTR-
- UGAUUCUGUUUAAAUAGCAC 20
lntronlO-410 19296
CFTR- IntronlO- - CUGAUUCUGUUUAAAUAGCAC 21
2043 20927
CFTR- IntronlO- - CCUGAUUCUGUUUAAAUAGCAC 22
2044 20928
CFTR- IntronlO- - CCCUGAUUCUGUUUAAAUAGCAC 23
2045 20929
CFTR- IntronlO- - CCCCUGAUUCUGUUUAAAUAGCAC 24
2046 20930
CFTR- IntronlO- - AGAGAAGGUCAAACUUGAC 19
2047 20931
CFTR- IntronlO- - UAGAGAAGGUCAAACUUGAC 20
2048 20932
CFTR- IntronlO- - AGUAGAGAAGGUCAAACUUGAC 22
2049 20933
CFTR- IntronlO- - U AG U AG AG AAGG U CAAACU UG AC 23
2050 20934
CFTR- IntronlO- - AUAGUAGAGAAGGUCAAACUUGAC 24
2051 20935
CFTR- IntronlO- - CUCUAUAUAAAGUGAUCC 18
2052 20936
724
5535.1 CFTR- IntronlO- - UCUCUAUAUAAAGUGAUCC 19
2053 20937
CFTR- IntronlO- - CUCUCUAUAUAAAGUGAUCC 20
2054 20938
CFTR- IntronlO- - UCUCUCUAUAUAAAGUGAUCC 21
2055 20939
CFTR- IntronlO- - UUCUCUCUAUAUAAAGUGAUCC 22
2056 20940
CFTR- IntronlO- - UUUCUCUCUAUAUAAAGUGAUCC 23
2057 20941
CFTR- IntronlO- - AUUUCUCUCUAUAUAAAGUGAUCC 24
2058 20942
CFTR- IntronlO- - AUUCUUUUGAUAUACUCC 18
2059 20943
CFTR- IntronlO- - UAUUCUUUUGAUAUACUCC 19
2060 20944
CFTR- IntronlO- - UUAUUCUUUUGAUAUACUCC 20
1213 20098
CFTR- IntronlO- - CUUAUUCUUUUGAUAUACUCC 21
2061 20945
CFTR- IntronlO- - CCUUAUUCUUUUGAUAUACUCC 22
2062 20946
CFTR- IntronlO- - UGCCUUAUUCUUUUGAUAUACUCC 24
2063 20947
CFTR- IntronlO- - UGCGCUUAUGAAACUUCC 18
2064 20948
CFTR- IntronlO- - UUGCGCUUAUGAAACUUCC 19
2065 20949
725
5535.1 CFTR- IntronlO- - CUUGCGCUUAUGAAACUUCC 20
2066 20950
CFTR- IntronlO- - UCUUGCGCUUAUGAAACUUCC 21
2067 20951
CFTR- IntronlO- - UGUCUUGCGCUUAUGAAACUUCC 23
2068 20952
CFTR- IntronlO- - AUGUCUUGCGCUUAUGAAACUUCC 24
2069 20953
CFTR- IntronlO- - AAACCAAACAAGCUUUCC 18
2070 20954
CFTR- IntronlO- - AAAACCAAACAAG CU U U CC 19
2071 20955
CFTR- IntronlO- - UAAAACCAAACAAGCUUUCC 20
2072 20956
CFTR- IntronlO- - CU U U U AAAACAAAAU AG C 18
2073 20957
CFTR- IntronlO- - AGCU U U U AAAACAAAAU AG C 20
1220 20105
CFTR- IntronlO- - AGGAAGACAGCUGGCUAUC 19
2074 20958
CFTR- IntronlO- - CAGGAAGACAGCUGGCUAUC 20
2075 20959
CFTR- IntronlO- - AGCAGGAAGACAGCUGGCUAUC 22
2076 20960
CFTR- IntronlO- - CAGCAGGAAGACAGCUGGCUAUC 23
2077 20961
CFTR- IntronlO- - ACAGCAGGAAGACAGCUGGCUAUC 24
2078 20962
726
5535.1 CFTR- IntronlO- - AGCUGGCUAUCCAGGAUUC 19
2079 20963
CFTR-
- CAGCUGGCUAUCCAGGAUUC 20
lntronlO-441 19327
CFTR- IntronlO- - ACAGCUGGCUAUCCAGGAUUC 21
2080 20964
CFTR- IntronlO- - AGACAGCUGGCUAUCCAGGAUUC 23
2081 20965
CFTR- IntronlO- - AAGACAGCUGGCUAUCCAGGAUUC 24
2082 20966
CFTR- IntronlO- - UUCUGUAAUUUUUGCUUC 18
2083 20967
CFTR- IntronlO- - AGACUUUGUAGUGAUCUUC 19
2084 20968
CFTR- IntronlO- - AAGACUUUGUAGUGAUCUUC 20
2085 20969
CFTR- IntronlO- - AGAAGACUUUGUAGUGAUCUUC 22
2086 20970
CFTR- IntronlO- - AGCUUUUCAAAAUACUUUC 19
2087 20971
CFTR- IntronlO- - AAGCUUUUCAAAAUACUUUC 20
2088 20972
CFTR- IntronlO- - UGAAGCUUUUCAAAAUACUUUC 22
2089 20973
CFTR- IntronlO- - UUGAAGCUUUUCAAAAUACUUUC 23
2090 20974
CFTR- IntronlO- - CUUGAAGCUUUUCAAAAUACUUUC 24
2091 20975
CFTR-
- AACAG U ACAAG AAAAAAG 18
IntronlO- 20976
727
5535.1 2092
CFTR- IntronlO- - UAACAGUACAAGAAAAAAG 19
2093 20977
CFTR- IntronlO- - UGCCAUUAACAGAUAAAG 18
2094 20978
CFTR- IntronlO- - U U GCCAU U AACAG AU AAAG 19
2095 20979
CFTR- IntronlO- - UU UGCCAUUAACAGAUAAAG 20
2096 20980
CFTR- IntronlO- - AUAUGAGAAAAGUCACAG 18
2097 20981
CFTR- IntronlO- - CAUAUGAGAAAAGUCACAG 19
2098 20982
CFTR- IntronlO- - UGGCAUAUGAGAAAAGUCACAG 22
2099 20983
CFTR- IntronlO- - AUGGCAUAUGAGAAAAGUCACAG 23
2100 20984
CFTR- IntronlO- - AAUGGCAUAUGAGAAAAGUCACAG 24
2101 20985
CFTR- IntronlO- - CCAACUGAUGUCAAGCAG 18
2102 20986
CFTR- IntronlO- - CCCAACUGAUGU CAAG C AG 19
2103 20987
CFTR- IntronlO- - ACCCAACUGAUGUCAAGCAG 20
2104 20988
CFTR- IntronlO- - AACCCAACUGAUGUCAAGCAG 21
2105 20989
CFTR-
- CGGAACCCAACUGAUGUCAAGCAG 24
IntronlO- 20990
728
5535.1 2106
CFTR- IntronlO- - AGUAUUAGAGGUUAAGGAG 19
2107 20991
CFTR- IntronlO- - AAGUAUUAGAGGUUAAGGAG 20
2108 20992
CFTR- IntronlO- - UAAGUAUUAGAGGUUAAGGAG 21
2109 20993
CFTR- IntronlO- - CUAAGUAUUAGAGGUUAAGGAG 22
2110 20994
CFTR- IntronlO- - UCUAAGUAUUAGAGGUUAAGGAG 23
2111 20995
CFTR- IntronlO- - UUCUAAGUAUUAGAGGUUAAGGAG 24
2112 20996
CFTR- IntronlO- - AGUCUUUUCCUCUUAAUAG 19
2113 20997
CFTR- IntronlO- - AAGUCUUUUCCUCUUAAUAG 20
2114 20998
CFTR- IntronlO- - UGAAGUCUUUUCCUCUUAAUAG 22
2115 20999
CFTR- IntronlO- - CUGAAGUCUUUUCCUCUUAAUAG 23
2116 21000
CFTR- IntronlO- - CCUGAAGUCUUUUCCUCUUAAUAG 24
2117 21001
CFTR- IntronlO- - UGAAAAGCAGCUAUGAAGG 19
2118 21002
CFTR- IntronlO- - AUGAAAAGCAGCUAUGAAGG 20
2119 21003
CFTR-
- UAUGAAAAGCAGCUAUGAAGG 21
IntronlO- 21004
729
5535.1 2120
CFTR- IntronlO- - UUAUGAAAAGCAGCUAUGAAGG 22
2121 21005
CFTR- IntronlO- - CUUAUGAAAAGCAGCUAUGAAGG 23
2122 21006
CFTR- IntronlO- - U U U CAACU U AU ACACAGG 18
2123 21007
CFTR- IntronlO- - AUUUCAACUUAUACACAGG 19
2124 21008
CFTR-
- CAU U U CAACU UAU ACACAGG 20
lntronlO-468 19354
CFTR- IntronlO- - UCAUUUCAACUUAUACACAGG 21
2125 21009
CFTR- IntronlO- - AUCAUUUCAACUUAUACACAGG 22
2126 21010
CFTR- IntronlO- - UAUCAUUUCAACUUAUACACAGG 23
2127 21011
CFTR- IntronlO- - AUAUCAUUUCAACUUAUACACAGG 24
2128 21012
CFTR- IntronlO- - UGGCAUAGAGUAAGACAGG 19
2129 21013
CFTR- IntronlO- - CUGGCAUAGAGUAAGACAGG 20
2130 21014
CFTR- IntronlO- - AGGCUGGCAUAGAGUAAGACAGG 23
2131 21015
CFTR- IntronlO- - AAUAAAUUUGGUGUCAGG 18
2132 21016
CFTR- IntronlO- - CAAUAAAUUUGGUGUCAGG 19
2133 21017
730
5535.1 CFTR- IntronlO- - UCAAUAAAUUUGGUGUCAGG 20
2134 21018
CFTR- IntronlO- - CUCAAUAAAUUUGGUGUCAGG 21
2135 21019
CFTR- IntronlO- - ACUCAAUAAAUUUGGUGUCAGG 22
2136 21020
CFTR- IntronlO- - CACUCAAUAAAUUUGGUGUCAGG 23
2137 21021
CFTR- IntronlO- - CCACUCAAUAAAUUUGGUGUCAGG 24
2138 21022
CFTR- IntronlO- - UGGUAGUGUGAAGAUGGGG 19
2139 21023
CFTR- IntronlO- - CUGGUAGUGUGAAGAUGGGG 20
2140 21024
CFTR- IntronlO- - AGGGAAUGCAGACUCUGGG 19
2141 21025
CFTR- IntronlO- - UAGGGAAUGCAGACUCUGGG 20
2142 21026
CFTR- IntronlO- - UU AGGGAAUGCAGACUCUGGG 21
2143 21027
CFTR- IntronlO- - AUUAGGGAAUGCAGACUCUGGG 22
2144 21028
CFTR- IntronlO- - UGGGGGAGCCCCAUAAAUG 19
2145 21029
CFTR- IntronlO- - UUUUUAUGUAACAAUAUG 18
2146 21030
CFTR- IntronlO- - CUUUUUAUGUAACAAUAUG 19
2147 21031
731
5535.1 CFTR- IntronlO- - UCUUUUUAUGUAACAAUAUG 20
2148 21032
CFTR- IntronlO- - CUCUUUUUAUGUAACAAUAUG 21
2149 21033
CFTR- IntronlO- - UCUCUUUUUAUGUAACAAUAUG 22
2150 21034
CFTR- IntronlO- - CUCUCUUUUUAUGUAACAAUAUG 23
2151 21035
CFTR- IntronlO- - CCUCUCUUUUUAUGUAACAAUAUG 24
2152 21036
CFTR- IntronlO- - UGAGAUUAGAGGCCACUG 18
2153 21037
CFTR- IntronlO- - UGCACAUAUGUUCAGACUG 19
2154 21038
CFTR- IntronlO- - UUGCACAUAUGUUCAGACUG 20
2155 21039
CFTR- IntronlO- - CUUGCACAUAUGUUCAGACUG 21
2156 21040
CFTR- IntronlO- - ACUUGCACAUAUGUUCAGACUG 22
2157 21041
CFTR- IntronlO- - UGUUAAAGAAUGACUGUG 18
2158 21042
CFTR- IntronlO- - UUGUUAAAGAAUGACUGUG 19
2159 21043
CFTR- IntronlO- - UU UGUUAAAGAAUGACUGUG 20
2160 21044
CFTR-
- UGGCAUCUCACCAGUGUGUG 20
lntronlO-492 19378
CFTR-
- AUGGCAUCUCACCAGUGUGUG 21
IntronlO- 21045
732
5535.1 2161
CFTR- IntronlO- - UAUGGCAUCUCACCAGUGUGUG 22
2162 21046
CFTR- IntronlO- - UUAUGGCAUCUCACCAGUGUGUG 23
2163 21047
CFTR- IntronlO- - CUUAUGGCAUCUCACCAGUGUGUG 24
2164 21048
CFTR- IntronlO- - UGAGGAGAACCAUAUUUUG 19
2165 21049
CFTR- IntronlO- - AUGAGGAGAACCAUAUUUUG 20
2166 21050
CFTR- IntronlO- - AGAUGAGGAGAACCAUAUUUUG 22
2167 21051
CFTR- IntronlO- - AAGAUGAGGAGAACCAUAUUUUG 23
2168 21052
CFTR- IntronlO- - UAAGAUGAGGAGAACCAUAUUUUG 24
2169 21053
CFTR- IntronlO- - CCAUAAAUGUUGAAUAAU 18
2170 21054
CFTR- IntronlO- - CCCAUAAAUGUUGAAUAAU 19
2171 21055
CFTR- IntronlO- - CCCCAUAAAUGUUGAAUAAU 20
1331 20216
CFTR- IntronlO- - AGCCCCAUAAAUGUUGAAUAAU 22
2172 21056
CFTR- IntronlO- - AGAUUUUUUCCCAUGUAAU 19
2173 21057
CFTR-
- CAGAUUUUUUCCCAUGUAAU 20
IntronlO- 21058
733
5535.1 2174
CFTR- IntronlO- - AUCACUAUUGAUUGACAU 18
2175 21059
CFTR- IntronlO- - AAUCACUAUUGAUUGACAU 19
2176 21060
CFTR- IntronlO- - UGAAUCACUAUUGAUUGACAU 21
2177 21061
CFTR- IntronlO- - AUGAAUCACUAUUGAUUGACAU 22
2178 21062
CFTR- IntronlO- - AAUGAAUCACUAUUGAUUGACAU 23
2179 21063
CFTR- IntronlO- - UAAUGAAUCACUAUUGAUUGACAU 24
2180 21064
CFTR- IntronlO- - UAGUUUCUAUUAAUAGAU 18
2181 21065
CFTR- IntronlO- - UGUAGUUUCUAUUAAUAGAU 20
2182 21066
CFTR- IntronlO- - CGUGUAGUUUCUAUUAAUAGAU 22
2183 21067
CFTR- IntronlO- - UCGUGUAGUUUCUAUUAAUAGAU 23
2184 21068
CFTR- IntronlO- - UUCGUGUAGUUUCUAUUAAUAGAU 24
2185 21069
CFTR- IntronlO- - AGAAAGAGCUUUCUAGUAU 19
2186 21070
CFTR- IntronlO- - AAAGCUGUGCAUUUUCCU 18
2187 21071
CFTR-
- AAAAGCUGUGCAUUUUCCU 19
IntronlO- 21072
734
5535.1 2188
CFTR- IntronlO- - AAAAAGCUGUGCAUUUUCCU 20
2189 21073
CFTR- IntronlO- - UGUUCAAAUUAUUUCUACUGCU 22
2190 21074
CFTR- IntronlO- - UUGUUCAAAUUAUUUCUACUGCU 23
2191 21075
CFTR- IntronlO- - UGUAGGCUAUAUGUAUCU 18
2192 21076
CFTR- IntronlO- - CUGUAGGCUAUAUGUAUCU 19
2193 21077
CFTR- IntronlO- - UCUGUAGGCUAUAUGUAUCU 20
2194 21078
CFTR- IntronlO- - AGACUAAGGCUUAUUUCU 18
2195 21079
CFTR- IntronlO- - AAGACUAAGGCUUAUUUCU 19
2196 21080
CFTR- IntronlO- - AAAGACUAAGGCUUAUUUCU 20
2197 21081
CFTR- IntronlO- - UAAAGACUAAGGCUUAUUUCU 21
2198 21082
CFTR- IntronlO- - CGUAAAGACUAAGGCUUAUUUCU 23
2199 21083
CFTR- IntronlO- - UCGUAAAGACUAAGGCUUAUUUCU 24
2200 21084
CFTR- IntronlO- - A AG A AG AG A A AG G G G U G U 18
2201 21085
CFTR-
- U A AG A AG AG A A AG G G G U G U 19
IntronlO- 21086
735
5535.1 2202
CFTR- IntronlO- - A U A AG A AG AG A A AG G G G U G U 20
1378 20262
CFTR- IntronlO- - UGAUAAGAAGAGAAAGGGGUGU 22
2203 21087
CFTR- IntronlO- - UUGAUAAGAAGAGAAAGGGGUGU 23
2204 21088
CFTR- IntronlO- - AGUUGUUAUCUCUGAAAUU 19
2205 21089
CFTR- IntronlO- - AAGUUGUUAUCUCUGAAAUU 20
2206 21090
CFTR- IntronlO- - CAAGUUGUUAUCUCUGAAAUU 21
2207 21091
CFTR- IntronlO- - UCAAGUUGUUAUCUCUGAAAUU 22
2208 21092
CFTR- IntronlO- - AUCAAGUUGUUAUCUCUGAAAUU 23
2209 21093
CFTR- IntronlO- - UAUCAAGUUGUUAUCUCUGAAAUU 24
2210 21094
CFTR- IntronlO- - ACGGUAAGCUCAAGCAUU 18
2211 21095
CFTR- IntronlO- - UACGGUAAGCUCAAGCAUU 19
2212 21096
CFTR- IntronlO- - UUACGGUAAGCUCAAGCAUU 20
2213 21097
CFTR- IntronlO- - AUUACGGUAAGCUCAAGCAUU 21
2214 21098
CFTR-
- UAUUACGGUAAGCUCAAGCAUU 22
IntronlO- 21099
736
5535.1 2215
CFTR- IntronlO- - CUAUUACGGUAAGCUCAAGCAUU 23
2216 21100
CFTR- IntronlO- - CUGCCUUUUAGUAGUAUU 18
2217 21101
CFTR- IntronlO- - AGGCUGCCUUUUAGUAGUAUU 21
2218 21102
CFTR- IntronlO- - AGGAGGCUGCCUUUUAGUAGUAUU 24
2219 21103
CFTR- IntronlO- - AGAUUAGCUUAUAUACUU 18
2220 21104
CFTR- IntronlO- - UAGAUUAGCUUAUAUACUU 19
2221 21105
CFTR-
- AUAGAUUAGCUUAUAUACUU 20
lntronlO-550 19436
CFTR- IntronlO- - AAUAGAUUAGCUUAUAUACUU 21
2222 21106
CFTR- IntronlO- - UGAAUAGAUUAGCUUAUAUACUU 23
2223 21107
CFTR- IntronlO- - UUGAAUAGAUUAGCUUAUAUACUU 24
2224 21108
CFTR- IntronlO- - UUUUCCAAGCGGUCCCUU 18
2225 21109
CFTR- IntronlO- - UUUUUCCAAGCGGUCCCUU 19
2226 21110
CFTR- IntronlO- - UUUUUUCCAAGCGGUCCCUU 20
2227 21111
CFTR- IntronlO- - UUUUUUUCCAAGCGGUCCCUU 21
2228 21112
737
5535.1 CFTR- IntronlO- - UUUUUUUUCCAAGCGGUCCCUU 22
2229 21113
CFTR- IntronlO- - AUUUUUUUUCCAAGCGGUCCCUU 23
2230 21114
CFTR- IntronlO- - AAUUUUUUUUCCAAGCGGUCCCUU 24
2231 21115
CFTR- IntronlO- - AGAGGAAGGCAGUGGUCCCUU 21
2232 21116
CFTR- IntronlO- - UAGAGGAAGGCAGUGGUCCCUU 22
2233 21117
CFTR- IntronlO- - UUAGAGGAAGGCAGUGGUCCCUU 23
2234 21118
CFTR- IntronlO- - AGAUGUGCAAAAAUAGCUU 19
2235 21119
CFTR-
- UAGAUGUGCAAAAAUAGCUU 20
lntronlO-552 19438
CFTR- IntronlO- - AUAGAUGUGCAAAAAUAGCUU 21
2236 21120
CFTR- IntronlO- - UGAUAGAUGUGCAAAAAUAGCUU 23
2237 21121
CFTR- IntronlO- - AUGAUAGAUGUGCAAAAAUAGCUU 24
2238 21122
CFTR- IntronlO- - ACAUGACCUUCCUUUCUU 18
2239 21123
CFTR- IntronlO- - UACAUGACCUUCCUUUCUU 19
2240 21124
CFTR- IntronlO- - UUACAUGACCUUCCUUUCUU 20
2241 21125
CFTR-
- UGUUACAUGACCUUCCUUUCUU 22
IntronlO- 21126
738
5535.1 2242
CFTR- IntronlO- - CUGUUACAUGACCUUCCUUUCUU 23
2243 21127
CFTR- IntronlO- - UCUGUUACAUGACCUUCCUUUCUU 24
2244 21128
CFTR- IntronlO- - UAAUGGGAGAAACAGGUU 18
2245 21129
CFTR- IntronlO- - AUAAUGGGAGAAACAGGUU 19
2246 21130
CFTR- IntronlO- - AGCACUGGAGUUACCUGUU 19
2247 21131
CFTR- IntronlO- - UAGCACUGGAGUUACCUGUU 20
2248 21132
CFTR- IntronlO- - AUAGCACUGGAGUUACCUGUU 21
2249 21133
CFTR- IntronlO- - AAUAGCACUGGAGUUACCUGUU 22
2250 21134
CFTR- IntronlO- - AAAUAGCACUGGAGUUACCUGUU 23
2251 21135
CFTR- IntronlO- - UAAAUAGCACUGGAGUUACCUGUU 24
2252 21136
CFTR- IntronlO- - CAAAUAGUUUUAUCAAUAUUU 21
2253 21137
CFTR- IntronlO- - UGCAAAUAGUUUUAUCAAUAUUU 23
2254 21138
CFTR- IntronlO- - CUGCAAAUAGUUUUAUCAAUAUUU 24
2255 21139
CFTR-
- UUGGAUGGAGCUUGGUUU 18
IntronlO- 21140
739
5535.1 2256
CFTR- IntronlO- - UUUGGAUGGAGCUUGGUUU 19
2257 21141
CFTR-
- UUUUGGAUGGAGCUUGGUUU 20
lntronlO-563 19449
CFTR- IntronlO- - AGGUUUUGGAUGGAGCUUGGUUU 23
2258 21142
CFTR- IntronlO- - CAGGUUUUGGAUGGAGCUUGGUUU 24
2259 21143
CFTR- IntronlO- - UG U CCU CCACAAAU AU U U U 19
2260 21144
CFTR- IntronlO- - AUGUCCUCCACAAAUAUUUU 20
2261 21145
Table 41C provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within intron 10, start with a 5'G and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 41C
Figure imgf000741_0001
740
5535.1 CFTR- IntronlO- + GGACAGAUGAGAGACAGUAAAGAA 24
2265 21149
CFTR- IntronlO- + GUGUUCUCACAUGGCAGAA 19
2266 21150
CFTR- IntronlO- + GCUGUGUUCUCACAUGGCAGAA 22
2267 21151
CFTR- IntronlO- + GUUCUUAGGGUGGGAUAUGGAGAA 24
2268 21152
CFTR- IntronlO- + G A AG A A A AG U A U C A A U A A 18
2269 21153
CFTR- IntronlO- + GGAAGAAAAGUAUCAAUAA 19
2270 21154
CFTR- IntronlO- + GUUUUUACCAUUAUCUACACA 21
2271 21155
CFTR- IntronlO- + GAUAUGGAGAAGAGGAUGACCA 22
2272 21156
CFTR- IntronlO- + GGAUAUGGAGAAGAGGAUGACCA 23
2273 21157
CFTR- IntronlO- + GGGAUAUGGAGAAGAGGAUGACCA 24
2274 21158
CFTR- IntronlO- + GAAGUUCAGCCUGGGUGA 18
2275 21159
CFTR- IntronlO- + GCAAAAAUUACAGAACCUAUA 21
2276 21160
CFTR- IntronlO- + GAAGCAAAAAUUACAGAACCUAUA 24
2277 21161
CFTR- IntronlO- + GCUUCCUCCCUUGUCUCCCUA 21
2278 21162
741
5535.1 CFTR- IntronlO- + GUCUUCUCAGACUUUUAUUUUA 22
2279 21163
CFTR- IntronlO- + GUUUCCAAAUUUUUUUUA 18
2280 21164
CFTR- IntronlO- + GACAAGUUUCCAAAUUUUUUUUA 23
2281 21165
CFTR- IntronlO- + GUGUGGCUUAUAAACAAC 18
2282 21166
CFTR- IntronlO- + GAACUGUGUGGCUUAUAAACAAC 23
2283 21167
CFTR- IntronlO- + GAAGAUACUAAAAAAAGUUAC 21
2284 21168
CFTR- IntronlO- + GGAAGAUACUAAAAAAAGUUAC 22
2285 21169
CFTR- IntronlO- + GGGAAGAUACUAAAAAAAGUUAC 23
2286 21170
CFTR- IntronlO- + GAAAGGUCAAUUGAGCCC 18
2287 21171
CFTR- IntronlO- + GGAAAGGUCAAUUGAGCCC 19
2288 21172
CFTR- IntronlO- + GCGGAAAGGUCAAUUGAGCCC 21
2289 21173
CFTR- IntronlO- + GAAGCGGAAAGGUCAAUUGAGCCC 24
2290 21174
CFTR- IntronlO- + GCUACUUGGAAGACUCUUCC 20
2291 21175
CFTR- IntronlO- + GAUCACACCACUGAAGUUCAGC 22
2292 21176
742
5535.1 CFTR- IntronlO- + GAGUUUCACUGUGUUAGC 18
2293 21177
CFTR- IntronlO- + GGAGUUUCACUGUGUUAGC 19
2294 21178
CFTR- IntronlO- + GACGGAGUUUCACUGUGUUAGC 22
2295 21179
CFTR- IntronlO- + GAGACGGAGUUUCACUGUGUUAGC 24
2296 21180
CFTR- IntronlO- + GUCUCACUCUGUCACCCAGGC 21
2297 21181
CFTR- IntronlO- + GAGUCUCACUCUGUCACCCAGGC 23
2298 21182
CFTR- IntronlO- + GCCUCUGCCUCCAAAAGUGC 20
2299 21183
CFTR- IntronlO- + GCCAUUCUCCUGCCUCAGCCUC 22
2300 21184
CFTR- IntronlO- + GCUCACUGCAAGUUCUGCCUC 21
2301 21185
CFTR- IntronlO- + GGCUCACUGCAAGUUCUGCCUC 22
2302 21186
CFTR- IntronlO- + GAUCUUCCUUCAAAGCAUGUC 21
2303 21187
CFTR- IntronlO- + GGAUCUUCCUUCAAAGCAUGUC 22
2304 21188
CFTR- IntronlO- + GUGAUAUUUUUCAUUAUGAUUC 22
2305 21189
CFTR- IntronlO- + GGUGAUAUUUUUCAUUAUGAUUC 23
2306 21190
743
5535.1 CFTR- IntronlO- + GCUACUUGGGAGGCUGAGGCAG 22
2307 21191
CFTR- IntronlO- + GCUACUUGGGAGGGUGAGGCAG 22
2308 21192
CFTR-
+ GUUUGUGUUUUUUGUAGAGG 20
lntronlO-701 19587
CFTR- IntronlO- + GCACUUUGGGAGGCCGAGGCGG 22
2309 21193
CFTR- IntronlO- + GAACAAAAAUUAAAACUAAUGG 22
2310 21194
CFTR- IntronlO- + GUGAACAAAAAUUAAAACUAAUGG 24
2311 21195
CFTR- IntronlO- + GUAGUCCCAGCUACUUGG 18
2312 21196
CFTR- IntronlO- + GCCUGUAGUCCCAGCUACUUGG 22
2313 21197
CFTR- IntronlO- + GUGCCUGUAGUCCCAGCUACUUGG 24
2314 21198
CFTR- IntronlO- + GCAAUACCAUCACCUUGGGAAU 22
2315 21199
CFTR- IntronlO- + GAAUUAGGAUUUCAACAU 18
2316 21200
CFTR- IntronlO- + GGAAUUAGGAUUUCAACAU 19
2317 21201
CFTR- IntronlO- + GGGAAUUAGGAUUUCAACAU 20
2318 21202
CFTR- IntronlO- + GAUCAAGGUGCCAGCAGAU 19
2319 21203
CFTR-
+ GUGAUAGUUGCACAACUAU 19
IntronlO- 21204
744
5535.1 2320
CFTR- IntronlO- + GGUGAUAGUUGCACAACUAU 20
2321 21205
CFTR- IntronlO- + GAGGUGAUAGUUGCACAACUAU 22
2322 21206
CFTR- IntronlO- + GGAGGUGAUAGUUGCACAACUAU 23
2323 21207
CFTR- IntronlO- + GUUUAUUUACAUUUCUCUUUACU 23
2324 21208
CFTR- IntronlO- + GAAAAUGU UAAAU U U U CCCU 20
2325 21209
CFTR- IntronlO- + GAAAU U U AAU UGCCAG UAAG U CU 23
2326 21210
CFTR- IntronlO- + GUUCUCACAUGGCAGAAAGGGGU 23
2327 21211
CFTR- IntronlO- + GCAUCACUAGUGGCACUUUGU 21
2328 21212
CFTR- IntronlO- + GUGCAUCACUAGUGGCACUUUGU 23
2329 21213
CFTR- IntronlO- + GACCCUUUAUCAACAUGAAGGUU 23
2330 21214
CFTR- IntronlO- + GAAAUAUAGAUUUAAUCUUAUUU 23
2331 21215
CFTR- IntronlO- + GGAAAUAUAGAUUUAAUCUUAUUU 24
2332 21216
CFTR- IntronlO- + GUAUUUCUAGGCUAGACAGUUU 22
2333 21217
CFTR-
+ GGUAUUUCUAGGCUAGACAGUUU 23
IntronlO- 21218
745
5535.1 2334
CFTR- IntronlO- + GUUCAAGCCUGUAUUGUUU 19
2335 21219
CFTR- IntronlO- + GCAGUUCAAGCCUGUAUUGUUU 22
2336 21220
CFTR- IntronlO- - G AAU AU U U AAACACU U CUG AG AAA 24
2337 21221
CFTR- IntronlO- - GACAUGCUUUGAAGGAAGAUCCAA 24
2338 21222
CFTR- IntronlO- - G AACCAU AU U U UG AAG AA 18
2339 21223
CFTR- IntronlO- - G AG AACCAU AU U U UG AAG AA 20
2340 21224
CFTR- IntronlO- - GUAUAUUAUAGAAAUUUAA 19
2341 21225
CFTR- IntronlO- - GGUAUAUUAUAGAAAUUUAA 20
2342 21226
CFTR- IntronlO- - GACAGGUAUAUUAUAGAAAUUUAA 24
2343 21227
CFTR- IntronlO- - GUGGAUUUUUGACUAUACA 19
2344 21228
CFTR- IntronlO- - GAGGUCACUGAGGCUGGCA 19
2345 21229
CFTR- IntronlO- - GGAGGUCACUGAGGCUGGCA 20
2346 21230
CFTR- IntronlO- - GUAAGGAGGUCACUGAGGCUGGCA 24
2347 21231
CFTR-
- GAUAUGAAGUUAAAAACAUCA 21
IntronlO- 21232
746
5535.1 2348
CFTR- IntronlO- - GAGAUAUGAAGUUAAAAACAUCA 23
2349 21233
CFTR- IntronlO- - GG AG AU AUG AAG U U AAAAACAU CA 24
2350 21234
CFTR- IntronlO- - GACCAGAAUGAAAUUAGA 18
2351 21235
CFTR- IntronlO- - GAUGAUUCCAAGCUUUCUGGA 21
2352 21236
CFTR- IntronlO- - G AAAU AAAU U U AAAG ACAUG A 21
2353 21237
CFTR- IntronlO- - GG AAAU AAAU U U AAAG ACAUG A 22
2354 21238
CFTR- IntronlO- - G AGG AAAU AAAU U U AAAG ACAUG A 24
2355 21239
CFTR- IntronlO- - GAGAAGACAAAGCUAGUGA 19
2356 21240
CFTR- IntronlO- - GUCUGAGAAGACAAAGCUAGUGA 23
2357 21241
CFTR- IntronlO- - GCACUCUAGCCUGGGUGA 18
2358 21242
CFTR- IntronlO- - GCCACUGCACUCUAGCCUGGGUGA 24
2359 21243
CFTR- IntronlO- - GCACCCCUAACCUUCAUGUUGAUA 24
2360 21244
CFTR- IntronlO- - GACUUGCAGGAGGUGAGGGAUUA 23
2361 21245
CFTR-
- GCCAAUAAAAGGUUUGUUA 19
IntronlO- 21246
747
5535.1 2362
CFTR- IntronlO- - GCAUAUAUAUAUUUUUAAC 19
2363 21247
CFTR- IntronlO- - GUGGAGUCAAAAAUUAUAC 19
2364 21248
CFTR- IntronlO- - GUUUAGUGCAAUGCCAUAAACC 22
2365 21249
CFTR- IntronlO- - GAAAAAGUAAGAUAUGCC 18
2366 21250
CFTR- IntronlO- - GGUGAAUUGCUUGAGUCC 18
2367 21251
CFTR- IntronlO- - GCAGGUGAAUUGCUUGAGUCC 21
2368 21252
CFTR- IntronlO- - GGCAGGUGAAUUGCUUGAGUCC 22
2369 21253
CFTR- IntronlO- - GAGGCAGGUGAAUUGCUUGAGUCC 24
2370 21254
CFTR- IntronlO- - GAAAACAAAUUUUCUUUGUUUUCC 24
2371 21255
CFTR- IntronlO- - GCGCCACUGCACUCUAGC 18
2372 21256
CFTR- IntronlO- - GAUCGCGCCACUGCACUCUAGC 22
2373 21257
CFTR- IntronlO- - GAGAUCGCGCCACUGCACUCUAGC 24
2374 21258
CFTR- IntronlO- - GGGUUUCACCGUUUUAGC 18
2375 21259
CFTR-
- GGGGUUUCACCGUUUUAGC 19
IntronlO- 21260
748
5535.1 2376
CFTR- IntronlO- - GACGGGGUUUCACCGUUUUAGC 22
2377 21261
CFTR- IntronlO- - GAGACGGGGUUUCACCGUUUUAGC 24
2378 21262
CFTR- IntronlO- - GUCUCGCUCUGUCGCCCAGGC 21
2379 21263
CFTR- IntronlO- - GAGUCUCGCUCUGUCGCCCAGGC 23
2380 21264
CFTR- IntronlO- - GGAGUCUCGCUCUGUCGCCCAGGC 24
2381 21265
CFTR- IntronlO- - GGGUUUCACCAUGUUGGC 18
2382 21266
CFTR- IntronlO- - GGGGUUUCACCAUGUUGGC 19
2383 21267
CFTR- IntronlO- - GACGGGGUUUCACCAUGUUGGC 22
2384 21268
CFTR- IntronlO- - GAGACGGGGUUUCACCAUGUUGGC 24
2385 21269
CFTR-
- GCCUCGGCCUCCCAAAGUGC 20
lntronlO-686 19572
CFTR- IntronlO- - GCCCGCCUCGGCCUCCCAAAGUGC 24
2386 21270
CFTR- IntronlO- - GCAGAGGCAGGUGAAUUGC 19
2387 21271
CFTR- IntronlO- - GGCAGAGGCAGGUGAAUUGC 20
2388 21272
CFTR- IntronlO- - GAGGCAGAGGCAGGUGAAUUGC 22
2389 21273
749
5535.1 CFTR- IntronlO- - GGAGGCAGAGGCAGGUGAAUUGC 23
2390 21274
CFTR- IntronlO- - GCUCACUGCAAGCUCCGCCUC 21
2391 21275
CFTR- IntronlO- - GGCUCACUGCAAGCUCCGCCUC 22
2392 21276
CFTR- IntronlO- - G U UG U AACAG U ACAAG AAAAAAG 23
2393 21277
CFTR- IntronlO- - GCUUUGCCAUUAACAGAUAAAG 22
2394 21278
CFTR- IntronlO- - GCACUUUUGGAGGCAGAGGCAG 22
2395 21279
CFTR- IntronlO- - GCUACUCGGGAGGCUGAGGCAG 22
2396 21280
CFTR- IntronlO- - GACAAGGGAGGAAGCAAGGAG 21
2397 21281
CFTR- IntronlO- - GAGACAAGGGAGGAAGCAAGGAG 23
2398 21282
CFTR- IntronlO- - GGAGACAAGGGAGGAAGCAAGGAG 24
2399 21283
CFTR- IntronlO- - GACAUCCAAAUAGAGAUGUUAG 22
2400 21284
CFTR- IntronlO- - GCAUAGAGUAAGACAGGGAGGG 22
2401 21285
CFTR- IntronlO- - GGCAUAGAGUAAGACAGGGAGGG 23
2402 21286
CFTR- IntronlO- - GCAUAGUAUUCUAUCAUAUGG 21
2403 21287
750
5535.1 CFTR- IntronlO- - GAUGCAUAGUAUUCUAUCAUAUGG 24
2404 21288
CFTR- IntronlO- - GCUUUCUGGACUGAGUAACUGG 22
2405 21289
CFTR- IntronlO- - GUAUAUAUGUGUGUCUGG 18
2406 21290
CFTR- IntronlO- - GUAUGUAUAUAUGUGUGUCUGG 22
2407 21291
CFTR- IntronlO- - GCCCAGGCUGGAGUGCAGUGG 21
2408 21292
CFTR- IntronlO- - GUCGCCCAGGCUGGAGUGCAGUGG 24
2409 21293
CFTR- IntronlO- - GCUACUUGGGAGGCUGAGGUGG 22
2410 21294
CFTR- IntronlO- - GGUGGGGGAGCCCCAUAAAUG 21
2411 21295
CFTR- IntronlO- - GGGUGGGGGAGCCCCAUAAAUG 22
2412 21296
CFTR- IntronlO- - GGGUGAGAUUAGAGGCCACUG 21
2413 21297
CFTR- IntronlO- - GCUUCAGCCUCCCAAAGUG 19
2414 21298
CFTR- IntronlO- - GAACAAAGACUUGCAGGAGGUG 22
2415 21299
CFTR- IntronlO- - GUUUGUUAAAGAAUGACUGUG 21
2416 21300
CFTR- IntronlO- - GGUUUGUUAAAGAAUGACUGUG 22
2417 21301
751
5535.1 CFTR- IntronlO- - GCUAUUAGUAGUUAAGUUUUUG 22
2418 21302
CFTR- IntronlO- - GGCUAUUAGUAGUUAAGUUUUUG 23
2419 21303
CFTR- IntronlO- - GGGAGGUGAUUAGUCCAU 18
2420 21304
CFTR- IntronlO- - GCCUUUGGGAGGUGAUUAGUCCAU 24
2421 21305
CFTR- IntronlO- - GAUGCAUAGUAUUCUAUCAU 20
2422 21306
CFTR- IntronlO- - GAUGAGAAAGAGCUUUCUAGUAU 23
2423 21307
CFTR- IntronlO- - GUCUGUAGGCUAUAUGUAUCU 21
2424 21308
CFTR-
- GCCUCGGCCUCCCAAAGUGU 20
lntronlO-716 19602
CFTR- IntronlO- - GCCUGCCUCGGCCUCCCAAAGUGU 24
2425 21309
CFTR- IntronlO- - GGAAGGCAGUGGUCCCUU 18
2426 21310
CFTR-
- GAGGAAGGCAGUGGUCCCUU 20
lntronlO-127 19013
CFTR- IntronlO- - GAAGCAAGGAGAUGAGUU 18
2427 21311
CFTR- IntronlO- - GGAAGCAAGGAGAUGAGUU 19
2428 21312
CFTR- IntronlO- - GAGGAAGCAAGGAGAUGAGUU 21
2429 21313
CFTR- IntronlO- - GGAGGAAGCAAGGAGAUGAGUU 22
2430 21314
752
5535.1 CFTR- IntronlO- - GGGAGGAAGCAAGGAGAUGAGUU 23
2431 21315
CFTR- IntronlO- - GAAAGAUAAUGGGAGAAACAGGUU 24
2432 21316
CFTR- IntronlO- - GCAUGGGUCCACUUAUUU 18
2433 21317
CFTR- IntronlO- - GAACUGCAUGGGUCCACUUAUUU 23
2434 21318
CFTR- IntronlO- - GCUUUUUUGUUGUUUUUCUAGUUU 24
2435 21319
CFTR- IntronlO- - G U U AAU ACAU UGG AAAAU U U U 21
2436 21320
CFTR- IntronlO- - GUAUGUCCUCCACAAAUAUUUU 22
2437 21321
Table 41D provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within intron 10, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 41D
Figure imgf000754_0001
753
5535.1 2440
CFTR- IntronlO- + CAACAAAAAAG CGAAGAAAAA 21
2441 21325
CFTR- IntronlO- + ACAACAAAAAAGCGAAGAAAAA 22
2442 21326
CFTR- IntronlO- + AACAACAAAAAAG CGAAGAAAAA 23
2443 21327
CFTR- IntronlO- + AAACAACAAAAAAGCGAAGAAAAA 24
2444 21328
CFTR- IntronlO- + AUACAUAUGAUUUUAUGAAAA 21
2445 21329
CFTR- IntronlO- + CAUACAUAUGAUUUUAUGAAAA 22
2446 21330
CFTR- IntronlO- + ACAUACAUAUGAUUUUAUGAAAA 23
2447 21331
CFTR- IntronlO- + UACAUACAUAUGAUUUUAUGAAAA 24
2448 21332
CFTR- IntronlO- + AGAUAAUACUACUGACUAAAA 21
2449 21333
CFTR- IntronlO- + AAGAUAAUACUACUGACUAAAA 22
2450 21334
CFTR- IntronlO- + AAAGAUAAUACUACUGACUAAAA 23
2451 21335
CFTR- IntronlO- + AAAAGAUAAUACUACUGACUAAAA 24
2452 21336
CFTR- IntronlO- + AUAAACAAACAAAGGAAA 18
2453 21337
CFTR-
+ AAUAAACAAACAAAGGAAA 19
IntronlO- 21338
754
5535.1 2454
CFTR- IntronlO- + AAAUAAACAAACAAAGGAAA 20
1097 19982
CFTR- IntronlO- + CAAAUAAACAAACAAAGGAAA 21
2455 21339
CFTR- IntronlO- + CCAAAUAAACAAACAAAGGAAA 22
2456 21340
CFTR- IntronlO- + ACCAAAUAAACAAACAAAGGAAA 23
2457 21341
CFTR- IntronlO- + AACCAAAUAAACAAACAAAGGAAA 24
2458 21342
CFTR- IntronlO- + UAAGACCUAAUCUCUAAA 18
2459 21343
CFTR- IntronlO- + AGUAAGACCUAAUCUCUAAA 20
2460 21344
CFTR- IntronlO- + AGAGUAAGACCUAAUCUCUAAA 22
2461 21345
CFTR- IntronlO- + CAGAGUAAGACCUAAUCUCUAAA 23
2462 21346
CFTR- IntronlO- + ACAGAGUAAGACCUAAUCUCUAAA 24
2463 21347
CFTR- IntronlO- + CAGAUGAGAGACAGUAAAGAA 21
2464 21348
CFTR- IntronlO- + ACAGAUGAGAGACAGUAAAGAA 22
2465 21349
CFTR- IntronlO- + UGUUCUCACAUGGCAGAA 18
2466 21350
CFTR-
+ UGUGUUCUCACAUGGCAGAA 20
IntronlO- 19991
755
5535.1 1106
CFTR- IntronlO- + CUGUGUUCUCACAUGGCAGAA 21
2467 21351
CFTR- IntronlO- + UGCUGUGUUCUCACAUGGCAGAA 23
2468 21352
CFTR- IntronlO- + CUGCUGUGUUCUCACAUGGCAGAA 24
2469 21353
CFTR- IntronlO- + CUUAGGGUGGGAUAUGGAGAA 21
2470 21354
CFTR- IntronlO- + UCUUAGGGUGGGAUAUGGAGAA 22
2471 21355
CFTR- IntronlO- + UUCUUAGGGUGGGAUAUGGAGAA 23
2472 21356
CFTR- IntronlO- + AG G A AG A A A AG U A U C A A U A A 20
1110 19995
CFTR- IntronlO- + C AG G A AG A A A AG U A U C A A U A A 21
2473 21357
CFTR- IntronlO- + U C AG G A AG A A A AG U A U C A A U A A 22
2474 21358
CFTR- IntronlO- + A U C AG G A AG A A A AG U A U C A A U A A 23
2475 21359
CFTR- IntronlO- + AAUCAGGAAGAAAAGUAUCAAUAA 24
2476 21360
CFTR- IntronlO- + AGUUUUUACCAUUAUCUACACA 22
2477 21361
CFTR- IntronlO- + AAGUUUUUACCAUUAUCUACACA 23
2478 21362
CFTR-
+ CAAG U U U U U ACCAU UAU CU ACACA 24
IntronlO- 21363
756
5535.1 2479
CFTR- IntronlO- + AUAUGGAGAAGAGGAUGACCA 21
2480 21364
CFTR- IntronlO- + AAAAGAGACACACCUAAAGCA 21
2481 21365
CFTR- IntronlO- + UAAAAGAGACACACCUAAAGCA 22
2482 21366
CFTR- IntronlO- + CUAAAAGAGACACACCUAAAGCA 23
2483 21367
CFTR- IntronlO- + ACUAAAAGAGACACACCUAAAGCA 24
2484 21368
CFTR- IntronlO- + CAAUAGUGAUUCAUUAUAUCA 21
2485 21369
CFTR- IntronlO- + UCAAUAGUGAUUCAUUAUAUCA 22
2486 21370
CFTR- IntronlO- + AUCAAUAGUGAUUCAUUAUAUCA 23
2487 21371
CFTR- IntronlO- + AAUCAAUAGUGAUUCAUUAUAUCA 24
2488 21372
CFTR- IntronlO- + UUGUAUUUUUAGUAGAGA 18
2489 21373
CFTR- IntronlO- + UUUGUAUUUUUAGUAGAGA 19
2490 21374
CFTR- IntronlO- + UUUUGUAUUUUUAGUAGAGA 20
1141 20026
CFTR- IntronlO- + UUUUUGUAUUUUUAGUAGAGA 21
2491 21375
CFTR-
+ UUUUUUGUAUUUUUAGUAGAGA 22
IntronlO- 21376
757
5535.1 2492
CFTR- IntronlO- + AUUUUUUGUAUUUUUAGUAGAGA 23
2493 21377
CFTR- IntronlO- + AAUUUUUUGUAUUUUUAGUAGAGA 24
2494 21378
CFTR- IntronlO- + UAUUUAUUUAUUUAGAGA 18
2495 21379
CFTR- IntronlO- + UUAUUUAUUUAUUUAGAGA 19
2496 21380
CFTR- IntronlO- + UUUAUUUAUUUAUUUAGAGA 20
2497 21381
CFTR- IntronlO- + AUUUAUUUAUUUAUUUAGAGA 21
2498 21382
CFTR- IntronlO- + UAUUUAUUUAUUUAUUUAGAGA 22
2499 21383
CFTR- IntronlO- + UUAUUUAUUUAUUUAUUUAGAGA 23
2500 21384
CFTR- IntronlO- + UUUAUUUAUUUAUUUAUUUAGAGA 24
2501 21385
CFTR- IntronlO- + ACUAAAAGGCAGCCUCCUAGA 21
2502 21386
CFTR- IntronlO- + UACUAAAAGGCAGCCUCCUAGA 22
2503 21387
CFTR- IntronlO- + CUACUAAAAGGCAGCCUCCUAGA 23
2504 21388
CFTR- IntronlO- + ACUACUAAAAGGCAGCCUCCUAGA 24
2505 21389
CFTR-
+ UGAAGUUCAGCCUGGGUGA 19
IntronlO- 21390
758
5535.1 2506
CFTR- IntronlO- + CUGAAGUUCAGCCUGGGUGA 20
2507 21391
CFTR- IntronlO- + ACUGAAGUUCAGCCUGGGUGA 21
2508 21392
CFTR- IntronlO- + CACUGAAGUUCAGCCUGGGUGA 22
2509 21393
CFTR- IntronlO- + CCACUGAAGUUCAGCCUGGGUGA 23
2510 21394
CFTR- IntronlO- + ACCACUGAAGUUCAGCCUGGGUGA 24
2511 21395
CFTR- IntronlO- + CAAAUUACCAAAUUGUAUUGA 21
2512 21396
CFTR- IntronlO- + ACAAAU U ACCAAAU UG U AU UG A 22
2513 21397
CFTR- IntronlO- + UACAAAUUACCAAAUUGUAUUGA 23
2514 21398
CFTR- IntronlO- + AUACAAAUUACCAAAUUGUAUUGA 24
2515 21399
CFTR- IntronlO- + AGCAAAAAUUACAGAACCUAUA 22
2516 21400
CFTR- IntronlO- + AAGCAAAAAUUACAGAACCUAUA 23
2517 21401
CFTR- IntronlO- + UUUGUUACAACAGUCUUUAUA 21
2518 21402
CFTR- IntronlO- + UUUUGUUACAACAGUCUUUAUA 22
2519 21403
CFTR-
+ CUUUUGUUACAACAGUCUUUAUA 23
IntronlO- 21404
759
5535.1 2520
CFTR- IntronlO- + UCUUUUGUUACAACAGUCUUUAUA 24
2521 21405
CFTR- IntronlO- + UGCUUCCUCCCUUGUCUCCCUA 22
2522 21406
CFTR- IntronlO- + UUGCUUCCUCCCUUGUCUCCCUA 23
2523 21407
CFTR- IntronlO- + CUUGCUUCCUCCCUUGUCUCCCUA 24
2524 21408
CFTR- IntronlO- + CCUUUGUACAUUUUCCUA 18
2525 21409
CFTR- IntronlO- + UCCUUUGUACAUUUUCCUA 19
2526 21410
CFTR- IntronlO- + AUCCUUUGUACAUUUUCCUA 20
2527 21411
CFTR- IntronlO- + AAUCCUUUGUACAUUUUCCUA 21
2528 21412
CFTR- IntronlO- + CAAUCCUUUGUACAUUUUCCUA 22
2529 21413
CFTR- IntronlO- + UCAAUCCUUUGUACAUUUUCCUA 23
2530 21414
CFTR- IntronlO- + UUCAAUCCUUUGUACAUUUUCCUA 24
2531 21415
CFTR- IntronlO- + AG AU AAAAU UAUAAAU U A 18
2532 21416
CFTR- IntronlO- + AAGAUAAAAU UAUAAAU U A 19
2533 21417
CFTR-
+ AAAGAU AAAAU UAUAAAU U A 20
IntronlO- 21418
760
5535.1 2534
CFTR- IntronlO- + U AAAG AU AAAAU U AU AAAU U A 21
2535 21419
CFTR- IntronlO- + AU AAAG AU AAAAU U AU AAAU U A 22
2536 21420
CFTR- IntronlO- + AAU AAAG AU AAAAU U AU AAAU U A 23
2537 21421
CFTR- IntronlO- + U AAU AAAG AU AAAAU U AU AAAU U A 24
2538 21422
CFTR- IntronlO- + UCUCAGACUUUUAUUUUA 18
2539 21423
CFTR- IntronlO- + UUCUCAGACUUUUAUUUUA 19
2540 21424
CFTR- IntronlO- + CUUCUCAGACUUUUAUUUUA 20
2541 21425
CFTR- IntronlO- + UCUUCUCAGACUUUUAUUUUA 21
2542 21426
CFTR- IntronlO- + UGUCUUCUCAGACUUUUAUUUUA 23
2543 21427
CFTR- IntronlO- + UUGUCUUCUCAGACUUUUAUUUUA 24
2544 21428
CFTR- IntronlO- + AGUUUCCAAAUUUUUUUUA 19
2545 21429
CFTR- IntronlO- + AAGUUUCCAAAUUUUUUUUA 20
2546 21430
CFTR- IntronlO- + CAAGUUUCCAAAUUUUUUUUA 21
2547 21431
CFTR-
+ ACAAGUUUCCAAAUUUUUUUUA 22
IntronlO- 21432
761
5535.1 2548
CFTR- IntronlO- + AGACAAGUUUCCAAAUUUUUUUUA 24
2549 21433
CFTR- IntronlO- + UGUGUGGCUUAUAAACAAC 19
2550 21434
CFTR- IntronlO- + CUGUGUGGCUUAUAAACAAC 20
1180 20065
CFTR- IntronlO- + ACUGUGUGGCUUAUAAACAAC 21
2551 21435
CFTR- IntronlO- + AACUGUGUGGCUUAUAAACAAC 22
2552 21436
CFTR- IntronlO- + UGAACUGUGUGGCUUAUAAACAAC 24
2553 21437
CFTR- IntronlO- + UGGGAAGAUACUAAAAAAAGUUAC 24
2554 21438
CFTR- IntronlO- + CGGAAAGGUCAAUUGAGCCC 20
1194 20079
CFTR- IntronlO- + AGCGGAAAGGUCAAUUGAGCCC 22
2555 21439
CFTR- IntronlO- + AAGCGGAAAGGUCAAUUGAGCCC 23
2556 21440
CFTR- IntronlO- + UACUUGGAAGACUCUUCC 18
2557 21441
CFTR- IntronlO- + CUACUUGGAAGACUCUUCC 19
2558 21442
CFTR- IntronlO- + UGCUACUUGGAAGACUCUUCC 21
2559 21443
CFTR-
+ CUGCUACUUGGAAGACUCUUCC 22
IntronlO- 21444
762
5535.1 2560
CFTR- IntronlO- + CCUGCUACUUGGAAGACUCUUCC 23
2561 21445
CFTR- IntronlO- + ACCUGCUACUUGGAAGACUCUUCC 24
2562 21446
CFTR- IntronlO- + ACACCACUGAAGUUCAGC 18
2563 21447
CFTR- IntronlO- + CACACCACUGAAGUUCAGC 19
2564 21448
CFTR- IntronlO- + UCACACCACUGAAGUUCAGC 20
2565 21449
CFTR- IntronlO- + AUCACACCACUGAAGUUCAGC 21
2566 21450
CFTR- IntronlO- + UGAUCACACCACUGAAGUUCAGC 23
2567 21451
CFTR- IntronlO- + AUGAUCACACCACUGAAGUUCAGC 24
2568 21452
CFTR- IntronlO- + CGGAGUUUCACUGUGUUAGC 20
2569 21453
CFTR- IntronlO- + ACGGAGUUUCACUGUGUUAGC 21
2570 21454
CFTR- IntronlO- + AGACGGAGUUUCACUGUGUUAGC 23
2571 21455
CFTR- IntronlO- + UCACUCUGUCACCCAGGC 18
2572 21456
CFTR- IntronlO- + CUCACUCUGUCACCCAGGC 19
2573 21457
CFTR-
+ UCUCACUCUGUCACCCAGGC 20
IntronlO- 21458
763
5535.1 2574
CFTR- IntronlO- + AGUCUCACUCUGUCACCCAGGC 22
2575 21459
CFTR- IntronlO- + AGAGUCUCACUCUGUCACCCAGGC 24
2576 21460
CFTR- IntronlO- + UUUUGAGCCUAUCACCUAGGC 21
2577 21461
CFTR- IntronlO- + UUUUUGAGCCUAUCACCUAGGC 22
2578 21462
CFTR- IntronlO- + UUUUUUGAGCCUAUCACCUAGGC 23
2579 21463
CFTR- IntronlO- + UUUUUUUGAGCCUAUCACCUAGGC 24
2580 21464
CFTR- IntronlO- + CUCUGCCUCCAAAAGUGC 18
2581 21465
CFTR- IntronlO- + CCUCUGCCUCCAAAAGUGC 19
2582 21466
CFTR- IntronlO- + UGCCUCUGCCUCCAAAAGUGC 21
2583 21467
CFTR- IntronlO- + CUGCCUCUGCCUCCAAAAGUGC 22
2584 21468
CFTR- IntronlO- + CCUGCCUCUGCCUCCAAAAGUGC 23
2585 21469
CFTR- IntronlO- + ACCUGCCUCUGCCUCCAAAAGUGC 24
2586 21470
CFTR- IntronlO- + UUCUCCUGCCUCAGCCUC 18
2587 16501
CFTR-
+ AUUCUCCUGCCUCAGCCUC 19
IntronlO- 16502
764
5535.1 2588
CFTR- IntronlO- + CAUUCUCCUGCCUCAGCCUC 20
2589 21471
CFTR- IntronlO- + CCAUUCUCCUGCCUCAGCCUC 21
2590 21472
CFTR- IntronlO- + CGCCAUUCUCCUGCCUCAGCCUC 23
2591 21473
CFTR- IntronlO- + ACGCCAUUCUCCUGCCUCAGCCUC 24
2592 21474
CFTR- IntronlO- + CACUGCAAGUUCUGCCUC 18
2593 21475
CFTR- IntronlO- + UCACUGCAAGUUCUGCCUC 19
2594 21476
CFTR- IntronlO- + CUCACUGCAAGUUCUGCCUC 20
2595 21477
CFTR- IntronlO- + CGGCUCACUGCAAGUUCUGCCUC 23
2596 21478
CFTR- IntronlO- + UCGGCUCACUGCAAGUUCUGCCUC 24
2597 21479
CFTR- IntronlO- + UAUUGCUUUCAUUAAGUC 18
2598 21480
CFTR- IntronlO- + CUAUUGCUUUCAUUAAGUC 19
2599 21481
CFTR- IntronlO- + ACUAUUGCUUUCAUUAAGUC 20
2600 21482
CFTR- IntronlO- + CUUCCUUCAAAGCAUGUC 18
2601 21483
CFTR-
+ UCUUCCUUCAAAGCAUGUC 19
IntronlO- 21484
765
5535.1 2602
CFTR- IntronlO- + AUCUUCCUUCAAAGCAUGUC 20
2603 21485
CFTR- IntronlO- + UGGAUCUUCCUUCAAAGCAUGUC 23
2604 21486
CFTR- IntronlO- + UUGGAUCUUCCUUCAAAGCAUGUC 24
2605 21487
CFTR- IntronlO- + UGAUAUUUUUCAUUAUGAUUC 21
2606 21488
CFTR- IntronlO- + UGGUGAUAUUUUUCAUUAUGAUUC 24
2607 21489
CFTR- IntronlO- + CUUGGGAGGCUGAGGCAG 18
2608 21490
CFTR- IntronlO- + ACUUGGGAGGCUGAGGCAG 19
2609 21491
CFTR- IntronlO- + UACUUGGGAGGCUGAGGCAG 20
2610 21492
CFTR- IntronlO- + CUACUUGGGAGGCUGAGGCAG 21
2611 21493
CFTR- IntronlO- + AGCUACUUGGGAGGCUGAGGCAG 23
2612 21494
CFTR- IntronlO- + CAGCUACUUGGGAGGCUGAGGCAG 24
2613 21495
CFTR- IntronlO- + CUUGGGAGGGUGAGGCAG 18
2614 21496
CFTR- IntronlO- + ACUUGGGAGGGUGAGGCAG 19
2615 21497
CFTR-
+ UACUUGGGAGGGUGAGGCAG 20
IntronlO- 21498
766
5535.1 2616
CFTR- IntronlO- + CUACUUGGGAGGGUGAGGCAG 21
2617 21499
CFTR- IntronlO- + AGCUACUUGGGAGGGUGAGGCAG 23
2618 21500
CFTR- IntronlO- + CAGCUACUUGGGAGGGUGAGGCAG 24
2619 21501
CFTR- IntronlO- + UAAAAAUACAAAAAUUAG 18
2620 21502
CFTR- IntronlO- + CU AAAAAU ACAAAAAU U AG 19
2621 21503
CFTR- IntronlO- + ACU AAAAAU ACAAAAAU U AG 20
2622 21504
CFTR- IntronlO- + U ACU AAAAAU ACAAAAAU U AG 21
2623 21505
CFTR- IntronlO- + CU ACU AAAAAU ACAAAAAU U AG 22
2624 21506
CFTR- IntronlO- + UCUACUAAAAAUACAAAAAUUAG 23
2625 21507
CFTR- IntronlO- + CUCUACUAAAAAUACAAAAAUUAG 24
2626 21508
CFTR- IntronlO- + UGAUCUUGAAGACAUACG 18
2627 21509
CFTR- IntronlO- + UUGAUCUUGAAGACAUACG 19
2628 21510
CFTR- IntronlO- + AUUGAUCUUGAAGACAUACG 20
2629 21511
CFTR-
+ UUGUGUUUUUUGUAGAGG 18
IntronlO- 21512
767
5535.1 2630
CFTR- IntronlO- + UUUGUGUUUUUUGUAGAGG 19
2631 21513
CFTR- IntronlO- + UGUUUGUGUUUUUUGUAGAGG 21
2632 21514
CFTR- IntronlO- + UUGUUUGUGUUUUUUGUAGAGG 22
2633 21515
CFTR- IntronlO- + UUUGUUUGUGUUUUUUGUAGAGG 23
2634 21516
CFTR- IntronlO- + UUUUGUUUGUGUUUUUUGUAGAGG 24
2635 21517
CFTR- IntronlO- + UUUGGGAGGCCGAGGCGG 18
2636 21518
CFTR- IntronlO- + CUUUGGGAGGCCGAGGCGG 19
2637 21519
CFTR- IntronlO- + ACUUUGGGAGGCCGAGGCGG 20
2638 21520
CFTR- IntronlO- + CACUUUGGGAGGCCGAGGCGG 21
2639 21521
CFTR- IntronlO- + AGCACUUUGGGAGGCCGAGGCGG 23
2640 21522
CFTR- IntronlO- + CAGCACUUUGGGAGGCCGAGGCGG 24
2641 21523
CFTR- IntronlO- + AAAAAUUAAAACUAAUGG 18
2642 21524
CFTR- IntronlO- + CAAAAAUUAAAACUAAUGG 19
2643 21525
CFTR-
+ ACAAAAAUUAAAACUAAUGG 20
IntronlO- 21526
768
5535.1 2644
CFTR- IntronlO- + AACAAAAAUUAAAACUAAUGG 21
2645 21527
CFTR- IntronlO- + UGAACAAAAAUUAAAACUAAUGG 23
2646 21528
CFTR- IntronlO- + CUUUAACAAACCUUUUAUUGG 21
2647 21529
CFTR- IntronlO- + UCUUUAACAAACCUUUUAUUGG 22
2648 21530
CFTR- IntronlO- + UUCUUUAACAAACCUUUUAUUGG 23
2649 21531
CFTR- IntronlO- + AUUCUUUAACAAACCUUUUAUUGG 24
2650 21532
CFTR- IntronlO- + UGUAGUCCCAGCUACUUGG 19
2651 21533
CFTR- IntronlO- + CUGUAGUCCCAGCUACUUGG 20
2652 21534
CFTR- IntronlO- + CCUGUAGUCCCAGCUACUUGG 21
2653 21535
CFTR- IntronlO- + UGCCUGUAGUCCCAGCUACUUGG 23
2654 21536
CFTR- IntronlO- + AAAGGAAAUGGGGUAUAAGUG 21
2655 21537
CFTR- IntronlO- + CAAAGGAAAUGGGGUAUAAGUG 22
2656 21538
CFTR- IntronlO- + ACAAAGGAAAUGGGGUAUAAGUG 23
2657 21539
CFTR-
+ AACAAAGGAAAUGGGGUAUAAGUG 24
IntronlO- 21540
769
5535.1 2658
CFTR- IntronlO- + ACUACUAAUAGCCUAUUG 18
2659 21541
CFTR- IntronlO- + AACUACUAAUAGCCUAUUG 19
2660 21542
CFTR- IntronlO- + UAACUACUAAUAGCCUAUUG 20
2661 21543
CFTR- IntronlO- + UUAACUACUAAUAGCCUAUUG 21
2662 21544
CFTR- IntronlO- + CUUAACUACUAAUAGCCUAUUG 22
2663 21545
CFTR- IntronlO- + ACUUAACUACUAAUAGCCUAUUG 23
2664 21546
CFTR- IntronlO- + AACUUAACUACUAAUAGCCUAUUG 24
2665 21547
CFTR- IntronlO- + UAAAACUAAUGGCAGAAU 18
2666 21548
CFTR- IntronlO- + U UAAAACUAAUGGCAGAAU 19
2667 21549
CFTR- IntronlO- + AUUAAAACUAAUGGCAGAAU 20
2668 21550
CFTR- IntronlO- + AAUUAAAACUAAUGGCAGAAU 21
2669 21551
CFTR- IntronlO- + AAAU UAAAACUAAUGGCAGAAU 22
2670 21552
CFTR- IntronlO- + AAAAUUAAAACUAAUGGCAGAAU 23
2671 21553
CFTR-
+ AAAAAUUAAAACUAAUGGCAGAAU 24
IntronlO- 21554
770
5535.1 2672
CFTR- IntronlO- + UACCAUCACCUUGGGAAU 18
2673 21555
CFTR- IntronlO- + AUACCAUCACCUUGGGAAU 19
2674 21556
CFTR- IntronlO- + AAUACCAUCACCUUGGGAAU 20
2675 21557
CFTR- IntronlO- + CAAUACCAUCACCUUGGGAAU 21
2676 21558
CFTR- IntronlO- + UGCAAUACCAUCACCUUGGGAAU 23
2677 21559
CFTR- IntronlO- + CUGCAAUACCAUCACCUUGGGAAU 24
2678 21560
CFTR- IntronlO- + UGGGAAUUAGGAUUUCAACAU 21
2679 21561
CFTR- IntronlO- + UUGGGAAUUAGGAUUUCAACAU 22
2680 21562
CFTR- IntronlO- + CUUGGGAAUUAGGAUUUCAACAU 23
2681 21563
CFTR- IntronlO- + CCUUGGGAAUUAGGAUUUCAACAU 24
2682 21564
CFTR- IntronlO- + AUCAAGGUGCCAGCAGAU 18
2683 21565
CFTR- IntronlO- + AGAUCAAGGUGCCAGCAGAU 20
2684 21566
CFTR- IntronlO- + AAGAUCAAGGUGCCAGCAGAU 21
2685 21567
CFTR-
+ CAAGAUCAAGGUGCCAGCAGAU 22
IntronlO- 21568
771
5535.1 2686
CFTR- IntronlO- + CCAAGAUCAAGGUGCCAGCAGAU 23
2687 21569
CFTR- IntronlO- + UCCAAGAUCAAGGUGCCAGCAGAU 24
2688 21570
CFTR- IntronlO- + UGAUAGUUGCACAACUAU 18
2689 21571
CFTR- IntronlO- + AGGUGAUAGUUGCACAACUAU 21
2690 21572
CFTR- IntronlO- + AGGAGGUGAUAGUUGCACAACUAU 24
2691 21573
CFTR- IntronlO- + UUUACAUUUCUCUUUACU 18
2692 21574
CFTR- IntronlO- + AUUUACAUUUCUCUUUACU 19
2693 21575
CFTR- IntronlO- + UAUUUACAUUUCUCUUUACU 20
2694 21576
CFTR- IntronlO- + UUAUUUACAUUUCUCUUUACU 21
2695 21577
CFTR- IntronlO- + UUUAUUUACAUUUCUCUUUACU 22
2696 21578
CFTR- IntronlO- + UGUUUAUUUACAUUUCUCUUUACU 24
2697 21579
CFTR- IntronlO- + AAAUGUUAAAUUUUCCCU 18
2698 21580
CFTR- IntronlO- + AAAAUGUUAAAUUUUCCCU 19
2699 21581
CFTR-
+ AGUUACUCAGUCCAGAAAGCU 21
IntronlO- 21582
772
5535.1 2700
CFTR- IntronlO- + CAGUUACUCAGUCCAGAAAGCU 22
2701 21583
CFTR- IntronlO- + CCAGUUACUCAGUCCAGAAAGCU 23
2702 21584
CFTR- IntronlO- + U CCAG U U ACU CAG U CCAG AAAG CU 24
2703 21585
CFTR- IntronlO- + AAUUUAAUUGCCAGUAAGUCU 21
2704 21586
CFTR- IntronlO- + AAAU U U AAU UGCCAG UAAG U CU 22
2705 21587
CFTR- IntronlO- + UGAAAUUUAAUUGCCAGUAAGUCU 24
2706 21588
CFTR- IntronlO- + UAUGCCAGGUUAAGUUGUUCU 21
2707 21589
CFTR- IntronlO- + AUAUGCCAGGUUAAGUUGUUCU 22
2708 21590
CFTR- IntronlO- + AAUAUGCCAGGUUAAGUUGUUCU 23
2709 21591
CFTR- IntronlO- + AAAUAUGCCAGGUUAAGUUGUUCU 24
2710 21592
CFTR- IntronlO- + CACAUGGCAGAAAGGGGU 18
2711 21593
CFTR- IntronlO- + UCACAUGGCAGAAAGGGGU 19
2712 21594
CFTR- IntronlO- + CUCACAUGGCAGAAAGGGGU 20
2713 21595
CFTR-
+ UCUCACAUGGCAGAAAGGGGU 21
IntronlO- 21596
773
5535.1 2714
CFTR- IntronlO- + UUCUCACAUGGCAGAAAGGGGU 22
2715 21597
CFTR- IntronlO- + UGUUCUCACAUGGCAGAAAGGGGU 24
2716 21598
CFTR- IntronlO- + UCACUAGUGGCACUUUGU 18
2717 21599
CFTR- IntronlO- + AUCACUAGUGGCACUUUGU 19
2718 21600
CFTR- IntronlO- + CAUCACUAGUGGCACUUUGU 20
2719 21601
CFTR- IntronlO- + UGCAUCACUAGUGGCACUUUGU 22
2720 21602
CFTR- IntronlO- + CGUGCAUCACUAGUGGCACUUUGU 24
2721 21603
CFTR- IntronlO- + CUGCAAUACCAUCACCUU 18
2722 21604
CFTR- IntronlO- + CCUGCAAUACCAUCACCUU 19
2723 21605
CFTR- IntronlO- + CCCUGCAAUACCAUCACCUU 20
1395 20279
CFTR- IntronlO- + ACCCUGCAAUACCAUCACCUU 21
2724 21606
CFTR- IntronlO- + CACCCUGCAAUACCAUCACCUU 22
2725 21607
CFTR- IntronlO- + CCACCCUGCAAUACCAUCACCUU 23
2726 21608
CFTR-
+ CCCACCCUGCAAUACCAUCACCUU 24
IntronlO- 21609
774
5535.1 2727
CFTR- IntronlO- + A U A A A AG A A A U G CAAG U U 18
2728 21610
CFTR- IntronlO- + AAU A A A AG A A A U G CAAG U U 19
2729 21611
CFTR- IntronlO- + U A A U AAAAG AAA U G C A AG U U 20
2730 21612
CFTR- IntronlO- + A U A A U A A A AG A A A U G CAAG U U 21
2731 21613
CFTR- IntronlO- + UAUAAUAAAAGAAAUGCAAGUU 22
2732 21614
CFTR- IntronlO- + U UAU AAU AAAAG AAAUG CAAG U U 23
2733 21615
CFTR- IntronlO- + CU UAU AAU AAAAG AAAUG CAAG U U 24
2734 21616
CFTR- IntronlO- + CCCUUUAUCAACAUGAAGGUU 21
2735 21617
CFTR- IntronlO- + ACCCUUUAUCAACAUGAAGGUU 22
2736 21618
CFTR- IntronlO- + UGACCCUUUAUCAACAUGAAGGUU 24
2737 21619
CFTR- IntronlO- + AUAGAUUUAAUCUUAUUU 18
2738 21620
CFTR- IntronlO- + UAUAGAUUUAAUCUUAUUU 19
2739 21621
CFTR- IntronlO- + AUAUAGAUUUAAUCUUAUUU 20
2740 21622
CFTR-
+ AAUAUAGAUUUAAUCUUAUUU 21
IntronlO- 21623
775
5535.1 2741
CFTR- IntronlO- + AAAUAUAGAUUUAAUCUUAUUU 22
2742 21624
CFTR- IntronlO- + UUCUAGGCUAGACAGUUU 18
2743 21625
CFTR- IntronlO- + UUUCUAGGCUAGACAGUUU 19
2744 21626
CFTR- IntronlO- + AUUUCUAGGCUAGACAGUUU 20
2745 21627
CFTR- IntronlO- + UAUUUCUAGGCUAGACAGUUU 21
2746 21628
CFTR- IntronlO- + CGGUAUUUCUAGGCUAGACAGUUU 24
2747 21629
CFTR- IntronlO- + UUCAAGCCUGUAUUGUUU 18
2748 21630
CFTR- IntronlO- + AGUUCAAGCCUGUAUUGUUU 20
2749 21631
CFTR- IntronlO- + CAGUUCAAGCCUGUAUUGUUU 21
2750 21632
CFTR- IntronlO- + UGCAGUUCAAGCCUGUAUUGUUU 23
2751 21633
CFTR- IntronlO- + AUGCAGUUCAAGCCUGUAUUGUUU 24
2752 21634
CFTR- IntronlO- - UAUUUAAACACUUCUGAGAAA 21
2753 21635
CFTR- IntronlO- - AUAUUUAAACACUUCUGAGAAA 22
2754 21636
CFTR-
- AAU AU U U AAACACU U CUG AG AAA 23
IntronlO- 21637
776
5535.1 2755
CFTR- IntronlO- - AUGCUUUGAAGGAAGAUCCAA 21
2756 21638
CFTR- IntronlO- - CAUGCUUUGAAGGAAGAUCCAA 22
2757 21639
CFTR- IntronlO- - ACAUGCUUUGAAGGAAGAUCCAA 23
2758 21640
CFTR- IntronlO- - AG AACCAU AU U U UG AAG AA 19
2759 21641
CFTR- IntronlO- - UAUAUUAUAGAAAUUUAA 18
2760 21642
CFTR- IntronlO- - AGGUAUAUUAUAGAAAUUUAA 21
2761 21643
CFTR- IntronlO- - CAGGUAUAUUAUAGAAAUUUAA 22
2762 21644
CFTR- IntronlO- - ACAGGUAUAUUAUAGAAAUUUAA 23
2763 21645
CFTR- IntronlO- - UGGAUUUUUGACUAUACA 18
2764 21646
CFTR- IntronlO- - CGUGGAUUUUUGACUAUACA 20
2765 21647
CFTR- IntronlO- - ACGUGGAUUUUUGACUAUACA 21
2766 21648
CFTR- IntronlO- - UACGUGGAUUUUUGACUAUACA 22
2767 21649
CFTR- IntronlO- - AUACGUGGAUUUUUGACUAUACA 23
2768 21650
CFTR-
- UAUACGUGGAUUUUUGACUAUACA 24
IntronlO- 21651
777
5535.1 2769
CFTR- IntronlO- - UCAUUAGGAAAAUGUACA 18
2770 21652
CFTR- IntronlO- - CUCAUUAGGAAAAUGUACA 19
2771 21653
CFTR- IntronlO- - ACUCAUUAGGAAAAUGUACA 20
2772 21654
CFTR- IntronlO- - AGGUCACUGAGGCUGGCA 18
2773 21655
CFTR- IntronlO- - AGGAGGUCACUGAGGCUGGCA 21
2774 21656
CFTR- IntronlO- - AAGGAGGUCACUGAGGCUGGCA 22
2775 21657
CFTR- IntronlO- - UAAGGAGGUCACUGAGGCUGGCA 23
2776 21658
CFTR- IntronlO- - AGAUAUGAAGUUAAAAACAUCA 22
2777 21659
CFTR- IntronlO- - UUAGUAUAGAAUUUUGCAUCA 21
2778 21660
CFTR- IntronlO- - AUUAGUAUAGAAUUUUGCAUCA 22
2779 21661
CFTR- IntronlO- - UAUUAGUAUAGAAUUUUGCAUCA 23
2780 21662
CFTR- IntronlO- - AUAUUAGUAUAGAAUUUUGCAUCA 24
2781 21663
CFTR- IntronlO- - UAAAGAGCCUUUUCUUUUUCA 21
2782 21664
CFTR-
- AUAAAGAGCCUUUUCUUUUUCA 22
IntronlO- 21665
778
5535.1 2783
CFTR- IntronlO- - UAUAAAGAGCCUUUUCUUUUUCA 23
2784 21666
CFTR- IntronlO- - UUAUAAAGAGCCUUUUCUUUUUCA 24
2785 21667
CFTR- IntronlO- - AGAUCUAGCUAAAAUAUAAGA 21
2786 21668
CFTR- IntronlO- - AAGAUCUAGCUAAAAUAUAAGA 22
2787 21669
CFTR- IntronlO- - AAAGAUCUAGCUAAAAUAUAAGA 23
2788 21670
CFTR- IntronlO- - AAAAGAUCUAGCUAAAAUAUAAGA 24
2789 21671
CFTR- IntronlO- - AUUUUUGUAUUUUUAGUAGAGA 22
2790 21672
CFTR- IntronlO- - AAUUUUUGUAUUUUUAGUAGAGA 23
2791 21673
CFTR- IntronlO- - UAAUUUUUGUAUUUUUAGUAGAGA 24
2792 21674
CFTR- IntronlO- - UUACUAUUAUUUUUGAGA 18
2793 21675
CFTR- IntronlO- - AUUACUAUUAUUUUUGAGA 19
2794 21676
CFTR- IntronlO- - UAUUACUAUUAUUUUUGAGA 20
2795 21677
CFTR- IntronlO- - AUAUUACUAUUAUUUUUGAGA 21
2796 21678
CFTR-
- AAUAUUACUAUUAUUUUUGAGA 22
IntronlO- 21679
779
5535.1 2797
CFTR- IntronlO- - UAAUAUUACUAUUAUUUUUGAGA 23
2798 21680
CFTR- IntronlO- - UUAAUAUUACUAUUAUUUUUGAGA 24
2799 21681
CFTR- IntronlO- - UUUUUUUUUUUUUUGAGA 18
2800 21682
CFTR- IntronlO- - UUUUUUUUUUUUUUUGAGA 19
2801 21683
CFTR- IntronlO- - UUUUUUUUUUUUUUUUGAGA 20
1142 20027
CFTR- IntronlO- - UUUUUUUUUUUUUUUUUGAGA 21
2802 21684
CFTR- IntronlO- - UUUUUUUUUUUUUUUUUUGAGA 22
2803 21685
CFTR- IntronlO- - UUUUUUUUUUUUUUUUUUUGAGA 23
2804 21686
CFTR- IntronlO- - UUUUUUUUUUUUUUUUUUUUGAGA 24
2805 21687
CFTR- IntronlO- - UGACCAGAAUGAAAUUAGA 19
2806 21688
CFTR- IntronlO- - UUGACCAGAAUGAAAUUAGA 20
2807 21689
CFTR- IntronlO- - AUUAGGAAAAUGUACAAAGGA 21
2808 21690
CFTR- IntronlO- - CAUUAGGAAAAUGUACAAAGGA 22
2809 21691
CFTR-
- U C A U U AG G A A A A U G U AC A A AG G A 23
IntronlO- 21692
780
5535.1 2810
CFTR- IntronlO- - CUCAUUAGGAAAAUGUACAAAGGA 24
2811 21693
CFTR- IntronlO- - AGAUGAUUCCAAGCUUUCUGGA 22
2812 21694
CFTR- IntronlO- - AAGAUGAUUCCAAGCUUUCUGGA 23
2813 21695
CFTR- IntronlO- - AAAGAUGAUUCCAAGCUUUCUGGA 24
2814 21696
CFTR- IntronlO- - AUAAAUUUAAAGACAUGA 18
2815 21697
CFTR- IntronlO- - AAUAAAU U U AAAG ACAUG A 19
2816 21698
CFTR- IntronlO- - AAAUAAAU U U AAAG ACAUG A 20
2817 21699
CFTR- IntronlO- - AGGAAAUAAAU U U AAAG ACAUG A 23
2818 21700
CFTR- IntronlO- - AGAAGACAAAGCUAGUGA 18
2819 21701
CFTR- IntronlO- - UGAGAAGACAAAGCUAGUGA 20
2820 21702
CFTR- IntronlO- - CUGAGAAGACAAAGCUAGUGA 21
2821 21703
CFTR- IntronlO- - UCUGAGAAGACAAAGCUAGUGA 22
2822 21704
CFTR- IntronlO- - AGUCUGAGAAGACAAAGCUAGUGA 24
2823 21705
CFTR-
- UGCACUCUAGCCUGGGUGA 19
IntronlO- 21706
781
5535.1 2824
CFTR- IntronlO- - CUGCACUCUAGCCUGGGUGA 20
2825 21707
CFTR- IntronlO- - ACUGCACUCUAGCCUGGGUGA 21
2826 21708
CFTR- IntronlO- - CACUGCACUCUAGCCUGGGUGA 22
2827 21709
CFTR- IntronlO- - CCACUGCACUCUAGCCUGGGUGA 23
2828 21710
CFTR- IntronlO- - CCCCUAACCUUCAUGUUGAUA 21
2829 21711
CFTR- IntronlO- - ACCCCUAACCUUCAUGUUGAUA 22
2830 21712
CFTR- IntronlO- - CACCCCUAACCUUCAUGUUGAUA 23
2831 21713
CFTR- IntronlO- - AAAAUACUUUCUAGAAUUAUA 21
2832 21714
CFTR- IntronlO- - CAAAAUACUUUCUAGAAUUAUA 22
2833 21715
CFTR- IntronlO- - UCAAAAUACUUUCUAGAAUUAUA 23
2834 21716
CFTR- IntronlO- - U U CAAAAU ACU U UCUAGAAUUAUA 24
2835 21717
CFTR- IntronlO- - CGUUUUUGCUUGCUUUUUAUA 21
2836 21718
CFTR- IntronlO- - ACGUUUUUGCUUGCUUUUUAUA 22
2837 21719
CFTR-
- CACGUUUUUGCUUGCUUUUUAUA 23
IntronlO- 21720
782
5535.1 2838
CFTR- IntronlO- - UCACGUUUUUGCUUGCUUUUUAUA 24
2839 21721
CFTR- IntronlO- - CUUGCAGGAGGUGAGGGAUUA 21
2840 21722
CFTR- IntronlO- - ACUUGCAGGAGGUGAGGGAUUA 22
2841 21723
CFTR- IntronlO- - AGACUUGCAGGAGGUGAGGGAUUA 24
2842 21724
CFTR- IntronlO- - CCAAUAAAAGGUUUGUUA 18
2843 21725
CFTR- IntronlO- - AGCCAAUAAAAGGUUUGUUA 20
2844 21726
CFTR- IntronlO- - UAAGUUAGCAAUGGUCUAAAC 21
2845 21727
CFTR- IntronlO- - AUAAGUUAGCAAUGGUCUAAAC 22
2846 21728
CFTR- IntronlO- - AAU AAG U U AGCAAUGG U CU AAAC 23
2847 21729
CFTR- IntronlO- - AAAUAAGUUAGCAAUGGUCUAAAC 24
2848 21730
CFTR- IntronlO- - UAAACUUUGUUUUUCAAC 18
2849 21731
CFTR- IntronlO- - UUAAACUUUGUUUUUCAAC 19
2850 21732
CFTR- IntronlO- - UUUAAACUUUGUUUUUCAAC 20
2851 21733
CFTR-
- AUUUAAACUUUGUUUUUCAAC 21
IntronlO- 21734
783
5535.1 2852
CFTR- IntronlO- - UAUUUAAACUUUGUUUUUCAAC 22
2853 21735
CFTR- IntronlO- - AUAUUUAAACUUUGUUUUUCAAC 23
2854 21736
CFTR- IntronlO- - CAUAUUUAAACUUUGUUUUUCAAC 24
2855 21737
CFTR- IntronlO- - CAUAUAUAUAUUUUUAAC 18
2856 21738
CFTR- IntronlO- - UGCAUAUAUAUAUUUUUAAC 20
2857 21739
CFTR- IntronlO- - AUGCAUAUAUAUAUUUUUAAC 21
2858 21740
CFTR- IntronlO- - UAUGCAUAUAUAUAUUUUUAAC 22
2859 21741
CFTR- IntronlO- - AUAUGCAUAUAUAUAUUUUUAAC 23
2860 21742
CFTR- IntronlO- - AAUAUGCAUAUAUAUAUUUUUAAC 24
2861 21743
CFTR- IntronlO- - UGGAGUCAAAAAUUAUAC 18
2862 21744
CFTR- IntronlO- - UGUGGAGUCAAAAAUUAUAC 20
2863 21745
CFTR- IntronlO- - UUGUGGAGUCAAAAAUUAUAC 21
2864 21746
CFTR- IntronlO- - UUUGUGGAGUCAAAAAUUAUAC 22
2865 21747
CFTR-
- UU UUGUGGAGUCAAAAAUUAUAC 23
IntronlO- 21748
784
5535.1 2866
CFTR- IntronlO- - UUUUUGUGGAGUCAAAAAUUAUAC 24
2867 21749
CFTR- IntronlO- - AGUGCAAUGCCAUAAACC 18
2868 21750
CFTR- IntronlO- - UAGUGCAAUGCCAUAAACC 19
2869 21751
CFTR- IntronlO- - UUAGUGCAAUGCCAUAAACC 20
2870 21752
CFTR- IntronlO- - UUUAGUGCAAUGCCAUAAACC 21
2871 21753
CFTR- IntronlO- - UGUUUAGUGCAAUGCCAUAAACC 23
2872 21754
CFTR- IntronlO- - AUGUUUAGUGCAAUGCCAUAAACC 24
2873 21755
CFTR- IntronlO- - AGAAAAAGUAAGAUAUGCC 19
2874 21756
CFTR- IntronlO- - A AG A A A A AG UAAGAUAUGCC 20
2875 21757
CFTR- IntronlO- - UAAGAAAAAGUAAGAUAUGCC 21
2876 21758
CFTR- IntronlO- - UUAAGAAAAAGUAAGAUAUGCC 22
2877 21759
CFTR- IntronlO- - AUUAAGAAAAAGUAAGAUAUGCC 23
2878 21760
CFTR- IntronlO- - AAUUAAGAAAAAGUAAGAUAUGCC 24
2879 21761
CFTR-
- AGGUGAAUUGCUUGAGUCC 19
IntronlO- 21762
785
5535.1 2880
CFTR- IntronlO- - CAGGUGAAUUGCUUGAGUCC 20
1217 20102
CFTR- IntronlO- - AGGCAGGUGAAUUGCUUGAGUCC 23
2881 21763
CFTR- IntronlO- - CUAAAACCAAACAAGCUUUCC 21
2882 21764
CFTR- IntronlO- - ACU AAAACC AAACAAG C U U U CC 22
2883 21765
CFTR- IntronlO- - UACUAAAACCAAACAAGCUUUCC 23
2884 21766
CFTR- IntronlO- - CUACUAAAACCAAACAAGCUUUCC 24
2885 21767
CFTR- IntronlO- - AAAUUUUCUUUGUUUUCC 18
2886 21768
CFTR- IntronlO- - CAAAUUUUCUUUGUUUUCC 19
2887 21769
CFTR- IntronlO- - ACAAAUUUUCUUUGUUUUCC 20
2888 21770
CFTR- IntronlO- - AACAAAUUUUCUUUGUUUUCC 21
2889 21771
CFTR- IntronlO- - AAACAAAUUUUCUUUGUUUUCC 22
2890 21772
CFTR- IntronlO- - AAAACAAAUUUUCUUUGUUUUCC 23
2891 21773
CFTR- IntronlO- - CAGCUUUU A A A AC A A A A U AG C 21
2892 21774
CFTR-
- ACAGCUUUUAAAACAAAAUAGC 22
IntronlO- 21775
786
5535.1 2893
CFTR- IntronlO- - AACAG CU U U U AAAACAAAAU AG C 23
2894 21776
CFTR- IntronlO- - AAACAGCUUUUAAAACAAAAUAGC 24
2895 21777
CFTR- IntronlO- - CGCGCCACUGCACUCUAGC 19
2896 21778
CFTR- IntronlO- - UCGCGCCACUGCACUCUAGC 20
2897 21779
CFTR- IntronlO- - AUCGCGCCACUGCACUCUAGC 21
2898 21780
CFTR- IntronlO- - AGAUCGCGCCACUGCACUCUAGC 23
2899 21781
CFTR- IntronlO- - CGGGGUUUCACCGUUUUAGC 20
1224 20109
CFTR- IntronlO- - ACGGGGUUUCACCGUUUUAGC 21
2900 21782
CFTR- IntronlO- - AGACGGGGUUUCACCGUUUUAGC 23
2901 21783
CFTR- IntronlO- - UCGCUCUGUCGCCCAGGC 18
2902 21784
CFTR- IntronlO- - CUCGCUCUGUCGCCCAGGC 19
2903 21785
CFTR- IntronlO- - UCUCGCUCUGUCGCCCAGGC 20
1226 20111
CFTR- IntronlO- - AGUCUCGCUCUGUCGCCCAGGC 22
2904 21786
CFTR-
- CGGGGUUUCACCAUGUUGGC 20
IntronlO- 21787
787
5535.1 2905
CFTR- IntronlO- - ACGGGGUUUCACCAUGUUGGC 21
2906 21788
CFTR- IntronlO- - AGACGGGGUUUCACCAUGUUGGC 23
2907 21789
CFTR- IntronlO- - AAUACAGGCUUGAACUGC 18
2908 21790
CFTR- IntronlO- - CAAUACAGGCUUGAACUGC 19
2909 21791
CFTR- IntronlO- - ACAAUACAGGCUUGAACUGC 20
2910 21792
CFTR- IntronlO- - AACAAUACAGGCUUGAACUGC 21
2911 21793
CFTR- IntronlO- - AAACAAUACAGGCUUGAACUGC 22
2912 21794
CFTR- IntronlO- - UAAACAAUACAGGCUUGAACUGC 23
2913 21795
CFTR- IntronlO- - UUAAACAAUACAGGCUUGAACUGC 24
2914 21796
CFTR- IntronlO- - CUCGGCCUCCCAAAGUGC 18
2915 21797
CFTR- IntronlO- - CCUCGGCCUCCCAAAGUGC 19
2916 21798
CFTR- IntronlO- - CGCCUCGGCCUCCCAAAGUGC 21
2917 21799
CFTR- IntronlO- - CCGCCUCGGCCUCCCAAAGUGC 22
2918 21800
CFTR-
- CCCGCCUCGGCCUCCCAAAGUGC 23
IntronlO- 21801
788
5535.1 2919
CFTR- IntronlO- - CAGAGGCAGGUGAAUUGC 18
2920 21802
CFTR- IntronlO- - AGGCAGAGGCAGGUGAAUUGC 21
2921 21803
CFTR- IntronlO- - UGGAGGCAGAGGCAGGUGAAUUGC 24
2922 21804
CFTR- IntronlO- - CACUGCAAGCUCCGCCUC 18
2923 21805
CFTR- IntronlO- - UCACUGCAAGCUCCGCCUC 19
2924 21806
CFTR- IntronlO- - CUCACUGCAAGCUCCGCCUC 20
2925 21807
CFTR- IntronlO- - CGGCUCACUGCAAGCUCCGCCUC 23
2926 21808
CFTR- IntronlO- - UCGGCUCACUGCAAGCUCCGCCUC 24
2927 21809
CFTR- IntronlO- - AGGUUCUGUAAUUUUUGCUUC 21
2928 21810
CFTR- IntronlO- - UAGGUUCUGUAAUUUUUGCUUC 22
2929 21811
CFTR- IntronlO- - AUAGGUUCUGUAAUUUUUGCUUC 23
2930 21812
CFTR- IntronlO- - UAUAGGUUCUGUAAUUUUUGCUUC 24
2931 21813
CFTR- IntronlO- - UGUAACAGUACAAGAAAAAAG 21
2932 21814
CFTR-
- U U G U AACAG U ACAAG AAAAAAG 22
IntronlO- 21815
789
5535.1 2933
CFTR- IntronlO- - AG U UG U AACAG U ACAAG AAAAAAG 24
2934 21816
CFTR- IntronlO- - CUUUGCCAUUAACAGAUAAAG 21
2935 21817
CFTR- IntronlO- - UGCUUUGCCAUUAACAGAUAAAG 23
2936 21818
CFTR- IntronlO- - UUGCUUUGCCAUUAACAGAUAAAG 24
2937 21819
CFTR- IntronlO- - UUUUGGAGGCAGAGGCAG 18
2938 21820
CFTR- IntronlO- - CUUUUGGAGGCAGAGGCAG 19
2939 21821
CFTR- IntronlO- - ACUUUUGGAGGCAGAGGCAG 20
2940 21822
CFTR- IntronlO- - CACUUUUGGAGGCAGAGGCAG 21
2941 21823
CFTR- IntronlO- - AGCACUUUUGGAGGCAGAGGCAG 23
2942 21824
CFTR- IntronlO- - UAGCACUUUUGGAGGCAGAGGCAG 24
2943 21825
CFTR- IntronlO- - CUCGGGAGGCUGAGGCAG 18
2944 21826
CFTR- IntronlO- - ACUCGGGAGGCUGAGGCAG 19
2945 21827
CFTR- IntronlO- - UACUCGGGAGGCUGAGGCAG 20
2946 21828
CFTR-
- CUACUCGGGAGGCUGAGGCAG 21
IntronlO- 21829
790
5535.1 2947
CFTR- IntronlO- - AGCUACUCGGGAGGCUGAGGCAG 23
2948 21830
CFTR- IntronlO- - CAGCUACUCGGGAGGCUGAGGCAG 24
2949 21831
CFTR- IntronlO- - AAGGGAGGAAGCAAGGAG 18
2950 21832
CFTR- IntronlO- - CAAGG G AG G AAG CAAG G AG 19
2951 21833
CFTR- IntronlO- - ACAAGGGAGGAAGCAAGGAG 20
2952 21834
CFTR- IntronlO- - AGACAAGGGAGGAAGCAAGGAG 22
2953 21835
CFTR- IntronlO- - ACAAACAAAAGAAAAUAG 18
2954 21836
CFTR- IntronlO- - CACAAACAAAAGAAAAUAG 19
2955 21837
CFTR- IntronlO- - ACACAAACAAAAGAAAAUAG 20
2956 21838
CFTR- IntronlO- - AACACAAACAAAAGAAAAUAG 21
2957 21839
CFTR- IntronlO- - AAACACAAACAAAAGAAAAUAG 22
2958 21840
CFTR- IntronlO- - AAAACACAAACAAAAGAAAAUAG 23
2959 21841
CFTR- IntronlO- - AAAAACACAAACAAAAGAAAAUAG 24
2960 21842
CFTR-
- U CCAAAU AG AG AUG U U AG 18
IntronlO- 21843
791
5535.1 2961
CFTR- IntronlO- - AUCCAAAUAGAGAUGUUAG 19
2962 21844
CFTR- IntronlO- - CAUCCAAAUAGAGAUGUUAG 20
2963 21845
CFTR- IntronlO- - ACAU CCAAAU AG AG AUG U U AG 21
2964 21846
CFTR- IntronlO- - UGACAUCCAAAUAGAGAUGUUAG 23
2965 21847
CFTR- IntronlO- - UUGACAUCCAAAUAGAGAUGUUAG 24
2966 21848
CFTR- IntronlO- - AGAGUAAGACAGGGAGGG 18
2967 21849
CFTR- IntronlO- - UAGAGUAAGACAGGGAGGG 19
2968 21850
CFTR- IntronlO- - AUAGAGUAAGACAGGGAGGG 20
2969 21851
CFTR- IntronlO- - CAUAGAGUAAGACAGGGAGGG 21
2970 21852
CFTR- IntronlO- - UGGCAUAGAGUAAGACAGGGAGGG 24
2971 21853
CFTR- IntronlO- - UAGUAUUCUAUCAUAUGG 18
2972 21854
CFTR- IntronlO- - AUAGUAUUCUAUCAUAUGG 19
2973 21855
CFTR- IntronlO- - CAUAGUAUUCUAUCAUAUGG 20
2974 21856
CFTR-
- UGCAUAGUAUUCUAUCAUAUGG 22
IntronlO- 21857
792
5535.1 2975
CFTR- IntronlO- - AUGCAUAGUAUUCUAUCAUAUGG 23
2976 21858
CFTR- IntronlO- - UCUGGACUGAGUAACUGG 18
2977 21859
CFTR- IntronlO- - UUCUGGACUGAGUAACUGG 19
2978 21860
CFTR- IntronlO- - UUUCUGGACUGAGUAACUGG 20
2979 21861
CFTR- IntronlO- - CUUUCUGGACUGAGUAACUGG 21
2980 21862
CFTR- IntronlO- - AGCUUUCUGGACUGAGUAACUGG 23
2981 21863
CFTR- IntronlO- - AAGCUUUCUGGACUGAGUAACUGG 24
2982 21864
CFTR- IntronlO- - UGUAUAUAUGUGUGUCUGG 19
2983 21865
CFTR- IntronlO- - AUGUAUAUAUGUGUGUCUGG 20
2984 21866
CFTR- IntronlO- - UAUGUAUAUAUGUGUGUCUGG 21
2985 21867
CFTR- IntronlO- - UGUAUGUAUAUAUGUGUGUCUGG 23
2986 21868
CFTR- IntronlO- - AUGUAUGUAUAUAUGUGUGUCUGG 24
2987 21869
CFTR- IntronlO- - CAGGCUGGAGUGCAGUGG 18
2988 21870
CFTR-
- CCAGGCUGGAGUGCAGUGG 19
IntronlO- 21871
793
5535.1 2989
CFTR- IntronlO- - CCCAGGCUGGAGUGCAGUGG 20
1304 20189
CFTR- IntronlO- - CGCCCAGGCUGGAGUGCAGUGG 22
2990 21872
CFTR- IntronlO- - UCGCCCAGGCUGGAGUGCAGUGG 23
2991 21873
CFTR- IntronlO- - CUUGGGAGGCUGAGGUGG 18
2992 21874
CFTR- IntronlO- - ACUUGGGAGGCUGAGGUGG 19
2993 21875
CFTR- IntronlO- - UACUUGGGAGGCUGAGGUGG 20
2994 21876
CFTR- IntronlO- - CUACUUGGGAGGCUGAGGUGG 21
2995 21877
CFTR- IntronlO- - AGCUACUUGGGAGGCUGAGGUGG 23
2996 21878
CFTR- IntronlO- - CAGCUACUUGGGAGGCUGAGGUGG 24
2997 21879
CFTR- IntronlO- - UGGGUGGGGGAGCCCCAUAAAUG 23
2998 21880
CFTR- IntronlO- - UUGGGUGGGGGAGCCCCAUAAAUG 24
2999 21881
CFTR- IntronlO- - AAUUAGCCAGACGUGAUG 18
3000 21882
CFTR- IntronlO- - AAAUUAGCCAGACGUGAUG 19
3001 21883
CFTR-
- AAAAUUAGCCAGACGUGAUG 20
IntronlO- 21884
794
5535.1 3002
CFTR- IntronlO- - AAAAAUUAGCCAGACGUGAUG 21
3003 21885
CFTR- IntronlO- - A A A A A A UUAGCCAGACGUGAUG 22
3004 21886
CFTR- IntronlO- - C A A A A A A UUAGCCAGACGUGAUG 23
3005 21887
CFTR- IntronlO- - ACAAAAAAUUAGCCAGACGUGAUG 24
3006 21888
CFTR- IntronlO- - UGGGUGAGAUUAGAGGCCACUG 22
3007 21889
CFTR- IntronlO- - CUGGGUGAGAUUAGAGGCCACUG 23
3008 21890
CFTR- IntronlO- - UCUGGGUGAGAUUAGAGGCCACUG 24
3009 21891
CFTR- IntronlO- - CUUCAGCCUCCCAAAGUG 18
3010 21892
CFTR- IntronlO- - CGCUUCAGCCUCCCAAAGUG 20
3011 21893
CFTR- IntronlO- - CCGCUUCAGCCUCCCAAAGUG 21
3012 21894
CFTR- IntronlO- - UCCGCUUCAGCCUCCCAAAGUG 22
3013 21895
CFTR- IntronlO- - UUCCGCUUCAGCCUCCCAAAGUG 23
3014 21896
CFTR- IntronlO- - UUUCCGCUUCAGCCUCCCAAAGUG 24
3015 21897
CFTR-
- AAAGACUUGCAGGAGGUG 18
IntronlO- 21898
795
5535.1 3016
CFTR- IntronlO- - CAAAGACUUGCAGGAGGUG 19
3017 21899
CFTR- IntronlO- - ACAAAGACUUGCAGGAGGUG 20
1317 20202
CFTR- IntronlO- - AACAAAGACUUGCAGGAGGUG 21
3018 21900
CFTR- IntronlO- - UGAA CAAAGACUUGCAGGAGGUG 23
3019 21901
CFTR- IntronlO- - UUGAACAAAGACUUGCAGGAGGUG 24
3020 21902
CFTR- IntronlO- - AGGUUUGUUAAAGAAUGACUGUG 23
3021 21903
CFTR- IntronlO- - AAGGUUUGUUAAAGAAUGACUGUG 24
3022 21904
CFTR- IntronlO- - CCCAAGGUGAUGGUAUUG 18
3023 21905
CFTR- IntronlO- - UCCCAAGGUGAUGGUAUUG 19
3024 21906
CFTR- IntronlO- - UUCCCAAGGUGAUGGUAUUG 20
3025 21907
CFTR- IntronlO- - AUUCCCAAGGUGAUGGUAUUG 21
3026 21908
CFTR- IntronlO- - AAUUCCCAAGGUGAUGGUAUUG 22
3027 21909
CFTR- IntronlO- - UAAUUCCCAAGGUGAUGGUAUUG 23
3028 21910
CFTR-
- CUAAUUCCCAAGGUGAUGGUAUUG 24
IntronlO- 21911
796
5535.1 3029
CFTR- IntronlO- - UUAGUAGUUAAGUUUUUG 18
3030 21912
CFTR- IntronlO- - AUUAGUAGUUAAGUUUUUG 19
3031 21913
CFTR- IntronlO- - UAUUAGUAGUUAAGUUUUUG 20
1325 20210
CFTR- IntronlO- - CUAUUAGUAGUUAAGUUUUUG 21
3032 21914
CFTR- IntronlO- - AGGCUAUUAGUAGUUAAGUUUUUG 24
3033 21915
CFTR- IntronlO- - UCAGAUUUUUUCCCAUGUAAU 21
3034 21916
CFTR- IntronlO- - UUCAGAUUUUUUCCCAUGUAAU 22
3035 21917
CFTR- IntronlO- - AUUCAGAUUUUUUCCCAUGUAAU 23
3036 21918
CFTR- IntronlO- - AAUUCAGAUUUUUUCCCAUGUAAU 24
3037 21919
CFTR- IntronlO- - UGGGAGGUGAUUAGUCCAU 19
3038 21920
CFTR- IntronlO- - UUGGGAGGUGAUUAGUCCAU 20
3039 21921
CFTR- IntronlO- - UUUGGGAGGUGAUUAGUCCAU 21
3040 21922
CFTR- IntronlO- - CUUUGGGAGGUGAUUAGUCCAU 22
3041 21923
CFTR-
- CCUUUGGGAGGUGAUUAGUCCAU 23
IntronlO- 21924
797
5535.1 3042
CFTR- IntronlO- - UGCAUAGUAUUCUAUCAU 18
3043 21925
CFTR- IntronlO- - AUGCAUAGUAUUCUAUCAU 19
3044 21926
CFTR- IntronlO- - AGAUGCAUAGUAUUCUAUCAU 21
3045 21927
CFTR- IntronlO- - UAGAUGCAUAGUAUUCUAUCAU 22
3046 21928
CFTR- IntronlO- - AUAGAUGCAUAGUAUUCUAUCAU 23
3047 21929
CFTR- IntronlO- - AAUAGAUGCAUAGUAUUCUAUCAU 24
3048 21930
CFTR- IntronlO- - UGAGAAAGAGCUUUCUAGUAU 21
3049 21931
CFTR- IntronlO- - AUGAGAAAGAGCUUUCUAGUAU 22
3050 21932
CFTR- IntronlO- - AGAUGAGAAAGAGCUUUCUAGUAU 24
3051 21933
CFTR- IntronlO- - UAAAAAGCUGUGCAUUUUCCU 21
3052 21934
CFTR- IntronlO- - UUAAAAAGCUGUGCAUUUUCCU 22
3053 21935
CFTR- IntronlO- - UUUAAAAAGCUGUGCAUUUUCCU 23
3054 21936
CFTR- IntronlO- - UUUUAAAAAGCUGUGCAUUUUCCU 24
3055 21937
CFTR-
- CAAAUUAUUUCUACUGCU 18
IntronlO- 21938
798
5535.1 3056
CFTR- IntronlO- - UCAAAUUAUUUCUACUGCU 19
3057 21939
CFTR-
- UUCAAAUUAUUUCUACUGCU 20
lntronlO-521 19407
CFTR- IntronlO- - UGUCUGUAGGCUAUAUGUAUCU 22
3058 21940
CFTR- IntronlO- - UUGUCUGUAGGCUAUAUGUAUCU 23
3059 21941
CFTR- IntronlO- - AUUGUCUGUAGGCUAUAUGUAUCU 24
3060 21942
CFTR- IntronlO- - CUCGGCCUCCCAAAGUGU 18
3061 21943
CFTR- IntronlO- - CCUCGGCCUCCCAAAGUGU 19
3062 21944
CFTR- IntronlO- - UGCCUCGGCCUCCCAAAGUGU 21
3063 21945
CFTR- IntronlO- - CUGCCUCGGCCUCCCAAAGUGU 22
3064 21946
CFTR- IntronlO- - CCUGCCUCGGCCUCCCAAAGUGU 23
3065 21947
CFTR- IntronlO- - AGGAAGGCAGUGGUCCCUU 19
3066 21948
CFTR- IntronlO- - AGGAAGCAAGGAGAUGAGUU 20
1399 20283
CFTR- IntronlO- - AGGGAGGAAGCAAGGAGAUGAGUU 24
3067 21949
CFTR- IntronlO- - AGAUAAUGGGAGAAACAGGUU 21
3068 21950
799
5535.1 CFTR- IntronlO- - AAGAUAAUGGGAGAAACAGGUU 22
3069 21951
CFTR- IntronlO- - AAAGAUAAUGGGAGAAACAGGUU 23
3070 21952
CFTR- IntronlO- - AUAGUUUUAUCAAUAUUU 18
3071 21953
CFTR- IntronlO- - AAUAGUUUUAUCAAUAUUU 19
3072 21954
CFTR- IntronlO- - AAAU AG UUUUAUCAAUAUUU 20
1405 20289
CFTR- IntronlO- - UGCAUGGGUCCACUUAUUU 19
3073 21955
CFTR- IntronlO- - CUGCAUGGGUCCACUUAUUU 20
3074 21956
CFTR- IntronlO- - ACUGCAUGGGUCCACUUAUUU 21
3075 21957
CFTR- IntronlO- - AACUGCAUGGGUCCACUUAUUU 22
3076 21958
CFTR- IntronlO- - UGAACUGCAUGGGUCCACUUAUUU 24
3077 21959
CFTR- IntronlO- - UUGUUGUUUUUCUAGUUU 18
3078 21960
CFTR- IntronlO- - UUUGUUGUUUUUCUAGUUU 19
3079 21961
CFTR- IntronlO- - UUUUGUUGUUUUUCUAGUUU 20
3080 21962
CFTR- IntronlO- - UUUUUGUUGUUUUUCUAGUUU 21
3081 21963
800
5535.1 CFTR- IntronlO- - UUUUUUGUUGUUUUUCUAGUUU 22
3082 21964
CFTR- IntronlO- - CUUUUUUGUUGUUUUUCUAGUUU 23
3083 21965
CFTR- IntronlO- - AAUACAUUGGAAAAUUUU 18
3084 21966
CFTR- IntronlO- - UAAUACAUUGGAAAAUUUU 19
3085 21967
CFTR- IntronlO- - U U AAU ACAU UGG AAAAU U U U 20
1411 20295
CFTR- IntronlO- - AG U U AAU ACAU UGG AAAAU U U U 22
3086 21968
CFTR- IntronlO- - CAGU UAAUACAUUGGAAAAUUUU 23
3087 21969
CFTR- IntronlO- - U CAG U U AAU ACAU UGG AAAAU U U U 24
3088 21970
CFTR- IntronlO- - UAUGUCCUCCACAAAUAUUUU 21
3089 21971
CFTR- IntronlO- - AGUAUGUCCUCCACAAAUAUUUU 23
3090 21972
CFTR- IntronlO- - AAGUAUGUCCUCCACAAAUAUUUU 24
3091 21973
Table 41E provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the fifth tier parameters. The targeting domains bind within intron 10, and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 41E
801
5535.1 5th Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
CFTR- IntronlO- + AAAAAAAAAAAAAAAAAA 18
3092 21974
CFTR- IntronlO- + AAAAAAAAAAAAAAAAAAA 19
3093 21975
CFTR- IntronlO- + AAAAAAAAAAAAAAAAAAAA 20
3094 21976
CFTR- IntronlO- + AAAAAAAAAAAAAAAAAAAAA 21
3095 21977
CFTR- IntronlO- + AAAAAAAAAAAAAAAAAAAAAA 22
3096 21978
CFTR- IntronlO- + AAAAAAAAAAAAAAAAAAAAAAA 23
3097 21979
CFTR- IntronlO- + CAAAAAAAAAAAAAAAAAAAAAAA 24
3098 21980
CFTR- IntronlO- + U AG AAAAAC AACAAAAAA 18
3099 21981
CFTR- IntronlO- + CUAGAAAAACAACAAAAAA 19
3100 21982
CFTR- IntronlO- + ACUAGAAAAACAACAAAAAA 20
3101 21983
CFTR- IntronlO- + AACUAGAAAAACAACAAAAAA 21
3102 21984
CFTR- IntronlO- + AAACUAGAAAAACAACAAAAAA 22
3103 21985
CFTR- IntronlO- + AAAACUAGAAAAACAACAAAAAA 23
3104 21986
802
5535.1 CFTR- IntronlO- + AAAAACUAGAAAAACAACAAAAAA 24
3105 21987
CFTR- IntronlO- + CAAACAAAGAAACAAAAA 18
3106 21988
CFTR- IntronlO- + ACAAACAAAGAAACAAAAA 19
3107 21989
CFTR- IntronlO- + U ACAAAC AAAG AAAC AAAAA 20
3108 21990
CFTR- IntronlO- + AUACAAACAAAGAAACAAAAA 21
3109 21991
CFTR- IntronlO- + AAUACAAACAAAGAAACAAAAA 22
3110 21992
CFTR- IntronlO- + AAAUACAAACAAAGAAACAAAAA 23
3111 21993
CFTR- IntronlO- + UAAAUACAAACAAAGAAACAAAAA 24
3112 21994
CFTR- IntronlO- + CAU AU UG U U ACAU AAAAA 18
3113 21995
CFTR- IntronlO- + GCAUAUUGUUACAUAAAAA 19
3114 21996
CFTR- IntronlO- + UGCAUAUUGUUACAUAAAAA 20
3115 21997
CFTR- IntronlO- + CUGCAUAUUGUUACAUAAAAA 21
3116 21998
CFTR- IntronlO- + UCUGCAUAUUGUUACAUAAAAA 22
3117 21999
CFTR- IntronlO- + CUCUGCAUAUUGUUACAUAAAAA 23
3118 22000
803
5535.1 CFTR- IntronlO- + ACUCUGCAUAUUGUUACAUAAAAA 24
3119 22001
CFTR- IntronlO- + G U G C A U A A AG G U U G A A A A 18
3120 22002
CFTR- IntronlO- + AGUGCAUAAAGGUUGAAAA 19
3121 22003
CFTR-
+ GAGUGCAUAAAGGUUGAAAA 20
lntronlO-65 18951
CFTR- IntronlO- + AGAGUGCAUAAAGGUUGAAAA 21
3122 22004
CFTR- IntronlO- + A AG AG U G C A U A A AG G U U G A A A A 22
3123 22005
CFTR- IntronlO- + AAAGAGUGCAU A A AG G U U G A A A A 23
3124 22006
CFTR- IntronlO- + CAAAGAGUGCAUAAAGGUUGAAAA 24
3125 22007
CFTR- IntronlO- + U U U CCU CAAU AG U UAAAA 18
3126 22008
CFTR- IntronlO- + AUUUCCUCAAUAGUUAAAA 19
3127 22009
CFTR- IntronlO- + UAUUUCCUCAAUAGUUAAAA 20
3128 22010
CFTR- IntronlO- + UUAUUUCCUCAAUAGUUAAAA 21
3129 22011
CFTR- IntronlO- + UUUAUUUCCUCAAUAGUUAAAA 22
3130 22012
CFTR- IntronlO- + AUUUAUUUCCUCAAUAGUUAAAA 23
3131 22013
CFTR-
+ AAUUUAUUUCCUCAAUAGUUAAAA 24
IntronlO- 22014
804
5535.1 3132
CFTR- IntronlO- + UAGU AAAAAAAAAU CAAA 18
3133 22015
CFTR- IntronlO- + U U AG U AAAAAAAAAU CAAA 19
3134 22016
CFTR- IntronlO- + A U U AG U A A A A A A A A A U CAAA 20
1092 19977
CFTR- IntronlO- + AAU U AG U A A A A A A A A A U CAAA 21
3135 22017
CFTR- IntronlO- + AAAU UAGU AAAAAAAAAU CAAA 22
3136 22018
CFTR- IntronlO- + AAAAU U AG U AAAAAAAAAU CAAA 23
3137 22019
CFTR- IntronlO- + CAAAAUUAGUAAAAAAAAAUCAAA 24
3138 22020
CFTR- IntronlO- + GCUAAAAUGACAAUCAAA 18
3139 22021
CFTR- IntronlO- + AGCUAAAAUGACAAUCAAA 19
3140 22022
CFTR-
+ CAGCUAAAAUGACAAUCAAA 20
lntronlO-335 19221
CFTR- IntronlO- + ACAGCUAAAAUGACAAUCAAA 21
3141 22023
CFTR- IntronlO- + CACAGCUAAAAUGACAAUCAAA 22
3142 22024
CFTR- IntronlO- + CCACAGCUAAAAUGACAAUCAAA 23
3143 22025
CFTR- IntronlO- + ACCACAGCUAAAAUGACAAUCAAA 24
3144 22026
805
5535.1 CFTR- IntronlO- + AGGAUAUCUUAGGUCAAA 18
3145 22027
CFTR- IntronlO- + UAGGAUAUCUUAGGUCAAA 19
3146 22028
CFTR- IntronlO- + UUAGGAUAUCUUAGGUCAAA 20
3147 22029
CFTR- IntronlO- + CUU AGGAUAUCUUAGGUCAAA 21
3148 22030
CFTR- IntronlO- + CCUUAGGAUAUCUUAGGUCAAA 22
3149 22031
CFTR- IntronlO- + CCCUUAGGAUAUCUUAGGUCAAA 23
3150 22032
CFTR- IntronlO- + UCCCUUAGGAUAUCUUAGGUCAAA 24
3151 22033
CFTR- IntronlO- + AAUGCAGGAGAAUGGAAA 18
3152 22034
CFTR- IntronlO- + GAAUGCAGGAGAAUGGAAA 19
3153 22035
CFTR- IntronlO- + GGAAUGCAGGAGAAUGGAAA 20
3154 22036
CFTR- IntronlO- + GGGAAUGCAGGAGAAUGGAAA 21
3155 22037
CFTR- IntronlO- + AGGGAAUGCAGGAGAAUGGAAA 22
3156 22038
CFTR- IntronlO- + GAGGGAAUGCAGGAGAAUGGAAA 23
3157 22039
CFTR- IntronlO- + UGAGGGAAUGCAGGAGAAUGGAAA 24
3158 22040
806
5535.1 CFTR- IntronlO- + C A A A U AC A U U C A A U G AAA 18
3159 22041
CFTR- IntronlO- + CCAAAUACAUUCAAUGAAA 19
3160 22042
CFTR- IntronlO- + CCCAAAUACAUUCAAUGAAA 20
3161 22043
CFTR- IntronlO- + GCCCAAAUACAUUCAAUGAAA 21
3162 22044
CFTR- IntronlO- + GGCCCAAAUACAUUCAAUGAAA 22
3163 22045
CFTR- IntronlO- + AGGCCCAAAUACAUUCAAUGAAA 23
3164 22046
CFTR- IntronlO- + CAGG CCCAAAU ACAU U CAAUG AAA 24
3165 22047
CFTR- IntronlO- + AGUGCAUAAAGGUUGAAA 18
3166 22048
CFTR- IntronlO- + GAGUGCAUAAAGGUUGAAA 19
3167 22049
CFTR- IntronlO- + AGAGUGCAU A A AG G U U G A A A 20
3168 22050
CFTR- IntronlO- + AAGAGUGCAUAAAGGUUGAAA 21
3169 22051
CFTR- IntronlO- + A A AG AG U G C A U A A AG G U U G AAA 22
3170 22052
CFTR- IntronlO- + CAAAGAGUGCAUAAAGGUUGAAA 23
3171 22053
CFTR- IntronlO- + GCAAAGAGUGCAUAAAGGUUGAAA 24
3172 22054
807
5535.1 CFTR- IntronlO- + UGCAUAUUGUUACAUAAA 18
3173 22055
CFTR- IntronlO- + CUGCAUAUUGUUACAUAAA 19
3174 22056
CFTR- IntronlO- + UCUGCAUAUUGUUACAUAAA 20
3175 22057
CFTR- IntronlO- + CUCUGCAUAUUGUUACAUAAA 21
3176 22058
CFTR- IntronlO- + ACUCUGCAUAUUGUUACAUAAA 22
3177 22059
CFTR- IntronlO- + AACUCUGCAUAUUGUUACAUAAA 23
3178 22060
CFTR- IntronlO- + AAACUCUGCAUAUUGUUACAUAAA 24
3179 22061
CFTR- IntronlO- + UCGUAUGUAGGAAAACAA 18
3180 22062
CFTR- IntronlO- + UUCGUAUGU AG G A A A A C A A 19
3181 22063
CFTR- IntronlO- + UUUCGUAUGUAGGAAAACAA 20
3182 22064
CFTR- IntronlO- + GUUUCGUAUGUAGGAAAACAA 21
3183 22065
CFTR- IntronlO- + UGUUUCGUAUGUAGGAAAACAA 22
3184 22066
CFTR- IntronlO- + CUGUUUCGUAUGUAGGAAAACAA 23
3185 22067
CFTR- IntronlO- + GCUGUUUCGUAUGUAGGAAAACAA 24
3186 22068
808
5535.1 CFTR- IntronlO- + AACCAAAUAAACAAACAA 18
3187 22069
CFTR- IntronlO- + AAACCAAAUAAACAAACAA 19
3188 22070
CFTR- IntronlO- + A A A AC C A A A U AAACAAACAA 20
1099 19984
CFTR- IntronlO- + AAAAACCAAAUAAACAAACAA 21
3189 22071
CFTR- IntronlO- + UAAAAACCAAAUAAACAAACAA 22
3190 22072
CFTR- IntronlO- + G UAAAAACCAAAUAAACAAACAA 23
3191 22073
CFTR- IntronlO- + AGUAAAAACCAAAUAAACAAACAA 24
3192 22074
CFTR- IntronlO- + UGUGUGGCUUAUAAACAA 18
3193 22075
CFTR- IntronlO- + CUGUGUGGCUUAUAAACAA 19
3194 22076
CFTR- IntronlO- + ACUGUGUGGCUUAUAAACAA 20
3195 22077
CFTR- IntronlO- + AACUGUGUGGCUUAUAAACAA 21
3196 22078
CFTR- IntronlO- + GAACUGUGUGGCUUAUAAACAA 22
3197 22079
CFTR- IntronlO- + UGAACUGUGUGGCUUAUAAACAA 23
3198 22080
CFTR- IntronlO- + AUGAACUGUGUGGCUUAUAAACAA 24
3199 22081
809
5535.1 CFTR- IntronlO- + CAGCUGUGAUGCAGACAA 18
3200 22082
CFTR- IntronlO- + UCAGCUGUGAUGCAGACAA 19
3201 22083
CFTR- IntronlO- + UUCAGCUGUGAUGCAGACAA 20
3202 22084
CFTR- IntronlO- + CUUCAGCUGUGAUGCAGACAA 21
3203 22085
CFTR- IntronlO- + GCUUCAGCUGUGAUGCAGACAA 22
3204 22086
CFTR- IntronlO- + UGCUUCAGCUGUGAUGCAGACAA 23
3205 22087
CFTR- IntronlO- + CUGCUUCAGCUGUGAUGCAGACAA 24
3206 22088
CFTR- IntronlO- + UAAUGAGUU ACAAU ACAA 18
3207 22089
CFTR- IntronlO- + U U AAUG AG U U ACAAU ACAA 19
3208 22090
CFTR- IntronlO- + AU U AAUG AG U U ACAAU ACAA 20
3209 22091
CFTR- IntronlO- + AAU U AAUG AG U U ACAAU ACAA 21
3210 22092
CFTR- IntronlO- + AAAU U AAUG AG U U ACAAU ACAA 22
3211 22093
CFTR- IntronlO- + U AAAU U AAUG AG U U ACAAU ACAA 23
3212 22094
CFTR- IntronlO- + AU AAAU U AAUG AG U U ACAAU ACAA 24
3213 22095
810
5535.1 CFTR- IntronlO- + AGCUUACCGUAAUAGCAA 18
3214 22096
CFTR- IntronlO- + GAGCUUACCGUAAUAGCAA 19
3215 22097
CFTR- IntronlO- + UGAGCUUACCGUAAUAGCAA 20
3216 22098
CFTR- IntronlO- + UUGAGCUUACCGUAAUAGCAA 21
3217 22099
CFTR- IntronlO- + CUUGAGCUUACCGUAAUAGCAA 22
3218 22100
CFTR- IntronlO- + GCUUGAGCUUACCGUAAUAGCAA 23
3219 22101
CFTR- IntronlO- + UGCUUGAGCUUACCGUAAUAGCAA 24
3220 22102
CFTR- IntronlO- + GGUCAAUUGUAUUAGCAA 18
3221 22103
CFTR- IntronlO- + GGGUCAAUUGUAUUAGCAA 19
3222 22104
CFTR- IntronlO- + AGGGUCAAUUGUAUUAGCAA 20
3223 22105
CFTR- IntronlO- + AAGGGUCAAUUGUAUUAGCAA 21
3224 22106
CFTR- IntronlO- + U AAGGG U CAAU UG U AU U AG CAA 22
3225 22107
CFTR- IntronlO- + U U AAGGG U CAAU UG U AU U AG CAA 23
3226 22108
CFTR- IntronlO- + U U U AAGGG U CAAU UG U AU U AG CAA 24
3227 22109
811
5535.1 CFTR- IntronlO- + UUAGU AAAAAAAAAU CAA 18
3228 22110
CFTR- IntronlO- + AU U AG U AAAAAAAAAU CAA 19
3229 22111
CFTR- IntronlO- + AAUUAGU AAAAAAAAAU CAA 20
3230 22112
CFTR- IntronlO- + AAAU U AG U AAAAAAAAAU CAA 21
3231 22113
CFTR- IntronlO- + AAAAUUAGU AAAAAAAAAU CAA 22
3232 22114
CFTR- IntronlO- + CAAAAU U AG U AAAAAAAAAU CAA 23
3233 22115
CFTR- IntronlO- + ACAAAAUUAGUAAAAAAAAAUCAA 24
3234 22116
CFTR- IntronlO- + AG C U A A A A U G AC A A U C A A 18
3235 22117
CFTR- IntronlO- + C AG C U A A A A U G AC A A U C A A 19
3236 22118
CFTR- IntronlO- + A C AG C U A A A A U G AC A A U C A A 20
3237 22119
CFTR- IntronlO- + CACAGCUAAAAUGACAAUCAA 21
3238 22120
CFTR- IntronlO- + C C AC AG C U A A A A U G AC A A U CAA 22
3239 22121
CFTR- IntronlO- + ACCACAGCUAAAAUGACAAUCAA 23
3240 22122
CFTR- IntronlO- + UACCACAGCUAAAAUGACAAUCAA 24
3241 22123
812
5535.1 CFTR- IntronlO- + CUGAAGCGG A A AG G U C A A 18
3242 22124
CFTR- IntronlO- + G C U G A AG CG G A A AG G U C A A 19
3243 22125
CFTR- IntronlO- + GGCUGAAGCGGAAAGGUCAA 20
3244 22126
CFTR- IntronlO- + AGGCUGAAGCGGAAAGGUCAA 21
3245 22127
CFTR- IntronlO- + G AG G C UGAAG CG G AAAG G U CAA 22
3246 22128
CFTR- IntronlO- + GGAGGCUGAAGCGGAAAGGUCAA 23
3247 22129
CFTR- IntronlO- + GGGAGGCUGAAGCGGAAAGGUCAA 24
3248 22130
CFTR- IntronlO- + CACCUGAAAUAUAUUCAA 18
3249 22131
CFTR- IntronlO- + UCACCUGAAAUAUAUUCAA 19
3250 22132
CFTR- IntronlO- + AUCACCUGAAAUAUAUUCAA 20
3251 22133
CFTR- IntronlO- + UAUCACCUGAAAUAUAUUCAA 21
3252 22134
CFTR- IntronlO- + AUAUCACCUGAAAUAUAUUCAA 22
3253 22135
CFTR- IntronlO- + AAUAUCACCUGAAAUAUAUUCAA 23
3254 22136
CFTR- IntronlO- + UAAUAUCACCUGAAAUAUAUUCAA 24
3255 22137
813
5535.1 CFTR- IntronlO- + AAAAAAAAAAAAAAAGAA 18
3256 22138
CFTR- IntronlO- + AAAAAAAAAAAAAAAAGAA 19
3257 22139
CFTR- IntronlO- + AAAAAAAAAAAAAAAAAGAA 20
3258 22140
CFTR- IntronlO- + AAAAAAAAAAAAAAAAAAGAA 21
3259 22141
CFTR- IntronlO- + AAAAAAAAAAAAAAAAAAAGAA 22
3260 22142
CFTR- IntronlO- + AAAAAAAAAAAAAAAAAAAAGAA 23
3261 22143
CFTR- IntronlO- + AAAAAAAAAAAAAAAAAAAAAGAA 24
3262 22144
CFTR- IntronlO- + GAAAUAUAUU CAAAAG AA 18
3263 22145
CFTR- IntronlO- + UGAAAUAUAUUCAAAAGAA 19
3264 22146
CFTR- IntronlO- + CUGAAAUAUAUUCAAAAGAA 20
1103 19988
CFTR- IntronlO- + CCUGAAAUAUAUUCAAAAGAA 21
3265 22147
CFTR- IntronlO- + ACCUGAAAUAUAUUCAAAAGAA 22
3266 22148
CFTR- IntronlO- + CACCUGAAAUAUAUUCAAAAGAA 23
3267 22149
CFTR- IntronlO- + U CACCUG AAAU AU AU U CAAAAG AA 24
3268 22150
814
5535.1 CFTR- IntronlO- + AAAAAUACGAUAUAAGAA 18
3269 22151
CFTR- IntronlO- + CAAAAAUACGAUAUAAGAA 19
3270 22152
CFTR- IntronlO- + GCAAAAAUACGAUAUAAGAA 20
3271 22153
CFTR- IntronlO- + UGCAAAAAUACGAUAUAAGAA 21
3272 22154
CFTR- IntronlO- + U UGCAAAAAU ACG AU AU AAG AA 22
3273 22155
CFTR- IntronlO- + GUUGCAAAAAUACGAUAUAAGAA 23
3274 22156
CFTR- IntronlO- + AGUUGCAAAAAUACGAUAUAAGAA 24
3275 22157
CFTR- IntronlO- + UGAGGGAAUGCAGGAGAA 18
3276 22158
CFTR- IntronlO- + AUGAGGGAAUGCAGGAGAA 19
3277 22159
CFTR-
+ GAUGAGGGAAUGCAGGAGAA 20
lntronlO-649 19535
CFTR- IntronlO- + GGAUGAGGGAAUGCAGGAGAA 21
3278 22160
CFTR- IntronlO- + UGGAUGAGGGAAUGCAGGAGAA 22
3279 22161
CFTR- IntronlO- + UUGGAUGAGGGAAUGCAGGAGAA 23
3280 22162
CFTR- IntronlO- + GUUGGAUGAGGGAAUGCAGGAGAA 24
3281 22163
CFTR-
+ AAUAAACAAACAAAGGAA 18
IntronlO- 22164
815
5535.1 3282
CFTR- IntronlO- + AAAUAAACAAACAAAGGAA 19
3283 22165
CFTR- IntronlO- + C A A A U A A AC A A AC A A AG G A A 20
3284 22166
CFTR- IntronlO- + CCAAAUAAACAAACAAAGGAA 21
3285 22167
CFTR- IntronlO- + ACCAAAUAAACAAACAAAGGAA 22
3286 22168
CFTR- IntronlO- + AACCAAAUAAACAAACAAAGGAA 23
3287 22169
CFTR- IntronlO- + AAACCAAAUAAACAAACAAAGGAA 24
3288 22170
CFTR- IntronlO- + A A A AC U GAGUAGAAGGAA 18
3289 22171
CFTR- IntronlO- + U A A A AC U GAGUAGAAGGAA 19
3290 22172
CFTR-
+ CUAAAACUGAGUAGAAGGAA 20
lntronlO-349 19235
CFTR- IntronlO- + ACUAAAACUGAGUAGAAGGAA 21
3291 22173
CFTR- IntronlO- + GACUAAAACUGAGUAGAAGGAA 22
3292 22174
CFTR- IntronlO- + UGACUAAAACUGAGUAGAAGGAA 23
3293 22175
CFTR- IntronlO- + CUGACUAAAACUGAGUAGAAGGAA 24
3294 22176
CFTR- IntronlO- + UAAACAGAAUCAGGGGAA 18
3295 22177
816
5535.1 CFTR- IntronlO- + U U A A AC AG A A U C AG G G G A A 19
3296 22178
CFTR- IntronlO- + U U U A A AC AG A A U C AG G G G A A 20
3297 22179
CFTR- IntronlO- + AUUUAAACAGAAUCAGGGGAA 21
3298 22180
CFTR- IntronlO- + UAUUUAAACAGAAUCAGGGGAA 22
3299 22181
CFTR- IntronlO- + CUAUUUAAACAGAAUCAGGGGAA 23
3300 22182
CFTR- IntronlO- + GCUAUUUAAACAGAAUCAGGGGAA 24
3301 22183
CFTR- IntronlO- + GCACUUUGGGAGGCUGAA 18
3302 22184
CFTR- IntronlO- + AGCACUUUGGGAGGCUGAA 19
3303 22185
CFTR- IntronlO- + CAGCACUUUGGGAGGCUGAA 20
3304 22186
CFTR- IntronlO- + CCAGCACUUUGGGAGGCUGAA 21
3305 22187
CFTR- IntronlO- + CCCAGCACUUUGGGAGGCUGAA 22
3306 22188
CFTR- IntronlO- + ACCCAGCACUUUGGGAGGCUGAA 23
3307 22189
CFTR- IntronlO- + AACCCAGCACUUUGGGAGGCUGAA 24
3308 22190
CFTR- IntronlO- + GUACAUUUAAUAUCUGAA 18
3309 22191
817
5535.1 CFTR- IntronlO- + UGUACAUUUAAUAUCUGAA 19
3310 22192
CFTR- IntronlO- + AUGUACAUUUAAUAUCUGAA 20
3311 22193
CFTR- IntronlO- + GAUGUACAUUUAAUAUCUGAA 21
3312 22194
CFTR- IntronlO- + UGAUGUACAUUUAAUAUCUGAA 22
3313 22195
CFTR- IntronlO- + AUGAUGUACAUUUAAUAUCUGAA 23
3314 22196
CFTR- IntronlO- + AAUGAUGUACAUUUAAUAUCUGAA 24
3315 22197
CFTR- IntronlO- + A A A A A A A U U C AC A A A U A A 18
3316 22198
CFTR- IntronlO- + AAAAAAAAUUCACAAAUAA 19
3317 22199
CFTR- IntronlO- + GAAAAAAAAUUCACAAAUAA 20
3318 22200
CFTR- IntronlO- + UGAAAAAAAAUUCACAAAUAA 21
3319 22201
CFTR- IntronlO- + CUGAAAAAAAAUUCACAAAUAA 22
3320 22202
CFTR- IntronlO- + ACUGAAAAAAAAUUCACAAAUAA 23
3321 22203
CFTR- IntronlO- + AACUGAAAAAAAAUUCACAAAUAA 24
3322 22204
CFTR- IntronlO- + UGAGGCAAUGAUCAAUAA 18
3323 22205
818
5535.1 CFTR- IntronlO- + GUGAGGCAAUGAUCAAUAA 19
3324 22206
CFTR- IntronlO- + AGUGAGGCAAUGAUCAAUAA 20
3325 22207
CFTR- IntronlO- + UAGUGAGGCAAUGAUCAAUAA 21
3326 22208
CFTR- IntronlO- + AUAGUGAGGCAAUGAUCAAUAA 22
3327 22209
CFTR- IntronlO- + CAUAGUGAGGCAAUGAUCAAUAA 23
3328 22210
CFTR- IntronlO- + CCAUAGUGAGGCAAUGAUCAAUAA 24
3329 22211
CFTR- IntronlO- + AGAACCUAUAAGGAAUAA 18
3330 22212
CFTR- IntronlO- + CAGAACCUAUAAGGAAUAA 19
3331 22213
CFTR- IntronlO- + ACAGAACCUAUAAGGAAUAA 20
3332 22214
CFTR- IntronlO- + UACAGAACCUAUAAGGAAUAA 21
3333 22215
CFTR- IntronlO- + U UACAGAACCUAUAAGGAAUAA 22
3334 22216
CFTR- IntronlO- + AUUACAGAACCUAUAAGGAAUAA 23
3335 22217
CFTR- IntronlO- + AAUUACAGAACCUAUAAGGAAUAA 24
3336 22218
CFTR- IntronlO- + ACAGUGACUUCAUAAUAA 18
3337 22219
819
5535.1 CFTR- IntronlO- + UACAGUGACUUCAUAAUAA 19
3338 22220
CFTR- IntronlO- + AUACAGUGACUUCAUAAUAA 20
1111 19996
CFTR- IntronlO- + AAUACAGUGACUUCAUAAUAA 21
3339 22221
CFTR- IntronlO- + CAAUACAGUGACUUCAUAAUAA 22
3340 22222
CFTR- IntronlO- + ACAAUACAGUGACUUCAUAAUAA 23
3341 22223
CFTR- IntronlO- + GACAAUACAGUGACUUCAUAAUAA 24
3342 22224
CFTR- IntronlO- + UUACACUACUUAUAAUAA 18
3343 22225
CFTR- IntronlO- + U U U ACACU ACU U AU AAU AA 19
3344 22226
CFTR- IntronlO- + UUUUACACUACUUAUAAUAA 20
3345 22227
CFTR- IntronlO- + AUUUUACACUACUUAUAAUAA 21
3346 22228
CFTR- IntronlO- + UAUUUUACACUACUUAUAAUAA 22
3347 22229
CFTR- IntronlO- + AUAUUUUACACUACUUAUAAUAA 23
3348 22230
CFTR- IntronlO- + GAUAUUUUACACUACUUAUAAUAA 24
3349 22231
CFTR- IntronlO- + CAAGUAGAAAAAAGAUAA 18
3350 22232
820
5535.1 CFTR- IntronlO- + G C A AG U AG A A A A A AG A U A A 19
3351 22233
CFTR- IntronlO- + AGCAAGUAGAAAAAAGAUAA 20
3352 22234
CFTR- IntronlO- + AAGCAAGUAG A A A A A AG A U A A 21
3353 22235
CFTR- IntronlO- + A A AG C A AG U AG A A A A A AG A U A A 22
3354 22236
CFTR- IntronlO- + CAAAGCAAGUAGAAAAAAGAUAA 23
3355 22237
CFTR- IntronlO- + GCAAAGCAAGUAGAAAAAAGAUAA 24
3356 22238
CFTR- IntronlO- + AUAAUAUACAAGAUAUAA 18
3357 22239
CFTR- IntronlO- + AAUAAUAUACAAGAUAUAA 19
3358 22240
CFTR- IntronlO- + UAAUAAUAUACAAGAUAUAA 20
3359 22241
CFTR- IntronlO- + GUAAUAAUAUACAAGAUAUAA 21
3360 22242
CFTR- IntronlO- + AG UAAUAAUAUACAAGAUAUAA 22
3361 22243
CFTR- IntronlO- + UAGUAAUAAUAUACAAGAUAUAA 23
3362 22244
CFTR- IntronlO- + CUAGUAAUAAUAUACAAGAUAUAA 24
3363 22245
CFTR- IntronlO- + UAACUUUAUGCUAACUAA 18
3364 22246
821
5535.1 CFTR- IntronlO- + CUAACUUUAUGCUAACUAA 19
3365 22247
CFTR- IntronlO- + CCUAACUUUAUGCUAACUAA 20
3366 22248
CFTR- IntronlO- + ACCUAACUUUAUGCUAACUAA 21
3367 22249
CFTR- IntronlO- + AACCUAACUUUAUGCUAACUAA 22
3368 22250
CFTR- IntronlO- + AAACCUAACUUUAUGCUAACUAA 23
3369 22251
CFTR- IntronlO- + CAAACCUAACUUUAUGCUAACUAA 24
3370 22252
CFTR- IntronlO- + AG U AAAG U AACAAAG UAA 18
3371 22253
CFTR- IntronlO- + CAG U AAAG U AACAAAG UAA 19
3372 22254
CFTR- IntronlO- + U CAG UAAAGU AACAAAG UAA 20
3373 22255
CFTR- IntronlO- + A U C AG U AAAG U AACAAAG U A A 21
3374 22256
CFTR- IntronlO- + U A U C AG U AAAG U AACAAAG U A A 22
3375 22257
CFTR- IntronlO- + U UAU CAG UAAAGU AACAAAG UAA 23
3376 22258
CFTR- IntronlO- + U U UAU CAG U AAAG U AACAAAG UAA 24
3377 22259
CFTR- IntronlO- + AG C U A A U AAA U AAAG U A A 18
3378 22260
822
5535.1 CFTR- IntronlO- + A AG C U A A U AAA U AAAG U A A 19
3379 22261
CFTR- IntronlO- + AAAG CU AAU AAAU AAAG UAA 20
3380 22262
CFTR- IntronlO- + UAAAGCU AAU AAAU AAAG UAA 21
3381 22263
CFTR- IntronlO- + U U AAAG CU AAU AAAU AAAG UAA 22
3382 22264
CFTR- IntronlO- + U U U AAAG CU AAU AAAU AAAG UAA 23
3383 22265
CFTR- IntronlO- + AUUUAAAGCUAAUAAAUAAAGUAA 24
3384 22266
CFTR- IntronlO- + UUCUAGAAAACAAUGUAA 18
3385 22267
CFTR- IntronlO- + U U U CU AG AAAACAAUG UAA 19
3386 22268
CFTR- IntronlO- + U U U U CU AG AAAACAAUG UAA 20
1114 19999
CFTR- IntronlO- + AUUUUCUAGAAAACAAUGUAA 21
3387 22269
CFTR- IntronlO- + GAUUUUCUAGAAAACAAUGUAA 22
3388 22270
CFTR- IntronlO- + AG AU U U U CU AG AAAACAAUG UAA 23
3389 22271
CFTR- IntronlO- + CAG AU U U U CU AG AAAACAAUG UAA 24
3390 22272
CFTR- IntronlO- + UAUAAGUGUGGAGUGUAA 18
3391 22273
823
5535.1 CFTR- IntronlO- + GUAUAAGUGUGGAGUGUAA 19
3392 22274
CFTR-
+ GGUAUAAGUGUGGAGUGUAA 20
lntronlO-72 18958
CFTR- IntronlO- + GGGUAUAAGUGUGGAGUGUAA 21
3393 22275
CFTR- IntronlO- + GGGGUAUAAGUGUGGAGUGUAA 22
3394 22276
CFTR- IntronlO- + UGGGGUAUAAGUGUGGAGUGUAA 23
3395 22277
CFTR- IntronlO- + AUGGGGUAUAAGUGUGGAGUGUAA 24
3396 22278
CFTR- IntronlO- + UGAACUCUAAUCUAUUAA 18
3397 22279
CFTR- IntronlO- + UUGAACUCUAAUCUAUUAA 19
3398 22280
CFTR- IntronlO- + AUUGAACUCUAAUCUAUUAA 20
3399 22281
CFTR- IntronlO- + AAUUGAACUCUAAUCUAUUAA 21
3400 22282
CFTR- IntronlO- + GAAUUGAACUCUAAUCUAUUAA 22
3401 22283
CFTR- IntronlO- + UGAAUUGAACUCUAAUCUAUUAA 23
3402 22284
CFTR- IntronlO- + CUGAAUUGAACUCUAAUCUAUUAA 24
3403 22285
CFTR- IntronlO- + GCUUAACCCAUCUAUUAA 18
3404 22286
CFTR-
+ GGCUUAACCCAUCUAUUAA 19
IntronlO- 22287
824
5535.1 3405
CFTR- IntronlO- + UGGCUUAACCCAUCUAUUAA 20
3406 22288
CFTR- IntronlO- + UUGGCUUAACCCAUCUAUUAA 21
3407 22289
CFTR- IntronlO- + GUUGGCUUAACCCAUCUAUUAA 22
3408 22290
CFTR- IntronlO- + AGUUGGCUUAACCCAUCUAUUAA 23
3409 22291
CFTR- IntronlO- + CAGUUGGCUUAACCCAUCUAUUAA 24
3410 22292
CFTR- IntronlO- + AAUUUUCCAAUGUAUUAA 18
3411 22293
CFTR- IntronlO- + AAAU UUUCCAAUGUAUUAA 19
3412 22294
CFTR- IntronlO- + AAAAUUUUCCAAUGUAUUAA 20
3413 22295
CFTR- IntronlO- + AAAAAU UUUCCAAUGUAUUAA 21
3414 22296
CFTR- IntronlO- + CAAAAAU UUUCCAAUGUAUUAA 22
3415 22297
CFTR- IntronlO- + CCAAAAAU U U U CCAAUG U AU U AA 23
3416 22298
CFTR- IntronlO- + CCCAAAAAUUUUCCAAUGUAUUAA 24
3417 22299
CFTR- IntronlO- + AGCCUAGAUGAUUAUUAA 18
3418 22300
CFTR-
+ CAGCCUAGAUGAUUAUUAA 19
IntronlO- 22301
825
5535.1 3419
CFTR- IntronlO- + GCAGCCUAGAUGAUUAUUAA 20
3420 22302
CFTR- IntronlO- + UGCAGCCUAGAUGAUUAUUAA 21
3421 22303
CFTR- IntronlO- + UUGCAGCCUAGAUGAUUAUUAA 22
3422 22304
CFTR- IntronlO- + UUUGCAGCCUAGAUGAUUAUUAA 23
3423 22305
CFTR- IntronlO- + UUUUGCAGCCUAGAUGAUUAUUAA 24
3424 22306
CFTR- IntronlO- + UAUUUCCUCAAUAGUUAA 18
3425 22307
CFTR- IntronlO- + UUAUUUCCUCAAUAGUUAA 19
3426 22308
CFTR- IntronlO- + UUUAUUUCCUCAAUAGUUAA 20
3427 22309
CFTR- IntronlO- + AUUUAUUUCCUCAAUAGUUAA 21
3428 22310
CFTR- IntronlO- + AAUUUAUUUCCUCAAUAGUUAA 22
3429 22311
CFTR- IntronlO- + AAAU UUAUUUCCUCAAUAGUUAA 23
3430 22312
CFTR- IntronlO- + U AAAU UUAUUUCCUCAAUAGUUAA 24
3431 22313
CFTR- IntronlO- + CAACAUUCUUGGAAAACA 18
3432 22314
CFTR-
+ ACAACAUUCUUGGAAAACA 19
IntronlO- 22315
826
5535.1 3433
CFTR- IntronlO- + AACAACAUUCUUGGAAAACA 20
3434 22316
CFTR- IntronlO- + GAACAACAUUCUUGGAAAACA 21
3435 22317
CFTR- IntronlO- + UGAACAACAUUCUUGGAAAACA 22
3436 22318
CFTR- IntronlO- + UUGAACAACAUUCUUGGAAAACA 23
3437 22319
CFTR- IntronlO- + U U UG AACAACAU U CU U GG AAAACA 24
3438 22320
CFTR- IntronlO- + AAUGAAACAAAUAAAACA 18
3439 22321
CFTR- IntronlO- + AAAUGAAACAAAUAAAACA 19
3440 22322
CFTR- IntronlO- + GAAAUGAAACAAAUAAAACA 20
3441 22323
CFTR- IntronlO- + AGAAAUGAAACAAAUAAAACA 21
3442 22324
CFTR- IntronlO- + AAGAAAUGAAACAAAUAAAACA 22
3443 22325
CFTR- IntronlO- + AAAGAAAUGAAACAAAUAAAACA 23
3444 22326
CFTR- IntronlO- + AAAAGAAAUGAAACAAAUAAAACA 24
3445 22327
CFTR- IntronlO- + AAACCAAAUAAACAAACA 18
3446 22328
CFTR-
+ AAAACCAAAUAAACAAACA 19
IntronlO- 22329
827
5535.1 3447
CFTR- IntronlO- + AAAAACCAAAUAAACAAACA 20
3448 22330
CFTR- IntronlO- + UAAAAACCAAAUAAACAAACA 21
3449 22331
CFTR- IntronlO- + GUAAAAACCAAAUAAACAAACA 22
3450 22332
CFTR- IntronlO- + AG UAAAAACCAAAUAAACAAACA 23
3451 22333
CFTR- IntronlO- + AAGUAAAAACCAAAUAAACAAACA 24
3452 22334
CFTR- IntronlO- + AAACUGUAAAUACAAACA 18
3453 22335
CFTR- IntronlO- + AAAACUGUAAAUACAAACA 19
3454 22336
CFTR- IntronlO- + UAAAACUGUAAAUACAAACA 20
3455 22337
CFTR- IntronlO- + UUAAAACUGUAAAUACAAACA 21
3456 22338
CFTR- IntronlO- + CUUAAAACUGUAAAUACAAACA 22
3457 22339
CFTR- IntronlO- + ACUUAAAACUGUAAAUACAAACA 23
3458 22340
CFTR- IntronlO- + AACUUAAAACUGUAAAUACAAACA 24
3459 22341
CFTR- IntronlO- + GACAAUCAAAUGGGAACA 18
3460 22342
CFTR-
+ UGACAAUCAAAUGGGAACA 19
IntronlO- 22343
828
5535.1 3461
CFTR-
+ AUGACAAUCAAAUGGGAACA 20
lntronlO-363 19249
CFTR- IntronlO- + AAUGACAAUCAAAUGGGAACA 21
3462 22344
CFTR- IntronlO- + AAAUGACAAUCAAAUGGGAACA 22
3463 22345
CFTR- IntronlO- + AAAAUGACAAUCAAAUGGGAACA 23
3464 22346
CFTR- IntronlO- + UAAAAUGACAAUCAAAUGGGAACA 24
3465 22347
CFTR- IntronlO- + AACCUAUAAGGAAUAACA 18
3466 22348
CFTR- IntronlO- + GAACCUAUAAGGAAUAACA 19
3467 22349
CFTR-
+ AGAACCUAUAAGGAAUAACA 20
lntronlO-364 19250
CFTR- IntronlO- + CAGAACCUAUAAGGAAUAACA 21
3468 22350
CFTR- IntronlO- + ACAGAACCUAUAAGGAAUAACA 22
3469 22351
CFTR- IntronlO- + UACAGAACCUAUAAGGAAUAACA 23
3470 22352
CFTR- IntronlO- + UUACAGAACCUAUAAGGAAUAACA 24
3471 22353
CFTR- IntronlO- + GAGAGAGAACUGCUCACA 18
3472 22354
CFTR- IntronlO- + GGAGAGAGAACUGCUCACA 19
3473 22355
829
5535.1 CFTR- IntronlO- + UGGAGAGAGAACUGCUCACA 20
1122 20007
CFTR- IntronlO- + CUGGAGAGAGAACUGCUCACA 21
3474 22356
CFTR- IntronlO- + ACUGGAGAGAGAACUGCUCACA 22
3475 22357
CFTR- IntronlO- + UACUGGAGAGAGAACUGCUCACA 23
3476 22358
CFTR- IntronlO- + UUACUGGAGAGAGAACUGCUCACA 24
3477 22359
CFTR- IntronlO- + UUUACAAUUCUUAUUACA 18
3478 22360
CFTR- IntronlO- + UUUUACAAUUCUUAUUACA 19
3479 22361
CFTR- IntronlO- + AUUUUACAAUUCUUAUUACA 20
1125 20010
CFTR- IntronlO- + AAUUUUACAAUUCUUAUUACA 21
3480 22362
CFTR- IntronlO- + AAAU U U U ACAAU U CU U AU U ACA 22
3481 22363
CFTR- IntronlO- + UAAAUUUUACAAUUCUUAUUACA 23
3482 22364
CFTR- IntronlO- + G U AAAU U U U ACAAU U CU U AU U ACA 24
3483 22365
CFTR- IntronlO- + CAGGAGUUCAAGGUUACA 18
3484 22366
CFTR- IntronlO- + CCAGGAGUUCAAGGUUACA 19
3485 22367
830
5535.1 CFTR- IntronlO- + CCCAG GAG U U CAAG G U U ACA 20
3486 22368
CFTR- IntronlO- + GCCCAGG AG U U CAAGG U U ACA 21
3487 22369
CFTR- IntronlO- + AGCCCAGGAGUUCAAGGUUACA 22
3488 22370
CFTR- IntronlO- + GAGCCCAGGAGUUCAAGGUUACA 23
3489 22371
CFTR- IntronlO- + U GAG CCCAG GAG U U CAAG G U U AC A 24
3490 22372
CFTR- IntronlO- + UGAGCUAUGAUCACACCA 18
3491 22373
CFTR- IntronlO- + GUGAGCUAUGAUCACACCA 19
3492 22374
CFTR- IntronlO- + AGUGAGCUAUGAUCACACCA 20
3493 22375
CFTR- IntronlO- + CAGUGAGCUAUGAUCACACCA 21
3494 22376
CFTR- IntronlO- + ACAGUGAGCUAUGAUCACACCA 22
3495 22377
CFTR- IntronlO- + UACAGUGAGCUAUGAUCACACCA 23
3496 22378
CFTR- IntronlO- + UUACAGUGAGCUAUGAUCACACCA 24
3497 22379
CFTR- IntronlO- + GGCCUCUAAUCUCACCCA 18
3498 22380
CFTR- IntronlO- + UGGCCUCUAAUCUCACCCA 19
3499 22381
831
5535.1 CFTR- IntronlO- + GUGGCCUCUAAUCUCACCCA 20
3500 22382
CFTR- IntronlO- + AGUGGCCUCUAAUCUCACCCA 21
3501 22383
CFTR- IntronlO- + CAGUGGCCUCUAAUCUCACCCA 22
3502 22384
CFTR- IntronlO- + CCAGUGGCCUCUAAUCUCACCCA 23
3503 22385
CFTR- IntronlO- + UCCAGUGGCCUCUAAUCUCACCCA 24
3504 22386
CFTR- IntronlO- + CAGCUAAAGUAUUACCCA 18
3505 22387
CFTR- IntronlO- + ACAGCUAAAG U AU U ACCCA 19
3506 22388
CFTR- IntronlO- + UACAGCUAAAGUAUUACCCA 20
3507 22389
CFTR- IntronlO- + AU ACAG CU AAAG U AU U ACCCA 21
3508 22390
CFTR- IntronlO- + UAUACAGCUAAAGUAUUACCCA 22
3509 22391
CFTR- IntronlO- + AUAUACAGCUAAAGUAUUACCCA 23
3510 22392
CFTR- IntronlO- + AAUAUACAGCUAAAGUAUUACCCA 24
3511 22393
CFTR- IntronlO- + AGUGUUUAAAUAUUCCCA 18
3512 22394
CFTR- IntronlO- + AAGUGUUUAAAUAUUCCCA 19
3513 22395
CFTR- + G AAG UG U U U AAAU AU U CCCA 20 18962
832
5535.1 lntronlO-76
CFTR- IntronlO- + AGAAGUGUUUAAAUAUUCCCA 21
3514 22396
CFTR- IntronlO- + CAGAAGUGUUUAAAUAUUCCCA 22
3515 22397
CFTR- IntronlO- + U CAG AAG UG U U U AAAU AU U CCCA 23
3516 22398
CFTR- IntronlO- + CUCAGAAGUGUUUAAAUAUUCCCA 24
3517 22399
CFTR- IntronlO- + UAGUAUUAAGUAUAGCCA 18
3518 22400
CFTR- IntronlO- + UUAGUAUUAAGUAUAGCCA 19
3519 22401
CFTR- IntronlO- + AUUAGUAUUAAGUAUAGCCA 20
3520 22402
CFTR- IntronlO- + UAUUAGUAUUAAGUAUAGCCA 21
3521 22403
CFTR- IntronlO- + UUAUUAGUAUUAAGUAUAGCCA 22
3522 22404
CFTR- IntronlO- + GUUAUUAGUAUUAAGUAUAGCCA 23
3523 22405
CFTR- IntronlO- + AGUUAUUAGUAUUAAGUAUAGCCA 24
3524 22406
CFTR- IntronlO- + UGAGUAUACUUUAUGCCA 18
3525 22407
CFTR- IntronlO- + GUGAGUAUACUUUAUGCCA 19
3526 22408
CFTR- IntronlO- + UGUGAGUAUACUUUAUGCCA 20
3527 22409
833
5535.1 CFTR- IntronlO- + AUGUGAGUAUACUUUAUGCCA 21
3528 22410
CFTR- IntronlO- + UAUGUGAGUAUACUUUAUGCCA 22
3529 22411
CFTR- IntronlO- + CUAUGUGAGUAUACUUUAUGCCA 23
3530 22412
CFTR- IntronlO- + ACUAUGUGAGUAUACUUUAUGCCA 24
3531 22413
CFTR- IntronlO- + GAAGGAAAGGAGGUAGCA 18
3532 22414
CFTR- IntronlO- + AG AAG G AAAG GAG G U AG CA 19
3533 22415
CFTR- IntronlO- + U AG AAG G AAAG GAG G U AG CA 20
3534 22416
CFTR- IntronlO- + G U AG AAG G AAAG GAG G U AG CA 21
3535 22417
CFTR- IntronlO- + AGUAGAAGGAAAGGAGGUAGCA 22
3536 22418
CFTR- IntronlO- + GAGUAGAAGGAAAGGAGGUAGCA 23
3537 22419
CFTR- IntronlO- + U G AG U AG AAG G AAAG GAG G U AG CA 24
3538 22420
CFTR- IntronlO- + UUCAACAUAUGAAUGGCA 18
3539 22421
CFTR- IntronlO- + UUUCAACAUAUGAAUGGCA 19
3540 22422
CFTR- IntronlO- + AUUUCAACAUAUGAAUGGCA 20
1128 20013
834
5535.1 CFTR- IntronlO- + GAUUUCAACAUAUGAAUGGCA 21
3541 22423
CFTR- IntronlO- + GGAUUUCAACAUAUGAAUGGCA 22
3542 22424
CFTR- IntronlO- + AGGAUUUCAACAUAUGAAUGGCA 23
3543 22425
CFTR- IntronlO- + UAGGAUUUCAACAUAUGAAUGGCA 24
3544 22426
CFTR- IntronlO- + CGGGAGGCGGAGCUUGCA 18
3545 22427
CFTR- IntronlO- + CCGGGAGGCGGAGCUUGCA 19
3546 22428
CFTR- IntronlO- + CCCGGGAGGCGGAGCUUGCA 20
3547 22429
CFTR- IntronlO- + ACCCGGGAGGCGGAGCUUGCA 21
3548 22430
CFTR- IntronlO- + AACCCGGGAGGCGGAGCUUGCA 22
3549 22431
CFTR- IntronlO- + GAACCCGGGAGGCGGAGCUUGCA 23
3550 22432
CFTR- IntronlO- + UGAACCCGGGAGGCGGAGCUUGCA 24
3551 22433
CFTR- IntronlO- + CGGGAGGCAGAGGUUGCA 18
3552 22434
CFTR- IntronlO- + CCGGGAGGCAGAGGUUGCA 19
3553 22435
CFTR- IntronlO- + CCCGGGAGGCAGAGGUUGCA 20
3554 22436
835
5535.1 CFTR- IntronlO- + GCCCGGGAGGCAGAGGUUGCA 21
3555 22437
CFTR- IntronlO- + AGCCCGGGAGGCAGAGGUUGCA 22
3556 22438
CFTR- IntronlO- + GAGCCCGGGAGGCAGAGGUUGCA 23
3557 22439
CFTR- IntronlO- + UGAGCCCGGGAGGCAGAGGUUGCA 24
3558 22440
CFTR- IntronlO- + GCUAUUUAAACAGAAUCA 18
3559 22441
CFTR- IntronlO- + UG CU AU U U AAACAG AAU CA 19
3560 22442
CFTR-
+ GUGCUAUUUAAACAGAAUCA 20
lntronlO-77 18963
CFTR- IntronlO- + AGUGCUAUUUAAACAGAAUCA 21
3561 22443
CFTR- IntronlO- + CAGUGCUAUUUAAACAGAAUCA 22
3562 22444
CFTR- IntronlO- + CCAGUGCUAUUUAAACAGAAUCA 23
3563 22445
CFTR- IntronlO- + UCCAGUGCUAUUUAAACAGAAUCA 24
3564 22446
CFTR- IntronlO- + AGUACAAAAGGACUAUCA 18
3565 22447
CFTR- IntronlO- + UAGUACAAAAGGACUAUCA 19
3566 22448
CFTR- IntronlO- + AUAGUACAAAAGGACUAUCA 20
3567 22449
CFTR-
+ GAUAGUACAAAAGGACUAUCA 21
IntronlO- 22450
836
5535.1 3568
CFTR- IntronlO- + UGAUAGUACAAAAGGACUAUCA 22
3569 22451
CFTR- IntronlO- + AUGAUAGUACAAAAGGACUAUCA 23
3570 22452
CFTR- IntronlO- + GAUGAUAGUACAAAAGGACUAUCA 24
3571 22453
CFTR- IntronlO- + UUAGGAUAUCUUAGGUCA 18
3572 22454
CFTR- IntronlO- + CUUAGGAUAUCUUAGGUCA 19
3573 22455
CFTR- IntronlO- + CCUUAGGAUAUCUUAGGUCA 20
3574 22456
CFTR- IntronlO- + CCCUUAGGAUAUCUUAGGUCA 21
3575 22457
CFTR- IntronlO- + UCCCUUAGGAUAUCUUAGGUCA 22
3576 22458
CFTR- IntronlO- + UUCCCUUAGGAUAUCUUAGGUCA 23
3577 22459
CFTR- IntronlO- + UUUCCCUUAGGAUAUCUUAGGUCA 24
3578 22460
CFTR- IntronlO- + UAUUCUUUUAUGUGGUCA 18
3579 22461
CFTR- IntronlO- + AUAUUCUUUUAUGUGGUCA 19
3580 22462
CFTR- IntronlO- + UAUAUUCUUUUAUGUGGUCA 20
3581 22463
CFTR-
+ AUAUAUUCUUUUAUGUGGUCA 21
IntronlO- 22464
837
5535.1 3582
CFTR- IntronlO- + AAUAUAUUCUUUUAUGUGGUCA 22
3583 22465
CFTR- IntronlO- + GAAUAUAUUCUUUUAUGUGGUCA 23
3584 22466
CFTR- IntronlO- + CGAAUAUAUUCUUUUAUGUGGUCA 24
3585 22467
CFTR- IntronlO- + CU U CACU AAAAU AAU U CA 18
3586 22468
CFTR- IntronlO- + GCUUCACUAAAAUAAUUCA 19
3587 22469
CFTR- IntronlO- + UGCUUCACUAAAAUAAUUCA 20
1133 20018
CFTR- IntronlO- + UUGCUUCACUAAAAUAAUUCA 21
3588 22470
CFTR- IntronlO- + AUUGCUUCACUAAAAUAAUUCA 22
3589 22471
CFTR- IntronlO- + UAUUGCUUCACUAAAAUAAUUCA 23
3590 22472
CFTR- IntronlO- + AUAUUGCUUCACUAAAAUAAUUCA 24
3591 22473
CFTR- IntronlO- + AAUCUAAAAGCUAAUUCA 18
3592 22474
CFTR- IntronlO- + AAAUCUAAAAGCUAAUUCA 19
3593 22475
CFTR-
+ UAAAUCUAAAAGCUAAUUCA 20
lntronlO-369 19255
CFTR- IntronlO- + GU AAAUCUAAAAGCUAAUUCA 21
3594 22476
838
5535.1 CFTR- IntronlO- + AGUAAAUCUAAAAGCUAAUUCA 22
3595 22477
CFTR- IntronlO- + AAGUAAAUCUAAAAGCUAAUUCA 23
3596 22478
CFTR- IntronlO- + UAAGUAAAUCUAAAAGCUAAUUCA 24
3597 22479
CFTR- IntronlO- + CAGG CCCAAAU ACAU U CA 18
3598 22480
CFTR- IntronlO- + GCAGGCCCAAAUACAUUCA 19
3599 22481
CFTR- IntronlO- + UGCAGGCCCAAAUACAUUCA 20
3600 22482
CFTR- IntronlO- + AUGCAGGCCCAAAUACAUUCA 21
3601 22483
CFTR- IntronlO- + UAUGCAGGCCCAAAUACAUUCA 22
3602 22484
CFTR- IntronlO- + AUAUGCAGGCCCAAAUACAUUCA 23
3603 22485
CFTR- IntronlO- + CAUAUGCAGGCCCAAAUACAUUCA 24
3604 22486
CFTR- IntronlO- + GAAUUGG UACAAAU U U CA 18
3605 22487
CFTR- IntronlO- + CGAAUUGGUACAAAUUUCA 19
3606 22488
CFTR-
+ ACGAAUUGGUACAAAUUUCA 20
lntronlO-370 19256
CFTR- IntronlO- + UACGAAUUGGUACAAAUUUCA 21
3607 22489
CFTR-
+ GU ACGAAUUGGUACAAAUUUCA 22
IntronlO- 22490
839
5535.1 3608
CFTR- IntronlO- + AGUACGAAUUGGUACAAAUUUCA 23
3609 22491
CFTR- IntronlO- + GAGUACGAAUUGGUACAAAUUUCA 24
3610 22492
CFTR- IntronlO- + UGAAAUAUAUUCAAAAGA 18
3611 22493
CFTR- IntronlO- + CUGAAAUAUAUUCAAAAGA 19
3612 22494
CFTR- IntronlO- + CCUGAAAUAUAUUCAAAAGA 20
3613 22495
CFTR- IntronlO- + ACCUGAAAUAUAUUCAAAAGA 21
3614 22496
CFTR- IntronlO- + CACCUGAAAUAUAUUCAAAAGA 22
3615 22497
CFTR- IntronlO- + UCACCUGAAAUAUAUUCAAAAGA 23
3616 22498
CFTR- IntronlO- + AUCACCUGAAAUAUAUUCAAAAGA 24
3617 22499
CFTR- IntronlO- + GAUGAGAGACAGUAAAGA 18
3618 22500
CFTR- IntronlO- + AGAUGAGAGACAGUAAAGA 19
3619 22501
CFTR- IntronlO- + CAGAUGAGAGACAGUAAAGA 20
3620 22502
CFTR- IntronlO- + ACAGAUGAGAGACAGUAAAGA 21
3621 22503
CFTR-
+ GACAGAUGAGAGACAGUAAAGA 22
IntronlO- 22504
840
5535.1 3622
CFTR- IntronlO- + GGACAGAUGAGAGACAGUAAAGA 23
3623 22505
CFTR- IntronlO- + UGGACAGAUGAGAGACAGUAAAGA 24
3624 22506
CFTR- IntronlO- + AAU AAU AACAU U U U AAG A 18
3625 22507
CFTR- IntronlO- + AAAU AAU AACAU U U U AAG A 19
3626 22508
CFTR- IntronlO- + AAAAU AAU AACAU U U U AAG A 20
3627 22509
CFTR- IntronlO- + AAAAAU AAU AACAU U U U AAG A 21
3628 22510
CFTR- IntronlO- + G AAAAAU AAU AACAU U U U AAG A 22
3629 22511
CFTR- IntronlO- + AG AAAAAU AAU AACAU U U U AAG A 23
3630 22512
CFTR- IntronlO- + AAG AAAAAU AAU AACAU U U U AAG A 24
3631 22513
CFTR- IntronlO- + UCCAGCCUGGGCGACAGA 18
3632 22514
CFTR- IntronlO- + CUCCAGCCUGGGCGACAGA 19
3633 22515
CFTR- IntronlO- + ACUCCAGCCUGGGCGACAGA 20
3634 22516
CFTR- IntronlO- + CACUCCAGCCUGGGCGACAGA 21
3635 22517
CFTR-
+ GCACUCCAGCCUGGGCGACAGA 22
IntronlO- 22518
841
5535.1 3636
CFTR- IntronlO- + UGCACUCCAGCCUGGGCGACAGA 23
3637 22519
CFTR- IntronlO- + CUGCACUCCAGCCUGGGCGACAGA 24
3638 22520
CFTR- IntronlO- + GUGUUCUCACAUGGCAGA 18
3639 22521
CFTR- IntronlO- + UGUGUUCUCACAUGGCAGA 19
3640 22522
CFTR- IntronlO- + CUGUGUUCUCACAUGGCAGA 20
3641 22523
CFTR- IntronlO- + GCUGUGUUCUCACAUGGCAGA 21
3642 22524
CFTR- IntronlO- + UGCUGUGUUCUCACAUGGCAGA 22
3643 22525
CFTR- IntronlO- + CUGCUGUGUUCUCACAUGGCAGA 23
3644 22526
CFTR- IntronlO- + CCUGCUGUGUUCUCACAUGGCAGA 24
3645 22527
CFTR- IntronlO- + UGAAUGGCAGGGGAGAGA 18
3646 22528
CFTR- IntronlO- + AUGAAUGGCAGGGGAGAGA 19
3647 22529
CFTR- IntronlO- + UAUGAAUGGCAGGGGAGAGA 20
3648 22530
CFTR- IntronlO- + AUAUGAAUGGCAGGGGAGAGA 21
3649 22531
CFTR-
+ CAUAUGAAUGGCAGGGGAGAGA 22
IntronlO- 22532
842
5535.1 3650
CFTR- IntronlO- + ACAUAUGAAUGGCAGGGGAGAGA 23
3651 22533
CFTR- IntronlO- + AACAUAUGAAUGGCAGGGGAGAGA 24
3652 22534
CFTR- IntronlO- + AUGAGGGAAUGCAGGAGA 18
3653 22535
CFTR- IntronlO- + GAUGAGGGAAUGCAGGAGA 19
3654 22536
CFTR- IntronlO- + GGAUGAGGGAAUGCAGGAGA 20
3655 22537
CFTR- IntronlO- + UGGAUGAGGGAAUGCAGGAGA 21
3656 22538
CFTR- IntronlO- + UUGGAUGAGGGAAUGCAGGAGA 22
3657 22539
CFTR- IntronlO- + GUUGGAUGAGGGAAUGCAGGAGA 23
3658 22540
CFTR- IntronlO- + GGUUGGAUGAGGGAAUGCAGGAGA 24
3659 22541
CFTR- IntronlO- + GAUCACGAGGUCAGGAGA 18
3660 22542
CFTR- IntronlO- + GGAUCACGAGGUCAGGAGA 19
3661 22543
CFTR- IntronlO- + CGGAUCACGAGGUCAGGAGA 20
3662 22544
CFTR- IntronlO- + GCGGAUCACGAGGUCAGGAGA 21
3663 22545
CFTR-
+ GGCGGAUCACGAGGUCAGGAGA 22
IntronlO- 22546
843
5535.1 3664
CFTR- IntronlO- + GGGCGGAUCACGAGGUCAGGAGA 23
3665 22547
CFTR- IntronlO- + CGGGCGGAUCACGAGGUCAGGAGA 24
3666 22548
CFTR- IntronlO- + UAGGAAAACAACUGGAGA 18
3667 22549
CFTR- IntronlO- + GUAGGAAAACAACUGGAGA 19
3668 22550
CFTR- IntronlO- + UGUAGGAAAACAACUGGAGA 20
3669 22551
CFTR- IntronlO- + AUGUAGGAAAACAACUGGAGA 21
3670 22552
CFTR- IntronlO- + UAUGUAGGAAAACAACUGGAGA 22
3671 22553
CFTR- IntronlO- + GUAUGUAGGAAAACAACUGGAGA 23
3672 22554
CFTR- IntronlO- + CGUAUGUAGGAAAACAACUGGAGA 24
3673 22555
CFTR- IntronlO- + UAUGCAAUUUACUGGAGA 18
3674 22556
CFTR- IntronlO- + AUAUGCAAUUUACUGGAGA 19
3675 22557
CFTR- IntronlO- + AAUAUGCAAUUUACUGGAGA 20
3676 22558
CFTR- IntronlO- + CAAUAUGCAAUUUACUGGAGA 21
3677 22559
CFTR-
+ GCAAUAUGCAAUUUACUGGAGA 22
IntronlO- 22560
844
5535.1 3678
CFTR- IntronlO- + UGCAAUAUGCAAUUUACUGGAGA 23
3679 22561
CFTR- IntronlO- + CUGCAAUAUGCAAUUUACUGGAGA 24
3680 22562
CFTR- IntronlO- + GAACUAGAGUCACAUAGA 18
3681 22563
CFTR- IntronlO- + UGAACUAGAGUCACAUAGA 19
3682 22564
CFTR- IntronlO- + GUGAACUAGAGUCACAUAGA 20
3683 22565
CFTR- IntronlO- + AGUGAACUAGAGUCACAUAGA 21
3684 22566
CFTR- IntronlO- + UAGUGAACUAGAGUCACAUAGA 22
3685 22567
CFTR- IntronlO- + U U AG UG AACU AG AG U CACAU AG A 23
3686 22568
CFTR- IntronlO- + AUUAGUGAACUAGAGUCACAUAGA 24
3687 22569
CFTR- IntronlO- + AUUGAUUAUAUAUAUAGA 18
3688 22570
CFTR- IntronlO- + UAUUGAUUAUAUAUAUAGA 19
3689 22571
CFTR- IntronlO- + AUAUUGAUUAUAUAUAUAGA 20
3690 22572
CFTR- IntronlO- + UAUAUUGAUUAUAUAUAUAGA 21
3691 22573
CFTR-
+ GUAUAUUGAUUAUAUAUAUAGA 22
IntronlO- 22574
845
5535.1 3692
CFTR- IntronlO- + UGUAUAUUGAUUAUAUAUAUAGA 23
3693 22575
CFTR- IntronlO- + AUGUAUAUUGAUUAUAUAUAUAGA 24
3694 22576
CFTR- IntronlO- + AGGAUCACUUUAUAUAGA 18
3695 22577
CFTR- IntronlO- + UAGGAUCACUUUAUAUAGA 19
3696 22578
CFTR- IntronlO- + CUAGGAUCACUUUAUAUAGA 20
3697 22579
CFTR- IntronlO- + UCUAGGAUCACUUUAUAUAGA 21
3698 22580
CFTR- IntronlO- + UUCUAGGAUCACUUUAUAUAGA 22
3699 22581
CFTR- IntronlO- + AUUCUAGGAUCACUUUAUAUAGA 23
3700 22582
CFTR- IntronlO- + GAUUCUAGGAUCACUUUAUAUAGA 24
3701 22583
CFTR- IntronlO- + UGACUAAAACUGAGUAGA 18
3702 22584
CFTR- IntronlO- + CUGACUAAAACUGAGUAGA 19
3703 22585
CFTR-
+ ACUGACUAAAACUGAGUAGA 20
lntronlO-374 19260
CFTR- IntronlO- + UACUGACUAAAACUGAGUAGA 21
3704 22586
CFTR- IntronlO- + CUACUGACUAAAACUGAGUAGA 22
3705 22587
846
5535.1 CFTR- IntronlO- + ACUACUGACUAAAACUGAGUAGA 23
3706 22588
CFTR- IntronlO- + UACUACUGACUAAAACUGAGUAGA 24
3707 22589
CFTR- IntronlO- + GCACUCCAGCCUGGGCGA 18
3708 22590
CFTR- IntronlO- + UGCACUCCAGCCUGGGCGA 19
3709 22591
CFTR- IntronlO- + CUGCACUCCAGCCUGGGCGA 20
3710 22592
CFTR- IntronlO- + ACUGCACUCCAGCCUGGGCGA 21
3711 22593
CFTR- IntronlO- + CACUGCACUCCAGCCUGGGCGA 22
3712 22594
CFTR- IntronlO- + CCACUGCACUCCAGCCUGGGCGA 23
3713 22595
CFTR- IntronlO- + GCCACUGCACUCCAGCCUGGGCGA 24
3714 22596
CFTR- IntronlO- + UGACUUCAUAAUAAAGGA 18
3715 22597
CFTR- IntronlO- + GUGACUUCAUAAUAAAGGA 19
3716 22598
CFTR- IntronlO- + AGUGACUUCAUAAUAAAGGA 20
3717 22599
CFTR- IntronlO- + CAGUGACUUCAUAAUAAAGGA 21
3718 22600
CFTR- IntronlO- + ACAGUGACUUCAUAAUAAAGGA 22
3719 22601
847
5535.1 CFTR- IntronlO- + UACAGUGACUUCAUAAUAAAGGA 23
3720 22602
CFTR- IntronlO- + AUACAGUGACUUCAUAAUAAAGGA 24
3721 22603
CFTR- IntronlO- + AUGCAGACAACAGAAGGA 18
3722 22604
CFTR- IntronlO- + GAUGCAGACAACAGAAGGA 19
3723 22605
CFTR- IntronlO- + UGAUGCAGACAACAGAAGGA 20
3724 22606
CFTR- IntronlO- + GUG AUGCAGACAACAGAAGGA 21
3725 22607
CFTR- IntronlO- + UGUGAUGCAGACAACAGAAGGA 22
3726 22608
CFTR- IntronlO- + CUGUGAUGCAGACAACAGAAGGA 23
3727 22609
CFTR- IntronlO- + GCUGUGAUGCAGACAACAGAAGGA 24
3728 22610
CFTR- IntronlO- + UAAAACUGAGUAGAAGGA 18
3729 22611
CFTR- IntronlO- + CUAAAACUGAGUAGAAGGA 19
3730 22612
CFTR- IntronlO- + ACUAAAACUGAGUAGAAGGA 20
3731 22613
CFTR- IntronlO- + GACUAAAACUGAGUAGAAGGA 21
3732 22614
CFTR- IntronlO- + UGACUAAAACUGAGUAGAAGGA 22
3733 22615
848
5535.1 CFTR- IntronlO- + CUGACUAAAACUGAGUAGAAGGA 23
3734 22616
CFTR- IntronlO- + ACUGACUAAAACUGAGUAGAAGGA 24
3735 22617
CFTR- IntronlO- + UGUAGGAAAACAACUGGA 18
3736 22618
CFTR- IntronlO- + AUGUAGGAAAACAACUGGA 19
3737 22619
CFTR- IntronlO- + UAUGUAGGAAAACAACUGGA 20
3738 22620
CFTR- IntronlO- + GU AUGUAGGAAAACAACUGGA 21
3739 22621
CFTR- IntronlO- + CGUAUGUAGGAAAACAACUGGA 22
3740 22622
CFTR- IntronlO- + UCGUAUGUAGGAAAACAACUGGA 23
3741 22623
CFTR- IntronlO- + UUCGUAUGUAGGAAAACAACUGGA 24
3742 22624
CFTR- IntronlO- + AAUAUGCAAUUUACUGGA 18
3743 22625
CFTR- IntronlO- + CAAUAUGCAAUUUACUGGA 19
3744 22626
CFTR- IntronlO- + GCAAUAUGCAAUUUACUGGA 20
3745 22627
CFTR- IntronlO- + UGCAAUAUGCAAUUUACUGGA 21
3746 22628
CFTR- IntronlO- + CUGCAAUAUGCAAUUUACUGGA 22
3747 22629
849
5535.1 CFTR- IntronlO- + ACUGCAAUAUGCAAUUUACUGGA 23
3748 22630
CFTR- IntronlO- + UACUGCAAUAUGCAAUUUACUGGA 24
3749 22631
CFTR- IntronlO- + UUUCAUCUUACUUGAUGA 18
3750 22632
CFTR- IntronlO- + GUUUCAUCUUACUUGAUGA 19
3751 22633
CFTR- IntronlO- + AGUUUCAUCUUACUUGAUGA 20
3752 22634
CFTR- IntronlO- + CAGUUUCAUCUUACUUGAUGA 21
3753 22635
CFTR- IntronlO- + ACAGUUUCAUCUUACUUGAUGA 22
3754 22636
CFTR- IntronlO- + AACAGUUUCAUCUUACUUGAUGA 23
3755 22637
CFTR- IntronlO- + UAACAGUUUCAUCUUACUUGAUGA 24
3756 22638
CFTR- IntronlO- + U G ACACCAAAU U U AU UG A 18
3757 22639
CFTR- IntronlO- + CUGACACCAAAUUUAUUGA 19
3758 22640
CFTR- IntronlO- + CCUGACACCAAAUUUAUUGA 20
3759 22641
CFTR- IntronlO- + GCCUGACACCAAAUUUAUUGA 21
3760 22642
CFTR- IntronlO- + AGCCUGACACCAAAUUUAUUGA 22
3761 22643
850
5535.1 CFTR- IntronlO- + CAGCCUGACACCAAAUUUAUUGA 23
3762 22644
CFTR- IntronlO- + CCAGCCUGACACCAAAUUUAUUGA 24
3763 22645
CFTR- IntronlO- + CUAAUAGCCUAUUGUUGA 18
3764 22646
CFTR- IntronlO- + ACUAAUAGCCUAUUGUUGA 19
3765 22647
CFTR- IntronlO- + UACUAAUAGCCUAUUGUUGA 20
3766 22648
CFTR- IntronlO- + CUACUAAUAGCCUAUUGUUGA 21
3767 22649
CFTR- IntronlO- + ACUACUAAUAGCCUAUUGUUGA 22
3768 22650
CFTR- IntronlO- + AACUACUAAUAGCCUAUUGUUGA 23
3769 22651
CFTR- IntronlO- + UAACUACUAAUAGCCUAUUGUUGA 24
3770 22652
CFTR- IntronlO- + CCUUGGAAUAUAAAAAUA 18
3771 22653
CFTR- IntronlO- + UCCUUGGAAUAUAAAAAUA 19
3772 22654
CFTR- IntronlO- + GUCCUUGGAAUAUAAAAAUA 20
3773 22655
CFTR- IntronlO- + AGUCCUUGGAAUAUAAAAAUA 21
3774 22656
CFTR- IntronlO- + CAGUCCUUGGAAUAUAAAAAUA 22
3775 22657
851
5535.1 CFTR- IntronlO- + ACAGUCCUUGGAAUAUAAAAAUA 23
3776 22658
CFTR- IntronlO- + GACAGUCCUUGGAAUAUAAAAAUA 24
3777 22659
CFTR- IntronlO- + CUUUGUGUUAACAAAAUA 18
3778 22660
CFTR- IntronlO- + UCUUUGUGUUAACAAAAUA 19
3779 22661
CFTR- IntronlO- + UUCUUUGUGUUAACAAAAUA 20
3780 22662
CFTR- IntronlO- + GUUCUUUGUGUUAACAAAAUA 21
3781 22663
CFTR- IntronlO- + UGUUCUUUGUGUUAACAAAAUA 22
3782 22664
CFTR- IntronlO- + UUGUUCUUUGUGUUAACAAAAUA 23
3783 22665
CFTR- IntronlO- + GUUGUUCUUUGUGUUAACAAAAUA 24
3784 22666
CFTR- IntronlO- + GGAAGAAAAGUAUCAAUA 18
3785 22667
CFTR- IntronlO- + AGGAAGAAAAGUAUCAAUA 19
3786 22668
CFTR- IntronlO- + C AG G A AG A A A AG U A U C A A U A 20
3787 22669
CFTR- IntronlO- + U C AG G A AG A A A AG U A U C A A U A 21
3788 22670
CFTR- IntronlO- + A U C AG G A AG A A A AG U A U C A A U A 22
3789 22671
852
5535.1 CFTR- IntronlO- + AAUCAGGAAGAAAAGUAUCAAUA 23
3790 22672
CFTR- IntronlO- + UAAUCAGGAAGAAAAGUAUCAAUA 24
3791 22673
CFTR- IntronlO- + UCCUCUGUGCUUUGAAUA 18
3792 22674
CFTR- IntronlO- + GUCCUCUGUGCUUUGAAUA 19
3793 22675
CFTR-
+ AGUCCUCUGUGCUUUGAAUA 20
lntronlO-382 19268
CFTR- IntronlO- + AAGUCCUCUGUGCUUUGAAUA 21
3794 22676
CFTR- IntronlO- + CAAGUCCUCUGUGCUUUGAAUA 22
3795 22677
CFTR- IntronlO- + GCAAGUCCUCUGUGCUUUGAAUA 23
3796 22678
CFTR- IntronlO- + UGCAAGUCCUCUGUGCUUUGAAUA 24
3797 22679
CFTR- IntronlO- + UACAGUGACUUCAUAAUA 18
3798 22680
CFTR- IntronlO- + AUACAGUGACUUCAUAAUA 19
3799 22681
CFTR- IntronlO- + AAUACAGUGACUUCAUAAUA 20
3800 22682
CFTR- IntronlO- + CAAUACAGUGACUUCAUAAUA 21
3801 22683
CFTR- IntronlO- + ACAAUACAGUGACUUCAUAAUA 22
3802 22684
CFTR-
+ GACAAUACAGUGACUUCAUAAUA 23
IntronlO- 22685
853
5535.1 3803
CFTR- IntronlO- + AGACAAUACAGUGACUUCAUAAUA 24
3804 22686
CFTR- IntronlO- + CCUAGAUGAUUAUUAAUA 18
3805 22687
CFTR- IntronlO- + GCCUAGAUGAUUAUUAAUA 19
3806 22688
CFTR-
+ AGCCUAGAUGAUUAUUAAUA 20
lntronlO-384 19270
CFTR- IntronlO- + CAGCCUAGAUGAUUAUUAAUA 21
3807 22689
CFTR- IntronlO- + GCAGCCUAGAUGAUUAUUAAUA 22
3808 22690
CFTR- IntronlO- + UGCAGCCUAGAUGAUUAUUAAUA 23
3809 22691
CFTR- IntronlO- + UUGCAGCCUAGAUGAUUAUUAAUA 24
3810 22692
CFTR- IntronlO- + UAGUAUAAUUUUUUAAUA 18
3811 22693
CFTR- IntronlO- + AUAGUAUAAUUUUUUAAUA 19
3812 22694
CFTR- IntronlO- + UAUAGUAUAAUUUUUUAAUA 20
3813 22695
CFTR- IntronlO- + CUAUAGUAUAAUUUUUUAAUA 21
3814 22696
CFTR- IntronlO- + CCUAUAGUAUAAUUUUUUAAUA 22
3815 22697
CFTR- IntronlO- + UCCUAUAGUAUAAUUUUUUAAUA 23
3816 22698
854
5535.1 CFTR- IntronlO- + CUCCUAUAGUAUAAUUUUUUAAUA 24
3817 22699
CFTR- IntronlO- + UGAAACAAAUAAAACAUA 18
3818 22700
CFTR- IntronlO- + AUGAAACAAAUAAAACAUA 19
3819 22701
CFTR- IntronlO- + AAUGAAACAAAUAAAACAUA 20
3820 22702
CFTR- IntronlO- + AAAUGAAACAAAUAAAACAUA 21
3821 22703
CFTR- IntronlO- + GAAAUGAAACAAAUAAAACAUA 22
3822 22704
CFTR- IntronlO- + AGAAAUGAAACAAAUAAAACAUA 23
3823 22705
CFTR- IntronlO- + AAGAAAUGAAACAAAUAAAACAUA 24
3824 22706
CFTR- IntronlO- + CUAAAACUCAGUACCAUA 18
3825 22707
CFTR- IntronlO- + GCUAAAACUCAGUACCAUA 19
3826 22708
CFTR- IntronlO- + AGCUAAAACUCAGUACCAUA 20
3827 22709
CFTR- IntronlO- + AAGCUAAAACUCAGUACCAUA 21
3828 22710
CFTR- IntronlO- + UAAGCUAAAACUCAGUACCAUA 22
3829 22711
CFTR- IntronlO- + AUAAGCUAAAACUCAGUACCAUA 23
3830 22712
855
5535.1 CFTR- IntronlO- + AAUAAGCUAAAACUCAGUACCAUA 24
3831 22713
CFTR- IntronlO- + AAAAUAUAUAUAUGCAUA 18
3832 22714
CFTR- IntronlO- + AAAAAUAUAUAUAUGCAUA 19
3833 22715
CFTR- IntronlO- + UAAAAAUAUAUAUAUGCAUA 20
3834 22716
CFTR- IntronlO- + UUAAAAAUAUAUAUAUGCAUA 21
3835 22717
CFTR- IntronlO- + GU UAAAAAUAUAUAUAUGCAUA 22
3836 22718
CFTR- IntronlO- + GGUUAAAAAUAUAUAUAUGCAUA 23
3837 22719
CFTR- IntronlO- + AGGUUAAAAAUAUAUAUAUGCAUA 24
3838 22720
CFTR- IntronlO- + ACAUAGAGAAAACUCAUA 18
3839 22721
CFTR- IntronlO- + AACAUAGAGAAAACUCAUA 19
3840 22722
CFTR- IntronlO- + AAACAUAGAGAAAACUCAUA 20
1168 20053
CFTR- IntronlO- + AAAACAUAGAGAAAACUCAUA 21
3841 22723
CFTR- IntronlO- + UAAAACAUAGAGAAAACUCAUA 22
3842 22724
CFTR- IntronlO- + AUAAAACAUAGAGAAAACUCAUA 23
3843 22725
856
5535.1 CFTR- IntronlO- + AAUAAAACAUAGAGAAAACUCAUA 24
3844 22726
CFTR- IntronlO- + GGAAAGUUGUCCAAGAUA 18
3845 22727
CFTR- IntronlO- + UGGAAAGUUGUCCAAGAUA 19
3846 22728
CFTR- IntronlO- + AUGGAAAGUUGUCCAAGAUA 20
3847 22729
CFTR- IntronlO- + UAUGGAAAGUUGUCCAAGAUA 21
3848 22730
CFTR- IntronlO- + AUAUGGAAAGUUGUCCAAGAUA 22
3849 22731
CFTR- IntronlO- + AAUAUGGAAAGUUGUCCAAGAUA 23
3850 22732
CFTR- IntronlO- + GAAUAUGGAAAGUUGUCCAAGAUA 24
3851 22733
CFTR- IntronlO- + UGUUCUUAGGGUGGGAUA 18
3852 22734
CFTR- IntronlO- + UUGUUCUUAGGGUGGGAUA 19
3853 22735
CFTR-
+ GU UGUUCUUAGGGUGGGAUA 20
lntronlO-84 18970
CFTR- IntronlO- + AGUUGUUCUUAGGGUGGGAUA 21
3854 22736
CFTR- IntronlO- + AAGUUGUUCUUAGGGUGGGAUA 22
3855 22737
CFTR- IntronlO- + UAAGUUGUUCUUAGGGUGGGAUA 23
3856 22738
CFTR-
+ UUAAGUUGUUCUUAGGGUGGGAUA 24
IntronlO- 22739
857
5535.1 3857
CFTR- IntronlO- + AUAUUGAUUAUAUAUAUA 18
3858 22740
CFTR- IntronlO- + UAUAUUGAUUAUAUAUAUA 19
3859 22741
CFTR- IntronlO- + GUAUAUUGAUUAUAUAUAUA 20
3860 22742
CFTR- IntronlO- + UGUAUAUUGAUUAUAUAUAUA 21
3861 22743
CFTR- IntronlO- + AUGUAUAUUGAUUAUAUAUAUA 22
3862 22744
CFTR- IntronlO- + AAUGUAUAUUGAUUAUAUAUAUA 23
3863 22745
CFTR- IntronlO- + AAAUGUAUAUUGAUUAUAUAUAUA 24
3864 22746
CFTR- IntronlO- + GUAUAUUGAUUAUAUAUA 18
3865 22747
CFTR- IntronlO- + UGUAUAUUGAUUAUAUAUA 19
3866 22748
CFTR- IntronlO- + AUGUAUAUUGAUUAUAUAUA 20
3867 22749
CFTR- IntronlO- + AAUGUAUAUUGAUUAUAUAUA 21
3868 22750
CFTR- IntronlO- + AAAUGUAUAUUGAUUAUAUAUA 22
3869 22751
CFTR- IntronlO- + AAAAUGUAUAUUGAUUAUAUAUA 23
3870 22752
CFTR-
+ AAAAAUGUAUAUUGAUUAUAUAUA 24
IntronlO- 22753
858
5535.1 3871
CFTR- IntronlO- + CUAGGAUCACUUUAUAUA 18
3872 22754
CFTR- IntronlO- + UCUAGGAUCACUUUAUAUA 19
3873 22755
CFTR- IntronlO- + UUCUAGGAUCACUUUAUAUA 20
3874 22756
CFTR- IntronlO- + AUUCUAGGAUCACUUUAUAUA 21
3875 22757
CFTR- IntronlO- + GAUUCUAGGAUCACUUUAUAUA 22
3876 22758
CFTR- IntronlO- + UGAUUCUAGGAUCACUUUAUAUA 23
3877 22759
CFTR- IntronlO- + AUGAUUCUAGGAUCACUUUAUAUA 24
3878 22760
CFTR- IntronlO- + CCUGAAAGCAGUGUUAUA 18
3879 22761
CFTR- IntronlO- + UCCUGAAAGCAGUGUUAUA 19
3880 22762
CFTR- IntronlO- + CUCCUGAAAGCAGUGUUAUA 20
3881 22763
CFTR- IntronlO- + GCUCCUGAAAGCAGUGUUAUA 21
3882 22764
CFTR- IntronlO- + GGCUCCUGAAAGCAGUGUUAUA 22
3883 22765
CFTR- IntronlO- + UGGCUCCUGAAAGCAGUGUUAUA 23
3884 22766
CFTR-
+ UUGGCUCCUGAAAGCAGUGUUAUA 24
IntronlO- 22767
859
5535.1 3885
CFTR- IntronlO- + UUCUAGGAUCACUUUAUA 18
3886 22768
CFTR- IntronlO- + AUUCUAGGAUCACUUUAUA 19
3887 22769
CFTR- IntronlO- + GAUUCUAGGAUCACUUUAUA 20
3888 22770
CFTR- IntronlO- + UGAUUCUAGGAUCACUUUAUA 21
3889 22771
CFTR- IntronlO- + AUGAUUCUAGGAUCACUUUAUA 22
3890 22772
CFTR- IntronlO- + UAUGAUUCUAGGAUCACUUUAUA 23
3891 22773
CFTR- IntronlO- + UUAUGAUUCUAGGAUCACUUUAUA 24
3892 22774
CFTR- IntronlO- + GACAGAUGAGAGACAGUA 18
3893 22775
CFTR- IntronlO- + GGACAGAUGAGAGACAGUA 19
3894 22776
CFTR- IntronlO- + UGGACAGAUGAGAGACAGUA 20
3895 22777
CFTR- IntronlO- + AUGGACAGAUGAGAGACAGUA 21
3896 22778
CFTR- IntronlO- + AAUGGACAGAUGAGAGACAGUA 22
3897 22779
CFTR- IntronlO- + AAAUGGACAGAUGAGAGACAGUA 23
3898 22780
CFTR-
+ AAAAUGGACAGAUGAGAGACAGUA 24
IntronlO- 22781
860
5535.1 3899
CFTR- IntronlO- + UUUCUAGAAAACAAUGUA 18
3900 22782
CFTR- IntronlO- + UUUUCUAGAAAACAAUGUA 19
3901 22783
CFTR- IntronlO- + AUUUUCUAGAAAACAAUGUA 20
3902 22784
CFTR- IntronlO- + GAUUUUCUAGAAAACAAUGUA 21
3903 22785
CFTR- IntronlO- + AGAUUUUCUAGAAAACAAUGUA 22
3904 22786
CFTR- IntronlO- + CAG AU U U U CU AG AAAACAAUG U A 23
3905 22787
CFTR- IntronlO- + ACAG AU U U U CU AG AAAACAAUG U A 24
3906 22788
CFTR- IntronlO- + GUAUAAGUGUGGAGUGUA 18
3907 22789
CFTR- IntronlO- + GGUAUAAGUGUGGAGUGUA 19
3908 22790
CFTR- IntronlO- + GGGUAUAAGUGUGGAGUGUA 20
3909 22791
CFTR- IntronlO- + GGGGUAUAAGUGUGGAGUGUA 21
3910 22792
CFTR- IntronlO- + UGGGGUAUAAGUGUGGAGUGUA 22
3911 22793
CFTR- IntronlO- + AUGGGGUAUAAGUGUGGAGUGUA 23
3912 22794
CFTR-
+ AAUGGGGUAUAAGUGUGGAGUGUA 24
IntronlO- 22795
861
5535.1 3913
CFTR- IntronlO- + UUCUUGAAG C A A A A A U U A 18
3914 22796
CFTR- IntronlO- + AUUCUUGAAGCAAAAAUUA 19
3915 22797
CFTR- IntronlO- + UAUUCUUGAAGCAAAAAUUA 20
3916 22798
CFTR- IntronlO- + AUAUUCUUGAAGCAAAAAUUA 21
3917 22799
CFTR- IntronlO- + AAU AU U CU UG AAGCAAAAAU U A 22
3918 22800
CFTR- IntronlO- + CAAU AU U CU UG AAG CAAAAAU U A 23
3919 22801
CFTR- IntronlO- + GCAAUAUUCUUGAAGCAAAAAUUA 24
3920 22802
CFTR- IntronlO- + CUGAAU AACACGCCAU U A 18
3921 22803
CFTR- IntronlO- + GCUGAAUAACACGCCAUUA 19
3922 22804
CFTR- IntronlO- + GGCUGAAUAACACGCCAUUA 20
3923 22805
CFTR- IntronlO- + UGGCUGAAUAACACGCCAUUA 21
3924 22806
CFTR- IntronlO- + UUGGCUGAAUAACACGCCAUUA 22
3925 22807
CFTR- IntronlO- + AUUGGCUGAAUAACACGCCAUUA 23
3926 22808
CFTR-
+ UAUUGGCUGAAUAACACGCCAUUA 24
IntronlO- 22809
862
5535.1 3927
CFTR- IntronlO- + UUAUCAGAGCUCAUAUUA 18
3928 22810
CFTR- IntronlO- + UUUAUCAGAGCUCAUAUUA 19
3929 22811
CFTR- IntronlO- + UUUUAUCAGAGCUCAUAUUA 20
3930 22812
CFTR- IntronlO- + AUUUUAUCAGAGCUCAUAUUA 21
3931 22813
CFTR- IntronlO- + GAUUUUAUCAGAGCUCAUAUUA 22
3932 22814
CFTR- IntronlO- + UGAUUUUAUCAGAGCUCAUAUUA 23
3933 22815
CFTR- IntronlO- + CUGAUUUUAUCAGAGCUCAUAUUA 24
3934 22816
CFTR- IntronlO- + CAAAUGCUUGACCACUUA 18
3935 22817
CFTR- IntronlO- + ACAAAUGCUUGACCACUUA 19
3936 22818
CFTR- IntronlO- + CACAAAUGCUUGACCACUUA 20
3937 22819
CFTR- IntronlO- + ACA CAAAUGCUUGACCACUUA 21
3938 22820
CFTR- IntronlO- + UACACAAAUGCUUGACCACUUA 22
3939 22821
CFTR- IntronlO- + GUACACAAAUGCUUGACCACUUA 23
3940 22822
CFTR-
+ AGUACACAAAUGCUUGACCACUUA 24
IntronlO- 22823
863
5535.1 3941
CFTR- IntronlO- + AU U AAU AACAAAAU CU U A 18
3942 22824
CFTR- IntronlO- + U AU U AAU AACAAAAU CU U A 19
3943 22825
CFTR- IntronlO- + AUAUUAAUAACAAAAUCUUA 20
3944 22826
CFTR- IntronlO- + AAU AU U AAU AACAAAAU CU U A 21
3945 22827
CFTR- IntronlO- + UAAUAUUAAUAACAAAAUCUUA 22
3946 22828
CFTR- IntronlO- + GUAAUAUUAAUAACAAAAUCUUA 23
3947 22829
CFTR- IntronlO- + AGUAAUAUUAAUAACAAAAUCUUA 24
3948 22830
CFTR- IntronlO- + ACAUAUUUGGGUAAGUUA 18
3949 22831
CFTR- IntronlO- + AACAUAUUUGGGUAAGUUA 19
3950 22832
CFTR- IntronlO- + AAACAUAUUUGGGUAAGUUA 20
3951 22833
CFTR- IntronlO- + CAAACAUAUUUGGGUAAGUUA 21
3952 22834
CFTR- IntronlO- + GCAAACAUAUUUGGGUAAGUUA 22
3953 22835
CFTR- IntronlO- + UGCAAACAUAUUUGGGUAAGUUA 23
3954 22836
CFTR-
+ CUGCAAACAUAUUUGGGUAAGUUA 24
IntronlO- 22837
864
5535.1 3955
CFTR- IntronlO- + ACUGCAAUAUGCAAUUUA 18
3956 22838
CFTR- IntronlO- + UACUGCAAUAUGCAAUUUA 19
3957 22839
CFTR- IntronlO- + UUACUGCAAUAUGCAAUUUA 20
3958 22840
CFTR- IntronlO- + UUUACUGCAAUAUGCAAUUUA 21
3959 22841
CFTR- IntronlO- + UUUUACUGCAAUAUGCAAUUUA 22
3960 22842
CFTR- IntronlO- + UUUUUACUGCAAUAUGCAAUUUA 23
3961 22843
CFTR- IntronlO- + CUUUUUACUGCAAUAUGCAAUUUA 24
3962 22844
CFTR- IntronlO- + CCUAUUAUUCAACAUUUA 18
3963 22845
CFTR- IntronlO- + CCCUAUUAUUCAACAUUUA 19
3964 22846
CFTR-
+ CCCCUAUUAUUCAACAUUUA 20
lntronlO-398 19284
CFTR- IntronlO- + ACCCCUAUUAUUCAACAUUUA 21
3965 22847
CFTR- IntronlO- + AACCCCUAUUAUUCAACAUUUA 22
3966 22848
CFTR- IntronlO- + AAACCCCUAUUAUUCAACAUUUA 23
3967 22849
CFTR- IntronlO- + CAAACCCCU AU U AU U CAACAU U U A 24
3968 22850
865
5535.1 CFTR- IntronlO- + U A A A A AG C A AG C A A A A AC 18
3969 22851
CFTR- IntronlO- + AUAAAAAG CAAG CAAAAAC 19
3970 22852
CFTR- IntronlO- + U A U A A A A AG C A AG C A A A A AC 20
3971 22853
CFTR- IntronlO- + GUAUAAAAAGCAAGCAAAAAC 21
3972 22854
CFTR- IntronlO- + U G U A U A A A A AG CAAG CAAAAAC 22
3973 22855
CFTR- IntronlO- + C U G U A U A A A A AG CAAG CAAAAAC 23
3974 22856
CFTR- IntronlO- + UCUGUAUAAAAAGCAAGCAAAAAC 24
3975 22857
CFTR- IntronlO- + AACAUCUAACUCAAAAAC 18
3976 22858
CFTR- IntronlO- + AAACAUCUAACUCAAAAAC 19
3977 22859
CFTR- IntronlO- + CAAACAUCUAACUCAAAAAC 20
3978 22860
CFTR- IntronlO- + UCAAACAUCUAACUCAAAAAC 21
3979 22861
CFTR- IntronlO- + GUCAAACAUCUAACUCAAAAAC 22
3980 22862
CFTR- IntronlO- + CG U CA AACAU C U AAC U CAAAAAC 23
3981 22863
CFTR- IntronlO- + GCGUCAAACAUCUAACUCAAAAAC 24
3982 22864
866
5535.1 CFTR- IntronlO- + CGUAUGUAGGAAAACAAC 18
3983 22865
CFTR- IntronlO- + UCGUAUGUAGGAAAACAAC 19
3984 22866
CFTR-
+ UUCGUAUGUAGGAAAACAAC 20
lntronlO-402 19288
CFTR- IntronlO- + UUUCGUAUGUAGGAAAACAAC 21
3985 22867
CFTR- IntronlO- + GUUUCGUAUGUAGGAAAACAAC 22
3986 22868
CFTR- IntronlO- + UGUUUCGUAUGUAGGAAAACAAC 23
3987 22869
CFTR- IntronlO- + CUGUUUCGUAUGUAGGAAAACAAC 24
3988 22870
CFTR- IntronlO- + GCUUACCGUAAUAGCAAC 18
3989 22871
CFTR- IntronlO- + AGCUUACCGUAAUAGCAAC 19
3990 22872
CFTR-
+ GAGCUUACCGUAAUAGCAAC 20
lntronlO-660 19546
CFTR- IntronlO- + UGAGCUUACCGUAAUAGCAAC 21
3991 22873
CFTR- IntronlO- + UUGAGCUUACCGUAAUAGCAAC 22
3992 22874
CFTR- IntronlO- + CUUGAGCUUACCGUAAUAGCAAC 23
3993 22875
CFTR- IntronlO- + GCUUGAGCUUACCGUAAUAGCAAC 24
3994 22876
CFTR- IntronlO- + CAUUGACCCUUUAUCAAC 18
3995 22877
867
5535.1 CFTR- IntronlO- + CCAUUGACCCUUUAUCAAC 19
3996 22878
CFTR- IntronlO- + ACCAUUGACCCUUUAUCAAC 20
3997 22879
CFTR- IntronlO- + UACCAUUGACCCUUUAUCAAC 21
3998 22880
CFTR- IntronlO- + AUACCAUUGACCCUUUAUCAAC 22
3999 22881
CFTR- IntronlO- + UAUACCAUUGACCCUUUAUCAAC 23
4000 22882
CFTR- IntronlO- + AUAUACCAUUGACCCUUUAUCAAC 24
4001 22883
CFTR- IntronlO- + UGACAAUCAAAUGGGAAC 18
4002 22884
CFTR- IntronlO- + AUGACAAUCAAAUGGGAAC 19
4003 22885
CFTR- IntronlO- + AAUGACAAUCAAAUGGGAAC 20
4004 22886
CFTR- IntronlO- + AAAUGACAAUCAAAUGGGAAC 21
4005 22887
CFTR- IntronlO- + AAAAUGACAAUCAAAUGGGAAC 22
4006 22888
CFTR- IntronlO- + UAAAAUGACAAUCAAAUGGGAAC 23
4007 22889
CFTR- IntronlO- + CUAAAAUGACAAUCAAAUGGGAAC 24
4008 22890
CFTR- IntronlO- + CAGGAGAAUGGCGUGAAC 18
4009 22891
868
5535.1 CFTR- IntronlO- + GCAGGAGAAUGGCGUGAAC 19
4010 22892
CFTR- IntronlO- + GGCAGGAGAAUGGCGUGAAC 20
4011 22893
CFTR- IntronlO- + AGGCAGGAGAAUGGCGUGAAC 21
4012 22894
CFTR- IntronlO- + GAGGCAGGAGAAUGGCGUGAAC 22
4013 22895
CFTR- IntronlO- + UGAGGCAGGAGAAUGGCGUGAAC 23
4014 22896
CFTR- IntronlO- + CUGAGGCAGGAGAAUGGCGUGAAC 24
4015 22897
CFTR- IntronlO- + GAACCUAUAAGGAAUAAC 18
4016 22898
CFTR- IntronlO- + AGAACCUAUAAGGAAUAAC 19
4017 22899
CFTR-
+ CAGAACCUAUAAGGAAUAAC 20
lntronlO-403 19289
CFTR- IntronlO- + ACAGAACCUAUAAGGAAUAAC 21
4018 22900
CFTR- IntronlO- + UACAGAACCUAUAAGGAAUAAC 22
4019 22901
CFTR- IntronlO- + U UACAGAACCUAUAAGGAAUAAC 23
4020 22902
CFTR- IntronlO- + AUUACAGAACCUAUAAGGAAUAAC 24
4021 22903
CFTR- IntronlO- + AAAAUAUGCGAGAACCAC 18
4022 22904
CFTR-
+ AAAAAUAUGCGAGAACCAC 19
IntronlO- 22905
869
5535.1 4023
CFTR- IntronlO- + GAAAAAUAUGCGAGAACCAC 20
4024 22906
CFTR- IntronlO- + UGAAAAAUAUGCGAGAACCAC 21
4025 22907
CFTR- IntronlO- + AUGAAAAAUAUGCGAGAACCAC 22
4026 22908
CFTR- IntronlO- + GAUGAAAAAUAUGCGAGAACCAC 23
4027 22909
CFTR- IntronlO- + UGAUGAAAAAUAUGCGAGAACCAC 24
4028 22910
CFTR- IntronlO- + AGUAUUAAGUAUAGCCAC 18
4029 22911
CFTR- IntronlO- + UAGUAUUAAGUAUAGCCAC 19
4030 22912
CFTR-
+ UUAGUAUUAAGUAUAGCCAC 20
lntronlO-408 19294
CFTR- IntronlO- + AUUAGUAUUAAGUAUAGCCAC 21
4031 22913
CFTR- IntronlO- + UAUUAGUAUUAAGUAUAGCCAC 22
4032 22914
CFTR- IntronlO- + UUAUUAGUAUUAAGUAUAGCCAC 23
4033 22915
CFTR- IntronlO- + GUUAUUAGUAUUAAGUAUAGCCAC 24
4034 22916
CFTR- IntronlO- + UUUAAUAAAUAAUAUCAC 18
4035 22917
CFTR- IntronlO- + UUUUAAUAAAUAAUAUCAC 19
4036 22918
870
5535.1 CFTR- IntronlO- + AU U U U AAU AAAU AAU AU CAC 20
4037 22919
CFTR- IntronlO- + AAU U U U AAU AAAU AAU AU CAC 21
4038 22920
CFTR- IntronlO- + AAAU U U U AAU AAAU AAU AU CAC 22
4039 22921
CFTR- IntronlO- + U AAAU U U U AAU AAAU AAU AU CAC 23
4040 22922
CFTR- IntronlO- + U U AAAU U U U AAU AAAU AAU AU CAC 24
4041 22923
CFTR- IntronlO- + GGAGAGAGAACUGCUCAC 18
4042 22924
CFTR- IntronlO- + UGGAGAGAGAACUGCUCAC 19
4043 22925
CFTR- IntronlO- + CUGGAGAGAGAACUGCUCAC 20
4044 22926
CFTR- IntronlO- + ACUGGAGAGAGAACUGCUCAC 21
4045 22927
CFTR- IntronlO- + UACUGGAGAGAGAACUGCUCAC 22
4046 22928
CFTR- IntronlO- + UUACUGGAGAGAGAACUGCUCAC 23
4047 22929
CFTR- IntronlO- + UUUACUGGAGAGAGAACUGCUCAC 24
4048 22930
CFTR- IntronlO- + AAGACAUUUAAUGUAGAC 18
4049 22931
CFTR- IntronlO- + CAAG ACAU U U AAUG U AG AC 19
4050 22932
871
5535.1 CFTR- IntronlO- + GCAAGACAUUUAAUGUAGAC 20
4051 22933
CFTR- IntronlO- + CGCAAGACAUUUAAUGUAGAC 21
4052 22934
CFTR- IntronlO- + GCGCAAGACAUUUAAUGUAGAC 22
4053 22935
CFTR- IntronlO- + AGCGCAAGACAUUUAAUGUAGAC 23
4054 22936
CFTR- IntronlO- + AAGCGCAAGACAUUUAAUGUAGAC 24
4055 22937
CFTR- IntronlO- + UUUAGCCCAUUCUAAUAC 18
4056 22938
CFTR- IntronlO- + CUUUAGCCCAUUCUAAUAC 19
4057 22939
CFTR- IntronlO- + CCUUUAGCCCAUUCUAAUAC 20
4058 22940
CFTR- IntronlO- + CCCUUUAGCCCAUUCUAAUAC 21
4059 22941
CFTR- IntronlO- + GCCCUUUAGCCCAUUCUAAUAC 22
4060 22942
CFTR- IntronlO- + UGCCCUUUAGCCCAUUCUAAUAC 23
4061 22943
CFTR- IntronlO- + UUGCCCUUUAGCCCAUUCUAAUAC 24
4062 22944
CFTR- IntronlO- + UAUUUGUGGAGGACAUAC 18
4063 22945
CFTR- IntronlO- + AUAUUUGUGGAGGACAUAC 19
4064 22946
872
5535.1 CFTR- IntronlO- + AAUAUUUGUGGAGGACAUAC 20
4065 22947
CFTR- IntronlO- + AAAUAUUUGUGGAGGACAUAC 21
4066 22948
CFTR- IntronlO- + AAAAUAUUUGUGGAGGACAUAC 22
4067 22949
CFTR- IntronlO- + AAAAAUAUUUGUGGAGGACAUAC 23
4068 22950
CFTR- IntronlO- + AAAAAAUAUUUGUGGAGGACAUAC 24
4069 22951
CFTR- IntronlO- + GCCUGUAGUCCCAGCUAC 18
4070 22952
CFTR- IntronlO- + CGCCUGUAGUCCCAGCUAC 19
4071 22953
CFTR- IntronlO- + GCGCCUGUAGUCCCAGCUAC 20
4072 22954
CFTR- IntronlO- + GGCGCCUGUAGUCCCAGCUAC 21
4073 22955
CFTR- IntronlO- + GGGCGCCUGUAGUCCCAGCUAC 22
4074 22956
CFTR- IntronlO- + CGGGCGCCUGUAGUCCCAGCUAC 23
4075 22957
CFTR- IntronlO- + GCGGGCGCCUGUAGUCCCAGCUAC 24
4076 22958
CFTR- IntronlO- + UGCCUGUAGUCCCAGCUAC 19
4077 22959
CFTR- IntronlO- + GUGCCUGUAGUCCCAGCUAC 20
4078 22960
873
5535.1 CFTR- IntronlO- + CGUGCCUGUAGUCCCAGCUAC 21
4079 22961
CFTR- IntronlO- + GCGUGCCUGUAGUCCCAGCUAC 22
4080 22962
CFTR- IntronlO- + UGCGUGCCUGUAGUCCCAGCUAC 23
4081 22963
CFTR- IntronlO- + GUGCGUGCCUGUAGUCCCAGCUAC 24
4082 22964
CFTR- IntronlO- + ACUUGCUUCACCUGCUAC 18
4083 22965
CFTR- IntronlO- + CACUUGCUUCACCUGCUAC 19
4084 22966
CFTR- IntronlO- + GCACUUGCUUCACCUGCUAC 20
4085 22967
CFTR- IntronlO- + UGCACUUGCUUCACCUGCUAC 21
4086 22968
CFTR- IntronlO- + UUGCACUUGCUUCACCUGCUAC 22
4087 22969
CFTR- IntronlO- + UUUGCACUUGCUUCACCUGCUAC 23
4088 22970
CFTR- IntronlO- + CUUUGCACUUGCUUCACCUGCUAC 24
4089 22971
CFTR- IntronlO- + AAAUCUUAUAGAGAUUAC 18
4090 22972
CFTR- IntronlO- + AAAAUCUUAUAGAGAUUAC 19
4091 22973
CFTR- IntronlO- + CAAAAU CU U AU AG AG AU U AC 20
4092 22974
874
5535.1 CFTR- IntronlO- + ACAAAAUCUUAUAGAGAUUAC 21
4093 22975
CFTR- IntronlO- + AACAAAAU CU U AU AG AG AU U AC 22
4094 22976
CFTR- IntronlO- + UAACAAAAUCUUAUAGAGAUUAC 23
4095 22977
CFTR- IntronlO- + AUAACAAAAUCUUAUAGAGAUUAC 24
4096 22978
CFTR- IntronlO- + UUUUACAAUUCUUAUUAC 18
4097 22979
CFTR- IntronlO- + AUUUUACAAUUCUUAUUAC 19
4098 22980
CFTR- IntronlO- + AAUUUUACAAUUCUUAUUAC 20
4099 22981
CFTR- IntronlO- + AAAUUUUACAAUUCUUAUUAC 21
4100 22982
CFTR- IntronlO- + UAAAUUUUACAAUUCUUAUUAC 22
4101 22983
CFTR- IntronlO- + GUAAAUUUUACAAUUCUUAUUAC 23
4102 22984
CFTR- IntronlO- + AG U AAAU U U U ACAAU UCUUAUUAC 24
4103 22985
CFTR- IntronlO- + CUGCAAUAUGCAAUUUAC 18
4104 22986
CFTR- IntronlO- + ACUGCAAUAUGCAAUUUAC 19
4105 22987
CFTR- IntronlO- + UACUGCAAUAUGCAAUUUAC 20
1190 20075
875
5535.1 CFTR- IntronlO- + UUACUGCAAUAUGCAAUUUAC 21
4106 22988
CFTR- IntronlO- + UUUACUGCAAUAUGCAAUUUAC 22
4107 22989
CFTR- IntronlO- + UUUUACUGCAAUAUGCAAUUUAC 23
4108 22990
CFTR- IntronlO- + UUUUUACUGCAAUAUGCAAUUUAC 24
4109 22991
CFTR- IntronlO- + U U UG U ACAAAAU U AAACC 18
4110 22992
CFTR- IntronlO- + CU U UG U ACAAAAU U AAACC 19
4111 22993
CFTR- IntronlO- + CCU UUGU ACAAAAU U AAACC 20
4112 22994
CFTR- IntronlO- + UCCUUUGUACAAAAUUAAACC 21
4113 22995
CFTR- IntronlO- + UUCCUUUGUACAAAAUUAAACC 22
4114 22996
CFTR- IntronlO- + AUUCCUUUGUACAAAAUUAAACC 23
4115 22997
CFTR- IntronlO- + AAU U CCU U UG U ACAAAAU U AAACC 24
4116 22998
CFTR- IntronlO- + AGGAGAAUGGCGUGAACC 18
4117 22999
CFTR- IntronlO- + CAGGAGAAUGGCGUGAACC 19
4118 23000
CFTR-
+ GCAGGAGAAUGGCGUGAACC 20
lntronlO-661 19547
CFTR-
+ GGCAGGAGAAUGGCGUGAACC 21
IntronlO- 23001
876
5535.1 4119
CFTR- IntronlO- + AGGCAGGAGAAUGGCGUGAACC 22
4120 23002
CFTR- IntronlO- + GAGGCAGGAGAAUGGCGUGAACC 23
4121 23003
CFTR- IntronlO- + UGAGGCAGGAGAAUGGCGUGAACC 24
4122 23004
CFTR- IntronlO- + GGUCUUGAUCUCCUAACC 18
4123 23005
CFTR- IntronlO- + UGGUCUUGAUCUCCUAACC 19
4124 23006
CFTR- IntronlO- + AUGGUCUUGAUCUCCUAACC 20
4125 23007
CFTR- IntronlO- + GAUGGUCUUGAUCUCCUAACC 21
4126 23008
CFTR- IntronlO- + GGAUGGUCUUGAUCUCCUAACC 22
4127 23009
CFTR- IntronlO- + AGGAUGGUCUUGAUCUCCUAACC 23
4128 23010
CFTR- IntronlO- + CAGGAUGGUCUUGAUCUCCUAACC 24
4129 23011
CFTR- IntronlO- + CCCUGCAAUACCAUCACC 18
4130 23012
CFTR- IntronlO- + ACCCUGCAAUACCAUCACC 19
4131 23013
CFTR- IntronlO- + CACCCUGCAAUACCAUCACC 20
4132 23014
CFTR-
+ CCACCCUGCAAUACCAUCACC 21
IntronlO- 23015
877
5535.1 4133
CFTR- IntronlO- + CCCACCCUGCAAUACCAUCACC 22
4134 23016
CFTR- IntronlO- + CCCCACCCUGCAAUACCAUCACC 23
4135 23017
CFTR- IntronlO- + GCCCCACCCUGCAAUACCAUCACC 24
4136 23018
CFTR- IntronlO- + GUGGCCUCUAAUCUCACC 18
4137 23019
CFTR- IntronlO- + AGUGGCCUCUAAUCUCACC 19
4138 23020
CFTR- IntronlO- + CAGUGGCCUCUAAUCUCACC 20
4139 23021
CFTR- IntronlO- + CCAGUGGCCUCUAAUCUCACC 21
4140 23022
CFTR- IntronlO- + UCCAGUGGCCUCUAAUCUCACC 22
4141 23023
CFTR- IntronlO- + CUCCAGUGGCCUCUAAUCUCACC 23
4142 23024
CFTR- IntronlO- + UCUCCAGUGGCCUCUAAUCUCACC 24
4143 23025
CFTR- IntronlO- + CUGCUAUAACAAAAUACC 18
4144 23026
CFTR- IntronlO- + GCUGCUAUAACAAAAUACC 19
4145 23027
CFTR- IntronlO- + GGCUGCUAUAACAAAAUACC 20
4146 23028
CFTR-
+ AGGCUGCUAUAACAAAAUACC 21
IntronlO- 23029
878
5535.1 4147
CFTR- IntronlO- + CAGGCUGCUAUAACAAAAUACC 22
4148 23030
CFTR- IntronlO- + UCAGGCUGCUAUAACAAAAUACC 23
4149 23031
CFTR- IntronlO- + UUCAGGCUGCUAUAACAAAAUACC 24
4150 23032
CFTR- IntronlO- + UACAGCUAAAGUAUUACC 18
4151 23033
CFTR- IntronlO- + AUACAGCUAAAGUAUUACC 19
4152 23034
CFTR- IntronlO- + UAUACAGCUAAAGUAUUACC 20
4153 23035
CFTR- IntronlO- + AUAUACAGCUAAAGUAUUACC 21
4154 23036
CFTR- IntronlO- + AAUAUACAGCUAAAGUAUUACC 22
4155 23037
CFTR- IntronlO- + UAAUAUACAGCUAAAGUAUUACC 23
4156 23038
CFTR- IntronlO- + AUAAUAUACAGCUAAAGUAUUACC 24
4157 23039
CFTR- IntronlO- + GGAGAAUGGCGUGAACCC 18
4158 23040
CFTR- IntronlO- + AGGAGAAUGGCGUGAACCC 19
4159 23041
CFTR- IntronlO- + CAGGAGAAUGGCGUGAACCC 20
1191 20076
CFTR-
+ GCAGGAGAAUGGCGUGAACCC 21
IntronlO- 23042
879
5535.1 4160
CFTR- IntronlO- + GGCAGGAGAAUGGCGUGAACCC 22
4161 23043
CFTR- IntronlO- + AGGCAGGAGAAUGGCGUGAACCC 23
4162 23044
CFTR- IntronlO- + GAGGCAGGAGAAUGGCGUGAACCC 24
4163 23045
CFTR- IntronlO- + GGAGAAUUGCUUGAGCCC 18
4164 23046
CFTR- IntronlO- + AGGAGAAUUGCUUGAGCCC 19
4165 23047
CFTR- IntronlO- + CAGGAGAAUUGCUUGAGCCC 20
1195 20080
CFTR- IntronlO- + GCAGGAGAAUUGCUUGAGCCC 21
4166 23048
CFTR- IntronlO- + GGCAGGAGAAUUGCUUGAGCCC 22
4167 23049
CFTR- IntronlO- + AGGCAGGAGAAUUGCUUGAGCCC 23
4168 23050
CFTR- IntronlO- + GAGGCAGGAGAAUUGCUUGAGCCC 24
4169 23051
CFTR- IntronlO- + AAGUGUUUAAAUAUUCCC 18
4170 23052
CFTR- IntronlO- + GAAGUGUUUAAAUAUUCCC 19
4171 23053
CFTR- IntronlO- + AGAAGUGUUUAAAUAUUCCC 20
4172 23054
CFTR-
+ CAGAAGUGUUUAAAUAUUCCC 21
IntronlO- 23055
880
5535.1 4173
CFTR- IntronlO- + UCAGAAGUGUUUAAAUAUUCCC 22
4174 23056
CFTR- IntronlO- + CUCAGAAGUGUUUAAAUAUUCCC 23
4175 23057
CFTR- IntronlO- + UCUCAGAAGUGUUUAAAUAUUCCC 24
4176 23058
CFTR- IntronlO- + GGAAAGGUCAAUUGAGCC 18
4177 23059
CFTR- IntronlO- + CGGAAAGGUCAAUUGAGCC 19
4178 23060
CFTR- IntronlO- + GCGGAAAGGUCAAUUGAGCC 20
4179 23061
CFTR- IntronlO- + AGCGGAAAGGUCAAUUGAGCC 21
4180 23062
CFTR- IntronlO- + AAGCGGAAAGGUCAAUUGAGCC 22
4181 23063
CFTR- IntronlO- + GAAGCGGAAAGGUCAAUUGAGCC 23
4182 23064
CFTR- IntronlO- + UGAAGCGGAAAGGUCAAUUGAGCC 24
4183 23065
CFTR- IntronlO- + AGGAGAAUUGCUUGAGCC 18
4184 23066
CFTR- IntronlO- + CAGGAGAAUUGCUUGAGCC 19
4185 23067
CFTR-
+ GCAGGAGAAUUGCUUGAGCC 20
lntronlO-665 19551
CFTR- IntronlO- + GGCAGGAGAAUUGCUUGAGCC 21
4186 23068
881
5535.1 CFTR- IntronlO- + AGGCAGGAGAAUUGCUUGAGCC 22
4187 23069
CFTR- IntronlO- + GAGGCAGGAGAAUUGCUUGAGCC 23
4188 23070
CFTR- IntronlO- + UGAGGCAGGAGAAUUGCUUGAGCC 24
4189 23071
CFTR- IntronlO- + GGCACUUGUUGACAGUCC 18
4190 23072
CFTR- IntronlO- + AGGCACUUGUUGACAGUCC 19
4191 23073
CFTR- IntronlO- + UAGGCACUUGUUGACAGUCC 20
4192 23074
CFTR- IntronlO- + CUAGGCACUUGUUGACAGUCC 21
4193 23075
CFTR- IntronlO- + GCUAGGCACUUGUUGACAGUCC 22
4194 23076
CFTR- IntronlO- + UGCUAGGCACUUGUUGACAGUCC 23
4195 23077
CFTR- IntronlO- + GUGCUAGGCACUUGUUGACAGUCC 24
4196 23078
CFTR- IntronlO- + CUACCAGCCCCCUCUUCC 18
4197 23079
CFTR- IntronlO- + ACUACCAGCCCCCUCUUCC 19
4198 23080
CFTR- IntronlO- + CACUACCAGCCCCCUCUUCC 20
4199 23081
CFTR- IntronlO- + ACACUACCAGCCCCCUCUUCC 21
4200 23082
882
5535.1 CFTR- IntronlO- + CACACUACCAGCCCCCUCUUCC 22
4201 23083
CFTR- IntronlO- + UCACACUACCAGCCCCCUCUUCC 23
4202 23084
CFTR- IntronlO- + UUCACACUACCAGCCCCCUCUUCC 24
4203 23085
CFTR- IntronlO- + CAAGAUAGUGGG A A A AG C 18
4204 23086
CFTR- IntronlO- + CCAAGAUAGUGGG A A A AG C 19
4205 23087
CFTR- IntronlO- + UCCAAGAUAGUGGGAAAAGC 20
4206 23088
CFTR- IntronlO- + GUCCAAGAUAGUGGGAAAAGC 21
4207 23089
CFTR- IntronlO- + UGUCCAAGAUAGUGGGAAAAGC 22
4208 23090
CFTR- IntronlO- + UUGUCCAAGAUAGUGGGAAAAGC 23
4209 23091
CFTR- IntronlO- + GUUGUCCAAGAUAGUGGGAAAAGC 24
4210 23092
CFTR- IntronlO- + UUACUCAGUCCAGAAAGC 18
4211 23093
CFTR- IntronlO- + G U U ACU CAG U CCAGAAAG C 19
4212 23094
CFTR- IntronlO- + AGUUACUCAGUCCAGAAAGC 20
4213 23095
CFTR- IntronlO- + CAGUUACUCAGUCCAG A A AG C 21
4214 23096
883
5535.1 CFTR- IntronlO- + CCAGUUACUCAGUCCAGAAAGC 22
4215 23097
CFTR- IntronlO- + U CCAG U U ACU CAG U CCAG AAAG C 23
4216 23098
CFTR- IntronlO- + U U CCAG U U ACU CAG U CCAG AAAGC 24
4217 23099
CFTR- IntronlO- + CCGCCACUGCACUCCAGC 18
4218 23100
CFTR- IntronlO- + CCCGCCACUGCACUCCAGC 19
4219 23101
CFTR- IntronlO- + UCCCGCCACUGCACUCCAGC 20
4220 23102
CFTR- IntronlO- + AUCCCGCCACUGCACUCCAGC 21
4221 23103
CFTR- IntronlO- + GAUCCCGCCACUGCACUCCAGC 22
4222 23104
CFTR- IntronlO- + AGAUCCCGCCACUGCACUCCAGC 23
4223 23105
CFTR- IntronlO- + GAGAUCCCGCCACUGCACUCCAGC 24
4224 23106
CFTR- IntronlO- + CAGGAGAAUUGCUUGAGC 18
4225 23107
CFTR- IntronlO- + GCAGGAGAAUUGCUUGAGC 19
4226 23108
CFTR- IntronlO- + GGCAGGAGAAUUGCUUGAGC 20
4227 23109
CFTR- IntronlO- + AGGCAGGAGAAUUGCUUGAGC 21
4228 23110
884
5535.1 CFTR- IntronlO- + GAGGCAGGAGAAUUGCUUGAGC 22
4229 23111
CFTR- IntronlO- + UGAGGCAGGAGAAUUGCUUGAGC 23
4230 23112
CFTR- IntronlO- + GUGAGGCAGGAGAAUUGCUUGAGC 24
4231 23113
CFTR- IntronlO- + ACCUCAGCCUCCCAAGUAGC 20
1222 20107
CFTR- IntronlO- + CACCUCAGCCUCCCAAGUAGC 21
4232 23114
CFTR- IntronlO- + CCACCUCAGCCUCCCAAGUAGC 22
4233 23115
CFTR- IntronlO- + CCCACCUCAGCCUCCCAAGUAGC 23
4234 23116
CFTR- IntronlO- + UCCCACCUCAGCCUCCCAAGUAGC 24
4235 23117
CFTR- IntronlO- + CUCAGCCUCCCGAGUAGC 18
4236 23118
CFTR- IntronlO- + CCUCAGCCUCCCGAGUAGC 19
4237 23119
CFTR-
+ GCCUCAGCCUCCCGAGUAGC 20
lntronlO-675 19561
CFTR- IntronlO- + UGCCUCAGCCUCCCGAGUAGC 21
4238 23120
CFTR- IntronlO- + CUGCCUCAGCCUCCCGAGUAGC 22
4239 23121
CFTR- IntronlO- + CCUGCCUCAGCCUCCCGAGUAGC 23
4240 23122
CFTR-
+ UCCUGCCUCAGCCUCCCGAGUAGC 24
IntronlO- 23123
885
5535.1 4241
CFTR- IntronlO- + AAACUCAUAAGGGACCGC 18
4242 23124
CFTR- IntronlO- + AAAACUCAUAAGGGACCGC 19
4243 23125
CFTR- IntronlO- + GAAAACUCAUAAGGGACCGC 20
4244 23126
CFTR- IntronlO- + AGAAAACUCAUAAGGGACCGC 21
4245 23127
CFTR- IntronlO- + GAGAAAACUCAUAAGGGACCGC 22
4246 23128
CFTR- IntronlO- + AGAGAAAACUCAUAAGGGACCGC 23
4247 23129
CFTR- IntronlO- + UAGAGAAAACUCAUAAGGGACCGC 24
4248 23130
CFTR- IntronlO- + UCUCACAGUUCUGGAGGC 18
4249 23131
CFTR- IntronlO- + UUCUCACAGUUCUGGAGGC 19
4250 23132
CFTR- IntronlO- + UUUCUCACAGUUCUGGAGGC 20
1229 20114
CFTR- IntronlO- + AUUUCUCACAGUUCUGGAGGC 21
4251 23133
CFTR- IntronlO- + UAUUUCUCACAGUUCUGGAGGC 22
4252 23134
CFTR- IntronlO- + UUAUUUCUCACAGUUCUGGAGGC 23
4253 23135
CFTR-
+ UUUAUUUCUCACAGUUCUGGAGGC 24
IntronlO- 23136
886
5535.1 4254
CFTR- IntronlO- + UACUUGGGAGGCUGAGGC 18
4255 23137
CFTR- IntronlO- + CUACUUGGGAGGCUGAGGC 19
4256 23138
CFTR-
+ GCUACUUGGGAGGCUGAGGC 20
lntronlO-681 19567
CFTR- IntronlO- + AGCUACUUGGGAGGCUGAGGC 21
4257 23139
CFTR- IntronlO- + CAGCUACUUGGGAGGCUGAGGC 22
4258 23140
CFTR- IntronlO- + CCAGCUACUUGGGAGGCUGAGGC 23
4259 23141
CFTR- IntronlO- + CCCAGCUACUUGGGAGGCUGAGGC 24
4260 23142
CFTR- IntronlO- + UACUUGGGAGGGUGAGGC 18
4261 23143
CFTR- IntronlO- + CUACUUGGGAGGGUGAGGC 19
4262 23144
CFTR-
+ GCUACUUGGGAGGGUGAGGC 20
lntronlO-682 19568
CFTR- IntronlO- + AGCUACUUGGGAGGGUGAGGC 21
4263 23145
CFTR- IntronlO- + CAGCUACUUGGGAGGGUGAGGC 22
4264 23146
CFTR- IntronlO- + CCAGCUACUUGGGAGGGUGAGGC 23
4265 23147
CFTR- IntronlO- + CCCAGCUACUUGGGAGGGUGAGGC 24
4266 23148
887
5535.1 CFTR- IntronlO- + CUGAGGCAGGAGAAUGGC 18
4267 23149
CFTR- IntronlO- + GCUGAGGCAGGAGAAUGGC 19
4268 23150
CFTR- IntronlO- + GGCUGAGGCAGGAGAAUGGC 20
4269 23151
CFTR- IntronlO- + AGGCUGAGGCAGGAGAAUGGC 21
4270 23152
CFTR- IntronlO- + GAGGCUGAGGCAGGAGAAUGGC 22
4271 23153
CFTR- IntronlO- + GGAGGCUGAGGCAGGAGAAUGGC 23
4272 23154
CFTR- IntronlO- + GGGAGGCUGAGGCAGGAGAAUGGC 24
4273 23155
CFTR- IntronlO- + UUUCAACAUAUGAAUGGC 18
4274 23156
CFTR- IntronlO- + AUUUCAACAUAUGAAUGGC 19
4275 23157
CFTR-
+ GAUUUCAACAUAUGAAUGGC 20
lntronlO-683 19569
CFTR- IntronlO- + GGAUUUCAACAUAUGAAUGGC 21
4276 23158
CFTR- IntronlO- + AGGAUUUCAACAUAUGAAUGGC 22
4277 23159
CFTR- IntronlO- + UAGGAUUUCAACAUAUGAAUGGC 23
4278 23160
CFTR- IntronlO- + UUAGGAUUUCAACAUAUGAAUGGC 24
4279 23161
CFTR-
+ AAUGGCUAUCCACAAUGC 18
IntronlO- 23162
888
5535.1 4280
CFTR- IntronlO- + AAAUGGCUAUCCACAAUGC 19
4281 23163
CFTR- IntronlO- + UAAAUGGCUAUCCACAAUGC 20
4282 23164
CFTR- IntronlO- + UUAAAUGGCUAUCCACAAUGC 21
4283 23165
CFTR- IntronlO- + UUUAAAUGGCUAUCCACAAUGC 22
4284 23166
CFTR- IntronlO- + UUUUAAAUGGCUAUCCACAAUGC 23
4285 23167
CFTR- IntronlO- + GUUUUAAAUGGCUAUCCACAAUGC 24
4286 23168
CFTR- IntronlO- + GGUUGGAUGAGGGAAUGC 18
4287 23169
CFTR- IntronlO- + UGGUUGGAUGAGGGAAUGC 19
4288 23170
CFTR-
+ UUGGUUGGAUGAGGGAAUGC 20
lntronlO-431 19317
CFTR- IntronlO- + CUUGGUUGGAUGAGGGAAUGC 21
4289 23171
CFTR- IntronlO- + CCUUGGUUGGAUGAGGGAAUGC 22
4290 23172
CFTR- IntronlO- + ACCUUGGUUGGAUGAGGGAAUGC 23
4291 23173
CFTR- IntronlO- + UACCUUGGUUGGAUGAGGGAAUGC 24
4292 23174
CFTR- IntronlO- + ACAUGAUGAAAAAUAUGC 18
4293 23175
889
5535.1 CFTR- IntronlO- + AACAUGAUGAAAAAUAUGC 19
4294 23176
CFTR- IntronlO- + AAACAUGAUGAAAAAUAUGC 20
4295 23177
CFTR- IntronlO- + UAAACAUGAUGAAAAAUAUGC 21
4296 23178
CFTR- IntronlO- + CUAAACAUGAUGAAAAAUAUGC 22
4297 23179
CFTR- IntronlO- + ACUAAACAUGAUGAAAAAUAUGC 23
4298 23180
CFTR- IntronlO- + CACUAAACAUGAUGAAAAAUAUGC 24
4299 23181
CFTR- IntronlO- + CAAUUUUAAUAAAACUGC 18
4300 23182
CFTR- IntronlO- + UCAAUUUUAAUAAAACUGC 19
4301 23183
CFTR- IntronlO- + AUCAAUUUUAAUAAAACUGC 20
4302 23184
CFTR- IntronlO- + CAUCAAUUUUAAUAAAACUGC 21
4303 23185
CFTR- IntronlO- + UCAUCAAUUUUAAUAAAACUGC 22
4304 23186
CFTR- IntronlO- + CUCAUCAAUUUUAAUAAAACUGC 23
4305 23187
CFTR- IntronlO- + GCUCAUCAAUUUUAAUAAAACUGC 24
4306 23188
CFTR- IntronlO- + GUGAGGCAGGAGAAUUGC 18
4307 23189
890
5535.1 CFTR- IntronlO- + GGUGAGGCAGGAGAAUUGC 19
4308 23190
CFTR- IntronlO- + GGGUGAGGCAGGAGAAUUGC 20
4309 23191
CFTR- IntronlO- + AGGGUGAGGCAGGAGAAUUGC 21
4310 23192
CFTR- IntronlO- + GAGGGUGAGGCAGGAGAAUUGC 22
4311 23193
CFTR- IntronlO- + GGAGGGUGAGGCAGGAGAAUUGC 23
4312 23194
CFTR- IntronlO- + GGGAGGGUGAGGCAGGAGAAUUGC 24
4313 23195
CFTR- IntronlO- + GCCACCAUCAUCACUUGC 18
4314 23196
CFTR- IntronlO- + AGCCACCAUCAUCACUUGC 19
4315 23197
CFTR- IntronlO- + AAGCCACCAUCAUCACUUGC 20
4316 23198
CFTR- IntronlO- + CAAGCCACCAUCAUCACUUGC 21
4317 23199
CFTR- IntronlO- + UCAAGCCACCAUCAUCACUUGC 22
4318 23200
CFTR- IntronlO- + AUCAAGCCACCAUCAUCACUUGC 23
4319 23201
CFTR- IntronlO- + GAUCAAGCCACCAUCAUCACUUGC 24
4320 23202
CFTR- IntronlO- + A C A A AG U A AC AG A A A A U C 18
4321 23203
891
5535.1 CFTR- IntronlO- + AACAAAG U AACAG AAAAU C 19
4322 23204
CFTR- IntronlO- + U AACAAAG U AACAG AAAAU C 20
4323 23205
CFTR- IntronlO- + GU AACAAAG U AACAG AAAAU C 21
4324 23206
CFTR- IntronlO- + AG U AACAAAG U AACAG AAAAU C 22
4325 23207
CFTR- IntronlO- + AAG U AACAAAG U AACAG AAAAU C 23
4326 23208
CFTR- IntronlO- + AAAG U AACAAAG U AACAG AAAAU C 24
4327 23209
CFTR- IntronlO- + UGCUAUUUAAACAGAAUC 18
4328 23210
CFTR- IntronlO- + GUGCUAUUUAAACAGAAUC 19
4329 23211
CFTR-
+ AGUGCUAUUUAAACAGAAUC 20
lntronlO-433 19319
CFTR- IntronlO- + CAGUGCUAUUUAAACAGAAUC 21
4330 23212
CFTR- IntronlO- + CCAGUGCUAUUUAAACAGAAUC 22
4331 23213
CFTR- IntronlO- + UCCAGUGCUAUUUAAACAGAAUC 23
4332 23214
CFTR- IntronlO- + CUCCAGUGCUAUUUAAACAGAAUC 24
4333 23215
CFTR- IntronlO- + UUUAGUAGAAACCUAAUC 18
4334 23216
CFTR-
+ UUUUAGUAGAAACCUAAUC 19
IntronlO- 23217
892
5535.1 4335
CFTR-
+ G U U U U AG U AG AAACCU AAU C 20
Intronl0-91 18977
CFTR- IntronlO- + GG U U U U AG U AG AAACCU AAU C 21
4336 23218
CFTR- IntronlO- + UGGUUUUAGUAGAAACCUAAUC 22
4337 23219
CFTR- IntronlO- + UUGGUUUUAGUAGAAACCUAAUC 23
4338 23220
CFTR- IntronlO- + UUUGGUUUUAGUAGAAACCUAAUC 24
4339 23221
CFTR- IntronlO- + GGCCGAGGCAGGCAGAUC 18
4340 23222
CFTR- IntronlO- + AGGCCGAGGCAGGCAGAUC 19
4341 23223
CFTR- IntronlO- + GAGGCCGAGGCAGGCAGAUC 20
4342 23224
CFTR- IntronlO- + GGAGGCCGAGGCAGGCAGAUC 21
4343 23225
CFTR- IntronlO- + GGGAGGCCGAGGCAGGCAGAUC 22
4344 23226
CFTR- IntronlO- + UGGGAGGCCGAGGCAGGCAGAUC 23
4345 23227
CFTR- IntronlO- + UUGGGAGGCCGAGGCAGGCAGAUC 24
4346 23228
CFTR- IntronlO- + GGCCGAGGCGGGCGGAUC 18
4347 23229
CFTR- IntronlO- + AGGCCGAGGCGGGCGGAUC 19
4348 23230
893
5535.1 CFTR- IntronlO- + GAGGCCGAGGCGGGCGGAUC 20
4349 23231
CFTR- IntronlO- + GGAGGCCGAGGCGGGCGGAUC 21
4350 23232
CFTR- IntronlO- + GGGAGGCCGAGGCGGGCGGAUC 22
4351 23233
CFTR- IntronlO- + UGGGAGGCCGAGGCGGGCGGAUC 23
4352 23234
CFTR- IntronlO- + UUGGGAGGCCGAGGCGGGCGGAUC 24
4353 23235
CFTR- IntronlO- + UCUAUCAUAGAAUUGAUC 18
4354 23236
CFTR- IntronlO- + AUCUAUCAUAGAAUUGAUC 19
4355 23237
CFTR- IntronlO- + CAUCUAUCAUAGAAUUGAUC 20
4356 23238
CFTR- IntronlO- + ACAUCUAUCAUAGAAUUGAUC 21
4357 23239
CFTR- IntronlO- + CACAUCUAUCAUAGAAUUGAUC 22
4358 23240
CFTR- IntronlO- + GCACAUCUAUCAUAGAAUUGAUC 23
4359 23241
CFTR- IntronlO- + UGCACAUCUAUCAUAGAAUUGAUC 24
4360 23242
CFTR- IntronlO- + AUACUGGGUUCAUUUAUC 18
4361 23243
CFTR- IntronlO- + UAUACUGGGUUCAUUUAUC 19
4362 23244
894
5535.1 CFTR- IntronlO- + UUAUACUGGGUUCAUUUAUC 20
4363 23245
CFTR- IntronlO- + UUUAUACUGGGUUCAUUUAUC 21
4364 23246
CFTR- IntronlO- + CUUUAUACUGGGUUCAUUUAUC 22
4365 23247
CFTR- IntronlO- + UCUUUAUACUGGGUUCAUUUAUC 23
4366 23248
CFTR- IntronlO- + GUCUUUAUACUGGGUUCAUUUAUC 24
4367 23249
CFTR- IntronlO- + CACGCUGGUCUCAAACUC 18
4368 23250
CFTR- IntronlO- + CCACGCUGGUCUCAAACUC 19
4369 23251
CFTR- IntronlO- + CCCACGCUGGUCUCAAACUC 20
4370 23252
CFTR- IntronlO- + GCCCACGCUGGUCUCAAACUC 21
4371 23253
CFTR- IntronlO- + UGCCCACGCUGGUCUCAAACUC 22
4372 23254
CFTR- IntronlO- + UUGCCCACGCUGGUCUCAAACUC 23
4373 23255
CFTR- IntronlO- + GUUGCCCACGCUGGUCUCAAACUC 24
4374 23256
CFTR- IntronlO- + GUAUUAGCAAGUGGACUC 18
4375 23257
CFTR- IntronlO- + UGUAUUAGCAAGUGGACUC 19
4376 23258
895
5535.1 CFTR- IntronlO- + UUGUAUUAGCAAGUGGACUC 20
4377 23259
CFTR- IntronlO- + AUUGUAUUAGCAAGUGGACUC 21
4378 23260
CFTR- IntronlO- + AAUUGUAUUAGCAAGUGGACUC 22
4379 23261
CFTR- IntronlO- + CAAUUGUAUUAGCAAGUGGACUC 23
4380 23262
CFTR- IntronlO- + UCAAUUGUAUUAGCAAGUGGACUC 24
4381 23263
CFTR- IntronlO- + ACUAAAGACUUCACCCUC 18
4382 23264
CFTR- IntronlO- + UACUAAAGACUUCACCCUC 19
4383 23265
CFTR- IntronlO- + UUACUAAAGACUUCACCCUC 20
4384 23266
CFTR- IntronlO- + UUUACUAAAGACUUCACCCUC 21
4385 23267
CFTR- IntronlO- + AUUUACUAAAGACUUCACCCUC 22
4386 23268
CFTR- IntronlO- + CAUUUACUAAAGACUUCACCCUC 23
4387 23269
CFTR- IntronlO- + UCAUUUACUAAAGACUUCACCCUC 24
4388 23270
CFTR- IntronlO- + CCACCCAAUUUUUGGCUC 18
4389 23271
CFTR- IntronlO- + CCCACCCAAUUUUUGGCUC 19
4390 23272
896
5535.1 CFTR- IntronlO- + CCCCACCCAAUUUUUGGCUC 20
4391 23273
CFTR- IntronlO- + CCCCCACCCAAUUUUUGGCUC 21
4392 23274
CFTR- IntronlO- + UCCCCCACCCAAUUUUUGGCUC 22
4393 23275
CFTR- IntronlO- + CUCCCCCACCCAAUUUUUGGCUC 23
4394 23276
CFTR- IntronlO- + GCUCCCCCACCCAAUUUUUGGCUC 24
4395 23277
CFTR- IntronlO- + UAUAGAGAGAAACAUCUC 18
4396 23278
CFTR- IntronlO- + AUAUAGAGAGAAACAUCUC 19
4397 23279
CFTR- IntronlO- + UAUAUAGAGAGAAACAUCUC 20
1238 20123
CFTR- IntronlO- + AUAUAUAGAGAGAAACAUCUC 21
4398 23280
CFTR- IntronlO- + UAUAUAUAGAGAGAAACAUCUC 22
4399 23281
CFTR- IntronlO- + AUAUAUAUAGAGAGAAACAUCUC 23
4400 23282
CFTR- IntronlO- + UAUAUAUAUAGAGAGAAACAUCUC 24
4401 23283
CFTR- IntronlO- + UUUAAUUGCCAGUAAGUC 18
4402 23284
CFTR- IntronlO- + AUUUAAUUGCCAGUAAGUC 19
4403 23285
897
5535.1 CFTR- IntronlO- + AAUUUAAUUGCCAGUAAGUC 20
4404 23286
CFTR- IntronlO- + AAAUUUAAUUGCCAGUAAGUC 21
4405 23287
CFTR- IntronlO- + GAAAUUUAAUUGCCAGUAAGUC 22
4406 23288
CFTR- IntronlO- + UGAAAUUUAAUUGCCAGUAAGUC 23
4407 23289
CFTR- IntronlO- + CUGAAAUUUAAUUGCCAGUAAGUC 24
4408 23290
CFTR- IntronlO- + CCUUCCAGUUACUCAGUC 18
4409 23291
CFTR- IntronlO- + UCCUUCCAGUUACUCAGUC 19
4410 23292
CFTR- IntronlO- + AUCCUUCCAGUUACUCAGUC 20
4411 23293
CFTR- IntronlO- + UAUCCUUCCAGUUACUCAGUC 21
4412 23294
CFTR- IntronlO- + UUAUCCUUCCAGUUACUCAGUC 22
4413 23295
CFTR- IntronlO- + UUUAUCCUUCCAGUUACUCAGUC 23
4414 23296
CFTR- IntronlO- + AUUUAUCCUUCCAGUUACUCAGUC 24
4415 23297
CFTR- IntronlO- + AUAAGCCAGCUUUCAGUC 18
4416 23298
CFTR- IntronlO- + CAUAAGCCAGCUUUCAGUC 19
4417 23299
898
5535.1 CFTR- IntronlO- + CCAUAAGCCAGCUUUCAGUC 20
4418 23300
CFTR- IntronlO- + GCCAUAAGCCAGCUUUCAGUC 21
4419 23301
CFTR- IntronlO- + UGCCAUAAGCCAGCUUUCAGUC 22
4420 23302
CFTR- IntronlO- + AUGCCAUAAGCCAGCUUUCAGUC 23
4421 23303
CFTR- IntronlO- + GAUGCCAUAAGCCAGCUUUCAGUC 24
4422 23304
CFTR- IntronlO- + CGGGCGGAUCACGAGGUC 18
4423 23305
CFTR- IntronlO- + GCGGGCGGAUCACGAGGUC 19
4424 23306
CFTR-
+ GGCGGGCGGAUCACGAGGUC 20
lntronlO-688 19574
CFTR- IntronlO- + AGGCGGGCGGAUCACGAGGUC 21
4425 23307
CFTR- IntronlO- + GAGGCGGGCGGAUCACGAGGUC 22
4426 23308
CFTR- IntronlO- + CGAGGCGGGCGGAUCACGAGGUC 23
4427 23309
CFTR- IntronlO- + CCGAGGCGGGCGGAUCACGAGGUC 24
4428 23310
CFTR- IntronlO- + CAGGCAGAUCAUGAGGUC 18
4429 23311
CFTR- IntronlO- + GCAGGCAGAUCAUGAGGUC 19
4430 23312
CFTR-
+ GGCAGGCAGAUCAUGAGGUC 20
IntronlO- 23313
899
5535.1 4431
CFTR- IntronlO- + AGGCAGGCAGAUCAUGAGGUC 21
4432 23314
CFTR- IntronlO- + GAGGCAGGCAGAUCAUGAGGUC 22
4433 23315
CFTR- IntronlO- + CGAGGCAGGCAGAUCAUGAGGUC 23
4434 23316
CFTR- IntronlO- + CCGAGGCAGGCAGAUCAUGAGGUC 24
4435 23317
CFTR- IntronlO- + GCUUCACUAAAAUAAUUC 18
4436 23318
CFTR- IntronlO- + UGCUUCACUAAAAUAAUUC 19
4437 23319
CFTR- IntronlO- + UUGCUUCACUAAAAUAAUUC 20
4438 23320
CFTR- IntronlO- + AUUGCUUCACUAAAAUAAUUC 21
4439 23321
CFTR- IntronlO- + UAUUGCUUCACUAAAAUAAUUC 22
4440 23322
CFTR- IntronlO- + AUAUUGCUUCACUAAAAUAAUUC 23
4441 23323
CFTR- IntronlO- + AAUAUUGCUUCACUAAAAUAAUUC 24
4442 23324
CFTR- IntronlO- + GAUUAUUCGGUAUAAUUC 18
4443 23325
CFTR- IntronlO- + AGAUUAUUCGGUAUAAUUC 19
4444 23326
CFTR-
+ UAGAUUAUUCGGUAUAAUUC 20
IntronlO- 23327
900
5535.1 4445
CFTR- IntronlO- + UUAGAUUAUUCGGUAUAAUUC 21
4446 23328
CFTR- IntronlO- + CUUAGAUUAUUCGGUAUAAUUC 22
4447 23329
CFTR- IntronlO- + UCUUAGAUUAUUCGGUAUAAUUC 23
4448 23330
CFTR- IntronlO- + GUCUUAGAUUAUUCGGUAUAAUUC 24
4449 23331
CFTR- IntronlO- + AAAUCUAAAAGCUAAUUC 18
4450 23332
CFTR- IntronlO- + UAAAUCUAAAAGCUAAUUC 19
4451 23333
CFTR- IntronlO- + GUAAAUCUAAAAGCUAAUUC 20
4452 23334
CFTR- IntronlO- + AGUAAAUCUAAAAGCUAAUUC 21
4453 23335
CFTR- IntronlO- + A AG U AAA U C U A A A AG C U A A U U C 22
4454 23336
CFTR- IntronlO- + UAAGUAAAUCUAAAAGCUAAUUC 23
4455 23337
CFTR- IntronlO- + AUAAGUAAAUCUAAAAGCUAAUUC 24
4456 23338
CFTR- IntronlO- + AUAAUUUGAACAACAUUC 18
4457 23339
CFTR- IntronlO- + AAUAAU U UG AACAACAU U C 19
4458 23340
CFTR-
+ AAAUAAU U UG AACAACAU U C 20
IntronlO- 23341
901
5535.1 4459
CFTR- IntronlO- + G AAAU AAU U UG AACAACAU U C 21
4460 23342
CFTR- IntronlO- + AG AAAU AAU U UG AACAACAU U C 22
4461 23343
CFTR- IntronlO- + U AG AAAU AAU U UG AACAACAU U C 23
4462 23344
CFTR- IntronlO- + G U AG AAAU AAU U UG AACAACAU U C 24
4463 23345
CFTR- IntronlO- + AUUUAAAAAGCAAUAUUC 18
4464 23346
CFTR- IntronlO- + AAU U U AAAAAG CAAU AUUC 19
4465 23347
CFTR- IntronlO- + AAAU U U AAAAAG C A A U A U U C 20
4466 23348
CFTR- IntronlO- + U AAA U U U AAAAAG C A A U A U U C 21
4467 23349
CFTR- IntronlO- + U U AAAU U U AAAAAG C A A U A U U C 22
4468 23350
CFTR- IntronlO- + AU U AAAU U U AAAAAG CAAU AU U C 23
4469 23351
CFTR- IntronlO- + U AU U AAAU U U AAAAAG CAAU AU U C 24
4470 23352
CFTR- IntronlO- + ACACAAUGGGUUAUAUUC 18
4471 23353
CFTR- IntronlO- + UACACAAUGGGUUAUAUUC 19
4472 23354
CFTR-
+ CUACACAAUGGGUUAUAUUC 20
IntronlO- 23355
902
5535.1 4473
CFTR- IntronlO- + UCUACACAAUGGGUUAUAUUC 21
4474 23356
CFTR- IntronlO- + AUCUACACAAUGGGUUAUAUUC 22
4475 23357
CFTR- IntronlO- + UAUCUACACAAUGGGUUAUAUUC 23
4476 23358
CFTR- IntronlO- + UUAUCUACACAAUGGGUUAUAUUC 24
4477 23359
CFTR- IntronlO- + AGUAUUUUGAAAAGCUUC 18
4478 23360
CFTR- IntronlO- + AAGUAUUUUGAAAAGCUUC 19
4479 23361
CFTR- IntronlO- + AAAGUAUUUUGAAAAGCUUC 20
4480 23362
CFTR- IntronlO- + GAAAGUAUUUUGAAAAGCUUC 21
4481 23363
CFTR- IntronlO- + AGAAAGUAUUUUGAAAAGCUUC 22
4482 23364
CFTR- IntronlO- + UAGAAAGUAUUUUGAAAAGCUUC 23
4483 23365
CFTR- IntronlO- + CUAGAAAGUAUUUUGAAAAGCUUC 24
4484 23366
CFTR- IntronlO- + AUUUAUUUCUCACAGUUC 18
4485 23367
CFTR- IntronlO- + AAUUUAUUUCUCACAGUUC 19
4486 23368
CFTR-
+ GAAUUUAUUUCUCACAGUUC 20
lntronlO-689 19575
903
5535.1 CFTR- IntronlO- + GGAAUUUAUUUCUCACAGUUC 21
4487 23369
CFTR- IntronlO- + AGGAAUUUAUUUCUCACAGUUC 22
4488 23370
CFTR- IntronlO- + CAGGAAUUUAUUUCU CACAG U U C 23
4489 23371
CFTR- IntronlO- + ACAGGAAUUUAUUUCUCACAGUUC 24
4490 23372
CFTR- IntronlO- + CGAAUUGGUACAAAUUUC 18
4491 23373
CFTR- IntronlO- + ACG AAU UGG U ACAAAU U U C 19
4492 23374
CFTR-
+ UACGAAUUGGUACAAAUUUC 20
Intron 10-443 19329
CFTR- IntronlO- + GUACGAAUUGGUACAAAUUUC 21
4493 23375
CFTR- IntronlO- + AG U ACG AAU UGG U ACAAAU U U C 22
4494 23376
CFTR- IntronlO- + GAG U ACG AAU UGG U ACAAAU U U C 23
4495 23377
CFTR- IntronlO- + UGAGUACGAAUUGGUACAAAUUUC 24
4496 23378
CFTR- IntronlO- + GAAAAUUUGUUUUCUUUC 18
4497 23379
CFTR- IntronlO- + AGAAAAUUUGUUUUCUUUC 19
4498 23380
CFTR- IntronlO- + AAGAAAAUUUGUUUUCUUUC 20
1248 20133
CFTR-
+ AAAGAAAAUUUGUUUUCUUUC 21
IntronlO- 23381
904
5535.1 4499
CFTR- IntronlO- + CAAAGAAAAUUUGUUUUCUUUC 22
4500 23382
CFTR- IntronlO- + ACAAAGAAAAUUUGUUUUCUUUC 23
4501 23383
CFTR- IntronlO- + AACAAAGAAAAUUUGUUUUCUUUC 24
4502 23384
CFTR- IntronlO- + U CAAAG CU ACAG AU U U U C 18
4503 23385
CFTR- IntronlO- + AUCAAAGCUACAGAUUUUC 19
4504 23386
CFTR- IntronlO- + AAUCAAAGCUACAGAUUUUC 20
4505 23387
CFTR- IntronlO- + AAAUCAAAGCUACAGAUUUUC 21
4506 23388
CFTR- IntronlO- + UAAAUCAAAGCUACAGAUUUUC 22
4507 23389
CFTR- IntronlO- + AUAAAUCAAAGCUACAGAUUUUC 23
4508 23390
CFTR- IntronlO- + UAUAAAUCAAAGCUACAGAUUUUC 24
4509 23391
CFTR- IntronlO- + UUGCUUUAU UAAGAAAAG 18
4510 23392
CFTR- IntronlO- + AUUGCUUUAUUAAGAAAAG 19
4511 23393
CFTR- IntronlO- + GAUUGCUUUAUUAAGAAAAG 20
4512 23394
CFTR-
+ UGAUUGCUUUAUUAAGAAAAG 21
IntronlO- 23395
905
5535.1 4513
CFTR- IntronlO- + CUGAUUGCUUUAUUAAGAAAAG 22
4514 23396
CFTR- IntronlO- + GCUGAUUGCUUUAUUAAGAAAAG 23
4515 23397
CFTR- IntronlO- + UGCUGAUUGCUUUAUUAAGAAAAG 24
4516 23398
CFTR- IntronlO- + GGAUAUCUUAGGUCAAAG 18
4517 23399
CFTR- IntronlO- + AGGAUAUCUUAGGUCAAAG 19
4518 23400
CFTR-
+ UAGGAUAUCUUAGGUCAAAG 20
Intron 10-447 19333
CFTR- IntronlO- + UUAGGAUAUCUUAGGUCAAAG 21
4519 23401
CFTR- IntronlO- + CUU AGGAUAUCUUAGGUCAAAG 22
4520 23402
CFTR- IntronlO- + CCUUAGGAUAUCUUAGGUCAAAG 23
4521 23403
CFTR- IntronlO- + CCCUUAGGAUAUCUUAGGUCAAAG 24
4522 23404
CFTR- IntronlO- + UGUUAAUGG C A A AG C A AG 18
4523 23405
CFTR- IntronlO- + CUGUUAAUGGCAAAGCAAG 19
4524 23406
CFTR- IntronlO- + UCUGUUAAUGGCAAAGCAAG 20
4525 23407
CFTR- IntronlO- + AUCUGUUAAUGGCAAAGCAAG 21
4526 23408
906
5535.1 CFTR- IntronlO- + UAUCUGUUAAUGGCAAAGCAAG 22
4527 23409
CFTR- IntronlO- + UUAUCUGUUAAUGGCAAAGCAAG 23
4528 23410
CFTR- IntronlO- + UUUAUCUGUUAAUGGCAAAGCAAG 24
4529 23411
CFTR- IntronlO- + UUGGGUAAGUUAUAGAAG 18
4530 23412
CFTR- IntronlO- + UUUGGGUAAGUUAUAGAAG 19
4531 23413
CFTR- IntronlO- + AUUUGGGUAAGUUAUAGAAG 20
4532 23414
CFTR- IntronlO- + UAUUUGGGUAAGUUAUAGAAG 21
4533 23415
CFTR- IntronlO- + AUAUUUGGGUAAGUUAUAGAAG 22
4534 23416
CFTR- IntronlO- + CAUAUUUGGGUAAGUUAUAGAAG 23
4535 23417
CFTR- IntronlO- + ACAUAUUUGGGUAAGUUAUAGAAG 24
4536 23418
CFTR- IntronlO- + CACUUUGGGAGGCUGAAG 18
4537 23419
CFTR- IntronlO- + GCACUUUGGGAGGCUGAAG 19
4538 23420
CFTR- IntronlO- + AGCACUUUGGGAGGCUGAAG 20
1252 20137
CFTR- IntronlO- + CAGCACUUUGGGAGGCUGAAG 21
4539 23421
907
5535.1 CFTR- IntronlO- + CCAGCACUUUGGGAGGCUGAAG 22
4540 23422
CFTR- IntronlO- + CCCAGCACUUUGGGAGGCUGAAG 23
4541 23423
CFTR- IntronlO- + ACCCAGCACUUUGGGAGGCUGAAG 24
4542 23424
CFTR- IntronlO- + UACUAUUUUCCCUAUAAG 18
4543 23425
CFTR- IntronlO- + AUACUAUUUUCCCUAUAAG 19
4544 23426
CFTR- IntronlO- + CAUACUAUUUUCCCUAUAAG 20
4545 23427
CFTR- IntronlO- + ACAUACUAUUUUCCCUAUAAG 21
4546 23428
CFTR- IntronlO- + GACAUACUAUUUUCCCUAUAAG 22
4547 23429
CFTR- IntronlO- + UGACAUACUAUUUUCCCUAUAAG 23
4548 23430
CFTR- IntronlO- + UUGACAUACUAUUUUCCCUAUAAG 24
4549 23431
CFTR- IntronlO- + AUUCCUCCUGUGUAUAAG 18
4550 23432
CFTR- IntronlO- + AAUUCCUCCUGUGUAUAAG 19
4551 23433
CFTR- IntronlO- + AAAUUCCUCCUGUGUAUAAG 20
4552 23434
CFTR- IntronlO- + GAAAUUCCUCCUGUGUAUAAG 21
4553 23435
908
5535.1 CFTR- IntronlO- + AGAAAUUCCUCCUGUGUAUAAG 22
4554 23436
CFTR- IntronlO- + GAGAAAUUCCUCCUGUGUAUAAG 23
4555 23437
CFTR- IntronlO- + AGAGAAAUUCCUCCUGUGUAUAAG 24
4556 23438
CFTR- IntronlO- + CUUAACCCAUCUAUUAAG 18
4557 23439
CFTR- IntronlO- + GCUUAACCCAUCUAUUAAG 19
4558 23440
CFTR-
+ GGCUUAACCCAUCUAUUAAG 20
lntronlO-97 18983
CFTR- IntronlO- + UGGCUUAACCCAUCUAUUAAG 21
4559 23441
CFTR- IntronlO- + UUGGCUUAACCCAUCUAUUAAG 22
4560 23442
CFTR- IntronlO- + GUUGGCUUAACCCAUCUAUUAAG 23
4561 23443
CFTR- IntronlO- + AGUUGGCUUAACCCAUCUAUUAAG 24
4562 23444
CFTR- IntronlO- + CUGUGAUGCAGACAACAG 18
4563 23445
CFTR- IntronlO- + GCUGUGAUGCAGACAACAG 19
4564 23446
CFTR- IntronlO- + AGCUGUGAUGCAGACAACAG 20
4565 23447
CFTR- IntronlO- + CAGCUGUGAUGCAGACAACAG 21
4566 23448
CFTR-
+ UCAGCUGUGAUGCAGACAACAG 22
IntronlO- 23449
909
5535.1 4567
CFTR- IntronlO- + UUCAGCUGUGAUGCAGACAACAG 23
4568 23450
CFTR- IntronlO- + C U U CAG CUGUGAUG CAG AC AACAG 24
4569 23451
CFTR- IntronlO- + AGAAUGGAAAAUGGACAG 18
4570 23452
CFTR- IntronlO- + GAGAAUGGAAAAUGGACAG 19
4571 23453
CFTR- IntronlO- + GGAGAAUGGAAAAUGGACAG 20
4572 23454
CFTR- IntronlO- + AGGAGAAUGGAAAAUGGACAG 21
4573 23455
CFTR- IntronlO- + CAGGAGAAUGGAAAAUGGACAG 22
4574 23456
CFTR- IntronlO- + GCAGGAGAAUGGAAAAUGGACAG 23
4575 23457
CFTR- IntronlO- + UGCAGGAGAAUGGAAAAUGGACAG 24
4576 23458
CFTR- IntronlO- + AGCUAAAGUAUUACCCAG 18
4577 23459
CFTR- IntronlO- + CAGCUAAAGUAUUACCCAG 19
4578 23460
CFTR-
+ ACAGCUAAAG U AU U ACCCAG 20
lntronlO-451 19337
CFTR- IntronlO- + UACAGCUAAAG U AU U ACCCAG 21
4579 23461
CFTR- IntronlO- + AUACAGCUAAAGUAUUACCCAG 22
4580 23462
910
5535.1 CFTR- IntronlO- + UAUACAGCUAAAGUAUUACCCAG 23
4581 23463
CFTR- IntronlO- + AUAUACAGCUAAAGUAUUACCCAG 24
4582 23464
CFTR- IntronlO- + GAUAAAAAUUCCAAGCAG 18
4583 23465
CFTR- IntronlO- + U G A U A A A A A U U C C A AG C AG 19
4584 23466
CFTR- IntronlO- + A U G A U A A A A A U U C C A AG C AG 20
4585 23467
CFTR- IntronlO- + A A U G A U A A A A A UUCCAAGCAG 21
4586 23468
CFTR- IntronlO- + A A A U G A U A A A A A U U C C A AG C AG 22
4587 23469
CFTR- IntronlO- + AAAAUGAUAAAAAUUCCAAGCAG 23
4588 23470
CFTR- IntronlO- + AAAAAUGAUAAAAAUUCCAAGCAG 24
4589 23471
CFTR- IntronlO- + AAG G AAAG G AG G U AG CAG 18
4590 23472
CFTR- IntronlO- + GAAGGAAAGGAGGUAGCAG 19
4591 23473
CFTR- IntronlO- + AGAAGGAAAGGAGGUAGCAG 20
1260 20145
CFTR- IntronlO- + UAGAAGGAAAGGAGGUAGCAG 21
4592 23474
CFTR- IntronlO- + G U AG AAG G AAAG GAG G U AG CAG 22
4593 23475
911
5535.1 CFTR- IntronlO- + AGUAGAAGGAAAGGAGGUAGCAG 23
4594 23476
CFTR- IntronlO- + GAGUAGAAGGAAAGGAGGUAGCAG 24
4595 23477
CFTR- IntronlO- + UCAACAUAUGAAUGGCAG 18
4596 23478
CFTR- IntronlO- + UUCAACAUAUGAAUGGCAG 19
4597 23479
CFTR- IntronlO- + UUUCAACAUAUGAAUGGCAG 20
1263 20148
CFTR- IntronlO- + AUUUCAACAUAUGAAUGGCAG 21
4598 23480
CFTR- IntronlO- + GAUUUCAACAUAUGAAUGGCAG 22
4599 23481
CFTR- IntronlO- + GGAUUUCAACAUAUGAAUGGCAG 23
4600 23482
CFTR- IntronlO- + AGGAUUUCAACAUAUGAAUGGCAG 24
4601 23483
CFTR- IntronlO- + CU AU U U AAACAG AAU CAG 18
4602 23484
CFTR- IntronlO- + GCUAUUUAAACAGAAUCAG 19
4603 23485
CFTR-
+ UG CU AU U U AAACAG AAU CAG 20
lntronlO-453 19339
CFTR- IntronlO- + GUGCUAUUUAAACAGAAUCAG 21
4604 23486
CFTR- IntronlO- + AGUGCUAUUUAAACAGAAUCAG 22
4605 23487
CFTR-
+ CAGUGCUAUUUAAACAGAAUCAG 23
IntronlO- 23488
912
5535.1 4606
CFTR- IntronlO- + CCAGUGCUAUUUAAACAGAAUCAG 24
4607 23489
CFTR- IntronlO- + CAUAAUAAGACAGCUCAG 18
4608 23490
CFTR- IntronlO- + ACAUAAUAAGACAGCUCAG 19
4609 23491
CFTR- IntronlO- + AACAUAAUAAGACAGCUCAG 20
4610 23492
CFTR- IntronlO- + A A AC A U A A U A AG AC AG C U C AG 21
4611 23493
CFTR- IntronlO- + AAAACAUAAUAAGACAGCUCAG 22
4612 23494
CFTR- IntronlO- + CAAAACAUAAUAAGACAGCUCAG 23
4613 23495
CFTR- IntronlO- + ACAAAACAUAAUAAGACAGCUCAG 24
4614 23496
CFTR- IntronlO- + AAGAGGAAAAGACUUCAG 18
4615 23497
CFTR- IntronlO- + UAAGAGGAAAAGACUUCAG 19
4616 23498
CFTR- IntronlO- + UUAAGAGGAAAAGACUUCAG 20
4617 23499
CFTR- IntronlO- + AU U AAG AGG AAAAG ACU U CAG 21
4618 23500
CFTR- IntronlO- + U AU U AAG AGG AAAAG ACU U CAG 22
4619 23501
CFTR-
+ CUAUUAAGAGGAAAAGACUUCAG 23
IntronlO- 23502
913
5535.1 4620
CFTR- IntronlO- + U CU AU U AAG AGG AAAAG ACU U CAG 24
4621 23503
CFTR- IntronlO- + UGUUACAUAAAAAGAGAG 18
4622 23504
CFTR- IntronlO- + UUGUUACAUAAAAAGAGAG 19
4623 23505
CFTR- IntronlO- + AU UG U U ACAU AAAAAG AG AG 20
4624 23506
CFTR- IntronlO- + U AU UG U U ACAU AAAAAG AG AG 21
4625 23507
CFTR- IntronlO- + AUAUUGUUACAUAAAAAGAGAG 22
4626 23508
CFTR- IntronlO- + CAUAUUGUUACAUAAAAAGAGAG 23
4627 23509
CFTR- IntronlO- + GCAUAUUGUUACAUAAAAAGAGAG 24
4628 23510
CFTR- IntronlO- + UUUGUAUUUUUAGUAGAG 18
4629 23511
CFTR- IntronlO- + UUUUGUAUUUUUAGUAGAG 19
4630 23512
CFTR- IntronlO- + UUUUUGUAUUUUUAGUAGAG 20
4631 23513
CFTR- IntronlO- + UUUUUUGUAUUUUUAGUAGAG 21
4632 23514
CFTR- IntronlO- + AUUUUUUGUAUUUUUAGUAGAG 22
4633 23515
CFTR-
+ AAUUUUUUGUAUUUUUAGUAGAG 23
IntronlO- 23516
914
5535.1 4634
CFTR- IntronlO- + UAAUUUUUUGUAUUUUUAGUAGAG 24
4635 23517
CFTR- IntronlO- + UUUGUGUUUUUUGUAGAG 18
4636 23518
CFTR- IntronlO- + GUUUGUGUUUUUUGUAGAG 19
4637 23519
CFTR- IntronlO- + UGUUUGUGUUUUUUGUAGAG 20
4638 23520
CFTR- IntronlO- + UUGUUUGUGUUUUUUGUAGAG 21
4639 23521
CFTR- IntronlO- + UUUGUUUGUGUUUUUUGUAGAG 22
4640 23522
CFTR- IntronlO- + UUUUGUUUGUGUUUUUUGUAGAG 23
4641 23523
CFTR- IntronlO- + CUUUUGUUUGUGUUUUUUGUAGAG 24
4642 23524
CFTR- IntronlO- + GCACUUUGGGAGGCCGAG 18
4643 23525
CFTR- IntronlO- + AGCACUUUGGGAGGCCGAG 19
4644 23526
CFTR- IntronlO- + CAGCACUUUGGGAGGCCGAG 20
4645 23527
CFTR- IntronlO- + CCAGCACUUUGGGAGGCCGAG 21
4646 23528
CFTR- IntronlO- + CCCAGCACUUUGGGAGGCCGAG 22
4647 23529
CFTR-
+ UCCCAGCACUUUGGGAGGCCGAG 23
IntronlO- 23530
915
5535.1 4648
CFTR- IntronlO- + AUCCCAGCACUUUGGGAGGCCGAG 24
4649 23531
CFTR- IntronlO- + CUAAUGGCAGAAUUCGAG 18
4650 23532
CFTR- IntronlO- + ACUAAUGGCAGAAUUCGAG 19
4651 23533
CFTR- IntronlO- + AACUAAUGGCAGAAUUCGAG 20
4652 23534
CFTR- IntronlO- + AAACUAAUGGCAGAAUUCGAG 21
4653 23535
CFTR- IntronlO- + AAAACUAAUGGCAGAAUUCGAG 22
4654 23536
CFTR- IntronlO- + UAAAACUAAUGGCAGAAUUCGAG 23
4655 23537
CFTR- IntronlO- + UUAAAACUAAUGGCAGAAUUCGAG 24
4656 23538
CFTR- IntronlO- + AUGGCGUGAACCCGGGAG 18
4657 23539
CFTR- IntronlO- + AAUGGCGUGAACCCGGGAG 19
4658 23540
CFTR- IntronlO- + GAAUGGCGUGAACCCGGGAG 20
4659 23541
CFTR- IntronlO- + AGAAUGGCGUGAACCCGGGAG 21
4660 23542
CFTR- IntronlO- + GAGAAUGGCGUGAACCCGGGAG 22
4661 23543
CFTR-
+ GGAGAAUGGCGUGAACCCGGGAG 23
IntronlO- 23544
916
5535.1 4662
CFTR- IntronlO- + AGGAGAAUGGCGUGAACCCGGGAG 24
4663 23545
CFTR- IntronlO- + UUAGGGUGGGAUAUGGAG 18
4664 23546
CFTR- IntronlO- + CUUAGGGUGGGAUAUGGAG 19
4665 23547
CFTR- IntronlO- + UCUUAGGGUGGGAUAUGGAG 20
4666 23548
CFTR- IntronlO- + UUCUUAGGGUGGGAUAUGGAG 21
4667 23549
CFTR- IntronlO- + GUUCUUAGGGUGGGAUAUGGAG 22
4668 23550
CFTR- IntronlO- + UGUUCUUAGGGUGGGAUAUGGAG 23
4669 23551
CFTR- IntronlO- + UUGUUCUUAGGGUGGGAUAUGGAG 24
4670 23552
CFTR- IntronlO- + CUACUGACUAAAACUGAG 18
4671 23553
CFTR- IntronlO- + ACUACUGACUAAAACUGAG 19
4672 23554
CFTR- IntronlO- + UACUACUGACUAAAACUGAG 20
4673 23555
CFTR- IntronlO- + AUACUACUGACUAAAACUGAG 21
4674 23556
CFTR- IntronlO- + AAUACUACUGACUAAAACUGAG 22
4675 23557
CFTR-
+ UAAUACUACUGACUAAAACUGAG 23
IntronlO- 23558
917
5535.1 4676
CFTR- IntronlO- + AUAAUACUACUGACUAAAACUGAG 24
4677 23559
CFTR- IntronlO- + GGCGGAGCUUGCAGUGAG 18
4678 23560
CFTR- IntronlO- + AGGCGGAGCUUGCAGUGAG 19
4679 23561
CFTR- IntronlO- + GAGGCGGAGCUUGCAGUGAG 20
4680 23562
CFTR- IntronlO- + GGAGGCGGAGCUUGCAGUGAG 21
4681 23563
CFTR- IntronlO- + GGGAGGCGGAGCUUGCAGUGAG 22
4682 23564
CFTR- IntronlO- + CGGGAGGCGGAGCUUGCAGUGAG 23
4683 23565
CFTR- IntronlO- + CCGGGAGGCGGAGCUUGCAGUGAG 24
4684 23566
CFTR- IntronlO- + GGCAGAGGUUGCAGUGAG 18
4685 23567
CFTR- IntronlO- + AGGCAGAGGUUGCAGUGAG 19
4686 23568
CFTR- IntronlO- + GAGGCAGAGGUUGCAGUGAG 20
4687 23569
CFTR- IntronlO- + GGAGGCAGAGGUUGCAGUGAG 21
4688 23570
CFTR- IntronlO- + GGGAGGCAGAGGUUGCAGUGAG 22
4689 23571
CFTR-
+ CGGGAGGCAGAGGUUGCAGUGAG 23
IntronlO- 23572
918
5535.1 4690
CFTR- IntronlO- + CCGGGAGGCAGAGGUUGCAGUGAG 24
4691 23573
CFTR- IntronlO- + G ACACCAAAU U U AU UG AG 18
4692 23574
CFTR- IntronlO- + U G ACACCAAAU U U AU UG AG 19
4693 23575
CFTR-
+ CUG ACACCAAAU U U AU U GAG 20
lntronlO-457 19343
CFTR- IntronlO- + CCUGACACCAAAUUUAUUGAG 21
4694 23576
CFTR- IntronlO- + GCCUGACACCAAAUUUAUUGAG 22
4695 23577
CFTR- IntronlO- + AGCCUGACACCAAAUUUAUUGAG 23
4696 23578
CFTR- IntronlO- + CAGCCUGACACCAAAUUUAUUGAG 24
4697 23579
CFTR- IntronlO- + UAAUAGCCUAUUGUUGAG 18
4698 23580
CFTR- IntronlO- + CUAAUAGCCUAUUGUUGAG 19
4699 23581
CFTR- IntronlO- + ACUAAUAGCCUAUUGUUGAG 20
1271 20156
CFTR- IntronlO- + UACUAAUAGCCUAUUGUUGAG 21
4700 23582
CFTR- IntronlO- + CUACUAAUAGCCUAUUGUUGAG 22
4701 23583
CFTR- IntronlO- + ACUACUAAUAGCCUAUUGUUGAG 23
4702 23584
919
5535.1 CFTR- IntronlO- + AACUACUAAUAGCCUAUUGUUGAG 24
4703 23585
CFTR- IntronlO- + CUAGAUGAUUAUUAAUAG 18
4704 23586
CFTR- IntronlO- + CCUAGAUGAUUAUUAAUAG 19
4705 23587
CFTR-
+ GCCUAGAUGAUUAUUAAUAG 20
lntronlO-100 18986
CFTR- IntronlO- + AGCCUAGAUGAUUAUUAAUAG 21
4706 23588
CFTR- IntronlO- + CAGCCUAGAUGAUUAUUAAUAG 22
4707 23589
CFTR- IntronlO- + GCAGCCUAGAUGAUUAUUAAUAG 23
4708 23590
CFTR- IntronlO- + UGCAGCCUAGAUGAUUAUUAAUAG 24
4709 23591
CFTR- IntronlO- + GAAAGUUGUCCAAGAUAG 18
4710 23592
CFTR- IntronlO- + GGAAAGUUGUCCAAGAUAG 19
4711 23593
CFTR-
+ UGGAAAGUUGUCCAAGAUAG 20
lntronlO-459 19345
CFTR- IntronlO- + AUGGAAAGUUGUCCAAGAUAG 21
4712 23594
CFTR- IntronlO- + UAUGGAAAGUUGUCCAAGAUAG 22
4713 23595
CFTR- IntronlO- + AUAUGGAAAGUUGUCCAAGAUAG 23
4714 23596
CFTR- IntronlO- + AAUAUGGAAAGUUGUCCAAGAUAG 24
4715 23597
920
5535.1 CFTR- IntronlO- + CCUCAGCCUCCCAAGUAG 18
4716 23598
CFTR- IntronlO- + ACCUCAGCCUCCCAAGUAG 19
4717 23599
CFTR- IntronlO- + CACCUCAGCCUCCCAAGUAG 20
4718 23600
CFTR- IntronlO- + CCACCUCAGCCUCCCAAGUAG 21
4719 23601
CFTR- IntronlO- + CCCACCUCAGCCUCCCAAGUAG 22
4720 23602
CFTR- IntronlO- + UCCCACCUCAGCCUCCCAAGUAG 23
4721 23603
CFTR- IntronlO- + CUCCCACCUCAGCCUCCCAAGUAG 24
4722 23604
CFTR- IntronlO- + GGUAAGUUAUAGAAGUAG 18
4723 23605
CFTR- IntronlO- + GGG UAAG U U AU AG AAG U AG 19
4724 23606
CFTR- IntronlO- + UGGGUAAGUUAUAGAAGUAG 20
4725 23607
CFTR- IntronlO- + UUGGGUAAGUUAUAGAAGUAG 21
4726 23608
CFTR- IntronlO- + UUUGGGUAAGUUAUAGAAGUAG 22
4727 23609
CFTR- IntronlO- + AUUUGGGUAAGUUAUAGAAGUAG 23
4728 23610
CFTR- IntronlO- + UAUUUGGGUAAGUUAUAGAAGUAG 24
4729 23611
921
5535.1 CFTR- IntronlO- + CCUCAGCCUCCCGAGUAG 18
4730 23612
CFTR- IntronlO- + GCCUCAGCCUCCCGAGUAG 19
4731 23613
CFTR- IntronlO- + UGCCUCAGCCUCCCGAGUAG 20
4732 23614
CFTR- IntronlO- + CUGCCUCAGCCUCCCGAGUAG 21
4733 23615
CFTR- IntronlO- + CCUGCCUCAGCCUCCCGAGUAG 22
4734 23616
CFTR- IntronlO- + UCCUGCCUCAGCCUCCCGAGUAG 23
4735 23617
CFTR- IntronlO- + CUCCUGCCUCAGCCUCCCGAGUAG 24
4736 23618
CFTR- IntronlO- + CUGACUAAAACUGAGUAG 18
4737 23619
CFTR- IntronlO- + ACUGACUAAAACUGAGUAG 19
4738 23620
CFTR- IntronlO- + UACUGACUAAAACUGAGUAG 20
4739 23621
CFTR- IntronlO- + CUACUGACUAAAACUGAGUAG 21
4740 23622
CFTR- IntronlO- + ACUACUGACUAAAACUGAGUAG 22
4741 23623
CFTR- IntronlO- + UACUACUGACUAAAACUGAGUAG 23
4742 23624
CFTR- IntronlO- + AUACUACUGACUAAAACUGAGUAG 24
4743 23625
922
5535.1 CFTR- IntronlO- + U AG AAG G AAAG G AG G U AG 18
4744 23626
CFTR- IntronlO- + G U AG AAGG AAAGG AGG U AG 19
4745 23627
CFTR- IntronlO- + AGUAGAAGGAAAGGAGGUAG 20
4746 23628
CFTR- IntronlO- + GAGUAGAAGGAAAGGAGGUAG 21
4747 23629
CFTR- IntronlO- + UGAGUAGAAGGAAAGGAGGUAG 22
4748 23630
CFTR- IntronlO- + CUGAGUAGAAGGAAAGGAGGUAG 23
4749 23631
CFTR- IntronlO- + ACUGAGUAGAAGGAAAGGAGGUAG 24
4750 23632
CFTR- IntronlO- + AGGGAGAAAUGUAUGUAG 18
4751 23633
CFTR- IntronlO- + CAGGGAGAAAUGUAUGUAG 19
4752 23634
CFTR- IntronlO- + ACAGGGAGAAAUGUAUGUAG 20
4753 23635
CFTR- IntronlO- + AACAGGGAGAAAUGUAUGUAG 21
4754 23636
CFTR- IntronlO- + UAA CAGGGAGAAAUGUAUGUAG 22
4755 23637
CFTR- IntronlO- + AUAACAGGGAGAAAUGUAUGUAG 23
4756 23638
CFTR- IntronlO- + AAUAACAGGGAGAAAUGUAUGUAG 24
4757 23639
923
5535.1 CFTR- IntronlO- + AAAAAU ACAAAAAAU U AG 18
4758 23640
CFTR- IntronlO- + U AAAAAU ACAAAAAAU U AG 19
4759 23641
CFTR- IntronlO- + CU AAAAAU ACAAAAAAU U AG 20
4760 23642
CFTR- IntronlO- + ACU AAAAAU ACAAAAAAU U AG 21
4761 23643
CFTR- IntronlO- + U ACU AAAAAU ACAAAAAAU U AG 22
4762 23644
CFTR- IntronlO- + CU ACU AAAAAU ACAAAAAAU U AG 23
4763 23645
CFTR- IntronlO- + UCUACUAAAAAUACAAAAAAUUAG 24
4764 23646
CFTR- IntronlO- + AAGCUUGUUUGGUUUUAG 18
4765 23647
CFTR- IntronlO- + AAAGCUUGUUUGGUUUUAG 19
4766 23648
CFTR- IntronlO- + GAAAGCUUGUUUGGUUUUAG 20
4767 23649
CFTR- IntronlO- + GGAAAGCUUGUUUGGUUUUAG 21
4768 23650
CFTR- IntronlO- + UGGAAAGCUUGUUUGGUUUUAG 22
4769 23651
CFTR- IntronlO- + AUGGAAAGCUUGUUUGGUUUUAG 23
4770 23652
CFTR- IntronlO- + CAUGGAAAGCUUGUUUGGUUUUAG 24
4771 23653
924
5535.1 CFTR- IntronlO- + AAUUUUUUGUAUUUUUAG 18
4772 23654
CFTR- IntronlO- + UAAUUUUUUGUAUUUUUAG 19
4773 23655
CFTR- IntronlO- + CUAAUUUUUUGUAUUUUUAG 20
4774 23656
CFTR- IntronlO- + GCUAAUUUUUUGUAUUUUUAG 21
4775 23657
CFTR- IntronlO- + GGCUAAUUUUUUGUAUUUUUAG 22
4776 23658
CFTR- IntronlO- + UGGCUAAUUUUUUGUAUUUUUAG 23
4777 23659
CFTR- IntronlO- + CUGGCUAAUUUUUUGUAUUUUUAG 24
4778 23660
CFTR- IntronlO- + ACCAUCCCGGCUAAAACG 18
4779 23661
CFTR- IntronlO- + GACCAUCCCGGCUAAAACG 19
4780 23662
CFTR- IntronlO- + AGACCAUCCCGGCUAAAACG 20
4781 23663
CFTR- IntronlO- + GAGACCAUCCCGGCUAAAACG 21
4782 23664
CFTR- IntronlO- + CGAGACCAUCCCGGCUAAAACG 22
4783 23665
CFTR- IntronlO- + UCGAGACCAUCCCGGCUAAAACG 23
4784 23666
CFTR- IntronlO- + AUCGAGACCAUCCCGGCUAAAACG 24
4785 23667
925
5535.1 CFTR- IntronlO- + AAAAAC AACAAAAAAG CG 18
4786 23668
CFTR- IntronlO- + G A AAAACAAC AAAAAAG CG 19
4787 23669
CFTR- IntronlO- + AG AAAAAC AACAAAAAAG CG 20
4788 23670
CFTR- IntronlO- + U AG AAAAAC AACAAAAAAG CG 21
4789 23671
CFTR- IntronlO- + CUAGAAAAACAACAAAAAAGCG 22
4790 23672
CFTR- IntronlO- + ACUAGAAAAACAACAAAAAAGCG 23
4791 23673
CFTR- IntronlO- + AACUAGAAAAACAACAAAAAAGCG 24
4792 23674
CFTR- IntronlO- + GCAAAGAGUGCAUAAAGG 18
4793 23675
CFTR- IntronlO- + AG C A A AG AG U G C A U A A AG G 19
4794 23676
CFTR- IntronlO- + AAGCAAAGAGUGCAUAAAGG 20
4795 23677
CFTR- IntronlO- + AAAG CAAAG AG UG CAU AAAGG 21
4796 23678
CFTR- IntronlO- + U A A AG C A A AG AG U G C A U A A AG G 22
4797 23679
CFTR- IntronlO- + CUAAAGCAAAGAGUGCAUAAAGG 23
4798 23680
CFTR- IntronlO- + CCUAAAGCAAAGAGUGCAUAAAGG 24
4799 23681
926
5535.1 CFTR- IntronlO- + UAUAAGAAAUGAAACAGG 18
4800 23682
CFTR- IntronlO- + AUAUAAGAAAUGAAACAGG 19
4801 23683
CFTR- IntronlO- + GAUAUAAGAAAUGAAACAGG 20
4802 23684
CFTR- IntronlO- + CGAUAUAAGAAAUGAAACAGG 21
4803 23685
CFTR- IntronlO- + ACGAUAUAAGAAAUGAAACAGG 22
4804 23686
CFTR- IntronlO- + UACGAUAUAAGAAAUGAAACAGG 23
4805 23687
CFTR- IntronlO- + AUACGAUAUAAGAAAUGAAACAGG 24
4806 23688
CFTR- IntronlO- + CCUAUAAGGAAUAACAGG 18
4807 23689
CFTR- IntronlO- + ACCUAUAAGGAAUAACAGG 19
4808 23690
CFTR- IntronlO- + AACCUAUAAGGAAUAACAGG 20
4809 23691
CFTR- IntronlO- + GAACCUAUAAGGAAUAACAGG 21
4810 23692
CFTR- IntronlO- + AGAACCUAUAAGGAAUAACAGG 22
4811 23693
CFTR- IntronlO- + CAGAACCUAUAAGGAAUAACAGG 23
4812 23694
CFTR- IntronlO- + ACAGAACCUAUAAGGAAUAACAGG 24
4813 23695
927
5535.1 CFTR- IntronlO- + AGUAGAAACCUAAUCAGG 18
4814 23696
CFTR- IntronlO- + UAGUAGAAACCUAAUCAGG 19
4815 23697
CFTR- IntronlO- + UUAGUAGAAACCUAAUCAGG 20
4816 23698
CFTR- IntronlO- + UUUAGUAGAAACCUAAUCAGG 21
4817 23699
CFTR- IntronlO- + UUUUAGUAGAAACCUAAUCAGG 22
4818 23700
CFTR- IntronlO- + G U U U U AG U AG AAACCU AAU CAGG 23
4819 23701
CFTR- IntronlO- + GG U U U U AG U AG AAACCU AAU CAGG 24
4820 23702
CFTR- IntronlO- + GAAAGGAGGUAGCAGAGG 18
4821 23703
CFTR- IntronlO- + GGAAAGGAGGUAGCAGAGG 19
4822 23704
CFTR- IntronlO- + AGGAAAGGAGGUAGCAGAGG 20
4823 23705
CFTR- IntronlO- + AAGGAAAGGAGGUAGCAGAGG 21
4824 23706
CFTR- IntronlO- + GAAGGAAAGGAGGUAGCAGAGG 22
4825 23707
CFTR- IntronlO- + AGAAGGAAAGGAGGUAGCAGAGG 23
4826 23708
CFTR- IntronlO- + UAGAAGGAAAGGAGGUAGCAGAGG 24
4827 23709
928
5535.1 CFTR- IntronlO- + GUUACAUAAAAAGAGAGG 18
4828 23710
CFTR- IntronlO- + UGUU ACAU AAAAAG AGAGG 19
4829 23711
CFTR-
+ UUGUU ACAU AAAAAG AGAGG 20
lntronlO-469 19355
CFTR- IntronlO- + AUUGUUACAUAAAAAGAGAGG 21
4830 23712
CFTR- IntronlO- + UAUUGUUACAUAAAAAGAGAGG 22
4831 23713
CFTR- IntronlO- + AU AU UG U U ACAU AAAAAG AG AGG 23
4832 23714
CFTR- IntronlO- + CAU AU UG U U ACAU AAAAAG AG AGG 24
4833 23715
CFTR- IntronlO- + UGGCGUGAACCCGGGAGG 18
4834 23716
CFTR- IntronlO- + AUGGCGUGAACCCGGGAGG 19
4835 23717
CFTR- IntronlO- + AAUGGCGUGAACCCGGGAGG 20
1287 20172
CFTR- IntronlO- + GAAUGGCGUGAACCCGGGAGG 21
4836 23718
CFTR- IntronlO- + AGAAUGGCGUGAACCCGGGAGG 22
4837 23719
CFTR- IntronlO- + GAGAAUGGCGUGAACCCGGGAGG 23
4838 23720
CFTR- IntronlO- + GGAGAAUGGCGUGAACCCGGGAGG 24
4839 23721
CFTR-
+ UUGCUUGAGCCCGGGAGG 18
IntronlO- 23722
929
5535.1 4840
CFTR- IntronlO- + AUUGCUUGAGCCCGGGAGG 19
4841 23723
CFTR- IntronlO- + AAUUGCUUGAGCCCGGGAGG 20
4842 23724
CFTR- IntronlO- + GAAUUGCUUGAGCCCGGGAGG 21
4843 23725
CFTR- IntronlO- + AGAAUUGCUUGAGCCCGGGAGG 22
4844 23726
CFTR- IntronlO- + GAGAAUUGCUUGAGCCCGGGAGG 23
4845 23727
CFTR- IntronlO- + GGAGAAUUGCUUGAGCCCGGGAGG 24
4846 23728
CFTR- IntronlO- + UCCCAGCUACUUGGGAGG 18
4847 23729
CFTR- IntronlO- + GUCCCAGCUACUUGGGAGG 19
4848 23730
CFTR- IntronlO- + AGUCCCAGCUACUUGGGAGG 20
4849 23731
CFTR- IntronlO- + UAGUCCCAGCUACUUGGGAGG 21
4850 23732
CFTR- IntronlO- + GUAGUCCCAGCUACUUGGGAGG 22
4851 23733
CFTR- IntronlO- + UGUAGUCCCAGCUACUUGGGAGG 23
4852 23734
CFTR- IntronlO- + CUGUAGUCCCAGCUACUUGGGAGG 24
4853 23735
CFTR-
+ UCCCAACACUUUGGGAGG 18
IntronlO- 23736
930
5535.1 4854
CFTR- IntronlO- + AUCCCAACACUUUGGGAGG 19
4855 23737
CFTR- IntronlO- + AAUCCCAACACUUUGGGAGG 20
4856 23738
CFTR- IntronlO- + UAAUCCCAACACUUUGGGAGG 21
4857 23739
CFTR- IntronlO- + GU AAUCCCAACACUUUGGGAGG 22
4858 23740
CFTR- IntronlO- + UGUAAUCCCAACACUUUGGGAGG 23
4859 23741
CFTR- IntronlO- + CUGUAAUCCCAACACUUUGGGAGG 24
4860 23742
CFTR- IntronlO- + ACCCAGCACUUUGGGAGG 18
4861 23743
CFTR- IntronlO- + AACCCAGCACUUUGGGAGG 19
4862 23744
CFTR- IntronlO- + AAACCCAGCACUUUGGGAGG 20
4863 23745
CFTR- IntronlO- + UAAACCCAGCACUUUGGGAGG 21
4864 23746
CFTR- IntronlO- + AUAAACCCAGCACUUUGGGAGG 22
4865 23747
CFTR- IntronlO- + UAUAAACCCAGCACUUUGGGAGG 23
4866 23748
CFTR- IntronlO- + CUAUAAACCCAGCACUUUGGGAGG 24
4867 23749
CFTR-
+ UCCCAGCACUUUGGGAGG 18
IntronlO- 23750
931
5535.1 4868
CFTR- IntronlO- + AUCCCAGCACUUUGGGAGG 19
4869 23751
CFTR- IntronlO- + AAUCCCAGCACUUUGGGAGG 20
4870 23752
CFTR- IntronlO- + UAAUCCCAGCACUUUGGGAGG 21
4871 23753
CFTR- IntronlO- + GU AAUCCCAGCACUUUGGGAGG 22
4872 23754
CFTR- IntronlO- + UGUAAUCCCAGCACUUUGGGAGG 23
4873 23755
CFTR- IntronlO- + CUGUAAUCCCAGCACUUUGGGAGG 24
4874 23756
CFTR- IntronlO- + UUCUCACAGUUCUGGAGG 18
4875 23757
CFTR- IntronlO- + UUUCUCACAGUUCUGGAGG 19
4876 23758
CFTR- IntronlO- + AUUUCUCACAGUUCUGGAGG 20
4877 23759
CFTR- IntronlO- + UAUUUCUCACAGUUCUGGAGG 21
4878 23760
CFTR- IntronlO- + UUAUUUCUCACAGUUCUGGAGG 22
4879 23761
CFTR- IntronlO- + UUUAUUUCUCACAGUUCUGGAGG 23
4880 23762
CFTR- IntronlO- + AUUUAUUUCUCACAGUUCUGGAGG 24
4881 23763
CFTR-
+ CAGCUACUUGGGAGGCUGAGG 21
IntronlO- 23764
932
5535.1 4882
CFTR- IntronlO- + CCAGCUACUUGGGAGGCUGAGG 22
4883 23765
CFTR- IntronlO- + CCCAGCUACUUGGGAGGCUGAGG 23
4884 23766
CFTR- IntronlO- + UCCCAGCUACUUGGGAGGCUGAGG 24
4885 23767
CFTR- IntronlO- + CUACUUGGGAGGGUGAGG 18
4886 23768
CFTR- IntronlO- + GCUACUUGGGAGGGUGAGG 19
4887 23769
CFTR- IntronlO- + AGCUACUUGGGAGGGUGAGG 20
4888 23770
CFTR- IntronlO- + CAGCUACUUGGGAGGGUGAGG 21
4889 23771
CFTR- IntronlO- + CCAGCUACUUGGGAGGGUGAGG 22
4890 23772
CFTR- IntronlO- + CCCAGCUACUUGGGAGGGUGAGG 23
4891 23773
CFTR- IntronlO- + UCCCAGCUACUUGGGAGGGUGAGG 24
4892 23774
CFTR- IntronlO- + GGUUAAGUUGUUCUUAGG 18
4893 23775
CFTR- IntronlO- + AGGUUAAGUUGUUCUUAGG 19
4894 23776
CFTR- IntronlO- + CAGGUUAAGUUGUUCUUAGG 20
4895 23777
CFTR-
+ CCAGGUUAAGUUGUUCUUAGG 21
IntronlO- 23778
933
5535.1 4896
CFTR- IntronlO- + GCCAGGUUAAGUUGUUCUUAGG 22
4897 23779
CFTR- IntronlO- + UGCCAGGUUAAGUUGUUCUUAGG 23
4898 23780
CFTR- IntronlO- + AUGCCAGGUUAAGUUGUUCUUAGG 24
4899 23781
CFTR- IntronlO- + CUCACAUGGCAGAAAGGG 18
4900 23782
CFTR- IntronlO- + UCUCACAUGGCAGAAAGGG 19
4901 23783
CFTR- IntronlO- + UUCUCACAUGGCAGAAAGGG 20
4902 23784
CFTR- IntronlO- + GUUCUCACAUGGCAGAAAGGG 21
4903 23785
CFTR- IntronlO- + UGUUCUCACAUGGCAGAAAGGG 22
4904 23786
CFTR- IntronlO- + GUGUUCUCACAUGGCAGAAAGGG 23
4905 23787
CFTR- IntronlO- + UGUGUUCUCACAUGGCAGAAAGGG 24
4906 23788
CFTR- IntronlO- + AACAUAUGAAUGGCAGGG 18
4907 23789
CFTR- IntronlO- + CAACAUAUGAAUGGCAGGG 19
4908 23790
CFTR- IntronlO- + UCAACAUAUGAAUGGCAGGG 20
4909 23791
CFTR-
+ UUCAACAUAUGAAUGGCAGGG 21
IntronlO- 23792
934
5535.1 4910
CFTR- IntronlO- + UUUCAACAUAUGAAUGGCAGGG 22
4911 23793
CFTR- IntronlO- + AUUUCAACAUAUGAAUGGCAGGG 23
4912 23794
CFTR- IntronlO- + GAUUUCAACAUAUGAAUGGCAGGG 24
4913 23795
CFTR- IntronlO- + UUGGUACAAAUUUCAGGG 18
4914 23796
CFTR- IntronlO- + AUUGGUACAAAUUUCAGGG 19
4915 23797
CFTR- IntronlO- + AAUUGGUACAAAUUUCAGGG 20
4916 23798
CFTR- IntronlO- + GAAUUGGUACAAAUUUCAGGG 21
4917 23799
CFTR- IntronlO- + CGAAUUGGUACAAAUUUCAGGG 22
4918 23800
CFTR- IntronlO- + ACGAAUUGGUACAAAUUUCAGGG 23
4919 23801
CFTR- IntronlO- + UACGAAUUGGUACAAAUUUCAGGG 24
4920 23802
CFTR- IntronlO- + AUUUCAACAUAUGAAUGG 18
4921 23803
CFTR- IntronlO- + GAUUUCAACAUAUGAAUGG 19
4922 23804
CFTR- IntronlO- + GGAUUUCAACAUAUGAAUGG 20
4923 23805
CFTR-
+ AGGAUUUCAACAUAUGAAUGG 21
IntronlO- 23806
935
5535.1 4924
CFTR- IntronlO- + UAGGAUUUCAACAUAUGAAUGG 22
4925 23807
CFTR- IntronlO- + UUAGGAUUUCAACAUAUGAAUGG 23
4926 23808
CFTR- IntronlO- + AUUAGGAUUUCAACAUAUGAAUGG 24
4927 23809
CFTR- IntronlO- + UGCUGUGUUCUCACAUGG 18
4928 23810
CFTR- IntronlO- + CUGCUGUGUUCUCACAUGG 19
4929 23811
CFTR- IntronlO- + CCUGCUGUGUUCUCACAUGG 20
4930 23812
CFTR- IntronlO- + UCCUGCUGUGUUCUCACAUGG 21
4931 23813
CFTR- IntronlO- + UUCCUGCUGUGUUCUCACAUGG 22
4932 23814
CFTR- IntronlO- + CUUCCUGCUGUGUUCUCACAUGG 23
4933 23815
CFTR- IntronlO- + UCUUCCUGCUGUGUUCUCACAUGG 24
4934 23816
CFTR- IntronlO- + AUUGGCUACCUUGGUUGG 18
4935 23817
CFTR- IntronlO- + GAUUGGCUACCUUGGUUGG 19
4936 23818
CFTR- IntronlO- + GGAUUGGCUACCUUGGUUGG 20
4937 23819
CFTR-
+ UGGAUUGGCUACCUUGGUUGG 21
IntronlO- 23820
936
5535.1 CFTR- IntronlO- + CUGGAUUGGCUACCUUGGUUGG 22
4939 23821
CFTR- IntronlO- + CCUGGAUUGGCUACCUUGGUUGG 23
4940 23822
CFTR- IntronlO- + ACCUGGAUUGGCUACCUUGGUUGG 24
4941 23823
CFTR- IntronlO- + UGGUUGGAUGAGGGAAUG 18
4942 23824
CFTR- IntronlO- + UUGGUUGGAUGAGGGAAUG 19
4943 23825
CFTR- IntronlO- + CUUGGUUGGAUGAGGGAAUG 20
4944 23826
CFTR- IntronlO- + CCUUGGUUGGAUGAGGGAAUG 21
4945 23827
CFTR- IntronlO- + ACCUUGGUUGGAUGAGGGAAUG 22
4946 23828
CFTR- IntronlO- + UACCUUGGUUGGAUGAGGGAAUG 23
4947 23829
CFTR- IntronlO- + CUACCUUGGUUGGAUGAGGGAAUG 24
4948 23830
CFTR- IntronlO- + GAAAGCAGUGUUAUAAUG 18
4949 23831
CFTR- IntronlO- + UGAAAGCAGUGUUAUAAUG 19
4950 23832
CFTR- IntronlO- + CUGAAAGCAGUGUUAUAAUG 20
4951 23833
CFTR-
+ CCUGAAAGCAGUGUUAUAAUG 21
IntronlO- 23834
937
5535.1 4952
CFTR- IntronlO- + UCCUGAAAGCAGUGUUAUAAUG 22
4953 23835
CFTR- IntronlO- + CUCCUGAAAGCAGUGUUAUAAUG 23
4954 23836
CFTR- IntronlO- + GCUCCUGAAAGCAGUGUUAUAAUG 24
4955 23837
CFTR- IntronlO- + GGCAUUGCACUAAACAUG 18
4956 23838
CFTR- IntronlO- + UGGCAUUGCACUAAACAUG 19
4957 23839
CFTR- IntronlO- + AUGGCAUUGCACUAAACAUG 20
4958 23840
CFTR- IntronlO- + UAUGGCAUUGCACUAAACAUG 21
4959 23841
CFTR- IntronlO- + UUAUGGCAUUGCACUAAACAUG 22
4960 23842
CFTR- IntronlO- + UUUAUGGCAUUGCACUAAACAUG 23
4961 23843
CFTR- IntronlO- + GUUUAUGGCAUUGCACUAAACAUG 24
4962 23844
CFTR- IntronlO- + ACCAUCCUGGCCAACAUG 18
4963 23845
CFTR- IntronlO- + UACCAUCCUGGCCAACAUG 19
4964 23846
CFTR- IntronlO- + AUACCAUCCUGGCCAACAUG 20
4965 23847
CFTR-
+ AAUACCAUCCUGGCCAACAUG 21
IntronlO- 23848
938
5535.1 4966
CFTR- IntronlO- + CAAUACCAUCCUGGCCAACAUG 22
4967 23849
CFTR- IntronlO- + UCAAUACCAUCCUGGCCAACAUG 23
4968 23850
CFTR- IntronlO- + AUCAAUACCAUCCUGGCCAACAUG 24
4969 23851
CFTR- IntronlO- + A A A AG AUAAGUGAAGAUG 18
4970 23852
CFTR- IntronlO- + AAAAAGAUAAGUGAAGAUG 19
4971 23853
CFTR- IntronlO- + A A A A A AG AUAAGUGAAGAUG 20
4972 23854
CFTR- IntronlO- + GAAAAAAGAUAAGUGAAGAUG 21
4973 23855
CFTR- IntronlO- + AGAAAAAAGAUAAGUGAAGAUG 22
4974 23856
CFTR- IntronlO- + UAGAAAAAAGAUAAGUGAAGAUG 23
4975 23857
CFTR- IntronlO- + GUAGAAAAAAGAUAAGUGAAGAUG 24
4976 23858
CFTR- IntronlO- + GGCUACCUUGGUUGGAUG 18
4977 23859
CFTR- IntronlO- + UGGCUACCUUGGUUGGAUG 19
4978 23860
CFTR-
+ UUGGCUACCUUGGUUGGAUG 20
lntronlO-481 19367
CFTR- IntronlO- + AUUGGCUACCUUGGUUGGAUG 21
4979 23861
939
5535.1 CFTR- IntronlO- + GAUUGGCUACCUUGGUUGGAUG 22
4980 23862
CFTR- IntronlO- + GGAUUGGCUACCUUGGUUGGAUG 23
4981 23863
CFTR- IntronlO- + UGGAUUGGCUACCUUGGUUGGAUG 24
4982 23864
CFTR- IntronlO- + UUCUUAGGGUGGGAUAUG 18
4983 23865
CFTR- IntronlO- + GUUCUUAGGGUGGGAUAUG 19
4984 23866
CFTR- IntronlO- + UGUUCUUAGGGUGGGAUAUG 20
4985 23867
CFTR- IntronlO- + UUGUUCUUAGGGUGGGAUAUG 21
4986 23868
CFTR- IntronlO- + GUUGUUCUUAGGGUGGGAUAUG 22
4987 23869
CFTR- IntronlO- + AGUUGUUCUUAGGGUGGGAUAUG 23
4988 23870
CFTR- IntronlO- + AAGUUGUUCUUAGGGUGGGAUAUG 24
4989 23871
CFTR- IntronlO- + UAAAAGCUGUUUCGUAUG 18
4990 23872
CFTR- IntronlO- + UUAAAAGCUGUUUCGUAUG 19
4991 23873
CFTR- IntronlO- + UUUAAAAGCUGUUUCGUAUG 20
4992 23874
CFTR- IntronlO- + UUUUAAAAGCUGUUUCGUAUG 21
4993 23875
940
5535.1 CFTR- IntronlO- + GUUUUAAAAGCUGUUUCGUAUG 22
4994 23876
CFTR- IntronlO- + UGUUUUAAAAGCUGUUUCGUAUG 23
4995 23877
CFTR- IntronlO- + UUGUUUUAAAAGCUGUUUCGUAUG 24
4996 23878
CFTR- IntronlO- + UAUGUAGGAAAACAACUG 18
4997 23879
CFTR- IntronlO- + GUAUGUAGGAAAACAACUG 19
4998 23880
CFTR- IntronlO- + CGUAUGUAGGAAAACAACUG 20
4999 23881
CFTR- IntronlO- + UCGUAUGUAGGAAAACAACUG 21
5000 23882
CFTR- IntronlO- + UUCGUAUGUAGGAAAACAACUG 22
5001 23883
CFTR- IntronlO- + UUUCGUAUGUAGGAAAACAACUG 23
5002 23884
CFTR- IntronlO- + GUUUCGUAUGUAGGAAAACAACUG 24
5003 23885
CFTR- IntronlO- + GAAACUCCCCACACACUG 18
5004 23886
CFTR- IntronlO- + UGAAACUCCCCACACACUG 19
5005 23887
CFTR- IntronlO- + CUGAAACUCCCCACACACUG 20
5006 23888
CFTR- IntronlO- + ACUGAAACUCCCCACACACUG 21
5007 23889
941
5535.1 CFTR- IntronlO- + GACUGAAACUCCCCACACACUG 22
5008 23890
CFTR- IntronlO- + GGACUGAAACUCCCCACACACUG 23
5009 23891
CFTR- IntronlO- + AGGACUGAAACUCCCCACACACUG 24
5010 23892
CFTR- IntronlO- + GCAAUAUGCAAUUUACUG 18
5011 23893
CFTR- IntronlO- + UGCAAUAUGCAAUUUACUG 19
5012 23894
CFTR- IntronlO- + CUGCAAUAUGCAAUUUACUG 20
5013 23895
CFTR- IntronlO- + ACUGCAAUAUGCAAUUUACUG 21
5014 23896
CFTR- IntronlO- + UACUGCAAUAUGCAAUUUACUG 22
5015 23897
CFTR- IntronlO- + UUACUGCAAUAUGCAAUUUACUG 23
5016 23898
CFTR- IntronlO- + UUUACUGCAAUAUGCAAUUUACUG 24
5017 23899
CFTR- IntronlO- + CAUCUGUUAGUAAUGCUG 18
5018 23900
CFTR- IntronlO- + UCAUCUGUUAGUAAUGCUG 19
5019 23901
CFTR-
+ AUCAUCUGUUAGUAAUGCUG 20
lntronlO-485 19371
CFTR- IntronlO- + UAUCAUCUGUUAGUAAUGCUG 21
5020 23902
CFTR-
+ AUAUCAUCUGUUAGUAAUGCUG 22
IntronlO- 23903
942
5535.1 5021
CFTR- IntronlO- + AAUAUCAUCUGUUAGUAAUGCUG 23
5022 23904
CFTR- IntronlO- + UAAUAUCAUCUGUUAGUAAUGCUG 24
5023 23905
CFTR- IntronlO- + AAUUAGCCGGGCGUAGUG 18
5024 23906
CFTR- IntronlO- + AAAUUAGCCGGGCGUAGUG 19
5025 23907
CFTR- IntronlO- + AAAAUUAGCCGGGCGUAGUG 20
5026 23908
CFTR- IntronlO- + AAAAAUUAGCCGGGCGUAGUG 21
5027 23909
CFTR- IntronlO- + AAAAAAUUAGCCGGGCGUAGUG 22
5028 23910
CFTR- IntronlO- + CAAAAAAUUAGCCGGGCGUAGUG 23
5029 23911
CFTR- IntronlO- + ACAAAAAAUUAGCCGGGCGUAGUG 24
5030 23912
CFTR- IntronlO- + UCUGUUAGUAAUGCUGUG 18
5031 23913
CFTR- IntronlO- + AUCUGUUAGUAAUGCUGUG 19
5032 23914
CFTR-
+ CAUCUGUUAGUAAUGCUGUG 20
lntronlO-490 19376
CFTR- IntronlO- + UCAUCUGUUAGUAAUGCUGUG 21
5033 23915
CFTR- IntronlO- + AUCAUCUGUUAGUAAUGCUGUG 22
5034 23916
943
5535.1 CFTR- IntronlO- + UAUCAUCUGUUAGUAAUGCUGUG 23
5035 23917
CFTR- IntronlO- + AUAUCAUCUGUUAGUAAUGCUGUG 24
5036 23918
CFTR- IntronlO- + AUUCAAAAAAUAUUUGUG 18
5037 23919
CFTR- IntronlO- + UAUUCAAAAAAUAUUUGUG 19
5038 23920
CFTR- IntronlO- + CUAUUCAAAAAAUAUUUGUG 20
5039 23921
CFTR- IntronlO- + UCUAUUCAAAAAAUAUUUGUG 21
5040 23922
CFTR- IntronlO- + AUCUAUUCAAAAAAUAUUUGUG 22
5041 23923
CFTR- IntronlO- + AAUCUAUUCAAAAAAUAUUUGUG 23
5042 23924
CFTR- IntronlO- + UAAUCUAUUCAAAAAAUAUUUGUG 24
5043 23925
CFTR- IntronlO- + CUAUUCAAAAAAUAUUUG 18
5044 23926
CFTR- IntronlO- + UCUAUUCAAAAAAUAUUUG 19
5045 23927
CFTR- IntronlO- + AUCUAUUCAAAAAAUAUUUG 20
1323 20208
CFTR- IntronlO- + AAU CU AU U CAAAAAAU AU U UG 21
5046 23928
CFTR- IntronlO- + UAAUCUAUU CAAAAAAU AU U UG 22
5047 23929
944
5535.1 CFTR- IntronlO- + CUAAUCUAUUCAAAAAAUAUUUG 23
5048 23930
CFTR- IntronlO- + GCUAAUCUAUUCAAAAAAUAUUUG 24
5049 23931
CFTR- IntronlO- + CUUAUAUUUUUAUUUUUG 18
5050 23932
CFTR- IntronlO- + ACUUAUAUUUUUAUUUUUG 19
5051 23933
CFTR- IntronlO- + CACUUAUAUUUUUAUUUUUG 20
5052 23934
CFTR- IntronlO- + CCACUUAUAUUUUUAUUUUUG 21
5053 23935
CFTR- IntronlO- + GCCACUUAUAUUUUUAUUUUUG 22
5054 23936
CFTR- IntronlO- + GGCCACUUAUAUUUUUAUUUUUG 23
5055 23937
CFTR- IntronlO- + AGGCCACUUAUAUUUUUAUUUUUG 24
5056 23938
CFTR- IntronlO- + UUUUGUUUGUGUUUUUUG 18
5057 23939
CFTR- IntronlO- + CUUUUGUUUGUGUUUUUUG 19
5058 23940
CFTR- IntronlO- + UCUUUUGUUUGUGUUUUUUG 20
5059 23941
CFTR- IntronlO- + UUCUUUUGUUUGUGUUUUUUG 21
5060 23942
CFTR- IntronlO- + UUUCUUUUGUUUGUGUUUUUUG 22
5061 23943
945
5535.1 CFTR- IntronlO- + UUUUCUUUUGUUUGUGUUUUUUG 23
5062 23944
CFTR- IntronlO- + AUUUUCUUUUGUUUGUGUUUUUUG 24
5063 23945
CFTR- IntronlO- + CUAAAAUGACAAUCAAAU 18
5064 23946
CFTR- IntronlO- + GCUAAAAUGACAAUCAAAU 19
5065 23947
CFTR-
+ AGCUAAAAUGACAAUCAAAU 20
lntronlO-498 19384
CFTR- IntronlO- + CAGCUAAAAUGACAAUCAAAU 21
5066 23948
CFTR- IntronlO- + ACAGCUAAAAUGACAAUCAAAU 22
5067 23949
CFTR- IntronlO- + CACAGCUAAAAUGACAAUCAAAU 23
5068 23950
CFTR- IntronlO- + CCACAGCUAAAAUGACAAUCAAAU 24
5069 23951
CFTR- IntronlO- + AACAAUACAAAGAUAAAU 18
5070 23952
CFTR- IntronlO- + UAACAAUACAAAGAUAAAU 19
5071 23953
CFTR- IntronlO- + U UAACAAUACAAAGAUAAAU 20
5072 23954
CFTR- IntronlO- + U U UAACAAUACAAAGAUAAAU 21
5073 23955
CFTR- IntronlO- + AU U UAACAAUACAAAGAUAAAU 22
5074 23956
CFTR-
+ G AU U UAACAAUACAAAGAUAAAU 23
IntronlO- 23957
946
5535.1 5075
CFTR- IntronlO- + AG AU U U AACAAU ACAAAG AU AAAU 24
5076 23958
CFTR- IntronlO- + GUUAUAUGUCCUGACAAU 18
5077 23959
CFTR- IntronlO- + UGUUAUAUGUCCUGACAAU 19
5078 23960
CFTR- IntronlO- + AUGUUAUAUGUCCUGACAAU 20
5079 23961
CFTR- IntronlO- + UAUGUUAUAUGUCCUGACAAU 21
5080 23962
CFTR- IntronlO- + AUAUGUUAUAUGUCCUGACAAU 22
5081 23963
CFTR- IntronlO- + AAUAUGUUAUAUGUCCUGACAAU 23
5082 23964
CFTR- IntronlO- + AAAUAUGUUAUAUGUCCUGACAAU 24
5083 23965
CFTR- IntronlO- + GUGCUAUUUAAACAGAAU 18
5084 23966
CFTR- IntronlO- + AGUGCUAUUUAAACAGAAU 19
5085 23967
CFTR- IntronlO- + CAG UG CU AU U U AAACAG AAU 20
5086 23968
CFTR- IntronlO- + CCAGUGCUAUU U AAACAG AAU 21
5087 23969
CFTR- IntronlO- + UCCAGUGCUAUUUAAACAGAAU 22
5088 23970
CFTR-
+ CUCCAGUGCUAUUUAAACAGAAU 23
IntronlO- 23971
947
5535.1 5089
CFTR- IntronlO- + ACU CCAG UG CU AU U U AAACAG AAU 24
5090 23972
CFTR- IntronlO- + GUCCUCUGUGCUUUGAAU 18
5091 23973
CFTR- IntronlO- + AGUCCUCUGUGCUUUGAAU 19
5092 23974
CFTR- IntronlO- + AAGUCCUCUGUGCUUUGAAU 20
5093 23975
CFTR- IntronlO- + CAAGUCCUCUGUGCUUUGAAU 21
5094 23976
CFTR- IntronlO- + GCAAGUCCUCUGUGCUUUGAAU 22
5095 23977
CFTR- IntronlO- + UGCAAGUCCUCUGUGCUUUGAAU 23
5096 23978
CFTR- IntronlO- + GUGCAAGUCCUCUGUGCUUUGAAU 24
5097 23979
CFTR- IntronlO- + CCAAGCAGUAGAAAUAAU 18
5098 23980
CFTR- IntronlO- + UCCAAGCAGUAGAAAUAAU 19
5099 23981
CFTR- IntronlO- + UUCCAAGCAGUAGAAAUAAU 20
5100 23982
CFTR- IntronlO- + A U U C C A AG C AG U AG A A A U A A U 21
5101 23983
CFTR- IntronlO- + AAUUCCAAGCAGUAGAAAUAAU 22
5102 23984
CFTR-
+ AAAUUCCAAGCAGUAGAAAUAAU 23
IntronlO- 23985
948
5535.1 5103
CFTR- IntronlO- + AAAAUUCCAAGCAGUAGAAAUAAU 24
5104 23986
CFTR- IntronlO- + U U U U AG U AG AAACCU AAU 18
5105 23987
CFTR- IntronlO- + GUUUUAGUAGAAACCUAAU 19
5106 23988
CFTR- IntronlO- + GG U U U U AG U AG AAACCU AAU 20
5107 23989
CFTR- IntronlO- + UGGUUUUAGUAGAAACCUAAU 21
5108 23990
CFTR- IntronlO- + UUGGUUUUAGUAGAAACCUAAU 22
5109 23991
CFTR- IntronlO- + UUUGGUUUUAGUAGAAACCUAAU 23
5110 23992
CFTR- IntronlO- + GUUUGGUUUUAGUAGAAACCUAAU 24
5111 23993
CFTR- IntronlO- + GCCUAGAUGAUUAUUAAU 18
5112 23994
CFTR- IntronlO- + AGCCUAGAUGAUUAUUAAU 19
5113 23995
CFTR-
+ CAGCCUAGAUGAUUAUUAAU 20
lntronlO-503 19389
CFTR- IntronlO- + GCAGCCUAGAUGAUUAUUAAU 21
5114 23996
CFTR- IntronlO- + UGCAGCCUAGAUGAUUAUUAAU 22
5115 23997
CFTR- IntronlO- + UUGCAGCCUAGAUGAUUAUUAAU 23
5116 23998
949
5535.1 CFTR- IntronlO- + UUUGCAGCCUAGAUGAUUAUUAAU 24
5117 23999
CFTR- IntronlO- + UUACAAUUCUUAUUACAU 18
5118 24000
CFTR- IntronlO- + UUUACAAUUCUUAUUACAU 19
5119 24001
CFTR- IntronlO- + UUUUACAAUUCUUAUUACAU 20
1333 20218
CFTR- IntronlO- + AUUUUACAAUUCUUAUUACAU 21
5120 24002
CFTR- IntronlO- + AAUUUUACAAUUCUUAUUACAU 22
5121 24003
CFTR- IntronlO- + AAAU U U U ACAAU U CU U AU U ACAU 23
5122 24004
CFTR- IntronlO- + UAAAUUUUACAAUUCUUAUUACAU 24
5123 24005
CFTR- IntronlO- + AGGUAUAGUCAGUCCCAU 18
5124 24006
CFTR- IntronlO- + CAGGUAUAGUCAGUCCCAU 19
5125 24007
CFTR- IntronlO- + ACAGGUAUAGUCAGUCCCAU 20
5126 24008
CFTR- IntronlO- + GACAGGUAUAGUCAGUCCCAU 21
5127 24009
CFTR- IntronlO- + AGACAGGUAUAGUCAGUCCCAU 22
5128 24010
CFTR- IntronlO- + CAGACAGGUAUAGUCAGUCCCAU 23
5129 24011
950
5535.1 CFTR- IntronlO- + CCAGACAGGUAUAGUCAGUCCCAU 24
5130 24012
CFTR- IntronlO- + AACAUAGAGAAAACUCAU 18
5131 24013
CFTR- IntronlO- + AAACAUAGAGAAAACUCAU 19
5132 24014
CFTR- IntronlO- + AAAACAUAGAGAAAACUCAU 20
5133 24015
CFTR- IntronlO- + UAAAACAUAGAGAAAACUCAU 21
5134 24016
CFTR- IntronlO- + AUAAAACAUAGAGAAAACUCAU 22
5135 24017
CFTR- IntronlO- + AAUAAAACAUAGAGAAAACUCAU 23
5136 24018
CFTR- IntronlO- + AAAUAAAACAUAGAGAAAACUCAU 24
5137 24019
CFTR- IntronlO- + CUAUUUUCCCUAUAAGAU 18
5138 24020
CFTR- IntronlO- + ACUAUUUUCCCUAUAAGAU 19
5139 24021
CFTR- IntronlO- + UACUAUUUUCCCUAUAAGAU 20
5140 24022
CFTR- IntronlO- + AUACUAUUUUCCCUAUAAGAU 21
5141 24023
CFTR- IntronlO- + CAUACUAUUUUCCCUAUAAGAU 22
5142 24024
CFTR- IntronlO- + ACAUACUAUUUUCCCUAUAAGAU 23
5143 24025
951
5535.1 CFTR- IntronlO- + GACAUACUAUUUUCCCUAUAAGAU 24
5144 24026
CFTR- IntronlO- + AAUGGAAAAUGGACAGAU 18
5145 24027
CFTR- IntronlO- + GAAUGGAAAAUGGACAGAU 19
5146 24028
CFTR- IntronlO- + AGAAUGGAAAAUGGACAGAU 20
5147 24029
CFTR- IntronlO- + GAGAAUGGAAAAUGGACAGAU 21
5148 24030
CFTR- IntronlO- + GGAGAAUGGAAAAUGGACAGAU 22
5149 24031
CFTR- IntronlO- + AGGAGAAUGGAAAAUGGACAGAU 23
5150 24032
CFTR- IntronlO- + CAGGAGAAUGGAAAAUGGACAGAU 24
5151 24033
CFTR- IntronlO- + UUGUUCUUAGGGUGGGAU 18
5152 24034
CFTR- IntronlO- + GUUGUUCUUAGGGUGGGAU 19
5153 24035
CFTR- IntronlO- + AGUUGUUCUUAGGGUGGGAU 20
5154 24036
CFTR- IntronlO- + AAGUUGUUCUUAGGGUGGGAU 21
5155 24037
CFTR- IntronlO- + UAAGUUGUUCUUAGGGUGGGAU 22
5156 24038
CFTR- IntronlO- + UUAAGUUGUUCUUAGGGUGGGAU 23
5157 24039
952
5535.1 CFTR- IntronlO- + GUUAAGUUGUUCUUAGGGUGGGAU 24
5158 24040
CFTR- IntronlO- + UGGCUACCUUGGUUGGAU 18
5159 24041
CFTR- IntronlO- + UUGGCUACCUUGGUUGGAU 19
5160 24042
CFTR- IntronlO- + AUUGGCUACCUUGGUUGGAU 20
5161 24043
CFTR- IntronlO- + GAUUGGCUACCUUGGUUGGAU 21
5162 24044
CFTR- IntronlO- + GGAUUGGCUACCUUGGUUGGAU 22
5163 24045
CFTR- IntronlO- + UGGAUUGGCUACCUUGGUUGGAU 23
5164 24046
CFTR- IntronlO- + CUGGAUUGGCUACCUUGGUUGGAU 24
5165 24047
CFTR- IntronlO- + AAACAUGAUGAAAAAUAU 18
5166 24048
CFTR- IntronlO- + UAAACAUGAUGAAAAAUAU 19
5167 24049
CFTR- IntronlO- + CUAAACAUGAUGAAAAAUAU 20
5168 24050
CFTR- IntronlO- + ACUAAACAUGAUGAAAAAUAU 21
5169 24051
CFTR- IntronlO- + CACUAAACAUGAUGAAAAAUAU 22
5170 24052
CFTR- IntronlO- + GCACUAAACAUGAUGAAAAAUAU 23
5171 24053
953
5535.1 CFTR- IntronlO- + UGCACUAAACAUGAUGAAAAAUAU 24
5172 24054
CFTR- IntronlO- + UUUGUGUUAACAAAAUAU 18
5173 24055
CFTR- IntronlO- + CUUUGUGUUAACAAAAUAU 19
5174 24056
CFTR-
+ UCUUUGUGUUAACAAAAUAU 20
lntronlO-506 19392
CFTR- IntronlO- + UUCUUUGUGUUAACAAAAUAU 21
5175 24057
CFTR- IntronlO- + GUUCUUUGUGUUAACAAAAUAU 22
5176 24058
CFTR- IntronlO- + UGUUCUUUGUGUUAACAAAAUAU 23
5177 24059
CFTR- IntronlO- + UUGUUCUUUGUGUUAACAAAAUAU 24
5178 24060
CFTR- IntronlO- + GUUGCAAAAAUACGAUAU 18
5179 24061
CFTR- IntronlO- + AGUUGCAAAAAUACGAUAU 19
5180 24062
CFTR- IntronlO- + GAGUUGCAAAAAUACGAUAU 20
5181 24063
CFTR- IntronlO- + GGAGUUGCAAAAAUACGAUAU 21
5182 24064
CFTR- IntronlO- + AGGAGUUGCAAAAAUACGAUAU 22
5183 24065
CFTR- IntronlO- + AAGGAGUUGCAAAAAUACGAUAU 23
5184 24066
CFTR-
+ AAAGGAGUUGCAAAAAUACGAUAU 24
IntronlO- 24067
954
5535.1 5185
CFTR- IntronlO- + AAAAAU U ACAG AACCU AU 18
5186 24068
CFTR- IntronlO- + CAAAAAUUACAGAACCUAU 19
5187 24069
CFTR- IntronlO- + GCAAAAAUUACAGAACCUAU 20
5188 24070
CFTR- IntronlO- + AG CAAAAAUUACAGAACCUAU 21
5189 24071
CFTR- IntronlO- + AAGCAAAAAUU ACAG AACCU AU 22
5190 24072
CFTR- IntronlO- + GAAGCAAAAAUUACAGAACCUAU 23
5191 24073
CFTR- IntronlO- + UGAAGCAAAAAUUACAGAACCUAU 24
5192 24074
CFTR- IntronlO- + AAAUGCUUGACCACUUAU 18
5193 24075
CFTR- IntronlO- + CAAAUGCUUGACCACUUAU 19
5194 24076
CFTR-
+ ACAAAUGCUUGACCACUUAU 20
lntronlO-508 19394
CFTR- IntronlO- + CACAAAUGCUUGACCACUUAU 21
5195 24077
CFTR- IntronlO- + ACA CAAAUGCUUGACCACUUAU 22
5196 24078
CFTR- IntronlO- + UACACAAAUGCUUGACCACUUAU 23
5197 24079
CFTR- IntronlO- + GUACACAAAUGCUUGACCACUUAU 24
5198 24080
955
5535.1 CFTR- IntronlO- + AAAAAGCACUGAUUUUAU 18
5199 24081
CFTR- IntronlO- + GAAAAAGCACUGAUUUUAU 19
5200 24082
CFTR- IntronlO- + CGAAAAAGCACUGAUUUUAU 20
5201 24083
CFTR- IntronlO- + UCGAAAAAGCACUGAUUUUAU 21
5202 24084
CFTR- IntronlO- + CUCGAAAAAGCACUGAUUUUAU 22
5203 24085
CFTR- IntronlO- + CCUCGAAAAAGCACUGAUUUUAU 23
5204 24086
CFTR- IntronlO- + ACCUCGAAAAAGCACUGAUUUUAU 24
5205 24087
CFTR- IntronlO- + ACAAAG AU U U AU AU AACU 18
5206 24088
CFTR- IntronlO- + AACAAAG AU U U AU AU AACU 19
5207 24089
CFTR- IntronlO- + G AACAAAG AU U U AU AU AACU 20
5208 24090
CFTR- IntronlO- + U G AACAAAG AU U U AU AU AACU 21
5209 24091
CFTR- IntronlO- + G UG AACAAAG AU U U AU AU AACU 22
5210 24092
CFTR- IntronlO- + AG UG AACAAAG AU U U AU AU AACU 23
5211 24093
CFTR- IntronlO- + CAGUGAACAAAGAUUUAUAUAACU 24
5212 24094
956
5535.1 CFTR- IntronlO- + GCCUGUAAUCCCAACACU 18
5213 24095
CFTR- IntronlO- + UGCCUGUAAUCCCAACACU 19
5214 24096
CFTR- IntronlO- + AUGCCUGUAAUCCCAACACU 20
5215 24097
CFTR- IntronlO- + CAUGCCUGUAAUCCCAACACU 21
5216 24098
CFTR- IntronlO- + UCAUGCCUGUAAUCCCAACACU 22
5217 24099
CFTR- IntronlO- + CUCAUGCCUGUAAUCCCAACACU 23
5218 24100
CFTR- IntronlO- + GCUCAUGCCUGUAAUCCCAACACU 24
5219 24101
CFTR- IntronlO- + GCCUAUAAACCCAGCACU 18
5220 24102
CFTR- IntronlO- + UGCCUAUAAACCCAGCACU 19
5221 24103
CFTR- IntronlO- + AUGCCUAUAAACCCAGCACU 20
5222 24104
CFTR- IntronlO- + CAUGCCUAUAAACCCAGCACU 21
5223 24105
CFTR- IntronlO- + UCAUGCCUAUAAACCCAGCACU 22
5224 24106
CFTR- IntronlO- + CUCAUGCCUAUAAACCCAGCACU 23
5225 24107
CFTR- IntronlO- + GCUCAUGCCUAUAAACCCAGCACU 24
5226 24108
957
5535.1 CFTR- IntronlO- + GCCUGUAAUCCCAGCACU 18
5227 24109
CFTR- IntronlO- + CGCCUGUAAUCCCAGCACU 19
5228 24110
CFTR- IntronlO- + ACGCCUGUAAUCCCAGCACU 20
5229 24111
CFTR- IntronlO- + CACGCCUGUAAUCCCAGCACU 21
5230 24112
CFTR- IntronlO- + UCACGCCUGUAAUCCCAGCACU 22
5231 24113
CFTR- IntronlO- + CUCACGCCUGUAAUCCCAGCACU 23
5232 24114
CFTR- IntronlO- + GCUCACGCCUGUAAUCCCAGCACU 24
5233 24115
CFTR- IntronlO- + UCCCGAGUAGCUGGGACU 18
5234 24116
CFTR- IntronlO- + CUCCCGAGUAGCUGGGACU 19
5235 24117
CFTR- IntronlO- + CCUCCCGAGUAGCUGGGACU 20
5236 24118
CFTR- IntronlO- + GCCUCCCGAGUAGCUGGGACU 21
5237 24119
CFTR- IntronlO- + AGCCUCCCGAGUAGCUGGGACU 22
5238 24120
CFTR- IntronlO- + CAGCCUCCCGAGUAGCUGGGACU 23
5239 24121
CFTR- IntronlO- + UCAGCCUCCCGAGUAGCUGGGACU 24
5240 24122
958
5535.1 CFTR- IntronlO- + CCUGUAGUCCCAGCUACU 18
5241 17604
CFTR- IntronlO- + GCCUGUAGUCCCAGCUACU 19
5242 17605
CFTR- IntronlO- + CGCCUGUAGUCCCAGCUACU 20
1344 20229
CFTR- IntronlO- + GCGCCUGUAGUCCCAGCUACU 21
5243 24123
CFTR- IntronlO- + GGCGCCUGUAGUCCCAGCUACU 22
5244 24124
CFTR- IntronlO- + GGGCGCCUGUAGUCCCAGCUACU 23
5245 24125
CFTR- IntronlO- + CGGGCGCCUGUAGUCCCAGCUACU 24
5246 24126
CFTR- IntronlO- + UGCCUGUAGUCCCAGCUACU 20
1345 17606
CFTR- IntronlO- + CGUGCCUGUAGUCCCAGCUACU 22
5247 24127
CFTR- IntronlO- + GCGUGCCUGUAGUCCCAGCUACU 23
5248 24128
CFTR- IntronlO- + UGCGUGCCUGUAGUCCCAGCUACU 24
5249 24129
CFTR- IntronlO- + CUUGCUUCACCUGCUACU 18
5250 24130
CFTR- IntronlO- + ACUUGCUUCACCUGCUACU 19
5251 24131
CFTR-
+ CACUUGCUUCACCUGCUACU 20
lntronlO-512 19398
CFTR-
+ GCACUUGCUUCACCUGCUACU 21
IntronlO- 24132
959
5535.1 5252
CFTR- IntronlO- + UGCACUUGCUUCACCUGCUACU 22
5253 24133
CFTR- IntronlO- + UUGCACUUGCUUCACCUGCUACU 23
5254 24134
CFTR- IntronlO- + UUUGCACUUGCUUCACCUGCUACU 24
5255 24135
CFTR- IntronlO- + AAUCUUAUAGAGAUUACU 18
5256 24136
CFTR- IntronlO- + AAAUCUUAUAGAGAUUACU 19
5257 24137
CFTR-
+ AAAAUCUUAUAGAGAUUACU 20
lntronlO-513 19399
CFTR- IntronlO- + CAAAAUCUUAUAGAGAUUACU 21
5258 24138
CFTR- IntronlO- + ACAAAAUCUUAUAGAGAUUACU 22
5259 24139
CFTR- IntronlO- + AACAAAAU CU UAU AG AG AU U ACU 23
5260 24140
CFTR- IntronlO- + UAACAAAAUCUUAUAGAGAUUACU 24
5261 24141
CFTR- IntronlO- + CCUGCAAUACCAUCACCU 18
5262 24142
CFTR- IntronlO- + CCCUGCAAUACCAUCACCU 19
5263 24143
CFTR- IntronlO- + ACCCUGCAAUACCAUCACCU 20
1346 20230
CFTR- IntronlO- + CACCCUGCAAUACCAUCACCU 21
5264 24144
960
5535.1 CFTR- IntronlO- + CCACCCUGCAAUACCAUCACCU 22
5265 24145
CFTR- IntronlO- + CCCACCCUGCAAUACCAUCACCU 23
5266 24146
CFTR- IntronlO- + CCCCACCCUGCAAUACCAUCACCU 24
5267 24147
CFTR- IntronlO- + AACUCAUAAGGGACCGCU 18
5268 24148
CFTR- IntronlO- + AAACUCAUAAGGGACCGCU 19
5269 24149
CFTR-
+ AAAACUCAUAAGGGACCGCU 20
lntronlO-518 19404
CFTR- IntronlO- + GAAAACUCAUAAGGGACCGCU 21
5270 24150
CFTR- IntronlO- + AGAAAACUCAUAAGGGACCGCU 22
5271 24151
CFTR- IntronlO- + GAGAAAACUCAUAAGGGACCGCU 23
5272 24152
CFTR- IntronlO- + AGAGAAAACUCAUAAGGGACCGCU 24
5273 24153
CFTR- IntronlO- + CUCACAGUUCUGGAGGCU 18
5274 24154
CFTR- IntronlO- + UCUCACAGUUCUGGAGGCU 19
5275 24155
CFTR- IntronlO- + UUCUCACAGUUCUGGAGGCU 20
1357 20241
CFTR- IntronlO- + UUUCUCACAGUUCUGGAGGCU 21
5276 24156
CFTR-
+ AUUUCUCACAGUUCUGGAGGCU 22
IntronlO- 24157
961
5535.1 5277
CFTR- IntronlO- + UAUUUCUCACAGUUCUGGAGGCU 23
5278 24158
CFTR- IntronlO- + UUAUUUCUCACAGUUCUGGAGGCU 24
5279 24159
CFTR- IntronlO- + UCAUCUGUUAGUAAUGCU 18
5280 24160
CFTR- IntronlO- + AUCAUCUGUUAGUAAUGCU 19
5281 24161
CFTR- IntronlO- + UAUCAUCUGUUAGUAAUGCU 20
5282 24162
CFTR- IntronlO- + AUAUCAUCUGUUAGUAAUGCU 21
5283 24163
CFTR- IntronlO- + AAUAUCAUCUGUUAGUAAUGCU 22
5284 24164
CFTR- IntronlO- + UAAUAUCAUCUGUUAGUAAUGCU 23
5285 24165
CFTR- IntronlO- + AUAAUAUCAUCUGUUAGUAAUGCU 24
5286 24166
CFTR- IntronlO- + AGCAGAUUUGGGUCUGCU 18
5287 24167
CFTR- IntronlO- + CAGCAGAUUUGGGUCUGCU 19
5288 24168
CFTR- IntronlO- + CCAGCAGAUUUGGGUCUGCU 20
5289 24169
CFTR- IntronlO- + GCCAGCAGAUUUGGGUCUGCU 21
5290 24170
CFTR-
+ UGCCAGCAGAUUUGGGUCUGCU 22
IntronlO- 24171
962
5535.1 5291
CFTR- IntronlO- + GUGCCAGCAGAUUUGGGUCUGCU 23
5292 24172
CFTR- IntronlO- + GGUGCCAGCAGAUUUGGGUCUGCU 24
5293 24173
CFTR- IntronlO- + AUAUAGAGAGAAACAUCU 18
5294 24174
CFTR- IntronlO- + UAUAUAGAGAGAAACAUCU 19
5295 24175
CFTR- IntronlO- + AUAUAUAGAGAGAAACAUCU 20
5296 24176
CFTR- IntronlO- + UAUAUAUAGAGAGAAACAUCU 21
5297 24177
CFTR- IntronlO- + AUAUAUAUAGAGAGAAACAUCU 22
5298 24178
CFTR- IntronlO- + UAUAUAUAUAGAGAGAAACAUCU 23
5299 24179
CFTR- IntronlO- + UUAUAUAUAUAGAGAGAAACAUCU 24
5300 24180
CFTR- IntronlO- + AUAGAGAGAAACAUCUCU 18
5301 24181
CFTR- IntronlO- + UAUAGAGAGAAACAUCUCU 19
5302 24182
CFTR- IntronlO- + AUAUAGAGAGAAACAUCUCU 20
1365 20249
CFTR- IntronlO- + UAUAUAGAGAGAAACAUCUCU 21
5303 24183
CFTR-
+ AUAUAUAGAGAGAAACAUCUCU 22
IntronlO- 24184
963
5535.1 5304
CFTR- IntronlO- + UAUAUAUAGAGAGAAACAUCUCU 23
5305 24185
CFTR- IntronlO- + AUAUAUAUAGAGAGAAACAUCUCU 24
5306 24186
CFTR- IntronlO- + AU U AAU U U U AAAAAU U CU 18
5307 24187
CFTR- IntronlO- + AAU U AAU U U U AAAAAU U CU 19
5308 24188
CFTR- IntronlO- + G AAU U AAU U U U AAAAAU U CU 20
5309 24189
CFTR- IntronlO- + AG AAU U AAU U U U AAAAAU U CU 21
5310 24190
CFTR- IntronlO- + CAG AAU U AAU U U U AAAAAU U CU 22
5311 24191
CFTR- IntronlO- + GCAG AAU U AAU U U U AAAAAU U CU 23
5312 24192
CFTR- IntronlO- + CG CAG AAU U AAU U U U AAAAAU U CU 24
5313 24193
CFTR- IntronlO- + UAAUUUGAACAACAUUCU 18
5314 24194
CFTR- IntronlO- + AUAAUUUGAACAACAUUCU 19
5315 24195
CFTR-
+ AAU AAU U UG AACAACAU U CU 20
lntronlO-527 19413
CFTR- IntronlO- + AAAUAAUUUGAACAACAUUCU 21
5316 24196
CFTR- IntronlO- + GAAAUAAUUUGAACAACAUUCU 22
5317 24197
964
5535.1 CFTR- IntronlO- + AG AAAU AAU U UG AACAACAU U CU 23
5318 24198
CFTR- IntronlO- + U AG AAAU AAU U UG AACAACAU U CU 24
5319 24199
CFTR- IntronlO- + UUAGUAAACUCCGUUUCU 18
5320 24200
CFTR- IntronlO- + GUUAGUAAACUCCGUUUCU 19
5321 24201
CFTR- IntronlO- + AGUUAGUAAACUCCGUUUCU 20
5322 24202
CFTR- IntronlO- + GAGUUAGUAAACUCCGUUUCU 21
5323 24203
CFTR- IntronlO- + UGAGUUAGUAAACUCCGUUUCU 22
5324 24204
CFTR- IntronlO- + UUGAGUUAGUAAACUCCGUUUCU 23
5325 24205
CFTR- IntronlO- + AUUGAGUUAGUAAACUCCGUUUCU 24
5326 24206
CFTR- IntronlO- + CCUGACAAUAAGAAAAGU 18
5327 24207
CFTR- IntronlO- + UCCUGACAAUAAGAAAAGU 19
5328 24208
CFTR- IntronlO- + GU CCUGACAAUAAGAAAAGU 20
5329 24209
CFTR- IntronlO- + UGUCCUGACAAUAAGAAAAGU 21
5330 24210
CFTR- IntronlO- + AUGUCCUGACAAUAAGAAAAGU 22
5331 24211
965
5535.1 CFTR- IntronlO- + UAUGUCCUGACAAUAAGAAAAGU 23
5332 24212
CFTR- IntronlO- + AUAUGUCCUGACAAUAAGAAAAGU 24
5333 24213
CFTR- IntronlO- + AGUGCUAGGAUUACAAGU 18
5334 24214
CFTR- IntronlO- + AAGUGCUAGGAUUACAAGU 19
5335 24215
CFTR- IntronlO- + AAAGUGCUAGGAUUACAAGU 20
5336 24216
CFTR- IntronlO- + AAAAGUGCUAGGAUUACAAGU 21
5337 24217
CFTR- IntronlO- + C A A A AG UGCUAGGAUUA C A AG U 22
5338 24218
CFTR- IntronlO- + CCAAAAGUGCUAGGAUUACAAGU 23
5339 24219
CFTR- IntronlO- + UCCAAAAGUGCUAGGAUUACAAGU 24
5340 24220
CFTR- IntronlO- + AGGAAAUGGGGUAUAAGU 18
5341 24221
CFTR- IntronlO- + AAGGAAAUGGGGUAUAAGU 19
5342 24222
CFTR- IntronlO- + AAAGGAAAUGGGGUAUAAGU 20
5343 24223
CFTR- IntronlO- + CAAAGGAAAUGGGGUAUAAGU 21
5344 24224
CFTR- IntronlO- + ACAAAGGAAAUGGGGUAUAAGU 22
5345 24225
966
5535.1 CFTR- IntronlO- + AACAAAGGAAAUGGGGUAUAAGU 23
5346 24226
CFTR- IntronlO- + AAACAAAGGAAAUGGGGUAUAAGU 24
5347 24227
CFTR- IntronlO- + ACAGAAAUAU U CAGCAG U 18
5348 24228
CFTR- IntronlO- + GACAGAAAUAU U CAGCAG U 19
5349 24229
CFTR- IntronlO- + AGACAGAAAUAUUCAGCAGU 20
5350 24230
CFTR- IntronlO- + G AG AC AG AAA UAUUCAGCAGU 21
5351 24231
CFTR- IntronlO- + AGAGACAGAAAUAUUCAGCAGU 22
5352 24232
CFTR- IntronlO- + GAGAGACAGAAAUAUUCAGCAGU 23
5353 24233
CFTR- IntronlO- + GGAGAGACAGAAAUAUUCAGCAGU 24
5354 24234
CFTR- IntronlO- + AAAGUUGUCCAAGAUAGU 18
5355 24235
CFTR- IntronlO- + GAAAGUUGUCCAAGAUAGU 19
5356 24236
CFTR-
+ GGAAAGUUGUCCAAGAUAGU 20
lntronlO-120 19006
CFTR- IntronlO- + UGGAAAGUUGUCCAAGAUAGU 21
5357 24237
CFTR- IntronlO- + AUGGAAAGUUGUCCAAGAUAGU 22
5358 24238
CFTR-
+ UAUGGAAAGUUGUCCAAGAUAGU 23
IntronlO- 24239
967
5535.1 5359
CFTR- IntronlO- + AUAUGGAAAGUUGUCCAAGAUAGU 24
5360 24240
CFTR- IntronlO- + CUUUAUCAACAUGAAGGU 18
5361 24241
CFTR- IntronlO- + CCUUUAUCAACAUGAAGGU 19
5362 24242
CFTR- IntronlO- + CCCUUUAUCAACAUGAAGGU 20
5363 24243
CFTR- IntronlO- + ACCCUUUAUCAACAUGAAGGU 21
5364 24244
CFTR- IntronlO- + GACCCUUUAUCAACAUGAAGGU 22
5365 24245
CFTR- IntronlO- + UGACCCUUUAUCAACAUGAAGGU 23
5366 24246
CFTR- IntronlO- + UUGACCCUUUAUCAACAUGAAGGU 24
5367 24247
CFTR- IntronlO- + UGAGGGUCUCUCUAAGGU 18
5368 24248
CFTR- IntronlO- + GUGAGGGUCUCUCUAAGGU 19
5369 24249
CFTR- IntronlO- + GGUGAGGGUCUCUCUAAGGU 20
5370 24250
CFTR- IntronlO- + GGGUGAGGGUCUCUCUAAGGU 21
5371 24251
CFTR- IntronlO- + GGGGUGAGGGUCUCUCUAAGGU 22
5372 24252
CFTR-
+ AGGGGUGAGGGUCUCUCUAAGGU 23
IntronlO- 24253
968
5535.1 5373
CFTR- IntronlO- + AAGGGGUGAGGGUCUCUCUAAGGU 24
5374 24254
CFTR- IntronlO- + UUACAUAAAAAGAGAGGU 18
5375 24255
CFTR- IntronlO- + GUUACAUAAAAAGAGAGGU 19
5376 24256
CFTR-
+ UGUUACAUAAAAAGAGAGGU 20
lntronlO-535 19421
CFTR- IntronlO- + UUGUUACAUAAAAAGAGAGGU 21
5377 24257
CFTR- IntronlO- + AUUGUUACAUAAAAAGAGAGGU 22
5378 24258
CFTR- IntronlO- + U AU UG U U ACAU AAAAAG AG AGG U 23
5379 24259
CFTR- IntronlO- + AU AU UG U U ACAU AAAAAG AG AGG U 24
5380 24260
CFTR- IntronlO- + GCGGGCGGAUCACGAGGU 18
5381 24261
CFTR- IntronlO- + GGCGGGCGGAUCACGAGGU 19
5382 24262
CFTR- IntronlO- + AGGCGGGCGGAUCACGAGGU 20
5383 24263
CFTR- IntronlO- + GAGGCGGGCGGAUCACGAGGU 21
5384 24264
CFTR- IntronlO- + CGAGGCGGGCGGAUCACGAGGU 22
5385 24265
CFTR- IntronlO- + CCGAGGCGGGCGGAUCACGAGGU 23
5386 24266
969
5535.1 CFTR- IntronlO- + GCCGAGGCGGGCGGAUCACGAGGU 24
5387 24267
CFTR- IntronlO- + UAUAUUCUUUUAUGUGGU 18
5388 24268
CFTR- IntronlO- + AUAUAUUCUUUUAUGUGGU 19
5389 24269
CFTR- IntronlO- + AAUAUAUUCUUUUAUGUGGU 20
5390 24270
CFTR- IntronlO- + GAAUAUAUUCUUUUAUGUGGU 21
5391 24271
CFTR- IntronlO- + CGAAUAUAUUCUUUUAUGUGGU 22
5392 24272
CFTR- IntronlO- + ACGAAUAUAUUCUUUUAUGUGGU 23
5393 24273
CFTR- IntronlO- + CACGAAUAUAUUCUUUUAUGUGGU 24
5394 24274
CFTR- IntronlO- + AAAAGCUGUUUCGUAUGU 18
5395 24275
CFTR- IntronlO- + UAAAAGCUGUUUCGUAUGU 19
5396 24276
CFTR-
+ UUAAAAGCUGUUUCGUAUGU 20
lntronlO-539 19425
CFTR- IntronlO- + UUUAAAAGCUGUUUCGUAUGU 21
5397 24277
CFTR- IntronlO- + UUUUAAAAGCUGUUUCGUAUGU 22
5398 24278
CFTR- IntronlO- + GUUUUAAAAGCUGUUUCGUAUGU 23
5399 24279
CFTR-
+ UGUUUUAAAAGCUGUUUCGUAUGU 24
IntronlO- 24280
970
5535.1 5400
CFTR- IntronlO- + AUCUGUUAGUAAUGCUGU 18
5401 24281
CFTR- IntronlO- + CAUCUGUUAGUAAUGCUGU 19
5402 24282
CFTR-
+ UCAUCUGUUAGUAAUGCUGU 20
lntronlO-540 19426
CFTR- IntronlO- + AUCAUCUGUUAGUAAUGCUGU 21
5403 24283
CFTR- IntronlO- + UAUCAUCUGUUAGUAAUGCUGU 22
5404 24284
CFTR- IntronlO- + AUAUCAUCUGUUAGUAAUGCUGU 23
5405 24285
CFTR- IntronlO- + AAUAUCAUCUGUUAGUAAUGCUGU 24
5406 24286
CFTR- IntronlO- + AUAGAGACAAGGUGGUGU 18
5407 24287
CFTR- IntronlO- + AAUAGAGACAAGGUGGUGU 19
5408 24288
CFTR- IntronlO- + UAAUAGAGACAAGGUGGUGU 20
5409 24289
CFTR- IntronlO- + AUAAUAGAGACAAGGUGGUGU 21
5410 24290
CFTR- IntronlO- + AAUAAUAGAGACAAGGUGGUGU 22
5411 24291
CFTR- IntronlO- + CAAUAAUAGAGACAAGGUGGUGU 23
5412 24292
CFTR- IntronlO- + UCAAUAAUAGAGACAAGGUGGUGU 24
5413 24293
971
5535.1 CFTR- IntronlO- + G A AAG AAAAU G U U U U U G U 18
5414 24294
CFTR- IntronlO- + AGAAAGAAAAUGUUUUUGU 19
5415 24295
CFTR- IntronlO- + A AG A A AG A A A A UGUUUUUGU 20
5416 24296
CFTR- IntronlO- + UAAGAAAGAAAAUGUUUUUGU 21
5417 24297
CFTR- IntronlO- + UUAAGAAAGAAAAUGUUUUUGU 22
5418 24298
CFTR- IntronlO- + UUUAAGAAAGAAAAUGUUUUUGU 23
5419 24299
CFTR- IntronlO- + U U U U AAG AAAG AAAAUG U U U U UG U 24
5420 24300
CFTR- IntronlO- + UGGCUUAACCCAUCUAUU 18
5421 24301
CFTR- IntronlO- + UUGGCUUAACCCAUCUAUU 19
5422 24302
CFTR- IntronlO- + GUUGGCUUAACCCAUCUAUU 20
5423 24303
CFTR- IntronlO- + AGUUGGCUUAACCCAUCUAUU 21
5424 24304
CFTR- IntronlO- + CAGUUGGCUUAACCCAUCUAUU 22
5425 24305
CFTR- IntronlO- + UCAGUUGGCUUAACCCAUCUAUU 23
5426 24306
CFTR- IntronlO- + UUCAGUUGGCUUAACCCAUCUAUU 24
5427 24307
972
5535.1 CFTR- IntronlO- + AUAAUUCUAGAAAGUAUU 18
5428 24308
CFTR- IntronlO- + UAUAAUUCUAGAAAGUAUU 19
5429 24309
CFTR- IntronlO- + GU AUAAUUCUAGAAAGUAUU 20
5430 24310
CFTR- IntronlO- + GGUAUAAUUCUAGAAAGUAUU 21
5431 24311
CFTR- IntronlO- + CGGUAUAAUUCUAGAAAGUAUU 22
5432 24312
CFTR- IntronlO- + UCGGUAUAAUUCUAGAAAGUAUU 23
5433 24313
CFTR- IntronlO- + UUCGGUAUAAUUCUAGAAAGUAUU 24
5434 24314
CFTR- IntronlO- + UUUAUUUAUUUAUUUAUU 18
5435 24315
CFTR- IntronlO- + AUUUAUUUAUUUAUUUAUU 19
5436 24316
CFTR- IntronlO- + UAUUUAUUUAUUUAUUUAUU 20
5437 24317
CFTR- IntronlO- + UUAUUUAUUUAUUUAUUUAUU 21
5438 24318
CFTR- IntronlO- + UUUAUUUAUUUAUUUAUUUAUU 22
5439 24319
CFTR- IntronlO- + AUUUAUUUAUUUAUUUAUUUAUU 23
5440 24320
CFTR- IntronlO- + UAUUUAUUUAUUUAUUUAUUUAUU 24
5441 24321
973
5535.1 CFTR- IntronlO- + UUUGCUGAUUGCUUUAUU 18
5442 24322
CFTR- IntronlO- + AUUUGCUGAUUGCUUUAUU 19
5443 24323
CFTR- IntronlO- + AAUUUGCUGAUUGCUUUAUU 20
5444 24324
CFTR- IntronlO- + AAAUUUGCUGAUUGCUUUAUU 21
5445 24325
CFTR- IntronlO- + GAAAUUUGCUGAUUGCUUUAUU 22
5446 24326
CFTR- IntronlO- + GGAAAUUUGCUGAUUGCUUUAUU 23
5447 24327
CFTR- IntronlO- + AGGAAAUUUGCUGAUUGCUUUAUU 24
5448 24328
CFTR- IntronlO- + CCUGUAAUCCCAACACUU 18
5449 24329
CFTR- IntronlO- + GCCUGUAAUCCCAACACUU 19
5450 24330
CFTR- IntronlO- + UGCCUGUAAUCCCAACACUU 20
1391 20275
CFTR- IntronlO- + AUGCCUGUAAUCCCAACACUU 21
5451 24331
CFTR- IntronlO- + CAUGCCUGUAAUCCCAACACUU 22
5452 24332
CFTR- IntronlO- + UCAUGCCUGUAAUCCCAACACUU 23
5453 24333
CFTR- IntronlO- + CUCAUGCCUGUAAUCCCAACACUU 24
5454 24334
974
5535.1 CFTR- IntronlO- + CCUAUAAACCCAGCACUU 18
5455 24335
CFTR- IntronlO- + GCCUAUAAACCCAGCACUU 19
5456 24336
CFTR- IntronlO- + UGCCUAUAAACCCAGCACUU 20
1392 20276
CFTR- IntronlO- + AUGCCUAUAAACCCAGCACUU 21
5457 24337
CFTR- IntronlO- + CAUGCCUAUAAACCCAGCACUU 22
5458 24338
CFTR- IntronlO- + UCAUGCCUAUAAACCCAGCACUU 23
5459 24339
CFTR- IntronlO- + CUCAUGCCUAUAAACCCAGCACUU 24
5460 24340
CFTR- IntronlO- + CCUGUAAUCCCAGCACUU 18
5461 24341
CFTR- IntronlO- + GCCUGUAAUCCCAGCACUU 19
5462 24342
CFTR- IntronlO- + CGCCUGUAAUCCCAGCACUU 20
1393 20277
CFTR- IntronlO- + ACGCCUGUAAUCCCAGCACUU 21
5463 24343
CFTR- IntronlO- + CACGCCUGUAAUCCCAGCACUU 22
5464 24344
CFTR- IntronlO- + UCACGCCUGUAAUCCCAGCACUU 23
5465 24345
CFTR- IntronlO- + CUCACGCCUGUAAUCCCAGCACUU 24
5466 24346
975
5535.1 CFTR- IntronlO- + GAACCAUUUUAUAGACUU 18
5467 24347
CFTR- IntronlO- + GGAACCAUUUUAUAGACUU 19
5468 24348
CFTR- IntronlO- + AGGAACCAUUUUAUAGACUU 20
5469 24349
CFTR- IntronlO- + AAGGAACCAUUUUAUAGACUU 21
5470 24350
CFTR- IntronlO- + CAAGGAACCAUUUUAUAGACUU 22
5471 24351
CFTR- IntronlO- + ACAAGGAACCAUUUUAUAGACUU 23
5472 24352
CFTR- IntronlO- + AACAAGGAACCAUUUUAUAGACUU 24
5473 24353
CFTR- IntronlO- + CUGUAGUCCCAGCUACUU 18
5474 24354
CFTR- IntronlO- + CCUGUAGUCCCAGCUACUU 19
5475 24355
CFTR-
+ GCCUGUAGUCCCAGCUACUU 20
lntronlO-720 19606
CFTR- IntronlO- + CGCCUGUAGUCCCAGCUACUU 21
5476 24356
CFTR- IntronlO- + GCGCCUGUAGUCCCAGCUACUU 22
5477 24357
CFTR- IntronlO- + GGCGCCUGUAGUCCCAGCUACUU 23
5478 24358
CFTR- IntronlO- + GGGCGCCUGUAGUCCCAGCUACUU 24
5479 24359
CFTR-
+ UGCCUGUAGUCCCAGCUACUU 21
IntronlO- 24360
976
5535.1 5480
CFTR- IntronlO- + GUGCCUGUAGUCCCAGCUACUU 22
5481 24361
CFTR- IntronlO- + CGUGCCUGUAGUCCCAGCUACUU 23
5482 24362
CFTR- IntronlO- + GCGUGCCUGUAGUCCCAGCUACUU 24
5483 24363
CFTR- IntronlO- + AAUUUAUUUCUCACAGUU 18
5484 24364
CFTR- IntronlO- + GAAUUUAUUUCUCACAGUU 19
5485 24365
CFTR- IntronlO- + GGAAUUUAUUUCUCACAGUU 20
5486 24366
CFTR- IntronlO- + AGGAAUUUAUUUCUCACAGUU 21
5487 24367
CFTR- IntronlO- + CAGGAAUUUAUUUCUCACAGUU 22
5488 24368
CFTR- IntronlO- + ACAGGAAUUUAUUUCUCACAGUU 23
5489 24369
CFTR- IntronlO- + AACAGG AAU U U AU U U CU CACAG U U 24
5490 24370
CFTR- IntronlO- + CUUGACAUCAGUUGGGUU 18
5491 24371
CFTR- IntronlO- + GCUUGACAUCAGUUGGGUU 19
5492 24372
CFTR- IntronlO- + UGCUUGACAUCAGUUGGGUU 20
5493 24373
CFTR-
+ CUGCUUGACAUCAGUUGGGUU 21
IntronlO- 24374
977
5535.1 5494
CFTR- IntronlO- + UCUGCUUGACAUCAGUUGGGUU 22
5495 24375
CFTR- IntronlO- + UUCUGCUUGACAUCAGUUGGGUU 23
5496 24376
CFTR- IntronlO- + CUUCUGCUUGACAUCAGUUGGGUU 24
5497 24377
CFTR- IntronlO- + AAAAU AU ACCCAAAAU U U 18
5498 24378
CFTR- IntronlO- + U AAAAU AU ACCCAAAAU U U 19
5499 24379
CFTR- IntronlO- + AU AAAAU AU ACCCAAAAU U U 20
5500 24380
CFTR- IntronlO- + UAU AAAAU AU ACCCAAAAU U U 21
5501 24381
CFTR- IntronlO- + AUAU AAAAU AU ACCCAAAAU U U 22
5502 24382
CFTR- IntronlO- + AAUAU AAAAU AU ACCCAAAAU U U 23
5503 24383
CFTR- IntronlO- + AAAU AU AAAAU AU ACCCAAAAU U U 24
5504 24384
CFTR- IntronlO- + ACGAAUUGGUACAAAUUU 18
5505 24385
CFTR- IntronlO- + UACGAAUUGGUACAAAUUU 19
5506 24386
CFTR- IntronlO- + GU ACGAAUUGGUACAAAUUU 20
5507 24387
CFTR-
+ AGUACGAAUUGGUACAAAUUU 21
IntronlO- 24388
978
5535.1 5508
CFTR- IntronlO- + GAGUACGAAUUGGUACAAAUUU 22
5509 24389
CFTR- IntronlO- + UGAGUACGAAUUGGUACAAAUUU 23
5510 24390
CFTR- IntronlO- + AUGAGUACGAAUUGGUACAAAUUU 24
5511 24391
CFTR- IntronlO- + CCCUAUUAUUCAACAUUU 18
5512 24392
CFTR- IntronlO- + CCCCUAUUAUUCAACAUUU 19
5513 24393
CFTR- IntronlO- + ACCCCUAUUAUUCAACAUUU 20
5514 24394
CFTR- IntronlO- + AACCCCUAUUAUUCAACAUUU 21
5515 24395
CFTR- IntronlO- + AAACCCCU AU U AU U CAACAU U U 22
5516 24396
CFTR- IntronlO- + CAAACCCCU AU U AU U CAACAU U U 23
5517 24397
CFTR- IntronlO- + UCAAACCCCUAUUAUUCAACAUUU 24
5518 24398
CFTR- IntronlO- + U CU AU U CAAAAAAU AU U U 18
5519 24399
CFTR- IntronlO- + AUCUAUUCAAAAAAUAUUU 19
5520 24400
CFTR- IntronlO- + AAUCUAUUCAAAAAAUAUUU 20
5521 24401
CFTR-
+ UAAUCUAUU CAAAAAAU AU U U 21
IntronlO- 24402
979
5535.1 5522
CFTR- IntronlO- + CUAAUCUAUUCAAAAAAUAUUU 22
5523 24403
CFTR- IntronlO- + GCUAAUCUAUUCAAAAAAUAUUU 23
5524 24404
CFTR- IntronlO- + AGCUAAUCUAUUCAAAAAAUAUUU 24
5525 24405
CFTR- IntronlO- + CGAGUUAUCUCCGUAUUU 18
5526 24406
CFTR- IntronlO- + ACGAGUUAUCUCCGUAUUU 19
5527 24407
CFTR- IntronlO- + CACGAGUUAUCUCCGUAUUU 20
5528 24408
CFTR- IntronlO- + UCACGAGUUAUCUCCGUAUUU 21
5529 24409
CFTR- IntronlO- + GUCACGAGUUAUCUCCGUAUUU 22
5530 24410
CFTR- IntronlO- + AGUCACGAGUUAUCUCCGUAUUU 23
5531 24411
CFTR- IntronlO- + AAGUCACGAGUUAUCUCCGUAUUU 24
5532 24412
CFTR- IntronlO- + CUGUAAUCCCAACACUUU 18
5533 24413
CFTR- IntronlO- + CCUGUAAUCCCAACACUUU 19
5534 24414
CFTR-
+ GCCUGUAAUCCCAACACUUU 20
lntronlO-722 19608
CFTR- IntronlO- + UGCCUGUAAUCCCAACACUUU 21
5535 24415
980
5535.1 CFTR- IntronlO- + AUGCCUGUAAUCCCAACACUUU 22
5536 24416
CFTR- IntronlO- + CAUGCCUGUAAUCCCAACACUUU 23
5537 24417
CFTR- IntronlO- + UCAUGCCUGUAAUCCCAACACUUU 24
5538 24418
CFTR- IntronlO- + CUAUAAACCCAGCACUUU 18
5539 24419
CFTR- IntronlO- + CCUAUAAACCCAGCACUUU 19
5540 24420
CFTR-
+ GCCUAUAAACCCAGCACUUU 20
lntronlO-723 19609
CFTR- IntronlO- + UGCCUAUAAACCCAGCACUUU 21
5541 24421
CFTR- IntronlO- + AUGCCUAUAAACCCAGCACUUU 22
5542 24422
CFTR- IntronlO- + CAUGCCUAUAAACCCAGCACUUU 23
5543 24423
CFTR- IntronlO- + UCAUGCCUAUAAACCCAGCACUUU 24
5544 24424
CFTR- IntronlO- + CUGUAAUCCCAGCACUUU 18
5545 24425
CFTR- IntronlO- + CCUGUAAUCCCAGCACUUU 19
5546 24426
CFTR-
+ GCCUGUAAUCCCAGCACUUU 20
lntronlO-724 19610
CFTR- IntronlO- + CGCCUGUAAUCCCAGCACUUU 21
5547 24427
CFTR- IntronlO- + ACGCCUGUAAUCCCAGCACUUU 22
5548 24428
981
5535.1 CFTR- IntronlO- + CACGCCUGUAAUCCCAGCACUUU 23
5549 24429
CFTR- IntronlO- + UCACGCCUGUAAUCCCAGCACUUU 24
5550 24430
CFTR- IntronlO- + UGAUAAAUAAUUGCCUUU 18
5551 24431
CFTR- IntronlO- + UUGAUAAAUAAUUGCCUUU 19
5552 24432
CFTR- IntronlO- + AUUGAUAAAUAAUUGCCUUU 20
5553 24433
CFTR- IntronlO- + UAUUGAUAAAUAAUUGCCUUU 21
5554 24434
CFTR- IntronlO- + AUAUUGAUAAAUAAUUGCCUUU 22
5555 24435
CFTR- IntronlO- + GAUAUUGAUAAAUAAUUGCCUUU 23
5556 24436
CFTR- IntronlO- + AGAUAUUGAUAAAUAAUUGCCUUU 24
5557 24437
CFTR- IntronlO- + AAAUAAGCCUUAGUCUUU 18
5558 24438
CFTR- IntronlO- + GAAAUAAGCCUUAGUCUUU 19
5559 24439
CFTR- IntronlO- + AGAAAUAAGCCUUAGUCUUU 20
5560 24440
CFTR- IntronlO- + GAGAAAUAAGCCUUAGUCUUU 21
5561 24441
CFTR- IntronlO- + AG AG AAAU AAGCCU U AG U CU U U 22
5562 24442
982
5535.1 CFTR- IntronlO- + CAG AG AAAU AAGCCU U AG U CU U U 23
5563 24443
CFTR- IntronlO- + CCAGAGAAAUAAGCCUUAGUCUUU 24
5564 24444
CFTR- IntronlO- + AGAAAAUUUGUUUUCUUU 18
5565 24445
CFTR- IntronlO- + AAGAAAAUUUGUUUUCUUU 19
5566 24446
CFTR- IntronlO- + AAAGAAAAUUUGUUUUCUUU 20
5567 24447
CFTR- IntronlO- + CAAAGAAAAUUUGUUUUCUUU 21
5568 24448
CFTR- IntronlO- + ACAAAG AAAAU UUGUUUUCUUU 22
5569 24449
CFTR- IntronlO- + AACAAAGAAAAUUUGUUUUCUUU 23
5570 24450
CFTR- IntronlO- + AAACAAAG AAAAU UUGUUUUCUUU 24
5571 24451
CFTR- IntronlO- + G AAAAAU AAU AACAU U U U 18
5572 24452
CFTR- IntronlO- + AG AAAAAU AAU AACAU U U U 19
5573 24453
CFTR- IntronlO- + AAG AAAAAU AAU AACAU U U U 20
5574 24454
CFTR- IntronlO- + AAAG AAAAAU AAU AACAU U U U 21
5575 24455
CFTR- IntronlO- + AAAAG AAAAAU AAU AACAU U U U 22
5576 24456
983
5535.1 CFTR- IntronlO- + U AAAAG AAAAAU AAU AACAU U U U 23
5577 24457
CFTR- IntronlO- + AU AAAAG AAAAAU AAU AACAU U U U 24
5578 24458
CFTR- IntronlO- + AUACAUACAUAUGAUUUU 18
5579 24459
CFTR- IntronlO- + UAUACAUACAUAUGAUUUU 19
5580 24460
CFTR- IntronlO- + AUAUACAUACAUAUGAUUUU 20
5581 24461
CFTR- IntronlO- + UAUAUACAUACAUAUGAUUUU 21
5582 24462
CFTR- IntronlO- + AUAUAUACAUACAUAUGAUUUU 22
5583 24463
CFTR- IntronlO- + CAUAUAUACAUACAUAUGAUUUU 23
5584 24464
CFTR- IntronlO- + ACAUAUAUACAUACAUAUGAUUUU 24
5585 24465
CFTR- IntronlO- + CACCAAUUUUUUUUUUUU 18
5586 24466
CFTR- IntronlO- + ACACCAAUUUUUUUUUUUU 19
5587 24467
CFTR- IntronlO- + AACACCAAUUUUUUUUUUUU 20
5588 24468
CFTR- IntronlO- + AAACACCAAUUUUUUUUUUUU 21
5589 24469
CFTR- IntronlO- + CAAACACCAAUUUUUUUUUUUU 22
5590 24470
984
5535.1 CFTR- IntronlO- + GCAAACACCAAUUUUUUUUUUUU 23
5591 24471
CFTR- IntronlO- + UGCAAACACCAAUUUUUUUUUUUU 24
5592 24472
CFTR- IntronlO- - UAAAAAUGUUAAUGAAAA 18
5593 24473
CFTR- IntronlO- - GUAAAAAUGUUAAUGAAAA 19
5594 24474
CFTR- IntronlO- - GG UAAAAAUGUUAAUGAAAA 20
5595 24475
CFTR- IntronlO- - AGGUAAAAAUGUUAAUGAAAA 21
5596 24476
CFTR- IntronlO- - UAGGUAAAAAUGUUAAUGAAAA 22
5597 24477
CFTR- IntronlO- - GUAGGUAAAAAUGUUAAUGAAAA 23
5598 24478
CFTR- IntronlO- - UGUAGGUAAAAAUGUUAAUGAAAA 24
5599 24479
CFTR- IntronlO- - AU U U AU UAAAAU U UAAAA 18
5600 24480
CFTR- IntronlO- - U AU U U AU UAAAAU U UAAAA 19
5601 24481
CFTR- IntronlO- - UUAUUUAU UAAAAU U UAAAA 20
5602 24482
CFTR- IntronlO- - AUUAUUUAU UAAAAU U UAAAA 21
5603 24483
CFTR- IntronlO- - UAUUAUUUAU UAAAAU U UAAAA 22
5604 24484
985
5535.1 CFTR- IntronlO- - AUAUUAUUUAU U AAAAU U U AAAA 23
5605 24485
CFTR- IntronlO- - GAUAUUAUUUAU U AAAAU U U AAAA 24
5606 24486
CFTR- IntronlO- - CGAAUAAUCUAAGACAAA 18
5607 24487
CFTR- IntronlO- - CCGAAUAAUCUAAGACAAA 19
5608 24488
CFTR- IntronlO- - ACCGAAUAAUCUAAGACAAA 20
5609 24489
CFTR- IntronlO- - UACCGAAUAAUCUAAGACAAA 21
5610 24490
CFTR- IntronlO- - AUACCGAAUAAUCUAAGACAAA 22
5611 24491
CFTR- IntronlO- - UAUACCGAAUAAUCUAAGACAAA 23
5612 24492
CFTR- IntronlO- - UUAUACCGAAUAAUCUAAGACAAA 24
5613 24493
CFTR- IntronlO- - GCCUAUUUGACAUCCAAA 18
5614 24494
CFTR- IntronlO- - UGCCUAUUUGACAUCCAAA 19
5615 24495
CFTR- IntronlO- - AUGCCUAUUUGACAUCCAAA 20
5616 24496
CFTR- IntronlO- - AAUGCCUAUUUGACAUCCAAA 21
5617 24497
CFTR- IntronlO- - AAAUGCCUAUUUGACAUCCAAA 22
5618 24498
986
5535.1 CFTR- IntronlO- - GAAAUGCCUAUUUGACAUCCAAA 23
5619 24499
CFTR- IntronlO- - UGAAAUGCCUAUUUGACAUCCAAA 24
5620 24500
CFTR- IntronlO- - GACAAACAGAAAAAGAAA 18
5621 24501
CFTR- IntronlO- - AGACAAACAGAAAAAGAAA 19
5622 24502
CFTR- IntronlO- - AAGACAAACAGAAAAAGAAA 20
5623 24503
CFTR- IntronlO- - UAAGACAAACAGAAAAAGAAA 21
5624 24504
CFTR- IntronlO- - CUAAGACAAACAGAAAAAGAAA 22
5625 24505
CFTR- IntronlO- - UCUAAGACAAACAGAAAAAGAAA 23
5626 24506
CFTR- IntronlO- - AUCUAAGACAAACAGAAAAAGAAA 24
5627 24507
CFTR- IntronlO- - AUCUAAGACAAACAGAAA 18
5628 24508
CFTR- IntronlO- - AAUCUAAGACAAACAGAAA 19
5629 24509
CFTR- IntronlO- - UAAUCUAAGACAAACAGAAA 20
5630 24510
CFTR- IntronlO- - AUAAUCUAAGACAAACAGAAA 21
5631 24511
CFTR- IntronlO- - AAUAAUCUAAGACAAACAGAAA 22
5632 24512
987
5535.1 CFTR- IntronlO- - GAAUAAUCUAAGACAAACAGAAA 23
5633 24513
CFTR- IntronlO- - CGAAUAAUCUAAGACAAACAGAAA 24
5634 24514
CFTR- IntronlO- - GGCACCAUUCACAGUAAA 18
5635 24515
CFTR- IntronlO- - UGGCACCAUUCACAGUAAA 19
5636 24516
CFTR- IntronlO- - CUGGCACCAUUCACAGUAAA 20
5637 24517
CFTR- IntronlO- - CCUGGCACCAUUCACAGUAAA 21
5638 24518
CFTR- IntronlO- - ACCUGGCACCAUUCACAGUAAA 22
5639 24519
CFTR- IntronlO- - UACCUGGCACCAUUCACAGUAAA 23
5640 24520
CFTR- IntronlO- - CUACCUGGCACCAUUCACAGUAAA 24
5641 24521
CFTR- IntronlO- - CCACUGGAGAGUUUUAAA 18
5642 24522
CFTR- IntronlO- - GCCACUGGAGAGUUUUAAA 19
5643 24523
CFTR- IntronlO- - GGCCACUGGAGAGUUUUAAA 20
5644 24524
CFTR- IntronlO- - AGGCCACUGGAGAGUUUUAAA 21
5645 24525
CFTR- IntronlO- - GAGGCCACUGGAGAGUUUUAAA 22
5646 24526
988
5535.1 CFTR- IntronlO- - AGAGGCCACUGGAGAGUUUUAAA 23
5647 24527
CFTR- IntronlO- - UAGAGGCCACUGGAGAGUUUUAAA 24
5648 24528
CFTR- IntronlO- - UACAAAAAACACAAACAA 18
5649 24529
CFTR- IntronlO- - CUACAAAAAACACAAACAA 19
5650 24530
CFTR- IntronlO- - UCUACAAAAAACACAAACAA 20
5651 24531
CFTR- IntronlO- - CUCUACAAAAAACACAAACAA 21
5652 24532
CFTR- IntronlO- - CCUCUACAAAAAACACAAACAA 22
5653 24533
CFTR- IntronlO- - ACCUCUACAAAAAACACAAACAA 23
5654 24534
CFTR- IntronlO- - CACCUCUACAAAAAACACAAACAA 24
5655 24535
CFTR- IntronlO- - UAAAGACUGUUGUAACAA 18
5656 24536
CFTR- IntronlO- - AUAAAGACUGUUGUAACAA 19
5657 24537
CFTR- IntronlO- - UAUAAAGACUGUUGUAACAA 20
5658 24538
CFTR- IntronlO- - GU AUAAAGACUGUUGUAACAA 21
5659 24539
CFTR- IntronlO- - AGUAUAAAGACUGUUGUAACAA 22
5660 24540
989
5535.1 CFTR- IntronlO- - CAGUAUAAAGACUGUUGUAACAA 23
5661 24541
CFTR- IntronlO- - CCAGUAUAAAGACUGUUGUAACAA 24
5662 24542
CFTR- IntronlO- - UAUUCUGUAGGGAGACAA 18
5663 24543
CFTR- IntronlO- - CUAUUCUGUAGGGAGACAA 19
5664 24544
CFTR-
- GCUAUUCUGUAGGGAGACAA 20
lntronlO-66 18952
CFTR- IntronlO- - GGCUAUUCUGUAGGGAGACAA 21
5665 24545
CFTR- IntronlO- - AGGCUAUUCUGUAGGGAGACAA 22
5666 24546
CFTR- IntronlO- - UAGGCUAUUCUGUAGGGAGACAA 23
5667 24547
CFTR- IntronlO- - UUAGGCUAUUCUGUAGGGAGACAA 24
5668 24548
CFTR- IntronlO- - AUAGAUGGGUUAAGCCAA 18
5669 24549
CFTR- IntronlO- - AAUAGAUGGGUUAAGCCAA 19
5670 24550
CFTR- IntronlO- - UAAUAGAUGGGUUAAGCCAA 20
5671 24551
CFTR- IntronlO- - UUAAUAGAUGGGUUAAGCCAA 21
5672 24552
CFTR- IntronlO- - CUUAAUAGAUGGGUUAAGCCAA 22
5673 24553
CFTR-
- UCUUAAUAGAUGGGUUAAGCCAA 23
IntronlO- 24554
990
5535.1 5674
CFTR- IntronlO- - CUCUUAAUAGAUGGGUUAAGCCAA 24
5675 24555
CFTR- IntronlO- - AG AAAG AAAAAACAG CAA 18
5676 24556
CFTR- IntronlO- - UAGAAAGAAAAAACAGCAA 19
5677 24557
CFTR- IntronlO- - U U AG AAAG AAAAAACAG CAA 20
5678 24558
CFTR- IntronlO- - AU UAGAAAGAAAAAACAGCAA 21
5679 24559
CFTR- IntronlO- - GAU UAGAAAGAAAAAACAGCAA 22
5680 24560
CFTR- IntronlO- - AGAUUAGAAAGAAAAAACAGCAA 23
5681 24561
CFTR- IntronlO- - UAGAUUAGAAAGAAAAAACAGCAA 24
5682 24562
CFTR- IntronlO- - ACUGUUGUAACAAAAGAA 18
5683 24563
CFTR- IntronlO- - GACUGUUGUAACAAAAGAA 19
5684 24564
CFTR- IntronlO- - AGACUGUUGUAACAAAAGAA 20
5685 24565
CFTR- IntronlO- - AAGACUGUUGUAACAAAAGAA 21
5686 24566
CFTR- IntronlO- - AAAG AC U G U U G UAACAAAAGAA 22
5687 24567
CFTR-
- UAAAGACUGUUGUAACAAAAGAA 23
IntronlO- 24568
991
5535.1 5688
CFTR- IntronlO- - A U AAAG AC U G U U G U AAC AAAAG AA 24
5689 24569
CFTR- IntronlO- - GAAGGAAAUGAGGAAGAA 18
5690 24570
CFTR- IntronlO- - AGAAGGAAAUGAGGAAGAA 19
5691 24571
CFTR- IntronlO- - AAGAAGGAAAUGAGGAAGAA 20
1105 19990
CFTR- IntronlO- - AAAGAAGGAAAUGAGGAAGAA 21
5692 24572
CFTR- IntronlO- - GAAAGAAGGAAAUGAGGAAGAA 22
5693 24573
CFTR- IntronlO- - AGAAAGAAGGAAAUGAGGAAGAA 23
5694 24574
CFTR- IntronlO- - AAGAAAGAAGGAAAUGAGGAAGAA 24
5695 24575
CFTR- IntronlO- - AAAGAGGGUUGAUAAGAA 18
5696 24576
CFTR- IntronlO- - GAAAGAGGGUUGAUAAGAA 19
5697 24577
CFTR- IntronlO- - GGAAAGAGGGUUGAUAAGAA 20
5698 24578
CFTR- IntronlO- - AGGAAAGAGGGUUGAUAAGAA 21
5699 24579
CFTR- IntronlO- - AAGGAAAGAGGGUUGAUAAGAA 22
5700 24580
CFTR-
- AAAGGAAAGAGGGUUGAUAAGAA 23
IntronlO- 24581
992
5535.1 5701
CFTR- IntronlO- - UAAAGGAAAGAGGGUUGAUAAGAA 24
5702 24582
CFTR- IntronlO- - AUCACCUGAGCCUGAGAA 18
5703 24583
CFTR- IntronlO- - GAUCACCUGAGCCUGAGAA 19
5704 24584
CFTR- IntronlO- - GGAUCACCUGAGCCUGAGAA 20
5705 24585
CFTR- IntronlO- - AGGAUCACCUGAGCCUGAGAA 21
5706 24586
CFTR- IntronlO- - GAGGAUCACCUGAGCCUGAGAA 22
5707 24587
CFTR- IntronlO- - GGAGGAUCACCUGAGCCUGAGAA 23
5708 24588
CFTR- IntronlO- - GGGAGGAUCACCUGAGCCUGAGAA 24
5709 24589
CFTR- IntronlO- - UUUAAACACUUCUGAGAA 18
5710 24590
CFTR- IntronlO- - AUUUAAACACUUCUGAGAA 19
5711 24591
CFTR- IntronlO- - UAUUUAAACACUUCUGAGAA 20
5712 24592
CFTR- IntronlO- - AUAUUUAAACACUUCUGAGAA 21
5713 24593
CFTR- IntronlO- - AAUAUUUAAACACUUCUGAGAA 22
5714 24594
CFTR-
- GAAUAUUUAAACACUUCUGAGAA 23
IntronlO- 24595
993
5535.1 5715
CFTR- IntronlO- - GGAAUAUUUAAACACUUCUGAGAA 24
5716 24596
CFTR- IntronlO- - AAGGAAUUUUAUAUAGAA 18
5717 24597
CFTR- IntronlO- - AAAGG AAU UUUAUAUAGAA 19
5718 24598
CFTR- IntronlO- - CAAAGGAAUUUUAUAUAGAA 20
5719 24599
CFTR- IntronlO- - ACAAAGG AAU UUUAUAUAGAA 21
5720 24600
CFTR- IntronlO- - U ACAAAGG AAU UUUAUAUAGAA 22
5721 24601
CFTR- IntronlO- - G U ACAAAGG AAU U U U AU AU AG AA 23
5722 24602
CFTR- IntronlO- - UGUACAAAGGAAUUUUAUAUAGAA 24
5723 24603
CFTR- IntronlO- - AAGUCUAGUUUCAAGGAA 18
5724 24604
CFTR- IntronlO- - CAAG U C U AG U U U CAAG G AA 19
5725 24605
CFTR- IntronlO- - ACAAGUCUAGUUUCAAGGAA 20
5726 24606
CFTR- IntronlO- - UACAAG U CU AG U U U CAAGG AA 21
5727 24607
CFTR- IntronlO- - GUACAAGUCUAGUUUCAAGGAA 22
5728 24608
CFTR-
- UGUACAAGUCUAGUUUCAAGGAA 23
IntronlO- 24609
994
5535.1 5729
CFTR- IntronlO- - AUG U ACAAG U CU AG U U U CAAGG AA 24
5730 24610
CFTR- IntronlO- - GAAGGAAGAAAGAAGGAA 18
5731 24611
CFTR- IntronlO- - GGAAGGAAGAAAGAAGGAA 19
5732 24612
CFTR- IntronlO- - AGGAAGGAAGAAAGAAGGAA 20
5733 24613
CFTR- IntronlO- - GAGGAAGGAAGAAAGAAGGAA 21
5734 24614
CFTR- IntronlO- - AGAGGAAGGAAGAAAGAAGGAA 22
5735 24615
CFTR- IntronlO- - GAGAGGAAGGAAGAAAGAAGGAA 23
5736 24616
CFTR- IntronlO- - AGAGAGGAAGGAAGAAAGAAGGAA 24
5737 24617
CFTR- IntronlO- - UUUUAGUAGUAUUAGGAA 18
5738 24618
CFTR- IntronlO- - CUUUUAGUAGUAUUAGGAA 19
5739 24619
CFTR-
- CCUUUUAGUAGUAUUAGGAA 20
lntronlO-350 19236
CFTR- IntronlO- - GCCUUUUAGUAGUAUUAGGAA 21
5740 24620
CFTR- IntronlO- - UGCCUUUUAGUAGUAUUAGGAA 22
5741 24621
CFTR- IntronlO- - CUGCCUUUUAGUAGUAUUAGGAA 23
5742 24622
995
5535.1 CFTR- IntronlO- - GCUGCCUUUUAGUAGUAUUAGGAA 24
5743 24623
CFTR- IntronlO- - U G AAA U U AG A A AG A A U A A 18
5744 24624
CFTR- IntronlO- - AUGAAAUUAGAAAGAAUAA 19
5745 24625
CFTR- IntronlO- - AAUGAAAUUAGAAAGAAUAA 20
5746 24626
CFTR- IntronlO- - GAAUGAAAUUAGAAAGAAUAA 21
5747 24627
CFTR- IntronlO- - AGAAUGAAAUUAGAAAGAAUAA 22
5748 24628
CFTR- IntronlO- - CAGAAUGAAAUUAGAAAGAAUAA 23
5749 24629
CFTR- IntronlO- - CCAGAAUGAAAUUAGAAAGAAUAA 24
5750 24630
CFTR- IntronlO- - AAAUAUAAGAUUGAAUAA 18
5751 24631
CFTR- IntronlO- - AAAAUAUAAGAUUGAAUAA 19
5752 24632
CFTR- IntronlO- - UAAAAUAUAAGAUUGAAUAA 20
5753 24633
CFTR- IntronlO- - CU AAAAUAUAAGAUUGAAUAA 21
5754 24634
CFTR- IntronlO- - GCUAAAAUAUAAGAUUGAAUAA 22
5755 24635
CFTR- IntronlO- - AGCUAAAAUAUAAGAUUGAAUAA 23
5756 24636
996
5535.1 CFTR- IntronlO- - UAGCUAAAAUAUAAGAUUGAAUAA 24
5757 24637
CFTR- IntronlO- - CCCAUAAAUGUUGAAUAA 18
5758 24638
CFTR- IntronlO- - CCCCAUAAAUGUUGAAUAA 19
5759 24639
CFTR- IntronlO- - GCCCCAUAAAUGUUGAAUAA 20
5760 24640
CFTR- IntronlO- - AGCCCCAUAAAUGUUGAAUAA 21
5761 24641
CFTR- IntronlO- - GAGCCCCAUAAAUGUUGAAUAA 22
5762 24642
CFTR- IntronlO- - GGAGCCCCAUAAAUGUUGAAUAA 23
5763 24643
CFTR- IntronlO- - GGGAGCCCCAUAAAUGUUGAAUAA 24
5764 24644
CFTR- IntronlO- - AGCUUAUUCUUGUAAUAA 18
5765 24645
CFTR- IntronlO- - UAGCUUAUUCUUGUAAUAA 19
5766 24646
CFTR- IntronlO- - UUAGCUUAUUCUUGUAAUAA 20
5767 24647
CFTR- IntronlO- - UUUAGCUUAUUCUUGUAAUAA 21
5768 24648
CFTR- IntronlO- - UUUUAGCUUAUUCUUGUAAUAA 22
5769 24649
CFTR- IntronlO- - GUUUUAGCUUAUUCUUGUAAUAA 23
5770 24650
997
5535.1 CFTR- IntronlO- - AGUUUUAGCUUAUUCUUGUAAUAA 24
5771 24651
CFTR- IntronlO- - CGUUUACUAGAAAGAUAA 18
5772 24652
CFTR- IntronlO- - CCGUUUACUAGAAAGAUAA 19
5773 24653
CFTR-
- GCCGUUUACUAGAAAGAUAA 20
lntronlO-69 18955
CFTR- IntronlO- - UGCCGUUUACUAGAAAGAUAA 21
5774 24654
CFTR- IntronlO- - G UG CCG U U U ACU AG AAAG AU AA 22
5775 24655
CFTR- IntronlO- - UGUGCCGUUUACUAGAAAGAUAA 23
5776 24656
CFTR- IntronlO- - AUGUGCCGUUUACUAGAAAGAUAA 24
5777 24657
CFTR- IntronlO- - CCUGCAAUUUCGAGAUAA 18
5778 24658
CFTR- IntronlO- - GCCUGCAAUUUCGAGAUAA 19
5779 24659
CFTR- IntronlO- - UGCCUGCAAUUUCGAGAUAA 20
5780 24660
CFTR- IntronlO- - UUGCCUGCAAUUUCGAGAUAA 21
5781 24661
CFTR- IntronlO- - GUUGCCUGCAAUUUCGAGAUAA 22
5782 24662
CFTR- IntronlO- - AGUUGCCUGCAAUUUCGAGAUAA 23
5783 24663
CFTR-
- CAGUUGCCUGCAAUUUCGAGAUAA 24
IntronlO- 24664
998
5535.1 5784
CFTR- IntronlO- - AGAUUAGUGUCUUUAUAA 18
5785 24665
CFTR- IntronlO- - GAGAUUAGUGUCUUUAUAA 19
5786 24666
CFTR- IntronlO- - UGAGAUUAGUGUCUUUAUAA 20
5787 24667
CFTR- IntronlO- - AUGAGAUUAGUGUCUUUAUAA 21
5788 24668
CFTR- IntronlO- - AAUGAGAUUAGUGUCUUUAUAA 22
5789 24669
CFTR- IntronlO- - AAAUGAGAUUAGUGUCUUUAUAA 23
5790 24670
CFTR- IntronlO- - UAAAUGAGAUUAGUGUCUUUAUAA 24
5791 24671
CFTR- IntronlO- - UGACCUAAGAUAUCCUAA 18
5792 24672
CFTR- IntronlO- - UUGACCUAAGAUAUCCUAA 19
5793 24673
CFTR-
- UUUGACCUAAGAUAUCCUAA 20
lntronlO-358 19244
CFTR- IntronlO- - CUUUGACCUAAGAUAUCCUAA 21
5794 24674
CFTR- IntronlO- - UCUUUGACCUAAGAUAUCCUAA 22
5795 24675
CFTR- IntronlO- - CUCUUUGACCUAAGAUAUCCUAA 23
5796 24676
CFTR- IntronlO- - CCUCUUUGACCUAAGAUAUCCUAA 24
5797 24677
999
5535.1 CFTR- IntronlO- - GGCUGGAUAAGAUUCUAA 18
5798 24678
CFTR- IntronlO- - GGGCUGGAUAAGAUUCUAA 19
5799 24679
CFTR-
- GGGGCUGGAUAAGAUUCUAA 20
Intronl0-71 18957
CFTR- IntronlO- - UGGGGCUGGAUAAGAUUCUAA 21
5800 24680
CFTR- IntronlO- - AUGGGGCUGGAUAAGAUUCUAA 22
5801 24681
CFTR- IntronlO- - GAUGGGGCUGGAUAAGAUUCUAA 23
5802 24682
CFTR- IntronlO- - AGAUGGGGCUGGAUAAGAUUCUAA 24
5803 24683
CFTR- IntronlO- - AG U U U U AAACAG AAG U AA 18
5804 24684
CFTR- IntronlO- - G AG U U U U AAACAG AAG U AA 19
5805 24685
CFTR- IntronlO- - AG AG U U U U AAACAG AAG U AA 20
5806 24686
CFTR- IntronlO- - G AG AG U U U U AAACAG AAG U AA 21
5807 24687
CFTR- IntronlO- - GG AG AG U U U U AAACAG AAG U AA 22
5808 24688
CFTR- IntronlO- - UGG AG AG U U U U AAACAG AAG U AA 23
5809 24689
CFTR- IntronlO- - CUGG AG AG U U U U AAACAG AAG U AA 24
5810 24690
CFTR-
- A AAG AAG G AAG G AAG U AA 18
IntronlO- 24691
1000
5535.1 5811
CFTR- IntronlO- - G A AAG AAG G AAG G AAG U AA 19
5812 24692
CFTR- IntronlO- - G G A A AG A AG G A AG G A AG U AA 20
5813 24693
CFTR- IntronlO- - AGGAAAGAAGGAAGGAAGUAA 21
5814 24694
CFTR- IntronlO- - A AG G A A AG A AG G AAG G AAG U A A 22
5815 24695
CFTR- IntronlO- - GAAGGAAAGAAGGAAGGAAGUAA 23
5816 24696
CFTR- IntronlO- - GGAAGGAAAGAAGGAAGGAAGUAA 24
5817 24697
CFTR- IntronlO- - GCUUUCUGGACUGAGUAA 18
5818 24698
CFTR- IntronlO- - AGCUUUCUGGACUGAGUAA 19
5819 24699
CFTR- IntronlO- - AAGCUUUCUGGACUGAGUAA 20
5820 24700
CFTR- IntronlO- - CAAGCUUUCUGGACUGAGUAA 21
5821 24701
CFTR- IntronlO- - CCAAGCUUUCUGGACUGAGUAA 22
5822 24702
CFTR- IntronlO- - UCCAAGCUUUCUGGACUGAGUAA 23
5823 24703
CFTR- IntronlO- - UUCCAAGCUUUCUGGACUGAGUAA 24
5824 24704
CFTR-
- GGGUGAAGUCUUUAGUAA 18
IntronlO- 24705
1001
5535.1 5825
CFTR- IntronlO- - AGGGUGAAGUCUUUAGUAA 19
5826 24706
CFTR- IntronlO- - GAGGGUGAAGUCUUUAGUAA 20
5827 24707
CFTR- IntronlO- - UGAGGGUGAAGUCUUUAGUAA 21
5828 24708
CFTR- IntronlO- - AUGAGGGUGAAGUCUUUAGUAA 22
5829 24709
CFTR- IntronlO- - CAUGAGGGUGAAGUCUUUAGUAA 23
5830 24710
CFTR- IntronlO- - CCAUGAGGGUGAAGUCUUUAGUAA 24
5831 24711
CFTR- IntronlO- - AUAAGUGGCCUUUAAACA 18
5832 24712
CFTR- IntronlO- - UAUAAGUGGCCUUUAAACA 19
5833 24713
CFTR- IntronlO- - AUAUAAGUGGCCUUUAAACA 20
5834 24714
CFTR- IntronlO- - AAUAUAAGUGGCCUUU AAACA 21
5835 24715
CFTR- IntronlO- - AAAUAUAAGUGGCCUUUAAACA 22
5836 24716
CFTR- IntronlO- - AAAAUAUAAGUGGCCUUUAAACA 23
5837 24717
CFTR- IntronlO- - AAAAAU AU AAG UGG CCU U U AAACA 24
5838 24718
CFTR-
- ACCAUCCUGGCUAACACA 18
IntronlO- 24719
1002
5535.1 5839
CFTR- IntronlO- - GACCAUCCUGGCUAACACA 19
5840 24720
CFTR- IntronlO- - AGACCAUCCUGGCUAACACA 20
5841 24721
CFTR- IntronlO- - AAGACCAUCCUGGCUAACACA 21
5842 24722
CFTR- IntronlO- - CAAGACCAUCCUGGCUAACACA 22
5843 24723
CFTR- IntronlO- - UCAAGACCAUCCUGGCUAACACA 23
5844 24724
CFTR- IntronlO- - AUCAAGACCAUCCUGGCUAACACA 24
5845 24725
CFTR- IntronlO- - CAAUAUUUUGUUAACACA 18
5846 24726
CFTR- IntronlO- - CCAAU AU U U UG U U AACACA 19
5847 24727
CFTR- IntronlO- - U CCAAU AU U U UG U U AACACA 20
5848 24728
CFTR- IntronlO- - U U CCAAU AU U U UG U U AACACA 21
5849 24729
CFTR- IntronlO- - U U U CCAAU AU U U UG U U AACACA 22
5850 24730
CFTR- IntronlO- - GUUUCCAAUAUUUUGUUAACACA 23
5851 24731
CFTR- IntronlO- - UGUUUCCAAUAUUUUGUUAACACA 24
5852 24732
CFTR-
- UUCCAUAUUCAAAGCACA 18
IntronlO- 24733
1003
5535.1 5853
CFTR- IntronlO- - UUUCCAUAUUCAAAGCACA 19
5854 24734
CFTR- IntronlO- - CUUUCCAUAUUCAAAGCACA 20
5855 24735
CFTR- IntronlO- - ACUUUCCAUAUUCAAAGCACA 21
5856 24736
CFTR- IntronlO- - AACU UUCCAUAUU CAAAG CACA 22
5857 24737
CFTR- IntronlO- - CAACU U U CCAU AU U CAAAGCACA 23
5858 24738
CFTR- IntronlO- - ACAACUUUCCAUAUUCAAAGCACA 24
5859 24739
CFTR- IntronlO- - CAUAUGAGAAAAGUCACA 18
5860 24740
CFTR- IntronlO- - GCAUAUGAGAAAAGUCACA 19
5861 24741
CFTR- IntronlO- - GGCAUAUGAGAAAAGUCACA 20
5862 24742
CFTR- IntronlO- - UGGCAUAUGAGAAAAGUCACA 21
5863 24743
CFTR- IntronlO- - AUGGCAUAUGAGAAAAGUCACA 22
5864 24744
CFTR- IntronlO- - AAUGGCAUAUGAGAAAAGUCACA 23
5865 24745
CFTR- IntronlO- - CAAUGGCAUAUGAGAAAAGUCACA 24
5866 24746
CFTR-
- CUGGCAUAGAGUAAGACA 18
IntronlO- 24747
1004
5535.1 5867
CFTR- IntronlO- - GCUGGCAUAGAGUAAGACA 19
5868 24748
CFTR-
- GGCUGGCAUAGAGUAAGACA 20
lntronlO-74 18960
CFTR- IntronlO- - AGGCUGGCAUAGAGUAAGACA 21
5869 24749
CFTR- IntronlO- - GAGGCUGGCAUAGAGUAAGACA 22
5870 24750
CFTR- IntronlO- - UGAGGCUGGCAUAGAGUAAGACA 23
5871 24751
CFTR- IntronlO- - CUGAGGCUGGCAUAGAGUAAGACA 24
5872 24752
CFTR- IntronlO- - CUAUUCUGUAGGGAGACA 18
5873 24753
CFTR- IntronlO- - GCUAUUCUGUAGGGAGACA 19
5874 24754
CFTR-
- GGCUAUUCUGUAGGGAGACA 20
lntronlO-75 18961
CFTR- IntronlO- - AGGCUAUUCUGUAGGGAGACA 21
5875 24755
CFTR- IntronlO- - UAGGCUAUUCUGUAGGGAGACA 22
5876 24756
CFTR- IntronlO- - UUAGGCUAUUCUGUAGGGAGACA 23
5877 24757
CFTR- IntronlO- - UUUAGGCUAUUCUGUAGGGAGACA 24
5878 24758
CFTR- IntronlO- - UUUUUUUCAGUUAAUACA 18
5879 24759
1005
5535.1 CFTR- IntronlO- - UUUUUUUUCAGUUAAUACA 19
5880 24760
CFTR- IntronlO- - AUUUUUUUUCAGUUAAUACA 20
5881 24761
CFTR- IntronlO- - AAUUUUUUUUCAGUUAAUACA 21
5882 24762
CFTR- IntronlO- - GAAUUUUUUUUCAGUUAAUACA 22
5883 24763
CFTR- IntronlO- - UGAAUUUUUUUUCAGUUAAUACA 23
5884 24764
CFTR- IntronlO- - GUGAAUUUUUUUUCAGUUAAUACA 24
5885 24765
CFTR- IntronlO- - AUCAUUUCAACUUAUACA 18
5886 24766
CFTR- IntronlO- - UAUCAUUUCAACUUAUACA 19
5887 24767
CFTR- IntronlO- - AUAUCAUUUCAACUUAUACA 20
5888 24768
CFTR- IntronlO- - AAUAUCAUUUCAACUUAUACA 21
5889 24769
CFTR- IntronlO- - AAAUAUCAUUUCAACUUAUACA 22
5890 24770
CFTR- IntronlO- - AAAAUAUCAUUUCAACUUAUACA 23
5891 24771
CFTR- IntronlO- - U AAAAU AU CAU U U CAACU U AU ACA 24
5892 24772
CFTR- IntronlO- - UAGGUUUAAUUUUGUACA 18
5893 24773
1006
5535.1 CFTR- IntronlO- - CUAGGUUUAAUUUUGUACA 19
5894 24774
CFTR- IntronlO- - UCUAGGUUUAAUUUUGUACA 20
5895 24775
CFTR- IntronlO- - UUCUAGGUUUAAUUUUGUACA 21
5896 24776
CFTR- IntronlO- - CUUCUAGGUUUAAUUUUGUACA 22
5897 24777
CFTR- IntronlO- - ACUUCUAGGUUUAAUUUUGUACA 23
5898 24778
CFTR- IntronlO- - CACUUCUAGGUUUAAUUUUGUACA 24
5899 24779
CFTR- IntronlO- - GGGUGAGAUUAGAGGCCA 18
5900 24780
CFTR- IntronlO- - UGGGUGAGAUUAGAGGCCA 19
5901 24781
CFTR- IntronlO- - CUGGGUGAGAUUAGAGGCCA 20
5902 24782
CFTR- IntronlO- - UCUGGGUGAGAUUAGAGGCCA 21
5903 24783
CFTR- IntronlO- - CUCUGGGUGAGAUUAGAGGCCA 22
5904 24784
CFTR- IntronlO- - UCUCUGGGUGAGAUUAGAGGCCA 23
5905 24785
CFTR- IntronlO- - UUCUCUGGGUGAGAUUAGAGGCCA 24
5906 24786
CFTR- IntronlO- - CUUUCCAUAUUCAAAGCA 18
5907 24787
1007
5535.1 CFTR- IntronlO- - ACUUUCCAUAUUCAAAGCA 19
5908 24788
CFTR- IntronlO- - AACUUUCCAUAUUCAAAGCA 20
5909 24789
CFTR- IntronlO- - CAACU UUCCAUAUU CAAAGCA 21
5910 24790
CFTR- IntronlO- - ACAACUUUCCAUAUUCAAAGCA 22
5911 24791
CFTR- IntronlO- - G ACAACU UUCCAUAUU CAAAGCA 23
5912 24792
CFTR- IntronlO- - GG ACAACU U U CCAU AU U CAAAG CA 24
5913 24793
CFTR- IntronlO- - GAGACAAGGGAGGAAGCA 18
5914 24794
CFTR- IntronlO- - GGAGACAAGGGAGGAAGCA 19
5915 24795
CFTR-
- GGGAGACAAGGGAGGAAGCA 20
lntronlO-650 19536
CFTR- IntronlO- - AGGGAGACAAGGGAGGAAGCA 21
5916 24796
CFTR- IntronlO- - UAGGGAGACAAGGGAGGAAGCA 22
5917 24797
CFTR- IntronlO- - GUAGGGAGACAAGGGAGGAAGCA 23
5918 24798
CFTR- IntronlO- - UGUAGGGAGACAAGGGAGGAAGCA 24
5919 24799
CFTR- IntronlO- - GAUUCUGUUUAAAUAGCA 18
5920 24800
CFTR-
- UGAUUCUGUUUAAAUAGCA 19
IntronlO- 24801
1008
5535.1 5921
CFTR- IntronlO- - CUGAUUCUGUUUAAAUAGCA 20
5922 24802
CFTR- IntronlO- - CCUGAUUCUGUUUAAAUAGCA 21
5923 24803
CFTR- IntronlO- - CCCUGAUUCUGUUUAAAUAGCA 22
5924 24804
CFTR- IntronlO- - CCCCUGAUUCUGUUUAAAUAGCA 23
5925 24805
CFTR- IntronlO- - UCCCCUGAUUCUGUUUAAAUAGCA 24
5926 24806
CFTR- IntronlO- - AGUGCCACUAGUGAUGCA 18
5927 24807
CFTR- IntronlO- - AAGUGCCACUAGUGAUGCA 19
5928 24808
CFTR- IntronlO- - AAAGUGCCACUAGUGAUGCA 20
1129 20014
CFTR- IntronlO- - CAAAGUGCCACUAGUGAUGCA 21
5929 24809
CFTR- IntronlO- - ACAAAGUGCCACUAGUGAUGCA 22
5930 24810
CFTR- IntronlO- - UACAAAGUGCCACUAGUGAUGCA 23
5931 24811
CFTR- IntronlO- - AUACAAAGUGCCACUAGUGAUGCA 24
5932 24812
CFTR- IntronlO- - UGAGAAGUGGAGGCUGCA 18
5933 24813
CFTR-
- CUGAGAAGUGGAGGCUGCA 19
IntronlO- 24814
1009
5535.1 5934
CFTR- IntronlO- - CCUGAGAAGUGGAGGCUGCA 20
5935 24815
CFTR- IntronlO- - GCCUGAGAAGUGGAGGCUGCA 21
5936 24816
CFTR- IntronlO- - AGCCUGAGAAGUGGAGGCUGCA 22
5937 24817
CFTR- IntronlO- - GAGCCUGAGAAGUGGAGGCUGCA 23
5938 24818
CFTR- IntronlO- - UGAGCCUGAGAAGUGGAGGCUGCA 24
5939 24819
CFTR- IntronlO- - CAGGAGGCAGAACUUGCA 18
5940 24820
CFTR- IntronlO- - CCAGGAGGCAGAACUUGCA 19
5941 24821
CFTR- IntronlO- - CCCAGGAGGCAGAACUUGCA 20
5942 24822
CFTR- IntronlO- - ACCCAGGAGGCAGAACUUGCA 21
5943 24823
CFTR- IntronlO- - AACCCAGGAGGCAGAACUUGCA 22
5944 24824
CFTR- IntronlO- - GAACCCAGGAGGCAGAACUUGCA 23
5945 24825
CFTR- IntronlO- - UGAACCCAGGAGGCAGAACUUGCA 24
5946 24826
CFTR- IntronlO- - GGCAUAUGAGAAAAGUCA 18
5947 24827
CFTR-
- UGGCAUAUGAGAAAAGUCA 19
IntronlO- 24828
1010
5535.1 5948
CFTR- IntronlO- - AUGGCAUAUGAGAAAAGUCA 20
5949 24829
CFTR- IntronlO- - AAUGGCAUAUGAGAAAAGUCA 21
5950 24830
CFTR- IntronlO- - CAAUGGCAUAUGAGAAAAGUCA 22
5951 24831
CFTR- IntronlO- - ACAAUGGCAUAUGAGAAAAGUCA 23
5952 24832
CFTR- IntronlO- - AACAAUGGCAUAUGAGAAAAGUCA 24
5953 24833
CFTR- IntronlO- - AG AACAG U AAGG AGG U CA 18
5954 24834
CFTR- IntronlO- - AAG AACAG U AAGG AGG U CA 19
5955 24835
CFTR- IntronlO- - GAAGAACAGUAAGGAGGUCA 20
5956 24836
CFTR- IntronlO- - UGAAGAACAGUAAGGAGGUCA 21
5957 24837
CFTR- IntronlO- - UUGAAGAACAGUAAGGAGGUCA 22
5958 24838
CFTR- IntronlO- - U U U G AAG AACAG U AAG GAG G U C A 23
5959 24839
CFTR- IntronlO- - G U U UG AAG AACAG U AAGG AGG U CA 24
5960 24840
CFTR- IntronlO- - GAGGGUAGAAUACUGUCA 18
5961 24841
CFTR-
- GGAGGGUAGAAUACUGUCA 19
IntronlO- 24842
1011
5535.1 5962
CFTR- IntronlO- - GGGAGGGUAGAAUACUGUCA 20
5963 24843
CFTR- IntronlO- - AGGGAGGGUAGAAUACUGUCA 21
5964 24844
CFTR- IntronlO- - CAGGGAGGGUAGAAUACUGUCA 22
5965 24845
CFTR- IntronlO- - ACAGGGAGGGUAGAAUACUGUCA 23
5966 24846
CFTR- IntronlO- - GACAGGGAGGGUAGAAUACUGUCA 24
5967 24847
CFTR- IntronlO- - UGUACAAGUCUAGUUUCA 18
5968 24848
CFTR- IntronlO- - AUGUACAAGUCUAGUUUCA 19
5969 24849
CFTR-
- GAUGUACAAGUCUAGUUUCA 20
lntronlO-79 18965
CFTR- IntronlO- - GGAUGUACAAGUCUAGUUUCA 21
5970 24850
CFTR- IntronlO- - UGGAUGUACAAGUCUAGUUUCA 22
5971 24851
CFTR- IntronlO- - UUGGAUGUACAAGUCUAGUUUCA 23
5972 24852
CFTR- IntronlO- - GUUGGAUGUACAAGUCUAGUUUCA 24
5973 24853
CFTR- IntronlO- - AAGACAAACAGAAAAAGA 18
5974 24854
CFTR- IntronlO- - UAAGACAAACAGAAAAAGA 19
5975 24855
1012
5535.1 CFTR- IntronlO- - CUAAGACAAACAGAAAAAGA 20
5976 24856
CFTR- IntronlO- - UCUAAGACAAACAGAAAAAGA 21
5977 24857
CFTR- IntronlO- - AUCUAAGACAAACAGAAAAAGA 22
5978 24858
CFTR- IntronlO- - AAUCUAAGACAAACAGAAAAAGA 23
5979 24859
CFTR- IntronlO- - UAAUCUAAGACAAACAGAAAAAGA 24
5980 24860
CFTR- IntronlO- - CAAACAGAAAAAGAAAGA 18
5981 24861
CFTR- IntronlO- - ACAAACAGAAAAAGAAAGA 19
5982 24862
CFTR- IntronlO- - GACAAACAGAAAAAGAAAGA 20
5983 24863
CFTR- IntronlO- - AGACAAACAGAAAAAGAAAGA 21
5984 24864
CFTR- IntronlO- - AAGACAAACAGAAAAAGAAAGA 22
5985 24865
CFTR- IntronlO- - UAAGACAAACAGAAAAAGAAAGA 23
5986 24866
CFTR- IntronlO- - CUAAGACAAACAGAAAAAGAAAGA 24
5987 24867
CFTR- IntronlO- - GAGAGGAAGGAAGAAAGA 18
5988 24868
CFTR- IntronlO- - AGAGAGGAAGGAAGAAAGA 19
5989 24869
1013
5535.1 CFTR- IntronlO- - AAGAGAGGAAGGAAGAAAGA 20
1137 20022
CFTR- IntronlO- - AAAGAGAGGAAGGAAGAAAGA 21
5990 24870
CFTR- IntronlO- - GAAAGAGAGGAAGGAAGAAAGA 22
5991 24871
CFTR- IntronlO- - AGAAAGAGAGGAAGGAAGAAAGA 23
5992 24872
CFTR- IntronlO- - AAGAAAGAGAGGAAGGAAGAAAGA 24
5993 24873
CFTR- IntronlO- - G AAG G AAG G AAG G AAAG A 18
5994 24874
CFTR- IntronlO- - GGAAGGAAGGAAGGAAAGA 19
5995 24875
CFTR- IntronlO- - AG G AAG G AAG G AAG G AAAG A 20
1138 20023
CFTR- IntronlO- - G AG G AAG G AAG G AAG G AAAG A 21
5996 24876
CFTR- IntronlO- - GGAGGAAGGAAGGAAGGAAAGA 22
5997 24877
CFTR- IntronlO- - AG GAG G AAG G AAG G AAG G AAAG A 23
5998 24878
CFTR- IntronlO- - U AG GAG G AAG G AAG G AAG G AAAG A 24
5999 24879
CFTR- IntronlO- - GUCUAGUUUCAAGGAAGA 18
6000 24880
CFTR- IntronlO- - AGUCUAGUUUCAAGGAAGA 19
6001 24881
1014
5535.1 CFTR-
- AAGUCUAGUUU C A AG G A AG A 20
lntronlO-372 19258
CFTR- IntronlO- - CAAGUCUAGUUUCAAGGAAGA 21
6002 24882
CFTR- IntronlO- - ACAAGUCUAGUUUCAAGGAAGA 22
6003 24883
CFTR- IntronlO- - UACAAGUCUAGUUUCAAGGAAGA 23
6004 24884
CFTR- IntronlO- - GUACAAGUCUAGUUUCAAGGAAGA 24
6005 24885
CFTR- IntronlO- - GAAAGAGAGGAAGGAAGA 18
6006 24886
CFTR- IntronlO- - AGAAAGAGAGGAAGGAAGA 19
6007 24887
CFTR- IntronlO- - AAGAAAGAGAGGAAGGAAGA 20
6008 24888
CFTR- IntronlO- - A A AG A A AG AG AGGAAGGAAGA 21
6009 24889
CFTR- IntronlO- - AAAAGAAAGAGAGGAAGGAAGA 22
6010 24890
CFTR- IntronlO- - AAAAAGAAAGAGAGGAAGGAAGA 23
6011 24891
CFTR- IntronlO- - GAAAAAGAAAGAGAGGAAGGAAGA 24
6012 24892
CFTR- IntronlO- - AGAAGGAAAUGAGGAAGA 18
6013 24893
CFTR- IntronlO- - AAGAAGGAAAUGAGGAAGA 19
6014 24894
CFTR-
- AAAGAAGGAAAUGAGGAAGA 20
IntronlO- 24895
1015
5535.1 6015
CFTR- IntronlO- - G A A AG A AG G AAA UGAGGAAGA 21
6016 24896
CFTR- IntronlO- - AGAAAGAAGGAAAUGAGGAAGA 22
6017 24897
CFTR- IntronlO- - AAGAAAGAAGGAAAUGAGGAAGA 23
6018 24898
CFTR- IntronlO- - GAAGAAAGAAGGAAAUGAGGAAGA 24
6019 24899
CFTR- IntronlO- - GGGCUGGUAGUGUGAAGA 18
6020 24900
CFTR- IntronlO- - GGGGCUGGUAGUGUGAAGA 19
6021 24901
CFTR-
- GGGGGCUGGUAGUGUGAAGA 20
Intronl0-80 18966
CFTR- IntronlO- - AGGGGGCUGGUAGUGUGAAGA 21
6022 24902
CFTR- IntronlO- - GAGGGGGCUGGUAGUGUGAAGA 22
6023 24903
CFTR- IntronlO- - AGAGGGGGCUGGUAGUGUGAAGA 23
6024 24904
CFTR- IntronlO- - AAGAGGGGGCUGGUAGUGUGAAGA 24
6025 24905
CFTR- IntronlO- - AGAAGGAAGGAAGUAAGA 18
6026 24906
CFTR- IntronlO- - A AG A AG G A AG G A AG U A AG A 19
6027 24907
CFTR- IntronlO- - AAAGAAGGAAGGAAGUAAGA 20
1139 20024
1016
5535.1 CFTR- IntronlO- - G A A AG A AG G A AG G A AG U A AG A 21
6028 24908
CFTR- IntronlO- - G G A A AG A AG G A AG G A AG UAAGA 22
6029 24909
CFTR- IntronlO- - AGGAAAGAAGGAAGGAAGUAAGA 23
6030 24910
CFTR- IntronlO- - AAGGAAAGAAGGAAGGAAGUAAGA 24
6031 24911
CFTR- IntronlO- - GGCUGGCAUAGAGUAAGA 18
6032 24912
CFTR- IntronlO- - AGGCUGGCAUAGAGUAAGA 19
6033 24913
CFTR- IntronlO- - GAGGCUGGCAUAGAGUAAGA 20
6034 24914
CFTR- IntronlO- - UGAGGCUGGCAUAGAGUAAGA 21
6035 24915
CFTR- IntronlO- - CUGAGGCUGGCAUAGAGUAAGA 22
6036 24916
CFTR- IntronlO- - ACUGAGGCUGGCAUAGAGUAAGA 23
6037 24917
CFTR- IntronlO- - CACUGAGGCUGGCAUAGAGUAAGA 24
6038 24918
CFTR- IntronlO- - UCUAGCCUGGGUGACAGA 18
6039 24919
CFTR- IntronlO- - CUCUAGCCUGGGUGACAGA 19
6040 24920
CFTR- IntronlO- - ACUCUAGCCUGGGUGACAGA 20
6041 24921
1017
5535.1 CFTR- IntronlO- - CACUCUAGCCUGGGUGACAGA 21
6042 24922
CFTR- IntronlO- - GCACUCUAGCCUGGGUGACAGA 22
6043 24923
CFTR- IntronlO- - UGCACUCUAGCCUGGGUGACAGA 23
6044 24924
CFTR- IntronlO- - CUGCACUCUAGCCUGGGUGACAGA 24
6045 24925
CFTR- IntronlO- - AGGUCAAACUUGACCAGA 18
6046 24926
CFTR- IntronlO- - AAGGUCAAACUUGACCAGA 19
6047 24927
CFTR- IntronlO- - GAAGGUCAAACUUGACCAGA 20
6048 24928
CFTR- IntronlO- - AGAAGGUCAAACUUGACCAGA 21
6049 24929
CFTR- IntronlO- - GAGAAGGUCAAACUUGACCAGA 22
6050 24930
CFTR- IntronlO- - AGAGAAGGUCAAACUUGACCAGA 23
6051 24931
CFTR- IntronlO- - UAGAGAAGGUCAAACUUGACCAGA 24
6052 24932
CFTR- IntronlO- - AAUU U AACAU U U U CCAGA 18
6053 24933
CFTR- IntronlO- - AAAU U U AACAU U U U CCAGA 19
6054 24934
CFTR- IntronlO- - AAAAU U U AACAU U U U CCAGA 20
6055 24935
1018
5535.1 CFTR- IntronlO- - G AAAAU U U AACAU U U U CCAG A 21
6056 24936
CFTR- IntronlO- - GG AAAAU U U AACAU U U U CCAG A 22
6057 24937
CFTR- IntronlO- - GGG AAAAU U U AACAU U U U CCAG A 23
6058 24938
CFTR- IntronlO- - AGGG AAAAU U U AACAU U U U CCAG A 24
6059 24939
CFTR- IntronlO- - A AG U G C A A AG C U U U C AG A 18
6060 24940
CFTR- IntronlO- - CAAG U G CAAAG C U U U C AG A 19
6061 24941
CFTR-
- GCAAGUG CAAAG CU U U C AG A 20
lntronlO-82 18968
CFTR- IntronlO- - AG CAAG U G CAAAG C U U U C AG A 21
6062 24942
CFTR- IntronlO- - AAG CAAG U G CAAAG C U U U C AG A 22
6063 24943
CFTR- IntronlO- - GAAGCAAGUGCAAAGCUUUCAGA 23
6064 24944
CFTR- IntronlO- - UGAAGCAAGUG CAAAG C U U U C AG A 24
6065 24945
CFTR- IntronlO- - AGGGUUGAUAAGAAGAGA 18
6066 24946
CFTR- IntronlO- - GAGGGUUGAUAAGAAGAGA 19
6067 24947
CFTR- IntronlO- - AGAGGGUUGAUAAGAAGAGA 20
6068 24948
CFTR-
- AAGAGGGUUGAUAAGAAGAGA 21
IntronlO- 24949
1019
5535.1 6069
CFTR- IntronlO- - AAAGAGGGUUGAUAAGAAGAGA 22
6070 24950
CFTR- IntronlO- - GAAAGAGGGUUGAUAAGAAGAGA 23
6071 24951
CFTR- IntronlO- - GGAAAGAGGGUUGAUAAGAAGAGA 24
6072 24952
CFTR- IntronlO- - AUCAAAUUAGAGAUGAGA 18
6073 24953
CFTR- IntronlO- - AAUCAAAUUAGAGAUGAGA 19
6074 24954
CFTR- IntronlO- - GAAUCAAAUUAGAGAUGAGA 20
6075 24955
CFTR- IntronlO- - AGAAUCAAAUUAGAGAUGAGA 21
6076 24956
CFTR- IntronlO- - AAGAAUCAAAUUAGAGAUGAGA 22
6077 24957
CFTR- IntronlO- - AAAGAAUCAAAUUAGAGAUGAGA 23
6078 24958
CFTR- IntronlO- - GAAAGAAUCAAAUUAGAGAUGAGA 24
6079 24959
CFTR- IntronlO- - A A A A A A UAGUAGAUUAGA 18
6080 24960
CFTR- IntronlO- - GAAAAAAUAGUAGAUUAGA 19
6081 24961
CFTR- IntronlO- - U G A A A A A A UAGUAGAUUAGA 20
6082 24962
CFTR-
- CUGAAAAAAUAGUAGAUUAGA 21
IntronlO- 24963
1020
5535.1 6083
CFTR- IntronlO- - UCUGAAAAAAUAGUAGAUUAGA 22
6084 24964
CFTR- IntronlO- - AUCUGAAAAAAUAGUAGAUUAGA 23
6085 24965
CFTR- IntronlO- - CAU CUG AAAAAAU AG U AG AU U AG A 24
6086 24966
CFTR- IntronlO- - GAGCUUUCUAGUAUUAGA 18
6087 24967
CFTR- IntronlO- - AGAGCUUUCUAGUAUUAGA 19
6088 24968
CFTR- IntronlO- - AAGAGCUUUCUAGUAUUAGA 20
6089 24969
CFTR- IntronlO- - AAAGAGCUUUCUAGUAUUAGA 21
6090 24970
CFTR- IntronlO- - GAAAGAGCUUUCUAGUAUUAGA 22
6091 24971
CFTR- IntronlO- - AGAAAGAGCUUUCUAGUAUUAGA 23
6092 24972
CFTR- IntronlO- - GAGAAAGAGCUUUCUAGUAUUAGA 24
6093 24973
CFTR- IntronlO- - GGAUAAGAUUCUAAAGGA 18
6094 24974
CFTR- IntronlO- - UGGAUAAGAUUCUAAAGGA 19
6095 24975
CFTR- IntronlO- - CUGGAUAAGAUUCUAAAGGA 20
6096 24976
CFTR-
- GCUGGAUAAGAUUCUAAAGGA 21
IntronlO- 24977
1021
5535.1 6097
CFTR- IntronlO- - GGCUGGAUAAGAUUCUAAAGGA 22
6098 24978
CFTR- IntronlO- - GGGCUGGAUAAGAUUCUAAAGGA 23
6099 24979
CFTR- IntronlO- - GGGGCUGGAUAAGAUUCUAAAGGA 24
6100 24980
CFTR- IntronlO- - GAAGGAAGGAAAGAAGGA 18
6101 24981
CFTR- IntronlO- - GGAAGGAAGGAAAGAAGGA 19
6102 24982
CFTR- IntronlO- - AGGAAGGAAGGAAAGAAGGA 20
1145 20030
CFTR- IntronlO- - AAG G AAG G AAG G AAAG AAG G A 21
6103 24983
CFTR- IntronlO- - GAAGGAAGGAAGG A A AG A AG G A 22
6104 24984
CFTR- IntronlO- - GGAAGGAAGGAAGGAAAGAAGGA 23
6105 24985
CFTR- IntronlO- - AGGAAGGAAGGAAGGAAAGAAGGA 24
6106 24986
CFTR- IntronlO- - GGAGGAAGGAAGGAAGGA 18
6107 24987
CFTR- IntronlO- - AGGAGGAAGGAAGGAAGGA 19
6108 24988
CFTR- IntronlO- - UAGGAGGAAGGAAGGAAGGA 20
6109 24989
CFTR-
- GU AGGAGGAAGGAAGGAAGGA 21
IntronlO- 24990
1022
5535.1 6110
CFTR- IntronlO- - AG U AGG AGG AAGG AAGG AAGG A 22
6111 24991
CFTR- IntronlO- - AAGUAGGAGGAAGGAAGGAAGGA 23
6112 24992
CFTR- IntronlO- - GAAGUAGGAGGAAGGAAGGAAGGA 24
6113 24993
CFTR- IntronlO- - AGUAGGAGGAAGGAAGGA 18
6114 24994
CFTR- IntronlO- - AAG U AGG AGG AAGG AAGG A 19
6115 24995
CFTR-
- GAAG U AGG AGG AAGG AAGG A 20
lntronlO-652 19538
CFTR- IntronlO- - GGAAGUAGGAGGAAGGAAGGA 21
6116 24996
CFTR- IntronlO- - AGGAAGUAGGAGGAAGGAAGGA 22
6117 24997
CFTR- IntronlO- - AAGGAAGUAGGAGGAAGGAAGGA 23
6118 24998
CFTR- IntronlO- - AAAGGAAGUAGGAGGAAGGAAGGA 24
6119 24999
CFTR- IntronlO- - AGGAAGUAGGAGGAAGGA 18
6120 25000
CFTR- IntronlO- - AAGGAAGUAGGAGGAAGGA 19
6121 25001
CFTR- IntronlO- - AAAGGAAGUAGGAGGAAGGA 20
1146 20031
CFTR- IntronlO- - GAAAGGAAGUAGGAGGAAGGA 21
6122 25002
1023
5535.1 CFTR- IntronlO- - AGAAAGGAAGUAGGAGGAAGGA 22
6123 25003
CFTR- IntronlO- - AAGAAAGGAAGUAGGAGGAAGGA 23
6124 25004
CFTR- IntronlO- - GAAGAAAGGAAGUAGGAGGAAGGA 24
6125 25005
CFTR- IntronlO- - UUAGAAAGAAUAAGAGGA 18
6126 25006
CFTR- IntronlO- - AUUAGAAAGAAUAAGAGGA 19
6127 25007
CFTR- IntronlO- - AAUUAGAAAGAAUAAGAGGA 20
6128 25008
CFTR- IntronlO- - AAAU U AG AAAG AAU AAG AGG A 21
6129 25009
CFTR- IntronlO- - GAAAUUAGAAAGAAUAAGAGGA 22
6130 25010
CFTR- IntronlO- - UGAAAUUAGAAAGAAUAAGAGGA 23
6131 25011
CFTR- IntronlO- - AUGAAAUUAGAAAGAAUAAGAGGA 24
6132 25012
CFTR- IntronlO- - AGAAAAAGAAAGAGAGGA 18
6133 25013
CFTR- IntronlO- - CAGAAAAAGAAAGAGAGGA 19
6134 25014
CFTR- IntronlO- - A C AG A A A A AG A A AG AG AG G A 20
1149 20034
CFTR- IntronlO- - AACAGAAAAAGAAAGAGAGGA 21
6135 25015
1024
5535.1 CFTR- IntronlO- - A A AC AG A A A A AG A A AG AG AG G A 22
6136 25016
CFTR- IntronlO- - CAAACAGAAAAAGAAAGAGAGGA 23
6137 25017
CFTR- IntronlO- - ACAAACAGAAAAAGAAAGAGAGGA 24
6138 25018
CFTR- IntronlO- - AGAAAGGAAGUAGGAGGA 18
6139 25019
CFTR- IntronlO- - AAGAAAGGAAGUAGGAGGA 19
6140 25020
CFTR-
- GAAGAAAGGAAGUAGGAGGA 20
lntronlO-653 19539
CFTR- IntronlO- - GGAAGAAAGGAAGUAGGAGGA 21
6141 25021
CFTR- IntronlO- - AGG AAGAAAGGAAGUAGGAGGA 22
6142 25022
CFTR- IntronlO- - GAGGAAGAAAGGAAGUAGGAGGA 23
6143 25023
CFTR- IntronlO- - UGAGGAAGAAAGGAAGUAGGAGGA 24
6144 25024
CFTR- IntronlO- - CUUUUAGUAGUAUUAGGA 18
6145 25025
CFTR- IntronlO- - CCUUUUAGUAGUAUUAGGA 19
6146 25026
CFTR- IntronlO- - GCCUUUUAGUAGUAUUAGGA 20
6147 25027
CFTR- IntronlO- - UGCCUUUUAGUAGUAUUAGGA 21
6148 25028
CFTR-
- CUGCCUUUUAGUAGUAUUAGGA 22
IntronlO- 25029
1025
5535.1 6149
CFTR- IntronlO- - GCUGCCUUUUAGUAGUAUUAGGA 23
6150 25030
CFTR- IntronlO- - GGCUGCCUUUUAGUAGUAUUAGGA 24
6151 25031
CFTR- IntronlO- - GGAGAAACAGGUUUUGGA 18
6152 25032
CFTR- IntronlO- - GGGAGAAACAGGUUUUGGA 19
6153 25033
CFTR- IntronlO- - UGGGAGAAACAGGUUUUGGA 20
1157 20042
CFTR- IntronlO- - AUGGGAGAAACAGGUUUUGGA 21
6154 25034
CFTR- IntronlO- - AAUGGGAGAAACAGGUUUUGGA 22
6155 25035
CFTR- IntronlO- - UAAUGGGAGAAACAGGUUUUGGA 23
6156 25036
CFTR- IntronlO- - AUAAUGGGAGAAACAGGUUUUGGA 24
6157 25037
CFTR- IntronlO- - AUCACUGGAUGCCCUUGA 18
6158 25038
CFTR- IntronlO- - CAUCACUGGAUGCCCUUGA 19
6159 25039
CFTR- IntronlO- - GCAUCACUGGAUGCCCUUGA 20
6160 25040
CFTR- IntronlO- - UGCAUCACUGGAUGCCCUUGA 21
6161 25041
CFTR-
- UUGCAUCACUGGAUGCCCUUGA 22
IntronlO- 25042
1026
5535.1 6162
CFTR- IntronlO- - UUUGCAUCACUGGAUGCCCUUGA 23
6163 25043
CFTR- IntronlO- - UUUUGCAUCACUGGAUGCCCUUGA 24
6164 25044
CFTR- IntronlO- - AUUCAGGACAUGCUUUGA 18
6165 25045
CFTR- IntronlO- - GAUUCAGGACAUGCUUUGA 19
6166 25046
CFTR- IntronlO- - AGAUUCAGGACAUGCUUUGA 20
1164 20049
CFTR- IntronlO- - CAGAUUCAGGACAUGCUUUGA 21
6167 25047
CFTR- IntronlO- - UCAGAUUCAGGACAUGCUUUGA 22
6168 25048
CFTR- IntronlO- - AUCAGAUUCAGGACAUGCUUUGA 23
6169 25049
CFTR- IntronlO- - GAUCAGAUUCAGGACAUGCUUUGA 24
6170 25050
CFTR- IntronlO- - CUGUCUAGCCUAGAAAUA 18
6171 25051
CFTR- IntronlO- - ACUGUCUAGCCUAGAAAUA 19
6172 25052
CFTR- IntronlO- - AACUGUCUAGCCUAGAAAUA 20
6173 25053
CFTR- IntronlO- - AAACUGUCUAGCCUAGAAAUA 21
6174 25054
CFTR-
- CAAACUGUCUAGCCUAGAAAUA 22
IntronlO- 25055
1027
5535.1 6175
CFTR- IntronlO- - ACAAACUGUCUAGCCUAGAAAUA 23
6176 25056
CFTR- IntronlO- - CACAAACUGUCUAGCCUAGAAAUA 24
6177 25057
CFTR- IntronlO- - CCGGUGUCUUCUGAAAUA 18
6178 25058
CFTR- IntronlO- - ACCGGUGUCUUCUGAAAUA 19
6179 25059
CFTR-
- AACCGGUGUCUUCUGAAAUA 20
lntronlO-380 19266
CFTR- IntronlO- - UAACCGGUGUCUUCUGAAAUA 21
6180 25060
CFTR- IntronlO- - UUAACCGGUGUCUUCUGAAAUA 22
6181 25061
CFTR- IntronlO- - AUUAACCGGUGUCUUCUGAAAUA 23
6182 25062
CFTR- IntronlO- - AAUUAACCGGUGUCUUCUGAAAUA 24
6183 25063
CFTR- IntronlO- - AGUGAUCCUAGAAUCAUA 18
6184 25064
CFTR- IntronlO- - AAGUGAUCCUAGAAUCAUA 19
6185 25065
CFTR- IntronlO- - AAAGUGAUCCUAGAAUCAUA 20
6186 25066
CFTR- IntronlO- - UAAAGUGAUCCUAGAAUCAUA 21
6187 25067
CFTR- IntronlO- - AUAAAGUGAUCCUAGAAUCAUA 22
6188 25068
1028
5535.1 CFTR- IntronlO- - UAUAAAGUGAUCCUAGAAUCAUA 23
6189 25069
CFTR- IntronlO- - AUAUAAAGUGAUCCUAGAAUCAUA 24
6190 25070
CFTR- IntronlO- - CCGUUUACUAGAAAGAUA 18
6191 25071
CFTR- IntronlO- - GCCGUUUACUAGAAAGAUA 19
6192 25072
CFTR- IntronlO- - UGCCGUUUACUAGAAAGAUA 20
6193 25073
CFTR- IntronlO- - GUGCCGUUUACUAGAAAGAUA 21
6194 25074
CFTR- IntronlO- - UGUGCCGUUUACUAGAAAGAUA 22
6195 25075
CFTR- IntronlO- - AUGUGCCGUUUACUAGAAAGAUA 23
6196 25076
CFTR- IntronlO- - AAUGUGCCGUUUACUAGAAAGAUA 24
6197 25077
CFTR- IntronlO- - CUUGGUAUUUACCAUAUA 18
6198 25078
CFTR- IntronlO- - GCUUGGUAUUUACCAUAUA 19
6199 25079
CFTR- IntronlO- - UGCUUGGUAUUUACCAUAUA 20
6200 25080
CFTR- IntronlO- - UUGCUUGGUAUUUACCAUAUA 21
6201 25081
CFTR- IntronlO- - GUUGCUUGGUAUUUACCAUAUA 22
6202 25082
1029
5535.1 CFTR- IntronlO- - AGUUGCUUGGUAUUUACCAUAUA 23
6203 25083
CFTR- IntronlO- - GAGUUGCUUGGUAUUUACCAUAUA 24
6204 25084
CFTR- IntronlO- - UUACACUCUAGCAUUAUA 18
6205 25085
CFTR- IntronlO- - AUUACACUCUAGCAUUAUA 19
6206 25086
CFTR- IntronlO- - AAUUACACUCUAGCAUUAUA 20
6207 25087
CFTR- IntronlO- - UAAUUACACUCUAGCAUUAUA 21
6208 25088
CFTR- IntronlO- - AUAAUUACACUCUAGCAUUAUA 22
6209 25089
CFTR- IntronlO- - UAUAAUUACACUCUAGCAUUAUA 23
6210 25090
CFTR- IntronlO- - UUAUAAUUACACUCUAGCAUUAUA 24
6211 25091
CFTR- IntronlO- - AAAGUUUCUCAUCUUAUA 18
6212 25092
CFTR- IntronlO- - AAAAGUUUCUCAUCUUAUA 19
6213 25093
CFTR- IntronlO- - AAAAAGUUUCUCAUCUUAUA 20
1171 20056
CFTR- IntronlO- - UAAAAAGUUUCUCAUCUUAUA 21
6214 25094
CFTR- IntronlO- - UUAAAAAGUUUCUCAUCUUAUA 22
6215 25095
1030
5535.1 CFTR- IntronlO- - UUUAAAAAGUUUCUCAUCUUAUA 23
6216 25096
CFTR- IntronlO- - AUUUAAAAAGUUUCUCAUCUUAUA 24
6217 25097
CFTR- IntronlO- - GUACAAAGGAAUUUUAUA 18
6218 25098
CFTR- IntronlO- - UGUACAAAGGAAUUUUAUA 19
6219 25099
CFTR- IntronlO- - UUGUACAAAGGAAUUUUAUA 20
6220 25100
CFTR- IntronlO- - UU UGUACAAAGGAAUUUUAUA 21
6221 25101
CFTR- IntronlO- - UUUUGUACAAAGGAAUUUUAUA 22
6222 25102
CFTR- IntronlO- - AU U U UG U ACAAAGG AAU U U U AU A 23
6223 25103
CFTR- IntronlO- - AAU U U UG U ACAAAGG AAU U U U AU A 24
6224 25104
CFTR- IntronlO- - CUUGCUCUCUUUUAACUA 18
6225 25105
CFTR- IntronlO- - ACUUGCUCUCUUUUAACUA 19
6226 25106
CFTR- IntronlO- - AACUUGCUCUCUUUUAACUA 20
6227 25107
CFTR- IntronlO- - AAACUUGCUCUCUUUUAACUA 21
6228 25108
CFTR- IntronlO- - AAAACUUGCUCUCUUUUAACUA 22
6229 25109
1031
5535.1 CFTR- IntronlO- - AAAAACUUGCUCUCUUUUAACUA 23
6230 25110
CFTR- IntronlO- - UAAAAACUUGCUCUCUUUUAACUA 24
6231 25111
CFTR- IntronlO- - U AU U AAAAAAU U AU ACU A 18
6232 25112
CFTR- IntronlO- - CU AU U AAAAAAU U AU ACU A 19
6233 25113
CFTR- IntronlO- - ACUAUUAAAAAAUUAUACUA 20
6234 25114
CFTR- IntronlO- - CACU AU U AAAAAAU UAU ACU A 21
6235 25115
CFTR- IntronlO- - U CACU AU U AAAAAAU UAU ACU A 22
6236 25116
CFTR- IntronlO- - U U CACU AU U AAAAAAU UAU ACU A 23
6237 25117
CFTR- IntronlO- - GUUCACUAUUAAAAAAUUAUACUA 24
6238 25118
CFTR- IntronlO- - UUGACCUAAGAUAUCCUA 18
6239 25119
CFTR- IntronlO- - UUUGACCUAAGAUAUCCUA 19
6240 25120
CFTR-
- CUUUGACCUAAGAUAUCCUA 20
lntronlO-387 19273
CFTR- IntronlO- - UCUUUGACCUAAGAUAUCCUA 21
6241 25121
CFTR- IntronlO- - CUCUUUGACCUAAGAUAUCCUA 22
6242 25122
CFTR-
- CCUCUUUGACCUAAGAUAUCCUA 23
IntronlO- 25123
1032
5535.1 6243
CFTR- IntronlO- - UCCUCUUUGACCUAAGAUAUCCUA 24
6244 25124
CFTR- IntronlO- - UAGUAUUAGAAUGGGCUA 18
6245 25125
CFTR- IntronlO- - CUAGUAUUAGAAUGGGCUA 19
6246 25126
CFTR- IntronlO- - UCUAGUAUUAGAAUGGGCUA 20
6247 25127
CFTR- IntronlO- - UUCUAGUAUUAGAAUGGGCUA 21
6248 25128
CFTR- IntronlO- - UUUCUAGUAUUAGAAUGGGCUA 22
6249 25129
CFTR- IntronlO- - CUUUCUAGUAUUAGAAUGGGCUA 23
6250 25130
CFTR- IntronlO- - GCUUUCUAGUAUUAGAAUGGGCUA 24
6251 25131
CFTR- IntronlO- - GGGCUGGAUAAGAUUCUA 18
6252 25132
CFTR- IntronlO- - GGGGCUGGAUAAGAUUCUA 19
6253 25133
CFTR- IntronlO- - UGGGGCUGGAUAAGAUUCUA 20
6254 25134
CFTR- IntronlO- - AUGGGGCUGGAUAAGAUUCUA 21
6255 25135
CFTR- IntronlO- - GAUGGGGCUGGAUAAGAUUCUA 22
6256 25136
CFTR-
- AGAUGGGGCUGGAUAAGAUUCUA 23
IntronlO- 25137
1033
5535.1 6257
CFTR- IntronlO- - AAGAUGGGGCUGGAUAAGAUUCUA 24
6258 25138
CFTR- IntronlO- - CUGGUUUGAAGAACAGUA 18
6259 25139
CFTR- IntronlO- - UCUGGUUUGAAGAACAGUA 19
6260 25140
CFTR-
- GUCUGGUUUGAAGAACAGUA 20
lntronlO-86 18972
CFTR- IntronlO- - UGUCUGGUUUGAAGAACAGUA 21
6261 25141
CFTR- IntronlO- - CUGUCUGGUUUGAAGAACAGUA 22
6262 25142
CFTR- IntronlO- - CCUGUCUGGUUUGAAGAACAGUA 23
6263 25143
CFTR- IntronlO- - ACCUGUCUGGUUUGAAGAACAGUA 24
6264 25144
CFTR- IntronlO- - CUGGCACCAUUCACAGUA 18
6265 25145
CFTR- IntronlO- - CCUGGCACCAUUCACAGUA 19
6266 25146
CFTR- IntronlO- - ACCUGGCACCAUUCACAGUA 20
6267 25147
CFTR- IntronlO- - UACCUGGCACCAUUCACAGUA 21
6268 25148
CFTR- IntronlO- - CUACCUGGCACCAUUCACAGUA 22
6269 25149
CFTR- IntronlO- - CCUACCUGGCACCAUUCACAGUA 23
6270 25150
1034
5535.1 CFTR- IntronlO- - CCCUACCUGGCACCAUUCACAGUA 24
6271 25151
CFTR- IntronlO- - U U A A U G A A AG C A A U AG U A 18
6272 25152
CFTR- IntronlO- - CUUAAUGAAAGCAAUAGUA 19
6273 25153
CFTR- IntronlO- - ACUUAAUGAAAGCAAUAGUA 20
6274 25154
CFTR- IntronlO- - GACUUAAUGAAAGCAAUAGUA 21
6275 25155
CFTR- IntronlO- - UGACUUAAUGAAAGCAAUAGUA 22
6276 25156
CFTR- IntronlO- - GUGACUUAAUGAAAGCAAUAGUA 23
6277 25157
CFTR- IntronlO- - CGUGACUUAAUGAAAGCAAUAGUA 24
6278 25158
CFTR- IntronlO- - GGCUUGAUCCAGGUAGUA 18
6279 25159
CFTR- IntronlO- - UGGCUUGAUCCAGGUAGUA 19
6280 25160
CFTR- IntronlO- - GUGGCUUGAUCCAGGUAGUA 20
6281 25161
CFTR- IntronlO- - GGUGGCUUGAUCCAGGUAGUA 21
6282 25162
CFTR- IntronlO- - UGGUGGCUUGAUCCAGGUAGUA 22
6283 25163
CFTR- IntronlO- - AUGGUGGCUUGAUCCAGGUAGUA 23
6284 25164
1035
5535.1 CFTR- IntronlO- - GAUGGUGGCUUGAUCCAGGUAGUA 24
6285 25165
CFTR- IntronlO- - UUUUUAGGCUAUUCUGUA 18
6286 25166
CFTR- IntronlO- - GUUUUUAGGCUAUUCUGUA 19
6287 25167
CFTR-
- UGUUUUUAGGCUAUUCUGUA 20
lntronlO-390 19276
CFTR- IntronlO- - AUGUUUUUAGGCUAUUCUGUA 21
6288 25168
CFTR- IntronlO- - AAUGUUUUUAGGCUAUUCUGUA 22
6289 25169
CFTR- IntronlO- - UAAUGUUUUUAGGCUAUUCUGUA 23
6290 25170
CFTR- IntronlO- - CUAAUGUUUUUAGGCUAUUCUGUA 24
6291 25171
CFTR- IntronlO- - CACUUGACAGGUAUAUUA 18
6292 25172
CFTR- IntronlO- - GCACUUGACAGGUAUAUUA 19
6293 25173
CFTR- IntronlO- - AGCACUUGACAGGUAUAUUA 20
6294 25174
CFTR- IntronlO- - UAGCACUUGACAGGUAUAUUA 21
6295 25175
CFTR- IntronlO- - CUAGCACUUGACAGGUAUAUUA 22
6296 25176
CFTR- IntronlO- - CCUAGCACUUGACAGGUAUAUUA 23
6297 25177
CFTR-
- GCCUAGCACUUGACAGGUAUAUUA 24
IntronlO- 25178
1036
5535.1 6298
CFTR- IntronlO- - GAGAUAACUCGUGACUUA 18
6299 25179
CFTR- IntronlO- - GGAGAUAACUCGUGACUUA 19
6300 25180
CFTR- IntronlO- - CGGAGAUAACUCGUGACUUA 20
6301 25181
CFTR- IntronlO- - ACGGAGAUAACUCGUGACUUA 21
6302 25182
CFTR- IntronlO- - UACGGAGAUAACUCGUGACUUA 22
6303 25183
CFTR- IntronlO- - AUACGGAGAUAACUCGUGACUUA 23
6304 25184
CFTR- IntronlO- - AAUACGGAGAUAACUCGUGACUUA 24
6305 25185
CFTR- IntronlO- - U U UAU AAAAG AAACCU U A 18
6306 25186
CFTR- IntronlO- - CU U UAU AAAAG AAACCU U A 19
6307 25187
CFTR- IntronlO- - U CU U UAU AAAAG AAACCU U A 20
6308 25188
CFTR- IntronlO- - G U CU U UAU AAAAG AAACCU U A 21
6309 25189
CFTR- IntronlO- - UG U CU U UAU AAAAG AAACCU U A 22
6310 25190
CFTR- IntronlO- - G UG U CU U UAU AAAAG AAACCU U A 23
6311 25191
CFTR-
- AGUGUCUUUAUAAAAGAAACCUUA 24
IntronlO- 25192
1037
5535.1 6312
CFTR- IntronlO- - AGAGACCCUCACACCUUA 18
6313 25193
CFTR- IntronlO- - GAGAGACCCUCACACCUUA 19
6314 25194
CFTR- IntronlO- - AGAGAGACCCUCACACCUUA 20
6315 25195
CFTR- IntronlO- - UAGAGAGACCCUCACACCUUA 21
6316 25196
CFTR- IntronlO- - UUAGAGAGACCCUCACACCUUA 22
6317 25197
CFTR- IntronlO- - CUUAGAGAGACCCUCACACCUUA 23
6318 25198
CFTR- IntronlO- - CCUUAGAGAGACCCUCACACCUUA 24
6319 25199
CFTR- IntronlO- - AAAAAGUUUCUCAUCUUA 18
6320 25200
CFTR- IntronlO- - UAAAAAGUUUCUCAUCUUA 19
6321 25201
CFTR- IntronlO- - UUAAAAAGUUUCUCAUCUUA 20
6322 25202
CFTR- IntronlO- - UUUAAAAAGUUUCUCAUCUUA 21
6323 25203
CFTR- IntronlO- - AUUUAAAAAGUUUCUCAUCUUA 22
6324 25204
CFTR- IntronlO- - AAU U U AAAAAG UUUCUCAUCUUA 23
6325 25205
CFTR-
- UAAUUUAAAAAGUUUCUCAUCUUA 24
IntronlO- 25206
1038
5535.1 6326
CFTR- IntronlO- - GCUAUGAAGGCAGAGUUA 18
6327 25207
CFTR- IntronlO- - AGCUAUGAAGGCAGAGUUA 19
6328 25208
CFTR- IntronlO- - CAGCUAUGAAGGCAGAGUUA 20
6329 25209
CFTR- IntronlO- - GCAGCUAUGAAGGCAGAGUUA 21
6330 25210
CFTR- IntronlO- - AGCAGCUAUGAAGGCAGAGUUA 22
6331 25211
CFTR- IntronlO- - AAGCAGCUAUGAAGGCAGAGUUA 23
6332 25212
CFTR- IntronlO- - AAAGCAGCUAUGAAGGCAGAGUUA 24
6333 25213
CFTR- IntronlO- - UCUAAGUAUUAGAGGUUA 18
6334 25214
CFTR- IntronlO- - UUCUAAGUAUUAGAGGUUA 19
6335 25215
CFTR-
- AUUCUAAGUAUUAGAGGUUA 20
lntronlO-397 19283
CFTR- IntronlO- - CAU UCUAAGUAUUAGAGGUUA 21
6336 25216
CFTR- IntronlO- - GCAU UCUAAGUAUUAGAGGUUA 22
6337 25217
CFTR- IntronlO- - GGCAUUCUAAGUAUUAGAGGUUA 23
6338 25218
CFTR- IntronlO- - GGGCAUUCUAAGUAUUAGAGGUUA 24
6339 25219
1039
5535.1 CFTR- IntronlO- - CUGUAGGUAAAAAUGUUA 18
6340 25220
CFTR- IntronlO- - GCUGUAGGUAAAAAUGUUA 19
6341 25221
CFTR- IntronlO- - UGCUGUAGGUAAAAAUGUUA 20
6342 25222
CFTR- IntronlO- - CUGCUGUAGGUAAAAAUGUUA 21
6343 25223
CFTR- IntronlO- - GCUGCUGUAGGUAAAAAUGUUA 22
6344 25224
CFTR- IntronlO- - UGCUGCUGUAGGUAAAAAUGUUA 23
6345 25225
CFTR- IntronlO- - CUGCUGCUGUAGGUAAAAAUGUUA 24
6346 25226
CFTR- IntronlO- - U AAG AAU UG U AAAAU U U A 18
6347 25227
CFTR- IntronlO- - AU AAG AAU UG U AAAAU U U A 19
6348 25228
CFTR- IntronlO- - AAU AAG AAU UG U AAAAU U U A 20
6349 25229
CFTR- IntronlO- - U AAU AAG AAU UG U AAAAU U U A 21
6350 25230
CFTR- IntronlO- - G U AAU AAG AAU UG U AAAAU U U A 22
6351 25231
CFTR- IntronlO- - UG U AAU AAG AAU UG U AAAAU U U A 23
6352 25232
CFTR- IntronlO- - AUG U AAU AAG AAU UG U AAAAU U U A 24
6353 25233
1040
5535.1 CFTR- IntronlO- - CUUCCUUGAAUUAUUUUA 18
6354 25234
CFTR- IntronlO- - ACUUCCUUGAAUUAUUUUA 19
6355 25235
CFTR- IntronlO- - AACUUCCUUGAAUUAUUUUA 20
6356 25236
CFTR- IntronlO- - AAACUUCCUUGAAUUAUUUUA 21
6357 25237
CFTR- IntronlO- - GAAACUUCCUUGAAUUAUUUUA 22
6358 25238
CFTR- IntronlO- - UGAAACUUCCUUGAAUUAUUUUA 23
6359 25239
CFTR- IntronlO- - AUGAAACUUCCUUGAAUUAUUUUA 24
6360 25240
CFTR- IntronlO- - UGUUAUAGCAGCCUGAAC 18
6361 25241
CFTR- IntronlO- - UUGUUAUAGCAGCCUGAAC 19
6362 25242
CFTR- IntronlO- - UUUGUUAUAGCAGCCUGAAC 20
6363 25243
CFTR- IntronlO- - UUUUGUUAUAGCAGCCUGAAC 21
6364 25244
CFTR- IntronlO- - AUUUUGUUAUAGCAGCCUGAAC 22
6365 25245
CFTR- IntronlO- - UAUUUUGUUAUAGCAGCCUGAAC 23
6366 25246
CFTR- IntronlO- - GUAUUUUGUUAUAGCAGCCUGAAC 24
6367 25247
1041
5535.1 CFTR- IntronlO- - GCUUAUUCUUGUAAUAAC 18
6368 25248
CFTR- IntronlO- - AGCUUAUUCUUGUAAUAAC 19
6369 25249
CFTR-
- UAGCUUAUUCUUGUAAUAAC 20
Intron 10-404 19290
CFTR- IntronlO- - UUAGCUUAUUCUUGUAAUAAC 21
6370 25250
CFTR- IntronlO- - UUUAGCUUAUUCUUGUAAUAAC 22
6371 25251
CFTR- IntronlO- - UUUUAGCUUAUUCUUGUAAUAAC 23
6372 25252
CFTR- IntronlO- - GUUUUAGCUUAUUCUUGUAAUAAC 24
6373 25253
CFTR- IntronlO- - GGCCUGCAUAUGUCUAAC 18
6374 25254
CFTR- IntronlO- - GGGCCUGCAUAUGUCUAAC 19
6375 25255
CFTR- IntronlO- - UGGGCCUGCAUAUGUCUAAC 20
6376 25256
CFTR- IntronlO- - UUGGGCCUGCAUAUGUCUAAC 21
6377 25257
CFTR- IntronlO- - UUUGGGCCUGCAUAUGUCUAAC 22
6378 25258
CFTR- IntronlO- - AUUUGGGCCUGCAUAUGUCUAAC 23
6379 25259
CFTR- IntronlO- - UAUUUGGGCCUGCAUAUGUCUAAC 24
6380 25260
CFTR-
- CUUUCUGGACUGAGUAAC 18
IntronlO- 25261
1042
5535.1 6381
CFTR- IntronlO- - GCUUUCUGGACUGAGUAAC 19
6382 25262
CFTR- IntronlO- - AGCUUUCUGGACUGAGUAAC 20
1182 20067
CFTR- IntronlO- - AAGCUUUCUGGACUGAGUAAC 21
6383 25263
CFTR- IntronlO- - CAAGCUUUCUGGACUGAGUAAC 22
6384 25264
CFTR- IntronlO- - CCAAGCUUUCUGGACUGAGUAAC 23
6385 25265
CFTR- IntronlO- - UCCAAGCUUUCUGGACUGAGUAAC 24
6386 25266
CFTR- IntronlO- - UCAUUUCAACUUAUACAC 18
6387 25267
CFTR- IntronlO- - AUCAUUUCAACUUAUACAC 19
6388 25268
CFTR-
- UAUCAUUUCAACUUAUACAC 20
lntronlO-407 19293
CFTR- IntronlO- - AUAUCAUUUCAACUUAUACAC 21
6389 25269
CFTR- IntronlO- - AAUAUCAUUUCAACUUAUACAC 22
6390 25270
CFTR- IntronlO- - AAAUAUCAUUUCAACUUAUACAC 23
6391 25271
CFTR- IntronlO- - AAAAU AU CAU U U CAACU UAU ACAC 24
6392 25272
CFTR- IntronlO- - GGUGAGAUUAGAGGCCAC 18
6393 25273
1043
5535.1 CFTR- IntronlO- - GGGUGAGAUUAGAGGCCAC 19
6394 25274
CFTR-
- UGGGUGAGAUUAGAGGCCAC 20
lntronlO-409 19295
CFTR- IntronlO- - CUGGGUGAGAUUAGAGGCCAC 21
6395 25275
CFTR- IntronlO- - UCUGGGUGAGAUUAGAGGCCAC 22
6396 25276
CFTR- IntronlO- - CUCUGGGUGAGAUUAGAGGCCAC 23
6397 25277
CFTR- IntronlO- - UCUCUGGGUGAGAUUAGAGGCCAC 24
6398 25278
CFTR- IntronlO- - CUGAGGUGGGAGGAUCAC 18
6399 25279
CFTR- IntronlO- - GCUGAGGUGGGAGGAUCAC 19
6400 25280
CFTR- IntronlO- - GGCUGAGGUGGGAGGAUCAC 20
6401 25281
CFTR- IntronlO- - AGGCUGAGGUGGGAGGAUCAC 21
6402 25282
CFTR- IntronlO- - GAGGCUGAGGUGGGAGGAUCAC 22
6403 25283
CFTR- IntronlO- - GGAGGCUGAGGUGGGAGGAUCAC 23
6404 25284
CFTR- IntronlO- - GGGAGGCUGAGGUGGGAGGAUCAC 24
6405 25285
CFTR- IntronlO- - GUUUGUCUUUAAUUUCAC 18
6406 25286
CFTR-
- GGUUUGUCUUUAAUUUCAC 19
IntronlO- 25287
1044
5535.1 6407
CFTR- IntronlO- - AGGUUUGUCUUUAAUUUCAC 20
6408 25288
CFTR- IntronlO- - UAGGUUUGUCUUUAAUUUCAC 21
6409 25289
CFTR- IntronlO- - UUAGGUUUGUCUUUAAUUUCAC 22
6410 25290
CFTR- IntronlO- - GUUAGGUUUGUCUUUAAUUUCAC 23
6411 25291
CFTR- IntronlO- - AGUUAGGUUUGUCUUUAAUUUCAC 24
6412 25292
CFTR- IntronlO- - GG AAAU AAAU U U AAAG AC 18
6413 25293
CFTR- IntronlO- - AGG AAAU AAAU U U AAAG AC 19
6414 25294
CFTR- IntronlO- - G AGG AAAU AAAU U U AAAG AC 20
6415 25295
CFTR- IntronlO- - UG AGGAAAU AAAU UU AAAG AC 21
6416 25296
CFTR- IntronlO- - U U G AGG AAAU AAAU U U AAAG AC 22
6417 25297
CFTR- IntronlO- - AU UG AGG AAAU AAAU U U AAAG AC 23
6418 25298
CFTR- IntronlO- - U AU UG AGG AAAU AAAU U U AAAG AC 24
6419 25299
CFTR- IntronlO- - GCUGGCAUAGAGUAAGAC 18
6420 25300
CFTR-
- GGCUGGCAUAGAGUAAGAC 19
IntronlO- 25301
1045
5535.1 6421
CFTR-
- AGGCUGGCAUAGAGUAAGAC 20
lntronlO-412 19298
CFTR- IntronlO- - GAGGCUGGCAUAGAGUAAGAC 21
6422 25302
CFTR- IntronlO- - UGAGGCUGGCAUAGAGUAAGAC 22
6423 25303
CFTR- IntronlO- - CUGAGGCUGGCAUAGAGUAAGAC 23
6424 25304
CFTR- IntronlO- - ACUGAGGCUGGCAUAGAGUAAGAC 24
6425 25305
CFTR- IntronlO- - GCUAUUCUGUAGGGAGAC 18
6426 25306
CFTR- IntronlO- - GGCUAUUCUGUAGGGAGAC 19
6427 25307
CFTR- IntronlO- - AGGCUAUUCUGUAGGGAGAC 20
6428 25308
CFTR- IntronlO- - UAGGCUAUUCUGUAGGGAGAC 21
6429 25309
CFTR- IntronlO- - UU AGGCUAUUCUGUAGGGAGAC 22
6430 25310
CFTR- IntronlO- - UUUAGGCUAUUCUGUAGGGAGAC 23
6431 25311
CFTR- IntronlO- - UUUUAGGCUAUUCUGUAGGGAGAC 24
6432 25312
CFTR- IntronlO- - AAGAAUUGAAUAUGAGAC 18
6433 25313
CFTR- IntronlO- - GAAGAAUUGAAUAUGAGAC 19
6434 25314
1046
5535.1 CFTR- IntronlO- - UGAAGAAUUGAAUAUGAGAC 20
6435 25315
CFTR- IntronlO- - UUGAAGAAUUGAAUAUGAGAC 21
6436 25316
CFTR- IntronlO- - UUUGAAGAAUUGAAUAUGAGAC 22
6437 25317
CFTR- IntronlO- - UUUUGAAGAAUUGAAUAUGAGAC 23
6438 25318
CFTR- IntronlO- - AUUUUGAAGAAUUGAAUAUGAGAC 24
6439 25319
CFTR- IntronlO- - GCCCGUAGUCCCAGCUAC 18
6440 25320
CFTR- IntronlO- - UGCCCGUAGUCCCAGCUAC 19
6441 25321
CFTR- IntronlO- - GUGCCCGUAGUCCCAGCUAC 20
6442 25322
CFTR- IntronlO- - GGUGCCCGUAGUCCCAGCUAC 21
6443 25323
CFTR- IntronlO- - GGGUGCCCGUAGUCCCAGCUAC 22
6444 25324
CFTR- IntronlO- - CGGGUGCCCGUAGUCCCAGCUAC 23
6445 25325
CFTR- IntronlO- - GCGGGUGCCCGUAGUCCCAGCUAC 24
6446 25326
CFTR- IntronlO- - UGUGCCUGUAGUCCCAGCUAC 21
6447 25327
CFTR- IntronlO- - GUGUGCCUGUAGUCCCAGCUAC 22
6448 25328
1047
5535.1 CFTR- IntronlO- - UGUGUGCCUGUAGUCCCAGCUAC 23
6449 25329
CFTR- IntronlO- - GUGUGUGCCUGUAGUCCCAGCUAC 24
6450 25330
CFTR- IntronlO- - GAAAAG UUGUAACAG U AC 18
6451 25331
CFTR- IntronlO- - GGAAAAGUUGUAACAGUAC 19
6452 25332
CFTR- IntronlO- - CGGAAAAG UUGUAACAG U AC 20
6453 25333
CFTR- IntronlO- - ACGGAAAAGUUGUAACAGUAC 21
6454 25334
CFTR- IntronlO- - CACGG AAAAG UUGUAACAG U AC 22
6455 25335
CFTR- IntronlO- - GCACGGAAAAGUUGUAACAGUAC 23
6456 25336
CFTR- IntronlO- - UGCACGGAAAAGUUGUAACAGUAC 24
6457 25337
CFTR- IntronlO- - GAUAAAUGUGCCGUUUAC 18
6458 25338
CFTR- IntronlO- - GGAUAAAUGUGCCGUUUAC 19
6459 25339
CFTR- IntronlO- - AGGAUAAAUGUGCCGUUUAC 20
6460 25340
CFTR- IntronlO- - AAGGAUAAAUGUGCCGUUUAC 21
6461 25341
CFTR- IntronlO- - GAAGGAUAAAUGUGCCGUUUAC 22
6462 25342
1048
5535.1 CFTR- IntronlO- - GGAAGGAUAAAUGUGCCGUUUAC 23
6463 25343
CFTR- IntronlO- - UGGAAGGAUAAAUGUGCCGUUUAC 24
6464 25344
CFTR- IntronlO- - UCAUAGCUCACUGUAACC 18
6465 25345
CFTR- IntronlO- - AUCAUAGCUCACUGUAACC 19
6466 25346
CFTR- IntronlO- - GAUCAUAGCUCACUGUAACC 20
6467 25347
CFTR- IntronlO- - UGAUCAUAGCUCACUGUAACC 21
6468 25348
CFTR- IntronlO- - GUGAUCAUAGCUCACUGUAACC 22
6469 25349
CFTR- IntronlO- - UGUGAUCAUAGCUCACUGUAACC 23
6470 25350
CFTR- IntronlO- - GUGUGAUCAUAGCUCACUGUAACC 24
6471 25351
CFTR- IntronlO- - GUCUAGCCUAGAAAUACC 18
6472 25352
CFTR- IntronlO- - UGUCUAGCCUAGAAAUACC 19
6473 25353
CFTR- IntronlO- - CUGUCUAGCCUAGAAAUACC 20
6474 25354
CFTR- IntronlO- - ACUGUCUAGCCUAGAAAUACC 21
6475 25355
CFTR- IntronlO- - AACUGUCUAGCCUAGAAAUACC 22
6476 25356
1049
5535.1 CFTR- IntronlO- - AAACUGUCUAGCCUAGAAAUACC 23
6477 25357
CFTR- IntronlO- - CAAACUGUCUAGCCUAGAAAUACC 24
6478 25358
CFTR- IntronlO- - GAGGAAGGCAGUGGUCCC 18
6479 25359
CFTR- IntronlO- - AGAGGAAGGCAGUGGUCCC 19
6480 25360
CFTR- IntronlO- - UAGAGGAAGGCAGUGGUCCC 20
6481 25361
CFTR- IntronlO- - UU AGAGGAAGGCAGUGGUCCC 21
6482 25362
CFTR- IntronlO- - GUUAGAGGAAGGCAGUGGUCCC 22
6483 25363
CFTR- IntronlO- - AGUUAGAGGAAGGCAGUGGUCCC 23
6484 25364
CFTR- IntronlO- - GAGUUAGAGGAAGGCAGUGGUCCC 24
6485 25365
CFTR- IntronlO- - CUCACAAACUGUCUAGCC 18
6486 25366
CFTR- IntronlO- - ACUCACAAACUGUCUAGCC 19
6487 25367
CFTR- IntronlO- - AACUCACAAACUGUCUAGCC 20
6488 25368
CFTR- IntronlO- - AAACUCACAAACUGUCUAGCC 21
6489 25369
CFTR- IntronlO- - AAAACUCACAAACUGUCUAGCC 22
6490 25370
1050
5535.1 CFTR- IntronlO- - AAAAACUCACAAACUGUCUAGCC 23
6491 25371
CFTR- IntronlO- - AAAAAACUCACAAACUGUCUAGCC 24
6492 25372
CFTR- IntronlO- - UGAAUGAAUGUGGUAUCC 18
6493 25373
CFTR- IntronlO- - GUGAAUGAAUGUGGUAUCC 19
6494 25374
CFTR-
- AGUGAAUGAAUGUGGUAUCC 20
lntronlO-425 19311
CFTR- IntronlO- - UAGUGAAUGAAUGUGGUAUCC 21
6495 25375
CFTR- IntronlO- - CUAGUGAAUGAAUGUGGUAUCC 22
6496 25376
CFTR- IntronlO- - GCUAGUGAAUGAAUGUGGUAUCC 23
6497 25377
CFTR- IntronlO- - AGCUAGUGAAUGAAUGUGGUAUCC 24
6498 25378
CFTR- IntronlO- - UUGGGAGGUGAUUAGUCC 18
6499 25379
CFTR- IntronlO- - UUUGGGAGGUGAUUAGUCC 19
6500 25380
CFTR- IntronlO- - CUUUGGGAGGUGAUUAGUCC 20
6501 25381
CFTR- IntronlO- - CCUUUGGGAGGUGAUUAGUCC 21
6502 25382
CFTR- IntronlO- - GCCUUUGGGAGGUGAUUAGUCC 22
6503 25383
CFTR-
- GGCCUUUGGGAGGUGAUUAGUCC 23
IntronlO- 25384
1051
5535.1 6504
CFTR- IntronlO- - GGGCCUUUGGGAGGUGAUUAGUCC 24
6505 25385
CFTR- IntronlO- - UCUUUAUUUUUAUAUUCC 18
6506 25386
CFTR- IntronlO- - UUCUUUAUUUUUAUAUUCC 19
6507 25387
CFTR- IntronlO- - CUUCUUUAUUUUUAUAUUCC 20
6508 25388
CFTR- IntronlO- - UCUUCUUUAUUUUUAUAUUCC 21
6509 25389
CFTR- IntronlO- - GUCUUCUUUAUUUUUAUAUUCC 22
6510 25390
CFTR- IntronlO- - UGUCUUCUUUAUUUUUAUAUUCC 23
6511 25391
CFTR- IntronlO- - AUGUCUUCUUUAUUUUUAUAUUCC 24
6512 25392
CFTR- IntronlO- - GUUGUCAAAUGUCCUUCC 18
6513 25393
CFTR- IntronlO- - UGUUGUCAAAUGUCCUUCC 19
6514 25394
CFTR- IntronlO- - AUGUUGUCAAAUGUCCUUCC 20
6515 25395
CFTR- IntronlO- - GAUGUUGUCAAAUGUCCUUCC 21
6516 25396
CFTR- IntronlO- - AGAUGUUGUCAAAUGUCCUUCC 22
6517 25397
CFTR-
- UAGAUGUUGUCAAAUGUCCUUCC 23
IntronlO- 25398
1052
5535.1 6518
CFTR- IntronlO- - GUAGAUGUUGUCAAAUGUCCUUCC 24
6519 25399
CFTR- IntronlO- - CUUUUUUUAGUAUCUUCC 18
6520 25400
CFTR- IntronlO- - ACUUUUUUUAGUAUCUUCC 19
6521 25401
CFTR- IntronlO- - AACUUUUUUUAGUAUCUUCC 20
6522 25402
CFTR- IntronlO- - UAACUUUUUUUAGUAUCUUCC 21
6523 25403
CFTR- IntronlO- - GUAACUUUUUUUAGUAUCUUCC 22
6524 25404
CFTR- IntronlO- - GGUAACUUUUUUUAGUAUCUUCC 23
6525 25405
CFTR- IntronlO- - AGGUAACUUUUUUUAGUAUCUUCC 24
6526 25406
CFTR- IntronlO- - GGAGACAAGGGAGGAAGC 18
6527 25407
CFTR- IntronlO- - GGGAGACAAGGGAGGAAGC 19
6528 25408
CFTR- IntronlO- - AGGGAGACAAGGGAGGAAGC 20
6529 25409
CFTR- IntronlO- - UAGGGAGACAAGGGAGGAAGC 21
6530 25410
CFTR- IntronlO- - GUAGGGAGACAAGGGAGGAAGC 22
6531 25411
CFTR-
- UGUAGGGAGACAAGGGAGGAAGC 23
IntronlO- 25412
1053
5535.1 6532
CFTR- IntronlO- - CUGUAGGGAGACAAGGGAGGAAGC 24
6533 25413
CFTR- IntronlO- - GCCAUGUGAGAACACAGC 18
6534 25414
CFTR- IntronlO- - UGCCAUGUGAGAACACAGC 19
6535 25415
CFTR- IntronlO- - CUGCCAUGUGAGAACACAGC 20
1218 20103
CFTR- IntronlO- - UCUGCCAUGUGAGAACACAGC 21
6536 25416
CFTR- IntronlO- - UUCUGCCAUGUGAGAACACAGC 22
6537 25417
CFTR- IntronlO- - UUUCUGCCAUGUGAGAACACAGC 23
6538 25418
CFTR- IntronlO- - CUUUCUGCCAUGUGAGAACACAGC 24
6539 25419
CFTR- IntronlO- - CAGGAGUUUGAGACCAGC 18
6540 25420
CFTR- IntronlO- - CCAGGAGUUUGAGACCAGC 19
6541 25421
CFTR- IntronlO- - UCCAGGAGUUUGAGACCAGC 20
6542 25422
CFTR- IntronlO- - GUCCAGGAGUUUGAGACCAGC 21
6543 25423
CFTR- IntronlO- - AGUCCAGGAGUUUGAGACCAGC 22
6544 25424
CFTR-
- G AG U CCAGG AG U U UG AG ACCAGC 23
IntronlO- 25425
1054
5535.1 6545
CFTR- IntronlO- - UGAGUCCAGGAGUUUGAGACCAGC 24
6546 25426
CFTR- IntronlO- - GUAUUUUGUUAUAGCAGC 18
6547 25427
CFTR- IntronlO- - GGUAUUUUGUUAUAGCAGC 19
6548 25428
CFTR- IntronlO- - UGGUAUUUUGUUAUAGCAGC 20
6549 25429
CFTR- IntronlO- - AUGGUAUUUUGUUAUAGCAGC 21
6550 25430
CFTR- IntronlO- - CAUGGUAUUUUGUUAUAGCAGC 22
6551 25431
CFTR- IntronlO- - UCAUGGUAUUUUGUUAUAGCAGC 23
6552 25432
CFTR- IntronlO- - UUCAUGGUAUUUUGUUAUAGCAGC 24
6553 25433
CFTR- IntronlO- - UGGGAGGAUCACCUGAGC 18
6554 25434
CFTR- IntronlO- - GUGGGAGGAUCACCUGAGC 19
6555 25435
CFTR- IntronlO- - GGUGGGAGGAUCACCUGAGC 20
6556 25436
CFTR- IntronlO- - AGGUGGGAGGAUCACCUGAGC 21
6557 25437
CFTR- IntronlO- - GAGGUGGGAGGAUCACCUGAGC 22
6558 25438
CFTR-
- UGAGGUGGGAGGAUCACCUGAGC 23
IntronlO- 25439
1055
5535.1 6559
CFTR- IntronlO- - CUGAGGUGGGAGGAUCACCUGAGC 24
6560 25440
CFTR- IntronlO- - CUCACCCUCCCAAGUAGC 18
6561 25441
CFTR- IntronlO- - CCUCACCCUCCCAAGUAGC 19
6562 25442
CFTR-
- GCCUCACCCUCCCAAGUAGC 20
lntronlO-672 19558
CFTR- IntronlO- - UGCCUCACCCUCCCAAGUAGC 21
6563 25443
CFTR- IntronlO- - CUGCCUCACCCUCCCAAGUAGC 22
6564 25444
CFTR- IntronlO- - CCUGCCUCACCCUCCCAAGUAGC 23
6565 25445
CFTR- IntronlO- - UCCUGCCUCACCCUCCCAAGUAGC 24
6566 25446
CFTR- IntronlO- - CUCAGCCUCCCAAGUAGC 18
6567 25447
CFTR- IntronlO- - CCUCAGCCUCCCAAGUAGC 19
6568 25448
CFTR-
- GCCUCAGCCUCCCAAGUAGC 20
lntronlO-673 19559
CFTR- IntronlO- - UGCCUCAGCCUCCCAAGUAGC 21
6569 25449
CFTR- IntronlO- - CUGCCUCAGCCUCCCAAGUAGC 22
6570 25450
CFTR- IntronlO- - CCUGCCUCAGCCUCCCAAGUAGC 23
6571 25451
1056
5535.1 CFTR- IntronlO- - UCCUGCCUCAGCCUCCCAAGUAGC 24
6572 25452
CFTR- IntronlO- - CCCUUAAACAAUACAGGC 18
6573 25453
CFTR- IntronlO- - ACCCU U AAACAAU ACAGGC 19
6574 25454
CFTR- IntronlO- - GACCCUUAAACAAUACAGGC 20
6575 25455
CFTR- IntronlO- - UG ACCCU U AAACAAU ACAGGC 21
6576 25456
CFTR- IntronlO- - UUGACCCUUAAACAAUACAGGC 22
6577 25457
CFTR- IntronlO- - AUUGACCCUUAAACAAUACAGGC 23
6578 25458
CFTR- IntronlO- - AAU UG ACCCU U AAACAAU ACAGG C 24
6579 25459
CFTR- IntronlO- - AGUGCUGGGAUUACAGGC 18
6580 25460
CFTR- IntronlO- - AAGUGCUGGGAUUACAGGC 19
6581 25461
CFTR- IntronlO- - AAAGUGCUGGGAUUACAGGC 20
6582 25462
CFTR- IntronlO- - CAAAGUGCUGGGAUUACAGGC 21
6583 25463
CFTR- IntronlO- - CCAAAGUGCUGGGAUUACAGGC 22
6584 25464
CFTR- IntronlO- - CCCAAAGUGCUGGGAUUACAGGC 23
6585 25465
1057
5535.1 CFTR- IntronlO- - UCCCAAAGUGCUGGGAUUACAGGC 24
6586 25466
CFTR- IntronlO- - AGUGUUGGGAUUACAGGC 18
6587 25467
CFTR- IntronlO- - AAGUGUUGGGAUUACAGGC 19
6588 25468
CFTR- IntronlO- - AAAGUGUUGGGAUUACAGGC 20
6589 25469
CFTR- IntronlO- - CAAAGUGUUGGGAUUACAGGC 21
6590 25470
CFTR- IntronlO- - CCAAAGUGUUGGGAUUACAGGC 22
6591 25471
CFTR- IntronlO- - CCCAAAGUGUUGGGAUUACAGGC 23
6592 25472
CFTR- IntronlO- - UCCCAAAGUGUUGGGAUUACAGGC 24
6593 25473
CFTR- IntronlO- - GUCUUACUGUCACCAGGC 18
6594 25474
CFTR- IntronlO- - AGUCUUACUGUCACCAGGC 19
6595 25475
CFTR-
- GAGUCUUACUGUCACCAGGC 20
lntronlO-677 19563
CFTR- IntronlO- - AGAGUCUUACUGUCACCAGGC 21
6596 25476
CFTR- IntronlO- - CAGAGUCUUACUGUCACCAGGC 22
6597 25477
CFTR- IntronlO- - ACAGAGUCUUACUGUCACCAGGC 23
6598 25478
CFTR-
- GACAGAGUCUUACUGUCACCAGGC 24
IntronlO- 25479
1058
5535.1 6599
CFTR- IntronlO- - UACUCGGGAGGCUGAGGC 18
6600 25480
CFTR- IntronlO- - CUACUCGGGAGGCUGAGGC 19
6601 25481
CFTR-
- GCUACUCGGGAGGCUGAGGC 20
lntronlO-680 19566
CFTR- IntronlO- - AGCUACUCGGGAGGCUGAGGC 21
6602 25482
CFTR- IntronlO- - CAGCUACUCGGGAGGCUGAGGC 22
6603 25483
CFTR- IntronlO- - CCAGCUACUCGGGAGGCUGAGGC 23
6604 25484
CFTR- IntronlO- - CCCAGCUACUCGGGAGGCUGAGGC 24
6605 25485
CFTR- IntronlO- - AGUGCUGGGUUUAUAGGC 18
6606 25486
CFTR- IntronlO- - AAGUGCUGGGUUUAUAGGC 19
6607 25487
CFTR- IntronlO- - AAAGUGCUGGGUUUAUAGGC 20
6608 25488
CFTR- IntronlO- - CAAAGUGCUGGGUUUAUAGGC 21
6609 25489
CFTR- IntronlO- - CCAAAGUGCUGGGUUUAUAGGC 22
6610 25490
CFTR- IntronlO- - CCCAAAGUGCUGGGUUUAUAGGC 23
6611 25491
CFTR- IntronlO- - UCCCAAAGUGCUGGGUUUAUAGGC 24
6612 25492
1059
5535.1 CFTR- IntronlO- - AAGUGCCACUAGUGAUGC 18
6613 25493
CFTR- IntronlO- - AAAGUGCCACUAGUGAUGC 19
6614 25494
CFTR- IntronlO- - CAAAGUGCCACUAGUGAUGC 20
6615 25495
CFTR- IntronlO- - ACAAAGUGCCACUAGUGAUGC 21
6616 25496
CFTR- IntronlO- - UACAAAGUGCCACUAGUGAUGC 22
6617 25497
CFTR- IntronlO- - AUACAAAGUGCCACUAGUGAUGC 23
6618 25498
CFTR- IntronlO- - CAUACAAAGUGCCACUAGUGAUGC 24
6619 25499
CFTR- IntronlO- - UCAAAUUAUUUCUACUGC 18
6620 25500
CFTR- IntronlO- - UUCAAAUUAUUUCUACUGC 19
6621 25501
CFTR- IntronlO- - GUUCAAAUUAUUUCUACUGC 20
6622 25502
CFTR- IntronlO- - UGUUCAAAUUAUUUCUACUGC 21
6623 25503
CFTR- IntronlO- - UUGUUCAAAUUAUUUCUACUGC 22
6624 25504
CFTR- IntronlO- - GUUGUUCAAAUUAUUUCUACUGC 23
6625 25505
CFTR- IntronlO- - UGUUGUUCAAAUUAUUUCUACUGC 24
6626 25506
1060
5535.1 CFTR- IntronlO- - AUUUGAACAAAGACUUGC 18
6627 25507
CFTR- IntronlO- - CAUUUGAACAAAGACUUGC 19
6628 25508
CFTR- IntronlO- - ACAUUUG AACAAAG ACU UGC 20
1236 20121
CFTR- IntronlO- - AACAUUUGAACAAAGACUUGC 21
6629 25509
CFTR- IntronlO- - UAACAUUUGAACAAAGACUUGC 22
6630 25510
CFTR- IntronlO- - G U AACAU U UG AACAAAG ACU UG C 23
6631 25511
CFTR- IntronlO- - G G U AACAU U U G AACAAAG AC U UGC 24
6632 25512
CFTR- IntronlO- - G AG U U U ACU AACU CAAU C 18
6633 25513
CFTR- IntronlO- - GGAGUUUACUAACUCAAUC 19
6634 25514
CFTR- IntronlO- - CGGAGUUUACUAACUCAAUC 20
6635 25515
CFTR- IntronlO- - ACGGAGUUUACUAACUCAAUC 21
6636 25516
CFTR- IntronlO- - AACGGAGUUUACUAACUCAAUC 22
6637 25517
CFTR- IntronlO- - AAACGGAGUUUACUAACUCAAUC 23
6638 25518
CFTR- IntronlO- - G AAACGG AG U U U ACU AACU CAAU C 24
6639 25519
1061
5535.1 CFTR- IntronlO- - UCUGCUGGCACCUUGAUC 18
6640 25520
CFTR- IntronlO- - AUCUGCUGGCACCUUGAUC 19
6641 25521
CFTR- IntronlO- - AAUCUGCUGGCACCUUGAUC 20
6642 25522
CFTR- IntronlO- - AAAUCUGCUGGCACCUUGAUC 21
6643 25523
CFTR- IntronlO- - CAAAUCUGCUGGCACCUUGAUC 22
6644 25524
CFTR- IntronlO- - CCAAAUCUGCUGGCACCUUGAUC 23
6645 25525
CFTR- IntronlO- - CCCAAAUCUGCUGGCACCUUGAUC 24
6646 25526
CFTR- IntronlO- - CUUGCUUUUCCCACUAUC 18
6647 25527
CFTR- IntronlO- - UCUUGCUUUUCCCACUAUC 19
6648 25528
CFTR- IntronlO- - UUCUUGCUUUUCCCACUAUC 20
6649 25529
CFTR- IntronlO- - CUUCUUGCUUUUCCCACUAUC 21
6650 25530
CFTR- IntronlO- - GCUUCUUGCUUUUCCCACUAUC 22
6651 25531
CFTR- IntronlO- - UGCUUCUUGCUUUUCCCACUAUC 23
6652 25532
CFTR- IntronlO- - UUGCUUCUUGCUUUUCCCACUAUC 24
6653 25533
1062
5535.1 CFTR- IntronlO- - GUGAAUGAAUGUGGUAUC 18
6654 25534
CFTR- IntronlO- - AGUGAAUGAAUGUGGUAUC 19
6655 25535
CFTR- IntronlO- - UAGUGAAUGAAUGUGGUAUC 20
6656 25536
CFTR- IntronlO- - CUAGUGAAUGAAUGUGGUAUC 21
6657 25537
CFTR- IntronlO- - GCUAGUGAAUGAAUGUGGUAUC 22
6658 25538
CFTR- IntronlO- - AGCUAGUGAAUGAAUGUGGUAUC 23
6659 25539
CFTR- IntronlO- - AAGCUAGUGAAUGAAUGUGGUAUC 24
6660 25540
CFTR- IntronlO- - CACUGUAACCUUGAACUC 18
6661 25541
CFTR- IntronlO- - UCACUGUAACCUUGAACUC 19
6662 25542
CFTR- IntronlO- - CUCACUGUAACCUUGAACUC 20
6663 25543
CFTR- IntronlO- - GCUCACUGUAACCUUGAACUC 21
6664 25544
CFTR- IntronlO- - AGCUCACUGUAACCUUGAACUC 22
6665 25545
CFTR- IntronlO- - UAGCUCACUGUAACCUUGAACUC 23
6666 25546
CFTR- IntronlO- - AUAGCUCACUGUAACCUUGAACUC 24
6667 25547
1063
5535.1 CFTR- IntronlO- - AGAAAUUAAGAAAGACUC 18
6668 25548
CFTR- IntronlO- - UAGAAAUUAAGAAAGACUC 19
6669 25549
CFTR- IntronlO- - A U AG AAA U U A AG A A AG AC U C 20
6670 25550
CFTR- IntronlO- - AAUAGAAAUUAAGAAAGACUC 21
6671 25551
CFTR- IntronlO- - AAAUAGAAAUUAAGAAAGACUC 22
6672 25552
CFTR- IntronlO- - AAAAUAGAAAUUAAGAAAGACUC 23
6673 25553
CFTR- IntronlO- - GAAAAUAGAAAUUAAGAAAGACUC 24
6674 25554
CFTR- IntronlO- - AUUAGGGAAUGCAGACUC 18
6675 25555
CFTR- IntronlO- - GAUUAGGGAAUGCAGACUC 19
6676 25556
CFTR-
- GGAUUAGGGAAUGCAGACUC 20
lntronlO-92 18978
CFTR- IntronlO- - GGGAUUAGGGAAUGCAGACUC 21
6677 25557
CFTR- IntronlO- - AGGGAUUAGGGAAUGCAGACUC 22
6678 25558
CFTR- IntronlO- - GAGGGAUUAGGGAAUGCAGACUC 23
6679 25559
CFTR- IntronlO- - UGAGGGAUUAGGGAAUGCAGACUC 24
6680 25560
CFTR-
- UAUUCUUUUGAUAUACUC 18
IntronlO- 25561
1064
5535.1 6681
CFTR- IntronlO- - UUAUUCUUUUGAUAUACUC 19
6682 25562
CFTR- IntronlO- - CUUAUUCUUUUGAUAUACUC 20
6683 25563
CFTR- IntronlO- - CCUUAUUCUUUUGAUAUACUC 21
6684 25564
CFTR- IntronlO- - GCCUUAUUCUUUUGAUAUACUC 22
6685 25565
CFTR- IntronlO- - UGCCUUAUUCUUUUGAUAUACUC 23
6686 25566
CFTR- IntronlO- - AUGCCUUAUUCUUUUGAUAUACUC 24
6687 25567
CFTR- IntronlO- - CCGUAGUCCCAGCUACUC 18
6688 25568
CFTR- IntronlO- - CCCGUAGUCCCAGCUACUC 19
6689 25569
CFTR-
- GCCCGUAGUCCCAGCUACUC 20
lntronlO-687 19573
CFTR- IntronlO- - UGCCCGUAGUCCCAGCUACUC 21
6690 25570
CFTR- IntronlO- - GUGCCCGUAGUCCCAGCUACUC 22
6691 25571
CFTR- IntronlO- - GGUGCCCGUAGUCCCAGCUACUC 23
6692 25572
CFTR- IntronlO- - GGGUGCCCGUAGUCCCAGCUACUC 24
6693 25573
CFTR- IntronlO- - CUUGGACUUCCCAGCCUC 18
6694 25574
1065
5535.1 CFTR- IntronlO- - UCUUGGACUUCCCAGCCUC 19
6695 25575
CFTR- IntronlO- - AUCUUGGACUUCCCAGCCUC 20
6696 25576
CFTR- IntronlO- - GAUCUUGGACUUCCCAGCCUC 21
6697 25577
CFTR- IntronlO- - UGAUCUUGGACUUCCCAGCCUC 22
6698 25578
CFTR- IntronlO- - UUGAUCUUGGACUUCCCAGCCUC 23
6699 25579
CFTR- IntronlO- - CUUGAUCUUGGACUUCCCAGCCUC 24
6700 25580
CFTR- IntronlO- - CACUGCAACCUCUGCCUC 18
6701 25581
CFTR- IntronlO- - UCACUGCAACCUCUGCCUC 19
6702 25582
CFTR- IntronlO- - CUCACUGCAACCUCUGCCUC 20
6703 25583
CFTR- IntronlO- - GCUCACUGCAACCUCUGCCUC 21
6704 25584
CFTR- IntronlO- - GGCUCACUGCAACCUCUGCCUC 22
6705 25585
CFTR- IntronlO- - CGGCUCACUGCAACCUCUGCCUC 23
6706 25586
CFTR- IntronlO- - UCGGCUCACUGCAACCUCUGCCUC 24
6707 25587
CFTR- IntronlO- - AAAAAGUUUAGUGGUCUC 18
6708 25588
1066
5535.1 CFTR- IntronlO- - GAAAAAGUUUAGUGGUCUC 19
6709 25589
CFTR- IntronlO- - AGAAAAAGUUUAGUGGUCUC 20
6710 25590
CFTR- IntronlO- - GAGAAAAAGUUUAGUGGUCUC 21
6711 25591
CFTR- IntronlO- - UGAGAAAAAGUUUAGUGGUCUC 22
6712 25592
CFTR- IntronlO- - GUGAGAAAAAGUUUAGUGGUCUC 23
6713 25593
CFTR- IntronlO- - UGUGAGAAAAAGUUUAGUGGUCUC 24
6714 25594
CFTR- IntronlO- - AGGUGAAUUGCUUGAGUC 18
6715 25595
CFTR- IntronlO- - CAGGUGAAUUGCUUGAGUC 19
6716 25596
CFTR- IntronlO- - GCAGGUGAAUUGCUUGAGUC 20
6717 25597
CFTR- IntronlO- - GGCAGGUGAAUUGCUUGAGUC 21
6718 25598
CFTR- IntronlO- - AGGCAGGUGAAUUGCUUGAGUC 22
6719 25599
CFTR- IntronlO- - GAGGCAGGUGAAUUGCUUGAGUC 23
6720 25600
CFTR- IntronlO- - AGAGGCAGGUGAAUUGCUUGAGUC 24
6721 25601
CFTR- IntronlO- - UAUGUAUAUAUGUGUGUC 18
6722 25602
1067
5535.1 CFTR- IntronlO- - GUAUGUAUAUAUGUGUGUC 19
6723 25603
CFTR- IntronlO- - UGUAUGUAUAUAUGUGUGUC 20
1242 20127
CFTR- IntronlO- - AUGUAUGUAUAUAUGUGUGUC 21
6724 25604
CFTR- IntronlO- - UAUGUAUGUAUAUAUGUGUGUC 22
6725 25605
CFTR- IntronlO- - AUAUGUAUGUAUAUAUGUGUGUC 23
6726 25606
CFTR- IntronlO- - CAUAUGUAUGUAUAUAUGUGUGUC 24
6727 25607
CFTR- IntronlO- - GACCAAAACUUUAUUGUC 18
6728 25608
CFTR- IntronlO- - GGACCAAAACUUUAUUGUC 19
6729 25609
CFTR-
- AGGACCAAAACUUUAUUGUC 20
Intron 10-440 19326
CFTR- IntronlO- - AAGGACCAAAACUUUAUUGUC 21
6730 25610
CFTR- IntronlO- - AAAGG ACCAAAACU UUAUUGUC 22
6731 25611
CFTR- IntronlO- - AAAAGGACCAAAACUUUAUUGUC 23
6732 25612
CFTR- IntronlO- - CAAAAGGACCAAAACUUUAUUGUC 24
6733 25613
CFTR- IntronlO- - CAUUAUAACACUGCUUUC 18
6734 25614
CFTR-
- UCAUUAUAACACUGCUUUC 19
IntronlO- 25615
1068
5535.1 6735
CFTR- IntronlO- - UUCAUUAUAACACUGCUUUC 20
1247 20132
CFTR- IntronlO- - CUUCAUUAUAACACUGCUUUC 21
6736 25616
CFTR- IntronlO- - UCUUCAUUAUAACACUGCUUUC 22
6737 25617
CFTR- IntronlO- - CUCUUCAUUAUAACACUGCUUUC 23
6738 25618
CFTR- IntronlO- - GCUCUUCAUUAUAACACUGCUUUC 24
6739 25619
CFTR- IntronlO- - AUGUACAAGUCUAGUUUC 18
6740 25620
CFTR- IntronlO- - GAUGUACAAGUCUAGUUUC 19
6741 25621
CFTR- IntronlO- - GGAUGUACAAGUCUAGUUUC 20
6742 25622
CFTR- IntronlO- - UGGAUGUACAAGUCUAGUUUC 21
6743 25623
CFTR- IntronlO- - UUGGAUGUACAAGUCUAGUUUC 22
6744 25624
CFTR- IntronlO- - GUUGGAUGUACAAGUCUAGUUUC 23
6745 25625
CFTR- IntronlO- - AGUUGGAUGUACAAGUCUAGUUUC 24
6746 25626
CFTR- IntronlO- - GGAAAAU U U AACAU U U U C 18
6747 25627
CFTR-
- GGGAAAAU U U AACAU U U U C 19
IntronlO- 25628
1069
5535.1 6748
CFTR- IntronlO- - AGGG AAAAU U U AACAU U U U C 20
6749 25629
CFTR- IntronlO- - AAGGG AAAAU U U AACAU U U U C 21
6750 25630
CFTR- IntronlO- - U AAGGG AAAAU U U AACAU U U U C 22
6751 25631
CFTR- IntronlO- - CU AAGGG AAAAU U U AACAU U U U C 23
6752 25632
CFTR- IntronlO- - CCU AAGGG AAAAU U U AACAU U U U C 24
6753 25633
CFTR- IntronlO- - UUCCAUUACAUUGUUUUC 18
6754 25634
CFTR- IntronlO- - UUUCCAUUACAUUGUUUUC 19
6755 25635
CFTR- IntronlO- - GUUUCCAUUACAUUGUUUUC 20
6756 25636
CFTR- IntronlO- - UGUUUCCAUUACAUUGUUUUC 21
6757 25637
CFTR- IntronlO- - GUGUUUCCAUUACAUUGUUUUC 22
6758 25638
CFTR- IntronlO- - AGUGUUUCCAUUACAUUGUUUUC 23
6759 25639
CFTR- IntronlO- - UAGUGUUUCCAUUACAUUGUUUUC 24
6760 25640
CFTR- IntronlO- - AU U AAAAU AUAUAAAAAG 18
6761 25641
CFTR-
- AAU U AAAAU AUAUAAAAAG 19
IntronlO- 25642
1070
5535.1 6762
CFTR- IntronlO- - AAAU U A A A A U A U A U A A A A AG 20
6763 25643
CFTR- IntronlO- - AAAAU U A A A A U A U A U A AAA AG 21
6764 25644
CFTR- IntronlO- - GAAAAU U AAAAU AUAUAAAAAG 22
6765 25645
CFTR- IntronlO- - UGAAAAUUAAAAUAUAUAAAAAG 23
6766 25646
CFTR- IntronlO- - AUGAAAAUUAAAAUAUAUAAAAAG 24
6767 25647
CFTR- IntronlO- - AGAGAGGAAGGAAGAAAG 18
6768 25648
CFTR- IntronlO- - AAGAGAGGAAGGAAGAAAG 19
6769 25649
CFTR- IntronlO- - AAAGAGAGGAAGGAAGAAAG 20
6770 25650
CFTR- IntronlO- - GAAAGAGAGGAAGG AAG AAAG 21
6771 25651
CFTR- IntronlO- - AG AAAG AG AG G AAG G AAG AAAG 22
6772 25652
CFTR- IntronlO- - AAGAAAGAGAGGAAGGAAGAAAG 23
6773 25653
CFTR- IntronlO- - A AAG AAAG AG AG G AAG G AAG AAAG 24
6774 25654
CFTR- IntronlO- - GGAAGGAAGGAAGGAAAG 18
6775 25655
CFTR-
- AGGAAGGAAGGAAGG AAAG 19
IntronlO- 25656
1071
5535.1 6776
CFTR- IntronlO- - GAGGAAGGAAGGAAGGAAAG 20
6777 25657
CFTR- IntronlO- - GG AG G AAG G AAG G AAG G AAAG 21
6778 25658
CFTR- IntronlO- - AGGAGGAAGGAAGGAAGGAAAG 22
6779 25659
CFTR- IntronlO- - UAGGAGGAAGGAAGGAAGGAAAG 23
6780 25660
CFTR- IntronlO- - GUAGGAGGAAGGAAGGAAGGAAAG 24
6781 25661
CFTR- IntronlO- - AACCCAACUGAUGUCAAG 18
6782 25662
CFTR- IntronlO- - GAACCCAACUGAUGUCAAG 19
6783 25663
CFTR- IntronlO- - GGAACCCAACUGAUGUCAAG 20
6784 25664
CFTR- IntronlO- - CGGAACCCAACUGAUGUCAAG 21
6785 25665
CFTR- IntronlO- - CCGGAACCCAACUGAUGUCAAG 22
6786 25666
CFTR- IntronlO- - CCCGGAACCCAACUGAUGUCAAG 23
6787 25667
CFTR- IntronlO- - UCCCGGAACCCAACUGAUGUCAAG 24
6788 25668
CFTR- IntronlO- - UCACCUGAGCCUGAGAAG 18
6789 25669
CFTR-
- AUCACCUGAGCCUGAGAAG 19
IntronlO- 25670
1072
5535.1 6790
CFTR-
- GAUCACCUGAGCCUGAGAAG 20
lntronlO-692 19578
CFTR- IntronlO- - GGAUCACCUGAGCCUGAGAAG 21
6791 25671
CFTR- IntronlO- - AGGAUCACCUGAGCCUGAGAAG 22
6792 25672
CFTR- IntronlO- - GAGGAUCACCUGAGCCUGAGAAG 23
6793 25673
CFTR- IntronlO- - GGAGGAUCACCUGAGCCUGAGAAG 24
6794 25674
CFTR- IntronlO- - AAUGAGGAAGAAAGGAAG 18
6795 25675
CFTR- IntronlO- - AAAUGAGGAAGAAAGGAAG 19
6796 25676
CFTR- IntronlO- - GAAAUGAGGAAGAAAGGAAG 20
6797 25677
CFTR- IntronlO- - G G AAA U G AG G A AG A A AG G A AG 21
6798 25678
CFTR- IntronlO- - AG G A A A U G AG G A AG A A AG G A AG 22
6799 25679
CFTR- IntronlO- - AAGGAAAUGAGGAAGAAAGGAAG 23
6800 25680
CFTR- IntronlO- - GAAGGAAAUGAGGAAGAAAGGAAG 24
6801 25681
CFTR- IntronlO- - AG U CU AG U U U CAAGG AAG 18
6802 25682
CFTR- IntronlO- - AAG U CU AG U U U CAAGG AAG 19
6803 25683
1073
5535.1 CFTR-
- CAAG U C U AG U U U CAAGGAAG 20
Intron 10-449 19335
CFTR- IntronlO- - A C A AG UCUAGUUU C A AG G A AG 21
6804 25684
CFTR- IntronlO- - UACAAG U CU AG U U U CAAGGAAG 22
6805 25685
CFTR- IntronlO- - GUACAAGUCUAGUUUCAAGGAAG 23
6806 25686
CFTR- IntronlO- - UGUACAAGUCUAGUUUCAAGGAAG 24
6807 25687
CFTR- IntronlO- - GGGGCUGGUAGUGUGAAG 18
6808 25688
CFTR- IntronlO- - GGGGGCUGGUAGUGUGAAG 19
6809 25689
CFTR- IntronlO- - AGGGGGCUGGUAGUGUGAAG 20
6810 25690
CFTR- IntronlO- - GAGGGGGCUGGUAGUGUGAAG 21
6811 25691
CFTR- IntronlO- - AGAGGGGGCUGGUAGUGUGAAG 22
6812 25692
CFTR- IntronlO- - AAGAGGGGGCUGGUAGUGUGAAG 23
6813 25693
CFTR- IntronlO- - GAAGAGGGGGCUGGUAGUGUGAAG 24
6814 25694
CFTR- IntronlO- - GAAAU U AG AAAG AAU AAG 18
6815 25695
CFTR- IntronlO- - U G AAA U U AG A A AG A A U A AG 19
6816 25696
CFTR-
- AUGAAAUUAGAAAGAAUAAG 20
IntronlO- 20139
1074
5535.1 1254
CFTR- IntronlO- - AAUGAAAUUAGAAAGAAUAAG 21
6817 25697
CFTR- IntronlO- - GAAUGAAAUUAGAAAGAAUAAG 22
6818 25698
CFTR- IntronlO- - AGAAUGAAAUUAGAAAGAAUAAG 23
6819 25699
CFTR- IntronlO- - CAGAAUGAAAUUAGAAAGAAUAAG 24
6820 25700
CFTR- IntronlO- - AUAGGAUUAAUGGAUAAG 18
6821 25701
CFTR- IntronlO- - AAUAGGAUUAAUGGAUAAG 19
6822 25702
CFTR- IntronlO- - CAAUAGGAUUAAUGGAUAAG 20
6823 25703
CFTR- IntronlO- - CCAAUAGGAUUAAUGGAUAAG 21
6824 25704
CFTR- IntronlO- - UCCAAUAGGAUUAAUGGAUAAG 22
6825 25705
CFTR- IntronlO- - AUCCAAUAGGAUUAAUGGAUAAG 23
6826 25706
CFTR- IntronlO- - GAUCCAAUAGGAUUAAUGGAUAAG 24
6827 25707
CFTR- IntronlO- - GGAAAGAGGGUUGAUAAG 18
6828 25708
CFTR- IntronlO- - AGGAAAGAGGGUUGAUAAG 19
6829 25709
CFTR-
- A AG G A A AG AGGGUUGAUAAG 20
IntronlO- 25710
1075
5535.1 6830
CFTR- IntronlO- - AAAGGAAAGAGGGUUGAUAAG 21
6831 25711
CFTR- IntronlO- - UAAAGGAAAGAGGGUUGAUAAG 22
6832 25712
CFTR- IntronlO- - CUAAAGGAAAGAGGGUUGAUAAG 23
6833 25713
CFTR- IntronlO- - UCUAAAGGAAAGAGGGUUGAUAAG 24
6834 25714
CFTR- IntronlO- - UAUUUAUCAAUAUCUAAG 18
6835 25715
CFTR- IntronlO- - UUAUUUAUCAAUAUCUAAG 19
6836 25716
CFTR- IntronlO- - AUUAUUUAUCAAUAUCUAAG 20
6837 25717
CFTR- IntronlO- - AAUUAUUUAUCAAUAUCUAAG 21
6838 25718
CFTR- IntronlO- - CAAU U AU U U AU CAAU AU CU AAG 22
6839 25719
CFTR- IntronlO- - GCAAUUAUUUAUCAAUAUCUAAG 23
6840 25720
CFTR- IntronlO- - GGCAAUUAUUUAUCAAUAUCUAAG 24
6841 25721
CFTR- IntronlO- - GCUCAUUCAUCAAGUAAG 18
6842 25722
CFTR- IntronlO- - UGCUCAUUCAUCAAGUAAG 19
6843 25723
CFTR-
- AUGCUCAUUCAUCAAGUAAG 20
IntronlO- 25724
1076
5535.1 6844
CFTR- IntronlO- - AAUGCUCAUUCAUCAAGUAAG 21
6845 25725
CFTR- IntronlO- - AAAUGCUCAUUCAUCAAGUAAG 22
6846 25726
CFTR- IntronlO- - CAAAUGCUCAUUCAUCAAGUAAG 23
6847 25727
CFTR- IntronlO- - UCAAAUGCUCAUUCAUCAAGUAAG 24
6848 25728
CFTR- IntronlO- - A AG AAG G AAG G AAG UAAG 18
6849 25729
CFTR- IntronlO- - A A AG A AG G A AG G A AG U A AG 19
6850 25730
CFTR-
- G A AAG AAG G AAG G AAG UAAG 20
lntronlO-693 19579
CFTR- IntronlO- - G G A AAG AAG G AAG G AAG UAAG 21
6851 25731
CFTR- IntronlO- - AGGAAAGAAGGAAGG AAG UAAG 22
6852 25732
CFTR- IntronlO- - AAGGAAAGAAGGAAGGAAGUAAG 23
6853 25733
CFTR- IntronlO- - GAAGGAAAGAAGGAAGGAAGUAAG 24
6854 25734
CFTR- IntronlO- - UGCCAUGUGAGAACACAG 18
6855 25735
CFTR- IntronlO- - CUGCCAUGUGAGAACACAG 19
6856 25736
CFTR- IntronlO- - UCUGCCAUGUGAGAACACAG 20
6857 25737
1077
5535.1 CFTR- IntronlO- - UUCUGCCAUGUGAGAACACAG 21
6858 25738
CFTR- IntronlO- - UUUCUGCCAUGUGAGAACACAG 22
6859 25739
CFTR- IntronlO- - CUUUCUGCCAUGUGAGAACACAG 23
6860 25740
CFTR- IntronlO- - CCUUUCUGCCAUGUGAGAACACAG 24
6861 25741
CFTR- IntronlO- - AUUUCAACUUAUACACAG 18
6862 25742
CFTR- IntronlO- - CAU U U CAACU U AU ACACAG 19
6863 25743
CFTR- IntronlO- - UCAUUUCAACUUAUACACAG 20
6864 25744
CFTR- IntronlO- - AUCAUUUCAACUUAUACACAG 21
6865 25745
CFTR- IntronlO- - UAUCAUUUCAACUUAUACACAG 22
6866 25746
CFTR- IntronlO- - AUAUCAUUUCAACUUAUACACAG 23
6867 25747
CFTR- IntronlO- - AAU AU CAU U U CAACU UAU ACACAG 24
6868 25748
CFTR- IntronlO- - CUGUUGUCUGCAUCACAG 18
6869 25749
CFTR- IntronlO- - UCUGUUGUCUGCAUCACAG 19
6870 25750
CFTR- IntronlO- - UUCUGUUGUCUGCAUCACAG 20
6871 25751
1078
5535.1 CFTR- IntronlO- - CUUCUGUUGUCUGCAUCACAG 21
6872 25752
CFTR- IntronlO- - CCUUCUGUUGUCUGCAUCACAG 22
6873 25753
CFTR- IntronlO- - UCCUUCUGUUGUCUGCAUCACAG 23
6874 25754
CFTR- IntronlO- - GUCCUUCUGUUGUCUGCAUCACAG 24
6875 25755
CFTR- IntronlO- - GAGUCUUCCAAGUAGCAG 18
6876 25756
CFTR- IntronlO- - AG AG U CU U CCAAG U AG CAG 19
6877 25757
CFTR- IntronlO- - AAG AG U CU U CCAAG U AG CAG 20
6878 25758
CFTR- IntronlO- - GAAGAG UCUU CCAAG U AG CAG 21
6879 25759
CFTR- IntronlO- - GGAAGAGUCUUCCAAGUAGCAG 22
6880 25760
CFTR- IntronlO- - GGGAAGAGUCUUCCAAGUAGCAG 23
6881 25761
CFTR- IntronlO- - UGGGAAGAGUCUUCCAAGUAGCAG 24
6882 25762
CFTR- IntronlO- - CCAAAACU U U AU UG U CAG 18
6883 25763
CFTR- IntronlO- - ACCAAAACUUUAUUGUCAG 19
6884 25764
CFTR- IntronlO- - GACCAAAACUUUAUUGUCAG 20
6885 25765
1079
5535.1 CFTR- IntronlO- - GGACCAAAACUUUAUUGUCAG 21
6886 25766
CFTR- IntronlO- - AGGACCAAAACUUUAUUGUCAG 22
6887 25767
CFTR- IntronlO- - AAGGACCAAAACUUUAUUGUCAG 23
6888 25768
CFTR- IntronlO- - AAAGGACCAAAACUUUAUUGUCAG 24
6889 25769
CFTR- IntronlO- - CAAGUG CAAAGCU U U CAG 18
6890 25770
CFTR- IntronlO- - G C A AG U G C A A AG C U U U C AG 19
6891 25771
CFTR- IntronlO- - AG C A AG U G C A A AG C U U U C AG 20
6892 25772
CFTR- IntronlO- - A AG CAAGUG C A A AG C U U U C AG 21
6893 25773
CFTR- IntronlO- - G A AG C A AG U G C A A AG C U U U C AG 22
6894 25774
CFTR- IntronlO- - U G A AG C A AG U G C A A AG C U U U C AG 23
6895 25775
CFTR- IntronlO- - GUGAAGCAAGUG C A A AG C U U U C AG 24
6896 25776
CFTR- IntronlO- - AAACAGAAAAAGAAAGAG 18
6897 25777
CFTR- IntronlO- - CAAACAGAAAAAGAAAGAG 19
6898 25778
CFTR- IntronlO- - ACAAACAGAAAAAGAAAGAG 20
1269 20154
1080
5535.1 CFTR- IntronlO- - GACAAACAGAAAAAGAAAGAG 21
6899 25779
CFTR- IntronlO- - AGACAAACAGAAAAAGAAAGAG 22
6900 25780
CFTR- IntronlO- - AAGACAAACAGAAAAAGAAAGAG 23
6901 25781
CFTR- IntronlO- - UAAGACAAACAGAAAAAGAAAGAG 24
6902 25782
CFTR- IntronlO- - AUUUUUGUAUUUUUAGUAGAG 21
6903 25783
CFTR- IntronlO- - AAUUUUUGUAUUUUUAGUAGAG 22
6904 25784
CFTR- IntronlO- - UAAUUUUUGUAUUUUUAGUAGAG 23
6905 25785
CFTR- IntronlO- - CUAAUUUUUGUAUUUUUAGUAGAG 24
6906 25786
CFTR- IntronlO- - GAAAGAAUCAAAUUAGAG 18
6907 25787
CFTR- IntronlO- - UGAAAGAAUCAAAUUAGAG 19
6908 25788
CFTR- IntronlO- - A U G A A AG A A U C A A A U U AG AG 20
6909 25789
CFTR- IntronlO- - CAUGAAAGAAUCAAAUUAGAG 21
6910 25790
CFTR- IntronlO- - ACAUGAAAGAAUCAAAUUAGAG 22
6911 25791
CFTR- IntronlO- - GACAUGAAAGAAUCAAAUUAGAG 23
6912 25792
1081
5535.1 CFTR- IntronlO- - AGACAUGAAAGAAUCAAAUUAGAG 24
6913 25793
CFTR- IntronlO- - AACAAAGACUUGCAGGAG 18
6914 25794
CFTR- IntronlO- - GAACAAAGACUUGCAGGAG 19
6915 25795
CFTR- IntronlO- - UGAACAAAGACUUGCAGGAG 20
6916 25796
CFTR- IntronlO- - UUGAACAAAGACUUGCAGGAG 21
6917 25797
CFTR- IntronlO- - UUUGAACAAAGACUUGCAGGAG 22
6918 25798
CFTR- IntronlO- - AUUUGAACAAAGACUUGCAGGAG 23
6919 25799
CFTR- IntronlO- - CAU U U G AAC AAAG AC U U G CAG GAG 24
6920 25800
CFTR- IntronlO- - AUCAAUAUCUAAGAUGAG 18
6921 25801
CFTR- IntronlO- - UAUCAAUAUCUAAGAUGAG 19
6922 25802
CFTR- IntronlO- - UU AUCAAUAUCUAAGAUGAG 20
6923 25803
CFTR- IntronlO- - UU UAUCAAUAUCUAAGAUGAG 21
6924 25804
CFTR- IntronlO- - AUUUAUCAAUAUCUAAGAUGAG 22
6925 25805
CFTR- IntronlO- - UAUUUAUCAAUAUCUAAGAUGAG 23
6926 25806
1082
5535.1 CFTR- IntronlO- - UUAUUUAUCAAUAUCUAAGAUGAG 24
6927 25807
CFTR- IntronlO- - GCUACUUGGGAGGCUGAG 18
6928 25808
CFTR- IntronlO- - AGCUACUUGGGAGGCUGAG 19
6929 25809
CFTR- IntronlO- - CAGCUACUUGGGAGGCUGAG 20
6930 25810
CFTR- IntronlO- - CCAGCUACUUGGGAGGCUGAG 21
6931 25811
CFTR- IntronlO- - CCCAGCUACUUGGGAGGCUGAG 22
6932 25812
CFTR- IntronlO- - UCCCAGCUACUUGGGAGGCUGAG 23
6933 25813
CFTR- IntronlO- - GUCCCAGCUACUUGGGAGGCUGAG 24
6934 25814
CFTR- IntronlO- - GGCAGAACUUGCAGUGAG 18
6935 25815
CFTR- IntronlO- - AGGCAGAACUUGCAGUGAG 19
6936 25816
CFTR- IntronlO- - GAGGCAGAACUUGCAGUGAG 20
6937 25817
CFTR- IntronlO- - GGAGGCAGAACUUGCAGUGAG 21
6938 25818
CFTR- IntronlO- - AGGAGGCAGAACUUGCAGUGAG 22
6939 25819
CFTR- IntronlO- - CAGGAGGCAGAACUUGCAGUGAG 23
6940 25820
1083
5535.1 CFTR- IntronlO- - CCAGGAGGCAGAACUUGCAGUGAG 24
6941 25821
CFTR- IntronlO- - UUUUUUUUUUUUUUUGAG 18
6942 25822
CFTR- IntronlO- - UUUUUUUUUUUUUUUUGAG 19
6943 25823
CFTR- IntronlO- - UUUUUUUUUUUUUUUUUGAG 20
6944 25824
CFTR- IntronlO- - UUUUUUUUUUUUUUUUUUGAG 21
6945 25825
CFTR- IntronlO- - UUUUUUUUUUUUUUUUUUUGAG 22
6946 25826
CFTR- IntronlO- - UUUUUUUUUUUUUUUUUUUUGAG 23
6947 25827
CFTR- IntronlO- - UUUUUUUUUUUUUUUUUUUUUGAG 24
6948 25828
CFTR- IntronlO- - G C U U U U A A A AC A A A A U AG 18
6949 25829
CFTR- IntronlO- - AGCU U U U AAAACAAAAU AG 19
6950 25830
CFTR- IntronlO- - CAG CU U U U AAAACAAAAU AG 20
6951 25831
CFTR- IntronlO- - ACAG CU U U U AAAACAAAAU AG 21
6952 25832
CFTR- IntronlO- - AACAGCU U U U AAAACAAAAU AG 22
6953 25833
CFTR- IntronlO- - AAACAG CU U U U AAAACAAAAU AG 23
6954 25834
1084
5535.1 CFTR- IntronlO- - G AAACAGCU U U U AAAACAAAAU AG 24
6955 25835
CFTR- IntronlO- - ACUUAAUGAAAGCAAUAG 18
6956 25836
CFTR- IntronlO- - GACUUAAUGAAAGCAAUAG 19
6957 25837
CFTR- IntronlO- - UGACUUAAUGAAAGCAAUAG 20
6958 25838
CFTR- IntronlO- - GUGACUUAAUGAAAGCAAUAG 21
6959 25839
CFTR- IntronlO- - CGUGACUUAAUGAAAGCAAUAG 22
6960 25840
CFTR- IntronlO- - UCGUGACUUAAUGAAAGCAAUAG 23
6961 25841
CFTR- IntronlO- - CUCGUGACUUAAUGAAAGCAAUAG 24
6962 25842
CFTR- IntronlO- - U AAAAAAU U AU ACU AU AG 18
6963 25843
CFTR- IntronlO- - U U AAAAAAU U AU ACU AU AG 19
6964 25844
CFTR- IntronlO- - AU U AAAAAAU U AU ACU AU AG 20
6965 25845
CFTR- IntronlO- - UAUUAAAAAAUUAUACUAUAG 21
6966 25846
CFTR- IntronlO- - CUAUUAAAAAAUUAUACUAUAG 22
6967 25847
CFTR- IntronlO- - ACUAUUAAAAAAUUAUACUAUAG 23
6968 25848
1085
5535.1 CFTR- IntronlO- - CACUAUUAAAAAAUUAUACUAUAG 24
6969 25849
CFTR- IntronlO- - GUAGUGGAAGUAGUAUAG 18
6970 25850
CFTR- IntronlO- - AGUAGUGGAAGUAGUAUAG 19
6971 25851
CFTR- IntronlO- - UAGUAGUGGAAGUAGUAUAG 20
6972 25852
CFTR- IntronlO- - GUAGUAGUGGAAGUAGUAUAG 21
6973 25853
CFTR- IntronlO- - GGUAGUAGUGGAAGUAGUAUAG 22
6974 25854
CFTR- IntronlO- - AGGUAGUAGUGGAAGUAGUAUAG 23
6975 25855
CFTR- IntronlO- - CAGGUAGUAGUGGAAGUAGUAUAG 24
6976 25856
CFTR- IntronlO- - CCUCACCCUCCCAAGUAG 18
6977 25857
CFTR- IntronlO- - GCCUCACCCUCCCAAGUAG 19
6978 25858
CFTR- IntronlO- - UGCCUCACCCUCCCAAGUAG 20
6979 25859
CFTR- IntronlO- - CUGCCUCACCCUCCCAAGUAG 21
6980 25860
CFTR- IntronlO- - CCUGCCUCACCCUCCCAAGUAG 22
6981 25861
CFTR- IntronlO- - UCCUGCCUCACCCUCCCAAGUAG 23
6982 25862
1086
5535.1 CFTR- IntronlO- - CUCCUGCCUCACCCUCCCAAGUAG 24
6983 25863
CFTR- IntronlO- - GCCUCAGCCUCCCAAGUAG 19
6984 25864
CFTR- IntronlO- - UGCCUCAGCCUCCCAAGUAG 20
6985 25865
CFTR- IntronlO- - CUGCCUCAGCCUCCCAAGUAG 21
6986 25866
CFTR- IntronlO- - CCUGCCUCAGCCUCCCAAGUAG 22
6987 25867
CFTR- IntronlO- - UCCUGCCUCAGCCUCCCAAGUAG 23
6988 25868
CFTR- IntronlO- - CUCCUGCCUCAGCCUCCCAAGUAG 24
6989 25869
CFTR- IntronlO- - GAGGAAGAAAGGAAGUAG 18
6990 25870
CFTR- IntronlO- - UGAGGAAGAAAGGAAGUAG 19
6991 25871
CFTR- IntronlO- - AUGAGGAAGAAAGGAAGUAG 20
6992 25872
CFTR- IntronlO- - AAUGAGGAAGAAAGGAAGUAG 21
6993 25873
CFTR- IntronlO- - AAAUGAGGAAGAAAGGAAGUAG 22
6994 25874
CFTR- IntronlO- - GAAAUGAGGAAGAAAGGAAGUAG 23
6995 25875
CFTR- IntronlO- - GGAAAUGAGGAAGAAAGGAAGUAG 24
6996 25876
1087
5535.1 CFTR- IntronlO- - GCUUGAUCCAGGUAGUAG 18
6997 25877
CFTR- IntronlO- - GGCUUGAUCCAGGUAGUAG 19
6998 25878
CFTR-
- UGGCUUGAUCCAGGUAGUAG 20
lntronlO-461 19347
CFTR- IntronlO- - GUGGCUUGAUCCAGGUAGUAG 21
6999 25879
CFTR- IntronlO- - GGUGGCUUGAUCCAGGUAGUAG 22
7000 25880
CFTR- IntronlO- - UGGUGGCUUGAUCCAGGUAGUAG 23
7001 25881
CFTR- IntronlO- - AUGGUGGCUUGAUCCAGGUAGUAG 24
7002 25882
CFTR- IntronlO- - CUAUGAAGGCAGAGUUAG 18
7003 25883
CFTR- IntronlO- - GCUAUGAAGGCAGAGUUAG 19
7004 25884
CFTR-
- AGCUAUGAAGGCAGAGUUAG 20
lntronlO-464 19350
CFTR- IntronlO- - CAGCUAUGAAGGCAGAGUUAG 21
7005 25885
CFTR- IntronlO- - GCAGCUAUGAAGGCAGAGUUAG 22
7006 25886
CFTR- IntronlO- - AGCAGCUAUGAAGGCAGAGUUAG 23
7007 25887
CFTR- IntronlO- - AAGCAGCUAUGAAGGCAGAGUUAG 24
7008 25888
CFTR- IntronlO- - GGGGUUUCACCGUUUUAG 18
7009 25889
1088
5535.1 CFTR- IntronlO- - CGGGGUUUCACCGUUUUAG 19
7010 25890
CFTR- IntronlO- - ACGGGGUUUCACCGUUUUAG 20
7011 25891
CFTR- IntronlO- - GACGGGGUUUCACCGUUUUAG 21
7012 25892
CFTR- IntronlO- - AGACGGGGUUUCACCGUUUUAG 22
7013 25893
CFTR- IntronlO- - G AG ACGGGG U U U CACCG U U U U AG 23
7014 25894
CFTR- IntronlO- - AGAGACGGGGUUUCACCGUUUUAG 24
7015 25895
CFTR- IntronlO- - UAAUUUUUGUAUUUUUAG 18
7016 25896
CFTR- IntronlO- - CUAAUUUUUGUAUUUUUAG 19
7017 25897
CFTR- IntronlO- - GCUAAUUUUUGUAUUUUUAG 20
7018 25898
CFTR- IntronlO- - AGCUAAUUUUUGUAUUUUUAG 21
7019 25899
CFTR- IntronlO- - CAGCUAAUUUUUGUAUUUUUAG 22
7020 25900
CFTR- IntronlO- - UCAGCUAAUUUUUGUAUUUUUAG 23
7021 25901
CFTR- IntronlO- - CUCAGCUAAUUUUUGUAUUUUUAG 24
7022 25902
CFTR- IntronlO- - CGGCUAAUUUUUUGUAUUUUUAG 23
7023 25903
1089
5535.1 CFTR- IntronlO- - CCGGCUAAUUUUUUGUAUUUUUAG 24
7024 25904
CFTR- IntronlO- - UCAGAGAAGUAAUCGGCG 18
7025 25905
CFTR- IntronlO- - GUCAGAGAAGUAAUCGGCG 19
7026 25906
CFTR- IntronlO- - UGUCAGAGAAGUAAUCGGCG 20
7027 25907
CFTR- IntronlO- - CUGUCAGAGAAGUAAUCGGCG 21
7028 25908
CFTR- IntronlO- - ACUGUCAGAGAAGUAAUCGGCG 22
7029 25909
CFTR- IntronlO- - UACUGUCAGAGAAGUAAUCGGCG 23
7030 25910
CFTR- IntronlO- - AUACUGUCAGAGAAGUAAUCGGCG 24
7031 25911
CFTR- IntronlO- - UUCUGUAGGGAGACAAGG 18
7032 25912
CFTR- IntronlO- - AUUCUGUAGGGAGACAAGG 19
7033 25913
CFTR- IntronlO- - UAUUCUGUAGGGAGACAAGG 20
7034 25914
CFTR- IntronlO- - CUAUUCUGUAGGGAGACAAGG 21
7035 25915
CFTR- IntronlO- - GCUAUUCUGUAGGGAGACAAGG 22
7036 25916
CFTR- IntronlO- - GGCUAUUCUGUAGGGAGACAAGG 23
7037 25917
1090
5535.1 CFTR- IntronlO- - AGGCUAUUCUGUAGGGAGACAAGG 24
7038 25918
CFTR- IntronlO- - ACAAGUCUAGUUUCAAGG 18
7039 25919
CFTR- IntronlO- - UACAAGUCUAGUUUCAAGG 19
7040 25920
CFTR- IntronlO- - GUACAAGUCUAGUUUCAAGG 20
7041 25921
CFTR- IntronlO- - UGUACAAGUCUAGUUUCAAGG 21
7042 25922
CFTR- IntronlO- - AUGUACAAGUCUAGUUUCAAGG 22
7043 25923
CFTR- IntronlO- - GAUGUACAAGUCUAGUUUCAAGG 23
7044 25924
CFTR- IntronlO- - GGAUGUACAAGUCUAGUUUCAAGG 24
7045 25925
CFTR- IntronlO- - GGAAGGAAGGAAAGAAGG 18
7046 25926
CFTR- IntronlO- - AG G AAG G AAG G AAAG AAG G 19
7047 25927
CFTR- IntronlO- - AAGGAAGGAAGGAAAGAAGG 20
7048 25928
CFTR- IntronlO- - G AAG G AAG G AAG G AAAG AAG G 21
7049 25929
CFTR- IntronlO- - GGAAGGAAGGAAGGAAAGAAGG 22
7050 25930
CFTR- IntronlO- - AG G AAG G AAG G AAG G AAAG AAGG 23
7051 25931
1091
5535.1 CFTR- IntronlO- - GAGGAAGGAAGGAAGGAAAGAAGG 24
7052 25932
CFTR- IntronlO- - AAGUAGGAGGAAGGAAGG 18
7053 25933
CFTR- IntronlO- - GAAGUAGGAGGAAGGAAGG 19
7054 25934
CFTR- IntronlO- - GGAAG U AGG AGG AAGG AAGG 20
7055 25935
CFTR- IntronlO- - AGGAAGUAGGAGGAAGGAAGG 21
7056 25936
CFTR- IntronlO- - AAGGAAGU AGG AGG AAGG AAGG 22
7057 25937
CFTR- IntronlO- - AAAGGAAGUAGGAGGAAGGAAGG 23
7058 25938
CFTR- IntronlO- - GAAAGGAAGUAGGAGGAAGGAAGG 24
7059 25939
CFTR- IntronlO- - A A A AG A A AG AG AG G A AG G 18
7060 25940
CFTR- IntronlO- - AAAAAGAAAGAGAGGAAGG 19
7061 25941
CFTR- IntronlO- - G A A A A AG A A AG AG AG G AAG G 20
7062 25942
CFTR- IntronlO- - AGAAAAAGAAAGAGAGGAAGG 21
7063 25943
CFTR- IntronlO- - CAGAAAAAGAAAGAGAGGAAGG 22
7064 25944
CFTR- IntronlO- - ACAGAAAAAGAAAGAGAGGAAGG 23
7065 25945
1092
5535.1 CFTR- IntronlO- - AAC AG AAAAAG AAAG AG AG G AAG G 24
7066 25946
CFTR- IntronlO- - AAGGAAGUAGGAGGAAGG 18
7067 25947
CFTR- IntronlO- - AAAGGAAGUAGGAGGAAGG 19
7068 25948
CFTR- IntronlO- - GAAAGGAAGUAGGAGGAAGG 20
7069 25949
CFTR- IntronlO- - AGAAAGGAAGUAGGAGGAAGG 21
7070 25950
CFTR- IntronlO- - AAGAAAGGAAGUAGGAGGAAGG 22
7071 25951
CFTR- IntronlO- - GAAGAAAGGAAGUAGGAGGAAGG 23
7072 25952
CFTR- IntronlO- - GGAAGAAAGGAAGUAGGAGGAAGG 24
7073 25953
CFTR- IntronlO- - AGUCUUACUGUCACCAGG 18
7074 25954
CFTR- IntronlO- - GAGUCUUACUGUCACCAGG 19
7075 25955
CFTR- IntronlO- - AGAGUCUUACUGUCACCAGG 20
7076 25956
CFTR- IntronlO- - CAGAGUCUUACUGUCACCAGG 21
7077 25957
CFTR- IntronlO- - ACAGAGUCUUACUGUCACCAGG 22
7078 25958
CFTR- IntronlO- - G ACAG AG UCUUACUGU CACCAGG 23
7079 25959
1093
5535.1 CFTR- IntronlO- - AGACAGAGUCUUACUGUCACCAGG 24
7080 25960
CFTR- IntronlO- - CUUACUCUGUCACCCAGG 18
7081 25961
CFTR- IntronlO- - UCUUACUCUGUCACCCAGG 19
7082 25962
CFTR- IntronlO- - GUCUUACUCUGUCACCCAGG 20
7083 25963
CFTR- IntronlO- - GGUCUUACUCUGUCACCCAGG 21
7084 25964
CFTR- IntronlO- - AGGUCUUACUCUGUCACCCAGG 22
7085 25965
CFTR- IntronlO- - UAGGUCUUACUCUGUCACCCAGG 23
7086 25966
CFTR- IntronlO- - UUAGGUCUUACUCUGUCACCCAGG 24
7087 25967
CFTR- IntronlO- - CUCGCUCUGUCGCCCAGG 18
7088 25968
CFTR- IntronlO- - UCUCGCUCUGUCGCCCAGG 19
7089 25969
CFTR- IntronlO- - GUCUCGCUCUGUCGCCCAGG 20
7090 25970
CFTR- IntronlO- - AGUCUCGCUCUGUCGCCCAGG 21
7091 25971
CFTR- IntronlO- - GAGUCUCGCUCUGUCGCCCAGG 22
7092 25972
CFTR- IntronlO- - GGAGUCUCGCUCUGUCGCCCAGG 23
7093 25973
1094
5535.1 CFTR- IntronlO- - CGGAGUCUCGCUCUGUCGCCCAGG 24
7094 25974
CFTR- IntronlO- - AGGUGAUGGUAUUGCAGG 18
7095 25975
CFTR- IntronlO- - AAGGUGAUGGUAUUGCAGG 19
7096 25976
CFTR- IntronlO- - CAAGGUGAUGGUAUUGCAGG 20
7097 25977
CFTR- IntronlO- - CCAAGGUGAUGGUAUUGCAGG 21
7098 25978
CFTR- IntronlO- - CCCAAGGUGAUGGUAUUGCAGG 22
7099 25979
CFTR- IntronlO- - UCCCAAGGUGAUGGUAUUGCAGG 23
7100 25980
CFTR- IntronlO- - UUCCCAAGGUGAUGGUAUUGCAGG 24
7101 25981
CFTR- IntronlO- - CAGAAAAAGAAAGAGAGG 18
7102 25982
CFTR- IntronlO- - ACAGAAAAAGAAAGAGAGG 19
7103 25983
CFTR- IntronlO- - AACAGAAAAAGAAAGAGAGG 20
7104 25984
CFTR- IntronlO- - AAACAGAAAAAGAAAGAGAGG 21
7105 25985
CFTR- IntronlO- - CAAACAGAAAAAGAAAGAGAGG 22
7106 25986
CFTR- IntronlO- - ACAAACAGAAAAAGAAAGAGAGG 23
7107 25987
1095
5535.1 CFTR- IntronlO- - GACAAACAGAAAAAGAAAGAGAGG 24
7108 25988
CFTR- IntronlO- - UGGCGUGAACCCAGGAGG 18
7109 25989
CFTR- IntronlO- - AUGGCGUGAACCCAGGAGG 19
7110 25990
CFTR- IntronlO- - AAUGGCGUGAACCCAGGAGG 20
7111 25991
CFTR- IntronlO- - GAAUGGCGUGAACCCAGGAGG 21
7112 25992
CFTR- IntronlO- - AGAAUGGCGUGAACCCAGGAGG 22
7113 25993
CFTR- IntronlO- - GAGAAUGGCGUGAACCCAGGAGG 23
7114 25994
CFTR- IntronlO- - GGAGAAUGGCGUGAACCCAGGAGG 24
7115 25995
CFTR- IntronlO- - AAGAAAGGAAGUAGGAGG 18
7116 25996
CFTR- IntronlO- - GAAGAAAGGAAGUAGGAGG 19
7117 25997
CFTR- IntronlO- - GGAAGAAAGGAAGUAGGAGG 20
7118 25998
CFTR- IntronlO- - AGGAAGAAAGGAAGUAGGAGG 21
7119 25999
CFTR- IntronlO- - GAGG AAGAAAGGAAGUAGGAGG 22
7120 26000
CFTR- IntronlO- - UGAGGAAGAAAGGAAGUAGGAGG 23
7121 26001
1096
5535.1 CFTR- IntronlO- - AUGAGGAAGAAAGGAAGUAGGAGG 24
7122 26002
CFTR- IntronlO- - UCCCAGCUACUCGGGAGG 18
7123 26003
CFTR- IntronlO- - GUCCCAGCUACUCGGGAGG 19
7124 26004
CFTR- IntronlO- - AGUCCCAGCUACUCGGGAGG 20
7125 26005
CFTR- IntronlO- - UAGUCCCAGCUACUCGGGAGG 21
7126 26006
CFTR- IntronlO- - GU AGUCCCAGCUACUCGGGAGG 22
7127 26007
CFTR- IntronlO- - CGUAGUCCCAGCUACUCGGGAGG 23
7128 26008
CFTR- IntronlO- - CCGUAGUCCCAGCUACUCGGGAGG 24
7129 26009
CFTR- IntronlO- - AGUAAUCGGCGGUGGAGG 18
7130 26010
CFTR- IntronlO- - AAGUAAUCGGCGGUGGAGG 19
7131 26011
CFTR- IntronlO- - GAAGUAAUCGGCGGUGGAGG 20
7132 26012
CFTR- IntronlO- - AGAAGUAAUCGGCGGUGGAGG 21
7133 26013
CFTR- IntronlO- - GAGAAGUAAUCGGCGGUGGAGG 22
7134 26014
CFTR- IntronlO- - AGAGAAGUAAUCGGCGGUGGAGG 23
7135 26015
1097
5535.1 CFTR- IntronlO- - CAGAGAAGUAAUCGGCGGUGGAGG 24
7136 26016
CFTR- IntronlO- - UCCUAGCACUUUUGGAGG 18
7137 26017
CFTR- IntronlO- - AUCCUAGCACUUUUGGAGG 19
7138 26018
CFTR- IntronlO- - AAUCCUAGCACUUUUGGAGG 20
7139 26019
CFTR- IntronlO- - UAAUCCUAGCACUUUUGGAGG 21
7140 26020
CFTR- IntronlO- - GUAAUCCUAGCACUUUUGGAGG 22
7141 26021
CFTR- IntronlO- - UGUAAUCCUAGCACUUUUGGAGG 23
7142 26022
CFTR- IntronlO- - UUGUAAUCCUAGCACUUUUGGAGG 24
7143 26023
CFTR- IntronlO- - AGAAAGAAGGAAAUGAGG 18
7144 26024
CFTR- IntronlO- - AAGAAAGAAGGAAAUGAGG 19
7145 26025
CFTR- IntronlO- - GAAGAAAGAAGGAAAUGAGG 20
7146 26026
CFTR- IntronlO- - G G A AG A A AG A AG G AAA U G AG G 21
7147 26027
CFTR- IntronlO- - AG G AAG AAAG AAG G AAAU G AG G 22
7148 26028
CFTR- IntronlO- - AAGGAAGAAAGAAGGAAAUGAGG 23
7149 26029
1098
5535.1 CFTR- IntronlO- - GAAGGAAGAAAGAAGGAAAUGAGG 24
7150 26030
CFTR- IntronlO- - GGUGAUUAGUCCAUGAGG 18
7151 26031
CFTR- IntronlO- - AGGUGAUUAGUCCAUGAGG 19
7152 26032
CFTR- IntronlO- - GAGGUGAUUAGUCCAUGAGG 20
7153 26033
CFTR- IntronlO- - GGAGGUGAUUAGUCCAUGAGG 21
7154 26034
CFTR- IntronlO- - GGGAGGUGAUUAGUCCAUGAGG 22
7155 26035
CFTR- IntronlO- - UGGGAGGUGAUUAGUCCAUGAGG 23
7156 26036
CFTR- IntronlO- - UUGGGAGGUGAUUAGUCCAUGAGG 24
7157 26037
CFTR- IntronlO- - CUACUCGGGAGGCUGAGG 18
7158 26038
CFTR- IntronlO- - GCUACUCGGGAGGCUGAGG 19
7159 26039
CFTR- IntronlO- - AGCUACUCGGGAGGCUGAGG 20
7160 26040
CFTR- IntronlO- - CAGCUACUCGGGAGGCUGAGG 21
7161 26041
CFTR- IntronlO- - CCAGCUACUCGGGAGGCUGAGG 22
7162 26042
CFTR- IntronlO- - CCCAGCUACUCGGGAGGCUGAGG 23
7163 26043
1099
5535.1 CFTR- IntronlO- - UCCCAGCUACUCGGGAGGCUGAGG 24
7164 26044
CFTR- IntronlO- - CUACUUGGGAGGCUGAGG 18
7165 26045
CFTR- IntronlO- - GCUACUUGGGAGGCUGAGG 19
7166 26046
CFTR- IntronlO- - AGCUACUUGGGAGGCUGAGG 20
1288 20173
CFTR- IntronlO- - AAAAAAUUAUACUAUAGG 18
7167 26047
CFTR- IntronlO- - UAAAAAAUUAUACUAUAGG 19
7168 26048
CFTR- IntronlO- - UU AAAAAAUUAUACUAUAGG 20
1289 20174
CFTR- IntronlO- - AUUAAAAAAUUAUACUAUAGG 21
7169 26049
CFTR- IntronlO- - UAUUAAAAAAUUAUACUAUAGG 22
7170 26050
CFTR- IntronlO- - CUAUUAAAAAAUUAUACUAUAGG 23
7171 26051
CFTR- IntronlO- - ACUAUUAAAAAAUUAUACUAUAGG 24
7172 26052
CFTR- IntronlO- - AGGAAGAAAGGAAGUAGG 18
7173 26053
CFTR- IntronlO- - GAGGAAGAAAGGAAGUAGG 19
7174 26054
CFTR- IntronlO- - UG AGGAAGAAAGGAAGUAGG 20
1290 20175
1100
5535.1 CFTR- IntronlO- - AUGAGGAAGAAAGGAAGUAGG 21
7175 26055
CFTR- IntronlO- - AAUGAGGAAG A A AG G A AG U AG G 22
7176 26056
CFTR- IntronlO- - AAAUGAGGAAGAAAGGAAGUAGG 23
7177 26057
CFTR- IntronlO- - GAAAUGAGGAAGAAAGGAAGUAGG 24
7178 26058
CFTR- IntronlO- - CAGAGAAGUAAUCGGCGG 18
7179 26059
CFTR- IntronlO- - UCAGAGAAGUAAUCGGCGG 19
7180 26060
CFTR-
- GUCAGAGAAGUAAUCGGCGG 20
lntronlO-105 18991
CFTR- IntronlO- - UGUCAGAGAAGUAAUCGGCGG 21
7181 26061
CFTR- IntronlO- - CUGUCAGAGAAGUAAUCGGCGG 22
7182 26062
CFTR- IntronlO- - ACUGUCAGAGAAGUAAUCGGCGG 23
7183 26063
CFTR- IntronlO- - UACUGUCAGAGAAGUAAUCGGCGG 24
7184 26064
CFTR- IntronlO- - UCUGUAGGGAGACAAGGG 18
7185 26065
CFTR- IntronlO- - UUCUGUAGGGAGACAAGGG 19
7186 26066
CFTR-
- AUUCUGUAGGGAGACAAGGG 20
lntronlO-473 19359
CFTR- IntronlO- - UAUUCUGUAGGGAGACAAGGG 21
7187 26067
1101
5535.1 CFTR- IntronlO- - CUAUUCUGUAGGGAGACAAGGG 22
7188 26068
CFTR- IntronlO- - GCUAUUCUGUAGGGAGACAAGGG 23
7189 26069
CFTR- IntronlO- - GGCUAUUCUGUAGGGAGACAAGGG 24
7190 26070
CFTR- IntronlO- - GGUGAUGGUAUUGCAGGG 18
7191 26071
CFTR- IntronlO- - AGGUGAUGGUAUUGCAGGG 19
7192 26072
CFTR- IntronlO- - AAGGUGAUGGUAUUGCAGGG 20
1292 20177
CFTR- IntronlO- - CAAGGUGAUGGUAUUGCAGGG 21
7193 26073
CFTR- IntronlO- - CCAAGGUGAUGGUAUUGCAGGG 22
7194 26074
CFTR- IntronlO- - CCCAAGGUGAUGGUAUUGCAGGG 23
7195 26075
CFTR- IntronlO- - UCCCAAGGUGAUGGUAUUGCAGGG 24
7196 26076
CFTR- IntronlO- - C AG G AG CCA A A A A U U G G G 18
7197 26077
CFTR- IntronlO- - UCAGGAGCCAAAAAUUGGG 19
7198 26078
CFTR-
- UUCAGGAGCCAAAAAUUGGG 20
lntronlO-476 19362
CFTR- IntronlO- - UU UCAGGAGCCAAAAAUUGGG 21
7199 26079
CFTR-
- CUU UCAGGAGCCAAAAAUUGGG 22
IntronlO- 26080
1102
5535.1 7200
CFTR- IntronlO- - GCUUUCAGGAGCCAAAAAUUGGG 23
7201 26081
CFTR- IntronlO- - UGCUUUCAGGAGCCAAAAAUUGGG 24
7202 26082
CFTR- IntronlO- - UUACUAGAAAGAUAAUGG 18
7203 26083
CFTR- IntronlO- - UUUACUAGAAAGAUAAUGG 19
7204 26084
CFTR- IntronlO- - GUUUACUAGAAAGAUAAUGG 20
7205 26085
CFTR- IntronlO- - CGUUUACUAGAAAGAUAAUGG 21
7206 26086
CFTR- IntronlO- - CCGUUUACUAGAAAGAUAAUGG 22
7207 26087
CFTR- IntronlO- - GCCGUUUACUAGAAAGAUAAUGG 23
7208 26088
CFTR- IntronlO- - UGCCGUUUACUAGAAAGAUAAUGG 24
7209 26089
CFTR- IntronlO- - UAAGGCUUAUUUCUCUGG 18
7210 26090
CFTR- IntronlO- - CUAAGGCUUAUUUCUCUGG 19
7211 26091
CFTR- IntronlO- - ACUAAGGCUUAUUUCUCUGG 20
7212 26092
CFTR- IntronlO- - GACUAAGGCUUAUUUCUCUGG 21
7213 26093
CFTR-
- AGACUAAGGCUUAUUUCUCUGG 22
IntronlO- 26094
1103
5535.1 7214
CFTR- IntronlO- - AAGACUAAGGCUUAUUUCUCUGG 23
7215 26095
CFTR- IntronlO- - AAAGACUAAGGCUUAUUUCUCUGG 24
7216 26096
CFTR- IntronlO- - UAGAGGUUAAGGAGGUGG 18
7217 26097
CFTR- IntronlO- - UUAGAGGUUAAGGAGGUGG 19
7218 26098
CFTR- IntronlO- - AUUAGAGGUUAAGGAGGUGG 20
7219 26099
CFTR- IntronlO- - UAUUAGAGGUUAAGGAGGUGG 21
7220 26100
CFTR- IntronlO- - GUAUUAGAGGUUAAGGAGGUGG 22
7221 26101
CFTR- IntronlO- - AGUAUUAGAGGUUAAGGAGGUGG 23
7222 26102
CFTR- IntronlO- - AAGUAUUAGAGGUUAAGGAGGUGG 24
7223 26103
CFTR- IntronlO- - GAGCCAAAAAUUGGGUGG 18
7224 26104
CFTR- IntronlO- - GGAGCCAAAAAUUGGGUGG 19
7225 26105
CFTR-
- AGGAGCCAAAAAUUGGGUGG 20
lntronlO-478 19364
CFTR- IntronlO- - CAGGAGCCAAAAAUUGGGUGG 21
7226 26106
CFTR- IntronlO- - UCAGGAGCCAAAAAUUGGGUGG 22
7227 26107
1104
5535.1 CFTR- IntronlO- - UUCAGGAGCCAAAAAUUGGGUGG 23
7228 26108
CFTR- IntronlO- - UUUCAGGAGCCAAAAAUUGGGUGG 24
7229 26109
CFTR- IntronlO- - UCAGGAGCCAAAAAUUGG 18
7230 26110
CFTR- IntronlO- - UUCAGGAGC C A A A A A U U G G 19
7231 26111
CFTR- IntronlO- - UUUCAGGAGC C A A A A A U U G G 20
7232 26112
CFTR- IntronlO- - CUUUCAGGAGCCAAAAAUUGG 21
7233 26113
CFTR- IntronlO- - GCUUUCAGGAGCCAAAAAUUGG 22
7234 26114
CFTR- IntronlO- - UGCUUUCAGGAGCCAAAAAUUGG 23
7235 26115
CFTR- IntronlO- - CUGCUUUCAGGAGCCAAAAAUUGG 24
7236 26116
CFTR- IntronlO- - GGGAGAAACAGGUUUUGG 18
7237 26117
CFTR- IntronlO- - UGGGAGAAACAGGUUUUGG 19
7238 26118
CFTR- IntronlO- - AUGGGAGAAACAGGUUUUGG 20
7239 26119
CFTR- IntronlO- - AAUGGGAGAAACAGGUUUUGG 21
7240 26120
CFTR- IntronlO- - UAAUGGGAGAAACAGGUUUUGG 22
7241 26121
1105
5535.1 CFTR- IntronlO- - AUAAUGGGAGAAACAGGUUUUGG 23
7242 26122
CFTR- IntronlO- - GAUAAUGGGAGAAACAGGUUUUGG 24
7243 26123
CFTR- IntronlO- - GGAAGAAAGAAGGAAAUG 18
7244 26124
CFTR- IntronlO- - AGGAAGAAAGAAGGAAAUG 19
7245 26125
CFTR- IntronlO- - A AG G A AG A A AG A AG G AAA U G 20
1311 20196
CFTR- IntronlO- - GAAGGAAGAAAGAAGGAAAUG 21
7246 26126
CFTR- IntronlO- - G G A AG G A AG A A AG A AG G AAA U G 22
7247 26127
CFTR- IntronlO- - AGGAAGGAAGAAAGAAGGAAAUG 23
7248 26128
CFTR- IntronlO- - GAGGAAGGAAGAAAGAAGGAAAUG 24
7249 26129
CFTR- IntronlO- - UUAUCAAUAUCUAAGAUG 18
7250 26130
CFTR- IntronlO- - UUUAUCAAUAUCUAAGAUG 19
7251 26131
CFTR-
- AUUUAUCAAUAUCUAAGAUG 20
lntronlO-480 19366
CFTR- IntronlO- - UAUUUAUCAAUAUCUAAGAUG 21
7252 26132
CFTR- IntronlO- - UUAUUUAUCAAUAUCUAAGAUG 22
7253 26133
CFTR-
- AUUAUUUAUCAAUAUCUAAGAUG 23
IntronlO- 26134
1106
5535.1 7254
CFTR- IntronlO- - AAUUAUUUAUCAAUAUCUAAGAUG 24
7255 26135
CFTR- IntronlO- - UCCCCUGCCAUUCAUAUG 18
7256 26136
CFTR- IntronlO- - CUCCCCUGCCAUUCAUAUG 19
7257 26137
CFTR- IntronlO- - UCUCCCCUGCCAUUCAUAUG 20
7258 26138
CFTR- IntronlO- - CUCUCCCCUGCCAUUCAUAUG 21
7259 26139
CFTR- IntronlO- - UCUCUCCCCUGCCAUUCAUAUG 22
7260 26140
CFTR- IntronlO- - GUCUCUCCCCUGCCAUUCAUAUG 23
7261 26141
CFTR- IntronlO- - UGUCUCUCCCCUGCCAUUCAUAUG 24
7262 26142
CFTR- IntronlO- - UGUUUUUAGGCUAUUCUG 18
7263 26143
CFTR- IntronlO- - AUGUUUUUAGGCUAUUCUG 19
7264 26144
CFTR- IntronlO- - AAUGUUUUUAGGCUAUUCUG 20
7265 26145
CFTR- IntronlO- - UAAUGUUUUUAGGCUAUUCUG 21
7266 26146
CFTR- IntronlO- - CUAAUGUUUUUAGGCUAUUCUG 22
7267 26147
CFTR-
- GCUAAUGUUUUUAGGCUAUUCUG 23
IntronlO- 26148
1107
5535.1 7268
CFTR- IntronlO- - GGCUAAUGUUUUUAGGCUAUUCUG 24
7269 26149
CFTR- IntronlO- - CCUCGGCCUCCCAAAGUG 18
7270 26150
CFTR- IntronlO- - GCCUCGGCCUCCCAAAGUG 19
7271 26151
CFTR- IntronlO- - CGCCUCGGCCUCCCAAAGUG 20
7272 26152
CFTR- IntronlO- - CCGCCUCGGCCUCCCAAAGUG 21
7273 26153
CFTR- IntronlO- - CCCGCCUCGGCCUCCCAAAGUG 22
7274 26154
CFTR- IntronlO- - GCCCGCCUCGGCCUCCCAAAGUG 23
7275 26155
CFTR- IntronlO- - CGCCCGCCUCGGCCUCCCAAAGUG 24
7276 26156
CFTR- IntronlO- - UGCCUCGGCCUCCCAAAGUG 20
7277 26157
CFTR- IntronlO- - CUGCCUCGGCCUCCCAAAGUG 21
7278 26158
CFTR- IntronlO- - CCUGCCUCGGCCUCCCAAAGUG 22
7279 26159
CFTR- IntronlO- - GCCUGCCUCGGCCUCCCAAAGUG 23
7280 26160
CFTR- IntronlO- - UGCCUGCCUCGGCCUCCCAAAGUG 24
7281 26161
CFTR-
- CCAGGCUGGAGUGCAGUG 18
IntronlO- 26162
1108
5535.1 7282
CFTR- IntronlO- - CCCAGGCUGGAGUGCAGUG 19
7283 26163
CFTR- IntronlO- - GCCCAGGCUGGAGUGCAGUG 20
7284 26164
CFTR- IntronlO- - CGCCCAGGCUGGAGUGCAGUG 21
7285 26165
CFTR- IntronlO- - UCGCCCAGGCUGGAGUGCAGUG 22
7286 26166
CFTR- IntronlO- - GUCGCCCAGGCUGGAGUGCAGUG 23
7287 26167
CFTR- IntronlO- - UGUCGCCCAGGCUGGAGUGCAGUG 24
7288 26168
CFTR- IntronlO- - UAAGAAGAGAAAGGGGUG 18
7289 26169
CFTR- IntronlO- - A U A AG A AG AG A A AG G G G U G 19
7290 26170
CFTR- IntronlO- - GAUAAGAAGAGAAAGGGGUG 20
7291 26171
CFTR- IntronlO- - UGAUAAGAAGAGAAAGGGGUG 21
7292 26172
CFTR- IntronlO- - UUGAUAAGAAGAGAAAGGGGUG 22
7293 26173
CFTR- IntronlO- - GUUGAUAAGAAGAGAAAGGGGUG 23
7294 26174
CFTR- IntronlO- - GGUUGAUAAGAAGAGAAAGGGGUG 24
7295 26175
CFTR-
- AGGUUAAGGAGGUGGGUG 18
IntronlO- 26176
1109
5535.1 7296
CFTR- IntronlO- - GAGGUUAAGGAGGUGGGUG 19
7297 26177
CFTR- IntronlO- - AGAGGUUAAGGAGGUGGGUG 20
7298 26178
CFTR- IntronlO- - UAGAGGUUAAGGAGGUGGGUG 21
7299 26179
CFTR- IntronlO- - UUAGAGGUUAAGGAGGUGGGUG 22
7300 26180
CFTR- IntronlO- - AUUAGAGGUUAAGGAGGUGGGUG 23
7301 26181
CFTR- IntronlO- - UAUUAGAGGUUAAGGAGGUGGGUG 24
7302 26182
CFTR- IntronlO- - GGAGCCAAAAAUUGGGUG 18
7303 26183
CFTR- IntronlO- - AGGAGCCAAAAAUUGGGUG 19
7304 26184
CFTR-
- C AG G AG CCA A A A A U U G G G U G 20
lntronlO-489 19375
CFTR- IntronlO- - UCAGGAGCCAAAAAUUGGGUG 21
7305 26185
CFTR- IntronlO- - UUCAGGAGCCAAAAAUUGGGUG 22
7306 26186
CFTR- IntronlO- - UUUCAGGAGCCAAAAAUUGGGUG 23
7307 26187
CFTR- IntronlO- - CUUUCAGGAGCCAAAAAUUGGGUG 24
7308 26188
CFTR- IntronlO- - UGGCAUCUCACCAGUGUG 18
7309 26189
1110
5535.1 CFTR- IntronlO- - AUGGCAUCUCACCAGUGUG 19
7310 26190
CFTR-
- UAUGGCAUCUCACCAGUGUG 20
lntronlO-491 19377
CFTR- IntronlO- - UUAUGGCAUCUCACCAGUGUG 21
7311 26191
CFTR- IntronlO- - CUUAUGGCAUCUCACCAGUGUG 22
7312 26192
CFTR- IntronlO- - GCUUAUGGCAUCUCACCAGUGUG 23
7313 26193
CFTR- IntronlO- - GGCUUAUGGCAUCUCACCAGUGUG 24
7314 26194
CFTR- IntronlO- - UUAUAAAAAAUAAUUGUG 18
7315 26195
CFTR- IntronlO- - UUUAUAAAAAAUAAUUGUG 19
7316 26196
CFTR- IntronlO- - U U U UAU AAAAAAU AAU UG UG 20
7317 26197
CFTR- IntronlO- - U U U U UAU AAAAAAU AAU UG UG 21
7318 26198
CFTR- IntronlO- - AUUUUUAUAAAAAAUAAUUGUG 22
7319 26199
CFTR- IntronlO- - GAUUUUUAUAAAAAAUAAUUGUG 23
7320 26200
CFTR- IntronlO- - AG AU U U U UAU AAAAAAU AAU UG UG 24
7321 26201
CFTR- IntronlO- - G CAG U U U U AU U AAAAU UG 18
7322 26202
CFTR-
- GGCAGUUUUAUUAAAAUUG 19
IntronlO- 26203
1111
5535.1 7323
CFTR- IntronlO- - AGG CAG U U U U AU U AAAAU UG 20
7324 26204
CFTR- IntronlO- - CAGGCAGUUUUAUUAAAAUUG 21
7325 26205
CFTR- IntronlO- - UCAGGCAGUUUUAUUAAAAUUG 22
7326 26206
CFTR- IntronlO- - U U CAGG CAG U U U U AU U AAAAU UG 23
7327 26207
CFTR- IntronlO- - U U U CAGG CAG U U U U AU U AAAAU UG 24
7328 26208
CFTR- IntronlO- - GCUCUCUUUUAACUAUUG 18
7329 26209
CFTR- IntronlO- - UGCUCUCUUUUAACUAUUG 19
7330 26210
CFTR-
- UUGCUCUCUUUUAACUAUUG 20
lntronlO-495 19381
CFTR- IntronlO- - CUUGCUCUCUUUUAACUAUUG 21
7331 26211
CFTR- IntronlO- - ACUUGCUCUCUUUUAACUAUUG 22
7332 26212
CFTR- IntronlO- - AACUUGCUCUCUUUUAACUAUUG 23
7333 26213
CFTR- IntronlO- - AAACUUGCUCUCUUUUAACUAUUG 24
7334 26214
CFTR- IntronlO- - CAU U UG AACAAAG ACU U G 18
7335 26215
CFTR- IntronlO- - ACAUUUGAACAAAGACUUG 19
7336 26216
1112
5535.1 CFTR- IntronlO- - AACAU UUGAACAAAGACUUG 20
7337 26217
CFTR- IntronlO- - U AACAU UUG AACAAAG ACU UG 21
7338 26218
CFTR- IntronlO- - G U AACAU U UG AACAAAG ACU UG 22
7339 26219
CFTR- IntronlO- - GG U AACAU U UG AACAAAG ACU UG 23
7340 26220
CFTR- IntronlO- - AGGUAACAUUUGAACAAAGACUUG 24
7341 26221
CFTR- IntronlO- - UUUAGCUGUGGUACUUUG 18
7342 26222
CFTR- IntronlO- - UUUUAGCUGUGGUACUUUG 19
7343 26223
CFTR- IntronlO- - AUUUUAGCUGUGGUACUUUG 20
7344 26224
CFTR- IntronlO- - CAUUUUAGCUGUGGUACUUUG 21
7345 26225
CFTR- IntronlO- - UCAUUUUAGCUGUGGUACUUUG 22
7346 26226
CFTR- IntronlO- - GUCAUUUUAGCUGUGGUACUUUG 23
7347 26227
CFTR- IntronlO- - UGUCAUUUUAGCUGUGGUACUUUG 24
7348 26228
CFTR- IntronlO- - GAUUCAGGACAUGCUUUG 18
7349 26229
CFTR- IntronlO- - AGAUUCAGGACAUGCUUUG 19
7350 26230
1113
5535.1 CFTR- IntronlO- - CAGAUUCAGGACAUGCUUUG 20
7351 26231
CFTR- IntronlO- - UCAGAUUCAGGACAUGCUUUG 21
7352 26232
CFTR- IntronlO- - AUCAGAUUCAGGACAUGCUUUG 22
7353 26233
CFTR- IntronlO- - GAUCAGAUUCAGGACAUGCUUUG 23
7354 26234
CFTR- IntronlO- - UGAUCAGAUUCAGGACAUGCUUUG 24
7355 26235
CFTR- IntronlO- - CUAUACCUGUCUGGUUUG 18
7356 26236
CFTR- IntronlO- - ACUAUACCUGUCUGGUUUG 19
7357 26237
CFTR- IntronlO- - GACUAUACCUGUCUGGUUUG 20
7358 26238
CFTR- IntronlO- - UGACUAUACCUGUCUGGUUUG 21
7359 26239
CFTR- IntronlO- - CUGACUAUACCUGUCUGGUUUG 22
7360 26240
CFTR- IntronlO- - ACUGACUAUACCUGUCUGGUUUG 23
7361 26241
CFTR- IntronlO- - GACUGACUAUACCUGUCUGGUUUG 24
7362 26242
CFTR- IntronlO- - CUUACCCAAAUAUGUUUG 18
7363 26243
CFTR- IntronlO- - ACUUACCCAAAUAUGUUUG 19
7364 26244
1114
5535.1 CFTR- IntronlO- - AACUUACCCAAAUAUGUUUG 20
7365 26245
CFTR- IntronlO- - UAACUUACCCAAAUAUGUUUG 21
7366 26246
CFTR- IntronlO- - AUAACUUACCCAAAUAUGUUUG 22
7367 26247
CFTR- IntronlO- - UAUAACUUACCCAAAUAUGUUUG 23
7368 26248
CFTR- IntronlO- - CUAUAACUUACCCAAAUAUGUUUG 24
7369 26249
CFTR- IntronlO- - U U ACCCAAU AAAAAAAAU 18
7370 26250
CFTR- IntronlO- - G U U ACCCAAU AAAAAAAAU 19
7371 26251
CFTR- IntronlO- - UG U U ACCCAAU AAAAAAAAU 20
7372 26252
CFTR- IntronlO- - U UG U U ACCCAAU AAAAAAAAU 21
7373 26253
CFTR- IntronlO- - AUUGUUACCCAAUAAAAAAAAU 22
7374 26254
CFTR- IntronlO- - U AU UG U U ACCCAAU AAAAAAAAU 23
7375 26255
CFTR- IntronlO- - U U AU UG U U ACCCAAU AAAAAAAAU 24
7376 26256
CFTR- IntronlO- - UUUUGCAAAAUACAAAAU 18
7377 26257
CFTR- IntronlO- - U U U U U G C A A A A U AC A A A A U 19
7378 26258
1115
5535.1 CFTR- IntronlO- - CU U U U UG CAAAAU ACAAAAU 20
7379 26259
CFTR- IntronlO- - ACU U U U UG CAAAAU ACAAAAU 21
7380 26260
CFTR- IntronlO- - CACUUUUUGCAAAAUACAAAAU 22
7381 26261
CFTR- IntronlO- - G CACU U U U U GCAAAAU ACAAAAU 23
7382 26262
CFTR- IntronlO- - UGCACUUUUUGCAAAAUACAAAAU 24
7383 26263
CFTR- IntronlO- - AACAAAAGAAAAGAAAAU 18
7384 26264
CFTR- IntronlO- - UAACAAAAGAAAAGAAAAU 19
7385 26265
CFTR- IntronlO- - GU AACAAAAGAAAAGAAAAU 20
7386 26266
CFTR- IntronlO- - UG UAACAAAAGAAAAGAAAAU 21
7387 26267
CFTR- IntronlO- - U UG UAACAAAAGAAAAGAAAAU 22
7388 26268
CFTR- IntronlO- - GUUGUAACAAAAGAAAAGAAAAU 23
7389 26269
CFTR- IntronlO- - UGUUGUAACAAAAGAAAAGAAAAU 24
7390 26270
CFTR- IntronlO- - GACAUGAAAGAAUCAAAU 18
7391 26271
CFTR- IntronlO- - AGACAUGAAAGAAUCAAAU 19
7392 26272
1116
5535.1 CFTR- IntronlO- - AAGACAUGAAAGAAUCAAAU 20
7393 26273
CFTR- IntronlO- - AAAGACAUGAAAGAAUCAAAU 21
7394 26274
CFTR- IntronlO- - U A A AG AC A U G A A AG A A U C A A A U 22
7395 26275
CFTR- IntronlO- - UUAAAGACAUGAAAGAAUCAAAU 23
7396 26276
CFTR- IntronlO- - U U U AAAG ACAUG AAAG AAU CAAAU 24
7397 26277
CFTR- IntronlO- - GUGGUACUUUGUAGAAAU 18
7398 26278
CFTR- IntronlO- - UGUGGUACUUUGUAGAAAU 19
7399 26279
CFTR- IntronlO- - CUGUGGUACUUUGUAGAAAU 20
7400 26280
CFTR- IntronlO- - GCUGUGGUACUUUGUAGAAAU 21
7401 26281
CFTR- IntronlO- - AGCUGUGGUACUUUGUAGAAAU 22
7402 26282
CFTR- IntronlO- - UAGCUGUGGUACUUUGUAGAAAU 23
7403 26283
CFTR- IntronlO- - UUAGCUGUGGUACUUUGUAGAAAU 24
7404 26284
CFTR- IntronlO- - AGGAAGAAAGAAGGAAAU 18
7405 26285
CFTR- IntronlO- - AAGGAAGAAAGAAGGAAAU 19
7406 26286
1117
5535.1 CFTR- IntronlO- - GAAGGAAGAAAGAAGGAAAU 20
7407 26287
CFTR- IntronlO- - GGAAGGAAGAAAGAAGGAAAU 21
7408 26288
CFTR- IntronlO- - AGGAAGGAAGAAAGAAGGAAAU 22
7409 26289
CFTR- IntronlO- - GAGGAAGGAAGAAAGAAGGAAAU 23
7410 26290
CFTR- IntronlO- - AGAGGAAGGAAGAAAGAAGGAAAU 24
7411 26291
CFTR- IntronlO- - ACU UGACCAG AAUGAAAU 18
7412 26292
CFTR- IntronlO- - AACUUGACCAGAAUGAAAU 19
7413 26293
CFTR- IntronlO- - AAACU UGACCAG AAUGAAAU 20
7414 26294
CFTR- IntronlO- - CAAACUUGACCAGAAUGAAAU 21
7415 26295
CFTR- IntronlO- - UCAAACUUGACCAGAAUGAAAU 22
7416 26296
CFTR- IntronlO- - GUCAAACUUGACCAGAAUGAAAU 23
7417 26297
CFTR- IntronlO- - GGUCAAACUUGACCAGAAUGAAAU 24
7418 26298
CFTR- IntronlO- - ACCGGUGUCUUCUGAAAU 18
7419 26299
CFTR- IntronlO- - AACCGGUGUCUUCUGAAAU 19
7420 26300
1118
5535.1 CFTR- IntronlO- - UAACCGGUGUCUUCUGAAAU 20
7421 26301
CFTR- IntronlO- - UUAACCGGUGUCUUCUGAAAU 21
7422 26302
CFTR- IntronlO- - AUUAACCGGUGUCUUCUGAAAU 22
7423 26303
CFTR- IntronlO- - AAUUAACCGGUGUCUUCUGAAAU 23
7424 26304
CFTR- IntronlO- - UAAUUAACCGGUGUCUUCUGAAAU 24
7425 26305
CFTR- IntronlO- - UUGGGGUUUUUUGACAAU 18
7426 26306
CFTR- IntronlO- - UUUGGGGUUUUUUGACAAU 19
7427 26307
CFTR- IntronlO- - UUUUGGGGUUUUUUGACAAU 20
7428 26308
CFTR- IntronlO- - UUUUUGGGGUUUUUUGACAAU 21
7429 26309
CFTR- IntronlO- - AUUUUUGGGGUUUUUUGACAAU 22
7430 26310
CFTR- IntronlO- - AAUUUUUGGGGUUUUUUGACAAU 23
7431 26311
CFTR- IntronlO- - AAAUUUUUGGGGUUUUUUGACAAU 24
7432 26312
CFTR- IntronlO- - AAUGAAAUUAGAAAGAAU 18
7433 26313
CFTR- IntronlO- - GAAUGAAAUUAGAAAGAAU 19
7434 26314
1119
5535.1 CFTR- IntronlO- - AGAAUGAAAUUAGAAAGAAU 20
7435 26315
CFTR- IntronlO- - C AG A A U G AAA U U AG A A AG A A U 21
7436 26316
CFTR- IntronlO- - CCAGAAUGAAAUUAGAAAGAAU 22
7437 26317
CFTR- IntronlO- - ACCAGAAUGAAAUUAGAAAGAAU 23
7438 26318
CFTR- IntronlO- - GACCAGAAUGAAAUUAGAAAGAAU 24
7439 26319
CFTR- IntronlO- - UAUUUUGAAGAAUUGAAU 18
7440 26320
CFTR- IntronlO- - AUAUUUUGAAGAAUUGAAU 19
7441 26321
CFTR- IntronlO- - CAU AU U UUGAAGAAU U GAAU 20
7442 26322
CFTR- IntronlO- - CCAUAUUUUGAAGAAUUGAAU 21
7443 26323
CFTR- IntronlO- - ACCAUAUUUUGAAGAAUUGAAU 22
7444 26324
CFTR- IntronlO- - AACCAUAUUUUGAAGAAUUGAAU 23
7445 26325
CFTR- IntronlO- - GAACCAUAUUUUGAAGAAUUGAAU 24
7446 26326
CFTR- IntronlO- - UGGUACUACUGUAAUAAU 18
7447 26327
CFTR- IntronlO- - AUGGUACUACUGUAAUAAU 19
7448 26328
1120
5535.1 CFTR- IntronlO- - UAUGGUACUACUGUAAUAAU 20
7449 26329
CFTR- IntronlO- - AUAUGGUACUACUGUAAUAAU 21
7450 26330
CFTR- IntronlO- - CAUAUGGUACUACUGUAAUAAU 22
7451 26331
CFTR- IntronlO- - ACAUAUGGUACUACUGUAAUAAU 23
7452 26332
CFTR- IntronlO- - UACAUAUGGUACUACUGUAAUAAU 24
7453 26333
CFTR- IntronlO- - GUUUACUAGAAAGAUAAU 18
7454 26334
CFTR- IntronlO- - CGUUUACUAGAAAGAUAAU 19
7455 26335
CFTR-
- CCGUUUACUAGAAAGAUAAU 20
lntronlO-501 19387
CFTR- IntronlO- - GCCGUUUACUAGAAAGAUAAU 21
7456 26336
CFTR- IntronlO- - UGCCGUUUACUAGAAAGAUAAU 22
7457 26337
CFTR- IntronlO- - G UG CCG U U U ACU AG AAAG AU AAU 23
7458 26338
CFTR- IntronlO- - UGUGCCGUUUACUAGAAAGAUAAU 24
7459 26339
CFTR- IntronlO- - UGACUCUAGUUCACUAAU 18
7460 26340
CFTR- IntronlO- - GUGACUCUAGUUCACUAAU 19
7461 26341
CFTR-
- UGUGACUCUAGUUCACUAAU 20
IntronlO- 26342
1121
5535.1 7462
CFTR- IntronlO- - AUGUGACUCUAGUUCACUAAU 21
7463 26343
CFTR- IntronlO- - UAUGUGACUCUAGUUCACUAAU 22
7464 26344
CFTR- IntronlO- - CUAUGUGACUCUAGUUCACUAAU 23
7465 26345
CFTR- IntronlO- - UCUAUGUGACUCUAGUUCACUAAU 24
7466 26346
CFTR- IntronlO- - AACAUUGAAAGGUAACAU 18
7467 26347
CFTR- IntronlO- - AAACAU UG AAAGG U AACAU 19
7468 26348
CFTR- IntronlO- - U AAACAU UG AAAGG U AACAU 20
7469 26349
CFTR- IntronlO- - UU AAACAU UG AAAGG U AACAU 21
7470 26350
CFTR- IntronlO- - U U U AAACAU UG AAAGG U AACAU 22
7471 26351
CFTR- IntronlO- - CU U U AAACAU UG AAAGG U AACAU 23
7472 26352
CFTR- IntronlO- - CCUUUAAACAUUGAAAGGUAACAU 24
7473 26353
CFTR- IntronlO- - UUUUUUCAGUUAAUACAU 18
7474 26354
CFTR- IntronlO- - UUUUUUUCAGUUAAUACAU 19
7475 26355
CFTR-
- UUUUUUUUCAGUUAAUACAU 20
IntronlO- 20217
1122
5535.1 1332
CFTR- IntronlO- - AUUUUUUUUCAGUUAAUACAU 21
7476 26356
CFTR- IntronlO- - AAUUUUUUUUCAGUUAAUACAU 22
7477 26357
CFTR- IntronlO- - GAAUUUUUUUUCAGUUAAUACAU 23
7478 26358
CFTR- IntronlO- - UGAAUUUUUUUUCAGUUAAUACAU 24
7479 26359
CFTR- IntronlO- - GCAUAUUUGGAGAUACAU 18
7480 26360
CFTR- IntronlO- - GGCAUAUUUGGAGAUACAU 19
7481 26361
CFTR- IntronlO- - UGGCAUAUUUGGAGAUACAU 20
7482 26362
CFTR- IntronlO- - CUGGCAUAUUUGGAGAUACAU 21
7483 26363
CFTR- IntronlO- - CCUGGCAUAUUUGGAGAUACAU 22
7484 26364
CFTR- IntronlO- - ACCUGGCAUAUUUGGAGAUACAU 23
7485 26365
CFTR- IntronlO- - AACCUGGCAUAUUUGGAGAUACAU 24
7486 26366
CFTR- IntronlO- - CCAGUUGUUUUCCUACAU 18
7487 26367
CFTR- IntronlO- - UCCAGUUGUUUUCCUACAU 19
7488 26368
CFTR-
- CUCCAGUUGUUUUCCUACAU 20
IntronlO- 26369
1123
5535.1 7489
CFTR- IntronlO- - UCUCCAGUUGUUUUCCUACAU 21
7490 26370
CFTR- IntronlO- - CUCUCCAGUUGUUUUCCUACAU 22
7491 26371
CFTR- IntronlO- - UCUCUCCAGUUGUUUUCCUACAU 23
7492 26372
CFTR- IntronlO- - CUCUCUCCAGUUGUUUUCCUACAU 24
7493 26373
CFTR- IntronlO- - CUCACCCCUUUCUGCCAU 18
7494 26374
CFTR- IntronlO- - CCUCACCCCUUUCUGCCAU 19
7495 26375
CFTR- IntronlO- - CCCUCACCCCUUUCUGCCAU 20
7496 26376
CFTR- IntronlO- - ACCCUCACCCCUUUCUGCCAU 21
7497 26377
CFTR- IntronlO- - GACCCUCACCCCUUUCUGCCAU 22
7498 26378
CFTR- IntronlO- - AGACCCUCACCCCUUUCUGCCAU 23
7499 26379
CFTR- IntronlO- - GAGACCCUCACCCCUUUCUGCCAU 24
7500 26380
CFTR- IntronlO- - UAAGUUGAACAAUGGCAU 18
7501 26381
CFTR- IntronlO- - AUAAGUUGAACAAUGGCAU 19
7502 26382
CFTR-
- GAUAAGUUGAACAAUGGCAU 20
IntronlO- 26383
1124
5535.1 7503
CFTR- IntronlO- - GGAUAAGUUGAACAAUGGCAU 21
7504 26384
CFTR- IntronlO- - UGGAUAAGUUGAACAAUGGCAU 22
7505 26385
CFTR- IntronlO- - AUGGAUAAGUUGAACAAUGGCAU 23
7506 26386
CFTR- IntronlO- - AAUGGAUAAGUUGAACAAUGGCAU 24
7507 26387
CFTR- IntronlO- - AAAAUAUCACCAACUCAU 18
7508 26388
CFTR- IntronlO- - AAAAAUAUCACCAACUCAU 19
7509 26389
CFTR- IntronlO- - GAAAAAUAUCACCAACUCAU 20
7510 26390
CFTR- IntronlO- - UGAAAAAUAUCACCAACUCAU 21
7511 26391
CFTR- IntronlO- - AUGAAAAAUAUCACCAACUCAU 22
7512 26392
CFTR- IntronlO- - AAUGAAAAAUAUCACCAACUCAU 23
7513 26393
CFTR- IntronlO- - UAAUGAAAAAUAUCACCAACUCAU 24
7514 26394
CFTR- IntronlO- - UUUGUAAAUUUGUUUCAU 18
7515 26395
CFTR- IntronlO- - UUUUGUAAAUUUGUUUCAU 19
7516 26396
CFTR-
- AUUUUGUAAAUUUGUUUCAU 20
IntronlO- 26397
1125
5535.1 7517
CFTR- IntronlO- - AAUUUUGUAAAUUUGUUUCAU 21
7518 26398
CFTR- IntronlO- - UAAUUUUGUAAAUUUGUUUCAU 22
7519 26399
CFTR- IntronlO- - CUAAUUUUGUAAAUUUGUUUCAU 23
7520 26400
CFTR- IntronlO- - ACUAAUUUUGUAAAUUUGUUUCAU 24
7521 26401
CFTR- IntronlO- - UUUAUCAAUAUCUAAGAU 18
7522 26402
CFTR- IntronlO- - AUUUAUCAAUAUCUAAGAU 19
7523 26403
CFTR- IntronlO- - UAUUUAUCAAUAUCUAAGAU 20
7524 26404
CFTR- IntronlO- - UUAUUUAUCAAUAUCUAAGAU 21
7525 26405
CFTR- IntronlO- - AUUAUUUAUCAAUAUCUAAGAU 22
7526 26406
CFTR- IntronlO- - AAUUAUUUAUCAAUAUCUAAGAU 23
7527 26407
CFTR- IntronlO- - CAAUUAUUUAUCAAUAUCUAAGAU 24
7528 26408
CFTR- IntronlO- - A AG A A U C A A A UUAGAGAU 18
7529 26409
CFTR- IntronlO- - AAAGAAUCAAAUUAGAGAU 19
7530 26410
CFTR-
- G A A AG A A U C A A A UUAGAGAU 20
IntronlO- 26411
1126
5535.1 7531
CFTR- IntronlO- - U G A A AG A A U C A A A UUAGAGAU 21
7532 26412
CFTR- IntronlO- - AUGAAAGAAUCAAAUUAGAGAU 22
7533 26413
CFTR- IntronlO- - CAUGAAAGAAUCAAAUUAGAGAU 23
7534 26414
CFTR- IntronlO- - ACAUGAAAGAAUCAAAUUAGAGAU 24
7535 26415
CFTR- IntronlO- - UUUGGAAUUUUGGGAGAU 18
7536 26416
CFTR- IntronlO- - UUUUGGAAUUUUGGGAGAU 19
7537 26417
CFTR- IntronlO- - AUUUUGGAAUUUUGGGAGAU 20
7538 26418
CFTR- IntronlO- - UAUUUUGGAAUUUUGGGAGAU 21
7539 26419
CFTR- IntronlO- - AUAUUUUGGAAUUUUGGGAGAU 22
7540 26420
CFTR- IntronlO- - AAUAUUUUGGAAUUUUGGGAGAU 23
7541 26421
CFTR- IntronlO- - CAAUAUUUUGGAAUUUUGGGAGAU 24
7542 26422
CFTR- IntronlO- - UAUUUCUCUGGGUGAGAU 18
7543 26423
CFTR- IntronlO- - UUAUUUCUCUGGGUGAGAU 19
7544 26424
CFTR-
- CUUAUUUCUCUGGGUGAGAU 20
IntronlO- 26425
1127
5535.1 7545
CFTR- IntronlO- - GCUUAUUUCUCUGGGUGAGAU 21
7546 26426
CFTR- IntronlO- - GGCUUAUUUCUCUGGGUGAGAU 22
7547 26427
CFTR- IntronlO- - AGGCUUAUUUCUCUGGGUGAGAU 23
7548 26428
CFTR- IntronlO- - AAGGCUUAUUUCUCUGGGUGAGAU 24
7549 26429
CFTR- IntronlO- - UCUGAAAAAAUAGUAGAU 18
7550 26430
CFTR- IntronlO- - AUCUGAAAAAAUAGUAGAU 19
7551 26431
CFTR- IntronlO- - CAUCUGAAAAAAUAGUAGAU 20
7552 26432
CFTR- IntronlO- - ACAUCUGAAAAAAUAGUAGAU 21
7553 26433
CFTR- IntronlO- - UACAUCUGAAAAAAUAGUAGAU 22
7554 26434
CFTR- IntronlO- - AUACAUCUGAAAAAAUAGUAGAU 23
7555 26435
CFTR- IntronlO- - GAUACAUCUGAAAAAAUAGUAGAU 24
7556 26436
CFTR- IntronlO- - UUGCAGGAGGUGAGGGAU 18
7557 26437
CFTR- IntronlO- - CUUGCAGGAGGUGAGGGAU 19
7558 26438
CFTR-
- ACUUGCAGGAGGUGAGGGAU 20
IntronlO- 26439
1128
5535.1 7559
CFTR- IntronlO- - GACUUGCAGGAGGUGAGGGAU 21
7560 26440
CFTR- IntronlO- - AGACUUGCAGGAGGUGAGGGAU 22
7561 26441
CFTR- IntronlO- - AAGACUUGCAGGAGGUGAGGGAU 23
7562 26442
CFTR- IntronlO- - AAAGACUUGCAGGAGGUGAGGGAU 24
7563 26443
CFTR- IntronlO- - A A AG G A A AG AGGGUUGAU 18
7564 26444
CFTR- IntronlO- - UAAAGGAAAGAGGGUUGAU 19
7565 26445
CFTR- IntronlO- - CUAAAGGAAAGAGGGUUGAU 20
7566 26446
CFTR- IntronlO- - UCUAAAGGAAAGAGGGUUGAU 21
7567 26447
CFTR- IntronlO- - UUCUAAAGGAAAGAGGGUUGAU 22
7568 26448
CFTR- IntronlO- - AUUCUAAAGGAAAGAGGGUUGAU 23
7569 26449
CFTR- IntronlO- - GAUUCUAAAGGAAAGAGGGUUGAU 24
7570 26450
CFTR- IntronlO- - AGUUGAACAAUGGCAUAU 18
7571 26451
CFTR- IntronlO- - AAGUUGAACAAUGGCAUAU 19
7572 26452
CFTR-
- UAAGUUGAACAAUGGCAUAU 20
IntronlO- 26453
1129
5535.1 7573
CFTR- IntronlO- - AUAAGUUGAACAAUGGCAUAU 21
7574 26454
CFTR- IntronlO- - GAUAAGUUGAACAAUGGCAUAU 22
7575 26455
CFTR- IntronlO- - GGAUAAGUUGAACAAUGGCAUAU 23
7576 26456
CFTR- IntronlO- - UGGAUAAGUUGAACAAUGGCAUAU 24
7577 26457
CFTR- IntronlO- - CAACUUAACCUGGCAUAU 18
7578 26458
CFTR- IntronlO- - ACAACUUAACCUGGCAUAU 19
7579 26459
CFTR- IntronlO- - AACAACUUAACCUGGCAUAU 20
7580 26460
CFTR- IntronlO- - GAACAACUUAACCUGGCAUAU 21
7581 26461
CFTR- IntronlO- - AGAA CAACUUAACCUGGCAUAU 22
7582 26462
CFTR- IntronlO- - AAGAACAACUUAACCUGGCAUAU 23
7583 26463
CFTR- IntronlO- - UAAGAACAACUUAACCUGGCAUAU 24
7584 26464
CFTR- IntronlO- - AU U AAAAAAU U AU ACU AU 18
7585 26465
CFTR- IntronlO- - U AU U AAAAAAU U AU ACU AU 19
7586 26466
CFTR-
- CUAUUAAAAAAUUAUACUAU 20
IntronlO- 20222
1130
5535.1 1337
CFTR- IntronlO- - ACUAUUAAAAAAUUAUACUAU 21
7587 26467
CFTR- IntronlO- - CACUAUUAAAAAAUUAUACUAU 22
7588 26468
CFTR- IntronlO- - U CACU AU U AAAAAAU U AU ACU AU 23
7589 26469
CFTR- IntronlO- - UUCACUAUUAAAAAAUUAUACUAU 24
7590 26470
CFTR- IntronlO- - UUUAUAAAGCUGUACUAU 18
7591 26471
CFTR- IntronlO- - GUUUAUAAAGCUGUACUAU 19
7592 26472
CFTR- IntronlO- - GGUUUAUAAAGCUGUACUAU 20
7593 26473
CFTR- IntronlO- - AGGUUUAUAAAGCUGUACUAU 21
7594 26474
CFTR- IntronlO- - UAGGUUUAUAAAGCUGUACUAU 22
7595 26475
CFTR- IntronlO- - UUAGGUUUAUAAAGCUGUACUAU 23
7596 26476
CFTR- IntronlO- - UUUAGGUUUAUAAAGCUGUACUAU 24
7597 26477
CFTR- IntronlO- - UAAGGGCAUUCUAAGUAU 18
7598 26478
CFTR- IntronlO- - CUAAGGGCAUUCUAAGUAU 19
7599 26479
CFTR-
- CCUAAGGGCAUUCUAAGUAU 20
IntronlO- 26480
1131
5535.1 7600
CFTR- IntronlO- - GCCUAAGGGCAUUCUAAGUAU 21
7601 26481
CFTR- IntronlO- - AGCCUAAGGGCAUUCUAAGUAU 22
7602 26482
CFTR- IntronlO- - UAGCCUAAGGGCAUUCUAAGUAU 23
7603 26483
CFTR- IntronlO- - UUAGCCUAAGGGCAUUCUAAGUAU 24
7604 26484
CFTR- IntronlO- - GCUGCCUUUUAGUAGUAU 18
7605 26485
CFTR- IntronlO- - GGCUGCCUUUUAGUAGUAU 19
7606 26486
CFTR- IntronlO- - AGGCUGCCUUUUAGUAGUAU 20
7607 26487
CFTR- IntronlO- - GAGGCUGCCUUUUAGUAGUAU 21
7608 26488
CFTR- IntronlO- - GGAGGCUGCCUUUUAGUAGUAU 22
7609 26489
CFTR- IntronlO- - AGGAGGCUGCCUUUUAGUAGUAU 23
7610 26490
CFTR- IntronlO- - UAGGAGGCUGCCUUUUAGUAGUAU 24
7611 26491
CFTR- IntronlO- - CUUUUUCAUUGAAUGUAU 18
7612 26492
CFTR- IntronlO- - UCUUUUUCAUUGAAUGUAU 19
7613 26493
CFTR-
- UUCUUUUUCAUUGAAUGUAU 20
IntronlO- 26494
1132
5535.1 7614
CFTR- IntronlO- - UUUCUUUUUCAUUGAAUGUAU 21
7615 26495
CFTR- IntronlO- - UUUUCUUUUUCAUUGAAUGUAU 22
7616 26496
CFTR- IntronlO- - CUUUUCUUUUUCAUUGAAUGUAU 23
7617 26497
CFTR- IntronlO- - CCUUUUCUUUUUCAUUGAAUGUAU 24
7618 26498
CFTR- IntronlO- - CAAUUUGGUAAUUUGUAU 18
7619 26499
CFTR- IntronlO- - ACAAUUUGGUAAUUUGUAU 19
7620 26500
CFTR- IntronlO- - UACAAUUUGGUAAUUUGUAU 20
7621 26501
CFTR- IntronlO- - AUACAAUUUGGUAAUUUGUAU 21
7622 26502
CFTR- IntronlO- - AAUACAAUUUGGUAAUUUGUAU 22
7623 26503
CFTR- IntronlO- - CAAUACAAUUUGGUAAUUUGUAU 23
7624 26504
CFTR- IntronlO- - UCAAUACAAUUUGGUAAUUUGUAU 24
7625 26505
CFTR- IntronlO- - AUUUUUAACCUGGAUUAU 18
7626 26506
CFTR- IntronlO- - UAUUUUUAACCUGGAUUAU 19
7627 26507
CFTR-
- AUAUUUUUAACCUGGAUUAU 20
IntronlO- 26508
1133
5535.1 7628
CFTR- IntronlO- - UAUAUUUUUAACCUGGAUUAU 21
7629 26509
CFTR- IntronlO- - AUAUAUUUUUAACCUGGAUUAU 22
7630 26510
CFTR- IntronlO- - UAUAUAUUUUUAACCUGGAUUAU 23
7631 26511
CFTR- IntronlO- - AUAUAUAUUUUUAACCUGGAUUAU 24
7632 26512
CFTR- IntronlO- - AAAAGUUUCUCAUCUUAU 18
7633 26513
CFTR- IntronlO- - AAAAAGUUUCUCAUCUUAU 19
7634 26514
CFTR- IntronlO- - UAAAAAGUUUCUCAUCUUAU 20
1339 20224
CFTR- IntronlO- - UUAAAAAGUUUCUCAUCUUAU 21
7635 26515
CFTR- IntronlO- - UUUAAAAAGUUUCUCAUCUUAU 22
7636 26516
CFTR- IntronlO- - AUUUAAAAAGUUUCUCAUCUUAU 23
7637 26517
CFTR- IntronlO- - AAU U U AAAAAG UUUCUCAUCUUAU 24
7638 26518
CFTR- IntronlO- - UUCCCAGCCUCCAGAACU 18
7639 26519
CFTR- IntronlO- - CUUCCCAGCCUCCAGAACU 19
7640 26520
CFTR-
- ACUUCCCAGCCUCCAGAACU 20
IntronlO- 26521
1134
5535.1 7641
CFTR- IntronlO- - GACUUCCCAGCCUCCAGAACU 21
7642 26522
CFTR- IntronlO- - GGACUUCCCAGCCUCCAGAACU 22
7643 26523
CFTR- IntronlO- - UGGACUUCCCAGCCUCCAGAACU 23
7644 26524
CFTR- IntronlO- - UUGGACUUCCCAGCCUCCAGAACU 24
7645 26525
CFTR- IntronlO- - GAUUAGGGAAUGCAGACU 18
7646 26526
CFTR- IntronlO- - GGAUUAGGGAAUGCAGACU 19
7647 26527
CFTR- IntronlO- - GGGAUUAGGGAAUGCAGACU 20
7648 26528
CFTR- IntronlO- - AGGGAUUAGGGAAUGCAGACU 21
7649 26529
CFTR- IntronlO- - GAGGGAUUAGGGAAUGCAGACU 22
7650 26530
CFTR- IntronlO- - UGAGGGAUUAGGGAAUGCAGACU 23
7651 26531
CFTR- IntronlO- - GUGAGGGAUUAGGGAAUGCAGACU 24
7652 26532
CFTR- IntronlO- - AGAAUUGAAUAUGAGACU 18
7653 26533
CFTR- IntronlO- - AAGAAUUGAAUAUGAGACU 19
7654 26534
CFTR-
- GAAGAAUUGAAUAUGAGACU 20
lntronlO-114 19000
1135
5535.1 CFTR- IntronlO- - UGAAGAAUUGAAUAUGAGACU 21
7655 26535
CFTR- IntronlO- - UUGAAGAAUUGAAUAUGAGACU 22
7656 26536
CFTR- IntronlO- - UUUGAAGAAUUGAAUAUGAGACU 23
7657 26537
CFTR- IntronlO- - UUUUGAAGAAUUGAAUAUGAGACU 24
7658 26538
CFTR- IntronlO- - UAGAUUAGCUUAUAUACU 18
7659 26539
CFTR- IntronlO- - AUAGAUUAGCUUAUAUACU 19
7660 26540
CFTR- IntronlO- - AAUAGAUUAGCUUAUAUACU 20
7661 26541
CFTR- IntronlO- - GAAUAGAUUAGCUUAUAUACU 21
7662 26542
CFTR- IntronlO- - UGAAUAGAUUAGCUUAUAUACU 22
7663 26543
CFTR- IntronlO- - UUGAAUAGAUUAGCUUAUAUACU 23
7664 26544
CFTR- IntronlO- - UUUGAAUAGAUUAGCUUAUAUACU 24
7665 26545
CFTR- IntronlO- - CCCGUAGUCCCAGCUACU 18
7666 26546
CFTR- IntronlO- - GCCCGUAGUCCCAGCUACU 19
7667 26547
CFTR- IntronlO- - UGCCCGUAGUCCCAGCUACU 20
1343 20228
1136
5535.1 CFTR- IntronlO- - GUGCCCGUAGUCCCAGCUACU 21
7668 26548
CFTR- IntronlO- - GGUGCCCGUAGUCCCAGCUACU 22
7669 26549
CFTR- IntronlO- - GGGUGCCCGUAGUCCCAGCUACU 23
7670 26550
CFTR- IntronlO- - CGGGUGCCCGUAGUCCCAGCUACU 24
7671 26551
CFTR- IntronlO- - GUGCCUGUAGUCCCAGCUACU 21
7672 26552
CFTR- IntronlO- - UGUGCCUGUAGUCCCAGCUACU 22
7673 26553
CFTR- IntronlO- - GUGUGCCUGUAGUCCCAGCUACU 23
7674 26554
CFTR- IntronlO- - UGUGUGCCUGUAGUCCCAGCUACU 24
7675 26555
CFTR- IntronlO- - UCUUUAUAAAAGAAACCU 18
7676 26556
CFTR- IntronlO- - G U CU U UAU AAAAG AAACCU 19
7677 26557
CFTR- IntronlO- - UGUCUUUAUAAAAGAAACCU 20
7678 26558
CFTR- IntronlO- - GUGUCUUUAUAAAAGAAACCU 21
7679 26559
CFTR- IntronlO- - AGUGUCUUUAUAAAAGAAACCU 22
7680 26560
CFTR- IntronlO- - UAGUGUCUU UAU AAAAG AAACCU 23
7681 26561
1137
5535.1 CFTR- IntronlO- - UUAGUGUCUUUAUAAAAGAAACCU 24
7682 26562
CFTR- IntronlO- - AGAGAGACCCUCACACCU 18
7683 26563
CFTR- IntronlO- - UAGAGAGACCCUCACACCU 19
7684 26564
CFTR- IntronlO- - UUAGAGAGACCCUCACACCU 20
7685 26565
CFTR- IntronlO- - CUUAGAGAGACCCUCACACCU 21
7686 26566
CFTR- IntronlO- - CCUUAGAGAGACCCUCACACCU 22
7687 26567
CFTR- IntronlO- - ACCUUAGAGAGACCCUCACACCU 23
7688 26568
CFTR- IntronlO- - AACCUUAGAGAGACCCUCACACCU 24
7689 26569
CFTR- IntronlO- - UUCUCCAUAUCCCACCCU 18
7690 26570
CFTR- IntronlO- - CUUCUCCAUAUCCCACCCU 19
7691 26571
CFTR- IntronlO- - UCUUCUCCAUAUCCCACCCU 20
7692 26572
CFTR- IntronlO- - CUCUUCUCCAUAUCCCACCCU 21
7693 26573
CFTR- IntronlO- - CCUCUUCUCCAUAUCCCACCCU 22
7694 26574
CFTR- IntronlO- - UCCUCUUCUCCAUAUCCCACCCU 23
7695 26575
1138
5535.1 CFTR- IntronlO- - AUCCUCUUCUCCAUAUCCCACCCU 24
7696 26576
CFTR- IntronlO- - AGGAAGGCAGUGGUCCCU 18
7697 26577
CFTR- IntronlO- - GAGGAAGGCAGUGGUCCCU 19
7698 26578
CFTR-
- AGAGGAAGGCAGUGGUCCCU 20
lntronlO-515 19401
CFTR- IntronlO- - UAGAGGAAGGCAGUGGUCCCU 21
7699 26579
CFTR- IntronlO- - UU AGAGGAAGGCAGUGGUCCCU 22
7700 26580
CFTR- IntronlO- - GUUAGAGGAAGGCAGUGGUCCCU 23
7701 26581
CFTR- IntronlO- - AGUUAGAGGAAGGCAGUGGUCCCU 24
7702 26582
CFTR- IntronlO- - GGAGGAUCACCUGAGCCU 18
7703 26583
CFTR- IntronlO- - GGGAGGAUCACCUGAGCCU 19
7704 26584
CFTR- IntronlO- - UGGGAGGAUCACCUGAGCCU 20
7705 26585
CFTR- IntronlO- - GUGGGAGGAUCACCUGAGCCU 21
7706 26586
CFTR- IntronlO- - GGUGGGAGGAUCACCUGAGCCU 22
7707 26587
CFTR- IntronlO- - AGGUGGGAGGAUCACCUGAGCCU 23
7708 26588
CFTR-
- GAGGUGGGAGGAUCACCUGAGCCU 24
IntronlO- 26589
1139
5535.1 7709
CFTR- IntronlO- - GGGUGUAGGGGUUAGCCU 18
7710 26590
CFTR- IntronlO- - GGGGUGUAGGGGUUAGCCU 19
7711 26591
CFTR- IntronlO- - AGGGGUGUAGGGGUUAGCCU 20
7712 26592
CFTR- IntronlO- - AAGGGGUGUAGGGGUUAGCCU 21
7713 26593
CFTR- IntronlO- - AAAGGGGUGUAGGGGUUAGCCU 22
7714 26594
CFTR- IntronlO- - GAAAGGGGUGUAGGGGUUAGCCU 23
7715 26595
CFTR- IntronlO- - AGAAAGGGGUGUAGGGGUUAGCCU 24
7716 26596
CFTR- IntronlO- - UAUUGCAGGGUGGGGCCU 18
7717 26597
CFTR- IntronlO- - GUAUUGCAGGGUGGGGCCU 19
7718 26598
CFTR- IntronlO- - GGUAUUGCAGGGUGGGGCCU 20
7719 26599
CFTR- IntronlO- - UGGUAUUGCAGGGUGGGGCCU 21
7720 26600
CFTR- IntronlO- - AUGGUAUUGCAGGGUGGGGCCU 22
7721 26601
CFTR- IntronlO- - GAUGGUAUUGCAGGGUGGGGCCU 23
7722 26602
CFTR-
- UGAUGGUAUUGCAGGGUGGGGCCU 24
IntronlO- 26603
1140
5535.1 7723
CFTR- IntronlO- - UUUGACCUAAGAUAUCCU 18
7724 26604
CFTR- IntronlO- - CUUUGACCUAAGAUAUCCU 19
7725 26605
CFTR- IntronlO- - UCUUUGACCUAAGAUAUCCU 20
7726 26606
CFTR- IntronlO- - CUCUUUGACCUAAGAUAUCCU 21
7727 26607
CFTR- IntronlO- - CCUCUUUGACCUAAGAUAUCCU 22
7728 26608
CFTR- IntronlO- - UCCUCUUUGACCUAAGAUAUCCU 23
7729 26609
CFTR- IntronlO- - UUCCUCUUUGACCUAAGAUAUCCU 24
7730 26610
CFTR- IntronlO- - AGCUUAUGAAAAGCAGCU 18
7731 26611
CFTR- IntronlO- - UAGCUUAUGAAAAGCAGCU 19
7732 26612
CFTR- IntronlO- - AUAGCUUAUGAAAAGCAGCU 20
7733 26613
CFTR- IntronlO- - UAUAGCUUAUGAAAAGCAGCU 21
7734 26614
CFTR- IntronlO- - UUAUAGCUUAUGAAAAGCAGCU 22
7735 26615
CFTR- IntronlO- - GUUAUAGCUUAUGAAAAGCAGCU 23
7736 26616
CFTR-
- AGUUAUAGCUUAUGAAAAGCAGCU 24
IntronlO- 26617
1141
5535.1 7737
CFTR- IntronlO- - AGAUGUGCAAAAAUAGCU 18
7738 26618
CFTR- IntronlO- - UAGAUGUGCAAAAAUAGCU 19
7739 26619
CFTR- IntronlO- - AUAGAUGUGCAAAAAUAGCU 20
7740 26620
CFTR- IntronlO- - GAUAGAUGUGCAAAAAUAGCU 21
7741 26621
CFTR- IntronlO- - UGAUAGAUGUGCAAAAAUAGCU 22
7742 26622
CFTR- IntronlO- - AUGAUAGAUGUGCAAAAAUAGCU 23
7743 26623
CFTR- IntronlO- - UAUGAUAGAUGUGCAAAAAUAGCU 24
7744 26624
CFTR- IntronlO- - UCAGAUUCAGGACAUGCU 18
7745 26625
CFTR- IntronlO- - AUCAGAUUCAGGACAUGCU 19
7746 26626
CFTR- IntronlO- - GAUCAGAUUCAGGACAUGCU 20
7747 26627
CFTR- IntronlO- - UGAUCAGAUUCAGGACAUGCU 21
7748 26628
CFTR- IntronlO- - GUGAUCAGAUUCAGGACAUGCU 22
7749 26629
CFTR- IntronlO- - AGUGAUCAGAUUCAGGACAUGCU 23
7750 26630
CFTR-
- AAGUGAUCAGAUUCAGGACAUGCU 24
IntronlO- 26631
1142
5535.1 7751
CFTR- IntronlO- - AGUUUACUAACUCAAUCU 18
7752 26632
CFTR- IntronlO- - GAGUUUACUAACUCAAUCU 19
7753 26633
CFTR-
- GGAGUUUACUAACUCAAUCU 20
lntronlO-118 19004
CFTR- IntronlO- - CGGAGUUUACUAACUCAAUCU 21
7754 26634
CFTR- IntronlO- - ACGGAGUUUACUAACUCAAUCU 22
7755 26635
CFTR- IntronlO- - AACGGAGUUUACUAACUCAAUCU 23
7756 26636
CFTR- IntronlO- - AAACGGAGUUUACUAACUCAAUCU 24
7757 26637
CFTR- IntronlO- - UUUAUCAAGUUGUUAUCU 18
7758 26638
CFTR- IntronlO- - AUUUAUCAAGUUGUUAUCU 19
7759 26639
CFTR- IntronlO- - AAUUUAUCAAGUUGUUAUCU 20
7760 26640
CFTR- IntronlO- - AAAUUUAUCAAGUUGUUAUCU 21
7761 26641
CFTR- IntronlO- - UAAAUUUAUCAAGUUGUUAUCU 22
7762 26642
CFTR- IntronlO- - AUAAAUUUAUCAAGUUGUUAUCU 23
7763 26643
CFTR- IntronlO- - GAUAAAUUUAUCAAGUUGUUAUCU 24
7764 26644
1143
5535.1 CFTR- IntronlO- - UUAGGGAAUGCAGACUCU 18
7765 26645
CFTR- IntronlO- - AUUAGGGAAUGCAGACUCU 19
7766 26646
CFTR-
- GAUUAGGGAAUGCAGACUCU 20
lntronlO-119 19005
CFTR- IntronlO- - GGAUUAGGGAAUGCAGACUCU 21
7767 26647
CFTR- IntronlO- - GGGAUUAGGGAAUGCAGACUCU 22
7768 26648
CFTR- IntronlO- - AGGGAUUAGGGAAUGCAGACUCU 23
7769 26649
CFTR- IntronlO- - GAGGGAUUAGGGAAUGCAGACUCU 24
7770 26650
CFTR- IntronlO- - CC A A U A A A A U A A A AG U C U 18
7771 26651
CFTR- IntronlO- - C CC A A U A A A A U A A A AG U C U 19
7772 26652
CFTR- IntronlO- - ACCCAAUAAAAUAAAAGUCU 20
7773 26653
CFTR- IntronlO- - AACCCAAUAAAAUAAAAGUCU 21
7774 26654
CFTR- IntronlO- - AAACCCAAUAAAAUAAAAGUCU 22
7775 26655
CFTR- IntronlO- - AAAACCCAAUAAAAUAAAAGUCU 23
7776 26656
CFTR- IntronlO- - GAAAACCCAAUAAAAUAAAAGUCU 24
7777 26657
CFTR-
- GAAUAUUUAAACACUUCU 18
IntronlO- 26658
1144
5535.1 7778
CFTR- IntronlO- - GGAAUAUUUAAACACUUCU 19
7779 26659
CFTR- IntronlO- - GGGAAUAUUUAAACACUUCU 20
7780 26660
CFTR- IntronlO- - UGGGAAUAUUUAAACACUUCU 21
7781 26661
CFTR- IntronlO- - UUGGGAAUAUUUAAACACUUCU 22
7782 26662
CFTR- IntronlO- - CUUGGGAAUAUUUAAACACUUCU 23
7783 26663
CFTR- IntronlO- - CCUUGGGAAUAUUUAAACACUUCU 24
7784 26664
CFTR- IntronlO- - ACCCAAU AAAAU AAAAG U 18
7785 26665
CFTR- IntronlO- - AACCCAAU AAAAU AAAAG U 19
7786 26666
CFTR- IntronlO- - AAACCCAAU AAAAU AAAAG U 20
7787 26667
CFTR- IntronlO- - AAAACCCAAU AAAAU AAAAG U 21
7788 26668
CFTR- IntronlO- - G AAAACCCAAU AAAAU AAAAG U 22
7789 26669
CFTR- IntronlO- - AG AAAACCCAAU AAAAU AAAAG U 23
7790 26670
CFTR- IntronlO- - AAG AAAACCCAAU AAAAU AAAAG U 24
7791 26671
CFTR-
- AUGAGGAAGAAAGGAAGU 18
IntronlO- 26672
1145
5535.1 7792
CFTR- IntronlO- - AAUGAGGAAGAAAGGAAGU 19
7793 26673
CFTR- IntronlO- - AAAUGAGGAAGAAAGGAAGU 20
1369 20253
CFTR- IntronlO- - GAAAUGAGGAAGAAAGGAAGU 21
7794 26674
CFTR- IntronlO- - GG AAAUGAGGAAGAAAGGAAGU 22
7795 26675
CFTR- IntronlO- - AGGAAAUGAGGAAGAAAGGAAGU 23
7796 26676
CFTR- IntronlO- - AAGGAAAUGAGGAAGAAAGGAAGU 24
7797 26677
CFTR- IntronlO- - G G A A AG A AG G A AG G A AG U 18
7798 26678
CFTR- IntronlO- - AGGAAAGAAGGAAGGAAGU 19
7799 26679
CFTR- IntronlO- - A AG G A A AG A AG G A AG G AAG U 20
7800 26680
CFTR- IntronlO- - GAAGGAAAGAAGGAAGGAAGU 21
7801 26681
CFTR- IntronlO- - GGAAGGAAAGAAGGAAGGAAGU 22
7802 26682
CFTR- IntronlO- - AGGAAGGAAAGAAGGAAGGAAGU 23
7803 26683
CFTR- IntronlO- - AAGGAAGGAAAGAAGGAAGGAAGU 24
7804 26684
CFTR-
- GGUUUGGGAAUAUUAAGU 18
IntronlO- 26685
1146
5535.1 7805
CFTR- IntronlO- - UGGUUUGGGAAUAUUAAGU 19
7806 26686
CFTR- IntronlO- - UUGGUUUGGGAAUAUUAAGU 20
7807 26687
CFTR- IntronlO- - CUUGGUUUGGGAAUAUUAAGU 21
7808 26688
CFTR- IntronlO- - GCUUGGUUUGGGAAUAUUAAGU 22
7809 26689
CFTR- IntronlO- - AGCUUGGUUUGGGAAUAUUAAGU 23
7810 26690
CFTR- IntronlO- - GAGCUUGGUUUGGGAAUAUUAAGU 24
7811 26691
CFTR- IntronlO- - UCUGGUUUGAAGAACAGU 18
7812 26692
CFTR- IntronlO- - GUCUGGUUUGAAGAACAGU 19
7813 26693
CFTR- IntronlO- - UGUCUGGUUUGAAGAACAGU 20
7814 26694
CFTR- IntronlO- - CUGUCUGGUUUGAAGAACAGU 21
7815 26695
CFTR- IntronlO- - CCUGUCUGGUUUGAAGAACAGU 22
7816 26696
CFTR- IntronlO- - ACCUGUCUGGUUUGAAGAACAGU 23
7817 26697
CFTR- IntronlO- - UACCUGUCUGGUUUGAAGAACAGU 24
7818 26698
CFTR-
- CAGCUAUGAAGGCAGAGU 18
IntronlO- 26699
1147
5535.1 7819
CFTR- IntronlO- - GCAGCUAUGAAGGCAGAGU 19
7820 26700
CFTR- IntronlO- - AGCAGCUAUGAAGGCAGAGU 20
7821 26701
CFTR- IntronlO- - AAGCAGCUAUGAAGGCAGAGU 21
7822 26702
CFTR- IntronlO- - AAAGCAGCUAUGAAGGCAGAGU 22
7823 26703
CFTR- IntronlO- - A A A AG CAGCUAUGAAGGCAGAGU 23
7824 26704
CFTR- IntronlO- - GAAAAGCAGCUAUGAAGGCAGAGU 24
7825 26705
CFTR- IntronlO- - UUGCUUGAGUCCAGGAGU 18
7826 26706
CFTR- IntronlO- - AUUGCUUGAGUCCAGGAGU 19
7827 26707
CFTR- IntronlO- - AAUUGCUUGAGUCCAGGAGU 20
7828 26708
CFTR- IntronlO- - GAAUUGCUUGAGUCCAGGAGU 21
7829 26709
CFTR- IntronlO- - UGAAUUGCUUGAGUCCAGGAGU 22
7830 26710
CFTR- IntronlO- - GUGAAUUGCUUGAGUCCAGGAGU 23
7831 26711
CFTR- IntronlO- - GGUGAAUUGCUUGAGUCCAGGAGU 24
7832 26712
CFTR-
- GGAAGCAAGGAGAUGAGU 18
IntronlO- 26713
1148
5535.1 7833
CFTR- IntronlO- - AGGAAGCAAGGAGAUGAGU 19
7834 26714
CFTR- IntronlO- - GAGGAAGCAAGGAGAUGAGU 20
7835 26715
CFTR- IntronlO- - GGAGGAAGCAAGGAGAUGAGU 21
7836 26716
CFTR- IntronlO- - GGGAGGAAGCAAGGAGAUGAGU 22
7837 26717
CFTR- IntronlO- - AGGGAGGAAGCAAGGAGAUGAGU 23
7838 26718
CFTR- IntronlO- - AAGGGAGGAAGCAAGGAGAUGAGU 24
7839 26719
CFTR- IntronlO- - UAGUGGAAGUAGUAUAGU 18
7840 26720
CFTR- IntronlO- - GUAGUGGAAGUAGUAUAGU 19
7841 26721
CFTR-
- AGUAGUGGAAGUAGUAUAGU 20
lntronlO-533 19419
CFTR- IntronlO- - UAGUAGUGGAAGUAGUAUAGU 21
7842 26722
CFTR- IntronlO- - GUAGUAGUGGAAGUAGUAUAGU 22
7843 26723
CFTR- IntronlO- - GGUAGUAGUGGAAGUAGUAUAGU 23
7844 26724
CFTR- IntronlO- - AGGUAGUAGUGGAAGUAGUAUAGU 24
7845 26725
CFTR- IntronlO- - GAAGAGGGGGCUGGUAGU 18
7846 26726
1149
5535.1 CFTR- IntronlO- - GGAAGAGGGGGCUGGUAGU 19
7847 26727
CFTR- IntronlO- - AGGAAGAGGGGGCUGGUAGU 20
7848 26728
CFTR- IntronlO- - AAGGAAGAGGGGGCUGGUAGU 21
7849 26729
CFTR- IntronlO- - CAAGGAAGAGGGGGCUGGUAGU 22
7850 26730
CFTR- IntronlO- - UCAAGGAAGAGGGGGCUGGUAGU 23
7851 26731
CFTR- IntronlO- - UUCAAGGAAGAGGGGGCUGGUAGU 24
7852 26732
CFTR- IntronlO- - GAUGCUAAUCAUCUCCGU 18
7853 26733
CFTR- IntronlO- - UGAUGCUAAUCAUCUCCGU 19
7854 26734
CFTR- IntronlO- - GUGAUGCUAAUCAUCUCCGU 20
7855 26735
CFTR- IntronlO- - CGUGAUGCUAAUCAUCUCCGU 21
7856 26736
CFTR- IntronlO- - ACGUGAUGCUAAUCAUCUCCGU 22
7857 26737
CFTR- IntronlO- - CACGUGAUGCUAAUCAUCUCCGU 23
7858 26738
CFTR- IntronlO- - CCACGUGAUGCUAAUCAUCUCCGU 24
7859 26739
CFTR- IntronlO- - GCAGCUAUGCCAGCAGGU 18
7860 26740
1150
5535.1 CFTR- IntronlO- - UGCAGCUAUGCCAGCAGGU 19
7861 26741
CFTR- IntronlO- - GUGCAGCUAUGCCAGCAGGU 20
7862 26742
CFTR- IntronlO- - AGUGCAGCUAUGCCAGCAGGU 21
7863 26743
CFTR- IntronlO- - CAGUGCAGCUAUGCCAGCAGGU 22
7864 26744
CFTR- IntronlO- - UCAGUGCAGCUAUGCCAGCAGGU 23
7865 26745
CFTR- IntronlO- - AUCAGUGCAGCUAUGCCAGCAGGU 24
7866 26746
CFTR- IntronlO- - UCAGUGCUUUUUCGAGGU 18
7867 26747
CFTR- IntronlO- - AUCAGUGCUUUUUCGAGGU 19
7868 26748
CFTR- IntronlO- - AAUCAGUGCUUUUUCGAGGU 20
7869 26749
CFTR- IntronlO- - AAAUCAGUGCUUUUUCGAGGU 21
7870 26750
CFTR- IntronlO- - AAAAUCAGUGCUUUUUCGAGGU 22
7871 26751
CFTR- IntronlO- - UAAAAUCAGUGCUUUUUCGAGGU 23
7872 26752
CFTR- IntronlO- - AUAAAAUCAGUGCUUUUUCGAGGU 24
7873 26753
CFTR- IntronlO- - CAAAGACUUGCAGGAGGU 18
7874 26754
1151
5535.1 CFTR- IntronlO- - ACAAAGACUUGCAGGAGGU 19
7875 26755
CFTR- IntronlO- - AACAAAGACUUGCAGGAGGU 20
7876 26756
CFTR- IntronlO- - GAACAAAGACUUGCAGGAGGU 21
7877 26757
CFTR- IntronlO- - UGAACAAAGACUUGCAGGAGGU 22
7878 26758
CFTR- IntronlO- - U UG AACAAAG ACU UG CAGG AGG U 23
7879 26759
CFTR- IntronlO- - U U UG AACAAAG ACU UG CAGG AGG U 24
7880 26760
CFTR- IntronlO- - GUAAUCGGCGGUGGAGGU 18
7881 26761
CFTR- IntronlO- - AGUAAUCGGCGGUGGAGGU 19
7882 26762
CFTR-
- AAGUAAUCGGCGGUGGAGGU 20
lntronlO-536 19422
CFTR- IntronlO- - GAAGUAAUCGGCGGUGGAGGU 21
7883 26763
CFTR- IntronlO- - AGAAGUAAUCGGCGGUGGAGGU 22
7884 26764
CFTR- IntronlO- - GAGAAGUAAUCGGCGGUGGAGGU 23
7885 26765
CFTR- IntronlO- - AGAGAAGUAAUCGGCGGUGGAGGU 24
7886 26766
CFTR- IntronlO- - UACUUGGGAGGCUGAGGU 18
7887 26767
CFTR-
- CUACUUGGGAGGCUGAGGU 19
IntronlO- 26768
1152
5535.1 7888
CFTR-
- GCUACUUGGGAGGCUGAGGU 20
lntronlO-713 19599
CFTR- IntronlO- - AGCUACUUGGGAGGCUGAGGU 21
7889 26769
CFTR- IntronlO- - CAGCUACUUGGGAGGCUGAGGU 22
7890 26770
CFTR- IntronlO- - CCAGCUACUUGGGAGGCUGAGGU 23
7891 26771
CFTR- IntronlO- - CCCAGCUACUUGGGAGGCUGAGGU 24
7892 26772
CFTR- IntronlO- - AGGAGCCAAAAAUUGGGU 18
7893 26773
CFTR- IntronlO- - C AG G AG CCA A A A A U U G G G U 19
7894 26774
CFTR-
- UCAGGAGCCAAAAAUUGGGU 20
lntronlO-537 19423
CFTR- IntronlO- - UUCAGGAGCCAAAAAUUGGGU 21
7895 26775
CFTR- IntronlO- - UUUCAGGAGCCAAAAAUUGGGU 22
7896 26776
CFTR- IntronlO- - CUUUCAGGAGCCAAAAAUUGGGU 23
7897 26777
CFTR- IntronlO- - GCUUUCAGGAGCCAAAAAUUGGGU 24
7898 26778
CFTR- IntronlO- - UGACUAUACCUGUCUGGU 18
7899 26779
CFTR- IntronlO- - CUGACUAUACCUGUCUGGU 19
7900 26780
1153
5535.1 CFTR- IntronlO- - ACUGACUAUACCUGUCUGGU 20
7901 26781
CFTR- IntronlO- - GACUGACUAUACCUGUCUGGU 21
7902 26782
CFTR- IntronlO- - GGACUGACUAUACCUGUCUGGU 22
7903 26783
CFTR- IntronlO- - GGGACUGACUAUACCUGUCUGGU 23
7904 26784
CFTR- IntronlO- - UGGGACUGACUAUACCUGUCUGGU 24
7905 26785
CFTR- IntronlO- - UUUUGGAUGGAGCUUGGU 18
7906 26786
CFTR- IntronlO- - GUUUUGGAUGGAGCUUGGU 19
7907 26787
CFTR- IntronlO- - GGUUUUGGAUGGAGCUUGGU 20
7908 26788
CFTR- IntronlO- - AGGUUUUGGAUGGAGCUUGGU 21
7909 26789
CFTR- IntronlO- - CAGGUUUUGGAUGGAGCUUGGU 22
7910 26790
CFTR- IntronlO- - ACAGGUUUUGGAUGGAGCUUGGU 23
7911 26791
CFTR- IntronlO- - AACAGGUUUUGGAUGGAGCUUGGU 24
7912 26792
CFTR- IntronlO- - GGUACUUUGUAGAAAUGU 18
7913 26793
CFTR- IntronlO- - UGGUACUUUGUAGAAAUGU 19
7914 26794
1154
5535.1 CFTR- IntronlO- - GUGGUACUUUGUAGAAAUGU 20
7915 26795
CFTR- IntronlO- - UGUGGUACUUUGUAGAAAUGU 21
7916 26796
CFTR- IntronlO- - CUGUGGUACUUUGUAGAAAUGU 22
7917 26797
CFTR- IntronlO- - GCUGUGGUACUUUGUAGAAAUGU 23
7918 26798
CFTR- IntronlO- - AGCUGUGGUACUUUGUAGAAAUGU 24
7919 26799
CFTR- IntronlO- - CACCCCUUUCUGCCAUGU 18
7920 26800
CFTR- IntronlO- - UCACCCCUUUCUGCCAUGU 19
7921 26801
CFTR- IntronlO- - CUCACCCCUUUCUGCCAUGU 20
7922 26802
CFTR- IntronlO- - CCUCACCCCUUUCUGCCAUGU 21
7923 26803
CFTR- IntronlO- - CCCUCACCCCUUUCUGCCAUGU 22
7924 26804
CFTR- IntronlO- - ACCCUCACCCCUUUCUGCCAUGU 23
7925 26805
CFTR- IntronlO- - GACCCUCACCCCUUUCUGCCAUGU 24
7926 26806
CFTR- IntronlO- - CCCAGCCUCCAGAACUGU 18
7927 26807
CFTR- IntronlO- - UCCCAGCCUCCAGAACUGU 19
7928 26808
1155
5535.1 CFTR- IntronlO- - UUCCCAGCCUCCAGAACUGU 20
7929 26809
CFTR- IntronlO- - CUUCCCAGCCUCCAGAACUGU 21
7930 26810
CFTR- IntronlO- - ACUUCCCAGCCUCCAGAACUGU 22
7931 26811
CFTR- IntronlO- - GACUUCCCAGCCUCCAGAACUGU 23
7932 26812
CFTR- IntronlO- - GGACUUCCCAGCCUCCAGAACUGU 24
7933 26813
CFTR- IntronlO- - GGGAGGGUAGAAUACUGU 18
7934 26814
CFTR- IntronlO- - AGGGAGGGUAGAAUACUGU 19
7935 26815
CFTR- IntronlO- - CAGGGAGGGUAGAAUACUGU 20
7936 26816
CFTR- IntronlO- - ACAGGGAGGGUAGAAUACUGU 21
7937 26817
CFTR- IntronlO- - GACAGGGAGGGUAGAAUACUGU 22
7938 26818
CFTR- IntronlO- - AGACAGGGAGGGUAGAAUACUGU 23
7939 26819
CFTR- IntronlO- - AAGACAGGGAGGGUAGAAUACUGU 24
7940 26820
CFTR- IntronlO- - GUUUUUAGGCUAUUCUGU 18
7941 26821
CFTR- IntronlO- - UGUUUUUAGGCUAUUCUGU 19
7942 26822
1156
5535.1 CFTR-
- AUGUUUUUAGGCUAUUCUGU 20
lntronlO-541 19427
CFTR- IntronlO- - AAUGUUUUUAGGCUAUUCUGU 21
7943 26823
CFTR- IntronlO- - UAAUGUUUUUAGGCUAUUCUGU 22
7944 26824
CFTR- IntronlO- - CUAAUGUUUUUAGGCUAUUCUGU 23
7945 26825
CFTR- IntronlO- - GCUAAUGUUUUUAGGCUAUUCUGU 24
7946 26826
CFTR- IntronlO- - AUGGCAUCUCACCAGUGU 18
7947 26827
CFTR- IntronlO- - UAUGGCAUCUCACCAGUGU 19
7948 26828
CFTR- IntronlO- - UUAUGGCAUCUCACCAGUGU 20
7949 26829
CFTR- IntronlO- - CUUAUGGCAUCUCACCAGUGU 21
7950 26830
CFTR- IntronlO- - GCUUAUGGCAUCUCACCAGUGU 22
7951 26831
CFTR- IntronlO- - GGCUUAUGGCAUCUCACCAGUGU 23
7952 26832
CFTR- IntronlO- - UGGCUUAUGGCAUCUCACCAGUGU 24
7953 26833
CFTR- IntronlO- - GGCAUCUCACCAGUGUGU 18
7954 26834
CFTR- IntronlO- - UGGCAUCUCACCAGUGUGU 19
7955 26835
CFTR-
- AUGGCAUCUCACCAGUGUGU 20
lntronlO-542 19428
1157
5535.1 CFTR- IntronlO- - UAUGGCAUCUCACCAGUGUGU 21
7956 26836
CFTR- IntronlO- - UUAUGGCAUCUCACCAGUGUGU 22
7957 26837
CFTR- IntronlO- - CUUAUGGCAUCUCACCAGUGUGU 23
7958 26838
CFTR- IntronlO- - GCUUAUGGCAUCUCACCAGUGUGU 24
7959 26839
CFTR- IntronlO- - GUAUGUAUAUAUGUGUGU 18
7960 26840
CFTR- IntronlO- - UGUAUGUAUAUAUGUGUGU 19
7961 26841
CFTR- IntronlO- - AUGUAUGUAUAUAUGUGUGU 20
7962 26842
CFTR- IntronlO- - UAUGUAUGUAUAUAUGUGUGU 21
7963 26843
CFTR- IntronlO- - AUAUGUAUGUAUAUAUGUGUGU 22
7964 26844
CFTR- IntronlO- - CAUAUGUAUGUAUAUAUGUGUGU 23
7965 26845
CFTR- IntronlO- - UCAUAUGUAUGUAUAUAUGUGUGU 24
7966 26846
CFTR- IntronlO- - UCUAACUUUUCUUAUUGU 18
7967 26847
CFTR- IntronlO- - UUCUAACUUUUCUUAUUGU 19
7968 26848
CFTR- IntronlO- - CUUCUAACUUUUCUUAUUGU 20
7969 26849
1158
5535.1 CFTR- IntronlO- - ACUUCUAACUUUUCUUAUUGU 21
7970 26850
CFTR- IntronlO- - UACUUCUAACUUUUCUUAUUGU 22
7971 26851
CFTR- IntronlO- - UUACUUCUAACUUUUCUUAUUGU 23
7972 26852
CFTR- IntronlO- - UUUACUUCUAACUUUUCUUAUUGU 24
7973 26853
CFTR- IntronlO- - GGACCAAAACUUUAUUGU 18
7974 26854
CFTR- IntronlO- - AGGACCAAAACUUUAUUGU 19
7975 26855
CFTR- IntronlO- - AAGGACCAAAACUUUAUUGU 20
7976 26856
CFTR- IntronlO- - AAAGG ACCAAAACU U U AU UG U 21
7977 26857
CFTR- IntronlO- - AAAAGG ACCAAAACU U U AU UG U 22
7978 26858
CFTR- IntronlO- - CAAAAGGACCAAAACUUUAUUGU 23
7979 26859
CFTR- IntronlO- - GCAAAAGGACCAAAACUUUAUUGU 24
7980 26860
CFTR- IntronlO- - U ACCCAAU AAAAAAAAU U 18
7981 26861
CFTR- IntronlO- - U U ACCCAAU AAAAAAAAU U 19
7982 26862
CFTR-
- G U U ACCCAAU AAAAAAAAU U 20
lntronlO-124 19010
CFTR-
- UG U U ACCCAAU AAAAAAAAU U 21
IntronlO- 26863
1159
5535.1 7983
CFTR- IntronlO- - U UG U U ACCCAAU AAAAAAAAU U 22
7984 26864
CFTR- IntronlO- - AU UG U U ACCCAAU AAAAAAAAU U 23
7985 26865
CFTR- IntronlO- - U AU UG U U ACCCAAU AAAAAAAAU U 24
7986 26866
CFTR- IntronlO- - AG AAAU ACCG AG AAAAU U 18
7987 26867
CFTR- IntronlO- - U AG AAAU ACCG AG AAAAU U 19
7988 26868
CFTR- IntronlO- - CU AG AAAU ACCGAG AAAAU U 20
7989 26869
CFTR- IntronlO- - CCU AGAAAUACCGAG AAAAU U 21
7990 26870
CFTR- IntronlO- - GCCU AG AAAU ACCG AGAAAAUU 22
7991 26871
CFTR- IntronlO- - AGCCUAGAAAUACCGAGAAAAUU 23
7992 26872
CFTR- IntronlO- - UAGCCUAGAAAUACCGAGAAAAUU 24
7993 26873
CFTR- IntronlO- - U UAAUG AAAAU AG AAAU U 18
7994 26874
CFTR- IntronlO- - GUUAAUGAAAAUAGAAAUU 19
7995 26875
CFTR- IntronlO- - UGUUAAUGAAAAUAGAAAUU 20
7996 26876
CFTR-
- AUGUUAAUGAAAAUAGAAAUU 21
IntronlO- 26877
1160
5535.1 7997
CFTR- IntronlO- - AAUG U U AAUG AAAAU AG AAAU U 22
7998 26878
CFTR- IntronlO- - AAAUGUUAAUGAAAAUAGAAAUU 23
7999 26879
CFTR- IntronlO- - AAAAUG U U AAUG AAAAU AG AAAU U 24
8000 26880
CFTR- IntronlO- - CUACAGUUGCCUGCAAUU 18
8001 26881
CFTR- IntronlO- - GCUACAGUUGCCUGCAAUU 19
8002 26882
CFTR- IntronlO- - AGCUACAGUUGCCUGCAAUU 20
8003 26883
CFTR- IntronlO- - CAGCUACAGUUGCCUGCAAUU 21
8004 26884
CFTR- IntronlO- - GCAGCUACAGUUGCCUGCAAUU 22
8005 26885
CFTR- IntronlO- - UGCAGCUACAGUUGCCUGCAAUU 23
8006 26886
CFTR- IntronlO- - CUGCAGCUACAGUUGCCUGCAAUU 24
8007 26887
CFTR- IntronlO- - UAUCAAUAUUUUGGAAUU 18
8008 26888
CFTR- IntronlO- - UUAUCAAUAUUUUGGAAUU 19
8009 26889
CFTR- IntronlO- - UUUAUCAAUAUUUUGGAAUU 20
8010 26890
CFTR-
- UUUUAUCAAUAUUUUGGAAUU 21
IntronlO- 26891
1161
5535.1 8011
CFTR- IntronlO- - GUUUUAUCAAUAUUUUGGAAUU 22
8012 26892
CFTR- IntronlO- - AGUUUUAUCAAUAUUUUGGAAUU 23
8013 26893
CFTR- IntronlO- - UAGUUUUAUCAAUAUUUUGGAAUU 24
8014 26894
CFTR- IntronlO- - GGUACUACUGUAAUAAUU 18
8015 26895
CFTR- IntronlO- - UGGUACUACUGUAAUAAUU 19
8016 26896
CFTR- IntronlO- - AUGGUACUACUGUAAUAAUU 20
1381 20265
CFTR- IntronlO- - UAUGGUACUACUGUAAUAAUU 21
8017 26897
CFTR- IntronlO- - AUAUGGUACUACUGUAAUAAUU 22
8018 26898
CFTR- IntronlO- - CAUAUGGUACUACUGUAAUAAUU 23
8019 26899
CFTR- IntronlO- - ACAUAUGGUACUACUGUAAUAAUU 24
8020 26900
CFTR- IntronlO- - AAAUAUCACCAACUCAUU 18
8021 26901
CFTR- IntronlO- - AAAAUAUCACCAACUCAUU 19
8022 26902
CFTR-
- AAAAAUAUCACCAACUCAUU 20
lntronlO-544 19430
CFTR- IntronlO- - GAAAAAUAUCACCAACUCAUU 21
8023 26903
1162
5535.1 CFTR- IntronlO- - UGAAAAAUAUCACCAACUCAUU 22
8024 26904
CFTR- IntronlO- - AUGAAAAAUAUCACCAACUCAUU 23
8025 26905
CFTR- IntronlO- - AAUGAAAAAUAUCACCAACUCAUU 24
8026 26906
CFTR- IntronlO- - GUAGGAAGUGAUCAGAUU 18
8027 26907
CFTR- IntronlO- - AGUAGGAAGUGAUCAGAUU 19
8028 26908
CFTR- IntronlO- - UAGUAGGAAGUGAUCAGAUU 20
8029 26909
CFTR- IntronlO- - AUAGUAGGAAGUGAUCAGAUU 21
8030 26910
CFTR- IntronlO- - UAUAGUAGGAAGUGAUCAGAUU 22
8031 26911
CFTR- IntronlO- - GUAUAGUAGGAAGUGAUCAGAUU 23
8032 26912
CFTR- IntronlO- - AG U AU AG U AGG AAG UG AU CAG AU U 24
8033 26913
CFTR- IntronlO- - AGCUGGCUAUCCAGGAUU 18
8034 26914
CFTR- IntronlO- - CAGCUGGCUAUCCAGGAUU 19
8035 26915
CFTR- IntronlO- - ACAGCUGGCUAUCCAGGAUU 20
8036 26916
CFTR- IntronlO- - GACAGCUGGCUAUCCAGGAUU 21
8037 26917
1163
5535.1 CFTR- IntronlO- - AGACAGCUGGCUAUCCAGGAUU 22
8038 26918
CFTR- IntronlO- - AAGACAGCUGGCUAUCCAGGAUU 23
8039 26919
CFTR- IntronlO- - GAAGACAGCUGGCUAUCCAGGAUU 24
8040 26920
CFTR- IntronlO- - UGCAGGAGGUGAGGGAUU 18
8041 26921
CFTR- IntronlO- - UUGCAGGAGGUGAGGGAUU 19
8042 26922
CFTR- IntronlO- - CUUGCAGGAGGUGAGGGAUU 20
1384 20268
CFTR- IntronlO- - ACUUGCAGGAGGUGAGGGAUU 21
8043 26923
CFTR- IntronlO- - GACU UGCAGGAGGUGAGGGAUU 22
8044 26924
CFTR- IntronlO- - AGACUUGCAGGAGGUGAGGGAUU 23
8045 26925
CFTR- IntronlO- - AAGACUUGCAGGAGGUGAGGGAUU 24
8046 26926
CFTR- IntronlO- - AAUAGUUUUAUCAAUAUU 18
8047 26927
CFTR- IntronlO- - AAAU AG UUUUAUCAAUAUU 19
8048 26928
CFTR- IntronlO- - CAAAUAGUUUUAUCAAUAUU 20
8049 26929
CFTR- IntronlO- - GCAAAUAGUUUUAUCAAUAUU 21
8050 26930
1164
5535.1 CFTR- IntronlO- - UGCAAAUAGUUUUAUCAAUAUU 22
8051 26931
CFTR- IntronlO- - CUGCAAAUAGUUUUAUCAAUAUU 23
8052 26932
CFTR- IntronlO- - UCUGCAAAUAGUUUUAUCAAUAUU 24
8053 26933
CFTR- IntronlO- - G AUG AGG AGAACCAU AU U 18
8054 26934
CFTR- IntronlO- - AGAUGAGGAGAACCAUAUU 19
8055 26935
CFTR- IntronlO- - AAGAUGAGGAGAACCAUAUU 20
8056 26936
CFTR- IntronlO- - UAAGAUGAGGAGAACCAUAUU 21
8057 26937
CFTR- IntronlO- - CUAAGAUGAGGAGAACCAUAUU 22
8058 26938
CFTR- IntronlO- - UCUAAGAUGAGGAGAACCAUAUU 23
8059 26939
CFTR- IntronlO- - AUCUAAGAUGAGGAGAACCAUAUU 24
8060 26940
CFTR- IntronlO- - AACUUAACCUGGCAUAUU 18
8061 26941
CFTR- IntronlO- - CAACUUAACCUGGCAUAUU 19
8062 26942
CFTR-
- ACAACUUAACCUGGCAUAUU 20
lntronlO-546 19432
CFTR- IntronlO- - AACAACUUAACCUGGCAUAUU 21
8063 26943
CFTR-
- GAACAACUUAACCUGGCAUAUU 22
IntronlO- 26944
1165
5535.1 8064
CFTR- IntronlO- - AGAACAACUUAACCUGGCAUAUU 23
8065 26945
CFTR- IntronlO- - AAGAACAACUUAACCUGGCAUAUU 24
8066 26946
CFTR- IntronlO- - UGCUCUCUUUUAACUAUU 18
8067 26947
CFTR- IntronlO- - UUGCUCUCUUUUAACUAUU 19
8068 26948
CFTR- IntronlO- - CUUGCUCUCUUUUAACUAUU 20
8069 26949
CFTR- IntronlO- - ACUUGCUCUCUUUUAACUAUU 21
8070 26950
CFTR- IntronlO- - AACUUGCUCUCUUUUAACUAUU 22
8071 26951
CFTR- IntronlO- - AAACUUGCUCUCUUUUAACUAUU 23
8072 26952
CFTR- IntronlO- - AAAACUUGCUCUCUUUUAACUAUU 24
8073 26953
CFTR- IntronlO- - GUUUUUCUUUCCUUUAUU 18
8074 26954
CFTR- IntronlO- - UGUUUUUCUUUCCUUUAUU 19
8075 26955
CFTR- IntronlO- - AUGUUUUUCUUUCCUUUAUU 20
8076 26956
CFTR- IntronlO- - UAUGUUUUUCUUUCCUUUAUU 21
8077 26957
CFTR-
- UUAUGUUUUUCUUUCCUUUAUU 22
IntronlO- 26958
1166
5535.1 8078
CFTR- IntronlO- - UUUAUGUUUUUCUUUCCUUUAUU 23
8079 26959
CFTR- IntronlO- - UUUUAUGUUUUUCUUUCCUUUAUU 24
8080 26960
CFTR- IntronlO- - GGGAAUAUUUAAACACUU 18
8081 26961
CFTR- IntronlO- - UGGGAAUAUUUAAACACUU 19
8082 26962
CFTR- IntronlO- - UUGGGAAUAUUUAAACACUU 20
8083 26963
CFTR- IntronlO- - CUUGGGAAUAUUUAAACACUU 21
8084 26964
CFTR- IntronlO- - CCUUGGGAAUAUUUAAACACUU 22
8085 26965
CFTR- IntronlO- - CCCUUGGGAAUAUUUAAACACUU 23
8086 26966
CFTR- IntronlO- - UCCCUUGGGAAUAUUUAAACACUU 24
8087 26967
CFTR- IntronlO- - CUUGUAAUCCUAGCACUU 18
8088 26968
CFTR- IntronlO- - ACUUGUAAUCCUAGCACUU 19
8089 26969
CFTR- IntronlO- - CACUUGUAAUCCUAGCACUU 20
8090 26970
CFTR- IntronlO- - ACACUUGUAAUCCUAGCACUU 21
8091 26971
CFTR-
- CACACUUGUAAUCCUAGCACUU 22
IntronlO- 26972
1167
5535.1 8092
CFTR- IntronlO- - UCACACUUGUAAUCCUAGCACUU 23
8093 26973
CFTR- IntronlO- - CUCACACUUGUAAUCCUAGCACUU 24
8094 26974
CFTR- IntronlO- - GAAUUGAAUAUGAGACUU 18
8095 26975
CFTR- IntronlO- - AGAAUUGAAUAUGAGACUU 19
8096 26976
CFTR- IntronlO- - AAGAAUUGAAUAUGAGACUU 20
1394 20278
CFTR- IntronlO- - GAAGAAUUGAAUAUGAGACUU 21
8097 26977
CFTR- IntronlO- - UGAAGAAUUGAAUAUGAGACUU 22
8098 26978
CFTR- IntronlO- - UUGAAGAAUUGAAUAUGAGACUU 23
8099 26979
CFTR- IntronlO- - UUUGAAGAAUUGAAUAUGAGACUU 24
8100 26980
CFTR- IntronlO- - UGUGCCUGUAGUCCCAGCUACUU 23
8101 26981
CFTR- IntronlO- - GUGUGCCUGUAGUCCCAGCUACUU 24
8102 26982
CFTR- IntronlO- - AUUGCAGGGUGGGGCCUU 18
8103 26983
CFTR- IntronlO- - UAUUGCAGGGUGGGGCCUU 19
8104 26984
CFTR-
- GU AUUGCAGGGUGGGGCCUU 20
lntronlO-721 19607
1168
5535.1 CFTR- IntronlO- - GGUAUUGCAGGGUGGGGCCUU 21
8105 26985
CFTR- IntronlO- - UGGUAUUGCAGGGUGGGGCCUU 22
8106 26986
CFTR- IntronlO- - AUGGUAUUGCAGGGUGGGGCCUU 23
8107 26987
CFTR- IntronlO- - GAUGGUAUUGCAGGGUGGGGCCUU 24
8108 26988
CFTR- IntronlO- - ACAGUGCAGUUAUAGCUU 18
8109 26989
CFTR- IntronlO- - GACAGUGCAGUUAUAGCUU 19
8110 26990
CFTR- IntronlO- - UGACAGUGCAGUUAUAGCUU 20
8111 26991
CFTR- IntronlO- - CUGACAGUGCAGUUAUAGCUU 21
8112 26992
CFTR- IntronlO- - GCUGACAGUGCAGUUAUAGCUU 22
8113 26993
CFTR- IntronlO- - GGCUGACAGUGCAGUUAUAGCUU 23
8114 26994
CFTR- IntronlO- - UGGCUGACAGUGCAGUUAUAGCUU 24
8115 26995
CFTR- IntronlO- - AUUAAAUGUCUUGCGCUU 18
8116 26996
CFTR- IntronlO- - CAUUAAAUGUCUUGCGCUU 19
8117 26997
CFTR- IntronlO- - ACAUUAAAUGUCUUGCGCUU 20
8118 26998
1169
5535.1 CFTR- IntronlO- - UACAUUAAAUGUCUUGCGCUU 21
8119 26999
CFTR- IntronlO- - CUACAUUAAAUGUCUUGCGCUU 22
8120 27000
CFTR- IntronlO- - UCUACAUUAAAUGUCUUGCGCUU 23
8121 27001
CFTR- IntronlO- - GUCUACAUUAAAUGUCUUGCGCUU 24
8122 27002
CFTR- IntronlO- - GGCAAUAGGUAUUUGCUU 18
8123 27003
CFTR- IntronlO- - GGGCAAUAGGUAUUUGCUU 19
8124 27004
CFTR- IntronlO- - AGGGCAAUAGGUAUUUGCUU 20
8125 27005
CFTR- IntronlO- - AAGGGCAAUAGGUAUUUGCUU 21
8126 27006
CFTR- IntronlO- - AAAGGGCAAUAGGUAUUUGCUU 22
8127 27007
CFTR- IntronlO- - UAAAGGGCAAUAGGUAUUUGCUU 23
8128 27008
CFTR- IntronlO- - CUAAAGGGCAAUAGGUAUUUGCUU 24
8129 27009
CFTR- IntronlO- - AAUUUAACUGAAUAUCUU 18
8130 27010
CFTR- IntronlO- - AAAUUUAACUGAAUAUCUU 19
8131 27011
CFTR- IntronlO- - GAAAUUUAACUGAAUAUCUU 20
8132 27012
1170
5535.1 CFTR- IntronlO- - AGAAAUUUAACUGAAUAUCUU 21
8133 27013
CFTR- IntronlO- - UAGAAAUUUAACUGAAUAUCUU 22
8134 27014
CFTR- IntronlO- - AUAGAAAUUUAACUGAAUAUCUU 23
8135 27015
CFTR- IntronlO- - UAUAGAAAUUUAACUGAAUAUCUU 24
8136 27016
CFTR- IntronlO- - AUAAUUAACCGGUGUCUU 18
8137 27017
CFTR- IntronlO- - UAUAAUUAACCGGUGUCUU 19
8138 27018
CFTR- IntronlO- - UUAUAAUUAACCGGUGUCUU 20
8139 27019
CFTR- IntronlO- - GUUAUAAUUAACCGGUGUCUU 21
8140 27020
CFTR- IntronlO- - UGUUAUAAUUAACCGGUGUCUU 22
8141 27021
CFTR- IntronlO- - CUGUUAUAAUUAACCGGUGUCUU 23
8142 27022
CFTR- IntronlO- - ACUGUUAUAAUUAACCGGUGUCUU 24
8143 27023
CFTR- IntronlO- - UUCUAAGUAUUAGAGGUU 18
8144 27024
CFTR- IntronlO- - AUUCUAAGUAUUAGAGGUU 19
8145 27025
CFTR- IntronlO- - CAUUCUAAGUAUUAGAGGUU 20
8146 27026
1171
5535.1 CFTR- IntronlO- - GCAUUCUAAGUAUUAGAGGUU 21
8147 27027
CFTR- IntronlO- - GGCAUUCUAAGUAUUAGAGGUU 22
8148 27028
CFTR- IntronlO- - GGGCAUUCUAAGUAUUAGAGGUU 23
8149 27029
CFTR- IntronlO- - AGGGCAUUCUAAGUAUUAGAGGUU 24
8150 27030
CFTR- IntronlO- - CAGUGCUUUUUCGAGGUU 18
8151 27031
CFTR- IntronlO- - UCAGUGCUUUUUCGAGGUU 19
8152 27032
CFTR-
- AUCAGUGCUUUUUCGAGGUU 20
lntronlO-556 19442
CFTR- IntronlO- - AAUCAGUGCUUUUUCGAGGUU 21
8153 27033
CFTR- IntronlO- - AAAUCAGUGCUUUUUCGAGGUU 22
8154 27034
CFTR- IntronlO- - AAAAUCAGUGCUUUUUCGAGGUU 23
8155 27035
CFTR- IntronlO- - UAAAAUCAGUGCUUUUUCGAGGUU 24
8156 27036
CFTR- IntronlO- - UUUGGAUGGAGCUUGGUU 18
8157 27037
CFTR- IntronlO- - UUUUGGAUGGAGCUUGGUU 19
8158 27038
CFTR-
- GUUUUGGAUGGAGCUUGGUU 20
lntronlO-128 19014
CFTR- IntronlO- - GGU UUUGGAUGGAGCUUGGUU 21
8159 27039
1172
5535.1 CFTR- IntronlO- - AGGUUUUGGAUGGAGCUUGGUU 22
8160 27040
CFTR- IntronlO- - CAGGUUUUGGAUGGAGCUUGGUU 23
8161 27041
CFTR- IntronlO- - ACAGGUUUUGGAUGGAGCUUGGUU 24
8162 27042
CFTR- IntronlO- - UAAUACAUUGGAAAAUUU 18
8163 27043
CFTR- IntronlO- - UU AAU ACAU UGGAAAAUUU 19
8164 27044
CFTR- IntronlO- - GU UAAUACAUUGGAAAAUUU 20
8165 27045
CFTR- IntronlO- - AG U U AAU ACAU UGG AAAAU U U 21
8166 27046
CFTR- IntronlO- - CAG U U AAU ACAU UGG AAAAU U U 22
8167 27047
CFTR- IntronlO- - U CAG U U AAU ACAU UGG AAAAU U U 23
8168 27048
CFTR- IntronlO- - U U CAG U U AAU ACAU UGG AAAAU U U 24
8169 27049
CFTR- IntronlO- - AUCAAUAUUUUGGAAUUU 18
8170 27050
CFTR- IntronlO- - UAUCAAUAUUUUGGAAUUU 19
8171 27051
CFTR- IntronlO- - UUAUCAAUAUUUUGGAAUUU 20
1402 20286
CFTR- IntronlO- - UUUAUCAAUAUUUUGGAAUUU 21
8172 27052
1173
5535.1 CFTR- IntronlO- - UUUUAUCAAUAUUUUGGAAUUU 22
8173 27053
CFTR- IntronlO- - GUUUUAUCAAUAUUUUGGAAUUU 23
8174 27054
CFTR- IntronlO- - AGUUUUAUCAAUAUUUUGGAAUUU 24
8175 27055
CFTR- IntronlO- - UUAAUAUUACUAUUAUUU 18
8176 27056
CFTR- IntronlO- - AUUAAUAUUACUAUUAUUU 19
8177 27057
CFTR- IntronlO- - UAUUAAUAUUACUAUUAUUU 20
8178 27058
CFTR- IntronlO- - UUAUUAAUAUUACUAUUAUUU 21
8179 27059
CFTR- IntronlO- - GUUAUUAAUAUUACUAUUAUUU 22
8180 27060
CFTR- IntronlO- - UGUUAUUAAUAUUACUAUUAUUU 23
8181 27061
CFTR- IntronlO- - UUGUUAUUAAUAUUACUAUUAUUU 24
8182 27062
CFTR- IntronlO- - AAACAAGGAUGUUUAUUU 18
8183 27063
CFTR- IntronlO- - UAAACAAGGAUGUUUAUUU 19
8184 27064
CFTR- IntronlO- - CUAAACAAGGAUGUUUAUUU 20
8185 27065
CFTR- IntronlO- - UCUAAACAAGGAUGUUUAUUU 21
8186 27066
1174
5535.1 CFTR- IntronlO- - GUCUAAACAAGGAUGUUUAUUU 22
8187 27067
CFTR- IntronlO- - GGUCUAAACAAGGAUGUUUAUUU 23
8188 27068
CFTR- IntronlO- - UGGUCUAAACAAGGAUGUUUAUUU 24
8189 27069
CFTR- IntronlO- - UUGUAAUCCUAGCACUUU 18
8190 27070
CFTR- IntronlO- - CUUGUAAUCCUAGCACUUU 19
8191 27071
CFTR- IntronlO- - ACUUGUAAUCCUAGCACUUU 20
1408 20292
CFTR- IntronlO- - CACUUGUAAUCCUAGCACUUU 21
8192 27072
CFTR- IntronlO- - ACACUUGUAAUCCUAGCACUUU 22
8193 27073
CFTR- IntronlO- - CACACUUGUAAUCCUAGCACUUU 23
8194 27074
CFTR- IntronlO- - UCACACUUGUAAUCCUAGCACUUU 24
8195 27075
CFTR- IntronlO- - UUGCAGGGUGGGGCCUUU 18
8196 27076
CFTR- IntronlO- - AUUGCAGGGUGGGGCCUUU 19
8197 27077
CFTR- IntronlO- - UAUUGCAGGGUGGGGCCUUU 20
1409 20293
CFTR- IntronlO- - GU AUUGCAGGGUGGGGCCUUU 21
8198 27078
1175
5535.1 CFTR- IntronlO- - GGUAUUGCAGGGUGGGGCCUUU 22
8199 27079
CFTR- IntronlO- - UGGUAUUGCAGGGUGGGGCCUUU 23
8200 27080
CFTR- IntronlO- - AUGGUAUUGCAGGGUGGGGCCUUU 24
8201 27081
CFTR- IntronlO- - AAGAUGAUUCCAAGCUUU 18
8202 27082
CFTR- IntronlO- - AAAGAUGAUUCCAAGCUUU 19
8203 27083
CFTR- IntronlO- - CAAAGAUGAUUCCAAGCUUU 20
8204 27084
CFTR- IntronlO- - UCAAAGAUGAUUCCAAGCUUU 21
8205 27085
CFTR- IntronlO- - GUCAAAGAUGAUUCCAAGCUUU 22
8206 27086
CFTR- IntronlO- - AGUCAAAGAUGAUUCCAAGCUUU 23
8207 27087
CFTR- IntronlO- - GAGUCAAAGAUGAUUCCAAGCUUU 24
8208 27088
CFTR- IntronlO- - UCAUUAUAACACUGCUUU 18
8209 27089
CFTR- IntronlO- - UUCAUUAUAACACUGCUUU 19
8210 27090
CFTR- IntronlO- - CUUCAUUAUAACACUGCUUU 20
8211 27091
CFTR- IntronlO- - UCUUCAUUAUAACACUGCUUU 21
8212 27092
1176
5535.1 CFTR- IntronlO- - CUCUUCAUUAUAACACUGCUUU 22
8213 27093
CFTR- IntronlO- - GCUCUUCAUUAUAACACUGCUUU 23
8214 27094
CFTR- IntronlO- - AGCUCUUCAUUAUAACACUGCUUU 24
8215 27095
CFTR- IntronlO- - AUUUAACUGAAUAUCUUU 18
8216 27096
CFTR- IntronlO- - AAUUUAACUGAAUAUCUUU 19
8217 27097
CFTR- IntronlO- - AAAUUUAACUGAAUAUCUUU 20
1410 20294
CFTR- IntronlO- - GAAAUUUAACUGAAUAUCUUU 21
8218 27098
CFTR- IntronlO- - AGAAAUUUAACUGAAUAUCUUU 22
8219 27099
CFTR- IntronlO- - UAGAAAUUUAACUGAAUAUCUUU 23
8220 27100
CFTR- IntronlO- - AUAGAAAUUUAACUGAAUAUCUUU 24
8221 27101
CFTR- IntronlO- - UCAAUAUUUUGGAAUUUU 18
8222 27102
CFTR- IntronlO- - AUCAAUAUUUUGGAAUUUU 19
8223 27103
CFTR- IntronlO- - UAUCAAUAUUUUGGAAUUUU 20
1412 20296
CFTR- IntronlO- - UUAUCAAUAUUUUGGAAUUUU 21
8224 27104
1177
5535.1 CFTR- IntronlO- - UUUAUCAAUAUUUUGGAAUUUU 22
8225 27105
CFTR- IntronlO- - UUUUAUCAAUAUUUUGGAAUUUU 23
8226 27106
CFTR- IntronlO- - GUUUUAUCAAUAUUUUGGAAUUUU 24
8227 27107
CFTR- IntronlO- - GAUAAAAUCAGUGCUUUU 18
8228 27108
CFTR- IntronlO- - UGAUAAAAUCAGUGCUUUU 19
8229 27109
CFTR- IntronlO- - CUGAUAAAAUCAGUGCUUUU 20
8230 27110
CFTR- IntronlO- - UCUGAUAAAAUCAGUGCUUUU 21
8231 27111
CFTR- IntronlO- - CUCUGAUAAAAUCAGUGCUUUU 22
8232 27112
CFTR- IntronlO- - GCUCUGAUAAAAUCAGUGCUUUU 23
8233 27113
CFTR- IntronlO- - AGCUCUGAUAAAAUCAGUGCUUUU 24
8234 27114
CFTR- IntronlO- - UUAAAAUUUUAUUCUUUU 18
8235 27115
CFTR- IntronlO- - UUUAAAAUUUUAUUCUUUU 19
8236 27116
CFTR- IntronlO- - UUUUAAAAUUUUAUUCUUUU 20
8237 27117
CFTR- IntronlO- - UUUUUAAAAUUUUAUUCUUUU 21
8238 27118
1178
5535.1 CFTR- IntronlO- - AUUUUUAAAAUUUUAUUCUUUU 22
8239 27119
CFTR- IntronlO- - AAUUUUUAAAAUUUUAUUCUUUU 23
8240 27120
CFTR- IntronlO- - UAAUUUUUAAAAUUUUAUUCUUUU 24
8241 27121
CFTR- IntronlO- - AUCAUUUUGACCAUUUUU 18
8242 27122
CFTR- IntronlO- - UAUCAUUUUGACCAUUUUU 19
8243 27123
CFTR- IntronlO- - UUAUCAUUUUGACCAUUUUU 20
8244 27124
CFTR- IntronlO- - UUUAUCAUUUUGACCAUUUUU 21
8245 27125
CFTR- IntronlO- - AUUUAUCAUUUUGACCAUUUUU 22
8246 27126
CFTR- IntronlO- - AAUUUAUCAUUUUGACCAUUUUU 23
8247 27127
CFTR- IntronlO- - AAAUUUAUCAUUUUGACCAUUUUU 24
8248 27128
CFTR- IntronlO- - AUUAGUAGUUAAGUUUUU 18
8249 27129
CFTR- IntronlO- - UAUUAGUAGUUAAGUUUUU 19
8250 27130
CFTR- IntronlO- - CUAUUAGUAGUUAAGUUUUU 20
8251 27131
CFTR- IntronlO- - GCUAUUAGUAGUUAAGUUUUU 21
8252 27132
1179
5535.1 CFTR- IntronlO- - GGCUAUUAGUAGUUAAGUUUUU 22
8253 27133
CFTR- IntronlO- - AGGCUAUUAGUAGUUAAGUUUUU 23
8254 27134
CFTR- IntronlO- - UAGGCUAUUAGUAGUUAAGUUUUU 24
8255 27135
CFTR- IntronlO- - AACACUUUAUAGUUUUUU 18
8256 27136
CFTR- IntronlO- - GAACACUUUAUAGUUUUUU 19
8257 27137
CFTR- IntronlO- - GGAACACUUUAUAGUUUUUU 20
8258 27138
CFTR- IntronlO- - UGGAACACUUUAUAGUUUUUU 21
8259 27139
CFTR- IntronlO- - AUGGAACACUUUAUAGUUUUUU 22
8260 27140
CFTR- IntronlO- - AAUGGAACACUUUAUAGUUUUUU 23
8261 27141
CFTR- IntronlO- - GAAUGGAACACUUUAUAGUUUUUU 24
8262 27142
CFTR- IntronlO- - UUUUUUUUUUUUUUUUUU 18
8263 27143
CFTR- IntronlO- - uuuuuuuuuuuuuuuuuuu 19
8264 27144
CFTR- IntronlO- - uuuuuuuuuuuuuuuuuuuu 20
8265 27145
CFTR- IntronlO- - uuuuuuuuuuuuuuuuuuuuu 21
8266 27146
1180
5535.1 CFTR- IntronlO- - uuuuuuuuuuuuuuuuuuuuuu 22
8267 27147
CFTR- IntronlO- - uuuuuuuuuuuuuuuuuuuuuuu 23
8268 27148
CFTR- IntronlO- - cuuuuuuuuuuuuuuuuuuuuuuu 24
8269 27149
Table 42A provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the first tier parameters. The targeting domains bind within intron 10, have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 42A
Figure imgf001182_0001
1181
5535.1 CFTR-lntronlO-
+ G G U AG C AG AG G AAG AAAAAG 20
8278 27158
CFTR-lntronlO-
- GCCAUACACUCUAAAUAGAG 20
8279 27159
CFTR-lntronlO-
- GUUUUCUAGAAAAUCUGUAG 20
8280 27160
CFTR-lntronlO-
- GGAGAUACAUCUGAAAAAAU 20
8281 27161
CFTR-lntronlO-
- GCAGGAAGACAGCUGGCUAU 20
8282 27162
Table 42B provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the second tier parameters. The targeting domains bind within intron 10 and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 42B
Figure imgf001183_0001
1182
5535.1 8291
CFTR-lntronlO-
- AUACACUCUAAAUAGAG 17
8292 27172
CFTR-lntronlO-
- UUCUAGAAAAUCUGUAG 17
8293 27173
CFTR-lntronlO-
- AAGGCUUAUUUCUCUGG 17
8294 27174
CFTR-lntronlO-
+ CAAAUUGUAUUGAGUGG 17
8295 27175
CFTR-lntronlO-
- UAUAUAUAUGACACUAU 17
8296 27176
CFTR-lntronlO-
+ CUACUAAAAGGCAGCCU 17
8297 27177
CFTR-lntronlO-
+ UGAUCCUUU UGCAGCCU 17
8298 27178
CFTR-lntronlO-
- CUU UCCAUGAAUUAGCU 17
8299 27179
CFTR-lntronlO-
- AUUUCCAAGUAAUCUCU 17
8300 27180
CFTR-lntronlO-
- UUCGUGUAGUUUCUAUU 17
8301 27181
CFTR-lntronlO-
- AAAAG U CACAG AGG AG U CAA 20
8302 27182
CFTR-lntronlO-
+ ACAAAAGGACUAUCAGUGAA 20
8303 27183
CFTR-lntronlO-
+ UGAGUUGGUGAUAUUU UUCA 20
8304 27184
CFTR-lntronlO-
- UUAACUGAAUAUCUUUAGGA 20
8305 27185
CFTR-lntronlO-
+ AAUAAAGUAAUAGAAGCAUA 20
8306 27186
CFTR-lntronlO-
+ AAAGCUCUUUCUCAUCUCUA 20
8307 27187
CFTR-lntronlO-
+ AU AU U AAU AACAAAAU CU U A 20
3944 22826
CFTR-lntronlO-
- UCUAUGAUAUAAUGAAUCAC 20
8308 27188
CFTR-lntronlO-
- UAAAAUGGUUCCUUGUUCCC 20
8309 27189
CFTR-lntronlO-
- UGGAAACUUGUCU UCU UUUC 20
8310 27190
1183
5535.1 CFTR-lntronlO-
- UAGUGUGAAGAUGGGGCUGG 20
8311 27191
CFTR-lntronlO-
- ACUAAGGCUUAUUUCUCUGG 20
7212 26092
CFTR-lntronlO-
+ UACCAAAUUGUAUUGAGUGG 20
8312 27192
CFTR-lntronlO-
+ AUACUACUAAAAGGCAGCCU 20
8313 27193
CFTR-lntronlO-
- UAUAUUUCCAAGUAAUCUCU 20
8314 27194
CFTR-lntronlO-
+ UGUGGAGUGUAAAGGAAAUU 20
8315 27195
CFTR-lntronlO-
- AUAUUCGUGUAGUUUCUAUU 20
8316 27196
Table 42C provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the third tier parameters. The targeting domains bind within intron 10 and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 42C
Figure imgf001185_0001
1184
5535.1 CFTR-lntronlO-
+ GAAGAUACU A A A A A A AG U U A 20
8324 27204
CFTR-lntronlO-
- GUUGUGCAACUAUCACCUCC 20
8325 27205
CFTR-lntronlO-
- GAAGUGGAGGCUGCAGUGAG 20
8326 27206
CFTR-lntronlO-
+ GCAUCACUAGUGGCACUUUG 20
8327 27207
CFTR-lntronlO-
+ GAUAAAUUUUAACUUUUUAU 20
8328 27208
Table 42D provides exemplary targeting domains for correcting a mutation (e.g., 3272- 26->G) in the CFTR gene selected according to the fourth tier parameters. The targeting domains bind within intron 10. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the Table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 42D
Figure imgf001186_0001
1185
5535.1 CFTR-lntronlO-
+ U U AAU AACAAAAU CU U A 17
8338 27218
CFTR-lntronlO-
- AUGAUAUAAUGAAUCAC 17
8339 27219
CFTR-lntronlO-
+ CACACAUAUAUACAUAC 17
8340 27220
CFTR-lntronlO-
+ UCCAAGAUCAAGGUGCC 17
8341 27221
CFTR-lntronlO-
+ C A A A U A U AAA U C A A AG C 17
8342 27222
CFTR-lntronlO-
+ AG C AG AG G A AG A A A A AG 17
8343 27223
CFTR-lntronlO-
- AAUGUUGAAUAAUAGGG 17
8344 27224
CFTR-lntronlO-
- AGGGUGGGGCCUUUGGG 17
956 19841
CFTR-lntronlO-
- UGUGAAGAUGGGGCUGG 17
8345 27225
CFTR-lntronlO-
+ CUCUGCCUCCAAAAGUG 17
8346 27226
CFTR-lntronlO-
- CUCGGCCUCCCAAAGUG 17
8347 27227
CFTR-lntronlO-
- UAGUAUAGUAGGAAGUG 17
8348 27228
CFTR-lntronlO-
+ UCACUAGUGGCACUUUG 17
8349 27229
CFTR-lntronlO-
- U CCACAAAU AU U U U U UG 17
8350 27230
CFTR-lntronlO-
- AAAGAUCUAGCU A A A A U 17
8351 27231
CFTR-lntronlO-
+ AAAUUUUAACUUUUUAU 17
8352 27232
CFTR-lntronlO-
- UU UAUUGAUACUUUUCU 17
8353 27233
CFTR-lntronlO-
- AAAGACUUGCAGGAGGU 17
8354 27234
CFTR-lntronlO-
+ UUUCUUUUUCUGU UUGU 17
8355 27235
CFTR-lntronlO-
- UGGGUAUAUUUUAUAU U 17
8356 27236
CFTR-lntronlO-
- CAGUAGUAUUAUCUUU U 17
8357 27237
1186
5535.1 CFTR-lntronlO-
- UAAAAUUUUAUUCUUUU 17
8358 27238
CFTR-lntronlO-
+ U UAUAGAGAUUACUUGGAAA 20
8359 27239
CFTR-lntronlO-
- AUACUUUGGAAUUUGUUAAA 20
8360 27240
CFTR-lntronlO-
+ ACAACCCAAAUGUCAAUCAA 20
8361 27241
CFTR-lntronlO-
+ CAAUACCAUCACCUUGGGAA 20
8362 27242
CFTR-lntronlO-
- UU UUGUAUUUAUAU UCAUAA 20
8363 27243
CFTR-lntronlO-
- UU UAUAUAGAAAUGAGGUAA 20
8364 27244
CFTR-lntronlO-
- AUGCAUAUAUAUAUUUUUAA 20
8365 27245
CFTR-lntronlO-
- AUGCUUUGAAGGAAGAUCCA 20
8366 27246
CFTR-lntronlO-
- UUGUGGAGUCAAAAAU UAUA 20
8367 27247
CFTR-lntronlO-
+ AGACACACAUAUAUACAUAC 20
8368 27248
CFTR-lntronlO-
- AACUCAUUAGGAAAAUGUAC 20
8369 27249
CFTR-lntronlO-
+ AAG U CCAAG AU CAAGG UG CC 20
8370 27250
CFTR-lntronlO-
+ A A AC A A A U A U AAA U C A A AG C 20
8371 27251
CFTR-lntronlO-
+ AUCUCCUAACCUCGAAAAAG 20
8372 27252
CFTR-lntronlO-
+ AGAGAGAACUGCUCACACGG 20
8373 27253
CFTR-lntronlO-
- AUAAAUGUUGAAUAAUAGGG 20
8374 27254
CFTR-lntronlO-
- UGCAGGGUGGGGCCUU UGGG 20
1300 20185
CFTR-lntronlO-
+ UGCCUCUGCCUCCAAAAGUG 20
8375 27255
CFTR-lntronlO-
- CGCCUCGGCCUCCCAAAGUG 20
7272 26152
CFTR-lntronlO-
- UGCCUCGGCCUCCCAAAGUG 20
7277 26157
1187
5535.1 CFTR-lntronlO-
- AAGUAGUAUAGUAGGAAGUG 20
8376 27256
CFTR-lntronlO-
- UCCUCCACAAAUAUUUUUUG 20
8377 27257
CFTR-lntronlO-
- ACAAAAGAUCUAGCUAAAAU 20
8378 27258
CFTR-lntronlO-
- ACAUAUAUAUAUGACACUAU 20
8379 27259
CFTR-lntronlO-
+ ACAUGAUCCUUUUGCAGCCU 20
8380 27260
CFTR-lntronlO-
- AAGCUUUCCAUGAAUUAGCU 20
8381 27261
CFTR-lntronlO-
- UCCUUUAUUGAUACUUUUCU 20
8382 27262
CFTR-lntronlO-
- AACAAAGACUUGCAGGAGGU 20
7876 26756
CFTR-lntronlO-
+ CUCUUUCUUUUUCUGUUUGU 20
8383 27263
CFTR-lntronlO-
- UUUUGGGUAUAUUUUAUAUU 20
8384 27264
CFTR-lntronlO-
- AGUCAGUAGUAUUAUCUUUU 20
8385 27265
CFTR-lntronlO-
- UUUUAAAAUUUUAUUCUUUU 20
8237 27117
Table 43A provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., with 500 bp downstream from the start codon), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogeness Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 43A
Figure imgf001189_0001
1188
5535.1 SCNNlA-329 - GCCUCACUCGGGUUCCA 17 4178
SCNNlA-330 - GGGAGAAUGUGGGCGCA 17 4179
SCNNlA-141 + GCGGUGGAACUCGAUCA 17 551
SCNNlA-80 - GCCCAUACCAGGUCUCA 17 529
SCNNlA-106 - GCACAACCGCAUGAAGA 17 540
SCNNlA-132 + GGAGCACACCAGGCGGA 17 547
SCNNlA-121 + GUUGAUGUUGAGGCUGA 17 545
SCNNlA-331 + GGACUAACCGACCUGUA 17 4180
SCNNlA-332 - GCACCCUCAAUCCCUAC 17 4181
SCNNlA-93 - GAACAAG CG U G AG G AG C 17 533
SCNNlA-147 + GGCUGCUGGGGCGCCGC 17 554
SCNNlA-117 + GUGCAGAUGGUCACUGC 17 544
SCNNlA-333 - GAUGGGAGAGGGCACUC 17 4182
SCNNlA-107 - GCAUGAAGACGGCCUUC 17 541
SCNNlA-334 - GACAUGGGCAUGGCCAG 17 4183
SCNNlA-142 + GGCCUCCUCCUCCGCCG 17 552
SCNNlA-150 + GGGGCGCCGCAGGUUCG 17 555
SCNNlA-131 + GCUGGGAGCACACCAGG 17 546
SCNNlA-103 - GCCCACGGCGGAGGAGG 17 539
SCNNlA-102 - GCAGCCCACGGCGGAGG 17 538
SCNNlA-139 + GCUCUCGGUAGGAGCGG 17 550
SCNNlA-116 + GGUGCAGAUGGUCACUG 17 543
SCNNlA-98 - GCUGGGCCCCGAACCUG 17 535
SCNNlA-335 - GGCGCAGGGUGGGACAU 17 4184
SCNNlA-336 + GGUCAAGGCUGAGCUCU 17 4185
SCNNlA-143 + GCCUCCUCCUCCGCCGU 17 553
SCNNlA-337 - GAAUGUGGGCGCAGGGU 17 4186
SCNNlA-338 + GGGACUAACCGACCUGU 17 4187
SCNNlA-339 + GAGCCCCGGAGUGGAUU 17 4188
SCNNlA-340 - GUGGGACAUGGGCAUGGCCA 20 4189
SCNNlA-341 - GCAGCCUCACUCGGGUUCCA 20 4190
SCNNlA-342 - GAGCAGUAUCAAGGUAAGCA 20 4191
SCNNlA-15 - GGGAACAAGCGUGAGGAGCA 20 507
SCNNlA-62 + GGAGCGGUGGAACUCGAUCA 20 525
SCNNlA-343 - GUGAUGGGAGAGGGCACUCA 20 4192
SCNNlA-1 - GCAGCCCAUACCAGGUCUCA 20 503
SCNNlA-36 + GUAGGGAUUGAGGGUGCAGA 20 516
SCNNlA-76 + GCCCUGGAGUGGACUGUGGA 20 528
SCNNlA-10 - GUCCACUCCAGGGCUCAUGA 20 505
SCNNlA-42 + GAGGUUGAUGUUGAGGCUGA 20 519
SCNNlA-344 + GUAUGGGCUGCAGAGGUCUA 20 4193
SCNNlA-345 + GAGGGACUAACCGACCUGUA 20 4194
1189
5535.1 SCNNlA-32 - GCACCUUUGGCAUGAUGUAC 20 514
SCNNlA-51 + GGUUGUGCUGGGAGCACACC 20 522
SCNNlA-346 + GUGCCCUCUCCCAUCACCCC 20 4195
SCNNlA-347 - GGUGGGACAUGGGCAUGGCC 20 4196
SCNNlA-348 - GGCAGCCUCACUCGGGUUCC 20 4197
SCNNlA-176 - GCUCAUGAAGGGGAACAAGC 20 811
SCNNlA-68 + GUGGGCUGCUGGGGCGCCGC 20 526
SCNNlA-349 - GAGUGGGAGAAUGUGGGCGC 20 4198
SCNNlA-350 - GGUGAUGGGAGAGGGCACUC 20 4199
SCNNlA-351 - GGCCAGGGGCAGCCUCACUC 20 4200
SCNNlA-352 + GAUUGGGGAGAGCAAGGGUC 20 4201
SCNNlA-16 - GGAACAAGCGUGAGGAGCAG 20 508
SCNNlA-44 + GGUUGAUGUUGAGGCUGACG 20 520
SCNNlA-353 - GCUCUCCCCAAUCCACUCCG 20 4202
SCNNlA-39 + GGGUGCAGAUGGUCACUGCG 20 518
SCNNlA-71 + GCUGGGGCGCCGCAGGUUCG 20 527
SCNNlA-21 - GGCGCCCCAGCAGCCCACGG 20 510
SCNNlA-22 - GCCCCAGCAGCCCACGGCGG 20 511
SCNNlA-354 - GGGAGAAUGUGGGCGCAGGG 20 4203
SCNNlA-2 - GCCCAUACCAGGUCUCAUGG 20 497
SCNNlA-37 + GAGGGUGCAGAUGGUCACUG 20 517
SCNNlA-19 - GGGGCUGGGCCCCGAACCUG 20 509
SCNNlA-355 - GUGGGCGCAGGGUGGGACAU 20 4204
SCNNlA-356 + GGUAUGGGCUGCAGAGGUCU 20 4205
SCNNlA-58 + GAACUCGAAGAGCUCUCGGU 20 524
SCNNlA-357 - GGAGAAUGUGGGCGCAGGGU 20 4206
SCNNlA-33 - GGCAUGAUGUACUGGCAAUU 20 515
SCNNlA-31 - GUGCUGUGGCUCUGCACCUU 20 513
Table 43B provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., with 500 bp downstream from the start codon) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogeness Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 43B
Figure imgf001191_0001
1190
5535.1 Length
SCNNlA-125 + CCAGUACAUCAUGCCAA 17 632
SCNNlA-358 - CCAGCUGUCCCUUCCAA 17 4207
SCNNlA-359 - AG U A U C A AG G U A AG C A A 17 4208
SCNNlA-90 - ACUCCAGGGCUCAUGAA 17 611
SCNNlA-360 - ACUCCGGGGCUCAUGAA 17 4209
SCNNlA-104 - AACAACACCACCAUCCA 17 617
SCNNlA-88 - CUCCACAGUCCACUCCA 17 609
SCNNlA-361 - CAGUAUCAAGGUAAGCA 17 4210
SCNNlA-94 - AACAAG CG U G AG G AG CA 17 613
SCNNlA-362 - UAUCAUGAGCAGUAUCA 17 4211
SCNNlA-363 - AUGGGAGAGGGCACUCA 17 4212
SCNNlA-126 + CCACAGCACUGCCCAGA 17 633
SCNNlA-82 - AUACCAGGUCUCAUGGA 17 501
SCNNlA-364 + UGAUACCUCCCCUUGGA 17 4213
SCNNlA-89 - CACUCCAGGGCUCAUGA 17 610
SCNNlA-365 - CACUCCGGGGCUCAUGA 17 4214
SCNNlA-366 - UCGGGUUCCAGGGGUGA 17 4215
SCNNlA-367 + CGACCUGUAGGGAUUGA 17 4216
SCNNlA-157 + CUCCAUGAGACCUGGUA 17 502
SCNNlA-122 + UUGAUGUUGAGGCUGAC 17 629
SCNNlA-111 - CCUUUGGCAUGAUGUAC 17 622
SCNNlA-130 + UGUGCUGGGAGCACACC 17 637
SCNNlA-156 + UUCCCCUCCAUGAGACC 17 653
SCNNlA-368 - CCUCUGCAGCCCAUACC 17 4217
SCNNlA-369 + CCGAGUGAGGCUGCCCC 17 4218
SCNNlA-370 - UCUCCCCAAUCCACUCC 17 4219
SCNNlA-87 - CCUCCACAGUCCACUCC 17 608
SCNNlA-371 - AGCCUCACUCGGGUUCC 17 4220
SCNNlA-124 + AGUACUCUCCGAAAAGC 17 631
SCNNlA-260 - C A U G A AG G G G AACAAG C 17 868
SCNNlA-84 - CAUGGAGGGGAACAAGC 17 607
SCNNlA-372 + CCCUUGGAAGGGACAGC 17 4221
SCNNlA-373 - UGGGAGAAUGUGGGCGC 17 4222
SCNNlA-144 + CCUCCGCCGUGGGCUGC 17 643
SCNNlA-128 + UCUUCAUGCGGUUGUGC 17 635
SCNNlA-140 + AGCGGUGGAACUCGAUC 17 642
SCNNlA-374 - CUCUCCCCAAUCCACUC 17 4223
SCNNlA-375 - CAGGGGCAGCCUCACUC 17 4224
SCNNlA-376 + UGGGGAGAGCAAGGGUC 17 4225
SCNNlA-149 + UGGGGCGCCGCAGGUUC 17 647
SCNNlA-377 - CAGCUGUCCCUUCCAAG 17 4226
1191
5535.1 SCNNlA-91 - CUCCAGGGCUCAUGAAG 17 612
SCNNlA-378 - CUCCGGGGCUCAUGAAG 17 4227
SCNNlA-379 - CCUCACUCGGGUUCCAG 17 4228
SCNNlA-95 - ACAAGCGUGAGGAGCAG 17 614
SCNNlA-380 + CCUGGUAUGGGCUGCAG 17 4229
SCNNlA-138 + AGAGCUCUCGGUAGGAG 17 641
SCNNlA-381 + CUUCAUGAGCCCCGGAG 17 4230
SCNNlA-152 + CUUCAUGAGCCCUGGAG 17 649
SCNNlA-123 + UGAUGUUGAGGCUGACG 17 630
SCNNlA-382 - CUCCCCAAUCCACUCCG 17 4231
SCNNlA-118 + UGCAGAUGGUCACUGCG 17 626
SCNNlA-101 - CCAGCAGCCCACGGCGG 17 616
SCNNlA-383 - AGAAUGUGGGCGCAGGG 17 4232
SCNNlA-384 - CUGUCCCUUCCAAGGGG 17 4233
SCNNlA-81 - CAUACCAGGUCUCAUGG 17 605
SCNNlA-127 + AGAAGGCCGUCUUCAUG 17 634
SCNNlA-146 + UCCGCCGUGGGCUGCUG 17 645
SCNNlA-385 + CCCCUGGAACCCGAGUG 17 4234
SCNNlA-386 + CCGACCUGUAGGGAUUG 17 4235
SCNNlA-387 + AGCCCCGGAGUGGAUUG 17 4236
SCNNlA-119 + CGAGCUUGUCCGAGUUG 17 627
SCNNlA-120 + AGUUGAGGUUGAUGUUG 17 628
SCNNlA-388 + UGAGCCCCGGAGUGGAU 17 4237
SCNNlA-389 - CGGGUUCCAGGGGUGAU 17 4238
SCNNlA-158 + UCCAUGAGACCUGGUAU 17 654
SCNNlA-114 - CAACAUCAACCUCAACU 17 625
SCNNlA-97 - CGUGAGGAGCAGGGGCU 17 615
SCNNlA-145 + CUCCGCCGUGGGCUGCU 17 644
SCNNlA-129 + CUUCAUGCGGUUGUGCU 17 636
SCNNlA-136 + AGAACUCGAAGAGCUCU 17 639
SCNNlA-390 + AUGGGCUGCAGAGGUCU 17 4239
SCNNlA-108 - CAUGAAGACGGCCUUCU 17 619
SCNNlA-391 - CCUCAAUCCCUACAGGU 17 4240
SCNNlA-137 + CUCGAAGAGCUCUCGGU 17 640
SCNNlA-112 - AUGAUGUACUGGCAAUU 17 623
SCNNlA-110 - CUGUGGCUCUGCACCUU 17 621
SCNNlA-148 + CUGGGGCGCCGCAGGUU 17 646
SCNNlA-392 - AGCAAGGGAACCUGGUU 17 4241
SCNNlA-113 - CAAUUCGGCCUGCUUUU 17 624
SCNNlA-46 + UUGCCAGUACAUCAUGCCAA 20 580
SCNNlA-393 - AGCAGUAUCAAGGUAAGCAA 20 4242
SCNNlA-394 + CAUGAUACCUCCCCUUGGAA 20 4243
1192
5535.1 SCNNlA-395 - UGUGGGCGCAGGGUGGGACA 20 4244
SCNNlA-20 - UGCGGCGCCCCAGCAGCCCA 20 565
SCNNlA-25 - UGCAACAACACCACCAUCCA 20 567
SCNNlA-396 - AGUGGGAGAAUGUGGGCGCA 20 4245
SCNNlA-397 - AGGUAUCAUGAGCAGUAUCA 20 4246
SCNNlA-398 + AUUGGGGAGAGCAAGGGUCA 20 4247
SCNNlA-27 - CCAGCACAACCGCAUGAAGA 20 569
SCNNlA-53 + CUGGGAGCACACCAGGCGGA 20 585
SCNNlA-3 - CCCAUACCAGGUCUCAUGGA 20 556
SCNNlA-399 + UCAUGAUACCUCCCCUUGGA 20 4248
SCNNlA-400 - AUCCACUCCGGGGCUCAUGA 20 4249
SCNNlA-401 - CACUCGGGUUCCAGGGGUGA 20 4250
SCNNlA-402 + AACCGACCUGUAGGGAUUGA 20 4251
SCNNlA-78 + CCCCUCCAUGAGACCUGGUA 20 500
SCNNlA-43 + AGGUUGAUGUUGAGGCUGAC 20 578
SCNNlA-403 - UCUGCACCCUCAAUCCCUAC 20 4252
SCNNlA-404 - U C A AG G U A AG C A AG G G A AC C 20 4253
SCNNlA-405 - AGACCUCUGCAGCCCAUACC 20 4254
SCNNlA-406 + AACCCGAGUGAGGCUGCCCC 20 4255
SCNNlA-407 - UAGUCCCUCUGCCCCUUCCC 20 4256
SCNNlA-408 - UGCUCUCCCCAAUCCACUCC 20 4257
SCNNlA-8 - AGCCCUCCACAGUCCACUCC 20 559
SCNNlA-45 + UGAAGUACUCUCCGAAAAGC 20 579
SCNNlA-5 - UCUCAUGGAGGGGAACAAGC 20 557
SCNNlA-409 + CUCCCCUUGGAAGGGACAGC 20 4258
SCNNlA-17 - CAAGCGUGAGGAGCAGGGGC 20 563
SCNNlA-38 + AGGGUGCAGAUGGUCACUGC 20 575
SCNNlA-65 + CCUCCUCCGCCGUGGGCUGC 20 594
SCNNlA-49 + CCGUCUUCAUGCGGUUGUGC 20 582
SCNNlA-61 + AGGAGCGGUGGAACUCGAUC 20 591
SCNNlA-410 - UUGCUCUCCCCAAUCCACUC 20 4259
SCNNlA-411 + UCAGGGUCAAGGCUGAGCUC 20 4260
SCNNlA-28 - ACCGCAUGAAGACGGCCUUC 20 570
SCNNlA-70 + UGCUGGGGCGCCGCAGGUUC 20 598
SCNNlA-412 - AUCCAGCUGUCCCUUCCAAG 20 4261
SCNNlA-413 - UGGGACAUGGGCAUGGCCAG 20 4262
SCNNlA-414 - CAGCCUCACUCGGGUUCCAG 20 4263
SCNNlA-415 + AGACCUGGUAUGGGCUGCAG 20 4264
SCNNlA-59 + CGAAGAGCUCUCGGUAGGAG 20 589
SCNNlA-4 - CCAUACCAGGUCUCAUGGAG 20 498
SCNNlA-63 + CAGGGCCUCCUCCUCCGCCG 20 592
SCNNlA-52 + UGUGCUGGGAGCACACCAGG 20 584
1193
5535.1 SCNNlA-23 - CCAGCAGCCCACGGCGGAGG 20 566
SCNNlA-60 + AGAGCUCUCGGUAGGAGCGG 20 590
SCNNlA-416 - CAGCUGUCCCUUCCAAGGGG 20 4265
SCNNlA-75 + AGCCCUGGAGUGGACUGUGG 20 602
SCNNlA-48 + CCCAGAAGGCCGUCUUCAUG 20 581
SCNNlA-74 + AUGAGCCCUGGAGUGGACUG 20 601
SCNNlA-67 + UCCUCCGCCGUGGGCUGCUG 20 596
SCNNlA-417 + UCACCCCUGGAACCCGAGUG 20 4266
SCNNlA-13 - CA U G AAG GG G AAC AAG CG U G 20 562
SCNNlA-418 + UAACCGACCUGUAGGGAUUG 20 4267
SCNNlA-419 + AUGAGCCCCGGAGUGGAUUG 20 4268
SCNNlA-40 + AGACGAGCUUGUCCGAGUUG 20 576
SCNNlA-41 + CCGAGUUGAGGUUGAUGUUG 20 577
SCNNlA-420 + UCAUGAGCCCCGGAGUGGAU 20 4269
SCNNlA-421 - ACUCGGGUUCCAGGGGUGAU 20 4270
SCNNlA-79 + CCCUCCAUGAGACCUGGUAU 20 604
SCNNlA-35 - CCUCAACAUCAACCUCAACU 20 574
SCNNlA-18 - AAGCGUGAGGAGCAGGGGCU 20 564
SCNNlA-66 + CUCCUCCGCCGUGGGCUGCU 20 595
SCNNlA-50 + CGUCUUCAUGCGGUUGUGCU 20 583
SCNNlA-57 + AGAAGAACUCGAAGAGCUCU 20 588
SCNNlA-422 + CAGGGUCAAGGCUGAGCUCU 20 4271
SCNNlA-29 - CCGCAUGAAGACGGCCUUCU 20 571
SCNNlA-64 + AGGGCCUCCUCCUCCGCCGU 20 593
SCNNlA-423 - CACCCUCAAUCCCUACAGGU 20 4272
SCNNlA-424 + AGAGGGACUAACCGACCUGU 20 4273
SCNNlA-425 + CAUGAGCCCCGGAGUGGAUU 20 4274
SCNNlA-69 + CUGCUGGGGCGCCGCAGGUU 20 597
SCNNlA-34 - UGGCAAUUCGGCCUGCUUUU 20 573
Table 43C provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the third tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., with 500 bp downstream from the start codon) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogeness Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 43C
3rd Tier
1194
5535.1 Target Site gRNA Name DNA Strand Targeting Domain
Length Seq ID
SCNNlA-426 - GGACAUGGGCAUGGCCA 17 4275
SCNNlA-427 + GUGGAUUGGGGAGAGCA 17 4276
SCNNlA-428 + GGGGAGAGCAAGGGUCA 17 4277
SCNNlA-115 + GGGAUUGAGGGUGCAGA 17 542
SCNNlA-134 + GCGGAUGGCGCCGUGGA 17 548
SCNNlA-429 - GGGACAUGGGCAUGGCC 17 4278
SCNNlA-86 - GAACAAGCUGGAGGAGC 17 531
SCNNlA-96 - GCGUGAGGAGCAGGGGC 17 534
SCNNlA-430 + GGGUCAAGGCUGAGCUC 17 4279
SCNNlA-100 - GCCCCAGCAGCCCACGG 17 537
SCNNlA-135 + GAUGGCGCCGUGGAUGG 17 549
SCNNlA-431 - GAAGGGGAACAAGCUGG 17 4280
SCNNlA-85 - GGAGGGGAACAAGCUGG 17 530
SCNNlA-92 - GAAGGGGAACAAGCGUG 17 532
SCNNlA-432 + GAGUGGAUUGGGGAGAGCAA 20 4281
SCNNlA-9 - GCCCUCCACAGUCCACUCCA 20 499
SCNNlA-433 + GGAGUGGAUUGGGGAGAGCA 20 4282
SCNNlA-434 + GAGAGCAAGGGUCAGGGUCA 20 4283
SCNNlA-47 + GAGCCACAGCACUGCCCAGA 20 521
SCNNlA-435 - GUUCCAGGGGUGAUGGGAGA 20 4284
SCNNlA-7 - GGGGAACAAGCUGGAGGAGC 20 504
SCNNlA-14 - GGGGAACAAGCGUGAGGAGC 20 506
SCNNlA-436 - GGUUCCAGGGGUGAUGGGAG 20 4285
SCNNlA-24 - GCAGCCCACGGCGGAGGAGG 20 512
SCNNlA-56 + GCGGAUGGCGCCGUGGAUGG 20 523
SCNNlA-437 - GUAAGCAAGGGAACCUGGUU 20 4286
Table 43D provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., with 500 bp downstream from the start codon). It is
contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogeness Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 43D
Figure imgf001196_0001
1195
5535.1 Length
SCNNlA-438 + UGGAUUGGGGAGAGCAA 17 4287
SCNNlA-439 - UCCAGCUGUCCCUUCCA 17 4288
SCNNlA-440 - AGGGUGGGACAUGGGCA 17 4289
SCNNlA-441 + AGCAAGGGUCAGGGUCA 17 4290
SCNNlA-442 + ACCAGGGAAGGGGCAGA 17 4291
SCNNlA-443 - CCAGGGGUGAUGGGAGA 17 4292
SCNNlA-155 + CUGGAGUGGACUGUGGA 17 652
SCNNlA-444 + UGGGCUGCAGAGGUCUA 17 4293
SCNNlA-445 - AGGUAAGCAAGGGAACC 17 4294
SCNNlA-446 + CCCUCUCCCAUCACCCC 17 4295
SCNNlA-151 + UUCCCCUUCAUGAGCCC 17 648
SCNNlA-447 - UCCCUCUGCCCCUUCCC 17 4296
SCNNlA-105 - CCACGGCGCCAUCCGCC 17 618
SCNNlA-448 - UCCAGGGGUGAUGGGAG 17 4297
SCNNlA-83 - UACCAGGUCUCAUGGAG 17 606
SCNNlA-133 + CCAGGCGGAUGGCGCCG 17 638
SCNNlA-154 + CCUGGAGUGGACUGUGG 17 651
SCNNlA-153 + AGCCCUGGAGUGGACUG 17 650
SCNNlA-109 - CCUUCUGGGCAGUGCUG 17 620
SCNNlA-449 - CCAGGGGCAGCCUCACU 17 4298
SCNNlA-450 + CUCAUGAUACCUCCCCU 17 4299
SCNNlA-11 - UCCACUCCAGGGCUCAUGAA 20 560
SCNNlA-451 - UCCACUCCGGGGCUCAUGAA 20 4300
SCNNlA-452 - CGCAGGGUGGGACAUGGGCA 20 4301
SCNNlA-55 + CAGGCGGAUGGCGCCGUGGA 20 587
SCNNlA-77 + UUGUUCCCCUCCAUGAGACC 20 603
SCNNlA-72 + UUGUUCCCCUUCAUGAGCCC 20 599
SCNNlA-26 - CAUCCACGGCGCCAUCCGCC 20 568
SCNNlA-12 - CCACUCCAGGGCUCAUGAAG 20 561
SCNNlA-453 - CCACUCCGGGGCUCAUGAAG 20 4302
SCNNlA-454 + CCCCUUCAUGAGCCCCGGAG 20 4303
SCNNlA-73 + CCCCUUCAUGAGCCCUGGAG 20 600
SCNNlA-54 + ACACCAGGCGGAUGGCGCCG 20 586
SCNNlA-455 - CAUGAAGGGGAACAAGCUGG 20 4304
SCNNlA-6 - CAUGGAGGGGAACAAGCUGG 20 558
SCNNlA-30 - CGGCCUUCUGGGCAGUGCUG 20 572
SCNNlA-456 - UGGCCAGGGGCAGCCUCACU 20 4305
SCNNlA-457 + CUGCUCAUGAUACCUCCCCU 20 4306
Table 43E provides exemplary targeting domains for knocking out the SCNNIA gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence
1196
5535.1 of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogeness Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 43E
Figure imgf001198_0001
1197
5535.1 SCNNlA-489 + GUUGUUGAUUCCAGGCA 17 4338
SCNNlA-490 + CCAGGGUGGCAUAGGCA 17 4339
SCNNlA-491 - UCCAGGCCGAGGGGGCA 17 4340
SCNNlA-492 + GGGGACACUAACCUGCA 17 4341
SCNNlA-493 + GACCCUCAGGCGCUGCA 17 4342
SCNNlA-494 - CUCCAGGGGGCUCUGCA 17 4343
SCNNlA-495 - GCCCGGGUAAUGGUGCA 17 4344
SCNNlA-496 + CUCUGCGCGCAGCAUCA 17 4345
SCNNlA-497 - ACCAGACAUACUCAUCA 17 4346
SCNNlA-498 + GAAUGGGGGUGUCAUCA 17 4347
SCNNlA-499 - CCAGGAGAGCAUGAUCA 17 4348
SCNNlA-500 - GUCCCGCCCCCGCCUCA 17 4349
SCNNlA-501 + CCUCUCCUUCCCUCUCA 17 4350
SCNNlA-502 + AGGGGGAGGGGCUGUCA 17 4351
SCNNlA-503 - UGAGUCUCCCUCUGUCA 17 4352
SCNNlA-504 - AGUCAACAUCUUCUUCA 17 4353
SCNNlA-505 + AAGGGGCGAGGGGAAGA 17 4354
SCNNlA-506 - ACCUCUCCUCUCACAGA 17 4355
SCNNlA-507 + CGACCUACCGUGACAGA 17 4356
SCNNlA-508 + CUUAGGUGUGGGGCAGA 17 4357
SCNNlA-509 + CAGAGACUAGAGUCAGA 17 4358
SCNNlA-510 + GGAGGGUGGAGAGGAGA 17 4359
SCNNlA-511 + GCAGAGCCCCCUGGAGA 17 4360
SCNNlA-512 + GCUGUCAAGGCUGGAGA 17 4361
SCNNlA-513 - GUUGUCUGUGGUGGAGA 17 4362
SCNNlA-514 - CUGGGGGGGCCCUGAGA 17 4363
SCNNlA-515 - CUGCUGGUUACUCACGA 17 4364
SCNNlA-516 + GAGAGGUACAUUGACGA 17 4365
SCNNlA-517 + ACCUGGGAUGUCACCGA 17 4366
SCNNlA-518 - GAGGCCCGCAGCGCCGA 17 4367
SCNNlA-519 - ACUGGUCUCCAGGCCGA 17 4368
SCNNlA-520 - UCCUCAUGCUGCUCCGA 17 4369
SCNNlA-521 + UCCCCCGCAGGUCGCGA 17 4370
SCNNlA-522 + GGUACCUGAAGGGGCGA 17 4371
SCNNlA-523 + CCACGCUACGGGCUCGA 17 4372
SCNNlA-524 + GGCAGAAGUGGGAAGGA 17 4373
SCNNlA-525 + GCCCAGGUUGGACAGGA 17 4374
SCNNlA-526 + ACACCUGGAAGGGAGGA 17 4375
SCNNlA-527 - CUCCAUCAGCAUGAGGA 17 4376
SCNNlA-528 - AGAGUGUGGGGAAGGGA 17 4377
SCNNlA-529 + GUGUCCUCCUCCAGGGA 17 4378
SCNNlA-530 - GGGGGCCCUGAGAGGGA 17 4379
1198
5535.1 SCNNlA-531 + CAACCUGUACCCGGGGA 17 4380
SCNNlA-532 + UGGCAUAGGCAGGGGGA 17 4381
SCNNlA-533 + GCUGGUCACGCUGGGGA 17 4382
SCNNlA-534 - CAGGUAGAGUGUGGGGA 17 4383
SCNNlA-535 + UGGGGGCAGAAGUGGGA 17 4384
SCNNlA-536 - CCCCCAGGUGGACUGGA 17 4385
SCNNlA-537 + GUGAAUACACACCUGGA 17 4386
SCNNlA-538 - UGACUGGGAGGCCUGGA 17 4387
SCNNlA-539 - GGUAGGUCGUGCCUGGA 17 4388
SCNNlA-540 - CCUGCCUUUAUGGAUGA 17 4389
SCNNlA-541 + AAUUUCCGGGUACCUGA 17 4390
SCNNlA-542 - CCCCUUGCAGCGCCUGA 17 4391
SCNNlA-543 + UGCCUUCCUCAUGCUGA 17 4392
SCNNlA-544 - AGGGGUGGAUGCGGUGA 17 4393
SCNNlA-545 + GGCCACGAGAGUGGUGA 17 4394
SCNNlA-546 + UGACCUCUUGUUGUUGA 17 4395
SCNNlA-547 + UGCUGUGUGUACUUUGA 17 4396
SCNNlA-548 - CUCUCUCUUUCCUGAUA 17 4397
SCNNlA-549 + CAUCAGGGACAGACCUA 17 4398
SCNNlA-550 + AGCUGGAGGCCACGCUA 17 4399
SCNNlA-551 + UCAGGAAAGAGAGAGUA 17 4400
SCNNlA-552 - UUCCACCACCCGAUGUA 17 4401
SCNNlA-553 - AGACUUGGGGGCGAUUA 17 4402
SCNNlA-554 - GGAUGAACCUGCCUUUA 17 4403
SCNNlA-555 + GGGUAAAGGUUCUCAAC 17 4404
SCNNlA-556 + AGGACAGGUGGAGGAAC 17 4405
SCNNlA-557 + CCGAGGAGCCGAACCAC 17 4406
SCNNlA-558 - CAUCUCUCUGUACCCAC 17 4407
SCNNlA-559 + CGAACCACAGGCUCCAC 17 4408
SCNNlA-560 - CCCGGGUAAUGGUGCAC 17 4409
SCNNlA-561 + AUUUGUUCUGGUUGCAC 17 4410
SCNNlA-562 - UCCCGCCCCCGCCUCAC 17 4411
SCNNlA-563 + UCUCUGGCAGCCUCGAC 17 4412
SCNNlA-564 + CACGCUACGGGCUCGAC 17 4413
SCNNlA-565 - AGGUGGACUGGAAGGAC 17 4414
SCNNlA-566 + GGGCCCCCCCAGAGGAC 17 4415
SCNNlA-567 - ACAACCCCCAGGUGGAC 17 4416
SCNNlA-568 + GGCUGCCCAGGUUGGAC 17 4417
SCNNlA-569 - AAGGCAAGGAUGCUGAC 17 4418
SCNNlA-570 - CUGCUGUCCACAGUGAC 17 4419
SCNNlA-571 - GGUUCCGAAGCCGAUAC 17 4420
SCNNlA-572 + GCUGGAGGCCACGCUAC 17 4421
1199
5535.1 SCNNlA-573 - UCCCCUUCCCCGGGUAC 17 4422
SCNNlA-574 + AGGAGCUGUAUUUGUAC 17 4423
SCNNlA-575 - CACCCUCCUGUCCAACC 17 4424
SCNNlA-576 - CCAGGUCUCCUGCAACC 17 4425
SCNNlA-577 + CUGAGGAGAAGUCAACC 17 4426
SCNNlA-578 - CGCCUGCCGCUUCAACC 17 4427
SCNNlA-579 + AGGAGUGAAUACACACC 17 4428
SCNNlA-580 - CUUCUCCUCAGACCACC 17 4429
SCNNlA-581 + AGUCCUUCCAGUCCACC 17 4430
SCNNlA-582 + CCUGGUUGCAGGAGACC 17 4431
SCNNlA-583 + CUUCCCCACACUCUACC 17 4432
SCNNlA-584 - UCGCCCCUUCAGGUACC 17 4433
SCNNlA-585 + GCCCGUGCACCAUUACC 17 4434
SCNNlA-586 - GGGUUCAUAGGAAACCC 17 4435
SCNNlA-587 - CCCUGCCUAUGCCACCC 17 4436
SCNNlA-588 - GGAGGUAGCCUCCACCC 17 4437
SCNNlA-589 + CCCGUGCACCAUUACCC 17 4438
SCNNlA-590 + CCCUGGAGUCUCACCCC 17 4439
SCNNlA-591 - GCGGGACAACAACCCCC 17 4440
SCNNlA-592 + GCCCCUGCAGAGCCCCC 17 4441
SCNNlA-593 - UUAGUGUCCCCUUCCCC 17 4442
SCNNlA-594 + ACUUGGUGAAACAGCCC 17 4443
SCNNlA-595 + GAGAUGGGCGGGGGCCC 17 4444
SCNNlA-596 - CACAGUGACUGGGGCCC 17 4445
SCNNlA-597 - AGAGGUCAGUCCUGCCC 17 4446
SCNNlA-598 + GGCUCCACUGGCUGCCC 17 4447
SCNNlA-599 - GCCCUCGGUGACAUCCC 17 4448
SCNNlA-600 - AGAGACUCUGCCAUCCC 17 4449
SCNNlA-601 + GCAGGGUGGGGGCUCCC 17 4450
SCNNlA-602 - GUUAGUGUCCCCUUCCC 17 4451
SCNNlA-603 - CUGUCCUUGUCCCAGCC 17 4452
SCNNlA-604 + AUGGAGGUCUCCACGCC 17 4453
SCNNlA-605 + CAGGACUGACUCACGCC 17 4454
SCNNlA-606 - AUGCUGACUGGGAGGCC 17 4455
SCNNlA-607 - GGCUUUAACUUGCGGCC 17 4456
SCNNlA-608 + CCCCUGCCCCCUCGGCC 17 4457
SCNNlA-609 + GGAGAGGGAGCAGGGCC 17 4458
SCNNlA-610 - CCACAGUGACUGGGGCC 17 4459
SCNNlA-611 - UGGAUGUCUUCCAUGCC 17 4460
SCNNlA-612 + AAGGAGGGGAGGAUGCC 17 4461
SCNNlA-613 - CGUGAGUCAGUCCUGCC 17 4462
SCNNlA-614 - UCACGGUAGGUCGUGCC 17 4463
1200
5535.1 SCNNlA-615 + CAUCACAGGCUCCAUCC 17 4464
SCNNlA-616 - UCCUGGGGUGAGACUCC 17 4465
SCNNlA-617 + CCAGCGUGUCCUCCUCC 17 4466
SCNNlA-618 - CUGCUACUAUAAGCUCC 17 4467
SCNNlA-619 - GGCCCCCGCCCAUCUCC 17 4468
SCNNlA-620 + CCUUGAUCAUGCUCUCC 17 4469
SCNNlA-621 - AGCCGAUACUGGUCUCC 17 4470
SCNNlA-622 + CGCCCCCAAGUCUGUCC 17 4471
SCNNlA-623 + UCACCGUUGUUGAUUCC 17 4472
SCNNlA-624 - CCACCCUCCUCCCUUCC 17 4473
SCNNlA-625 - UAUUCACUCCUGCUUCC 17 4474
SCNNlA-626 - ACAGAAAG CACAG U U CC 17 4475
SCNNlA-627 + GCUCCUCUUUAAUUUCC 17 4476
SCNNlA-628 + GGCGCCAUGGAGCAAGC 17 4477
SCNNlA-629 + GUUGUUGUCCCGCAAGC 17 4478
SCNNlA-630 + CAUGCUCUCCUGGAAGC 17 4479
SCNNlA-631 - U U C AAAG U AC ACAC AG C 17 4480
SCNNlA-632 + CAGUCACUGUGGACAGC 17 4481
SCNNlA-633 + CUGCGGGCCUCACCAGC 17 4482
SCNNlA-634 + GGAACAUGAUGACCAGC 17 4483
SCNNlA-635 - GAAGAUCGGCUUCCAGC 17 4484
SCNNlA-636 + AGUAACCAGCAGAGAGC 17 4485
SCNNlA-637 - GGAAAUUAAAGAGGAGC 17 4486
SCNNlA-638 - AGAGGAGCUGGAGGAGC 17 4487
SCNNlA-639 + AAGGCUGGAGAGGGAGC 17 4488
SCNNlA-640 + GCGACGGCUGCGGGAGC 17 4489
SCNNlA-641 + AGCAGAGAGCUGGUAGC 17 4490
SCNNlA-642 - CCUGGAGGAGGACACGC 17 4491
SCNNlA-643 + CUGGUAGCUGGUCACGC 17 4492
SCNNlA-644 + GCGGCAGAGUCCCCCGC 17 4493
SCNNlA-645 + CCAUCAUCCAUAAAGGC 17 4494
SCNNlA-646 + GGAGGGGCUGUCAAGGC 17 4495
SCNNlA-647 + AGAGCAAGGAGCCAGGC 17 4496
SCNNlA-648 + GACGGGCCCCGUGAGGC 17 4497
SCNNlA-649 + CCCAGGGUGGCAUAGGC 17 4498
SCNNlA-650 + GACCUGGUUGAAGCGGC 17 4499
SCNNlA-651 + GUGGCUGGGACCAGGGC 17 4500
SCNNlA-652 - GGUAAUGGUGCACGGGC 17 4501
SCNNlA-653 - CUCCAGGCCGAGGGGGC 17 4502
SCNNlA-654 + CCCCGUGAGGCGGGGGC 17 4503
SCNNlA-655 + GCCCCCUGGAGAUGGGC 17 4504
SCNNlA-656 + AGGGAGCAGGGCCUGGC 17 4505
1201
5535.1 SCNNlA-657 - UUCACCACUCUCGUGGC 17 4506
SCNNlA-658 - AGUGCCGGAAGCCAUGC 17 4507
SCNNlA-659 - CAGCCGUCGCGACCUGC 17 4508
SCNNlA-660 - GCUCGUCUUUGACCUGC 17 4509
SCNNlA-661 + GGGCCCCUCGGCGCUGC 17 4510
SCNNlA-662 + CAGGUCGCGACGGCUGC 17 4511
SCNNlA-663 - UCUCCAGGGGGCUCUGC 17 4512
SCNNlA-664 - AGCUACCAGCUCUCUGC 17 4513
SCNNlA-665 - GCUGUUUCACCAAGUGC 17 4514
SCNNlA-666 - CGUGGCCUCCAGCUUGC 17 4515
SCNNlA-667 + GACUCACGCCUGGUUGC 17 4516
SCNNlA-668 + AGCAGUUUCCAUACAUC 17 4517
SCNNlA-669 + GCUCUGCGCGCAGCAUC 17 4518
SCNNlA-670 + UCUGUCGCGAUAGCAUC 17 4519
SCNNlA-671 - UACCAGACAUACUCAUC 17 4520
SCNNlA-672 + GAGAGUAAUUCCUUAUC 17 4521
SCNNlA-673 - AGAACAACUCCAACCUC 17 4522
SCNNlA-674 + GCGGGGGCGGGACCCUC 17 4523
SCNNlA-675 - UUCCUCCACCUGUCCUC 17 4524
SCNNlA-676 - AGGGGGCAGGGGUGCUC 17 4525
SCNNlA-677 + ACCUCUCCUUCCCUCUC 17 4526
SCNNlA-678 + AGGGAUGGCAGAGUCUC 17 4527
SCNNlA-679 + GCGAGGGGAAGAGGGUC 17 4528
SCNNlA-680 + CCCCUGAUGAGUAUGUC 17 4529
SCNNlA-681 - CUUCCCCUCGCCCCUUC 17 4530
SCNNlA-682 + CUAACCUGCAUGGCUUC 17 4531
SCNNlA-683 + CACAGUACUCCACGUUC 17 4532
SCNNlA-684 + AGCAGUCCGAUUUGUUC 17 4533
SCNNlA-685 + AGCUCCUCUUUAAUUUC 17 4534
SCNNlA-686 - G U ACCCGG AAAU UAAAG 17 4535
SCNNlA-687 - AC ACCG U C AACAAC AAG 17 4536
SCNNlA-688 + CCCUCAGGCGCUGCAAG 17 4537
SCNNlA-689 + UGGGGUGGGGGCAGAAG 17 4538
SCNNlA-690 + GAAGGGGCGAGGGGAAG 17 4539
SCNNlA-691 + ACCUGUACCCGGGGAAG 17 4540
SCNNlA-692 + UGUUGAUGUAGUGGAAG 17 4541
SCNNlA-693 + UUUCCGGGUACCUGAAG 17 4542
SCNNlA-694 + AGGAGACCUGGUUGAAG 17 4543
SCNNlA-695 + ACGACCUACCGUGACAG 17 4544
SCNNlA-696 + UCUCAGGGCCCCCCCAG 17 4545
SCNNlA-697 - CCAACCUGGGCAGCCAG 17 4546
SCNNlA-698 + GCAUGGAAGACAUCCAG 17 4547
1202
5535.1 SCNNlA-699 - CCCCCGCCCAUCUCCAG 17 4548
SCNNlA-700 + GUCACUGUGGACAGCAG 17 4549
SCNNlA-701 + CAGGGUGGCAUAGGCAG 17 4550
SCNNlA-702 - CCAGGCCGAGGGGGCAG 17 4551
SCNNlA-703 + UCUUAGGUGUGGGGCAG 17 4552
SCNNlA-704 - UCCAGGGGGCUCUGCAG 17 4553
SCNNlA-705 - CCAGACAUACUCAUCAG 17 4554
SCNNlA-706 + ACAGAGACUAGAGUCAG 17 4555
SCNNlA-707 + AGAGACUAGAGUCAGAG 17 4556
SCNNlA-708 + GGAGCCGGCCACGAGAG 17 4557
SCNNlA-709 - AGGCCCGCAGCGCCGAG 17 4558
SCNNlA-710 - CUGGUCUCCAGGCCGAG 17 4559
SCNNlA-711 + GUACCUGAAGGGGCGAG 17 4560
SCNNlA-712 - CCCUGAGAGGGAAGGAG 17 4561
SCNNlA-713 + GCAGAAGUGGGAAGGAG 17 4562
SCNNlA-714 + AGGAGGGUGGAGAGGAG 17 4563
SCNNlA-715 + ACCAUCUGUGAGAGGAG 17 4564
SCNNlA-716 - UGGAUGCGGUGAGGGAG 17 4565
SCNNlA-717 + GGCAUAGGCAGGGGGAG 17 4566
SCNNlA-718 - ACACCUAAGAAAUGGAG 17 4567
SCNNlA-719 + GGCUGUCAAGGCUGGAG 17 4568
SCNNlA-720 + AAGGGAGGAGGGUGGAG 17 4569
SCNNlA-721 - UCUGGGGGGGCCCUGAG 17 4570
SCNNlA-722 + GGGUGACCAUCUGUGAG 17 4571
SCNNlA-723 + AUCAGGGACAGACCUAG 17 4572
SCNNlA-724 + ACAGGAUGUUGAUGUAG 17 4573
SCNNlA-725 - UCCGCGGCCCCAGAACG 17 4574
SCNNlA-726 - CCCGCCCCCGCCUCACG 17 4575
SCNNlA-727 + CACCACAGACAACACCG 17 4576
SCNNlA-728 + UACCUGGGAUGUCACCG 17 4577
SCNNlA-729 - UGAGGCCCGCAGCGCCG 17 4578
SCNNlA-730 - UACUGGUCUCCAGGCCG 17 4579
SCNNlA-731 + UCCACGUUCUGGGGCCG 17 4580
SCNNlA-732 - CCUACAUCUUCUAUCCG 17 4581
SCNNlA-733 - GGCCCAACCUGAUUCCG 17 4582
SCNNlA-734 - CCGUCGAGCCCGUAGCG 17 4583
SCNNlA-735 + ACGGGCCCCGUGAGGCG 17 4584
SCNNlA-736 + GGGUACCUGAAGGGGCG 17 4585
SCNNlA-737 + CCCCCUGGAGAUGGGCG 17 4586
SCNNlA-738 - UAACUUGCGGCCUGGCG 17 4587
SCNNlA-739 - AGCCGUCGCGACCUGCG 17 4588
SCNNlA-740 - CUCCUUCACCACUCUCG 17 4589
1203
5535.1 SCNNlA-741 - ACAUCAACAUCCUGUCG 17 4590
SCNNlA-742 + GGGCAGAAGUGGGAAGG 17 4591
SCNNlA-743 + CCCCCCCAGAGGACAGG 17 4592
SCNNlA-744 + UGCCCAGGUUGGACAGG 17 4593
SCNNlA-745 - GGACAACAACCCCCAGG 17 4594
SCNNlA-746 + UGGUGAAACAGCCCAGG 17 4595
SCNNlA-747 - CCCCGCCCAUCUCCAGG 17 4596
SCNNlA-748 + AGGGUGGCAUAGGCAGG 17 4597
SCNNlA-749 - GGGCAGGGGUGCUCAGG 17 4598
SCNNlA-750 - UGGUCUCCAGGCCGAGG 17 4599
SCNNlA-751 + CACACCUGGAAGGGAGG 17 4600
SCNNlA-752 - UCUGCCAUCCCUGGAGG 17 4601
SCNNlA-753 + CGACGGGCCCCGUGAGG 17 4602
SCNNlA-754 + CGGGCCCCGUGAGGCGG 17 4603
SCNNlA-755 + CCCCUGGAGAUGGGCGG 17 4604
SCNNlA-756 - GCCGUCGCGACCUGCGG 17 4605
SCNNlA-757 + AUACACACCUGGAAGGG 17 4606
SCNNlA-758 + UGGGCGGGGGCCCAGGG 17 4607
SCNNlA-759 + AGGGGAGGAUGCCAGGG 17 4608
SCNNlA-760 + AGGUGUGGGGCAGAGGG 17 4609
SCNNlA-761 + CCUGGAAGGGAGGAGGG 17 4610
SCNNlA-762 + AGUUUCCAUACAUCGGG 17 4611
SCNNlA-763 - GACAUACUCAUCAGGGG 17 4612
SCNNlA-764 + GAAGUGGGAAGGAGGGG 17 4613
SCNNlA-765 + GUGGCAUAGGCAGGGGG 17 4614
SCNNlA-766 + GCCCCGUGAGGCGGGGG 17 4615
SCNNlA-767 + AGGACAGAGACAUGGGG 17 4616
SCNNlA-768 - CCACCUGUCCUCUGGGG 17 4617
SCNNlA-769 + AGCCCCCUGGAGAUGGG 17 4618
SCNNlA-770 - UGUGGGGAAGGGAUGGG 17 4619
SCNNlA-771 - CAAGGAUGCUGACUGGG 17 4620
SCNNlA-772 - UCCACCUGUCCUCUGGG 17 4621
SCNNlA-773 + UUCCUAGGAAAGAAUGG 17 4622
SCNNlA-774 - GCCUUUAUGGAUGAUGG 17 4623
SCNNlA-775 + CUUCCUCAUGCUGAUGG 17 4624
SCNNlA-776 + CCUUCCAGUCCACCUGG 17 4625
SCNNlA-777 - GACUCUGCCAUCCCUGG 17 4626
SCNNlA-778 + GUUGUCCCGCAAGCUGG 17 4627
SCNNlA-779 - AAUUAAAGAGGAGCUGG 17 4628
SCNNlA-780 - CUCCACCUGUCCUCUGG 17 4629
SCNNlA-781 + CCCCAGAGGACAGGUGG 17 4630
SCNNlA-782 + GGAGGAUGCCAGGGUGG 17 4631
1204
5535.1 SCNNlA-783 + UUCCAUACAUCGGGUGG 17 4632
SCNNlA-784 + ACAGAGACAUGGGGUGG 17 4633
SCNNlA-785 - GGGGAAGGGAUGGGUGG 17 4634
SCNNlA-786 - CUCGGUGUUGUCUGUGG 17 4635
SCNNlA-787 - ACCCUGGACAGACUUGG 17 4636
SCNNlA-788 + AUUCCUAGGAAAGAAUG 17 4637
SCNNlA-789 + ACAAGGACAGAGACAUG 17 4638
SCNNlA-790 + ACCUUCGGAGCAGCAUG 17 4639
SCNNlA-791 - AGACCUCCAUCAGCAUG 17 4640
SCNNlA-792 - CUCAUCAGGGGUGGAUG 17 4641
SCNNlA-793 + GCGUCUGCUCUGUGAUG 17 4642
SCNNlA-794 - UGAUCUCUUGGUGUAUG 17 4643
SCNNlA-795 + CCGGGCCCCAGUCACUG 17 4644
SCNNlA-796 - GCUGUCCACAGUGACUG 17 4645
SCNNlA-797 + UCCUUCCAGUCCACCUG 17 4646
SCNNlA-798 - GCAGCCGUCGCGACCUG 17 4647
SCNNlA-799 + AUAGUAGCAGUACCCUG 17 4648
SCNNlA-800 - GCAGCCAGUGGAGCCUG 17 4649
SCNNlA-801 - ACCCCUUGCAGCGCCUG 17 4650
SCNNlA-802 - AG AAAG C ACAG U U CC U G 17 4651
SCNNlA-803 + GGUAGCUGGUCACGCUG 17 4652
SCNNlA-804 + CGGGCCCCUCGGCGCUG 17 4653
SCNNlA-805 + GCAGGUCGCGACGGCUG 17 4654
SCNNlA-806 - CCUCCACCUGUCCUCUG 17 4655
SCNNlA-807 + ACAGCCCAGGUGGUCUG 17 4656
SCNNlA-808 - CUCCUCGGUGUUGUCUG 17 4657
SCNNlA-809 + CAGUACUCCACGUUCUG 17 4658
SCNNlA-810 - ACAU CCCAGG U AG AG UG 17 4659
SCNNlA-811 - AGCAUGAUCAAGGAGUG 17 4660
SCNNlA-812 + GCUCGACGGGCCCCGUG 17 4661
SCNNlA-813 - AGUACACACAGCAGGUG 17 4662
SCNNlA-814 + ACUCCAUUUCUUAGGUG 17 4663
SCNNlA-815 - CAGGGGUGGAUGCGGUG 17 4664
SCNNlA-816 + AGGCGCUGCAAGGGGUG 17 4665
SCNNlA-817 + GACAGAGACAUGGGGUG 17 4666
SCNNlA-818 - UGGGGAAGGGAUGGGUG 17 4667
SCNNlA-819 - UCGGCUUCCAGCUGGUG 17 4668
SCNNlA-820 - AUCCCAGGUAGAGUGUG 17 4669
SCNNlA-821 + UCCAUUUCUUAGGUGUG 17 4670
SCNNlA-822 - AUGGUGGCUUUAACUUG 17 4671
SCNNlA-823 - AACCCUGGACAGACUUG 17 4672
SCNNlA-824 - GCGUGGCCUCCAGCUUG 17 4673
1205
5535.1 SCNNlA-825 - G U G C AACC AG AAC AAAU 17 4674
SCNNlA-826 + CAUUCCUAGGAAAGAAU 17 4675
SCNNlA-827 + AGAGGGAGACUCAGAAU 17 4676
SCNNlA-828 - CAUUCUUUCCUAGGAAU 17 4677
SCNNlA-829 + GACAAGGACAGAGACAU 17 4678
SCNNlA-830 + UAGCAGUUUCCAUACAU 17 4679
SCNNlA-831 + GGGGCCCAGGGUGGCAU 17 4680
SCNNlA-832 - GGUGUAUGUGGGUUCAU 17 4681
SCNNlA-833 - UGGAAGGACUGGAAGAU 17 4682
SCNNlA-834 + CAGAGCCCCCUGGAGAU 17 4683
SCNNlA-835 + AGAGGUACAUUGACGAU 17 4684
SCNNlA-836 - GAGUGUGGGGAAGGGAU 17 4685
SCNNlA-837 + GGCCUGGAGACCAGUAU 17 4686
SCNNlA-838 + GCAUGGCUUCCGGCACU 17 4687
SCNNlA-839 - GAAACCCUGGACAGACU 17 4688
SCNNlA-840 - AGGCAAGGAUGCUGACU 17 4689
SCNNlA-841 - UGCUGUCCACAGUGACU 17 4690
SCNNlA-842 - ACCCUCCUGUCCAACCU 17 4691
SCNNlA-843 - UUCUCCUCAGACCACCU 17 4692
SCNNlA-844 + GUCCUUCCAGUCCACCU 17 4693
SCNNlA-845 + GCAUCAGGGACAGACCU 17 4694
SCNNlA-846 + UUCCCCACACUCUACCU 17 4695
SCNNlA-847 - CCUGCCUAUGCCACCCU 17 4696
SCNNlA-848 - GCUCUCUCUGCACCCCU 17 4697
SCNNlA-849 + GAGCACCCCUGCCCCCU 17 4698
SCNNlA-850 - UUACUCACGAUGGCCCU 17 4699
SCNNlA-851 - CCUGUGGUUCGGCUCCU 17 4700
SCNNlA-852 + CUGGAAGACCCAUUCCU 17 4701
SCNNlA-853 - C AG A A AG C ACAG U U CC U 17 4702
SCNNlA-854 - CACCCCCAUUCUUUCCU 17 4703
SCNNlA-855 - CUGGAGGAGGACACGCU 17 4704
SCNNlA-856 + UGGUAGCUGGUCACGCU 17 4705
SCNNlA-857 + GGGAGCAGGGCCUGGCU 17 4706
SCNNlA-858 - UCCUCCACCUGUCCUCU 17 4707
SCNNlA-859 + AACAUCACUGCCAUUCU 17 4708
SCNNlA-860 + ACAGUACUCCACGUUCU 17 4709
SCNNlA-861 + GGGGUGGGGGCAGAAGU 17 4710
SCNNlA-862 + UGCAGAGAGAGCAGAGU 17 4711
SCNNlA-863 + AUCAGGAAAGAGAGAGU 17 4712
SCNNlA-864 + CCACUGGCUGCCCAGGU 17 4713
SCNNlA-865 + CUGCCACGGAAUCAGGU 17 4714
SCNNlA-866 + GGAAGACAUCCAGAGGU 17 4715
1206
5535.1 SCNNlA-867 - UCUCCCUCUGUCACGGU 17 4716
SCNNlA-868 + GGUGUGGGGCAGAGGGU 17 4717
SCNNlA-869 + GGACAGAGACAUGGGGU 17 4718
SCNNlA-870 - GUGGGGAAGGGAUGGGU 17 4719
SCNNlA-871 + CCGCGGAUAGAAGAUGU 17 4720
SCNNlA-872 - GAUCUCUUGGUGUAUGU 17 4721
SCNNlA-873 + UAGUAGCAGUACCCUGU 17 4722
SCNNlA-874 + AGAAAGGUGCUCAGUGU 17 4723
SCNNlA-875 - CAUCCCAGGUAGAGUGU 17 4724
SCNNlA-876 + CUCCAUUUCUUAGGUGU 17 4725
SCNNlA-877 - AAACCCUGGACAGACUU 17 4726
SCNNlA-878 + GAAGAAGAUGUUGACUU 17 4727
SCNNlA-879 + AUCGGCUUCGGAACCUU 17 4728
SCNNlA-880 + GAGACCAGUAUCGGCUU 17 4729
SCNNlA-881 + UGGCCACUCCAUUUCUU 17 4730
SCNNlA-882 + UGCCACGGAAUCAGGUU 17 4731
SCNNlA-883 - CAGUGGAGCCUGUGGUU 17 4732
SCNNlA-884 - UCUGCCCCACACCUAAGAAA 20 4733
SCNNlA-885 - UCCAUGCCUGGAAUCAACAA 20 4734
SCNNlA-886 + GGGACCCUCAGGCGCUGCAA 20 4735
SCNNlA-887 + GACCCAUUCCUAGGAAAGAA 20 4736
SCNNlA-888 - UAUGGCGACUGCACCAAGAA 20 4737
SCNNlA-889 + GUCACGCUGGGGAUGGAGAA 20 4738
SCNNlA-890 - CCCCCAUUCUUUCCUAGGAA 20 4739
SCNNlA-891 - CCCAGGUAGAGUGUGGGGAA 20 4740
SCNNlA-892 + GAGUGAAUACACACCUGGAA 20 4741
SCNNlA-893 + UUAAUUUCCGGGUACCUGAA 20 4742
SCNNlA-894 + CCUGCUGUGUGUACUUUGAA 20 4743
SCNNlA-895 + AAAGCCACCAUCAUCCAUAA 20 4744
SCNNlA-896 + GUGUGUACUUUGAAGGGUAA 20 4745
SCNNlA-897 - AGUGACUGGGGCCCGGGUAA 20 4746
SCNNlA-898 - GGCAUCUCUCUGUACCCACA 20 4747
SCNNlA-899 + CUGGGACAAGGACAGAGACA 20 4748
SCNNlA-900 + AGCAGGGCCUGGCUGGGACA 20 4749
SCNNlA-901 - AGGAGAGGUUUCUCACACCA 20 4750
SCNNlA-902 + UGGAGAUGGGCGGGGGCCCA 20 4751
SCNNlA-903 + GGAAGGAGGGGAGGAUGCCA 20 4752
SCNNlA-904 - GUUCCUGGGGUGAGACUCCA 20 4753
SCNNlA-905 + GCCCAGCGUGUCCUCCUCCA 20 4754
SCNNlA-906 - GAAGCUCCCUGCUUGCUCCA 20 4755
SCNNlA-907 - UGGGCCCCCGCCCAUCUCCA 20 4756
SCNNlA-908 + AUCGCCCCCAAGUCUGUCCA 20 4757
1207
5535.1 SCNNlA-909 + AGGGCGCCAUGGAGCAAGCA 20 4758
SCNNlA-910 + CCCAGUCACUGUGGACAGCA 20 4759
SCNNlA-911 + UCAAGGCUGGAGAGGGAGCA 20 4760
SCNNlA-912 - CCAUCAGCAUGAGGAAGGCA 20 4761
SCNNlA-913 + ACCGUUGUUGAUUCCAGGCA 20 4762
SCNNlA-914 + GGCCCAGGGUGGCAUAGGCA 20 4763
SCNNlA-915 - GUCUCCAGGCCGAGGGGGCA 20 4764
SCNNlA-916 + GAAGGGGACACUAACCUGCA 20 4765
SCNNlA-917 + CGGGACCCUCAGGCGCUGCA 20 4766
SCNNlA-918 - CAUCUCCAGGGGGCUCUGCA 20 4767
SCNNlA-919 - GGGGCCCGGGUAAUGGUGCA 20 4768
SCNNlA-920 + CUGCUCUGCGCGCAGCAUCA 20 4769
SCNNlA-921 - UCUACCAGACAUACUCAUCA 20 4770
SCNNlA-922 + AAAGAAUGGGGGUGUCAUCA 20 4771
SCNNlA-923 - CUUCCAGGAGAGCAUGAUCA 20 4772
SCNNlA-924 - AGGGUCCCGCCCCCGCCUCA 20 4773
SCNNlA-925 + AAACCUCUCCUUCCCUCUCA 20 4774
SCNNlA-926 + GGCAGGGGGAGGGGCUGUCA 20 4775
SCNNlA-927 - UUCUGAGUCUCCCUCUGUCA 20 4776
SCNNlA-928 - C A A AG UCAACAUCUUCUUCA 20 4777
SCNNlA-929 + CUGAAGGGGCGAGGGGAAGA 20 4778
SCNNlA-930 - UGUACCUCUCCUCUCACAGA 20 4779
SCNNlA-931 + GCACGACCUACCGUGACAGA 20 4780
SCNNlA-932 + UUUCUUAGGUGUGGGGCAGA 20 4781
SCNNlA-933 + ACACAGAGACUAGAGUCAGA 20 4782
SCNNlA-934 + GGAGGAGGGUGGAGAGGAGA 20 4783
SCNNlA-935 + CCUGCAGAGCCCCCUGGAGA 20 4784
SCNNlA-936 + GGGGCUGUCAAGGCUGGAGA 20 4785
SCNNlA-937 - GGUGUUGUCUGUGGUGGAGA 20 4786
SCNNlA-938 - CCUCUGGGGGGGCCCUGAGA 20 4787
SCNNlA-939 - UCUCUGCUGGUUACUCACGA 20 4788
SCNNlA-940 + GAGGAGAGGUACAUUGACGA 20 4789
SCNNlA-941 + UCUACCUGGGAUGUCACCGA 20 4790
SCNNlA-942 - GGUGAGGCCCGCAGCGCCGA 20 4791
SCNNlA-943 - GAUACUGGUCUCCAGGCCGA 20 4792
SCNNlA-944 - UGUUCCUCAUGCUGCUCCGA 20 4793
SCNNlA-945 + GAGUCCCCCGCAGGUCGCGA 20 4794
SCNNlA-946 + CCGGGUACCUGAAGGGGCGA 20 4795
SCNNlA-947 + AGGCCACGCUACGGGCUCGA 20 4796
SCNNlA-948 + GGGGGCAGAAGUGGGAAGGA 20 4797
SCNNlA-949 + GCUGCCCAGGUUGGACAGGA 20 4798
SCNNlA-950 + UACACACCUGGAAGGGAGGA 20 4799
1208
5535.1 SCNNlA-951 - GACCUCCAUCAGCAUGAGGA 20 4800
SCNNlA-952 - GGUAGAGUGUGGGGAAGGGA 20 4801
SCNNlA-953 + AGCGUGUCCUCCUCCAGGGA 20 4802
SCNNlA-954 - UGGGGGGGCCCUGAGAGGGA 20 4803
SCNNlA-955 + GGGUGGCAUAGGCAGGGGGA 20 4804
SCNNlA-956 + GUAGCUGGUCACGCUGGGGA 20 4805
SCNNlA-957 - UCCCAGGUAGAGUGUGGGGA 20 4806
SCNNlA-958 + GGGUGGGGGCAGAAGUGGGA 20 4807
SCNNlA-959 - CAACCCCCAGGUGGACUGGA 20 4808
SCNNlA-960 + GGAGUGAAUACACACCUGGA 20 4809
SCNNlA-961 - UGCUGACUGGGAGGCCUGGA 20 4810
SCNNlA-962 - CACGGUAGGUCGUGCCUGGA 20 4811
SCNNlA-963 - GAACCUGCCUUUAUGGAUGA 20 4812
SCNNlA-964 + UUUAAUUUCCGGGUACCUGA 20 4813
SCNNlA-965 - GCACCCCUUGCAGCGCCUGA 20 4814
SCNNlA-966 + CCUUGCCUUCCUCAUGCUGA 20 4815
SCNNlA-967 - AUCAGGGGUGGAUGCGGUGA 20 4816
SCNNlA-968 + GCCGGCCACGAGAGUGGUGA 20 4817
SCNNlA-969 + GACUGACCUCUUGUUGUUGA 20 4818
SCNNlA-970 + ACCUGCUGUGUGUACUUUGA 20 4819
SCNNlA-971 - CUACUCUCUCUUUCCUGAUA 20 4820
SCNNlA-972 + CAGCAUCAGGGACAGACCUA 20 4821
SCNNlA-973 + GCAAGCUGGAGGCCACGCUA 20 4822
SCNNlA-974 + U U AU CAGG AAAG AG AG AG U A 20 4823
SCNNlA-975 - CACUUCCACCACCCGAUGUA 20 4824
SCNNlA-976 - GACAGACUUGGGGGCGAUUA 20 4825
SCNNlA-977 - GCAGGAUGAACCUGCCUUUA 20 4826
SCNNlA-978 + GAAGGG UAAAGG U U CU CAAC 20 4827
SCNNlA-979 + CAGAGGACAGGUGGAGGAAC 20 4828
SCNNlA-980 + ACACCGAGGAGCCGAACCAC 20 4829
SCNNlA-981 - AGGCAUCUCUCUGUACCCAC 20 4830
SCNNlA-982 + AGCCGAACCACAGGCUCCAC 20 4831
SCNNlA-983 - GGGCCCGGGUAAUGGUGCAC 20 4832
SCNNlA-984 + CCGAUUUGUUCUGGUUGCAC 20 4833
SCNNlA-985 - GGGUCCCGCCCCCGCCUCAC 20 4834
SCNNlA-986 + GAGUCUCUGGCAGCCUCGAC 20 4835
SCNNlA-987 + GGCCACGCUACGGGCUCGAC 20 4836
SCNNlA-988 - CCCAGGUGGACUGGAAGGAC 20 4837
SCNNlA-989 + UCAGGGCCCCCCCAGAGGAC 20 4838
SCNNlA-990 - ACAACAACCCCCAGGUGGAC 20 4839
SCNNlA-991 + ACUGGCUGCCCAGGUUGGAC 20 4840
SCNNlA-992 - AGGAAGGCAAGGAUGCUGAC 20 4841
1209
5535.1 SCNNlA-993 - CCCCUGCUGUCCACAGUGAC 20 4842
SCNNlA-994 - GAAGGUUCCGAAGCCGAUAC 20 4843
SCNNlA-995 + CAAGCUGGAGGCCACGCUAC 20 4844
SCNNlA-996 - GUGUCCCCUUCCCCGGGUAC 20 4845
SCNNlA-997 + UGAAGGAGCUGUAUUUGUAC 20 4846
SCNNlA-998 - GGUCACCCUCCUGUCCAACC 20 4847
SCNNlA-999 - CAACCAGGUCUCCUGCAACC 20 4848
SCNNlA-1000 + GGUCUGAGGAGAAGUCAACC 20 4849
SCNNlA-1001 - CUUCGCCUGCCGCUUCAACC 20 4850
SCNNlA-1002 + AGCAGGAGUGAAUACACACC 20 4851
SCNNlA-1003 - UGACUUCUCCUCAGACCACC 20 4852
SCNNlA-1004 + UCCAGUCCUUCCAGUCCACC 20 4853
SCNNlA-1005 + ACGCCUGGUUGCAGGAGACC 20 4854
SCNNlA-1006 + UCCCUUCCCCACACUCUACC 20 4855
SCNNlA-1007 - CCCUCGCCCCUUCAGGUACC 20 4856
SCNNlA-1008 + CCUGCCCGUGCACCAUUACC 20 4857
SCNNlA-1009 - UGUGGGUUCAUAGGAAACCC 20 4858
SCNNlA-1010 - UCCCCCUGCCUAUGCCACCC 20 4859
SCNNlA-1011 - UCAGGAGGUAGCCUCCACCC 20 4860
SCNNlA-1012 + CUGCCCGUGCACCAUUACCC 20 4861
SCNNlA-1013 + GCUCCCUGGAGUCUCACCCC 20 4862
SCNNlA-1014 - CUUGCGGGACAACAACCCCC 20 4863
SCNNlA-1015 + CUGGCCCCUGCAGAGCCCCC 20 4864
SCNNlA-1016 - AGGUUAGUGUCCCCUUCCCC 20 4865
SCNNlA-1017 + GGCACUUGGUGAAACAGCCC 20 4866
SCNNlA-1018 + CUGGAGAUGGGCGGGGGCCC 20 4867
SCNNlA-1019 - GUCCACAGUGACUGGGGCCC 20 4868
SCNNlA-1020 - ACAAGAGGUCAGUCCUGCCC 20 4869
SCNNlA-1021 + ACAGGCUCCACUGGCUGCCC 20 4870
SCNNlA-1022 - AUGGCCCUCGGUGACAUCCC 20 4871
SCNNlA-1023 - GCCAGAGACUCUGCCAUCCC 20 4872
SCNNlA-1024 - CAGGUUAGUGUCCCCUUCCC 20 4873
SCNNlA-1025 - UCUCUGUCCUUGUCCCAGCC 20 4874
SCNNlA-1026 + CUGAUGGAGGUCUCCACGCC 20 4875
SCNNlA-1027 + AGGCAGGACUGACUCACGCC 20 4876
SCNNlA-1028 - AGGAUGCUGACUGGGAGGCC 20 4877
SCNNlA-1029 - GGUGGCUUUAACUUGCGGCC 20 4878
SCNNlA-1030 + GCACCCCUGCCCCCUCGGCC 20 4879
SCNNlA-1031 + GCUGGAGAGGGAGCAGGGCC 20 4880
SCNNlA-1032 - UGUCCACAGUGACUGGGGCC 20 4881
SCNNlA-1033 - CUCUGGAUGUCUUCCAUGCC 20 4882
SCNNlA-1034 + GGGAAGGAGGGGAGGAUGCC 20 4883
1210
5535.1 SCNNlA-1035 - AGGCGUGAGUCAGUCCUGCC 20 4884
SCNNlA-1036 - CUGUCACGGUAGGUCGUGCC 20 4885
SCNNlA-1037 - AGUUCCUGGGGUGAGACUCC 20 4886
SCNNlA-1038 + UGCCCAGCGUGUCCUCCUCC 20 4887
SCNNlA-1039 - GUACUGCUACUAUAAGCUCC 20 4888
SCNNlA-1040 - CUGGGCCCCCGCCCAUCUCC 20 4889
SCNNlA-1041 + ACUCCUUGAUCAUGCUCUCC 20 4890
SCNNlA-1042 - CGAAGCCGAUACUGGUCUCC 20 4891
SCNNlA-1043 + AAUCGCCCCCAAGUCUGUCC 20 4892
SCNNlA-1044 + UUCUCACCGUUGUUGAUUCC 20 4893
SCNNlA-1045 - UCUCCACCCUCCUCCCUUCC 20 4894
SCNNlA-1046 - GUGUAUUCACUCCUGCUUCC 20 4895
SCNNlA-1047 - ACUACAGAAAGCACAGUUCC 20 4896
SCNNlA-1048 + CCAGCUCCUCUUUAAUUUCC 20 4897
SCNNlA-1049 + GAGGGCGCCAUGGAGCAAGC 20 4898
SCNNlA-1050 + GGGGUUGUUGUCCCGCAAGC 20 4899
SCNNlA-1051 + GAUCAUGCUCUCCUGGAAGC 20 4900
SCNNlA-1052 - CCCU U CAAAG U ACACACAG C 20 4901
SCNNlA-1053 + CCCCAGUCACUGUGGACAGC 20 4902
SCNNlA-1054 + GCGCUGCGGGCCUCACCAGC 20 4903
SCNNlA-1055 + UGAGGAACAUGAUGACCAGC 20 4904
SCNNlA-1056 - CUGGAAGAUCGGCUUCCAGC 20 4905
SCNNlA-1057 + GUGAGUAACCAGCAGAGAGC 20 4906
SCNNlA-1058 - CCCGGAAAUUAAAGAGGAGC 20 4907
SCNNlA-1059 - UAAAGAGGAGCUGGAGGAGC 20 4908
SCNNlA-1060 + GUCAAGGCUGGAGAGGGAGC 20 4909
SCNNlA-1061 + GUCGCGACGGCUGCGGGAGC 20 4910
SCNNlA-1062 + ACCAGCAGAGAGCUGGUAGC 20 4911
SCNNlA-1063 - AUCCCUGGAGGAGGACACGC 20 4912
SCNNlA-1064 + GAGCUGGUAGCUGGUCACGC 20 4913
SCNNlA-1065 + GGUGCGGCAGAGUCCCCCGC 20 4914
SCNNlA-1066 + CCACCAUCAUCCAUAAAGGC 20 4915
SCNNlA-1067 + GGGGGAGGGGCUGUCAAGGC 20 4916
SCNNlA-1068 + CUCGACGGGCCCCGUGAGGC 20 4917
SCNNlA-1069 + GGGCCCAGGGUGGCAUAGGC 20 4918
SCNNlA-1070 + GGAGACCUGGUUGAAGCGGC 20 4919
SCNNlA-1071 + CUUGUGGCUGGGACCAGGGC 20 4920
SCNNlA-1072 - CCGGGUAAUGGUGCACGGGC 20 4921
SCNNlA-1073 - GGUCUCCAGGCCGAGGGGGC 20 4922
SCNNlA-1074 + GGGCCCCGUGAGGCGGGGGC 20 4923
SCNNlA-1075 + AGAGCCCCCUGGAGAUGGGC 20 4924
SCNNlA-1076 + GAGAGGGAGCAGGGCCUGGC 20 4925
1211
5535.1 SCNNlA-1077 - UCCUUCACCACUCUCGUGGC 20 4926
SCNNlA-1078 - CCAAGUGCCGGAAGCCAUGC 20 4927
SCNNlA-1079 - CCGCAGCCGUCGCGACCUGC 20 4928
SCNNlA-1080 - UGAGCUCGUCUUUGACCUGC 20 4929
SCNNlA-1081 + GGCGGGCCCCUCGGCGCUGC 20 4930
SCNNlA-1082 + CCGCAGGUCGCGACGGCUGC 20 4931
SCNNlA-1083 - CCAUCUCCAGGGGGCUCUGC 20 4932
SCNNlA-1084 - ACCAGCUACCAGCUCUCUGC 20 4933
SCNNlA-1085 - UGGGCUGUUUCACCAAGUGC 20 4934
SCNNlA-1086 - UAGCGUGGCCUCCAGCUUGC 20 4935
SCNNlA-1087 + ACUGACUCACGCCUGGUUGC 20 4936
SCNNlA-1088 + UAUAGCAGUUUCCAUACAUC 20 4937
SCNNlA-1089 + UCUGCUCUGCGCGCAGCAUC 20 4938
SCNNlA-1090 + UGUUCUGUCGCGAUAGCAUC 20 4939
SCNNlA-1091 - UUCUACCAGACAUACUCAUC 20 4940
SCNNlA-1092 + AGUGAGAGUAAUUCCUUAUC 20 4941
SCNNlA-1093 - ACAAGAACAACUCCAACCUC 20 4942
SCNNlA-1094 + GAGGCGGGGGCGGGACCCUC 20 4943
SCNNlA-1095 - CAGUUCCUCCACCUGUCCUC 20 4944
SCNNlA-1096 - CCGAGGGGGCAGGGGUGCUC 20 4945
SCNNlA-1097 + GAAACCUCUCCUUCCCUCUC 20 4946
SCNNlA-1098 + UCCAGGGAUGGCAGAGUCUC 20 4947
SCNNlA-1099 + GGGGCGAGGGGAAGAGGGUC 20 4948
SCNNlA-1100 + CCACCCCUGAUGAGUAUGUC 20 4949
SCNNlA-1101 - CCUCUUCCCCUCGCCCCUUC 20 4950
SCNNlA-1102 + ACACUAACCUGCAUGGCUUC 20 4951
SCNNlA-1103 + AGUCACAGUACUCCACGUUC 20 4952
SCNNlA-1104 + AG AAG CAGUCCGAUUUGUUC 20 4953
SCNNlA-1105 + UCCAGCUCCUCUUUAAUUUC 20 4954
SCNNlA-1106 - CAGGUACCCGGAAAUUAAAG 20 4955
SCNNlA-1107 - AU U ACACCG U CAACAACAAG 20 4956
SCNNlA-1108 + GGACCCUCAGGCGCUGCAAG 20 4957
SCNNlA-1109 + ACAUGGGGUGGGGGCAGAAG 20 4958
SCNNlA-1110 + CCUGAAGGGGCGAGGGGAAG 20 4959
SCNNlA-1111 + GGAUGUUGAUGUAGUGGAAG 20 4960
SCNNlA-1112 + UAAUUUCCGGGUACCUGAAG 20 4961
SCNNlA-1113 + UGCAGGAGACCUGGUUGAAG 20 4962
SCNNlA-1114 + GGCACGACCUACCGUGACAG 20 4963
SCNNlA-1115 + CCCUCUCAGGGCCCCCCCAG 20 4964
SCNNlA-1116 - UGUCCAACCUGGGCAGCCAG 20 4965
SCNNlA-1117 + CAGGCAUGGAAGACAUCCAG 20 4966
SCNNlA-1118 - GGGCCCCCGCCCAUCUCCAG 20 4967
1212
5535.1 SCNNlA-1119 + CCAGUCACUGUGGACAGCAG 20 4968
SCNNlA-1120 + GCCCAGGGUGGCAUAGGCAG 20 4969
SCNNlA-1121 - UCUCCAGGCCGAGGGGGCAG 20 4970
SCNNlA-1122 + AUUUCUUAGGUGUGGGGCAG 20 4971
SCNNlA-1123 - AUCUCCAGGGGGCUCUGCAG 20 4972
SCNNlA-1124 - CUACCAGACAUACUCAUCAG 20 4973
SCNNlA-1125 + GACACAGAGACUAGAGUCAG 20 4974
SCNNlA-1126 + CACAGAGACUAGAGUCAGAG 20 4975
SCNNlA-1127 + GCGGGAGCCGGCCACGAGAG 20 4976
SCNNlA-1128 - GUGAGGCCCGCAGCGCCGAG 20 4977
SCNNlA-1129 - AUACUGGUCUCCAGGCCGAG 20 4978
SCNNlA-1130 + CGGGUACCUGAAGGGGCGAG 20 4979
SCNNlA-1131 - GGGCCCUGAGAGGGAAGGAG 20 4980
SCNNlA-1132 + GGGGCAGAAGUGGGAAGGAG 20 4981
SCNNlA-1133 + GGGAGGAGGGUGGAGAGGAG 20 4982
SCNNlA-1134 + GUGACCAUCUGUGAGAGGAG 20 4983
SCNNlA-1135 - GGGUGGAUGCGGUGAGGGAG 20 4984
SCNNlA-1136 + GGUGGCAUAGGCAGGGGGAG 20 4985
SCNNlA-1137 - CCCACACCUAAGAAAUGGAG 20 4986
SCNNlA-1138 + AGGGGCUGUCAAGGCUGGAG 20 4987
SCNNlA-1139 + UGGAAGGGAGGAGGGUGGAG 20 4988
SCNNlA-1140 - UCCUCUGGGGGGGCCCUGAG 20 4989
SCNNlA-1141 + GGAGGGUGACCAUCUGUGAG 20 4990
SCNNlA-1142 + AGCAUCAGGGACAGACCUAG 20 4991
SCNNlA-1143 + UCGACAGGAUGUUGAUGUAG 20 4992
SCNNlA-1144 - CUAUCCGCGGCCCCAGAACG 20 4993
SCNNlA-1145 - GGUCCCGCCCCCGCCUCACG 20 4994
SCNNlA-1146 + CUCCACCACAGACAACACCG 20 4995
SCNNlA-1147 + CUCUACCUGGGAUGUCACCG 20 4996
SCNNlA-1148 - UGGUGAGGCCCGCAGCGCCG 20 4997
SCNNlA-1149 - CGAUACUGGUCUCCAGGCCG 20 4998
SCNNlA-1150 + UACUCCACGUUCUGGGGCCG 20 4999
SCNNlA-1151 - GUGCCUACAUCUUCUAUCCG 20 5000
SCNNlA-1152 - UGAGGCCCAACCUGAUUCCG 20 5001
SCNNlA-1153 - GGCCCGUCGAGCCCGUAGCG 20 5002
SCNNlA-1154 + UCGACGGGCCCCGUGAGGCG 20 5003
SCNNlA-1155 + UCCGGGUACCUGAAGGGGCG 20 5004
SCNNlA-1156 + GAGCCCCCUGGAGAUGGGCG 20 5005
SCNNlA-1157 - CUUUAACUUGCGGCCUGGCG 20 5006
SCNNlA-1158 - CGCAGCCGUCGCGACCUGCG 20 5007
SCNNlA-1159 - CAGCUCCUUCACCACUCUCG 20 5008
SCNNlA-1160 - ACUACAUCAACAUCCUGUCG 20 5009
1213
5535.1 SCNNlA-1161 + UGGGGGCAGAAGUGGGAAGG 20 5010
SCNNlA-1162 + GGGCCCCCCCAGAGGACAGG 20 5011
SCNNlA-1163 + GGCUGCCCAGGUUGGACAGG 20 5012
SCNNlA-1164 - GCGGGACAACAACCCCCAGG 20 5013
SCNNlA-1165 + ACUUGGUGAAACAGCCCAGG 20 5014
SCNNlA-1166 - GGCCCCCGCCCAUCUCCAGG 20 5015
SCNNlA-1167 + CCCAGGGUGGCAUAGGCAGG 20 5016
SCNNlA-1168 - AGGGGGCAGGGGUGCUCAGG 20 5017
SCNNlA-1169 - UACUGGUCUCCAGGCCGAGG 20 5018
SCNNlA-1170 + AUACACACCUGGAAGGGAGG 20 5019
SCNNlA-1171 - GACUCUGCCAUCCCUGGAGG 20 5020
SCNNlA-1172 + GCUCGACGGGCCCCGUGAGG 20 5021
SCNNlA-1173 + CGACGGGCCCCGUGAGGCGG 20 5022
SCNNlA-1174 + AGCCCCCUGGAGAUGGGCGG 20 5023
SCNNlA-1175 - GCAGCCGUCGCGACCUGCGG 20 5024
SCNNlA-1176 + UGAAUACACACCUGGAAGGG 20 5025
SCNNlA-1177 + AGAUGGGCGGGGGCCCAGGG 20 5026
SCNNlA-1178 + AGGAGGGGAGGAUGCCAGGG 20 5027
SCNNlA-1179 + CUUAGGUGUGGGGCAGAGGG 20 5028
SCNNlA-1180 + ACACCUGGAAGGGAGGAGGG 20 5029
SCNNlA-1181 + AGCAGUUUCCAUACAUCGGG 20 5030
SCNNlA-1182 - CCAGACAUACUCAUCAGGGG 20 5031
SCNNlA-1183 + GCAGAAGUGGGAAGGAGGGG 20 5032
SCNNlA-1184 + AGGGUGGCAUAGGCAGGGGG 20 5033
SCNNlA-1185 + CGGGCCCCGUGAGGCGGGGG 20 5034
SCNNlA-1186 + ACAAGGACAGAGACAUGGGG 20 5035
SCNNlA-1187 - CCUCCACCUGUCCUCUGGGG 20 5036
SCNNlA-1188 + CAGAGCCCCCUGGAGAUGGG 20 5037
SCNNlA-1189 - GAGUGUGGGGAAGGGAUGGG 20 5038
SCNNlA-1190 - AGGCAAGGAUGCUGACUGGG 20 5039
SCNNlA-1191 - UCCUCCACCUGUCCUCUGGG 20 5040
SCNNlA-1192 + CCAUUCCUAGGAAAGAAUGG 20 5041
SCNNlA-1193 - CCUGCCUUUAUGGAUGAUGG 20 5042
SCNNlA-1194 + UGCCUUCCUCAUGCUGAUGG 20 5043
SCNNlA-1195 + AGUCCUUCCAGUCCACCUGG 20 5044
SCNNlA-1196 - AGAGACUCUGCCAUCCCUGG 20 5045
SCNNlA-1197 + GUUGUUGUCCCGCAAGCUGG 20 5046
SCNNlA-1198 - GGAAAUUAAAGAGGAGCUGG 20 5047
SCNNlA-1199 - UUCCUCCACCUGUCCUCUGG 20 5048
SCNNlA-1200 + CCCCCCCAGAGGACAGGUGG 20 5049
SCNNlA-1201 + AGGGGAGGAUGCCAGGGUGG 20 5050
SCNNlA-1202 + AGUUUCCAUACAUCGGGUGG 20 5051
1214
5535.1 SCNNlA-1203 + AGGACAGAGACAUGGGGUGG 20 5052
SCNNlA-1204 - UGUGGGGAAGGGAUGGGUGG 20 5053
SCNNlA-1205 - CUCCUCGGUGUUGUCUGUGG 20 5054
SCNNlA-1206 - G AAACCCUGGACAGACU UGG 20 5055
SCNNlA-1207 + CCCAUUCCUAGGAAAGAAUG 20 5056
SCNNlA-1208 + GGGACAAGGACAGAGACAUG 20 5057
SCNNlA-1209 + GGAACCUUCGGAGCAGCAUG 20 5058
SCNNlA-1210 - UGGAGACCUCCAUCAGCAUG 20 5059
SCNNlA-1211 - AUACUCAUCAGGGGUGGAUG 20 5060
SCNNlA-1212 + AGAGCGUCUGCUCUGUGAUG 20 5061
SCNNlA-1213 + UACCCGGGCCCCAGUCACUG 20 5062
SCNNlA-1214 - CCUGCUGUCCACAGUGACUG 20 5063
SCNNlA-1215 + CAGUCCUUCCAGUCCACCUG 20 5064
SCNNlA-1216 - CCCGCAGCCGUCGCGACCUG 20 5065
SCNNlA-1217 + CUUAUAGUAGCAGUACCCUG 20 5066
SCNNlA-1218 - UGGGCAGCCAGUGGAGCCUG 20 5067
SCNNlA-1219 - CGCACCCCUUGCAGCGCCUG 20 5068
SCNNlA-1220 - UACAGAAAGCACAGUUCCUG 20 5069
SCNNlA-1221 + GCUGGUAGCUGGUCACGCUG 20 5070
SCNNlA-1222 + GGGCGGGCCCCUCGGCGCUG 20 5071
SCNNlA-1223 + CCCGCAGGUCGCGACGGCUG 20 5072
SCNNlA-1224 - GUUCCUCCACCUGUCCUCUG 20 5073
SCNNlA-1225 + GAAACAGCCCAGGUGGUCUG 20 5074
SCNNlA-1226 - CGGCUCCUCGGUGUUGUCUG 20 5075
SCNNlA-1227 + UCACAGUACUCCACGUUCUG 20 5076
SCNNlA-1228 - GUGACAUCCCAGGUAGAGUG 20 5077
SCNNlA-1229 - GAGAGCAUGAUCAAGGAGUG 20 5078
SCNNlA-1230 + CGGGCUCGACGGGCCCCGUG 20 5079
SCNNlA-1231 - C AAAG U AC ACAC AG C AG G U G 20 5080
SCNNlA-1232 + GCCACUCCAUUUCUUAGGUG 20 5081
SCNNlA-1233 - CAUCAGGGGUGGAUGCGGUG 20 5082
SCNNlA-1234 + CUCAGGCGCUGCAAGGGGUG 20 5083
SCNNlA-1235 + AAGGACAGAGACAUGGGGUG 20 5084
SCNNlA-1236 - GUGUGGGGAAGGGAUGGGUG 20 5085
SCNNlA-1237 - AGAUCGGCUUCCAGCUGGUG 20 5086
SCNNlA-1238 - GACAUCCCAGGUAGAGUGUG 20 5087
SCNNlA-1239 + CACUCCAUUUCUUAGGUGUG 20 5088
SCNNlA-1240 - AUGAUGGUGGCUUUAACUUG 20 5089
SCNNlA-1241 - GGAAACCCUGGACAGACUUG 20 5090
SCNNlA-1242 - GUAGCGUGGCCUCCAGCUUG 20 5091
SCNNlA-1243 - CCAGUGCAACCAGAACAAAU 20 5092
SCNNlA-1244 + ACCCAUUCCUAGGAAAGAAU 20 5093
1215
5535.1 SCNNlA-1245 + GACAGAGGGAGACUCAGAAU 20 5094
SCNNlA-1246 - CCCCAUUCUUUCCUAGGAAU 20 5095
SCNNlA-1247 + UGGGACAAGGACAGAGACAU 20 5096
SCNNlA-1248 + GUAUAGCAGUUUCCAUACAU 20 5097
SCNNlA-1249 + GCGGGGGCCCAGGGUGGCAU 20 5098
SCNNlA-1250 - CUUGGUGUAUGUGGGUUCAU 20 5099
SCNNlA-1251 - GACUGGAAGGACUGGAAGAU 20 5100
SCNNlA-1252 + CUGCAGAGCCCCCUGGAGAU 20 5101
SCNNlA-1253 + AGGAGAGGUACAUUGACGAU 20 5102
SCNNlA-1254 - GUAGAGUGUGGGGAAGGGAU 20 5103
SCNNlA-1255 + CUCGGCCUGGAGACCAGUAU 20 5104
SCNNlA-1256 + CCUGCAUGGCUUCCGGCACU 20 5105
SCNNlA-1257 - UAGGAAACCCUGGACAGACU 20 5106
SCNNlA-1258 - GGAAGGCAAGGAUGCUGACU 20 5107
SCNNlA-1259 - CCCUGCUGUCCACAGUGACU 20 5108
SCNNlA-1260 - GUCACCCUCCUGUCCAACCU 20 5109
SCNNlA-1261 - GACUUCUCCUCAGACCACCU 20 5110
SCNNlA-1262 + CCAGUCCUUCCAGUCCACCU 20 5111
SCNNlA-1263 + GCAGCAUCAGGGACAGACCU 20 5112
SCNNlA-1264 + CCCUUCCCCACACUCUACCU 20 5113
SCNNlA-1265 - CCCCCUGCCUAUGCCACCCU 20 5114
SCNNlA-1266 - UCUGCUCUCUCUGCACCCCU 20 5115
SCNNlA-1267 + CCUGAGCACCCCUGCCCCCU 20 5116
SCNNlA-1268 - UGGUUACUCACGAUGGCCCU 20 5117
SCNNlA-1269 - GAGCCUGUGGUUCGGCUCCU 20 5118
SCNNlA-1270 + CAUCUGGAAGACCCAUUCCU 20 5119
SCNNlA-1271 - CUACAGAAAG CACAG U U CCU 20 5120
SCNNlA-1272 - UGACACCCCCAUUCUUUCCU 20 5121
SCNNlA-1273 - UCCCUGGAGGAGGACACGCU 20 5122
SCNNlA-1274 + AGCUGGUAGCUGGUCACGCU 20 5123
SCNNlA-1275 + AGAGGGAGCAGGGCCUGGCU 20 5124
SCNNlA-1276 - AGUUCCUCCACCUGUCCUCU 20 5125
SCNNlA-1277 + AGGAACAUCACUGCCAUUCU 20 5126
SCNNlA-1278 + GUCACAGUACUCCACGUUCU 20 5127
SCNNlA-1279 + CAUGGGGUGGGGGCAGAAGU 20 5128
SCNNlA-1280 + GGGUGCAGAGAGAGCAGAGU 20 5129
SCNNlA-1281 + CUUAUCAGGAAAGAGAGAGU 20 5130
SCNNlA-1282 + GCUCCACUGGCUGCCCAGGU 20 5131
SCNNlA-1283 + UGGCUGCCACGGAAUCAGGU 20 5132
SCNNlA-1284 + CAUGGAAGACAUCCAGAGGU 20 5133
SCNNlA-1285 - GAGUCUCCCUCUGUCACGGU 20 5134
SCNNlA-1286 + UUAGGUGUGGGGCAGAGGGU 20 5135
1216
5535.1 SCNNlA-1287 + CAAGGACAGAGACAUGGGGU 20 5136
SCNNlA-1288 - AGUGUGGGGAAGGGAUGGGU 20 5137
SCNNlA-1289 + GGGCCGCGGAUAGAAGAUGU 20 5138
SCNNlA-1290 - UCUGAUCUCUUGGUGUAUGU 20 5139
SCNNlA-1291 + UUAUAGUAGCAGUACCCUGU 20 5140
SCNNlA-1292 + UGGAGAAAGGUGCUCAGUGU 20 5141
SCNNlA-1293 - UGACAUCCCAGGUAGAGUGU 20 5142
SCNNlA-1294 + CCACUCCAUUUCUUAGGUGU 20 5143
SCNNlA-1295 - AGGAAACCCUGGACAGACUU 20 5144
SCNNlA-1296 + CUUGAAGAAGAUGUUGACUU 20 5145
SCNNlA-1297 + AGUAUCGGCUUCGGAACCUU 20 5146
SCNNlA-1298 + CUGGAGACCAGUAUCGGCUU 20 5147
SCNNlA-1299 + CUUUGGCCACUCCAUUUCUU 20 5148
SCNNlA-1300 + GGCUGCCACGGAAUCAGGUU 20 5149
SCNNlA-1301 - AGCCAGUGGAGCCUGUGGUU 20 5150
Table 44A provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., with 500 bp downstream from the start codon), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 44A
Figure imgf001218_0001
1217
5535.1 SCNN lA-1313 + GGUAUGGGCUGCAGAGGUC 19 5162
SCNN lA-1314 + GACCUGGUAUGGGCUGCAGAGGUC 24 5163
SCNN lA-1315 + GAUACCUCCCCUUGGAAGGGACAG 24 5164
SCNN lA-1316 + GUGCUGGGAGCACACCAG 18 5165
SCNN lA-1317 + GUUGUGCUGGGAGCACACCAG 21 5166
SCNN lA-1318 + GGUUGUGCUGGGAGCACACCAG 22 5167
SCNN lA-1319 + GCGGUUGUGCUGGGAGCACACCAG 24 5168
SCNN lA-1320 + GUACUCUCCGAAAAGCAGG 19 5169
SCNN lA-1321 + GAAGUACUCUCCGAAAAGCAGG 22 5170
SCNN lA-1322 + GAUUGGGGAGAGCAAGGGU 19 5171
SCNN lA-1323 + GGAUUGGGGAGAGCAAGGGU 20 5172
SCNN lA-1324 + GUGGAUUGGGGAGAGCAAGGGU 22 5173
SCNN lA-1325 + GAGUGGAUUGGGGAGAGCAAGGGU 24
5174
SCNN lA-1326 + GAGGGACUAACCGACCUGU 19 5175
SCNN lA-1327 + GCAGAGGGACUAACCGACCUGU 22 5176
SCNN lA-1328 + GGCAGAGGGACUAACCGACCUGU 23 5177
SCNN lA-1329 + GGGCAGAGGGACUAACCGACCUGU 24 5178
SCNN lA-1330 + GCGGGGAAGACGAGCU UGU 19 5179
SCNN lA-1331 + GACUAACCGACCUGUAGGGAUU 22 5180
SCNN lA-1332 + GGACUAACCGACCUGUAGGGAUU 23 5181
SCNN lA-1333 + GGGACUAACCGACCUGUAGGGAUU 24 5182
SCNN lA-1334 - GCGGAGGAGGAGGCCCUGA 19 5183
SCN N lA-189 - GGCGGAGGAGGAGGCCCUGA 20 819
SCNN lA-1335 - GGCCAGGGGCAGCCUCAC 18 5184
SCNN lA-1336 - GCAGCCUCACUCGGGUUCC 19 5185
SCN N lA-348 - GGCAGCCUCACUCGGGU UCC 20 4197
SCN N lA-197 - GCAAUUCGGCCUGCU UUUCG 20 826
SCNN lA-1337 - GGCAAUUCGGCCUGCU UUUCG 21 5186
SCNN lA-1338 - GCUCCUACCGAGAGCUCU 18 5187
SCN N lA-437 - GUAAGCAAGGGAACCUGGUU 20 4286
SCNN lA-1339 - GGUAAGCAAGGGAACCUGGUU 21 5188
Table 44B provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., with 500 bp downstream from the start codon), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
1218
5535.1 Table 44B
Figure imgf001220_0001
1219
5535.1 SCNNlA-1375 + UGAAGUACUCUCCGAAAAGCAGG 23 5224
SCNNlA-1376 + CUGAAGUACUCUCCG A A A AG C AG G 24 5225
SCNNlA-1377 + AUUGGGGAGAGCAAGGGU 18 5226
SCNNlA-1378 + UGGAUUGGGGAGAGCAAGGGU 21 5227
SCNNlA-1379 + AGUGGAUUGGGGAGAGCAAGGGU 23 5228
SCNNlA-1380 + AGGGACUAACCGACCUGU 18 5229
SCNNlA-424 + AGAGGGACUAACCGACCUGU 20 4273
SCNNlA-1381 + CAGAGGGACUAACCGACCUGU 21 5230
SCNNlA-1382 + CGGGGAAGACGAGCUUGU 18 5231
SCNNlA-237 + UGCGGGGAAGACGAGCUUGU 20 857
SCNNlA-1383 + CUGCGGGGAAGACGAGCUUGU 21 5232
SCNNlA-1384 + ACUGCGGGGAAGACGAGCUUGU 22 5233
SCNNlA-1385 + CACUGCGGGGAAGACGAGCUUGU 23 5234
SCNNlA-1386 + UCACUGCGGGGAAGACGAGCUUGU 24 5235
SCNNlA-1387 + AACCGACCUGUAGGGAUU 18 5236
SCNNlA-1388 + UAACCGACCUGUAGGGAUU 19 5237
SCNNlA-1389 + CUAACCGACCUGUAGGGAUU 20 5238
SCNNlA-1390 + ACUAACCGACCUGUAGGGAUU 21 5239
SCNNlA-1391 - CGGAGGAGGAGGCCCUGA 18 5240
SCNNlA-1392 - UGGCCAGGGGCAGCCUCAC 19 5241
SCNNlA-1393 - AUGGCCAGGGGCAGCCUCAC 20 5242
SCNNlA-1394 - CAGCCUCACUCGGGUUCC 18 5243
SCNNlA-1395 - AAUUCGGCCUGCUUUUCG 18 5244
SCNNlA-1396 - CAAUUCGGCCUGCUUUUCG 19 5245
SCNNlA-1397 - UGGCAAUUCGGCCUGCUUUUCG 22 5246
SCNNlA-1398 - CUGGCAAUUCGGCCUGCUUUUCG 23 5247
SCNNlA-1399 - ACUGGCAAUUCGGCCUGCUUUUCG 24 5248
SCNNlA-1400 - CGCUCCUACCGAGAGCUCU 19 5249
SCNNlA-192 - CCGCUCCUACCGAGAGCUCU 20 822
SCNNlA-1401 - ACCGCUCCUACCGAGAGCUCU 21 5250
SCNNlA-1402 - CACCGCUCCUACCGAGAGCUCU 22 5251
SCNNlA-1403 - CCACCGCUCCUACCGAGAGCUCU 23 5252
SCNNlA-1404 - UCCACCGCUCCUACCGAGAGCUCU 24 5253
SCNNlA-1405 - AAGCAAGGGAACCUGGUU 18 5254
SCNNlA-1406 - UAAGCAAGGGAACCUGGUU 19 5255
SCNNlA-1407 - AGGUAAGCAAGGGAACCUGGUU 22 5256
SCNNlA-1408 - AAGGUAAGCAAGGGAACCUGGUU 23 5257
SCNNlA-1409 - C A AG G U A AG C A AG GGAACCUGGUU 24 5258
Table 44C provides exemplary targeting domains for knocking out the SCNNIA gene selected according to the third tier parameters. The targeting domains bind within the first 500 bp
1220
5535.1 of the coding sequence (e.g., with 500 bp downstream from the start codon), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 44C
Figure imgf001222_0001
1221
5535.1 SCNNlA-1438 - GCAUGGCCAGGGGCAGCCUCAC 22 5287
SCNNlA-1439 - GGCAUGGCCAGGGGCAGCCUCAC 23 5288
SCNNlA-1440 - GGGCAUGGCCAGGGGCAGCCUCAC 24 5289
SCNNlA-1441 - GGGCAGCCUCACUCGGGUUCC 21 5290
SCNNlA-1442 - GGGGCAGCCUCACUCGGGUUCC 22 5291
SCNNlA-1443 - AGGGGCAGCCUCACUCGGGUUCC 23 5292
SCNNlA-1444 - CAGGGGCAGCCUCACUCGGGUUCC 24 5293
Table 44D provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., with 500 bp downstream from the start codon), have a high level of orthogonality and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 44D
Figure imgf001223_0001
1222
5535.1 SCNNlA-1464 + UUGUUCCCCUUCAUGAGCCCUGGA 24 5313
SCNNlA-1465 + CAUGAGCCCCGGAGUGGA 18 5314
SCNNlA-1466 + UCAUGAGCCCCGGAGUGGA 19 5315
SCNNlA-1467 + UUCAUGAGCCCCGGAGUGGA 20 5316
SCNNlA-1468 + CUUCAUGAGCCCCGGAGUGGA 21 5317
SCNNlA-1469 + CCUUCAUGAGCCCCGGAGUGGA 22 5318
SCNNlA-1470 + CCCUUCAUGAGCCCCGGAGUGGA 23 5319
SCNNlA-1471 + CCCCUUCAUGAGCCCCGGAGUGGA 24 5320
SCNNlA-1472 + AUGAUACCUCCCCUUGGA 18 5321
SCNNlA-1473 + CAUGAUACCUCCCCUUGGA 19 5322
SCNNlA-399 + UCAUGAUACCUCCCCUUGGA 20 4248
SCNNlA-1474 + CUCAUGAUACCUCCCCUUGGA 21 5323
SCNNlA-1475 + GCUCAUGAUACCUCCCCUUGGA 22 5324
SCNNlA-1476 + UGCUCAUGAUACCUCCCCUUGGA 23 5325
SCNNlA-1477 + CUGCUCAUGAUACCUCCCCUUGGA 24 5326
SCNNlA-1478 + GUGUUGUUGCAGAAGAAC 18 5327
SCNNlA-1479 + GGUGUUGUUGCAGAAGAAC 19 5328
SCNNlA-220 + UGGUGUUGUUGCAGAAGAAC 20 843
SCNNlA-1480 + GUGGUGUUGUUGCAGAAGAAC 21 5329
SCNNlA-1481 + GGUGGUGUUGUUGCAGAAGAAC 22 5330
SCNNlA-1482 + UGGUGGUGUUGUUGCAGAAGAAC 23 5331
SCNNlA-1483 + AUGGUGGUGUUGUUGCAGAAGAAC 24
5332
SCNNlA-1484 + UGCCCUCUCCCAUCACCC 18 5333
SCNNlA-1485 + GUGCCCUCUCCCAUCACCC 19 5334
SCNNlA-1486 + AGUGCCCUCUCCCAUCACCC 20 5335
SCNNlA-1487 + GAGUGCCCUCUCCCAUCACCC 21 5336
SCNNlA-1488 + UGAGUGCCCUCUCCCAUCACCC 22 5337
SCNNlA-1489 + CUGAGUGCCCUCUCCCAUCACCC 23 5338
SCNNlA-1490 + CCUGAGUGCCCUCUCCCAUCACCC 24 5339
SCNNlA-1491 + GCCCUCUCCCAUCACCCC 18 5340
SCNNlA-1492 + UGCCCUCUCCCAUCACCCC 19 5341
SCNNlA-346 + GUGCCCUCUCCCAUCACCCC 20 4195
SCNNlA-1493 + AGUGCCCUCUCCCAUCACCCC 21 5342
SCNNlA-1494 + GAGUGCCCUCUCCCAUCACCCC 22 5343
SCNNlA-1495 + UGAGUGCCCUCUCCCAUCACCCC 23 5344
SCNNlA-1496 + CUGAGUGCCCUCUCCCAUCACCCC 24 5345
SCNNlA-1497 + UGCUCAUGAUACCUCCCC 18 5346
SCNNlA-1498 + CUGCUCAUGAUACCUCCCC 19 5347
SCNNlA-1499 + ACUGCUCAUGAUACCUCCCC 20 5348
SCNNlA-1500 + UACUGCUCAUGAUACCUCCCC 21 5349
SCNNlA-1501 + AUACUGCUCAUGAUACCUCCCC 22 5350
1223
5535.1 SCNNlA-1502 + GAUACUGCUCAUGAUACCUCCCC 23 5351
SCNNlA-1503 + UGAUACUGCUCAUGAUACCUCCCC 24 5352
SCNNlA-1504 + UGUUCCCCUUCAUGAGCC 18 5353
SCNNlA-1505 + UUGUUCCCCUUCAUGAGCC 19 5354
SCNNlA-207 + CUUGUUCCCCUUCAUGAGCC 20 834
SCNNlA-1506 + GCUUGUUCCCCUUCAUGAGCC 21 5355
SCNNlA-1507 + AGCUUGUUCCCCUUCAUGAGCC 22 5356
SCNNlA-1508 + CAGCUUGUUCCCCUUCAUGAGCC 23 5357
SCNNlA-1509 + CCAGCUUGUUCCCCUUCAUGAGCC 24 5358
SCNNlA-1510 + CGCUUGUUCCCCUUCAUGAGCC 22 5359
SCNNlA-1511 + ACGCUUGUUCCCCUUCAUGAGCC 23 5360
SCNNlA-1512 + CACGCUUGUUCCCCUUCAUGAGCC 24 5361
SCNNlA-1513 + AGGGCCUCCUCCUCCGCC 18 5362
SCNNlA-1514 + CAGGGCCUCCUCCUCCGCC 19 5363
SCNNlA-213 + UCAGGGCCUCCUCCUCCGCC 20 838
SCNNlA-1515 + AUCAGGGCCUCCUCCUCCGCC 21 5364
SCNNlA-1516 + GAUCAGGGCCUCCUCCUCCGCC 22 5365
SCNNlA-1517 + CGAUCAGGGCCUCCUCCUCCGCC 23 5366
SCNNlA-1518 + UCGAUCAGGGCCUCCUCCUCCGCC 24 5367
SCNNlA-1519 + CAGAGCCACAGCACUGCC 18 5368
SCNNlA-1520 + GCAGAGCCACAGCACUGCC 19 5369
SCNNlA-228 + UGCAGAGCCACAGCACUGCC 20 849
SCNNlA-1521 + GUGCAGAGCCACAGCACUGCC 21 5370
SCNNlA-1522 + GGUGCAGAGCCACAGCACUGCC 22 5371
SCNNlA-1523 + AGGUGCAGAGCCACAGCACUGCC 23 5372
SCNNlA-1524 + AAGGUGCAGAGCCACAGCACUGCC 24 5373
SCNNlA-1525 + UCCAGCUUGUUCCCCUCC 18 5374
SCNNlA-1526 + CUCCAGCUUGUUCCCCUCC 19 5375
SCNNlA-200 + CCUCCAGCUUGUUCCCCUCC 20 829
SCNNlA-1527 + UCCUCCAGCUUGUUCCCCUCC 21 5376
SCNNlA-1528 + CUCCUCCAGCUUGUUCCCCUCC 22 5377
SCNNlA-1529 + GCUCCUCCAGCUUGUUCCCCUCC 23 5378
SCNNlA-1530 + UGCUCCUCCAGCUUGUUCCCCUCC 24 5379
SCNNlA-1531 + GGUGCAGAUGGUCACUGC 18 5380
SCNNlA-1532 + GGGUGCAGAUGGUCACUGC 19 5381
SCNNlA-38 + AGGGUGCAGAUGGUCACUGC 20 575
SCNNlA-1533 + GAGGGUGCAGAUGGUCACUGC 21 5382
SCNNlA-1534 + UGAGGGUGCAGAUGGUCACUGC 22 5383
SCNNlA-1535 + UUGAGGGUGCAGAUGGUCACUGC 23 5384
SCNNlA-1536 + AUUGAGGGUGCAGAUGGUCACUGC 24 5385
SCNNlA-1537 + UCCUCCGCCGUGGGCUGC 18 5386
SCNNlA-1538 + CUCCUCCGCCGUGGGCUGC 19 5387
1224
5535.1 SCNNlA-65 + CCUCCUCCGCCGUGGGCUGC 20 594
SCNNlA-1539 + UCCUCCUCCGCCGUGGGCUGC 21 5388
SCNNlA-1540 + CUCCUCCUCCGCCGUGGGCUGC 22 5389
SCNNlA-1541 + CCUCCUCCUCCGCCGUGGGCUGC 23 5390
SCNNlA-1542 + GCCUCCUCCUCCGCCGUGGGCUGC 24 5391
SCNNlA-1543 + GUCUUCAUGCGGUUGUGC 18 5392
SCNNlA-1544 + CGUCUUCAUGCGGUUGUGC 19 5393
SCNNlA-49 + CCGUCUUCAUGCGGUUGUGC 20 582
SCNNlA-1545 + GCCGUCUUCAUGCGGUUGUGC 21 5394
SCNNlA-1546 + GGCCGUCUUCAUGCGGUUGUGC 22 5395
SCNNlA-1547 + AGGCCGUCUUCAUGCGGUUGUGC 23 5396
SCNNlA-1548 + AAGGCCGUCUUCAUGCGGUUGUGC 24 5397
SCNNlA-1549 + UCCAGCUUGUUCCCCUUC 18 5398
SCNNlA-1550 + CUCCAGCUUGUUCCCCUUC 19 5399
SCNNlA-1551 + CCUCCAGCUUGUUCCCCUUC 20 5400
SCNNlA-1552 + UCCUCCAGCUUGUUCCCCUUC 21 5401
SCNNlA-1553 + CUCCUCCAGCUUGUUCCCCUUC 22 5402
SCNNlA-1554 + GCUCCUCCAGCUUGUUCCCCUUC 23 5403
SCNNlA-1555 + UGCUCCUCCAGCUUGUUCCCCUUC 24 5404
SCNNlA-1556 + UCACGCUUGUUCCCCUUC 18 5405
SCNNlA-1557 + CUCACGCUUGUUCCCCUUC 19 5406
SCNNlA-208 + CCUCACGCUUGUUCCCCUUC 20 835
SCNNlA-1558 + UCCUCACGCUUGUUCCCCUUC 21 5407
SCNNlA-1559 + CUCCUCACGCUUGUUCCCCUUC 22 5408
SCNNlA-1560 + GCUCCUCACGCUUGUUCCCCUUC 23 5409
SCNNlA-1561 + UGCUCCUCACGCUUGUUCCCCUUC 24 5410
SCNNlA-1562 + AUGGUCACUGCGGGGAAG 18 5411
SCNNlA-1563 + GAUGGUCACUGCGGGGAAG 19 5412
SCNNlA-238 + AGAUGGUCACUGCGGGGAAG 20 858
SCNNlA-1564 + CAGAUGGUCACUGCGGGGAAG 21 5413
SCNNlA-1565 + GCAGAUGGUCACUGCGGGGAAG 22 5414
SCNNlA-1566 + UGCAGAUGGUCACUGCGGGGAAG 23 5415
SCNNlA-1567 + GUGCAGAUGGUCACUGCGGGGAAG 24 5416
SCNNlA-1568 + AUGGUGGUGUUGUUGCAG 18 5417
SCNNlA-1569 + GAUGGUGGUGUUGUUGCAG 19 5418
SCNNlA-221 + GGAUGGUGGUGUUGUUGCAG 20 844
SCNNlA-1570 + UGGAUGGUGGUGUUGUUGCAG 21 5419
SCNNlA-1571 + GUGGAUGGUGGUGUUGUUGCAG 22 5420
SCNNlA-1572 + CGUGGAUGGUGGUGUUGUUGCAG 23 5421
SCNNlA-1573 + CCGUGGAUGGUGGUGUUGUUGCAG 24
5422
SCNNlA-1574 + AAGACGAGCUUGUCCGAG 18 5423
1225
5535.1 SCNNlA-1575 + GAAGACGAGCUUGUCCGAG 19 5424
SCNNlA-236 + GGAAGACGAGCUUGUCCGAG 20 856
SCNNlA-1576 + GGGAAGACGAGCUUGUCCGAG 21 5425
SCNNlA-1577 + GGGGAAGACGAGCUUGUCCGAG 22 5426
SCNNlA-1578 + CGGGGAAGACGAGCUUGUCCGAG 23 5427
SCNNlA-1579 + GCGGGGAAGACGAGCUUGUCCGAG 24 5428
SCNNlA-1580 + UUGAGGCUGACGGGGUAG 18 5429
SCNNlA-1581 + GUUGAGGCUGACGGGGUAG 19 5430
SCNNlA-232 + UGUUGAGGCUGACGGGGUAG 20 853
SCNNlA-1582 + AUGUUGAGGCUGACGGGGUAG 21 5431
SCNNlA-1583 + GAUGUUGAGGCUGACGGGGUAG 22 5432
SCNNlA-1584 + UGAUGUUGAGGCUGACGGGGUAG 23 5433
SCNNlA-1585 + UUGAUGUUGAGGCUGACGGGGUAG 24
5434
SCNNlA-1586 + GAGCUCUCGGUAGGAGCG 18 5435
SCNNlA-1587 + AGAGCUCUCGGUAGGAGCG 19 5436
SCNNlA-216 + AAGAGCUCUCGGUAGGAGCG 20 840
SCNNlA-1588 + GAAGAGCUCUCGGUAGGAGCG 21 5437
SCNNlA-1589 + CGAAGAGCUCUCGGUAGGAGCG 22 5438
SCNNlA-1590 + UCGAAGAGCUCUCGGUAGGAGCG 23 5439
SCNNlA-1591 + CUCGAAGAGCUCUCGGUAGGAGCG 24 5440
SCNNlA-1592 + GUGCAGAUGGUCACUGCG 18 5441
SCNNlA-1593 + GGUGCAGAUGGUCACUGCG 19 5442
SCNNlA-39 + GGGUGCAGAUGGUCACUGCG 20 518
SCNNlA-1594 + AGGGUGCAGAUGGUCACUGCG 21 5443
SCNNlA-1595 + GAGGGUGCAGAUGGUCACUGCG 22 5444
SCNNlA-1596 + UGAGGGUGCAGAUGGUCACUGCG 23 5445
SCNNlA-1597 + UUGAGGGUGCAGAUGGUCACUGCG 24 5446
SCNNlA-1598 + UUGUUGCAGAAGAACUCG 18 5447
SCNNlA-1599 + GUUGUUGCAGAAGAACUCG 19 5448
SCNNlA-219 + UGUUGUUGCAGAAGAACUCG 20 842
SCNNlA-1600 + GUGUUGUUGCAGAAGAACUCG 21 5449
SCNNlA-1601 + GGUGUUGUUGCAGAAGAACUCG 22 5450
SCNNlA-1602 + UGGUGUUGUUGCAGAAGAACUCG 23 5451
SCNNlA-1603 + GUGGUGUUGUUGCAGAAGAACUCG 24
5452
SCNNlA-1604 + CAAGGGUCAGGGUCAAGG 18 5453
SCNNlA-1605 + G C A AG GGUCAGGGUCAAGG 19 5454
SCNNlA-1606 + AGCAAGGGUCAGGGUCAAGG 20 5455
SCNNlA-1607 + GAGCAAGGGUCAGGGUCAAGG 21 5456
SCNNlA-1608 + AGAGCAAGGGUCAGGGUCAAGG 22 5457
SCNNlA-1609 + GAGAGCAAGGGUCAGGGUCAAGG 23 5458
1226
5535.1 SCNNlA-1610 + GGAGAGCAAGGGUCAGGGUCAAGG 24 5459
SCNNlA-1611 + AGCUCUCGGUAGGAGCGG 18 5460
SCNNlA-1612 + GAGCUCUCGGUAGGAGCGG 19 5461
SCNNlA-60 + AGAGCUCUCGGUAGGAGCGG 20 590
SCNNlA-1613 + AAGAGCUCUCGGUAGGAGCGG 21 5462
SCNNlA-1614 + GAAGAGCUCUCGGUAGGAGCGG 22 5463
SCNNlA-1615 + CGAAGAGCUCUCGGUAGGAGCGG 23 5464
SCNNlA-1616 + UCGAAGAGCUCUCGGUAGGAGCGG 24 5465
SCNNlA-1617 + AACUCGAAGAGCUCUCGG 18 5466
SCNNlA-1618 + GAACUCGAAGAGCUCUCGG 19 5467
SCNNlA-218 + AGAACUCGAAGAGCUCUCGG 20 841
SCNNlA-1619 + AAGAACUCGAAGAGCUCUCGG 21 5468
SCNNlA-1620 + GAAGAACUCGAAGAGCUCUCGG 22 5469
SCNNlA-1621 + AGAAGAACUCGAAGAGCUCUCGG 23 5470
SCNNlA-1622 + CAGAAGAACUCGAAGAGCUCUCGG 24 5471
SCNNlA-1623 + GCCCCGGAGUGGAUUGGG 18 5472
SCNNlA-1624 + AGCCCCGGAGUGGAUUGGG 19 5473
SCNNlA-1625 + GAGCCCCGGAGUGGAUUGGG 20 5474
SCNNlA-1626 + UGAGCCCCGGAGUGGAUUGGG 21 5475
SCNNlA-1627 + AUGAGCCCCGGAGUGGAUUGGG 22 5476
SCNNlA-1628 + CAUGAGCCCCGGAGUGGAUUGGG 23 5477
SCNNlA-1629 + UCAUGAGCCCCGGAGUGGAUUGGG 24 5478
SCNNlA-1630 + CAUGAUACCUCCCCUUGG 18 5479
SCNNlA-1631 + UCAUGAUACCUCCCCUUGG 19 5480
SCNNlA-1632 + CUCAUGAUACCUCCCCUUGG 20 5481
SCNNlA-1633 + GCUCAUGAUACCUCCCCUUGG 21 5482
SCNNlA-1634 + UGCUCAUGAUACCUCCCCUUGG 22 5483
SCNNlA-1635 + CUGCUCAUGAUACCUCCCCUUGG 23 5484
SCNNlA-1636 + ACUGCUCAUGAUACCUCCCCUUGG 24 5485
SCNNlA-1637 + UCCGAGUUGAGGUUGAUG 18 5486
SCNNlA-1638 + GUCCGAGUUGAGGUUGAUG 19 5487
SCNNlA-235 + UGUCCGAGUUGAGGUUGAUG 20 855
SCNNlA-1639 + UUGUCCGAGUUGAGGUUGAUG 21 5488
SCNNlA-1640 + CUUGUCCGAGUUGAGGUUGAUG 22 5489
SCNNlA-1641 + GCUUGUCCGAGUUGAGGUUGAUG 23 5490
SCNNlA-1642 + AGCUUGUCCGAGUUGAGGUUGAUG 24
5491
SCNNlA-1643 + GGGUGCAGAUGGUCACUG 18 5492
SCNNlA-1644 + AGGGUGCAGAUGGUCACUG 19 5493
SCNNlA-37 + GAGGGUGCAGAUGGUCACUG 20 517
SCNNlA-1645 + UGAGGGUGCAGAUGGUCACUG 21 5494
SCNNlA-1646 + UUGAGGGUGCAGAUGGUCACUG 22 5495
1227
5535.1 SCNNlA-1647 + AUUGAGGGUGCAGAUGGUCACUG 23 5496
SCNNlA-1648 + GAUUGAGGGUGCAGAUGGUCACUG 24
5497
SCNNlA-1649 + GAGCCCUGGAGUGGACUG 18 5498
SCNNlA-1650 + UGAGCCCUGGAGUGGACUG 19 5499
SCNNlA-74 + AUGAGCCCUGGAGUGGACUG 20 601
SCNNlA-1651 + CAUGAGCCCUGGAGUGGACUG 21 5500
SCNNlA-1652 + UCAUGAGCCCUGGAGUGGACUG 22 5501
SCNNlA-1653 + UUCAUGAGCCCUGGAGUGGACUG 23 5502
SCNNlA-1654 + CUUCAUGAGCCCUGGAGUGGACUG 24 5503
SCNNlA-1655 + GAGGGACUAACCGACCUG 18 5504
SCNNlA-1656 + AGAGGGACUAACCGACCUG 19 5505
SCNNlA-1657 + CAGAGGGACUAACCGACCUG 20 5506
SCNNlA-1658 + GCAGAGGGACUAACCGACCUG 21 5507
SCNNlA-1659 + GGCAGAGGGACUAACCGACCUG 22 5508
SCNNlA-1660 + GGGCAGAGGGACUAACCGACCUG 23 5509
SCNNlA-1661 + GGGGCAGAGGGACUAACCGACCUG 24 5510
SCNNlA-1662 + AGGUUGAUGUUGAGGCUG 18 5511
SCNNlA-1663 + GAGGUUGAUGUUGAGGCUG 19 5512
SCNNlA-234 + UGAGGUUGAUGUUGAGGCUG 20 854
SCNNlA-1664 + UUGAGGUUGAUGUUGAGGCUG 21 5513
SCNNlA-1665 + GUUGAGGUUGAUGUUGAGGCUG 22 5514
SCNNlA-1666 + AGUUGAGGUUGAUGUUGAGGCUG 23 5515
SCNNlA-1667 + GAGUUGAGGUUGAUGUUGAGGCUG 24
5516
SCNNlA-1668 + GAGACCUGGUAUGGGCUG 18 5517
SCNNlA-1669 + UGAGACCUGGUAUGGGCUG 19 5518
SCNNlA-1670 + AUGAGACCUGGUAUGGGCUG 20 5519
SCNNlA-1671 + CAUGAGACCUGGUAUGGGCUG 21 5520
SCNNlA-1672 + CCAUGAGACCUGGUAUGGGCUG 22 5521
SCNNlA-1673 + UCCAUGAGACCUGGUAUGGGCUG 23 5522
SCNNlA-1674 + CUCCAUGAGACCUGGUAUGGGCUG 24 5523
SCNNlA-1675 + CUCCUCCGCCGUGGGCUG 18 5524
SCNNlA-1676 + CCUCCUCCGCCGUGGGCUG 19 5525
SCNNlA-212 + UCCUCCUCCGCCGUGGGCUG 20 837
SCNNlA-1677 + CUCCUCCUCCGCCGUGGGCUG 21 5526
SCNNlA-1678 + CCUCCUCCUCCGCCGUGGGCUG 22 5527
SCNNlA-1679 + GCCUCCUCCUCCGCCGUGGGCUG 23 5528
SCNNlA-1680 + GGCCUCCUCCUCCGCCGUGGGCUG 24 5529
SCNNlA-1681 + UACAUCAUGCCAAAGGUG 18 5530
SCNNlA-1682 + GUACAUCAUGCCAAAGGUG 19 5531
SCNNlA-229 + AGUACAUCAUGCCAAAGGUG 20 850
1228
5535.1 SCNNlA-1683 + CAGUACAUCAUGCCAAAGGUG 21 5532
SCNNlA-1684 + CCAGUACAUCAUGCCAAAGGUG 22 5533
SCNNlA-1685 + GCCAGUACAUCAUGCCAAAGGUG 23 5534
SCNNlA-1686 + UGCCAGUACAUCAUGCCAAAGGUG 24 5535
SCNNlA-1687 + GCCCUGGAGUGGACUGUG 18 5536
SCNNlA-1688 + AGCCCUGGAGUGGACUGUG 19 5537
SCNNlA-202 + GAGCCCUGGAGUGGACUGUG 20 831
SCNNlA-1689 + UGAGCCCUGGAGUGGACUGUG 21 5538
SCNNlA-1690 + AUGAGCCCUGGAGUGGACUGUG 22 5539
SCNNlA-1691 + CAUGAGCCCUGGAGUGGACUGUG 23 5540
SCNNlA-1692 + UCAUGAGCCCUGGAGUGGACUGUG 24 5541
SCNNlA-1693 + CGUCUUCAUGCGGUUGUG 18 5542
SCNNlA-1694 + CCGUCUUCAUGCGGUUGUG 19 5543
SCNNlA-227 + GCCGUCUUCAUGCGGUUGUG 20 848
SCNNlA-1695 + GGCCGUCUUCAUGCGGUUGUG 21 5544
SCNNlA-1696 + AGGCCGUCUUCAUGCGGUUGUG 22 5545
SCNNlA-1697 + AAGGCCGUCUUCAUGCGGUUGUG 23 5546
SCNNlA-1698 + GAAGGCCGUCUUCAUGCGGUUGUG 24 5547
SCNNlA-1699 + GAGCCCCGGAGUGGAUUG 18 5548
SCNNlA-1700 + UGAGCCCCGGAGUGGAUUG 19 5549
SCNNlA-419 + AUGAGCCCCGGAGUGGAUUG 20 4268
SCNNlA-1701 + CAUGAGCCCCGGAGUGGAUUG 21 5550
SCNNlA-1702 + UCAUGAGCCCCGGAGUGGAUUG 22 5551
SCNNlA-1703 + UUCAUGAGCCCCGGAGUGGAUUG 23 5552
SCNNlA-1704 + CUUCAUGAGCCCCGGAGUGGAUUG 24 5553
SCNNlA-1705 + UGGAUGGUGGUGUUGUUG 18 5554
SCNNlA-1706 + GUGGAUGGUGGUGUUGUUG 19 5555
SCNNlA-222 + CGUGGAUGGUGGUGUUGUUG 20 845
SCNNlA-1707 + CCGUGGAUGGUGGUGUUGUUG 21 5556
SCNNlA-1708 + GCCGUGGAUGGUGGUGUUGUUG 22 5557
SCNNlA-1709 + CGCCGUGGAUGGUGGUGUUGUUG 23 5558
SCNNlA-1710 + GCGCCGUGGAUGGUGGUGUUGUUG 24
5559
SCNNlA-1711 + GGAGCGGUGGAACUCGAU 18 5560
SCNNlA-1712 + AGGAGCGGUGGAACUCGAU 19 5561
SCNNlA-214 + UAGGAGCGGUGGAACUCGAU 20 839
SCNNlA-1713 + GUAGGAGCGGUGGAACUCGAU 21 5562
SCNNlA-1714 + GGUAGGAGCGGUGGAACUCGAU 22 5563
SCNNlA-1715 + CGGUAGGAGCGGUGGAACUCGAU 23 5564
SCNNlA-1716 + UCGGUAGGAGCGGUGGAACUCGAU 24 5565
SCNNlA-1717 + AUGAGCCCCGGAGUGGAU 18 5566
SCNNlA-1718 + CAUGAGCCCCGGAGUGGAU 19 5567
1229
5535.1 SCNNlA-420 + UCAUGAGCCCCGGAGUGGAU 20 4269
SCNNlA-1719 + UUCAUGAGCCCCGGAGUGGAU 21 5568
SCNNlA-1720 + CUUCAUGAGCCCCGGAGUGGAU 22 5569
SCNNlA-1721 + CCUUCAUGAGCCCCGGAGUGGAU 23 5570
SCNNlA-1722 + CCCUUCAUGAGCCCCGGAGUGGAU 24 5571
SCNNlA-1723 + AGGGUGCAGAUGGUCACU 18 5572
SCNNlA-1724 + GAGGGUGCAGAUGGUCACU 19 5573
SCNNlA-242 + UGAGGGUGCAGAUGGUCACU 20 859
SCNNlA-1725 + UUGAGGGUGCAGAUGGUCACU 21 5574
SCNNlA-1726 + AUUGAGGGUGCAGAUGGUCACU 22 5575
SCNNlA-1727 + GAUUGAGGGUGCAGAUGGUCACU 23 5576
SCNNlA-1728 + GGAUUGAGGGUGCAGAUGGUCACU 24
5577
SCNNlA-1729 + UGAGCCCUGGAGUGGACU 18 5578
SCNNlA-1730 + AUGAGCCCUGGAGUGGACU 19 5579
SCNNlA-204 + CAUGAGCCCUGGAGUGGACU 20 832
SCNNlA-1731 + UCAUGAGCCCUGGAGUGGACU 21 5580
SCNNlA-1732 + UUCAUGAGCCCUGGAGUGGACU 22 5581
SCNNlA-1733 + CUUCAUGAGCCCUGGAGUGGACU 23 5582
SCNNlA-1734 + CCUUCAUGAGCCCUGGAGUGGACU 24 5583
SCNNlA-1735 + GCUCAUGAUACCUCCCCU 18 5584
SCNNlA-1736 + UGCUCAUGAUACCUCCCCU 19 5585
SCNNlA-457 + CUGCUCAUGAUACCUCCCCU 20 4306
SCNNlA-1737 + ACUGCUCAUGAUACCUCCCCU 21 5586
SCNNlA-1738 + UACUGCUCAUGAUACCUCCCCU 22 5587
SCNNlA-1739 + AUACUGCUCAUGAUACCUCCCCU 23 5588
SCNNlA-1740 + GAUACUGCUCAUGAUACCUCCCCU 24 5589
SCNNlA-1741 + CAGGGUCAAGGCUGAGCU 18 5590
SCNNlA-1742 + UCAGGGUCAAGGCUGAGCU 19 5591
SCNNlA-1743 + GUCAGGGUCAAGGCUGAGCU 20 5592
SCNNlA-1744 + GGUCAGGGUCAAGGCUGAGCU 21 5593
SCNNlA-1745 + GGGUCAGGGUCAAGGCUGAGCU 22 5594
SCNNlA-1746 + AGGGUCAGGGUCAAGGCUGAGCU 23 5595
SCNNlA-1747 + AAGGGUCAGGGUCAAGGCUGAGCU 24 5596
SCNNlA-1748 + UCUUCAUGCGGUUGUGCU 18 5597
SCNNlA-1749 + GUCUUCAUGCGGUUGUGCU 19 5598
SCNNlA-50 + CGUCUUCAUGCGGUUGUGCU 20 583
SCNNlA-1750 + CCGUCUUCAUGCGGUUGUGCU 21 5599
SCNNlA-1751 + GCCGUCUUCAUGCGGUUGUGCU 22 5600
SCNNlA-1752 + GGCCGUCUUCAUGCGGUUGUGCU 23 5601
SCNNlA-1753 + AGGCCGUCUUCAUGCGGUUGUGCU 24 5602
SCNNlA-1754 + GGGUAGCUGAAGUACUCU 18 5603
1230
5535.1 SCNNlA-1755 + GGGGUAGCUGAAGUACUCU 19 5604
SCNNlA-231 + CGGGGUAGCUGAAGUACUCU 20 852
SCNNlA-1756 + ACGGGGUAGCUGAAGUACUCU 21 5605
SCNNlA-1757 + GACGGGGUAGCUGAAGUACUCU 22 5606
SCNNlA-1758 + UGACGGGGUAGCUGAAGUACUCU 23 5607
SCNNlA-1759 + CUGACGGGGUAGCUGAAGUACUCU 24 5608
SCNNlA-1760 + UGCUGGGGCGCCGCAGGU 18 5609
SCNNlA-1761 + CUGCUGGGGCGCCGCAGGU 19 5610
SCNNlA-210 + GCUGCUGGGGCGCCGCAGGU 20 836
SCNNlA-1762 + GGCUGCUGGGGCGCCGCAGGU 21 5611
SCNNlA-1763 + GGGCUGCUGGGGCGCCGCAGGU 22 5612
SCNNlA-1764 + UGGGCUGCUGGGGCGCCGCAGGU 23 5613
SCNNlA-1765 + GUGGGCUGCUGGGGCGCCGCAGGU 24 5614
SCNNlA-1766 + ACUCGAAGAGCUCUCGGU 18 5615
SCNNlA-1767 + AACUCGAAGAGCUCUCGGU 19 5616
SCNNlA-58 + GAACUCGAAGAGCUCUCGGU 20 524
SCNNlA-1768 + AGAACUCGAAGAGCUCUCGGU 21 5617
SCNNlA-1769 + AAGAACUCGAAGAGCUCUCGGU 22 5618
SCNNlA-1770 + GAAGAACUCGAAGAGCUCUCGGU 23 5619
SCNNlA-1771 + AGAAGAACUCGAAGAGCUCUCGGU 24 5620
SCNNlA-1772 + CCCUCCAUGAGACCUGGU 18 5621
SCNNlA-1773 + CCCCUCCAUGAGACCUGGU 19 5622
SCNNlA-199 + UCCCCUCCAUGAGACCUGGU 20 828
SCNNlA-1774 + UUCCCCUCCAUGAGACCUGGU 21 5623
SCNNlA-1775 + GUUCCCCUCCAUGAGACCUGGU 22 5624
SCNNlA-1776 + UGUUCCCCUCCAUGAGACCUGGU 23 5625
SCNNlA-1777 + UUGUUCCCCUCCAUGAGACCUGGU 24 5626
SCNNlA-1778 + UGAGCCCCGGAGUGGAUU 18 5627
SCNNlA-1779 + AUGAGCCCCGGAGUGGAUU 19 5628
SCNNlA-425 + CAUGAGCCCCGGAGUGGAUU 20 4274
SCNNlA-1780 + UCAUGAGCCCCGGAGUGGAUU 21 5629
SCNNlA-1781 + UUCAUGAGCCCCGGAGUGGAUU 22 5630
SCNNlA-1782 + CUUCAUGAGCCCCGGAGUGGAUU 23 5631
SCNNlA-1783 + CCUUCAUGAGCCCCGGAGUGGAUU 24 5632
SCNNlA-1784 + GCUGGGGCGCCGCAGGUU 18 5633
SCNNlA-1785 + UGCUGGGGCGCCGCAGGUU 19 5634
SCNNlA-69 + CUGCUGGGGCGCCGCAGGUU 20 597
SCNNlA-1786 + GCUGCUGGGGCGCCGCAGGUU 21 5635
SCNNlA-1787 + GGCUGCUGGGGCGCCGCAGGUU 22 5636
SCNNlA-1788 + GGGCUGCUGGGGCGCCGCAGGUU 23 5637
SCNNlA-1789 + UGGGCUGCUGGGGCGCCGCAGGUU 24 5638
SCNNlA-1790 - C AG U A U C A AG G U A AG C A A 18 5639
1231
5535.1 SCNNlA-1791 - GCAGUAUCAAGGUAAGCAA 19 5640
SCNNlA-393 - AG C AG U A U C A AG G U A AG C A A 20 4242
SCNNlA-1792 - GAGCAGUAUCAAGGUAAGCAA 21 5641
SCNNlA-1793 - UGAGCAGUAU C A AG G U A AG C A A 22 5642
SCNNlA-1794 - AUGAGCAGUAUCAAGGUAAGCAA 23 5643
SCNNlA-1795 - CAUGAGCAGUAUCAAGGUAAGCAA 24 5644
SCNNlA-1796 - CACUCCAGGGCUCAUGAA 18 5645
SCNNlA-1797 - CCACUCCAGGGCUCAUGAA 19 5646
SCNNlA-11 - UCCACUCCAGGGCUCAUGAA 20 560
SCNNlA-1798 - GUCCACUCCAGGGCUCAUGAA 21 5647
SCNNlA-1799 - AGUCCACUCCAGGGCUCAUGAA 22 5648
SCNNlA-1800 - CAGUCCACUCCAGGGCUCAUGAA 23 5649
SCNNlA-1801 - ACAGUCCACUCCAGGGCUCAUGAA 24 5650
SCNNlA-1802 - CACUCCGGGGCUCAUGAA 18 5651
SCNNlA-1803 - CCACUCCGGGGCUCAUGAA 19 5652
SCNNlA-451 - UCCACUCCGGGGCUCAUGAA 20 4300
SCNNlA-1804 - AUCCACUCCGGGGCUCAUGAA 21 5653
SCNNlA-1805 - AAUCCACUCCGGGGCUCAUGAA 22 5654
SCNNlA-1806 - CAAUCCACUCCGGGGCUCAUGAA 23 5655
SCNNlA-1807 - CCAAUCCACUCCGGGGCUCAUGAA 24 5656
SCNNlA-1808 - G C AG U A U C A AG G U A AG C A 18 5657
SCNNlA-1809 - AGCAGUAUCAAGGUAAGCA 19 5658
SCNNlA-342 - GAGCAGUAUCAAGGUAAGCA 20 4191
SCNNlA-1810 - UGAGCAGUAUCAAGGUAAGCA 21 5659
SCNNlA-1811 - AUGAGCAGUAUCAAGGUAAGCA 22 5660
SCNNlA-1812 - CAUGAGCAGUAUCAAGGUAAGCA 23 5661
SCNNlA-1813 - UCAUGAGCAGUAUCAAGGUAAGCA 24 5662
SCNNlA-1814 - AGCCCAUACCAGGUCUCA 18 5663
SCNNlA-1815 - CAGCCCAUACCAGGUCUCA 19 5664
SCNNlA-1 - GCAGCCCAUACCAGGUCUCA 20 503
SCNNlA-1816 - UGCAGCCCAUACCAGGUCUCA 21 5665
SCNNlA-1817 - CUGCAGCCCAUACCAGGUCUCA 22 5666
SCNNlA-1818 - UCUGCAGCCCAUACCAGGUCUCA 23 5667
SCNNlA-1819 - CUCUGCAGCCCAUACCAGGUCUCA 24 5668
SCNNlA-1820 - GUUCCAGGGGUGAUGGGA 18 5669
SCNNlA-1821 - GGUUCCAGGGGUGAUGGGA 19 5670
SCNNlA-1822 - GGGUUCCAGGGGUGAUGGGA 20 5671
SCNNlA-1823 - CGGGUUCCAGGGGUGAUGGGA 21 5672
SCNNlA-1824 - UCGGGUUCCAGGGGUGAUGGGA 22 5673
SCNNlA-1825 - CUCGGGUUCCAGGGGUGAUGGGA 23 5674
SCNNlA-1826 - ACUCGGGUUCCAGGGGUGAUGGGA 24 5675
SCNNlA-1827 - CAUACCAGGUCUCAUGGA 18 5676
1232
5535.1 SCNNlA-1828 - CCAUACCAGGUCUCAUGGA 19 5677
SCNNlA-3 - CCCAUACCAGGUCUCAUGGA 20 556
SCNNlA-1829 - GCCCAUACCAGGUCUCAUGGA 21 5678
SCNNlA-1830 - AGCCCAUACCAGGUCUCAUGGA 22 5679
SCNNlA-1831 - CAGCCCAUACCAGGUCUCAUGGA 23 5680
SCNNlA-1832 - GCAGCCCAUACCAGGUCUCAUGGA 24 5681
SCNNlA-1833 - CCACUCCAGGGCUCAUGA 18 5682
SCNNlA-1834 - UCCACUCCAGGGCUCAUGA 19 5683
SCNNlA-10 - GUCCACUCCAGGGCUCAUGA 20 505
SCNNlA-1835 - AGUCCACUCCAGGGCUCAUGA 21 5684
SCNNlA-1836 - CAGUCCACUCCAGGGCUCAUGA 22 5685
SCNNlA-1837 - ACAGUCCACUCCAGGGCUCAUGA 23 5686
SCNNlA-1838 - CACAGUCCACUCCAGGGCUCAUGA 24 5687
SCNNlA-1839 - CCACUCCGGGGCUCAUGA 18 5688
SCNNlA-1840 - UCCACUCCGGGGCUCAUGA 19 5689
SCNNlA-400 - AUCCACUCCGGGGCUCAUGA 20 4249
SCNNlA-1841 - AAUCCACUCCGGGGCUCAUGA 21 5690
SCNNlA-1842 - CAAUCCACUCCGGGGCUCAUGA 22 5691
SCNNlA-1843 - CCAAUCCACUCCGGGGCUCAUGA 23 5692
SCNNlA-1844 - CCCAAUCCACUCCGGGGCUCAUGA 24 5693
SCNNlA-1845 - CUCGGGUUCCAGGGGUGA 18 5694
SCNNlA-1846 - ACUCGGGUUCCAGGGGUGA 19 5695
SCNNlA-401 - CACUCGGGUUCCAGGGGUGA 20 4250
SCNNlA-1847 - UCACUCGGGUUCCAGGGGUGA 21 5696
SCNNlA-1848 - CUCACUCGGGUUCCAGGGGUGA 22 5697
SCNNlA-1849 - CCUCACUCGGGUUCCAGGGGUGA 23 5698
SCNNlA-1850 - GCCUCACUCGGGUUCCAGGGGUGA 24 5699
SCNNlA-1851 - CGAGUUCCACCGCUCCUA 18 5700
SCNNlA-1852 - UCGAGUUCCACCGCUCCUA 19 5701
SCNNlA-190 - AUCGAGUUCCACCGCUCCUA 20 820
SCNNlA-1853 - GAUCGAGUUCCACCGCUCCUA 21 5702
SCNNlA-1854 - UGAUCGAGUUCCACCGCUCCUA 22 5703
SCNNlA-1855 - CUGAUCGAGUUCCACCGCUCCUA 23 5704
SCNNlA-1856 - CCUGAUCGAGUUCCACCGCUCCUA 24 5705
SCNNlA-1857 - CUCAACAUCAACCUCAAC 18 5706
SCNNlA-1858 - CCUCAACAUCAACCUCAAC 19 5707
SCNNlA-198 - GCCUCAACAUCAACCUCAAC 20 827
SCNNlA-1859 - AGCCUCAACAUCAACCUCAAC 21 5708
SCNNlA-1860 - CAG CC U CAAC AU C AACC U C AAC 22 5709
SCNNlA-1861 - UCAGCCUCAACAUCAACCUCAAC 23 5710
SCNNlA-1862 - GUCAGCCUCAACAUCAACCUCAAC 24 5711
SCNNlA-1863 - GUGGGCGCAGGGUGGGAC 18 5712
1233
5535.1 SCNNlA-1864 - UGUGGGCGCAGGGUGGGAC 19 5713
SCNNlA-1865 - AUGUGGGCGCAGGGUGGGAC 20 5714
SCNNlA-1866 - AAUGUGGGCGCAGGGUGGGAC 21 5715
SCNNlA-1867 - GAAUGUGGGCGCAGGGUGGGAC 22 5716
SCNNlA-1868 - AGAAUGUGGGCGCAGGGUGGGAC 23 5717
SCNNlA-1869 - GAGAAUGUGGGCGCAGGGUGGGAC 24
5718
SCNNlA-1870 - AGUUCCACCGCUCCUACC 18 5719
SCNNlA-1871 - GAGUUCCACCGCUCCUACC 19 5720
SCNNlA-191 - CGAGUUCCACCGCUCCUACC 20 821
SCNNlA-1872 - UCGAGUUCCACCGCUCCUACC 21 5721
SCNNlA-1873 - AUCGAGUUCCACCGCUCCUACC 22 5722
SCNNlA-1874 - GAUCGAGUUCCACCGCUCCUACC 23 5723
SCNNlA-1875 - UGAUCGAGUUCCACCGCUCCUACC 24 5724
SCNNlA-1876 - GAGAGGGCACUCAGGGCC 18 5725
SCNNlA-1877 - GGAGAGGGCACUCAGGGCC 19 5726
SCNNlA-1878 - GGGAGAGGGCACUCAGGGCC 20 5727
SCNNlA-1879 - UGGGAGAGGGCACUCAGGGCC 21 5728
SCNNlA-1880 - AUGGGAGAGGGCACUCAGGGCC 22 5729
SCNNlA-1881 - GAUGGGAGAGGGCACUCAGGGCC 23 5730
SCNNlA-1882 - UGAUGGGAGAGGGCACUCAGGGCC 24 5731
SCNNlA-1883 - AGGAGCAGGGGCUGGGCC 18 5732
SCNNlA-1884 - GAGGAGCAGGGGCUGGGCC 19 5733
SCNNlA-182 - UGAGGAGCAGGGGCUGGGCC 20 815
SCNNlA-1885 - GUGAGGAGCAGGGGCUGGGCC 21 5734
SCNNlA-1886 - CGUGAGGAGCAGGGGCUGGGCC 22 5735
SCNNlA-1887 - GCGUGAGGAGCAGGGGCUGGGCC 23 5736
SCNNlA-1888 - AGCGUGAGGAGCAGGGGCUGGGCC 24 5737
SCNNlA-1889 - UGGGACAUGGGCAUGGCC 18 5738
SCNNlA-1890 - GUGGGACAUGGGCAUGGCC 19 5739
SCNNlA-347 - GGUGGGACAUGGGCAUGGCC 20 4196
SCNNlA-1891 - GGGUGGGACAUGGGCAUGGCC 21 5740
SCNNlA-1892 - AGGGUGGGACAUGGGCAUGGCC 22 5741
SCNNlA-1893 - CAGGGUGGGACAUGGGCAUGGCC 23 5742
SCNNlA-1894 - GCAGGGUGGGACAUGGGCAUGGCC 24 5743
SCNNlA-1895 - UCAUGAAGGGGAACAAGC 18 5744
SCNNlA-1896 - CUCAUGAAGGGGAACAAGC 19 5745
SCNNlA-176 - GCUCAUGAAGGGGAACAAGC 20 811
SCNNlA-1897 - GGCUCAUGAAGGGGAACAAGC 21 5746
SCNNlA-1898 - GGGCUCAUGAAGGGGAACAAGC 22 5747
SCNNlA-1899 - AGGGCUCAUGAAGGGGAACAAGC 23 5748
SCNNlA-1900 - CAGGGCUCAUGAAGGGGAACAAGC 24 5749
1234
5535.1 SCNNlA-1901 - GGGGCUCAUGAAGGGGAACAAGC 23 5750
SCNNlA-1902 - CGGGGCUCAUGAAGGGGAACAAGC 24 5751
SCNNlA-1903 - UCAUGGAGGGGAACAAGC 18 5752
SCNNlA-1904 - CUCAUGGAGGGGAACAAGC 19 5753
SCNNlA-5 - UCUCAUGGAGGGGAACAAGC 20 557
SCNNlA-1905 - GUCUCAUGGAGGGGAACAAGC 21 5754
SCNNlA-1906 - GGUCUCAUGGAGGGGAACAAGC 22 5755
SCNNlA-1907 - AGGUCUCAUGGAGGGGAACAAGC 23 5756
SCNNlA-1908 - CAGGUCUCAUGGAGGGGAACAAGC 24 5757
SCNNlA-1909 - AG C AG U A U C A AG G U A AG C 18 5758
SCNNlA-1910 - GAGCAGUAUCAAGGUAAGC 19 5759
SCNNlA-1911 - UGAGCAGUAU C A AG G U A AG C 20 5760
SCNNlA-1912 - AUGAGCAGUAUCAAGGUAAGC 21 5761
SCNNlA-1913 - CAUGAGCAGUAUCAAGGUAAGC 22 5762
SCNNlA-1914 - UCAUGAGCAGUAUCAAGGUAAGC 23 5763
SCNNlA-1915 - AUCAUGAGCAGUAUCAAGGUAAGC 24 5764
SCNNlA-1916 - GGAACAAGCGUGAGGAGC 18 5765
SCNNlA-1917 - GGGAACAAGCGUGAGGAGC 19 5766
SCNNlA-14 - GGGGAACAAGCGUGAGGAGC 20 506
SCNNlA-1918 - AGGGGAACAAGCGUGAGGAGC 21 5767
SCNNlA-1919 - AAGGGGAACAAGCGUGAGGAGC 22 5768
SCNNlA-1920 - GAAGGGGAACAAGCGUGAGGAGC 23 5769
SCNNlA-1921 - UGAAGGGGAACAAGCGUGAGGAGC 24 5770
SCNNlA-1922 - UGCUCCCAGCACAACCGC 18 5771
SCNNlA-1923 - GUGCUCCCAGCACAACCGC 19 5772
SCNNlA-193 - UGUGCUCCCAGCACAACCGC 20 823
SCNNlA-1924 - GUGUGCUCCCAGCACAACCGC 21 5773
SCNNlA-1925 - GGUGUGCUCCCAGCACAACCGC 22 5774
SCNNlA-1926 - UGGUGUGCUCCCAGCACAACCGC 23 5775
SCNNlA-1927 - CUGGUGUGCUCCCAGCACAACCGC 24 5776
SCNNlA-1928 - GUGGGACAUGGGCAUGGC 18 5777
SCNNlA-1929 - GGUGGGACAUGGGCAUGGC 19 5778
SCNNlA-1930 - GGGUGGGACAUGGGCAUGGC 20 5779
SCNNlA-1931 - AGGGUGGGACAUGGGCAUGGC 21 5780
SCNNlA-1932 - CAGGGUGGGACAUGGGCAUGGC 22 5781
SCNNlA-1933 - GCAGGGUGGGACAUGGGCAUGGC 23 5782
SCNNlA-1934 - CGCAGGGUGGGACAUGGGCAUGGC 24 5783
SCNNlA-1935 - CUUCCAAGGGGAGGUAUC 18 5784
SCNNlA-1936 - CCUUCCAAGGGGAGGUAUC 19 5785
SCNNlA-1937 - CCCUUCCAAGGGGAGGUAUC 20 5786
SCNNlA-1938 - UCCCUUCCAAGGGGAGGUAUC 21 5787
SCNNlA-1939 - GUCCCUUCCAAGGGGAGGUAUC 22 5788
1235
5535.1 SCNNlA-1940 - UGUCCCUUCCAAGGGGAGGUAUC 23 5789
SCNNlA-1941 - CUGUCCCUUCCAAGGGGAGGUAUC 24 5790
SCNNlA-1942 - GCUCUCCCCAAUCCACUC 18 5791
SCNNlA-1943 - UGCUCUCCCCAAUCCACUC 19 5792
SCNNlA-410 - UUGCUCUCCCCAAUCCACUC 20 4259
SCNNlA-1944 - CUUGCUCUCCCCAAUCCACUC 21 5793
SCNNlA-1945 - CCUUGCUCUCCCCAAUCCACUC 22 5794
SCNNlA-1946 - CCCUUGCUCUCCCCAAUCCACUC 23 5795
SCNNlA-1947 - ACCCUUGCUCUCCCCAAUCCACUC 24 5796
SCNNlA-1948 - GCCCUCCACAGUCCACUC 18 5797
SCNNlA-1949 - AGCCCUCCACAGUCCACUC 19 5798
SCNNlA-170 - UAGCCCUCCACAGUCCACUC 20 808
SCNNlA-1950 - CUAGCCCUCCACAGUCCACUC 21 5799
SCNNlA-1951 - UCUAGCCCUCCACAGUCCACUC 22 5800
SCNNlA-1952 - CUCUAGCCCUCCACAGUCCACUC 23 5801
SCNNlA-1953 - ACUCUAGCCCUCCACAGUCCACUC 24 5802
SCNNlA-1954 - CAGUCCACUCCAGGGCUC 18 5803
SCNNlA-1955 - ACAGUCCACUCCAGGGCUC 19 5804
SCNNlA-171 - CACAGUCCACUCCAGGGCUC 20 809
SCNNlA-1956 - CCACAGUCCACUCCAGGGCUC 21 5805
SCNNlA-1957 - UCCACAGUCCACUCCAGGGCUC 22 5806
SCNNlA-1958 - CUCCACAGUCCACUCCAGGGCUC 23 5807
SCNNlA-1959 - CCUCCACAGUCCACUCCAGGGCUC 24 5808
SCNNlA-1960 - CAAUCCACUCCGGGGCUC 18 5809
SCNNlA-1961 - CCAAUCCACUCCGGGGCUC 19 5810
SCNNlA-1962 - CCCAAUCCACUCCGGGGCUC 20 5811
SCNNlA-1963 - CCCCAAUCCACUCCGGGGCUC 21 5812
SCNNlA-1964 - UCCCCAAUCCACUCCGGGGCUC 22 5813
SCNNlA-1965 - CUCCCCAAUCCACUCCGGGGCUC 23 5814
SCNNlA-1966 - UCUCCCCAAUCCACUCCGGGGCUC 24 5815
SCNNlA-1967 - CAGCCCAUACCAGGUCUC 18 5816
SCNNlA-1968 - GCAGCCCAUACCAGGUCUC 19 5817
SCNNlA-159 - UGCAGCCCAUACCAGGUCUC 20 803
SCNNlA-1969 - CUGCAGCCCAUACCAGGUCUC 21 5818
SCNNlA-1970 - UCUGCAGCCCAUACCAGGUCUC 22 5819
SCNNlA-1971 - CUCUGCAGCCCAUACCAGGUCUC 23 5820
SCNNlA-1972 - CCUCUGCAGCCCAUACCAGGUCUC 24 5821
SCNNlA-1973 - GCAGCCUCACUCGGGUUC 18 5822
SCNNlA-1974 - GGCAGCCUCACUCGGGUUC 19 5823
SCNNlA-1975 - GGGCAGCCUCACUCGGGUUC 20 5824
SCNNlA-1976 - GGGGCAGCCUCACUCGGGUUC 21 5825
SCNNlA-1977 - AGGGGCAGCCUCACUCGGGUUC 22 5826
1236
5535.1 SCNNlA-1978 - CAGGGGCAGCCUCACUCGGGUUC 23 5827
SCNNlA-1979 - CCAGGGGCAGCCUCACUCGGGUUC 24 5828
SCNNlA-1980 - CUCAUGAAGGGGAACAAG 18 5829
SCNNlA-1981 - GCUCAUGAAGGGGAACAAG 19 5830
SCNNlA-1982 - GGCUCAUGAAGGGGAACAAG 20 5831
SCNNlA-1983 - GGGCUCAUGAAGGGGAACAAG 21 5832
SCNNlA-1984 - GGGGCUCAUGAAGGGGAACAAG 22 5833
SCNNlA-1985 - CGGGGCUCAUGAAGGGGAACAAG 23 5834
SCNNlA-1986 - CCGGGGCUCAUGAAGGGGAACAAG 24 5835
SCNNlA-1987 - CUCAUGGAGGGGAACAAG 18 5836
SCNNlA-1988 - UCUCAUGGAGGGGAACAAG 19 5837
SCNNlA-165 - GUCUCAUGGAGGGGAACAAG 20 805
SCNNlA-1989 - GGUCUCAUGGAGGGGAACAAG 21 5838
SCNNlA-1990 - AGGUCUCAUGGAGGGGAACAAG 22 5839
SCNNlA-1991 - CAGGUCUCAUGGAGGGGAACAAG 23 5840
SCNNlA-1992 - CCAGGUCUCAUGGAGGGGAACAAG 24 5841
SCNNlA-1993 - CCAGCUGUCCCUUCCAAG 18 5842
SCNNlA-1994 - UCCAGCUGUCCCUUCCAAG 19 5843
SCNNlA-412 - AUCCAGCUGUCCCUUCCAAG 20 4261
SCNNlA-1995 - ACUCCAGGGCUCAUGAAG 18 5844
SCNNlA-1996 - CACUCCAGGGCUCAUGAAG 19 5845
SCNNlA-12 - CCACUCCAGGGCUCAUGAAG 20 561
SCNNlA-1997 - UCCACUCCAGGGCUCAUGAAG 21 5846
SCNNlA-1998 - GUCCACUCCAGGGCUCAUGAAG 22 5847
SCNNlA-1999 - AGUCCACUCCAGGGCUCAUGAAG 23 5848
SCNNlA-2000 - CAGUCCACUCCAGGGCUCAUGAAG 24 5849
SCNNlA-2001 - ACUCCGGGGCUCAUGAAG 18 5850
SCNNlA-2002 - CACUCCGGGGCUCAUGAAG 19 5851
SCNNlA-453 - CCACUCCGGGGCUCAUGAAG 20 4302
SCNNlA-2003 - UCCACUCCGGGGCUCAUGAAG 21 5852
SCNNlA-2004 - AUCCACUCCGGGGCUCAUGAAG 22 5853
SCNNlA-2005 - AAUCCACUCCGGGGCUCAUGAAG 23 5854
SCNNlA-2006 - CAAUCCACUCCGGGGCUCAUGAAG 24 5855
SCNNlA-2007 - GGGAACAAGCUGGAGGAG 18 5856
SCNNlA-2008 - GGGGAACAAGCUGGAGGAG 19 5857
SCNNlA-169 - AGGGGAACAAGCUGGAGGAG 20 807
SCNNlA-2009 - AAGGGGAACAAGCUGGAGGAG 21 5858
SCNNlA-2010 - GAAGGGGAACAAGCUGGAGGAG 22 5859
SCNNlA-2011 - UGAAGGGGAACAAGCUGGAGGAG 23 5860
SCNNlA-2012 - AUGAAGGGGAACAAGCUGGAGGAG 24 5861
SCNNlA-2013 - GAGGGGAACAAGCUGGAGGAG 21 5862
SCNNlA-2014 - GGAGGGGAACAAGCUGGAGGAG 22 5863
1237
5535.1 SCNNlA-2015 - UGGAGGGGAACAAGCUGGAGGAG 23 5864
SCNNlA-2016 - AUGGAGGGGAACAAGCUGGAGGAG 24 5865
SCNNlA-2017 - GGGAACAAGCGUGAGGAG 18 5866
SCNNlA-2018 - GGGGAACAAGCGUGAGGAG 19 5867
SCNNlA-179 - AGGGGAACAAGCGUGAGGAG 20 813
SCNNlA-2019 - AAGGGGAACAAGCGUGAGGAG 21 5868
SCNNlA-2020 - GAAGGGGAACAAGCGUGAGGAG 22 5869
SCNNlA-2021 - UGAAGGGGAACAAGCGUGAGGAG 23 5870
SCNNlA-2022 - AUGAAGGGGAACAAGCGUGAGGAG 24 5871
SCNNlA-2023 - CAGCAGCCCACGGCGGAG 18 5872
SCNNlA-2024 - CCAGCAGCCCACGGCGGAG 19 5873
SCNNlA-187 - CCCAGCAGCCCACGGCGGAG 20 818
SCNNlA-2025 - CCCCAGCAGCCCACGGCGGAG 21 5874
SCNNlA-2026 - GCCCCAGCAGCCCACGGCGGAG 22 5875
SCNNlA-2027 - CGCCCCAGCAGCCCACGGCGGAG 23 5876
SCNNlA-2028 - GCGCCCCAGCAGCCCACGGCGGAG 24 5877
SCNNlA-2029 - AUACCAGGUCUCAUGGAG 18 5878
SCNNlA-2030 - CAUACCAGGUCUCAUGGAG 19 5879
SCNNlA-4 - CCAUACCAGGUCUCAUGGAG 20 498
SCNNlA-2031 - CCCAUACCAGGUCUCAUGGAG 21 5880
SCNNlA-2032 - GCCCAUACCAGGUCUCAUGGAG 22 5881
SCNNlA-2033 - AGCCCAUACCAGGUCUCAUGGAG 23 5882
SCNNlA-2034 - CAGCCCAUACCAGGUCUCAUGGAG 24 5883
SCNNlA-2035 - GCGCCCCAGCAGCCCACG 18 5884
SCNNlA-2036 - GGCGCCCCAGCAGCCCACG 19 5885
SCNNlA-183 - CGGCGCCCCAGCAGCCCACG 20 816
SCNNlA-2037 - GCGGCGCCCCAGCAGCCCACG 21 5886
SCNNlA-2038 - UGCGGCGCCCCAGCAGCCCACG 22 5887
SCNNlA-2039 - CUGCGGCGCCCCAGCAGCCCACG 23 5888
SCNNlA-2040 - CCUGCGGCGCCCCAGCAGCCCACG 24 5889
SCNNlA-2041 - CCCCAGCAGCCCACGGCG 18 5890
SCNNlA-2042 - GCCCCAGCAGCCCACGGCG 19 5891
SCNNlA-185 - CGCCCCAGCAGCCCACGGCG 20 817
SCNNlA-2043 - GCGCCCCAGCAGCCCACGGCG 21 5892
SCNNlA-2044 - GGCGCCCCAGCAGCCCACGGCG 22 5893
SCNNlA-2045 - CGGCGCCCCAGCAGCCCACGGCG 23 5894
SCNNlA-2046 - GCGGCGCCCCAGCAGCCCACGGCG 24 5895
SCNNlA-2047 - GGAGAAUGUGGGCGCAGG 18 5896
SCNNlA-2048 - GGGAGAAUGUGGGCGCAGG 19 5897
SCNNlA-2049 - UGGGAGAAUGUGGGCGCAGG 20 5898
SCNNlA-2050 - AGCAGCCCACGGCGGAGG 18 5899
SCNNlA-2051 - CAGCAGCCCACGGCGGAGG 19 5900
1238
5535.1 SCNNlA-23 - CCAGCAGCCCACGGCGGAGG 20 566
SCNNlA-2052 - CCCAGCAGCCCACGGCGGAGG 21 5901
SCNNlA-2053 - CCCCAGCAGCCCACGGCGGAGG 22 5902
SCNNlA-2054 - GCCCCAGCAGCCCACGGCGGAGG 23 5903
SCNNlA-2055 - CGCCCCAGCAGCCCACGGCGGAGG 24 5904
SCNNlA-2056 - CGCCCCAGCAGCCCACGG 18 5905
SCNNlA-2057 - GCGCCCCAGCAGCCCACGG 19 5906
SCNNlA-21 - GGCGCCCCAGCAGCCCACGG 20 510
SCNNlA-2058 - CGGCGCCCCAGCAGCCCACGG 21 5907
SCNNlA-2059 - GCGGCGCCCCAGCAGCCCACGG 22 5908
SCNNlA-2060 - UGCGGCGCCCCAGCAGCCCACGG 23 5909
SCNNlA-2061 - CUGCGGCGCCCCAGCAGCCCACGG 24 5910
SCNNlA-2062 - CCCAGCAGCCCACGGCGG 18 5911
SCNNlA-2063 - CCCCAGCAGCCCACGGCGG 19 5912
SCNNlA-22 - GCCCCAGCAGCCCACGGCGG 20 511
SCNNlA-2064 - CGCCCCAGCAGCCCACGGCGG 21 5913
SCNNlA-2065 - GCGCCCCAGCAGCCCACGGCGG 22 5914
SCNNlA-2066 - GGCGCCCCAGCAGCCCACGGCGG 23 5915
SCNNlA-2067 - CGGCGCCCCAGCAGCCCACGGCGG 24 5916
SCNNlA-2068 - GAGAAUGUGGGCGCAGGG 18 5917
SCNNlA-2069 - GGAGAAUGUGGGCGCAGGG 19 5918
SCNNlA-354 - GGGAGAAUGUGGGCGCAGGG 20 4203
SCNNlA-2070 - UGGGAGAAUGUGGGCGCAGGG 21 5919
SCNNlA-2071 - GUGGGAGAAUGUGGGCGCAGGG 22 5920
SCNNlA-2072 - AGUGGGAGAAUGUGGGCGCAGGG 23 5921
SCNNlA-2073 - GAGUGGGAGAAUGUGGGCGCAGGG 24
5922
SCNNlA-2074 - AAGCGUGAGGAGCAGGGG 18 5923
SCNNlA-2075 - CAAG CG U G AG G AG CAG G GG 19 5924
SCNNlA-181 - ACAAGCGUGAGGAGCAGGGG 20 814
SCNNlA-2076 - AACAAGCGUGAGGAGCAGGGG 21 5925
SCNNlA-2077 - GAACAAGCGUGAGGAGCAGGGG 22 5926
SCNNlA-2078 - GGAACAAGCGUGAGGAGCAGGGG 23 5927
SCNNlA-2079 - GGGAACAAGCGUGAGGAGCAGGGG 24 5928
SCNNlA-2080 - CCAUACCAGGUCUCAUGG 18 5929
SCNNlA-2081 - CCCAUACCAGGUCUCAUGG 19 5930
SCNNlA-2 - GCCCAUACCAGGUCUCAUGG 20 497
SCNNlA-2082 - AGCCCAUACCAGGUCUCAUGG 21 5931
SCNNlA-2083 - CAGCCCAUACCAGGUCUCAUGG 22 5932
SCNNlA-2084 - GCAGCCCAUACCAGGUCUCAUGG 23 5933
SCNNlA-2085 - UGCAGCCCAUACCAGGUCUCAUGG 24 5934
SCNNlA-2086 - GGGUUCCAGGGGUGAUGG 18 5935
1239
5535.1 SCNNlA-2087 - CGGGUUCCAGGGGUGAUGG 19 5936
SCNNlA-2088 - UCGGGUUCCAGGGGUGAUGG 20 5937
SCNNlA-2089 - CUCGGGUUCCAGGGGUGAUGG 21 5938
SCNNlA-2090 - ACUCGGGUUCCAGGGGUGAUGG 22 5939
SCNNlA-2091 - CACUCGGGUUCCAGGGGUGAUGG 23 5940
SCNNlA-2092 - UCACUCGGGUUCCAGGGGUGAUGG 24 5941
SCNNlA-2093 - U G AAG GG G AAC AAG C U G G 18 5942
SCNNlA-2094 - AUGAAGGGGAACAAGCUGG 19 5943
SCNNlA-455 - CAUGAAGGGGAACAAGCUGG 20 4304
SCNNlA-2095 - UCAUGAAGGGGAACAAGCUGG 21 5944
SCNNlA-2096 - CUCAUGAAGGGGAACAAGCUGG 22 5945
SCNNlA-2097 - GCUCAUGAAGGGGAACAAGCUGG 23 5946
SCNNlA-2098 - GGCUCAUGAAGGGGAACAAGCUGG 24 5947
SCNNlA-2099 - UGGAGGGGAACAAGCUGG 18 5948
SCNNlA-2100 - AUGGAGGGGAACAAGCUGG 19 5949
SCNNlA-6 - CAUGGAGGGGAACAAGCUGG 20 558
SCNNlA-2101 - UCAUGGAGGGGAACAAGCUGG 21 5950
SCNNlA-2102 - CUCAUGGAGGGGAACAAGCUGG 22 5951
SCNNlA-2103 - UCUCAUGGAGGGGAACAAGCUGG 23 5952
SCNNlA-2104 - GUCUCAUGGAGGGGAACAAGCUGG 24 5953
SCNNlA-2105 - UCCACUCCAGGGCUCAUG 18 5954
SCNNlA-2106 - GUCCACUCCAGGGCUCAUG 19 5955
SCNNlA-172 - AGUCCACUCCAGGGCUCAUG 20 810
SCNNlA-2107 - CAGUCCACUCCAGGGCUCAUG 21 5956
SCNNlA-2108 - ACAGUCCACUCCAGGGCUCAUG 22 5957
SCNNlA-2109 - CACAGUCCACUCCAGGGCUCAUG 23 5958
SCNNlA-2110 - CCA CAGUCCACUCCAGGGCUCAUG 24 5959
SCNNlA-2111 - UCCACUCCGGGGCUCAUG 18 5960
SCNNlA-2112 - AUCCACUCCGGGGCUCAUG 19 5961
SCNNlA-2113 - AAUCCACUCCGGGGCUCAUG 20 5962
SCNNlA-2114 - CAAUCCACUCCGGGGCUCAUG 21 5963
SCNNlA-2115 - CCAAUCCACUCCGGGGCUCAUG 22 5964
SCNNlA-2116 - CCCAAUCCACUCCGGGGCUCAUG 23 5965
SCNNlA-2117 - CCCCAAUCCACUCCGGGGCUCAUG 24 5966
SCNNlA-2118 - CCCAUACCAGGUCUCAUG 18 5967
SCNNlA-2119 - GCCCAUACCAGGUCUCAUG 19 5968
SCNNlA-161 - AGCCCAUACCAGGUCUCAUG 20 804
SCNNlA-2120 - CAGCCCAUACCAGGUCUCAUG 21 5969
SCNNlA-2121 - GCAGCCCAUACCAGGUCUCAUG 22 5970
SCNNlA-2122 - UGCAGCCCAUACCAGGUCUCAUG 23 5971
SCNNlA-2123 - CUGCAGCCCAUACCAGGUCUCAUG 24 5972
SCNNlA-2124 - AUGAAGGGGAACAAGCUG 18 5973
1240
5535.1 SCNNlA-2125 - CAUGAAGGGGAACAAGCUG 19 5974
SCNNlA-2126 - UCAUGAAGGGGAACAAGCUG 20 5975
SCNNlA-2127 - CUCAUGAAGGGGAACAAGCUG 21 5976
SCNNlA-2128 - GCUCAUGAAGGGGAACAAGCUG 22 5977
SCNNlA-2129 - GGCUCAUGAAGGGGAACAAGCUG 23 5978
SCNNlA-2130 - GGGCUCAUGAAGGGGAACAAGCUG 24 5979
SCNNlA-2131 - AUGGAGGGGAACAAGCUG 18 5980
SCNNlA-2132 - CAUGGAGGGGAACAAGCUG 19 5981
SCNNlA-167 - UCAUGGAGGGGAACAAGCUG 20 806
SCNNlA-2133 - CUCAUGGAGGGGAACAAGCUG 21 5982
SCNNlA-2134 - UCUCAUGGAGGGGAACAAGCUG 22 5983
SCNNlA-2135 - GUCUCAUGGAGGGGAACAAGCUG 23 5984
SCNNlA-2136 - GGUCUCAUGGAGGGGAACAAGCUG 24 5985
SCNNlA-2137 - UGAAGGGGAACAAGCGUG 18 5986
SCNNlA-2138 - AUGAAGGGGAACAAGCGUG 19 5987
SCNNlA-13 - CA U G AAG GG G AAC AAG CG U G 20 562
SCNNlA-2139 - UCAUGAAGGGGAACAAGCGUG 21 5988
SCNNlA-2140 - CUCAUGAAGGGGAACAAGCGUG 22 5989
SCNNlA-2141 - GCUCAUGAAGGGGAACAAGCGUG 23 5990
SCNNlA-2142 - GGCUCAUGAAGGGGAACAAGCGUG 24 5991
SCNNlA-2143 - ACUCGGGUUCCAGGGGUG 18 5992
SCNNlA-2144 - CACUCGGGUUCCAGGGGUG 19 5993
SCNNlA-2145 - UCACUCGGGUUCCAGGGGUG 20 5994
SCNNlA-2146 - CUCACUCGGGUUCCAGGGGUG 21 5995
SCNNlA-2147 - CCUCACUCGGGUUCCAGGGGUG 22 5996
SCNNlA-2148 - GCCUCACUCGGGUUCCAGGGGUG 23 5997
SCNNlA-2149 - AGCCUCACUCGGGUUCCAGGGGUG 24 5998
SCNNlA-2150 - UCGGGUUCCAGGGGUGAU 18 5999
SCNNlA-2151 - CUCGGGUUCCAGGGGUGAU 19 6000
SCNNlA-421 - ACUCGGGUUCCAGGGGUGAU 20 4270
SCNNlA-2152 - CACUCGGGUUCCAGGGGUGAU 21 6001
SCNNlA-2153 - UCACUCGGGUUCCAGGGGUGAU 22 6002
SCNNlA-2154 - CUCACUCGGGUUCCAGGGGUGAU 23 6003
SCNNlA-2155 - CCUCACUCGGGUUCCAGGGGUGAU 24 6004
SCNNlA-2156 - UGCUCUCCCCAAUCCACU 18 6005
SCNNlA-2157 - UUGCUCUCCCCAAUCCACU 19 6006
SCNNlA-2158 - CUUGCUCUCCCCAAUCCACU 20 6007
SCNNlA-2159 - CCUUGCUCUCCCCAAUCCACU 21 6008
SCNNlA-2160 - CCCUUGCUCUCCCCAAUCCACU 22 6009
SCNNlA-2161 - ACCCUUGCUCUCCCCAAUCCACU 23 6010
SCNNlA-2162 - GACCCUUGCUCUCCCCAAUCCACU 24 6011
SCNNlA-2163 - GUGAUGGGAGAGGGCACU 18 6012
1241
5535.1 SCNNlA-2164 - GGUGAUGGGAGAGGGCACU 19 6013
SCNNlA-2165 - GGGUGAUGGGAGAGGGCACU 20 6014
SCNNlA-2166 - GGGGUGAUGGGAGAGGGCACU 21 6015
SCNNlA-2167 - AGGGGUGAUGGGAGAGGGCACU 22 6016
SCNNlA-2168 - CAGGGGUGAUGGGAGAGGGCACU 23 6017
SCNNlA-2169 - CCAGGGGUGAUGGGAGAGGGCACU 24 6018
SCNNlA-2170 - AUGAAGGGG A AC A AG CG U 18 6019
SCNNlA-2171 - CAUGAAGGGGAACAAGCGU 19 6020
SCNNlA-177 - UCAUGAAGGGGAACAAGCGU 20 812
SCNNlA-2172 - CUCAUGAAGGGGAACAAGCGU 21 6021
SCNNlA-2173 - GCUCAUGAAGGGGAACAAGCGU 22 6022
SCNNlA-2174 - GGCUCAUGAAGGGGAACAAGCGU 23 6023
SCNNlA-2175 - GGGCUCAUGAAGGGGAACAAGCGU 24 6024
SCNNlA-2176 - UAAGCAAGGGAACCUGGU 18 6025
SCNNlA-2177 - GUAAGCAAGGGAACCUGGU 19 6026
SCNNlA-2178 - GGUAAGCAAGGGAACCUGGU 20 6027
SCNNlA-2179 - AGGUAAGCAAGGGAACCUGGU 21 6028
SCNNlA-2180 - AAGGUAAGCAAGGGAACCUGGU 22 6029
SCNNlA-2181 - CAAGGUAAGCAAGGGAACCUGGU 23 6030
SCNNlA-2182 - UCAAGGUAAGCAAGGGAACCUGGU 24 6031
SCNNlA-2183 - CCGCAUGAAGACGGCCUU 18 6032
SCNNlA-2184 - ACCGCAUGAAGACGGCCUU 19 6033
SCNNlA-194 - AACCGCAUGAAGACGGCCUU 20 824
SCNNlA-2185 - CAACCGCAUGAAGACGGCCUU 21 6034
SCNNlA-2186 - ACAACCGCAUGAAGACGGCCUU 22 6035
SCNNlA-2187 - CACAACCGCAUGAAGACGGCCUU 23 6036
SCNNlA-2188 - GCACAACCGCAUGAAGACGGCCUU 24 6037
SCNNlA-2189 - GGCAAUUCGGCCUGCUUU 18 6038
SCNNlA-2190 - UGGCAAUUCGGCCUGCUUU 19 6039
SCNNlA-195 - CUGGCAAUUCGGCCUGCUUU 20 825
SCNNlA-2191 - ACUGGCAAUUCGGCCUGCUUU 21 6040
SCNNlA-2192 - UACUGGCAAUUCGGCCUGCUUU 22 6041
SCNNlA-2193 - GUACUGGCAAUUCGGCCUGCUUU 23 6042
SCNNlA-2194 - UGUACUGGCAAUUCGGCCUGCUUU 24 6043
SCNNlA-2195 - GCAAUUCGGCCUGCUUUU 18 6044
SCNNlA-2196 - GGCAAUUCGGCCUGCUUUU 19 6045
SCNNlA-34 - UGGCAAUUCGGCCUGCUUUU 20 573
SCNNlA-2197 - CUGGCAAUUCGGCCUGCUUUU 21 6046
SCNNlA-2198 - ACUGGCAAUUCGGCCUGCUUUU 22 6047
SCNNlA-2199 - UACUGGCAAUUCGGCCUGCUUUU 23 6048
SCNNlA-2200 - GUACUGGCAAUUCGGCCUGCUUUU 24 6049
1242
5535.1 Table 44E provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene), starts with a 5'G and PAM is
NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 44E
Figure imgf001244_0001
1243
5535.1 SCNNlA-2228 + GUUGCACUGGACACAGAGAC 20 6077
SCNNlA-2229 + GGUUGCACUGGACACAGAGAC 21 6078
SCNNlA-2230 + GCCCCCUGGAGAUGGGCGGGGGCC 24 6079
SCNNlA-2231 + GUACUCCACGUUCUGGGGCC 20 6080
SCNNlA-2232 + GCCCAGCGUGUCCUCCUCC 19 6081
SCNNlA-2233 + GUUGCCCAGCGUGUCCUCCUCC 22 6082
SCNNlA-1051 + GAUCAUGCUCUCCUGGAAGC 20 4900
SCNNlA-2234 + GGAAGGAGGGGAGGAUGC 18 6083
SCNNlA-2235 + GGGAAGGAGGGGAGGAUGC 19 6084
SCNNlA-2236 + GUGGGAAGGAGGGGAGGAUGC 21 6085
SCNNlA-2237 + GAAGUGGGAAGGAGGGGAGGAUGC 24
6086
SCNNlA-2238 + GAUGUCACCGAGGGCCAUC 19 6087
SCNNlA-2239 + GGAUGUCACCGAGGGCCAUC 20 6088
SCNNlA-2240 + GGGAUGUCACCGAGGGCCAUC 21 6089
SCNNlA-2241 + GCCAUAAUCGCCCCCAAGUCUGUC 24 6090
SCNNlA-2242 + GCUGCCCAGGUUGGACAG 18 6091
SCNNlA-2243 + GGCUGCCCAGGUUGGACAG 19 6092
SCNNlA-2244 + GCCCCAGUCACUGUGGACAGCAG 23 6093
SCNNlA-2245 + GGCCCCAGUCACUGUGGACAGCAG 24 6094
SCNNlA-2246 + GACCUAGGGGUGCAGAGAGAG 21 6095
SCNNlA-2247 + GAAUACACACCUGGAAGGGAG 21 6096
SCNNlA-2248 + GUGAAUACACACCUGGAAGGGAG 23 6097
SCNNlA-2249 + GCGCUGCAAGGGGUGCGG 18 6098
SCNNlA-2250 + GGCGCUGCAAGGGGUGCGG 19 6099
SCNNlA-2251 + GCAGAAGUGGGAAGGAGGG 19 6100
SCNNlA-2252 + GGCAGAAGUGGGAAGGAGGG 20 6101
SCNNlA-2253 + GGGCAGAAGUGGGAAGGAGGG 21 6102
SCNNlA-2254 + GGGGCAGAAGUGGGAAGGAGGG 22 6103
SCNNlA-2255 + GGGGGCAGAAGUGGGAAGGAGGG 23 6104
SCNNlA-2256 + GUCCUCCUCCAGGGAUGG 18 6105
SCNNlA-2257 + GUGUCCUCCUCCAGGGAUGG 20 6106
SCNNlA-2258 + GCGUGUCCUCCUCCAGGGAUGG 22 6107
SCNNlA-2259 + GCCUCACCUGCUGUGUGUACUUUG 24 6108
SCNNlA-2260 + GACCCAUUCCUAGGAAAGAAU 21 6109
SCNNlA-2261 + GAAGACCCAUUCCUAGGAAAGAAU 24 6110
SCNNlA-2262 + GACCUACCGUGACAGAGGGAGACU 24 6111
SCNNlA-1263 + GCAGCAUCAGGGACAGACCU 20 5112
SCNNlA-2263 + GCGCAGCAUCAGGGACAGACCU 22 6112
SCNNlA-2264 + GCGCGCAGCAUCAGGGACAGACCU 24 6113
SCNNlA-2265 + GCUUAUAGUAGCAGUACCCU 20 6114
SCNNlA-2266 + GAGCUUAUAGUAGCAGUACCCU 22 6115
1244
5535.1 SCNNlA-2267 + GGAGCUUAUAGUAGCAGUACCCU 23 6116
SCNNlA-2268 + GCUGGUAGCUGGUCACGCU 19 6117
SCNNlA-2269 + GAGCUGGUAGCUGGUCACGCU 21 6118
SCNNlA-2270 + GAGAGCUGGUAGCUGGUCACGCU 23 6119
SCNNlA-2271 + GCAUGGAAGACAUCCAGAGGU 21 6120
SCNNlA-2272 + GGCAUGGAAGACAUCCAGAGGU 22 6121
SCNNlA-2273 + GCUCCUCCAGCUCCUCUUUAAUUU 24 6122
SCNNlA-2274 - GGCAUCUCUCUGUACCCA 18 6123
SCNNlA-2275 - GAACAGGCAUCUCUCUGUACCCA 23 6124
SCNNlA-2276 - GCUUCCAGGAGAGCAUGAUCA 21 6125
SCNNlA-2277 - GACACCCCCAUUCUUUCCUAGGA 23 6126
SCNNlA-2278 - GACAUCCCAGGUAGAGUGUGGGGA 24 6127
SCNNlA-2279 - GACCCUACUCUCUCUUUCCUGAUA 24 6128
SCNNlA-2280 - GAUUAUGGCGACUGCACC 18 6129
SCNNlA-2281 - GCGAUUAUGGCGACUGCACC 20 6130
SCNNlA-2282 - GGCGAUUAUGGCGACUGCACC 21 6131
SCNNlA-2283 - GGGCGAUUAUGGCGACUGCACC 22 6132
SCNNlA-2284 - GGGGCGAUUAUGGCGACUGCACC 23 6133
SCNNlA-2285 - GGGGGCGAUUAUGGCGACUGCACC 24 6134
SCNNlA-2286 - GCAGGUUAGUGUCCCCUUCC 20 6135
SCNNlA-2287 - GACUACAGAAAG CACAG U U CC 21 6136
SCNNlA-2288 - GUGACUACAGAAAGCACAGUUCC 23 6137
SCNNlA-2289 - GACCUCCAUCAGCAUGAGGAAGGC 24 6138
SCNNlA-2290 - GGUCUCCUGCAACCAGGC 18 6139
SCNNlA-2291 - GUCUCCAGGCCGAGGGGGC 19 6140
SCNNlA-1073 - GGUCUCCAGGCCGAGGGGGC 20 4922
SCNNlA-2292 - GUCCACAGUGACUGGGGC 18 6141
SCNNlA-2293 - GCUGUCCACAGUGACUGGGGC 21 6142
SCNNlA-2294 - GCUUCUACCAGACAUACUCAUC 22 6143
SCNNlA-2295 - GUCCCUGAUGCUGCGCGCAGAG 22 6144
SCNNlA-2296 - GCCCUCGGUGACAUCCCAGG 20 6145
SCNNlA-2297 - GGCCCUCGGUGACAUCCCAGG 21 6146
SCNNlA-2298 - GAUGGCCCUCGGUGACAUCCCAGG 24 6147
SCNNlA-2299 - GUAGAGUGUGGGGAAGGG 18 6148
SCNNlA-2300 - GGUAGAGUGUGGGGAAGGG 19 6149
SCNNlA-2301 - GCCCGGGUAAUGGUGCACGGG 21 6150
SCNNlA-2302 - GGCCCGGGUAAUGGUGCACGGG 22 6151
SCNNlA-2303 - GGGCCCGGGUAAUGGUGCACGGG 23 6152
SCNNlA-2304 - GGGGCCCGGGUAAUGGUGCACGGG 24 6153
SCNNlA-2305 - GUGGGGAAGGGAUGGGUG 18 6154
SCNNlA-1236 - GUGUGGGGAAGGGAUGGGUG 20 5085
SCNNlA-2306 - GAGUGUGGGGAAGGGAUGGGUG 22 6155
1245
5535.1 SCNNlA-2307 - GACAAGAACAACUCCAACCU 20 6156
SCNNlA-2308 - GCACCCCUUGCAGCGCCU 18 6157
SCNNlA-2309 - GCCGCACCCCUUGCAGCGCCU 21 6158
SCNNlA-2310 - GACACCCCCAUUCUUUCCU 19 6159
SCNNlA-2311 - GAUGACACCCCCAUUCUUUCCU 22 6160
SCNNlA-2312 - GCUGAACUACAAAACCAAUU 20 6161
SCNNlA-2313 - GAGCUGAACUACAAAACCAAUU 22 6162
SCNNlA-2314 - GGAGCUGAACUACAAAACCAAUU 23 6163
SCNNlA-2315 - GCAGGAUGAACCUGCCUUU 19 6164
SCNNlA-2316 - GGCAGGAUGAACCUGCCUUU 20 6165
SCNNlA-2317 - GGGCAGGAUGAACCUGCCUUU 21 6166
Table 44F provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the six tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene) and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 44F
Figure imgf001247_0001
1246
5535.1 SCNNlA-2332 + CAUUUCUUAGGUGUGGGGCA 20 6181
SCNNlA-2333 + CCAUUUCUUAGGUGUGGGGCA 21 6182
SCNNlA-2334 + UCCAUUUCUUAGGUGUGGGGCA 22 6183
SCNNlA-2335 + CUCCAUUUCUUAGGUGUGGGGCA 23 6184
SCNNlA-2336 + ACUCCAUUUCUUAGGUGUGGGGCA 24 6185
SCNNlA-917 + CGGGACCCUCAGGCGCUGCA 20 4766
SCNNlA-2337 + AUUCCUUAUCAGGAAAGA 18 6186
SCNNlA-2338 + AAUUCCUUAUCAGGAAAGA 19 6187
SCNNlA-2339 + UAAUUCCUUAU CAGG AAAG A 20 6188
SCNNlA-2340 + AGUAAUUCCUUAUCAGGAAAGA 22 6189
SCNNlA-2341 + AG AG U AAU U CCU UAU CAGG AAAG A 24 6190
SCNNlA-2342 + AGUCUCUGGCAGCCUCGA 18 6191
SCNNlA-2343 + AGAGUCUCUGGCAGCCUCGA 20 6192
SCNNlA-2344 + CAGAGUCUCUGGCAGCCUCGA 21 6193
SCNNlA-2345 + UGGCAGAGUCUCUGGCAGCCUCGA 24 6194
SCNNlA-2346 + UGCUCUCCUGGAAGCAGGA 19 6195
SCNNlA-2347 + AUGCUCUCCUGGAAGCAGGA 20 6196
SCNNlA-2348 + CAUGCUCUCCUGGAAGCAGGA 21 6197
SCNNlA-2349 + UCAUGCUCUCCUGGAAGCAGGA 22 6198
SCNNlA-2350 + AUCAUGCUCUCCUGGAAGCAGGA 23 6199
SCNNlA-2351 + UGGAAGACCCAUUCCUAGGA 20 6200
SCNNlA-2352 + CUGGAAGACCCAUUCCUAGGA 21 6201
SCNNlA-2353 + UCUGGAAGACCCAUUCCUAGGA 22 6202
SCNNlA-2354 + AUCUGGAAGACCCAUUCCUAGGA 23 6203
SCNNlA-2355 + CAUCUGGAAGACCCAUUCCUAGGA 24 6204
SCNNlA-2356 + CGGCUGCGGGAGCCGGCCAC 20 6205
SCNNlA-2357 + ACGGCUGCGGGAGCCGGCCAC 21 6206
SCNNlA-2358 + CGACGGCUGCGGGAGCCGGCCAC 23 6207
SCNNlA-2359 + UGCACUGGACACAGAGAC 18 6208
SCNNlA-2360 + UUGCACUGGACACAGAGAC 19 6209
SCNNlA-2361 + UGGUUGCACUGGACACAGAGAC 22 6210
SCNNlA-2362 + CUGGUUGCACUGGACACAGAGAC 23 6211
SCNNlA-2363 + UCUGGUUGCACUGGACACAGAGAC 24 6212
SCNNlA-2364 + CCUUCCCCACACUCUACC 18 6213
SCNNlA-2365 + CCCUUCCCCACACUCUACC 19 6214
SCNNlA-1006 + UCCCUUCCCCACACUCUACC 20 4855
SCNNlA-2366 + AUCCCUUCCCCACACUCUACC 21 6215
SCNNlA-2367 + CAUCCCUUCCCCACACUCUACC 22 6216
SCNNlA-2368 + CCAUCCCUUCCCCACACUCUACC 23 6217
SCNNlA-2369 + CCCAUCCCUUCCCCACACUCUACC 24 6218
SCNNlA-2370 + UGGAGAUGGGCGGGGGCC 18 6219
SCNNlA-2371 + CUGGAGAUGGGCGGGGGCC 19 6220
1247
5535.1 SCNNlA-2372 + CCUGGAGAUGGGCGGGGGCC 20 6221
SCNNlA-2373 + CCCUGGAGAUGGGCGGGGGCC 21 6222
SCNNlA-2374 + CCCCUGGAGAUGGGCGGGGGCC 22 6223
SCNNlA-2375 + CCCCCUGGAGAUGGGCGGGGGCC 23 6224
SCNNlA-2376 + ACUCCACGUUCUGGGGCC 18 6225
SCNNlA-2377 + UACUCCACGUUCUGGGGCC 19 6226
SCNNlA-2378 + AGUACUCCACGUUCUGGGGCC 21 6227
SCNNlA-2379 + CAGUACUCCACGUUCUGGGGCC 22 6228
SCNNlA-2380 + ACAGUACUCCACGUUCUGGGGCC 23 6229
SCNNlA-2381 + CACAGUACUCCACGUUCUGGGGCC 24 6230
SCNNlA-2382 + CCCAGCGUGUCCUCCUCC 18 6231
SCNNlA-1038 + UGCCCAGCGUGUCCUCCUCC 20 4887
SCNNlA-2383 + UUGCCCAGCGUGUCCUCCUCC 21 6232
SCNNlA-2384 + AGUUGCCCAGCGUGUCCUCCUCC 23 6233
SCNNlA-2385 + AAGUUGCCCAGCGUGUCCUCCUCC 24 6234
SCNNlA-2386 + UCAUGCUCUCCUGGAAGC 18 6235
SCNNlA-2387 + AUCAUGCUCUCCUGGAAGC 19 6236
SCNNlA-2388 + UGAUCAUGCUCUCCUGGAAGC 21 6237
SCNNlA-2389 + UUGAUCAUGCUCUCCUGGAAGC 22 6238
SCNNlA-2390 + CUUGAUCAUGCUCUCCUGGAAGC 23 6239
SCNNlA-2391 + CCUUGAUCAUGCUCUCCUGGAAGC 24 6240
SCNNlA-2392 + UGGGAAGGAGGGGAGGAUGC 20 6241
SCNNlA-2393 + AGUGGGAAGGAGGGGAGGAUGC 22 6242
SCNNlA-2394 + AAGUGGGAAGGAGGGGAGGAUGC 23 6243
SCNNlA-2395 + AUGUCACCGAGGGCCAUC 18 6244
SCNNlA-2396 + UGGGAUGUCACCGAGGGCCAUC 22 6245
SCNNlA-2397 + CUGGGAUGUCACCGAGGGCCAUC 23 6246
SCNNlA-2398 + CCUGGGAUGUCACCGAGGGCCAUC 24 6247
SCNNlA-2399 + AUCGCCCCCAAGUCUGUC 18 6248
SCNNlA-2400 + AAUCGCCCCCAAGUCUGUC 19 6249
SCNNlA-2401 + UAAUCGCCCCCAAGUCUGUC 20 6250
SCNNlA-2402 + AUAAUCGCCCCCAAGUCUGUC 21 6251
SCNNlA-2403 + CAUAAUCGCCCCCAAGUCUGUC 22 6252
SCNNlA-2404 + CCAUAAUCGCCCCCAAGUCUGUC 23 6253
SCNNlA-2405 + UGGCUGCCCAGGUUGGACAG 20 6254
SCNNlA-2406 + CUGGCUGCCCAGGUUGGACAG 21 6255
SCNNlA-2407 + ACUGGCUGCCCAGGUUGGACAG 22 6256
SCNNlA-2408 + CACUGGCUGCCCAGGUUGGACAG 23 6257
SCNNlA-2409 + CCACUGGCUGCCCAGGUUGGACAG 24 6258
SCNNlA-2410 + AGUCACUGUGGACAGCAG 18 6259
SCNNlA-2411 + CAG U CAC U G U G G ACAG C AG 19 6260
SCNNlA-1119 + CCAGUCACUGUGGACAGCAG 20 4968
1248
5535.1 SCNNlA-2412 + CCCAGUCACUGUGGACAGCAG 21 6261
SCNNlA-2413 + CCCCAGUCACUGUGGACAGCAG 22 6262
SCNNlA-2414 + UUAUCAGGAAAGAGAGAG 18 6263
SCNNlA-2415 + CUUAUCAGGAAAGAGAGAG 19 6264
SCNNlA-2416 + CCUUAUCAGGAAAGAGAGAG 20 6265
SCNNlA-2417 + UCCUUAUCAGGAAAGAGAGAG 21 6266
SCNNlA-2418 + UUCCUUAUCAGGAAAGAGAGAG 22 6267
SCNNlA-2419 + AUUCCUUAU CAGG AAAG AG AG AG 23 6268
SCNNlA-2420 + AAUUCCUUAUCAGGAAAGAGAGAG 24 6269
SCNNlA-2421 + CUAGGGGUGCAGAGAGAG 18 6270
SCNNlA-2422 + CCUAGGGGUGCAGAGAGAG 19 6271
SCNNlA-2423 + ACCUAGGGGUGCAGAGAGAG 20 6272
SCNNlA-2424 + AGACCUAGGGGUGCAGAGAGAG 22 6273
SCNNlA-2425 + CAGACCUAGGGGUGCAGAGAGAG 23 6274
SCNNlA-2426 + ACAGACCUAGGGGUGCAGAGAGAG 24 6275
SCNNlA-2427 + UACACACCUGGAAGGGAG 18 6276
SCNNlA-2428 + AUACACACCUGGAAGGGAG 19 6277
SCNNlA-2429 + AAUACACACCUGGAAGGGAG 20 6278
SCNNlA-2430 + UGAAUACACACCUGGAAGGGAG 22 6279
SCNNlA-2431 + AGUGAAUACACACCUGGAAGGGAG 24 6280
SCNNlA-2432 + AGGCGCUGCAAGGGGUGCGG 20 6281
SCNNlA-2433 + CAGGCGCUGCAAGGGGUGCGG 21 6282
SCNNlA-2434 + UCAGGCGCUGCAAGGGGUGCGG 22 6283
SCNNlA-2435 + CUCAGGCGCUGCAAGGGGUGCGG 23 6284
SCNNlA-2436 + CCUCAGGCGCUGCAAGGGGUGCGG 24 6285
SCNNlA-2437 + CAGAAGUGGGAAGGAGGG 18 6286
SCNNlA-2438 + UGGGGGCAGAAGUGGGAAGGAGGG 24
6287
SCNNlA-2439 + UGUCCUCCUCCAGGGAUGG 19 6288
SCNNlA-2440 + CGUGUCCUCCUCCAGGGAUGG 21 6289
SCNNlA-2441 + AGCGUGUCCUCCUCCAGGGAUGG 23 6290
SCNNlA-2442 + CAGCGUGUCCUCCUCCAGGGAUGG 24 6291
SCNNlA-2443 + UCACCGCAUCCACCCCUG 18 6292
SCNNlA-2444 + CUCACCGCAUCCACCCCUG 19 6293
SCNNlA-2445 + CCUCACCGCAUCCACCCCUG 20 6294
SCNNlA-2446 + CCCUCACCGCAUCCACCCCUG 21 6295
SCNNlA-2447 + UCCCUCACCGCAUCCACCCCUG 22 6296
SCNNlA-2448 + CUCCCUCACCGCAUCCACCCCUG 23 6297
SCNNlA-2449 + ACUCCCUCACCGCAUCCACCCCUG 24 6298
SCNNlA-2450 + CCUGCUGUGUGUACUUUG 18 6299
SCNNlA-2451 + ACCUGCUGUGUGUACUUUG 19 6300
SCNNlA-2452 + CACCUGCUGUGUGUACUUUG 20 6301
1249
5535.1 SCNNlA-2453 + UCACCUGCUGUGUGUACUUUG 21 6302
SCNNlA-2454 + CUCACCUGCUGUGUGUACUUUG 22 6303
SCNNlA-2455 + CCUCACCUGCUGUGUGUACUUUG 23 6304
SCNNlA-2456 + CCAUUCCUAGGAAAGAAU 18 6305
SCNNlA-2457 + CCCAUUCCUAGGAAAGAAU 19 6306
SCNNlA-1244 + ACCCAUUCCUAGGAAAGAAU 20 5093
SCNNlA-2458 + AGACCCAUUCCUAGGAAAGAAU 22 6307
SCNNlA-2459 + AAGACCCAUUCCUAGGAAAGAAU 23 6308
SCNNlA-2460 + CCGUGACAGAGGGAGACU 18 6309
SCNNlA-2461 + ACCGUGACAGAGGGAGACU 19 6310
SCNNlA-2462 + UACCGUGACAGAGGGAGACU 20 6311
SCNNlA-2463 + CUACCGUGACAGAGGGAGACU 21 6312
SCNNlA-2464 + CCUACCGUGACAGAGGGAGACU 22 6313
SCNNlA-2465 + ACCUACCGUGACAGAGGGAGACU 23 6314
SCNNlA-2466 + AGUCCUUCCAGUCCACCU 18 6315
SCNNlA-2467 + CAGUCCUUCCAGUCCACCU 19 6316
SCNNlA-1262 + CCAGUCCUUCCAGUCCACCU 20 5111
SCNNlA-2468 + UCCAGUCCUUCCAGUCCACCU 21 6317
SCNNlA-2469 + UUCCAGUCCUUCCAGUCCACCU 22 6318
SCNNlA-2470 + CUUCCAGUCCUUCCAGUCCACCU 23 6319
SCNNlA-2471 + UCUUCCAGUCCUUCCAGUCCACCU 24 6320
SCNNlA-2472 + AGCAUCAGGGACAGACCU 18 6321
SCNNlA-2473 + CAGCAUCAGGGACAGACCU 19 6322
SCNNlA-2474 + CGCAGCAUCAGGGACAGACCU 21 6323
SCNNlA-2475 + CGCGCAGCAUCAGGGACAGACCU 23 6324
SCNNlA-2476 + UUAUAGUAGCAGUACCCU 18 6325
SCNNlA-2477 + CUUAUAGUAGCAGUACCCU 19 6326
SCNNlA-2478 + AGCUUAUAGUAGCAGUACCCU 21 6327
SCNNlA-2479 + UGGAGCUUAUAGUAGCAGUACCCU 24 6328
SCNNlA-2480 + CUGGUAGCUGGUCACGCU 18 6329
SCNNlA-1274 + AGCUGGUAGCUGGUCACGCU 20 5123
SCNNlA-2481 + AGAGCUGGUAGCUGGUCACGCU 22 6330
SCNNlA-2482 + AGAGAGCUGGUAGCUGGUCACGCU 24 6331
SCNNlA-2483 + ACAUCGGGUGGUGGAAGU 18 6332
SCNNlA-2484 + UACAUCGGGUGGUGGAAGU 19 6333
SCNNlA-2485 + AUACAUCGGGUGGUGGAAGU 20 6334
SCNNlA-2486 + CAUACAUCGGGUGGUGGAAGU 21 6335
SCNNlA-2487 + CCAUACAUCGGGUGGUGGAAGU 22 6336
SCNNlA-2488 + UCCAUACAUCGGGUGGUGGAAGU 23 6337
SCNNlA-2489 + UUCCAUACAUCGGGUGGUGGAAGU 24 6338
SCNNlA-2490 + UGGAAGACAUCCAGAGGU 18 6339
SCNNlA-2491 + AUGGAAGACAUCCAGAGGU 19 6340
1250
5535.1 SCNNlA-1284 + CAUGGAAGACAUCCAGAGGU 20 5133
SCNNlA-2492 + AGGCAUGGAAGACAUCCAGAGGU 23 6341
SCNNlA-2493 + CAGGCAUGGAAGACAUCCAGAGGU 24 6342
SCNNlA-2494 + CCAGCUCCUCUUUAAUUU 18 6343
SCNNlA-2495 + UCCAGCUCCUCUUUAAUUU 19 6344
SCNNlA-2496 + CUCCAGCUCCUCUUUAAUUU 20 6345
SCNNlA-2497 + CCUCCAGCUCCUCUUUAAUUU 21 6346
SCNNlA-2498 + UCCUCCAGCUCCUCUUUAAUUU 22 6347
SCNNlA-2499 + CUCCUCCAGCUCCUCUUUAAUUU 23 6348
SCNNlA-2500 - UGCCCCACACCUAAGAAA 18 6349
SCNNlA-2501 - CUGCCCCACACCUAAGAAA 19 6350
SCNNlA-884 - UCUGCCCCACACCUAAGAAA 20 4733
SCNNlA-2502 - CUCUGCCCCACACCUAAGAAA 21 6351
SCNNlA-2503 - CCUCUGCCCCACACCUAAGAAA 22 6352
SCNNlA-2504 - CCCUCUGCCCCACACCUAAGAAA 23 6353
SCNNlA-2505 - ACCCUCUGCCCCACACCUAAGAAA 24 6354
SCNNlA-2506 - AGGCAUCUCUCUGUACCCA 19 6355
SCNNlA-2507 - CAGGCAUCUCUCUGUACCCA 20 6356
SCNNlA-2508 - ACAGGCAUCUCUCUGUACCCA 21 6357
SCNNlA-2509 - AACAGGCAUCUCUCUGUACCCA 22 6358
SCNNlA-2510 - AGAACAGGCAUCUCUCUGUACCCA 24 6359
SCNNlA-2511 - UCCAGGAGAGCAUGAUCA 18 6360
SCNNlA-2512 - UUCCAGGAGAGCAUGAUCA 19 6361
SCNNlA-923 - CUUCCAGGAGAGCAUGAUCA 20 4772
SCNNlA-2513 - UGCUUCCAGGAGAGCAUGAUCA 22 6362
SCNNlA-2514 - CUGCUUCCAGGAGAGCAUGAUCA 23 6363
SCNNlA-2515 - CCUGCUUCCAGGAGAGCAUGAUCA 24 6364
SCNNlA-2516 - CCCCAUUCUUUCCUAGGA 18 6365
SCNNlA-2517 - CCCCCAUUCUUUCCUAGGA 19 6366
SCNNlA-2518 - ACCCCCAUUCUUUCCUAGGA 20 6367
SCNNlA-2519 - CACCCCCAUUCUUUCCUAGGA 21 6368
SCNNlA-2520 - ACACCCCCAUUCUUUCCUAGGA 22 6369
SCNNlA-2521 - UGACACCCCCAUUCUUUCCUAGGA 24 6370
SCNNlA-2522 - CCAGGUAGAGUGUGGGGA 18 6371
SCNNlA-2523 - CCCAGGUAGAGUGUGGGGA 19 6372
SCNNlA-957 - UCCCAGGUAGAGUGUGGGGA 20 4806
SCNNlA-2524 - AUCCCAGGUAGAGUGUGGGGA 21 6373
SCNNlA-2525 - CAUCCCAGGUAGAGUGUGGGGA 22 6374
SCNNlA-2526 - ACAUCCCAGGUAGAGUGUGGGGA 23 6375
SCNNlA-2527 - CAGGGGUGGAUGCGGUGA 18 6376
SCNNlA-2528 - UCAGGGGUGGAUGCGGUGA 19 6377
SCNNlA-967 - AUCAGGGGUGGAUGCGGUGA 20 4816
1251
5535.1 SCNNlA-2529 - CAUCAGGGGUGGAUGCGGUGA 21 6378
SCNNlA-2530 - UCAUCAGGGGUGGAUGCGGUGA 22 6379
SCNNlA-2531 - CUCAUCAGGGGUGGAUGCGGUGA 23 6380
SCNNlA-2532 - ACUCAUCAGGGGUGGAUGCGGUGA 24 6381
SCNNlA-2533 - ACUCUCUCUUUCCUGAUA 18 6382
SCNNlA-2534 - UACUCUCUCUUUCCUGAUA 19 6383
SCNNlA-971 - CUACUCUCUCUUUCCUGAUA 20 4820
SCNNlA-2535 - CCUACUCUCUCUUUCCUGAUA 21 6384
SCNNlA-2536 - CCCUACUCUCUCUUUCCUGAUA 22 6385
SCNNlA-2537 - ACCCUACUCUCUCUUUCCUGAUA 23 6386
SCNNlA-2538 - CGAUUAUGGCGACUGCACC 19 6387
SCNNlA-2539 - CUGGAUGUCUUCCAUGCC 18 6388
SCNNlA-2540 - UCUGGAUGUCUUCCAUGCC 19 6389
SCNNlA-1033 - CUCUGGAUGUCUUCCAUGCC 20 4882
SCNNlA-2541 - CCUCUGGAUGUCUUCCAUGCC 21 6390
SCNNlA-2542 - ACCUCUGGAUGUCUUCCAUGCC 22 6391
SCNNlA-2543 - AACCUCUGGAUGUCUUCCAUGCC 23 6392
SCNNlA-2544 - CAACCUCUGGAUGUCUUCCAUGCC 24 6393
SCNNlA-2545 - AGGUUAGUGUCCCCUUCC 18 6394
SCNNlA-2546 - CAGGUUAGUGUCCCCUUCC 19 6395
SCNNlA-2547 - UGCAGGUUAGUGUCCCCUUCC 21 6396
SCNNlA-2548 - AUGCAGGUUAGUGUCCCCUUCC 22 6397
SCNNlA-2549 - CAUGCAGGUUAGUGUCCCCUUCC 23 6398
SCNNlA-2550 - CCAUGCAGGUUAGUGUCCCCUUCC 24 6399
SCNNlA-2551 - UACAGAAAG CACAG U U CC 18 6400
SCNNlA-2552 - CUACAGAAAG CACAG U U CC 19 6401
SCNNlA-1047 - ACUACAGAAAGCACAGUUCC 20 4896
SCNNlA-2553 - UGACUACAGAAAG CACAG U U CC 22 6402
SCNNlA-2554 - UGUGACUACAGAAAGCACAGUUCC 24 6403
SCNNlA-2555 - CAUCAGCAUGAGGAAGGC 18 6404
SCNNlA-2556 - CCAUCAGCAUGAGGAAGGC 19 6405
SCNNlA-2557 - UCCAUCAGCAUGAGGAAGGC 20 6406
SCNNlA-2558 - CUCCAUCAGCAUGAGGAAGGC 21 6407
SCNNlA-2559 - CCUCCAUCAGCAUGAGGAAGGC 22 6408
SCNNlA-2560 - ACCUCCAUCAGCAUGAGGAAGGC 23 6409
SCNNlA-2561 - AGGUCUCCUGCAACCAGGC 19 6410
SCNNlA-2562 - CAGGUCUCCUGCAACCAGGC 20 6411
SCNNlA-2563 - CCAGGUCUCCUGCAACCAGGC 21 6412
SCNNlA-2564 - ACCAGGUCUCCUGCAACCAGGC 22 6413
SCNNlA-2565 - AACCAGGUCUCCUGCAACCAGGC 23 6414
SCNNlA-2566 - CAACCAGGUCUCCUGCAACCAGGC 24 6415
SCNNlA-2567 - UCUCCAGGCCGAGGGGGC 18 6416
1252
5535.1 SCNNlA-2568 - UGGUCUCCAGGCCGAGGGGGC 21 6417
SCNNlA-2569 - CUGGUCUCCAGGCCGAGGGGGC 22 6418
SCNNlA-2570 - ACUGGUCUCCAGGCCGAGGGGGC 23 6419
SCNNlA-2571 - UACUGGUCUCCAGGCCGAGGGGGC 24 6420
SCNNlA-2572 - UGUCCACAGUGACUGGGGC 19 6421
SCNNlA-2573 - CUGUCCACAGUGACUGGGGC 20 6422
SCNNlA-2574 - UGCUGUCCACAGUGACUGGGGC 22 6423
SCNNlA-2575 - CUGCUGUCCACAGUGACUGGGGC 23 6424
SCNNlA-2576 - CCUGCUGUCCACAGUGACUGGGGC 24 6425
SCNNlA-2577 - UGUCACGGUAGGUCGUGC 18 6426
SCNNlA-2578 - CUGUCACGGUAGGUCGUGC 19 6427
SCNNlA-2579 - UCUGUCACGGUAGGUCGUGC 20 6428
SCNNlA-2580 - CUCUGUCACGGUAGGUCGUGC 21 6429
SCNNlA-2581 - CCUCUGUCACGGUAGGUCGUGC 22 6430
SCNNlA-2582 - CCCUCUGUCACGGUAGGUCGUGC 23 6431
SCNNlA-2583 - UCCCUCUGUCACGGUAGGUCGUGC 24 6432
SCNNlA-2584 - CUACCAGACAUACUCAUC 18 6433
SCNNlA-2585 - UCUACCAGACAUACUCAUC 19 6434
SCNNlA-1091 - UUCUACCAGACAUACUCAUC 20 4940
SCNNlA-2586 - CUUCUACCAGACAUACUCAUC 21 6435
SCNNlA-2587 - UGCUUCUACCAGACAUACUCAUC 23 6436
SCNNlA-2588 - CUGCUUCUACCAGACAUACUCAUC 24 6437
SCNNlA-2589 - CUGAUGCUGCGCGCAGAG 18 6438
SCNNlA-2590 - CCUGAUGCUGCGCGCAGAG 19 6439
SCNNlA-2591 - CCCUGAUGCUGCGCGCAGAG 20 6440
SCNNlA-2592 - UCCCUGAUGCUGCGCGCAGAG 21 6441
SCNNlA-2593 - UGUCCCUGAUGCUGCGCGCAGAG 23 6442
SCNNlA-2594 - CUGUCCCUGAUGCUGCGCGCAGAG 24 6443
SCNNlA-2595 - AUCCGCGGCCCCAGAACG 18 6444
SCNNlA-2596 - UAUCCGCGGCCCCAGAACG 19 6445
SCNNlA-1144 - CUAUCCGCGGCCCCAGAACG 20 4993
SCNNlA-2597 - UCUAUCCGCGGCCCCAGAACG 21 6446
SCNNlA-2598 - UUCUAUCCGCGGCCCCAGAACG 22 6447
SCNNlA-2599 - CUUCUAUCCGCGGCCCCAGAACG 23 6448
SCNNlA-2600 - UCUUCUAUCCGCGGCCCCAGAACG 24 6449
SCNNlA-2601 - CCUCGGUGACAUCCCAGG 18 6450
SCNNlA-2602 - CCCUCGGUGACAUCCCAGG 19 6451
SCNNlA-2603 - UGGCCCUCGGUGACAUCCCAGG 22 6452
SCNNlA-2604 - AUGGCCCUCGGUGACAUCCCAGG 23 6453
SCNNlA-2605 - AGGUAGAGUGUGGGGAAGGG 20 6454
SCNNlA-2606 - CAGGUAGAGUGUGGGGAAGGG 21 6455
SCNNlA-2607 - CCAGGUAGAGUGUGGGGAAGGG 22 6456
1253
5535.1 SCNNlA-2608 - CCCAGGUAGAGUGUGGGGAAGGG 23 6457
SCNNlA-2609 - UCCCAGGUAGAGUGUGGGGAAGGG 24
6458
SCNNlA-2610 - CAGACAUACUCAUCAGGG 18 6459
SCNNlA-2611 - CCAGACAUACUCAUCAGGG 19 6460
SCNNlA-2612 - ACCAGACAUACUCAUCAGGG 20 6461
SCNNlA-2613 - UACCAGACAUACUCAUCAGGG 21 6462
SCNNlA-2614 - CUACCAGACAUACUCAUCAGGG 22 6463
SCNNlA-2615 - UCUACCAGACAUACUCAUCAGGG 23 6464
SCNNlA-2616 - UUCUACCAGACAUACUCAUCAGGG 24 6465
SCNNlA-2617 - CGGGUAAUGGUGCACGGG 18 6466
SCNNlA-2618 - CCGGGUAAUGGUGCACGGG 19 6467
SCNNlA-2619 - CCCGGGUAAUGGUGCACGGG 20 6468
SCNNlA-2620 - UGUGGGGAAGGGAUGGGUG 19 6469
SCNNlA-2621 - AGUGUGGGGAAGGGAUGGGUG 21 6470
SCNNlA-2622 - AGAGUGUGGGGAAGGGAUGGGUG 23 6471
SCNNlA-2623 - UAGAGUGUGGGGAAGGGAUGGGUG 24
6472
SCNNlA-2624 - CAAG AACAAC U CC AACC U 18 6473
SCNNlA-2625 - ACAAGAACAACUCCAACCU 19 6474
SCNNlA-2626 - UGACAAGAACAACUCCAACCU 21 6475
SCNNlA-2627 - AUGACAAGAACAACUCCAACCU 22 6476
SCNNlA-2628 - AAUGACAAGAACAACUCCAACCU 23 6477
SCNNlA-2629 - CAAUGACAAGAACAACUCCAACCU 24 6478
SCNNlA-2630 - CGCACCCCUUGCAGCGCCU 19 6479
SCNNlA-2631 - CCGCACCCCUUGCAGCGCCU 20 6480
SCNNlA-2632 - UGCCGCACCCCUUGCAGCGCCU 22 6481
SCNNlA-2633 - CUGCCGCACCCCUUGCAGCGCCU 23 6482
SCNNlA-2634 - UCUGCCGCACCCCUUGCAGCGCCU 24 6483
SCNNlA-2635 - ACACCCCCAUUCUUUCCU 18 6484
SCNNlA-1272 - UGACACCCCCAUUCUUUCCU 20 5121
SCNNlA-2636 - AUGACACCCCCAUUCUUUCCU 21 6485
SCNNlA-2637 - UGAUGACACCCCCAUUCUUUCCU 23 6486
SCNNlA-2638 - UUGAUGACACCCCCAUUCUUUCCU 24 6487
SCNNlA-2639 - UGAACU ACAAAACCAAU U 18 6488
SCNNlA-2640 - CUGAACUACAAAACCAAUU 19 6489
SCNNlA-2641 - AGCUGAACUACAAAACCAAUU 21 6490
SCNNlA-2642 - AGGAGCUGAACUACAAAACCAAUU 24 6491
SCNNlA-2643 - CAGGAUGAACCUGCCUUU 18 6492
SCNNlA-2644 - CGGGCAGGAUGAACCUGCCUUU 22 6493
SCNNlA-2645 - ACGGGCAGGAUGAACCUGCCUUU 23 6494
SCNNlA-2646 - CACGGGCAGGAUGAACCUGCCUUU 24 6495
1254
5535.1 Table 44G provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the seven tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene) and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 44G
Figure imgf001256_0001
1255
5535.1 SCNNlA-2672 + AGAGACAUGGGGUGGGGGCAGAA 23 6521
SCNNlA-2673 + CAGAGACAUGGGGUGGGGGCAGAA 24 6522
SCNNlA-2674 + GUGAAUACACACCUGGAA 18 6523
SCNNlA-2675 + AGUGAAUACACACCUGGAA 19 6524
SCNNlA-892 + GAGUGAAUACACACCUGGAA 20 4741
SCNNlA-2676 + GGAGUGAAUACACACCUGGAA 21 6525
SCNNlA-2677 + AGGAGUGAAUACACACCUGGAA 22 6526
SCNNlA-2678 + CAGGAGUGAAUACACACCUGGAA 23 6527
SCNNlA-2679 + GCAGGAGUGAAUACACACCUGGAA 24 6528
SCNNlA-2680 + AUACAUCGGGUGGUGGAA 18 6529
SCNNlA-2681 + CAUACAUCGGGUGGUGGAA 19 6530
SCNNlA-2682 + CCAUACAUCGGGUGGUGGAA 20 6531
SCNNlA-2683 + UCCAUACAUCGGGUGGUGGAA 21 6532
SCNNlA-2684 + UUCCAUACAUCGGGUGGUGGAA 22 6533
SCNNlA-2685 + UUUCCAUACAUCGGGUGGUGGAA 23 6534
SCNNlA-2686 + GUUUCCAUACAUCGGGUGGUGGAA 24 6535
SCNNlA-2687 + UCUCCACCACAGACAACA 18 6536
SCNNlA-2688 + AUCUCCACCACAGACAACA 19 6537
SCNNlA-2689 + CAU CU CCACCACAG ACAACA 20 6538
SCNNlA-2690 + CCAUCUCCACCACAGACAACA 21 6539
SCNNlA-2691 + GCCAUCUCCACCACAGACAACA 22 6540
SCNNlA-2692 + AGCCAUCUCCACCACAGACAACA 23 6541
SCNNlA-2693 + CAG CCAUCUCCACCACAGACAACA 24 6542
SCNNlA-2694 + UUCUGGUUGCACUGGACA 18 6543
SCNNlA-2695 + GUUCUGGUUGCACUGGACA 19 6544
SCNNlA-2696 + UGUUCUGGUUGCACUGGACA 20 6545
SCNNlA-2697 + UUGUUCUGGUUGCACUGGACA 21 6546
SCNNlA-2698 + UUUGUUCUGGUUGCACUGGACA 22 6547
SCNNlA-2699 + AUUUGUUCUGGUUGCACUGGACA 23 6548
SCNNlA-2700 + GAUUUGUUCUGGUUGCACUGGACA 24 6549
SCNNlA-2701 + GCACGACCUACCGUGACA 18 6550
SCNNlA-2702 + GGCACGACCUACCGUGACA 19 6551
SCNNlA-2703 + AGGCACGACCUACCGUGACA 20 6552
SCNNlA-2704 + CAGGCACGACCUACCGUGACA 21 6553
SCNNlA-2705 + CCAGGCACGACCUACCGUGACA 22 6554
SCNNlA-2706 + UCCAGGCACGACCUACCGUGACA 23 6555
SCNNlA-2707 + AUCCAGGCACGACCUACCGUGACA 24 6556
SCNNlA-2708 + CAGUACCCUGUGGGUACA 18 6557
SCNNlA-2709 + GCAGUACCCUGUGGGUACA 19 6558
SCNNlA-2710 + AGCAGUACCCUGUGGGUACA 20 6559
SCNNlA-2711 + UAGCAGUACCCUGUGGGUACA 21 6560
SCNNlA-2712 + GUAGCAGUACCCUGUGGGUACA 22 6561
1256
5535.1 SCNNlA-2713 + AGUAGCAGUACCCUGUGGGUACA 23 6562
SCNNlA-2714 + UAGUAGCAGUACCCUGUGGGUACA 24 6563
SCNNlA-2715 + CCUCUCAGGGCCCCCCCA 18 6564
SCNNlA-2716 + CCCUCUCAGGGCCCCCCCA 19 6565
SCNNlA-2717 + UCCCUCUCAGGGCCCCCCCA 20 6566
SCNNlA-2718 + UUCCCUCUCAGGGCCCCCCCA 21 6567
SCNNlA-2719 + CUUCCCUCUCAGGGCCCCCCCA 22 6568
SCNNlA-2720 + CCUUCCCUCUCAGGGCCCCCCCA 23 6569
SCNNlA-2721 + UCCUUCCCUCUCAGGGCCCCCCCA 24 6570
SCNNlA-2722 + GGCGCCAUGGAGCAAGCA 18 6571
SCNNlA-2723 + GGGCGCCAUGGAGCAAGCA 19 6572
SCNNlA-909 + AGGGCGCCAUGGAGCAAGCA 20 4758
SCNNlA-2724 + GAGGGCGCCAUGGAGCAAGCA 21 6573
SCNNlA-2725 + AGAGGGCGCCAUGGAGCAAGCA 22 6574
SCNNlA-2726 + CAGAGGGCGCCAUGGAGCAAGCA 23 6575
SCNNlA-2727 + GCAGAGGGCGCCAUGGAGCAAGCA 24 6576
SCNNlA-2728 + CAGUCACUGUGGACAGCA 18 6577
SCNNlA-2729 + CCAGUCACUGUGGACAGCA 19 6578
SCNNlA-910 + CCCAGUCACUGUGGACAGCA 20 4759
SCNNlA-2730 + CCCCAGUCACUGUGGACAGCA 21 6579
SCNNlA-2731 + GCCCCAGUCACUGUGGACAGCA 22 6580
SCNNlA-2732 + GGCCCCAGUCACUGUGGACAGCA 23 6581
SCNNlA-2733 + GGGCCCCAGUCACUGUGGACAGCA 24 6582
SCNNlA-2734 + CAUCGUGAGUAACCAGCA 18 6583
SCNNlA-2735 + CCAUCGUGAGUAACCAGCA 19 6584
SCNNlA-2736 + GCCAUCGUGAGUAACCAGCA 20 6585
SCNNlA-2737 + GGCCAUCGUGAGUAACCAGCA 21 6586
SCNNlA-2738 + GGGCCAUCGUGAGUAACCAGCA 22 6587
SCNNlA-2739 + AGGGCCAUCGUGAGUAACCAGCA 23 6588
SCNNlA-2740 + GAGGGCCAUCGUGAGUAACCAGCA 24 6589
SCNNlA-2741 + CGUUGUUGAUUCCAGGCA 18 6590
SCNNlA-2742 + CCGUUGUUGAUUCCAGGCA 19 6591
SCNNlA-913 + ACCGUUGUUGAUUCCAGGCA 20 4762
SCNNlA-2743 + CACCGUUGUUGAUUCCAGGCA 21 6592
SCNNlA-2744 + UCACCGUUGUUGAUUCCAGGCA 22 6593
SCNNlA-2745 + CUCACCGUUGUUGAUUCCAGGCA 23 6594
SCNNlA-2746 + UCUCACCGUUGUUGAUUCCAGGCA 24 6595
SCNNlA-2747 + CCCAGGGUGGCAUAGGCA 18 6596
SCNNlA-2748 + GCCCAGGGUGGCAUAGGCA 19 6597
SCNNlA-914 + GGCCCAGGGUGGCAUAGGCA 20 4763
SCNNlA-2749 + GGGCCCAGGGUGGCAUAGGCA 21 6598
SCNNlA-2750 + GGGGCCCAGGGUGGCAUAGGCA 22 6599
1257
5535.1 SCNNlA-2751 + GGGGGCCCAGGGUGGCAUAGGCA 23 6600
SCNNlA-2752 + CGGGGGCCCAGGGUGGCAUAGGCA 24 6601
SCNNlA-2753 + GACAGACCUAGGGGUGCA 18 6602
SCNNlA-2754 + GGACAGACCUAGGGGUGCA 19 6603
SCNNlA-2755 + GGGACAGACCUAGGGGUGCA 20 6604
SCNNlA-2756 + AGGGACAGACCUAGGGGUGCA 21 6605
SCNNlA-2757 + CAGGGACAGACCUAGGGGUGCA 22 6606
SCNNlA-2758 + UCAGGGACAGACCUAGGGGUGCA 23 6607
SCNNlA-2759 + AUCAGGGACAGACCUAGGGGUGCA 24 6608
SCNNlA-2760 + CGAUUUGUUCUGGUUGCA 18 6609
SCNNlA-2761 + CCGAUUUGUUCUGGUUGCA 19 6610
SCNNlA-2762 + UCCGAUUUGUUCUGGUUGCA 20 6611
SCNNlA-2763 + GUCCGAUUUGUUCUGGUUGCA 21 6612
SCNNlA-2764 + AGUCCGAUUUGUUCUGGUUGCA 22 6613
SCNNlA-2765 + CAGUCCGAUUUGUUCUGGUUGCA 23 6614
SCNNlA-2766 + GCAGUCCGAUUUGUUCUGGUUGCA 24 6615
SCNNlA-2767 + ACACAGAGACUAGAGUCA 18 6616
SCNNlA-2768 + GACACAGAGACUAGAGUCA 19 6617
SCNNlA-2769 + GGACACAGAGACUAGAGUCA 20 6618
SCNNlA-2770 + UGGACACAGAGACUAGAGUCA 21 6619
SCNNlA-2771 + CUGGACACAGAGACUAGAGUCA 22 6620
SCNNlA-2772 + ACUGGACACAGAGACUAGAGUCA 23 6621
SCNNlA-2773 + CACUGGACACAGAGACUAGAGUCA 24 6622
SCNNlA-2774 + CUGUAUUUGUACAGGUCA 18 6623
SCNNlA-2775 + GCUGUAUUUGUACAGGUCA 19 6624
SCNNlA-2776 + AGCUGUAUUUGUACAGGUCA 20 6625
SCNNlA-2777 + GAGCUGUAUUUGUACAGGUCA 21 6626
SCNNlA-2778 + GGAGCUGUAUUUGUACAGGUCA 22 6627
SCNNlA-2779 + AGGAGCUGUAUUUGUACAGGUCA 23 6628
SCNNlA-2780 + AAGGAGCUGUAUUUGUACAGGUCA 24 6629
SCNNlA-2781 + ACUCUACCUGGGAUGUCA 18 6630
SCNNlA-2782 + CACUCUACCUGGGAUGUCA 19 6631
SCNNlA-2783 + ACACUCUACCUGGGAUGUCA 20 6632
SCNNlA-2784 + CACACUCUACCUGGGAUGUCA 21 6633
SCNNlA-2785 + CCACACUCUACCUGGGAUGUCA 22 6634
SCNNlA-2786 + CCCACACUCUACCUGGGAUGUCA 23 6635
SCNNlA-2787 + CCCCACACUCUACCUGGGAUGUCA 24 6636
SCNNlA-2788 + UUGGAGUUGUUCUUGUCA 18 6637
SCNNlA-2789 + GUUGGAGUUGUUCUUGUCA 19 6638
SCNNlA-2790 + GGUUGGAGUUGUUCUUGUCA 20 6639
SCNNlA-2791 + AGGUUGGAGUUGUUCUUGUCA 21 6640
SCNNlA-2792 + GAGGUUGGAGUUGUUCUUGUCA 22 6641
1258
5535.1 SCNNlA-2793 + AGAGGUUGGAGUUGUUCUUGUCA 23 6642
SCNNlA-2794 + CAGAGGUUGGAGUUGUUCUUGUCA 24
6643
SCNNlA-2795 + ACCCAUUCCUAGGAAAGA 18 6644
SCNNlA-2796 + GACCCAUUCCUAGGAAAGA 19 6645
SCNNlA-2797 + AGACCCAUUCCUAGGAAAGA 20 6646
SCNNlA-2798 + AAGACCCAUUCCUAGGAAAGA 21 6647
SCNNlA-2799 + GAAGACCCAUUCCUAGGAAAGA 22 6648
SCNNlA-2800 + GGAAGACCCAUUCCUAGGAAAGA 23 6649
SCNNlA-2801 + UGGAAGACCCAUUCCUAGGAAAGA 24 6650
SCNNlA-2802 + ACGACCUACCGUGACAGA 18 6651
SCNNlA-2803 + CACGACCUACCGUGACAGA 19 6652
SCNNlA-931 + GCACGACCUACCGUGACAGA 20 4780
SCNNlA-2804 + GGCACGACCUACCGUGACAGA 21 6653
SCNNlA-2805 + AGGCACGACCUACCGUGACAGA 22 6654
SCNNlA-2806 + CAGGCACGACCUACCGUGACAGA 23 6655
SCNNlA-2807 + CCAGGCACGACCUACCGUGACAGA 24 6656
SCNNlA-2808 + CAGACCUAGGGGUGCAGA 18 6657
SCNNlA-2809 + ACAGACCUAGGGGUGCAGA 19 6658
SCNNlA-2810 + GACAGACCUAGGGGUGCAGA 20 6659
SCNNlA-2811 + GGACAGACCUAGGGGUGCAGA 21 6660
SCNNlA-2812 + GGGACAGACCUAGGGGUGCAGA 22 6661
SCNNlA-2813 + AGGGACAGACCUAGGGGUGCAGA 23 6662
SCNNlA-2814 + CAGGGACAGACCUAGGGGUGCAGA 24 6663
SCNNlA-2815 + ACAGAGACUAGAGUCAGA 18 6664
SCNNlA-2816 + CACAGAGACUAGAGUCAGA 19 6665
SCNNlA-933 + ACACAGAGACUAGAGUCAGA 20 4782
SCNNlA-2817 + GACACAGAGACUAGAGUCAGA 21 6666
SCNNlA-2818 + GGACACAGAGACUAGAGUCAGA 22 6667
SCNNlA-2819 + UGGACACAGAGACUAGAGUCAGA 23 6668
SCNNlA-2820 + CUGGACACAGAGACUAGAGUCAGA 24 6669
SCNNlA-2821 + GGCUGUCAAGGCUGGAGA 18 6670
SCNNlA-2822 + GGGCUGUCAAGGCUGGAGA 19 6671
SCNNlA-936 + GGGGCUGUCAAGGCUGGAGA 20 4785
SCNNlA-2823 + AGGGGCUGUCAAGGCUGGAGA 21 6672
SCNNlA-2824 + GAGGGGCUGUCAAGGCUGGAGA 22 6673
SCNNlA-2825 + GGAGGGGCUGUCAAGGCUGGAGA 23 6674
SCNNlA-2826 + GGGAGGGGCUGUCAAGGCUGGAGA 24
6675
SCNNlA-2827 + GGGUACCUGAAGGGGCGA 18 6676
SCNNlA-2828 + CGGGUACCUGAAGGGGCGA 19 6677
SCNNlA-946 + CCGGGUACCUGAAGGGGCGA 20 4795
1259
5535.1 SCNNlA-2829 + UCCGGGUACCUGAAGGGGCGA 21 6678
SCNNlA-2830 + UUCCGGGUACCUGAAGGGGCGA 22 6679
SCNNlA-2831 + UUUCCGGGUACCUGAAGGGGCGA 23 6680
SCNNlA-2832 + AUUUCCGGGUACCUGAAGGGGCGA 24 6681
SCNNlA-2833 + GCCUGGCUGGGACAAGGA 18 6682
SCNNlA-2834 + GGCCUGGCUGGGACAAGGA 19 6683
SCNNlA-2835 + GGGCCUGGCUGGGACAAGGA 20 6684
SCNNlA-2836 + AGGGCCUGGCUGGGACAAGGA 21 6685
SCNNlA-2837 + CAGGGCCUGGCUGGGACAAGGA 22 6686
SCNNlA-2838 + GCAGGGCCUGGCUGGGACAAGGA 23 6687
SCNNlA-2839 + AGCAGGGCCUGGCUGGGACAAGGA 24 6688
SCNNlA-2840 + GGGCAGAAGUGGGAAGGA 18 6689
SCNNlA-2841 + GGGGCAGAAGUGGGAAGGA 19 6690
SCNNlA-948 + GGGGGCAGAAGUGGGAAGGA 20 4797
SCNNlA-2842 + UGGGGGCAGAAGUGGGAAGGA 21 6691
SCNNlA-2843 + GUGGGGGCAGAAGUGGGAAGGA 22 6692
SCNNlA-2844 + GGUGGGGGCAGAAGUGGGAAGGA 23 6693
SCNNlA-2845 + GGGUGGGGGCAGAAGUGGGAAGGA 24
6694
SCNNlA-2846 + AGUAAUUCCUUAUCAGGA 18 6695
SCNNlA-2847 + GAGUAAUUCCUUAUCAGGA 19 6696
SCNNlA-2848 + AGAGUAAUUCCUUAUCAGGA 20 6697
SCNNlA-2849 + GAGAGUAAUUCCUUAUCAGGA 21 6698
SCNNlA-2850 + UGAGAGUAAUUCCUUAUCAGGA 22 6699
SCNNlA-2851 + GUGAGAGUAAUUCCUUAUCAGGA 23 6700
SCNNlA-2852 + AGUGAGAGUAAUUCCUUAUCAGGA 24 6701
SCNNlA-2853 + GGAGGAGGGUGGAGAGGA 18 6702
SCNNlA-2854 + GGGAGGAGGGUGGAGAGGA 19 6703
SCNNlA-2855 + AGGGAGGAGGGUGGAGAGGA 20 6704
SCNNlA-2856 + AAGGGAGGAGGGUGGAGAGGA 21 6705
SCNNlA-2857 + GAAGGGAGGAGGGUGGAGAGGA 22 6706
SCNNlA-2858 + GGAAGGGAGGAGGGUGGAGAGGA 23 6707
SCNNlA-2859 + UGGAAGGGAGGAGGGUGGAGAGGA 24
6708
SCNNlA-2860 + ACGUUCUGGGGCCGCGGA 18 6709
SCNNlA-2861 + CACGUUCUGGGGCCGCGGA 19 6710
SCNNlA-2862 + CCACGUUCUGGGGCCGCGGA 20 6711
SCNNlA-2863 + UCCACGUUCUGGGGCCGCGGA 21 6712
SCNNlA-2864 + CUCCACGUUCUGGGGCCGCGGA 22 6713
SCNNlA-2865 + ACUCCACGUUCUGGGGCCGCGGA 23 6714
SCNNlA-2866 + UACUCCACGUUCUGGGGCCGCGGA 24 6715
SCNNlA-2867 + ACUGUGGACAGCAGGGGA 18 6716
1260
5535.1 SCNNlA-2868 + CACUGUGGACAGCAGGGGA 19 6717
SCNNlA-2869 + UCACUGUGGACAGCAGGGGA 20 6718
SCNNlA-2870 + GUCACUGUGGACAGCAGGGGA 21 6719
SCNNlA-2871 + AGUCACUGUGGACAGCAGGGGA 22 6720
SCNNlA-2872 + CAGUCACUGUGGACAGCAGGGGA 23 6721
SCNNlA-2873 + CCAGUCACUGUGGACAGCAGGGGA 24 6722
SCNNlA-2874 + AGCUGGUCACGCUGGGGA 18 6723
SCNNlA-2875 + UAGCUGGUCACGCUGGGGA 19 6724
SCNNlA-956 + GUAGCUGGUCACGCUGGGGA 20 4805
SCNNlA-2876 + GGUAGCUGGUCACGCUGGGGA 21 6725
SCNNlA-2877 + UGGUAGCUGGUCACGCUGGGGA 22 6726
SCNNlA-2878 + CUGGUAGCUGGUCACGCUGGGGA 23 6727
SCNNlA-2879 + GCUGGUAGCUGGUCACGCUGGGGA 24 6728
SCNNlA-2880 + GUGGGGGCAGAAGUGGGA 18 6729
SCNNlA-2881 + GGUGGGGGCAGAAGUGGGA 19 6730
SCNNlA-958 + GGGUGGGGGCAGAAGUGGGA 20 4807
SCNNlA-2882 + GGGGUGGGGGCAGAAGUGGGA 21 6731
SCNNlA-2883 + UGGGGUGGGGGCAGAAGUGGGA 22 6732
SCNNlA-2884 + AUGGGGUGGGGGCAGAAGUGGGA 23 6733
SCNNlA-2885 + CAUGGGGUGGGGGCAGAAGUGGGA 24
6734
SCNNlA-2886 + AGUGAAUACACACCUGGA 18 6735
SCNNlA-2887 + GAGUGAAUACACACCUGGA 19 6736
SCNNlA-960 + GGAGUGAAUACACACCUGGA 20 4809
SCNNlA-2888 + AGGAGUGAAUACACACCUGGA 21 6737
SCNNlA-2889 + CAGGAGUGAAUACACACCUGGA 22 6738
SCNNlA-2890 + GCAGGAGUGAAUACACACCUGGA 23 6739
SCNNlA-2891 + AGCAGGAGUGAAUACACACCUGGA 24 6740
SCNNlA-2892 + GGGGCUGUCAAGGCUGGA 18 6741
SCNNlA-2893 + AGGGGCUGUCAAGGCUGGA 19 6742
SCNNlA-2894 + GAGGGGCUGUCAAGGCUGGA 20 6743
SCNNlA-2895 + GGAGGGGCUGUCAAGGCUGGA 21 6744
SCNNlA-2896 + GGGAGGGGCUGUCAAGGCUGGA 22 6745
SCNNlA-2897 + GGGGAGGGGCUGUCAAGGCUGGA 23 6746
SCNNlA-2898 + GGGGGAGGGGCUGUCAAGGCUGGA 24
6747
SCNNlA-2899 + GGAAGGGAGGAGGGUGGA 18 6748
SCNNlA-2900 + UGGAAGGGAGGAGGGUGGA 19 6749
SCNNlA-2901 + CUGGAAGGGAGGAGGGUGGA 20 6750
SCNNlA-2902 + CCUGGAAGGGAGGAGGGUGGA 21 6751
SCNNlA-2903 + ACCUGGAAGGGAGGAGGGUGGA 22 6752
SCNNlA-2904 + CACCUGGAAGGGAGGAGGGUGGA 23 6753
1261
5535.1 SCNNlA-2905 + ACACCUGGAAGGGAGGAGGGUGGA 24 6754
SCNNlA-2906 + CUGGCUGCCCAGGUUGGA 18 6755
SCNNlA-2907 + ACUGGCUGCCCAGGUUGGA 19 6756
SCNNlA-2908 + CACUGGCUGCCCAGGUUGGA 20 6757
SCNNlA-2909 + CCACUGGCUGCCCAGGUUGGA 21 6758
SCNNlA-2910 + UCCACUGGCUGCCCAGGUUGGA 22 6759
SCNNlA-2911 + CUCCACUGGCUGCCCAGGUUGGA 23 6760
SCNNlA-2912 + GCUCCACUGGCUGCCCAGGUUGGA 24 6761
SCNNlA-2913 + UAAUUUCCGGGUACCUGA 18 6762
SCNNlA-2914 + UUAAUUUCCGGGUACCUGA 19 6763
SCNNlA-964 + UUUAAUUUCCGGGUACCUGA 20 4813
SCNNlA-2915 + CUUUAAUUUCCGGGUACCUGA 21 6764
SCNNlA-2916 + UCUUUAAUUUCCGGGUACCUGA 22 6765
SCNNlA-2917 + CUCUUUAAUUUCCGGGUACCUGA 23 6766
SCNNlA-2918 + CCUCUUUAAUUUCCGGGUACCUGA 24 6767
SCNNlA-2919 + UUGCCUUCCUCAUGCUGA 18 6768
SCNNlA-2920 + CUUGCCUUCCUCAUGCUGA 19 6769
SCNNlA-966 + CCUUGCCUUCCUCAUGCUGA 20 4815
SCNNlA-2921 + UCCUUGCCUUCCUCAUGCUGA 21 6770
SCNNlA-2922 + AUCCUUGCCUUCCUCAUGCUGA 22 6771
SCNNlA-2923 + CAUCCUUGCCUUCCUCAUGCUGA 23 6772
SCNNlA-2924 + GCAUCCUUGCCUUCCUCAUGCUGA 24 6773
SCNNlA-2925 + AGGCACGACCUACCGUGA 18 6774
SCNNlA-2926 + CAGGCACGACCUACCGUGA 19 6775
SCNNlA-2927 + CCAGGCACGACCUACCGUGA 20 6776
SCNNlA-2928 + UCCAGGCACGACCUACCGUGA 21 6777
SCNNlA-2929 + AUCCAGGCACGACCUACCGUGA 22 6778
SCNNlA-2930 + CAUCCAGGCACGACCUACCGUGA 23 6779
SCNNlA-2931 + CCAUCCAGGCACGACCUACCGUGA 24 6780
SCNNlA-2932 + CGGCCACGAGAGUGGUGA 18 6781
SCNNlA-2933 + CCGGCCACGAGAGUGGUGA 19 6782
SCNNlA-968 + GCCGGCCACGAGAGUGGUGA 20 4817
SCNNlA-2934 + AGCCGGCCACGAGAGUGGUGA 21 6783
SCNNlA-2935 + GAGCCGGCCACGAGAGUGGUGA 22 6784
SCNNlA-2936 + GGAGCCGGCCACGAGAGUGGUGA 23 6785
SCNNlA-2937 + GGGAGCCGGCCACGAGAGUGGUGA 24 6786
SCNNlA-2938 + GAGGGUGACCAUCUGUGA 18 6787
SCNNlA-2939 + GGAGGGUGACCAUCUGUGA 19 6788
SCNNlA-2940 + AGGAGGGUGACCAUCUGUGA 20 6789
SCNNlA-2941 + CAGGAGGGUGACCAUCUGUGA 21 6790
SCNNlA-2942 + ACAGGAGGGUGACCAUCUGUGA 22 6791
SCNNlA-2943 + GACAGGAGGGUGACCAUCUGUGA 23 6792
1262
5535.1 SCNNlA-2944 + GGACAGGAGGGUGACCAUCUGUGA 24 6793
SCNNlA-2945 + AGCAGUACCCUGUGGGUA 18 6794
SCNNlA-2946 + UAGCAGUACCCUGUGGGUA 19 6795
SCNNlA-2947 + GUAGCAGUACCCUGUGGGUA 20 6796
SCNNlA-2948 + AGUAGCAGUACCCUGUGGGUA 21 6797
SCNNlA-2949 + UAGUAGCAGUACCCUGUGGGUA 22 6798
SCNNlA-2950 + AUAGUAGCAGUACCCUGUGGGUA 23 6799
SCNNlA-2951 + UAUAGUAGCAGUACCCUGUGGGUA 24 6800
SCNNlA-2952 + CGACAGGAUGUUGAUGUA 18 6801
SCNNlA-2953 + UCGACAGGAUGUUGAUGUA 19 6802
SCNNlA-2954 + CUCGACAGGAUGUUGAUGUA 20 6803
SCNNlA-2955 + CCUCGACAGGAUGUUGAUGUA 21 6804
SCNNlA-2956 + GCCUCGACAGGAUGUUGAUGUA 22 6805
SCNNlA-2957 + AGCCUCGACAGGAUGUUGAUGUA 23 6806
SCNNlA-2958 + CAGCCUCGACAGGAUGUUGAUGUA 24 6807
SCNNlA-2959 + AGGGUAAAGGUUCUCAAC 18 6808
SCNNlA-2960 + AAGGGUAAAGGUUCUCAAC 19 6809
SCNNlA-978 + GAAGGGUAAAGGUUCUCAAC 20 4827
SCNNlA-2961 + UGAAGGGUAAAGGUUCUCAAC 21 6810
SCNNlA-2962 + UUGAAGGGUAAAGGUUCUCAAC 22 6811
SCNNlA-2963 + UUUGAAGGGUAAAGGUUCUCAAC 23 6812
SCNNlA-2964 + CUUUGAAGGGUAAAGGUUCUCAAC 24 6813
SCNNlA-2965 + GUCUGAGGAGAAGUCAAC 18 6814
SCNNlA-2966 + GGUCUGAGGAGAAGUCAAC 19 6815
SCNNlA-2967 + U G G U C U GAG GAG AAG U CAAC 20 6816
SCNNlA-2968 + GUGGUCUGAGGAGAAGUCAAC 21 6817
SCNNlA-2969 + GGUGGUCUGAGGAGAAGUCAAC 22 6818
SCNNlA-2970 + AGGUGGUCUGAGGAGAAGUCAAC 23 6819
SCNNlA-2971 + CAG G U G G U C U GAG GAG AAG U CAAC 24 6820
SCNNlA-2972 + GCAGGAGUGAAUACACAC 18 6821
SCNNlA-2973 + AGCAGGAGUGAAUACACAC 19 6822
SCNNlA-2974 + AAGCAGGAGUGAAUACACAC 20 6823
SCNNlA-2975 + GAAGCAGGAGUGAAUACACAC 21 6824
SCNNlA-2976 + GGAAGCAGGAGUGAAUACACAC 22 6825
SCNNlA-2977 + UGGAAGCAGGAGUGAAUACACAC 23 6826
SCNNlA-2978 + CUGGAAGCAGGAGUGAAUACACAC 24 6827
SCNNlA-2979 + CCAGUCCUUCCAGUCCAC 18 6828
SCNNlA-2980 + UCCAGUCCUUCCAGUCCAC 19 6829
SCNNlA-2981 + UUCCAGUCCUUCCAGUCCAC 20 6830
SCNNlA-2982 + CUUCCAGUCCUUCCAGUCCAC 21 6831
SCNNlA-2983 + UCUUCCAGUCCUUCCAGUCCAC 22 6832
SCNNlA-2984 + AUCUUCCAGUCCUUCCAGUCCAC 23 6833
1263
5535.1 SCNNlA-2985 + GAUCUUCCAGUCCUUCCAGUCCAC 24 6834
SCNNlA-2986 + UGGGACAAGGACAGAGAC 18 6835
SCNNlA-2987 + CUGGGACAAGGACAGAGAC 19 6836
SCNNlA-2988 + GCUGGGACAAGGACAGAGAC 20 6837
SCNNlA-2989 + GGCUGGGACAAGGACAGAGAC 21 6838
SCNNlA-2990 + UGGCUGGGACAAGGACAGAGAC 22 6839
SCNNlA-2991 + CUGGCUGGGACAAGGACAGAGAC 23 6840
SCNNlA-2992 + CCUGGCUGGGACAAGGACAGAGAC 24 6841
SCNNlA-2993 + GCAGGGCCUGGCUGGGAC 18 6842
SCNNlA-2994 + AGCAGGGCCUGGCUGGGAC 19 6843
SCNNlA-2995 + GAGCAGGGCCUGGCUGGGAC 20 6844
SCNNlA-2996 + GGAGCAGGGCCUGGCUGGGAC 21 6845
SCNNlA-2997 + GGGAGCAGGGCCUGGCUGGGAC 22 6846
SCNNlA-2998 + AGGGAGCAGGGCCUGGCUGGGAC 23 6847
SCNNlA-2999 + GAGGGAGCAGGGCCUGGCUGGGAC 24 6848
SCNNlA-3000 + UGGCUGCCCAGGUUGGAC 18 6849
SCNNlA-3001 + CUGGCUGCCCAGGUUGGAC 19 6850
SCNNlA-991 + ACUGGCUGCCCAGGUUGGAC 20 4840
SCNNlA-3002 + CACUGGCUGCCCAGGUUGGAC 21 6851
SCNNlA-3003 + CCACUGGCUGCCCAGGUUGGAC 22 6852
SCNNlA-3004 + UCCACUGGCUGCCCAGGUUGGAC 23 6853
SCNNlA-3005 + CUCCACUGGCUGCCCAGGUUGGAC 24 6854
SCNNlA-3006 + CCCUUCCCCACACUCUAC 18 6855
SCNNlA-3007 + UCCCUUCCCCACACUCUAC 19 6856
SCNNlA-3008 + AUCCCUUCCCCACACUCUAC 20 6857
SCNNlA-3009 + CAUCCCUUCCCCACACUCUAC 21 6858
SCNNlA-3010 + CCAUCCCUUCCCCACACUCUAC 22 6859
SCNNlA-3011 + CCCAUCCCUUCCCCACACUCUAC 23 6860
SCNNlA-3012 + ACCCAUCCCUUCCCCACACUCUAC 24 6861
SCNNlA-3013 + UCUUUAAUUUCCGGGUAC 18 6862
SCNNlA-3014 + CUCUUUAAUUUCCGGGUAC 19 6863
SCNNlA-3015 + CCUCUUUAAUUUCCGGGUAC 20 6864
SCNNlA-3016 + UCCUCUUUAAUUUCCGGGUAC 21 6865
SCNNlA-3017 + CUCCUCUUUAAUUUCCGGGUAC 22 6866
SCNNlA-3018 + GCUCCUCUUUAAUUUCCGGGUAC 23 6867
SCNNlA-3019 + AGCUCCUCUUUAAUUUCCGGGUAC 24 6868
SCNNlA-3020 + CUGCCCGUGCACCAUUAC 18 6869
SCNNlA-3021 + CCUGCCCGUGCACCAUUAC 19 6870
SCNNlA-3022 + UCCUGCCCGUGCACCAUUAC 20 6871
SCNNlA-3023 + AUCCUGCCCGUGCACCAUUAC 21 6872
SCNNlA-3024 + CAUCCUGCCCGUGCACCAUUAC 22 6873
SCNNlA-3025 + UCAUCCUGCCCGUGCACCAUUAC 23 6874
1264
5535.1 SCNNlA-3026 + UUCAUCCUGCCCGUGCACCAUUAC 24 6875
SCNNlA-3027 + UCUGAGGAGAAGUCAACC 18 6876
SCNNlA-3028 + GUCUGAGGAGAAGUCAACC 19 6877
SCNNlA-1000 + GGUCUGAGGAGAAGUCAACC 20 4849
SCNNlA-3029 + UGGUCUGAGGAGAAGUCAACC 21 6878
SCNNlA-3030 + GUGGUCUGAGGAGAAGUCAACC 22 6879
SCNNlA-3031 + GGUGGUCUGAGGAGAAGUCAACC 23 6880
SCNNlA-3032 + AGGUGGUCUGAGGAGAAGUCAACC 24 6881
SCNNlA-3033 + UCCACCACAGACAACACC 18 6882
SCNNlA-3034 + CUCCACCACAGACAACACC 19 6883
SCNNlA-3035 + UCUCCACCACAGACAACACC 20 6884
SCNNlA-3036 + AUCUCCACCACAGACAACACC 21 6885
SCNNlA-3037 + CAUCUCCACCACAGACAACACC 22 6886
SCNNlA-3038 + CCAUCUCCACCACAGACAACACC 23 6887
SCNNlA-3039 + GCCAUCUCCACCACAGACAACACC 24 6888
SCNNlA-3040 + CAGGAGUGAAUACACACC 18 6889
SCNNlA-3041 + GCAGGAGUGAAUACACACC 19 6890
SCNNlA-1002 + AGCAGGAGUGAAUACACACC 20 4851
SCNNlA-3042 + AAGCAGGAGUGAAUACACACC 21 6891
SCNNlA-3043 + GAAGCAGGAGUGAAUACACACC 22 6892
SCNNlA-3044 + GGAAGCAGGAGUGAAUACACACC 23 6893
SCNNlA-3045 + UGGAAGCAGGAGUGAAUACACACC 24 6894
SCNNlA-3046 + UAUGAACCCACAUACACC 18 6895
SCNNlA-3047 + CUAUGAACCCACAUACACC 19 6896
SCNNlA-3048 + CCUAUGAACCCACAUACACC 20 6897
SCNNlA-3049 + UCCUAUGAACCCACAUACACC 21 6898
SCNNlA-3050 + UUCCUAUGAACCCACAUACACC 22 6899
SCNNlA-3051 + UUUCCUAUGAACCCACAUACACC 23 6900
SCNNlA-3052 + GUUUCCUAUGAACCCACAUACACC 24 6901
SCNNlA-3053 + CAGUCCUUCCAGUCCACC 18 6902
SCNNlA-3054 + CCAGUCCUUCCAGUCCACC 19 6903
SCNNlA-1004 + UCCAGUCCUUCCAGUCCACC 20 4853
SCNNlA-3055 + UUCCAGUCCUUCCAGUCCACC 21 6904
SCNNlA-3056 + CUUCCAGUCCUUCCAGUCCACC 22 6905
SCNNlA-3057 + UCUUCCAGUCCUUCCAGUCCACC 23 6906
SCNNlA-3058 + AUCUUCCAGUCCUUCCAGUCCACC 24 6907
SCNNlA-3059 + UCUACCUGGGAUGUCACC 18 6908
SCNNlA-3060 + CUCUACCUGGGAUGUCACC 19 6909
SCNNlA-3061 + ACUCUACCUGGGAUGUCACC 20 6910
SCNNlA-3062 + CACUCUACCUGGGAUGUCACC 21 6911
SCNNlA-3063 + ACACUCUACCUGGGAUGUCACC 22 6912
SCNNlA-3064 + CACACUCUACCUGGGAUGUCACC 23 6913
1265
5535.1 SCNNlA-3065 + CCACACUCUACCUGGGAUGUCACC 24 6914
SCNNlA-3066 + CAGCAUCAGGGACAGACC 18 6915
SCNNlA-3067 + GCAGCAUCAGGGACAGACC 19 6916
SCNNlA-3068 + CGCAGCAUCAGGGACAGACC 20 6917
SCNNlA-3069 + GCGCAGCAUCAGGGACAGACC 21 6918
SCNNlA-3070 + CGCGCAGCAUCAGGGACAGACC 22 6919
SCNNlA-3071 + GCGCGCAGCAUCAGGGACAGACC 23 6920
SCNNlA-3072 + UGCGCGCAGCAUCAGGGACAGACC 24 6921
SCNNlA-3073 + CUCCCUGGAGUCUCACCC 18 6922
SCNNlA-3074 + GCUCCCUGGAGUCUCACCC 19 6923
SCNNlA-3075 + GGCUCCCUGGAGUCUCACCC 20 6924
SCNNlA-3076 + GGGCUCCCUGGAGUCUCACCC 21 6925
SCNNlA-3077 + GGGGCUCCCUGGAGUCUCACCC 22 6926
SCNNlA-3078 + GGGGGCUCCCUGGAGUCUCACCC 23 6927
SCNNlA-3079 + UGGGGGCUCCCUGGAGUCUCACCC 24 6928
SCNNlA-3080 + UCCCUGGAGUCUCACCCC 18 6929
SCNNlA-3081 + CUCCCUGGAGUCUCACCCC 19 6930
SCNNlA-1013 + GCUCCCUGGAGUCUCACCCC 20 4862
SCNNlA-3082 + GGCUCCCUGGAGUCUCACCCC 21 6931
SCNNlA-3083 + GGGCUCCCUGGAGUCUCACCCC 22 6932
SCNNlA-3084 + GGGGCUCCCUGGAGUCUCACCCC 23 6933
SCNNlA-3085 + GGGGGCUCCCUGGAGUCUCACCCC 24 6934
SCNNlA-3086 + UCCCUCUCAGGGCCCCCC 18 6935
SCNNlA-3087 + UUCCCUCUCAGGGCCCCCC 19 6936
SCNNlA-3088 + CUUCCCUCUCAGGGCCCCCC 20 6937
SCNNlA-3089 + CCUUCCCUCUCAGGGCCCCCC 21 6938
SCNNlA-3090 + UCCUUCCCUCUCAGGGCCCCCC 22 6939
SCNNlA-3091 + CUCCUUCCCUCUCAGGGCCCCCC 23 6940
SCNNlA-3092 + UCUCCUUCCCUCUCAGGGCCCCCC 24 6941
SCNNlA-3093 + GGCCCCUGCAGAGCCCCC 18 6942
SCNNlA-3094 + UGGCCCCUGCAGAGCCCCC 19 6943
SCNNlA-1015 + CUGGCCCCUGCAGAGCCCCC 20 4864
SCNNlA-3095 + ACUGGCCCCUGCAGAGCCCCC 21 6944
SCNNlA-3096 + AACUGGCCCCUGCAGAGCCCCC 22 6945
SCNNlA-3097 + GAACUGGCCCCUGCAGAGCCCCC 23 6946
SCNNlA-3098 + GGAACUGGCCCCUGCAGAGCCCCC 24 6947
SCNNlA-3099 + UGGCCCCUGCAGAGCCCC 18 6948
SCNNlA-3100 + CUGGCCCCUGCAGAGCCCC 19 6949
SCNNlA-3101 + ACUGGCCCCUGCAGAGCCCC 20 6950
SCNNlA-3102 + AACUGGCCCCUGCAGAGCCCC 21 6951
SCNNlA-3103 + GAACUGGCCCCUGCAGAGCCCC 22 6952
SCNNlA-3104 + GGAACUGGCCCCUGCAGAGCCCC 23 6953
1266
5535.1 SCNNlA-3105 + AGGAACUGGCCCCUGCAGAGCCCC 24 6954
SCNNlA-3106 + ACGGGCUCGACGGGCCCC 18 6955
SCNNlA-3107 + UACGGGCUCGACGGGCCCC 19 6956
SCNNlA-3108 + CUACGGGCUCGACGGGCCCC 20 6957
SCNNlA-3109 + GCUACGGGCUCGACGGGCCCC 21 6958
SCNNlA-3110 + CGCUACGGGCUCGACGGGCCCC 22 6959
SCNNlA-3111 + ACGCUACGGGCUCGACGGGCCCC 23 6960
SCNNlA-3112 + CACGCUACGGGCUCGACGGGCCCC 24 6961
SCNNlA-3113 + CGGCUGCGGGAGCCGGCC 18 6962
SCNNlA-3114 + ACGGCUGCGGGAGCCGGCC 19 6963
SCNNlA-3115 + GACGGCUGCGGGAGCCGGCC 20 6964
SCNNlA-3116 + CGACGGCUGCGGGAGCCGGCC 21 6965
SCNNlA-3117 + GCGACGGCUGCGGGAGCCGGCC 22 6966
SCNNlA-3118 + CGCGACGGCUGCGGGAGCCGGCC 23 6967
SCNNlA-3119 + UCGCGACGGCUGCGGGAGCCGGCC 24 6968
SCNNlA-3120 + ACCCCUGCCCCCUCGGCC 18 6969
SCNNlA-3121 + CACCCCUGCCCCCUCGGCC 19 6970
SCNNlA-1030 + GCACCCCUGCCCCCUCGGCC 20 4879
SCNNlA-3122 + AGCACCCCUGCCCCCUCGGCC 21 6971
SCNNlA-3123 + GAGCACCCCUGCCCCCUCGGCC 22 6972
SCNNlA-3124 + UGAGCACCCCUGCCCCCUCGGCC 23 6973
SCNNlA-3125 + CUGAGCACCCCUGCCCCCUCGGCC 24 6974
SCNNlA-3126 + GUUUUGUAGUUCAGCUCC 18 6975
SCNNlA-3127 + GGUUUUGUAGUUCAGCUCC 19 6976
SCNNlA-3128 + UGGUUUUGUAGUUCAGCUCC 20 6977
SCNNlA-3129 + UUGGUUUUGUAGUUCAGCUCC 21 6978
SCNNlA-3130 + AUUGGUUUUGUAGUUCAGCUCC 22 6979
SCNNlA-3131 + AAUUGGUUUUGUAGUUCAGCUCC 23 6980
SCNNlA-3132 + GAAUUGGUUUUGUAGUUCAGCUCC 24 6981
SCNNlA-3133 + UCCUUGAUCAUGCUCUCC 18 6982
SCNNlA-3134 + CUCCUUGAUCAUGCUCUCC 19 6983
SCNNlA-1041 + ACUCCUUGAUCAUGCUCUCC 20 4890
SCNNlA-3135 + CACUCCUUGAUCAUGCUCUCC 21 6984
SCNNlA-3136 + ACACUCCUUGAUCAUGCUCUCC 22 6985
SCNNlA-3137 + CACACUCCUUGAUCAUGCUCUCC 23 6986
SCNNlA-3138 + CCACACUCCUUGAUCAUGCUCUCC 24 6987
SCNNlA-3139 + AUCUGGAAGACCCAUUCC 18 6988
SCNNlA-3140 + CAUCUGGAAGACCCAUUCC 19 6989
SCNNlA-3141 + GCAUCUGGAAGACCCAUUCC 20 6990
SCNNlA-3142 + AGCAUCUGGAAGACCCAUUCC 21 6991
SCNNlA-3143 + UAGCAUCUGGAAGACCCAUUCC 22 6992
SCNNlA-3144 + AUAGCAUCUGGAAGACCCAUUCC 23 6993
1267
5535.1 SCNNlA-3145 + GAUAGCAUCUGGAAGACCCAUUCC 24 6994
SCNNlA-3146 + GGGCGCCAUGGAGCAAGC 18 6995
SCNNlA-3147 + AGGGCGCCAUGGAGCAAGC 19 6996
SCNNlA-1049 + GAGGGCGCCAUGGAGCAAGC 20 4898
SCNNlA-3148 + AGAGGGCGCCAUGGAGCAAGC 21 6997
SCNNlA-3149 + CAGAGGGCGCCAUGGAGCAAGC 22 6998
SCNNlA-3150 + GCAGAGGGCGCCAUGGAGCAAGC 23 6999
SCNNlA-3151 + AGCAGAGGGCGCCAUGGAGCAAGC 24 7000
SCNNlA-3152 + GGUUGUUGUCCCGCAAGC 18 7001
SCNNlA-3153 + GGGUUGUUGUCCCGCAAGC 19 7002
SCNNlA-1050 + GGGGUUGUUGUCCCGCAAGC 20 4899
SCNNlA-3154 + GGGGGUUGUUGUCCCGCAAGC 21 7003
SCNNlA-3155 + UGGGGGUUGUUGUCCCGCAAGC 22 7004
SCNNlA-3156 + CUGGGGGUUGUUGUCCCGCAAGC 23 7005
SCNNlA-3157 + CCUGGGGGUUGUUGUCCCGCAAGC 24 7006
SCNNlA-3158 + CCAGUCACUGUGGACAGC 18 7007
SCNNlA-3159 + CCCAGUCACUGUGGACAGC 19 7008
SCNNlA-1053 + CCCCAGUCACUGUGGACAGC 20 4902
SCNNlA-3160 + GCCCCAGUCACUGUGGACAGC 21 7009
SCNNlA-3161 + GGCCCCAGUCACUGUGGACAGC 22 7010
SCNNlA-3162 + GGGCCCCAGUCACUGUGGACAGC 23 7011
SCNNlA-3163 + CGGGCCCCAGUCACUGUGGACAGC 24 7012
SCNNlA-3164 + GCUGCGGGCCUCACCAGC 18 7013
SCNNlA-3165 + CGCUGCGGGCCUCACCAGC 19 7014
SCNNlA-1054 + GCGCUGCGGGCCUCACCAGC 20 4903
SCNNlA-3166 + GGCGCUGCGGGCCUCACCAGC 21 7015
SCNNlA-3167 + CGGCGCUGCGGGCCUCACCAGC 22 7016
SCNNlA-3168 + UCGGCGCUGCGGGCCUCACCAGC 23 7017
SCNNlA-3169 + CUCGGCGCUGCGGGCCUCACCAGC 24 7018
SCNNlA-3170 + CGGAACCUUCGGAGCAGC 18 7019
SCNNlA-3171 + UCGGAACCUUCGGAGCAGC 19 7020
SCNNlA-3172 + UUCGGAACCUUCGGAGCAGC 20 7021
SCNNlA-3173 + CUUCGGAACCUUCGGAGCAGC 21 7022
SCNNlA-3174 + GCUUCGGAACCUUCGGAGCAGC 22 7023
SCNNlA-3175 + GGCUUCGGAACCUUCGGAGCAGC 23 7024
SCNNlA-3176 + CGGCUUCGGAACCUUCGGAGCAGC 24 7025
SCNNlA-3177 + GCUGGUAGCUGGUCACGC 18 7026
SCNNlA-3178 + AGCUGGUAGCUGGUCACGC 19 7027
SCNNlA-1064 + GAGCUGGUAGCUGGUCACGC 20 4913
SCNNlA-3179 + AGAGCUGGUAGCUGGUCACGC 21 7028
SCNNlA-3180 + GAGAGCUGGUAGCUGGUCACGC 22 7029
SCNNlA-3181 + AGAGAGCUGGUAGCUGGUCACGC 23 7030
1268
5535.1 SCNNlA-3182 + CAGAGAGCUGGUAGCUGGUCACGC 24 7031
SCNNlA-3183 + GGGAGGGGCUGUCAAGGC 18 7032
SCNNlA-3184 + GGGGAGGGGCUGUCAAGGC 19 7033
SCNNlA-1067 + GGGGGAGGGGCUGUCAAGGC 20 4916
SCNNlA-3185 + AGGGGGAGGGGCUGUCAAGGC 21 7034
SCNNlA-3186 + CAGGGGGAGGGGCUGUCAAGGC 22 7035
SCNNlA-3187 + GCAGGGGGAGGGGCUGUCAAGGC 23 7036
SCNNlA-3188 + GGCAGGGGGAGGGGCUGUCAAGGC 24 7037
SCNNlA-3189 + CCGUUGUUGAUUCCAGGC 18 7038
SCNNlA-3190 + ACCGUUGUUGAUUCCAGGC 19 7039
SCNNlA-3191 + CACCGUUGUUGAUUCCAGGC 20 7040
SCNNlA-3192 + UCACCGUUGUUGAUUCCAGGC 21 7041
SCNNlA-3193 + CUCACCGUUGUUGAUUCCAGGC 22 7042
SCNNlA-3194 + UCUCACCGUUGUUGAUUCCAGGC 23 7043
SCNNlA-3195 + UUCUCACCGUUGUUGAUUCCAGGC 24 7044
SCNNlA-3196 + CGACGGGCCCCGUGAGGC 18 7045
SCNNlA-3197 + UCGACGGGCCCCGUGAGGC 19 7046
SCNNlA-1068 + CUCGACGGGCCCCGUGAGGC 20 4917
SCNNlA-3198 + GCUCGACGGGCCCCGUGAGGC 21 7047
SCNNlA-3199 + GGCUCGACGGGCCCCGUGAGGC 22 7048
SCNNlA-3200 + GGGCUCGACGGGCCCCGUGAGGC 23 7049
SCNNlA-3201 + CGGGCUCGACGGGCCCCGUGAGGC 24 7050
SCNNlA-3202 + GCCCAGGGUGGCAUAGGC 18 7051
SCNNlA-3203 + GGCCCAGGGUGGCAUAGGC 19 7052
SCNNlA-1069 + GGGCCCAGGGUGGCAUAGGC 20 4918
SCNNlA-3204 + GGGGCCCAGGGUGGCAUAGGC 21 7053
SCNNlA-3205 + GGGGGCCCAGGGUGGCAUAGGC 22 7054
SCNNlA-3206 + CGGGGGCCCAGGGUGGCAUAGGC 23 7055
SCNNlA-3207 + GCGGGGGCCCAGGGUGGCAUAGGC 24 7056
SCNNlA-3208 + CACCCCUGCCCCCUCGGC 18 7057
SCNNlA-3209 + GCACCCCUGCCCCCUCGGC 19 7058
SCNNlA-3210 + AGCACCCCUGCCCCCUCGGC 20 7059
SCNNlA-3211 + GAGCACCCCUGCCCCCUCGGC 21 7060
SCNNlA-3212 + UGAGCACCCCUGCCCCCUCGGC 22 7061
SCNNlA-3213 + CUGAGCACCCCUGCCCCCUCGGC 23 7062
SCNNlA-3214 + CCUGAGCACCCCUGCCCCCUCGGC 24 7063
SCNNlA-3215 + CCGGGUACCUGAAGGGGC 18 7064
SCNNlA-3216 + UCCGGGUACCUGAAGGGGC 19 7065
SCNNlA-3217 + UUCCGGGUACCUGAAGGGGC 20 7066
SCNNlA-3218 + UUUCCGGGUACCUGAAGGGGC 21 7067
SCNNlA-3219 + AUUUCCGGGUACCUGAAGGGGC 22 7068
SCNNlA-3220 + AAUUUCCGGGUACCUGAAGGGGC 23 7069
1269
5535.1 SCNNlA-3221 + UAAUUUCCGGGUACCUGAAGGGGC 24 7070
SCNNlA-3222 + AGCCCCCUGGAGAUGGGC 18 7071
SCNNlA-3223 + GAGCCCCCUGGAGAUGGGC 19 7072
SCNNlA-1075 + AGAGCCCCCUGGAGAUGGGC 20 4924
SCNNlA-3224 + CAGAGCCCCCUGGAGAUGGGC 21 7073
SCNNlA-3225 + GCAGAGCCCCCUGGAGAUGGGC 22 7074
SCNNlA-3226 + UGCAGAGCCCCCUGGAGAUGGGC 23 7075
SCNNlA-3227 + CUGCAGAGCCCCCUGGAGAUGGGC 24 7076
SCNNlA-3228 + GAGGGAGCAGGGCCUGGC 18 7077
SCNNlA-3229 + AGAGGGAGCAGGGCCUGGC 19 7078
SCNNlA-1076 + GAGAGGGAGCAGGGCCUGGC 20 4925
SCNNlA-3230 + GGAGAGGGAGCAGGGCCUGGC 21 7079
SCNNlA-3231 + UGGAGAGGGAGCAGGGCCUGGC 22 7080
SCNNlA-3232 + CUGGAGAGGGAGCAGGGCCUGGC 23 7081
SCNNlA-3233 + GCUGGAGAGGGAGCAGGGCCUGGC 24 7082
SCNNlA-3234 + GGGACCCUCAGGCGCUGC 18 7083
SCNNlA-3235 + CGGGACCCUCAGGCGCUGC 19 7084
SCNNlA-3236 + GCGGGACCCUCAGGCGCUGC 20 7085
SCNNlA-3237 + GGCGGGACCCUCAGGCGCUGC 21 7086
SCNNlA-3238 + GGGCGGGACCCUCAGGCGCUGC 22 7087
SCNNlA-3239 + GGGGCGGGACCCUCAGGCGCUGC 23 7088
SCNNlA-3240 + GGGGGCGGGACCCUCAGGCGCUGC 24 7089
SCNNlA-3241 + GCAGGUCGCGACGGCUGC 18 7090
SCNNlA-3242 + CGCAGGUCGCGACGGCUGC 19 7091
SCNNlA-1082 + CCGCAGGUCGCGACGGCUGC 20 4931
SCNNlA-3243 + CCCGCAGGUCGCGACGGCUGC 21 7092
SCNNlA-3244 + CCCCGCAGGUCGCGACGGCUGC 22 7093
SCNNlA-3245 + CCCCCGCAGGUCGCGACGGCUGC 23 7094
SCNNlA-3246 + UCCCCCGCAGGUCGCGACGGCUGC 24 7095
SCNNlA-3247 + UGACUCACGCCUGGUUGC 18 7096
SCNNlA-3248 + CUGACUCACGCCUGGUUGC 19 7097
SCNNlA-1087 + ACUGACUCACGCCUGGUUGC 20 4936
SCNNlA-3249 + GACUGACUCACGCCUGGUUGC 21 7098
SCNNlA-3250 + GGACUGACUCACGCCUGGUUGC 22 7099
SCNNlA-3251 + AGGACUGACUCACGCCUGGUUGC 23 7100
SCNNlA-3252 + CAGGACUGACUCACGCCUGGUUGC 24 7101
SCNNlA-3253 + CCAGGCAUGGAAGACAUC 18 7102
SCNNlA-3254 + UCCAGGCAUGGAAGACAUC 19 7103
SCNNlA-3255 + UUCCAGGCAUGGAAGACAUC 20 7104
SCNNlA-3256 + AUUCCAGGCAUGGAAGACAUC 21 7105
SCNNlA-3257 + GAUUCCAGGCAUGGAAGACAUC 22 7106
SCNNlA-3258 + UGAUUCCAGGCAUGGAAGACAUC 23 7107
1270
5535.1 SCNNlA-3259 + UUGAUUCCAGGCAUGGAAGACAUC 24 7108
SCNNlA-3260 + UGCUCUGCGCGCAGCAUC 18 7109
SCNNlA-3261 + CUGCUCUGCGCGCAGCAUC 19 7110
SCNNlA-1089 + UCUGCUCUGCGCGCAGCAUC 20 4938
SCNNlA-3262 + UUCUGCUCUGCGCGCAGCAUC 21 7111
SCNNlA-3263 + AUUCUGCUCUGCGCGCAGCAUC 22 7112
SCNNlA-3264 + CAUUCUGCUCUGCGCGCAGCAUC 23 7113
SCNNlA-3265 + UCAUUCUGCUCUGCGCGCAGCAUC 24 7114
SCNNlA-3266 + UUCUGUCGCGAUAGCAUC 18 7115
SCNNlA-3267 + GUUCUGUCGCGAUAGCAUC 19 7116
SCNNlA-1090 + UGUUCUGUCGCGAUAGCAUC 20 4939
SCNNlA-3268 + UUGUUCUGUCGCGAUAGCAUC 21 7117
SCNNlA-3269 + AUUGUUCUGUCGCGAUAGCAUC 22 7118
SCNNlA-3270 + AAUUGUUCUGUCGCGAUAGCAUC 23 7119
SCNNlA-3271 + UAAUUGUUCUGUCGCGAUAGCAUC 24 7120
SCNNlA-3272 + UGAGAGUAAUUCCUUAUC 18 7121
SCNNlA-3273 + GUGAGAGUAAUUCCUUAUC 19 7122
SCNNlA-1092 + AGUGAGAGUAAUUCCUUAUC 20 4941
SCNNlA-3274 + AAGUGAGAGUAAUUCCUUAUC 21 7123
SCNNlA-3275 + GAAGUGAGAGUAAUUCCUUAUC 22 7124
SCNNlA-3276 + GGAAGUGAGAGUAAUUCCUUAUC 23 7125
SCNNlA-3277 + UGGAAGUGAGAGUAAUUCCUUAUC 24 7126
SCNNlA-3278 + CAGGGUGGAGGCUACCUC 18 7127
SCNNlA-3279 + CCAGGGUGGAGGCUACCUC 19 7128
SCNNlA-3280 + GCCAGGGUGGAGGCUACCUC 20 7129
SCNNlA-3281 + UGCCAGGGUGGAGGCUACCUC 21 7130
SCNNlA-3282 + AUGCCAGGGUGGAGGCUACCUC 22 7131
SCNNlA-3283 + GAUGCCAGGGUGGAGGCUACCUC 23 7132
SCNNlA-3284 + GGAUGCCAGGGUGGAGGCUACCUC 24 7133
SCNNlA-3285 + GCCCAGCGUGUCCUCCUC 18 7134
SCNNlA-3286 + UGCCCAGCGUGUCCUCCUC 19 7135
SCNNlA-3287 + UUGCCCAGCGUGUCCUCCUC 20 7136
SCNNlA-3288 + GUUGCCCAGCGUGUCCUCCUC 21 7137
SCNNlA-3289 + AGUUGCCCAGCGUGUCCUCCUC 22 7138
SCNNlA-3290 + AAGUUGCCCAGCGUGUCCUCCUC 23 7139
SCNNlA-3291 + GAAGUUGCCCAGCGUGUCCUCCUC 24 7140
SCNNlA-3292 + CUCCUUGAUCAUGCUCUC 18 7141
SCNNlA-3293 + ACUCCUUGAUCAUGCUCUC 19 7142
SCNNlA-3294 + CACUCCUUGAUCAUGCUCUC 20 7143
SCNNlA-3295 + ACACUCCUUGAUCAUGCUCUC 21 7144
SCNNlA-3296 + CACACUCCUUGAUCAUGCUCUC 22 7145
SCNNlA-3297 + CCACACUCCUUGAUCAUGCUCUC 23 7146
1271
5535.1 SCNNlA-3298 + GCCACACUCCUUGAUCAUGCUCUC 24 7147
SCNNlA-3299 + UCACAGUACUCCACGUUC 18 7148
SCNNlA-3300 + GUCACAGUACUCCACGUUC 19 7149
SCNNlA-1103 + AGUCACAGUACUCCACGUUC 20 4952
SCNNlA-3301 + UAGUCACAGUACUCCACGUUC 21 7150
SCNNlA-3302 + GUAGUCACAGUACUCCACGUUC 22 7151
SCNNlA-3303 + UGUAGUCACAGUACUCCACGUUC 23 7152
SCNNlA-3304 + CUGUAGUCACAGUACUCCACGUUC 24 7153
SCNNlA-3305 + AUGACCAGCAGGUCAAAG 18 7154
SCNNlA-3306 + GAUGACCAGCAGGUCAAAG 19 7155
SCNNlA-3307 + UGAUGACCAGCAGGUCAAAG 20 7156
SCNNlA-3308 + AUGAUGACCAGCAGGUCAAAG 21 7157
SCNNlA-3309 + CAUGAUGACCAGCAGGUCAAAG 22 7158
SCNNlA-3310 + ACAUGAUGACCAGCAGGUCAAAG 23 7159
SCNNlA-3311 + AACAUGAUGACCAGCAGGUCAAAG 24 7160
SCNNlA-3312 + AGGGCGCCAUGGAGCAAG 18 7161
SCNNlA-3313 + GAGGGCGCCAUGGAGCAAG 19 7162
SCNNlA-3314 + AGAGGGCGCCAUGGAGCAAG 20 7163
SCNNlA-3315 + CAGAGGGCGCCAUGGAGCAAG 21 7164
SCNNlA-3316 + GCAGAGGGCGCCAUGGAGCAAG 22 7165
SCNNlA-3317 + AGCAGAGGGCGCCAUGGAGCAAG 23 7166
SCNNlA-3318 + AAGCAGAGGGCGCCAUGGAGCAAG 24 7167
SCNNlA-3319 + GGGUUGUUGUCCCGCAAG 18 7168
SCNNlA-3320 + GGGGUUGUUGUCCCGCAAG 19 7169
SCNNlA-3321 + GGGGGUUGUUGUCCCGCAAG 20 7170
SCNNlA-3322 + UGGGGGUUGUUGUCCCGCAAG 21 7171
SCNNlA-3323 + CUGGGGGUUGUUGUCCCGCAAG 22 7172
SCNNlA-3324 + CCUGGGGGUUGUUGUCCCGCAAG 23 7173
SCNNlA-3325 + ACCUGGGGGUUGUUGUCCCGCAAG 24 7174
SCNNlA-3326 + AUGGGGUGGGGGCAGAAG 18 7175
SCNNlA-3327 + CAUGGGGUGGGGGCAGAAG 19 7176
SCNNlA-1109 + ACAUGGGGUGGGGGCAGAAG 20 4958
SCNNlA-3328 + GACAUGGGGUGGGGGCAGAAG 21 7177
SCNNlA-3329 + AGACAUGGGGUGGGGGCAGAAG 22 7178
SCNNlA-3330 + GAGACAUGGGGUGGGGGCAGAAG 23 7179
SCNNlA-3331 + AGAGACAUGGGGUGGGGGCAGAAG 24
7180
SCNNlA-3332 + UUGAAGCGGCAGGCGAAG 18 7181
SCNNlA-3333 + GUUGAAGCGGCAGGCGAAG 19 7182
SCNNlA-3334 + GGUUGAAGCGGCAGGCGAAG 20 7183
SCNNlA-3335 + UGGUUGAAGCGGCAGGCGAAG 21 7184
SCNNlA-3336 + CUGGUUGAAGCGGCAGGCGAAG 22 7185
1272
5535.1 SCNNlA-3337 + CCUGGUUGAAGCGGCAGGCGAAG 23 7186
SCNNlA-3338 + ACCUGGUUGAAGCGGCAGGCGAAG 24 7187
SCNNlA-3339 + GGGGGCAGAAGUGGGAAG 18 7188
SCNNlA-3340 + UGGGGGCAGAAGUGGGAAG 19 7189
SCNNlA-3341 + GUGGGGGCAGAAGUGGGAAG 20 7190
SCNNlA-3342 + GGUGGGGGCAGAAGUGGGAAG 21 7191
SCNNlA-3343 + GGGUGGGGGCAGAAGUGGGAAG 22 7192
SCNNlA-3344 + GGGGUGGGGGCAGAAGUGGGAAG 23 7193
SCNNlA-3345 + UGGGGUGGGGGCAGAAGUGGGAAG 24
7194
SCNNlA-3346 + AUCAUGCUCUCCUGGAAG 18 7195
SCNNlA-3347 + GAUCAUGCUCUCCUGGAAG 19 7196
SCNNlA-3348 + UGAUCAUGCUCUCCUGGAAG 20 7197
SCNNlA-3349 + UUGAUCAUGCUCUCCUGGAAG 21 7198
SCNNlA-3350 + CUUGAUCAUGCUCUCCUGGAAG 22 7199
SCNNlA-3351 + CCUUGAUCAUGCUCUCCUGGAAG 23 7200
SCNNlA-3352 + UCCUUGAUCAUGCUCUCCUGGAAG 24 7201
SCNNlA-3353 + GGCCCCCCCAGAGGACAG 18 7202
SCNNlA-3354 + GGGCCCCCCCAGAGGACAG 19 7203
SCNNlA-3355 + AGGGCCCCCCCAGAGGACAG 20 7204
SCNNlA-3356 + CAGGGCCCCCCCAGAGGACAG 21 7205
SCNNlA-3357 + UCAGGGCCCCCCCAGAGGACAG 22 7206
SCNNlA-3358 + CUCAGGGCCCCCCCAGAGGACAG 23 7207
SCNNlA-3359 + UCUCAGGGCCCCCCCAGAGGACAG 24 7208
SCNNlA-3360 + CCCAGUCACUGUGGACAG 18 7209
SCNNlA-3361 + CCCCAGUCACUGUGGACAG 19 7210
SCNNlA-3362 + GCCCCAGUCACUGUGGACAG 20 7211
SCNNlA-3363 + GGCCCCAGUCACUGUGGACAG 21 7212
SCNNlA-3364 + GGGCCCCAGUCACUGUGGACAG 22 7213
SCNNlA-3365 + CGGGCCCCAGUCACUGUGGACAG 23 7214
SCNNlA-3366 + CCGGGCCCCAGUCACUGUGGACAG 24 7215
SCNNlA-3367 + CACGACCUACCGUGACAG 18 7216
SCNNlA-3368 + GCACGACCUACCGUGACAG 19 7217
SCNNlA-1114 + GGCACGACCUACCGUGACAG 20 4963
SCNNlA-3369 + AGGCACGACCUACCGUGACAG 21 7218
SCNNlA-3370 + CAGGCACGACCUACCGUGACAG 22 7219
SCNNlA-3371 + CCAGGCACGACCUACCGUGACAG 23 7220
SCNNlA-3372 + UCCAGGCACGACCUACCGUGACAG 24 7221
SCNNlA-3373 + GCCAUCGUGAGUAACCAG 18 7222
SCNNlA-3374 + GGCCAUCGUGAGUAACCAG 19 7223
SCNNlA-3375 + GGGCCAUCGUGAGUAACCAG 20 7224
SCNNlA-3376 + AGGGCCAUCGUGAGUAACCAG 21 7225
1273
5535.1 SCNNlA-3377 + GAGGGCCAUCGUGAGUAACCAG 22 7226
SCNNlA-3378 + CGAGGGCCAUCGUGAGUAACCAG 23 7227
SCNNlA-3379 + CCGAGGGCCAUCGUGAGUAACCAG 24 7228
SCNNlA-3380 + CGCUGCGGGCCUCACCAG 18 7229
SCNNlA-3381 + GCGCUGCGGGCCUCACCAG 19 7230
SCNNlA-3382 + GGCGCUGCGGGCCUCACCAG 20 7231
SCNNlA-3383 + CGGCGCUGCGGGCCUCACCAG 21 7232
SCNNlA-3384 + UCGGCGCUGCGGGCCUCACCAG 22 7233
SCNNlA-3385 + CUCGGCGCUGCGGGCCUCACCAG 23 7234
SCNNlA-3386 + CCUCGGCGCUGCGGGCCUCACCAG 24 7235
SCNNlA-3387 + CCAGGGUGGCAUAGGCAG 18 7236
SCNNlA-3388 + CCCAGGGUGGCAUAGGCAG 19 7237
SCNNlA-1120 + GCCCAGGGUGGCAUAGGCAG 20 4969
SCNNlA-3389 + GGCCCAGGGUGGCAUAGGCAG 21 7238
SCNNlA-3390 + GGGCCCAGGGUGGCAUAGGCAG 22 7239
SCNNlA-3391 + GGGGCCCAGGGUGGCAUAGGCAG 23 7240
SCNNlA-3392 + GGGGGCCCAGGGUGGCAUAGGCAG 24 7241
SCNNlA-3393 + ACCUGGUUGAAGCGGCAG 18 7242
SCNNlA-3394 + GACCUGGUUGAAGCGGCAG 19 7243
SCNNlA-3395 + AGACCUGGUUGAAGCGGCAG 20 7244
SCNNlA-3396 + GAGACCUGGUUGAAGCGGCAG 21 7245
SCNNlA-3397 + GGAGACCUGGUUGAAGCGGCAG 22 7246
SCNNlA-3398 + AGGAGACCUGGUUGAAGCGGCAG 23 7247
SCNNlA-3399 + CAGGAGACCUGGUUGAAGCGGCAG 24 7248
SCNNlA-3400 + CACAGAGACUAGAGUCAG 18 7249
SCNNlA-3401 + ACACAGAGACUAGAGUCAG 19 7250
SCNNlA-1125 + GACACAGAGACUAGAGUCAG 20 4974
SCNNlA-3402 + GGACACAGAGACUAGAGUCAG 21 7251
SCNNlA-3403 + UGGACACAGAGACUAGAGUCAG 22 7252
SCNNlA-3404 + CUGGACACAGAGACUAGAGUCAG 23 7253
SCNNlA-3405 + ACUGGACACAGAGACUAGAGUCAG 24 7254
SCNNlA-3406 + AGGGAGGAGGGUGGAGAG 18 7255
SCNNlA-3407 + AAGGGAGGAGGGUGGAGAG 19 7256
SCNNlA-3408 + GAAGGGAGGAGGGUGGAGAG 20 7257
SCNNlA-3409 + GGAAGGGAGGAGGGUGGAGAG 21 7258
SCNNlA-3410 + UGGAAGGGAGGAGGGUGGAGAG 22 7259
SCNNlA-3411 + CUGGAAGGGAGGAGGGUGGAGAG 23 7260
SCNNlA-3412 + CCUGGAAGGGAGGAGGGUGGAGAG 24
7261
SCNNlA-3413 + GGUGACCAUCUGUGAGAG 18 7262
SCNNlA-3414 + GGGUGACCAUCUGUGAGAG 19 7263
SCNNlA-3415 + AGGGUGACCAUCUGUGAGAG 20 7264
1274
5535.1 SCNNlA-3416 + GAGGGUGACCAUCUGUGAGAG 21 7265
SCNNlA-3417 + GGAGGGUGACCAUCUGUGAGAG 22 7266
SCNNlA-3418 + AGGAGGGUGACCAUCUGUGAGAG 23 7267
SCNNlA-3419 + CAGGAGGGUGACCAUCUGUGAGAG 24 7268
SCNNlA-3420 + GGUACCUGAAGGGGCGAG 18 7269
SCNNlA-3421 + GGGUACCUGAAGGGGCGAG 19 7270
SCNNlA-1130 + CGGGUACCUGAAGGGGCGAG 20 4979
SCNNlA-3422 + CCGGGUACCUGAAGGGGCGAG 21 7271
SCNNlA-3423 + UCCGGGUACCUGAAGGGGCGAG 22 7272
SCNNlA-3424 + UUCCGGGUACCUGAAGGGGCGAG 23 7273
SCNNlA-3425 + UUUCCGGGUACCUGAAGGGGCGAG 24 7274
SCNNlA-3426 + GGCAGAAGUGGGAAGGAG 18 7275
SCNNlA-3427 + GGGCAGAAGUGGGAAGGAG 19 7276
SCNNlA-1132 + GGGGCAGAAGUGGGAAGGAG 20 4981
SCNNlA-3428 + GGGGGCAGAAGUGGGAAGGAG 21 7277
SCNNlA-3429 + UGGGGGCAGAAGUGGGAAGGAG 22 7278
SCNNlA-3430 + GUGGGGGCAGAAGUGGGAAGGAG 23 7279
SCNNlA-3431 + GGUGGGGGCAGAAGUGGGAAGGAG 24
7280
SCNNlA-3432 + ACAGACAACACCGAGGAG 18 7281
SCNNlA-3433 + CACAGACAACACCGAGGAG 19 7282
SCNNlA-3434 + CCACAGACAACACCGAGGAG 20 7283
SCNNlA-3435 + ACCACAGACAACACCGAGGAG 21 7284
SCNNlA-3436 + CACCACAGACAACACCGAGGAG 22 7285
SCNNlA-3437 + CCACCACAGACAACACCGAGGAG 23 7286
SCNNlA-3438 + UCCACCACAGACAACACCGAGGAG 24 7287
SCNNlA-3439 + UCAAGGCUGGAGAGGGAG 18 7288
SCNNlA-3440 + GUCAAGGCUGGAGAGGGAG 19 7289
SCNNlA-3441 + UGUCAAGGCUGGAGAGGGAG 20 7290
SCNNlA-3442 + CUGUCAAGGCUGGAGAGGGAG 21 7291
SCNNlA-3443 + GCUGUCAAGGCUGGAGAGGGAG 22 7292
SCNNlA-3444 + GGCUGUCAAGGCUGGAGAGGGAG 23 7293
SCNNlA-3445 + GGGCUGUCAAGGCUGGAGAGGGAG 24
7294
SCNNlA-3446 + CUGCAGAGCCCCCUGGAG 18 7295
SCNNlA-3447 + CCUGCAGAGCCCCCUGGAG 19 7296
SCNNlA-3448 + CCCUGCAGAGCCCCCUGGAG 20 7297
SCNNlA-3449 + CCCCUGCAGAGCCCCCUGGAG 21 7298
SCNNlA-3450 + GCCCCUGCAGAGCCCCCUGGAG 22 7299
SCNNlA-3451 + GGCCCCUGCAGAGCCCCCUGGAG 23 7300
SCNNlA-3452 + UGGCCCCUGCAGAGCCCCCUGGAG 24 7301
SCNNlA-3453 + GGGCUGUCAAGGCUGGAG 18 7302
1275
5535.1 SCNNlA-3454 + GGGGCUGUCAAGGCUGGAG 19 7303
SCNNlA-1138 + AGGGGCUGUCAAGGCUGGAG 20 4987
SCNNlA-3455 + GAGGGGCUGUCAAGGCUGGAG 21 7304
SCNNlA-3456 + GGAGGGGCUGUCAAGGCUGGAG 22 7305
SCNNlA-3457 + GGGAGGGGCUGUCAAGGCUGGAG 23 7306
SCNNlA-3458 + GGGGAGGGGCUGUCAAGGCUGGAG 24
7307
SCNNlA-3459 + GAAGGGAGGAGGGUGGAG 18 7308
SCNNlA-3460 + GGAAGGGAGGAGGGUGGAG 19 7309
SCNNlA-1139 + UGGAAGGGAGGAGGGUGGAG 20 4988
SCNNlA-3461 + CUGGAAGGGAGGAGGGUGGAG 21 7310
SCNNlA-3462 + CCUGGAAGGGAGGAGGGUGGAG 22 7311
SCNNlA-3463 + ACCUGGAAGGGAGGAGGGUGGAG 23 7312
SCNNlA-3464 + CACCUGGAAGGGAGGAGGGUGGAG 24 7313
SCNNlA-3465 + CAGCCCAGGUGGUCUGAG 18 7314
SCNNlA-3466 + ACAGCCCAGGUGGUCUGAG 19 7315
SCNNlA-3467 + AA CAGCCCAGGUGGUCUGAG 20 7316
SCNNlA-3468 + AAACAGCCCAGGUGGUCUGAG 21 7317
SCNNlA-3469 + GAAA CAGCCCAGGUGGUCUGAG 22 7318
SCNNlA-3470 + UGAAA CAGCCCAGGUGGUCUGAG 23 7319
SCNNlA-3471 + GUGAAA CAGCCCAGGUGGUCUGAG 24 7320
SCNNlA-3472 + CUCGACGGGCCCCGUGAG 18 7321
SCNNlA-3473 + GCUCGACGGGCCCCGUGAG 19 7322
SCNNlA-3474 + GGCUCGACGGGCCCCGUGAG 20 7323
SCNNlA-3475 + GGGCUCGACGGGCCCCGUGAG 21 7324
SCNNlA-3476 + CGGGCUCGACGGGCCCCGUGAG 22 7325
SCNNlA-3477 + ACGGGCUCGACGGGCCCCGUGAG 23 7326
SCNNlA-3478 + UACGGGCUCGACGGGCCCCGUGAG 24 7327
SCNNlA-3479 + AGGGUGACCAUCUGUGAG 18 7328
SCNNlA-3480 + GAGGGUGACCAUCUGUGAG 19 7329
SCNNlA-1141 + GGAGGGUGACCAUCUGUGAG 20 4990
SCNNlA-3481 + AGGAGGGUGACCAUCUGUGAG 21 7330
SCNNlA-3482 + CAGGAGGGUGACCAUCUGUGAG 22 7331
SCNNlA-3483 + ACAGGAGGGUGACCAUCUGUGAG 23 7332
SCNNlA-3484 + GACAGGAGGGUGACCAUCUGUGAG 24 7333
SCNNlA-3485 + GACAGGAUGUUGAUGUAG 18 7334
SCNNlA-3486 + CGACAGGAUGUUGAUGUAG 19 7335
SCNNlA-1143 + UCGACAGGAUGUUGAUGUAG 20 4992
SCNNlA-3487 + CUCGACAGGAUGUUGAUGUAG 21 7336
SCNNlA-3488 + CCUCGACAGGAUGUUGAUGUAG 22 7337
SCNNlA-3489 + GCCUCGACAGGAUGUUGAUGUAG 23 7338
SCNNlA-3490 + AGCCUCGACAGGAUGUUGAUGUAG 24 7339
1276
5535.1 SCNNlA-3491 + AGCUGGUAGCUGGUCACG 18 7340
SCNNlA-3492 + GAGCUGGUAGCUGGUCACG 19 7341
SCNNlA-3493 + AGAGCUGGUAGCUGGUCACG 20 7342
SCNNlA-3494 + GAGAGCUGGUAGCUGGUCACG 21 7343
SCNNlA-3495 + AGAGAGCUGGUAGCUGGUCACG 22 7344
SCNNlA-3496 + CAGAGAGCUGGUAGCUGGUCACG 23 7345
SCNNlA-3497 + GCAGAGAGCUGGUAGCUGGUCACG 24 7346
SCNNlA-3498 + AGGAGAGGUACAUUGACG 18 7347
SCNNlA-3499 + GAGGAGAGGUACAUUGACG 19 7348
SCNNlA-3500 + AGAGGAGAGGUACAUUGACG 20 7349
SCNNlA-3501 + GAGAGGAGAGGUACAUUGACG 21 7350
SCNNlA-3502 + UGAGAGGAGAGGUACAUUGACG 22 7351
SCNNlA-3503 + GUGAGAGGAGAGGUACAUUGACG 23 7352
SCNNlA-3504 + UGUGAGAGGAGAGGUACAUUGACG 24
7353
SCNNlA-3505 + CCACCACAGACAACACCG 18 7354
SCNNlA-3506 + UCCACCACAGACAACACCG 19 7355
SCNNlA-1146 + CUCCACCACAGACAACACCG 20 4995
SCNNlA-3507 + UCUCCACCACAGACAACACCG 21 7356
SCNNlA-3508 + AUCUCCACCACAGACAACACCG 22 7357
SCNNlA-3509 + CAUCUCCACCACAGACAACACCG 23 7358
SCNNlA-3510 + CCAUCUCCACCACAGACAACACCG 24 7359
SCNNlA-3511 + CGGGUACCUGAAGGGGCG 18 7360
SCNNlA-3512 + CCGGGUACCUGAAGGGGCG 19 7361
SCNNlA-1155 + UCCGGGUACCUGAAGGGGCG 20 5004
SCNNlA-3513 + UUCCGGGUACCUGAAGGGGCG 21 7362
SCNNlA-3514 + UUUCCGGGUACCUGAAGGGGCG 22 7363
SCNNlA-3515 + AUUUCCGGGUACCUGAAGGGGCG 23 7364
SCNNlA-3516 + AAUUUCCGGGUACCUGAAGGGGCG 24 7365
SCNNlA-3517 + GGCCACGCUACGGGCUCG 18 7366
SCNNlA-3518 + AGGCCACGCUACGGGCUCG 19 7367
SCNNlA-3519 + GAGGCCACGCUACGGGCUCG 20 7368
SCNNlA-3520 + GGAGGCCACGCUACGGGCUCG 21 7369
SCNNlA-3521 + UGGAGGCCACGCUACGGGCUCG 22 7370
SCNNlA-3522 + CUGGAGGCCACGCUACGGGCUCG 23 7371
SCNNlA-3523 + GCUGGAGGCCACGCUACGGGCUCG 24 7372
SCNNlA-3524 + GGGGAGGGGCUGUCAAGG 18 7373
SCNNlA-3525 + GGGGGAGGGGCUGUCAAGG 19 7374
SCNNlA-3526 + AGGGGGAGGGGCUGUCAAGG 20 7375
SCNNlA-3527 + CAGGGGGAGGGGCUGUCAAGG 21 7376
SCNNlA-3528 + GCAGGGGGAGGGGCUGUCAAGG 22 7377
SCNNlA-3529 + GGCAGGGGGAGGGGCUGUCAAGG 23 7378
1277
5535.1 SCNNlA-3530 + AGGCAGGGGGAGGGGCUGUCAAGG 24
7379
SCNNlA-3531 + GGGGCAGAAGUGGGAAGG 18 7380
SCNNlA-3532 + GGGGGCAGAAGUGGGAAGG 19 7381
SCNNlA-1161 + UGGGGGCAGAAGUGGGAAGG 20 5010
SCNNlA-3533 + GUGGGGGCAGAAGUGGGAAGG 21 7382
SCNNlA-3534 + GGUGGGGGCAGAAGUGGGAAGG 22 7383
SCNNlA-3535 + GGGUGGGGGCAGAAGUGGGAAGG 23 7384
SCNNlA-3536 + GGGGUGGGGGCAGAAGUGGGAAGG 24
7385
SCNNlA-3537 + GAAUACACACCUGGAAGG 18 7386
SCNNlA-3538 + UGAAUACACACCUGGAAGG 19 7387
SCNNlA-3539 + GUGAAUACACACCUGGAAGG 20 7388
SCNNlA-3540 + AGUGAAUACACACCUGGAAGG 21 7389
SCNNlA-3541 + GAGUGAAUACACACCUGGAAGG 22 7390
SCNNlA-3542 + GGAGUGAAUACACACCUGGAAGG 23 7391
SCNNlA-3543 + AGGAGUGAAUACACACCUGGAAGG 24 7392
SCNNlA-3544 + GCCCCCCCAGAGGACAGG 18 7393
SCNNlA-3545 + GGCCCCCCCAGAGGACAGG 19 7394
SCNNlA-1162 + GGGCCCCCCCAGAGGACAGG 20 5011
SCNNlA-3546 + AGGGCCCCCCCAGAGGACAGG 21 7395
SCNNlA-3547 + CAGGGCCCCCCCAGAGGACAGG 22 7396
SCNNlA-3548 + UCAGGGCCCCCCCAGAGGACAGG 23 7397
SCNNlA-3549 + CUCAGGGCCCCCCCAGAGGACAGG 24 7398
SCNNlA-3550 + CUCCACUGGCUGCCCAGG 18 7399
SCNNlA-3551 + GCUCCACUGGCUGCCCAGG 19 7400
SCNNlA-3552 + GGCUCCACUGGCUGCCCAGG 20 7401
SCNNlA-3553 + AGGCUCCACUGGCUGCCCAGG 21 7402
SCNNlA-3554 + CAGGCUCCACUGGCUGCCCAGG 22 7403
SCNNlA-3555 + ACAGGCUCCACUGGCUGCCCAGG 23 7404
SCNNlA-3556 + CACAGGCUCCACUGGCUGCCCAGG 24 7405
SCNNlA-3557 + GGAGGGGAGGAUGCCAGG 18 7406
SCNNlA-3558 + AGGAGGGGAGGAUGCCAGG 19 7407
SCNNlA-3559 + AAGGAGGGGAGGAUGCCAGG 20 7408
SCNNlA-3560 + GAAGGAGGGGAGGAUGCCAGG 21 7409
SCNNlA-3561 + GGAAGGAGGGGAGGAUGCCAGG 22 7410
SCNNlA-3562 + GGGAAGGAGGGGAGGAUGCCAGG 23 7411
SCNNlA-3563 + UGGGAAGGAGGGGAGGAUGCCAGG 24
7412
SCNNlA-3564 + CAGGGUGGCAUAGGCAGG 18 7413
SCNNlA-3565 + CCAGGGUGGCAUAGGCAGG 19 7414
SCNNlA-1167 + CCCAGGGUGGCAUAGGCAGG 20 5016
1278
5535.1 SCNNlA-3566 + GCCCAGGGUGGCAUAGGCAGG 21 7415
SCNNlA-3567 + GGCCCAGGGUGGCAUAGGCAGG 22 7416
SCNNlA-3568 + GGGCCCAGGGUGGCAUAGGCAGG 23 7417
SCNNlA-3569 + GGGGCCCAGGGUGGCAUAGGCAGG 24 7418
SCNNlA-3570 + AUGGAAGACAUCCAGAGG 18 7419
SCNNlA-3571 + CAUGGAAGACAUCCAGAGG 19 7420
SCNNlA-3572 + GCAUGGAAGACAUCCAGAGG 20 7421
SCNNlA-3573 + GGCAUGGAAGACAUCCAGAGG 21 7422
SCNNlA-3574 + AGGCAUGGAAGACAUCCAGAGG 22 7423
SCNNlA-3575 + CAGGCAUGGAAGACAUCCAGAGG 23 7424
SCNNlA-3576 + CCAGGCAUGGAAGACAUCCAGAGG 24 7425
SCNNlA-3577 + UUAGGUGUGGGGCAGAGG 18 7426
SCNNlA-3578 + CUUAGGUGUGGGGCAGAGG 19 7427
SCNNlA-3579 + UCUUAGGUGUGGGGCAGAGG 20 7428
SCNNlA-3580 + UUCUUAGGUGUGGGGCAGAGG 21 7429
SCNNlA-3581 + UUUCUUAGGUGUGGGGCAGAGG 22 7430
SCNNlA-3582 + AUUUCUUAGGUGUGGGGCAGAGG 23 7431
SCNNlA-3583 + CAUUUCUUAGGUGUGGGGCAGAGG 24
7432
SCNNlA-3584 + CACCUGGAAGGGAGGAGG 18 7433
SCNNlA-3585 + ACACCUGGAAGGGAGGAGG 19 7434
SCNNlA-3586 + CACACCUGGAAGGGAGGAGG 20 7435
SCNNlA-3587 + ACACACCUGGAAGGGAGGAGG 21 7436
SCNNlA-3588 + UACACACCUGGAAGGGAGGAGG 22 7437
SCNNlA-3589 + AUACACACCUGGAAGGGAGGAGG 23 7438
SCNNlA-3590 + AAUACACACCUGGAAGGGAGGAGG 24 7439
SCNNlA-3591 + UCGACGGGCCCCGUGAGG 18 7440
SCNNlA-3592 + CUCGACGGGCCCCGUGAGG 19 7441
SCNNlA-1172 + GCUCGACGGGCCCCGUGAGG 20 5021
SCNNlA-3593 + GGCUCGACGGGCCCCGUGAGG 21 7442
SCNNlA-3594 + GGGCUCGACGGGCCCCGUGAGG 22 7443
SCNNlA-3595 + CGGGCUCGACGGGCCCCGUGAGG 23 7444
SCNNlA-3596 + ACGGGCUCGACGGGCCCCGUGAGG 24 7445
SCNNlA-3597 + GGCCCAGGGUGGCAUAGG 18 7446
SCNNlA-3598 + GGGCCCAGGGUGGCAUAGG 19 7447
SCNNlA-3599 + GGGGCCCAGGGUGGCAUAGG 20 7448
SCNNlA-3600 + GGGGGCCCAGGGUGGCAUAGG 21 7449
SCNNlA-3601 + CGGGGGCCCAGGGUGGCAUAGG 22 7450
SCNNlA-3602 + GCGGGGGCCCAGGGUGGCAUAGG 23 7451
SCNNlA-3603 + GGCGGGGGCCCAGGGUGGCAUAGG 24 7452
SCNNlA-3604 + AAUACACACCUGGAAGGG 18 7453
SCNNlA-3605 + GAAUACACACCUGGAAGGG 19 7454
1279
5535.1 SCNNlA-1176 + UGAAUACACACCUGGAAGGG 20 5025
SCNNlA-3606 + GUGAAUACACACCUGGAAGGG 21 7455
SCNNlA-3607 + AGUGAAUACACACCUGGAAGGG 22 7456
SCNNlA-3608 + GAGUGAAUACACACCUGGAAGGG 23 7457
SCNNlA-3609 + GGAGUGAAUACACACCUGGAAGGG 24 7458
SCNNlA-3610 + UUCCGGGUACCUGAAGGG 18 7459
SCNNlA-3611 + UUUCCGGGUACCUGAAGGG 19 7460
SCNNlA-3612 + AUUUCCGGGUACCUGAAGGG 20 7461
SCNNlA-3613 + AAUUUCCGGGUACCUGAAGGG 21 7462
SCNNlA-3614 + UAAUUUCCGGGUACCUGAAGGG 22 7463
SCNNlA-3615 + UUAAUUUCCGGGUACCUGAAGGG 23 7464
SCNNlA-3616 + UUUAAUUUCCGGGUACCUGAAGGG 24 7465
SCNNlA-3617 + UUGUGGCUGGGACCAGGG 18 7466
SCNNlA-3618 + CUUGUGGCUGGGACCAGGG 19 7467
SCNNlA-3619 + UCUUGUGGCUGGGACCAGGG 20 7468
SCNNlA-3620 + GAGGGGAGGAUGCCAGGG 18 7469
SCNNlA-3621 + GGAGGGGAGGAUGCCAGGG 19 7470
SCNNlA-1178 + AGGAGGGGAGGAUGCCAGGG 20 5027
SCNNlA-3622 + AAGGAGGGGAGGAUGCCAGGG 21 7471
SCNNlA-3623 + GAAGGAGGGGAGGAUGCCAGGG 22 7472
SCNNlA-3624 + GGAAGGAGGGGAGGAUGCCAGGG 23 7473
SCNNlA-3625 + GGGAAGGAGGGGAGGAUGCCAGGG 24
7474
SCNNlA-3626 + UAGGUGUGGGGCAGAGGG 18 7475
SCNNlA-3627 + UUAGGUGUGGGGCAGAGGG 19 7476
SCNNlA-1179 + CUUAGGUGUGGGGCAGAGGG 20 5028
SCNNlA-3628 + UCUUAGGUGUGGGGCAGAGGG 21 7477
SCNNlA-3629 + UUCUUAGGUGUGGGGCAGAGGG 22 7478
SCNNlA-3630 + UUUCUUAGGUGUGGGGCAGAGGG 23 7479
SCNNlA-3631 + AUUUCUUAGGUGUGGGGCAGAGGG 24
7480
SCNNlA-3632 + ACCUGGAAGGGAGGAGGG 18 7481
SCNNlA-3633 + CACCUGGAAGGGAGGAGGG 19 7482
SCNNlA-1180 + ACACCUGGAAGGGAGGAGGG 20 5029
SCNNlA-3634 + CACACCUGGAAGGGAGGAGGG 21 7483
SCNNlA-3635 + ACACACCUGGAAGGGAGGAGGG 22 7484
SCNNlA-3636 + UACACACCUGGAAGGGAGGAGGG 23 7485
SCNNlA-3637 + AUACACACCUGGAAGGGAGGAGGG 24 7486
SCNNlA-3638 + GGGUGGCAUAGGCAGGGG 18 7487
SCNNlA-3639 + AGGGUGGCAUAGGCAGGGG 19 7488
SCNNlA-3640 + CAGGGUGGCAUAGGCAGGGG 20 7489
SCNNlA-3641 + CCAGGGUGGCAUAGGCAGGGG 21 7490
1280
5535.1 SCNNlA-3642 + CCCAGGGUGGCAUAGGCAGGGG 22 7491
SCNNlA-3643 + GCCCAGGGUGGCAUAGGCAGGGG 23 7492
SCNNlA-3644 + GGCCCAGGGUGGCAUAGGCAGGGG 24 7493
SCNNlA-3645 + ACCUGAAGGGGCGAGGGG 18 7494
SCNNlA-3646 + UACCUGAAGGGGCGAGGGG 19 7495
SCNNlA-3647 + GUACCUGAAGGGGCGAGGGG 20 7496
SCNNlA-3648 + GGUACCUGAAGGGGCGAGGGG 21 7497
SCNNlA-3649 + GGGUACCUGAAGGGGCGAGGGG 22 7498
SCNNlA-3650 + CGGGUACCUGAAGGGGCGAGGGG 23 7499
SCNNlA-3651 + CCGGGUACCUGAAGGGGCGAGGGG 24 7500
SCNNlA-3652 + GGGCCCCGUGAGGCGGGG 18 7501
SCNNlA-3653 + CGGGCCCCGUGAGGCGGGG 19 7502
SCNNlA-3654 + ACGGGCCCCGUGAGGCGGGG 20 7503
SCNNlA-3655 + GACGGGCCCCGUGAGGCGGGG 21 7504
SCNNlA-3656 + CGACGGGCCCCGUGAGGCGGGG 22 7505
SCNNlA-3657 + UCGACGGGCCCCGUGAGGCGGGG 23 7506
SCNNlA-3658 + CUCGACGGGCCCCGUGAGGCGGGG 24 7507
SCNNlA-3659 + GGUGGCAUAGGCAGGGGG 18 7508
SCNNlA-3660 + GGGUGGCAUAGGCAGGGGG 19 7509
SCNNlA-1184 + AGGGUGGCAUAGGCAGGGGG 20 5033
SCNNlA-3661 + CAGGGUGGCAUAGGCAGGGGG 21 7510
SCNNlA-3662 + CCAGGGUGGCAUAGGCAGGGGG 22 7511
SCNNlA-3663 + CCCAGGGUGGCAUAGGCAGGGGG 23 7512
SCNNlA-3664 + GCCCAGGGUGGCAUAGGCAGGGGG 24 7513
SCNNlA-3665 + GGCCCCGUGAGGCGGGGG 18 7514
SCNNlA-3666 + GGGCCCCGUGAGGCGGGGG 19 7515
SCNNlA-1185 + CGGGCCCCGUGAGGCGGGGG 20 5034
SCNNlA-3667 + ACGGGCCCCGUGAGGCGGGGG 21 7516
SCNNlA-3668 + GACGGGCCCCGUGAGGCGGGGG 22 7517
SCNNlA-3669 + CGACGGGCCCCGUGAGGCGGGGG 23 7518
SCNNlA-3670 + UCGACGGGCCCCGUGAGGCGGGGG 24 7519
SCNNlA-3671 + AGAGACAUGGGGUGGGGG 18 7520
SCNNlA-3672 + CAGAGACAUGGGGUGGGGG 19 7521
SCNNlA-3673 + ACAGAGACAUGGGGUGGGGG 20 7522
SCNNlA-3674 + GACAGAGACAUGGGGUGGGGG 21 7523
SCNNlA-3675 + GGACAGAGACAUGGGGUGGGGG 22 7524
SCNNlA-3676 + AGGACAGAGACAUGGGGUGGGGG 23 7525
SCNNlA-3677 + AAGGACAGAGACAUGGGGUGGGGG 24
7526
SCNNlA-3678 + AAGGACAGAGACAUGGGG 18 7527
SCNNlA-3679 + CAAGGACAGAGACAUGGGG 19 7528
SCNNlA-1186 + ACAAGGACAGAGACAUGGGG 20 5035
1281
5535.1 SCNNlA-3680 + GACAAGGACAGAGACAUGGGG 21 7529
SCNNlA-3681 + GGACAAGGACAGAGACAUGGGG 22 7530
SCNNlA-3682 + GGGACAAGGACAGAGACAUGGGG 23 7531
SCNNlA-3683 + UGGGACAAGGACAGAGACAUGGGG 24 7532
SCNNlA-3684 + UAGCUGGUCACGCUGGGG 18 7533
SCNNlA-3685 + GUAGCUGGUCACGCUGGGG 19 7534
SCNNlA-3686 + GGUAGCUGGUCACGCUGGGG 20 7535
SCNNlA-3687 + UGGUAGCUGGUCACGCUGGGG 21 7536
SCNNlA-3688 + CUGGUAGCUGGUCACGCUGGGG 22 7537
SCNNlA-3689 + GCUGGUAGCUGGUCACGCUGGGG 23 7538
SCNNlA-3690 + AGCUGGUAGCUGGUCACGCUGGGG 24 7539
SCNNlA-3691 + CAUUUCUUAGGUGUGGGG 18 7540
SCNNlA-3692 + CCAUUUCUUAGGUGUGGGG 19 7541
SCNNlA-3693 + UCCAUUUCUUAGGUGUGGGG 20 7542
SCNNlA-3694 + CUCCAUUUCUUAGGUGUGGGG 21 7543
SCNNlA-3695 + ACUCCAUUUCUUAGGUGUGGGG 22 7544
SCNNlA-3696 + CACUCCAUUUCUUAGGUGUGGGG 23 7545
SCNNlA-3697 + CCACUCCAUUUCUUAGGUGUGGGG 24 7546
SCNNlA-3698 + CAAGGACAGAGACAUGGG 18 7547
SCNNlA-3699 + ACAAGGACAGAGACAUGGG 19 7548
SCNNlA-3700 + GACAAGGACAGAGACAUGGG 20 7549
SCNNlA-3701 + GGACAAGGACAGAGACAUGGG 21 7550
SCNNlA-3702 + GGGACAAGGACAGAGACAUGGG 22 7551
SCNNlA-3703 + UGGGACAAGGACAGAGACAUGGG 23 7552
SCNNlA-3704 + CUGGGACAAGGACAGAGACAUGGG 24 7553
SCNNlA-3705 + GAGCCCCCUGGAGAUGGG 18 7554
SCNNlA-3706 + AGAGCCCCCUGGAGAUGGG 19 7555
SCNNlA-1188 + CAGAGCCCCCUGGAGAUGGG 20 5037
SCNNlA-3707 + GCAGAGCCCCCUGGAGAUGGG 21 7556
SCNNlA-3708 + UGCAGAGCCCCCUGGAGAUGGG 22 7557
SCNNlA-3709 + CUGCAGAGCCCCCUGGAGAUGGG 23 7558
SCNNlA-3710 + CCUGCAGAGCCCCCUGGAGAUGGG 24 7559
SCNNlA-3711 + GGUGGGGGCAGAAGUGGG 18 7560
SCNNlA-3712 + GGGUGGGGGCAGAAGUGGG 19 7561
SCNNlA-3713 + GGGGUGGGGGCAGAAGUGGG 20 7562
SCNNlA-3714 + UGGGGUGGGGGCAGAAGUGGG 21 7563
SCNNlA-3715 + AUGGGGUGGGGGCAGAAGUGGG 22 7564
SCNNlA-3716 + CAUGGGGUGGGGGCAGAAGUGGG 23 7565
SCNNlA-3717 + ACAUGGGGUGGGGGCAGAAGUGGG 24
7566
SCNNlA-3718 + UGUGGGGCAGAGGGUGGG 18 7567
SCNNlA-3719 + GUGUGGGGCAGAGGGUGGG 19 7568
1282
5535.1 SCNNlA-3720 + GGUGUGGGGCAGAGGGUGGG 20 7569
SCNNlA-3721 + AGGUGUGGGGCAGAGGGUGGG 21 7570
SCNNlA-3722 + UAGGUGUGGGGCAGAGGGUGGG 22 7571
SCNNlA-3723 + UUAGGUGUGGGGCAGAGGGUGGG 23 7572
SCNNlA-3724 + CUUAGGUGUGGGGCAGAGGGUGGG 24
7573
SCNNlA-3725 + AGAGCCCCCUGGAGAUGG 18 7574
SCNNlA-3726 + CAGAGCCCCCUGGAGAUGG 19 7575
SCNNlA-3727 + GCAGAGCCCCCUGGAGAUGG 20 7576
SCNNlA-3728 + UGCAGAGCCCCCUGGAGAUGG 21 7577
SCNNlA-3729 + CUGCAGAGCCCCCUGGAGAUGG 22 7578
SCNNlA-3730 + CCUGCAGAGCCCCCUGGAGAUGG 23 7579
SCNNlA-3731 + CCCUGCAGAGCCCCCUGGAGAUGG 24 7580
SCNNlA-3732 + GAGUGAAUACACACCUGG 18 7581
SCNNlA-3733 + GGAGUGAAUACACACCUGG 19 7582
SCNNlA-3734 + AGGAGUGAAUACACACCUGG 20 7583
SCNNlA-3735 + CAGGAGUGAAUACACACCUGG 21 7584
SCNNlA-3736 + GCAGGAGUGAAUACACACCUGG 22 7585
SCNNlA-3737 + AGCAGGAGUGAAUACACACCUGG 23 7586
SCNNlA-3738 + AAGCAGGAGUGAAUACACACCUGG 24 7587
SCNNlA-3739 + UGGUUGCAGGAGACCUGG 18 7588
SCNNlA-3740 + CUGGUUGCAGGAGACCUGG 19 7589
SCNNlA-3741 + CCUGGUUGCAGGAGACCUGG 20 7590
SCNNlA-3742 + GCCUGGUUGCAGGAGACCUGG 21 7591
SCNNlA-3743 + CGCCUGGUUGCAGGAGACCUGG 22 7592
SCNNlA-3744 + ACGCCUGGUUGCAGGAGACCUGG 23 7593
SCNNlA-3745 + CACGCCUGGUUGCAGGAGACCUGG 24 7594
SCNNlA-3746 + AGAGGGAGCAGGGCCUGG 18 7595
SCNNlA-3747 + GAGAGGGAGCAGGGCCUGG 19 7596
SCNNlA-3748 + GGAGAGGGAGCAGGGCCUGG 20 7597
SCNNlA-3749 + UGGAGAGGGAGCAGGGCCUGG 21 7598
SCNNlA-3750 + CUGGAGAGGGAGCAGGGCCUGG 22 7599
SCNNlA-3751 + GCUGGAGAGGGAGCAGGGCCUGG 23 7600
SCNNlA-3752 + GGCUGGAGAGGGAGCAGGGCCUGG 24 7601
SCNNlA-3753 + CCUGAUGAGUAUGUCUGG 18 7602
SCNNlA-3754 + CCCUGAUGAGUAUGUCUGG 19 7603
SCNNlA-3755 + CCCCUGAUGAGUAUGUCUGG 20 7604
SCNNlA-3756 + ACCCCUGAUGAGUAUGUCUGG 21 7605
SCNNlA-3757 + CACCCCUGAUGAGUAUGUCUGG 22 7606
SCNNlA-3758 + CCACCCCUGAUGAGUAUGUCUGG 23 7607
SCNNlA-3759 + UCCACCCCUGAUGAGUAUGUCUGG 24 7608
SCNNlA-3760 + CCCCCAGAGGACAGGUGG 18 7609
1283
5535.1 SCNNlA-3761 + CCCCCCAGAGGACAGGUGG 19 7610
SCNNlA-1200 + CCCCCCCAGAGGACAGGUGG 20 5049
SCNNlA-3762 + GCCCCCCCAGAGGACAGGUGG 21 7611
SCNNlA-3763 + GGCCCCCCCAGAGGACAGGUGG 22 7612
SCNNlA-3764 + GGGCCCCCCCAGAGGACAGGUGG 23 7613
SCNNlA-3765 + AGGGCCCCCCCAGAGGACAGGUGG 24 7614
SCNNlA-3766 + UUUCCAUACAUCGGGUGG 18 7615
SCNNlA-3767 + GUUUCCAUACAUCGGGUGG 19 7616
SCNNlA-1202 + AGUUUCCAUACAUCGGGUGG 20 5051
SCNNlA-3768 + CAGUUUCCAUACAUCGGGUGG 21 7617
SCNNlA-3769 + GCAGUUUCCAUACAUCGGGUGG 22 7618
SCNNlA-3770 + AGCAGUUUCCAUACAUCGGGUGG 23 7619
SCNNlA-3771 + UAGCAGUUUCCAUACAUCGGGUGG 24 7620
SCNNlA-3772 + AACCUUCGGAGCAGCAUG 18 7621
SCNNlA-3773 + GAACCUUCGGAGCAGCAUG 19 7622
SCNNlA-1209 + GGAACCUUCGGAGCAGCAUG 20 5058
SCNNlA-3774 + CGGAACCUUCGGAGCAGCAUG 21 7623
SCNNlA-3775 + UCGGAACCUUCGGAGCAGCAUG 22 7624
SCNNlA-3776 + UUCGGAACCUUCGGAGCAGCAUG 23 7625
SCNNlA-3777 + CUUCGGAACCUUCGGAGCAGCAUG 24 7626
SCNNlA-3778 + CUGGUCACGCUGGGGAUG 18 7627
SCNNlA-3779 + GCUGGUCACGCUGGGGAUG 19 7628
SCNNlA-3780 + AGCUGGUCACGCUGGGGAUG 20 7629
SCNNlA-3781 + UAGCUGGUCACGCUGGGGAUG 21 7630
SCNNlA-3782 + GUAGCUGGUCACGCUGGGGAUG 22 7631
SCNNlA-3783 + GGUAGCUGGUCACGCUGGGGAUG 23 7632
SCNNlA-3784 + UGGUAGCUGGUCACGCUGGGGAUG 24
7633
SCNNlA-3785 + UUAAUUUCCGGGUACCUG 18 7634
SCNNlA-3786 + UUUAAUUUCCGGGUACCUG 19 7635
SCNNlA-3787 + CUUUAAUUUCCGGGUACCUG 20 7636
SCNNlA-3788 + UCUUUAAUUUCCGGGUACCUG 21 7637
SCNNlA-3789 + CUCUUUAAUUUCCGGGUACCUG 22 7638
SCNNlA-3790 + CCUCUUUAAUUUCCGGGUACCUG 23 7639
SCNNlA-3791 + UCCUCUUUAAUUUCCGGGUACCUG 24 7640
SCNNlA-3792 + UGGAGGAACUGGCCCCUG 18 7641
SCNNlA-3793 + GUGGAGGAACUGGCCCCUG 19 7642
SCNNlA-3794 + GGUGGAGGAACUGGCCCCUG 20 7643
SCNNlA-3795 + AGGUGGAGGAACUGGCCCCUG 21 7644
SCNNlA-3796 + CAGGUGGAGGAACUGGCCCCUG 22 7645
SCNNlA-3797 + ACAGGUGGAGGAACUGGCCCCUG 23 7646
SCNNlA-3798 + GACAGGUGGAGGAACUGGCCCCUG 24 7647
1284
5535.1 SCNNlA-3799 + GAGGGGCUGUCAAGGCUG 18 7648
SCNNlA-3800 + GGAGGGGCUGUCAAGGCUG 19 7649
SCNNlA-3801 + GGGAGGGGCUGUCAAGGCUG 20 7650
SCNNlA-3802 + GGGGAGGGGCUGUCAAGGCUG 21 7651
SCNNlA-3803 + GGGGGAGGGGCUGUCAAGGCUG 22 7652
SCNNlA-3804 + AGGGGGAGGGGCUGUCAAGGCUG 23 7653
SCNNlA-3805 + CAGGGGGAGGGGCUGUCAAGGCUG 24 7654
SCNNlA-3806 + CGCAGGUCGCGACGGCUG 18 7655
SCNNlA-3807 + CCGCAGGUCGCGACGGCUG 19 7656
SCNNlA-1223 + CCCGCAGGUCGCGACGGCUG 20 5072
SCNNlA-3808 + CCCCGCAGGUCGCGACGGCUG 21 7657
SCNNlA-3809 + CCCCCGCAGGUCGCGACGGCUG 22 7658
SCNNlA-3810 + UCCCCCGCAGGUCGCGACGGCUG 23 7659
SCNNlA-3811 + GUCCCCCGCAGGUCGCGACGGCUG 24 7660
SCNNlA-3812 + CUUGCCUUCCUCAUGCUG 18 7661
SCNNlA-3813 + CCUUGCCUUCCUCAUGCUG 19 7662
SCNNlA-3814 + UCCUUGCCUUCCUCAUGCUG 20 7663
SCNNlA-3815 + AUCCUUGCCUUCCUCAUGCUG 21 7664
SCNNlA-3816 + CAUCCUUGCCUUCCUCAUGCUG 22 7665
SCNNlA-3817 + GCAUCCUUGCCUUCCUCAUGCUG 23 7666
SCNNlA-3818 + AGCAUCCUUGCCUUCCUCAUGCUG 24 7667
SCNNlA-3819 + AACAGCCCAGGUGGUCUG 18 7668
SCNNlA-3820 + AAACAGCCCAGGUGGUCUG 19 7669
SCNNlA-1225 + GAAACAGCCCAGGUGGUCUG 20 5074
SCNNlA-3821 + UGAAACAGCCCAGGUGGUCUG 21 7670
SCNNlA-3822 + GUGAAACAGCCCAGGUGGUCUG 22 7671
SCNNlA-3823 + GGUGAAACAGCCCAGGUGGUCUG 23 7672
SCNNlA-3824 + UGGUGAAACAGCCCAGGUGGUCUG 24 7673
SCNNlA-3825 + GAGCCGGCCACGAGAGUG 18 7674
SCNNlA-3826 + GGAGCCGGCCACGAGAGUG 19 7675
SCNNlA-3827 + GGGAGCCGGCCACGAGAGUG 20 7676
SCNNlA-3828 + CGGGAGCCGGCCACGAGAGUG 21 7677
SCNNlA-3829 + GCGGGAGCCGGCCACGAGAGUG 22 7678
SCNNlA-3830 + UGCGGGAGCCGGCCACGAGAGUG 23 7679
SCNNlA-3831 + CUGCGGGAGCCGGCCACGAGAGUG 24 7680
SCNNlA-3832 + CCCCCCAGAGGACAGGUG 18 7681
SCNNlA-3833 + CCCCCCCAGAGGACAGGUG 19 7682
SCNNlA-3834 + GCCCCCCCAGAGGACAGGUG 20 7683
SCNNlA-3835 + GGCCCCCCCAGAGGACAGGUG 21 7684
SCNNlA-3836 + GGGCCCCCCCAGAGGACAGGUG 22 7685
SCNNlA-3837 + AGGGCCCCCCCAGAGGACAGGUG 23 7686
SCNNlA-3838 + CAGGGCCCCCCCAGAGGACAGGUG 24 7687
1285
5535.1 SCNNlA-3839 + CACUCCAUUUCUUAGGUG 18 7688
SCNNlA-3840 + CCACUCCAUUUCUUAGGUG 19 7689
SCNNlA-1232 + GCCACUCCAUUUCUUAGGUG 20 5081
SCNNlA-3841 + GGCCACUCCAUUUCUUAGGUG 21 7690
SCNNlA-3842 + UGGCCACUCCAUUUCUUAGGUG 22 7691
SCNNlA-3843 + UUGGCCACUCCAUUUCUUAGGUG 23 7692
SCNNlA-3844 + UUUGGCCACUCCAUUUCUUAGGUG 24 7693
SCNNlA-3845 + CUGGAAGGGAGGAGGGUG 18 7694
SCNNlA-3846 + CCUGGAAGGGAGGAGGGUG 19 7695
SCNNlA-3847 + ACCUGGAAGGGAGGAGGGUG 20 7696
SCNNlA-3848 + CACCUGGAAGGGAGGAGGGUG 21 7697
SCNNlA-3849 + ACACCUGGAAGGGAGGAGGGUG 22 7698
SCNNlA-3850 + CACACCUGGAAGGGAGGAGGGUG 23 7699
SCNNlA-3851 + ACACACCUGGAAGGGAGGAGGGUG 24 7700
SCNNlA-3852 + GUUUCCAUACAUCGGGUG 18 7701
SCNNlA-3853 + AGUUUCCAUACAUCGGGUG 19 7702
SCNNlA-3854 + CAGUUUCCAUACAUCGGGUG 20 7703
SCNNlA-3855 + GCAGUUUCCAUACAUCGGGUG 21 7704
SCNNlA-3856 + AGCAGUUUCCAUACAUCGGGUG 22 7705
SCNNlA-3857 + UAGCAGUUUCCAUACAUCGGGUG 23 7706
SCNNlA-3858 + AUAGCAGUUUCCAUACAUCGGGUG 24 7707
SCNNlA-3859 + GGGACAGACCUAGGGGUG 18 7708
SCNNlA-3860 + AGGGACAGACCUAGGGGUG 19 7709
SCNNlA-3861 + CAGGGACAGACCUAGGGGUG 20 7710
SCNNlA-3862 + UCAGGGACAGACCUAGGGGUG 21 7711
SCNNlA-3863 + AUCAGGGACAGACCUAGGGGUG 22 7712
SCNNlA-3864 + CAUCAGGGACAGACCUAGGGGUG 23 7713
SCNNlA-3865 + GCAUCAGGGACAGACCUAGGGGUG 24 7714
SCNNlA-3866 + CCGGCCACGAGAGUGGUG 18 7715
SCNNlA-3867 + GCCGGCCACGAGAGUGGUG 19 7716
SCNNlA-3868 + AGCCGGCCACGAGAGUGGUG 20 7717
SCNNlA-3869 + GAGCCGGCCACGAGAGUGGUG 21 7718
SCNNlA-3870 + GGAGCCGGCCACGAGAGUGGUG 22 7719
SCNNlA-3871 + GGGAGCCGGCCACGAGAGUGGUG 23 7720
SCNNlA-3872 + CGGGAGCCGGCCACGAGAGUGGUG 24 7721
SCNNlA-3873 + CAUGGCUUCCGGCACUUG 18 7722
SCNNlA-3874 + GCAUGGCUUCCGGCACUUG 19 7723
SCNNlA-3875 + UGCAUGGCUUCCGGCACUUG 20 7724
SCNNlA-3876 + CUGCAUGGCUUCCGGCACUUG 21 7725
SCNNlA-3877 + CCUGCAUGGCUUCCGGCACUUG 22 7726
SCNNlA-3878 + ACCUGCAUGGCUUCCGGCACUUG 23 7727
SCNNlA-3879 + AACCUGCAUGGCUUCCGGCACUUG 24 7728
1286
5535.1 SCNNlA-3880 + UUGUAGUUCAGCUCCUUG 18 7729
SCNNlA-3881 + UUUGUAGUUCAGCUCCUUG 19 7730
SCNNlA-3882 + UUUUGUAGUUCAGCUCCUUG 20 7731
SCNNlA-3883 + GUUUUGUAGUUCAGCUCCUUG 21 7732
SCNNlA-3884 + GGUUUUGUAGUUCAGCUCCUUG 22 7733
SCNNlA-3885 + UGGUUUUGUAGUUCAGCUCCUUG 23 7734
SCNNlA-3886 + UUGGUUUUGUAGUUCAGCUCCUUG 24
7735
SCNNlA-3887 + CUGACUCACGCCUGGUUG 18 7736
SCNNlA-3888 + ACUGACUCACGCCUGGUUG 19 7737
SCNNlA-3889 + GACUGACUCACGCCUGGUUG 20 7738
SCNNlA-3890 + GGACUGACUCACGCCUGGUUG 21 7739
SCNNlA-3891 + AGGACUGACUCACGCCUGGUUG 22 7740
SCNNlA-3892 + CAGGACUGACUCACGCCUGGUUG 23 7741
SCNNlA-3893 + GCAGGACUGACUCACGCCUGGUUG 24 7742
SCNNlA-3894 + GAACCUUCGGAGCAGCAU 18 7743
SCNNlA-3895 + GGAACCUUCGGAGCAGCAU 19 7744
SCNNlA-3896 + CGGAACCUUCGGAGCAGCAU 20 7745
SCNNlA-3897 + UCGGAACCUUCGGAGCAGCAU 21 7746
SCNNlA-3898 + UUCGGAACCUUCGGAGCAGCAU 22 7747
SCNNlA-3899 + CUUCGGAACCUUCGGAGCAGCAU 23 7748
SCNNlA-3900 + GCUUCGGAACCUUCGGAGCAGCAU 24 7749
SCNNlA-3901 + CUGCUCUGCGCGCAGCAU 18 7750
SCNNlA-3902 + UCUGCUCUGCGCGCAGCAU 19 7751
SCNNlA-3903 + UUCUGCUCUGCGCGCAGCAU 20 7752
SCNNlA-3904 + AUUCUGCUCUGCGCGCAGCAU 21 7753
SCNNlA-3905 + CAUUCUGCUCUGCGCGCAGCAU 22 7754
SCNNlA-3906 + UCAUUCUGCUCUGCGCGCAGCAU 23 7755
SCNNlA-3907 + GUCAUUCUGCUCUGCGCGCAGCAU 24 7756
SCNNlA-3908 + GUUCUGUCGCGAUAGCAU 18 7757
SCNNlA-3909 + UGUUCUGUCGCGAUAGCAU 19 7758
SCNNlA-3910 + UUGUUCUGUCGCGAUAGCAU 20 7759
SCNNlA-3911 + AUUGUUCUGUCGCGAUAGCAU 21 7760
SCNNlA-3912 + AAUUGUUCUGUCGCGAUAGCAU 22 7761
SCNNlA-3913 + UAAUUGUUCUGUCGCGAUAGCAU 23 7762
SCNNlA-3914 + GUAAUUGUUCUGUCGCGAUAGCAU 24 7763
SCNNlA-3915 + GUGAGAGUAAUUCCUUAU 18 7764
SCNNlA-3916 + AGUGAGAGUAAUUCCUUAU 19 7765
SCNNlA-3917 + AAGUGAGAGUAAUUCCUUAU 20 7766
SCNNlA-3918 + GAAGUGAGAGUAAUUCCUUAU 21 7767
SCNNlA-3919 + GGAAGUGAGAGUAAUUCCUUAU 22 7768
SCNNlA-3920 + UGGAAGUGAGAGUAAUUCCUUAU 23 7769
1287
5535.1 SCNNlA-3921 + GUGGAAGUGAGAGUAAUUCCUUAU 24
7770
SCNNlA-3922 + ACCCGGGCCCCAGUCACU 18 7771
SCNNlA-3923 + UACCCGGGCCCCAGUCACU 19 7772
SCNNlA-3924 + UUACCCGGGCCCCAGUCACU 20 7773
SCNNlA-3925 + AUUACCCGGGCCCCAGUCACU 21 7774
SCNNlA-3926 + CAUUACCCGGGCCCCAGUCACU 22 7775
SCNNlA-3927 + CCAUUACCCGGGCCCCAGUCACU 23 7776
SCNNlA-3928 + ACCAUUACCCGGGCCCCAGUCACU 24 7777
SCNNlA-3929 + UCACCUGCUGUGUGUACU 18 7778
SCNNlA-3930 + CUCACCUGCUGUGUGUACU 19 7779
SCNNlA-3931 + CCUCACCUGCUGUGUGUACU 20 7780
SCNNlA-3932 + GCCUCACCUGCUGUGUGUACU 21 7781
SCNNlA-3933 + GGCCUCACCUGCUGUGUGUACU 22 7782
SCNNlA-3934 + GGGCCUCACCUGCUGUGUGUACU 23 7783
SCNNlA-3935 + UGGGCCUCACCUGCUGUGUGUACU 24 7784
SCNNlA-3936 + GUAUCGGCUUCGGAACCU 18 7785
SCNNlA-3937 + AGUAUCGGCUUCGGAACCU 19 7786
SCNNlA-3938 + CAGUAUCGGCUUCGGAACCU 20 7787
SCNNlA-3939 + CCAGUAUCGGCUUCGGAACCU 21 7788
SCNNlA-3940 + ACCAGUAUCGGCUUCGGAACCU 22 7789
SCNNlA-3941 + GACCAGUAUCGGCUUCGGAACCU 23 7790
SCNNlA-3942 + AGACCAGUAUCGGCUUCGGAACCU 24 7791
SCNNlA-3943 + UCUGGAAGACCCAUUCCU 18 7792
SCNNlA-3944 + AUCUGGAAGACCCAUUCCU 19 7793
SCNNlA-1270 + CAUCUGGAAGACCCAUUCCU 20 5119
SCNNlA-3945 + GCAUCUGGAAGACCCAUUCCU 21 7794
SCNNlA-3946 + AGCAUCUGGAAGACCCAUUCCU 22 7795
SCNNlA-3947 + UAGCAUCUGGAAGACCCAUUCCU 23 7796
SCNNlA-3948 + AUAGCAUCUGGAAGACCCAUUCCU 24 7797
SCNNlA-3949 + GUCUGUCCAGGGUUUCCU 18 7798
SCNNlA-3950 + AGUCUGUCCAGGGUUUCCU 19 7799
SCNNlA-3951 + AAGUCUGUCCAGGGUUUCCU 20 7800
SCNNlA-3952 + CAAGUCUGUCCAGGGUUUCCU 21 7801
SCNNlA-3953 + CCAAGUCUGUCCAGGGUUUCCU 22 7802
SCNNlA-3954 + CCCAAGUCUGUCCAGGGUUUCCU 23 7803
SCNNlA-3955 + CCCCAAGUCUGUCCAGGGUUUCCU 24 7804
SCNNlA-3956 + CAAGCUGGAGGCCACGCU 18 7805
SCNNlA-3957 + GCAAGCUGGAGGCCACGCU 19 7806
SCNNlA-3958 + CGCAAGCUGGAGGCCACGCU 20 7807
SCNNlA-3959 + CCGCAAGCUGGAGGCCACGCU 21 7808
SCNNlA-3960 + CCCGCAAGCUGGAGGCCACGCU 22 7809
1288
5535.1 SCNNlA-3961 + UCCCGCAAGCUGGAGGCCACGCU 23 7810
SCNNlA-3962 + GUCCCGCAAGCUGGAGGCCACGCU 24 7811
SCNNlA-3963 + CCGCAGGUCGCGACGGCU 18 7812
SCNNlA-3964 + CCCGCAGGUCGCGACGGCU 19 7813
SCNNlA-3965 + CCCCGCAGGUCGCGACGGCU 20 7814
SCNNlA-3966 + CCCCCGCAGGUCGCGACGGCU 21 7815
SCNNlA-3967 + UCCCCCGCAGGUCGCGACGGCU 22 7816
SCNNlA-3968 + GUCCCCCGCAGGUCGCGACGGCU 23 7817
SCNNlA-3969 + AGUCCCCCGCAGGUCGCGACGGCU 24 7818
SCNNlA-3970 + UGGAGACCAGUAUCGGCU 18 7819
SCNNlA-3971 + CUGGAGACCAGUAUCGGCU 19 7820
SCNNlA-3972 + CCUGGAGACCAGUAUCGGCU 20 7821
SCNNlA-3973 + GCCUGGAGACCAGUAUCGGCU 21 7822
SCNNlA-3974 + GGCCUGGAGACCAGUAUCGGCU 22 7823
SCNNlA-3975 + CGGCCUGGAGACCAGUAUCGGCU 23 7824
SCNNlA-3976 + UCGGCCUGGAGACCAGUAUCGGCU 24 7825
SCNNlA-3977 + ACAGGAGGGUGACCAUCU 18 7826
SCNNlA-3978 + GACAGGAGGGUGACCAUCU 19 7827
SCNNlA-3979 + GGACAGGAGGGUGACCAUCU 20 7828
SCNNlA-3980 + UGGACAGGAGGGUGACCAUCU 21 7829
SCNNlA-3981 + UUGGACAGGAGGGUGACCAUCU 22 7830
SCNNlA-3982 + GUUGGACAGGAGGGUGACCAUCU 23 7831
SCNNlA-3983 + GGUUGGACAGGAGGGUGACCAUCU 24 7832
SCNNlA-3984 + AAACCUCUCCUUCCCUCU 18 7833
SCNNlA-3985 + GAAACCUCUCCUUCCCUCU 19 7834
SCNNlA-3986 + AGAAACCUCUCCUUCCCUCU 20 7835
SCNNlA-3987 + GAGAAACCUCUCCUUCCCUCU 21 7836
SCNNlA-3988 + UGAGAAACCUCUCCUUCCCUCU 22 7837
SCNNlA-3989 + GUGAGAAACCUCUCCUUCCCUCU 23 7838
SCNNlA-3990 + UGUGAGAAACCUCUCCUUCCCUCU 24 7839
SCNNlA-3991 + AAACAGCCCAGGUGGUCU 18 7840
SCNNlA-3992 + GAAACAGCCCAGGUGGUCU 19 7841
SCNNlA-3993 + UGAAACAGCCCAGGUGGUCU 20 7842
SCNNlA-3994 + GUGAAACAGCCCAGGUGGUCU 21 7843
SCNNlA-3995 + GGUGAAACAGCCCAGGUGGUCU 22 7844
SCNNlA-3996 + UGGUGAAACAGCCCAGGUGGUCU 23 7845
SCNNlA-3997 + UUGGUGAAACAGCCCAGGUGGUCU 24 7846
SCNNlA-3998 + UGGGGUGGGGGCAGAAGU 18 7847
SCNNlA-3999 + AUGGGGUGGGGGCAGAAGU 19 7848
SCNNlA-1279 + CAUGGGGUGGGGGCAGAAGU 20 5128
SCNNlA-4000 + ACAUGGGGUGGGGGCAGAAGU 21 7849
SCNNlA-4001 + GACAUGGGGUGGGGGCAGAAGU 22 7850
1289
5535.1 SCNNlA-4002 + AGACAUGGGGUGGGGGCAGAAGU 23 7851
SCNNlA-4003 + GAGACAUGGGGUGGGGGCAGAAGU 24
7852
SCNNlA-4004 + GGACACAGAGACUAGAGU 18 7853
SCNNlA-4005 + UGGACACAGAGACUAGAGU 19 7854
SCNNlA-4006 + CUGGACACAGAGACUAGAGU 20 7855
SCNNlA-4007 + ACUGGACACAGAGACUAGAGU 21 7856
SCNNlA-4008 + CACUGGACACAGAGACUAGAGU 22 7857
SCNNlA-4009 + GCACUGGACACAGAGACUAGAGU 23 7858
SCNNlA-4010 + UGCACUGGACACAGAGACUAGAGU 24 7859
SCNNlA-4011 + CCACUCCAUUUCUUAGGU 18 7860
SCNNlA-4012 + GCCACUCCAUUUCUUAGGU 19 7861
SCNNlA-4013 + GGCCACUCCAUUUCUUAGGU 20 7862
SCNNlA-4014 + UGGCCACUCCAUUUCUUAGGU 21 7863
SCNNlA-4015 + UUGGCCACUCCAUUUCUUAGGU 22 7864
SCNNlA-4016 + UUUGGCCACUCCAUUUCUUAGGU 23 7865
SCNNlA-4017 + CUUUGGCCACUCCAUUUCUUAGGU 24 7866
SCNNlA-4018 + AGGUGUGGGGCAGAGGGU 18 7867
SCNNlA-4019 + UAGGUGUGGGGCAGAGGGU 19 7868
SCNNlA-1286 + UUAGGUGUGGGGCAGAGGGU 20 5135
SCNNlA-4020 + CUUAGGUGUGGGGCAGAGGGU 21 7869
SCNNlA-4021 + UCUUAGGUGUGGGGCAGAGGGU 22 7870
SCNNlA-4022 + UUCUUAGGUGUGGGGCAGAGGGU 23 7871
SCNNlA-4023 + UUUCUUAGGUGUGGGGCAGAGGGU 24
7872
SCNNlA-4024 + GGAAAGAGAGAGUAGGGU 18 7873
SCNNlA-4025 + AGGAAAGAGAGAGUAGGGU 19 7874
SCNNlA-4026 + CAGGAAAGAGAGAGUAGGGU 20 7875
SCNNlA-4027 + UCAGGAAAGAGAGAGUAGGGU 21 7876
SCNNlA-4028 + AUCAGGAAAGAGAGAGUAGGGU 22 7877
SCNNlA-4029 + UAUCAGGAAAGAGAGAGUAGGGU 23 7878
SCNNlA-4030 + UUAUCAGGAAAGAGAGAGUAGGGU 24
7879
SCNNlA-4031 + AGGACAGAGACAUGGGGU 18 7880
SCNNlA-4032 + AAGGACAGAGACAUGGGGU 19 7881
SCNNlA-1287 + CAAGGACAGAGACAUGGGGU 20 5136
SCNNlA-4033 + ACAAGGACAGAGACAUGGGGU 21 7882
SCNNlA-4034 + GACAAGGACAGAGACAUGGGGU 22 7883
SCNNlA-4035 + GGACAAGGACAGAGACAUGGGGU 23 7884
SCNNlA-4036 + GGGACAAGGACAGAGACAUGGGGU 24 7885
SCNNlA-4037 + UGAAACAGCCCAGGUGGU 18 7886
SCNNlA-4038 + GUGAAACAGCCCAGGUGGU 19 7887
1290
5535.1 SCNNlA-4039 + GGUGAAACAGCCCAGGUGGU 20 7888
SCNNlA-4040 + UGGUGAAACAGCCCAGGUGGU 21 7889
SCNNlA-4041 + UUGGUGAAACAGCCCAGGUGGU 22 7890
SCNNlA-4042 + CUUGGUGAAACAGCCCAGGUGGU 23 7891
SCNNlA-4043 + ACUUGGUGAAACAGCCCAGGUGGU 24 7892
SCNNlA-4044 + AGGAGGGUGACCAUCUGU 18 7893
SCNNlA-4045 + CAGGAGGGUGACCAUCUGU 19 7894
SCNNlA-4046 + ACAGGAGGGUGACCAUCUGU 20 7895
SCNNlA-4047 + GACAGGAGGGUGACCAUCUGU 21 7896
SCNNlA-4048 + GGACAGGAGGGUGACCAUCUGU 22 7897
SCNNlA-4049 + UGGACAGGAGGGUGACCAUCUGU 23 7898
SCNNlA-4050 + UUGGACAGGAGGGUGACCAUCUGU 24 7899
SCNNlA-4051 + UAUCGGCUUCGGAACCUU 18 7900
SCNNlA-4052 + GUAUCGGCUUCGGAACCUU 19 7901
SCNNlA-1297 + AGUAUCGGCUUCGGAACCUU 20 5146
SCNNlA-4053 + CAGUAUCGGCUUCGGAACCUU 21 7902
SCNNlA-4054 + CCAGUAUCGGCUUCGGAACCUU 22 7903
SCNNlA-4055 + ACCAGUAUCGGCUUCGGAACCUU 23 7904
SCNNlA-4056 + GACCAGUAUCGGCUUCGGAACCUU 24 7905
SCNNlA-4057 + GGAGACCAGUAUCGGCUU 18 7906
SCNNlA-4058 + UGGAGACCAGUAUCGGCUU 19 7907
SCNNlA-1298 + CUGGAGACCAGUAUCGGCUU 20 5147
SCNNlA-4059 + CCUGGAGACCAGUAUCGGCUU 21 7908
SCNNlA-4060 + GCCUGGAGACCAGUAUCGGCUU 22 7909
SCNNlA-4061 + GGCCUGGAGACCAGUAUCGGCUU 23 7910
SCNNlA-4062 + CGGCCUGGAGACCAGUAUCGGCUU 24 7911
SCNNlA-4063 + GUCACAGUACUCCACGUU 18 7912
SCNNlA-4064 + AGUCACAGUACUCCACGUU 19 7913
SCNNlA-4065 + UAGUCACAGUACUCCACGUU 20 7914
SCNNlA-4066 + GUAGUCACAGUACUCCACGUU 21 7915
SCNNlA-4067 + UGUAGUCACAGUACUCCACGUU 22 7916
SCNNlA-4068 + CUGUAGUCACAGUACUCCACGUU 23 7917
SCNNlA-4069 + UCUGUAGUCACAGUACUCCACGUU 24 7918
SCNNlA-4070 - CAG UG CAACCAG AACAAA 18 7919
SCNNlA-4071 - CCAGUG CAACCAG AACAAA 19 7920
SCNNlA-4072 - U CC AG U G CAACCAG AACAAA 20 7921
SCNNlA-4073 - GUCCAGUGCAACCAGAACAAA 21 7922
SCNNlA-4074 - UGUCCAGUGCAACCAGAACAAA 22 7923
SCNNlA-4075 - GUGUCCAGUG C A AC CAG AACAAA 23 7924
SCNNlA-4076 - UGUGUCCAGUG CAACCAG AACAAA 24 7925
SCNNlA-4077 - AGGUACCCGGAAAUUAAA 18 7926
SCNNlA-4078 - CAGG U ACCCGG AAAU U AAA 19 7927
1291
5535.1 SCNNlA-4079 - UCAGGUACCCGGAAAUUAAA 20 7928
SCNNlA-4080 - UUCAGGUACCCGGAAAUUAAA 21 7929
SCNNlA-4081 - CU U CAGG U ACCCGG AAAU U AAA 22 7930
SCNNlA-4082 - CCU U CAGG U ACCCGG AAAU U AAA 23 7931
SCNNlA-4083 - CCCUUCAGGUACCCGGAAAUUAAA 24 7932
SCNNlA-4084 - CUGCCCCACACCUAAGAA 18 7933
SCNNlA-4085 - UCUGCCCCACACCUAAGAA 19 7934
SCNNlA-4086 - CUCUGCCCCACACCUAAGAA 20 7935
SCNNlA-4087 - CCUCUGCCCCACACCUAAGAA 21 7936
SCNNlA-4088 - CCCUCUGCCCCACACCUAAGAA 22 7937
SCNNlA-4089 - ACCCUCUGCCCCACACCUAAGAA 23 7938
SCNNlA-4090 - CACCCUCUGCCCCACACCUAAGAA 24 7939
SCNNlA-4091 - GUCCAACCUGGGCAGCCA 18 7940
SCNNlA-4092 - UGUCCAACCUGGGCAGCCA 19 7941
SCNNlA-4093 - CUGUCCAACCUGGGCAGCCA 20 7942
SCNNlA-4094 - CCUGUCCAACCUGGGCAGCCA 21 7943
SCNNlA-4095 - UCCUGUCCAACCUGGGCAGCCA 22 7944
SCNNlA-4096 - CUCCUGUCCAACCUGGGCAGCCA 23 7945
SCNNlA-4097 - CCUCCUGUCCAACCUGGGCAGCCA 24 7946
SCNNlA-4098 - UCCUGGGGUGAGACUCCA 18 7947
SCNNlA-4099 - UUCCUGGGGUGAGACUCCA 19 7948
SCNNlA-904 - GUUCCUGGGGUGAGACUCCA 20 4753
SCNNlA-4100 - AGUUCCUGGGGUGAGACUCCA 21 7949
SCNNlA-4101 - CAGUUCCUGGGGUGAGACUCCA 22 7950
SCNNlA-4102 - ACAGUUCCUGGGGUGAGACUCCA 23 7951
SCNNlA-4103 - CACAGUUCCUGGGGUGAGACUCCA 24 7952
SCNNlA-4104 - GGCCCCCGCCCAUCUCCA 18 7953
SCNNlA-4105 - GGGCCCCCGCCCAUCUCCA 19 7954
SCNNlA-907 - UGGGCCCCCGCCCAUCUCCA 20 4756
SCNNlA-4106 - CUGGGCCCCCGCCCAUCUCCA 21 7955
SCNNlA-4107 - CCUGGGCCCCCGCCCAUCUCCA 22 7956
SCNNlA-4108 - CCCUGGGCCCCCGCCCAUCUCCA 23 7957
SCNNlA-4109 - ACCCUGGGCCCCCGCCCAUCUCCA 24 7958
SCNNlA-4110 - AGGAGCUGGACCGCAUCA 18 7959
SCNNlA-4111 - GAGGAGCUGGACCGCAUCA 19 7960
SCNNlA-4112 - GGAGGAGCUGGACCGCAUCA 20 7961
SCNNlA-4113 - UGGAGGAGCUGGACCGCAUCA 21 7962
SCNNlA-4114 - CUGGAGGAGCUGGACCGCAUCA 22 7963
SCNNlA-4115 - GCUGGAGGAGCUGGACCGCAUCA 23 7964
SCNNlA-4116 - AGCUGGAGGAGCUGGACCGCAUCA 24 7965
SCNNlA-4117 - GGUCCCGCCCCCGCCUCA 18 7966
SCNNlA-4118 - GGGUCCCGCCCCCGCCUCA 19 7967
1292
5535.1 SCNNlA-924 - AGGGUCCCGCCCCCGCCUCA 20 4773
SCNNlA-4119 - GAGGGUCCCGCCCCCGCCUCA 21 7968
SCNNlA-4120 - UGAGGGUCCCGCCCCCGCCUCA 22 7969
SCNNlA-4121 - CUGAGGGUCCCGCCCCCGCCUCA 23 7970
SCNNlA-4122 - CCUGAGGGUCCCGCCCCCGCCUCA 24 7971
SCNNlA-4123 - AAGUCAACAUCUUCUUCA 18 7972
SCNNlA-4124 - AAAGUCAACAUCUUCUUCA 19 7973
SCNNlA-928 - C A A AG UCAACAUCUUCUUCA 20 4777
SCNNlA-4125 - CCA AAG U C AACAU C U U C U U C A 21 7974
SCNNlA-4126 - GCCAAAGUCAACAUCUUCUUCA 22 7975
SCNNlA-4127 - GGCCAAAGUCAACAUCUUCUUCA 23 7976
SCNNlA-4128 - UGGCCAAAGUCAACAUCUUCUUCA 24 7977
SCNNlA-4129 - UUGGUGUAUGUGGGUUCA 18 7978
SCNNlA-4130 - CUUGGUGUAUGUGGGUUCA 19 7979
SCNNlA-4131 - UCUUGGUGUAUGUGGGUUCA 20 7980
SCNNlA-4132 - CUCUUGGUGUAUGUGGGUUCA 21 7981
SCNNlA-4133 - UCUCUUGGUGUAUGUGGGUUCA 22 7982
SCNNlA-4134 - AUCUCUUGGUGUAUGUGGGUUCA 23 7983
SCNNlA-4135 - GAUCUCUUGGUGUAUGUGGGUUCA 24
7984
SCNNlA-4136 - UCUGGGGGGGCCCUGAGA 18 7985
SCNNlA-4137 - CUCUGGGGGGGCCCUGAGA 19 7986
SCNNlA-938 - CCUCUGGGGGGGCCCUGAGA 20 4787
SCNNlA-4138 - UCCUCUGGGGGGGCCCUGAGA 21 7987
SCNNlA-4139 - GUCCUCUGGGGGGGCCCUGAGA 22 7988
SCNNlA-4140 - UGUCCUCUGGGGGGGCCCUGAGA 23 7989
SCNNlA-4141 - CUGUCCUCUGGGGGGGCCCUGAGA 24 7990
SCNNlA-4142 - UACUGGUCUCCAGGCCGA 18 7991
SCNNlA-4143 - AUACUGGUCUCCAGGCCGA 19 7992
SCNNlA-943 - GAUACUGGUCUCCAGGCCGA 20 4792
SCNNlA-4144 - CGAUACUGGUCUCCAGGCCGA 21 7993
SCNNlA-4145 - CCGAUACUGGUCUCCAGGCCGA 22 7994
SCNNlA-4146 - GCCGAUACUGGUCUCCAGGCCGA 23 7995
SCNNlA-4147 - AGCCGAUACUGGUCUCCAGGCCGA 24 7996
SCNNlA-4148 - UUCCAGAUGCUAUCGCGA 18 7997
SCNNlA-4149 - CUUCCAGAUGCUAUCGCGA 19 7998
SCNNlA-4150 - UCUUCCAGAUGCUAUCGCGA 20 7999
SCNNlA-4151 - GUCUUCCAGAUGCUAUCGCGA 21 8000
SCNNlA-4152 - GGUCUUCCAGAUGCUAUCGCGA 22 8001
SCNNlA-4153 - GGGUCUUCCAGAUGCUAUCGCGA 23 8002
SCNNlA-4154 - UGGGUCUUCCAGAUGCUAUCGCGA 24 8003
SCNNlA-4155 - CCAGGUGGACUGGAAGGA 18 8004
1293
5535.1 SCNNlA-4156 - CCCAGGUGGACUGGAAGGA 19 8005
SCNNlA-4157 - CCCCAGGUGGACUGGAAGGA 20 8006
SCNNlA-4158 - CCCCCAGGUGGACUGGAAGGA 21 8007
SCNNlA-4159 - ACCCCCAGGUGGACUGGAAGGA 22 8008
SCNNlA-4160 - AACCCCCAGGUGGACUGGAAGGA 23 8009
SCNNlA-4161 - CAACCCCCAGGUGGACUGGAAGGA 24 8010
SCNNlA-4162 - GGGGGGCCCUGAGAGGGA 18 8011
SCNNlA-4163 - GGGGGGGCCCUGAGAGGGA 19 8012
SCNNlA-954 - UGGGGGGGCCCUGAGAGGGA 20 4803
SCNNlA-4164 - CUGGGGGGGCCCUGAGAGGGA 21 8013
SCNNlA-4165 - UCUGGGGGGGCCCUGAGAGGGA 22 8014
SCNNlA-4166 - CUCUGGGGGGGCCCUGAGAGGGA 23 8015
SCNNlA-4167 - CCUCUGGGGGGGCCCUGAGAGGGA 24 8016
SCNNlA-4168 - CGGUAGGUCGUGCCUGGA 18 8017
SCNNlA-4169 - ACGGUAGGUCGUGCCUGGA 19 8018
SCNNlA-962 - CACGGUAGGUCGUGCCUGGA 20 4811
SCNNlA-4170 - UCACGGUAGGUCGUGCCUGGA 21 8019
SCNNlA-4171 - GUCACGGUAGGUCGUGCCUGGA 22 8020
SCNNlA-4172 - UGUCACGGUAGGUCGUGCCUGGA 23 8021
SCNNlA-4173 - CUGUCACGGUAGGUCGUGCCUGGA 24 8022
SCNNlA-4174 - CAACAACCCCCAGGUGGA 18 8023
SCNNlA-4175 - ACAACAACCCCCAGGUGGA 19 8024
SCNNlA-4176 - GACAACAACCCCCAGGUGGA 20 8025
SCNNlA-4177 - GGACAACAACCCCCAGGUGGA 21 8026
SCNNlA-4178 - GGGACAACAACCCCCAGGUGGA 22 8027
SCNNlA-4179 - CGGGACAACAACCCCCAGGUGGA 23 8028
SCNNlA-4180 - GCGGGACAACAACCCCCAGGUGGA 24 8029
SCNNlA-4181 - CCUCUGGGGGGGCCCUGA 18 8030
SCNNlA-4182 - UCCUCUGGGGGGGCCCUGA 19 8031
SCNNlA-4183 - GUCCUCUGGGGGGGCCCUGA 20 8032
SCNNlA-4184 - UGUCCUCUGGGGGGGCCCUGA 21 8033
SCNNlA-4185 - CUGUCCUCUGGGGGGGCCCUGA 22 8034
SCNNlA-4186 - CCUGUCCUCUGGGGGGGCCCUGA 23 8035
SCNNlA-4187 - ACCUGUCCUCUGGGGGGGCCCUGA 24 8036
SCNNlA-4188 - GGAAGGCAAGGAUGCUGA 18 8037
SCNNlA-4189 - AGGAAGGCAAGGAUGCUGA 19 8038
SCNNlA-4190 - GAGGAAGGCAAGGAUGCUGA 20 8039
SCNNlA-4191 - UGAGGAAGGCAAGGAUGCUGA 21 8040
SCNNlA-4192 - AUGAGGAAGGCAAGGAUGCUGA 22 8041
SCNNlA-4193 - CAUGAGGAAGGCAAGGAUGCUGA 23 8042
SCNNlA-4194 - GCAUGAGGAAGGCAAGGAUGCUGA 24 8043
SCNNlA-4195 - CCCUGCUGUCCACAGUGA 18 8044
1294
5535.1 SCNNlA-4196 - CCCCUGCUGUCCACAGUGA 19 8045
SCNNlA-4197 - UCCCCUGCUGUCCACAGUGA 20 8046
SCNNlA-4198 - UUCCCCUGCUGUCCACAGUGA 21 8047
SCNNlA-4199 - AUUCCCCUGCUGUCCACAGUGA 22 8048
SCNNlA-4200 - CAUUCCCCUGCUGUCCACAGUGA 23 8049
SCNNlA-4201 - UCAUUCCCCUGCUGUCCACAGUGA 24 8050
SCNNlA-4202 - CGUGGAGUACUGUGACUA 18 8051
SCNNlA-4203 - ACGUGGAGUACUGUGACUA 19 8052
SCNNlA-4204 - AACGUGGAGUACUGUGACUA 20 8053
SCNNlA-4205 - GAACGUGGAGUACUGUGACUA 21 8054
SCNNlA-4206 - AGAACGUGGAGUACUGUGACUA 22 8055
SCNNlA-4207 - CAGAACGUGGAGUACUGUGACUA 23 8056
SCNNlA-4208 - CCAGAACGUGGAGUACUGUGACUA 24 8057
SCNNlA-4209 - CUUCCACCACCCGAUGUA 18 8058
SCNNlA-4210 - ACUUCCACCACCCGAUGUA 19 8059
SCNNlA-975 - CACUUCCACCACCCGAUGUA 20 4824
SCNNlA-4211 - UCACUUCCACCACCCGAUGUA 21 8060
SCNNlA-4212 - CUCACUUCCACCACCCGAUGUA 22 8061
SCNNlA-4213 - UCUCACUUCCACCACCCGAUGUA 23 8062
SCNNlA-4214 - CUCUCACUUCCACCACCCGAUGUA 24 8063
SCNNlA-4215 - UCAGGUACCCGGAAAUUA 18 8064
SCNNlA-4216 - UUCAGGUACCCGGAAAUUA 19 8065
SCNNlA-4217 - CUUCAGGUACCCGGAAAUUA 20 8066
SCNNlA-4218 - CCUUCAGGUACCCGGAAAUUA 21 8067
SCNNlA-4219 - CCCUUCAGGUACCCGGAAAUUA 22 8068
SCNNlA-4220 - CCCCUUCAGGUACCCGGAAAUUA 23 8069
SCNNlA-4221 - GCCCCUUCAGGUACCCGGAAAUUA 24 8070
SCNNlA-4222 - AAU U ACACCG U CAACAAC 18 8071
SCNNlA-4223 - CAAU U ACACCG U CAACAAC 19 8072
SCNNlA-4224 - ACAAU U ACACCG U CAACAAC 20 8073
SCNNlA-4225 - AACAAU U ACACCG U CAACAAC 21 8074
SCNNlA-4226 - GAACAAU U ACACCG U CAACAAC 22 8075
SCNNlA-4227 - AG AACAAU U ACACCG U CAACAAC 23 8076
SCNNlA-4228 - CAG AACAAU U ACACCG U CAACAAC 24 8077
SCNNlA-4229 - GUCACCCUCCUGUCCAAC 18 8078
SCNNlA-4230 - GGUCACCCUCCUGUCCAAC 19 8079
SCNNlA-4231 - UGGUCACCCUCCUGUCCAAC 20 8080
SCNNlA-4232 - AUGGUCACCCUCCUGUCCAAC 21 8081
SCNNlA-4233 - GAUGGUCACCCUCCUGUCCAAC 22 8082
SCNNlA-4234 - AGAUGGUCACCCUCCUGUCCAAC 23 8083
SCNNlA-4235 - CAGAUGGUCACCCUCCUGUCCAAC 24 8084
SCNNlA-4236 - CUCUGUGUCCAGUGCAAC 18 8085
1295
5535.1 SCNNlA-4237 - UCUCUGUGUCCAGUGCAAC 19 8086
SCNNlA-4238 - GUCUCUGUGUCCAGUGCAAC 20 8087
SCNNlA-4239 - AGUCUCUGUGUCCAGUGCAAC 21 8088
SCNNlA-4240 - UAGUCUCUGUGUCCAGUGCAAC 22 8089
SCNNlA-4241 - CUAGUCUCUGUGUCCAGUGCAAC 23 8090
SCNNlA-4242 - UCUAGUCUCUGUGUCCAGUGCAAC 24 8091
SCNNlA-4243 - UAUCCGCGGCCCCAGAAC 18 8092
SCNNlA-4244 - CUAUCCGCGGCCCCAGAAC 19 8093
SCNNlA-4245 - UCUAUCCGCGGCCCCAGAAC 20 8094
SCNNlA-4246 - UUCUAUCCGCGGCCCCAGAAC 21 8095
SCNNlA-4247 - CUUCUAUCCGCGGCCCCAGAAC 22 8096
SCNNlA-4248 - UCUUCUAUCCGCGGCCCCAGAAC 23 8097
SCNNlA-4249 - AUCUUCUAUCCGCGGCCCCAGAAC 24 8098
SCNNlA-4250 - GACUUCUCCUCAGACCAC 18 8099
SCNNlA-4251 - UGACUUCUCCUCAGACCAC 19 8100
SCNNlA-4252 - UUGACUUCUCCUCAGACCAC 20 8101
SCNNlA-4253 - GUUGACUUCUCCUCAGACCAC 21 8102
SCNNlA-4254 - GGUUGACUUCUCCUCAGACCAC 22 8103
SCNNlA-4255 - AGGUUGACUUCUCCUCAGACCAC 23 8104
SCNNlA-4256 - CAGGUUGACUUCUCCUCAGACCAC 24 8105
SCNNlA-4257 - AGGAAACCCUGGACAGAC 18 8106
SCNNlA-4258 - UAGGAAACCCUGGACAGAC 19 8107
SCNNlA-4259 - AUAGGAAACCCUGGACAGAC 20 8108
SCNNlA-4260 - CAUAGGAAACCCUGGACAGAC 21 8109
SCNNlA-4261 - UCAUAGGAAACCCUGGACAGAC 22 8110
SCNNlA-4262 - UUCAUAGGAAACCCUGGACAGAC 23 8111
SCNNlA-4263 - GUUCAUAGGAAACCCUGGACAGAC 24 8112
SCNNlA-4264 - CAGGUGGACUGGAAGGAC 18 8113
SCNNlA-4265 - CCAGGUGGACUGGAAGGAC 19 8114
SCNNlA-988 - CCCAGGUGGACUGGAAGGAC 20 4837
SCNNlA-4266 - CCCCAGGUGGACUGGAAGGAC 21 8115
SCNNlA-4267 - CCCCCAGGUGGACUGGAAGGAC 22 8116
SCNNlA-4268 - ACCCCCAGGUGGACUGGAAGGAC 23 8117
SCNNlA-4269 - AACCCCCAGGUGGACUGGAAGGAC 24 8118
SCNNlA-4270 - AACAACCCCCAGGUGGAC 18 8119
SCNNlA-4271 - CAACAACCCCCAGGUGGAC 19 8120
SCNNlA-990 - ACAACAACCCCCAGGUGGAC 20 4839
SCNNlA-4272 - GACAACAACCCCCAGGUGGAC 21 8121
SCNNlA-4273 - GG ACAACAACCCCCAGGUGGAC 22 8122
SCNNlA-4274 - GGGACAACAACCCCCAGGUGGAC 23 8123
SCNNlA-4275 - CGGGACAACAACCCCCAGGUGGAC 24 8124
SCNNlA-4276 - UGCUAUACUUUCAAUGAC 18 8125
1296
5535.1 SCNNlA-4277 - CUGCUAUACUUUCAAUGAC 19 8126
SCNNlA-4278 - ACUGCUAUACUUUCAAUGAC 20 8127
SCNNlA-4279 - AACUGCUAUACUUUCAAUGAC 21 8128
SCNNlA-4280 - AAACUGCUAUACUUUCAAUGAC 22 8129
SCNNlA-4281 - GAAACUGCUAUACUUUCAAUGAC 23 8130
SCNNlA-4282 - GGAAACUGCUAUACUUUCAAUGAC 24 8131
SCNNlA-4283 - GAAGGCAAGGAUGCUGAC 18 8132
SCNNlA-4284 - GGAAGGCAAGGAUGCUGAC 19 8133
SCNNlA-992 - AGGAAGGCAAGGAUGCUGAC 20 4841
SCNNlA-4285 - GAGGAAGGCAAGGAUGCUGAC 21 8134
SCNNlA-4286 - UGAGGAAGGCAAGGAUGCUGAC 22 8135
SCNNlA-4287 - AUGAGGAAGGCAAGGAUGCUGAC 23 8136
SCNNlA-4288 - CAUGAGGAAGGCAAGGAUGCUGAC 24 8137
SCNNlA-4289 - CCUGCUGUCCACAGUGAC 18 8138
SCNNlA-4290 - CCCUGCUGUCCACAGUGAC 19 8139
SCNNlA-993 - CCCCUGCUGUCCACAGUGAC 20 4842
SCNNlA-4291 - UCCCCUGCUGUCCACAGUGAC 21 8140
SCNNlA-4292 - UUCCCCUGCUGUCCACAGUGAC 22 8141
SCNNlA-4293 - AUUCCCCUGCUGUCCACAGUGAC 23 8142
SCNNlA-4294 - CAUUCCCCUGCUGUCCACAGUGAC 24 8143
SCNNlA-4295 - CCUCGCCCCUUCAGGUAC 18 8144
SCNNlA-4296 - CCCUCGCCCCUUCAGGUAC 19 8145
SCNNlA-4297 - CCCCUCGCCCCUUCAGGUAC 20 8146
SCNNlA-4298 - UCCCCUCGCCCCUUCAGGUAC 21 8147
SCNNlA-4299 - UUCCCCUCGCCCCUUCAGGUAC 22 8148
SCNNlA-4300 - CUUCCCCUCGCCCCUUCAGGUAC 23 8149
SCNNlA-4301 - UCUUCCCCUCGCCCCUUCAGGUAC 24 8150
SCNNlA-4302 - GUGGGUUCAUAGGAAACC 18 8151
SCNNlA-4303 - UGUGGGUUCAUAGGAAACC 19 8152
SCNNlA-4304 - AUGUGGGUUCAUAGGAAACC 20 8153
SCNNlA-4305 - UAUGUGGGUUCAUAGGAAACC 21 8154
SCNNlA-4306 - GUAUGUGGGUUCAUAGGAAACC 22 8155
SCNNlA-4307 - UGUAUGUGGGUUCAUAGGAAACC 23 8156
SCNNlA-4308 - GUGUAUGUGGGUUCAUAGGAAACC 24 8157
SCNNlA-4309 - CCCCCUGCCUAUGCCACC 18 8158
SCNNlA-4310 - UCCCCCUGCCUAUGCCACC 19 8159
SCNNlA-4311 - CUCCCCCUGCCUAUGCCACC 20 8160
SCNNlA-4312 - CCUCCCCCUGCCUAUGCCACC 21 8161
SCNNlA-4313 - CCCUCCCCCUGCCUAUGCCACC 22 8162
SCNNlA-4314 - CCCCUCCCCCUGCCUAUGCCACC 23 8163
SCNNlA-4315 - GCCCCUCCCCCUGCCUAUGCCACC 24 8164
SCNNlA-4316 - CUCGCCCCUUCAGGUACC 18 8165
1297
5535.1 SCNNlA-4317 - CCUCGCCCCUUCAGGUACC 19 8166
SCNNlA-1007 - CCCUCGCCCCUUCAGGUACC 20 4856
SCNNlA-4318 - CCCCUCGCCCCUUCAGGUACC 21 8167
SCNNlA-4319 - UCCCCUCGCCCCUUCAGGUACC 22 8168
SCNNlA-4320 - UUCCCCUCGCCCCUUCAGGUACC 23 8169
SCNNlA-4321 - CUUCCCCUCGCCCCUUCAGGUACC 24 8170
SCNNlA-4322 - AUCUUCUAUCCGCGGCCC 18 8171
SCNNlA-4323 - CAUCUUCUAUCCGCGGCCC 19 8172
SCNNlA-4324 - ACAUCUUCUAUCCGCGGCCC 20 8173
SCNNlA-4325 - UACAUCUUCUAUCCGCGGCCC 21 8174
SCNNlA-4326 - CUACAUCUUCUAUCCGCGGCCC 22 8175
SCNNlA-4327 - CCUACAUCUUCUAUCCGCGGCCC 23 8176
SCNNlA-4328 - GCCUACAUCUUCUAUCCGCGGCCC 24 8177
SCNNlA-4329 - CAGAGACUCUGCCAUCCC 18 8178
SCNNlA-4330 - CCAGAGACUCUGCCAUCCC 19 8179
SCNNlA-1023 - GCCAGAGACUCUGCCAUCCC 20 4872
SCNNlA-4331 - UGCCAGAGACUCUGCCAUCCC 21 8180
SCNNlA-4332 - CUGCCAGAGACUCUGCCAUCCC 22 8181
SCNNlA-4333 - GCUGCCAGAGACUCUGCCAUCCC 23 8182
SCNNlA-4334 - GGCUGCCAGAGACUCUGCCAUCCC 24 8183
SCNNlA-4335 - GGUGAGGCCCGCAGCGCC 18 8184
SCNNlA-4336 - UGGUGAGGCCCGCAGCGCC 19 8185
SCNNlA-4337 - CUGGUGAGGCCCGCAGCGCC 20 8186
SCNNlA-4338 - GCUGGUGAGGCCCGCAGCGCC 21 8187
SCNNlA-4339 - AGCUGGUGAGGCCCGCAGCGCC 22 8188
SCNNlA-4340 - CAGCUGGUGAGGCCCGCAGCGCC 23 8189
SCNNlA-4341 - CCAGCUGGUGAGGCCCGCAGCGCC 24 8190
SCNNlA-4342 - GAUACUGGUCUCCAGGCC 18 8191
SCNNlA-4343 - CGAUACUGGUCUCCAGGCC 19 8192
SCNNlA-4344 - CCGAUACUGGUCUCCAGGCC 20 8193
SCNNlA-4345 - GCCGAUACUGGUCUCCAGGCC 21 8194
SCNNlA-4346 - AGCCGAUACUGGUCUCCAGGCC 22 8195
SCNNlA-4347 - AAGCCGAUACUGGUCUCCAGGCC 23 8196
SCNNlA-4348 - GAAGCCGAUACUGGUCUCCAGGCC 24 8197
SCNNlA-4349 - GAUGCUGACUGGGAGGCC 18 8198
SCNNlA-4350 - GGAUGCUGACUGGGAGGCC 19 8199
SCNNlA-1028 - AGGAUGCUGACUGGGAGGCC 20 4877
SCNNlA-4351 - AAGGAUGCUGACUGGGAGGCC 21 8200
SCNNlA-4352 - CAAGGAUGCUGACUGGGAGGCC 22 8201
SCNNlA-4353 - GCAAGGAUGCUGACUGGGAGGCC 23 8202
SCNNlA-4354 - GGCAAGGAUGCUGACUGGGAGGCC 24 8203
SCNNlA-4355 - CUGUCCUCUGGGGGGGCC 18 8204
1298
5535.1 SCNNlA-4356 - CCUGUCCUCUGGGGGGGCC 19 8205
SCNNlA-4357 - ACCUGUCCUCUGGGGGGGCC 20 8206
SCNNlA-4358 - CACCUGUCCUCUGGGGGGGCC 21 8207
SCNNlA-4359 - CCACCUGUCCUCUGGGGGGGCC 22 8208
SCNNlA-4360 - UCCACCUGUCCUCUGGGGGGGCC 23 8209
SCNNlA-4361 - CUCCACCUGUCCUCUGGGGGGGCC 24 8210
SCNNlA-4362 - CCAGAGACUCUGCCAUCC 18 8211
SCNNlA-4363 - GCCAGAGACUCUGCCAUCC 19 8212
SCNNlA-4364 - UGCCAGAGACUCUGCCAUCC 20 8213
SCNNlA-4365 - CUGCCAGAGACUCUGCCAUCC 21 8214
SCNNlA-4366 - GCUGCCAGAGACUCUGCCAUCC 22 8215
SCNNlA-4367 - GGCUGCCAGAGACUCUGCCAUCC 23 8216
SCNNlA-4368 - AGGCUGCCAGAGACUCUGCCAUCC 24 8217
SCNNlA-4369 - UUCCUGGGGUGAGACUCC 18 8218
SCNNlA-4370 - GUUCCUGGGGUGAGACUCC 19 8219
SCNNlA-1037 - AGUUCCUGGGGUGAGACUCC 20 4886
SCNNlA-4371 - CAGUUCCUGGGGUGAGACUCC 21 8220
SCNNlA-4372 - ACAGUUCCUGGGGUGAGACUCC 22 8221
SCNNlA-4373 - CACAGUUCCUGGGGUGAGACUCC 23 8222
SCNNlA-4374 - GCACAGUUCCUGGGGUGAGACUCC 24 8223
SCNNlA-4375 - GGGCCCCCGCCCAUCUCC 18 8224
SCNNlA-4376 - UGGGCCCCCGCCCAUCUCC 19 8225
SCNNlA-1040 - CUGGGCCCCCGCCCAUCUCC 20 4889
SCNNlA-4377 - CCUGGGCCCCCGCCCAUCUCC 21 8226
SCNNlA-4378 - CCCUGGGCCCCCGCCCAUCUCC 22 8227
SCNNlA-4379 - ACCCUGGGCCCCCGCCCAUCUCC 23 8228
SCNNlA-4380 - CACCCUGGGCCCCCGCCCAUCUCC 24 8229
SCNNlA-4381 - GUAUUCACUCCUGCUUCC 18 8230
SCNNlA-4382 - UGUAUUCACUCCUGCUUCC 19 8231
SCNNlA-1046 - GUGUAUUCACUCCUGCUUCC 20 4895
SCNNlA-4383 - UGUGUAUUCACUCCUGCUUCC 21 8232
SCNNlA-4384 - GUGUGUAUUCACUCCUGCUUCC 22 8233
SCNNlA-4385 - GGUGUGUAUUCACUCCUGCUUCC 23 8234
SCNNlA-4386 - AGGUGUGUAUUCACUCCUGCUUCC 24 8235
SCNNlA-4387 - GACACCCCCAUUCUUUCC 18 8236
SCNNlA-4388 - UGACACCCCCAUUCUUUCC 19 8237
SCNNlA-4389 - AUGACACCCCCAUUCUUUCC 20 8238
SCNNlA-4390 - GAUGACACCCCCAUUCUUUCC 21 8239
SCNNlA-4391 - UGAUGACACCCCCAUUCUUUCC 22 8240
SCNNlA-4392 - UUGAUGACACCCCCAUUCUUUCC 23 8241
SCNNlA-4393 - CUUGAUGACACCCCCAUUCUUUCC 24 8242
SCNNlA-4394 - GUGGAGACCUCCAUCAGC 18 8243
1299
5535.1 SCNNlA-4395 - CGUGGAGACCUCCAUCAGC 19 8244
SCNNlA-4396 - GCGUGGAGACCUCCAUCAGC 20 8245
SCNNlA-4397 - GGCGUGGAGACCUCCAUCAGC 21 8246
SCNNlA-4398 - UGGCGUGGAGACCUCCAUCAGC 22 8247
SCNNlA-4399 - CUGGCGUGGAGACCUCCAUCAGC 23 8248
SCNNlA-4400 - CCUGGCGUGGAGACCUCCAUCAGC 24 8249
SCNNlA-4401 - CGGAAAUUAAAGAGGAGC 18 8250
SCNNlA-4402 - CCGGAAAUUAAAGAGGAGC 19 8251
SCNNlA-1058 - CCCGGAAAUUAAAGAGGAGC 20 4907
SCNNlA-4403 - ACCCGGAAAUUAAAGAGGAGC 21 8252
SCNNlA-4404 - UACCCGGAAAUUAAAGAGGAGC 22 8253
SCNNlA-4405 - GUACCCGGAAAUUAAAGAGGAGC 23 8254
SCNNlA-4406 - GGUACCCGGAAAUUAAAGAGGAGC 24 8255
SCNNlA-4407 - CCGCACCCCUUGCAGCGC 18 8256
SCNNlA-4408 - GCCGCACCCCUUGCAGCGC 19 8257
SCNNlA-4409 - UGCCGCACCCCUUGCAGCGC 20 8258
SCNNlA-4410 - CUGCCGCACCCCUUGCAGCGC 21 8259
SCNNlA-4411 - UCUGCCGCACCCCUUGCAGCGC 22 8260
SCNNlA-4412 - CUCUGCCGCACCCCUUGCAGCGC 23 8261
SCNNlA-4413 - ACUCUGCCGCACCCCUUGCAGCGC 24 8262
SCNNlA-4414 - GGAUGCUGACUGGGAGGC 18 8263
SCNNlA-4415 - AGGAUGCUGACUGGGAGGC 19 8264
SCNNlA-4416 - AAGGAUGCUGACUGGGAGGC 20 8265
SCNNlA-4417 - CAAGGAUGCUGACUGGGAGGC 21 8266
SCNNlA-4418 - GCAAGGAUGCUGACUGGGAGGC 22 8267
SCNNlA-4419 - GGCAAGGAUGCUGACUGGGAGGC 23 8268
SCNNlA-4420 - AGGCAAGGAUGCUGACUGGGAGGC 24 8269
SCNNlA-4421 - UUUAACUUGCGGCCUGGC 18 8270
SCNNlA-4422 - CUUUAACUUGCGGCCUGGC 19 8271
SCNNlA-4423 - GCUUUAACUUGCGGCCUGGC 20 8272
SCNNlA-4424 - GGCUUUAACUUGCGGCCUGGC 21 8273
SCNNlA-4425 - UGGCUUUAACUUGCGGCCUGGC 22 8274
SCNNlA-4426 - GUGGCUUUAACUUGCGGCCUGGC 23 8275
SCNNlA-4427 - GGUGGCUUUAACUUGCGGCCUGGC 24 8276
SCNNlA-4428 - UCUGGAUGUCUUCCAUGC 18 8277
SCNNlA-4429 - CUCUGGAUGUCUUCCAUGC 19 8278
SCNNlA-4430 - CCUCUGGAUGUCUUCCAUGC 20 8279
SCNNlA-4431 - ACCUCUGGAUGUCUUCCAUGC 21 8280
SCNNlA-4432 - AACCUCUGGAUGUCUUCCAUGC 22 8281
SCNNlA-4433 - CAACCUCUGGAUGUCUUCCAUGC 23 8282
SCNNlA-4434 - CCAACCUCUGGAUGUCUUCCAUGC 24 8283
SCNNlA-4435 - GCAGCCGUCGCGACCUGC 18 8284
1300
5535.1 SCNNlA-4436 - CGCAGCCGUCGCGACCUGC 19 8285
SCNNlA-1079 - CCGCAGCCGUCGCGACCUGC 20 4928
SCNNlA-4437 - CCCGCAGCCGUCGCGACCUGC 21 8286
SCNNlA-4438 - UCCCGCAGCCGUCGCGACCUGC 22 8287
SCNNlA-4439 - CUCCCGCAGCCGUCGCGACCUGC 23 8288
SCNNlA-4440 - GCUCCCGCAGCCGUCGCGACCUGC 24 8289
SCNNlA-4441 - ACAUCCUGUCGAGGCUGC 18 8290
SCNNlA-4442 - AACAUCCUGUCGAGGCUGC 19 8291
SCNNlA-4443 - CAACAUCCUGUCGAGGCUGC 20 8292
SCNNlA-4444 - UCAACAUCCUGUCGAGGCUGC 21 8293
SCNNlA-4445 - AUCAACAUCCUGUCGAGGCUGC 22 8294
SCNNlA-4446 - CAUCAACAUCCUGUCGAGGCUGC 23 8295
SCNNlA-4447 - ACAUCAACAUCCUGUCGAGGCUGC 24 8296
SCNNlA-4448 - AUCUCCAGGGGGCUCUGC 18 8297
SCNNlA-4449 - CAUCUCCAGGGGGCUCUGC 19 8298
SCNNlA-1083 - CCAUCUCCAGGGGGCUCUGC 20 4932
SCNNlA-4450 - CCCAUCUCCAGGGGGCUCUGC 21 8299
SCNNlA-4451 - GCCCAUCUCCAGGGGGCUCUGC 22 8300
SCNNlA-4452 - CGCCCAUCUCCAGGGGGCUCUGC 23 8301
SCNNlA-4453 - CCGCCCAUCUCCAGGGGGCUCUGC 24 8302
SCNNlA-4454 - GGCUGUUUCACCAAGUGC 18 8303
SCNNlA-4455 - GGGCUGUUUCACCAAGUGC 19 8304
SCNNlA-1085 - UGGGCUGUUUCACCAAGUGC 20 4934
SCNNlA-4456 - CUGGGCUGUUUCACCAAGUGC 21 8305
SCNNlA-4457 - CCUGGGCUGUUUCACCAAGUGC 22 8306
SCNNlA-4458 - ACCUGGGCUGUUUCACCAAGUGC 23 8307
SCNNlA-4459 - CACCUGGGCUGUUUCACCAAGUGC 24 8308
SCNNlA-4460 - GGGCCCGGGUAAUGGUGC 18 8309
SCNNlA-4461 - GGGGCCCGGGUAAUGGUGC 19 8310
SCNNlA-4462 - UGGGGCCCGGGUAAUGGUGC 20 8311
SCNNlA-4463 - CUGGGGCCCGGGUAAUGGUGC 21 8312
SCNNlA-4464 - ACUGGGGCCCGGGUAAUGGUGC 22 8313
SCNNlA-4465 - GACUGGGGCCCGGGUAAUGGUGC 23 8314
SCNNlA-4466 - UGACUGGGGCCCGGGUAAUGGUGC 24 8315
SCNNlA-4467 - UUCCAGGAGAGCAUGAUC 18 8316
SCNNlA-4468 - CUUCCAGGAGAGCAUGAUC 19 8317
SCNNlA-4469 - GCUUCCAGGAGAGCAUGAUC 20 8318
SCNNlA-4470 - UGCUUCCAGGAGAGCAUGAUC 21 8319
SCNNlA-4471 - CUGCUUCCAGGAGAGCAUGAUC 22 8320
SCNNlA-4472 - CCUGCUUCCAGGAGAGCAUGAUC 23 8321
SCNNlA-4473 - UCCUGCUUCCAGGAGAGCAUGAUC 24 8322
SCNNlA-4474 - GUUCCUGGGGUGAGACUC 18 8323
1301
5535.1 SCNNlA-4475 - AGUUCCUGGGGUGAGACUC 19 8324
SCNNlA-4476 - CAGUUCCUGGGGUGAGACUC 20 8325
SCNNlA-4477 - ACAGUUCCUGGGGUGAGACUC 21 8326
SCNNlA-4478 - CACAGUUCCUGGGGUGAGACUC 22 8327
SCNNlA-4479 - GCACAGUUCCUGGGGUGAGACUC 23 8328
SCNNlA-4480 - AGCACAGUUCCUGGGGUGAGACUC 24 8329
SCNNlA-4481 - GGGUCCCGCCCCCGCCUC 18 8330
SCNNlA-4482 - AGGGUCCCGCCCCCGCCUC 19 8331
SCNNlA-4483 - GAGGGUCCCGCCCCCGCCUC 20 8332
SCNNlA-4484 - UGAGGGUCCCGCCCCCGCCUC 21 8333
SCNNlA-4485 - CUGAGGGUCCCGCCCCCGCCUC 22 8334
SCNNlA-4486 - CCUGAGGGUCCCGCCCCCGCCUC 23 8335
SCNNlA-4487 - GCCUGAGGGUCCCGCCCCCGCCUC 24 8336
SCNNlA-4488 - GUUCCUCCACCUGUCCUC 18 8337
SCNNlA-4489 - AGUUCCUCCACCUGUCCUC 19 8338
SCNNlA-1095 - CAGUUCCUCCACCUGUCCUC 20 4944
SCNNlA-4490 - CCAGUUCCUCCACCUGUCCUC 21 8339
SCNNlA-4491 - GCCAGUUCCUCCACCUGUCCUC 22 8340
SCNNlA-4492 - GGCCAGUUCCUCCACCUGUCCUC 23 8341
SCNNlA-4493 - GGGCCAGUUCCUCCACCUGUCCUC 24 8342
SCNNlA-4494 - GAGGGGGCAGGGGUGCUC 18 8343
SCNNlA-4495 - CGAGGGGGCAGGGGUGCUC 19 8344
SCNNlA-1096 - CCGAGGGGGCAGGGGUGCUC 20 4945
SCNNlA-4496 - GCCGAGGGGGCAGGGGUGCUC 21 8345
SCNNlA-4497 - GGCCGAGGGGGCAGGGGUGCUC 22 8346
SCNNlA-4498 - AGGCCGAGGGGGCAGGGGUGCUC 23 8347
SCNNlA-4499 - CAGGCCGAGGGGGCAGGGGUGCUC 24 8348
SCNNlA-4500 - UGGGCCCCCGCCCAUCUC 18 8349
SCNNlA-4501 - CUGGGCCCCCGCCCAUCUC 19 8350
SCNNlA-4502 - CCUGGGCCCCCGCCCAUCUC 20 8351
SCNNlA-4503 - CCCUGGGCCCCCGCCCAUCUC 21 8352
SCNNlA-4504 - ACCCUGGGCCCCCGCCCAUCUC 22 8353
SCNNlA-4505 - CACCCUGGGCCCCCGCCCAUCUC 23 8354
SCNNlA-4506 - CCACCCUGGGCCCCCGCCCAUCUC 24 8355
SCNNlA-4507 - UGUAUUCACUCCUGCUUC 18 8356
SCNNlA-4508 - GUGUAUUCACUCCUGCUUC 19 8357
SCNNlA-4509 - UGUGUAUUCACUCCUGCUUC 20 8358
SCNNlA-4510 - GUGUGUAUUCACUCCUGCUUC 21 8359
SCNNlA-4511 - GGUGUGUAUUCACUCCUGCUUC 22 8360
SCNNlA-4512 - AGGUGUGUAUUCACUCCUGCUUC 23 8361
SCNNlA-4513 - CAGGUGUGUAUUCACUCCUGCUUC 24 8362
SCNNlA-4514 - AAAGUCAACAUCUUCUUC 18 8363
1302
5535.1 SCNNlA-4515 - CAAAGUCAACAUCUUCUUC 19 8364
SCNNlA-4516 - CCAAAGUCAACAUCUUCUUC 20 8365
SCNNlA-4517 - GCCAAAGUCAACAUCUUCUUC 21 8366
SCNNlA-4518 - GGCCAAAGUCAACAUCUUCUUC 22 8367
SCNNlA-4519 - UGGCCAAAGUCAACAUCUUCUUC 23 8368
SCNNlA-4520 - GUGGCCAAAGUCAACAUCUUCUUC 24 8369
SCNNlA-4521 - CUACAGAAAGCACAGUUC 18 8370
SCNNlA-4522 - ACUACAGAAAG CACAG U U C 19 8371
SCNNlA-4523 - GACUACAGAAAGCACAGUUC 20 8372
SCNNlA-4524 - UGACUACAGAAAGCACAGUUC 21 8373
SCNNlA-4525 - G UG ACUACAGAAAG CACAG U U C 22 8374
SCNNlA-4526 - UGUGACUACAGAAAGCACAGUUC 23 8375
SCNNlA-4527 - CUGUGACUACAGAAAGCACAGUUC 24 8376
SCNNlA-4528 - GGUACCCGGAAAUUAAAG 18 8377
SCNNlA-4529 - AGG U ACCCGG AAAU UAAAG 19 8378
SCNNlA-1106 - CAGG U ACCCGG AAAU UAAAG 20 4955
SCNNlA-4530 - U CAGG U ACCCGG AAAU UAAAG 21 8379
SCNNlA-4531 - U U CAGG U ACCCGG AAAU UAAAG 22 8380
SCNNlA-4532 - CU U CAGG U ACCCGG AAAU UAAAG 23 8381
SCNNlA-4533 - CCUUCAGGUACCCGGAAAUUAAAG 24 8382
SCNNlA-4534 - GGGGCCCUGAGAGGGAAG 18 8383
SCNNlA-4535 - GGGGGCCCUGAGAGGGAAG 19 8384
SCNNlA-4536 - GGGGGGCCCUGAGAGGGAAG 20 8385
SCNNlA-4537 - GGGGGGGCCCUGAGAGGGAAG 21 8386
SCNNlA-4538 - UGGGGGGGCCCUGAGAGGGAAG 22 8387
SCNNlA-4539 - CUGGGGGGGCCCUGAGAGGGAAG 23 8388
SCNNlA-4540 - UCUGGGGGGGCCCUGAGAGGGAAG 24 8389
SCNNlA-4541 - CGGGACAACAACCCCCAG 18 8390
SCNNlA-4542 - GCGGGACAACAACCCCCAG 19 8391
SCNNlA-4543 - UGCGGGACAACAACCCCCAG 20 8392
SCNNlA-4544 - UUGCGGGACAACAACCCCCAG 21 8393
SCNNlA-4545 - CUUGCGGGACAACAACCCCCAG 22 8394
SCNNlA-4546 - GCUUGCGGGACAACAACCCCCAG 23 8395
SCNNlA-4547 - AGCUUGCGGGACAACAACCCCCAG 24 8396
SCNNlA-4548 - UCCAACCUGGGCAGCCAG 18 8397
SCNNlA-4549 - GUCCAACCUGGGCAGCCAG 19 8398
SCNNlA-1116 - UGUCCAACCUGGGCAGCCAG 20 4965
SCNNlA-4550 - CUGUCCAACCUGGGCAGCCAG 21 8399
SCNNlA-4551 - CCUGUCCAACCUGGGCAGCCAG 22 8400
SCNNlA-4552 - UCCUGUCCAACCUGGGCAGCCAG 23 8401
SCNNlA-4553 - CUCCUGUCCAACCUGGGCAGCCAG 24 8402
SCNNlA-4554 - AUUCACUCCUGCUUCCAG 18 8403
1303
5535.1 SCNNlA-4555 - UAUUCACUCCUGCUUCCAG 19 8404
SCNNlA-4556 - GUAUUCACUCCUGCUUCCAG 20 8405
SCNNlA-4557 - UGUAUUCACUCCUGCUUCCAG 21 8406
SCNNlA-4558 - GUGUAUUCACUCCUGCUUCCAG 22 8407
SCNNlA-4559 - UGUGUAUUCACUCCUGCUUCCAG 23 8408
SCNNlA-4560 - GUGUGUAUUCACUCCUGCUUCCAG 24 8409
SCNNlA-4561 - U CAAAG U ACAC ACAG CAG 18 8410
SCNNlA-4562 - U U CAAAG U ACACACAG CAG 19 8411
SCNNlA-4563 - C U U CAAAG U ACAC ACAG CAG 20 8412
SCNNlA-4564 - CCU U CAAAG U ACACACAG CAG 21 8413
SCNNlA-4565 - CCCU U CAAAG U ACACACAGCAG 22 8414
SCNNlA-4566 - ACCCU U CAAAG U ACACACAGCAG 23 8415
SCNNlA-4567 - U ACCCU U CAAAG U ACACACAG CAG 24 8416
SCNNlA-4568 - AACAUCUUCUUCAAGGAG 18 8417
SCNNlA-4569 - CAACAUCUUCUUCAAGGAG 19 8418
SCNNlA-4570 - UCAACAUCUUCUUCAAGGAG 20 8419
SCNNlA-4571 - GUCAACAUCUUCUUCAAGGAG 21 8420
SCNNlA-4572 - AGUCAACAUCUUCUUCAAGGAG 22 8421
SCNNlA-4573 - AAGUCAACAUCUUCUUCAAGGAG 23 8422
SCNNlA-4574 - AAAG U CAAC AU CU U C U U CAAG GAG 24 8423
SCNNlA-4575 - CCGGAAAU U AAAG AGG AG 18 8424
SCNNlA-4576 - CCCGG AAAU U AAAG AGG AG 19 8425
SCNNlA-4577 - ACCCGGAAAUUAAAGAGGAG 20 8426
SCNNlA-4578 - U ACCCGG AAAU U AAAG AGG AG 21 8427
SCNNlA-4579 - GUACCCGGAAAUUAAAGAGGAG 22 8428
SCNNlA-4580 - GGU ACCCGGAAAUUAAAGAGGAG 23 8429
SCNNlA-4581 - AGGUACCCGGAAAUUAAAGAGGAG 24 8430
SCNNlA-4582 - AAAGAGGAGCUGGAGGAG 18 8431
SCNNlA-4583 - UAAAGAGGAGCUGGAGGAG 19 8432
SCNNlA-4584 - UUAAAGAGGAGCUGGAGGAG 20 8433
SCNNlA-4585 - AUUAAAGAGGAGCUGGAGGAG 21 8434
SCNNlA-4586 - AAUUAAAGAGGAGCUGGAGGAG 22 8435
SCNNlA-4587 - AAAUUAAAGAGGAGCUGGAGGAG 23 8436
SCNNlA-4588 - GAAAUUAAAGAGGAGCUGGAGGAG 24 8437
SCNNlA-4589 - ACUCUGCCAUCCCUGGAG 18 8438
SCNNlA-4590 - GACUCUGCCAUCCCUGGAG 19 8439
SCNNlA-4591 - AGACUCUGCCAUCCCUGGAG 20 8440
SCNNlA-4592 - GAGACUCUGCCAUCCCUGGAG 21 8441
SCNNlA-4593 - AGAGACUCUGCCAUCCCUGGAG 22 8442
SCNNlA-4594 - CAGAGACUCUGCCAUCCCUGGAG 23 8443
SCNNlA-4595 - CCAGAGACUCUGCCAUCCCUGGAG 24 8444
SCNNlA-4596 - CUCUGGGGGGGCCCUGAG 18 8445
1304
5535.1 SCNNlA-4597 - CCUCUGGGGGGGCCCUGAG 19 8446
SCNNlA-1140 - UCCUCUGGGGGGGCCCUGAG 20 4989
SCNNlA-4598 - GUCCUCUGGGGGGGCCCUGAG 21 8447
SCNNlA-4599 - UGUCCUCUGGGGGGGCCCUGAG 22 8448
SCNNlA-4600 - CUGUCCUCUGGGGGGGCCCUGAG 23 8449
SCNNlA-4601 - CCUGUCCUCUGGGGGGGCCCUGAG 24 8450
SCNNlA-4602 - UGCCUGGAAUCAACAACG 18 8451
SCNNlA-4603 - AUGCCUGGAAUCAACAACG 19 8452
SCNNlA-4604 - CAUGCCUGGAAUCAACAACG 20 8453
SCNNlA-4605 - CCAUGCCUGGAAUCAACAACG 21 8454
SCNNlA-4606 - UCCAUGCCUGGAAUCAACAACG 22 8455
SCNNlA-4607 - UUCCAUGCCUGGAAUCAACAACG 23 8456
SCNNlA-4608 - CUUCCAUGCCUGGAAUCAACAACG 24 8457
SCNNlA-4609 - UCCCUGGAGGAGGACACG 18 8458
SCNNlA-4610 - AUCCCUGGAGGAGGACACG 19 8459
SCNNlA-4611 - CAUCCCUGGAGGAGGACACG 20 8460
SCNNlA-4612 - CCAUCCCUGGAGGAGGACACG 21 8461
SCNNlA-4613 - GCCAUCCCUGGAGGAGGACACG 22 8462
SCNNlA-4614 - UGCCAUCCCUGGAGGAGGACACG 23 8463
SCNNlA-4615 - CUGCCAUCCCUGGAGGAGGACACG 24 8464
SCNNlA-4616 - CCCGCCUCACGGGGCCCG 18 8465
SCNNlA-4617 - CCCCGCCUCACGGGGCCCG 19 8466
SCNNlA-4618 - CCCCCGCCUCACGGGGCCCG 20 8467
SCNNlA-4619 - GCCCCCGCCUCACGGGGCCCG 21 8468
SCNNlA-4620 - CGCCCCCGCCUCACGGGGCCCG 22 8469
SCNNlA-4621 - CCGCCCCCGCCUCACGGGGCCCG 23 8470
SCNNlA-4622 - CCCGCCCCCGCCUCACGGGGCCCG 24 8471
SCNNlA-4623 - GUGAGGCCCGCAGCGCCG 18 8472
SCNNlA-4624 - GGUGAGGCCCGCAGCGCCG 19 8473
SCNNlA-1148 - UGGUGAGGCCCGCAGCGCCG 20 4997
SCNNlA-4625 - CUGGUGAGGCCCGCAGCGCCG 21 8474
SCNNlA-4626 - GCUGGUGAGGCCCGCAGCGCCG 22 8475
SCNNlA-4627 - AGCUGGUGAGGCCCGCAGCGCCG 23 8476
SCNNlA-4628 - CAGCUGGUGAGGCCCGCAGCGCCG 24 8477
SCNNlA-4629 - AUACUGGUCUCCAGGCCG 18 8478
SCNNlA-4630 - GAUACUGGUCUCCAGGCCG 19 8479
SCNNlA-1149 - CGAUACUGGUCUCCAGGCCG 20 4998
SCNNlA-4631 - CCGAUACUGGUCUCCAGGCCG 21 8480
SCNNlA-4632 - GCCGAUACUGGUCUCCAGGCCG 22 8481
SCNNlA-4633 - AGCCGAUACUGGUCUCCAGGCCG 23 8482
SCNNlA-4634 - AAGCCGAUACUGGUCUCCAGGCCG 24 8483
SCNNlA-4635 - CUGGUGAGGCCCGCAGCG 18 8484
1305
5535.1 SCNNlA-4636 - GCUGGUGAGGCCCGCAGCG 19 8485
SCNNlA-4637 - AGCUGGUGAGGCCCGCAGCG 20 8486
SCNNlA-4638 - CAGCUGGUGAGGCCCGCAGCG 21 8487
SCNNlA-4639 - CCAGCUGGUGAGGCCCGCAGCG 22 8488
SCNNlA-4640 - UCCAGCUGGUGAGGCCCGCAGCG 23 8489
SCNNlA-4641 - UUCCAGCUGGUGAGGCCCGCAGCG 24 8490
SCNNlA-4642 - UGUCCCUGAUGCUGCGCG 18 8491
SCNNlA-4643 - CUGUCCCUGAUGCUGCGCG 19 8492
SCNNlA-4644 - UCUGUCCCUGAUGCUGCGCG 20 8493
SCNNlA-4645 - GUCUGUCCCUGAUGCUGCGCG 21 8494
SCNNlA-4646 - GGUCUGUCCCUGAUGCUGCGCG 22 8495
SCNNlA-4647 - AGGUCUGUCCCUGAUGCUGCGCG 23 8496
SCNNlA-4648 - UAGGUCUGUCCCUGAUGCUGCGCG 24 8497
SCNNlA-4649 - UUAACUUGCGGCCUGGCG 18 8498
SCNNlA-4650 - UUUAACUUGCGGCCUGGCG 19 8499
SCNNlA-1157 - CUUUAACUUGCGGCCUGGCG 20 5006
SCNNlA-4651 - GCUUUAACUUGCGGCCUGGCG 21 8500
SCNNlA-4652 - GGCUUUAACUUGCGGCCUGGCG 22 8501
SCNNlA-4653 - UGGCUUUAACUUGCGGCCUGGCG 23 8502
SCNNlA-4654 - GUGGCUUUAACUUGCGGCCUGGCG 24 8503
SCNNlA-4655 - UCAUCAGGGGUGGAUGCG 18 8504
SCNNlA-4656 - CUCAUCAGGGGUGGAUGCG 19 8505
SCNNlA-4657 - ACUCAUCAGGGGUGGAUGCG 20 8506
SCNNlA-4658 - UACUCAUCAGGGGUGGAUGCG 21 8507
SCNNlA-4659 - AUACUCAUCAGGGGUGGAUGCG 22 8508
SCNNlA-4660 - CAUACUCAUCAGGGGUGGAUGCG 23 8509
SCNNlA-4661 - ACAUACUCAUCAGGGGUGGAUGCG 24 8510
SCNNlA-4662 - CAGCCGUCGCGACCUGCG 18 8511
SCNNlA-4663 - GCAGCCGUCGCGACCUGCG 19 8512
SCNNlA-1158 - CGCAGCCGUCGCGACCUGCG 20 5007
SCNNlA-4664 - CCGCAGCCGUCGCGACCUGCG 21 8513
SCNNlA-4665 - CCCGCAGCCGUCGCGACCUGCG 22 8514
SCNNlA-4666 - UCCCGCAGCCGUCGCGACCUGCG 23 8515
SCNNlA-4667 - CUCCCGCAGCCGUCGCGACCUGCG 24 8516
SCNNlA-4668 - CCGAUACUGGUCUCCAGG 18 8517
SCNNlA-4669 - GCCGAUACUGGUCUCCAGG 19 8518
SCNNlA-4670 - AGCCGAUACUGGUCUCCAGG 20 8519
SCNNlA-4671 - AAGCCGAUACUGGUCUCCAGG 21 8520
SCNNlA-4672 - GAAGCCGAUACUGGUCUCCAGG 22 8521
SCNNlA-4673 - CGAAGCCGAUACUGGUCUCCAGG 23 8522
SCNNlA-4674 - CCGAAGCCGAUACUGGUCUCCAGG 24 8523
SCNNlA-4675 - UAAUGGUGCACGGGCAGG 18 8524
1306
5535.1 SCNNlA-4676 - GUAAUGGUGCACGGGCAGG 19 8525
SCNNlA-4677 - GGUAAUGGUGCACGGGCAGG 20 8526
SCNNlA-4678 - GGGUAAUGGUGCACGGGCAGG 21 8527
SCNNlA-4679 - CGGGUAAUGGUGCACGGGCAGG 22 8528
SCNNlA-4680 - CCGGGUAAUGGUGCACGGGCAGG 23 8529
SCNNlA-4681 - CCCGGGUAAUGGUGCACGGGCAGG 24 8530
SCNNlA-4682 - GGGGGGGCCCUGAGAGGG 18 8531
SCNNlA-4683 - UGGGGGGGCCCUGAGAGGG 19 8532
SCNNlA-4684 - CUGGGGGGGCCCUGAGAGGG 20 8533
SCNNlA-4685 - UCUGGGGGGGCCCUGAGAGGG 21 8534
SCNNlA-4686 - CUCUGGGGGGGCCCUGAGAGGG 22 8535
SCNNlA-4687 - CCUCUGGGGGGGCCCUGAGAGGG 23 8536
SCNNlA-4688 - UCCUCUGGGGGGGCCCUGAGAGGG 24 8537
SCNNlA-4689 - GUCUCCAGGCCGAGGGGG 18 8538
SCNNlA-4690 - GGUCUCCAGGCCGAGGGGG 19 8539
SCNNlA-4691 - UGGUCUCCAGGCCGAGGGGG 20 8540
SCNNlA-4692 - CUGGUCUCCAGGCCGAGGGGG 21 8541
SCNNlA-4693 - ACUGGUCUCCAGGCCGAGGGGG 22 8542
SCNNlA-4694 - UACUGGUCUCCAGGCCGAGGGGG 23 8543
SCNNlA-4695 - AUACUGGUCUCCAGGCCGAGGGGG 24 8544
SCNNlA-4696 - CCCAGGUAGAGUGUGGGG 18 8545
SCNNlA-4697 - UCCCAGGUAGAGUGUGGGG 19 8546
SCNNlA-4698 - AUCCCAGGUAGAGUGUGGGG 20 8547
SCNNlA-4699 - CAUCCCAGGUAGAGUGUGGGG 21 8548
SCNNlA-4700 - ACAUCCCAGGUAGAGUGUGGGG 22 8549
SCNNlA-4701 - GACAUCCCAGGUAGAGUGUGGGG 23 8550
SCNNlA-4702 - UGACAUCCCAGGUAGAGUGUGGGG 24 8551
SCNNlA-4703 - GUGUGGGGAAGGGAUGGG 18 8552
SCNNlA-4704 - AGUGUGGGGAAGGGAUGGG 19 8553
SCNNlA-1189 - GAGUGUGGGGAAGGGAUGGG 20 5038
SCNNlA-4705 - AGAGUGUGGGGAAGGGAUGGG 21 8554
SCNNlA-4706 - UAGAGUGUGGGGAAGGGAUGGG 22 8555
SCNNlA-4707 - GUAGAGUGUGGGGAAGGGAUGGG 23 8556
SCNNlA-4708 - GGUAGAGUGUGGGGAAGGGAUGGG 24
8557
SCNNlA-4709 - GAAAGCACAGUUCCUGGG 18 8558
SCNNlA-4710 - AGAAAGCACAGUUCCUGGG 19 8559
SCNNlA-4711 - CAGAAAGCACAGUUCCUGGG 20 8560
SCNNlA-4712 - ACAGAAAGCACAGUUCCUGGG 21 8561
SCNNlA-4713 - UACAGAAAGCACAGUUCCUGGG 22 8562
SCNNlA-4714 - CUACAGAAAGCACAGUUCCUGGG 23 8563
SCNNlA-4715 - ACUACAGAAAGCACAGUUCCUGGG 24 8564
1307
5535.1 SCNNlA-4716 - UGUCUGUGGUGGAGAUGG 18 8565
SCNNlA-4717 - UUGUCUGUGGUGGAGAUGG 19 8566
SCNNlA-4718 - GUUGUCUGUGGUGGAGAUGG 20 8567
SCNNlA-4719 - UGUUGUCUGUGGUGGAGAUGG 21 8568
SCNNlA-4720 - GUGUUGUCUGUGGUGGAGAUGG 22 8569
SCNNlA-4721 - GGUGUUGUCUGUGGUGGAGAUGG 23 8570
SCNNlA-4722 - CGGUGUUGUCUGUGGUGGAGAUGG 24
8571
SCNNlA-4723 - AGUGUGGGGAAGGGAUGG 18 8572
SCNNlA-4724 - GAGUGUGGGGAAGGGAUGG 19 8573
SCNNlA-4725 - AGAGUGUGGGGAAGGGAUGG 20 8574
SCNNlA-4726 - UAGAGUGUGGGGAAGGGAUGG 21 8575
SCNNlA-4727 - GUAGAGUGUGGGGAAGGGAUGG 22 8576
SCNNlA-4728 - GGUAGAGUGUGGGGAAGGGAUGG 23 8577
SCNNlA-4729 - AGGUAGAGUGUGGGGAAGGGAUGG 24
8578
SCNNlA-4730 - AACCCCCAGGUGGACUGG 18 8579
SCNNlA-4731 - CAACCCCCAGGUGGACUGG 19 8580
SCNNlA-4732 - ACAACCCCCAGGUGGACUGG 20 8581
SCNNlA-4733 - AACAACCCCCAGGUGGACUGG 21 8582
SCNNlA-4734 - CAACAACCCCCAGGUGGACUGG 22 8583
SCNNlA-4735 - ACAACAACCCCCAGGUGGACUGG 23 8584
SCNNlA-4736 - GACAA CAACCCCCAGGUGGACUGG 24 8585
SCNNlA-4737 - AGACUCUGCCAUCCCUGG 18 8586
SCNNlA-4738 - GAGACUCUGCCAUCCCUGG 19 8587
SCNNlA-1196 - AGAGACUCUGCCAUCCCUGG 20 5045
SCNNlA-4739 - CAGAGACUCUGCCAUCCCUGG 21 8588
SCNNlA-4740 - CCAGAGACUCUGCCAUCCCUGG 22 8589
SCNNlA-4741 - GCCAGAGACUCUGCCAUCCCUGG 23 8590
SCNNlA-4742 - UGCCAGAGACUCUGCCAUCCCUGG 24 8591
SCNNlA-4743 - ACGGUAGGUCGUGCCUGG 18 8592
SCNNlA-4744 - CACGGUAGGUCGUGCCUGG 19 8593
SCNNlA-4745 - UCACGGUAGGUCGUGCCUGG 20 8594
SCNNlA-4746 - GUCACGGUAGGUCGUGCCUGG 21 8595
SCNNlA-4747 - UGUCACGGUAGGUCGUGCCUGG 22 8596
SCNNlA-4748 - CUGUCACGGUAGGUCGUGCCUGG 23 8597
SCNNlA-4749 - UCUGUCACGGUAGGUCGUGCCUGG 24 8598
SCNNlA-4750 - AAAUUAAAGAGGAGCUGG 18 8599
SCNNlA-4751 - GAAAUUAAAGAGGAGCUGG 19 8600
SCNNlA-1198 - GGAAAUUAAAGAGGAGCUGG 20 5047
SCNNlA-4752 - CGGAAAUUAAAGAGGAGCUGG 21 8601
SCNNlA-4753 - CCGGAAAUUAAAGAGGAGCUGG 22 8602
1308
5535.1 SCNNlA-4754 - CCCGGAAAUUAAAGAGGAGCUGG 23 8603
SCNNlA-4755 - ACCCGGAAAUUAAAGAGGAGCUGG 24 8604
SCNNlA-4756 - CCUCCACCUGUCCUCUGG 18 8605
SCNNlA-4757 - UCCUCCACCUGUCCUCUGG 19 8606
SCNNlA-1199 - UUCCUCCACCUGUCCUCUGG 20 5048
SCNNlA-4758 - GUUCCUCCACCUGUCCUCUGG 21 8607
SCNNlA-4759 - AGUUCCUCCACCUGUCCUCUGG 22 8608
SCNNlA-4760 - CAGUUCCUCCACCUGUCCUCUGG 23 8609
SCNNlA-4761 - CCAGUUCCUCCACCUGUCCUCUGG 24 8610
SCNNlA-4762 - CCUCGGUGUUGUCUGUGG 18 8611
SCNNlA-4763 - UCCUCGGUGUUGUCUGUGG 19 8612
SCNNlA-1205 - CUCCUCGGUGUUGUCUGUGG 20 5054
SCNNlA-4764 - GCUCCUCGGUGUUGUCUGUGG 21 8613
SCNNlA-4765 - GGCUCCUCGGUGUUGUCUGUGG 22 8614
SCNNlA-4766 - CGGCUCCUCGGUGUUGUCUGUGG 23 8615
SCNNlA-4767 - UCGGCUCCUCGGUGUUGUCUGUGG 24 8616
SCNNlA-4768 - GAGACCUCCAUCAGCAUG 18 8617
SCNNlA-4769 - GGAGACCUCCAUCAGCAUG 19 8618
SCNNlA-1210 - UGGAGACCUCCAUCAGCAUG 20 5059
SCNNlA-4770 - GUGGAGACCUCCAUCAGCAUG 21 8619
SCNNlA-4771 - CGUGGAGACCUCCAUCAGCAUG 22 8620
SCNNlA-4772 - GCGUGGAGACCUCCAUCAGCAUG 23 8621
SCNNlA-4773 - GGCGUGGAGACCUCCAUCAGCAUG 24 8622
SCNNlA-4774 - CGCAGCCGUCGCGACCUG 18 8623
SCNNlA-4775 - CCGCAGCCGUCGCGACCUG 19 8624
SCNNlA-1216 - CCCGCAGCCGUCGCGACCUG 20 5065
SCNNlA-4776 - UCCCGCAGCCGUCGCGACCUG 21 8625
SCNNlA-4777 - CUCCCGCAGCCGUCGCGACCUG 22 8626
SCNNlA-4778 - GCUCCCGCAGCCGUCGCGACCUG 23 8627
SCNNlA-4779 - GGCUCCCGCAGCCGUCGCGACCUG 24 8628
SCNNlA-4780 - GAGACUCUGCCAUCCCUG 18 8629
SCNNlA-4781 - AGAGACUCUGCCAUCCCUG 19 8630
SCNNlA-4782 - CAGAGACUCUGCCAUCCCUG 20 8631
SCNNlA-4783 - CCAGAGACUCUGCCAUCCCUG 21 8632
SCNNlA-4784 - GCCAGAGACUCUGCCAUCCCUG 22 8633
SCNNlA-4785 - UGCCAGAGACUCUGCCAUCCCUG 23 8634
SCNNlA-4786 - CUGCCAGAGACUCUGCCAUCCCUG 24 8635
SCNNlA-4787 - CACUACAUCAACAUCCUG 18 8636
SCNNlA-4788 - CCACUACAUCAACAUCCUG 19 8637
SCNNlA-4789 - UCCACUACAUCAACAUCCUG 20 8638
SCNNlA-4790 - UUCCACUACAUCAACAUCCUG 21 8639
SCNNlA-4791 - CUUCCACUACAUCAACAUCCUG 22 8640
1309
5535.1 SCNNlA-4792 - GCUUCCACUACAUCAACAUCCUG 23 8641
SCNNlA-4793 - CGCUUCCACUACAUCAACAUCCUG 24 8642
SCNNlA-4794 - AUGGCAGUGAUGUUCCUG 18 8643
SCNNlA-4795 - AAUGGCAGUGAUGUUCCUG 19 8644
SCNNlA-4796 - GAAUGGCAGUGAUGUUCCUG 20 8645
SCNNlA-4797 - AGAAUGGCAGUGAUGUUCCUG 21 8646
SCNNlA-4798 - AAGAAUGGCAGUGAUGUUCCUG 22 8647
SCNNlA-4799 - CAAGAAUGGCAGUGAUGUUCCUG 23 8648
SCNNlA-4800 - CCAAGAAUGGCAGUGAUGUUCCUG 24 8649
SCNNlA-4801 - AAGAUCGGCUUCCAGCUG 18 8650
SCNNlA-4802 - GAAGAUCGGCUUCCAGCUG 19 8651
SCNNlA-4803 - GGAAGAUCGGCUUCCAGCUG 20 8652
SCNNlA-4804 - UGGAAGAUCGGCUUCCAGCUG 21 8653
SCNNlA-4805 - CUGGAAGAUCGGCUUCCAGCUG 22 8654
SCNNlA-4806 - ACUGGAAGAUCGGCUUCCAGCUG 23 8655
SCNNlA-4807 - GACUGGAAGAUCGGCUUCCAGCUG 24 8656
SCNNlA-4808 - GAAAUUAAAGAGGAGCUG 18 8657
SCNNlA-4809 - GGAAAUUAAAGAGGAGCUG 19 8658
SCNNlA-4810 - CGGAAAUUAAAGAGGAGCUG 20 8659
SCNNlA-4811 - CCGGAAAUUAAAGAGGAGCUG 21 8660
SCNNlA-4812 - CCCGGAAAUUAAAGAGGAGCUG 22 8661
SCNNlA-4813 - ACCCGGAAAUUAAAGAGGAGCUG 23 8662
SCNNlA-4814 - UACCCGGAAAUUAAAGAGGAGCUG 24 8663
SCNNlA-4815 - UCCUCCACCUGUCCUCUG 18 8664
SCNNlA-4816 - UUCCUCCACCUGUCCUCUG 19 8665
SCNNlA-1224 - GUUCCUCCACCUGUCCUCUG 20 5073
SCNNlA-4817 - AGUUCCUCCACCUGUCCUCUG 21 8666
SCNNlA-4818 - CAGUUCCUCCACCUGUCCUCUG 22 8667
SCNNlA-4819 - CCAGUUCCUCCACCUGUCCUCUG 23 8668
SCNNlA-4820 - GCCAGUUCCUCCACCUGUCCUCUG 24 8669
SCNNlA-4821 - CAUCUCCAGGGGGCUCUG 18 8670
SCNNlA-4822 - CCAUCUCCAGGGGGCUCUG 19 8671
SCNNlA-4823 - CCCAUCUCCAGGGGGCUCUG 20 8672
SCNNlA-4824 - GCCCAUCUCCAGGGGGCUCUG 21 8673
SCNNlA-4825 - CGCCCAUCUCCAGGGGGCUCUG 22 8674
SCNNlA-4826 - CCGCCCAUCUCCAGGGGGCUCUG 23 8675
SCNNlA-4827 - CCCGCCCAUCUCCAGGGGGCUCUG 24 8676
SCNNlA-4828 - GGGCUGUUUCACCAAGUG 18 8677
SCNNlA-4829 - UGGGCUGUUUCACCAAGUG 19 8678
SCNNlA-4830 - CUGGGCUGUUUCACCAAGUG 20 8679
SCNNlA-4831 - CCUGGGCUGUUUCACCAAGUG 21 8680
SCNNlA-4832 - ACCUGGGCUGUUUCACCAAGUG 22 8681
1310
5535.1 SCNNlA-4833 - CACCUGGGCUGUUUCACCAAGUG 23 8682
SCNNlA-4834 - CCACCUGGGCUGUUUCACCAAGUG 24 8683
SCNNlA-4835 - GACAUCCCAGGUAGAGUG 18 8684
SCNNlA-4836 - UGACAUCCCAGGUAGAGUG 19 8685
SCNNlA-1228 - GUGACAUCCCAGGUAGAGUG 20 5077
SCNNlA-4837 - GGUGACAUCCCAGGUAGAGUG 21 8686
SCNNlA-4838 - CGGUGACAUCCCAGGUAGAGUG 22 8687
SCNNlA-4839 - UCGGUGACAUCCCAGGUAGAGUG 23 8688
SCNNlA-4840 - CUCGGUGACAUCCCAGGUAGAGUG 24 8689
SCNNlA-4841 - UCAGGGGUGGAUGCGGUG 18 8690
SCNNlA-4842 - AUCAGGGGUGGAUGCGGUG 19 8691
SCNNlA-1233 - CAUCAGGGGUGGAUGCGGUG 20 5082
SCNNlA-4843 - UCAUCAGGGGUGGAUGCGGUG 21 8692
SCNNlA-4844 - CUCAUCAGGGGUGGAUGCGGUG 22 8693
SCNNlA-4845 - ACUCAUCAGGGGUGGAUGCGGUG 23 8694
SCNNlA-4846 - UACUCAUCAGGGGUGGAUGCGGUG 24 8695
SCNNlA-4847 - UCCUCGGUGUUGUCUGUG 18 8696
SCNNlA-4848 - CUCCUCGGUGUUGUCUGUG 19 8697
SCNNlA-4849 - GCUCCUCGGUGUUGUCUGUG 20 8698
SCNNlA-4850 - GGCUCCUCGGUGUUGUCUGUG 21 8699
SCNNlA-4851 - CGGCUCCUCGGUGUUGUCUGUG 22 8700
SCNNlA-4852 - UCGGCUCCUCGGUGUUGUCUGUG 23 8701
SCNNlA-4853 - UUCGGCUCCUCGGUGUUGUCUGUG 24 8702
SCNNlA-4854 - CAUCCCAGGUAGAGUGUG 18 8703
SCNNlA-4855 - ACAUCCCAGGUAGAGUGUG 19 8704
SCNNlA-1238 - GACAUCCCAGGUAGAGUGUG 20 5087
SCNNlA-4856 - UGACAUCCCAGGUAGAGUGUG 21 8705
SCNNlA-4857 - GUGACAUCCCAGGUAGAGUGUG 22 8706
SCNNlA-4858 - GGUGACAUCCCAGGUAGAGUGUG 23 8707
SCNNlA-4859 - CGGUGACAUCCCAGGUAGAGUGUG 24 8708
SCNNlA-4860 - AGCGUGGCCUCCAGCUUG 18 8709
SCNNlA-4861 - UAGCGUGGCCUCCAGCUUG 19 8710
SCNNlA-1242 - GUAGCGUGGCCUCCAGCUUG 20 5091
SCNNlA-4862 - CGUAGCGUGGCCUCCAGCUUG 21 8711
SCNNlA-4863 - CCGUAGCGUGGCCUCCAGCUUG 22 8712
SCNNlA-4864 - CCCGUAGCGUGGCCUCCAGCUUG 23 8713
SCNNlA-4865 - GCCCGUAGCGUGGCCUCCAGCUUG 24 8714
SCNNlA-4866 - GGAGACCUCCAUCAGCAU 18 8715
SCNNlA-4867 - UGGAGACCUCCAUCAGCAU 19 8716
SCNNlA-4868 - GUGGAGACCUCCAUCAGCAU 20 8717
SCNNlA-4869 - CGUGGAGACCUCCAUCAGCAU 21 8718
SCNNlA-4870 - GCGUGGAGACCUCCAUCAGCAU 22 8719
1311
5535.1 SCNNlA-4871 - GGCGUGGAGACCUCCAUCAGCAU 23 8720
SCNNlA-4872 - UGGCGUGGAGACCUCCAUCAGCAU 24 8721
SCNNlA-4873 - UCUACCAGACAUACUCAU 18 8722
SCNNlA-4874 - UUCUACCAGACAUACUCAU 19 8723
SCNNlA-4875 - CUUCUACCAGACAUACUCAU 20 8724
SCNNlA-4876 - GCUUCUACCAGACAUACUCAU 21 8725
SCNNlA-4877 - UGCUUCUACCAGACAUACUCAU 22 8726
SCNNlA-4878 - CUGCUUCUACCAGACAUACUCAU 23 8727
SCNNlA-4879 - ACUGCUUCUACCAGACAUACUCAU 24 8728
SCNNlA-4880 - UGGUGUAUGUGGGUUCAU 18 8729
SCNNlA-4881 - UUGGUGUAUGUGGGUUCAU 19 8730
SCNNlA-1250 - CUUGGUGUAUGUGGGUUCAU 20 5099
SCNNlA-4882 - UCUUGGUGUAUGUGGGUUCAU 21 8731
SCNNlA-4883 - CUCUUGGUGUAUGUGGGUUCAU 22 8732
SCNNlA-4884 - UCUCUUGGUGUAUGUGGGUUCAU 23 8733
SCNNlA-4885 - AUCUCUUGGUGUAUGUGGGUUCAU 24
8734
SCNNlA-4886 - UACUCUCUCUUUCCUGAU 18 8735
SCNNlA-4887 - CUACUCUCUCUUUCCUGAU 19 8736
SCNNlA-4888 - CCUACUCUCUCUUUCCUGAU 20 8737
SCNNlA-4889 - CCCUACUCUCUCUUUCCUGAU 21 8738
SCNNlA-4890 - ACCCUACUCUCUCUUUCCUGAU 22 8739
SCNNlA-4891 - GACCCUACUCUCUCUUUCCUGAU 23 8740
SCNNlA-4892 - UGACCCUACUCUCUCUUUCCUGAU 24 8741
SCNNlA-4893 - GGAAACCCUGGACAGACU 18 8742
SCNNlA-4894 - AGGAAACCCUGGACAGACU 19 8743
SCNNlA-1257 - UAGGAAACCCUGGACAGACU 20 5106
SCNNlA-4895 - AUAGGAAACCCUGGACAGACU 21 8744
SCNNlA-4896 - CAUAGGAAACCCUGGACAGACU 22 8745
SCNNlA-4897 - UCAUAGGAAACCCUGGACAGACU 23 8746
SCNNlA-4898 - UUCAUAGGAAACCCUGGACAGACU 24 8747
SCNNlA-4899 - AAGGCAAGGAUGCUGACU 18 8748
SCNNlA-4900 - GAAGGCAAGGAUGCUGACU 19 8749
SCNNlA-1258 - GGAAGGCAAGGAUGCUGACU 20 5107
SCNNlA-4901 - AGGAAGGCAAGGAUGCUGACU 21 8750
SCNNlA-4902 - GAGGAAGGCAAGGAUGCUGACU 22 8751
SCNNlA-4903 - UGAGGAAGGCAAGGAUGCUGACU 23 8752
SCNNlA-4904 - AUGAGGAAGGCAAGGAUGCUGACU 24 8753
SCNNlA-4905 - ACCCUCUGCCCCACACCU 18 8754
SCNNlA-4906 - CACCCUCUGCCCCACACCU 19 8755
SCNNlA-4907 - CCACCCUCUGCCCCACACCU 20 8756
SCNNlA-4908 - CCCACCCUCUGCCCCACACCU 21 8757
1312
5535.1 SCNNlA-4909 - UCCCACCCUCUGCCCCACACCU 22 8758
SCNNlA-4910 - UUCCCACCCUCUGCCCCACACCU 23 8759
SCNNlA-4911 - CUUCCCACCCUCUGCCCCACACCU 24 8760
SCNNlA-4912 - CCGCAGCCGUCGCGACCU 18 8761
SCNNlA-4913 - CCCGCAGCCGUCGCGACCU 19 8762
SCNNlA-4914 - UCCCGCAGCCGUCGCGACCU 20 8763
SCNNlA-4915 - CUCCCGCAGCCGUCGCGACCU 21 8764
SCNNlA-4916 - GCUCCCGCAGCCGUCGCGACCU 22 8765
SCNNlA-4917 - GGCUCCCGCAGCCGUCGCGACCU 23 8766
SCNNlA-4918 - CGGCUCCCGCAGCCGUCGCGACCU 24 8767
SCNNlA-4919 - GUCCUCUGGGGGGGCCCU 18 8768
SCNNlA-4920 - UGUCCUCUGGGGGGGCCCU 19 8769
SCNNlA-4921 - CUGUCCUCUGGGGGGGCCCU 20 8770
SCNNlA-4922 - CCUGUCCUCUGGGGGGGCCCU 21 8771
SCNNlA-4923 - ACCUGUCCUCUGGGGGGGCCCU 22 8772
SCNNlA-4924 - CACCUGUCCUCUGGGGGGGCCCU 23 8773
SCNNlA-4925 - CCACCUGUCCUCUGGGGGGGCCCU 24 8774
SCNNlA-4926 - AGUUCCUCCACCUGUCCU 18 8775
SCNNlA-4927 - CAGUUCCUCCACCUGUCCU 19 8776
SCNNlA-4928 - CCAGUUCCUCCACCUGUCCU 20 8777
SCNNlA-4929 - GCCAGUUCCUCCACCUGUCCU 21 8778
SCNNlA-4930 - GGCCAGUUCCUCCACCUGUCCU 22 8779
SCNNlA-4931 - GGGCCAGUUCCUCCACCUGUCCU 23 8780
SCNNlA-4932 - GGGGCCAGUUCCUCCACCUGUCCU 24 8781
SCNNlA-4933 - CAUGUUCCUCAUGCUGCU 18 8782
SCNNlA-4934 - UCAUGUUCCUCAUGCUGCU 19 8783
SCNNlA-4935 - AUCAUGUUCCUCAUGCUGCU 20 8784
SCNNlA-4936 - CAUCAUGUUCCUCAUGCUGCU 21 8785
SCNNlA-4937 - UCAUCAUGUUCCUCAUGCUGCU 22 8786
SCNNlA-4938 - GUCAUCAUGUUCCUCAUGCUGCU 23 8787
SCNNlA-4939 - GGUCAUCAUGUUCCUCAUGCUGCU 24 8788
SCNNlA-4940 - CGAGGGGGCAGGGGUGCU 18 8789
SCNNlA-4941 - CCGAGGGGGCAGGGGUGCU 19 8790
SCNNlA-4942 - GCCGAGGGGGCAGGGGUGCU 20 8791
SCNNlA-4943 - GGCCGAGGGGGCAGGGGUGCU 21 8792
SCNNlA-4944 - AGGCCGAGGGGGCAGGGGUGCU 22 8793
SCNNlA-4945 - CAGGCCGAGGGGGCAGGGGUGCU 23 8794
SCNNlA-4946 - CCAGGCCGAGGGGGCAGGGGUGCU 24 8795
SCNNlA-4947 - UUCCUCCACCUGUCCUCU 18 8796
SCNNlA-4948 - GUUCCUCCACCUGUCCUCU 19 8797
SCNNlA-1276 - AGUUCCUCCACCUGUCCUCU 20 5125
SCNNlA-4949 - CAGUUCCUCCACCUGUCCUCU 21 8798
1313
5535.1 SCNNlA-4950 - CCAGUUCCUCCACCUGUCCUCU 22 8799
SCNNlA-4951 - GCCAGUUCCUCCACCUGUCCUCU 23 8800
SCNNlA-4952 - GGCCAGUUCCUCCACCUGUCCUCU 24 8801
SCNNlA-4953 - UGACAUCCCAGGUAGAGU 18 8802
SCNNlA-4954 - GUGACAUCCCAGGUAGAGU 19 8803
SCNNlA-4955 - GGUGACAUCCCAGGUAGAGU 20 8804
SCNNlA-4956 - CGGUGACAUCCCAGGUAGAGU 21 8805
SCNNlA-4957 - UCGGUGACAUCCCAGGUAGAGU 22 8806
SCNNlA-4958 - CUCGGUGACAUCCCAGGUAGAGU 23 8807
SCNNlA-4959 - CCUCGGUGACAUCCCAGGUAGAGU 24 8808
SCNNlA-4960 - CCUGGAAUCAACAACGGU 18 8809
SCNNlA-4961 - GCCUGGAAUCAACAACGGU 19 8810
SCNNlA-4962 - UGCCUGGAAUCAACAACGGU 20 8811
SCNNlA-4963 - AUGCCUGGAAUCAACAACGGU 21 8812
SCNNlA-4964 - CAUGCCUGGAAUCAACAACGGU 22 8813
SCNNlA-4965 - CCAUGCCUGGAAUCAACAACGGU 23 8814
SCNNlA-4966 - UCCAUGCCUGGAAUCAACAACGGU 24 8815
SCNNlA-4967 - AUCAGGGGUGGAUGCGGU 18 8816
SCNNlA-4968 - CAUCAGGGGUGGAUGCGGU 19 8817
SCNNlA-4969 - UCAUCAGGGGUGGAUGCGGU 20 8818
SCNNlA-4970 - CUCAUCAGGGGUGGAUGCGGU 21 8819
SCNNlA-4971 - ACUCAUCAGGGGUGGAUGCGGU 22 8820
SCNNlA-4972 - UACUCAUCAGGGGUGGAUGCGGU 23 8821
SCNNlA-4973 - AUACUCAUCAGGGGUGGAUGCGGU 24 8822
SCNNlA-4974 - UGUGGGGAAGGGAUGGGU 18 8823
SCNNlA-4975 - GUGUGGGGAAGGGAUGGGU 19 8824
SCNNlA-1288 - AGUGUGGGGAAGGGAUGGGU 20 5137
SCNNlA-4976 - GAGUGUGGGGAAGGGAUGGGU 21 8825
SCNNlA-4977 - AGAGUGUGGGGAAGGGAUGGGU 22 8826
SCNNlA-4978 - UAGAGUGUGGGGAAGGGAUGGGU 23 8827
SCNNlA-4979 - GUAGAGUGUGGGGAAGGGAUGGGU 24
8828
SCNNlA-4980 - ACUUCCACCACCCGAUGU 18 8829
SCNNlA-4981 - CACUUCCACCACCCGAUGU 19 8830
SCNNlA-4982 - UCACUUCCACCACCCGAUGU 20 8831
SCNNlA-4983 - CUCACUUCCACCACCCGAUGU 21 8832
SCNNlA-4984 - UCUCACUUCCACCACCCGAUGU 22 8833
SCNNlA-4985 - CUCUCACUUCCACCACCCGAUGU 23 8834
SCNNlA-4986 - ACUCUCACUUCCACCACCCGAUGU 24 8835
SCNNlA-4987 - ACAU CCCAGG U AG AG UG U 18 8836
SCNNlA-4988 - GACAUCCCAGGUAGAGUGU 19 8837
SCNNlA-1293 - UGACAUCCCAGGUAGAGUGU 20 5142
1314
5535.1 SCNN lA-4989 - GUGACAUCCCAGGUAGAGUGU 21 8838
SCNN lA-4990 - GGUGACAUCCCAGGUAGAGUGU 22 8839
SCNN lA-4991 - CGGUGACAUCCCAGGUAGAGUGU 23 8840
SCNN lA-4992 - UCGGUGACAUCCCAGGUAGAGUGU 24 8841
SCNN lA-4993 - GAAACCCUGGACAGACUU 18 8842
SCNN lA-4994 - GGAAACCCUGGACAGACUU 19 8843
SCNN lA-1295 - AGGAAACCCUGGACAGACUU 20 5144
SCNN lA-4995 - UAGGAAACCCUGGACAGACUU 21 8844
SCNN lA-4996 - AUAGGAAACCCUGGACAGACUU 22 8845
SCNN lA-4997 - CAUAGGAAACCCUGGACAGACUU 23 8846
SCNN lA-4998 - UCAUAGGAAACCCUGGACAGACUU 24 8847
SCNN lA-4999 - UAGCGUGGCCUCCAGCUU 18 8848
SCNN lA-5000 - GUAGCGUGGCCUCCAGCUU 19 8849
SCNN lA-5001 - CGUAGCGUGGCCUCCAGCUU 20 8850
SCNN lA-5002 - CCGUAGCGUGGCCUCCAGCUU 21 8851
SCNN lA-5003 - CCCGUAGCGUGGCCUCCAGCUU 22 8852
SCNN lA-5004 - GCCCGUAGCGUGGCCUCCAGCUU 23 8853
SCNN lA-5005 - AGCCCGUAGCGUGGCCUCCAGCUU 24 8854
SCNN lA-5006 - CAUGCUGCUCCGAAGGUU 18 8855
SCNN lA-5007 - UCAUGCUGCUCCGAAGGUU 19 8856
SCNN lA-5008 - CUCAUGCUGCUCCGAAGGUU 20 8857
SCNN lA-5009 - CCUCAUGCUGCUCCGAAGGUU 21 8858
SCNN lA-5010 - UCCUCAUGCUGCUCCGAAGGUU 22 8859
SCNN lA-5011 - UUCCUCAUGCUGCUCCGAAGGUU 23 8860
SCNN lA-5012 - GUUCCUCAUGCUGCUCCGAAGGUU 24 8861
SCNN lA-5013 - GGCAGUGAUGUUCCUGUU 18 8862
SCNN lA-5014 - UGGCAGUGAUGUUCCUGUU 19 8863
SCNN lA-5015 - AUGGCAGUGAUGUUCCUGUU 20 8864
SCNN lA-5016 - AAUGGCAGUGAUGUUCCUGUU 21 8865
SCNN lA-5017 - GAAUGGCAGUGAUGUUCCUGUU 22 8866
SCNN lA-5018 - AGAAUGGCAGUGAUGUUCCUGUU 23 8867
SCNN lA-5019 - AAGAAUGGCAGUGAUGUUCCUGU U 24 8868
Table 45A provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., with 500 bp downstream from the start codon), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
1315
5535.1 Table 45A
Figure imgf001317_0001
Table 45B provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., with 500 bp downstream from the start codon) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 45B
Figure imgf001317_0002
Table 45C provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the third tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., with 500 bp downstream from the start codon) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 45C
1316
5535.1 3rd Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
SCNNlA-5028 + GGCCCAGCCCCUGCUCC 17 8877
SCNNlA-5029 + GAGGGCUAGAGUCCUGCUCC 20 8878
SCNNlA-5030 + GAGGUCUAGGGUCCUGCUCC 20 8879
Table 45D provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., with 500 bp downstream from the start codon). It is
contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 45D
Figure imgf001318_0001
Table 45E provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 45E
Figure imgf001318_0002
1317
5535.1 SCNNlA-485 + GCGCCAUGGAGCAAGCA 17 4334
SCNNlA-5035 + UAUGUCUGGUAGAAGCA 17 8884
SCNNlA-5036 - UCCAGGUGUGUAUUCAC 17 8885
SCNNlA-577 + CUGAGGAGAAGUCAACC 17 4426
SCNNlA-5037 - GCUUGCUCCAUGGCGCC 17 8886
SCNNlA-5038 - GCAACUUCAUCUUCGCC 17 8887
SCNNlA-5039 - GAGCCCGUAGCGUGGCC 17 8888
SCNNlA-5040 - ACUGGAAGGACUGGAAG 17 8889
SCNNlA-5041 - GCAACCAGAACAAAUCG 17 8890
SCNNlA-5042 - AUGCGGUGAGGGAGUGG 17 8891
SCNNlA-787 - ACCCUGGACAGACUUGG 17 4636
SCNNlA-5043 + AAGGGGACACUAACCUG 17 8892
SCNNlA-5044 - CUGCCUUUAUGGAUGAU 17 8893
SCNNlA-5045 - AACAACGGUGAGAAGCU 17 8894
SCNNlA-5046 + UCGGCCUGGAGACCAGU 17 8895
SCNNlA-5047 + AGGGAGCUUCUCACCGU 17 8896
SCNNlA-5048 + CUGGAGUCUCACCCCAGGAA 20 8897
SCNNlA-5049 - CACACAGCAGGUGAGGCCCA 20 8898
SCNNlA-909 + AGGGCGCCAUGGAGCAAGCA 20 4758
SCNNlA-5050 + GAGUAUGUCUGGUAGAAGCA 20 8899
SCNNlA-5051 - CCUUCCAGGUGUGUAUUCAC 20 8900
SCNNlA-1000 + GGUCUGAGGAGAAGUCAACC 20 4849
SCNNlA-5052 - CCUGCUUGCUCCAUGGCGCC 20 8901
SCNNlA-5053 - UGGGCAACUUCAUCUUCGCC 20 8902
SCNNlA-5054 - GUCGAGCCCGUAGCGUGGCC 20 8903
SCNNlA-5055 - UGGACUGGAAGGACUGGAAG 20 8904
SCNNlA-5056 - AGUGCAACCAGAACAAAUCG 20 8905
SCNNlA-5057 - UGGAUGCGGUGAGGGAGUGG 20 8906
SCNNlA-1206 - G AAACCCUGGACAGACU UGG 20 5055
SCNNlA-5058 + GGGAAGGGGACACUAACCUG 20 8907
SCNNlA-5059 - AACCUGCCUUUAUGGAUGAU 20 8908
SCNNlA-5060 - AUCAACAACGGUGAGAAGCU 20 8909
SCNNlA-5061 + CCCUCGGCCUGGAGACCAGU 20 8910
SCNNlA-5062 + AGCAGGGAGCUUCUCACCGU 20 8911
Table 46A provides exemplary targeting domains for knocking down the SCNN1A gene selected according to the first tier parameters. The targeting domains bind within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting
1318
5535.1 domains in the table can be used with a S. pyogenes eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region the SCNNIA gene.
Table 46A
Figure imgf001320_0001
1319
5535.1 SCNNlA-5089 - GAGGAGAGGCCGUUCUA 17 8938
SCNNlA-5090 - GGAGACUGGAGUUUCUA 17 8939
SCNNlA-5091 - GGACCAUGCCCAAUGUA 17 8940
SCNNlA-5092 - GGAAUCCUGGUUGACAC 17 8941
SCNNlA-5093 + GGCUGCCGCUUCCUCAC 17 8942
SCNNlA-5094 + GGGCUUUAGACGCAGAC 17 8943
SCNNlA-5095 + GAAAGCCGGUGUCAACC 17 8944
SCNNlA-5096 + GAGCAUUGAUACACACC 17 8945
SCNNlA-5097 + GAUUCUGUCUCUGCCCC 17 8946
SCNNlA-5098 - GGGCGGGCUCCCCAGCC 17 8947
SCNNlA-5099 - GCUGAGCCUCUAGCUCC 17 8948
SCNNlA-5100 - GGGCGAUUACACAUUCC 17 8949
SCNNlA-5101 + GUCCCAAGUGUGCUUCC 17 8950
SCNNlA-5102 - GGUGGCGAGGAAUCAGC 17 8951
SCNNlA-5103 + G C C A A A AG UGCCGGAGC 17 8952
SCNNlA-5104 + GAGGAUGUGGCCAGCGC 17 8953
SCNNlA-5105 + GAAGCUGGGGGCUAGGC 17 8954
SCNNlA-5106 + GAAGGCGGACUCUGGGC 17 8955
SCNNlA-5107 + GGAGCCCGCCCGCUGGC 17 8956
SCNNlA-5108 + GCCUAGGGGCUCACUGC 17 8957
SCNNlA-5109 + GGAGCCAGCAGACCUGC 17 8958
SCNNlA-5110 - GCUGGGCCUUUGUCUGC 17 8959
SCNNlA-5111 + GUUGGGGCCAAAAGUGC 17 8960
SCNNlA-5112 + GCAGGCACUGAAGGUGC 17 8961
SCNNlA-5113 + GUCUGCUCUCUGGGUGC 17 8962
SCNNlA-5114 - GCUGAGCACCUUAUUGC 17 8963
SCNNlA-5115 - GGGGCAGAGACAGAAUC 17 8964
SCNNlA-5116 + GUGGGAGCAGCGCACUC 17 8965
SCNNlA-333 - GAUGGGAGAGGGCACUC 17 4182
SCNNlA-5117 - GGCCCUCGCGCUGCCUC 17 8966
SCNNlA-5118 + GGCAGUACUCCAGGCUC 17 8967
SCNNlA-5119 - GGUGUGUAUCAAUGCUC 17 8968
SCNNlA-5120 - GAGUUUCUAGGGGUCUC 17 8969
SCNNlA-5121 - GGACACAGCUCGAGGUC 17 8970
SCNNlA-5122 - GCUAGUGGUUGGAUUUC 17 8971
SCNNlA-5123 + GCUAGAGGCUCAGCAAG 17 8972
SCNNlA-5124 + GGAAUGUGGGCAACCAG 17 8973
SCNNlA-334 - GACAUGGGCAUGGCCAG 17 4183
SCNNlA-5125 + GGGCUAGGGGAGCCUAG 17 8974
SCNNlA-5126 + GUGCUUCCAGGAGCUAG 17 8975
SCNNlA-5127 - GAGACUGGAGUUUCUAG 17 8976
SCNNlA-5128 + GGGCACUGAGUGAGUAG 17 8977
1320
5535.1 SCNNlA-5129 - GUCCACAGUGUCCUGCG 17 8978
SCNNlA-5130 - GGACAAAACUCGAAAGG 17 8979
SCNNlA-5131 + GACGCAGACAGGCAAGG 17 8980
SCNNlA-5132 + GGAACCGGGAGGACAGG 17 8981
SCNNlA-5133 + GGAGCAGCGCACUCAGG 17 8982
SCNNlA-5134 - GUAGAUAGCCCCAGAGG 17 8983
SCNNlA-5135 - GGGCCUAGAGUGAGAGG 17 8984
SCNNlA-5136 + GCAUUGAUACACACCGG 17 8985
SCNNlA-5137 + GCACUGAAGGUGCAGGG 17 8986
SCNNlA-5138 + GACCCAAAAAGGGCUGG 17 8987
SCNNlA-5139 - GGUCUGGACAAGGUUGG 17 8988
SCNNlA-5140 - GGGGUCUCUGGGAUAUG 17 8989
SCNNlA-5141 + GGCCACGCAGGACACUG 17 8990
SCNNlA-5142 + GUGCAGCGGCCUGGCUG 17 8991
SCNNlA-5143 + GGGUCCAACCUGGUCUG 17 8992
SCNNlA-5144 + GAUAAAUCAGUUUUCUG 17 8993
SCNNlA-5145 + GUGAGUAGAGGCAGGUG 17 8994
SCNNlA-5146 - GCUGCACCUGUCAGGUG 17 8995
SCNNlA-5147 - GGUCUCUGGGAUAUGUG 17 8996
SCNNlA-335 - GGCGCAGGGUGGGACAU 17 4184
SCNNlA-5148 + GAGCCAGGUCCUUACAU 17 8997
SCNNlA-5149 + GCGAAGGACAGAGAGAU 17 8998
SCNNlA-5150 + GGGCUAGGCGGGGCCCU 17 8999
SCNNlA-5151 - GAAAACUGAUUUAUCCU 17 9000
SCNNlA-5152 + GUGCUGGGUUAUCUCCU 17 9001
SCNNlA-5153 - GUAUCAAUGCUCAGGCU 17 9002
SCNNlA-5154 + GGUGCAGCGGCCUGGCU 17 9003
SCNNlA-336 + GGUCAAGGCUGAGCUCU 17 4185
SCNNlA-5155 + GGAUUCGUCUGCUCUCU 17 9004
SCNNlA-5156 - GAGAUGACACCUUCUCU 17 9005
SCNNlA-5157 - GGGAGACUGGAGUUUCU 17 9006
SCNNlA-5158 - GGGAUAUGUGGGGCAGU 17 9007
SCNNlA-5159 + GAGCAGCGCACUCAGGU 17 9008
SCNNlA-337 - GAAUGUGGGCGCAGGGU 17 4186
SCNNlA-5160 - GGGUCUCUGGGAUAUGU 17 9009
SCNNlA-5161 + GUUCUUUUUUACACUGU 17 9010
SCNNlA-5162 - GGGUGAGGCUGACCUGU 17 9011
SCNNlA-5163 - GUUGCCCUCCUAGCUGU 17 9012
SCNNlA-5164 - GGGUCAGUUUCUUCAUU 17 9013
SCNNlA-339 + GAGCCCCGGAGUGGAUU 17 4188
SCNNlA-5165 - GGGAGCCCUCCUUCCUU 17 9014
SCNNlA-5166 + GCAGACCUGCGGGAGUU 17 9015
1321
5535.1 SCNNlA-5167 + GCAAGUGGGCAGCCCUCCAA 20 9016
SCNNlA-5168 + GUCUCCAGGAAGGAGAGCAA 20 9017
SCNNlA-5169 + GCAAAUAGUUUUCAUAUCAA 20 9018
SCNNlA-5170 + GGAGGGCAACACAAGGAGAA 20 9019
SCNNlA-5171 + GGAGCUGGGCUUCCCUAGAA 20 9020
SCNNlA-5172 - GUGCUAGGACAAAACUCGAA 20 9021
SCNNlA-5173 - GCUGCCAGAUUCAACUGGAA 20 9022
SCNNlA-5174 + GGAUGUGGCCAGCGCUGGAA 20 9023
SCNNlA-5175 - GCCCCUCCCGGGUCUGGACA 20 9024
SCNNlA-5176 + GAAGAAACUGACCCUUCCCA 20 9025
SCNNlA-5177 + GAGAUAAGACAUAAGAGCCA 20 9026
SCNNlA-5178 + GCCCGCCCGCUGGCCGGCCA 20 9027
SCNNlA-340 - GUGGGACAUGGGCAUGGCCA 20 4189
SCNNlA-341 - GCAGCCUCACUCGGGUUCCA 20 4190
SCNNlA-342 - GAGCAGUAUCAAGGUAAGCA 20 4191
SCNNlA-5179 + GGAGUGCCAAGUGGUGAGCA 20 9028
SCNNlA-5180 - G C U G G C A A A U AG A A A AG G C A 20 9029
SCNNlA-5181 + GCUUUAGACGCAGACAGGCA 20 9030
SCNNlA-5182 - GCCUAGAGUGAGAGGGGGCA 20 9031
SCNNlA-5183 + GAGAAGGCGGACUCUGGGCA 20 9032
SCNNlA-5184 - GUGCUGAGCACCUUAUUGCA 20 9033
SCNNlA-5185 + GGCAAAUAGUUUUCAUAUCA 20 9034
SCNNlA-343 - GUGAUGGGAGAGGGCACUCA 20 4192
SCNNlA-5186 + GGAAGGCUGCCGCUUCCUCA 20 9035
SCNNlA-1 - GCAGCCCAUACCAGGUCUCA 20 503
SCNNlA-5187 + GCCAGCGCUGGAAAGGAAGA 20 9036
SCNNlA-5188 - GCUGAGGGCCUAGAGUGAGA 20 9037
SCNNlA-5189 + GGCAACCAGAGGCAGCGCGA 20 9038
SCNNlA-5190 + GCCGGGAGUUUUCCGAAGGA 20 9039
SCNNlA-5191 + GGAGUUUUCCGAAGGAAGGA 20 9040
SCNNlA-5192 + GCCCGCUGGCCGGCCAGGGA 20 9041
SCNNlA-5193 + GGCCCUGCACGCGGCAGGGA 20 9042
SCNNlA-76 + GCCCUGGAGUGGACUGUGGA 20 528
SCNNlA-5194 - GACCUGUGGGUGCCCUUGGA 20 9043
SCNNlA-5195 + GAGGAGGAGAAAUUCGUUGA 20 9044
SCNNlA-5196 + GCAUGGUCCUCCCUGCAAUA 20 9045
SCNNlA-5197 + GCCUGCAAUACAAUAAGAUA 20 9046
SCNNlA-5198 + GACAUAAGAGCCAAGGGCUA 20 9047
SCNNlA-344 + GUAUGGGCUGCAGAGGUCUA 20 4193
SCNNlA-5199 - GCAGAGGAGAGGCCGUUCUA 20 9048
SCNNlA-5200 - GGAGGACCAUGCCCAAUGUA 20 9049
SCNNlA-5201 + GAAAUCCAACCACUAGCUUA 20 9050
1322
5535.1 SCNNlA-5202 - GUUUGGCUGCCAGAUUCAAC 20 9051
SCNNlA-5203 + GCUCCCGAGGGCAGGUGAAC 20 9052
SCNNlA-5204 + GCCUGAGCAUUGAUACACAC 20 9053
SCNNlA-5205 + GAAGGCUGCCGCUUCCUCAC 20 9054
SCNNlA-5206 + GAGUGCAGGAAUGUGGUCAC 20 9055
SCNNlA-5207 - GGACCUGGCUCAAGGGAGAC 20 9056
SCNNlA-5208 + GGCAUGGCACACGCCUAGAC 20 9057
SCNNlA-5209 + GGGUGGGGAACCGGGAGGAC 20 9058
SCNNlA-5210 + GGUUGCGGCUGGACUGGGAC 20 9059
SCNNlA-5211 + GGCAGGUGAACUGGGAGUAC 20 9060
SCNNlA-5212 + G U CAACCAGG AU U CCAAACC 20 9061
SCNNlA-5213 - GUCCCAGUCCAGCCGCAACC 20 9062
SCNNlA-5214 + GAGGGCCUGGGUGGGGAACC 20 9063
SCNNlA-5215 + GAUCGGGGCUCAGGUGCACC 20 9064
SCNNlA-5216 - GCCUAGCCCCCAGCUUCACC 20 9065
SCNNlA-5217 + GGACACUGUGGACACAGACC 20 9066
SCNNlA-5218 - GUCCUCCCGGUUCCCCACCC 20 9067
SCNNlA-346 + GUGCCCUCUCCCAUCACCCC 20 4195
SCNNlA-5219 + GCACACGCCUAGACAGGCCC 20 9068
SCNNlA-5220 - GCUUCACCUGGGCCCCUCCC 20 9069
SCNNlA-5221 + GCUGAGGAGGAGUCAGAGCC 20 9070
SCNNlA-347 - GGUGGGACAUGGGCAUGGCC 20 4196
SCNNlA-5222 - GCGAUUACACAUUCCUGGCC 20 9071
SCNNlA-5223 + GUGAGAAGAAUUGCAAUGCC 20 9072
SCNNlA-5224 - GGGAACCUGGUUUGGAAUCC 20 9073
SCNNlA-5225 + GGGAUGCGUCUGCCUCCUCC 20 9074
SCNNlA-5226 + GGAGUCCCAAGUGUGCUUCC 20 9075
SCNNlA-348 - GGCAGCCUCACUCGGGUUCC 20 4197
SCNNlA-5227 + GUGCACCUGGAUGUGAAAGC 20 9076
SCNNlA-176 - GCUCAUGAAGGGGAACAAGC 20 811
SCNNlA-5228 - GCAACCUGGGAGUGGGAAGC 20 9077
SCNNlA-5229 - GGGGGUGGCGAGGAAUCAGC 20 9078
SCNNlA-5230 - GCUGCUCCCACUUAGUGAGC 20 9079
SCNNlA-349 - GAGUGGGAGAAUGUGGGCGC 20 4198
SCNNlA-5231 - GUGUGUAUCAAUGCUCAGGC 20 9080
SCNNlA-5232 + GAAUCAGACCCAAAAAGGGC 20 9081
SCNNlA-5233 + GAAGGAGGGCUCCCGAGGGC 20 9082
SCNNlA-5234 + GACAGGUGCAGCGGCCUGGC 20 9083
SCNNlA-5235 + GGAGCCUAGGGGCUCACUGC 20 9084
SCNNlA-5236 + GGAGUUGGGGCCAAAAGUGC 20 9085
SCNNlA-5237 - GGUGCUGAGCACCUUAUUGC 20 9086
SCNNlA-5238 + GGUUCCUUUCCAGUUGAAUC 20 9087
1323
5535.1 SCNNlA-350 - GGUGAUGGGAGAGGGCACUC 20 4199
SCNNlA-351 - GGCCAGGGGCAGCCUCACUC 20 4200
SCNNlA-5239 + GGGCUCACUGCAGGAGACUC 20 9088
SCNNlA-5240 + GGACCUGAGAAGGCGGACUC 20 9089
SCNNlA-5241 - GUUCUAGGGAAGCCCAGCUC 20 9090
SCNNlA-5242 - GCCCUCCUAGCUGUGGGCUC 20 9091
SCNNlA-352 + GAUUGGGGAGAGCAAGGGUC 20 4201
SCNNlA-5243 - GCCAGGCCGCUGCACCUGUC 20 9092
SCNNlA-5244 - GCGAGGAAUCAGCAGGAAAG 20 9093
SCNNlA-5245 + GGAGCUAGAGGCUCAGCAAG 20 9094
SCNNlA-5246 - GUGAGAGGGGGCAAGGCAAG 20 9095
SCNNlA-5247 + GGCCAGCGCUGGAAAGGAAG 20 9096
SCNNlA-5248 + GCAGGAAUGUGGGCAACCAG 20 9097
SCNNlA-5249 - GCAAGAGACUGCCGCAAGAG 20 9098
SCNNlA-5250 - GAAACAGAAGGCAGAUAGAG 20 9099
SCNNlA-5251 - GUCCAGCCGCAACCUGGGAG 20 9100
SCNNlA-5252 - GGGUCUGGACAAGGUUGGAG 20 9101
SCNNlA-5253 - GCCAUGCUGCCUUAAGCUAG 20 9102
SCNNlA-5254 + GAGGGGCACUGAGUGAGUAG 20 9103
SCNNlA-353 - GCUCUCCCCAAUCCACUCCG 20 4202
SCNNlA-5255 + GGGCAACCAGAGGCAGCGCG 20 9104
SCNNlA-5256 + GUGAAGCUGGGGGCUAGGCG 20 9105
SCNNlA-5257 + GACAGACUCAUGGGGGAUCG 20 9106
SCNNlA-5258 + GAGUACUGGACCUGAGAAGG 20 9107
SCNNlA-5259 + GGGAGUUUUCCGAAGGAAGG 20 9108
SCNNlA-5260 + GUGGGAGCAGCGCACUCAGG 20 9109
SCNNlA-5261 - GUAGAUAGCCCCAGAGGAGG 20 9110
SCNNlA-5262 - GGUCUGGACAAGGUUGGAGG 20 9111
SCNNlA-354 - GGGAGAAUGUGGGCGCAGGG 20 4203
SCNNlA-5263 - G G C A A A U AG A A A AG G C AG G G 20 9112
SCNNlA-5264 + GGCCUGGGUGGGGAACCGGG 20 9113
SCNNlA-5265 + GCAUUGAUACACACCGGGGG 20 9114
SCNNlA-2 - GCCCAUACCAGGUCUCAUGG 20 497
SCNNlA-5266 - GCUGGCUCCAGGAAAGGUGG 20 9115
SCNNlA-5267 + GUCACAGAGUUGCAGGAAUG 20 9116
SCNNlA-5268 + GAGGGCCACGCAGGACACUG 20 9117
SCNNlA-5269 - GCACUCUGGGCUGCCUCCUG 20 9118
SCNNlA-5270 - GCCGCUGCACCUGUCAGGUG 20 9119
SCNNlA-5271 - GGCCUUUGUCUGCUGGCUUG 20 9120
SCNNlA-355 - GUGGGCGCAGGGUGGGACAU 20 4204
SCNNlA-5272 + GAGACAGACUCAUGGGGGAU 20 9121
SCNNlA-5273 - GUCUCCUGCAGUGAGCCCCU 20 9122
1324
5535.1 SCNNlA-5274 - GGCUGACCUGUGGGUGCCCU 20 9123
SCNNlA-5275 + GCCAAGGGCUAGGGGAGCCU 20 9124
SCNNlA-5276 + GCCUUGCCCCCUCUCACUCU 20 9125
SCNNlA-5277 + GACCUGAGAAGGCGGACUCU 20 9126
SCNNlA-356 + GGUAUGGGCUGCAGAGGUCU 20 4205
SCNNlA-5278 + GCCAGCAGACCUGCGGGAGU 20 9127
SCNNlA-5279 - GAGGAAGCCACAGACCAGGU 20 9128
SCNNlA-357 - GGAGAAUGUGGGCGCAGGGU 20 4206
SCNNlA-5280 + GCGCUGGAAAGGAAGAGGGU 20 9129
SCNNlA-5281 - GUGCAGGGCCUGGGUUGUGU 20 9130
SCNNlA-5282 - GAAGGGUCAGUUUCUUCAUU 20 9131
SCNNlA-5283 - GAGUCUCCUCCAGCCCUUUU 20 9132
Table 46B provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the second tier parameters. The targeting domains bind within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS) and have a high level of
orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
Table 46B
Figure imgf001326_0001
1325
5535.1 SCNNlA-360 - ACUCCGGGGCUCAUGAA 17 4209
SCNNlA-5294 + AUUAGCAUCUCAAUUAA 17 9143
SCNNlA-5295 - CCUCCCGGGUCUGGACA 17 9144
SCNNlA-5296 - UUGAGAUCAAACAGCCA 17 9145
SCNNlA-5297 + AUAAGACAUAAGAGCCA 17 9146
SCNNlA-5298 - ACCUUUUCACAGAGCCA 17 9147
SCNNlA-5299 + CGCCCGCUGGCCGGCCA 17 9148
SCNNlA-88 - CUCCACAGUCCACUCCA 17 609
SCNNlA-5300 + AAGUGGGCAGCCCUCCA 17 9149
SCNNlA-5301 + C U G AAU C U U G AC AAG CA 17 9150
SCNNlA-361 - CAGUAUCAAGGUAAGCA 17 4210
SCNNlA-5302 - ACUCUGUGACCACAGCA 17 9151
SCNNlA-5303 + ACUAGCUUAAGGCAGCA 17 9152
SCNNlA-5304 + U C A A U U A A AG G U G AG C A 17 9153
SCNNlA-5305 - UGAGAGGGGGCAAGGCA 17 9154
SCNNlA-5306 + UUAGACGCAGACAGGCA 17 9155
SCNNlA-5307 + AGGCCCUGCACGCGGCA 17 9156
SCNNlA-5308 - CUUCCCUGCCGCGUGCA 17 9157
SCNNlA-5309 + C AGG CAC U G AAG G U G C A 17 9158
SCNNlA-5310 - CUGAGCACCUUAUUGCA 17 9159
SCNNlA-362 - UAUCAUGAGCAGUAUCA 17 4211
SCNNlA-363 - AUGGGAGAGGGCACUCA 17 4212
SCNNlA-5311 + UUCCUGAGACAGACUCA 17 9160
SCNNlA-5312 + AGGCUGCCGCUUCCUCA 17 9161
SCNNlA-5313 - UGUAAGGACCUGGCUCA 17 9162
SCNNlA-5314 + AGCGCUGGAAAGGAAGA 17 9163
SCNNlA-5315 + AGGGCAACACAAGGAGA 17 9164
SCNNlA-5316 + UGGUGGGGGCAAAUAGA 17 9165
SCNNlA-5317 + AGCCGGGAGUUUUCCGA 17 9166
SCNNlA-5318 + AACCAGAGGCAGCGCGA 17 9167
SCNNlA-5319 + UGAGCCCACAGCUAGGA 17 9168
SCNNlA-5320 + CGCUGGCCGGCCAGGGA 17 9169
SCNNlA-5321 + CCUGCACGCGGCAGGGA 17 9170
SCNNlA-5322 + CUUGUCCAGACCCGGGA 17 9171
SCNNlA-5323 + UGAGCAGGGCGGGGGGA 17 9172
SCNNlA-5324 - UGACACCUUCUCUGGGA 17 9173
SCNNlA-82 - AUACCAGGUCUCAUGGA 17 501
SCNNlA-364 + UGAUACCUCCCCUUGGA 17 4213
SCNNlA-5325 - CUGUGGGUGCCCUUGGA 17 9174
SCNNlA-365 - CACUCCGGGGCUCAUGA 17 4214
SCNNlA-5326 - CUGCACCUGUCAGGUGA 17 9175
SCNNlA-366 - UCGGGUUCCAGGGGUGA 17 4215
1326
5535.1 SCNNlA-5327 + UGGUCCUCCCUGCAAUA 17 9176
SCNNlA-5328 + CGAAGGACAGAGAGAUA 17 9177
SCNNlA-5329 + AGGGCUAGGGGAGCCUA 17 9178
SCNNlA-5330 - AAGAACAGAAUGUCCUA 17 9179
SCNNlA-5331 + AUAAGAGCCAAGGGCUA 17 9180
SCNNlA-157 + CUCCAUGAGACCUGGUA 17 502
SCNNlA-5332 + AUCCAACCACUAGCUUA 17 9181
SCNNlA-5333 - UGGCUGCCAGAUUCAAC 17 9182
SCNNlA-5334 + CCCGAGGGCAGGUGAAC 17 9183
SCNNlA-5335 + UGAGCAUUGAUACACAC 17 9184
SCNNlA-5336 + CCUCCAAGGGCACCCAC 17 9185
SCNNlA-5337 + UUCCUCACGGGCCCCAC 17 9186
SCNNlA-5338 - AGAGCAGACGAAUCCAC 17 9187
SCNNlA-5339 + UGCAGGAAUGUGGUCAC 17 9188
SCNNlA-5340 - CCUGGCUCAAGGGAGAC 17 9189
SCNNlA-5341 + AUGGCACACGCCUAGAC 17 9190
SCNNlA-5342 + CCAGGGAUGGAAGCGAC 17 9191
SCNNlA-5343 + UGGGGAACCGGGAGGAC 17 9192
SCNNlA-5344 + UGCGGCUGGACUGGGAC 17 9193
SCNNlA-5345 + CCAGGUUGCGGCUGGAC 17 9194
SCNNlA-5346 + CCUCCCCCUCACCUGAC 17 9195
SCNNlA-5347 + AGGUGAACUGGGAGUAC 17 9196
SCNNlA-5348 + AGGCUCAGGGUCCAACC 17 9197
SCNNlA-5349 - CCAGUCCAGCCGCAACC 17 9198
SCNNlA-5350 + CCAACCUUGUCCAGACC 17 9199
SCNNlA-156 + UUCCCCUCCAUGAGACC 17 653
SCNNlA-5351 - UGCCCAAUGUAAGGACC 17 9200
SCNNlA-368 - CCUCUGCAGCCCAUACC 17 4217
SCNNlA-5352 - CUCCCGGUUCCCCACCC 17 9201
SCNNlA-5353 + UAAGGUGCUCAGCACCC 17 9202
SCNNlA-5354 + CAACCUUGUCCAGACCC 17 9203
SCNNlA-369 + CCGAGUGAGGCUGCCCC 17 4218
SCNNlA-5355 - AGGCCUAUCUCCUCCCC 17 9204
SCNNlA-5356 + ACACAGACCCGGAGCCC 17 9205
SCNNlA-5357 + AGACCCGGGAGGGGCCC 17 9206
SCNNlA-5358 - CCUGUCGCUUCCAUCCC 17 9207
SCNNlA-5359 - AGGUUGGACCCUGAGCC 17 9208
SCNNlA-5360 + CCAGUCUCCCUUGAGCC 17 9209
SCNNlA-5361 + CCGCCCGCUGGCCGGCC 17 9210
SCNNlA-5362 + UGACAGGUGCAGCGGCC 17 9211
SCNNlA-5363 - CUGCCGCGUGCAGGGCC 17 9212
SCNNlA-5364 + AGAAGAAUUGCAAUGCC 17 9213
1327
5535.1 SCNNlA-5365 + UUACACUGUUGGCUGCC 17 9214
SCNNlA-5366 - UCCCGGCUUUCACAUCC 17 9215
SCNNlA-5367 - AGCUGAGACACAGAUCC 17 9216
SCNNlA-5368 - UUCCUUCGGAAAACUCC 17 9217
SCNNlA-370 - UCUCCCCAAUCCACUCC 17 4219
SCNNlA-87 - CCUCCACAGUCCACUCC 17 608
SCNNlA-5369 + AG AAAAG G C AG U AC U CC 17 9218
SCNNlA-5370 - UUCACCUGGGCCCCUCC 17 9219
SCNNlA-5371 + AUGCGUCUGCCUCCUCC 17 9220
SCNNlA-5372 + UUUGGUCUUCUUCCUCC 17 9221
SCNNlA-5373 + AAAGGGAGUCUGUCUCC 17 9222
SCNNlA-371 - AGCCUCACUCGGGUUCC 17 4220
SCNNlA-5374 + CUUCUUAAAGUGAAAGC 17 9223
SCNNlA-5375 + CACCUGGAUGUGAAAGC 17 9224
SCNNlA-260 - C A U G A AG G G G A AC A AG C 17 868
SCNNlA-84 - CAUGGAGGGGAACAAGC 17 607
SCNNlA-5376 + AGGGGCCCAGGUGAAGC 17 9225
SCNNlA-5377 - AACUCUGUGACCACAGC 17 9226
SCNNlA-372 + CCCUUGGAAGGGACAGC 17 4221
SCNNlA-5378 - AUCCCUGGCCGGCCAGC 17 9227
SCNNlA-5379 + CUCAAUUAAAGGUGAGC 17 9228
SCNNlA-5380 + C A AG C A AG G AG U U U AG C 17 9229
SCNNlA-5381 + CAGCGCGAGGGCCACGC 17 9230
SCNNlA-5382 + CUGGGGAGCCCGCCCGC 17 9231
SCNNlA-5383 - UUGGCCCCAACUCCCGC 17 9232
SCNNlA-5384 - CUCUUCCUUUCCAGCGC 17 9233
SCNNlA-373 - UGGGAGAAUGUGGGCGC 17 4222
SCNNlA-5385 - U G G C A A A U AG A A A AG G C 17 9234
SCNNlA-5386 - UGUAUCAAUGCUCAGGC 17 9235
SCNNlA-5387 + ACUGAGUGAGUAGAGGC 17 9236
SCNNlA-5388 + CAGGCCCUGCACGCGGC 17 9237
SCNNlA-5389 + CACUCCCAGGUUGCGGC 17 9238
SCNNlA-5390 + UCAGACCCAAAAAGGGC 17 9239
SCNNlA-5391 + UUAAAGGUGAGCAGGGC 17 9240
SCNNlA-5392 - CUGGCCGGCCAGCGGGC 17 9241
SCNNlA-5393 - UCGCUUCCAUCCCUGGC 17 9242
SCNNlA-5394 + AGGUGCAGCGGCCUGGC 17 9243
SCNNlA-5395 + AGAGAAGAGGUCUCUGC 17 9244
SCNNlA-5396 - AACUCCCGCAGGUCUGC 17 9245
SCNNlA-5397 - CCUUCCCUGCCGCGUGC 17 9246
SCNNlA-5398 - CAGACUCCCUUUGGUGC 17 9247
SCNNlA-5399 - UUAUCUUAUUGUAUUGC 17 9248
1328
5535.1 SCNNlA-5400 + UGUGGUCACAGAGUUGC 17 9249
SCNNlA-5401 + UCCUUUCCAGUUGAAUC 17 9250
SCNNlA-5402 + CAGACUCAUGGGGGAUC 17 9251
SCNNlA-5403 - CGAAAGGUGGCCCUAUC 17 9252
SCNNlA-374 - CUCUCCCCAAUCCACUC 17 4223
SCNNlA-375 - CAGGGGCAGCCUCACUC 17 4224
SCNNlA-5404 + CUCACUGCAGGAGACUC 17 9253
SCNNlA-5405 + CCUGAGAAGGCGGACUC 17 9254
SCNNlA-5406 + AGGUCAGCCUCACCCUC 17 9255
SCNNlA-5407 - CCAGUUCACCUGCCCUC 17 9256
SCNNlA-5408 - CUAGGGAAGCCCAGCUC 17 9257
SCNNlA-5409 + AUGGGGGAUCGGGGCUC 17 9258
SCNNlA-5410 - CUCCUAGCUGUGGGCUC 17 9259
SCNNlA-5411 + UGGAUUCGUCUGCUCUC 17 9260
SCNNlA-5412 - CCCCAUGAGUCUGUCUC 17 9261
SCNNlA-5413 - AGAGAUGACACCUUCUC 17 9262
SCNNlA-5414 - CCAGAGUCCGCCUUCUC 17 9263
SCNNlA-376 + UGGGGAGAGCAAGGGUC 17 4225
SCNNlA-5415 + AAUUGCAAUGCCUGGUC 17 9264
SCNNlA-5416 - AGGCCGCUGCACCUGUC 17 9265
SCNNlA-5417 + AGGAGUGGAGUGCCAAG 17 9266
SCNNlA-377 - CAGCUGUCCCUUCCAAG 17 4226
SCNNlA-5418 + CAGCGCUGGAAAGGAAG 17 9267
SCNNlA-5419 + ACCCGGAGCCCAGGAAG 17 9268
SCNNlA-5420 - UGGGGCCCGUGAGGAAG 17 9269
SCNNlA-378 - CUCCGGGGCUCAUGAAG 17 4227
SCNNlA-5421 + CCUCCCCGCUCACUAAG 17 9270
SCNNlA-5422 - UAAGUAGAUAGCCCCAG 17 9271
SCNNlA-5423 - CAUCCCUGGCCGGCCAG 17 9272
SCNNlA-5424 - CUCGAGGUCAGGGCCAG 17 9273
SCNNlA-379 - CCUCACUCGGGUUCCAG 17 4228
SCNNlA-5425 - CCCUAUCAGGGAAGCAG 17 9274
SCNNlA-5426 - CUCUGUGACCACAGCAG 17 9275
SCNNlA-5427 - UGGGAUAUGUGGGGCAG 17 9276
SCNNlA-5428 + AGGCGGACUCUGGGCAG 17 9277
SCNNlA-380 + CCUGGUAUGGGCUGCAG 17 4229
SCNNlA-5429 + UCACCUGACAGGUGCAG 17 9278
SCNNlA-5430 - AGAGACUGCCGCAAGAG 17 9279
SCNNlA-5431 - AGGGCCUAGAGUGAGAG 17 9280
SCNNlA-381 + CUUCAUGAGCCCCGGAG 17 4230
SCNNlA-5432 + UUGUCCAGACCCGGGAG 17 9281
SCNNlA-5433 - CAAGGCAAGGGGGGGAG 17 9282
1329
5535.1 SCNNlA-5434 - CAGCCGCAACCUGGGAG 17 9283
SCNNlA-5435 - UCUGGACAAGGUUGGAG 17 9284
SCNNlA-5436 - UGAGGGCCUAGAGUGAG 17 9285
SCNNlA-5437 - UGCUCCCACUUAGUGAG 17 9286
SCNNlA-5438 - AUGCUGCCUUAAGCUAG 17 9287
SCNNlA-5439 + UAAGAGCCAAGGGCUAG 17 9288
SCNNlA-5440 + AACCCAGGCCCUGCACG 17 9289
SCNNlA-5441 + AGCAUUGAUACACACCG 17 9290
SCNNlA-5442 + CUCCCACACAGAGCCCG 17 9291
SCNNlA-5443 + AGGAAGGAGGGCUCCCG 17 9292
SCNNlA-382 - CUCCCCAAUCCACUCCG 17 4231
SCNNlA-5444 - CUCCCACUUAGUGAGCG 17 9293
SCNNlA-5445 + CAACCAGAGGCAGCGCG 17 9294
SCNNlA-5446 + UAAAGGUGAGCAGGGCG 17 9295
SCNNlA-5447 + AGACUCAUGGGGGAUCG 17 9296
SCNNlA-5448 - AAU CAGG ACACAG CU CG 17 9297
SCNNlA-5449 + AGUUUUCCGAAGGAAGG 17 9298
SCNNlA-5450 + CUCACGGGCCCCACAGG 17 9299
SCNNlA-5451 + AAAGGUGAGCAGGGCGG 17 9300
SCNNlA-5452 + AUUAAAGGUGAGCAGGG 17 9301
SCNNlA-383 - AGAAUGUGGGCGCAGGG 17 4232
SCNNlA-5453 - AGCACCUUAUUGCAGGG 17 9302
SCNNlA-5454 + CUGGGUGGGGAACCGGG 17 9303
SCNNlA-5455 + CCUUGUCCAGACCCGGG 17 9304
SCNNlA-5456 - CCUGGCCGGCCAGCGGG 17 9305
SCNNlA-5457 + AAGGUGAGCAGGGCGGG 17 9306
SCNNlA-384 - CUGUCCCUUCCAAGGGG 17 4233
SCNNlA-5458 - CCACUUAGUGAGCGGGG 17 9307
SCNNlA-5459 + UUGAUACACACCGGGGG 17 9308
SCNNlA-5460 + CCUAGACAGGCCCUGGG 17 9309
SCNNlA-5461 + CUGAGACAGACUCAUGG 17 9310
SCNNlA-81 - CAUACCAGGUCUCAUGG 17 605
SCNNlA-5462 - UGAGACACAGAUCCUGG 17 9311
SCNNlA-5463 - UGUCUGCUGGCUUGUGG 17 9312
SCNNlA-5464 - CCUGUGGGUGCCCUUGG 17 9313
SCNNlA-5465 + ACAGAGUUGCAGGAAUG 17 9314
SCNNlA-5466 + CCUGAGACAGACUCAUG 17 9315
SCNNlA-5467 - UGUUGCCCUCCUAGCUG 17 9316
SCNNlA-5468 + UGUAAUCGCCCCUGCUG 17 9317
SCNNlA-385 + CCCCUGGAACCCGAGUG 17 4234
SCNNlA-5469 - CUCCUGUGGGGCCCGUG 17 9318
SCNNlA-5470 - AAUCCACGGGCUCUGUG 17 9319
1330
5535.1 SCNNlA-387 + AGCCCCGGAGUGGAUUG 17 4236
SCNNlA-5471 + UGUGGCUUCCUCUCUUG 17 9320
SCNNlA-5472 + CAGACCUGCGGGAGUUG 17 9321
SCNNlA-5473 + UCCUGAGACAGACUCAU 17 9322
SCNNlA-5474 + ACACCGGGGGAGGAGAU 17 9323
SCNNlA-5475 + ACAGACUCAUGGGGGAU 17 9324
SCNNlA-388 + UGAGCCCCGGAGUGGAU 17 4237
SCNNlA-5476 + UCCUCUGCUUCCCUGAU 17 9325
SCNNlA-389 - CGGGUUCCAGGGGUGAU 17 4238
SCNNlA-5477 + AGGAGAAAUUCGUUGAU 17 9326
SCNNlA-158 + UCCAUGAGACCUGGUAU 17 654
SCNNlA-5478 + CCGAGGGCAGGUGAACU 17 9327
SCNNlA-5479 - UCUCCUUGCUCACCACU 17 9328
SCNNlA-5480 + CAGGUUGCGGCUGGACU 17 9329
SCNNlA-5481 - CAGUCCAGCCGCAACCU 17 9330
SCNNlA-5482 - AGCCCCCAGCUUCACCU 17 9331
SCNNlA-5483 - UAGGCUCCCCUAGCCCU 17 9332
SCNNlA-5484 + ACGCCUAGACAGGCCCU 17 9333
SCNNlA-5485 - UGACCUGUGGGUGCCCU 17 9334
SCNNlA-5486 + AAGGGCUAGGGGAGCCU 17 9335
SCNNlA-5487 - UGCCGCGUGCAGGGCCU 17 9336
SCNNlA-5488 + AUCCUGAGCCCACAGCU 17 9337
SCNNlA-5489 + CCAAAAGUGCCGGAGCU 17 9338
SCNNlA-5490 + CAUAAGAGCCAAGGGCU 17 9339
SCNNlA-5491 - CCACAUUCCUGCACUCU 17 9340
SCNNlA-5492 + UUGCCCCCUCUCACUCU 17 9341
SCNNlA-5493 + CUGAGAAGGCGGACUCU 17 9342
SCNNlA-5494 - AGUUUCUAGGGGUCUCU 17 9343
SCNNlA-390 + AUGGGCUGCAGAGGUCU 17 4239
SCNNlA-5495 + AGGGCUCCAGGAGGUCU 17 9344
SCNNlA-5496 - AGAGGAGAGGCCGUUCU 17 9345
SCNNlA-5497 + CUAGAGGCUCAGCAAGU 17 9346
SCNNlA-5498 + CUCCCCGCUCACUAAGU 17 9347
SCNNlA-5499 + AGCAGACCUGCGGGAGU 17 9348
SCNNlA-5500 - AGCCGCAACCUGGGAGU 17 9349
SCNNlA-5501 - CCGGGUCUGGACAAGGU 17 9350
SCNNlA-5502 + AGUGAGUAGAGGCAGGU 17 9351
SCNNlA-5503 - UGCCUUAAGCUAGUGGU 17 9352
SCNNlA-5504 + CAGAGUUGCAGGAAUGU 17 9353
SCNNlA-5505 - UCUGGGCUGCCUCCUGU 17 9354
SCNNlA-5506 - AUCCACGGGCUCUGUGU 17 9355
SCNNlA-5507 + AGCCAGGUCCUUACAUU 17 9356
1331
5535.1 SCNNlA-5508 - CUCCUGGAAGCACACUU 17 9357
SCNNlA-5509 - UGGAGACAGACUCCCUU 17 9358
SCNNlA-5510 - UUUUGCUGCAUUAAGUU 17 9359
SCNNlA-392 - AGCAAGGGAACCUGGUU 17 4241
SCNNlA-5511 - CCCAGCUCCGGCACUUU 17 9360
SCNNlA-5512 - UCUCCUCCAGCCCUUUU 17 9361
SCNNlA-5513 - CUCCUCCAGCCCUUUUU 17 9362
SCNNlA-5514 + UCAGAGAAUCAGACCCAAAA 20 9363
SCNNlA-5515 + UAGAAGGAGCCAGCACCAAA 20 9364
SCNNlA-5516 - CAUGAGCUGGCAAAUAGAAA 20 9365
SCNNlA-5517 + AUCUCCUUGGCUCUGUGAAA 20 9366
SCNNlA-5518 + AUAGAAGGAGCCAGCACCAA 20 9367
SCNNlA-5519 - UCCUGGAGGAAGAAGACCAA 20 9368
SCNNlA-5520 + AGAUAAGACAUAAGAGCCAA 20 9369
SCNNlA-5521 - AAUCCAGCUGUCCCUUCCAA 20 9370
SCNNlA-393 - AG C AG U A U C A AG G U A AG C A A 20 4242
SCNNlA-5522 - AAUGUAAGGACCUGGCUCAA 20 9371
SCNNlA-5523 + CCCUGGCUGUUUGAUCUCAA 20 9372
SCNNlA-5524 - AGGUCUGCUGGCUCCAGGAA 20 9373
SCNNlA-5525 - AACUGAUUUAUCCUUGGGAA 20 9374
SCNNlA-394 + CAUGAUACCUCCCCUUGGAA 20 4243
SCNNlA-5526 + CUCAUUAGCAUCUCAAUUAA 20 9375
SCNNlA-5527 + ACAGCUAGGAGGGCAACACA 20 9376
SCNNlA-395 - UGUGGGCGCAGGGUGGGACA 20 4244
SCNNlA-5528 - CCUUUGAGAUCAAACAGCCA 20 9377
SCNNlA-5529 - CCAGAG AGCAGACGAAU CCA 20 9378
SCNNlA-5530 + AGCAAGUGGGCAGCCCUCCA 20 9379
SCNNlA-5531 - AAAUCCAGCUGUCCCUUCCA 20 9380
SCNNlA-5532 + CUGCUGAAUCUUGACAAGCA 20 9381
SCNNlA-5533 + UGUCUCCAGGAAGGAGAGCA 20 9382
SCNNlA-5534 + AUCUCAAUUAAAGGUGAGCA 20 9383
SCNNlA-396 - AGUGGGAGAAUGUGGGCGCA 20 4245
SCNNlA-5535 + CCGGAGCCCAGGAAGAGGCA 20 9384
SCNNlA-5536 + CCCAGGCCCUGCACGCGGCA 20 9385
SCNNlA-5537 + CCAGGUCCUUACAUUGGGCA 20 9386
SCNNlA-5538 - AGCCUUCCCUGCCGCGUGCA 20 9387
SCNNlA-5539 + AAG C AGG CAC U G AAG G U G C A 20 9388
SCNNlA-5540 - CUCGAAAGGUGGCCCUAUCA 20 9389
SCNNlA-397 - AGGUAUCAUGAGCAGUAUCA 20 4246
SCNNlA-5541 + AAGGCAGUACUCCAGGCUCA 20 9390
SCNNlA-5542 - CAAUGUAAGGACCUGGCUCA 20 9391
SCNNlA-398 + AUUGGGGAGAGCAAGGGUCA 20 4247
1332
5535.1 SCNNlA-5543 + UGGGAGUACUGGACCUGAGA 20 9392
SCNNlA-5544 + CAGAGCCGGGAGUUUUCCGA 20 9393
SCNNlA-5545 + ACAAUAGAGAGGGACAGCGA 20 9394
SCNNlA-5546 + AAGGGAGUCUGUCUCCAGGA 20 9395
SCNNlA-5547 + UCCUGAGCCCACAGCUAGGA 20 9396
SCNNlA-5548 + AACCUUGUCCAGACCCGGGA 20 9397
SCNNlA-5549 + CCUGGAUGUGAAAGCCGGGA 20 9398
SCNNlA-5550 - AGAUGACACCUUCUCUGGGA 20 9399
SCNNlA-5551 - AAACUGAUUUAUCCUUGGGA 20 9400
SCNNlA-3 - CCCAUACCAGGUCUCAUGGA 20 556
SCNNlA-5552 - UUUGUCUGCUGGCUUGUGGA 20 9401
SCNNlA-399 + UCAUGAUACCUCCCCUUGGA 20 4248
SCNNlA-5553 - CGGGUCUGGACAAGGUUGGA 20 9402
SCNNlA-400 - AUCCACUCCGGGGCUCAUGA 20 4249
SCNNlA-5554 - CUCUUCUCUGCAGGGCCUGA 20 9403
SCNNlA-5555 - CGGGCUCUGUGUGGGAGUGA 20 9404
SCNNlA-5556 - CCGCUGCACCUGUCAGGUGA 20 9405
SCNNlA-401 - CACUCGGGUUCCAGGGGUGA 20 4250
SCNNlA-5557 + UCUCCUCUGCUUCCCUGAUA 20 9406
SCNNlA-5558 - AAGGGAGACUGGAGUUUCUA 20 9407
SCNNlA-78 + CCCCUCCAUGAGACCUGGUA 20 500
SCNNlA-5559 - UUUGGAAUCCUGGUUGACAC 20 9408
SCNNlA-5560 + AGCCCUCCAAGGGCACCCAC 20 9409
SCNNlA-5561 + CGCUUCCUCACGGGCCCCAC 20 9410
SCNNlA-5562 - CAGAGAGCAGACGAAUCCAC 20 9411
SCNNlA-5563 + CAGGGGCUUUAGACGCAGAC 20 9412
SCNNlA-5564 + CGGCCAGGGAUGGAAGCGAC 20 9413
SCNNlA-5565 + CUCCCAGGUUGCGGCUGGAC 20 9414
SCNNlA-5566 + UCCAGGCUCAGGGUCCAACC 20 9415
SCNNlA-5567 + AGUGAAAGCCGGUGUCAACC 20 9416
SCNNlA-404 - U C A AG G U A AG C A AG G G A AC C 20 4253
SCNNlA-5568 + CCUGAGCAUUGAUACACACC 20 9417
SCNNlA-5569 + CCUCCAACCUUGUCCAGACC 20 9418
SCNNlA-5570 - CCAUGCCCAAUGUAAGGACC 20 9419
SCNNlA-5571 - AGCAGGAAAGAGGAGGGACC 20 9420
SCNNlA-405 - AGACCUCUGCAGCCCAUACC 20 4254
SCNNlA-5572 + CUCCAACCUUGUCCAGACCC 20 9421
SCNNlA-406 + AACCCGAGUGAGGCUGCCCC 20 4255
SCNNlA-5573 + CCUGAUUCUGUCUCUGCCCC 20 9422
SCNNlA-5574 - UGCAGGCCUAUCUCCUCCCC 20 9423
SCNNlA-5575 + UGGACACAGACCCGGAGCCC 20 9424
SCNNlA-5576 - AUUCCUGUCGCUUCCAUCCC 20 9425
1333
5535.1 SCNNlA-5577 - AACGAAUUUCUCCUCCUCCC 20 9426
SCNNlA-5578 - ACCUUUGAGAUCAAACAGCC 20 9427
SCNNlA-5579 - AGCGGGCGGGCUCCCCAGCC 20 9428
SCNNlA-5580 + ACAAGGAGAAGGGGCCAGCC 20 9429
SCNNlA-5581 - ACCAGGUUGGACCCUGAGCC 20 9430
SCNNlA-5582 + ACUCCAGUCUCCCUUGAGCC 20 9431
SCNNlA-5583 + ACACUGUUGGCUGCCAGGCC 20 9432
SCNNlA-5584 + ACCUGACAGGUGCAGCGGCC 20 9433
SCNNlA-5585 - UCCCUGCCGCGUGCAGGGCC 20 9434
SCNNlA-5586 + UUUUUACACUGUUGGCUGCC 20 9435
SCNNlA-5587 - CCUUCCCGGCUUUCACAUCC 20 9436
SCNNlA-5588 - AGGAGCUGAGACACAGAUCC 20 9437
SCNNlA-5589 - UCCUUCCUUCGGAAAACUCC 20 9438
SCNNlA-408 - UGCUCUCCCCAAUCCACUCC 20 4257
SCNNlA-8 - AGCCCUCCACAGUCCACUCC 20 559
SCNNlA-5590 + AAGAGAAAAGGCAGUACUCC 20 9439
SCNNlA-5591 - UGGAGGCAGCCCAGACCUCC 20 9440
SCNNlA-5592 - AGCUUCACCUGGGCCCCUCC 20 9441
SCNNlA-5593 - UUUCUGCCCUCCUGUCCUCC 20 9442
SCNNlA-5594 - CUUGCUGAGCCUCUAGCUCC 20 9443
SCNNlA-5595 - CCCGCAGGUCUGCUGGCUCC 20 9444
SCNNlA-5596 + ACCAAAGGGAGUCUGUCUCC 20 9445
SCNNlA-5597 - CAGGGGCGAUUACACAUUCC 20 9446
SCNNlA-5598 - UCCCCCCUUGCUCUCCUUCC 20 9447
SCNNlA-5 - UCUCAUGGAGGGGAACAAGC 20 557
SCNNlA-5599 - UGCAACUCUGUGACCACAGC 20 9448
SCNNlA-409 + CUCCCCUUGGAAGGGACAGC 20 4258
SCNNlA-5600 - UCCAUCCCUGGCCGGCCAGC 20 9449
SCNNlA-5601 + CAUCUCAAUUAAAGGUGAGC 20 9450
SCNNlA-5602 + UGACAAGCAAGGAGUUUAGC 20 9451
SCNNlA-5603 + AGGCAGCGCGAGGGCCACGC 20 9452
SCNNlA-5604 + UGGCUGGGGAGCCCGCCCGC 20 9453
SCNNlA-5605 - CUUUUGGCCCCAACUCCCGC 20 9454
SCNNlA-5606 - ACCCUCUUCCUUUCCAGCGC 20 9455
SCNNlA-5607 - UCGAGGUCAGGGCCAGAGGC 20 9456
SCNNlA-5608 + ACGCAGACAGGCAAGGAGGC 20 9457
SCNNlA-5609 + ACCCAGGCCCUGCACGCGGC 20 9458
SCNNlA-5610 + UCCCACUCCCAGGUUGCGGC 20 9459
SCNNlA-5611 + CAAUUAAAGGUGAGCAGGGC 20 9460
SCNNlA-5612 - UCCCUGGCCGGCCAGCGGGC 20 9461
SCNNlA-5613 + UGAGAAGGCGGACUCUGGGC 20 9462
SCNNlA-5614 - CUGUCGCUUCCAUCCCUGGC 20 9463
1334
5535.1 SCNNlA-5615 + CCUGGAGCCAGCAGACCUGC 20 9464
SCNNlA-5616 + AAGAGAGAAGAGGUCUCUGC 20 9465
SCNNlA-5617 - CCCAACUCCCGCAGGUCUGC 20 9466
SCNNlA-5618 - CAGGCUGGGCCUUUGUCUGC 20 9467
SCNNlA-5619 - CAGCCUUCCCUGCCGCGUGC 20 9468
SCNNlA-5620 + A A AG CAGGCACUGAAGGUGC 20 9469
SCNNlA-5621 + UUCGUCUGCUCUCUGGGUGC 20 9470
SCNNlA-5622 - ACCUUAUCUUAUUGUAUUGC 20 9471
SCNNlA-5623 + UGCUGUGGUCACAGAGUUGC 20 9472
SCNNlA-5624 - CCUGGGGCAGAGACAGAAUC 20 9473
SCNNlA-5625 + AGACAGACUCAUGGGGGAUC 20 9474
SCNNlA-5626 - ACUCGAAAGGUGGCCCUAUC 20 9475
SCNNlA-410 - UUGCUCUCCCCAAUCCACUC 20 4259
SCNNlA-5627 + UAAGUGGGAGCAGCGCACUC 20 9476
SCNNlA-5628 + AAAAGGGCUGGAGGAGACUC 20 9477
SCNNlA-5629 + CACAGGUCAGCCUCACCCUC 20 9478
SCNNlA-5630 - CGUGGCCCUCGCGCUGCCUC 20 9479
SCNNlA-411 + UCAGGGUCAAGGCUGAGCUC 20 4260
SCNNlA-5631 + AAAGGCAGUACUCCAGGCUC 20 9480
SCNNlA-5632 + CUCAUGGGGGAUCGGGGCUC 20 9481
SCNNlA-5633 - CCCGGUGUGUAUCAAUGCUC 20 9482
SCNNlA-5634 + CCGUGGAUUCGUCUGCUCUC 20 9483
SCNNlA-5635 - CUGGAGUUUCUAGGGGUCUC 20 9484
SCNNlA-5636 - AUCCCCCAUGAGUCUGUCUC 20 9485
SCNNlA-5637 - AGCAGAGAUGACACCUUCUC 20 9486
SCNNlA-5638 - UGCCCAGAGUCCGCCUUCUC 20 9487
SCNNlA-5639 - UCAGGACACAGCUCGAGGUC 20 9488
SCNNlA-5640 + AAGAAUUGCAAUGCCUGGUC 20 9489
SCNNlA-5641 - UAAGCUAGUGGUUGGAUUUC 20 9490
SCNNlA-5642 + AUAAGGAGUGGAGUGCCAAG 20 9491
SCNNlA-412 - AUCCAGCUGUCCCUUCCAAG 20 4261
SCNNlA-5643 + CAGACCCGGAGCCCAGGAAG 20 9492
SCNNlA-5644 - CUGUGGGGCCCGUGAGGAAG 20 9493
SCNNlA-5645 + UCUCCUCCCCGCUCACUAAG 20 9494
SCNNlA-5646 - CGCUAAGUAGAUAGCCCCAG 20 9495
SCNNlA-5647 - UUCCAUCCCUGGCCGGCCAG 20 9496
SCNNlA-5648 - CAGCUCGAGGUCAGGGCCAG 20 9497
SCNNlA-413 - UGGGACAUGGGCAUGGCCAG 20 4262
SCNNlA-414 - CAGCCUCACUCGGGUUCCAG 20 4263
SCNNlA-5649 - UGGCCCUAUCAGGGAAGCAG 20 9498
SCNNlA-5650 - CAACUCUGUGACCACAGCAG 20 9499
SCNNlA-5651 - CUCUGGGAUAUGUGGGGCAG 20 9500
1335
5535.1 SCNNlA-5652 + AGAAGGCGGACUCUGGGCAG 20 9501
SCNNlA-415 + AGACCUGGUAUGGGCUGCAG 20 4264
SCNNlA-5653 - CUGAGGGCCUAGAGUGAGAG 20 9502
SCNNlA-5654 + UGCAGCAAAAGGAUAAGGAG 20 9503
SCNNlA-5655 + ACCUUGUCCAGACCCGGGAG 20 9504
SCNNlA-4 - CCAUACCAGGUCUCAUGGAG 20 498
SCNNlA-5656 + AAGGGGCCAGCCAGGCUGAG 20 9505
SCNNlA-5657 - AGCUGAGGGCCUAGAGUGAG 20 9506
SCNNlA-5658 - CGCUGCUCCCACUUAGUGAG 20 9507
SCNNlA-5659 - CGCUGCACCUGUCAGGUGAG 20 9508
SCNNlA-5660 + CAAGGGCUAGGGGAGCCUAG 20 9509
SCNNlA-5661 + AGUGUGCUUCCAGGAGCUAG 20 9510
SCNNlA-5662 + ACAUAAGAGCCAAGGGCUAG 20 9511
SCNNlA-5663 - AGGGAGACUGGAGUUUCUAG 20 9512
SCNNlA-5664 + CACAACCCAGGCCCUGCACG 20 9513
SCNNlA-5665 + CUGAGCAUUGAUACACACCG 20 9514
SCNNlA-5666 + UCACUCCCACACAGAGCCCG 20 9515
SCNNlA-5667 + CGAAGGAAGGAGGGCUCCCG 20 9516
SCNNlA-5668 - CUGCUCCCACUUAGUGAGCG 20 9517
SCNNlA-5669 + AAUUAAAGGUGAGCAGGGCG 20 9518
SCNNlA-5670 - CAAGGUUGGAGGGGGUGGCG 20 9519
SCNNlA-5671 - UGUGUCCACAGUGUCCUGCG 20 9520
SCNNlA-5672 - CAGAAUCAGGACACAGCUCG 20 9521
SCNNlA-5673 - CUAGGACAAAACUCGAAAGG 20 9522
SCNNlA-5674 + UUAGACGCAGACAGGCAAGG 20 9523
SCNNlA-5675 + UUCCUCACGGGCCCCACAGG 20 9524
SCNNlA-5676 + UGGGGAACCGGGAGGACAGG 20 9525
SCNNlA-5677 + ACUGAGUGAGUAGAGGCAGG 20 9526
SCNNlA-5678 - UAAGUAGAUAGCCCCAGAGG 20 9527
SCNNlA-5679 - UGAGGGCCUAGAGUGAGAGG 20 9528
SCNNlA-5680 + AUCCUGAGCCCACAGCUAGG 20 9529
SCNNlA-5681 + AGGUGAAGCUGGGGGCUAGG 20 9530
SCNNlA-5682 + UGAGCAUUGAUACACACCGG 20 9531
SCNNlA-5683 + AUUAAAGGUGAGCAGGGCGG 20 9532
SCNNlA-5684 + CAGGCACUGAAGGUGCAGGG 20 9533
SCNNlA-5685 - CUGAGCACCUUAUUGCAGGG 20 9534
SCNNlA-5686 + CAACCUUGUCCAGACCCGGG 20 9535
SCNNlA-5687 - AUCCCUGGCCGGCCAGCGGG 20 9536
SCNNlA-5688 + UUAAAGGUGAGCAGGGCGGG 20 9537
SCNNlA-416 - CAGCUGUCCCUUCCAAGGGG 20 4265
SCNNlA-5689 - CUCCCACUUAGUGAGCGGGG 20 9538
SCNNlA-5690 - CUGGACAAGGUUGGAGGGGG 20 9539
1336
5535.1 SCNNlA-5691 + ACGCCUAGACAGGCCCUGGG 20 9540
SCNNlA-5692 + UUCCUGAGACAGACUCAUGG 20 9541
SCNNlA-5693 - AGCUGAGACACAGAUCCUGG 20 9542
SCNNlA-5694 + UCAGACCCAAAAAGGGCUGG 20 9543
SCNNlA-75 + AGCCCUGGAGUGGACUGUGG 20 602
SCNNlA-5695 - CUUUGUCUGCUGGCUUGUGG 20 9544
SCNNlA-5696 - UGACCUGUGGGUGCCCUUGG 20 9545
SCNNlA-5697 - CCGGGUCUGGACAAGGUUGG 20 9546
SCNNlA-5698 + CUUCCUGAGACAGACUCAUG 20 9547
SCNNlA-5699 + CUGAAGGUGCAGGGAGGAUG 20 9548
SCNNlA-5700 - CUAGGGGUCUCUGGGAUAUG 20 9549
SCNNlA-5701 + UCCUGGAGCCAGCAGACCUG 20 9550
SCNNlA-5702 - CUGAGGGUGAGGCUGACCUG 20 9551
SCNNlA-5703 - UCUCUUCUCUGCAGGGCCUG 20 9552
SCNNlA-5704 - UUGUGUUGCCCUCCUAGCUG 20 9553
SCNNlA-5705 + CAGGUGCAGCGGCCUGGCUG 20 9554
SCNNlA-5706 + AUGUGUAAUCGCCCCUGCUG 20 9555
SCNNlA-5707 + AGAAUUCUCCUCCUCCUCUG 20 9556
SCNNlA-5708 + UCAGGGUCCAACCUGGUCUG 20 9557
SCNNlA-5709 + AAGGAUAAAUCAGUUUUCUG 20 9558
SCNNlA-5710 - CUGGGAUAUGUGGGGCAGUG 20 9559
SCNNlA-417 + UCACCCCUGGAACCCGAGUG 20 4266
SCNNlA-5711 - ACGGGCUCUGUGUGGGAGUG 20 9560
SCNNlA-5712 - UGCCUCCUGUGGGGCCCGUG 20 9561
SCNNlA-5713 + UGAGUGAGUAGAGGCAGGUG 20 9562
SCNNlA-5714 - CUCUGCAGGGCCUGAGGGUG 20 9563
SCNNlA-5715 - AGGGGUCUCUGGGAUAUGUG 20 9564
SCNNlA-5716 - ACUCUGGGCUGCCUCCUGUG 20 9565
SCNNlA-5717 - ACGAAUCCACGGGCUCUGUG 20 9566
SCNNlA-5718 - CGUGCAGGGCCUGGGUUGUG 20 9567
SCNNlA-419 + AUGAGCCCCGGAGUGGAUUG 20 4268
SCNNlA-5719 + CAGCAGACCUGCGGGAGUUG 20 9568
SCNNlA-5720 + CUGAGGUUAGAAAACAAAAU 20 9569
SCNNlA-5721 + CUUGAGCCAGGUCCUUACAU 20 9570
SCNNlA-5722 + ACAGCGAAGGACAGAGAGAU 20 9571
SCNNlA-5723 + UACACACCGGGGGAGGAGAU 20 9572
SCNNlA-420 + UCAUGAGCCCCGGAGUGGAU 20 4269
SCNNlA-5724 + CUCUCCUCUGCUUCCCUGAU 20 9573
SCNNlA-421 - ACUCGGGUUCCAGGGGUGAU 20 4270
SCNNlA-5725 + AGGAGGAGAAAUUCGUUGAU 20 9574
SCNNlA-79 + CCCUCCAUGAGACCUGGUAU 20 604
SCNNlA-5726 + CUCCCGAGGGCAGGUGAACU 20 9575
1337
5535.1 SCNNlA-5727 - CUAGCUCCUGGAAGCACACU 20 9576
SCNNlA-5728 - CUCUCUCCUUGCUCACCACU 20 9577
SCNNlA-5729 + AAAAAGGGCUGGAGGAGACU 20 9578
SCNNlA-5730 + UCCCAGGUUGCGGCUGGACU 20 9579
SCNNlA-5731 - UCCCAGUCCAGCCGCAACCU 20 9580
SCNNlA-5732 - CCUAGCCCCCAGCUUCACCU 20 9581
SCNNlA-5733 - CCCUAGGCUCCCCUAGCCCU 20 9582
SCNNlA-5734 + CACACGCCUAGACAGGCCCU 20 9583
SCNNlA-5735 + UGGGGGCUAGGCGGGGCCCU 20 9584
SCNNlA-5736 - ACUCCCAGUUCACCUGCCCU 20 9585
SCNNlA-5737 - CCCUGCCGCGUGCAGGGCCU 20 9586
SCNNlA-5738 + UGGGUGCUGGGUUAUCUCCU 20 9587
SCNNlA-5739 - UCCUGGAGCCCUGCAGUCCU 20 9588
SCNNlA-5740 + AGGAUCCUGAGCCCACAGCU 20 9589
SCNNlA-5741 - UGUGUAUCAAUGCUCAGGCU 20 9590
SCNNlA-5742 + CGCAGACAGGCAAGGAGGCU 20 9591
SCNNlA-5743 + AGACAUAAGAGCCAAGGGCU 20 9592
SCNNlA-5744 + ACAGGUGCAGCGGCCUGGCU 20 9593
SCNNlA-5745 + UCGUCUGCUCUCUGGGUGCU 20 9594
SCNNlA-5746 - UGACCACAUUCCUGCACUCU 20 9595
SCNNlA-422 + CAGGGUCAAGGCUGAGCUCU 20 4271
SCNNlA-5747 + CGUGGAUUCGUCUGCUCUCU 20 9596
SCNNlA-5748 - UGGAGUUUCUAGGGGUCUCU 20 9597
SCNNlA-5749 + UGCAGGGCUCCAGGAGGUCU 20 9598
SCNNlA-5750 - AGCAGAGGAGAGGCCGUUCU 20 9599
SCNNlA-5751 - CAAGGGAGACUGGAGUUUCU 20 9600
SCNNlA-5752 + CUCCUCCCCGCUCACUAAGU 20 9601
SCNNlA-5753 - UCUGGGAUAUGUGGGGCAGU 20 9602
SCNNlA-5754 - UCCAGCCGCAACCUGGGAGU 20 9603
SCNNlA-5755 - CUCCCGGGUCUGGACAAGGU 20 9604
SCNNlA-5756 + CUGAGUGAGUAGAGGCAGGU 20 9605
SCNNlA-5757 + UGGGAGCAGCGCACUCAGGU 20 9606
SCNNlA-5758 - UGCUGCCUUAAGCUAGUGGU 20 9607
SCNNlA-5759 - AGGGAGGAGUGGGAGAAUGU 20 9608
SCNNlA-5760 + U C ACAG AG U U G CAG G AA U G U 20 9609
SCNNlA-5761 - UAGGGGUCUCUGGGAUAUGU 20 9610
SCNNlA-5762 + UCUGUUCUUUUUUACACUGU 20 9611
SCNNlA-5763 - UGAGGGUGAGGCUGACCUGU 20 9612
SCNNlA-5764 - CACUCUGGGCUGCCUCCUGU 20 9613
SCNNlA-5765 - UGUGUUGCCCUCCUAGCUGU 20 9614
SCNNlA-5766 - CGAAUCCACGGGCUCUGUGU 20 9615
SCNNlA-5767 + UUGAGCCAGGUCCUUACAUU 20 9616
1338
5535.1 SCNNlA-425 + CAUGAGCCCCGGAGUGGAUU 20 4274
SCNNlA-5768 - UAGCUCCUGGAAGCACACUU 20 9617
SCNNlA-5769 - UCCUGGAGACAGACUCCCUU 20 9618
SCNNlA-5770 - CUCGGGAGCCCUCCUUCCUU 20 9619
SCNNlA-5771 - UCCUUUUGCUGCAUUAAGUU 20 9620
SCNNlA-5772 + CCAGCAGACCUGCGGGAGUU 20 9621
SCNNlA-5773 - U UAAG U U UGG AAAG AG AU U U 20 9622
SCNNlA-5774 - AAGCCCAGCUCCGGCACUUU 20 9623
SCNNlA-5775 - AGUCUCCUCCAGCCCUUUUU 20 9624
Table 46C provides exemplary targeting domains for knocking down the SCNN1A gene selected according to the third tier parameters. The targeting domains bind within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS) and start with a 5'G. It is
contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNN1A gene (e.g., reduce or eliminate SCNN1A gene expression, SCNN1A protein function, or the level of SCNN1A protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNN1A gene
Table 46C
Figure imgf001340_0001
1339
5535.1 SCNNlA-5788 - GAAAGGUGGAGGAGGGA 17 9637
SCNNlA-5789 + GGACAGAGAGAUAGGGA 17 9638
SCNNlA-5790 + GGGAAAGCAGGCACUGA 17 9639
SCNNlA-5791 + GACAGGAUGGCAGGUGA 17 9640
SCNNlA-5792 + GGGCCUGGGUGGGGAAC 17 9641
SCNNlA-5793 + GGCCUGGGUGGGGAACC 17 9642
SCNNlA-5794 - GAAUUUCUCCUCCUCCC 17 9643
SCNNlA-5795 + GAGGAGGAGUCAGAGCC 17 9644
SCNNlA-5796 + GCCAGGCUGAGAGGGCC 17 9645
SCNNlA-429 - GGGACAUGGGCAUGGCC 17 4278
SCNNlA-5797 - GCCUCUUCCUGGGCUCC 17 9646
SCNNlA-5798 - GCAGGUCUGCUGGCUCC 17 9647
SCNNlA-5799 + GAAGAGGCAGGG A A AG C 17 9648
SCNNlA-5800 - GCCAGAAAGAGGAGAGC 17 9649
SCNNlA-86 - GAACAAGCUGGAGGAGC 17 531
SCNNlA-5801 - GGAUUUCAGGCAUGAGC 17 9650
SCNNlA-5802 - GCUCCCACUUAGUGAGC 17 9651
SCNNlA-5803 + GGAGCCCAGGAAGAGGC 17 9652
SCNNlA-5804 - GGGAGAGGAAGAGAGGC 17 9653
SCNNlA-5805 - GAGAGGGAGUGAGAGGC 17 9654
SCNNlA-5806 - GAUUAGAGAGAGGAGGC 17 9655
SCNNlA-5807 - GGCUUGUGGAGGGAGGC 17 9656
SCNNlA-5808 + GGAGGGCUCCCGAGGGC 17 9657
SCNNlA-5809 - GGCCCUCUCAGCCUGGC 17 9658
SCNNlA-5810 + GAGGCAGCCCAGAGUGC 17 9659
SCNNlA-5811 + GAAUUCUCCUCCUCCUC 17 9660
SCNNlA-430 + GGGUCAAGGCUGAGCUC 17 4279
SCNNlA-5812 - GGAGGCAGGCCAG A A AG 17 9661
SCNNlA-5813 + GACAGGAGGGCAGAAAG 17 9662
SCNNlA-5814 + GGCAACACAAGGAGAAG 17 9663
SCNNlA-5815 - GGGGGGGAGAGGAAGAG 17 9664
SCNNlA-5816 + GGUGAGCAAGGAGAGAG 17 9665
SCNNlA-5817 - GAGGCAGGAUUAGAGAG 17 9666
SCNNlA-5818 - GAGGAGGGAGGGAGGAG 17 9667
SCNNlA-5819 + GAGCAGGGCGGGGGGAG 17 9668
SCNNlA-5820 + GGGCCAGCCAGGCUGAG 17 9669
SCNNlA-5821 - GAUAGAGAGGGAGUGAG 17 9670
SCNNlA-5822 - GGUUGGAGGGGGUGGCG 17 9671
SCNNlA-5823 - GCUGGCUCCAGGAAAGG 17 9672
SCNNlA-5824 - GAGGGGGCAAGGCAAGG 17 9673
SCNNlA-5825 + GACUGCAGGGCUCCAGG 17 9674
SCNNlA-5826 + GAGUGAGUAGAGGCAGG 17 9675
1340
5535.1 SCNNlA-5827 + GAGCAAGGAGAGAGAGG 17 9676
SCNNlA-5828 - GCAGGAUUAGAGAGAGG 17 9677
SCNNlA-5829 - GAGGAGGGACCAGGAGG 17 9678
SCNNlA-5830 - GAUAGCCCCAGAGGAGG 17 9679
SCNNlA-5831 + GGGGGGAGGGGCUGAGG 17 9680
SCNNlA-5832 - GCACCUGUCAGGUGAGG 17 9681
SCNNlA-5833 - GGCAGAGACAGAAAGGG 17 9682
SCNNlA-5834 + GCUGGAAAGGAAGAGGG 17 9683
SCNNlA-5835 - GGAAAGGUGGAGGAGGG 17 9684
SCNNlA-5836 - GGGGGCAAGGCAAGGGG 17 9685
SCNNlA-5837 - GACAAGGUUGGAGGGGG 17 9686
SCNNlA-5838 + GUGAGCAGGGCGGGGGG 17 9687
SCNNlA-5839 + GGCUGAGAGGGCCUGGG 17 9688
SCNNlA-5840 + GAGUAGAGGCAGGUGGG 17 9689
SCNNlA-5841 - GGCCUGGGUUGUGUGGG 17 9690
SCNNlA-431 - GAAGGGGAACAAGCUGG 17 4280
SCNNlA-85 - GGAGGGGAACAAGCUGG 17 530
SCNNlA-5842 + GGCCCAGGUGAAGCUGG 17 9691
SCNNlA-5843 - GGCUCCAGGAAAGGUGG 17 9692
SCNNlA-5844 + GUGGGGGGCAGUGGUGG 17 9693
SCNNlA-5845 - GGAGGAGUGGGAGAAUG 17 9694
SCNNlA-5846 - GGAGCCCUGCAGUCCUG 17 9695
SCNNlA-5847 + GGGCCCAGGUGAAGCUG 17 9696
SCNNlA-5848 - GCCAGAGGCUGGAGCUG 17 9697
SCNNlA-5849 + GACAGGCAAGGAGGCUG 17 9698
SCNNlA-5850 + GGCGGGGGGAGGGGCUG 17 9699
SCNNlA-5851 - GGAUAUGUGGGGCAGUG 17 9700
SCNNlA-5852 - GGCUCUGUGUGGGAGUG 17 9701
SCNNlA-5853 + GGACAGGAUGGCAGGUG 17 9702
SCNNlA-5854 + GGUGGGGGGCAGUGGUG 17 9703
SCNNlA-5855 - GCAGGGCCUGGGUUGUG 17 9704
SCNNlA-5856 - GCUCCUGGAAGCACACU 17 9705
SCNNlA-5857 + GGGGCCCAGGUGAAGCU 17 9706
SCNNlA-5858 - GAAGCCACAGACCAGGU 17 9707
SCNNlA-5859 + GCUGAGAGGGCCUGGGU 17 9708
SCNNlA-5860 - GAGGAGUGGGAGAAUGU 17 9709
SCNNlA-5861 - GAGGGGGAGGAGAGGUU 17 9710
SCNNlA-5862 + GCCUUCUGUUUCUCUUU 17 9711
SCNNlA-5863 - GAAGGGGGCAGAGACAGAAA 20 9712
SCNNlA-432 + GAGUGGAUUGGGGAGAGCAA 20 4281
SCNNlA-5864 - GGAAGGGGGCAGAGACAGAA 20 9713
SCNNlA-5865 - GAGGAAGAAGACCAAAGGAA 20 9714
1341
5535.1 SCNNlA-5866 - G AG ACCU U U U CACAG AG CCA 20 9715
SCNNlA-9 - GCCCUCCACAGUCCACUCCA 20 499
SCNNlA-5867 - GCAACUCUGUGACCACAGCA 20 9716
SCNNlA-433 + GGAGUGGAUUGGGGAGAGCA 20 4282
SCNNlA-5868 - GAGUGAGAGGGGGCAAGGCA 20 9717
SCNNlA-5869 + GGAAAGGAAGAGGGUGGGCA 20 9718
SCNNlA-5870 + GUCUCUGCCCCAGGACUGCA 20 9719
SCNNlA-434 + GAGAGCAAGGGUCAGGGUCA 20 4283
SCNNlA-5871 - GAGACCCAAAGAGAAACAGA 20 9720
SCNNlA-435 - GUUCCAGGGGUGAUGGGAGA 20 4284
SCNNlA-5872 + GAAGGAAGGAGGGCUCCCGA 20 9721
SCNNlA-5873 - GGAGGAAGAAGACCAAAGGA 20 9722
SCNNlA-5874 + GGGGAACCGGGAGGACAGGA 20 9723
SCNNlA-5875 - G G A A U C AG C AG G A A AG AG G A 20 9724
SCNNlA-5876 + GUGAGCAAGGAGAGAGAGGA 20 9725
SCNNlA-5877 - GCUCCAGGAAAGGUGGAGGA 20 9726
SCNNlA-5878 + GAAGGACAGAGAGAUAGGGA 20 9727
SCNNlA-5879 + G C AGG G AAAG CAG G C AC U G A 20 9728
SCNNlA-5880 - GGGCCAGAGGCUGGAGCUGA 20 9729
SCNNlA-5881 + GGGGACAGGAUGGCAGGUGA 20 9730
SCNNlA-5882 + GAGAGCCACCCACACAACCC 20 9731
SCNNlA-5883 + GCCUCCAGCUUCCCACUCCC 20 9732
SCNNlA-5884 - GGGAGUGAGGGAGGCCUUCC 20 9733
SCNNlA-5885 + GGGAGGGGCCCAGGUGAAGC 20 9734
SCNNlA-5886 + GGCUGAGGAGGAGUCAGAGC 20 9735
SCNNlA-7 - GGGGAACAAGCUGGAGGAGC 20 504
SCNNlA-5887 + GGGGCCAAAAGUGCCGGAGC 20 9736
SCNNlA-5888 - GUUGGAUUUCAGGCAUGAGC 20 9737
SCNNlA-5889 - GGGGGGAGAGGAAGAGAGGC 20 9738
SCNNlA-5890 + GGCACUGAGUGAGUAGAGGC 20 9739
SCNNlA-5891 - GCUGGCUUGUGGAGGGAGGC 20 9740
SCNNlA-5892 + GGUGAAGCUGGGGGCUAGGC 20 9741
SCNNlA-5893 - GUGACCACAUUCCUGCACUC 20 9742
SCNNlA-5894 + GAGGACAGGAGGGCAGAAAG 20 9743
SCNNlA-5895 + GAGGGCAACACAAGGAGAAG 20 9744
SCNNlA-5896 + GAAAGAGGGAGACAAUAGAG 20 9745
SCNNlA-5897 - GUGGAGGAGGGAGGGAGGAG 20 9746
SCNNlA-5898 + GAGAGAUAGGGAUGGAGGAG 20 9747
SCNNlA-5899 + GGUGAGCAGGGCGGGGGGAG 20 9748
SCNNlA-5900 - GGGCAAGGCAAGGGGGGGAG 20 9749
SCNNlA-436 - GGUUCCAGGGGUGAUGGGAG 20 4285
SCNNlA-5901 - GCAGAUAGAGAGGGAGUGAG 20 9750
1342
5535.1 SCNNlA-5902 + GGGACAGGAUGGCAGGUGAG 20 9751
SCNNlA-5903 - GGAAGAAGACCAAAGGAAGG 20 9752
SCNNlA-5904 + GGUGAGCAAGGAGAGAGAGG 20 9753
SCNNlA-5905 - GAGGCAGGAUUAGAGAGAGG 20 9754
SCNNlA-5906 - GGCUCCAGGAAAGGUGGAGG 20 9755
SCNNlA-5907 + GGCGGGGGGAGGGGCUGAGG 20 9756
SCNNlA-5908 - GCUGCACCUGUCAGGUGAGG 20 9757
SCNNlA-5909 - GGGGGCAGAGACAGAAAGGG 20 9758
SCNNlA-5910 - GAGAGGGGGCAAGGCAAGGG 20 9759
SCNNlA-5911 - GAAAGGUGGAGGAGGGAGGG 20 9760
SCNNlA-5912 - GUCUGCUGGCUUGUGGAGGG 20 9761
SCNNlA-5913 - GCUCUGUGUGGGAGUGAGGG 20 9762
SCNNlA-5914 - GCACCUGUCAGGUGAGGGGG 20 9763
SCNNlA-5915 + GGACAGAGAGAUAGGGAUGG 20 9764
SCNNlA-5916 + GAGUGAGUAGAGGCAGGUGG 20 9765
SCNNlA-5917 - GAGGGAGGAGUGGGAGAAUG 20 9766
SCNNlA-5918 + GAGGGGCCCAGGUGAAGCUG 20 9767
SCNNlA-5919 + GCAGACAGGCAAGGAGGCUG 20 9768
SCNNlA-5920 + GGGGGACAGGAUGGCAGGUG 20 9769
SCNNlA-5921 + GCAGGUGGGGGGCAGUGGUG 20 9770
SCNNlA-5922 + GUCUGUGGCUUCCUCUCUUG 20 9771
SCNNlA-5923 + GGAGGGGCCCAGGUGAAGCU 20 9772
SCNNlA-5924 + GGGCCAAAAGUGCCGGAGCU 20 9773
SCNNlA-5925 - GAGACAGAAAGGGAGGUGCU 20 9774
SCNNlA-5926 - GCAGAGAUGACACCUUCUCU 20 9775
SCNNlA-5927 + GAGCUAGAGGCUCAGCAAGU 20 9776
SCNNlA-5928 + GGCAGGUGGGGGGCAGUGGU 20 9777
SCNNlA-5929 - GGUGAGGGGGAGGAGAGGUU 20 9778
SCNNlA-437 - GUAAGCAAGGGAACCUGGUU 20 4286
Table 46D provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the fourth tier parameters. The targeting domains bind within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene
1343
5535.1 Table 46D
Figure imgf001345_0001
1344
5535.1 SCNNlA-5961 + CAAGGAGGCUGGGGGAC 17 9810
SCNNlA-5962 + AACCAGGAUUCCAAACC 17 9811
SCNNlA-445 - AGGUAAGCAAGGGAACC 17 4294
SCNNlA-5963 + CGGGGCUCAGGUGCACC 17 9812
SCNNlA-5964 - UAGCCCCCAGCUUCACC 17 9813
SCNNlA-5965 + CACUGUGGACACAGACC 17 9814
SCNNlA-5966 - AGAGGAAGCCACAGACC 17 9815
SCNNlA-5967 - AGGAAAGAGGAGGGACC 17 9816
SCNNlA-5968 + AGCCACCCACACAACCC 17 9817
SCNNlA-446 + CCCUCUCCCAUCACCCC 17 4295
SCNNlA-151 + UUCCCCUUCAUGAGCCC 17 648
SCNNlA-5969 + CACGCCUAGACAGGCCC 17 9818
SCNNlA-5970 + UCCAGCUUCCCACUCCC 17 9819
SCNNlA-5971 - UCACCUGGGCCCCUCCC 17 9820
SCNNlA-5972 + ACCUGGAUGUGAAAGCC 17 9821
SCNNlA-5973 - UUUGAGAUCAAACAGCC 17 9822
SCNNlA-5974 + AGGAGAAGGGGCCAGCC 17 9823
SCNNlA-5975 - CCCAGGCCCUCUCAGCC 17 9824
SCNNlA-5976 + CUGUUGGCUGCCAGGCC 17 9825
SCNNlA-5977 - AUUACACAUUCCUGGCC 17 9826
SCNNlA-5978 - AACCUGGUUUGGAAUCC 17 9827
SCNNlA-5979 - AGGCAGCCCAGACCUCC 17 9828
SCNNlA-5980 - CUGCCCUCCUGUCCUCC 17 9829
SCNNlA-5981 + CAGGACUGCAGGGCUCC 17 9830
SCNNlA-5982 - CUGGAGCCCUGCAGUCC 17 9831
SCNNlA-5983 - AGUGAGGGAGGCCUUCC 17 9832
SCNNlA-5984 - CCCCUUGCUCUCCUUCC 17 9833
SCNNlA-5985 - CUUUCCCUGCCUCUUCC 17 9834
SCNNlA-5986 + CCCUCCUCCACCUUUCC 17 9835
SCNNlA-5987 - ACCUGGGAGUGGGAAGC 17 9836
SCNNlA-5988 + UGAGGAGGAGUCAGAGC 17 9837
SCNNlA-5989 - AGGUCAGGGCCAGAGGC 17 9838
SCNNlA-5990 + CAGACAGGCAAGGAGGC 17 9839
SCNNlA-5991 + CUGGGGGACAGGAUGGC 17 9840
SCNNlA-5992 + CUCUGCCCCAGGACUGC 17 9841
SCNNlA-5993 - UCUUCUCUCUUCUCUGC 17 9842
SCNNlA-5994 - ACCACAUUCCUGCACUC 17 9843
SCNNlA-5995 + AGGGCUGGAGGAGACUC 17 9844
SCNNlA-5996 + CCCUCAGCUCCAGCCUC 17 9845
SCNNlA-5997 - UGCCUCUUCCUGGGCUC 17 9846
SCNNlA-5998 + CAGGGCUCCAGGAGGUC 17 9847
SCNNlA-5999 - UGGGCCCCUCCCGGGUC 17 9848
1345
5535.1 SCNNlA-6000 + UCCUGCUCUCCUCUUUC 17 9849
SCNNlA-6001 - AG G A A U C AG C AG G A A AG 17 9850
SCNNlA-6002 + CCAGGAAGGAGAGCAAG 17 9851
SCNNlA-6003 - AGAGGGGGCAAGGCAAG 17 9852
SCNNlA-6004 + UGCAGAGAAGAGAGAAG 17 9853
SCNNlA-6005 - AAGAAGACCAAAGGAAG 17 9854
SCNNlA-6006 + AGGCAGGUGGGGGGCAG 17 9855
SCNNlA-6007 + AGAGGGAGACAAUAGAG 17 9856
SCNNlA-6008 - ACAGAAGGCAGAUAGAG 17 9857
SCNNlA-6009 + AGCAAAAGGAUAAGGAG 17 9858
SCNNlA-6010 - UCAGGGAAGCAGAGGAG 17 9859
SCNNlA-6011 - CAGGUGAGGGGGAGGAG 17 9860
SCNNlA-6012 + AGAUAGGGAUGGAGGAG 17 9861
SCNNlA-448 - UCCAGGGGUGAUGGGAG 17 4297
SCNNlA-83 - UACCAGGUCUCAUGGAG 17 606
SCNNlA-6013 + ACAGGAUGGCAGGUGAG 17 9862
SCNNlA-6014 - UGCACCUGUCAGGUGAG 17 9863
SCNNlA-6015 + AAGCUGGGGGCUAGGCG 17 9864
SCNNlA-6016 + CAGGAAGGAGAGCAAGG 17 9865
SCNNlA-6017 + UACUGGACCUGAGAAGG 17 9866
SCNNlA-6018 - AGAAGACCAAAGGAAGG 17 9867
SCNNlA-6019 - AAAGAGGAGGGACCAGG 17 9868
SCNNlA-6020 - A A U C AG C AG G A A AG AG G 17 9869
SCNNlA-6021 + AGACAGGCCCUGGGAGG 17 9870
SCNNlA-6022 + AGAGAUAGGGAUGGAGG 17 9871
SCNNlA-6023 - UCCAGGAAAG G U G G AG G 17 9872
SCNNlA-6024 - CUGGACAAGGUUGGAGG 17 9873
SCNNlA-6025 + CUGAGCCCACAGCUAGG 17 9874
SCNNlA-6026 + UGAAGCUGGGGGCUAGG 17 9875
SCNNlA-6027 + AGGAAGGAGAGCAAGGG 17 9876
SCNNlA-6028 - AGGGGGCAAGGCAAGGG 17 9877
SCNNlA-6029 - AAA U AG A A A AG G C AG G G 17 9878
SCNNlA-6030 - AGGUGGAGGAGGGAGGG 17 9879
SCNNlA-6031 - UGCUGGCUUGUGGAGGG 17 9880
SCNNlA-6032 - CUGUGUGGGAGUGAGGG 17 9881
SCNNlA-6033 - CCUGUCAGGUGAGGGGG 17 9882
SCNNlA-6034 + CAGAGAGAUAGGGAUGG 17 9883
SCNNlA-6035 - UGGGAGUGGGAAGCUGG 17 9884
SCNNlA-6036 + ACAGGCAAGGAGGCUGG 17 9885
SCNNlA-6037 + CAGGUGGGGGGCAGUGG 17 9886
SCNNlA-6038 + UGAGUAGAGGCAGGUGG 17 9887
SCNNlA-154 + CCUGGAGUGGACUGUGG 17 651
1346
5535.1 SCNNlA-6039 + CCCAGAGUGCAGGAAUG 17 9888
SCNNlA-6040 + AAGGUGCAGGGAGGAUG 17 9889
SCNNlA-153 + AGCCCUGGAGUGGACUG 17 650
SCNNlA-6041 + UGGAGCCAGCAGACCUG 17 9890
SCNNlA-6042 - AGGGUGAGGCUGACCUG 17 9891
SCNNlA-6043 - CUUCUCUGCAGGGCCUG 17 9892
SCNNlA-6044 - CUCUGGGCUGCCUCCUG 17 9893
SCNNlA-6045 + AUUCUCCUCCUCCUCUG 17 9894
SCNNlA-6046 - UGCAGGGCCUGAGGGUG 17 9895
SCNNlA-6047 + CUGAGAGGGCCUGGGUG 17 9896
SCNNlA-6048 - CUGGGCUGCCUCCUGUG 17 9897
SCNNlA-6049 - CUUUGUCUGCUGGCUUG 17 9898
SCNNlA-6050 + UUCCCACUCCCAGGUUG 17 9899
SCNNlA-6051 + AG G U U AG A A A AC A A A A U 17 9900
SCNNlA-449 - CCAGGGGCAGCCUCACU 17 4298
SCNNlA-6052 + AAGGGCUGGAGGAGACU 17 9901
SCNNlA-6053 - UCCUGCAGUGAGCCCCU 17 9902
SCNNlA-450 + CUCAUGAUACCUCCCCU 17 4299
SCNNlA-6054 - CCCAGUUCACCUGCCCU 17 9903
SCNNlA-6055 + CCAGGCUGAGAGGGCCU 17 9904
SCNNlA-6056 - UGGAGCCCUGCAGUCCU 17 9905
SCNNlA-6057 - A A AG A AC AG A A U G U C C U 17 9906
SCNNlA-6058 - UUUCCCUGCCUCUUCCU 17 9907
SCNNlA-6059 + AGACAGGCAAGGAGGCU 17 9908
SCNNlA-6060 + AGGUGAAGCUGGGGGCU 17 9909
SCNNlA-6061 - ACAGAAAGGGAGGUGCU 17 9910
SCNNlA-6062 + UCUGCUCUCUGGGUGCU 17 9911
SCNNlA-6063 + AAUUCUCCUCCUCCUCU 17 9912
SCNNlA-6064 - CCUCCCAGGGCCUGUCU 17 9913
SCNNlA-6065 - AGGAGGGAGGGAGGAGU 17 9914
SCNNlA-6066 + CUGGAAAGGAAGAGGGU 17 9915
SCNNlA-6067 + AGGUGGGGGGCAGUGGU 17 9916
SCNNlA-6068 - CAGGGCCUGGGUUGUGU 17 9917
SCNNlA-6069 - AAAACUGAUUUAUCCUU 17 9918
SCNNlA-6070 + UCUCUGCCCCCUUCCUU 17 9919
SCNNlA-6071 + UGCCUUCUGUUUCUCUU 17 9920
SCNNlA-6072 - AGUUUGGAAAGAGAUUU 17 9921
SCNNlA-6073 + CAGAGAAUCAGACCCAAAAA 20 9922
SCNNlA-6074 + UUAAAAGAUUGUCUUUAAAA 20 9923
SCNNlA-6075 + UCCAAACUUAAUGCAGCAAA 20 9924
SCNNlA-6076 + UAGCAGGCAAAGAAGAGAAA 20 9925
SCNNlA-6077 - AGUCUGUCUCAGGAAGUAAA 20 9926
1347
5535.1 SCNNlA-6078 + CUCCACAAGCCAGCAGACAA 20 9927
SCNNlA-6079 - AGUGAGAGGGGGCAAGGCAA 20 9928
SCNNlA-451 - UCCACUCCGGGGCUCAUGAA 20 4300
SCNNlA-6080 - ACGAAUUUCUCCUCCUCCCA 20 9929
SCNNlA-6081 + ACCACUAGCUUAAGGCAGCA 20 9930
SCNNlA-452 - CGCAGGGUGGGACAUGGGCA 20 4301
SCNNlA-6082 - CCUCUUCUCUCUUCUCUGCA 20 9931
SCNNlA-6083 + UACUUCCUGAGACAGACUCA 20 9932
SCNNlA-6084 - CAGGACACAGCUCGAGGUCA 20 9933
SCNNlA-6085 + AGGACAGGAGGGCAGAAAGA 20 9934
SCNNlA-6086 + UCAGGAAGCCUUCCCAGAGA 20 9935
SCNNlA-6087 + AAAGAGGGAGACAAUAGAGA 20 9936
SCNNlA-6088 - AAACAGAAGGCAGAUAGAGA 20 9937
SCNNlA-6089 + AGGAGGGCAACACAAGGAGA 20 9938
SCNNlA-6090 + AGGGGCCAGCCAGGCUGAGA 20 9939
SCNNlA-6091 + CAGUGGUGGGGGCAAAUAGA 20 9940
SCNNlA-6092 + CAAAGAUCUGAACAAGUAGA 20 9941
SCNNlA-6093 + AAGGAGGCUGGGGGACAGGA 20 9942
SCNNlA-6094 + AGAGAGAUAGGGAUGGAGGA 20 9943
SCNNlA-6095 - CAGGAAAGGUGGAGGAGGGA 20 9944
SCNNlA-6096 + AGGUGAGCAGGGCGGGGGGA 20 9945
SCNNlA-6097 + CAGCGAAGGACAGAGAGAUA 20 9946
SCNNlA-6098 + CUUAAUGCAGCAAAAGGAUA 20 9947
SCNNlA-6099 + CCAAGGGCUAGGGGAGCCUA 20 9948
SCNNlA-6100 - A A A A AG A AC AG A A U G U C C U A 20 9949
SCNNlA-6101 + AGAGGGCCUGGGUGGGGAAC 20 9950
SCNNlA-6102 + AGGCAAGGAGGCUGGGGGAC 20 9951
SCNNlA-6103 + UCUCCUCCCCCUCACCUGAC 20 9952
SCNNlA-6104 - AAGAGAGGAAGCCACAGACC 20 9953
SCNNlA-77 + UUGUUCCCCUCCAUGAGACC 20 603
SCNNlA-6105 + CAAUAAGGUGCUCAGCACCC 20 9954
SCNNlA-72 + UUGUUCCCCUUCAUGAGCCC 20 599
SCNNlA-6106 + UCCAGACCCGGGAGGGGCCC 20 9955
SCNNlA-6107 + UGCACCUGGAUGUGAAAGCC 20 9956
SCNNlA-6108 - CCACCCAGGCCCUCUCAGCC 20 9957
SCNNlA-6109 + AGCCCGCCCGCUGGCCGGCC 20 9958
SCNNlA-6110 + CCAGCCAGGCUGAGAGGGCC 20 9959
SCNNlA-6111 + UCCUUUGGUCUUCUUCCUCC 20 9960
SCNNlA-6112 + CCCCAGGACUGCAGGGCUCC 20 9961
SCNNlA-6113 - CCUGCCUCUUCCUGGGCUCC 20 9962
SCNNlA-6114 - CUCCUGGAGCCCUGCAGUCC 20 9963
SCNNlA-6115 - CUGCUUUCCCUGCCUCUUCC 20 9964
1348
5535.1 SCNNlA-6116 + CCUCCCUCCUCCACCUUUCC 20 9965
SCNNlA-6117 + CAGGAAGAGGCAGGGAAAGC 20 9966
SCNNlA-6118 + CGACUUCUUAAAGUGAAAGC 20 9967
SCNNlA-6119 - CAGGCCAGAAAGAGGAGAGC 20 9968
SCNNlA-6120 + AGGGAGGAUGUGGCCAGCGC 20 9969
SCNNlA-6121 - AG C U G G C A A A U AG A A A AG G C 20 9970
SCNNlA-6122 + CCCGGAGCCCAGGAAGAGGC 20 9971
SCNNlA-6123 - AUAGAGAGGGAGUGAGAGGC 20 9972
SCNNlA-6124 - CAGGAUUAGAGAGAGGAGGC 20 9973
SCNNlA-6125 + AGGCUGGGGGACAGGAUGGC 20 9974
SCNNlA-6126 - CCAGGCCCUCUCAGCCUGGC 20 9975
SCNNlA-6127 + UGGGGAGCCCGCCCGCUGGC 20 9976
SCNNlA-6128 + UGUCUCUGCCCCAGGACUGC 20 9977
SCNNlA-6129 - ACCUCUUCUCUCUUCUCUGC 20 9978
SCNNlA-6130 + CAGGAGGCAGCCCAGAGUGC 20 9979
SCNNlA-6131 - AGACAGACUCCCUUUGGUGC 20 9980
SCNNlA-6132 - CUCCCAGUUCACCUGCCCUC 20 9981
SCNNlA-6133 + AGGCCCUCAGCUCCAGCCUC 20 9982
SCNNlA-6134 + UCAGAAUUCUCCUCCUCCUC 20 9983
SCNNlA-6135 - CCCUGCCUCUUCCUGGGCUC 20 9984
SCNNlA-6136 + CUGCAGGGCUCCAGGAGGUC 20 9985
SCNNlA-6137 - ACCUGGGCCCCUCCCGGGUC 20 9986
SCNNlA-6138 + CUCUCCUGCUCUCCUCUUUC 20 9987
SCNNlA-6139 - AGAGGAGGCAGGCCAGAAAG 20 9988
SCNNlA-6140 + UCUCCAGGAAGGAGAGCAAG 20 9989
SCNNlA-6141 + CCCUGCAGAGAAGAGAGAAG 20 9990
SCNNlA-6142 - AGGAAGAAGACCAAAGGAAG 20 9991
SCNNlA-453 - CCACUCCGGGGCUCAUGAAG 20 4302
SCNNlA-6143 + UAGAGGCAGGUGGGGGGCAG 20 9992
SCNNlA-6144 + CCCUCACCUGACAGGUGCAG 20 9993
SCNNlA-6145 - CAAGGGGGGGAGAGGAAGAG 20 9994
SCNNlA-6146 + AGUGGUGAGCAAGGAGAGAG 20 9995
SCNNlA-6147 - AGAGAGGCAGGAUUAGAGAG 20 9996
SCNNlA-6148 - CUAUCAGGGAAGCAGAGGAG 20 9997
SCNNlA-6149 - UGUCAGGUGAGGGGGAGGAG 20 9998
SCNNlA-454 + CCCCUUCAUGAGCCCCGGAG 20 4303
SCNNlA-6150 - UCUGCUGGCUCCAGGAAAGG 20 9999
SCNNlA-6151 + CUCCAGGAAGGAGAGCAAGG 20 10000
SCNNlA-6152 - UGAGAGGGGGCAAGGCAAGG 20 10001
SCNNlA-6153 - AGGAAAGAGGAGGGACCAGG 20 10002
SCNNlA-6154 + CAGGACUGCAGGGCUCCAGG 20 10003
SCNNlA-6155 - AGGAAUCAGCAGGAAAGAGG 20 10004
1349
5535.1 SCNNlA-6156 - AAAGAGGAGGGACCAGGAGG 20 10005
SCNNlA-6157 + CCUAGACAGGCCCUGGGAGG 20 10006
SCNNlA-6158 + CAGAGAGAUAGGGAUGGAGG 20 10007
SCNNlA-6159 + UCCAGGAAGGAGAGCAAGGG 20 10008
SCNNlA-6160 + UCAAUUAAAGGUGAGCAGGG 20 10009
SCNNlA-6161 + AGCGCUGGAAAGGAAGAGGG 20 10010
SCNNlA-6162 - CCAGGAAAGGUGGAGGAGGG 20 10011
SCNNlA-6163 - AGAGGGGGCAAGGCAAGGGG 20 10012
SCNNlA-6164 + AAGGUGAGCAGGGCGGGGGG 20 10013
SCNNlA-6165 + CCAGGCUGAGAGGGCCUGGG 20 10014
SCNNlA-6166 + AGUGAGUAGAGGCAGGUGGG 20 10015
SCNNlA-6167 - CAGGGCCUGGGUUGUGUGGG 20 10016
SCNNlA-455 - CAUGAAGGGGAACAAGCUGG 20 4304
SCNNlA-6 - CAUGGAGGGGAACAAGCUGG 20 558
SCNNlA-6168 - ACCUGGGAGUGGGAAGCUGG 20 10017
SCNNlA-6169 + AGGGGCCCAGGUGAAGCUGG 20 10018
SCNNlA-6170 + CAGACAGGCAAGGAGGCUGG 20 10019
SCNNlA-6171 + AGGCAGGUGGGGGGCAGUGG 20 10020
SCNNlA-6172 + CAGGUGGGGGGCAGUGGUGG 20 10021
SCNNlA-6173 + CAGCCCAGAGUGCAGGAAUG 20 10022
SCNNlA-6174 - CCUGGAGCCCUGCAGUCCUG 20 10023
SCNNlA-6175 - AGGGCCAGAGGCUGGAGCUG 20 10024
SCNNlA-6176 + CAGGGCGGGGGGAGGGGCUG 20 10025
SCNNlA-6177 + AGGCUGAGAGGGCCUGGGUG 20 10026
SCNNlA-6178 + AGCUUCCCACUCCCAGGUUG 20 10027
SCNNlA-6179 + ACUUCCUGAGACAGACUCAU 20 10028
SCNNlA-456 - UGGCCAGGGGCAGCCUCACU 20 4305
SCNNlA-457 + CUGCUCAUGAUACCUCCCCU 20 4306
SCNNlA-6180 + CAGCCAGGCUGAGAGGGCCU 20 10029
SCNNlA-6181 - UCAGAAAACUGAUUUAUCCU 20 10030
SCNNlA-6182 - AAAAAAGAACAGAAUGUCCU 20 10031
SCNNlA-6183 - UGCUUUCCCUGCCUCUUCCU 20 10032
SCNNlA-6184 + CCCAGGUGAAGCUGGGGGCU 20 10033
SCNNlA-6185 + CAGAAUUCUCCUCCUCCUCU 20 10034
SCNNlA-6186 - CCUCCUCCCAGGGCCUGUCU 20 10035
SCNNlA-6187 - UGGAGGAGGGAGGGAGGAGU 20 10036
SCNNlA-6188 + CAGGCUGAGAGGGCCUGGGU 20 10037
SCNNlA-6189 - CAGAAAACUGAUUUAUCCUU 20 10038
SCNNlA-6190 + CUGUCUCUGCCCCCUUCCUU 20 10039
SCNNlA-6191 + AUCUGCCUUCUGUUUCUCUU 20 10040
SCNNlA-6192 + UCUGCCUUCUGUUUCUCUUU 20 10041
1350
5535.1 Table 46E provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the fifth tier parameters. The targeting domains bind within the additional 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), e.g., extending to lkb upstream and downstream of a TSS. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
Table 46E
Figure imgf001352_0001
1351
5535.1 SCNNlA-106 - GCACAACCGCAUGAAGA 17 540
SCNNlA-126 + CCACAGCACUGCCCAGA 17 633
SCNNlA-442 + ACCAGGGAAGGGGCAGA 17 4291
SCNNlA-115 + GGGAUUGAGGGUGCAGA 17 542
SCNNlA-6210 - UUUGGGGAGGGAAAGGA 17 10059
SCNNlA-132 + GGAGCACACCAGGCGGA 17 547
SCNNlA-6211 + GGCGCAGGCACCAGGGA 17 10060
SCNNlA-6212 - UGGCUCCCCUUUGGGGA 17 10061
SCNNlA-6213 - UGGUGCCUGCGCCUGGA 17 10062
SCNNlA-134 + GCGGAUGGCGCCGUGGA 17 548
SCNNlA-155 + CUGGAGUGGACUGUGGA 17 652
SCNNlA-89 - CACUCCAGGGCUCAUGA 17 610
SCNNlA-6214 - CAGAGCCUCAGACCUGA 17 10063
SCNNlA-121 + GUUGAUGUUGAGGCUGA 17 545
SCNNlA-367 + CGACCUGUAGGGAUUGA 17 4216
SCNNlA-6215 - GGAAAGGAAGGGGACUA 17 10064
SCNNlA-6216 + CCACGUCCUGCCGGGUA 17 10065
SCNNlA-331 + GGACUAACCGACCUGUA 17 4180
SCNNlA-6217 - G ACAG AU AU ACAAAU U A 17 10066
SCNNlA-6218 + CUGGAGCGGGCUAGAAC 17 10067
SCNNlA-6219 - GGUGCUGAGGUGCUCAC 17 10068
SCNNlA-6220 + UUAUUUAUCUUAGAGAC 17 10069
SCNNlA-6221 + UGAGCUCUACCUGGGAC 17 10070
SCNNlA-122 + UUGAUGUUGAGGCUGAC 17 629
SCNNlA-332 - GCACCCUCAAUCCCUAC 17 4181
SCNNlA-111 - CCUUUGGCAUGAUGUAC 17 622
SCNNlA-130 + UGUGCUGGGAGCACACC 17 637
SCNNlA-6222 + UUCCAGGCGCAGGCACC 17 10071
SCNNlA-6223 - UUGGCUCAGCCCAGACC 17 10072
SCNNlA-6224 + AAUAGAAAUCUGAGACC 17 10073
SCNNlA-6225 + CUGCAGCAUUCUAGACC 17 10074
SCNNlA-6226 - AUUGCCACUCCCAUACC 17 10075
SCNNlA-6227 + CAGCAGUGAGCUCUACC 17 10076
SCNNlA-6228 + UGAGCACCUCAGCACCC 17 10077
SCNNlA-151 + UUCCCCUUCAUGAGCCC 17 648
SCNNlA-6229 - ACUGACACCCCUGUCCC 17 10078
SCNNlA-447 - UCCCUCUGCCCCUUCCC 17 4296
SCNNlA-105 - CCACGGCGCCAUCCGCC 17 618
SCNNlA-6230 - UCCCUGGUGCCUGCGCC 17 10079
SCNNlA-5364 + AGAAGAAUUGCAAUGCC 17 9213
SCNNlA-6231 + CCCUGCCACGUCCUGCC 17 10080
SCNNlA-87 - CCUCCACAGUCCACUCC 17 608
1352
5535.1 SCNNlA-6232 - CUGUUCUAGCCCGCUCC 17 10081
SCNNlA-6233 - ACUUCUGACCAAAGUCC 17 10082
SCNNlA-6234 - GCCUGGAAGGGUGGUCC 17 10083
SCNNlA-6235 + CCCUGGACCACCCUUCC 17 10084
SCNNlA-124 + AGUACUCUCCGAAAAGC 17 631
SCNNlA-93 - GAACAAG CG U G AG G AG C 17 533
SCNNlA-6236 + CAUUCUAGACCUGGAGC 17 10085
SCNNlA-147 + GGCUGCUGGGGCGCCGC 17 554
SCNNlA-6237 + ACCACCCUUCCAGGCGC 17 10086
SCNNlA-6238 + UGCACUAUCCUCUAGGC 17 10087
SCNNlA-6239 - CCACUCCCAUACCCGGC 17 10088
SCNNlA-96 - GCGUGAGGAGCAGGGGC 17 534
SCNNlA-6240 - UGAGGUGCUCACUGGGC 17 10089
SCNNlA-6241 - ACCCGGCAGGACGUGGC 17 10090
SCNNlA-6242 - CAGGUAGAGCUCACUGC 17 10091
SCNNlA-117 + GUGCAGAUGGUCACUGC 17 544
SCNNlA-6243 + ACCCUGCCACGUCCUGC 17 10092
SCNNlA-144 + CCUCCGCCGUGGGCUGC 17 643
SCNNlA-128 + UCUUCAUGCGGUUGUGC 17 635
SCNNlA-140 + AGCGGUGGAACUCGAUC 17 642
SCNNlA-6244 + UGUCAGUUCCCACCCUC 17 10093
SCNNlA-5415 + AAUUGCAAUGCCUGGUC 17 9264
SCNNlA-107 - GCAUGAAGACGGCCUUC 17 541
SCNNlA-149 + UGGGGCGCCGCAGGUUC 17 647
SCNNlA-6245 + CCUUUCCCUCCCCAAAG 17 10094
SCNNlA-6246 - UGGGGAGGGAAAGGAAG 17 10095
SCNNlA-6247 + CGCAGGCACCAGGGAAG 17 10096
SCNNlA-91 - CUCCAGGGCUCAUGAAG 17 612
SCNNlA-6248 + AGCUCUACCUGGGACAG 17 10097
SCNNlA-95 - ACAAGCGUGAGGAGCAG 17 614
SCNNlA-6249 + C AC C AG G G A AG G G G C AG 17 10098
SCNNlA-138 + AGAGCUCUCGGUAGGAG 17 641
SCNNlA-6250 + CCUGCCGGGUAUGGGAG 17 10099
SCNNlA-6251 + GCAUUCUAGACCUGGAG 17 10100
SCNNlA-152 + CUUCAUGAGCCCUGGAG 17 649
SCNNlA-6252 - GCUGUACUCCAGCCUAG 17 10101
SCNNlA-6253 - CCAUACCCGGCAGGACG 17 10102
SCNNlA-123 + UGAUGUUGAGGCUGACG 17 630
SCNNlA-142 + GGCCUCCUCCUCCGCCG 17 552
SCNNlA-133 + CCAGGCGGAUGGCGCCG 17 638
SCNNlA-118 + UGCAGAUGGUCACUGCG 17 626
SCNNlA-150 + GGGGCGCCGCAGGUUCG 17 555
1353
5535.1 SCNNlA-131 + GCUGGGAGCACACCAGG 17 546
SCNNlA-103 - GCCCACGGCGGAGGAGG 17 539
SCNNlA-102 - GCAGCCCACGGCGGAGG 17 538
SCNNlA-100 - GCCCCAGCAGCCCACGG 17 537
SCNNlA-139 + GCUCUCGGUAGGAGCGG 17 550
SCNNlA-101 - CCAGCAGCCCACGGCGG 17 616
SCNNlA-6254 + UGGGCUGAGCCAAAGGG 17 10103
SCNNlA-6255 - GCCUGCGCCUGGAAGGG 17 10104
SCNNlA-6256 - AGCCUCAGACCUGAGGG 17 10105
SCNNlA-6257 - GUGGCUCCCCUUUGGGG 17 10106
SCNNlA-135 + GAUGGCGCCGUGGAUGG 17 549
SCNNlA-6258 - AGAUAUACAAAUUAUGG 17 10107
SCNNlA-154 + CCUGGAGUGGACUGUGG 17 651
SCNNlA-127 + AGAAGGCCGUCUUCAUG 17 634
SCNNlA-116 + GGUGCAGAUGGUCACUG 17 543
SCNNlA-153 + AGCCCUGGAGUGGACUG 17 650
SCNNlA-98 - GCUGGGCCCCGAACCUG 17 535
SCNNlA-6259 - GCAGAGCCUCAGACCUG 17 10108
SCNNlA-146 + UCCGCCGUGGGCUGCUG 17 645
SCNNlA-109 - CCUUCUGGGCAGUGCUG 17 620
SCNNlA-6260 - GGUGGUCCAGGGUGCUG 17 10109
SCNNlA-6261 + UCCCACCCUCAGGUCUG 17 10110
SCNNlA-92 - GAAGGGGAACAAGCGUG 17 532
SCNNlA-6262 + ACAGGCUUGGUGUUGUG 17 10111
SCNNlA-386 + CCGACCUGUAGGGAUUG 17 4235
SCNNlA-119 + CGAGCUUGUCCGAGUUG 17 627
SCNNlA-120 + AGUUGAGGUUGAUGUUG 17 628
SCNNlA-6263 - AUGGUGGCUCCCCUUUG 17 10112
SCNNlA-6264 + GACAGAGACCAUGCUAU 17 10113
SCNNlA-6265 + CACGUCCUGCCGGGUAU 17 10114
SCNNlA-114 - CAACAUCAACCUCAACU 17 625
SCNNlA-6266 - UAGAAUGCUGCAGCACU 17 10115
SCNNlA-6267 - GUGCUGAGGUGCUCACU 17 10116
SCNNlA-6268 + AGCAGUGAGCUCUACCU 17 10117
SCNNlA-6269 + GCGGGCUAGAACAGGCU 17 10118
SCNNlA-97 - CGUGAGGAGCAGGGGCU 17 615
SCNNlA-145 + CUCCGCCGUGGGCUGCU 17 644
SCNNlA-129 + CUUCAUGCGGUUGUGCU 17 636
SCNNlA-6270 + AUCAUGCACUAUCCUCU 17 10119
SCNNlA-136 + AGAACUCGAAGAGCUCU 17 639
SCNNlA-6271 + AUUGCAAUGCCUGGUCU 17 10120
SCNNlA-108 - CAUGAAGACGGCCUUCU 17 619
1354
5535.1 SCNNlA-143 + GCCUCCUCCUCCGCCGU 17 553
SCNNlA-391 - CCUCAAUCCCUACAGGU 17 4240
SCNNlA-137 + CUCGAAGAGCUCUCGGU 17 640
SCNNlA-6272 - GCCUCAGACCUGAGGGU 17 10121
SCNNlA-338 + GGGACUAACCGACCUGU 17 4187
SCNNlA-112 - AUGAUGUACUGGCAAUU 17 623
SCNNlA-6273 + AUCUGAGACCUGGACUU 17 10122
SCNNlA-110 - CUGUGGCUCUGCACCUU 17 621
SCNNlA-6274 - GCAGGGUCACCACCCUU 17 10123
SCNNlA-6275 - UUAUGGUGGCUCCCCUU 17 10124
SCNNlA-148 + CUGGGGCGCCGCAGGUU 17 646
SCNNlA-6276 - UAUGGUGGCUCCCCUUU 17 10125
SCNNlA-113 - CAAUUCGGCCUGCUUUU 17 624
SCNNlA-6277 - U A AG A A A A U A A A AG C A A A A A 20 10126
SCNNlA-6278 - UUAAAAGAUCAUCUUUAAAA 20 10127
SCNNlA-6279 + CCUUCCUUUCCCUCCCCAAA 20 10128
SCNNlA-6280 + CUGGUCUGGGCUGAGCCAAA 20 10129
SCNNlA-6281 + CCCUUCCUUUCCCUCCCCAA 20 10130
SCNNlA-6282 + CCUGGUCUGGGCUGAGCCAA 20 10131
SCNNlA-46 + UUGCCAGUACAUCAUGCCAA 20 580
SCNNlA-6283 - CCUUUGGGGAGGGAAAGGAA 20 10132
SCNNlA-6284 + CAGGCGCAGGCACCAGGGAA 20 10133
SCNNlA-6285 - GCUCCCCUUUGGGGAGGGAA 20 10134
SCNNlA-6286 - CCUGGUGCCUGCGCCUGGAA 20 10135
SCNNlA-11 - UCCACUCCAGGGCUCAUGAA 20 560
SCNNlA-6287 - AAAUACAUGUAAGUUUAUAA 20 10136
SCNNlA-6288 - AGGGAAAGGAAGGGGACUAA 20 10137
SCNNlA-6289 + AGUGAGCUCUACCUGGGACA 20 10138
SCNNlA-6290 + CCUUCCAGGCGCAGGCACCA 20 10139
SCNNlA-20 - UGCGGCGCCCCAGCAGCCCA 20 565
SCNNlA-25 - UGCAACAACACCACCAUCCA 20 567
SCNNlA-9 - GCCCUCCACAGUCCACUCCA 20 499
SCNNlA-6291 - GCGCCUGGAAGGGUGGUCCA 20 10140
SCNNlA-15 - GGGAACAAGCGUGAGGAGCA 20 507
SCNNlA-6292 - GUAGAAACAUACCUAUAGCA 20 10141
SCNNlA-6293 - AUACCCGGCAGGACGUGGCA 20 10142
SCNNlA-62 + GGAGCGGUGGAACUCGAUCA 20 525
SCNNlA-27 - CCAGCACAACCGCAUGAAGA 20 569
SCNNlA-47 + GAGCCACAGCACUGCCCAGA 20 521
SCNNlA-6294 + GGCACCAGGGAAGGGGCAGA 20 10143
SCNNlA-36 + GUAGGGAUUGAGGGUGCAGA 20 516
SCNNlA-6295 - CCCUUUGGGGAGGGAAAGGA 20 10144
1355
5535.1 SCNNlA-53 + CUGGGAGCACACCAGGCGGA 20 585
SCNNlA-6296 + CCAGGCGCAGGCACCAGGGA 20 10145
SCNNlA-6297 - UGGUGGCUCCCCUUUGGGGA 20 10146
SCNNlA-6298 - CCCUGGUGCCUGCGCCUGGA 20 10147
SCNNlA-55 + CAGGCGGAUGGCGCCGUGGA 20 587
SCNNlA-76 + GCCCUGGAGUGGACUGUGGA 20 528
SCNNlA-10 - GUCCACUCCAGGGCUCAUGA 20 505
SCNNlA-6299 - AGGCAGAGCCUCAGACCUGA 20 10148
SCNNlA-42 + GAGGUUGAUGUUGAGGCUGA 20 519
SCNNlA-402 + AACCGACCUGUAGGGAUUGA 20 4251
SCNNlA-6300 - GAGGGAAAGGAAGGGGACUA 20 10149
SCNNlA-6301 + CUGCCACGUCCUGCCGGGUA 20 10150
SCNNlA-345 + GAGGGACUAACCGACCUGUA 20 4194
SCNNlA-6302 - AU AG ACAG AU AU ACAAAU U A 20 10151
SCNNlA-6303 + GACCUGGAGCGGGCUAGAAC 20 10152
SCNNlA-6304 - CAGGGUGCUGAGGUGCUCAC 20 10153
SCNNlA-6305 + UUCUUAUUUAUCUUAGAGAC 20 10154
SCNNlA-6306 + CAGUGAGCUCUACCUGGGAC 20 10155
SCNNlA-43 + AGGUUGAUGUUGAGGCUGAC 20 578
SCNNlA-403 - UCUGCACCCUCAAUCCCUAC 20 4252
SCNNlA-32 - GCACCUUUGGCAUGAUGUAC 20 514
SCNNlA-51 + GGUUGUGCUGGGAGCACACC 20 522
SCNNlA-6307 + CCCUUCCAGGCGCAGGCACC 20 10156
SCNNlA-6308 - CCUUUGGCUCAGCCCAGACC 20 10157
SCNNlA-6309 + GAAAAUAGAAAUCUGAGACC 20 10158
SCNNlA-6310 + GUGCUGCAGCAUUCUAGACC 20 10159
SCNNlA-6311 - CGCAUUGCCACUCCCAUACC 20 10160
SCNNlA-6312 + UGCCAGCAGUGAGCUCUACC 20 10161
SCNNlA-6313 + CAGUGAGCACCUCAGCACCC 20 10162
SCNNlA-72 + UUGUUCCCCUUCAUGAGCCC 20 599
SCNNlA-6314 - GGAACUGACACCCCUGUCCC 20 10163
SCNNlA-407 - UAGUCCCUCUGCCCCUUCCC 20 4256
SCNNlA-26 - CAUCCACGGCGCCAUCCGCC 20 568
SCNNlA-6315 - CCUUCCCUGGUGCCUGCGCC 20 10164
SCNNlA-5223 + GUGAGAAGAAUUGCAAUGCC 20 9072
SCNNlA-6316 + UGACCCUGCCACGUCCUGCC 20 10165
SCNNlA-8 - AGCCCUCCACAGUCCACUCC 20 559
SCNNlA-6317 - AGCCUGUUCUAGCCCGCUCC 20 10166
SCNNlA-6318 - UGGACUUCUGACCAAAGUCC 20 10167
SCNNlA-6319 - UGCGCCUGGAAGGGUGGUCC 20 10168
SCNNlA-6320 + GCACCCUGGACCACCCUUCC 20 10169
SCNNlA-45 + UGAAGUACUCUCCGAAAAGC 20 579
1356
5535.1 SCNNlA-14 - GGGGAACAAGCGUGAGGAGC 20 506
SCNNlA-6321 + CAGCAUUCUAGACCUGGAGC 20 10170
SCNNlA-68 + GUGGGCUGCUGGGGCGCCGC 20 526
SCNNlA-6322 + UGGACCACCCUUCCAGGCGC 20 10171
SCNNlA-6323 + UCAUGCACUAUCCUCUAGGC 20 10172
SCNNlA-6324 - UUGCCACUCCCAUACCCGGC 20 10173
SCNNlA-17 - CAAGCGUGAGGAGCAGGGGC 20 563
SCNNlA-6325 - UGCUGAGGUGCUCACUGGGC 20 10174
SCNNlA-6326 - CAUACCCGGCAGGACGUGGC 20 10175
SCNNlA-6327 - UCCCAGGUAGAGCUCACUGC 20 10176
SCNNlA-38 + AGGGUGCAGAUGGUCACUGC 20 575
SCNNlA-6328 + GUGACCCUGCCACGUCCUGC 20 10177
SCNNlA-65 + CCUCCUCCGCCGUGGGCUGC 20 594
SCNNlA-49 + CCGUCUUCAUGCGGUUGUGC 20 582
SCNNlA-61 + AGGAGCGGUGGAACUCGAUC 20 591
SCNNlA-6329 + GGGUGUCAGUUCCCACCCUC 20 10178
SCNNlA-5640 + AAGAAUUGCAAUGCCUGGUC 20 9489
SCNNlA-28 - ACCGCAUGAAGACGGCCUUC 20 570
SCNNlA-70 + UGCUGGGGCGCCGCAGGUUC 20 598
SCNNlA-6330 + CUUCCUUUCCCUCCCCAAAG 20 10179
SCNNlA-6331 - CUUUGGGGAGGGAAAGGAAG 20 10180
SCNNlA-6332 + AGGCGCAGGCACCAGGGAAG 20 10181
SCNNlA-12 - CCACUCCAGGGCUCAUGAAG 20 561
SCNNlA-6333 + GUGAGCUCUACCUGGGACAG 20 10182
SCNNlA-16 - GGAACAAGCGUGAGGAGCAG 20 508
SCNNlA-6334 + AGGCACCAGGGAAGGGGCAG 20 10183
SCNNlA-59 + CGAAGAGCUCUCGGUAGGAG 20 589
SCNNlA-6335 + CGUCCUGCCGGGUAUGGGAG 20 10184
SCNNlA-6336 + GCAGCAUUCUAGACCUGGAG 20 10185
SCNNlA-73 + CCCCUUCAUGAGCCCUGGAG 20 600
SCNNlA-6337 - GCUGCUGUACUCCAGCCUAG 20 10186
SCNNlA-6338 - CUCCCAUACCCGGCAGGACG 20 10187
SCNNlA-44 + GGUUGAUGUUGAGGCUGACG 20 520
SCNNlA-63 + CAGGGCCUCCUCCUCCGCCG 20 592
SCNNlA-54 + ACACCAGGCGGAUGGCGCCG 20 586
SCNNlA-39 + GGGUGCAGAUGGUCACUGCG 20 518
SCNNlA-71 + GCUGGGGCGCCGCAGGUUCG 20 527
SCNNlA-52 + UGUGCUGGGAGCACACCAGG 20 584
SCNNlA-24 - GCAGCCCACGGCGGAGGAGG 20 512
SCNNlA-23 - CCAGCAGCCCACGGCGGAGG 20 566
SCNNlA-21 - GGCGCCCCAGCAGCCCACGG 20 510
SCNNlA-60 + AGAGCUCUCGGUAGGAGCGG 20 590
1357
5535.1 SCNNlA-22 - GCCCCAGCAGCCCACGGCGG 20 511
SCNNlA-6339 + GUCUGGGCUGAGCCAAAGGG 20 10188
SCNNlA-6340 - GGUGCCUGCGCCUGGAAGGG 20 10189
SCNNlA-6341 - CAGAGCCUCAGACCUGAGGG 20 10190
SCNNlA-6342 - AUGGUGGCUCCCCUUUGGGG 20 10191
SCNNlA-56 + GCGGAUGGCGCCGUGGAUGG 20 523
SCNNlA-6343 - GACAGAUAUACAAAUUAUGG 20 10192
SCNNlA-75 + AGCCCUGGAGUGGACUGUGG 20 602
SCNNlA-48 + CCCAGAAGGCCGUCUUCAUG 20 581
SCNNlA-37 + GAGGGUGCAGAUGGUCACUG 20 517
SCNNlA-74 + AUGAGCCCUGGAGUGGACUG 20 601
SCNNlA-19 - GGGGCUGGGCCCCGAACCUG 20 509
SCNNlA-6344 - CAGGCAGAGCCUCAGACCUG 20 10193
SCNNlA-67 + UCCUCCGCCGUGGGCUGCUG 20 596
SCNNlA-30 - CGGCCUUCUGGGCAGUGCUG 20 572
SCNNlA-6345 - AAGGGUGGUCCAGGGUGCUG 20 10194
SCNNlA-6346 + AGUUCCCACCCUCAGGUCUG 20 10195
SCNNlA-13 - CA U G AAG GG G AAC AAG CG U G 20 562
SCNNlA-6347 + AGAACAGGCUUGGUGUUGUG 20 10196
SCNNlA-418 + UAACCGACCUGUAGGGAUUG 20 4267
SCNNlA-40 + AGACGAGCUUGUCCGAGUUG 20 576
SCNNlA-41 + CCGAGUUGAGGUUGAUGUUG 20 577
SCNNlA-6348 - AUUAUGGUGGCUCCCCUUUG 20 10197
SCNNlA-6349 + UAUGACAGAGACCAUGCUAU 20 10198
SCNNlA-6350 + UGCCACGUCCUGCCGGGUAU 20 10199
SCNNlA-35 - CCUCAACAUCAACCUCAACU 20 574
SCNNlA-6351 - GUCUAGAAUGCUGCAGCACU 20 10200
SCNNlA-6352 - AGGGUGCUGAGGUGCUCACU 20 10201
SCNNlA-6353 + GCCAGCAGUGAGCUCUACCU 20 10202
SCNNlA-6354 + GGAGCGGGCUAGAACAGGCU 20 10203
SCNNlA-18 - AAGCGUGAGGAGCAGGGGCU 20 564
SCNNlA-66 + CUCCUCCGCCGUGGGCUGCU 20 595
SCNNlA-50 + CGUCUUCAUGCGGUUGUGCU 20 583
SCNNlA-6355 + AGGAUCAUGCACUAUCCUCU 20 10204
SCNNlA-57 + AGAAGAACUCGAAGAGCUCU 20 588
SCNNlA-6356 + AGAAUUGCAAUGCCUGGUCU 20 10205
SCNNlA-29 - CCGCAUGAAGACGGCCUUCU 20 571
SCNNlA-64 + AGGGCCUCCUCCUCCGCCGU 20 593
SCNNlA-423 - CACCCUCAAUCCCUACAGGU 20 4272
SCNNlA-58 + GAACUCGAAGAGCUCUCGGU 20 524
SCNNlA-6357 - AGAGCCUCAGACCUGAGGGU 20 10206
SCNNlA-424 + AGAGGGACUAACCGACCUGU 20 4273
1358
5535.1 SCNNlA-33 - GGCAUGAUGUACUGGCAAUU 20 515
SCNNlA-6358 + GAAAUCUGAGACCUGGACUU 20 10207
SCNNlA-31 - GUGCUGUGGCUCUGCACCUU 20 513
SCNNlA-6359 - GUGGCAGGGUCACCACCCUU 20 10208
SCNNlA-6360 - AAAUUAUGGUGGCUCCCCUU 20 10209
SCNNlA-69 + CUGCUGGGGCGCCGCAGGUU 20 597
SCNNlA-6361 - AAUUAUGGUGGCUCCCCUUU 20 10210
SCNNlA-34 - UGGCAAUUCGGCCUGCUUUU 20 573
Table 47 A provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the first tier parameters. The targeting domains bind within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), have a high level of orthogonality, start with a 5'G, and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. Aureus eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
Table 47A
Figure imgf001360_0001
1359
5535.1 SCNNlA-6376 + GCCAGGGAUGGAAGCGAC 18 10225
SCNNlA-6377 + GGCCAGGGAUGGAAGCGAC 19 10226
SCNNlA-6378 + GCCGGCCAGGGAUGGAAGCGAC 22 10227
SCNNlA-6379 + GGCCGGCCAGGGAUGGAAGCGAC 23 10228
SCNNlA-6380 + GAAGAAACUGACCCUUCCC 19 10229
SCNNlA-6381 + GCCCCACAGGAGGCAGCC 18 10230
SCNNlA-6382 + GGCCCCACAGGAGGCAGCC 19 10231
SCNNlA-6383 + GGGCCCCACAGGAGGCAGCC 20 10232
SCNNlA-5221 + GCUGAGGAGGAGUCAGAGCC 20 9070
SCNNlA-6384 + GCCCGCCCGCUGGCCGGCC 19 10233
SCNNlA-6385 + GAGCCCGCCCGCUGGCCGGCC 21 10234
SCNNlA-6386 + GGAGCCCGCCCGCUGGCCGGCC 22 10235
SCNNlA-6387 + GGGAGCCCGCCCGCUGGCCGGCC 23 10236
SCNNlA-6388 + GGGGAGCCCGCCCGCUGGCCGGCC 24 10237
SCNNlA-1305 + GUCAAGGCUGAGCUCUGGGCC 21 5154
SCNNlA-1306 + GGUCAAGGCUGAGCUCUGGGCC 22 5155
SCNNlA-1307 + GGGUCAAGGCUGAGCUCUGGGCC 23 5156
SCNNlA-1308 + GAGUGGAUUGGGGAGAGC 18 5157
SCNNlA-1309 + GGAGUGGAUUGGGGAGAGC 19 5158
SCNNlA-1310 + GCCCCGGAGUGGAUUGGGGAGAGC 24 5159
SCNNlA-1311 + GCCCUGGAGUGGACUGUGGAGGGC 24 5160
SCNNlA-6389 + GGAGGCAGCCCAGAGUGC 18 10238
SCNNlA-6390 + GCUGUGGUCACAGAGUUGC 19 10239
SCNNlA-1312 + GUAUGGGCUGCAGAGGUC 18 5161
SCNNlA-1313 + GGUAUGGGCUGCAGAGGUC 19 5162
SCNNlA-1314 + GACCUGGUAUGGGCUGCAGAGGUC 24 5163
SCNNlA-1315 + GAUACCUCCCCUUGGAAGGGACAG 24 5164
SCNNlA-6391 + GGACUGGUUCCUUUCCAG 18 10240
SCNNlA-6392 + GGGACUGGUUCCUUUCCAG 19 10241
SCNNlA-6393 + GACUGGGACUGGUUCCUUUCCAG 23 10242
SCNNlA-6394 + GGACUGGGACUGGUUCCUUUCCAG 24 10243
SCNNlA-6395 + GCAGCAAAAGGAUAAGGAG 19 10244
SCNNlA-6396 + GGCAAAGAUCUGAACAAGUAG 21 10245
SCNNlA-6397 + GGGCAAAGAUCUGAACAAGUAG 22 10246
SCNNlA-6398 + GGGGCAAAGAUCUGAACAAGUAG 23 10247
SCNNlA-6399 + GCAGGCACUGAAGGUGCAGG 20 10248
SCNNlA-6400 + GG G AG CAG CG CAC U C AG G 18 10249
SCNNlA-5260 + GUGGGAGCAGCGCACUCAGG 20 9109
SCNNlA-6401 + GAUUCGUCUGCUCUCUGGGUG 21 10250
SCNNlA-6402 + GGAUUCGUCUGCUCUCUGGGUG 22 10251
SCNNlA-6403 + GUGGAUUCGUCUGCUCUCUGGGUG 24
10252
1360
5535.1 SCNNlA-6404 + GCCCGUGGAUUCGUCUGCUCU 21 10253
SCNNlA-6405 + GAGCCCGUGGAUUCGUCUGCUCU 23 10254
SCNNlA-1322 + GAUUGGGGAGAGCAAGGGU 19 5171
SCNNlA-1323 + GGAUUGGGGAGAGCAAGGGU 20 5172
SCNNlA-1324 + GUGGAUUGGGGAGAGCAAGGGU 22 5173
SCNNlA-1325 + GAGUGGAUUGGGGAGAGCAAGGGU 24
5174
SCNNlA-6406 + GCAGAGCUAU A A AC AG A A U U 20 10255
SCNNlA-6407 + GAGCAGAGCUAUAAACAGAAUU 22 10256
SCNNlA-6408 + GGAGCAGAGCUAUAAACAGAAUU 23 10257
SCNNlA-6409 + GCUUCCCUGAUAGGGCCACCUU 22 10258
SCNNlA-6410 - G CCAACAG UG U AAAAAAG AA 20 10259
SCNNlA-6411 - G C AG C C A AC AG U G U A A A A A AG A A 23 10260
SCNNlA-6412 - GGCAGCCAACAGUGUAAAAAAGAA 24 10261
SCNNlA-6413 - GAGAAAAUAUAGCCCAUCA 19 10262
SCNNlA-6414 - GGAGAAAAUAUAGCCCAUCA 20 10263
SCNNlA-6415 - GCAGUCCUGGGGCAGAGA 18 10264
SCNNlA-6416 - GGUCUGGACAAGGUUGGA 18 10265
SCNNlA-6417 - GGGUCUGGACAAGGUUGGA 19 10266
SCNNlA-6418 - GAGGCAGACGCAUCCCAC 18 10267
SCNNlA-6419 - GGAGGCAGACGCAUCCCAC 19 10268
SCNNlA-6420 - GAGGAGGCAGACGCAUCCCAC 21 10269
SCNNlA-6421 - GGAGGAGGCAGACGCAUCCCAC 22 10270
SCNNlA-1335 - GGCCAGGGGCAGCCUCAC 18 5184
SCNNlA-6422 - GACCUGGCUCAAGGGAGAC 19 10271
SCNNlA-5207 - GGACCUGGCUCAAGGGAGAC 20 9056
SCNNlA-6423 - GCACCUGAGCCCCGAUCCCCC 21 10272
SCNNlA-6424 - GUGCACCUGAGCCCCGAUCCCCC 23 10273
SCNNlA-6425 - GGUGCACCUGAGCCCCGAUCCCCC 24 10274
SCNNlA-6426 - GACCAGGUUGGACCCUGAGCC 21 10275
SCNNlA-6427 - GCGUCUAAAGCCCCUGCC 18 10276
SCNNlA-6428 - GUCUGCGUCUAAAGCCCCUGCC 22 10277
SCNNlA-1336 - GCAGCCUCACUCGGGUUCC 19 5185
SCNNlA-348 - GGCAGCCUCACUCGGGUUCC 20 4197
SCNNlA-6429 - GAACCUUUGAGAUCAAACAGC 21 10278
SCNNlA-6430 - GCCUUCCCUGCCGCGUGCAGGGC 23 10279
SCNNlA-6431 - GCUUCACCUGGGCCCCUC 18 10280
SCNNlA-6432 - GUUGUGUGGGUGGCUCUC 18 10281
SCNNlA-6433 - GGUUGUGUGGGUGGCUCUC 19 10282
SCNNlA-6434 - GGGUUGUGUGGGUGGCUCUC 20 10283
SCNNlA-6435 - GGAGUUUCUAGGGGUCUC 18 10284
SCNNlA-6436 - GACUGGAGUUUCUAGGGGUCUC 22 10285
1361
5535.1 SCNNlA-6437 - GAGACUGGAGUUUCUAGGGGUCUC 24 10286
SCNNlA-6438 - GAUAACCCAGCACCCAGAGAGCAG 24 10287
SCNNlA-6439 - GAUAGCCCCAGAGGAGGAG 19 10288
SCNNlA-6440 - GUAGAUAGCCCCAGAGGAGGAG 22 10289
SCNNlA-6441 - GAGUGGGAGAAUGUGGGCG 19 10290
SCNNlA-6442 - GGAGUGGGAGAAUGUGGGCG 20 10291
SCNNlA-6443 - GACAAGGUUGGAGGGGGUGGCG 22 10292
SCNNlA-6444 - GGACAAGGUUGGAGGGGGUGGCG 23 10293
SCNNlA-6445 - GCUGCCUUAAGCUAGUGG 18 10294
SCNNlA-6446 - GCCAUGCUGCCUUAAGCUAGUGG 23 10295
SCNNlA-6447 - GUCCCAGUCCAGCCGCAACCU 21 10296
SCNNlA-6448 - GCCUGAGGGUGAGGCUGACCU 21 10297
SCNNlA-6449 - GGCCUGAGGGUGAGGCUGACCU 22 10298
SCNNlA-6450 - GGGCCUGAGGGUGAGGCUGACCU 23 10299
SCNNlA-6451 - GCCCUCCUAGCUGUGGGCU 19 10300
SCNNlA-6452 - GCUCAAGGGAGACUGGAGUUUCU 23 10301
SCNNlA-6453 - GGCUCAAGGGAGACUGGAGUUUCU 24 10302
SCNNlA-6454 - GAAUCCACGGGCUCUGUGU 19 10303
SCNNlA-6455 - GACGAAUCCACGGGCUCUGUGU 22 10304
SCNNlA-6456 - GUGCAGGGCCUGGGUUGU 18 10305
SCNNlA-6457 - GCGUGCAGGGCCUGGGUUGU 20 10306
SCNNlA-6458 - GCCGCGUGCAGGGCCUGGGUUGU 23 10307
SCNNlA-437 - GUAAGCAAGGGAACCUGGUU 20 4286
SCNNlA-1339 - GGUAAGCAAGGGAACCUGGUU 21 5188
SCNNlA-6459 - GAGUCUCCUCCAGCCCUUU 19 10308
Table 47B provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the second tier parameters. The targeting domains bind within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), have a high level of orthogonality and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. Aureus eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
Table 47B
2nd Tier
1362
5535.1 Target Site gRNA Name DNA Strand Targeting Domain
Length Seq ID
SCNNlA-6460 + AG A AG G AG C C AG C AC C A A A 19 10309
SCNNlA-5515 + UAGAAGGAGCCAG C AC C A A A 20 9364
SCNNlA-6461 + UAGGAGCAGAGCUAUAAA 18 10310
SCNNlA-6462 + AUAGGAGCAGAGCUAUAAA 19 10311
SCNNlA-6463 + AAUAGGAGCAGAGCUAUAAA 20 10312
SCNNlA-6464 + AAA UAGGAGCAGAGCUAU AAA 21 10313
SCNNlA-6465 + A A A A UAGGAGCAGAGCUAU AAA 22 10314
SCNNlA-6466 + CAAAAUAGGAGCAGAGCUAUAAA 23 10315
SCNNlA-6467 + ACAAAAUAGGAGCAGAGCUAUAAA 24 10316
SCNNlA-6468 + UUUCCAAACUUAAUGCAGCAA 21 10317
SCNNlA-6469 + CUUUCCAAACUUAAUGCAGCAA 22 10318
SCNNlA-6470 + UCUUUCCAAACUUAAUGCAGCAA 23 10319
SCNNlA-6471 + CUCUUUCCAAACUUAAUGCAGCAA 24 10320
SCNNlA-6472 + UGGCCAGCGCUGGAAAGGAA 20 10321
SCNNlA-6473 + UGUGGCCAGCGCUGGAAAGGAA 22 10322
SCNNlA-6474 + AUGUGGCCAGCGCUGGAAAGGAA 23 10323
SCNNlA-6475 + UGCUGAAUCUUGACAAGCA 19 10324
SCNNlA-5532 + CUGCUGAAUCUUGACAAGCA 20 9381
SCNNlA-6476 + UCUGCUGAAUCUUGACAAGCA 21 10325
SCNNlA-6477 + CUCUGCUGAAUCUUGACAAGCA 22 10326
SCNNlA-6478 + UCUCUGCUGAAUCUUGACAAGCA 23 10327
SCNNlA-6479 + AUCUCUGCUGAAUCUUGACAAGCA 24 10328
SCNNlA-6480 + AGGGAUGGAGGAGGGGCA 18 10329
SCNNlA-6481 + UAGGGAUGGAGGAGGGGCA 19 10330
SCNNlA-6482 + AUAGGGAUGGAGGAGGGGCA 20 10331
SCNNlA-6483 + UCGCCCCUGCUGUGGUCA 18 10332
SCNNlA-6484 + AUCGCCCCUGCUGUGGUCA 19 10333
SCNNlA-6485 + AAUCGCCCCUGCUGUGGUCA 20 10334
SCNNlA-6486 + UAAUCGCCCCUGCUGUGGUCA 21 10335
SCNNlA-6487 + UGUAAUCGCCCCUGCUGUGGUCA 23 10336
SCNNlA-6488 + U A A U G C AG C A A A AG G A U A 18 10337
SCNNlA-6489 + U U A A U G C AG C A A A AG G A U A 19 10338
SCNNlA-6098 + CUUAAUGCAGCAAAAGGAUA 20 9947
SCNNlA-6490 + AGUGAAAGCCGGUGUCAAC 19 10339
SCNNlA-6491 + A AG U G AAAG CCGGUGUCAAC 20 10340
SCNNlA-6492 + AAAG U G AAAG CCGGUGUCAAC 21 10341
SCNNlA-6493 + UAAAGUGAAAGCCGGUGUCAAC 22 10342
SCNNlA-6494 + U U AAAG UG AAAG CCGG UG U CAAC 23 10343
SCNNlA-6495 + CU U AAAG UG AAAG CCGG UG U CAAC 24 10344
SCNNlA-1344 + UCCCAUCACCCCUGGAAC 18 5193
1363
5535.1 SCNNlA-1345 + CUCCCAUCACCCCUGGAAC 19 5194
SCNNlA-1346 + UCUCCCAUCACCCCUGGAAC 20 5195
SCNNlA-1347 + CUCUCCCAUCACCCCUGGAAC 21 5196
SCNNlA-1348 + CCUCUCCCAUCACCCCUGGAAC 22 5197
SCNNlA-1349 + CCCUCUCCCAUCACCCCUGGAAC 23 5198
SCNNlA-6496 + AUCGGGGCUCAGGUGCAC 18 10345
SCNNlA-6497 + UGGGGGAUCGGGGCUCAGGUGCAC 24 10346
SCNNlA-5564 + CGGCCAGGGAUGGAAGCGAC 20 9413
SCNNlA-6498 + CCGGCCAGGGAUGGAAGCGAC 21 10347
SCNNlA-6499 + UGGCCGGCCAGGGAUGGAAGCGAC 24 10348
SCNNlA-6500 + CACUCCCACACAGAGCCC 18 10349
SCNNlA-6501 + UCACUCCCACACAGAGCCC 19 10350
SCNNlA-6502 + CUCACUCCCACACAGAGCCC 20 10351
SCNNlA-6503 + AAGAAACUGACCCUUCCC 18 10352
SCNNlA-6504 + UGAAGAAACUGACCCUUCCC 20 10353
SCNNlA-6505 + AUGAAGAAACUGACCCUUCCC 21 10354
SCNNlA-6506 + AAUGAAGAAACUGACCCUUCCC 22 10355
SCNNlA-6507 + UAAUGAAGAAACUGACCCUUCCC 23 10356
SCNNlA-6508 + CUAAUGAAGAAACUGACCCUUCCC 24 10357
SCNNlA-6509 + CGGGCCCCACAGGAGGCAGCC 21 10358
SCNNlA-6510 + ACGGGCCCCACAGGAGGCAGCC 22 10359
SCNNlA-6511 + CACGGGCCCCACAGGAGGCAGCC 23 10360
SCNNlA-6512 + UCACGGGCCCCACAGGAGGCAGCC 24 10361
SCNNlA-6513 + UGAGGAGGAGUCAGAGCC 18 10362
SCNNlA-6514 + CUGAGGAGGAGUCAGAGCC 19 10363
SCNNlA-6515 + ACUGUUGGCUGCCAGGCC 18 10364
SCNNlA-6516 + CACUGUUGGCUGCCAGGCC 19 10365
SCNNlA-5583 + ACACUGUUGGCUGCCAGGCC 20 9432
SCNNlA-6517 + UACACUGUUGGCUGCCAGGCC 21 10366
SCNNlA-6518 + UUACACUGUUGGCUGCCAGGCC 22 10367
SCNNlA-6519 + UUUACACUGUUGGCUGCCAGGCC 23 10368
SCNNlA-6520 + UUUUACACUGUUGGCUGCCAGGCC 24 10369
SCNNlA-6521 + CCCGCCCGCUGGCCGGCC 18 10370
SCNNlA-6109 + AGCCCGCCCGCUGGCCGGCC 20 9958
SCNNlA-1350 + AAGGCUGAGCUCUGGGCC 18 5199
SCNNlA-1351 + CAAGGCUGAGCUCUGGGCC 19 5200
SCNNlA-1352 + UCAAGGCUGAGCUCUGGGCC 20 5201
SCNNlA-1353 + AGGGUCAAGGCUGAGCUCUGGGCC 24 5202
SCNNlA-1354 + CGGAGUGGAUUGGGGAGAGC 20 5203
SCNNlA-1355 + CCGGAGUGGAUUGGGGAGAGC 21 5204
SCNNlA-1356 + CCCGGAGUGGAUUGGGGAGAGC 22 5205
SCNNlA-1357 + CCCCGGAGUGGAUUGGGGAGAGC 23 5206
1364
5535.1 SCNNlA-1358 + CUGGAGUGGACUGUGGAGGGC 21 5207
SCNNlA-1359 + CCUGGAGUGGACUGUGGAGGGC 22 5208
SCNNlA-1360 + CCCUGGAGUGGACUGUGGAGGGC 23 5209
SCNNlA-6522 + UGGAGCCAGCAGACCUGC 18 10371
SCNNlA-6523 + CUGGAGCCAGCAGACCUGC 19 10372
SCNNlA-5615 + CCUGGAGCCAGCAGACCUGC 20 9464
SCNNlA-6524 + AGGAGGCAGCCCAGAGUGC 19 10373
SCNNlA-6130 + CAGGAGGCAGCCCAGAGUGC 20 9979
SCNNlA-6525 + ACAGGAGGCAGCCCAGAGUGC 21 10374
SCNNlA-6526 + CACAGGAGGCAGCCCAGAGUGC 22 10375
SCNNlA-6527 + CCACAGGAGGCAGCCCAGAGUGC 23 10376
SCNNlA-6528 + CCCACAGGAGGCAGCCCAGAGUGC 24 10377
SCNNlA-6529 + CUGUGGUCACAGAGUUGC 18 10378
SCNNlA-5623 + UGCUGUGGUCACAGAGUUGC 20 9472
SCNNlA-6530 + CUGCUGUGGUCACAGAGUUGC 21 10379
SCNNlA-6531 + CCUGCUGUGGUCACAGAGUUGC 22 10380
SCNNlA-6532 + CCCUGCUGUGGUCACAGAGUUGC 23 10381
SCNNlA-6533 + CCCCUGCUGUGGUCACAGAGUUGC 24 10382
SCNNlA-6534 + CCUUUGGUCUUCUUCCUC 18 10383
SCNNlA-6535 + UCCUUUGGUCUUCUUCCUC 19 10384
SCNNlA-6536 + UUCCUUUGGUCUUCUUCCUC 20 10385
SCNNlA-1361 + UGGUAUGGGCUGCAGAGGUC 20 5210
SCNNlA-1362 + CUGGUAUGGGCUGCAGAGGUC 21 5211
SCNNlA-1363 + CCUGGUAUGGGCUGCAGAGGUC 22 5212
SCNNlA-1364 + ACCUGGUAUGGGCUGCAGAGGUC 23 5213
SCNNlA-1365 + UCCCCUUGGAAGGGACAG 18 5214
SCNNlA-1366 + CUCCCCUUGGAAGGGACAG 19 5215
SCNNlA-1367 + CCUCCCCUUGGAAGGGACAG 20 5216
SCNNlA-1368 + ACCUCCCCUUGGAAGGGACAG 21 5217
SCNNlA-1369 + UACCUCCCCUUGGAAGGGACAG 22 5218
SCNNlA-1370 + AUACCUCCCCUUGGAAGGGACAG 23 5219
SCNNlA-6537 + UGGGACUGGUUCCUUUCCAG 20 10386
SCNNlA-6538 + CUGGGACUGGUUCCUUUCCAG 21 10387
SCNNlA-6539 + ACUGGGACUGGUUCCUUUCCAG 22 10388
SCNNlA-6540 + CAGCAAAAGGAUAAGGAG 18 10389
SCNNlA-5654 + UGCAGCAAAAGGAUAAGGAG 20 9503
SCNNlA-6541 + AUGCAGCAAAAGGAUAAGGAG 21 10390
SCNNlA-6542 + AAUGCAGCAAAAGGAUAAGGAG 22 10391
SCNNlA-6543 + UAAUGCAGCAAAAGGAUAAGGAG 23 10392
SCNNlA-6544 + UUAAUGCAGCAAAAGGAUAAGGAG 24 10393
SCNNlA-6545 + UAUCAAGGGCUCUGUGAG 18 10394
SCNNlA-6546 + AUAUCAAGGGCUCUGUGAG 19 10395
1365
5535.1 SCNNlA-6547 + CAUAUCAAGGGCUCUGUGAG 20 10396
SCNNlA-6548 + UCAUAUCAAGGGCUCUGUGAG 21 10397
SCNNlA-6549 + UUCAUAUCAAGGGCUCUGUGAG 22 10398
SCNNlA-6550 + UUUCAUAUCAAGGGCUCUGUGAG 23 10399
SCNNlA-6551 + UUUUCAUAUCAAGGGCUCUGUGAG 24 10400
SCNNlA-6552 + AGGGGCAAAGAUCUGAACAAGUAG 24 10401
SCNNlA-6553 + AGGCACUGAAGGUGCAGG 18 10402
SCNNlA-6554 + C AGG CAC U G AAG G U G C AG G 19 10403
SCNNlA-6555 + UGGGAGCAGCGCACUCAGG 19 10404
SCNNlA-6556 + AGUGGGAGCAGCGCACUCAGG 21 10405
SCNNlA-6557 + AAGUGGGAGCAGCGCACUCAGG 22 10406
SCNNlA-6558 + UAAGUGGGAGCAGCGCACUCAGG 23 10407
SCNNlA-6559 + CUAAGUGGGAGCAGCGCACUCAGG 24 10408
SCNNlA-6560 + CAGGAAGGAGAGCAAGGG 18 10409
SCNNlA-6561 + CCAGGAAGGAGAGCAAGGG 19 10410
SCNNlA-6159 + UCCAGGAAGGAGAGCAAGGG 20 10008
SCNNlA-6562 + UCCUGAGACAGACUCAUG 18 10411
SCNNlA-6563 + UUCCUGAGACAGACUCAUG 19 10412
SCNNlA-5698 + CUUCCUGAGACAGACUCAUG 20 9547
SCNNlA-6564 + ACUUCCUGAGACAGACUCAUG 21 10413
SCNNlA-6565 + UACUUCCUGAGACAGACUCAUG 22 10414
SCNNlA-6566 + UUACUUCCUGAGACAGACUCAUG 23 10415
SCNNlA-6567 + UUUACUUCCUGAGACAGACUCAUG 24 10416
SCNNlA-6568 + UCGUCUGCUCUCUGGGUG 18 10417
SCNNlA-6569 + UUCGUCUGCUCUCUGGGUG 19 10418
SCNNlA-6570 + AUUCGUCUGCUCUCUGGGUG 20 10419
SCNNlA-6571 + UGGAUUCGUCUGCUCUCUGGGUG 23 10420
SCNNlA-6572 + AGCGAAGGACAGAGAGAU 18 10421
SCNNlA-6573 + CAGCGAAGGACAGAGAGAU 19 10422
SCNNlA-5722 + ACAGCGAAGGACAGAGAGAU 20 9571
SCNNlA-6574 + CCCGAGGGCAGGUGAACU 18 10423
SCNNlA-6575 + UCCCGAGGGCAGGUGAACU 19 10424
SCNNlA-5726 + CUCCCGAGGGCAGGUGAACU 20 9575
SCNNlA-6576 + AAGGCAGUACUCCAGGCU 18 10425
SCNNlA-6577 + AAAGGCAGUACUCCAGGCU 19 10426
SCNNlA-6578 + AAAAG G C AG U AC U CC AG G C U 20 10427
SCNNlA-6579 + CGUGGAUUCGUCUGCUCU 18 10428
SCNNlA-6580 + CCGUGGAUUCGUCUGCUCU 19 10429
SCNNlA-6581 + CCCGUGGAUUCGUCUGCUCU 20 10430
SCNNlA-6582 + AGCCCGUGGAUUCGUCUGCUCU 22 10431
SCNNlA-6583 + AGAGCCCGUGGAUUCGUCUGCUCU 24 10432
SCNNlA-6584 + UCUGCCUUCUGUUUCUCU 18 10433
1366
5535.1 SCNNlA-6585 + AUCUGCCUUCUGUUUCUCU 19 10434
SCNNlA-6586 + UAUCUGCCUUCUGUUUCUCU 20 10435
SCNNlA-6587 + CUAUCUGCCUUCUGUUUCUCU 21 10436
SCNNlA-6588 + UCUAUCUGCCUUCUGUUUCUCU 22 10437
SCNNlA-6589 + CUCUAUCUGCCUUCUGUUUCUCU 23 10438
SCNNlA-6590 + UCUCUAUCUGCCUUCUGUUUCUCU 24 10439
SCNNlA-1377 + AUUGGGGAGAGCAAGGGU 18 5226
SCNNlA-1378 + UGGAUUGGGGAGAGCAAGGGU 21 5227
SCNNlA-1379 + AGUGGAUUGGGGAGAGCAAGGGU 23 5228
SCNNlA-6591 + AGAGCUAUAAACAGAAUU 18 10440
SCNNlA-6592 + CAGAGCUAU A A AC AG A A U U 19 10441
SCNNlA-6593 + AGCAGAGCUAU A A AC AG A A U U 21 10442
SCNNlA-6594 + AGGAGCAGAGCUAUAAACAGAAUU 24 10443
SCNNlA-6595 + CUUCCCUGAUAGGGCCACCUU 21 10444
SCNNlA-6596 + UGCUUCCCUGAUAGGGCCACCUU 23 10445
SCNNlA-6597 + CUGCUUCCCUGAUAGGGCCACCUU 24 10446
SCNNlA-6598 - CAACAGUGUAAAAAAGAA 18 10447
SCNNlA-6599 - CCAACAGUGUAAAAAAGAA 19 10448
SCNNlA-6600 - AG CCAACAGUGUAAAAAAGAA 21 10449
SCNNlA-6601 - CAG CCAACAG U GUAAAAAAGAA 22 10450
SCNNlA-6602 - AGAAAAUAUAGCCCAUCA 18 10451
SCNNlA-6603 - UGCAGUCCUGGGGCAGAGA 19 10452
SCNNlA-6604 - CUGCAGUCCUGGGGCAGAGA 20 10453
SCNNlA-5553 - CGGGUCUGGACAAGGUUGGA 20 9402
SCNNlA-6605 - CCGGGUCUGGACAAGGUUGGA 21 10454
SCNNlA-6606 - CCCGGGUCUGGACAAGGUUGGA 22 10455
SCNNlA-6607 - UCCCGGGUCUGGACAAGGUUGGA 23 10456
SCNNlA-6608 - CUCCCGGGUCUGGACAAGGUUGGA 24 10457
SCNNlA-6609 - AGGAGGCAGACGCAUCCCAC 20 10458
SCNNlA-6610 - AGGAGGAGGCAGACGCAUCCCAC 23 10459
SCNNlA-6611 - CAGGAGGAGGCAGACGCAUCCCAC 24 10460
SCNNlA-1392 - UGGCCAGGGGCAGCCUCAC 19 5241
SCNNlA-1393 - AUGGCCAGGGGCAGCCUCAC 20 5242
SCNNlA-6612 - ACCUGGCUCAAGGGAGAC 18 10461
SCNNlA-6613 - CCUGAGCCCCGAUCCCCC 18 10462
SCNNlA-6614 - ACCUGAGCCCCGAUCCCCC 19 10463
SCNNlA-6615 - CACCUGAGCCCCGAUCCCCC 20 10464
SCNNlA-6616 - UGCACCUGAGCCCCGAUCCCCC 22 10465
SCNNlA-6617 - CAGGUUGGACCCUGAGCC 18 10466
SCNNlA-6618 - CCAGGUUGGACCCUGAGCC 19 10467
SCNNlA-5581 - ACCAGGUUGGACCCUGAGCC 20 9430
SCNNlA-6619 - AGACCAGGUUGGACCCUGAGCC 22 10468
1367
5535.1 SCNNlA-6620 - CAGACCAGGUUGGACCCUGAGCC 23 10469
SCNNlA-6621 - ACAGACCAGGUUGGACCCUGAGCC 24 10470
SCNNlA-6622 - UGCGUCUAAAGCCCCUGCC 19 10471
SCNNlA-6623 - CUGCGUCUAAAGCCCCUGCC 20 10472
SCNNlA-6624 - UCUGCGUCUAAAGCCCCUGCC 21 10473
SCNNlA-6625 - UGUCUGCGUCUAAAGCCCCUGCC 23 10474
SCNNlA-6626 - CUGUCUGCGUCUAAAGCCCCUGCC 24 10475
SCNNlA-1394 - CAGCCUCACUCGGGUUCC 18 5243
SCNNlA-6627 - CCUUUGAGAUCAAACAGC 18 10476
SCNNlA-6628 - ACCUUUGAGAUCAAACAGC 19 10477
SCNNlA-6629 - AACCUUUGAGAUCAAACAGC 20 10478
SCNNlA-6630 - AGAACCUUUGAGAUCAAACAGC 22 10479
SCNNlA-6631 - CAGAACCUUUGAGAUCAAACAGC 23 10480
SCNNlA-6632 - UCAGAACCUUUGAGAUCAAACAGC 24 10481
SCNNlA-6633 - CCCUGCCGCGUGCAGGGC 18 10482
SCNNlA-6634 - UCCCUGCCGCGUGCAGGGC 19 10483
SCNNlA-6635 - UUCCCUGCCGCGUGCAGGGC 20 10484
SCNNlA-6636 - CUUCCCUGCCGCGUGCAGGGC 21 10485
SCNNlA-6637 - CCUUCCCUGCCGCGUGCAGGGC 22 10486
SCNNlA-6638 - AGCCUUCCCUGCCGCGUGCAGGGC 24 10487
SCNNlA-6639 - AGCUUCACCUGGGCCCCUC 19 10488
SCNNlA-6640 - CAGCUUCACCUGGGCCCCUC 20 10489
SCNNlA-6641 - CCAGCUUCACCUGGGCCCCUC 21 10490
SCNNlA-6642 - CCCAGCUUCACCUGGGCCCCUC 22 10491
SCNNlA-6643 - CCCCAGCUUCACCUGGGCCCCUC 23 10492
SCNNlA-6644 - CCCCCAGCUUCACCUGGGCCCCUC 24 10493
SCNNlA-6645 - UGGAGUUUCUAGGGGUCUC 19 10494
SCNNlA-5635 - CUGGAGUUUCUAGGGGUCUC 20 9484
SCNNlA-6646 - ACUGGAGUUUCUAGGGGUCUC 21 10495
SCNNlA-6647 - AGACUGGAGUUUCUAGGGGUCUC 23 10496
SCNNlA-6648 - CCAGCACCCAGAGAGCAG 18 10497
SCNNlA-6649 - CCCAG CACCCAG AG AG CAG 19 10498
SCNNlA-6650 - ACCCAGCACCCAGAGAGCAG 20 10499
SCNNlA-6651 - AACCCAGCACCCAGAGAGCAG 21 10500
SCNNlA-6652 - UAACCCAGCACCCAGAGAGCAG 22 10501
SCNNlA-6653 - AUAACCCAGCACCCAGAGAGCAG 23 10502
SCNNlA-6654 - AUAGCCCCAGAGGAGGAG 18 10503
SCNNlA-6655 - AGAUAGCCCCAGAGGAGGAG 20 10504
SCNNlA-6656 - UAGAUAGCCCCAGAGGAGGAG 21 10505
SCNNlA-6657 - AGUAGAUAGCCCCAGAGGAGGAG 23 10506
SCNNlA-6658 - AAGUAGAUAGCCCCAGAGGAGGAG 24 10507
SCNNlA-6659 - AGUGGGAGAAUGUGGGCG 18 10508
1368
5535.1 SCNNlA-6660 - AGGUUGGAGGGGGUGGCG 18 10509
SCNNlA-6661 - AAGGUUGGAGGGGGUGGCG 19 10510
SCNNlA-5670 - CAAGGUUGGAGGGGGUGGCG 20 9519
SCNNlA-6662 - ACAAGGUUGGAGGGGGUGGCG 21 10511
SCNNlA-6663 - UGGACAAGGUUGGAGGGGGUGGCG 24
10512
SCNNlA-6664 - AACUGAUUUAUCCUUGGG 18 10513
SCNNlA-6665 - AAACUGAUUUAUCCUUGGG 19 10514
SCNNlA-6666 - AAAACUGAUUUAUCCUUGGG 20 10515
SCNNlA-6667 - UGCUGCCUUAAGCUAGUGG 19 10516
SCNNlA-6668 - AUGCUGCCUUAAGCUAGUGG 20 10517
SCNNlA-6669 - CAUGCUGCCUUAAGCUAGUGG 21 10518
SCNNlA-6670 - CCAUGCUGCCUUAAGCUAGUGG 22 10519
SCNNlA-6671 - UGCCAUGCUGCCUUAAGCUAGUGG 24 10520
SCNNlA-6672 - CCAGUCCAGCCGCAACCU 18 10521
SCNNlA-6673 - CCCAG U CCAG CCG CAACCU 19 10522
SCNNlA-5731 - UCCCAGUCCAGCCGCAACCU 20 9580
SCNNlA-6674 - AG U CCCAG U CCAG CCG CAACCU 22 10523
SCNNlA-6675 - CAG U CCCAG U CCAG CCG CAACCU 23 10524
SCNNlA-6676 - CCAGUCCCAGUCCAGCCGCAACCU 24 10525
SCNNlA-6677 - UGAGGGUGAGGCUGACCU 18 10526
SCNNlA-6678 - CUGAGGGUGAGGCUGACCU 19 10527
SCNNlA-6679 - CCUGAGGGUGAGGCUGACCU 20 10528
SCNNlA-6680 - AGGGCCUGAGGGUGAGGCUGACCU 24 10529
SCNNlA-6681 - CUCUUCUCUGCAGGGCCU 18 10530
SCNNlA-6682 - UCUCUUCUCUGCAGGGCCU 19 10531
SCNNlA-6683 - CUCUCUUCUCUGCAGGGCCU 20 10532
SCNNlA-6684 - UCUCUCUUCUCUGCAGGGCCU 21 10533
SCNNlA-6685 - UUCUCUCUUCUCUGCAGGGCCU 22 10534
SCNNlA-6686 - CUUCUCUCUUCUCUGCAGGGCCU 23 10535
SCNNlA-6687 - UCUUCUCUCUUCUCUGCAGGGCCU 24 10536
SCNNlA-6688 - CCUGCCUCUUCCUGGGCU 18 10537
SCNNlA-6689 - CCCUGCCUCUUCCUGGGCU 19 10538
SCNNlA-6690 - UCCCUGCCUCUUCCUGGGCU 20 10539
SCNNlA-6691 - CCCUCCUAGCUGUGGGCU 18 10540
SCNNlA-6692 - UGCCCUCCUAGCUGUGGGCU 20 10541
SCNNlA-6693 - AGGGAGACUGGAGUUUCU 18 10542
SCNNlA-6694 - AAGGGAGACUGGAGUUUCU 19 10543
SCNNlA-5751 - CAAGGGAGACUGGAGUUUCU 20 9600
SCNNlA-6695 - UCAAGGGAGACUGGAGUUUCU 21 10544
SCNNlA-6696 - CUCAAGGGAGACUGGAGUUUCU 22 10545
SCNNlA-6697 - AAUCCACGGGCUCUGUGU 18 10546
1369
5535.1 SCNNlA-5766 - CGAAUCCACGGGCUCUGUGU 20 9615
SCNNlA-6698 - ACGAAUCCACGGGCUCUGUGU 21 10547
SCNNlA-6699 - AGACGAAUCCACGGGCUCUGUGU 23 10548
SCNNlA-6700 - CAGACGAAUCCACGGGCUCUGUGU 24 10549
SCNNlA-6701 - CGUGCAGGGCCUGGGUUGU 19 10550
SCNNlA-6702 - CGCGUGCAGGGCCUGGGUUGU 21 10551
SCNNlA-6703 - CCGCGUGCAGGGCCUGGGUUGU 22 10552
SCNNlA-6704 - UGCCGCGUGCAGGGCCUGGGUUGU 24 10553
SCNNlA-1405 - AAGCAAGGGAACCUGGUU 18 5254
SCNNlA-1406 - UAAGCAAGGGAACCUGGUU 19 5255
SCNNlA-1407 - AGGUAAGCAAGGGAACCUGGUU 22 5256
SCNNlA-1408 - A AG G U A AG C A AG GGAACCUGGUU 23 5257
SCNNlA-1409 - C A AG G U A AG C A AG GGAACCUGGUU 24 5258
SCNNlA-6705 - AGUCUCCUCCAGCCCUUU 18 10554
SCNNlA-6706 - CGAGUCUCCUCCAGCCCUUU 20 10555
SCNNlA-6707 - CCGAGUCUCCUCCAGCCCUUU 21 10556
SCNNlA-6708 - CCCGAGUCUCCUCCAGCCCUUU 22 10557
SCNNlA-6709 - UCCCGAGUCUCCUCCAGCCCUUU 23 10558
SCNNlA-6710 - CUCCCGAGUCUCCUCCAGCCCUUU 24 10559
Table 47C provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the third tier parameters. The targeting domains bind within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. Aureus eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene
Table 47C
Figure imgf001371_0001
1370
5535.1 SCNNlA-6715 + CCAAACUUAAUGCAGCAA 18 10564
SCNNlA-6716 + U C C A A AC U UAAUGCAGCAA 19 10565
SCNNlA-6717 + UUCCAAACUUAAUGCAGCAA 20 10566
SCNNlA-6718 + GAUAGGGAUGGAGGAGGGGCA 21 10567
SCNNlA-6719 + AGAUAGGGAUGGAGGAGGGGCA 22 10568
SCNNlA-6720 + GAGAUAGGGAUGGAGGAGGGGCA 23 10569
SCNNlA-6721 + AGAGAUAGGGAUGGAGGAGGGGCA 24
10570
SCNNlA-6722 + GGAGAGAGAGGAGGGUCA 18 10571
SCNNlA-6723 + AGGAGAGAGAGGAGGGUCA 19 10572
SCNNlA-6724 + AAGGAGAGAGAGGAGGGUCA 20 10573
SCNNlA-6725 + CAAGGAGAGAGAGGAGGGUCA 21 10574
SCNNlA-6726 + GCAAGGAGAGAGAGGAGGGUCA 22 10575
SCNNlA-6727 + AGCAAGGAGAGAGAGGAGGGUCA 23 10576
SCNNlA-6728 + GAGCAAGGAGAGAGAGGAGGGUCA 24 10577
SCNNlA-1410 + CCCUUCAUGAGCCCCGGA 18 5259
SCNNlA-1411 + CCCCUUCAUGAGCCCCGGA 19 5260
SCNNlA-1412 + UCCCCUUCAUGAGCCCCGGA 20 5261
SCNNlA-1413 + UUCCCCUUCAUGAGCCCCGGA 21 5262
SCNNlA-1414 + GUUCCCCUUCAUGAGCCCCGGA 22 5263
SCNNlA-1415 + UGUUCCCCUUCAUGAGCCCCGGA 23 5264
SCNNlA-1416 + UUGUUCCCCUUCAUGAGCCCCGGA 24 5265
SCNNlA-6729 + GGCAAGGAGGCUGGGGGA 18 10578
SCNNlA-6730 + AGGCAAGGAGGCUGGGGGA 19 10579
SCNNlA-6731 + CAGGCAAGGAGGCUGGGGGA 20 10580
SCNNlA-6732 + ACAGGCAAGGAGGCUGGGGGA 21 10581
SCNNlA-6733 + GACAGGCAAGGAGGCUGGGGGA 22 10582
SCNNlA-6734 + AGACAGGCAAGGAGGCUGGGGGA 23 10583
SCNNlA-6735 + CAGACAGGCAAGGAGGCUGGGGGA 24 10584
SCNNlA-6736 + AUGGAGGAGGGGCACUGA 18 10585
SCNNlA-6737 + GAUGGAGGAGGGGCACUGA 19 10586
SCNNlA-6738 + GGAUGGAGGAGGGGCACUGA 20 10587
SCNNlA-6739 + GGGAUGGAGGAGGGGCACUGA 21 10588
SCNNlA-6740 + AGGGAUGGAGGAGGGGCACUGA 22 10589
SCNNlA-6741 + UAGGGAUGGAGGAGGGGCACUGA 23 10590
SCNNlA-6742 + AUAGGGAUGGAGGAGGGGCACUGA 24
10591
SCNNlA-6743 + ACUUAAUGCAGCAAAAGGAUA 21 10592
SCNNlA-6744 + AACUUAAUGCAGCAAAAGGAUA 22 10593
SCNNlA-6745 + AAACUUAAUGCAGCAAAAGGAUA 23 10594
SCNNlA-6746 + C A A AC U U A A U G C AG C A A A AG G A U A 24 10595
SCNNlA-6747 + CCUCACUCCCACACAGAGCCC 21 10596
1371
5535.1 SCNNlA-6748 + CCCUCACUCCCACACAGAGCCC 22 10597
SCNNlA-6749 + UCCCUCACUCCCACACAGAGCCC 23 10598
SCNNlA-6750 + CUCCCUCACUCCCACACAGAGCCC 24 10599
SCNNlA-1417 + GUUCCCCUUCAUGAGCCC 18 5266
SCNNlA-1418 + UGUUCCCCUUCAUGAGCCC 19 5267
SCNNlA-72 + UUGUUCCCCUUCAUGAGCCC 20 599
SCNNlA-1419 + CUUGUUCCCCUUCAUGAGCCC 21 5268
SCNNlA-1420 + GCUUGUUCCCCUUCAUGAGCCC 22 5269
SCNNlA-1421 + AGCUUGUUCCCCUUCAUGAGCCC 23 5270
SCNNlA-1422 + CAGCUUGUUCCCCUUCAUGAGCCC 24 5271
SCNNlA-6751 + GGCUGAGGAGGAGUCAGAGCC 21 10600
SCNNlA-6752 + GGGCUGAGGAGGAGUCAGAGCC 22 10601
SCNNlA-6753 + GGGGCUGAGGAGGAGUCAGAGCC 23 10602
SCNNlA-6754 + AGGGGCUGAGGAGGAGUCAGAGCC 24 10603
SCNNlA-6755 + CAGCCAGGCUGAGAGGGC 18 10604
SCNNlA-6756 + CCAGCCAGGCUGAGAGGGC 19 10605
SCNNlA-6757 + GCCAGCCAGGCUGAGAGGGC 20 10606
SCNNlA-6758 + GGCCAGCCAGGCUGAGAGGGC 21 10607
SCNNlA-6759 + GGGCCAGCCAGGCUGAGAGGGC 22 10608
SCNNlA-6760 + GGGGCCAGCCAGGCUGAGAGGGC 23 10609
SCNNlA-6761 + AGGGGCCAGCCAGGCUGAGAGGGC 24 10610
SCNNlA-1431 + GAGUGGACUGUGGAGGGC 18 5280
SCNNlA-1432 + GGAGUGGACUGUGGAGGGC 19 5281
SCNNlA-201 + UGGAGUGGACUGUGGAGGGC 20 830
SCNNlA-6762 + UCCUGGAGCCAGCAGACCUGC 21 10611
SCNNlA-6763 + UUCCUGGAGCCAGCAGACCUGC 22 10612
SCNNlA-6764 + UUUCCUGGAGCCAGCAGACCUGC 23 10613
SCNNlA-6765 + CUUUCCUGGAGCCAGCAGACCUGC 24 10614
SCNNlA-6766 + CUUCCUUUGGUCUUCUUCCUC 21 10615
SCNNlA-6767 + CCUUCCUUUGGUCUUCUUCCUC 22 10616
SCNNlA-6768 + CCCUUCCUUUGGUCUUCUUCCUC 23 10617
SCNNlA-6769 + CCCCUUCCUUUGGUCUUCUUCCUC 24 10618
SCNNlA-6770 + GUGAGCAAGGAGAGAGAG 18 10619
SCNNlA-6771 + GGUGAGCAAGGAGAGAGAG 19 10620
SCNNlA-6772 + UGGUGAGCAAGGAGAGAGAG 20 10621
SCNNlA-6773 + GUGGUGAGCAAGGAGAGAGAG 21 10622
SCNNlA-6774 + AGUGGUGAGCAAGGAGAGAGAG 22 10623
SCNNlA-6775 + AAGUGGUGAGCAAGGAGAGAGAG 23 10624
SCNNlA-6776 + CAAGUGGUGAGCAAGGAGAGAGAG 24 10625
SCNNlA-6777 + AAAGAUCUGAACAAGUAG 18 10626
SCNNlA-6778 + C AAAG AU C U G AAC AAG U AG 19 10627
SCNNlA-6779 + G C A A AG A U C U G A AC A AG U AG 20 10628
1372
5535.1 SCNNlA-6780 + AGCAGGCACUGAAGGUGCAGG 21 10629
SCNNlA-6781 + AAGCAGGCACUGAAGGUGCAGG 22 10630
SCNNlA-6782 + A A AG CAGGCACUGAAGGUGCAGG 23 10631
SCNNlA-6783 + G A A AG CAGGCACUGAAGGUGCAGG 24 10632
SCNNlA-6784 + CGGGGGGAGGGGCUGAGG 18 10633
SCNNlA-6785 + GCGGGGGGAGGGGCUGAGG 19 10634
SCNNlA-5907 + GGCGGGGGGAGGGGCUGAGG 20 9756
SCNNlA-6786 + GGGCGGGGGGAGGGGCUGAGG 21 10635
SCNNlA-6787 + AGGGCGGGGGGAGGGGCUGAGG 22 10636
SCNNlA-6788 + CAGGGCGGGGGGAGGGGCUGAGG 23 10637
SCNNlA-6789 + GCAGGGCGGGGGGAGGGGCUGAGG 24
10638
SCNNlA-6790 + CUCCAGGAAGGAGAGCAAGGG 21 10639
SCNNlA-6791 + UCUCCAGGAAGGAGAGCAAGGG 22 10640
SCNNlA-6792 + GUCUCCAGGAAGGAGAGCAAGGG 23 10641
SCNNlA-6793 + UGUCUCCAGGAAGGAGAGCAAGGG 24 10642
SCNNlA-6794 + GAGAAGGUGUCAUCUCUG 18 10643
SCNNlA-6795 + AGAGAAGGUGUCAUCUCUG 19 10644
SCNNlA-6796 + CAGAGAAGGUGUCAUCUCUG 20 10645
SCNNlA-6797 + CCAGAGAAGGUGUCAUCUCUG 21 10646
SCNNlA-6798 + CCCAGAGAAGGUGUCAUCUCUG 22 10647
SCNNlA-6799 + UCCCAGAGAAGGUGUCAUCUCUG 23 10648
SCNNlA-6800 + UUCCCAGAGAAGGUGUCAUCUCUG 24 10649
SCNNlA-6801 + GACAGCGAAGGACAGAGAGAU 21 10650
SCNNlA-6802 + GGACAGCGAAGGACAGAGAGAU 22 10651
SCNNlA-6803 + GGGACAGCGAAGGACAGAGAGAU 23 10652
SCNNlA-6804 + AGGGACAGCGAAGGACAGAGAGAU 24 10653
SCNNlA-6805 + GCUCCCGAGGGCAGGUGAACU 21 10654
SCNNlA-6806 + GGCUCCCGAGGGCAGGUGAACU 22 10655
SCNNlA-6807 + GGGCUCCCGAGGGCAGGUGAACU 23 10656
SCNNlA-6808 + AGGGCUCCCGAGGGCAGGUGAACU 24 10657
SCNNlA-6809 + GAAAAG G C AG U AC U CC AG G C U 21 10658
SCNNlA-6810 + AGAAAAGGCAGUACUCCAGGCU 22 10659
SCNNlA-6811 + GAGAAAAGGCAGUACUCCAGGCU 23 10660
SCNNlA-6812 + AGAGAAAAGGCAGUACUCCAGGCU 24 10661
SCNNlA-6813 + CCCUGAUAGGGCCACCUU 18 10662
SCNNlA-6814 + UCCCUGAUAGGGCCACCUU 19 10663
SCNNlA-6815 + UUCCCUGAUAGGGCCACCUU 20 10664
SCNNlA-6816 - UGGAGAAAAUAUAGCCCAUCA 21 10665
SCNNlA-6817 - UUGGAGAAAAUAUAGCCCAUCA 22 10666
SCNNlA-6818 - UUUGGAGAAAAUAUAGCCCAUCA 23 10667
SCNNlA-6819 - UUUUGGAGAAAAUAUAGCCCAUCA 24 10668
1373
5535.1 SCNNlA-6820 - CCUGCAGUCCUGGGGCAGAGA 21 10669
SCNNlA-6821 - CCCUGCAGUCCUGGGGCAGAGA 22 10670
SCNNlA-6822 - GCCCUGCAGUCCUGGGGCAGAGA 23 10671
SCNNlA-6823 - AGCCCUGCAGUCCUGGGGCAGAGA 24 10672
SCNNlA-6824 - ACAGAAGGCAGAUAGAGA 18 10673
SCNNlA-6825 - AACAGAAGGCAGAUAGAGA 19 10674
SCNNlA-6088 - AAACAGAAGGCAGAUAGAGA 20 9937
SCNNlA-6826 - G A A AC AG AAGGCAGAUAGAGA 21 10675
SCNNlA-6827 - AGAAACAGAAGGCAGAUAGAGA 22 10676
SCNNlA-6828 - GAGAAACAGAAGGCAGAUAGAGA 23 10677
SCNNlA-6829 - AGAGAAACAGAAGGCAGAUAGAGA 24 10678
SCNNlA-1437 - CAUGGCCAGGGGCAGCCUCAC 21 5286
SCNNlA-1438 - GCAUGGCCAGGGGCAGCCUCAC 22 5287
SCNNlA-1439 - GGCAUGGCCAGGGGCAGCCUCAC 23 5288
SCNNlA-1440 - GGGCAUGGCCAGGGGCAGCCUCAC 24 5289
SCNNlA-6830 - AGGACCUGGCUCAAGGGAGAC 21 10679
SCNNlA-6831 - AAGGACCUGGCUCAAGGGAGAC 22 10680
SCNNlA-6832 - UAAGGACCUGGCUCAAGGGAGAC 23 10681
SCNNlA-6833 - GUAAGGACCUGGCUCAAGGGAGAC 24 10682
SCNNlA-6834 - AGGCUGGAGCUGAGGGCC 18 10683
SCNNlA-6835 - GAGGCUGGAGCUGAGGGCC 19 10684
SCNNlA-6836 - AGAGGCUGGAGCUGAGGGCC 20 10685
SCNNlA-6837 - CAGAGGCUGGAGCUGAGGGCC 21 10686
SCNNlA-6838 - CCAGAGGCUGGAGCUGAGGGCC 22 10687
SCNNlA-6839 - GCCAGAGGCUGGAGCUGAGGGCC 23 10688
SCNNlA-6840 - GGCCAGAGGCUGGAGCUGAGGGCC 24 10689
SCNNlA-1441 - GGGCAGCCUCACUCGGGUUCC 21 5290
SCNNlA-1442 - GGGGCAGCCUCACUCGGGUUCC 22 5291
SCNNlA-1443 - AGGGGCAGCCUCACUCGGGUUCC 23 5292
SCNNlA-1444 - CAGGGGCAGCCUCACUCGGGUUCC 24 5293
SCNNlA-6841 - UGGGUUGUGUGGGUGGCUCUC 21 10690
SCNNlA-6842 - CUGGGUUGUGUGGGUGGCUCUC 22 10691
SCNNlA-6843 - CCUGGGUUGUGUGGGUGGCUCUC 23 10692
SCNNlA-6844 - GCCUGGGUUGUGUGGGUGGCUCUC 24
10693
SCNNlA-6845 - CUUCUCUGGGAAGGCUUC 18 10694
SCNNlA-6846 - CCUUCUCUGGGAAGGCUUC 19 10695
SCNNlA-6847 - ACCUUCUCUGGGAAGGCUUC 20 10696
SCNNlA-6848 - CACCUUCUCUGGGAAGGCUUC 21 10697
SCNNlA-6849 - ACACCUUCUCUGGGAAGGCUUC 22 10698
SCNNlA-6850 - GACACCUUCUCUGGGAAGGCUUC 23 10699
SCNNlA-6851 - UGACACCUUCUCUGGGAAGGCUUC 24 10700
1374
5535.1 SCNNlA-6852 - AGGAGUGGGAGAAUGUGGGCG 21 10701
SCNNlA-6853 - GAGGAGUGGGAGAAUGUGGGCG 22 10702
SCNNlA-6854 - GGAGGAGUGGGAGAAUGUGGGCG 23 10703
SCNNlA-6855 - GGGAGGAGUGGGAGAAUGUGGGCG 24
10704
SCNNlA-6856 - GGGGGAGAGGAAGAGAGG 18 10705
SCNNlA-6857 - GGGGGGAGAGGAAGAGAGG 19 10706
SCNNlA-6858 - GGGGGGGAGAGGAAGAGAGG 20 10707
SCNNlA-6859 - AGGGGGGGAGAGGAAGAGAGG 21 10708
SCNNlA-6860 - AAGGGGGGGAGAGGAAGAGAGG 22 10709
SCNNlA-6861 - CAAGGGGGGGAGAGGAAGAGAGG 23 10710
SCNNlA-6862 - GCAAGGGGGGGAGAGGAAGAGAGG 24
10711
SCNNlA-6863 - AAGGUGGAGGAGGGAGGG 18 10712
SCNNlA-6864 - AAAGGUGGAGGAGGGAGGG 19 10713
SCNNlA-5911 - GAAAGGUGGAGGAGGGAGGG 20 9760
SCNNlA-6865 - GGAAAGGUGGAGGAGGGAGGG 21 10714
SCNNlA-6866 - AGGAAAGGUGGAGGAGGGAGGG 22 10715
SCNNlA-6867 - CAGGAAAGGUGGAGGAGGGAGGG 23 10716
SCNNlA-6868 - CCAGGAAAGGUGGAGGAGGGAGGG 24
10717
SCNNlA-6869 - GAAAACUGAUUUAUCCUUGGG 21 10718
SCNNlA-6870 - AGAAAACUGAUUUAUCCUUGGG 22 10719
SCNNlA-6871 - CAGAAAACUGAUUUAUCCUUGGG 23 10720
SCNNlA-6872 - UCAGAAAACUGAUUUAUCCUUGGG 24 10721
SCNNlA-6873 - GGAGGGAGGGAGGAGUGG 18 10722
SCNNlA-6874 - AGGAGGGAGGGAGGAGUGG 19 10723
SCNNlA-6875 - GAGGAGGGAGGGAGGAGUGG 20 10724
SCNNlA-6876 - GGAGGAGGGAGGGAGGAGUGG 21 10725
SCNNlA-6877 - UGGAGGAGGGAGGGAGGAGUGG 22 10726
SCNNlA-6878 - GUGGAGGAGGGAGGGAGGAGUGG 23 10727
SCNNlA-6879 - GGUGGAGGAGGGAGGGAGGAGUGG 24
10728
SCNNlA-6880 - UUCCCUGCCUCUUCCUGGGCU 21 10729
SCNNlA-6881 - UUUCCCUGCCUCUUCCUGGGCU 22 10730
SCNNlA-6882 - CUUUCCCUGCCUCUUCCUGGGCU 23 10731
SCNNlA-6883 - GCUUUCCCUGCCUCUUCCUGGGCU 24 10732
SCNNlA-6884 - UUGCCCUCCUAGCUGUGGGCU 21 10733
SCNNlA-6885 - GUUGCCCUCCUAGCUGUGGGCU 22 10734
SCNNlA-6886 - UGUUGCCCUCCUAGCUGUGGGCU 23 10735
SCNNlA-6887 - GUGUUGCCCUCCUAGCUGUGGGCU 24 10736
SCNNlA-6888 - CAG AGG AGG AGG AG AAU U 18 10737
1375
5535.1 SCNNlA-6889 - CCAGAGGAGGAGGAGAAUU 19 10738
SCNNlA-6890 - CCCAGAGGAGGAGGAGAAUU 20 10739
SCNNlA-6891 - CCCCAGAGGAGGAGGAGAAUU 21 10740
SCNNlA-6892 - GCCCCAGAGGAGGAGGAGAAUU 22 10741
SCNNlA-6893 - AGCCCCAGAGGAGGAGGAGAAUU 23 10742
SCNNlA-6894 - UAGCCCCAGAGGAGGAGGAGAAUU 24 10743
Table 47D provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the fourth tier parameters. The targeting domains bind within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. Aureus eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
Table 47D
Figure imgf001377_0001
1376
5535.1 SCNNlA-6913 + GGGGGGCAGUGGUGGGGGCAAA 22 10762
SCNNlA-6914 + UGGGGGGCAGUGGUGGGGGCAAA 23 10763
SCNNlA-6915 + GUGGGGGGCAGUGGUGGGGGCAAA 24
10764
SCNNlA-6916 + AGGACAGGAGGGCAGAAA 18 10765
SCNNlA-6917 + GAGGACAGGAGGGCAGAAA 19 10766
SCNNlA-6918 + GGAGGACAGGAGGGCAGAAA 20 10767
SCNNlA-6919 + GGGAGGACAGGAGGGCAGAAA 21 10768
SCNNlA-6920 + CGGGAGGACAGGAGGGCAGAAA 22 10769
SCNNlA-6921 + CCGGGAGGACAGGAGGGCAGAAA 23 10770
SCNNlA-6922 + ACCGGGAGGACAGGAGGGCAGAAA 24 10771
SCNNlA-6923 + CUCUUGCGACUUCUUAAA 18 10772
SCNNlA-6924 + UCUCUUGCGACUUCUUAAA 19 10773
SCNNlA-6925 + GUCUCUUGCGACUUCUUAAA 20 10774
SCNNlA-6926 + AGUCUCUUGCGACUUCUUAAA 21 10775
SCNNlA-6927 + CAGUCUCUUGCGACUUCUUAAA 22 10776
SCNNlA-6928 + GCAGUCUCUUGCGACUUCUUAAA 23 10777
SCNNlA-6929 + GGCAGUCUCUUGCGACUUCUUAAA 24 10778
SCNNlA-6930 + UAAAAGAUUGUCUUUAAA 18 10779
SCNNlA-6931 + UUAAAAGAUUGUCUUUAAA 19 10780
SCNNlA-6932 + UUUAAAAGAUUGUCUUUAAA 20 10781
SCNNlA-6933 + CUUUAAAAGAUUGUCUUUAAA 21 10782
SCNNlA-6934 + ACUUUAAAAGAUUGUCUUUAAA 22 10783
SCNNlA-6935 + CACU U U AAAAG AU UG U CU U U AAA 23 10784
SCNNlA-6936 + ACACUUUAAAAGAUUGUCUUUAAA 24 10785
SCNNlA-6937 + GCAGAAAGAGGGAGACAA 18 10786
SCNNlA-6938 + GGCAGAAAGAGGGAGACAA 19 10787
SCNNlA-6939 + GGGCAGAAAGAGGGAGACAA 20 10788
SCNNlA-6940 + AGGGCAGAAAGAGGGAGACAA 21 10789
SCNNlA-6941 + GAGGGCAGAAAGAGGGAGACAA 22 10790
SCNNlA-6942 + GGAGGGCAGAAAGAGGGAGACAA 23 10791
SCNNlA-6943 + AGGAGGGCAGAAAGAGGGAGACAA 24 10792
SCNNlA-6944 + AGAAGGAGCCAGCACCAA 18 10793
SCNNlA-6945 + UAGAAGGAGCCAGCACCAA 19 10794
SCNNlA-5518 + AUAGAAGGAGCCAGCACCAA 20 9367
SCNNlA-6946 + AAUAGAAGGAGCCAGCACCAA 21 10795
SCNNlA-6947 + AAAUAGAAGGAGCCAGCACCAA 22 10796
SCNNlA-6948 + C A A A UAGAAGGAGCCAGCACCAA 23 10797
SCNNlA-6949 + GCAAAUAGAAGGAGCCAGCACCAA 24 10798
SCNNlA-6950 + GAGCUAGAGGCUCAGCAA 18 10799
SCNNlA-6951 + GGAGCUAGAGGCUCAGCAA 19 10800
SCNNlA-6952 + AGGAGCUAGAGGCUCAGCAA 20 10801
1377
5535.1 SCNNlA-6953 + CAGGAGCUAGAGGCUCAGCAA 21 10802
SCNNlA-6954 + CCAGGAGCUAGAGGCUCAGCAA 22 10803
SCNNlA-6955 + UCCAGGAGCUAGAGGCUCAGCAA 23 10804
SCNNlA-6956 + UUCCAGGAGCUAGAGGCUCAGCAA 24 10805
SCNNlA-6957 + CUCCAGGAAGGAGAGCAA 18 10806
SCNNlA-6958 + UCUCCAGGAAGGAGAGCAA 19 10807
SCNNlA-5168 + GUCUCCAGGAAGGAGAGCAA 20 9017
SCNNlA-6959 + UGUCUCCAGGAAGGAGAGCAA 21 10808
SCNNlA-6960 + CUGUCUCCAGGAAGGAGAGCAA 22 10809
SCNNlA-6961 + UCUGUCUCCAGGAAGGAGAGCAA 23 10810
SCNNlA-6962 + GUCUGUCUCCAGGAAGGAGAGCAA 24 10811
SCNNlA-6963 + AGUUUAGCAGG C A A AG A A 18 10812
SCNNlA-6964 + GAG U U U AGCAGG CAAAG AA 19 10813
SCNNlA-6965 + GGAGUUUAGCAGGCAAAGAA 20 10814
SCNNlA-6966 + AGGAGUUUAGCAGGCAAAGAA 21 10815
SCNNlA-6967 + AAGGAGUUUAGCAGGCAAAGAA 22 10816
SCNNlA-6968 + CAAGGAGUUUAGCAGGCAAAGAA 23 10817
SCNNlA-6969 + G CAAG GAG U U U AG C AG G C AAAG AA 24 10818
SCNNlA-6970 + CUCAGGCCCUGCAGAGAA 18 10819
SCNNlA-6971 + CCUCAGGCCCUGCAGAGAA 19 10820
SCNNlA-6972 + CCCUCAGGCCCUGCAGAGAA 20 10821
SCNNlA-6973 + ACCCUCAGGCCCUGCAGAGAA 21 10822
SCNNlA-6974 + CACCCUCAGGCCCUGCAGAGAA 22 10823
SCNNlA-6975 + UCACCCUCAGGCCCUGCAGAGAA 23 10824
SCNNlA-6976 + CUCACCCUCAGGCCCUGCAGAGAA 24 10825
SCNNlA-6977 + GAGGGCCUGGGUGGGGAA 18 10826
SCNNlA-6978 + AGAGGGCCUGGGUGGGGAA 19 10827
SCNNlA-6979 + GAGAGGGCCUGGGUGGGGAA 20 10828
SCNNlA-6980 + UGAGAGGGCCUGGGUGGGGAA 21 10829
SCNNlA-6981 + CUGAGAGGGCCUGGGUGGGGAA 22 10830
SCNNlA-6982 + GCUGAGAGGGCCUGGGUGGGGAA 23 10831
SCNNlA-6983 + GGCUGAGAGGGCCUGGGUGGGGAA 24
10832
SCNNlA-6984 + AUGUGGCCAGCGCUGGAA 18 10833
SCNNlA-6985 + GAUGUGGCCAGCGCUGGAA 19 10834
SCNNlA-5174 + GGAUGUGGCCAGCGCUGGAA 20 9023
SCNNlA-6986 + AGGAUGUGGCCAGCGCUGGAA 21 10835
SCNNlA-6987 + GAGGAUGUGGCCAGCGCUGGAA 22 10836
SCNNlA-6988 + GGAGGAUGUGGCCAGCGCUGGAA 23 10837
SCNNlA-6989 + GGGAGGAUGUGGCCAGCGCUGGAA 24 10838
SCNNlA-6990 + CUCCCGAGGGCAGGUGAA 18 10839
SCNNlA-6991 + GCUCCCGAGGGCAGGUGAA 19 10840
1378
5535.1 SCNNlA-6992 + GGCUCCCGAGGGCAGGUGAA 20 10841
SCNNlA-6993 + GGGCUCCCGAGGGCAGGUGAA 21 10842
SCNNlA-6994 + AGGGCUCCCGAGGGCAGGUGAA 22 10843
SCNNlA-6995 + GAGGGCUCCCGAGGGCAGGUGAA 23 10844
SCNNlA-6996 + GGAGGGCUCCCGAGGGCAGGUGAA 24 10845
SCNNlA-6997 + CUCCUCCCCGCUCACUAA 18 10846
SCNNlA-6998 + UCUCCUCCCCGCUCACUAA 19 10847
SCNNlA-6999 + GUCUCCUCCCCGCUCACUAA 20 10848
SCNNlA-7000 + GGUCUCCUCCCCGCUCACUAA 21 10849
SCNNlA-7001 + AGGUCUCCUCCCCGCUCACUAA 22 10850
SCNNlA-7002 + CAGGUCUCCUCCCCGCUCACUAA 23 10851
SCNNlA-7003 + GCAGGUCUCCUCCCCGCUCACUAA 24 10852
SCNNlA-7004 + AGCUAGGAGGGCAACACA 18 10853
SCNNlA-7005 + CAGCUAGGAGGGCAACACA 19 10854
SCNNlA-5527 + ACAGCUAGGAGGGCAACACA 20 9376
SCNNlA-7006 + CACAGCUAGGAGGGCAACACA 21 10855
SCNNlA-7007 + CCACAGCUAGGAGGGCAACACA 22 10856
SCNNlA-7008 + CCCA CAGCUAGGAGGGCAACACA 23 10857
SCNNlA-7009 + GCCCACAGCUAGGAGGGCAACACA 24 10858
SCNNlA-7010 + CCUGAGCAUUGAUACACA 18 10859
SCNNlA-7011 + GCCUGAGCAUUGAUACACA 19 10860
SCNNlA-7012 + AGCCUGAGCAUUGAUACACA 20 10861
SCNNlA-7013 + CAGCCUGAGCAUUGAUACACA 21 10862
SCNNlA-7014 + CCAGCCUGAGCAUUGAUACACA 22 10863
SCNNlA-7015 + CCCAGCCUGAGCAUUGAUACACA 23 10864
SCNNlA-7016 + GCCCAGCCUGAGCAUUGAUACACA 24 10865
SCNNlA-7017 + GCCUCCCUCACUCCCACA 18 10866
SCNNlA-7018 + GGCCUCCCUCACUCCCACA 19 10867
SCNNlA-7019 + AGGCCUCCCUCACUCCCACA 20 10868
SCNNlA-7020 + AAGGCCUCCCUCACUCCCACA 21 10869
SCNNlA-7021 + GAAGGCCUCCCUCACUCCCACA 22 10870
SCNNlA-7022 + GGAAGGCCUCCCUCACUCCCACA 23 10871
SCNNlA-7023 + GGGAAGGCCUCCCUCACUCCCACA 24 10872
SCNNlA-7024 + GAGGGACAGCGAAGGACA 18 10873
SCNNlA-7025 + AGAGGGACAGCGAAGGACA 19 10874
SCNNlA-7026 + GAGAGGGACAGCGAAGGACA 20 10875
SCNNlA-7027 + AGAGAGGGACAGCGAAGGACA 21 10876
SCNNlA-7028 + UAGAGAGGGACAGCGAAGGACA 22 10877
SCNNlA-7029 + AUAGAGAGGGACAGCGAAGGACA 23 10878
SCNNlA-7030 + AAUAGAGAGGGACAGCGAAGGACA 24 10879
SCNNlA-7031 + AGACAAUAGAGAGGGACA 18 10880
SCNNlA-7032 + GAGACAAUAGAGAGGGACA 19 10881
1379
5535.1 SCNNlA-7033 + GGAGACAAUAGAGAGGGACA 20 10882
SCNNlA-7034 + GGGAGACAAUAGAGAGGGACA 21 10883
SCNNlA-7035 + AGGGAGACAAUAGAGAGGGACA 22 10884
SCNNlA-7036 + GAGGGAGACAAUAGAGAGGGACA 23 10885
SCNNlA-7037 + AGAGGGAGACAAUAGAGAGGGACA 24 10886
SCNNlA-7038 + UUGAGCCAGGUCCUUACA 18 10887
SCNNlA-7039 + CUUGAGCCAGGUCCUUACA 19 10888
SCNNlA-7040 + CCUUGAGCCAGGUCCUUACA 20 10889
SCNNlA-7041 + CCCUUGAGCCAGGUCCUUACA 21 10890
SCNNlA-7042 + UCCCUUGAGCCAGGUCCUUACA 22 10891
SCNNlA-7043 + CUCCCUUGAGCCAGGUCCUUACA 23 10892
SCNNlA-7044 + UCUCCCUUGAGCCAGGUCCUUACA 24 10893
SCNNlA-7045 + UAGAAGGAGCCAGCACCA 18 10894
SCNNlA-7046 + AUAGAAGGAGCCAGCACCA 19 10895
SCNNlA-7047 + AAUAGAAGGAGCCAGCACCA 20 10896
SCNNlA-7048 + AAAUAGAAGGAGCCAGCACCA 21 10897
SCNNlA-7049 + CAAAUAGAAGGAGCCAGCACCA 22 10898
SCNNlA-7050 + GCAAAUAGAAGGAGCCAGCACCA 23 10899
SCNNlA-7051 + GGCAAAUAGAAGGAGCCAGCACCA 24 10900
SCNNlA-7052 + GCUUCCUCACGGGCCCCA 18 10901
SCNNlA-7053 + CGCUUCCUCACGGGCCCCA 19 10902
SCNNlA-7054 + CCGCUUCCUCACGGGCCCCA 20 10903
SCNNlA-7055 + GCCGCUUCCUCACGGGCCCCA 21 10904
SCNNlA-7056 + UGCCGCUUCCUCACGGGCCCCA 22 10905
SCNNlA-7057 + CUGCCGCUUCCUCACGGGCCCCA 23 10906
SCNNlA-7058 + GCUGCCGCUUCCUCACGGGCCCCA 24 10907
SCNNlA-7059 + ACUCAGGAAGCCUUCCCA 18 10908
SCNNlA-7060 + GACUCAGGAAGCCUUCCCA 19 10909
SCNNlA-7061 + AGACUCAGGAAGCCUUCCCA 20 10910
SCNNlA-7062 + GAGACUCAGGAAGCCUUCCCA 21 10911
SCNNlA-7063 + GGAGACUCAGGAAGCCUUCCCA 22 10912
SCNNlA-7064 + AGGAGACUCAGGAAGCCUUCCCA 23 10913
SCNNlA-7065 + CAGGAGACUCAGGAAGCCUUCCCA 24 10914
SCNNlA-7066 + UCUCCAGGAAGGAGAGCA 18 10915
SCNNlA-7067 + GUCUCCAGGAAGGAGAGCA 19 10916
SCNNlA-5533 + UGUCUCCAGGAAGGAGAGCA 20 9382
SCNNlA-7068 + CUGUCUCCAGGAAGGAGAGCA 21 10917
SCNNlA-7069 + UCUGUCUCCAGGAAGGAGAGCA 22 10918
SCNNlA-7070 + GUCUGUCUCCAGGAAGGAGAGCA 23 10919
SCNNlA-7071 + AGUCUGUCUCCAGGAAGGAGAGCA 24 10920
SCNNlA-7072 + AGUGCCAAGUGGUGAGCA 18 10921
SCNNlA-7073 + GAGUGCCAAGUGGUGAGCA 19 10922
1380
5535.1 SCNNlA-5179 + GGAGUGCCAAGUGGUGAGCA 20 9028
SCNNlA-7074 + UGGAGUGCCAAGUGGUGAGCA 21 10923
SCNNlA-7075 + GUGGAGUGCCAAGUGGUGAGCA 22 10924
SCNNlA-7076 + AGUGGAGUGCCAAGUGGUGAGCA 23 10925
SCNNlA-7077 + GAGUGGAGUGCCAAGUGGUGAGCA 24 10926
SCNNlA-7078 + U U U AG ACGCAG ACAGG CA 18 10927
SCNNlA-7079 + CUUUAGACGCAGACAGGCA 19 10928
SCNNlA-5181 + GCUUUAGACGCAGACAGGCA 20 9030
SCNNlA-7080 + GGCUUUAGACGCAGACAGGCA 21 10929
SCNNlA-7081 + GGGCUUUAGACGCAGACAGGCA 22 10930
SCNNlA-7082 + GGGGCUUUAGACGCAGACAGGCA 23 10931
SCNNlA-7083 + AGGGGCUUUAGACGCAGACAGGCA 24 10932
SCNNlA-7084 + AGGCAGGGAAAGCAGGCA 18 10933
SCNNlA-7085 + G AG G C AGG G AAAG CAG G CA 19 10934
SCNNlA-7086 + AG AG G C AGG G AAAG CAG G C A 20 10935
SCNNlA-7087 + AAGAGGCAGGGAAAGCAGGCA 21 10936
SCNNlA-7088 + GAAGAGGCAG G G A A AG C AG G C A 22 10937
SCNNlA-7089 + GGAAGAGGCAGGGAAAGCAGGCA 23 10938
SCNNlA-7090 + AGGAAGAGGCAGGGAAAGCAGGCA 24 10939
SCNNlA-7091 + CAAGGAGUUUAGCAGGCA 18 10940
SCNNlA-7092 + GCAAGGAGUUUAGCAGGCA 19 10941
SCNNlA-7093 + AG C A AG GAG UUUAGCAGGCA 20 10942
SCNNlA-7094 + AAGCAAGGAGUUUAGCAGGCA 21 10943
SCNNlA-7095 + C A AG C A AG GAG UUUAGCAGGCA 22 10944
SCNNlA-7096 + ACAAG CAAG G AG U U U AG CAG G C A 23 10945
SCNNlA-7097 + GACAAGCAAGGAGUUUAGCAGGCA 24 10946
SCNNlA-7098 + GGAGCCCAGGAAGAGGCA 18 10947
SCNNlA-7099 + CGGAGCCCAGGAAGAGGCA 19 10948
SCNNlA-5535 + CCGGAGCCCAGGAAGAGGCA 20 9384
SCNNlA-7100 + CCCGGAGCCCAGGAAGAGGCA 21 10949
SCNNlA-7101 + ACCCGGAGCCCAGGAAGAGGCA 22 10950
SCNNlA-7102 + GACCCGGAGCCCAGGAAGAGGCA 23 10951
SCNNlA-7103 + AGACCCGGAGCCCAGGAAGAGGCA 24 10952
SCNNlA-7104 + CAGGCCCUGCACGCGGCA 18 10953
SCNNlA-7105 + CCAGGCCCUGCACGCGGCA 19 10954
SCNNlA-5536 + CCCAGGCCCUGCACGCGGCA 20 9385
SCNNlA-7106 + ACCCAGGCCCUGCACGCGGCA 21 10955
SCNNlA-7107 + AACCCAGGCCCUGCACGCGGCA 22 10956
SCNNlA-7108 + CAACCCAGGCCCUGCACGCGGCA 23 10957
SCNNlA-7109 + ACAACCCAGGCCCUGCACGCGGCA 24 10958
SCNNlA-7110 + UCACCCUCAGGCCCUGCA 18 10959
SCNNlA-7111 + CUCACCCUCAGGCCCUGCA 19 10960
1381
5535.1 SCNNlA-7112 + CCUCACCCUCAGGCCCUGCA 20 10961
SCNNlA-7113 + GCCUCACCCUCAGGCCCUGCA 21 10962
SCNNlA-7114 + AGCCUCACCCUCAGGCCCUGCA 22 10963
SCNNlA-7115 + CAGCCUCACCCUCAGGCCCUGCA 23 10964
SCNNlA-7116 + UCAGCCUCACCCUCAGGCCCUGCA 24 10965
SCNNlA-7117 + GCAGGCACUGAAGGUGCA 18 10966
SCNNlA-7118 + AG C AGG CAC U G AAG G U G C A 19 10967
SCNNlA-5539 + AAGCAGGCACUGAAGGUGCA 20 9388
SCNNlA-7119 + AAAG C AGG CAC U G AAG G U G C A 21 10968
SCNNlA-7120 + G A A AG CAGGCACUGAAGGUGCA 22 10969
SCNNlA-7121 + GGAAAGCAGGCACUGAAGGUGCA 23 10970
SCNNlA-7122 + GGGAAAGCAGGCACUGAAGGUGCA 24 10971
SCNNlA-7123 + CUUCCUGAGACAGACUCA 18 10972
SCNNlA-7124 + ACUUCCUGAGACAGACUCA 19 10973
SCNNlA-6083 + UACUUCCUGAGACAGACUCA 20 9932
SCNNlA-7125 + UUACUUCCUGAGACAGACUCA 21 10974
SCNNlA-7126 + UUUACUUCCUGAGACAGACUCA 22 10975
SCNNlA-7127 + AUUUACUUCCUGAGACAGACUCA 23 10976
SCNNlA-7128 + CAUUUACUUCCUGAGACAGACUCA 24 10977
SCNNlA-7129 + GACAGGAGGGCAGAAAGA 18 10978
SCNNlA-7130 + GGACAGGAGGGCAGAAAGA 19 10979
SCNNlA-6085 + AGGACAGGAGGGCAGAAAGA 20 9934
SCNNlA-7131 + GAGGACAGGAGGGCAGAAAGA 21 10980
SCNNlA-7132 + GGAGGACAGGAGGGCAGAAAGA 22 10981
SCNNlA-7133 + GGGAGGACAGGAGGGCAGAAAGA 23 10982
SCNNlA-7134 + CGGGAGGACAGGAGGGCAGAAAGA 24 10983
SCNNlA-7135 + CAGGCCCUGCAGAGAAGA 18 10984
SCNNlA-7136 + UCAGGCCCUGCAGAGAAGA 19 10985
SCNNlA-7137 + CUCAGGCCCUGCAGAGAAGA 20 10986
SCNNlA-7138 + CCUCAGGCCCUGCAGAGAAGA 21 10987
SCNNlA-7139 + CCCUCAGGCCCUGCAGAGAAGA 22 10988
SCNNlA-7140 + ACCCUCAGGCCCUGCAGAGAAGA 23 10989
SCNNlA-7141 + CACCCUCAGGCCCUGCAGAGAAGA 24 10990
SCNNlA-7142 + GGAGGACAGGAGGGCAGA 18 10991
SCNNlA-7143 + GGGAGGACAGGAGGGCAGA 19 10992
SCNNlA-7144 + CGGGAGGACAGGAGGGCAGA 20 10993
SCNNlA-7145 + CCGGGAGGACAGGAGGGCAGA 21 10994
SCNNlA-7146 + ACCGGGAGGACAGGAGGGCAGA 22 10995
SCNNlA-7147 + AACCGGGAGGACAGGAGGGCAGA 23 10996
SCNNlA-7148 + GAACCGGGAGGACAGGAGGGCAGA 24 10997
SCNNlA-7149 + CAGCGAAGGACAGAGAGA 18 10998
SCNNlA-7150 + ACAGCGAAGGACAGAGAGA 19 10999
1382
5535.1 SCNNlA-7151 + GACAGCGAAGGACAGAGAGA 20 11000
SCNNlA-7152 + GGACAGCGAAGGACAGAGAGA 21 11001
SCNNlA-7153 + GGGACAGCGAAGGACAGAGAGA 22 11002
SCNNlA-7154 + AGGGACAGCGAAGGACAGAGAGA 23 11003
SCNNlA-7155 + GAGGGACAGCGAAGGACAGAGAGA 24 11004
SCNNlA-7156 + GUGGUGAGCAAGGAGAGA 18 11005
SCNNlA-7157 + AGUGGUGAGCAAGGAGAGA 19 11006
SCNNlA-7158 + AAGUGGUGAGCAAGGAGAGA 20 11007
SCNNlA-7159 + CAAGUGGUGAGCAAGGAGAGA 21 11008
SCNNlA-7160 + CCAAGUGGUGAGCAAGGAGAGA 22 11009
SCNNlA-7161 + GCCAAGUGGUGAGCAAGGAGAGA 23 11010
SCNNlA-7162 + UGCCAAGUGGUGAGCAAGGAGAGA 24 11011
SCNNlA-7163 + GAGGGCAACACAAGGAGA 18 11012
SCNNlA-7164 + GGAGGGCAACACAAGGAGA 19 11013
SCNNlA-6089 + AGGAGGGCAACACAAGGAGA 20 9938
SCNNlA-7165 + UAGGAGGGCAACACAAGGAGA 21 11014
SCNNlA-7166 + CUAGGAGGGCAACACAAGGAGA 22 11015
SCNNlA-7167 + GCUAGGAGGGCAACACAAGGAGA 23 11016
SCNNlA-7168 + AGCUAGGAGGGCAACACAAGGAGA 24 11017
SCNNlA-7169 + AAGUGGUGAGCAAGGAGA 18 11018
SCNNlA-7170 + CAAGUGGUGAGCAAGGAGA 19 11019
SCNNlA-7171 + CCAAGUGGUGAGCAAGGAGA 20 11020
SCNNlA-7172 + GCCAAGUGGUGAGCAAGGAGA 21 11021
SCNNlA-7173 + UGCCAAGUGGUGAGCAAGGAGA 22 11022
SCNNlA-7174 + GUGCCAAGUGGUGAGCAAGGAGA 23 11023
SCNNlA-7175 + AGUGCCAAGUGGUGAGCAAGGAGA 24 11024
SCNNlA-7176 + GUGGUGGGGGCAAAUAGA 18 11025
SCNNlA-7177 + AGUGGUGGGGGCAAAUAGA 19 11026
SCNNlA-6091 + CAGUGGUGGGGGCAAAUAGA 20 9940
SCNNlA-7178 + GCAGUGGUGGGGGCAAAUAGA 21 11027
SCNNlA-7179 + GGCAGUGGUGGGGGCAAAUAGA 22 11028
SCNNlA-7180 + GGGCAGUGGUGGGGGCAAAUAGA 23 11029
SCNNlA-7181 + GGGGCAGUGGUGGGGGCAAAUAGA 24
11030
SCNNlA-7182 + AAAGAGGGAGACAAUAGA 18 11031
SCNNlA-7183 + GAAAGAGGGAGACAAUAGA 19 11032
SCNNlA-7184 + AGAAAGAGGGAGACAAUAGA 20 11033
SCNNlA-7185 + CAGAAAGAGGGAGACAAUAGA 21 11034
SCNNlA-7186 + GCAGAAAGAGGGAGACAAUAGA 22 11035
SCNNlA-7187 + GGCAGAAAGAGGGAGACAAUAGA 23 11036
SCNNlA-7188 + GGGCAGAAAGAGGGAGACAAUAGA 24 11037
SCNNlA-1445 + AUCACCCCUGGAACCCGA 18 5294
1383
5535.1 SCNNlA-1446 + CAUCACCCCUGGAACCCGA 19 5295
SCNNlA-1447 + CCAUCACCCCUGGAACCCGA 20 5296
SCNNlA-1448 + CCCAUCACCCCUGGAACCCGA 21 5297
SCNNlA-1449 + UCCCAUCACCCCUGGAACCCGA 22 5298
SCNNlA-1450 + CUCCCAUCACCCCUGGAACCCGA 23 5299
SCNNlA-1451 + UCUCCCAUCACCCCUGGAACCCGA 24 5300
SCNNlA-7189 + GAGCCGGGAGUUUUCCGA 18 11038
SCNNlA-7190 + AGAGCCGGGAGUUUUCCGA 19 11039
SCNNlA-5544 + CAGAGCCGGGAGUUUUCCGA 20 9393
SCNNlA-7191 + UCAGAGCCGGGAGUUUUCCGA 21 11040
SCNNlA-7192 + GUCAGAGCCGGGAGUUUUCCGA 22 11041
SCNNlA-7193 + AGUCAGAGCCGGGAGUUUUCCGA 23 11042
SCNNlA-7194 + GAGUCAGAGCCGGGAGUUUUCCGA 24 11043
SCNNlA-7195 + GGCCAGGGAUGGAAGCGA 18 11044
SCNNlA-7196 + CGGCCAGGGAUGGAAGCGA 19 11045
SCNNlA-7197 + CCGGCCAGGGAUGGAAGCGA 20 11046
SCNNlA-7198 + GCCGGCCAGGGAUGGAAGCGA 21 11047
SCNNlA-7199 + GGCCGGCCAGGGAUGGAAGCGA 22 11048
SCNNlA-7200 + UGGCCGGCCAGGGAUGGAAGCGA 23 11049
SCNNlA-7201 + CUGGCCGGCCAGGGAUGGAAGCGA 24 11050
SCNNlA-7202 + CCAAGUGGUGAGCAAGGA 18 11051
SCNNlA-7203 + G CCAAG U G G U G AG C AAG G A 19 11052
SCNNlA-7204 + UGCCAAGUGGUGAGCAAGGA 20 11053
SCNNlA-7205 + GUGCCAAGUGGUGAGCAAGGA 21 11054
SCNNlA-7206 + AGUGCCAAGUGGUGAGCAAGGA 22 11055
SCNNlA-7207 + GAGUGCCAAGUGGUGAGCAAGGA 23 11056
SCNNlA-7208 + GGAGUGCCAAGUGGUGAGCAAGGA 24 11057
SCNNlA-7209 + CGGGAGUUUUCCGAAGGA 18 11058
SCNNlA-7210 + CCGGGAGUUUUCCGAAGGA 19 11059
SCNNlA-5190 + GCCGGGAGUUUUCCGAAGGA 20 9039
SCNNlA-7211 + AGCCGGGAGUUUUCCGAAGGA 21 11060
SCNNlA-7212 + GAGCCGGGAGUUUUCCGAAGGA 22 11061
SCNNlA-7213 + AG AG CCGGG AG U U U UCCGAAGGA 23 11062
SCNNlA-7214 + CAGAGCCGGGAGUUUUCCGAAGGA 24 11063
SCNNlA-7215 + GAGAGGGACAGCGAAGGA 18 11064
SCNNlA-7216 + AGAGAGGGACAGCGAAGGA 19 11065
SCNNlA-7217 + UAGAGAGGGACAGCGAAGGA 20 11066
SCNNlA-7218 + AUAGAGAGGGACAGCGAAGGA 21 11067
SCNNlA-7219 + AAUAGAGAGGGACAGCGAAGGA 22 11068
SCNNlA-7220 + CAAUAGAGAGGGACAGCGAAGGA 23 11069
SCNNlA-7221 + ACAAUAGAGAGGGACAGCGAAGGA 24 11070
SCNNlA-7222 + GCAGCAAAAGGAUAAGGA 18 11071
1384
5535.1 SCNNlA-7223 + UGCAGCAAAAGGAUAAGGA 19 11072
SCNNlA-7224 + AUGCAGCAAAAGGAUAAGGA 20 11073
SCNNlA-7225 + A A U G C AG C A A A AG G A U A AG G A 21 11074
SCNNlA-7226 + UAAUGCAGCAAAAGGAUAAGGA 22 11075
SCNNlA-7227 + UUAAUGCAGCAAAAGGAUAAGGA 23 11076
SCNNlA-7228 + CUUAAUGCAGCAAAAGGAUAAGGA 24 11077
SCNNlA-7229 + GGGAGUCUGUCUCCAGGA 18 11078
SCNNlA-7230 + AGGGAGUCUGUCUCCAGGA 19 11079
SCNNlA-5546 + AAGGGAGUCUGUCUCCAGGA 20 9395
SCNNlA-7231 + AAAGGGAGUCUGUCUCCAGGA 21 11080
SCNNlA-7232 + CAAAGGGAGUCUGUCUCCAGGA 22 11081
SCNNlA-7233 + CCAAAGGGAGUCUGUCUCCAGGA 23 11082
SCNNlA-7234 + ACCAAAGGGAGUCUGUCUCCAGGA 24 11083
SCNNlA-7235 + GGUGGGGAACCGGGAGGA 18 11084
SCNNlA-7236 + GGGUGGGGAACCGGGAGGA 19 11085
SCNNlA-7237 + UGGGUGGGGAACCGGGAGGA 20 11086
SCNNlA-7238 + CUGGGUGGGGAACCGGGAGGA 21 11087
SCNNlA-7239 + CCUGGGUGGGGAACCGGGAGGA 22 11088
SCNNlA-7240 + GCCUGGGUGGGGAACCGGGAGGA 23 11089
SCNNlA-7241 + GGCCUGGGUGGGGAACCGGGAGGA 24 11090
SCNNlA-7242 + CCGCUGGCCGGCCAGGGA 18 11091
SCNNlA-7243 + CCCGCUGGCCGGCCAGGGA 19 11092
SCNNlA-5192 + GCCCGCUGGCCGGCCAGGGA 20 9041
SCNNlA-7244 + CGCCCGCUGGCCGGCCAGGGA 21 11093
SCNNlA-7245 + CCGCCCGCUGGCCGGCCAGGGA 22 11094
SCNNlA-7246 + CCCGCCCGCUGGCCGGCCAGGGA 23 11095
SCNNlA-7247 + GCCCGCCCGCUGGCCGGCCAGGGA 24 11096
SCNNlA-7248 + AGGACAGAGAGAUAGGGA 18 11097
SCNNlA-7249 + AAGGACAGAGAGAUAGGGA 19 11098
SCNNlA-5878 + GAAGGACAGAGAGAUAGGGA 20 9727
SCNNlA-7250 + CGAAGGACAGAGAGAUAGGGA 21 11099
SCNNlA-7251 + GCGAAGGACAGAGAGAUAGGGA 22 11100
SCNNlA-7252 + AGCGAAGGACAGAGAGAUAGGGA 23 11101
SCNNlA-7253 + CAGCGAAGGACAGAGAGAUAGGGA 24 11102
SCNNlA-7254 + AGACAGACUCAUGGGGGA 18 11103
SCNNlA-7255 + GAGACAGACUCAUGGGGGA 19 11104
SCNNlA-7256 + UGAGACAGACUCAUGGGGGA 20 11105
SCNNlA-7257 + CUGAGACAGACUCAUGGGGGA 21 11106
SCNNlA-7258 + CCUGAGACAGACUCAUGGGGGA 22 11107
SCNNlA-7259 + UCCUGAGACAGACUCAUGGGGGA 23 11108
SCNNlA-7260 + UUCCUGAGACAGACUCAUGGGGGA 24 11109
SCNNlA-7261 + GAUGUGGCCAGCGCUGGA 18 11110
1385
5535.1 SCNNlA-7262 + GGAUGUGGCCAGCGCUGGA 19 11111
SCNNlA-7263 + AGGAUGUGGCCAGCGCUGGA 20 11112
SCNNlA-7264 + GAGGAUGUGGCCAGCGCUGGA 21 11113
SCNNlA-7265 + GGAGGAUGUGGCCAGCGCUGGA 22 11114
SCNNlA-7266 + GGGAGGAUGUGGCCAGCGCUGGA 23 11115
SCNNlA-7267 + AGGGAGGAUGUGGCCAGCGCUGGA 24 11116
SCNNlA-7268 + UCCCAGGUUGCGGCUGGA 18 11117
SCNNlA-7269 + CUCCCAGGUUGCGGCUGGA 19 11118
SCNNlA-7270 + ACUCCCAGGUUGCGGCUGGA 20 11119
SCNNlA-7271 + CACUCCCAGGUUGCGGCUGGA 21 11120
SCNNlA-7272 + CCACUCCCAGGUUGCGGCUGGA 22 11121
SCNNlA-7273 + CCCACUCCCAGGUUGCGGCUGGA 23 11122
SCNNlA-7274 + UCCCACUCCCAGGUUGCGGCUGGA 24 11123
SCNNlA-1465 + CAUGAGCCCCGGAGUGGA 18 5314
SCNNlA-1466 + UCAUGAGCCCCGGAGUGGA 19 5315
SCNNlA-1467 + UUCAUGAGCCCCGGAGUGGA 20 5316
SCNNlA-1468 + CUUCAUGAGCCCCGGAGUGGA 21 5317
SCNNlA-1469 + CCUUCAUGAGCCCCGGAGUGGA 22 5318
SCNNlA-1470 + CCCUUCAUGAGCCCCGGAGUGGA 23 5319
SCNNlA-1471 + CCCCUUCAUGAGCCCCGGAGUGGA 24 5320
SCNNlA-1472 + AUGAUACCUCCCCUUGGA 18 5321
SCNNlA-1473 + CAUGAUACCUCCCCUUGGA 19 5322
SCNNlA-399 + UCAUGAUACCUCCCCUUGGA 20 4248
SCNNlA-1474 + CUCAUGAUACCUCCCCUUGGA 21 5323
SCNNlA-1475 + GCUCAUGAUACCUCCCCUUGGA 22 5324
SCNNlA-1476 + UGCUCAUGAUACCUCCCCUUGGA 23 5325
SCNNlA-1477 + CUGCUCAUGAUACCUCCCCUUGGA 24 5326
SCNNlA-7275 + UCUCCUCUGCUUCCCUGA 18 11124
SCNNlA-7276 + CUCUCCUCUGCUUCCCUGA 19 11125
SCNNlA-7277 + CCUCUCCUCUGCUUCCCUGA 20 11126
SCNNlA-7278 + GCCUCUCCUCUGCUUCCCUGA 21 11127
SCNNlA-7279 + GGCCUCUCCUCUGCUUCCCUGA 22 11128
SCNNlA-7280 + CGGCCUCUCCUCUGCUUCCCUGA 23 11129
SCNNlA-7281 + ACGGCCUCUCCUCUGCUUCCCUGA 24 11130
SCNNlA-7282 + AGGGGCCAGCCAGGCUGA 18 11131
SCNNlA-7283 + AAGGGGCCAGCCAGGCUGA 19 11132
SCNNlA-7284 + GAAGGGGCCAGCCAGGCUGA 20 11133
SCNNlA-7285 + AGAAGGGGCCAGCCAGGCUGA 21 11134
SCNNlA-7286 + GAGAAGGGGCCAGCCAGGCUGA 22 11135
SCNNlA-7287 + GGAGAAGGGGCCAGCCAGGCUGA 23 11136
SCNNlA-7288 + AGGAGAAGGGGCCAGCCAGGCUGA 24 11137
SCNNlA-7289 + AGAAAGAGGGAGACAAUA 18 11138
1386
5535.1 SCNNlA-7290 + CAGAAAGAGGGAGACAAUA 19 11139
SCNNlA-7291 + GCAGAAAGAGGGAGACAAUA 20 11140
SCNNlA-7292 + GGCAGAAAGAGGGAGACAAUA 21 11141
SCNNlA-7293 + GGGCAGAAAGAGGGAGACAAUA 22 11142
SCNNlA-7294 + AGGGCAGAAAGAGGGAGACAAUA 23 11143
SCNNlA-7295 + GAGGGCAGAAAGAGGGAGACAAUA 24 11144
SCNNlA-7296 + UUUUUCUUCAUUGUCCUA 18 11145
SCNNlA-7297 + AUUUUUCUUCAUUGUCCUA 19 11146
SCNNlA-7298 + GAUUUUUCUUCAUUGUCCUA 20 11147
SCNNlA-7299 + GGAUUUUUCUUCAUUGUCCUA 21 11148
SCNNlA-7300 + UGGAUUUUUCUUCAUUGUCCUA 22 11149
SCNNlA-7301 + CUGGAUUUUUCUUCAUUGUCCUA 23 11150
SCNNlA-7302 + GCUGGAUUUUUCUUCAUUGUCCUA 24 11151
SCNNlA-7303 + CAUAAGAGCCAAGGGCUA 18 11152
SCNNlA-7304 + ACAUAAGAGCCAAGGGCUA 19 11153
SCNNlA-5198 + GACAUAAGAGCCAAGGGCUA 20 9047
SCNNlA-7305 + AGACAUAAGAGCCAAGGGCUA 21 11154
SCNNlA-7306 + AAGACAUAAGAGCCAAGGGCUA 22 11155
SCNNlA-7307 + UAAGACAUAAGAGCCAAGGGCUA 23 11156
SCNNlA-7308 + AUAAGACAUAAGAGCCAAGGGCUA 24 11157
SCNNlA-7309 + GCAGGUGAACUGGGAGUA 18 11158
SCNNlA-7310 + GGCAGGUGAACUGGGAGUA 19 11159
SCNNlA-7311 + GGGCAGGUGAACUGGGAGUA 20 11160
SCNNlA-7312 + AGGGCAGGUGAACUGGGAGUA 21 11161
SCNNlA-7313 + GAGGGCAGGUGAACUGGGAGUA 22 11162
SCNNlA-7314 + CGAGGGCAGGUGAACUGGGAGUA 23 11163
SCNNlA-7315 + CCGAGGGCAGGUGAACUGGGAGUA 24 11164
SCNNlA-7316 + UGCAGGAAUGUGGGCAAC 18 11165
SCNNlA-7317 + UUGCAGGAAUGUGGGCAAC 19 11166
SCNNlA-7318 + GUUGCAGGAAUGUGGGCAAC 20 11167
SCNNlA-7319 + AGUUGCAGGAAUGUGGGCAAC 21 11168
SCNNlA-7320 + GAGUUGCAGGAAUGUGGGCAAC 22 11169
SCNNlA-7321 + AGAGUUGCAGGAAUGUGGGCAAC 23 11170
SCNNlA-7322 + CAGAGUUGCAGGAAUGUGGGCAAC 24 11171
SCNNlA-7323 + AGGGCCUGGGUGGGGAAC 18 11172
SCNNlA-7324 + GAGGGCCUGGGUGGGGAAC 19 11173
SCNNlA-6101 + AGAGGGCCUGGGUGGGGAAC 20 9950
SCNNlA-7325 + GAGAGGGCCUGGGUGGGGAAC 21 11174
SCNNlA-7326 + UGAGAGGGCCUGGGUGGGGAAC 22 11175
SCNNlA-7327 + CUGAGAGGGCCUGGGUGGGGAAC 23 11176
SCNNlA-7328 + GCUGAGAGGGCCUGGGUGGGGAAC 24 11177
SCNNlA-7329 + UCCCGAGGGCAGGUGAAC 18 11178
1387
5535.1 SCNNlA-7330 + CUCCCGAGGGCAGGUGAAC 19 11179
SCNNlA-5203 + GCUCCCGAGGGCAGGUGAAC 20 9052
SCNNlA-7331 + GGCUCCCGAGGGCAGGUGAAC 21 11180
SCNNlA-7332 + GGGCUCCCGAGGGCAGGUGAAC 22 11181
SCNNlA-7333 + AGGGCUCCCGAGGGCAGGUGAAC 23 11182
SCNNlA-7334 + GAGGGCUCCCGAGGGCAGGUGAAC 24 11183
SCNNlA-7335 + CAGCUAGGAGGGCAACAC 18 11184
SCNNlA-7336 + ACAGCUAGGAGGGCAACAC 19 11185
SCNNlA-7337 + CACAGCUAGGAGGGCAACAC 20 11186
SCNNlA-7338 + CCACAGCUAGGAGGGCAACAC 21 11187
SCNNlA-7339 + CCCA CAGCUAGGAGGGCAACAC 22 11188
SCNNlA-7340 + GCCCA CAGCUAGGAGGGCAACAC 23 11189
SCNNlA-7341 + AGCCCACAGCUAGGAGGGCAACAC 24 11190
SCNNlA-7342 + CUGAGCAUUGAUACACAC 18 11191
SCNNlA-7343 + CCUGAGCAUUGAUACACAC 19 11192
SCNNlA-5204 + GCCUGAGCAUUGAUACACAC 20 9053
SCNNlA-7344 + AGCCUGAGCAUUGAUACACAC 21 11193
SCNNlA-7345 + CAGCCUGAGCAUUGAUACACAC 22 11194
SCNNlA-7346 + CCAGCCUGAGCAUUGAUACACAC 23 11195
SCNNlA-7347 + CCCAGCCUGAGCAUUGAUACACAC 24 11196
SCNNlA-7348 + CUUCCUCACGGGCCCCAC 18 11197
SCNNlA-7349 + GCUUCCUCACGGGCCCCAC 19 11198
SCNNlA-5561 + CGCUUCCUCACGGGCCCCAC 20 9410
SCNNlA-7350 + CCGCUUCCUCACGGGCCCCAC 21 11199
SCNNlA-7351 + GCCGCUUCCUCACGGGCCCCAC 22 11200
SCNNlA-7352 + UGCCGCUUCCUCACGGGCCCCAC 23 11201
SCNNlA-7353 + CUGCCGCUUCCUCACGGGCCCCAC 24 11202
SCNNlA-7354 + GACACUGUGGACACAGAC 18 11203
SCNNlA-7355 + GGACACUGUGGACACAGAC 19 11204
SCNNlA-7356 + AGGACACUGUGGACACAGAC 20 11205
SCNNlA-7357 + CAGGACACUGUGGACACAGAC 21 11206
SCNNlA-7358 + GCAGGACACUGUGGACACAGAC 22 11207
SCNNlA-7359 + CGCAGGACACUGUGGACACAGAC 23 11208
SCNNlA-7360 + ACGCAGGACACUGUGGACACAGAC 24 11209
SCNNlA-7361 + CUCCAACCUUGUCCAGAC 18 11210
SCNNlA-7362 + CCUCCAACCUUGUCCAGAC 19 11211
SCNNlA-7363 + CCCUCCAACCUUGUCCAGAC 20 11212
SCNNlA-7364 + CCCCUCCAACCUUGUCCAGAC 21 11213
SCNNlA-7365 + CCCCCUCCAACCUUGUCCAGAC 22 11214
SCNNlA-7366 + ACCCCCUCCAACCUUGUCCAGAC 23 11215
SCNNlA-7367 + CACCCCCUCCAACCUUGUCCAGAC 24 11216
SCNNlA-7368 + AAAAGGGCUGGAGGAGAC 18 11217
1388
5535.1 SCNNlA-7369 + AAAAAGGGCUGGAGGAGAC 19 11218
SCNNlA-7370 + CAAAAAGGGCUGGAGGAGAC 20 11219
SCNNlA-7371 + CCAAAAAGGGCUGGAGGAGAC 21 11220
SCNNlA-7372 + CCCAAAAAGGGCUGGAGGAGAC 22 11221
SCNNlA-7373 + ACCCAAAAAGGGCUGGAGGAGAC 23 11222
SCNNlA-7374 + GACCCAAAAAGGGCUGGAGGAGAC 24 11223
SCNNlA-7375 + GUGGGGAACCGGGAGGAC 18 11224
SCNNlA-7376 + GGUGGGGAACCGGGAGGAC 19 11225
SCNNlA-5209 + GGGUGGGGAACCGGGAGGAC 20 9058
SCNNlA-7377 + UGGGUGGGGAACCGGGAGGAC 21 11226
SCNNlA-7378 + CUGGGUGGGGAACCGGGAGGAC 22 11227
SCNNlA-7379 + CCUGGGUGGGGAACCGGGAGGAC 23 11228
SCNNlA-7380 + GCCUGGGUGGGGAACCGGGAGGAC 24 11229
SCNNlA-7381 + GAACUGGGAGUACUGGAC 18 11230
SCNNlA-7382 + UGAACUGGGAGUACUGGAC 19 11231
SCNNlA-7383 + GUGAACUGGGAGUACUGGAC 20 11232
SCNNlA-7384 + GGUGAACUGGGAGUACUGGAC 21 11233
SCNNlA-7385 + AGGUGAACUGGGAGUACUGGAC 22 11234
SCNNlA-7386 + CAGGUGAACUGGGAGUACUGGAC 23 11235
SCNNlA-7387 + GCAGGUGAACUGGGAGUACUGGAC 24 11236
SCNNlA-7388 + CCCAGGUUGCGGCUGGAC 18 11237
SCNNlA-7389 + UCCCAGGUUGCGGCUGGAC 19 11238
SCNNlA-5565 + CUCCCAGGUUGCGGCUGGAC 20 9414
SCNNlA-7390 + ACUCCCAGGUUGCGGCUGGAC 21 11239
SCNNlA-7391 + CACUCCCAGGUUGCGGCUGGAC 22 11240
SCNNlA-7392 + CCACUCCCAGGUUGCGGCUGGAC 23 11241
SCNNlA-7393 + CCCACUCCCAGGUUGCGGCUGGAC 24 11242
SCNNlA-7394 + GGGCCUGGGUGGGGAACC 18 11243
SCNNlA-7395 + AGGGCCUGGGUGGGGAACC 19 11244
SCNNlA-5214 + GAGGGCCUGGGUGGGGAACC 20 9063
SCNNlA-7396 + AGAGGGCCUGGGUGGGGAACC 21 11245
SCNNlA-7397 + GAGAGGGCCUGGGUGGGGAACC 22 11246
SCNNlA-7398 + UGAGAGGGCCUGGGUGGGGAACC 23 11247
SCNNlA-7399 + CUGAGAGGGCCUGGGUGGGGAACC 24 11248
SCNNlA-7400 + UGAGCAUUGAUACACACC 18 11249
SCNNlA-7401 + CUGAGCAUUGAUACACACC 19 11250
SCNNlA-5568 + CCUGAGCAUUGAUACACACC 20 9417
SCNNlA-7402 + GCCUGAGCAUUGAUACACACC 21 11251
SCNNlA-7403 + AGCCUGAGCAUUGAUACACACC 22 11252
SCNNlA-7404 + CAGCCUGAGCAUUGAUACACACC 23 11253
SCNNlA-7405 + CCAGCCUGAGCAUUGAUACACACC 24 11254
SCNNlA-7406 + ACACUGUGGACACAGACC 18 11255
1389
5535.1 SCNNlA-7407 + GACACUGUGGACACAGACC 19 11256
SCNNlA-5217 + GGACACUGUGGACACAGACC 20 9066
SCNNlA-7408 + AGGACACUGUGGACACAGACC 21 11257
SCNNlA-7409 + CAGGACACUGUGGACACAGACC 22 11258
SCNNlA-7410 + GCAGGACACUGUGGACACAGACC 23 11259
SCNNlA-7411 + CGCAGGACACUGUGGACACAGACC 24 11260
SCNNlA-7412 + UCCAACCUUGUCCAGACC 18 11261
SCNNlA-7413 + CUCCAACCUUGUCCAGACC 19 11262
SCNNlA-5569 + CCUCCAACCUUGUCCAGACC 20 9418
SCNNlA-7414 + CCCUCCAACCUUGUCCAGACC 21 11263
SCNNlA-7415 + CCCCUCCAACCUUGUCCAGACC 22 11264
SCNNlA-7416 + CCCCCUCCAACCUUGUCCAGACC 23 11265
SCNNlA-7417 + ACCCCCUCCAACCUUGUCCAGACC 24 11266
SCNNlA-7418 + CAGCCUCUGGCCCUGACC 18 11267
SCNNlA-7419 + CCAGCCUCUGGCCCUGACC 19 11268
SCNNlA-7420 + UCCAGCCUCUGGCCCUGACC 20 11269
SCNNlA-7421 + CUCCAGCCUCUGGCCCUGACC 21 11270
SCNNlA-7422 + GCUCCAGCCUCUGGCCCUGACC 22 11271
SCNNlA-7423 + AGCUCCAGCCUCUGGCCCUGACC 23 11272
SCNNlA-7424 + CAGCUCCAGCCUCUGGCCCUGACC 24 11273
SCNNlA-1484 + UGCCCUCUCCCAUCACCC 18 5333
SCNNlA-1485 + GUGCCCUCUCCCAUCACCC 19 5334
SCNNlA-1486 + AGUGCCCUCUCCCAUCACCC 20 5335
SCNNlA-1487 + GAGUGCCCUCUCCCAUCACCC 21 5336
SCNNlA-1488 + UGAGUGCCCUCUCCCAUCACCC 22 5337
SCNNlA-1489 + CUGAGUGCCCUCUCCCAUCACCC 23 5338
SCNNlA-1490 + CCUGAGUGCCCUCUCCCAUCACCC 24 5339
SCNNlA-7425 + CCAACCUUGUCCAGACCC 18 11274
SCNNlA-7426 + UCCAACCUUGUCCAGACCC 19 11275
SCNNlA-5572 + CUCCAACCUUGUCCAGACCC 20 9421
SCNNlA-7427 + CCUCCAACCUUGUCCAGACCC 21 11276
SCNNlA-7428 + CCCUCCAACCUUGUCCAGACCC 22 11277
SCNNlA-7429 + CCCCUCCAACCUUGUCCAGACCC 23 11278
SCNNlA-7430 + CCCCCUCCAACCUUGUCCAGACCC 24 11279
SCNNlA-1491 + GCCCUCUCCCAUCACCCC 18 5340
SCNNlA-1492 + UGCCCUCUCCCAUCACCCC 19 5341
SCNNlA-346 + GUGCCCUCUCCCAUCACCCC 20 4195
SCNNlA-1493 + AGUGCCCUCUCCCAUCACCCC 21 5342
SCNNlA-1494 + GAGUGCCCUCUCCCAUCACCCC 22 5343
SCNNlA-1495 + UGAGUGCCCUCUCCCAUCACCCC 23 5344
SCNNlA-1496 + CUGAGUGCCCUCUCCCAUCACCCC 24 5345
SCNNlA-7431 + ACAUAUCCCAGAGACCCC 18 11280
1390
5535.1 SCNNlA-7432 + CACAUAUCCCAGAGACCCC 19 11281
SCNNlA-7433 + CCACAUAUCCCAGAGACCCC 20 11282
SCNNlA-7434 + CCCACAUAUCCCAGAGACCCC 21 11283
SCNNlA-7435 + CCCCACAUAUCCCAGAGACCCC 22 11284
SCNNlA-7436 + GCCCCACAUAUCCCAGAGACCCC 23 11285
SCNNlA-7437 + UGCCCCACAUAUCCCAGAGACCCC 24 11286
SCNNlA-1497 + UGCUCAUGAUACCUCCCC 18 5346
SCNNlA-1498 + CUGCUCAUGAUACCUCCCC 19 5347
SCNNlA-1499 + ACUGCUCAUGAUACCUCCCC 20 5348
SCNNlA-1500 + UACUGCUCAUGAUACCUCCCC 21 5349
SCNNlA-1501 + AUACUGCUCAUGAUACCUCCCC 22 5350
SCNNlA-1502 + GAUACUGCUCAUGAUACCUCCCC 23 5351
SCNNlA-1503 + UGAUACUGCUCAUGAUACCUCCCC 24 5352
SCNNlA-7438 + GACACAGACCCGGAGCCC 18 11287
SCNNlA-7439 + GGACACAGACCCGGAGCCC 19 11288
SCNNlA-5575 + UGGACACAGACCCGGAGCCC 20 9424
SCNNlA-7440 + GUGGACACAGACCCGGAGCCC 21 11289
SCNNlA-7441 + UGUGGACACAGACCCGGAGCCC 22 11290
SCNNlA-7442 + CUGUGGACACAGACCCGGAGCCC 23 11291
SCNNlA-7443 + ACUGUGGACACAGACCCGGAGCCC 24 11292
SCNNlA-7444 + ACACGCCUAGACAGGCCC 18 11293
SCNNlA-7445 + CACACGCCUAGACAGGCCC 19 11294
SCNNlA-5219 + GCACACGCCUAGACAGGCCC 20 9068
SCNNlA-7446 + GGCACACGCCUAGACAGGCCC 21 11295
SCNNlA-7447 + UGGCACACGCCUAGACAGGCCC 22 11296
SCNNlA-7448 + AUGGCACACGCCUAGACAGGCCC 23 11297
SCNNlA-7449 + CAUGGCACACGCCUAGACAGGCCC 24 11298
SCNNlA-7450 + GGGGGCUAGGCGGGGCCC 18 11299
SCNNlA-7451 + UGGGGGCUAGGCGGGGCCC 19 11300
SCNNlA-7452 + CUGGGGGCUAGGCGGGGCCC 20 11301
SCNNlA-7453 + GCUGGGGGCUAGGCGGGGCCC 21 11302
SCNNlA-7454 + AGCUGGGGGCUAGGCGGGGCCC 22 11303
SCNNlA-7455 + AAGCUGGGGGCUAGGCGGGGCCC 23 11304
SCNNlA-7456 + GAAGCUGGGGGCUAGGCGGGGCCC 24 11305
SCNNlA-7457 + CUGAUUCUGUCUCUGCCC 18 11306
SCNNlA-7458 + CCUGAUUCUGUCUCUGCCC 19 11307
SCNNlA-7459 + UCCUGAUUCUGUCUCUGCCC 20 11308
SCNNlA-7460 + GUCCUGAUUCUGUCUCUGCCC 21 11309
SCNNlA-7461 + UGUCCUGAUUCUGUCUCUGCCC 22 11310
SCNNlA-7462 + GUGUCCUGAUUCUGUCUCUGCCC 23 11311
SCNNlA-7463 + UGUGUCCUGAUUCUGUCUCUGCCC 24 11312
SCNNlA-7464 + GAAGGAAGGAGGGCUCCC 18 11313
1391
5535.1 SCNNlA-7465 + CGAAGGAAGGAGGGCUCCC 19 11314
SCNNlA-7466 + CCGAAGGAAGGAGGGCUCCC 20 11315
SCNNlA-7467 + UCCGAAGGAAGGAGGGCUCCC 21 11316
SCNNlA-7468 + UUCCGAAGGAAGGAGGGCUCCC 22 11317
SCNNlA-7469 + UUUCCGAAGGAAGGAGGGCUCCC 23 11318
SCNNlA-7470 + UUUUCCGAAGGAAGGAGGGCUCCC 24 11319
SCNNlA-7471 + UAGAAACUCCAGUCUCCC 18 11320
SCNNlA-7472 + CUAGAAACUCCAGUCUCCC 19 11321
SCNNlA-7473 + CCUAGAAACUCCAGUCUCCC 20 11322
SCNNlA-7474 + CCCUAGAAACUCCAGUCUCCC 21 11323
SCNNlA-7475 + CCCCUAGAAACUCCAGUCUCCC 22 11324
SCNNlA-7476 + ACCCCUAGAAACUCCAGUCUCCC 23 11325
SCNNlA-7477 + GACCCCUAGAAACUCCAGUCUCCC 24 11326
SCNNlA-7478 + GCCGGAGCUGGGCUUCCC 18 11327
SCNNlA-7479 + UGCCGGAGCUGGGCUUCCC 19 11328
SCNNlA-7480 + GUGCCGGAGCUGGGCUUCCC 20 11329
SCNNlA-7481 + AGUGCCGGAGCUGGGCUUCCC 21 11330
SCNNlA-7482 + AAGUGCCGGAGCUGGGCUUCCC 22 11331
SCNNlA-7483 + AAAGUGCCGGAGCUGGGCUUCCC 23 11332
SCNNlA-7484 + AAAAGUGCCGGAGCUGGGCUUCCC 24 11333
SCNNlA-7485 + CACCUGGAUGUGAAAGCC 18 11334
SCNNlA-7486 + GCACCUGGAUGUGAAAGCC 19 11335
SCNNlA-6107 + UGCACCUGGAUGUGAAAGCC 20 9956
SCNNlA-7487 + GUGCACCUGGAUGUGAAAGCC 21 11336
SCNNlA-7488 + GGUGCACCUGGAUGUGAAAGCC 22 11337
SCNNlA-7489 + AGGUGCACCUGGAUGUGAAAGCC 23 11338
SCNNlA-7490 + CAGGUGCACCUGGAUGUGAAAGCC 24 11339
SCNNlA-7491 + AGAUAAGACAUAAGAGCC 18 11340
SCNNlA-7492 + GAGAUAAGACAUAAGAGCC 19 11341
SCNNlA-7493 + AGAGAUAAGACAUAAGAGCC 20 11342
SCNNlA-7494 + CAGAGAUAAGACAUAAGAGCC 21 11343
SCNNlA-7495 + UCAGAGAUAAGACAUAAGAGCC 22 11344
SCNNlA-7496 + CUCAGAGAUAAGACAUAAGAGCC 23 11345
SCNNlA-7497 + UCUCAGAGAUAAGACAUAAGAGCC 24 11346
SCNNlA-7498 + GGACACAGACCCGGAGCC 18 11347
SCNNlA-7499 + UGGACACAGACCCGGAGCC 19 11348
SCNNlA-7500 + GUGGACACAGACCCGGAGCC 20 11349
SCNNlA-7501 + UGUGGACACAGACCCGGAGCC 21 11350
SCNNlA-7502 + CUGUGGACACAGACCCGGAGCC 22 11351
SCNNlA-7503 + ACUGUGGACACAGACCCGGAGCC 23 11352
SCNNlA-7504 + CACUGUGGACACAGACCCGGAGCC 24 11353
SCNNlA-7505 + CCAAGGGCUAGGGGAGCC 18 11354
1392
5535.1 SCNNlA-7506 + GCCAAGGGCUAGGGGAGCC 19 11355
SCNNlA-7507 + AGCCAAGGGCUAGGGGAGCC 20 11356
SCNNlA-7508 + GAGCCAAGGGCUAGGGGAGCC 21 11357
SCNNlA-7509 + AGAGCCAAGGGCUAGGGGAGCC 22 11358
SCNNlA-7510 + AAGAGCCAAGGGCUAGGGGAGCC 23 11359
SCNNlA-7511 + UAAGAGCCAAGGGCUAGGGGAGCC 24 11360
SCNNlA-1504 + UGUUCCCCUUCAUGAGCC 18 5353
SCNNlA-1505 + UUGUUCCCCUUCAUGAGCC 19 5354
SCNNlA-207 + CUUGUUCCCCUUCAUGAGCC 20 834
SCNNlA-1506 + GCUUGUUCCCCUUCAUGAGCC 21 5355
SCNNlA-1507 + AGCUUGUUCCCCUUCAUGAGCC 22 5356
SCNNlA-1508 + CAGCUUGUUCCCCUUCAUGAGCC 23 5357
SCNNlA-1509 + CCAGCUUGUUCCCCUUCAUGAGCC 24 5358
SCNNlA-7512 + CACACGCCUAGACAGGCC 18 11361
SCNNlA-7513 + GCACACGCCUAGACAGGCC 19 11362
SCNNlA-7514 + GGCACACGCCUAGACAGGCC 20 11363
SCNNlA-7515 + UGGCACACGCCUAGACAGGCC 21 11364
SCNNlA-7516 + AUGGCACACGCCUAGACAGGCC 22 11365
SCNNlA-7517 + CAUGGCACACGCCUAGACAGGCC 23 11366
SCNNlA-7518 + GCAUGGCACACGCCUAGACAGGCC 24 11367
SCNNlA-7519 + CCACUGCCCCACAUAUCC 18 11368
SCNNlA-7520 + CCCACUGCCCCACAUAUCC 19 11369
SCNNlA-7521 + CCCCACUGCCCCACAUAUCC 20 11370
SCNNlA-7522 + UCCCCACUGCCCCACAUAUCC 21 11371
SCNNlA-7523 + GUCCCCACUGCCCCACAUAUCC 22 11372
SCNNlA-7524 + UGUCCCCACUGCCCCACAUAUCC 23 11373
SCNNlA-7525 + CUGUCCCCACUGCCCCACAUAUCC 24 11374
SCNNlA-1525 + UCCAGCUUGUUCCCCUCC 18 5374
SCNNlA-1526 + CUCCAGCUUGUUCCCCUCC 19 5375
SCNNlA-200 + CCUCCAGCUUGUUCCCCUCC 20 829
SCNNlA-1527 + UCCUCCAGCUUGUUCCCCUCC 21 5376
SCNNlA-1528 + CUCCUCCAGCUUGUUCCCCUCC 22 5377
SCNNlA-1529 + GCUCCUCCAGCUUGUUCCCCUCC 23 5378
SCNNlA-1530 + UGCUCCUCCAGCUUGUUCCCCUCC 24 5379
SCNNlA-7526 + GCAAGUGGGCAGCCCUCC 18 11375
SCNNlA-7527 + AGCAAGUGGGCAGCCCUCC 19 11376
SCNNlA-7528 + CAGCAAGUGGGCAGCCCUCC 20 11377
SCNNlA-7529 + UCAGCAAGUGGGCAGCCCUCC 21 11378
SCNNlA-7530 + CUCAGCAAGUGGGCAGCCCUCC 22 11379
SCNNlA-7531 + GCUCAGCAAGUGGGCAGCCCUCC 23 11380
SCNNlA-7532 + GGCUCAGCAAGUGGGCAGCCCUCC 24 11381
SCNNlA-7533 + CCAGGACUGCAGGGCUCC 18 11382
1393
5535.1 SCNNlA-7534 + CCCAGGACUGCAGGGCUCC 19 11383
SCNNlA-6112 + CCCCAGGACUGCAGGGCUCC 20 9961
SCNNlA-7535 + GCCCCAGGACUGCAGGGCUCC 21 11384
SCNNlA-7536 + UGCCCCAGGACUGCAGGGCUCC 22 11385
SCNNlA-7537 + CUGCCCCAGGACUGCAGGGCUCC 23 11386
SCNNlA-7538 + UCUGCCCCAGGACUGCAGGGCUCC 24 11387
SCNNlA-7539 + CAAAGGGAGUCUGUCUCC 18 11388
SCNNlA-7540 + CCAAAGGGAGUCUGUCUCC 19 11389
SCNNlA-5596 + ACCAAAGGGAGUCUGUCUCC 20 9445
SCNNlA-7541 + CACCAAAGGGAGUCUGUCUCC 21 11390
SCNNlA-7542 + GCACCAAAGGGAGUCUGUCUCC 22 11391
SCNNlA-7543 + AGCACCAAAGGGAGUCUGUCUCC 23 11392
SCNNlA-7544 + CAGCACCAAAGGGAGUCUGUCUCC 24 11393
SCNNlA-7545 + AGACUCAGGAAGCCUUCC 18 11394
SCNNlA-7546 + GAGACUCAGGAAGCCUUCC 19 11395
SCNNlA-7547 + GGAGACUCAGGAAGCCUUCC 20 11396
SCNNlA-7548 + AGGAGACUCAGGAAGCCUUCC 21 11397
SCNNlA-7549 + CAGGAGACUCAGGAAGCCUUCC 22 11398
SCNNlA-7550 + GCAGGAGACUCAGGAAGCCUUCC 23 11399
SCNNlA-7551 + UGCAGGAGACUCAGGAAGCCUUCC 24 11400
SCNNlA-7552 + AGUCCCAAGUGUGCUUCC 18 11401
SCNNlA-7553 + GAGUCCCAAGUGUGCUUCC 19 11402
SCNNlA-5226 + GGAGUCCCAAGUGUGCUUCC 20 9075
SCNNlA-7554 + GGGAGUCCCAAGUGUGCUUCC 21 11403
SCNNlA-7555 + GGGGAGUCCCAAGUGUGCUUCC 22 11404
SCNNlA-7556 + GGGGGAGUCCCAAGUGUGCUUCC 23 11405
SCNNlA-7557 + GGGGGGAGUCCCAAGUGUGCUUCC 24 11406
SCNNlA-7558 + UCCCUCCUCCACCUUUCC 18 11407
SCNNlA-7559 + CUCCCUCCUCCACCUUUCC 19 11408
SCNNlA-6116 + CCUCCCUCCUCCACCUUUCC 20 9965
SCNNlA-7560 + CCCUCCCUCCUCCACCUUUCC 21 11409
SCNNlA-7561 + UCCCUCCCUCCUCCACCUUUCC 22 11410
SCNNlA-7562 + CUCCCUCCCUCCUCCACCUUUCC 23 11411
SCNNlA-7563 + CCUCCCUCCCUCCUCCACCUUUCC 24 11412
SCNNlA-7564 + GCACCUGGAUGUGAAAGC 18 11413
SCNNlA-7565 + UGCACCUGGAUGUGAAAGC 19 11414
SCNNlA-5227 + GUGCACCUGGAUGUGAAAGC 20 9076
SCNNlA-7566 + GGUGCACCUGGAUGUGAAAGC 21 11415
SCNNlA-7567 + AGGUGCACCUGGAUGUGAAAGC 22 11416
SCNNlA-7568 + CAGGUGCACCUGGAUGUGAAAGC 23 11417
SCNNlA-7569 + UCAGGUGCACCUGGAUGUGAAAGC 24 11418
SCNNlA-7570 + UGCUGAAUCUUGACAAGC 18 11419
1394
5535.1 SCNNlA-7571 + CUGCUGAAUCUUGACAAGC 19 11420
SCNNlA-7572 + UCUGCUGAAUCUUGACAAGC 20 11421
SCNNlA-7573 + CUCUGCUGAAUCUUGACAAGC 21 11422
SCNNlA-7574 + UCUCUGCUGAAUCUUGACAAGC 22 11423
SCNNlA-7575 + AUCUCUGCUGAAUCUUGACAAGC 23 11424
SCNNlA-7576 + CAUCUCUGCUGAAUCUUGACAAGC 24 11425
SCNNlA-7577 + GAGGGGCCCAGGUGAAGC 18 11426
SCNNlA-7578 + GGAGGGGCCCAGGUGAAGC 19 11427
SCNNlA-5885 + GGGAGGGGCCCAGGUGAAGC 20 9734
SCNNlA-7579 + CGGGAGGGGCCCAGGUGAAGC 21 11428
SCNNlA-7580 + CCGGGAGGGGCCCAGGUGAAGC 22 11429
SCNNlA-7581 + CCCGGGAGGGGCCCAGGUGAAGC 23 11430
SCNNlA-7582 + ACCCGGGAGGGGCCCAGGUGAAGC 24 11431
SCNNlA-7583 + GGAUCCUGAGCCCACAGC 18 11432
SCNNlA-7584 + AGGAUCCUGAGCCCACAGC 19 11433
SCNNlA-7585 + AAGGAUCCUGAGCCCACAGC 20 11434
SCNNlA-7586 + GAAGGAUCCUGAGCCCACAGC 21 11435
SCNNlA-7587 + AGAAGGAUCCUGAGCCCACAGC 22 11436
SCNNlA-7588 + UAGAAGGAUCCUGAGCCCACAGC 23 11437
SCNNlA-7589 + GUAGAAGGAUCCUGAGCCCACAGC 24 11438
SCNNlA-7590 + AGCAGACAAAGGCCCAGC 18 11439
SCNNlA-7591 + C AG C AG AC A A AG G C C C AG C 19 11440
SCNNlA-7592 + C C AG C AG AC A A AG G C C C AG C 20 11441
SCNNlA-7593 + G CCAGCAG ACAAAGG CCCAG C 21 11442
SCNNlA-7594 + AGCCAGCAGACAAAGGCCCAGC 22 11443
SCNNlA-7595 + AAGCCAG CAG ACAAAGG CCCAG C 23 11444
SCNNlA-7596 + CAAGCCAG CAG ACAAAGG CCCAG C 24 11445
SCNNlA-7597 + UGGGCAACCAGAGGCAGC 18 11446
SCNNlA-7598 + GUGGGCAACCAGAGGCAGC 19 11447
SCNNlA-7599 + UGUGGGCAACCAGAGGCAGC 20 11448
SCNNlA-7600 + AUGUGGGCAACCAGAGGCAGC 21 11449
SCNNlA-7601 + AAUGUGGGCAACCAGAGGCAGC 22 11450
SCNNlA-7602 + GAAUGUGGGCAACCAGAGGCAGC 23 11451
SCNNlA-7603 + GGAAUGUGGGCAACCAGAGGCAGC 24 11452
SCNNlA-7604 + CUGAGGAGGAGUCAGAGC 18 11453
SCNNlA-7605 + GCUGAGGAGGAGUCAGAGC 19 11454
SCNNlA-5886 + GGCUGAGGAGGAGUCAGAGC 20 9735
SCNNlA-7606 + GGGCUGAGGAGGAGUCAGAGC 21 11455
SCNNlA-7607 + GGGGCUGAGGAGGAGUCAGAGC 22 11456
SCNNlA-7608 + AGGGGCUGAGGAGGAGUCAGAGC 23 11457
SCNNlA-7609 + GAGGGGCUGAGGAGGAGUCAGAGC 24 11458
SCNNlA-7610 + GUCUCCAGGAAGGAGAGC 18 11459
1395
5535.1 SCNNlA-7611 + UGUCUCCAGGAAGGAGAGC 19 11460
SCNNlA-7612 + CUGUCUCCAGGAAGGAGAGC 20 11461
SCNNlA-7613 + UCUGUCUCCAGGAAGGAGAGC 21 11462
SCNNlA-7614 + GUCUGUCUCCAGGAAGGAGAGC 22 11463
SCNNlA-7615 + AGUCUGUCUCCAGGAAGGAGAGC 23 11464
SCNNlA-7616 + GAGUCUGUCUCCAGGAAGGAGAGC 24 11465
SCNNlA-7617 + AAGUGUGCUUCCAGGAGC 18 11466
SCNNlA-7618 + CAAGUGUGCUUCCAGGAGC 19 11467
SCNNlA-7619 + CCAAGUGUGCUUCCAGGAGC 20 11468
SCNNlA-7620 + CCCAAGUGUGCUUCCAGGAGC 21 11469
SCNNlA-7621 + UCCCAAGUGUGCUUCCAGGAGC 22 11470
SCNNlA-7622 + GUCCCAAGUGUGCUUCCAGGAGC 23 11471
SCNNlA-7623 + AGUCCCAAGUGUGCUUCCAGGAGC 24 11472
SCNNlA-7624 + GAGUGCCAAGUGGUGAGC 18 11473
SCNNlA-7625 + GGAGUGCCAAGUGGUGAGC 19 11474
SCNNlA-7626 + UGGAGUGCCAAGUGGUGAGC 20 11475
SCNNlA-7627 + GUGGAGUGCCAAGUGGUGAGC 21 11476
SCNNlA-7628 + AGUGGAGUGCCAAGUGGUGAGC 22 11477
SCNNlA-7629 + GAGUGGAGUGCCAAGUGGUGAGC 23 11478
SCNNlA-7630 + GGAGUGGAGUGCCAAGUGGUGAGC 24
11479
SCNNlA-7631 + GGAGGAUGUGGCCAGCGC 18 11480
SCNNlA-7632 + GGGAGGAUGUGGCCAGCGC 19 11481
SCNNlA-6120 + AGGGAGGAUGUGGCCAGCGC 20 9969
SCNNlA-7633 + CAGGGAGGAUGUGGCCAGCGC 21 11482
SCNNlA-7634 + GCAGGGAGGAUGUGGCCAGCGC 22 11483
SCNNlA-7635 + UGCAGGGAGGAUGUGGCCAGCGC 23 11484
SCNNlA-7636 + GUGCAGGGAGGAUGUGGCCAGCGC 24 11485
SCNNlA-7637 + GGCAACCAGAGGCAGCGC 18 11486
SCNNlA-7638 + GGGCAACCAGAGGCAGCGC 19 11487
SCNNlA-7639 + UGGGCAACCAGAGGCAGCGC 20 11488
SCNNlA-7640 + GUGGGCAACCAGAGGCAGCGC 21 11489
SCNNlA-7641 + UGUGGGCAACCAGAGGCAGCGC 22 11490
SCNNlA-7642 + AUGUGGGCAACCAGAGGCAGCGC 23 11491
SCNNlA-7643 + AAUGUGGGCAACCAGAGGCAGCGC 24 11492
SCNNlA-7644 + CUUUAGACGCAGACAGGC 18 11493
SCNNlA-7645 + GCUUUAGACGCAGACAGGC 19 11494
SCNNlA-7646 + GGCUUUAGACGCAGACAGGC 20 11495
SCNNlA-7647 + GGGCUUUAGACGCAGACAGGC 21 11496
SCNNlA-7648 + GGGGCUUUAGACGCAGACAGGC 22 11497
SCNNlA-7649 + AGGGGCUUUAGACGCAGACAGGC 23 11498
SCNNlA-7650 + CAGGGGCUUUAGACGCAGACAGGC 24 11499
1396
5535.1 SCNNlA-7651 + CACUGUUGGCUGCCAGGC 18 11500
SCNNlA-7652 + ACACUGUUGGCUGCCAGGC 19 11501
SCNNlA-7653 + UACACUGUUGGCUGCCAGGC 20 11502
SCNNlA-7654 + UUACACUGUUGGCUGCCAGGC 21 11503
SCNNlA-7655 + UUUACACUGUUGGCUGCCAGGC 22 11504
SCNNlA-7656 + UUUUACACUGUUGGCUGCCAGGC 23 11505
SCNNlA-7657 + UUUUUACACUGUUGGCUGCCAGGC 24 11506
SCNNlA-7658 + CGGAGCCCAGGAAGAGGC 18 11507
SCNNlA-7659 + CCGGAGCCCAGGAAGAGGC 19 11508
SCNNlA-6122 + CCCGGAGCCCAGGAAGAGGC 20 9971
SCNNlA-7660 + ACCCGGAGCCCAGGAAGAGGC 21 11509
SCNNlA-7661 + GACCCGGAGCCCAGGAAGAGGC 22 11510
SCNNlA-7662 + AGACCCGGAGCCCAGGAAGAGGC 23 11511
SCNNlA-7663 + CAGACCCGGAGCCCAGGAAGAGGC 24 11512
SCNNlA-7664 + GCAGACAGGCAAGGAGGC 18 11513
SCNNlA-7665 + CGCAGACAGGCAAGGAGGC 19 11514
SCNNlA-5608 + ACGCAGACAGGCAAGGAGGC 20 9457
SCNNlA-7666 + GACGCAGACAGGCAAGGAGGC 21 11515
SCNNlA-7667 + AGACGCAGACAGGCAAGGAGGC 22 11516
SCNNlA-7668 + UAGACGCAGACAGGCAAGGAGGC 23 11517
SCNNlA-7669 + UUAGACGCAGACAGGCAAGGAGGC 24 11518
SCNNlA-7670 + GCCCGCCCGCUGGCCGGC 18 11519
SCNNlA-7671 + AGCCCGCCCGCUGGCCGGC 19 11520
SCNNlA-7672 + GAGCCCGCCCGCUGGCCGGC 20 11521
SCNNlA-7673 + GGAGCCCGCCCGCUGGCCGGC 21 11522
SCNNlA-7674 + GGGAGCCCGCCCGCUGGCCGGC 22 11523
SCNNlA-7675 + GGGGAGCCCGCCCGCUGGCCGGC 23 11524
SCNNlA-7676 + UGGGGAGCCCGCCCGCUGGCCGGC 24 11525
SCNNlA-7677 + CCAGGCCCUGCACGCGGC 18 11526
SCNNlA-7678 + CCCAGGCCCUGCACGCGGC 19 11527
SCNNlA-5609 + ACCCAGGCCCUGCACGCGGC 20 9458
SCNNlA-7679 + AACCCAGGCCCUGCACGCGGC 21 11528
SCNNlA-7680 + CAACCCAGGCCCUGCACGCGGC 22 11529
SCNNlA-7681 + ACAACCCAGGCCCUGCACGCGGC 23 11530
SCNNlA-7682 + CACAACCCAGGCCCUGCACGCGGC 24 11531
SCNNlA-7683 + AUCAGACCCAAAAAGGGC 18 11532
SCNNlA-7684 + AAUCAGACCCAAAAAGGGC 19 11533
SCNNlA-5232 + GAAUCAGACCCAAAAAGGGC 20 9081
SCNNlA-7685 + AGAAUCAGACCCAAAAAGGGC 21 11534
SCNNlA-7686 + GAGAAUCAGACCCAAAAAGGGC 22 11535
SCNNlA-7687 + AGAGAAUCAGACCCAAAAAGGGC 23 11536
SCNNlA-7688 + CAGAGAAUCAGACCCAAAAAGGGC 24 11537
1397
5535.1 SCNNlA-7689 + GACAUAAGAGCCAAGGGC 18 11538
SCNNlA-7690 + AGACAUAAGAGCCAAGGGC 19 11539
SCNNlA-7691 + AAGACAUAAGAGCCAAGGGC 20 11540
SCNNlA-7692 + UAAGACAUAAGAGCCAAGGGC 21 11541
SCNNlA-7693 + AUAAGACAUAAGAGCCAAGGGC 22 11542
SCNNlA-7694 + GAUAAGACAUAAGAGCCAAGGGC 23 11543
SCNNlA-7695 + AGAUAAGACAUAAGAGCCAAGGGC 24 11544
SCNNlA-7696 + AUUAAAGGUGAGCAGGGC 18 11545
SCNNlA-7697 + AAUUAAAGGUGAGCAGGGC 19 11546
SCNNlA-5611 + C A A U U A A AG GUGAGCAGGGC 20 9460
SCNNlA-7698 + UCAAUUAAAGGUGAGCAGGGC 21 11547
SCNNlA-7699 + CUCAAUUAAAGGUGAGCAGGGC 22 11548
SCNNlA-7700 + UCUCAAUUAAAGGUGAGCAGGGC 23 11549
SCNNlA-7701 + AUCUCAAUUAAAGGUGAGCAGGGC 24 11550
SCNNlA-7702 + AGAAGGCGGACUCUGGGC 18 11551
SCNNlA-7703 + GAGAAGGCGGACUCUGGGC 19 11552
SCNNlA-5613 + UGAGAAGGCGGACUCUGGGC 20 9462
SCNNlA-7704 + CUGAGAAGGCGGACUCUGGGC 21 11553
SCNNlA-7705 + CCUGAGAAGGCGGACUCUGGGC 22 11554
SCNNlA-7706 + ACCUGAGAAGGCGGACUCUGGGC 23 11555
SCNNlA-7707 + GACCUGAGAAGGCGGACUCUGGGC 24 11556
SCNNlA-7708 + CAGGUGCAGCGGCCUGGC 18 11557
SCNNlA-7709 + ACAGGUGCAGCGGCCUGGC 19 11558
SCNNlA-5234 + GACAGGUGCAGCGGCCUGGC 20 9083
SCNNlA-7710 + UGACAGGUGCAGCGGCCUGGC 21 11559
SCNNlA-7711 + CUGACAGGUGCAGCGGCCUGGC 22 11560
SCNNlA-7712 + CCUGACAGGUGCAGCGGCCUGGC 23 11561
SCNNlA-7713 + ACCUGACAGGUGCAGCGGCCUGGC 24 11562
SCNNlA-7714 + CUAUUUGCCAGCUCAUGC 18 11563
SCNNlA-7715 + UCUAUUUGCCAGCUCAUGC 19 11564
SCNNlA-7716 + UUCUAUUUGCCAGCUCAUGC 20 11565
SCNNlA-7717 + UUUCUAUUUGCCAGCUCAUGC 21 11566
SCNNlA-7718 + UUUUCUAUUUGCCAGCUCAUGC 22 11567
SCNNlA-7719 + CUUUUCUAUUUGCCAGCUCAUGC 23 11568
SCNNlA-7720 + CCUUUUCUAUUUGCCAGCUCAUGC 24 11569
SCNNlA-7721 + AGCCUAGGGGCUCACUGC 18 11570
SCNNlA-7722 + GAGCCUAGGGGCUCACUGC 19 11571
SCNNlA-5235 + GGAGCCUAGGGGCUCACUGC 20 9084
SCNNlA-7723 + GGGAGCCUAGGGGCUCACUGC 21 11572
SCNNlA-7724 + GGGGAGCCUAGGGGCUCACUGC 22 11573
SCNNlA-7725 + AGGGGAGCCUAGGGGCUCACUGC 23 11574
SCNNlA-7726 + UAGGGGAGCCUAGGGGCUCACUGC 24 11575
1398
5535.1 SCNNlA-7727 + AGUUGGGGCCAAAAGUGC 18 11576
SCNNlA-7728 + GAGUUGGGGCCAAAAGUGC 19 11577
SCNNlA-5236 + GGAGUUGGGGCCAAAAGUGC 20 9085
SCNNlA-7729 + GGGAGUUGGGGCCAAAAGUGC 21 11578
SCNNlA-7730 + CGGGAGUUGGGGCCAAAAGUGC 22 11579
SCNNlA-7731 + GCGGGAGUUGGGGCCAAAAGUGC 23 11580
SCNNlA-7732 + UGCGGGAGUUGGGGCCAAAAGUGC 24 11581
SCNNlA-7733 + AGCAGGCACUGAAGGUGC 18 11582
SCNNlA-7734 + AAG C AGG CAC U G AAG G U G C 19 11583
SCNNlA-5620 + AAAG C AGG CAC U G AAG G U G C 20 9469
SCNNlA-7735 + GAAAGCAGGCACUGAAGGUGC 21 11584
SCNNlA-7736 + GGAAAGCAGGCACUGAAGGUGC 22 11585
SCNNlA-7737 + GGGAAAGCAGGCACUGAAGGUGC 23 11586
SCNNlA-7738 + AGGGAAAGCAGGCACUGAAGGUGC 24 11587
SCNNlA-7739 + UGAACAAGUAGAAGGAUC 18 11588
SCNNlA-7740 + CUGAACAAGUAGAAGGAUC 19 11589
SCNNlA-7741 + UCUGAACAAGUAGAAGGAUC 20 11590
SCNNlA-7742 + AUCUGAACAAGUAGAAGGAUC 21 11591
SCNNlA-7743 + GAUCUGAACAAGUAGAAGGAUC 22 11592
SCNNlA-7744 + AGAUCUGAACAAGUAGAAGGAUC 23 11593
SCNNlA-7745 + AAGAUCUGAACAAGUAGAAGGAUC 24 11594
SCNNlA-7746 + GCAAAUAGUUUUCAUAUC 18 11595
SCNNlA-7747 + GGCAAAUAGUUUUCAUAUC 19 11596
SCNNlA-7748 + UGGCAAAUAGUUUUCAUAUC 20 11597
SCNNlA-7749 + AUGGCAAAUAGUUUUCAUAUC 21 11598
SCNNlA-7750 + CAUGGCAAAUAGUUUUCAUAUC 22 11599
SCNNlA-7751 + GCAUGGCAAAUAGUUUUCAUAUC 23 11600
SCNNlA-7752 + AGCAUGGCAAAUAGUUUUCAUAUC 24 11601
SCNNlA-7753 + ACUUCCUGAGACAGACUC 18 11602
SCNNlA-7754 + UACUUCCUGAGACAGACUC 19 11603
SCNNlA-7755 + UUACUUCCUGAGACAGACUC 20 11604
SCNNlA-7756 + UUUACUUCCUGAGACAGACUC 21 11605
SCNNlA-7757 + AUUUACUUCCUGAGACAGACUC 22 11606
SCNNlA-7758 + CAUUUACUUCCUGAGACAGACUC 23 11607
SCNNlA-7759 + CCAUUUACUUCCUGAGACAGACUC 24 11608
SCNNlA-7760 + GCUCACUGCAGGAGACUC 18 11609
SCNNlA-7761 + GGCUCACUGCAGGAGACUC 19 11610
SCNNlA-5239 + GGGCUCACUGCAGGAGACUC 20 9088
SCNNlA-7762 + GGGGCUCACUGCAGGAGACUC 21 11611
SCNNlA-7763 + AGGGGCUCACUGCAGGAGACUC 22 11612
SCNNlA-7764 + UAGGGGCUCACUGCAGGAGACUC 23 11613
SCNNlA-7765 + CUAGGGGCUCACUGCAGGAGACUC 24 11614
1399
5535.1 SCNNlA-7766 + AAGGGCUGGAGGAGACUC 18 11615
SCNNlA-7767 + AAAGGGCUGGAGGAGACUC 19 11616
SCNNlA-5628 + AAAAGGGCUGGAGGAGACUC 20 9477
SCNNlA-7768 + AAAAAGGGCUGGAGGAGACUC 21 11617
SCNNlA-7769 + CAAAAAGGGCUGGAGGAGACUC 22 11618
SCNNlA-7770 + CCAAAAAGGGCUGGAGGAGACUC 23 11619
SCNNlA-7771 + CCCAAAAAGGGCUGGAGGAGACUC 24 11620
SCNNlA-7772 + AGAAUUCUCCUCCUCCUC 18 11621
SCNNlA-7773 + CAGAAUUCUCCUCCUCCUC 19 11622
SCNNlA-6134 + UCAGAAUUCUCCUCCUCCUC 20 9983
SCNNlA-7774 + UUCAGAAUUCUCCUCCUCCUC 21 11623
SCNNlA-7775 + AUUCAGAAUUCUCCUCCUCCUC 22 11624
SCNNlA-7776 + AAUUCAGAAUUCUCCUCCUCCUC 23 11625
SCNNlA-7777 + GAAUUCAGAAUUCUCCUCCUCCUC 24 11626
SCNNlA-7778 + GAAGGCUGCCGCUUCCUC 18 11627
SCNNlA-7779 + GGAAGGCUGCCGCUUCCUC 19 11628
SCNNlA-7780 + GGGAAGGCUGCCGCUUCCUC 20 11629
SCNNlA-7781 + AGGGAAGGCUGCCGCUUCCUC 21 11630
SCNNlA-7782 + CAGGGAAGGCUGCCGCUUCCUC 22 11631
SCNNlA-7783 + GCAGGGAAGGCUGCCGCUUCCUC 23 11632
SCNNlA-7784 + GGCAGGGAAGGCUGCCGCUUCCUC 24 11633
SCNNlA-7785 + CCCAGGACUGCAGGGCUC 18 11634
SCNNlA-7786 + CCCCAGGACUGCAGGGCUC 19 11635
SCNNlA-7787 + GCCCCAGGACUGCAGGGCUC 20 11636
SCNNlA-7788 + UGCCCCAGGACUGCAGGGCUC 21 11637
SCNNlA-7789 + CUGCCCCAGGACUGCAGGGCUC 22 11638
SCNNlA-7790 + UCUGCCCCAGGACUGCAGGGCUC 23 11639
SCNNlA-7791 + CUCUGCCCCAGGACUGCAGGGCUC 24 11640
SCNNlA-7792 + CCGAAGGAAGGAGGGCUC 18 11641
SCNNlA-7793 + UCCGAAGGAAGGAGGGCUC 19 11642
SCNNlA-7794 + UUCCGAAGGAAGGAGGGCUC 20 11643
SCNNlA-7795 + UUUCCGAAGGAAGGAGGGCUC 21 11644
SCNNlA-7796 + UUUUCCGAAGGAAGGAGGGCUC 22 11645
SCNNlA-7797 + GUUUUCCGAAGGAAGGAGGGCUC 23 11646
SCNNlA-7798 + AGUUUUCCGAAGGAAGGAGGGCUC 24 11647
SCNNlA-7799 + CCAAAGGGAGUCUGUCUC 18 11648
SCNNlA-7800 + ACCAAAGGGAGUCUGUCUC 19 11649
SCNNlA-7801 + CACCAAAGGGAGUCUGUCUC 20 11650
SCNNlA-7802 + GCACCAAAGGGAGUCUGUCUC 21 11651
SCNNlA-7803 + AGCACCAAAGGGAGUCUGUCUC 22 11652
SCNNlA-7804 + CAGCACCAAAGGGAGUCUGUCUC 23 11653
SCNNlA-7805 + CCAGCACCAAAGGGAGUCUGUCUC 24 11654
1400
5535.1 SCNNlA-7806 + GCUUUUGCCAUUUACUUC 18 11655
SCNNlA-7807 + CGCUUUUGCCAUUUACUUC 19 11656
SCNNlA-7808 + GCGCUUUUGCCAUUUACUUC 20 11657
SCNNlA-7809 + AGCGCUUUUGCCAUUUACUUC 21 11658
SCNNlA-7810 + UAGCGCUUUUGCCAUUUACUUC 22 11659
SCNNlA-7811 + UUAGCGCUUUUGCCAUUUACUUC 23 11660
SCNNlA-7812 + CUUAGCGCUUUUGCCAUUUACUUC 24 11661
SCNNlA-1549 + UCCAGCUUGUUCCCCUUC 18 5398
SCNNlA-1550 + CUCCAGCUUGUUCCCCUUC 19 5399
SCNNlA-1551 + CCUCCAGCUUGUUCCCCUUC 20 5400
SCNNlA-1552 + UCCUCCAGCUUGUUCCCCUUC 21 5401
SCNNlA-1553 + CUCCUCCAGCUUGUUCCCCUUC 22 5402
SCNNlA-1554 + GCUCCUCCAGCUUGUUCCCCUUC 23 5403
SCNNlA-1555 + UGCUCCUCCAGCUUGUUCCCCUUC 24 5404
SCNNlA-7813 + GAGUCCCAAGUGUGCUUC 18 11662
SCNNlA-7814 + GGAGUCCCAAGUGUGCUUC 19 11663
SCNNlA-7815 + GGGAGUCCCAAGUGUGCUUC 20 11664
SCNNlA-7816 + GGGGAGUCCCAAGUGUGCUUC 21 11665
SCNNlA-7817 + GGGGGAGUCCCAAGUGUGCUUC 22 11666
SCNNlA-7818 + GGGGGGAGUCCCAAGUGUGCUUC 23 11667
SCNNlA-7819 + AGGGGGGAGUCCCAAGUGUGCUUC 24 11668
SCNNlA-7820 + CUCCCUCCUCCACCUUUC 18 11669
SCNNlA-7821 + CCUCCCUCCUCCACCUUUC 19 11670
SCNNlA-7822 + CCCUCCCUCCUCCACCUUUC 20 11671
SCNNlA-7823 + UCCCUCCCUCCUCCACCUUUC 21 11672
SCNNlA-7824 + CUCCCUCCCUCCUCCACCUUUC 22 11673
SCNNlA-7825 + CCUCCCUCCCUCCUCCACCUUUC 23 11674
SCNNlA-7826 + UCCUCCCUCCCUCCUCCACCUUUC 24 11675
SCNNlA-7827 + GGAGUUUAGCAGGCAAAG 18 11676
SCNNlA-7828 + AGGAGUUUAGCAGGCAAAG 19 11677
SCNNlA-7829 + AAGGAGUUUAGCAGGCAAAG 20 11678
SCNNlA-7830 + CAAGGAGUUUAGCAGGCAAAG 21 11679
SCNNlA-7831 + G C A AG GAG UUUAGCAGG C A A AG 22 11680
SCNNlA-7832 + AGCAAGGAGUUUAGCAGGCAAAG 23 11681
SCNNlA-7833 + AAGCAAGGAGUUUAGCAGG C A A AG 24 11682
SCNNlA-7834 + GGACAGGAGGGCAGAAAG 18 11683
SCNNlA-7835 + AGGACAGGAGGGCAGAAAG 19 11684
SCNNlA-5894 + GAGGACAGGAGGGCAGAAAG 20 9743
SCNNlA-7836 + GGAGGACAGGAGGGCAGAAAG 21 11685
SCNNlA-7837 + GGGAGGACAGGAGGGCAGAAAG 22 11686
SCNNlA-7838 + CGGGAGGACAGGAGGGCAGAAAG 23 11687
SCNNlA-7839 + CCGGGAGGACAGGAGGGCAGAAAG 24 11688
1401
5535.1 SCNNlA-7840 + UGCACCUGGAUGUGAAAG 18 11689
SCNNlA-7841 + GUGCACCUGGAUGUGAAAG 19 11690
SCNNlA-7842 + GGUGCACCUGGAUGUGAAAG 20 11691
SCNNlA-7843 + AGGUGCACCUGGAUGUGAAAG 21 11692
SCNNlA-7844 + CAGGUGCACCUGGAUGUGAAAG 22 11693
SCNNlA-7845 + UCAGGUGCACCUGGAUGUGAAAG 23 11694
SCNNlA-7846 + CUCAGGUGCACCUGGAUGUGAAAG 24 11695
SCNNlA-7847 + UUAGCAUCUCAAUUAAAG 18 11696
SCNNlA-7848 + AUUAGCAUCUCAAUUAAAG 19 11697
SCNNlA-7849 + CAU U AGCAU CU CAAU UAAAG 20 11698
SCNNlA-7850 + UCAUUAGCAUCUCAAUUAAAG 21 11699
SCNNlA-7851 + CUCAUUAGCAUCUCAAUUAAAG 22 11700
SCNNlA-7852 + UCUCAUUAGCAUCUCAAUUAAAG 23 11701
SCNNlA-7853 + AUCUCAUUAGCAUCUCAAUUAAAG 24 11702
SCNNlA-7854 + G G C AAAG AU C U G AAC AAG 18 11703
SCNNlA-7855 + GGGCAAAGAUCUGAACAAG 19 11704
SCNNlA-7856 + GGGGCAAAGAUCUGAACAAG 20 11705
SCNNlA-7857 + AGGGGCAAAGAUCUGAACAAG 21 11706
SCNNlA-7858 + GAGGGGCAAAGAUCUGAACAAG 22 11707
SCNNlA-7859 + UGAGGGGCAAAGAUCUGAACAAG 23 11708
SCNNlA-7860 + GUGAGGGGCAAAGAUCUGAACAAG 24 11709
SCNNlA-7861 + CUAGGAGGGCAACACAAG 18 11710
SCNNlA-7862 + GCUAGGAGGGCAACACAAG 19 11711
SCNNlA-7863 + AGCUAGGAGGGCAACACAAG 20 11712
SCNNlA-7864 + CAGCUAGGAGGGCAACACAAG 21 11713
SCNNlA-7865 + ACAGCUAGGAGGGCAACACAAG 22 11714
SCNNlA-7866 + CACAGCUAGGAGGGCAACACAAG 23 11715
SCNNlA-7867 + CCACAGCUAGGAGGGCAACACAAG 24 11716
SCNNlA-7868 + UCCAGGAAGGAGAGCAAG 18 11717
SCNNlA-7869 + CUCCAGGAAGGAGAGCAAG 19 11718
SCNNlA-6140 + UCUCCAGGAAGGAGAGCAAG 20 9989
SCNNlA-7870 + GUCUCCAGGAAGGAGAGCAAG 21 11719
SCNNlA-7871 + UGUCUCCAGGAAGGAGAGCAAG 22 11720
SCNNlA-7872 + CUGUCUCCAGGAAGGAGAGCAAG 23 11721
SCNNlA-7873 + UCUGUCUCCAGGAAGGAGAGCAAG 24 11722
SCNNlA-7874 + UGCCAAGUGGUGAGCAAG 18 11723
SCNNlA-7875 + GUGCCAAGUGGUGAGCAAG 19 11724
SCNNlA-7876 + AGUGCCAAGUGGUGAGCAAG 20 11725
SCNNlA-7877 + GAGUGCCAAGUGGUGAGCAAG 21 11726
SCNNlA-7878 + GGAGUGCCAAGUGGUGAGCAAG 22 11727
SCNNlA-7879 + UGGAGUGC C A AG U G G U G AG C A AG 23 11728
SCNNlA-7880 + GUGGAGUGCCAAGUGGUGAGCAAG 24 11729
1402
5535.1 SCNNlA-7881 + AGUACUGGACCUGAGAAG 18 11730
SCNNlA-7882 + GAGUACUGGACCUGAGAAG 19 11731
SCNNlA-7883 + GGAGUACUGGACCUGAGAAG 20 11732
SCNNlA-7884 + GGGAGUACUGGACCUGAGAAG 21 11733
SCNNlA-7885 + UGGGAGUACUGGACCUGAGAAG 22 11734
SCNNlA-7886 + CUGGGAGUACUGGACCUGAGAAG 23 11735
SCNNlA-7887 + ACUGGGAGUACUGGACCUGAGAAG 24 11736
SCNNlA-7888 + GGAGUUUUCCGAAGGAAG 18 11737
SCNNlA-7889 + GGG AG U U U UCCGAAGGAAG 19 11738
SCNNlA-7890 + CGGGAGUUUUCCGAAGGAAG 20 11739
SCNNlA-7891 + CCGGGAGUUU UCCGAAGGAAG 21 11740
SCNNlA-7892 + GCCGGGAGUUUUCCGAAGGAAG 22 11741
SCNNlA-7893 + AGCCGGG AG U U U U CCGAAGGAAG 23 11742
SCNNlA-7894 + GAGCCGGGAGUUUUCCGAAGGAAG 24 11743
SCNNlA-7895 + GAGUCUGUCUCCAGGAAG 18 11744
SCNNlA-7896 + GGAGUCUGUCUCCAGGAAG 19 11745
SCNNlA-7897 + GGGAGUCUGUCUCCAGGAAG 20 11746
SCNNlA-7898 + AGGGAGUCUGUCUCCAGGAAG 21 11747
SCNNlA-7899 + AAGGGAGUCUGUCUCCAGGAAG 22 11748
SCNNlA-7900 + AAAGGGAGUCUGUCUCCAGGAAG 23 11749
SCNNlA-7901 + CAAAGGGAGUCUGUCUCCAGGAAG 24 11750
SCNNlA-7902 + GGAGGGGCCCAGGUGAAG 18 11751
SCNNlA-7903 + GGGAGGGGCCCAGGUGAAG 19 11752
SCNNlA-7904 + CGGGAGGGGCCCAGGUGAAG 20 11753
SCNNlA-7905 + CCGGGAGGGGCCCAGGUGAAG 21 11754
SCNNlA-7906 + CCCGGGAGGGGCCCAGGUGAAG 22 11755
SCNNlA-7907 + ACCCGGGAGGGGCCCAGGUGAAG 23 11756
SCNNlA-7908 + GACCCGGGAGGGGCCCAGGUGAAG 24 11757
SCNNlA-7909 + UCCUCCCCGCUCACUAAG 18 11758
SCNNlA-7910 + CUCCUCCCCGCUCACUAAG 19 11759
SCNNlA-5645 + UCUCCUCCCCGCUCACUAAG 20 9494
SCNNlA-7911 + GUCUCCUCCCCGCUCACUAAG 21 11760
SCNNlA-7912 + GGUCUCCUCCCCGCUCACUAAG 22 11761
SCNNlA-7913 + AGGUCUCCUCCCCGCUCACUAAG 23 11762
SCNNlA-7914 + CAGGUCUCCUCCCCGCUCACUAAG 24 11763
SCNNlA-7915 + GGGGAACCGGGAGGACAG 18 11764
SCNNlA-7916 + UGGGGAACCGGGAGGACAG 19 11765
SCNNlA-7917 + GUGGGGAACCGGGAGGACAG 20 11766
SCNNlA-7918 + GGUGGGGAACCGGGAGGACAG 21 11767
SCNNlA-7919 + GGGUGGGGAACCGGGAGGACAG 22 11768
SCNNlA-7920 + UGGGUGGGGAACCGGGAGGACAG 23 11769
SCNNlA-7921 + CUGGGUGGGGAACCGGGAGGACAG 24 11770
1403
5535.1 SCNNlA-7922 + GACCCGGGAGGGGCCCAG 18 11771
SCNNlA-7923 + AGACCCGGGAGGGGCCCAG 19 11772
SCNNlA-7924 + CAGACCCGGGAGGGGCCCAG 20 11773
SCNNlA-7925 + CCAGACCCGGGAGGGGCCCAG 21 11774
SCNNlA-7926 + UCCAGACCCGGGAGGGGCCCAG 22 11775
SCNNlA-7927 + GUCCAGACCCGGGAGGGGCCCAG 23 11776
SCNNlA-7928 + UGUCCAGACCCGGGAGGGGCCCAG 24 11777
SCNNlA-7929 + CUGAGUGAGUAGAGGCAG 18 11778
SCNNlA-7930 + ACUGAGUGAGUAGAGGCAG 19 11779
SCNNlA-7931 + CACUGAGUGAGUAGAGGCAG 20 11780
SCNNlA-7932 + GCACUGAGUGAGUAGAGGCAG 21 11781
SCNNlA-7933 + GGCACUGAGUGAGUAGAGGCAG 22 11782
SCNNlA-7934 + GGGCACUGAGUGAGUAGAGGCAG 23 11783
SCNNlA-7935 + GGGGCACUGAGUGAGUAGAGGCAG 24 11784
SCNNlA-7936 + GAGGGCUCCCGAGGGCAG 18 11785
SCNNlA-7937 + GGAGGGCUCCCGAGGGCAG 19 11786
SCNNlA-7938 + AGGAGGGCUCCCGAGGGCAG 20 11787
SCNNlA-7939 + AAGGAGGGCUCCCGAGGGCAG 21 11788
SCNNlA-7940 + GAAGGAGGGCUCCCGAGGGCAG 22 11789
SCNNlA-7941 + GGAAGGAGGGCUCCCGAGGGCAG 23 11790
SCNNlA-7942 + AGGAAGGAGGGCUCCCGAGGGCAG 24 11791
SCNNlA-7943 + UGGGGGACAGGAUGGCAG 18 11792
SCNNlA-7944 + CUGGGGGACAGGAUGGCAG 19 11793
SCNNlA-7945 + GCUGGGGGACAGGAUGGCAG 20 11794
SCNNlA-7946 + GGCUGGGGGACAGGAUGGCAG 21 11795
SCNNlA-7947 + AGGCUGGGGGACAGGAUGGCAG 22 11796
SCNNlA-7948 + GAGGCUGGGGGACAGGAUGGCAG 23 11797
SCNNlA-7949 + GGAGGCUGGGGGACAGGAUGGCAG 24
11798
SCNNlA-7950 + UGGGAGCAGCGCACUCAG 18 11799
SCNNlA-7951 + GUGGGAGCAGCGCACUCAG 19 11800
SCNNlA-7952 + AGUGGGAGCAGCGCACUCAG 20 11801
SCNNlA-7953 + AAGUGGGAGCAGCGCACUCAG 21 11802
SCNNlA-7954 + UAAGUGGGAGCAGCGCACUCAG 22 11803
SCNNlA-7955 + CUAAGUGGGAGCAGCGCACUCAG 23 11804
SCNNlA-7956 + ACUAAGUGGGAGCAGCGCACUCAG 24 11805
SCNNlA-7957 + CCCUCAGGCCCUGCAGAG 18 11806
SCNNlA-7958 + ACCCUCAGGCCCUGCAGAG 19 11807
SCNNlA-7959 + CACCCUCAGGCCCUGCAGAG 20 11808
SCNNlA-7960 + UCACCCUCAGGCCCUGCAGAG 21 11809
SCNNlA-7961 + CUCACCCUCAGGCCCUGCAGAG 22 11810
SCNNlA-7962 + CCUCACCCUCAGGCCCUGCAGAG 23 11811
1404
5535.1 SCNNlA-7963 + GCCUCACCCUCAGGCCCUGCAGAG 24 11812
SCNNlA-7964 + GCUGAGGAGGAGUCAGAG 18 11813
SCNNlA-7965 + GGCUGAGGAGGAGUCAGAG 19 11814
SCNNlA-7966 + GGGCUGAGGAGGAGUCAGAG 20 11815
SCNNlA-7967 + GGGGCUGAGGAGGAGUCAGAG 21 11816
SCNNlA-7968 + AGGGGCUGAGGAGGAGUCAGAG 22 11817
SCNNlA-7969 + GAGGGGCUGAGGAGGAGUCAGAG 23 11818
SCNNlA-7970 + GGAGGGGCUGAGGAGGAGUCAGAG 24
11819
SCNNlA-7971 + GCCCUGCAGAGAAGAGAG 18 11820
SCNNlA-7972 + GGCCCUGCAGAGAAGAGAG 19 11821
SCNNlA-7973 + AGGCCCUGCAGAGAAGAGAG 20 11822
SCNNlA-7974 + CAGGCCCUGCAGAGAAGAGAG 21 11823
SCNNlA-7975 + UCAGGCCCUGCAGAGAAGAGAG 22 11824
SCNNlA-7976 + CUCAGGCCCUGCAGAGAAGAGAG 23 11825
SCNNlA-7977 + CCUCAGGCCCUGCAGAGAAGAGAG 24 11826
SCNNlA-7978 + UGGUGAGCAAGGAGAGAG 18 11827
SCNNlA-7979 + GUGGUGAGCAAGGAGAGAG 19 11828
SCNNlA-6146 + AGUGGUGAGCAAGGAGAGAG 20 9995
SCNNlA-7980 + AAGUGGUGAGCAAGGAGAGAG 21 11829
SCNNlA-7981 + CAAGUGGUGAGCAAGGAGAGAG 22 11830
SCNNlA-7982 + CCAAGUGGUGAGCAAGGAGAGAG 23 11831
SCNNlA-7983 + GCCAAGUGGUGAGCAAGGAGAGAG 24 11832
SCNNlA-7984 + AAGAGGGAGACAAUAGAG 18 11833
SCNNlA-7985 + AAAGAGGGAGACAAUAGAG 19 11834
SCNNlA-5896 + GAAAGAGGGAGACAAUAGAG 20 9745
SCNNlA-7986 + AGAAAGAGGGAGACAAUAGAG 21 11835
SCNNlA-7987 + CAGAAAGAGGGAGACAAUAGAG 22 11836
SCNNlA-7988 + GCAGAAAGAGGGAGACAAUAGAG 23 11837
SCNNlA-7989 + GGCAGAAAGAGGGAGACAAUAGAG 24 11838
SCNNlA-7990 + GGAGGGCAACACAAGGAG 18 11839
SCNNlA-7991 + AGGAGGGCAACACAAGGAG 19 11840
SCNNlA-7992 + UAGGAGGGCAACACAAGGAG 20 11841
SCNNlA-7993 + CUAGGAGGGCAACACAAGGAG 21 11842
SCNNlA-7994 + GCUAGGAGGGCAACACAAGGAG 22 11843
SCNNlA-7995 + AGCUAGGAGGGCAACACAAGGAG 23 11844
SCNNlA-7996 + CAGCUAGGAGGGCAACACAAGGAG 24 11845
SCNNlA-7997 + GACAGGCCCUGGGAGGAG 18 11846
SCNNlA-7998 + AGACAGGCCCUGGGAGGAG 19 11847
SCNNlA-7999 + UAGACAGGCCCUGGGAGGAG 20 11848
SCNNlA-8000 + CUAGACAGGCCCUGGGAGGAG 21 11849
SCNNlA-8001 + CCUAGACAGGCCCUGGGAGGAG 22 11850
1405
5535.1 SCNNlA-8002 + GCCUAGACAGGCCCUGGGAGGAG 23 11851
SCNNlA-8003 + CGCCUAGACAGGCCCUGGGAGGAG 24 11852
SCNNlA-8004 + UAGAAAACAAAAUAGGAG 18 11853
SCNNlA-8005 + UUAGAAAACAAAAUAGGAG 19 11854
SCNNlA-8006 + GUUAGAAAACAAAAUAGGAG 20 11855
SCNNlA-8007 + GG U UAGAAAACAAAAUAGGAG 21 11856
SCNNlA-8008 + AGGUUAGAAAACAAAAUAGGAG 22 11857
SCNNlA-8009 + GAGGUUAGAAAACAAAAUAGGAG 23 11858
SCNNlA-8010 + UGAGGUUAGAAAACAAAAUAGGAG 24 11859
SCNNlA-8011 + GGGCCAAAAGUGCCGGAG 18 11860
SCNNlA-8012 + GGGGCCAAAAGUGCCGGAG 19 11861
SCNNlA-8013 + UGGGGCCAAAAGUGCCGGAG 20 11862
SCNNlA-8014 + UUGGGGCCAAAAGUGCCGGAG 21 11863
SCNNlA-8015 + GUUGGGGCCAAAAGUGCCGGAG 22 11864
SCNNlA-8016 + AGUUGGGGCCAAAAGUGCCGGAG 23 11865
SCNNlA-8017 + GAGUUGGGGCCAAAAGUGCCGGAG 24 11866
SCNNlA-8018 + CCAGCAGACCUGCGGGAG 18 11867
SCNNlA-8019 + GCCAGCAGACCUGCGGGAG 19 11868
SCNNlA-8020 + AGCCAGCAGACCUGCGGGAG 20 11869
SCNNlA-8021 + GAGCCAGCAGACCUGCGGGAG 21 11870
SCNNlA-8022 + GGAGCCAGCAGACCUGCGGGAG 22 11871
SCNNlA-8023 + UGGAGCCAGCAGACCUGCGGGAG 23 11872
SCNNlA-8024 + CUGGAGCCAGCAGACCUGCGGGAG 24 11873
SCNNlA-8025 + CUAGACAGGCCCUGGGAG 18 11874
SCNNlA-8026 + CCUAGACAGGCCCUGGGAG 19 11875
SCNNlA-8027 + GCCUAGACAGGCCCUGGGAG 20 11876
SCNNlA-8028 + CGCCUAGACAGGCCCUGGGAG 21 11877
SCNNlA-8029 + ACGCCUAGACAGGCCCUGGGAG 22 11878
SCNNlA-8030 + CACGCCUAGACAGGCCCUGGGAG 23 11879
SCNNlA-8031 + ACACGCCUAGACAGGCCCUGGGAG 24 11880
SCNNlA-8032 + AGAGAGAUAGGGAUGGAG 18 11881
SCNNlA-8033 + CAGAGAGAUAGGGAUGGAG 19 11882
SCNNlA-8034 + ACAGAGAGAUAGGGAUGGAG 20 11883
SCNNlA-8035 + GACAGAGAGAUAGGGAUGGAG 21 11884
SCNNlA-8036 + GGACAGAGAGAUAGGGAUGGAG 22 11885
SCNNlA-8037 + AGGACAGAGAGAUAGGGAUGGAG 23 11886
SCNNlA-8038 + AAGGACAGAGAGAUAGGGAUGGAG 24 11887
SCNNlA-8039 + GCGGGGGGAGGGGCUGAG 18 11888
SCNNlA-8040 + GGCGGGGGGAGGGGCUGAG 19 11889
SCNNlA-8041 + GGGCGGGGGGAGGGGCUGAG 20 11890
SCNNlA-8042 + AGGGCGGGGGGAGGGGCUGAG 21 11891
SCNNlA-8043 + CAGGGCGGGGGGAGGGGCUGAG 22 11892
1406
5535.1 SCNNlA-8044 + GCAGGGCGGGGGGAGGGGCUGAG 23 11893
SCNNlA-8045 + AGCAGGGCGGGGGGAGGGGCUGAG 24
11894
SCNNlA-8046 + GGAGGGGCACUGAGUGAG 18 11895
SCNNlA-8047 + AGGAGGGGCACUGAGUGAG 19 11896
SCNNlA-8048 + GAGGAGGGGCACUGAGUGAG 20 11897
SCNNlA-8049 + GGAGGAGGGGCACUGAGUGAG 21 11898
SCNNlA-8050 + UGGAGGAGGGGCACUGAGUGAG 22 11899
SCNNlA-8051 + AUGGAGGAGGGGCACUGAGUGAG 23 11900
SCNNlA-8052 + GAUGGAGGAGGGGCACUGAGUGAG 24
11901
SCNNlA-8053 + AUCUCAAUUAAAGGUGAG 18 11902
SCNNlA-8054 + CAUCUCAAUUAAAGGUGAG 19 11903
SCNNlA-8055 + GCAUCUCAAUUAAAGGUGAG 20 11904
SCNNlA-8056 + AGCAUCUCAAUUAAAGGUGAG 21 11905
SCNNlA-8057 + UAGCAUCUCAAUUAAAGGUGAG 22 11906
SCNNlA-8058 + UUAGCAUCUCAAUUAAAGGUGAG 23 11907
SCNNlA-8059 + AUUAGCAUCUCAAUUAAAGGUGAG 24 11908
SCNNlA-8060 + AGUGGUGGGGGCAAAUAG 18 11909
SCNNlA-8061 + CAGUGGUGGGGGCAAAUAG 19 11910
SCNNlA-8062 + GCAGUGGUGGGGGCAAAUAG 20 11911
SCNNlA-8063 + GGCAGUGGUGGGGGCAAAUAG 21 11912
SCNNlA-8064 + GGGCAGUGGUGGGGGCAAAUAG 22 11913
SCNNlA-8065 + GGGGCAGUGGUGGGGGCAAAUAG 23 11914
SCNNlA-8066 + GGGGGCAGUGGUGGGGGCAAAUAG 24
11915
SCNNlA-8067 + UCCUGAGCCCACAGCUAG 18 11916
SCNNlA-8068 + AUCCUGAGCCCACAGCUAG 19 11917
SCNNlA-8069 + GAUCCUGAGCCCACAGCUAG 20 11918
SCNNlA-8070 + GGAUCCUGAGCCCACAGCUAG 21 11919
SCNNlA-8071 + AGGAUCCUGAGCCCACAGCUAG 22 11920
SCNNlA-8072 + AAGGAUCCUGAGCCCACAGCUAG 23 11921
SCNNlA-8073 + GAAGGAUCCUGAGCCCACAGCUAG 24 11922
SCNNlA-8074 + AUAAGAGCCAAGGGCUAG 18 11923
SCNNlA-8075 + CAUAAGAGCCAAGGGCUAG 19 11924
SCNNlA-5662 + ACAUAAGAGCCAAGGGCUAG 20 9511
SCNNlA-8076 + GACAUAAGAGCCAAGGGCUAG 21 11925
SCNNlA-8077 + AGACAUAAGAGCCAAGGGCUAG 22 11926
SCNNlA-8078 + AAGACAUAAGAGCCAAGGGCUAG 23 11927
SCNNlA-8079 + UAAGACAUAAGAGCCAAGGGCUAG 24 11928
SCNNlA-8080 + GGUGAAGCUGGGGGCUAG 18 11929
SCNNlA-8081 + AGGUGAAGCUGGGGGCUAG 19 11930
1407
5535.1 SCNNlA-8082 + CAGGUGAAGCUGGGGGCUAG 20 11931
SCNNlA-8083 + CCAGGUGAAGCUGGGGGCUAG 21 11932
SCNNlA-8084 + CCCAGGUGAAGCUGGGGGCUAG 22 11933
SCNNlA-8085 + GCCCAGGUGAAGCUGGGGGCUAG 23 11934
SCNNlA-8086 + GGCCCAGGUGAAGCUGGGGGCUAG 24 11935
SCNNlA-8087 + GGCAGCGCGAGGGCCACG 18 11936
SCNNlA-8088 + AGGCAGCGCGAGGGCCACG 19 11937
SCNNlA-8089 + GAGGCAGCGCGAGGGCCACG 20 11938
SCNNlA-8090 + AGAGGCAGCGCGAGGGCCACG 21 11939
SCNNlA-8091 + CAGAGGCAGCGCGAGGGCCACG 22 11940
SCNNlA-8092 + CCAGAGGCAGCGCGAGGGCCACG 23 11941
SCNNlA-8093 + ACCAGAGGCAGCGCGAGGGCCACG 24 11942
SCNNlA-8094 + GAGCAUUGAUACACACCG 18 11943
SCNNlA-8095 + UGAGCAUUGAUACACACCG 19 11944
SCNNlA-5665 + CUGAGCAUUGAUACACACCG 20 9514
SCNNlA-8096 + CCUGAGCAUUGAUACACACCG 21 11945
SCNNlA-8097 + GCCUGAGCAUUGAUACACACCG 22 11946
SCNNlA-8098 + AGCCUGAGCAUUGAUACACACCG 23 11947
SCNNlA-8099 + CAGCCUGAGCAUUGAUACACACCG 24 11948
SCNNlA-8100 + AGAGCCGGGAGUUUUCCG 18 11949
SCNNlA-8101 + CAGAGCCGGGAGUUUUCCG 19 11950
SCNNlA-8102 + UCAGAGCCGGGAGUUUUCCG 20 11951
SCNNlA-8103 + GUCAGAGCCGGGAGUUUUCCG 21 11952
SCNNlA-8104 + AGUCAGAGCCGGGAGUUUUCCG 22 11953
SCNNlA-8105 + GAG U CAG AGCCGGG AG U U U U CCG 23 11954
SCNNlA-8106 + GGAGUCAGAGCCGGGAGUUUUCCG 24 11955
SCNNlA-8107 + CAAUAGAGAGGGACAGCG 18 11956
SCNNlA-8108 + ACAAUAGAGAGGGACAGCG 19 11957
SCNNlA-8109 + GACAAUAGAGAGGGACAGCG 20 11958
SCNNlA-8110 + AGACAAUAGAGAGGGACAGCG 21 11959
SCNNlA-8111 + GAGACAAUAGAGAGGGACAGCG 22 11960
SCNNlA-8112 + GGAGACAAUAGAGAGGGACAGCG 23 11961
SCNNlA-8113 + GGGAGACAAUAGAGAGGGACAGCG 24 11962
SCNNlA-8114 + GGGAGGAUGUGGCCAGCG 18 11963
SCNNlA-8115 + AGGGAGGAUGUGGCCAGCG 19 11964
SCNNlA-8116 + CAGGGAGGAUGUGGCCAGCG 20 11965
SCNNlA-8117 + GCAGGGAGGAUGUGGCCAGCG 21 11966
SCNNlA-8118 + UGCAGGGAGGAUGUGGCCAGCG 22 11967
SCNNlA-8119 + GUGCAGGGAGGAUGUGGCCAGCG 23 11968
SCNNlA-8120 + GGUGCAGGGAGGAUGUGGCCAGCG 24 11969
SCNNlA-8121 + UUAAAGGUGAGCAGGGCG 18 11970
SCNNlA-8122 + AUUAAAGGUGAGCAGGGCG 19 11971
1408
5535.1 SCNNlA-5669 + A A U U A A AG GUGAGCAGGGCG 20 9518
SCNNlA-8123 + CAAUUAAAGGUGAGCAGGGCG 21 11972
SCNNlA-8124 + UCAAUUAAAGGUGAGCAGGGCG 22 11973
SCNNlA-8125 + CUCAAUUAAAGGUGAGCAGGGCG 23 11974
SCNNlA-8126 + UCUCAAUUAAAGGUGAGCAGGGCG 24 11975
SCNNlA-8127 + UGGCCAGCGCUGGAAAGG 18 11976
SCNNlA-8128 + GUGGCCAGCGCUGGAAAGG 19 11977
SCNNlA-8129 + UGUGGCCAGCGCUGGAAAGG 20 11978
SCNNlA-8130 + AUGUGGCCAGCGCUGGAAAGG 21 11979
SCNNlA-8131 + GAUGUGGCCAGCGCUGGAAAGG 22 11980
SCNNlA-8132 + GGAUGUGGCCAGCGCUGGAAAGG 23 11981
SCNNlA-8133 + AGGAUGUGGCCAGCGCUGGAAAGG 24 11982
SCNNlA-8134 + CCAGGAAGGAGAGCAAGG 18 11983
SCNNlA-8135 + UCCAGGAAGGAGAGCAAGG 19 11984
SCNNlA-6151 + CUCCAGGAAGGAGAGCAAGG 20 10000
SCNNlA-8136 + UCUCCAGGAAGGAGAGCAAGG 21 11985
SCNNlA-8137 + GUCUCCAGGAAGGAGAGCAAGG 22 11986
SCNNlA-8138 + UGUCUCCAGGAAGGAGAGCAAGG 23 11987
SCNNlA-8139 + CUGUCUCCAGGAAGGAGAGCAAGG 24 11988
SCNNlA-1604 + CAAGGGUCAGGGUCAAGG 18 5453
SCNNlA-1605 + GCAAGGGUCAGGGUCAAGG 19 5454
SCNNlA-1606 + AGCAAGGGUCAGGGUCAAGG 20 5455
SCNNlA-1607 + GAGCAAGGGUCAGGGUCAAGG 21 5456
SCNNlA-1608 + AGAGCAAGGGUCAGGGUCAAGG 22 5457
SCNNlA-1609 + GAGAGCAAGGGUCAGGGUCAAGG 23 5458
SCNNlA-1610 + GGAGAGCAAGGGUCAGGGUCAAGG 24 5459
SCNNlA-8140 + CCGGGAGUUUUCCGAAGG 18 11989
SCNNlA-8141 + GCCGGGAGUUUUCCGAAGG 19 11990
SCNNlA-8142 + AGCCGGGAGUUUUCCGAAGG 20 11991
SCNNlA-8143 + GAGCCGGGAGUUUUCCGAAGG 21 11992
SCNNlA-8144 + AGAGCCGGGAGUUUUCCGAAGG 22 11993
SCNNlA-8145 + CAG AG CCGGG AG U U U UCCGAAGG 23 11994
SCNNlA-8146 + UCAGAGCCGGGAGUUUUCCGAAGG 24 11995
SCNNlA-8147 + ACAGACCCGGAGCCCAGG 18 11996
SCNNlA-8148 + CACAGACCCGGAGCCCAGG 19 11997
SCNNlA-8149 + ACACAGACCCGGAGCCCAGG 20 11998
SCNNlA-8150 + GACACAGACCCGGAGCCCAGG 21 11999
SCNNlA-8151 + GGACACAGACCCGGAGCCCAGG 22 12000
SCNNlA-8152 + UGGACACAGACCCGGAGCCCAGG 23 12001
SCNNlA-8153 + GUGGACACAGACCCGGAGCCCAGG 24 12002
SCNNlA-8154 + GAGAAGGGGCCAGCCAGG 18 12003
SCNNlA-8155 + GGAGAAGGGGCCAGCCAGG 19 12004
1409
5535.1 SCNNlA-8156 + AGGAGAAGGGGCCAGCCAGG 20 12005
SCNNlA-8157 + AAGGAGAAGGGGCCAGCCAGG 21 12006
SCNNlA-8158 + CAAGGAGAAGGGGCCAGCCAGG 22 12007
SCNNlA-8159 + ACAAGGAGAAGGGGCCAGCCAGG 23 12008
SCNNlA-8160 + CACAAGGAGAAGGGGCCAGCCAGG 24 12009
SCNNlA-8161 + AGGGAGUCUGUCUCCAGG 18 12010
SCNNlA-8162 + AAGGGAGUCUGUCUCCAGG 19 12011
SCNNlA-8163 + AAAGGGAGUCUGUCUCCAGG 20 12012
SCNNlA-8164 + CAAAGGGAGUCUGUCUCCAGG 21 12013
SCNNlA-8165 + CCAAAGGGAGUCUGUCUCCAGG 22 12014
SCNNlA-8166 + ACCAAAGGGAGUCUGUCUCCAGG 23 12015
SCNNlA-8167 + CACCAAAGGGAGUCUGUCUCCAGG 24 12016
SCNNlA-8168 + C A A U U A A AG GUGAGCAGG 18 12017
SCNNlA-8169 + UCAAUUAAAGGUGAGCAGG 19 12018
SCNNlA-8170 + CUCAAUUAAAGGUGAGCAGG 20 12019
SCNNlA-8171 + UCUCAAUUAAAGGUGAGCAGG 21 12020
SCNNlA-8172 + AUCUCAAUUAAAGGUGAGCAGG 22 12021
SCNNlA-8173 + CAUCUCAAUUAAAGGUGAGCAGG 23 12022
SCNNlA-8174 + GCAUCUCAAUUAAAGGUGAGCAGG 24 12023
SCNNlA-8175 + UGAGUGAGUAGAGGCAGG 18 12024
SCNNlA-8176 + CUGAGUGAGUAGAGGCAGG 19 12025
SCNNlA-5677 + ACUGAGUGAGUAGAGGCAGG 20 9526
SCNNlA-8177 + CACUGAGUGAGUAGAGGCAGG 21 12026
SCNNlA-8178 + GCACUGAGUGAGUAGAGGCAGG 22 12027
SCNNlA-8179 + GGCACUGAGUGAGUAGAGGCAGG 23 12028
SCNNlA-8180 + GGGCACUGAGUGAGUAGAGGCAGG 24 12029
SCNNlA-8181 + GCGCUGGAAAGGAAGAGG 18 12030
SCNNlA-8182 + AGCGCUGGAAAGGAAGAGG 19 12031
SCNNlA-8183 + CAGCGCUGGAAAGGAAGAGG 20 12032
SCNNlA-8184 + CCAGCGCUGGAAAGGAAGAGG 21 12033
SCNNlA-8185 + GCCAGCGCUGGAAAGGAAGAGG 22 12034
SCNNlA-8186 + GGCCAGCGCUGGAAAGGAAGAGG 23 12035
SCNNlA-8187 + UGGCCAGCGCUGGAAAGGAAGAGG 24 12036
SCNNlA-8188 + CCGGAGCCCAGGAAGAGG 18 12037
SCNNlA-8189 + CCCGGAGCCCAGGAAGAGG 19 12038
SCNNlA-8190 + ACCCGGAGCCCAGGAAGAGG 20 12039
SCNNlA-8191 + GACCCGGAGCCCAGGAAGAGG 21 12040
SCNNlA-8192 + AGACCCGGAGCCCAGGAAGAGG 22 12041
SCNNlA-8193 + CAGACCCGGAGCCCAGGAAGAGG 23 12042
SCNNlA-8194 + ACAGACCCGGAGCCCAGGAAGAGG 24 12043
SCNNlA-8195 + CGCAGACAGGCAAGGAGG 18 12044
SCNNlA-8196 + ACGCAGACAGGCAAGGAGG 19 12045
1410
5535.1 SCNNlA-8197 + GACGCAGACAGGCAAGGAGG 20 12046
SCNNlA-8198 + AGACGCAGACAGGCAAGGAGG 21 12047
SCNNlA-8199 + UAGACGCAGACAGGCAAGGAGG 22 12048
SCNNlA-8200 + UUAGACGCAGACAGGCAAGGAGG 23 12049
SCNNlA-8201 + UUUAGACGCAGACAGGCAAGGAGG 24 12050
SCNNlA-8202 + UAGACAGGCCCUGGGAGG 18 12051
SCNNlA-8203 + CUAGACAGGCCCUGGGAGG 19 12052
SCNNlA-6157 + CCUAGACAGGCCCUGGGAGG 20 10006
SCNNlA-8204 + GCCUAGACAGGCCCUGGGAGG 21 12053
SCNNlA-8205 + CGCCUAGACAGGCCCUGGGAGG 22 12054
SCNNlA-8206 + ACGCCUAGACAGGCCCUGGGAGG 23 12055
SCNNlA-8207 + CACGCCUAGACAGGCCCUGGGAGG 24 12056
SCNNlA-8208 + GAGAGAUAGGGAUGGAGG 18 12057
SCNNlA-8209 + AGAGAGAUAGGGAUGGAGG 19 12058
SCNNlA-6158 + CAGAGAGAUAGGGAUGGAGG 20 10007
SCNNlA-8210 + ACAGAGAGAUAGGGAUGGAGG 21 12059
SCNNlA-8211 + GACAGAGAGAUAGGGAUGGAGG 22 12060
SCNNlA-8212 + GGACAGAGAGAUAGGGAUGGAGG 23 12061
SCNNlA-8213 + AGGACAGAGAGAUAGGGAUGGAGG 24
12062
SCNNlA-8214 + GUGAAGCUGGGGGCUAGG 18 12063
SCNNlA-8215 + GGUGAAGCUGGGGGCUAGG 19 12064
SCNNlA-5681 + AGGUGAAGCUGGGGGCUAGG 20 9530
SCNNlA-8216 + CAGGUGAAGCUGGGGGCUAGG 21 12065
SCNNlA-8217 + CCAGGUGAAGCUGGGGGCUAGG 22 12066
SCNNlA-8218 + CCCAGGUGAAGCUGGGGGCUAGG 23 12067
SCNNlA-8219 + GCCCAGGUGAAGCUGGGGGCUAGG 24 12068
SCNNlA-8220 + GCCUGGGUGGGGAACCGG 18 12069
SCNNlA-8221 + GGCCUGGGUGGGGAACCGG 19 12070
SCNNlA-8222 + GGGCCUGGGUGGGGAACCGG 20 12071
SCNNlA-8223 + AGGGCCUGGGUGGGGAACCGG 21 12072
SCNNlA-8224 + GAGGGCCUGGGUGGGGAACCGG 22 12073
SCNNlA-8225 + AGAGGGCCUGGGUGGGGAACCGG 23 12074
SCNNlA-8226 + GAGAGGGCCUGGGUGGGGAACCGG 24 12075
SCNNlA-8227 + AGCAUUGAUACACACCGG 18 12076
SCNNlA-8228 + GAGCAUUGAUACACACCGG 19 12077
SCNNlA-5682 + UGAGCAUUGAUACACACCGG 20 9531
SCNNlA-8229 + CUGAGCAUUGAUACACACCGG 21 12078
SCNNlA-8230 + CCUGAGCAUUGAUACACACCGG 22 12079
SCNNlA-8231 + GCCUGAGCAUUGAUACACACCGG 23 12080
SCNNlA-8232 + AGCCUGAGCAUUGAUACACACCGG 24 12081
SCNNlA-8233 + AACCUUGUCCAGACCCGG 18 12082
1411
5535.1 SCNNlA-8234 + CAACCUUGUCCAGACCCGG 19 12083
SCNNlA-8235 + CCAACCUUGUCCAGACCCGG 20 12084
SCNNlA-8236 + UCCAACCUUGUCCAGACCCGG 21 12085
SCNNlA-8237 + CUCCAACCUUGUCCAGACCCGG 22 12086
SCNNlA-8238 + CCUCCAACCUUGUCCAGACCCGG 23 12087
SCNNlA-8239 + CCCUCCAACCUUGUCCAGACCCGG 24 12088
SCNNlA-8240 + CCCAGGCCCUGCACGCGG 18 12089
SCNNlA-8241 + ACCCAGGCCCUGCACGCGG 19 12090
SCNNlA-8242 + AACCCAGGCCCUGCACGCGG 20 12091
SCNNlA-8243 + CAACCCAGGCCCUGCACGCGG 21 12092
SCNNlA-8244 + ACAACCCAGGCCCUGCACGCGG 22 12093
SCNNlA-8245 + CACAACCCAGGCCCUGCACGCGG 23 12094
SCNNlA-8246 + ACACAACCCAGGCCCUGCACGCGG 24 12095
SCNNlA-8247 + UAAAGGUGAGCAGGGCGG 18 12096
SCNNlA-8248 + UUAAAGGUGAGCAGGGCGG 19 12097
SCNNlA-5683 + AUUAAAGGUGAGCAGGGCGG 20 9532
SCNNlA-8249 + AAUUAAAGGUGAGCAGGGCGG 21 12098
SCNNlA-8250 + CAAUUAAAGGUGAGCAGGGCGG 22 12099
SCNNlA-8251 + UCAAUUAAAGGUGAGCAGGGCGG 23 12100
SCNNlA-8252 + CUCAAUUAAAGGUGAGCAGGGCGG 24 12101
SCNNlA-8253 + CCCACUCCCAGGUUGCGG 18 12102
SCNNlA-8254 + UCCCACUCCCAGGUUGCGG 19 12103
SCNNlA-8255 + UUCCCACUCCCAGGUUGCGG 20 12104
SCNNlA-8256 + CUUCCCACUCCCAGGUUGCGG 21 12105
SCNNlA-8257 + GCUUCCCACUCCCAGGUUGCGG 22 12106
SCNNlA-8258 + AGCUUCCCACUCCCAGGUUGCGG 23 12107
SCNNlA-8259 + CAGCUUCCCACUCCCAGGUUGCGG 24 12108
SCNNlA-8260 + GGGCUGGAGGAGACUCGG 18 12109
SCNNlA-8261 + AGGGCUGGAGGAGACUCGG 19 12110
SCNNlA-8262 + AAGGGCUGGAGGAGACUCGG 20 12111
SCNNlA-8263 + AAAGGGCUGGAGGAGACUCGG 21 12112
SCNNlA-8264 + AAAAGGGCUGGAGGAGACUCGG 22 12113
SCNNlA-8265 + AAAAAGGGCUGGAGGAGACUCGG 23 12114
SCNNlA-8266 + CAAAAAGGGCUGGAGGAGACUCGG 24 12115
SCNNlA-8267 + AAUCAGACCCAAAAAGGG 18 12116
SCNNlA-8268 + GAAUCAGACCCAAAAAGGG 19 12117
SCNNlA-8269 + AGAAUCAGACCCAAAAAGGG 20 12118
SCNNlA-8270 + GAGAAUCAGACCCAAAAAGGG 21 12119
SCNNlA-8271 + AGAGAAUCAGACCCAAAAAGGG 22 12120
SCNNlA-8272 + CAGAGAAUCAGACCCAAAAAGGG 23 12121
SCNNlA-8273 + UCAGAGAAUCAGACCCAAAAAGGG 24 12122
SCNNlA-8274 + CCCGCUGGCCGGCCAGGG 18 12123
1412
5535.1 SCNNlA-8275 + GCCCGCUGGCCGGCCAGGG 19 12124
SCNNlA-8276 + CGCCCGCUGGCCGGCCAGGG 20 12125
SCNNlA-8277 + CCGCCCGCUGGCCGGCCAGGG 21 12126
SCNNlA-8278 + CCCGCCCGCUGGCCGGCCAGGG 22 12127
SCNNlA-8279 + GCCCGCCCGCUGGCCGGCCAGGG 23 12128
SCNNlA-8280 + AGCCCGCCCGCUGGCCGGCCAGGG 24 12129
SCNNlA-8281 + AAUUAAAGGUGAGCAGGG 18 12130
SCNNlA-8282 + C A A U U A A AG GUGAGCAGGG 19 12131
SCNNlA-6160 + UCAAUUAAAGGUGAGCAGGG 20 10009
SCNNlA-8283 + CUCAAUUAAAGGUGAGCAGGG 21 12132
SCNNlA-8284 + UCUCAAUUAAAGGUGAGCAGGG 22 12133
SCNNlA-8285 + AUCUCAAUUAAAGGUGAGCAGGG 23 12134
SCNNlA-8286 + CAUCUCAAUUAAAGGUGAGCAGGG 24 12135
SCNNlA-8287 + ACCGGGAGGACAGGAGGG 18 12136
SCNNlA-8288 + AACCGGGAGGACAGGAGGG 19 12137
SCNNlA-8289 + GAACCGGGAGGACAGGAGGG 20 12138
SCNNlA-8290 + GGAACCGGGAGGACAGGAGGG 21 12139
SCNNlA-8291 + GGGAACCGGGAGGACAGGAGGG 22 12140
SCNNlA-8292 + GGGGAACCGGGAGGACAGGAGGG 23 12141
SCNNlA-8293 + UGGGGAACCGGGAGGACAGGAGGG 24 12142
SCNNlA-8294 + AAGGACAGAGAGAUAGGG 18 12143
SCNNlA-8295 + GAAGGACAGAGAGAUAGGG 19 12144
SCNNlA-8296 + CGAAGGACAGAGAGAUAGGG 20 12145
SCNNlA-8297 + GCGAAGGACAGAGAGAUAGGG 21 12146
SCNNlA-8298 + AGCGAAGGACAGAGAGAUAGGG 22 12147
SCNNlA-8299 + CAGCGAAGGACAGAGAGAUAGGG 23 12148
SCNNlA-8300 + ACAGCGAAGGACAGAGAGAUAGGG 24 12149
SCNNlA-8301 + ACCUUGUCCAGACCCGGG 18 12150
SCNNlA-8302 + AACCUUGUCCAGACCCGGG 19 12151
SCNNlA-5686 + CAACCUUGUCCAGACCCGGG 20 9535
SCNNlA-8303 + CCAACCUUGUCCAGACCCGGG 21 12152
SCNNlA-8304 + UCCAACCUUGUCCAGACCCGGG 22 12153
SCNNlA-8305 + CUCCAACCUUGUCCAGACCCGGG 23 12154
SCNNlA-8306 + CCUCCAACCUUGUCCAGACCCGGG 24 12155
SCNNlA-8307 + AAAGGUGAGCAGGGCGGG 18 12156
SCNNlA-8308 + UAAAGGUGAGCAGGGCGGG 19 12157
SCNNlA-5688 + UUAAAGGUGAGCAGGGCGGG 20 9537
SCNNlA-8309 + AUUAAAGGUGAGCAGGGCGGG 21 12158
SCNNlA-8310 + AAUUAAAGGUGAGCAGGGCGGG 22 12159
SCNNlA-8311 + CAAUUAAAGGUGAGCAGGGCGGG 23 12160
SCNNlA-8312 + UCAAUUAAAGGUGAGCAGGGCGGG 24 12161
SCNNlA-8313 + GCAGGGCGGGGGGAGGGG 18 12162
1413
5535.1 SCNNlA-8314 + AGCAGGGCGGGGGGAGGGG 19 12163
SCNNlA-8315 + GAGCAGGGCGGGGGGAGGGG 20 12164
SCNNlA-8316 + UGAGCAGGGCGGGGGGAGGGG 21 12165
SCNNlA-8317 + GUGAGCAGGGCGGGGGGAGGGG 22 12166
SCNNlA-8318 + GGUGAGCAGGGCGGGGGGAGGGG 23 12167
SCNNlA-8319 + AGGUGAGCAGGGCGGGGGGAGGGG 24
12168
SCNNlA-8320 + CAUUGAUACACACCGGGG 18 12169
SCNNlA-8321 + GCAUUGAUACACACCGGGG 19 12170
SCNNlA-8322 + AGCAUUGAUACACACCGGGG 20 12171
SCNNlA-8323 + GAGCAUUGAUACACACCGGGG 21 12172
SCNNlA-8324 + UGAGCAUUGAUACACACCGGGG 22 12173
SCNNlA-8325 + CUGAGCAUUGAUACACACCGGGG 23 12174
SCNNlA-8326 + CCUGAGCAUUGAUACACACCGGGG 24 12175
SCNNlA-8327 + AUUGAUACACACCGGGGG 18 12176
SCNNlA-8328 + CAUUGAUACACACCGGGGG 19 12177
SCNNlA-5265 + GCAUUGAUACACACCGGGGG 20 9114
SCNNlA-8329 + AGCAUUGAUACACACCGGGGG 21 12178
SCNNlA-8330 + GAGCAUUGAUACACACCGGGGG 22 12179
SCNNlA-8331 + UGAGCAUUGAUACACACCGGGGG 23 12180
SCNNlA-8332 + CUGAGCAUUGAUACACACCGGGGG 24 12181
SCNNlA-8333 + AGGUGAGCAGGGCGGGGG 18 12182
SCNNlA-8334 + AAGGUGAGCAGGGCGGGGG 19 12183
SCNNlA-8335 + AAAGGUGAGCAGGGCGGGGG 20 12184
SCNNlA-8336 + UAAAGGUGAGCAGGGCGGGGG 21 12185
SCNNlA-8337 + UUAAAGGUGAGCAGGGCGGGGG 22 12186
SCNNlA-8338 + AUUAAAGGUGAGCAGGGCGGGGG 23 12187
SCNNlA-8339 + AAUUAAAGGUGAGCAGGGCGGGGG 24
12188
SCNNlA-8340 + GGUGAGCAGGGCGGGGGG 18 12189
SCNNlA-8341 + AGGUGAGCAGGGCGGGGGG 19 12190
SCNNlA-6164 + AAGGUGAGCAGGGCGGGGGG 20 10013
SCNNlA-8342 + AAAGGUGAGCAGGGCGGGGGG 21 12191
SCNNlA-8343 + UAAAGGUGAGCAGGGCGGGGGG 22 12192
SCNNlA-8344 + UUAAAGGUGAGCAGGGCGGGGGG 23 12193
SCNNlA-8345 + AUUAAAGGUGAGCAGGGCGGGGGG 24
12194
SCNNlA-8346 + GCCUAGACAGGCCCUGGG 18 12195
SCNNlA-8347 + CGCCUAGACAGGCCCUGGG 19 12196
SCNNlA-5691 + ACGCCUAGACAGGCCCUGGG 20 9540
SCNNlA-8348 + CACGCCUAGACAGGCCCUGGG 21 12197
SCNNlA-8349 + ACACGCCUAGACAGGCCCUGGG 22 12198
1414
5535.1 SCNNlA-8350 + CACACGCCUAGACAGGCCCUGGG 23 12199
SCNNlA-8351 + GCACACGCCUAGACAGGCCCUGGG 24 12200
SCNNlA-8352 + AGGCUGAGAGGGCCUGGG 18 12201
SCNNlA-8353 + CAGGCUGAGAGGGCCUGGG 19 12202
SCNNlA-6165 + CCAGGCUGAGAGGGCCUGGG 20 10014
SCNNlA-8354 + GCCAGGCUGAGAGGGCCUGGG 21 12203
SCNNlA-8355 + AGCCAGGCUGAGAGGGCCUGGG 22 12204
SCNNlA-8356 + CAGCCAGGCUGAGAGGGCCUGGG 23 12205
SCNNlA-8357 + CCAGCCAGGCUGAGAGGGCCUGGG 24 12206
SCNNlA-8358 + GAGAAGGCGGACUCUGGG 18 12207
SCNNlA-8359 + UGAGAAGGCGGACUCUGGG 19 12208
SCNNlA-8360 + CUGAGAAGGCGGACUCUGGG 20 12209
SCNNlA-8361 + CCUGAGAAGGCGGACUCUGGG 21 12210
SCNNlA-8362 + ACCUGAGAAGGCGGACUCUGGG 22 12211
SCNNlA-8363 + GACCUGAGAAGGCGGACUCUGGG 23 12212
SCNNlA-8364 + GGACCUGAGAAGGCGGACUCUGGG 24 12213
SCNNlA-1623 + GCCCCGGAGUGGAUUGGG 18 5472
SCNNlA-1624 + AGCCCCGGAGUGGAUUGGG 19 5473
SCNNlA-1625 + GAGCCCCGGAGUGGAUUGGG 20 5474
SCNNlA-1626 + UGAGCCCCGGAGUGGAUUGGG 21 5475
SCNNlA-1627 + AUGAGCCCCGGAGUGGAUUGGG 22 5476
SCNNlA-1628 + CAUGAGCCCCGGAGUGGAUUGGG 23 5477
SCNNlA-1629 + UCAUGAGCCCCGGAGUGGAUUGGG 24 5478
SCNNlA-8365 + ACAGAGAGAUAGGGAUGG 18 12214
SCNNlA-8366 + GACAGAGAGAUAGGGAUGG 19 12215
SCNNlA-5915 + GGACAGAGAGAUAGGGAUGG 20 9764
SCNNlA-8367 + AGGACAGAGAGAUAGGGAUGG 21 12216
SCNNlA-8368 + AAGGACAGAGAGAUAGGGAUGG 22 12217
SCNNlA-8369 + GAAGGACAGAGAGAUAGGGAUGG 23 12218
SCNNlA-8370 + CGAAGGACAGAGAGAUAGGGAUGG 24 12219
SCNNlA-8371 + CGCCUAGACAGGCCCUGG 18 12220
SCNNlA-8372 + ACGCCUAGACAGGCCCUGG 19 12221
SCNNlA-8373 + CACGCCUAGACAGGCCCUGG 20 12222
SCNNlA-8374 + ACACGCCUAGACAGGCCCUGG 21 12223
SCNNlA-8375 + CACACGCCUAGACAGGCCCUGG 22 12224
SCNNlA-8376 + GCACACGCCUAGACAGGCCCUGG 23 12225
SCNNlA-8377 + GGCACACGCCUAGACAGGCCCUGG 24 12226
SCNNlA-8378 + ACAGGUGCAGCGGCCUGG 18 12227
SCNNlA-8379 + GACAGGUGCAGCGGCCUGG 19 12228
SCNNlA-8380 + UGACAGGUGCAGCGGCCUGG 20 12229
SCNNlA-8381 + CUGACAGGUGCAGCGGCCUGG 21 12230
SCNNlA-8382 + CCUGACAGGUGCAGCGGCCUGG 22 12231
1415
5535.1 SCNNlA-8383 + ACCUGACAGGUGCAGCGGCCUGG 23 12232
SCNNlA-8384 + CACCUGACAGGUGCAGCGGCCUGG 24 12233
SCNNlA-8385 + CAGGCUGAGAGGGCCUGG 18 12234
SCNNlA-8386 + CCAGGCUGAGAGGGCCUGG 19 12235
SCNNlA-8387 + GCCAGGCUGAGAGGGCCUGG 20 12236
SCNNlA-8388 + AGCCAGGCUGAGAGGGCCUGG 21 12237
SCNNlA-8389 + CAGCCAGGCUGAGAGGGCCUGG 22 12238
SCNNlA-8390 + CCAGCCAGGCUGAGAGGGCCUGG 23 12239
SCNNlA-8391 + GCCAGCCAGGCUGAGAGGGCCUGG 24 12240
SCNNlA-8392 + AGACCCAAAAAGGGCUGG 18 12241
SCNNlA-8393 + CAGACCCAAAAAGGGCUGG 19 12242
SCNNlA-5694 + UCAGACCCAAAAAGGGCUGG 20 9543
SCNNlA-8394 + AUCAGACCCAAAAAGGGCUGG 21 12243
SCNNlA-8395 + AAUCAGACCCAAAAAGGGCUGG 22 12244
SCNNlA-8396 + GAAUCAGACCCAAAAAGGGCUGG 23 12245
SCNNlA-8397 + AGAAUCAGACCCAAAAAGGGCUGG 24 12246
SCNNlA-8398 + GCAGGUGGGGGGCAGUGG 18 12247
SCNNlA-8399 + GGCAGGUGGGGGGCAGUGG 19 12248
SCNNlA-6171 + AGGCAGGUGGGGGGCAGUGG 20 10020
SCNNlA-8400 + GAGGCAGGUGGGGGGCAGUGG 21 12249
SCNNlA-8401 + AGAGGCAGGUGGGGGGCAGUGG 22 12250
SCNNlA-8402 + UAGAGGCAGGUGGGGGGCAGUGG 23 12251
SCNNlA-8403 + GUAGAGGCAGGUGGGGGGCAGUGG 24
12252
SCNNlA-1630 + CAUGAUACCUCCCCUUGG 18 5479
SCNNlA-1631 + UCAUGAUACCUCCCCUUGG 19 5480
SCNNlA-1632 + CUCAUGAUACCUCCCCUUGG 20 5481
SCNNlA-1633 + GCUCAUGAUACCUCCCCUUGG 21 5482
SCNNlA-1634 + UGCUCAUGAUACCUCCCCUUGG 22 5483
SCNNlA-1635 + CUGCUCAUGAUACCUCCCCUUGG 23 5484
SCNNlA-1636 + ACUGCUCAUGAUACCUCCCCUUGG 24 5485
SCNNlA-8404 + UUCUUCAUUGUCCUAAUG 18 12253
SCNNlA-8405 + UUUCUUCAUUGUCCUAAUG 19 12254
SCNNlA-8406 + UUUUCUUCAUUGUCCUAAUG 20 12255
SCNNlA-8407 + UUUUUCUUCAUUGUCCUAAUG 21 12256
SCNNlA-8408 + AUUUUUCUUCAUUGUCCUAAUG 22 12257
SCNNlA-8409 + GAUUUUUCUUCAUUGUCCUAAUG 23 12258
SCNNlA-8410 + GGAUUUUUCUUCAUUGUCCUAAUG 24 12259
SCNNlA-8411 + GACAGAGAGAUAGGGAUG 18 12260
SCNNlA-8412 + GGACAGAGAGAUAGGGAUG 19 12261
SCNNlA-8413 + AGGACAGAGAGAUAGGGAUG 20 12262
SCNNlA-8414 + AAGGACAGAGAGAUAGGGAUG 21 12263
1416
5535.1 SCNNlA-8415 + GAAGGACAGAGAGAUAGGGAUG 22 12264
SCNNlA-8416 + CGAAGGACAGAGAGAUAGGGAUG 23 12265
SCNNlA-8417 + GCGAAGGACAGAGAGAUAGGGAUG 24 12266
SCNNlA-8418 + GAGCCUAGGGGCUCACUG 18 12267
SCNNlA-8419 + GGAGCCUAGGGGCUCACUG 19 12268
SCNNlA-8420 + GGGAGCCUAGGGGCUCACUG 20 12269
SCNNlA-8421 + GGGGAGCCUAGGGGCUCACUG 21 12270
SCNNlA-8422 + AGGGGAGCCUAGGGGCUCACUG 22 12271
SCNNlA-8423 + UAGGGGAGCCUAGGGGCUCACUG 23 12272
SCNNlA-8424 + CUAGGGGAGCCUAGGGGCUCACUG 24 12273
SCNNlA-8425 + GUCUCUGCCCCAGGACUG 18 12274
SCNNlA-8426 + UGUCUCUGCCCCAGGACUG 19 12275
SCNNlA-8427 + CUGUCUCUGCCCCAGGACUG 20 12276
SCNNlA-8428 + UCUGUCUCUGCCCCAGGACUG 21 12277
SCNNlA-8429 + UUCUGUCUCUGCCCCAGGACUG 22 12278
SCNNlA-8430 + AUUCUGUCUCUGCCCCAGGACUG 23 12279
SCNNlA-8431 + GAUUCUGUCUCUGCCCCAGGACUG 24 12280
SCNNlA-8432 + CUGGAGCCAGCAGACCUG 18 12281
SCNNlA-8433 + CCUGGAGCCAGCAGACCUG 19 12282
SCNNlA-5701 + UCCUGGAGCCAGCAGACCUG 20 9550
SCNNlA-8434 + UUCCUGGAGCCAGCAGACCUG 21 12283
SCNNlA-8435 + UUUCCUGGAGCCAGCAGACCUG 22 12284
SCNNlA-8436 + CUUUCCUGGAGCCAGCAGACCUG 23 12285
SCNNlA-8437 + CCUUUCCUGGAGCCAGCAGACCUG 24 12286
SCNNlA-8438 + CCUCACCCUCAGGCCCUG 18 12287
SCNNlA-8439 + GCCUCACCCUCAGGCCCUG 19 12288
SCNNlA-8440 + AGCCUCACCCUCAGGCCCUG 20 12289
SCNNlA-8441 + CAGCCUCACCCUCAGGCCCUG 21 12290
SCNNlA-8442 + UCAGCCUCACCCUCAGGCCCUG 22 12291
SCNNlA-8443 + GUCAGCCUCACCCUCAGGCCCUG 23 12292
SCNNlA-8444 + GGUCAGCCUCACCCUCAGGCCCUG 24 12293
SCNNlA-8445 + AGACAGGCAAGGAGGCUG 18 12294
SCNNlA-8446 + CAGACAGGCAAGGAGGCUG 19 12295
SCNNlA-5919 + GCAGACAGGCAAGGAGGCUG 20 9768
SCNNlA-8447 + CGCAGACAGGCAAGGAGGCUG 21 12296
SCNNlA-8448 + ACGCAGACAGGCAAGGAGGCUG 22 12297
SCNNlA-8449 + GACGCAGACAGGCAAGGAGGCUG 23 12298
SCNNlA-8450 + AGACGCAGACAGGCAAGGAGGCUG 24 12299
SCNNlA-8451 + CAGACCCAAAAAGGGCUG 18 12300
SCNNlA-8452 + UCAGACCCAAAAAGGGCUG 19 12301
SCNNlA-8453 + AUCAGACCCAAAAAGGGCUG 20 12302
SCNNlA-8454 + AAUCAGACCCAAAAAGGGCUG 21 12303
1417
5535.1 SCNNlA-8455 + GAAUCAGACCCAAAAAGGGCUG 22 12304
SCNNlA-8456 + AG A A U C AG ACC C A A A A AG G G C U G 23 12305
SCNNlA-8457 + GAGAAUCAGACCCAAAAAGGGCUG 24 12306
SCNNlA-8458 + GGGCGGGGGGAGGGGCUG 18 12307
SCNNlA-8459 + AGGGCGGGGGGAGGGGCUG 19 12308
SCNNlA-6176 + CAGGGCGGGGGGAGGGGCUG 20 10025
SCNNlA-8460 + GCAGGGCGGGGGGAGGGGCUG 21 12309
SCNNlA-8461 + AGCAGGGCGGGGGGAGGGGCUG 22 12310
SCNNlA-8462 + GAGCAGGGCGGGGGGAGGGGCUG 23 12311
SCNNlA-8463 + UGAGCAGGGCGGGGGGAGGGGCUG 24
12312
SCNNlA-1668 + GAGACCUGGUAUGGGCUG 18 5517
SCNNlA-1669 + UGAGACCUGGUAUGGGCUG 19 5518
SCNNlA-1670 + AUGAGACCUGGUAUGGGCUG 20 5519
SCNNlA-1671 + CAUGAGACCUGGUAUGGGCUG 21 5520
SCNNlA-1672 + CCAUGAGACCUGGUAUGGGCUG 22 5521
SCNNlA-1673 + UCCAUGAGACCUGGUAUGGGCUG 23 5522
SCNNlA-1674 + CUCCAUGAGACCUGGUAUGGGCUG 24 5523
SCNNlA-8464 + GGUGCAGCGGCCUGGCUG 18 12313
SCNNlA-8465 + AGGUGCAGCGGCCUGGCUG 19 12314
SCNNlA-5705 + CAGGUGCAGCGGCCUGGCUG 20 9554
SCNNlA-8466 + ACAGGUGCAGCGGCCUGGCUG 21 12315
SCNNlA-8467 + GACAGGUGCAGCGGCCUGGCUG 22 12316
SCNNlA-8468 + UGACAGGUGCAGCGGCCUGGCUG 23 12317
SCNNlA-8469 + CUGACAGGUGCAGCGGCCUGGCUG 24 12318
SCNNlA-8470 + GAGUUGGGGCCAAAAGUG 18 12319
SCNNlA-8471 + GGAGUUGGGGCCAAAAGUG 19 12320
SCNNlA-8472 + GGGAGUUGGGGCCAAAAGUG 20 12321
SCNNlA-8473 + CGGGAGUUGGGGCCAAAAGUG 21 12322
SCNNlA-8474 + GCGGGAGUUGGGGCCAAAAGUG 22 12323
SCNNlA-8475 + UGCGGGAGUUGGGGCCAAAAGUG 23 12324
SCNNlA-8476 + CUGCGGGAGUUGGGGCCAAAAGUG 24 12325
SCNNlA-8477 + GGAGUGGAGUGCCAAGUG 18 12326
SCNNlA-8478 + AGGAGUGGAGUGCCAAGUG 19 12327
SCNNlA-8479 + AAGGAGUGGAGUGCCAAGUG 20 12328
SCNNlA-8480 + UAAGGAGUGGAGUGCCAAGUG 21 12329
SCNNlA-8481 + AUAAGGAGUGGAGUGCCAAGUG 22 12330
SCNNlA-8482 + GAUAAGGAGUGGAGUGCCAAGUG 23 12331
SCNNlA-8483 + GGAUAAGGAGUGGAGUGCCAAGUG 24
12332
SCNNlA-8484 + GGCAGGUGGGGGGCAGUG 18 12333
SCNNlA-8485 + AGGCAGGUGGGGGGCAGUG 19 12334
1418
5535.1 SCNNlA-8486 + GAGGCAGGUGGGGGGCAGUG 20 12335
SCNNlA-8487 + AGAGGCAGGUGGGGGGCAGUG 21 12336
SCNNlA-8488 + UAGAGGCAGGUGGGGGGCAGUG 22 12337
SCNNlA-8489 + GUAGAGGCAGGUGGGGGGCAGUG 23 12338
SCNNlA-8490 + AGUAGAGGCAGGUGGGGGGCAGUG 24
12339
SCNNlA-8491 + AGGAGGCAGCCCAGAGUG 18 12340
SCNNlA-8492 + CAGGAGGCAGCCCAGAGUG 19 12341
SCNNlA-8493 + ACAGGAGGCAGCCCAGAGUG 20 12342
SCNNlA-8494 + CACAGGAGGCAGCCCAGAGUG 21 12343
SCNNlA-8495 + CCACAGGAGGCAGCCCAGAGUG 22 12344
SCNNlA-8496 + CCCA CAGGAGGCAGCCCAGAGUG 23 12345
SCNNlA-8497 + CCCCACAGGAGGCAGCCCAGAGUG 24 12346
SCNNlA-8498 + AAG C AGG CAC U G AAG G U G 18 12347
SCNNlA-8499 + A A AG CAGGCACUGAAGGUG 19 12348
SCNNlA-8500 + GAAAGCAGGCACUGAAGGUG 20 12349
SCNNlA-8501 + GGAAAGCAGGCACUGAAGGUG 21 12350
SCNNlA-8502 + GGGAAAGCAGGCACUGAAGGUG 22 12351
SCNNlA-8503 + AGGGAAAGCAGGCACUGAAGGUG 23 12352
SCNNlA-8504 + C AGG G AAAG CAG G C ACU G AAG G U G 24 12353
SCNNlA-8505 + AGUGAGUAGAGGCAGGUG 18 12354
SCNNlA-8506 + GAGUGAGUAGAGGCAGGUG 19 12355
SCNNlA-5713 + UGAGUGAGUAGAGGCAGGUG 20 9562
SCNNlA-8507 + CUGAGUGAGUAGAGGCAGGUG 21 12356
SCNNlA-8508 + ACUGAGUGAGUAGAGGCAGGUG 22 12357
SCNNlA-8509 + CACUGAGUGAGUAGAGGCAGGUG 23 12358
SCNNlA-8510 + GCACUGAGUGAGUAGAGGCAGGUG 24 12359
SCNNlA-8511 + GGGACAGGAUGGCAGGUG 18 12360
SCNNlA-8512 + GGGGACAGGAUGGCAGGUG 19 12361
SCNNlA-5920 + GGGGGACAGGAUGGCAGGUG 20 9769
SCNNlA-8513 + UGGGGGACAGGAUGGCAGGUG 21 12362
SCNNlA-8514 + CUGGGGGACAGGAUGGCAGGUG 22 12363
SCNNlA-8515 + GCUGGGGGACAGGAUGGCAGGUG 23 12364
SCNNlA-8516 + GGCUGGGGGACAGGAUGGCAGGUG 24
12365
SCNNlA-8517 + GCUGAGAGGGCCUGGGUG 18 12366
SCNNlA-8518 + GGCUGAGAGGGCCUGGGUG 19 12367
SCNNlA-6177 + AGGCUGAGAGGGCCUGGGUG 20 10026
SCNNlA-8519 + CAGGCUGAGAGGGCCUGGGUG 21 12368
SCNNlA-8520 + CCAGGCUGAGAGGGCCUGGGUG 22 12369
SCNNlA-8521 + GCCAGGCUGAGAGGGCCUGGGUG 23 12370
SCNNlA-8522 + AGCCAGGCUGAGAGGGCCUGGGUG 24 12371
1419
5535.1 SCNNlA-1699 + GAGCCCCGGAGUGGAUUG 18 5548
SCNNlA-1700 + UGAGCCCCGGAGUGGAUUG 19 5549
SCNNlA-419 + AUGAGCCCCGGAGUGGAUUG 20 4268
SCNNlA-1701 + CAUGAGCCCCGGAGUGGAUUG 21 5550
SCNNlA-1702 + UCAUGAGCCCCGGAGUGGAUUG 22 5551
SCNNlA-1703 + UUCAUGAGCCCCGGAGUGGAUUG 23 5552
SCNNlA-1704 + CUUCAUGAGCCCCGGAGUGGAUUG 24 5553
SCNNlA-8523 + GCUGUGGUCACAGAGUUG 18 12372
SCNNlA-8524 + UGCUGUGGUCACAGAGUUG 19 12373
SCNNlA-8525 + CUGCUGUGGUCACAGAGUUG 20 12374
SCNNlA-8526 + CCUGCUGUGGUCACAGAGUUG 21 12375
SCNNlA-8527 + CCCUGCUGUGGUCACAGAGUUG 22 12376
SCNNlA-8528 + CCCCUGCUGUGGUCACAGAGUUG 23 12377
SCNNlA-8529 + GCCCCUGCUGUGGUCACAGAGUUG 24 12378
SCNNlA-8530 + AGGAGGAGAAAUUCGUUG 18 12379
SCNNlA-8531 + GAGGAGGAGAAAUUCGUUG 19 12380
SCNNlA-8532 + GGAGGAGGAGAAAUUCGUUG 20 12381
SCNNlA-8533 + GGGAGGAGGAGAAAUUCGUUG 21 12382
SCNNlA-8534 + UGGGAGGAGGAGAAAUUCGUUG 22 12383
SCNNlA-8535 + CUGGGAGGAGGAGAAAUUCGUUG 23 12384
SCNNlA-8536 + CCUGGGAGGAGGAGAAAUUCGUUG 24 12385
SCNNlA-8537 + GAGGUUAGAAAACAAAAU 18 12386
SCNNlA-8538 + UGAGGUUAGAAAACAAAAU 19 12387
SCNNlA-5720 + CUG AGG U U AG AAAACAAAAU 20 9569
SCNNlA-8539 + UCUGAGGUUAGAAAACAAAAU 21 12388
SCNNlA-8540 + UUCUGAGGUUAGAAAACAAAAU 22 12389
SCNNlA-8541 + UUUCUGAGGUUAG A A A AC A A A A U 23 12390
SCNNlA-8542 + UUUUCUGAGGU U AG AAAAC AAAAU 24 12391
SCNNlA-8543 + U C ACAG AG U U G CAG G AA U 18 12392
SCNNlA-8544 + GUCACAGAGUUGCAGGAAU 19 12393
SCNNlA-8545 + GGUCACAGAGUUGCAGGAAU 20 12394
SCNNlA-8546 + UGGUCACAGAGUUGCAGGAAU 21 12395
SCNNlA-8547 + GUGGUCACAGAGUUGCAGGAAU 22 12396
SCNNlA-8548 + UGUGGUCACAGAGUUGCAGGAAU 23 12397
SCNNlA-8549 + CUGUGGUCACAGAGUUGCAGGAAU 24 12398
SCNNlA-8550 + UUCUCAGAGAUAAGACAU 18 12399
SCNNlA-8551 + UUUCUCAGAGAUAAGACAU 19 12400
SCNNlA-8552 + AUUUCUCAGAGAUAAGACAU 20 12401
SCNNlA-8553 + GAUUUCUCAGAGAUAAGACAU 21 12402
SCNNlA-8554 + AGAUUUCUCAGAGAUAAGACAU 22 12403
SCNNlA-8555 + CAGAUUUCUCAGAGAUAAGACAU 23 12404
SCNNlA-8556 + UCAGAUUUCUCAGAGAUAAGACAU 24 12405
1420
5535.1 SCNNlA-8557 + UUCCUGAGACAGACUCAU 18 12406
SCNNlA-8558 + CUUCCUGAGACAGACUCAU 19 12407
SCNNlA-6179 + ACUUCCUGAGACAGACUCAU 20 10028
SCNNlA-8559 + UACUUCCUGAGACAGACUCAU 21 12408
SCNNlA-8560 + UUACUUCCUGAGACAGACUCAU 22 12409
SCNNlA-8561 + UUUACUUCCUGAGACAGACUCAU 23 12410
SCNNlA-8562 + AUUUACUUCCUGAGACAGACUCAU 24 12411
SCNNlA-8563 + CAGGUGAGGGGCAAAGAU 18 12412
SCNNlA-8564 + GCAGGUGAGGGGCAAAGAU 19 12413
SCNNlA-8565 + GGCAGGUGAGGGGCAAAGAU 20 12414
SCNNlA-8566 + UGGCAGGUGAGGGGCAAAGAU 21 12415
SCNNlA-8567 + AUGGCAGGUGAGGGGCAAAGAU 22 12416
SCNNlA-8568 + GAUGGCAGGUGAGGGGCAAAGAU 23 12417
SCNNlA-8569 + GGAUGGCAGGUGAGGGGCAAAGAU 24
12418
SCNNlA-8570 + UUAAUGCAG C A A A AG G A U 18 12419
SCNNlA-8571 + CUUAAUGCAGCAAAAGGAU 19 12420
SCNNlA-8572 + ACUUAAUGCAG C A A A AG G A U 20 12421
SCNNlA-8573 + AACUUAAUGCAG C A A A AG G A U 21 12422
SCNNlA-8574 + AAACUUAAUGCAGCAAAAGGAU 22 12423
SCNNlA-8575 + C A A AC U U A A U G C AG C A A A AG G A U 23 12424
SCNNlA-8576 + C C A A AC U U A A U G C AG C A A A AG G A U 24 12425
SCNNlA-8577 + GACAGACUCAUGGGGGAU 18 12426
SCNNlA-8578 + AGACAGACUCAUGGGGGAU 19 12427
SCNNlA-5272 + GAGACAGACUCAUGGGGGAU 20 9121
SCNNlA-8579 + UGAGACAGACUCAUGGGGGAU 21 12428
SCNNlA-8580 + CUGAGACAGACUCAUGGGGGAU 22 12429
SCNNlA-8581 + CCUGAGACAGACUCAUGGGGGAU 23 12430
SCNNlA-8582 + UCCUGAGACAGACUCAUGGGGGAU 24 12431
SCNNlA-8583 + GCUCAGGUGCACCUGGAU 18 12432
SCNNlA-8584 + GGCUCAGGUGCACCUGGAU 19 12433
SCNNlA-8585 + GGGCUCAGGUGCACCUGGAU 20 12434
SCNNlA-8586 + GGGGCUCAGGUGCACCUGGAU 21 12435
SCNNlA-8587 + CGGGGCUCAGGUGCACCUGGAU 22 12436
SCNNlA-8588 + UCGGGGCUCAGGUGCACCUGGAU 23 12437
SCNNlA-8589 + AUCGGGGCUCAGGUGCACCUGGAU 24 12438
SCNNlA-1717 + AUGAGCCCCGGAGUGGAU 18 5566
SCNNlA-1718 + CAUGAGCCCCGGAGUGGAU 19 5567
SCNNlA-420 + UCAUGAGCCCCGGAGUGGAU 20 4269
SCNNlA-1719 + UUCAUGAGCCCCGGAGUGGAU 21 5568
SCNNlA-1720 + CUUCAUGAGCCCCGGAGUGGAU 22 5569
SCNNlA-1721 + CCUUCAUGAGCCCCGGAGUGGAU 23 5570
1421
5535.1 SCNNlA-1722 + CCCUUCAUGAGCCCCGGAGUGGAU 24 5571
SCNNlA-8590 + AGGGCCACGCAGGACACU 18 12439
SCNNlA-8591 + GAGGGCCACGCAGGACACU 19 12440
SCNNlA-8592 + CGAGGGCCACGCAGGACACU 20 12441
SCNNlA-8593 + GCGAGGGCCACGCAGGACACU 21 12442
SCNNlA-8594 + CGCGAGGGCCACGCAGGACACU 22 12443
SCNNlA-8595 + GCGCGAGGGCCACGCAGGACACU 23 12444
SCNNlA-8596 + AGCGCGAGGGCCACGCAGGACACU 24 12445
SCNNlA-8597 + GGCUCACUGCAGGAGACU 18 12446
SCNNlA-8598 + GGGCUCACUGCAGGAGACU 19 12447
SCNNlA-8599 + GGGGCUCACUGCAGGAGACU 20 12448
SCNNlA-8600 + AGGGGCUCACUGCAGGAGACU 21 12449
SCNNlA-8601 + UAGGGGCUCACUGCAGGAGACU 22 12450
SCNNlA-8602 + CUAGGGGCUCACUGCAGGAGACU 23 12451
SCNNlA-8603 + CCUAGGGGCUCACUGCAGGAGACU 24 12452
SCNNlA-8604 + AAAGGGCUGGAGGAGACU 18 12453
SCNNlA-8605 + AAAAGGGCUGGAGGAGACU 19 12454
SCNNlA-5729 + AAAAAGGGCUGGAGGAGACU 20 9578
SCNNlA-8606 + CAAAAAGGGCUGGAGGAGACU 21 12455
SCNNlA-8607 + CCAAAAAGGGCUGGAGGAGACU 22 12456
SCNNlA-8608 + CCCAAAAAGGGCUGGAGGAGACU 23 12457
SCNNlA-8609 + ACCCAAAAAGGGCUGGAGGAGACU 24 12458
SCNNlA-8610 + GACCUGAGAAGGCGGACU 18 12459
SCNNlA-8611 + GGACCUGAGAAGGCGGACU 19 12460
SCNNlA-8612 + UGGACCUGAGAAGGCGGACU 20 12461
SCNNlA-8613 + CUGGACCUGAGAAGGCGGACU 21 12462
SCNNlA-8614 + ACUGGACCUGAGAAGGCGGACU 22 12463
SCNNlA-8615 + UACUGGACCUGAGAAGGCGGACU 23 12464
SCNNlA-8616 + GUACUGGACCUGAGAAGGCGGACU 24 12465
SCNNlA-8617 + CCUGGAGCCAGCAGACCU 18 12466
SCNNlA-8618 + UCCUGGAGCCAGCAGACCU 19 12467
SCNNlA-8619 + UUCCUGGAGCCAGCAGACCU 20 12468
SCNNlA-8620 + UUUCCUGGAGCCAGCAGACCU 21 12469
SCNNlA-8621 + CUUUCCUGGAGCCAGCAGACCU 22 12470
SCNNlA-8622 + CCUUUCCUGGAGCCAGCAGACCU 23 12471
SCNNlA-8623 + ACCUUUCCUGGAGCCAGCAGACCU 24 12472
SCNNlA-8624 + ACUGGGAGUACUGGACCU 18 12473
SCNNlA-8625 + AACUGGGAGUACUGGACCU 19 12474
SCNNlA-8626 + GAACUGGGAGUACUGGACCU 20 12475
SCNNlA-8627 + UGAACUGGGAGUACUGGACCU 21 12476
SCNNlA-8628 + GUGAACUGGGAGUACUGGACCU 22 12477
SCNNlA-8629 + GGUGAACUGGGAGUACUGGACCU 23 12478
1422
5535.1 SCNNlA-8630 + AGGUGAACUGGGAGUACUGGACCU 24 12479
SCNNlA-1735 + GCUCAUGAUACCUCCCCU 18 5584
SCNNlA-1736 + UGCUCAUGAUACCUCCCCU 19 5585
SCNNlA-457 + CUGCUCAUGAUACCUCCCCU 20 4306
SCNNlA-1737 + ACUGCUCAUGAUACCUCCCCU 21 5586
SCNNlA-1738 + UACUGCUCAUGAUACCUCCCCU 22 5587
SCNNlA-1739 + AUACUGCUCAUGAUACCUCCCCU 23 5588
SCNNlA-1740 + GAUACUGCUCAUGAUACCUCCCCU 24 5589
SCNNlA-8631 + CACGCCUAGACAGGCCCU 18 12480
SCNNlA-8632 + ACACGCCUAGACAGGCCCU 19 12481
SCNNlA-5734 + CACACGCCUAGACAGGCCCU 20 9583
SCNNlA-8633 + GCACACGCCUAGACAGGCCCU 21 12482
SCNNlA-8634 + GGCACACGCCUAGACAGGCCCU 22 12483
SCNNlA-8635 + UGGCACACGCCUAGACAGGCCCU 23 12484
SCNNlA-8636 + AUGGCACACGCCUAGACAGGCCCU 24 12485
SCNNlA-8637 + CAAGGGCUAGGGGAGCCU 18 12486
SCNNlA-8638 + CCAAGGGCUAGGGGAGCCU 19 12487
SCNNlA-5275 + GCCAAGGGCUAGGGGAGCCU 20 9124
SCNNlA-8639 + AGCCAAGGGCUAGGGGAGCCU 21 12488
SCNNlA-8640 + GAGCCAAGGGCUAGGGGAGCCU 22 12489
SCNNlA-8641 + AGAGCCAAGGGCUAGGGGAGCCU 23 12490
SCNNlA-8642 + AAGAGCCAAGGGCUAGGGGAGCCU 24 12491
SCNNlA-8643 + CAGAAUUCUCCUCCUCCU 18 12492
SCNNlA-8644 + UCAGAAUUCUCCUCCUCCU 19 12493
SCNNlA-8645 + UUCAGAAUUCUCCUCCUCCU 20 12494
SCNNlA-8646 + AUUCAGAAUUCUCCUCCUCCU 21 12495
SCNNlA-8647 + AAUUCAGAAUUCUCCUCCUCCU 22 12496
SCNNlA-8648 + GAAUUCAGAAUUCUCCUCCUCCU 23 12497
SCNNlA-8649 + AGAAUUCAGAAUUCUCCUCCUCCU 24 12498
SCNNlA-8650 + AGGGGCCCAGGUGAAGCU 18 12499
SCNNlA-8651 + GAGGGGCCCAGGUGAAGCU 19 12500
SCNNlA-5923 + GGAGGGGCCCAGGUGAAGCU 20 9772
SCNNlA-8652 + GGGAGGGGCCCAGGUGAAGCU 21 12501
SCNNlA-8653 + CGGGAGGGGCCCAGGUGAAGCU 22 12502
SCNNlA-8654 + CCGGGAGGGGCCCAGGUGAAGCU 23 12503
SCNNlA-8655 + CCCGGGAGGGGCCCAGGUGAAGCU 24 12504
SCNNlA-8656 + GAUCCUGAGCCCACAGCU 18 12505
SCNNlA-8657 + GGAUCCUGAGCCCACAGCU 19 12506
SCNNlA-5740 + AGGAUCCUGAGCCCACAGCU 20 9589
SCNNlA-8658 + AAGGAUCCUGAGCCCACAGCU 21 12507
SCNNlA-8659 + GAAGGAUCCUGAGCCCACAGCU 22 12508
SCNNlA-8660 + AGAAGGAUCCUGAGCCCACAGCU 23 12509
1423
5535.1 SCNNlA-8661 + UAGAAGGAUCCUGAGCCCACAGCU 24 12510
SCNNlA-1741 + CAGGGUCAAGGCUGAGCU 18 5590
SCNNlA-1742 + UCAGGGUCAAGGCUGAGCU 19 5591
SCNNlA-1743 + GUCAGGGUCAAGGCUGAGCU 20 5592
SCNNlA-1744 + GGUCAGGGUCAAGGCUGAGCU 21 5593
SCNNlA-1745 + GGGUCAGGGUCAAGGCUGAGCU 22 5594
SCNNlA-1746 + AGGGUCAGGGUCAAGGCUGAGCU 23 5595
SCNNlA-1747 + AAGGGUCAGGGUCAAGGCUGAGCU 24 5596
SCNNlA-8662 + GAAGGGGCCAGCCAGGCU 18 12511
SCNNlA-8663 + AGAAGGGGCCAGCCAGGCU 19 12512
SCNNlA-8664 + GAGAAGGGGCCAGCCAGGCU 20 12513
SCNNlA-8665 + GGAGAAGGGGCCAGCCAGGCU 21 12514
SCNNlA-8666 + AGGAGAAGGGGCCAGCCAGGCU 22 12515
SCNNlA-8667 + AAGGAGAAGGGGCCAGCCAGGCU 23 12516
SCNNlA-8668 + CAAGGAGAAGGGGCCAGCCAGGCU 24 12517
SCNNlA-8669 + CAGACAGGCAAGGAGGCU 18 12518
SCNNlA-8670 + GCAGACAGGCAAGGAGGCU 19 12519
SCNNlA-5742 + CGCAGACAGGCAAGGAGGCU 20 9591
SCNNlA-8671 + ACGCAGACAGGCAAGGAGGCU 21 12520
SCNNlA-8672 + GACGCAGACAGGCAAGGAGGCU 22 12521
SCNNlA-8673 + AGACGCAGACAGGCAAGGAGGCU 23 12522
SCNNlA-8674 + UAGACGCAGACAGGCAAGGAGGCU 24 12523
SCNNlA-8675 + ACAUAAGAGCCAAGGGCU 18 12524
SCNNlA-8676 + GACAUAAGAGCCAAGGGCU 19 12525
SCNNlA-5743 + AGACAUAAGAGCCAAGGGCU 20 9592
SCNNlA-8677 + AAGACAUAAGAGCCAAGGGCU 21 12526
SCNNlA-8678 + UAAGACAUAAGAGCCAAGGGCU 22 12527
SCNNlA-8679 + AUAAGACAUAAGAGCCAAGGGCU 23 12528
SCNNlA-8680 + GAUAAGACAUAAGAGCCAAGGGCU 24 12529
SCNNlA-8681 + AGGGCGGGGGGAGGGGCU 18 12530
SCNNlA-8682 + CAGGGCGGGGGGAGGGGCU 19 12531
SCNNlA-8683 + GCAGGGCGGGGGGAGGGGCU 20 12532
SCNNlA-8684 + AGCAGGGCGGGGGGAGGGGCU 21 12533
SCNNlA-8685 + GAGCAGGGCGGGGGGAGGGGCU 22 12534
SCNNlA-8686 + UGAGCAGGGCGGGGGGAGGGGCU 23 12535
SCNNlA-8687 + GUGAGCAGGGCGGGGGGAGGGGCU 24
12536
SCNNlA-8688 + AGGUGCAGCGGCCUGGCU 18 12537
SCNNlA-8689 + CAGGUGCAGCGGCCUGGCU 19 12538
SCNNlA-5744 + ACAGGUGCAGCGGCCUGGCU 20 9593
SCNNlA-8690 + GACAGGUGCAGCGGCCUGGCU 21 12539
SCNNlA-8691 + UGACAGGUGCAGCGGCCUGGCU 22 12540
1424
5535.1 SCNNlA-8692 + CUGACAGGUGCAGCGGCCUGGCU 23 12541
SCNNlA-8693 + CCUGACAGGUGCAGCGGCCUGGCU 24 12542
SCNNlA-8694 + UUUCAUAUCAAGGGCUCU 18 12543
SCNNlA-8695 + UUUUCAUAUCAAGGGCUCU 19 12544
SCNNlA-8696 + GUUUUCAUAUCAAGGGCUCU 20 12545
SCNNlA-8697 + AGUUUUCAUAUCAAGGGCUCU 21 12546
SCNNlA-8698 + UAGUUUUCAUAUCAAGGGCUCU 22 12547
SCNNlA-8699 + AUAGUUUUCAUAUCAAGGGCUCU 23 12548
SCNNlA-8700 + AAUAGUUUUCAUAUCAAGGGCUCU 24 12549
SCNNlA-8701 + GGUUAUCUCCUUGGCUCU 18 12550
SCNNlA-8702 + GGGUUAUCUCCUUGGCUCU 19 12551
SCNNlA-8703 + UGGGUUAUCUCCUUGGCUCU 20 12552
SCNNlA-8704 + CUGGGUUAUCUCCUUGGCUCU 21 12553
SCNNlA-8705 + GCUGGGUUAUCUCCUUGGCUCU 22 12554
SCNNlA-8706 + UGCUGGGUUAUCUCCUUGGCUCU 23 12555
SCNNlA-8707 + GUGCUGGGUUAUCUCCUUGGCUCU 24 12556
SCNNlA-8708 + UGCAGAUCUCAGAUUUCU 18 12557
SCNNlA-8709 + GUGCAGAUCUCAGAUUUCU 19 12558
SCNNlA-8710 + AGUGCAGAUCUCAGAUUUCU 20 12559
SCNNlA-8711 + AAGUGCAGAUCUCAGAUUUCU 21 12560
SCNNlA-8712 + AAAGUGCAGAUCUCAGAUUUCU 22 12561
SCNNlA-8713 + AAAAGUGCAGAUCUCAGAUUUCU 23 12562
SCNNlA-8714 + CAAAAGUGCAGAUCUCAGAUUUCU 24 12563
SCNNlA-8715 + CCUCCCCGCUCACUAAGU 18 12564
SCNNlA-8716 + UCCUCCCCGCUCACUAAGU 19 12565
SCNNlA-5752 + CUCCUCCCCGCUCACUAAGU 20 9601
SCNNlA-8717 + UCUCCUCCCCGCUCACUAAGU 21 12566
SCNNlA-8718 + GUCUCCUCCCCGCUCACUAAGU 22 12567
SCNNlA-8719 + GGUCUCCUCCCCGCUCACUAAGU 23 12568
SCNNlA-8720 + AGGUCUCCUCCCCGCUCACUAAGU 24 12569
SCNNlA-8721 + GAGGGGCUGAGGAGGAGU 18 12570
SCNNlA-8722 + GGAGGGGCUGAGGAGGAGU 19 12571
SCNNlA-8723 + GGGAGGGGCUGAGGAGGAGU 20 12572
SCNNlA-8724 + GGGGAGGGGCUGAGGAGGAGU 21 12573
SCNNlA-8725 + GGGGGAGGGGCUGAGGAGGAGU 22 12574
SCNNlA-8726 + GGGGGGAGGGGCUGAGGAGGAGU 23 12575
SCNNlA-8727 + CGGGGGGAGGGGCUGAGGAGGAGU 24
12576
SCNNlA-8728 + CAGCAGACCUGCGGGAGU 18 12577
SCNNlA-8729 + CCAGCAGACCUGCGGGAGU 19 12578
SCNNlA-5278 + GCCAGCAGACCUGCGGGAGU 20 9127
SCNNlA-8730 + AGCCAGCAGACCUGCGGGAGU 21 12579
1425
5535.1 SCNNlA-8731 + GAGCCAGCAGACCUGCGGGAGU 22 12580
SCNNlA-8732 + GGAGCCAGCAGACCUGCGGGAGU 23 12581
SCNNlA-8733 + UGGAGCCAGCAGACCUGCGGGAGU 24 12582
SCNNlA-8734 + GAGUGAGUAGAGGCAGGU 18 12583
SCNNlA-8735 + UGAGUGAGUAGAGGCAGGU 19 12584
SCNNlA-5756 + CUGAGUGAGUAGAGGCAGGU 20 9605
SCNNlA-8736 + ACUGAGUGAGUAGAGGCAGGU 21 12585
SCNNlA-8737 + CACUGAGUGAGUAGAGGCAGGU 22 12586
SCNNlA-8738 + GCACUGAGUGAGUAGAGGCAGGU 23 12587
SCNNlA-8739 + GGCACUGAGUGAGUAGAGGCAGGU 24 12588
SCNNlA-8740 + GGGGACAGGAUGGCAGGU 18 12589
SCNNlA-8741 + GGGGGACAGGAUGGCAGGU 19 12590
SCNNlA-8742 + UGGGGGACAGGAUGGCAGGU 20 12591
SCNNlA-8743 + CUGGGGGACAGGAUGGCAGGU 21 12592
SCNNlA-8744 + GCUGGGGGACAGGAUGGCAGGU 22 12593
SCNNlA-8745 + GGCUGGGGGACAGGAUGGCAGGU 23 12594
SCNNlA-8746 + AGGCUGGGGGACAGGAUGGCAGGU 24
12595
SCNNlA-8747 + UGCAGGGCUCCAGGAGGU 18 12596
SCNNlA-8748 + CUGCAGGGCUCCAGGAGGU 19 12597
SCNNlA-8749 + ACUGCAGGGCUCCAGGAGGU 20 12598
SCNNlA-8750 + GACUGCAGGGCUCCAGGAGGU 21 12599
SCNNlA-8751 + GGACUGCAGGGCUCCAGGAGGU 22 12600
SCNNlA-8752 + AGGACUGCAGGGCUCCAGGAGGU 23 12601
SCNNlA-8753 + CAGGACUGCAGGGCUCCAGGAGGU 24 12602
SCNNlA-8754 + AAAUCAGUUUUCUGAGGU 18 12603
SCNNlA-8755 + UAAAUCAGUUUUCUGAGGU 19 12604
SCNNlA-8756 + AUAAAUCAGUUUUCUGAGGU 20 12605
SCNNlA-8757 + GAUAAAUCAGUUUUCUGAGGU 21 12606
SCNNlA-8758 + GGAUAAAUCAGUUUUCUGAGGU 22 12607
SCNNlA-8759 + AGGAUAAAUCAGUUUUCUGAGGU 23 12608
SCNNlA-8760 + AAGGAUAAAUCAGUUUUCUGAGGU 24 12609
SCNNlA-8761 + AAGGAGAGAGAGGAGGGU 18 12610
SCNNlA-8762 + CAAGGAGAGAGAGGAGGGU 19 12611
SCNNlA-8763 + GCAAGGAGAGAGAGGAGGGU 20 12612
SCNNlA-8764 + AGCAAGGAGAGAGAGGAGGGU 21 12613
SCNNlA-8765 + GAGCAAGGAGAGAGAGGAGGGU 22 12614
SCNNlA-8766 + UGAGCAAGGAGAGAGAGGAGGGU 23 12615
SCNNlA-8767 + GUGAGCAAGGAGAGAGAGGAGGGU 24
12616
SCNNlA-8768 + GGCUGAGAGGGCCUGGGU 18 12617
SCNNlA-8769 + AGGCUGAGAGGGCCUGGGU 19 12618
1426
5535.1 SCNNlA-6188 + CAGGCUGAGAGGGCCUGGGU 20 10037
SCNNlA-8770 + CCAGGCUGAGAGGGCCUGGGU 21 12619
SCNNlA-8771 + GCCAGGCUGAGAGGGCCUGGGU 22 12620
SCNNlA-8772 + AGCCAGGCUGAGAGGGCCUGGGU 23 12621
SCNNlA-8773 + CAGCCAGGCUGAGAGGGCCUGGGU 24 12622
SCNNlA-1772 + CCCUCCAUGAGACCUGGU 18 5621
SCNNlA-1773 + CCCCUCCAUGAGACCUGGU 19 5622
SCNNlA-199 + UCCCCUCCAUGAGACCUGGU 20 828
SCNNlA-1774 + UUCCCCUCCAUGAGACCUGGU 21 5623
SCNNlA-1775 + GUUCCCCUCCAUGAGACCUGGU 22 5624
SCNNlA-1776 + UGUUCCCCUCCAUGAGACCUGGU 23 5625
SCNNlA-1777 + UUGUUCCCCUCCAUGAGACCUGGU 24 5626
SCNNlA-8774 + CAGGUGGGGGGCAGUGGU 18 12623
SCNNlA-8775 + GCAGGUGGGGGGCAGUGGU 19 12624
SCNNlA-5928 + GGCAGGUGGGGGGCAGUGGU 20 9777
SCNNlA-8776 + AGGCAGGUGGGGGGCAGUGGU 21 12625
SCNNlA-8777 + GAGGCAGGUGGGGGGCAGUGGU 22 12626
SCNNlA-8778 + AGAGGCAGGUGGGGGGCAGUGGU 23 12627
SCNNlA-8779 + UAGAGGCAGGUGGGGGGCAGUGGU 24
12628
SCNNlA-8780 + UCAUAUCAAGGGCUCUGU 18 12629
SCNNlA-8781 + UUCAUAUCAAGGGCUCUGU 19 12630
SCNNlA-8782 + UUUCAUAUCAAGGGCUCUGU 20 12631
SCNNlA-8783 + UUUUCAUAUCAAGGGCUCUGU 21 12632
SCNNlA-8784 + GUUUUCAUAUCAAGGGCUCUGU 22 12633
SCNNlA-8785 + AGUUUUCAUAUCAAGGGCUCUGU 23 12634
SCNNlA-8786 + UAGUUUUCAUAUCAAGGGCUCUGU 24 12635
SCNNlA-1778 + UGAGCCCCGGAGUGGAUU 18 5627
SCNNlA-1779 + AUGAGCCCCGGAGUGGAUU 19 5628
SCNNlA-425 + CAUGAGCCCCGGAGUGGAUU 20 4274
SCNNlA-1780 + UCAUGAGCCCCGGAGUGGAUU 21 5629
SCNNlA-1781 + UUCAUGAGCCCCGGAGUGGAUU 22 5630
SCNNlA-1782 + CUUCAUGAGCCCCGGAGUGGAUU 23 5631
SCNNlA-1783 + CCUUCAUGAGCCCCGGAGUGGAUU 24 5632
SCNNlA-8787 + UGUUUGAUCUCAAAGGUU 18 12636
SCNNlA-8788 + CUGUUUGAUCUCAAAGGUU 19 12637
SCNNlA-8789 + GCUGUUUGAUCUCAAAGGUU 20 12638
SCNNlA-8790 + GGCUGUUUGAUCUCAAAGGUU 21 12639
SCNNlA-8791 + UGGCUGUUUGAUCUCAAAGGUU 22 12640
SCNNlA-8792 + CUGGCUGUUUGAUCUCAAAGGUU 23 12641
SCNNlA-8793 + CCUGGCUGUUUGAUCUCAAAGGUU 24 12642
SCNNlA-8794 + C A AG G A U AAA UCAGUUUU 18 12643
1427
5535.1 SCNNlA-8795 + C C A AG G A U AAA UCAGUUUU 19 12644
SCNNlA-8796 + CCCAAGG AU AAAU CAG U U U U 20 12645
SCNNlA-8797 + UCCCAAGGAUAAAUCAGUUUU 21 12646
SCNNlA-8798 + UUCCCAAGGAUAAAUCAGUUUU 22 12647
SCNNlA-8799 + CUUCCCAAGGAUAAAUCAGUUUU 23 12648
SCNNlA-8800 + CCU U CCCAAGG AU AAAU CAG U U U U 24 12649
SCNNlA-8801 + GUCAGAGCCGGGAGUUUU 18 12650
SCNNlA-8802 + AG U CAG AG CCGGGAGUUUU 19 12651
SCNNlA-8803 + GAGUCAGAGCCGGGAGUUUU 20 12652
SCNNlA-8804 + GGAGUCAGAGCCGGGAGUUUU 21 12653
SCNNlA-8805 + AGGAGUCAGAGCCGGGAGUUUU 22 12654
SCNNlA-8806 + GAGGAGUCAGAGCCGGGAGUUUU 23 12655
SCNNlA-8807 + GGAGGAGUCAGAGCCGGGAGUUUU 24
12656
SCNNlA-8808 - G C AG C C A AC AG U G U A A A A 18 12657
SCNNlA-8809 - G G C AG C C A AC AG U G U A A A A 19 12658
SCNNlA-8810 - UGGCAGCCAACAGUGUAAAA 20 12659
SCNNlA-8811 - CUGGCAGCCAACAGUGU A A A A 21 12660
SCNNlA-8812 - CCUGGCAGCCAACAGUGUAAAA 22 12661
SCNNlA-8813 - GCCUGGCAGCCAACAGUGU A A A A 23 12662
SCNNlA-8814 - GGCCUGGCAGC C A AC AG U G U A A A A 24 12663
SCNNlA-8815 - UCUUUUAAAGUGUACAAA 18 12664
SCNNlA-8816 - AUCUUUUAAAGUGUACAAA 19 12665
SCNNlA-8817 - AAUCUUUUAAAGUGUACAAA 20 12666
SCNNlA-8818 - CAAUCUUUUAAAGUGUACAAA 21 12667
SCNNlA-8819 - ACAAUCUUUUAAAGUGUACAAA 22 12668
SCNNlA-8820 - GACAAUCU U U U AAAG UG U ACAAA 23 12669
SCNNlA-8821 - AGACAAUCUUUUAAAGUGUACAAA 24 12670
SCNNlA-8822 - GAGCAGGAGAGACCCAAA 18 12671
SCNNlA-8823 - AGAGCAGGAGAGACCCAAA 19 12672
SCNNlA-8824 - GAGAGCAGGAGAGACCCAAA 20 12673
SCNNlA-8825 - GGAGAGCAGGAGAGACCCAAA 21 12674
SCNNlA-8826 - AGGAGAGCAGGAGAGACCCAAA 22 12675
SCNNlA-8827 - GAGGAGAGCAGGAGAGACCCAAA 23 12676
SCNNlA-8828 - AGAGGAGAGCAGGAGAGACCCAAA 24 12677
SCNNlA-8829 - CAGGCAUGAGCUGGCAAA 18 12678
SCNNlA-8830 - UCAGGCAUGAGCUGGCAAA 19 12679
SCNNlA-8831 - UUCAGGCAUGAGCUGGCAAA 20 12680
SCNNlA-8832 - UUUCAGGCAUGAGCUGGCAAA 21 12681
SCNNlA-8833 - AUUUCAGGCAUGAGCUGGCAAA 22 12682
SCNNlA-8834 - GAUUUCAGGCAUGAGCUGGCAAA 23 12683
SCNNlA-8835 - GGAUUUCAGGCAUGAGCUGGCAAA 24 12684
1428
5535.1 SCNNlA-8836 - AGGGGGCAGAGACAGAAA 18 12685
SCNNlA-8837 - AAGGGGGCAGAGACAGAAA 19 12686
SCNNlA-5863 - GAAGGGGGCAGAGACAGAAA 20 9712
SCNNlA-8838 - GGAAGGGGGCAGAGACAGAAA 21 12687
SCNNlA-8839 - AGGAAGGGGGCAGAGACAGAAA 22 12688
SCNNlA-8840 - AAGGAAGGGGGCAGAGACAGAAA 23 12689
SCNNlA-8841 - AAAGGAAGGGGGCAGAGACAGAAA 24 12690
SCNNlA-8842 - GAGGAGGCAGGCCAGAAA 18 12691
SCNNlA-8843 - AGAGGAGGCAGGCCAGAAA 19 12692
SCNNlA-8844 - GAGAGGAGGCAGGCCAGAAA 20 12693
SCNNlA-8845 - AGAGAGGAGGCAGGCCAGAAA 21 12694
SCNNlA-8846 - GAGAGAGGAGGCAGGCCAGAAA 22 12695
SCNNlA-8847 - AGAGAGAGGAGGCAGGCCAGAAA 23 12696
SCNNlA-8848 - UAGAGAGAGGAGGCAGGCCAGAAA 24 12697
SCNNlA-8849 - GAGAGACCCAAAGAGAAA 18 12698
SCNNlA-8850 - GGAGAGACCCAAAGAGAAA 19 12699
SCNNlA-8851 - AGGAGAGACCCAAAGAGAAA 20 12700
SCNNlA-8852 - CAGGAGAGACCCAAAGAGAAA 21 12701
SCNNlA-8853 - GCAGGAGAGACCCAAAGAGAAA 22 12702
SCNNlA-8854 - AGCAGGAGAGACCCAAAGAGAAA 23 12703
SCNNlA-8855 - GAGCAGGAGAGACCCAAAGAGAAA 24 12704
SCNNlA-8856 - CGAGGAAUCAGCAGGAAA 18 12705
SCNNlA-8857 - GCGAGGAAUCAGCAGGAAA 19 12706
SCNNlA-8858 - GGCGAGGAAUCAGCAGGAAA 20 12707
SCNNlA-8859 - UGGCGAGGAAUCAGCAGGAAA 21 12708
SCNNlA-8860 - GUGGCGAGGAAUCAGCAGGAAA 22 12709
SCNNlA-8861 - GGUGGCGAGGAAUCAGCAGGAAA 23 12710
SCNNlA-8862 - GG G U G G CG AG G AAU C AG CAG G AAA 24 12711
SCNNlA-8863 - CUGGAGGAAGAAGACCAA 18 12712
SCNNlA-8864 - CCUGGAGGAAGAAGACCAA 19 12713
SCNNlA-5519 - UCCUGGAGGAAGAAGACCAA 20 9368
SCNNlA-8865 - AUCCUGGAGGAAGAAGACCAA 21 12714
SCNNlA-8866 - GAUCCUGGAGGAAGAAGACCAA 22 12715
SCNNlA-8867 - AGAUCCUGGAGGAAGAAGACCAA 23 12716
SCNNlA-8868 - CAGAUCCUGGAGGAAGAAGACCAA 24 12717
SCNNlA-8869 - UCCAGCUGUCCCUUCCAA 18 12718
SCNNlA-8870 - AUCCAGCUGUCCCUUCCAA 19 12719
SCNNlA-5521 - AAUCCAGCUGUCCCUUCCAA 20 9370
SCNNlA-8871 - AAAUCCAGCUGUCCCUUCCAA 21 12720
SCNNlA-8872 - AAAAUCCAGCUGUCCCUUCCAA 22 12721
SCNNlA-8873 - AAAAAUCCAGCUGUCCCUUCCAA 23 12722
SCNNlA-8874 - GAAAAAUCCAGCUGUCCCUUCCAA 24 12723
1429
5535.1 SCNNlA-1790 - CAGUAUCAAGGUAAGCAA 18 5639
SCNNlA-1791 - G C AG U A U C A AG G U A AG C A A 19 5640
SCNNlA-393 - AGCAGUAUCAAGGUAAGCAA 20 4242
SCNNlA-1792 - GAGCAGUAUCAAGGUAAGCAA 21 5641
SCNNlA-1793 - UGAGCAGUAUCAAGGUAAGCAA 22 5642
SCNNlA-1794 - AUGAGCAGUAU C A AG G U A AG C A A 23 5643
SCNNlA-1795 - CAUGAGCAGUAUCAAGGUAAGCAA 24 5644
SCNNlA-8875 - CGCAAGAGACUGCCGCAA 18 12724
SCNNlA-8876 - UCGCAAGAGACUGCCGCAA 19 12725
SCNNlA-8877 - GUCGCAAGAGACUGCCGCAA 20 12726
SCNNlA-8878 - AGUCGCAAGAGACUGCCGCAA 21 12727
SCNNlA-8879 - AAG U CGCAAG AG ACUG CCG CAA 22 12728
SCNNlA-8880 - GAAGUCGCAAGAGACUGCCGCAA 23 12729
SCNNlA-8881 - AGAAGUCGCAAGAGACUGCCGCAA 24 12730
SCNNlA-8882 - UGAGAGGGGGCAAGGCAA 18 12731
SCNNlA-8883 - GUGAGAGGGGGCAAGGCAA 19 12732
SCNNlA-6079 - AGUGAGAGGGGGCAAGGCAA 20 9928
SCNNlA-8884 - GAGUGAGAGGGGGCAAGGCAA 21 12733
SCNNlA-8885 - AGAGUGAGAGGGGGCAAGGCAA 22 12734
SCNNlA-8886 - UAGAGUGAGAGGGGGCAAGGCAA 23 12735
SCNNlA-8887 - CUAGAGUGAGAGGGGGCAAGGCAA 24 12736
SCNNlA-8888 - UGUAAGGACCUGGCUCAA 18 12737
SCNNlA-8889 - AUGUAAGGACCUGGCUCAA 19 12738
SCNNlA-5522 - AAUGUAAGGACCUGGCUCAA 20 9371
SCNNlA-8890 - CAAUGUAAGGACCUGGCUCAA 21 12739
SCNNlA-8891 - CCAAUGUAAGGACCUGGCUCAA 22 12740
SCNNlA-8892 - CCCAAUGUAAGGACCUGGCUCAA 23 12741
SCNNlA-8893 - GCCCAAUGUAAGGACCUGGCUCAA 24 12742
SCNNlA-8894 - UUUGGCUGCCAGAUUCAA 18 12743
SCNNlA-8895 - GUUUGGCUGCCAGAUUCAA 19 12744
SCNNlA-8896 - GGUUUGGCUGCCAGAUUCAA 20 12745
SCNNlA-8897 - AGGUUUGGCUGCCAGAUUCAA 21 12746
SCNNlA-8898 - GAGGUUUGGCUGCCAGAUUCAA 22 12747
SCNNlA-8899 - AGAGGUUUGGCUGCCAGAUUCAA 23 12748
SCNNlA-8900 - GAGAGGUUUGGCUGCCAGAUUCAA 24 12749
SCNNlA-8901 - AAGGGGGCAGAGACAGAA 18 12750
SCNNlA-8902 - GAAGGGGGCAGAGACAGAA 19 12751
SCNNlA-5864 - GGAAGGGGGCAGAGACAGAA 20 9713
SCNNlA-8903 - AGGAAGGGGGCAGAGACAGAA 21 12752
SCNNlA-8904 - AAGGAAGGGGGCAGAGACAGAA 22 12753
SCNNlA-8905 - AAAGGAAGGGGGCAGAGACAGAA 23 12754
SCNNlA-8906 - CAAAGGAAGGGGGCAGAGACAGAA 24 12755
1430
5535.1 SCNNlA-8907 - GGAAGAAGACCAAAGGAA 18 12756
SCNNlA-8908 - AGGAAGAAGACCAAAGGAA 19 12757
SCNNlA-5865 - GAGGAAGAAGACCAAAGGAA 20 9714
SCNNlA-8909 - G G AG G AAG AAG ACCAAAG G AA 21 12758
SCNNlA-8910 - U G GAG G AAG AAG ACCAAAG GAA 22 12759
SCNNlA-8911 - CUGGAGGAAGAAGACCAAAGGAA 23 12760
SCNNlA-8912 - CCUGGAGGAAGAAGACCAAAGGAA 24 12761
SCNNlA-8913 - GCAAGGGGGGGAGAGGAA 18 12762
SCNNlA-8914 - GGCAAGGGGGGGAGAGGAA 19 12763
SCNNlA-8915 - AGGCAAGGGGGGGAGAGGAA 20 12764
SCNNlA-8916 - AAGGCAAGGGGGGGAGAGGAA 21 12765
SCNNlA-8917 - CAAGGCAAGGGGGGGAGAGGAA 22 12766
SCNNlA-8918 - GCAAGGCAAGGGGGGGAGAGGAA 23 12767
SCNNlA-8919 - GGCAAGGCAAGGGGGGGAGAGGAA 24 12768
SCNNlA-8920 - UGCCAGAUUCAACUGGAA 18 12769
SCNNlA-8921 - CUGCCAGAUUCAACUGGAA 19 12770
SCNNlA-5173 - GCUGCCAGAUUCAACUGGAA 20 9022
SCNNlA-8922 - GGCUGCCAGAUUCAACUGGAA 21 12771
SCNNlA-8923 - UGGCUGCCAGAUUCAACUGGAA 22 12772
SCNNlA-8924 - UUGGCUGCCAGAUUCAACUGGAA 23 12773
SCNNlA-8925 - UUUGGCUGCCAGAUUCAACUGGAA 24 12774
SCNNlA-1802 - CACUCCGGGGCUCAUGAA 18 5651
SCNNlA-1803 - CCACUCCGGGGCUCAUGAA 19 5652
SCNNlA-451 - UCCACUCCGGGGCUCAUGAA 20 4300
SCNNlA-1804 - AUCCACUCCGGGGCUCAUGAA 21 5653
SCNNlA-1805 - AAUCCACUCCGGGGCUCAUGAA 22 5654
SCNNlA-1806 - CAAUCCACUCCGGGGCUCAUGAA 23 5655
SCNNlA-1807 - CCAAUCCACUCCGGGGCUCAUGAA 24 5656
SCNNlA-8926 - CGCCCUGCUCACCUUUAA 18 12775
SCNNlA-8927 - CCGCCCUGCUCACCUUUAA 19 12776
SCNNlA-8928 - CCCGCCCUGCUCACCUUUAA 20 12777
SCNNlA-8929 - CCCCGCCCUGCUCACCUUUAA 21 12778
SCNNlA-8930 - CCCCCGCCCUGCUCACCUUUAA 22 12779
SCNNlA-8931 - CCCCCCGCCCUGCUCACCUUUAA 23 12780
SCNNlA-8932 - UCCCCCCGCCCUGCUCACCUUUAA 24 12781
SCNNlA-8933 - AGUUUCUUCAUUAGGACA 18 12782
SCNNlA-8934 - CAG U U U CU U CAU U AGG ACA 19 12783
SCNNlA-8935 - UCAGUUUCUUCAUUAGGACA 20 12784
SCNNlA-8936 - GUCAGUUUCUUCAUUAGGACA 21 12785
SCNNlA-8937 - GGUCAGUUUCUUCAUUAGGACA 22 12786
SCNNlA-8938 - GGGUCAGUUUCUUCAUUAGGACA 23 12787
SCNNlA-8939 - AGGGUCAGUUUCUUCAUUAGGACA 24 12788
1431
5535.1 SCNNlA-8940 - CCUGGAGGAAGAAGACCA 18 12789
SCNNlA-8941 - UCCUGGAGGAAGAAGACCA 19 12790
SCNNlA-8942 - AUCCUGGAGGAAGAAGACCA 20 12791
SCNNlA-8943 - GAUCCUGGAGGAAGAAGACCA 21 12792
SCNNlA-8944 - AGAUCCUGGAGGAAGAAGACCA 22 12793
SCNNlA-8945 - CAGAUCCUGGAGGAAGAAGACCA 23 12794
SCNNlA-8946 - ACAGAUCCUGGAGGAAGAAGACCA 24 12795
SCNNlA-8947 - GAGAUAACCCAGCACCCA 18 12796
SCNNlA-8948 - GGAGAUAACCCAGCACCCA 19 12797
SCNNlA-8949 - AGGAGAUAACCCAGCACCCA 20 12798
SCNNlA-8950 - AAGGAGAUAACCCAGCACCCA 21 12799
SCNNlA-8951 - CAAGGAGAUAACCCAGCACCCA 22 12800
SCNNlA-8952 - CCAAGGAGAUAACCCAGCACCCA 23 12801
SCNNlA-8953 - GCCAAGGAGAUAACCCAGCACCCA 24 12802
SCNNlA-8954 - GAGAGCAGGAGAGACCCA 18 12803
SCNNlA-8955 - GGAGAGCAGGAGAGACCCA 19 12804
SCNNlA-8956 - AGGAGAGCAGGAGAGACCCA 20 12805
SCNNlA-8957 - GAGGAGAGCAGGAGAGACCCA 21 12806
SCNNlA-8958 - AGAGGAGAGCAGGAGAGACCCA 22 12807
SCNNlA-8959 - AAGAGGAGAGCAGGAGAGACCCA 23 12808
SCNNlA-8960 - AAAGAGGAGAGCAGGAGAGACCCA 24 12809
SCNNlA-8961 - GCUAAGUAGAUAGCCCCA 18 12810
SCNNlA-8962 - CGCUAAGUAGAUAGCCCCA 19 12811
SCNNlA-8963 - GCGCUAAGUAGAUAGCCCCA 20 12812
SCNNlA-8964 - AGCGCUAAGUAGAUAGCCCCA 21 12813
SCNNlA-8965 - AAGCGCUAAGUAGAUAGCCCCA 22 12814
SCNNlA-8966 - AAAGCGCUAAGUAGAUAGCCCCA 23 12815
SCNNlA-8967 - AAAAGCGCUAAGUAGAUAGCCCCA 24 12816
SCNNlA-8968 - GACCUUUUCACAGAGCCA 18 12817
SCNNlA-8969 - AGACCUUUUCACAGAGCCA 19 12818
SCNNlA-5866 - GAGACCUUUUCACAGAGCCA 20 9715
SCNNlA-8970 - AGAGACCUUUUCACAGAGCCA 21 12819
SCNNlA-8971 - CAGAGACCUUUUCACAGAGCCA 22 12820
SCNNlA-8972 - GCAGAGACCUUU UCACAGAGCCA 23 12821
SCNNlA-8973 - UGCAGAG ACCU U U UCACAGAGCCA 24 12822
SCNNlA-8974 - UCCAUCCCUGGCCGGCCA 18 12823
SCNNlA-8975 - UUCCAUCCCUGGCCGGCCA 19 12824
SCNNlA-8976 - CUUCCAUCCCUGGCCGGCCA 20 12825
SCNNlA-8977 - GCUUCCAUCCCUGGCCGGCCA 21 12826
SCNNlA-8978 - CGCUUCCAUCCCUGGCCGGCCA 22 12827
SCNNlA-8979 - UCGCUUCCAUCCCUGGCCGGCCA 23 12828
SCNNlA-8980 - GUCGCUUCCAUCCCUGGCCGGCCA 24 12829
1432
5535.1 SCNNlA-8981 - AUCCAGCUGUCCCUUCCA 18 12830
SCNNlA-8982 - AAUCCAGCUGUCCCUUCCA 19 12831
SCNNlA-5531 - AAAUCCAGCUGUCCCUUCCA 20 9380
SCNNlA-8983 - AAAAUCCAGCUGUCCCUUCCA 21 12832
SCNNlA-8984 - AAAAAUCCAGCUGUCCCUUCCA 22 12833
SCNNlA-8985 - GAAAAAUCCAGCUGUCCCUUCCA 23 12834
SCNNlA-8986 - AGAAAAAUCCAGCUGUCCCUUCCA 24 12835
SCNNlA-8987 - GGCCCUAUCAGGGAAGCA 18 12836
SCNNlA-8988 - UGGCCCUAUCAGGGAAGCA 19 12837
SCNNlA-8989 - GUGGCCCUAUCAGGGAAGCA 20 12838
SCNNlA-8990 - GGUGGCCCUAUCAGGGAAGCA 21 12839
SCNNlA-8991 - AGGUGGCCCUAUCAGGGAAGCA 22 12840
SCNNlA-8992 - AAGGUGGCCCUAUCAGGGAAGCA 23 12841
SCNNlA-8993 - AAAGGUGGCCCUAUCAGGGAAGCA 24 12842
SCNNlA-1808 - GCAGUAUCAAGGUAAGCA 18 5657
SCNNlA-1809 - AGCAGUAUCAAGGUAAGCA 19 5658
SCNNlA-342 - GAGCAGUAUCAAGGUAAGCA 20 4191
SCNNlA-1810 - UGAGCAGUAUCAAGGUAAGCA 21 5659
SCNNlA-1811 - AUGAGCAGUAUCAAGGUAAGCA 22 5660
SCNNlA-1812 - CAUGAGCAGUAUCAAGGUAAGCA 23 5661
SCNNlA-1813 - UCAUGAGCAGUAUCAAGGUAAGCA 24 5662
SCNNlA-8994 - U G G C A A A U AG A A A AG G C A 18 12843
SCNNlA-8995 - C U G G C A A A U AG A A A AG G C A 19 12844
SCNNlA-5180 - G C U G G C A A A U AG A A A AG G C A 20 9029
SCNNlA-8996 - AG C U G G C A A A U AG A A A AG G C A 21 12845
SCNNlA-8997 - G AG C U G G C A A A U AG A A A AG G C A 22 12846
SCNNlA-8998 - UGAGCUGG C A A A U AG A A A AG G C A 23 12847
SCNNlA-8999 - AUGAGCUGGCAAAUAGAAAAGGCA 24 12848
SCNNlA-9000 - GUGAGAGGGGGCAAGGCA 18 12849
SCNNlA-9001 - AGUGAGAGGGGGCAAGGCA 19 12850
SCNNlA-5868 - GAGUGAGAGGGGGCAAGGCA 20 9717
SCNNlA-9002 - AGAGUGAGAGGGGGCAAGGCA 21 12851
SCNNlA-9003 - UAGAGUGAGAGGGGGCAAGGCA 22 12852
SCNNlA-9004 - CUAGAGUGAGAGGGGGCAAGGCA 23 12853
SCNNlA-9005 - CCUAGAGUGAGAGGGGGCAAGGCA 24 12854
SCNNlA-9006 - UCUGGGAUAUGUGGGGCA 18 12855
SCNNlA-9007 - CUCUGGGAUAUGUGGGGCA 19 12856
SCNNlA-9008 - UCUCUGGGAUAUGUGGGGCA 20 12857
SCNNlA-9009 - GUCUCUGGGAUAUGUGGGGCA 21 12858
SCNNlA-9010 - GGUCUCUGGGAUAUGUGGGGCA 22 12859
SCNNlA-9011 - GGGUCUCUGGGAUAUGUGGGGCA 23 12860
1433
5535.1 SCNNlA-9012 - GGGGUCUCUGGGAUAUGUGGGGCA 24
12861
SCNNlA-9013 - CUUCCUGAGUCUCCUGCA 18 12862
SCNNlA-9014 - GCUUCCUGAGUCUCCUGCA 19 12863
SCNNlA-9015 - GGCUUCCUGAGUCUCCUGCA 20 12864
SCNNlA-9016 - AGGCUUCCUGAGUCUCCUGCA 21 12865
SCNNlA-9017 - AAGGCUUCCUGAGUCUCCUGCA 22 12866
SCNNlA-9018 - GAAGGCUUCCUGAGUCUCCUGCA 23 12867
SCNNlA-9019 - GGAAGGCUUCCUGAGUCUCCUGCA 24 12868
SCNNlA-9020 - GCUGAGCACCUUAUUGCA 18 12869
SCNNlA-9021 - UGCUGAGCACCUUAUUGCA 19 12870
SCNNlA-5184 - GUGCUGAGCACCUUAUUGCA 20 9033
SCNNlA-9022 - GGUGCUGAGCACCUUAUUGCA 21 12871
SCNNlA-9023 - GGGUGCUGAGCACCUUAUUGCA 22 12872
SCNNlA-9024 - AGGGUGCUGAGCACCUUAUUGCA 23 12873
SCNNlA-9025 - CAGGGUGCUGAGCACCUUAUUGCA 24 12874
SCNNlA-9026 - CGAAAGGUGGCCCUAUCA 18 12875
SCNNlA-9027 - UCGAAAGGUGGCCCUAUCA 19 12876
SCNNlA-5540 - CUCGAAAGGUGGCCCUAUCA 20 9389
SCNNlA-9028 - ACUCGAAAGGUGGCCCUAUCA 21 12877
SCNNlA-9029 - AACUCGAAAGGUGGCCCUAUCA 22 12878
SCNNlA-9030 - AAACUCGAAAGGUGGCCCUAUCA 23 12879
SCNNlA-9031 - AAAACUCGAAAGGUGGCCCUAUCA 24 12880
SCNNlA-9032 - AUGUAAGGACCUGGCUCA 18 12881
SCNNlA-9033 - AAUGUAAGGACCUGGCUCA 19 12882
SCNNlA-5542 - CAAUGUAAGGACCUGGCUCA 20 9391
SCNNlA-9034 - CCAAUGUAAGGACCUGGCUCA 21 12883
SCNNlA-9035 - CCCAAUGUAAGGACCUGGCUCA 22 12884
SCNNlA-9036 - GCCCAAUGUAAGGACCUGGCUCA 23 12885
SCNNlA-9037 - UGCCCAAUGUAAGGACCUGGCUCA 24 12886
SCNNlA-1814 - AGCCCAUACCAGGUCUCA 18 5663
SCNNlA-1815 - CAGCCCAUACCAGGUCUCA 19 5664
SCNNlA-1 - GCAGCCCAUACCAGGUCUCA 20 503
SCNNlA-1816 - UGCAGCCCAUACCAGGUCUCA 21 5665
SCNNlA-1817 - CUGCAGCCCAUACCAGGUCUCA 22 5666
SCNNlA-1818 - UCUGCAGCCCAUACCAGGUCUCA 23 5667
SCNNlA-1819 - CUCUGCAGCCCAUACCAGGUCUCA 24 5668
SCNNlA-9038 - GCAUUGCAAUUCUUCUCA 18 12887
SCNNlA-9039 - GGCAUUGCAAUUCUUCUCA 19 12888
SCNNlA-9040 - AGGCAUUGCAAUUCUUCUCA 20 12889
SCNNlA-9041 - CAGGCAUUGCAAUUCUUCUCA 21 12890
SCNNlA-9042 - CCAGGCAUUGCAAUUCUUCUCA 22 12891
1434
5535.1 SCNNlA-9043 - ACCAGGCAUUGCAAUUCUUCUCA 23 12892
SCNNlA-9044 - GACCAGGCAUUGCAAUUCUUCUCA 24 12893
SCNNlA-9045 - AGUGCAGAGACCUUUUCA 18 12894
SCNNlA-9046 - CAGUGCAGAGACCUUUUCA 19 12895
SCNNlA-9047 - ACAGUGCAGAGACCUUUUCA 20 12896
SCNNlA-9048 - GACAGUGCAGAGACCUUUUCA 21 12897
SCNNlA-9049 - GGACAGUGCAGAGACCUUUUCA 22 12898
SCNNlA-9050 - GGGACAGUGCAGAGACCUUUUCA 23 12899
SCNNlA-9051 - GGGGACAGUGCAGAGACCUUUUCA 24 12900
SCNNlA-9052 - CAAGAGACUGCCGCAAGA 18 12901
SCNNlA-9053 - GCAAGAGACUGCCGCAAGA 19 12902
SCNNlA-9054 - CGCAAGAGACUGCCGCAAGA 20 12903
SCNNlA-9055 - UCGCAAGAGACUGCCGCAAGA 21 12904
SCNNlA-9056 - GUCGCAAGAGACUGCCGCAAGA 22 12905
SCNNlA-9057 - AGUCGCAAGAGACUGCCGCAAGA 23 12906
SCNNlA-9058 - AAGUCGCAAGAGACUGCCGCAAGA 24 12907
SCNNlA-9059 - GAAGGGGGCAGAGACAGA 18 12908
SCNNlA-9060 - GGAAGGGGGCAGAGACAGA 19 12909
SCNNlA-9061 - AGGAAGGGGGCAGAGACAGA 20 12910
SCNNlA-9062 - AAGGAAGGGGGCAGAGACAGA 21 12911
SCNNlA-9063 - AAAGGAAGGGGGCAGAGACAGA 22 12912
SCNNlA-9064 - CAAAGGAAGGGGGCAGAGACAGA 23 12913
SCNNlA-9065 - CCAAAGGAAGGGGGCAGAGACAGA 24 12914
SCNNlA-9066 - GAGAGGAGGCAGGCCAGA 18 12915
SCNNlA-9067 - AGAGAGGAGGCAGGCCAGA 19 12916
SCNNlA-9068 - GAGAGAGGAGGCAGGCCAGA 20 12917
SCNNlA-9069 - AGAGAGAGGAGGCAGGCCAGA 21 12918
SCNNlA-9070 - UAGAGAGAGGAGGCAGGCCAGA 22 12919
SCNNlA-9071 - UUAGAGAGAGGAGGCAGGCCAGA 23 12920
SCNNlA-9072 - AUUAGAGAGAGGAGGCAGGCCAGA 24 12921
SCNNlA-9073 - AGAGAAACAGAAGGCAGA 18 12922
SCNNlA-9074 - AAGAGAAACAGAAGGCAGA 19 12923
SCNNlA-9075 - AAAG AG AAAC AG AAG G C AG A 20 12924
SCNNlA-9076 - CAAAG AG AAAC AG AAG G C AG A 21 12925
SCNNlA-9077 - CCAAAGAGAAACAGAAGGCAGA 22 12926
SCNNlA-9078 - CCCAAAGAGAAACAGAAGGCAGA 23 12927
SCNNlA-9079 - ACCCAAAGAGAAACAGAAGGCAGA 24 12928
SCNNlA-9080 - AAAGGAAGGGGGCAGAGA 18 12929
SCNNlA-9081 - CAAAGGAAGGGGGCAGAGA 19 12930
SCNNlA-9082 - C C AAAG G A AG GGGGCAGAGA 20 12931
SCNNlA-9083 - ACCAAAGGAAGGGGGCAGAGA 21 12932
SCNNlA-9084 - GACCAAAGGAAGGGGGCAGAGA 22 12933
1435
5535.1 SCNNlA-9085 - AGACCAAAGGAAGGGGGCAGAGA 23 12934
SCNNlA-9086 - AAGACCAAAGGAAGGGGGCAGAGA 24 12935
SCNNlA-9087 - GAGAGGCAGGAUUAGAGA 18 12936
SCNNlA-9088 - AGAGAGGCAGGAUUAGAGA 19 12937
SCNNlA-9089 - AAGAGAGGCAGGAUUAGAGA 20 12938
SCNNlA-9090 - GAAGAGAGGCAGGAUUAGAGA 21 12939
SCNNlA-9091 - GGAAGAGAGGCAGGAUUAGAGA 22 12940
SCNNlA-9092 - AGGAAGAGAGGCAGGAUUAGAGA 23 12941
SCNNlA-9093 - GAGGAAGAGAGGCAGGAUUAGAGA 24 12942
SCNNlA-9094 - GACCUGGCUCAAGGGAGA 18 12943
SCNNlA-9095 - GGACCUGGCUCAAGGGAGA 19 12944
SCNNlA-9096 - AGGACCUGGCUCAAGGGAGA 20 12945
SCNNlA-9097 - AAGGACCUGGCUCAAGGGAGA 21 12946
SCNNlA-9098 - UAAGGACCUGGCUCAAGGGAGA 22 12947
SCNNlA-9099 - GUAAGGACCUGGCUCAAGGGAGA 23 12948
SCNNlA-9100 - UGUAAGGACCUGGCUCAAGGGAGA 24 12949
SCNNlA-9101 - UGAGGGCCUAGAGUGAGA 18 12950
SCNNlA-9102 - CUGAGGGCCUAGAGUGAGA 19 12951
SCNNlA-5188 - GCUGAGGGCCUAGAGUGAGA 20 9037
SCNNlA-9103 - AGCUGAGGGCCUAGAGUGAGA 21 12952
SCNNlA-9104 - GAGCUGAGGGCCUAGAGUGAGA 22 12953
SCNNlA-9105 - GGAGCUGAGGGCCUAGAGUGAGA 23 12954
SCNNlA-9106 - UGGAGCUGAGGGCCUAGAGUGAGA 24 12955
SCNNlA-9107 - AAACAGAAGGCAGAUAGA 18 12956
SCNNlA-9108 - GAAACAGAAGGCAGAUAGA 19 12957
SCNNlA-9109 - AGAAACAGAAGGCAGAUAGA 20 12958
SCNNlA-9110 - GAGAAACAGAAGGCAGAUAGA 21 12959
SCNNlA-9111 - AGAGAAACAGAAGGCAGAUAGA 22 12960
SCNNlA-9112 - AAG AG AAACAGAAGGCAGAUAGA 23 12961
SCNNlA-9113 - AAAGAGAAACAGAAGGCAGAUAGA 24 12962
SCNNlA-9114 - UGGAGCUGAGGGCCUAGA 18 12963
SCNNlA-9115 - CUGGAGCUGAGGGCCUAGA 19 12964
SCNNlA-9116 - GCUGGAGCUGAGGGCCUAGA 20 12965
SCNNlA-9117 - GGCUGGAGCUGAGGGCCUAGA 21 12966
SCNNlA-9118 - AGGCUGGAGCUGAGGGCCUAGA 22 12967
SCNNlA-9119 - GAGGCUGGAGCUGAGGGCCUAGA 23 12968
SCNNlA-9120 - AGAGGCUGGAGCUGAGGGCCUAGA 24 12969
SCNNlA-9121 - AAGAGAGGCAGGAUUAGA 18 12970
SCNNlA-9122 - GAAGAGAGGCAGGAUUAGA 19 12971
SCNNlA-9123 - GGAAGAGAGGCAGGAUUAGA 20 12972
SCNNlA-9124 - AGGAAGAGAGGCAGGAUUAGA 21 12973
SCNNlA-9125 - GAGGAAGAGAGGCAGGAUUAGA 22 12974
1436
5535.1 SCNNlA-9126 - AGAGGAAGAGAGGCAGGAUUAGA 23 12975
SCNNlA-9127 - GAGAGGAAGAGAGGCAGGAUUAGA 24 12976
SCNNlA-9128 - AGGAAGAAGACCAAAGGA 18 12977
SCNNlA-9129 - GAGGAAGAAGACCAAAGGA 19 12978
SCNNlA-5873 - GGAGGAAGAAGACCAAAGGA 20 9722
SCNNlA-9130 - UGGAGGAAGAAGACCAAAGGA 21 12979
SCNNlA-9131 - CUGGAGGAAGAAGACCAAAGGA 22 12980
SCNNlA-9132 - CCUGGAGGAAGAAGACCAAAGGA 23 12981
SCNNlA-9133 - UCCUGGAGGAAGAAGACCAAAGGA 24 12982
SCNNlA-9134 - GGCGAGGAAUCAGCAGGA 18 12983
SCNNlA-9135 - UGGCGAGGAAUCAGCAGGA 19 12984
SCNNlA-9136 - GUGGCGAGGAAUCAGCAGGA 20 12985
SCNNlA-9137 - GGUGGCGAGGAAUCAGCAGGA 21 12986
SCNNlA-9138 - GGGUGGCGAGGAAUCAGCAGGA 22 12987
SCNNlA-9139 - GGGGUGGCGAGGAAUCAGCAGGA 23 12988
SCNNlA-9140 - GGGGGUGGCGAGGAAUCAGCAGGA 24 12989
SCNNlA-9141 - UGGAGGAGGGAGGGAGGA 18 12990
SCNNlA-9142 - GUGGAGGAGGGAGGGAGGA 19 12991
SCNNlA-9143 - GGUGGAGGAGGGAGGGAGGA 20 12992
SCNNlA-9144 - AGGUGGAGGAGGGAGGGAGGA 21 12993
SCNNlA-9145 - AAGGUGGAGGAGGGAGGGAGGA 22 12994
SCNNlA-9146 - AAAGGUGGAGGAGGGAGGGAGGA 23 12995
SCNNlA-9147 - GAAAGGUGGAGGAGGGAGGGAGGA 24
12996
SCNNlA-9148 - UCCAGGAAAGGUGGAGGA 18 12997
SCNNlA-9149 - CUCCAGGAAAGGUGGAGGA 19 12998
SCNNlA-5877 - GCUCCAGGAAAGGUGGAGGA 20 9726
SCNNlA-9150 - GGCUCCAGGAAAGGUGGAGGA 21 12999
SCNNlA-9151 - UGGCUCCAGGAAAGGUGGAGGA 22 13000
SCNNlA-9152 - CUGGCUCCAGGAAAGGUGGAGGA 23 13001
SCNNlA-9153 - GCUGGCUCCAGGAAAGGUGGAGGA 24 13002
SCNNlA-9154 - AAGGCAGAUAGAGAGGGA 18 13003
SCNNlA-9155 - GAAGGCAGAUAGAGAGGGA 19 13004
SCNNlA-9156 - AGAAGGCAGAUAGAGAGGGA 20 13005
SCNNlA-9157 - CAGAAGGCAGAUAGAGAGGGA 21 13006
SCNNlA-9158 - ACAGAAGGCAGAUAGAGAGGGA 22 13007
SCNNlA-9159 - AACAGAAGGCAGAUAGAGAGGGA 23 13008
SCNNlA-9160 - AAA CAGAAGGCAGAUAGAGAGGGA 24 13009
SCNNlA-9161 - GGAAAGGUGGAGGAGGGA 18 13010
SCNNlA-9162 - AGGAAAGGUGGAGGAGGGA 19 13011
SCNNlA-6095 - CAGGAAAGGUGGAGGAGGGA 20 9944
SCNNlA-9163 - CCAGGAAAGGUGGAGGAGGGA 21 13012
1437
5535.1 SCNNlA-9164 - UCCAGGAAAGGUGGAGGAGGGA 22 13013
SCNNlA-9165 - CUCCAGGAAAGGUGGAGGAGGGA 23 13014
SCNNlA-9166 - GCUCCAGGAAAGGUGGAGGAGGGA 24 13015
SCNNlA-9167 - GGCAAGGCAAGGGGGGGA 18 13016
SCNNlA-9168 - GGGCAAGGCAAGGGGGGGA 19 13017
SCNNlA-9169 - GGGGCAAGGCAAGGGGGGGA 20 13018
SCNNlA-9170 - GGGGGCAAGGCAAGGGGGGGA 21 13019
SCNNlA-9171 - AGGGGGCAAGGCAAGGGGGGGA 22 13020
SCNNlA-9172 - GAGGGGGCAAGGCAAGGGGGGGA 23 13021
SCNNlA-9173 - AGAGGGGGCAAGGCAAGGGGGGGA 24
13022
SCNNlA-1820 - GUUCCAGGGGUGAUGGGA 18 5669
SCNNlA-1821 - GGUUCCAGGGGUGAUGGGA 19 5670
SCNNlA-1822 - GGGUUCCAGGGGUGAUGGGA 20 5671
SCNNlA-1823 - CGGGUUCCAGGGGUGAUGGGA 21 5672
SCNNlA-1824 - UCGGGUUCCAGGGGUGAUGGGA 22 5673
SCNNlA-1825 - CUCGGGUUCCAGGGGUGAUGGGA 23 5674
SCNNlA-1826 - ACUCGGGUUCCAGGGGUGAUGGGA 24 5675
SCNNlA-9174 - UCCAGCCGCAACCUGGGA 18 13023
SCNNlA-9175 - GUCCAGCCGCAACCUGGGA 19 13024
SCNNlA-9176 - AGUCCAGCCGCAACCUGGGA 20 13025
SCNNlA-9177 - CAGUCCAGCCGCAACCUGGGA 21 13026
SCNNlA-9178 - CCAGUCCAGCCGCAACCUGGGA 22 13027
SCNNlA-9179 - CCCAGUCCAGCCGCAACCUGGGA 23 13028
SCNNlA-9180 - UCCCAGUCCAGCCGCAACCUGGGA 24 13029
SCNNlA-9181 - CACGGGCUCUGUGUGGGA 18 13030
SCNNlA-9182 - CCACGGGCUCUGUGUGGGA 19 13031
SCNNlA-9183 - UCCACGGGCUCUGUGUGGGA 20 13032
SCNNlA-9184 - AUCCACGGGCUCUGUGUGGGA 21 13033
SCNNlA-9185 - AAUCCACGGGCUCUGUGUGGGA 22 13034
SCNNlA-9186 - GAAUCCACGGGCUCUGUGUGGGA 23 13035
SCNNlA-9187 - CGAAUCCACGGGCUCUGUGUGGGA 24 13036
SCNNlA-1827 - CAUACCAGGUCUCAUGGA 18 5676
SCNNlA-1828 - CCAUACCAGGUCUCAUGGA 19 5677
SCNNlA-3 - CCCAUACCAGGUCUCAUGGA 20 556
SCNNlA-1829 - GCCCAUACCAGGUCUCAUGGA 21 5678
SCNNlA-1830 - AGCCCAUACCAGGUCUCAUGGA 22 5679
SCNNlA-1831 - CAGCCCAUACCAGGUCUCAUGGA 23 5680
SCNNlA-1832 - GCAGCCCAUACCAGGUCUCAUGGA 24 5681
SCNNlA-9188 - CUGCCAGAUUCAACUGGA 18 13037
SCNNlA-9189 - GCUGCCAGAUUCAACUGGA 19 13038
SCNNlA-9190 - GGCUGCCAGAUUCAACUGGA 20 13039
1438
5535.1 SCNNlA-9191 - UGGCUGCCAGAUUCAACUGGA 21 13040
SCNNlA-9192 - UUGGCUGCCAGAUUCAACUGGA 22 13041
SCNNlA-9193 - UUUGGCUGCCAGAUUCAACUGGA 23 13042
SCNNlA-9194 - GUUUGGCUGCCAGAUUCAACUGGA 24 13043
SCNNlA-9195 - UGUCUGCUGGCUUGUGGA 18 13044
SCNNlA-9196 - UUGUCUGCUGGCUUGUGGA 19 13045
SCNNlA-5552 - UUUGUCUGCUGGCUUGUGGA 20 9401
SCNNlA-9197 - CUUUGUCUGCUGGCUUGUGGA 21 13046
SCNNlA-9198 - CCUUUGUCUGCUGGCUUGUGGA 22 13047
SCNNlA-9199 - GCCUUUGUCUGCUGGCUUGUGGA 23 13048
SCNNlA-9200 - GGCCUUUGUCUGCUGGCUUGUGGA 24
13049
SCNNlA-9201 - UGCUGCAUUAAGUUUGGA 18 13050
SCNNlA-9202 - UUGCUGCAUUAAGUUUGGA 19 13051
SCNNlA-9203 - UUUGCUGCAUUAAGUUUGGA 20 13052
SCNNlA-9204 - UUUUGCUGCAUUAAGUUUGGA 21 13053
SCNNlA-9205 - CUUUUGCUGCAUUAAGUUUGGA 22 13054
SCNNlA-9206 - CCUUUUGCUGCAUUAAGUUUGGA 23 13055
SCNNlA-9207 - UCCUUUUGCUGCAUUAAGUUUGGA 24 13056
SCNNlA-1839 - CCACUCCGGGGCUCAUGA 18 5688
SCNNlA-1840 - UCCACUCCGGGGCUCAUGA 19 5689
SCNNlA-400 - AUCCACUCCGGGGCUCAUGA 20 4249
SCNNlA-1841 - AAUCCACUCCGGGGCUCAUGA 21 5690
SCNNlA-1842 - CAAUCCACUCCGGGGCUCAUGA 22 5691
SCNNlA-1843 - CCAAUCCACUCCGGGGCUCAUGA 23 5692
SCNNlA-1844 - CCCAAUCCACUCCGGGGCUCAUGA 24 5693
SCNNlA-9208 - GCUGAGGGCCUAGAGUGA 18 13057
SCNNlA-9209 - AGCUGAGGGCCUAGAGUGA 19 13058
SCNNlA-9210 - GAGCUGAGGGCCUAGAGUGA 20 13059
SCNNlA-9211 - GGAGCUGAGGGCCUAGAGUGA 21 13060
SCNNlA-9212 - UGGAGCUGAGGGCCUAGAGUGA 22 13061
SCNNlA-9213 - CUGGAGCUGAGGGCCUAGAGUGA 23 13062
SCNNlA-9214 - GCUGGAGCUGAGGGCCUAGAGUGA 24 13063
SCNNlA-9215 - GGCUCUGUGUGGGAGUGA 18 13064
SCNNlA-9216 - GGGCUCUGUGUGGGAGUGA 19 13065
SCNNlA-5555 - CGGGCUCUGUGUGGGAGUGA 20 9404
SCNNlA-9217 - ACGGGCUCUGUGUGGGAGUGA 21 13066
SCNNlA-9218 - CACGGGCUCUGUGUGGGAGUGA 22 13067
SCNNlA-9219 - CCACGGGCUCUGUGUGGGAGUGA 23 13068
SCNNlA-9220 - UCCACGGGCUCUGUGUGGGAGUGA 24 13069
SCNNlA-9221 - GCUGCUCCCACUUAGUGA 18 13070
SCNNlA-9222 - CGCUGCUCCCACUUAGUGA 19 13071
1439
5535.1 SCNNlA-9223 - GCGCUGCUCCCACUUAGUGA 20 13072
SCNNlA-9224 - UGCGCUGCUCCCACUUAGUGA 21 13073
SCNNlA-9225 - GUGCGCUGCUCCCACUUAGUGA 22 13074
SCNNlA-9226 - AGUGCGCUGCUCCCACUUAGUGA 23 13075
SCNNlA-9227 - GAGUGCGCUGCUCCCACUUAGUGA 24 13076
SCNNlA-9228 - GCUGCACCUGUCAGGUGA 18 13077
SCNNlA-9229 - CGCUGCACCUGUCAGGUGA 19 13078
SCNNlA-5556 - CCGCUGCACCUGUCAGGUGA 20 9405
SCNNlA-9230 - GCCGCUGCACCUGUCAGGUGA 21 13079
SCNNlA-9231 - GGCCGCUGCACCUGUCAGGUGA 22 13080
SCNNlA-9232 - AGGCCGCUGCACCUGUCAGGUGA 23 13081
SCNNlA-9233 - CAGGCCGCUGCACCUGUCAGGUGA 24 13082
SCNNlA-1845 - CUCGGGUUCCAGGGGUGA 18 5694
SCNNlA-1846 - ACUCGGGUUCCAGGGGUGA 19 5695
SCNNlA-401 - CACUCGGGUUCCAGGGGUGA 20 4250
SCNNlA-1847 - UCACUCGGGUUCCAGGGGUGA 21 5696
SCNNlA-1848 - CUCACUCGGGUUCCAGGGGUGA 22 5697
SCNNlA-1849 - CCUCACUCGGGUUCCAGGGGUGA 23 5698
SCNNlA-1850 - GCCUCACUCGGGUUCCAGGGGUGA 24 5699
SCNNlA-9234 - AGAAACAGAAGGCAGAUA 18 13083
SCNNlA-9235 - GAGAAACAGAAGGCAGAUA 19 13084
SCNNlA-9236 - AG AGAAACAGAAGGCAGAUA 20 13085
SCNNlA-9237 - AAGAGAAACAGAAGGCAGAUA 21 13086
SCNNlA-9238 - AAAG AGAAACAGAAGGCAGAUA 22 13087
SCNNlA-9239 - CAAAG AGAAACAGAAGGCAGAUA 23 13088
SCNNlA-9240 - CCAAAGAGAAACAGAAGGCAGAUA 24 13089
SCNNlA-9241 - CCUUUAAUUGAGAUGCUA 18 13090
SCNNlA-9242 - ACCUUUAAUUGAGAUGCUA 19 13091
SCNNlA-9243 - CACCUUUAAUUGAGAUGCUA 20 13092
SCNNlA-9244 - UCACCUUUAAUUGAGAUGCUA 21 13093
SCNNlA-9245 - CUCACCUUUAAUUGAGAUGCUA 22 13094
SCNNlA-9246 - GCUCACCUUUAAUUGAGAUGCUA 23 13095
SCNNlA-9247 - UGCUCACCUUUAAUUGAGAUGCUA 24 13096
SCNNlA-9248 - AGAGGAGAGGCCGUUCUA 18 13097
SCNNlA-9249 - CAGAGGAGAGGCCGUUCUA 19 13098
SCNNlA-5199 - GCAGAGGAGAGGCCGUUCUA 20 9048
SCNNlA-9250 - AGCAGAGGAGAGGCCGUUCUA 21 13099
SCNNlA-9251 - AAGCAGAGGAGAGGCCGUUCUA 22 13100
SCNNlA-9252 - GAAGCAGAGGAGAGGCCGUUCUA 23 13101
SCNNlA-9253 - GGAAGCAGAGGAGAGGCCGUUCUA 24 13102
SCNNlA-9254 - GGAAGAGAGGCAGGAUUA 18 13103
SCNNlA-9255 - AGGAAGAGAGGCAGGAUUA 19 13104
1440
5535.1 SCNNlA-9256 - GAGGAAGAGAGGCAGGAUUA 20 13105
SCNNlA-9257 - AGAGGAAGAGAGGCAGGAUUA 21 13106
SCNNlA-9258 - GAGAGGAAGAGAGGCAGGAUUA 22 13107
SCNNlA-9259 - GGAGAGGAAGAGAGGCAGGAUUA 23 13108
SCNNlA-9260 - GGGAGAGGAAGAGAGGCAGGAUUA 24
13109
SCNNlA-9261 - GUGCGCUGCUCCCACUUA 18 13110
SCNNlA-9262 - AGUGCGCUGCUCCCACUUA 19 13111
SCNNlA-9263 - GAGUGCGCUGCUCCCACUUA 20 13112
SCNNlA-9264 - UGAGUGCGCUGCUCCCACUUA 21 13113
SCNNlA-9265 - CUGAGUGCGCUGCUCCCACUUA 22 13114
SCNNlA-9266 - CCUGAGUGCGCUGCUCCCACUUA 23 13115
SCNNlA-9267 - ACCUGAGUGCGCUGCUCCCACUUA 24 13116
SCNNlA-9268 - GAGGUGCUAGGACAAAAC 18 13117
SCNNlA-9269 - GGAGGUGCUAGGACAAAAC 19 13118
SCNNlA-9270 - GGGAGGUGCUAGGACAAAAC 20 13119
SCNNlA-9271 - AGGGAGGUGCUAGGACAAAAC 21 13120
SCNNlA-9272 - AAGGGAGGUGCUAGGACAAAAC 22 13121
SCNNlA-9273 - AAAGGGAGGUGCUAGGACAAAAC 23 13122
SCNNlA-9274 - GAAAGGGAGGUGCUAGGACAAAAC 24 13123
SCNNlA-9275 - UCCCAGUCCAGCCGCAAC 18 13124
SCNNlA-9276 - GUCCCAGUCCAGCCGCAAC 19 13125
SCNNlA-9277 - AGUCCCAGUCCAGCCGCAAC 20 13126
SCNNlA-9278 - CAG U CCCAG U CCAGCCG CAAC 21 13127
SCNNlA-9279 - CCAGUCCCAGUCCAGCCGCAAC 22 13128
SCNNlA-9280 - ACCAGUCCCAGUCCAGCCGCAAC 23 13129
SCNNlA-9281 - AACCAG UCCCAGUCCAGCCGCAAC 24 13130
SCNNlA-9282 - UUGGCUGCCAGAUUCAAC 18 13131
SCNNlA-9283 - UUUGGCUGCCAGAUUCAAC 19 13132
SCNNlA-5202 - GUUUGGCUGCCAGAUUCAAC 20 9051
SCNNlA-9284 - GGUUUGGCUGCCAGAUUCAAC 21 13133
SCNNlA-9285 - AGGUUUGGCUGCCAGAUUCAAC 22 13134
SCNNlA-9286 - GAGGUUUGGCUGCCAGAUUCAAC 23 13135
SCNNlA-9287 - AGAGGUUUGGCUGCCAGAUUCAAC 24 13136
SCNNlA-9288 - UAGCUCCUGGAAGCACAC 18 13137
SCNNlA-9289 - CUAGCUCCUGGAAGCACAC 19 13138
SCNNlA-9290 - UCUAGCUCCUGGAAGCACAC 20 13139
SCNNlA-9291 - CUCUAGCUCCUGGAAGCACAC 21 13140
SCNNlA-9292 - CCUCUAGCUCCUGGAAGCACAC 22 13141
SCNNlA-9293 - GCCUCUAGCUCCUGGAAGCACAC 23 13142
SCNNlA-9294 - AGCCUCUAGCUCCUGGAAGCACAC 24 13143
SCNNlA-9295 - UUUCACAUCCAGGUGCAC 18 13144
1441
5535.1 SCNNlA-9296 - CUUUCACAUCCAGGUGCAC 19 13145
SCNNlA-9297 - GCUUUCACAUCCAGGUGCAC 20 13146
SCNNlA-9298 - GGCUUUCACAUCCAGGUGCAC 21 13147
SCNNlA-9299 - CGGCUUUCACAUCCAGGUGCAC 22 13148
SCNNlA-9300 - CCGGCUUUCACAUCCAGGUGCAC 23 13149
SCNNlA-9301 - CCCGGCUUUCACAUCCAGGUGCAC 24 13150
SCNNlA-9302 - CCUAGCCCCCAGCUUCAC 18 13151
SCNNlA-9303 - GCCUAGCCCCCAGCUUCAC 19 13152
SCNNlA-9304 - CGCCUAGCCCCCAGCUUCAC 20 13153
SCNNlA-9305 - CCGCCUAGCCCCCAGCUUCAC 21 13154
SCNNlA-9306 - CCCGCCUAGCCCCCAGCUUCAC 22 13155
SCNNlA-9307 - CCCCGCCUAGCCCCCAGCUUCAC 23 13156
SCNNlA-9308 - GCCCCGCCUAGCCCCCAGCUUCAC 24 13157
SCNNlA-9309 - GCAGGAAAGAGGAGGGAC 18 13158
SCNNlA-9310 - AGCAGGAAAGAGGAGGGAC 19 13159
SCNNlA-9311 - CAGCAGGAAAGAGGAGGGAC 20 13160
SCNNlA-9312 - UCAGCAGGAAAGAGGAGGGAC 21 13161
SCNNlA-9313 - AUCAGCAGGAAAGAGGAGGGAC 22 13162
SCNNlA-9314 - AAUCAGCAGGAAAGAGGAGGGAC 23 13163
SCNNlA-9315 - GAAUCAGCAGGAAAGAGGAGGGAC 24 13164
SCNNlA-1863 - GUGGGCGCAGGGUGGGAC 18 5712
SCNNlA-1864 - UGUGGGCGCAGGGUGGGAC 19 5713
SCNNlA-1865 - AUGUGGGCGCAGGGUGGGAC 20 5714
SCNNlA-1866 - AAUGUGGGCGCAGGGUGGGAC 21 5715
SCNNlA-1867 - GAAUGUGGGCGCAGGGUGGGAC 22 5716
SCNNlA-1868 - AGAAUGUGGGCGCAGGGUGGGAC 23 5717
SCNNlA-1869 - GAGAAUGUGGGCGCAGGGUGGGAC 24
5718
SCNNlA-9316 - CCCAG U CCAG CCG CAACC 18 13165
SCNNlA-9317 - UCCCAGUCCAGCCGCAACC 19 13166
SCNNlA-5213 - GUCCCAGUCCAGCCGCAACC 20 9062
SCNNlA-9318 - AG U CCCAG U CCAG CCG CAACC 21 13167
SCNNlA-9319 - CAG U CCCAG U CCAG CCG CAACC 22 13168
SCNNlA-9320 - CCAG UCCCAGUCCAGCCGCAACC 23 13169
SCNNlA-9321 - ACCAGUCCCAGUCCAGCCGCAACC 24 13170
SCNNlA-9322 - AGGAGAUAACCCAGCACC 18 13171
SCNNlA-9323 - AAGGAGAUAACCCAGCACC 19 13172
SCNNlA-9324 - CAAGGAGAUAACCCAGCACC 20 13173
SCNNlA-9325 - CCAAGGAGAUAACCCAGCACC 21 13174
SCNNlA-9326 - GCCAAGGAGAUAACCCAGCACC 22 13175
SCNNlA-9327 - AGCCAAGGAGAUAACCCAGCACC 23 13176
SCNNlA-9328 - GAGCCAAGGAGAUAACCCAGCACC 24 13177
1442
5535.1 SCNNlA-9329 - CAGGAAAGAGGAGGGACC 18 13178
SCNNlA-9330 - GCAGGAAAGAGGAGGGACC 19 13179
SCNNlA-5571 - AGCAGGAAAGAGGAGGGACC 20 9420
SCNNlA-9331 - CAGCAGGAAAGAGGAGGGACC 21 13180
SCNNlA-9332 - UCAGCAGGAAAGAGGAGGGACC 22 13181
SCNNlA-9333 - AUCAGCAGGAAAGAGGAGGGACC 23 13182
SCNNlA-9334 - AAUCAGCAGGAAAGAGGAGGGACC 24 13183
SCNNlA-9335 - CACAGACCAGGUUGGACC 18 13184
SCNNlA-9336 - CCACAGACCAGGUUGGACC 19 13185
SCNNlA-9337 - GCCACAGACCAGGUUGGACC 20 13186
SCNNlA-9338 - AGCCACAG ACCAGG U UGG ACC 21 13187
SCNNlA-9339 - AAGCCACAGACCAGGUUGGACC 22 13188
SCNNlA-9340 - GAAGCCACAGACCAGGUUGGACC 23 13189
SCNNlA-9341 - GGAAGCCACAGACCAGGUUGGACC 24 13190
SCNNlA-9342 - GCGCUAAGUAGAUAGCCC 18 13191
SCNNlA-9343 - AGCGCUAAGUAGAUAGCCC 19 13192
SCNNlA-9344 - AAGCGCUAAGUAGAUAGCCC 20 13193
SCNNlA-9345 - AAAGCGCUAAGUAGAUAGCCC 21 13194
SCNNlA-9346 - AAAAGCGCUAAGUAGAUAGCCC 22 13195
SCNNlA-9347 - C A A A AG CGCUAAGUAGAUAGCCC 23 13196
SCNNlA-9348 - GCAAAAGCGCUAAGUAGAUAGCCC 24 13197
SCNNlA-9349 - CUGCCUCCUGUGGGGCCC 18 13198
SCNNlA-9350 - GCUGCCUCCUGUGGGGCCC 19 13199
SCNNlA-9351 - GGCUGCCUCCUGUGGGGCCC 20 13200
SCNNlA-9352 - GGGCUGCCUCCUGUGGGGCCC 21 13201
SCNNlA-9353 - UGGGCUGCCUCCUGUGGGGCCC 22 13202
SCNNlA-9354 - CUGGGCUGCCUCCUGUGGGGCCC 23 13203
SCNNlA-9355 - UCUGGGCUGCCUCCUGUGGGGCCC 24 13204
SCNNlA-9356 - CUCCCAGUUCACCUGCCC 18 13205
SCNNlA-9357 - ACUCCCAGUUCACCUGCCC 19 13206
SCNNlA-9358 - UACUCCCAGUUCACCUGCCC 20 13207
SCNNlA-9359 - GUACUCCCAGUUCACCUGCCC 21 13208
SCNNlA-9360 - AGUACUCCCAGUUCACCUGCCC 22 13209
SCNNlA-9361 - CAGUACUCCCAGUUCACCUGCCC 23 13210
SCNNlA-9362 - CCAGUACUCCCAGUUCACCUGCCC 24 13211
SCNNlA-9363 - GCUGACCUGUGGGUGCCC 18 13212
SCNNlA-9364 - GGCUGACCUGUGGGUGCCC 19 13213
SCNNlA-9365 - AGGCUGACCUGUGGGUGCCC 20 13214
SCNNlA-9366 - GAGGCUGACCUGUGGGUGCCC 21 13215
SCNNlA-9367 - UGAGGCUGACCUGUGGGUGCCC 22 13216
SCNNlA-9368 - GUGAGGCUGACCUGUGGGUGCCC 23 13217
SCNNlA-9369 - GGUGAGGCUGACCUGUGGGUGCCC 24 13218
1443
5535.1 SCNNlA-9370 - AGACCUUUUCACAGAGCC 18 13219
SCNNlA-9371 - GAG ACCU U U U CACAG AG CC 19 13220
SCNNlA-9372 - AGAGACCUUUUCACAGAGCC 20 13221
SCNNlA-9373 - CAG AG ACCU U U U CACAG AGCC 21 13222
SCNNlA-9374 - GCAGAGACCUUUUCACAGAGCC 22 13223
SCNNlA-9375 - UGCAGAG ACCU U U UCACAGAGCC 23 13224
SCNNlA-9376 - G UGCAGAG ACCU U U UCACAGAGCC 24 13225
SCNNlA-1876 - GAGAGGGCACUCAGGGCC 18 5725
SCNNlA-1877 - GGAGAGGGCACUCAGGGCC 19 5726
SCNNlA-1878 - GGGAGAGGGCACUCAGGGCC 20 5727
SCNNlA-1879 - UGGGAGAGGGCACUCAGGGCC 21 5728
SCNNlA-1880 - AUGGGAGAGGGCACUCAGGGCC 22 5729
SCNNlA-1881 - GAUGGGAGAGGGCACUCAGGGCC 23 5730
SCNNlA-1882 - UGAUGGGAGAGGGCACUCAGGGCC 24 5731
SCNNlA-1889 - UGGGACAUGGGCAUGGCC 18 5738
SCNNlA-1890 - GUGGGACAUGGGCAUGGCC 19 5739
SCNNlA-347 - GGUGGGACAUGGGCAUGGCC 20 4196
SCNNlA-1891 - GGGUGGGACAUGGGCAUGGCC 21 5740
SCNNlA-1892 - AGGGUGGGACAUGGGCAUGGCC 22 5741
SCNNlA-1893 - CAGGGUGGGACAUGGGCAUGGCC 23 5742
SCNNlA-1894 - GCAGGGUGGGACAUGGGCAUGGCC 24 5743
SCNNlA-9377 - CAGAGAGCAGACGAAUCC 18 13226
SCNNlA-9378 - CCAGAGAGCAGACGAAUCC 19 13227
SCNNlA-9379 - CCCAGAGAGCAGACGAAUCC 20 13228
SCNNlA-9380 - ACCCAGAGAGCAGACGAAUCC 21 13229
SCNNlA-9381 - CACCCAGAGAGCAGACGAAUCC 22 13230
SCNNlA-9382 - GCACCCAGAGAGCAGACGAAUCC 23 13231
SCNNlA-9383 - AGCACCCAGAGAGCAGACGAAUCC 24 13232
SCNNlA-9384 - GAGCUGAGACACAGAUCC 18 13233
SCNNlA-9385 - GGAGCUGAGACACAGAUCC 19 13234
SCNNlA-5588 - AGGAGCUGAGACACAGAUCC 20 9437
SCNNlA-9386 - CAGGAGCUGAGACACAGAUCC 21 13235
SCNNlA-9387 - GCAGGAGCUGAGACACAGAUCC 22 13236
SCNNlA-9388 - GGCAGGAGCUGAGACACAGAUCC 23 13237
SCNNlA-9389 - AGGCAGGAGCUGAGACACAGAUCC 24 13238
SCNNlA-9390 - CAG AAAACUG AU U U AU CC 18 13239
SCNNlA-9391 - UCAGAAAACUGAUUUAUCC 19 13240
SCNNlA-9392 - CUCAGAAAACUGAUUUAUCC 20 13241
SCNNlA-9393 - CCUCAGAAAACUGAUUUAUCC 21 13242
SCNNlA-9394 - ACCUCAGAAAACUGAUUUAUCC 22 13243
SCNNlA-9395 - AACCUCAGAAAACUGAUUUAUCC 23 13244
SCNNlA-9396 - UAACCUCAGAAAACUGAUUUAUCC 24 13245
1444
5535.1 SCNNlA-9397 - GAGGCAGCCCAGACCUCC 18 13246
SCNNlA-9398 - GGAGGCAGCCCAGACCUCC 19 13247
SCNNlA-5591 - UGGAGGCAGCCCAGACCUCC 20 9440
SCNNlA-9399 - CUGGAGGCAGCCCAGACCUCC 21 13248
SCNNlA-9400 - GCUGGAGGCAGCCCAGACCUCC 22 13249
SCNNlA-9401 - AGCUGGAGGCAGCCCAGACCUCC 23 13250
SCNNlA-9402 - AAGCUGGAGGCAGCCCAGACCUCC 24 13251
SCNNlA-9403 - ACGAAUUUCUCCUCCUCC 18 13252
SCNNlA-9404 - AACGAAUUUCUCCUCCUCC 19 13253
SCNNlA-9405 - CAACGAAUUUCUCCUCCUCC 20 13254
SCNNlA-9406 - UCAACGAAUUUCUCCUCCUCC 21 13255
SCNNlA-9407 - AUCAACGAAUUUCUCCUCCUCC 22 13256
SCNNlA-9408 - CAUCAACGAAUUUCUCCUCCUCC 23 13257
SCNNlA-9409 - CCAUCAACGAAUUUCUCCUCCUCC 24 13258
SCNNlA-9410 - UGCUGAGCCUCUAGCUCC 18 13259
SCNNlA-9411 - UUGCUGAGCCUCUAGCUCC 19 13260
SCNNlA-5594 - CUUGCUGAGCCUCUAGCUCC 20 9443
SCNNlA-9412 - ACUUGCUGAGCCUCUAGCUCC 21 13261
SCNNlA-9413 - CACUUGCUGAGCCUCUAGCUCC 22 13262
SCNNlA-9414 - CCACUUGCUGAGCCUCUAGCUCC 23 13263
SCNNlA-9415 - CCCACUUGCUGAGCCUCUAGCUCC 24 13264
SCNNlA-9416 - CGCAGGUCUGCUGGCUCC 18 13265
SCNNlA-9417 - CCGCAGGUCUGCUGGCUCC 19 13266
SCNNlA-5595 - CCCGCAGGUCUGCUGGCUCC 20 9444
SCNNlA-9418 - UCCCGCAGGUCUGCUGGCUCC 21 13267
SCNNlA-9419 - CUCCCGCAGGUCUGCUGGCUCC 22 13268
SCNNlA-9420 - ACUCCCGCAGGUCUGCUGGCUCC 23 13269
SCNNlA-9421 - AACUCCCGCAGGUCUGCUGGCUCC 24 13270
SCNNlA-9422 - CCUGGAGCCCUGCAGUCC 18 13271
SCNNlA-9423 - UCCUGGAGCCCUGCAGUCC 19 13272
SCNNlA-6114 - CUCCUGGAGCCCUGCAGUCC 20 9963
SCNNlA-9424 - CCUCCUGGAGCCCUGCAGUCC 21 13273
SCNNlA-9425 - ACCUCCUGGAGCCCUGCAGUCC 22 13274
SCNNlA-9426 - GACCUCCUGGAGCCCUGCAGUCC 23 13275
SCNNlA-9427 - AGACCUCCUGGAGCCCUGCAGUCC 24 13276
SCNNlA-9428 - A A A A AG A AC AG A A U G U C C 18 13277
SCNNlA-9429 - AAAAAAGAACAGAAUGUCC 19 13278
SCNNlA-9430 - UAAAAAAGAACAGAAUGUCC 20 13279
SCNNlA-9431 - GU AAAAAAGAACAGAAUGUCC 21 13280
SCNNlA-9432 - UGUAAAAAAGAACAGAAUGUCC 22 13281
SCNNlA-9433 - GUGUAAAAAAGAACAGAAUGUCC 23 13282
SCNNlA-9434 - AGUGUAAAAAAGAACAGAAUGUCC 24 13283
1445
5535.1 SCNNlA-9435 - AAUCCAGCUGUCCCUUCC 18 13284
SCNNlA-9436 - AAAUCCAGCUGUCCCUUCC 19 13285
SCNNlA-9437 - AAAAUCCAGCUGUCCCUUCC 20 13286
SCNNlA-9438 - AAAAAUCCAGCUGUCCCUUCC 21 13287
SCNNlA-9439 - GAAAAAUCCAGCUGUCCCUUCC 22 13288
SCNNlA-9440 - AGAAAAAUCCAGCUGUCCCUUCC 23 13289
SCNNlA-9441 - AAGAAAAAUCCAGCUGUCCCUUCC 24 13290
SCNNlA-9442 - CCCCCUUGCUCUCCUUCC 18 13291
SCNNlA-9443 - CCCCCCUUGCUCUCCUUCC 19 13292
SCNNlA-5598 - UCCCCCCUUGCUCUCCUUCC 20 9447
SCNNlA-9444 - CUCCCCCCUUGCUCUCCUUCC 21 13293
SCNNlA-9445 - ACUCCCCCCUUGCUCUCCUUCC 22 13294
SCNNlA-9446 - GACUCCCCCCUUGCUCUCCUUCC 23 13295
SCNNlA-9447 - GGACUCCCCCCUUGCUCUCCUUCC 24 13296
SCNNlA-1895 - UCAUGAAGGGGAACAAGC 18 5744
SCNNlA-1896 - CUCAUGAAGGGGAACAAGC 19 5745
SCNNlA-176 - GCUCAUGAAGGGGAACAAGC 20 811
SCNNlA-1897 - GGCUCAUGAAGGGGAACAAGC 21 5746
SCNNlA-1898 - GGGCUCAUGAAGGGGAACAAGC 22 5747
SCNNlA-1901 - GGGGCUCAUGAAGGGGAACAAGC 23 5750
SCNNlA-1902 - CGGGGCUCAUGAAGGGGAACAAGC 24 5751
SCNNlA-1903 - UCAUGGAGGGGAACAAGC 18 5752
SCNNlA-1904 - CUCAUGGAGGGGAACAAGC 19 5753
SCNNlA-5 - UCUCAUGGAGGGGAACAAGC 20 557
SCNNlA-1905 - GUCUCAUGGAGGGGAACAAGC 21 5754
SCNNlA-1906 - GGUCUCAUGGAGGGGAACAAGC 22 5755
SCNNlA-1907 - AGGUCUCAUGGAGGGGAACAAGC 23 5756
SCNNlA-1908 - CAGGUCUCAUGGAGGGGAACAAGC 24 5757
SCNNlA-9448 - AACCUGGGAGUGGGAAGC 18 13297
SCNNlA-9449 - CAACCUGGGAGUGGGAAGC 19 13298
SCNNlA-5228 - GCAACCUGGGAGUGGGAAGC 20 9077
SCNNlA-9450 - CGCAACCUGGGAGUGGGAAGC 21 13299
SCNNlA-9451 - CCGCAACCUGGGAGUGGGAAGC 22 13300
SCNNlA-9452 - GCCGCAACCUGGGAGUGGGAAGC 23 13301
SCNNlA-9453 - AGCCGCAACCUGGGAGUGGGAAGC 24 13302
SCNNlA-1909 - AGCAGUAUCAAGGUAAGC 18 5758
SCNNlA-1910 - GAGCAGUAUCAAGGUAAGC 19 5759
SCNNlA-1911 - UGAGCAGUAUCAAGGUAAGC 20 5760
SCNNlA-1912 - AUGAGCAGUAUCAAGGUAAGC 21 5761
SCNNlA-1913 - CAUGAGCAGUAUCAAGGUAAGC 22 5762
SCNNlA-1914 - UCAUGAGCAGUAUCAAGGUAAGC 23 5763
SCNNlA-1915 - AUCAUGAGCAGUAUCAAGGUAAGC 24 5764
1446
5535.1 SCNNlA-9454 - ACAG AAU CAGG ACACAG C 18 13303
SCNNlA-9455 - GACAGAAUCAGGACACAGC 19 13304
SCNNlA-9456 - AGACAGAAUCAGGACACAGC 20 13305
SCNNlA-9457 - GAGACAGAAUCAGGACACAGC 21 13306
SCNNlA-9458 - AGAGACAGAAUCAGGACACAGC 22 13307
SCNNlA-9459 - CAG AG ACAG AAU CAGG ACACAG C 23 13308
SCNNlA-9460 - GCAGAGACAGAAUCAGGACACAGC 24 13309
SCNNlA-9461 - CAACUCUGUGACCACAGC 18 13310
SCNNlA-9462 - GCAACUCUGUGACCACAGC 19 13311
SCNNlA-5599 - UGCAACUCUGUGACCACAGC 20 9448
SCNNlA-9463 - CUGCAACUCUGUGACCACAGC 21 13312
SCNNlA-9464 - CCUGCAACUCUGUGACCACAGC 22 13313
SCNNlA-9465 - UCCUGCAACUCUGUGACCACAGC 23 13314
SCNNlA-9466 - UUCCUGCAACUCUGUGACCACAGC 24 13315
SCNNlA-9467 - GGGUGGCGAGGAAUCAGC 18 13316
SCNNlA-9468 - GGGGUGGCGAGGAAUCAGC 19 13317
SCNNlA-5229 - GGGGGUGGCGAGGAAUCAGC 20 9078
SCNNlA-9469 - AGGGGGUGGCGAGGAAUCAGC 21 13318
SCNNlA-9470 - GAGGGGGUGGCGAGGAAUCAGC 22 13319
SCNNlA-9471 - GGAGGGGGUGGCGAGGAAUCAGC 23 13320
SCNNlA-9472 - UGGAGGGGGUGGCGAGGAAUCAGC 24
13321
SCNNlA-9473 - GGCCAGAAAGAGGAGAGC 18 13322
SCNNlA-9474 - AGGCCAGAAAGAGGAGAGC 19 13323
SCNNlA-6119 - CAGGCCAGAAAGAGGAGAGC 20 9968
SCNNlA-9475 - GCAGGCCAGAAAGAGGAGAGC 21 13324
SCNNlA-9476 - GGCAGGCCAGAAAGAGGAGAGC 22 13325
SCNNlA-9477 - AGGCAGGCCAGAAAGAGGAGAGC 23 13326
SCNNlA-9478 - GAGGCAGGCCAGAAAGAGGAGAGC 24 13327
SCNNlA-9479 - CCAGGUUGGACCCUGAGC 18 13328
SCNNlA-9480 - ACCAGGUUGGACCCUGAGC 19 13329
SCNNlA-9481 - GACCAGGUUGGACCCUGAGC 20 13330
SCNNlA-9482 - AGACCAGGUUGGACCCUGAGC 21 13331
SCNNlA-9483 - CAGACCAGGUUGGACCCUGAGC 22 13332
SCNNlA-9484 - ACAGACCAGGUUGGACCCUGAGC 23 13333
SCNNlA-9485 - CACAGACCAGGUUGGACCCUGAGC 24 13334
SCNNlA-9486 - UGCUCCCACUUAGUGAGC 18 13335
SCNNlA-9487 - CUGCUCCCACUUAGUGAGC 19 13336
SCNNlA-5230 - GCUGCUCCCACUUAGUGAGC 20 9079
SCNNlA-9488 - CGCUGCUCCCACUUAGUGAGC 21 13337
SCNNlA-9489 - GCGCUGCUCCCACUUAGUGAGC 22 13338
SCNNlA-9490 - UGCGCUGCUCCCACUUAGUGAGC 23 13339
1447
5535.1 SCNNlA-9491 - GUGCGCUGCUCCCACUUAGUGAGC 24 13340
SCNNlA-9492 - GUCGCAAGAGACUGCCGC 18 13341
SCNNlA-9493 - AGUCGCAAGAGACUGCCGC 19 13342
SCNNlA-9494 - AAGUCGCAAGAGACUGCCGC 20 13343
SCNNlA-9495 - GAAGUCGCAAGAGACUGCCGC 21 13344
SCNNlA-9496 - AGAAGUCGCAAGAGACUGCCGC 22 13345
SCNNlA-9497 - AAGAAGUCGCAAGAGACUGCCGC 23 13346
SCNNlA-9498 - UAAGAAGUCGCAAGAGACUGCCGC 24 13347
SCNNlA-9499 - UUCACUUUAAGAAGUCGC 18 13348
SCNNlA-9500 - UUUCACUUUAAGAAGUCGC 19 13349
SCNNlA-9501 - CUUUCACUUUAAGAAGUCGC 20 13350
SCNNlA-9502 - GCUUUCACUUUAAGAAGUCGC 21 13351
SCNNlA-9503 - GGCUUUCACUUUAAGAAGUCGC 22 13352
SCNNlA-9504 - CGGCUUUCACUUUAAGAAGUCGC 23 13353
SCNNlA-9505 - CCGGCUUUCACUUUAAGAAGUCGC 24 13354
SCNNlA-9506 - C U G G C A A A U AG A A A AG G C 18 13355
SCNNlA-9507 - GCUGGCAAAUAGAAAAGGC 19 13356
SCNNlA-6121 - AG C U G G C A A A U AG A A A AG G C 20 9970
SCNNlA-9508 - GAGCUGGCAAAUAGAAAAGGC 21 13357
SCNNlA-9509 - UGAGCUGGCAAAUAGAAAAGGC 22 13358
SCNNlA-9510 - AUGAGCUGGCAAAUAGAAAAGGC 23 13359
SCNNlA-9511 - CAUGAGCUGGCAAAUAGAAAAGGC 24 13360
SCNNlA-9512 - AGUGAGAGGGGGCAAGGC 18 13361
SCNNlA-9513 - GAGUGAGAGGGGGCAAGGC 19 13362
SCNNlA-9514 - AGAGUGAGAGGGGGCAAGGC 20 13363
SCNNlA-9515 - UAGAGUGAGAGGGGGCAAGGC 21 13364
SCNNlA-9516 - CUAGAGUGAGAGGGGGCAAGGC 22 13365
SCNNlA-9517 - CCUAGAGUGAGAGGGGGCAAGGC 23 13366
SCNNlA-9518 - GCCUAGAGUGAGAGGGGGCAAGGC 24 13367
SCNNlA-9519 - UAGAGAGAGGAGGCAGGC 18 13368
SCNNlA-9520 - UUAGAGAGAGGAGGCAGGC 19 13369
SCNNlA-9521 - AUUAGAGAGAGGAGGCAGGC 20 13370
SCNNlA-9522 - GAUUAGAGAGAGGAGGCAGGC 21 13371
SCNNlA-9523 - GGAUUAGAGAGAGGAGGCAGGC 22 13372
SCNNlA-9524 - AGGAUUAGAGAGAGGAGGCAGGC 23 13373
SCNNlA-9525 - CAGGAUUAGAGAGAGGAGGCAGGC 24 13374
SCNNlA-9526 - AGUGGUUGGAUUUCAGGC 18 13375
SCNNlA-9527 - UAGUGGUUGGAUUUCAGGC 19 13376
SCNNlA-9528 - CUAGUGGUUGGAUUUCAGGC 20 13377
SCNNlA-9529 - GCUAGUGGUUGGAUUUCAGGC 21 13378
SCNNlA-9530 - AGCUAGUGGUUGGAUUUCAGGC 22 13379
SCNNlA-9531 - AAGCUAGUGGUUGGAUUUCAGGC 23 13380
1448
5535.1 SCNNlA-9532 - UAAGCUAGUGGUUGGAUUUCAGGC 24
13381
SCNNlA-9533 - GAGGUCAGGGCCAGAGGC 18 13382
SCNNlA-9534 - CGAGGUCAGGGCCAGAGGC 19 13383
SCNNlA-5607 - UCGAGGUCAGGGCCAGAGGC 20 9456
SCNNlA-9535 - CUCGAGGUCAGGGCCAGAGGC 21 13384
SCNNlA-9536 - GCUCGAGGUCAGGGCCAGAGGC 22 13385
SCNNlA-9537 - AGCUCGAGGUCAGGGCCAGAGGC 23 13386
SCNNlA-9538 - CAGCUCGAGGUCAGGGCCAGAGGC 24 13387
SCNNlA-9539 - AGAGAGGGAGUGAGAGGC 18 13388
SCNNlA-9540 - UAGAGAGGGAGUGAGAGGC 19 13389
SCNNlA-6123 - AUAGAGAGGGAGUGAGAGGC 20 9972
SCNNlA-9541 - GAUAGAGAGGGAGUGAGAGGC 21 13390
SCNNlA-9542 - AGAUAGAGAGGGAGUGAGAGGC 22 13391
SCNNlA-9543 - CAGAUAGAGAGGGAGUGAGAGGC 23 13392
SCNNlA-9544 - GCAGAUAGAGAGGGAGUGAGAGGC 24 13393
SCNNlA-9545 - CUCUCUUCUCUGCAGGGC 18 13394
SCNNlA-9546 - UCUCUCUUCUCUGCAGGGC 19 13395
SCNNlA-9547 - UUCUCUCUUCUCUGCAGGGC 20 13396
SCNNlA-9548 - CUUCUCUCUUCUCUGCAGGGC 21 13397
SCNNlA-9549 - UCUUCUCUCUUCUCUGCAGGGC 22 13398
SCNNlA-9550 - CUCUUCUCUCUUCUCUGCAGGGC 23 13399
SCNNlA-9551 - CCUCUUCUCUCUUCUCUGCAGGGC 24 13400
SCNNlA-9552 - ACAGCUCGAGGUCAGGGC 18 13401
SCNNlA-9553 - CACAGCUCGAGGUCAGGGC 19 13402
SCNNlA-9554 - ACACAGCUCGAGGUCAGGGC 20 13403
SCNNlA-9555 - GACACAGCUCGAGGUCAGGGC 21 13404
SCNNlA-9556 - GGACACAGCUCGAGGUCAGGGC 22 13405
SCNNlA-9557 - AGGACACAGCUCGAGGUCAGGGC 23 13406
SCNNlA-9558 - CAGGACACAGCUCGAGGUCAGGGC 24 13407
SCNNlA-1928 - GUGGGACAUGGGCAUGGC 18 5777
SCNNlA-1929 - GGUGGGACAUGGGCAUGGC 19 5778
SCNNlA-1930 - GGGUGGGACAUGGGCAUGGC 20 5779
SCNNlA-1931 - AGGGUGGGACAUGGGCAUGGC 21 5780
SCNNlA-1932 - CAGGGUGGGACAUGGGCAUGGC 22 5781
SCNNlA-1933 - GCAGGGUGGGACAUGGGCAUGGC 23 5782
SCNNlA-1934 - CGCAGGGUGGGACAUGGGCAUGGC 24 5783
SCNNlA-9559 - AAGGUUGGAGGGGGUGGC 18 13408
SCNNlA-9560 - CAAGGUUGGAGGGGGUGGC 19 13409
SCNNlA-9561 - ACAAGGUUGGAGGGGGUGGC 20 13410
SCNNlA-9562 - GACAAGGUUGGAGGGGGUGGC 21 13411
SCNNlA-9563 - GGACAAGGUUGGAGGGGGUGGC 22 13412
1449
5535.1 SCNNlA-9564 - UGGACAAGGUUGGAGGGGGUGGC 23 13413
SCNNlA-9565 - CUGGACAAGGUUGGAGGGGGUGGC 24
13414
SCNNlA-9566 - AGACAGAAAGGGAGGUGC 18 13415
SCNNlA-9567 - GAGACAGAAAGGGAGGUGC 19 13416
SCNNlA-9568 - AGAGACAGAAAGGGAGGUGC 20 13417
SCNNlA-9569 - CAGAGACAGAAAGGGAGGUGC 21 13418
SCNNlA-9570 - GCAGAGACAGAAAGGGAGGUGC 22 13419
SCNNlA-9571 - GGCAGAGACAGAAAGGGAGGUGC 23 13420
SCNNlA-9572 - GGGCAGAGACAGAAAGGGAGGUGC 24 13421
SCNNlA-9573 - UGCUGAGCACCUUAUUGC 18 13422
SCNNlA-9574 - GUGCUGAGCACCUUAUUGC 19 13423
SCNNlA-5237 - GGUGCUGAGCACCUUAUUGC 20 9086
SCNNlA-9575 - GGGUGCUGAGCACCUUAUUGC 21 13424
SCNNlA-9576 - AGGGUGCUGAGCACCUUAUUGC 22 13425
SCNNlA-9577 - CAGGGUGCUGAGCACCUUAUUGC 23 13426
SCNNlA-9578 - CCAGGGUGCUGAGCACCUUAUUGC 24 13427
SCNNlA-9579 - GGAGCUGAGACACAGAUC 18 13428
SCNNlA-9580 - AGGAGCUGAGACACAGAUC 19 13429
SCNNlA-9581 - CAGGAGCUGAGACACAGAUC 20 13430
SCNNlA-9582 - GCAGGAGCUGAGACACAGAUC 21 13431
SCNNlA-9583 - GGCAGGAGCUGAGACACAGAUC 22 13432
SCNNlA-9584 - AGGCAGGAGCUGAGACACAGAUC 23 13433
SCNNlA-9585 - GAGGCAGGAGCUGAGACACAGAUC 24 13434
SCNNlA-9586 - UCGAAAGGUGGCCCUAUC 18 13435
SCNNlA-9587 - CUCGAAAGGUGGCCCUAUC 19 13436
SCNNlA-5626 - ACUCGAAAGGUGGCCCUAUC 20 9475
SCNNlA-9588 - AACUCGAAAGGUGGCCCUAUC 21 13437
SCNNlA-9589 - AAACUCGAAAGGUGGCCCUAUC 22 13438
SCNNlA-9590 - AAAACUCGAAAGGUGGCCCUAUC 23 13439
SCNNlA-9591 - CAAAACUCGAAAGGUGGCCCUAUC 24 13440
SCNNlA-1935 - CUUCCAAGGGGAGGUAUC 18 5784
SCNNlA-1936 - CCUUCCAAGGGGAGGUAUC 19 5785
SCNNlA-1937 - CCCUUCCAAGGGGAGGUAUC 20 5786
SCNNlA-1938 - UCCCUUCCAAGGGGAGGUAUC 21 5787
SCNNlA-1939 - GUCCCUUCCAAGGGGAGGUAUC 22 5788
SCNNlA-1940 - UGUCCCUUCCAAGGGGAGGUAUC 23 5789
SCNNlA-1941 - CUGUCCCUUCCAAGGGGAGGUAUC 24 5790
SCNNlA-1942 - GCUCUCCCCAAUCCACUC 18 5791
SCNNlA-1943 - UGCUCUCCCCAAUCCACUC 19 5792
SCNNlA-410 - UUGCUCUCCCCAAUCCACUC 20 4259
SCNNlA-1944 - CUUGCUCUCCCCAAUCCACUC 21 5793
1450
5535.1 SCNNlA-1945 - CCUUGCUCUCCCCAAUCCACUC 22 5794
SCNNlA-1946 - CCCUUGCUCUCCCCAAUCCACUC 23 5795
SCNNlA-1947 - ACCCUUGCUCUCCCCAAUCCACUC 24 5796
SCNNlA-1948 - GCCCUCCACAGUCCACUC 18 5797
SCNNlA-1949 - AGCCCUCCACAGUCCACUC 19 5798
SCNNlA-170 - UAGCCCUCCACAGUCCACUC 20 808
SCNNlA-1950 - CUAGCCCUCCACAGUCCACUC 21 5799
SCNNlA-1951 - UCUAGCCCUCCACAGUCCACUC 22 5800
SCNNlA-1952 - CUCUAGCCCUCCACAGUCCACUC 23 5801
SCNNlA-1953 - ACUCUAGCCCUCCACAGUCCACUC 24 5802
SCNNlA-9592 - GGAGGCAGCCCAGACCUC 18 13441
SCNNlA-9593 - UGGAGGCAGCCCAGACCUC 19 13442
SCNNlA-9594 - CUGGAGGCAGCCCAGACCUC 20 13443
SCNNlA-9595 - GCUGGAGGCAGCCCAGACCUC 21 13444
SCNNlA-9596 - AGCUGGAGGCAGCCCAGACCUC 22 13445
SCNNlA-9597 - AAGCUGGAGGCAGCCCAGACCUC 23 13446
SCNNlA-9598 - GAAGCUGGAGGCAGCCCAGACCUC 24 13447
SCNNlA-9599 - CCCAGUUCACCUGCCCUC 18 13448
SCNNlA-9600 - UCCCAGUUCACCUGCCCUC 19 13449
SCNNlA-6132 - CUCCCAGUUCACCUGCCCUC 20 9981
SCNNlA-9601 - ACUCCCAGUUCACCUGCCCUC 21 13450
SCNNlA-9602 - UACUCCCAGUUCACCUGCCCUC 22 13451
SCNNlA-9603 - GUACUCCCAGUUCACCUGCCCUC 23 13452
SCNNlA-9604 - AGUACUCCCAGUUCACCUGCCCUC 24 13453
SCNNlA-9605 - UUGCUGAGCCUCUAGCUC 18 13454
SCNNlA-9606 - CUUGCUGAGCCUCUAGCUC 19 13455
SCNNlA-9607 - ACUUGCUGAGCCUCUAGCUC 20 13456
SCNNlA-9608 - CACUUGCUGAGCCUCUAGCUC 21 13457
SCNNlA-9609 - CCACUUGCUGAGCCUCUAGCUC 22 13458
SCNNlA-9610 - CCCACUUGCUGAGCCUCUAGCUC 23 13459
SCNNlA-9611 - GCCCACUUGCUGAGCCUCUAGCUC 24 13460
SCNNlA-1960 - CAAUCCACUCCGGGGCUC 18 5809
SCNNlA-1961 - CCAAUCCACUCCGGGGCUC 19 5810
SCNNlA-1962 - CCCAAUCCACUCCGGGGCUC 20 5811
SCNNlA-1963 - CCCCAAUCCACUCCGGGGCUC 21 5812
SCNNlA-1964 - UCCCCAAUCCACUCCGGGGCUC 22 5813
SCNNlA-1965 - CUCCCCAAUCCACUCCGGGGCUC 23 5814
SCNNlA-1966 - UCUCCCCAAUCCACUCCGGGGCUC 24 5815
SCNNlA-9612 - AAUGUAAGGACCUGGCUC 18 13461
SCNNlA-9613 - CAAUGUAAGGACCUGGCUC 19 13462
SCNNlA-9614 - CCAAUGUAAGGACCUGGCUC 20 13463
SCNNlA-9615 - CCCAAUGUAAGGACCUGGCUC 21 13464
1451
5535.1 SCNNlA-9616 - GCCCAAUGUAAGGACCUGGCUC 22 13465
SCNNlA-9617 - UGCCCAAUGUAAGGACCUGGCUC 23 13466
SCNNlA-9618 - AUGCCCAAUGUAAGGACCUGGCUC 24 13467
SCNNlA-9619 - CCGCAGGUCUGCUGGCUC 18 13468
SCNNlA-9620 - CCCGCAGGUCUGCUGGCUC 19 13469
SCNNlA-9621 - UCCCGCAGGUCUGCUGGCUC 20 13470
SCNNlA-9622 - CUCCCGCAGGUCUGCUGGCUC 21 13471
SCNNlA-9623 - ACUCCCGCAGGUCUGCUGGCUC 22 13472
SCNNlA-9624 - AACUCCCGCAGGUCUGCUGGCUC 23 13473
SCNNlA-9625 - CAACUCCCGCAGGUCUGCUGGCUC 24 13474
SCNNlA-1967 - CAGCCCAUACCAGGUCUC 18 5816
SCNNlA-1968 - GCAGCCCAUACCAGGUCUC 19 5817
SCNNlA-159 - UGCAGCCCAUACCAGGUCUC 20 803
SCNNlA-1969 - CUGCAGCCCAUACCAGGUCUC 21 5818
SCNNlA-1970 - UCUGCAGCCCAUACCAGGUCUC 22 5819
SCNNlA-1971 - CUCUGCAGCCCAUACCAGGUCUC 23 5820
SCNNlA-1972 - CCUCUGCAGCCCAUACCAGGUCUC 24 5821
SCNNlA-9626 - CCCCCAUGAGUCUGUCUC 18 13475
SCNNlA-9627 - UCCCCCAUGAGUCUGUCUC 19 13476
SCNNlA-5636 - AUCCCCCAUGAGUCUGUCUC 20 9485
SCNNlA-9628 - GAUCCCCCAUGAGUCUGUCUC 21 13477
SCNNlA-9629 - CGAUCCCCCAUGAGUCUGUCUC 22 13478
SCNNlA-9630 - CCGAUCCCCCAUGAGUCUGUCUC 23 13479
SCNNlA-9631 - CCCGAUCCCCCAUGAGUCUGUCUC 24 13480
SCNNlA-9632 - CAGAGAUGACACCUUCUC 18 13481
SCNNlA-9633 - GCAGAGAUGACACCUUCUC 19 13482
SCNNlA-5637 - AGCAGAGAUGACACCUUCUC 20 9486
SCNNlA-9634 - CAGCAGAGAUGACACCUUCUC 21 13483
SCNNlA-9635 - UCAGCAGAGAUGACACCUUCUC 22 13484
SCNNlA-9636 - UUCAGCAGAGAUGACACCUUCUC 23 13485
SCNNlA-9637 - AUUCAGCAGAGAUGACACCUUCUC 24 13486
SCNNlA-9638 - UCCUGGAGCCCUGCAGUC 18 13487
SCNNlA-9639 - CUCCUGGAGCCCUGCAGUC 19 13488
SCNNlA-9640 - CCUCCUGGAGCCCUGCAGUC 20 13489
SCNNlA-9641 - ACCUCCUGGAGCCCUGCAGUC 21 13490
SCNNlA-9642 - GACCUCCUGGAGCCCUGCAGUC 22 13491
SCNNlA-9643 - AGACCUCCUGGAGCCCUGCAGUC 23 13492
SCNNlA-9644 - CAGACCUCCUGGAGCCCUGCAGUC 24 13493
SCNNlA-9645 - CCCCCCUUGCUCUCCUUC 18 13494
SCNNlA-9646 - UCCCCCCUUGCUCUCCUUC 19 13495
SCNNlA-9647 - CUCCCCCCUUGCUCUCCUUC 20 13496
SCNNlA-9648 - ACUCCCCCCUUGCUCUCCUUC 21 13497
1452
5535.1 SCNNlA-9649 - GACUCCCCCCUUGCUCUCCUUC 22 13498
SCNNlA-9650 - GGACUCCCCCCUUGCUCUCCUUC 23 13499
SCNNlA-9651 - GGGACUCCCCCCUUGCUCUCCUUC 24 13500
SCNNlA-9652 - UGCUUUCCCUGCCUCUUC 18 13501
SCNNlA-9653 - CUGCUUUCCCUGCCUCUUC 19 13502
SCNNlA-9654 - CCUGCUUUCCCUGCCUCUUC 20 13503
SCNNlA-9655 - GCCUGCUUUCCCUGCCUCUUC 21 13504
SCNNlA-9656 - UGCCUGCUUUCCCUGCCUCUUC 22 13505
SCNNlA-9657 - GUGCCUGCUUUCCCUGCCUCUUC 23 13506
SCNNlA-9658 - AGUGCCUGCUUUCCCUGCCUCUUC 24 13507
SCNNlA-9659 - GCAGAGGAGAGGCCGUUC 18 13508
SCNNlA-9660 - AGCAGAGGAGAGGCCGUUC 19 13509
SCNNlA-9661 - AAGCAGAGGAGAGGCCGUUC 20 13510
SCNNlA-9662 - GAAGCAGAGGAGAGGCCGUUC 21 13511
SCNNlA-9663 - GGAAGCAGAGGAGAGGCCGUUC 22 13512
SCNNlA-9664 - GGGAAGCAGAGGAGAGGCCGUUC 23 13513
SCNNlA-9665 - AGGGAAGCAGAGGAGAGGCCGUUC 24 13514
SCNNlA-1973 - GCAGCCUCACUCGGGUUC 18 5822
SCNNlA-1974 - GGCAGCCUCACUCGGGUUC 19 5823
SCNNlA-1975 - GGGCAGCCUCACUCGGGUUC 20 5824
SCNNlA-1976 - GGGGCAGCCUCACUCGGGUUC 21 5825
SCNNlA-1977 - AGGGGCAGCCUCACUCGGGUUC 22 5826
SCNNlA-1978 - CAGGGGCAGCCUCACUCGGGUUC 23 5827
SCNNlA-1979 - CCAGGGGCAGCCUCACUCGGGUUC 24 5828
SCNNlA-9666 - AAGGGAGACUGGAGUUUC 18 13515
SCNNlA-9667 - CAAGGGAGACUGGAGUUUC 19 13516
SCNNlA-9668 - UCAAGGGAGACUGGAGUUUC 20 13517
SCNNlA-9669 - CUCAAGGGAGACUGGAGUUUC 21 13518
SCNNlA-9670 - GCUCAAGGGAGACUGGAGUUUC 22 13519
SCNNlA-9671 - GGCUCAAGGGAGACUGGAGUUUC 23 13520
SCNNlA-9672 - UGGCUCAAGGGAGACUGGAGUUUC 24 13521
SCNNlA-9673 - AGGAGGCAGGCCAGAAAG 18 13522
SCNNlA-9674 - GAGGAGGCAGGCCAGAAAG 19 13523
SCNNlA-6139 - AGAGGAGGCAGGCCAGAAAG 20 9988
SCNNlA-9675 - GAGAGGAGGCAGGCCAGAAAG 21 13524
SCNNlA-9676 - AGAGAGGAGGCAGGCCAGAAAG 22 13525
SCNNlA-9677 - GAGAGAGGAGGCAGGCCAGAAAG 23 13526
SCNNlA-9678 - AGAGAGAGGAGGCAGGCCAGAAAG 24 13527
SCNNlA-9679 - CUGCUGGCUCCAGGAAAG 18 13528
SCNNlA-9680 - UCUGCUGGCUCCAGGAAAG 19 13529
SCNNlA-9681 - GUCUGCUGGCUCCAGGAAAG 20 13530
SCNNlA-9682 - GGUCUGCUGGCUCCAGGAAAG 21 13531
1453
5535.1 SCNNlA-9683 - AGGUCUGCUGGCUCCAGGAAAG 22 13532
SCNNlA-9684 - CAGGUCUGCUGGCUCCAGGAAAG 23 13533
SCNNlA-9685 - GCAGGUCUGCUGGCUCCAGGAAAG 24 13534
SCNNlA-9686 - G AG G A A U C AG C AG G A A AG 18 13535
SCNNlA-9687 - CGAGGAAUCAGCAGGAAAG 19 13536
SCNNlA-5244 - GCGAGGAAUCAGCAGGAAAG 20 9093
SCNNlA-9688 - GGCGAGGAAUCAGCAGGAAAG 21 13537
SCNNlA-9689 - UGGCGAGGAAUCAGCAGGAAAG 22 13538
SCNNlA-9690 - GUGGCGAGGAAUCAGCAGGAAAG 23 13539
SCNNlA-9691 - GGUGGCGAGGAAUCAGCAGGAAAG 24 13540
SCNNlA-1980 - CUCAUGAAGGGGAACAAG 18 5829
SCNNlA-1981 - GCUCAUGAAGGGGAACAAG 19 5830
SCNNlA-1982 - GGCUCAUGAAGGGGAACAAG 20 5831
SCNNlA-1983 - GGGCUCAUGAAGGGGAACAAG 21 5832
SCNNlA-1984 - GGGGCUCAUGAAGGGGAACAAG 22 5833
SCNNlA-1985 - CGGGGCUCAUGAAGGGGAACAAG 23 5834
SCNNlA-1986 - CCGGGGCUCAUGAAGGGGAACAAG 24 5835
SCNNlA-1987 - CUCAUGGAGGGGAACAAG 18 5836
SCNNlA-1988 - UCUCAUGGAGGGGAACAAG 19 5837
SCNNlA-165 - GUCUCAUGGAGGGGAACAAG 20 805
SCNNlA-1989 - GGUCUCAUGGAGGGGAACAAG 21 5838
SCNNlA-1990 - AGGUCUCAUGGAGGGGAACAAG 22 5839
SCNNlA-1991 - CAGGUCUCAUGGAGGGGAACAAG 23 5840
SCNNlA-1992 - CCAGGUCUCAUGGAGGGGAACAAG 24 5841
SCNNlA-1993 - CCAGCUGUCCCUUCCAAG 18 5842
SCNNlA-1994 - UCCAGCUGUCCCUUCCAAG 19 5843
SCNNlA-412 - AUCCAGCUGUCCCUUCCAAG 20 4261
SCNNlA-9692 - AAUCCAGCUGUCCCUUCCAAG 21 13541
SCNNlA-9693 - AAAUCCAGCUGUCCCUUCCAAG 22 13542
SCNNlA-9694 - AAAAUCCAGCUGUCCCUUCCAAG 23 13543
SCNNlA-9695 - AAAAAUCCAGCUGUCCCUUCCAAG 24 13544
SCNNlA-9696 - GAGAGGGGGCAAGGCAAG 18 13545
SCNNlA-9697 - UGAGAGGGGGCAAGGCAAG 19 13546
SCNNlA-5246 - GUGAGAGGGGGCAAGGCAAG 20 9095
SCNNlA-9698 - AGUGAGAGGGGGCAAGGCAAG 21 13547
SCNNlA-9699 - GAGUGAGAGGGGGCAAGGCAAG 22 13548
SCNNlA-9700 - AGAGUGAGAGGGGGCAAGGCAAG 23 13549
SCNNlA-9701 - UAGAGUGAGAGGGGGCAAGGCAAG 24 13550
SCNNlA-9702 - GUGGCCCUAUCAGGGAAG 18 13551
SCNNlA-9703 - GGUGGCCCUAUCAGGGAAG 19 13552
SCNNlA-9704 - AGGUGGCCCUAUCAGGGAAG 20 13553
SCNNlA-9705 - AAGGUGGCCCUAUCAGGGAAG 21 13554
1454
5535.1 SCNNlA-9706 - AAAGGUGGCCCUAUCAGGGAAG 22 13555
SCNNlA-9707 - GAAAGGUGGCCCUAUCAGGGAAG 23 13556
SCNNlA-9708 - CGAAAGGUGGCCCUAUCAGGGAAG 24 13557
SCNNlA-9709 - CAACCUGGGAGUGGGAAG 18 13558
SCNNlA-9710 - GCAACCUGGGAGUGGGAAG 19 13559
SCNNlA-9711 - CGCAACCUGGGAGUGGGAAG 20 13560
SCNNlA-9712 - CCGCAACCUGGGAGUGGGAAG 21 13561
SCNNlA-9713 - GCCGCAACCUGGGAGUGGGAAG 22 13562
SCNNlA-9714 - AGCCGCAACCUGGGAGUGGGAAG 23 13563
SCNNlA-9715 - CAGCCGCAACCUGGGAGUGGGAAG 24 13564
SCNNlA-2001 - ACUCCGGGGCUCAUGAAG 18 5850
SCNNlA-2002 - CACUCCGGGGCUCAUGAAG 19 5851
SCNNlA-453 - CCACUCCGGGGCUCAUGAAG 20 4302
SCNNlA-2003 - UCCACUCCGGGGCUCAUGAAG 21 5852
SCNNlA-2004 - AUCCACUCCGGGGCUCAUGAAG 22 5853
SCNNlA-2005 - AAUCCACUCCGGGGCUCAUGAAG 23 5854
SCNNlA-2006 - CAAUCCACUCCGGGGCUCAUGAAG 24 5855
SCNNlA-9716 - GCAACUCUGUGACCACAG 18 13565
SCNNlA-9717 - UGCAACUCUGUGACCACAG 19 13566
SCNNlA-9718 - CUGCAACUCUGUGACCACAG 20 13567
SCNNlA-9719 - CCUGCAACUCUGUGACCACAG 21 13568
SCNNlA-9720 - UCCUGCAACUCUGUGACCACAG 22 13569
SCNNlA-9721 - UUCCUGCAACUCUGUGACCACAG 23 13570
SCNNlA-9722 - AUUCCUGCAACUCUGUGACCACAG 24 13571
SCNNlA-9723 - GGAAAGAGGAGGGACCAG 18 13572
SCNNlA-9724 - AGGAAAGAGGAGGGACCAG 19 13573
SCNNlA-9725 - CAGGAAAGAGGAGGGACCAG 20 13574
SCNNlA-9726 - GCAGGAAAGAGGAGGGACCAG 21 13575
SCNNlA-9727 - AGCAGGAAAGAGGAGGGACCAG 22 13576
SCNNlA-9728 - CAGCAGGAAAGAGGAGGGACCAG 23 13577
SCNNlA-9729 - UCAGCAGGAAAGAGGAGGGACCAG 24 13578
SCNNlA-9730 - CUAAGUAGAUAGCCCCAG 18 13579
SCNNlA-9731 - GCUAAGUAGAUAGCCCCAG 19 13580
SCNNlA-5646 - CGCUAAGUAGAUAGCCCCAG 20 9495
SCNNlA-9732 - GCGCUAAGUAGAUAGCCCCAG 21 13581
SCNNlA-9733 - AGCGCUAAGUAGAUAGCCCCAG 22 13582
SCNNlA-9734 - AAGCGCUAAGUAGAUAGCCCCAG 23 13583
SCNNlA-9735 - AAAGCGCUAAGUAGAUAGCCCCAG 24 13584
SCNNlA-9736 - GCCCUAUCAGGGAAGCAG 18 13585
SCNNlA-9737 - GGCCCUAUCAGGGAAGCAG 19 13586
SCNNlA-5649 - UGGCCCUAUCAGGGAAGCAG 20 9498
SCNNlA-9738 - GUGGCCCUAUCAGGGAAGCAG 21 13587
1455
5535.1 SCNNlA-9739 - GGUGGCCCUAUCAGGGAAGCAG 22 13588
SCNNlA-9740 - AGGUGGCCCUAUCAGGGAAGCAG 23 13589
SCNNlA-9741 - AAGGUGGCCCUAUCAGGGAAGCAG 24 13590
SCNNlA-9742 - CCAGAAAGAGGAGAGCAG 18 13591
SCNNlA-9743 - G CCAG AAAG AGG AG AG CAG 19 13592
SCNNlA-9744 - GG CCAGAAAGAGGAGAGCAG 20 13593
SCNNlA-9745 - AGGCCAGAAAGAGGAGAGCAG 21 13594
SCNNlA-9746 - CAGGCCAGAAAGAGGAGAGCAG 22 13595
SCNNlA-9747 - GCAGGCCAGAAAGAGGAGAGCAG 23 13596
SCNNlA-9748 - GGCAGGCCAGAAAGAGGAGAGCAG 24 13597
SCNNlA-9749 - CUGGGAUAUGUGGGGCAG 18 13598
SCNNlA-9750 - UCUGGGAUAUGUGGGGCAG 19 13599
SCNNlA-5651 - CUCUGGGAUAUGUGGGGCAG 20 9500
SCNNlA-9751 - UCUCUGGGAUAUGUGGGGCAG 21 13600
SCNNlA-9752 - GUCUCUGGGAUAUGUGGGGCAG 22 13601
SCNNlA-9753 - GGUCUCUGGGAUAUGUGGGGCAG 23 13602
SCNNlA-9754 - GGGUCUCUGGGAUAUGUGGGGCAG 24
13603
SCNNlA-9755 - GGGGUGGCGAGGAAUCAG 18 13604
SCNNlA-9756 - GGGGGUGGCGAGGAAUCAG 19 13605
SCNNlA-9757 - AGGGGGUGGCGAGGAAUCAG 20 13606
SCNNlA-9758 - GAGGGGGUGGCGAGGAAUCAG 21 13607
SCNNlA-9759 - GGAGGGGGUGGCGAGGAAUCAG 22 13608
SCNNlA-9760 - UGGAGGGGGUGGCGAGGAAUCAG 23 13609
SCNNlA-9761 - UUGGAGGGGGUGGCGAGGAAUCAG 24
13610
SCNNlA-9762 - GGCCGCUGCACCUGUCAG 18 13611
SCNNlA-9763 - AGGCCGCUGCACCUGUCAG 19 13612
SCNNlA-9764 - CAGGCCGCUGCACCUGUCAG 20 13613
SCNNlA-9765 - CCAGGCCGCUGCACCUGUCAG 21 13614
SCNNlA-9766 - GCCAGGCCGCUGCACCUGUCAG 22 13615
SCNNlA-9767 - AGCCAGGCCGCUGCACCUGUCAG 23 13616
SCNNlA-9768 - CAGCCAGGCCGCUGCACCUGUCAG 24 13617
SCNNlA-9769 - UUGCUUGUCAAGAUUCAG 18 13618
SCNNlA-9770 - CUUGCUUGUCAAGAUUCAG 19 13619
SCNNlA-9771 - CCUUGCUUGUCAAGAUUCAG 20 13620
SCNNlA-9772 - UCCUUGCUUGUCAAGAUUCAG 21 13621
SCNNlA-9773 - CUCCUUGCUUGUCAAGAUUCAG 22 13622
SCNNlA-9774 - ACUCCUUGCUUGUCAAGAUUCAG 23 13623
SCNNlA-9775 - AACUCCUUGCUUGUCAAGAUUCAG 24 13624
SCNNlA-9776 - GAGGCAGGCCAGAAAGAG 18 13625
SCNNlA-9777 - GGAGGCAGGCCAGAAAGAG 19 13626
1456
5535.1 SCNNlA-9778 - AGGAGGCAGGCCAGAAAGAG 20 13627
SCNNlA-9779 - GAGGAGGCAGGCCAGAAAGAG 21 13628
SCNNlA-9780 - AGAGGAGGCAGGCCAGAAAGAG 22 13629
SCNNlA-9781 - GAGAGGAGGCAGGCCAGAAAGAG 23 13630
SCNNlA-9782 - AGAGAGGAGGCAGGCCAGAAAGAG 24 13631
SCNNlA-9783 - GGAAUCAGCAGGAAAGAG 18 13632
SCNNlA-9784 - AGGAAUCAGCAGGAAAGAG 19 13633
SCNNlA-9785 - GAGGAAUCAGCAGGAAAGAG 20 13634
SCNNlA-9786 - CGAGGAAUCAGCAGGAAAGAG 21 13635
SCNNlA-9787 - GCGAGGAAUCAGCAGGAAAGAG 22 13636
SCNNlA-9788 - GGCGAGGAAUCAGCAGGAAAGAG 23 13637
SCNNlA-9789 - UGGCGAGGAAUCAGCAGGAAAGAG 24 13638
SCNNlA-9790 - AAGAGACUGCCGCAAGAG 18 13639
SCNNlA-9791 - CAAGAGACUGCCGCAAGAG 19 13640
SCNNlA-5249 - GCAAGAGACUGCCGCAAGAG 20 9098
SCNNlA-9792 - CGCAAGAGACUGCCGCAAGAG 21 13641
SCNNlA-9793 - U CGCAAG AG ACUG CCG CAAG AG 22 13642
SCNNlA-9794 - G U CGCAAG AG ACUG CCG CAAG AG 23 13643
SCNNlA-9795 - AGUCGCAAGAGACUGCCGCAAGAG 24 13644
SCNNlA-9796 - AAGUAGAUAGCCCCAGAG 18 13645
SCNNlA-9797 - UAAGUAGAUAGCCCCAGAG 19 13646
SCNNlA-9798 - CUAAGUAGAUAGCCCCAGAG 20 13647
SCNNlA-9799 - GCUAAGUAGAUAGCCCCAGAG 21 13648
SCNNlA-9800 - CGCU AAGUAGAUAGCCCCAGAG 22 13649
SCNNlA-9801 - GCGCUAAGUAGAUAGCCCCAGAG 23 13650
SCNNlA-9802 - AGCGCUAAGUAGAUAGCCCCAGAG 24 13651
SCNNlA-9803 - CCUAUCAGGGAAGCAGAG 18 13652
SCNNlA-9804 - CCCUAUCAGGGAAGCAGAG 19 13653
SCNNlA-9805 - GCCCUAUCAGGGAAGCAGAG 20 13654
SCNNlA-9806 - GGCCCUAUCAGGGAAGCAGAG 21 13655
SCNNlA-9807 - UGGCCCUAUCAGGGAAGCAGAG 22 13656
SCNNlA-9808 - GUGGCCCUAUCAGGGAAGCAGAG 23 13657
SCNNlA-9809 - GGUGGCCCUAUCAGGGAAGCAGAG 24 13658
SCNNlA-9810 - AGAGGCAGGAUUAGAGAG 18 13659
SCNNlA-9811 - GAGAGGCAGGAUUAGAGAG 19 13660
SCNNlA-6147 - AGAGAGGCAGGAUUAGAGAG 20 9996
SCNNlA-9812 - AAGAGAGGCAGGAUUAGAGAG 21 13661
SCNNlA-9813 - GAAG AGAGGCAGGAUUAGAGAG 22 13662
SCNNlA-9814 - GGAAGAGAGGCAGGAUUAGAGAG 23 13663
SCNNlA-9815 - AGGAAGAGAGGCAGGAUUAGAGAG 24 13664
SCNNlA-9816 - AGGCCAGAAAGAGGAGAG 18 13665
SCNNlA-9817 - CAGGCCAGAAAGAGGAGAG 19 13666
1457
5535.1 SCNNlA-9818 - GCAGGCCAGAAAGAGGAGAG 20 13667
SCNNlA-9819 - GGCAGGCCAGAAAGAGGAGAG 21 13668
SCNNlA-9820 - AGGCAGGCCAGAAAGAGGAGAG 22 13669
SCNNlA-9821 - GAGGCAGGCCAGAAAGAGGAGAG 23 13670
SCNNlA-9822 - GGAGGCAGGCCAGAAAGAGGAGAG 24 13671
SCNNlA-9823 - AACAGAAGGCAGAUAGAG 18 13672
SCNNlA-9824 - AAACAGAAGGCAGAUAGAG 19 13673
SCNNlA-5250 - GAAACAGAAGGCAGAUAGAG 20 9099
SCNNlA-9825 - AGAAACAGAAGGCAGAUAGAG 21 13674
SCNNlA-9826 - GAGAAACAGAAGGCAGAUAGAG 22 13675
SCNNlA-9827 - AG AG AAACAGAAGGCAGAUAGAG 23 13676
SCNNlA-9828 - AAGAGAAACAGAAGGCAGAUAGAG 24 13677
SCNNlA-9829 - GGGAGUGAGAGGCAGGAG 18 13678
SCNNlA-9830 - AGGGAGUGAGAGGCAGGAG 19 13679
SCNNlA-9831 - GAGGGAGUGAGAGGCAGGAG 20 13680
SCNNlA-9832 - AGAGGGAGUGAGAGGCAGGAG 21 13681
SCNNlA-9833 - GAGAGGGAGUGAGAGGCAGGAG 22 13682
SCNNlA-9834 - AGAGAGGGAGUGAGAGGCAGGAG 23 13683
SCNNlA-9835 - UAGAGAGGGAGUGAGAGGCAGGAG 24
13684
SCNNlA-9836 - UAGAUAGCCCCAGAGGAG 18 13685
SCNNlA-9837 - GUAGAUAGCCCCAGAGGAG 19 13686
SCNNlA-9838 - AGUAGAUAGCCCCAGAGGAG 20 13687
SCNNlA-9839 - AAGUAGAUAGCCCCAGAGGAG 21 13688
SCNNlA-9840 - UAAGUAGAUAGCCCCAGAGGAG 22 13689
SCNNlA-9841 - CUAAGUAGAUAGCCCCAGAGGAG 23 13690
SCNNlA-9842 - GCUAAGUAGAUAGCCCCAGAGGAG 24 13691
SCNNlA-9843 - GGAGGAGGGAGGGAGGAG 18 13692
SCNNlA-9844 - UGGAGGAGGGAGGGAGGAG 19 13693
SCNNlA-5897 - GUGGAGGAGGGAGGGAGGAG 20 9746
SCNNlA-9845 - GGUGGAGGAGGGAGGGAGGAG 21 13694
SCNNlA-9846 - AGGUGGAGGAGGGAGGGAGGAG 22 13695
SCNNlA-9847 - AAGGUGGAGGAGGGAGGGAGGAG 23 13696
SCNNlA-9848 - AAAGGUGGAGGAGGGAGGGAGGAG 24
13697
SCNNlA-2007 - GGGAACAAGCUGGAGGAG 18 5856
SCNNlA-2008 - GGGGAACAAGCUGGAGGAG 19 5857
SCNNlA-169 - AGGGGAACAAGCUGGAGGAG 20 807
SCNNlA-2009 - AAGGGGAACAAGCUGGAGGAG 21 5858
SCNNlA-2010 - GAAGGGGAACAAGCUGGAGGAG 22 5859
SCNNlA-2011 - UGAAGGGGAACAAGCUGGAGGAG 23 5860
SCNNlA-2012 - AUGAAGGGGAACAAGCUGGAGGAG 24 5861
1458
5535.1 SCNNlA-2013 - GAGGGGAACAAGCUGGAGGAG 21 5862
SCNNlA-2014 - GGAGGGGAACAAGCUGGAGGAG 22 5863
SCNNlA-2015 - UGGAGGGGAACAAGCUGGAGGAG 23 5864
SCNNlA-2016 - AUGGAGGGGAACAAGCUGGAGGAG 24 5865
SCNNlA-9849 - CUGUCAGGUGAGGGGGAG 18 13698
SCNNlA-9850 - CCUGUCAGGUGAGGGGGAG 19 13699
SCNNlA-9851 - ACCUGUCAGGUGAGGGGGAG 20 13700
SCNNlA-9852 - CACCUGUCAGGUGAGGGGGAG 21 13701
SCNNlA-9853 - GCACCUGUCAGGUGAGGGGGAG 22 13702
SCNNlA-9854 - UGCACCUGUCAGGUGAGGGGGAG 23 13703
SCNNlA-9855 - CUGCACCUGUCAGGUGAGGGGGAG 24 13704
SCNNlA-9856 - GCAAGGCAAGGGGGGGAG 18 13705
SCNNlA-9857 - GGCAAGGCAAGGGGGGGAG 19 13706
SCNNlA-5900 - GGGCAAGGCAAGGGGGGGAG 20 9749
SCNNlA-9858 - GGGGCAAGGCAAGGGGGGGAG 21 13707
SCNNlA-9859 - GGGGGCAAGGCAAGGGGGGGAG 22 13708
SCNNlA-9860 - AGGGGGCAAGGCAAGGGGGGGAG 23 13709
SCNNlA-9861 - GAGGGGGCAAGGCAAGGGGGGGAG 24
13710
SCNNlA-9862 - CCAGCCGCAACCUGGGAG 18 13711
SCNNlA-9863 - UCCAGCCGCAACCUGGGAG 19 13712
SCNNlA-5251 - GUCCAGCCGCAACCUGGGAG 20 9100
SCNNlA-9864 - AGUCCAGCCGCAACCUGGGAG 21 13713
SCNNlA-9865 - CAGUCCAGCCGCAACCUGGGAG 22 13714
SCNNlA-9866 - CCAGUCCAGCCGCAACCUGGGAG 23 13715
SCNNlA-9867 - CCCAGUCCAGCCGCAACCUGGGAG 24 13716
SCNNlA-2029 - AUACCAGGUCUCAUGGAG 18 5878
SCNNlA-2030 - CAUACCAGGUCUCAUGGAG 19 5879
SCNNlA-4 - CCAUACCAGGUCUCAUGGAG 20 498
SCNNlA-2031 - CCCAUACCAGGUCUCAUGGAG 21 5880
SCNNlA-2032 - GCCCAUACCAGGUCUCAUGGAG 22 5881
SCNNlA-2033 - AGCCCAUACCAGGUCUCAUGGAG 23 5882
SCNNlA-2034 - CAGCCCAUACCAGGUCUCAUGGAG 24 5883
SCNNlA-9868 - CAGGGCCAGAGGCUGGAG 18 13717
SCNNlA-9869 - UCAGGGCCAGAGGCUGGAG 19 13718
SCNNlA-9870 - GUCAGGGCCAGAGGCUGGAG 20 13719
SCNNlA-9871 - GGUCAGGGCCAGAGGCUGGAG 21 13720
SCNNlA-9872 - AGGUCAGGGCCAGAGGCUGGAG 22 13721
SCNNlA-9873 - GAGGUCAGGGCCAGAGGCUGGAG 23 13722
SCNNlA-9874 - CGAGGUCAGGGCCAGAGGCUGGAG 24 13723
SCNNlA-9875 - GCUCCAGGAAAGGUGGAG 18 13724
SCNNlA-9876 - GGCUCCAGGAAAGGUGGAG 19 13725
1459
5535.1 SCNNlA-9877 - UGGCUCCAGGAAAGGUGGAG 20 13726
SCNNlA-9878 - CUGGCUCCAGGAAAGGUGGAG 21 13727
SCNNlA-9879 - GCUGGCUCCAGGAAAGGUGGAG 22 13728
SCNNlA-9880 - UGCUGGCUCCAGGAAAGGUGGAG 23 13729
SCNNlA-9881 - CUGCUGGCUCCAGGAAAGGUGGAG 24 13730
SCNNlA-9882 - CUGAGGGCCUAGAGUGAG 18 13731
SCNNlA-9883 - GCUGAGGGCCUAGAGUGAG 19 13732
SCNNlA-5657 - AGCUGAGGGCCUAGAGUGAG 20 9506
SCNNlA-9884 - GAGCUGAGGGCCUAGAGUGAG 21 13733
SCNNlA-9885 - GGAGCUGAGGGCCUAGAGUGAG 22 13734
SCNNlA-9886 - UGGAGCUGAGGGCCUAGAGUGAG 23 13735
SCNNlA-9887 - CUGGAGCUGAGGGCCUAGAGUGAG 24 13736
SCNNlA-9888 - CUGCUCCCACUUAGUGAG 18 13737
SCNNlA-9889 - GCUGCUCCCACUUAGUGAG 19 13738
SCNNlA-5658 - CGCUGCUCCCACUUAGUGAG 20 9507
SCNNlA-9890 - GCGCUGCUCCCACUUAGUGAG 21 13739
SCNNlA-9891 - UGCGCUGCUCCCACUUAGUGAG 22 13740
SCNNlA-9892 - GUGCGCUGCUCCCACUUAGUGAG 23 13741
SCNNlA-9893 - AGUGCGCUGCUCCCACUUAGUGAG 24 13742
SCNNlA-9894 - CUGCACCUGUCAGGUGAG 18 13743
SCNNlA-9895 - GCUGCACCUGUCAGGUGAG 19 13744
SCNNlA-5659 - CGCUGCACCUGUCAGGUGAG 20 9508
SCNNlA-9896 - CCGCUGCACCUGUCAGGUGAG 21 13745
SCNNlA-9897 - GCCGCUGCACCUGUCAGGUGAG 22 13746
SCNNlA-9898 - GGCCGCUGCACCUGUCAGGUGAG 23 13747
SCNNlA-9899 - AGGCCGCUGCACCUGUCAGGUGAG 24 13748
SCNNlA-9900 - GCUCCCACUUAGUGAGCG 18 13749
SCNNlA-9901 - UGCUCCCACUUAGUGAGCG 19 13750
SCNNlA-5668 - CUGCUCCCACUUAGUGAGCG 20 9517
SCNNlA-9902 - GCUGCUCCCACUUAGUGAGCG 21 13751
SCNNlA-9903 - CGCUGCUCCCACUUAGUGAGCG 22 13752
SCNNlA-9904 - GCGCUGCUCCCACUUAGUGAGCG 23 13753
SCNNlA-9905 - UGCGCUGCUCCCACUUAGUGAGCG 24 13754
SCNNlA-9906 - G C U G G C A A A U AG A A A AG G 18 13755
SCNNlA-9907 - AG C U G G C A A A U AG A A A AG G 19 13756
SCNNlA-9908 - GAGCUGGCAAAUAGAAAAGG 20 13757
SCNNlA-9909 - UGAGCUGGCAAAUAGAAAAGG 21 13758
SCNNlA-9910 - AUGAGCUGGCAAAUAGAAAAGG 22 13759
SCNNlA-9911 - CAUGAGCUGGCAAAUAGAAAAGG 23 13760
SCNNlA-9912 - GCAUGAGCUGGCAAAUAGAAAAGG 24 13761
SCNNlA-9913 - GAGGAAGAAGACCAAAGG 18 13762
SCNNlA-9914 - GGAGGAAGAAGACCAAAGG 19 13763
1460
5535.1 SCNNlA-9915 - UGGAGGAAGAAGACCAAAGG 20 13764
SCNNlA-9916 - CUGGAGGAAGAAGACCAAAGG 21 13765
SCNNlA-9917 - CCUGGAGGAAGAAGACCAAAGG 22 13766
SCNNlA-9918 - UCCUGGAGGAAGAAGACCAAAGG 23 13767
SCNNlA-9919 - AUCCUGGAGGAAGAAGACCAAAGG 24 13768
SCNNlA-9920 - UGCUGGCUCCAGGAAAGG 18 13769
SCNNlA-9921 - CUGCUGGCUCCAGGAAAGG 19 13770
SCNNlA-6150 - UCUGCUGGCUCCAGGAAAGG 20 9999
SCNNlA-9922 - GUCUGCUGGCUCCAGGAAAGG 21 13771
SCNNlA-9923 - GGUCUGCUGGCUCCAGGAAAGG 22 13772
SCNNlA-9924 - AGGUCUGCUGGCUCCAGGAAAGG 23 13773
SCNNlA-9925 - CAGGUCUGCUGGCUCCAGGAAAGG 24 13774
SCNNlA-9926 - UCCCGGGUCUGGACAAGG 18 13775
SCNNlA-9927 - CUCCCGGGUCUGGACAAGG 19 13776
SCNNlA-9928 - CCUCCCGGGUCUGGACAAGG 20 13777
SCNNlA-9929 - CCCUCCCGGGUCUGGACAAGG 21 13778
SCNNlA-9930 - CCCCUCCCGGGUCUGGACAAGG 22 13779
SCNNlA-9931 - GCCCCUCCCGGGUCUGGACAAGG 23 13780
SCNNlA-9932 - GGCCCCUCCCGGGUCUGGACAAGG 24 13781
SCNNlA-9933 - AGAGGGGGCAAGGCAAGG 18 13782
SCNNlA-9934 - GAGAGGGGGCAAGGCAAGG 19 13783
SCNNlA-6152 - UGAGAGGGGGCAAGGCAAGG 20 10001
SCNNlA-9935 - GUGAGAGGGGGCAAGGCAAGG 21 13784
SCNNlA-9936 - AGUGAGAGGGGGCAAGGCAAGG 22 13785
SCNNlA-9937 - GAGUGAGAGGGGGCAAGGCAAGG 23 13786
SCNNlA-9938 - AGAGUGAGAGGGGGCAAGGCAAGG 24 13787
SCNNlA-9939 - AGGAAGCCACAGACCAGG 18 13788
SCNNlA-9940 - GAGGAAGCCACAGACCAGG 19 13789
SCNNlA-9941 - AGAGGAAGCCACAGACCAGG 20 13790
SCNNlA-9942 - GAGAGGAAGCCACAGACCAGG 21 13791
SCNNlA-9943 - AGAGAGGAAGCCACAGACCAGG 22 13792
SCNNlA-9944 - AAGAGAGGAAGCCACAGACCAGG 23 13793
SCNNlA-9945 - CAAGAGAGGAAGCCACAGACCAGG 24 13794
SCNNlA-9946 - GAAAGAGGAGGGACCAGG 18 13795
SCNNlA-9947 - GGAAAGAGGAGGGACCAGG 19 13796
SCNNlA-6153 - AGGAAAGAGGAGGGACCAGG 20 10002
SCNNlA-9948 - CAGGAAAGAGGAGGGACCAGG 21 13797
SCNNlA-9949 - GCAGGAAAGAGGAGGGACCAGG 22 13798
SCNNlA-9950 - AGCAGGAAAGAGGAGGGACCAGG 23 13799
SCNNlA-9951 - CAGCAGGAAAGAGGAGGGACCAGG 24 13800
SCNNlA-2047 - GGAGAAUGUGGGCGCAGG 18 5896
SCNNlA-2048 - GGGAGAAUGUGGGCGCAGG 19 5897
1461
5535.1 SCNNlA-2049 - UGGGAGAAUGUGGGCGCAGG 20 5898
SCNNlA-9952 - GUGGGAGAAUGUGGGCGCAGG 21 13801
SCNNlA-9953 - AGUGGGAGAAUGUGGGCGCAGG 22 13802
SCNNlA-9954 - GAGUGGGAGAAUGUGGGCGCAGG 23 13803
SCNNlA-9955 - GGAGUGGGAGAAUGUGGGCGCAGG 24
13804
SCNNlA-9956 - UGAGCACCUUAUUGCAGG 18 13805
SCNNlA-9957 - CUGAGCACCUUAUUGCAGG 19 13806
SCNNlA-9958 - GCUGAGCACCUUAUUGCAGG 20 13807
SCNNlA-9959 - UGCUGAGCACCUUAUUGCAGG 21 13808
SCNNlA-9960 - GUGCUGAGCACCUUAUUGCAGG 22 13809
SCNNlA-9961 - GGUGCUGAGCACCUUAUUGCAGG 23 13810
SCNNlA-9962 - GGGUGCUGAGCACCUUAUUGCAGG 24 13811
SCNNlA-9963 - UGUGUAUCAAUGCUCAGG 18 13812
SCNNlA-9964 - GUGUGUAUCAAUGCUCAGG 19 13813
SCNNlA-9965 - GGUGUGUAUCAAUGCUCAGG 20 13814
SCNNlA-9966 - CGGUGUGUAUCAAUGCUCAGG 21 13815
SCNNlA-9967 - CCGGUGUGUAUCAAUGCUCAGG 22 13816
SCNNlA-9968 - CCCGGUGUGUAUCAAUGCUCAGG 23 13817
SCNNlA-9969 - CCCCGGUGUGUAUCAAUGCUCAGG 24 13818
SCNNlA-9970 - G A A U C AG C AG G A A AG AG G 18 13819
SCNNlA-9971 - G G A A U C AG C AG G A A AG AG G 19 13820
SCNNlA-6155 - AGGAAUCAGCAGGAAAGAGG 20 10004
SCNNlA-9972 - GAGGAAUCAGCAGGAAAGAGG 21 13821
SCNNlA-9973 - CGAGGAAUCAGCAGGAAAGAGG 22 13822
SCNNlA-9974 - GCGAGGAAUCAGCAGGAAAGAGG 23 13823
SCNNlA-9975 - GGCGAGGAAUCAGCAGGAAAGAGG 24 13824
SCNNlA-9976 - AGUAGAUAGCCCCAGAGG 18 13825
SCNNlA-9977 - AAGUAGAUAGCCCCAGAGG 19 13826
SCNNlA-5678 - UAAGUAGAUAGCCCCAGAGG 20 9527
SCNNlA-9978 - CUAAGUAGAUAGCCCCAGAGG 21 13827
SCNNlA-9979 - GCUAAGUAGAUAGCCCCAGAGG 22 13828
SCNNlA-9980 - CGCU AAGUAGAUAGCCCCAGAGG 23 13829
SCNNlA-9981 - GCGCUAAGUAGAUAGCCCCAGAGG 24 13830
SCNNlA-9982 - CGAGGUCAGGGCCAGAGG 18 13831
SCNNlA-9983 - UCGAGGUCAGGGCCAGAGG 19 13832
SCNNlA-9984 - CUCGAGGUCAGGGCCAGAGG 20 13833
SCNNlA-9985 - GCUCGAGGUCAGGGCCAGAGG 21 13834
SCNNlA-9986 - AGCUCGAGGUCAGGGCCAGAGG 22 13835
SCNNlA-9987 - CAGCUCGAGGUCAGGGCCAGAGG 23 13836
SCNNlA-9988 - ACAGCUCGAGGUCAGGGCCAGAGG 24 13837
SCNNlA-9989 - AGGCAAGGGGGGGAGAGG 18 13838
1462
5535.1 SCNNlA-9990 - AAGGCAAGGGGGGGAGAGG 19 13839
SCNNlA-9991 - CAAGGCAAGGGGGGGAGAGG 20 13840
SCNNlA-9992 - GCAAGGCAAGGGGGGGAGAGG 21 13841
SCNNlA-9993 - GGCAAGGCAAGGGGGGGAGAGG 22 13842
SCNNlA-9994 - GGGCAAGGCAAGGGGGGGAGAGG 23 13843
SCNNlA-9995 - GGGGCAAGGCAAGGGGGGGAGAGG 24
13844
SCNNlA-9996 - UAGAGAGGGAGUGAGAGG 18 13845
SCNNlA-9997 - AUAGAGAGGGAGUGAGAGG 19 13846
SCNNlA-9998 - GAUAGAGAGGGAGUGAGAGG 20 13847
SCNNlA-9999 - AGAUAGAGAGGGAGUGAGAGG 21 13848
SCNN1A-
- CAGAUAGAGAGGGAGUGAGAGG 22
10000 13849
SCNN1A-
- GCAGAUAGAGAGGGAGUGAGAGG 23
10001 13850
SCNN1A-
- GGCAGAUAGAGAGGGAGUGAGAGG 24
10002 13851
SCNN1A-
- AGAUAGCCCCAGAGGAGG 18
10003 13852
SCNN1A-
- UAGAUAGCCCCAGAGGAGG 19
10004 13853
SCNNlA-5261 - GUAGAUAGCCCCAGAGGAGG 20 9110
SCNN1A-
- AGUAGAUAGCCCCAGAGGAGG 21
10005 13854
SCNN1A-
- AAGUAGAUAGCCCCAGAGGAGG 22
10006 13855
SCNN1A-
- UAAGUAGAUAGCCCCAGAGGAGG 23
10007 13856
SCNN1A-
- CUAAGUAGAUAGCCCCAGAGGAGG 24
10008 13857
SCNN1A-
- CAGGAAAGGUGGAGGAGG 18
10009 13858
SCNN1A-
- CCAGGAAAGGUGGAGGAGG 19
10010 13859
SCNN1A-
- UCCAGGAAAGGUGGAGGAGG 20
10011 13860
SCNN1A-
- CUCCAGGAAAGGUGGAGGAGG 21
10012 13861
SCNN1A-
- GCUCCAGGAAAGGUGGAGGAGG 22
10013 13862
SCNN1A-
- GGCUCCAGGAAAGGUGGAGGAGG 23
10014 13863
SCNN1A- - UGGCUCCAGGAAAGGUGGAGGAGG 24 13864
1463
5535.1 10015
SCNN1A-
- AAAGGUGGAGGAGGGAGG 18
10016 13865
SCNN1A-
- GAAAGGUGGAGGAGGGAGG 19
10017 13866
SCNN1A-
- GGAAAGGUGGAGGAGGGAGG 20
10018 13867
SCNN1A-
- AGGAAAGGUGGAGGAGGGAGG 21
10019 13868
SCNN1A-
- CAGGAAAGGUGGAGGAGGGAGG 22
10020 13869
SCNN1A-
- CCAGGAAAGGUGGAGGAGGGAGG 23
10021 13870
SCNN1A-
- UCCAGGAAAGGUGGAGGAGGGAGG 24
10022 13871
SCNN1A-
- CUGGCUUGUGGAGGGAGG 18
10023 13872
SCNN1A-
- GCUGGCUUGUGGAGGGAGG 19
10024 13873
SCNN1A-
- UGCUGGCUUGUGGAGGGAGG 20
10025 13874
SCNN1A-
- CUGCUGGCUUGUGGAGGGAGG 21
10026 13875
SCNN1A-
- UCUGCUGGCUUGUGGAGGGAGG 22
10027 13876
SCNN1A-
- GUCUGCUGGCUUGUGGAGGGAGG 23
10028 13877
SCNN1A-
- UGUCUGCUGGCUUGUGGAGGGAGG 24
10029 13878
SCNN1A-
- AGACACAGAUCCUGGAGG 18
10030 13879
SCNN1A-
- GAGACACAGAUCCUGGAGG 19
10031 13880
SCNN1A-
- UGAGACACAGAUCCUGGAGG 20
10032 13881
SCNN1A-
- CUGAGACACAGAUCCUGGAGG 21
10033 13882
SCNN1A-
- GCUGAGACACAGAUCCUGGAGG 22
10034 13883
SCNN1A-
- AGCUGAGACACAGAUCCUGGAGG 23
10035 13884
SCNN1A-
- GAGCUGAGACACAGAUCCUGGAGG 24
10036 13885
1464
5535.1 SCNN1A-
- CUCCAGGAAAGGUGGAGG 18
10037 13886
SCNN1A-
- GCUCCAGGAAAGGUGGAGG 19
10038 13887
SCNNlA-5906 - GGCUCCAGGAAAGGUGGAGG 20 9755
SCNN1A-
- UGGCUCCAGGAAAGGUGGAGG 21
10039 13888
SCNN1A-
- CUGGCUCCAGGAAAGGUGGAGG 22
10040 13889
SCNN1A-
- GCUGGCUCCAGGAAAGGUGGAGG 23
10041 13890
SCNN1A-
- UGCUGGCUCCAGGAAAGGUGGAGG 24
10042 13891
SCNN1A-
- UCUCUGCAGGGCCUGAGG 18
10043 13892
SCNN1A-
- UUCUCUGCAGGGCCUGAGG 19
10044 13893
SCNN1A-
- CUUCUCUGCAGGGCCUGAGG 20
10045 13894
SCNN1A-
- UCUUCUCUGCAGGGCCUGAGG 21
10046 13895
SCNN1A-
- CUCUUCUCUGCAGGGCCUGAGG 22
10047 13896
SCNN1A-
- UCUCUUCUCUGCAGGGCCUGAGG 23
10048 13897
SCNN1A-
- CUCUCUUCUCUGCAGGGCCUGAGG 24
10049 13898
SCNN1A-
- UGCACCUGUCAGGUGAGG 18
10050 13899
SCNN1A-
- CUGCACCUGUCAGGUGAGG 19
10051 13900
SCNNlA-5908 - GCUGCACCUGUCAGGUGAGG 20 9757
SCNN1A-
- CGCUGCACCUGUCAGGUGAGG 21
10052 13901
SCNN1A-
- CCGCUGCACCUGUCAGGUGAGG 22
10053 13902
SCNN1A-
- GCCGCUGCACCUGUCAGGUGAGG 23
10054 13903
SCNN1A-
- GGCCGCUGCACCUGUCAGGUGAGG 24
10055 13904
SCNN1A-
- UCCCUGGCCGGCCAGCGG 18
10056 13905
SCNN1A- - AUCCCUGGCCGGCCAGCGG 19 13906
1465
5535.1 10057
SCNN1A-
- CAUCCCUGGCCGGCCAGCGG 20
10058 13907
SCNN1A-
- CCAUCCCUGGCCGGCCAGCGG 21
10059 13908
SCNN1A-
- UCCAUCCCUGGCCGGCCAGCGG 22
10060 13909
SCNN1A-
- UUCCAUCCCUGGCCGGCCAGCGG 23
10061 13910
SCNN1A-
- CUUCCAUCCCUGGCCGGCCAGCGG 24
10062 13911
SCNN1A-
- GAGGGGGCAAGGCAAGGG 18
10063 13912
SCNN1A-
- AGAGGGGGCAAGGCAAGGG 19
10064 13913
SCNNlA-5910 - GAGAGGGGGCAAGGCAAGGG 20 9759
SCNN1A-
- UGAGAGGGGGCAAGGCAAGGG 21
10065 13914
SCNN1A-
- GUGAGAGGGGGCAAGGCAAGGG 22
10066 13915
SCNN1A-
- AGUGAGAGGGGGCAAGGCAAGGG 23
10067 13916
SCNN1A-
- GAGUGAGAGGGGGCAAGGCAAGGG 24
10068 13917
SCNNlA-2068 - GAGAAUGUGGGCGCAGGG 18 5917
SCNNlA-2069 - GGAGAAUGUGGGCGCAGGG 19 5918
SCNNlA-354 - GGGAGAAUGUGGGCGCAGGG 20 4203
SCNNlA-2070 - UGGGAGAAUGUGGGCGCAGGG 21 5919
SCNNlA-2071 - GUGGGAGAAUGUGGGCGCAGGG 22 5920
SCNNlA-2072 - AGUGGGAGAAUGUGGGCGCAGGG 23 5921
SCNNlA-2073 - GAGUGGGAGAAUGUGGGCGCAGGG 24
5922
SCNN1A-
- AGGAAAGGUGGAGGAGGG 18
10069 13918
SCNN1A-
- CAGGAAAGGUGGAGGAGGG 19
10070 13919
SCNNlA-6162 - CCAGGAAAGGUGGAGGAGGG 20 10011
SCNN1A-
- UCCAGGAAAGGUGGAGGAGGG 21
10071 13920
SCNN1A-
- CUCCAGGAAAGGUGGAGGAGGG 22
10072 13921
SCNN1A-
- GCUCCAGGAAAGGUGGAGGAGGG 23
10073 13922
1466
5535.1 SCNN1A-
- GGCUCCAGGAAAGGUGGAGGAGGG 24
10074 13923
SCNN1A-
- UCCCACUUAGUGAGCGGG 18
10075 13924
SCNN1A-
- CUCCCACUUAGUGAGCGGG 19
10076 13925
SCNN1A-
- GCUCCCACUUAGUGAGCGGG 20
10077 13926
SCNN1A-
- UGCUCCCACUUAGUGAGCGGG 21
10078 13927
SCNN1A-
- CUGCUCCCACUUAGUGAGCGGG 22
10079 13928
SCNN1A-
- GCUGCUCCCACUUAGUGAGCGGG 23
10080 13929
SCNN1A-
- CGCUGCUCCCACUUAGUGAGCGGG 24
10081 13930
SCNN1A-
- AGGGGGCAAGGCAAGGGG 18
10082 13931
SCNN1A-
- GAGGGGGCAAGGCAAGGGG 19
10083 13932
SCNNlA-6163 - AGAGGGGGCAAGGCAAGGGG 20 10012
SCNN1A-
- GAGAGGGGGCAAGGCAAGGGG 21
10084 13933
SCNN1A-
- UGAGAGGGGGCAAGGCAAGGGG 22
10085 13934
SCNN1A-
- GUGAGAGGGGGCAAGGCAAGGGG 23
10086 13935
SCNN1A-
- AGUGAGAGGGGGCAAGGCAAGGGG 24
10087 13936
SCNN1A-
- CACCUGUCAGGUGAGGGG 18
10088 13937
SCNN1A-
- GCACCUGUCAGGUGAGGGG 19
10089 13938
SCNN1A-
- UGCACCUGUCAGGUGAGGGG 20
10090 13939
SCNN1A-
- CUGCACCUGUCAGGUGAGGGG 21
10091 13940
SCNN1A-
- GCUGCACCUGUCAGGUGAGGGG 22
10092 13941
SCNN1A-
- CGCUGCACCUGUCAGGUGAGGGG 23
10093 13942
SCNN1A-
- CCGCUGCACCUGUCAGGUGAGGGG 24
10094 13943
1467
5535.1 SCNN1A-
- CCCACUUAGUGAGCGGGG 18
10095 13944
SCNN1A-
- UCCCACUUAGUGAGCGGGG 19
10096 13945
SCNNlA-5689 - CUCCCACUUAGUGAGCGGGG 20 9538
SCNN1A-
- GCUCCCACUUAGUGAGCGGGG 21
10097 13946
SCNN1A-
- UGCUCCCACUUAGUGAGCGGGG 22
10098 13947
SCNN1A-
- CUGCUCCCACUUAGUGAGCGGGG 23
10099 13948
SCNN1A-
- GCUGCUCCCACUUAGUGAGCGGGG 24
10100 13949
SCNN1A-
- AAGACCAAAGGAAGGGGG 18
10101 13950
SCNN1A-
- GAAGACCAAAGGAAGGGGG 19
10102 13951
SCNN1A-
- AGAAGACCAAAGGAAGGGGG 20
10103 13952
SCNN1A-
- AAGAAGACCAAAGGAAGGGGG 21
10104 13953
SCNN1A-
- GAAGAAGACCAAAGGAAGGGGG 22
10105 13954
SCNN1A-
- GGAAGAAGACCAAAGGAAGGGGG 23
10106 13955
SCNN1A-
- AGGAAGAAGACCAAAGGAAGGGGG 24
10107 13956
SCNN1A-
- ACCUGUCAGGUGAGGGGG 18
10108 13957
SCNN1A-
- CACCUGUCAGGUGAGGGGG 19
10109 13958
SCNNlA-5914 - GCACCUGUCAGGUGAGGGGG 20 9763
SCNN1A-
- UGCACCUGUCAGGUGAGGGGG 21
10110 13959
SCNN1A-
- CUGCACCUGUCAGGUGAGGGGG 22
10111 13960
SCNN1A-
- GCUGCACCUGUCAGGUGAGGGGG 23
10112 13961
SCNN1A-
- CGCUGCACCUGUCAGGUGAGGGGG 24
10113 13962
SCNN1A-
- GGGGCAAGGCAAGGGGGG 18
10114 13963
SCNN1A- - GGGGGCAAGGCAAGGGGGG 19 13964
1468
5535.1 10115
SCNN1A-
- AGGGGGCAAGGCAAGGGGGG 20
10116 13965
SCNN1A-
- GAGGGGGCAAGGCAAGGGGGG 21
10117 13966
SCNN1A-
- AGAGGGGGCAAGGCAAGGGGGG 22
10118 13967
SCNN1A-
- GAGAGGGGGCAAGGCAAGGGGGG 23
10119 13968
SCNN1A-
- UGAGAGGGGGCAAGGCAAGGGGGG 24
10120 13969
SCNN1A-
- AGCCCUGCAGUCCUGGGG 18
10121 13970
SCNN1A-
- GAGCCCUGCAGUCCUGGGG 19
10122 13971
SCNN1A-
- GGAGCCCUGCAGUCCUGGGG 20
10123 13972
SCNN1A-
- UGGAGCCCUGCAGUCCUGGGG 21
10124 13973
SCNN1A-
- CUGGAGCCCUGCAGUCCUGGGG 22
10125 13974
SCNN1A-
- CCUGGAGCCCUGCAGUCCUGGGG 23
10126 13975
SCNN1A-
- UCCUGGAGCCCUGCAGUCCUGGGG 24
10127 13976
SCNNlA-2080 - CCAUACCAGGUCUCAUGG 18 5929
SCNNlA-2081 - CCCAUACCAGGUCUCAUGG 19 5930
SCNNlA-2 - GCCCAUACCAGGUCUCAUGG 20 497
SCNNlA-2082 - AGCCCAUACCAGGUCUCAUGG 21 5931
SCNNlA-2083 - CAGCCCAUACCAGGUCUCAUGG 22 5932
SCNNlA-2084 - GCAGCCCAUACCAGGUCUCAUGG 23 5933
SCNNlA-2085 - UGCAGCCCAUACCAGGUCUCAUGG 24 5934
SCNNlA-2086 - GGGUUCCAGGGGUGAUGG 18 5935
SCNNlA-2087 - CGGGUUCCAGGGGUGAUGG 19 5936
SCNNlA-2088 - UCGGGUUCCAGGGGUGAUGG 20 5937
SCNNlA-2089 - CUCGGGUUCCAGGGGUGAUGG 21 5938
SCNNlA-2090 - ACUCGGGUUCCAGGGGUGAUGG 22 5939
SCNNlA-2091 - CACUCGGGUUCCAGGGGUGAUGG 23 5940
SCNNlA-2092 - UCACUCGGGUUCCAGGGGUGAUGG 24 5941
SCNN1A-
- CUGAGACACAGAUCCUGG 18
10128 13977
SCNN1A-
- GCUGAGACACAGAUCCUGG 19
10129 13978
1469
5535.1 SCNNlA-5693 - AGCUGAGACACAGAUCCUGG 20 9542
SCNN1A-
- GAGCUGAGACACAGAUCCUGG 21
10130 13979
SCNN1A-
- GGAGCUGAGACACAGAUCCUGG 22
10131 13980
SCNN1A-
- AGGAGCUGAGACACAGAUCCUGG 23
10132 13981
SCNN1A-
- CAGGAGCUGAGACACAGAUCCUGG 24
10133 13982
SCNNlA-2093 - UGAAGGGGAACAAGCUGG 18 5942
SCNNlA-2094 - AUGAAGGGGAACAAGCUGG 19 5943
SCNNlA-455 - CAUGAAGGGGAACAAGCUGG 20 4304
SCNNlA-2095 - UCAUGAAGGGGAACAAGCUGG 21 5944
SCNNlA-2096 - CUCAUGAAGGGGAACAAGCUGG 22 5945
SCNNlA-2097 - GCUCAUGAAGGGGAACAAGCUGG 23 5946
SCNNlA-2098 - GGCUCAUGAAGGGGAACAAGCUGG 24 5947
SCNNlA-2099 - UGGAGGGGAACAAGCUGG 18 5948
SCNNlA-2100 - AUGGAGGGGAACAAGCUGG 19 5949
SCNNlA-6 - CAUGGAGGGGAACAAGCUGG 20 558
SCNNlA-2101 - UCAUGGAGGGGAACAAGCUGG 21 5950
SCNNlA-2102 - CUCAUGGAGGGGAACAAGCUGG 22 5951
SCNNlA-2103 - UCUCAUGGAGGGGAACAAGCUGG 23 5952
SCNNlA-2104 - GUCUCAUGGAGGGGAACAAGCUGG 24 5953
SCNN1A-
- UGGCUCCAGGAAAGGUGG 18
10134 13983
SCNN1A-
- CUGGCUCCAGGAAAGGUGG 19
10135 13984
SCNNlA-5266 - GCUGGCUCCAGGAAAGGUGG 20 9115
SCNN1A-
- UGCUGGCUCCAGGAAAGGUGG 21
10136 13985
SCNN1A-
- CUGCUGGCUCCAGGAAAGGUGG 22
10137 13986
SCNN1A-
- UCUGCUGGCUCCAGGAAAGGUGG 23
10138 13987
SCNN1A-
- GUCUGCUGGCUCCAGGAAAGGUGG 24
10139 13988
SCNN1A-
- UUGUCUGCUGGCUUGUGG 18
10140 13989
SCNN1A-
- UUUGUCUGCUGGCUUGUGG 19
10141 13990
SCNNlA-5695 - CUUUGUCUGCUGGCUUGUGG 20 9544
SCNN1A-
- CCUUUGUCUGCUGGCUUGUGG 21
10142 13991
1470
5535.1 SCNN1A-
- GCCUUUGUCUGCUGGCUUGUGG 22
10143 13992
SCNN1A-
- GGCCUUUGUCUGCUGGCUUGUGG 23
10144 13993
SCNN1A-
- GGGCCUUUGUCUGCUGGCUUGUGG 24
10145 13994
SCNN1A-
- GGGUCUGGACAAGGUUGG 18
10146 13995
SCNN1A-
- CGGGUCUGGACAAGGUUGG 19
10147 13996
SCNNlA-5697 - CCGGGUCUGGACAAGGUUGG 20 9546
SCNN1A-
- CCCGGGUCUGGACAAGGUUGG 21
10148 13997
SCNN1A-
- UCCCGGGUCUGGACAAGGUUGG 22
10149 13998
SCNN1A-
- CUCCCGGGUCUGGACAAGGUUGG 23
10150 13999
SCNN1A-
- CCUCCCGGGUCUGGACAAGGUUGG 24
10151 14000
SCNN1A-
- UUCUUCAUUAGGACAAUG 18
10152 14001
SCNN1A-
- UUUCUUCAUUAGGACAAUG 19
10153 14002
SCNN1A-
- GUUUCUUCAUUAGGACAAUG 20
10154 14003
SCNN1A-
- AGUUUCUUCAUUAGGACAAUG 21
10155 14004
SCNN1A-
- CAGUUUCUUCAUUAGGACAAUG 22
10156 14005
SCNN1A-
- UCAGUUUCUUCAUUAGGACAAUG 23
10157 14006
SCNN1A-
- GUCAGUUUCUUCAUUAGGACAAUG 24
10158 14007
SCNNlA-2111 - UCCACUCCGGGGCUCAUG 18 5960
SCNNlA-2112 - AUCCACUCCGGGGCUCAUG 19 5961
SCNNlA-2113 - AAUCCACUCCGGGGCUCAUG 20 5962
SCNNlA-2114 - CAAUCCACUCCGGGGCUCAUG 21 5963
SCNNlA-2115 - CCAAUCCACUCCGGGGCUCAUG 22 5964
SCNNlA-2116 - CCCAAUCCACUCCGGGGCUCAUG 23 5965
SCNNlA-2117 - CCCCAAUCCACUCCGGGGCUCAUG 24 5966
SCNNlA-2118 - CCCAUACCAGGUCUCAUG 18 5967
SCNNlA-2119 - GCCCAUACCAGGUCUCAUG 19 5968
SCNNlA-161 - AGCCCAUACCAGGUCUCAUG 20 804
1471
5535.1 SCNNlA-2120 - CAGCCCAUACCAGGUCUCAUG 21 5969
SCNNlA-2121 - GCAGCCCAUACCAGGUCUCAUG 22 5970
SCNNlA-2122 - UGCAGCCCAUACCAGGUCUCAUG 23 5971
SCNNlA-2123 - CUGCAGCCCAUACCAGGUCUCAUG 24 5972
SCNN1A-
- AGGGGUCUCUGGGAUAUG 18
10159 14008
SCNN1A-
- UAGGGGUCUCUGGGAUAUG 19
10160 14009
SCNNlA-5700 - CUAGGGGUCUCUGGGAUAUG 20 9549
SCNN1A-
- UCU AGGGGUCUCUGGGAUAUG 21
10161 14010
SCNN1A-
- UUCUAGGGGUCUCUGGGAUAUG 22
10162 14011
SCNN1A-
- UUUCUAGGGGUCUCUGGGAUAUG 23
10163 14012
SCNN1A-
- GUUUCUAGGGGUCUCUGGGAUAUG 24
10164 14013
SCNN1A-
- GAGCGGGGAGGAGACCUG 18
10165 14014
SCNN1A-
- UGAGCGGGGAGGAGACCUG 19
10166 14015
SCNN1A-
- GUGAGCGGGGAGGAGACCUG 20
10167 14016
SCNN1A-
- AGUGAGCGGGGAGGAGACCUG 21
10168 14017
SCNN1A-
- UAGUGAGCGGGGAGGAGACCUG 22
10169 14018
SCNN1A-
- UUAGUGAGCGGGGAGGAGACCUG 23
10170 14019
SCNN1A-
- CUUAGUGAGCGGGGAGGAGACCUG 24
10171 14020
SCNN1A-
- GCUGAGACACAGAUCCUG 18
10172 14021
SCNN1A-
- AGCUGAGACACAGAUCCUG 19
10173 14022
SCNN1A-
- GAGCUGAGACACAGAUCCUG 20
10174 14023
SCNN1A-
- GGAGCUGAGACACAGAUCCUG 21
10175 14024
SCNN1A-
- AGGAGCUGAGACACAGAUCCUG 22
10176 14025
SCNN1A-
- CAGGAGCUGAGACACAGAUCCUG 23
10177 14026
1472
5535.1 SCNN1A-
- GCAGGAGCUGAGACACAGAUCCUG 24
10178 14027
SCNN1A-
- ACUCUGGGCUGCCUCCUG 18
10179 14028
SCNN1A-
- CACUCUGGGCUGCCUCCUG 19
10180 14029
SCNNlA-5269 - GCACUCUGGGCUGCCUCCUG 20 9118
SCNN1A-
- UGCACUCUGGGCUGCCUCCUG 21
10181 14030
SCNN1A-
- CUGCACUCUGGGCUGCCUCCUG 22
10182 14031
SCNN1A-
- CCUGCACUCUGGGCUGCCUCCUG 23
10183 14032
SCNN1A-
- UCCUGCACUCUGGGCUGCCUCCUG 24
10184 14033
SCNNlA-2124 - AUGAAGGGGAACAAGCUG 18 5973
SCNNlA-2125 - CAUGAAGGGGAACAAGCUG 19 5974
SCNNlA-2126 - UCAUGAAGGGGAACAAGCUG 20 5975
SCNNlA-2127 - CUCAUGAAGGGGAACAAGCUG 21 5976
SCNNlA-2128 - GCUCAUGAAGGGGAACAAGCUG 22 5977
SCNNlA-2129 - GGCUCAUGAAGGGGAACAAGCUG 23 5978
SCNNlA-2130 - GGGCUCAUGAAGGGGAACAAGCUG 24 5979
SCNNlA-2131 - AUGGAGGGGAACAAGCUG 18 5980
SCNNlA-2132 - CAUGGAGGGGAACAAGCUG 19 5981
SCNNlA-167 - UCAUGGAGGGGAACAAGCUG 20 806
SCNNlA-2133 - CUCAUGGAGGGGAACAAGCUG 21 5982
SCNNlA-2134 - UCUCAUGGAGGGGAACAAGCUG 22 5983
SCNNlA-2135 - GUCUCAUGGAGGGGAACAAGCUG 23 5984
SCNNlA-2136 - GGUCUCAUGGAGGGGAACAAGCUG 24 5985
SCNN1A-
- CCUCUUCUCUCUUCUCUG 18
10185 14034
SCNN1A-
- ACCUCUUCUCUCUUCUCUG 19
10186 14035
SCNN1A-
- GACCUCUUCUCUCUUCUCUG 20
10187 14036
SCNN1A-
- AGACCUCUUCUCUCUUCUCUG 21
10188 14037
SCNN1A-
- GAGACCUCUUCUCUCUUCUCUG 22
10189 14038
SCNN1A-
- AGAGACCUCUUCUCUCUUCUCUG 23
10190 14039
SCNN1A-
- CAGAGACCUCUUCUCUCUUCUCUG 24
10191 14040
1473
5535.1 SCNN1A-
- GGGGCAGUGGGGACAGUG 18
10192 14041
SCNN1A-
- UGGGGCAGUGGGGACAGUG 19
10193 14042
SCNN1A-
- GUGGGGCAGUGGGGACAGUG 20
10194 14043
SCNN1A-
- UGUGGGGCAGUGGGGACAGUG 21
10195 14044
SCNN1A-
- AUGUGGGGCAGUGGGGACAGUG 22
10196 14045
SCNN1A-
- UAUGUGGGGCAGUGGGGACAGUG 23
10197 14046
SCNN1A-
- AUAUGUGGGGCAGUGGGGACAGUG 24
10198 14047
SCNN1A-
- GGGCUCUGUGUGGGAGUG 18
10199 14048
SCNN1A-
- CGGGCUCUGUGUGGGAGUG 19
10200 14049
SCNNlA-5711 - ACGGGCUCUGUGUGGGAGUG 20 9560
SCNN1A-
- CACGGGCUCUGUGUGGGAGUG 21
10201 14050
SCNN1A-
- CCACGGGCUCUGUGUGGGAGUG 22
10202 14051
SCNN1A-
- UCCACGGGCUCUGUGUGGGAGUG 23
10203 14052
SCNN1A-
- AUCCACGGGCUCUGUGUGGGAGUG 24
10204 14053
SCNN1A-
- CCUCCUGUGGGGCCCGUG 18
10205 14054
SCNN1A-
- GCCUCCUGUGGGGCCCGUG 19
10206 14055
SCNNlA-5712 - UGCCUCCUGUGGGGCCCGUG 20 9561
SCNN1A-
- CUGCCUCCUGUGGGGCCCGUG 21
10207 14056
SCNN1A-
- GCUGCCUCCUGUGGGGCCCGUG 22
10208 14057
SCNN1A-
- GGCUGCCUCCUGUGGGGCCCGUG 23
10209 14058
SCNN1A-
- GGGCUGCCUCCUGUGGGGCCCGUG 24
10210 14059
SCNN1A-
- AGCCUUCCCUGCCGCGUG 18
10211 14060
SCNN1A- - CAGCCUUCCCUGCCGCGUG 19 14061
1474
5535.1 10212
SCNN1A-
- GCAGCCUUCCCUGCCGCGUG 20
10213 14062
SCNN1A-
- GGCAGCCUUCCCUGCCGCGUG 21
10214 14063
SCNN1A-
- CGGCAGCCUUCCCUGCCGCGUG 22
10215 14064
SCNN1A-
- GCGGCAGCCUUCCCUGCCGCGUG 23
10216 14065
SCNN1A-
- AGCGGCAGCCUUCCCUGCCGCGUG 24
10217 14066
SCNN1A-
- CUGGCUCCAGGAAAGGUG 18
10218 14067
SCNN1A-
- GCUGGCUCCAGGAAAGGUG 19
10219 14068
SCNN1A-
- UGCUGGCUCCAGGAAAGGUG 20
10220 14069
SCNN1A-
- CUGCUGGCUCCAGGAAAGGUG 21
10221 14070
SCNN1A-
- UCUGCUGGCUCCAGGAAAGGUG 22
10222 14071
SCNN1A-
- GUCUGCUGGCUCCAGGAAAGGUG 23
10223 14072
SCNN1A-
- GGUCUGCUGGCUCCAGGAAAGGUG 24
10224 14073
SCNN1A-
- CGCUGCACCUGUCAGGUG 18
10225 14074
SCNN1A-
- CCGCUGCACCUGUCAGGUG 19
10226 14075
SCNNlA-5270 - GCCGCUGCACCUGUCAGGUG 20 9119
SCNN1A-
- GGCCGCUGCACCUGUCAGGUG 21
10227 14076
SCNN1A-
- AGGCCGCUGCACCUGUCAGGUG 22
10228 14077
SCNN1A-
- CAGGCCGCUGCACCUGUCAGGUG 23
10229 14078
SCNN1A-
- CCAGGCCGCUGCACCUGUCAGGUG 24
10230 14079
SCNN1A-
- GAUCAAACAGCCAGGGUG 18
10231 14080
SCNN1A-
- AGAUCAAACAGCCAGGGUG 19
10232 14081
SCNN1A- - GAGAUCAAACAGCCAGGGUG 20 14082
1475
5535.1 10233
SCNN1A-
- UGAGAUCAAACAGCCAGGGUG 21
10234 14083
SCNN1A-
- UUGAGAUCAAACAGCCAGGGUG 22
10235 14084
SCNN1A-
- UUUGAGAUCAAACAGCCAGGGUG 23
10236 14085
SCNN1A-
- CUUUGAGAUCAAACAGCCAGGGUG 24
10237 14086
SCNNlA-2143 - ACUCGGGUUCCAGGGGUG 18 5992
SCNNlA-2144 - CACUCGGGUUCCAGGGGUG 19 5993
SCNNlA-2145 - UCACUCGGGUUCCAGGGGUG 20 5994
SCNNlA-2146 - CUCACUCGGGUUCCAGGGGUG 21 5995
SCNNlA-2147 - CCUCACUCGGGUUCCAGGGGUG 22 5996
SCNNlA-2148 - GCCUCACUCGGGUUCCAGGGGUG 23 5997
SCNNlA-2149 - AGCCUCACUCGGGUUCCAGGGGUG 24 5998
SCNN1A-
- ACAAGGUUGGAGGGGGUG 18
10238 14087
SCNN1A-
- GACAAGGUUGGAGGGGGUG 19
10239 14088
SCNN1A-
- GGACAAGGUUGGAGGGGGUG 20
10240 14089
SCNN1A-
- UGGACAAGGUUGGAGGGGGUG 21
10241 14090
SCNN1A-
- CUGGACAAGGUUGGAGGGGGUG 22
10242 14091
SCNN1A-
- UCUGGACAAGGUUGGAGGGGGUG 23
10243 14092
SCNN1A-
- GUCUGGACAAGGUUGGAGGGGGUG 24
10244 14093
SCNN1A-
- GAAUCCACGGGCUCUGUG 18
10245 14094
SCNN1A-
- CGAAUCCACGGGCUCUGUG 19
10246 14095
SCNNlA-5717 - ACGAAUCCACGGGCUCUGUG 20 9566
SCNN1A-
- GACGAAUCCACGGGCUCUGUG 21
10247 14096
SCNN1A-
- AGACGAAUCCACGGGCUCUGUG 22
10248 14097
SCNN1A-
- CAGACGAAUCCACGGGCUCUGUG 23
10249 14098
SCNN1A-
- GCAGACGAAUCCACGGGCUCUGUG 24
10250 14099
1476
5535.1 SCNN1A-
- UUUGUCUGCUGGCUUGUG 18
10251 14100
SCNN1A-
- CUUUGUCUGCUGGCUUGUG 19
10252 14101
SCNN1A-
- CCUUUGUCUGCUGGCUUGUG 20
10253 14102
SCNN1A-
- GCCUUUGUCUGCUGGCUUGUG 21
10254 14103
SCNN1A-
- GGCCUUUGUCUGCUGGCUUGUG 22
10255 14104
SCNN1A-
- GGGCCUUUGUCUGCUGGCUUGUG 23
10256 14105
SCNN1A-
- UGGGCCUUUGUCUGCUGGCUUGUG 24
10257 14106
SCNN1A-
- GUGCUGAGCACCUUAUUG 18
10258 14107
SCNN1A-
- GGUGCUGAGCACCUUAUUG 19
10259 14108
SCNN1A-
- GGGUGCUGAGCACCUUAUUG 20
10260 14109
SCNN1A-
- AGGGUGCUGAGCACCUUAUUG 21
10261 14110
SCNN1A-
- CAGGGUGCUGAGCACCUUAUUG 22
10262 14111
SCNN1A-
- CCAGGGUGCUGAGCACCUUAUUG 23
10263 14112
SCNN1A-
- GCCAGGGUGCUGAGCACCUUAUUG 24
10264 14113
SCNN1A-
- UGGAGGGCUGCCCACUUG 18
10265 14114
SCNN1A-
- UUGGAGGGCUGCCCACUUG 19
10266 14115
SCNN1A-
- CUUGGAGGGCUGCCCACUUG 20
10267 14116
SCNN1A-
- CCUUGGAGGGCUGCCCACUUG 21
10268 14117
SCNN1A-
- CCCUUGGAGGGCUGCCCACUUG 22
10269 14118
SCNN1A-
- GCCCUUGGAGGGCUGCCCACUUG 23
10270 14119
SCNN1A-
- UGCCCUUGGAGGGCUGCCCACUUG 24
10271 14120
SCNN1A- - GACCUGUGGGUGCCCUUG 18 14121
1477
5535.1 10272
SCNN1A-
- UGACCUGUGGGUGCCCUUG 19
10273 14122
SCNN1A-
- CUGACCUGUGGGUGCCCUUG 20
10274 14123
SCNN1A-
- GCUGACCUGUGGGUGCCCUUG 21
10275 14124
SCNN1A-
- GGCUGACCUGUGGGUGCCCUUG 22
10276 14125
SCNN1A-
- AGGCUGACCUGUGGGUGCCCUUG 23
10277 14126
SCNN1A-
- GAGGCUGACCUGUGGGUGCCCUUG 24
10278 14127
SCNN1A-
- CCUUUGUCUGCUGGCUUG 18
10279 14128
SCNN1A-
- GCCUUUGUCUGCUGGCUUG 19
10280 14129
SCNNlA-5271 - GGCCUUUGUCUGCUGGCUUG 20 9120
SCNN1A-
- GGGCCUUUGUCUGCUGGCUUG 21
10281 14130
SCNN1A-
- UGGGCCUUUGUCUGCUGGCUUG 22
10282 14131
SCNN1A-
- CUGGGCCUUUGUCUGCUGGCUUG 23
10283 14132
SCNN1A-
- GCUGGGCCUUUGUCUGCUGGCUUG 24
10284 14133
SCNN1A-
- CGGGUCUGGACAAGGUUG 18
10285 14134
SCNN1A-
- CCGGGUCUGGACAAGGUUG 19
10286 14135
SCNN1A-
- CCCGGGUCUGGACAAGGUUG 20
10287 14136
SCNN1A-
- UCCCGGGUCUGGACAAGGUUG 21
10288 14137
SCNN1A-
- CUCCCGGGUCUGGACAAGGUUG 22
10289 14138
SCNN1A-
- CCUCCCGGGUCUGGACAAGGUUG 23
10290 14139
SCNN1A-
- CCCUCCCGGGUCUGGACAAGGUUG 24
10291 14140
SCNN1A-
- GUUUGGAAAGAGAUUUUG 18
10292 14141
SCNN1A- - AGUUUGGAAAGAGAUUUUG 19 14142
1478
5535.1 10293
SCNN1A-
- AAGUUUGGAAAGAGAUUUUG 20
10294 14143
SCNN1A-
- UAAGUUUGGAAAGAGAUUUUG 21
10295 14144
SCNN1A-
- UU AAGUUUGGAAAGAGAUUUUG 22
10296 14145
SCNN1A-
- AUUAAGUUUGGAAAGAGAUUUUG 23
10297 14146
SCNN1A-
- CAU U AAG U U UGG AAAG AG AU U U UG 24
10298 14147
SCNN1A-
- GUCUUAUCUCUGAGAAAU 18
10299 14148
SCNN1A-
- UGUCUUAUCUCUGAGAAAU 19
10300 14149
SCNN1A-
- AUGUCUUAUCUCUGAGAAAU 20
10301 14150
SCNN1A-
- UAUGUCUUAUCUCUGAGAAAU 21
10302 14151
SCNN1A-
- UUAUGUCUUAUCUCUGAGAAAU 22
10303 14152
SCNN1A-
- CUUAUGUCUUAUCUCUGAGAAAU 23
10304 14153
SCNN1A-
- UCUUAUGUCUUAUCUCUGAGAAAU 24
10305 14154
SCNN1A-
- CUGGGGCAGAGACAGAAU 18
10306 14155
SCNN1A-
- CCUGGGGCAGAGACAGAAU 19
10307 14156
SCNN1A-
- UCCUGGGGCAGAGACAGAAU 20
10308 14157
SCNN1A-
- GUCCUGGGGCAGAGACAGAAU 21
10309 14158
SCNN1A-
- AGUCCUGGGGCAGAGACAGAAU 22
10310 14159
SCNN1A-
- CAGUCCUGGGGCAGAGACAGAAU 23
10311 14160
SCNN1A-
- GCAGUCCUGGGGCAGAGACAGAAU 24
10312 14161
SCNN1A-
- AGGGAGGAGUGGGAGAAU 18
10313 14162
SCNN1A-
- GAGGGAGGAGUGGGAGAAU 19
10314 14163
1479
5535.1 SCNN1A-
- GGAGGGAGGAGUGGGAGAAU 20
10315 14164
SCNN1A-
- GGGAGGGAGGAGUGGGAGAAU 21
10316 14165
SCNN1A-
- AGGGAGGGAGGAGUGGGAGAAU 22
10317 14166
SCNN1A-
- GAGGGAGGGAGGAGUGGGAGAAU 23
10318 14167
SCNN1A-
- GGAGGGAGGGAGGAGUGGGAGAAU 24
10319 14168
SCNN1A-
- AAGGGUCAGUUUCUUCAU 18
10320 14169
SCNN1A-
- GAAGGGUCAGUUUCUUCAU 19
10321 14170
SCNN1A-
- GGAAGGGUCAGUUUCUUCAU 20
10322 14171
SCNN1A-
- GGGAAGGGUCAGUUUCUUCAU 21
10323 14172
SCNN1A-
- UGGGAAGGGUCAGUUUCUUCAU 22
10324 14173
SCNN1A-
- UUGGGAAGGGUCAGUUUCUUCAU 23
10325 14174
SCNN1A-
- CUUGGGAAGGGUCAGUUUCUUCAU 24
10326 14175
SCNN1A-
- GAGGAAGAGAGGCAGGAU 18
10327 14176
SCNN1A-
- AGAGGAAGAGAGGCAGGAU 19
10328 14177
SCNN1A-
- GAGAGGAAGAGAGGCAGGAU 20
10329 14178
SCNN1A-
- GGAGAGGAAGAGAGGCAGGAU 21
10330 14179
SCNN1A-
- GGGAGAGGAAGAGAGGCAGGAU 22
10331 14180
SCNN1A-
- GGGGAGAGGAAGAGAGGCAGGAU 23
10332 14181
SCNN1A-
- GGGGGAGAGGAAGAGAGGCAGGAU 24
10333 14182
SCNNlA-2150 - UCGGGUUCCAGGGGUGAU 18 5999
SCNNlA-2151 - CUCGGGUUCCAGGGGUGAU 19 6000
SCNNlA-421 - ACUCGGGUUCCAGGGGUGAU 20 4270
SCNNlA-2152 - CACUCGGGUUCCAGGGGUGAU 21 6001
SCNNlA-2153 - UCACUCGGGUUCCAGGGGUGAU 22 6002
1480
5535.1 SCNNlA-2154 - CUCACUCGGGUUCCAGGGGUGAU 23 6003
SCNNlA-2155 - CCUCACUCGGGUUCCAGGGGUGAU 24 6004
SCNN1A-
- UCUCACAGAGCCCUUGAU 18
10334 14183
SCNN1A-
- UUCUCACAGAGCCCUUGAU 19
10335 14184
SCNN1A-
- CUUCUCACAGAGCCCUUGAU 20
10336 14185
SCNN1A-
- UCUUCUCACAGAGCCCUUGAU 21
10337 14186
SCNN1A-
- UUCUUCUCACAGAGCCCUUGAU 22
10338 14187
SCNN1A-
- AUUCUUCUCACAGAGCCCUUGAU 23
10339 14188
SCNN1A-
- AAUUCUUCUCACAGAGCCCUUGAU 24
10340 14189
SCNN1A-
- UAGGGGUCUCUGGGAUAU 18
10341 14190
SCNN1A-
- CUAGGGGUCUCUGGGAUAU 19
10342 14191
SCNN1A-
- UCUAGGGGUCUCUGGGAUAU 20
10343 14192
SCNN1A-
- UUCUAGGGGUCUCUGGGAUAU 21
10344 14193
SCNN1A-
- UUUCUAGGGGUCUCUGGGAUAU 22
10345 14194
SCNN1A-
- GUUUCUAGGGGUCUCUGGGAUAU 23
10346 14195
SCNN1A-
- AGUUUCUAGGGGUCUCUGGGAUAU 24
10347 14196
SCNN1A-
- CUCGAAAGGUGGCCCUAU 18
10348 14197
SCNN1A-
- ACUCGAAAGGUGGCCCUAU 19
10349 14198
SCNN1A-
- AACUCGAAAGGUGGCCCUAU 20
10350 14199
SCNN1A-
- AAACUCGAAAGGUGGCCCUAU 21
10351 14200
SCNN1A-
- AAAACUCGAAAGGUGGCCCUAU 22
10352 14201
SCNN1A-
- CAAAACUCGAAAGGUGGCCCUAU 23
10353 14202
SCNN1A- - ACAAAACUCGAAAGGUGGCCCUAU 24 14203
1481
5535.1 10354
SCNN1A-
- AGCUCCUGGAAGCACACU 18
10355 14204
SCNN1A-
- UAGCUCCUGGAAGCACACU 19
10356 14205
SCNNlA-5727 - CUAGCUCCUGGAAGCACACU 20 9576
SCNN1A-
- UCUAGCUCCUGGAAGCACACU 21
10357 14206
SCNN1A-
- CUCUAGCUCCUGGAAGCACACU 22
10358 14207
SCNN1A-
- CCUCUAGCUCCUGGAAGCACACU 23
10359 14208
SCNN1A-
- GCCUCUAGCUCCUGGAAGCACACU 24
10360 14209
SCNNlA-2156 - UGCUCUCCCCAAUCCACU 18 6005
SCNNlA-2157 - UUGCUCUCCCCAAUCCACU 19 6006
SCNNlA-2158 - CUUGCUCUCCCCAAUCCACU 20 6007
SCNNlA-2159 - CCUUGCUCUCCCCAAUCCACU 21 6008
SCNNlA-2160 - CCCUUGCUCUCCCCAAUCCACU 22 6009
SCNNlA-2161 - ACCCUUGCUCUCCCCAAUCCACU 23 6010
SCNNlA-2162 - GACCCUUGCUCUCCCCAAUCCACU 24 6011
SCNNlA-2163 - GUGAUGGGAGAGGGCACU 18 6012
SCNNlA-2164 - GGUGAUGGGAGAGGGCACU 19 6013
SCNNlA-2165 - GGGUGAUGGGAGAGGGCACU 20 6014
SCNNlA-2166 - GGGGUGAUGGGAGAGGGCACU 21 6015
SCNNlA-2167 - AGGGGUGAUGGGAGAGGGCACU 22 6016
SCNNlA-2168 - CAGGGGUGAUGGGAGAGGGCACU 23 6017
SCNNlA-2169 - CCAGGGGUGAUGGGAGAGGGCACU 24 6018
SCNN1A-
- UGACCACAUUCCUGCACU 18
10361 14210
SCNN1A-
- GUGACCACAUUCCUGCACU 19
10362 14211
SCNN1A-
- AGUGACCACAUUCCUGCACU 20
10363 14212
SCNN1A-
- CAGUGACCACAUUCCUGCACU 21
10364 14213
SCNN1A-
- CCAGUGACCACAUUCCUGCACU 22
10365 14214
SCNN1A-
- GCCAGUGACCACAUUCCUGCACU 23
10366 14215
SCNN1A-
- AGCCAGUGACCACAUUCCUGCACU 24
10367 14216
SCNN1A- - AGGUGCUUUUCAGAACCU 18 14217
1482
5535.1 10368
SCNN1A-
- GAGGUGCUUUUCAGAACCU 19
10369 14218
SCNN1A-
- GGAGGUGCUUUUCAGAACCU 20
10370 14219
SCNN1A-
- GGGAGGUGCUUUUCAGAACCU 21
10371 14220
SCNN1A-
- AGGGAGGUGCUUUUCAGAACCU 22
10372 14221
SCNN1A-
- CAGGGAGGUGCUUUUCAGAACCU 23
10373 14222
SCNN1A-
- GCAGGGAGGUGCUUUUCAGAACCU 24
10374 14223
SCNN1A-
- UAUUUUGUUUUCUAACCU 18
10375 14224
SCNN1A-
- CUAUUUUGUUUUCUAACCU 19
10376 14225
SCNN1A-
- CCUAUUUUGUUUUCUAACCU 20
10377 14226
SCNN1A-
- UCCUAUUUUGUUUUCUAACCU 21
10378 14227
SCNN1A-
- CUCCUAUUUUGUUUUCUAACCU 22
10379 14228
SCNN1A-
- GCUCCUAUUUUGUUUUCUAACCU 23
10380 14229
SCNN1A-
- UGCUCCUAUUUUGUUUUCUAACCU 24
10381 14230
SCNN1A-
- UCCCAGUUCACCUGCCCU 18
10382 14231
SCNN1A-
- CUCCCAGUUCACCUGCCCU 19
10383 14232
SCNNlA-5736 - ACUCCCAGUUCACCUGCCCU 20 9585
SCNN1A-
- UACUCCCAGUUCACCUGCCCU 21
10384 14233
SCNN1A-
- GUACUCCCAGUUCACCUGCCCU 22
10385 14234
SCNN1A-
- AGUACUCCCAGUUCACCUGCCCU 23
10386 14235
SCNN1A-
- CAGUACUCCCAGUUCACCUGCCCU 24
10387 14236
SCNN1A-
- CUGACCUGUGGGUGCCCU 18
10388 14237
SCNN1A- - GCUGACCUGUGGGUGCCCU 19 14238
1483
5535.1 10389
SCNNlA-5274 - GGCUGACCUGUGGGUGCCCU 20 9123
SCNN1A-
- AGGCUGACCUGUGGGUGCCCU 21
10390 14239
SCNN1A-
- GAGGCUGACCUGUGGGUGCCCU 22
10391 14240
SCNN1A-
- UGAGGCUGACCUGUGGGUGCCCU 23
10392 14241
SCNN1A-
- GUGAGGCUGACCUGUGGGUGCCCU 24
10393 14242
SCNN1A-
- AGAAAACUGAUUUAUCCU 18
10394 14243
SCNN1A-
- CAGAAAACUGAUUUAUCCU 19
10395 14244
SCNNlA-6181 - UCAGAAAACUGAUUUAUCCU 20 10030
SCNN1A-
- CUCAGAAAACUGAUUUAUCCU 21
10396 14245
SCNN1A-
- CCUCAGAAAACUGAUUUAUCCU 22
10397 14246
SCNN1A-
- ACCUCAGAAAACUGAUUUAUCCU 23
10398 14247
SCNN1A-
- AACCUCAGAAAACUGAUUUAUCCU 24
10399 14248
SCNN1A-
- CACUCUGGGCUGCCUCCU 18
10400 14249
SCNN1A-
- GCACUCUGGGCUGCCUCCU 19
10401 14250
SCNN1A-
- UGCACUCUGGGCUGCCUCCU 20
10402 14251
SCNN1A-
- CUGCACUCUGGGCUGCCUCCU 21
10403 14252
SCNN1A-
- CCUGCACUCUGGGCUGCCUCCU 22
10404 14253
SCNN1A-
- UCCUGCACUCUGGGCUGCCUCCU 23
10405 14254
SCNN1A-
- UUCCUGCACUCUGGGCUGCCUCCU 24
10406 14255
SCNN1A-
- UCGGGAGCCCUCCUUCCU 18
10407 14256
SCNN1A-
- CUCGGGAGCCCUCCUUCCU 19
10408 14257
SCNN1A-
- CCUCGGGAGCCCUCCUUCCU 20
10409 14258
1484
5535.1 SCNN1A-
- CCCUCGGGAGCCCUCCUUCCU 21
10410 14259
SCNN1A-
- GCCCUCGGGAGCCCUCCUUCCU 22
10411 14260
SCNN1A-
- UGCCCUCGGGAGCCCUCCUUCCU 23
10412 14261
SCNN1A-
- CUGCCCUCGGGAGCCCUCCUUCCU 24
10413 14262
SCNN1A-
- GGGCCAGAGGCUGGAGCU 18
10414 14263
SCNN1A-
- AGGGCCAGAGGCUGGAGCU 19
10415 14264
SCNN1A-
- CAGGGCCAGAGGCUGGAGCU 20
10416 14265
SCNN1A-
- UCAGGGCCAGAGGCUGGAGCU 21
10417 14266
SCNN1A-
- GUCAGGGCCAGAGGCUGGAGCU 22
10418 14267
SCNN1A-
- GGUCAGGGCCAGAGGCUGGAGCU 23
10419 14268
SCNN1A-
- AGGUCAGGGCCAGAGGCUGGAGCU 24
10420 14269
SCNN1A-
- UGUGUUGCCCUCCUAGCU 18
10421 14270
SCNN1A-
- UUGUGUUGCCCUCCUAGCU 19
10422 14271
SCNN1A-
- CUUGUGUUGCCCUCCUAGCU 20
10423 14272
SCNN1A-
- CCUUGUGUUGCCCUCCUAGCU 21
10424 14273
SCNN1A-
- UCCUUGUGUUGCCCUCCUAGCU 22
10425 14274
SCNN1A-
- CUCCUUGUGUUGCCCUCCUAGCU 23
10426 14275
SCNN1A-
- UCUCCUUGUGUUGCCCUCCUAGCU 24
10427 14276
SCNN1A-
- GGCUCUUAUGUCUUAUCU 18
10428 14277
SCNN1A-
- UGGCUCUUAUGUCUUAUCU 19
10429 14278
SCNN1A-
- UUGGCUCUUAUGUCUUAUCU 20
10430 14279
SCNN1A- - CUUGGCUCUUAUGUCUUAUCU 21 14280
1485
5535.1 10431
SCNN1A-
- CCUUGGCUCUUAUGUCUUAUCU 22
10432 14281
SCNN1A-
- CCCUUGGCUCUUAUGUCUUAUCU 23
10433 14282
SCNN1A-
- GCCCUUGGCUCUUAUGUCUUAUCU 24
10434 14283
SCNN1A-
- CUCUUAUGUCUUAUCUCU 18
10435 14284
SCNN1A-
- GCUCUUAUGUCUUAUCUCU 19
10436 14285
SCNN1A-
- GGCUCUUAUGUCUUAUCUCU 20
10437 14286
SCNN1A-
- UGGCUCUUAUGUCUUAUCUCU 21
10438 14287
SCNN1A-
- UUGGCUCUUAUGUCUUAUCUCU 22
10439 14288
SCNN1A-
- CUUGGCUCUUAUGUCUUAUCUCU 23
10440 14289
SCNN1A-
- CCUUGGCUCUUAUGUCUUAUCUCU 24
10441 14290
SCNN1A-
- AGAGAUGACACCUUCUCU 18
10442 14291
SCNN1A-
- CAGAGAUGACACCUUCUCU 19
10443 14292
SCNNlA-5926 - GCAGAGAUGACACCUUCUCU 20 9775
SCNN1A-
- AGCAGAGAUGACACCUUCUCU 21
10444 14293
SCNN1A-
- CAGCAGAGAUGACACCUUCUCU 22
10445 14294
SCNN1A-
- UCAGCAGAGAUGACACCUUCUCU 23
10446 14295
SCNN1A-
- UUCAGCAGAGAUGACACCUUCUCU 24
10447 14296
SCNN1A-
- UGGAGUUUCUAGGGGUCU 18
10448 14297
SCNN1A-
- CUGGAGUUUCUAGGGGUCU 19
10449 14298
SCNN1A-
- ACUGGAGUUUCUAGGGGUCU 20
10450 14299
SCNN1A-
- GACUGGAGUUUCUAGGGGUCU 21
10451 14300
SCNN1A- - AGACUGGAGUUUCUAGGGGUCU 22 14301
1486
5535.1 10452
SCNN1A-
- GAGACUGGAGUUUCUAGGGGUCU 23
10453 14302
SCNN1A-
- GGAGACUGGAGUUUCUAGGGGUCU 24
10454 14303
SCNN1A-
- UCCCCCAUGAGUCUGUCU 18
10455 14304
SCNN1A-
- AUCCCCCAUGAGUCUGUCU 19
10456 14305
SCNN1A-
- GAUCCCCCAUGAGUCUGUCU 20
10457 14306
SCNN1A-
- CGAUCCCCCAUGAGUCUGUCU 21
10458 14307
SCNN1A-
- CCGAUCCCCCAUGAGUCUGUCU 22
10459 14308
SCNN1A-
- CCCGAUCCCCCAUGAGUCUGUCU 23
10460 14309
SCNN1A-
- CCCCGAUCCCCCAUGAGUCUGUCU 24
10461 14310
SCNN1A-
- GCAGAGAUGACACCUUCU 18
10462 14311
SCNN1A-
- AGCAGAGAUGACACCUUCU 19
10463 14312
SCNN1A-
- CAGCAGAGAUGACACCUUCU 20
10464 14313
SCNN1A-
- UCAGCAGAGAUGACACCUUCU 21
10465 14314
SCNN1A-
- UUCAGCAGAGAUGACACCUUCU 22
10466 14315
SCNN1A-
- AUUCAGCAGAGAUGACACCUUCU 23
10467 14316
SCNN1A-
- GAUUCAGCAGAGAUGACACCUUCU 24
10468 14317
SCNN1A-
- CAGAGGAGAGGCCGUUCU 18
10469 14318
SCNN1A-
- GCAGAGGAGAGGCCGUUCU 19
10470 14319
SCNNlA-5750 - AGCAGAGGAGAGGCCGUUCU 20 9599
SCNN1A-
- AAGCAGAGGAGAGGCCGUUCU 21
10471 14320
SCNN1A-
- GAAGCAGAGGAGAGGCCGUUCU 22
10472 14321
SCNN1A- - GGAAGCAGAGGAGAGGCCGUUCU 23 14322
1487
5535.1 10473
SCNN1A-
- GGGAAGCAGAGGAGAGGCCGUUCU 24
10474 14323
SCNN1A-
- CCUUUUGCUGCAUUAAGU 18
10475 14324
SCNN1A-
- UCCUUUUGCUGCAUUAAGU 19
10476 14325
SCNN1A-
- AUCCUUUUGCUGCAUUAAGU 20
10477 14326
SCNN1A-
- UAUCCUUUUGCUGCAUUAAGU 21
10478 14327
SCNN1A-
- UUAUCCUUUUGCUGCAUUAAGU 22
10479 14328
SCNN1A-
- CUUAUCCUUUUGCUGCAUUAAGU 23
10480 14329
SCNN1A-
- CCUUAUCCUUUUGCUGCAUUAAGU 24
10481 14330
SCNN1A-
- UGGGAUAUGUGGGGCAGU 18
10482 14331
SCNN1A-
- CUGGGAUAUGUGGGGCAGU 19
10483 14332
SCNNlA-5753 - UCUGGGAUAUGUGGGGCAGU 20 9602
SCNN1A-
- CUCUGGGAUAUGUGGGGCAGU 21
10484 14333
SCNN1A-
- UCUCUGGGAUAUGUGGGGCAGU 22
10485 14334
SCNN1A-
- GUCUCUGGGAUAUGUGGGGCAGU 23
10486 14335
SCNN1A-
- GGUCUCUGGGAUAUGUGGGGCAGU 24
10487 14336
SCNN1A-
- GAGCUGAGGGCCUAGAGU 18
10488 14337
SCNN1A-
- GGAGCUGAGGGCCUAGAGU 19
10489 14338
SCNN1A-
- UGGAGCUGAGGGCCUAGAGU 20
10490 14339
SCNN1A-
- CUGGAGCUGAGGGCCUAGAGU 21
10491 14340
SCNN1A-
- GCUGGAGCUGAGGGCCUAGAGU 22
10492 14341
SCNN1A-
- GGCUGGAGCUGAGGGCCUAGAGU 23
10493 14342
SCNN1A- - AGGCUGGAGCUGAGGGCCUAGAGU 24 14343
1488
5535.1 10494
SCNN1A-
- GAGGAGGGAGGGAGGAGU 18
10495 14344
SCNN1A-
- GGAGGAGGGAGGGAGGAGU 19
10496 14345
SCNNlA-6187 - UGGAGGAGGGAGGGAGGAGU 20 10036
SCNN1A-
- GUGGAGGAGGGAGGGAGGAGU 21
10497 14346
SCNN1A-
- GGUGGAGGAGGGAGGGAGGAGU 22
10498 14347
SCNN1A-
- AGGUGGAGGAGGGAGGGAGGAGU 23
10499 14348
SCNN1A-
- AAGGUGGAGGAGGGAGGGAGGAGU 24
10500 14349
SCNN1A-
- GGCAGAUAGAGAGGGAGU 18
10501 14350
SCNN1A-
- AGGCAGAUAGAGAGGGAGU 19
10502 14351
SCNN1A-
- AAGGCAGAUAGAGAGGGAGU 20
10503 14352
SCNN1A-
- GAAGGCAGAUAGAGAGGGAGU 21
10504 14353
SCNN1A-
- AGAAGGCAGAUAGAGAGGGAGU 22
10505 14354
SCNN1A-
- CAGAAGGCAGAUAGAGAGGGAGU 23
10506 14355
SCNN1A-
- ACAGAAGGCAGAUAGAGAGGGAGU 24
10507 14356
SCNN1A-
- CAGCCGCAACCUGGGAGU 18
10508 14357
SCNN1A-
- CCAGCCGCAACCUGGGAGU 19
10509 14358
SCNNlA-5754 - UCCAGCCGCAACCUGGGAGU 20 9603
SCNN1A-
- GUCCAGCCGCAACCUGGGAGU 21
10510 14359
SCNN1A-
- AGUCCAGCCGCAACCUGGGAGU 22
10511 14360
SCNN1A-
- CAGUCCAGCCGCAACCUGGGAGU 23
10512 14361
SCNN1A-
- CCAGUCCAGCCGCAACCUGGGAGU 24
10513 14362
SCNN1A-
- CGGGCUCUGUGUGGGAGU 18
10514 14363
1489
5535.1 SCNN1A-
- ACGGGCUCUGUGUGGGAGU 19
10515 14364
SCNN1A-
- CACGGGCUCUGUGUGGGAGU 20
10516 14365
SCNN1A-
- CCACGGGCUCUGUGUGGGAGU 21
10517 14366
SCNN1A-
- UCCACGGGCUCUGUGUGGGAGU 22
10518 14367
SCNN1A-
- AUCCACGGGCUCUGUGUGGGAGU 23
10519 14368
SCNN1A-
- AAUCCACGGGCUCUGUGUGGGAGU 24
10520 14369
SCNN1A-
- GCCUCCUGUGGGGCCCGU 18
10521 14370
SCNN1A-
- UGCCUCCUGUGGGGCCCGU 19
10522 14371
SCNN1A-
- CUGCCUCCUGUGGGGCCCGU 20
10523 14372
SCNN1A-
- GCUGCCUCCUGUGGGGCCCGU 21
10524 14373
SCNN1A-
- GGCUGCCUCCUGUGGGGCCCGU 22
10525 14374
SCNN1A-
- GGGCUGCCUCCUGUGGGGCCCGU 23
10526 14375
SCNN1A-
- UGGGCUGCCUCCUGUGGGGCCCGU 24
10527 14376
SCNN1A-
- CCCGGGUCUGGACAAGGU 18
10528 14377
SCNN1A-
- UCCCGGGUCUGGACAAGGU 19
10529 14378
SCNNlA-5755 - CUCCCGGGUCUGGACAAGGU 20 9604
SCNN1A-
- CCUCCCGGGUCUGGACAAGGU 21
10530 14379
SCNN1A-
- CCCUCCCGGGUCUGGACAAGGU 22
10531 14380
SCNN1A-
- CCCCUCCCGGGUCUGGACAAGGU 23
10532 14381
SCNN1A-
- GCCCCUCCCGGGUCUGGACAAGGU 24
10533 14382
SCNN1A-
- CCGCUGCACCUGUCAGGU 18
10534 14383
SCNN1A-
- GCCGCUGCACCUGUCAGGU 19
10535 14384
1490
5535.1 SCNN1A-
- GGCCGCUGCACCUGUCAGGU 20
10536 14385
SCNN1A-
- AGGCCGCUGCACCUGUCAGGU 21
10537 14386
SCNN1A-
- CAGGCCGCUGCACCUGUCAGGU 22
10538 14387
SCNN1A-
- CCAGGCCGCUGCACCUGUCAGGU 23
10539 14388
SCNN1A-
- GCCAGGCCGCUGCACCUGUCAGGU 24
10540 14389
SCNN1A-
- CAGGACACAGCUCGAGGU 18
10541 14390
SCNN1A-
- UCAGGACACAGCUCGAGGU 19
10542 14391
SCNN1A-
- AUCAGGACACAGCUCGAGGU 20
10543 14392
SCNN1A-
- AAUCAGGACACAGCUCGAGGU 21
10544 14393
SCNN1A-
- GAAUCAGGACACAGCUCGAGGU 22
10545 14394
SCNN1A-
- AGAAUCAGGACACAGCUCGAGGU 23
10546 14395
SCNN1A-
- CAG AAU CAGG ACACAG CU CG AGG U 24
10547 14396
SCNN1A-
- CCUGGGCCCCUCCCGGGU 18
10548 14397
SCNN1A-
- ACCUGGGCCCCUCCCGGGU 19
10549 14398
SCNN1A-
- CACCUGGGCCCCUCCCGGGU 20
10550 14399
SCNN1A-
- UCACCUGGGCCCCUCCCGGGU 21
10551 14400
SCNN1A-
- UUCACCUGGGCCCCUCCCGGGU 22
10552 14401
SCNN1A-
- CUUCACCUGGGCCCCUCCCGGGU 23
10553 14402
SCNN1A-
- GCUUCACCUGGGCCCCUCCCGGGU 24
10554 14403
SCNNlA-2176 - UAAGCAAGGGAACCUGGU 18 6025
SCNNlA-2177 - GUAAGCAAGGGAACCUGGU 19 6026
SCNNlA-2178 - GGUAAGCAAGGGAACCUGGU 20 6027
SCNNlA-2179 - AGGUAAGCAAGGGAACCUGGU 21 6028
SCNNlA-2180 - AAGGUAAGCAAGGGAACCUGGU 22 6029
1491
5535.1 SCNNlA-2181 - C A AG G U A AG C A AG GGAACCUGGU 23 6030
SCNNlA-2182 - UCAAGGUAAGCAAGGGAACCUGGU 24 6031
SCNN1A-
- GAGGACCAUGCCCAAUGU 18
10555 14404
SCNN1A-
- GGAGGACCAUGCCCAAUGU 19
10556 14405
SCNN1A-
- GGGAGGACCAUGCCCAAUGU 20
10557 14406
SCNN1A-
- AGGGAGGACCAUGCCCAAUGU 21
10558 14407
SCNN1A-
- CAGGGAGGACCAUGCCCAAUGU 22
10559 14408
SCNN1A-
- GCAGGGAGGACCAUGCCCAAUGU 23
10560 14409
SCNN1A-
- UGCAGGGAGGACCAUGCCCAAUGU 24
10561 14410
SCNN1A-
- CGAAUCCACGGGCUCUGU 18
10562 14411
SCNN1A-
- ACGAAUCCACGGGCUCUGU 19
10563 14412
SCNN1A-
- GACGAAUCCACGGGCUCUGU 20
10564 14413
SCNN1A-
- AGACGAAUCCACGGGCUCUGU 21
10565 14414
SCNN1A-
- CAGACGAAUCCACGGGCUCUGU 22
10566 14415
SCNN1A-
- GCAGACGAAUCCACGGGCUCUGU 23
10567 14416
SCNN1A-
- AGCAGACGAAUCCACGGGCUCUGU 24
10568 14417
SCNN1A-
- UGAGAUCUGCACUUUUGU 18
10569 14418
SCNN1A-
- CUGAGAUCUGCACUUUUGU 19
10570 14419
SCNN1A-
- UCUGAGAUCUGCACUUUUGU 20
10571 14420
SCNN1A-
- AUCUGAGAUCUGCACUUUUGU 21
10572 14421
SCNN1A-
- AAUCUGAGAUCUGCACUUUUGU 22
10573 14422
SCNN1A-
- AAAUCUGAGAUCUGCACUUUUGU 23
10574 14423
SCNN1A- - GAAAUCUGAGAUCUGCACUUUUGU 24 14424
1492
5535.1 10575
SCNN1A-
- UAAGUUUGGAAAGAGAUU 18
10576 14425
SCNN1A-
- UUAAGUUUGGAAAGAGAUU 19
10577 14426
SCNN1A-
- AU U AAG U U UGG AAAG AG AU U 20
10578 14427
SCNN1A-
- CAU U AAG U U UGG AAAG AG AU U 21
10579 14428
SCNN1A-
- GCAU U AAG U U UGG AAAG AG AU U 22
10580 14429
SCNN1A-
- UG CAU U AAG U U UGG AAAG AG AU U 23
10581 14430
SCNN1A-
- CUGCAUUAAGUUUGGAAAGAGAUU 24
10582 14431
SCNN1A-
- GAAAACUGAUUUAUCCUU 18
10583 14432
SCNN1A-
- AGAAAACUGAUUUAUCCUU 19
10584 14433
SCNNlA-6189 - CAGAAAACUGAUUUAUCCUU 20 10038
SCNN1A-
- UCAGAAAACUGAUUUAUCCUU 21
10585 14434
SCNN1A-
- CUCAGAAAACUGAUUUAUCCUU 22
10586 14435
SCNN1A-
- CCUCAGAAAACUGAUUUAUCCUU 23
10587 14436
SCNN1A-
- ACCUCAGAAAACUGAUUUAUCCUU 24
10588 14437
SCNN1A-
- CGGGAGCCCUCCUUCCUU 18
10589 14438
SCNN1A-
- UCGGGAGCCCUCCUUCCUU 19
10590 14439
SCNNlA-5770 - CUCGGGAGCCCUCCUUCCUU 20 9619
SCNN1A-
- CCUCGGGAGCCCUCCUUCCUU 21
10591 14440
SCNN1A-
- CCCUCGGGAGCCCUCCUUCCUU 22
10592 14441
SCNN1A-
- GCCCUCGGGAGCCCUCCUUCCUU 23
10593 14442
SCNN1A-
- UGCCCUCGGGAGCCCUCCUUCCUU 24
10594 14443
SCNN1A-
- GCCUUUGUCUGCUGGCUU 18
10595 14444
1493
5535.1 SCNN1A-
- GGCCUUUGUCUGCUGGCUU 19
10596 14445
SCNN1A-
- GGGCCUUUGUCUGCUGGCUU 20
10597 14446
SCNN1A-
- UGGGCCUUUGUCUGCUGGCUU 21
10598 14447
SCNN1A-
- CUGGGCCUUUGUCUGCUGGCUU 22
10599 14448
SCNN1A-
- GCUGGGCCUUUGUCUGCUGGCUU 23
10600 14449
SCNN1A-
- GGCUGGGCCUUUGUCUGCUGGCUU 24
10601 14450
SCNN1A-
- CUUUUGCUGCAUUAAGUU 18
10602 14451
SCNN1A-
- CCUUUUGCUGCAUUAAGUU 19
10603 14452
SCNNlA-5771 - UCCUUUUGCUGCAUUAAGUU 20 9620
SCNN1A-
- AUCCUUUUGCUGCAUUAAGUU 21
10604 14453
SCNN1A-
- UAUCCUUUUGCUGCAUUAAGUU 22
10605 14454
SCNN1A-
- UUAUCCUUUUGCUGCAUUAAGUU 23
10606 14455
SCNN1A-
- CUUAUCCUUUUGCUGCAUUAAGUU 24
10607 14456
SCNN1A-
- AAGUUUGGAAAGAGAUUU 18
10608 14457
SCNN1A-
- UAAGUUUGGAAAGAGAUUU 19
10609 14458
SCNNlA-5773 - UUAAGUUUGGAAAGAGAUUU 20 9622
SCNN1A-
- AU U AAG U U UGG AAAG AG AU U U 21
10610 14459
SCNN1A-
- CAU U AAG U U UGG AAAG AG AU U U 22
10611 14460
SCNN1A-
- GCAU U AAG U U UGG AAAG AG AU U U 23
10612 14461
SCNN1A-
- UG CAU U AAG U U UGG AAAG AG AU U U 24
10613 14462
SCNN1A-
- GACACCGGCUUUCACUUU 18
10614 14463
SCNN1A-
- UGACACCGGCUUUCACUUU 19
10615 14464
SCNN1A- - UUGACACCGGCUUUCACUUU 20 14465
1494
5535.1 10616
SCNN1A-
- GUUGACACCGGCUUUCACUUU 21
10617 14466
SCNN1A-
- GGUUGACACCGGCUUUCACUUU 22
10618 14467
SCNN1A-
- UGGUUGACACCGGCUUUCACUUU 23
10619 14468
SCNN1A-
- CUGGUUGACACCGGCUUUCACUUU 24
10620 14469
SCNN1A-
- AGGCAGGGAGGUGCUUUU 18
10621 14470
SCNN1A-
- AAGGCAGGGAGGUGCUUUU 19
10622 14471
SCNN1A-
- AAAGGCAGGGAGGUGCUUUU 20
10623 14472
SCNN1A-
- AAAAGGCAGGGAGGUGCUUUU 21
10624 14473
SCNN1A-
- GAAAAGGCAGGGAGGUGCUUUU 22
10625 14474
SCNN1A-
- AGAAAAGGCAGGGAGGUGCUUUU 23
10626 14475
SCNN1A-
- UAGAAAAGGCAGGGAGGUGCUUUU 24
10627 14476
Table 47E provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the fifth tier parameters. The targeting domains bind within the additional 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), e.g., extending to lkb upstream and downstream of a TSS, starts with a 5'G and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through co Any of the targeting domains in the table can be used with a S. Aureus eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA genemplementary base pairing. Any of the targeting domains in the Table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 47E
1495
5535.1 5th Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
SCNN1A-
+ GCCUGGUCUGGGCUGAGCCA 20
10628 14477
SCNNlA-1302 + GGUUGAUGUUGAGGCUGA 18 5151
SCNNlA-42 + GAGGUUGAUGUUGAGGCUGA 20 519
SCNNlA-1303 + GUUGAGGUUGAUGUUGAGGCUGA 23 5152
SCNN1A-
+ GUGAGCUCUACCUGGGAC 18
10629 14478
SCNN1A-
+ GCAGUGAGCUCUACCUGGGAC 21
10630 14479
SCNNlA-1417 + GUUCCCCUUCAUGAGCCC 18 5266
SCNNlA-1420 + GCUUGUUCCCCUUCAUGAGCCC 22 5269
SCNNlA-1427 + GCACACCAGGCGGAUGGCGCC 21 5276
SCNNlA-1429 + GAGCACACCAGGCGGAUGGCGCC 23 5278
SCNNlA-1430 + GGAGCACACCAGGCGGAUGGCGCC 24 5279
SCNN1A-
+ GAUCAUGCACUAUCCUCUAGGC 22
10631 14480
SCNN1A-
+ GGAUCAUGCACUAUCCUCUAGGC 23
10632 14481
SCNNlA-1316 + GUGCUGGGAGCACACCAG 18 5165
SCNNlA-1317 + GUUGUGCUGGGAGCACACCAG 21 5166
SCNNlA-1318 + GGUUGUGCUGGGAGCACACCAG 22 5167
SCNNlA-1319 + GCGGUUGUGCUGGGAGCACACCAG 24 5168
SCNNlA-1320 + GUACUCUCCGAAAAGCAGG 19 5169
SCNNlA-1321 + GAAGUACUCUCCGAAAAGCAGG 22 5170
SCNN1A-
+ GUGACCCUGCCACGUCCUG 19
10633 14482
SCNN1A-
+ GGUGACCCUGCCACGUCCUG 20
10634 14483
SCNN1A-
+ GUGGUGACCCUGCCACGUCCUG 22
10635 14484
SCNN1A-
+ GGUGGUGACCCUGCCACGUCCUG 23
10636 14485
SCNN1A-
+ GGGUGGUGACCCUGCCACGUCCUG 24
10637 14486
SCNN1A-
+ GCCACGUCCUGCCGGGUAU 19
10638 14487
SCNNlA-1326 + GAGGGACUAACCGACCUGU 19 5175
SCNNlA-1327 + GCAGAGGGACUAACCGACCUGU 22 5176
SCNNlA-1328 + GGCAGAGGGACUAACCGACCUGU 23 5177
SCNNlA-1329 + GGGCAGAGGGACUAACCGACCUGU 24 5178
1496
5535.1 SCNNlA-1330 + GCGGGGAAGACGAGCUUGU 19 5179
SCNNlA-1331 + GACUAACCGACCUGUAGGGAUU 22 5180
SCNNlA-1332 + GGACUAACCGACCUGUAGGGAUU 23 5181
SCNNlA-1333 + GGGACUAACCGACCUGUAGGGAUU 24 5182
SCNNlA-1334 - GCGGAGGAGGAGGCCCUGA 19 5183
SCNNlA-189 - GGCGGAGGAGGAGGCCCUGA 20 819
SCNN1A-
- GCUGCUGUACUCCAGCCUA 19
10639 14488
SCNN1A-
- GUUCUAGCCCGCUCCAGGUC 20
10640 14489
SCNN1A-
- GCCUGUUCUAGCCCGCUCCAGGUC 24
10641 14490
SCNN1A-
- GCGCCUGGAAGGGUGGUC 18
10642 14491
SCNN1A-
- GCCUGCGCCUGGAAGGGUGGUC 22
10643 14492
SCNN1A-
- GUGCCUGCGCCUGGAAGGGUGGUC 24
10644 14493
SCNNlA-197 - GCAAUUCGGCCUGCUUUUCG 20 826
SCNNlA-1337 - GGCAAUUCGGCCUGCUUUUCG 21 5186
SCNN1A-
- GCAGGCAGAGCCUCAGACCU 20
10645 14494
SCNN1A-
- GGCAGGCAGAGCCUCAGACCU 21
10646 14495
SCNN1A-
- GGGCAGGCAGAGCCUCAGACCU 22
10647 14496
SCNNlA-1338 - GCUCCUACCGAGAGCUCU 18 5187
Table 47F provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the six tier parameters. The targeting domains bind within the additional 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), e.g., extending to lkb upstream and downstream of a TSS and PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. Aureus eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
Table 47F
1497
5535.1 6th Tier
Target Site
gRNA Name DNA Strand Targeting Domain
Length Seq ID
SCNN1A-
+ CUGGUCUGGGCUGAGCCA 18
10648 14497
SCNN1A-
+ CCUGGUCUGGGCUGAGCCA 19
10649 14498
SCNN1A-
+ UGCCUGGUCUGGGCUGAGCCA 21
10650 14499
SCNN1A-
+ AUGCCUGGUCUGGGCUGAGCCA 22
10651 14500
SCNN1A-
+ AAUGCCUGGUCUGGGCUGAGCCA 23
10652 14501
SCNN1A-
+ CAAUGCCUGGUCUGGGCUGAGCCA 24
10653 14502
SCNN1A-
+ UCUUAUUUAUCUUAGAGA 18
10654 14503
SCNN1A-
+ UUCUUAUUUAUCUUAGAGA 19
10655 14504
SCNN1A-
+ UUUCUUAUUUAUCUUAGAGA 20
10656 14505
SCNN1A-
+ UUUUCUUAUUUAUCUUAGAGA 21
10657 14506
SCNN1A-
+ AUUUUCUUAUUUAUCUUAGAGA 22
10658 14507
SCNN1A-
+ UAUUUUCUUAUUUAUCUUAGAGA 23
10659 14508
SCNN1A-
+ UUAUUUUCUUAUUUAUCUUAGAGA 24
10660 14509
SCNNlA-1340 + AGGUUGAUGUUGAGGCUGA 19 5189
SCNNlA-1341 + UGAGGUUGAUGUUGAGGCUGA 21 5190
SCNNlA-1342 + UUGAGGUUGAUGUUGAGGCUGA 22 5191
SCNNlA-1343 + AGUUGAGGUUGAUGUUGAGGCUGA 24
5192
SCNN1A-
+ AGUGAGCUCUACCUGGGAC 19
10661 14510
SCNNlA-6306 + CAGUGAGCUCUACCUGGGAC 20 10155
SCNN1A-
+ AGCAGUGAGCUCUACCUGGGAC 22
10662 14511
SCNN1A-
+ CAGCAGUGAGCUCUACCUGGGAC 23
10663 14512
SCNN1A-
+ CCAGCAGUGAGCUCUACCUGGGAC 24
10664 14513
1498
5535.1 SCNNlA-1418 + UGUUCCCCUUCAUGAGCCC 19 5267
SCNNlA-72 + UUGUUCCCCUUCAUGAGCCC 20 599
SCNNlA-1419 + CUUGUUCCCCUUCAUGAGCCC 21 5268
SCNNlA-1423 + CGCUUGUUCCCCUUCAUGAGCCC 23 5272
SCNNlA-1424 + ACGCUUGUUCCCCUUCAUGAGCCC 24 5273
SCNNlA-1425 + CACCAGGCGGAUGGCGCC 18 5274
SCNNlA-1426 + ACACCAGGCGGAUGGCGCC 19 5275
SCNNlA-223 + CACACCAGGCGGAUGGCGCC 20 846
SCNNlA-1428 + AGCACACCAGGCGGAUGGCGCC 22 5277
SCNN1A-
+ AUGCACUAUCCUCUAGGC 18
10665 14514
SCNN1A-
+ CAUGCACUAUCCUCUAGGC 19
10666 14515
SCNNlA-6323 + UCAUGCACUAUCCUCUAGGC 20 10172
SCNN1A-
+ AUCAUGCACUAUCCUCUAGGC 21
10667 14516
SCNN1A-
+ AGGAUCAUGCACUAUCCUCUAGGC 24
10668 14517
SCNNlA-1371 + UGUGCUGGGAGCACACCAG 19 5220
SCNNlA-224 + UUGUGCUGGGAGCACACCAG 20 847
SCNNlA-1372 + CGGUUGUGCUGGGAGCACACCAG 23 5221
SCNNlA-1373 + UACUCUCCGAAAAGCAGG 18 5222
SCNNlA-230 + AGUACUCUCCGAAAAGCAGG 20 851
SCNNlA-1374 + AAGUACUCUCCGAAAAGCAGG 21 5223
SCNNlA-1375 + UGAAGUACUCUCCGAAAAGCAGG 23 5224
SCNNlA-1376 + CUGAAGUACUCUCCGAAAAGCAGG 24 5225
SCNN1A-
+ UGACCCUGCCACGUCCUG 18
10669 14518
SCNN1A-
+ UGGUGACCCUGCCACGUCCUG 21
10670 14519
SCNN1A-
+ CCACGUCCUGCCGGGUAU 18
10671 14520
SCNNlA-6350 + UGCCACGUCCUGCCGGGUAU 20 10199
SCNN1A-
+ CUGCCACGUCCUGCCGGGUAU 21
10672 14521
SCNN1A-
+ CCUGCCACGUCCUGCCGGGUAU 22
10673 14522
SCNN1A-
+ CCCUGCCACGUCCUGCCGGGUAU 23
10674 14523
SCNN1A-
+ ACCCUGCCACGUCCUGCCGGGUAU 24
10675 14524
SCNNlA-1380 + AGGGACUAACCGACCUGU 18 5229
SCNNlA-424 + AGAGGGACUAACCGACCUGU 20 4273
1499
5535.1 SCNNlA-1381 + CAGAGGGACUAACCGACCUGU 21 5230
SCNNlA-1382 + CGGGGAAGACGAGCUUGU 18 5231
SCNNlA-237 + UGCGGGGAAGACGAGCUUGU 20 857
SCNNlA-1383 + CUGCGGGGAAGACGAGCUUGU 21 5232
SCNNlA-1384 + ACUGCGGGGAAGACGAGCUUGU 22 5233
SCNNlA-1385 + CACUGCGGGGAAGACGAGCUUGU 23 5234
SCNNlA-1386 + UCACUGCGGGGAAGACGAGCUUGU 24 5235
SCNNlA-1387 + AACCGACCUGUAGGGAUU 18 5236
SCNNlA-1388 + UAACCGACCUGUAGGGAUU 19 5237
SCNNlA-1389 + CUAACCGACCUGUAGGGAUU 20 5238
SCNNlA-1390 + ACUAACCGACCUGUAGGGAUU 21 5239
SCNNlA-1391 - CGGAGGAGGAGGCCCUGA 18 5240
SCNNlA-1433 - CGGCGGAGGAGGAGGCCCUGA 21 5282
SCNNlA-1434 - ACGGCGGAGGAGGAGGCCCUGA 22 5283
SCNNlA-1435 - CACGGCGGAGGAGGAGGCCCUGA 23 5284
SCNNlA-1436 - CCACGGCGGAGGAGGAGGCCCUGA 24 5285
SCNN1A-
- CUGCUGUACUCCAGCCUA 18
10676 14525
SCNN1A-
- UGCUGCUGUACUCCAGCCUA 20
10677 14526
SCNN1A-
- AUGCUGCUGUACUCCAGCCUA 21
10678 14527
SCNN1A-
- CAUGCUGCUGUACUCCAGCCUA 22
10679 14528
SCNN1A-
- UCAUGCUGCUGUACUCCAGCCUA 23
10680 14529
SCNN1A-
- AUCAUGCUGCUGUACUCCAGCCUA 24
10681 14530
SCNN1A-
- UCUAGCCCGCUCCAGGUC 18
10682 14531
SCNN1A-
- UUCUAGCCCGCUCCAGGUC 19
10683 14532
SCNN1A-
- UGUUCUAGCCCGCUCCAGGUC 21
10684 14533
SCNN1A-
- CUGUUCUAGCCCGCUCCAGGUC 22
10685 14534
SCNN1A-
- CCUGUUCUAGCCCGCUCCAGGUC 23
10686 14535
SCNN1A-
- UGCGCCUGGAAGGGUGGUC 19
10687 14536
SCNN1A-
- CUGCGCCUGGAAGGGUGGUC 20
10688 14537
SCNN1A- - CCUGCGCCUGGAAGGGUGGUC 21 14538
1500
5535.1 10689
SCNN1A-
- UGCCUGCGCCUGGAAGGGUGGUC 23
10690 14539
SCNNlA-1395 - AAUUCGGCCUGCUUUUCG 18 5244
SCNNlA-1396 - CAAUUCGGCCUGCUUUUCG 19 5245
SCNNlA-1397 - UGGCAAUUCGGCCUGCUUUUCG 22 5246
SCNNlA-1398 - CUGGCAAUUCGGCCUGCUUUUCG 23 5247
SCNNlA-1399 - ACUGGCAAUUCGGCCUGCUUUUCG 24 5248
SCNN1A-
- CCUGGUGCCUGCGCCUGG 18
10691 14540
SCNN1A-
- CCCUGGUGCCUGCGCCUGG 19
10692 14541
SCNN1A-
- UCCCUGGUGCCUGCGCCUGG 20
10693 14542
SCNN1A-
- UUCCCUGGUGCCUGCGCCUGG 21
10694 14543
SCNN1A-
- CUUCCCUGGUGCCUGCGCCUGG 22
10695 14544
SCNN1A-
- CCUUCCCUGGUGCCUGCGCCUGG 23
10696 14545
SCNN1A-
- CCCUUCCCUGGUGCCUGCGCCUGG 24
10697 14546
SCNN1A-
- AUACCCGGCAGGACGUGG 18
10698 14547
SCNN1A-
- CAUACCCGGCAGGACGUGG 19
10699 14548
SCNN1A-
- CCAUACCCGGCAGGACGUGG 20
10700 14549
SCNN1A-
- CCCAUACCCGGCAGGACGUGG 21
10701 14550
SCNN1A-
- UCCCAUACCCGGCAGGACGUGG 22
10702 14551
SCNN1A-
- CUCCCAUACCCGGCAGGACGUGG 23
10703 14552
SCNN1A-
- ACUCCCAUACCCGGCAGGACGUGG 24
10704 14553
SCNN1A-
- AGGCAGAGCCUCAGACCU 18
10705 14554
SCNN1A-
- CAGGCAGAGCCUCAGACCU 19
10706 14555
SCNN1A-
- UGGGCAGGCAGAGCCUCAGACCU 23
10707 14556
SCNN1A- - CUGGGCAGGCAGAGCCUCAGACCU 24 14557
1501
5535.1 10708
SCNNlA-1400 - CGCUCCUACCGAGAGCUCU 19 5249
SCNNlA-192 - CCGCUCCUACCGAGAGCUCU 20 822
SCNNlA-1401 - ACCGCUCCUACCGAGAGCUCU 21 5250
SCNNlA-1402 - CACCGCUCCUACCGAGAGCUCU 22 5251
SCNNlA-1403 - CCACCGCUCCUACCGAGAGCUCU 23 5252
SCNNlA-1404 - UCCACCGCUCCUACCGAGAGCUCU 24 5253
Table 47G provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the seven tier parameters. The targeting domains bind within the additional 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), e.g., extending to lkb upstream and downstream of a TSS and PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. Aureus eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
Table 47G
Figure imgf001503_0001
1502
5535.1 SCNN1A-
+ CUUCCUUUCCCUCCCCAAA 19
10717 14566
SCNNlA-6279 + CCUUCCUUUCCCUCCCCAAA 20 10128
SCNN1A-
+ CCCUUCCUUUCCCUCCCCAAA 21
10718 14567
SCNN1A-
+ CCCCUUCCUUUCCCUCCCCAAA 22
10719 14568
SCNN1A-
+ UCCCCUUCCUUUCCCUCCCCAAA 23
10720 14569
SCNN1A-
+ GUCCCCUUCCUUUCCCUCCCCAAA 24
10721 14570
SCNN1A-
+ CUUCCUUUCCCUCCCCAA 18
10722 14571
SCNN1A-
+ CCUUCCUUUCCCUCCCCAA 19
10723 14572
SCNNlA-6281 + CCCUUCCUUUCCCUCCCCAA 20 10130
SCNN1A-
+ CCCCUUCCUUUCCCUCCCCAA 21
10724 14573
SCNN1A-
+ UCCCCUUCCUUUCCCUCCCCAA 22
10725 14574
SCNN1A-
+ GUCCCCUUCCUUUCCCUCCCCAA 23
10726 14575
SCNN1A-
+ AGUCCCCUUCCUUUCCCUCCCCAA 24
10727 14576
SCNN1A-
+ UUCCAGGCGCAGGCACCA 18
10728 14577
SCNN1A-
+ CUUCCAGGCGCAGGCACCA 19
10729 14578
SCNNlA-6290 + CCUUCCAGGCGCAGGCACCA 20 10139
SCNN1A-
+ CCCUUCCAGGCGCAGGCACCA 21
10730 14579
SCNN1A-
+ ACCCUUCCAGGCGCAGGCACCA 22
10731 14580
SCNN1A-
+ CACCCUUCCAGGCGCAGGCACCA 23
10732 14581
SCNN1A-
+ CCACCCUUCCAGGCGCAGGCACCA 24
10733 14582
SCNN1A-
+ CCUUCCUUUCCCUCCCCA 18
10734 14583
SCNN1A-
+ CCCUUCCUUUCCCUCCCCA 19
10735 14584
SCNN1A-
+ CCCCUUCCUUUCCCUCCCCA 20
10736 14585
1503
5535.1 SCNN1A-
+ UCCCCUUCCUUUCCCUCCCCA 21
10737 14586
SCNN1A-
+ GUCCCCUUCCUUUCCCUCCCCA 22
10738 14587
SCNN1A-
+ AGUCCCCUUCCUUUCCCUCCCCA 23
10739 14588
SCNN1A-
+ UAGUCCCCUUCCUUUCCCUCCCCA 24
10740 14589
SCNN1A-
+ UGAGGCUCUGCCUGCCCA 18
10741 14590
SCNN1A-
+ CUGAGGCUCUGCCUGCCCA 19
10742 14591
SCNN1A-
+ UCUGAGGCUCUGCCUGCCCA 20
10743 14592
SCNN1A-
+ GUCUGAGGCUCUGCCUGCCCA 21
10744 14593
SCNN1A-
+ GGUCUGAGGCUCUGCCUGCCCA 22
10745 14594
SCNN1A-
+ AGGUCUGAGGCUCUGCCUGCCCA 23
10746 14595
SCNN1A-
+ CAGGUCUGAGGCUCUGCCUGCCCA 24
10747 14596
SCNN1A-
+ GGCACCAGGGAAGGGGCA 18
10748 14597
SCNN1A-
+ AGGCACCAGGGAAGGGGCA 19
10749 14598
SCNN1A-
+ CAGGCACCAGGGAAGGGGCA 20
10750 14599
SCNN1A-
+ GCAGGCACCAGGGAAGGGGCA 21
10751 14600
SCNN1A-
+ CGCAGGCACCAGGGAAGGGGCA 22
10752 14601
SCNN1A-
+ GCGCAGGCACCAGGGAAGGGGCA 23
10753 14602
SCNN1A-
+ GGCGCAGGCACCAGGGAAGGGGCA 24
10754 14603
SCNN1A-
+ AGGCGCAGGCACCAGGGA 18
10755 14604
SCNN1A-
+ CAGGCGCAGGCACCAGGGA 19
10756 14605
SCNNlA-6296 + CCAGGCGCAGGCACCAGGGA 20 10145
SCNN1A-
+ UCCAGGCGCAGGCACCAGGGA 21
10757 14606
1504
5535.1 SCNN1A-
+ UUCCAGGCGCAGGCACCAGGGA 22
10758 14607
SCNN1A-
+ CUUCCAGGCGCAGGCACCAGGGA 23
10759 14608
SCNN1A-
+ CCUUCCAGGCGCAGGCACCAGGGA 24
10760 14609
SCNNlA-1452 + CUAACCGACCUGUAGGGA 18 5301
SCNNlA-1453 + ACUAACCGACCUGUAGGGA 19 5302
SCNNlA-1454 + GACUAACCGACCUGUAGGGA 20 5303
SCNNlA-1455 + GGACUAACCGACCUGUAGGGA 21 5304
SCNNlA-1456 + GGGACUAACCGACCUGUAGGGA 22 5305
SCNNlA-1457 + AGGGACUAACCGACCUGUAGGGA 23 5306
SCNNlA-1458 + GAGGGACUAACCGACCUGUAGGGA 24 5307
SCNN1A-
+ AGUGAGCUCUACCUGGGA 18
10761 14610
SCNN1A-
+ CAGUGAGCUCUACCUGGGA 19
10762 14611
SCNN1A-
+ GCAGUGAGCUCUACCUGGGA 20
10763 14612
SCNN1A-
+ AGCAGUGAGCUCUACCUGGGA 21
10764 14613
SCNN1A-
+ CAGCAGUGAGCUCUACCUGGGA 22
10765 14614
SCNN1A-
+ CCAGCAGUGAGCUCUACCUGGGA 23
10766 14615
SCNN1A-
+ GCCAGCAGUGAGCUCUACCUGGGA 24
10767 14616
SCNN1A-
+ CAGCAUUCUAGACCUGGA 18
10768 14617
SCNN1A-
+ GCAGCAUUCUAGACCUGGA 19
10769 14618
SCNN1A-
+ UGCAGCAUUCUAGACCUGGA 20
10770 14619
SCNN1A-
+ CUGCAGCAUUCUAGACCUGGA 21
10771 14620
SCNN1A-
+ GCUGCAGCAUUCUAGACCUGGA 22
10772 14621
SCNN1A-
+ UGCUGCAGCAUUCUAGACCUGGA 23
10773 14622
SCNN1A-
+ GUGCUGCAGCAUUCUAGACCUGGA 24
10774 14623
SCNNlA-1459 + CCCUUCAUGAGCCCUGGA 18 5308
SCNNlA-1460 + CCCCUUCAUGAGCCCUGGA 19 5309
1505
5535.1 SCNNlA-205 + UCCCCUUCAUGAGCCCUGGA 20 833
SCNNlA-1461 + UUCCCCUUCAUGAGCCCUGGA 21 5310
SCNNlA-1462 + GUUCCCCUUCAUGAGCCCUGGA 22 5311
SCNNlA-1463 + UGUUCCCCUUCAUGAGCCCUGGA 23 5312
SCNNlA-1464 + UUGUUCCCCUUCAUGAGCCCUGGA 24 5313
SCNN1A-
+ UAUAGUUCUUUUUUAUGA 18
10775 14624
SCNN1A-
+ AUAUAGUUCUUUUUUAUGA 19
10776 14625
SCNN1A-
+ UAUAUAGUUCUUUUUUAUGA 20
10777 14626
SCNN1A-
+ AUAUAUAGUUCUUUUUUAUGA 21
10778 14627
SCNN1A-
+ AAUAUAUAGUUCUUUUUUAUGA 22
10779 14628
SCNN1A-
+ AAAUAUAUAGUUCUUUUUUAUGA 23
10780 14629
SCNN1A-
+ AAAAUAUAUAGUUCUUUUUUAUGA 24
10781 14630
SCNN1A-
+ UACAAUUUUUCAGCAAUA 18
10782 14631
SCNN1A-
+ GUACAAUUUUUCAGCAAUA 19
10783 14632
SCNN1A-
+ AG UACAAU U U U U CAGCAAU A 20
10784 14633
SCNN1A-
+ CAGUACAAUUUUUCAGCAAUA 21
10785 14634
SCNN1A-
+ ACAGUACAAUUUUUCAGCAAUA 22
10786 14635
SCNN1A-
+ CACAGUACAAUUUUUCAGCAAUA 23
10787 14636
SCNN1A-
+ UCACAGUACAAUUUUUCAGCAAUA 24
10788 14637
SCNN1A-
+ CAGCAAU ACAGAAGUAU A 18
10789 14638
SCNN1A-
+ U CAG CAAUACAGAAG U AU A 19
10790 14639
SCNN1A-
+ UUCAGCAAUACAGAAGUAUA 20
10791 14640
SCNN1A-
+ UUUCAGCAAUACAGAAGUAUA 21
10792 14641
SCNN1A-
+ UUUUCAGCAAUACAGAAGUAUA 22
10793 14642
1506
5535.1 SCNN1A-
+ UUUUUCAGCAAUACAGAAGUAUA 23
10794 14643
SCNN1A-
+ AU U U U U CAGCAAU ACAG AAG U AU A 24
10795 14644
SCNN1A-
+ GCCACGUCCUGCCGGGUA 18
10796 14645
SCNN1A-
+ UGCCACGUCCUGCCGGGUA 19
10797 14646
SCNNlA-6301 + CUGCCACGUCCUGCCGGGUA 20 10150
SCNN1A-
+ CCUGCCACGUCCUGCCGGGUA 21
10798 14647
SCNN1A-
+ CCCUGCCACGUCCUGCCGGGUA 22
10799 14648
SCNN1A-
+ ACCCUGCCACGUCCUGCCGGGUA 23
10800 14649
SCNN1A-
+ GACCCUGCCACGUCCUGCCGGGUA 24
10801 14650
SCNNlA-1478 + GUGUUGUUGCAGAAGAAC 18 5327
SCNNlA-1479 + GGUGUUGUUGCAGAAGAAC 19 5328
SCNNlA-220 + UGGUGUUGUUGCAGAAGAAC 20 843
SCNNlA-1480 + GUGGUGUUGUUGCAGAAGAAC 21 5329
SCNNlA-1481 + GGUGGUGUUGUUGCAGAAGAAC 22 5330
SCNNlA-1482 + UGGUGGUGUUGUUGCAGAAGAAC 23 5331
SCNNlA-1483 + AUGGUGGUGUUGUUGCAGAAGAAC 24
5332
SCNN1A-
+ CCUUCCAGGCGCAGGCAC 18
10802 14651
SCNN1A-
+ CCCUUCCAGGCGCAGGCAC 19
10803 14652
SCNN1A-
+ ACCCUUCCAGGCGCAGGCAC 20
10804 14653
SCNN1A-
+ CACCCUUCCAGGCGCAGGCAC 21
10805 14654
SCNN1A-
+ CCACCCUUCCAGGCGCAGGCAC 22
10806 14655
SCNN1A-
+ ACCACCCUUCCAGGCGCAGGCAC 23
10807 14656
SCNN1A-
+ GACCACCCUUCCAGGCGCAGGCAC 24
10808 14657
SCNN1A-
+ AAAAUAGAAAUCUGAGAC 18
10809 14658
SCNN1A-
+ GAAAAUAGAAAUCUGAGAC 19
10810 14659
1507
5535.1 SCNN1A-
+ GGAAAAUAGAAAUCUGAGAC 20
10811 14660
SCNN1A-
+ AGGAAAAUAGAAAUCUGAGAC 21
10812 14661
SCNN1A-
+ GAGGAAAAUAGAAAUCUGAGAC 22
10813 14662
SCNN1A-
+ UGAGGAAAAUAGAAAUCUGAGAC 23
10814 14663
SCNN1A-
+ GUGAGGAAAAUAGAAAUCUGAGAC 24
10815 14664
SCNN1A-
+ UGCUGCAGCAUUCUAGAC 18
10816 14665
SCNN1A-
+ GUGCUGCAGCAUUCUAGAC 19
10817 14666
SCNN1A-
+ AGUGCUGCAGCAUUCUAGAC 20
10818 14667
SCNN1A-
+ UAGUGCUGCAGCAUUCUAGAC 21
10819 14668
SCNN1A-
+ CUAGUGCUGCAGCAUUCUAGAC 22
10820 14669
SCNN1A-
+ CCUAGUGCUGCAGCAUUCUAGAC 23
10821 14670
SCNN1A-
+ GCCUAGUGCUGCAGCAUUCUAGAC 24
10822 14671
SCNN1A-
+ AGUGAGCACCUCAGCACC 18
10823 14672
SCNN1A-
+ CAGUGAGCACCUCAGCACC 19
10824 14673
SCNN1A-
+ CC AG U G AG CACC U CAG C ACC 20
10825 14674
SCNN1A-
+ CCCAGUGAGCACCUCAGCACC 21
10826 14675
SCNN1A-
+ GCCCAGUGAGCACCUCAGCACC 22
10827 14676
SCNN1A-
+ UGCCCAGUGAGCACCUCAGCACC 23
10828 14677
SCNN1A-
+ CUGCCCAGUGAGCACCUCAGCACC 24
10829 14678
SCNN1A-
+ CUUCCAGGCGCAGGCACC 18
10830 14679
SCNN1A-
+ CCUUCCAGGCGCAGGCACC 19
10831 14680
SCNNlA-6307 + CCCUUCCAGGCGCAGGCACC 20 10156
1508
5535.1 SCNN1A-
+ ACCCUUCCAGGCGCAGGCACC 21
10832 14681
SCNN1A-
+ CACCCUUCCAGGCGCAGGCACC 22
10833 14682
SCNN1A-
+ CCACCCUUCCAGGCGCAGGCACC 23
10834 14683
SCNN1A-
+ ACCACCCUUCCAGGCGCAGGCACC 24
10835 14684
SCNN1A-
+ GCUGCAGCAUUCUAGACC 18
10836 14685
SCNN1A-
+ UGCUGCAGCAUUCUAGACC 19
10837 14686
SCNNlA-6310 + GUGCUGCAGCAUUCUAGACC 20 10159
SCNN1A-
+ AGUGCUGCAGCAUUCUAGACC 21
10838 14687
SCNN1A-
+ UAGUGCUGCAGCAUUCUAGACC 22
10839 14688
SCNN1A-
+ CUAGUGCUGCAGCAUUCUAGACC 23
10840 14689
SCNN1A-
+ CCUAGUGCUGCAGCAUUCUAGACC 24
10841 14690
SCNN1A-
+ CCAGCAGUGAGCUCUACC 18
10842 14691
SCNN1A-
+ GCCAGCAGUGAGCUCUACC 19
10843 14692
SCNNlA-6312 + UGCCAGCAGUGAGCUCUACC 20 10161
SCNNlA-1504 + UGUUCCCCUUCAUGAGCC 18 5353
SCNNlA-1505 + UUGUUCCCCUUCAUGAGCC 19 5354
SCNNlA-207 + CUUGUUCCCCUUCAUGAGCC 20 834
SCNNlA-1506 + GCUUGUUCCCCUUCAUGAGCC 21 5355
SCNNlA-1510 + CGCUUGUUCCCCUUCAUGAGCC 22 5359
SCNNlA-1511 + ACGCUUGUUCCCCUUCAUGAGCC 23 5360
SCNNlA-1512 + CACGCUUGUUCCCCUUCAUGAGCC 24 5361
SCNNlA-1513 + AGGGCCUCCUCCUCCGCC 18 5362
SCNNlA-1514 + CAGGGCCUCCUCCUCCGCC 19 5363
SCNNlA-213 + UCAGGGCCUCCUCCUCCGCC 20 838
SCNNlA-1515 + AUCAGGGCCUCCUCCUCCGCC 21 5364
SCNNlA-1516 + GAUCAGGGCCUCCUCCUCCGCC 22 5365
SCNNlA-1517 + CGAUCAGGGCCUCCUCCUCCGCC 23 5366
SCNNlA-1518 + UCGAUCAGGGCCUCCUCCUCCGCC 24 5367
SCNNlA-1519 + CAGAGCCACAGCACUGCC 18 5368
SCNNlA-1520 + GCAGAGCCACAGCACUGCC 19 5369
SCNNlA-228 + UGCAGAGCCACAGCACUGCC 20 849
1509
5535.1 SCNNlA-1521 + GUGCAGAGCCACAGCACUGCC 21 5370
SCNNlA-1522 + GGUGCAGAGCCACAGCACUGCC 22 5371
SCNNlA-1523 + AGGUGCAGAGCCACAGCACUGCC 23 5372
SCNNlA-1524 + AAGGUGCAGAGCCACAGCACUGCC 24 5373
SCNNlA-1431 + GAGUGGACUGUGGAGGGC 18 5280
SCNNlA-1432 + GGAGUGGACUGUGGAGGGC 19 5281
SCNNlA-201 + UGGAGUGGACUGUGGAGGGC 20 830
SCNNlA-1358 + CUGGAGUGGACUGUGGAGGGC 21 5207
SCNNlA-1359 + CCUGGAGUGGACUGUGGAGGGC 22 5208
SCNNlA-1360 + CCCUGGAGUGGACUGUGGAGGGC 23 5209
SCNNlA-1311 + GCCCUGGAGUGGACUGUGGAGGGC 24 5160
SCNN1A-
+ UCUAGACCUGGAGCGGGC 18
10844 14693
SCNN1A-
+ UUCUAGACCUGGAGCGGGC 19
10845 14694
SCNN1A-
+ AUUCUAGACCUGGAGCGGGC 20
10846 14695
SCNN1A-
+ CAU UCUAGACCUGGAGCGGGC 21
10847 14696
SCNN1A-
+ GCAUUCUAGACCUGGAGCGGGC 22
10848 14697
SCNN1A-
+ AGCAUUCUAGACCUGGAGCGGGC 23
10849 14698
SCNN1A-
+ CAGCAUUCUAGACCUGGAGCGGGC 24
10850 14699
SCNNlA-1531 + GGUGCAGAUGGUCACUGC 18 5380
SCNNlA-1532 + GGGUGCAGAUGGUCACUGC 19 5381
SCNNlA-38 + AGGGUGCAGAUGGUCACUGC 20 575
SCNNlA-1533 + GAGGGUGCAGAUGGUCACUGC 21 5382
SCNNlA-1534 + UGAGGGUGCAGAUGGUCACUGC 22 5383
SCNNlA-1535 + UUGAGGGUGCAGAUGGUCACUGC 23 5384
SCNNlA-1536 + AUUGAGGGUGCAGAUGGUCACUGC 24 5385
SCNNlA-1537 + UCCUCCGCCGUGGGCUGC 18 5386
SCNNlA-1538 + CUCCUCCGCCGUGGGCUGC 19 5387
SCNNlA-65 + CCUCCUCCGCCGUGGGCUGC 20 594
SCNNlA-1539 + UCCUCCUCCGCCGUGGGCUGC 21 5388
SCNNlA-1540 + CUCCUCCUCCGCCGUGGGCUGC 22 5389
SCNNlA-1541 + CCUCCUCCUCCGCCGUGGGCUGC 23 5390
SCNNlA-1542 + GCCUCCUCCUCCGCCGUGGGCUGC 24 5391
SCNNlA-1543 + GUCUUCAUGCGGUUGUGC 18 5392
SCNNlA-1544 + CGUCUUCAUGCGGUUGUGC 19 5393
SCNNlA-49 + CCGUCUUCAUGCGGUUGUGC 20 582
SCNNlA-1545 + GCCGUCUUCAUGCGGUUGUGC 21 5394
1510
5535.1 SCNNlA-1546 + GGCCGUCUUCAUGCGGUUGUGC 22 5395
SCNNlA-1547 + AGGCCGUCUUCAUGCGGUUGUGC 23 5396
SCNNlA-1548 + AAGGCCGUCUUCAUGCGGUUGUGC 24 5397
SCNNlA-1556 + UCACGCUUGUUCCCCUUC 18 5405
SCNNlA-1557 + CUCACGCUUGUUCCCCUUC 19 5406
SCNNlA-208 + CCUCACGCUUGUUCCCCUUC 20 835
SCNNlA-1558 + UCCUCACGCUUGUUCCCCUUC 21 5407
SCNNlA-1559 + CUCCUCACGCUUGUUCCCCUUC 22 5408
SCNNlA-1560 + GCUCCUCACGCUUGUUCCCCUUC 23 5409
SCNNlA-1561 + UGCUCCUCACGCUUGUUCCCCUUC 24 5410
SCNN1A-
+ U CCU U U CCCU CCCCAAAG 18
10851 14700
SCNN1A-
+ UUCCUUUCCCUCCCCAAAG 19
10852 14701
SCNNlA-6330 + CUUCCUUUCCCUCCCCAAAG 20 10179
SCNN1A-
+ CCUUCCUUUCCCUCCCCAAAG 21
10853 14702
SCNN1A-
+ CCCU U CCU U U CCCU CCCCAAAG 22
10854 14703
SCNN1A-
+ CCCCUUCCUUUCCCUCCCCAAAG 23
10855 14704
SCNN1A-
+ UCCCCUUCCUUUCCCUCCCCAAAG 24
10856 14705
SCNNlA-1562 + AUGGUCACUGCGGGGAAG 18 5411
SCNNlA-1563 + GAUGGUCACUGCGGGGAAG 19 5412
SCNNlA-238 + AGAUGGUCACUGCGGGGAAG 20 858
SCNNlA-1564 + CAGAUGGUCACUGCGGGGAAG 21 5413
SCNNlA-1565 + GCAGAUGGUCACUGCGGGGAAG 22 5414
SCNNlA-1566 + UGCAGAUGGUCACUGCGGGGAAG 23 5415
SCNNlA-1567 + GUGCAGAUGGUCACUGCGGGGAAG 24 5416
SCNN1A-
+ GCACCAGGGAAGGGGCAG 18
10857 14706
SCNN1A-
+ GGCACCAGGGAAGGGGCAG 19
10858 14707
SCNNlA-6334 + AGGCACCAGGGAAGGGGCAG 20 10183
SCNN1A-
+ CAGGCACCAGGGAAGGGGCAG 21
10859 14708
SCNN1A-
+ GCAGGCACCAGGGAAGGGGCAG 22
10860 14709
SCNN1A-
+ CGCAGGCACCAGGGAAGGGGCAG 23
10861 14710
SCNN1A-
+ GCGCAGGCACCAGGGAAGGGGCAG 24
10862 14711
1511
5535.1 SCNNlA-1568 + AUGGUGGUGUUGUUGCAG 18 5417
SCNNlA-1569 + GAUGGUGGUGUUGUUGCAG 19 5418
SCNNlA-221 + GGAUGGUGGUGUUGUUGCAG 20 844
SCNNlA-1570 + UGGAUGGUGGUGUUGUUGCAG 21 5419
SCNNlA-1571 + GUGGAUGGUGGUGUUGUUGCAG 22 5420
SCNNlA-1572 + CGUGGAUGGUGGUGUUGUUGCAG 23 5421
SCNNlA-1573 + CCGUGGAUGGUGGUGUUGUUGCAG 24
5422
SCNNlA-1574 + AAGACGAGCUUGUCCGAG 18 5423
SCNNlA-1575 + GAAGACGAGCUUGUCCGAG 19 5424
SCNNlA-236 + GGAAGACGAGCUUGUCCGAG 20 856
SCNNlA-1576 + GGGAAGACGAGCUUGUCCGAG 21 5425
SCNNlA-1577 + GGGGAAGACGAGCUUGUCCGAG 22 5426
SCNNlA-1578 + CGGGGAAGACGAGCUUGUCCGAG 23 5427
SCNNlA-1579 + GCGGGGAAGACGAGCUUGUCCGAG 24 5428
SCNNlA-1580 + UUGAGGCUGACGGGGUAG 18 5429
SCNNlA-1581 + GUUGAGGCUGACGGGGUAG 19 5430
SCNNlA-232 + UGUUGAGGCUGACGGGGUAG 20 853
SCNNlA-1582 + AUGUUGAGGCUGACGGGGUAG 21 5431
SCNNlA-1583 + GAUGUUGAGGCUGACGGGGUAG 22 5432
SCNNlA-1584 + UGAUGUUGAGGCUGACGGGGUAG 23 5433
SCNNlA-1585 + UUGAUGUUGAGGCUGACGGGGUAG 24
5434
SCNNlA-1586 + GAGCUCUCGGUAGGAGCG 18 5435
SCNNlA-1587 + AGAGCUCUCGGUAGGAGCG 19 5436
SCNNlA-216 + AAGAGCUCUCGGUAGGAGCG 20 840
SCNNlA-1588 + GAAGAGCUCUCGGUAGGAGCG 21 5437
SCNNlA-1589 + CGAAGAGCUCUCGGUAGGAGCG 22 5438
SCNNlA-1590 + UCGAAGAGCUCUCGGUAGGAGCG 23 5439
SCNNlA-1591 + CUCGAAGAGCUCUCGGUAGGAGCG 24 5440
SCNNlA-1592 + GUGCAGAUGGUCACUGCG 18 5441
SCNNlA-1593 + GGUGCAGAUGGUCACUGCG 19 5442
SCNNlA-39 + GGGUGCAGAUGGUCACUGCG 20 518
SCNNlA-1594 + AGGGUGCAGAUGGUCACUGCG 21 5443
SCNNlA-1595 + GAGGGUGCAGAUGGUCACUGCG 22 5444
SCNNlA-1596 + UGAGGGUGCAGAUGGUCACUGCG 23 5445
SCNNlA-1597 + UUGAGGGUGCAGAUGGUCACUGCG 24 5446
SCNNlA-1598 + UUGUUGCAGAAGAACUCG 18 5447
SCNNlA-1599 + GUUGUUGCAGAAGAACUCG 19 5448
SCNNlA-219 + UGUUGUUGCAGAAGAACUCG 20 842
SCNNlA-1600 + GUGUUGUUGCAGAAGAACUCG 21 5449
SCNNlA-1601 + GGUGUUGUUGCAGAAGAACUCG 22 5450
1512
5535.1 SCNNlA-1602 + UGGUGUUGUUGCAGAAGAACUCG 23 5451
SCNNlA-1603 + GUGGUGUUGUUGCAGAAGAACUCG 24
5452
SCNN1A-
+ CAUGCACUAUCCUCUAGG 18
10863 14712
SCNN1A-
+ UCAUGCACUAUCCUCUAGG 19
10864 14713
SCNN1A-
+ AUCAUGCACUAUCCUCUAGG 20
10865 14714
SCNN1A-
+ GAUCAUGCACUAUCCUCUAGG 21
10866 14715
SCNN1A-
+ GGAUCAUGCACUAUCCUCUAGG 22
10867 14716
SCNN1A-
+ AGGAUCAUGCACUAUCCUCUAGG 23
10868 14717
SCNN1A-
+ CAGGAUCAUGCACUAUCCUCUAGG 24
10869 14718
SCNNlA-1611 + AGCUCUCGGUAGGAGCGG 18 5460
SCNNlA-1612 + GAGCUCUCGGUAGGAGCGG 19 5461
SCNNlA-60 + AGAGCUCUCGGUAGGAGCGG 20 590
SCNNlA-1613 + AAGAGCUCUCGGUAGGAGCGG 21 5462
SCNNlA-1614 + GAAGAGCUCUCGGUAGGAGCGG 22 5463
SCNNlA-1615 + CGAAGAGCUCUCGGUAGGAGCGG 23 5464
SCNNlA-1616 + UCGAAGAGCUCUCGGUAGGAGCGG 24 5465
SCNNlA-1617 + AACUCGAAGAGCUCUCGG 18 5466
SCNNlA-1618 + GAACUCGAAGAGCUCUCGG 19 5467
SCNNlA-218 + AGAACUCGAAGAGCUCUCGG 20 841
SCNNlA-1619 + AAGAACUCGAAGAGCUCUCGG 21 5468
SCNNlA-1620 + GAAGAACUCGAAGAGCUCUCGG 22 5469
SCNNlA-1621 + AGAAGAACUCGAAGAGCUCUCGG 23 5470
SCNNlA-1622 + CAGAAGAACUCGAAGAGCUCUCGG 24 5471
SCNN1A-
+ CAGGCGCAGGCACCAGGG 18
10870 14719
SCNN1A-
+ CCAGGCGCAGGCACCAGGG 19
10871 14720
SCNN1A-
+ UCCAGGCGCAGGCACCAGGG 20
10872 14721
SCNN1A-
+ UUCCAGGCGCAGGCACCAGGG 21
10873 14722
SCNN1A-
+ CUUCCAGGCGCAGGCACCAGGG 22
10874 14723
SCNN1A-
+ CCUUCCAGGCGCAGGCACCAGGG 23
10875 14724
1513
5535.1 SCNN1A-
+ CCCUUCCAGGCGCAGGCACCAGGG 24
10876 14725
SCNN1A-
+ CAGGCACCAGGGAAGGGG 18
10877 14726
SCNN1A-
+ GCAGGCACCAGGGAAGGGG 19
10878 14727
SCNN1A-
+ CGCAGGCACCAGGGAAGGGG 20
10879 14728
SCNN1A-
+ GCGCAGGCACCAGGGAAGGGG 21
10880 14729
SCNN1A-
+ GGCGCAGGCACCAGGGAAGGGG 22
10881 14730
SCNN1A-
+ AGGCGCAGGCACCAGGGAAGGGG 23
10882 14731
SCNN1A-
+ CAGGCGCAGGCACCAGGGAAGGGG 24
10883 14732
SCNN1A-
+ UGCAAUGCCUGGUCUGGG 18
10884 14733
SCNN1A-
+ UUGCAAUGCCUGGUCUGGG 19
10885 14734
SCNN1A-
+ AUUGCAAUGCCUGGUCUGGG 20
10886 14735
SCNN1A-
+ AAUUGCAAUGCCUGGUCUGGG 21
10887 14736
SCNN1A-
+ GAAUUGCAAUGCCUGGUCUGGG 22
10888 14737
SCNN1A-
+ AGAAUUGCAAUGCCUGGUCUGGG 23
10889 14738
SCNN1A-
+ AAGAAUUGCAAUGCCUGGUCUGGG 24
10890 14739
SCNNlA-1637 + UCCGAGUUGAGGUUGAUG 18 5486
SCNNlA-1638 + GUCCGAGUUGAGGUUGAUG 19 5487
SCNNlA-235 + UGUCCGAGUUGAGGUUGAUG 20 855
SCNNlA-1639 + UUGUCCGAGUUGAGGUUGAUG 21 5488
SCNNlA-1640 + CUUGUCCGAGUUGAGGUUGAUG 22 5489
SCNNlA-1641 + GCUUGUCCGAGUUGAGGUUGAUG 23 5490
SCNNlA-1642 + AGCUUGUCCGAGUUGAGGUUGAUG 24
5491
SCNNlA-1643 + GGGUGCAGAUGGUCACUG 18 5492
SCNNlA-1644 + AGGGUGCAGAUGGUCACUG 19 5493
SCNNlA-37 + GAGGGUGCAGAUGGUCACUG 20 517
SCNNlA-1645 + UGAGGGUGCAGAUGGUCACUG 21 5494
SCNNlA-1646 + UUGAGGGUGCAGAUGGUCACUG 22 5495
1514
5535.1 SCNNlA-1647 + AUUGAGGGUGCAGAUGGUCACUG 23 5496
SCNNlA-1648 + GAUUGAGGGUGCAGAUGGUCACUG 24
5497
SCNNlA-1649 + GAGCCCUGGAGUGGACUG 18 5498
SCNNlA-1650 + UGAGCCCUGGAGUGGACUG 19 5499
SCNNlA-74 + AUGAGCCCUGGAGUGGACUG 20 601
SCNNlA-1651 + CAUGAGCCCUGGAGUGGACUG 21 5500
SCNNlA-1652 + UCAUGAGCCCUGGAGUGGACUG 22 5501
SCNNlA-1653 + UUCAUGAGCCCUGGAGUGGACUG 23 5502
SCNNlA-1654 + CUUCAUGAGCCCUGGAGUGGACUG 24 5503
SCNNlA-1655 + GAGGGACUAACCGACCUG 18 5504
SCNNlA-1656 + AGAGGGACUAACCGACCUG 19 5505
SCNNlA-1657 + CAGAGGGACUAACCGACCUG 20 5506
SCNNlA-1658 + GCAGAGGGACUAACCGACCUG 21 5507
SCNNlA-1659 + GGCAGAGGGACUAACCGACCUG 22 5508
SCNNlA-1660 + GGGCAGAGGGACUAACCGACCUG 23 5509
SCNNlA-1661 + GGGGCAGAGGGACUAACCGACCUG 24 5510
SCNNlA-1662 + AGGUUGAUGUUGAGGCUG 18 5511
SCNNlA-1663 + GAGGUUGAUGUUGAGGCUG 19 5512
SCNNlA-234 + UGAGGUUGAUGUUGAGGCUG 20 854
SCNNlA-1664 + UUGAGGUUGAUGUUGAGGCUG 21 5513
SCNNlA-1665 + GUUGAGGUUGAUGUUGAGGCUG 22 5514
SCNNlA-1666 + AGUUGAGGUUGAUGUUGAGGCUG 23 5515
SCNNlA-1667 + GAGUUGAGGUUGAUGUUGAGGCUG 24
5516
SCNNlA-1675 + CUCCUCCGCCGUGGGCUG 18 5524
SCNNlA-1676 + CCUCCUCCGCCGUGGGCUG 19 5525
SCNNlA-212 + UCCUCCUCCGCCGUGGGCUG 20 837
SCNNlA-1677 + CUCCUCCUCCGCCGUGGGCUG 21 5526
SCNNlA-1678 + CCUCCUCCUCCGCCGUGGGCUG 22 5527
SCNNlA-1679 + GCCUCCUCCUCCGCCGUGGGCUG 23 5528
SCNNlA-1680 + GGCCUCCUCCUCCGCCGUGGGCUG 24 5529
SCNNlA-1681 + UACAUCAUGCCAAAGGUG 18 5530
SCNNlA-1682 + GUACAUCAUGCCAAAGGUG 19 5531
SCNNlA-229 + AGUACAUCAUGCCAAAGGUG 20 850
SCNNlA-1683 + CAGUACAUCAUGCCAAAGGUG 21 5532
SCNNlA-1684 + CCAGUACAUCAUGCCAAAGGUG 22 5533
SCNNlA-1685 + GCCAGUACAUCAUGCCAAAGGUG 23 5534
SCNNlA-1686 + UGCCAGUACAUCAUGCCAAAGGUG 24 5535
SCNNlA-1687 + GCCCUGGAGUGGACUGUG 18 5536
SCNNlA-1688 + AGCCCUGGAGUGGACUGUG 19 5537
SCNNlA-202 + GAGCCCUGGAGUGGACUGUG 20 831
1515
5535.1 SCNNlA-1689 + UGAGCCCUGGAGUGGACUGUG 21 5538
SCNNlA-1690 + AUGAGCCCUGGAGUGGACUGUG 22 5539
SCNNlA-1691 + CAUGAGCCCUGGAGUGGACUGUG 23 5540
SCNNlA-1692 + UCAUGAGCCCUGGAGUGGACUGUG 24 5541
SCNNlA-1693 + CGUCUUCAUGCGGUUGUG 18 5542
SCNNlA-1694 + CCGUCUUCAUGCGGUUGUG 19 5543
SCNNlA-227 + GCCGUCUUCAUGCGGUUGUG 20 848
SCNNlA-1695 + GGCCGUCUUCAUGCGGUUGUG 21 5544
SCNNlA-1696 + AGGCCGUCUUCAUGCGGUUGUG 22 5545
SCNNlA-1697 + AAGGCCGUCUUCAUGCGGUUGUG 23 5546
SCNNlA-1698 + GAAGGCCGUCUUCAUGCGGUUGUG 24 5547
SCNN1A-
+ AACAGGCUUGGUGUUGUG 18
10891 14740
SCNN1A-
+ GAACAGGCUUGGUGUUGUG 19
10892 14741
SCNNlA-6347 + AGAACAGGCUUGGUGUUGUG 20 10196
SCNN1A-
+ UAGAACAGGCUUGGUGUUGUG 21
10893 14742
SCNN1A-
+ CUAGAACAGGCUUGGUGUUGUG 22
10894 14743
SCNN1A-
+ GCUAGAACAGGCUUGGUGUUGUG 23
10895 14744
SCNN1A-
+ GGCUAGAACAGGCUUGGUGUUGUG 24
10896 14745
SCNNlA-1705 + UGGAUGGUGGUGUUGUUG 18 5554
SCNNlA-1706 + GUGGAUGGUGGUGUUGUUG 19 5555
SCNNlA-222 + CGUGGAUGGUGGUGUUGUUG 20 845
SCNNlA-1707 + CCGUGGAUGGUGGUGUUGUUG 21 5556
SCNNlA-1708 + GCCGUGGAUGGUGGUGUUGUUG 22 5557
SCNNlA-1709 + CGCCGUGGAUGGUGGUGUUGUUG 23 5558
SCNNlA-1710 + GCGCCGUGGAUGGUGGUGUUGUUG 24
5559
SCNN1A-
+ UGUGAGGAAAAUAGAAAU 18
10897 14746
SCNN1A-
+ UUGUGAGGAAAAUAGAAAU 19
10898 14747
SCNN1A-
+ GU UGUGAGGAAAAUAGAAAU 20
10899 14748
SCNN1A-
+ UGUUGUGAGGAAAAUAGAAAU 21
10900 14749
SCNN1A-
+ GUGUUGUGAGGAAAAUAGAAAU 22
10901 14750
SCNN1A- + GGUGUUGUGAGGAAAAUAGAAAU 23 14751
1516
5535.1 10902
SCNN1A-
+ UGGUGUUGUGAGGAAAAUAGAAAU 24
10903 14752
SCNN1A-
+ GGGUAUGGGAGUGGCAAU 18
10904 14753
SCNN1A-
+ CGGGUAUGGGAGUGGCAAU 19
10905 14754
SCNN1A-
+ CCGGGUAUGGGAGUGGCAAU 20
10906 14755
SCNN1A-
+ GCCGGGUAUGGGAGUGGCAAU 21
10907 14756
SCNN1A-
+ UGCCGGGUAUGGGAGUGGCAAU 22
10908 14757
SCNN1A-
+ CUGCCGGGUAUGGGAGUGGCAAU 23
10909 14758
SCNN1A-
+ CCUGCCGGGUAUGGGAGUGGCAAU 24
10910 14759
SCNNlA-1711 + GGAGCGGUGGAACUCGAU 18 5560
SCNNlA-1712 + AGGAGCGGUGGAACUCGAU 19 5561
SCNNlA-214 + UAGGAGCGGUGGAACUCGAU 20 839
SCNNlA-1713 + GUAGGAGCGGUGGAACUCGAU 21 5562
SCNNlA-1714 + GGUAGGAGCGGUGGAACUCGAU 22 5563
SCNNlA-1715 + CGGUAGGAGCGGUGGAACUCGAU 23 5564
SCNNlA-1716 + UCGGUAGGAGCGGUGGAACUCGAU 24 5565
SCNNlA-1723 + AGGGUGCAGAUGGUCACU 18 5572
SCNNlA-1724 + GAGGGUGCAGAUGGUCACU 19 5573
SCNNlA-242 + UGAGGGUGCAGAUGGUCACU 20 859
SCNNlA-1725 + UUGAGGGUGCAGAUGGUCACU 21 5574
SCNNlA-1726 + AUUGAGGGUGCAGAUGGUCACU 22 5575
SCNNlA-1727 + GAUUGAGGGUGCAGAUGGUCACU 23 5576
SCNNlA-1728 + GGAUUGAGGGUGCAGAUGGUCACU 24
5577
SCNNlA-1729 + UGAGCCCUGGAGUGGACU 18 5578
SCNNlA-1730 + AUGAGCCCUGGAGUGGACU 19 5579
SCNNlA-204 + CAUGAGCCCUGGAGUGGACU 20 832
SCNNlA-1731 + UCAUGAGCCCUGGAGUGGACU 21 5580
SCNNlA-1732 + UUCAUGAGCCCUGGAGUGGACU 22 5581
SCNNlA-1733 + CUUCAUGAGCCCUGGAGUGGACU 23 5582
SCNNlA-1734 + CCUUCAUGAGCCCUGGAGUGGACU 24 5583
SCNNlA-1748 + UCUUCAUGCGGUUGUGCU 18 5597
SCNNlA-1749 + GUCUUCAUGCGGUUGUGCU 19 5598
SCNNlA-50 + CGUCUUCAUGCGGUUGUGCU 20 583
SCNNlA-1750 + CCGUCUUCAUGCGGUUGUGCU 21 5599
1517
5535.1 SCNNlA-1751 + GCCGUCUUCAUGCGGUUGUGCU 22 5600
SCNNlA-1752 + GGCCGUCUUCAUGCGGUUGUGCU 23 5601
SCNNlA-1753 + AGGCCGUCUUCAUGCGGUUGUGCU 24 5602
SCNN1A-
+ UUAUUUUCUUAUUUAUCU 18
10911 14760
SCNN1A-
+ UUUAUUUUCUUAUUUAUCU 19
10912 14761
SCNN1A-
+ UUUUAUUUUCUUAUUUAUCU 20
10913 14762
SCNN1A-
+ CUUUUAUUUUCUUAUUUAUCU 21
10914 14763
SCNN1A-
+ GCUUUUAUUUUCUUAUUUAUCU 22
10915 14764
SCNN1A-
+ UGCUUUUAUUUUCUUAUUUAUCU 23
10916 14765
SCNN1A-
+ UUGCUUUUAUUUUCUUAUUUAUCU 24
10917 14766
SCNNlA-1754 + GGGUAGCUGAAGUACUCU 18 5603
SCNNlA-1755 + GGGGUAGCUGAAGUACUCU 19 5604
SCNNlA-231 + CGGGGUAGCUGAAGUACUCU 20 852
SCNNlA-1756 + ACGGGGUAGCUGAAGUACUCU 21 5605
SCNNlA-1757 + GACGGGGUAGCUGAAGUACUCU 22 5606
SCNNlA-1758 + UGACGGGGUAGCUGAAGUACUCU 23 5607
SCNNlA-1759 + CUGACGGGGUAGCUGAAGUACUCU 24 5608
SCNNlA-1760 + UGCUGGGGCGCCGCAGGU 18 5609
SCNNlA-1761 + CUGCUGGGGCGCCGCAGGU 19 5610
SCNNlA-210 + GCUGCUGGGGCGCCGCAGGU 20 836
SCNNlA-1762 + GGCUGCUGGGGCGCCGCAGGU 21 5611
SCNNlA-1763 + GGGCUGCUGGGGCGCCGCAGGU 22 5612
SCNNlA-1764 + UGGGCUGCUGGGGCGCCGCAGGU 23 5613
SCNNlA-1765 + GUGGGCUGCUGGGGCGCCGCAGGU 24 5614
SCNN1A-
+ CAGUUCCCACCCUCAGGU 18
10918 14767
SCNN1A-
+ UCAGUUCCCACCCUCAGGU 19
10919 14768
SCNN1A-
+ GUCAGUUCCCACCCUCAGGU 20
10920 14769
SCNN1A-
+ UGUCAGUUCCCACCCUCAGGU 21
10921 14770
SCNN1A-
+ GUGUCAGUUCCCACCCUCAGGU 22
10922 14771
SCNN1A-
+ GGUGUCAGUUCCCACCCUCAGGU 23
10923 14772
1518
5535.1 SCNN1A-
+ GGGUGUCAGUUCCCACCCUCAGGU 24
10924 14773
SCNNlA-1766 + ACUCGAAGAGCUCUCGGU 18 5615
SCNNlA-1767 + AACUCGAAGAGCUCUCGGU 19 5616
SCNNlA-58 + GAACUCGAAGAGCUCUCGGU 20 524
SCNNlA-1768 + AGAACUCGAAGAGCUCUCGGU 21 5617
SCNNlA-1769 + AAGAACUCGAAGAGCUCUCGGU 22 5618
SCNNlA-1770 + GAAGAACUCGAAGAGCUCUCGGU 23 5619
SCNNlA-1771 + AGAAGAACUCGAAGAGCUCUCGGU 24 5620
SCNN1A-
+ UGCCACGUCCUGCCGGGU 18
10925 14774
SCNN1A-
+ CUGCCACGUCCUGCCGGGU 19
10926 14775
SCNN1A-
+ CCUGCCACGUCCUGCCGGGU 20
10927 14776
SCNN1A-
+ CCCUGCCACGUCCUGCCGGGU 21
10928 14777
SCNN1A-
+ ACCCUGCCACGUCCUGCCGGGU 22
10929 14778
SCNN1A-
+ GACCCUGCCACGUCCUGCCGGGU 23
10930 14779
SCNN1A-
+ UGACCCUGCCACGUCCUGCCGGGU 24
10931 14780
SCNN1A-
+ AGAAUUGCAAUGCCUGGU 18
10932 14781
SCNN1A-
+ AAGAAUUGCAAUGCCUGGU 19
10933 14782
SCNN1A-
+ GAAGAAUUGCAAUGCCUGGU 20
10934 14783
SCNN1A-
+ AGAAGAAUUGCAAUGCCUGGU 21
10935 14784
SCNN1A-
+ GAGAAGAAUUGCAAUGCCUGGU 22
10936 14785
SCNN1A-
+ UGAGAAGAAUUGCAAUGCCUGGU 23
10937 14786
SCNN1A-
+ GUGAGAAGAAUUGCAAUGCCUGGU 24
10938 14787
SCNN1A-
+ UGAGACCUGGACUUUGGU 18
10939 14788
SCNN1A-
+ CUGAGACCUGGACUUUGGU 19
10940 14789
SCNN1A-
+ UCUGAGACCUGGACUUUGGU 20
10941 14790
1519
5535.1 SCNN1A-
+ AUCUGAGACCUGGACUUUGGU 21
10942 14791
SCNN1A-
+ AAUCUGAGACCUGGACUUUGGU 22
10943 14792
SCNN1A-
+ AAAUCUGAGACCUGGACUUUGGU 23
10944 14793
SCNN1A-
+ GAAAUCUGAGACCUGGACUUUGGU 24
10945 14794
SCNN1A-
+ GAACAGGCUUGGUGUUGU 18
10946 14795
SCNN1A-
+ AGAACAGGCUUGGUGUUGU 19
10947 14796
SCNN1A-
+ UAGAACAGGCUUGGUGUUGU 20
10948 14797
SCNN1A-
+ CUAGAACAGGCUUGGUGUUGU 21
10949 14798
SCNN1A-
+ GCUAGAACAGGCUUGGUGUUGU 22
10950 14799
SCNN1A-
+ GGCUAGAACAGGCUUGGUGUUGU 23
10951 14800
SCNN1A-
+ GGGCUAGAACAGGCUUGGUGUUGU 24
10952 14801
SCNNlA-1784 + GCUGGGGCGCCGCAGGUU 18 5633
SCNNlA-1785 + UGCUGGGGCGCCGCAGGUU 19 5634
SCNNlA-69 + CUGCUGGGGCGCCGCAGGUU 20 597
SCNNlA-1786 + GCUGCUGGGGCGCCGCAGGUU 21 5635
SCNNlA-1787 + GGCUGCUGGGGCGCCGCAGGUU 22 5636
SCNNlA-1788 + GGGCUGCUGGGGCGCCGCAGGUU 23 5637
SCNNlA-1789 + UGGGCUGCUGGGGCGCCGCAGGUU 24 5638
SCNN1A-
+ UAGAACAGGCUUGGUGUU 18
10953 14802
SCNN1A-
+ CUAGAACAGGCUUGGUGUU 19
10954 14803
SCNN1A-
+ GCUAGAACAGGCUUGGUGUU 20
10955 14804
SCNN1A-
+ GGCUAGAACAGGCUUGGUGUU 21
10956 14805
SCNN1A-
+ GGGCUAGAACAGGCUUGGUGUU 22
10957 14806
SCNN1A-
+ CGGGCUAGAACAGGCUUGGUGUU 23
10958 14807
SCNN1A-
+ GCGGGCUAGAACAGGCUUGGUGUU 24
10959 14808
1520
5535.1 SCNN1A-
- AG A A A A U A A A AG C A A AAA 18
10960 14809
SCNN1A-
- A AG A A A A U A A A AG C A A A A A 19
10961 14810
SCNNlA-6277 - U A AG A A A A U A A A AG C A A A A A 20 10126
SCNN1A-
- A U A AG A A A A U A A A AG C AAA A A 21
10962 14811
SCNN1A-
- A A U A AG A A A A U A A A AG C A A A A A 22
10963 14812
SCNN1A-
- AAA U A AG A A A A U A A A AG C A A A A A 23
10964 14813
SCNN1A-
- UAAAUAAGAAAAUAAAAGCAAAAA 24
10965 14814
SCNN1A-
- A AG A A A A U A A A AG C A A AA 18
10966 14815
SCNN1A-
- U A AG A A A A U A A A AG C A AA A 19
10967 14816
SCNN1A-
- A U A AG A A A A U A A A AG C A A A A 20
10968 14817
SCNN1A-
- A A U A AG A A A A U A A A AG C A A A A 21
10969 14818
SCNN1A-
- A A A U A AG A A A A U A A A AG C A A A A 22
10970 14819
SCNN1A-
- U A A A U A AG A A A A U A A A AG C A A A A 23
10971 14820
SCNN1A-
- AUAAAUAAGAAAAUAAAAGCAAAA 24
10972 14821
SCNN1A-
- AUGGUCUCUGUCAUAAAA 18
10973 14822
SCNN1A-
- CAUGGUCUCUGUCAUAAAA 19
10974 14823
SCNN1A-
- GCAUGGUCUCUGUCAUAAAA 20
10975 14824
SCNN1A-
- AGCAUGGUCUCUGUCAUAAAA 21
10976 14825
SCNN1A-
- UAGCAUGGUCUCUGUCAUAAAA 22
10977 14826
SCNN1A-
- AUAGCAUGGUCUCUGUCAUAAAA 23
10978 14827
SCNN1A-
- UAUAGCAUGGUCUCUGUCAUAAAA 24
10979 14828
SCNN1A-
- UAAAAGAUCAUCUUUAAA 18
10980 14829
1521
5535.1 SCNN1A-
- U U A A A AG A U C A U C U U U AAA 19
10981 14830
SCNN1A-
- UUUAAAAGAUCAUCUUUAAA 20
10982 14831
SCNN1A-
- CUUUAAAAGAUCAUCUUUAAA 21
10983 14832
SCNN1A-
- ACU U U AAAAG AU CAU CU U U AAA 22
10984 14833
SCNN1A-
- CACUUUAAAAGAUCAUCUUUAAA 23
10985 14834
SCNN1A-
- ACACU U U AAAAG AU CAU CU U U AAA 24
10986 14835
SCNN1A-
- UUUGGGGAGGGAAAGGAA 18
10987 14836
SCNN1A-
- CUUUGGGGAGGGAAAGGAA 19
10988 14837
SCNNlA-6283 - CCUUUGGGGAGGGAAAGGAA 20 10132
SCNN1A-
- CCCUUUGGGGAGGGAAAGGAA 21
10989 14838
SCNN1A-
- CCCCUUUGGGGAGGGAAAGGAA 22
10990 14839
SCNN1A-
- UCCCCUUUGGGGAGGGAAAGGAA 23
10991 14840
SCNN1A-
- CUCCCCUUUGGGGAGGGAAAGGAA 24
10992 14841
SCNN1A-
- UCCCCUUUGGGGAGGGAA 18
10993 14842
SCNN1A-
- CUCCCCUUUGGGGAGGGAA 19
10994 14843
SCNNlA-6285 - GCUCCCCUUUGGGGAGGGAA 20 10134
SCNN1A-
- GGCUCCCCUUUGGGGAGGGAA 21
10995 14844
SCNN1A-
- UGGCUCCCCUUUGGGGAGGGAA 22
10996 14845
SCNN1A-
- GUGGCUCCCCUUUGGGGAGGGAA 23
10997 14846
SCNN1A-
- GGUGGCUCCCCUUUGGGGAGGGAA 24
10998 14847
SCNNlA-1796 - CACUCCAGGGCUCAUGAA 18 5645
SCNNlA-1797 - CCACUCCAGGGCUCAUGAA 19 5646
SCNNlA-11 - UCCACUCCAGGGCUCAUGAA 20 560
SCNNlA-1798 - GUCCACUCCAGGGCUCAUGAA 21 5647
SCNNlA-1799 - AGUCCACUCCAGGGCUCAUGAA 22 5648
1522
5535.1 SCNNlA-1800 - CAGUCCACUCCAGGGCUCAUGAA 23 5649
SCNNlA-1801 - ACAGUCCACUCCAGGGCUCAUGAA 24 5650
SCNN1A-
- GGAAAGGAAGGGGACUAA 18
10999 14848
SCNN1A-
- GGGAAAGGAAGGGGACUAA 19
11000 14849
SCNNlA-6288 - AGGGAAAGGAAGGGGACUAA 20 10137
SCNN1A-
- GAGGGAAAGGAAGGGGACUAA 21
11001 14850
SCNN1A-
- GGAGGGAAAGGAAGGGGACUAA 22
11002 14851
SCNN1A-
- GGGAGGGAAAGGAAGGGGACUAA 23
11003 14852
SCNN1A-
- GGGGAGGGAAAGGAAGGGGACUAA 24
11004 14853
SCNN1A-
- AGGGUGCUGAGGUGCUCA 18
11005 14854
SCNN1A-
- CAGGGUGCUGAGGUGCUCA 19
11006 14855
SCNN1A-
- CCAGGGUGCUGAGGUGCUCA 20
11007 14856
SCNN1A-
- UCCAGGGUGCUGAGGUGCUCA 21
11008 14857
SCNN1A-
- GUCCAGGGUGCUGAGGUGCUCA 22
11009 14858
SCNN1A-
- GGUCCAGGGUGCUGAGGUGCUCA 23
11010 14859
SCNN1A-
- UGGUCCAGGGUGCUGAGGUGCUCA 24
11011 14860
SCNN1A-
- CUUUGGGGAGGGAAAGGA 18
11012 14861
SCNN1A-
- CCUUUGGGGAGGGAAAGGA 19
11013 14862
SCNNlA-6295 - CCCUUUGGGGAGGGAAAGGA 20 10144
SCNN1A-
- CCCCUUUGGGGAGGGAAAGGA 21
11014 14863
SCNN1A-
- UCCCCUUUGGGGAGGGAAAGGA 22
11015 14864
SCNN1A-
- CUCCCCUUUGGGGAGGGAAAGGA 23
11016 14865
SCNN1A-
- GCUCCCCUUUGGGGAGGGAAAGGA 24
11017 14866
SCNN1A- - CUCCCCUUUGGGGAGGGA 18 14867
1523
5535.1 11018
SCNN1A-
- GCUCCCCUUUGGGGAGGGA 19
11019 14868
SCNN1A-
- GGCUCCCCUUUGGGGAGGGA 20
11020 14869
SCNN1A-
- UGGCUCCCCUUUGGGGAGGGA 21
11021 14870
SCNN1A-
- GUGGCUCCCCUUUGGGGAGGGA 22
11022 14871
SCNN1A-
- GGUGGCUCCCCUUUGGGGAGGGA 23
11023 14872
SCNN1A-
- UGGUGGCUCCCCUUUGGGGAGGGA 24
11024 14873
SCNN1A-
- GUGGCUCCCCUUUGGGGA 18
11025 14874
SCNN1A-
- GGUGGCUCCCCUUUGGGGA 19
11026 14875
SCNNlA-6297 - UGGUGGCUCCCCUUUGGGGA 20 10146
SCNN1A-
- AUGGUGGCUCCCCUUUGGGGA 21
11027 14876
SCNN1A-
- UAUGGUGGCUCCCCUUUGGGGA 22
11028 14877
SCNN1A-
- UUAUGGUGGCUCCCCUUUGGGGA 23
11029 14878
SCNN1A-
- AUUAUGGUGGCUCCCCUUUGGGGA 24
11030 14879
SCNNlA-1833 - CCACUCCAGGGCUCAUGA 18 5682
SCNNlA-1834 - UCCACUCCAGGGCUCAUGA 19 5683
SCNNlA-10 - GUCCACUCCAGGGCUCAUGA 20 505
SCNNlA-1835 - AGUCCACUCCAGGGCUCAUGA 21 5684
SCNNlA-1836 - CAGUCCACUCCAGGGCUCAUGA 22 5685
SCNNlA-1837 - ACAGUCCACUCCAGGGCUCAUGA 23 5686
SCNNlA-1838 - CACAGUCCACUCCAGGGCUCAUGA 24 5687
SCNN1A-
- GGGAAAGGAAGGGGACUA 18
11031 14880
SCNN1A-
- AGGGAAAGGAAGGGGACUA 19
11032 14881
SCNNlA-6300 - GAGGGAAAGGAAGGGGACUA 20 10149
SCNN1A-
- GGAGGGAAAGGAAGGGGACUA 21
11033 14882
SCNN1A-
- GGGAGGGAAAGGAAGGGGACUA 22
11034 14883
SCNN1A- - GGGGAGGGAAAGGAAGGGGACUA 23 14884
1524
5535.1 11035
SCNN1A-
- UGGGGAGGGAAAGGAAGGGGACUA 24
11036 14885
SCNNlA-1851 - CGAGUUCCACCGCUCCUA 18 5700
SCNNlA-1852 - UCGAGUUCCACCGCUCCUA 19 5701
SCNNlA-190 - AUCGAGUUCCACCGCUCCUA 20 820
SCNNlA-1853 - GAUCGAGUUCCACCGCUCCUA 21 5702
SCNNlA-1854 - UGAUCGAGUUCCACCGCUCCUA 22 5703
SCNNlA-1855 - CUGAUCGAGUUCCACCGCUCCUA 23 5704
SCNNlA-1856 - CCUGAUCGAGUUCCACCGCUCCUA 24 5705
SCNNlA-1857 - CUCAACAUCAACCUCAAC 18 5706
SCNNlA-1858 - CCUCAACAUCAACCUCAAC 19 5707
SCNNlA-198 - GCCUCAACAUCAACCUCAAC 20 827
SCNNlA-1859 - AGCCUCAACAUCAACCUCAAC 21 5708
SCNNlA-1860 - CAG CC U CAAC AU C AACC U C AAC 22 5709
SCNNlA-1861 - UCAGCCUCAACAUCAACCUCAAC 23 5710
SCNNlA-1862 - GUCAGCCUCAACAUCAACCUCAAC 24 5711
SCNN1A-
- GCAGGCAGAGCCUCAGAC 18
11037 14886
SCNN1A-
- GGCAGGCAGAGCCUCAGAC 19
11038 14887
SCNN1A-
- GGGCAGGCAGAGCCUCAGAC 20
11039 14888
SCNN1A-
- UGGGCAGGCAGAGCCUCAGAC 21
11040 14889
SCNN1A-
- CUGGGCAGGCAGAGCCUCAGAC 22
11041 14890
SCNN1A-
- ACUGGGCAGGCAGAGCCUCAGAC 23
11042 14891
SCNN1A-
- CACUGGGCAGGCAGAGCCUCAGAC 24
11043 14892
SCNNlA-1870 - AGUUCCACCGCUCCUACC 18 5719
SCNNlA-1871 - GAGUUCCACCGCUCCUACC 19 5720
SCNNlA-191 - CGAGUUCCACCGCUCCUACC 20 821
SCNNlA-1872 - UCGAGUUCCACCGCUCCUACC 21 5721
SCNNlA-1873 - AUCGAGUUCCACCGCUCCUACC 22 5722
SCNNlA-1874 - GAUCGAGUUCCACCGCUCCUACC 23 5723
SCNNlA-1875 - UGAUCGAGUUCCACCGCUCCUACC 24 5724
SCNN1A-
- UGCUGCUGUACUCCAGCC 18
11044 14893
SCNN1A-
- AUGCUGCUGUACUCCAGCC 19
11045 14894
SCNN1A- - CAUGCUGCUGUACUCCAGCC 20 14895
1525
5535.1 11046
SCNN1A-
- UCAUGCUGCUGUACUCCAGCC 21
11047 14896
SCNN1A-
- AUCAUGCUGCUGUACUCCAGCC 22
11048 14897
SCNN1A-
- GAUCAUGCUGCUGUACUCCAGCC 23
11049 14898
SCNN1A-
- UGAUCAUGCUGCUGUACUCCAGCC 24
11050 14899
SCNN1A-
- UUCCCUGGUGCCUGCGCC 18
11051 14900
SCNN1A-
- CUUCCCUGGUGCCUGCGCC 19
11052 14901
SCNNlA-6315 - CCUUCCCUGGUGCCUGCGCC 20 10164
SCNN1A-
- CCCUUCCCUGGUGCCUGCGCC 21
11053 14902
SCNN1A-
- CCCCUUCCCUGGUGCCUGCGCC 22
11054 14903
SCNN1A-
- GCCCCUUCCCUGGUGCCUGCGCC 23
11055 14904
SCNN1A-
- UGCCCCUUCCCUGGUGCCUGCGCC 24
11056 14905
SCNNlA-1883 - AGGAGCAGGGGCUGGGCC 18 5732
SCNNlA-1884 - GAGGAGCAGGGGCUGGGCC 19 5733
SCNNlA-182 - UGAGGAGCAGGGGCUGGGCC 20 815
SCNNlA-1885 - GUGAGGAGCAGGGGCUGGGCC 21 5734
SCNNlA-1886 - CGUGAGGAGCAGGGGCUGGGCC 22 5735
SCNNlA-1887 - GCGUGAGGAGCAGGGGCUGGGCC 23 5736
SCNNlA-1888 - AGCGUGAGGAGCAGGGGCUGGGCC 24 5737
SCNNlA-1895 - UCAUGAAGGGGAACAAGC 18 5744
SCNNlA-1896 - CUCAUGAAGGGGAACAAGC 19 5745
SCNNlA-176 - GCUCAUGAAGGGGAACAAGC 20 811
SCNNlA-1897 - GGCUCAUGAAGGGGAACAAGC 21 5746
SCNNlA-1898 - GGGCUCAUGAAGGGGAACAAGC 22 5747
SCNNlA-1899 - AGGGCUCAUGAAGGGGAACAAGC 23 5748
SCNNlA-1900 - CAGGGCUCAUGAAGGGGAACAAGC 24 5749
SCNNlA-1916 - GGAACAAGCGUGAGGAGC 18 5765
SCNNlA-1917 - GGGAACAAGCGUGAGGAGC 19 5766
SCNNlA-14 - GGGGAACAAGCGUGAGGAGC 20 506
SCNNlA-1918 - AGGGGAACAAGCGUGAGGAGC 21 5767
SCNNlA-1919 - AAGGGGAACAAGCGUGAGGAGC 22 5768
SCNNlA-1920 - GAAGGGGAACAAGCGUGAGGAGC 23 5769
SCNNlA-1921 - UGAAGGGGAACAAGCGUGAGGAGC 24 5770
1526
5535.1 SCNNlA-1922 - UGCUCCCAGCACAACCGC 18 5771
SCNNlA-1923 - GUGCUCCCAGCACAACCGC 19 5772
SCNNlA-193 - UGUGCUCCCAGCACAACCGC 20 823
SCNNlA-1924 - GUGUGCUCCCAGCACAACCGC 21 5773
SCNNlA-1925 - GGUGUGCUCCCAGCACAACCGC 22 5774
SCNNlA-1926 - UGGUGUGCUCCCAGCACAACCGC 23 5775
SCNNlA-1927 - CUGGUGUGCUCCCAGCACAACCGC 24 5776
SCNN1A-
- CUUCCCUGGUGCCUGCGC 18
11057 14906
SCNN1A-
- CCUUCCCUGGUGCCUGCGC 19
11058 14907
SCNN1A-
- CCCUUCCCUGGUGCCUGCGC 20
11059 14908
SCNN1A-
- CCCCUUCCCUGGUGCCUGCGC 21
11060 14909
SCNN1A-
- GCCCCUUCCCUGGUGCCUGCGC 22
11061 14910
SCNN1A-
- UGCCCCUUCCCUGGUGCCUGCGC 23
11062 14911
SCNN1A-
- CUGCCCCUUCCCUGGUGCCUGCGC 24
11063 14912
SCNNlA-1948 - GCCCUCCACAGUCCACUC 18 5797
SCNNlA-1949 - AGCCCUCCACAGUCCACUC 19 5798
SCNNlA-170 - UAGCCCUCCACAGUCCACUC 20 808
SCNNlA-1954 - CAGUCCACUCCAGGGCUC 18 5803
SCNNlA-1955 - ACAGUCCACUCCAGGGCUC 19 5804
SCNNlA-171 - CACAGUCCACUCCAGGGCUC 20 809
SCNNlA-1956 - CCACAGUCCACUCCAGGGCUC 21 5805
SCNNlA-1957 - UCCACAGUCCACUCCAGGGCUC 22 5806
SCNNlA-1958 - CUCCACAGUCCACUCCAGGGCUC 23 5807
SCNNlA-1959 - CCUCCACAGUCCACUCCAGGGCUC 24 5808
SCNNlA-1995 - ACUCCAGGGCUCAUGAAG 18 5844
SCNNlA-1996 - CACUCCAGGGCUCAUGAAG 19 5845
SCNNlA-12 - CCACUCCAGGGCUCAUGAAG 20 561
SCNNlA-1997 - UCCACUCCAGGGCUCAUGAAG 21 5846
SCNNlA-1998 - GUCCACUCCAGGGCUCAUGAAG 22 5847
SCNNlA-1999 - AGUCCACUCCAGGGCUCAUGAAG 23 5848
SCNNlA-2000 - CAGUCCACUCCAGGGCUCAUGAAG 24 5849
SCNNlA-2017 - GGGAACAAGCGUGAGGAG 18 5866
SCNNlA-2018 - GGGGAACAAGCGUGAGGAG 19 5867
SCNNlA-179 - AGGGGAACAAGCGUGAGGAG 20 813
SCNNlA-2019 - AAGGGGAACAAGCGUGAGGAG 21 5868
SCNNlA-2020 - GAAGGGGAACAAGCGUGAGGAG 22 5869
1527
5535.1 SCNNlA-2021 - UGAAGGGGAACAAGCGUGAGGAG 23 5870
SCNNlA-2022 - AUGAAGGGGAACAAGCGUGAGGAG 24 5871
SCNNlA-2023 - CAGCAGCCCACGGCGGAG 18 5872
SCNNlA-2024 - CCAGCAGCCCACGGCGGAG 19 5873
SCNNlA-187 - CCCAGCAGCCCACGGCGGAG 20 818
SCNNlA-2025 - CCCCAGCAGCCCACGGCGGAG 21 5874
SCNNlA-2026 - GCCCCAGCAGCCCACGGCGGAG 22 5875
SCNNlA-2027 - CGCCCCAGCAGCCCACGGCGGAG 23 5876
SCNNlA-2028 - GCGCCCCAGCAGCCCACGGCGGAG 24 5877
SCNNlA-2035 - GCGCCCCAGCAGCCCACG 18 5884
SCNNlA-2036 - GGCGCCCCAGCAGCCCACG 19 5885
SCNNlA-183 - CGGCGCCCCAGCAGCCCACG 20 816
SCNNlA-2037 - GCGGCGCCCCAGCAGCCCACG 21 5886
SCNNlA-2038 - UGCGGCGCCCCAGCAGCCCACG 22 5887
SCNNlA-2039 - CUGCGGCGCCCCAGCAGCCCACG 23 5888
SCNNlA-2040 - CCUGCGGCGCCCCAGCAGCCCACG 24 5889
SCNNlA-2041 - CCCCAGCAGCCCACGGCG 18 5890
SCNNlA-2042 - GCCCCAGCAGCCCACGGCG 19 5891
SCNNlA-185 - CGCCCCAGCAGCCCACGGCG 20 817
SCNNlA-2043 - GCGCCCCAGCAGCCCACGGCG 21 5892
SCNNlA-2044 - GGCGCCCCAGCAGCCCACGGCG 22 5893
SCNNlA-2045 - CGGCGCCCCAGCAGCCCACGGCG 23 5894
SCNNlA-2046 - GCGGCGCCCCAGCAGCCCACGGCG 24 5895
SCNN1A-
- CCUUUGGGGAGGGAAAGG 18
11064 14913
SCNN1A-
- CCCUUUGGGGAGGGAAAGG 19
11065 14914
SCNN1A-
- CCCCUUUGGGGAGGGAAAGG 20
11066 14915
SCNN1A-
- UCCCCUUUGGGGAGGGAAAGG 21
11067 14916
SCNN1A-
- CUCCCCUUUGGGGAGGGAAAGG 22
11068 14917
SCNN1A-
- GCUCCCCUUUGGGGAGGGAAAGG 23
11069 14918
SCNN1A-
- GGCUCCCCUUUGGGGAGGGAAAGG 24
11070 14919
SCNN1A-
- UGACACCCCUGUCCCAGG 18
11071 14920
SCNN1A-
- CUGACACCCCUGUCCCAGG 19
11072 14921
SCNN1A-
- ACUGACACCCCUGUCCCAGG 20
11073 14922
1528
5535.1 SCNN1A-
- AACUGACACCCCUGUCCCAGG 21
11074 14923
SCNN1A-
- GAACUGACACCCCUGUCCCAGG 22
11075 14924
SCNN1A-
- GGAACUGACACCCCUGUCCCAGG 23
11076 14925
SCNN1A-
- GGGAACUGACACCCCUGUCCCAGG 24
11077 14926
SCNN1A-
- AGGUGCUCACUGGGCAGG 18
11078 14927
SCNN1A-
- GAGGUGCUCACUGGGCAGG 19
11079 14928
SCNN1A-
- UGAGGUGCUCACUGGGCAGG 20
11080 14929
SCNN1A-
- CUGAGGUGCUCACUGGGCAGG 21
11081 14930
SCNN1A-
- GCUGAGGUGCUCACUGGGCAGG 22
11082 14931
SCNN1A-
- UGCUGAGGUGCUCACUGGGCAGG 23
11083 14932
SCNN1A-
- GUGCUGAGGUGCUCACUGGGCAGG 24
11084 14933
SCNNlA-2050 - AGCAGCCCACGGCGGAGG 18 5899
SCNNlA-2051 - CAGCAGCCCACGGCGGAGG 19 5900
SCNNlA-23 - CCAGCAGCCCACGGCGGAGG 20 566
SCNNlA-2052 - CCCAGCAGCCCACGGCGGAGG 21 5901
SCNNlA-2053 - CCCCAGCAGCCCACGGCGGAGG 22 5902
SCNNlA-2054 - GCCCCAGCAGCCCACGGCGGAGG 23 5903
SCNNlA-2055 - CGCCCCAGCAGCCCACGGCGGAGG 24 5904
SCNN1A-
- AGAGCCUCAGACCUGAGG 18
11085 14934
SCNN1A-
- CAGAGCCUCAGACCUGAGG 19
11086 14935
SCNN1A-
- GCAGAGCCUCAGACCUGAGG 20
11087 14936
SCNN1A-
- GGCAGAGCCUCAGACCUGAGG 21
11088 14937
SCNN1A-
- AGGCAGAGCCUCAGACCUGAGG 22
11089 14938
SCNN1A-
- CAGGCAGAGCCUCAGACCUGAGG 23
11090 14939
SCNN1A-
- GCAGGCAGAGCCUCAGACCUGAGG 24
11091 14940
1529
5535.1 SCNNlA-2056 - CGCCCCAGCAGCCCACGG 18 5905
SCNNlA-2057 - GCGCCCCAGCAGCCCACGG 19 5906
SCNNlA-21 - GGCGCCCCAGCAGCCCACGG 20 510
SCNNlA-2058 - CGGCGCCCCAGCAGCCCACGG 21 5907
SCNNlA-2059 - GCGGCGCCCCAGCAGCCCACGG 22 5908
SCNNlA-2060 - UGCGGCGCCCCAGCAGCCCACGG 23 5909
SCNNlA-2061 - CUGCGGCGCCCCAGCAGCCCACGG 24 5910
SCNN1A-
- UGCCACUCCCAUACCCGG 18
11092 14941
SCNN1A-
- UUGCCACUCCCAUACCCGG 19
11093 14942
SCNN1A-
- AUUGCCACUCCCAUACCCGG 20
11094 14943
SCNN1A-
- CAUUGCCACUCCCAUACCCGG 21
11095 14944
SCNN1A-
- GCAUUGCCACUCCCAUACCCGG 22
11096 14945
SCNN1A-
- CGCAUUGCCACUCCCAUACCCGG 23
11097 14946
SCNN1A-
- UCGCAUUGCCACUCCCAUACCCGG 24
11098 14947
SCNNlA-2062 - CCCAGCAGCCCACGGCGG 18 5911
SCNNlA-2063 - CCCCAGCAGCCCACGGCGG 19 5912
SCNNlA-22 - GCCCCAGCAGCCCACGGCGG 20 511
SCNNlA-2064 - CGCCCCAGCAGCCCACGGCGG 21 5913
SCNNlA-2065 - GCGCCCCAGCAGCCCACGGCGG 22 5914
SCNNlA-2066 - GGCGCCCCAGCAGCCCACGGCGG 23 5915
SCNNlA-2067 - CGGCGCCCCAGCAGCCCACGGCGG 24 5916
SCNN1A-
- GAGCCUCAGACCUGAGGG 18
11099 14948
SCNN1A-
- AGAGCCUCAGACCUGAGGG 19
11100 14949
SCNNlA-6341 - CAGAGCCUCAGACCUGAGGG 20 10190
SCNN1A-
- GCAGAGCCUCAGACCUGAGGG 21
11101 14950
SCNN1A-
- GGCAGAGCCUCAGACCUGAGGG 22
11102 14951
SCNN1A-
- AGGCAGAGCCUCAGACCUGAGGG 23
11103 14952
SCNN1A-
- CAGGCAGAGCCUCAGACCUGAGGG 24
11104 14953
SCNNlA-2074 - AAGCGUGAGGAGCAGGGG 18 5923
SCNNlA-2075 - CAAG CG U G AG G AG CAG G GG 19 5924
1530
5535.1 SCNNlA-181 - ACAAGCGUGAGGAGCAGGGG 20 814
SCNNlA-2076 - AACAAGCGUGAGGAGCAGGGG 21 5925
SCNNlA-2077 - GAACAAGCGUGAGGAGCAGGGG 22 5926
SCNNlA-2078 - GGAACAAGCGUGAGGAGCAGGGG 23 5927
SCNNlA-2079 - GGGAACAAGCGUGAGGAGCAGGGG 24 5928
SCNN1A-
- GGUGGCUCCCCUUUGGGG 18
11105 14954
SCNN1A-
- UGGUGGCUCCCCUUUGGGG 19
11106 14955
SCNNlA-6342 - AUGGUGGCUCCCCUUUGGGG 20 10191
SCNN1A-
- UAUGGUGGCUCCCCUUUGGGG 21
11107 14956
SCNN1A-
- UUAUGGUGGCUCCCCUUUGGGG 22
11108 14957
SCNN1A-
- AUUAUGGUGGCUCCCCUUUGGGG 23
11109 14958
SCNN1A-
- AAUUAUGGUGGCUCCCCUUUGGGG 24
11110 14959
SCNN1A-
- UGGUGGCUCCCCUUUGGG 18
11111 14960
SCNN1A-
- AUGGUGGCUCCCCUUUGGG 19
11112 14961
SCNN1A-
- UAUGGUGGCUCCCCUUUGGG 20
11113 14962
SCNN1A-
- UUAUGGUGGCUCCCCUUUGGG 21
11114 14963
SCNN1A-
- AUUAUGGUGGCUCCCCUUUGGG 22
11115 14964
SCNN1A-
- AAUUAUGGUGGCUCCCCUUUGGG 23
11116 14965
SCNN1A-
- AAAUUAUGGUGGCUCCCCUUUGGG 24
11117 14966
SCNNlA-2105 - UCCACUCCAGGGCUCAUG 18 5954
SCNNlA-2106 - GUCCACUCCAGGGCUCAUG 19 5955
SCNNlA-172 - AGUCCACUCCAGGGCUCAUG 20 810
SCNNlA-2107 - CAGUCCACUCCAGGGCUCAUG 21 5956
SCNNlA-2108 - ACAGUCCACUCCAGGGCUCAUG 22 5957
SCNNlA-2109 - CACAGUCCACUCCAGGGCUCAUG 23 5958
SCNNlA-2110 - CCA CAGUCCACUCCAGGGCUCAUG 24 5959
SCNNlA-2137 - UGAAGGGGAACAAGCGUG 18 5986
SCNNlA-2138 - AUGAAGGGGAACAAGCGUG 19 5987
SCNNlA-13 - CA U G AAG GG G AAC AAG CG U G 20 562
SCNNlA-2139 - UCAUGAAGGGGAACAAGCGUG 21 5988
1531
5535.1 SCNNlA-2140 - CUCAUGAAGGGGAACAAGCGUG 22 5989
SCNNlA-2141 - GCUCAUGAAGGGGAACAAGCGUG 23 5990
SCNNlA-2142 - GGCUCAUGAAGGGGAACAAGCGUG 24 5991
SCNN1A-
- GAAGGGUGGUCCAGGGUG 18
11118 14967
SCNN1A-
- GGAAGGGUGGUCCAGGGUG 19
11119 14968
SCNN1A-
- UGGAAGGGUGGUCCAGGGUG 20
11120 14969
SCNN1A-
- CUGGAAGGGUGGUCCAGGGUG 21
11121 14970
SCNN1A-
- CCUGGAAGGGUGGUCCAGGGUG 22
11122 14971
SCNN1A-
- GCCUGGAAGGGUGGUCCAGGGUG 23
11123 14972
SCNN1A-
- CGCCUGGAAGGGUGGUCCAGGGUG 24
11124 14973
SCNN1A-
- CUAUAUACUUCUGUAUUG 18
11125 14974
SCNN1A-
- UCUAUAUACUUCUGUAUUG 19
11126 14975
SCNN1A-
- CUCUAUAUACUUCUGUAUUG 20
11127 14976
SCNN1A-
- GCUCUAUAUACUUCUGUAUUG 21
11128 14977
SCNN1A-
- AGCUCUAUAUACUUCUGUAUUG 22
11129 14978
SCNN1A-
- AAGCUCUAUAUACUUCUGUAUUG 23
11130 14979
SCNN1A-
- GAAGCUCUAUAUACUUCUGUAUUG 24
11131 14980
SCNN1A-
- A AG C A A A A A UGGAAGUUG 18
11132 14981
SCNN1A-
- A A AG C A A A A A UGGAAGUUG 19
11133 14982
SCNN1A-
- A A A AG C A A A A A UGGAAGUUG 20
11134 14983
SCNN1A-
- U A A A AG C A A A A A UGGAAGUUG 21
11135 14984
SCNN1A-
- A U A A A AG C A A A A A UGGAAGUUG 22
11136 14985
SCNN1A-
- A A U A A A AG C A A A A A UGGAAGUUG 23
11137 14986
1532
5535.1 SCNN1A-
- AAAUAAAAGCAAAAAUGGAAGUUG 24
11138 14987
SCNN1A-
- UAUGGUGGCUCCCCUUUG 18
11139 14988
SCNN1A-
- UUAUGGUGGCUCCCCUUUG 19
11140 14989
SCNNlA-6348 - AUUAUGGUGGCUCCCCUUUG 20 10197
SCNN1A-
- AAUUAUGGUGGCUCCCCUUUG 21
11141 14990
SCNN1A-
- AAAUUAUGGUGGCUCCCCUUUG 22
11142 14991
SCNN1A-
- CAAAUUAUGGUGGCUCCCCUUUG 23
11143 14992
SCNN1A-
- ACAAAUUAUGGUGGCUCCCCUUUG 24
11144 14993
SCNN1A-
- CCUGUCUCUAAGAUAAAU 18
11145 14994
SCNN1A-
- UCCUGUCUCUAAGAUAAAU 19
11146 14995
SCNN1A-
- AUCCUGUCUCUAAGAUAAAU 20
11147 14996
SCNN1A-
- GAUCCUGUCUCUAAGAUAAAU 21
11148 14997
SCNN1A-
- UGAUCCUGUCUCUAAGAUAAAU 22
11149 14998
SCNN1A-
- AUGAUCCUGUCUCUAAGAUAAAU 23
11150 14999
SCNN1A-
- CAUGAUCCUGUCUCUAAGAUAAAU 24
11151 15000
SCNN1A-
- AGGGAAAGGAAGGGGACU 18
11152 15001
SCNN1A-
- GAGGGAAAGGAAGGGGACU 19
11153 15002
SCNN1A-
- GGAGGGAAAGGAAGGGGACU 20
11154 15003
SCNN1A-
- GGGAGGGAAAGGAAGGGGACU 21
11155 15004
SCNN1A-
- GGGGAGGGAAAGGAAGGGGACU 22
11156 15005
SCNN1A-
- UGGGGAGGGAAAGGAAGGGGACU 23
11157 15006
SCNN1A-
- UUGGGGAGGGAAAGGAAGGGGACU 24
11158 15007
1533
5535.1 SCNN1A-
- AAUUAUGGUGGCUCCCCU 18
11159 15008
SCNN1A-
- AAAUUAUGGUGGCUCCCCU 19
11160 15009
SCNN1A-
- CAAAUUAUGGUGGCUCCCCU 20
11161 15010
SCNN1A-
- ACAAAUUAUGGUGGCUCCCCU 21
11162 15011
SCNN1A-
- UACAAAUUAUGGUGGCUCCCCU 22
11163 15012
SCNN1A-
- AUACAAAUUAUGGUGGCUCCCCU 23
11164 15013
SCNN1A-
- UAUACAAAUUAUGGUGGCUCCCCU 24
11165 15014
SCNNlA-2170 - AUGAAGGGG A AC A AG CG U 18 6019
SCNNlA-2171 - CAUGAAGGGGAACAAGCGU 19 6020
SCNNlA-177 - UCAUGAAGGGGAACAAGCGU 20 812
SCNNlA-2172 - CUCAUGAAGGGGAACAAGCGU 21 6021
SCNNlA-2173 - GCUCAUGAAGGGGAACAAGCGU 22 6022
SCNNlA-2174 - GGCUCAUGAAGGGGAACAAGCGU 23 6023
SCNNlA-2175 - GGGCUCAUGAAGGGGAACAAGCGU 24 6024
SCNN1A-
- AGCCUCAGACCUGAGGGU 18
11166 15015
SCNN1A-
- GAGCCUCAGACCUGAGGGU 19
11167 15016
SCNNlA-6357 - AGAGCCUCAGACCUGAGGGU 20 10206
SCNN1A-
- CAGAGCCUCAGACCUGAGGGU 21
11168 15017
SCNN1A-
- GCAGAGCCUCAGACCUGAGGGU 22
11169 15018
SCNN1A-
- GGCAGAGCCUCAGACCUGAGGGU 23
11170 15019
SCNN1A-
- AGGCAGAGCCUCAGACCUGAGGGU 24
11171 15020
SCNN1A-
- AUUAUGGUGGCUCCCCUU 18
11172 15021
SCNN1A-
- AAUUAUGGUGGCUCCCCUU 19
11173 15022
SCNNlA-6360 - AAAUUAUGGUGGCUCCCCUU 20 10209
SCNN1A-
- CAAAUUAUGGUGGCUCCCCUU 21
11174 15023
SCNN1A-
- ACAAAUUAUGGUGGCUCCCCUU 22
11175 15024
1534
5535.1 SCNN1A-
- UACAAAUUAUGGUGGCUCCCCUU 23
11176 15025
SCNN1A-
- AUACAAAUUAUGGUGGCUCCCCUU 24
11177 15026
SCNNlA-2183 - CCGCAUGAAGACGGCCUU 18 6032
SCNNlA-2184 - ACCGCAUGAAGACGGCCUU 19 6033
SCNNlA-194 - AACCGCAUGAAGACGGCCUU 20 824
SCNNlA-2185 - CAACCGCAUGAAGACGGCCUU 21 6034
SCNNlA-2186 - ACAACCGCAUGAAGACGGCCUU 22 6035
SCNNlA-2187 - CACAACCGCAUGAAGACGGCCUU 23 6036
SCNNlA-2188 - GCACAACCGCAUGAAGACGGCCUU 24 6037
SCNN1A-
- UUAUGGUGGCUCCCCUUU 18
11178 15027
SCNN1A-
- AUUAUGGUGGCUCCCCUUU 19
11179 15028
SCNNlA-6361 - AAUUAUGGUGGCUCCCCUUU 20 10210
SCNN1A-
- AAAUUAUGGUGGCUCCCCUUU 21
11180 15029
SCNN1A-
- CAAAUUAUGGUGGCUCCCCUUU 22
11181 15030
SCNN1A-
- ACAAAUUAUGGUGGCUCCCCUUU 23
11182 15031
SCNN1A-
- UACAAAUUAUGGUGGCUCCCCUUU 24
11183 15032
SCNNlA-2189 - GGCAAUUCGGCCUGCUUU 18 6038
SCNNlA-2190 - UGGCAAUUCGGCCUGCUUU 19 6039
SCNNlA-195 - CUGGCAAUUCGGCCUGCUUU 20 825
SCNNlA-2191 - ACUGGCAAUUCGGCCUGCUUU 21 6040
SCNNlA-2192 - UACUGGCAAUUCGGCCUGCUUU 22 6041
SCNNlA-2193 - GUACUGGCAAUUCGGCCUGCUUU 23 6042
SCNNlA-2194 - UGUACUGGCAAUUCGGCCUGCUUU 24 6043
SCNNlA-2195 - GCAAUUCGGCCUGCUUUU 18 6044
SCNNlA-2196 - GGCAAUUCGGCCUGCUUUU 19 6045
SCNNlA-34 - UGGCAAUUCGGCCUGCUUUU 20 573
SCNNlA-2197 - CUGGCAAUUCGGCCUGCUUUU 21 6046
SCNNlA-2198 - ACUGGCAAUUCGGCCUGCUUUU 22 6047
SCNNlA-2199 - UACUGGCAAUUCGGCCUGCUUUU 23 6048
SCNNlA-2200 - GUACUGGCAAUUCGGCCUGCUUUU 24 6049
Table 48A provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the first tier parameters. The targeting domains bind within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), have a high level of orthogonality
1535
5535.1 and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. miningtidis eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of
SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
Table 48A
Figure imgf001537_0001
Table 48B provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the second tier parameters. The targeting domains bind within 500 bp (e.g. upstream or downstream) of a transcription start site (TSS) and have a high level of
orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the
1536
5535.1 table can be used with a N. miningtidis eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
Table 48B
Figure imgf001538_0001
1537
5535.1 SCNNlA-11227 + UCCUGGUCCCUCCUCUUUCC 20 15076
SCNNlA-11228 + CUGCACGCGGCAGGGAAGGC 20 15077
SCNNlA-11229 + CUUCCCUAGAACGGCCUCUC 20 15078
SCNNlA-11230 + CAGAGUGCAGGAAUGUGGUC 20 15079
SCNNlA-5650 - CAACUCUGUGACCACAGCAG 20 9499
SCNNlA-8013 + UGGGGCCAAAAGUGCCGGAG 20 11862
SCNNlA-5027 + UUCCCCUUCAUGAGCCCCGG 20 8876
SCNNlA-11231 - UCUCCUCCAGCCCUUUUUGG 20 15080
SCNNlA-11232 - CAUGCUGCCUUAAGCUAGUG 20 15081
SCNNlA-11233 - CCUGCUAAACUCCUUGCUUG 20 15082
SCNNlA-11234 + CUUCUAACAAAAGUGCAGAU 20 15083
SCNNlA-11235 - UCUUCUUUGCCUGCUAAACU 20 15084
SCNNlA-11236 + CUCCUCUGGGGCUAUCUACU 20 15085
SCNNlA-11237 - CUCAGGCUGGGCCUUUGUCU 20 15086
SCNNlA-11238 - AUCCUCCCUGCACCUUCAGU 20 15087
Table 48C provides exemplary targeting domains for knocking down the SCNN1A gene selected according to the third tier parameters. The targeting domains bind within 500 bp (e.g., upstream or downstream) of a transcription start site (TSS) and start with a 5'G. It is
contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. miningtidis eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a
transcription repressor domain) to alter the SCNN1A gene (e.g., reduce or eliminate SCNN1A gene expression, SCNN1A protein function, or the level of SCNN1A protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNN1A gene.
Table 48C
Figure imgf001539_0001
Table 48D provides exemplary targeting domains for knocking out the SCNN1A gene selected according to the fourth tier parameters. The targeting domains bind within 500 bp (e.g.,
1538
5535.1 upstream or downstream) of a transcription start site (TSS). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. miningtidis eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
Table 48D
Figure imgf001540_0001
Table 48E provides exemplary targeting domains for knocking down the SCNNIA gene selected according to the fifth tier parameters. The targeting domains bind within the additional 500 bp (e.g., upstream or downstream) of a transcription start site (TSS), e.g., extending to lkb upstream and downstream of a TSS. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. miningtidis eiCas9 molecule or eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain) to alter the SCNNIA gene (e.g., reduce or eliminate SCNNIA gene expression, SCNNIA protein function, or the level of SCNNIA protein). One or more gRNA may be used to target an eiCas9 to the promoter region of the SCNNIA gene.
Table 48E
Figure imgf001540_0002
1539
5535.1 SCNN lA-322 + UGGUCACUGCGGGGAAG 17 915
SCN N lA-5023 - GAUGUACUGGCAAUUCG 17 8872
SCN N lA-5025 + AGGGACUAACCGACCUG 17 8874
SCNN lA-11247 + GUUUCUACAACU UCCAU 17 15096
SCNN lA-11248 - CUGACCAAAGUCCAGGU 17 15097
SCNN lA-11249 + UAGACCUGGAGCGGGCUAGA 20 15098
SCNN lA-10791 + UUCAGCAAUACAGAAGUAUA 20 14640
SCN N lA-5031 + CGGGGCCCAGCCCCUGCUCC 20 8880
SCNN lA-238 + AGAUGGUCACUGCGGGGAAG 20 858
SCN N lA-5026 - CAUGAUGUACUGGCAAUUCG 20 8875
SCN N lA-1657 + CAGAGGGACUAACCGACCUG 20 5506
SCNN lA-11250 + UAUGUUUCUACAACUUCCAU 20 15099
SCNN lA-11251 - CUUCUGACCAAAGUCCAGGU 20 15100
III. Cas9 Molecules Cas9 molecules of a variety of species can be used in the methods and compositions described herein. While the S. pyogenes, S. aureus and S. thermophilus Cas9 molecules are the subject of much of the disclosure herein, Cas9 molecules of, derived from, or based on the Cas9 proteins of other species listed herein can be used as well. In other words, while the much of the description herein uses S. pyogenes and S. thermophilus Cas9 molecules, Cas9 molecules from the other species can replace them, e.g., Staphylococcus aureus and Neisseria meningitidis Cas9 molecules. Additional Cas9 species include: Acidovorax avenae, Actinobacillus
pleuropneumoniae, Actinobacillus succinogenes, Actinobacillus suis, Actinomyces sp., cycliphilus denitrificans, Aminomonas paucivorans, Bacillus cereus, Bacillus smithii, Bacillus thuringiensis, Bacteroides sp., Blastopirellula marina, Bradyrhizobium sp., Brevibacillus laterosporus, Campylobacter coli, Campylobacter jejuni, Campylobacter lari, Candidatus Puniceispirillum, Clostridium cellulolyticum, Clostridium perfringens, Corynebacterium accolens, Corynebacterium diphtheria, Corynebacterium matruchotii, Dinoroseobacter shibae, Eubacterium dolichum, gamma proteobacterium, Gluconacetobacter diazotrophicus,
Haemophilus parainfluenzae, Haemophilus sputorum, Helicobacter canadensis, Helicobacter cinaedi, Helicobacter mustelae, Ilyobacter polytropus, Kingella kingae, Lactobacillus crispatus, Listeria ivanovii, Listeria monocytogenes, Listeriaceae bacterium, Methylocystis sp.,
Methylosinus trichosporium, Mobiluncus mulieris, Neisseria bacilliformis, Neisseria cinerea,
1540
5535.1 Neisseria flavescens, Neisseria lactamica, Neisseria meningitidis, Neisseria sp., Neisseria wadsworthii, Nitrosomonas sp., Parvibaculum lavamentivorans, Pasteurella multocida, Phascolarctobacterium succinatutens, Ralstonia syzygii, Rhodopseudomonas palustris,
Rhodovulum sp., Simonsiella muelleri, Sphingomonas sp., Sporolactobacillus vineae,
Staphylococcus lugdunensis, Streptococcus sp., Subdoligranulum sp., Tistrella mobilis,
Treponema sp., or Verminephrobacter eiseniae.
A Cas9 molecule or Cas9 polypeptide, as that term is used herein, refers to a molecule or polypeptide that can interact with a guide RNA (gRNA) molecule and, in concert with the gRNA molecule, home or localizes to a site which comprises a target domain and PAM sequence. Cas9 molecule and Cas9 polypeptide, as those terms are used herein, refer to naturally occurring Cas9 molecules and to engineered, altered, or modified Cas9 molecules or Cas9 polypeptides that differ, e.g., by at least one amino acid residue, from a reference sequence, e.g., the most similar naturally occurring Cas9 molecule or a sequence of Table 50. Cas9 Domains
Crystal structures have been determined for two different naturally occurring bacterial Cas9 molecules (Jinek et al., Science, 343(6176): 1247997, 2014) and for S. pyogenes Cas9 with a guide RNA (e.g., a synthetic fusion of crRNA and tracrRNA) (Nishimasu et al., Cell, 156:935- 949, 2014; and Anders et al., Nature, 2014, doi: 10.1038/naturel3579).
A naturally occurring Cas9 molecule comprises two lobes: a recognition (REC) lobe and a nuclease (NUC) lobe; each of which further comprises domains described herein. Figs. 9A-9B provide a schematic of the organization of important Cas9 domains in the primary structure. The domain nomenclature and the numbering of the amino acid residues encompassed by each domain used throughout this disclosure is as described in Nishimasu et al. The numbering of the amino acid residues is with reference to Cas9 from S. pyogenes.
The REC lobe comprises the arginine-rich bridge helix (BH), the REC1 domain, and the REC2 domain. The REC lobe does not share structural similarity with other known proteins, indicating that it is a Cas9-specific functional domain. The BH domain is a long a helix and arginine rich region and comprises amino acids 60-93 of the sequence of S. pyogenes Cas9. The REC1 domain is important for recognition of the repeat: anti-repeat duplex, e.g., of a gRNA or a tracrRNA, and is therefore critical for Cas9 activity by recognizing the target sequence. The
1541
5535.1 REC1 domain comprises two REC1 motifs at amino acids 94 to 179 and 308 to 717 of the sequence of S. pyogenes Cas9. These two REC1 domains, though separated by the REC2 domain in the linear primary structure, assemble in the tertiary structure to form the REC1 domain. The REC2 domain, or parts thereof, may also play a role in the recognition of the repeat: anti-repeat duplex. The REC2 domain comprises amino acids 180-307 of the sequence of S. pyogenes Cas9.
The NUC lobe comprises the RuvC domain (also referred to herein as RuvC-like domain), the HNH domain (also referred to herein as HNH-like domain), and the PAM- interacting (PI) domain. The RuvC domain shares structural similarity to retroviral integrase superfamily members and cleaves a single strand, e.g., the non-complementary strand of the target nucleic acid molecule. The RuvC domain is assembled from the three split RuvC motifs (RuvC I, RuvCII, and RuvCIII, which are often commonly referred to in the art as RuvCI domain, or N-terminal RuvC domain, RuvCII domain, and RuvCIII domain) at amino acids 1- 59, 718-769, and 909-1098, respectively, of the sequence of S. pyogenes Cas9. Similar to the REC1 domain, the three RuvC motifs are linearly separated by other domains in the primary structure, however in the tertiary structure, the three RuvC motifs assemble and form the RuvC domain. The HNH domain shares structural similarity with HNH endonucleases, and cleaves a single strand, e.g., the complementary strand of the target nucleic acid molecule. The HNH domain lies between the RuvC II-III motifs and comprises amino acids 775-908 of the sequence of S. pyogenes Cas9. The PI domain interacts with the PAM of the target nucleic acid molecule, and comprises amino acids 1099-1368 of the sequence of S. pyogenes Cas9.
A RuvC-like domain and an HNH-like domain
In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises an HNH-like domain and a RuvC-like domain. In an embodiment, cleavage activity is dependent on a RuvC-like domain and an HNH-like domain. A Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, can comprise one or more of the following domains: a RuvC- like domain and an HNH-like domain. In an embodiment, a Cas9 molecule or Cas9 polypeptide is an eaCas9 molecule or eaCas9 polypeptide and the eaCas9 molecule or eaCas9 polypeptide comprises a RuvC-like domain, e.g., a RuvC-like domain described below, and/or an HNH-like domain, e.g., an HNH-like domain described below.
1542
5535.1 RuvC-like domains
In an embodiment, a RuvC-like domain cleaves, a single strand, e.g., the non- complementary strand of the target nucleic acid molecule. The Cas9 molecule or Cas9 polypeptide can include more than one RuvC-like domain (e.g., one, two, three or more RuvC- like domains). In an embodiment, a RuvC-like domain is at least 5, 6, 7, 8 amino acids in length but not more than 20, 19, 18, 17, 16 or 15 amino acids in length. In an embodiment, the Cas9 molecule or Cas9 polypeptide comprises an N-terminal RuvC-like domain of about 10 to 20 amino acids, e.g., about 15 amino acids in length.
N-terminal RuvC-like domains
Some naturally occurring Cas9 molecules comprise more than one RuvC-like domain with cleavage being dependent on the N-terminal RuvC-like domain. Accordingly, Cas9 molecules or Cas9 polypeptide can comprise an N-terminal RuvC-like domain. Exemplary N- terminal RuvC-like domains are described below.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an N-terminal RuvC-like domain comprising an amino acid sequence of formula I:
D-X1-G-X2-X3-X4-X5-G-X6-X7-X8-X9 (SEQ ID NO: 8),
wherein,
XI is selected from I, V, M, L and T (e.g., selected from I, V, and L);
X2 is selected from T, I, V, S, N, Y, E and L (e.g., selected from T, V, and I);
X3 is selected from N, S, G, A, D, T, R, M and F (e.g., A or N);
X4 is selected from S, Y, N and F (e.g., S);
X5 is selected from V, I, L, C, T and F (e.g., selected from V, I and L);
X6 is selected from W, F, V, Y, S and L (e.g., W);
X7 is selected from A, S, C, V and G (e.g., selected from A and S);
X8 is selected from V, I, L, A, M and H (e.g., selected from V, I, M and L); and
X9 is selected from any amino acid or is absent (e.g., selected from T, V, I, L, Δ, F, S, A, Y, M and R, or, e.g., selected from T, V, I, L and Δ).
In an embodiment, the N-terminal RuvC-like domain differs from a sequence of SEQ ID NO:8, by as many as 1 but no more than 2, 3, 4, or 5 residues.
1543
5535.1 In embodiment, the N-terminal RuvC-like domain is cleavage competent.
In embodiment, the N-terminal RuvC-like domain is cleavage incompetent.
In an embodiment, a eaCas9 molecule or eaCas9 polypeptide comprises an N-terminal RuvC-like domain comprising an amino acid sequence of formula II:
D-X1-G-X2-X3-S-X5-G-X6-X7-X8-X9, (SEQ ID NO: 9),
wherein
XI is selected from I, V, M, L and T (e.g., selected from I, V, and L);
X2 is selected from T, I, V, S, N, Y, E and L (e.g., selected from T, V, and I);
X3 is selected from N, S, G, A, D, T, R, M and F (e.g., A or N);
X5 is selected from V, I, L, C, T and F (e.g., selected from V, I and L);
X6 is selected from W, F, V, Y, S and L (e.g., W);
X7 is selected from A, S, C, V and G (e.g., selected from A and S);
X8 is selected from V, I, L, A, M and H (e.g., selected from V, I, M and L); and
X9 is selected from any amino acid or is absent (e.g., selected from T, V, I, L, Δ, F, S, A, Y, M and R or selected from e.g., T, V, I, L and Δ).
In an embodiment, the N-terminal RuvC-like domain differs from a sequence of SEQ ID NO:9 by as many as 1 but no more than 2, 3, 4, or 5 residues.
In an embodiment, the N-terminal RuvC-like domain comprises an amino acid sequence of formula III:
D-I-G-X2-X3-S-V-G-W-A-X8-X9 (SEQ ID NO: 10),
wherein
X2 is selected from T, I, V, S, N, Y, E and L (e.g., selected from T, V, and I);
X3 is selected from N, S, G, A, D, T, R, M and F (e.g., A or N);
X8 is selected from V, I, L, A, M and H (e.g., selected from V, I, M and L); and
X9 is selected from any amino acid or is absent (e.g., selected from T, V, I, L, Δ, F, S, A,
Y, M and R or selected from e.g., T, V, I, L and Δ).
In an embodiment, the N-terminal RuvC-like domain differs from a sequence of SEQ ID NO: 10 by as many as 1 but no more than, 2, 3, 4, or 5 residues.
In an embodiment, the N-terminal RuvC-like domain comprises an amino acid sequence of formula III:
D-I-G-T-N-S-V-G-W-A-V-X (SEQ ID NO: 11),
1544
5535.1 wherein
X is a non-polar alkyl amino acid or a hydroxyl amino acid, e.g., X is selected from V, I, L and T (e.g., the eaCas9 molecule can comprise an N-terminal RuvC-like domain shown in Figs. 2A-2G (is depicted as Y)).
In an embodiment, the N-terminal RuvC-like domain differs from a sequence of SEQ ID NO: 11 by as many as 1 but no more than, 2, 3, 4, or 5 residues.
In an embodiment, the N-terminal RuvC-like domain differs from a sequence of an N- terminal RuvC like domain disclosed herein, e.g., in Figs. 3A-3B or Figs. 7A-7B, as many as 1 but no more than 2, 3, 4, or 5 residues. In an embodiment, 1, 2, 3 or all of the highly conserved residues identified in Figs. 3A-3B or Figs. 7A-7B are present.
In an embodiment, the N-terminal RuvC-like domain differs from a sequence of an N- terminal RuvC-like domain disclosed herein, e.g., in Figs. 4A-4B or Figs. 7A-7B, as many as 1 but no more than 2, 3, 4, or 5 residues. In an embodiment, 1, 2, or all of the highly conserved residues identified in Figs. 4A-4B or Figs. 7A-7B are present.
Additional RuvC-like domains
In addition to the N-terminal RuvC-like domain, the Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, can comprise one or more additional RuvC-like domains. In an embodiment, the Cas9 molecule or Cas9 polypeptide can comprise two additional RuvC-like domains. Preferably, the additional RuvC-like domain is at least 5 amino acids in length and, e.g., less than 15 amino acids in length, e.g., 5 to 10 amino acids in length, e.g., 8 amino acids in length.
An additional RuvC-like domain can comprise an amino acid sequence:
I-X1-X2-E-X3-A-R-E (SEQ ID NO: 12), wherein
XI is V or H,
X2 is I, L or V (e.g., I or V); and
X3 is M or T.
In an embodiment, the additional RuvC-like domain comprises the amino acid sequence: I-V-X2-E-M-A-R-E (SEQ ID NO: 13), wherein
X2 is I, L or V (e.g., I or V) (e.g., the eaCas9 molecule or eaCas9 polypeptide can
1545
5535.1 comprise an additional RuvC-like domain shown in Fig. 2A-2G or Figs. 7A-7B (depicted as B)). An additional RuvC-like domain can comprise an amino acid sequence:
H-H-A-X1-D-A-X2-X3 (SEQ ID NO: 14), wherein
XI is H or L;
X2 is R or V; and
X3 is E or V.
In an embodiment, the additional RuvC-like domain comprises the amino acid sequence: H-H-A-H-D-A-Y-L (SEQ ID NO: 15).
In an embodiment, the additional RuvC-like domain differs from a sequence of SEQ ID NO: 12, 13, 14 or 15 by as many as 1 but no more than 2, 3, 4, or 5 residues.
In some embodiments, the sequence flanking the N-terminal RuvC-like domain is a sequences of formula V:
K-X1'-Y-X2'-X3'-X4'-Z-T-D-X9'-Y, (SEQ ID NO: 16).
wherein
Χ is selected from K and P,
X2' is selected from V, L, I, and F (e.g., V, I and L);
X3' is selected from G, A and S (e.g., G),
X4' is selected from L, I, V and F (e.g., L);
X9' is selected from D, E, N and Q; and
Z is an N-terminal RuvC-like domain, e.g., as described above.
HNH-like domains
In an embodiment, an HNH-like domain cleaves a single stranded complementary domain, e.g., a complementary strand of a double stranded nucleic acid molecule. In an embodiment, an HNH-like domain is at least 15, 20, 25 amino acids in length but not more than 40, 35 or 30 amino acids in length, e.g., 20 to 35 amino acids in length, e.g., 25 to 30 amino acids in length. Exemplary HNH-like domains are described below.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an HNH-like domain having an amino acid sequence of formula VI:
XI -X2-X3-H-X4-X5-P-X6-X7-X8-X9-X 10-X 11 -X 12-X 13-X 14-X 15-N-X 16-X 17-X 18-
X19-X20-X21-X22-X23-N (SEQ ID NO: 17), wherein
1546
5535.1 XI is selected from D, E, Q and N (e.g., D and E);
X2 is selected from L, I, R, Q, V, M and K;
X3 is selected from D and E;
X4 is selected from I, V, T, A and L (e.g., A, I and V);
X5 is selected from V, Y, I, L, F and W (e.g., V, I and L);
X6 is selected from Q, H, R, K, Y, I, L, F and W;
X7 is selected from S, A, D, T and K (e.g., S and A);
X8 is selected from F, L, V, K, Y, M, I, R, A, E, D and Q (e.g., F);
X9 is selected from L, R, T, I, V, S, C, Y, K, F and G;
X10 is selected from K, Q, Y, T, F, L, W, M, A, E, G, and S;
XI I is selected from D, S, N, R, L and T (e.g., D);
X12 is selected from D, N and S;
X13 is selected from S, A, T, G and R (e.g., S);
X14 is selected from I, L, F, S, R, Y, Q, W, D, K and H (e.g., I, L and F);
X15 is selected from D, S, I, N, E, A, H, F, L, Q, M, G, Y and V;
X16 is selected from K, L, R, M, T and F (e.g., L, R and K);
X17 is selected from V, L, I, A and T;
X18 is selected from L, I, V and A (e.g., L and I);
X19 is selected from T, V, C, E, S and A (e.g., T and V);
X20 is selected from R, F, T, W, E, L, N, C, K, V, S, Q, I, Y, H and A;
X21 is selected from S, P, R, K, N, A, H, Q, G and L;
X22 is selected from D, G, T, N, S, K, A, I, E, L, Q, R and Y; and
X23 is selected from K, V, A, E, Y, I, C, L, S, T, G, K, M, D and F.
In an embodiment, a HNH-like domain differs from a sequence of SEQ ID NO: 17 by at least one but no more than, 2, 3, 4, or 5 residues.
In an embodiment, the HNH-like domain is cleavage competent.
In an embodiment, the HNH-like domain is cleavage incompetent.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an HNH-like domain comprising an amino acid sequence of formula VII:
XI -X2-X3-H-X4-X5-P-X6-S-X8-X9-X 10-D-D-S-X 14-X 15-N-K- V-L-X 19-X20-X21 -
X22-X23-N (SEQ ID NO: 18),
1547
5535.1 wherein
XI is selected from D and E;
X2 is selected from L, I, R, Q, V, M and K;
X3 is selected from D and E;
X4 is selected from I, V, T, A and L (e.g., A, I and V);
X5 is selected from V, Y, I, L, F and W (e.g., V, I and L);
X6 is selected from Q, H, R, K, Y, I, L, F and W;
X8 is selected from F, L, V, K, Y, M, I, R, A, E, D and Q (e.g., F);
X9 is selected from L, R, T, I, V, S, C, Y, K, F and G;
X10 is selected from K, Q, Y, T, F, L, W, M, A, E, G, and S;
X14 is selected from I, L, F, S, R, Y, Q, W, D, K and H (e.g., I, L and F);
X15 is selected from D, S, I, N, E, A, H, F, L, Q, M, G, Y and V;
X19 is selected from T, V, C, E, S and A (e.g., T and V);
X20 is selected from R, F, T, W, E, L, N, C, K, V, S, Q, I, Y, H and A;
X21 is selected from S, P, R, K, N, A, H, Q, G and L;
X22 is selected from D, G, T, N, S, K, A, I, E, L, Q, R and Y; and
X23 is selected from K, V, A, E, Y, I, C, L, S, T, G, K, M, D and F.
In an embodiment, the HNH-like domain differs from a sequence of SEQ ID NO: 18 by 1, 2, 3, 4, or 5 residues.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an HNH-like domain comprising an amino acid sequence of formula VII:
X 1 - V-X3-H-I- V-P-X6-S-X8-X9-X 10-D-D-S-X 14-X 15-N-K- V-L-T-X20-X21 -X22-X23- N (SEQ ID NO: 19),
wherein
XI is selected from D and E;
X3 is selected from D and E;
X6 is selected from Q, H, R, K, Y, I, L and W;
X8 is selected from F, L, V, K, Y, M, I, R, A, E, D and Q (e.g., F);
X9 is selected from L, R, T, I, V, S, C, Y, K, F and G;
X10 is selected from K, Q, Y, T, F, L, W, M, A, E, G, and S;
X14 is selected from I, L, F, S, R, Y, Q, W, D, K and H (e.g., I, L and F);
1548
5535.1 X15 is selected from D, S, I, N, E, A, H, F, L, Q, M, G, Y and V;
X20 is selected from R, F, T, W, E, L, N, C, K, V, S, Q, I, Y, H and A;
X21 is selected from S, P, R, K, N, A, H, Q, G and L;
X22 is selected from D, G, T, N, S, K, A, I, E, L, Q, R and Y; and
X23 is selected from K, V, A, E, Y, I, C, L, S, T, G, K, M, D and F.
In an embodiment, the HNH-like domain differs from a sequence of SEQ ID NO: 19 by 1, 2, 3, 4, or 5 residues.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an HNH-like domain having an amino acid sequence of formula VIII:
D-X2-D-H-I-X5-P-Q-X7-F-X9-X 10-D-X 12-S-I-D-N-X 16- V-L-X 19-X20-S-X22-X23-N (SEQ ID NO:20),
wherein
X2 is selected from I and V;
X5 is selected from I and V;
X7 is selected from A and S;
X9 is selected from I and L;
X10 is selected from K and T;
X12 is selected from D and N;
X16 is selected from R, K and L; X19 is selected from T and V;
X20 is selected from S and R;
X22 is selected from K, D and A; and
X23 is selected from E, K, G and N (e.g., the eaCas9 molecule or eaCas9 polypeptide can comprise an HNH-like domain as described herein).
In an embodiment, the HNH-like domain differs from a sequence of SEQ ID NO: 20 by as many as 1 but no more than 2, 3, 4, or 5 residues.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises the amino acid sequence of formula IX:
L- Y- Y-L-Q-N-G-X 1 ' -D-M- Y-X2' -X3 ' -X4' -X5 ' -L-D-I— X6' -X7 ' -L-S-X8 ' - Y-Z-N-R- X9'-K-X10'-D-X11'-V-P (SEQ ID NO: 21),
wherein
Χ is selected from K and R;
1549
5535.1 X2' is selected from V and T;
X3' is selected from G and D;
X4' is selected from E, Q and D;
X5' is selected from E and D;
X6' is selected from D, N and H;
XV is selected from Y, R and N;
X8' is selected from Q, D and N; X9' is selected from G and E;
X10' is selected from S and G;
XI 1 ' is selected from D and N; and
Z is an HNH-like domain, e.g., as described above.
In an embodiment, the eaCas9 molecule or eaCas9 polypeptide comprises an amino acid sequence that differs from a sequence of SEQ ID NO:21 by as many as 1 but no more than 2, 3, 4, or 5 residues.
In an embodiment, the HNH-like domain differs from a sequence of an HNH-like domain disclosed herein, e.g., in Figs. 5A-5C or Figs. 7A-7B, as many as 1 but no more than 2, 3, 4, or 5 residues. In an embodiment, 1 or both of the highly conserved residues identified in Figs. 5A- 5C or Figs. 7A-7B are present.
In an embodiment, the HNH -like domain differs from a sequence of an HNH-like domain disclosed herein, e.g., in Figs. 6A-6B or Figs. 7A-7B, as many as 1 but no more than 2, 3, 4, or 5 residues. In an embodiment, 1, 2, all 3 of the highly conserved residues identified in Figs. 6A-6B or Figs. 7A-7B are present.
Cas9 Activities
Nuclease and Helicase Activities
In an embodiment, the Cas9 molecule or Cas9 polypeptide is capable of cleaving a target nucleic acid molecule. Typically wild type Cas9 molecules cleave both strands of a target nucleic acid molecule. Cas9 molecules and Cas9 polypeptides can be engineered to alter nuclease cleavage (or other properties), e.g., to provide a Cas9 molecule or Cas9 peolypeptide which is a nickase, or which lacks the ability to cleave target nucleic acid. A Cas9 molecule or Cas9 polypeptide that is capable of cleaving a target nucleic acid molecule is referred to herein as an eaCas9 (an enzymatically active Cas9) molecule or eaCas9 polypeptide. In an embodiment, an
1550
5535.1 eaCas9 molecule or eaCas9 polypeptide, comprises one or more of the following activities:
a nickase activity, i.e., the ability to cleave a single strand, e.g., the non-complementary strand or the complementary strand, of a nucleic acid molecule;
a double stranded nuclease activity, i.e., the ability to cleave both strands of a double stranded nucleic acid and create a double stranded break, which in an embodiment is the presence of two nickase activities;
an endonuclease activity;
an exonuclease activity; and
a helicase activity, i.e., the ability to unwind the helical structure of a double stranded nucleic acid.
In an embodiment, an enzymatically active Cas9 or an eaCas9 molecule or an eaCas9 polypeptide cleaves both DNA strands and results in a double stranded break. In an
embodiment, an eaCas9 molecule or eaCas9 polypeptide cleaves only one strand, e.g., the strand to which the gRNA hybridizes to, or the strand complementary to the strand the gRNA hybridizes with. In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises cleavage activity associated with an HNH-like domain. In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises cleavage activity associated with an N-terminal RuvC-like domain. In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises cleavage activity associated with an HNH-like domain and cleavage activity associated with an N-terminal RuvC-like domain. In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an active, or cleavage competent, HNH-like domain and an inactive, or cleavage incompetent, N- terminal RuvC-like domain. In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an inactive, or cleavage incompetent, HNH-like domain and an active, or cleavage competent, N-terminal RuvC-like domain.
Some Cas9 molecules or Cas9 polypeptides have the ability to interact with a gRNA molecule, and in conjunction with the gRNA molecule localize to a core target domain, but are incapable of cleaving the target nucleic acid, or incapable of cleaving at efficient rates. Cas9 molecules having no, or no substantial, cleavage activity are referred to herein as an eiCas9 molecule or eiCas9 polypeptide. For example, an eiCas9 molecule or eiCas9 polypeptide can lack cleavage activity or have substantially less, e.g., less than 20, 10, 5, 1 or 0.1 % of the
1551
5535.1 cleavage activity of a reference Cas9 molecule or eiCas9 polypeptide, as measured by an assay described herein.
Targeting and PAMs
A Cas9 molecule or Cas9 polypeptide, is a polypeptide that can interact with a guide
RNA (gRNA) molecule and, in concert with the gRNA molecule, localizes to a site which comprises a target domain and PAM sequence.
In an embodiment, the ability of an eaCas9 molecule or eaCas9 polypeptide to interact with and cleave a target nucleic acid is PAM sequence dependent. A PAM sequence is a sequence in the target nucleic acid. In an embodiment, cleavage of the target nucleic acid occurs upstream from the PAM sequence. EaCas9 molecules from different bacterial species can recognize different sequence motifs (e.g., PAM sequences). In an embodiment, an eaCas9 molecule of S. pyogenes recognizes the sequence motif NGG and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from that sequence. See, e.g., Mali et al., SCIENCE 2013; 339(6121): 823-826. In an embodiment, an eaCas9 molecule of S. thermophilus recognizes the sequence motif NGGNG and NNAGAAW (W = A or T) and directs cleavage of a core target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from these sequences. See, e.g., Horvath et al., SCIENCE 2010; 327(5962): 167-170, and Deveau et al., J BACTERIOL 2008; 190(4): 1390-1400. In an embodiment, an eaCas9 molecule of S. mutans recognizes the sequence motif NGG and/or NAAR (R = A or G) and directs cleavage of a core target nucleic acid sequence 1 to 10, e.g., 3 to 5 base pairs, upstream from this sequence. See, e.g., Deveau et al., J BACTERIOL 2008; 190(4): 1390-1400. In an embodiment, an eaCas9 molecule of S. aureus recognizes the sequence motif NNGRR (R = A or G) and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from that sequence. In an embodiment, an eaCas9 molecule of S. aureus recognizes the sequence motif NNGRRN (R = A or G) and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from that sequence. In an embodiment, an eaCas9 molecule of S. aureus recognizes the sequence motif NNGRRT (R = A or G) and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from that sequence. In an embodiment, an eaCas9 molecule of S. aureus recognizes the sequence motif NNGRRV (R = A or G, V = A, G or C) and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from
1552
5535.1 that sequence. In an embodiment, an eaCas9 molecule of Neisseria meningitidis recognizes the sequence motif NNNNGATT or NNNGCTT and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from that sequence. See, e.g., Hou et al., PNAS Early Edition 2013, 1-6. The ability of a Cas9 molecule to recognize a PAM sequence can be determined, e.g., using a transformation assay described in Jinek et al., SCIENCE 2012
337:816. In the aforementioned embodiments, N can be any nucleotide residue, e.g., any of A, G, C or T.
As is discussed herein, Cas9 molecules can be engineered to alter the PAM specificity of the Cas9 molecule.
Exemplary naturally occurring Cas9 molecules are described in Chylinski et al., RNA BIOLOGY 2013 10:5, 727-737. Such Cas9 molecules include Cas9 molecules of a cluster 1 bacterial family, cluster 2 bacterial family, cluster 3 bacterial family, cluster 4 bacterial family, cluster 5 bacterial family, cluster 6 bacterial family, a cluster 7 bacterial family, a cluster 8 bacterial family, a cluster 9 bacterial family, a cluster 10 bacterial family, a cluster 11 bacterial family, a cluster 12 bacterial family, a cluster 13 bacterial family, a cluster 14 bacterial family, a cluster 15 bacterial family, a cluster 16 bacterial family, a cluster 17 bacterial family, a cluster 18 bacterial family, a cluster 19 bacterial family, a cluster 20 bacterial family, a cluster 21 bacterial family, a cluster 22 bacterial family, a cluster 23 bacterial family, a cluster 24 bacterial family, a cluster 25 bacterial family, a cluster 26 bacterial family, a cluster 27 bacterial family, a cluster 28 bacterial family, a cluster 29 bacterial family, a cluster 30 bacterial family, a cluster 31 bacterial family, a cluster 32 bacterial family, a cluster 33 bacterial family, a cluster 34 bacterial family, a cluster 35 bacterial family, a cluster 36 bacterial family, a cluster 37 bacterial family, a cluster 38 bacterial family, a cluster 39 bacterial family, a cluster 40 bacterial family, a cluster 41 bacterial family, a cluster 42 bacterial family, a cluster 43 bacterial family, a cluster 44 bacterial family, a cluster 45 bacterial family, a cluster 46 bacterial family, a cluster 47 bacterial family, a cluster 48 bacterial family, a cluster 49 bacterial family, a cluster 50 bacterial family, a cluster 51 bacterial family, a cluster 52 bacterial family, a cluster 53 bacterial family, a cluster 54 bacterial family, a cluster 55 bacterial family, a cluster 56 bacterial family, a cluster 57 bacterial family, a cluster 58 bacterial family, a cluster 59 bacterial family, a cluster 60 bacterial family, a cluster 61 bacterial family, a cluster 62 bacterial family, a cluster 63 bacterial family, a cluster 64 bacterial family, a
1553
5535.1 cluster 65 bacterial family, a cluster 66 bacterial family, a cluster 67 bacterial family, a cluster 68 bacterial family, a cluster 69 bacterial family, a cluster 70 bacterial family, a cluster 71 bacterial family, a cluster 72 bacterial family, a cluster 73 bacterial family, a cluster 74 bacterial family, a cluster 75 bacterial family, a cluster 76 bacterial family, a cluster 77 bacterial family, or a cluster 78 bacterial family.
Exemplary naturally occurring Cas9 molecules include a Cas9 molecule of a cluster 1 bacterial family. Examples include a Cas9 molecule of: S. pyogenes (e.g., strain SF370, MGAS10270, MGAS10750, MGAS2096, MGAS315, MGAS5005, MGAS6180, MGAS9429, NZ131 and SSI-1), S. thermophilus (e.g., strain LMD-9), S. pseudoporcinus (e.g., strain SPIN 20026), S. mutans (e.g., strain UA159, NN2025), S. macacae (e.g., strain NCTC11558), S.
gallolyticus (e.g., strain UCN34, ATCC BAA-2069), S. equines (e.g., strain ATCC 9812, MGCS 124), S. dysdalactiae (e.g., strain GGS 124), S. bovis (e.g., strain ATCC 700338), S. anginosus (e.g., strain F0211), S. agalactiae (e.g., strain NEM316, A909), Listeria monocytogenes (e.g., strain F6854), Listeria innocua (L. innocua, e.g., strain Clipl l262), Enterococcus italicus (e.g., strain DSM 15952), or Enterococcus faecium (e.g., strain 1,231,408). Additional exemplary
Cas9 molecules are a Cas9 molecule of Neisseria meningitides (Hou et ah, PNAS Early Edition 2013, 1-6 and a S. aureus cas9 molecule.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence:
having 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology with;
differs at no more than, 2, 5, 10, 15, 20, 30, or 40% of the amino acid residues when compared with;
differs by at least 1, 2, 5, 10 or 20 amino acids, but by no more than 100, 80, 70, 60, 50, 40 or 30 amino acids from; or
is identical to any Cas9 molecule sequence described herein, or a naturally occurring Cas9 molecule sequence, e.g., a Cas9 molecule from a species listed herein or described in Chylinski et al, RNA BIOLOGY 2013 10:5, 727-737; Hou et al, PNAS Early Edition 2013, 1-6; SEQ ID NO: 1-4. In an embodiment, the Cas9 molecule or Cas9 polypeptide comprises one or more of the following activities: a nickase activity; a double stranded cleavage activity (e.g., an
1554
5535.1 endonuclease and/or exonuclease activity); a helicase activity; or the ability, together with a gRNA molecule, to localize to a target nucleic acid.
In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises any of the amino acid sequence of the consensus sequence of Figs. 2A-2G, wherein "*" indicates any amino acid found in the corresponding position in the amino acid sequence of a Cas9 molecule or Cas9
polypeptide of S. pyogenes, S. thermophilus, S. mutans and L. innocua, and "-" indicates any amino acid. In an embodiment, a Cas9 molecule differs from the sequence of the consensus sequence of Figs. 2A-2G by at least 1, but no more than 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues. In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises the amino acid sequence of SEQ ID NO:7 of Figs. 7A-7B, wherein "*" indicates any amino acid found in the corresponding position in the amino acid sequence of a Cas9 molecule or Cas9 polypeptide of S. pyogenes, or N. meningitides, "-" indicates any amino acid, and "-" indicates any amino acid or absent. In an embodiment, a Cas9 molecule or Cas9 polypeptide differs from the sequence of SEQ ID NO:6 or 7 disclosed in Figs. 7A-7B by at least 1, but no more than 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues.
A comparison of the sequence of a number of Cas9 molecules indicate that certain regions are conserved. These are identified below as:
region 1 ( residuesl to 180, or in the case of region l'residues 120 to 180)
region 2 ( residues360 to 480);
region 3 ( residues 660 to 720);
region 4 ( residues 817 to 900); and
region 5 ( residues 900 to 960);
In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises regions 1-5, together with sufficient additional Cas9 molecule sequence to provide a biologically active molecule, e.g., a Cas9 molecule having at least one activity described herein. In an embodiment, each of regions 1-5, independently, have 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology with the corresponding residues of a Cas9 molecule or Cas9 polypeptide described herein, e.g., a sequence from Figs. 2A-2G or from Figs. 7A-7B.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence referred to as region 1:
having 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology with
1555
5535.1 amino acids 1-180 (the numbering is according to the motif sequence in Figs. 2A-2G; 52% of residues in the four Cas9 sequences in Figs. 2A-2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes;
differs by at least 1, 2, 5, 10 or 20 amino acids but by no more than 90, 80, 70, 60, 50, 40 or 30 amino acids from amino acids 1-180 of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or Listeria innocua; or
is identical to 1-180 of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or L. innocua.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence referred to as region :
having 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology with amino acids 120-180 (55% of residues in the four Cas9 sequences in Figs. 2A- 2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S.
mutans or L. innocua;
differs by at least 1, 2, or 5 amino acids but by no more than 35, 30, 25, 20 or 10 amino acids from amino acids 120-180 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or L. innocua ; or
is identical to 120-180 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or L. innocua.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence referred to as region 2:
having 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology with amino acids 360-480 (52% of residues in the four Cas9 sequences in Figs. 2A- 2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S.
mutans or L. innocua;
differs by at least 1, 2, or 5 amino acids but by no more than 35, 30, 25, 20 or 10 amino acids from amino acids 360-480 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or L. innocua; or
is identical to 360-480 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or L. innocua.
1556
5535.1 In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence referred to as region 3:
having 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology with amino acids 660-720 (56% of residues in the four Cas9 sequences in Figs. 2A- 2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or L. innocua;
differs by at least 1, 2, or 5 amino acids but by no more than 35, 30, 25, 20 or 10 amino acids from amino acids 660-720 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or L. innocua; or
is identical to 660-720 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or L. innocua.
In an embodiment, a Cas9 molecule, e.g., an eaCas9 molecule, comprises an amino acid sequence referred to as region 4:
having 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology with amino acids 817-900 (55% of residues in the four Cas9 sequences in Figs. 2A-2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or L. innocua;
differs by at least 1, 2, or 5 amino acids but by no more than 35, 30, 25, 20 or 10 amino acids from amino acids 817-900 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or L. innocua; or
is identical to 817-900 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or L. innocua.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence referred to as region 5:
having 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or
99% homology with amino acids 900-960 (60% of residues in the four Cas9 sequences in Figs. 2A-2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or L. innocua;
differs by at least 1, 2, or 5 amino acids but by no more than 35, 30, 25, 20 or 10 amino acids from amino acids 900-960 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or L. innocua; or
1557
5535.1 is identical to 900-960 of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or L. innocua.
Engineered or Altered Cas9 Molecules and Cas9 Polypeptides
Cas9 molecules and Cas9 polypeptides described herein, e.g., naturally occurring Cas9 molecules can possess any of a number of properties, including: nickase activity, nuclease activity (e.g., endonuclease and/or exonuclease activity); helicase activity; the ability to associate functionally with a gRNA molecule; and the ability to target (or localize to) a site on a nucleic acid (e.g., PAM recognition and specificity). In an embodiment, a Cas9 molecule or Cas9 polypeptide can include all or a subset of these properties. In typical embodiments, a Cas9 molecule or Cas9 polypeptide have the ability to interact with a gRNA molecule and, in concert with the gRNA molecule, localize to a site in a nucleic acid. Other activities, e.g., PAM specificity, cleavage activity, or helicase activity can vary more widely in Cas9 molecules and Cas9 polypeptides.
Cas9 molecules include engineered Cas9 molecules and engineered Cas9 polypeptides
(engineered, as used in this context, means merely that the Cas9 molecule or Cas9 polypeptide differs from a reference sequences, and implies no process or origin limitation). An engineered Cas9 molecule or Cas9 polypeptide can comprise altered enzymatic properties, e.g., altered nuclease activity, (as compared with a naturally occurring or other reference Cas9 molecule) or altered helicase activity. As discussed herein, an engineered Cas9 molecule or Cas9 polypeptide can have nickase activity (as opposed to double strand nuclease activity). In an embodiment an engineered Cas9 molecule or Cas9 polypeptide can have an alteration that alters its size, e.g., a deletion of amino acid sequence that reduces its size, e.g., without significant effect on one or more, or any Cas9 activity. In an embodiment, an engineered Cas9 molecule or Cas9 polypeptide can comprise an alteration that affects PAM recognition. E.g., an engineered Cas9 molecule can be altered to recognize a PAM sequence other than that recognized by the endogenous wild-type PI domain. In an embodiment, a Cas9 molecule or Cas9 polypeptide can differ in sequence from a naturally occurring Cas9 molecule but not have significant alteration in one or more Cas9 activities.
Cas9 molecules or Cas9 polypeptides with desired properties can be made in a number of ways, e.g., by alteration of a parental, e.g., naturally occurring Cas9 molecules or Cas9
1558
5535.1 polypeptides to provide an altered Cas9 molecule or Cas9 polypeptide having a desired property. For example, one or more mutations or differences relative to a parental Cas9 molecule, e.g., a naturally occurring or engineered Cas9 molecule, can be introduced. Such mutations and differences comprise: substitutions (e.g., conservative substitutions or substitutions of non- essential amino acids); insertions; or deletions. In an embodiment, a Cas9 molecule or Cas9 polypeptide can comprises one or more mutations or differences, e.g., at least 1, 2, 3, 4, 5, 10, 15, 20, 30, 40 or 50 mutations, but less than 200, 100, or 80 mutations relative to a reference, e.g., a parental, Cas9 molecule.
In an embodiment, a mutation or mutations do not have a substantial effect on a Cas9 activity, e.g. a Cas9 activity described herein. In an embodiment, a mutation or mutations have a substantial effect on a Cas9 activity, e.g. a Cas9 activity described herein.
Non-Cleaving and Modified-Cleavage Cas9 Molecules and Cas9 Polypeptides
In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises a cleavage property that differs from naturally occurring Cas9 molecules, e.g., that differs from the naturally occurring Cas9 molecule having the closest homology. For example, a Cas9 molecule or Cas9 polypeptide can differ from naturally occurring Cas9 molecules, e.g., a Cas9 molecule of S. pyogenes, as follows: its ability to modulate, e.g., decreased or increased, cleavage of a double stranded nucleic acid (endonuclease and/or exonuclease activity), e.g., as compared to a naturally occurring Cas9 molecule (e.g., a Cas9 molecule of S. pyogenes); its ability to modulate, e.g., decreased or increased, cleavage of a single strand of a nucleic acid, e.g., a non-complementary strand of a nucleic acid molecule or a complementary strand of a nucleic acid molecule (nickase activity) , e.g., as compared to a naturally occurring Cas9 molecule (e.g., a Cas9 molecule of S. pyogenes); or the ability to cleave a nucleic acid molecule, e.g., a double stranded or single stranded nucleic acid molecule, can be eliminated.
Modified Cleavage eaCas9 Molecules and eaCas9 Polypeptides
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises one or more of the following activities: cleavage activity associated with an N-terminal RuvC-like domain; cleavage activity associated with an HNH-like domain; cleavage activity associated with an HNH-like domain and cleavage activity associated with an N-terminal RuvC-like domain.
1559
5535.1 In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an active, or cleavage competent, HNH-like domain (e.g., an HNH-like domain described herein, e.g., SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21) and an inactive, or cleavage incompetent, N-terminal RuvC-like domain. An exemplary inactive, or cleavage incompetent N-terminal RuvC-like domain can have a mutation of an aspartic acid in an N-terminal RuvC-like domain, e.g., an aspartic acid at position 9 of the consensus sequence disclosed in Figs. 2A-2G or an aspartic acid at position 10 of SEQ ID NO: 7, e.g., can be substituted with an alanine. In an embodiment, the eaCas9 molecule or eaCas9 polypeptide differs from wild type in the N-terminal RuvC-like domain and does not cleave the target nucleic acid, or cleaves with significantly less efficiency, e.g., less than 20, 10, 5, 1 or .1 % of the cleavage activity of a reference Cas9 molecule, e.g., as measured by an assay described herein. The reference Cas9 molecule can by a naturally occurring unmodified Cas9 molecule, e.g., a naturally occurring Cas9 molecule such as a Cas9 molecule of S. pyogenes, or S. thermophilus . In an embodiment, the reference Cas9 molecule is the naturally occurring Cas9 molecule having the closest sequence identity or homology.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an inactive, or cleavage incompetent, HNH domain and an active, or cleavage competent, N-terminal RuvC-like domain (e.g., a RuvC-like domain described herein, e.g., SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16). Exemplary inactive, or cleavage incompetent HNH-like domains can have a mutation at one or more of: a histidine in an HNH-like domain, e.g., a histidine shown at position 856 of the consensus sequence disclosed in Figs. 2A-2G, e.g., can be substituted with an alanine; and one or more asparagines in an HNH-like domain, e.g., an asparagine shown at position 870 of the consensus sequence disclosed in Figs. 2A-2G and/or at position 879 of the consensus sequence disclosed in Figs. 2A-2G, e.g., can be substituted with an alanine. In an embodiment, the eaCas9 differs from wild type in the HNH-like domain and does not cleave the target nucleic acid, or cleaves with significantly less efficiency, e.g., less than 20, 10, 5, 1 or 0.1% of the cleavage activity of a reference Cas9 molecule, e.g., as measured by an assay described herein. The reference Cas9 molecule can by a naturally occurring unmodified Cas9 molecule, e.g., a naturally occurring Cas9 molecule such as a Cas9 molecule of S. pyogenes, or S. thermophilus.
1560
5535.1 In an embodiment, the reference Cas9 molecule is the naturally occurring Cas9 molecule having the closest sequence identity or homology.
Alterations in the Ability to Cleave One or Both Strands of a Target Nucleic Acid
In an embodiment, exemplary Cas9 activities comprise one or more of PAM specificity, cleavage activity, and helicase activity. A mutation(s) can be present, e.g., in one or more RuvC- like domain, e.g., an N-terminal RuvC-like domain; an HNH-like domain; a region outside the RuvC-like domains and the HNH-like domain. In some embodiments, a mutation(s) is present in a RuvC-like domain, e.g., an N-terminal RuvC-like domain. In some embodiments, a mutation(s) is present in an HNH-like domain. In some embodiments, mutations are present in both a RuvC-like domain, e.g., an N-terminal RuvC-like domain and an HNH-like domain.
Exemplary mutations that may be made in the RuvC domain or HNH domain with reference to the S. pyogenes sequence include: D10A, E762A, H840A, N854A, N863A and/or D986A.
In an embodiment, a Cas9 molecule or Cas9 polypeptide is an eiCas9 molecule or eiCas9 polypeptide comprising one or more differences in a RuvC domain and/or in an HNH domain as compared to a reference Cas9 molecule, and the eiCas9 molecule or eiCas9 polypeptide does not cleave a nucleic acid, or cleaves with significantly less efficiency than does wildype, e.g., when compared with wild type in a cleavage assay, e.g., as described herein, cuts with less than 50, 25, 10, or 1% of a reference Cas9 molecule, as measured by an assay described herein.
Whether or not a particular sequence, e.g., a substitution, may affect one or more activity, such as targeting activity, cleavage activity, etc., can be evaluated or predicted, e.g., by evaluating whether the mutation is conservative or by the method described in Section IV. In an embodiment, a "non-essential" amino acid residue, as used in the context of a Cas9 molecule, is a residue that can be altered from the wild-type sequence of a Cas9 molecule, e.g., a naturally occurring Cas9 molecule, e.g., an eaCas9 molecule, without abolishing or more preferably, without substantially altering a Cas9 activity (e.g., cleavage activity), whereas changing an "essential" amino acid residue results in a substantial loss of activity (e.g., cleavage activity).
In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises a cleavage property that differs from naturally occurring Cas9 molecules, e.g., that differs from the naturally occurring Cas9 molecule having the closest homology. For example, a Cas9 molecule or Cas9
1561
5535.1 polypeptide can differ from naturally occurring Cas9 molecules, e.g., a Cas9 molecule of S aureus, S. pyogenes, or C. jejuni as follows: its ability to modulate, e.g., decreased or increased, cleavage of a double stranded break (endonuclease and/or exonuclease activity), e.g., as compared to a naturally occurring Cas9 molecule (e.g., a Cas9 molecule of S aureus, S.
pyogenes, or C. jejuni); its ability to modulate, e.g., decreased or increased, cleavage of a single strand of a nucleic acid, e.g., a non-complimentary strand of a nucleic acid molecule or a complementary strand of a nucleic acid molecule (nickase activity), e.g., as compared to a naturally occurring Cas9 molecule (e.g., a Cas9 molecule of S aureus, S. pyogenes, or C. jejuni); or the ability to cleave a nucleic acid molecule, e.g., a double stranded or single stranded nucleic acid molecule, can be eliminated.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide is an eaCas9 molecule or eaCas9 polypeptide comprising one or more of the following activities: cleavage activity associated with a RuvC domain; cleavage activity associated with an HNH domain; cleavage activity associated with an HNH domain and cleavage activity associated with a RuvC domain.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide is an eiCas9 molecule or eiCas9 polypeptide which does not cleave a nucleic acid molecule (either double stranded or single stranded nucleic acid molecules) or cleaves a nucleic acid molecule with significantly less efficiency, e.g., less than 20, 10, 5, 1 or 0.1% of the cleavage activity of a reference Cas9 molecule, e.g., as measured by an assay described herein. The reference Cas9 molecule can be a naturally occurring unmodified Cas9 molecule, e.g., a naturally occurring Cas9 molecule such as a Cas9 molecule of S. pyogenes, S. thermophilus, S. aureus, C. jejuni or N. meningitidis. In an embodiment, the reference Cas9 molecule is the naturally occurring Cas9 molecule having the closest sequence identity or homology. In an embodiment, the eiCas9 molecule or eiCas9 polypeptide lacks substantial cleavage activity associated with a RuvC domain and cleavage activity associated with an HNH domain.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide is an eaCas9 molecule or eaCas9 polypeptide comprising the fixed amino acid residues of S. pyogenes shown in the consensus sequence disclosed in Figs. 2A-2G, and has one or more amino acids that differ from the amino acid sequence of S. pyogenes (e.g., has a substitution) at one or more residue (e.g., 2, 3, 5, 10, 15, 20, 30, 50, 70, 80, 90, 100, 200 amino acid residues) represented by an "-" in the consensus sequence disclosed in Figs. 2A-2G or SEQ ID NO:7.
1562
5535.1 In an embodiment, the altered Cas9 molecule or Cas9 polypeptide comprises a sequence in which:
the sequence corresponding to the fixed sequence of the consensus sequence disclosed in Figs. 2A-2G differs at no more than 1, 2, 3, 4, 5, 10, 15, or 20% of the fixed residues in the consensus sequence disclosed in Figs. 2A-2G;
the sequence corresponding to the residues identified by "*" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, or 40% of the "*" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. pyogenes Cas9 molecule; and,
the sequence corresponding to the residues identified by "-" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 55, or 60% of the "-" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. pyogenes Cas9 molecule.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide is an eaCas9 molecule or eaCas9 polypeptide comprising the fixed amino acid residues of S. thermophilus shown in the consensus sequence disclosed in Figs. 2A-2G, and has one or more amino acids that differ from the amino acid sequence of S. thermophilus (e.g., has a substitution) at one or more residue (e.g., 2, 3, 5, 10, 15, 20, 30, 50, 70, 80, 90, 100, 200 amino acid residues) represented by an "-" in the consensus sequence disclosed in Figs. 2A-2G.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide comprises a sequence in which:
the sequence corresponding to the fixed sequence of the consensus sequence disclosed in Figs. 2A-2G differs at no more than 1, 2, 3, 4, 5, 10, 15, or 20% of the fixed residues in the consensus sequence disclosed in Figs. 2A-2G;
the sequence corresponding to the residues identified by "*" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, or 40% of the "*" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. thermophilus Cas9 molecule; and,
the sequence corresponding to the residues identified by "-" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 55, or 60% of
1563
5535.1 the "-" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. thermophilus Cas9 molecule.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide is an eaCas9 molecule or eaCas9 polypeptide comprising the fixed amino acid residues of S. mutans shown in the consensus sequence disclosed in Figs. 2A-2G, and has one or more amino acids that differ from the amino acid sequence of S. mutans (e.g., has a substitution) at one or more residue (e.g., 2, 3, 5, 10, 15, 20, 30, 50, 70, 80, 90, 100, 200 amino acid residues) represented by an "-" in the consensus sequence disclosed in Figs. 2A-2G.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide comprises a sequence in which:
the sequence corresponding to the fixed sequence of the consensus sequence disclosed in Figs. 2A-2G differs at no more than 1, 2, 3, 4, 5, 10, 15, or 20% of the fixed residues in the consensus sequence disclosed in Figs. 2A-2G;
the sequence corresponding to the residues identified by "*" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, or 40% of the "*" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. mutans Cas9 molecule; and,
the sequence corresponding to the residues identified by "-" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 55, or 60% of the "-" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. mutans Cas9 molecule.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide is an eaCas9 molecule or eaCas9 polypeptide comprising the fixed amino acid residues of L. innocula shown in the consensus sequence disclosed in Figs. 2A-2G, and has one or more amino acids that differ from the amino acid sequence of L. innocula (e.g., has a substitution) at one or more residue (e.g., 2, 3, 5, 10, 15, 20, 30, 50, 70, 80, 90, 100, 200 amino acid residues) represented by an "-"in the consensus sequence disclosed in Figs. 2A-2G.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide comprises a sequence in which:
1564
5535.1 the sequence corresponding to the fixed sequence of the consensus sequence disclosed in Figs. 2A-2G differs at no more than 1, 2, 3, 4, 5, 10, 15, or 20% of the fixed residues in the consensus sequence disclosed in Figs. 2A-2G;
the sequence corresponding to the residues identified by "*" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, or 40% of the "*" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an L. innocula Cas9 molecule; and,
the sequence corresponding to the residues identified by "-" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 55, or 60% of the "-" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an L. innocula Cas9 molecule.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide , e.g., an eaCas9 molecule or eaCas9 polypeptide, can be a fusion, e.g., of two of more different Cas9 molecules, e.g., of two or more naturally occurring Cas9 molecules of different species. For example, a fragment of a naturally occurring Cas9 molecule of one species can be fused to a fragment of a Cas9 molecule of a second species. As an example, a fragment of a Cas9 molecule of S.
pyogenes comprising an N-terminal RuvC-like domain can be fused to a fragment of a Cas9 molecule of a species other than S. pyogenes (e.g., S. thermophilus) comprising an HNH-like domain.
Cas9 Molecules or Cas9 Polypeptides with Altered PAM Recognition or No PAM Recognition
Naturally occurring Cas9 molecules can recognize specific PAM sequences, for example, the PAM recognition sequences described above for S. pyogenes, S. thermophiles, S. mutans, S. aureus and N. meningitidis.
In an embodiment, a Cas9 molecule or Cas9 polypeptide has the same PAM specificities as a naturally occurring Cas9 molecule. In another embodiment, a Cas9 molecule or Cas9 polypeptide has a PAM specificity not associated with a naturally occurring Cas9 molecule, or a PAM specificity not associated with the naturally occurring Cas9 molecule to which it has the closest sequence homology. For example, a naturally occurring Cas9 molecule or Cas9 polypeptide can be altered, e.g., to alter PAM recognition, e.g., to alter the PAM sequence that
1565
5535.1 the Cas9 molecule recognizes to decrease off target sites and/or improve specificity; or eliminate a PAM recognition requirement. In an embodiment, a Cas9 molecule or Cas9 polypeptide can be altered, e.g., to increase length of PAM recognition sequence and/or improve Cas9 specificity to high level of identity (e.g., 98%, 99% or 100% match between gRNA and a PAM sequence), e.g., to decrease off target sites and increase specificity. In an embodiment, the length of the PAM recognition sequence is at least 4, 5, 6, 7, 8, 9, 10 or 15 amino acids in length. In an embodiment, the Cas9 specificity requires at least 90%, 95%, 96%, 97%, 98%, 99% or more homology between the gRNA and the PAM sequence. Cas9 molecules or Cas9 polypeptides that recognize different PAM sequences and/or have reduced off-target activity can be generated using directed evolution. Exemplary methods and systems that can be used for directed evolution of Cas9 molecules are described, e.g., in Esvelt et al. NATURE 2011, 472(7344): 499- 503. Candidate Cas9 molecules can be evaluated, e.g., by methods described in Section IV.
Alterations of the PI domain, which mediates PAM recognition, are discussed below. Synthetic Cas9 Molecules and Cas9 Polypeptides with Altered PI Domains
Current genome-editing methods are limited in the diversity of target sequences that can be targeted by the PAM sequence that is recognized by the Cas9 molecule utilized. A synthetic Cas9 molecule (or Syn-Cas9 molecule), or synthetic Cas9 polypeptide (or Syn-Cas9
polypeptide), as that term is used herein, refers to a Cas9 molecule or Cas9 polypeptide that comprises a Cas9 core domain from one bacterial species and a functional altered PI domain, i.e., a PI domain other than that naturally associated with the Cas9 core domain, e.g., from a different bacterial species.
In an embodiment, the altered PI domain recognizes a PAM sequence that is different from the PAM sequence recognized by the naturally- occurring Cas9 from which the Cas9 core domain is derived. In an embodiment, the altered PI domain recognizes the same PAM sequence recognized by the naturally- occurring Cas9 from which the Cas9 core domain is derived, but with different affinity or specificity. A Syn-Cas9 molecule or Syn-Cas9 polypetide can be, respectively, a Syn-eaCas9 molecule or Syn-eaCas9 polypeptide or a Syn-eiCas9 molecule Syn- eiCas9 polypeptide.
An exemplary Syn-Cas9 molecule or Syn-Cas9 polypetide comprises:
1566
5535.1 a) a Cas9 core domain, e.g., a Cas9 core domain from Table 50 or 51, e.g., a S. aureus, S. pyogenes, or C. jejuni Cas9 core domain; and
b) an altered PI domain from a species X Cas9 sequence selected from Tables 53 and 54. In an embodiment, the RKR motif (the PAM binding motif) of said altered PI domain comprises: differences at 1, 2, or 3 amino acid residues; a difference in amino acid sequence at the first, second, or third position; differences in amino acid sequence at the first and second positions, the first and third positions, or the second and third positions; as compared with the sequence of the RKR motif of the native or endogenous PI domain associated with the Cas9 core domain.
In an embodiment, the Cas9 core domain comprises the Cas9 core domain from a species
X Cas9 from Table 50 and said altered PI domain comprises a PI domain from a species Y Cas9 from Table 50.
In an embodiment, the RKR motif of the species X Cas9 is other than the RKR motif of the species Y Cas9.
In an embodiment, the RKR motif of the altered PI domain is selected from XXY, XNG, and XNQ.
In an embodiment, the altered PI domain has at least 60, 70, 80, 90, 95, or 100% homology with the amino acid sequence of a naturally occurring PI domain of said species Y from Table 50.
In an embodiment, the altered PI domain differs by no more than 50, 40, 30, 25, 20, 15,
10, 5, 4, 3, 2, or 1 amino acid residue from the amino acid sequence of a naturally occurring PI domain of said second species from Table 50.
In an embodiment, the Cas9 core domain comprises a S. aureus core domain and altered
PI domain comprises: an A. denitrificans PI domain; a C. jejuni PI domain; a H. mustelae PI domain; or an altered PI domain of species X PI domain, wherein species X is selected from
Table 54.
In an embodiment, the Cas9 core domain comprises a S. pyogenes core domain and the altered PI domain comprises: an A. denitrificans PI domain; a C. jejuni PI domain; a H. mustelae PI domain; or an altered PI domain of species X PI domain, wherein species X is selected from Table 54.
1567
5535.1 In an embodiment, the Cas9 core domain comprises a C. jejuni core domain and the altered PI domain comprises: an A. denitrificans PI domain; a H. mustelae PI domain; or an altered PI domain of species X PI domain, wherein species X is selected from Table 54.
In an embodiment, the Cas9 molecule or Cas9 polypeptide further comprises a linker disposed between said Cas9 core domain and said altered PI domain.
In an embodiment, the linker comprises: a linker described elsewhere herein disposed between the Cas9 core domain and the heterologous PI domain. Suitable linkers are further described in Section V.
Exemplary altered PI domains for use in Syn-Cas9 molecules are described in Tables 53 and 54. The sequences for the 83 Cas9 orthologs referenced in Tables 53 and 54 are provided in Table 50. Table 52 provides the Cas9 orthologs with known PAM sequences and the corresponding RKR motif.
In an embodiment, a Syn-Cas9 molecule or Syn-Cas9 polypeptide may also be size- optimized, e.g., the Syn-Cas9 molecule or Syn-Cas9 polypeptide comprises one or more deletions, and optionally one or more linkers disposed between the amino acid residues flanking the deletions. In an embodiment, a Syn-Cas9 molecule or Syn-Cas9 polypeptide comprises a REC deletion.
Size-Optimized Cas9 Molecules and Cas9 Polypeptides
Engineered Cas9 molecules and engineered Cas9 polypeptides described herein include a
Cas9 molecule or Cas9 polypeptide comprising a deletion that reduces the size of the molecule while still retaining desired Cas9 properties, e.g., essentially native conformation, Cas9 nuclease activity, and/or target nucleic acid molecule recognition. Provided herein are Cas9 molecules or Cas9 polypeptides comprising one or more deletions and optionally one or more linkers, wherein a linker is disposed between the amino acid residues that flank the deletion. Methods for identifying suitable deletions in a reference Cas9 molecule, methods for generating Cas9 molecules with a deletion and a linker, and methods for using such Cas9 molecules will be apparent to one of ordinary skill in the art upon review of this document.
A Cas9 molecule, e.g., a S. aureus, S. pyogenes, or C. jejuni, Cas9 molecule, having a deletion is smaller, e.g., has reduced number of amino acids, than the corresponding naturally- occurring Cas9 molecule. The smaller size of the Cas9 molecules allows increased flexibility for
1568
5535.1 delivery methods, and thereby increases utility for genome-editing. A Cas9 molecule or Cas9 polypeptide can comprise one or more deletions that do not substantially affect or decrease the activity of the resultant Cas9 molecules or Cas9 polypeptides described herein. Activities that are retained in the Cas9 molecules or Cas9 polypeptides comprising a deletion as described herein include one or more of the following:
a nickase activity, i.e., the ability to cleave a single strand, e.g., the non-complementary strand or the complementary strand, of a nucleic acid molecule; a double stranded nuclease activity, i.e., the ability to cleave both strands of a double stranded nucleic acid and create a double stranded break, which in an embodiment is the presence of two nickase activities;
an endonuclease activity;
an exonuclease activity;
a helicase activity, i.e., the ability to unwind the helical structure of a double stranded nucleic acid;
and recognition activity of a nucleic acid molecule, e.g., a target nucleic acid or a gRNA. Activity of the Cas9 molecules or Cas9 polypeptides described herein can be assessed using the activity assays described herein or in the art.
Identifying regions suitable for deletion
Suitable regions of Cas9 molecules for deletion can be identified by a variety of methods. Naturally- occurring orthologous Cas9 molecules from various bacterial species, e.g., any one of those listed in Table 50, can be modeled onto the crystal structure of S. pyogenes Cas9
(Nishimasu et al., Cell, 156:935-949, 2014) to examine the level of conservation across the selected Cas9 orthologs with respect to the three-dimensional conformation of the protein. Less conserved or unconserved regions that are spatially located distant from regions involved in Cas9 activity, e.g., interface with the target nucleic acid molecule and/or gRNA, represent regions or domains are candidates for deletion without substantially affecting or decreasing Cas9 activity.
REC-Optimized Cas9 Molecules and Cas9 Polypeptides
A REC-optimized Cas9 molecule, or a REC-optimized Cas9 polypeptide, as that term is used herein, refers to a Cas9 molecule or Cas9 polypeptide that comprises a deletion in one or both of the REC2 domain and the RE1CT domain (collectively a REC deletion), wherein the
1569
5535.1 deletion comprises at least 10% of the amino acid residues in the cognate domain. A REC- optimized Cas9 molecule or Cas9 polypeptide can be an eaCas9 molecule or eaCas9 polypetide, or an eiCas9 molecule or eiCas9 polypeptide. An exemplary REC-optimized Cas9 molecule or REC-optimized Cas9 polypeptide comprises:
a) a deletion selected from:
i) a REC2 deletion;
ii) a REC ICT deletion; or
iii) a REC ISUB deletion.
Optionally, a linker is disposed between the amino acid residues that flank the deletion. In an embodiment, a Cas9 molecule or Cas9 polypeptide includes only one deletion, or only two deletions. A Cas9 molecule or Cas9 polypeptide can comprise a REC2 deletion and a RECICT deletion. A Cas9 molecule or Cas9 polypeptide can comprise a REC2 deletion and a REC ISUB deletion.
Generally, the deletion will contain at least 10% of the amino acids in the cognate domain, e.g., a REC2 deletion will include at least 10% of the amino acids in the REC2 domain.
A deletion can comprise: at least 10, 20, 30, 40, 50, 60, 70, 80, or 90% of the amino acid residues of its cognate domain; all of the amino acid residues of its cognate domain; an amino acid residue outside its cognate domain; a plurality of amino acid residues outside its cognate domain; the amino acid residue immediately N terminal to its cognate domain; the amino acid residue immediately C terminal to its cognate domain; the amino acid residue immediately N terminal to its cognate and the amino acid residue immediately C terminal to its cognate domain; a plurality of, e.g., up to 5, 10, 15, or 20, amino acid residues N terminal to its cognate domain; a plurality of, e.g., up to 5, 10, 15, or 20, amino acid residues C terminal to its cognate domain; a plurality of, e.g., up to 5, 10, 15, or 20, amino acid residues N terminal to to its cognate domain and a plurality of e.g., up to 5, 10, 15, or 20, amino acid residues C terminal to its cognate domain.
In an embodiment, a deletion does not extend beyond: its cognate domain; the N terminal amino acid residue of its cognate domain; the C terminal amino acid residue of its cognate domain.
A REC-optimized Cas9 molecule or REC-optimized Cas9 polypeptide can include a linker disposed between the amino acid residues that flank the deletion. Any linkers known in
1570
5535.1 the art that maintain the conformation or native fold of the Cas9 molecule (thereby retaining Cas9 activity) can be used between the amino acid resides that flank a REC deletion in a REC- optimized Cas9 molecule or REC-optimized Cas9 polypeptide. Linkers for use in generating recombinant proteins, e.g., multi-domain proteins, are known in the art (Chen et al., Adv Drug Delivery Rev, 65: 1357-69, 2013).
In an embodiment, a REC-optimized Cas9 molecule or REC-optimized Cas9 polypeptide comprises an amino acid sequence that, other than any REC deletion and associated linker, has at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, or 100% homology with the amino acid sequence of a naturally occurring Cas 9, e.g., a Cas9 molecule described in Table 50, e.g., a S. aureus Cas9 molecule, a S. pyogenes Cas9 molecule, or a C. jejuni Cas9 molecule.
In an embodiment, a a REC-optimized Cas9 molecule or REC-optimized Cas9 polypeptide comprises an amino acid sequence that, other than any REC deletion and associated linker, differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25, amino acid residues from the amino acid sequence of a naturally occurring Cas 9, e.g., a Cas9 molecule described in Table 50, e.g., a S. aureus Cas9 molecule, a S. pyogenes Cas9 molecule, or a C. jejuni Cas9 molecule.
In an embodiment, a REC-optimized Cas9 molecule or REC-optimized Cas9 polypeptide comprises an amino acid sequence that, other than any REC deletion and associate linker, differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25% of the, amino acid residues from the amino acid sequence of a naturally occurring Cas 9, e.g., a Cas9 molecule described in Table 50, e.g., a S. aureus Cas9 molecule, a S. pyogenes Cas9 molecule, or a C. jejuni Cas9 molecule.
For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman, (1988) Proc. Nat'l. Acad. Sci. USA
1571
5535.1 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Brent et al., (2003) Current Protocols in Molecular Biology).
Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402; and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller, (1988) Comput. Appl. Biosci. 4: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (1970) J. Mol. Biol.
48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
Sequence information for exemplary REC deletions are provided for 83 naturally- occurring Cas9 orthologs in Table 50.
The amino acid sequences of exemplary Cas9 molecules from different bacterial species are shown below.
Table 50. Amino Acid Sequence of Cas9 Orthologs
Figure imgf001573_0001
1572
5535.1 Bifidobacterium bifidum S 17 SEQ ID NO: 173 335 163 516 607 87 516 607 87 gil310286728 Iref 1 YP_003937986 308
Veillonella atypica ACS-134-V- SEQ ID NO: 185 339 155 574 663 79 574 663 79
Col7a 309
gil303229466lreflZP_07316256.1
Lactobacillus rhamnosus GG SEQ ID NO: 169 320 152 559 645 78 559 645 78 gil258509199lreflYP_003171950 310
.1
Filifactor alocis ATCC 35896 SEQ ID NO: 166 314 149 508 592 76 508 592 76 gil374307738lreflYP_005054169 311
.1
Oenococcus kitaharae DSM SEQ ID NO: 169 317 149 555 639 80 555 639 80
17330 312
gil366983953lgblEHN59352.1l
Fructobacillus fructosus KCTC SEQ ID NO: 168 314 147 488 571 76 488 571 76
3544 313
gil339625081 lreflZP_08660870.1
Catenibacterium mitsuokai DSM SEQ ID NO: 173 318 146 511 594 78 511 594 78
15897 314
gil224543312lreflZP_03683851.1
Finegoldia magna ATCC 29328 SEQ ID NO: 168 313 146 452 534 77 452 534 77 gill69823755lreflYP_001691366 315
.1
CoriobacteriumglomeransPW2 SEQ ID NO: 175 318 144 511 592 82 511 592 82 gil328956315lreflYP_004373648 316
.1
Eubacterium yurii ATCC 43715 SEQ ID NO: 169 310 142 552 633 76 552 633 76 gil306821691 lreflZP_07455288.1 317
Peptoniphilus duerdenii ATCC SEQ ID NO: 171 311 141 535 615 76 535 615 76 BAA- 1640 318
gil304438954lreflZP_07398877.1
Acidaminococcus sp. D21 SEQ ID NO: 167 306 140 511 591 75 511 591 75 gil227824983lreflZP_03989815.1 319
Lactobacillus farciminis KCTC SEQ ID NO: 171 310 140 542 621 85 542 621 85
3681 320
gil336394882lreflZP_08576281.1
Streptococcus sanguinis SK49 SEQ ID NO: 185 324 140 411 490 85 411 490 85 gil422884106lreflZP_l 6930555.1 321
Coprococcus catus GD-7 SEQ ID NO: 172 310 139 556 634 76 556 634 76 gil291520705lemblCBK78998.1 l 322
Streptococcus mutans UA159 SEQ ID NO: 176 314 139 392 470 84 392 470 84 gil24379809lreflNP_721764.11 323
Streptococcus pyogenes Ml SEQ ID NO: 176 314 139 523 600 82 523 600 82
GAS 324
gill3622193lgblAAK33936.1 l
Streptococcus thermophilus SEQ ID NO: 176 314 139 481 558 81 481 558 81 LMD-9 325
gil 1 16628213 Iref 1 YP_820832.11
1573
5535.1 Fusobacteriumnucleatum SEQ ID NO: 171 308 138 537 614 76 537 614 76 ATCC49256 326
gil34762592lreflZP_00143587.1 l
Planococcus antarcticus DSM SEQ ID NO: 162 299 138 538 614 94 538 614 94
14505 327
gil389815359lreflZP_10206685.1
Treponema denticola ATCC SEQ ID NO: 169 305 137 524 600 81 524 600 81
35405 328
gil42525843lreflNP_970941.11
Solobacterium moorei F0204 SEQ ID NO: 179 314 136 544 619 77 544 619 77 gil320528778lreflZP_08029929.1 329
Staphylococcus SEQ ID NO: 164 299 136 531 606 92 531 606 92 pseudintermedius ED99 330
gil323463801 lgblADX75954.11
Flavobacterium branchiophilum SEQ ID NO: 162 286 125 538 613 63 538 613 63
FL-15 331
gil347536497lreflYP_004843922
.1
Ignavibacterium album JCM SEQ ID NO: 223 329 107 357 432 90 357 432 90
16511 332
gil38581 1609lreflYP_005848005
.1
Bergeyella zoohelcum ATCC SEQ ID NO: 165 261 97 529 604 56 529 604 56
43767 333
gi 1423317190lref IZP_ 17295095.1
Nitrobacter hamburgensis X14 SEQ ID NO: 169 253 85 536 611 48 536 611 48 gil92109262lrefl YP_571550.11 334
Odoribacter laneus YIT 12061 SEQ ID NO: 164 242 79 535 610 63 535 610 63 gil374384763lreflZP_09642280.1 335
Legionella pneumophila str. SEQ ID NO: 164 239 76 402 476 67 402 476 67
Paris 336
gil54296138lreflYP_122507.1 l
Bacteroides sp. 20 3 SEQ ID NO: 198 269 72 530 604 83 530 604 83 gi 130131 1869 Iref IZP_07217791.1 337
Akkermansia muciniphila ATCC SEQ ID NO: 136 202 67 348 418 62 348 418 62
BAA-835 338
gill87736489lreflYP_001878601
Prevotella sp. C561 SEQ ID NO: 184 250 67 357 425 78 357 425 78 gil345885718lreflZP_08837074.1 339
Wolinella succinogenes DSM SEQ ID NO: 157 218 36 401 468 60 401 468 60
1740 340
gil34557932lreflNP_907747.11
Alicyclobacillus hesperidum SEQ ID NO: 142 196 55 416 482 61 416 482 61 URH17-3-68 341
gil403744858lreflZP_10953934.1
Caenispirillum salinarum AK4 SEQ ID NO: 161 214 54 330 393 68 330 393 68 gil427429481 lreflZP_l 891951 1.1 342
Eubacterium rectale ATCC SEQ ID NO: 133 185 53 322 384 60 322 384 60 33656 343
gil238924075lreflYP_002937591
.1
1574
5535.1 Mycoplasma synoviae 53 SEQ ID NO: 187 239 53 319 381 80 319 381 80 gil71894592lref 1 YP_278700.11 344
Porphyromonas sp. oral taxon SEQ ID NO: 150 202 53 309 371 60 309 371 60 279 str. F0450 345
gil402847315 Iref IZP_10895610.1
Streptococcus thermophilus SEQ ID NO: 127 178 139 424 486 81 424 486 81 LMD-9 346
gil 116627542lref 1 YP_820161.11
Roseburia inulinivorans DSM SEQ ID NO: 154 204 51 318 380 69 318 380 69
16841 347
gil225377804lreflZP_03755025.1
Methylosinus trichosporium SEQ ID NO: 144 193 50 426 488 64 426 488 64
OB3b 348
gil296446027lreflZP_06887976.1
Ruminococcus albus 8 SEQ ID NO: 139 187 49 351 412 55 351 412 55 gil325677756lreflZP_08157403.1 349
Bifidobacterium longum SEQ ID NO: 183 230 48 370 431 44 370 431 44 DJO10A 350
gill89440764lreflYP_001955845
Enterococcus faecalis TX0012 SEQ ID NO: 123 170 48 327 387 60 327 387 60 gil315149830lgblEFT93846.11 351
Mycoplasma mobile 163K SEQ ID NO: 179 226 48 314 374 79 314 374 79 gil47458868lreflYP_015730.1 l 352
Actinomyces coleocanis DSM SEQ ID NO: 147 193 47 358 418 40 358 418 40
15436 353
gil227494853lreflZP_03925169.1
Dinoroseobacter shibae DFL 12 SEQ ID NO: 138 184 47 338 398 48 338 398 48 gil 159042956lref 1 YP_001531750 354
.1
Actinomyces sp. oral taxon 180 SEQ ID NO: 183 228 46 349 409 40 349 409 40 str. F0310 355
gil315605738lreflZP_07880770.1
Alcanivorax sp. Wl 1-5 SEQ ID NO: 139 183 45 344 404 61 344 404 61 gil407803669lreflZP_l 1150502.1 356
Aminomonas paucivorans DSM SEQ ID NO: 134 178 45 341 401 63 341 401 63
12260 357
gi 1312879015 Iref IZP_07738815.1
Mycoplasma canis PG 14 SEQ ID NO: 139 183 45 319 379 76 319 379 76 gil384393286lgblEIE39736.11 358
Lactobacillus coryniformis SEQ ID NO: 141 184 44 328 387 61 328 387 61 KCTC 3535 359
gil336393381 lreflZP_08574780.1
Elusimicrobium minutum Peil91 SEQ ID NO: 177 219 43 322 381 47 322 381 47 gill87250660lreflYP_001875142 360
.1
Neisseria meningitidis Z2491 SEQ ID NO: 147 189 43 360 419 61 360 419 61 gil218767588lreflYP_002342100 361
.1
Pasteurella multocida str. Pm70 SEQ ID NO: 139 181 43 319 378 61 319 378 61 gill5602992lreflNP_246064.11 362
1575
5535.1 Rhodovulum sp. PH10 SEQ ID NO: 141 183 43 319 378 48 319 378 48 gil402849997lreflZP_10898214.1 363
Eubacterium dolichum DSM SEQ ID NO: 131 172 42 303 361 59 303 361 59
3991 364
gill60915782lreflZP_02077990.1
Nitratifractor salsuginis DSM SEQ ID NO: 143 184 42 347 404 61 347 404 61
16511 365
gil319957206lreflYP_004168469
.1
Rhodospirillum rubrum ATCC SEQ ID NO: 139 180 42 314 371 55 314 371 55
11170 366
gil83591793lreflYP_425545.1 l
Clostridium cellulolyticum H10 SEQ ID NO: 137 176 40 320 376 61 320 376 61 gil220930482lreflYP_002507391 367
.1
Helicobacter mustelae 12198 SEQ ID NO: 148 187 40 298 354 48 298 354 48 gi 1291276265 Iref 1 YP_003516037 368
.1
Ilyobacter polytropus DSM 2926 SEQ ID NO: 134 173 40 462 517 63 462 517 63 gil310780384lref 1 YP_003968716 369
.1
Sphaerochaeta globus str. Buddy SEQ ID NO: 163 202 40 335 389 45 335 389 45 gil325972003lreflYP_004248194 370
.1
Staphylococcus lugdunensis SEQ ID NO: 128 167 40 337 391 57 337 391 57 M23590 371
gil315659848lreflZP_07912707.1
Treponema sp. JC4 SEQ ID NO: 144 183 40 328 382 63 328 382 63 gil384109266lreflZP_10010146.1 372
uncultured delta proteobacterium SEQ ID NO: 154 193 40 313 365 55 313 365 55 HF0070 07E19 373
gi 1297182908 Igb 1 ADI 19058.11
Alicycliphilus denitrificans K601 SEQ ID NO: 140 178 39 317 366 48 317 366 48 gil330822845lreflYP_004386148 374
.1
Azospirillum sp. B510 SEQ ID NO: 205 243 39 342 389 46 342 389 46 gil288957741 lreflYP_003448082 375
.1
Bradyrhizobium sp. BTAil SEQ ID NO: 143 181 39 323 370 48 323 370 48 gill48255343lreflYP_001239928 376
.1
Parvibaculum lavamentivorans SEQ ID NO: 138 176 39 327 374 58 327 374 58
DS-1 377
gill54250555lreflYP_001411379
.1
Prevotella timonensis CRIS 5C- SEQ ID NO: 170 208 39 328 375 61 328 375 61
B l 378
gil282880052lreflZP_06288774.1
Bacillus smithii 7 3 47FAA SEQ ID NO: 134 171 38 401 448 63 401 448 63 gil365156657lreflZP_09352959.1 379
Cand. Puniceispirillum marinum SEQ ID NO: 135 172 38 344 391 53 344 391 53 IMCC1322 380
1576
5535.1 gil2940861 1 l lreflYP_003552871
.1
Barnesiella intestinihominis YIT SEQ ID NO: 140 176 37 371 417 60 371 417 60
1 1860 381
gi|404487228lreflZP_l 1022414.1
Ralstonia syzygii R24 SEQ ID NO: 140 176 37 395 440 50 395 440 50 gil344171927lemblCCA84553.1 l 382
Wolinella succinogenes DSM SEQ ID NO: 145 180 36 348 392 60 348 392 60
1740 383
gil34557790lreflNP_907605.11
Mycoplasma gallisepticum str. F SEQ ID NO: 144 177 34 373 416 71 373 416 71 gi 128493171 Olgb IADC31648.11 384
Acidothermus cellulolyticus 1 IB SEQ ID NO: 150 182 33 341 380 58 341 380 58 gil 1 17929158 Irefl YP_873709.11 385
Mycoplasma ovipneumoniae SEQ ID NO: 156 184 29 381 420 62 381 420 62
SCOl 386
gil363542550lreflZP_09312133.1
1577
5535.1 Table 51. Amino Acid Sequence of Cas9 Core Domains
Figure imgf001579_0001
Table 52. Identified PAM sequences and corresponding RKR motifs.
Figure imgf001579_0002
PI domains are provided in Tables 53 and 54.
Table 53. Altered PI Domains
Figure imgf001579_0003
Table 50
Akkermansia muciniphila ATCC BAA-835 871 1101 231 ALK
Ralstonia syzygii R24 821 1062 242 APY
Cand. Puniceispirillum marinum IMCC1322 815 1035 221 AYK
Fructobacillus fructosus KCTC 3544 1074 1323 250 DON
Eubacterium yurii ATCC 43715 1107 1391 285 DGY
Eubacterium dolichum DSM 3991 779 1096 318 DKK
Dinoroseobacter shibae DFL 12 851 1079 229 DPI
Clostridium cellulolyticum H10 767 1021 255 EGK
Pasteurella multocida str. Pm70 815 1056 242 EN
Mycoplasma canis PG 14 907 1233 327 EPK
Porphyromonas sp. oral taxon 279 str. F0450 935 1197 263 EPT
Filifactor alocis ATCC 35896 1094 1365 272 EVD
Aminomonas paucivorans DSM 12260 801 1052 252 EVY
Wolinella succinogenes DSM 1740 1034 1409 376 EYK
Oenococcus kitaharae DSM 17330 1119 1389 271 GAL
CoriobacteriumglomeransPW2 1126 1384 259 GDR
Peptoniphilus duerdenii ATCC BAA-1640 1091 1364 274 GDS
Bifidobacterium bifidum S17 1138 1420 283 GGL
Alicyclobacillus hesperidum URH17-3-68 876 1146 271 GGR
Roseburia inulinivorans DSM 16841 895 1152 258 GGT
Actinomyces coleocanis DSM 15436 843 1105 263 GKK
Odoribacter laneus YIT 12061 1103 1498 396 GKV
Coprococcus catus GD-7 1063 1338 276 GNQ
Enterococcus faecalis TX0012 829 1150 322 GRK
Bacillus smithii 7 3 47FAA 809 1088 280 GSK
Legionella pneumophila str. Paris 1021 1372 352 GTM
Bacteroides fragilis NCTC 9343 1140 1436 297 IPV
Mycoplasma ovipneumoniae SCOl 923 1265 343 IRI
Actinomyces sp. oral taxon 180 str. F0310 895 1181 287 KEK
Treponema sp. JC4 832 1062 231 KIS
Fusobacteriumnucleatum ATCC49256 1073 1374 302 KKV
Lactobacillus farciminis KCTC 3681 1101 1356 256 KKV
Nitratifractor salsuginis DSM 16511 840 1132 293 KMR
Lactobacillus coryniformis KCTC 3535 850 1119 270 KNK
Mycoplasma mobile 163K 916 1236 321 KNY
Flavobacterium branchiophilum FL-15 1182 1473 292 KQK
Prevotella timonensis CRIS 5C-B1 957 1218 262 KQQ
Methylosinus trichosporium OB3b 830 1082 253 KRP Prevotella sp. C561 1099 1424 326 KRY
Mycoplasma gallisepticum str. F 911 1269 359 KTA
Lactobacillus rhamnosus GG 1077 1363 287 KYG
Wolinella succinogenes DSM 1740 811 1059 249 LPN
Streptococcus thermophilus LMD-9 1099 1388 290 MLA
Treponema denticola ATCC 35405 1092 1395 304 NDS
Bergeyella zoohelcum ATCC 43767 1098 1415 318 NEK
Veillonella atypica ACS-134-V-Col7a 1107 1398 292 NGF
Neisseria meningitidis Z2491 835 1082 248 NHN
Ignavibacterium album JCM 16511 1296 1688 393 NKK
Ruminococcus albus 8 853 1156 304 NNF
Streptococcus thermophilus LMD-9 811 1121 311 N K
Barnesiella intestinihominis YIT 11860 871 1153 283 NPV
Azospirillum sp. B510 911 1168 258 PFH
Rhodospirillum rubrum ATCC 11170 863 1173 311 PRG
Planococcus antarcticus DSM 14505 1087 1333 247 PYY
Staphylococcus pseudintermedius ED99 1073 1334 262 QIV
Alcanivorax sp. Wl l-5 843 1113 271 RIE
Bradyrhizobium sp. BTAil 811 1064 254 RIY
Streptococcus pyogenes Ml GAS 1099 1368 270 RKR
Streptococcus mutans UA159 1078 1345 268 RKR
Streptococcus Pyogenes 1099 1368 270 RKR
Bacteroides sp. 20 3 1147 1517 371 RNI
S. aureus 772 1053 282 RNK
Solobacterium moorei F0204 1062 1327 266 RSG
Finegoldia magna ATCC 29328 1081 1348 268 RTE uncultured delta proteobacterium HF0070 07E19 770 1011 242 SGG
Acidaminococcus sp. D21 1064 1358 295 SIG
Eubacterium rectale ATCC 33656 824 1114 291 SKK
Caenispirillum salinarum AK4 1048 1442 395 SLV
Acidothermus cellulolyticus 11B 830 1138 309 SPS
Catenibacterium mitsuokai DSM 15897 1068 1329 262 SPT
Parvibaculum lavamentivorans DS-1 827 1037 211 TGN
Staphylococcus lugdunensis M23590 772 1054 283 TKK
Streptococcus sanguinis SK49 1123 1421 299 TRM
Elusimicrobium minutum Peil91 910 1195 286 TTG
Nitrobacter hamburgensis X14 914 1166 253 VAY
Mycoplasma synoviae 53 991 1314 324 VGF
Sphaerochaeta globus str. Buddy 877 1179 303 VKG Ilyobacter polytropus DSM 2926 837 1092 256 VNG
Rhodovulum sp. PH10 821 1059 239 VPY
Bifidobacterium longum DJOIOA 904 1187 284 VRK
Amino acid sequences described in Table 50:
SEQ ID NO: 304
MKRNYILGLDIGITSVGYGI IDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRI QRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDT GNELSTKEQI SRNSKALEEKYVAELQLERLKKDGEVRGS INRFKTSDYVKEAKQLLKVQKAYHQ LDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLY NALNDLNNLVITRDENEKLEYYEKFQI IENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGK PEFTNLKVYHDIKDITARKEI IENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQIS NLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSP VVKRSFIQS IKVINAI IKKYGLPNDI I IELAREKNSKDAQKMINEMQKRNRQTNERIEEI IRTT GKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHI IPRSVSFDNSFNNKVLVK QEENSKKGNRTPFQYLSSSDSKI SYETFKKHILNLAKGKGRI SKTKKEYLLEERDINRFSVQKD FINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKS INGGFTSFLRRKWKFKKERNKGYKHHAED ALI IA ADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKD YKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHH DPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDD YPNSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQA EFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLENMNDKRPPRI IKTIASKT QS IKKYSTDILGNLYEVKSKKHPQI IKKG
SEQ ID NO: 305
MDKKYS IGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHS IKKNLIGALLFDSGETAEATRL KRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAY HEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTY NQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMD GTEELLVKLNREDLLRKQRTFDNGS IPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRI PYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHS LLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD SVEI SGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTF KEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQ TTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINR LSDYDVDHIVPQSFLKDDS IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRK FDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAK SEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLS MPQVNIVKKTEVQTGGFSKES ILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKG KSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLI IKLPKYSLFELENGRKRMLAS AGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEI IEQI SEFSKRV ILADANLDKVLSAYNKHRDKPIREQAE I IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLD ATLIHQS ITGLYETRIDLSQLGGD
SEQ ID NO: 306
MARILAFDIGI SS IGWAFSENDELKDCGVRIFTKVENPKTGESLALPRRLARSARKRLARRKAR LNHLKHLIANEFKLNYEDYQSFDESLAKAYKGSLI SPYELRFRALNELLSKQDFARVILHIAKR RGYDDIKNSDDKEKGAILKAIKQNEEKLANYQSVGEYLYKEYFQKFKENSKEFTNVRNKKESYE RCIAQSFLKDELKLIFKKQREFGFSFSKKFEEEVLSVAFYKRALKDFSHLVGNCSFFTDEKRAP KNSPLAFMFVALTRI INLLNNLKNTEGILYTKDDLNALLNEVLKNGTLTYKQTKKLLGLSDDYE FKGEKGTYFIEFKKYKEFIKALGEHNLSQDDLNEIAKDITLIKDEIKLKKALAKYDLNQNQIDS LSKLEFKDHL I SFKALKLVTPLMLEGKKYDEACNELNLKVAINEDKKDFLPAFNETYYKDEVT NPVVLRAIKEYRKVLNALLKKYGKVHKINIELAREVGKNHSQRAKIEKEQNENYKAKKDAELEC EKLGLKINSKNILKLRLFKEQKEFCAYSGEKIKI SDLQDEKMLEIDHIYPYSRSFDDSYMNKVL VFTKQNQEKLNQTPFEAFGNDSAKWQKIEVLAKNLPTKKQKRILDKNYKDKEQKNFKDRNLNDT RYIARLVLNYTKDYLDFLPLSDDENTKLNDTQKGSKVHVEAKSGMLTSALRHTWGFSAKDRNNH LHHAIDAVI IAYANNS IVKAFSDFKKEQESNSAELYAKKI SELDYKNKRKFFEPFSGFRQKVLD KIDEIFVSKPERKKPSGALHEETFRKEEEFYQSYGGKEGVLKALELGKIRKVNGKIVKNGDMFR VDIFKHKKTNKFYAVPIYTMDFALKVLPNKAVARSKKGEIKDWILMDENYEFCFSLYKDSLILI QTKDMQEPEFVYY AFTSSTVSLIVSKHDNKFETLSKNQKILFKNANEKEVIAKS IGIQNLKVF EKYIVSALGEVTKAEFRQREDFKK
SEQ ID NO: 307
MKRILGLDLGTNS IGWALVNEAENKDERSS IVKLGVRVNPLTVDELTNFEKGKS ITTNADRTLK RGMRRNLQRYKLRRETLTEVLKEHKLITEDTILSENGNRTTFETYRLRAKAVTEEI SLEEFARV LLMINKKRGYKSSRKAKGVEEGTLIDGMDIARELYNNNLTPGELCLQLLDAGKKFLPDFYRSDL QNELDRIWEKQKEYYPEILTDVLKEELRGKKRDAVWAICAKYFVWKENYTEWNKEKGKTEQQER EHKLEGIYSKRKRDEAKRENLQWRVNGLKEKLSLEQLVIVFQEMNTQINNSSGYLGAI SDRSKE LYFNKQTVGQYQMEMLDKNPNASLRNMVFYRQDYLDEFNMLWEKQAVYHKELTEELKKEIRDI I IFYQRRLKSQKGLIGFCEFESRQIEVDIDGKKKIKTVGNRVI SRSSPLFQEFKIWQILNNIEVT VVGKKRKRRKLKENYSALFEELNDAEQLELNGSRRLCQEEKELLAQELFIRDKMTKSEVLKLLF DNPQELDLNFKTIDGNKTGYALFQAYSKMIEMSGHEPVDFKKPVEKVVEYIKAVFDLLNWNTDI LGFNSNEELDNQPYYKLWHLLYSFEGDNTPTGNGRLIQKMTELYGFEKEYATILANVSFQDDYG SLSAKAIHKILPHLKEGNRYDVACVYAGYRHSESSLTREEIANKVLKDRLMLLPKNSLHNPVVE KILNQMVNVINVI IDIYGKPDEIRVELARELKKNAKEREELTKS IAQTTKAHEEYKTLLQTEFG LTNVSRTDILRYKLYKELESCGYKTLYSNTYI SREKLFSKEFDIEHI IPQARLFDDSFSNKTLE ARSVNIEKGNKTAYDFVKEKFGESGADNSLEHYLNNIEDLFKSGKI SKTKYNKLKMAEQDIPDG FIERDLRNTQYIAKKALSMLNEI SHRVVATSGSVTDKLREDWQLIDVMKELNWEKYKALGLVEY FEDRDGRQIGRIKDWTKRNDHRHHAMDALTVAFTKDVFIQYFNNKNASLDPNANEHAIKNKYFQ NGRAIAPMPLREFRAEAKKHLENTLI S IKAKNKVITGNINKTRKKGGVNKNMQQTPRGQLHLET IYGSGKQYLTKEEKVNASFDMRKIGTVSKSAYRDALLKRLYENDNDPKKAFAGKNSLDKQPIWL DKEQMRKVPEKVKIVTLEAIYTIRKEI SPDLKVDKVIDVGVRKILIDRLNEYGNDAKKAFSNLD KNPIWLNKEKGI S IKRVTI SGI SNAQSLHVKKDKDGKPILDENGRNIPVDFVNTGNNHHVAVYY RPVIDKRGQLVVDEAGNPKYELEEVVVSFFEAVTRANLGLPI IDKDYKTTEGWQFLFSMKQNEY FVFPNEKTGFNPKEIDLLDVENYGLISPNLFRVQKFSLKNYVFRHHLETTIKDTSSILRGITWI DFRSSKGLDTIVKVRVNHIGQIVSVGEY
SEQ ID NO: 308 MSRKNYVDDYAI SLDIGNASVGWSAFTPNYRLVRAKGHELIGVRLFDPADTAESRRMARTTRRR YSRRRWRLRLLDALFDQALSEIDPSFLARRKYSWVHPDDENNADCWYGSVLFDSNEQDKRFYEK YPTIYHLRKALMEDDSQHDIREIYLAIHHMVKYRGNFLVEGTLESSNAFKEDELLKLLGRITRY EMSEGEQNSDIEQDDENKLVAPANGQLADALCATRGSRSMRVDNALEALSAVNDLSREQRAIVK AIFAGLEGNKLDLAKIFVSKEFSSENKKILGIYFNKSDYEEKCVQIVDSGLLDDEEREFLDRMQ GQYNAIALKQLLGRSTSVSDSKCASYDAHRANWNLIKLQLRTKENEKDINENYGILVGWKIDSG QRKSVRGESAYENMRKKANVFFKKMIETSDLSETDKNRLIHDIEEDKLFPIQRDSDNGVIPHQL HQNELKQI IKKQGKYYPFLLDAFEKDGKQINKIEGLLTFRVPYFVGPLVVPEDLQKSDNSENHW MVRKKKGEITPWNFDEMVDKDASGRKFIERLVGTDSYLLGEPTLPKNSLLYQEYEVLNELNNVR LSVRTGNHWNDKRRMRLGREEKTLLCQRLFMKGQTVTKRTAENLLRKEYGRTYELSGLSDESKF TSSLSTYGKMCRIFGEKYVNEHRDLMEKIVELQTVFEDKETLLHQLRQLEGI SEADCALLVNTH YTGWGRLSRKLLTTKAGECKI SDDFAPRKHS I IEIMRAEDRNLMEI ITDKQLGFSDWIEQENLG AENGSSLMEVVDDLRVSPKVKRGI IQS IRLIDDI SKAVGKRPSRIFLELADDIQPSGRTI SRKS RLQDLYRNANLGKEFKGIADELNACSDKDLQDDRLFLYYTQLGKDMYTGEELDLDRLSSAYDID HI IPQAVTQNDS IDNRVLVARAENARKTDSFTYMPQIADRMRNFWQILLDNGLI SRVKFERLTR QNEFSEREKERFVQRSLVETRQIMKNVATLMRQRYGNSAAVIGLNAELTKEMHRYLGFSHKNRD INDYHHAQDALCVGIAGQFAANRGFFADGEVSDGAQNSYNQYLRDYLRGYREKLSAEDRKQGRA FGFIVGSMRSQDEQKRVNPRTGEVVWSEEDKDYLRKVMNYRKMLVTQKVGDDFGALYDETRYAA TDPKGIKGIPFDGAKQDTSLYGGFSSAKPAYAVLIESKGKTRLVNVTMQEYSLLGDRPSDDELR KVLAKKKSEYAKANILLRHVPKMQLIRYGGGLMVIKSAGELNNAQQLWLPYEEYCYFDDLSQGK GSLEKDDLKKLLDS ILGSVQCLYPWHRFTEEELADLHVAFDKLPEDEKKNVITGIVSALHADAK TANLS IVGMTGSWRRMNNKSGYTFSDEDEFIFQSPSGLFEKRVTVGELKRKAKKEVNSKYRTNE KRLPTLSGASQP
SEQ ID NO: 309
METQTSNQLITSHLKDYPKQDYFVGLDIGTNSVGWAVTNTSYELLKFHSHKMWGSRLFEEGESA VTRRGFRSMRRRLERRKLRLKLLEELFADAMAQVDSTFFIRLHESKYHYEDKTTGHSSKHILFI DEDYTDQDYFTEYPTIYHLRKDLMENGTDDIRKLFLAVHHILKYRGNFLYEGATFNSNAFTFED VLKQALV ITFNCFDTNSAI SS I S ILMESGKTKSDKAKAIERLVDTYTVFDEVNTPDKPQKEQ VKEDKKTLKAFANLVLGLSANLIDLFGSVEDIDDDLKKLQIVGDTYDEKRDELAKVWGDEIHI I DDCKSVYDAI ILMS IKEPGLTI SQSKVKAFDKHKEDLVILKSLLKLDRNVYNEMFKSDKKGLHN YVHYIKQGRTEETSCSREDFYKYTKKIVEGLADSKDKEYILNEIELQTLLPLQRIKDNGVIPYQ LHLEELKVILDKCGPKFPFLHTVSDGFSVTEKLIKMLEFRIPYYVGPLNTHHNIDNGGFSWAVR KQAGRVTPWNFEEKIDREKSAAAFIKNLTNKCTYLFGEDVLPKSSLLYSEFMLLNELNNVRIDG KALAQGVKQHLIDSIFKQDHKKMTKNRIELFLKDNNYITKKHKPEITGLDGEIKNDLTSYRDMV RILGNNFDVSMAEDI ITDITIFGESKKMLRQTLRNKFGSQLNDETIKKLSKLRYRDWGRLSKKL LKGIDGCDKAGNGAPKTI IELMRNDSYNLMEILGDKFSFMECIEEENAKLAQGQVVNPHDI IDE LALSPAVKRAVWQALRIVDEVAHIKKALPSRIFVEVARTNKSEKKKKDSRQKRLSDLYSAIKKD DVLQSGLQDKEFGALKSGLANYDDAALRSKKLYLYYTQMGRCAYTG I IDLNQLNTDNYDIDHI YPRSLTKDDSFDNLVLCERTA AKKSDIYPIDNRIQTKQKPFWAFLKHQGLI SERKYERLTRIA PLTADDLSGFIARQLVETNQSVKATTTLLRRLYPDIDVVFVKAENVSDFRHNNNFIKVRSLNHH HHAKDAYLNIVVGNVYHEKFTRNFRLFFKKNGANRTYNLAKMFNYDVICTNAQDGKAWDVKTSM NTVKKMMASNDVRVTRRLLEQSGALADATIYKASVAAKAKDGAYIGMKTKYSVFADVTKYGGMT KIKNAYS I IVQYTGKKGEEIKEIVPLPIYLINRNATDIELIDYVKSVIPKAKDI S IKYRKLCIN QLVKVNGFYYYLGGKTNDKIYIDNAIELVVPHDIATYIKLLDKYDLLRKENKTLKASS ITTS IY INTSTVVSLNKVGIDVFDYFMSKLRTPLYMKMKGNKVDELSSTGRSKFIKMTLEEQS IYLLEV LNLLTNSKTTFDVKPLGITGSRSTIGVKIHNLDEFKI INES ITGLYSNEVTIV SEQ ID NO: 310
MTKLNQPYGIGLDIGSNS IGFAVVDANSHLLRLKGETAIGARLFREGQSAADRRGSRTTRRRLS RTRWRLSFLRDFFAPHITKIDPDFFLRQKYSEI SPKDKDRFKYEKRLFNDRTDAEFYEDYPSMY HLRLHLMTHTHKADPREIFLAIHHILKSRGHFLTPGAAKDFNTDKVDLEDIFPALTEAYAQVYP DLELTFDLAKADDFKAKLLDEQATPSDTQKALVNLLLSSDGEKEIVKKRKQVLTEFAKAITGLK TKFNLALGTEVDEADASNWQFSMGQLDDKWSNIETSMTDQGTEIFEQIQELYRARLLNGIVPAG MSLSQAKVADYGQHKEDLELFKTYLKKLNDHELAKTIRGLYDRYINGDDAKPFLREDFVKALTK EVTAHPNEVSEQLLNRMGQANFMLKQRTKANGAIPIQLQQRELDQI IANQSKYYDWLAAPNPVE AHRWKMPYQLDELLNFHIPYYVGPLITPKQQAESGENVFAWMVRKDPSGNITPYNFDEKVDREA SANTFIQRMKTTDTYLIGEDVLPKQSLLYQKYEVLNELNNVRINNECLGTDQKQRLIREVFERH SSVTIKQVADNLVAHGDFARRPEIRGLADEKRFLSSLSTYHQLKEILHEAIDDPTKLLDIENI I TWSTVFEDHTIFETKLAEIEWLDPKKINELSGIRYRGWGQFSRKLLDGLKLGNGHTVIQELMLS NHNLMQILADETLKETMTELNQDKLKTDDIEDVINDAYTSPSNKKALRQVLRVVEDIKHAANGQ DPSWLFIETADGTGTAGKRTQSRQKQIQTVYANAAQELIDSAVRGELEDKIADKASFTDRLVLY FMQGGRDIYTGAPLNIDQLSHYDIDHILPQSLIKDDSLDNRVLVNATINREKNNVFASTLFAGK MKATWRKWHEAGLI SGRKLRNLMLRPDEIDKFAKGFVARQLVETRQI IKLTEQIAAAQYPNTKI IAVKAGLSHQLREELDFPKNRDVNHYHHAFDAFLAARIGTYLLKRYPKLAPFFTYGEFAKVDVK KFREFNFIGALTHAKK I IAKDTGEIVWDKERDIRELDRIYNFKRMLITHEVYFETADLFKQTI YAAKDSKERGGSKQLIPKKQGYPTQVYGGYTQESGSYNALVRVAEADTTAYQVIKI SAQNASKI ASANLKSREKGKQLLNEIVVKQLAKRRKNWKPSANSFKIVIPRFGMGTLFQNAKYGLFMVNSDT YYRNYQELWLSRENQKLLKKLFS IKYEKTQMNHDALQVYKAI IDQVEKFFKLYDINQFRAKLSD AIERFEKLPINTDGNKIGKTETLRQILIGLQANGTRSNVKNLGIKTDLGLLQVGSGIKLDKDTQ IVYQSPSGLFKRRIPLADL
SEQ ID NO: 311
MTKEYYLGLDVGTNSVGWAVTDSQYNLCKFKKKDMWGIRLFESANTAKDRRLQRGNRRRLERKK QRIDLLQEIFSPEICKIDPTFFIRLNESRLHLEDKSNDFKYPLFIEKDYSDIEYYKEFPTIFHL RKHLIESEEKQDIRLIYLALHNI IKTRGHFLIDGDLQSAKQLRPILDTFLLSLQEEQNLSVSLS ENQKDEYEEILKNRS IAKSEKVKKLKNLFEI SDELEKEEKKAQSAVIENFCKFIVGNKGDVCKF LRVSKEELEIDSFSFSEGKYEDDIVKNLEEKVPEKVYLFEQMKAMYDWNILVDILETEEYI SFA KVKQYEKHKTNLRLLRDI ILKYCTKDEYNRMFNDEKEAGSYTAYVGKLKKNNKKYWIEKKRNPE EFYKSLGKLLDKIEPLKEDLEVLTMMIEECKNHTLLPIQKNKDNGVIPHQVHEVELKKILENAK KYYSFLTETDKDGYSVVQKIES IFRFRIPYYVGPLSTRHQEKGSNVWMVRKPGREDRIYPWNME EI IDFEKSNENFITRMTNKCTYLIGEDVLPKHSLLYSKYMVLNELNNVKVRGKKLPTSLKQKVF EDLFENKSKVTGKNLLEYLQIQDKDIQIDDLSGFDKDFKTSLKSYLDFKKQIFGEEIEKES IQN MIEDI IKWITIYGNDKEMLKRVIRANYSNQLTEEQMKKITGFQYSGWGNFSKMFLKGI SGSDVS TGETFDI ITAMWETDNNLMQILSKKFTFMDNVEDFNSGKVGKIDKITYDSTVKEMFLSPENKRA VWQTIQVAEEIKKVMGCEPKKIFIEMARGGEKVKKRTKSRKAQLLELYAACEEDCRELIKEIED RDERDFNSMKLFLYYTQFGKCMYSGDDIDINELIRGNSKWDRDHIYPQSKIKDDS IDNLVLVNK TYNAKKSNELLSEDIQKKMHSFWLSLLNKKLITKSKYDRLTRKGDFTDEELSGFIARQLVETRQ STKAIADIFKQIYSSEVVYVKSSLVSDFRKKPLNYLKSRRVNDYHHAKDAYLNIVVGNVYNKKF TSNPIQWMKKNRDTNYSLNKVFEHDVVINGEVIWEKCTYHEDTNTYDGGTLDRIRKIVERDNIL YTEYAYCEKGELFNATIQNKNGNSTVSLKKGLDVKKYGGYFSANTSYFSLIEFEDKKGDRARHI IGVPIYIANMLEHSPSAFLEYCEQKGYQNVRILVEKIKKNSLLI INGYPLRIRGENEVDTSFKR AIQLKLDQKNYELVRNIEKFLEKYVEKKGNYPIDENRDHITHEKMNQLYEVLLSKMKKFNKKGM ADPSDRIEKSKPKFIKLEDLIDKINVINKMLNLLRCDNDTKADLSLIELPKNAGSFVVKKNTIG KSKI ILVNQSVTGLYENRREL
SEQ ID NO: 312
MARDYSVGLDIGTSSVGWAAIDNKYHLIRAKSKNLIGVRLFDSAVTAEKRRGYRTTRRRLSRRH WRLRLLNDIFAGPLTDFGDENFLARLKYSWVHPQDQSNQAHFAAGLLFDSKEQDKDFYRKYPTI YHLRLALMNDDQKHDLREVYLAIHHLVKYRGHFLIEGDVKADSAFDVHTFADAIQRYAESNNSD ENLLGKIDEKKLSAALTDKHGSKSQRAETAETAFDILDLQSKKQIQAILKSVVGNQANLMAIFG LDSSAI SKDEQKNYKFSFDDADIDEKIADSEALLSDTEFEFLCDLKAAFDGLTLKMLLGDDKTV SAAMVRRFNEHQKDWEYIKSHIRNAKNAGNGLYEKSKKFDGINAAYLALQSDNEDDRKKAKKIF QDEI SSADIPDDVKADFLKKIDDDQFLPIQRTKNNGTIPHQLHRNELEQI IEKQGIYYPFLKDT YQENSHELNKITALINFRVPYYVGPLVEEEQKIADDGKNIPDPTNHWMVRKSNDTITPWNLSQV VDLDKSGRRFIERLTGTDTYLIGEPTLPKNSLLYQKFDVLQELNNIRVSGRRLDIRAKQDAFEH LFKVQKTVSATNLKDFLVQAGYI SEDTQIEGLADVNGKNFN ALTTYNYLVSVLGREFVENPSN EELLEEITELQTVFEDKKVLRRQLDQLDGLSDHNREKLSRKHYTGWGRI SKKLLTTKIVQNADK IDNQTFDVPRMNQS I IDTLYNTKMNLMEI IN AEDDFGVRAWIDKQNTTDGDEQDVYSLIDELA GPKEIKRGIVQSFRILDDITKAVGYAPKRVYLEFARKTQESHLTNSRKNQLSTLLKNAGLSELV TQVSQYDAAALQNDRLYLYFLQQGKDMYSGEKLNLDNLSNYDIDHI IPQAYTKDNSLDNRVLVS NITNRRKSDSSNYLPALIDKMRPFWSVLSKQGLLSKHKFANLTRTRDFDDMEKERFIARSLVET RQIIKNVASLIDSHFGGETKAVAIRSSLTADMRRYVDIPKNRDINDYHHAFDALLFSTVGQYTE NSGLMKKGQLSDSAGNQYNRYIKEWIHAARLNAQSQRVNPFGFVVGSMRNAAPGKLNPETGEIT PEENADWS IADLDYLHKVMNFRKITVTRRLKDQKGQLYDESRYPSVLHDAKSKAS INFDKHKPV DLYGGFSSAKPAYAALIKFKNKFRLVNVLRQWTYSDKNSEDYILEQIRGKYPKAEMVLSHIPYG QLVKKDGALVTI SSATELHNFEQLWLPLADYKLINTLLKTKEDNLVDILHNRLDLPEMTIESAF YKAFDS ILSFAFNRYALHQNALVKLQAHRDDFNALNYEDKQQTLERILDALHASPASSDLKKIN LSSGFGRLFSPSHFTLADTDEFIFQSVTGLFSTQKTVAQLYQETK
SEQ ID NO: 313
MVYDVGLDIGTGSVGWVALDENGKLARAKGKNLVGVRLFDTAQTAADRRGFRTTRRRLSRRKWR LRLLDELFSAEINEIDSSFFQRLKYSYVHPKDEENKAHYYGGYLFPTEEETKKFHRSYPTIYHL RQELMAQPNKRFDIREIYLAIHHLVKYRGHFLSSQEKITIGSTYNPEDLANAIEVYADEKGLSW ELNNPEQLTEI I SGEAGYGLNKSMKADEALKLFEFDNNQDKVAIKTLLAGLTGNQIDFAKLFGK DISDKDEAKLWKLKLDDEALEEKSQTILSQLTDEEIELFHAVVQAYDGFVLIGLLNGADSVSAA MVQLYDQHREDRKLLKSLAQKAGLKHKRFSEIYEQLALATDEATIKNGI STARELVEESNLSKE VKEDTLRRLDENEFLPKQRTKANSVIPHQLHLAELQKILQNQGQYYPFLLDTFEKEDGQDNKIE ELLRFRIPYYVGPLVTKKDVEHAGGDADNHWVERNEGFEKSRVTPWNFDKVFNRDKAARDFIER LTGNDTYLIGEKTLPQNSLRYQLFTVLNELNNVRVNGKKFDSKTKADLINDLFKARKTVSLSAL KDYLKAQGKGDVTITGLADESKFNSSLSSYNDLKKTFDAEYLENEDNQETLEKI IEIQTVFEDS KIASRELSKLPLDDDQVKKLSQTHYTGWGRLSEKLLDSKI IDERGQKVS ILDKLKSTSQNFMS I INNDKYGVQAWITEQNTGSSKLTFDEKVNELTTSPANKRGIKQSFAVLNDIKKAMKEEPRRVYL EFAREDQTSVRSVPRYNQLKEKYQSKSLSEEAKVLKKTLDGNKNKMSDDRYFLYFQQQGKDMYT GRPINFERLSQDYDIDHI IPQAFTKDDSLDNRVLVSRPENARKSDSFAYTDEVQKQDGSLWTSL LKSGFINRKKYERLTKAGKYLDGQKTGFIARQLVETRQI IKNVASLIEGEYENSKAVAIRSEIT ADMRLLVGIKKHREINSFHHAFDALLITAAGQYMQNRYPDRDSTNVYNEFDRYTNDYLKNLRQL SSRDEVRRLKSFGFVVGTMRKGNEDWSEENTSYLRKVMMFKNILTTKKTEKDRGPLNKETIFSP KSGKKLIPLNSKRSDTALYGGYSNVYSAYMTLVRANGKNLLIKIPI S IANQIEVGNLKINDYIV NNPAIKKFEKILI SKLPLGQLVNEDGNLIYLASNEYRHNAKQLWLSTTDADKIAS I SENSSDEE LLEAYDILTSENVKNRFPFFKKDIDKLSQVRDEFLDSDKRIAVIQTILRGLQIDAAYQAPVKI I SKKVSDWHKLQQSGGIKLSDNSEMIYQSATGIFETRVKI SDLL
SEQ ID NO: 314
IVDYCIGLDLGTGSVGWAVVDMNHRLMKRNGKHLWGSRLFSNAETAANRRASRS IRRRYNKRRE RIRLLRAILQDMVLEKDPTFFIRLEHTSFLDEEDKAKYLGTDYKDNYNLFIDEDFNDYTYYHKY PTIYHLRKALCESTEKADPRLIYLALHHIVKYRGNFLYEGQKFNMDASNIEDKLSDIFTQFTSF NNIPYEDDEKKNLEILEILKKPLSKKAKVDEVMTLIAPEKDYKSAFKELVTGIAGNKMNVTKMI LCEPIKQGDSEIKLKFSDSNYDDQFSEVEKDLGEYVEFVDALHNVYSWVELQTIMGATHTDNAS ISEAMVSRYNKHHDDLKLLKDCIKNNVPNKYFDMFRNDSEKSKGYYNYINRPSKAPVDEFYKYV KKCIEKVDTPEAKQILNDIELENFLLKQNSRTNGSVPYQMQLDEMIKI IDNQAEYYPILKEKRE QLLS ILTFRIPYYFGPLNETSEHAWIKRLEGKENQRILPWNYQDIVDVDATAEGFIKRMRSYCT YFPDEEVLPKNSLIVSKYEVYNELNKIRVDDKLLEVDVKNDIYNELFMKNKTVTEKKLKNWLVN NQCCSKDAEIKGFQKENQFSTSLTPWIDFTNIFGKIDQSNFDLIENI IYDLTVFEDKKIMKRRL KKKYALPDDKVKQILKLKYKDWSRLSKKLLDGIVADNRFGSSVTVLDVLEMSRLNLMEI INDKD LGYAQMIEEATSCPEDGKFTYEEVERLAGSPALKRGIWQSLQIVEEITKVMKCRPKYIYIEFER SEEAKERTESKIKKLENVYKDLDEQTKKEYKSVLEELKGFDNTKKI SSDSLFLYFTQLGKCMYS GKKLDIDSLDKYQIDHIVPQSLVKDDSFDNRVLVVPSENQRKLDDLVVPFDIRDKMYRFWKLLF DHELI SPKKFYSLIKTEYTERDEERFINRQLVETRQITKNVTQI IEDHYSTTKVAAIRANLSHE FRVKNHIYKNRDINDYHHAHDAYIVALIGGFMRDRYPNMHDSKAVYSEYMKMFRKNKNDQKRWK DGFVINSMNYPYEVDGKLIWNPDLINEIKKCFYYKDCYCTTKLDQKSGQLFNLTVLSNDAHADK GVTKAVVPVNKNRSDVHKYGGFSGLQYTIVAIEGQKKKGKKTELVKKI SGVPLHLKAAS INEKI NYIEEKEGLSDVRI IKD IPVNQMIEMDGGEYLLTSPTEYVNARQLVLNEKQCALIADIYNAIY KQDYDNLDDILMIQLYIELTNKMKVLYPAYRGIAEKFESMNENYVVI SKEEKA I IKQMLIVMH RGPQNGNIVYDDFKI SDRIGRLKTKNHNLNNIVFI SQSPTGIYTKKYKL
SEQ ID NO: 315
MKSEKKYYIGLDVGTNSVGWAVTDEFYNILRAKGKDLWGVRLFEKADTAANTRIFRSGRRRNDR KGMRLQILREIFEDEIKKVDKDFYDRLDESKFWAEDKKVSGKYSLFNDKNFSDKQYFEKFPTIF HLRKYLMEEHGKVDIRYYFLAINQMMKRRGHFLIDGQI SHVTDDKPLKEQLILLINDLLKIELE EELMDS IFEILADVNEKRTDKKNNLKELIKGQDFNKQEGNILNS IFES IVTGKAKIKNI I SDED ILEKIKEDNKEDFVLTGDSYEENLQYFEEVLQENITLFNTLKSTYDFLILQS ILKGKSTLSDAQ VERYDEHKKDLEILKKVIKKYDEDGKLFKQVFKEDNGNGYVSYIGYYLNKNKKITAKKKI SNIE FTKYVKGILEKQCDCEDEDVKYLLGKIEQENFLLKQI SS INSVIPHQIHLFELDKILENLAKNY PSFNNKKEEFTKIEKIRKTFTFRIPYYVGPLNDYHKNNGGNAWIFRNKGEKIRPWNFEKIVDLH KSEEEFIKRMLNQCTYLPEETVLPKSS ILYSEYMVLNELNNLRINGKPLDTDVKLKLIEELFKK KTKVTLKS IRDYMVRNNFADKEDFDNSEKNLEIASNMKSYIDFNNILEDKFDVEMVEDLIEKIT IHTGNKKLLKKYIEETYPDLSSSQIQKI INLKYKDWGRLSRKLLDGIKGTKKETEKTDTVINFL RNSSDNLMQI IGSQNYSFNEYIDKLRKKYIPQEI SYEVVENLYVSPSVKKMIWQVIRVTEEITK VMGYDPDKIFIEMAKSEEEKKTTI SRKNKLLDLYKAIKKDERDSQYEKLLTGLNKLDDSDLRSR KLYLYYTQMGRDMYTGEKIDLDKLFDSTHYDKDHI IPQSMKKDDS I INNLVLVNKNANQTTKGN IYPVPSS IRNNPKIYNYWKYLMEKEFI SKEKYNRLIRNTPLTNEELGGFINRQLVETRQSTKAI KELFEKFYQKSKI IPVKASLASDLRKDMNTLKSREVNDLHHAHDAFLNIVAGDVWNREFTSNPI NYVKENREGDKVKYSLSKDFTRPRKSKGKVIWTPEKGRKLIVDTLNKPSVLI SNESHVKKGELF NATIAGKKDYKKGKIYLPLKKDDRLQDVSKYGGYKAINGAFFFLVEHTKSKKRIRS IELFPLHL LSKFYEDKNTVLDYAINVLQLQDPKI I IDKINYRTEI I IDNFSYLISTKSNDGSITVKPNEQMY WRVDEI SNLKKIENKYKKDAILTEEDRKIMESYIDKIYQQFKAGKYKNRRTTDTI IEKYEI IDL DTLDNKQLYQLLVAFI SLSYKTSNNAVDFTVIGLGTECGKPRITNLPDNTYLVYKS ITGIYEKR IRIK
SEQ ID NO: 316
MKLRGIEDDYS IGLDMGTSSVGWAVTDERGTLAHFKRKPTWGSRLFREAQTAAVARMPRGQRRR YVRRRWRLDLLQKLFEQQMEQADPDFFIRLRQSRLLRDDRAEEHADYRWPLFNDCKFTERDYYQ RFPTIYHVRSWLMETDEQADIRLIYLALHNIVKHRGNFLREGQSLSAKSARPDEALNHLRETLR VWSSERGFECS IADNGS ILAMLTHPDLSPSDRRKKIAPLFDVKSDDAAADKKLGIALAGAVIGL KTEFKNIFGDFPCEDSS IYLSNDEAVDAVRSACPDDCAELFDRLCEVYSAYVLQGLLSYAPGQT I SANMVEKYRRYGEDLALLKKLVKIYAPDQYRMFFSGATYPGTGIYDAAQARGYTKYNLGPKKS EYKPSESMQYDDFRKAVEKLFAKTDARADERYRMMMDRFDKQQFLRRLKTSDNGS IYHQLHLEE LKAIVENQGRFYPFLKRDADKLVSLVSFRIPYYVGPLSTRNARTDQHGENRFAWSERKPGMQDE PIFPWNWES I IDRSKSAEKFILRMTGMCTYLQQEPVLPKSSLLYEEFCVLNELNGAHWS IDGDD EHRFDAADREGI IEELFRRKRTVSYGDVAGWMERERNQIGAHVCGGQGEKGFESKLGSYIFFCK DVFKVERLEQSDYPMIERI ILWNTLFEDRKILSQRLKEEYGSRLSAEQIKTICKKRFTGWGRLS EKFLTGITVQVDEDSVS IMDVLREGCPVSGKRGRAMVMMEILRDEELGFQKKVDDFNRAFFAEN AQALGVNELPGSPAVRRSLNQS IRIVDEIAS IAGKAPANIFIEVTRDEDPKKKGRRTKRRYNDL KDALEAFKKEDPELWRELCETAPNDMDERLSLYFMQRGKCLYSGRAIDIHQLSNAGIYEVDHI I PRTYVKDDSLENKALVYREENQRKTDMLLIDPEIRRRMSGYWRMLHEAKLIGDKKFRNLLRSRI DDKALKGFIARQLVETGQMVKLVRSLLEARYPETNI I SVKAS I SHDLRTAAELVKCREANDFHH AHDAFLACRVGLFIQKRHPCVYENPIGLSQVVRNYVRQQADIFKRCRTIPGSSGFIVNSFMTSG FDKETGEIFKDDWDAEAEVEGIRRSLNFRQCFI SRMPFEDHGVFWDATIYSPRAKKTAALPLKQ GLNPSRYGSFSREQFAYFFIYKARNPRKEQTLFEFAQVPVRLSAQIRQDENALERYARELAKDQ GLEFIRIERSKILKNQLIEIDGDRLCITGKEEVRNACELAFAQDEMRVIRMLVSEKPVSRECVI SLFNRILLHGDQASRRLSKQLKLALLSEAFSEASDNVQRNVVLGLIAIFNGSTNMVNLSDIGGS KFAGNVRIKYKKELASPKVNVHLIDQSVTGMFERRTKIGL
SEQ ID NO: 317
MENKQYYIGLDVGTNSVGWAVTDTSYNLLRAKGKDMWGARLFEKANTAAERRTKRTSRRRSERE KARKAMLKELFADEINRVDPSFFIRLEESKFFLDDRSENNRQRYTLFNDATFTDKDYYEKYKTI FHLRSALINSDEKFDVRLVFLAILNLFSHRGHFLNASLKGDGDIQGMDVFYNDLVESCEYFEIE LPRITNIDNFEKILSQKGKSRTKILEELSEELS I SKKDKSKYNLIKLI SGLEASVVELYNIEDI QDENKKIKIGFRESDYEESSLKVKEI IGDEYFDLVERAKSVHDMGLLSNI IGNSKYLCEARVEA YENHHKDLLKIKELLKKYDKKAYNDMFRKMTDKNYSAYVGSVNSNIAKERRSVDKRKIEDLYKY IEDTALKNIPDDNKDKIEILEKIKLGEFLKKQLTASNGVIPNQLQSRELRAILKKAENYLPFLK EKGEKNLTVSEMI IQLFEFQIPYYVGPLDKNPKKDNKANSWAKIKQGGRILPWNFEDKVDVKGS RKEFIEKMVRKCTYI SDEHTLPKQSLLYEKFMVLNEINNIKIDGEKI SVEAKQKIYNDLFVKGK KVSQKDIKKELI SLNIMDKDSVLSGTDTVCNAYLSS IGKFTGVFKEEINKQS IVDMIEDI IFLK TVYGDEKRFVKEEIVEKYGDEIDKDKIKRILGFKFSNWGNLSKSFLELEGADVGTGEVRS HQS LWETNFNLMELLSSRFTYMDELEKRVKKLEKPLSEWTIEDLDDMYLSSPVKRMIWQSMKIVDEI QTVIGYAPKRIFVEMTRSEGEKVRTKSRKDRLKELYNGIKEDSKQWVKELDSKDESYFRSKKMY LYYLQKGRCMYSGEVIELDKLMDDNLYDIDHIYPRSFVKDDSLDNLVLVKKEINNRKQNDPITP QIQASCQGFWKILHDQGFMSNEKYSRLTRKTQEFSDEEKLSFINRQIVETGQATKCMAQILQKS MGEDVDVVFSKARLVSEFRHKFELFKSRLINDFHHANDAYLNIVVGNSYFVKFTRNPANFIKDA RKNPDNPVYKYHMDRFFERDVKSKSEVAWIGQSEGNSGTIVIVKKTMAKNSPLITKKVEEGHGS ITKETIVGVKEIKFGRNKVEKADKTPKKPNLQAYRPIKTSDERLCNILRYGGRTS I S I SGYCLV EYVKKRKTIRSLEAIPVYLGRKDSLSEEKLLNYFRYNLNDGGKDSVSDIRLCLPFI STNSLVKI DGYLYYLGGKNDDRIQLYNAYQLKMKKEEVEYIRKIEKAVSMSKFDEIDREKNPVLTEEKNIEL YNKIQDKFENTVFSKRMSLVKYNKKDLSFGDFLKNKKSKFEEIDLEKQCKVLY I IFNLSNLKE VDLSDIGGSKSTGKCRCKKNITNYKEFKLIQQS ITGLYSCEKDLMTI
SEQ ID NO: 318
MKNLKEYYIGLDIGTASVGWAVTDESYNIPKFNGKKMWGVRLFDDAKTAEERRTQRGSRRRLNR RKERINLLQDLFATEI SKVDPNFFLRLDNSDLYREDKDEKLKSKYTLFNDKDFKDRDYHKKYPT IHHLIMDLIEDEGKKDIRLLYLACHYLLKNRGHFIFEGQKFDTKNSFDKS INDLKIHLRDEY I DLEFNNEDLIEI ITDTTLNKTNKKKELKNIVGDTKFLKAI SAIMIGSSQKLVDLFEDGEFEETT VKSVDFSTTAFDDKYSEYEEALGDTI SLLNILKS IYDSS ILENLLKDADKSKDGNKYI SKAFVK KFNKHGKDLKTLKRI IKKYLPSEYA IFRNKS INDNYVAYTKS ITSNKRTKASKFTKQEDFYK FIKKHLDTIKETKLNSSENEDLKLIDEMLTDIEFKTFIPKLKSSDNGVIPYQLKLMELKKILDN QSKYYDFLNESDEYGTVKDKVES IMEFRIPYYVGPLNPDSKYAWIKRENTKITPWNFKDIVDLD SSREEFIDRLIGRCTYLKEEKVLPKASLIYNEFMVLNELNNLKLNEFLITEEMKKAIFEELFKT KKKVTLKAVSNLLKKEFNLTGDILLSGTDGDFKQGLNSYIDFKNI IGDKVDRDDYRIKIEEI IK LIVLYEDDKTYLKKKIKSAYKNDFTDDEIKKIAALNYKDWGRLSKRFLTGIEGVDKTTGEKGS I IYFMREYNLNLMELMSGHYTFTEEVEKLNPVENRELCYEMVDELYLSPSVKRMLWQSLRVVDEI KRIIGKDPKKIFIEMARAKEAKNSRKESRKNKLLEFYKFGKKAFINEIGEERYNYLLNEINSEE ESKFRWDNLYLYYTQLGRCMYSLEPIDLADLKSN IYDQDHIYPKSKIYDDSLENRVLVKKNLN HEKGNQYPIPEKVLNKNAYGFWKILFDKGLIGQKKYTRLTRRTPFEERELAEFIERQIVETRQA TKETANLLK ICQDSEIVYSKAENASRFRQEFDI IKCRTVNDLHHMHDAYL IVVGNVYNTKFT KNPLNFIKDKDNVRSYNLENMFKYDVVRGSYTAWIADDSEGNVKAATIKKVKRELEGKNYRFTR MSYIGTGGLYDQNLMRKGKGQIPQKENTNKSNIEKYGGYNKASSAYFALIESDGKAGRERTLET IPIMVYNQEKYGNTEAVDKYLKDNLELQDPKILKDKIKINSLIKLDGFLYNIKGKTGDSLSIAG SVQLIVNKEEQKLIKKMDKFLVKKKDNKDIKVTSFD IKEEELIKLYKTLSDKLNNGIYSNKRN NQAKNI SEALDKFKEI S IEEKIDVLNQI ILLFQSYNNGCNLKS IGLSAKTGVVFIPKKLNYKEC KLINQSITGLFENEVDLLNL
SEQ ID NO: 319
MGKMYYLGLDIGTNSVGYAVTDPSYHLLKFKGEPMWGAHVFAAGNQSAERRSFRTSRRRLDRRQ QRVKLVQEIFAPVI SPIDPRFFIRLHESALWRDDVAETDKHIFFNDPTYTDKEYYSDYPTIHHL IVDLMESSEKHDPRLVYLAVAWLVAHRGHFLNEVDKDNIGDVLSFDAFYPEFLAFLSDNGVSPW VCESKALQATLLSRNSVNDKYKALKSLIFGSQKPEDNFDANI SEDGLIQLLAGKKVKVNKLFPQ ESNDASFTLNDKEDAIEEILGTLTPDECEWIAHIRRLFDWAIMKHALKDGRTI SESKVKLYEQH HHDLTQLKYFVKTYLAKEYDDIFRNVDSETTKNYVAYSYHVKEVKGTLPKNKATQEEFCKYVLG KVKNIECSEADKVDFDEMIQRLTDNSFMPKQVSGENRVIPYQLYYYELKTILNKAASYLPFLTQ CGKDAI SNQDKLLS IMTFRIPYFVGPLRKDNSEHAWLERKAGKIYPWNFNDKVDLDKSEEAFIR RMTNTCTYYPGEDVLPLDSLIYEKFMILNEINNIRIDGYPI SVDVKQQVFGLFEKKRRVTVKDI QNLLLSLGALDKHGKLTGIDTTIHSNYNTYHHFKSLMERGVLTRDDVERIVERMTYSDDTKRVR LWLNNNYGTLTADDVKHI SRLRKHDFGRLSKMFLTGLKGVHKETGERAS ILDFMWNTNDNLMQL LSECYTFSDEITKLQEAYYAKAQLSLNDFLDSMYI SNAVKRPIYRTLAVVNDIRKACGTAPKRI FIEMARDGESKKKRSVTRREQIKNLYRS IRKDFQQEVDFLEKILENKSDGQLQSDALYLYFAQL GRDMYTGDPIKLEHIKDQSFYNIDHIYPQSMVKDDSLDNKVLVQSEINGEKSSRYPLDAAIRNK MKPLWDAYYNHGLI SLKKYQRLTRSTPFTDDEKWDFINRQLVETRQSTKALAILLKRKFPDTEI VYSKAGLSSDFRHEFGLVKSRNINDLHHAKDAFLAIVTGNVYHERFNRRWFMVNQPYSVKTKTL FTHS IKNGNFVAWNGEEDLGRIVKMLKQNKNTIHFTRFSFDRKEGLFDIQPLKASTGLVPRKAG LDVVKYGGYDKSTAAYYLLVRFTLEDKKTQHKLMMIPVEGLYKARIDHDKEFLTDYAQTTI SEI LQKDKQKVI IMFPMGTRHIKLNSMI S IDGFYLS IGGKSSKGKSVLCHAMVPLIVPHKIECYIK AMESFARKFKENNKLRIVEKFDKITVEDNLNLYELFLQKLQHNPYNKFFSTQFDVLTNGRSTFT KLSPEEQVQTLLNILS IFKTCRSSGCDLKS INGSAQAARIMI SADLTGLSKKYSDIRLVEQSAS GLFVSKSQNLLEYL
SEQ ID NO: 320
MTKKEQPYNIGLDIGTSSVGWAVTNDNYDLLNIKKKNLWGVRLFEEAQTAKETRLNRSTRRRYR RRKNRINWLNEIFSEELAKTDPSFLIRLQNSWVSKKDPDRKRDKYNLFIDGPYTDKEYYREFPT IFHLRKELILNKDKADIRLIYLALH ILKYRGNFTYEHQKF I SNLNNNLSKELIELNQQLIKY DI SFPDDCDWNHI SDILIGRGNATQKSSNILKDFTLDKETKKLLKEVINLILGNVAHLNTIFKT SLTKDEEKLNFSGKDIESKLDDLDS ILDDDQFTVLDAANRIYSTITLNEILNGESYFSMAKVNQ YENHAIDLCKLRDMWHTTKNEEAVEQSRQAYDDYINKPKYGTKELYTSLKKFLKVALPTNLAKE AEEKI SKGTYLVKPRNSENGVVPYQLNKIEMEKI IDNQSQYYPFLKENKEKLLS ILSFRIPYYV GPLQSAEKNPFAWMERKSNGHARPWNFDEIVDREKSSNKFIRRMTVTDSYLVGEPVLPKNSLIY QRYEVLNELN IRITENLKTNPIGSRLTVETKQRIYNELFKKYKKVTVKKLTKWLIAQGYYKNP ILIGLSQKDEFNSTLTTYLDMKKIFGSSFMEDNKNYDQIEELIEWLTIFEDKQILNEKLHSSKY SYTPDQIKKI SNMRYKGWGRLSKKILMDITTETNTPQLLQLSNYS ILDLMWATNNNFI S IMSND KYDFKNYIENHNLNKNEDQNI SDLVNDIHVSPALKRGITQS IKIVQEIVKFMGHAPKHIFIEVT RETKKSEITTSREKRIKRLQSKLLNKANDFKPQLREYLVPNKKIQEELKKHKNDLSSERIMLYF LQNGKSLYSEESLNINKLSDYQVDHILPRTYIPDDSLENKALVLAKENQRKADDLLLNSNVIDR NLERWTYMLNNNMIGLKKFKNLTRRVITDKDKLGFIHRQLVQTSQMVKGVANILDNMYKNQGTT CIQARANLSTAFRKALSGQDDTYHFKHPELVKNRNVNDFHHAQDAYLASFLGTYRLRRFPTNEM LLMNGEYNKFYGQVKELYSKKKKLPDSRKNGFI I SPLVNGTTQYDRNTGEI IWNVGFRDKILKI FNYHQCNVTRKTEIKTGQFYDQTIYSPKNPKYKKLIAQKKDMDPNIYGGFSGDNKSSITIVKID NNKIKPVAIPIRLINDLKDKKTLQNWLEENVKHKKS IQI IKNNVPIGQI IYSKKVGLLSLNSDR EVANRQQLILPPEHSALLRLLQIPDEDLDQILAFYDKNILVEILQELITKMKKFYPFYKGEREF LIANIENFNQATTSEKVNSLEELITLLHANSTSAHLIFNNIEKKAFGRKTHGLTLNNTDFIYQS VTGLYETRIHIE
SEQ ID NO: 321
MTKFNKNYS IGLDIGVSSVGYAVVTEDYRVPAFKFKVLGNTEKEKIKKNLIGSTTFVSAQPAKG TRVFRVNRRRIDRRNHRITYLRDIFQKEIEKVDKNFYRRLDESFRVLGDKSEDLQIKQPFFGDK ELETAYHKKYPTIYHLRKHLADADKNSPVADIREVYMAI SHILKYRGHFLTLDKINPNNINMQN SWIDFIESCQEVFDLEI SDESKNIADIFKSSENRQEKVKKILPYFQQELLKKDKS IFKQLLQLL FGLKTKFKDCFELEEEPDLNFSKENYDENLENFLGSLEEDFSDVFAKLKVLRDTILLSGMLTYT GATHARFSATMVERYEEHRKDLQRFKFFIKQNLSEQDYLDIFGRKTQNGFDVDKETKGYVGYIT NKMVLTNPQKQKTIQQNFYDYI SGKITGIEGAEYFLNKI SDGTFLRKLRTSDNGAIPNQIHAYE LEKI IERQGKDYPFLLENKDKLLS ILTFKIPYYVGPLAKGSNSRFAWIKRATSSDILDDNDEDT RNGKIRPWNYQKLINMDETRDAFITNLIGNDI ILLNEKVLPKRSLIYEEVMLQNELTRVKYKDK YGKAHFFDSELRQNI INGLFKNNSKRVNAKSLIKYLSDNHKDLNAIEIVSGVEKGKSFNSTLKT YNDLKTIFSEELLDSEIYQKELEEI IKVITVFDDKKSIKNYLTKFFGHLEILDEEKINQLSKLR YSGWGRYSAKLLLDIRDEDTGFNLLQFLRNDEENRNLTKLI SDNTLSFEPKIKDIQSKSTIEDD IFDEIKKLAGSPAIKRGILNS IKIVDELVQI IGYPPHNIVIEMARENMTTEEGQKKAKTRKTKL ESALKNIENSLLENGKVPHSDEQLQSEKLYLYYLQNGKDMYTLDKTGSPAPLYLDQLDQYEVDH I IPYSFLPIDS IDNKVLTHRENNQQKLNNIPDKETVANMKPFWEKLYNAKLI SQTKYQRLTTSE RTPDGVLTESMKAGFIERQLVETRQI IKHVARILDNRFSDTKI ITLKSQLITNFRNTFHIAKIR ELNDYHHAHDAYLAVVVGQTLLKVYPKLAPELIYGHHAHFNRHEENKATLRKHLYSNIMRFFNN PDSKVSKDIWDCNRDLPI IKDVIYNSQINFVKRTMIKKGAFYNQNPVGKFNKQLAANNRYPLKT KALCLDTS IYGGYGPMNSALS I I I IAERFNEKKGKIETVKEFHDIFI IDYEKFNNNPFQFLNDT SENGFLKKNNINRVLGFYRIPKYSLMQKIDGTRMLFESKSNLHKATQFKLTKTQNELFFHMKRL LTKSNLMDLKSKSAIKESQNFILKHKEEFD I SNQLSAFSQKMLGNTTSLKNLIKGYNERKIKE IDIRDETIKYFYDNFIKMFSFVKSGAPKDINDFFDNKCTVARMRPKPDKKLLNATLIHQS ITGL YETRIDLSKLGED
SEQ ID NO: 322
MKQEYFLGLDMGTGSLGWAVTDSTYQVMRKHGKALWGTRLFESASTAEERRMFRTARRRLDRRN WRIQVLQEIFSEEI SKVDPGFFLRMKESKYYPEDKRDAEGNCPELPYALFVDDNYTDKNYHKDY PTIYHLRKMLMETTEIPDIRLVYLVLHHMMKHRGHFLLSGDI SQIKEFKSTFEQLIQNIQDEEL EWHI SLDDAAIQFVEHVLKDRNLTRSTKKSRLIKQLNAKSACEKAILNLLSGGTVKLSDIFNNK ELDESERPKVSFADSGYDDYIGIVEAELAEQYYI IASAKAVYDWSVLVEILGNSVS I SEAKIKV YQKHQADLKTLKKIVRQYMTKEDYKRVFVDTEEKLNNYSAYIGMTKKNGKKVDLKSKQCTQADF YDFLKKNVIKVIDHKEITQEIESEIEKENFLPKQVTKDNGVIPYQVHDYELKKILDNLGTRMPF IKENAEKIQQLFEFRIPYYVGPLNRVDDGKDGKFTWSVRKSDARIYPWNFTEVIDVEASAEKFI RRMTNKCTYLVGEDVLPKDSLVYSKFMVLNELNNLRLNGEKI SVELKQRIYEELFCKYRKVTRK KLERYLVIEGIAKKGVEITGIDGDFKASLTAYHDFKERLTDVQLSQRAKEAIVLNVVLFGDDKK LLKQRLSKMYPNLTTGQLKGICSLSYQGWGRLSKTFLEEITVPAPGTGEVWNIMTALWQTNDNL MQLLSRNYGFTNEVEEFNTLKKETDLSYKTVDELYVSPAVKRQIWQTLKVVKEIQKVMGNAPKR VFVEMAREKQEGKRSDSRKKQLVELYRACKNEERDWITELNAQSDQQLRSDKLFLYYIQKGRCM YSGETIQLDELWDNTKYDIDHIYPQSKTMDDSLNNRVLVKKNYNAIKSDTYPLSLDIQKKMMSF WKMLQQQGFITKEKYVRLVRSDELSADELAGFIERQIVETRQSTKAVATILKEALPDTEIVYVK AGNVSNFRQTYELLKVREMNDLHHAKDAYLNIVVGNAYFVKFTKNAAWFIRNNPGRSYNLKRMF EFDIERSGEIAWKAGNKGS IVTVKKVMQKN ILVTRKAYEVKGGLFDQQIMKKGKGQVPIKGND ERLADIEKYGGYNKAAGTYFMLVKSLDKKGKEIRTIEFVPLYLKNQIEINHESAIQYLAQERGL NSPEILLSKIKIDTLFKVDGFKMWLSGRTGNQLIFKGANQLILSHQEAAILKGVVKYVNRKNEN KDAKLSERDGMTEEKLLQLYDTFLDKLSNTVYS IRLSAQIKTLTEKRAKFIGLSNEDQCIVLNE ILHMFQCQSGSANLKLIGGPGSAGILVMNN ITACKQI SVINQSPTGIYEKEIDLIKL
SEQ ID NO: 323
MKKPYS IGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTAEDRRL KRTARRRYTRRRNRILYLQEIFSEEMGKVDDSFFHRLEDSFLVTEDKRGERHPIFGNLEEEVKY HENFPTIYHLRQYLADNPEKVDLRLVYLALAHI IKFRGHFLIEGKFDTRNNDVQRLFQEFLAVY DNTFENSSLQEQNVQVEEILTDKI SKSAKKDRVLKLFPNEKSNGRFAEFLKLIVGNQADFKKHF ELEEKAPLQFSKDTYEEELEVLLAQIGDNYAELFLSAKKLYDS ILLSGILTVTDVGTKAPLSAS MIQRYNEHQMDLAQLKQFIRQKLSDKYNEVFSDVSKDGYAGYIDGKTNQEAFYKYLKGLLNKIE GSGYFLDKIEREDFLRKQRTFDNGS IPHQIHLQEMRAI IRRQAEFYPFLADNQDRIEKLLTFRI PYYVGPLARGKSDFAWLSRKSADKITPWNFDEIVDKESSAEAFINRMTNYDLYLPNQKVLPKHS LLYEKFTVYNELTKVKYKTEQGKTAFFDANMKQEIFDGVFKVYRKVTKDKLMDFLEKEFDEFRI VDLTGLDKENKVFNASYGTYHDLCKILDKDFLDNSKNEKILEDIVLTLTLFEDREMIRKRLENY SDLLTKEQVKKLERRHYTGWGRLSAELIHGIRNKESRKTILDYLIDDGNSNRNFMQLINDDALS FKEEIAKAQVIGETDNLNQVVSDIAGSPAIKKGILQSLKIVDELVKIMGHQPENIVVEMARENQ FTNQGRRNSQQRLKGLTDS IKEFGSQILKEHPVENSQLQNDRLFLYYLQNGRDMYTGEELDIDY LSQYDIDHI IPQAFIKDNS IDNRVLTSSKENRGKSDDVPSKDVVRKMKSYWSKLLSAKLITQRK FDNLTKAERGGLTDDDKAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIRQVKIVTLKS NLVSNFRKEFELYKVREINDYHHAHDAYLNAVIGKALLGVYPQLEPEFVYGDYPHFHGHKENKA TAKKFFYS IMNFFKKDDVRTDKNGEI IWKKDEHI S IKKVLSYPQV IVKKVEEQTGGFSKES ILPKGNSDKLIPRKTKKFYWDTKKYGGFDSPIVAYS ILVIADIEKGKSKKLKTVKALVGVTIME KMTFERDPVAFLERKGYRNVQEE I IKLPKYSLFKLENGRKRLLASARELQKGNEIVLPNHLGT LLYHAKNIHKVDEPKHLDYVDKHKDEFKELLDVVSNFSKKYTLAEGNLEKIKELYAQNNGEDLK ELASSFINLLTFTAIGAPATFKFFDKNIDRKRYTSTTEILNATLIHQSITGLYETRIDLNKLGG D
SEQ ID NO: 324
MDKKYS IGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHS IKKNLIGALLFDSGETAEATRL KRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAY HEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTY NQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMD GTEELLVKLNREDLLRKQRTFDNGS IPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRI PYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHS LLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD SVEI SGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTF KEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQ TTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINR LSDYDVDHIVPQSFLKDDS IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRK FDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAK SEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLS MPQV IVKKTEVQTGGFSKES ILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKG KSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLI IKLPKYSLFELENGRKRMLAS AGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEI IEQI SEFSKRV ILADANLDKVLSAYNKHRDKPIREQAE I IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLD ATLIHQS ITGLYETRIDLSQLGGD
SEQ ID NO: 325
MTKPYS IGLDIGTNSVGWAVTTDNYKVPSKKMKVLGNTSKKYIKKNLLGVLLFDSGITAEGRRL KRTARRRYTRRRNRILYLQEIFSTEMATLDDAFFQRLDDSFLVPDDKRDSKYPIFGNLVEEKAY HDEFPTIYHLRKYLADSTKKADLRLVYLALAHMIKYRGHFLIEGEFNSKNNDIQKNFQDFLDTY NAIFESDLSLENSKQLEEIVKDKI SKLEKKDRILKLFPGEKNSGIFSEFLKLIVGNQADFRKCF NLDEKASLHFSKESYDEDLETLLGYIGDDYSDVFLKAKKLYDAILLSGFLTVTDNETEAPLSSA MIKRYNEHKEDLALLKEYIRNI SLKTYNEVFKDDTKNGYAGYIDGKTNQEDFYVYLKKLLAEFE GADYFLEKIDREDFLRKQRTFDNGS IPYQIHLQEMRAILDKQAKFYPFLAKNKERIEKILTFRI PYYVGPLARGNSDFAWS IRKRNEKITPWNFEDVIDKESSAEAFINRMTSFDLYLPEEKVLPKHS LLYETFNVYNELTKVRFIAESMRDYQFLDSKQKKDIVRLYFKDKRKVTDKDI IEYLHAIYGYDG IELKGIEKQFNSSLSTYHDLLNI INDKEFLDDSSNEAI IEEI IHTLTIFEDREMIKQRLSKFEN IFDKSVLKKLSRRHYTGWGKLSAKLINGIRDEKSGNTILDYLIDDGI SNRNFMQLIHDDALSFK KKIQKAQI IGDEDKGNIKEVVKSLPGSPAIKKGILQS IKIVDELVKVMGGRKPES IVVEMAREN QYTNQGKSNSQQRLKRLEKSLKELGSKILKENIPAKLSKIDNNALQNDRLYLYYLQNGKDMYTG DDLDIDRLSNYDIDHI IPQAFLKDNS IDNKVLVSSASNRGKSDDVPSLEVVKKRKTFWYQLLKS KLI SQRKFDNLTKAERGGLSPEDKAGFIQRQLVETRQITKHVARLLDEKFNNKKDENNRAVRTV KIITLKSTLVSQFRKDFELYKVREINDFHHAHDAYLNAVVASALLKKYPKLEPEFVYGDYPKYN SFRERKSATEKVYFYS IM IFKKS I SLADGRVIERPLIEVNEETGESVWNKESDLATVRRVLS YPQVNVVKKVEEQNHGLDRGKPKGLFNANLSSKPKPNSNENLVGAKEYLDPKKYGGYAGISNSF TVLVKGTIEKGAKKKITNVLEFQGI S ILDRINYRKDKLNFLLEKGYKDIELI IELPKYSLFELS DGSRRMLAS ILSTNNKRGEIHKGNQIFLSQKFVKLLYHAKRI SNTINENHRKYVENHKKEFEEL FYYILEFNENYVGAKKNGKLLNSAFQSWQNHS IDELCSSFIGPTGSERKGLFELTSRGSAADFE FLGVKIPRYRDYTPSSLLKDATLIHQSVTGLYETRIDLAKLGEG
SEQ ID NO: 326
MKKQKFSDYYLGFDIGTNSVGWCVTDLDYNVLRFNKKDMWGSRLFDEAKTAAERRVQRNSRRRL KRRKWRLNLLEEIFSDEIMKIDSNFFRRLKESSLWLEDKNSKEKFTLFNDDNYKDYDFYKQYPT IFHLRDELIKNPEKKDIRLIYLALHS IFKSRGHFLFEGQNLKEIKNFETLYNNLI SFLEDNGIN KS IDKD IEKLEKI ICDSGKGLKDKEKEFKGIFNSDKQLVAIFKLSVGSSVSLNDLFDTDEYKK EEVEKEKI SFREQIYEDDKPIYYS ILGEKIELLDIAKSFYDFMVLNNILSDSNYI SEAKVKLYE EHKKDLKNLKYI IRKYNKENYDKLFKDKNENNYPAYIGLNKEKDKKEVVEKSRLKIDDLIKVIK GYLPKPERIEEKDKTIFNEILNKIELKTILPKQRI SDNGTLPYQIHEVELEKILENQSKYYDFL NYEENGVSTKDKLLKTFKFRIPYYVGPLNSYHKDKGGNSWIVRKEEGKILPWNFEQKVDIEKSA EEFIKRMTNKCTYLNGEDVIPKDSFLYSEYI ILNELNKVQVNDEFLNEENKRKI IDELFKENKK VSEKKFKEYLLVNQIANRTVELKGIKDSFNSNYVSYIKFKDIFGEKLNLDIYKEI SEKS ILWKC LYGDDKKIFEKKIKNEYGDILNKDEIKKINSFKFNTWGRLSEKLLTGIEFINLETGECYSSVME ALRRTNYNLMELLSSKFTLQES IDNENKEMNEVSYRDLIEESYVSPSLKRAILQTLKIYEEIKK ITGRVPKKVFIEMARGGDESMKNKKIPARQEQLKKLYDSCGNDIANFS IDIKEMKNSLSSYDNN SLRQKKLYLYYLQFGKCMYTGREIDLDRLLQNNDTYDIDHIYPRSKVIKDDSFDNLVLVLKNEN AEKSNEYPVKKEIQEKMKSFWRFLKEKNFI SDEKYKRLTGKDDFELRGFMARQLVNVRQTTKEV GKILQQIEPEIKIVYSKAEIASSFREMFDFIKVRELNDTHHAKDAYLNIVAGNVYNTKFTEKPY RYLQEIKENYDVKKIYNYDIKNAWDKENSLEIVKKNMEKNTV ITRFIKEEKGELFNLNPIKKG ETSNEI I S IKPKLYDGKDNKLNEKYGYYTSLKAAYFIYVEHEKKNKKVKTFERITRIDSTLIKN EKNLIKYLVSQKKLLNPKI IKKIYKEQTLI IDSYPYTFTGVDSNKKVELKNKKQLYLEKKYEQI LKNALKFVEDNQGETEENYKFIYLKKRNNNEKNETIDAVKERY IEFNEMYDKFLEKLSSKDYK NYINNKLYTNFLNSKEKFKKLKLWEKSLILREFLKIFNKNTYGKYEIKDSQTKEKLFSFPEDTG RIRLGQSSLGNNKELLEESVTGLFVKKIKL
SEQ ID NO: 327
MKNYTIGLDIGVASVGWVCIDENYKILNYNNRHAFGVHEFESAESAAGRRLKRGMRRRYNRRKK RLQLLQSLFDSYITDSGFFSKTDSQHFWKNNNEFENRSLTEVLSSLRISSRKYPTIYHLRSDLI ESNKKMDLRLVYLALHNLVKYRGHFLQEGNWSEAASAEGMDDQLLELVTRYAELENLSPLDLSE SQWKAAETLLLNRNLTKTDQSKELTAMFGKEYEPFCKLVAGLGVSLHQLFPSSEQALAYKETKT KVQLSNENVEEVMELLLEEESALLEAVQPFYQQVVLYELLKGETYVAKAKVSAFKQYQKDMASL KNLLDKTFGEKVYRSYFI SDKNSQREYQKSHKVEVLCKLDQFNKEAKFAETFYKDLKKLLEDKS KTS IGTTEKDEMLRI IKAIDSNQFLQKQKGIQNAAIPHQNSLYEAEKILRNQQAHYPFITTEWI EKVKQILAFRIPYYIGPLVKDTTQSPFSWVERKGDAPITPWNFDEQIDKAASAEAFI SRMRKTC TYLKGQEVLPKSSLTYERFEVLNELNGIQLRTTGAESDFRHRLSYEMKCWI IDNVFKQYKTVST KRLLQELKKSPYADELYDEHTGEIKEVFGTQKENAFATSLSGYI SMKS ILGAVVDDNPAMTEEL IYWIAVFEDREILHLKIQEKYPS ITDVQRQKLALVKLPGWGRFSRLLIDGLPLDEQGQSVLDHM EQYSSVFMEVLKNKGFGLEKKIQKMNQHQVDGTKKIRYEDIEELAGSPALKRGIWRSVKIVEEL VSIFGEPANIVLEVAREDGEKKRTKSRKDQWEELTKTTLKNDPDLKSFIGEIKSQGDQRFNEQR FWLYVTQQGKCLYTGKALDIQNLSMYEVDHILPQNFVKDDSLDNLALVMPEANQRKNQVGQNKM PLEI IEANQQYAMRTLWERLHELKLI SSGKLGRLKKPSFDEVDKDKFIARQLVETRQI IKHVRD LLDERFSKSDIHLVKAGIVSKFRRFSEIPKIRDYNNKHHAMDALFAAALIQS ILGKYGKNFLAF DLSKKDRQKQWRSVKGSNKEFFLFKNFGNLRLQSPVTGEEVSGVEYMKHVYFELPWQTTKMTQT GDGMFYKES IFSPKVKQAKYVSPKTEKFVHDEVKNHS ICLVEFTFMKKEKEVQETKFIDLKVIE HHQFLKEPESQLAKFLAEKETNSPI IHARI IRTIPKYQKIWIEHFPYYFI STRELHNARQFEI S YELMEKVKQLSERSSVEELKIVFGLLIDQMNDNYPIYTKSS IQDRVQKFVDTQLYDFKSFEIGF EELKKAVAANAQRSDTFGSRI SKKPKPEEVAIGYES ITGLKYRKPRSVVGTKR
SEQ ID NO: 328
MKKEIKDYFLGLDVGTGSVGWAVTDTDYKLLKANRKDLWGMRCFETAETAEVRRLHRGARRRIE RRKKRIKLLQELFSQEIAKTDEGFFQRMKESPFYAEDKTILQENTLFNDKDFADKTYHKAYPTI NHLIKAWIENKVKPDPRLLYLACH I IKKRGHFLFEGDFDSENQFDTS IQALFEYLREDMEVDI DADSQKVKEILKDSSLKNSEKQSRLNKILGLKPSDKQKKAITNLI SGNKINFADLYDNPDLKDA EKNS I SFSKDDFDALSDDLAS ILGDSFELLLKAKAVYNCSVLSKVIGDEQYLSFAKVKIYEKHK TDLTKLKNVIKKHFPKDYKKVFGYNKNEKNNNNYSGYVGVCKTKSKKLI INNSVNQEDFYKFLK TILSAKSEIKEVNDILTEIETGTFLPKQI SKSNAEIPYQLRKMELEKILSNAEKHFSFLKQKDE KGLSHSEKI IMLLTFKIPYYIGPINDNHKKFFPDRCWVVKKEKSPSGKTTPWNFFDHIDKEKTA EAFITSRTNFCTYLVGESVLPKSSLLYSEYTVLNEINNLQI I IDGK ICDIKLKQKIYEDLFKK YKKITQKQISTFIKHEGICNKTDEVI ILGIDKECTSSLKSYIELK IFGKQVDEISTKNMLEEI IRWATIYDEGEGKTILKTKIKAEYGKYCSDEQIKKILNLKFSGWGRLSRKFLETVTSEMPGFSE PVNI ITAMRETQNNLMELLSSEFTFTENIKKINSGFEDAEKQFSYDGLVKPLFLSPSVKKMLWQ TLKLVKEISHITQAPPKKIFIEMAKGAELEPARTKTRLKILQDLYNNCKNDADAFSSEIKDLSG KIENEDNLRLRSDKLYLYYTQLGKCMYCGKPIEIGHVFDTSNYDIDHIYPQSKIKDDS I SNRVL VCSSCNKNKEDKYPLKSEIQSKQRGFWNFLQRNNFI SLEKLNRLTRATPI SDDETAKFIARQLV ETRQATKVAAKVLEKMFPETKIVYSKAETVSMFRNKFDIVKCREINDFHHAHDAYLNIVVGNVY NTKFTNNPWNFIKEKRDNPKIADTYNYYKVFDYDVKRNNITAWEKGKTI ITVKDMLKRNTPIYT RQAACKKGELFNQTIMKKGLGQHPLKKEGPFS I SKYGGYNKVSAAYYTLIEYEEKGNKIRSLE TIPLYLVKDIQKDQDVLKSYLTDLLGKKEFKILVPKIKINSLLKINGFPCHITGKTNDSFLLRP AVQFCCSNNEVLYFKKI IRFSEIRSQREKIGKTI SPYEDLSFRSYIKENLWKKTKNDEIGEKEF YDLLQKKNLEIYDMLLTKHKDTIYKKRPNSATIDILVKGKEKFKSLI IENQFEVILEILKLFSA TRNVSDLQHIGGSKYSGVAKIGNKI SSLDNCILIYQS ITGIFEKRIDLLKV
SEQ ID NO: 329
MEGQMKNNGNNLQQGNYYLGLDVGTSSVGWAVTDTDYNVLKFRGKSMWGARLFDEASTAEERRT HRGNRRRLARRKYRLLLLEQLFEKEIRKIDDNFFVRLHESNLWADDKSKPSKFLLFNDTNFTDK DYLKKYPTIYHLRSDLIHNSTEHDIRLVFLALHHLIKYRGHFIYDNSANGDVKTLDEAVSDFEE YLNENDIEFNIENKKEFINVLSDKHLTKKEKKI SLKKLYGDITDSENINI SVLIEMLSGSS I SL SNLFKDIEFDGKQNLSLDSDIEETLNDVVDILGDNIDLLIHAKEVYDIAVLTSSLGKHKYLCDA KVELFEKNKKDLMILKKYIKKNHPEDYKKIFSSPTEKKNYAAYSQTNSKNVCSQEEFCLFIKPY IRDMVKSENEDEVRIAKEVEDKSFLTKLKGTNNSVVPYQIHERELNQILKNIVAYLPFMNDEQE DI SVVDKIKLIFKFKIPYYVGPLNTKSTRSWVYRSDEKIYPWNFSNVIDLDKTAHEFMNRLIGR CTYTNDPVLPMDSLLYSKYNVLNEINPIKVNGKAIPVEVKQAIYTDLFENSKKKVTRKS IYIYL LKNGYIEKEDIVSGIDIEIKSKLKSHHDFTQIVQENKCTPEEIERI IKGILVYSDDKSMLRRWL KNNIKGLSENDVKYLAKLNYKEWGRLSKTLLTDIYTINPEDGEACS ILDIMWNTNATLMEILSN EKYQFKQNIENYKAENYDEKQNLHEELDDMYI SPAARRS IWQALRIVDEIVDIKKSAPKKIFIE MAREKKSAMKKKRTESRKDTLLELYKSCKSQADGFYDEELFEKLSNESNSRLRRDQLYLYYTQM GRSMYTGKRIDFDKLINDKNTYDIDHIYPRSKIKDDS ITNRVLVEKDINGEKTDIYPI SEDIRQ KMQPFWKILKEKGLINEEKYKRLTRNYELTDEELSSFVARQLVETQQSTKALATLLKKEYPSAK IVYSKAGNVSEFRNRKDKELPKFREINDLHHAKDAYLNIVVGNVYDTKFTEKFFNNIRNENYSL KRVFDFSVPGAWDAKGSTFNTIKKYMAKNNPI IAFAPYEVKGELFDQQIVPKGKGQFPIKQGKD IEKYGGYNKLSSAFLFAVEYKGKKARERSLETVYIKDVELYLQDPIKYCESVLGLKEPQI IKPK ILMGSLFS INNKKLVVTGRSGKQYVCHHIYQLS INDEDSQYLK IAKYLQEEPDG IERQ ILN ITSVN IKLFDVLCTKFNSNTYEI ILNSLKNDVNEGREKFSELDILEQC ILLQLLKAFKCNRE SSNLEKLNNKKQAGVIVIPHLFTKCSVFKVIHQS ITGLFEKEMDLLK
SEQ ID NO: 330
MGRKPYILSLDIGTGSVGYACMDKGFNVLKYHDKDALGVYLFDGALTAQERRQFRTSRRRKNRR IKRLGLLQELLAPLVQNPNFYQFQRQFAWKNDNMDFKNKSLSEVLSFLGYESKKYPTIYHLQEA LLLKDEKFDPELIYMALYHLVKYRGHFLFDHLKIENLTNNDNMHDFVELIETYENLNNIKLNLD YEKTKVIYEILKDNEMTKNDRAKRVKNMEKKLEQFS IMLLGLKFNEGKLFNHADNAEELKGANQ SHTFADNYEENLTPFLTVEQSEFIERANKIYLSLTLQDILKGKKSMAMSKVAAYDKFRNELKQV KDIVYKADSTRTQFKKIFVSSKKSLKQYDATPNDQTFSSLCLFDQYLIRPKKQYSLLIKELKKI IPQDSELYFEAENDTLLKVLNTTDNAS IPMQINLYEAETILRNQQKYHAEITDEMIEKVLSLIQ FRIPYYVGPLVNDHTASKFGWMERKSNES IKPWNFDEVVDRSKSATQFIRRMTNKCSYLINEDV LPKNSLLYQEMEVLNELNATQIRLQTDPKNRKYRMMPQIKLFAVEHIFKKYKTVSHSKFLEIML NSNHRENFMNHGEKLS IFGTQDDKKFASKLSSYQDMTKIFGDIEGKRAQIEEI IQWITIFEDKK ILVQKLKECYPELTSKQINQLKKLNYSGWGRLSEKLLTHAYQGHS I IELLRHSDENFMEILTND VYGFQNFIKEENQVQSNKIQHQDIANLTTSPALKKGIWSTIKLVRELTS IFGEPEKI IMEFATE DQQKGKKQKSRKQLWDD IKKNKLKSVDEYKYI IDVANKLNNEQLQQEKLWLYLSQNGKCMYSG QS IDLDALLSPNATKHYEVDHIFPRSFIKDDS IDNKVLVIKKMNQTKGDQVPLQFIQQPYERIA YWKSLNKAGLI SDSKLHKLMKPEFTAMDKEGFIQRQLVETRQI SVHVRDFLKEEYPNTKVIPMK AKMVSEFRKKFDIPKIRQMNDAHHAIDAYLNGVVYHGAQLAYPNVDLFDFNFKWEKVREKWKAL GEFNTKQKSRELFFFKKLEKMEVSQGERLI SKIKLDMNHFKINYSRKLA IPQQFYNQTAVSPK TAELKYESNKSNEVVYKGLTPYQTYVVAIKSVNKKGKEKMEYQMIDHYVFDFYKFQNGNEKELA LYLAQRENKDEVLDAQIVYSLNKGDLLYINNHPCYFVSRKEVINAKQFELTVEQQLSLYNVMNN KETNVEKLLIEYDFIAEKVINEYHHYLNSKLKEKRVRTFFSESNQTHEDFIKALDELFKVVTAS ATRSDKIGSRKNSMTHRAFLGKGKDVKIAYTS I SGLKTTKPKSLFKLAESRNEL
SEQ ID NO: 331
MAKILGLDLGTNS IGWAVVERENIDFSLIDKGVRIFSEGVKSEKGIESSRAAERTGYRSARKIK YRRKLRKYETLKVLSLNRMCPLS IEEVEEWKKSGFKDYPLNPEFLKWLSTDEESNVNPYFFRDR ASKHKVSLFELGRAFYHIAQRRGFLSNRLDQSAEGILEEHCPKIEAIVEDLI S IDEI STNITDY FFETGILDSNEKNGYAKDLDEGDKKLVSLYKSLLAILKKNESDFENCKSEI IERLNKKDVLGKV KGKIKDI SQAMLDGNYKTLGQYFYSLYSKEKIRNQYTSREEHYLSEFITICKVQGIDQINEEEK INEKKFDGLAKDLYKAIFFQRPLKSQKGLIGKCSFEKSKSRCAI SHPDFEEYRMWTYLNTIKIG TQSDKKLRFLTQDEKLKLVPKFYRKNDFNFDVLAKELIEKGSSFGFYKSSKKNDFFYWFNYKPT DTVAACQVAASLKNAIGEDWKTKSFKYQTINSNKEQVSRTVDYKDLWHLLTVATSDVYLYEFAI DKLGLDEKNAKAFSKTKLKKDFASLSLSAINKILPYLKEGLLYSHAVFVANIENIVDENIWKDE KQRDYIKTQI SEI IENYTLEKSRFEI INGLLKEYKSENEDGKRVYYSKEAEQSFENDLKKKLVL FYKSNEIENKEQQETIFNELLPIFIQQLKDYEFIKIQRLDQKVLIFLKGKNETGQIFCTEEKGT AEEKEKKIKNRLKKLYHPSDIEKFKKKI IKDEFGNEKIVLGSPLTPS IKNPMAMRALHQLRKVL NALILEGQIDEKTI IHIEMARELNDANKRKGIQDYQNDNKKFREDAIKEIKKLYFEDCKKEVEP TEDDILRYQLWMEQNRSEIYEEGKNI S ICDI IGSNPAYDIEHTIPRSRSQDNSQMNKTLCSQRF NREVKKQSMPIELNNHLEILPRIAHWKEEADNLTREIEI I SRS IKAAATKEIKDKKIRRRHYLT LKRDYLQGKYDRFIWEEPKVGFKNSQIPDTGI ITKYAQAYLKSYFKKVESVKGGMVAEFRKIWG IQESFIDENGMKHYKVKDRSKHTHHTIDAITIACMTKEKYDVLAHAWTLEDQQNKKEARS I IEA SKPWKTFKEDLLKIEEEILVSHYTPDNVKKQAKKIVRVRGKKQFVAEVERDVNGKAVPKKAASG KTIYKLDGEGKKLPRLQQGDTIRGSLHQDS IYGAIKNPLNTDEIKYVIRKDLES IKGSDVES IV DEVVKEKIKEAIANKVLLLSSNAQQKNKLVGTVWMNEEKRIAINKVRIYANSVKNPLHIKEHSL LSKSKHVHKQKVYGQNDENYAMAIYELDGKRDFELI IFNLAKLIKQGQGFYPLHKKKEIKGKI VFVPIEKRNKRDVVLKRGQQVVFYDKEVENPKDI SEIVDFKGRIYI IEGLS IQRIVRPSGKVDE YGVIMLRYFKEARKADDIKQDNFKPDGVFKLGENKPTRKMNHQFTAFVEGIDFKVLPSGKFEKI
SEQ ID NO: 332
MEFKKVLGLDIGTNS IGCALLSLPKS IQDYGKGGRLEWLTSRVIPLDADYMKAFIDGKNGLPQV ITPAGKRRQKRGSRRLKHRYKLRRSRLIRVFKTLNWLPEDFPLDNPKRIKETI STEGKFSFRI S DYVPI SDESYREFYREFGYPENEIEQVIEEINFRRKTKGKNKNPMIKLLPEDWVVYYLRKKALI KPTTKEELIRI IYLFNQRRGFKSSRKDLTETAILDYDEFAKRLAEKEKYSAENYETKFVS ITKV KEVVELKTDGRKGKKRFKVILEDSRIEPYEIERKEKPDWEGKEYTFLVTQKLEKGKFKQNKPDL PKEEDWALCTTALDNRMGSKHPGEFFFDELLKAFKEKRGYKIRQYPVNRWRYKKELEFIWTKQC QLNPELNNL INKEILRKLATVLYPSQSKFFGPKIKEFENSDVLHI I SEDI IYYQRDLKSQKSL I SECRYEKRKGIDGEIYGLKCIPKSSPLYQEFRIWQDIH IKVIRKESEVNGKKKI IDETQLY INENIKEKLFELFNSKDSLSEKDILELI SLNI INSGIKI SKKEEETTHRINLFANRKELKGNET KSRYRKVFKKLGFDGEYILNHPSKLNRLWHSDYSNDYADKEKTEKS ILSSLGWKNRNGKWEKSK NYDVFNLPLEVAKAIANLPPLKKEYGSYSALAIRKMLVVMRDGKYWQHPDQIAKDQENTSLMLF DKNLIQLTNNQRKVLNKYLLTLAEVQKRSTLIKQKLNEIEHNPYKLELVSDQDLEKQVLKSFLE KKNESDYLKGLKTYQAGYLIYGKHSEKDVPIVNSPDELGEYIRKKLPNNSLRNPIVEQVIRETI FIVRDVWKSFGI IDEIHIELGRELKNNSEERKKTSESQEKNFQEKERARKLLKELLNSSNFEHY DENGNKIFSSFTVNPNPDSPLDIEKFRIWKNQSGLTDEELNKKLKDEKIPTEIEVKKYILWLTQ KCRSPYTGKI IPLSKLFDSNVYEIEHI IPRSKMKNDSTNNLVICELGVNKAKGDRLAANFI SES NGKCKFGEVEYTLLKYGDYLQYCKDTFKYQKAKYKNLLATEPPEDFIERQINDTRYIGRKLAEL LTPVVKDSKNI IFTIGS ITSELKITWGLNGVWKDILRPRFKRLES I INKKLIFQDEDDPNKYHF DLS INPQLDKEGLKRLDHRHHALDATI IAATTREHVRYLNSLNAADNDEEKREYFLSLCNHKIR DFKLPWENFTSEVKSKLLSCVVSYKESKPILSDPFNKYLKWEYKNGKWQKVFAIQIKNDRWKAV RRSMFKEPIGTVWIKKIKEVSLKEAIKIQAIWEEVKNDPVRKKKEKYIYDDYAQKVIAKIVQEL GLSSSMRKQDDEKLNKFINEAKVSAGVNKNLNTTNKTIYNLEGRFYEKIKVAEYVLYKAKRMPL NKKEYIEKLSLQKMFNDLPNFILEKS ILDNYPEILKELESDNKYI IEPHKKNNPVNRLLLEHIL EYHNNPKEAFSTEGLEKLNKKAINKIGKPIKYITRLDGDINEEEIFRGAVFETDKGSNVYFVMY ENNQTKDREFLKPNPS I SVLKAIEHKNKIDFFAPNRLGFSRI ILSPGDLVYVPTNDQYVLIKDN SSNETI INWDDNEFI SNRIYQVKKFTGNSCYFLKNDIASLILSYSASNGVGEFGSQNI SEYSVD DPPIRIKDVCIKIRVDRLGNVRPL
SEQ ID NO: 333
MKHILGLDLGTNS IGWALIERNIEEKYGKI IGMGSRIVPMGAELSKFEQGQAQTKNADRRTNRG ARRLNKRYKQRRNKLIYILQKLDMLPSQIKLKEDFSDPNKIDKITILPI SKKQEQLTAFDLVSL RVKALTEKVGLEDLGKI IYKYNQLRGYAGGSLEPEKEDIFDEEQSKDKKNKSFIAFSKIVFLGE PQEEIFKNKKLNRRAI IVETEEGNFEGSTFLENIKVGDSLELLINISASKSGDTITIKLPNKTN WRKKMENIENQLKEKSKEMGREFYI SEFLLELLKENRWAKIRNNTILRARYESEFEAIWNEQVK HYPFLENLDKKTLIEIVSFIFPGEKESQKKYRELGLEKGLKYI IKNQVVFYQRELKDQSHLI SD CRYEPNEKAIAKSHPVFQEYKVWEQINKLIVNTKIEAGTNRKGEKKYKYIDRPIPTALKEWIFE ELQNKKEITFSAIFKKLKAEFDLREGIDFLNGMSPKDKLKGNETKLQLQKSLGELWDVLGLDS I NRQIELW ILYNEKGNEYDLTSDRTSKVLEFINKYGN IVDDNAEETAIRI SKIKFARAYSSLS LKAVERILPLVRAGKYFNNDFSQQLQSKILKLLNENVEDPFAKAAQTYLDNNQSVLSEGGVGNS IATILVYDKHTAKEYSHDELYKSYKEINLLKQGDLRNPLVEQI INEALVLIRDIWKNYGIKPNE IRVELARDLKNSAKERATIHKRNKDNQTINNKIKETLVKNKKELSLANIEKVKLWEAQRHLSPY TGQPIPLSDLFDKEKYDVDHI IPI SRYFDDSFTNKVI SEKSVNQEKANRTAMEYFEVGSLKYS I FTKEQFIAHVNEYFSGVKRKNLLATS IPEDPVQRQIKDTQYIAIRVKEELNKIVGNENVKTTTG SITDYLRNHWGLTDKFKLLLKERYEALLESEKFLEAEYDNYKKDFDSRKKEYEEKEVLFEEQEL TREEFIKEYKENYIRYKKNKLI IKGWSKRIDHRHHAIDALIVACTEPAHIKRLNDLNKVLQDWL VEHKSEFMPNFEGSNSELLEEILSLPENERTEIFTQIEKFRAIEMPWKGFPEQVEQKLKEI I I S HKPKDKLLLQYNKAGDRQIKLRGQLHEGTLYGI SQGKEAYRIPLTKFGGSKFATEK IQKIVSP FLSGFIANHLKEYNNKKEEAFSAEGIMDLNNKLAQYRNEKGELKPHTPI STVKIYYKDPSKNKK KKDEEDLSLQKLDREKAFNEKLYVKTGDNYLFAVLEGEIKTKKTSQIKRLYDI I SFFDATNFLK EEFRNAPDKKTFDKDLLFRQYFEERNKAKLLFTLKQGDFVYLPNENEEVILDKESPLYNQYWGD LKERGK IYVVQKFSKKQIYFIKHTIADI IKKDVEFGSQNCYETVEGRS IKENCFKLEIDRLGN IVKVIKR
SEQ ID NO: 334
MHVEIDFPHFSRGDSHLAMNKNEILRGSSVLYRLGLDLGSNSLGWFVTHLEKRGDRHEPVALGP GGVRIFPDGRDPQSGTSNAVDRRMARGARKRRDRFVERRKELIAALIKYNLLPDDARERRALEV LDPYALRKTALTDTLPAHHVGRALFHLNQRRGFQSNRKTDSKQSEDGAIKQAASRLATDKGNET LGVFFADMHLRKSYEDRQTAIRAELVRLGKDHLTGNARKKIWAKVRKRLFGDEVLPRADAPHGV RARATITGTKASYDYYPTRDMLRDEFNAIWAGQSAHHATITDEARTEIEHI IFYQRPLKPAIVG KCTLDPATRPFKEDPEGYRAPWSHPLAQRFRILSEARNLEIRDTGKGSRRLTKEQSDLVVAALL ANREVKFDKLRTLLKLPAEARFNLESDRRAALDGDQTAARLSDKKGFNKAWRGFPPERQIAIVA RLEETEDENELIAWLEKECALDGAAAARVANTTLPDGHCRLGLRAIKKIVPIMQDGLDEDGVAG AGYHIAAKRAGYDHAKLPTGEQLGRLPYYGQWLQDAVVGSGDARDQKEKQYGQFPNPTVHIGLG QLRRVVNDLIDKYGPPTEI S IEFTRALKLSEQQKAERQREQRRNQDKNKARAEELAKFGRPANP RNLLKMRLWEELAHDPLDRKCVYTGEQI S IERLLSDEVDIDHILPVAMTLDDSPANKI ICMRYA NRHKRKQTPSEAFGSSPTLQGHRYNWDDIAARATGLPRNKRWRFDANAREEFDKRGGFLARQLN ETGWLARLAKQYLGAVTDPNQIWVVPGRLTSMLRGKWGLNGLLPSDNYAGVQDKAEEFLASTDD MEFSGVKNRADHRHHAIDGLVTALTDRSLLWKMANAYDEEHEKFVIEPPWPTMRDDLKAALEKM VVSHKPDHGIEGKLHEDSAYGFVKPLDATGLKEEEAGNLVYRKAIESLNENEVDRIRDIQLRTI VRDHVNVEKTKGVALADALRQLQAPSDDYPQFKHGLRHVRILKKEKGDYLVPIANRASGVAYKA YSAGENFCVEVFETAGGKWDGEAVRRFDANKKNAGPKIAHAPQWRDANEGAKLVMRIHKGDLIR LDHEGRARIMVVHRLDAAAGRFKLADHNETGNLDKRHATNNDIDPFRWLMASYNTLKKLAAVPV RVDELGRVWRVMPN
SEQ ID NO: 335
METTLGIDLGTNS IGLALVDQEEHQILYSGVRIFPEGINKDTIGLGEKEESRNATRRAKRQMRR QYFRKKLRKAKLLELLIAYDMCPLKPEDVRRWKNWDKQQKSTVRQFPDTPAFREWLKQNPYELR KQAVTEDVTRPELGRILYQMIQRRGFLSSRKGKEEGKIFTGKDRMVGIDETRKNLQKQTLGAYL YDIAPKNGEKYRFRTERVRARYTLRDMYIREFEI IWQRQAGHLGLAHEQATRKKNIFLEGSATN VRNSKLITHLQAKYGRGHVLIEDTRITVTFQLPLKEVLGGKIEIEEEQLKFKSNESVLFWQRPL RSQKSLLSKCVFEGRNFYDPVHQKWI IAGPTPAPLSHPEFEEFRAYQFINNI IYGKNEHLTAIQ REAVFELMCTESKDFNFEKIPKHLKLFEKFNFDDTTKVPACTTI SQLRKLFPHPVWEEKREEIW HCFYFYDDNTLLFEKLQKDYALQTNDLEKIKKIRLSESYGNVSLKAIRRINPYLKKGYAYSTAV LLGGIRNSFGKRFEYFKEYEPEIEKAVCRILKEKNAEGEVIRKIKDYLVHNRFGFAKNDRAFQK LYHHSQAITTQAQKERLPETGNLRNPIVQQGLNELRRTVNKLLATCREKYGPSFKFDHIHVEMG RELRSSKTEREKQSRQIRENEKKNEAAKVKLAEYGLKAYRDNIQKYLLYKEIEEKGGTVCCPYT GKTLNI SHTLGSDNSVQIEHI IPYS I SLDDSLANKTLCDATFNREKGELTPYDFYQKDPSPEKW GASSWEEIEDRAFRLLPYAKAQRFIRRKPQESNEFI SRQLNDTRYI SKKAVEYLSAICSDVKAF PGQLTAELRHLWGLNNILQSAPDITFPLPVSATENHREYYVITNEQNEVIRLFPKQGETPRTEK GELLLTGEVERKVFRCKGMQEFQTDVSDGKYWRRIKLSSSVTWSPLFAPKPI SADGQIVLKGRI EKGVFVCNQLKQKLKTGLPDGSYWI SLPVI SQTFKEGESVNNSKLTSQQVQLFGRVREGIFRCH NYQCPASGADGNFWCTLDTDTAQPAFTPIKNAPPGVGGGQI ILTGDVDDKGIFHADDDLHYELP ASLPKGKYYGIFTVESCDPTLIPIELSAPKTSKGENLIEGNIWVDEHTGEVRFDPKKNREDQRH HAIDAIVIALSSQSLFQRLSTYNARRENKKRGLDSTEHFPSPWPGFAQDVRQSVVPLLVSYKQN PKTLCKI SKTLYKDGKKIHSCGNAVRGQLHKETVYGQRTAPGATEKSYHIRKDIRELKTSKHIG KVVDITIRQMLLKHLQENYHIDITQEFNIPSNAFFKEGVYRIFLPNKHGEPVPIKKIRMKEELG NAERLKD INQYVNPRNNHHVMIYQDADGNLKEEIVSFWSVIERQNQGQPIYQLPREGR IVS I LQINDTFLIGLKEEEPEVYRNDLSTLSKHLYRVQKLSGMYYTFRHHLASTLNNEREEFRIQSLE AWKRANPVKVQIDEIGRITFLNGPLC
SEQ ID NO: 336
MESSQILSPIGIDLGGKFTGVCLSHLEAFAELPNHANTKYSVILIDHNNFQLSQAQRRATRHRV RNKKRNQFVKRVALQLFQHILSRDLNAKEETALCHYLNNRGYTYVDTDLDEYIKDETTINLLKE LLPSESEHNFIDWFLQKMQSSEFRKILVSKVEEKKDDKELKNAVKNIKNFITGFEKNSVEGHRH RKVYFENIKSDITKDNQLDS IKKKIPSVCLSNLLGHLSNLQWKNLHRYLAKNPKQFDEQTFGNE FLRMLKNFRHLKGSQESLAVRNLIQQLEQSQDYI S ILEKTPPEITIPPYEARTNTGMEKDQSLL LNPEKLNNLYPNWRNLIPGI IDAHPFLEKDLEHTKLRDRKRI I SPSKQDEKRDSYILQRYLDLN KKIDKFKIKKQLSFLGQGKQLPANLIETQKEMETHFNSSLVSVLIQIASAYNKEREDAAQGIWF DNAFSLCELSNINPPRKQKILPLLVGAILSEDFINNKDKWAKFKIFWNTHKIGRTSLKSKCKEI EEARKNSGNAFKIDYEEALNHPEHSNNKALIKI IQTIPDI IQAIQSHLGHNDSQALIYHNPFSL SQLYTILETKRDGFHKNCVAVTCENYWRSQKTEIDPEI SYASRLPADSVRPFDGVLARMMQRLA YEIAMAKWEQIKHIPDNSSLLIPIYLEQNRFEFEESFKKIKGSSSDKTLEQAIEKQNIQWEEKF QRI INASM ICPYKGAS IGGQGEIDHIYPRSLSKKHFGVIFNSEVNLIYCSSQGNREKKEEHYL LEHLSPLYLKHQFGTDNVSDIKNFI SQNVA IKKYI SFHLLTPEQQKAARHALFLDYDDEAFKT ITKFLMSQQKARVNGTQKFLGKQIMEFLSTLADSKQLQLEFS IKQITAEEVHDHRELLSKQEPK LVKSRQQSFPSHAIDATLTMS IGLKEFPQFSQELDNSWFINHLMPDEVHLNPVRSKEKYNKP I SSTPLFKDSLYAERFIPVWVKGETFAIGFSEKDLFEIKPSNKEKLFTLLKTYSTKNPGESLQEL QAKSKAKWLYFPINKTLALEFLHHYFHKEIVTPDDTTVCHFINSLRYYTKKES ITVKILKEPMP VLSVKFESSKKNVLGSFKHTIALPATKDWERLFNHPNFLALKANPAPNPKEFNEFIRKYFLSDN NPNSDIPNNGHNIKPQKHKAVRKVFSLPVIPGNAGTMMRIRRKDNKGQPLYQLQTIDDTPSMGI QINEDRLVKQEVLMDAYKTRNLSTIDGINNSEGQAYATFDNWLTLPVSTFKPEI IKLEMKPHSK TRRYIRITQSLADFIKTIDEALMIKPSDS IDDPLNMPNEIVCKNKLFGNELKPRDGKMKIVSTG KIVTYEFESDSTPQWIQTLYVTQLKKQP
SEQ ID NO: 337
MKKIVGLDLGTNS IGWALINAYINKEHLYGIEACGSRI IPMDAAILGNFDKGNS I SQTADRTSY RGIRRLRERHLLRRERLHRILDLLGFLPKHYSDSLNRYGKFLNDIECKLPWVKDETGSYKFIFQ ESFKEMLANFTEHHPILIANNKKVPYDWTIYYLRKKALTQKI SKEELAWILLNFNQKRGYYQLR GEEEETPNKLVEYYSLKVEKVEDSGERKGKDTWYNVHLENGMIYRRTSNIPLDWEGKTKEFIVT TDLEADGSPKKDKEGNIKRSFRAPKDDDWTLIKKKTEADIDKIKMTVGAYIYDTLLQKPDQKIR GKLVRTIERKYYKNELYQILKTQSEFHEELRDKQLYIACLNELYPNNEPRRNS I STRDFCHLFI EDI IFYQRPLKSKKSLIDNCPYEENRYIDKESGEIKHAS IKCIAKSHPLYQEFRLWQFIVNLRI YRKETDVDVTQELLPTEADYVTLFEWLNEKKEIDQKAFFKYPPFGFKKTTSNYRWNYVEDKPYP CNETHAQI IARLGKAHIPKAFLSKEKEETLWHILYS IEDKQEIEKALHSFANKNNLSEEFIEQF KNFPPFKKEYGSYSAKAIKKLLPLMRMGKYWS IE IDNGTRIRINKI IDGEYDE IRERVRQKA INLTDITHFRALPLWLACYLVYDRHSEVKDIVKWKTPKDIDLYLKSFKQHSLRNPIVEQVITET LRTVRDIWQQVGHIDEIHIELGREMKNPADKRARMSQQMIKNENTNLRIKALLTEFLNPEFGIE NVRPYSPSQQDLLRIYEEGVLNS ILELPEDIGI ILGKFNQTDTLKRPTRSEILRYKLWLEQKYR SPYTGEMIPLSKLFTPAYEIEHI IPQSRYFDDSLSNKVICESEINKLKDRSLGYEFIKNHHGEK VELAFDKPVEVLSVEAYEKLVHESYSHNRSKMKKLLMEDIPDQFIERQLNDSRYI SKVVKSLLS IVREENEQEAI SKNVIPCTGGITDRLKKDWGINDVWNKIVLPRFIRLNELTESTRFTS INTNN TMIPSMPLELQKGFNKKRIDHRHHAMDAI I IACANR IVNYLNNVSASKNTKITRRDLQTLLCH KDKTDNNGNYKWVIDKPWETFTQDTLTALQKITVSFKQNLRVINKTTNHYQHYENGKKIVSNQS KGDSWAIRKSMHKETVHGEVNLRMIKTVSFNEALKKPQAIVEMDLKKKILAMLELGYDTKRIKN YFEENKDTWQDINPSKIKVYYFTKETKDRYFAVRKPIDTSFDKKKIKES ITDTGIQQIMLRHLE TKDNDPTLAFSPDGIDEMNRNILILNKGKKHQPIYKVRVYEKAEKFTVGQKGNKRTKFVEAAKG TNLFFAIYETEEIDKDTKKVIRKRSYSTIPLNVVIERQKQGLSSAPEDENGNLPKYILSPNDLV YVPTQEEINKGEVVMPIDRDRIYKMVDSSGITANFIPASTANLIFALPKATAEIYCNGENCIQN EYGIGSPQSKNQKAITGEMVKEICFPIKVDRLGNI IQVGSCILTN
SEQ ID NO: 338
MSRSLTFSFDIGYAS IGWAVIASASHDDADPSVCGCGTVLFPKDDCQAFKRREYRRLRR IRSR RVRIERIGRLLVQAQI ITPEMKETSGHPAPFYLASEALKGHRTLAPIELWHVLRWYAHNRGYDN NASWSNSLSEDGGNGEDTERVKHAQDLMDKHGTATMAETICRELKLEEGKADAPMEVSTPAYKN LNTAFPRLIVEKEVRRILELSAPLIPGLTAEI IELIAQHHPLTTEQRGVLLQHGIKLARRYRGS LLFGQLIPRFDNRI I SRCPVTWAQVYEAELKKGNSEQSARERAEKLSKVPTANCPEFYEYRMAR ILC IRADGEPLSAEIRRELMNQARQEGKLTKASLEKAI SSRLGKETETNVSNYFTLHPDSEEA LYLNPAVEVLQRSGIGQILSPSVYRIAANRLRRGKSVTPNYLLNLLKSRGESGEALEKKIEKES KKKEADYADTPLKPKYATGRAPYARTVLKKVVEEILDGEDPTRPARGEAHPDGELKAHDGCLYC LLDTDSSVNQHQKERRLDTMTNNHLVRHRMLILDRLLKDLIQDFADGQKDRI SRVCVEVGKELT TFSAMDSKKIQRELTLRQKSHTDAVNRLKRKLPGKALSANLIRKCRIAMDMNWTCPFTGATYGD HELENLELEHIVPHSFRQSNALSSLVLTWPGVNRMKGQRTGYDFVEQEQENPVPDKPNLHICSL NNYRELVEKLDDKKGHEDDRRRKKKRKALLMVRGLSHKHQSQNHEAMKEIGMTEGMMTQSSHLM KLACKS IKTSLPDAHIDMIPGAVTAEVRKAWDVFGVFKELCPEAADPDSGKILKENLRSLTHLH HALDACVLGLIPYI IPAHHNGLLRRVLAMRRIPEKLIPQVRPVANQRHYVLNDDGRMMLRDLSA SLKENIREQLMEQRVIQHVPADMGGALLKETMQRVLSVDGSGEDAMVSLSKKKDGKKEKNQVKA SKLVGVFPEGPSKLKALKAAIEIDGNYGVALDPKPVVIRHIKVFKRIMALKEQNGGKPVRILKK GMLIHLTSSKDPKHAGVWRIES IQDSKGGVKLDLQRAHCAVPKNKTHECNWREVDLI SLLKKYQ MKRYPTSYTGTPR
SEQ ID NO: 339
MTQKVLGLDLGTNS IGSAVRNLDLSDDLQWQLEFFSSDIFRSSVNKESNGREYSLAAQRSAHRR SRGLNEVRRRRLWATLNLLIKHGFCPMSSESLMRWCTYDKRKGLFREYPIDDKDFNAWILLDFN GDGRPDYSSPYQLRRELVTRQFDFEQPIERYKLGRALYHIAQHRGFKSSKGETLSQQETNSKPS STDEIPDVAGAMKASEEKLSKGLSTYMKEHNLLTVGAAFAQLEDEGVRVRNNNDYRAIRSQFQH EIETIFKFQQGLSVESELYERLI SEKKNVGTIFYKRPLRSQRGNVGKCTLERSKPRCAIGHPLF EKFRAWTLINNIKVRMSVDTLDEQLPMKLRLDLYNECFLAFVRTEFKFEDIRKYLEKRLGIHFS YNDKTINYKDSTSVAGCPITARFRKMLGEEWESFRVEGQKERQAHSKNNI SFHRVSYS IEDIWH FCYDAEEPEAVLAFAQETLRLERKKAEELVRIWSAMPQGYAMLSQKAIRNINKILMLGLKYSDA VILAKVPELVDVSDEELLS IAKDYYLVEAQVNYDKRINS IVNGLIAKYKSVSEEYRFADHNYEY LLDESDEKDI IRQIENSLGARRWSLMDANEQTDILQKVRDRYQDFFRSHERKFVESPKLGESFE NYLTKKFPMVEREQWKKLYHPSQITIYRPVSVGKDRSVLRLGNPDIGAIKNPTVLRVLNTLRRR VNQLLDDGVI SPDETRVVVETARELNDANRKWALDTYNRIRHDENEKIKKILEEFYPKRDGI ST DDIDKARYVIDQREVDYFTGSKTYNKDIKKYKFWLEQGGQCMYTGRTINLSNLFDPNAFDIEHT IPESLSFDSSDMNLTLCDAHYNRFIKKNHIPTDMPNYDKAITIDGKEYPAITSQLQRWVERVER LNRNVEYWKGQARRAQNKDRKDQCMREMHLWKMELEYWKKKLERFTVTEVTDGFKNSQLVDTRV ITRHAVLYLKS IFPHVDVQRGDVTAKFRKILGIQSVDEKKDRSLHSHHAIDATTLTI IPVSAKR DRMLELFAKIEEINKMLSFSGSEDRTGLIQELEGLKNKLQMEVKVCRIGHNVSEIGTFINDNII VNHHIKNQALTPVRRRLRKKGYIVGGVDNPRWQTGDALRGEIHKASYYGAITQFAKDDEGKVLM KEGRPQVNPTIKFVIRRELKYKKSAADSGFASWDDLGKAIVDKELFALMKGQFPAETSFKDACE QGIYMIKKGKNGMPDIKLHHIRHVRCEAPQSGLKIKEQTYKSEKEYKRYFYAAVGDLYAMCCYT NGKIREFRIYSLYDVSCHRKSDIEDIPEFITDKKGNRLMLDYKLRTGDMILLYKDNPAELYDLD NVNLSRRLYKINRFESQSNLVLMTHHLSTSKERGRSLGKTVDYQNLPES IRSSVKSLNFLIMGE NRDFVIKNGKI IFNHR
SEQ ID NO: 340
MLVSPI SVDLGGKNTGFFSFTDSLDNSQSGTVIYDESFVLSQVGRRSKRHSKRNNLRNKLVKRL FLLILQEHHGLS IDVLPDEIRGLFNKRGYTYAGFELDEKKKDALESDTLKEFLSEKLQS IDRDS DVEDFLNQIASNAESFKDYKKGFEAVFASATHSPNKKLELKDELKSEYGENAKELLAGLRVTKE ILDEFDKQENQGNLPRAKYFEELGEYIATNEKVKSFFDSNSLKLTDMTKLIG I SNYQLKELRR YFNDKEMEKGDIWIPNKLHKITERFVRSWHPKNDADRQRRAELMKDLKSKEIMELLTTTEPVMT IPPYDDMNNRGAVKCQTLRLNEEYLDKHLPNWRDIAKRLNHGKFNDDLADSTVKGYSEDSTLLH RLLDTSKEIDIYELRGKKPNELLVKTLGQSDANRLYGFAQNYYELIRQKVRAGIWVPVKNKDDS LNLEDNSNMLKRCNHNPPHKKNQIHNLVAGILGVKLDEAKFAEFEKELWSAKVGNKKLSAYCKN IEELRKTHGNTFKIDIEELRKKDPAELSKEEKAKLRLTDDVILNEWSQKIANFFDIDDKHRQRF NNLFSMAQLHTVIDTPRSGFSSTCKRCTAENRFRSETAFYNDETGEFHKKATATCQRLPADTQR PFSGKIERYIDKLGYELAKIKAKELEGMEAKEIKVPI ILEQNAFEYEESLRKSKTGSNDRVINS KKDRDGKKLAKAKENAEDRLKDKDKRIKAFSSGICPYCGDTIGDDGEIDHILPRSHTLKIYGTV FNPEGNLIYVHQKCNQAKADS IYKLSDIKAGVSAQWIEEQVANIKGYKTFSVLSAEQQKAFRYA LFLQNDNEAYKKVVDWLRTDQSARVNGTQKYLAKKIQEKLTKMLPNKHLSFEFILADATEVSEL RRQYARQNPLLAKAEKQAPSSHAIDAVMAFVARYQKVFKDGTPPNADEVAKLAMLDSWNPASNE PLTKGLSTNQKIEKMIKSGDYGQKNMREVFGKS IFGENAIGERYKPIVVQEGGYYIGYPATVKK GYELKNCKVVTSKNDIAKLEKI IKNQDLI SLKENQYIKIFS INKQTI SELSNRYFNMNYKNLVE RDKEIVGLLEFIVENCRYYTKKVDVKFAPKYIHETKYPFYDDWRRFDEAWRYLQENQNKTSSKD RFVIDKSSLNEYYQPDKNEYKLDVDTQPIWDDFCRWYFLDRYKTANDKKS IRIKARKTFSLLAE SGVQGKVFRAKRKIPTGYAYQALPMDNNVIAGDYANILLEANSKTLSLVPKSGI S IEKQLDKKL DVIKKTDVRGLAIDNNSFFNADFDTHGIRLIVENTSVKVGNFPI SAIDKSAKRMIFRALFEKEK GKRKKKTTI SFKESGPVQDYLKVFLKKIVKIQLRTDGS I S IVVRKNAADFTLSFRSEHIQKLL K
SEQ ID NO: 341
MAYRLGLDIGITSVGWAVVALEKDESGLKPVRIQDLGVRIFDKAEDSKTGASLALPRREARSAR RRTRRRRHRLWRVKRLLEQHGILSMEQIEALYAQRTSSPDVYALRVAGLDRCLIAEEIARVLIH IAHRRGFQSNRKSEIKDSDAGKLLKAVQENENLMQSKGYRTVAEMLVSEATKTDAEGKLVHGKK HGYVSNVRNKAGEYRHTVSRQAIVDEVRKIFAAQRALGNDVMSEELEDSYLKILCSQRNFDDGP GGDSPYGHGSVSPDGVRQS IYERMVGSCTFETGEKRAPRSSYSFERFQLLTKVVNLRIYRQQED GGRYPCELTQTERARVIDCAYEQTKITYGKLRKLLDMKDTESFAGLTYGLNRSRNKTEDTVFVE MKFYHEVRKALQRAGVFIQDLS IETLDQIGWILSVWKSDDNRRKKLSTLGLSDNVIEELLPLNG SKFGHLSLKAIRKILPFLEDGYSYDVACELAGYQFQGKTEYVKQRLLPPLGEGEVTNPVVRRAL SQAIKVVNAVIRKHGSPES IHIELARELSKNLDERRKIEKAQKENQKNNEQIKDEIREILGSAH VTGRDIVKYKLFKQQQEFCMYSGEKLDVTRLFEPGYAEVDHI IPYGI SFDDSYDNKVLVKTEQN RQKGNRTPLEYLRDKPEQKAKFIALVES IPLSQKKKNHLLMDKRAIDLEQEGFRERNLSDTRYI TRALMNHIQAWLLFDETASTRSKRVVCVNGAVTAYMRARWGLTKDRDAGDKHHAADAVVVACIG DSLIQRVTKYDKFKRNALADRNRYVQQVSKSEGITQYVDKETGEVFTWESFDERKFLPNEPLEP WPFFRDELLARLSDDPSKNIRAIGLLTYSETEQIDPIFVSRMPTRKVTGAAHKETIRSPRIVKV DDNKGTEIQVVVSKVALTELKLTKDGEIKDYFRPEDDPRLYNTLRERLVQFGGDAKAAFKEPVY KI SKDGSVRTPVRKVKIQEKLTLGVPVHGGRGIAENGGMVRIDVFAKGGKYYFVPIYVADVLKR ELPNRLATAHKPYSEWRVVDDSYQFKFSLYPNDAVMIKPSREVDITYKDRKEPVGCRIMYFVSA NIASAS I SLRTHDNSGELEGLGIQGLEVFEKYVVGPLGDTHPVYKERRMPFRVERKMN
SEQ ID NO: 342
MPVLSPLSPNAAQGRRRWSLALDIGEGS IGWAVAEVDAEGRVLQLTGTGVTLFPSAWSNENGTY VAHGAADRAVRGQQQRHDSRRRRLAGLARLCAPVLERSPEDLKDLTRTPPKADPRAIFFLRADA ARRPLDGPELFRVLHHMAAHRGIRLAELQEVDPPPESDADDAAPAATEDEDGTRRAAADERAFR RLMAEHMHRHGTQPTCGEIMAGRLRETPAGAQPVTRARDGLRVGGGVAVPTRALIEQEFDAIRA IQAPRHPDLPWDSLRRLVLDQAPIAVPPATPCLFLEELRRRGETFQGRTITREAIDRGLTVDPL IQALRIRETVGNLRLHERITEPDGRQRYVPRAMPELGLSHGELTAPERDTLVRALMHDPDGLAA KDGRIPYTRLRKLIGYDNSPVCFAQERDTSGGGITVNPTDPLMARWIDGWVDLPLKARSLYVRD VVARGADSAALARLLAEGAHGVPPVAAAAVPAATAAILESDIMQPGRYSVCPWAAEAILDAWAN APTEGFYDVTRGLFGFAPGEIVLEDLRRARGALLAHLPRTMAAARTPNRAAQQRGPLPAYESVI PSQLITSLRRAHKGRAADWSAADPEERNPFLRTWTGNAATDHILNQVRKTANEVITKYGNRRGW DPLPSRITVELAREAKHGVIRRNEIAKENRENEGRRKKESAALDTFCQDNTVSWQAGGLPKERA ALRLRLAQRQEFFCPYCAERPKLRATDLFSPAETEIDHVIERRMGGDGPDNLVLAHKDCNNAKG KKTPHEHAGDLLDSPALAALWQGWRKENADRLKGKGHKARTPREDKDFMDRVGWRFEEDARAKA EENQERRGRRMLHDTARATRLARLYLAAAVMPEDPAEIGAPPVETPPSPEDPTGYTAIYRTI SR VQPVNGSVTHMLRQRLLQRDKNRDYQTHHAEDACLLLLAGPAVVQAFNTEAAQHGADAPDDRPV DLMPTSDAYHQQRRARALGRVPLATVDAALADIVMPESDRQDPETGRVHWRLTRAGRGLKRRID DLTRNCVILSRPRRPSETGTPGALHNATHYGRREITVDGRTDTVVTQRMNARDLVALLDNAKIV PAARLDAAAPGDTILKEICTEIADRHDRVVDPEGTHARRWI SARLAALVPAHAEAVARDIAELA DLDALADADRTPEQEARRSALRQSPYLGRAI SAKKADGRARAREQEILTRALLDPHWGPRGLRH LIMREARAPSLVRIRANKTDAFGRPVPDAAVWVKTDGNAVSQLWRLTSVVTDDGRRIPLPKPIE KRIEI SNLEYARLNGLDEGAGVTGNNAPPRPLRQDIDRLTPLWRDHGTAPGGYLGTAVGELEDK ARSALRGKAMRQTLTDAGITAEAGWRLDSEGAVCDLEVAKGDTVKKDGKTYKVGVITQGIFGMP VDAAGSAPRTPEDCEKFEEQYGIKPWKAKGIPLA
SEQ ID NO: 343
MNYTEKEKLFMKYILALDIGIASVGWAILDKESETVIEAGSNIFPEASAADNQLRRDMRGAKRN NRRLKTRINDFIKLWENNNLSIPQFKSTEIVGLKVRAITEEITLDELYLILYSYLKHRGISYLE DALDDTVSGSSAYANGLKLNAKELETHYPCEIQQERLNTIGKYRGQSQI INENGEVLDLSNVFT IGAYRKEIQRVFEIQKKYHPELTDEFCDGYMLIFNRKRKYYEGPGNEKSRTDYGRFTTKLDANG NYITEDNIFEKLIGKCSVYPDELRAAAASYTAQEYNVLNDLNNLTINGRKLEENEKHEIVERIK SSNTINMRKI I SDCMGENIDDFAGARIDKSGKEIFHKFEVYNKMRKALLEIGIDI SNYSREELD EIGYIMTINTDKEAMMEAFQKSWIDLSDDVKQCLINMRKTNGALFNKWQSFSLKIMNELIPEMY AQPKEQMTLLTEMGVTKGTQEEFAGLKYIPVDVVSEDIFNPVVRRSVRI SFKILNAVLKKYKAL DTIVIEMPRDRNSEEQKKRINDSQKLNEKEMEYIEKKLAVTYGIKLSPSDFSSQKQLSLKLKLW NEQDGICLYSGKTIDPNDI INNPQLFEIDHI IPRS I SFDDARSNKVLVYRSENQKKGNQTPYYY LTHSHSEWSFEQYKATVMNLSKKKEYAI SRKKIQNLLYSEDITKMDVLKGFINR INDTSYASR LVLNTIQNFFMANEADTKVKVIKGSYTHQMRCNLKLDKNRDESYSHHAVDAMLIGYSELGYEAY HKLQGEFIDFETGEILRKDMWDENMSDEVYADYLYGKKWANIRNEVVKAEKNVKYWHYVMRKSN RGLCNQTIRGTREYDGKQYKINKLDIRTKEGIKVFAKLAFSKKDSDRERLLVYLNDRRTFDDLC KIYEDYSDAANPFVQYEKETGDI IRKYSKKHNGPRIDKLKYKDGEVGACIDI SHKYGFEKGSKK VILESLVPYRMDVYYKEENHSYYLVGVKQSDIKFEKGRNVIDEEAYARILVNEKMIQPGQSRAD LENLGFKFKLSFYKNDI IEYEKDGKIYTERLVSRTMPKQRNYIETKPIDKAKFEKQNLVGLGKT KFIKKYRYDILGNKYSCSEEKFTSFC
SEQ ID NO: 344
MLRLYCANNLVLNNVQNLWKYLLLLIFDKKI IFLFKIKVILIRRYMENNNKEKIVIGFDLGVAS VGWS IVNAETKEVIDLGVRLFSEPEKADYRRAKRTTRRLLRRKKFKREKFHKLILKNAEIFGLQ SRNEILNVYKDQSSKYRNILKLKINALKEEIKPSELVWILRDYLQNRGYFYKNEKLTDEFVSNS FPSKKLHEHYEKYGFFRGSVKLDNKLDNKKDKAKEKDEEEESDAKKESEELIFSNKQWINEIVK VFENQSYLTESFKEEYLKLFNYVRPFNKGPGSKNSRTAYGVFSTDIDPETNKFKDYSNIWDKTI GKCSLFEEEIRAPKNLPSALIFNLQNEICTIKNEFTEFKNWWLNAEQKSEILKFVFTELFNWKD KKYSDKKFNKNLQDKIKKYLLNFALENFNLNEEILKNRDLENDTVLGLKGVKYYEKSNATADAA LEFSSLKPLYVFIKFLKEKKLDLNYLLGLENTEILYFLDS IYLAI SYSSDLKERNEWFKKLLKE LYPKIKNNNLEI IENVEDIFEITDQEKFESFSKTHSLSREAFNHI IPLLLSNNEGKNYESLKHS NEELKKRTEKAELKAQQNQKYLKDNFLKEALVPLSVKTSVLQAIKIFNQI IKNFGKKYEI SQVV IEMARELTKPNLEKLLNNATNSNIKILKEKLDQTEKFDDFTKKKFIDKIENSVVFRNKLFLWFE QDRKDPYTQLDIKINEIEDETEIDHVIPYSKSADDSWFNKLLVKKSTNQLKKNKTVWEYYQNES DPEAKWNKFVAWAKRIYLVQKSDKESKDNSEKNS IFKNKKPNLKFK ITKKLFDPYKDLGFLAR NLNDTRYATKVFRDQLNNYSKHHSKDDENKLFKVVCMNGS ITSFLRKSMWRKNEEQVYRFNFWK KDRDQFFHHAVDAS I IAIFSLLTKTLYNKLRVYESYDVQRREDGVYLINKETGEVKKADKDYWK DQHNFLKIRENAIEIKNVLNNVDFQNQVRYSRKANTKLNTQLFNETLYGVKEFENNFYKLEKVN LFSRKDLRKFILEDLNEESEKNKKNENGSRKRILTEKYIVDEILQILENEEFKDSKSDINALNK YMDSLPSKFSEFFSQDFINKCKKENSLILTFDAIKHNDPKKVIKIKNLKFFREDATLKNKQAVH KDSKNQIKSFYESYKCVGFIWLKNKNDLEES IFVPINSRVIHFGDKDKDIFDFDSYNKEKLLNE INLKRPENKKFNS INEIEFVKFVKPGALLLNFENQQIYYI STLESSSLRAKIKLLNKMDKGKAV SMKKITNPDEYKI IEHVNPLGINLNWTKKLENNN
SEQ ID NO: 345
MLMSKHVLGLDLGVGS IGWCLIALDAQGDPAEILGMGSRVVPLNNATKAIEAFNAGAAFTASQE RTARRTMRRGFARYQLRRYRLRRELEKVGMLPDAALIQLPLLELWELRERAATAGRRLTLPELG RVLCHINQKRGYRHVKSDAAAIVGDEGEKKKDSNSAYLAGIRANDEKLQAEHKTVGQYFAEQLR QNQSESPTGGI SYRIKDQIFSRQCYIDEYDQIMAVQRVHYPDILTDEFIRMLRDEVIFMQRPLK SCKHLVSLCEFEKQERVMRVQQDDGKGGWQLVERRVKFGPKVAPKSSPLFQLCCIYEAVNNIRL TRPNGSPCDITPEERAKIVAHLQSSASLSFAALKKLLKEKALIADQLTSKSGLKGNSTRVALAS ALQPYPQYHHLLDMELETRMMTVQLTDEETGEVTEREVAVVTDSYVRKPLYRLWHILYS IEERE AMRRALITQLGMKEEDLDGGLLDQLYRLDFVKPGYGNKSAKFICKLLPQLQQGLGYSEACAAVG YRHSNSPTSEEITERTLLEKIPLLQRNELRQPLVEKILNQMINLVNALKAEYGIDEVRVELARE LKMSREERERMARNNKDREERNKGVAAKIRECGLYPTKPRIQKYMLWKEAGRQCLYCGRS IEEE QCLREGGMEVEHI IPKSVLYDDSYGNKTCACRRCNKEKGNRTALEYIRAKGREAEYMKRINDLL KEKKI SYSKHQRLRWLKEDIPSDFLERQLRLTQYI SRQAMAILQQGIRRVSASEGGVTARLRSL WGYGKILHTLNLDRYDSMGETERVSREGEATEELHITNWSKRMDHRHHAIDALVVACTRQSYIQ RLNRLSSEFGREDKKKEDQEAQEQQATETGRLSNLERWLTQRPHFSVRTVSDKVAEILI SYRPG QRVVTRGRNIYRKKMADGREVSCVQRGVLVPRGELMEASFYGKILSQGRVRIVKRYPLHDLKGE VVDPHLRELITTYNQELKSREKGAPIPPLCLDKDKKQEVRSVRCYAKTLSLDKAIPMCFDEKGE PTAFVKSASNHHLALYRTPKGKLVES IVTFWDAVDRARYGIPLVITHPREVMEQVLQRGDIPEQ VLSLLPPSDWVFVDSLQQDEMVVIGLSDEELQRALEAQNYRKI SEHLYRVQKMSSSYYVFRYHL ETSVADDKNTSGRIPKFHRVQSLKAYEERNIRKVRVDLLGRISLL
SEQ ID NO: 346
MSDLVLGLDIGIGSVGVGILNKVTGEI IHKNSRIFPAAQAENNLVRRTNRQGRRLARRKKHRRV RLNRLFEESGLITDFTKI S INLNPYQLRVKGLTDELSNEELFIALKNMVKHRGI SYLDDASDDG NSSVGDYAQIVKENSKQLETKTPGQIQLERYQTYGQLRGDFTVEKDGKKHRLINVFPTSAYRSE ALRILQTQQEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGRYRTSGETLDNIFGILI GKCTFYPDEFRAAKASYTAQEFNLLNDLNNLTVPTETKKLSKEQKNQI INYVKNEKAMGPAKLF KYIAKLLSCDVADIKGYRIDKSGKAEIHTFEAYRKMKTLETLDIEQMDRETLDKLAYVLTLNTE REGIQEALEHEFADGSFSQKQVDELVQFRKANSS IFGKGWHNFSVKLMMELIPELYETSEEQMT ILTRLGKQKTTSSSNKTKYIDEKLLTEEIYNPVVAKSVRQAIKIVNAAIKEYGDFDNIVIEMAR ETNEDDEKKAIQKIQKANKDEKDAAMLKAANQYNGKAELPHSVFHGHKQLATKIRLWHQQGERC LYTGKTI S IHDLINNSNQFEVDHILPLS ITFDDSLANKVLVYATANQEKGQRTPYQALDSMDDA WSFRELKAFVRESKTLSNKKKEYLLTEEDI SKFDVRKKFIERNLVDTRYASRVVLNALQEHFRA HKIDTKVSVVRGQFTSQLRRHWGIEKTRDTYHHHAVDALI IAASSQLNLWKKQKNTLVSYSEDQ LLDIETGELI SDDEYKESVFKAPYQHFVDTLKSKEFEDS ILFSYQVDSKFNRKI SDATIYATRQ AKVGKDKADETYVLGKIKDIYTQDGYDAFMKIYKKDKSKFLMYRHDPQTFEKVIEPILENYPNK QINEKGKEVPCNPFLKYKEEHGYIRKYSKKGNGPEIKSLKYYDSKLGNHIDITPKDSNNKVVLQ SVSPWRADVYFNKTTGKYEILGLKYADLQFEKGTGTYKI SQEKYNDIKKKEGVDSDSEFKFTLY KNDLLLVKDTETKEQQLFRFLSRTMPKQKHYVELKPYDKQKFEGGEALIKVLGNVANSGQCKKG LGKSNI S IYKVRTDVLGNQHI IKNEGDKPKLDF
SEQ ID NO: 347
MNAEHGKEGLLIMEENFQYRIGLDIGITSVGWAVLQNNSQDEPVRITDLGVRIFDVAENPKNGD ALAAPRRDARTTRRRLRRRRHRLERIKFLLQENGLIEMDSFMERYYKGNLPDVYQLRYEGLDRK LKDEELAQVLIHIAKHRGFRSTRKAETKEKEGGAVLKATTENQKIMQEKGYRTVGEMLYLDEAF HTECLWNEKGYVLTPRNRPDDYKHTILRSMLVEEVHAIFAAQRAHGNQKATEGLEEAYVEIMTS QRSFDMGPGLQPDGKPSPYAMEGFGDRVGKCTFEKDEYRAPKATYTAELFVALQKINHTKLIDE FGTGRFFSEEERKTI IGLLLSSKELKYGTIRKKLNIDPSLKFNSLNYSAKKEGETEEERVLDTE KAKFASMFWTYEYSKCLKDRTEEMPVGEKADLFDRIGEILTAYKNDDSRSSRLKELGLSGEEID GLLDLSPAKYQRVSLKAMRKMQPYLEDGLIYDKACEAAGYDFRALNDGNKKHLLKGEEINAIVN DITNPVVKRSVSQTIKVINAI IQKYGSPQAVNIELAREMSKNFQDRTNLEKEMKKRQQENERAK QQI IELGKQNPTGQDILKYRLWNDQGGYCLYSGKKIPLEELFDGGYDIDHILPYS ITFDDSYRN KVLVTAQENRQKGNRTPYEYFGADEKRWEDYEASVRLLVRDYKKQQKLLKKNFTEEERKEFKER NLNDTKYITRVVYNMIRQNLELEPFNHPEKKKQVWAVNGAVTSYLRKRWGLMQKDRSTDRHHAM DAVVIACCTDGMIHKI SRYMQGRELAYSRNFKFPDEETGEILNRDNFTREQWDEKFGVKVPLPW NSFRDELDIRLLNEDPKNFLLTHADVQRELDYPGWMYGEEESPIEEGRYINYIRPLFVSRMPNH KVTGSAHDATIRSARDYETRGVVITKVPLTDLKLNKDNEIEGYYDKDSDRLLYQALVRQLLLHG NDGKKAFAEDFHKPKADGTEGPVVRKVKIEKKQTSGVMVRGGTGIAANGEMVRIDVFRENGKYY FVPVYTADVVRKVLPNRAATHTKPYSEWRVMDDANFVFSLYSRDLIHVKSKKDIKTNLVNGGLL LQKEIFAYYTGADIATAS IAGFANDSNFKFRGLGIQSLEIFEKCQVDILGNI SVVRHENRQEFH
SEQ ID NO: 348
MRVLGLDAGIASLGWALIEIEESNRGELSQGTI IGAGTWMFDAPEEKTQAGAKLKSEQRRTFRG QRRVVRRRRQRMNEVRRILHSHGLLPSSDRDALKQPGLDPWRIRAEALDRLLGPVELAVALGHI ARHRGFKSNSKGAKTNDPADDTSKMKRAVNETREKLARFGSAAKMLVEDESFVLRQTPTKNGAS EIVRRFRNREGDYSRSLLRDDLAAEMRALFTAQARFQSAIATADLQTAFTKAAFFQRPLQDSEK LVGPCPFEVDEKRAPKRGYSFELFRFLSRLNHVTLRDGKQERTLTRDELALAAADFGAAAKVSF TALRKKLKLPETTVFVGVKADEESKLDVVARSGKAAEGTARLRSVIVDALGELAWGALLCSPEK LDKIAEVI SFRSDIGRI SEGLAQAGCNAPLVDALTAAASDGRFDPFTGAGHI SSKAARNILSGL RQGMTYDKACCAADYDHTASRERGAFDVGGHGREALKRILQEERI SRELVGSPTARKALIES IK QVKAIVERYGVPDRIHVELARDVGKS IEEREEITRGIEKRNRQKDKLRGLFEKEVGRPPQDGAR GKEELLRFELWSEQMGRCLYTDDYI SPSQLVATDDAVQVDHILPWSRFADDSYANKTLCMAKAN QDKKGRTPYEWFKAEKTDTEWDAFIVRVEALADMKGFKKRNYKLRNAEEAAAKFRNRNLNDTRW ACRLLAEALKQLYPKGEKDKDGKERRRVFSRPGALTDRLRRAWGLQWMKKSTKGDRIPDDRHHA LDAIVIAATTESLLQRATREVQEIEDKGLHYDLVKNVTPPWPGFREQAVEAVEKVFVARAERRR ARGKAHDATIRHIAVREGEQRVYERRKVAELKLADLDRVKDAERNARLIEKLRNWIEAGSPKDD PPLSPKGDPIFKVRLVTKSKVNIALDTGNPKRPGTVDRGEMARVDVFRKASKKGKYEYYLVPIY PHDIATMKTPPIRAVQAYKPEDEWPEMDSSYEFCWSLVPMTYLQVI SSKGEIFEGYYRGMNRSV GAIQLSAHSNSSDVVQGIGARTLTEFKKFNVDRFGRKHEVERELRTWRGETWRGKAYI
SEQ ID NO: 349
MGNYYLGLDVGIGS IGWAVINIEKKRIEDFNVRIFKSGEIQEKNRNSRASQQCRRSRGLRRLYR RKSHRKLRLKNYLS I IGLTTSEKIDYYYETADNNVIQLRNKGLSEKLTPEEIAACLIHICNNRG YKDFYEVNVEDIEDPDERNEYKEEHDS IVLI SNLMNEGGYCTPAEMICNCREFDEPNSVYRKFH NSAASKNHYLITRHMLVKEVDLILENQSKYYGILDDKTIAKIKDI IFAQRDFEIGPGKNERFRR FTGYLDS IGKCQFFKDQERGSRFTVIADIYAFVNVLSQYTYTNNRGESVFDTSFANDLINSALK NGSMDKRELKAIAKSYHIDI SDKNSDTSLTKCFKYIKVVKPLFEKYGYDWDKLIENYTDTDNNV LNRIGIVLSQAQTPKRRREKLKALNIGLDDGLINELTKLKLSGTANVSYKYMQGS IEAFCEGDL YGKYQAKFNKEIPDIDENAKPQKLPPFKNEDDCEFFKNPVVFRS INETRKLINAI IDKYGYPAA VNIETADELNKTFEDRAIDTKRNNDNQKENDRIVKEI IECIKCDEVHARHLIEKYKLWEAQEGK CLYSGETITKEDMLRDKDKLFEVDHIVPYSLILDNTINNKALVYAEENQKKGQRTPLMYMNEAQ AADYRVRVNTMFKSKKCSKKKYQYLMLPDLNDQELLGGWRSRNLNDTRYICKYLVNYLRKNLRF DRSYESSDEDDLKIRDHYRVFPVKSRFTSMFRRWWLNEKTWGRYDKAELKKLTYLDHAADAI I I ANCRPEYVVLAGEKLKLNKMYHQAGKRITPEYEQSKKACIDNLYKLFRMDRRTAEKLLSGHGRL TPI IPNLSEEVDKRLWDKNIYEQFWKDDKDKKSCEELYRENVASLYKGDPKFASSLSMPVI SLK PDHKYRGTITGEEAIRVKEIDGKLIKLKRKSISEITAESINSIYTDDKILIDSLKTIFEQADYK DVGDYLKKTNQHFFTTSSGKRVNKVTVIEKVPSRWLRKEIDDNNFSLLNDSSYYCIELYKDSKG DNNLQGIAMSDIVHDRKTKKLYLKPDFNYPDDYYTHVMYIFPGDYLRIKSTSKKSGEQLKFEGY FI SVKNVNENSFRFI SDNKPCAKDKRVS ITKKDIVIKLAVDLMGKVQGENNGKGI SCGEPLSLL KEKN
SEQ ID NO: 350
MLSRQLLGASHLARPVSYSYNVQDNDVHCSYGERCFMRGKRYRIGIDVGLNSVGLAAVEVSDEN SPVRLLNAQSVIHDGGVDPQKNKEAITRKNMSGVARRTRRMRRRKRERLHKLDMLLGKFGYPVI EPESLDKPFEEWHVRAELATRYIEDDELRRES I S IALRHMARHRGWRNPYRQVDSLI SDNPYSK QYGELKEKAKAYNDDATAAEEESTPAQLVVAMLDAGYAEAPRLRWRTGSKKPDAEGYLPVRLMQ EDNANELKQIFRVQRVPADEWKPLFRSVFYAVSPKGSAEQRVGQDPLAPEQARALKASLAFQEY RIANVITNLRIKDASAELRKLTVDEKQS IYDQLVSPSSEDITWSDLCDFLGFKRSQLKGVGSLT EDGEERI SSRPPRLTSVQRIYESDNKIRKPLVAWWKSASDNEHEAMIRLLSNTVDIDKVREDVA YASAIEFIDGLDDDALTKLDSVDLPSGRAAYSVETLQKLTRQMLTTDDDLHEARKTLFNVTDSW RPPADPIGEPLGNPSVDRVLKNVNRYLMNCQQRWGNPVSVNIEHVRSSFSSVAFARKDKREYEK NNEKRS IFRSSLSEQLRADEQMEKVRESDLRRLEAIQRQNGQCLYCGRTITFRTCEMDHIVPRK GVGSTNTRTNFAAVCAECNRMKSNTPFAIWARSEDAQTRGVSLAEAKKRVTMFTFNPKSYAPRE VKAFKQAVIARLQQTEDDAAIDNRS IESVAWMADELHRRIDWYFNAKQYVNSAS IDDAEAETMK TTVSVFQGRVTASARRAAGIEGKIHFIGQQSKTRLDRRHHAVDASVIAMMNTAAAQTLMERESL RESQRLIGLMPGERSWKEYPYEGTSRYESFHLWLDNMDVLLELLNDALDNDRIAVMQSQRYVLG NSIAHDATIHPLEKVPLGSAMSADLIRRASTPALWCALTRLPDYDEKEGLPEDSHREIRVHDTR YSADDEMGFFASQAAQIAVQEGSADIGSAIHHARVYRCWKTNAKGVRKYFYGMIRVFQTDLLRA CHDDLFTVPLPPQS I SMRYGEPRVVQALQSGNAQYLGSLVVGDEIEMDFSSLDVDGQIGEYLQF FSQFSGGNLAWKHWVVDGFFNQTQLRIRPRYLAAEGLAKAFSDDVVPDGVQKIVTKQGWLPPVN TASKTAVRIVRRNAFGEPRLSSAHHMPCSWQWRHE
SEQ ID NO: 351
MYS IGLDLGI SSVGWSVIDERTGNVIDLGVRLFSAKNSEKNLERRTNRGGRRLIRRKTNRLKDA KKILAAVGFYEDKSLKNSCPYQLRVKGLTEPLSRGEIYKVTLHILKKRGI SYLDEVDTEAAKES QDYKEQVRKNAQLLTKYTPGQIQLQRLKENNRVKTGINAQGNYQLNVFKVSAYANELATILKTQ QAFYPNELTDDWIALFVQPGIAEEAGLIYRKRPYYHGPGNEANNSPYGRWSDFQKTGEPAT IF DKLIGKDFQGELRASGLSLSAQQYNLLNDLTNLKIDGEVPLSSEQKEYILTELMTKEFTRFGVN DVVKLLGVKKERLSGWRLDKKGKPEIHTLKGYRNWRKIFAEAGIDLATLPTETIDCLAKVLTLN TEREGIENTLAFELPELSESVKLLVLDRYKELSQS I STQSWHRFSLKTLHLLIPELMNATSEQN TLLEQFQLKSDVRKRYSEYKKLPTKDVLAEIYNPTVNKTVSQAFKVIDALLVKYGKEQIRYITI EMPRDDNEEDEKKRIKELHAKNSQRKNDSQSYFMQKSGWSQEKFQTTIQKNRRFLAKLLYYYEQ DGICAYTGLPI SPELLVSDSTEIDHI IPI S I SLDDS INNKVLVLSKANQVKGQQTPYDAWMDGS FKKINGKFSNWDDYQKWVESRHFSHKKENNLLETRNIFDSEQVEKFLARNLNDTRYASRLVLNT LQSFFTNQETKVRVVNGSFTHTLRKKWGADLDKTRETHHHHAVDATLCAVTSFVKVSRYHYAVK EETGEKVMREIDFETGEIVNEMSYWEFKKSKKYERKTYQVKWPNFREQLKPVNLHPRIKFSHQV DRKANRKLSDATIYSVREKTEVKTLKSGKQKITTDEYTIGKIKDIYTLDGWEAFKKKQDKLLMK DLDEKTYERLLS IAETTPDFQEVEEKNGKVKRVKRSPFAVYCEENDIPAIQKYAKKNNGPLIRS LKYYDGKLNKHI ITKDSQGRPVEKTKNGRKVTLQSLKPYRYDIYQDLETKAYYTVQLYYSDLR FVEGKYGITEKEYMKKVAEQTKGQVVRFCFSLQKNDGLEIEWKDSQRYDVRFYNFQSANS INFK GLEQEMMPAENQFKQKPYNNGAINLNIAKYGKEGKKLRKFNTDILGKKHYLFYEKEPKNIIK
SEQ ID NO: 352
MYFYKNKENKLNKKVVLGLDLGIASVGWCLTDI SQKEDNKFPI ILHGVRLFETVDDSDDKLLNE TRRKKRGQRRRNRRLFTRKRDFIKYLIDNNI IELEFDKNPKILVRNFIEKYINPFSKNLELKYK SVTNLPIGFHNLRKAAINEKYKLDKSELIVLLYFYLSLRGAFFDNPEDTKSKEMNKNEIEIFDK NES IKNAEFPIDKI IEFYKI SGKIRSTINLKFGHQDYLKEIKQVFEKQNIDFMNYEKFAMEEKS FFSRIRNYSEGPGNEKSFSKYGLYANENGNPELI INEKGQKIYTKIFKTLWESKIGKCSYDKKL YRAPKNSFSAKVFDITNKLTDWKHKNEYI SERLKRKILLSRFLNKDSKSAVEKILKEENIKFEN LSEIAYNKDDNKINLPI INAYHSLTTIFKKHLINFENYLI SNENDLSKLMSFYKQQSEKLFVPN EKGSYEINQNNNVLHIFDAISNILNKFSTIQDRIRILEGYFEFSNLKKDVKSSEIYSEIAKLRE FSGTSSLSFGAYYKFIPNLISEGSKNYSTISYEEKALQNQKNNFSHSNLFEKTWVEDLIASPTV KRSLRQTMNLLKEIFKYSEKNNLEIEKIVVEVTRSSNNKHERKKIEGINKYRKEKYEELKKVYD LPNENTTLLKKLWLLRQQQGYDAYSLRKIEANDVINKPWNYDIDHIVPRS I SFDDSFSNLVIVN KLDNAKKSNDLSAKQFIEKIYGIEKLKEAKENWGNWYLRNANGKAFNDKGKFIKLYTIDNLDEF DNSDFINRNLSDTSYITNALVNHLTFSNSKYKYSVVSVNGKQTSNLRNQIAFVGIKNNKETERE WKRPEGFKSINSNDFLIREEGKNDVKDDVLIKDRSFNGHHAEDAYFITI ISQYFRSFKRIERLN VNYRKETRELDDLEKNNIKFKEKASFDNFLLINALDELNEKLNQMRFSRMVITKKNTQLFNETL YSGKYDKGKNTIKKVEKLNLLDNRTDKIKKIEEFFDEDKLKENELTKLHIFNHDKNLYETLKII WNEVKIEIKNKNLNEKNYFKYFVNKKLQEGKI SFNEWVPILDNDFKI IRKIRYIKFSSEEKETD EI IFSQSNFLKIDQRQNFSFHNTLYWVQIWVYKNQKDQYCFI S IDARNSKFEKDEIKINYEKLK TQKEKLQI INEEPILKINKGDLFENEEKELFYIVGRDEKPQKLEIKYILGKKIKDQKQIQKPVK KYFPNWKKVNLTYMGEIFKK
SEQ ID NO: 353
MDNKNYRIGIDVGLNS IGFCAVEVDQHDTPLGFLNLSVYRHDAGIDPNGKKTNTTRLAMSGVAR RTRRLFRKRKRRLAALDRFIEAQGWTLPDHADYKDPYTPWLVRAELAQTPIRDENDLHEKLAIA VRHIARHRGWRSPWVPVRSLHVEQPPSDQYLALKERVEAKTLLQMPEGATPAEMVVALDLSVDV NLRPKNREKTDTRPENKKPGFLGGKLMQSDNANELRKIAKIQGLDDALLRELIELVFAADSPKG ASGELVGYDVLPGQHGKRRAEKAHPAFQRYRIAS IVSNLRIRHLGSGADERLDVETQKRVFEYL LNAKPTADITWSDVAEEIGVERNLLMGTATQTADGERASAKPPVDVTNVAFATCKIKPLKEWWL NADYEARCVMVSALSHAEKLTEGTAAEVEVAEFLQNLSDEDNEKLDSFSLPIGRAAYSVDSLER LTKRMIENGEDLFEARVNEFGVSEDWRPPAEPIGARVGNPAVDRVLKAVNRYLMAAEAEWGAPL SV IEHVREGFI SKRQAVEIDRENQKRYQRNQAVRSQIADHINATSGVRGSDVTRYLAIQRQNG ECLYCGTAITFVNSEMDHIVPRAGLGSTNTRDNLVATCERCNKSKSNKPFAVWAAECGIPGVSV AEALKRVDFWIADGFASSKEHRELQKGVKDRLKRKVSDPEIDNRSMESVAWMARELAHRVQYYF DEKHTGTKVRVFRGSLTSAARKASGFESRVNFIGGNGKTRLDRRHHAMDAATVAMLRNSVAKTL VLRGNIRASERAIGAAETWKSFRGENVADRQIFESWSENMRVLVEKFNLALYNDEVS IFSSLRL QLGNGKAHDDTITKLQMHKVGDAWSLTEIDRASTPALWCALTRQPDFTWKDGLPANEDRTIIVN GTHYGPLDKVGIFGKAAASLLVRGGSVDIGSAIHHARIYRIAGKKPTYGMVRVFAPDLLRYRNE DLFNVELPPQSVSMRYAEPKVREAIREGKAEYLGWLVVGDELLLDLSSETSGQIAELQQDFPGT THWTVAGFFSPSRLRLRPVYLAQEGLGEDVSEGSKS I IAGQGWRPAVNKVFGSAMPEVIRRDGL GRKRRFSYSGLPVSWQG
SEQ ID NO: 354
MRLGLDIGTSS IGWWLYETDGAGSDARITGVVDGGVRIFSDGRDPKSGASLAVDRRAARAMRRR RDRYLRRRATLMKVLAETGLMPADPAEAKALEALDPFALRAAGLDEPLPLPHLGRALFHLNQRR GFKSNRKTDRGDNESGKIKDATARLDMEMMANGARTYGEFLHKRRQKATDPRHVPSVRTRLSIA NRGGPDGKEEAGYDFYPDRRHLEEEFHKLWAAQGAHHPELTETLRDLLFEKIFFQRPLKEPEVG LCLFSGHHGVPPKDPRLPKAHPLTQRRVLYETVNQLRVTADGREARPLTREERDQVIHALDNKK PTKSLSSMVLKLPALAKVLKLRDGERFTLETGVRDAIACDPLRASPAHPDRFGPRWS ILDADAQ WEVI SRIRRVQSDAEHAALVDWLTEAHGLDRAHAEATAHAPLPDGYGRLGLTATTRILYQLTAD VVTYADAVKACGWHHSDGRTGECFDRLPYYGEVLERHVIPGSYHPDDDDITRFGRITNPTVHIG LNQLRRLVNRI IETHGKPHQIVVELARDLKKSEEQKRADIKRIRDTTEAAKKRSEKLEELEIED NGRNRMLLRLWEDLNPDDAMRRFCPYTGTRI SAAMIFDGSCDVDHILPYSRTLDDSFPNRTLCL REANRQKRNQTPWQAWGDTPHWHAIAANLKNLPENKRWRFAPDAMTRFEGENGFLDRALKDTQY LARI SRSYLDTLFTKGGHVWVVPGRFTEMLRRHWGLNSLLSDAGRGAVKAKNRTDHRHHAIDAA VIAATDPGLLNRI SRAAGQGEAAGQSAELIARDTPPPWEGFRDDLRVRLDRI IVSHRADHGRID HAARKQGRDSTAGQLHQETAYS IVDDIHVASRTDLLSLKPAQLLDEPGRSGQVRDPQLRKALRV ATGGKTGKDFENALRYFASKPGPYQAIRRVRI IKPLQAQARVPVPAQDPIKAYQGGSNHLFEIW RLPDGEIEAQVITSFEAHTLEGEKRPHPAAKRLLRVHKGDMVALERDGRRVVGHVQKMDIANGL FIVPHNEANADTRNNDKSDPFKWIQIGARPAIASGIRRVSVDEIGRLRDGGTRPI
SEQ ID NO: 355
MLHCIAVIRVPPSEEPGFFETHADSCALCHHGCMTYAANDKAIRYRVGIDVGLRS IGFCAVEVD DEDHPIRILNSVVHVHDAGTGGPGETESLRKRSGVAARARRRGRAEKQRLKKLDVLLEELGWGV SSNELLDSHAPWHIRKRLVSEYIEDETERRQCLSVAMAHIARHRGWRNSFSKVDTLLLEQAPSD RMQGLKERVEDRTGLQFSEEVTQGELVATLLEHDGDVTIRGFVRKGGKATKVHGVLEGKYMQSD LVAELRQICRTQRVSETTFEKLVLS IFHSKEPAPSAARQRERVGLDELQLALDPAAKQPRAERA HPAFQKFKVVATLANMRIREQSAGERSLTSEELNRVARYLLNHTESESPTWDDVARKLEVPRHR LRGSSRASLETGGGLTYPPVDDTTVRVMSAEVDWLADWWDCANDESRGHMIDAI SNGCGSEPDD VEDEEVNELI SSATAEDMLKLELLAKKLPSGRVAYSLKTLREVTAAILETGDDLSQAITRLYGV DPGWVPTPAPIEAPVGNPSVDRVLKQVARWLKFASKRWGVPQTVNIEHTREGLKSASLLEEERE RWERFEARREIRQKEMYKRLGI SGPFRRSDQVRYEILDLQDCACLYCGNEINFQTFEVDHI IPR VDASSDSRRTNLAAVCHSCNSAKGGLAFGQWVKRGDCPSGVSLENAIKRVRSWSKDRLGLTEKA MGKRKSEVI SRLKTEMPYEEFDGRSMESVAWMAIELKKRIEGYFNSDRPEGCAAVQVNAYSGRL TACARRAAHVDKRVRLIRLKGDDGHHKNRFDRRNHAMDALVIALMTPAIARTIAVREDRREAQQ LTRAFESWKNFLGSEERMQDRWESWIGDVEYACDRLNELIDADKIPVTENLRLRNSGKLHADQP ESLKKARRGSKRPRPQRYVLGDALPADVINRVTDPGLWTALVRAPGFDSQLGLPADLNRGLKLR GKRI SADFPIDYFPTDSPALAVQGGYVGLEFHHARLYRI IGPKEKVKYALLRVCAIDLCGIDCD DLFEVELKPSS I SMRTADAKLKEAMGNGSAKQIGWLVLGDEIQIDPTKFPKQS IGKFLKECGPV SSWRVSALDTPSKITLKPRLLSNEPLLKTSRVGGHESDLVVAECVEKIMKKTGWVVEINALCQS GLIRVIRRNALGEVRTSPKSGLPI SLNLR
SEQ ID NO: 356
MRYRVGLDLGTASVGAAVFSMDEQGNPMELIWHYERLFSEPLVPDMGQLKPKKAARRLARQQRR QIDRRASRLRRIAIVSRRLGIAPGRNDSGVHGNDVPTLRAMAVNERIELGQLRAVLLRMGKKRG YGGTFKAVRKVGEAGEVASGASRLEEEMVALASVQNKDSVTVGEYLAARVEHGLPSKLKVAANN EYYAPEYALFRQYLGLPAIKGRPDCLPNMYALRHQIEHEFERIWATQSQFHDVMKDHGVKEEIR NAIFFQRPLKSPADKVGRCSLQTNLPRAPRAQIAAQNFRIEKQMADLRWGMGRRAEMLNDHQKA VIRELLNQQKELSFRKIYKELERAGCPGPEGKGLNMDRAALGGRDDLSGNTTLAAWRKLGLEDR WQELDEVTQIQVINFLADLGSPEQLDTDDWSCRFMGKNGRPRNFSDEFVAFMNELRMTDGFDRL SKMGFEGGRSSYS IKALKALTEWMIAPHWRETPETHRVDEEAAIRECYPESLATPAQGGRQSKL EPPPLTGNEVVDVALRQVRHTINMMIDDLGSVPAQIVVEMAREMKGGVTRRNDIEKQNKRFASE RKKAAQS IEENGKTPTPARILRYQLWIEQGHQCPYCESNI SLEQALSGAYTNFEHILPRTLTQI GRKRSELVLAHRECNDEKGNRTPYQAFGHDDRRWRIVEQRANALPKKSSRKTRLLLLKDFEGEA LTDES IDEFADRQLHESSWLAKVTTQWLSSLGSDVYVSRGSLTAELRRRWGLDTVIPQVRFESG MPVVDEEGAEITPEEFEKFRLQWEGHRVTREMRTDRRPDKRIDHRHHLVDAIVTALTSRSLYQQ YAKAWKVADEKQRHGRVDVKVELPMPILTIRDIALEAVRSVRI SHKPDRYPDGRFFEATAYGIA QRLDERSGEKVDWLVSRKSLTDLAPEKKS IDVDKVRANI SRIVGEAIRLHI SNIFEKRVSKGMT PQQALREPIEFQGNILRKVRCFYSKADDCVRIEHSSRRGHHYKMLLNDGFAYMEVPCKEGILYG VPNLVRPSEAVGIKRAPESGDFIRFYKGDTVKNIKTGRVYTIKQILGDGGGKLILTPVTETKPA DLLSAKWGRLKVGGRNIHLLRLCAE
SEQ ID NO: 357 MIGEHVRGGCLFDDHWTPNWGAFRLPNTVRTFTKAENPKDGSSLAEPRRQARGLRRRLRRKTQR LEDLRRLLAKEGVLSLSDLETLFRETPAKDPYQLRAEGLDRPLSFPEWVRVLYHITKHRGFQSN RRNPVEDGQERSRQEEEGKLLSGVGENERLLREGGYRTAGEMLARDPKFQDHRRNRAGDYSHTL SRSLLLEEARRLFQSQRTLGNPHASSNLEEAFLHLVAFQNPFASGEDIRNKAGHCSLEPDQIRA PRRSASAETFMLLQKTGNLRLIHRRTGEERPLTDKEREQIHLLAWKQEKVTHKTLRRHLEIPEE WLFTGLPYHRSGDKAEEKLFVHLAGIHEIRKALDKGPDPAVWDTLRSRRDLLDS IADTLTFYKN EDEILPRLESLGLSPENARALAPLSFSGTAHLSLSALGKLLPHLEEGKSYTQARADAGYAAPPP DRHPKLPPLEEADWRNPVVFRALTQTRKVVNALVRRYGPPWCIHLETARELSQPAKVRRRIETE QQANEKKKQQAEREFLDIVGTAPGPGDLLKMRLWREQGGFCPYCEEYLNPTRLAEPGYAEMDHI LPYSRSLDNGWHNRVLVHGKDNRDKGNRTPFEAFGGDTARWDRLVAWVQASHLSAPKKRNLLRE DFGEEAERELKDRNLTDTRFITKTAATLLRDRLTFHPEAPKDPVMTLNGRLTAFLRKQWGLHKN RKNGDLHHALDAAVLAVASRSFVYRLSSHNAAWGELPRGREAENGFSLPYPAFRSEVLARLCPT REEILLRLDQGGVGYDEAFRNGLRPVFVSRAPSRRLRGKAHMETLRSPKWKDHPEGPRTASRIP LKDLNLEKLERMVGKDRDRKLYEALRERLAAFGGNGKKAFVAPFRKPCRSGEGPLVRSLRIFDS GYSGVELRDGGEVYAVADHESMVRVDVYAKKNRFYLVPVYVADVARGIVKNRAIVAHKSEEEWD LVDGSFDFRFSLFPGDLVEIEKKDGAYLGYYKSCHRGDGRLLLDRHDRMPRESDCGTFYVSTRK DVLSMSKYQVDPLGEIRLVGSEKPPFVL
SEQ ID NO: 358
MEKKRKVTLGFDLGIASVGWAIVDSETNQVYKLGSRLFDAPDTNLERRTQRGTRRLLRRRKYRN QKFYNLVKRTEVFGLSSREAIENRFRELS IKYP I IELKTKALSQEVCPDEIAWILHDYLKNRG YFYDEKETKEDFDQQTVESMPSYKLNEFYKKYGYFKGALSQPTESEMKDNKDLKEAFFFDFSNK EWLKEINYFFNVQK ILSETFIEEFKKIFSFTRDI SKGPGSDNMPSPYGIFGEFGDNGQGGRYE HIWDKNIGKCS IFTNEQRAPKYLPSALIFNFLNELANIRLYSTDKKNIQPLWKLSSVDKLNILL NLFNLPI SEKKKKLTST INDIVKKES IKS IMI SVEDIDMIKDEWAGKEPNVYGVGLSGL IEE SAKENKFKFQDLKILNVLINLLDNVGIKFEFKDRNDI IKNLELLDNLYLFLIYQKESNNKDSS I DLFIAKNESLNIENLKLKLKEFLLGAGNEFENHNSKTHSLSKKAIDEILPKLLDNNEGWNLEAI KNYDEEIKSQIEDNSSLMAKQDKKYLNDNFLKDAILPPNVKVTFQQAILIFNKI IQKFSKDFEI DKVVIELAREMTQDQENDALKGIAKAQKSKKSLVEERLEAN IDKSVFNDKYEKLIYKIFLWI S QDFKDPYTGAQI SVNEIVNNKVEIDHI IPYSLCFDDSSANKVLVHKQSNQEKSNSLPYEYIKQG HSGWNWDEFTKYVKRVFVNNVDS ILSKKERLKKSENLLTASYDGYDKLGFLARNLNDTRYATIL FRDQLNNYAEHHLIDNKKMFKVIAMNGAVTSFIRKNMSYDNKLRLKDRSDFSHHAYDAAIIALF SNKTKTLYNLIDPSLNGI I SKRSEGYWVIEDRYTGEIKELKKEDWTS IKNNVQARKIAKEIEEY LIDLDDEVFFSRKTKRKTNRQLYNETIYGIATKTDEDGITNYYKKEKFS ILDDKDIYLRLLRER EKFVINQSNPEVIDQI IEI IESYGKENNIPSRDEAINIKYTKNKINYNLYLKQYMRSLTKSLDQ FSEEFINQMIANKTFVLYNPTKNTTRKIKFLRLVNDVKINDIRKNQVINKFNGKNNEPKAFYEN INSLGAIVFKNSANNFKTLS INTQIAIFGDKNWDIEDFKTYNMEKIEKYKEIYGIDKTYNFHSF IFPGTILLDKQNKEFYYI SS IQTVRDI IEIKFLNKIEFKDENKNQDTSKTPKRLMFGIKS IMNN YEQVDI SPFGINKKIFE
SEQ ID NO: 359
MGYRIGLDVGITSTGYAVLKTDKNGLPYKILTLDSVIYPRAENPQTGASLAEPRRIKRGLRRRT RRTKFRKQRTQQLFIHSGLLSKPEIEQILATPQAKYSVYELRVAGLDRRLTNSELFRVLYFFIG HRGFKSNRKAELNPENEADKKQMGQLLNS IEEIRKAIAEKGYRTVGELYLKDPKYNDHKRNKGY IDGYLSTPNRQMLVDEIKQILDKQRELGNEKLTDEFYATYLLGDENRAGIFQAQRDFDEGPGAG PYAGDQIKKMVGKDIFEPTEDRAAKATYTFQYFNLLQKMTSLNYQNTTGDTWHTLNGLDRQAI I DAVFAKAEKPTKTYKPTDFGELRKLLKLPDDARFNLVNYGSLQTQKEIETVEKKTRFVDFKAYH DLVKVLPEEMWQSRQLLDHIGTALTLYSSDKRRRRYFAEELNLPAELIEKLLPLNFSKFGHLS I KSMQNI IPYLEMGQVYSEATTNTGYDFRKKQI SKDTIREEITNPVVRRAVTKTIKIVEQI IRRY GKPDGI IELARELGRNFKERGDIQKRQDKNRQTNDKIAAELTELGIPVNGQ I IRYKLHKEQN GVDPYTGDQIPFERAFSEGYEVDHI IPYS I SWDDSYTNKVLTSAKCNREKGNRIPMVYLANNEQ RLNALT IAD I IRNSRKRQKLLKQKLSDEELKDWKQR INDTRFITRVLYNYFRQAIEFNPEL EKKQRVLPLNGEVTSKIRSRWGFLKVREDGDLHHAIDATVIAAITPKFIQQVTKYSQHQEVKNN QALWHDAEIKDAEYAAEAQRMDADLFNKIFNGFPLPWPEFLDELLARI SDNPVEMMKSRSWNTY TPIEIAKLKPVFVVRLANHKI SGPAHLDTIRSAKLFDEKGIVLSRVS ITKLKINKKGQVATGDG IYDPENSNNGDKVVYSAIRQALEAHNGSGELAFPDGYLEYVDHGTKKLVRKVRVAKKVSLPVRL KNKAAADNGSMVRIDVFNTGKKFVFVPIYIKDTVEQVLPNKAIARGKSLWYQITESDQFCFSLY PGDMVHIESKTGIKPKYSNKENNTSVVPIKNFYGYFDGADIATAS ILVRAHDSSYTARS IGIAG LLKFEKYQVDYFGRYHKVHEKKRQLFVKRDE
SEQ ID NO: 360
MQKNINTKQNHIYIKQAQKIKEKLGDKPYRIGLDLGVGS IGFAIVSMEENDGNVLLPKEI IMVG SRIFKASAGAADRKLSRGQRNNHRHTRERMRYLWKVLAEQKLALPVPADLDRKENSSEGETSAK RFLGDVLQKDIYELRVKSLDERLSLQELGYVLYHIAGHRGSSAIRTFENDSEEAQKENTENKKI AG IKRLMAKKNYRTYGEYLYKEFFENKEKHKREKI SNAANNHKFSPTRDLVIKEAEAILKKQA GKDGFHKELTEEYIEKLTKAIGYESEKLIPESGFCPYLKDEKRLPASHKLNEERRLWETLNNAR YSDPIVDIVTGEITGYYEKQFTKEQKQKLFDYLLTGSELTPAQTKKLLGLKNTNFEDI ILQGRD KKAQKIKGYKLIKLESMPFWARLSEAQQDSFLYDWNSCPDEKLLTEKLSNEYHLTEEEIDNAFN EIVLSSSYAPLGKSAMLI ILEKIKNDLSYTEAVEEALKEGKLTKEKQAIKDRLPYYGAVLQEST QKI IAKGFSPQFKDKGYKTPHTNKYELEYGRIANPVVHQTLNELRKLVNEI IDILGKKPCEIGL ETARELKKSAEDRSKLSREQNDNESNRNRIYEIYIRPQQQVI ITRRENPRNYILKFELLEEQKS QCPFCGGQI SPNDI INNQADIEHLFPIAESEDNGRNNLVI SHSACNADKAKRSPWAAFASAAKD SKYDYNRILSNVKE IPHKAWRFNQGAFEKFIENKPMAARFKTDNSYI SKVAHKYLACLFEKPN IICVKGSLTAQLRMAWGLQGLMIPFAKQLITEKESESFNKDVNSNKKIRLDNRHHALDAIVIAY ASRGYGNLLNKMAGKDYKINYSERNWLSKILLPPNNIVWENIDADLESFESSVKTALKNAFISV KHDHSDNGELVKGTMYKIFYSERGYTLTTYKKLSALKLTDPQKKKTPKDFLETALLKFKGRESE MKNEKIKSAIENNKRLFDVIQDNLEKAKKLLEEENEKSKAEGKKEKNINDAS IYQKAI SLSGDK YVQLSKKEPGKFFAI SKPTPTTTGYGYDTGDSLCVDLYYDNKGKLCGEI IRKIDAQQKNPLKYK EQGFTLFERIYGGDILEVDFDIHSDKNSFRNNTGSAPENRVFIKVGTFTEITNNNIQIWFGNI I KSTGGQDDSFTINSMQQYNPRKLILSSCGFIKYRSPILKNKEG
SEQ ID NO: 361
MAAFKPNPINYILGLDIGIASVGWAMVEIDEDENPICLIDLGVRVFERAEVPKTGDSLAMARRL ARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWS AVLLHLIKHRGYLSQRKNEGETADKELGALLKGVADNAHALQTGDFRTPAELALNKFEKESGHI RNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLG HCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQA RKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAI SRALEKEGLKDKKSPLNLSPELQDEIGT AFSLFKTDEDITGRLKDRIQPEILEALLKHI SFDKFVQI SLKALRRIVPLMEQGKRYDEACAEI YGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKS FKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLG RLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVE TSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITN LLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQ KTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSR APNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHK DDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYY LVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCH RGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVR
SEQ ID NO: 362
MQTTNLSYILGLDLGIASVGWAVVEINENEDPIGLIDVGVRIFERAEVPKTGESLALSRRLARS TRRLIRRRAHRLLLAKRFLKREGILSTIDLEKGLPNQAWELRVAGLERRLSAIEWGAVLLHLIK HRGYLSKRKNESQTNNKELGALLSGVAQNHQLLQSDDYRTPAELALKKFAKEEGHIRNQRGAYT HTFNRLDLLAELNLLFAQQHQFGNPHCKEHIQQYMTELLMWQKPALSGEAILKMLGKCTHEKNE FKAAKHTYSAERFVWLTKLNNLRILEDGAERALNEEERQLLINHPYEKSKLTYAQVRKLLGLSE QAIFKHLRYSKENAESATFMELKAWHAIRKALENQGLKDTWQDLAKKPDLLDEIGTAFSLYKTD EDIQQYLTNKVPNSVINALLVSLNFDKFIELSLKSLRKILPLMEQGKRYDQACREIYGHHYGEA NQKTSQLLPAIPAQEIRNPVVLRTLSQARKVINAI IRQYGSPARVHIETGRELGKSFKERREIQ KQQEDNRTKRESAVQKFKELFSDFSSEPKSKDILKFRLYEQQHGKCLYSGKEINIHRLNEKGYV EIDHALPFSRTWDDSFNNKVLVLASENQNKGNQTPYEWLQGKINSERWKNFVALVLGSQCSAAK KQRLLTQVIDDNKFIDRNLNDTRYIARFLSNYIQENLLLVGKNKKNVFTPNGQITALLRSRWGL IKARENNNRHHALDAIVVACATPSMQQKITRFIRFKEVHPYKIENRYEMVDQESGEI I SPHFPE PWAYFRQEVNIRVFDNHPDTVLKEMLPDRPQANHQFVQPLFVSRAPTRKMSGQGHMETIKSAKR LAEGI SVLRIPLTQLKPNLLENMVNKEREPALYAGLKARLAEFNQDPAKAFATPFYKQGGQQVK AIRVEQVQKSGVLVRENNGVADNAS IVRTDVFIKNNKFFLVPIYTWQVAKGILPNKAIVAHKNE DEWEEMDEGAKFKFSLFPNDLVELKTKKEYFFGYYIGLDRATG I SLKEHDGEI SKGKDGVYRV GVKLALSFEKYQVDELGKNRQICRPQQRQPVR
SEQ ID NO: 363
MGIRFAFDLGTNS IGWAVWRTGPGVFGEDTAASLDGSGVLIFKDGRNPKDGQSLATMRRVPRQS RKRRDRFVLRRRDLLAALRKAGLFPVDVEEGRRLAATDPYHLRAKALDESLTPHEMGRVIFHLN QRRGFRSNRKADRQDREKGKIAEGSKRLAETLAATNCRTLGEFLWSRHRGTPRTRSPTRIRMEG EGAKALYAFYPTREMVRAEFERLWTAQSRFAPDLLTPERHEEIAGILFRQRDLAPPKIGCCTFE PSERRLPRALPSVEARGIYERLAHLRITTGPVSDRGLTRPERDVLASALLAGKSLTFKAVRKTL KILPHALVNFEEAGEKGLDGALTAKLLSKPDHYGAAWHGLSFAEKDTFVGKLLDEADEERLIRR LVTENRLSEDAARRCAS IPLADGYGRLGRTANTEILAALVEETDETGTVVTYAEAVRRAGERTG RNWHHSDERDGVILDRLPYYGEILQRHVVPGSGEPEEKNEAARWGRLANPTVHIGLNQLRKVVN RLIAAHGRPDQIVVELARELKLNREQKERLDRENRKNREENERRTAILAEHGQRDTAENKIRLR LFEEQARANAGIALCPYTGRAIGIAELFTSEVEIDHILPVSLTLDDSLANRVLCRREANREKRR QTPFQAFGATPAWNDIVARAAKLPPNKRWRFDPAALERFEREGGFLGRQLNETKYLSRLAKIYL GKICDPDRVYVTPGTLTGLLRARWGLNS ILSDSNFKNRSDHRHHAVDAVVIGVLTRGMIQRIAH DAARAEDQDLDRVFRDVPVPFEDFRDHVRERVSTITVAVKPEHGKGGALHEDTSYGLVPDTDPN AALGNLVVRKPIRSLTAGEVDRVRDRALRARLGALAAPFRDESGRVRDAKGLAQALEAFGAENG IRRVRILKPDASVVTIADRRTGVPYRAVAPGENHHVDIVQMRDGSWRGFAASVFEVNRPGWRPE WEVKKLGGKLVMRLHKGDMVELSDKDGQRRVKVVQQIEI SANRVRLSPHNDGGKLQDRHADADD PFRWDLATIPLLKDRGCVAVRVDPIGVVTLRRSNV
SEQ ID NO: 364
MMEVFMGRLVLGLDIGITSVGFGI IDLDESEIVDYGVRLFKEGTAAENETRRTKRGGRRLKRRR VTRREDMLHLLKQAGI I STSFHPLNNPYDVRVKGLNERLNGEELATALLHLCKHRGSSVETIED DEAKAKEAGETKKVLSMNDQLLKSGKYVCEIQKERLRTNGHIRGHENNFKTRAYVDEAFQILSH QDLSNELKSAI ITI I SRKRMYYDGPGGPLSPTPYGRYTYFGQKEPIDLIEKMRGKCSLFPNEPR APKLAYSAELFNLLNDLNNLS IEGEKLTSEQKAMILKIVHEKGKITPKQLAKEVGVSLEQIRGF RIDTKGSPLLSELTGYKMIREVLEKSNDEHLEDHVFYDEIAEILTKTKDIEGRKKQI SELSSDL NEESVHQLAGLTKFTAYHSLSFKALRLINEEMLKTELNQMQS ITLFGLKQNNELSVKGMK IQA DDTAILSPVAKRAQRETFKVVNRLREIYGEFDS IVVEMAREKNSEEQRKAIRERQKFFEMRNKQ VADI IGDDRKINAKLREKLVLYQEQDGKTAYSLEPIDLKLLIDDPNAYEVDHI IPI S I SLDDS I TNKVLVTHRENQEKGNLTPI SAFVKGRFTKGSLAQYKAYCLKLKEK IKTNKGYRKKVEQYLLN ENDIYKYDIQKEFINRNLVDTSYASRVVLNTLTTYFKQNEIPTKVFTVKGSLTNAFRRKINLKK DRDEDYGHHAIDALI IASMPKMRLLSTIFSRYKIEDIYDESTGEVFSSGDDSMYYDDRYFAFIA SLKAIKVRKFSHKIDTKPNRSVADETIYSTRVIDGKEKVVKKYKDIYDPKFTALAEDILNNAYQ EKYLMALHDPQTFDQIVKVVNYYFEEMSKSEKYFTKDKKGRIKI SGMNPLSLYRDEHGMLKKYS KKGDGPAITQMKYFDGVLGNHIDI SAHYQVRDKKVVLQQI SPYRTDFYYSKENGYKFVTIRYKD VRWSEKKKKYVIDQQDYAMKKAEKKIDDTYEFQFSMHRDELIGITKAEGEALIYPDETWHNFNF FFHAGETPEILKFTATNNDKSNKIEVKPIHCYCKMRLMPTI SKKIVRIDKYATDVVGNLYKVKK NTLKFEFD
SEQ ID NO: 365
MKKILGVDLGITSFGYAILQETGKDLYRCLDNSVVMRNNPYDEKSGESSQS IRSTQKSMRRLIE KRKKRIRCVAQTMERYGILDYSETMKINDPKNNPIKNRWQLRAVDAWKRPLSPQELFAIFAHMA KHRGYKS IATEDLIYELELELGLNDPEKESEKKADERRQVYNALRHLEELRKKYGGETIAQTIH RAVEAGDLRSYRNHDDYEKMIRREDIEEEIEKVLLRQAELGALGLPEEQVSELIDELKACITDQ EMPTIDESLFGKCTFYKDELAAPAYSYLYDLYRLYKKLADLNIDGYEVTQEDREKVIEWVEKKI AQGKNLKKITHKDLRKILGLAPEQKIFGVEDERIVKGKKEPRTFVPFFFLADIAKFKELFASIQ KHPDALQIFRELAEILQRSKTPQEALDRLRALMAGKGIDTDDRELLELFKNKRSGTRELSHRYI LEALPLFLEGYDEKEVQRILGFDDREDYSRYPKSLRHLHLREGNLFEKEENPINNHAVKSLASW ALGLIADLSWRYGPFDEI ILETTRDALPEKIRKEIDKAMREREKALDKI IGKYKKEFPS IDKRL ARKIQLWERQKGLDLYSGKVINLSQLLDGSADIEHIVPQSLGGLSTDYNTIVTLKSVNAAKGNR LPGDWLAGNPDYRERIGMLSEKGLIDWKKRKNLLAQSLDEIYTENTHSKGIRATSYLEALVAQV LKRYYPFPDPELRKNGIGVRMIPGKVTSKTRSLLGIKSKSRETNFHHAEDALILSTLTRGWQNR LHRMLRDNYGKSEAELKELWKKYMPHIEGLTLADYIDEAFRRFMSKGEESLFYRDMFDTIRS I S YWVDKKPLSASSHKETVYSSRHEVPTLRKNILEAFDSLNVIKDRHKLTTEEFMKRYDKEIRQKL WLHRIGNTNDESYRAVEERATQIAQILTRYQLMDAQNDKEIDEKFQQALKELITSPIEVTGKLL RKMRFVYDKLNAMQIDRGLVETDKNMLGIHI SKGPNEKLIFRRMDVNNAHELQKERSGILCYLN EMLFIFNKKGLIHYGCLRSYLEKGQGSKYIALFNPRFPANPKAQPSKFTSDSKIKQVGIGSATG I IKAHLDLDGHVRSYEVFGTLPEGS IEWFKEESGYGRVEDDPHH
SEQ ID NO: 366
MRPIEPWILGLDIGTDSLGWAVFSCEEKGPPTAKELLGGGVRLFDSGRDAKDHTSRQAERGAFR RARRQTRTWPWRRDRLIALFQAAGLTPPAAETRQIALALRREAVSRPLAPDALWAALLHLAHHR GFRSNRIDKRERAAAKALAKAKPAKATAKATAPAKEADDEAGFWEGAEAALRQRMAASGAPTVG ALLADDLDRGQPVRMRYNQSDRDGVVAPTRALIAEELAEIVARQSSAYPGLDWPAVTRLVLDQR PLRSKGAGPCAFLPGEDRALRALPTVQDFI IRQTLANLRLPSTSADEPRPLTDEEHAKALALLS TARFVEWPALRRALGLKRGVKFTAETERNGAKQAARGTAGNLTEAILAPLIPGWSGWDLDRKDR VFSDLWAARQDRSALLALIGDPRGPTRVTEDETAEAVADAIQIVLPTGRASLSAKAARAIAQAM APGIGYDEAVTLALGLHHSHRPRQERLARLPYYAAALPDVGLDGDPVGPPPAEDDGAAAEAYYG RIGNI SVHIALNETRKIVNALLHRHGPILRLVMVETTRELKAGADERKRMIAEQAERERENAEI DVELRKSDRWMANARERRQRVRLARRQNNLCPYTSTPIGHADLLGDAYDIDHVIPLARGGRDSL DNMVLCQSDANKTKGDKTPWEAFHDKPGWIAQRDDFLARLDPQTAKALAWRFADDAGERVARKS AEDEDQGFLPRQLTDTGYIARVALRYLSLVTNEPNAVVATNGRLTGLLRLAWDITPGPAPRDLL PTPRDALRDDTAARRFLDGLTPPPLAKAVEGAVQARLAALGRSRVADAGLADALGLTLASLGGG GKNRADHRHHFIDAAMIAVTTRGLINQINQASGAGRILDLRKWPRTNFEPPYPTFRAEVMKQWD HIHPS IRPAHRDGGSLHAATVFGVRNRPDARVLVQRKPVEKLFLDANAKPLPADKIAEI IDGFA SPRMAKRFKALLARYQAAHPEVPPALAALAVARDPAFGPRGMTANTVIAGRSDGDGEDAGLITP FRANPKAAVRTMGNAVYEVWEIQVKGRPRWTHRVLTRFDRTQPAPPPPPENARLVMRLRRGDLV YWPLESGDRLFLVKKMAVDGRLALWPARLATGKATALYAQLSCPNINLNGDQGYCVQSAEGIRK EKIRTTSCTALGRLRLSKKAT
SEQ ID NO: 367
MKYTLGLDVGIASVGWAVIDKDNNKI IDLGVRCFDKAEESKTGESLATARRIARGMRRRI SRRS QRLRLVKKLFVQYEI IKDSSEFNRIFDTSRDGWKDPWELRYNALSRILKPYELVQVLTHITKRR GFKSNRKEDLSTTKEGVVITS IKNNSEMLRTKNYRTIGEMIFMETPENSNKRNKVDEYIHTIAR EDLLNEIKYIFS IQRKLGSPFVTEKLEHDFLNIWEFQRPFASGDS ILSKVGKCTLLKEELRAPT SCYTSEYFGLLQS INNLVLVEDNNTLTLNNDQRAKI IEYAHFKNEIKYSEIRKLLDIEPEILFK AHNLTHKNPSGNNESKKFYEMKSYHKLKSTLPTDIWGKLHSNKESLDNLFYCLTVYKNDNEIKD YLQANNLDYLIEYIAKLPTFNKFKHLSLVAMKRI IPFMEKGYKYSDACNMAELDFTGSSKLEKC NKLTVEPI IENVTNPVVIRALTQARKVINAI IQKYGLPYMV IELAREAGMTRQDRDNLKKEHE NNRKAREKI SDLIRQNGRVASGLDILKWRLWEDQGGRCAYSGKPIPVCDLLNDSLTQIDHIYPY SRSMDDSYMNKVLVLTDENQNKRSYTPYEVWGSTEKWEDFEARIYSMHLPQSKEKRLLNRNFIT KDLDSFI SRNLNDTRYI SRFLKNYIESYLQFSNDSPKSCVVCVNGQCTAQLRSRWGLNKNREES DLHHALDAAVIACADRKI IKEITNYYNERENHNYKVKYPLPWHSFRQDLMETLAGVFI SRAPRR KITGPAHDETIRSPKHFNKGLTSVKIPLTTVTLEKLETMVKNTKGGI SDKAVYNVLKNRLIEHN NKPLKAFAEKIYKPLKNGTNGAI IRS IRVETPSYTGVFRNEGKGI SDNSLMVRVDVFKKKDKYY LVPIYVAHMIKKELPSKAIVPLKPESQWELIDSTHEFLFSLYQNDYLVIKTKKGITEGYYRSCH RGTGSLSLMPHFANNKNVKIDIGVRTAI S IEKYNVDILGNKS IVKGEPRRGMEKYNSFKSN
SEQ ID NO: 368
MIRTLGIDIGIAS IGWAVIEGEYTDKGLENKEIVASGVRVFTKAENPKNKESLALPRTLARSAR RRNARKKGRIQQVKHYLSKALGLDLECFVQGEKLATLFQTSKDFLSPWELRERALYRVLDKEEL ARVILHIAKRRGYDDITYGVEDNDSGKIKKAIAENSKRIKEEQCKTIGEMMYKLYFQKSLNVRN KKESYNRCVGRSELREELKTIFQIQQELKSPWVNEELIYKLLGNPDAQSKQEREGLIFYQRPLK GFGDKIGKCSHIKKGENSPYRACKHAPSAEEFVALTKS INFLKNLTNRHGLCFSQEDMCVYLGK ILQEAQKNEKGLTYSKLKLLLDLPSDFEFLGLDYSGKNPEKAVFLSLPSTFKLNKITQDRKTQD KIANILGANKDWEAILKELESLQLSKEQIQTIKDAKLNFSKHINLSLEALYHLLPLMREGKRYD EGVEILQERGIFSKPQPKNRQLLPPLSELAKEESYFDIPNPVLRRALSEFRKVVNALLEKYGGF HYFHIELTRDVCKAKSARMQLEKINKKNKSENDAASQLLEVLGLPNTYNNRLKCKLWKQQEEYC LYSGEKITIDHLKDQRALQIDHAFPLSRSLDDSQSNKVLCLTSSNQEKSNKTPYEWLGSDEKKW DMYVGRVYSSNFSPSKKRKLTQKNFKERNEEDFLARNLVDTGYIGRVTKEYIKHSLSFLPLPDG KKEHIRI I SGSMTSTMRSFWGVQEKNRDHHLHHAQDAI I IACIEPSMIQKYTTYLKDKETHRLK SHQKAQILREGDHKLSLRWPMSNFKDKIQES IQNI IPSHHVSHKVTGELHQETVRTKEFYYQAF GGEEGVKKALKFGKIREINQGIVDNGAMVRVDIFKSKDKGKFYAVPIYTYDFAIGKLPNKAIVQ GKKNGI IKDWLEMDENYEFCFSLFKNDCIKIQTKEMQEAVLAIYKSTNSAKATIELEHLSKYAL KNEDEEKMFTDTDKEKNKTMTRESCGIQGLKVFQKVKLSVLGEVLEHKPRNRQNIALKTTPKHV SEQ ID NO: 369
MKYS IGLDIGIASVGWSVINKDKERIEDMGVRIFQKAENPKDGSSLASSRREKRGSRRRNRRKK HRLDRIK ILCESGLVKKNEIEKIYKNAYLKSPWELRAKSLEAKI SNKEIAQILLHIAKRRGFK SFRKTDRNADDTGKLLSGIQENKKIMEEKGYLTIGDMVAKDPKFNTHVRNKAGSYLFSFSRKLL EDEVRKIQAKQKELGNTHFTDDVLEKYIEVFNSQRNFDEGPSKPSPYYSEIGQIAKMIGNCTFE SSEKRTAKNTWSGERFVFLQKLNNFRIVGLSGKRPLTEEERDIVEKEVYLKKEVRYEKLRKILY LKEEERFGDLNYSKDEKQDKKTEKTKFISLIGNYTIKKLNLSEKLKSEIEEDKSKLDKI IEILT FNKSDKTIESNLKKLELSREDIEILLSEEFSGTLNLSLKAIKKILPYLEKGLSYNEACEKADYD YKNNGIKFKRGELLPVVDKDLIANPVVLRAI SQTRKVVNAI IRKYGTPHTIHVEVARDLAKSYD DRQTI IKENKKRELENEKTKKFI SEEFGIKNVKGKLLLKYRLYQEQEGRCAYSRKELSLSEVIL DESMTDIDHI IPYSRSMDDSYSNKVLVLSGENRKKSNLLPKEYFDRQGRDWDTFVLNVKAMKIH PRKKSNLLKEKFTREDNKDWKSRALNDTRYI SRFVANYLENALEYRDDSPKKRVFMIPGQLTAQ LRARWRLNKVRENGDLHHALDAAVVAVTDQKAINNI SNI SRYKELKNCKDVIPS IEYHADEETG EVYFEEVKDTRFPMPWSGFDLELQKRLESENPREEFYNLLSDKRYLGWFNYEEGFIEKLRPVFV SRMPNRGVKGQAHQETIRSSKKI SNQIAVSKKPLNS IKLKDLEKMQGRDTDRKLYEALKNRLEE YDDKPEKAFAEPFYKPTNSGKRGPLVRGIKVEEKQNVGVYVNGGQASNGSMVRIDVFRKNGKFY TVPIYVHQTLLKELPNRAINGKPYKDWDLIDGSFEFLYSFYPNDLIEIEFGKSKS IKNDNKLTK TEIPEVNLSEVLGYYRGMDTSTGAATIDTQDGKIQMRIGIKTVKNIKKYQVDVLGNVYKVKREK RQTF
SEQ ID NO: 370
MSKKVSRRYEEQAQEICQRLGSRPYS IGLDLGVGS IGVAVAAYDPIKKQPSDLVFVSSRIFIPS TGAAERRQKRGQRNSLRHRANRLKFLWKLLAERNLMLSYSEQDVPDPARLRFEDAVVRANPYEL RLKGLNEQLTLSELGYALYHIANHRGSSSVRTFLDEEKSSDDKKLEEQQAMTEQLAKEKGI STF IEVLTAFNTNGLIGYRNSESVKSKGVPVPTRDI I SNEIDVLLQTQKQFYQEILSDEYCDRIVSA ILFENEKIVPEAGCCPYFPDEKKLPRCHFLNEERRLWEAINNARIKMPMQEGAAKRYQSASFSD EQRHILFHIARSGTDITPKLVQKEFPALKTS I IVLQGKEKAIQKIAGFRFRRLEEKSFWKRLSE EQKDDFFSAWTNTPDDKRLSKYLMKHLLLTENEVVDALKTVSLIGDYGPIGKTATQLLMKHLED GLTYTEALERGMETGEFQELSVWEQQSLLPYYGQILTGSTQALMGKYWHSAFKEKRDSEGFFKP NTNSDEEKYGRIANPVVHQTLNELRKLMNELITILGAKPQEITVELARELKVGAEKREDI IKQQ TKQEKEAVLAYSKYCEPNNLDKRYIERFRLLEDQAFVCPYCLEHI SVADIAAGRADVDHIFPRD DTADNSYGNKVVAHRQCNDIKGKRTPYAAFSNTSAWGPIMHYLDETPGMWRKRRKFETNEEEYA KYLQSKGFVSRFESDNSYIAKAAKEYLRCLFNPNNVTAVGSLKGMETS ILRKAWNLQGIDDLLG SRHWSKDADTSPTMRKNRDDNRHHGLDAIVALYCSRSLVQMINTMSEQGKRAVEIEAMIPIPGY ASEPNLSFEAQRELFRKKILEFMDLHAFVSMKTDNDANGALLKDTVYS ILGADTQGEDLVFVVK KKIKDIGVKIGDYEEVASAIRGRITDKQPKWYPMEMKDKIEQLQSKNEAALQKYKESLVQAAAV LEESNRKLIESGKKPIQLSEKTI SKKALELVGGYYYLI SNNKRTKTFVVKEPSNEVKGFAFDTG SNLCLDFYHDAQGKLCGEI IRKIQAMNPSYKPAYMKQGYSLYVRLYQGDVCELRASDLTEAESN LAKTTHVRLPNAKPGRTFVI I ITFTEMGSGYQIYFSNLAKSKKGQDTSFTLTTIKNYDVRKVQL SSAGLVRYVSPLLVDKIEKDEVALCGE
SEQ ID NO: 371
MNQKFILGLDIGITSVGYGLIDYETKNI IDAGVRLFPEANVENNEGRRSKRGSRRLKRRRIHRL ERVKKLLEDYNLLDQSQIPQSTNPYAIRVKGLSEALSKDELVIALLHIAKRRGIHKIDVIDSND DVGNELSTKEQLNKNSKLLKDKFVCQIQLERMNEGQVRGEKNRFKTADI IKEI IQLLNVQKNFH QLDENFINKYIELVEMRREYFEGPGKGSPYGWEGDPKAWYETLMGHCTYFPDELRSVKYAYSAD LFNALNDLNNLVIQRDGLSKLEYHEKYHI IENVFKQKKKPTLKQIANEINVNPEDIKGYRITKS GKPQFTEFKLYHDLKSVLFDQS ILENEDVLDQIAEILTIYQDKDS IKSKLTELDILLNEEDKEN IAQLTGYTGTHRLSLKCIRLVLEEQWYSSRNQMEIFTHLNIKPKKINLTAANKIPKAMIDEFIL SPVVKRTFGQAINLINKI IEKYGVPEDI I IELARENNSKDKQKFINEMQKKNENTRKRINEI IG KYGNQNAKRLVEKIRLHDEQEGKCLYSLES IPLEDLLNNPNHYEVDHI IPRSVSFDNSYHNKVL VKQSENSKKSNLTPYQYFNSGKSKLSYNQFKQHILNLSKSQDRI SKKKKEYLLEERDINKFEVQ KEFINRNLVDTRYATRELTNYLKAYFSANNMNVKVKTINGSFTDYLRKVWKFKKERNHGYKHHA EDALI IA ADFLFKENKKLKAVNSVLEKPEIESKQLDIQVDSEDNYSEMFI IPKQVQDIKDFRN FKYSHRVDKKPNRQLINDTLYSTRKKDNSTYIVQTIKDIYAKDNTTLKKQFDKSPEKFLMYQHD PRTFEKLEVIMKQYANEKNPLAKYHEETGEYLTKYSKKNNGPIVKSLKYIGNKLGSHLDVTHQF KSSTKKLVKLS IKPYRFDVYLTDKGYKFITI SYLDVLKKDNYYYIPEQKYDKLKLGKAIDKNAK FIASFYKNDLIKLDGEIYKI IGVNSDTRNMIELDLPDIRYKEYCELN IKGEPRIKKTIGKKVN SIEKLTTDVLGNVFTNTQYTKPQLLFKRGN
SEQ ID NO: 372
MIMKLEKWRLGLDLGTNS IGWSVFSLDKDNSVQDLIDMGVRIFSDGRDPKTKEPLAVARRTARS QRKLIYRRKLRRKQVFKFLQEQGLFPKTKEECMTLKSLNPYELRIKALDEKLEPYELGRALFNL AVRRGFKSNRKDGSREEVSEKKSPDEIKTQADMQTHLEKAIKENGCRTITEFLYKNQGENGGIR FAPGRMTYYPTRKMYEEEFNLIRSKQEKYYPQVDWDDIYKAIFYQRPLKPQQRGYCIYENDKER TFKAMPCSQKLRILQDIGNLAYYEGGSKKRVELNDNQDKVLYELLNSKDKVTFDQMRKALCLAD SNSFNLEENRDFLIGNPTAVKMRSKNRFGKLWDEIPLEEQDLI IETI ITADEDDAVYEVIKKYD LTQEQRDFIVKNTILQSGTSMLCKEVSEKLVKRLEEIADLKYHEAVESLGYKFADQTVEKYDLL PYYGKVLPGSTMEIDLSAPETNPEKHYGKI SNPTVHVALNQTRVVV ALIKEYGKPSQIAIELS RDLKNNVEKKAEIARKQNQRAKENIAINDTI SALYHTAFPGKSFYPNRNDRMKYRLWSELGLGN KCIYCGKGI SGAELFTKEIEIEHILPFSRTLLDAESNLTVAHSSCNAFKAERSPFEAFGTNPSG YSWQEI IQRANQLKNTSKKNKFSPNAMDSFEKDSSFIARQLSDNQYIAKAALRYLKCLVENPSD VWTTNGSMTKLLRDKWEMDS ILCRKFTEKEVALLGLKPEQIGNYKKNRFDHRHHAIDAVVIGLT DRSMVQKLATKNSHKGNRIEIPEFPILRSDLIEKVKNIVVSFKPDHGAEGKLSKETLLGKIKLH GKETFVCRENIVSLSEKNLDDIVDEIKSKVKDYVAKHKGQKIEAVLSDFSKENGIKKVRCVNRV QTPIEITSGKI SRYLSPEDYFAAVIWEIPGEKKTFKAQYIRRNEVEKNSKGLNVVKPAVLENGK PHPAAKQVCLLHKDDYLEFSDKGKMYFCRIAGYAATNNKLDIRPVYAVSYCADWINSTNETMLT GYWKPTPTQNWVSVNVLFDKQKARLVTVSPIGRVFRK
SEQ ID NO: 373
MSSKAIDSLEQLDLFKPQEYTLGLDLGIKS IGWAILSGERIANAGVYLFETAEELNSTGNKLI S KAAERGRKRRIRRMLDRKARRGRHIRYLLEREGLPTDELEEVVVHQSNRTLWDVRAEAVERKLT KQELAAVLFHLVRHRGYFPNTKKLPPDDESDSADEEQGKINRATSRLREELKASDCKTIGQFLA QNRDRQRNREGDYSNLMARKLVFEEALQILAFQRKQGHELSKDFEKTYLDVLMGQRSGRSPKLG NCSLIPSELRAPSSAPSTEWFKFLQNLGNLQI SNAYREEWS IDAPRRAQI IDACSQRSTSSYWQ IRRDFQIPDEYRFNLVNYERRDPDVDLQEYLQQQERKTLANFRNWKQLEKI IGTGHPIQTLDEA ARLITLIKDDEKLSDQLADLLPEASDKAITQLCELDFTTAAKI SLEAMYRILPHMNQGMGFFDA CQQESLPEIGVPPAGDRVPPFDEMYNPVVNRVLSQSRKLINAVIDEYGMPAKIRVELARDLGKG RELRERIKLDQLDKSKQNDQRAEDFRAEFQQAPRGDQSLRYRLWKEQNCTCPYSGRMIPVNSVL SEDTQIDHILPI SQSFDNSLSNKVLCFTEENAQKSNRTPFEYLDAADFQRLEAI SGNWPEAKRN KLLHKSFGKVAEEWKSRALNDTRYLTSALADHLRHHLPDSKIQTVNGRITGYLRKQWGLEKDRD KHTHHAVDAIVVACTTPAIVQQVTLYHQDIRRYKKLGEKRPTPWPETFRQDVLDVEEEIFITRQ PKKVSGGIQTKDTLRKHRSKPDRQRVALTKVKLADLERLVEKDASNRNLYEHLKQCLEESGDQP TKAFKAPFYMPSGPEAKQRPILSKVTLLREKPEPPKQLTELSGGRRYDSMAQGRLDIYRYKPGG KRKDEYRVVLQRMIDLMRGEENVHVFQKGVPYDQGPEIEQNYTFLFSLYFDDLVEFQRSADSEV IRGYYRTFNIANGQLKI STYLEGRQDFDFFGANRLAHFAKVQVNLLGKVIK
SEQ ID NO: 374
MRSLRYRLALDLGSTSLGWALFRLDACNRPTAVIKAGVRIFSDGRNPKDGSSLAVTRRAARAMR RRRDRLLKRKTRMQAKLVEHGFFPADAGKRKALEQLNPYALRAKGLQEALLPGEFARALFHINQ RRGFKSNRKTDKKDNDSGVLKKAIGQLRQQMAEQGSRTVGEYLWTRLQQGQGVRARYREKPYTT EEGKKRIDKSYDLYIDRAMIEQEFDALWAAQAAFNPTLFHEAARADLKDTLLHQRPLRPVKPGR CTLLPEEERAPLALPSTQRFRIHQEVNHLRLLDENLREVALTLAQRDAVVTALETKAKLSFEQI RKLLKLSGSVQFNLEDAKRTELKGNATSAALARKELFGAAWSGFDEALQDEIVWQLVTEEGEGA LIAWLQTHTGVDEARAQAIVDVSLPEGYGNLSRKALARIVPALRAAVITYDKAVQAAGFDHHSQ LGFEYDASEVEDLVHPETGEIRSVFKQLPYYGKALQRHVAFGSGKPEDPDEKRYGKIANPTVHI GLNQVRMVVNALIRRYGRPTEVVIELARDLKQSREQKVEAQRRQADNQRRNARIRRS IAEVLGI GEERVRGSDIQKWICWEELSFDAADRRCPYSGVQI SAAMLLSDEVEVEHILPFSKTLDDSLNNR TVAMRQANRIKRNRTPWDARAEFEAQGWSYEDILQRAERMPLRKRYRFAPDGYERWLGDDKDFL ARALNDTRYLSRVAAEYLRLVCPGTRVIPGQLTALLRGKFGLNDVLGLDGEKNRNDHRHHAVDA CVIGVTDQGLMQRFATASAQARGDGLTRLVDGMPMPWPTYRDHVERAVRHIWVSHRPDHGFEGA MMEETSYGIRKDGS IKQRRKADGSAGREI SNLIRIHEATQPLRHGVSADGQPLAYKGYVGGSNY CIEITVNDKGKWEGEVI STFRAYGVVRAGGMGRLRNPHEGQNGRKLIMRLVIGDSVRLEVDGAE RTMRIVKI SGSNGQIFMAPIHEANVDARNTDKQDAFTYTSKYAGSLQKAKTRRVTI SPIGEVRD PGFKG
SEQ ID NO: 375
MARPAFRAPRREHVNGWTPDPHRI SKPFFILVSWHLLSRVVIDSSSGCFPGTSRDHTDKFAEWE CAVQPYRLSFDLGTNS IGWGLLNLDRQGKPREIRALGSRIFSDGRDPQDKASLAVARRLARQMR RRRDRYLTRRTRLMGALVRFGLMPADPAARKRLEVAVDPYLARERATRERLEPFEIGRALFHLN QRRGYKPVRTATKPDEEAGKVKEAVERLEAAIAAAGAPTLGAWFAWRKTRGETLRARLAGKGKE AAYPFYPARRMLEAEFDTLWAEQARHHPDLLTAEAREILRHRIFHQRPLKPPPVGRCTLYPDDG RAPRALPSAQRLRLFQELASLRVIHLDLSERPLTPAERDRIVAFVQGRPPKAGRKPGKVQKSVP FEKLRGLLELPPGTGFSLESDKRPELLGDETGARIAPAFGPGWTALPLEEQDALVELLLTEAEP ERAIAALTARWALDEATAAKLAGATLPDFHGRYGRRAVAELLPVLERETRGDPDGRVRPIRLDE AVKLLRGGKDHSDFSREGALLDALPYYGAVLERHVAFGTGNPADPEEKRVGRVANPTVHIALNQ LRHLVNAILARHGRPEEIVIELARDLKRSAEDRRREDKRQADNQKRNEERKRLILSLGERPTPR NLLKLRLWEEQGPVENRRCPYSGETI SMRMLLSEQVDIDHILPFSVSLDDSAANKVVCLREANR IKRNRSPWEAFGHDSERWAGILARAEALPKNKRWRFAPDALEKLEGEGGLRARHLNDTRHLSRL AVEYLRCVCPKVRVSPGRLTALLRRRWGIDAILAEADGPPPEVPAETLDPSPAEKNRADHRHHA LDAVVIGCIDRSMVQRVQLAAASAEREAAAREDNIRRVLEGFKEEPWDGFRAELERRARTIVVS HRPEHGIGGALHKETAYGPVDPPEEGFNLVVRKPIDGLSKDEINSVRDPRLRRALIDRLAIRRR DANDPATALAKAAEDLAAQPASRGIRRVRVLKKESNPIRVEHGGNPSGPRSGGPFHKLLLAGEV HHVDVALRADGRRWVGHWVTLFEAHGGRGADGAAAPPRLGDGERFLMRLHKGDCLKLEHKGRVR VMQVVKLEPSSNSVVVVEPHQVKTDRSKHVKI SCDQLRARGARRVTVDPLGRVRVHAPGARVGI GGDAGRTAMEPAEDIS
SEQ ID NO: 376
MKRTSLRAYRLGVDLGANSLGWFVVWLDDHGQPEGLGPGGVRIFPDGRNPQSKQSNAAGRRLAR SARRRRDRYLQRRGKLMGLLVKHGLMPADEPARKRLECLDPYGLRAKALDEVLPLHHVGRALFH LNQRRGLFANRAIEQGDKDASAIKAAAGRLQTSMQACGARTLGEFLNRRHQLRATVRARSPVGG DVQARYEFYPTRAMVDAEFEAIWAAQAPHHPTMTAEAHDTIREAIFSQRAMKRPS IGKCSLDPA TSQDDVDGFRCAWSHPLAQRFRIWQDVRNLAVVETGPTSSRLGKEDQDKVARALLQTDQLSFDE IRGLLGLPSDARFNLESDRRDHLKGDATGAILSARRHFGPAWHDRSLDRQIDIVALLESALDEA AIIASLGTTHSLDEAAAQRALSALLPDGYCRLGLRAIKRVLPLMEAGRTYAEAASAAGYDHALL PGGKLSPTGYLPYYGQWLQNDVVGSDDERDTNERRWGRLPNPTVHIGIGQLRRVVNELIRWHGP PAEITVELTRDLKLSPRRLAELEREQAENQRKNDKRTSLLRKLGLPASTHNLLKLRLWDEQGDV ASECPYTGEAIGLERLVSDDVDIDHLIPFS I SWDDSAANKVVCMRYANREKGNRTPFEAFGHRQ GRPYDWADIAERAARLPRGKRWRFGPGARAQFEELGDFQARLLNETSWLARVAKQYLAAVTHPH RIHVLPGRLTALLRATWELNDLLPGSDDRAAKSRKDHRHHAIDALVAALTDQALLRRMANAHDD TRRKIEVLLPWPTFRIDLETRLKAMLVSHKPDHGLQARLHEDTAYGTVEHPETEDGANLVYRKT FVDI SEKEIDRIRDRRLRDLVRAHVAGERQQGKTLKAAVLSFAQRRDIAGHPNGIRHVRLTKS I KPDYLVPIRDKAGRIYKSYNAGENAFVDILQAESGRWIARATTVFQANQANESHDAPAAQPIMR VFKGDMLRIDHAGAEKFVKIVRLSPSNNLLYLVEHHQAGVFQTRHDDPEDSFRWLFASFDKLRE WNAELVRIDTLGQPWRRKRGLETGSEDATRIGWTRPKKWP
SEQ ID NO: 377
MERIFGFDIGTTS IGFSVIDYSSTQSAGNIQRLGVRIFPEARDPDGTPLNQQRRQKRMMRRQLR RRRIRRKALNETLHEAGFLPAYGSADWPVVMADEPYELRRRGLEEGLSAYEFGRAIYHLAQHRH FKGRELEESDTPDPDVDDEKEAANERAATLKALKNEQTTLGAWLARRPPSDRKRGIHAHRNVVA EEFERLWEVQSKFHPALKSEEMRARI SDTIFAQRPVFWRKNTLGECRFMPGEPLCPKGSWLSQQ RRMLEKLNNLAIAGGNARPLDAEERDAILSKLQQQASMSWPGVRSALKALYKQRGEPGAEKSLK FNLELGGESKLLGNALEAKLADMFGPDWPAHPRKQEIRHAVHERLWAADYGETPDKKRVI ILSE KDRKAHREAAANSFVADFGITGEQAAQLQALKLPTGWEPYS IPALNLFLAELEKGERFGALVNG PDWEGWRRTNFPHRNQPTGEILDKLPSPASKEERERI SQLRNPTVVRTQNELRKVVNNLIGLYG KPDRIRIEVGRDVGKSKREREEIQSGIRRNEKQRKKATEDLIKNGIANPSRDDVEKWILWKEGQ ERCPYTGDQIGFNALFREGRYEVEHIWPRSRSFDNSPRNKTLCRKDVNIEKGNRMPFEAFGHDE DRWSAIQIRLQGMVSAKGGTGMSPGKVKRFLAKTMPEDFAARQLNDTRYAAKQILAQLKRLWPD MGPEAPVKVEAVTGQVTAQLRKLWTLNNILADDGEKTRADHRHHAIDALTVACTHPGMTNKLSR YWQLRDDPRAEKPALTPPWDTIRADAEKAVSEIVVSHRVRKKVSGPLHKETTYGDTGTDIKTKS GTYRQFVTRKKIESLSKGELDEIRDPRIKEIVAAHVAGRGGDPKKAFPPYPCVSPGGPEIRKVR LTSKQQLNLMAQTGNGYADLGSNHHIAIYRLPDGKADFEIVSLFDASRRLAQRNPIVQRTRADG ASFVMSLAAGEAIMIPEGSKKGIWIVQGVWASGQVVLERDTDADHSTTTRPMPNPILKDDAKKV SIDPIGRVRPSND
SEQ ID NO: 378
MNKRILGLDTGTNSLGWAVVDWDEHAQSYELIKYGDVIFQEGVKIEKGIESSKAAERSGYKAIR KQYFRRRLRKIQVLKVLVKYHLCPYLSDDDLRQWHLQKQYPKSDELMLWQRTSDEEGKNPYYDR HRCLHEKLDLTVEADRYTLGRALYHLTQRRGFLSNRLDTSADNKEDGVVKSGI SQLSTEMEEAG CEYLGDYFYKLYDAQGNKVRIRQRYTDRNKHYQHEFDAICEKQELSSELIEDLQRAIFFQLPLK SQRHGVGRCTFERGKPRCADSHPDYEEFRMLCFVNNIQVKGPHDLELRPLTYEEREKIEPLFFR KSKPNFDFEDIAKALAGKKNYAWIHDKEERAYKFNYRMTQGVPGCPTIAQLKS IFGDDWKTGIA ETYTLIQKKNGSKSLQEMVDDVWNVLYSFSSVEKLKEFAHHKLQLDEESAEKFAKIKLSHSFAA LSLKAIRKFLPFLRKGMYYTHASFFANIPTIVGKEIWNKEQNRKYIMENVGELVFNYQPKHREV QGTIEMLIKDFLANNFELPAGATDKLYHPSMIETYPNAQRNEFGILQLGSPRTNAIRNPMAMRS LHILRRVVNQLLKES I IDENTEVHVEYARELNDANKRRAIADRQKEQDKQHKKYGDEIRKLYKE ETGKDIEPTQTDVLKFQLWEEQNHHCLYTGEQIGITDFIGSNPKFDIEHTIPQSVGGDSTQMNL TLCDNRFNREVKKAKLPTELANHEEILTRIEPWKNKYEQLVKERDKQRTFAGMDKAVKDIRIQK RHKLQMEIDYWRGKYERFTMTEVPEGFSRRQGTGIGLI SRYAGLYLKSLFHQADSRNKSNVYVV KGVATAEFRKMWGLQSEYEKKCRDNHSHHCMDAITIACIGKREYDLMAEYYRMEETFKQGRGSK PKFSKPWATFTEDVL IYKNLLVVHDTPNNMPKHTKKYVQTS IGKVLAQGDTARGSLHLDTYYG AIERDGEIRYVVRRPLSSFTKPEELENIVDETVKRTIKEAIADKNFKQAIAEPIYMNEEKGILI KKVRCFAKSVKQPINIRQHRDLSKKEYKQQYHVMNENNYLLAIYEGLVKNKVVREFEIVSYIEA AKYYKRSQDRNIFSS IVPTHSTKYGLPLKTKLLMGQLVLMFEENPDEIQVDNTKDLVKRLYKVV GIEKDGRIKFKYHQEARKEGLPIFSTPYKNNDDYAPIFRQS INNINILVDGIDFTIDILGKVTL KE
SEQ ID NO: 379
MNYKMGLDIGIASVGWAVINLDLKRIEDLGVRIFDKAEHPQNGESLALPRRIARSARRRLRRRK HRLERIRRLLVSENVLTKEEMNLLFKQKKQIDVWQLRVDALERKLNNDELARVLLHLAKRRGFK SNRKSERNSKESSEFLKNIEENQS ILAQYRSVGEMIVKDSKFAYHKRNKLDSYSNMIARDDLER EIKLIFEKQREFNNPVCTERLEEKYLNIWSSQRPFASKEDIEKKVGFCTFEPKEKRAPKATYTF QSFIVWEHINKLRLVSPDETRALTEIERNLLYKQAFSKNKMTYYDIRKLLNLSDDIHFKGLLYD PKSSLKQIENIRFLELDSYHKIRKCIENVYGKDGIRMFNETDIDTFGYALTIFKDDEDIVAYLQ NEYITKNGKRVSNLANKVYDKSLIDELLNLSFSKFAHLSMKAIR ILPYMEQGEIYSKACELAG YNFTGPKKKEKALLLPVIPNIANPVVMRALTQSRKVVNAI IKKYGSPVS IHIELARDLSHSFDE RKKIQKDQTENRKKNETAIKQLIEYELTKNPTGLDIVKFKLWSEQQGRCMYSLKPIELERLLEP GYVEVDHILPYSRSLDDSYANKVLVLTKENREKGNHTPVEYLGLGSERWKKFEKFVLANKQFSK KKKQNLLRLRYEETEEKEFKERNLNDTRYI SKFFANFIKEHLKFADGDGGQKVYTINGKITAHL RSRWDFNKNREESDLHHAVDAVIVACATQGMIKKITEFYKAREQNKESAKKKEPIFPQPWPHFA DELKARLSKFPQES IEAFALGNYDRKKLESLRPVFVSRMPKRSVTGAAHQETLRRCVGIDEQSG KIQTAVKTKLSDIKLDKDGHFPMYQKESDPRTYEAIRQRLLEHNNDPKKAFQEPLYKPKKNGEP GPVIRTVKI IDTKNKVVHLDGSKTVAYNS IVRTDVFEKDGKYYCVPVYTMDIMKGTLPNKAIE ANKPYSEWKEMTEEYTFQFSLFPNDLVRIVLPREKTIKTSTNEEI I IKDIFAYYKTIDSATGGL ELI SHDRNFSLRGVGSKTLKRFEKYQVDVLG IHKVKGEKRVGLAAPTNQKKGKTVDSLQSVSD
SEQ ID NO: 380
MRRLGLDLGTNS IGWCLLDLGDDGEPVS IFRTGARIFSDGRDPKSLGSLKATRREARLTRRRRD RFIQRQKNLINALVKYGLMPADEIQRQALAYKDPYPIRKKALDEAIDPYEMGRAIFHINQRRGF KSNRKSADNEAGVVKQS IADLEMKLGEAGARTIGEFLADRQATNDTVRARRLSGTNALYEFYPD RYMLEQEFDTLWAKQAAFNPSLYIEAARERLKEIVFFQRKLKPQEVGRCIFLSDEDRI SKALPS FQRFRIYQELSNLAWIDHDGVAHRITASLALRDHLFDELEHKKKLTFKAMRAILRKQGVVDYPV GFNLESDNRDHLIGNLTSCIMRDAKKMIGSAWDRLDEEEQDSFILMLQDDQKGDDEVRS ILTQQ YGLSDDVAEDCLDVRLPDGHGSLSKKAIDRILPVLRDQGLIYYDAVKEAGLGEANLYDPYAALS DKLDYYGKALAGHVMGASGKFEDSDEKRYGTI SNPTVHIALNQVRAVVNELIRLHGKPDEVVIE IGRDLPMGADGKRELERFQKEGRAKNERARDELKKLGHIDSRESRQKFQLWEQLAKEPVDRCCP FTGKMMS I SDLFSDKVEIEHLLPFSLTLDDSMANKTVCFRQANRDKGNRAPFDAFGNSPAGYDW QEILGRSQNLPYAKRWRFLPDAMKRFEADGGFLERQLNDTRYI SRYTTEYI STI IPKNKIWVVT GRLTSLLRGFWGLNS ILRGHNTDDGTPAKKSRDDHRHHAIDAIVVGMTSRGLLQKVSKAARRSE DLDLTRLFEGRIDPWDGFRDEVKKHIDAI IVSHRPRKKSQGALHNDTAYGIVEHAENGASTVVH RVPITSLGKQSDIEKVRDPLIKSALLNETAGLSGKSFENAVQKWCADNS IKSLRIVETVS I IPI TDKEGVAYKGYKGDGNAYMDIYQDPTSSKWKGEIVSRFDANQKGFIPSWQSQFPTARLIMRLRI NDLLKLQDGEIEEIYRVQRLSGSKILMAPHTEANVDARDRDKNDTFKLTSKSPGKLQSASARKV HISPTGLIREG SEQ ID NO: 381
MK ILGLDLGLSS IGWSVIRENSEEQELVAMGSRVVSLTAAELSSFTQGNGVS INSQRTQKRTQ RKGYDRYQLRRTLLRNKLDTLGMLPDDSLSYLPKLQLWGLRAKAVTQRIELNELGRVLLHLNQK RGYKS IKSDFSGDKKITDYVKTVKTRYDELKEMRLTIGELFFRRLTENAFFRCKEQVYPRQAYV EEFDCIMNCQRKFYPDILTDETIRCIRDEI IYYQRPLKSCKYLVSRCEFEKRFYLNAAGKKTEA GPKVSPRTSPLFQVCRLWES IN IVVKDRRNEIVFI SAEQRAALFDFLNTHEKLKGSDLLKLLG LSKTYGYRLGEQFKTGIQGNKTRVEIERALGNYPDKKRLLQFNLQEESSSMVNTETGEI IPMI S LSFEQEPLYRLWHVLYS IDDREQLQSVLRQKFGIDDDEVLERLSAIDLVKAGFGNKSSKAIRRI LPFLQLGMNYAEACEAAGYNHSNNYTKAENEARALLDRLPAIKKNELRQPVVEKILNQMVNVVN ALMEKYGRFDEIRVELARELKQSKEERSNTYKS INKNQRENEQIAKRIVEYGVPTRSRIQKYKM WEESKHCCIYCGQPVDVGDFLRGFDVEVEHI IPKSLYFDDSFANKVCSCRSCNKEKNNRTAYDY MKSKGEKALSDYVERVNTMYTNNQI SKTKWQNLLTPVDKI S IDFIDRQLRESQYIARKAKEILT SICYNVTATSGSVTSFLRHVWGWDTVLHDLNFDRYKKVGLTEVIEVNHRGSVIRREQIKDWSKR FDHRHHAIDALTIACTKQAYIQRLNNLRAEEGPDFNKMSLERYIQSQPHFSVAQVREAVDRILV SFRAGKRAVTPGKRYIRKNRKRI SVQSVLIPRGALSEESVYGVIHVWEKDEQGHVIQKQRAVMK YPITS INREMLDKEKVVDKRIHRILSGRLAQYNDNPKEAFAKPVYIDKECRIPIRTVRCFAKPA INTLVPLKKDDKGNPVAWVNPGNNHHVAIYRDEDGKYKERTVTFWEAVDRCRVGIPAIVTQPDT IWD ILQRNDI SENVLESLPDVKWQFVLSLQQNEMFILGMNEEDYRYAMDQQDYALLNKYLYRV QKLSKSDYSFRYHTETSVEDKYDGKPNLKLSMQMGKLKRVS IKSLLGLNPHKVHI SVLGEIKEI S
SEQ ID NO: 382
MAEKQHRWGLDIGTNS IGWAVIALIEGRPAGLVATGSRIFSDGRNPKDGSSLAVERRGPRQMRR RRDRYLRRRDRFMQALINVGLMPGDAAARKALVTENPYVLRQRGLDQALTLPEFGRALFHLNQR RGFQSNRKTDRATAKESGKVKNAIAAFRAGMGNARTVGEALARRLEDGRPVRARMVGQGKDEHY ELYIAREWIAQEFDALWASQQRFHAEVLADAARDRLRAILLFQRKLLPVPVGKCFLEPNQPRVA AALPSAQRFRLMQELNHLRVMTLADKRERPLSFQERNDLLAQLVARPKCGFDMLRKIVFGANKE AYRFTIESERRKELKGCDTAAKLAKVNALGTRWQALSLDEQDRLVCLLLDGENDAVLADALREH YGLTDAQIDTLLGLSFEDGHMRLGRSALLRVLDALESGRDEQGLPLSYDKAVVAAGYPAHTADL ENGERDALPYYGELLWRYTQDAPTAKNDAERKFGKIANPTVHIGLNQLRKLVNALIQRYGKPAQ IVVELARNLKAGLEEKERIKKQQTANLERNERIRQKLQDAGVPDNRENRLRMRLFEELGQGNGL GTPCIYSGRQI SLQRLFSNDVQVDHILPFSKTLDDSFANKVLAQHDANRYKGNRGPFEAFGANR DGYAWDDIRARAAVLPRNKRNRFAETAMQDWLHNETDFLARQLTDTAYLSRVARQYLTAICSKD DVYVSPGRLTAMLRAKWGLNRVLDGVMEEQGRPAVKNRDDHRHHAIDAVVIGATDRAMLQQVAT LAARAREQDAERLIGDMPTPWPNFLEDVRAAVARCVVSHKPDHGPEGGLHNDTAYGIVAGPFED GRYRVRHRVSLFDLKPGDLSNVRCDAPLQAELEPIFEQDDARAREVALTALAERYRQRKVWLEE LMSVLPIRPRGEDGKTLPDSAPYKAYKGDSNYCYELFINERGRWDGELI STFRANQAAYRRFRN DPARFRRYTAGGRPLLMRLCINDYIAVGTAAERTIFRVVKMSENKITLAEHFEGGTLKQRDADK DDPFKYLTKSPGALRDLGARRIFVDLIGRVLDPGIKGD
SEQ ID NO: 383
MIERILGVDLGI SSLGWAIVEYDKDDEAANRI IDCGVRLFTAAETPKKKESPNKARREARGIRR VLNRRRVRMNMIKKLFLRAGLIQDVDLDGEGGMFYSKANRADVWELRHDGLYRLLKGDELARVL IHIAKHRGYKFIGDDEADEESGKVKKAGVVLRQNFEAAGCRTVGEWLWRERGANGKKRNKHGDY EI S IHRDLLVEEVEAIFVAQQEMRSTIATDALKAAYREIAFFVRPMQRIEKMVGHCTYFPEERR APKSAPTAEKFIAI SKFFSTVI IDNEGWEQKI IERKTLEELLDFAVSREKVEFRHLRKFLDLSD NEIFKGLHYKGKPKTAKKREATLFDPNEPTELEFDKVEAEKKAWI SLRGAAKLREALGNEFYGR FVALGKHADEATKILTYYKDEGQKRRELTKLPLEAEMVERLVKIGFSDFLKLSLKAIRDILPAM ESGARYDEAVLMLGVPHKEKSAILPPLNKTDIDILNPTVIRAFAQFRKVANALVRKYGAFDRVH FELAREINTKGEIEDIKESQRKNEKERKEAADWIAETSFQVPLTRKNILKKRLYIQQDGRCAYT GDVIELERLFDEGYCEIDHILPRSRSADDSFANKVLCLARANQQKTDRTPYEWFGHDAARWNAF ETRTSAPSNRVRTGKGKIDRLLKKNFDENSEMAFKDRNLNDTRYMARAIKTYCEQYWVFKNSHT KAPVQVRSGKLTSVLRYQWGLESKDRESHTHHAVDAI I IAFSTQGMVQKLSEYYRFKETHREKE RPKLAVPLANFRDAVEEATRIENTETVKEGVEVKRLLI SRPPRARVTGQAHEQTAKPYPRIKQV KNKKKWRLAPIDEEKFESFKADRVASANQKNFYETSTIPRVDVYHKKGKFHLVPIYLHEMVLNE LPNLSLGTNPEAMDENFFKFS IFKDDLI S IQTQGTPKKPAKI IMGYFKNMHGANMVLSS INNSP CEGFTCTPVSMDKKHKDKCKLCPEENRIAGRCLQGFLDYWSQEGLRPPRKEFECDQGVKFALDV KKYQIDPLGYYYEVKQEKRLGTIPQMRSAKKLVKK
SEQ ID NO: 384
MNNS IKSKPEVTIGLDLGVGSVGWAIVDNET I IHHLGSRLFSQAKTAEDRRSFRGVRRLIRRR KYKLKRFVNLIWKYNSYFGFKNKEDILNNYQEQQKLHNTVLNLKSEALNAKIDPKALSWILHDY LKNRGHFYEDNRDFNVYPTKELAKYFDKYGYYKGI IDSKEDNDNKLEEELTKYKFSNKHWLEEV KKVLSNQTGLPEKFKEEYESLFSYVRNYSEGPGS INSVSPYGIYHLDEKEGKVVQKYN IWDKT IGKCNIFPDEYRAPKNSPIAMIFNEINELSTIRSYS IYLTGWFINQEFKKAYLNKLLDLLIKTN GEKPIDARQFKKLREETIAES IGKETLKDVENEEKLEKEDHKWKLKGLKLNTNGKIQYNDLSSL AKFVHKLKQHLKLDFLLEDQYATLDKINFLQSLFVYLGKHLRYSNRVDSANLKEFSDSNKLFER ILQKQKDGLFKLFEQTDKDDEKILAQTHSLSTKAMLLAITRMTNLDNDEDNQKNNDKGWNFEAI KNFDQKFIDITKKNNNLSLKQNKRYLDDRFINDAILSPGVKRILREATKVFNAILKQFSEEYDV TKVVIELARELSEEKELENTKNYKKLIKKNGDKI SEGLKALGI SEDEIKDILKSPTKSYKFLLW LQQDHIDPYSLKEIAFDDIFTKTEKFEIDHI IPYS I SFDDSSSNKLLVLAESNQAKSNQTPYEF ISSGNAGIKWEDYEAYCRKFKDGDSSLLDSTQRSKKFAKMMKTDTSSKYDIGFLARNLNDTRYA TIVFRDALEDYANNHLVEDKPMFKVVCINGSVTSFLRKNFDDSSYAKKDRDK IHHAVDAS IIS IFSNETKTLFNQLTQFADYKLFKNTDGSWKKIDPKTGVVTEVTDENWKQIRVRNQVSEIAKVIE KYIQDS IERKARYSRKIENKT I SLFNDTVYSAKKVGYEDQIKRKNLKTLDIHESAKENKNSK VKRQFVYRKLVNVSLLNNDKLADLFAEKEDILMYRANPWVINLAEQIFNEYTENKKIKSQNVFE KYMLDLTKEFPEKFSEFLVKSMLRNKTAI IYDDKK IVHRIKRLKMLSSELKENKLSNVI IRSK NQSGTKLSYQDTINSLALMIMRS IDPTAKKQYIRVPLNTLNLHLGDHDFDLHNMDAYLKKPKFV KYLKANEIGDEYKPWRVLTSGTLLIHKKDKKLMYISSFQNLNDVIEIKNLIETEYKENDDSDSK KKKKANRFLMTLSTILNDYILLDAKDNFDILGLSKNRIDEILNSKLGLDKIVK
SEQ ID NO: 385
MGGSEVGTVPVTWRLGVDVGERS IGLAAVSYEEDKPKEILAAVSWIHDGGVGDERSGASRLALR GMARRARRLRRFRRARLRDLDMLLSELGWTPLPDKNVSPVDAWLARKRLAEEYVVDETERRRLL GYAVSHMARHRGWRNPWTTIKDLKNLPQPSDSWERTRESLEARYSVSLEPGTVGQWAGYLLQRA PGIRLNPTQQSAGRRAELSNATAFETRLRQEDVLWELRCIADVQGLPEDVVSNVIDAVFCQKRP SVPAERIGRDPLDPSQLRASRACLEFQEYRIVAAVANLRIRDGSGSRPLSLEERNAVIEALLAQ TERSLTWSDIALEILKLPNESDLTSVPEEDGPSSLAYSQFAPFDETSARIAEFIAKNRRKIPTF AQWWQEQDRTSRSDLVAALADNS IAGEEEQELLVHLPDAELEALEGLALPSGRVAYSRLTLSGL TRVMRDDGVDVHNARKTCFGVDDNWRPPLPALHEATGHPVVDRNLAILRKFLSSATMRWGPPQS IVVELARGASESRERQAEEEAARRAHRKANDRIRAELRASGLSDPSPADLVRARLLELYDCHCM YCGAPI SWENSELDHIVPRTDGGSNRHENLAITCGACNKEKGRRPFASWAETSNRVQLRDVIDR VQKLKYSGNMYWTRDEFSRYKKSVVARLKRRTSDPEVIQS IESTGYAAVALRDRLLSYGEKNGV AQVAVFRGGVTAEARRWLDI S IERLFSRVAIFAQSTSTKRLDRRHHAVDAVVLTTLTPGVAKTL ADARSRRVSAEFWRRPSDVNRHSTEEPQSPAYRQWKESCSGLGDLLI STAARDS IAVAAPLRLR PTGALHEETLRAFSEHTVGAAWKGAELRRIVEPEVYAAFLALTDPGGRFLKVSPSEDVLPADEN RHIVLSDRVLGPRDRVKLFPDDRGS IRVRGGAAYIASFHHARVFRWGSSHSPSFALLRVSLADL AVAGLLRDGVDVFTAELPPWTPAWRYAS IALVKAVESGDAKQVGWLVPGDELDFGPEGVTTAAG DLSMFLKYFPERHWVVTGFEDDKRINLKPAFLSAEQAEVLRTERSDRPDTLTEAGEILAQFFPR CWRATVAKVLCHPGLTVIRRTALGQPRWRRGHLPYSWRPWSADPWSGGTP
SEQ ID NO: 386
MHNKKNITIGFDLGIAS IGWAI IDSTTSKILDWGTRTFEERKTANERRAFRSTRRNIRRKAYRN QRFINLILKYKDLFELKNI SDIQRANKKDTENYEKI I SFFTEIYKKCAAKHSNILEVKVKALDS KIEKLDLIWILHDYLENRGFFYDLEEENVADKYEGIEHPS ILLYDFFKKNGFFKSNSS IPKDLG GYSFSNLQWVNEIKKLFEVQEINPEFSEKFLNLFTSVRDYAKGPGSEHSASEYGIFQKDEKGKV FKKYDNIWDKTIGKCSFFVEENRSPVNYPSYEIFNLLNQLINLSTDLKTTNKKIWQLSSNDRNE LLDELLKVKEKAKI I S I SLKKNEIKKI ILKDFGFEKSDIDDQDTIEGRKI IKEEPTTKLEVTKH LLATIYSHSSDSNWININNILEFLPYLDAICI ILDREKSRGQDEVLKKLTEKNIFEVLKIDREK QLDFVKS IFSNTKFNFKKIGNFSLKAIREFLPKMFEQNKNSEYLKWKDEEIRRKWEEQKSKLGK TDKKTKYLNPRIFQDEI I SPGTKNTFEQAVLVLNQI IKKYSKENI IDAI I IESPREKNDKKTIE EIKKRNKKGKGKTLEKLFQILNLENKGYKLSDLETKPAKLLDRLRFYHQQDGIDLYTLDKINID QLINGSQKYEIEHI IPYSMSYDNSQANKILTEKAENLKKGKLIASEYIKRNGDEFYNKYYEKAK ELFINKYKKNKKLDSYVDLDEDSAKNRFRFLTLQDYDEFQVEFLARNLNDTRYSTKLFYHALVE HFENNEFFTYIDENSSKHKVKI STIKGHVTKYFRAKPVQKNNGPNENLNNNKPEKIEKNRENNE HHAVDAAIVAI IGNKNPQIANLLTLADNKTDKKFLLHDENYKENIETGELVKIPKFEVDKLAKV EDLKKI IQEKYEEAKKHTAIKFSRKTRTILNGGLSDETLYGFKYDEKEDKYFKI IKKKLVTSKN EELKKYFENPFGKKADGKSEYTVLMAQSHLSEFNKLKEIFEKYNGFSNKTGNAFVEYMNDLALK EPTLKAEIESAKSVEKLLYYNFKPSDQFTYHDNINNKSFKRFYKNIRI IEYKS IPIKFKILSKH DGGKSFKDTLFSLYSLVYKVYENGKESYKS IPVTSQMRNFGIDEFDFLDENLYNKEKLDIYKSD FAKPIPVNCKPVFVLKKGS ILKKKSLDIDDFKETKETEEGNYYFI STI SKRFNRDTAYGLKPLK LSVVKPVAEPSTNPIFKEYIPIHLDELGNEYPVKIKEHTDDEKLMCTIK
Nucleic Acids Encoding Cas9 Molecules
Nucleic acids encoding the Cas9 molecules or Cas9 polypeptides, e.g., an eaCas9 molecule or eaCas9 polypeptide are provided herein.
Exemplary nucleic acids encoding Cas9 molecules are described in Cong et ah, SCIENCE 2013, 399(6121):819-823; Wang et al, CELL 2013, 153(4):910-918; Mali et al, SCIENCE 2013, 399(6121):823-826; Jinek et al, SCIENCE 2012, 337(6096):816-821. Another exemplary nucleic acid encoding a Cas9 molecule or Cas9 polypeptide is shown in Fig. 8.
In an embodiment, a nucleic acid encoding a Cas9 molecule or Cas9 polypeptide can be a synthetic nucleic acid sequence. For example, the synthetic nucleic acid molecule can be chemically modified, e.g., as described in Section VIII. In an embodiment, the Cas9 mRNA has one or more (e.g., all of the following properties: it is capped, polyadenylated, substituted with 5- methylcytidine and/or pseudouridine. In addition, or alternatively, the synthetic nucleic acid sequence can be codon optimized, e.g., at least one non-common codon or less-common codon has been replaced by a common codon. For example, the synthetic nucleic acid can direct the synthesis of an optimized messenger mRNA, e.g., optimized for expression in a mammalian expression system, e.g., described herein.
In addition, or alternatively, a nucleic acid encoding a Cas9 molecule or Cas9 polypeptide may comprise a nuclear localization sequence (NLS). Nuclear localization sequences are known in the art.
Provided below is an exemplary codon optimized nucleic acid sequence encoding a Cas9 molecule of S. pyogenes.
ATGGATAAAA AGTACAGCAT CGGGCTGGAC ATCGGTACAA ACTCAGTGGG GTGGGCCGTG ATTACGGACG AGTACAAGGT ACCCTCCAAA AAATTTAAAG TGCTGGGTAA CACGGACAGA CACTCTATAA AGAAAAATCT TATTGGAGCC TTGCTGTTCG ACTCAGGCGA GACAGCCGAA GCCACAAGGT TGAAGCGGAC CGCCAGGAGG CGGTATACCA GGAGAAAGAA CCGCATATGC TACCTGCAAG AAATCTTCAG TAACGAGATG GCAAAGGTTG ACGATAGCTT TTTCCATCGC CTGGAAGAAT CCTTTCTTGT TGAGGAAGAC AAGAAGCACG AACGGCACCC CATCTTTGGC AATATTGTCG ACGAAGTGGC ATATCACGAA AAGTACCCGA CTATCTACCA CCTCAGGAAG AAGCTGGTGG ACTCTACCGA TAAGGCGGAC CTCAGACTTA TTTATTTGGC ACTCGCCCAC AT GAT T AAA T TTAGAGGACA TTTCTTGATC GAGGGCGACC TGAACCCGGA CAACAGTGAC GTCGATAAGC TGTTCATCCA ACTTGTGCAG ACCTACAATC AACTGTTCGA AGAAAACCCT ATAAATGCTT CAGGAGTCGA CGCTAAAGCA ATCCTGTCCG CGCGCCTCTC AAAATCTAGA AGACTTGAGA ATCTGATTGC TCAGTTGCCC GGGGAAAAGA AAAATGGATT GTTTGGCAAC CTGATCGCCC TCAGTCTCGG ACTGACCCCA AATTTCAAAA GTAACTTCGA CCTGGCCGAA GACGCTAAGC TCCAGCTGTC CAAGGACACA TACGATGACG ACCTCGACAA TCTGCTGGCC CAGATTGGGG ATCAGTACGC CGATCTCTTT TTGGCAGCAA AGAACCTGTC CGACGCCATC CTGTTGAGCG ATATCTTGAG AGTGAACACC GAAATTACTA AAGCACCCCT TAGCGCATCT ATGATCAAGC GGTACGACGA GCATCATCAG GATCTGACCC TGCTGAAGGC TCTTGTGAGG CAACAGCTCC CCGAAAAATA CAAGGAAATC TTCTTTGACC AGAGCAAAAA CGGCTACGCT GGCTATATAG ATGGTGGGGC CAGTCAGGAG GAATTCTATA AATTCATCAA GCCCATTCTC GAGAAAATGG ACGGCACAGA GGAGTTGCTG GTCAAACTTA ACAGGGAGGA CCTGCTGCGG AAGCAGCGGA CCTTTGACAA CGGGTCTATC CCCCACCAGA TTCATCTGGG CGAACTGCAC GCAATCCTGA GGAGGCAGGA GGATTTTTAT CCTTTTCTTA AAGATAACCG CGAGAAAATA GAAAAGATTC TTACATTCAG GATCCCGTAC TACGTGGGAC CTCTCGCCCG GGGCAATTCA CGGTTTGCCT GGATGACAAG GAAGTCAGAG GAGACTATTA CACCTTGGAA CTTCGAAGAA GTGGTGGACA AGGGTGCATC TGCCCAGTCT TTCATCGAGC GGATGACAAA TTTTGACAAG AACCTCCCTA ATGAGAAGGT GCTGCCCAAA CATTCTCTGC TCTACGAGTA CTTTACCGTC TACAATGAAC TGACTAAAGT CAAGTACGTC ACCGAGGGAA TGAGGAAGCC GGCATTCCTT AGTGGAGAAC AGAAGAAGGC GATTGTAGAC CTGTTGTTCA AGACCAACAG GAAGGTGACT GTGAAGCAAC TTAAAGAAGA CTACTTTAAG AAGATCGAAT GTTTTGACAG TGTGGAAATT TCAGGGGTTG AAGACCGCTT CAATGCGTCA TTGGGGACTT ACCATGATCT TCTCAAGATC ATAAAGGACA AAGACTTCCT GGACAACGAA GAAAATGAGG ATATTCTCGA AGACATCGTC CTCACCCTGA CCCTGTTCGA AGACAGGGAA ATGATAGAAG AGCGCTTGAA AACCTATGCC CACCTCTTCG ACGATAAAGT TATGAAGCAG CTGAAGCGCA GGAGATACAC AGGATGGGGA AGATTGTCAA GGAAGCTGAT CAATGGAATT AGGGATAAAC AGAGTGGCAA GACCATACTG GATTTCCTCA AATCTGATGG CTTCGCCAAT AGGAACTTCA TGCAACTGAT TCACGATGAC TCTCTTACCT TCAAGGAGGA CATTCAAAAG GCTCAGGTGA GCGGGCAGGG AGACTCCCTT CATGAACACA TCGCGAATTT GGCAGGTTCC CCCGCTATTA AAAAGGGCAT CCTTCAAACT GTCAAGGTGG TGGATGAATT GGTCAAGGTA ATGGGCAGAC ATAAGCCAGA AAATATTGTG ATCGAGATGG CCCGCGAAAA CCAGACCACA CAGAAGGGCC AGAAAAATAG TAGAGAGCGG ATGAAGAGGA TCGAGGAGGG CATCAAAGAG CTGGGATCTC AGATTCTCAA AGAACACCCC GTAGAAAACA CACAGCTGCA GAACGAAAAA TTGTACTTGT ACTATCTGCA GAACGGCAGA GACATGTACG TCGACCAAGA ACTTGATATT AATAGACTGT CCGACTATGA CGTAGACCAT ATCGTGCCCC AGTCCTTCCT GAAGGACGAC TCCATTGATA ACAAAGTCTT GACAAGAAGC GACAAGAACA GGGGTAAAAG TGATAATGTG CCTAGCGAGG AGGTGGTGAA AAAAATGAAG AACTACTGGC GACAGCTGCT TAATGCAAAG CTCATTACAC AACGGAAGTT CGATAATCTG ACGAAAGCAG AGAGAGGTGG CTTGTCTGAG TTGGACAAGG CAGGGTTTAT TAAGCGGCAG CTGGTGGAAA CTAGGCAGAT CACAAAGCAC GTGGCGCAGA TTTTGGACAG CCGGATGAAC ACAAAATACG ACGAAAATGA TAAACTGATA CGAGAGGTCA AAGTTATCAC GCTGAAAAGC AAGCTGGTGT CCGATTTTCG GAAAGACTTC CAGTTCTACA AAGTTCGCGA GATTAATAAC TACCATCATG CTCACGATGC GTACCTGAAC GCTGTTGTCG GGACCGCCTT GATAAAGAAG TACCCAAAGC TGGAATCCGA GTTCGTATAC GGGGATTACA AAGTGTACGA TGTGAGGAAA ATGATAGCCA AGTCCGAGCA GGAGATTGGA AAGGCCACAG CTAAGTACTT CTTTTATTCT AACATCATGA ATTTTTTTAA GACGGAAATT ACCCTGGCCA ACGGAGAGAT CAGAAAGCGG CCCCTTATAG AGACAAATGG TGAAACAGGT GAAATCGTCT GGGATAAGGG CAGGGATTTC GCTACTGTGA GGAAGGTGCT GAGTATGCCA CAGGTAAATA TCGTGAAAAA AACCGAAGTA CAGACCGGAG GATTTTCCAA GGAAAGCATT TTGCCTAAAA GAAACTCAGA CAAGCTCATC GCCCGCAAGA AAGATTGGGA CCCTAAGAAA TACGGGGGAT TTGACTCACC CACCGTAGCC TATTCTGTGC TGGTGGTAGC TAAGGTGGAA AAAGGAAAGT CTAAGAAGCT GAAGTCCGTG AAGGAACTCT TGGGAATCAC TATCATGGAA AGATCATCCT TTGAAAAGAA CCCTATCGAT TTCCTGGAGG CTAAGGGTTA CAAGGAGGTC AAGAAAGACC TCATCATTAA ACTGCCAAAA TACTCTCTCT TCGAGCTGGA AAATGGCAGG AAGAGAATGT TGGCCAGCGC CGGAGAGCTG CAAAAGGGAA ACGAGCTTGC TCTGCCCTCC AAATATGTTA ATTTTCTCTA TCTCGCTTCC CACTATGAAA AGCTGAAAGG GTCTCCCGAA GATAACGAGC AGAAGCAGCT GTTCGTCGAA CAGCACAAGC ACTATCTGGA TGAAATAATC GAACAAATAA GCGAGTTCAG CAAAAGGGTT ATCCTGGCGG ATGCTAATTT GGACAAAGTA CTGTCTGCTT ATAACAAGCA CCGGGATAAG CCTATTAGGG AACAAGCCGA GAATATAATT CACCTCTTTA CACTCACGAA TCTCGGAGCC CCCGCCGCCT TCAAATACTT TGATACGACT ATCGACCGGA
AACGGTATAC CAGTACCAAA GAGGTCCTCG ATGCCACCCT CATCCACCAG TCAATTACTG GCCTGTACGA AACACGGATC GACCTCTCTC AACTGGGCGG CGACTAG
(SEQ ID NO: 22)
Provided below is the corresponding amino acid sequence of a S. pyogenes Cas9 molecule.
MDKKYS IGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHS IKKNLIGALLFDSGETAEATRL KRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAY HEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTY NQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMD GTEELLVKLNREDLLRKQRTFDNGS IPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRI PYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHS LLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD SVEI SGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTF KEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQ TTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINR LSDYDVDHIVPQSFLKDDS IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRK FDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAK SEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLS MPQV IVKKTEVQTGGFSKES ILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKG KSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLI IKLPKYSLFELENGRKRMLAS AGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEI IEQI SEFSKRV ILADANLDKVLSAYNKHRDKPIREQAE I IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLD ATLIHQS ITGLYETRIDLSQLGGD*
(SEQ ID NO: 23)
Provided below is an exemplary codon optimized nucleic acid sequence encoding a Cas9 molecule of N. meningitidis.
ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCAGCG TGGGCTGGGCCATGGTGGAGATCGACGAGGACGAGAACCCCATCTGCCTGATCGACCTGGGTGT GCGCGTGTTCGAGCGCGCTGAGGTGCCCAAGACTGGTGACAGTCTGGCTATGGCTCGCCGGCTT GCTCGCTCTGTTCGGCGCCTTACTCGCCGGCGCGCTCACCGCCTTCTGCGCGCTCGCCGCCTGC TGAAGCGCGAGGGTGTGCTGCAGGCTGCCGACTTCGACGAGAACGGCCTGATCAAGAGCCTGCC CAACACTCCTTGGCAGCTGCGCGCTGCCGCTCTGGACCGCAAGCTGACTCCTCTGGAGTGGAGC GCCGTGCTGCTGCACCTGATCAAGCACCGCGGCTACCTGAGCCAGCGCAAGAACGAGGGCGAGA CCGCCGACAAGGAGCTGGGTGCTCTGCTGAAGGGCGTGGCCGACAACGCCCACGCCCTGCAGAC TGGTGACTTCCGCACTCCTGCTGAGCTGGCCCTGAACAAGTTCGAGAAGGAGAGCGGCCACATC CGCAACCAGCGCGGCGACTACAGCCACACCTTCAGCCGCAAGGACCTGCAGGCCGAGCTGATCC TGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGAGCGGCGGCCTGAAGGAGGGCAT CGAGACCCTGCTGATGACCCAGCGCCCCGCCCTGAGCGGCGACGCCGTGCAGAAGATGCTGGGC
CACTGCACCTTCGAGCCAGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGCTTCA
TCTGGCTGACCAAGCTGAACAACCTGCGCATCCTGGAGCAGGGCAGCGAGCGCCCCCTGACCGA
CACCGAGCGCGCCACCCTGATGGACGAGCCCTACCGCAAGAGCAAGCTGACCTACGCCCAGGCC
CGCAAGCTGCTGGGTCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGCTACGGCAAGGACAACG
CCGAGGCCAGCACCCTGATGGAGATGAAGGCCTACCACGCCATCAGCCGCGCCCTGGAGAAGGA
GGGCCTGAAGGACAAGAAGAGTCCTCTGAACCTGAGCCCCGAGCTGCAGGACGAGATCGGCACC
GCCTTCAGCCTGTTCAAGACCGACGAGGACATCACCGGCCGCCTGAAGGACCGCATCCAGCCCG
AGATCCTGGAGGCCCTGCTGAAGCACATCAGCTTCGACAAGTTCGTGCAGATCAGCCTGAAGGC
CCTGCGCCGCATCGTGCCCCTGATGGAGCAGGGCAAGCGCTACGACGAGGCCTGCGCCGAGATC
TACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCTCCTATCCCCGCCG
ACGAGATCCGCAACCCCGTGGTGCTGCGCGCCCTGAGCCAGGCCCGCAAGGTGATCAACGGCGT
GGTGCGCCGCTACGGCAGCCCCGCCCGCATCCACATCGAGACCGCCCGCGAGGTGGGCAAGAGC
TTCAAGGACCGCAAGGAGATCGAGAAGCGCCAGGAGGAGAACCGCAAGGACCGCGAGAAGGCCG
CCGCCAAGTTCCGCGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGAGCAAGGACATCCTGAA
GCTGCGCCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACAGCGGCAAGGAGATCAACCTGGGC
CGCCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCAGCCGCACCTGGGACG
ACAGCTTCAACAACAAGGTGCTGGTGCTGGGCAGCGAGAACCAGAACAAGGGCAACCAGACCCC
CTACGAGTACTTCAACGGCAAGGACAACAGCCGCGAGTGGCAGGAGTTCAAGGCCCGCGTGGAG
ACCAGCCGCTTCCCCCGCAGCAAGAAGCAGCGCATCCTGCTGCAGAAGTTCGACGAGGACGGCT
TCAAGGAGCGCAACCTGAACGACACCCGCTACGTGAACCGCTTCCTGTGCCAGTTCGTGGCCGA
CCGCATGCGCCTGACCGGCAAGGGCAAGAAGCGCGTGTTCGCCAGCAACGGCCAGATCACCAAC
CTGCTGCGCGGCTTCTGGGGCCTGCGCAAGGTGCGCGCCGAGAACGACCGCCACCACGCCCTGG
ACGCCGTGGTGGTGGCCTGCAGCACCGTGGCCATGCAGCAGAAGATCACCCGCTTCGTGCGCTA
CAAGGAGATGAACGCCTTCGACGGTAAAACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAG
AAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGCGTGTTCGGCA
AGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGCACCCTGCTGGC
CGAGAAGCTGAGCAGCCGCCCTGAGGCCGTGCACGAGTACGTGACTCCTCTGTTCGTGAGCCGC
GCCCCCAACCGCAAGATGAGCGGTCAGGGTCACATGGAGACCGTGAAGAGCGCCAAGCGCCTGG
ACGAGGGCGTGAGCGTGCTGCGCGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGAT
GGTGAACCGCGAGCGCGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGCCTGGAGGCCCACAAG
GACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGCACCC
AGCAGGTGAAGGCCGTGCGCGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGCAACCACAA
CGGCATCGCCGACAACGCCACCATGGTGCGCGTGGACGTGTTCGAGAAGGGCGACAAGTACTAC
CTGGTGCCCATCTACAGCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGCGCCGTGGTGCAGG
GCAAGGACGAGGAGGACTGGCAGCTGATCGACGACAGCTTCAACTTCAAGTTCAGCCTGCACCC
CAACGACCTGGTGGAGGTGATCACCAAGAAGGCCCGCATGTTCGGCTACTTCGCCAGCTGCCAC
CGCGGCACCGGCAACATCAACATCCGCATCCACGACCTGGACCACAAGATCGGCAAGAACGGCA
TCCTGGAGGGCATCGGCGTGAAGACCGCCCTGAGCTTCCAGAAGTACCAGATCGACGAGCTGGG
CAAGGAGATCCGCCCCTGCCGCCTGAAGAAGCGCCCTCCTGTGCGCTAA
(SEQ ID NO: 24)
Provided below is the corresponding amino acid sequence of a N. meningitidis Cas9 molecule.
MAAFKPNPINYILGLDIGIASVGWAMVEIDEDENPICLIDLGVRVFERAEVPKTGDSLAMARRL ARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWS AVLLHLIKHRGYLSQRKNEGETADKELGALLKGVADNAHALQTGDFRTPAELALNKFEKESGHI RNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLG HCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQA RKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAI SRALEKEGLKDKKSPLNLSPELQDEIGT AFSLFKTDEDITGRLKDRIQPEILEALLKHI SFDKFVQI SLKALRRIVPLMEQGKRYDEACAEI YGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKS FKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLG RLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVE TSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITN LLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQ KTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSR APNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHK DDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYY LVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCH RGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVR* (SEQ ID NO: 25)
Provided below is an amino acid sequence of a S. aureus Cas9 molecule.
MKRNYILGLDIGITSVGYGI IDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRI QRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDT GNELSTKEQI SRNSKALEEKYVAELQLERLKKDGEVRGS INRFKTSDYVKEAKQLLKVQKAYHQ LDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLY NALNDLNNLVITRDENEKLEYYEKFQI IENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGK PEFTNLKVYHDIKDITARKEI IENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQIS NLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSP VVKRSFIQS IKVINAI IKKYGLPNDI I IELAREKNSKDAQKMINEMQKRNRQTNERIEEI IRTT GKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHI IPRSVSFDNSFNNKVLVK QEENSKKGNRTPFQYLSSSDSKI SYETFKKHILNLAKGKGRI SKTKKEYLLEERDINRFSVQKD FINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKS INGGFTSFLRRKWKFKKERNKGYKHHAED ALI IA ADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKD YKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHH DPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDD YPNSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQA EFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLENMNDKRPPRI IKTIASKT QS IKKYSTDILGNLYEVKSKKHPQI IKKG*
(SEQ ID NO: 26)
Provided below is an exemplary codon optimized nucleic acid sequence encoding a Cas9 molecule of S. aureus Cas9.
ATGAAAAGGAACTACATTCTGGGGCTGGACATCGGGATTACAAGCGTGGGGTATGGGATTATTG ACTATGAAACAAGGGACGTGATCGACGCAGGCGTCAGACTGTTCAAGGAGGCCAACGTGGAAAA CAATGAGGGACGGAGAAGCAAGAGGGGAGCCAGGCGCCTGAAACGACGGAGAAGGCACAGAATC CAGAGGGTGAAGAAACTGCTGTTCGATTACAACCTGCTGACCGACCATTCTGAGCTGAGTGGAA TTAATCCTTATGAAGCCAGGGTGAAAGGCCTGAGTCAGAAGCTGTCAGAGGAAGAGTTTTCCGC AGCTCTGCTGCACCTGGCTAAGCGCCGAGGAGTGCATAACGTCAATGAGGTGGAAGAGGACACC GGCAACGAGCTGTCTACAAAGGAACAGATCTCACGCAATAGCAAAGCTCTGGAAGAGAAGTATG TCGCAGAGCTGCAGCTGGAACGGCTGAAGAAAGATGGCGAGGTGAGAGGGTCAATTAATAGGTT CAAGACAAGCGACTACGTCAAAGAAGCCAAGCAGCTGCTGAAAGTGCAGAAGGCTTACCACCAG CTGGATCAGAGCTTCATCGATACTTATATCGACCTGCTGGAGACTCGGAGAACCTACTATGAGG GACCAGGAGAAGGGAGCCCCTTCGGATGGAAAGACATCAAGGAATGGTACGAGATGCTGATGGG ACATTGCACCTATTTTCCAGAAGAGCTGAGAAGCGTCAAGTACGCTTATAACGCAGATCTGTAC AACGCCCTGAATGACCTGAACAACCTGGTCATCACCAGGGATGAAAACGAGAAACTGGAATACT ATGAGAAGTTCCAGATCATCGAAAACGTGTTTAAGCAGAAGAAAAAGCCTACACTGAAACAGAT TGCTAAGGAGATCCTGGTCAACGAAGAGGACATCAAGGGCTACCGGGTGACAAGCACTGGAAAA CCAGAGTTCACCAATCTGAAAGTGTATCACGATATTAAGGACATCACAGCACGGAAAGAAATCA TTGAGAACGCCGAACTGCTGGATCAGATTGCTAAGATCCTGACTATCTACCAGAGCTCCGAGGA CATCCAGGAAGAGCTGACTAACCTGAACAGCGAGCTGACCCAGGAAGAGATCGAACAGATTAGT AATCTGAAGGGGTACACCGGAACACACAACCTGTCCCTGAAAGCTATCAATCTGATTCTGGATG AGCTGTGGCATACAAACGACAATCAGATTGCAATCTTTAACCGGCTGAAGCTGGTCCCAAAAAA GGTGGACCTGAGTCAGCAGAAAGAGATCCCAACCACACTGGTGGACGATTTCATTCTGTCACCC GTGGTCAAGCGGAGCTTCATCCAGAGCATCAAAGTGATCAACGCCATCATCAAGAAGTACGGCC TGCCCAATGATATCATTATCGAGCTGGCTAGGGAGAAGAACAGCAAGGACGCACAGAAGATGAT CAATGAGATGCAGAAACGAAACCGGCAGACCAATGAACGCATTGAAGAGATTATCCGAACTACC GGGAAAGAGAACGCAAAGTACCTGATTGAAAAAATCAAGCTGCACGATATGCAGGAGGGAAAGT GTCTGTATTCTCTGGAGGCCATCCCCCTGGAGGACCTGCTGAACAATCCATTCAACTACGAGGT CGATCATATTATCCCCAGAAGCGTGTCCTTCGACAATTCCTTTAACAACAAGGTGCTGGTCAAG CAGGAAGAGAACTCTAAAAAGGGCAATAGGACTCCTTTCCAGTACCTGTCTAGTTCAGATTCCA AGATCTCTTACGAAACCTTTAAAAAGCACATTCTGAATCTGGCCAAAGGAAAGGGCCGCATCAG CAAGACCAAAAAGGAGTACCTGCTGGAAGAGCGGGACATCAACAGATTCTCCGTCCAGAAGGAT TTTATTAACCGGAATCTGGTGGACACAAGATACGCTACTCGCGGCCTGATGAATCTGCTGCGAT CCTATTTCCGGGTGAACAATCTGGATGTGAAAGTCAAGTCCATCAACGGCGGGTTCACATCTTT TCTGAGGCGCAAATGGAAGTTTAAAAAGGAGCGCAACAAAGGGTACAAGCACCATGCCGAAGAT GCTCTGATTATCGCAAATGCCGACTTCATCTTTAAGGAGTGGAAAAAGCTGGACAAAGCCAAGA AAGTGATGGAGAACCAGATGTTCGAAGAGAAGCAGGCCGAATCTATGCCCGAAATCGAGACAGA ACAGGAGTACAAGGAGATTTTCATCACTCCTCACCAGATCAAGCATATCAAGGATTTCAAGGAC TACAAGTACTCTCACCGGGTGGATAAAAAGCCCAACAGAGAGCTGATCAATGACACCCTGTATA GTACAAGAAAAGACGATAAGGGGAATACCCTGATTGTGAACAATCTGAACGGACTGTACGACAA AGATAATGACAAGCTGAAAAAGCTGATCAACAAAAGTCCCGAGAAGCTGCTGATGTACCACCAT GATCCTCAGACATATCAGAAACTGAAGCTGATTATGGAGCAGTACGGCGACGAGAAGAACCCAC TGTATAAGTACTATGAAGAGACTGGGAACTACCTGACCAAGTATAGCAAAAAGGATAATGGCCC CGTGATCAAGAAGATCAAGTACTATGGGAACAAGCTGAATGCCCATCTGGACATCACAGACGAT TACCCTAACAGTCGCAACAAGGTGGTCAAGCTGTCACTGAAGCCATACAGATTCGATGTCTATC TGGACAACGGCGTGTATAAATTTGTGACTGTCAAGAATCTGGATGTCATCAAAAAGGAGAACTA CTATGAAGTGAATAGCAAGTGCTACGAAGAGGCTAAAAAGCTGAAAAAGATTAGCAACCAGGCA GAGTTCATCGCCTCCTTTTACAACAACGACCTGATTAAGATCAATGGCGAACTGTATAGGGTCA TCGGGGTGAACAATGATCTGCTGAACCGCATTGAAGTGAATATGATTGACATCACTTACCGAGA GTATCTGGAAAACATGAATGATAAGCGCCCCCCTCGAATTATCAAAACAATTGCCTCTAAGACT CAGAGTATCAAAAAGTACTCAACCGACATTCTGGGAAACCTGTATGAGGTGAAGAGCAAAAAGC ACCCTCAGATTATCAAAAAGGGC
(SEQ ID NO: 39)
If any of the above Cas9 sequences are fused with a peptide or polypeptide at the C- terminus, it is understood that the stop codon will be removed. Other Cas Molecules and Cas9 Polypeptides
Various types of Cas molecules or Cas9 polypeptides can be used to practice the inventions disclosed herein. In some embodiments, Cas molecules of Type II Cas systems are used. In other embodiments, Cas molecules of other Cas systems are used. For example, Type I or Type III Cas molecules may be used. Exemplary Cas molecules (and Cas systems) are described, e.g., in Haft et al, PLoS COMPUTATIONAL BIOLOGY 2005, 1(6): e60 and Makarova et al, NATURE REVIEW MICROBIOLOGY 2011, 9:467-477, the contents of both references are incorporated herein by reference in their entirety. Exemplary Cas molecules (and Cas systems) are also shown in Table 55.
Figure imgf001627_0001
Table 55: Cas Systems
Gene System type Name from Structure of Families (and Representatives name* or subtype Haft ei a/.§ encoded protein superfamily) of
(PDB encoded
accessions)1 protein
• Subtype I-B cse4, csh2, COG3649
• Subtype I-C cspl and cst2 (RAMP)
• Subtype I-E
cas8al • Subtype I- cmxl, cstl, NA BH0338-like LA3191 and
A** csx8, csx 13 PG2018
and CXXC- CXXC
cas8a2 • Subtype I- csa4 and csx9 NA PH0918 AF0070, AF1873,
A** MJ0385, PF0637,
PH0918 and SSO1401 cas8b • Subtype I- cshl and NA BH0338-like MTH1090 and
B** TM1802 TM1802 cas8c • Subtype I- csdl and csp2 NA BH0338-like BH0338
C**
cas9 • Type II** csnl and csxl2 NA COG3513 FTN_0757 and
SPyl046 cas 10 • Type III** cmr2, csml NA COG1353 MTH326, Rv2823c and csxll and TM1794 caslOd • Subtype I- csc3 NA COG1353 slr7011
D**
csyl • Subtype I- csyl NA yl724-like yl724
F**
csy2 • Subtype I-F csy2 NA (RAMP) yl725
csy3 • Subtype I-F csy3 NA (RAMP) yl726
csel • Subtype I- csel NA YgcL-like ygcL
E**
cse2 • Subtype I-E cse2 2ZCA YgcK-like ygcK
cscl • Subtype I-D cscl NA alrl563-like alrl563
(RAMP)
csc2 • Subtype I-D cscl and csc2 NA COG1337 slr7012
(RAMP)
csa5 • Subtype I-A csa5 NA AF1870 AF1870, MJ0380,
PF0643 and SS01398 csn2 • Subtype II- csn2 NA SPyl049-like SPyl049
A
csml • Subtype III- csml NA COG1421 MTH1081 and
A** SERP2460 csm.3 • Subtype III- csc2 and csm.3 NA COG1337 MTH1080 and
A (RAMP) SERP2459 csm.4 • Subtype Ill- csm4 NA COG 1567 MTH1079 and Table 55: Cas Systems
Gene System type Name from Structure of Families (and Representatives name* or subtype Hatt et al encoded protein superfamily) of
(PDB encoded
accessions)1 protein
A (RAMP) SERP2458 csm5 • Subtype III- csm5 NA COG1332 MTH1078 and
A (RAMP) SERP2457 csm.6 • Subtype III- APE2256 and 2WTE COG1517 APE2256 and
A csm.6 SS01445 cmrl • Subtype Hi- cmrl NA COG 1367 PF1130
fi (RAMP)
cmr3 • Subtype Hi- cmr3 NA COG 1769 PF1128
fi (RAMP)
cmr4 • Subtype Hi- cmr4 NA COG1336 PF1126
fi (RAMP)
cmr5 • Subtype III- cmr5 2ZOP and 20EB COG3337 MTH324 and PF1125
cmr6 • Subtype Hi- cmr6 NA COG 1604 PF1124
fi (RAMP)
csbl • Subtype I-U GSU0053 NA (RAMP) Balac_1306 and
GSU0053 csbl • Subtype I- NA NA (RAMP) Balac_1305 and
U GSU0054 csb3 • Subtype I-U NA NA (RAMP) Balac_1303 csx 17 • Subtype I-U NA NA NA Btus_2683 csx 14 • Subtype I-U NA NA NA GSU0052 csx 10 • Subtype I-U csx 10 NA (RAMP) Caur_2274 csx 16 • Subtype III- VVA1548 NA NA VVA1548
U
csaX • Subtype III- csaX NA NA SS01438
U
csx3 • Subtype III- csx3 NA NA AF1864
U
csxl • Subtype III- csa3, csxl, lXMX and 2171 COG1517 and MJ1666, NE0113,
U csx2, DXTHG, COG4006 PF1127 and TM1812
NE0113 and
TIGR02710
csx 15 • Unknown NA NA TTE2665 TTE2665 csfl • Type U csfl NA NA AFE_1038 csfl • Type U csfl NA (RAMP) AFE_1039 csf3 • Type U csf3 NA (RAMP) AFE_1040 csf4 • Type U csf4 NA NA AFE_1037 IV. Functional Analysis of Candidate Molecules
Candidate Cas9 molecules, candidate gRNA molecules, candidate Cas9 molecule/gRNA molecule complexes, can be evaluated by art-known methods or as described herein. For example, exemplary methods for evaluating the endonuclease activity of Cas9 molecule are described, e.g., in Jinek et al., SCIENCE 2012, 337(6096):816-821.
Binding and Cleavage Assay: Testing the endonuclease activity of Cas9 molecule
The ability of a Cas9 molecule/gRNA molecule complex to bind to and cleave a target nucleic acid can be evaluated in a plasmid cleavage assay. In this assay, synthetic or in vitro- transcribed gRNA molecule is pre-annealed prior to the reaction by heating to 95 °C and slowly cooling down to room temperature. Native or restriction digest-linearized plasmid DNA (300 ng (~8 nM)) is incubated for 60 min at 37°C with purified Cas9 protein molecule (50-500 nM) and gRNA (50-500 nM, 1: 1) in a Cas9 plasmid cleavage buffer (20 mM HEPES pH 7.5, 150 mM KC1, 0.5 mM DTT, 0.1 mM EDTA) with or without 10 mM MgCl2. The reactions are stopped with 5X DNA loading buffer (30% glycerol, 1.2% SDS, 250 mM EDTA), resolved by a 0.8 or 1% agarose gel electrophoresis and visualized by ethidium bromide staining. The resulting cleavage products indicate whether the Cas9 molecule cleaves both DNA strands, or only one of the two strands. For example, linear DNA products indicate the cleavage of both DNA strands. Nicked open circular products indicate that only one of the two strands is cleaved.
Alternatively, the ability of a Cas9 molecule/gRNA molecule complex to bind to and cleave a target nucleic acid can be evaluated in an oligonucleotide DNA cleavage assay. In this assay, DNA oligonucleotides (10 pmol) are radiolabeled by incubating with 5 units T4 polynucleotide kinase and -3-6 pmol (-20-40 mCi) [γ-32Ρ]-ΑΤΡ in IX T4 polynucleotide kinase reaction buffer at 37°C for 30 min, in a 50
Figure imgf001630_0001
reaction. After heat inactivation (65°C for 20 min), reactions are purified through a column to remove unincorporated label. Duplex substrates (100 nM) are generated by annealing labeled oligonucleotides with equimolar amounts of unlabeled complementary oligonucleotide at 95 °C for 3 min, followed by slow cooling to room temperature. For cleavage assays, gRNA molecules are annealed by heating to 95°C for 30 s, followed by slow cooling to room temperature. Cas9 (500 nM final concentration) is pre- incubated with the annealed gRNA molecules (500 nM) in cleavage assay buffer (20 mM
HEPES pH 7.5, 100 mM KC1, 5 mM MgC12, 1 mM DTT, 5% glycerol) in a total volume of 9 μΐ. Reactions are initiated by the addition of 1 μΐ target DNA (10 nM) and incubated for 1 h at 37°C. Reactions are quenched by the addition of 20 μΐ of loading dye (5 mM EDTA, 0.025% SDS, 5% glycerol in formamide) and heated to 95°C for 5 min. Cleavage products are resolved on 12% denaturing polyacrylamide gels containing 7 M urea and visualized by phosphorimaging. The resulting cleavage products indicate that whether the complementary strand, the non- complementary strand, or both, are cleaved.
One or both of these assays can be used to evaluate the suitability of a candidate gRNA molecule or candidate Cas9 molecule.
Binding Assay: Testing the binding of Cas9 molecule to target DNA
Exemplary methods for evaluating the binding of Cas9 molecule to target DNA are described, e.g., in Jinek et al., SCIENCE 2012; 337(6096):816-821.
For example, in an electrophoretic mobility shift assay, target DNA duplexes are formed by mixing of each strand (10 nmol) in deionized water, heating to 95 °C for 3 min and slow cooling to room temperature. All DNAs are purified on 8% native gels containing IX TBE. DNA bands are visualized by UV shadowing, excised, and eluted by soaking gel pieces in DEPC-treated H20. Eluted DNA is ethanol precipitated and dissolved in DEPC-treated H20. DNA samples are 5' end labeled with [γ-32Ρ]-ΑΤΡ using T4 polynucleotide kinase for 30 min at 37°C. Polynucleotide kinase is heat denatured at 65°C for 20 min, and unincorporated radiolabel is removed using a column. Binding assays are performed in buffer containing 20 mM HEPES pH 7.5, 100 mM KC1, 5 mM MgCl2, 1 mM DTT and 10% glycerol in a total volume of 10 μΐ. Cas9 protein molecule is programmed with equimolar amounts of pre-annealed gRNA molecule and titrated from 100 pM to 1 μΜ. Radiolabeled DNA is added to a final concentration of 20 pM. Samples are incubated for 1 h at 37°C and resolved at 4°C on an 8% native polyacrylamide gel containing IX TBE and 5 mM MgCl2. Gels are dried and DNA visualized by
pho sphorimaging .
Differential Scanning Flourimetry (DSF)
The thermostability of Cas9-gRNA ribonucleoprotein (RNP) complexes can be measured via DSF. This technique measures the thermostability of a protein, which can increase under favorable conditions such as the addition of a binding RNA molecule, e.g., a gRNA. The assay is performed using two different protocols, one to test the best stoichiometric ratio of gRNA:Cas9 protein and another to determine the best solution conditions for RNP formation.
To determine the best solution to form RNP complexes, a 2uM solution of Cas9 in water+10x SYPRO Orange® (Life Techonologies cat#S-6650) and dispensed into a 384 well plate. An equimolar amount of gRNA diluted in solutions with varied pH and salt is then added. After incubating at room temperature for lO'and brief centrifugation to remove any bubbles,a Bio-Rad CFX384™ Real-Time System CI 000 Touch™ Thermal Cycler with the Bio-Rad CFX Manager software is used to run a gradient from 20°C to 90°C with a 1° increase in temperature every 10 seconds.
The second assay consists of mixing various concentrations of gRNA with 2uM Cas9 in optimal buffer from assay 1 above and incubating at RT for 10' in a 384 well plate. An equal volume of optimal buffer + lOx SYPRO Orange® (Life Techonologies cat#S-6650) is added and the plate sealed with Microseal® B adhesive (MSB-1001). Following brief centrifugation to remove any bubbles, a Bio-Rad CFX384™ Real-Time System CIOOO Touch™ Thermal Cycler with the Bio-Rad CFX Manager software is used to run a gradient from 20°C to 90°C with a 1° increase in temperature every 10 seconds.
V. Genome Editing Approaches
Mutations in the CFTR gene may be corrected using one of the approaches or pathways described herein, e.g., using HDR and/or NHEJ. In an embodiment, a mutation in the CFTR gene is corrected by homology directed repair (HDR) using a template nucleic acid (see Section V.l).
Also described herein are methods for targeted knockout of one or both alleles of the SCNN1A gene using NHEJ (see Section V.2).
V.l HDR Repair, HDR mediated knockin and Template Nucleic Acids
As described herein, nuclease-induced homology directed repair (HDR) can be used to alter a target sequence and correct (e.g., repair or edit) a mutation in the genome. While not wishing to be bound by theory, it is believed that alteration of the target sequence occurs by homology-directed repair (HDR) with a donor template or template nucleic acid. For example, the donor template or the template nucleic acid provides for alteration of the target sequence. It is contemplated that a plasmid donor can be used as a template for homologous recombination. It is further contemplated that a single stranded donor template can be used as a template for alteration of the target sequence by alternate methods of homology directed repair (e.g., single strand annealing) between the target sequence and the donor template. Donor template-effected alteration of a target sequence depends on cleavage by a Cas9 molecule. Cleavage by Cas9 can comprise a double strand break or one, two or more single strand breaks.
Mutations that can be corrected by HDR using a template nucleic acid include point mutations. In an embodiment, a point mutation can be corrected by either a single double-strand break or two single strand breaks. In an embodiment, a point mutation can be corrected by (1) a single double-strand break, (2) two single strand breaks, (3) two double stranded breaks with a break occurring on each side of the target sequence, or (4) four single stranded breaks with a pair of single stranded breaks occurring on each side of the target sequence.
Mutations in the CFTR gene that can be corrected (e.g., altered) by HDR with a template nucleic acid include deletion mutation at F508 (F508del) or point mutation at G551, e.g., G551D.
Double strand break mediated correction or knockin
In an embodiment, double strand cleavage is effected by a Cas9 molecule having cleavage activity associated with an HNH-like domain and cleavage activity associated with anRuvC-like domain, e.g., an N-terminal RuvC-like domain, e.g., a wild type Cas9. Such embodiments require only a single gRNA.
Single strand break mediated correction or knockin
In other embodiments, two single strand breaks, or nicks, are effected by a Cas9 molecule having nickase activity, e.g., cleavage activity associated with an HNH-like domain or cleavage activity associated with an N-terminal RuvC-like domain. Such embodiments require two gRNAs, one for placement of each single strand break. In an embodiment, the Cas9 molecule having nickase activity cleaves the strand to which the gRNA hybridizes, but not the strand that is complementary to the strand to which the gRNA hybridizes. In an embodiment, the Cas9 molecule having nickase activity does not cleave the strand to which the gRNA hybridizes, but rather cleaves the strand that is complementary to the strand to which the gRNA hybridizes. In an embodiment, the nickase has HNH activity, e.g., a Cas9 molecule having the RuvC activity inactivated, e.g., a Cas9 molecule having a mutation at D10, e.g., the D10A mutation. D10A inactivates RuvC; therefore, the Cas9 nickase has (only) HNH activity and will cut on the strand to which the gRNA hybridizes (e.g., the complementary strand, which does not have the NGG PAM on it). In other embodiments, a Cas9 molecule having an H840, e.g., an H840A, mutation can be used as a nickase. H840A inactivates HNH; therefore, the Cas9 nickase has (only) RuvC activity and cuts on the non-complementary strand (e.g., the strand that has the NGG PAM and whose sequence is identical to the gRNA). In other embodiments, a Cas9 molecule having an N863, e.g., an N863A mutation can be used as a nickase. N863A inactivates HNH therefore the Cas9 nickase has (only) RuvC activity and cuts on the non-complementary strand (the strand that has the PAM and whose sequence is identical to the gRNA).
In an embodiment, in which a nickase and two gRNAs are used to position two single strand nicks, one nick is on the + strand and one nick is on the - strand of the target nucleic acid. The PAMs are outwardly facing. The gRNAs can be selected such that the gRNAs are separated by, from about 0-50, 0-100, or 0-200 nucleotides. In an embodiment, there is no overlap between the target sequence that is complementary to the targeting domains of the two gRNAs. In an embodiment, the gRNAs do not overlap and are separated by as much as 50, 100, or 200 nucleotides. In an embodiment, the use of two gRNAs can increase specificity, e.g., by decreasing off-target binding (Ran et al., Cell 2013; 154(6): 1380-1389).
In an embodiment, a single nick can be used to induce HDR. It is contemplated herein that a single nick can be used to increase the ratio of HR to NHEJ at a given cleavage site.
Placement of double strand or single strand breaks relative to the target position
The double strand break or single strand break in one of the strands should be sufficiently close to the target position such that correction occurs. In an embodiment, the distance is not more than 50, 100, 200, 300, 350 or 400 nucleotides. While not wishing to be bound by theory, it is believed that the break should be sufficiently close to the target sequence such that the break is within the region that is subject to exonuclease-mediated removal during end resection. If the distance between the target sequence and a break is too great, the mutation may not be included in the end resection and, therefore, may not be corrected, as donor sequence may only be used to correct sequence within the end resection region. In an embodiment, in which a gRNA (unimolecular (or chimeric) or modular gRNA) and Cas9 nuclease induce a double strand break for the purpose of inducing HDR-mediated correction, the cleavage site is between 0 to 200 bp (e.g., 0 to 175, 0 to 150, 0 to 125, 0 to 100, 0 to 75, 0 to 50, 0 to 25, 25 to 200, 25 to 175, 25 to 150, 25 to 125, 25 to 100, 25 to 75, 25 to 50, 50 to 200, 50 to 175, 50 to 150, 50 to 125, 50 to 100, 50 to 75, 75 to 200, 75 to 175, 75 to 150, 75 to 125, 75 to 100 bp) away from the target position. In an embodiment, the cleavage site is between 0 to 100 bp (e.g., 0 to 75, 0 to 50, 0 to 25, 25 to 100, 25 to 75, 25 to 50, 50 to 100, 50 to 75 or 75 to 100 bp) away from the target position.
In an embodiment, in which two gRNAs (independently, unimolecular (or chimeric) or modular gRNA) complexing with Cas9 nickases induce two single strand breaks for the purpose of inducing HDR-mediated correction, the closer nick is between 0 to 200 bp (e.g., 0 to 175, 0 to 150, 0 to 125, 0 to 100, 0 to 75, 0 to 50, 0 to 25, 25 to 200, 25 to 175, 25 to 150, 25 to 125, 25 to 100, 25 to 75, 25 to 50, 50 to 200, 50 to 175, 50 to 150, 50 to 125, 50 to 100, 50 to 75, 75 to 200, 75 to 175, 75 to 150, 75 to 125, 75 to 100 bp) away from the target position and the two nicks will ideally be within 25 to 55 bp of each other (e.g., 25 to 50, 25 to 45, 25 to 40, 25 to 35, 25 to 30, 30 to 55, 30 to 50, 30 to 45, 30 to 40, 30 to 35, 35 to 55, 35 to 50, 35 to 45, 35 to 40, 40 to 55, 40 to 50, 40 to 45 bp) and no more than 100 bp away from each other (e.g., no more than 90, 80, 70, 60, 50, 40, 30, 20, 10 or 5 bp away from each other). In an embodiment, the cleavage site is between 0 to 100 bp (e.g., 0 to 75, 0 to 50, 0 to 25, 25 to 100, 25 to 75, 25 to 50, 50 to 100, 50 to 75 or 75 to 100 bp) away from the target position.
In one embodiment, two gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to position a double-strand break on both sides of a target position. In an alternate embodiment, three gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to position a double strand break (i.e., one gRNA complexes with a cas9 nuclease) and two single strand breaks or paired single stranded breaks (i.e., two gRNAs complex with Cas9 nickases) on either side of the target position. In another embodiment, four gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to generate two pairs of single stranded breaks (i.e., two pairs of two gRNAs complex with Cas9 nickases) on either side of the target position. The double strand break(s) or the closer of the two single strand nicks in a pair will ideally be within 0-500 bp of the target position (e.g., no more than 450, 400, 350, 300, 250, 200, 150, 100, 50 or 25 bp from the target position). When nickases are used, the two nicks in a pair are within 25-55 bp of each other (e.g., between 25 to 50, 25 to 45, 25 to 40, 25 to 35, 25 to 30, 50 to 55, 45 to 55, 40 to 55, 35 to 55, 30 to 55, 30 to 50, 35 to 50, 40 to 50 , 45 to 50, 35 to 45, or 40 to 45 bp) and no more than 100 bp away from each other (e.g., no more than 90, 80, 70, 60, 50, 40, 30, 20 or 10 bp). In an embodiment, the gRNAs are configured to place a single strand break on either side of the target position. In an embodiment, the gRNAs are configured to place a single strand break on the same side (either 5' or 3') of the target position.
Regardless of whether a break is a double strand or a single strand break, the gRNA should be configured to avoid unwanted target chromosome elements, such as repeated elements, e.g., an Alu repeat, in the target domain. In addition, a break, whether a double strand or a single strand break, should be sufficiently distant from any sequence that should not be altered. For example, cleavage sites positioned within introns should be sufficiently distant from any intron/exon border, or naturally occurring splice signal, to avoid alteration of the exonic sequence or unwanted splicing events.
Length of the homology arms
The homology arm should extend at least as far as the region in which end resection may occur, e.g., in order to allow the resected single stranded overhang to find a complementary region within the donor template. The overall length could be limited by parameters such as plasmid size or viral packaging limits. In an embodiment, a homology arm does not extend into repeated elements, e.g., Alu repeats, LINE repeats.
Exemplary homology arm lengths include a least 50, 100, 250, 500, 750 or 1000 nucleotides.
Target position, as used herein, refers to a site on a target nucleic acid (e.g., the chromosome) that is modified by a Cas9 molecule-dependent process. For example, the target position can be a modified Cas9 molecule cleavage of the target nucleic acid and template nucleic acid directed modification, e.g., correction, of the target position. In an embodiment, a target position can be a site between two nucleotides, e.g., adjacent nucleotides, on the target nucleic acid into which one or more nucleotides is added. The target position may comprise one or more nucleotides that are altered, e.g., corrected, by a template nucleic acid. In an
embodiment, the target position is within a target sequence (e.g., the sequence to which the gRNA binds). In an embodiment, a target position is upstream or downstream of a target sequence (e.g., the sequence to which the gRNA binds).
A template nucleic acid, as that term is used herein, refers to a nucleic acid sequence which can be used in conjunction with a Cas9 molecule and a gRNA molecule to alter the structure of a target position. In an embodiment, the target nucleic acid is modified to have the some or all of the sequence of the template nucleic acid, typically at or near cleavage site(s). In an embodiment, the template nucleic acid is single stranded. In an alternate embodiment, the template nucleic acid is double stranded. In an embodiment, the template nucleic acid is DNA, e.g., double stranded DNA. In an alternate embodiment, the template nucleic acid is single stranded DNA. In an embodiment, the template nucleic acid is encoded on the same vector backbone, e.g. AAV genome, plasmid DNA, as the Cas9 and gRNA. In an embodiment, the template nucleic acid is excised from a vector backbone in vivo, e.g., it is flanked by gRNA recognition sequences.
In an embodiment, the template nucleic acid alters the structure of the target position by participating in a homology directed repair event. In an embodiment, the template nucleic acid alters the sequence of the target position. In an embodiment, the template nucleic acid results in the incorporation of a modified, or non-naturally occurring base into the target nucleic acid.
Typically, the template sequence undergoes a breakage mediated or catalyzed recombination with the target sequence. In an embodiment, the template nucleic acid includes sequence that corresponds to a site on the target sequence that is cleaved by an eaCas9 mediated cleavage event. In an embodiment, the template nucleic acid includes sequence that corresponds to both, a first site on the target sequence that is cleaved in a first Cas9 mediated event, and a second site on the target sequence that is cleaved in a second Cas9 mediated event.
In an embodiment, the template nucleic acid can include sequence which results in an alteration in the coding sequence of a translated sequence, e.g., one which results in the substitution of one amino acid for another in a protein product, e.g., transforming a mutant allele into a wild type allele, transforming a wild type allele into a mutant allele, and/or introducing a stop codon, insertion of an amino acid residue, deletion of an amino acid residue, or a nonsense mutation.
In another embodiment, the template nucleic acid can include sequence which results in an alteration in a non-coding sequence, e.g., an alteration in an exon or in a 5' or 3' non- translated or non-transcribed region. Such alterations include an alteration in a control element, e.g., a promoter, enhancer, and an alteration in a cis-acting or trans-acting control element.
A template nucleic acid having homology with a target position in the CFTR gene can be used to alter the structure of a target sequence. The template sequence can be used to alter an unwanted structure, e.g., an unwanted or mutant nucleotide.
A template nucleic acid comprises the following components:
[5' homology arm] -[replacement sequence] -[3' homology arm].
The homology arms provide for recombination into the chromosome, thus replacing the undesired element, e.g., a mutation or signature, with the replacement sequence. In an embodiment, the homology arms flank the most distal cleavage sites.
In an embodiment, the 3' end of the 5' homology arm is the position next to the 5' end of the replacement sequence. In an embodiment, the 5' homology arm can extend at least 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, or 2000 nucleotides 5' from the 5' end of the replacement sequence.
In an embodiment, the 5' end of the 3' homology arm is the position next to the 3' end of the replacement sequence. In an embodiment, the 3' homology arm can extend at least 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, or 2000 nucleotides 3' from the 3' end of the replacement sequence.
Exemplary Template Nucleic Acids
Exemplary template nucleic acids (also referred to herein as donor constructs) to correct a mutation, e.g., F508del target position in the CFTR gene, are provided.
Suitable sequence for the 5' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
AAAATACAAAAAATTAGCCAGACGTGATGGCGGGTGCCCGTAGTCCCAGCTACTCGGGAGGCTG AGGCAGGAGAATGGCGTGAACCCAGGAGGCAGAACTTGCAGTGAGCCGAGATCGCGCCACTGCA CTCTAGCCTGGGTGACAGAGTGAGACTCTGTCTCTAAATAAATAAATAAATAAATAAATAAATA AATAAAATCAGTGCTTTTTCTTCCTCTGCTACCTCCTTTCCTTCTACTCAGTTTTAGTCAGTAG TATTATCTTTTTTCAGATTTATCTTTGTATTGTTAAATCTGCTTATGCTTCTATTACTTTATTT ATTAGCTTTAAATGATACCTTTTGACTTTCAGCTTTTCTTAATAAAGCAATCAGCAAATTTCCT TTACACTCCACACTTATACCCCATTTCCTTTGTTTGTTTATTTGGTTTTTACTTCTAACTTTTC TTATTGTCAGGACATATAACATATTTAAACTTTGTTTTTCAACTCGAATTCTGCCATTAGTTTT
AATTTTTGTTCACAGTTATATAAATCTTTGTTCACTGATAGTCCTTTTGTACTATCATCTCTTA
AATGACTTTATACTCCAAGAAAGGCTCATGGGAACAATATTACCTGAATATGTCTCTATTACTT
AATCTGTACCTAATAATATGAAGGTAATCTACTTTGTAGGATTTCTGTGAAGATTAAATAAATT
AATATAGTTAAAGCACATAGAACAGCACTCGACACAGAGTGAGCACTTGGCAACTGTTAGCTGT
TACTAACCTTTCCCATTCTTCCTCCAAACCTATTCCAACTATCTGAATCATGTGCCCCTTCTCT
GTGAACCTCTATCATAATACTTGTCACACTGTATTGTAATTGTCTCTTTTACTTTCCCTTGTAT
CTTTTGTGCATAGCAGAGTACCTGAAACAGGAAGTATTTTAAATATTTTGAATCAAATGAGTTA
ATAGAATCTTTACAAATAAGAATATACACTTCTGCTTAGGATGATAATTGGAGGCAAGTGAATC
CTGAGCGTGATTTGATAATGACCTAATAATGATGGGTTTTATTTCCAGACTTCACTTCTAATGG
TGATTATGGGAGAACTGGAGCCTTCAGAGGGTAAAATTAAGCACAGTGGAAGAATTTCATTCTG
TTCTCAGTTTTCCTGGATTATGCCTGGCACCATTAAAGAAAATATCAT
SEQ ID NO: 27266 (5 Ή arm)
Suitable sequence for the 3' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
TGGTGTTTCCTATGATGAATATAGATACAGAAGCGTCATCAAAGCATGCCAACTAGAAGAGGTA AGAAACTATGTGAAAACTTTTTGATTATGCATATGAACCCTTCACACTACCCAAATTATATATT TGGCTCCATATTCAATCGGTTAGTCTACATATATTTATGTTTCCTCTATGGGTAAGCTACTGTG AATGGATCAATTAATAAAACACATGACCTATGCTTTAAGAAGCTTGCAAACACATGAAATAAAT GCAATTTATTTTTTAAATAATGGGTTCATTTGATCACAATAAATGCATTTTATGAAATGGTGAG AATTTTGTTCACTCATTAGTGAGACAAACGTCCTCAATGGTTATTTATATGGCATGCATATAAG TGATATGTGGTATCTTTTTAAAAGATACCACAAAATATGCATCTTTAAAAATATACTCCAAAAA TTATTAAGATTATTTTAATAATTTTAATAATACTATAGCCTAATGGAATGAGCATTGATCTGCC AGCAGAGAATTAGAGGGGTAAAATTGTGAAGATATTGTATCCCTGGCTTTGAACAAATACCATA TAACTTCTAGTGACTGCAATTCTTTGATGCAGAGGCAAAATGAAGATGATGTCATTACTCATTT CACAACAATATTGGAGAATGAGCTAATTATCTGAAAATTACATGAAGTATTCCAAGAGAAACCA GTATATGGATCTTGTGCTGTTCACTATGTAAATTGTGTGATGGTGGGTTCAGTAGTTATTGCTG TAAATGTTAGGGCAGGGAATATGTTACTATGAAGTTTATTGACAGTATACTCCAAATAGTGTTT GTGATTCAAAAGCAATATCTTTGATAGTTGGCATTTGCAATTCCTTTATATAATCTTTTATGAA AAAAATTGCAGAGAAAGTAAAATGTAGCTTAAAATACAGTATCCAAAAAAATGGAAAAGGGCAA ACCGTGGATTAGATAGAAATGGCAATTCTTATAAAAAGGGTTGCATGCTTACATGAATGGCTTT CCATGTATATACTCAGTCATTCAACAGTTTTTTTTTTAGAGCCCCATTCTTATTTTTTATACAC TTTGAGAGCATAATGAAAAGAAAAGCTACCTGCAAAAGTTTTGGACTTACCTCAAAGAGGATAT
ACTTCATTCCTCAAAAGGCCTTCTTCCAGGAATAGTATTTCATAACCT
SEQ ID NO: 27267 (3Ή arm)
In an embodiment, the replacement sequence comprises or consists of CTT residues.
In an embodiment, to correct a mutation, e.g., F508del target site in the CFTR gene, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted bases to correct the F508del mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AAAATACAAAAAATTAGCCAGACGTGATGGCGGGTGCCCGTAGTCCCAGCTACTCGGGAGGCTG AGGCAGGAGAATGGCGTGAACCCAGGAGGCAGAACTTGCAGTGAGCCGAGATCGCGCCACTGCA CTCTAGCCTGGGTGACAGAGTGAGACTCTGTCTCTAAATAAATAAATAAATAAATAAATAAATA AATAAAATCAGTGCTTTTTCTTCCTCTGCTACCTCCTTTCCTTCTACTCAGTTTTAGTCAGTAG TATTATCTTTTTTCAGATTTATCTTTGTATTGTTAAATCTGCTTATGCTTCTATTACTTTATTT ATTAGCTTTAAATGATACCTTTTGACTTTCAGCTTTTCTTAATAAAGCAATCAGCAAATTTCCT TTACACTCCACACTTATACCCCATTTCCTTTGTTTGTTTATTTGGTTTTTACTTCTAACTTTTC TTATTGTCAGGACATATAACATATTTAAACTTTGTTTTTCAACTCGAATTCTGCCATTAGTTTT AATTTTTGTTCACAGTTATATAAATCTTTGTTCACTGATAGTCCTTTTGTACTATCATCTCTTA AATGACTTTATACTCCAAGAAAGGCTCATGGGAACAATATTACCTGAATATGTCTCTATTACTT AATCTGTACCTAATAATATGAAGGTAATCTACTTTGTAGGATTTCTGTGAAGATTAAATAAATT AATATAGTTAAAGCACATAGAACAGCACTCGACACAGAGTGAGCACTTGGCAACTGTTAGCTGT TACTAACCTTTCCCATTCTTCCTCCAAACCTATTCCAACTATCTGAATCATGTGCCCCTTCTCT GTGAACCTCTATCATAATACTTGTCACACTGTATTGTAATTGTCTCTTTTACTTTCCCTTGTAT CTTTTGTGCATAGCAGAGTACCTGAAACAGGAAGTATTTTAAATATTTTGAATCAAATGAGTTA ATAGAATCTTTACAAATAAGAATATACACTTCTGCTTAGGATGATAATTGGAGGCAAGTGAATC CTGAGCGTGATTTGATAATGACCTAATAATGATGGGTTTTATTTCCAGACTTCACTTCTAATGG TGATTATGGGAGAACTGGAGCCTTCAGAGGGTAAAATTAAGCACAGTGGAAGAATTTCATTCTG TTCTCAGTTTTCCTGGATTATGCCTGGCACCATTAAAGAAAATATCATct tTGGTGTTTCCTAT GATGAATATAGATACAGAAGCGTCATCAAAGCATGCCAACTAGAAGAGGTAAGAAACTATGTGA AAACTTTTTGATTATGCATATGAACCCTTCACACTACCCAAATTATATATTTGGCTCCATATTC AATCGGTTAGTCTACATATATTTATGTTTCCTCTATGGGTAAGCTACTGTGAATGGATCAATTA ATAAAACACATGACCTATGCTTTAAGAAGCTTGCAAACACATGAAATAAATGCAATTTATTTTT TAAATAATGGGTTCATTTGATCACAATAAATGCATTTTATGAAATGGTGAGAATTTTGTTCACT CATTAGTGAGACAAACGTCCTCAATGGTTATTTATATGGCATGCATATAAGTGATATGTGGTAT CTTTTTAAAAGATACCACAAAATATGCATCTTTAAAAATATACTCCAAAAATTATTAAGATTAT TTTAATAATTTTAATAATACTATAGCCTAATGGAATGAGCATTGATCTGCCAGCAGAGAATTAG AGGGGTAAAATTGTGAAGATATTGTATCCCTGGCTTTGAACAAATACCATATAACTTCTAGTGA CTGCAATTCTTTGATGCAGAGGCAAAATGAAGATGATGTCATTACTCATTTCACAACAATATTG GAGAATGAGCTAATTATCTGAAAATTACATGAAGTATTCCAAGAGAAACCAGTATATGGATCTT GTGCTGTTCACTATGTAAATTGTGTGATGGTGGGTTCAGTAGTTATTGCTGTAAATGTTAGGGC AGGGAATATGTTACTATGAAGTTTATTGACAGTATACTCCAAATAGTGTTTGTGATTCAAAAGC AATATCTTTGATAGTTGGCATTTGCAATTCCTTTATATAATCTTTTATGAAAAAAATTGCAGAG AAAGTAAAATGTAGCTTAAAATACAGTATCCAAAAAAATGGAAAAGGGCAAACCGTGGATTAGA TAGAAATGGCAATTCTTATAAAAAGGGTTGCATGCTTACATGAATGGCTTTCCATGTATATACT CAGTCATTCAACAGTTTTTTTTTTAGAGCCCCATTCTTATTTTTTATACACTTTGAGAGCATAA TGAAAAGAAAAGCTACCTGCAAAAGTTTTGGACTTACCTCAAAGAGGATATACTTCATTCCTCA AAAGGCCTTCTTCCAGGAATAGTATTTCATAACCT
(Template Construct 1; SEQ ID NO: 27268)
As described below in Table 49, shorter homology arms, e.g., 5' and/or 3' homology arms may be used.
It is contemplated herein that one or both homology arms may be shortened to avoid including certain sequence repeat elements, e.g., Alu repeats, LINE elements. For example, a 5' homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3' homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5' and the 3' homology arms may be shortened to avoid including certain sequence repeat elements.
In an embodiment, to correct F508del mutation in the CFTR gene, the 5' homology arm may be shortened less than 500 nucleotides, e.g., approximately 450 nucleotides, e.g., 428 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted bases to correct the F508del mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AACCTTTCCCATTCTTCCTCCAAACCTATTCCAACTATCTGAATCATGTGCCCCTTCTCTGTGA
ACCTCTATCATAATACTTGTCACACTGTATTGTAATTGTCTCTTTTACTTTCCCTTGTATCTTT
TGTGCATAGCAGAGTACCTGAAACAGGAAGTATTTTAAATATTTTGAATCAAATGAGTTAATAG
AATCTTTACAAATAAGAATATACACTTCTGCTTAGGATGATAATTGGAGGCAAGTGAATCCTGA
GCGTGATTTGATAATGACCTAATAATGATGGGTTTTATTTCCAGACTTCACTTCTAATGGTGAT
TATGGGAGAACTGGAGCCTTCAGAGGGTAAAATTAAGCACAGTGGAAGAATTTCATTCTGTTCT
CAGTTTTCCTGGATTATGCCTGGCACCATTAAAGAAAATATCATcttTGGTGTTTCCTATGATG
AATATAGATACAGAAGCGTCATCAAAGCATGCCAACTAGAAGAGGTAAGAAACTATGTGAAAAC
TTTTTGATTATGCATATGAACCCTTCACACTACCCAAATTATATATTTGGCTCCATATTCAATC
GGTTAGTCTACATATATTTATGTTTCCTCTATGGGTAAGCTACTGTGAATGGATCAATTAATAA
AACACATGACCTATGCTTTAAGAAGCTTGCAAACACATGAAATAAATGCAATTTATTTTTTAAA
TAATGGGTTCATTTGATCACAATAAATGCATTTTATGAAATGGTGAGAATTTTGTTCACTCATT
AGTGAGACAAACGTCCTCAATGGTTATTTATATGGCATGCATATAAGTGATATGTGGTATCTTT
TTAAAAGATACCACAAAATATGCATCTTTAAAAATATACTCCAAAAATTATTAAGATTATTTTA
ATAATTTTAATAATACTATAGCCTAATGGAATGAGCATTGATCTGCCAGCAGAGAATTAGAGGG
GTAAAATTGTGAAGATATTGTATCCCTGGCTTTGAACAAATACCATATAACTTCTAGTGACTGC
AATTCTTTGATGCAGAGGCAAAATGAAGATGATGTCATTACTCATTTCACAACAATATTGGAGA
ATGAGCTAATTATCTGAAAATTACATGAAGTATTCCAAGAGAAACCAGTATATGGATCTTGTGC
TGTTCACTATGTAAATTGTGTGATGGTGGGTTCAGTAGTTATTGCTGTAAATGTTAGGGCAGGG
AATATGTTACTATGAAGTTTATTGACAGTATACTCCAAATAGTGTTTGTGATTCAAAAGCAATA
TCTTTGATAGTTGGCATTTGCAATTCCTTTATATAATCTTTTATGAAAAAAATTGCAGAGAAAG
TAAAATGTAGCTTAAAATACAGTATCCAAAAAAATGGAAAAGGGCAAACCGTGGATTAGATAGA
AATGGCAATTCTTATAAAAAGGGTTGCATGCTTACATGAATGGCTTTCCATGTATATACTCAGT
CATTCAACAGTTTTTTTTTTAGAGCCCCATTCTTATTTTTTATACACTTTGAGAGCATAATGAA
AAGAAAAGCTACCTGCAAAAGTTTTGGACTTACCTCAAAGAGGATATACTTCATTCCTCAAAAG
GCCTTCTTCCAGGAATAGTATTTCATAACCT
(Template Construct 2; SEQ ID NO: 27269)
In an embodiment, to correct F508del mutation in the CFTR gene, the 5' homology arm may be shortened to approximately 500 nucleotides. The 5' homology arm is shown as bold sequence, the inserted bases to correct the F508del mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence. AATTAATATAGTTAAAGCACATAGAACAGCACTCGACACAGAGTGAGCACTTGGCAACTGTTAG
CTGTTACTAACCTTTCCCATTCTTCCTCCAAACCTATTCCAACTATCTGAATCATGTGCCCCTT
CTCTGTGAACCTCTATCATAATACTTGTCACACTGTATTGTAATTGTCTCTTTTACTTTCCCTT
GTATCTTTTGTGCATAGCAGAGTACCTGAAACAGGAAGTATTTTAAATATTTTGAATCAAATGA
GTTAATAGAATCTTTACAAATAAGAATATACACTTCTGCTTAGGATGATAATTGGAGGCAAGTG
AATCCTGAGCGTGATTTGATAATGACCTAATAATGATGGGTTTTATTTCCAGACTTCACTTCTA
ATGGTGATTATGGGAGAACTGGAGCCTTCAGAGGGTAAAATTAAGCACAGTGGAAGAATTTCAT
TCTGTTCTCAGTTTTCCTGGATTATGCCTGGCACCArrAAAGAAAATArCArctt TGGTGTTTC
CTATGATGAATATAGATACAGAAGCGTCATCAAAGCATGCCAACTAGAAGAGGTAAGAAACTAT
GTGAAAACTTTTTGATTATGCATATGAACCCTTCACACTACCCAAATTATATATTTGGCTCCAT
ATTCAATCGGTTAGTCTACATATATTTATGTTTCCTCTATGGGTAAGCTACTGTGAATGGATCA
ATTAATAAAACACATGACCTATGCTTTAAGAAGCTTGCAAACACATGAAATAAATGCAATTTAT
TTTTTAAATAATGGGTTCATTTGATCACAATAAATGCATTTTATGAAATGGTGAGAATTTTGTT
CACTCATTAGTGAGACAAACGTCCTCAATGGTTATTTATATGGCATGCATATAAGTGATATGTG
GTATCTTTTTAAAAGATACCACAAAATATGCATCTTTAAAAATATACTCCAAAAATTATTAAGA
T T AT T T TAATAAT T T T AAT AAT AC T AT AGCC T AAT GGAAT GAG
(Template Construct 3; SEQ ID NO: 27270)
It is contemplated herein that, in an embodiment, template nucleic acids for correcting a mutation may designed for use as a single- stranded oligonucleotide (ssODN). When using a ssODN, 5' and 3' homology arms may range up to about 200 base pairs (bp) in length, e.g., at least 25, 50, 75, 100, 125, 150, 175, or 200 bp in length. Longer homology arms are also contemplated for ssODNs as improvements in oligonucleotide synthesis continue to be made.
In an embodiment, an ssODN may be used to correct a mutation, e.g., F508del target site in the CFTR gene. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted bases to correct the F508del mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TAAGCACAGTGGAAGAATTTCATTCTGTTCTCAGTTTTCCTGGATTATGCCTGGCACCATTAAA GAAAATATCATctt TGGTGTTTCCTATGATGAATATAGATACAGAAGCGTCATCAAAGCATGCC AAC T AG AAG AG G T AAG AAAC T AT G T (Template Construct 4; SEQ ID NO: 27271) Exemplary template nucleic acids (also referred to herein as donor constructs) to correction a mutation, e.g., G542X target site in the CFTR gene, are provided.
Suitable sequence for the 5' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
TGTCCATATGGTAGATAAATGGAACAAATGAATAACAGAAGTAACCATTTTGATACTTTAGATA
TAGATAATATTGGATTATTTCTGGATTGTGAAAGAAGAAGGAAGAAGCATATGGAAGAGAAGTT
TTAGTAGAGGGGAGGAAGGAGGAGGTGGAAACGAATGTACAAGGATGGGAGGAGAAAAGGGAGA
GAGACTTTTTTTTTTTTAAGGCGAGAGTTTACTACCTATCTAACTCTTCGCATTCTTGAAGTCT
CAGACCAAATCCCATCGGTTTGAAAGCCTCTAGGGTATTCTATCTATTGTATACTTCTGTTATG
TACAAAATTAATTTGCCAATTAATTGTGAACTGTTTTATAAACTATCTTAAAATGGTTAGTTAA
ATCTTTGGGATAGTATTTAGCTTTCTCCAGGATTATGACTTACCTTCTAAATTAGACATACAAT
GCCTAGGAGTCAAGGACTATTTTGCATAAATTCCAGTCTTCTTTTACAATGCCTAGAATGATTG
TTACCACAGAAATATTCATTACCTGGGAGAAAGGATGACAGGAGGGGCAGAATGAATGGAGAGA
GGTCGTGAGAATGAGGTGCTGAGGATGGACGAGGAAGAAAGCTGTTTTAGTTGGGAGGATAGGT
GACAGAAGCATGGAAAGGAATTGCCTTGGACCCATGGAAGCCCAGTGAAGATACTTAGATCCTG
CAGGGGTGTGAATAATGTTCTTTTAGTTTCTCTTCTTAGGAGGTTTGTTCATTTTGGGAGATTT
CTTTTGAAAAGAGTGAACTTAAATTGGAGAAAAGTACATTTTAGTATGTTGATAACATTTGAAT
TTGTAAAATGGACCTATGGATGATCTACACATATTTATATACCCATAAATATACACATATTTTA
ATTTTTGGTATTTTATAATTATTATTTAATGATCATTCATGACATTTTAAAAATTACAGAAAAA
TTTACATCTAAAATTTCAGCAATGTTGTTTTTGACCAACTAAATAAATTGCATTTGAAATAATG
GAGATGCAATGTTCAAAATTTCAACTGTGGTTAAAGCAATAGTGTGATATATGATTACATTAGA
AGGAAGATGTGCCTTTCAAATTCAGATTGAGCATACTAAAAGTGACTCTCTAATTTTCTATTTT
TGGTAATAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTT
SEQ ID NO: 27272 (5Ή arm)
Suitable sequence for the 3' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
GAGAAGGTGGAATCACACTGAGTGGAGGTCAACGAGCAAGAATTTCTTTAGCAAGGTGAATAAC TAATTATTGGTCTAGCAAGCATTTGCTGTAAATGTCATTCATGTAAAAAAATTACAGACATTTC TCTATTGCTTTATATTCTGTTTCTGGAATTGAAAAAATCCTGGGGTTTTATGGCTAGTGGGTTA AGAATCACATTTAAGAACTATAAATAATGGTATAGTATCCAGATTTGGTAGAGATTATGGTTAC TCAGAATCTGTGCCCGTATCTTGGTGTCAGTGTATTTGTTTGCCTCATAGTATAGTTTACTACA AATGGAAAACTCTAGGATTCTGCATAATACTGGACAGAGAAGATGTAAATATCTGTTAGTTCCA TCATAGACCCTGCCACTCCAATGTACACACCAGCTTTAGGCTTCTTGGTATAGATAAACATACA
TTTTCAAAATTTTTCATCATAATTTTCATAACAAAATAGGAAGGCAAATGATGTCACTTGGCTT
AAAATCTATAATATTTAAAATAAACAGGACAAATGCATTAACATTGTTGGGGGAGGAGGTCCCT
TAGTAGAAACACTCTTGGTCCAAGCATTTTAAAGCTGTCAAAGAGATGTAAATATAGATAATGT
ATGTCAAGGAGAGAGCTTTGTGGTTAAACTGTAACTTTCAGTTTAAACAATTATTGGTGACTCT
GATGTCAAATGTTTCTCAAGCTTTATCTGAACAAAATTCTTCTCACTTTGTTGCCAAAGTCGTT
AACAAGAAATCACATTGACTCATTGATGTTTTGGCTCCTTTCCCTTACTTTCTGTTGCTTTCCA
AAAGCTGAGACAGGAAACTAACCCTAACTGAGCACCTGCAATTGCCTGGTAGTATTCTAGTCAT
GTGTGTACTTTTGTGTGTATGTAATCCCCTTACAGCTCTGCAAAGTAAGAATTGTTCTCCCTGC
TTTACAGAAGAGATCATAAGATAATTGAGGCTGTTAGATGTTAACTTGCCAAAAGCCATACAGG
AAAATGGTAGAGTCACAGTTTGAACCAGGTCCTTTTGATTCTTTACATTAAACCATGCTTTGAT
CTTGGAAATACACTGTAAGGCAATAAATCAATAGATACGGATAATTCACAGGCTTCTAAATAAA
TGGAAGTTGATTGTTTTTATCTGTGAGCCAAAGTAAGACTTATTCTAA
SEQ ID NO: 27273 (3Ή arm)
In an embodiment, the replacement sequence comprises or consists of a Guanine (G) residue.
In an embodiment, to correct a mutation, e.g., G542X target site in the CFTR gene, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the G542X mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TGTCCATATGGTAGATAAATGGAACAAATGAATAACAGAAGTAACCATTTTGATACTTTAGATA TAGATAATATTGGATTATTTCTGGATTGTGAAAGAAGAAGGAAGAAGCATATGGAAGAGAAGTT TTAGTAGAGGGGAGGAAGGAGGAGGTGGAAACGAATGTACAAGGATGGGAGGAGAAAAGGGAGA GAGACTTTTTTTTTTTTAAGGCGAGAGTTTACTACCTATCTAACTCTTCGCATTCTTGAAGTCT CAGACCAAATCCCATCGGTTTGAAAGCCTCTAGGGTATTCTATCTATTGTATACTTCTGTTATG TACAAAATTAATTTGCCAATTAATTGTGAACTGTTTTATAAACTATCTTAAAATGGTTAGTTAA ATCTTTGGGATAGTATTTAGCTTTCTCCAGGATTATGACTTACCTTCTAAATTAGACATACAAT GCCTAGGAGTCAAGGACTATTTTGCATAAATTCCAGTCTTCTTTTACAATGCCTAGAATGATTG TTACCACAGAAATATTCATTACCTGGGAGAAAGGATGACAGGAGGGGCAGAATGAATGGAGAGA GGTCGTGAGAATGAGGTGCTGAGGATGGACGAGGAAGAAAGCTGTTTTAGTTGGGAGGATAGGT
GACAGAAGCATGGAAAGGAATTGCCTTGGACCCATGGAAGCCCAGTGAAGATACTTAGATCCTG
CAGGGGTGTGAATAATGTTCTTTTAGTTTCTCTTCTTAGGAGGTTTGTTCATTTTGGGAGATTT
CTTTTGAAAAGAGTGAACTTAAATTGGAGAAAAGTACATTTTAGTATGTTGATAACATTTGAAT
TTGTAAAATGGACCTATGGATGATCTACACATATTTATATACCCATAAATATACACATATTTTA
ATTTTTGGTATTTTATAATTATTATTTAATGATCATTCATGACATTTTAAAAATTACAGAAAAA
TTTACATCTAAAATTTCAGCAATGTTGTTTTTGACCAACTAAATAAATTGCATTTGAAATAATG
GAGATGCAATGTTCAAAATTTCAACTGTGGTTAAAGCAATAGTGTGATATATGATTACATTAGA
AGGAAGATGTGCCTTTCAAATTCAGATTGAGCATACTAAAAGTGACTCTCTAATTTTCTATTTT
TGGTAATAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTTgGAGAAGGT GGAAT C A
CACTGAGTGGAGGTCAACGAGCAAGAATTTCTTTAGCAAGGTGAATAACTAATTATTGGTCTAG
CAAGCATTTGCTGTAAATGTCATTCATGTAAAAAAATTACAGACATTTCTCTATTGCTTTATAT
TCTGTTTCTGGAATTGAAAAAATCCTGGGGTTTTATGGCTAGTGGGTTAAGAATCACATTTAAG
AACTATAAATAATGGTATAGTATCCAGATTTGGTAGAGATTATGGTTACTCAGAATCTGTGCCC
GTATCTTGGTGTCAGTGTATTTGTTTGCCTCATAGTATAGTTTACTACAAATGGAAAACTCTAG
GATTCTGCATAATACTGGACAGAGAAGATGTAAATATCTGTTAGTTCCATCATAGACCCTGCCA
CTCCAATGTACACACCAGCTTTAGGCTTCTTGGTATAGATAAACATACATTTTCAAAATTTTTC
ATCATAATTTTCATAACAAAATAGGAAGGCAAATGATGTCACTTGGCTTAAAATCTATAATATT
TAAAATAAACAGGACAAATGCATTAACATTGTTGGGGGAGGAGGTCCCTTAGTAGAAACACTCT
TGGTCCAAGCATTTTAAAGCTGTCAAAGAGATGTAAATATAGATAATGTATGTCAAGGAGAGAG
CTTTGTGGTTAAACTGTAACTTTCAGTTTAAACAATTATTGGTGACTCTGATGTCAAATGTTTC
TCAAGCTTTATCTGAACAAAATTCTTCTCACTTTGTTGCCAAAGTCGTTAACAAGAAATCACAT
TGACTCATTGATGTTTTGGCTCCTTTCCCTTACTTTCTGTTGCTTTCCAAAAGCTGAGACAGGA
AACTAACCCTAACTGAGCACCTGCAATTGCCTGGTAGTATTCTAGTCATGTGTGTACTTTTGTG
TGTATGTAATCCCCTTACAGCTCTGCAAAGTAAGAATTGTTCTCCCTGCTTTACAGAAGAGATC
ATAAGATAATTGAGGCTGTTAGATGTTAACTTGCCAAAAGCCATACAGGAAAATGGTAGAGTCA
CAGTTTGAACCAGGTCCTTTTGATTCTTTACATTAAACCATGCTTTGATCTTGGAAATACACTG
TAAGGCAATAAATCAATAGATACGGATAATTCACAGGCTTCTAAATAAATGGAAGTTGATTGTT
TTTATCTGTGAGCCAAAGTAAGACTTATTCTAA
(Template Construct 5; SEQ ID NO: 27274)
As described below in Table 49, shorter homology arms, e.g., 5' and/or 3' homology arms may be used. It is contemplated herein that one or both homology arms may be shortened to avoid including certain sequence repeat elements, e.g., Alu repeats, LINE elements. For example, a 5' homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3' homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5' and the 3' homology arms may be shortened to avoid including certain sequence repeat elements.
In an embodiment, to correct G542X mutation in the CFTR gene, the 5' homology arm may be shortened less than 1000 nucleotides, e.g., e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the G542X mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
CCTGCAGGGGTGTGAATAATGTTCTTTTAGTTTCTCTTCTTAGGAGGTTTGTTCATTTTGGGAG
ATTTCTTTTGAAAAGAGTGAACTTAAATTGGAGAAAAGTACATTTTAGTATGTTGATAACATTT
GAATTTGTAAAATGGACCTATGGATGATCTACACATATTTATATACCCATAAATATACACATAT
TTTAATTTTTGGTATTTTATAATTATTATTTAATGATCATTCATGACATTTTAAAAATTACAGA
AAAATTTACATCTAAAATTTCAGCAATGTTGTTTTTGACCAACTAAATAAATTGCATTTGAAAT
AATGGAGATGCAATGTTCAAAATTTCAACTGTGGTTAAAGCAATAGTGTGATATATGATTACAT
TAGAAGGAAGATGTGCCTTTCAAATTCAGATTGAGCATACTAAAAGTGACTCTCTAATTTTCTA
TTTTTGGTAATAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTTgGAGAAGGTGGA
ATCACACTGAGTGGAGGTCAACGAGCAAGAAT T TCT T TAGCAAGGTGAATAACTAAT TAT TGGT
CTAGCAAGCAT T TGCTGTAAATGTCAT TCATGTAAAAAAAT TACAGACAT T TCTCTAT TGCT T T
ATAT TCTGT T TCTGGAAT TGAAAAAATCCTGGGGT T T TATGGCTAGTGGGT TAAGAATCACAT T
TAAGAACTATAAATAATGGTATAGTATCCAGAT T TGGTAGAGAT TATGGT TACTCAGAATCTGT
GCCCGTATCT TGGTGTCAGTGTAT T TGT T TGCCTCATAGTATAGT T TACTACAAATGGAAAACT
CTAGGAT TCTGCATAATACTGGACAGAGAAGATGTAAATATCTGT TAGT TCCATCATAGACCCT
GCCACTCCAATGTACACACCAGCT T TAGGCT TCT TGGTATAGATAAACATACAT T T TCAAAAT T
T T T CAT C AT AAT T T T C AT AAC AAAAT AGGAAGGC AAAT GAT
(Template Construct 6; SEQ ID NO: 27275)
It is contemplated herein that template nucleic acids for correcting a mutation may designed for use as a single- stranded oligonucleotide (ssODN). When using a ssODN, 5' and 3' homology arms may range up to about 200 base pairs (bp) in length, e.g., at least 25, 50, 75, 100, 125, 150, 175, or 200 bp in length. Longer homology arms are also contemplated for ssODNs as improvements in oligonucleotide synthesis continue to be made.
In an embodiment, an ssODN may be used to correct a mutation, e.g., G542X target site in the CFTR gene. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted bases to correct the G542X mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTTGCAGAGAAAGACA
ATATAGTTCTTgGAGAAGGTGGAATCACACTGAGTGGAGGTCAACGAGCAAGAAT T TCT T TAGC
AAGGTGAATAACTAAT TAT TGGT
(Template Construct 7; SEQ ID NO: 27276)
It is contemplated herein that, in an embodiment, a Cas9 molecule could potentially cleave donor constructs either prior to or following homology directed repair (e.g., homologous recombination), resulting in a possible non-homologous-end-joining event and further DNA sequence mutation at the chromosomal locus of interest. Therefore, to avoid cleavage of the donor sequence before and/or after Cas9-mediated homology directed repair, alternate versions of the donor sequence may be used where silent mutations are introduced. These silent mutations may disrupt Cas9 binding and cleavage, but not disrupt the amino acid sequence of the repaired gene. For example, mutations may include those made to a donor sequence to repair the CFTR gene, the mutant form which can cause CF or CF-like disease. In an embodiment, a silent mutation that disrupts Cas9 binding and cleavage, but does not disrupt the amino acid sequence of the repaired gene, is a sense mutation.
In an embodiment, to correct a mutation, e.g., G542X target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the G542X mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence. TGTCCATATGGTAGATAAATGGAACAAATGAATAACAGAAGTAACCATTTTGATACTTTAGATA TAGATAATATTGGATTATTTCTGGATTGTGAAAGAAGAAGGAAGAAGCATATGGAAGAGAAGTT TTAGTAGAGGGGAGGAAGGAGGAGGTGGAAACGAATGTACAAGGATGGGAGGAGAAAAGGGAGA GAGACTTTTTTTTTTTTAAGGCGAGAGTTTACTACCTATCTAACTCTTCGCATTCTTGAAGTCT CAGACCAAATCCCATCGGTTTGAAAGCCTCTAGGGTATTCTATCTATTGTATACTTCTGTTATG TACAAAATTAATTTGCCAATTAATTGTGAACTGTTTTATAAACTATCTTAAAATGGTTAGTTAA ATCTTTGGGATAGTATTTAGCTTTCTCCAGGATTATGACTTACCTTCTAAATTAGACATACAAT GCCTAGGAGTCAAGGACTATTTTGCATAAATTCCAGTCTTCTTTTACAATGCCTAGAATGATTG TTACCACAGAAATATTCATTACCTGGGAGAAAGGATGACAGGAGGGGCAGAATGAATGGAGAGA GGTCGTGAGAATGAGGTGCTGAGGATGGACGAGGAAGAAAGCTGTTTTAGTTGGGAGGATAGGT GACAGAAGCATGGAAAGGAATTGCCTTGGACCCATGGAAGCCCAGTGAAGATACTTAGATCCTG CAGGGGTGTGAATAATGTTCTTTTAGTTTCTCTTCTTAGGAGGTTTGTTCATTTTGGGAGATTT CTTTTGAAAAGAGTGAACTTAAATTGGAGAAAAGTACATTTTAGTATGTTGATAACATTTGAAT TTGTAAAATGGACCTATGGATGATCTACACATATTTATATACCCATAAATATACACATATTTTA ATTTTTGGTATTTTATAATTATTATTTAATGATCATTCATGACATTTTAAAAATTACAGAAAAA TTTACATCTAAAATTTCAGCAATGTTGTTTTTGACCAACTAAATAAATTGCATTTGAAATAATG GAGATGCAATGTTCAAAATTTCAACTGTGGTTAAAGCAATAGTGTGATATATGATTACATTAGA AGGAAGATGTGCCTTTCAAATTCAGATTGAGCATACTAAAAGTGACTCTCTAATTTTCTATTTT TGGTAATAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTagGtGAAGGTGGAATCA CACTGAGTGGAGGTCAACGAGCAAGAATTTCTTTAGCAAGGTGAATAACTAATTATTGGTCTAG CAAGCATTTGCTGTAAATGTCATTCATGTAAAAAAATTACAGACATTTCTCTATTGCTTTATAT TCTGTTTCTGGAATTGAAAAAATCCTGGGGTTTTATGGCTAGTGGGTTAAGAATCACATTTAAG AACTATAAATAATGGTATAGTATCCAGATTTGGTAGAGATTATGGTTACTCAGAATCTGTGCCC GTATCTTGGTGTCAGTGTATTTGTTTGCCTCATAGTATAGTTTACTACAAATGGAAAACTCTAG GATTCTGCATAATACTGGACAGAGAAGATGTAAATATCTGTTAGTTCCATCATAGACCCTGCCA CTCCAATGTACACACCAGCTTTAGGCTTCTTGGTATAGATAAACATACATTTTCAAAATTTTTC ATCATAATTTTCATAACAAAATAGGAAGGCAAATGATGTCACTTGGCTTAAAATCTATAATATT TAAAATAAACAGGACAAATGCATTAACATTGTTGGGGGAGGAGGTCCCTTAGTAGAAACACTCT TGGTCCAAGCATTTTAAAGCTGTCAAAGAGATGTAAATATAGATAATGTATGTCAAGGAGAGAG CTTTGTGGTTAAACTGTAACTTTCAGTTTAAACAATTATTGGTGACTCTGATGTCAAATGTTTC TCAAGCTTTATCTGAACAAAATTCTTCTCACTTTGTTGCCAAAGTCGTTAACAAGAAATCACAT TGACTCATTGATGTTTTGGCTCCTTTCCCTTACTTTCTGTTGCTTTCCAAAAGCTGAGACAGGA AACTAACCCTAACTGAGCACCTGCAATTGCCTGGTAGTATTCTAGTCATGTGTGTACTTTTGTG
TGTATGTAATCCCCTTACAGCTCTGCAAAGTAAGAATTGTTCTCCCTGCTTTACAGAAGAGATC
ATAAGATAATTGAGGCTGTTAGATGTTAACTTGCCAAAAGCCATACAGGAAAATGGTAGAGTCA
CAGTTTGAACCAGGTCCTTTTGATTCTTTACATTAAACCATGCTTTGATCTTGGAAATACACTG
TAAGGCAATAAATCAATAGATACGGATAATTCACAGGCTTCTAAATAAATGGAAGTTGATTGTT
TTTATCTGTGAGCCAAAGTAAGACTTATTCTAA
(Template Construct 8; SEQ ID NO: 27277)
In an embodiment, to correct a mutation, e.g., G542X target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the 5' homology arm may be shortened less than 750 nucleotides, e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the G542X mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
CCTGCAGGGGTGTGAATAATGTTCTTTTAGTTTCTCTTCTTAGGAGGTTTGTTCATTTTGGGAG
ATTTCTTTTGAAAAGAGTGAACTTAAATTGGAGAAAAGTACATTTTAGTATGTTGATAACATTT
GAATTTGTAAAATGGACCTATGGATGATCTACACATATTTATATACCCATAAATATACACATAT
TTTAATTTTTGGTATTTTATAATTATTATTTAATGATCATTCATGACATTTTAAAAATTACAGA
AAAATTTACATCTAAAATTTCAGCAATGTTGTTTTTGACCAACTAAATAAATTGCATTTGAAAT
AATGGAGATGCAATGTTCAAAATTTCAACTGTGGTTAAAGCAATAGTGTGATATATGATTACAT
TAGAAGGAAGATGTGCCTTTCAAATTCAGATTGAGCATACTAAAAGTGACTCTCTAATTTTCTA
TTTTTGGTAATAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTagGtGAAGGTGGA
ATCACACTGAGTGGAGGTCAACGAGCAAGAATTTCTTTAGCAAGGTGAATAACTAATTATTGGT
CTAGCAAGCATTTGCTGTAAATGTCATTCATGTAAAAAAATTACAGACATTTCTCTATTGCTTT
ATATTCTGTTTCTGGAATTGAAAAAATCCTGGGGTTTTATGGCTAGTGGGTTAAGAATCACATT
TAAGAACTATAAATAATGGTATAGTATCCAGATTTGGTAGAGATTATGGTTACTCAGAATCTGT
GCCCGTATCTTGGTGTCAGTGTATTTGTTTGCCTCATAGTATAGTTTACTACAAATGGAAAACT
CTAGGATTCTGCATAATACTGGACAGAGAAGATGTAAATATCTGTTAGTTCCATCATAGACCCT
GCCACTCCAATGTACACACCAGCTTTAGGCTTCTTGGTATAGATAAACATACATTTTCAAAATT
T T T CAT C AT AAT T T T C AT AAC AAAAT AGGAAGGC AAAT GAT
(Template Construct 9; SEQ ID NO: 27278) In an embodiment, an ssODN may be to correct a mutation, e.g., G542X target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted base to correct the G542X mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTTGCAGAGAAAGACA
ATATAGTTCTagGtGAAGGTGGAATCACACTGAGTGGAGGTCAACGAGCAAGAATTTCTTTAGC
AAGGTGAATAACTAATTATTGGT
(Template Construct 10; SEQ ID NO: 27279)
The underlined A has been changed from a T to A at that position and the underlined T has been changed from an A to T at that position so that wild-type CFTR is still transcribed, but the PAM sequence AGG has been modified to reduce or eliminate Cas9 cleavage at that locus.
Exemplary template nucleic acids (also referred to herein as donor constructs) to correction a mutation, e.g., G551D target site in the CFTR gene, are provided.
Suitable sequence for the 5' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
TGAATAACAGAAGTAACCATTTTGATACTTTAGATATAGATAATATTGGATTATTTCTGGATTG TGAAAGAAGAAGGAAGAAGCATATGGAAGAGAAGTTTTAGTAGAGGGGAGGAAGGAGGAGGTGG AAACGAAT GT AC AAGGAT GGGAGGAGAAAAGGGAGAGAGAC TTTTTTTTTTT T AAGGCGAGAGT TTACTACCTATCTAACTCTTCGCATTCTTGAAGTCTCAGACCAAATCCCATCGGTTTGAAAGCC TCTAGGGTATTCTATCTATTGTATACTTCTGTTATGTACAAAATTAATTTGCCAATTAATTGTG AACTGTTTTATAAACTATCTTAAAATGGTTAGTTAAATCTTTGGGATAGTATTTAGCTTTCTCC AGGATTATGACTTACCTTCTAAATTAGACATACAATGCCTAGGAGTCAAGGACTATTTTGCATA AATTCCAGTCTTCTTTTACAATGCCTAGAATGATTGTTACCACAGAAATATTCATTACCTGGGA GAAAGGATGACAGGAGGGGCAGAATGAATGGAGAGAGGTCGTGAGAATGAGGTGCTGAGGATGG ACGAGGAAGAAAGCTGTTTTAGTTGGGAGGATAGGTGACAGAAGCATGGAAAGGAATTGCCTTG GACCCATGGAAGCCCAGTGAAGATACTTAGATCCTGCAGGGGTGTGAATAATGTTCTTTTAGTT TCTCTTCTTAGGAGGTTTGTTCATTTTGGGAGATTTCTTTTGAAAAGAGTGAACTTAAATTGGA GAAAAGTACATTTTAGTATGTTGATAACATTTGAATTTGTAAAATGGACCTATGGATGATCTAC ACATATTTATATACCCATAAATATACACATATTTTAATTTTTGGTATTTTATAATTATTATTTA
ATGATCATTCATGACATTTTAAAAATTACAGAAAAATTTACATCTAAAATTTCAGCAATGTTGT
TTTTGACCAACTAAATAAATTGCATTTGAAATAATGGAGATGCAATGTTCAAAATTTCAACTGT
GGTTAAAGCAATAGTGTGATATATGATTACATTAGAAGGAAGATGTGCCTTTCAAATTCAGATT
GAGCATACTAAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTTGCAG
AGAAAGAC AAT AT AGT T C T T GGAGAAGGT GGAAT C AC AC T GAGTGGAG
SEQ ID NO: 27280 (5Ή arm)
Suitable sequence for the 3' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
TCAACGAGCAAGAATTTCTTTAGCAAGGTGAATAACTAATTATTGGTCTAGCAAGCATTTGCTG
TAAATGTCATTCATGTAAAAAAATTACAGACATTTCTCTATTGCTTTATATTCTGTTTCTGGAA
TTGAAAAAATCCTGGGGTTTTATGGCTAGTGGGTTAAGAATCACATTTAAGAACTATAAATAAT
GGTATAGTATCCAGATTTGGTAGAGATTATGGTTACTCAGAATCTGTGCCCGTATCTTGGTGTC
AGTGTATTTGTTTGCCTCATAGTATAGTTTACTACAAATGGAAAACTCTAGGATTCTGCATAAT
ACTGGACAGAGAAGATGTAAATATCTGTTAGTTCCATCATAGACCCTGCCACTCCAATGTACAC
ACCAGCTTTAGGCTTCTTGGTATAGATAAACATACATTTTCAAAATTTTTCATCATAATTTTCA
TAACAAAATAGGAAGGCAAATGATGTCACTTGGCTTAAAATCTATAATATTTAAAATAAACAGG
ACAAATGCATTAACATTGTTGGGGGAGGAGGTCCCTTAGTAGAAACACTCTTGGTCCAAGCATT
TTAAAGCTGTCAAAGAGATGTAAATATAGATAATGTATGTCAAGGAGAGAGCTTTGTGGTTAAA
CTGTAACTTTCAGTTTAAACAATTATTGGTGACTCTGATGTCAAATGTTTCTCAAGCTTTATCT
GAACAAAATTCTTCTCACTTTGTTGCCAAAGTCGTTAACAAGAAATCACATTGACTCATTGATG
TTTTGGCTCCTTTCCCTTACTTTCTGTTGCTTTCCAAAAGCTGAGACAGGAAACTAACCCTAAC
TGAGCACCTGCAATTGCCTGGTAGTATTCTAGTCATGTGTGTACTTTTGTGTGTATGTAATCCC
CTTACAGCTCTGCAAAGTAAGAATTGTTCTCCCTGCTTTACAGAAGAGATCATAAGATAATTGA
GGCTGTTAGATGTTAACTTGCCAAAAGCCATACAGGAAAATGGTAGAGTCACAGTTTGAACCAG
GTCCTTTTGATTCTTTACATTAAACCATGCTTTGATCTTGGAAATACACTGTAAGGCAATAAAT
CAATAGATACGGATAATTCACAGGCTTCTAAATAAATGGAAGTTGATTGTTTTTATCTGTGAGC
C AAAGT AAGAC T T AT T CTAAGAAT T CC AC AAAT T T AGAT AAGAT AGAG
SEQ ID NO: 27281 (3Ή arm)
In an embodiment, the replacement sequence comprises or consists of a Guanine (G) residue. In an embodiment, to correct a mutation, e.g., G551D target site in the CFTR gene, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, codon 551 is shown as underlined sequence, the inserted base to correct the G551D mutation is shown as non-bold and boxed sequence, and the 3' homology arm is shown as no emphasis sequence.
TGAATAACAGAAGTAACCATTTTGATACTTTAGATATAGATAATATTGGATTATTTCTGGATTG TGAAAGAAGAAGGAAGAAGCATATGGAAGAGAAGTTTTAGTAGAGGGGAGGAAGGAGGAGGTGG AAACGAATGTACAAGGATGGGAGGAGAAAAGGGAGAGAGACTTTTTTTTTTTTAAGGCGAGAGT TTACTACCTATCTAACTCTTCGCATTCTTGAAGTCTCAGACCAAATCCCATCGGTTTGAAAGCC TCTAGGGTATTCTATCTATTGTATACTTCTGTTATGTACAAAATTAATTTGCCAATTAATTGTG AACTGTTTTATAAACTATCTTAAAATGGTTAGTTAAATCTTTGGGATAGTATTTAGCTTTCTCC AGGATTATGACTTACCTTCTAAATTAGACATACAATGCCTAGGAGTCAAGGACTATTTTGCATA AATTCCAGTCTTCTTTTACAATGCCTAGAATGATTGTTACCACAGAAATATTCATTACCTGGGA GAAAGGATGACAGGAGGGGCAGAATGAATGGAGAGAGGTCGTGAGAATGAGGTGCTGAGGATGG ACGAGGAAGAAAGCTGTTTTAGTTGGGAGGATAGGTGACAGAAGCATGGAAAGGAATTGCCTTG GACCCATGGAAGCCCAGTGAAGATACTTAGATCCTGCAGGGGTGTGAATAATGTTCTTTTAGTT TCTCTTCTTAGGAGGTTTGTTCATTTTGGGAGATTTCTTTTGAAAAGAGTGAACTTAAATTGGA GAAAAGTACATTTTAGTATGTTGATAACATTTGAATTTGTAAAATGGACCTATGGATGATCTAC ACATATTTATATACCCATAAATATACACATATTTTAATTTTTGGTATTTTATAATTATTATTTA
ATGATCATTCATGACATTTTAAAAATTACAGAAAAATTTACATCTAAAATTTCAGCAATGTTGT TTTTGACCAACTAAATAAATTGCATTTGAAATAATGGAGATGCAATGTTCAAAATTTCAACTGT GGTTAAAGCAATAGTGTGATATATGATTACATTAGAAGGAAGATGTGCCTTTCAAATTCAGATT GAGCATACTAAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTTGCAG
AGAAAGACAATATAGTTCTTGGAGAAGGTGGAATCACACTGAGTGGAG[G|TCAACGAGCAAGAAT
T TCT T TAGCAAGGTGAATAACTAAT TAT TGGTCTAGCAAGCAT T TGCTGTAAATGTCAT TCATG TAAAAAAAT TACAGACAT T TCTCTAT TGCT T TATAT TCTGT T TCTGGAAT TGAAAAAATCCTGG GGT T T TATGGCTAGTGGGT TAAGAATCACAT T TAAGAACTATAAATAATGGTATAGTATCCAGA T T TGGTAGAGAT TATGGT TACTCAGAATCTGTGCCCGTATCT TGGTGTCAGTGTAT T TGT T TGC CTCATAGTATAGT T TACTACAAATGGAAAACTCTAGGAT TCTGCATAATACTGGACAGAGAAGA TGTAAATATCTGT TAGT TCCATCATAGACCCTGCCACTCCAATGTACACACCAGCT T TAGGCT T CTTGGTATAGATAAACATACATTTTCAAAATTTTTCATCATAATTTTCATAACAAAATAGGAAG
GCAAATGATGTCACTTGGCTTAAAATCTATAATATTTAAAATAAACAGGACAAATGCATTAACA
TTGTTGGGGGAGGAGGTCCCTTAGTAGAAACACTCTTGGTCCAAGCATTTTAAAGCTGTCAAAG
AGATGTAAATATAGATAATGTATGTCAAGGAGAGAGCTTTGTGGTTAAACTGTAACTTTCAGTT
TAAACAATTATTGGTGACTCTGATGTCAAATGTTTCTCAAGCTTTATCTGAACAAAATTCTTCT
CACTTTGTTGCCAAAGTCGTTAACAAGAAATCACATTGACTCATTGATGTTTTGGCTCCTTTCC
CTTACTTTCTGTTGCTTTCCAAAAGCTGAGACAGGAAACTAACCCTAACTGAGCACCTGCAATT
GCCTGGTAGTATTCTAGTCATGTGTGTACTTTTGTGTGTATGTAATCCCCTTACAGCTCTGCAA
AGTAAGAATTGTTCTCCCTGCTTTACAGAAGAGATCATAAGATAATTGAGGCTGTTAGATGTTA
ACTTGCCAAAAGCCATACAGGAAAATGGTAGAGTCACAGTTTGAACCAGGTCCTTTTGATTCTT
TACATTAAACCATGCTTTGATCTTGGAAATACACTGTAAGGCAATAAATCAATAGATACGGATA
ATTCACAGGCTTCTAAATAAATGGAAGTTGATTGTTTTTATCTGTGAGCCAAAGTAAGACTTAT
TCTAAGAATTCCACAAATTTAGATAAGATAGAG
(Template Construct 11; SEQ ID NO: 27282)
As described below in Table 49, shorter homology arms, e.g., 5' and/or 3' homology arms may be used.
It is contemplated herein that one or both homology arms may be shortened to avoid including certain sequence repeat elements, e.g., Alu repeats, LINE elements. For example, a 5' homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3' homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5' and the 3' homology arms may be shortened to avoid including certain sequence repeat elements.
In an embodiment, to correct G551D mutation in the CFTR gene, the 5' homology arm may be shortened less than 1000 nucleotides, e.g., approximately 750 nucleotides, e.g., 724 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, codon 551 is shown as underlined sequence, the inserted base to correct the G551D mutation is shown as non-bold and boxed sequence, and the 3' homology arm is shown as no emphasis sequence.
AATGATTGTTACCACAGAAATATTCATTACCTGGGAGAAAGGATGACAGGAGGGGCAGAATGAA TGGAGAGAGGTCGTGAGAATGAGGTGCTGAGGATGGACGAGGAAGAAAGCTGTTTTAGTTGGGA GGATAGGTGACAGAAGCATGGAAAGGAATTGCCTTGGACCCATGGAAGCCCAGTGAAGATACTT AGATCCTGCAGGGGTGTGAATAATGTTCTTTTAGTTTCTCTTCTTAGGAGGTTTGTTCATTTTG GGAGATTTCTTTTGAAAAGAGTGAACTTAAATTGGAGAAAAGTACATTTTAGTATGTTGATAAC ATTTGAATTTGTAAAATGGACCTATGGATGATCTACACATATTTATATACCCATAAATATACAC ATATTTTAATTTTTGGTATTTTATAATTATTATTTAATGATCATTCATGACATTTTAAAAATTA
CAGAAAAATTTACATCTAAAATTTCAGCAATGTTGTTTTTGACCAACTAAATAAATTGCATTTG AAATAATGGAGATGCAATGTTCAAAATTTCAACTGTGGTTAAAGCAATAGTGTGATATATGATT ACATTAGAAGGAAGATGTGCCTTTCAAATTCAGATTGAGCATACTAAAAGTGACTCTCTAATTT TCTATTTTTGGTAATAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTTGGAGAAGG
TGGAATCACACTGAGTGGAG[G|TCAACGAGCAAGAAT T T C T T T AGC AAGGT GAAT AAC T AAT TAT TGGTCTAGCAAGCATTTGCTGTAAATGTCATTCATGTAAAAAAATTACAGACATTTCTCTATTG CTTTATATTCTGTTTCTGGAATTGAAAAAATCCTGGGGTTTTATGGCTAGTGGGTTAAGAATCA CATTTAAGAACTATAAATAATGGTATAGTATCCAGATTTGGTAGAGATTATGGTTACTCAGAAT CTGTGCCCGTATCTTGGTGTCAGTGTATTTGTTTGCCTCATAGTATAGTTTACTACAAATGGAA AACTCTAGGATTCTGCATAATACTGGACAGAGAAGATGTAAATATCTGTTAGTTCCATCATAGA CCCTGCCACTCCAATGTACACACCAGCTTTAGGCTTCTTGGTATAGATAAACATACATTTTCAA AATTTTTCATCATAATTTTCATAACAAAATAGGAAGGCAAATGATGTCACTTGGCTTAAAATCT ATAATATTTAAAATAAACAGGACAAATGCATTAACATTGTTGGGGGAGGAGGTCCCTTAGTAGA AACACTCTTGGTCCAAGCATTTTAAAGCTGTCAAAGAGATGTAAATATAGATAATGTATGTCAA GGAGAGAGCTTTGTGGTTAAACTGTAACTTTCAGTTTAAACAATTATTGGTGACTCTGATGTCA AATGTTTCTCAAGCTTTATCTGAACAAAATTCTTCTCACTTTGTTGCCAAAGTCGTTAACAAGA AATCACATTGACTCATTGATGTTTTGGCTCCTTTCCCTTACTTTCTGTTGCTTTCCAAAAGCTG AGACAGGA
(Template Construct 12; SEQ ID NO: 27283)
In an embodiment, to correct G551D mutation in the CFTR gene, the 5' homology arm may be shortened less than 750 nucleotides, e.g., e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the G551D mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AGTTTCTCTTCTTAGGAGGTTTGTTCATTTTGGGAGATTTCTTTTGAAAAGAGTGAACTTAAAT TGGAGAAAAGTACATTTTAGTATGTTGATAACATTTGAATTTGTAAAATGGACCTATGGATGAT CTACACATATTTATATACCCATAAATATACACATATTTTAATTTTTGGTATTTTATAATTATTA TTTAATGATCATTCATGACATTTTAAAAATTACAGAAAAATTTACATCTAAAATTTCAGCAATG
TTGTTTTTGACCAACTAAATAAATTGCATTTGAAATAATGGAGATGCAATGTTCAAAATTTCAA
CTGTGGTTAAAGCAATAGTGTGATATATGATTACATTAGAAGGAAGATGTGCCTTTCAAATTCA
GATTGAGCATACTAAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTT
GCAGAGAAAGACAATATAGTTCTTGGAGAAGGTGGAATCACACTGAGTGGAGgTCAACGAGCAA
GAATTTCTTTAGCAAGGTGAATAACTAATTATTGGTCTAGCAAGCATTTGCTGTAAATGTCATT
CATGTAAAAAAATTACAGACATTTCTCTATTGCTTTATATTCTGTTTCTGGAATTGAAAAAATC
CTGGGGTTTTATGGCTAGTGGGTTAAGAATCACATTTAAGAACTATAAATAATGGTATAGTATC
CAGATTTGGTAGAGATTATGGTTACTCAGAATCTGTGCCCGTATCTTGGTGTCAGTGTATTTGT
TTGCCTCATAGTATAGTTTACTACAAATGGAAAACTCTAGGATTCTGCATAATACTGGACAGAG
AAGATGTAAATATCTGTTAGTTCCATCATAGACCCTGCCACTCCAATGTACACACCAGCTTTAG
GCTTCTTGGTATAGATAAACATACATTTTCAAAATTTTTCATCATAATTTTCATAACAAAATAG
GAAGGCAAATGATGTCACTTGGCTTAAAATCTATAATATTT
(Template Construct 13; SEQ ID NO: 27284)
It is contemplated herein that template nucleic acids for correcting a mutation may designed for use as a single- stranded oligonucleotide (ssODN). When using a ssODN, 5' and 3' homology arms may range up to about 200 base pairs (bp) in length, e.g., at least 25, 50, 75, 100, 125, 150, 175, or 200 bp in length. Longer homology arms are also contemplated for ssODNs as improvements in oligonucleotide synthesis continue to be made.
In an embodiment, an ssODN may be used to correct a mutation, e.g., G551D target site in the CFTR gene. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted bases to correct the G542X mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
GGTAATAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTTGGAGAAGGTGGAATCAC
ACTGAGTGGAGgTCAACGAGCAAGAATTTCTTTAGCAAGGTGAATAACTAATTATTGGTCTAGC
AAGCATTTGCTGTAAATGTCATT
(Template Construct 14; SEQ ID NO: 27285)
In an embodiment, to correct a mutation, e.g., G551D target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the G551D mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TGAATAACAGAAGTAACCATTTTGATACTTTAGATATAGATAATATTGGATTATTTCTGGATTG TGAAAGAAGAAGGAAGAAGCATATGGAAGAGAAGTTTTAGTAGAGGGGAGGAAGGAGGAGGTGG AAACGAATGTACAAGGATGGGAGGAGAAAAGGGAGAGAGACTTTTTTTTTTTTAAGGCGAGAGT TTACTACCTATCTAACTCTTCGCATTCTTGAAGTCTCAGACCAAATCCCATCGGTTTGAAAGCC TCTAGGGTATTCTATCTATTGTATACTTCTGTTATGTACAAAATTAATTTGCCAATTAATTGTG AACTGTTTTATAAACTATCTTAAAATGGTTAGTTAAATCTTTGGGATAGTATTTAGCTTTCTCC AGGATTATGACTTACCTTCTAAATTAGACATACAATGCCTAGGAGTCAAGGACTATTTTGCATA AATTCCAGTCTTCTTTTACAATGCCTAGAATGATTGTTACCACAGAAATATTCATTACCTGGGA GAAAGGATGACAGGAGGGGCAGAATGAATGGAGAGAGGTCGTGAGAATGAGGTGCTGAGGATGG ACGAGGAAGAAAGCTGTTTTAGTTGGGAGGATAGGTGACAGAAGCATGGAAAGGAATTGCCTTG GACCCATGGAAGCCCAGTGAAGATACTTAGATCCTGCAGGGGTGTGAATAATGTTCTTTTAGTT TCTCTTCTTAGGAGGTTTGTTCATTTTGGGAGATTTCTTTTGAAAAGAGTGAACTTAAATTGGA GAAAAGTACATTTTAGTATGTTGATAACATTTGAATTTGTAAAATGGACCTATGGATGATCTAC ACATATTTATATACCCATAAATATACACATATTTTAATTTTTGGTATTTTATAATTATTATTTA ATGATCATTCATGACATTTTAAAAATTACAGAAAAATTTACATCTAAAATTTCAGCAATGTTGT TTTTGACCAACTAAATAAATTGCATTTGAAATAATGGAGATGCAATGTTCAAAATTTCAACTGT GGTTAAAGCAATAGTGTGATATATGATTACATTAGAAGGAAGATGTGCCTTTCAAATTCAGATT GAGCATACTAAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTTGCAG AGAAAGACAATATAGTTCTTGGAGAAGGTGGAATCACACTGtcTGGAGgTCAACGAGCAAGAAT TTCTTTAGCAAGGTGAATAACTAATTATTGGTCTAGCAAGCATTTGCTGTAAATGTCATTCATG TAAAAAAATTACAGACATTTCTCTATTGCTTTATATTCTGTTTCTGGAATTGAAAAAATCCTGG GGTTTTATGGCTAGTGGGTTAAGAATCACATTTAAGAACTATAAATAATGGTATAGTATCCAGA TTTGGTAGAGATTATGGTTACTCAGAATCTGTGCCCGTATCTTGGTGTCAGTGTATTTGTTTGC CTCATAGTATAGTTTACTACAAATGGAAAACTCTAGGATTCTGCATAATACTGGACAGAGAAGA TGTAAATATCTGTTAGTTCCATCATAGACCCTGCCACTCCAATGTACACACCAGCTTTAGGCTT CTTGGTATAGATAAACATACATTTTCAAAATTTTTCATCATAATTTTCATAACAAAATAGGAAG GCAAATGATGTCACTTGGCTTAAAATCTATAATATTTAAAATAAACAGGACAAATGCATTAACA TTGTTGGGGGAGGAGGTCCCTTAGTAGAAACACTCTTGGTCCAAGCATTTTAAAGCTGTCAAAG
AGATGTAAATATAGATAATGTATGTCAAGGAGAGAGCTTTGTGGTTAAACTGTAACTTTCAGTT
TAAACAATTATTGGTGACTCTGATGTCAAATGTTTCTCAAGCTTTATCTGAACAAAATTCTTCT
CACTTTGTTGCCAAAGTCGTTAACAAGAAATCACATTGACTCATTGATGTTTTGGCTCCTTTCC
CTTACTTTCTGTTGCTTTCCAAAAGCTGAGACAGGAAACTAACCCTAACTGAGCACCTGCAATT
GCCTGGTAGTATTCTAGTCATGTGTGTACTTTTGTGTGTATGTAATCCCCTTACAGCTCTGCAA
AGTAAGAATTGTTCTCCCTGCTTTACAGAAGAGATCATAAGATAATTGAGGCTGTTAGATGTTA
ACTTGCCAAAAGCCATACAGGAAAATGGTAGAGTCACAGTTTGAACCAGGTCCTTTTGATTCTT
TACATTAAACCATGCTTTGATCTTGGAAATACACTGTAAGGCAATAAATCAATAGATACGGATA
ATTCACAGGCTTCTAAATAAATGGAAGTTGATTGTTTTTATCTGTGAGCCAAAGTAAGACTTAT
TCTAAGAATTCCACAAATTTAGATAAGATAGAG
(Template Construct 15; SEQ ID NO: 27286)
In an embodiment, to correct a mutation, e.g., G551D target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the 5' homology arm may be shortened less than 750 nucleotides, e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the G551D mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AGTTTCTCTTCTTAGGAGGTTTGTTCATTTTGGGAGATTTCTTTTGAAAAGAGTGAACTTAAAT TGGAGAAAAGTACATTTTAGTATGTTGATAACATTTGAATTTGTAAAATGGACCTATGGATGAT CTACACATATTTATATACCCATAAATATACACATATTTTAATTTTTGGTATTTTATAATTATTA TTTAATGATCATTCATGACATTTTAAAAATTACAGAAAAATTTACATCTAAAATTTCAGCAATG TTGTTTTTGACCAACTAAATAAATTGCATTTGAAATAATGGAGATGCAATGTTCAAAATTTCAA CTGTGGTTAAAGCAATAGTGTGATATATGATTACATTAGAAGGAAGATGTGCCTTTCAAATTCA GATTGAGCATACTAAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTT GCAGAGAAAGACAATATAGTTCTTGGAGAAGGTGGAATCACACTGtcTGGAGgTCAACGAGCAA GAATTTCTTTAGCAAGGTGAATAACTAATTATTGGTCTAGCAAGCATTTGCTGTAAATGTCATT CATGTAAAAAAATTACAGACATTTCTCTATTGCTTTATATTCTGTTTCTGGAATTGAAAAAATC CTGGGGTTTTATGGCTAGTGGGTTAAGAATCACATTTAAGAACTATAAATAATGGTATAGTATC CAGATTTGGTAGAGATTATGGTTACTCAGAATCTGTGCCCGTATCTTGGTGTCAGTGTATTTGT TTGCCTCATAGTATAGTTTACTACAAATGGAAAACTCTAGGATTCTGCATAATACTGGACAGAG
AAGATGTAAATATCTGTTAGTTCCATCATAGACCCTGCCACTCCAATGTACACACCAGCTTTAG
GCTTCTTGGTATAGATAAACATACATTTTCAAAATTTTTCATCATAATTTTCATAACAAAATAG
GAAGGCAAATGATGTCACTTGGCTTAAAATCTATAATATTT
(Template Construct 16; SEQ ID NO: 27287)
In an embodiment, an ssODN may be to correct a mutation, e.g., G551D target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted base to correct the G551D mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
GGTAATAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTTGGAGAAGGTGGAATCAC ACTGtcTGGAGgTCAACGAGCAAGAATTTCTTTAGCAAGGTGAATAACTAATTATTGGTCTAGC AAGCATTTGCTGTAAATGTCATT
(Template Construct 18; SEQ ID NO: 27288)
The underlined T has been changed from a A to T at that position and the underlined C has been changed from an G to C at that position so that wild-type CFTR is still transcribed, but the PAM sequence TGG has been modified to reduce or eliminate Cas9 cleavage at that locus.
Exemplary template nucleic acids (also referred to herein as donor constructs) to correction a mutation, e.g., N1303K target site in the CFTR gene, are provided.
Suitable sequence for the 5' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
GTTTCTGAGACATTTGACAACAACTTTTTCTTTAAGTCATCAGTTATGCCCCGGGGTATGAAAT TTCTAACATGATCCTCAGTAAACTTGGCTGCCTTGCTGAGGATACTCTCCATCTGCCTGAGAGA CACAGACACCATTAATTGGGAATTGACTTGACTTGTGTGGTTCCTTGTGGACCAGATGGCCACT AAATATTCTCATTTCAAGGCAATTGGTAAAAACTACACTTCAAGAAATTTCATTCTTAATTCCC CTTAGTGGATGTTATTAACCAAAGGCAAAAGAAAAAAAGGGTAAAAAAAATATTCTAAATGTTA ATATCAAAAATATTATTTTCAATTCACCCCAGGCACAGAGAACTAAGTATTATTATTGCTATTG CACCGGCATTCCCCAATGAGACAGTGATTTTCTTTTAAGACATTTTTAAATAATATAGGCAGAA TTAAGTAGACGGTGATCTGGTAAGTAGATGTTTCAGGGTAACAGCTGTGCAATGCTCCATGCAG GGAATTAGATTGTCATTTTATTCCTTACCAGGAACATACATTCAGTTAAACAATTATTTGACTT
CTGCTCTTCCACTGATTTCTAAGTTGAGGCTCTCTCTTGTGCCTGTCTGATCAGATAAGTAGAG
TTGTGCCTTGGTTTATAGATGAGATAAATGTGTATTTGAATAAGCATAAGTTAAAGAAATTTTA
AAATCCCTTAGGAAGCTAGGCTTATCAGAGAAATCCAAGGAAATACATTAACAAACTAGGAATT
TGTTCTAACAGGTTAATTATAACTCATAAACTTATTGGGTTTTTTTACCTTTTAATTTTATATT
ACATTTGCTTATAATAAGGAATATTGCTAGGAATAAAATTTTTTAATATTCTACAATTAACAAT
TATCTCAATTTCTTTATTCTAAAGACATTGGGATTAGAAAAATGTTCACAAGGGACTCCAAATA
TTGCTGTAGTATTTGTTTCTTAAAAGAATGATACAAAGCAGACATGATAAAATATTAAAATTTG
AGAGAACTTGATGGTAAGTACATGGGTGTTTCTTATTTTAAAATAATTTTTCTACTTGAAATAT
TTTACAATACAATAAGGGAAAAATAAAAAGTTATTTAAGTTATTCATACTTTCTTCTTCTTTTC
TTTTTTGCTATAGAAAGTATTTATTTTTTCTGGAACATTTAGAAAAAA
SEQ ID NO: 27289 (5Ή arm)
Suitable sequence for the 3' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
TTGGATCCCTATGAACAGTGGAGTGATCAAGAAATATGGAAAGTTGCAGATGAGGTAAGGCTGC TAACTGAAATGATTTTGAAAGGGGTAACTCATACCAACACAAATGGCTGATATAGCTGACATCA TTCTACACACTTTGTGTGCATGTATGTGTGTGCACAACTTTAAAATGGAGTACCCTAACATACC TGGAGCAACAGGTACTTTTGACTGGACCTACCCCTAACTGAAATGATTTTGAAAGAGGTAACTC ATACCAACACAAATGGTTGATATGGCTAAGATCATTCTACACACTTTGTGTGCATGTATTTCTG TGCACAACTTCAAAATGGAGTACCCTAAAATACCTGGCGCGACAAGTACTTTTGACTGAGCCTA CTTCTCTCCTCACTGGTATGGCTCCAACCATCAGGCCCTATCTTGGTCCATTTAGGCTGCTAAA ATAAAATACCAAAGACTGAGCTGCTTATAAGCAATCTTTGGAGGCTGAGAAGTCAAAGATCAAG GTGCCAGCAGGTTTGCTGTCTCGTGAGAGCATACTTCCTGGTTCATTGATGGTGCTTTCTTGCT GTGTCCTCACATAATGGAAAGGGCAAGACCTCTCTGGTGTCTCTTTTACAATGGCACTAATCCC ATCATGAGGGCTTTGTTCTCATGACCTAATCACCTCCCACATGTCCTACATTCTAATACTATCA CCTTGGGGGTTAGGATTTTAACATATGAATTTGAGGAGGTGGCGGGGGGGACACAAATATTTAG ACCATAGCATTTCACTCCTGACCTCCAAAGTTCATGTCTTCTTCACATGCAAAATACATTCATT CCATCCCAATAGCCCCCAAAGTCTTAACTTGTTCCAGCATCAACTTACAAGGCTAAAGTCCAAG GTTTCATCTAAATATCAGCTAAATCAGCACAAACAGCTAAATCAGGTAGAGTGGGACTTAAGGT GTGATTCCTCTTTAGGCAGATTGCTCTCCAACTATGAAATTGTGAAATCAAACCTATTATGTAC TTTCAAAATAAAATGGTGAAACAGGCACAGGCTAGACAGTCCCATTTCAAAAAAGAGAAATAGA AAAGAAAAAAGGAGTGACAGGTCTCTATAAGTCTAAAACT T TAAGGCT TGAGAATAAT T TGCT T
TGCT T TGCCTCCAGGCTCACTGGGGTGGTGTCT TACCTCTGGACACAC
SEQ ID NO: 27290 (3Ή arm)
In an embodiment, the replacement sequence comprises or consists of a Cytosine (C) residue.
In an embodiment, to correct a mutation, e.g., N1303K target site in the CFTR gene, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the G542X mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
GTTTCTGAGACATTTGACAACAACTTTTTCTTTAAGTCATCAGTTATGCCCCGGGGTATGAAAT TTCTAACATGATCCTCAGTAAACTTGGCTGCCTTGCTGAGGATACTCTCCATCTGCCTGAGAGA CACAGACACCATTAATTGGGAATTGACTTGACTTGTGTGGTTCCTTGTGGACCAGATGGCCACT AAATATTCTCATTTCAAGGCAATTGGTAAAAACTACACTTCAAGAAATTTCATTCTTAATTCCC CTTAGTGGATGTTATTAACCAAAGGCAAAAGAAAAAAAGGGTAAAAAAAATATTCTAAATGTTA ATATCAAAAATATTATTTTCAATTCACCCCAGGCACAGAGAACTAAGTATTATTATTGCTATTG CACCGGCATTCCCCAATGAGACAGTGATTTTCTTTTAAGACATTTTTAAATAATATAGGCAGAA TTAAGTAGACGGTGATCTGGTAAGTAGATGTTTCAGGGTAACAGCTGTGCAATGCTCCATGCAG GGAATTAGATTGTCATTTTATTCCTTACCAGGAACATACATTCAGTTAAACAATTATTTGACTT CTGCTCTTCCACTGATTTCTAAGTTGAGGCTCTCTCTTGTGCCTGTCTGATCAGATAAGTAGAG TTGTGCCTTGGTTTATAGATGAGATAAATGTGTATTTGAATAAGCATAAGTTAAAGAAATTTTA AAATCCCTTAGGAAGCTAGGCTTATCAGAGAAATCCAAGGAAATACATTAACAAACTAGGAATT TGTTCTAACAGGTTAATTATAACTCATAAACTTATTGGGTTTTTTTACCTTTTAATTTTATATT ACATTTGCTTATAATAAGGAATATTGCTAGGAATAAAATTTTTTAATATTCTACAATTAACAAT TATCTCAATTTCTTTATTCTAAAGACATTGGGATTAGAAAAATGTTCACAAGGGACTCCAAATA TTGCTGTAGTATTTGTTTCTTAAAAGAATGATACAAAGCAGACATGATAAAATATTAAAATTTG AGAGAACTTGATGGTAAGTACATGGGTGTTTCTTATTTTAAAATAATTTTTCTACTTGAAATAT TTTACAATACAATAAGGGAAAAATAAAAAGTTATTTAAGTTATTCATACTTTCTTCTTCTTTTC TTTTTTGCTATAGAAAGTATTTATTTTTTCTGGAACATTTAGAAAAAAc T TGGATCCCTAT G AA CAGTGGAGTGATCAAGAAATATGGAAAGT TGCAGATGAGGTAAGGCTGCTAACTGAAATGAT T T TGAAAGGGGTAACTCATACCAACACAAATGGCTGATATAGCTGACATCATTCTACACACTTTGT
GTGCATGTATGTGTGTGCACAACTTTAAAATGGAGTACCCTAACATACCTGGAGCAACAGGTAC
TTTTGACTGGACCTACCCCTAACTGAAATGATTTTGAAAGAGGTAACTCATACCAACACAAATG
GTTGATATGGCTAAGATCATTCTACACACTTTGTGTGCATGTATTTCTGTGCACAACTTCAAAA
TGGAGTACCCTAAAATACCTGGCGCGACAAGTACTTTTGACTGAGCCTACTTCTCTCCTCACTG
GTATGGCTCCAACCATCAGGCCCTATCTTGGTCCATTTAGGCTGCTAAAATAAAATACCAAAGA
CTGAGCTGCTTATAAGCAATCTTTGGAGGCTGAGAAGTCAAAGATCAAGGTGCCAGCAGGTTTG
CTGTCTCGTGAGAGCATACTTCCTGGTTCATTGATGGTGCTTTCTTGCTGTGTCCTCACATAAT
GGAAAGGGCAAGACCTCTCTGGTGTCTCTTTTACAATGGCACTAATCCCATCATGAGGGCTTTG
TTCTCATGACCTAATCACCTCCCACATGTCCTACATTCTAATACTATCACCTTGGGGGTTAGGA
TTTTAACATATGAATTTGAGGAGGTGGCGGGGGGGACACAAATATTTAGACCATAGCATTTCAC
TCCTGACCTCCAAAGTTCATGTCTTCTTCACATGCAAAATACATTCATTCCATCCCAATAGCCC
CCAAAGTCTTAACTTGTTCCAGCATCAACTTACAAGGCTAAAGTCCAAGGTTTCATCTAAATAT
CAGCTAAATCAGCACAAACAGCTAAATCAGGTAGAGTGGGACTTAAGGTGTGATTCCTCTTTAG
GCAGATTGCTCTCCAACTATGAAATTGTGAAATCAAACCTATTATGTACTTTCAAAATAAAATG
GTGAAACAGGCACAGGCTAGACAGTCCCATTTCAAAAAAGAGAAATAGAAAAGAAAAAAGGAGT
GACAGGTCTCTATAAGTCTAAAACTTTAAGGCTTGAGAATAATTTGCTTTGCTTTGCCTCCAGG
CTCACTGGGGTGGTGTCTTACCTCTGGACACAC
(Template Construct 19; SEQ ID NO: 27291)
As described below in Table 49, shorter homology arms, e.g., 5' and/or 3' homology arms may be used.
It is contemplated herein that one or both homology arms may be shortened to avoid including certain sequence repeat elements, e.g., Alu repeats, LINE elements. For example, a 5' homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3' homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5' and the 3' homology arms may be shortened to avoid including certain sequence repeat elements.
In an embodiment, to correct N1303K mutation in the CFTR gene, the 5' homology arm may be shortened less than 1000 nucleotides, e.g., e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the N1303K mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TTTAAAATCCCTTAGGAAGCTAGGCTTATCAGAGAAATCCAAGGAAATACATTAACAAACTAGG
AATTTGTTCTAACAGGTTAATTATAACTCATAAACTTATTGGGTTTTTTTACCTTTTAATTTTA
TATTACATTTGCTTATAATAAGGAATATTGCTAGGAATAAAATTTTTTAATATTCTACAATTAA
CAATTATCTCAATTTCTTTATTCTAAAGACATTGGGATTAGAAAAATGTTCACAAGGGACTCCA
AATATTGCTGTAGTATTTGTTTCTTAAAAGAATGATACAAAGCAGACATGATAAAATATTAAAA
TTTGAGAGAACTTGATGGTAAGTACATGGGTGTTTCTTATTTTAAAATAATTTTTCTACTTGAA
ATATTTTACAATACAATAAGGGAAAAATAAAAAGTTATTTAAGTTATTCATACTTTCTTCTTCT
TTTCTTTTTTGCTATAGAAAGTATTTATTTTTTCTGGAACATTTAGAAAAAAc T TGGATCCCTA
TGAACAGTGGAGTGATCAAGAAATATGGAAAGT TGCAGATGAGGTAAGGCTGCTAACTGAAATG
AT T T TGAAAGGGGTAACTCATACCAACACAAATGGCTGATATAGCTGACATCAT TCTACACACT
T TGTGTGCATGTATGTGTGTGCACAACT T TAAAATGGAGTACCCTAACATACCTGGAGCAACAG
GTACT T T TGACTGGACCTACCCCTAACTGAAATGAT T T TGAAAGAGGTAACTCATACCAACACA
AATGGT TGATATGGCTAAGATCAT TCTACACACT T TGTGTGCATGTAT T TCTGTGCACAACT TC
AAAATGGAGTACCCTAAAATACCTGGCGCGACAAGTACT T T TGACTGAGCCTACT TCTCTCCTC
ACTGGTATGGCTCCAACCATCAGGCCCTATCT TGGTCCAT T TAGGCTGCTAAAATAAAATACCA
AAGACTGAGCTGCT TATAAGCAATCT T TGGAGGCTGAGAAG
(Template Construct 20; SEQ ID NO: 27292)
It is contemplated herein that template nucleic acids for correcting a mutation may designed for use as a single- stranded oligonucleotide (ssODN). When using a ssODN, 5' and 3' homology arms may range up to about 200 base pairs (bp) in length, e.g., at least 25, 50, 75, 100, 125, 150, 175, or 200 bp in length. Longer homology arms are also contemplated for ssODNs as improvements in oligonucleotide synthesis continue to be made.
In an embodiment, an ssODN may be used to correct a mutation, e.g., N1303K target site in the CFTR gene. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted bases to correct the N1303K mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence. AGTTATTCATACTTTCTTCTTCTTTTCTTTTTTGCTATAGAAAGTATTTATTTTTTCTGGAACA
TTTAGAAAAAAcT TGGATCCCTATGAACAGTGGAGTGATCAAGAAATATGGAAAGT TGCAGATG
AGGTAAGGCTGCTAACTGAAATG
(Template Construct 21; SEQ ID NO: 27293)
In an embodiment, to correct a mutation, e.g., N1303K target site in the CFTR gene, and concomitantly introduce a silent sense mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the N1303K mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
GTTTCTGAGACATTTGACAACAACTTTTTCTTTAAGTCATCAGTTATGCCCCGGGGTATGAAAT TTCTAACATGATCCTCAGTAAACTTGGCTGCCTTGCTGAGGATACTCTCCATCTGCCTGAGAGA CACAGACACCATTAATTGGGAATTGACTTGACTTGTGTGGTTCCTTGTGGACCAGATGGCCACT AAATATTCTCATTTCAAGGCAATTGGTAAAAACTACACTTCAAGAAATTTCATTCTTAATTCCC CTTAGTGGATGTTATTAACCAAAGGCAAAAGAAAAAAAGGGTAAAAAAAATATTCTAAATGTTA ATATCAAAAATATTATTTTCAATTCACCCCAGGCACAGAGAACTAAGTATTATTATTGCTATTG CACCGGCATTCCCCAATGAGACAGTGATTTTCTTTTAAGACATTTTTAAATAATATAGGCAGAA TTAAGTAGACGGTGATCTGGTAAGTAGATGTTTCAGGGTAACAGCTGTGCAATGCTCCATGCAG GGAATTAGATTGTCATTTTATTCCTTACCAGGAACATACATTCAGTTAAACAATTATTTGACTT CTGCTCTTCCACTGATTTCTAAGTTGAGGCTCTCTCTTGTGCCTGTCTGATCAGATAAGTAGAG TTGTGCCTTGGTTTATAGATGAGATAAATGTGTATTTGAATAAGCATAAGTTAAAGAAATTTTA AAATCCCTTAGGAAGCTAGGCTTATCAGAGAAATCCAAGGAAATACATTAACAAACTAGGAATT TGTTCTAACAGGTTAATTATAACTCATAAACTTATTGGGTTTTTTTACCTTTTAATTTTATATT ACATTTGCTTATAATAAGGAATATTGCTAGGAATAAAATTTTTTAATATTCTACAATTAACAAT TATCTCAATTTCTTTATTCTAAAGACATTGGGATTAGAAAAATGTTCACAAGGGACTCCAAATA TTGCTGTAGTATTTGTTTCTTAAAAGAATGATACAAAGCAGACATGATAAAATATTAAAATTTG AGAGAACTTGATGGTAAGTACATGGGTGTTTCTTATTTTAAAATAATTTTTCTACTTGAAATAT TTTACAATACAATAAGGGAAAAATAAAAAGTTATTTAAGTTATTCATACTTTCTTCTTCTTTTC TTTTTTGCTATAGAAAGTATTTATTTTTTCTGGAACATTTAGAAAAAAc cT cGATCCCTATGAA CAGTGGAGTGATCAAGAAATATGGAAAGTTGCAGATGAGGTAAGGCTGCTAACTGAAATGATTT
TGAAAGGGGTAACTCATACCAACACAAATGGCTGATATAGCTGACATCATTCTACACACTTTGT
GTGCATGTATGTGTGTGCACAACTTTAAAATGGAGTACCCTAACATACCTGGAGCAACAGGTAC
TTTTGACTGGACCTACCCCTAACTGAAATGATTTTGAAAGAGGTAACTCATACCAACACAAATG
GTTGATATGGCTAAGATCATTCTACACACTTTGTGTGCATGTATTTCTGTGCACAACTTCAAAA
TGGAGTACCCTAAAATACCTGGCGCGACAAGTACTTTTGACTGAGCCTACTTCTCTCCTCACTG
GTATGGCTCCAACCATCAGGCCCTATCTTGGTCCATTTAGGCTGCTAAAATAAAATACCAAAGA
CTGAGCTGCTTATAAGCAATCTTTGGAGGCTGAGAAGTCAAAGATCAAGGTGCCAGCAGGTTTG
CTGTCTCGTGAGAGCATACTTCCTGGTTCATTGATGGTGCTTTCTTGCTGTGTCCTCACATAAT
GGAAAGGGCAAGACCTCTCTGGTGTCTCTTTTACAATGGCACTAATCCCATCATGAGGGCTTTG
TTCTCATGACCTAATCACCTCCCACATGTCCTACATTCTAATACTATCACCTTGGGGGTTAGGA
TTTTAACATATGAATTTGAGGAGGTGGCGGGGGGGACACAAATATTTAGACCATAGCATTTCAC
TCCTGACCTCCAAAGTTCATGTCTTCTTCACATGCAAAATACATTCATTCCATCCCAATAGCCC
CCAAAGTCTTAACTTGTTCCAGCATCAACTTACAAGGCTAAAGTCCAAGGTTTCATCTAAATAT
CAGCTAAATCAGCACAAACAGCTAAATCAGGTAGAGTGGGACTTAAGGTGTGATTCCTCTTTAG
GCAGATTGCTCTCCAACTATGAAATTGTGAAATCAAACCTATTATGTACTTTCAAAATAAAATG
GTGAAACAGGCACAGGCTAGACAGTCCCATTTCAAAAAAGAGAAATAGAAAAGAAAAAAGGAGT
GACAGGTCTCTATAAGTCTAAAACTTTAAGGCTTGAGAATAATTTGCTTTGCTTTGCCTCCAGG
CTCACTGGGGTGGTGTCTTACCTCTGGACACAC
(Template Construct 22; SEQ ID NO: 27294)
In an embodiment, to correct a mutation, e.g., N1303K target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the 5' homology arm may be shortened less than 750 nucleotides, e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the N1303K mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TTTAAAATCCCTTAGGAAGCTAGGCTTATCAGAGAAATCCAAGGAAATACATTAACAAACTAGG AATTTGTTCTAACAGGTTAATTATAACTCATAAACTTATTGGGTTTTTTTACCTTTTAATTTTA TATTACATTTGCTTATAATAAGGAATATTGCTAGGAATAAAATTTTTTAATATTCTACAATTAA CAATTATCTCAATTTCTTTATTCTAAAGACATTGGGATTAGAAAAATGTTCACAAGGGACTCCA AATATTGCTGTAGTATTTGTTTCTTAAAAGAATGATACAAAGCAGACATGATAAAATATTAAAA TTTGAGAGAACTTGATGGTAAGTACATGGGTGTTTCTTATTTTAAAATAATTTTTCTACTTGAA ATATTTTACAATACAATAAGGGAAAAATAAAAAGTTATTTAAGTTATTCATACTTTCTTCTTCT TTTCTTTTTTGCTATAGAAAGTATTTATTTTTTCTGGAACATTTAGAAAAAAc cT cGATCCCTA
TGAACAGTGGAGTGATCAAGAAATATGGAAAGT TGCAGATGAGGTAAGGCTGCTAACTGAAATG
AT T T TGAAAGGGGTAACTCATACCAACACAAATGGCTGATATAGCTGACATCAT TCTACACACT
T TGTGTGCATGTATGTGTGTGCACAACT T TAAAATGGAGTACCCTAACATACCTGGAGCAACAG
GTACT T T TGACTGGACCTACCCCTAACTGAAATGAT T T TGAAAGAGGTAACTCATACCAACACA
AATGGT TGATATGGCTAAGATCAT TCTACACACT T TGTGTGCATGTAT T TCTGTGCACAACT TC
AAAATGGAGTACCCTAAAATACCTGGCGCGACAAGTACT T T TGACTGAGCCTACT TCTCTCCTC
ACTGGTATGGCTCCAACCATCAGGCCCTATCT TGGTCCAT T TAGGCTGCTAAAATAAAATACCA
AAGACTGAGCTGCT TATAAGCAATCT T TGGAGGCTGAGAAG
(Template Construct 23; SEQ ID NO: 27295)
In an embodiment, an ssODN may be to correct a mutation, e.g., N1303K target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted base to correct the N1303K mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AGTTATTCATACTTTCTTCTTCTTTTCTTTTTTGCTATAGAAAGTATTTATTTTTTCTGGAACA
TTTAGAAAAAAccTcGATCCCTATGAACAGTGGAGTGATCAAGAAATATGGAAAGTTGCAGATG
AGGTAAGGCTGCTAACTGAAATG
(Template Construct 24; SEQ ID NO: 27296)
The underlined C has been changed from a G to C so that wild-type CFTR is still transcribed, but the PAM sequence TGG has been modified to reduce or eliminate Cas9 cleavage at that locus.
Exemplary template nucleic acids (also referred to herein as donor constructs) to correction a mutation, e.g., Rl 17H target site in the CFTR gene, are provided.
Suitable sequence for the 5' homology arm can be selected from (e.g., includes a portion of) or include the following sequence: AACCCCTCAAATTAAGGGATGAGGCAGAATAATGCTTGGCAATACCAGGGGTAGGCTGCAGTCT
TTCTTGGAAATATATATTTTAAATGGAACCAATTATCATAGCATCATTTCCTCTCAGGGTTACC
CTCTGATCCCTATTTTACTAAATCGTTATAAAACAAAATGAGGAATTATGTGTCCTTCCCTTTT
GAAGCCAATGTAACAAGATGGGTAAGAATTAGACCTCCTGAGTTCAAAATCCCTGGATTCAGAT
CTATTCCTGTATATTCAGGAGAAGTGGTAATAAATTCGATGGACAATTTGGTTTAGTAGTCGAT
TGAGGACCCTGATGAGGTATATTTGGGAAAACATAACTTCCGCTCTCTCTCATTGACTCACGGG
CCTTTGAGGAGTCCAGGAGTCATTGGAATCTGGCCTGAGGTTGAGGCTGCTGGCAAAACTCCTT
CCCCAAAGTCCATTCCTATTGCTGACTGAGAAGGGACTAGCATTGGAAGTGGCTGATTTTAAAT
ACCGCTAGTGCTGGTGTGCTCCTCCCTCCCATTCCCAGCTCTGCTTTGTGTAGTTGCCTTGAGA
AGCTAAGTTCATTCTGAAAATAATGCCATTGCACAAAACACTTTTGAAAGTTCTAGTTTGAAAT
TACATCAGGTCACTTGGTCTGTGTGGCCTCAGTTTCTTCATCTGCCATGTGAAAATAATAATGC
CTACTCTGT AG C AAAG AAAG TCTCTATAGT AAAC AAAAAAAAAG CCTACTCTGATACT G AAAG T
TGTTATGAAAAATAAAAAAGGGAAATGCTTTAGAAACTGTTAAGTGCTATGTAGATGTTACTAA
TTAACAAACCATTTCAGAAACTATACTTTTTATTTTATGGCCACTATTCACTGTTTAACTTAAA
ATACCTCATATGTAAACTTGTCTCCCACTGTTGCTATAACAAATCCCAAGTCTTATTTCAAAGT
ACCAAGATATTGAAAATAGTGCTAAGAGTTTCACATATGGTATGACCCTCTATATAAACTCATT
TTAAGTCTCCTCTAAAGATGAAAAGTCTTGTGTTGAAATTCTCAGGGTATTTTATGAGAAATAA
ATGAAATTTAATTTCTCTGTTTTTCCCCTTTTGTAGGAAGTCACCAAAGCAGTACAGCCTCTCT
TACTGGGAAGAATCATAGCTTCCTATGACCCGGATAACAAGGAGGAAC
SEQ ID NO: 27297 (5Ή arm)
Suitable sequence for the 3' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
CTCTATCGCGATTTATCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAGGACACTGCTCCTA CACCCAGCCATTTTTGGCCTTCATCACATTGGAATGCAGATGAGAATAGCTATGTTTAGTTTGA TTTATAAGAAGGTAATACTTCCTTGCACAGGCCCCATGGCACATATATTCTGTATCGTACATGT TTTAATGTCATAAATTAGGTAGTGAGCTGGTACAAGTAAGGGATAAATGCTGAAATTAATTTAA TATGCCTATTAAATAAATGGCAGGAATAATTAATGCTCTTAATTATCCTTGATAATTTAATTGA CTTAAACTGATAATTATTGAGTATCTTCTGTAAACTGCCTCTGTTGTAGTTTTTTTTTTCTCCT AATCATGTTATCATTTTTTTGGAATCCATGGTTTCCTGTTAAGATGACTCACACAGCCTACATA AAAGTAATTGACAAAATATCATCTTATAGTAAAATGCCACATATCTTTATGTTCAGCAAGAAGA GTATAATATATGATTGTTAATGATAACCCAAACAACAAAAGATTTCACCTTAACTGGTTGTCAT AAGTAGTAGTATCCACCGCCTTATTTTGAGTTGGATTTTTATCATCCTATGAGCCCTACAAATT TAAAGTTTTTGGAACAGCACGTGCATTGAACCCATAAGAACCTACTCTGCTTTTCTGCATGTAT
TGTCCAGACAAGAGACCAAATTGCCGAGGCATCATTTAGGTGAATTCTAATTAACATTTAGCTA
CCTTACAACCACAATTCAAGGTTGTTTCAAAGGCATGTGCTTGCATCATCCTGATTCACTACCA
TGTGTTACTAACTTGGATCTGCAAAGTCATTATAAAAAGCTGTTTTGATGGACTTATTTGGATA
TTGCTTTACCCTTCTTCTCTCTTTTCTTTTATCAATGTAAAAACATTATATGTTAAATACTTGG
CTTTTAAGAGCATAGATCTGAAATCTGCCTCTAGCAAATAACCCATAACACTTCTAAGATATAC
CTGCAAGGTCAATTGTGTTGTAAAACCTTGATAACCATACTTTATTGTTCAAAAAAGCCTTTTA
TGAAGGCAGAAGTTAAAAAAAAAAAACAAAAAAAACAGAGTCCACAGTTATCACCTCAGCTACA
ATCTCATCAGTTCACAAGTACCAGCAAAACATGTGATAAGTCAACAAA
SEQ ID NO: 27298 (3Ή arm)
In an embodiment, the replacement sequence comprises or consists of a Guanine (G) residue.
In an embodiment, to correct a mutation, e.g., Rl 17H target site in the CFTR gene, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the Rl 17H mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AACCCCTCAAATTAAGGGATGAGGCAGAATAATGCTTGGCAATACCAGGGGTAGGCTGCAGTCT TTCTTGGAAATATATATTTTAAATGGAACCAATTATCATAGCATCATTTCCTCTCAGGGTTACC CTCTGATCCCTATTTTACTAAATCGTTATAAAACAAAATGAGGAATTATGTGTCCTTCCCTTTT GAAGCCAATGTAACAAGATGGGTAAGAATTAGACCTCCTGAGTTCAAAATCCCTGGATTCAGAT CTATTCCTGTATATTCAGGAGAAGTGGTAATAAATTCGATGGACAATTTGGTTTAGTAGTCGAT TGAGGACCCTGATGAGGTATATTTGGGAAAACATAACTTCCGCTCTCTCTCATTGACTCACGGG CCTTTGAGGAGTCCAGGAGTCATTGGAATCTGGCCTGAGGTTGAGGCTGCTGGCAAAACTCCTT CCCCAAAGTCCATTCCTATTGCTGACTGAGAAGGGACTAGCATTGGAAGTGGCTGATTTTAAAT ACCGCTAGTGCTGGTGTGCTCCTCCCTCCCATTCCCAGCTCTGCTTTGTGTAGTTGCCTTGAGA AGCTAAGTTCATTCTGAAAATAATGCCATTGCACAAAACACTTTTGAAAGTTCTAGTTTGAAAT TACATCAGGTCACTTGGTCTGTGTGGCCTCAGTTTCTTCATCTGCCATGTGAAAATAATAATGC CTACTCTGTAGCAAAGAAAGTCTCTATAGTAAACAAAAAAAAAGCCTACTCTGATACTGAAAGT TGTTATGAAAAATAAAAAAGGGAAATGCTTTAGAAACTGTTAAGTGCTATGTAGATGTTACTAA TTAACAAACCATTTCAGAAACTATACTTTTTATTTTATGGCCACTATTCACTGTTTAACTTAAA
ATACCTCATATGTAAACTTGTCTCCCACTGTTGCTATAACAAATCCCAAGTCTTATTTCAAAGT
ACCAAGATATTGAAAATAGTGCTAAGAGTTTCACATATGGTATGACCCTCTATATAAACTCATT
TTAAGTCTCCTCTAAAGATGAAAAGTCTTGTGTTGAAATTCTCAGGGTATTTTATGAGAAATAA
ATGAAATTTAATTTCTCTGTTTTTCCCCTTTTGTAGGAAGTCACCAAAGCAGTACAGCCTCTCT
TACTGGGAAGAATCATAGCTTCCTATGACCCGGATAACAAGGAGGAACgC T C T AT CGCGAT T T A
TCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAGGACACTGCTCCTACACCCAGCCATTTTT
GGCCTTCATCACATTGGAATGCAGATGAGAATAGCTATGTTTAGTTTGATTTATAAGAAGGTAA
TACTTCCTTGCACAGGCCCCATGGCACATATATTCTGTATCGTACATGTTTTAATGTCATAAAT
TAGGTAGTGAGCTGGTACAAGTAAGGGATAAATGCTGAAATTAATTTAATATGCCTATTAAATA
AATGGCAGGAATAATTAATGCTCTTAATTATCCTTGATAATTTAATTGACTTAAACTGATAATT
ATTGAGTATCTTCTGTAAACTGCCTCTGTTGTAGTTTTTTTTTTCTCCTAATCATGTTATCATT
TTTTTGGAATCCATGGTTTCCTGTTAAGATGACTCACACAGCCTACATAAAAGTAATTGACAAA
ATATCATCTTATAGTAAAATGCCACATATCTTTATGTTCAGCAAGAAGAGTATAATATATGATT
GTTAATGATAACCCAAACAACAAAAGATTTCACCTTAACTGGTTGTCATAAGTAGTAGTATCCA
CCGCCTTATTTTGAGTTGGATTTTTATCATCCTATGAGCCCTACAAATTTAAAGTTTTTGGAAC
AGCACGTGCATTGAACCCATAAGAACCTACTCTGCTTTTCTGCATGTATTGTCCAGACAAGAGA
CCAAATTGCCGAGGCATCATTTAGGTGAATTCTAATTAACATTTAGCTACCTTACAACCACAAT
TCAAGGTTGTTTCAAAGGCATGTGCTTGCATCATCCTGATTCACTACCATGTGTTACTAACTTG
GATCTGCAAAGTCATTATAAAAAGCTGTTTTGATGGACTTATTTGGATATTGCTTTACCCTTCT
TCTCTCTTTTCTTTTATCAATGTAAAAACATTATATGTTAAATACTTGGCTTTTAAGAGCATAG
ATCTGAAATCTGCCTCTAGCAAATAACCCATAACACTTCTAAGATATACCTGCAAGGTCAATTG
TGTTGTAAAACCTTGATAACCATACTTTATTGTTCAAAAAAGCCTTTTATGAAGGCAGAAGTTA
AAAAAAAAAAACAAAAAAAACAGAGTCCACAGTTATCACCTCAGCTACAATCTCATCAGTTCAC
AAGTACCAGCAAAACATGTGATAAGTCAACAAA
(Template Construct 25; SEQ ID NO: 27299)
As described below in Table 49, shorter homology arms, e.g., 5' and/or 3' homology arms may be used.
It is contemplated herein that one or both homology arms may be shortened to avoid including certain sequence repeat elements, e.g., Alu repeats, LINE elements. For example, a 5' homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3' homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5' and the 3' homology arms may be shortened to avoid including certain sequence repeat elements.
In an embodiment, to correct Rl 17H mutation in the CFTR gene, the 5' homology arm may be shortened less than 1000 nucleotides, e.g., e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the Rl 17H mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
ATGCCTACTCTGTAGCAAAGAAAGTCTCTATAGTAAACAAAAAAAAAGCCTACTCTGATACTGA
AAGTTGTTATGAAAAATAAAAAAGGGAAATGCTTTAGAAACTGTTAAGTGCTATGTAGATGTTA
CTAATTAACAAACCATTTCAGAAACTATACTTTTTATTTTATGGCCACTATTCACTGTTTAACT
TAAAATACCTCATATGTAAACTTGTCTCCCACTGTTGCTATAACAAATCCCAAGTCTTATTTCA
AAGTACCAAGATATTGAAAATAGTGCTAAGAGTTTCACATATGGTATGACCCTCTATATAAACT
CATTTTAAGTCTCCTCTAAAGATGAAAAGTCTTGTGTTGAAATTCTCAGGGTATTTTATGAGAA
ATAAATGAAATTTAATTTCTCTGTTTTTCCCCTTTTGTAGGAAGTCACCAAAGCAGTACAGCCT
CTCTTACTGGGAAGAATCATAGCTTCCTATGACCCGGATAACAAGGAGGAACgC T C T AT CGCGA
TTTATCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAGGACACTGCTCCTACACCCAGCCAT
TTTTGGCCTTCATCACATTGGAATGCAGATGAGAATAGCTATGTTTAGTTTGATTTATAAGAAG
GTAATACTTCCTTGCACAGGCCCCATGGCACATATATTCTGTATCGTACATGTTTTAATGTCAT
AAATTAGGTAGTGAGCTGGTACAAGTAAGGGATAAATGCTGAAATTAATTTAATATGCCTATTA
AATAAATGGCAGGAATAATTAATGCTCTTAATTATCCTTGATAATTTAATTGACTTAAACTGAT
AATTATTGAGTATCTTCTGTAAACTGCCTCTGTTGTAGTTTTTTTTTTCTCCTAATCATGTTAT
CATTTTTTTGGAATCCATGGTTTCCTGTTAAGATGACTCACACAGCCTACATAAAAGTAATTGA
CAAAATATCATCTTATAGTAAAATGCCACATATCTTTATGT
(Template Construct 26; SEQ ID NO: 27300)
It is contemplated herein that template nucleic acids for correcting a mutation may designed for use as a single- stranded oligonucleotide (ssODN). When using a ssODN, 5' and 3' homology arms may range up to about 200 base pairs (bp) in length, e.g., at least 25, 50, 75, 100, 125, 150, 175, or 200 bp in length. Longer homology arms are also contemplated for ssODNs as improvements in oligonucleotide synthesis continue to be made.
In an embodiment, an ssODN may be used to correct a mutation, e.g., Rl 17H target site in the CFTR gene. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted bases to correct the Rl 17H mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AAGTCACCAAAGCAGTACAGCCTCTCTTACTGGGAAGAATCATAGCTTCCTATGACCCGGATAA
CAAGGAGGAACqCTCTATCGCGAT T TATCTAGGCATAGGCT TATGCCT TCTCT T TAT TGTGAGG
ACACTGCTCCTACACCCAGCCAT
(Template Construct 27; SEQ ID NO: 27301)
In an embodiment, to correct a mutation, e.g., Rl 17H target site in the CFTR gene, and concomitantly introduce a silent sense mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the Rl 17H mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AACCCCTCAAATTAAGGGATGAGGCAGAATAATGCTTGGCAATACCAGGGGTAGGCTGCAGTCT TTCTTGGAAATATATATTTTAAATGGAACCAATTATCATAGCATCATTTCCTCTCAGGGTTACC CTCTGATCCCTATTTTACTAAATCGTTATAAAACAAAATGAGGAATTATGTGTCCTTCCCTTTT GAAGCCAATGTAACAAGATGGGTAAGAATTAGACCTCCTGAGTTCAAAATCCCTGGATTCAGAT CTATTCCTGTATATTCAGGAGAAGTGGTAATAAATTCGATGGACAATTTGGTTTAGTAGTCGAT TGAGGACCCTGATGAGGTATATTTGGGAAAACATAACTTCCGCTCTCTCTCATTGACTCACGGG CCTTTGAGGAGTCCAGGAGTCATTGGAATCTGGCCTGAGGTTGAGGCTGCTGGCAAAACTCCTT CCCCAAAGTCCATTCCTATTGCTGACTGAGAAGGGACTAGCATTGGAAGTGGCTGATTTTAAAT ACCGCTAGTGCTGGTGTGCTCCTCCCTCCCATTCCCAGCTCTGCTTTGTGTAGTTGCCTTGAGA AGCTAAGTTCATTCTGAAAATAATGCCATTGCACAAAACACTTTTGAAAGTTCTAGTTTGAAAT TACATCAGGTCACTTGGTCTGTGTGGCCTCAGTTTCTTCATCTGCCATGTGAAAATAATAATGC CTACTCTGTAGCAAAGAAAGTCTCTATAGTAAACAAAAAAAAAGCCTACTCTGATACTGAAAGT TGTTATGAAAAATAAAAAAGGGAAATGCTTTAGAAACTGTTAAGTGCTATGTAGATGTTACTAA TTAACAAACCATTTCAGAAACTATACTTTTTATTTTATGGCCACTATTCACTGTTTAACTTAAA ATACCTCATATGTAAACTTGTCTCCCACTGTTGCTATAACAAATCCCAAGTCTTATTTCAAAGT ACCAAGATATTGAAAATAGTGCTAAGAGTTTCACATATGGTATGACCCTCTATATAAACTCATT TTAAGTCTCCTCTAAAGATGAAAAGTCTTGTGTTGAAATTCTCAGGGTATTTTATGAGAAATAA
ATGAAATTTAATTTCTCTGTTTTTCCCCTTTTGTAGGAAGTCACCAAAGCAGTACAGCCTCTCT
TACTGGGAAGAATCATAGCTTCCTATGACCCGGATAAtAAaGAaGAACgCTCTATCGCGATTTA
TCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAGGACACTGCTCCTACACCCAGCCATTTTT
GGCCTTCATCACATTGGAATGCAGATGAGAATAGCTATGTTTAGTTTGATTTATAAGAAGGTAA
TACTTCCTTGCACAGGCCCCATGGCACATATATTCTGTATCGTACATGTTTTAATGTCATAAAT
TAGGTAGTGAGCTGGTACAAGTAAGGGATAAATGCTGAAATTAATTTAATATGCCTATTAAATA
AATGGCAGGAATAATTAATGCTCTTAATTATCCTTGATAATTTAATTGACTTAAACTGATAATT
ATTGAGTATCTTCTGTAAACTGCCTCTGTTGTAGTTTTTTTTTTCTCCTAATCATGTTATCATT
TTTTTGGAATCCATGGTTTCCTGTTAAGATGACTCACACAGCCTACATAAAAGTAATTGACAAA
ATATCATCTTATAGTAAAATGCCACATATCTTTATGTTCAGCAAGAAGAGTATAATATATGATT
GTTAATGATAACCCAAACAACAAAAGATTTCACCTTAACTGGTTGTCATAAGTAGTAGTATCCA
CCGCCTTATTTTGAGTTGGATTTTTATCATCCTATGAGCCCTACAAATTTAAAGTTTTTGGAAC
AGCACGTGCATTGAACCCATAAGAACCTACTCTGCTTTTCTGCATGTATTGTCCAGACAAGAGA
CCAAATTGCCGAGGCATCATTTAGGTGAATTCTAATTAACATTTAGCTACCTTACAACCACAAT
TCAAGGTTGTTTCAAAGGCATGTGCTTGCATCATCCTGATTCACTACCATGTGTTACTAACTTG
GATCTGCAAAGTCATTATAAAAAGCTGTTTTGATGGACTTATTTGGATATTGCTTTACCCTTCT
TCTCTCTTTTCTTTTATCAATGTAAAAACATTATATGTTAAATACTTGGCTTTTAAGAGCATAG
ATCTGAAATCTGCCTCTAGCAAATAACCCATAACACTTCTAAGATATACCTGCAAGGTCAATTG
TGTTGTAAAACCTTGATAACCATACTTTATTGTTCAAAAAAGCCTTTTATGAAGGCAGAAGTTA
AAAAAAAAAAACAAAAAAAACAGAGTCCACAGTTATCACCTCAGCTACAATCTCATCAGTTCAC
AAGTACCAGCAAAACATGTGATAAGTCAACAAA
(Template Construct 28; SEQ ID NO: 27302)
In an embodiment, to correct a mutation, e.g., Rl 17H target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the 5' homology arm may be shortened less than 750 nucleotides, e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the Rl 17H mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence. ATGCCTACTCTGTAGCAAAGAAAGTCTCTATAGTAAACAAAAAAAAAGCCTACTCTGATACTGA
AAGTTGTTATGAAAAATAAAAAAGGGAAATGCTTTAGAAACTGTTAAGTGCTATGTAGATGTTA
CTAATTAACAAACCATTTCAGAAACTATACTTTTTATTTTATGGCCACTATTCACTGTTTAACT
TAAAATACCTCATATGTAAACTTGTCTCCCACTGTTGCTATAACAAATCCCAAGTCTTATTTCA
AAGTACCAAGATATTGAAAATAGTGCTAAGAGTTTCACATATGGTATGACCCTCTATATAAACT
CATTTTAAGTCTCCTCTAAAGATGAAAAGTCTTGTGTTGAAATTCTCAGGGTATTTTATGAGAA
ATAAATGAAATTTAATTTCTCTGTTTTTCCCCTTTTGTAGGAAGTCACCAAAGCAGTACAGCCT
CTCTTACTGGGAAGAATCATAGCTTCCTATGACCCGGATAA t AAaGAaGAACgC TCTATCGCGA
TTTATCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAGGACACTGCTCCTACACCCAGCCAT
TTTTGGCCTTCATCACATTGGAATGCAGATGAGAATAGCTATGTTTAGTTTGATTTATAAGAAG
GTAATACTTCCTTGCACAGGCCCCATGGCACATATATTCTGTATCGTACATGTTTTAATGTCAT
AAATTAGGTAGTGAGCTGGTACAAGTAAGGGATAAATGCTGAAATTAATTTAATATGCCTATTA
AATAAATGGCAGGAATAATTAATGCTCTTAATTATCCTTGATAATTTAATTGACTTAAACTGAT
AATTATTGAGTATCTTCTGTAAACTGCCTCTGTTGTAGTTTTTTTTTTCTCCTAATCATGTTAT
CATTTTTTTGGAATCCATGGTTTCCTGTTAAGATGACTCACACAGCCTACATAAAAGTAATTGA
CAAAATATCATCTTATAGTAAAATGCCACATATCTTTATGT
(Template Construct 29; SEQ ID NO: 27303)
In an embodiment, an ssODN may be to correct a mutation, e.g., Rl 17H target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted base to correct the Rl 17H mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AAGTCACCAAAGCAGTACAGCCTCTCTTACTGGGAAGAATCATAGCTTCCTATGACCCGGATAA
tAAaGAaGAACgCTCTATCGCGATTTATCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAGG
ACACTGCTCCTACACCCAGCCAT
(Template Construct 30; SEQ ID NO: 27304)
The underlined T has been changed from an A to T at that position and each underlined A has been changed from a T to A at that position so that wild-type CFTR is still transcribed, but the PAM sequence TGG has been modified to reduce or eliminate Cas9 cleavage at that locus. Exemplary template nucleic acids (also referred to herein as donor constructs) to correction a mutation, e.g., W1282X target site in the CFTR gene, are provided.
Suitable sequence for the 5' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
T T T T T AT T AT AT AT T T T T GAAGT AT T GAT AT GT AGT GAAT TAGAAAT T T AAAAAGAAAAC AAAA
CTGTCCTTCACTACAGATTGAAAAGCATTATACTAAAAGACCATTTGCTCAGTTATAGTATATA
AAGGCCAAATGACTTAAAAACAAATTATGTAAGGAGAAGGAAACAACCATTTATTCAGTGCCAC
TAACTGTCAGCCAGTTTTTTCAGTGGTCAGTTAATGACTGCAGTAGTGTTCTACCTTGCTCAAA
GCACCCTCCTCAAGTTCTGGCATCTAAGCTGACATCAGAACACAGAGTTGGGGCTCTCTGTGGG
TCACCTCTAGCACTTGATCTCCTCATGCAGTGCATGGTGCTCTCACGTCTATGCTATGTTCTTA
TGGTCTTTAGGTAACAAGAATAATTTTCTTTCTTTTCCTTACTATACATTTTGCTTTCTGAAAT
TCCCTTCTCGCCAATCCAGGTGAATGTCAGAATGTGATTTGACAACTGTCCAAAGTACTCATTC
ACTGAGGAGTGGTAAGGCCTTCGCCCAACCTGCCTTCTCTGGGAATATACTGCTGCCTGAACAT
ATCATTGTTTATTGCCAGGCTTGAACTTCACCAAATTAATTTATTAGGGTCAACATCTAAATAT
TAGAACTATTTCAGATTAATTTTTAAGTCGTATCCACTTTGGGTACTAGATCAAATTGCAGGTC
TCTGCTTCTGGCTTGAGCCTATGTTTAGAGATGATGTGCATGAAGACACTCTTTGCTTTTCCTT
TATGCAAAATGGGCATTTTCAATCTTTTTGTCATTAGTAAAGGTCAGTGATAAAGGAAGTCTGC
ATCAGGGGTCCAATTCCTTATGGCCAGTTTCTCTATTCTGTTCCAAGGTTGTTTGTCTCCATAT
ATCAACATTGGTCAGGATTGAAAGTGTGCAACAAGGTTTGAATGAATAAGTGAAAATCTTCCAC
TGGTGACAGGATAAAATATTCCAATGGTTTTTATTGAAGTACAATACTGAATTATGTTTATGGC
ATGGTACCTATATGTCACAGAAGTGATCCCATCACTTTTACCTTATAGGTGGGCCTCTTGGGAA
GAAC TGGAT C AGGGAAGAGT AC T T T GT T AT CAGCT T T T T T GAGAC T AC T GAAC AC T GAAGGAGA
AATCCAGATCGATGGTGTGTCTTGGGATTCAATAACTTTGCAACAGTG
SEQ ID NO: 27305 (5Ή arm)
Suitable sequence for the 3' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
AGGAAAGCCTTTGGAGTGATACCACAGGTGAGCAAAAGGACTTAGCCAGAAAAAAGGCAACTAA ATTATATTTTTTACTGCTATTTGATACTTGTACTCAAGAAATTCATATTACTCTGCAAAATATA TTTGTTATGCATTGCTGTCTTTTTTCTCCAGTGCAGTTTTCTCATAGGCAGAAAAGATGTCTCT AAAAGTTTGGAATTCTCAAATTCTGGTTATTGAAATGTTCATAGCTTTGATAGTGTTTTTCAGA AGACCAAATTTACAGTGGGAGCCTTGGGCTTTTGTTTTTTAACAGCTCTTTTTTGTTCCTGCTT CAGTGGCCTGACCTCCAAGTTAGCAATCGCCAGGTTGAGAAATGCTTTGCGAGACATAACAGAT GCTCCTGAAATAACAAACACTTGGAATCATGAGGTAGTGGAATTGAAAATAGAAAGTGTAGTGA
TTGTTTTTTGTTATTTGGATGGGATGAACAATGTCAGATTAGTCTGTAACTATTTTTTTTTAAT
GTCACTCTGATTTGGTCACAAAGGATCTCTAGTCTCATTGCCTTAGTATCATTCTACGAATTAG
AATGTGTTACTGTGTAAGAGCACTTCTTGTATATGAGAGAAATAGCAACAGTTCCAGTTTAAAG
TGATATAAATGGAAACCAAGAAATGTCTTTACTGGGACCAAATCTGGACAGCATTTACTGTATT
TTTGCTGGTATTTTCTCTAGTCTTTCCGGGTATATTCACATTTAATGATCACTTTTCTCCCTTT
GTGCTAATGGACACTGAATCCATTCCACTACCATAGTTCTTGCTAATACTACTCTACTTTTTAC
ACAAAATTAAAATGCCAGGAGCACCTCCAGGTAGACTGACTATAAATCTAGACTGAAAAAAAAG
CTTGTATTTCTTAACAGATTACCTTGTGGAACATTTGCTCCTTTCAACTAATGAGGCACTAAAT
ATTGTAACTGCTCAACTGGTGCTTTTAATTTATTTGTCTAGACTTTGTCATGTTGCCAGAAGCT
TTATCCTGGTTGGAGTTTTGAAAACAGTATTGTTTCTTCAGAAAGAAAAAAGGGATTGTCAGAT
GATCTAAAAATAAAGAAACACTGGAAATACAAGTATCCCAAGGTGATAGCATTAGGCAAGATAA
AAAT G T T GAAAAG C G AAAAAG AAC TGGTTGATAGAGAAGTGTTGTTAT
SEQ ID NO: 27306 (3Ή arm)
In an embodiment, the replacement sequence comprises or consists of a Guanine (G) residue.
In an embodiment, to correct a mutation, e.g., W1282X target site in the CFTR gene, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the W1282X mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TTTTTATTATATATTTTTGAAGTATTGATATGTAGTGAATTAGAAATTTAAAAAGAAAACAAAA CTGTCCTTCACTACAGATTGAAAAGCATTATACTAAAAGACCATTTGCTCAGTTATAGTATATA AAGGCCAAATGACTTAAAAACAAATTATGTAAGGAGAAGGAAACAACCATTTATTCAGTGCCAC TAACTGTCAGCCAGTTTTTTCAGTGGTCAGTTAATGACTGCAGTAGTGTTCTACCTTGCTCAAA GCACCCTCCTCAAGTTCTGGCATCTAAGCTGACATCAGAACACAGAGTTGGGGCTCTCTGTGGG TCACCTCTAGCACTTGATCTCCTCATGCAGTGCATGGTGCTCTCACGTCTATGCTATGTTCTTA TGGTCTTTAGGTAACAAGAATAATTTTCTTTCTTTTCCTTACTATACATTTTGCTTTCTGAAAT TCCCTTCTCGCCAATCCAGGTGAATGTCAGAATGTGATTTGACAACTGTCCAAAGTACTCATTC ACTGAGGAGTGGTAAGGCCTTCGCCCAACCTGCCTTCTCTGGGAATATACTGCTGCCTGAACAT ATCATTGTTTATTGCCAGGCTTGAACTTCACCAAATTAATTTATTAGGGTCAACATCTAAATAT
TAGAACTATTTCAGATTAATTTTTAAGTCGTATCCACTTTGGGTACTAGATCAAATTGCAGGTC
TCTGCTTCTGGCTTGAGCCTATGTTTAGAGATGATGTGCATGAAGACACTCTTTGCTTTTCCTT
TATGCAAAATGGGCATTTTCAATCTTTTTGTCATTAGTAAAGGTCAGTGATAAAGGAAGTCTGC
ATCAGGGGTCCAATTCCTTATGGCCAGTTTCTCTATTCTGTTCCAAGGTTGTTTGTCTCCATAT
ATCAACATTGGTCAGGATTGAAAGTGTGCAACAAGGTTTGAATGAATAAGTGAAAATCTTCCAC
TGGTGACAGGATAAAATATTCCAATGGTTTTTATTGAAGTACAATACTGAATTATGTTTATGGC
ATGGTACCTATATGTCACAGAAGTGATCCCATCACTTTTACCTTATAGGTGGGCCTCTTGGGAA
GAACTGGATCAGGGAAGAGTACTTTGTTATCAGCTTTTTTGAGACTACTGAACACTGAAGGAGA
AATCCAGATCGATGGTGTGTCTTGGGATTCAATAACTTTGCAACAGTGgAGGAAAGCC T T T GGA
GTGATACCACAGGTGAGCAAAAGGACTTAGCCAGAAAAAAGGCAACTAAATTATATTTTTTACT
GCTATTTGATACTTGTACTCAAGAAATTCATATTACTCTGCAAAATATATTTGTTATGCATTGC
TGTCTTTTTTCTCCAGTGCAGTTTTCTCATAGGCAGAAAAGATGTCTCTAAAAGTTTGGAATTC
TCAAATTCTGGTTATTGAAATGTTCATAGCTTTGATAGTGTTTTTCAGAAGACCAAATTTACAG
TGGGAGCCTTGGGCTTTTGTTTTTTAACAGCTCTTTTTTGTTCCTGCTTCAGTGGCCTGACCTC
CAAGTTAGCAATCGCCAGGTTGAGAAATGCTTTGCGAGACATAACAGATGCTCCTGAAATAACA
AACACTTGGAATCATGAGGTAGTGGAATTGAAAATAGAAAGTGTAGTGATTGTTTTTTGTTATT
TGGATGGGATGAACAATGTCAGATTAGTCTGTAACTATTTTTTTTTAATGTCACTCTGATTTGG
TCACAAAGGATCTCTAGTCTCATTGCCTTAGTATCATTCTACGAATTAGAATGTGTTACTGTGT
AAGAGCACTTCTTGTATATGAGAGAAATAGCAACAGTTCCAGTTTAAAGTGATATAAATGGAAA
CCAAGAAATGTCTTTACTGGGACCAAATCTGGACAGCATTTACTGTATTTTTGCTGGTATTTTC
TCTAGTCTTTCCGGGTATATTCACATTTAATGATCACTTTTCTCCCTTTGTGCTAATGGACACT
GAATCCATTCCACTACCATAGTTCTTGCTAATACTACTCTACTTTTTACACAAAATTAAAATGC
CAGGAGCACCTCCAGGTAGACTGACTATAAATCTAGACTGAAAAAAAAGCTTGTATTTCTTAAC
AGATTACCTTGTGGAACATTTGCTCCTTTCAACTAATGAGGCACTAAATATTGTAACTGCTCAA
CTGGTGCTTTTAATTTATTTGTCTAGACTTTGTCATGTTGCCAGAAGCTTTATCCTGGTTGGAG
T T T T GAAAAC AGT AT TGTTTCTT C AGAAAGAAAAAAGGGAT T GT C AGAT GAT C T AAAAAT AAAG
AAACACTGGAAATACAAGTATCCCAAGGTGATAGCATTAGGCAAGATAAAAATGTTGAAAAGCG
AAAAAG AAC TGGTTGATAGAGAAGTGTTGTTAT
(Template Construct 31; SEQ ID NO: 27307)
As described below in Table 49, shorter homology arms, e.g., 5' and/or 3' homology arms may be used. It is contemplated herein that one or both homology arms may be shortened to avoid including certain sequence repeat elements, e.g., Alu repeats, LINE elements. For example, a 5' homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3' homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5' and the 3' homology arms may be shortened to avoid including certain sequence repeat elements.
In an embodiment, to correct W1282X mutation in the CFTR gene, the 5' homology arm may be shortened less than 1000 nucleotides, e.g., e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the W1282X mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
GGTCTCTGCTTCTGGCTTGAGCCTATGTTTAGAGATGATGTGCATGAAGACACTCTTTGCTTTT
CCTTTATGCAAAATGGGCATTTTCAATCTTTTTGTCATTAGTAAAGGTCAGTGATAAAGGAAGT
CTGCATCAGGGGTCCAATTCCTTATGGCCAGTTTCTCTATTCTGTTCCAAGGTTGTTTGTCTCC
ATATATCAACATTGGTCAGGATTGAAAGTGTGCAACAAGGTTTGAATGAATAAGTGAAAATCTT
CCACTGGTGACAGGATAAAATATTCCAATGGTTTTTATTGAAGTACAATACTGAATTATGTTTA
TGGCATGGTACCTATATGTCACAGAAGTGATCCCATCACTTTTACCTTATAGGTGGGCCTCTTG
GGAAGAACTGGATCAGGGAAGAGTACTTTGTTATCAGCTTTTTTGAGACTACTGAACACTGAAG
GAGAAATCCAGATCGATGGTGTGTCTTGGGATTCAATAACTTTGCAACAGTGgAGGAAAGCCTT
TGGAGTGATACCACAGGTGAGCAAAAGGACTTAGCCAGAAAAAAGGCAACTAAATTATATTTTT
TACTGCTATTTGATACTTGTACTCAAGAAATTCATATTACTCTGCAAAATATATTTGTTATGCA
TTGCTGTCTTTTTTCTCCAGTGCAGTTTTCTCATAGGCAGAAAAGATGTCTCTAAAAGTTTGGA
ATTCTCAAATTCTGGTTATTGAAATGTTCATAGCTTTGATAGTGTTTTTCAGAAGACCAAATTT
ACAGTGGGAGCCTTGGGCTTTTGTTTTTTAACAGCTCTTTTTTGTTCCTGCTTCAGTGGCCTGA
CCTCCAAGTTAGCAATCGCCAGGTTGAGAAATGCTTTGCGAGACATAACAGATGCTCCTGAAAT
AACAAACACTTGGAATCATGAGGTAGTGGAATTGAAAATAGAAAGTGTAGTGATTGTTTTTTGT
TATTTGGATGGGATGAACAATGTCAGATTAGTCTGTAACTA
(Template Construct 32; SEQ ID NO: 27308)
It is contemplated herein that template nucleic acids for correcting a mutation may designed for use as a single- stranded oligonucleotide (ssODN). When using a ssODN, 5' and 3' homology arms may range up to about 200 base pairs (bp) in length, e.g., at least 25, 50, 75, 100, 125, 150, 175, or 200 bp in length. Longer homology arms are also contemplated for ssODNs as improvements in oligonucleotide synthesis continue to be made.
In an embodiment, an ssODN may be used to correct a mutation, e.g., W1282X target site in the CFTR gene. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted bases to correct the W1282X mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TTTGAGACTACTGAACACTGAAGGAGAAATCCAGATCGATGGTGTGTCTTGGGATTCAATAACT
TTGCAACAGTGgAGGAAAGCCT T TGGAGTGATACCACAGGTGAGCAAAAGGACT TAGCCAGAAA
AAAGGC AAC T AAAT T AT AT T T T
(Template Construct 33; SEQ ID NO: 27309)
In an embodiment, to correct a mutation, e.g., W1282X target site in the CFTR gene, and concomitantly introduce a silent sense mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the W1282X mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TTTTTATTATATATTTTTGAAGTATTGATATGTAGTGAATTAGAAATTTAAAAAGAAAACAAAA CTGTCCTTCACTACAGATTGAAAAGCATTATACTAAAAGACCATTTGCTCAGTTATAGTATATA AAGGCCAAATGACTTAAAAACAAATTATGTAAGGAGAAGGAAACAACCATTTATTCAGTGCCAC TAACTGTCAGCCAGTTTTTTCAGTGGTCAGTTAATGACTGCAGTAGTGTTCTACCTTGCTCAAA GCACCCTCCTCAAGTTCTGGCATCTAAGCTGACATCAGAACACAGAGTTGGGGCTCTCTGTGGG TCACCTCTAGCACTTGATCTCCTCATGCAGTGCATGGTGCTCTCACGTCTATGCTATGTTCTTA TGGTCTTTAGGTAACAAGAATAATTTTCTTTCTTTTCCTTACTATACATTTTGCTTTCTGAAAT TCCCTTCTCGCCAATCCAGGTGAATGTCAGAATGTGATTTGACAACTGTCCAAAGTACTCATTC ACTGAGGAGTGGTAAGGCCTTCGCCCAACCTGCCTTCTCTGGGAATATACTGCTGCCTGAACAT ATCATTGTTTATTGCCAGGCTTGAACTTCACCAAATTAATTTATTAGGGTCAACATCTAAATAT TAGAACTATTTCAGATTAATTTTTAAGTCGTATCCACTTTGGGTACTAGATCAAATTGCAGGTC TCTGCTTCTGGCTTGAGCCTATGTTTAGAGATGATGTGCATGAAGACACTCTTTGCTTTTCCTT TATGCAAAATGGGCATTTTCAATCTTTTTGTCATTAGTAAAGGTCAGTGATAAAGGAAGTCTGC
ATCAGGGGTCCAATTCCTTATGGCCAGTTTCTCTATTCTGTTCCAAGGTTGTTTGTCTCCATAT
ATCAACATTGGTCAGGATTGAAAGTGTGCAACAAGGTTTGAATGAATAAGTGAAAATCTTCCAC
TGGTGACAGGATAAAATATTCCAATGGTTTTTATTGAAGTACAATACTGAATTATGTTTATGGC
ATGGTACCTATATGTCACAGAAGTGATCCCATCACTTTTACCTTATAGGTGGGCCTCTTGGGAA
GAACTGGATCAGGGAAGAGTACTTTGTTATCAGCTTTTTTGAGACTACTGAACACTGAAGGAGA
AATCCAGATCGATGGTGTGTCTTGGGATTCAATAACTTTGCAACAGTGgAG a AAAGCC T T T GGA
GTGATACCACAGGTGAGCAAAAGGACTTAGCCAGAAAAAAGGCAACTAAATTATATTTTTTACT
GCTATTTGATACTTGTACTCAAGAAATTCATATTACTCTGCAAAATATATTTGTTATGCATTGC
TGTCTTTTTTCTCCAGTGCAGTTTTCTCATAGGCAGAAAAGATGTCTCTAAAAGTTTGGAATTC
TCAAATTCTGGTTATTGAAATGTTCATAGCTTTGATAGTGTTTTTCAGAAGACCAAATTTACAG
TGGGAGCCTTGGGCTTTTGTTTTTTAACAGCTCTTTTTTGTTCCTGCTTCAGTGGCCTGACCTC
CAAGTTAGCAATCGCCAGGTTGAGAAATGCTTTGCGAGACATAACAGATGCTCCTGAAATAACA
AACACTTGGAATCATGAGGTAGTGGAATTGAAAATAGAAAGTGTAGTGATTGTTTTTTGTTATT
TGGATGGGATGAACAATGTCAGATTAGTCTGTAACTATTTTTTTTTAATGTCACTCTGATTTGG
TCACAAAGGATCTCTAGTCTCATTGCCTTAGTATCATTCTACGAATTAGAATGTGTTACTGTGT
AAGAGCACTTCTTGTATATGAGAGAAATAGCAACAGTTCCAGTTTAAAGTGATATAAATGGAAA
CCAAGAAATGTCTTTACTGGGACCAAATCTGGACAGCATTTACTGTATTTTTGCTGGTATTTTC
TCTAGTCTTTCCGGGTATATTCACATTTAATGATCACTTTTCTCCCTTTGTGCTAATGGACACT
GAATCCATTCCACTACCATAGTTCTTGCTAATACTACTCTACTTTTTACACAAAATTAAAATGC
CAGGAGCACCTCCAGGTAGACTGACTATAAATCTAGACTGAAAAAAAAGCTTGTATTTCTTAAC
AGATTACCTTGTGGAACATTTGCTCCTTTCAACTAATGAGGCACTAAATATTGTAACTGCTCAA
CTGGTGCTTTTAATTTATTTGTCTAGACTTTGTCATGTTGCCAGAAGCTTTATCCTGGTTGGAG
T T T T GAAAAC AGT AT TGTTTCTT C AGAAAGAAAAAAGGGAT T GT C AGAT GAT C T AAAAAT AAAG
AAACACTGGAAATACAAGTATCCCAAGGTGATAGCATTAGGCAAGATAAAAATGTTGAAAAGCG
AAAAAG AAC TGGTTGATAGAGAAGTGTTGTTAT
(Template Construct 34; SEQ ID NO: 27310)
In an embodiment, to correct a mutation, e.g., W1282X target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the 5' homology arm may be shortened less than 750 nucleotides, e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the W1282X mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
GGTCTCTGCTTCTGGCTTGAGCCTATGTTTAGAGATGATGTGCATGAAGACACTCTTTGCTTTT CCTTTATGCAAAATGGGCATTTTCAATCTTTTTGTCATTAGTAAAGGTCAGTGATAAAGGAAGT CTGCATCAGGGGTCCAATTCCTTATGGCCAGTTTCTCTATTCTGTTCCAAGGTTGTTTGTCTCC ATATATCAACATTGGTCAGGATTGAAAGTGTGCAACAAGGTTTGAATGAATAAGTGAAAATCTT CCACTGGTGACAGGATAAAATATTCCAATGGTTTTTATTGAAGTACAATACTGAATTATGTTTA TGGCATGGTACCTATATGTCACAGAAGTGATCCCATCACTTTTACCTTATAGGTGGGCCTCTTG GGAAGAACTGGATCAGGGAAGAGTACTTTGTTATCAGCTTTTTTGAGACTACTGAACACTGAAG GAGAAATCCAGATCGATGGTGTGTCTTGGGATTCAATAACTTTGCAACAGTGgAGaAAAGCCTT TGGAGTGATACCACAGGTGAGCAAAAGGACTTAGCCAGAAAAAAGGCAACTAAATTATATTTTT TACTGCTATTTGATACTTGTACTCAAGAAATTCATATTACTCTGCAAAATATATTTGTTATGCA TTGCTGTCTTTTTTCTCCAGTGCAGTTTTCTCATAGGCAGAAAAGATGTCTCTAAAAGTTTGGA ATTCTCAAATTCTGGTTATTGAAATGTTCATAGCTTTGATAGTGTTTTTCAGAAGACCAAATTT ACAGTGGGAGCCTTGGGCTTTTGTTTTTTAACAGCTCTTTTTTGTTCCTGCTTCAGTGGCCTGA CCTCCAAGTTAGCAATCGCCAGGTTGAGAAATGCTTTGCGAGACATAACAGATGCTCCTGAAAT AACAAACACTTGGAATCATGAGGTAGTGGAATTGAAAATAGAAAGTGTAGTGATTGTTTTTTGT TATTTGGATGGGATGAACAATGTCAGATTAGTCTGTAACTA
In an embodiment, an ssODN may be to correct a mutation, e.g., W1282X target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted base to correct the W1282X mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TTTGAGACTACTGAACACTGAAGGAGAAATCCAGATCGATGGTGTGTCTTGGGATTCAATAACT
TTGCAACAGTGgAGaAAAGCCTTTGGAGTGATACCACAGGTGAGCAAAAGGACTTAGCCAGAAA
AAAGGC AAC T AAAT T AT AT T T T
(Template Construct 35; SEQ ID NO: 27311) The underlined A has been changed from a T to A at that position so that wild-type CFTR is still transcribed, but the PAM sequence AGG has been modified to reduce or eliminate Cas9 cleavage at that locus.
Exemplary template nucleic acids (also referred to herein as donor constructs) to correction a mutation, e.g., R553X target site in the CFTR gene, are provided.
Suitable sequence for the 5' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
AACAGAAGTAACCATTTTGATACTTTAGATATAGATAATATTGGATTATTTCTGGATTGTGAAA
GAAGAAGGAAGAAGCATATGGAAGAGAAGTTTTAGTAGAGGGGAGGAAGGAGGAGGTGGAAACG
AAT GT AC AAGGAT GGGAGGAGAAAAGGGAGAGAGAC TTTTTTTTTTT T AAGGCGAGAGT T T AC T
ACCTATCTAACTCTTCGCATTCTTGAAGTCTCAGACCAAATCCCATCGGTTTGAAAGCCTCTAG
GGTATTCTATCTATTGTATACTTCTGTTATGTACAAAATTAATTTGCCAATTAATTGTGAACTG
TTTTATAAACTATCTTAAAATGGTTAGTTAAATCTTTGGGATAGTATTTAGCTTTCTCCAGGAT
TATGACTTACCTTCTAAATTAGACATACAATGCCTAGGAGTCAAGGACTATTTTGCATAAATTC
CAGTCTTCTTTTACAATGCCTAGAATGATTGTTACCACAGAAATATTCATTACCTGGGAGAAAG
GATGACAGGAGGGGCAGAATGAATGGAGAGAGGTCGTGAGAATGAGGTGCTGAGGATGGACGAG
GAAGAAAGCTGTTTTAGTTGGGAGGATAGGTGACAGAAGCATGGAAAGGAATTGCCTTGGACCC
ATGGAAGCCCAGTGAAGATACTTAGATCCTGCAGGGGTGTGAATAATGTTCTTTTAGTTTCTCT
TCTTAGGAGGTTTGTTCATTTTGGGAGATTTCTTTTGAAAAGAGTGAACTTAAATTGGAGAAAA
GTACATTTTAGTATGTTGATAACATTTGAATTTGTAAAATGGACCTATGGATGATCTACACATA
TTTATATACCCATAAATATACACATATTTTAATTTTTGGTATTTTATAATTATTATTTAATGAT
CATTCATGACATTTTAAAAATTACAGAAAAATTTACATCTAAAATTTCAGCAATGTTGTTTTTG
ACCAACTAAATAAATTGCATTTGAAATAATGGAGATGCAATGTTCAAAATTTCAACTGTGGTTA
AAGCAATAGTGTGATATATGATTACATTAGAAGGAAGATGTGCCTTTCAAATTCAGATTGAGCA
TACTAAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTTGCAGAGAAA
GAC AAT AT AGT T C T T GGAGAAGGT GGAAT C AC AC T GAGT GGAGGT C AA
SEQ ID NO: 27312 (5Ή arm)
Suitable sequence for the 3' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
GAGCAAGAATTTCTTTAGCAAGGTGAATAACTAATTATTGGTCTAGCAAGCATTTGCTGTAAAT GTCATTCATGTAAAAAAATTACAGACATTTCTCTATTGCTTTATATTCTGTTTCTGGAATTGAA AAAATCCTGGGGTTTTATGGCTAGTGGGTTAAGAATCACATTTAAGAACTATAAATAATGGTAT
AGTATCCAGATTTGGTAGAGATTATGGTTACTCAGAATCTGTGCCCGTATCTTGGTGTCAGTGT
ATTTGTTTGCCTCATAGTATAGTTTACTACAAATGGAAAACTCTAGGATTCTGCATAATACTGG
ACAGAGAAGATGTAAATATCTGTTAGTTCCATCATAGACCCTGCCACTCCAATGTACACACCAG
CTTTAGGCTTCTTGGTATAGATAAACATACATTTTCAAAATTTTTCATCATAATTTTCATAACA
AAATAGGAAGGCAAATGATGTCACTTGGCTTAAAATCTATAATATTTAAAATAAACAGGACAAA
TGCATTAACATTGTTGGGGGAGGAGGTCCCTTAGTAGAAACACTCTTGGTCCAAGCATTTTAAA
GCTGTCAAAGAGATGTAAATATAGATAATGTATGTCAAGGAGAGAGCTTTGTGGTTAAACTGTA
ACTTTCAGTTTAAACAATTATTGGTGACTCTGATGTCAAATGTTTCTCAAGCTTTATCTGAACA
AAATTCTTCTCACTTTGTTGCCAAAGTCGTTAACAAGAAATCACATTGACTCATTGATGTTTTG
GCTCCTTTCCCTTACTTTCTGTTGCTTTCCAAAAGCTGAGACAGGAAACTAACCCTAACTGAGC
ACCTGCAATTGCCTGGTAGTATTCTAGTCATGTGTGTACTTTTGTGTGTATGTAATCCCCTTAC
AGCTCTGCAAAGTAAGAATTGTTCTCCCTGCTTTACAGAAGAGATCATAAGATAATTGAGGCTG
TTAGATGTTAACTTGCCAAAAGCCATACAGGAAAATGGTAGAGTCACAGTTTGAACCAGGTCCT
TTTGATTCTTTACATTAAACCATGCTTTGATCTTGGAAATACACTGTAAGGCAATAAATCAATA
GATACGGATAATTCACAGGCTTCTAAATAAATGGAAGTTGATTGTTTTTATCTGTGAGCCAAAG
TAAGAC T T AT T CTAAGAAT T CC AC AAAT T T AGAT AAGAT AGAGT AT AT
SEQ ID NO: 27313 (3 Ή arm)
In an embodiment, the replacement sequence comprises or consists of a Cytosine (C) residue.
In an embodiment, to correct a mutation, e.g., R553X target site in the CFTR gene, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the R553X mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AACAGAAGTAACCATTTTGATACTTTAGATATAGATAATATTGGATTATTTCTGGATTGTGAAA GAAGAAGGAAGAAGCATATGGAAGAGAAGTTTTAGTAGAGGGGAGGAAGGAGGAGGTGGAAACG AATGTACAAGGATGGGAGGAGAAAAGGGAGAGAGACTTTTTTTTTTTTAAGGCGAGAGTTTACT ACCTATCTAACTCTTCGCATTCTTGAAGTCTCAGACCAAATCCCATCGGTTTGAAAGCCTCTAG GGTATTCTATCTATTGTATACTTCTGTTATGTACAAAATTAATTTGCCAATTAATTGTGAACTG TTTTATAAACTATCTTAAAATGGTTAGTTAAATCTTTGGGATAGTATTTAGCTTTCTCCAGGAT TATGACTTACCTTCTAAATTAGACATACAATGCCTAGGAGTCAAGGACTATTTTGCATAAATTC CAGTCTTCTTTTACAATGCCTAGAATGATTGTTACCACAGAAATATTCATTACCTGGGAGAAAG GATGACAGGAGGGGCAGAATGAATGGAGAGAGGTCGTGAGAATGAGGTGCTGAGGATGGACGAG GAAGAAAGCTGTTTTAGTTGGGAGGATAGGTGACAGAAGCATGGAAAGGAATTGCCTTGGACCC ATGGAAGCCCAGTGAAGATACTTAGATCCTGCAGGGGTGTGAATAATGTTCTTTTAGTTTCTCT TCTTAGGAGGTTTGTTCATTTTGGGAGATTTCTTTTGAAAAGAGTGAACTTAAATTGGAGAAAA GTACATTTTAGTATGTTGATAACATTTGAATTTGTAAAATGGACCTATGGATGATCTACACATA TTTATATACCCATAAATATACACATATTTTAATTTTTGGTATTTTATAATTATTATTTAATGAT CATTCATGACATTTTAAAAATTACAGAAAAATTTACATCTAAAATTTCAGCAATGTTGTTTTTG ACCAACTAAATAAATTGCATTTGAAATAATGGAGATGCAATGTTCAAAATTTCAACTGTGGTTA AAGCAATAGTGTGATATATGATTACATTAGAAGGAAGATGTGCCTTTCAAATTCAGATTGAGCA TACTAAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTTGCAGAGAAA GACAATATAGTTCTTGGAGAAGGTGGAATCACACTGAGTGGAGGTCAAc GAGCAAGAAT T T C T T TAGCAAGGTGAATAACTAATTATTGGTCTAGCAAGCATTTGCTGTAAATGTCATTCATGTAAAA AAATTACAGACATTTCTCTATTGCTTTATATTCTGTTTCTGGAATTGAAAAAATCCTGGGGTTT TATGGCTAGTGGGTTAAGAATCACATTTAAGAACTATAAATAATGGTATAGTATCCAGATTTGG TAGAGATTATGGTTACTCAGAATCTGTGCCCGTATCTTGGTGTCAGTGTATTTGTTTGCCTCAT AGTATAGTTTACTACAAATGGAAAACTCTAGGATTCTGCATAATACTGGACAGAGAAGATGTAA ATATCTGTTAGTTCCATCATAGACCCTGCCACTCCAATGTACACACCAGCTTTAGGCTTCTTGG T AT AGAT AAAC AT AC AT T T T CAAAAT T T T T CAT C AT AAT T T T C AT AAC AAAAT AGGAAGGC AAA TGATGTCACTTGGCTTAAAATCTATAATATTTAAAATAAACAGGACAAATGCATTAACATTGTT GGGGGAGGAGGTCCCTTAGTAGAAACACTCTTGGTCCAAGCATTTTAAAGCTGTCAAAGAGATG TAAAT AT AGAT AATGTATGTCAAGGAGAGAGCTTTGTGGTTAAACTGTAACTTTCAGTTT AAAC AATTATTGGTGACTCTGATGTCAAATGTTTCTCAAGCTTTATCTGAACAAAATTCTTCTCACTT TGTTGCCAAAGTCGTTAACAAGAAATCACATTGACTCATTGATGTTTTGGCTCCTTTCCCTTAC TTTCTGTTGCTTTCCAAAAGCTGAGACAGGAAACTAACCCTAACTGAGCACCTGCAATTGCCTG GTAGTATTCTAGTCATGTGTGTACTTTTGTGTGTATGTAATCCCCTTACAGCTCTGCAAAGTAA GAATTGTTCTCCCTGCTTTACAGAAGAGATCATAAGATAATTGAGGCTGTTAGATGTTAACTTG CCAAAAGCCATACAGGAAAATGGTAGAGTCACAGTTTGAACCAGGTCCTTTTGATTCTTTACAT TAAACCATGCTTTGATCTTGGAAATACACTGTAAGGCAATAAATCAAT AGAT ACGGAT AAT TCA CAGGCTTCTAAATAAATGGAAGTTGATTGTTTTTATCTGTGAGCCAAAGTAAGACTTATTCTAA GAAT T CC AC AAAT T T AGAT AAGAT AGAGT AT AT
(Template Construct 36; SEQ ID NO: 27314)
As described below in Table 49, shorter homology arms, e.g., 5' and/or 3' homology arms may be used.
It is contemplated herein that one or both homology arms may be shortened to avoid including certain sequence repeat elements, e.g., Alu repeats, LINE elements. For example, a 5' homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3' homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5' and the 3' homology arms may be shortened to avoid including certain sequence repeat elements.
In an embodiment, to correct R553X mutation in the CFTR gene, the 5' homology arm may be shortened less than 1000 nucleotides, e.g., e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the R553X mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
CTCTTCTTAGGAGGTTTGTTCATTTTGGGAGATTTCTTTTGAAAAGAGTGAACTTAAATTGGAG AAAAGTACATTTTAGTATGTTGATAACATTTGAATTTGTAAAATGGACCTATGGATGATCTACA CATATTTATATACCCATAAATATACACATATTTTAATTTTTGGTATTTTATAATTATTATTTAA TGATCATTCATGACATTTTAAAAATTACAGAAAAATTTACATCTAAAATTTCAGCAATGTTGTT TTTGACCAACTAAATAAATTGCATTTGAAATAATGGAGATGCAATGTTCAAAATTTCAACTGTG GTTAAAGCAATAGTGTGATATATGATTACATTAGAAGGAAGATGTGCCTTTCAAATTCAGATTG AGCATACTAAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTTGCAGA GAAAGACAATATAGTTCTTGGAGAAGGTGGAATCACACTGAGTGGAGGTCAAcGAGCAAGAATT TCTTTAGCAAGGTGAATAACTAATTATTGGTCTAGCAAGCATTTGCTGTAAATGTCATTCATGT AAAAAAATTACAGACATTTCTCTATTGCTTTATATTCTGTTTCTGGAATTGAAAAAATCCTGGG GTTTTATGGCTAGTGGGTTAAGAATCACATTTAAGAACTATAAATAATGGTATAGTATCCAGAT TTGGTAGAGATTATGGTTACTCAGAATCTGTGCCCGTATCTTGGTGTCAGTGTATTTGTTTGCC TCATAGTATAGTTTACTACAAATGGAAAACTCTAGGATTCTGCATAATACTGGACAGAGAAGAT GTAAATATCTGTTAGTTCCATCATAGACCCTGCCACTCCAATGTACACACCAGCTTTAGGCTTC T TGGTATAGATAAACATACAT T T TCAAAAT T T T TCATCATAAT T T TCATAACAAAATAGGAAGG
CAAATGATGTCACT TGGCT TAAAATCTATAATAT T TAAAAT
(Template Construct 37; SEQ ID NO: 27315)
It is contemplated herein that template nucleic acids for correcting a mutation may designed for use as a single- stranded oligonucleotide (ssODN). When using a ssODN, 5' and 3' homology arms may range up to about 200 base pairs (bp) in length, e.g., at least 25, 50, 75, 100, 125, 150, 175, or 200 bp in length. Longer homology arms are also contemplated for ssODNs as improvements in oligonucleotide synthesis continue to be made.
In an embodiment, an ssODN may be used to correct a mutation, e.g., R553X target site in the CFTR gene. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted bases to correct the R553X mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTTGGAGAAGGTGGAATCACACTGA
GTGGAGGTCAAcGAGCAAGAAT T TCT T TAGCAAGGTGAATAACTAAT TAT TGGTCTAGCAAGCA
T T TGCTGTAAATGTCAT TCATGT
(Template Construct 38; SEQ ID NO: 27316)
In an embodiment, to correct a mutation, e.g., R553X target site in the CFTR gene, and concomitantly introduce a silent sense mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the R553X mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AACAGAAGTAACCATTTTGATACTTTAGATATAGATAATATTGGATTATTTCTGGATTGTGAAA GAAGAAGGAAGAAGCATATGGAAGAGAAGTTTTAGTAGAGGGGAGGAAGGAGGAGGTGGAAACG AATGTACAAGGATGGGAGGAGAAAAGGGAGAGAGACTTTTTTTTTTTTAAGGCGAGAGTTTACT ACCTATCTAACTCTTCGCATTCTTGAAGTCTCAGACCAAATCCCATCGGTTTGAAAGCCTCTAG GGTATTCTATCTATTGTATACTTCTGTTATGTACAAAATTAATTTGCCAATTAATTGTGAACTG TTTTATAAACTATCTTAAAATGGTTAGTTAAATCTTTGGGATAGTATTTAGCTTTCTCCAGGAT TATGACTTACCTTCTAAATTAGACATACAATGCCTAGGAGTCAAGGACTATTTTGCATAAATTC CAGTCTTCTTTTACAATGCCTAGAATGATTGTTACCACAGAAATATTCATTACCTGGGAGAAAG GATGACAGGAGGGGCAGAATGAATGGAGAGAGGTCGTGAGAATGAGGTGCTGAGGATGGACGAG GAAGAAAGCTGTTTTAGTTGGGAGGATAGGTGACAGAAGCATGGAAAGGAATTGCCTTGGACCC ATGGAAGCCCAGTGAAGATACTTAGATCCTGCAGGGGTGTGAATAATGTTCTTTTAGTTTCTCT TCTTAGGAGGTTTGTTCATTTTGGGAGATTTCTTTTGAAAAGAGTGAACTTAAATTGGAGAAAA GTACATTTTAGTATGTTGATAACATTTGAATTTGTAAAATGGACCTATGGATGATCTACACATA TTTATATACCCATAAATATACACATATTTTAATTTTTGGTATTTTATAATTATTATTTAATGAT CATTCATGACATTTTAAAAATTACAGAAAAATTTACATCTAAAATTTCAGCAATGTTGTTTTTG ACCAACTAAATAAATTGCATTTGAAATAATGGAGATGCAATGTTCAAAATTTCAACTGTGGTTA AAGCAATAGTGTGATATATGATTACATTAGAAGGAAGATGTGCCTTTCAAATTCAGATTGAGCA TACTAAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTTGCAGAGAAA GACAATATAGTTCTTGGAGAAGGTGGAATCACACTGt caGGAGGTCAAc GAGCAAGAAT T T C T T TAGCAAGGTGAATAACTAATTATTGGTCTAGCAAGCATTTGCTGTAAATGTCATTCATGTAAAA AAATTACAGACATTTCTCTATTGCTTTATATTCTGTTTCTGGAATTGAAAAAATCCTGGGGTTT TATGGCTAGTGGGTTAAGAATCACATTTAAGAACTATAAATAATGGTATAGTATCCAGATTTGG TAGAGATTATGGTTACTCAGAATCTGTGCCCGTATCTTGGTGTCAGTGTATTTGTTTGCCTCAT AGTATAGTTTACTACAAATGGAAAACTCTAGGATTCTGCATAATACTGGACAGAGAAGATGTAA ATATCTGTTAGTTCCATCATAGACCCTGCCACTCCAATGTACACACCAGCTTTAGGCTTCTTGG T AT AGAT AAAC AT AC AT T T T CAAAAT T T T T CAT C AT AAT T T T C AT AAC AAAAT AGGAAGGC AAA TGATGTCACTTGGCTTAAAATCTATAATATTTAAAATAAACAGGACAAATGCATTAACATTGTT GGGGGAGGAGGTCCCTTAGTAGAAACACTCTTGGTCCAAGCATTTTAAAGCTGTCAAAGAGATG TAAAT AT AGAT AATGTATGTCAAGGAGAGAGCTTTGTGGTTAAACTGTAACTTTCAGTTT AAAC AATTATTGGTGACTCTGATGTCAAATGTTTCTCAAGCTTTATCTGAACAAAATTCTTCTCACTT TGTTGCCAAAGTCGTTAACAAGAAATCACATTGACTCATTGATGTTTTGGCTCCTTTCCCTTAC TTTCTGTTGCTTTCCAAAAGCTGAGACAGGAAACTAACCCTAACTGAGCACCTGCAATTGCCTG GTAGTATTCTAGTCATGTGTGTACTTTTGTGTGTATGTAATCCCCTTACAGCTCTGCAAAGTAA GAATTGTTCTCCCTGCTTTACAGAAGAGATCATAAGATAATTGAGGCTGTTAGATGTTAACTTG CCAAAAGCCATACAGGAAAATGGTAGAGTCACAGTTTGAACCAGGTCCTTTTGATTCTTTACAT TAAACCATGCTTTGATCTTGGAAATACACTGTAAGGCAATAAATCAAT AGAT ACGGAT AAT TCA CAGGCTTCTAAATAAATGGAAGTTGATTGTTTTTATCTGTGAGCCAAAGTAAGACTTATTCTAA GAAT T CC AC AAAT T T AGAT AAGAT AGAGT AT AT (Template Construct 39; SEQ ID NO: 27317)
In an embodiment, to correct a mutation, e.g., R553X target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the 5' homology arm may be shortened less than 750 nucleotides, e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the R553X mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
CTCTTCTTAGGAGGTTTGTTCATTTTGGGAGATTTCTTTTGAAAAGAGTGAACTTAAATTGGAG
AAAAGTACATTTTAGTATGTTGATAACATTTGAATTTGTAAAATGGACCTATGGATGATCTACA
CATATTTATATACCCATAAATATACACATATTTTAATTTTTGGTATTTTATAATTATTATTTAA
TGATCATTCATGACATTTTAAAAATTACAGAAAAATTTACATCTAAAATTTCAGCAATGTTGTT
TTTGACCAACTAAATAAATTGCATTTGAAATAATGGAGATGCAATGTTCAAAATTTCAACTGTG
GTTAAAGCAATAGTGTGATATATGATTACATTAGAAGGAAGATGTGCCTTTCAAATTCAGATTG
AGCATACTAAAAGTGACTCTCTAATTTTCTATTTTTGGTAATAGGACATCTCCAAGTTTGCAGA
GAAAGACAATATAGTTCTTGGAGAAGGTGGAATCACACTGt caGGAGGTCAAcGAGCAAGAAT T
TCTTTAGCAAGGTGAATAACTAATTATTGGTCTAGCAAGCATTTGCTGTAAATGTCATTCATGT
AAAAAAATTACAGACATTTCTCTATTGCTTTATATTCTGTTTCTGGAATTGAAAAAATCCTGGG
GTTTTATGGCTAGTGGGTTAAGAATCACATTTAAGAACTATAAATAATGGTATAGTATCCAGAT
TTGGTAGAGATTATGGTTACTCAGAATCTGTGCCCGTATCTTGGTGTCAGTGTATTTGTTTGCC
TCATAGTATAGTTTACTACAAATGGAAAACTCTAGGATTCTGCATAATACTGGACAGAGAAGAT
GTAAATATCTGTTAGTTCCATCATAGACCCTGCCACTCCAATGTACACACCAGCTTTAGGCTTC
TTGGTATAGATAAACATACATTTTCAAAATTTTTCATCATAATTTTCATAACAAAATAGGAAGG
CAAATGATGTCACTTGGCTTAAAATCTATAATATTTAAAAT
(Template Construct 40; SEQ ID NO: 27318)
In an embodiment, an ssODN may be to correct a mutation, e.g., R553X target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted base to correct the R553X mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTTGGAGAAGGTGGAATCACACTGt caGGAGGTCAAcGAGCAAGAATTTCTTTAGCAAGGTGAATAACTAATTATTGGTCTAGCAAGCA
TTTGCTGTAAATGTCATTCATGT
(Template Construct 41; SEQ ID NO: 27319)
The underlined T has been changed from an A to T at that position, the underlined C has been changed from a G to C at that position, and the underlined A has been changed from a T to A at that position, so that wild-type CFTR is still transcribed, but the PAM sequence AGG has been modified to reduce or eliminate Cas9 cleavage at that locus.
Exemplary template nucleic acids (also referred to herein as donor constructs) to correction a mutation, e.g., an intronic 2789+5bp (G-^A) target site in the CFTR gene, are provided.
Suitable sequence for the 5' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
TTTTTCTGTTTCATTCTGTGGTAAAGGTATCATTTGGCTAATTGTATAATTTCAGTGTCATTTC TAATATTCCAATTGTGATAGTATCAACACAAGATTAAATTTCTCTACATGGTTTATGAGAATGG AATGCCAAATTGAAATAGAACAGAGCACAGATGATCTAAATATAAAAAGAACTACAAAAATCAC AGTTGTTTAAAAAGGTTTTTTGTTTGTTTATATATGGTGCAGAACATTTGTTCCTTAGCCAAAT GTTTCCACCTTGAGAAAGCTATAGAGATTCTATGTAGTCCTAGTACCAATAATATGTTTTAACC TGAATGTACCTTATCTTTATTCATAAACTGTGACTTTTTACACTGCTGAAACTTTTTTTTTTAA GACAATCTCACTCTGTCGTCCAGTCTGGAGTGCAGCAGTGGTGTGATCTTGGCTCACTGCAACC TCTACCTTCTGTGTTCAAGCAATTCTGGTGCCTCGGCCACCTGAGTAGTTGGGATCACAGGTGT ACACCACCAGGCCTGGCTAATAGTTTTTGATATTTCTAGTAGAGATGAGTTTTGCCACATTGGC CAGGCTGGCCTGAAACTCCTGGCCTCAAGTGATCTGCCTGCCTTGGCCTCCCAAAGTGTTGGTA TTACAAGTGTGAGCCACTGTGCCTGGCCTGAAACTCATAATTCATTTCCATTAATATTAATCTC ACCTTTTCCAATAATTAATTGATTTCACAAGTATTAGTCCCCTATAATCATTGAATGGCTAATA AAATTATTTATAGCAAACAGATTAATTATCTGCCAGCAGTCTGAGATTAGTTTCTTTAAAAAAT GTTTATTATTTAAAACATTCAGCTGTGATCTTGGCTTTCTTGTGAGGTTCAATAGTTTCTATTG AGTAAAGGAGAGAAATGGCAGAGAATTTACTTCAGTGAAATTTGAATTCCATTAACTTAATGTG GTCTCATCACAAATAATAGTACTTAGAACACCTAGTACAGCTGCTGGACCCAGGAACACAAAGC AAAGGAAGATGAAATTGTGTGTACCTTGATATTGGTACACACATCAAATGGTGTGATGTGAATT TAGATGTGGGCATGGGAGGAATAGGTGAAGATGTTAGAAAAAAAATCAACTGTGTCTTGTTCCA TTCCAGGTGGCTGCTTCTTTGGTTGTGCTGTGGCTCCTTGGAAAGTGA SEQ ID NO: 27320 (5Ή arm)
Suitable sequence for the 3' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
TATTCCATGTCCTATTGTGTAGATTGTGTTTTATTTCTGTTGATTAAATATTGTAATCCACTAT
GTTTGTATGTATTGTAATCCACTTTGTTTCATTTCTCCCAAGCATTATGGTAGTGGAAAGATAA
GGTTTTTTGTTTAAATGATGACCATTAGTTGGGTGAGGTGACACATTCCTGTAGTCCTAGCTCC
TCCACAGGCTGACGCAGGAGGATCACTTGAGCCCAGGAGTTCAGGGCTGTAGTGTTGTATCATT
GTGAGTAGCCACCGCACTCCAGCCTGGACAATATAGTGAGATCCTATATCTAAAATAAAATAAA
ATAAAATGAATAAATTGTGAGCATGTGCAGCTCCTGCAGTTTCTAAAGAATATAGTTCTGTTCA
GTTTCTGTGAAACACAATAAAAATATTTGAAATAACATTACATATTTAGGGTTTTCTTCAAATT
TTTTAATTTAATAAAGAACAACTCAATCTCTATCAATAGTGAGAAAACATATCTATTTTCTTGC
AATAATAGTATGATTTTGAGGTTAAGGGTGCATGCTCTTCTAATGCAAAATATTGTATTTATTT
AGACTCAAGTTTAGTTCCATTTACATGTATTGGAAATTCAGTAAGTAACTTTGGCTGCCAAATA
ACGATTTCCTATTTGCTTTACAGCACTCCTCTTCAAGACAAAGGGAATAGTACTCATAGTAGAA
ATAACAGCTATGCAGTGATTATCACCAGCACCAGTTCGTATTATGTGTTTTACATTTACGTGGG
AGTAGCCGACACTTTGCTTGCTATGGGATTCTTCAGAGGTCTACCACTGGTGCATACTCTAATC
ACAGTGTCGAAAATTTTACACCACAAAATGTTACATTCTGTTCTTCAAGCACCTATGTCAACCC
TCAACACGTTGAAAGCAGGTACTTTACTAGGTCTAAGAAATGAAACTGCTGATCCACCATCAAT
AGGGCCTGTGGTTTTGTTGGTTTTCTAATGGCAGTGCTGGCTTTTGCACAGAGGCATGTGCCCT
TTGTTGAACCTCCATTTGACTGGCATGCACATGTCTCAGATATTATAGGTTATCATATATTGTT
GCTCCTAATATTTCTGTGTTAGATAATTAGAGTAGCTTGGTTTGTAAGAATGTGATGTTGGTGG
GACTGTAGCAGAACAAGAAGGCCCTTATGGGTCAGTCATACCTCTCTT
SEQ ID NO: 27321 (3Ή arm)
In an embodiment, the replacement sequence comprises or consists of a Guanine (G) residue.
In an embodiment, to correct a mutation, e.g., an intronic 2789+5bp (G-^A) target site in the CFTR gene, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the intronic 2789+5bp (G-^A) mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TTTTTCTGTTTCATTCTGTGGTAAAGGTATCATTTGGCTAATTGTATAATTTCAGTGTCATTTC TAATATTCCAATTGTGATAGTATCAACACAAGATTAAATTTCTCTACATGGTTTATGAGAATGG AATGCCAAATTGAAATAGAACAGAGCACAGATGATCTAAATATAAAAAGAACTACAAAAATCAC AGTTGTTTAAAAAGGTTTTTTGTTTGTTTATATATGGTGCAGAACATTTGTTCCTTAGCCAAAT GTTTCCACCTTGAGAAAGCTATAGAGATTCTATGTAGTCCTAGTACCAATAATATGTTTTAACC TGAATGTACCTTATCTTTATTCATAAACTGTGACTTTTTACACTGCTGAAACTTTTTTTTTTAA GACAATCTCACTCTGTCGTCCAGTCTGGAGTGCAGCAGTGGTGTGATCTTGGCTCACTGCAACC TCTACCTTCTGTGTTCAAGCAATTCTGGTGCCTCGGCCACCTGAGTAGTTGGGATCACAGGTGT ACACCACCAGGCCTGGCTAATAGTTTTTGATATTTCTAGTAGAGATGAGTTTTGCCACATTGGC CAGGCTGGCCTGAAACTCCTGGCCTCAAGTGATCTGCCTGCCTTGGCCTCCCAAAGTGTTGGTA TTACAAGTGTGAGCCACTGTGCCTGGCCTGAAACTCATAATTCATTTCCATTAATATTAATCTC ACCTTTTCCAATAATTAATTGATTTCACAAGTATTAGTCCCCTATAATCATTGAATGGCTAATA AAATTATTTATAGCAAACAGATTAATTATCTGCCAGCAGTCTGAGATTAGTTTCTTTAAAAAAT GTTTATTATTTAAAACATTCAGCTGTGATCTTGGCTTTCTTGTGAGGTTCAATAGTTTCTATTG AGTAAAGGAGAGAAATGGCAGAGAATTTACTTCAGTGAAATTTGAATTCCATTAACTTAATGTG GTCTCATCACAAATAATAGTACTTAGAACACCTAGTACAGCTGCTGGACCCAGGAACACAAAGC AAAGGAAGATGAAATTGTGTGTACCTTGATATTGGTACACACATCAAATGGTGTGATGTGAATT TAGATGTGGGCATGGGAGGAATAGGTGAAGATGTTAGAAAAAAAATCAACTGTGTCTTGTTCCA TTCCAGGTGGCTGCTTCTTTGGTTGTGCTGTGGCTCCTTGGAAAGTGAgTATTCCATGTCCTAT TGTGTAGATTGTGTTTTATTTCTGTTGATTAAATATTGTAATCCACTATGTTTGTATGTATTGT AATCCACTTTGTTTCATTTCTCCCAAGCATTATGGTAGTGGAAAGATAAGGTTTTTTGTTTAAA TGATGACCATTAGTTGGGTGAGGTGACACATTCCTGTAGTCCTAGCTCCTCCACAGGCTGACGC AGGAGGATCACTTGAGCCCAGGAGTTCAGGGCTGTAGTGTTGTATCATTGTGAGTAGCCACCGC ACTCCAGCCTGGACAATATAGTGAGATCCTATATCTAAAATAAAATAAAATAAAATGAATAAAT TGTGAGCATGTGCAGCTCCTGCAGTTTCTAAAGAATATAGTTCTGTTCAGTTTCTGTGAAACAC AAT AAAAAT AT T T GAAAT AAC AT T AC AT AT TTAGGGTTTTCTT C AAAT T T T T T AAT T T AAT AAA GAACAACTCAATCTCTATCAATAGTGAGAAAACATATCTATTTTCTTGCAATAATAGTATGATT TTGAGGTTAAGGGTGCATGCTCTTCTAATGCAAAATATTGTATTTATTTAGACTCAAGTTTAGT TCCATTTACATGTATTGGAAATTCAGTAAGTAACTTTGGCTGCCAAATAACGATTTCCTATTTG CTTTACAGCACTCCTCTTCAAGACAAAGGGAATAGTACTCATAGTAGAAATAACAGCTATGCAG
TGATTATCACCAGCACCAGTTCGTATTATGTGTTTTACATTTACGTGGGAGTAGCCGACACTTT
GCTTGCTATGGGATTCTTCAGAGGTCTACCACTGGTGCATACTCTAATCACAGTGTCGAAAATT
TTACACCACAAAATGTTACATTCTGTTCTTCAAGCACCTATGTCAACCCTCAACACGTTGAAAG
CAGGTACTTTACTAGGTCTAAGAAATGAAACTGCTGATCCACCATCAATAGGGCCTGTGGTTTT
GTTGGTTTTCTAATGGCAGTGCTGGCTTTTGCACAGAGGCATGTGCCCTTTGTTGAACCTCCAT
TTGACTGGCATGCACATGTCTCAGATATTATAGGTTATCATATATTGTTGCTCCTAATATTTCT
GTGTTAGATAATTAGAGTAGCTTGGTTTGTAAGAATGTGATGTTGGTGGGACTGTAGCAGAACA
AGAAGGCCCTTATGGGTCAGTCATACCTCTCTT
(Template Construct 42; SEQ ID NO: 27322)
As described below in Table 49, shorter homology arms, e.g., 5' and/or 3' homology arms may be used.
It is contemplated herein that one or both homology arms may be shortened to avoid including certain sequence repeat elements, e.g., Alu repeats, LINE elements. For example, a 5' homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3' homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5' and the 3' homology arms may be shortened to avoid including certain sequence repeat elements.
In an embodiment, to correct an intronic 2789+5bp (G-^A) mutation in the CFTR gene, the 5' homology arm may be shortened less than 1000 nucleotides, e.g., e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the intronic 2789+5bp (G-^A) mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TCTCACCTTTTCCAATAATTAATTGATTTCACAAGTATTAGTCCCCTATAATCATTGAATGGCT AATAAAATTATTTATAGCAAACAGATTAATTATCTGCCAGCAGTCTGAGATTAGTTTCTTTAAA AAATGTTTATTATTTAAAACATTCAGCTGTGATCTTGGCTTTCTTGTGAGGTTCAATAGTTTCT ATTGAGTAAAGGAGAGAAATGGCAGAGAATTTACTTCAGTGAAATTTGAATTCCATTAACTTAA TGTGGTCTCATCACAAATAATAGTACTTAGAACACCTAGTACAGCTGCTGGACCCAGGAACACA AAGCAAAGGAAGATGAAATTGTGTGTACCTTGATATTGGTACACACATCAAATGGTGTGATGTG AATTTAGATGTGGGCATGGGAGGAATAGGTGAAGATGTTAGAAAAAAAATCAACTGTGTCTTGT TCCATTCCAGGTGGCTGCTTCTTTGGTTGTGCTGTGGCTCCTTGGAAAGTGAgTAT TCCATGTC
CTATTGTGTAGATTGTGTTTTATTTCTGTTGATTAAATATTGTAATCCACTATGTTTGTATGTA
TTGTAATCCACTTTGTTTCATTTCTCCCAAGCATTATGGTAGTGGAAAGATAAGGTTTTTTGTT
TAAATGATGACCATTAGTTGGGTGAGGTGACACATTCCTGTAGTCCTAGCTCCTCCACAGGCTG
ACGCAGGAGGATCACTTGAGCCCAGGAGTTCAGGGCTGTAGTGTTGTATCATTGTGAGTAGCCA
CCGCACTCCAGCCTGGACAATATAGTGAGATCCTATATCTAAAATAAAATAAAATAAAATGAAT
AAATTGTGAGCATGTGCAGCTCCTGCAGTTTCTAAAGAATATAGTTCTGTTCAGTTTCTGTGAA
ACACAATAAAAATATTTGAAATAACATTACATATTTAGGGTTTTCTTCAAATTTTTTAATTTAA
TAAAGAACAACTCAATCTCTATCAATAGTGAGAAAACATAT
(Template Construct 43; SEQ ID NO: 27323)
It is contemplated herein that template nucleic acids for correcting a mutation may designed for use as a single- stranded oligonucleotide (ssODN). When using a ssODN, 5' and 3' homology arms may range up to about 200 base pairs (bp) in length, e.g., at least 25, 50, 75, 100, 125, 150, 175, or 200 bp in length. Longer homology arms are also contemplated for ssODNs as improvements in oligonucleotide synthesis continue to be made.
In an embodiment, an ssODN may be used to correct a mutation, e.g., an intronic
2789+5bp (G-^A) target site in the CFTR gene. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted bases to correct the intronic 2789+5bp (G-^A) mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AAAAAAAATCAACTGTGTCTTGTTCCATTCCAGGTGGCTGCTTCTTTGGTTGTGCTGTGGCTCC
TTGGAAAGTGAgTATTCCATGTCCTATTGTGTAGATTGTGTTTTATTTCTGTTGATTAAATATT
GTAATCCACTATGTTTGTATGTA
(Template Construct 44; SEQ ID NO: 27324)
In an embodiment, to correct a mutation, e.g., an intronic 2789+5bp (G-^A) target site in the CFTR gene, and concomitantly introduce a silent sense mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the intronic 2789+5bp (G-^A) mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TTTTTCTGTTTCATTCTGTGGTAAAGGTATCATTTGGCTAATTGTATAATTTCAGTGTCATTTC TAATATTCCAATTGTGATAGTATCAACACAAGATTAAATTTCTCTACATGGTTTATGAGAATGG AATGCCAAATTGAAATAGAACAGAGCACAGATGATCTAAATATAAAAAGAACTACAAAAATCAC AGTTGTTTAAAAAGGTTTTTTGTTTGTTTATATATGGTGCAGAACATTTGTTCCTTAGCCAAAT GTTTCCACCTTGAGAAAGCTATAGAGATTCTATGTAGTCCTAGTACCAATAATATGTTTTAACC TGAATGTACCTTATCTTTATTCATAAACTGTGACTTTTTACACTGCTGAAACTTTTTTTTTTAA GACAATCTCACTCTGTCGTCCAGTCTGGAGTGCAGCAGTGGTGTGATCTTGGCTCACTGCAACC TCTACCTTCTGTGTTCAAGCAATTCTGGTGCCTCGGCCACCTGAGTAGTTGGGATCACAGGTGT ACACCACCAGGCCTGGCTAATAGTTTTTGATATTTCTAGTAGAGATGAGTTTTGCCACATTGGC CAGGCTGGCCTGAAACTCCTGGCCTCAAGTGATCTGCCTGCCTTGGCCTCCCAAAGTGTTGGTA TTACAAGTGTGAGCCACTGTGCCTGGCCTGAAACTCATAATTCATTTCCATTAATATTAATCTC ACCTTTTCCAATAATTAATTGATTTCACAAGTATTAGTCCCCTATAATCATTGAATGGCTAATA AAATTATTTATAGCAAACAGATTAATTATCTGCCAGCAGTCTGAGATTAGTTTCTTTAAAAAAT GTTTATTATTTAAAACATTCAGCTGTGATCTTGGCTTTCTTGTGAGGTTCAATAGTTTCTATTG AGTAAAGGAGAGAAATGGCAGAGAATTTACTTCAGTGAAATTTGAATTCCATTAACTTAATGTG GTCTCATCACAAATAATAGTACTTAGAACACCTAGTACAGCTGCTGGACCCAGGAACACAAAGC AAAGGAAGATGAAATTGTGTGTACCTTGATATTGGTACACACATCAAATGGTGTGATGTGAATT TAGATGTGGGCATGGGAGGAATAGGTGAAGATGTTAGAAAAAAAATCAACTGTGTCTTGTTCCA TTCCAGGTGGCTGCTTCTTTGGTTGTGCTGTGGCTCCTTGGAAAGTGAgTATTggATGTCCTAT TGTGTAGATTGTGTTTTATTTCTGTTGATTAAATATTGTAATCCACTATGTTTGTATGTATTGT AATCCACTTTGTTTCATTTCTCCCAAGCATTATGGTAGTGGAAAGATAAGGTTTTTTGTTTAAA TGATGACCATTAGTTGGGTGAGGTGACACATTCCTGTAGTCCTAGCTCCTCCACAGGCTGACGC AGGAGGATCACTTGAGCCCAGGAGTTCAGGGCTGTAGTGTTGTATCATTGTGAGTAGCCACCGC ACTCCAGCCTGGACAATATAGTGAGATCCTATATCTAAAATAAAATAAAATAAAATGAATAAAT TGTGAGCATGTGCAGCTCCTGCAGTTTCTAAAGAATATAGTTCTGTTCAGTTTCTGTGAAACAC AAT AAAAAT AT T T GAAAT AAC AT T AC AT AT TTAGGGTTTTCTT C AAAT T T T T T AAT T T AAT AAA GAACAACTCAATCTCTATCAATAGTGAGAAAACATATCTATTTTCTTGCAATAATAGTATGATT TTGAGGTTAAGGGTGCATGCTCTTCTAATGCAAAATATTGTATTTATTTAGACTCAAGTTTAGT TCCATTTACATGTATTGGAAATTCAGTAAGTAACTTTGGCTGCCAAATAACGATTTCCTATTTG CTTTACAGCACTCCTCTTCAAGACAAAGGGAATAGTACTCATAGTAGAAATAACAGCTATGCAG TGATTATCACCAGCACCAGTTCGTATTATGTGTTTTACATTTACGTGGGAGTAGCCGACACTTT
GCTTGCTATGGGATTCTTCAGAGGTCTACCACTGGTGCATACTCTAATCACAGTGTCGAAAATT
TTACACCACAAAATGTTACATTCTGTTCTTCAAGCACCTATGTCAACCCTCAACACGTTGAAAG
CAGGTACTTTACTAGGTCTAAGAAATGAAACTGCTGATCCACCATCAATAGGGCCTGTGGTTTT
GTTGGTTTTCTAATGGCAGTGCTGGCTTTTGCACAGAGGCATGTGCCCTTTGTTGAACCTCCAT
TTGACTGGCATGCACATGTCTCAGATATTATAGGTTATCATATATTGTTGCTCCTAATATTTCT
GTGTTAGATAATTAGAGTAGCTTGGTTTGTAAGAATGTGATGTTGGTGGGACTGTAGCAGAACA
AGAAGGCCCTTATGGGTCAGTCATACCTCTCTT
(Template Construct 45; SEQ ID NO: 27325)
In an embodiment, to correct a mutation, e.g., an intronic 2789+5bp (G-^A) target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the 5' homology arm may be shortened less than 750 nucleotides, e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the intronic 2789+5bp (G-^A) mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TCTCACCTTTTCCAATAATTAATTGATTTCACAAGTATTAGTCCCCTATAATCATTGAATGGCT AATAAAATTATTTATAGCAAACAGATTAATTATCTGCCAGCAGTCTGAGATTAGTTTCTTTAAA AAATGTTTATTATTTAAAACATTCAGCTGTGATCTTGGCTTTCTTGTGAGGTTCAATAGTTTCT ATTGAGTAAAGGAGAGAAATGGCAGAGAATTTACTTCAGTGAAATTTGAATTCCATTAACTTAA TGTGGTCTCATCACAAATAATAGTACTTAGAACACCTAGTACAGCTGCTGGACCCAGGAACACA AAGCAAAGGAAGATGAAATTGTGTGTACCTTGATATTGGTACACACATCAAATGGTGTGATGTG AATTTAGATGTGGGCATGGGAGGAATAGGTGAAGATGTTAGAAAAAAAATCAACTGTGTCTTGT TCCATTCCAGGTGGCTGCTTCTTTGGTTGTGCTGTGGCTCCTTGGAAAGTGAgTATTggATGTC CTATTGTGTAGATTGTGTTTTATTTCTGTTGATTAAATATTGTAATCCACTATGTTTGTATGTA TTGTAATCCACTTTGTTTCATTTCTCCCAAGCATTATGGTAGTGGAAAGATAAGGTTTTTTGTT TAAATGATGACCATTAGTTGGGTGAGGTGACACATTCCTGTAGTCCTAGCTCCTCCACAGGCTG ACGCAGGAGGATCACTTGAGCCCAGGAGTTCAGGGCTGTAGTGTTGTATCATTGTGAGTAGCCA CCGCACTCCAGCCTGGACAATATAGTGAGATCCTATATCTAAAATAAAATAAAATAAAATGAAT AAATTGTGAGCATGTGCAGCTCCTGCAGTTTCTAAAGAATATAGTTCTGTTCAGTTTCTGTGAA AC AC AAT AAAAAT AT T T GAAAT AAC AT T AC AT AT TTAGGGTTTTCTT C AAAT T T T T T AAT T T AA T AAAG AAC AAC TCAATCTCTATCAATAGT G AG AAAAC AT AT
(Template Construct 46; SEQ ID NO: 27326)
In an embodiment, an ssODN may be to correct a mutation, e.g., an intronic 2789+5bp (G-^A) target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted base to correct the intronic 2789+5bp (G-^A) mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AAAAAAAATCAACTGTGTCTTGTTCCATTCCAGGTGGCTGCTTCTTTGGTTGTGCTGTGGCTCC
TTGGAAAGTGAgTATTggATGTCCTATTGTGTAGATTGTGTTTTATTTCTGTTGATTAAATATT
GTAATCCACTATGTTTGTATGTA
(Template Construct 47; SEQ ID NO: 27327)
The underlined G has been changed from a C to G at that position, so that wild-type CFTR is still transcribed, but the PAM sequence CCA has been modified to reduce or eliminate Cas9 cleavage at that locus.
Exemplary template nucleic acids (also referred to herein as donor constructs) to correction a mutation, e.g., an intronic 3272-26bp (A- G) target site in the CFTR gene, are provided.
Suitable sequence for the 5' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
GTGCACATGTACCCTAAAACTTAAAGTATAATAAAAAAAATAAAAAAAAGTTTGAGGTGTTTAA AG TAT GC AAAAAAAAAAAAAG AAAT AAAT C AC T G AC AC AC TTTGTCCACTTTGCAATGT G AAAA TGTTTACTCACCAACATGTTTTCTTTGATCTTACAGTTGTTATTAATTGTGATTGGAGCTATAG CAGTTGTCGCAGTTTTACAACCCTACATCTTTGTTGCAACAGTGCCAGTGATAGTGGCTTTTAT TATGTTGAGAGCATATTTCCTCCAAACCTCACAGCAACTCAAACAACTGGAATCTGAAGGTATG ACAGTGAATGTGCGATACTCATCTTGTAAAAAAGCTATAAGAGCTATTTGAGATTCTTTATTGT TAATCTACTTAAAAAAAATTCTGCTTTTAAACTTTTACATCATATAACAATAATTTTTTTCTAC ATGCATGTGTATATAAAAGGAAACTATATTACAAAGTACACATGGATTTTTTTTCTTAATTAAT GACCATGTGACTTCATTTTGGTTTTAAAATAGGTATATAGAATCTTACCACAGTTGGTGTACAG GACATTCATTTATAATAAACTTATATCAGTCAAATTAAACAAGGATAGTGCTGCTATTACTAAA
GGTTTCTCTGGGTTCCCAAATGATACTTGACCAAATTTGTCCCTTTGGCTTGTTGTCTTCAGAC
ACCCTTTCTTCATGTGTTGGAGCTGCCATTTCGTGTGCCCCCAAACTCTACTTGAGCTGTTAGG
GAATCACATTTTGCAGTGACAGCCTTAGTGTGGGTGCATTTTCAGGCAATACTTTTTCAGTATA
TTTCTGCTTTGTAGATTATTAGCTAAATCAAGTCACATAAACTTCCTTAATTTAGATACTTGAA
AAAATTGTCTTAAAAGAAAATTTTTTTAGTAAGAATTAATTTAGAATTAGCCAGAAAACTCCCA
GTGGTAGCCAAGAAAGAGGAATAAATATTGGTGGTAATTTTTTAAGTTCCCATCTCTGGTAGCC
AAGTAAAAAAAGAGGGTAACTCATTAATAAAATAACAAATCATATCTATTCAAAGAATGGCACC
AGTGTGAAAAAAAGCTTTTTAACCAATGACATTTGTGATATGATTATTCTAATTTAGTCTTTTT
CAGGTACAAGATATTATGAAATTACATTTTGTGTTTATGTTATTTGCA
SEQ ID NO: 27328 (5Ή arm)
Suitable sequence for the 3' homology arm can be selected from (e.g., includes a portion of) or include the following sequence:
TGTTTTCTATGGAAATATTTCACAGGCAGGAGTCCAATTTTCACTCATCTTGTTACAAGCTTAA AAGGACTATGGACACTTCGTGCCTTCGGACGGCAGCCTTACTTTGAAACTCTGTTCCACAAAGC TCTGAATTTACATACTGCCAACTGGTTCTTGTACCTGTCAACACTGCGCTGGTTCCAAATGAGA ATAGAAATGATTTTTGTCATCTTCTTCATTGCTGTTACCTTCATTTCCATTTTAACAACAGGTA CTATGAACTCATTAACTTTAGCTAAGCATTTAAGTAAAAAATTTTCAATGAATAAAATGCTGCA TTCTATAGGTTATCAATTTTTGATATCTTTAGAGTTTAGTAATTAACAAATTTGTTGGTTTATT ATTGAACAAGTGATTTCTTTGAATTTCCATTGTTTTATTGTTAAACAAATAATTTCCTTGAAAT CGGAT AT AT AT AT AT AT ATGT AT AT AT AT AT AT AT AT AT AT AT AT AT AT ACAT AT AT AT AT AT A GTATTATCCCTGTTTTCACAGTTTTAAAAACCGATGCACACAGATTGTCAGATAGCAATTCTGT GATTGAAGGGGAAATATGTCACCTCTTCATACTCATATTGGTGAAGGGTCCTAGCTTCAAAATT AATAGATTCCTAAAGAGGGGAAATGAAACATCCGCATTTACACACACACACACACACACACACA CAGAGTTCCTCTTGTCGGTAAGTTTTGTTTTTTTTAAATCTCTACTAGATAAAATTTGTTATCT AATTGTGAGTTTTACACAAAGAAAAACTGTCACAGAAAAGAAAGACAGTGTCACATTTTTCAAA AGAAAAAGAAGAAAAGAAAGTGCCATGTTTTTCAAATACAAATGTTCTGGATTGATTTTAGGAT CTTTAGTGAAAAACAAAGTATTTCATAATAAGTAAAATAAAAATCTATGTAGGTAAATTTGTTT CTCTAATTTAAGAATTTGAATTTCTGAGTATTTATGATAAGTGTTGAAATAACTTCTTATATGT GACAGTGAATACTGGCAGAGCAAATGCCAAATCAATGCCAAATCTGTAGGATCATTTGATTGTA GGAACAGAATTCTACTCAAACCGAAAGCAGGCATTTGCTGGAGTTACAGAAAGGCCTCATGGAA CACCGAGAAGGTGGTGCCATTCGACTCTTAAAGAAGCTGCAACAGGCA SEQ ID NO: 27329 (3Ή arm)
In an embodiment, the replacement sequence comprises or consists of an Adenine (A) residue.
In an embodiment, to correct a mutation, e.g., an intronic 3272-26bp (A- G) target site in the CFTR gene, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the intronic 3272-26bp (A- G) mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
GTGCACATGTACCCTAAAACTTAAAGTATAATAAAAAAAATAAAAAAAAGTTTGAGGTGTTTAA AGTATGCAAAAAAAAAAAAAGAAATAAATCACTGACACACTTTGTCCACTTTGCAATGTGAAAA TGTTTACTCACCAACATGTTTTCTTTGATCTTACAGTTGTTATTAATTGTGATTGGAGCTATAG CAGTTGTCGCAGTTTTACAACCCTACATCTTTGTTGCAACAGTGCCAGTGATAGTGGCTTTTAT TATGTTGAGAGCATATTTCCTCCAAACCTCACAGCAACTCAAACAACTGGAATCTGAAGGTATG ACAGTGAATGTGCGATACTCATCTTGTAAAAAAGCTATAAGAGCTATTTGAGATTCTTTATTGT TAATCTACTTAAAAAAAATTCTGCTTTTAAACTTTTACATCATATAACAATAATTTTTTTCTAC ATGCATGTGTATATAAAAGGAAACTATATTACAAAGTACACATGGATTTTTTTTCTTAATTAAT GACCATGTGACTTCATTTTGGTTTTAAAATAGGTATATAGAATCTTACCACAGTTGGTGTACAG GACATTCATTTATAATAAACTTATATCAGTCAAATTAAACAAGGATAGTGCTGCTATTACTAAA GGTTTCTCTGGGTTCCCAAATGATACTTGACCAAATTTGTCCCTTTGGCTTGTTGTCTTCAGAC ACCCTTTCTTCATGTGTTGGAGCTGCCATTTCGTGTGCCCCCAAACTCTACTTGAGCTGTTAGG GAATCACATTTTGCAGTGACAGCCTTAGTGTGGGTGCATTTTCAGGCAATACTTTTTCAGTATA TTTCTGCTTTGTAGATTATTAGCTAAATCAAGTCACATAAACTTCCTTAATTTAGATACTTGAA AAAATTGTCTTAAAAGAAAATTTTTTTAGTAAGAATTAATTTAGAATTAGCCAGAAAACTCCCA GTGGTAGCCAAGAAAGAGGAATAAATATTGGTGGTAATTTTTTAAGTTCCCATCTCTGGTAGCC AAGTAAAAAAAGAGGGTAACTCATTAATAAAATAACAAATCATATCTATTCAAAGAATGGCACC AGTGTGAAAAAAAGCTTTTTAACCAATGACATTTGTGATATGATTATTCTAATTTAGTCTTTTT CAGGTACAAGATATTATGAAATTACATTTTGTGTTTATGTTATTTGCAa T G T T T T C T ATGG AAA TAT T TCACAGGCAGGAGTCCAAT T T TCACTCATCT TGT TACAAGCT TAAAAGGACTATGGACAC T TCGTGCCT TCGGACGGCAGCCT TACT T TGAAACTCTGT TCCACAAAGCTCTGAAT T TACATAC TGCCAACTGGT TCT TGTACCTGTCAACACTGCGCTGGT TCCAAATGAGAATAGAAATGAT T T T T GTCATCTTCTTCATTGCTGTTACCTTCATTTCCATTTTAACAACAGGTACTATGAACTCATTAA
CTTTAGCTAAGCATTTAAGTAAAAAATTTTCAATGAATAAAATGCTGCATTCTATAGGTTATCA
ATTTTTGATATCTTTAGAGTTTAGTAATTAACAAATTTGTTGGTTTATTATTGAACAAGTGATT
TCTTTGAATTTCCATTGTTTTATTGTTAAACAAATAATTTCCTTGAAATCGGATATATATATAT
ATATGTATATATATATATATATATATATATATATACATATATATATATAGTATTATCCCTGTTT
TCACAGTTTTAAAAACCGATGCACACAGATTGTCAGATAGCAATTCTGTGATTGAAGGGGAAAT
ATGTCACCTCTTCATACTCATATTGGTGAAGGGTCCTAGCTTCAAAATTAATAGATTCCTAAAG
AGGGGAAATGAAACATCCGCATTTACACACACACACACACACACACACACAGAGTTCCTCTTGT
CGGTAAGTTTTGTTTTTTTTAAATCTCTACTAGATAAAATTTGTTATCTAATTGTGAGTTTTAC
AC AAAG AAAAAC T G T C AC AG AAAAG AAAG AC AG TGTCACATTTTT C AAAAG AAAAAG AAG AAAA
GAAAGTGCCATGTTTTTCAAATACAAATGTTCTGGATTGATTTTAGGATCTTTAGTGAAAAACA
AAGTATTTCATAATAAGTAAAATAAAAATCTATGTAGGTAAATTTGTTTCTCTAATTTAAGAAT
TTGAATTTCTGAGTATTTATGATAAGTGTTGAAATAACTTCTTATATGTGACAGTGAATACTGG
CAGAGCAAATGCCAAATCAATGCCAAATCTGTAGGATCATTTGATTGTAGGAACAGAATTCTAC
TCAAACCGAAAGCAGGCATTTGCTGGAGTTACAGAAAGGCCTCATGGAACACCGAGAAGGTGGT
GCCATTCGACTCTTAAAGAAGCTGCAACAGGCA
(Template Construct 48; SEQ ID NO: 27330)
As described below in Table 49, shorter homology arms, e.g., 5' and/or 3' homology arms may be used.
It is contemplated herein that one or both homology arms may be shortened to avoid including certain sequence repeat elements, e.g., Alu repeats, LINE elements. For example, a 5' homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3' homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5' and the 3' homology arms may be shortened to avoid including certain sequence repeat elements.
In an embodiment, to correct an intronic 3272-26bp (A- G) mutation in the CFTR gene, the 5' homology arm may be shortened less than 1000 nucleotides, e.g., e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the intronic 3272-26bp (A- G) mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence. AGACACCCTTTCTTCATGTGTTGGAGCTGCCATTTCGTGTGCCCCCAAACTCTACTTGAGCTGT
TAGGGAATCACATTTTGCAGTGACAGCCTTAGTGTGGGTGCATTTTCAGGCAATACTTTTTCAG
TATATTTCTGCTTTGTAGATTATTAGCTAAATCAAGTCACATAAACTTCCTTAATTTAGATACT
TGAAAAAATTGTCTTAAAAGAAAATTTTTTTAGTAAGAATTAATTTAGAATTAGCCAGAAAACT
CCCAGTGGTAGCCAAGAAAGAGGAATAAATATTGGTGGTAATTTTTTAAGTTCCCATCTCTGGT
AGCCAAGTAAAAAAAGAGGGTAACTCATTAATAAAATAACAAATCATATCTATTCAAAGAATGG
CACCAGTGTGAAAAAAAGCTTTTTAACCAATGACATTTGTGATATGATTATTCTAATTTAGTCT
TTTTCAGGTACAAGATATTATGAAATTACATTTTGTGTTTATGTTATTTGCAa T G T T T T CTATG
GAAATATTTCACAGGCAGGAGTCCAATTTTCACTCATCTTGTTACAAGCTTAAAAGGACTATGG
ACACTTCGTGCCTTCGGACGGCAGCCTTACTTTGAAACTCTGTTCCACAAAGCTCTGAATTTAC
ATACTGCCAACTGGTTCTTGTACCTGTCAACACTGCGCTGGTTCCAAATGAGAATAGAAATGAT
TTTTGTCATCTTCTTCATTGCTGTTACCTTCATTTCCATTTTAACAACAGGTACTATGAACTCA
TTAACTTTAGCTAAGCATTTAAGTAAAAAATTTTCAATGAATAAAATGCTGCATTCTATAGGTT
ATCAATTTTTGATATCTTTAGAGTTTAGTAATTAACAAATTTGTTGGTTTATTATTGAACAAGT
GATTTCTTTGAATTTCCATTGTTTTATTGTTAAACAAATAATTTCCTTGAAATCGGATATATAT
AT AT AT ATGT AT AT AT AT AT AT AT AT AT AT AT AT AT AT ACA
(Template Construct 49; SEQ ID NO: 27331)
It is contemplated herein that template nucleic acids for correcting a mutation may designed for use as a single- stranded oligonucleotide (ssODN). When using a ssODN, 5' and 3' homology arms may range up to about 200 base pairs (bp) in length, e.g., at least 25, 50, 75, 100, 125, 150, 175, or 200 bp in length. Longer homology arms are also contemplated for ssODNs as improvements in oligonucleotide synthesis continue to be made.
In an embodiment, an ssODN may be used to correct a mutation, e.g., an intronic 3272- 26bp (A- G) target site in the CFTR gene. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted bases to correct the intronic 3272-26bp (A- G) mutation is shown as lower case sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
ATATGATTATTCTAATTTAGTCTTTTTCAGGTACAAGATATTATGAAATTACATTTTGTGTTTA
TGTTATTTGCAaTGTTTTCTATGGAAATATTTCACAGGCAGGAGTCCAATTTTCACTCATCTTG T T AC AAG C T T AAAAG GACTATGG
(Template Construct 50; SEQ ID NO: 27332) In an embodiment, to correct a mutation, e.g., an intronic 3272-26bp (A- G) target site in the CFTR gene, and concomitantly introduce a silent sense mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the inserted base to correct the intronic 3272-26bp (A- G) mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
GTGCACATGTACCCTAAAACTTAAAGTATAATAAAAAAAATAAAAAAAAGTTTGAGGTGTTTAA AGTATGCAAAAAAAAAAAAAGAAATAAATCACTGACACACTTTGTCCACTTTGCAATGTGAAAA TGTTTACTCACCAACATGTTTTCTTTGATCTTACAGTTGTTATTAATTGTGATTGGAGCTATAG CAGTTGTCGCAGTTTTACAACCCTACATCTTTGTTGCAACAGTGCCAGTGATAGTGGCTTTTAT TATGTTGAGAGCATATTTCCTCCAAACCTCACAGCAACTCAAACAACTGGAATCTGAAGGTATG ACAGTGAATGTGCGATACTCATCTTGTAAAAAAGCTATAAGAGCTATTTGAGATTCTTTATTGT TAATCTACTTAAAAAAAATTCTGCTTTTAAACTTTTACATCATATAACAATAATTTTTTTCTAC ATGCATGTGTATATAAAAGGAAACTATATTACAAAGTACACATGGATTTTTTTTCTTAATTAAT GACCATGTGACTTCATTTTGGTTTTAAAATAGGTATATAGAATCTTACCACAGTTGGTGTACAG GACATTCATTTATAATAAACTTATATCAGTCAAATTAAACAAGGATAGTGCTGCTATTACTAAA GGTTTCTCTGGGTTCCCAAATGATACTTGACCAAATTTGTCCCTTTGGCTTGTTGTCTTCAGAC ACCCTTTCTTCATGTGTTGGAGCTGCCATTTCGTGTGCCCCCAAACTCTACTTGAGCTGTTAGG GAATCACATTTTGCAGTGACAGCCTTAGTGTGGGTGCATTTTCAGGCAATACTTTTTCAGTATA TTTCTGCTTTGTAGATTATTAGCTAAATCAAGTCACATAAACTTCCTTAATTTAGATACTTGAA AAAATTGTCTTAAAAGAAAATTTTTTTAGTAAGAATTAATTTAGAATTAGCCAGAAAACTCCCA GTGGTAGCCAAGAAAGAGGAATAAATATTGGTGGTAATTTTTTAAGTTCCCATCTCTGGTAGCC AAGTAAAAAAAGAGGGTAACTCATTAATAAAATAACAAATCATATCTATTCAAAGAATGGCACC AGTGTGAAAAAAAGCTTTTTAACCAATGACATTTGTGATATGATTATTCTAATTTAGTCTTTTT CAGGTACAAGATATTATGAAATTACATTTTGTGTTTATGTTATTTGCAaTGTTTTCTATccAAA TATTTCACAGGCAGGAGTCCAATTTTCACTCATCTTGTTACAAGCTTAAAAGGACTATGGACAC TTCGTGCCTTCGGACGGCAGCCTTACTTTGAAACTCTGTTCCACAAAGCTCTGAATTTACATAC TGCCAACTGGTTCTTGTACCTGTCAACACTGCGCTGGTTCCAAATGAGAATAGAAATGATTTTT GTCATCTTCTTCATTGCTGTTACCTTCATTTCCATTTTAACAACAGGTACTATGAACTCATTAA CTTTAGCTAAGCATTTAAGTAAAAAATTTTCAATGAATAAAATGCTGCATTCTATAGGTTATCA
ATTTTTGATATCTTTAGAGTTTAGTAATTAACAAATTTGTTGGTTTATTATTGAACAAGTGATT
TCTTTGAATTTCCATTGTTTTATTGTTAAACAAATAATTTCCTTGAAATCGGATATATATATAT
ATATGTATATATATATATATATATATATATATATACATATATATATATAGTATTATCCCTGTTT
TCACAGTTTTAAAAACCGATGCACACAGATTGTCAGATAGCAATTCTGTGATTGAAGGGGAAAT
ATGTCACCTCTTCATACTCATATTGGTGAAGGGTCCTAGCTTCAAAATTAATAGATTCCTAAAG
AGGGGAAATGAAACATCCGCATTTACACACACACACACACACACACACACAGAGTTCCTCTTGT
CGGTAAGTTTTGTTTTTTTTAAATCTCTACTAGATAAAATTTGTTATCTAATTGTGAGTTTTAC
AC AAAG AAAAAC T G T C AC AG AAAAG AAAG AC AG TGTCACATTTTT C AAAAG AAAAAG AAG AAAA
GAAAGTGCCATGTTTTTCAAATACAAATGTTCTGGATTGATTTTAGGATCTTTAGTGAAAAACA
AAGTATTTCATAATAAGTAAAATAAAAATCTATGTAGGTAAATTTGTTTCTCTAATTTAAGAAT
TTGAATTTCTGAGTATTTATGATAAGTGTTGAAATAACTTCTTATATGTGACAGTGAATACTGG
CAGAGCAAATGCCAAATCAATGCCAAATCTGTAGGATCATTTGATTGTAGGAACAGAATTCTAC
TCAAACCGAAAGCAGGCATTTGCTGGAGTTACAGAAAGGCCTCATGGAACACCGAGAAGGTGGT
GCCATTCGACTCTTAAAGAAGCTGCAACAGGCA
(Template Construct 51; SEQ ID NO: 27333)
In an embodiment, to correct a mutation, e.g., an intronic 3272-26bp (A- G) target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the 5' homology arm may be shortened less than 750 nucleotides, e.g., 500 nucleotides, to avoid inclusion of a LINE repeat element in the 5' homology arm. The 5' homology arm is shown as bold sequence, the inserted base to correct the intronic 3272-26bp (A- G) mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
AGACACCCTTTCTTCATGTGTTGGAGCTGCCATTTCGTGTGCCCCCAAACTCTACTTGAGCTGT TAGGGAATCACATTTTGCAGTGACAGCCTTAGTGTGGGTGCATTTTCAGGCAATACTTTTTCAG TATATTTCTGCTTTGTAGATTATTAGCTAAATCAAGTCACATAAACTTCCTTAATTTAGATACT TGAAAAAATTGTCTTAAAAGAAAATTTTTTTAGTAAGAATTAATTTAGAATTAGCCAGAAAACT CCCAGTGGTAGCCAAGAAAGAGGAATAAATATTGGTGGTAATTTTTTAAGTTCCCATCTCTGGT AGCCAAGTAAAAAAAGAGGGTAACTCATTAATAAAATAACAAATCATATCTATTCAAAGAATGG CACCAGTGTGAAAAAAAGCTTTTTAACCAATGACATTTGTGATATGATTATTCTAATTTAGTCT TTTTCAGGTACAAGATATTATGAAATTACATTTTGTGTTTATGTTATTTGCAa TGTTTTCTATc cAAATATTTCACAGGCAGGAGTCCAATTTTCACTCATCTTGTTACAAGCTTAAAAGGACTATGG
ACACTTCGTGCCTTCGGACGGCAGCCTTACTTTGAAACTCTGTTCCACAAAGCTCTGAATTTAC
ATACTGCCAACTGGTTCTTGTACCTGTCAACACTGCGCTGGTTCCAAATGAGAATAGAAATGAT
TTTTGTCATCTTCTTCATTGCTGTTACCTTCATTTCCATTTTAACAACAGGTACTATGAACTCA
TTAACTTTAGCTAAGCATTTAAGTAAAAAATTTTCAATGAATAAAATGCTGCATTCTATAGGTT
ATCAATTTTTGATATCTTTAGAGTTTAGTAATTAACAAATTTGTTGGTTTATTATTGAACAAGT
GATTTCTTTGAATTTCCATTGTTTTATTGTTAAACAAATAATTTCCTTGAAATCGGATATATAT
AT AT AT ATGT AT AT AT AT AT AT AT AT AT AT AT AT AT AT ACA
(Template Construct 52; SEQ ID NO: 27334)
In an embodiment, an ssODN may be to correct a mutation, e.g., an intronic 3272-26bp (A- G) target site in the CFTR gene, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage. For example, the ssODN may include 5' and 3' homology arms as shown below. The 5' homology arm is shown as bold sequence, the inserted base to correct the intronic 3272-26bp (A- G) mutation is shown as lower case sequence, the silent sense mutation is shown as lower case underlined and italicized sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
ATATGATTATTCTAATTTAGTCTTTTTCAGGTACAAGATATTATGAAATTACATTTTGTGTTTA
TGTTATTTGCAaTGTTTTCTATccAAATATTTCACAGGCAGGAGTCCAATTTTCACTCATCTTG T T AC AAG C T T AAAAG GACTATGG
(Template Construct 53; SEQ ID NO: 27335)
The underlined C has been changed from a G to C at that position, so that wild-type CFTR is still transcribed, but the PAM sequence TGG has been modified to reduce or eliminate Cas9 cleavage at that locus.
Table 49 below provides exemplary template nucleic acids. In an embodiment, the template nucleic acid includes the 5' homology arm and the 3' homology arm of a row from Table 49. In other embodiments, a 5' homology arm from the first column can be combined with a 3' homology arm from Table 49. In each embodiment, a combination of the 5' and 3' homology arms include a replacement sequence, e.g., Cytosine-Thymine-Thymine (CTT) residues or a Guanine (G) residue. Table 49
Figure imgf001703_0001
1500 or more 1500 or more
1600 or more 1600 or more
1700 or more 1700 or more
1800 or more 1800 or more
1900 or more 1900 or more
1200 or more 1200 or more
At least 50 but not long enough to At least 50 but not long enough to include a repeated element. include a repeated element.
At least 100 but not long enough to At least 100 but not long enough to include a repeated element. include a repeated element.
At least 150 but not long enough to At least 150 but not long enough to include a repeated element. include a repeated element.
5 to 100 nucleotides 5 to 100 nucleotides
10 to 150 nucleotides 10 to 150 nucleotides
20 to 150 nucleotides 20 to 150 nucleotides
Template Construct No. 1
Template Construct No. 2
Template Construct No. 3
Template Construct No. 4
In an embodiment, a single or dual nickase eaCas9 is used to cleave the target DNA near the site of the mutation, or signature, to be modified, e.g., replaced. While not wishing to be bound by theory, in an embodiment, it is believed that the Cas9 mediated break induces HDR with the template nucleic acid to replace the target DNA sequence with the template sequence.
Targeted Knockin by cDNA Insertion
In an embodiment, homology-directed repair of the CFTR gene is used to target an intronic region between exons X and Y, wherein exons X and Y are any exons between exon 1 and exon 27, given that exon X and exon Y are adjacent and exon X has a lower number than exon Y, and deliver a Cas9 molecule, CRIPSR-gRNAs, and homology-directed repair templates that include homology arms, splice acceptor, contiguous coding sequence of exons (X+l) through exon 27 of CFTR gene and polyadenylation signal.
In an embodiment, one single strand break, two single strand breaks, one double strand break or two double strand breaks are introduced (e.g., positioned by one, two, three, or four gRNA molecule/s) at or in close proximity to a CF target knockin position in the CFTR gene. The CF target knockin position is the intronic region between CFTR exons X and Y. Altering the CF target knockin position refers to homology-directed repair of genomic sequence including the delivery of cDNA template of contiguous exons (X+l) through exon 27 of CFTR gene. Targeted knockin of CFTR cDNA leads to the cessation of production of mutant or truncated CFTR protein and results in the production of wild-type CFTR protein. Targeted knockin of CFTR cDNA prevents the development or progression of lung, gastrointestinal and/or reproductive disease in a subject due to the cessation of production of mutant CFTR protein and restoration of wild-type CFTR protein production. This approach cures and/or prevents the progression of lung, gastrointestinal and/or reproductive disease in any subject with CF or CF-like disease deficiency who has a mutation in exon (X+l) through exon 27 of the CFTR gene, or in any subject who has a mutation in an intronic or exonic region of the CFTR gene that is after intron X.
In an embodiment, homology-directed repair of the CFTR gene in any subject with CF mutations in exons 3 through 27 and introns 2 through 26 by targeting intronic region between exons 2 and 3 and with delivery of a homology-directed repair template including homology arms, splice acceptor, coding sequence of contiguous exons 3-27 of CFTR gene and
polyadenylation signal. The CF target position is the intronic region between exons 2 and 3. Altering the CF target position refers to homology-directed repair of genomic sequence including the delivery of cDNA template of exons 3-27 of CFTR gene. This approach cures and/or prevents the progression of lung, gastrointestinal and/or reproductive disease in any subject with CF or CF-like disease deficiency who has a mutation in exons 3-27 of the CFTR gene, or in any subject who has a mutation in an intronic or exonic region of the CFTR gene that is on or after the second intron, including but not limited to the following mutations: e.g., F508del,
G551D,G542X, N1303K, R117H, W1282X, R553X, c.3717+12191C>T, 2657+5G>A, or c.3140-26A>G.
In an embodiment, a cDNA insert construct comprises a 5' homology arm, a splice acceptor, a cDNA insert (e.g., CFTR exons 3 to 27, e.g., CFTR exons 11 to 27), a 3' homology arm, and a polyadenylation signal. Splice acceptors and polyadenylation signals are well known to one of skill in the art.
It is contemplated herein that, in an embodiment, a Cas9 molecule could potentially cleave cDNA insert constructs either prior to or following homology directed repair (e.g., homologous recombination), resulting in a possible non-homologous-end-joining event and further DNA sequence mutation at the chromosomal locus of interest. Therefore, to avoid cleavage of the cDNA insert sequence before and/or after Cas9-mediated homology directed repair, alternate versions of the homology arms may be used where silent mutations are introduced into a PAM. These silent mutations may disrupt Cas9 binding and cleavage, but not disrupt the amino acid sequence of the cDNA insert.
Exemplary template cDNA (also referred to herein as cDNA inserts) to introduce wild- type sequence, e.g., exons 3 to 27 of the CFTR gene, are provided. In an embodiment, the CRISPR-Cas9 binding site is CTCAAGTGATCTGCCCACCT TGG (SEQ ID NO: 27336) (PAM is underlined TGG).
In an embodiment, to insert CFTR cDNA (e.g., CFTR exons 3 to 27) into intron 2, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the CRISPR-Cas9 binding site is shown as italicized sequence, the PAM site is underlined, the silent sense mutation in the PAM is shown as lower case underlined sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
CAATCAAAAGGTTAGGATCCTTTTGATTGCCAGTGACAGAAACCCAATTTACTAGCTTAAGTAA ATAAAAGGAACGAATTTATTGGCTCATGAAGCCTGAACTATGTGAAGACCTAGGTGGAGAACTG GCCTTAGGAACTCAATGGGACCAAGGACTCAAATGCCACCTGGTGGCATTTGCCTTATGCTGGT TTTATTTTCTCAGACCGGACCAGCTTTCTACATAAAGTGGGTCCCTGGTTAGAACTCTTTGCTC CTATCTTTAAGGACCACGAAAGAAGGAGCCCTTTGTCCTTGGCTAAATGTGAAAAATCCCAGAG ACTCTTGAGTCATAGTGCTTACCCCTTGGGCCACTCATAGTCTAGAATGAACTAGGCTGAGTCT CGTGCCAACAGCACAGGCCTGATGCCAGATAAAAGGGTGAGTGAAGGGGGATAAAAAATAAGAC ATAGCTACTAAATTATTGCACCAAAGTAAAAACATTGAGTTGACTTGCAATTTGTTTCTTTTAA TTAAATTCATTTCCTTTTTTTGGCATTTTGAAGGCAAAGTAAGATATTAAACTTTATTTTTATT GATTTTATTCAAAGAATTAAGCTAGTGGGAGTAGCAGATTCACACTTCTAAGATCAAGGGCCAG CTTCTATTATTGAACACTTGGTGTGTGCAAATGCCATGAGGTAGGGATACTTTGTTTTGTTTTT TATTTTTTATTGGGTTCGATCTCTTTTGTTTATGATGTATCCCCAAGTGCCTAGAATAGGGCCT GGCATATGGTATATACTCAATAAATATTTGTTGAATGAATCCATGATGGAATGTGAAATGGCTA GCATTACATAGAAACCTGTAGCATTGCTGGAGAGATAAAATATATAAACATAATCCATTGCAGG TATATTGACAAGTTCAAAATAATATAATGGGTATTGAATATCTAAATGTTTGTTGTTGTTGTTG CTGTTGTTTTTGAGACAGAGTCTTGCTCTGTTGCCCAGGCTGGAGTGTAATGGTGCAATTTTGG CTCACTGCAAACTTCGTCTCCTGGGTTCAAGTGATTCTCCTGCCTCAGCCTCTCGAGTAGCTGG GTTTACAGGCACTCGCCACAATGCCTGGCTAATTTTTGTATTTTAGTAGATGTGGAGTTTCGCC ATGTTGGCCAGGCTGGTCTTGAACTCCTGACCrCAAGTGArCrGCCCACCrTaaCCTCCCAAAA TGCTGGGATTATAGGTGTGAGCCACTATGCCCAGCTTTGAATATCTAAGTTTTAATTGGATGCT GAGGGAATGATTAATCAGAGTAGGGCTGGGTTAATTGAAAAATGTGATACATTTGTATTTATGG CCAGATAGAGAACATGAATCTGAATTTGCAGAATTATCTGGCTTAACATTTTTTTCTTTCCAGT TTTCACTGTATCCCCCATGTTGATTCAATTTAAAAAATATACCTATTTTACTTCAATTCAACAA TGCTATGCCAGTACAAACCCATACGTTCTATTATTTTTGTTTTGTTTTGTTTTTGTATCTCCAC CCTGTTACTTCTTTTCTTATAAAATTGGTATTTGAAATTTATTGAAATATTTTGGAAGAGTGAC ATACCATTTTTGGTACTTTGTACCTCTGCACCCTTGGGAAGTGACCCTGGCTTCACATTTCATA ACTGCCTTGTGACCATGGCCCTCAAGTGGTTGCCAGATGGTTGAAGAACATTAACCTATCTGGC TCAATTTTGTGACCATGGATTGAATCCTCTACATAACTGCAGTGTGCAAACCACACATCCGTTC CAAGATTGTAGTCAGGATATGAACTTTTTAAGAATAAAACTTCTTCCCTTCTGATCTGGGCCTG GTATGTGGTCCTACTAGAACCACATCACCTACTCTTGGTGCTAACAATTTGTGGCACCAAGTTG TTCAAGTTTCACCCATTAAAGAAATTCCCCGACCTTGCCTTCTCCTCAGGTAACTACCCCATTC TATTTTTTCTTTCATAGCTAACATTCTCTGCTCTCCTGGTCTCTCTACTTCACTTTCATTTACA TCTCAGCTCCTGAAGTATGGTTTCCACCATGTTCCTAAAACTACATTGCCCAGGGTCACTAGAG ACCTCTTATGAAATATAACAACACCTTTCTACATTACTTCCGTGTGGACCACTTTTTCACATTG AACCCATTTTGTTGGTTTATGTACACACCCCTTCCTTGGCTTTCCCATCTGATCCATTTCTCCT TTGATGGAGAAGGTGAGTCTGCTCCATATTTAGCTTCTTACTCTGAGTAACCAAATGTTATGGA TGGGAGGTTAGCTCTGTGTGTGAGAGAAAGGTGGAGAAGCATGTGGGGAGGGAAATAGATGGGA AAAGGTAATTAGGCTTTATAGAAGGGCTCTCA
(SEQ ID NO: 27337) The underlined A has been changed from a G to A at that position so that wild-type CFTR is still transcribed, but the PAM sequence TGG has been modified to TAA to reduce or eliminate Cas9 cleavage at that locus.
In an embodiment, suitable sequence for the cDNA insert of CFTR exons 3 to 27, can be selected from (e.g., includes a portion of) or include the following sequence:
AGAATGGGATAGAGAGCTGGCTTCAAAGAAAAATCCTAAACTCATTAATGCCCTTCGGCGATGT TTTTTCTGGAGATTTATGTTCTATGGAATCTTTTTATATTTAGGGGAAGTCACCAAAGCAGTAC AGCCTCTCTTACTGGGAAGAATCATAGCTTCCTATGACCCGGATAACAAGGAGGAACGCTCTAT CGCGATTTATCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAGGACACTGCTCCTACACCCA GCCATTTTTGGCCTTCATCACATTGGAATGCAGATGAGAATAGCTATGTTTAGTTTGATTTATA AGAAGACTTTAAAGCTGTCAAGCCGTGTTCTAGATAAAATAAGTATTGGACAACTTGTTAGTCT CCTTTCCAACAACCTGAACAAATTTGATGAAGGACTTGCATTGGCACATTTCGTGTGGATCGCT CCTTTGCAAGTGGCACTCCTCATGGGGCTAATCTGGGAGTTGTTACAGGCGTCTGCCTTCTGTG GACTTGGTTTCCTGATAGTCCTTGCCCTTTTTCAGGCTGGGCTAGGGAGAATGATGATGAAGTA C AGAGAT C AGAGAGC T GGGAAGAT C AGT GAAAGAC T T GT GAT T ACC T CAGAAAT GAT T GAAAAT ATCCAATCTGTTAAGGCATACTGCTGGGAAGAAGCAATGGAAAAAATGATTGAAAACTTAAGAC AAACAGAACTGAAACTGACTCGGAAGGCAGCCTATGTGAGATACTTCAATAGCTCAGCCTTCTT CTTCTCAGGGTTCTTTGTGGTGTTTTTATCTGTGCTTCCCTATGCACTAATCAAAGGAATCATC CTCCGGAAAATATTCACCACCATCTCATTCTGCATTGTTCTGCGCATGGCGGTCACTCGGCAAT TTCCCTGGGCTGTACAAACATGGTATGACTCTCTTGGAGCAATAAACAAAATACAGGATTTCTT ACAAAAGCAAGAATATAAGACATTGGAATATAACTTAACGACTACAGAAGTAGTGATGGAGAAT GTAACAGCCTTCTGGGAGGAGGGATTTGGGGAATTATTTGAGAAAGCAAAACAAAACAATAACA ATAGAAAAACTTCTAATGGTGATGACAGCCTCTTCTTCAGTAATTTCTCACTTCTTGGTACTCC TGTCCTGAAAGATATTAATTTCAAGATAGAAAGAGGACAGTTGTTGGCGGTTGCTGGATCCACT GGAGCAGGCAAGACTTCACTTCTAATGGTGATTATGGGAGAACTGGAGCCTTCAGAGGGTAAAA TTAAGCACAGTGGAAGAATTTCATTCTGTTCTCAGTTTTCCTGGATTATGCCTGGCACCATTAA AGAAAATATCATCTTTGGTGTTTCCTATGATGAATATAGATACAGAAGCGTCATCAAAGCATGC CAACTAGAAGAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTTGGAGAAGGTGGAA TCACACTGAGTGGAGGTCAACGAGCAAGAATTTCTTTAGCAAGAGCAGTATACAAAGATGCTGA TTTGTATTTATTAGACTCTCCTTTTGGATACCTAGATGTTTTAACAGAAAAAGAAATATTTGAA AGCTGTGTCTGTAAACTGATGGCTAACAAAACTAGGATTTTGGTCACTTCTAAAATGGAACATT TAAAGAAAGCTGACAAAATATTAATTTTGCATGAAGGTAGCAGCTATTTTTATGGGACATTTTC AGAACTCCAAAATCTACAGCCAGACTTTAGCTCAAAACTCATGGGATGTGATTCTTTCGACCAA TTTAGTGCAGAAAGAAGAAATTCAATCCTAACTGAGACCTTACACCGTTTCTCATTAGAAGGAG ATGCTCCTGTCTCCTGGACAGAAACAAAAAAACAATCTTTTAAACAGACTGGAGAGTTTGGGGA AAAAAGGAAGAATTCTATTCTCAATCCAATCAACTCTATACGAAAATTTTCCATTGTGCAAAAG ACTCCCTTACAAATGAATGGCATCGAAGAGGATTCTGATGAGCCTTTAGAGAGAAGGCTGTCCT TAGTACCAGATTCTGAGCAGGGAGAGGCGATACTGCCTCGCATCAGCGTGATCAGCACTGGCCC CACGCTTCAGGCACGAAGGAGGCAGTCTGTCCTGAACCTGATGACACACTCAGTTAACCAAGGT CAGAACATTCACCGAAAGACAACAGCATCCACACGAAAAGTGTCACTGGCCCCTCAGGCAAACT TGACTGAACTGGATATATATTCAAGAAGGTTATCTCAAGAAACTGGCTTGGAAATAAGTGAAGA AATTAACGAAGAAGACTTAAAGGAGTGCTTTTTTGATGATATGGAGAGCATACCAGCAGTGACT ACATGGAACACATACCTTCGATATATTACTGTCCACAAGAGCTTAATTTTTGTGCTAATTTGGT GCTTAGTAATTTTTCTGGCAGAGGTGGCTGCTTCTTTGGTTGTGCTGTGGCTCCTTGGAAACAC TCCTCTTCAAGACAAAGGGAATAGTACTCATAGTAGAAATAACAGCTATGCAGTGATTATCACC AGCACCAGTTCGTATTATGTGTTTTACATTTACGTGGGAGTAGCCGACACTTTGCTTGCTATGG GATTCTTCAGAGGTCTACCACTGGTGCATACTCTAATCACAGTGTCGAAAATTTTACACCACAA AATGTTACATTCTGTTCTTCAAGCACCTATGTCAACCCTCAACACGTTGAAAGCAGGTGGGATT CTTAATAGATTCTCCAAAGATATAGCAATTTTGGATGACCTTCTGCCTCTTACCATATTTGACT TCATCCAGTTGTTATTAATTGTGATTGGAGCTATAGCAGTTGTCGCAGTTTTACAACCCTACAT CTTTGTTGCAACAGTGCCAGTGATAGTGGCTTTTATTATGTTGAGAGCATATTTCCTCCAAACC TCACAGCAACTCAAACAACTGGAATCTGAAGGCAGGAGTCCAATTTTCACTCATCTTGTTACAA GCTTAAAAGGACTATGGACACTTCGTGCCTTCGGACGGCAGCCTTACTTTGAAACTCTGTTCCA CAAAGCTCTGAATTTACATACTGCCAACTGGTTCTTGTACCTGTCAACACTGCGCTGGTTCCAA ATGAGAATAGAAATGATTTTTGTCATCTTCTTCATTGCTGTTACCTTCATTTCCATTTTAACAA CAGGAGAAGGAGAAGGAAGAGTTGGTATTATCCTGACTTTAGCCATGAATATCATGAGTACATT GCAGTGGGCTGTAAACTCCAGCATAGATGTGGATAGCTTGATGCGATCTGTGAGCCGAGTCTTT AAGTTCATTGACATGCCAACAGAAGGTAAACCTACCAAGTCAACCAAACCATACAAGAATGGCC AACTCTCGAAAGTTATGATTATTGAGAATTCACACGTGAAGAAAGATGACATCTGGCCCTCAGG GGGCCAAATGACTGTCAAAGATCTCACAGCAAAATACACAGAAGGTGGAAATGCCATATTAGAG AACATTTCCTTCTCAATAAGTCCTGGCCAGAGGGTGGGCCTCTTGGGAAGAACTGGATCAGGGA AGAGT AC T T T GT T AT CAGCT T T T T T GAGAC T AC T GAAC AC T G AAGG AG AAAT C C AG AT C G AT GG TGTGTCTTGGGATTCAATAACTTTGCAACAGTGGAGGAAAGCCTTTGGAGTGATACCACAGAAA GTATTTATTTTTTCTGGAACATTTAGAAAAAACTTGGATCCCTATGAACAGTGGAGTGATCAAG AAATATGGAAAGTTGCAGATGAGGTTGGGCTCAGATCTGTGATAGAACAGTTTCCTGGGAAGCT
TGACTTTGTCCTTGTGGATGGGGGCTGTGTCCTAAGCCATGGCCACAAGCAGTTGATGTGCTTG
GCTAGATCTGTTCTCAGTAAGGCGAAGATCTTGCTGCTTGATGAACCCAGTGCTCATTTGGATC
CAGTAACATACCAAATAATTAGAAGAACTCTAAAACAAGCATTTGCTGATTGCACAGTAATTCT
CTGTGAACACAGGATAGAAGCAATGCTGGAATGCCAACAATTTTTGGTCATAGAAGAGAACAAA
GTGCGGCAGTACGATTCCATCCAGAAACTGCTGAACGAGAGGAGCCTCTTCCGGCAAGCCATCA
GCCCCTCCGACAGGGTGAAGCTCTTTCCCCACCGGAACTCAAGCAAGTGCAAGTCTAAGCCCCA
GATTGCTGCTCTGAAAGAGGAGACAGAAGAAGAGGTGCAAGATACAAGGCTTTAG
(SEQ ID NO: 27338)
It is contemplated herein that one or both homology arms may be shortened to avoid including certain sequence repeat elements, e.g., Alu repeats, LINE elements. For example, a 5' homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3' homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5' and the 3' homology arms may be shortened to avoid including certain sequence repeat elements.
In an embodiment, to insert CFTR cDNA (e.g., CFTR exons 3 to 27) into intron 2, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may be shorted to approximately 500bp. The 5' homology arm is shown as bold sequence, the CRISPR-Cas9 binding site is shown as italicized sequence, the PAM site is underlined, the silent sense mutation in the PAM is shown as lower case underlined sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
TTTTTATTTTTTATTGGGTTCGATCTCTTTTGTTTATGATGTATCCCCAAGTGCCTAGAATAGG GCCTGGCATATGGTATATACTCAATAAATATTTGTTGAATGAATCCATGATGGAATGTGAAATG GCTAGCATTACATAGAAACCTGTAGCATTGCTGGAGAGATAAAATATATAAACATAATCCATTG CAGGTATATTGACAAGTTCAAAATAATATAATGGGTATTGAATATCTAAATGTTTGTTGTTGTT GTTGCTGTTGTTTTTGAGACAGAGTCTTGCTCTGTTGCCCAGGCTGGAGTGTAATGGTGCAATT TTGGCTCACTGCAAACTTCGTCTCCTGGGTTCAAGTGATTCTCCTGCCTCAGCCTCTCGAGTAG CTGGGTTTACAGGCACTCGCCACAATGCCTGGCTAATTTTTGTATTTTAGTAGATGTGGAGTTT CGCCATGTTGGCCAGGCTGGTCTTGAACTCCTGACCrCAAGTGArCrGCCCACCrTaaCCTCCC AAAATGCTGGGATTATAGGTGTGAGCCACTATGCCCAGCTTTGAATATCTAAGTTTTAATTGGA TGCTGAGGGAATGATTAATCAGAGTAGGGCTGGGTTAATTGAAAAATGTGATACATTTGTATTT
ATGGCCAGATAGAGAACATGAATCTGAATTTGCAGAATTATCTGGCTTAACATTTTTTTCTTTC
CAGTTTTCACTGTATCCCCCATGTTGATTCAATTTAAAAAATATACCTATTTTACTTCAATTCA
ACAATGCTATGCCAGTACAAACCCATACGTTCTATTATTTTTGTTTTGTTTTGTTTTTGTATCT
CCACCCTGTTACTTCTTTTCTTATAAAATTGGTATTTGAAATTTATTGAAATATTTTGGAAGAG
TGACATACCATTTTTGGTACTTTGTACCTCTGCACCCTTGGGAAGTGACCCTGGCTTCACATTT
CATAACTGCCTTGTGACCATGGCCCTCAAGTGGTTGCCAG
(SEQ ID NO: 27339)
The underlined A has been changed from a G to A at that position so that wild-type CFTR is still transcribed, but the PAM sequence TGG has been modified to TAA to reduce or eliminate Cas9 cleavage at that locus.
Exemplary template cDNA (also referred to herein as cDNA inserts) to introduce wild- type sequence, e.g., exons 11 to 27 of the CFTR gene, are provided. In an embodiment, the CRISPPv-Cas9 binding site is AGTGAATGAATGTGGTATCCCGG (SEQ ID NO: 27340)(PAM is underlined CGG).
In an embodiment, to insert CFTR cDNA (e.g., CFTR exons 11 to 27) into intron 10, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may each comprise about 1000 base pairs (bp) of sequence flanking the most distal gRNAs (e.g., 1200bp of sequence on either side of the mutation). The 5' homology arm is shown as bold sequence, the CRISPR-Cas9 binding site is shown as italicized sequence, the PAM site is underlined, the silent sense mutation in the PAM is shown as lower case underlined sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
CTAAATAGAGTGCTGATTTCCCCACAGCATTACTAACAGATGATATTATCTAATTTAAAAAGTT TCTCATCTTATAGGGAAAATAGTATGTCAATGTATTCTTAACTTGCATTTCTTTTATTATAAGT AGTGTAAAATATCATTTCAACTTATACACAGGAGGAATTTCTCTCTATATAAAGTGATCCTAGA ATCATAATGAAAAATATCACCAACTCATTAGGAAAATGTACAAAGGATTGAATAGATATCTCAT CAAAAATAAAAATATAAGTGGCCTTTAAACATTGAAAGGTAACATTTGAACAAAGACTTGCAGG AGGTGAGGGATTAGGGAATGCAGACTCTGGGAAGAGTCTTCCAAGTAGCAGGTGAAGCAAGTGC AAAGCTTTCAGATGGGACTGACTATACCTGTCTGGTTTGAAGAACAGTAAGGAGGTCACTGAGG CTGGCATAGAGTAAGACAGGGAGGGTAGAATACTGTCAGAGAAGTAATCGGCGGTGGAGGTAGG GGGTAAACCATAAAGTGCTCGTAAAGACTAAGGCTTATTTCTCTGGGTGAGATTAGAGGCCACT
GGAGAGTTTTAAACAGAAGTAACAGGGCCACTTTGGCTAATGTTTTTAGGCTATTCTGTAGGGA
GACAAGGGAGGAAGCAAGGAGATGAGTTAGGAGTCTATTGTGCCAGTTCAGGCAAGTGATGATG
GTGGCTTGATCCAGGTAGTAGTGGAAGTAGTATAGTAGGAAGTGATCAGATTCAGGACATGCTT
TGAAGGAAGATCCAATAGGATTAATGGATAAGTTGAACAATGGCATATGAGAAAAGTCACAGAG
GAGTCAAAGATGATTCCAAGCTTTCTGGACTGAGTAACTGGAAGGATAAATGTGCCGTTTACTA
GAAAGATAATGGGAGAAACAGGTTTTGGATGGAGCTTGGTTTGGGAATATTAAGTTTGAAATGC
CTATTTGACATCCAAATAGAGATGTTAGTTGGATGTACAAGTCTAGTTTCAAGGAAGAGGGGGC
TGGTAGTGTGAAGATGGGGCTGGATAAGATTCTAAAGGAAAGAGGGTTGATAAGAAGAGAAAGG
GGTGTAGGGGTTAGCCTAAGGGCATTCTAAGTATTAGAGGTTAAGGAGGTGGGTGAAGAAAACC
CAATAAAATAAAAGTCTGAGAAGACAAAGCTAGTGAATGAATGTGGTATCCCttAACCCAACTG
ATGTCAAGCAGAAGGGTGTTATCAACTAGGTCAAATGCTCATTCATCAAGTAAGATGAAACTGT
TATAATTAACCGGTGTCTTCTGAAATACGGAGATAACTCGTGACTTAATGAAAGCAATAGTAGA
GAAGGTCAAACTTGACCAGAATGAAATTAGAAAGAATAAGAGGAAAGAAAAGACCAAATACAGA
CAACCATTGATGCCTTATTCTTTTGATATACTCCTGGAGTCCACTTGCTAATACAATTGACCCT
TAAACAATACAGGCTTGAACTGCATGGGTCCACTTATTTGTGAATTTTTTTTCAGTTAATACAT
TGGAAAATTTTTGGGGTTTTTTGACAATTTGAAAAAACTCACAAACTGTCTAGCCTAGAAATAC
CGAGAAAATTAAGAAAAAGTAAGATATGCCATGAATGCATAAAATATATGTAGACACTAGCCTA
TTTTATCATTTGCTACTATAAAATATACACAATCTATTATAAAAAGTTAAAATTTATCAAAACT
TAACACACACTAACACCTACCCTACCTGGCACCATTCACAGTAAAGAGAAATGTAAATAAACAT
AAAAATGTAGTATTAAACCATAATGGCATAAAACTAATTGTAGTACATATGGTACTACTGTAAT
AATTTGGAAGCCACTTCCTGTTGCTATTACGGTAAGCTCAAGCATTGTGGATAGCCATTTAAAA
CACCACGTGATGCTAATCATCTCCGTGTGAGCAGTTCTCTCTCCAGTAAATTGCATATTGCAGT
AAAAAGTGATCTCTAGTGGTTCTCGCATATTTTTCATCATGTTTAGTGCAATGCCATAAACCTT
GAATAACATCAAGCAATCCATACAAAGTGCCACTAGTGATGCACGGAAAAGTTGTAACAGTACA
AGAAAAAAGTTGAGTTGCTTGGTATTTACCATATATTGAGGTCTGCAGCTACAGTTGCCTGCAA
TTTCGAGATAAATGAACCCAGTATAAAGACTGTTGTAACAAAAGAAAAGAAAATGTGAAACCAT
CAGTGCAGCTATGCCAGCAGGTGTGAAGTCTTGCACTTTTTGCAAAATACAAAATATGAAATAT
GTGTTAATTGACTGTTTATGTTATCTGTAAGGTTTCCACTCAACAATAGGCTATTAGTAGTTAA
GTTTTTGTGGAGTCAAAAATTATACGTGGATT
(SEQ ID NO: 27341) The underlined T has been changed from a G to T at that position so that wild-type CFTR is still transcribed, but the PAM sequence CGG has been modified to CTT to reduce or eliminate Cas9 cleavage at that locus.
In an embodiment, suitable sequence for the cDNA insert of CFTR exons 11 to 27, can be selected from (e.g., includes a portion of) or include the following sequence:
ACTTCACTTCTAATGGTGATTATGGGAGAACTGGAGCCTTCAGAGGGTAAAATTAAGCACAGTG GAAGAATTTCATTCTGTTCTCAGTTTTCCTGGATTATGCCTGGCACCATTAAAGAAAATATCAT CTTTGGTGTTTCCTATGATGAATATAGATACAGAAGCGTCATCAAAGCATGCCAACTAGAAGAG GACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTTGGAGAAGGTGGAATCACACTGAGTG GAGGTCAACGAGCAAGAATTTCTTTAGCAAGAGCAGTATACAAAGATGCTGATTTGTATTTATT AGACTCTCCTTTTGGATACCTAGATGTTTTAACAGAAAAAGAAATATTTGAAAGCTGTGTCTGT AAACTGATGGCTAACAAAACTAGGATTTTGGTCACTTCTAAAATGGAACATTTAAAGAAAGCTG ACAAAATATTAATTTTGCATGAAGGTAGCAGCTATTTTTATGGGACATTTTCAGAACTCCAAAA TCTACAGCCAGACTTTAGCTCAAAACTCATGGGATGTGATTCTTTCGACCAATTTAGTGCAGAA AGAAGAAATTCAATCCTAACTGAGACCTTACACCGTTTCTCATTAGAAGGAGATGCTCCTGTCT CCTGGACAGAAACAAAAAAACAATCTTTTAAACAGACTGGAGAGTTTGGGGAAAAAAGGAAGAA TTCTATTCTCAATCCAATCAACTCTATACGAAAATTTTCCATTGTGCAAAAGACTCCCTTACAA ATGAATGGCATCGAAGAGGATTCTGATGAGCCTTTAGAGAGAAGGCTGTCCTTAGTACCAGATT CTGAGCAGGGAGAGGCGATACTGCCTCGCATCAGCGTGATCAGCACTGGCCCCACGCTTCAGGC ACGAAGGAGGCAGTCTGTCCTGAACCTGATGACACACTCAGTTAACCAAGGTCAGAACATTCAC CGAAAGACAACAGCATCCACACGAAAAGTGTCACTGGCCCCTCAGGCAAACTTGACTGAACTGG ATATATATTCAAGAAGGTTATCTCAAGAAACTGGCTTGGAAATAAGTGAAGAAATTAACGAAGA AGACTTAAAGGAGTGCTTTTTTGATGATATGGAGAGCATACCAGCAGTGACTACATGGAACACA TACCTTCGATATATTACTGTCCACAAGAGCTTAATTTTTGTGCTAATTTGGTGCTTAGTAATTT TTCTGGCAGAGGTGGCTGCTTCTTTGGTTGTGCTGTGGCTCCTTGGAAACACTCCTCTTCAAGA CAAAGGGAATAGTACTCATAGTAGAAATAACAGCTATGCAGTGATTATCACCAGCACCAGTTCG TATTATGTGTTTTACATTTACGTGGGAGTAGCCGACACTTTGCTTGCTATGGGATTCTTCAGAG GTCTACCACTGGTGCATACTCTAATCACAGTGTCGAAAATTTTACACCACAAAATGTTACATTC TGTTCTTCAAGCACCTATGTCAACCCTCAACACGTTGAAAGCAGGTGGGATTCTTAATAGATTC TCCAAAGATATAGCAATTTTGGATGACCTTCTGCCTCTTACCATATTTGACTTCATCCAGTTGT TATTAATTGTGATTGGAGCTATAGCAGTTGTCGCAGTTTTACAACCCTACATCTTTGTTGCAAC AGTGCCAGTGATAGTGGCTTTTATTATGTTGAGAGCATATTTCCTCCAAACCTCACAGCAACTC AAACAACTGGAATCTGAAGGCAGGAGTCCAATTTTCACTCATCTTGTTACAAGCTTAAAAGGAC
TATGGACACTTCGTGCCTTCGGACGGCAGCCTTACTTTGAAACTCTGTTCCACAAAGCTCTGAA
TTTACATACTGCCAACTGGTTCTTGTACCTGTCAACACTGCGCTGGTTCCAAATGAGAATAGAA
ATGATTTTTGTCATCTTCTTCATTGCTGTTACCTTCATTTCCATTTTAACAACAGGAGAAGGAG
AAGGAAGAGTTGGTATTATCCTGACTTTAGCCATGAATATCATGAGTACATTGCAGTGGGCTGT
AAACTCCAGCATAGATGTGGATAGCTTGATGCGATCTGTGAGCCGAGTCTTTAAGTTCATTGAC
ATGCCAACAGAAGGTAAACCTACCAAGTCAACCAAACCATACAAGAATGGCCAACTCTCGAAAG
TTATGATTATTGAGAATTCACACGTGAAGAAAGATGACATCTGGCCCTCAGGGGGCCAAATGAC
TGTCAAAGATCTCACAGCAAAATACACAGAAGGTGGAAATGCCATATTAGAGAACATTTCCTTC
TCAATAAGTCCTGGCCAGAGGGTGGGCCTCTTGGGAAGAACTGGATCAGGGAAGAGTACTTTGT
TATCAGCTTTTTTGAGACTACTGAACACTGAAGGAGAAATCCAGATCGATGGTGTGTCTTGGGA
TTCAATAACTTTGCAACAGTGGAGGAAAGCCTTTGGAGTGATACCACAGAAAGTATTTATTTTT
TCTGGAACATTTAGAAAAAACTTGGATCCCTATGAACAGTGGAGTGATCAAGAAATATGGAAAG
TTGCAGATGAGGTTGGGCTCAGATCTGTGATAGAACAGTTTCCTGGGAAGCTTGACTTTGTCCT
TGTGGATGGGGGCTGTGTCCTAAGCCATGGCCACAAGCAGTTGATGTGCTTGGCTAGATCTGTT
CTCAGTAAGGCGAAGATCTTGCTGCTTGATGAACCCAGTGCTCATTTGGATCCAGTAACATACC
AAATAATTAGAAGAACTCTAAAACAAGCATTTGCTGATTGCACAGTAATTCTCTGTGAACACAG
GATAGAAGCAATGCTGGAATGCCAACAATTTTTGGTCATAGAAGAGAACAAAGTGCGGCAGTAC
GATTCCATCCAGAAACTGCTGAACGAGAGGAGCCTCTTCCGGCAAGCCATCAGCCCCTCCGACA
GGGTGAAGCTCTTTCCCCACCGGAACTCAAGCAAGTGCAAGTCTAAGCCCCAGATTGCTGCTCT
GAAAGAGGAGACAGAAGAAGAGGTGCAAGATACAAGGCTTTAG
(SEQ ID NO: 27342)
In an embodiment, to insert CFTR cDNA (e.g., CFTR exons 11 to 27) into intron 10, and concomitantly introduce a silent mutation to disrupt subsequent Cas9 binding and cleavage, the homology arms, e.g., the 5' and 3' homology arms, may be shorted to approximately 500bp. The 5' homology arm is shown as bold sequence, the CRISPR-Cas9 binding site is shown as italicized sequence, the PAM site is underlined, the silent sense mutation in the PAM is shown as lower case underlined sequence, and the 3' homology arm is shown as no emphasis capitalized sequence.
GATGGTGGCTTGATCCAGGTAGTAGTGGAAGTAGTATAGTAGGAAGTGATCAGATTCAGGACAT GCTTTGAAGGAAGATCCAATAGGATTAATGGATAAGTTGAACAATGGCATATGAGAAAAGTCAC AGAGGAGTCAAAGATGATTCCAAGCTTTCTGGACTGAGTAACTGGAAGGATAAATGTGCCGTTT
ACTAGAAAGATAATGGGAGAAACAGGTTTTGGATGGAGCTTGGTTTGGGAATATTAAGTTTGAA
ATGCCTATTTGACATCCAAATAGAGATGTTAGTTGGATGTACAAGTCTAGTTTCAAGGAAGAGG
GGGCTGGTAGTGTGAAGATGGGGCTGGATAAGATTCTAAAGGAAAGAGGGTTGATAAGAAGAGA
AAGGGGTGTAGGGGTTAGCCTAAGGGCATTCTAAGTATTAGAGGTTAAGGAGGTGGGTGAAGAA
AACCCAATAAAATAAAAGTCTGAGAAGACAAAGCTAGrGAA TGAA TGTGGTA TCCCtt AACCCA
ACTGATGTCAAGCAGAAGGGTGTTATCAACTAGGTCAAATGCTCATTCATCAAGTAAGATGAAA
CTGTTATAATTAACCGGTGTCTTCTGAAATACGGAGATAACTCGTGACTTAATGAAAGCAATAG
TAGAGAAGGTCAAACTTGACCAGAATGAAATTAGAAAGAATAAGAGGAAAGAAAAGACCAAATA
CAGACAACCATTGATGCCTTATTCTTTTGATATACTCCTGGAGTCCACTTGCTAATACAATTGA
CCCTTAAACAATACAGGCTTGAACTGCATGGGTCCACTTATTTGTGAATTTTTTTTCAGTTAAT
ACATTGGAAAATTTTTGGGGTTTTTTGACAATTTGAAAAAACTCACAAACTGTCTAGCCTAGAA
ATACCGAGAAAATTAAGAAAAAGTAAGATATGCCATGAATGCATAAAATATATGTAGACACTAG
CCTATTTTATCATTTGCTACTATAAAATATACACAATCTA
(SEQ ID NO: 27343)
The underlined T has been changed from a G to T at that position so that wild-type CFTR is still transcribed, but the PAM sequence CGG has been modified to CTT to reduce or eliminate Cas9 cleavage at that locus.
V.2 NHEJ Approaches for Gene Targeting
As described herein, nuclease-induced non-homologous end-joining (NHEJ) can be used to target gene-specific knockouts. Nuclease-induced NHEJ can also be used to remove (e.g., delete) sequence insertions in a gene of interest.
While not wishing to be bound by theory, it is believed that, in an embodiment, the genomic alterations associated with the methods described herein rely on nuclease-induced NHEJ and the error-prone nature of the NHEJ repair pathway. NHEJ repairs a double-strand break in the DNA by joining together the two ends; however, generally, the original sequence is restored only if two compatible ends, exactly as they were formed by the double-strand break, are perfectly ligated. The DNA ends of the double-strand break are frequently the subject of enzymatic processing, resulting in the addition or removal of nucleotides, at one or both strands, prior to rejoining of the ends. This results in the presence of insertion and/or deletion (indel) mutations in the DNA sequence at the site of the NHEJ repair. Two-thirds of these mutations typically alter the reading frame and, therefore, produce a non-functional protein. Additionally, mutations that maintain the reading frame, but which insert or delete a significant amount of sequence, can destroy functionality of the protein. This is locus dependent as mutations in critical functional domains are likely less tolerable than mutations in non-critical regions of the protein.
The indel mutations generated by NHEJ are unpredictable in nature; however, at a given break site certain indel sequences are favored and are over represented in the population, likely due to small regions of microhomology. The lengths of deletions can vary widely; most commonly in the 1-50 bp range, but they can easily reach greater than 100-200 bp. Insertions tend to be shorter and often include short duplications of the sequence immediately surrounding the break site. However, it is possible to obtain large insertions, and in these cases, the inserted sequence has often been traced to other regions of the genome or to plasmid DNA present in the cells.
Because NHEJ is a mutagenic process, it can also be used to delete small sequence motifs as long as the generation of a specific final sequence is not required. If a double- strand break is targeted near to a short target sequence, the deletion mutations caused by the NHEJ repair often span, and therefore remove, the unwanted nucleotides. For the deletion of larger DNA segments, introducing two double-strand breaks, one on each side of the sequence, can result in NHEJ between the ends with removal of the entire intervening sequence. Both of these approaches can be used to delete specific DNA sequences; however, the error-prone nature of NHEJ may still produce indel mutations at the site of repair.
Both double strand cleaving eaCas9 molecules and single strand, or nickase, eaCas9 molecules can be used in the methods and compositions described herein to generate NHEJ- mediated indels. NHEJ-mediated indels targeted to the gene, e.g., a coding region, e.g., an early coding region of a gene of interest can be used to knockout (i.e., eliminate expression of) a gene of interest. For example, early coding region of a gene of interest includes sequence
immediately following a transcription start site, within a first exon of the coding sequence, or within 500 bp of the transcription start site (e.g., less than 500, 450, 400, 350, 300, 250, 200, 150, 100 or 50 bp). Placement of double strand or single strand breaks relative to the target position In an embodiment, in which a gRNA and Cas9 nuclease generate a double strand break for the purpose of inducing NHEJ-mediated indels, a gRNA, e.g., a unimolecular (or chimeric) or modular gRNA molecule, is configured to position one double-strand break in close proximity to a nucleotide of the target position. In an embodiment, the cleavage site is between 0-30 bp away from the target position (e.g., less than 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 bp from the target position).
In an embodiment, in which two gRNAs complexing with Cas9 nickases induce two single strand breaks for the purpose of inducing NHEJ-mediated indels, two gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to position two single-strand breaks to provide for NHEJ repair a nucleotide of the target position. In an embodiment, the gRNAs are configured to position cuts at the same position, or within a few nucleotides of one another, on different strands, essentially mimicking a double strand break. In an embodiment, the closer nick is between 0-30 bp away from the target position (e.g., less than 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 bp from the target position), and the two nicks are within 25-55 bp of each other (e.g., between 25 to 50, 25 to 45, 25 to 40, 25 to 35, 25 to 30, 50 to 55, 45 to 55, 40 to 55, 35 to 55, 30 to 55, 30 to 50, 35 to 50, 40 to 50 , 45 to 50, 35 to 45, or 40 to 45 bp) and no more than 100 bp away from each other (e.g., no more than 90, 80, 70, 60, 50, 40, 30, 20 or 10 bp). In an embodiment, the gRNAs are configured to place a single strand break on either side of a nucleotide of the target position.
Both double strand cleaving eaCas9 molecules and single strand, or nickase, eaCas9 molecules can be used in the methods and compositions described herein to generate breaks both sides of a target position. Double strand or paired single strand breaks may be generated on both sides of a target position to remove the nucleic acid sequence between the two cuts (e.g., the region between the two breaks in deleted). In one embodiment, two gRNAs, e.g.,
independently, unimolecular (or chimeric) or modular gRNA, are configured to position a double-strand break on both sides of a target position. In an alternate embodiment, three gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to position a double strand break (i.e., one gRNA complexes with a cas9 nuclease) and two single strand breaks or paired single stranded breaks (i.e., two gRNAs complex with Cas9 nickases) on either side of the target position. In another embodiment, four gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to generate two pairs of single stranded breaks (i.e., two pairs of two gRNAs complex with Cas9 nickases) on either side of the target position. The double strand break(s) or the closer of the two single strand nicks in a pair will ideally be within 0-500 bp of the target position (e.g., no more than 450, 400, 350, 300, 250, 200, 150, 100, 50 or 25 bp from the target position). When nickases are used, the two nicks in a pair are within 25-55 bp of each other (e.g., between 25 to 50, 25 to 45, 25 to 40, 25 to 35, 25 to 30, 50 to 55, 45 to 55, 40 to 55, 35 to 55, 30 to 55, 30 to 50, 35 to 50, 40 to 50 , 45 to 50, 35 to 45, or 40 to 45 bp) and no more than 100 bp away from each other (e.g., no more than 90, 80, 70, 60, 50, 40, 30, 20 or 10 bp).
V.3 Single- Strand Annealing
Single strand annealing (SSA) is another DNA repair process that repairs a double-strand break between two repeat sequences present in a target nucleic acid. Repeat sequences utilized by the SSA pathway are generally greater than 30 nucleotides in length. Resection at the break ends occurs to reveal repeat sequences on both strands of the target nucleic acid. After resection, single strand overhangs containing the repeat sequences are coated with RPA protein to prevent the repeats sequences from inappropriate annealing, e.g., to themselves. RAD52 binds to and each of the repeat sequences on the overhangs and aligns the sequences to enable the annealing of the complementary repeat sequences. After annealing, the single-strand flaps of the overhangs are cleaved. New DNA synthesis fills in any gaps, and ligation restores the DNA duplex. As a result of the processing, the DNA sequence between the two repeats is deleted. The length of the deletion can depend on many factors including the location of the two repeats utilized, and the pathway or processivity of the resection.
In contrast to HDR pathways, SSA does not require a template nucleic acid to alter or correct a target nucleic acid sequence. Instead, the complementary repeat sequence is utilized.
V. 4 Other DNA Repair Pathways
SSBR (single strand break repair)
Single- stranded breaks (SSB) in the genome are repaired by the SSBR pathway, which is a distinct mechanism from the DSB repair mechanisms discussed above. The SSBR pathway has four major stages: SSB detection, DNA end processing, DNA gap filling, and DNA ligation. A more detailed explanation is given in Caldecott, Nature Reviews Genetics 9, 619-631 (August 2008), and a summary is given here.
In the first stage, when a SSB forms, PARP1 and/or PARP2 recognize the break and recruit repair machinery. The binding and activity of PARP1 at DNA breaks is transient and it seems to accelerate SSBr by promoting the focal accumulation or stability of SSBr protein complexes at the lesion. Arguably the most important of these SSBr proteins is XRCCl, which functions as a molecular scaffold that interacts with, stabilizes, and stimulates multiple enzymatic components of the SSBr process including the protein responsible for cleaning the DNA 3' and 5' ends. For instance, XRCCl interacts with several proteins (DNA polymerase beta, PNK, and three nucleases, APE1, APTX, and APLF) that promote end processing. APE1 has endonuclease activity. APLF exhibits endonuclease and 3' to 5' exonuclease activities. APTX has endonuclease and 3' to 5' exonuclease activity.
This end processing is an important stage of SSBR since the 3'- and/or 5 '-termini of most, if not all, SSBs are 'damaged'. End processing generally involves restoring a damaged 3'- end to a hydroxylated state and and/or a damaged 5' end to a phosphate moiety, so that the ends become ligation-competent. Enzymes that can process damaged 3' termini include PNKP, APE1, and TDP1. Enzymes that can process damaged 5' termini include PNKP, DNA polymerase beta, and APTX. LIG3 (DNA ligase III) can also participate in end processing. Once the ends are cleaned, gap filling can occur.
At the DNA gap filling stage, the proteins typically present are PARP1, DNA polymerase beta, XRCCl, FEN1 (flap endonculease 1), DNA polymerase delta/epsilon, PCNA, and LIG1. There are two ways of gap filling, the short patch repair and the long patch repair. Short patch repair involves the insertion of a single nucleotide that is missing. At some SSBs, "gap filling" might continue displacing two or more nucleotides (displacement of up to 12 bases have been reported). FEN1 is an endonuclease that removes the displaced 5'-residues. Multiple DNA polymerases, including Pol β , are involved in the repair of SSBs, with the choice of DNA polymerase influenced by the source and type of SSB.
In the fourth stage, a DNA ligase such as LIG1 (Ligase I) or LIG3 (Ligase III) catalyzes joining of the ends. Short patch repair uses Ligase III and long patch repair uses Ligase I.
Sometimes, SSBR is replication-coupled. This pathway can involve one or more of CtIP, MRN, ERCC1, and FEN1. Additional factors that may promote SSBR include: aPARP, PARP1, PARP2, PARG, XRCC1, DNA polymerase b, DNA polymerase d, DNA polymerase e, PCNA, LIGl, PNK, PNKP, APEl, APTX, APLF, TDPl, LIG3, FENl, CtIP, MRN, and ERCCl.
MMR (mismatch repair)
Cells contain three excision repair pathways: MMR, BER, and NER. The excision repair pathways hace a common feature in that they typically recognize a lesion on one strand of the DNA, then exo/endonucleaseases remove the lesion and leave a 1-30 nucleotide gap that is sub- sequentially filled in by DNA polymerase and finally sealed with ligase. A more complete picture is given in Li, Cell Research (2008) 18:85-98, and a summary is provided here.
Mismatch repair (MMR) operates on mispaired DNA bases.
The MSH2/6 or MSH2/3 complexes both have ATPases activity that plays an important role in mismatch recognition and the initiation of repair. MSH2/6 preferentially recognizes base- base mismatches and identifies mispairs of 1 or 2 nucleotides, while MSH2/3 preferentially recognizes larger ID mispairs.
hMLHl heterodimerizes with hPMS2 to form hMutL which possesses an ATPase activity and is important for multiple steps of MMR. It possesses a PCNA/replication factor C (RFC)-dependent endonuclease activity which plays an important role in 3 ' nick-directed MMR involving EXOl. (EXOl is a participant in both HR and MMR.) It regulates termination of mismatch-provoked excision. Ligase I is the relevant ligase for this pathway. Additional factors that may promote MMR include: EXOl, MSH2, MSH3, MSH6, MLH1, PMS2, MLH3, DNA Pol d, RPA, HMGB1, RFC, and DNA ligase I.
Base excision repair (BER)
The base excision repair (BER) pathway is active throughout the cell cycle; it is responsible primarily for removing small, non-helix-distorting base lesions from the genome. In contrast, the related Nucleotide Excision Repair pathway (discussed in the next section) repairs bulky helix-distorting lesions. A more detailed explanation is given in Caldecott, Nature
Reviews Genetics 9, 619-631 (August 2008), and a summary is given here.
Upon DNA base damage, base excision repair (BER) is initiated and the process can be simplified into five major steps: (a) removal of the damaged DNA base; (b) incision of the subsequent a basic site; (c) clean-up of the DNA ends; (d) insertion of the correct nucleotide into the repair gap; and (e) ligation of the remaining nick in the DNA backbone. These last steps are similar to the SSBR.
In the first step, a damage- specific DNA glycosylase excises the damaged base through cleavage of the N-glycosidic bond linking the base to the sugar phosphate backbone. Then AP endonuclease-1 (APE1) or bifunctional DNA glycosylases with an associated lyase activity incised the phosphodiester backbone to create a DNA single strand break (SSB). The third step of BER involves cleaning-up of the DNA ends. The fourth step in BER is conducted by Pol β that adds a new complementary nucleotide into the repair gap and in the final step
XRCCl/Ligase III seals the remaining nick in the DNA backbone. This completes the short- patch BER pathway in which the majority (-80%) of damaged DNA bases are repaired.
However, if the 57 -ends in step 3 are resistant to end processing activity, following one nucleotide insertion by Pol β there is then a polymerase switch to the replicative DNA polymerases, Pol δ/ε, which then add -2-8 more nucleotides into the DNA repair gap. This creates a 5 ' -flap structure, which is recognized and excised by flap endonuclease-1 (FEN-1) in association with the processivity factor proliferating cell nuclear antigen (PCNA). DNA ligase I then seals the remaining nick in the DNA backbone and completes long-patch BER. Additional factors that may promote the BER pathway include: DNA glycosylase, APE1, Polb, Pold, Pole, XRCC1, Ligase III, FEN-1, PCNA, RECQL4, WRN, MYH, PNKP, and APTX.
Nucleotide excision repair (NER)
Nucleotide excision repair (NER) is an important excision mechanism that removes bulky helix-distorting lesions from DNA. Additional details about NER are given in Marteijn et al., Nature Reviews Molecular Cell Biology 15, 465-481 (2014), and a summary is given here. NER a broad pathway encompassing two smaller pathways: global genomic NER (GG-NER) and transcription coupled repair NER (TC-NER). GG-NER and TC-NER use different factors for recognizing DNA damage. However, they utilize the same machinery for lesion incision, repair, and ligation.
Once damage is recognized, the cell removes a short single- stranded DNA segment that contains the lesion. Endonucleases XPF/ERCC1 and XPG (encoded by ERCC5) remove the lesion by cutting the damaged strand on either side of the lesion, resulting in a single-strand gap of 22-30 nucleotides. Next, the cell performs DNA gap filling synthesis and ligation. Involved in this process are: PCNA, RFC, DNA Pol δ, DNA Pol ε or DNA Pol κ, and DNA ligase I or XRCCl/Ligase III. Replicating cells tend to use DNA pol ε and DNA ligase I, while non- replicating cells tend to use DNA Pol δ, DNA Pol κ, and the XRCC1/ Ligase III complex to perform the ligation step.
NER can involve the following factors: XPA-G, POLH, XPF, ERCC1, XPA-G, and LIG1. Transcription-coupled NER (TC-NER) can involve the following factors: CSA, CSB, XPB, XPD, XPG, ERCC1, and TTDA. Additional factors that may promote the NER repair pathway include XPA-G, POLH, XPF, ERCC1, XPA-G, LIG1, CSA, CSB, XPA, XPB, XPC, XPD, XPF, XPG, TTDA, UVSSA, USP7, CETN2, RAD23B, UV-DDB, CAK subcomplex, RPA, and PCNA.
Interstrand Crosslink (ICL)
A dedicated pathway called the ICL repair pathway repairs interstrand crosslinks.
Interstrand crosslinks, or covalent crosslinks between bases in different DNA strand, can occur during replication or transcription. ICL repair involves the coordination of multiple repair processes, in particular, nucleolytic activity, translesion synthesis (TLS), and HDR. Nucleases are recruited to excise the ICL on either side of the crosslinked bases, while TLS and HDR are coordinated to repair the cut strands. ICL repair can involve the following factors:
endonucleases, e.g., XPF and RAD51C, endonucleases such as RAD51, translesion polymerases, e.g., DNA polymerase zeta and Revl), and the Fanconi anemia (FA) proteins, e.g., FancJ.
Other pathways
Several other DNA repair pathways exist in mammals.
Translesion synthesis (TLS) is a pathway for repairing a single stranded break left after a defective replication event and involves translesion polymerases, e.g., DNA pol and Revl..
Error-free postreplication repair (PRR) is another pathway for repairing a single stranded break left after a defective replication event.
V.5 Targeted Knockdown
Unlike CRISPR/Cas-mediated gene knockout, which permanently eliminates expression by mutating the gene at the DNA level, CRISPR/Cas knockdown allows for temporary reduction of gene expression through the use of artificial transcription factors. Mutating key residues in both DNA cleavage domains of the Cas9 protein (e.g. the DIOA and H840A mutations) results in the generation of a catalytically inactive Cas9 (eiCas9 which is also known as dead Cas9 or dCas9) molecule. A catalytically inactive Cas9 complexes with a gRNA and localizes to the DNA sequence specified by that gRNA's targeting domain, however, it does not cleave the target DNA. Fusion of the dCas9 to an effector domain, e.g., a transcription repression domain, enables recruitment of the effector to any DNA site specified by the gRNA. Although an enzymatically inactive (eiCas9) Cas9 molecule itself can block transcription when recruited to early regions in the coding sequence, more robust repression can be achieved by fusing a transcriptional repression domain (for example KRAB, SID or ERD) to the Cas9 and recruiting it to the target knockdown position, e.g., within lOOObp of sequence 3' of the start codon or within 500 bp of a promoter region 5' of the start codon of a gene. It is likely that targeting DNAsel hypersensitive sites (DHSs) of the promoter may yield more efficient gene repression or activation because these regions are more likely to be accessible to the Cas9 protein and are also more likely to harbor sites for endogenous transcription factors. Especially for gene repression, it is contemplated herein that blocking the binding site of an endogenous transcription factor would aid in downregulating gene expression. In an embodiment, one or more eiCas9 molecules may be used to block binding of one or more endogenous transcription factors. In another embodiment, an eiCas9 molecule can be fused to a chromatin modifying protein. Altering chromatin status can result in decreased expression of the target gene. One or more eiCas9 molecules fused to one or more chromatin modifying proteins may be used to alter chromatin status.
In an embodiment, a gRNA molecule can be targeted to a known transcription response elements (e.g., promoters, enhancers, etc.), a known upstream activating sequences (UAS), and/or sequences of unknown or known function that are suspected of being able to control expression of the target DNA.
CRISPR/Cas-mediated gene knockdown can be used to reduce expression of an unwanted allele or transcript. Contemplated herein are scenarios wherein permanent destruction of the gene is not ideal. In these scenarios, site-specific repression may be used to temporarily reduce or eliminate expression. It is also contemplated herein that the off-target effects of a Cas- repressor may be less severe than those of a Cas-nuclease as a nuclease can cleave any DNA sequence and cause mutations whereas a Cas-repressor may only have an effect if it targets the promoter region of an actively transcribed gene. However, while nuclease-mediated knockout is permanent, repression may only persist as long as the Cas-repressor is present in the cells. Once the repressor is no longer present, it is likely that endogenous transcription factors and gene regulatory elements would restore expression to its natural state.
V.6 Examples of gRNAs in Genome Editing Methods
gRNA molecules as described herein can be used with Cas9 molecules that generate a double strand break or a single strand break to alter the sequence of a target nucleic acid, e.g., a target position or target genetic signature. gRNA molecules useful in these methods are described below.
In an embodiment, the gRNA, e.g., a chimeric gRNA, is configured such that it comprises one or more of the following properties;
a) it can position, e.g., when targeting a Cas9 molecule that makes double strand breaks, a double strand break (i) within 50, 100, 150 or 200 nucleotides of a target position, or (ii) sufficiently close that the target position is within the region of end resection;
b) it has a targeting domain of at least 17 nucleotides, e.g., a targeting domain of (i) 17, (ii) 18, or (iii) 20 nucleotides; and
c)
(i) the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from a naturally occurring S.
pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail and proximal domain, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom;
(ii) there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom; (iii) there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain, e.g., at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S.
thermophilus , S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides therefrom;
iv) the tail domain is at least 10, 15, 20, 25, 30, 35 or 40 nucleotides in length, e.g., it comprises at least 10, 15, 20, 25, 30, 35 or 40 nucleotides from a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain; or, or a sequence that differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides therefrom; or
(v) the tail domain comprises 15, 20, 25, 30, 35, 40 nucleotides or all of the corresponding portions of a naturally occurring tail domain, e.g., a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain.
In an embodiment, the gRNA is configured such that it comprises properties: a and b(i).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(ii).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(iii).
In an embodiment, the gRNA is configured such that it comprises properties: a and c.
In an embodiment, the gRNA is configured such that in comprises properties: a, b, and c.
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(i), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(i), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(iii), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(iii), and c(ii).
In an embodiment, the gRNA, e.g., a chimeric gRNA, is configured such that it comprises one or more of the following properties; a) it can position, e.g., when targeting a Cas9 molecule that makes single strand breaks, a single strand break (i) within 50, 100, 150 or 200 nucleotides of a target position, or (ii) sufficiently close that the target position is within the region of end resection;
b) it has a targeting domain of at least 17 nucleotides, e.g., a targeting domain of (i) 17, (ii) 18, or (iii) 20 nucleotides; and
c)
(i) the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from a naturally occurring S.
pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail and proximal domain, or a sequence that differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides therefrom;
(ii) there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides therefrom;
(iii) there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain, e.g., at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S.
thermophilus, S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom;
iv) the tail domain is at least 10, 15, 20, 25, 30, 35 or 40 nucleotides in length, e.g., it comprises at least 10, 15, 20, 25, 30, 35 or 40 nucleotides from a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain; or, a sequence that differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides therefrom; or (v) the tail domain comprises 15, 20, 25, 30, 35, 40 nucleotides or all of the corresponding portions of a naturally occurring tail domain, e.g., a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain.
In an embodiment, the gRNA is configured such that it comprises properties: a and b(i).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(ii).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(iii).
In an embodiment, the gRNA is configured such that it comprises properties: a and c.
In an embodiment, the gRNA is configured such that in comprises properties: a, b, and c.
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(i), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(i), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(iii), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(iii), and c(ii).
In an embodiment, the gRNA is used with a Cas9 nickase molecule having HNH activity, e.g., a Cas9 molecule having the RuvC activity inactivated, e.g., a Cas9 molecule having a mutation at D10, e.g., the D10A mutation.
In an embodiment, the gRNA is used with a Cas9 nickase molecule having RuvC activity, e.g., a Cas9 molecule having the HNH activity inactivated, e.g., a Cas9 molecule having a mutation at H840, e.g., a H840A.
In an embodiment, the gRNAs are used with a Cas9 nickase molecule having RuvC activity, e.g., a Cas9 molecule having the HNH activity inactivated, e.g., a Cas9 molecule having a mutation at N863, e.g., an N863A mutation.
In an embodiment, a pair of gRNAs, e.g., a pair of chimeric gRNAs, comprising a first and a second gRNA, is configured such that they comprises one or more of the following properties;
a) one or both of the gRNAs can position, e.g., when targeting a Cas9 molecule that makes single strand breaks, a single strand break within (i) 50, 100, 150 or 200 nucleotides of a target position, or (ii) sufficiently close that the target position is within the region of end resection;
b) one or both have a targeting domain of at least 17 nucleotides, e.g., a targeting domain of (i) 17 or (ii) 18 nucleotides;
c) for one or both:
(i) the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from a naturally occurring S.
pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail and proximal domain, or a sequence that differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides therefrom;
(ii) there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides therefrom;
(iii) there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain, e.g., at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S.
thermophilus, S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom;
iv) the tail domain is at least 10, 15, 20, 25, 30, 35 or 40 nucleotides in length, e.g., it comprises at least 10, 15, 20, 25, 30, 35 or 40 nucleotides from a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain; or, or a sequence that differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides therefrom; or (v) the tail domain comprises 15, 20, 25, 30, 35, 40 nucleotides or all of the corresponding portions of a naturally occurring tail domain, e.g., a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain; d) the gRNAs are configured such that, when hybridized to target nucleic acid, they are separated by 0-50, 0-100, 0-200, at least 10, at least 20, at least 30 or at least 50 nucleotides; e) the breaks made by the first gRNA and second gRNA are on different strands; and f) the PAMs are facing outwards.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(iii).
In an embodiment, one or both of the gRNAs configured such that it comprises properties: a and c.
In an embodiment, one or both of the gRNAs is configured such that in comprises properties: a, b, and c.
In an embodiment, one or both of the gRNAs is configured such that in comprises properties: a(i), b(i), and c(i).
In an embodiment, one or both of the gRNAs is configured such that in comprises properties: a(i), b(i), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that in comprises properties: a(i), b(i), c, and d.
In an embodiment, one or both of the gRNAs is configured such that in comprises properties: a(i), b(i), c, and e.
In an embodiment, one or both of the gRNAs is configured such that in comprises properties: a(i), b(i), c, d, and e.
In an embodiment, one or both of the gRNAs is configured such that in comprises properties: a(i), b(iii), and c(i).
In an embodiment, one or both of the gRNAs is configured such that in comprises properties: a(i), b(iii), and c(ii). In an embodiment, one or both of the gRNAs is configured such that in comprises properties: a(i), b(iii), c, and d.
In an embodiment, one or both of the gRNAs is configured such that in comprises properties: a(i), b(iii), c, and e.
In an embodiment, one or both of the gRNAs is configured such that in comprises properties: a(i), b(iii), c, d, and e.
In an embodiment, the gRNAs are used with a Cas9 nickase molecule having HNH activity, e.g., a Cas9 molecule having the RuvC activity inactivated, e.g., a Cas9 molecule having a mutation at D 10, e.g., the D10A mutation.
In an embodiment, the gRNAs are used with a Cas9 nickase molecule having RuvC activity, e.g., a Cas9 molecule having the HNH activity inactivated, e.g., a Cas9 molecule having a mutation at H840, e.g., a H840A.
In an embodiment, the gRNAs are used with a Cas9 nickase molecule having RuvC activity, e.g., a Cas9 molecule having the HNH activity inactivated, e.g., a Cas9 molecule having a mutation at N863, e.g., a N863A mutation.
VI. Target Cells
Cas9 molecules, gRNA molecules (e.g., a Cas9 molecule/gRNA molecule complex), and donor nucleic acids can be used to manipulate a cell, e.g., to edit a target nucleic acid, in a wide variety of cells.
In an embodiment, a cell is manipulated by editing (e.g., correcting or introducing a mutation in) the CFTR and/or SCNN1A target genes, e.g., as described herein. In an
embodiment, the expression of the CFTR and/or SCNN1A target genes is modulated, e.g., in vivo. In another embodiment, the expression of the CFTR and/or SCNN1A target genes is modulated, e.g., ex vivo.
The Cas9 and gRNA molecules described herein can be delivered to a target cell.
Methods and compositions discussed herein, provide for treating or delaying the onset or progression of diseases of the lung and airways, including the nose, trachea, bronchus, bronchioles, alveoli, submucosal ducts and submucosal glands. In an embodiment, the target cell is an airway cell, e.g., a nasal epithelial cell, e.g., a tracheal epithelial cell. In an embodiment, the target cell is a lung epithelial cell, e.g., a bronchial epithelial cell, e.g., a proximal bronchial epithelial cell, e.g., a bronchiolar epithelial cell, e.g., an alveolar epithelial cell, e.g., a clara cell, e.g., a ciliated cell, e.g., a goblet cell, e.g., a basal cell, e.g., an acinus cell. Methods and compositions discussed herein, provide for treating or delaying the onset or progression of diseases of the gastrointestinal tract, including pancreas, bile ducts, gallbladder, small intestine, large intestine and salivary glands. In an embodiment, the target cell is a gastrointestinal epithelial cell. In an embodiment, the target cell is a biliary epithelial cell. In an embodiment, the target cell is a pancreatic ductal epithelial cell. In an embodiment, the target cell is a gastrointestinal cell, e.g., an enteroendocrine cell, e.g., a Brunner's gland cell. In an
embodiment, the target cell is a hepatobiliary epithelial cell. In an embodiment, the target cell is a gallbladder epithelial cell. In an embodiment, the target cell is a large intestine epithelial cell. In an embodiment, the target cell is a small intestine epithelial cell. In an embodiment, the target cell is a jejunum epithelial cell. In an embodiment, the target cell is an epithelial cell of the iluem. In an embodiment, the target cell is a duodenum epithelial cell. Methods and
compositions discussed herein, provide for treating or delaying the onset or progression of diseases of the reproductive tract, including the epididymis. In an embodiment, the target cell is a reproductive epithelial cell, e.g. an epididymal epithelial cell. In an embodiment, the target cell is a pulmonary stem cell. In an embodiment, the target cell is a gastrointestinal stem cell.
In an embodiment, the target cell is manipulated ex vivo by editing (e.g., correcting or introducing a mutation in) the CFTR and/or SCNN1A target genes and/or modulating the expression of the CFTR and/or SCNN1A target genes, and administered to the subject. A suitable cell for such manipulation can include a stem cell such as, by way of example, an embryonic stem cell, an induced pluripotent stem cell, a pulmonary stem cell, a gastrointestinal stem cell and a mesenchymal stem cell. In an embodiment, the cell is an induced pluripotent stem cell (iPS) cell or a cell derived from an iPS cell, e.g., an iPS cell generated from the subject, modified to correct or introduce the mutation and differentiated into a clinically relevant cell such as a pulmonary stem cell, a gastrointestinal stem cell, a pulmonary epithelial cell, a bronchial epithelial cell, a proximal bronchial epithelial cell, a bronchiolar epithelial cell, an alveolar epithelial cell, a clara cell, a ciliated cell, a goblet cell, a basal cell, an acinus cell, a gastrointestinal epithelial cell, a biliary epithelial cell, a pancreatic ductal epithelial cell, a hepatobiliary epithelial cell, an enteroendocrine cell, a Brunner' s gland cell, a reproductive epithelial cell, or an epididymal epithelial cell. VII. Delivery, Formulations and Routes of Administration
The components, e.g., a Cas9 molecule and gRNA molecule (e.g., a Cas9
molecule/gRNA molecule complex), and a donor template nucleic acid can be delivered or formulated in a variety of forms, see, e.g., Tables 56-57. In an embodiment, one Cas9 molecule and two or more (e.g., 2, 3, 4, or more) different gRNA molecules are delivered, e.g., by an AAV vector. In an embodiment, the sequence encoding the Cas9 molecule and the sequence(s) encoding the two or more (e.g., 2, 3, 4, or more) different gRNA molecules are present on the same nucleic acid molecule, e.g., an AAV vector. When a Cas9 or gRNA component is encoded as DNA for delivery, the DNA will typically but not necessarily include a control region, e.g., comprising a promoter, to effect expression. Useful promoters for Cas9 molecule sequences include CMV, EFS, EF-la, MSCV, PGK, CAG control promoters. In an embodiment, the promoter is a constitutive promoter. In another embodiment, the promoter is a tissue specific promoter. Useful promoters for gRNAs include HI, 7SK, tRNA and U6 promoters. Promoters with similar or dissimilar strengths can be selected to tune the expression of components.
Sequences encoding a Cas9 molecule can comprise a nuclear localization signal (NLS), e.g., an SV40 NLS. In an embodiment, the sequence encoding a Cas9 molecule comprises at least two nuclear localization signals. In an embodiment a promoter for a Cas9 molecule or a gRNA molecule can be, independently, inducible, tissue specific, or cell specific.
Table 56 provides examples of how the components can be formulated, delivered, or administered.
Table 56
Figure imgf001732_0001
encoded on separate molecules. In this
embodiment, the donor template is provided on the same DNA molecule that encodes the gRNA.
DNA DNA In this embodiment, a Cas9 molecule, typically an eaCas9 molecule, and a gRNA are transcribed from DNA, here from a single molecule. In this embodiment, the donor template is provided as a separate DNA molecule.
DNA 1 DNA 1 DNA In this embodiment, a Cas9 molecule, typically an eaCas9 molecule, and a gRNA are transcribed from DNA. In this embodiment, they are encoded on separate molecules. In this embodiment, the donor template is provided on the same DNA molecule that encodes the Cas9.
DNA RNA DNA In this embodiment, a Cas9 molecule, typically an eaCas9 molecule, is transcribed from DNA, and a gRNA is provided as in vitro transcribed or synthesized RNA. In this embodiment, the donor template is provided as a separate DNA molecule.
DNA RNA DNA In this embodiment, a Cas9 molecule, typically an eaCas9 molecule, is transcribed from DNA, and a gRNA is provided as in vitro transcribed or synthesized RNA. In this embodiment, the donor template is provided on the same DNA molecule that encodes the Cas9.
mRNA RNA DNA In this embodiment, a Cas9 molecule, typically an eaCas9 molecule, is translated from in vitro transcribed mRNA, and a gRNA is provided as in vitro transcribed or synthesized RNA. In this embodiment, the donor template is provided as a DNA molecule.
mRNA DNA DNA In this embodiment, a Cas9 molecule, typically an eaCas9 molecule, is translated from in vitro transcribed mRNA, and a gRNA is transcribed from DNA. In this embodiment, the donor template is provided as a separate DNA molecule.
mRNA Dl ^A In this embodiment, a Cas9 molecule, typically an eaCas9 molecule, is translated from in vitro transcribed mRNA, and a gRNA is transcribed from DNA. In this embodiment, the donor template is provided on the same DNA molecule that encodes the gRNA.
Protein DNA DNA In this embodiment, a Cas9 molecule, typically an eaCas9 molecule, is provided as a protein, and a gRNA is transcribed from DNA. In this
embodiment, the donor template is provided as a separate DNA molecule.
Protein Dl In this embodiment, a Cas9 molecule, typically an eaCas9 molecule, is provided as a protein, and a gRNA is transcribed from DNA. In this embodiment, the donor template is provided on the same DNA molecule that encodes the gRNA.
Protein RNA DNA In this embodiment, an eaCas9 molecule is
provided as a protein, and a gRNA is provided as transcribed or synthesized RNA. In this embodiment, the donor template is provided as a DNA molecule.
Table 57 summarizes various delivery methods for the components of a Cas system, e.g., the Cas9 molecule component and the gRNA molecule component, as described herein.
Table 57
Figure imgf001734_0001
Polymeric YES Transient Depends on Nucleic Acids
Nanoparticles what is and Proteins
delivered
Biological Attenuated YES Transient NO Nucleic Acids
Non-Viral Bacteria
Delivery Engineered YES Transient NO Nucleic Acids
Vehicles Bacteriophages
Mammalian YES Transient NO Nucleic Acids
Virus-like
Particles
Biological YES Transient NO Nucleic Acids liposomes:
Erythrocyte
Ghosts and
Exosomes
DNA-based Delivery of a Cas9 molecule and/or one or more gRNA molecule
Nucleic acids encoding Cas9 molecules (e.g., eaCas9 molecules), gRNA molecules, a donor template nucleic acid, or a combination thereof , can be administered to subjects or delivered into cells by art-known methods or as described herein. For example, Cas9-encoding and/or gRNA-encoding DNA, as well as donor nucleic acids can be delivered, e.g., by vectors (e.g., viral or non-viral vectors), non-vector based methods (e.g., using naked DNA or DNA complexes), or a combination thereof.
DNA encoding Cas9 molecules (e.g., eaCas9 molecules) and/or gRNA molecules, as well as template nucleic acids, can be conjugated to molecules (e.g., N-acetylgalactosamine), thereby promoting uptake by the target cells (e.g., the target cells described herein).
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a vector (e.g., viral vector/virus or plasmid). In some embodiments the donor nucleic acid is delivered by a vector (e.g., a viral vector/virus or plasmid).
A vector can comprise a sequence that encodes a Cas9 molecule and/or a gRNA molecule. A vector can comprise a donor nucleic acid. A vector can also comprise a sequence encoding a signal peptide {e.g., for nuclear localization, nucleolar localization, mitochondrial localization), fused, e.g., to a Cas9 molecule sequence. For example, ae vector can comprise a nuclear localization sequence (e.g., from SV40) fused to the sequence encoding the Cas9 molecule. One or more regulatory/control elements, e.g., a promoter, an enhancer, an intron, a polyadenylation signal, a Kozak consensus sequence, internal ribosome entry sites (IRES), a 2A sequence, and splice acceptor or donor can be included in the vectors. In some embodiments, the promoter is recognized by RNA polymerase II (e.g., a CMV promoter). In other embodiments, the promoter is recognized by RNA polymerase III (e.g., a U6 promoter). In some embodiments, the promoter is a regulated promoter (e.g., inducible promoter). In other embodiments, the promoter is a constitutive promoter. In some embodiments, the promoter is a tissue specific promoter. In some embodiments, the promoter is a viral promoter. In other embodiments, the promoter is a non-viral promoter.
In some embodiments, the vector or delivery vehicle is a viral vector (e.g., for generation of recombinant viruses). In some embodiments, the virus is a DNA virus (e.g., dsDNA or ssDNA virus). In other embodiments, the virus is an RNA virus (e.g., an ssRNA virus).
Exemplary viral vectors/viruses include, e.g., retroviruses, lentiviruses, adenovirus, adeno- associated virus (AAV), vaccinia viruses, poxviruses, and herpes simplex viruses.
In some embodiments, the virus infects dividing cells. In other embodiments, the virus infects non-dividing cells. In some embodiments, the virus infects both dividing and non- dividing cells. In some embodiments, the virus can integrate into the host genome. In some embodiments, the virus is engineered to have reduced immunity, e.g., in human. In some embodiments, the virus is replication-competent. In other embodiments, the virus is replication- defective, e.g., having one or more coding regions for the genes necessary for additional rounds of virion replication and/or packaging replaced with other genes or deleted. In some
embodiments, the virus causes transient expression of the Cas9 molecule and/or the gRNA molecule. In other embodiments, the virus causes long-lasting, e.g., at least 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 9 months, 1 year, 2 years, or permanent expression, of the Cas9 molecule and/or the gRNA molecule. The packaging capacity of the viruses may vary, e.g., from at least about 4 kb to at least about 30 kb, e.g., at least about 5 kb, 10 kb, 15 kb, 20 kb, 25 kb, 30 kb, 35 kb, 40 kb, 45 kb, or 50 kb.
In an embodiment, the viral vector recognizes a specific cell type or tissue. For example, the viral vector can be pseudotyped with a different/alternative viral envelope glycoprotein; engineered with a cell type-specific receptor (e.g., genetic modification(s) of one or more viral envelope glycoproteins to incorporate a targeting ligand such as a peptide ligand, a single chain antibody, or a growth factor); and/or engineered to have a molecular bridge with dual specificities with one end recognizing a viral glycoprotein and the other end recognizing a moiety of the target cell surface (e.g., a ligand-receptor, monoclonal antibody, avidin-biotin and chemical conjugation).
Exemplary viral vectors/viruses include, e.g., retroviruses, lentiviruses, adenovirus, adeno-associated virus (AAV), vaccinia viruses, poxviruses, and herpes simplex viruses.
In some embodiments, the Cas9- and/or gRNA-encoding sequence is delivered by a recombinant retrovirus. In some embodiments, the donor nucleic acid is delivered by a recombinant retrovirus. In some embodiments, the retrovirus (e.g., Moloney murine leukemia virus) comprises a reverse transcriptase, e.g., that allows integration into the host genome. In some embodiments, the retrovirus is replication-competent. In other embodiments, the retrovirus is replication-defective, e.g., having one of more coding regions for the genes necessary for additional rounds of virion replication and packaging replaced with other genes, or deleted.
In some embodiments, the Cas9- and/or gRNA-encoding sequence is delivered by a recombinant lentivirus. In some embodiments, the donor nucleic acid is delivered by a recombinant lentivirus. For example, the lentivirus is replication-defective, e.g., does not comprise one or more genes required for viral replication.
In some embodiments, the Cas9- and/or gRNA-encoding sequence is delivered by a recombinant adenovirus. In some embodiments, the donor nucleic acid is delivered by a recombinant adenoviru. In some embodiments, the adenovirus is engineered to have reduced immunity in human.
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a recombinant AAV. In some embodiments, the AAV does not incorporate its genome into that of a host cell, e.g., a target cell as describe herein. In some embodiments, the AAV can incorporate at least part of its genome into that of a host cell, e.g., a target cell as described herein. In some embodiments, the AAV is a self-complementary adeno-associated virus (scAAV), e.g., a scAAV that packages both strands which anneal together to form double stranded DNA. AAV serotypes that may be used in the disclosed methods, include AAV1, AAV2, modified AAV2 (e.g., modifications at Y444F, Y500F, Y730F and/or S662V), AAV3, modified AAV3 (e.g., modifications at Y705F, Y731F and/or T492V), AAV4, AAV5, AAV6, modified AAV6 (e.g., modifications at S663V and/or T492V), AAV8, AAV 8.2, AAV9, AAV rh 10, and pseudotyped AAV, such as AAV2/8, AAV2/5 and AAV2/6 can also be used in the disclosed methods. In an embodiment, an AAV capsid that can be used in the methods described herein is a capsid sequence from serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV.rh8, AAV.rhlO, AAV.rh32/33, AAV.rh43, AAV.rh64Rl, or AAV7m8.
In an embodiment, the Cas9- and/or gRNA-encoding DNA is delivered in a re- engineered AAV capsid, e.g., with 50% or greater, e.g., 60% or greater, 70% or greater, 80% or greater, 90% or greater, or 95% or greater, sequence homology with a capsid sequence from serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV.rh8, AAV.rhl0, AAV.rh32/33, AAV.rh43, or AAV.rh64Rl.
In an embodiment, the Cas9- and/or gRNA-encoding DNA is delivered by a chimeric AAV capsid. In an embodiment, the donor nucleic acid is delivered by a chimeric AAV capsid. Exemplary chimeric AAV capsids include, but are not limited to, AAV9il, AAV2i8, AAV-DJ, AAV2G9, AAV2i8G9, or AAV8G9.
In an embodiment, the AAV is a self-complementary adeno-associated virus (scAAV), e.g., a scAAV that packages both strands which anneal together to form double stranded DNA.
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a hybrid virus, e.g., a hybrid of one or more of the viruses described herein. In an embodiment, the hybrid virus is hybrid of an AAV (e.g., of any AAV serotype), with a Bocavirus, B19 virus, porcine AAV, goose AAV, feline AAV, canine AAV, or MVM.
A Packaging cell is used to form a virus particle that is capable of infecting a target cell. Such a cell includes a 293 cell, which can package adenovirus, and a ψ2 cell or a PA317 cell, which can package retrovirus. A viral vector used in gene therapy is usually generated by a producer cell line that packages a nucleic acid vector into a viral particle. The vector typically contains the minimal viral sequences required for packaging and subsequent integration into a host or target cell (if applicable), with other viral sequences being replaced by an expression cassette encoding the protein to be expressed, eg. Cas9. For example, an AAV vector used in gene therapy typically only possesses inverted terminal repeat (ITR) sequences from the AAV genome which are required for packaging and gene expression in the host or target cell. The missing viral functions can be supplied in trans by the packaging cell line and/or plasmid containing E2A, E4, and VA genes from adenovirus, and plasmid encoding Rep and Cap genes from AAV, as described in "Triple Transfection Protocol." Henceforth, the viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. In embodiment, the viral DNA is packaged in a producer cell line, which contains El A and/or E1B genes from adenovirus. The cell line is also infected with adenovirus as a helper. The helper virus (e.g., adenovirus or HSV) or helper plasmid promotes replication of the AAV vector and expression of AAV genes from the helper plasmid with ITRs. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV.
In an embodiment, the viral vector has the ability of cell type and/or tissue type recognition. For example, the viral vector can be pseudotyped with a different/alternative viral envelope glycoprotein; engineered with a cell type-specific receptor (e.g., geneticmodification of the viral envelope glycoproteins to incorporate targeting ligands such as a peptide ligand, a single chain antibodie, a growth factor); and/or engineered to have a molecular bridge with dual specificities with one end recognizing a viral glycoprotein and the other end recognizing a moiety of the target cell surface (e.g., ligand-receptor, monoclonal antibody, avidin-biotin and chemical conjugation).
In an embodiment, the viral vector achieves cell type specific expression. For example, a tissue-specific promoter can be constructed to restrict expression of the transgene (Cas 9 and gRNA) in only the target cell. The specificity of the vector can also be mediated by microRNA- dependent control of transgene expression. In an embodiment, the viral vector has increased efficiency of fusion of the viral vector and a target cell membrane. For example, a fusion protein such as fusion-competent hemagglutin (HA) can be incorporated to increase viral uptake into cells. In an embodiment, the viral vector has the ability of nuclear localization. For example, aviruse that requires the breakdown of the nuclear envelope (during cell division) and therefore will not infect a non-diving cell can be altered to incorporate a nuclear localization peptide in the matrix protein of the virus thereby enabling the transduction of non-proliferating cells.
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a non- vector based method (e.g., using naked DNA or DNA complexes). For example, the DNA can be delivered, e.g., by organically modified silica or silicate (Ormosil), electroporation, transient cell compression or squeezing (e.g., as described in Lee, et al [2012] Nano Lett 12: 6322-27), gene gun, sonoporation, magnetofection, lipid-mediated transfection, dendrimers, inorganic nanoparticles, calcium phosphates, or a combination thereof.
In an embodiment, delivery via electroporation comprises mixing the cells with the Cas9- and/or gRNA-encoding DNA in a cartridge, chamber or cuvette and applying one or more electrical impulses of defined duration and amplitude. In an embodiment, delivery via electroporation is performed using a system in which cells are mixed with the Cas9-and/or gRNA-encoding DNA in a vessel connected to a device (eg, a pump) which feeds the mixture into a cartridge, chamber or cuvette wherein one or more electrical impulses of defined duration and amplitude are applied, after which the cells are delivered to a second vessel.
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a combination of a vector and a non-vector based method. In some embodiments, the donor nucleic acid is delivered by a combination of a vector and a non-vector based method. For example, a virosome comprises a liposome combined with an inactivated virus (e.g., HIV or influenza virus), which can result in more efficient gene transfer, e.g., in a respiratory epithelial cell than either a viral or a liposomal method alone.
In an embodiment, the delivery vehicle is a non- viral vector. In an embodiment, the non- viral vector is an inorganic nanoparticle. Exemplary inorganic nanoparticles include, e.g., magnetic nanoparticles (e.g., FesMnOi) or silica. The outer surface of the nanoparticle can be conjugated with a positively charged polymer (e.g., polyethylenimine, polylysine, polyserine) which allows for attachment (e.g., conjugation or entrapment) of payload. In an embodiment, the non-viral vector is an organic nanoparticle. Exemplary organic nanoparticles include, e.g., SNALP liposomes (e.g., SNALP liposomes that contain cationic lipids together with neutral helper lipids and polyethylene glycol (PEG)-conjugated lipids) and protamine-nucleic acid complexes, e.g., protamine-nucleic acid complexes coated with lipid coating.
Exemplary lipids for gene transfer are shown below in Table 58.
Table 58: Lipids Used for Gene Transfer
Figure imgf001740_0001
Dioctadecylamidoglycylspermine DOGS Cationic
N- (3- Aminopropyl) -N,N-dimethyl-2,3-bis(dodecyloxy) - 1 - GAP-DLRIE Cationic propanaminium bromide
Cetyltrimethylammonium bromide CTAB Cationic
6-Lauroxyhexyl ornithinate LHON Cationic l-(2,3-Dioleoyloxypropyl)-2,4,6-trimethylpyridinium 2Oc Cationic
2,3-Dioleyloxy-N-[2(sperminecarboxamido-ethyl]-N,N- DOSPA Cationic dimethyl-l-propanaminium trifluoroacetate
l,2-Dioleyl-3-trimethylammonium-propane DOPA Cationic
N-(2-Hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-l- MDRIE Cationic propanaminium bromide
Dimyristooxypropyl dimethyl hydroxyethyl ammonium DMRI Cationic bromide
3P-[N-(N',N'-Dimethylaminoethane)-carbamoyl]cholesterol DC-Choi Cationic
Bis-guanidium-tren-cholesterol BGTC Cationic l,3-Diodeoxy-2-(6-carboxy-spermyl)-propylamide DOSPER Cationic
Dimethyloctadecylammonium bromide DDAB Cationic
Dioctadecylamidoglicylspermidin DSL Cationic rac-[(2,3-Dioctadecyloxypropyl)(2-hydroxyethyl)]- CLIP-1 Cationic dimethylammonium chloride
rac-[2(2,3-Dihexadecyloxypropyl- CLIP-6 Cationic oxymethyloxy)ethyl]trimethylammonium bromide
Ethyldimyristoylphosphatidylcholine EDMPC Cationic l,2-Distearyloxy-N,N-dimethyl-3-aminopropane DSDMA Cationic
1,2-Dimyristoyl-trimethylammonium propane DMTAP Cationic
Ο,Ο'-Dimyristyl-N-lysyl aspartate DMKE Cationic l,2-Distearoyl-sn-glycero-3-ethylphosphocholine DSEPC Cationic
N-Palmitoyl D-erythro-sphingosyl carbamoyl-spermine CCS Cationic
N-t-Butyl-N0-tetradecyl-3-tetradecylaminopropionamidine diC14-amidine Cationic
Octadecenolyoxy[ethyl-2-heptadecenyl-3 hydroxyethyl] DOTIM Cationic imidazolinium chloride
Nl-Cholesteryloxycarbonyl-3,7-diazanonane-l,9-diamine CDAN Cationic
2-(3-[Bis(3-amino-propyl)-amino]propylamino)-N- RPR209120 Cationic ditetradecylcarbamoylme-ethyl-acetamide
l,2-dilinoleyloxy-3- dimethylaminopropane DLinDMA Cationic
2,2-dilinoleyl-4-dimethylaminoethyl- [ 1 ,3] - dioxolane DLin-KC2- Cationic
DMA
dilinoleyl- methyl-4-dimethylaminobutyrate DLin-MC3- Cationic
DMA
Exemplary polymers for gene transfer are shown below in Table 59.
Table 59: Polymers Used for Gene Transfer
Figure imgf001741_0001
Polyethylenimine PEI
Dithiobis(succinimidylpropionate) DSP
Dimethyl-3,3'-dithiobispropionimidate DTBP
Poly(ethylene imine) biscarbamate PEIC
Poly(L-lysine) PLL
Histidine modified PLL
Poly(N-vinylpyrrolidone) PVP
Poly(propylenimine) PPI
Poly(amidoamine) PAMAM
Poly(amido ethylenimine) SS-PAEI
Triethylenetetramine TETA
Poly ( β- aminoester)
Poly(4-hydroxy-L-proline ester) PHP
Poly(allylamine)
Poly(a-[4-aminobutyl]-L-glycolic acid) PAGA
Poly(D,L-lactic-co-glycolic acid) PLGA
Poly(N-ethyl-4-vinylpyridinium bromide)
Poly (pho sphazene) s PPZ
Poly (pho sphoester) s PPE
Poly (pho sphoramidate) s PPA
Poly(N-2-hydroxypropylmethacrylamide) pHPMA
Poly (2-(dimethylamino)ethyl methacrylate) pDMAEMA
Poly(2-aminoethyl propylene phosphate) PPE-EA
Chitosan
Galactosylated chitosan
N-Dodacylated chitosan
Histone
Collagen
Dextran- spermine D-SPM
In an embodiment, the vehicle has targeting modifications to increase target cell update of nanoparticles and liposomes, e.g., cell specific antigens, monoclonal antibodies, single chain antibodies, aptamers, polymers, sugars, and cell penetrating peptides. In an embodiment, the vehicle uses fusogenic and endosome-destabilizing peptides/polymers. In an embodiment, the vehicle undergoes acid-triggered conformational changes (e.g., to accelerate endosomal escape of the cargo). In an embodiment, a stimuli-cleavable polymer is used, e.g., for release in a cellular compartment. For example, disulfide-based cationic polymers that are cleaved in the reducing cellular environment can be used.
In an embodiment, the delivery vehicle is a biological non-viral delivery vehicle. In an embodiment, the vehicle is an attenuated bacterium (e.g., naturally or artificially engineered to be invasive but attenuated to prevent pathogenesis and expressing the transgene (e.g., Listeria monocytogenes, certain Salmonella strains, Bifidobacterium longum, and modified Escherichia coli), bacteria having nutritional and tissue-specific tropism to target specific tissues, bacteria having modified surface proteins to alter target tissue specificity). In an embodiment, the vehicle is a genetically modified bacteriophage (e.g., engineered phages having large packaging capacity, less immunogenic, containing mammalian plasmid maintenance sequences and having incorporated targeting ligands). In an embodiment, the vehicle is a mammalian virus-like particle. For example, modified viral particles can be generated (e.g., by purification of the "empty" particles followed by ex vivo assembly of the virus with the desired cargo). The vehicle can also be engineered to incorporate targeting ligands to alter target tissue specificity. In an embodiment, the vehicle is a biological liposome. For example, the biological liposome is a phospholipid-based particle derived from human cells (e.g., erythrocyte ghosts, which are red blood cells broken down into spherical structures derived from the subject (e.g., tissue targeting can be achieved by attachment of various tissue or cell-specific ligands), or secretory exosomes - subject (i.e., patient) derived membrane-bound nanovescicle (30 -100 nm) of endocytic origin (e.g., can be produced from various cell types and can therefore be taken up by cells without the need of for targeting ligands).
In an embodiment, the delivery vehicle is a powder comprising, e.g., calcium carbonate, sucrose, mannitol, dextrose, or lactose.
In an embodiment, components are delivered as an aerosol.
In an embodiment, one or more nucleic acid molecules (e.g., DNA molecules) other than the components of a Cas system, e.g., the Cas9 molecule component and/or the gRNA molecule component described herein, are delivered. In an embodiment, the nucleic acid molecule is delivered at the same time as one or more of the components of the Cas system are delivered. In an embodiment, the nucleic acid molecule is delivered before or after (e.g., less than about 30 minutes, 1 hour, 2 hours, 3 hours, 6 hours, 9 hours, 12 hours, 1 day, 2 days, 3 days, 1 week, 2 weeks, or 4 weeks) one or more of the components of the Cas system are delivered. In an embodiment, the nucleic acid molecule is delivered by a different means than one or more of the components of the Cas system, e.g., the Cas9 molecule component and/or the gRNA molecule component, are delivered. The nucleic acid molecule can be delivered by any of the delivery methods described herein. For example, the nucleic acid molecule can be delivered by a viral vector, e.g., an integration-deficient lentivirus, and the Cas9 molecule component and/or the gRNA molecule component can be delivered by electroporation, e.g., such that the toxicity caused by nucleic acids (e.g., DNAs) can be reduced. In an embodiment, the nucleic acid molecule encodes a therapeutic protein, e.g., a protein described herein. In an embodiment, the nucleic acid molecule encodes an RNA molecule, e.g., an RNA molecule described herein.
Delivery of RNA encoding a Cas9 molecule
RNA encoding Cas9 molecules (e.g., eaCas9 molecules or eiCas9 molecules) and/or gRNA molecules, can be delivered into cells, e.g., target cells described herein, by art-known methods or as described herein. For example, Cas9-encoding and/or gRNA-encoding RNA can be delivered, e.g., by microinjection, electroporation, transient cell compression or squeezing (e.g., as described in Lee, et al [2012] Nano Lett 12: 6322-27), lipid-mediated transfection, lipid- mediated transfection, peptide-mediated delivery, or a combination thereof. Cas9-encoding and/or gRNA-encoding RNA can be conjugated to molecules promoting uptake by the target cells (e.g., target cells described herein).
In an embodiment, delivery via electroporation comprises mixing the cells with the RNA encoding Cas9 molecules (e.g., eaCas9 molecules, eiCas9 molecules or eiCas9 fusion protiens) and/or gRNA molecules, with or without donor nucleic acid molecules in a cartridge, chamber or cuvette and applying one or more electrical impulses of defined duration and amplitude. In an embodiment, delivery via electroporation is performed using a system in which cells are mixed with the RNA encoding Cas9 molecules (e.g., eaCas9 molecules, eiCas9 molecules or eiCas9 fusion protiens) and/or gRNA molecules, with or without donor nucleic acid molecules in a vessel connected to a device (eg, a pump) which feeds the mixture into a cartridge, chamber or cuvette wherein one or more electrical impulses of defined duration and amplitude are applied, after which the cells are delivered to a second vessel.
Delivery Cas9 molecule protein
Cas9 molecules (e.g., eaCas9 molecules or eiCas9 molecules) can be delivered into cells by art-known methods or as described herein. For example, Cas9 protein molecules can be delivered, e.g., by microinjection, electroporation, lipid-mediated transfection, peptide-mediated delivery, or a combination thereof. Delivery can be accompanied by DNA encoding a gRNA or by a gRNA. Cas9 protein can be conjugated to molecules promoting uptake by the target cells (e.g., target cells described herein).
In an embodiment, delivery via electroporation comprises mixing the cells with the Cas9 molecules (e.g., eaCas9 molecules, eiCas9 molecules or eiCas9 fusion protiens) and/or gRNA molecules, with or without donor nucleic acid, in a cartridge, chamber or cuvette and applying one or more electrical impulses of defined duration and amplitude. In an embodiment, delivery via electroporation is performed using a system in which cells are mixed with the Cas9 molecules (e.g., eaCas9 molecules, eiCas9 molecules or eiCas9 fusion protiens) and/or gRNA molecules, with or without donor nucleic acid in a vessel connected to a device (eg, a pump) which feeds the mixture into a cartridge, chamber or cuvette wherein one or more electrical impulses of defined duration and amplitude are applied, after which the cells are delivered to a second vessel.
Route of Administration
Systemic modes of administration include oral and parenteral routes. Parenteral routes include, by way of example, intravenous, intra-arterial, intraosseous, intramuscular, intradermal, subcutaneous and intraperitoneal routes. Components administered systemically may be modified or formulated to target the components to specific cells, e.g., airway epithelial cells, pulmonary epithelial cells, gastrointestinal epithelial cells, biliary epithelial cells, pancreatic ductal epithelial cells, reproductive epithelial cells or pulmonary stem cells.
Local modes of administration include, by way of example, inhalation, intra-nasal instillation, and intraparenchymal injection, e.g., intraparenchymal injection into the lung, bronchial tree, liver, pancreas, pancreatic duct, bile duct, gastrointestinal tract or reproductive tract. In an embodiment, significantly smaller amounts of the components (compared with systemic approaches) may exert an effect when administered locally (for example, by inhalation) compared to when administered systemically (for example, intravenously). Local modes of administration can reduce or eliminate the incidence of potentially toxic side effects that may occur when therapeutically effective amounts of a component are administered systemically.
In an embodiment, components described herein are delivered by inhalation.
In an embodiment, nanoparticle or viral, e.g., AAV vector, delivery is via inhalation. In an embodiment, subjects are treated with mucus loosening agents and/or chest physical therapy prior to administration of components by inhalation.
Administration may be provided as a periodic bolus or as continuous infusion from an internal reservoir or from an external reservoir (for example, from an intravenous bag).
Components may be administered locally, for example, by continuous release from a sustained release drug delivery device.
In addition, components may be formulated to permit release over a prolonged period of time. A release system can include a matrix of a biodegradable material or a material which releases the incorporated components by diffusion. The components can be homogeneously or heterogeneously distributed within the release system. A variety of release systems may be useful, however, the choice of the appropriate system will depend upon rate of release required by a particular application. Both non-degradable and degradable release systems can be used. Suitable release systems include polymers and polymeric matrices, non-polymeric matrices, or inorganic and organic excipients and diluents such as, but not limited to, calcium carbonate and sugar (for example, trehalose). Release systems may be natural or synthetic. However, synthetic release systems are preferred because generally they are more reliable, more reproducible and produce more defined release profiles. The release system material can be selected so that components having different molecular weights are released by diffusion through or degradation of the material.
Representative synthetic, biodegradable polymers include, for example: polyamides such as poly(amino acids) and poly(peptides); polyesters such as poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), and poly(caprolactone); poly(anhydrides); polyorthoesters;
polycarbonates; and chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof. Representative synthetic, non- degradable polymers include, for example: polyethers such as poly(ethylene oxide),
poly(ethylene glycol), and poly(tetramethylene oxide); vinyl polymers-polyacrylates and polymethacrylates such as methyl, ethyl, other alkyl, hydroxyethyl methacrylate, acrylic and methacrylic acids, and others such as poly(vinyl alcohol), poly(vinyl pyrolidone), and poly(vinyl acetate); poly(urethanes); cellulose and its derivatives such as alkyl, hydroxyalkyl, ethers, esters, nitrocellulose, and various cellulose acetates; polysiloxanes; and any chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof.
Poly(lactide-co-glycolide) microsphere can also be used for injection. Typically the microspheres are composed of a polymer of lactic acid and glycolic acid, which are structured to form hollow spheres. The spheres can be approximately 15-30 microns in diameter and can be loaded with components described herein.
Bi-Modal or Differential Delivery of Components
Separate delivery of the components of a Cas system, e.g., the Cas9 molecule component and the gRNA molecule component, and more particularly, delivery of the components by differing modes, can enhance performance, e.g., by improving tissue specificity and safety.
In an embodiment, the Cas9 molecule and the gRNA molecule are delivered by different modes, or as sometimes referred to herein as differential modes. Different or differential modes, as used herein, refer modes of delivery that confer different pharmacodynamic or
pharmacokinetic properties on the subject component molecule, e.g., a Cas9 molecule, gRNA molecule, or template nucleic acid. For example, the modes of delivery can result in different tissue distribution, different half-life, or different temporal distribution, e.g., in a selected compartment, tissue, or organ.
Some modes of delivery, e.g., delivery by a nucleic acid vector that persists in a cell, or in progeny of a cell, e.g., by autonomous replication or insertion into cellular nucleic acid, result in more persistent expression of and presence of a component. Examples include viral, e.g., adeno- associated virus or lentivirus, delivery.
By way of example, the components, e.g., a Cas9 molecule and a gRNA molecule, can be delivered by modes that differ in terms of resulting half-life or persistent of the delivered component the body, or in a particular compartment, tissue or organ. In an embodiment, a gRNA molecule can be delivered by such modes. The Cas9 molecule component can be delivered by a mode which results in less persistence or less exposure to the body or a particular compartment or tissue or organ.
More generally, in an embodiment, a first mode of delivery is used to deliver a first component and a second mode of delivery is used to deliver a second component. The first mode of delivery confers a first pharmacodynamic or pharmacokinetic property. The first pharmacodynamic property can be, e.g., distribution, persistence, or exposure, of the component, or of a nucleic acid that encodes the component, in the body, a compartment, tissue or organ. The second mode of delivery confers a second pharmacodynamic or pharmacokinetic property. The second pharmacodynamic property can be, e.g., distribution, persistence, or exposure, of the component, or of a nucleic acid that encodes the component, in the body, a compartment, tissue or organ.
In an embodiment, the first pharmacodynamic or pharmacokinetic property, e.g., distribution, persistence or exposure, is more limited than the second pharmacodynamic or pharmacokinetic property.
In an embodiment, the first mode of delivery is selected to optimize, e.g., minimize, a pharmacodynamic or pharmacokinetic property, e.g., distribution, persistence or exposure.
In an embodiment, the second mode of delivery is selected to optimize, e.g., maximize, a pharmacodynamic or pharmcokinetic property, e.g., distribution, persistence or exposure.
In an embodiment, the first mode of delivery comprises the use of a relatively persistent element, e.g., a nucleic acid, e.g., a plasmid or viral vector, e.g., an AAV or lentivirus. As such vectors are relatively persistent product transcribed from them would be relatively persistent.
In an embodiment, the second mode of delivery comprises a relatively transient element, e.g., an RNA or protein.
In an embodiment, the first component comprises gRNA, and the delivery mode is relatively persistent, e.g., the gRNA is transcribed from a plasmid or viral vector, e.g., an AAV or lentivirus. Transcription of these genes would be of little physiological consequence because the genes do not encode for a protein product, and the gRNAs are incapable of acting in isolation. The second component, a Cas9 molecule, is delivered in a transient manner, for example as mRNA or as protein, ensuring that the full Cas9 molecule/gRNA molecule complex is only present and active for a short period of time.
Furthermore, the components can be delivered in different molecular form or with different delivery vectors that complement one another to enhance safety and tissue specificity.
Use of differential delivery modes can enhance performance, safety and efficacy. E.g., the likelihood of an eventual off-target modification can be reduced. Delivery of immunogenic components, e.g., Cas9 molecules, by less persistent modes can reduce immunogenicity, as peptides from the bacterially-derived Cas enzyme are displayed on the surface of the cell by MHC molecules. A two-part delivery system can alleviate these drawbacks.
Differential delivery modes can be used to deliver components to different, but overlapping target regions. The formation active complex is minimized outside the overlap of the target regions. Thus, in an embodiment, a first component, e.g., a gRNA molecule is delivered by a first delivery mode that results in a first spatial, e.g., tissue, distribution. A second component, e.g., a Cas9 molecule is delivered by a second delivery mode that results in a second spatial, e.g., tissue, distribution. In an embodiment, the first mode comprises a first element selected from a liposome, nanoparticle, e.g., polymeric nanoparticle, and a nucleic acid, e.g., viral vector. The second mode comprises a second element selected from the group. In an embodiment, the first mode of delivery comprises a first targeting element, e.g., a cell specific receptor or an antibody, and the second mode of delivery does not include that element. In embodiment, the second mode of delivery comprises a second targeting element, e.g., a second cell specific receptor or second antibody.
When the Cas9 molecule is delivered in a virus delivery vector, a liposome, or polymeric nanoparticle, there is the potential for delivery to and therapeutic activity in multiple tissues, when it may be desirable to only target a single tissue. A two-part delivery system can resolve this challenge and enhance tissue specificity. If the gRNA molecule and the Cas9 molecule are packaged in separated delivery vehicles with distinct but overlapping tissue tropism, the fully functional complex is only be formed in the tissue that is targeted by both vectors.
Ex vivo delivery
In some embodiments, components described in Table 56 are introduced into cells which are then introduced into the subject e.g., cells are removed from a subject, manipulated ex vivo and then introduced into the subject. Methods of introducing the components can include, e.g., any of the delivery methods described herein, e.g., any of the delivery methods described in Table 57.
VIII. Modified Nucleosides, Nucleotides, and Nucleic Acids
Modified nucleosides and modified nucleotides can be present in nucleic acids, e.g., particularly gRNA, but also other forms of RNA, e.g., mRNA, RNAi, or siRNA. As described herein, "nucleoside" is defined as a compound containing a five-carbon sugar molecule (a pentose or ribose) or derivative thereof, and an organic base, purine or pyrimidine, or a derivative thereof. As described herein, "nucleotide" is defined as a nucleoside further comprising a phosphate group.
Modified nucleosides and nucleotides can include one or more of:
(i) alteration, e.g., replacement, of one or both of the non-linking phosphate oxygens and/or of one or more of the linking phosphate oxygens in the phosphodiester backbone linkage;
(ii) alteration, e.g., replacement, of a constituent of the ribose sugar, e.g., of the 2' hydroxyl on the ribose sugar;
(iii) wholesale replacement of the phosphate moiety with "dephospho" linkers;
(iv) modification or replacement of a naturally occurring nucleobase;
(v) replacement or modification of the ribose-phosphate backbone;
(vi) modification of the 3' end or 5' end of the oligonucleotide, e.g., removal,
modification or replacement of a terminal phosphate group or conjugation of a moiety; and
(vii) modification of the sugar.
The modifications listed above can be combined to provide modified nucleosides and nucleotides that can have two, three, four, or more modifications. For example, a modified nucleoside or nucleotide can have a modified sugar and a modified nucleobase. In an
embodiment, every base of a gRNA is modified, e.g., all bases have a modified phosphate group, e.g., all are phosphorothioate groups. In an embodiment, all, or substantially all, of the phosphate groups of a unimolecular or modular gRNA molecule are replaced with
phosphorothioate groups.
In an embodiment, modified nucleotides, e.g., nucleotides having modifications as described herein, can be incorporated into a nucleic acid, e.g., a "modified nucleic acid." In some embodiments, the modified nucleic acids comprise one, two, three or more modified nucleotides. In some embodiments, at least 5% (e.g., at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%) of the positions in a modified nucleic acid are a modified nucleotides. Unmodified nucleic acids can be prone to degradation by, e.g., cellular nucleases. For example, nucleases can hydrolyze nucleic acid phosphodiester bonds. Accordingly, in one aspect the modified nucleic acids described herein can contain one or more modified nucleosides or nucleotides, e.g., to introduce stability toward nucleases.
In some embodiments, the modified nucleosides, modified nucleotides, and modified nucleic acids described herein can exhibit a reduced innate immune response when introduced into a population of cells, both in vivo and ex vivo. The term "innate immune response" includes a cellular response to exogenous nucleic acids, including single stranded nucleic acids, generally of viral or bacterial origin, which involves the induction of cytokine expression and release, particularly the interferons, and cell death. In some embodiments, the modified nucleosides, modified nucleotides, and modified nucleic acids described herein can disrupt binding of a major groove interacting partner with the nucleic acid. In some embodiments, the modified
nucleosides, modified nucleotides, and modified nucleic acids described herein can exhibit a reduced innate immune response when introduced into a population of cells, both in vivo and ex vivo, and also disrupt binding of a major groove interacting partner with the nucleic acid.
Definitions of Chemical Groups
As used herein, "alkyl" is meant to refer to a saturated hydrocarbon group which is straight-chained or branched. Example alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like. An alkyl group can contain from 1 to about 20, from 2 to about 20, from 1 to about 12, from 1 to about 8, from 1 to about 6, from 1 to about 4, or from 1 to about 3 carbon atoms.
As used herein, "aryl" refers to monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbons such as, for example, phenyl, naphthyl, anthracenyl,
phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, aryl groups have from 6 to about 20 carbon atoms.
As used herein, "alkenyl" refers to an aliphatic group containing at least one double bond.
As used herein, "alkynyl" refers to a straight or branched hydrocarbon chain containing 2-12 carbon atoms and characterized in having one or more triple bonds. Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl, and 3-hexynyl. As used herein, "arylalkyl" or "aralkyl" refers to an alkyl moiety in which an alkyl hydrogen atom is replaced by an aryl group. Aralkyl includes groups in which more than one hydrogen atom has been replaced by an aryl group. Examples of "arylalkyl" or "aralkyl" include benzyl, 2-phenylethyl, 3-phenylpropyl, 9-fluorenyl, benzhydryl, and trityl groups.
As used herein, "cycloalkyl" refers to a cyclic, bicyclic, tricyclic, or polycyclic non- aromatic hydrocarbon groups having 3 to 12 carbons. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl.
As used herein, "heterocyclyl" refers to a monovalent radical of a heterocyclic ring system. Representative heterocyclyls include, without limitation, tetrahydrofuranyl,
tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, and morpholinyl.
As used herein, "heteroaryl" refers to a monovalent radical of a heteroaromatic ring system. Examples of heteroaryl moieties include, but are not limited to, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrrolyl, furanyl, indolyl, thiophenyl pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, indolizinyl, purinyl, naphthyridinyl, quinolyl, and pteridinyl.
Phosphate Backbone Modifications
The Phosphate Group
In some embodiments, the phosphate group of a modified nucleotide can be modified by replacing one or more of the oxygens with a different substituent. Further, the modified nucleotide, e.g., modified nucleotide present in a modified nucleic acid, can include the wholesale replacement of an unmodified phosphate moiety with a modified phosphate as described herein. In some embodiments, the modification of the phosphate backbone can include alterations that result in either an uncharged linker or a charged linker with
unsymmetrical charge distribution.
Examples of modified phosphate groups include, phosphorothioate, phosphoroselenates, borano phosphates, borano phosphate esters, hydrogen phosphonates, phosphoroamidates, alkyl or aryl phosphonates and phosphotriesters. In some embodiments, one of the non-bridging phosphate oxygen atoms in the phosphate backbone moiety can be replaced by any of the following groups: sulfur (S), selenium (Se), BR3 (wherein R can be, e.g., hydrogen, alkyl, or aryl), C (e.g., an alkyl group, an aryl group, and the like), H, NR2 (wherein R can be, e.g., hydrogen, alkyl, or aryl), or OR (wherein R can be, e.g., alkyl or aryl). The phosphorous atom in an unmodified phosphate group is achiral. However, replacement of one of the non-bridging oxygens with one of the above atoms or groups of atoms can render the phosphorous atom chiral; that is to say that a phosphorous atom in a phosphate group modified in this way is a stereogenic center. The stereogenic phosphorous atom can possess either the "R" configuration (herein Rp) or the "S" configuration (herein Sp).
Phosphorodithioates have both non-bridging oxygens replaced by sulfur. The phosphorus center in the phosphorodithioates is achiral which precludes the formation of oligoribonucleotide diastereomers. In some embodiments, modifications to one or both non-bridging oxygens can also include the replacement of the non-bridging oxygens with a group independently selected from S, Se, B, C, H, N, and OR (R can be, e.g., alkyl or aryl).
The phosphate linker can also be modified by replacement of a bridging oxygen, (i.e., the oxygen that links the phosphate to the nucleoside), with nitrogen (bridged phosphoroamidates), sulfur (bridged phosphorothioates) and carbon (bridged methylenephosphonates). The replacement can occur at either linking oxygen or at both of the linking oxygens.
Replacement of the Phosphate Group
The phosphate group can be replaced by non-phosphorus containing connectors. In some embodiments, the charge phosphate group can be replaced by a neutral moiety.
Examples of moieties which can replace the phosphate group can include, without limitation, e.g., methyl phosphonate, hydroxylamino, siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo,
methylenedimethylhydrazo and methyleneoxymethylimino.
Replacement of the Ribophosphate Backbone
Scaffolds that can mimic nucleic acids can also be constructed wherein the phosphate linker and ribose sugar are replaced by nuclease resistant nucleoside or nucleotide surrogates. In some embodiments, the nucleobases can be tethered by a surrogate backbone. Examples can include, without limitation, the morpholino, cyclobutyl, pyrrolidine and peptide nucleic acid (PNA) nucleoside surrogates.
Sugar Modifications The modified nucleosides and modified nucleotides can include one or more modifications to the sugar group. For example, the 2' hydroxyl group (OH) can be modified or replaced with a number of different "oxy" or "deoxy" substituents. In some embodiments, modifications to the 2' hydroxyl group can enhance the stability of the nucleic acid since the hydroxyl can no longer be deprotonated to form a 2' -alkoxide ion. The 2' -alkoxide can catalyze degradation by intramolecular nucleophilic attack on the linker phosphorus atom.
Examples of "oxy"-2' hydroxyl group modifications can include alkoxy or aryloxy (OR, wherein "R" can be, e.g., alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or a sugar);
polyethyleneglycols (PEG), 0(CH2CH20)nCH2CH2OR wherein R can be, e.g., H or optionally substituted alkyl, and n can be an integer from 0 to 20 (e.g., from 0 to 4, from 0 to 8, from 0 to 10, from 0 to 16, from 1 to 4, from 1 to 8, from 1 to 10, from 1 to 16, from 1 to 20, from 2 to 4, from 2 to 8, from 2 to 10, from 2 to 16, from 2 to 20, from 4 to 8, from 4 to 10, from 4 to 16, and from 4 to 20). In some embodiments, the "oxy"-2' hydroxyl group modification can include "locked" nucleic acids (LNA) in which the 2' hydroxyl can be connected, e.g., by a C1-6 alkylene or Ci_6 heteroalkylene bridge, to the 4' carbon of the same ribose sugar, where exemplary bridges can include methylene, propylene, ether, or amino bridges; O-amino (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine, or polyamino) and aminoalkoxy, 0(CH2)n-amino, (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine, or polyamino). In some embodiments, the "oxy"-2' hydroxyl group modification can include the methoxyethyl group (MOE),
(OCH2CH2OCH3, e.g., a PEG derivative).
"Deoxy" modifications can include hydrogen (i.e. deoxyribose sugars, e.g., at the overhang portions of partially ds RNA); halo (e.g., bromo, chloro, fluoro, or iodo); amino (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, or amino acid); NH(CH2CH2NH)nCH2CH2- amino (wherein amino can be, e.g., as described herein), -NHC(0)R (wherein R can be, e.g., alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar), cyano; mercapto; alkyl-thio-alkyl;
thioalkoxy; and alkyl, cycloalkyl, aryl, alkenyl and alkynyl, which may be optionally substituted with e.g., an amino as described herein. The sugar group can also contain one or more carbons that possess the opposite stereochemical configuration than that of the corresponding carbon in ribose. Thus, a modified nucleic acid can include nucleotides containing e.g., arabinose, as the sugar. The nucleotide "monomer" can have an alpha linkage at the position on the sugar, e.g., alpha-nucleosides. The modified nucleic acids can also include "abasic" sugars, which lack a nucleobase at C- . These abasic sugars can also be further modified at one or more of the constituent sugar atoms. The modified nucleic acids can also include one or more sugars that are in the L form, e.g. L- nucleosides.
Generally, RNA includes the sugar group ribose, which is a 5-membered ring having an oxygen. Exemplary modified nucleosides and modified nucleotides can include, without limitation, replacement of the oxygen in ribose (e.g., with sulfur (S), selenium (Se), or alkylene, such as, e.g., methylene or ethylene); addition of a double bond (e.g., to replace ribose with cyclopentenyl or cyclohexenyl); ring contraction of ribose (e.g., to form a 4-membered ring of cyclobutane or oxetane); ring expansion of ribose (e.g., to form a 6- or 7-membered ring having an additional carbon or heteroatom, such as for example, anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino that also has a phosphoramidate backbone). In some embodiments, the modified nucleotides can include multicyclic forms (e.g., tricyclo; and "unlocked" forms, such as glycol nucleic acid (GNA) (e.g., R-GNA or S-GNA, where ribose is replaced by glycol units attached to phosphodiester bonds), threose nucleic acid (TNA, where ribose is replaced with a-L-threofuranosyl-(3'→2')).
Modifications on the Nucleobase
The modified nucleosides and modified nucleotides described herein, which can be incorporated into a modified nucleic acid, can include a modified nucleobase. Examples of nucleobases include, but are not limited to, adenine (A), guanine (G), cytosine (C), and uracil (U). These nucleobases can be modified or wholly replaced to provide modified nucleosides and modified nucleotides that can be incorporated into modified nucleic acids. The nucleobase of the nucleotide can be independently selected from a purine, a pyrimidine, a purine or pyrimidine analog. In some embodiments, the nucleobase can include, for example, naturally-occurring and synthetic derivatives of a base.
Uracil In some embodiments, the modified nucleobase is a modified uracil. Exemplary nucleobases and nucleosides having a modified uracil include without limitation pseudouridine (ψ), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio- uridine (s2U), 4-thio-uridine (s4U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy- uridine (ho5U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridine or 5-bromo-uridine), 3-
3 5 5
methyl-uridine (m U), 5-methoxy-uridine (mo U), uridine 5-oxyacetic acid (cmo U), uridine 5- oxyacetic acid methyl ester (mcmo5U), 5-carboxymethyl-uridine (cm5U), 1-carboxymethyl- pseudouridine, 5-carboxyhydroxymethyl-uridine (chm5U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm5U), 5-methoxycarbonylmethyl-uridine (mcm5U), 5- methoxycarbonylmethyl-2-thio-uridine (mcm5s2U), 5-aminomethyl-2-thio-uridine (nm5s2U), 5- methylaminomethyl-uridine (mnm5U), 5-methylaminomethyl-2-thio-uridine (mnm5s2U), 5-
5 2 5 methylaminomethyl-2-seleno-uridine (mnm se U), 5-carbamoylmethyl-uridine (ncm U), 5- carboxymethylaminomethyl-uridine (cmnm5U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm 5s2U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (xcm5U),
1- taurinomethyl -pseudouridine, 5-taurinomethyl-2-thio-uridine(xm5s2U), l-taurinomethyl-4- thio-pseudouridine, 5-methyl-uridine (m5U, i.e., having the nucleobase deoxythymine), 1- methyl-pseudouridine (πι'ψ), 5-methyl-2-thio-uridine (m5s2U), l-methyl-4-thio-pseudouridine
Figure imgf001756_0001
2-thio-l-methyl- pseudouridine, 1 -methyl- 1 -deaza-pseudouridine, 2-thio- 1 -methyl- 1 -deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m5D),
2- thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio- uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, Nl-methyl-pseudouridine,
3- (3-amino-3-carboxypropyl)uridine (acp U), l-methyl-3-(3-amino-3-
3 5
carboxypropyl)pseudouridine (acp ψ), 5-(isopentenylaminomethyl)uridine (inm U), 5- (isopentenylaminomethyl)-2-thio-uridine (inm5s2U), a-thio-uridine, 2'-0-methyl-uridine (Um), 5,2'-0-dimethyl-uridine (m5Um), 2'-0-methyl-pseudouridine (ψπι), 2-thio-2'-0-methyl-uridine (s2Um), 5-methoxycarbonylmethyl-2'-0-methyl -uridine (mem 5Um), 5-carbamoylmethyl-2'-0- methyl-uridine (ncm 5Um), 5-carboxymethylaminomethyl-2'-0-methyl-uridine (cmnm 5Um),
3 5
3,2'-0-dimethyl-uridine (m Um), 5-(isopentenylaminomethyl)-2'-0-methyl-uridine (inm Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine, 2'-OH-ara-uridine, 5-(2- carbomethoxyvinyl) uridine, 5-[3-(l-E-propenylamino)uridine, pyrazolo[3,4-d]pyrimidines, xanthine, and hypoxanthine.
Cytosine
In some embodiments, the modified nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having a modified cytosine include without limitation 5-aza- cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine (m C), N4-acetyl-cytidine (act), 5- formyl-cytidine (f5C), N4-methyl-cytidine (m4C), 5-methyl-cytidine (m5C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C), 1-methyl-pseudoisocytidine, pyrrolo- cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine (s2C), 2-thio-5-methyl-cytidine, 4-thio- pseudoisocytidine, 4-thio- 1-methyl-pseudoisocytidine, 4-thio-l -methyl- 1-deaza- pseudoisocytidine, 1 -methyl- 1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl- zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy- 5 -methyl- cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy- 1-methyl-pseudoisocytidine, lysidine (k C), a-thio-cytidine, 2'-0-methyl-cytidine (Cm), 5,2'-0-dimethyl-cytidine (m5Cm), N4-acetyl-2'-0- methyl-cytidine (ac4Cm), N4,2'-0-dimethyl-cytidine (m4Cm), 5-formyl-2'-0-methyl-cytidine (f 5Cm), N4,N4,2'-0-trimethyl-cytidine (m4 2Cm), 1-thio-cytidine, 2'-F-ara-cytidine, 2'-F-cytidine, and 2'-OH-ara-cytidine.
Adenine
In some embodiments, the modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having a modified adenine include without limitation 2-amino- purine, 2,6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenosine, 7- deaza-8-aza-adenosine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6- diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1 -methyl- adenosine (i A), 2-methyl- adenosine (m2A), N6-methyl-adenosine (m6A), 2-methylthio-N6-methyl-adenosine (ms2m6A), N6-isopentenyl-adenosine (i6A), 2-methylthio-N6-isopentenyl-adenosine (ms2i6A), N6-(cis- hydroxyisopentenyl)adenosine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms2io6A), N6-glycinylcarbamoyl-adenosine (g6A), N6-threonylcarbamoyl-adenosine (t6A), N6- methyl-N6-threonylcarbamoyl-adenosine (m6t6A), 2-methylthio-N6-threonylcarbamoyl- adenosine (ms2g6A), N6,N6-dimethyl-adenosine (m6 2A), N6-hydroxynorvalylcarbamoyl- adenosine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenosine (ms2hn6A), N6- acetyl-adenosine (ac6A), 7-methyl-adenosine, 2-methylthio-adenosine, 2-methoxy-adenosine, a- thio-adenosine, 2'-0-methyl-adenosine (Am), N6,2'-0-dimethyl-adenosine (m6Am), N6-Methyl- 2'-deoxyadenosine, N6,N6,2'-0-trimethyl-adenosine (m6 2Am), l,2'-0-dimethyl-adenosine (i Am), 2'-0-ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl -purine, 1-thio- adenosine, 8-azido-adenosine, 2'-F-ara-adenosine, 2'-F-adenosine, 2'-OH-ara-adenosine, and N6- ( 19- amino-pentaoxanonadecyl) - adeno sine .
Guanine
In some embodiments, the modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having a modified guanine include without limitation inosine (I), 1- methyl-inosine (iVl), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW), peroxywybutosine (o2yW), hydroxy wybuto sine (OHyW), undermodified hydroxy wybuto sine (OHyW*), 7-deaza-guanosine, queuosine (Q),
epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl-queuosine (manQ), 7-cyano-7- deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ , archaeosine (G+), 7-deaza- 8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine (m G), 6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, l-methyl-guanosine (m'G), N2-methyl-guanosine (m 2 G), N2,N2-dimethyl-guanosine (m 2 2G),
N2,7-dimethyl-guanosine (m 2 ,7G), N2, N2,7-dimethyl-guanosine (m 2 ,2,7G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, l-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2- dimethyl-6-thio-guanosine, a-thio-guanosine, 2'-0-methyl-guanosine (Gm), N2-methyl-2'-0- methyl-guanosine (m 2"Gm), N2,N2-dimethyl-2'-0-methyl- guano sine (m 2 2Gm), l-methyl-2'-0- methyl-guanosine (m'Gm), N2,7-dimethyl-2'-0-methyl-guanosine (m",7Gm), 2'-0-methyl- inosine (Im), l,2'-0-dimethyl-inosine (m'lm), 06-phenyl-2'-deoxyinosine, 2'-0-ribosylguanosine (phosphate) (Gr(p)), 1-thio-guanosine, 06-methyl- guanosine, 06-Methyl-2'-deoxy guanosine, z - F-ara-guanosine, and 2'-F-guanosine.
Exemplary Modified gRNAs
In some embodiments, the modified nucleic acids can be modified gRNAs. It is to be understood that any of the gRNAs described herein can be modified in accordance with this section, including any gRNA that comprises a targeting domain from Tables 1A-1E, 2A-2E, 3A- 3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A- 22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A- 31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A- 40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E.
Through experimentation (results not shown) we have found that the guide RNA (gRNA) component of the CRISPR/Cas system is more efficient at editing genes in T cells when it has been modified at or near its 5' end (e.g., when the 5' end of a gRNA is modified by the inclusion of a eukaryotic mRNA cap structure or cap analog). While not wishing to be bound by theory it is believed that these and other modified gRNAs described herein elicit a reduced innate immune response from certain circulatory cell types (e.g., T cells) and that this might be responsible for the observed improvements. The present invention encompasses the realization that minimizing the innate immune response of circulating cells (e.g., T cells) to gRNAs could be advantageous when using gRNAs to edit circulating cells (whether ex vivo or in vivo) and could also be advantageous when using gRNAs to edit non-circulating cells, e.g., when a gRNA is
administered systemically or locally for in vivo gene editing purposes. The present invention also encompasses the realization that the improvements observed with a 5' capped gRNA can be extended to gRNAs that have been modified in other ways to achieve the same type of structural or functional result (e.g., by the inclusion of modified nucleosides or nucleotides, or when an in vitro transcribed gRNA is modified by treatment with a phosphatase such as calf intestinal alkaline phosphatase to remove the 5' triphosphate group). While not wishing to be bound by theory, in some embodiments, the modified gRNAs described herein may contain one or more modifications (e.g., modified nucleosides or nucleotides) which introduce stability toward nucleases (e.g., by the inclusion of modified nucleosides or nucleotides and/or a 3' polyA tract).
Thus, in one aspect, methods and compositions discussed herein provide methods and compositions for gene editing by using gRNAs which have been modified at or near their 5' end (e.g., within 1-10, 1-5, or 1-2 nucleotides of their 5' end). In an embodiment, the 5' end of a gRNA is modified by the inclusion of a eukaryotic mRNA cap structure or cap analog (e.g., a G(5')ppp(5')G cap analog, a m7G(5')ppp(5')G cap analog, or a 3 '-0-Me-m7G(5')ppp(5')G anti reverse cap analog (ARC A)). The cap or cap analog can be included during either chemical synthesis or in vitro transcription of the gRNA. In an embodiment, an in vitro transcribed gRNA is modified by treatment with a phosphatase (e.g., calf intestinal alkaline phosphatase) to remove the 5' triphosphate group.
In another aspect, methods and compositions discussed herein provide methods and compositions for gene editing by using gRNAs which include one or more modified nucleosides or nucleotides that are described herein. In some embodiments, the inclusion of the one or more modified nucleosides or nucleotides causes the gRNA to elicit a reduced innate immune response in certain circulating cell types (e.g., T cells, macrophages, dendritic cells, and/or B cells) as compared to an otherwise unmodified gRNA.
While some of the exemplary modifications discussed in this section may be included at any position within the gRNA sequence, in some embodiments, a gRNA comprises a
modification at or near its 5' end (e.g., within 1-10, 1-5, or 1-2 nucleotides of its 5' end). In some embodiments, a gRNA comprises a modification at or near its 3' end (e.g., within 1-10, 1- 5, or 1-2 nucleotides of its 3' end). In some embodiments, a gRNA comprises both a
modification at or near its 5' end and a modification at or near its 3' end.
In an embodiment, the 3' end of a gRNA is modified by the addition of one or more (e.g., 25-200) adenine (A) residues. The polyA tract can be contained in the nucleic acid (e.g., plasmid, PCR product, viral genome) encoding the gRNA, or can be added to the gRNA during chemical synthesis, or following in vitro transcription using a polyadenosine polymerase (e.g., E. coli Poly(A)Polymerase).
In an embodiment, in vitro transcribed gRNA contains both a 5' cap structure or cap analog and a 3' polyA tract. In an embodiment, an in vitro transcribed gRNA is modified by treatment with a phosphatase (e.g., calf intestinal alkaline phosphatase) to remove the 5' triphosphate group and comprises a 3' polyA tract.
In some embodiments, gRNAs can be modified at a 3' terminal U ribose. For example, the two terminal hydroxyl groups of the U ribose can be oxidized to aldehyde groups and a concomitant opening of the ribose ring to afford a modified nucleoside as shown below:
Figure imgf001760_0001
wherein "U" can be an unmodified or modified uridine. In another embodiment, the 3' terminal U can be modified with a 2' 3' cyclic phosphate as shown below:
Figure imgf001761_0001
wherein "U" can be an unmodified or modified uridine.
In some embodiments, the gRNA molecules may contain 3' nucleotides which can be stabilized against degradation, e.g., by incorporating one or more of the modified nucleotides described herein. In this embodiment, e.g., uridines can be replaced with modified uridines, e.g., 5-(2-amino)propyl uridine, and 5-bromo uridine, or with any of the modified uridines described herein; adenosines, cytidines and guanosines can be replaced with modified adenosines, cytidines and guanosines, e.g., with modifications at the 8-position, e.g., 8-bromo guanosine, or with any of the modified adenosines, cytidines or guanosines described herein.
In some embodiments, sugar-modified ribonucleotides can be incorporated into the gRNA, e.g., wherein the 2' OH-group is replaced by a group selected from H, -OR, -R (wherein R can be, e.g., alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar), halo, -SH, -SR (wherein R can be, e.g., alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar), amino (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclylamino, arylamino, diarylamino,
heteroarylamino, diheteroarylamino, or amino acid); or cyano (-CN). In some embodiments, the phosphate backbone can be modified as described herein, e.g., with a phosphothioate group. In some embodiments, one or more of the nucleotides of the gRNA can each independently be a modified or unmodified nucleotide including, but not limited to 2' -sugar modified, such as, 2'-0- methyl, 2'-0-methoxyethyl, or 2'-Fluoro modified including, e.g., 2'-F or 2'-0-methyl, adenosine (A), 2'-F or 2'-0-methyl, cytidine (C), 2'-F or 2'-0-methyl, uridine (U), 2'-F or 2'-0- methyl, thymidine (T), 2'-F or 2'-0-methyl, guanosine (G), 2'-0-methoxyethyl-5-methyluridine (Teo), 2'-0-methoxyethyladenosine (Aeo), 2'-0-methoxyethyl-5-methylcytidine (m5Ceo), and any combinations thereof.
In some embodiments, a gRNA can include "locked" nucleic acids (LNA) in which the 2' OH-group can be connected, e.g., by a CI -6 alkylene or CI -6 heteroalkylene bridge, to the 4' carbon of the same ribose sugar, where exemplary bridges can include methylene, propylene, ether, or amino bridges; O-amino (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclylamino, arylamino, diarylamino, heteroarylamino, or diheteroarylamino,
ethylenediamine, or polyamino) and aminoalkoxy or 0(CH2)n-amino (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclylamino, arylamino, diarylamino,
heteroarylamino, or diheteroarylamino, ethylenediamine, or polyamino).
In some embodiments, a gRNA can include a modified nucleotide which is multicyclic (e.g., tricyclo; and "unlocked" forms, such as glycol nucleic acid (GNA) (e.g., R-GNA or S- GNA, where ribose is replaced by glycol units attached to phosphodiester bonds), or threose nucleic acid (TNA, where ribose is replaced with a-L-threofuranosyl-(3'→2')).
Generally, gRNA molecules include the sugar group ribose, which is a 5-membered ring having an oxygen. Exemplary modified gRNAs can include, without limitation, replacement of the oxygen in ribose (e.g., with sulfur (S), selenium (Se), or alkylene, such as, e.g., methylene or ethylene); addition of a double bond (e.g., to replace ribose with cyclopentenyl or cyclohexenyl); ring contraction of ribose (e.g., to form a 4-membered ring of cyclobutane or oxetane); ring expansion of ribose (e.g., to form a 6- or 7-membered ring having an additional carbon or heteroatom, such as for example, anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino that also has a phosphoramidate backbone). Although the majority of sugar analog alterations are localized to the 2' position, other sites are amenable to modification, including the 4' position. In an embodiment, a gRNA comprises a 4'-S, 4'-Se or a 4'-C- aminomethyl-2' -O-Me modification.
In some embodiments, deaza nucleotides, e.g., 7-deaza-adenosine, can be incorporated into the gRNA. In some embodiments, O- and N-alkylated nucleotides, e.g., N6-methyl adenosine, can be incorporated into the gRNA. In some embodiments, one or more or all of the nucleotides in a gRNA molecule are deoxynucleotides.
miRNA binding sites
microRNAs (or miRNAs) are naturally occurring cellular 19-25 nucleotide long noncoding RNAs. They bind to nucleic acid molecules having an appropriate miRNA binding site, e.g., in the 3' UTR of an mRNA, and down-regulate gene expression. While not wishing to be bound by theory it is believed that the down regulation is either by reducing nucleic acid molecule stability or by inhibiting translation. An RNA species disclosed herein, e.g., an mRNA encoding Cas9 can comprise an miRNA binding site, e.g., in its 3'UTR. The miRNA binding site can be selected to promote down regulation of expression is a selected cell type. By way of example, the incorporation of a binding site for miR-122, a microRNA abundant in liver, can inhibit the expression of the gene of interest in the liver.
Examples
The following Examples are merely illustrative and are not intended to limit the scope or content of the invention in any way.
Example 1: Evaluation of candidate guide RNAs (gRNAs)
The suitability of candidate gRNAs can be evaluated as described in this example.
Although described for a chimeric gRNA, the approach can also be used to evaluate modular gRNAs.
Cloning gRNAs into Vectors
For each gRNA, a pair of overlapping oligonucleotides is designed and obtained.
Oligonucleotides are annealed and ligated into a digested vector backbone containing an upstream U6 promoter and the remaining sequence of a long chimeric gRNA. Plasmid is sequence-verified and prepped to generate sufficient amounts of transfection-quality DNA. Alternate promoters maybe used to drive in vivo transcription (e.g. HI promoter) or for in vitro transcription (e.g., a T7 promoter).
Cloning gRNAs in linear dsDNA molecule (STITCHR)
For each gRNA, a single oligonucleotide is designed and obtained. The U6 promoter and the gRNA scaffold (e.g. including everything except the targeting domain, e.g., including sequences derived from the crRNA and tracrRNA, e.g., including a first complementarity domain; a linking domain; a second complementarity domain; a proximal domain; and a tail domain) are separately PCR amplified and purified as dsDNA molecules. The gRNA-specific oligonucleotide is used in a PCR reaction to stitch together the U6 and the gRNA scaffold, linked by the targeting domain specified in the oligonucleotide. Resulting dsDNA molecule (STITCHR product) is purified for transfection. Alternate promoters may be used to drive in vivo transcription (e.g., HI promoter) or for in vitro transcription (e.g., T7 promoter). Any gRNA scaffold may be used to create gRNAs compatible with Cas9s from any bacterial species.
Initial gRNA Screen
Each gRNA to be tested is transfected, along with a plasmid expressing Cas9 and a small amount of a GFP-expressing plasmid into human cells. In preliminary experiments, these cells can be immortalized human cell lines such as 293T, K562 or U20S. Alternatively, primary human cells may be used. In this case, cells may be relevant to the eventual therapeutic cell target (for example, an erythroid cell). The use of primary cells similar to the potential therapeutic target cell population may provide important information on gene targeting rates in the context of endogenous chromatin and gene expression.
Transfection may be performed using lipid transfection (such as Lipofectamine or Fugene) or by electroporation (such as Lonza Nucleofection). Following transfection, GFP expression can be determined either by fluorescence microscopy or by flow cytometry to confirm consistent and high levels of transfection. These preliminary transfections can comprise different gRNAs and different targeting approaches (17-mers, 20-mers, nuclease, dual-nickase, etc.) to determine which gRNAs/combinations of gRNAs give the greatest activity.
Efficiency of cleavage with each gRNA may be assessed by measuring NHEJ-induced indel formation at the target locus by a T7El-type assay or by sequencing. Alternatively, other mismatch- sensitive enzymes, such as Cell/Surveyor nuclease, may also be used.
For the T7E1 assay, PCR amplicons are approximately 500-700bp with the intended cut site placed asymmetrically in the amplicon. Following amplification, purification and size- verification of PCR products, DNA is denatured and re-hybridized by heating to 95 °C and then slowly cooling. Hybridized PCR products are then digested with T7 Endonuclease I (or other mismatch- sensitive enzyme) which recognizes and cleaves non-perfectly matched DNA. If indels are present in the original template DNA, when the amplicons are denatured and re- annealed, this results in the hybridization of DNA strands harboring different indels and therefore lead to double- stranded DNA that is not perfectly matched. Digestion products may be visualized by gel electrophoresis or by capillary electrophoresis. The fraction of DNA that is cleaved (density of cleavage products divided by the density of cleaved and uncleaved) may be used to estimate a percent NHEJ using the following equation: NHEJ = (1-(1 -fraction cleaved)'72). The T7E1 assay is sensitive down to about 2-5% NHEJ. Sequencing may be used instead of, or in addition to, the T7E1 assay. For Sanger sequencing, purified PCR amplicons are cloned into a plasmid backbone, transformed, miniprepped and sequenced with a single primer. Sanger sequencing may be used for determining the exact nature of indels after determining the NHEJ rate by T7E1.
Sequencing may also be performed using next generation sequencing techniques. When using next generation sequencing, amplicons may be 300-500bp with the intended cut site placed asymmetrically. Following PCR, next generation sequencing adapters and barcodes (for example Illumina multiplex adapters and indexes) may be added to the ends of the amplicon, e.g., for use in high throughput sequencing (for example on an Illumina MiSeq). This method allows for detection of very low NHEJ rates.
Example 2: Assessment of Gene Targeting by NHEJ
The gRNAs that induce the greatest levels of NHEJ in initial tests can be selected for further evaluation of gene targeting efficiency. In this case, cells are derived from disease subjects and, therefore, harbor the relevant mutation.
Following transfection (usually 2-3 days post-transfection,) genomic DNA may be isolated from a bulk population of transfected cells and PCR may be used to amplify the target region. Following PCR, gene targeting efficiency to generate the desired mutations (either knockout of a target gene or removal of a target sequence motif) may be determined by sequencing. For Sanger sequencing, PCR amplicons may be 500-700 bp long. For next generation sequencing, PCR amplicons may be 300-500 bp long. If the goal is to knockout gene function, sequencing may be used to assess what percent of alleles have undergone NHEJ- induced indels that result in a frameshift or large deletion or insertion that would be expected to destroy gene function. If the goal is to remove a specific sequence motif, sequencing may be used to assess what percent of alleles have undergone NHEJ-induced deletions that span this sequence.
Example 3: Assessment of Gene Targeting by HDR
The gRNAs that induce the greatest levels of NHEJ in initial tests can be selected for further evaluation of gene targeting efficiency. In this case, cells are derived from disease subjects and, therefore, harbor the relevant mutation. Following transfection (usually 2-3 days post-transfection,) genomic DNA may be isolated from a bulk population of transfected cells and PCR may be used to amplify the target region. Following PCR, gene targeting efficiency can be determined by several methods.
Determination of gene targeting frequency involves measuring the percentage of alleles that have undergone homologous directed repair (HDR) with the donor template and which therefore have incorporated desired correction. If the desired HDR event creates or destroys a restriction enzyme site, the frequency of gene targeting may be determined by a RFLP assay. If no restriction site is created or destroyed, sequencing may be used to determine gene targeting frequency. If a RFLP assay is used, sequencing may still be used to verify the desired HDR event and ensure that no other mutations are present. At least one of the primers is placed in the endogenous gene sequence outside of the region included in the homology arms, which prevents amplification of donor template still present in the cells. Therefore, the length of the homology arms present in the donor template may affect the length of the PCR amplicon. PCR amplicons can either span the entire donor region (both primers placed outside the homology arms) or they can span only part of the donor region and a single junction between donor and endogenous DNA (one internal and one external primer). If the amplicons span less than entire donor region, two different PCRs should be used to amplify and sequence both the 5' and the 3' junction.
If the PCR amplicon is short (less than 600bp) it is possible to use next generation sequencing. Following PCR, next generation sequencing adapters and barcodes (for example Illumina multiplex adapters and indexes) may be added to the ends of the amplicon, e.g., for use in high throughput sequencing (for example on an Illumina MiSeq). This method allows for detection of very low gene targeting rates.
If the PCR amplicon is too long for next generation sequencing, Sanger sequencing can be performed. For Sanger sequencing, purified PCR amplicons will be cloned into a plasmid backbone (for example, TOPO cloned using the LifeTech Zero Blunt® TOPO® cloning kit), transformed, miniprepped and sequenced.
Incorporation by Reference
All publications, patents, and patent applications mentioned herein are hereby
incorporated by reference in their entirety as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

CLAIMS What is claimed is:
1. A gRNA molecule comprising a targeting domain which is complementary with a target domain from the CFTR or SCNN1A gene.
2. The gRNA molecule of claim 1, wherein said targeting domain is configured to provide a cleavage event selected from a double strand break and a single strand break, within 500, 400, 300, 200, 100, 50, 25 or 10 nucleotides of a CF target mutant position or a CF target knockout position.
3. The gRNA molecule of claim 1 or 2, wherein said targeting domain is configured to target an early coding region of the SCNN1A gene.
4. The gRNA molecule of claim 1 or 2, wherein said targeting domain is configured to target an intronic region of the CFTR gene.
5. The gRNA molecule of claim 1 or 2, wherein said targeting domain is configured to target a mutation in the CFTR gene.
6. The gRNA molecule of claim 1, wherein said targeting domain is configured to target an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fusion protein, sufficiently close to a CF target knockdown position to reduce, decrease or repress expression of the SCNN1A gene.
7. The gRNA molecule of claim 1, 2, or 6, wherein said targeting domain is configured to target the promoter region of the SCNN1A gene.
8. The gRNA molecule of any of claims 1-7, wherein said targeting domain comprises a sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence from any of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E.
9. The gRNA molecule of any of claims 1-3 or 6-8, wherein said targeting domain is selected from those in Tables 3A-3D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A- 47G, or 48A-48E.
10. The gRNA molecule of any of claims 1, 2, 4, 5 or 8, wherein said targeting domain is selected from those in Tables 1A-1E, 2A-2E, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D.
11. The gRNA molecule of any of claims 1, 2, 4, 5 or 8, wherein said targeting domain is selected from those in Tables 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, or 42A-42D.
12. The gRNA molecule of any of claims 1, 2, 5 or 8, wherein said targeting domain is
selected from those in those in Tables 1A-1E, 2A-2E, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A- 16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, or 36A-36D.
13. The gRNA molecule of any of claims 1-12, wherein said gRNA is a modular gRNA
molecule.
14. The gRNA molecule of any of claimsl-12, wherein said gRNA is a chimeric gRNA
molecule.
15. The gRNA molecule of any of claims 1-14, wherein said targeting domain is 16
nucleotides or more in length.
16. The gRNA molecule of any of claims 1-15, wherein said targeting domain is 16
nucleotides in length.
17. The gRNA molecule of any of claims 1-16, wherein said targeting domain is 17 or 18 nucleotides in length.
18. The gRNA molecule of any of claims 1-17, wherein said targeting domain is 19
nucleotides in length.
19. The gRNA molecule of any of claims 1-18, wherein said targeting domain is 20 nucleotides in length.
20. The gRNA molecule of any of claims 1-19, wherein said targeting domain is 21 nucleotides in length.
21. The gRNA molecule of any of claims 1-20, wherein said targeting domain is 22 nucleotides in length.
22. The gRNA molecule of any of claims 1-21, wherein said targeting domain is 23 nucleotides in length.
23. The gRNA molecule of any of claims 1-22, wherein said targeting domain is 24 nucleotides in length.
24. The gRNA molecule of any of claims 1-23, wherein said targeting domain is 25 nucleotides in length.
25. The gRNA molecule of any of claims 1-24, wherein said targeting domain is 26 nucleotides in length.
26. The gRNA molecule of any of claims 1-25, comprising from 5' to 3':
a targeting domain;
a first complementarity domain;
a linking domain;
a second complementarity domain;
a proximal domain; and
a tail domain.
27. The gRNA molecule of any of claims 1-26, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 20 nucleotides length; and
a targeting domain of 17 or 18 nucleotides in length.
28. The gRNA molecule of any of claims 1-27, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 25 nucleotides length; and
a targeting domain of 17 or 18 nucleotides in length.
29. The gRNA molecule of any of claims 1-28, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and
a targeting domain of 17 nucleotides in length.
30. The gRNA molecule of any of claims 1-29, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and
a targeting domain of 17 nucleotides in length.
31. A nucleic acid that comprises: (a) sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a CF target domain in the CFTR gene or SCNN1A gene.
32. The nucleic acid of claim 31, wherein said gRNA molecule is a gRNA molecule of any of claims 1-30.
33. The nucleic acid of claim 31 or 32, wherein said targeting domain is configured to
provide a cleavage event selected from a double strand break and a single strand break, within 500, 400, 300, 200, 100, 50, 25 or 10 nucleotides of the CF target mutant position or the CF target knockout position.
34. The nucleic acid of any of claims 31-33, wherein said targeting domain is configured to target an early coding region of the SCNN1A gene.
35. The nucleic acid of any of claims 31-33, wherein said targeting domain is configured to target an intronic region of the CFTR gene.
36. The nucleic acid of any of claims 31-33, wherein said targeting domain is configured to target a mutation in the CFTR gene.
37. The nucleic acid of claim 31 or 32, wherein said targeting domain is configured to target an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fusion protein, sufficiently close to a CF target knockdown position to reduce, decrease or repress expression of the SCNN1A gene.
38. The nucleic acid of claim 31, 32 or 37, wherein said targeting domain is configured to target the promoter region of the SCNN1A gene.
39. The nucleic acid of any of claims 31-38, wherein said targeting domain comprises a sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence from any of Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E.
40. The nucleic acid of any of claims 31-38, wherein said targeting domain comprises a
sequence that is the same as a targeting domain sequence from any of Tables 1A-1E, 2A- 2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A- 12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A- 20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E.
41. The nucleic acid of any of claims 31-40, wherein said gRNA is a modular gRNA
molecule.
42. The nucleic acid of any of claims 31-40, wherein said gRNA is a chimeric gRNA
molecule.
43. The nucleic acid of any of claims 31-42, wherein said targeting domain is 16 nucleotides or more in length.
44. The nucleic acid of any of claims 31-43, wherein said targeting domain is 17 nucleotides in length.
45. The nucleic acid of any of claims 31-44, wherein said targeting domain is 18 nucleotides in length.
46. The nucleic acid of any of claims 31-45, wherein said targeting domain is 19 nucleotides in length.
47. The nucleic acid of any of claims 31-46, wherein said targeting domain is 20 nucleotides in length.
48. The nucleic acid of any of claims 31-47, wherein said targeting domain is 21 nucleotides in length.
49. The nucleic acid of any of claims 31-48, wherein said targeting domain is 22 nucleotides in length.
50. The nucleic acid of any of claims 31-49, wherein said targeting domain is 23 nucleotides in length.
51. The nucleic acid of any of claims 31-50, wherein said targeting domain is 24 nucleotides in length.
52. The nucleic acid of any of claims 31-51, wherein said targeting domain is 25 nucleotides in length.
53. The nucleic acid of any of claims 31-52, wherein said targeting domain is 26 nucleotides in length.
54. The nucleic acid of any of claims 31-53, comprising from 5' to 3' :
a targeting domain;
a first complementarity domain;
a linking domain;
a second complementarity domain;
a proximal domain; and
a tail domain.
55. The nucleic acid of any of claims 31-54, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain of 17 or 18 nucleotides in length.
56. The nucleic acid of any of claims 31-55, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 25 nucleotides in length; and a targeting domain of 17 or 18 nucleotides in length.
57. The nucleic acid of any of claims 31-56, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain of 17 nucleotides in length.
58. The nucleic acid of any of claims 31-57, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain of 17 nucleotides in length.
59. The nucleic acid of any of claims 31-58, further comprising: (b) sequence that encodes a Cas9 molecule.
60. The nucleic acid of claim 59, wherein said Cas9 molecule is an eaCas9 molecule.
61. The nucleic acid of claim 60, wherein said eaCas9 molecule comprises a nickase
molecule.
62. The nucleic acid of claim 60, wherein said eaCas9 molecule forms a double strand break in a target nucleic acid.
63. The nucleic acid of any of claims 60-61, wherein said eaCas9 molecule forms a single strand break in a target nucleic acid.
64. The nucleic acid of any of claims 60, 61 or 63, wherein said single strand break is formed in the strand of the target nucleic acid to which the targeting domain of said gRNA molecule is complementary.
65. The nucleic acid of any of claims 60, 61 or 63, wherein said single strand break is formed in the strand of the target nucleic acid other than the strand to which to which the targeting domain of said gRNA is complementary.
66. The nucleic acid of any of claims 60, 61 or 63, wherein said eaCas9 molecule comprises HNH-like domain cleavage activity but has no, or no significant, N-terminal RuvC-like domain cleavage activity.
67. The nucleic acid of any of claims 60, 61, 63 or 66, wherein said eaCas9 molecule is an HNH-like domain nickase.
68. The nucleic acid of any of claims 60, 61, 63, 66, or 67, wherein said eaCas9 molecule comprises a mutation at D10.
69. The nucleic acid of any of claims 60, 61, or 63, wherein said eaCas9 molecule comprises N-terminal RuvC-like domain cleavage activity but has no, or no significant, HNH-like domain cleavage activity.
70. The nucleic acid of any of claims 60, 61, 63 or 69, wherein said eaCas9 molecule is an N- terminal RuvC-like domain nickase.
71. The nucleic acid of any of claims 60, 61, 63, 69 or 70, wherein said eaCas9 molecule comprises a mutation at H840 or N863.
72. The nucleic acid of claim 59, wherein said Cas9 molecule is an eiCas9 molecule.
73. The nucleic acid of claim 72, wherein said Cas9 molecule is an eiCas9-fusion protein molecule.
74. The nucleic acid of claim 72 or 73, wherein the eiCas9 fusion protein molecule is an eiCas9-transcription repressor domain fusion or eiCas9-chormatin modifying protein fusion.
75. The nucleic acid of any of claims 31-73, further comprising: (c) sequence that encodes a second gRNA molecule described herein having a targeting domain that is
complementary to a second target domain of the CFTR gene or SCNN1A gene.
76. The nucleic acid of claim 75, wherein said second gRNA molecule is a gRNA molecule of any of claims 1-30.
77. The nucleic acid of claim 75 or 76, wherein said targeting domain of said second gRNA is configured to provide a cleavage event selected from a double strand break and a single strand break, within 500, 400, 300, 200, 100, 50, 25 or 10 nucleotides of the CF target mutant position or the CF target knockout position.
78. The nucleic acid of any of claims 75-77, wherein said targeting domain of said second gRNA moelecule is configured to target an early coding region of the SCNN1A gene.
79. The nucleic acid of any of claims 75-77, wherein said targeting domain of said second gRNA moelecule is configured to target a mutation in the CFTR gene.
80. The nucleic acid of claim 75 or 76, wherein said targeting domain is configured to target an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fusion protein, sufficiently close to a CF target knockdown position to reduce, decrease or repress expression of the SCNN1A gene.
81. The nucleic acid of claim 75, 76 or 80, wherein said targeting domain of said second gRNA molecule is configured to target the promoter region of the SCNN1A gene.
82. The nucleic acid of any one of claims 75-81, wherein said targeting domain of said
second gRNA comprises a sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence from any of Tables 1A-1E, 2A-2E, 3A- 3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E.
83. The nucleic acid of any one of claims 75-80, wherein said targeting domain of said
second gRNA is selected from those in Tables 1A-1E, 2A-2E, 3A-3D, 4A-4D, 5A-5E, 6A-6C, 7A-7D, 8A-8E, 9A-9B, lOA-lOC, 11A-11E, 12A-12C, 13A-13D, 14A-14E, 15A-15C, or 16A-16D, 17A-17E, 18A-18C, 19A-19D, 20A-20E, 21A-21B, 22A-22D, 23A-23E, 24A-24D, 25A-25D, 26A-26E, 27A-27D, 28A-28D, 29A-29E, 30A-30B, 31A-31D, 32A-32D, 33A-33B, 34A-34D, 35A-35D, 36A-36D, 37A-37D, 38A-38E, 39A-39D, 40A-40D, 41A-41E, 42A-42D, 43A-43E, 44A-44G, 45A-45E, 46A-46E, 47A-47G, or 48A-48E.
84. The nucleic acid of any of claims 75-83, wherein said second gRNA molecule is a
modular gRNA molecule.
85. The nucleic acid of any of claims 75-83, wherein said second gRNA molecule is a
chimeric gRNA molecule.
86. The nucleic acid of any of claims 75-85, wherein said targeting domain is 16 nucleotides or more in length.
87. The nucleic acid of any of claims 75-86, wherein said targeting domain is 17 nucleotides in length.
88. The nucleic acid of any of claims 75-87, wherein said targeting domain is 18 nucleotides in length.
89. The nucleic acid of any of claims 75-88, wherein said targeting domain is 19 nucleotides in length.
90. The nucleic acid of any of claims 75-89, wherein said targeting domain is 20 nucleotides in length.
91. The nucleic acid of any of claims 75-90, wherein said targeting domain is 21 nucleotides in length.
92. The nucleic acid of any of claims 75-91, wherein said targeting domain is 22 nucleotides in length.
93. The nucleic acid of any of claims 75-92, wherein said targeting domain is 23 nucleotides in length.
94. The nucleic acid of any of claims 75-93, wherein said targeting domain is 24 nucleotides in length.
95. The nucleic acid of any of claims 75-94, wherein said targeting domain is 25 nucleotides in length.
96. The nucleic acid of any of claims 75-95, wherein said targeting domain is 26 nucleotides in length.
97. The nucleic acid of any of claims 75-96, wherein said second gRNA molecule comprises from 5' to 3':
a targeting domain;
a first complementarity domain;
a linking domain;
a second complementarity domain;
a proximal domain; and
a tail domain.
98. The nucleic acid of any of claims 75-97, wherein said second gRNA molecule comprises: a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain of 17 or 18 nucleotides in length.
99. The nucleic acid of any of claims 75-98, wherein said second molecule gRNA molecule comprises:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 25 nucleotides in length; and a targeting domain of 17 or 18 nucleotides in length.
100. The nucleic acid of any of claims 75-99, wherein said second gRNA molecule comprises:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain of 17 nucleotides in length.
101. The nucleic acid of any of claims 75-100, wherein said second gRNA molecule comprises:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain of 17 nucleotides in length.
102. The nucleic acid of any of claims 75-101, further comprising a third gRNA
molecule.
103. The nucleic acid of claim 102, further comprising a fourth gRNA molecule.
104. The nucleic acid of claim 31, further comprising: (b) sequence that encodes a Cas9 molecule of any of claims 59-74.
105. The nucleic acid of claim 104, wherein said nucleic acid does not comprise (c) a sequence that encodes a second gRNA molecule.
106. The nucleic acid of claim 104, wherein each of (a) and (b) is present on the same nucleic acid molecule.
107. The nucleic acid of claim 106, wherein said nucleic acid molecule is an AAV vector.
108. The nucleic acid of any of claims 59-105, wherein: (a) is present on a first nucleic acid molecule; and (b) is present on a second nucleic acid molecule.
109. The nucleic acid of claim 108, wherein said first and second nucleic acid
molecules are AAV vectors.
110. The nucleic acid of claim 104, further comprising (c) a sequence that encodes a second gRNA molecule of any of claims 1-30.
111. The nucleic acid of any of claims 31103, 108, or 109, wherein each of (a) and (c) is present on the same nucleic acid molecule.
112. The nucleic acid of claim 111, wherein said nucleic acid molecule is an AAV vector.
113. The nucleic acid any of claims 31-103, 108, or 109, wherein: (a) is present on a first nucleic acid molecule; and (c) is present on a second nucleic acid molecule.
114. The nucleic acid of claim 113, wherein said first and second nucleic acid
molecules are AAV vectors.
115. The nucleic acid of claim 31, further comprising: (b) sequence that encodes a Cas9 molecule of any of claims 59-74; and
(c) sequence that encode a second gRNA molecule of clams 75-101.
116. The nucleic acid of any of claims 75-103, or 110-112, wherein each of (a), (b), and (c) are present on the same nucleic acid molecule.
117. The nucleic acid of claim 116, wherein said nucleic acid molecule is an AAV vector.
118. The nucleic acid of any of claims 315-103, or 110-112, wherein:
one of (a), (b), and (c) is encoded on a first nucleic acid molecule; and
a second and third of (a), (b), and (c) is encoded on a second nucleic acid molecule.
119. The nucleic acid of claim 118, wherein said first and second nucleic acid
molecules are AAV vectors.
120. The nucleic acid of any of claims 31-103, 108, 109, 111, 112, 118, or 119, wherein: (a) is present on a first nucleic acid molecule; and (b) and (c) are present on a second nucleic acid molecule.
121. The nucleic acid of claim 120, wherein said first and second nucleic acid
molecules are AAV vectors.
122. The nucleic acid of any of claims 31-103, 108-112, 118 or 119, wherein: (b) is present on a first nucleic acid molecule; and (a) and (c) are present on a second nucleic acid molecule.
123. The nucleic acid of claim 122, wherein said first and second nucleic acid
molecules are AAV vectors.
124. The nucleic acid of any of claims 315-103, 106, 107, 113, 114, 118, or 119, wherein: (c) is present on a first nucleic acid molecule; and (b) and (a) are present on a second nucleic acid molecule.
125. The nucleic acid of claim 124, wherein said first and second nucleic acid
molecules are AAV vectors.
126. The nucleic acid of any of claims 108, 113, 118, 120, 122, or 124, wherein said first nucleic acid molecule is other than an AAV vector and said second nucleic acid molecule is an AAV vector.
127. The nucleic acid of any of claims 31-126, wherein said nucleic acid comprises a promoter operably linked to the sequence that encodes said gRNA molecule of (a).
128. The nucleic acid of claims 31-103 or 106-127, wherein said nucleic acid comprises a second promoter operably linked to the sequence that encodes the second gRNA molecule of (c).
129. The nucleic acid of claim 128, wherein the promoter and second promoter differ from one another.
130. The nucleic acid of claim 128, wherein the promoter and second promoter are the same.
131. The nucleic acid of any of claims 31-130, wherein said nucleic acid comprises a promoter operably linked to the sequence that encodes the Cas9 molecule of (b).
132. A composition comprising the (a) gRNA molecule of any of claims 1-30.
133. The composition of claim 132, further comprising (b) a Cas9 molecule of any of claims 59-74.
134. The composition of any of claims 132 or 133, further comprising (c) a second gRNA molecule of any of claims 75-101.
135. The composition of claim 134, further comprising a third gRNA molecule.
136. The composition of claim 135, further comprising a fourth gRNA molecule.
137. The composition of any one of claims 133-136, further comprising (d) a template nucleic acid.
138. A method of altering a cell comprising contacting said cell with:
(a) a gRNA of any of claims 1-30;
(b) a Cas9 molecule of any of claims 59-74;
optionally, (c) a second gRNA molecule of any of claims 75-101; and
optionally, (d) a template nucleic acid.
139. The method of claim 138, further comprising a third gRNA molecule.
140. The method of claim 139, further comprising a fourth gRNA molecule.
141. The method of claim 138, comprising contacting said cell with (a), (b), optionally (c) and optionally (d).
142. The method of any of claims 138-141, wherein said gRNA molecule of (a) is selected from any of claims 1-30.
143. The method of any of claims 138-142, wherein said cell is from a subject
suffering from CF or CF-like disease.
144. The method of any of claims 138-142, wherein said cell is from a subject having a mutation at a CF target position in the CFTR gene or from a subject which would benefit from having a mutation at a CF target position in the SCNNIA gene.
145. The method of any of claims 138-144, wherein said cell is a pulmonary epithelial cell.
146. The method of any of claims 138-144, wherein said cell is a gastrointestinal
epithelial cell, a biliary epithelial cell, or a pancreatic ductal epithelial cell.
147. The method of any of claims 138-144, wherein said cell is a stem cell.
148. The method of any of claims 138-144, wherein said cell is an iPS cell or a cell derived from an iPS cell.
149. The method of claim 138-148, wherein said contacting is performed ex vivo.
150. The method of claim 138-149, wherein said contacted cell is returned to said subject's body.
151. The method of claim 138-148, wherein said contacting is performed in vivo.
152. The method of any of claims 138-151, wherein said cell is from a subject that has CF or CF-like disease.
153. The method of any of claims 138-152, comprising acquiring knowledge of the sequence of the CF target position in said cell.
154. The method of claim 153, comprising acquiring knowledge of the sequence of the CF target position in said cell by sequencing a portion of the CFTR gene or SCNNIA gene.
155. The method of any of claims 138-154, comprising correcting a mutation or
introducing a mutation at the CF target position.
156. The method of any of claims 138-155, wherein contacting comprises contacting said cell with a nucleic acid that encodes at least one of (a), (b), (c) and (d).
157. The method of any of claims 138-156, wherein contacting comprises contacting the cell with a nucleic acid of any of claims 31-131.
158. The method of any of claims 138-157, wherein contacting comprises delivering to said cell said Cas9 molecule of (b) and a nucleic acid which encodes and (a) and optionally (c) and/or (d).
159. The method of any of claims 138-158, wherein contacting comprises delivering to said cell said Cas9 molecule of (b), said gRNA molecule of (a) and optionally said second gRNA molecule of (c).
160. The method of any of claims 138-159, wherein contacting comprises delivering to said cell said gRNA molecule of (a), optionally said second gRNA molecule of (c) and a nucleic acid that encodes the Cas9 molecule of (b).
161. A method of treating a subject, comprising contacting a subject (or a cell from said subject) with:
(a) a gRNA of any of claims 1-30;
(b) a Cas9 molecule of any of claims 59-74;
optionally, (c) a second gRNA of any of claims 75-101; and
optionally, (d) a template nucleic acid.
162. The method of claim 161, further comprising a third gRNA molecule.
163. The method of claim 162, further comprising a fourth gRNA molecule.
164. The method of any one of claims 161-163, further comprising contacting said subject with (a), (b), optionally (c) and optionally (d).
165. The method of claims any one of claims 161-164, wherein said subject is
suffering from CF or CF-like disease.
166. The method of any of claims 161-165, wherein said subject has a mutation at the CF target position in the CFTR gene or would benefit from having a mutation at the CF target position in the SCNNIA gene.
167. The method of any of claims 161-166, comprising acquiring knowledge of the sequence of the CF target position in said subject.
168. The method of claim 167, comprising acquiring knowledge of the sequence of the CF target position in said subject by sequencing a portion of the CFTR gene or SCNNIA gene.
169. The method of claim 161-168, comprising correcting a mutation at the CF target position in the CFTR gene or introducing a mutation at the CF target position in the SCNNIA gene.
170. The method of any of claims 161-169, wherein a cell of said subject is contacted ex vivo with (a), (b), and optionally (c) and/or (d).
171. The method of claim 170, wherein said cell is returned to the subject's body.
172. The method of any of claims 161-169, wherein treatment comprises introducing a cell into said subject's body, wherein said cell subject is contacted ex vivo with (a), (b), and optionally (c) and/or (d).
173. The method of any of claims 161-169, wherein said contacting step is performed in vivo.
174. The method of any of claims 161-169 or 173, wherein said contacting step
comprises inhalation delivery.
175. The method of any of claims 161-169 or 173, wherein said contacting step
comprises intravenous delivery.
176. The method of any of claims 161-169 or 173, wherein said contacting step
comprises intraparenchymal delivery.
177. The method of any of claims 161-169 or 173, wherein said contacting step
comprises intraparenchymal delivery to lung tissue or bronchial tree.
178. The method of any of claims 161-169 or 173-177, comprising contacting said subject or a cell from said subject with a nucleic acid that encodes at least one of (a), (b), and (c).
179. The method of any of claims 161-169 or 173-178, comprising contacting said subject or a cell from said subject with a nucleic acid of any of any of claims 31-103.
180. The method of any of claims 161-179, wherein the contacting step comprises delivering to said subject or a cell from said subject said Cas9 molecule of (b) and a nucleic acid which encodes and (a) and optionally (c), and optionally (d).
181. The method of any of claims 161-180, wherein the contacting step comprises delivering to said subject said Cas9 molecule of (b), said gRNA of (a) and optionally said second gRNA of (c), and optionally said template nucleic acid of (d).
182. The method of any of claims 161-181, wherein the contacting step comprises delivering to said subject said gRNA of (a), optionally said second gRNA of (c) and a nucleic acid that encodes the Cas9 molecule of (b).
183. A reaction mixture comprising a gRNA, a nucleic acid, or a composition
described herein, and a cell from a subject having CF or CF-like disease, a subject having a mutation at a CF target position of the CFTR gene, or a subject which would benefit from having a mutation at a CF target position of the SCNN1A gene.
184. A kit comprising, (a) gRNA molecule of any of claims 1-30, or nucleic acid that encodes said gRNA, and one or more of the following:
(b) a Cas9 molecule of any of claims 59-74;
(c) a second gRNA molecule of any of claims 75-101;
(d) a template nucleic acid; and
(e) nucleic acid that encodes one or more of (b) and (c).
185. The kit of claim 184, comprising nucleic acid that encodes one or more of (a), (b) (c) and (d).
186. The kit of claim 184 or 185, further comprising a third gRNA molecule targeting a CF target mutant position, a CF target knockout position, or a CF target knockdown position.
187. The kit of claim 186, further comprising a fourth gRNA molecule targeting a CF target mutant position, a CF target knockout position, or a CF target knockdown position.
188. A gRNA molecule of any of claims 1-30 for use in treating CF or CF-like disease in a subject.
189. The gRNA molecule of claim 188, wherein the gRNA molecule is used in
combination with (b) a Cas9 molecule of any of claims 59-74.
190. The gRNA molecule of claim 188 or 189, wherein the gRNA molecule is used in combination with (c) a second gRNA molecule of any of claims 75-101.
191. Use of a gRNA molecule of any of claims 1-30, in the manufacture of a
medicament for treating CF or CF-like disease in a subject.
192. The use of claim 191, wherein the medicament further comprises (b) a Cas9
molecule of any of claims 59-74.
193. The use of claim 191 or 192, wherein the medicament further comprises (c) a second gRNA molecule of any of claims 75-101.
194. A composition of any of claims 132-136 for use in treating CF or CF-like disease in a subject.
PCT/US2015/023960 2014-04-09 2015-04-01 Crispr/cas-related methods and compositions for treating cystic fibrosis WO2015157070A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP19157864.0A EP3556858A3 (en) 2014-04-09 2015-04-01 Crispr/cas-related methods and compositions for treating cystic fibrosis
EP15721376.0A EP3129485B2 (en) 2014-04-09 2015-04-01 Crispr/cas-related methods and compositions for treating cystic fibrosis
US15/288,475 US11028394B2 (en) 2014-04-09 2016-10-07 CRISPR/CAS-related methods and compositions for treating cystic fibrosis
US17/246,081 US20210380987A1 (en) 2014-04-09 2021-04-30 Crispr/cas-related methods and compositions for treating cystic fibrosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977488P 2014-04-09 2014-04-09
US61/977,488 2014-04-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/288,475 Continuation US11028394B2 (en) 2014-04-09 2016-10-07 CRISPR/CAS-related methods and compositions for treating cystic fibrosis

Publications (2)

Publication Number Publication Date
WO2015157070A2 true WO2015157070A2 (en) 2015-10-15
WO2015157070A3 WO2015157070A3 (en) 2015-12-30

Family

ID=53059403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/023960 WO2015157070A2 (en) 2014-04-09 2015-04-01 Crispr/cas-related methods and compositions for treating cystic fibrosis

Country Status (3)

Country Link
US (2) US11028394B2 (en)
EP (2) EP3556858A3 (en)
WO (1) WO2015157070A2 (en)

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
KR20180065414A (en) * 2016-12-07 2018-06-18 연세대학교 산학협력단 Guide RNA sequences for CFTR gene deletion, T84 cell having mutated CFTR protein and use thereof
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
WO2018232265A1 (en) 2017-06-16 2018-12-20 Lonza Ltd Universal self-regulating mammalian cell line platform for the production of biologics
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US10227581B2 (en) 2013-08-22 2019-03-12 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2019178427A1 (en) 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
WO2020014618A1 (en) 2018-07-13 2020-01-16 Lonza Ltd Methods for improving production of biological products by reducing the level of endogenous protein
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
WO2020237217A1 (en) 2019-05-23 2020-11-26 Vor Biopharma, Inc Compositions and methods for cd33 modification
WO2021041977A1 (en) 2019-08-28 2021-03-04 Vor Biopharma, Inc. Compositions and methods for cd123 modification
WO2021041971A1 (en) 2019-08-28 2021-03-04 Vor Biopharma, Inc. Compositions and methods for cll1 modification
WO2021123920A1 (en) * 2019-12-18 2021-06-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
CN113461179A (en) * 2021-08-06 2021-10-01 南京农业大学 Application of rhodopseudomonas palustris ZT-MG2 in eutrophic water body treatment
US11180751B2 (en) 2015-06-18 2021-11-23 The Broad Institute, Inc. CRISPR enzymes and systems
WO2022047165A1 (en) 2020-08-28 2022-03-03 Vor Biopharma Inc. Compositions and methods for cd123 modification
WO2022047168A1 (en) 2020-08-28 2022-03-03 Vor Biopharma Inc. Compositions and methods for cll1 modification
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
WO2022056489A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd38 modification
WO2022056459A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd5 modification
WO2022061115A1 (en) 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
WO2022067240A1 (en) 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
WO2022072643A1 (en) 2020-09-30 2022-04-07 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2022093983A1 (en) 2020-10-27 2022-05-05 Vor Biopharma, Inc. Compositions and methods for treating hematopoietic malignancy
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
WO2022104090A1 (en) 2020-11-13 2022-05-19 Vor Biopharma Inc. Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors
WO2022147347A1 (en) 2020-12-31 2022-07-07 Vor Biopharma Inc. Compositions and methods for cd34 gene modification
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11466271B2 (en) 2017-02-06 2022-10-11 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
WO2022216619A1 (en) * 2021-04-05 2022-10-13 The Board Of Regents Of The University Of Texas System Compositions, methods and uses for treating cystic fibrosis and related disorders
WO2022217086A1 (en) 2021-04-09 2022-10-13 Vor Biopharma Inc. Photocleavable guide rnas and methods of use thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2023283585A2 (en) 2021-07-06 2023-01-12 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2023015182A1 (en) 2021-08-02 2023-02-09 Vor Biopharma Inc. Compositions and methods for gene modification
WO2023049926A2 (en) 2021-09-27 2023-03-30 Vor Biopharma Inc. Fusion polypeptides for genetic editing and methods of use thereof
WO2023086422A1 (en) 2021-11-09 2023-05-19 Vor Biopharma Inc. Compositions and methods for erm2 modification
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2023164636A1 (en) 2022-02-25 2023-08-31 Vor Biopharma Inc. Compositions and methods for homology-directed repair gene modification
WO2023196816A1 (en) 2022-04-04 2023-10-12 Vor Biopharma Inc. Compositions and methods for mediating epitope engineering
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2024015925A2 (en) 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11903973B2 (en) 2018-08-28 2024-02-20 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
US11975029B2 (en) 2017-02-28 2024-05-07 Vor Biopharma Inc. Compositions and methods for inhibition of lineage specific proteins
WO2024168312A1 (en) 2023-02-09 2024-08-15 Vor Biopharma Inc. Methods for treating hematopoietic malignancy
EP3965779A4 (en) * 2019-05-05 2024-10-02 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Restoration of the cftr function by splicing modulation

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
ES2878451T3 (en) 2014-11-14 2021-11-18 Voyager Therapeutics Inc Modulating polynucleotides
US10525076B2 (en) * 2015-02-20 2020-01-07 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting genes associated with cystic fibrosis
CN106893739A (en) * 2015-11-17 2017-06-27 香港中文大学 For the new method and system of target gene operation
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
CN110494555B (en) 2017-03-24 2024-04-02 纽约市哥伦比亚大学理事会 Generation of lung bud organoids with branched structures and use thereof for modeling lung disease
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
EP3652310B1 (en) * 2017-07-10 2023-05-03 The Hospital for Sick Children Gene editing system for correcting splicing defects
WO2019217429A1 (en) 2018-05-07 2019-11-14 The Trustees Of Columbia University In The City Of New York Lung and airway progenitors generated from human pluripotent stem cells and related treatments
CN108795902A (en) * 2018-07-05 2018-11-13 深圳三智医学科技有限公司 A kind of safe and efficient CRISPR/Cas9 gene editings technology
DE112019005166T5 (en) 2018-10-16 2021-07-29 Blueallele, Llc METHOD OF SPECIFIC INSERTION OF DNA INTO GENES
WO2020118073A1 (en) * 2018-12-05 2020-06-11 Vertex Pharmaceuticals Incorporated Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene
EP3897675A4 (en) * 2018-12-21 2022-10-12 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for airway tissue regeneration
WO2022008557A2 (en) * 2020-07-08 2022-01-13 UCB Biopharma SRL Modulation of cftr expression
CA3212237A1 (en) * 2021-03-19 2022-09-22 The University Of British Columbia Guide rnas and compositions for editing huntingtin gene, and methods related thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013293270B2 (en) * 2012-07-25 2018-08-16 Massachusetts Institute Of Technology Inducible DNA binding proteins and genome perturbation tools and applications thereof
ES2786193T3 (en) 2012-12-12 2020-10-09 Broad Inst Inc Genetic engineering and optimization of improved enzyme systems, methods, and compositions for sequence manipulation
EP3011035B1 (en) * 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences

Cited By (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006520B2 (en) 2011-07-22 2024-06-11 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10954548B2 (en) 2013-08-09 2021-03-23 President And Fellows Of Harvard College Nuclease profiling system
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US11920181B2 (en) 2013-08-09 2024-03-05 President And Fellows Of Harvard College Nuclease profiling system
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10227581B2 (en) 2013-08-22 2019-03-12 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US11299755B2 (en) 2013-09-06 2022-04-12 President And Fellows Of Harvard College Switchable CAS9 nucleases and uses thereof
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US10912833B2 (en) 2013-09-06 2021-02-09 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US10190137B2 (en) 2013-11-07 2019-01-29 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US10640788B2 (en) 2013-11-07 2020-05-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAs
US11390887B2 (en) 2013-11-07 2022-07-19 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US11124782B2 (en) 2013-12-12 2021-09-21 President And Fellows Of Harvard College Cas variants for gene editing
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11578343B2 (en) 2014-07-30 2023-02-14 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11180751B2 (en) 2015-06-18 2021-11-23 The Broad Institute, Inc. CRISPR enzymes and systems
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
WO2017158153A1 (en) 2016-03-17 2017-09-21 Imba - Institut Für Molekulare Biotechnologie Gmbh Conditional crispr sgrna expression
US11702651B2 (en) 2016-08-03 2023-07-18 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10947530B2 (en) 2016-08-03 2021-03-16 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11999947B2 (en) 2016-08-03 2024-06-04 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US12084663B2 (en) 2016-08-24 2024-09-10 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
KR101908593B1 (en) * 2016-12-07 2018-10-16 연세대학교 산학협력단 Guide RNA sequences for CFTR gene deletion, T84 cell having mutated CFTR protein and use thereof
KR20180065414A (en) * 2016-12-07 2018-06-18 연세대학교 산학협력단 Guide RNA sequences for CFTR gene deletion, T84 cell having mutated CFTR protein and use thereof
US11820969B2 (en) 2016-12-23 2023-11-21 President And Fellows Of Harvard College Editing of CCR2 receptor gene to protect against HIV infection
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11466271B2 (en) 2017-02-06 2022-10-11 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
US11975029B2 (en) 2017-02-28 2024-05-07 Vor Biopharma Inc. Compositions and methods for inhibition of lineage specific proteins
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2018232265A1 (en) 2017-06-16 2018-12-20 Lonza Ltd Universal self-regulating mammalian cell line platform for the production of biologics
US12054733B2 (en) 2017-06-16 2024-08-06 Lonza Ltd Universal self-regulating mammalian cell line platform for the production of biologics
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11932884B2 (en) 2017-08-30 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
EP4257696A2 (en) 2018-03-14 2023-10-11 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
WO2019178427A1 (en) 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
WO2020014618A1 (en) 2018-07-13 2020-01-16 Lonza Ltd Methods for improving production of biological products by reducing the level of endogenous protein
US11903973B2 (en) 2018-08-28 2024-02-20 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
US11643652B2 (en) 2019-03-19 2023-05-09 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11795452B2 (en) 2019-03-19 2023-10-24 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
EP3965779A4 (en) * 2019-05-05 2024-10-02 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Restoration of the cftr function by splicing modulation
WO2020237217A1 (en) 2019-05-23 2020-11-26 Vor Biopharma, Inc Compositions and methods for cd33 modification
WO2021041977A1 (en) 2019-08-28 2021-03-04 Vor Biopharma, Inc. Compositions and methods for cd123 modification
WO2021041971A1 (en) 2019-08-28 2021-03-04 Vor Biopharma, Inc. Compositions and methods for cll1 modification
WO2021123920A1 (en) * 2019-12-18 2021-06-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US12031126B2 (en) 2020-05-08 2024-07-09 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2022047168A1 (en) 2020-08-28 2022-03-03 Vor Biopharma Inc. Compositions and methods for cll1 modification
WO2022047165A1 (en) 2020-08-28 2022-03-03 Vor Biopharma Inc. Compositions and methods for cd123 modification
WO2022056489A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd38 modification
WO2022056459A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd5 modification
WO2022061115A1 (en) 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
WO2022067240A1 (en) 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
WO2022072643A1 (en) 2020-09-30 2022-04-07 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
WO2022093983A1 (en) 2020-10-27 2022-05-05 Vor Biopharma, Inc. Compositions and methods for treating hematopoietic malignancy
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
WO2022104090A1 (en) 2020-11-13 2022-05-19 Vor Biopharma Inc. Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors
WO2022147347A1 (en) 2020-12-31 2022-07-07 Vor Biopharma Inc. Compositions and methods for cd34 gene modification
WO2022216619A1 (en) * 2021-04-05 2022-10-13 The Board Of Regents Of The University Of Texas System Compositions, methods and uses for treating cystic fibrosis and related disorders
WO2022217086A1 (en) 2021-04-09 2022-10-13 Vor Biopharma Inc. Photocleavable guide rnas and methods of use thereof
WO2023283585A2 (en) 2021-07-06 2023-01-12 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
WO2023015182A1 (en) 2021-08-02 2023-02-09 Vor Biopharma Inc. Compositions and methods for gene modification
CN113461179A (en) * 2021-08-06 2021-10-01 南京农业大学 Application of rhodopseudomonas palustris ZT-MG2 in eutrophic water body treatment
WO2023049926A2 (en) 2021-09-27 2023-03-30 Vor Biopharma Inc. Fusion polypeptides for genetic editing and methods of use thereof
WO2023086422A1 (en) 2021-11-09 2023-05-19 Vor Biopharma Inc. Compositions and methods for erm2 modification
WO2023164636A1 (en) 2022-02-25 2023-08-31 Vor Biopharma Inc. Compositions and methods for homology-directed repair gene modification
WO2023196816A1 (en) 2022-04-04 2023-10-12 Vor Biopharma Inc. Compositions and methods for mediating epitope engineering
WO2024015925A2 (en) 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
WO2024168312A1 (en) 2023-02-09 2024-08-15 Vor Biopharma Inc. Methods for treating hematopoietic malignancy

Also Published As

Publication number Publication date
EP3556858A2 (en) 2019-10-23
US11028394B2 (en) 2021-06-08
US20170022507A1 (en) 2017-01-26
EP3129485A2 (en) 2017-02-15
US20210380987A1 (en) 2021-12-09
EP3129485B2 (en) 2022-12-21
WO2015157070A3 (en) 2015-12-30
EP3129485B1 (en) 2019-06-12
EP3556858A3 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
US20210380987A1 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
US20230026726A1 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
US11268086B2 (en) CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)
EP3443088B1 (en) Grna fusion molecules, gene editing systems, and methods of use thereof
US20240360471A1 (en) Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
US11512311B2 (en) Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
EP3274453B1 (en) Crispr/cas-mediated gene conversion
US11180793B2 (en) Evaluation of Cas9 molecule/guide RNA molecule complexes
EP3114227B1 (en) Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US20170007679A1 (en) Crispr/cas-related methods and compositions for treating hiv infection and aids
WO2015148860A1 (en) Crispr/cas-related methods and compositions for treating beta-thalassemia
EP3748004A1 (en) Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
EP3540061A1 (en) Crispr/cas-related methods and compositions for treating primary open angle glaucoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15721376

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015721376

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015721376

Country of ref document: EP